Cyclin	B-GENE-Y
E	I-GENE-Y
-	O
cdk2	B-GENE-Y
activation	O
is	O
associated	O
with	O
cell	O
cycle	O
arrest	O
and	O
inhibition	O
of	O
DNA	O
replication	O
induced	O
by	O
the	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
inhibitor	O
Tomudex	B-CHEMICAL
.	O

Tomudex	B-CHEMICAL
(	O
ZD1694	B-CHEMICAL
)	O
is	O
a	O
specific	O
antifolate	O
-	O
based	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
inhibitor	O
active	O
in	O
a	O
variety	O
of	O
solid	O
tumor	O
malignancies	O
.	O

Studies	O
were	O
carried	O
out	O
in	O
vitro	O
to	O
evaluate	O
downstream	O
molecular	O
alterations	O
induced	O
as	O
a	O
consequence	O
of	O
the	O
potent	O
and	O
sustained	O
inhibition	O
of	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
by	O
Tomudex	B-CHEMICAL
.	O

Twenty	O
-	O
four	O
hours	O
following	O
the	O
initial	O
2	O
-	O
h	O
treatment	O
with	O
Tomudex	B-CHEMICAL
,	O
human	O
A253	O
head	O
and	O
neck	O
squamous	O
carcinoma	O
cells	O
,	O
not	O
expressing	O
p53	B-GENE-Y
and	O
p21	B-GENE-Y
(	O
WAF1	B-GENE-Y
)	O
,	O
were	O
accumulated	O
with	O
DNA	O
content	O
characteristic	O
of	O
early	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
with	O
a	O
concomitant	O
reduction	O
of	O
cells	O
in	O
G1	O
and	O
G2	O
/	O
M	O
phases	O
.	O

The	O
changes	O
in	O
cyclin	B-GENE-N
and	O
cdk	B-GENE-N
protein	O
expression	O
and	O
their	O
kinase	B-GENE-N
activities	O
were	O
examined	O
in	O
control	O
and	O
drug	O
-	O
treated	O
A253	O
cells	O
.	O

Tomudex	B-CHEMICAL
treatment	O
resulted	O
in	O
the	O
decrease	O
in	O
p27	B-GENE-Y
(	I-GENE-Y
kip1	I-GENE-Y
)	I-GENE-Y
expression	O
,	O
with	O
an	O
increase	O
in	O
cyclin	B-GENE-Y
E	I-GENE-Y
and	O
cdk2	B-GENE-Y
protein	O
expression	O
and	O
kinase	B-GENE-N
activities	O
24	O
h	O
after	O
a	O
2	O
-	O
h	O
exposure	O
.	O

Although	O
cyclin	B-GENE-Y
A	I-GENE-Y
protein	O
expression	O
was	O
markedly	O
increased	O
,	O
cyclin	B-GENE-Y
A	I-GENE-Y
kinase	B-GENE-N
activity	O
was	O
only	O
slightly	O
increased	O
.	O

Cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
cyclin	B-GENE-Y
B	I-GENE-Y
,	O
cdk4	B-GENE-Y
,	O
and	O
cdc2	B-GENE-Y
protein	O
expression	O
and	O
kinase	B-GENE-N
activities	O
remain	O
constant	O
.	O

Lack	O
of	O
activation	O
of	O
cyclin	B-GENE-N
A	I-GENE-N
-	I-GENE-N
and	I-GENE-N
B	I-GENE-N
-	O
cdc2	B-GENE-Y
was	O
associated	O
with	O
a	O
reduced	O
proportion	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phases	O
.	O

Increased	O
cyclin	B-GENE-Y
E	I-GENE-Y
-	O
cdk2	B-GENE-Y
protein	O
expression	O
was	O
accompanied	O
by	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
,	O
with	O
a	O
decrease	O
in	O
E2F	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
.	O

These	O
results	O
propose	O
that	O
cyclin	B-GENE-Y
E	I-GENE-Y
-	O
cdk2	B-GENE-Y
kinase	B-GENE-N
can	O
negatively	O
regulate	O
DNA	O
replication	O
.	O

The	O
studies	O
with	O
dThyd	O
rescue	O
from	O
cyclin	B-GENE-Y
E	I-GENE-Y
-	O
cdk2	B-GENE-Y
protein	O
overexpression	O
and	O
growth	O
inhibition	O
by	O
Tomudex	B-CHEMICAL
indicate	O
that	O
increased	O
cyclin	B-GENE-Y
E	I-GENE-Y
-	O
cdk2	B-GENE-Y
protein	O
expression	O
is	O
associated	O
with	O
effective	O
inhibition	O
of	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
and	O
resultant	O
dNTP	O
pool	O
imbalance	O
.	O

Provision	O
of	O
dThyd	O
more	O
than	O
24	O
h	O
after	O
exposure	O
to	O
Tomudex	B-CHEMICAL
allowed	O
cells	O
to	O
replicate	O
DNA	O
for	O
a	O
single	O
cycle	O
back	O
to	O
G1	O
,	O
but	O
did	O
not	O
prevent	O
the	O
profound	O
growth	O
-	O
inhibitory	O
effect	O
manifested	O
in	O
the	O
following	O
5	O
days	O
.	O

Tomudex	B-CHEMICAL
treatment	O
resulted	O
in	O
a	O
time	O
-	O
dependent	O
induction	O
of	O
the	O
megabase	O
DNA	O
fragments	O
,	O
followed	O
by	O
secondary	O
50	O
-	O
to	O
300	O
-	O
kb	O
DNA	O
fragmentation	O
.	O

The	O
50	O
-	O
to	O
300	O
-	O
kb	O
DNA	O
fragmentation	O
may	O
be	O
derived	O
from	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
associated	O
with	O
cyclin	B-GENE-Y
E	I-GENE-Y
-	O
cdk2	B-GENE-Y
activation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
megabase	O
DNA	O
fragmentation	O
is	O
induced	O
as	O
a	O
consequence	O
of	O
inhibition	O
of	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
by	O
Tomudex	B-CHEMICAL
and	O
kilobase	O
DNA	O
fragmentation	O
may	O
correlate	O
with	O
the	O
reduction	O
of	O
p27	B-GENE-Y
(	I-GENE-Y
kip1	I-GENE-Y
)	I-GENE-Y
expression	O
and	O
the	O
increase	O
in	O
cyclin	B-GENE-Y
E	I-GENE-Y
and	O
cdk2	B-GENE-Y
kinase	B-GENE-N
activities	O
.	O

Activation	O
of	O
cyclin	B-GENE-Y
E	I-GENE-Y
and	O
cdk2	B-GENE-Y
kinases	B-GENE-N
allows	O
cells	O
to	O
transit	O
from	O
G1	O
to	O
S	O
phase	O
accompanied	O
by	O
the	O
inhibition	O
of	O
DNA	O
synthesis	O
.	O

The	O
changes	O
in	O
cell	O
cycle	O
regulatory	O
proteins	O
associated	O
with	O
growth	O
inhibition	O
and	O
DNA	O
damage	O
by	O
Tomudex	B-CHEMICAL
are	O
not	O
p53	B-GENE-Y
dependent	O
.	O

New	O
aspects	O
in	O
the	O
management	O
of	O
obesity	O
:	O
operation	O
and	O
the	O
impact	O
of	O
lipase	B-GENE-N
inhibitors	O
.	O

Obesity	O
is	O
an	O
increasing	O
health	O
problem	O
in	O
most	O
developed	O
countries	O
and	O
its	O
prevalence	O
is	O
also	O
increasing	O
in	O
developing	O
countries	O
.	O

There	O
has	O
been	O
no	O
great	O
success	O
with	O
dietary	O
means	O
and	O
life	O
style	O
modification	O
for	O
permanent	O
weight	O
loss	O
.	O

Various	O
surgical	O
treatment	O
methods	O
for	O
obesity	O
are	O
now	O
available	O
.	O

They	O
are	O
aimed	O
at	O
limiting	O
oral	O
energy	O
intake	O
with	O
or	O
without	O
causing	O
dumping	O
or	O
inducing	O
selective	O
maldigestion	O
and	O
malabsorption	O
.	O

Based	O
on	O
current	O
literature	O
,	O
up	O
to	O
75	O
%	O
of	O
excess	O
weight	O
is	O
lost	O
by	O
surgical	O
treatment	O
with	O
concomitant	O
disappearance	O
of	O
hyperlipidaemias	O
,	O
type	O
2	O
diabetes	O
,	O
hypertension	O
or	O
sleep	O
apnoea	O
.	O

The	O
main	O
indication	O
for	O
operative	O
treatment	O
is	O
morbid	O
obesity	O
(	O
body	O
mass	O
index	O
greater	O
than	O
40	O
kg	O
/	O
m2	O
)	O
or	O
severe	O
obesity	O
(	O
body	O
mass	O
index	O
>	O
35	O
kg	O
/	O
m2	O
)	O
with	O
comorbidities	O
of	O
obesity	O
.	O

Orlistat	B-CHEMICAL
is	O
a	O
new	O
inhibitor	O
of	O
pancreatic	B-GENE-Y
lipase	I-GENE-Y
enzyme	O
.	O

At	O
doses	O
of	O
120	O
mg	O
three	O
times	O
per	O
day	O
with	O
meals	O
it	O
results	O
in	O
a	O
30	O
%	O
reduction	O
in	O
dietary	O
fat	O
absorption	O
,	O
which	O
equals	O
approximately	O
200	O
kcal	O
daily	O
energy	O
deficit	O
.	O

In	O
the	O
long	O
term	O
,	O
orlistat	B-CHEMICAL
has	O
been	O
shown	O
to	O
be	O
more	O
effective	O
than	O
placebo	O
in	O
reducing	O
body	O
weight	O
and	O
serum	O
total	O
and	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
cholesterol	B-CHEMICAL
levels	O
.	O

Orlistat	B-CHEMICAL
has	O
a	O
lowering	O
effect	O
on	O
serum	O
cholesterol	B-CHEMICAL
independent	O
of	O
weight	O
loss	O
.	O

Along	O
with	O
weight	O
loss	O
,	O
orlistat	B-CHEMICAL
also	O
favourably	O
affects	O
blood	O
pressure	O
and	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-Y
levels	O
in	O
obese	O
individuals	O
and	O
in	O
obese	O
type	O
2	O
diabetic	O
patients	O
.	O

Cyclopentenone	B-CHEMICAL
prostaglandins	I-CHEMICAL
suppress	O
activation	O
of	O
microglia	O
:	O
down	O
-	O
regulation	O
of	O
inducible	B-GENE-Y
nitric	I-GENE-Y
-	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
by	O
15	B-CHEMICAL
-	I-CHEMICAL
deoxy	I-CHEMICAL
-	I-CHEMICAL
Delta12	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
prostaglandin	I-CHEMICAL
J2	I-CHEMICAL
.	O

Mechanisms	O
leading	O
to	O
down	O
-	O
regulation	O
of	O
activated	O
microglia	O
and	O
astrocytes	O
are	O
poorly	O
understood	O
,	O
in	O
spite	O
of	O
the	O
potentially	O
detrimental	O
role	O
of	O
activated	O
glia	O
in	O
neurodegeneration	O
.	O

Prostaglandins	B-CHEMICAL
,	O
produced	O
both	O
by	O
neurons	O
and	O
glia	O
,	O
may	O
serve	O
as	O
mediators	O
of	O
glial	O
and	O
neuronal	O
functions	O
.	O

We	O
examined	O
the	O
influence	O
of	O
cyclopentenone	B-CHEMICAL
prostaglandins	I-CHEMICAL
and	O
their	O
precursors	O
on	O
activated	O
glia	O
.	O

As	O
models	O
of	O
glial	O
activation	O
,	O
production	O
of	O
inducible	B-GENE-Y
nitric	I-GENE-Y
-	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
was	O
studied	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
rat	O
microglia	O
,	O
a	O
murine	O
microglial	O
cell	O
line	O
BV	O
-	O
2	O
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
1beta	I-GENE-Y
-	O
stimulated	O
rat	O
astrocytes	O
.	O

Cyclopentenone	B-CHEMICAL
prostaglandins	I-CHEMICAL
were	O
potent	O
inhibitors	O
of	O
iNOS	B-GENE-Y
induction	O
and	O
were	O
more	O
effective	O
than	O
their	O
precursors	O
,	O
prostaglandins	B-CHEMICAL
E2	I-CHEMICAL
and	I-CHEMICAL
D2	I-CHEMICAL
.	O

15	B-CHEMICAL
-	I-CHEMICAL
Deoxy	I-CHEMICAL
-	I-CHEMICAL
Delta12	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
prostaglandin	I-CHEMICAL
J2	I-CHEMICAL
(	O
15d	B-CHEMICAL
-	I-CHEMICAL
PGJ2	I-CHEMICAL
)	O
was	O
the	O
most	O
potent	O
prostaglandin	B-CHEMICAL
among	O
those	O
tested	O
.	O

In	O
activated	O
microglia	O
,	O
15d	B-CHEMICAL
-	I-CHEMICAL
PGJ2	I-CHEMICAL
suppressed	O
iNOS	B-GENE-N
promoter	I-GENE-N
activity	O
,	O
iNOS	B-GENE-Y
mRNA	O
,	O
and	O
protein	O
levels	O
.	O

The	O
action	O
of	O
15d	B-CHEMICAL
-	I-CHEMICAL
PGJ2	I-CHEMICAL
does	O
not	O
appear	O
to	O
involve	O
its	O
nuclear	O
receptor	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
PPARgamma	B-GENE-Y
)	O
because	O
troglitazone	B-CHEMICAL
,	O
a	O
specific	O
ligand	O
of	O
PPARgamma	B-GENE-Y
,	O
was	O
unable	O
to	O
inhibit	O
iNOS	B-GENE-Y
induction	O
,	O
and	O
neither	O
troglitazone	B-CHEMICAL
nor	O
15d	B-CHEMICAL
-	I-CHEMICAL
PGJ2	I-CHEMICAL
could	O
stimulate	O
the	O
activity	O
of	O
a	O
PPAR	B-GENE-N
-	O
dependent	O
promoter	O
in	O
the	O
absence	O
of	O
cotransfected	O
PPARgamma	B-GENE-Y
.	O

15d	B-CHEMICAL
-	I-CHEMICAL
PGJ2	I-CHEMICAL
did	O
not	O
block	O
nuclear	O
translocation	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NFkappaB	B-GENE-N
,	O
but	O
it	O
did	O
inhibit	O
the	O
activity	O
of	O
an	O
NFkappaB	B-GENE-N
reporter	O
construct	O
,	O
suggesting	O
that	O
the	O
mechanism	O
of	O
suppression	O
of	O
microglial	O
iNOS	B-GENE-Y
by	O
15d	B-CHEMICAL
-	I-CHEMICAL
PGJ2	I-CHEMICAL
may	O
involve	O
interference	O
with	O
NFkappaB	B-GENE-N
transcriptional	O
activity	O
in	O
the	O
nucleus	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
novel	O
pathway	O
mediated	O
by	O
cyclopentenone	B-CHEMICAL
prostaglandins	I-CHEMICAL
,	O
which	O
may	O
represent	O
part	O
of	O
a	O
feedback	O
mechanism	O
leading	O
to	O
the	O
cessation	O
of	O
inflammatory	O
glial	O
responses	O
in	O
the	O
brain	O
.	O

Phospholipase	B-GENE-Y
A2	I-GENE-Y
inhibitors	O
p	B-CHEMICAL
-	I-CHEMICAL
bromophenacyl	I-CHEMICAL
bromide	I-CHEMICAL
and	O
arachidonyl	B-CHEMICAL
trifluoromethyl	I-CHEMICAL
ketone	I-CHEMICAL
suppressed	O
interleukin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
expression	O
in	O
murine	O
primary	O
splenocytes	O
.	O

Phospholipase	B-GENE-Y
A2	I-GENE-Y
(	O
PLA2	B-GENE-Y
)	O
has	O
been	O
postulated	O
to	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
cytokine	B-GENE-N
expression	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
PLA2	B-GENE-Y
inhibitors	O
p	B-CHEMICAL
-	I-CHEMICAL
bromophenacyl	I-CHEMICAL
bromide	I-CHEMICAL
(	O
BPB	B-CHEMICAL
)	O
and	O
arachidonyl	B-CHEMICAL
trifluoromethyl	I-CHEMICAL
ketone	I-CHEMICAL
(	O
AACOCF3	B-CHEMICAL
)	O
on	O
interleukin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
expression	O
in	O
murine	O
primary	O
splenocytes	O
.	O

Pretreatment	O
of	O
the	O
splenocytes	O
with	O
both	O
BPB	B-CHEMICAL
and	O
AACOCF3	B-CHEMICAL
suppressed	O
phorbol	B-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
myristate	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
plus	O
ionomycin	O
-	O
induced	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
secretion	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Inhibition	O
>	O
90	O
%	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
secretion	O
was	O
observed	O
at	O
1	O
microM	O
BPB	B-CHEMICAL
and	O
10	O
microM	O
AACOCF3	B-CHEMICAL
compared	O
to	O
the	O
respective	O
vehicle	O
control	O
.	O

Likewise	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
steady	O
-	O
state	O
mRNA	O
expression	O
was	O
inhibited	O
by	O
both	O
PLA2	B-GENE-Y
inhibitors	O
in	O
a	O
concentration	O
-	O
dependent	O
fashion	O
with	O
>	O
90	O
%	O
inhibition	O
at	O
1	O
microM	O
BPB	B-CHEMICAL
and	O
20	O
microM	O
AACOCF3	B-CHEMICAL
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrated	O
that	O
PLA2	B-GENE-Y
inhibitors	O
BPB	B-CHEMICAL
and	O
AACOCF3	B-CHEMICAL
are	O
robust	O
inhibitors	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
murine	O
splenocytes	O
.	O

Moreover	O
,	O
these	O
findings	O
suggest	O
that	O
drugs	O
and	O
chemicals	O
which	O
inhibit	O
PLA2	B-GENE-Y
may	O
have	O
marked	O
effects	O
on	O
T	O
-	O
cell	O
function	O
.	O

Both	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1F	I-GENE-Y
receptors	O
modulate	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
expression	O
within	O
rat	O
trigeminal	O
nucleus	O
caudalis	O
.	O

A	O
possible	O
mechanism	O
of	O
action	O
of	O
antimigraine	O
drugs	O
such	O
as	O
sumatriptan	B-CHEMICAL
is	O
inhibition	O
of	O
the	O
trigeminovascular	O
pathway	O
.	O

Sumatriptan	O
'	O
s	O
effects	O
might	O
be	O
mediated	O
by	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT1F	I-GENE-Y
receptors	O
.	O

To	O
establish	O
the	O
relative	O
importance	O
of	O
these	O
subtypes	O
,	O
we	O
compared	O
the	O
effects	O
of	O
sumatriptan	B-CHEMICAL
with	O
those	O
of	O
a	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT1F	I-GENE-Y
receptor	O
agonist	O
(	O
LY	B-CHEMICAL
344864	I-CHEMICAL
)	O
on	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
protein	O
expression	O
in	O
the	O
trigeminal	O
nucleus	O
caudalis	O
.	O

c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
expression	O
was	O
induced	O
in	O
urethane	B-CHEMICAL
-	O
anaesthetized	O
rats	O
by	O
intracisternal	O
capsaicin	B-CHEMICAL
administration	O
.	O

Sumatriptan	B-CHEMICAL
and	O
LY	B-CHEMICAL
344864	I-CHEMICAL
decreased	O
the	O
number	O
of	O
capsaicin	B-CHEMICAL
-	O
induced	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
-	O
like	O
immunoreactive	O
cells	O
within	O
trigeminal	O
nucleus	O
caudalis	O
(	O
ID50	O
=	O
0	O
.	O
04	O
and	O
0	O
.	O
6	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
effect	O
of	O
sumatriptan	B-CHEMICAL
,	O
but	O
not	O
of	O
LY	B-CHEMICAL
344864	I-CHEMICAL
,	O
was	O
prevented	O
by	O
pretreatment	O
with	O
the	O
antagonist	O
SDZ	B-CHEMICAL
21	I-CHEMICAL
-	I-CHEMICAL
009	I-CHEMICAL
,	O
which	O
displays	O
high	O
affinity	O
for	O
rat	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
.	O

LY	B-CHEMICAL
344864	I-CHEMICAL
appears	O
to	O
attenuate	O
c	O
-	O
fos	O
-	O
like	O
immunoreactivity	O
via	O
5	B-GENE-Y
-	I-GENE-Y
HT1F	I-GENE-Y
receptors	O
,	O
while	O
sumatriptan	B-CHEMICAL
acts	O
via	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
.	O

The	O
fact	O
that	O
activation	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT1F	I-GENE-Y
receptors	O
is	O
sufficient	O
to	O
modulate	O
the	O
activity	O
of	O
the	O
trigeminal	O
system	O
suggests	O
that	O
this	O
receptor	O
may	O
be	O
a	O
target	O
for	O
antimigraine	O
drugs	O
with	O
improved	O
safety	O
profile	O
.	O

Inhibition	O
of	O
gelatinase	B-GENE-Y
A	I-GENE-Y
(	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
by	O
batimastat	B-CHEMICAL
and	O
captopril	B-CHEMICAL
reduces	O
tumor	O
growth	O
and	O
lung	O
metastases	O
in	O
mice	O
bearing	O
Lewis	O
lung	O
carcinoma	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
the	O
synthetic	O
matrix	B-GENE-N
metalloproteinase	I-GENE-N
inhibitor	O
,	O
batimastat	B-CHEMICAL
(	O
BB	B-CHEMICAL
-	I-CHEMICAL
94	I-CHEMICAL
)	O
and	O
the	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitor	O
,	O
captopril	B-CHEMICAL
,	O
on	O
metalloproteinase	B-GENE-N
activity	O
of	O
murine	O
Lewis	O
-	O
lung	O
-	O
carcinoma	O
cells	O
(	O
3LL	O
)	O
in	O
vitro	O
,	O
and	O
on	O
local	O
growth	O
and	O
lung	O
metastasis	O
of	O
the	O
same	O
tumor	O
implanted	O
intramuscularly	O
in	O
syngeneic	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
effect	O
of	O
BB	B-CHEMICAL
-	I-CHEMICAL
94	I-CHEMICAL
and	O
captopril	B-CHEMICAL
on	O
the	O
survival	O
of	O
the	O
3LL	O
-	O
tumor	O
-	O
bearing	O
mice	O
was	O
also	O
examined	O
.	O

Here	O
we	O
report	O
that	O
captopril	B-CHEMICAL
treatment	O
resulted	O
in	O
decreased	O
transcription	O
and	O
protein	O
levels	O
of	O
gelatinase	B-GENE-Y
A	I-GENE-Y
by	O
3LL	O
cells	O
.	O

Both	O
BB	B-CHEMICAL
-	I-CHEMICAL
94	I-CHEMICAL
and	O
captopril	O
also	O
prevented	O
substrate	O
degradation	O
by	O
gelatinase	B-GENE-N
A	I-GENE-N
and	I-GENE-N
B	I-GENE-N
released	O
in	O
conditioned	O
medium	O
by	O
cultured	O
cells	O
.	O

Treatment	O
of	O
tumor	O
-	O
bearing	O
animals	O
with	O
BB	B-CHEMICAL
-	I-CHEMICAL
94	I-CHEMICAL
(	O
i	O
.	O
p	O
.	O
)	O
or	O
captopril	B-CHEMICAL
(	O
in	O
drinking	O
water	O
)	O
resulted	O
in	O
significant	O
inhibition	O
of	O
the	O
mean	O
tumor	O
volume	O
(	O
25	O
and	O
33	O
%	O
respectively	O
)	O
and	O
of	O
the	O
mean	O
lung	O
metastasis	O
number	O
(	O
26	O
and	O
29	O
%	O
respectively	O
)	O
.	O

When	O
both	O
agents	O
were	O
given	O
,	O
they	O
acted	O
in	O
synergy	O
,	O
resulting	O
in	O
51	O
and	O
80	O
%	O
inhibition	O
of	O
tumor	O
growth	O
and	O
metastasis	O
.	O

The	O
survival	O
time	O
of	O
the	O
mice	O
treated	O
with	O
both	O
BB	B-CHEMICAL
-	I-CHEMICAL
94	I-CHEMICAL
and	O
captopril	B-CHEMICAL
was	O
also	O
significantly	O
longer	O
compared	O
with	O
the	O
groups	O
treated	O
with	O
each	O
agent	O
alone	O
or	O
with	O
the	O
vehicle	O
.	O

Our	O
data	O
support	O
the	O
hypothesis	O
of	O
an	O
essential	O
role	O
of	O
metalloproteinase	B-GENE-N
(	I-GENE-N
s	I-GENE-N
)	I-GENE-N
in	O
the	O
metastatic	O
process	O
.	O

Moreover	O
,	O
blockade	O
of	O
invasion	O
,	O
angiogenesis	O
and	O
other	O
processes	O
mediated	O
by	O
metalloproteinases	B-GENE-N
may	O
underlie	O
the	O
anti	O
-	O
tumor	O
and	O
anti	O
-	O
metastatic	O
effect	O
of	O
BB	B-CHEMICAL
-	I-CHEMICAL
94	I-CHEMICAL
and	O
captopril	B-CHEMICAL
and	O
their	O
combination	O
.	O

It	O
is	O
conceivable	O
that	O
this	O
combination	O
could	O
be	O
tested	O
in	O
selected	O
clinical	O
conditions	O
as	O
an	O
adjuvant	O
modality	O
to	O
cytotoxic	O
therapy	O
.	O

Comparison	O
of	O
inhibitory	O
effects	O
of	O
meloxicam	B-CHEMICAL
and	O
diclofenac	B-CHEMICAL
on	O
human	O
thromboxane	B-CHEMICAL
biosynthesis	O
after	O
single	O
doses	O
and	O
at	O
steady	O
state	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
extent	O
of	O
human	B-GENE-Y
cyclooxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
inhibition	O
by	O
meloxicam	B-CHEMICAL
,	O
which	O
has	O
been	O
reported	O
to	O
preferentially	O
inhibit	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

The	O
effects	O
of	O
meloxicam	B-CHEMICAL
were	O
compared	O
with	O
those	O
of	O
diclofenac	B-CHEMICAL
,	O
a	O
nonselective	O
COX	B-GENE-N
inhibitor	O
.	O

METHODS	O
:	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibition	O
was	O
determined	O
by	O
measuring	O
thromboxane	B-CHEMICAL
B2	I-CHEMICAL
(	O
TXB2	B-CHEMICAL
)	O
-	O
generation	O
from	O
clotting	O
whole	O
blood	O
ex	O
vivo	O
after	O
single	O
oral	O
doses	O
of	O
7	O
.	O
5	O
and	O
15	O
mg	O
meloxicam	B-CHEMICAL
and	O
75	O
mg	O
diclofenac	B-CHEMICAL
and	O
at	O
steady	O
state	O
(	O
15	O
mg	O
meloxicam	B-CHEMICAL
daily	O
and	O
150	O
mg	O
diclofenac	B-CHEMICAL
daily	O
)	O
.	O

The	O
effect	O
was	O
expressed	O
as	O
percentage	O
inhibition	O
of	O
serum	O
TXB2	B-CHEMICAL
generation	O
and	O
was	O
directly	O
related	O
to	O
the	O
serum	O
drug	O
concentration	O
with	O
use	O
of	O
a	O
standard	O
sigmoidal	O
E	O
(	O
max	O
)	O
model	O
.	O

RESULTS	O
:	O
In	O
terms	O
of	O
inhibition	O
of	O
TXB2	B-CHEMICAL
generation	O
,	O
diclofenac	B-CHEMICAL
was	O
about	O
1	O
order	O
of	O
magnitude	O
more	O
potent	O
than	O
meloxicam	B-CHEMICAL
,	O
indicated	O
by	O
a	O
diclofenac	B-CHEMICAL
EC50	O
(	O
concentration	O
of	O
drug	O
required	O
to	O
cause	O
50	O
%	O
of	O
maximum	O
effect	O
)	O
that	O
was	O
about	O
10	O
times	O
lower	O
than	O
that	O
of	O
meloxicam	B-CHEMICAL
(	O
EC50	O
diclofenac	B-CHEMICAL
single	O
doses	O
:	O
37	O
.	O
50	O
+	O
/	O
-	O
29	O
.	O
64	O
;	O
EC50	O
meloxicam	B-CHEMICAL
single	O
doses	O
:	O
677	O
.	O
50	O
+	O
/	O
-	O
189	O
.	O
08	O
)	O
.	O

However	O
,	O
serum	O
concentrations	O
of	O
meloxicam	B-CHEMICAL
after	O
administration	O
of	O
15	O
mg	O
were	O
approximately	O
10	O
-	O
fold	O
higher	O
than	O
those	O
of	O
diclofenac	B-CHEMICAL
.	O

Therefore	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
area	O
under	O
the	O
effect	O
time	O
curve	O
(	O
P	O
=	O
.	O
115	O
)	O
and	O
the	O
mean	O
effect	O
(	O
P	O
=	O
.	O
424	O
)	O
between	O
meloxicam	B-CHEMICAL
and	O
diclofenac	B-CHEMICAL
.	O

The	O
EC50	O
of	O
both	O
drugs	O
was	O
significantly	O
higher	O
at	O
steady	O
state	O
(	O
diclofenac	B-CHEMICAL
steady	O
state	O
:	O
87	O
.	O
07	O
+	O
/	O
-	O
55	O
.	O
24	O
ng	O
/	O
mL	O
;	O
meloxicam	B-CHEMICAL
steady	O
state	O
:	O
1850	O
.	O
12	O
+	O
/	O
-	O
829	O
.	O
93	O
ng	O
/	O
mL	O
)	O
than	O
after	O
a	O
single	O
dose	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
show	O
that	O
meloxicam	B-CHEMICAL
inhibits	O
TXB2	B-CHEMICAL
generation	O
at	O
clinically	O
relevant	O
doses	O
,	O
although	O
less	O
potently	O
than	O
diclofenac	B-CHEMICAL
.	O

Thus	O
our	O
data	O
suggest	O
that	O
the	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
preference	O
of	O
meloxicam	B-CHEMICAL
observed	O
in	O
vitro	O
may	O
not	O
result	O
in	O
clinical	O
advantages	O
when	O
the	O
higher	O
dose	O
of	O
15	O
mg	O
is	O
needed	O
.	O

Because	O
of	O
the	O
increase	O
in	O
EC50	O
at	O
steady	O
state	O
,	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
relatively	O
spared	O
when	O
the	O
lower	O
dose	O
of	O
7	O
.	O
5	O
mg	O
is	O
administered	O
.	O

Cloning	O
and	O
characterization	O
of	O
a	O
novel	O
human	B-GENE-N
phosphodiesterase	I-GENE-N
that	O
hydrolyzes	O
both	O
cAMP	B-CHEMICAL
and	O
cGMP	B-CHEMICAL
(	O
PDE10A	B-GENE-Y
)	O
.	O

cDNA	O
encoding	O
a	O
novel	O
phosphodiesterase	B-GENE-N
(	O
PDE	B-GENE-N
)	O
was	O
isolated	O
from	O
a	O
human	O
fetal	O
lung	O
cDNA	O
library	O
and	O
designated	O
PDE10A	B-GENE-Y
.	O

The	O
deduced	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
contains	O
779	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
including	O
a	O
putative	O
cGMP	B-GENE-N
binding	I-GENE-N
sequence	I-GENE-N
in	O
the	O
amino	B-CHEMICAL
-	O
terminal	O
portion	O
of	O
the	O
molecule	O
and	O
a	O
catalytic	O
domain	O
that	O
is	O
16	O
-	O
47	O
%	O
identical	O
in	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
to	O
those	O
of	O
other	O
PDE	B-GENE-N
families	O
.	O

Recombinant	O
PDE10A	B-GENE-Y
transfected	O
and	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
hydrolyzed	O
cAMP	B-CHEMICAL
and	O
cGMP	B-CHEMICAL
with	O
Km	O
values	O
of	O
0	O
.	O
26	O
and	O
7	O
.	O
2	O
microM	O
,	O
respectively	O
,	O
and	O
Vmax	O
with	O
cGMP	B-CHEMICAL
was	O
almost	O
twice	O
that	O
with	O
cAMP	B-CHEMICAL
.	O

Of	O
the	O
PDE	B-GENE-N
inhibitors	O
tested	O
,	O
dipyridamole	B-CHEMICAL
was	O
most	O
effective	O
,	O
with	O
IC50	O
values	O
of	O
1	O
.	O
2	O
and	O
0	O
.	O
45	O
microM	O
for	O
inhibition	O
of	O
cAMP	B-CHEMICAL
and	O
cGMP	B-CHEMICAL
hydrolysis	O
,	O
respectively	O
.	O

cGMP	B-CHEMICAL
inhibited	O
hydrolysis	O
of	O
cAMP	B-CHEMICAL
,	O
and	O
cAMP	B-CHEMICAL
inhibited	O
cGMP	B-CHEMICAL
hydrolysis	O
with	O
IC50	O
values	O
of	O
14	O
and	O
0	O
.	O
39	O
microM	O
,	O
respectively	O
.	O

Thus	O
,	O
PDE10A	B-GENE-Y
exhibited	O
properties	O
of	O
a	O
cAMP	B-GENE-N
PDE	I-GENE-N
and	O
a	O
cAMP	B-GENE-N
-	I-GENE-N
inhibited	I-GENE-N
cGMP	I-GENE-N
PDE	I-GENE-N
.	O

PDE10A	B-GENE-Y
transcripts	O
were	O
particularly	O
abundant	O
in	O
the	O
putamen	O
and	O
caudate	O
nucleus	O
regions	O
of	O
brain	O
and	O
in	O
thyroid	O
and	O
testis	O
,	O
and	O
in	O
much	O
lower	O
amounts	O
in	O
other	O
tissues	O
.	O

The	O
PDE10A	B-GENE-Y
gene	O
was	O
located	O
on	O
chromosome	O
6q26	O
by	O
fluorescent	O
in	O
situ	O
hybridization	O
analysis	O
.	O

PDE10A	B-GENE-Y
represents	O
a	O
new	O
member	O
of	O
the	O
PDE	B-GENE-N
superfamily	O
,	O
exhibiting	O
unique	O
kinetic	O
properties	O
and	O
inhibitor	O
sensitivity	O
.	O

Tryptophan	B-GENE-Y
hydroxylase	I-GENE-Y
mRNA	O
levels	O
are	O
elevated	O
by	O
repeated	O
immobilization	O
stress	O
in	O
rat	O
raphe	O
nuclei	O
but	O
not	O
in	O
pineal	O
gland	O
.	O

Repeated	O
stress	O
triggers	O
a	O
wide	O
range	O
of	O
adaptive	O
changes	O
in	O
the	O
central	O
nervous	O
system	O
including	O
the	O
elevation	O
of	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
metabolism	O
and	O
an	O
increased	O
susceptibility	O
to	O
affective	O
disorders	O
.	O

To	O
begin	O
to	O
examine	O
whether	O
these	O
changes	O
are	O
mediated	O
by	O
alterations	O
in	O
gene	O
expression	O
for	O
tryptophan	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
TPH	B-GENE-Y
)	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
biosynthesis	O
,	O
we	O
quantitated	O
its	O
mRNA	O
levels	O
by	O
competitive	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

Repeated	O
immobilization	O
stress	O
(	O
2	O
h	O
,	O
7	O
days	O
)	O
elicited	O
a	O
six	O
-	O
or	O
ten	O
-	O
fold	O
rise	O
in	O
TPH	B-GENE-Y
mRNA	O
in	O
median	O
raphe	O
nucleus	O
(	O
MRN	O
)	O
and	O
dorsal	O
raphe	O
nucleus	O
(	O
DRN	O
)	O
,	O
respectively	O
,	O
without	O
significantly	O
altering	O
TPH	B-GENE-Y
mRNA	O
levels	O
in	O
the	O
pineal	O
gland	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
change	O
in	O
mRNA	O
levels	O
for	O
GTP	B-GENE-Y
cyclohydrolase	I-GENE-Y
I	I-GENE-Y
(	O
GTPCH	B-GENE-Y
)	O
,	O
the	O
rate	O
limiting	O
enzyme	O
in	O
synthesis	O
of	O
the	O
tetrahydrobiopterin	B-CHEMICAL
(	O
BH4	B-CHEMICAL
)	O
,	O
the	O
obligate	O
cofactor	O
for	O
TPH	B-GENE-Y
.	O

This	O
is	O
the	O
first	O
study	O
to	O
reveal	O
stress	O
-	O
elicited	O
activation	O
of	O
TPH	B-GENE-Y
gene	O
expression	O
.	O

Altered	O
vasoreactivity	O
to	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
in	O
experimental	O
diabetic	O
neuropathy	O
:	O
role	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
.	O

We	O
evaluated	O
the	O
effects	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
and	O
an	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitor	O
(	O
cilazapril	B-CHEMICAL
)	O
on	O
nerve	O
blood	O
flow	O
(	O
NBF	O
)	O
and	O
electrophysiology	O
in	O
control	O
and	O
diabetic	O
rats	O
.	O

When	O
applied	O
locally	O
to	O
the	O
sciatic	O
nerve	O
,	O
the	O
dose	O
-	O
response	O
curve	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
was	O
more	O
potent	O
in	O
experimental	O
diabetic	O
neuropathy	O
(	O
EDN	O
)	O
than	O
control	O
rats	O
.	O

No	O
difference	O
existed	O
in	O
plasma	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
levels	O
between	O
EDN	O
and	O
controls	O
.	O

The	O
rats	O
were	O
given	O
typical	O
rat	O
pellets	O
or	O
pellets	O
treated	O
with	O
10	O
mg	O
/	O
kg	O
per	O
day	O
cilazapril	B-CHEMICAL
for	O
4	O
weeks	O
.	O

Diabetes	O
caused	O
a	O
significant	O
reduction	O
in	O
NBF	O
,	O
nerve	O
conduction	O
velocity	O
,	O
and	O
compound	O
muscle	O
action	O
potential	O
(	O
CMAP	O
)	O
amplitudes	O
.	O

NBF	O
was	O
significantly	O
increased	O
in	O
diabetic	O
rats	O
supplemented	O
with	O
cilazapril	B-CHEMICAL
diet	O
,	O
and	O
nerve	O
conduction	O
velocity	O
and	O
amplitudes	O
of	O
the	O
CMAP	O
were	O
also	O
improved	O
after	O
4	O
weeks	O
on	O
this	O
diet	O
.	O

Direct	O
application	O
10	O
(	O
-	O
3	O
)	O
mol	O
/	O
L	O
cilazapril	B-CHEMICAL
on	O
sciatic	O
nerve	O
did	O
not	O
increase	O
NBF	O
in	O
normal	O
and	O
EDN	O
rats	O
.	O

We	O
topically	O
applied	O
the	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
(	O
NOS	B-GENE-N
)	O
inhibitor	O
,	O
NG	B-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
,	O
on	O
sciatic	O
nerve	O
and	O
observed	O
reduced	O
inhibition	O
of	O
NBF	O
in	O
EDN	O
,	O
which	O
was	O
correctable	O
with	O
a	O
cilazapril	B-CHEMICAL
diet	O
.	O

These	O
results	O
suggest	O
that	O
diabetic	O
neuropathy	O
may	O
have	O
an	O
increasing	O
vasopressor	O
action	O
with	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
and	O
this	O
is	O
likely	O
to	O
be	O
the	O
mechanism	O
of	O
NOS	B-GENE-N
inhibition	O
.	O

Angiotensin	B-GENE-Y
II	I-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitors	O
may	O
have	O
potential	O
in	O
the	O
treatment	O
of	O
diabetic	O
neuropathy	O
.	O

Analysis	O
of	O
alpha	B-GENE-N
1L	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
pharmacology	O
in	O
rat	O
small	O
mesenteric	O
artery	O
.	O

1	O
.	O

To	O
illuminate	O
the	O
controversy	O
on	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	O
or	O
alpha	B-GENE-N
1L	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
involvement	O
in	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
small	O
mesenteric	O
artery	O
(	O
SMA	O
)	O
,	O
we	O
have	O
studied	O
the	O
effects	O
of	O
subtype	O
-	O
selective	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
and	O
antagonists	O
under	O
different	O
experimental	O
conditions	O
.	O

2	O
.	O

The	O
agonist	O
potency	O
order	O
in	O
rat	O
SMA	O
was	O
:	O
A61603	B-CHEMICAL
>	O
>	O
SKF89748	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
>	O
cirazoline	B-CHEMICAL
>	O
noradrenaline	B-CHEMICAL
>	O
ST	B-CHEMICAL
-	I-CHEMICAL
587	I-CHEMICAL
>	O
methoxamine	B-CHEMICAL
.	O

Prazosin	B-CHEMICAL
antagonized	O
all	O
agonists	O
with	O
a	O
low	O
potency	O
(	O
pA2	O
:	O
8	O
.	O
29	O
-	O
8	O
.	O
80	O
)	O
indicating	O
the	O
involvement	O
of	O
alpha	B-GENE-N
1L	I-GENE-N
-	O
rather	O
than	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

3	O
.	O

The	O
putative	O
alpha	B-GENE-N
1L	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
JTH	B-CHEMICAL
-	I-CHEMICAL
601	I-CHEMICAL
,	O
but	O
not	O
the	O
alpha	B-GENE-Y
1B	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
chloroethylclonidine	B-CHEMICAL
(	O
10	O
microM	O
)	O
antagonized	O
noradrenaline	B-CHEMICAL
-	O
induced	O
contractions	O
of	O
SMA	O
.	O

The	O
potency	O
of	O
the	O
selective	O
alpha	B-GENE-Y
1D	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
BMY	B-CHEMICAL
7378	I-CHEMICAL
against	O
noradrenaline	B-CHEMICAL
(	O
pA2	O
=	O
6	O
.	O
16	O
+	O
/	O
-	O
0	O
.	O
13	O
)	O
and	O
of	O
the	O
selective	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
RS	B-CHEMICAL
-	I-CHEMICAL
17053	I-CHEMICAL
against	O
noradrenaline	B-CHEMICAL
(	O
pKB	O
=	O
8	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
10	O
)	O
and	O
against	O
the	O
selective	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
A	B-CHEMICAL
-	I-CHEMICAL
61603	I-CHEMICAL
(	O
pKB	O
=	O
8	O
.	O
40	O
+	O
/	O
-	O
0	O
.	O
09	O
)	O
were	O
too	O
low	O
to	O
account	O
for	O
alpha	B-GENE-Y
1D	I-GENE-Y
-	O
and	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
involvement	O
.	O

4	O
.	O

The	O
potency	O
of	O
RS	B-CHEMICAL
-	I-CHEMICAL
17053	I-CHEMICAL
(	O
pKB	O
/	O
pA2	O
'	O
s	O
=	O
7	O
.	O
72	O
-	O
8	O
.	O
46	O
)	O
was	O
not	O
affected	O
by	O
lowering	O
temperature	O
,	O
changing	O
experimental	O
protocol	O
or	O
inducing	O
myogenic	O
tone	O
via	O
KCl	B-CHEMICAL
or	O
U46619	B-CHEMICAL
.	O

5	O
.	O

Selective	O
protection	O
of	O
a	O
putative	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
population	O
against	O
the	O
irreversible	O
action	O
of	O
phenoxybenzamine	B-CHEMICAL
also	O
failed	O
to	O
increase	O
the	O
potency	O
of	O
RS	B-CHEMICAL
-	I-CHEMICAL
17053	I-CHEMICAL
(	O
pA2	O
=	O
8	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
06	O
against	O
A61603	O
)	O
.	O

6	O
.	O

Combined	O
concentration	O
-	O
ratio	O
analysis	O
demonstrated	O
that	O
tamsulosin	B-CHEMICAL
,	O
which	O
does	O
not	O
discriminate	O
between	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	O
and	O
alpha	B-GENE-N
1L	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
and	O
RS	B-CHEMICAL
-	I-CHEMICAL
17053	I-CHEMICAL
competed	O
for	O
binding	O
at	O
the	O
same	O
site	O
in	O
the	O
SMA	O
.	O

7	O
.	O

In	O
summary	O
,	O
data	O
obtained	O
in	O
our	O
experiments	O
in	O
rat	O
SMA	O
indicate	O
that	O
the	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
mediating	O
noradrenaline	B-CHEMICAL
-	O
induced	O
contraction	O
displays	O
a	O
distinct	O
alpha	B-GENE-N
1L	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
pharmacology	O
.	O

This	O
study	O
does	O
not	O
provide	O
evidence	O
for	O
the	O
hypothesis	O
that	O
alpha	B-GENE-N
1L	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
represent	O
an	O
affinity	O
state	O
of	O
the	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
in	O
functional	O
assays	O
.	O

Furthermore	O
,	O
there	O
is	O
no	O
co	O
-	O
existing	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
in	O
the	O
SMA	O
.	O

Success	O
of	O
pyridostigmine	B-CHEMICAL
,	O
physostigmine	B-CHEMICAL
,	O
eptastigmine	B-CHEMICAL
and	O
phosphotriesterase	B-GENE-N
treatments	O
in	O
acute	O
sarin	B-CHEMICAL
intoxication	O
.	O

The	O
acute	O
toxicity	O
of	O
organophosphorus	B-CHEMICAL
(	O
OP	O
)	O
compounds	O
in	O
mammals	O
is	O
due	O
to	O
their	O
irreversible	O
inhibition	O
of	O
acetylcholinesterase	B-GENE-N
(	O
AChE	B-GENE-N
)	O
in	O
the	O
nervous	O
system	O
,	O
which	O
leads	O
to	O
increased	O
synaptic	O
acetylcholine	B-CHEMICAL
levels	O
.	O

The	O
protective	O
actions	O
of	O
intravenously	O
(	O
i	O
.	O
v	O
.	O
)	O
administered	O
pyridostigmine	B-CHEMICAL
,	O
physostigmine	B-CHEMICAL
,	O
eptastigmine	B-CHEMICAL
,	O
and	O
an	O
organophosphate	B-GENE-N
hydrolase	I-GENE-N
,	O
phosphotriesterase	B-GENE-N
,	O
in	O
acute	O
sarin	B-CHEMICAL
intoxication	O
were	O
studied	O
in	O
mice	O
.	O

The	O
acute	O
intragastric	O
(	O
i	O
.	O
g	O
.	O
)	O
toxicity	O
(	O
LD50	O
)	O
of	O
sarin	B-CHEMICAL
with	O
and	O
without	O
the	O
pretreatments	O
was	O
tested	O
by	O
the	O
up	O
-	O
and	O
-	O
down	O
method	O
.	O

The	O
mice	O
received	O
pyridostigmine	B-CHEMICAL
(	O
0	O
.	O
06	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
,	O
physostigmine	B-CHEMICAL
(	O
0	O
.	O
09	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
,	O
the	O
physostigmine	B-CHEMICAL
derivative	O
eptastigmine	B-CHEMICAL
(	O
0	O
.	O
90	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
or	O
phosphotriesterase	B-GENE-N
(	O
104	O
U	O
/	O
g	O
,	O
10	O
.	O
7	O
microg	O
/	O
g	O
body	O
weight	O
)	O
10	O
min	O
prior	O
to	O
the	O
i	O
.	O
g	O
.	O
administration	O
of	O
sarin	B-CHEMICAL
.	O

Physostigmine	B-CHEMICAL
was	O
also	O
administered	O
with	O
phosphotriesterase	B-GENE-N
.	O

Phosphotriesterase	B-GENE-N
was	O
the	O
most	O
effective	O
antidote	O
in	O
sarin	B-CHEMICAL
intoxication	O
.	O

The	O
LD50	O
value	O
for	O
sarin	B-CHEMICAL
increased	O
3	O
.	O
4	O
-	O
fold	O
in	O
mice	O
receiving	O
phosphotriesterase	B-GENE-N
.	O

Physostigmine	B-CHEMICAL
was	O
the	O
most	O
effective	O
carbamate	B-CHEMICAL
in	O
sarin	B-CHEMICAL
exposure	O
.	O

The	O
protective	O
ratios	O
of	O
physostigmine	B-CHEMICAL
and	O
pyridostigmine	B-CHEMICAL
were	O
1	O
.	O
5	O
-	O
and	O
1	O
.	O
2	O
-	O
1	O
.	O
3	O
-	O
fold	O
,	O
respectively	O
.	O

Eptastigmine	B-CHEMICAL
did	O
not	O
give	O
any	O
protection	O
against	O
sarin	B-CHEMICAL
toxicity	O
.	O

Both	O
the	O
phosphotriesterase	B-GENE-N
and	O
physostigmine	B-CHEMICAL
treatments	O
protected	O
the	O
brain	O
AChE	B-GENE-Y
activities	O
measured	O
24	O
h	O
after	O
sarin	B-CHEMICAL
exposure	O
.	O

In	O
phosphotriesterase	B-GENE-N
and	O
physostigmine	B-CHEMICAL
-	O
treated	O
mice	O
,	O
a	O
4	O
-	O
and	O
2	O
-	O
fold	O
higher	O
sarin	B-CHEMICAL
dose	O
,	O
respectively	O
,	O
was	O
needed	O
to	O
cause	O
a	O
50	O
%	O
inhibition	O
of	O
brain	O
AChE	B-GENE-Y
activity	O
.	O

Moreover	O
,	O
the	O
combination	O
of	O
phosphotriesterase	B-GENE-N
-	O
physostigmine	B-CHEMICAL
increased	O
the	O
LD50	O
value	O
for	O
sarin	B-CHEMICAL
4	O
.	O
3	O
-	O
fold	O
.	O

The	O
animals	O
pretreated	O
with	O
phosphotriesterase	B-GENE-N
-	O
ephysostigmine	B-CHEMICAL
tolerated	O
four	O
times	O
the	O
lethal	O
dose	O
in	O
control	O
animals	O
,	O
furthermore	O
their	O
survival	O
time	O
was	O
2	O
-	O
3	O
h	O
in	O
comparison	O
to	O
20	O
min	O
in	O
controls	O
.	O

In	O
conclusion	O
,	O
phosphotriesterase	B-GENE-N
and	O
physostigmine	B-CHEMICAL
were	O
the	O
most	O
effective	O
treatments	O
against	O
sarin	B-CHEMICAL
intoxication	O
.	O

However	O
,	O
eptastigmine	B-CHEMICAL
did	O
not	O
provide	O
any	O
protection	O
against	O
sarin	B-CHEMICAL
toxicity	O
.	O

Torasemide	B-CHEMICAL
inhibits	O
angiotensin	B-GENE-Y
II	I-GENE-Y
-	O
induced	O
vasoconstriction	O
and	O
intracellular	O
calcium	B-CHEMICAL
increase	O
in	O
the	O
aorta	O
of	O
spontaneously	O
hypertensive	O
rats	O
.	O

Torasemide	B-CHEMICAL
is	O
a	O
loop	O
diuretic	O
that	O
is	O
effective	O
at	O
low	O
once	O
-	O
daily	O
doses	O
in	O
the	O
treatment	O
of	O
arterial	O
hypertension	O
.	O

Because	O
its	O
antihypertensive	O
mechanism	O
of	O
action	O
may	O
not	O
be	O
based	O
entirely	O
on	O
the	O
elimination	O
of	O
salt	O
and	O
water	O
from	O
the	O
body	O
,	O
a	O
vasodilator	O
effect	O
of	O
this	O
drug	O
can	O
be	O
considered	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
ability	O
of	O
different	O
concentrations	O
of	O
torasemide	B-CHEMICAL
to	O
modify	O
angiotensin	B-GENE-Y
II	I-GENE-Y
(	O
Ang	B-GENE-Y
II	I-GENE-Y
)	O
-	O
induced	O
vascular	O
responses	O
was	O
examined	O
,	O
with	O
the	O
use	O
of	O
an	O
organ	O
bath	O
system	O
,	O
in	O
endothelium	O
-	O
denuded	O
aortic	O
rings	O
from	O
spontaneously	O
hypertensive	O
rats	O
.	O

Ang	B-GENE-Y
II	I-GENE-Y
-	O
induced	O
increases	O
of	O
intracellular	O
free	O
calcium	B-CHEMICAL
concentration	O
(	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
)	O
were	O
also	O
examined	O
by	O
image	O
analysis	O
in	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
from	O
spontaneously	O
hypertensive	O
rats	O
.	O

A	O
dose	O
-	O
response	O
curve	O
to	O
Ang	B-GENE-Y
II	I-GENE-Y
was	O
plotted	O
for	O
cumulative	O
concentrations	O
(	O
from	O
10	O
(	O
-	O
9	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
)	O
in	O
endothelium	O
-	O
denuded	O
aortic	O
rings	O
(	O
pD	O
(	O
2	O
)	O
=	O
7	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
3	O
)	O
.	O

Isometric	O
contraction	O
induced	O
by	O
a	O
submaximal	O
concentration	O
of	O
Ang	B-GENE-Y
II	I-GENE-Y
(	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
was	O
reduced	O
in	O
a	O
dose	O
-	O
dependent	O
way	O
by	O
torasemide	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
04	O
micromol	O
/	O
L	O
)	O
.	O

Incubation	O
of	O
VSMCs	O
with	O
different	O
concentrations	O
of	O
Ang	B-GENE-Y
II	I-GENE-Y
(	O
from	O
10	O
(	O
-	O
10	O
)	O
to	O
10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
)	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
rise	O
of	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
(	O
pD	O
(	O
2	O
)	O
=	O
7	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
3	O
)	O
.	O

The	O
stimulatory	O
effect	O
of	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
induced	O
by	O
a	O
submaximal	O
concentration	O
of	O
Ang	B-GENE-Y
II	I-GENE-Y
(	O
10	O
(	O
-	O
7	O
)	O
mol	O
/	O
L	O
)	O
was	O
blocked	O
by	O
torasemide	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
3	O
nmol	O
/	O
L	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
torasemide	B-CHEMICAL
blocks	O
the	O
vasoconstrictor	O
action	O
of	O
Ang	B-GENE-Y
II	I-GENE-Y
in	O
vitro	O
.	O

This	O
action	O
can	O
be	O
related	O
to	O
the	O
ability	O
of	O
torasemide	B-CHEMICAL
to	O
block	O
the	O
increase	O
of	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
induced	O
by	O
Ang	B-GENE-Y
II	I-GENE-Y
in	O
VSMCs	O
.	O

It	O
is	O
proposed	O
that	O
these	O
actions	O
might	O
be	O
involved	O
in	O
the	O
antihypertensive	O
effect	O
of	O
torasemide	B-CHEMICAL
observed	O
in	O
vivo	O
.	O

Tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
binds	O
tetrahydrobiopterin	B-CHEMICAL
cofactor	O
with	O
negative	O
cooperativity	O
,	O
as	O
shown	O
by	O
kinetic	O
analyses	O
and	O
surface	O
plasmon	O
resonance	O
detection	O
.	O

Kinetic	O
studies	O
of	O
tetrameric	O
recombinant	O
human	B-GENE-Y
tyrosine	I-GENE-Y
hydroxylase	I-GENE-Y
isoform	I-GENE-Y
1	I-GENE-Y
(	O
hTH1	B-GENE-Y
)	O
have	O
revealed	O
properties	O
so	O
far	O
not	O
reported	O
for	O
this	O
enzyme	O
.	O

Firstly	O
,	O
with	O
the	O
natural	O
cofactor	O
(	B-CHEMICAL
6R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Lerythro	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydrobiopterin	I-CHEMICAL
(	O
H4biopterin	B-CHEMICAL
)	O
a	O
time	O
-	O
dependent	O
change	O
(	O
burst	O
)	O
in	O
enzyme	O
activity	O
was	O
observed	O
,	O
with	O
a	O
half	O
-	O
time	O
of	O
about	O
20	O
s	O
for	O
the	O
kinetic	O
transient	O
.	O

Secondly	O
,	O
nonhyperbolic	O
saturation	O
behaviour	O
was	O
found	O
for	O
H4biopterin	B-CHEMICAL
with	O
a	O
pronounced	O
negative	O
cooperativity	O
(	O
0	O
.	O
39	O
<	O
h	O
<	O
0	O
.	O
58	O
;	O
[	O
S	O
]	O
0	O
.	O
5	O
=	O
24	O
+	O
/	O
-	O
4	O
microM	O
)	O
.	O

On	O
phosphorylation	O
of	O
Ser40	B-CHEMICAL
by	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
,	O
the	O
affinity	O
for	O
H4biopterin	B-CHEMICAL
increased	O
(	O
[	O
S	O
]	O
0	O
.	O
5	O
=	O
11	O
+	O
/	O
-	O
2	O
microM	O
)	O
and	O
the	O
negative	O
cooperativity	O
was	O
amplified	O
(	O
h	O
=	O
0	O
.	O
27	O
+	O
/	O
-	O
0	O
.	O
03	O
)	O
.	O

The	O
dimeric	O
C	B-CHEMICAL
-	O
terminal	O
deletion	O
mutant	O
(	O
Delta473	O
-	O
528	O
)	O
of	O
hTH1	B-GENE-Y
also	O
showed	O
negative	O
cooperativity	O
of	O
H4biopterin	B-CHEMICAL
binding	O
(	O
h	O
=	O
0	O
.	O
4	O
)	O
.	O

Cooperativity	O
was	O
not	O
observed	O
with	O
the	O
cofactor	O
analogues	O
6	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydropterin	I-CHEMICAL
(	O
h	O
=	O
0	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
1	O
;	O
Km	O
=	O
62	O
.	O
7	O
+	O
/	O
-	O
5	O
.	O
7	O
microM	O
)	O
and	O
3	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydropterin	I-CHEMICAL
(	O
H43	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
pterin	I-CHEMICAL
)	O
(	O
h	O
=	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
;	O
Km	O
=	O
687	O
+	O
/	O
-	O
50	O
microM	O
)	O
.	O

In	O
the	O
presence	O
of	O
1	O
mM	O
H43	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
pterin	I-CHEMICAL
,	O
used	O
as	O
a	O
competitive	O
cofactor	O
analogue	O
to	O
BH4	O
,	O
hyperbolic	O
saturation	O
curves	O
were	O
also	O
found	O
for	O
H4biopterin	B-CHEMICAL
(	O
h	O
=	O
1	O
.	O
0	O
)	O
,	O
thus	O
confirming	O
the	O
genuine	O
nature	O
of	O
the	O
kinetic	O
negative	O
cooperativity	O
.	O

This	O
cooperativity	O
was	O
confirmed	O
by	O
real	O
-	O
time	O
biospecific	O
interaction	O
analysis	O
by	O
surface	O
plasmon	O
resonance	O
detection	O
.	O

The	O
equilibrium	O
binding	O
of	O
H4biopterin	B-CHEMICAL
to	O
the	O
immobilized	O
iron	O
-	O
free	O
apoenzyme	O
results	O
in	O
a	O
saturable	O
positive	O
resonance	O
unit	O
(	O
DeltaRU	O
)	O
response	O
with	O
negative	O
cooperativity	O
(	O
h	O
=	O
0	O
.	O
52	O
-	O
0	O
.	O
56	O
)	O
.	O

Infrared	O
spectroscopic	O
studies	O
revealed	O
a	O
reduced	O
thermal	O
stability	O
both	O
of	O
the	O
apo	O
-	O
and	O
the	O
holo	O
-	O
hTH1	B-GENE-Y
on	O
binding	O
of	O
H4biopterin	B-CHEMICAL
and	O
Lerythro	B-CHEMICAL
-	I-CHEMICAL
dihydrobiopterin	I-CHEMICAL
(	O
H2biopterin	B-CHEMICAL
)	O
.	O

Moreover	O
,	O
the	O
ligand	O
-	O
bound	O
forms	O
of	O
the	O
enzyme	O
also	O
showed	O
a	O
decreased	O
resistance	O
to	O
limited	O
tryptic	O
proteolysis	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
binding	O
of	O
H4biopterin	B-CHEMICAL
at	O
the	O
active	O
site	O
induces	O
a	O
destabilizing	O
conformational	O
change	O
in	O
the	O
enzyme	O
which	O
could	O
be	O
related	O
to	O
the	O
observed	O
negative	O
cooperativity	O
.	O

Thus	O
,	O
our	O
studies	O
provide	O
new	O
insight	O
into	O
the	O
regulation	O
of	O
TH	B-GENE-Y
by	O
the	O
concentration	O
of	O
H4biopterin	B-CHEMICAL
which	O
may	O
have	O
significant	O
implications	O
for	O
the	O
physiological	O
regulation	O
of	O
catecholamine	B-CHEMICAL
biosynthesis	O
in	O
neuroendocrine	O
cells	O
.	O

[	O
Psychopharmacological	O
profile	O
of	O
venlafaxine	B-CHEMICAL
]	O
.	O

Venlafaxine	B-CHEMICAL
is	O
an	O
antidepressant	O
which	O
blocks	O
reuptake	O
of	O
noradrenaline	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
dopamine	B-CHEMICAL
.	O

These	O
data	O
have	O
been	O
confirmed	O
by	O
behavioral	O
tests	O
.	O

It	O
has	O
been	O
shown	O
that	O
by	O
decreasing	O
the	O
overall	O
cerebral	O
quantity	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
NA	B-CHEMICAL
,	O
venlafaxine	B-CHEMICAL
continued	O
to	O
have	O
an	O
antidepressant	O
action	O
in	O
animal	O
models	O
.	O

In	O
addition	O
,	O
the	O
drug	O
has	O
been	O
shown	O
to	O
act	O
preferentially	O
on	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
.	O

[	O
Brugada	O
syndrome	O
]	O
.	O

In	O
1992	O
we	O
described	O
a	O
new	O
syndrome	O
consisting	O
of	O
syncopal	O
episodes	O
and	O
/	O
or	O
sudden	O
death	O
in	O
patients	O
with	O
a	O
structurally	O
normal	O
heart	O
and	O
a	O
characteristic	O
electrocardiogram	O
displaying	O
a	O
pattern	O
resembling	O
right	O
bundle	O
branch	O
block	O
with	O
an	O
ST	O
segment	O
elevation	O
in	O
leads	O
V1	O
to	O
V3	O
.	O

In	O
1998	O
it	O
was	O
described	O
that	O
the	O
disease	O
is	O
genetically	O
determined	O
with	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
transmission	O
.	O

Three	O
different	O
mutations	O
have	O
been	O
identified	O
.	O

All	O
three	O
mutations	O
affect	O
the	O
structure	O
and	O
the	O
function	O
of	O
the	O
sodium	B-GENE-N
channel	I-GENE-N
SCN5A	B-GENE-Y
.	O

Two	O
mutations	O
result	O
in	O
total	O
loss	O
of	O
function	O
of	O
the	O
sodium	B-GENE-N
channel	I-GENE-N
.	O

The	O
other	O
mutation	O
results	O
in	O
acceleration	O
of	O
the	O
recovery	O
of	O
the	O
sodium	B-GENE-N
channel	I-GENE-N
from	O
inactivation	O
.	O

The	O
disease	O
causes	O
4	O
to	O
10	O
sudden	O
deaths	O
per	O
10	O
,	O
000	O
inhabitants	O
per	O
year	O
in	O
areas	O
like	O
Thailand	O
and	O
Laos	O
.	O

Up	O
to	O
50	O
%	O
of	O
the	O
yearly	O
sudden	O
deaths	O
in	O
patients	O
with	O
a	O
normal	O
heart	O
might	O
be	O
caused	O
by	O
this	O
syndrome	O
.	O

The	O
diagnosis	O
is	O
easily	O
made	O
by	O
means	O
of	O
the	O
electrocardiogram	O
(	O
ECG	O
)	O
.	O

The	O
presence	O
of	O
concealed	O
and	O
intermittent	O
forms	O
,	O
however	O
,	O
makes	O
the	O
diagnosis	O
difficult	O
in	O
some	O
patients	O
.	O

The	O
ECG	O
can	O
be	O
modulated	O
by	O
changes	O
in	O
autonomic	O
balance	O
and	O
the	O
administration	O
of	O
antiarrhythmic	O
drugs	O
.	O

Beta	O
-	O
adrenergic	O
stimulation	O
normalises	O
the	O
ECG	O
,	O
while	O
i	O
.	O
v	O
.	O
ajmaline	B-CHEMICAL
,	O
flecainide	B-CHEMICAL
or	O
procainamide	B-CHEMICAL
accentuate	O
the	O
ST	O
segment	O
elevation	O
and	O
are	O
capable	O
of	O
unmasking	O
concealed	O
and	O
intermittent	O
forms	O
of	O
the	O
disease	O
.	O

The	O
prognosis	O
is	O
poor	O
for	O
patients	O
who	O
do	O
not	O
receive	O
an	O
implantable	O
cardioverter	O
-	O
defibrillator	O
.	O

Antiarrhythmic	O
drugs	O
like	O
amiodarone	B-CHEMICAL
or	O
beta	O
-	O
blockers	O
do	O
not	O
prevent	O
sudden	O
death	O
in	O
symptomatic	O
or	O
asymptomatic	O
individuals	O
.	O

Common	O
resistance	O
mechanisms	O
to	O
deoxynucleoside	O
analogues	O
in	O
variants	O
of	O
the	O
human	O
erythroleukaemic	O
line	O
K562	O
.	O

Resistant	O
variants	O
of	O
the	O
human	O
leukaemic	O
line	O
K562	O
were	O
developed	O
using	O
selection	O
with	O
the	O
deoxynucleoside	O
analogues	O
cytosine	B-CHEMICAL
arabinoside	I-CHEMICAL
,	O
2	B-CHEMICAL
-	I-CHEMICAL
chlorodeoxyadenosine	I-CHEMICAL
,	O
fludarabine	B-CHEMICAL
and	O
gemcitabine	B-CHEMICAL
.	O

The	O
resistant	O
lines	O
displayed	O
a	O
high	O
degree	O
of	O
cross	O
resistance	O
to	O
all	O
deoxynucleoside	O
analogues	O
,	O
with	O
little	O
or	O
no	O
cross	O
resistance	O
to	O
other	O
agents	O
.	O

There	O
was	O
a	O
profound	O
accumulation	O
defect	O
of	O
all	O
nucleoside	O
analogues	O
in	O
the	O
resistant	O
variants	O
but	O
no	O
significant	O
defect	O
in	O
nucleoside	O
transport	O
in	O
any	O
of	O
the	O
variants	O
.	O

5	B-GENE-Y
'	I-GENE-Y
nucleotidase	I-GENE-Y
activity	O
was	O
strongly	O
increased	O
and	O
deoxycytidine	B-GENE-Y
kinase	I-GENE-Y
activity	O
was	O
moderately	O
reduced	O
in	O
all	O
of	O
the	O
resistant	O
variants	O
,	O
resulting	O
in	O
reduced	O
accumulation	O
of	O
triphosphate	B-CHEMICAL
analogues	O
.	O

In	O
addition	O
a	O
deletion	O
in	O
one	O
of	O
the	O
alleles	O
of	O
the	O
deoxycytidine	B-GENE-Y
kinase	I-GENE-Y
was	O
detected	O
in	O
the	O
fludarabine	B-CHEMICAL
-	O
resistant	O
line	O
.	O

Ribonucleotide	B-GENE-N
reductase	I-GENE-N
activity	O
was	O
found	O
to	O
be	O
strongly	O
increased	O
in	O
the	O
gemcitabine	B-CHEMICAL
-	O
selected	O
line	O
and	O
purine	B-GENE-Y
nucleoside	I-GENE-Y
phosphorylase	I-GENE-Y
was	O
increased	O
in	O
the	O
2	B-CHEMICAL
-	I-CHEMICAL
chlorodeoxyadenosine	I-CHEMICAL
-	O
selected	O
line	O
.	O

Free	O
nucleotide	B-CHEMICAL
pools	O
were	O
increased	O
in	O
the	O
2	B-CHEMICAL
-	I-CHEMICAL
chlorodeoxyadenosine	I-CHEMICAL
-	O
selected	O
line	O
.	O

There	O
was	O
no	O
expression	O
of	O
the	O
mdr1	B-GENE-Y
gene	O
by	O
the	O
resistant	O
lines	O
.	O

Karyotypic	O
analysis	O
and	O
FISH	O
experiments	O
using	O
a	O
6q21	O
specific	O
probe	O
showed	O
alterations	O
in	O
the	O
6	O
(	O
q16	O
-	O
q22	O
)	O
region	O
which	O
contains	O
the	O
5	B-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
nucleotidase	I-GENE-Y
gene	O
.	O

Early	O
events	O
in	O
the	O
activation	O
and	O
degradation	O
of	O
deoxynucleoside	O
analogues	O
appear	O
to	O
constitute	O
common	O
mechanisms	O
of	O
resistance	O
to	O
these	O
compounds	O
.	O

Angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibition	O
and	O
AT1	B-GENE-N
receptor	O
blockade	O
modify	O
the	O
pressure	O
-	O
natriuresis	O
relationship	O
by	O
additive	O
mechanisms	O
in	O
rats	O
with	O
human	B-GENE-Y
renin	I-GENE-Y
and	O
angiotensinogen	B-GENE-Y
genes	O
.	O

The	O
intrarenal	O
factors	O
responsible	O
for	O
hypertension	O
in	O
double	O
-	O
transgenic	O
rats	O
(	O
dTGR	O
)	O
harboring	O
human	B-GENE-Y
renin	I-GENE-Y
and	O
human	B-GENE-Y
angiotensinogen	I-GENE-Y
genes	O
are	O
unclear	O
.	O

The	O
pressure	O
-	O
natriuresis	O
and	O
-	O
diuresis	O
relationships	O
in	O
response	O
to	O
chronic	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
(	O
ACE	B-GENE-Y
)	O
inhibition	O
and	O
AT1	B-GENE-N
receptor	O
blockade	O
were	O
evaluated	O
.	O

Renal	B-GENE-Y
renin	I-GENE-Y
-	O
angiotensin	B-CHEMICAL
and	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
system	O
gene	O
expression	O
was	O
also	O
investigated	O
.	O

Six	O
-	O
week	O
-	O
old	O
dTGR	O
were	O
treated	O
for	O
3	O
wk	O
with	O
submaximal	O
doses	O
of	O
cilazapril	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
or	O
losartan	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
or	O
with	O
the	O
drug	O
combination	O
.	O

In	O
untreated	O
dTGR	O
,	O
pressure	O
-	O
natriuresis	O
relationships	O
were	O
maximally	O
shifted	O
rightward	O
by	O
approximately	O
70	O
to	O
80	O
mmHg	O
,	O
and	O
both	O
renal	O
blood	O
flow	O
(	O
RBF	O
)	O
and	O
GFR	O
were	O
markedly	O
decreased	O
.	O

Submaximal	O
cilazapril	B-CHEMICAL
and	O
losartan	B-CHEMICAL
dosages	O
both	O
decreased	O
systolic	O
BP	O
by	O
30	O
mmHg	O
and	O
shifted	O
the	O
pressure	O
-	O
natriuresis	O
curves	O
leftward	O
by	O
25	O
to	O
30	O
mmHg	O
.	O

Cilazapril	B-CHEMICAL
increased	O
RBF	O
and	O
GFR	O
to	O
values	O
observed	O
in	O
normotensive	O
control	O
animals	O
but	O
did	O
not	O
significantly	O
affect	O
fractional	O
sodium	B-CHEMICAL
excretion	O
(	O
FENa	O
)	O
or	O
fractional	O
water	O
excretion	O
(	O
FEH2O	O
)	O
curves	O
.	O

In	O
contrast	O
,	O
losartan	B-CHEMICAL
had	O
no	O
significant	O
effect	O
on	O
RBF	O
or	O
GFR	O
but	O
shifted	O
the	O
FENa	O
and	O
FEH2O	O
curves	O
leftward	O
.	O

The	O
cilazapril	B-CHEMICAL
and	O
losartan	B-CHEMICAL
combination	O
completely	O
normalized	O
BP	O
and	O
shifted	O
the	O
pressure	O
-	O
natriuresis	O
curves	O
leftward	O
more	O
than	O
did	O
either	O
drug	O
alone	O
.	O

When	O
cilazapril	B-CHEMICAL
and	O
losartan	B-CHEMICAL
were	O
administered	O
at	O
higher	O
doses	O
(	O
30	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
,	O
the	O
two	O
drugs	O
equally	O
shifted	O
the	O
pressure	O
-	O
natriuresis	O
curves	O
leftward	O
,	O
by	O
50	O
mmHg	O
.	O

Both	O
drugs	O
increased	O
RBF	O
and	O
GFR	O
;	O
however	O
,	O
only	O
losartan	B-CHEMICAL
shifted	O
FENa	O
and	O
FEH2O	O
curves	O
leftward	O
.	O

Human	B-GENE-N
and	I-GENE-N
rat	I-GENE-N
renin	I-GENE-N
and	O
angiotensinogen	B-GENE-N
genes	O
were	O
downregulated	O
in	O
dTGR	O
and	O
were	O
increased	O
by	O
losartan	B-CHEMICAL
and	O
cilazapril	B-CHEMICAL
treatments	O
,	O
whereas	O
no	O
changes	O
in	O
the	O
expression	O
of	O
rat	B-GENE-Y
ACE	I-GENE-Y
and	O
AT1A	B-GENE-Y
receptor	O
genes	O
were	O
observed	O
.	O

Endothelial	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
expression	O
was	O
increased	O
by	O
cilazapril	B-CHEMICAL
but	O
not	O
by	O
losartan	B-CHEMICAL
.	O

Neither	O
inducible	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
nor	O
neural	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
gene	O
expression	O
was	O
affected	O
by	O
drug	O
treatments	O
.	O

Therefore	O
,	O
submaximal	O
ACE	B-GENE-Y
inhibition	O
enhanced	O
sodium	B-CHEMICAL
excretion	O
mainly	O
by	O
increasing	O
RBF	O
and	O
GFR	O
,	O
whereas	O
submaximal	O
AT1	B-GENE-N
receptor	O
blockade	O
decreased	O
tubular	O
sodium	B-CHEMICAL
and	O
water	O
reabsorption	O
.	O

The	O
combination	O
of	O
the	O
two	O
drugs	O
produced	O
an	O
additive	O
effect	O
.	O

The	O
ACE	B-GENE-Y
inhibitor	O
effects	O
may	O
involve	O
increased	O
endothelial	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
expression	O
,	O
perhaps	O
related	O
to	O
the	O
inhibition	O
of	O
bradykinin	B-CHEMICAL
degradation	O
.	O

Effects	O
of	O
venlafaxine	B-CHEMICAL
on	O
extracellular	O
concentrations	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
noradrenaline	B-CHEMICAL
in	O
the	O
rat	O
frontal	O
cortex	O
:	O
augmentation	O
via	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptor	O
antagonism	O
.	O

Venlafaxine	B-CHEMICAL
is	O
a	O
novel	O
serotonin	B-CHEMICAL
/	O
noradrenaline	B-CHEMICAL
reuptake	O
inhibitor	O
(	O
SNRI	O
)	O
which	O
has	O
been	O
shown	O
clinically	O
to	O
be	O
an	O
effective	O
antidepressant	O
(	O
AD	O
)	O
with	O
a	O
faster	O
onset	O
of	O
action	O
than	O
serotonin	B-CHEMICAL
specific	O
reuptake	O
inhibitors	O
(	O
SSRI	O
)	O
.	O

Preclinically	O
,	O
venlafaxine	B-CHEMICAL
has	O
been	O
shown	O
to	O
potently	O
inhibit	O
dorsal	O
raphe	O
neuronal	O
(	O
DRN	O
)	O
firing	O
through	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
mediated	O
mechanism	O
,	O
in	O
a	O
similar	O
manner	O
to	O
SSRIs	O
.	O

Here	O
we	O
demonstrate	O
the	O
acute	O
neurochemical	O
effects	O
of	O
venlafaxine	B-CHEMICAL
on	O
extracellular	O
concentrations	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
noradrenaline	B-CHEMICAL
(	O
NA	B-CHEMICAL
)	O
from	O
the	O
rat	O
frontal	O
cortex	O
using	O
in	O
vivo	O
microdialysis	O
.	O

Administration	O
of	O
venlafaxine	B-CHEMICAL
(	O
3	O
-	O
50	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
resulted	O
in	O
a	O
significant	O
dose	O
-	O
dependent	O
increase	O
in	O
extracellular	O
NA	B-CHEMICAL
,	O
but	O
produced	O
no	O
significant	O
increase	O
in	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
concentrations	O
.	O

Combination	O
treatment	O
with	O
the	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
antagonist	O
WAY100635	B-CHEMICAL
produced	O
a	O
dose	O
-	O
dependent	O
augmentation	O
of	O
venlafaxine	B-CHEMICAL
-	O
induced	O
(	O
3	O
-	O
30	O
mg	O
/	O
kg	O
s	O
.	O
c	O
)	O
extracellular	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
concentrations	O
,	O
but	O
had	O
no	O
further	O
effect	O
on	O
NA	B-CHEMICAL
above	O
that	O
produced	O
by	O
venlafaxine	B-CHEMICAL
alone	O
.	O

WAY100635	B-CHEMICAL
,	O
at	O
doses	O
as	O
low	O
as	O
0	O
.	O
03	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
,	O
maintained	O
this	O
potentiation	O
effect	O
.	O

The	O
beta	O
-	O
adrenergic	O
/	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptor	O
antagonist	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
and	O
the	O
selective	O
5	B-GENE-N
-	I-GENE-N
HT1B	I-GENE-N
/	I-GENE-N
D	I-GENE-N
antagonist	O
GR127935	B-CHEMICAL
produced	O
no	O
significant	O
augmentation	O
of	O
venlafaxine	B-CHEMICAL
-	O
induced	O
changes	O
in	O
either	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
or	O
NA	B-CHEMICAL
.	O

Using	O
the	O
alpha1	B-GENE-N
and	I-GENE-N
alpha2	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
,	O
prazosin	B-CHEMICAL
and	O
idazoxane	B-CHEMICAL
,	O
we	O
also	O
demonstrate	O
the	O
role	O
of	O
the	O
alpha	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
the	O
augmentation	O
of	O
venlafaxine	B-CHEMICAL
-	O
induced	O
changes	O
.	O

The	O
possible	O
mechanisms	O
underlying	O
venlafaxines	B-CHEMICAL
improved	O
clinical	O
AD	O
action	O
and	O
the	O
potential	O
for	O
further	O
enhancement	O
of	O
this	O
SNRIs	O
clinical	O
effects	O
are	O
discussed	O
.	O

Effect	O
of	O
thiazinotrienomycin	B-CHEMICAL
B	I-CHEMICAL
,	O
an	O
ansamycin	B-CHEMICAL
antibiotic	O
,	O
on	O
the	O
function	O
of	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
in	O
human	O
stomach	O
tumor	O
cells	O
.	O

Thiazinotrienomycin	B-CHEMICAL
B	I-CHEMICAL
(	O
TT	B-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
)	O
,	O
an	O
ansamycin	B-CHEMICAL
isolated	O
from	O
fermentation	O
broths	O
of	O
Streptomyces	O
sp	O
.	O

MJ672	O
-	O
m3	O
,	O
inhibited	O
the	O
growth	O
in	O
vitro	O
of	O
human	O
stomach	O
tumor	O
SC	O
-	O
6	O
cells	O
over	O
10	O
times	O
more	O
strongly	O
than	O
the	O
growth	O
of	O
other	O
human	O
tumor	O
cells	O
,	O
such	O
as	O
HeLa	O
(	O
cervix	O
)	O
,	O
T24	O
(	O
bladder	O
)	O
and	O
LX	O
-	O
1	O
(	O
lung	O
)	O
.	O

The	O
extent	O
of	O
growth	O
inhibition	O
by	O
TT	O
-	O
B	O
of	O
SC	O
-	O
6	O
,	O
but	O
not	O
of	O
LX	O
-	O
1	O
nor	O
T24	O
,	O
was	O
lowered	O
in	O
a	O
competitive	O
manner	O
by	O
raising	O
serum	O
concentrations	O
in	O
the	O
culture	O
medium	O
.	O

TT	B-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
inhibited	O
the	O
cell	O
cycle	O
progression	O
of	O
SC	O
-	O
6	O
at	O
an	O
early	O
stage	O
of	O
the	O
progression	O
from	O
G0	O
/	O
G1	O
to	O
S	O
.	O

The	O
inhibition	O
was	O
again	O
competitive	O
with	O
serum	O
concentrations	O
in	O
the	O
culture	O
medium	O
.	O

No	O
direct	O
inhibition	O
of	O
DNA	O
synthesis	O
was	O
observed	O
at	O
the	O
concentration	O
range	O
which	O
caused	O
the	O
cell	O
cycle	O
arrest	O
.	O

TT	B-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
and	O
anti	O
-	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
anti	O
-	O
EGFR	B-GENE-Y
)	O
were	O
antagonistic	O
to	O
each	O
other	O
in	O
inhibiting	O
the	O
cell	O
cycle	O
progression	O
of	O
SC	O
-	O
6	O
from	O
G0	O
/	O
G1	O
to	O
S	O
,	O
suggesting	O
that	O
the	O
two	O
compounds	O
share	O
the	O
same	O
target	O
,	O
EGFR	B-GENE-Y
.	O

The	O
kinase	B-GENE-N
activity	O
of	O
EGFR	B-GENE-Y
was	O
little	O
inhibited	O
by	O
TT	B-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
in	O
a	O
cell	O
-	O
free	O
system	O
.	O

Structural	O
basis	O
for	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibition	O
upon	O
lovastatin	B-CHEMICAL
binding	O
to	O
the	O
CD11a	B-GENE-N
I	I-GENE-N
-	I-GENE-N
domain	I-GENE-N
.	O

The	O
lymphocyte	B-GENE-Y
function	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
antigen	I-GENE-Y
(	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
belongs	O
to	O
the	O
family	O
of	O
beta2	B-GENE-Y
-	I-GENE-Y
integrins	I-GENE-Y
and	O
plays	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
activation	O
and	O
leukocyte	O
migration	O
to	O
sites	O
of	O
inflammation	O
.	O

We	O
report	O
here	O
that	O
lovastatin	B-CHEMICAL
,	O
a	O
drug	O
clinically	O
used	O
for	O
lowering	O
cholesterol	B-CHEMICAL
levels	O
,	O
inhibits	O
the	O
interaction	O
of	O
human	B-GENE-Y
LFA	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
with	O
its	O
counter	O
-	O
receptor	O
intercellular	B-GENE-Y
adhesion	I-GENE-Y
molecule	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Using	O
nuclear	O
magnetic	O
resonance	O
spectroscopy	O
and	O
X	O
-	O
ray	O
crystallography	O
we	O
show	O
that	O
the	O
inhibitor	O
binds	O
to	O
a	O
highly	O
conserved	O
domain	O
of	O
the	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
chain	I-GENE-Y
called	O
the	O
I	B-GENE-N
-	I-GENE-N
domain	I-GENE-N
.	O

The	O
first	O
three	O
-	O
dimensional	O
structure	O
of	O
an	O
integrin	B-GENE-N
inhibitor	O
bound	O
to	O
its	O
receptor	O
reveals	O
atomic	O
details	O
for	O
a	O
hitherto	O
unknown	O
mode	O
of	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibition	O
.	O

It	O
also	O
sheds	O
light	O
into	O
possible	O
mechanisms	O
of	O
LFA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mediated	O
signalling	O
and	O
will	O
support	O
the	O
design	O
of	O
novel	O
anti	O
-	O
adhesive	O
and	O
immunosuppressive	O
drugs	O
.	O

Threshold	O
concentrations	O
of	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
:	O
the	O
effects	O
on	O
contractions	O
induced	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
in	O
isolated	O
rat	O
cerebral	O
and	O
mesenteric	O
arteries	O
.	O

This	O
study	O
compares	O
the	O
effects	O
of	O
threshold	O
concentrations	O
of	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
in	O
isolated	O
rat	O
basilar	O
arteries	O
with	O
those	O
in	O
mesenteric	O
arterial	O
branches	O
and	O
investigates	O
the	O
mechanisms	O
of	O
inhibitory	O
and	O
potentiating	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
effects	O
.	O

In	O
basilar	O
arteries	O
,	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
reduces	O
the	O
contractions	O
induced	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
,	O
by	O
the	O
thromboxane	B-CHEMICAL
A2	I-CHEMICAL
agonist	O
U46619	B-CHEMICAL
,	O
and	O
by	O
vasopressin	B-CHEMICAL
.	O

The	O
inhibitory	O
effect	O
of	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
on	O
the	O
contraction	O
induced	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
is	O
abolished	O
by	O
deendothelialization	O
,	O
by	O
the	O
endothelin	B-GENE-Y
ET	I-GENE-Y
(	I-GENE-Y
B	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
RES	B-CHEMICAL
701	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	O
by	O
indomethacin	B-CHEMICAL
,	O
or	O
by	O
glibenclamide	B-CHEMICAL
.	O

In	O
mesenteric	O
arteries	O
,	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
potentiates	O
the	O
contractile	O
effects	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
,	O
U46619	B-CHEMICAL
,	O
and	O
vasopressin	B-CHEMICAL
.	O

The	O
potentiation	O
of	O
the	O
contractile	O
effect	O
induced	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
is	O
only	O
somewhat	O
modified	O
by	O
deendothelialization	O
,	O
but	O
abolished	O
by	O
the	O
thromboxane	B-GENE-Y
A2	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
GR32191	B-CHEMICAL
and	O
ridogrel	B-CHEMICAL
.	O

U46619	B-CHEMICAL
potentiates	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
-	O
effect	O
in	O
mesenteric	O
arteries	O
.	O

Thus	O
,	O
though	O
the	O
contractile	O
endothelin	B-GENE-N
ET	I-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
were	O
not	O
blocked	O
,	O
threshold	O
concentrations	O
of	O
endothelin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
inhibited	O
contractile	O
effects	O
in	O
the	O
rat	O
basilar	O
artery	O
via	O
activation	O
of	O
endothelial	B-GENE-Y
ET	I-GENE-Y
(	I-GENE-Y
B	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
.	O

Prostaglandins	B-CHEMICAL
and	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
K	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
are	O
involved	O
in	O
this	O
inhibitory	O
action	O
.	O

In	O
contrast	O
,	O
endothelin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
potentiates	O
contractile	O
actions	O
in	O
mesenteric	O
arteries	O
via	O
the	O
release	O
of	O
endogeneous	O
thromboxane	B-CHEMICAL
A2	I-CHEMICAL
from	O
non	O
-	O
endothelial	O
cells	O
.	O

The	O
study	O
points	O
out	O
the	O
completely	O
different	O
role	O
of	O
the	O
endothelium	O
in	O
combined	O
effects	O
of	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
between	O
cerebral	O
and	O
mesenteric	O
arteries	O
.	O

Synthesis	O
and	O
antagonistic	O
activity	O
at	O
muscarinic	B-GENE-N
receptor	I-GENE-N
subtypes	O
of	O
some	O
2	B-CHEMICAL
-	I-CHEMICAL
carbonyl	I-CHEMICAL
derivatives	O
of	O
diphenidol	B-CHEMICAL
.	O

A	O
series	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
carbonyl	I-CHEMICAL
analogues	O
of	O
the	O
muscarinic	O
antagonist	O
diphenidol	B-CHEMICAL
bearing	O
1	O
-	O
substituents	O
of	O
different	O
lipophilic	O
,	O
electronic	O
,	O
and	O
steric	O
properties	O
was	O
synthesized	O
and	O
their	O
affinity	O
for	O
the	O
M2	B-GENE-N
and	I-GENE-N
M3	I-GENE-N
muscarinic	I-GENE-N
receptor	I-GENE-N
subtypes	O
was	O
evaluated	O
by	O
functional	O
tests	O
.	O

Two	O
derivatives	O
(	O
2g	O
and	O
2d	O
)	O
showed	O
an	O
M2	B-GENE-Y
-	O
selective	O
profile	O
which	O
was	O
confirmed	O
by	O
functional	O
tests	O
on	O
the	O
M1	B-GENE-N
and	I-GENE-N
M4	I-GENE-N
receptors	I-GENE-N
.	O

A	O
possible	O
relationship	O
between	O
M2	B-GENE-Y
selectivity	O
and	O
lipophilicity	O
of	O
the	O
1	O
-	O
substituent	O
was	O
suggested	O
by	O
structure	O
-	O
activity	O
analysis	O
.	O

This	O
work	O
showed	O
that	O
appropriate	O
structural	O
modification	O
of	O
diphenidol	B-CHEMICAL
can	O
lead	O
to	O
M2	B-GENE-Y
-	O
selective	O
muscarinic	O
antagonists	O
of	O
possible	O
interest	O
in	O
the	O
field	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Chloride	B-GENE-N
channels	I-GENE-N
in	O
renal	O
disease	O
.	O

Recent	O
studies	O
of	O
hereditary	O
renal	O
tubular	O
disorders	O
have	O
facilitated	O
the	O
identification	O
and	O
roles	O
of	O
chloride	B-GENE-N
channels	I-GENE-N
and	I-GENE-N
cotransporters	I-GENE-N
in	O
the	O
regulation	O
of	O
the	O
most	O
abundant	O
anion	O
,	O
Cl	B-CHEMICAL
-	I-CHEMICAL
,	O
in	O
the	O
ECF	O
.	O

Thus	O
,	O
mutations	O
that	O
result	O
in	O
a	O
loss	O
of	O
function	O
of	O
the	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
chloride	I-GENE-N
channel	I-GENE-N
,	O
CLC	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
,	O
are	O
associated	O
with	O
Dent	O
'	O
s	O
disease	O
,	O
which	O
is	O
characterized	O
by	O
low	O
-	O
molecular	O
weight	O
proteinuria	O
,	O
hypercalciuria	O
,	O
nephrolithiasis	O
,	O
and	O
renal	O
failure	O
.	O

Mutations	O
of	O
another	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
chloride	I-GENE-N
channel	I-GENE-N
,	O
CLC	B-GENE-Y
-	I-GENE-Y
Kb	I-GENE-Y
,	O
are	O
associated	O
with	O
a	O
form	O
of	O
Bartter	O
'	O
s	O
syndrome	O
,	O
whereas	O
other	O
forms	O
of	O
Bartter	O
'	O
s	O
syndrome	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
bumetanide	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
sodium	I-GENE-N
-	I-GENE-N
potassium	I-GENE-N
-	I-GENE-N
chloride	I-GENE-N
cotransporter	I-GENE-N
(	O
NKCC2	B-GENE-Y
)	O
and	O
the	O
potassium	B-GENE-N
channel	I-GENE-N
,	O
ROMK	B-GENE-Y
.	O

Finally	O
,	O
mutations	O
of	O
the	O
thiazide	B-GENE-Y
-	I-GENE-Y
sensitive	I-GENE-Y
sodium	I-GENE-Y
-	I-GENE-Y
chloride	I-GENE-Y
cotransporter	I-GENE-Y
(	O
NCCT	B-GENE-Y
)	O
are	O
associated	O
with	O
Gitelman	O
'	O
s	O
syndrome	O
.	O

These	O
studies	O
have	O
helped	O
to	O
elucidate	O
some	O
of	O
the	O
renal	O
tubular	O
mechanisms	O
regulating	O
mineral	O
homeostasis	O
and	O
the	O
role	O
of	O
chloride	B-GENE-N
channels	I-GENE-N
.	O

Pretreatment	O
renal	O
vascular	O
tone	O
predicts	O
the	O
effect	O
of	O
specific	O
renin	B-GENE-Y
inhibition	O
on	O
natriuresis	O
in	O
essential	O
hypertension	O
.	O

BACKGROUND	O
:	O
In	O
essential	O
hypertension	O
an	O
elevated	O
renal	O
vascular	O
resistance	O
(	O
RVR	O
)	O
may	O
be	O
a	O
marker	O
of	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
-	O
aldosterone	B-CHEMICAL
system	O
-	O
mediated	O
impairment	O
of	O
renal	O
sodium	B-CHEMICAL
excretion	O
.	O

This	O
hypothesis	O
was	O
tested	O
by	O
investigating	O
whether	O
,	O
in	O
subjects	O
with	O
essential	O
hypertension	O
,	O
the	O
natriuretic	O
response	O
to	O
specific	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
-	O
aldosterone	B-CHEMICAL
system	O
(	O
RAAS	O
)	O
blockade	O
by	O
renin	B-GENE-Y
-	O
inhibitor	O
remikiren	B-CHEMICAL
could	O
be	O
predicted	O
from	O
pretreatment	O
renal	O
vascular	O
tone	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Renal	O
hemodynamics	O
,	O
and	O
the	O
effects	O
of	O
single	O
(	O
n	O
=	O
17	O
)	O
and	O
multiple	O
doses	O
(	O
n	O
=	O
8	O
,	O
8	O
days	O
)	O
of	O
remikiren	B-CHEMICAL
(	O
600	O
mg	O
day	O
-	O
1	O
)	O
on	O
sodium	B-CHEMICAL
excretion	O
were	O
studied	O
under	O
conditions	O
of	O
carefully	O
controlled	O
sodium	B-CHEMICAL
balance	O
.	O

RESULTS	O
:	O
Pretreatment	O
renal	O
vascular	O
tone	O
showed	O
considerable	O
individual	O
differences	O
:	O
filtration	O
fraction	O
(	O
FF	O
)	O
ranged	O
from	O
21	O
.	O
2	O
to	O
30	O
.	O
3	O
%	O
and	O
RVR	O
from	O
18	O
.	O
8	O
to	O
33	O
.	O
5	O
10	O
-	O
2	O
mmHg	O
min	O
mL	O
-	O
1	O
in	O
the	O
single	O
dose	O
study	O
,	O
and	O
FF	O
from	O
20	O
.	O
8	O
to	O
24	O
.	O
9	O
%	O
and	O
RVR	O
from	O
14	O
.	O
8	O
to	O
28	O
.	O
8	O
10	O
-	O
2	O
mmHg	O
min	O
mL	O
-	O
1	O
in	O
the	O
multiple	O
dose	O
study	O
.	O

Remikiren	B-CHEMICAL
induced	O
a	O
fall	O
in	O
blood	O
pressure	O
,	O
FF	O
and	O
RVR	O
,	O
with	O
considerable	O
interindividual	O
variability	O
in	O
natriuretic	O
response	O
.	O

During	O
single	O
dose	O
,	O
cumulative	O
sodium	B-CHEMICAL
loss	O
was	O
5	O
.	O
1	O
mmol	O
per	O
5	O
h	O
(	O
-	O
8	O
.	O
8	O
to	O
+	O
24	O
.	O
6	O
)	O
,	O
whereas	O
after	O
8	O
days	O
treatment	O
cumulative	O
sodium	B-CHEMICAL
loss	O
was	O
72	O
+	O
/	O
-	O
30	O
mmol	O
(	O
-	O
46	O
to	O
+	O
187	O
)	O
.	O

The	O
natriuretic	O
response	O
to	O
remikiren	B-CHEMICAL
during	O
single	O
as	O
well	O
as	O
multiple	O
dose	O
significantly	O
correlated	O
with	O
pretreatment	O
renal	O
vascular	O
tone	O
(	O
estimated	O
from	O
FF	O
and	O
RVR	O
)	O
but	O
not	O
with	O
remikiren	B-CHEMICAL
-	O
induced	O
changes	O
in	O
renal	O
hemodynamics	O
or	O
in	O
hormonal	O
parameters	O
.	O

Cumulative	O
sodium	B-CHEMICAL
loss	O
was	O
largest	O
in	O
patients	O
with	O
a	O
higher	O
pretreatment	O
FF	O
and	O
RVR	O
(	O
r	O
=	O
0	O
.	O
74	O
,	O
P	O
<	O
0	O
.	O
001	O
and	O
r	O
=	O
0	O
.	O
52	O
,	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
,	O
single	O
dose	O
;	O
and	O
r	O
=	O
0	O
.	O
75	O
,	O
P	O
<	O
0	O
.	O
05	O
and	O
r	O
=	O
0	O
.	O
73	O
,	O
P	O
<	O
0	O
.	O
05	O
,	O
respectively	O
,	O
multiple	O
dose	O
)	O
.	O

CONCLUSION	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
in	O
essential	O
hypertension	O
an	O
elevated	O
renal	O
vascular	O
tone	O
is	O
a	O
marker	O
of	O
RAAS	O
-	O
mediated	O
impairment	O
of	O
sodium	B-CHEMICAL
excretion	O
.	O

Structure	O
of	O
acetylcholinesterase	B-GENE-Y
complexed	O
with	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
galanthamine	I-CHEMICAL
at	O
2	O
.	O
3	O
A	O
resolution	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Galanthamine	I-CHEMICAL
(	O
GAL	B-CHEMICAL
)	O
,	O
an	O
alkaloid	O
from	O
the	O
flower	O
,	O
the	O
common	O
snowdrop	O
(	O
Galanthus	O
nivalis	O
)	O
,	O
shows	O
anticholinesterase	O
activity	O
.	O

This	O
property	O
has	O
made	O
GAL	O
the	O
target	O
of	O
research	O
as	O
to	O
its	O
effectiveness	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

We	O
have	O
solved	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
GAL	O
bound	O
in	O
the	O
active	O
site	O
of	O
Torpedo	B-GENE-Y
californica	I-GENE-Y
acetylcholinesterase	I-GENE-Y
(	O
TcAChE	B-GENE-Y
)	O
to	O
2	O
.	O
3	O
A	O
resolution	O
.	O

The	O
inhibitor	O
binds	O
at	O
the	O
base	O
of	O
the	O
active	O
site	O
gorge	O
of	O
TcAChE	B-GENE-Y
,	O
interacting	O
with	O
both	O
the	O
choline	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
site	I-GENE-N
(	O
Trp	B-CHEMICAL
-	O
84	O
)	O
and	O
the	O
acyl	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
pocket	I-GENE-N
(	O
Phe	B-CHEMICAL
-	O
288	O
,	O
Phe	B-CHEMICAL
-	O
290	O
)	O
.	O

The	O
tertiary	B-CHEMICAL
amine	I-CHEMICAL
group	O
of	O
GAL	O
does	O
not	O
interact	O
closely	O
with	O
Trp	B-CHEMICAL
-	O
84	O
;	O
rather	O
,	O
the	O
double	O
bond	O
of	O
its	O
cyclohexene	B-CHEMICAL
ring	O
stacks	O
against	O
the	O
indole	B-CHEMICAL
ring	O
.	O

The	O
tertiary	O
amine	O
appears	O
to	O
make	O
a	O
non	O
-	O
conventional	O
hydrogen	B-CHEMICAL
bond	O
,	O
via	O
its	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
group	O
,	O
to	O
Asp	B-CHEMICAL
-	O
72	O
,	O
near	O
the	O
top	O
of	O
the	O
gorge	O
.	O

The	O
hydroxyl	B-CHEMICAL
group	O
of	O
the	O
inhibitor	O
makes	O
a	O
strong	O
hydrogen	B-CHEMICAL
bond	O
(	O
2	O
.	O
7	O
A	O
)	O
with	O
Glu	B-CHEMICAL
-	O
199	O
.	O

The	O
relatively	O
tight	O
binding	O
of	O
GAL	O
to	O
TcAChE	B-GENE-Y
appears	O
to	O
arise	O
from	O
a	O
number	O
of	O
moderate	O
to	O
weak	O
interactions	O
with	O
the	O
protein	O
,	O
coupled	O
to	O
a	O
low	O
entropy	O
cost	O
for	O
binding	O
due	O
to	O
the	O
rigid	O
nature	O
of	O
the	O
inhibitor	O
.	O

Preferential	O
block	O
of	O
late	O
sodium	B-CHEMICAL
current	O
in	O
the	O
LQT3	B-GENE-Y
DeltaKPQ	I-GENE-Y
mutant	I-GENE-Y
by	O
the	O
class	O
I	O
(	O
C	O
)	O
antiarrhythmic	O
flecainide	B-CHEMICAL
.	O

Flecainide	B-CHEMICAL
block	O
of	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
current	O
(	O
I	O
(	O
Na	B-CHEMICAL
)	O
)	O
was	O
investigated	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
or	O
the	O
long	B-GENE-Y
QT	I-GENE-Y
syndrome	I-GENE-Y
3	I-GENE-Y
(	I-GENE-Y
LQT3	I-GENE-Y
)	I-GENE-Y
sodium	I-GENE-Y
channel	I-GENE-Y
alpha	I-GENE-Y
subunit	O
mutation	O
with	O
three	O
amino	B-CHEMICAL
acids	I-CHEMICAL
deleted	O
(	O
DeltaKPQ	B-GENE-Y
)	O
stably	O
transfected	O
into	O
human	O
embryonic	O
kidney	O
293	O
cells	O
using	O
whole	O
-	O
cell	O
,	O
patch	O
-	O
clamp	O
recordings	O
.	O

Flecainide	B-CHEMICAL
(	O
1	O
-	O
300	O
mM	O
)	O
caused	O
tonic	O
and	O
use	O
-	O
dependent	O
block	O
(	O
UDB	O
)	O
of	O
I	O
(	O
Na	B-CHEMICAL
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Compared	O
with	O
WT	O
,	O
DeltaKPQ	B-GENE-Y
I	O
(	O
Na	B-CHEMICAL
)	O
was	O
more	O
sensitive	O
to	O
flecainide	B-CHEMICAL
,	O
and	O
flecainide	B-CHEMICAL
preferentially	O
inhibited	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
(	O
mean	O
current	O
between	O
20	O
and	O
23	O
.	O
5	O
ms	O
after	O
depolarization	O
)	O
compared	O
with	O
peak	O
I	O
(	O
Na	B-CHEMICAL
)	O
.	O

The	O
IC	O
(	O
50	O
)	O
value	O
of	O
peak	O
and	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
for	O
WT	O
was	O
127	O
+	O
/	O
-	O
6	O
and	O
44	O
+	O
/	O
-	O
2	O
microM	O
(	O
n	O
=	O
20	O
)	O
and	O
for	O
DeltaKPQ	B-GENE-Y
was	O
80	O
+	O
/	O
-	O
9	O
and	O
19	O
+	O
/	O
-	O
2	O
microM	O
(	O
n	O
=	O
31	O
)	O
respectively	O
.	O

UDB	O
of	O
peak	O
I	O
(	O
Na	B-CHEMICAL
)	O
was	O
greater	O
and	O
developed	O
more	O
slowly	O
during	O
pulse	O
trains	O
for	O
DeltaKPQ	B-GENE-Y
than	O
for	O
WT	O
.	O

The	O
IC	O
(	O
50	O
)	O
value	O
for	O
UDB	O
of	O
peak	O
I	O
(	O
Na	O
)	O
for	O
WT	O
was	O
29	O
+	O
/	O
-	O
4	O
microM	O
(	O
n	O
=	O
20	O
)	O
and	O
for	O
DeltaKPQ	B-GENE-Y
was	O
11	O
+	O
/	O
-	O
1	O
microM	O
(	O
n	O
=	O
26	O
)	O
.	O

For	O
DeltaKPQ	B-GENE-Y
,	O
UDB	O
of	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
was	O
greater	O
than	O
for	O
peak	O
I	O
(	O
Na	B-CHEMICAL
)	O
.	O

Recovery	O
from	O
block	O
was	O
slower	O
for	O
DeltaKPQ	B-GENE-Y
than	O
for	O
WT	O
.	O

We	O
conclude	O
that	O
DeltaKPQ	B-GENE-Y
interacts	O
differently	O
with	O
flecainide	B-CHEMICAL
than	O
with	O
WT	O
,	O
leading	O
to	O
increased	O
block	O
and	O
slowed	O
recovery	O
,	O
especially	O
for	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
.	O

These	O
data	O
provide	O
insights	O
into	O
mechanisms	O
for	O
flecainide	B-CHEMICAL
block	O
and	O
provide	O
a	O
rationale	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
that	O
open	O
channel	O
block	O
may	O
be	O
a	O
useful	O
pharmacological	O
property	O
for	O
treatment	O
of	O
LQT3	O
.	O

Synergistic	O
effects	O
of	O
new	O
chemopreventive	O
agents	O
and	O
conventional	O
cytotoxic	O
agents	O
against	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

Non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
cells	O
have	O
constitutively	O
high	O
expression	O
of	O
cytosolic	B-GENE-Y
phospholipase	I-GENE-Y
A2	I-GENE-Y
(	O
cPLA2	B-GENE-Y
)	O
and	O
cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
2	I-GENE-Y
.	O

These	O
NSCLC	O
cells	O
also	O
have	O
increased	O
prostaglandin	B-CHEMICAL
expression	O
(	O
PGE2	B-CHEMICAL
)	O
.	O

Many	O
lung	O
cancers	O
also	O
express	O
12	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
RNA	O
and	O
12	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
protein	O
and	O
biosynthesize	O
12	B-CHEMICAL
(	I-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hydroxyeicosatetraenoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
which	O
correlates	O
with	O
their	O
metastatic	O
potential	O
.	O

Several	O
studies	O
have	O
demonstrated	O
that	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
could	O
inhibit	O
the	O
in	O
vitro	O
growth	O
of	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

In	O
this	O
report	O
,	O
we	O
evaluated	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
,	O
a	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
;	O
exisulind	B-CHEMICAL
(	O
sulindac	B-CHEMICAL
sulfone	I-CHEMICAL
)	O
,	O
a	O
novel	O
proapoptotic	O
agent	O
that	O
does	O
not	O
inhibit	O
COX	B-GENE-N
enzymes	O
;	O
and	O
nordihydroguaiaretic	B-CHEMICAL
acid	I-CHEMICAL
(	O
NDGA	B-CHEMICAL
)	O
,	O
a	O
lipoxygenase	B-GENE-N
inhibitor	O
on	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

We	O
compared	O
these	O
effects	O
with	O
those	O
of	O
13	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
a	O
chemoprevention	O
agent	O
,	O
and	O
with	O
the	O
cytotoxic	O
chemotherapeutic	O
agents	O
paclitaxel	B-CHEMICAL
and	O
cisplatin	B-CHEMICAL
,	O
alone	O
or	O
in	O
combination	O
.	O

Our	O
goal	O
was	O
to	O
develop	O
new	O
chemoprevention	O
and	O
treatment	O
strategies	O
.	O

Each	O
of	O
the	O
six	O
agents	O
tested	O
inhibited	O
the	O
in	O
vitro	O
growth	O
of	O
three	O
NSCLC	O
and	O
three	O
SCLC	O
cell	O
lines	O
at	O
the	O
highest	O
concentration	O
.	O

Paclitaxel	B-CHEMICAL
was	O
the	O
most	O
potent	O
agent	O
(	O
IC50	O
=	O
0	O
.	O
003	O
-	O
0	O
.	O
150	O
microM	O
)	O
;	O
sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
,	O
NDGA	B-CHEMICAL
,	O
and	O
13	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
had	O
intermediate	O
potency	O
(	O
IC50	O
=	O
4	O
-	O
80	O
microM	O
)	O
,	O
and	O
cisplatin	B-CHEMICAL
and	O
exisulind	B-CHEMICAL
were	O
the	O
least	O
potent	O
(	O
IC50	O
=	O
150	O
-	O
500	O
microM	O
)	O
.	O

Combination	O
studies	O
showed	O
synergistic	O
interactions	O
for	O
sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
,	O
exisulind	B-CHEMICAL
,	O
and	O
NDGA	B-CHEMICAL
with	O
paclitaxel	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
,	O
and	O
13	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
regardless	O
of	O
drug	O
-	O
resistance	O
phenotype	O
.	O

At	O
high	O
concentrations	O
,	O
the	O
combination	O
of	O
13	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
and	O
each	O
of	O
the	O
five	O
other	O
drugs	O
resulted	O
in	O
a	O
strong	O
synergistic	O
effect	O
.	O

These	O
studies	O
provide	O
a	O
rationale	O
for	O
chemoprevention	O
(	O
exisulind	B-CHEMICAL
+	O
/	O
-	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
+	O
/	O
-	O
NDGA	B-CHEMICAL
)	O
and	O
therapeutic	O
(	O
exisulind	B-CHEMICAL
+	O
/	O
-	O
paclitaxel	B-CHEMICAL
+	O
/	O
-	O
cisplatin	B-CHEMICAL
)	O
studies	O
in	O
patients	O
at	O
risk	O
for	O
,	O
or	O
with	O
,	O
lung	O
cancer	O
.	O

Lithium	B-CHEMICAL
modulates	O
desensitization	O
of	O
the	O
glutamate	B-GENE-N
receptor	I-GENE-N
subtype	O
gluR3	B-GENE-Y
in	O
Xenopus	O
oocytes	O
.	O

Analysis	O
of	O
splice	O
variants	O
and	O
site	O
-	O
directed	O
mutants	O
of	O
the	O
AMPA	B-GENE-N
receptor	I-GENE-N
GluR3	B-GENE-Y
expressed	O
in	O
Xenopus	O
oocytes	O
has	O
shown	O
that	O
lithium	B-CHEMICAL
produces	O
a	O
large	O
potentiation	O
of	O
the	O
GluR3	B-GENE-Y
flop	I-GENE-Y
splice	O
variant	O
and	O
suggested	O
that	O
lithium	B-CHEMICAL
might	O
inhibit	O
rapid	O
desensitization	O
,	O
which	O
is	O
characteristic	O
of	O
this	O
receptor	O
(	O
Karkanias	O
,	O
N	O
.	O
and	O
Papke	O
,	O
R	O
.	O
,	O
Subtype	O
-	O
specific	O
effects	O
of	O
lithium	B-CHEMICAL
on	O
glutamate	B-GENE-N
receptor	I-GENE-N
function	O
.	O
J	O
.	O
Neurophysiol	O
.	O
,	O
81	O
(	O
1999	O
)	O
1506	O
-	O
1512	O
)	O
.	O

We	O
now	O
show	O
that	O
mutation	O
of	O
the	O
769R	O
/	O
G	O
desensitization	O
site	O
(	O
Lomeli	O
,	O
H	O
.	O
M	O
.	O
J	O
.	O
,	O
Melcher	O
,	O
T	O
.	O
,	O
Hoger	O
,	O
T	O
.	O
,	O
Geiger	O
,	O
J	O
.	O
R	O
.	O
,	O
Kuner	O
,	O
T	O
.	O
,	O
Monyer	O
,	O
H	O
.	O
,	O
Higuchi	O
,	O
M	O
.	O
B	O
.	O
A	O
.	O
and	O
Seeburg	O
,	O
P	O
.	O
H	O
,	O
Control	O
of	O
kinetic	O
properties	O
of	O
AMPA	B-GENE-N
receptor	I-GENE-N
channels	O
by	O
nuclear	O
RNA	O
editing	O
.	O
Science	O
,	O
9	O
(	O
266	O
)	O
(	O
1994	O
)	O
1709	O
-	O
1713	O
)	O
greatly	O
attenuates	O
the	O
lithium	B-CHEMICAL
-	O
induced	O
potentiation	O
of	O
GluR3	B-GENE-Y
.	O

Additionally	O
,	O
experiments	O
with	O
the	O
non	O
-	O
desensitizing	O
site	O
-	O
directed	O
mutant	O
GluR3	B-GENE-Y
(	O
L507Y	B-GENE-N
)	O
(	O
Stern	O
-	O
Bach	O
,	O
Y	O
.	O
,	O
Russo	O
,	O
S	O
.	O
,	O
Neuman	O
,	O
M	O
.	O
and	O
Rosenmund	O
,	O
C	O
.	O
,	O
A	O
point	O
mutation	O
in	O
the	O
glutamate	B-CHEMICAL
binding	O
site	O
blocks	O
desensitization	O
of	O
AMPA	B-GENE-N
receptors	I-GENE-N
.	O
Neuron	O
,	O
21	O
(	O
1998	O
)	O
907	O
-	O
918	O
)	O
further	O
confirms	O
that	O
lithium	B-CHEMICAL
enhances	O
GluR3	B-GENE-Y
responses	O
by	O
reducing	O
desensitization	O
,	O
since	O
lithium	O
'	O
s	O
effects	O
are	O
reversed	O
in	O
this	O
mutant	O
.	O

Lithium	O
'	O
s	O
effects	O
on	O
GluR3	B-GENE-Y
desensitization	O
are	O
distinct	O
from	O
the	O
effects	O
of	O
aniracetam	B-CHEMICAL
on	O
desensitization	O
.	O

Specifically	O
,	O
aniracetam	B-CHEMICAL
,	O
which	O
potentiates	O
wild	O
-	O
type	O
AMPA	B-GENE-N
receptors	I-GENE-N
,	O
is	O
ineffective	O
on	O
the	O
non	O
-	O
desensitizing	O
GluR3	B-GENE-Y
(	O
L507Y	B-GENE-N
)	O
mutant	O
,	O
but	O
has	O
synergistic	O
effects	O
with	O
lithium	B-CHEMICAL
on	O
wild	O
-	O
type	O
receptors	O
.	O

The	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
series	O
modulates	O
high	B-GENE-N
-	I-GENE-N
voltage	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
calcium	I-GENE-N
channels	I-GENE-N
probably	O
through	O
the	O
EP3	B-GENE-Y
receptor	I-GENE-Y
in	O
rat	O
paratracheal	O
ganglia	O
.	O

The	O
modulation	O
of	O
high	B-GENE-N
-	I-GENE-N
voltage	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
(	I-GENE-N
HVA	I-GENE-N
)	I-GENE-N
Ca2	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
by	O
the	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
series	O
(	O
PGE1	B-CHEMICAL
and	O
PGE2	B-CHEMICAL
)	O
was	O
studied	O
in	O
the	O
paratracheal	O
ganglion	O
cells	O
.	O

Prostaglandin	B-CHEMICAL
E1	I-CHEMICAL
,	I-CHEMICAL
E2	I-CHEMICAL
,	I-CHEMICAL
STA2	B-CHEMICAL
(	O
a	O
stable	O
analogue	O
of	O
thromboxane	B-CHEMICAL
A2	I-CHEMICAL
)	O
,	O
17	B-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
trinor	I-CHEMICAL
-	I-CHEMICAL
PGE2	I-CHEMICAL
(	O
an	O
EP1	B-GENE-Y
-	O
selective	O
agonist	O
)	O
and	O
sulprostone	B-CHEMICAL
(	O
an	O
EP3	B-GENE-Y
-	O
selective	O
agonist	O
)	O
inhibited	O
the	O
HVA	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
current	O
(	O
HVA	O
ICa	O
)	O
dose	O
-	O
dependently	O
,	O
and	O
the	O
rank	O
order	O
of	O
potency	O
to	O
inhibit	O
HVA	B-GENE-N
Ca2	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
was	O
sulprostone	B-CHEMICAL
>	O
PGE2	B-CHEMICAL
,	O
PGE1	B-CHEMICAL
>	O
STA2	B-CHEMICAL
>	O
>	O
17	B-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
trinor	I-CHEMICAL
-	I-CHEMICAL
PGE2	I-CHEMICAL
.	O

SC	B-CHEMICAL
-	I-CHEMICAL
51089	I-CHEMICAL
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
,	O
a	O
selective	O
EP1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
showed	O
no	O
effect	O
on	O
the	O
PGE1	B-CHEMICAL
-	O
or	O
PGE2	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
the	O
HVA	O
ICa	O
,	O
thereby	O
indicating	O
that	O
PGE1	B-CHEMICAL
-	O
and	O
PGE2	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
the	O
HVA	B-GENE-N
Ca2	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
is	O
possibly	O
mediated	O
by	O
the	O
EP3	B-GENE-Y
receptor	I-GENE-Y
.	O

The	O
PGE1	B-CHEMICAL
-	O
sensitive	O
component	O
of	O
the	O
current	O
was	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
omega	O
-	O
conotoxin	O
-	O
GVIA	O
(	O
3x10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
but	O
not	O
with	O
nifedipine	B-CHEMICAL
(	O
3x10	O
(	O
-	O
6	O
)	O
M	O
)	O
.	O

PGE1	B-CHEMICAL
and	O
PGE2	B-CHEMICAL
also	O
inhibited	O
the	O
remaining	O
ICa	O
in	O
a	O
saturating	O
concentration	O
of	O
nifedipine	B-CHEMICAL
,	O
omega	O
-	O
conotoxin	O
-	O
GVIA	O
and	O
omega	O
-	O
conotoxin	O
-	O
MVIIC	O
,	O
suggesting	O
that	O
R	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca2	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
are	O
involved	O
.	O

The	O
inhibitory	O
effect	O
of	O
PGE1	B-CHEMICAL
or	O
sulprostone	B-CHEMICAL
was	O
prevented	O
by	O
pretreatment	O
with	O
pertussis	B-GENE-N
toxin	I-GENE-N
[	O
islet	B-GENE-N
activating	I-GENE-N
protein	I-GENE-N
(	O
IAP	B-GENE-N
)	O
]	O
or	O
phorbol	B-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
myristate	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
(	O
PMA	B-CHEMICAL
)	O
,	O
and	O
the	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	O
PKC	B-GENE-N
)	O
inhibitor	O
chelerythrine	B-CHEMICAL
blocked	O
the	O
action	O
of	O
PMA	B-CHEMICAL
.	O

It	O
was	O
concluded	O
that	O
PGE1	B-CHEMICAL
selectively	O
reduces	O
both	O
N	O
-	O
and	O
R	O
-	O
type	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
by	O
activating	O
a	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
probably	O
through	O
the	O
EP3	B-GENE-Y
receptor	I-GENE-Y
in	O
paratracheal	O
ganglion	O
cells	O
.	O

[	O
Effect	O
of	O
mifepristone	B-CHEMICAL
on	O
the	O
expression	O
of	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
messenger	O
RNA	O
and	O
protein	O
in	O
uterine	O
leiomyomata	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
expression	O
of	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
(	O
PR	B-GENE-Y
)	O
mRNA	O
and	O
PR	B-GENE-Y
protein	I-GENE-Y
levels	O
in	O
the	O
myometrium	O
and	O
leiomyomata	O
from	O
untreated	O
and	O
mifepristone	B-CHEMICAL
pretreated	O
women	O
with	O
leiomyoma	O
and	O
to	O
examine	O
the	O
mechanism	O
of	O
mifepristone	B-CHEMICAL
treatment	O
on	O
uterine	O
leiomyomata	O
.	O

METHODS	O
:	O
Expression	O
of	O
PR	B-GENE-N
mRNA	I-GENE-N
and	O
PR	B-GENE-Y
protein	I-GENE-Y
were	O
determined	O
by	O
Northern	O
blot	O
and	O
HAP	O
of	O
single	O
-	O
dose	O
saturated	O
analysis	O
in	O
myometrium	O
and	O
leiomyomata	O
(	O
center	O
and	O
marginal	O
area	O
)	O
from	O
27	O
untreated	O
and	O
6	O
mifepristone	B-CHEMICAL
pretreated	O
women	O
with	O
leiomyomata	O
.	O

RESULTS	O
:	O
PR	B-GENE-N
mRNA	I-GENE-N
abundance	O
and	O
PR	B-GENE-Y
protein	I-GENE-Y
levels	O
in	O
both	O
myomatous	O
center	O
and	O
marginal	O
area	O
were	O
significantly	O
greater	O
than	O
those	O
in	O
corporal	O
myometrium	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
both	O
follicular	O
and	O
luteal	O
phases	O
,	O
but	O
similar	O
between	O
myomatous	O
center	O
and	O
marginal	O
area	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

6	O
cases	O
pretreated	O
with	O
mifepristone	B-CHEMICAL
25	O
mg	O
/	O
day	O
for	O
3	O
months	O
were	O
operated	O
,	O
all	O
but	O
one	O
patient	O
displayed	O
a	O
decrease	O
in	O
leiomyomata	O
volume	O
.	O

PR	B-GENE-N
mRNA	I-GENE-N
abundance	O
in	O
both	O
myometruim	O
and	O
leiomyomata	O
(	O
center	O
and	O
marginal	O
area	O
)	O
was	O
significantly	O
decreased	O
in	O
4	O
patients	O
continuing	O
mifepristone	B-CHEMICAL
treatment	O
before	O
the	O
operation	O
but	O
not	O
in	O
the	O
other	O
2	O
patients	O
stopping	O
RU486	B-CHEMICAL
1	O
month	O
before	O
operation	O
.	O

PR	B-GENE-Y
protein	I-GENE-Y
levels	O
in	O
these	O
tissues	O
showed	O
significant	O
decrease	O
in	O
all	O
6	O
cases	O
.	O

CONCLUSION	O
:	O
There	O
are	O
overexpression	O
of	O
PRmRNA	B-GENE-N
and	O
PR	B-GENE-Y
protein	I-GENE-Y
in	O
leiomyomata	O
.	O

One	O
of	O
the	O
mechanism	O
of	O
mifepristone	B-CHEMICAL
action	O
on	O
decreasing	O
leiomyomata	O
volume	O
may	O
be	O
related	O
to	O
suppression	O
on	O
expression	O
of	O
PR	B-GENE-Y
gene	I-GENE-Y
.	O

It	O
seems	O
that	O
suppression	O
on	O
transcription	O
of	O
PR	B-GENE-Y
gene	I-GENE-Y
is	O
reversible	O
,	O
but	O
on	O
translation	O
of	O
PR	B-GENE-Y
gene	I-GENE-Y
may	O
maintain	O
in	O
a	O
relatively	O
longer	O
period	O
.	O

Felbamate	B-CHEMICAL
block	O
of	O
recombinant	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptors	I-GENE-N
:	O
selectivity	O
for	O
the	O
NR2B	B-GENE-Y
subunit	O
.	O

The	O
anticonvulsant	O
felbamate	B-CHEMICAL
blocks	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
asparate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
but	O
fails	O
to	O
exhibit	O
the	O
neurobehavioral	O
toxicity	O
characteristic	O
of	O
other	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonists	O
.	O

To	O
investigate	O
the	O
possibility	O
that	O
felbamate	O
'	O
s	O
favorable	O
toxicity	O
profile	O
could	O
be	O
related	O
to	O
NMDA	B-GENE-N
receptor	I-GENE-N
subtype	O
selectivity	O
,	O
we	O
examined	O
the	O
specificity	O
of	O
felbamate	B-CHEMICAL
block	O
of	O
recombinant	O
NMDA	B-GENE-N
receptors	I-GENE-N
composed	O
of	O
the	O
NR1a	B-GENE-Y
subunit	O
and	O
various	O
NR2	B-GENE-N
subunits	O
.	O

Felbamate	B-CHEMICAL
produced	O
a	O
rapid	O
,	O
concentration	O
-	O
dependent	O
block	O
of	O
currents	O
evoked	O
by	O
50	O
microM	O
NMDA	B-CHEMICAL
and	O
10	O
microM	O
glycine	B-CHEMICAL
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
expressing	O
the	O
rat	B-GENE-Y
NR1a	I-GENE-Y
subunit	O
,	O
and	O
either	O
the	O
NR2A	B-GENE-Y
,	O
NR2B	B-GENE-Y
or	O
NR2C	B-GENE-Y
subunits	O
;	O
the	O
IC50	O
values	O
for	O
block	O
were	O
2	O
.	O
6	O
,	O
0	O
.	O
52	O
and	O
2	O
.	O
4	O
mM	O
,	O
respectively	O
(	O
holding	O
potential	O
,	O
-	O
60	O
mV	O
)	O
.	O

The	O
Hill	O
coefficient	O
values	O
were	O
<	O
1	O
and	O
,	O
in	O
kinetic	O
analyses	O
,	O
onset	O
and	O
recovery	O
from	O
block	O
were	O
well	O
fit	O
by	O
double	O
exponential	O
functions	O
,	O
indicating	O
binding	O
to	O
more	O
than	O
one	O
blocking	O
site	O
on	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
channel	O
complex	O
.	O

The	O
higher	O
affinity	O
of	O
felbamate	B-CHEMICAL
block	O
of	O
NMDA	B-GENE-N
receptors	I-GENE-N
containing	O
the	O
NR2B	B-GENE-Y
subunit	O
could	O
be	O
accounted	O
for	O
by	O
more	O
rapid	O
association	O
and	O
slower	O
dissociation	O
from	O
these	O
sites	O
.	O

We	O
conclude	O
that	O
felbamate	B-CHEMICAL
exhibits	O
modest	O
selectivity	O
for	O
NMDA	B-GENE-N
receptors	I-GENE-N
composed	O
of	O
NR1a	B-GENE-Y
/	O
NR2B	B-GENE-Y
subunits	O
.	O

This	O
selectivity	O
could	O
,	O
in	O
part	O
,	O
account	O
for	O
the	O
more	O
favorable	O
clinical	O
profile	O
of	O
felbamate	B-CHEMICAL
in	O
comparison	O
with	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonists	O
that	O
do	O
not	O
show	O
subunit	O
selectivity	O
.	O

Comparison	O
of	O
the	O
effect	O
of	O
rofecoxib	B-CHEMICAL
(	O
a	O
cyclooxygenase	B-GENE-Y
2	I-GENE-Y
inhibitor	O
)	O
,	O
ibuprofen	B-CHEMICAL
,	O
and	O
placebo	O
on	O
the	O
gastroduodenal	O
mucosa	O
of	O
patients	O
with	O
osteoarthritis	O
:	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
Rofecoxib	B-CHEMICAL
Osteoarthritis	O
Endoscopy	O
Multinational	O
Study	O
Group	O
.	O

OBJECTIVE	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
tested	O
the	O
hypothesis	O
that	O
rofecoxib	B-CHEMICAL
,	O
a	O
drug	O
that	O
specifically	O
inhibits	O
cyclooxygenase	B-GENE-Y
2	I-GENE-Y
,	O
would	O
cause	O
fewer	O
gastroduodenal	O
ulcers	O
than	O
ibuprofen	B-CHEMICAL
(	O
in	O
a	O
multicenter	O
trial	O
)	O
,	O
and	O
its	O
side	O
effects	O
would	O
be	O
equivalent	O
to	O
those	O
of	O
placebo	O
(	O
in	O
a	O
prespecified	O
analysis	O
combining	O
the	O
results	O
with	O
another	O
trial	O
of	O
identical	O
design	O
)	O
.	O

METHODS	O
:	O
Seven	O
hundred	O
seventy	O
-	O
five	O
patients	O
with	O
osteoarthritis	O
were	O
randomized	O
to	O
receive	O
rofecoxib	B-CHEMICAL
at	O
a	O
dosage	O
of	O
25	O
mg	O
or	O
50	O
mg	O
once	O
daily	O
,	O
ibuprofen	O
800	O
mg	O
3	O
times	O
daily	O
,	O
or	O
placebo	O
.	O

Gastroduodenal	O
ulceration	O
was	O
assessed	O
by	O
endoscopy	O
at	O
6	O
,	O
12	O
,	O
and	O
(	O
for	O
active	O
treatment	O
)	O
24	O
weeks	O
.	O

The	O
primary	O
and	O
secondary	O
end	O
points	O
were	O
the	O
incidence	O
of	O
gastroduodenal	O
ulcers	O
at	O
12	O
and	O
24	O
weeks	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Ulcers	O
were	O
significantly	O
less	O
common	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
following	O
treatment	O
with	O
rofecoxib	B-CHEMICAL
(	O
25	O
mg	O
or	O
50	O
mg	O
)	O
than	O
with	O
ibuprofen	B-CHEMICAL
after	O
12	O
weeks	O
(	O
5	O
.	O
3	O
%	O
and	O
8	O
.	O
8	O
%	O
versus	O
29	O
.	O
2	O
%	O
,	O
respectively	O
)	O
or	O
24	O
weeks	O
(	O
9	O
.	O
9	O
%	O
and	O
12	O
.	O
4	O
%	O
versus	O
46	O
.	O
8	O
%	O
,	O
respectively	O
)	O
.	O

In	O
the	O
combined	O
analysis	O
,	O
the	O
12	O
-	O
week	O
ulcer	O
incidence	O
with	O
25	O
mg	O
rofecoxib	B-CHEMICAL
(	O
4	O
.	O
7	O
%	O
)	O
and	O
with	O
placebo	O
(	O
7	O
.	O
3	O
%	O
)	O
satisfied	O
prespecified	O
criteria	O
for	O
equivalence	O
.	O

CONCLUSION	O
:	O
At	O
2	O
-	O
4	O
times	O
the	O
therapeutically	O
effective	O
dose	O
,	O
rofecoxib	B-CHEMICAL
caused	O
fewer	O
endoscopically	O
detected	O
ulcers	O
than	O
did	O
ibuprofen	B-CHEMICAL
.	O

Rofecoxib	O
at	O
a	O
dose	O
of	O
25	O
mg	O
(	O
the	O
highest	O
dose	O
recommended	O
for	O
osteoarthritis	O
)	O
satisfied	O
prespecified	O
criteria	O
for	O
equivalence	O
to	O
placebo	O
.	O

Inhibition	O
by	O
troglitazone	B-CHEMICAL
of	O
the	O
antigen	O
-	O
induced	O
production	O
of	O
leukotrienes	B-CHEMICAL
in	O
immunoglobulin	B-GENE-N
E	I-GENE-N
-	O
sensitized	O
RBL	O
-	O
2H3	O
cells	O
.	O

1	O
.	O

The	O
effect	O
of	O
troglitazone	B-CHEMICAL
,	O
an	O
anti	O
-	O
diabetic	O
drug	O
with	O
insulin	B-GENE-N
-	O
sensitizing	O
action	O
,	O
on	O
antigen	O
-	O
induced	O
production	O
of	O
leukotriene	B-CHEMICAL
(	I-CHEMICAL
LT	I-CHEMICAL
)	I-CHEMICAL
B	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	I-CHEMICAL
C	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
and	I-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
and	O
prostaglandin	B-CHEMICAL
D	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
PGD	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
was	O
examined	O
in	O
dinitrophenol	B-CHEMICAL
(	O
DNP	B-CHEMICAL
)	O
-	O
specific	O
immunoglobulin	B-GENE-N
E	I-GENE-N
(	O
IgE	B-GENE-N
)	O
-	O
sensitized	O
RBL	O
-	O
2H3	O
mast	O
cells	O
following	O
stimulation	O
by	O
the	O
antigen	O
,	O
DNP	B-CHEMICAL
-	O
conjugated	O
human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
.	O

Levels	O
of	O
LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	O
C	O
(	O
4	O
)	O
and	O
E	O
(	O
4	O
)	O
and	O
PGD	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
in	O
the	O
conditioned	O
medium	O
were	O
enzyme	O
-	O
immunoassayed	O
.	O

2	O
.	O

Troglitazone	B-CHEMICAL
inhibited	O
the	O
antigen	O
-	O
induced	O
production	O
of	O
LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	O
C	O
(	O
4	O
)	O
and	O
E	O
(	O
4	O
)	O
and	O
the	O
potency	O
of	O
the	O
inhibition	O
was	O
comparable	O
to	O
that	O
of	O
zileuton	B-CHEMICAL
,	O
a	O
specific	O
inhibitor	O
of	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
(	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
)	O
and	O
a	O
clinically	O
used	O
anti	O
-	O
asthmatic	O
drug	O
.	O

Neither	O
troglitazone	B-CHEMICAL
nor	O
zileuton	B-CHEMICAL
affected	O
antigen	O
-	O
induced	O
production	O
of	O
PGD	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
,	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
release	O
from	O
membrane	O
phospholipids	O
and	O
degranulation	O
.	O

3	O
.	O

Troglitazone	B-CHEMICAL
inhibited	O
LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
production	O
by	O
the	O
supernatant	O
fraction	O
of	O
RBL	O
-	O
2H3	O
cell	O
lysate	O
with	O
similar	O
potency	O
to	O
zileuton	B-CHEMICAL
,	O
suggesting	O
that	O
troglitazone	B-CHEMICAL
inhibits	O
LT	O
production	O
by	O
direct	O
inhibition	O
of	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
activity	O
.	O

4	O
.	O

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
troglitazone	B-CHEMICAL
as	O
well	O
as	O
zileuton	B-CHEMICAL
inhibited	O
LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
production	O
in	O
A23187	B-CHEMICAL
-	O
stimulated	O
rat	O
peritoneal	O
neutrophils	O
.	O

5	O
.	O

These	O
findings	O
suggest	O
that	O
troglitazone	B-CHEMICAL
inhibits	O
antigen	O
-	O
induced	O
LT	O
production	O
in	O
the	O
IgE	B-GENE-N
-	O
sensitized	O
RBL	O
-	O
2H3	O
cells	O
and	O
A23187	B-CHEMICAL
-	O
stimulated	O
rat	O
peritoneal	O
neutrophils	O
by	O
direct	O
inhibition	O
of	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
activity	O
.	O

SPACRCAN	B-GENE-N
,	O
a	O
novel	O
human	B-GENE-N
interphotoreceptor	I-GENE-N
matrix	I-GENE-N
hyaluronan	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteoglycan	I-GENE-N
synthesized	O
by	O
photoreceptors	O
and	O
pinealocytes	O
.	O

The	O
interphotoreceptor	O
matrix	O
is	O
a	O
unique	O
extracellular	O
complex	O
occupying	O
the	O
interface	O
between	O
photoreceptors	O
and	O
the	O
retinal	O
pigment	O
epithelium	O
in	O
the	O
fundus	O
of	O
the	O
eye	O
.	O

Because	O
of	O
the	O
putative	O
supportive	O
role	O
in	O
photoreceptor	O
maintenance	O
,	O
it	O
is	O
likely	O
that	O
constituent	O
molecules	O
play	O
key	O
roles	O
in	O
photoreceptor	O
function	O
and	O
may	O
be	O
targets	O
for	O
inherited	O
retinal	B-CHEMICAL
disease	O
.	O

In	O
this	O
study	O
we	O
identify	O
and	O
characterize	O
SPACRCAN	B-GENE-N
,	O
a	O
novel	O
chondroitin	O
proteoglycan	O
in	O
this	O
matrix	O
.	O

SPACRCAN	B-GENE-N
was	O
cloned	O
from	O
a	O
human	O
retinal	B-CHEMICAL
cDNA	O
library	O
and	O
the	O
gene	O
localized	O
to	O
chromosome	O
3q11	O
.	O
2	O
.	O

Analysis	O
of	O
SPACRCAN	B-GENE-N
mRNA	O
and	O
protein	O
revealed	O
that	O
SPACRCAN	B-GENE-N
is	O
expressed	O
exclusively	O
by	O
photoreceptors	O
and	O
pinealocytes	O
.	O

SPACRCAN	B-GENE-N
synthesized	O
by	O
photoreceptors	O
is	O
localized	O
to	O
the	O
interphotoreceptor	O
matrix	O
where	O
it	O
surrounds	O
both	O
rods	O
and	O
cones	O
.	O

The	O
functional	O
protein	O
contains	O
1160	O
amino	B-CHEMICAL
acids	I-CHEMICAL
with	O
a	O
large	O
central	O
mucin	B-GENE-N
domain	I-GENE-N
,	O
three	O
consensus	O
sites	O
for	O
glycosaminoglycan	O
attachment	O
,	O
two	O
epidermal	O
growth	O
factor	O
-	O
like	O
repeats	O
,	O
a	O
putative	O
hyaluronan	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
motif	I-GENE-N
,	O
and	O
a	O
potential	O
transmembrane	O
domain	O
near	O
the	O
C	B-CHEMICAL
-	O
terminal	O
.	O

Lectin	B-GENE-N
and	O
Western	O
blotting	O
indicate	O
an	O
M	O
(	O
r	O
)	O
around	O
400	O
,	O
000	O
before	O
and	O
230	O
,	O
000	O
after	O
chondroitinase	B-GENE-N
ABC	I-GENE-N
digestion	O
.	O

Removal	O
of	O
N	B-CHEMICAL
-	O
and	O
O	B-CHEMICAL
-	O
linked	O
oligosaccharides	O
reduces	O
the	O
M	O
(	O
r	O
)	O
to	O
approximately	O
160	O
,	O
000	O
,	O
suggesting	O
that	O
approximately	O
60	O
%	O
of	O
the	O
mass	O
of	O
SPACRCAN	B-GENE-N
is	O
carbohydrate	B-CHEMICAL
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
SPACRCAN	B-GENE-N
binds	O
hyaluronan	B-GENE-N
and	O
propose	O
that	O
associations	O
between	O
SPACRCAN	B-GENE-N
and	O
hyaluronan	B-GENE-N
may	O
be	O
involved	O
in	O
organization	O
of	O
the	O
insoluble	O
interphotoreceptor	O
matrix	O
,	O
particularly	O
as	O
SPACRCAN	B-GENE-N
is	O
the	O
major	O
proteoglycan	O
present	O
in	O
this	O
matrix	O
.	O

Polyamine	B-CHEMICAL
depletion	O
delays	O
apoptosis	O
of	O
rat	O
intestinal	O
epithelial	O
cells	O
.	O

The	O
polyamines	B-CHEMICAL
spermidine	B-CHEMICAL
,	O
spermine	B-CHEMICAL
,	O
and	O
their	O
precursor	O
putrescine	B-CHEMICAL
are	O
essential	O
for	O
cell	O
growth	O
and	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
.	O

Recent	O
studies	O
suggest	O
that	O
excessive	O
accumulation	O
of	O
polyamines	B-CHEMICAL
favors	O
either	O
malignant	O
transformation	O
or	O
apoptosis	O
,	O
depending	O
on	O
the	O
cell	O
type	O
and	O
the	O
stimulus	O
.	O

This	O
study	O
examines	O
the	O
involvement	O
of	O
polyamines	B-CHEMICAL
in	O
the	O
induction	O
of	O
apoptosis	O
by	O
the	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
I	I-GENE-Y
inhibitor	O
,	O
camptothecin	O
.	O

In	O
IEC	O
-	O
6	O
cells	O
,	O
camptothecin	B-CHEMICAL
induced	O
apoptosis	O
within	O
6	O
h	O
,	O
accompanied	O
by	O
detachment	O
of	O
cells	O
.	O

Detached	O
cells	O
showed	O
DNA	O
laddering	O
and	O
caspase	B-GENE-Y
3	I-GENE-Y
induction	O
,	O
characteristic	O
features	O
of	O
apoptosis	O
.	O

Depletion	O
of	O
putrescine	B-CHEMICAL
,	O
spermidine	B-CHEMICAL
,	O
and	O
spermine	B-CHEMICAL
by	O
DL	B-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
difluoromethylornithine	I-CHEMICAL
(	O
DFMO	B-CHEMICAL
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
ornithine	B-GENE-Y
decarboxylase	I-GENE-Y
(	O
ODC	B-GENE-Y
)	O
that	O
is	O
the	O
first	O
rate	O
-	O
limiting	O
enzyme	O
for	O
polyamine	B-CHEMICAL
biosynthesis	O
,	O
decreased	O
the	O
apoptotic	O
index	O
.	O

Delayed	O
apoptosis	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
caspase	B-GENE-Y
3	I-GENE-Y
activity	O
in	O
polyamine	B-CHEMICAL
-	O
depleted	O
cells	O
.	O

Addition	O
of	O
putrescine	B-CHEMICAL
restored	O
the	O
induction	O
of	O
apoptosis	O
as	O
indicated	O
by	O
an	O
increase	O
in	O
the	O
number	O
of	O
detached	O
cells	O
and	O
caspase	B-GENE-Y
3	I-GENE-Y
activity	O
.	O

Polyamine	B-CHEMICAL
depletion	O
did	O
not	O
change	O
the	O
level	O
of	O
caspase	B-GENE-Y
3	I-GENE-Y
protein	O
.	O

Inhibition	O
of	O
S	B-GENE-Y
-	I-GENE-Y
adenosylmethionine	I-GENE-Y
decarboxylase	I-GENE-Y
by	O
a	O
specific	O
inhibitor	O
[	O
diethylglyoxal	B-CHEMICAL
bis	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
guanylhydrazone	I-CHEMICAL
)	I-CHEMICAL
;	O
DEGBG	B-CHEMICAL
]	O
led	O
to	O
depletion	O
of	O
spermidine	B-CHEMICAL
and	O
spermine	B-CHEMICAL
with	O
a	O
significant	O
accumulation	O
of	O
putrescine	B-CHEMICAL
and	O
induction	O
of	O
ODC	B-GENE-Y
.	O

The	O
DEGBG	B-CHEMICAL
-	O
treated	O
cells	O
showed	O
an	O
increase	O
in	O
apoptosis	O
,	O
suggesting	O
the	O
importance	O
of	O
putrescine	B-CHEMICAL
in	O
the	O
apoptotic	O
process	O
.	O

Addition	O
of	O
putrescine	B-CHEMICAL
to	O
DFMO	B-CHEMICAL
-	O
treated	O
cell	O
extracts	O
did	O
not	O
increase	O
caspase	B-GENE-Y
3	I-GENE-Y
activity	O
.	O

The	O
above	O
results	O
indicate	O
that	O
polyamine	B-CHEMICAL
depletion	O
delays	O
the	O
onset	O
of	O
apoptosis	O
in	O
IEC	O
-	O
6	O
cells	O
and	O
confers	O
protection	O
against	O
DNA	O
damaging	O
agents	O
,	O
suggesting	O
that	O
polyamines	B-CHEMICAL
might	O
be	O
involved	O
in	O
the	O
caspase	B-GENE-N
activating	O
signal	O
cascade	O
.	O

The	O
role	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
and	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
on	O
the	O
modulation	O
of	O
acute	O
fluoxetine	B-CHEMICAL
-	O
induced	O
changes	O
in	O
extracellular	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
:	O
the	O
mechanism	O
of	O
action	O
of	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
.	O

Some	O
clinical	O
evidence	O
has	O
suggested	O
that	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
can	O
be	O
effective	O
at	O
producing	O
a	O
shortened	O
time	O
to	O
onset	O
of	O
antidepressant	O
activity	O
when	O
co	O
-	O
administered	O
with	O
a	O
serotonin	B-CHEMICAL
specific	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
.	O

This	O
effect	O
has	O
been	O
attributed	O
to	O
the	O
antagonist	O
effects	O
of	O
pindolol	B-CHEMICAL
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptor	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
pharmacology	O
of	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
,	O
WAY	B-CHEMICAL
-	I-CHEMICAL
100635	I-CHEMICAL
(	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
antagonist	O
)	O
,	O
GR127935	B-CHEMICAL
(	O
a	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
antagonist	O
)	O
,	O
and	O
isamoltane	B-CHEMICAL
(	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
antagonist	O
)	O
,	O
when	O
given	O
acutely	O
in	O
combination	O
with	O
fluoxetine	B-CHEMICAL
,	O
using	O
in	O
vivo	O
microdialysis	O
in	O
the	O
frontal	O
cortex	O
of	O
the	O
freely	O
moving	O
rat	O
.	O

We	O
have	O
determined	O
that	O
the	O
acute	O
fluoxetine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
extracellular	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
can	O
be	O
augmented	O
by	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
,	O
WAY100635	B-CHEMICAL
,	O
GR127935	B-CHEMICAL
and	O
isamoltane	B-CHEMICAL
with	O
maximum	O
increases	O
of	O
216	O
+	O
/	O
-	O
32	O
%	O
,	O
235	O
+	O
/	O
-	O
49	O
%	O
,	O
240	O
+	O
/	O
-	O
18	O
%	O
and	O
171	O
+	O
/	O
-	O
47	O
%	O
of	O
preinjection	O
control	O
levels	O
,	O
respectively	O
.	O

Combination	O
of	O
both	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
and	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
autoreceptor	O
antagonists	O
with	O
fluoxetine	B-CHEMICAL
produced	O
additive	O
increases	O
in	O
extracellular	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
(	O
i	O
.	O
e	O
.	O
WAY100635	B-CHEMICAL
+	O
GR127935	B-CHEMICAL
+	O
fluoxetine	B-CHEMICAL
and	O
WAY100635	B-CHEMICAL
+	O
isamoltane	B-CHEMICAL
+	O
fluoxetine	B-CHEMICAL
produced	O
a	O
four	O
-	O
and	O
five	O
-	O
fold	O
potentiation	O
,	O
respectively	O
)	O
,	O
suggesting	O
that	O
this	O
strategy	O
may	O
be	O
useful	O
in	O
further	O
augmenting	O
the	O
action	O
of	O
a	O
SSRI	O
in	O
the	O
treatment	O
of	O
depression	O
.	O

In	O
addition	O
,	O
by	O
comparing	O
the	O
combined	O
administration	O
of	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
with	O
either	O
WAY100635	B-CHEMICAL
,	O
GR127935	B-CHEMICAL
or	O
isamoltane	B-CHEMICAL
,	O
we	O
have	O
determined	O
that	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
pindolol	I-CHEMICAL
produces	O
much	O
of	O
its	O
acute	O
potentiation	O
of	O
fluoxetine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
extracellular	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
via	O
its	O
action	O
at	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
/	I-GENE-N
D	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
in	O
addition	O
to	O
any	O
activity	O
it	O
has	O
at	O
the	O
presynaptic	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptor	O
.	O

Orlistat	B-CHEMICAL
,	O
a	O
new	O
lipase	B-GENE-N
inhibitor	O
for	O
the	O
management	O
of	O
obesity	O
.	O

Orlistat	B-CHEMICAL
,	O
a	O
weight	O
-	O
loss	O
agent	O
with	O
a	O
novel	O
mechanism	O
of	O
action	O
,	O
recently	O
was	O
approved	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
obesity	O
.	O

It	O
inhibits	O
gastric	B-GENE-N
and	I-GENE-N
pancreatic	I-GENE-N
lipases	I-GENE-N
in	O
the	O
lumen	O
of	O
the	O
gastrointestinal	O
tract	O
to	O
decrease	O
systemic	O
absorption	O
of	O
dietary	O
fat	O
.	O

In	O
several	O
trials	O
lasting	O
up	O
to	O
2	O
years	O
,	O
orlistat	B-CHEMICAL
was	O
more	O
effective	O
than	O
diet	O
alone	O
for	O
weight	O
reduction	O
and	O
maintenance	O
of	O
lost	O
weight	O
.	O

Orlistat	B-CHEMICAL
treatment	O
also	O
results	O
in	O
modest	O
improvements	O
in	O
total	O
cholesterol	B-CHEMICAL
,	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
,	O
blood	O
pressure	O
,	O
and	O
fasting	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-Y
concentrations	O
.	O

The	O
major	O
adverse	O
effects	O
are	O
gastrointestinal	O
,	O
usually	O
occur	O
early	O
in	O
therapy	O
,	O
and	O
tend	O
to	O
decrease	O
with	O
continued	O
treatment	O
.	O

Because	O
orlistat	B-CHEMICAL
may	O
decrease	O
the	O
absorption	O
of	O
fat	O
-	O
soluble	O
vitamins	B-CHEMICAL
,	O
a	O
standard	O
multiple	O
-	O
vitamin	B-CHEMICAL
supplement	O
is	O
recommended	O
daily	O
during	O
therapy	O
to	O
prevent	O
abnormalities	O
in	O
vitamin	B-CHEMICAL
serum	O
concentrations	O
.	O

The	O
potential	O
for	O
severe	O
gastrointestinal	O
discomfort	O
and	O
the	O
modest	O
degree	O
of	O
weight	O
loss	O
may	O
limit	O
the	O
agent	O
'	O
s	O
clinical	O
utility	O
.	O

Its	O
long	O
-	O
term	O
safety	O
and	O
effectiveness	O
for	O
weight	O
maintenance	O
,	O
cost	O
-	O
effectiveness	O
of	O
treatment	O
,	O
and	O
overall	O
reduction	O
in	O
obesity	O
-	O
related	O
morbidity	O
and	O
mortality	O
remain	O
to	O
be	O
determined	O
.	O

Evaluation	O
of	O
flutamide	B-CHEMICAL
genotoxicity	O
in	O
rats	O
and	O
in	O
primary	O
human	O
hepatocytes	O
.	O

Flutamide	B-CHEMICAL
,	O
an	O
effective	O
competitive	O
inhibitor	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
used	O
orally	O
for	O
palliative	O
treatment	O
of	O
prostatic	O
carcinoma	O
and	O
regulation	O
of	O
prostatic	O
hyperplasia	O
was	O
evaluated	O
for	O
its	O
genotoxic	O
effects	O
in	O
the	O
intact	O
rat	O
and	O
in	O
primary	O
cultures	O
of	O
human	O
hepatocytes	O
.	O

Negative	O
responses	O
were	O
obtained	O
in	O
all	O
the	O
in	O
vivo	O
assays	O
as	O
well	O
as	O
in	O
the	O
in	O
vitro	O
assay	O
.	O

In	O
rats	O
given	O
a	O
single	O
oral	O
dose	O
of	O
500	O
mg	O
/	O
kg	O
flutamide	B-CHEMICAL
,	O
fragmentation	O
and	O
repair	O
of	O
liver	O
DNA	O
were	O
absent	O
,	O
and	O
no	O
increase	O
was	O
observed	O
in	O
the	O
frequency	O
of	O
micronucleated	O
hepatocytes	O
.	O

In	O
the	O
liver	O
of	O
rats	O
given	O
flutamide	B-CHEMICAL
as	O
initiating	O
agent	O
at	O
the	O
dose	O
of	O
500	O
mg	O
/	O
kg	O
/	O
week	O
for	O
6	O
successive	O
weeks	O
,	O
gamma	B-GENE-N
-	I-GENE-N
glutamyltraspeptidase	I-GENE-N
-	O
positive	O
foci	O
were	O
detected	O
only	O
in	O
3	O
of	O
10	O
rats	O
.	O

There	O
was	O
no	O
evidence	O
of	O
a	O
promoting	O
effect	O
on	O
the	O
development	O
of	O
aberrant	O
crypt	O
foci	O
in	O
rats	O
given	O
100	O
mg	O
/	O
kg	O
flutamide	B-CHEMICAL
on	O
alternate	O
days	O
for	O
8	O
successive	O
weeks	O
.	O

In	O
primary	O
cultures	O
of	O
human	O
hepatocytes	O
from	O
one	O
male	O
and	O
one	O
female	O
donor	O
DNA	O
fragmentation	O
as	O
measured	O
by	O
the	O
Comet	O
assays	O
,	O
and	O
DNA	O
repair	O
synthesis	O
as	O
revealed	O
by	O
quantitative	O
autoradiography	O
,	O
were	O
absent	O
after	O
a	O
20	O
hr	O
exposure	O
to	O
flutamide	B-CHEMICAL
concentrations	O
ranging	O
from	O
18	O
to	O
56	O
microM	O
.	O

Taken	O
as	O
a	O
whole	O
,	O
our	O
results	O
seem	O
to	O
indicate	O
that	O
flutamide	B-CHEMICAL
is	O
a	O
non	O
-	O
genotoxic	O
drug	O
.	O

Long	O
acting	O
beta	O
-	O
agonists	O
versus	O
theophylline	B-CHEMICAL
for	O
maintenance	O
treatment	O
of	O
asthma	O
.	O

BACKGROUND	O
:	O
Theophylline	B-CHEMICAL
and	O
long	O
acting	O
beta2	O
-	O
agonists	O
are	O
bronchodilators	O
used	O
for	O
the	O
management	O
of	O
persistent	O
asthma	O
symptoms	O
,	O
especially	O
nocturnal	O
asthma	O
.	O

They	O
represent	O
different	O
classes	O
of	O
drug	O
with	O
differing	O
side	O
-	O
effect	O
profiles	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
comparative	O
efficacy	O
,	O
safety	O
and	O
side	O
-	O
effects	O
of	O
long	O
-	O
acting	O
beta	O
-	O
agonists	O
and	O
theophylline	B-CHEMICAL
in	O
the	O
maintenance	O
treatment	O
of	O
asthma	O
.	O

SEARCH	O
STRATEGY	O
:	O
Randomised	O
,	O
controlled	O
trials	O
(	O
RCTs	O
)	O
were	O
identified	O
using	O
the	O
Cochrane	O
Airways	O
Group	O
register	O
.	O

The	O
register	O
was	O
searched	O
using	O
the	O
following	O
terms	O
:	O
asthma	O
and	O
theophylline	B-CHEMICAL
and	O
long	O
acting	O
beta	O
-	O
agonist	O
or	O
formoterol	B-CHEMICAL
or	O
foradile	B-CHEMICAL
or	O
eformoterol	B-CHEMICAL
or	O
salmeterol	B-CHEMICAL
or	O
bambuterol	B-CHEMICAL
or	O
bitolterol	B-CHEMICAL
.	O

Titles	O
and	O
abstracts	O
were	O
then	O
screened	O
to	O
identify	O
potentially	O
relevant	O
studies	O
.	O

The	O
bibliography	O
of	O
each	O
RCT	O
was	O
searched	O
for	O
additional	O
RCTs	O
.	O

Authors	O
of	O
identified	O
RCTs	O
were	O
contacted	O
for	O
other	O
relevant	O
published	O
and	O
unpublished	O
studies	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
included	O
studies	O
were	O
RCTs	O
involving	O
adults	O
and	O
children	O
with	O
clinical	O
evidence	O
of	O
asthma	O
.	O

These	O
studies	O
must	O
have	O
compared	O
oral	O
sustained	O
release	O
and	O
/	O
or	O
dose	O
adjusted	O
theophylline	B-CHEMICAL
with	O
an	O
inhaled	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Potentially	O
relevant	O
trials	O
,	O
identified	O
by	O
screening	O
titles	O
and	O
/	O
or	O
abstracts	O
,	O
were	O
obtained	O
.	O

Two	O
reviewers	O
independently	O
assessed	O
full	O
text	O
versions	O
of	O
these	O
trials	O
to	O
decided	O
whether	O
the	O
trial	O
should	O
be	O
included	O
in	O
the	O
review	O
,	O
and	O
assessed	O
its	O
methodological	O
quality	O
.	O

Where	O
there	O
was	O
disagreement	O
between	O
reviewers	O
,	O
this	O
was	O
resolved	O
by	O
consensus	O
,	O
or	O
reference	O
to	O
a	O
third	O
party	O
.	O

Data	O
were	O
extracted	O
by	O
two	O
independent	O
reviewers	O
.	O

Inter	O
-	O
rater	O
reliability	O
was	O
assessed	O
by	O
simple	O
agreement	O
.	O

Study	O
authors	O
were	O
contacted	O
to	O
clarify	O
randomisation	O
methods	O
,	O
provide	O
missing	O
data	O
,	O
verify	O
the	O
data	O
extracted	O
and	O
identify	O
unpublished	O
studies	O
.	O

Relevant	O
pharmaceutical	O
manufacturers	O
were	O
also	O
contacted	O
.	O

MAIN	O
RESULTS	O
:	O
Six	O
trials	O
met	O
the	O
inclusion	O
criteria	O
.	O

Five	O
used	O
salmeterol	B-CHEMICAL
and	O
one	O
,	O
biltoterol	B-CHEMICAL
.	O

They	O
were	O
of	O
varying	O
quality	O
.	O

There	O
was	O
a	O
trend	O
for	O
salmeterol	B-CHEMICAL
to	O
improve	O
FEV1	O
more	O
than	O
theophylline	B-CHEMICAL
in	O
three	O
studies	O
and	O
salmeterol	B-CHEMICAL
use	O
was	O
associated	O
with	O
more	O
symptom	O
free	O
nights	O
.	O

Bitolterol	B-CHEMICAL
,	O
used	O
in	O
only	O
one	O
study	O
,	O
was	O
reported	O
to	O
be	O
less	O
effective	O
than	O
theophylline	B-CHEMICAL
.	O

Subjects	O
taking	O
salmeterol	B-CHEMICAL
experienced	O
fewer	O
adverse	O
events	O
than	O
those	O
using	O
theophylline	B-CHEMICAL
(	O
Relative	O
Risk	O
0	O
.	O
38	O
;	O
95	O
%	O
Confidence	O
Intervals	O
0	O
.	O
25	O
,	O
0	O
.	O
57	O
)	O
.	O

Significant	O
reductions	O
were	O
reported	O
for	O
central	O
nervous	O
system	O
adverse	O
events	O
(	O
Relative	O
Risk	O
0	O
.	O
51	O
;	O
95	O
%	O
Confidence	O
Intervals	O
0	O
.	O
30	O
,	O
0	O
.	O
88	O
)	O
and	O
gastrointestinal	O
adverse	O
events	O
(	O
Relative	O
Risk	O
0	O
.	O
32	O
;	O
95	O
%	O
Confidence	O
Intervals	O
0	O
.	O
17	O
,	O
0	O
.	O
59	O
)	O
.	O

REVIEWER	O
'	O
S	O
CONCLUSIONS	O
:	O
Salmeterol	B-CHEMICAL
may	O
be	O
more	O
effective	O
than	O
theophylline	B-CHEMICAL
in	O
reducing	O
asthma	O
symptoms	O
including	O
night	O
waking	O
and	O
improving	O
lung	O
function	O
.	O

More	O
adverse	O
events	O
occurred	O
in	O
subjects	O
using	O
theophylline	B-CHEMICAL
when	O
compared	O
to	O
salmeterol	B-CHEMICAL
.	O

Neostigmine	B-CHEMICAL
:	O
safe	O
and	O
effective	O
treatment	O
for	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
.	O

BACKGROUND	O
:	O
Ogilvie	O
'	O
s	O
syndrome	O
,	O
or	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
,	O
is	O
a	O
common	O
and	O
relatively	O
dangerous	O
condition	O
.	O

If	O
left	O
untreated	O
,	O
it	O
may	O
cause	O
ischemic	O
necrosis	O
and	O
colonic	O
perforation	O
,	O
with	O
a	O
mortality	O
rate	O
as	O
high	O
as	O
50	O
percent	O
.	O

Neostigmine	B-CHEMICAL
enhances	O
excitatory	O
parasympathetic	O
activity	O
by	O
competing	O
with	O
acetylcholine	B-CHEMICAL
for	O
attachment	O
to	O
acetylcholinesterase	B-GENE-Y
at	O
sites	O
of	O
cholinergic	O
transmission	O
and	O
enhancing	O
cholinergic	O
action	O
.	O

We	O
hypothesized	O
that	O
neostigmine	B-CHEMICAL
would	O
restore	O
peristalsis	O
in	O
patients	O
with	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
.	O

METHODS	O
:	O
Twenty	O
-	O
eight	O
patients	O
at	O
Fletcher	O
Allen	O
Health	O
Care	O
and	O
The	O
Cleveland	O
Clinic	O
Foundation	O
were	O
treated	O
for	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
with	O
neostigmine	B-CHEMICAL
2	O
.	O
5	O
mg	O
IV	O
over	O
3	O
minutes	O
while	O
being	O
monitored	O
with	O
telemetry	O
.	O

Mechanical	O
obstruction	O
had	O
been	O
excluded	O
.	O

RESULTS	O
:	O
Complete	O
clinical	O
resolution	O
of	O
large	O
bowel	O
distention	O
occurred	O
in	O
26	O
of	O
the	O
28	O
patients	O
.	O

Time	O
to	O
pass	O
flatus	O
varied	O
from	O
30	O
seconds	O
to	O
10	O
minutes	O
after	O
administration	O
of	O
neostigmine	B-CHEMICAL
.	O

No	O
adverse	O
effects	O
or	O
complications	O
were	O
noted	O
.	O

Of	O
the	O
two	O
patients	O
who	O
did	O
not	O
resolve	O
,	O
one	O
had	O
a	O
sigmoid	O
cancer	O
that	O
required	O
resection	O
and	O
one	O
patient	O
died	O
from	O
multiorgan	O
failure	O
.	O

CONCLUSION	O
:	O
This	O
study	O
supports	O
the	O
theory	O
that	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
is	O
the	O
result	O
of	O
excessive	O
parasympathetic	O
suppression	O
rather	O
than	O
sympathetic	O
overactivity	O
.	O

We	O
have	O
shown	O
that	O
neostigmine	B-CHEMICAL
is	O
a	O
safe	O
and	O
effective	O
treatment	O
for	O
acute	O
colonic	O
pseudo	O
-	O
obstruction	O
.	O

Contrasting	O
effects	O
of	O
N5	B-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
tetrahydrobiopterin	I-CHEMICAL
derivatives	O
on	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
dihydropteridine	B-GENE-Y
reductase	I-GENE-Y
and	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
.	O

Tetrahydrobiopterin	B-CHEMICAL
[	O
(	B-CHEMICAL
6R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
biopterin	I-CHEMICAL
,	O
H	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
]	O
is	O
one	O
of	O
several	O
cofactors	O
of	O
nitric	B-GENE-N
oxide	I-GENE-N
synthases	I-GENE-N
(	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
14	I-GENE-Y
.	I-GENE-Y
13	I-GENE-Y
.	I-GENE-Y
39	I-GENE-Y
)	O
.	O

Here	O
we	O
compared	O
the	O
action	O
of	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	O
substituted	O
derivatives	O
on	O
recombinant	O
rat	B-GENE-Y
neuronal	I-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
with	O
their	O
effects	O
on	O
dihydropteridine	B-GENE-Y
reductase	I-GENE-Y
(	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
99	I-GENE-Y
.	I-GENE-Y
7	I-GENE-Y
)	O
and	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
14	I-GENE-Y
.	I-GENE-Y
16	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
,	O
the	O
well	O
-	O
studied	O
classical	O
H	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
-	O
dependent	O
reactions	O
.	O

H	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
substituted	O
at	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
with	O
methyl	B-CHEMICAL
,	O
hydroxymethyl	B-CHEMICAL
,	O
formyl	B-CHEMICAL
and	O
acetyl	B-CHEMICAL
groups	O
were	O
used	O
.	O

Substitution	O
at	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
occurs	O
at	O
a	O
position	O
critical	O
to	O
the	O
redox	O
cycle	O
of	O
the	O
cofactor	O
in	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
/	O
dihydropteridine	B-GENE-Y
reductase	I-GENE-Y
.	O

We	O
also	O
included	O
N	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
,	O
a	O
derivative	O
substituted	O
at	O
a	O
position	O
not	O
directly	O
involved	O
in	O
redox	O
cycling	O
,	O
as	O
a	O
control	O
.	O

As	O
compared	O
with	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
,	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
formyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
bound	O
with	O
twice	O
the	O
capacity	O
but	O
stimulated	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
to	O
a	O
lesser	O
extent	O
.	O

Depending	O
on	O
the	O
substituent	O
used	O
,	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	O
substituted	O
derivatives	O
were	O
redox	O
-	O
active	O
:	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	O
and	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hydroxyl	I-CHEMICAL
methyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
,	O
but	O
not	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
formyl	I-CHEMICAL
-	O
and	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
,	O
reduced	O
2	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dichlorophenol	I-CHEMICAL
indophenol	I-CHEMICAL
.	O

N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Substituted	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
derivatives	O
were	O
not	O
oxidized	O
to	O
products	O
serving	O
as	O
substrates	O
for	O
dihydropteridine	B-GENE-Y
reductase	I-GENE-Y
and	O
,	O
depending	O
on	O
the	O
substituent	O
,	O
were	O
competitive	O
inhibitors	O
of	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
:	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	O
and	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hydroxymethyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
inhibited	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
whereas	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
formyl	I-CHEMICAL
-	O
and	O
N	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
H	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
had	O
no	O
effect	O
.	O

Our	O
data	O
demonstrate	O
differences	O
in	O
the	O
mechanism	O
of	O
stimulation	O
of	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
and	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
by	O
H	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
.	O

They	O
are	O
compatible	O
with	O
a	O
novel	O
,	O
non	O
-	O
classical	O
,	O
redox	O
-	O
active	O
contribution	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
biopterin	I-CHEMICAL
to	O
the	O
catalysis	O
of	O
the	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
reaction	O
.	O

Dose	O
-	O
dependent	O
release	O
of	O
endogenous	O
tissue	B-GENE-Y
factor	I-GENE-Y
pathway	O
inhibitor	O
by	O
different	O
low	O
molecular	O
weight	O
heparins	O
.	O

Tissue	B-GENE-Y
factor	I-GENE-Y
pathway	O
inhibitor	O
(	O
TFPI	O
)	O
is	O
released	O
to	O
circulating	O
blood	O
after	O
intravenous	O
and	O
subcutaneous	O
injections	O
of	O
heparins	O
,	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
antithrombotic	O
effect	O
of	O
heparins	O
.	O

A	O
previous	O
study	O
suggested	O
different	O
abilities	O
of	O
various	O
low	O
molecular	O
weight	O
heparins	O
(	O
LMWH	O
)	O
to	O
release	O
endogenous	O
TFPI	O
,	O
but	O
the	O
dose	O
-	O
response	O
relationship	O
was	O
not	O
determined	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
dose	O
-	O
response	O
relationship	O
for	O
escalating	O
doses	O
of	O
two	O
LMWHs	O
,	O
dalteparin	O
and	O
enoxaparin	O
,	O
on	O
the	O
release	O
of	O
endogenous	O
TFPI	O
was	O
investigated	O
.	O

Six	O
healthy	O
male	O
participants	O
were	O
given	O
50	O
,	O
100	O
and	O
200	O
U	O
/	O
kg	O
dalteparin	O
and	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
and	O
2	O
.	O
0	O
mg	O
/	O
kg	O
enoxaparin	O
as	O
a	O
single	O
subcutaneous	O
injection	O
.	O

The	O
study	O
was	O
a	O
randomized	O
,	O
cross	O
-	O
over	O
design	O
with	O
a	O
1	O
-	O
week	O
wash	O
-	O
out	O
period	O
between	O
each	O
injection	O
.	O

Peak	O
free	O
TFPI	O
antigen	O
and	O
TFPI	O
activity	O
were	O
detected	O
after	O
only	O
1	O
h	O
,	O
whereas	O
anti	O
-	O
activated	O
factor	B-GENE-Y
X	I-GENE-Y
(	O
anti	O
-	O
FXa	B-GENE-Y
)	O
and	O
anti	O
-	O
activated	O
factor	B-GENE-N
II	I-GENE-N
(	O
anti	O
-	O
FIIa	B-GENE-Y
)	O
activities	O
were	O
detected	O
after	O
2	O
-	O
6	O
h	O
.	O

Putative	O
therapeutic	O
equivalent	O
doses	O
of	O
dalteparin	O
and	O
enoxaparin	O
gave	O
similar	O
release	O
of	O
endogenous	O
TFPI	O
,	O
but	O
dissimilar	O
effects	O
on	O
anti	O
-	O
FXa	B-GENE-Y
and	O
anti	O
-	O
FIIa	B-GENE-Y
activities	O
.	O

Betaxolol	B-CHEMICAL
,	O
a	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
,	O
reduces	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
into	O
cortical	O
synaptosomes	O
by	O
direct	O
interaction	O
with	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
:	O
comparison	O
with	O
other	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
.	O

Betaxolol	B-CHEMICAL
,	O
a	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
used	O
for	O
the	O
treatment	O
of	O
glaucoma	O
,	O
is	O
known	O
to	O
be	O
neuroprotective	O
in	O
paradigms	O
of	O
ischaemia	O
/	O
excitotoxicity	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
betaxolol	B-CHEMICAL
and	O
other	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
interact	O
directly	O
with	O
neurotoxin	O
binding	O
to	O
sites	O
1	O
and	O
2	O
of	O
the	O
voltage	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
(	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
)	O
in	O
rat	O
cerebrocortical	O
synaptosomes	O
.	O

Betaxolol	B-CHEMICAL
inhibited	O
specific	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
batrachotoxinin	I-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
20	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
benzoate	I-CHEMICAL
(	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
BTX	I-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
)	O
binding	O
to	O
neurotoxin	B-GENE-N
site	I-GENE-N
2	I-GENE-N
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
9	O
.	O
8	O
microM	O
.	O

Comparison	O
of	O
all	O
the	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
tested	O
revealed	O
a	O
potency	O
order	O
of	O
propranolol	B-CHEMICAL
>	O
betaxolol	B-CHEMICAL
approximately	O
levobetaxolol	B-CHEMICAL
>	O
levobunolol	B-CHEMICAL
approximately	O
carteolol	B-CHEMICAL
>	O
/	O
=	O
timolol	B-CHEMICAL
>	O
atenolol	B-CHEMICAL
.	O

None	O
of	O
the	O
drugs	O
caused	O
a	O
significant	O
inhibition	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
saxitoxin	I-CHEMICAL
binding	O
to	O
neurotoxin	B-GENE-N
receptor	I-GENE-N
site	I-GENE-N
1	I-GENE-N
,	O
even	O
at	O
concentrations	O
as	O
high	O
as	O
250	O
microM	O
.	O

Saturation	O
experiments	O
showed	O
that	O
betaxolol	B-CHEMICAL
increased	O
the	O
K	O
(	O
D	O
)	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
BTX	I-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
binding	O
but	O
had	O
no	O
effect	O
on	O
the	O
B	O
(	O
max	O
)	O
.	O

The	O
association	O
kinetics	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
BTX	I-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
were	O
unaffected	O
by	O
betaxolol	B-CHEMICAL
,	O
but	O
the	O
drug	O
significantly	O
accelerated	O
the	O
dissociation	O
rate	O
of	O
the	O
radioligand	O
.	O

These	O
findings	O
argue	O
for	O
a	O
competitive	O
,	O
indirect	O
,	O
allosteric	O
mode	O
of	O
inhibition	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
BTX	I-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
binding	O
by	O
betaxolol	B-CHEMICAL
.	O

Betaxolol	B-CHEMICAL
inhibited	O
veratridine	B-CHEMICAL
-	O
stimulated	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
in	O
rat	O
cortical	O
synaptosomes	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
28	O
.	O

3	O
microM	O
.	O

Carteolol	B-CHEMICAL
,	O
levobunolol	B-CHEMICAL
,	O
timolol	B-CHEMICAL
and	O
atenolol	B-CHEMICAL
were	O
significantly	O
less	O
effective	O
than	O
betaxolol	B-CHEMICAL
at	O
reducing	O
veratridine	B-CHEMICAL
-	O
evoked	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
.	O

The	O
ability	O
of	O
betaxolol	B-CHEMICAL
to	O
interact	O
with	O
neurotoxin	O
site	O
2	O
of	O
the	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
and	O
inhibit	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
may	O
have	O
a	O
role	O
in	O
its	O
neuroprotective	O
action	O
in	O
paradigms	O
of	O
excitotoxicity	O
/	O
ischaemia	O
and	O
in	O
its	O
therapeutic	O
effect	O
in	O
glaucoma	O
.	O

Different	O
mechanisms	O
of	O
acquired	O
resistance	O
to	O
fluorinated	B-CHEMICAL
pyrimidines	I-CHEMICAL
in	O
human	O
colorectal	O
cancer	O
cells	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyuridine	I-CHEMICAL
(	O
FdUrd	B-CHEMICAL
)	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
trifluorothymidine	I-CHEMICAL
(	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
)	O
are	O
antimetabolites	O
which	O
are	O
metabolized	O
to	O
their	O
corresponding	O
active	O
forms	O
which	O
inhibit	O
DNA	O
synthesis	O
via	O
inhibition	O
of	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
(	O
TS	B-GENE-Y
)	O
.	O

To	O
investigate	O
ways	O
of	O
overcoming	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
-	O
resistance	O
,	O
we	O
established	O
acquired	O
-	O
resistant	O
colorectal	O
cancer	O
cell	O
lines	O
against	O
these	O
three	O
drugs	O
by	O
continuous	O
and	O
step	O
-	O
wise	O
escalation	O
of	O
drugs	O
,	O
and	O
analyzed	O
the	O
cytotoxicity	O
and	O
the	O
mechanism	O
of	O
resistance	O
to	O
the	O
drugs	O
.	O

When	O
cells	O
were	O
incubated	O
with	O
the	O
3	O
drugs	O
for	O
72	O
h	O
,	O
the	O
resistance	O
ratio	O
to	O
parental	O
DLD	O
-	O
1	O
human	O
colorectal	O
tumor	O
cells	O
was	O
65	O
.	O
2	O
for	O
DLD	O
-	O
1	O
/	O
5	O
-	O
FU	O
,	O
9	O
.	O
7	O
for	O
DLD	O
-	O
1	O
/	O
FdUrd	B-CHEMICAL
and	O
448	O
.	O
6	O
for	O
DLD	O
-	O
1	O
/	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
cells	O
.	O

DLD	O
-	O
1	O
/	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
cells	O
did	O
not	O
show	O
any	O
cross	O
-	O
resistance	O
against	O
FdUrd	B-CHEMICAL
and	O
F	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
dThd	I-CHEMICAL
.	O

However	O
,	O
DLD	O
-	O
1	O
/	O
FdUrd	B-CHEMICAL
cells	O
showed	O
3	O
-	O
and	O
9	O
-	O
fold	O
increased	O
resistance	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
,	O
respectively	O
,	O
and	O
DLD	O
-	O
1	O
/	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
cells	O
also	O
showed	O
about	O
90	O
-	O
fold	O
resistance	O
to	O
FdUrd	B-CHEMICAL
.	O

Analysis	O
of	O
enzyme	O
activities	O
and	O
gene	O
expression	O
associated	O
with	O
pyrimidine	B-CHEMICAL
metabolism	O
indicated	O
that	O
a	O
significant	O
decrease	O
in	O
orotate	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
activity	O
in	O
DLD	O
-	O
1	O
/	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
cells	O
,	O
a	O
7	O
-	O
fold	O
increase	O
of	O
TS	B-GENE-Y
mRNA	O
in	O
DLD	O
-	O
1	O
/	O
FdUrd	B-CHEMICAL
cells	O
,	O
and	O
a	O
37	O
-	O
fold	O
decrease	O
in	O
thymidine	B-GENE-Y
kinase	I-GENE-Y
activity	O
of	O
DLD	O
-	O
1	O
/	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
cells	O
were	O
the	O
major	O
mechanisms	O
of	O
drug	O
resistance	O
.	O

These	O
findings	O
were	O
closely	O
associated	O
with	O
the	O
cytotoxicity	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
,	O
FdUrd	B-CHEMICAL
and	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
against	O
the	O
established	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
-	O
,	O
FdUrd	B-CHEMICAL
-	O
or	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
-	O
resistant	O
cells	O
.	O

When	O
DLD	O
-	O
1	O
/	O
FdUrd	B-CHEMICAL
cells	O
expressing	O
increased	O
TS	B-GENE-Y
mRNA	O
were	O
treated	O
with	O
FdUrd	B-CHEMICAL
and	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
for	O
only	O
4	O
h	O
,	O
the	O
resistance	O
ratios	O
of	O
DLD	O
-	O
1	O
/	O
FdUrd	B-CHEMICAL
cells	O
to	O
parental	O
DLD	O
-	O
1	O
cells	O
were	O
markedly	O
different	O
for	O
FdUrd	B-CHEMICAL
and	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
,	O
suggesting	O
that	O
the	O
cytotoxicity	O
with	O
short	O
-	O
time	O
exposure	O
to	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
is	O
due	O
to	O
a	O
mechanism	O
other	O
than	O
TS	B-GENE-Y
inhibition	O
,	O
although	O
the	O
cytotoxicity	O
of	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
in	O
the	O
short	O
-	O
time	O
is	O
low	O
compared	O
to	O
that	O
of	O
long	O
-	O
time	O
exposure	O
.	O

In	O
conclusion	O
,	O
F3	B-CHEMICAL
(	I-CHEMICAL
d	I-CHEMICAL
)	I-CHEMICAL
Thd	I-CHEMICAL
,	O
an	O
antimetabolite	O
that	O
inhibits	O
TS	B-GENE-Y
activity	O
,	O
may	O
be	O
effective	O
against	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
and	O
/	O
or	O
FdUrd	B-CHEMICAL
-	O
resistance	O
in	O
colorectal	O
cancer	O
cells	O
caused	O
by	O
amplification	O
of	O
TS	B-GENE-N
and	O
/	O
or	O
deletion	O
of	O
orotate	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
.	O

Zymogen	O
factor	B-GENE-Y
IX	I-GENE-Y
potentiates	O
factor	B-GENE-Y
IXa	I-GENE-Y
-	O
catalyzed	O
factor	B-GENE-Y
X	I-GENE-Y
activation	O
.	O

Intrinsic	O
factor	B-GENE-Y
X	I-GENE-Y
activation	O
is	O
accelerated	O
>	O
10	O
(	O
7	O
)	O
-	O
fold	O
by	O
assembly	O
of	O
the	O
entire	O
complex	O
on	O
the	O
activated	O
platelet	O
surface	O
.	O

We	O
have	O
now	O
observed	O
that	O
increasing	O
the	O
concentration	O
of	O
zymogen	O
factor	B-GENE-Y
IX	I-GENE-Y
to	O
physiologic	O
levels	O
(	O
approximately	O
100	O
nM	O
)	O
potentiates	O
factor	B-GENE-Y
IXa	I-GENE-Y
-	O
catalyzed	O
activation	O
of	O
factor	B-GENE-Y
X	I-GENE-Y
on	O
both	O
activated	O
platelets	O
and	O
on	O
negatively	O
charged	O
phospholipid	O
vesicles	O
.	O

In	O
the	O
presence	O
and	O
absence	O
of	O
factor	B-GENE-Y
VIIIa	I-GENE-Y
,	O
factor	B-GENE-Y
IX	I-GENE-Y
(	O
100	O
nM	O
)	O
lowered	O
the	O
K	O
(	O
d	O
,	O
appFIXa	B-GENE-Y
)	O
approximately	O
4	O
-	O
fold	O
on	O
platelets	O
and	O
2	O
-	O
10	O
-	O
fold	O
on	O
lipid	O
vesicles	O
.	O

Treatment	O
of	O
two	O
factor	B-GENE-Y
IX	I-GENE-Y
preparations	O
with	O
active	O
-	O
site	O
inhibitors	O
did	O
not	O
affect	O
these	O
observations	O
.	O

Autoradiographs	O
of	O
PAGE	O
-	O
separated	O
reactions	O
containing	O
either	O
(	B-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	O
labeled	O
factor	B-GENE-Y
IX	I-GENE-Y
or	O
(	B-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	O
labeled	O
factor	B-GENE-Y
X	I-GENE-Y
showed	O
that	O
the	O
increased	O
factor	B-GENE-Y
X	I-GENE-Y
activation	O
was	O
not	O
due	O
to	O
factor	B-GENE-Y
Xa	I-GENE-Y
-	O
mediated	O
feedback	O
activation	O
of	O
factor	B-GENE-Y
IX	I-GENE-Y
and	O
that	O
there	O
was	O
increased	O
cleavage	O
of	O
factor	B-GENE-Y
X	I-GENE-Y
heavy	I-GENE-Y
chain	I-GENE-Y
in	O
the	O
presence	O
of	O
factor	B-GENE-Y
IX	I-GENE-Y
in	O
comparison	O
with	O
control	O
reactions	O
but	O
only	O
in	O
the	O
presence	O
of	O
both	O
the	O
enzyme	O
and	O
the	O
surface	O
.	O

Since	O
plasma	O
concentrations	O
of	O
prothrombin	B-GENE-Y
,	O
factor	B-GENE-Y
VII	I-GENE-Y
,	O
protein	B-GENE-Y
C	I-GENE-Y
,	O
or	O
protein	B-GENE-Y
S	I-GENE-Y
did	O
not	O
by	O
themselves	O
potentiate	O
factor	B-GENE-N
Xa	I-GENE-N
generation	O
and	O
did	O
not	O
interfere	O
with	O
the	O
potentiation	O
of	O
the	O
reaction	O
of	O
factor	B-GENE-Y
IX	I-GENE-Y
,	O
the	O
effect	O
is	O
specific	O
for	O
factor	B-GENE-Y
IX	I-GENE-Y
and	O
is	O
not	O
attributable	O
to	O
the	O
Gla	B-GENE-N
domain	I-GENE-N
of	O
all	O
vitamin	B-CHEMICAL
K	I-CHEMICAL
-	O
dependent	O
proteins	O
.	O

These	O
observations	O
indicate	O
that	O
under	O
physiologic	O
conditions	O
,	O
plasma	O
levels	O
of	O
the	O
zymogen	O
factor	B-GENE-Y
IX	I-GENE-Y
specifically	O
increase	O
the	O
affinity	O
of	O
factor	B-GENE-Y
IXa	I-GENE-Y
for	O
the	O
intrinsic	O
factor	B-GENE-Y
X	I-GENE-Y
activation	O
complex	O
.	O

Kinetic	O
and	O
stereochemical	O
studies	O
on	O
novel	O
inactivators	O
of	O
C	B-CHEMICAL
-	O
terminal	O
amidation	O
.	O

C	B-CHEMICAL
-	O
terminal	O
amidation	O
,	O
a	O
required	O
post	O
-	O
translational	O
modification	O
for	O
the	O
bioactivation	O
of	O
many	O
neuropeptides	O
,	O
entails	O
sequential	O
enzymic	O
action	O
by	O
peptidylglycine	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
mono	I-GENE-Y
-	I-GENE-Y
oxygenase	I-GENE-Y
(	O
PAM	B-GENE-Y
,	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
14	I-GENE-Y
.	I-GENE-Y
17	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
)	O
and	O
peptidylamidoglycolate	B-GENE-Y
lyase	I-GENE-Y
(	O
PGL	B-GENE-Y
,	O
EC	B-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
)	O
.	O

Here	O
we	O
introduce	O
novel	O
compounds	O
in	O
which	O
an	O
olefinic	O
functionality	O
is	O
incorporated	O
into	O
peptide	O
analogues	O
as	O
the	O
most	O
potent	O
turnover	O
-	O
dependent	O
inactivators	O
of	O
PAM	B-GENE-Y
.	O

Kinetic	O
parameters	O
for	O
PAM	B-GENE-Y
inactivation	O
by	O
4	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
acetamido	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
hex	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
enoic	I-CHEMICAL
acid	I-CHEMICAL
and	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
acetamido	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
thienyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hex	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
enoic	I-CHEMICAL
acid	I-CHEMICAL
were	O
obtained	O
by	O
using	O
both	O
the	O
conventional	O
dilution	O
assay	O
method	O
and	O
the	O
more	O
complex	O
progress	O
curve	O
method	O
.	O

The	O
results	O
obtained	O
from	O
the	O
progress	O
curve	O
method	O
establish	O
that	O
these	O
compounds	O
exhibit	O
the	O
kinetic	O
characteristics	O
of	O
pure	O
competitive	O
inactivators	O
(	O
i	O
.	O
e	O
.	O
no	O
ESI	O
complex	O
forms	O
during	O
inactivation	O
)	O
.	O

On	O
the	O
basis	O
of	O
k	O
(	O
inact	O
)	O
/	O
K	O
(	O
i	O
)	O
values	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
acetamido	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
thienyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hex	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
enoic	I-CHEMICAL
acid	I-CHEMICAL
is	O
almost	O
two	O
orders	O
of	O
magnitude	O
more	O
potent	O
than	O
benzoylacrylate	B-CHEMICAL
,	O
a	O
chemically	O
analogous	O
olefinic	O
inactivator	O
that	O
lacks	O
the	O
peptide	O
moiety	O
.	O

Stereochemical	O
studies	O
established	O
that	O
PAM	B-GENE-Y
inactivation	O
by	O
4	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
acetamido	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
thienyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hex	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
enoic	I-CHEMICAL
acid	I-CHEMICAL
is	O
stereospecific	O
with	O
respect	O
to	O
the	O
moiety	O
at	O
the	O
P	O
(	O
2	O
)	O
position	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
results	O
with	O
substrates	O
and	O
reversible	O
inhibitors	O
.	O

In	O
contrast	O
,	O
2	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dioxo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
acetamido	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenylhexanoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
which	O
is	O
a	O
competitive	O
inhibitor	O
with	O
respect	O
to	O
ascorbate	B-CHEMICAL
,	O
exhibits	O
a	O
low	O
degree	O
of	O
stereospecificity	O
in	O
binding	O
to	O
the	O
ascorbate	B-CHEMICAL
sites	O
of	O
both	O
PAM	B-GENE-Y
and	O
dopamine	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
.	O

Chromosomal	O
localization	O
,	O
gene	O
structure	O
,	O
and	O
expression	O
pattern	O
of	O
DDAH1	B-GENE-Y
:	O
comparison	O
with	O
DDAH2	B-GENE-Y
and	O
implications	O
for	O
evolutionary	O
origins	O
.	O

Endogenously	O
produced	O
asymmetrically	O
methylated	O
arginine	B-CHEMICAL
residues	O
are	O
competitive	O
inhibitors	O
of	O
all	O
three	O
isoforms	O
of	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
(	O
NOS	B-GENE-N
)	O
.	O

The	O
enzyme	O
dimethylarginine	B-GENE-N
dimethylaminohydrolase	I-GENE-N
(	O
DDAH	B-GENE-N
)	O
specifically	O
hydrolyzes	O
these	O
asymmetrically	O
methylated	O
arginine	B-CHEMICAL
residues	O
to	O
citrulline	O
and	O
methylamines	O
.	O

Previously	O
we	O
have	O
proposed	O
that	O
regulation	O
of	O
asymmetric	O
methylarginine	B-CHEMICAL
concentration	O
by	O
DDAH	B-GENE-N
may	O
provide	O
a	O
novel	O
mechanism	O
for	O
the	O
regulation	O
of	O
NOS	B-GENE-N
activity	O
in	O
vivo	O
.	O

Recently	O
we	O
reported	O
the	O
cloning	O
of	O
human	B-GENE-N
DDAH	I-GENE-N
and	O
identified	O
a	O
novel	O
human	B-GENE-N
DDAH	I-GENE-N
isoform	O
(	O
DDAH	B-GENE-Y
I	I-GENE-Y
and	O
DDAH	B-GENE-Y
II	I-GENE-Y
,	O
respectively	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
DDAH1	B-GENE-Y
gene	O
maps	O
to	O
chromosome	O
1p22	O
and	O
confirm	O
that	O
DDAH2	B-GENE-Y
maps	O
to	O
the	O
MHC	O
III	O
region	O
of	O
chromosome	O
6p21	O
.	O
3	O
.	O

Extensive	O
analysis	O
of	O
the	O
distribution	O
of	O
DDAH1	B-GENE-Y
and	O
DDAH2	B-GENE-Y
mRNA	O
in	O
50	O
human	O
tissues	O
indicates	O
differential	O
expression	O
of	O
DDAH	B-GENE-N
isoforms	O
in	O
brain	O
regions	O
,	O
in	O
immune	O
cells	O
,	O
and	O
during	O
development	O
.	O

DDAH2	B-GENE-Y
expression	O
predominates	O
in	O
highly	O
vascularized	O
tissues	O
that	O
express	O
the	O
endothelial	B-GENE-Y
NOS	I-GENE-Y
isoform	O
and	O
in	O
immune	O
tissues	O
that	O
can	O
express	O
iNOS	B-GENE-Y
.	O

Whereas	O
DDAH2	B-GENE-Y
is	O
expressed	O
at	O
relatively	O
high	O
levels	O
in	O
all	O
fetal	O
tissues	O
examined	O
,	O
DDAH1	B-GENE-Y
expression	O
varies	O
little	O
between	O
fetal	O
and	O
adult	O
tissues	O
.	O

The	O
chromosomal	O
localization	O
of	O
the	O
DDAHs	B-GENE-N
is	O
consistent	O
with	O
gene	O
duplication	O
,	O
and	O
consistent	O
with	O
this	O
,	O
comparison	O
of	O
the	O
gene	O
structures	O
indicates	O
that	O
the	O
intron	O
/	O
exon	O
organization	O
is	O
highly	O
conserved	O
.	O

Phylogenetic	O
analysis	O
of	O
DDAH	B-GENE-N
sequences	O
from	O
diverse	O
species	O
suggests	O
that	O
DDAH	B-GENE-N
gene	O
duplication	O
occurred	O
prior	O
to	O
the	O
emergence	O
of	O
bony	O
fish	O
some	O
400	O
million	O
years	O
ago	O
.	O

Overall	O
the	O
data	O
suggest	O
that	O
DDAH2	B-GENE-Y
may	O
be	O
the	O
more	O
ancient	O
of	O
the	O
two	O
genes	O
.	O

Accumulation	O
of	O
cystathionine	B-CHEMICAL
,	O
cystathionine	B-CHEMICAL
ketimine	I-CHEMICAL
,	O
and	O
perhydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
thiazepine	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dicarboxylic	I-CHEMICAL
acid	I-CHEMICAL
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
of	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
-	O
treated	O
rats	O
.	O

Experimental	O
cystathioninuria	O
was	O
induced	O
in	O
rats	O
by	O
administration	O
of	O
the	O
cystathionine	B-GENE-Y
gamma	I-GENE-Y
-	I-GENE-Y
lyase	I-GENE-Y
inhibitor	O
,	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
.	O

The	O
cystathionine	B-CHEMICAL
metabolites	O
,	O
cystathionine	B-CHEMICAL
ketimine	I-CHEMICAL
(	O
CK	B-CHEMICAL
)	O
and	O
perhydro	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
thiazepine	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dicarboxylic	I-CHEMICAL
acid	I-CHEMICAL
(	O
PHTZDC	B-CHEMICAL
)	O
,	O
were	O
identified	O
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
in	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
-	O
treated	O
rats	O
.	O

The	O
concentration	O
of	O
CK	B-CHEMICAL
and	O
PHTZDC	B-CHEMICAL
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
increased	O
gradually	O
after	O
administration	O
of	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
,	O
and	O
reached	O
the	O
highest	O
value	O
at	O
about	O
20	O
hours	O
.	O

CK	B-CHEMICAL
and	O
PHTZDC	B-CHEMICAL
accumulated	O
in	O
whole	O
brain	O
and	O
various	O
regions	O
of	O
the	O
brain	O
in	O
proportion	O
to	O
the	O
amount	O
of	O
accumulated	O
cystathionine	O
after	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
administration	O
.	O

The	O
concentration	O
of	O
these	O
compounds	O
in	O
the	O
cerebellum	O
was	O
higher	O
versus	O
the	O
other	O
regions	O
of	O
the	O
rat	O
brain	O
.	O

Species	O
-	O
specific	O
pharmacological	O
properties	O
of	O
human	B-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

On	O
the	O
basis	O
of	O
data	O
obtained	O
in	O
rabbits	O
,	O
the	O
imidazoline	B-GENE-N
receptor	I-GENE-N
ligand	O
rilmenidine	B-CHEMICAL
has	O
been	O
suggested	O
to	O
decrease	O
blood	O
pressure	O
in	O
humans	O
by	O
activating	O
central	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

A	O
prerequisite	O
for	O
this	O
hypothesis	O
was	O
the	O
unproved	O
assumption	O
that	O
rabbit	O
and	O
human	O
alpha	B-GENE-N
(	I-GENE-N
2A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
are	O
equally	O
activated	O
by	O
rilmenidine	B-CHEMICAL
.	O

Because	O
alpha	B-GENE-N
(	I-GENE-N
2A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
the	O
brain	O
and	O
on	O
cardiovascular	O
sympathetic	O
nerve	O
terminals	O
are	O
identical	O
,	O
the	O
latter	O
were	O
used	O
as	O
a	O
model	O
for	O
the	O
former	O
to	O
confirm	O
or	O
disprove	O
this	O
assumption	O
.	O

Human	O
atrial	O
appendages	O
and	O
rabbit	O
pulmonary	O
arteries	O
were	O
used	O
to	O
determine	O
the	O
potencies	O
of	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
in	O
inhibiting	O
the	O
electrically	O
(	O
2	O
Hz	O
)	O
evoked	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
norepinephrine	I-CHEMICAL
release	O
and	O
of	O
antagonists	O
in	O
counteracting	O
the	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
-	O
mediated	O
inhibition	O
induced	O
by	O
moxonidine	B-CHEMICAL
.	O

In	O
the	O
rabbit	O
pulmonary	O
artery	O
,	O
rilmenidine	B-CHEMICAL
and	O
oxymetazoline	B-CHEMICAL
are	O
potent	O
full	O
agonists	O
,	O
whereas	O
in	O
the	O
human	O
atrial	O
appendages	O
they	O
are	O
antagonists	O
at	O
the	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
autoreceptors	I-GENE-N
,	O
sharing	O
this	O
property	O
with	O
rauwolscine	B-CHEMICAL
,	O
phentolamine	B-CHEMICAL
,	O
and	O
idazoxan	B-CHEMICAL
.	O

In	O
contrast	O
,	O
prazosin	B-CHEMICAL
is	O
ineffective	O
.	O

In	O
addition	O
,	O
a	O
partial	O
nucleotide	O
and	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
the	O
rabbit	B-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
(	O
a	O
region	O
known	O
to	O
substantially	O
influence	O
the	O
pharmacological	O
characteristics	O
of	O
the	O
alpha	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
)	O
revealed	O
marked	O
differences	O
between	O
the	O
rabbit	O
and	O
the	O
human	O
alpha	B-GENE-N
(	I-GENE-N
2A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
.	O

The	O
sympathetic	O
nerves	O
of	O
both	O
the	O
human	O
atrial	O
appendages	O
and	O
rabbit	O
pulmonary	O
artery	O
are	O
endowed	O
with	O
alpha	B-GENE-N
(	I-GENE-N
2A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
autoreceptors	I-GENE-N
,	O
at	O
which	O
,	O
however	O
,	O
both	O
rilmenidine	B-CHEMICAL
and	O
oxymetazoline	B-CHEMICAL
exhibit	O
different	O
properties	O
(	O
antagonism	O
and	O
agonism	O
,	O
respectively	O
)	O
.	O

The	O
antagonistic	O
property	O
of	O
rilmenidine	B-CHEMICAL
at	O
human	B-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
indicates	O
that	O
in	O
contrast	O
to	O
the	O
suggestion	O
based	O
on	O
rabbit	O
data	O
,	O
the	O
hypotensive	O
property	O
of	O
the	O
drug	O
in	O
humans	O
is	O
not	O
due	O
to	O
activation	O
of	O
alpha	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
but	O
other	O
,	O
presumably	O
I	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
imidazoline	I-GENE-Y
receptors	I-GENE-Y
,	O
are	O
probably	O
involved	O
.	O

Mechanisms	O
of	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
human	B-GENE-Y
kappa	I-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
:	O
internalization	O
is	O
required	O
for	O
down	O
-	O
regulation	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
human	B-GENE-Y
kappa	I-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
(	O
hkor	B-GENE-Y
)	O
stably	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
underwent	O
down	O
-	O
regulation	O
after	O
prolonged	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
treatment	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
mechanisms	O
underlying	O
this	O
process	O
.	O

U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
caused	O
a	O
significant	O
down	O
-	O
regulation	O
of	O
the	O
hkor	B-GENE-Y
,	O
although	O
etorphine	B-CHEMICAL
did	O
not	O
.	O

Neither	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
nor	O
etorphine	B-CHEMICAL
caused	O
down	O
-	O
regulation	O
of	O
the	O
rat	B-GENE-Y
kappa	I-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
.	O

Thus	O
,	O
similar	O
to	O
internalization	O
,	O
there	O
are	O
agonist	O
and	O
species	O
differences	O
in	O
down	O
-	O
regulation	O
of	O
kappa	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptors	I-GENE-Y
.	O

Expression	O
of	O
the	O
dominant	O
negative	O
mutants	O
arrestin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
319	O
-	O
418	O
)	O
or	O
dynamin	B-GENE-Y
I	I-GENE-Y
-	O
K44A	B-GENE-N
significantly	O
reduced	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
hkor	B-GENE-Y
.	O

Coexpression	O
of	O
GRK2	B-GENE-Y
or	O
GRK2	B-GENE-Y
and	O
arrestin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
permitted	O
etorphine	B-CHEMICAL
to	O
induce	O
down	O
-	O
regulation	O
of	O
the	O
hkor	B-GENE-Y
,	O
although	O
expression	O
of	O
arrestin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
or	O
dynamin	B-GENE-Y
I	I-GENE-Y
alone	O
did	O
not	O
.	O

Expression	O
of	O
the	O
dominant	O
negative	O
mutants	O
rab5A	B-GENE-Y
-	O
N133I	B-GENE-N
or	O
rab7	B-GENE-N
-	O
N125I	B-GENE-N
blunted	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
-	O
induced	O
down	O
-	O
regulation	O
.	O

Pretreatment	O
with	O
lysosomal	O
enzyme	O
inhibitors	O
[	B-CHEMICAL
(	I-CHEMICAL
2S	I-CHEMICAL
,	I-CHEMICAL
3S	I-CHEMICAL
)	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
epoxysuccinyl	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
leucylamido	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylbutane	I-CHEMICAL
ethyl	I-CHEMICAL
ester	I-CHEMICAL
or	I-CHEMICAL
chloroquine	I-CHEMICAL
]	I-CHEMICAL
or	O
proteasome	B-GENE-N
inhibitors	O
(	O
proteasome	B-GENE-N
inhibitor	O
I	O
,	O
MG	B-CHEMICAL
-	I-CHEMICAL
132	I-CHEMICAL
,	O
or	O
lactacystin	B-CHEMICAL
)	O
decreased	O
the	O
extent	O
of	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
-	O
induced	O
down	O
-	O
regulation	O
.	O

A	O
combination	O
of	O
chloroquine	B-CHEMICAL
and	O
proteasome	B-GENE-N
inhibitor	O
I	O
abolished	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
-	O
induced	O
down	O
-	O
regulation	O
.	O

These	O
results	O
indicate	O
that	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
-	O
induced	O
down	O
-	O
regulation	O
of	O
the	O
hkor	B-GENE-Y
involves	O
GRK	B-GENE-N
-	O
,	O
arrestin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
,	O
dynamin	B-GENE-N
-	O
,	O
rab5	B-GENE-N
-	O
,	O
and	O
rab7	B-GENE-N
-	O
dependent	O
mechanisms	O
and	O
receptors	O
seem	O
to	O
be	O
trafficked	O
to	O
lysosomes	O
and	O
proteasomes	B-GENE-N
for	O
degradation	O
.	O

Thus	O
,	O
U50	B-CHEMICAL
,	I-CHEMICAL
488H	I-CHEMICAL
-	O
induced	O
internalization	O
and	O
down	O
-	O
regulation	O
of	O
the	O
hkor	B-GENE-Y
share	O
initial	O
common	O
mechanisms	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
these	O
results	O
represent	O
the	O
first	O
report	O
on	O
the	O
involvement	O
of	O
both	O
rab5	B-GENE-N
and	O
rab7	B-GENE-N
in	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
a	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
.	O

In	O
addition	O
,	O
this	O
study	O
is	O
among	O
the	O
first	O
to	O
show	O
the	O
involvement	O
of	O
proteasomes	B-GENE-N
in	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
a	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
.	O

Oral	O
administration	O
of	O
tetrahydrobiopterin	B-CHEMICAL
prevents	O
endothelial	O
dysfunction	O
and	O
vascular	O
oxidative	O
stress	O
in	O
the	O
aortas	O
of	O
insulin	B-GENE-N
-	O
resistant	O
rats	O
.	O

We	O
have	O
reported	O
that	O
a	O
deficiency	O
of	O
tetrahydrobiopterin	B-CHEMICAL
(	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
)	O
,	O
an	O
active	O
cofactor	O
of	O
endothelial	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
(	O
eNOS	B-GENE-Y
)	O
,	O
contributes	O
to	O
the	O
endothelial	O
dysfunction	O
through	O
reduced	O
eNOS	B-GENE-Y
activity	O
and	O
increased	O
superoxide	B-CHEMICAL
anion	I-CHEMICAL
(	O
O	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
)	O
generation	O
in	O
the	O
insulin	B-GENE-N
-	O
resistant	O
state	O
.	O

To	O
further	O
confirm	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
dietary	O
treatment	O
with	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
on	O
endothelium	O
-	O
dependent	O
arterial	O
relaxation	O
and	O
vascular	O
oxidative	O
stress	O
in	O
the	O
aortas	O
of	O
insulin	B-GENE-N
-	O
resistant	O
rats	O
.	O

Oral	O
supplementation	O
of	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
(	O
10	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
.	O
d	O
(	O
-	O
1	O
)	O
)	O
for	O
8	O
weeks	O
significantly	O
increased	O
the	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
content	O
in	O
cardiovascular	O
tissues	O
of	O
rats	O
fed	O
high	O
levels	O
of	O
fructose	B-CHEMICAL
(	O
fructose	B-CHEMICAL
-	O
fed	O
rats	O
)	O
.	O

Impairment	O
of	O
endothelium	O
-	O
dependent	O
arterial	O
relaxation	O
in	O
the	O
aortic	O
strips	O
of	O
the	O
fructose	B-CHEMICAL
-	O
fed	O
rats	O
was	O
reversed	O
with	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
treatment	O
.	O

The	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
treatment	O
was	O
associated	O
with	O
a	O
2	O
-	O
fold	O
increase	O
in	O
eNOS	B-GENE-Y
activity	O
as	O
well	O
as	O
a	O
70	O
%	O
reduction	O
in	O
endothelial	O
O	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
production	O
compared	O
with	O
those	O
in	O
fructose	B-CHEMICAL
-	O
fed	O
rats	O
.	O

The	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
treatment	O
also	O
partially	O
improved	O
the	O
insulin	B-GENE-N
sensitivity	O
and	O
blood	O
pressure	O
,	O
as	O
well	O
as	O
the	O
serum	O
triglyceride	B-CHEMICAL
concentration	O
,	O
in	O
the	O
fructose	B-CHEMICAL
-	O
fed	O
rats	O
.	O

Moreover	O
,	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
treatment	O
of	O
the	O
fructose	B-CHEMICAL
-	O
fed	O
rats	O
markedly	O
reduced	O
the	O
lipid	O
peroxide	B-CHEMICAL
content	O
of	O
both	O
aortic	O
and	O
cardiac	O
tissues	O
and	O
inhibited	O
the	O
activation	O
of	O
2	O
redox	O
-	O
sensitive	O
transcription	O
factors	O
,	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
and	O
activating	B-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
which	O
were	O
increased	O
in	O
fructose	B-CHEMICAL
-	O
fed	O
rats	O
.	O

The	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
treatment	O
of	O
control	O
rats	O
did	O
not	O
have	O
any	O
significant	O
effects	O
on	O
these	O
parameters	O
.	O

These	O
results	O
indicate	O
that	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
augmentation	O
is	O
essential	O
for	O
the	O
restoration	O
of	O
eNOS	B-GENE-Y
function	O
and	O
the	O
reduction	O
of	O
vascular	O
oxidative	O
stress	O
in	O
insulin	B-GENE-N
-	O
resistant	O
rats	O
.	O

Fumarate	B-GENE-N
reductase	I-GENE-N
is	O
essential	O
for	O
Helicobacter	O
pylori	O
colonization	O
of	O
the	O
mouse	O
stomach	O
.	O

Fumarate	B-GENE-N
reductase	I-GENE-N
(	O
FRD	B-GENE-N
)	O
is	O
the	O
key	O
enzyme	O
in	O
fumarate	B-CHEMICAL
respiration	O
induced	O
by	O
anaerobic	O
growth	O
of	O
bacteria	O
.	O

In	O
Helicobacter	O
pylori	O
,	O
this	O
enzyme	O
appears	O
to	O
be	O
constitutively	O
expressed	O
under	O
microaerobic	O
conditions	O
and	O
is	O
not	O
essential	O
for	O
its	O
survival	O
in	O
vitro	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
FRD	B-GENE-N
in	O
the	O
colonization	O
of	O
H	O
.	O
pylori	O
was	O
investigated	O
using	O
a	O
mouse	O
model	O
.	O

The	O
frdA	B-GENE-Y
gene	O
coding	O
for	O
subunit	B-GENE-Y
A	I-GENE-Y
of	I-GENE-Y
FRD	I-GENE-Y
,	O
and	O
two	O
control	O
genes	O
,	O
copA	B-GENE-Y
and	O
copP	B-GENE-Y
associated	O
with	O
the	O
export	O
of	O
copper	B-CHEMICAL
out	O
of	O
H	O
.	O
pylori	O
,	O
were	O
inactivated	O
by	O
insertion	O
of	O
the	O
chloramphenicol	B-CHEMICAL
acetyltransferase	O
cassette	O
into	O
these	O
individual	O
genes	O
.	O

The	O
isogenic	O
mutants	O
of	O
H	O
.	O
pylori	O
strain	O
AH244	O
were	O
obtained	O
by	O
natural	O
transformation	O
.	O

Seventy	O
-	O
five	O
ICR	O
mice	O
(	O
15	O
mice	O
/	O
group	O
)	O
were	O
orogastrically	O
dosed	O
with	O
either	O
the	O
wild	O
type	O
H	O
.	O
pylori	O
strain	O
AH244	O
,	O
its	O
isogenic	O
mutants	O
,	O
or	O
Brucella	O
broth	O
(	O
negative	O
control	O
)	O
.	O

Five	O
mice	O
from	O
each	O
group	O
were	O
killed	O
at	O
2	O
,	O
4	O
and	O
8	O
weeks	O
post	O
-	O
inoculation	O
(	O
WPI	O
)	O
,	O
respectively	O
.	O

H	O
.	O
pylori	O
colonization	O
was	O
not	O
detected	O
in	O
mouse	O
gastric	O
mucosa	O
infected	O
with	O
the	O
frdA	B-GENE-Y
mutant	O
at	O
any	O
time	O
point	O
in	O
the	O
study	O
by	O
both	O
quantitative	O
culture	O
and	O
PCR	O
.	O

In	O
contrast	O
,	O
the	O
mice	O
inoculated	O
with	O
either	O
wild	O
type	O
AH244	O
,	O
copA	B-GENE-Y
or	O
copPH	B-GENE-Y
.	O
pylori	O
mutants	O
became	O
readily	O
infected	O
.	O

These	O
data	O
indicate	O
that	O
FRD	B-GENE-N
plays	O
a	O
crucial	O
role	O
in	O
H	O
.	O
pylori	O
survival	O
in	O
the	O
gastric	O
mucosa	O
of	O
mice	O
.	O

Given	O
that	O
FRD	B-GENE-N
,	O
present	O
in	O
all	O
H	O
.	O
pylori	O
strains	O
,	O
is	O
immunogenic	O
in	O
H	O
.	O
pylori	O
-	O
infected	O
patients	O
and	O
H	O
.	O
pylori	O
growth	O
in	O
vitro	O
can	O
be	O
inhibited	O
by	O
three	O
anthelmintics	O
(	O
morantel	B-CHEMICAL
,	O
oxantel	B-CHEMICAL
and	O
thiabendazole	B-CHEMICAL
)	O
,	O
this	O
enzyme	O
could	O
potentially	O
be	O
used	O
both	O
as	O
a	O
novel	O
drug	O
target	O
as	O
well	O
as	O
in	O
the	O
development	O
of	O
vaccines	O
for	O
H	O
.	O
pylori	O
prevention	O
and	O
eradication	O
.	O

Conformational	O
epitopes	O
on	O
the	O
diabetes	O
autoantigen	O
GAD65	B-GENE-Y
identified	O
by	O
peptide	O
phage	O
display	O
and	O
molecular	O
modeling	O
.	O

The	O
major	B-GENE-N
diabetes	I-GENE-N
autoantigen	I-GENE-N
,	O
glutamic	B-GENE-N
acid	I-GENE-N
decarboxylase	I-GENE-N
(	O
GAD65	B-GENE-Y
)	O
,	O
contains	O
a	O
region	O
of	O
sequence	O
similarity	O
,	O
including	O
six	O
identical	O
residues	O
PEVKEK	B-CHEMICAL
,	O
to	O
the	O
P2C	B-GENE-Y
protein	I-GENE-Y
of	O
coxsackie	O
B	O
virus	O
,	O
suggesting	O
that	O
cross	O
-	O
reactivity	O
between	O
coxsackie	O
B	O
virus	O
and	O
GAD65	B-GENE-Y
can	O
initiate	O
autoimmune	O
diabetes	O
.	O

We	O
used	O
the	O
human	O
islet	O
cell	O
mAbs	O
MICA3	O
and	O
MICA4	O
to	O
identify	O
the	O
Ab	O
epitopes	O
of	O
GAD65	B-GENE-Y
by	O
screening	O
phage	O
-	O
displayed	O
random	O
peptide	O
libraries	O
.	O

The	O
identified	O
peptide	O
sequences	O
could	O
be	O
mapped	O
to	O
a	O
homology	O
model	O
of	O
the	O
pyridoxal	B-GENE-N
phosphate	I-GENE-N
(	I-GENE-N
PLP	I-GENE-N
)	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
of	O
GAD65	B-GENE-Y
.	O

For	O
MICA3	O
,	O
a	O
surface	O
loop	O
containing	O
the	O
sequence	O
PEVKEK	B-CHEMICAL
and	O
two	O
adjacent	O
exposed	O
helixes	O
were	O
identified	O
in	O
the	O
PLP	B-GENE-N
binding	I-GENE-N
domain	I-GENE-N
as	O
well	O
as	O
a	O
region	O
of	O
the	O
C	B-CHEMICAL
terminus	O
of	O
GAD65	B-GENE-Y
that	O
has	O
previously	O
been	O
identified	O
as	O
critical	O
for	O
MICA3	O
binding	O
.	O

To	O
confirm	O
that	O
the	O
loop	O
containing	O
the	O
PEVKEK	B-CHEMICAL
sequence	O
contributes	O
to	O
the	O
MICA3	O
epitope	O
,	O
this	O
loop	O
was	O
deleted	O
by	O
mutagenesis	O
.	O

This	O
reduced	O
binding	O
of	O
MICA3	O
by	O
70	O
%	O
.	O

Peptide	O
sequences	O
selected	O
using	O
MICA4	O
were	O
rich	O
in	O
basic	O
or	O
hydroxyl	B-CHEMICAL
-	O
containing	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
and	O
the	O
surface	O
of	O
the	O
GAD65	B-GENE-N
PLP	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
surrounding	O
Lys358	O
,	O
which	O
is	O
known	O
to	O
be	O
critical	O
for	O
MICA4	O
binding	O
,	O
was	O
likewise	O
rich	O
in	O
these	O
amino	B-CHEMICAL
acids	I-CHEMICAL
.	O

Also	O
,	O
the	O
two	O
phage	O
most	O
reactive	O
with	O
MICA4	O
encoded	O
the	O
motif	O
VALxG	B-GENE-N
,	O
and	O
the	O
reverse	O
of	O
this	O
sequence	O
,	O
LAV	B-CHEMICAL
,	O
was	O
located	O
in	O
this	O
same	O
region	O
.	O

Thus	O
,	O
we	O
have	O
defined	O
the	O
MICA3	O
and	O
MICA4	O
epitopes	O
on	O
GAD65	B-GENE-Y
using	O
the	O
combination	O
of	O
phage	O
display	O
,	O
molecular	O
modeling	O
,	O
and	O
mutagenesis	O
and	O
have	O
provided	O
compelling	O
evidence	O
for	O
the	O
involvement	O
of	O
the	O
PEVKEK	B-CHEMICAL
loop	O
in	O
the	O
MICA3	O
epitope	O
.	O

Effects	O
of	O
a	O
serotonin	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
SB	B-CHEMICAL
-	I-CHEMICAL
207266	I-CHEMICAL
on	O
gastrointestinal	O
motor	O
and	O
sensory	O
function	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
Serotonin	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
are	O
located	O
on	O
enteric	O
cholinergic	O
neurones	O
and	O
may	O
regulate	O
peristalsis	O
.	O

5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptors	O
on	O
primary	O
afferent	O
neurones	O
have	O
been	O
postulated	O
to	O
modulate	O
visceral	O
sensation	O
.	O

While	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
agonists	O
are	O
used	O
as	O
prokinetic	O
agents	O
,	O
the	O
physiological	O
role	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptors	O
in	O
the	O
human	O
gut	O
is	O
unknown	O
.	O

AIMS	O
:	O
Our	O
aim	O
was	O
to	O
characterise	O
the	O
role	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptors	O
in	O
regulating	O
gastrointestinal	O
motor	O
and	O
sensory	O
function	O
in	O
healthy	O
subjects	O
under	O
baseline	O
and	O
stimulated	O
conditions	O
with	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptor	O
antagonist	O
.	O

METHODS	O
:	O
Part	O
A	O
compared	O
the	O
effects	O
of	O
placebo	O
to	O
four	O
doses	O
of	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptor	O
antagonist	O
(	O
SB	B-CHEMICAL
-	I-CHEMICAL
207266	I-CHEMICAL
)	O
on	O
the	O
cisapride	B-CHEMICAL
mediated	O
increase	O
in	O
plasma	O
aldosterone	B-CHEMICAL
(	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
mediated	O
response	O
)	O
and	O
orocaecal	O
transit	O
in	O
18	O
subjects	O
.	O

In	O
part	O
B	O
,	O
52	O
healthy	O
subjects	O
received	O
placebo	O
,	O
or	O
0	O
.	O
05	O
,	O
0	O
.	O
5	O
,	O
or	O
5	O
mg	O
of	O
SB	B-CHEMICAL
-	I-CHEMICAL
207266	I-CHEMICAL
for	O
10	O
-	O
12	O
days	O
;	O
gastric	O
,	O
small	O
bowel	O
,	O
and	O
colonic	O
transit	O
were	O
measured	O
by	O
scintigraphy	O
on	O
days	O
7	O
-	O
9	O
,	O
and	O
fasting	O
and	O
postprandial	O
colonic	O
motor	O
function	O
,	O
compliance	O
,	O
and	O
sensation	O
during	O
distensions	O
were	O
assessed	O
on	O
day	O
12	O
.	O

RESULTS	O
:	O
Part	O
A	O
:	O
0	O
.	O
5	O
,	O
5	O
,	O
and	O
20	O
mg	O
doses	O
of	O
SB	B-CHEMICAL
-	I-CHEMICAL
207266	I-CHEMICAL
had	O
significant	O
and	O
quantitatively	O
similar	O
effects	O
,	O
antagonising	O
the	O
cisapride	O
mediated	O
increase	O
in	O
plasma	O
aldosterone	B-CHEMICAL
and	O
acceleration	O
of	O
orocaecal	O
transit	O
.	O

Part	O
B	O
:	O
SB	B-CHEMICAL
-	I-CHEMICAL
207266	I-CHEMICAL
tended	O
to	O
delay	O
colonic	O
transit	O
(	O
geometric	O
centre	O
of	O
isotope	O
at	O
24	O
(	O
p	O
=	O
0	O
.	O
06	O
)	O
and	O
48	O
hours	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
)	O
,	O
but	O
did	O
not	O
have	O
dose	O
related	O
effects	O
on	O
transit	O
,	O
fasting	O
or	O
postprandial	O
colonic	O
motor	O
activity	O
,	O
compliance	O
,	O
or	O
sensation	O
.	O

CONCLUSION	O
:	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptors	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cisapride	B-CHEMICAL
stimulated	O
orocaecal	O
transit	O
;	O
SB	B-CHEMICAL
207266	I-CHEMICAL
tends	O
to	O
modulate	O
colonic	O
transit	O
but	O
not	O
sensory	O
functions	O
or	O
compliance	O
in	O
healthy	O
human	O
subjects	O
.	O

Amphetamine	B-CHEMICAL
-	O
type	O
central	O
nervous	O
system	O
stimulants	O
release	O
norepinephrine	B-CHEMICAL
more	O
potently	O
than	O
they	O
release	O
dopamine	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
.	O

A	O
large	O
body	O
of	O
evidence	O
supports	O
the	O
hypothesis	O
that	O
mesolimbic	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
mediates	O
,	O
in	O
animal	O
models	O
,	O
the	O
reinforcing	O
effects	O
of	O
central	O
nervous	O
system	O
stimulants	O
such	O
as	O
cocaine	B-CHEMICAL
and	O
amphetamine	B-CHEMICAL
.	O

The	O
role	O
DA	B-CHEMICAL
plays	O
in	O
mediating	O
amphetamine	B-CHEMICAL
-	O
type	O
subjective	O
effects	O
of	O
stimulants	O
in	O
humans	O
remains	O
to	O
be	O
established	O
.	O

Both	O
amphetamine	B-CHEMICAL
and	O
cocaine	B-CHEMICAL
increase	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
via	O
stimulation	O
of	O
release	O
and	O
inhibition	O
of	O
reuptake	O
,	O
respectively	O
.	O

If	O
increases	O
in	O
NE	B-CHEMICAL
mediate	O
amphetamine	B-CHEMICAL
-	O
type	O
subjective	O
effects	O
of	O
stimulants	O
in	O
humans	O
,	O
then	O
one	O
would	O
predict	O
that	O
stimulant	O
medications	O
that	O
produce	O
amphetamine	B-CHEMICAL
-	O
type	O
subjective	O
effects	O
in	O
humans	O
should	O
share	O
the	O
ability	O
to	O
increase	O
NE	B-CHEMICAL
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
,	O
using	O
in	O
vitro	O
methods	O
,	O
the	O
neurochemical	O
mechanism	O
of	O
action	O
of	O
amphetamine	B-CHEMICAL
,	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
)	O
,	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
methamphetamine	I-CHEMICAL
,	O
ephedrine	B-CHEMICAL
,	O
phentermine	B-CHEMICAL
,	O
and	O
aminorex	B-CHEMICAL
.	O

As	O
expected	O
,	O
their	O
rank	O
order	O
of	O
potency	O
for	O
DA	B-CHEMICAL
release	O
was	O
similar	O
to	O
their	O
rank	O
order	O
of	O
potency	O
in	O
published	O
self	O
-	O
administration	O
studies	O
.	O

Interestingly	O
,	O
the	O
results	O
demonstrated	O
that	O
the	O
most	O
potent	O
effect	O
of	O
these	O
stimulants	O
is	O
to	O
release	O
NE	B-CHEMICAL
.	O

Importantly	O
,	O
the	O
oral	O
dose	O
of	O
these	O
stimulants	O
,	O
which	O
produce	O
amphetamine	B-CHEMICAL
-	O
type	O
subjective	O
effects	O
in	O
humans	O
,	O
correlated	O
with	O
the	O
their	O
potency	O
in	O
releasing	O
NE	B-CHEMICAL
,	O
not	O
DA	B-CHEMICAL
,	O
and	O
did	O
not	O
decrease	O
plasma	O
prolactin	B-GENE-Y
,	O
an	O
effect	O
mediated	O
by	O
DA	B-CHEMICAL
release	O
.	O

These	O
results	O
suggest	O
that	O
NE	B-CHEMICAL
may	O
contribute	O
to	O
the	O
amphetamine	B-CHEMICAL
-	O
type	O
subjective	O
effects	O
of	O
stimulants	O
in	O
humans	O
.	O

Characterization	O
of	O
insulin	B-GENE-N
-	I-GENE-N
like	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
related	I-GENE-N
proteins	I-GENE-N
(	I-GENE-N
IGFBP	I-GENE-N
-	I-GENE-N
rPs	I-GENE-N
)	I-GENE-N
1	I-GENE-N
,	I-GENE-N
2	I-GENE-N
,	I-GENE-N
and	I-GENE-N
3	I-GENE-N
in	O
human	O
prostate	O
epithelial	O
cells	O
:	O
potential	O
roles	O
for	O
IGFBP	B-GENE-N
-	I-GENE-N
rP1	I-GENE-N
and	I-GENE-N
2	I-GENE-N
in	O
senescence	O
of	O
the	O
prostatic	O
epithelium	O
.	O

Insulin	B-GENE-N
-	I-GENE-N
like	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
(	I-GENE-N
IGF	I-GENE-N
)	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	I-GENE-N
IGFBP	I-GENE-N
)	I-GENE-N
-	I-GENE-N
related	I-GENE-N
proteins	I-GENE-N
(	O
IGFBP	B-GENE-N
-	I-GENE-N
rPs	I-GENE-N
)	O
are	O
newly	O
described	O
cysteine	B-CHEMICAL
-	O
rich	O
proteins	O
that	O
share	O
significant	O
aminoterminal	O
structural	O
similarity	O
with	O
the	O
conventional	O
IGFBPs	B-GENE-N
and	O
are	O
involved	O
in	O
a	O
diversity	O
of	O
biological	O
functions	O
,	O
including	O
growth	O
regulation	O
.	O

IGFBP	B-GENE-Y
-	I-GENE-Y
rP1	I-GENE-Y
(	O
MAC25	B-GENE-Y
/	O
Angiomodulin	B-GENE-Y
/	O
prostacyclin	B-GENE-Y
-	I-GENE-Y
stimulating	I-GENE-Y
factor	I-GENE-Y
)	O
is	O
a	O
potential	O
tumor	O
-	O
suppressor	O
gene	O
that	O
is	O
differentially	O
expressed	O
in	O
meningiomas	O
,	O
mammary	O
and	O
prostatic	O
cancers	O
,	O
compared	O
with	O
their	O
malignant	O
counterparts	O
.	O

We	O
have	O
previously	O
shown	O
that	O
IGFBP	B-GENE-Y
-	I-GENE-Y
rP1	I-GENE-Y
is	O
preferentially	O
produced	O
by	O
primary	O
cultures	O
of	O
human	O
prostate	O
epithelial	O
cells	O
(	O
HPECs	O
)	O
and	O
by	O
poorly	O
tumorigenic	O
P69SV40T	O
cells	O
,	O
compared	O
with	O
the	O
cancerous	O
prostatic	O
LNCaP	O
,	O
DU145	O
,	O
PC	O
-	O
3	O
,	O
and	O
M12	O
cells	O
.	O

We	O
now	O
show	O
that	O
IGFBP	B-GENE-Y
-	I-GENE-Y
rP1	I-GENE-Y
increases	O
during	O
senescence	O
of	O
HPEC	O
.	O

IGFBP	B-GENE-Y
-	I-GENE-Y
rP2	I-GENE-Y
(	O
also	O
known	O
as	O
connective	B-GENE-Y
tissue	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
)	O
,	O
a	O
downstream	O
effector	O
of	O
transforming	B-GENE-N
growth	I-GENE-N
factor	I-GENE-N
(	I-GENE-N
TGF	I-GENE-N
)	I-GENE-N
-	I-GENE-N
beta	I-GENE-N
and	O
modulator	O
of	O
growth	O
for	O
both	O
fibroblasts	O
and	O
endothelial	O
cells	O
,	O
was	O
detected	O
in	O
most	O
of	O
the	O
normal	O
and	O
malignant	O
prostatic	O
epithelial	O
cells	O
tested	O
,	O
with	O
a	O
marked	O
up	O
-	O
regulation	O
of	O
IGFBP	B-GENE-Y
-	I-GENE-Y
rP2	I-GENE-Y
during	O
senescence	O
of	O
HPEC	O
.	O

Moreover	O
,	O
IGFBP	B-GENE-Y
-	I-GENE-Y
rP2	I-GENE-Y
noticeably	O
increased	O
in	O
response	O
to	O
TGF	B-GENE-Y
-	I-GENE-Y
beta1	I-GENE-Y
and	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
atRA	B-CHEMICAL
)	O
in	O
HPEC	O
and	O
PC	O
-	O
3	O
cells	O
,	O
and	O
it	O
decreased	O
in	O
response	O
to	O
IGF	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
in	O
HPEC	O
.	O

IGFBP	B-GENE-Y
-	I-GENE-Y
rP3	I-GENE-Y
[	O
nephroblastoma	B-GENE-Y
overexpressed	I-GENE-Y
(	O
NOV	B-GENE-Y
)	O
]	O
,	O
the	O
protein	O
product	O
of	O
the	O
NOV	B-GENE-Y
protooncogene	O
,	O
was	O
not	O
detected	O
in	O
HPEC	O
but	O
was	O
expressed	O
in	O
the	O
tumorigenic	O
DU145	O
and	O
PC	O
-	O
3	O
cells	O
.	O

It	O
was	O
also	O
synthesized	O
by	O
the	O
SV40	O
-	O
T	O
antigen	O
-	O
transformed	O
P69	O
and	O
malignant	O
M12	O
cells	O
,	O
where	O
it	O
was	O
down	O
-	O
regulated	O
by	O
atRA	B-CHEMICAL
.	O

These	O
observations	O
suggest	O
biological	O
roles	O
of	O
IGFBP	B-GENE-N
-	I-GENE-N
rPs	I-GENE-N
in	O
the	O
human	O
prostate	O
.	O

IGFBP	B-GENE-Y
-	I-GENE-Y
rP1	I-GENE-Y
and	O
IGFBP	B-GENE-Y
-	I-GENE-Y
rP2	I-GENE-Y
are	O
likely	O
to	O
negatively	O
regulate	O
growth	O
,	O
because	O
they	O
seem	O
to	O
increase	O
during	O
senescence	O
of	O
the	O
prostate	O
epithelium	O
and	O
in	O
response	O
to	O
growth	O
inhibitors	O
(	O
TGF	B-GENE-Y
-	I-GENE-Y
beta1	I-GENE-Y
and	O
atRA	O
)	O
.	O

Although	O
the	O
data	O
collected	O
on	O
IGFBP	B-GENE-Y
-	I-GENE-Y
rP3	I-GENE-Y
in	O
prostate	O
are	O
modest	O
,	O
its	O
role	O
as	O
a	O
growth	O
stimulator	O
and	O
/	O
or	O
protooncogene	O
is	O
supported	O
by	O
its	O
preferential	O
expression	O
in	O
cancerous	O
cells	O
and	O
its	O
down	O
-	O
regulation	O
by	O
atRA	B-CHEMICAL
.	O

Neuropsychological	O
and	O
conditioned	O
blocking	O
performance	O
in	O
patients	O
with	O
schizophrenia	O
:	O
assessment	O
of	O
the	O
contribution	O
of	O
neuroleptic	O
dose	O
,	O
serum	O
levels	O
and	O
dopamine	B-GENE-Y
D2	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
.	O

Patients	O
with	O
schizophrenia	O
show	O
impairments	O
of	O
attention	O
and	O
neuropsychological	O
performance	O
,	O
but	O
the	O
extent	O
to	O
which	O
this	O
is	O
attributable	O
to	O
antipsychotic	O
medication	O
remains	O
largely	O
unexplored	O
.	O

We	O
describe	O
here	O
the	O
putative	O
influence	O
of	O
the	O
dose	O
of	O
antipsychotic	O
medication	O
(	O
chlorpromazine	B-CHEMICAL
equivalents	O
,	O
CPZ	B-CHEMICAL
)	O
,	O
the	O
antipsychotic	O
serum	O
concentration	O
of	O
dopamine	B-GENE-Y
(	I-GENE-Y
DA	I-GENE-Y
)	I-GENE-Y
D2	I-GENE-Y
-	O
blocking	O
activity	O
and	O
the	O
approximated	O
central	O
dopamine	B-CHEMICAL
D2	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
(	O
DA	B-CHEMICAL
D2	B-GENE-Y
-	O
occupancy	O
)	O
,	O
on	O
conditioned	O
blocking	O
(	O
CB	O
)	O
measures	O
of	O
attention	O
and	O
performance	O
on	O
a	O
neuropsychological	O
battery	O
,	O
in	O
108	O
patients	O
with	O
schizophrenia	O
(	O
compared	O
with	O
62	O
healthy	O
controls	O
)	O
.	O

Antipsychotic	O
serum	O
concentration	O
and	O
D2	B-GENE-Y
-	O
occupancy	O
were	O
higher	O
in	O
patients	O
with	O
a	O
paranoid	O
versus	O
non	O
-	O
paranoid	O
diagnosis	O
,	O
and	O
in	O
female	O
versus	O
male	O
patients	O
(	O
independent	O
of	O
symptom	O
severity	O
)	O
.	O

Controlling	O
for	O
D2	B-GENE-Y
-	O
occupancy	O
removed	O
the	O
difference	O
between	O
high	O
CB	O
in	O
paranoid	O
and	O
impaired	O
low	O
CB	O
in	O
non	O
-	O
paranoid	O
patients	O
.	O

Similar	O
partial	O
correlations	O
for	O
antipsychotic	O
drug	O
dose	O
and	O
serum	O
levels	O
of	O
DA	B-CHEMICAL
D2	B-GENE-Y
-	O
blocking	O
activity	O
with	O
performance	O
of	O
the	O
trail	O
-	O
making	O
and	O
picture	O
completion	O
tests	O
(	O
negative	O
)	O
and	O
the	O
block	O
-	O
design	O
task	O
(	O
positive	O
)	O
showed	O
the	O
functional	O
importance	O
of	O
DA	B-CHEMICAL
-	O
related	O
activity	O
.	O

High	O
estimates	O
of	O
central	O
DA	B-CHEMICAL
D2	B-GENE-Y
-	O
occupancy	O
were	O
related	O
to	O
impaired	O
verbal	O
fluency	O
but	O
were	O
associated	O
with	O
improved	O
recall	O
of	O
stories	O
,	O
especially	O
in	O
paranoid	O
patients	O
.	O

This	O
,	O
the	O
first	O
study	O
of	O
its	O
kind	O
,	O
tentatively	O
imputes	O
a	O
role	O
for	O
DA	B-CHEMICAL
D2	B-GENE-Y
-	O
related	O
activity	O
in	O
left	O
frontal	O
(	O
e	O
.	O
g	O
.	O
CB	O
,	O
verbal	O
fluency	O
)	O
and	O
temporal	O
lobe	O
functions	O
(	O
verbal	O
recall	O
)	O
as	O
well	O
as	O
in	O
some	O
non	O
-	O
verbal	O
abilities	O
mediated	O
more	O
in	O
the	O
right	O
hemisphere	O
in	O
patients	O
with	O
schizophrenia	O
.	O

alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
adrenergic	I-GENE-Y
receptors	I-GENE-Y
in	O
gonadotrophin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
neurones	O
:	O
relation	O
to	O
Transport	O
-	O
P	O
.	O

1	O
.	O

Peptidergic	O
neurones	O
accumulate	O
amines	B-CHEMICAL
via	O
an	O
unusual	O
uptake	O
process	O
,	O
designated	O
Transport	O
-	O
P	O
.	O

[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
prazosin	I-CHEMICAL
binds	O
to	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
adrenoceptors	I-GENE-N
on	O
these	O
cells	O
and	O
is	O
displaceable	O
by	O
unlabelled	O
prazosin	B-CHEMICAL
in	O
concentrations	O
up	O
to	O
10	O
(	O
-	O
7	O
)	O
M	O
.	O

However	O
,	O
at	O
greater	O
concentrations	O
of	O
prazosin	B-CHEMICAL
,	O
there	O
is	O
a	O
paradoxical	O
accumulation	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
prazosin	I-CHEMICAL
which	O
we	O
have	O
attributed	O
to	O
Transport	O
-	O
P	O
.	O

Uptake	O
of	O
prazosin	B-CHEMICAL
via	O
Transport	O
-	O
P	O
is	O
detectable	O
at	O
10	O
(	O
-	O
10	O
)	O
M	O
prazosin	B-CHEMICAL
concentration	O
,	O
is	O
linear	O
up	O
to	O
10	O
(	O
-	O
7	O
)	O
M	O
and	O
at	O
greater	O
concentrations	O
becomes	O
non	O
-	O
linear	O
.	O

In	O
contrast	O
,	O
in	O
noradrenergic	O
neurones	O
,	O
noradrenaline	B-CHEMICAL
uptake	O
is	O
linear	O
and	O
saturates	O
above	O
10	O
(	O
-	O
7	O
)	O
M	O
.	O

In	O
noradrenergic	O
neurones	O
and	O
in	O
non	O
-	O
neuronal	O
cells	O
,	O
there	O
is	O
no	O
uptake	O
of	O
prazosin	B-CHEMICAL
in	O
concentrations	O
up	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
,	O
suggesting	O
that	O
Transport	O
-	O
P	O
is	O
a	O
specialised	O
function	O
of	O
peptidergic	O
neurones	O
.	O

2	O
.	O

Using	O
a	O
mouse	O
peptidergic	O
(	O
gonadotrophin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
,	O
GnRH	B-CHEMICAL
)	O
neuronal	O
cell	O
line	O
which	O
possesses	O
Transport	O
-	O
P	O
,	O
we	O
have	O
studied	O
the	O
interaction	O
of	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
adrenoceptors	I-GENE-N
with	O
Transport	O
-	O
P	O
.	O

Polymerase	O
chain	O
reactions	O
and	O
DNA	O
sequencing	O
of	O
the	O
products	O
demonstrated	O
that	O
only	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
sub	I-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
of	I-GENE-Y
adrenoceptors	I-GENE-Y
is	O
present	O
in	O
GnRH	B-CHEMICAL
cells	O
.	O

3	O
.	O

In	O
COS	O
cells	O
transfected	O
with	O
alpha	B-GENE-Y
(	I-GENE-Y
1b	I-GENE-Y
)	I-GENE-Y
adrenoceptor	I-GENE-Y
cDNA	O
and	O
in	O
DDT	O
(	O
1	O
)	O
MF	O
-	O
2	O
cells	O
which	O
express	O
native	O
alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
adrenoceptors	I-GENE-Y
,	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
prazosin	I-CHEMICAL
was	O
displaced	O
by	O
unlabelled	O
prazosin	B-CHEMICAL
in	O
a	O
normal	O
equilibrium	O
process	O
,	O
with	O
no	O
prazosin	B-CHEMICAL
paradox	O
in	O
concentrations	O
up	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
.	O

In	O
DDT	O
(	O
1	O
)	O
MF	O
-	O
2	O
cells	O
,	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
prazosin	I-CHEMICAL
was	O
displaced	O
likewise	O
by	O
a	O
series	O
of	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
adrenergic	O
agonists	O
,	O
none	O
of	O
which	O
increased	O
the	O
binding	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
prazosin	I-CHEMICAL
.	O

Hence	O
,	O
the	O
prazosin	B-CHEMICAL
paradox	O
is	O
not	O
due	O
to	O
some	O
function	O
of	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
adrenoceptors	I-GENE-N
,	O
such	O
as	O
internalization	O
of	O
ligand	O
-	O
receptor	O
complexes	O
.	O

4	O
.	O

In	O
neurones	O
which	O
possess	O
Transport	O
-	O
P	O
,	O
transfection	O
with	O
alpha	B-GENE-Y
(	I-GENE-Y
1b	I-GENE-Y
)	I-GENE-Y
adrenoceptor	I-GENE-Y
cDNA	O
resulted	O
in	O
over	O
-	O
expression	O
of	O
alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
adrenoceptors	I-GENE-Y
,	O
but	O
the	O
prazosin	B-CHEMICAL
paradox	O
was	O
unaltered	O
.	O

Thus	O
,	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
adrenoceptors	I-GENE-N
and	O
Transport	O
-	O
P	O
mediate	O
distinct	O
functions	O
in	O
peptidergic	O
neurones	O
.	O

Biophysical	O
properties	O
,	O
pharmacology	O
,	O
and	O
modulation	O
of	O
human	O
,	O
neuronal	O
L	O
-	O
type	O
(	O
alpha	B-GENE-Y
(	I-GENE-Y
1D	I-GENE-Y
)	I-GENE-Y
,	O
Ca	B-GENE-Y
(	I-GENE-Y
V	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
)	O
voltage	O
-	O
dependent	O
calcium	B-CHEMICAL
currents	O
.	O

Voltage	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
calcium	I-GENE-N
channels	I-GENE-N
(	O
VDCCs	O
)	O
are	O
multimeric	O
complexes	O
composed	O
of	O
a	O
pore	O
-	O
forming	O
alpha	O
(	O
1	O
)	O
subunit	O
together	O
with	O
several	O
accessory	O
subunits	O
,	O
including	O
alpha	O
(	O
2	O
)	O
delta	O
,	O
beta	O
,	O
and	O
,	O
in	O
some	O
cases	O
,	O
gamma	O
subunits	O
.	O

A	O
family	O
of	O
VDCCs	B-GENE-N
known	O
as	O
the	O
L	B-GENE-N
-	I-GENE-N
type	I-GENE-N
channels	I-GENE-N
are	O
formed	O
specifically	O
from	O
alpha	O
(	O
1S	O
)	O
(	O
skeletal	O
muscle	O
)	O
,	O
alpha	O
(	O
1C	O
)	O
(	O
in	O
heart	O
and	O
brain	O
)	O
,	O
alpha	O
(	O
1D	O
)	O
(	O
mainly	O
in	O
brain	O
,	O
heart	O
,	O
and	O
endocrine	O
tissue	O
)	O
,	O
and	O
alpha	O
(	O
1F	O
)	O
(	O
retina	O
)	O
.	O

Neuroendocrine	O
L	O
-	O
type	O
currents	O
have	O
a	O
significant	O
role	O
in	O
the	O
control	O
of	O
neurosecretion	O
and	O
can	O
be	O
inhibited	O
by	O
GTP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
(	I-GENE-N
G	I-GENE-N
-	I-GENE-N
)	I-GENE-N
proteins	I-GENE-N
.	O

However	O
,	O
the	O
subunit	O
composition	O
of	O
the	O
VDCCs	B-GENE-N
underlying	O
these	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	O
regulated	O
neuroendocrine	O
L	O
-	O
type	O
currents	O
is	O
unknown	O
.	O

To	O
investigate	O
the	O
biophysical	O
and	O
pharmacological	O
properties	O
and	O
role	O
of	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
modulation	O
of	O
alpha	B-GENE-Y
(	I-GENE-Y
1D	I-GENE-Y
)	I-GENE-Y
calcium	I-GENE-Y
channels	I-GENE-Y
,	O
we	O
have	O
examined	O
calcium	B-GENE-N
channel	I-GENE-N
currents	O
formed	O
by	O
the	O
human	B-GENE-Y
neuronal	I-GENE-Y
L	I-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
1D	I-GENE-Y
)	I-GENE-Y
subunit	O
,	O
co	O
-	O
expressed	O
with	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
1	O
and	O
beta	O
(	O
3a	O
)	O
,	O
stably	O
expressed	O
in	O
a	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cell	O
line	O
,	O
using	O
whole	O
cell	O
and	O
perforated	O
patch	O
-	O
clamp	O
techniques	O
.	O

The	O
alpha	O
(	O
1D	O
)	O
-	O
expressing	O
cell	O
line	O
exhibited	O
L	O
-	O
type	O
currents	O
with	O
typical	O
characteristics	O
.	O

The	O
currents	O
were	O
high	O
-	O
voltage	O
activated	O
(	O
peak	O
at	O
+	O
20	O
mV	O
in	O
20	O
mM	O
Ba2	B-CHEMICAL
+	I-CHEMICAL
)	O
and	O
showed	O
little	O
inactivation	O
in	O
external	O
Ba2	B-CHEMICAL
+	I-CHEMICAL
,	O
while	O
displaying	O
rapid	O
inactivation	O
kinetics	O
in	O
external	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
.	O

The	O
L	O
-	O
type	O
currents	O
were	O
inhibited	O
by	O
the	O
1	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
dihydropyridine	I-CHEMICAL
(	O
DHP	B-CHEMICAL
)	O
antagonists	O
nifedipine	B-CHEMICAL
and	O
nicardipine	B-CHEMICAL
and	O
were	O
enhanced	O
by	O
the	O
DHP	B-CHEMICAL
agonist	O
BayK	B-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
8644	I-CHEMICAL
.	O

However	O
,	O
alpha	B-GENE-Y
(	I-GENE-Y
1D	I-GENE-Y
)	I-GENE-Y
L	O
-	O
type	O
currents	O
were	O
not	O
modulated	O
by	O
activation	O
of	O
a	O
number	O
of	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
pathways	O
.	O

Activation	O
of	O
endogenous	O
somatostatin	B-GENE-Y
receptor	I-GENE-Y
subtype	I-GENE-Y
2	I-GENE-Y
(	O
sst2	B-GENE-Y
)	O
by	O
somatostatin	B-CHEMICAL
-	I-CHEMICAL
14	I-CHEMICAL
or	O
activation	O
of	O
transiently	O
transfected	O
rat	B-GENE-N
D2	I-GENE-N
dopamine	I-GENE-N
receptors	I-GENE-N
(	O
rD2	B-GENE-N
(	O
long	O
)	O
)	O
by	O
quinpirole	B-CHEMICAL
had	O
no	O
effect	O
.	O

Direct	O
activation	O
of	O
G	O
-	O
proteins	O
by	O
the	O
nonhydrolyzable	O
GTP	B-CHEMICAL
analogue	O
,	O
guanosine	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
0	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
thiotriphospate	I-CHEMICAL
)	I-CHEMICAL
also	O
had	O
no	O
effect	O
on	O
the	O
alpha	O
(	O
1D	O
)	O
currents	O
.	O

In	O
contrast	O
,	O
in	O
the	O
same	O
system	O
,	O
N	B-CHEMICAL
-	O
type	O
currents	O
,	O
formed	O
from	O
transiently	O
transfected	O
alpha	O
(	O
1B	O
)	O
/	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
1	O
/	O
beta	O
(	O
3	O
)	O
,	O
showed	O
strong	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	O
mediated	O
inhibition	O
.	O

Furthermore	O
,	O
the	O
I	O
-	O
II	O
loop	O
from	O
the	O
alpha	O
(	O
1D	O
)	O
clone	O
,	O
expressed	O
as	O
a	O
glutathione	B-GENE-N
-	I-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
(	O
GST	B-GENE-N
)	O
fusion	O
protein	O
,	O
did	O
not	O
bind	O
Gbetagamma	O
,	O
unlike	O
the	O
alpha	B-GENE-N
(	I-GENE-N
1B	I-GENE-N
)	I-GENE-N
I	I-GENE-N
-	I-GENE-N
II	I-GENE-N
loop	I-GENE-N
fusion	O
protein	O
.	O

These	O
data	O
show	O
that	O
the	O
biophysical	O
and	O
pharmacological	O
properties	O
of	O
recombinant	O
human	O
alpha	O
(	O
1D	O
)	O
L	O
-	O
type	O
currents	O
are	O
similar	O
to	O
alpha	O
(	O
1C	O
)	O
currents	O
,	O
and	O
these	O
currents	O
are	O
also	O
resistant	O
to	O
modulation	O
by	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
/	I-GENE-N
o	I-GENE-N
)	I-GENE-N
-	O
linked	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
.	O

Glioma	O
cell	O
sensitivity	O
to	O
topotecan	B-CHEMICAL
:	O
the	O
role	O
of	O
p53	B-GENE-Y
and	O
topotecan	B-CHEMICAL
-	O
induced	O
DNA	O
damage	O
.	O

Topotecan	B-CHEMICAL
is	O
a	O
topoisomerase	B-GENE-Y
I	I-GENE-Y
inhibitor	O
which	O
is	O
currently	O
evaluated	O
as	O
an	O
adjuvant	O
agent	O
for	O
malignant	O
glioma	O
.	O

Here	O
,	O
we	O
analysed	O
the	O
effects	O
of	O
topotecan	B-CHEMICAL
on	O
12	O
human	O
malignant	O
glioma	O
cell	O
lines	O
in	O
vitro	O
.	O

All	O
cell	O
lines	O
expressed	O
topoisomerase	B-GENE-Y
I	I-GENE-Y
mRNA	O
.	O

High	O
p53	B-GENE-Y
protein	O
levels	O
,	O
but	O
not	O
genetic	O
or	O
functional	O
p53	B-GENE-Y
status	O
,	O
were	O
associated	O
with	O
increased	O
topotecan	B-CHEMICAL
-	O
induced	O
DNA	O
/	O
topoisomerase	B-GENE-Y
I	I-GENE-Y
complex	O
formation	O
.	O

Neither	O
functional	O
p53	B-GENE-Y
status	O
,	O
nor	O
p53	B-GENE-Y
protein	O
levels	O
,	O
nor	O
complex	O
formation	O
predicted	O
topotecan	B-CHEMICAL
-	O
induced	O
growth	O
inhibition	O
.	O

We	O
thus	O
confirm	O
a	O
possible	O
role	O
for	O
p53	B-GENE-Y
protein	O
in	O
modulating	O
topoisomerase	B-GENE-Y
I	I-GENE-Y
activity	O
but	O
conclude	O
that	O
the	O
major	O
molecular	O
determinants	O
of	O
topotecan	B-CHEMICAL
sensitivity	O
in	O
glioma	O
cells	O
await	O
identification	O
.	O

Clinical	O
effects	O
of	O
pranlukast	B-CHEMICAL
,	O
an	O
oral	O
leukotriene	B-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
in	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
:	O
a	O
4	O
week	O
randomized	O
multicentre	O
controlled	O
trial	O
.	O

OBJECTIVE	O
:	O
Leukotriene	B-CHEMICAL
antagonists	O
are	O
increasingly	O
used	O
in	O
asthma	O
management	O
.	O

Pranlukast	B-CHEMICAL
is	O
a	O
new	O
,	O
orally	O
active	O
,	O
selective	O
inhibitor	O
of	O
CysLt1	B-GENE-Y
leukotriene	B-GENE-N
receptor	I-GENE-N
.	O

The	O
present	O
clinical	O
trial	O
was	O
performed	O
to	O
study	O
the	O
effect	O
and	O
safety	O
of	O
pranlukast	B-CHEMICAL
in	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
.	O

METHODOLOGY	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
parallel	O
group	O
study	O
was	O
performed	O
in	O
eight	O
medical	O
centres	O
in	O
Korea	O
.	O

Mild	O
-	O
to	O
-	O
moderate	O
asthma	O
patients	O
who	O
had	O
been	O
treated	O
with	O
beta2	O
-	O
agonists	O
and	O
/	O
or	O
inhaled	O
corticosteroids	B-CHEMICAL
were	O
studied	O
.	O

The	O
patients	O
'	O
symptoms	O
were	O
evaluated	O
by	O
asthma	O
diary	O
and	O
twice	O
-	O
daily	O
peak	O
flow	O
monitoring	O
.	O

RESULTS	O
:	O
Of	O
the	O
206	O
patients	O
enrolled	O
,	O
197	O
were	O
eligible	O
for	O
analysis	O
.	O

The	O
pranlukast	B-CHEMICAL
group	O
(	O
n	O
=	O
98	O
)	O
showed	O
statistically	O
significant	O
improvement	O
in	O
asthma	O
symptoms	O
,	O
including	O
asthma	O
attack	O
rate	O
,	O
daily	O
living	O
score	O
,	O
and	O
morning	O
and	O
evening	O
asthma	O
scores	O
.	O

Pranlukast	B-CHEMICAL
significantly	O
reduced	O
the	O
consumption	O
of	O
beta2	O
-	O
agonist	O
.	O

Compared	O
with	O
the	O
placebo	O
group	O
,	O
forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
and	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
were	O
not	O
significantly	O
higher	O
in	O
the	O
pranlukast	B-CHEMICAL
group	O
.	O

Morning	O
and	O
evening	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
were	O
significantly	O
increased	O
after	O
pranlukast	B-CHEMICAL
treatment	O
at	O
weeks	O
2	O
and	O
4	O
(	O
380	O
.	O
8	O
+	O
/	O
-	O
10	O
.	O
1	O
L	O
/	O
min	O
at	O
baseline	O
,	O
394	O
.	O
5	O
+	O
/	O
-	O
10	O
.	O
1	O
at	O
week	O
2	O
,	O
396	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
4	O
at	O
week	O
4	O
)	O
.	O

There	O
were	O
no	O
serious	O
adverse	O
reactions	O
.	O

CONCLUSION	O
:	O
Pranlukast	B-CHEMICAL
,	O
an	O
oral	O
leukotriene	B-CHEMICAL
antagonist	O
,	O
was	O
well	O
tolerated	O
and	O
was	O
effective	O
for	O
the	O
management	O
of	O
mild	O
-	O
to	O
-	O
moderate	O
asthma	O
.	O

Atp	O
-	O
bound	O
topoisomerase	B-GENE-Y
ii	I-GENE-Y
as	O
a	O
target	O
for	O
antitumor	O
drugs	O
.	O

Topoisomerase	B-GENE-Y
II	I-GENE-Y
(	O
TOP2	B-GENE-Y
)	O
poisons	O
interfere	O
with	O
the	O
breakage	O
/	O
reunion	O
reaction	O
of	O
TOP2	B-GENE-Y
resulting	O
in	O
DNA	O
cleavage	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
show	O
that	O
two	O
different	O
classes	O
(	O
ATP	B-CHEMICAL
-	O
sensitive	O
and	O
-	O
insensitive	O
)	O
of	O
TOP2	B-GENE-Y
poisons	O
can	O
be	O
identified	O
based	O
on	O
their	O
differential	O
sensitivity	O
to	O
the	O
ATP	B-CHEMICAL
-	O
bound	O
conformation	O
of	O
TOP2	B-GENE-Y
.	O

First	O
,	O
in	O
the	O
presence	O
of	O
1	O
mm	O
ATP	B-CHEMICAL
or	O
the	O
nonhydrolyzable	O
analog	O
adenosine	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
gamma	I-CHEMICAL
-	I-CHEMICAL
imino	I-CHEMICAL
)	I-CHEMICAL
triphosphate	I-CHEMICAL
,	O
TOP2	B-GENE-Y
-	O
mediated	O
DNA	O
cleavage	O
induced	O
by	O
ATP	B-CHEMICAL
-	O
sensitive	O
TOP2	B-GENE-Y
poisons	O
(	O
e	O
.	O
g	O
.	O
doxorubicin	B-CHEMICAL
,	O
etoposide	B-CHEMICAL
,	O
mitoxantrone	B-CHEMICAL
,	O
and	O
4	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
acridinylamino	I-CHEMICAL
)	I-CHEMICAL
methanesulfon	I-CHEMICAL
-	I-CHEMICAL
m	I-CHEMICAL
-	I-CHEMICAL
anisidide	I-CHEMICAL
)	O
was	O
30	O
-	O
100	O
-	O
fold	O
stimulated	O
,	O
whereas	O
DNA	O
cleavage	O
induced	O
by	O
ATP	B-CHEMICAL
-	O
insensitive	O
TOP2	B-GENE-Y
poisons	O
(	O
e	O
.	O
g	O
.	O
amonafide	B-CHEMICAL
,	O
batracylin	B-CHEMICAL
,	O
and	O
menadione	B-CHEMICAL
)	O
was	O
only	O
slightly	O
(	O
less	O
than	O
3	O
-	O
fold	O
)	O
affected	O
.	O

In	O
addition	O
,	O
ADP	B-CHEMICAL
was	O
shown	O
to	O
strongly	O
antagonize	O
TOP2	B-GENE-Y
-	O
mediated	O
DNA	O
cleavage	O
induced	O
by	O
ATP	B-CHEMICAL
-	O
sensitive	O
but	O
not	O
ATP	B-CHEMICAL
-	O
insensitive	O
TOP2	B-GENE-Y
poisons	O
.	O

Second	O
,	O
C427A	B-GENE-N
mutant	O
human	B-GENE-Y
TOP2alpha	I-GENE-Y
,	O
which	O
exhibits	O
reduced	O
ATPase	B-GENE-N
activity	O
,	O
was	O
shown	O
to	O
exhibit	O
cross	O
-	O
resistance	O
to	O
all	O
ATP	B-CHEMICAL
-	O
sensitive	O
but	O
not	O
ATP	B-CHEMICAL
-	O
insensitive	O
TOP2	B-GENE-Y
poisons	O
.	O

Third	O
,	O
using	O
ciprofloxacin	B-CHEMICAL
competition	O
assay	O
,	O
TOP2	B-GENE-Y
-	O
mediated	O
DNA	O
cleavage	O
induced	O
by	O
ATP	B-CHEMICAL
-	O
sensitive	O
but	O
not	O
ATP	B-CHEMICAL
-	O
insensitive	O
poisons	O
was	O
shown	O
to	O
be	O
antagonized	O
by	O
ciprofloxacin	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
ATP	B-CHEMICAL
-	O
bound	O
TOP2	B-GENE-Y
may	O
be	O
the	O
specific	O
target	O
of	O
ATP	B-CHEMICAL
-	O
sensitive	O
TOP2	B-GENE-Y
poisons	O
.	O

Using	O
Lac	B-GENE-N
repressor	I-GENE-N
-	I-GENE-N
operator	I-GENE-N
complexes	I-GENE-N
as	O
roadblocks	O
,	O
we	O
show	O
that	O
ATP	B-CHEMICAL
-	O
bound	O
TOP2	B-GENE-Y
acts	O
as	O
a	O
circular	O
clamp	O
capable	O
of	O
entering	O
DNA	O
ends	O
and	O
sliding	O
on	O
unobstructed	O
duplex	O
DNA	O
.	O

Antithrombin	O
binding	O
of	O
low	O
molecular	O
weight	O
heparins	O
and	O
inhibition	O
of	O
factor	B-GENE-Y
Xa	I-GENE-Y
.	O

Fluorescence	O
and	O
stopped	O
flow	O
methods	O
were	O
used	O
to	O
compare	O
clinically	O
used	O
heparins	O
with	O
regard	O
to	O
their	O
ability	O
to	O
bind	O
to	O
antithrombin	B-GENE-Y
and	O
to	O
accelerate	O
the	O
inactivation	O
of	O
factor	B-GENE-Y
Xa	I-GENE-Y
.	O

Titration	O
of	O
antithrombin	B-GENE-Y
with	O
both	O
low	O
molecular	O
weight	O
heparin	O
(	O
LMWH	O
)	O
(	O
enoxaparin	O
,	O
fragmin	O
and	O
ardeparin	O
)	O
and	O
unfractionated	O
heparin	O
(	O
UFH	O
)	O
produced	O
an	O
equivalent	O
fluorescence	O
increase	O
and	O
indicates	O
similar	O
affinity	O
of	O
all	O
heparin	O
preparations	O
to	O
antithrombin	B-GENE-Y
.	O

However	O
,	O
relative	O
to	O
UFH	O
enoxaparin	O
,	O
the	O
LMWH	O
with	O
the	O
smallest	O
average	O
molecular	O
mass	O
,	O
contained	O
only	O
12	O
%	O
material	O
with	O
high	O
affinity	O
for	O
antithrombin	B-GENE-Y
.	O

The	O
rate	O
of	O
factor	B-GENE-Y
Xa	I-GENE-Y
inhibition	O
by	O
antithrombin	B-GENE-Y
increased	O
with	O
the	O
concentration	O
of	O
the	O
examined	O
heparins	O
to	O
the	O
same	O
limiting	O
value	O
,	O
but	O
the	O
concentration	O
required	O
for	O
maximal	O
acceleration	O
depended	O
on	O
the	O
preparation	O
.	O

According	O
to	O
these	O
data	O
the	O
high	O
affinity	O
fraction	O
of	O
the	O
heparin	O
preparations	O
increased	O
the	O
intrinsic	O
fluorescence	O
and	O
inhibitory	O
activity	O
equally	O
without	O
additional	O
effects	O
by	O
variations	O
in	O
chain	O
length	O
and	O
chemical	O
composition	O
.	O

In	O
contrast	O
,	O
in	O
the	O
presence	O
of	O
Ca	B-CHEMICAL
UFH	O
accelerated	O
the	O
inhibition	O
of	O
factor	B-GENE-Y
Xa	I-GENE-Y
by	O
antithrombin	B-GENE-Y
10	O
-	O
fold	O
more	O
efficiently	O
than	O
comparable	O
concentrations	O
of	O
the	O
high	O
affinity	O
fractions	O
of	O
enoxaparin	O
and	O
fragmin	O
.	O

The	O
bell	O
-	O
shaped	O
dependence	O
of	O
this	O
accelerating	O
effect	O
suggests	O
simultaneous	O
binding	O
of	O
both	O
proteins	O
to	O
heparin	O
.	O

In	O
conclusion	O
,	O
under	O
physiologic	O
conditions	O
the	O
anti	O
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
activity	O
of	O
heparin	O
results	O
from	O
a	O
composite	O
effect	O
of	O
chain	O
length	O
and	O
the	O
content	O
of	O
material	O
with	O
high	O
affinity	O
to	O
antithrombin	B-GENE-Y
.	O

Thus	O
,	O
the	O
reduced	O
antithrombotic	O
activity	O
of	O
LMWH	O
relative	O
to	O
UFH	O
results	O
from	O
a	O
smaller	O
content	O
of	O
high	O
affinity	O
material	O
and	O
the	O
absence	O
of	O
a	O
stimulating	O
effect	O
of	O
calcium	B-CHEMICAL
.	O

Mutations	O
in	O
the	O
follicle	B-GENE-N
-	I-GENE-N
stimulating	I-GENE-N
hormone	I-GENE-N
-	I-GENE-N
beta	I-GENE-N
(	O
FSH	B-GENE-N
beta	I-GENE-N
)	O
and	O
FSH	B-GENE-N
receptor	I-GENE-N
genes	O
in	O
mice	O
and	O
humans	O
.	O

Follicle	B-GENE-N
-	I-GENE-N
stimulating	I-GENE-N
hormone	I-GENE-N
(	O
FSH	B-GENE-N
)	O
,	O
a	O
dimeric	O
glycoprotein	O
synthesized	O
in	O
the	O
anterior	O
pituitary	O
gland	O
,	O
is	O
important	O
for	O
the	O
production	O
of	O
sex	O
steroids	B-CHEMICAL
and	O
gametes	O
.	O

FSH	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
(	O
FSH	B-GENE-Y
beta	I-GENE-Y
)	O
and	O
FSH	B-GENE-Y
receptor	I-GENE-Y
(	O
FSHR	B-GENE-Y
)	O
knockout	O
mice	O
display	O
impaired	O
ovarian	O
follicular	O
development	O
and	O
infertility	O
in	O
females	O
and	O
small	O
testes	O
,	O
oligospermia	O
,	O
and	O
fertility	O
in	O
males	O
.	O

Humans	O
with	O
FSH	B-GENE-Y
beta	I-GENE-Y
gene	O
mutations	O
tend	O
to	O
have	O
a	O
more	O
severe	O
phenotype	O
than	O
those	O
with	O
FSHR	B-GENE-Y
gene	O
mutations	O
,	O
although	O
infertility	O
and	O
varying	O
degrees	O
of	O
impaired	O
sex	O
steroid	B-CHEMICAL
production	O
occur	O
in	O
both	O
types	O
of	O
mutations	O
.	O

Data	O
from	O
human	O
and	O
mouse	O
mutations	O
in	O
the	O
FSH	B-GENE-N
beta	I-GENE-N
and	O
FSHR	B-GENE-N
genes	O
suggest	O
that	O
FSH	B-GENE-N
is	O
necessary	O
for	O
normal	O
pubertal	O
development	O
and	O
fertility	O
in	O
males	O
and	O
females	O
.	O

Acyl	B-GENE-N
-	I-GENE-N
CoA	I-GENE-N
synthetase	I-GENE-N
isoforms	I-GENE-N
1	I-GENE-N
,	I-GENE-N
4	I-GENE-N
,	I-GENE-N
and	I-GENE-N
5	I-GENE-N
are	O
present	O
in	O
different	O
subcellular	O
membranes	O
in	O
rat	O
liver	O
and	O
can	O
be	O
inhibited	O
independently	O
.	O

Inhibition	O
studies	O
have	O
suggested	O
that	O
acyl	B-GENE-N
-	I-GENE-N
CoA	I-GENE-N
synthetase	I-GENE-N
(	O
ACS	B-GENE-N
,	O
EC	O
)	O
isoforms	O
might	O
regulate	O
the	O
use	O
of	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
by	O
different	O
metabolic	O
pathways	O
.	O

In	O
order	O
to	O
determine	O
whether	O
the	O
subcellular	O
locations	O
differed	O
for	O
each	O
of	O
the	O
three	O
ACSs	B-GENE-N
present	O
in	O
liver	O
and	O
whether	O
these	O
isoforms	O
were	O
regulated	O
independently	O
,	O
non	O
-	O
cross	O
-	O
reacting	O
peptide	O
antibodies	O
were	O
raised	O
against	O
ACS1	B-GENE-Y
,	O
ACS4	B-GENE-Y
,	O
and	O
ACS5	B-GENE-Y
.	O

ACS1	B-GENE-Y
was	O
identified	O
in	O
endoplasmic	O
reticulum	O
,	O
mitochondria	O
-	O
associated	O
membrane	O
(	O
MAM	O
)	O
,	O
and	O
cytosol	O
,	O
but	O
not	O
in	O
mitochondria	O
.	O

ACS4	B-GENE-Y
was	O
present	O
primarily	O
in	O
MAM	O
,	O
and	O
the	O
76	O
-	O
kDa	O
ACS5	B-GENE-Y
protein	O
was	O
located	O
in	O
mitochondrial	O
membrane	O
.	O

Consistent	O
with	O
these	O
locations	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
ethylmaleimide	I-CHEMICAL
,	O
an	O
inhibitor	O
of	O
ACS4	B-GENE-Y
,	O
inhibited	O
ACS	B-GENE-N
activity	O
47	O
%	O
in	O
MAM	O
and	O
28	O
%	O
in	O
endoplasmic	O
reticulum	O
.	O

Troglitazone	B-CHEMICAL
,	O
a	O
second	O
ACS4	B-GENE-Y
inhibitor	O
,	O
inhibited	O
ACS	B-GENE-N
activity	O
<	O
10	O
%	O
in	O
microsomes	O
and	O
mitochondria	O
and	O
45	O
%	O
in	O
MAM	O
.	O

Triacsin	B-CHEMICAL
C	I-CHEMICAL
,	O
a	O
competitive	O
inhibitor	O
of	O
both	O
ACS1	B-GENE-Y
and	O
ACS4	B-GENE-Y
,	O
inhibited	O
ACS	B-GENE-N
activity	O
similarly	O
in	O
endoplasmic	O
reticulum	O
,	O
MAM	O
,	O
and	O
mitochondria	O
,	O
suggesting	O
that	O
a	O
hitherto	O
unidentified	O
triacsin	B-CHEMICAL
-	O
sensitive	O
ACS	B-GENE-N
is	O
present	O
in	O
mitochondria	O
.	O

ACS1	B-GENE-Y
,	O
ACS4	B-GENE-Y
,	O
and	O
ACS5	B-GENE-Y
were	O
regulated	O
independently	O
by	O
fasting	O
and	O
re	O
-	O
feeding	O
.	O

Fasting	O
rats	O
for	O
48	O
h	O
resulted	O
in	O
a	O
decrease	O
in	O
ACS4	B-GENE-Y
protein	O
,	O
and	O
an	O
increase	O
in	O
ACS5	B-GENE-Y
.	O

Re	O
-	O
feeding	O
normal	O
chow	O
or	O
a	O
high	O
sucrose	B-CHEMICAL
diet	O
for	O
24	O
h	O
after	O
a	O
48	O
-	O
h	O
fast	O
increased	O
both	O
ACS1	B-GENE-Y
and	O
ACS4	B-GENE-Y
protein	O
expression	O
1	O
.	O
5	O
-	O
2	O
.	O
0	O
-	O
fold	O
,	O
consistent	O
with	O
inhibition	O
studies	O
.	O

These	O
results	O
suggest	O
that	O
ACS1	B-GENE-Y
and	O
ACS4	B-GENE-Y
may	O
be	O
linked	O
to	O
triacylglycerol	B-CHEMICAL
synthesis	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
may	O
be	O
functionally	O
channeled	O
to	O
specific	O
metabolic	O
pathways	O
through	O
different	O
ACS	B-GENE-N
isoforms	O
in	O
unique	O
subcellular	O
locations	O
.	O

Differential	O
inhibition	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
quinuclinidyl	I-CHEMICAL
benzilate	I-CHEMICAL
binding	O
to	O
muscarinic	B-GENE-N
receptors	I-GENE-N
in	O
rat	O
brain	O
membranes	O
with	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
.	O

The	O
potential	O
interaction	O
of	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
with	O
cholinergic	B-GENE-N
receptors	I-GENE-N
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
therapeutic	O
and	O
/	O
or	O
side	O
-	O
effects	O
associated	O
with	O
this	O
class	O
of	O
compound	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
capacity	O
of	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
to	O
interact	O
with	O
muscarinic	B-GENE-N
receptors	I-GENE-N
was	O
assessed	O
by	O
their	O
ability	O
to	O
displace	O
both	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
quinuclinidyl	I-CHEMICAL
benzilate	I-CHEMICAL
binding	O
in	O
rat	O
brain	O
membranes	O
.	O

The	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
quinuclinidyl	I-CHEMICAL
benzilate	I-CHEMICAL
/	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
affinity	O
ratios	O
permitted	O
predictions	O
to	O
be	O
made	O
of	O
either	O
the	O
antagonist	O
or	O
agonist	O
properties	O
of	O
the	O
different	O
compounds	O
.	O

A	O
series	O
of	O
compounds	O
,	O
representative	O
of	O
the	O
principal	O
classes	O
of	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
,	O
displaced	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
binding	O
with	O
high	O
-	O
to	O
-	O
moderate	O
potency	O
(	O
ambenonium	B-CHEMICAL
>	O
neostigmine	B-CHEMICAL
=	O
pyridostigmine	B-CHEMICAL
=	O
tacrine	B-CHEMICAL
>	O
physostigmine	B-CHEMICAL
>	O
edrophonium	B-CHEMICAL
=	O
galanthamine	B-CHEMICAL
>	O
desoxypeganine	B-CHEMICAL
)	O
whereas	O
only	O
ambenonium	B-CHEMICAL
and	O
tacrine	B-CHEMICAL
displaced	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
quinuclinidyl	I-CHEMICAL
benzilate	I-CHEMICAL
binding	O
.	O

Inhibitors	O
such	O
as	O
desoxypeganine	B-CHEMICAL
,	O
parathion	O
and	O
gramine	O
demonstrated	O
negligible	O
inhibition	O
of	O
the	O
binding	O
of	O
both	O
radioligands	O
.	O

Scatchard	O
plots	O
constructed	O
from	O
the	O
inhibition	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
binding	O
in	O
the	O
absence	O
and	O
presence	O
of	O
different	O
inhibitors	O
showed	O
an	O
unaltered	O
Bmax	O
and	O
a	O
reduced	O
affinity	O
constant	O
,	O
indicative	O
of	O
potential	O
competitive	O
or	O
allosteric	O
mechanisms	O
.	O

The	O
capacity	O
of	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
,	O
with	O
the	O
exception	O
of	O
tacrine	B-CHEMICAL
and	O
ambenonium	B-CHEMICAL
,	O
to	O
displace	O
bound	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
in	O
preference	O
to	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
quinuclinidyl	I-CHEMICAL
benzilate	I-CHEMICAL
predicts	O
that	O
the	O
former	O
compounds	O
could	O
act	O
as	O
potential	O
agonists	O
at	O
muscarinic	B-GENE-N
receptors	I-GENE-N
.	O

Moreover	O
,	O
the	O
rank	O
order	O
for	O
potency	O
in	O
inhibiting	O
acetylcholinesterase	B-GENE-Y
(	O
ambenonium	B-CHEMICAL
>	O
neostigmine	B-CHEMICAL
=	O
physostigmine	B-CHEMICAL
=	O
tacrine	B-CHEMICAL
>	O
pyridostigmine	B-CHEMICAL
=	O
edrophonium	B-CHEMICAL
=	O
galanthamine	B-CHEMICAL
>	O
desoxypeganine	B-CHEMICAL
>	O
parathion	B-CHEMICAL
>	O
gramine	B-CHEMICAL
)	O
indicated	O
that	O
the	O
most	O
effective	O
inhibitors	O
of	O
acetylcholinesterase	B-GENE-Y
also	O
displaced	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
to	O
the	O
greatest	O
extent	O
.	O

The	O
capacity	O
of	O
these	O
inhibitors	O
to	O
displace	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	O
M	O
binding	O
preclude	O
their	O
utilisation	O
for	O
the	O
prevention	O
of	O
acetylcholine	B-CHEMICAL
catabolism	O
in	O
rat	O
brain	O
membranes	O
,	O
the	O
latter	O
being	O
required	O
to	O
estimate	O
the	O
binding	O
of	O
acetylcholine	O
to	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
-	O
labelled	O
muscarinic	B-GENE-N
receptors	I-GENE-N
.	O

However	O
,	O
fasciculin	O
-	O
2	O
,	O
a	O
potent	O
peptide	O
inhibitor	O
of	O
acetylcholinesterase	B-GENE-Y
(	O
IC50	O
24	O
nM	O
)	O
,	O
did	O
prevent	O
catabolism	O
of	O
acetylcholine	B-CHEMICAL
in	O
rat	O
brain	O
membranes	O
with	O
an	O
atypical	O
inhibition	O
isotherm	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
binding	O
,	O
thus	O
permitting	O
an	O
estimation	O
of	O
the	O
"	O
global	O
affinity	O
"	O
of	O
acetylcholine	B-CHEMICAL
(	O
Ki	O
85	O
nM	O
)	O
for	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
oxotremorine	I-CHEMICAL
-	I-CHEMICAL
M	I-CHEMICAL
-	O
labelled	O
muscarinic	B-GENE-N
receptors	I-GENE-N
in	O
rat	O
brain	O
.	O

Functional	O
consequences	O
of	O
the	O
arrhythmogenic	O
G306R	B-GENE-N
KvLQT1	B-GENE-Y
K	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
mutant	O
probed	O
by	O
viral	O
gene	O
transfer	O
in	O
cardiomyocytes	O
.	O

IKs	O
,	O
the	O
slow	O
component	O
of	O
the	O
delayed	O
rectifier	O
potassium	B-CHEMICAL
current	O
,	O
figures	O
prominently	O
in	O
the	O
repolarization	O
of	O
heart	O
cells	O
.	O

The	O
K	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
gene	O
KvLQT1	B-GENE-Y
is	O
mutated	O
in	O
the	O
heritable	O
long	O
QT	O
(	O
LQT	O
)	O
syndrome	O
.	O

Heterologous	O
coexpression	O
of	O
KvLQT1	B-GENE-Y
and	O
the	O
accessory	O
protein	O
minK	B-GENE-Y
yields	O
an	O
IKs	O
-	O
like	O
current	O
.	O

Nevertheless	O
,	O
the	O
links	O
between	O
KvLQT1	B-GENE-Y
and	O
cardiac	O
IKs	O
are	O
largely	O
inferential	O
.	O

Since	O
the	O
LQT	O
syndrome	O
mutant	O
KvLQT1	B-GENE-Y
-	O
G306R	B-GENE-N
suppresses	O
channel	O
activity	O
when	O
coexpressed	O
with	O
wild	O
-	O
type	O
KvLQT1	B-GENE-Y
in	O
a	O
heterologous	O
system	O
,	O
overexpression	O
of	O
this	O
mutant	O
in	O
cardiomyocytes	O
should	O
reduce	O
or	O
eliminate	O
native	O
IKs	O
if	O
KvLQT1	B-GENE-Y
is	O
indeed	O
the	O
major	O
molecular	O
component	O
of	O
this	O
current	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
created	O
the	O
adenovirus	O
AdRMGI	O
-	O
KvLQT1	B-GENE-Y
-	O
G306R	B-GENE-N
,	O
which	O
overexpresses	O
KvLQT1	B-GENE-Y
-	O
G306R	B-GENE-N
channels	O
.	O

In	O
>	O
60	O
%	O
of	O
neonatal	O
mouse	O
myocytes	O
,	O
a	O
sizable	O
IKs	O
could	O
be	O
measured	O
using	O
perforated	O
-	O
patch	O
recordings	O
(	O
8	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
6	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
13	O
)	O
.	O

IKs	O
was	O
increased	O
by	O
forskolin	B-CHEMICAL
and	O
blocked	O
by	O
clofilium	B-CHEMICAL
or	O
indapamide	B-CHEMICAL
but	O
not	O
by	O
E	B-CHEMICAL
-	I-CHEMICAL
4031	I-CHEMICAL
.	O

While	O
cells	O
infected	O
with	O
a	O
reporter	O
virus	O
expressing	O
only	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
displayed	O
IKs	O
similar	O
to	O
that	O
in	O
uninfected	O
cells	O
,	O
AdRMGI	O
-	O
KvLQT1	B-GENE-Y
-	O
G306R	B-GENE-N
-	O
infected	O
cells	O
showed	O
a	O
significantly	O
reduced	O
IKs	O
(	O
2	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
1	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
when	O
measured	O
60	O
-	O
72	O
h	O
after	O
infection	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
adult	O
guinea	O
-	O
pig	O
myocytes	O
(	O
5	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
2	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
9	O
,	O
for	O
control	O
vs	O
.	O
0	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
pA	O
pF	O
-	O
1	O
,	O
n	O
=	O
5	O
,	O
for	O
AdRMGI	O
-	O
KvLQT1	B-GENE-Y
-	O
G306R	B-GENE-N
-	O
infected	O
cells	O
)	O
.	O

We	O
conclude	O
that	O
KvLQT1	B-GENE-Y
is	O
the	O
major	O
molecular	O
component	O
of	O
IKs	O
.	O

Our	O
results	O
further	O
establish	O
a	O
dominant	O
-	O
negative	O
mechanism	O
for	O
the	O
G306R	B-GENE-N
LQT	O
syndrome	O
mutation	O
.	O

Plasma	O
N	B-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
pro	I-GENE-Y
-	I-GENE-Y
brain	I-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
and	O
adrenomedullin	B-GENE-Y
:	O
prognostic	O
utility	O
and	O
prediction	O
of	O
benefit	O
from	O
carvedilol	B-CHEMICAL
in	O
chronic	O
ischemic	O
left	O
ventricular	O
dysfunction	O
.	O

Australia	O
-	O
New	O
Zealand	O
Heart	O
Failure	O
Group	O
.	O

OBJECTIVES	O
:	O
We	O
sought	O
to	O
assess	O
plasma	O
concentrations	O
of	O
the	O
amino	B-GENE-Y
(	I-GENE-Y
N	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
portion	I-GENE-Y
of	I-GENE-Y
pro	I-GENE-Y
-	I-GENE-Y
brain	I-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
(	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
)	O
and	O
adrenomedullin	B-GENE-Y
for	O
prediction	O
of	O
adverse	O
outcomes	O
and	O
responses	O
to	O
treatment	O
in	O
297	O
patients	O
with	O
ischemic	O
left	O
ventricular	O
(	O
LV	O
)	O
dysfunction	O
who	O
were	O
randomly	O
assigned	O
to	O
receive	O
carvedilol	B-CHEMICAL
or	O
placebo	O
.	O

BACKGROUND	O
:	O
Although	O
neurohormonal	O
status	O
has	O
known	O
prognostic	O
significance	O
in	O
heart	O
failure	O
,	O
the	O
predictive	O
power	O
of	O
either	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
or	O
adrenomedullin	B-GENE-Y
in	O
chronic	O
ischemic	O
LV	O
dysfunction	O
has	O
not	O
been	O
previously	O
reported	O
.	O

METHODS	O
:	O
Plasma	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
and	O
adrenomedullin	B-GENE-Y
were	O
measured	O
in	O
297	O
patients	O
with	O
chronic	O
ischemic	O
(	O
LV	O
)	O
dysfunction	O
before	O
randomization	O
to	O
carvedilol	B-CHEMICAL
or	O
placebo	O
,	O
added	O
to	O
established	O
treatment	O
with	O
a	O
converting	O
enzyme	O
inhibitor	O
and	O
loop	O
diuretic	O
(	O
with	O
or	O
without	O
digoxin	O
)	O
.	O

The	O
patients	O
'	O
clinical	O
outcomes	O
,	O
induding	O
mortality	O
and	O
heart	O
failure	O
events	O
,	O
were	O
recorded	O
for	O
18	O
months	O
.	O

RESULTS	O
:	O
Above	O
-	O
median	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
and	O
adrenomedullin	B-GENE-Y
levels	O
conferred	O
increased	O
risks	O
(	O
all	O
p	O
<	O
0	O
.	O
001	O
)	O
of	O
mortality	O
(	O
risk	O
ratios	O
[	O
95	O
%	O
confidence	O
intervals	O
]	O
:	O
4	O
.	O
67	O
[	O
2	O
-	O
10	O
.	O
9	O
]	O
and	O
3	O
.	O
92	O
[	O
1	O
.	O
76	O
-	O
8	O
.	O
7	O
]	O
,	O
respectively	O
)	O
and	O
hospital	O
admission	O
with	O
heart	O
failure	O
(	O
4	O
.	O
7	O
[	O
2	O
.	O
2	O
-	O
10	O
.	O
3	O
]	O
and	O
2	O
.	O
4	O
[	O
1	O
.	O
3	O
-	O
4	O
.	O
5	O
]	O
,	O
respectively	O
)	O
.	O

Both	O
of	O
these	O
predicted	O
death	O
or	O
heart	O
failure	O
independent	O
of	O
age	O
,	O
New	O
York	O
Heart	O
Association	O
functional	O
class	O
,	O
LV	O
ejection	O
fraction	O
,	O
previous	O
myocardial	O
infarction	O
or	O
previous	O
admission	O
with	O
heart	O
failure	O
.	O

Carvedilol	B-CHEMICAL
reduced	O
the	O
risk	O
of	O
death	O
or	O
heart	O
failure	O
in	O
patients	O
with	O
above	O
-	O
median	O
levels	O
of	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
or	O
adrenomedullin	B-GENE-Y
,	O
or	O
both	O
,	O
to	O
rates	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
patients	O
with	O
levels	O
below	O
the	O
median	O
value	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
established	O
ischemic	O
LV	O
dysfunction	O
,	O
plasma	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
and	O
adrenomedullin	B-GENE-Y
are	O
independent	O
predictors	O
of	O
mortality	O
and	O
heart	O
failure	O
.	O

Carvedilol	B-CHEMICAL
reduced	O
mortality	O
and	O
heart	O
failure	O
in	O
patients	O
with	O
higher	O
pre	O
-	O
treatment	O
plasma	O
N	B-GENE-Y
-	I-GENE-Y
BNP	I-GENE-Y
and	O
adrenomedullin	B-GENE-Y
.	O

Indomethacin	B-CHEMICAL
activates	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
and	O
antagonizes	O
the	O
effect	O
of	O
the	O
specific	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
inhibitor	O
acetazolamide	B-CHEMICAL
,	O
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

OBJECTIVES	O
:	O
In	O
this	O
paper	O
we	O
investigated	O
the	O
effect	O
of	O
indomethacin	B-CHEMICAL
,	O
acetazolamide	B-CHEMICAL
and	O
their	O
combination	O
in	O
vitro	O
and	O
in	O
vivo	O
on	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
(	O
CA	B-GENE-N
)	O
isozymes	O
.	O

METHOD	O
:	O
In	O
vitro	O
experiments	O
followed	O
the	O
effect	O
of	O
the	O
two	O
substances	O
at	O
concentrations	O
between	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
4	O
)	O
M	O
on	O
purified	O
human	B-GENE-N
red	I-GENE-N
cell	I-GENE-N
CA	I-GENE-N
I	I-GENE-N
and	I-GENE-N
II	I-GENE-N
as	O
well	O
as	O
on	O
human	B-GENE-Y
gastric	I-GENE-Y
mucosa	I-GENE-Y
CA	I-GENE-Y
IV	I-GENE-Y
using	O
dose	O
-	O
response	O
relationships	O
.	O

Kinetic	O
studies	O
were	O
also	O
performed	O
.	O

The	O
effects	O
of	O
single	O
and	O
combined	O
administration	O
of	O
indomethacin	B-CHEMICAL
and	O
acetazolamide	B-CHEMICAL
on	O
red	O
cell	O
CA	B-GENE-N
and	O
on	O
gastric	O
acid	O
secretion	O
were	O
studied	O
in	O
vivo	O
.	O

RESULTS	O
:	O
Indomethacin	B-CHEMICAL
,	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O
induces	O
an	O
increase	O
in	O
erythorcyte	O
CA	B-GENE-Y
I	I-GENE-Y
and	O
CA	B-GENE-Y
II	I-GENE-Y
activity	O
.	O

Acetazolamide	B-CHEMICAL
,	O
a	O
specific	O
inhibitor	O
of	O
CA	B-GENE-N
,	O
reduces	O
the	O
activity	O
of	O
CA	B-GENE-Y
I	I-GENE-Y
and	O
CA	B-GENE-Y
II	I-GENE-Y
from	O
red	O
cells	O
.	O

Indomethacin	B-CHEMICAL
completely	O
antagonizes	O
CA	B-GENE-N
activity	O
,	O
i	O
.	O
e	O
.	O
abolishes	O
the	O
inhibitory	O
effect	O
of	O
acetazolamide	B-CHEMICAL
on	O
CA	B-GENE-N
.	O

In	O
humans	O
,	O
an	O
increase	O
or	O
decrease	O
in	O
erythrocyte	O
CA	B-GENE-Y
II	I-GENE-Y
activity	O
is	O
correlated	O
with	O
an	O
increase	O
or	O
decrease	O
in	O
gastric	O
acid	O
secretion	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
show	O
that	O
indomethacin	B-CHEMICAL
,	O
a	O
known	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
inhibitor	O
,	O
is	O
also	O
an	O
activator	O
of	O
CA	B-GENE-N
.	O

Our	O
data	O
also	O
prove	O
that	O
indomethacin	B-CHEMICAL
is	O
not	O
only	O
an	O
activator	O
of	O
CA	B-GENE-N
but	O
also	O
antagonizes	O
the	O
effect	O
of	O
acetazolamide	B-CHEMICAL
,	O
a	O
specific	O
inhibitor	O
of	O
this	O
enzyme	O
.	O

In	O
view	O
of	O
the	O
role	O
of	O
CA	B-GENE-N
in	O
acid	O
-	O
base	O
balance	O
as	O
well	O
as	O
the	O
fact	O
that	O
an	O
increase	O
or	O
decrease	O
in	O
its	O
activity	O
is	O
accompanied	O
by	O
an	O
increase	O
or	O
decrease	O
in	O
intra	O
-	O
and	O
extracellular	O
pH	O
,	O
our	O
results	O
suggest	O
that	O
:	O
firstly	O
,	O
CA	B-GENE-N
activation	O
induced	O
by	O
indomethacin	B-CHEMICAL
might	O
cause	O
changes	O
in	O
COX	B-GENE-N
activity	O
;	O
secondly	O
,	O
PGs	O
are	O
synthetized	O
as	O
a	O
consequence	O
of	O
the	O
changes	O
in	O
COX	B-GENE-N
activity	O
,	O
a	O
hypothesis	O
that	O
requires	O
further	O
study	O
.	O

The	O
antipsychotic	O
drugs	O
sertindole	B-CHEMICAL
and	O
pimozide	B-CHEMICAL
block	O
erg3	B-GENE-Y
,	O
a	O
human	B-GENE-N
brain	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
.	O

The	O
antipsychotic	O
drugs	O
sertindole	B-CHEMICAL
and	O
pimozide	B-CHEMICAL
are	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
on	O
the	O
electrocardiogram	O
via	O
a	O
high	O
affinity	O
block	O
of	O
the	O
cardiac	B-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
known	O
as	O
HERG	B-GENE-Y
(	O
human	B-GENE-Y
ether	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
gene	I-GENE-Y
;	O
erg1	B-GENE-Y
)	O
.	O

We	O
wished	O
to	O
test	O
whether	O
these	O
drugs	O
also	O
displayed	O
high	O
affinity	O
for	O
the	O
related	O
neuronal	B-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
erg3	B-GENE-Y
.	O

The	O
cDNA	O
encoding	O
erg3	B-GENE-Y
channel	O
was	O
cloned	O
from	O
a	O
human	O
brain	O
library	O
.	O

Northern	O
analysis	O
confirmed	O
that	O
the	O
channel	O
was	O
localized	O
to	O
brain	O
relative	O
to	O
other	O
tissues	O
including	O
heart	O
,	O
liver	O
and	O
lung	O
.	O

Within	O
the	O
brain	O
,	O
erg3	B-GENE-Y
was	O
expressed	O
in	O
higher	O
amounts	O
in	O
the	O
frontal	O
lobe	O
and	O
cerebellum	O
relative	O
to	O
the	O
temporal	O
,	O
parietal	O
and	O
occipital	O
lobes	O
.	O

Transient	O
expression	O
of	O
erg3	B-GENE-Y
in	O
Chinese	O
hamster	O
ovary	O
cells	O
produced	O
outwardly	O
directed	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
currents	O
that	O
activated	O
at	O
approximately	O
-	O
50	O
mV	O
and	O
produced	O
a	O
large	O
transient	O
component	O
at	O
positive	O
membrane	O
potentials	O
.	O

Inward	O
tail	O
currents	O
measured	O
at	O
-	O
100	O
mV	O
were	O
blocked	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
by	O
sertindole	B-CHEMICAL
resulting	O
in	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
43	O
nM	O
.	O

Significant	O
inhibition	O
was	O
observed	O
at	O
concentrations	O
as	O
low	O
as	O
3	O
nM	O
.	O

Block	O
of	O
erg3	B-GENE-Y
by	O
sertindole	B-CHEMICAL
also	O
displayed	O
a	O
positive	O
voltage	O
-	O
dependence	O
.	O

Pimozide	B-CHEMICAL
blocked	O
erg3	B-GENE-Y
channel	O
currents	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
103	O
nM	O
and	O
significant	O
inhibition	O
was	O
noted	O
at	O
concentrations	O
of	O
10	O
nM	O
and	O
higher	O
.	O

We	O
conclude	O
that	O
erg3	B-GENE-Y
can	O
be	O
blocked	O
by	O
certain	O
antipsychotic	O
drugs	O
like	O
sertindole	B-CHEMICAL
and	O
pimozide	B-CHEMICAL
.	O

Inhibition	O
of	O
erg3	B-GENE-Y
or	O
related	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
in	O
the	O
brain	O
may	O
contribute	O
to	O
the	O
efficacy	O
/	O
side	O
effect	O
profiles	O
of	O
some	O
antipsychotic	O
drugs	O
.	O

Complexities	O
of	O
androgen	B-CHEMICAL
action	O
.	O

Androgens	B-CHEMICAL
mediate	O
a	O
wide	O
range	O
of	O
processes	O
during	O
embryogenesis	O
and	O
in	O
the	O
adult	O
.	O

In	O
mammals	O
,	O
the	O
principal	O
androgens	B-CHEMICAL
are	O
testosterone	B-CHEMICAL
and	O
its	O
5alpha	O
-	O
reduced	O
metabolite	O
,	O
5alpha	B-CHEMICAL
-	I-CHEMICAL
dihydrotestosterone	I-CHEMICAL
(	O
DHT	B-CHEMICAL
)	O
.	O

Although	O
these	O
androgenic	O
hormones	O
are	O
diverse	O
in	O
character	O
,	O
it	O
is	O
believed	O
that	O
their	O
effects	O
are	O
mediated	O
via	O
the	O
protein	O
products	O
of	O
a	O
single	O
androgen	B-GENE-Y
receptor	I-GENE-Y
gene	O
encoded	O
on	O
the	O
X	O
-	O
chromosome	O
.	O

A	O
great	O
deal	O
of	O
information	O
has	O
now	O
accumulated	O
pertaining	O
to	O
the	O
mechanisms	O
by	O
which	O
nuclear	B-GENE-N
receptors	I-GENE-N
,	O
such	O
as	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
,	O
modulate	O
the	O
activity	O
of	O
responsive	O
genes	O
.	O

The	O
studies	O
have	O
demonstrated	O
the	O
participation	O
of	O
a	O
number	O
of	O
ancillary	O
proteins	O
in	O
modulating	O
activation	O
or	O
repression	O
by	O
nuclear	B-GENE-N
receptors	I-GENE-N
.	O

In	O
addition	O
to	O
studies	O
focused	O
on	O
the	O
mechanisms	O
of	O
nuclear	B-GENE-N
receptor	I-GENE-N
function	O
,	O
additional	O
work	O
has	O
illuminated	O
the	O
mechanism	O
by	O
which	O
androgens	B-CHEMICAL
are	O
metabolized	O
in	O
selected	O
tissues	O
.	O

This	O
information	O
provides	O
a	O
perspective	O
on	O
the	O
number	O
of	O
levels	O
of	O
complexity	O
by	O
which	O
differential	O
gene	O
regulation	O
by	O
androgens	B-CHEMICAL
may	O
occur	O
in	O
different	O
tissues	O
and	O
in	O
different	O
cell	O
types	O
.	O

Binding	O
site	O
of	O
amiloride	B-CHEMICAL
to	O
urokinase	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
depends	O
on	O
species	O
.	O

A	O
novel	O
drug	O
candidate	O
is	O
checked	O
on	O
its	O
potency	O
on	O
animal	O
models	O
before	O
it	O
can	O
advance	O
to	O
human	O
phase	O
of	O
the	O
research	O
.	O

Usually	O
negative	O
results	O
on	O
animal	O
phase	O
disqualify	O
it	O
.	O

Targeting	O
specific	O
enzymes	O
by	O
small	O
chemicals	O
raises	O
the	O
question	O
about	O
the	O
appropriateness	O
of	O
this	O
approach	O
.	O

As	O
an	O
example	O
,	O
the	O
urokinase	B-GENE-Y
(	O
uPA	B-GENE-Y
)	O
is	O
recognized	O
as	O
an	O
important	O
enzyme	O
responsible	O
for	O
cancer	O
metastasis	O
and	O
angiogenesis	O
.	O

It	O
is	O
therefore	O
important	O
to	O
ask	O
the	O
question	O
if	O
a	O
small	O
chemical	O
will	O
inhibit	O
uPA	B-GENE-N
of	O
different	O
species	O
with	O
the	O
same	O
or	O
different	O
potency	O
.	O

Using	O
DNA	O
sequence	O
and	O
known	O
structure	O
of	O
uPA	B-GENE-N
we	O
have	O
modeled	O
3D	O
structures	O
of	O
uPAs	B-GENE-N
for	O
several	O
different	O
species	O
.	O

By	O
theoretical	O
calculations	O
we	O
have	O
determined	O
most	O
probable	O
structure	O
of	O
amiloride	B-CHEMICAL
/	O
uPAs	B-GENE-N
complexes	O
.	O

Catalytic	O
triad	O
(	O
B57	O
,	O
B102	O
,	O
B195	O
)	O
and	O
specificity	O
pocket	O
(	O
B187	O
-	O
B197	O
,	O
B212	O
-	O
B229	O
)	O
are	O
highly	O
conserved	O
in	O
all	O
cases	O
,	O
and	O
are	O
the	O
regions	O
responsible	O
for	O
proteolytic	O
activity	O
and	O
recognition	O
of	O
the	O
substrate	O
.	O

Significant	O
differences	O
were	O
observed	O
in	O
a	O
different	O
region	O
(	O
loop	O
B93	O
-	O
B101	O
)	O
,	O
that	O
we	O
identified	O
as	O
binding	O
site	O
of	O
amiloride	B-CHEMICAL
to	O
the	O
tissue	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
tPA	B-GENE-Y
)	O
.	O

Although	O
tPA	B-GENE-Y
shares	O
the	O
same	O
function	O
of	O
activating	O
plasminogen	O
and	O
it	O
is	O
structurally	O
similar	O
to	O
uPA	B-GENE-Y
.	O

Amiloride	B-CHEMICAL
is	O
a	O
specific	O
inhibitor	O
of	O
uPA	B-GENE-N
but	O
does	O
not	O
inhibit	O
tPA	B-GENE-Y
.	O

Our	O
study	O
shows	O
that	O
predicted	O
position	O
of	O
amiloride	B-CHEMICAL
depends	O
on	O
species	O
and	O
in	O
some	O
cases	O
was	O
located	O
,	O
as	O
expected	O
,	O
in	O
the	O
specificity	O
pocket	O
,	O
but	O
in	O
the	O
other	O
cases	O
close	O
to	O
the	O
loop	O
B93	O
-	O
B101	O
.	O

This	O
location	O
could	O
weaken	O
affinity	O
of	O
binding	O
or	O
prevent	O
inhibition	O
of	O
uPA	B-GENE-Y
.	O

Therefore	O
,	O
drug	O
screening	O
and	O
elimination	O
process	O
based	O
solely	O
on	O
animal	O
study	O
,	O
without	O
careful	O
structural	O
analysis	O
,	O
could	O
lead	O
to	O
the	O
elimination	O
of	O
potential	O
drugs	O
for	O
humans	O
.	O

The	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
ZD1839	B-CHEMICAL
(	O
"	O
Iressa	B-CHEMICAL
"	O
)	O
inhibits	O
HER2	B-GENE-Y
-	O
driven	O
signaling	O
and	O
suppresses	O
the	O
growth	O
of	O
HER2	B-GENE-Y
-	O
overexpressing	O
tumor	O
cells	O
.	O

The	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
is	O
commonly	O
overexpressed	O
in	O
many	O
human	O
tumors	O
and	O
provides	O
a	O
new	O
target	O
for	O
anticancer	O
drug	O
development	O
.	O

ZD1839	B-CHEMICAL
(	O
"	O
Iressa	B-CHEMICAL
"	O
)	O
,	O
a	O
quinazoline	B-CHEMICAL
tyrosine	I-CHEMICAL
kinase	O
inhibitor	O
selective	O
for	O
the	O
EGFR	B-GENE-Y
,	O
has	O
shown	O
good	O
activity	O
in	O
preclinical	O
studies	O
and	O
in	O
the	O
early	O
phase	O
of	O
clinical	O
trials	O
.	O

However	O
,	O
because	O
it	O
remains	O
unclear	O
which	O
tumor	O
types	O
are	O
the	O
best	O
targets	O
for	O
treatment	O
with	O
this	O
agent	O
,	O
the	O
molecular	O
characteristics	O
that	O
correlate	O
with	O
tumor	O
sensitivity	O
to	O
ZD1839	B-CHEMICAL
have	O
been	O
studied	O
.	O

In	O
a	O
panel	O
of	O
human	O
breast	O
cancer	O
and	O
other	O
epithelial	O
tumor	O
cell	O
lines	O
,	O
HER2	B-GENE-Y
-	O
overexpressing	O
tumors	O
were	O
particularly	O
sensitive	O
to	O
ZD1839	B-CHEMICAL
.	O

Growth	O
inhibition	O
of	O
these	O
tumor	O
cell	O
lines	O
was	O
associated	O
with	O
the	O
dephosphorylation	O
of	O
EGFR	B-GENE-Y
,	O
HER2	B-GENE-Y
,	O
and	O
HER3	B-GENE-Y
,	O
accompanied	O
by	O
the	O
loss	O
of	O
association	O
of	O
HER3	O
with	O
phosphatidylinositol	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
,	O
and	O
down	O
-	O
regulation	O
of	O
Akt	B-GENE-N
activity	O
.	O

These	O
studies	O
suggest	O
that	O
HER2	B-GENE-Y
-	O
overexpressing	O
tumors	O
are	O
particularly	O
susceptible	O
to	O
the	O
inhibition	O
of	O
HER	B-GENE-N
family	O
tyrosine	B-GENE-N
kinase	I-GENE-N
signaling	O
and	O
suggest	O
novel	O
strategies	O
to	O
treat	O
these	O
particularly	O
aggressive	O
tumors	O
.	O

Influence	O
of	O
the	O
dopamine	B-GENE-N
D2	I-GENE-N
receptor	I-GENE-N
(	I-GENE-N
DRD2	I-GENE-N
)	I-GENE-N
exon	I-GENE-N
8	I-GENE-N
genotype	O
on	O
efficacy	O
of	O
tiapride	B-CHEMICAL
and	O
clinical	O
outcome	O
of	O
alcohol	B-CHEMICAL
withdrawal	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
allelic	O
variants	O
of	O
the	O
human	B-GENE-N
dopamine	I-GENE-N
D2	I-GENE-N
receptor	I-GENE-N
E8	I-GENE-N
genotype	O
are	O
associated	O
with	O
(	O
i	O
)	O
dopamine	B-GENE-Y
D2	I-GENE-Y
antagonist	O
tiapride	O
dose	O
in	O
treatment	O
of	O
alcohol	B-CHEMICAL
withdrawal	O
(	O
n	O
=	O
50	O
)	O
and	O
(	O
ii	O
)	O
with	O
anxiety	O
and	O
depression	O
in	O
patients	O
during	O
alcoholism	O
detoxification	O
therapy	O
(	O
admission	O
n	O
=	O
87	O
;	O
discharge	O
n	O
=	O
50	O
)	O
.	O

DRD2	B-GENE-N
E8	I-GENE-N
A	O
/	O
A	O
genotype	O
was	O
associated	O
with	O
increased	O
dose	O
of	O
tiapride	B-CHEMICAL
during	O
a	O
9	O
-	O
day	O
detoxification	O
therapy	O
and	O
with	O
increased	O
anxiety	O
and	O
depression	O
scores	O
on	O
admission	O
and	O
2	O
weeks	O
later	O
.	O

The	O
findings	O
suggest	O
a	O
pharmacogenetic	O
influence	O
of	O
DRD2	B-GENE-N
E8	I-GENE-N
genotype	O
on	O
tiapride	O
efficacy	O
in	O
alcohol	O
withdrawal	O
.	O

In	O
an	O
earlier	O
report	O
,	O
DRD2	B-GENE-Y
E8	O
A	O
/	O
A	O
genotype	O
was	O
associated	O
with	O
reduced	O
responsiveness	O
to	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
agonist	O
apomorphine	B-CHEMICAL
;	O
however	O
,	O
it	O
is	O
not	O
clear	O
whether	O
both	O
findings	O
share	O
the	O
same	O
biological	O
basis	O
.	O

Earlier	O
findings	O
concerning	O
association	O
of	O
DRD2	B-GENE-N
E8	I-GENE-N
A	O
/	O
A	O
with	O
increased	O
anxiety	O
and	O
depression	O
are	O
replicated	O
for	O
the	O
first	O
time	O
.	O

The	O
effects	O
of	O
mitiglinide	B-CHEMICAL
(	O
KAD	B-CHEMICAL
-	I-CHEMICAL
1229	I-CHEMICAL
)	O
,	O
a	O
new	O
anti	O
-	O
diabetic	O
drug	O
,	O
on	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
K	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
and	O
insulin	B-GENE-Y
secretion	O
:	O
comparison	O
with	O
the	O
sulfonylureas	B-CHEMICAL
and	O
nateglinide	B-CHEMICAL
.	O

Mitiglinide	B-CHEMICAL
(	O
KAD	B-CHEMICAL
-	I-CHEMICAL
1229	I-CHEMICAL
)	O
,	O
a	O
new	O
anti	O
-	O
diabetic	O
drug	O
,	O
is	O
thought	O
to	O
stimulate	O
insulin	B-GENE-Y
secretion	O
by	O
closing	O
the	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
K	I-GENE-N
+	I-GENE-N
(	I-GENE-N
K	I-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
in	O
pancreatic	O
beta	O
-	O
cells	O
.	O

However	O
,	O
its	O
selectivity	O
for	O
the	O
various	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
mitiglinide	B-CHEMICAL
on	O
various	O
cloned	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
(	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR1	B-GENE-Y
,	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR2A	B-GENE-Y
,	O
and	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR2B	B-GENE-Y
)	O
reconstituted	O
in	O
COS	O
-	O
1	O
cells	O
,	O
and	O
compared	O
them	O
to	O
another	O
meglitinide	B-CHEMICAL
-	O
related	O
compound	O
,	O
nateglinide	B-CHEMICAL
.	O

Patch	O
-	O
clamp	O
analysis	O
using	O
inside	O
-	O
out	O
recording	O
configuration	O
showed	O
that	O
mitiglinide	B-CHEMICAL
inhibits	O
the	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR1	B-GENE-Y
channel	O
currents	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
value	O
,	O
100	O
nM	O
)	O
but	O
does	O
not	O
significantly	O
inhibit	O
either	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR2A	B-GENE-Y
or	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR2B	B-GENE-Y
channel	O
currents	O
even	O
at	O
high	O
doses	O
(	O
more	O
than	O
10	O
microM	O
)	O
.	O

Nateglinide	B-CHEMICAL
inhibits	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR1	B-GENE-Y
and	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR2B	B-GENE-Y
channels	O
at	O
100	O
nM	O
,	O
and	O
inhibits	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR2A	B-GENE-Y
channels	O
at	O
high	O
concentrations	O
(	O
1	O
microM	O
)	O
.	O

Binding	O
experiments	O
on	O
mitiglinide	B-CHEMICAL
,	O
nateglinide	B-CHEMICAL
,	O
and	O
repaglinide	B-CHEMICAL
to	O
SUR1	B-GENE-Y
expressed	O
in	O
COS	O
-	O
1	O
cells	O
revealed	O
that	O
they	O
inhibit	O
the	O
binding	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
glibenclamide	I-CHEMICAL
to	O
SUR1	B-GENE-Y
(	O
IC50	O
values	O
:	O
mitiglinide	B-CHEMICAL
,	O
280	O
nM	O
;	O
nateglinide	B-CHEMICAL
,	O
8	O
microM	O
;	O
repaglinide	B-CHEMICAL
,	O
1	O
.	O
6	O
microM	O
)	O
,	O
suggesting	O
that	O
they	O
all	O
share	O
a	O
glibenclamide	B-CHEMICAL
binding	O
site	O
.	O

The	O
insulin	B-GENE-N
responses	O
to	O
glucose	B-CHEMICAL
,	O
mitiglinide	B-CHEMICAL
,	O
tolbutamide	B-CHEMICAL
,	O
and	O
glibenclamide	B-CHEMICAL
in	O
MIN6	O
cells	O
after	O
chronic	O
mitiglinide	B-CHEMICAL
,	O
nateglinide	B-CHEMICAL
,	O
or	O
repaglinide	B-CHEMICAL
treatment	O
were	O
comparable	O
to	O
those	O
after	O
chronic	O
tolbutamide	B-CHEMICAL
and	O
glibenclamide	B-CHEMICAL
treatment	O
.	O

These	O
results	O
indicate	O
that	O
,	O
similar	O
to	O
the	O
sulfonylureas	B-CHEMICAL
,	O
mitiglinide	B-CHEMICAL
is	O
highly	O
specific	O
to	O
the	O
Kir6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR1	B-GENE-Y
complex	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
pancreatic	O
beta	O
-	O
cell	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
,	O
and	O
suggest	O
that	O
mitiglinide	B-CHEMICAL
may	O
be	O
a	O
clinically	O
useful	O
anti	O
-	O
diabetic	O
drug	O
.	O

Effect	O
of	O
fenoterol	B-CHEMICAL
-	O
induced	O
constitutive	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
activity	O
on	O
contractile	O
receptor	O
function	O
in	O
airway	O
smooth	O
muscle	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
fenoterol	B-CHEMICAL
-	O
induced	O
constitutive	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
activity	O
on	O
muscarinic	B-GENE-N
receptor	I-GENE-N
agonist	O
-	O
and	O
histamine	B-CHEMICAL
-	O
induced	O
bovine	O
tracheal	O
smooth	O
muscle	O
contractions	O
.	O

Bovine	O
tracheal	O
smooth	O
muscle	O
strips	O
were	O
incubated	O
with	O
10	O
microM	O
fenoterol	B-CHEMICAL
or	O
vehicle	O
for	O
various	O
periods	O
of	O
time	O
(	O
5	O
,	O
30	O
min	O
,	O
18	O
h	O
)	O
at	O
37	O
degrees	O
C	O
.	O

After	O
extensive	O
washout	O
(	O
3	O
h	O
,	O
37	O
degrees	O
C	O
)	O
,	O
isometric	O
contractions	O
were	O
measured	O
to	O
the	O
full	O
muscarinic	B-GENE-N
receptor	I-GENE-N
agonist	O
methacholine	B-CHEMICAL
,	O
the	O
partial	O
muscarinic	B-GENE-N
receptor	I-GENE-N
agonist	O
4	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
m	I-CHEMICAL
-	I-CHEMICAL
chlorophenyl	I-CHEMICAL
-	I-CHEMICAL
carbamoyloxy	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
butynyltrimethylammonium	I-CHEMICAL
(	O
McN	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
343	I-CHEMICAL
)	O
and	O
histamine	B-CHEMICAL
.	O

Fenoterol	B-CHEMICAL
treatment	O
significantly	O
reduced	O
the	O
sensitivity	O
(	O
pEC	O
(	O
50	O
)	O
)	O
to	O
methacholine	B-CHEMICAL
in	O
a	O
time	O
-	O
dependent	O
manner	O
,	O
without	O
affecting	O
maximal	O
contraction	O
(	O
E	O
(	O
max	O
)	O
)	O
.	O

Fenoterol	B-CHEMICAL
treatment	O
similarly	O
reduced	O
the	O
pEC	O
(	O
50	O
)	O
of	O
McN	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
343	I-CHEMICAL
and	O
histamine	B-CHEMICAL
;	O
however	O
,	O
E	O
(	O
max	O
)	O
values	O
were	O
also	O
reduced	O
,	O
to	O
approximately	O
70	O
%	O
of	O
control	O
after	O
18	O
-	O
h	O
treatment	O
.	O

The	O
inverse	O
agonist	O
timolol	B-CHEMICAL
,	O
having	O
no	O
effect	O
on	O
control	O
preparations	O
,	O
consistently	O
restored	O
the	O
reduced	O
pEC	O
(	O
50	O
)	O
and	O
E	O
(	O
max	O
)	O
values	O
of	O
the	O
contractile	O
agonists	O
.	O

Remarkably	O
,	O
in	O
the	O
presence	O
of	O
timolol	O
the	O
pEC	O
(	O
50	O
)	O
values	O
of	O
McN	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
343	I-CHEMICAL
and	O
histamine	B-CHEMICAL
in	O
fenoterol	B-CHEMICAL
-	O
treated	O
airways	O
were	O
significantly	O
enhanced	O
compared	O
to	O
controls	O
.	O

In	O
conclusion	O
,	O
fenoterol	B-CHEMICAL
-	O
induced	O
constitutive	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
activity	O
reduces	O
muscarinic	B-GENE-N
receptor	I-GENE-N
agonist	O
-	O
and	O
histamine	B-CHEMICAL
-	O
induced	O
contractions	O
of	O
bovine	O
tracheal	O
smooth	O
muscle	O
,	O
which	O
can	O
be	O
reversed	O
by	O
the	O
inverse	O
agonist	O
timolol	B-CHEMICAL
.	O

Moreover	O
,	O
after	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
treatment	O
,	O
inverse	O
agonism	O
by	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
may	O
cause	O
enhanced	O
airway	O
reactivity	O
to	O
contractile	O
mediators	O
.	O

Comparison	O
of	O
vaginal	B-GENE-N
aminopeptidase	I-GENE-N
enzymatic	O
activities	O
in	O
various	O
animals	O
and	O
in	O
humans	O
.	O

The	O
specific	O
enzymatic	O
activity	O
of	O
four	O
different	O
aminopeptidases	B-GENE-N
(	O
aminopeptidase	B-GENE-N
N	I-GENE-N
,	O
leucine	B-GENE-N
aminopeptidase	I-GENE-N
,	O
aminopeptidase	B-GENE-N
A	I-GENE-N
and	O
aminopeptidase	B-GENE-N
B	I-GENE-N
)	O
in	O
vaginal	O
homogenates	O
from	O
rabbit	O
,	O
rat	O
,	O
guinea	O
-	O
pig	O
,	O
sheep	O
and	O
humans	O
was	O
compared	O
.	O

The	O
purpose	O
of	O
the	O
study	O
was	O
to	O
find	O
an	O
appropriate	O
animal	O
model	O
that	O
can	O
be	O
used	O
in	O
degradation	O
studies	O
of	O
protein	O
and	O
peptide	O
drugs	O
.	O

Different	O
substrates	O
were	O
used	O
as	O
the	O
relative	O
specific	O
substrates	O
for	O
the	O
determination	O
of	O
aminopeptidase	B-GENE-N
enzymatic	O
activity	O
:	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
naphthylamide	I-CHEMICAL
of	O
L	B-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
for	O
aminopeptidase	B-GENE-N
N	I-GENE-N
,	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
naphthylamide	I-CHEMICAL
of	O
L	B-CHEMICAL
-	I-CHEMICAL
leucine	I-CHEMICAL
for	O
leucine	B-GENE-N
aminopeptidase	I-GENE-N
,	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
naphthylamide	I-CHEMICAL
of	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamic	I-CHEMICAL
acid	I-CHEMICAL
for	O
aminopeptidase	B-GENE-N
A	I-GENE-N
and	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
naphthylamide	I-CHEMICAL
of	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
for	O
aminopeptidase	B-GENE-N
B	I-GENE-N
.	O

The	O
vaginal	B-GENE-N
aminopeptidase	I-GENE-N
enzymatic	O
activity	O
of	O
different	O
species	O
was	O
determined	O
spectrofluorometrically	O
.	O

The	O
inhibition	O
of	O
aminopeptidase	B-GENE-N
activity	O
in	O
the	O
presence	O
of	O
bestatin	B-CHEMICAL
and	O
puromycin	B-CHEMICAL
inhibitors	O
was	O
also	O
investigated	O
.	O

The	O
results	O
showed	O
the	O
presence	O
of	O
aminopeptidase	B-GENE-N
enzymatic	O
activity	O
in	O
all	O
vaginal	O
homogenates	O
in	O
the	O
order	O
:	O
sheep	O
>	O
guinea	O
-	O
pig	O
>	O
rabbit	O
>	O
or	O
=	O
human	O
>	O
or	O
=	O
rat	O
.	O

Based	O
on	O
the	O
results	O
of	O
the	O
hydrolysis	O
and	O
inhibition	O
of	O
the	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
naphthylamide	I-CHEMICAL
substrates	O
,	O
it	O
was	O
difficult	O
to	O
have	O
an	O
exact	O
decision	O
on	O
the	O
aminopeptidase	B-GENE-N
type	O
in	O
the	O
vaginal	O
homogenates	O
from	O
the	O
species	O
studied	O
.	O

It	O
was	O
found	O
that	O
the	O
aminopeptidase	B-GENE-N
activity	O
in	O
rat	O
,	O
rabbit	O
and	O
humans	O
was	O
not	O
statistically	O
different	O
.	O

Therefore	O
,	O
we	O
suggest	O
that	O
rats	O
and	O
rabbits	O
could	O
be	O
used	O
as	O
model	O
animals	O
for	O
vaginal	O
enzymatic	O
activity	O
studies	O
and	O
for	O
determination	O
of	O
the	O
degradation	O
of	O
protein	O
and	O
peptide	O
drugs	O
in	O
the	O
vagina	O
.	O

Aromatase	B-GENE-Y
inhibitors	O
for	O
male	O
infertility	O
.	O

PURPOSE	O
:	O
Testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratio	O
levels	O
in	O
infertile	O
men	O
improve	O
during	O
treatment	O
with	O
the	O
aromatase	B-GENE-Y
inhibitor	O
,	O
testolactone	B-CHEMICAL
,	O
and	O
resulting	O
changes	O
in	O
semen	O
parameters	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
anastrozole	B-CHEMICAL
,	O
a	O
more	O
selective	O
aromatase	B-GENE-Y
inhibitor	O
,	O
on	O
the	O
hormonal	O
and	O
semen	O
profiles	O
of	O
infertile	O
men	O
with	O
abnormal	O
baseline	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
total	O
of	O
140	O
subfertile	O
men	O
with	O
abnormal	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
were	O
treated	O
with	O
100	O
to	O
200	O
mg	O
.	O
testolactone	B-CHEMICAL
daily	O
or	O
1	O
mg	O
.	O
anastrozole	B-CHEMICAL
daily	O
.	O

Changes	O
in	O
testosterone	B-CHEMICAL
,	O
estradiol	B-CHEMICAL
,	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
and	O
semen	O
parameters	O
were	O
evaluated	O
during	O
therapy	O
.	O

The	O
effect	O
of	O
obesity	O
,	O
diagnosis	O
of	O
the	O
Klinefelter	O
syndrome	O
,	O
and	O
presence	O
of	O
varicocele	O
and	O
/	O
or	O
history	O
of	O
varicocele	O
repair	O
on	O
treatment	O
results	O
was	O
studied	O
.	O

RESULTS	O
:	O
Men	O
treated	O
with	O
testolactone	B-CHEMICAL
had	O
an	O
increase	O
in	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
during	O
therapy	O
(	O
mean	O
plus	O
or	O
minus	O
standard	O
error	O
of	O
the	O
mean	O
5	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
2	O
versus	O
12	O
.	O
4	O
+	O
/	O
-	O
1	O
.	O
1	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
change	O
was	O
confirmed	O
in	O
subgroups	O
of	O
men	O
with	O
the	O
Klinefelter	O
syndrome	O
,	O
a	O
history	O
of	O
varicocele	O
repair	O
and	O
those	O
with	O
varicocele	O
.	O

A	O
total	O
of	O
12	O
oligospermic	O
men	O
had	O
semen	O
analysis	O
before	O
and	O
during	O
testolactone	B-CHEMICAL
treatment	O
with	O
an	O
increase	O
in	O
sperm	O
concentration	O
(	O
5	O
.	O
5	O
versus	O
11	O
.	O
2	O
million	O
sperm	O
per	O
ml	O
.	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
motility	O
(	O
14	O
.	O
7	O
%	O
versus	O
21	O
.	O
0	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
morphology	O
(	O
6	O
.	O
5	O
%	O
versus	O
12	O
.	O
8	O
%	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
and	O
motility	O
index	O
(	O
606	O
.	O
3	O
versus	O
1685	O
.	O
2	O
million	O
motile	O
sperm	O
per	O
ejaculate	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
appreciated	O
.	O

During	O
anastrozole	B-CHEMICAL
treatment	O
,	O
similar	O
changes	O
in	O
the	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
were	O
seen	O
(	O
7	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
versus	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
0	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
improvement	O
of	O
hormonal	O
parameters	O
was	O
noted	O
for	O
all	O
subgroups	O
except	O
those	O
patients	O
with	O
the	O
Klinefelter	O
syndrome	O
.	O

A	O
total	O
of	O
25	O
oligospermic	O
men	O
with	O
semen	O
analysis	O
before	O
and	O
during	O
anastrozole	B-CHEMICAL
treatment	O
had	O
an	O
increase	O
in	O
semen	O
volume	O
(	O
2	O
.	O
9	O
versus	O
3	O
.	O
5	O
ml	O
.	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
sperm	O
concentration	O
(	O
5	O
.	O
5	O
versus	O
15	O
.	O
6	O
million	O
sperm	O
per	O
ml	O
.	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
motility	O
index	O
(	O
832	O
.	O
8	O
versus	O
2930	O
.	O
8	O
million	O
motile	O
sperm	O
per	O
ejaculate	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

These	O
changes	O
were	O
similar	O
to	O
those	O
observed	O
in	O
men	O
treated	O
with	O
testolactone	B-CHEMICAL
.	O

No	O
significant	O
difference	O
in	O
serum	O
testosterone	B-CHEMICAL
levels	O
during	O
treatment	O
with	O
testolactone	B-CHEMICAL
and	O
anastrozole	B-CHEMICAL
was	O
observed	O
.	O

However	O
,	O
the	O
anastrozole	B-CHEMICAL
treatment	O
group	O
did	O
have	O
a	O
statistically	O
better	O
improvement	O
of	O
serum	O
estradiol	B-CHEMICAL
concentration	O
and	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Men	O
who	O
are	O
infertile	O
with	O
a	O
low	O
serum	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratio	O
can	O
be	O
treated	O
with	O
an	O
aromatase	B-GENE-Y
inhibitor	O
.	O

With	O
treatment	O
,	O
an	O
increase	O
in	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratio	O
occurred	O
in	O
association	O
with	O
increased	O
semen	O
parameters	O
.	O

Anastrozole	B-CHEMICAL
and	O
testolactone	B-CHEMICAL
have	O
similar	O
effects	O
on	O
hormonal	O
profiles	O
and	O
semen	O
analysis	O
.	O

Anastrazole	B-CHEMICAL
appears	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
testolactone	B-CHEMICAL
for	O
treating	O
men	O
with	O
abnormal	O
testosterone	B-CHEMICAL
-	O
to	O
-	O
estradiol	B-CHEMICAL
ratios	O
,	O
except	O
for	O
the	O
subset	O
with	O
the	O
Klinefelter	O
syndrome	O
,	O
who	O
appeared	O
to	O
be	O
more	O
effectively	O
treated	O
with	O
testolactone	B-CHEMICAL
.	O

Methylenedioxymethamphetamine	B-CHEMICAL
decreases	O
plasmalemmal	O
and	O
vesicular	O
dopamine	B-CHEMICAL
transport	O
:	O
mechanisms	O
and	O
implications	O
for	O
neurotoxicity	O
.	O

Administration	O
of	O
a	O
high	O
-	O
dose	O
regimen	O
of	O
methamphetamine	B-CHEMICAL
(	O
METH	B-CHEMICAL
)	O
rapidly	O
and	O
profoundly	O
decreases	O
plasmalemmal	O
and	O
vesicular	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
transport	O
in	O
the	O
striatum	O
,	O
as	O
assessed	O
in	O
synaptosomes	O
and	O
purified	O
vesicles	O
,	O
respectively	O
.	O

To	O
determine	O
whether	O
these	O
responses	O
were	O
common	O
to	O
other	O
amphetamines	B-CHEMICAL
of	O
abuse	O
,	O
effects	O
of	O
methylenedioxymethamphetamine	B-CHEMICAL
(	O
MDMA	B-CHEMICAL
)	O
on	O
the	O
plasmalemmal	O
DA	B-GENE-Y
transporter	I-GENE-Y
(	O
DAT	B-GENE-Y
)	O
and	O
vesicular	B-GENE-Y
monoamine	I-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
VMAT	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
were	O
assessed	O
.	O

Similar	O
to	O
effects	O
of	O
METH	B-CHEMICAL
reported	O
previously	O
,	O
multiple	O
high	O
-	O
dose	O
MDMA	B-CHEMICAL
administrations	O
rapidly	O
(	O
within	O
1	O
h	O
)	O
decreased	O
plasmalemmal	O
DA	B-CHEMICAL
uptake	O
,	O
as	O
assessed	O
ex	O
vivo	O
in	O
synaptosomes	O
prepared	O
from	O
treated	O
rats	O
.	O

Unlike	O
effects	O
of	O
multiple	O
METH	B-CHEMICAL
injections	O
,	O
this	O
deficit	O
was	O
reversed	O
completely	O
24	O
h	O
after	O
drug	O
treatment	O
.	O

Also	O
in	O
contrast	O
to	O
effects	O
of	O
multiple	O
METH	B-CHEMICAL
injections	O
,	O
1	O
)	O
MDMA	B-CHEMICAL
caused	O
little	O
or	O
no	O
decrease	O
in	O
binding	O
of	O
the	O
DAT	B-GENE-Y
ligand	O
WIN35428	B-CHEMICAL
,	O
and	O
2	O
)	O
neither	O
prevention	O
of	O
hyperthermia	O
nor	O
prior	O
depletion	O
of	O
DA	B-CHEMICAL
prevented	O
the	O
MDMA	B-CHEMICAL
-	O
induced	O
reduction	O
in	O
plasmalemmal	O
DA	B-CHEMICAL
transport	O
.	O

However	O
,	O
a	O
role	O
for	O
phosphorylation	O
was	O
suggested	O
because	O
pretreatment	O
with	O
protein	B-GENE-Y
kinase	I-GENE-Y
C	I-GENE-Y
inhibitors	O
attenuated	O
the	O
deficit	O
caused	O
by	O
MDMA	B-CHEMICAL
in	O
an	O
in	O
vitro	O
model	O
system	O
.	O

In	O
addition	O
to	O
affecting	O
DAT	B-GENE-Y
function	O
,	O
MDMA	B-CHEMICAL
rapidly	O
decreased	O
vesicular	O
DA	B-CHEMICAL
transport	O
as	O
assessed	O
in	O
striatal	O
vesicles	O
prepared	O
from	O
treated	O
rats	O
.	O

Unlike	O
effects	O
of	O
multiple	O
METH	B-CHEMICAL
injections	O
reported	O
previously	O
,	O
this	O
decrease	O
partially	O
recovered	O
by	O
24	O
h	O
after	O
drug	O
treatment	O
.	O

Taken	O
together	O
,	O
these	O
results	O
reveal	O
several	O
differences	O
between	O
effects	O
of	O
MDMA	B-CHEMICAL
and	O
previously	O
reported	O
METH	B-CHEMICAL
on	O
DAT	B-GENE-Y
and	O
VMAT	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
;	O
differences	O
that	O
may	O
underlie	O
the	O
dissimilar	O
neurotoxic	O
profile	O
of	O
these	O
agents	O
.	O

Chemoprevention	O
for	O
high	O
-	O
risk	O
women	O
:	O
tamoxifen	B-CHEMICAL
and	O
beyond	O
.	O

The	O
demonstration	O
by	O
the	O
National	O
Surgical	O
Adjuvant	O
Breast	O
Project	O
(	O
NSABP	O
)	O
that	O
5	O
years	O
of	O
tamoxifen	B-CHEMICAL
therapy	O
is	O
associated	O
with	O
an	O
approximate	O
50	O
%	O
reduction	O
in	O
breast	O
cancer	O
incidence	O
in	O
high	O
-	O
risk	O
women	O
was	O
a	O
milestone	O
in	O
breast	O
cancer	O
prevention	O
.	O

Because	O
tamoxifen	B-CHEMICAL
is	O
associated	O
with	O
increased	O
risk	O
of	O
side	O
-	O
effects	O
such	O
as	O
hot	O
flashes	O
,	O
menstrual	O
abnormalities	O
,	O
uterine	O
cancer	O
,	O
and	O
thromboembolic	O
phenomena	O
,	O
its	O
use	O
will	O
not	O
be	O
advisable	O
or	O
acceptable	O
for	O
all	O
high	O
-	O
risk	O
women	O
.	O

Women	O
over	O
50	O
years	O
of	O
age	O
appear	O
to	O
be	O
at	O
highest	O
risk	O
for	O
serious	O
adverse	O
events	O
,	O
such	O
as	O
uterine	O
cancer	O
and	O
thromboembolic	O
phenomena	O
.	O

Individuals	O
in	O
whom	O
tamoxifen	B-CHEMICAL
-	O
associated	O
breast	O
cancer	O
risk	O
reduction	O
appears	O
to	O
outweigh	O
risk	O
of	O
serious	O
side	O
-	O
effects	O
include	O
women	O
with	O
prior	O
in	O
situ	O
or	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
-	O
positive	O
invasive	O
cancer	O
,	O
atypical	O
hyperplasia	O
,	O
and	O
/	O
or	O
women	O
ages	O
35	O
-	O
49	O
with	O
a	O
calculated	O
Gail	O
5	O
-	O
year	O
risk	O
of	O
>	O
or	O
=	O
1	O
.	O
7	O
%	O
,	O
hysterectomized	O
women	O
aged	O
50	O
and	O
older	O
with	O
a	O
5	O
-	O
year	O
Gail	O
risk	O
of	O
>	O
or	O
=	O
2	O
.	O
5	O
%	O
,	O
and	O
nonhysterectomized	O
women	O
aged	O
50	O
and	O
older	O
with	O
a	O
5	O
-	O
year	O
Gail	O
risk	O
of	O
>	O
5	O
.	O
0	O
%	O
.	O

It	O
is	O
not	O
yet	O
clear	O
whether	O
tamoxifen	B-CHEMICAL
can	O
reduce	O
breast	O
cancer	O
incidence	O
in	O
women	O
with	O
BRCA1	B-GENE-Y
and	O
BRCA2	B-GENE-Y
mutations	O
,	O
although	O
preliminary	O
evidence	O
favors	O
benefit	O
for	O
at	O
least	O
those	O
with	O
a	O
BRCA2	B-GENE-Y
mutation	O
.	O

Raloxifene	B-CHEMICAL
is	O
a	O
selective	O
ER	B-GENE-Y
modulator	O
with	O
less	O
uterine	O
estrogen	B-CHEMICAL
agonist	O
activity	O
than	O
tamoxifen	B-CHEMICAL
,	O
and	O
it	O
is	O
hoped	O
that	O
it	O
will	O
result	O
in	O
fewer	O
uterine	O
cancers	O
but	O
will	O
be	O
equally	O
efficacious	O
in	O
reducing	O
the	O
risk	O
of	O
breast	O
cancer	O
.	O

The	O
NSABP	O
is	O
currently	O
conducting	O
a	O
randomized	O
study	O
of	O
tamoxifen	B-CHEMICAL
versus	O
raloxifene	B-CHEMICAL
in	O
high	O
-	O
risk	O
postmenopausal	O
women	O
.	O

Approximately	O
one	O
third	O
of	O
invasive	O
cancers	O
are	O
ER	B-GENE-Y
negative	O
.	O

Tamoxifen	B-CHEMICAL
does	O
not	O
reduce	O
the	O
incidence	O
of	O
ER	B-GENE-Y
-	O
negative	O
cancers	O
,	O
nor	O
does	O
it	O
appear	O
to	O
be	O
effective	O
in	O
preventing	O
the	O
appearance	O
of	O
one	O
third	O
of	O
ER	B-GENE-Y
-	O
positive	O
cancers	O
.	O

Priorities	O
in	O
prevention	O
research	O
are	O
to	O
develop	O
(	O
a	O
)	O
biomarkers	O
to	O
refine	O
short	O
-	O
term	O
risk	O
assessments	O
based	O
on	O
epidemiologic	O
models	O
,	O
(	O
b	O
)	O
biomarkers	O
predictive	O
of	O
response	O
to	O
specific	O
classes	O
of	O
preventive	O
agents	O
,	O
(	O
c	O
)	O
drugs	O
with	O
fewer	O
side	O
-	O
effects	O
and	O
/	O
or	O
effective	O
in	O
ER	B-GENE-Y
-	O
negative	O
or	O
ER	B-GENE-Y
-	O
positive	O
tamoxifen	B-CHEMICAL
-	O
resistant	O
precancerous	O
disease	O
,	O
and	O
(	O
d	O
)	O
efficient	O
clinical	O
trial	O
models	O
to	O
assess	O
new	O
agent	O
efficacy	O
.	O

Breast	O
intraepithelial	O
neoplasia	O
(	O
IEN	O
)	O
may	O
be	O
sampled	O
by	O
minimally	O
invasive	O
techniques	O
and	O
is	O
an	O
attractive	O
short	O
-	O
term	O
risk	O
biomarker	O
.	O

Molecular	O
abnormalities	O
observed	O
in	O
IEN	O
may	O
be	O
used	O
to	O
select	O
potential	O
agents	O
for	O
testing	O
/	O
therapy	O
,	O
and	O
modulation	O
of	O
these	O
abnormalities	O
may	O
be	O
used	O
in	O
phase	O
I	O
trials	O
to	O
select	O
appropriate	O
doses	O
and	O
in	O
phase	O
II	O
trials	O
to	O
assess	O
response	O
.	O

Breast	O
density	O
volume	O
and	O
certain	O
serum	O
markers	O
such	O
as	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
are	O
also	O
being	O
studied	O
as	O
potential	O
risk	O
and	O
response	O
biomarkers	O
.	O

Reversal	O
or	O
prevention	O
of	O
advanced	O
IEN	O
as	O
well	O
as	O
modulation	O
of	O
other	O
risk	O
biomarkers	O
in	O
randomized	O
phase	O
II	O
and	O
phase	O
III	O
trials	O
is	O
being	O
evaluated	O
as	O
a	O
means	O
of	O
more	O
efficiently	O
evaluating	O
prevention	O
drugs	O
in	O
the	O
future	O
.	O

A	O
number	O
of	O
agents	O
are	O
being	O
developed	O
that	O
target	O
molecular	O
abnormalities	O
in	O
IEN	O
,	O
have	O
fewer	O
or	O
different	O
side	O
effects	O
than	O
tamoxifen	B-CHEMICAL
,	O
and	O
may	O
be	O
effective	O
in	O
ER	B-GENE-Y
-	O
negative	O
or	O
tamoxifen	B-CHEMICAL
-	O
resistant	O
disease	O
.	O

Inhibition	O
of	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
MIP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
transcription	O
and	O
translation	O
by	O
mimosine	B-CHEMICAL
in	O
muscle	O
tissue	O
infected	O
with	O
the	O
parasite	O
Trichinella	O
spiralis	O
.	O

Mimosine	B-CHEMICAL
is	O
a	O
non	O
-	O
toxic	O
plant	O
aminoacid	B-CHEMICAL
which	O
is	O
an	O
effective	O
inhibitor	O
of	O
DNA	O
replication	O
by	O
acting	O
at	O
the	O
S	O
-	O
phase	O
.	O

In	O
this	O
study	O
we	O
infected	O
mice	O
with	O
T	O
.	O
spiralis	O
,	O
a	O
nematode	O
parasite	O
,	O
and	O
studied	O
the	O
inflammatory	O
response	O
through	O
the	O
determination	O
of	O
MIP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
a	O
C	B-GENE-N
-	I-GENE-N
X	I-GENE-N
-	I-GENE-N
C	I-GENE-N
chemokine	I-GENE-N
and	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
a	O
C	B-GENE-N
-	I-GENE-N
C	I-GENE-N
chemokine	I-GENE-N
in	O
the	O
inflamed	O
area	O
around	O
the	O
parasitic	O
cyst	O
.	O

The	O
animals	O
were	O
infected	O
and	O
their	O
diaphragms	O
were	O
tested	O
for	O
inflammatory	O
response	O
.	O

MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
MIP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
tested	O
after	O
1	O
,	O
10	O
,	O
20	O
,	O
30	O
,	O
and	O
40	O
days	O
post	O
inoculation	O
,	O
before	O
and	O
after	O
mimosine	B-CHEMICAL
treatment	O
.	O

The	O
inflammatory	O
index	O
was	O
calculated	O
by	O
counting	O
the	O
white	O
blood	O
cells	O
around	O
the	O
nematode	O
cysts	O
,	O
while	O
expression	O
of	O
MIP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
calculated	O
by	O
ELISA	O
method	O
and	O
transcription	O
by	O
Northern	O
blot	O
and	O
RT	O
-	O
PCR	O
.	O

Here	O
we	O
found	O
that	O
mimosine	B-CHEMICAL
strongly	O
inhibited	O
the	O
inflammatory	O
index	O
in	O
the	O
diaphragmatic	O
tissue	O
at	O
10	O
,	O
20	O
,	O
30	O
and	O
40	O
days	O
post	O
-	O
treatment	O
.	O

In	O
these	O
experiments	O
,	O
mimosine	B-CHEMICAL
had	O
no	O
effect	O
on	O
the	O
number	O
of	O
cysts	O
produced	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
transcription	O
and	O
translation	O
was	O
completely	O
inhibited	O
by	O
mimosine	B-CHEMICAL
,	O
while	O
MIP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
transcription	O
and	O
translation	O
was	O
partially	O
inhibited	O
at	O
30	O
and	O
40	O
days	O
;	O
yet	O
it	O
was	O
totally	O
inhibited	O
after	O
10	O
and	O
20	O
days	O
in	O
encysted	O
diaphragm	O
tissue	O
infected	O
by	O
T	O
.	O
spiralis	O
.	O

Our	O
studies	O
suggest	O
that	O
mimosine	B-CHEMICAL
has	O
an	O
inhibitory	O
effect	O
through	O
the	O
inhibition	O
of	O
cytoplasmatic	O
serine	O
hydroxymethyltransferase	O
altering	O
the	O
cell	O
cycle	O
of	O
white	O
blood	O
cells	O
.	O

This	O
study	O
suggests	O
for	O
the	O
first	O
time	O
the	O
premise	O
that	O
mimosine	B-CHEMICAL
acts	O
as	O
an	O
anti	O
-	O
inflammatory	O
compound	O
.	O

G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
as	O
direct	O
targets	O
of	O
inhaled	O
anesthetics	O
.	O

The	O
molecular	O
pharmacology	O
of	O
inhalational	O
anesthetics	O
remains	O
poorly	O
understood	O
.	O

Despite	O
accumulating	O
evidence	O
suggesting	O
that	O
neuronal	O
membrane	O
proteins	O
are	O
potential	O
targets	O
of	O
inhaled	O
anesthetics	O
,	O
most	O
currently	O
favored	O
membrane	O
protein	O
targets	O
lack	O
any	O
direct	O
evidence	O
for	O
anesthetic	O
binding	O
.	O

We	O
report	O
herein	O
the	O
location	O
of	O
the	O
binding	O
site	O
for	O
the	O
inhaled	O
anesthetic	O
halothane	B-CHEMICAL
at	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residue	O
level	O
of	O
resolution	O
in	O
the	O
ligand	O
binding	O
cavity	O
in	O
a	O
prototypical	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
,	O
bovine	B-GENE-Y
rhodopsin	I-GENE-Y
.	O

Tryptophan	B-CHEMICAL
fluorescence	O
quenching	O
and	O
direct	O
photoaffinity	O
labeling	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
halothane	I-CHEMICAL
suggested	O
an	O
interhelical	O
location	O
of	O
halothane	B-CHEMICAL
with	O
a	O
stoichiometry	O
of	O
1	O
(	O
halothane	B-CHEMICAL
/	O
rhodopsin	O
molar	O
ratio	O
)	O
.	O

Radiosequence	O
analysis	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
halothane	I-CHEMICAL
-	O
labeled	O
rhodopsin	B-GENE-Y
revealed	O
that	O
halothane	B-CHEMICAL
contacts	O
an	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residue	O
(	O
Trp265	O
)	O
lining	O
the	O
ligand	O
binding	O
cavity	O
in	O
the	O
transmembrane	O
core	O
of	O
the	O
receptor	O
.	O

The	O
predicted	O
functional	O
consequence	O
,	O
competition	O
between	O
halothane	B-CHEMICAL
and	O
the	O
ligand	O
retinal	O
,	O
was	O
shown	O
here	O
by	O
spectroscopy	O
and	O
is	O
known	O
to	O
exist	O
in	O
vivo	O
.	O

These	O
data	O
suggest	O
that	O
competition	O
with	O
endogenous	O
ligands	O
may	O
be	O
a	O
general	O
mechanism	O
of	O
the	O
action	O
of	O
halothane	B-CHEMICAL
at	O
this	O
large	O
family	O
of	O
signaling	O
proteins	O
.	O

Modulation	O
of	O
TNF	B-GENE-Y
and	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
release	O
from	O
dispersed	O
human	O
nasal	O
polyp	O
cells	O
and	O
human	O
whole	O
blood	O
by	O
inhibitors	O
of	O
different	O
PDE	B-GENE-N
isoenzymes	O
and	O
glucocorticoids	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
the	O
inhibitors	O
of	O
different	O
PDE	B-GENE-N
isoenzymes	O
(	O
PDE	B-GENE-N
1	I-GENE-N
-	I-GENE-N
5	I-GENE-N
)	O
on	O
the	O
production	O
of	O
two	O
pro	O
-	O
inflammatory	O
cytokines	B-GENE-N
-	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
)	O
and	O
granulocyte	B-GENE-Y
-	I-GENE-Y
macrophage	I-GENE-Y
colony	I-GENE-Y
-	I-GENE-Y
stimulating	I-GENE-Y
factor	I-GENE-Y
(	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
)	O
.	O

Two	O
in	O
vitro	O
models	O
were	O
used	O
to	O
compare	O
the	O
antiinflammatory	O
properties	O
of	O
PDE	B-GENE-N
inhibitors	O
with	O
that	O
of	O
glucocorticoids	O
.	O

The	O
effect	O
on	O
TNF	B-GENE-Y
release	O
from	O
diluted	O
human	O
blood	O
following	O
lipopolysaccharide	O
(	O
LPS	O
from	O
Salmonella	O
abortus	O
equi	O
)	O
stimulation	O
as	O
well	O
as	O
the	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
and	O
TNF	B-GENE-Y
release	O
from	O
human	O
nasal	O
polyp	O
cells	O
following	O
allergic	O
stimulation	O
were	O
investigated	O
.	O

Both	O
models	O
proofed	O
to	O
be	O
well	O
suited	O
for	O
the	O
characterisation	O
of	O
the	O
antiinflammatory	O
properties	O
of	O
new	O
chemical	O
entities	O
.	O

In	O
diluted	O
human	O
blood	O
and	O
dispersed	O
human	O
nasal	O
polyp	O
cells	O
the	O
induced	O
TNF	B-GENE-Y
release	O
was	O
most	O
potently	O
suppressed	O
by	O
selective	O
PDE4	B-GENE-N
inhibitors	O
.	O

Amrinone	B-CHEMICAL
and	O
milrinone	B-CHEMICAL
,	O
selective	O
PDE3	B-GENE-N
inhibitors	O
,	O
suppressed	O
TNF	B-GENE-Y
secretion	O
to	O
a	O
lesser	O
extent	O
.	O

The	O
effects	O
of	O
theophylline	B-CHEMICAL
(	O
unspecific	O
PDE	B-GENE-N
inhibitor	O
)	O
,	O
vinpocetine	B-CHEMICAL
(	O
PDE1	B-GENE-N
inhibitor	O
)	O
,	O
EHNA	O
(	O
PDE2	B-GENE-Y
inhibitor	O
)	O
and	O
the	O
PDE5	B-GENE-Y
inhibitors	O
zaprinast	B-CHEMICAL
and	O
E	B-CHEMICAL
4021	I-CHEMICAL
were	O
weak	O
.	O

In	O
human	O
blood	O
,	O
the	O
tested	O
glucocorticoids	O
beclomethasone	B-CHEMICAL
,	O
dexamethasone	B-CHEMICAL
and	O
fluticasone	B-CHEMICAL
inhibited	O
the	O
LPS	O
induced	O
TNF	B-GENE-Y
release	O
potently	O
in	O
a	O
concentration	O
dependent	O
manner	O
,	O
whereas	O
in	O
dispersed	O
human	O
nasal	O
polyp	O
cells	O
,	O
the	O
effect	O
of	O
the	O
glucocorticoids	O
on	O
allergically	O
induced	O
TNF	B-GENE-Y
release	O
,	O
with	O
the	O
exception	O
of	O
dexamethasone	B-CHEMICAL
,	O
was	O
much	O
less	O
pronounced	O
.	O

Glucocorticoids	O
were	O
the	O
most	O
potent	O
inhibitors	O
of	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
release	O
and	O
the	O
effect	O
correlates	O
well	O
with	O
the	O
affinity	O
to	O
the	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
.	O

The	O
selective	O
PDE	B-GENE-N
4	I-GENE-N
inhibitors	O
,	O
and	O
to	O
a	O
certain	O
extent	O
the	O
PDE3	B-GENE-N
inhibitors	O
amrinone	B-CHEMICAL
and	O
milrinone	B-CHEMICAL
,	O
reduced	O
the	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
release	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

In	O
all	O
investigations	O
selective	O
PDE4	B-GENE-N
inhibitors	O
reduced	O
TNF	B-GENE-Y
release	O
to	O
a	O
much	O
higher	O
degree	O
(	O
4	O
-	O
10	O
fold	O
)	O
than	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
release	O
.	O

Central	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
stimulation	O
by	O
m	B-CHEMICAL
-	I-CHEMICAL
CPBG	I-CHEMICAL
increases	O
blood	O
glucose	B-CHEMICAL
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
central	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptors	O
on	O
the	O
control	O
of	O
blood	O
glucose	B-CHEMICAL
in	O
stressed	O
and	O
non	O
-	O
stressed	O
rats	O
in	O
both	O
fasted	O
and	O
fed	O
states	O
.	O

Adult	O
Wistar	O
male	O
rats	O
had	O
each	O
their	O
third	O
ventricle	O
cannulated	O
7	O
days	O
before	O
the	O
experiments	O
.	O

Injections	O
of	O
m	B-CHEMICAL
-	I-CHEMICAL
CPBG	I-CHEMICAL
,	O
a	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
agonist	O
,	O
induced	O
a	O
significant	O
increase	O
in	O
blood	O
glucose	B-CHEMICAL
in	O
non	O
-	O
stressed	O
rats	O
in	O
both	O
fasted	O
and	O
in	O
fed	O
states	O
.	O

The	O
same	O
procedure	O
was	O
unable	O
to	O
modify	O
stress	O
-	O
induced	O
hyperglycemia	O
.	O

The	O
hyperglycemic	O
effect	O
of	O
m	B-CHEMICAL
-	I-CHEMICAL
CPBG	I-CHEMICAL
central	O
administration	O
was	O
blocked	O
by	O
pretreatment	O
with	O
ondansetron	O
,	O
a	O
specific	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
antagonist	O
,	O
indicating	O
that	O
the	O
effects	O
here	O
obtained	O
with	O
m	B-CHEMICAL
-	I-CHEMICAL
CPBG	I-CHEMICAL
were	O
a	O
result	O
of	O
its	O
interaction	O
with	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptors	O
.	O

Third	O
ventricle	O
injections	O
of	O
ondansetron	B-CHEMICAL
alone	O
were	O
not	O
able	O
to	O
modify	O
blood	O
glucose	B-CHEMICAL
in	O
non	O
-	O
stressed	O
animals	O
and	O
did	O
not	O
change	O
the	O
hyperglycemic	O
responses	O
observed	O
after	O
immobilization	O
stress	O
.	O

We	O
conclude	O
that	O
pharmacological	O
activation	O
of	O
the	O
central	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
induces	O
a	O
hyperglycemic	O
effect	O
in	O
non	O
-	O
stressed	O
animals	O
.	O

Cysteinyl	B-CHEMICAL
leukotriene	I-CHEMICAL
-	O
dependent	O
interleukin	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
production	O
leading	O
to	O
eosinophilia	O
during	O
late	O
asthmatic	O
response	O
in	O
guinea	O
-	O
pigs	O
.	O

BACKGROUND	O
:	O
Allergic	O
airway	O
eosinophilia	O
is	O
suppressed	O
by	O
cysteinyl	B-GENE-Y
leukotriene	I-GENE-Y
(	I-GENE-Y
CysLT	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
(	O
CysLT1	B-GENE-Y
receptor	O
)	O
antagonists	O
in	O
several	O
species	O
including	O
humans	O
and	O
guinea	O
-	O
pigs	O
,	O
suggesting	O
that	O
CysLTs	B-CHEMICAL
are	O
directly	O
or	O
indirectly	O
involved	O
in	O
induction	O
of	O
the	O
response	O
.	O

OBJECTIVE	O
:	O
We	O
examined	O
the	O
effect	O
of	O
CysLT	B-CHEMICAL
antagonists	O
(	O
pranlukast	B-CHEMICAL
and	O
MCI	B-CHEMICAL
-	I-CHEMICAL
826	I-CHEMICAL
)	O
on	O
antigen	O
inhalation	O
-	O
induced	O
eosinophilia	O
in	O
peripheral	O
blood	O
and	O
lung	O
,	O
and	O
on	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
activity	O
in	O
serum	O
during	O
late	O
increase	O
of	O
airway	O
resistance	O
(	O
late	O
asthmatic	O
response	O
,	O
LAR	O
)	O
in	O
sensitized	O
guinea	O
-	O
pigs	O
.	O

METHODS	O
:	O
Guinea	O
-	O
pigs	O
inhaled	O
ovalbumin	B-GENE-Y
(	O
OVA	B-GENE-Y
)	O
+	O
Al	B-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
3	I-CHEMICAL
and	O
OVA	B-GENE-Y
mists	O
alternately	O
for	O
sensitization	O
and	O
challenge	O
,	O
respectively	O
,	O
once	O
every	O
2	O
weeks	O
.	O

At	O
the	O
fifth	O
challenge	O
,	O
the	O
effects	O
of	O
CysLT	B-CHEMICAL
antagonists	O
and	O
an	O
anti	O
-	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
antibody	O
(	O
TRFK	O
-	O
5	O
)	O
on	O
the	O
occurrence	O
of	O
LAR	O
,	O
and	O
blood	O
and	O
lung	O
eosinophilia	O
,	O
which	O
appeared	O
at	O
5	O
h	O
after	O
challenge	O
,	O
were	O
examined	O
.	O

The	O
time	O
-	O
course	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
activity	O
in	O
the	O
serum	O
after	O
the	O
challenge	O
was	O
evaluated	O
by	O
measuring	O
in	O
vitro	O
'	O
eosinophil	O
survival	O
prolongation	O
activity	O
'	O
.	O

The	O
influence	O
of	O
CysLT	B-CHEMICAL
antagonists	O
on	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
activity	O
was	O
assessed	O
.	O

RESULTS	O
:	O
CysLT	B-CHEMICAL
antagonists	O
and	O
TRFK	O
-	O
5	O
completely	O
abolished	O
blood	O
and	O
lung	O
eosinophilia	O
.	O

LAR	O
was	O
suppressed	O
by	O
both	O
MCI	B-CHEMICAL
-	I-CHEMICAL
826	I-CHEMICAL
and	O
TRFK	O
-	O
5	O
by	O
40	O
-	O
50	O
%	O
.	O

Sera	O
obtained	O
from	O
sensitized	O
,	O
challenged	O
animals	O
3	O
h	O
and	O
4	O
h	O
after	O
challenge	O
induced	O
an	O
obvious	O
prolongation	O
of	O
eosinophil	O
survival	O
.	O

The	O
activity	O
of	O
the	O
sera	O
was	O
completely	O
neutralized	O
by	O
prior	O
exposure	O
to	O
TRFK	O
-	O
5	O
,	O
suggesting	O
that	O
it	O
reflected	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
activity	O
.	O

Increased	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
activity	O
in	O
the	O
serum	O
was	O
inhibited	O
by	O
both	O
pranlukast	B-CHEMICAL
and	O
MCI	B-CHEMICAL
-	I-CHEMICAL
826	I-CHEMICAL
by	O
over	O
90	O
%	O
.	O

CONCLUSIONS	O
:	O
CysLTs	B-CHEMICAL
produced	O
after	O
antigen	O
provocation	O
sequentially	O
induced	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
production	O
from	O
some	O
immune	O
component	O
cells	O
via	O
CysLT1	B-GENE-Y
receptor	O
activation	O
.	O

Thus	O
,	O
it	O
is	O
likely	O
that	O
CysLTs	B-CHEMICAL
indirectly	O
cause	O
antigen	O
-	O
induced	O
eosinophilia	O
through	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
production	O
.	O

Minocycline	B-CHEMICAL
inhibits	O
cytochrome	B-GENE-Y
c	I-GENE-Y
release	O
and	O
delays	O
progression	O
of	O
amyotrophic	O
lateral	O
sclerosis	O
in	O
mice	O
.	O

Minocycline	B-CHEMICAL
mediates	O
neuroprotection	O
in	O
experimental	O
models	O
of	O
neurodegeneration	O
.	O

It	O
inhibits	O
the	O
activity	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
inducible	B-GENE-Y
form	I-GENE-Y
of	I-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthetase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
and	O
p38	B-GENE-N
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
.	O

Although	O
minocycline	B-CHEMICAL
does	O
not	O
directly	O
inhibit	O
these	O
enzymes	O
,	O
the	O
effects	O
may	O
result	O
from	O
interference	O
with	O
upstream	O
mechanisms	O
resulting	O
in	O
their	O
secondary	O
activation	O
.	O

Because	O
the	O
above	O
-	O
mentioned	O
factors	O
are	O
important	O
in	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
we	O
tested	O
minocycline	B-CHEMICAL
in	O
mice	O
with	O
ALS	O
.	O

Here	O
we	O
report	O
that	O
minocycline	B-CHEMICAL
delays	O
disease	O
onset	O
and	O
extends	O
survival	O
in	O
ALS	O
mice	O
.	O

Given	O
the	O
broad	O
efficacy	O
of	O
minocycline	B-CHEMICAL
,	O
understanding	O
its	O
mechanisms	O
of	O
action	O
is	O
of	O
great	O
importance	O
.	O

We	O
find	O
that	O
minocycline	B-CHEMICAL
inhibits	O
mitochondrial	O
permeability	O
-	O
transition	O
-	O
mediated	O
cytochrome	B-GENE-Y
c	I-GENE-Y
release	O
.	O

Minocycline	B-CHEMICAL
-	O
mediated	O
inhibition	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
release	O
is	O
demonstrated	O
in	O
vivo	O
,	O
in	O
cells	O
,	O
and	O
in	O
isolated	O
mitochondria	O
.	O

Understanding	O
the	O
mechanism	O
of	O
action	O
of	O
minocycline	B-CHEMICAL
will	O
assist	O
in	O
the	O
development	O
and	O
testing	O
of	O
more	O
powerful	O
and	O
effective	O
analogues	O
.	O

Because	O
of	O
the	O
safety	O
record	O
of	O
minocycline	B-CHEMICAL
,	O
and	O
its	O
ability	O
to	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
this	O
drug	O
may	O
be	O
a	O
novel	O
therapy	O
for	O
ALS	O
.	O

Tetrahydrobiopterin	B-CHEMICAL
in	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
synthesis	O
:	O
a	O
novel	O
biological	O
role	O
for	O
pteridines	B-CHEMICAL
.	O

Ever	O
since	O
the	O
discovery	O
that	O
(	B-CHEMICAL
6R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
biopterin	I-CHEMICAL
(	O
BH4	B-CHEMICAL
)	O
is	O
a	O
cofactor	O
of	O
NOS	B-GENE-N
,	O
its	O
function	O
has	O
been	O
the	O
object	O
of	O
intense	O
research	O
and	O
occasional	O
controversy	O
.	O

Only	O
in	O
the	O
last	O
couple	O
of	O
years	O
a	O
consensus	O
has	O
been	O
reached	O
on	O
what	O
constitutes	O
the	O
main	O
role	O
of	O
BH4	B-CHEMICAL
in	O
NO	B-CHEMICAL
synthesis	O
.	O

In	O
this	O
review	O
we	O
aim	O
to	O
provide	O
an	O
outline	O
of	O
the	O
various	O
ways	O
in	O
which	O
BH4	B-CHEMICAL
affects	O
NOS	B-GENE-N
catalysis	O
.	O

First	O
we	O
give	O
a	O
brief	O
general	O
description	O
of	O
the	O
structure	O
and	O
catalytic	O
mechanism	O
of	O
NOS	B-GENE-N
,	O
with	O
special	O
emphasis	O
on	O
those	O
aspects	O
of	O
catalysis	O
that	O
are	O
actively	O
debated	O
,	O
and	O
that	O
directly	O
or	O
indirectly	O
involve	O
BH4	B-CHEMICAL
.	O

Foremost	O
among	O
those	O
issues	O
is	O
uncoupled	O
catalysis	O
,	O
i	O
.	O
e	O
.	O
the	O
NOS	B-GENE-N
-	O
catalyzed	O
oxidation	O
of	O
NADPH	B-CHEMICAL
in	O
the	O
absence	O
of	O
substrate	O
or	O
pterin	O
that	O
does	O
not	O
result	O
in	O
NO	B-CHEMICAL
production	O
.	O

We	O
also	O
shortly	O
discuss	O
the	O
ongoing	O
debate	O
on	O
whether	O
NO	B-CHEMICAL
is	O
the	O
actual	O
reaction	O
product	O
of	O
NOS	B-GENE-N
catalysis	O
,	O
as	O
well	O
as	O
the	O
phenomenon	O
of	O
NO	B-CHEMICAL
-	O
mediated	O
autoinhibition	O
.	O

We	O
describe	O
the	O
function	O
of	O
BH4	B-CHEMICAL
in	O
aromatic	B-CHEMICAL
amino	I-CHEMICAL
acid	I-CHEMICAL
hydroxylation	O
,	O
and	O
discuss	O
the	O
allosteric	O
and	O
structural	O
effects	O
that	O
BH4	B-CHEMICAL
exerts	O
on	O
NOS	B-GENE-N
.	O

Next	O
we	O
turn	O
our	O
attention	O
to	O
what	O
is	O
now	O
becoming	O
accepted	O
as	O
the	O
central	O
function	O
of	O
BH4	B-CHEMICAL
:	O
its	O
capacity	O
to	O
act	O
as	O
a	O
1	O
-	O
electron	O
donor	O
during	O
reductive	O
activation	O
of	O
the	O
oxyferrous	B-CHEMICAL
complex	O
of	O
the	O
heme	O
.	O

Finally	O
,	O
we	O
illustrate	O
how	O
BH4	B-CHEMICAL
might	O
transform	O
the	O
NOS	B-GENE-N
dimer	O
into	O
an	O
efficient	O
S	B-GENE-N
-	I-GENE-N
nitrosoglutathione	I-GENE-N
synthase	I-GENE-N
,	O
and	O
briefly	O
touch	O
on	O
some	O
more	O
speculative	O
aspects	O
of	O
the	O
role	O
of	O
BH4	B-CHEMICAL
in	O
NO	B-CHEMICAL
synthesis	O
.	O

A	O
comparison	O
of	O
the	O
effects	O
of	O
nabumetone	B-CHEMICAL
vs	O
meloxicam	B-CHEMICAL
on	O
serum	O
thromboxane	B-CHEMICAL
B2	I-CHEMICAL
and	O
platelet	O
function	O
in	O
healthy	O
volunteers	O
.	O

AIMS	O
:	O
To	O
compare	O
the	O
effects	O
of	O
nabumetone	B-CHEMICAL
and	O
meloxicam	B-CHEMICAL
,	O
two	O
cyclo	B-GENE-Y
-	I-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
preferential	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
on	O
platelet	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
and	O
platelet	O
function	O
.	O

METHODS	O
:	O
Twelve	O
healthy	O
volunteers	O
(	O
3	O
male	O
,	O
9	O
female	O
,	O
median	O
age	O
22	O
years	O
)	O
participated	O
in	O
an	O
open	O
,	O
randomized	O
,	O
cross	O
-	O
over	O
trial	O
of	O
nabumetone	B-CHEMICAL
1000	O
mg	O
twice	O
daily	O
vs	O
meloxicam	B-CHEMICAL
7	O
.	O
5	O
mg	O
twice	O
daily	O
during	O
1	O
week	O
with	O
2	O
weeks	O
wash	O
-	O
out	O
.	O

After	O
a	O
second	O
2	O
week	O
wash	O
-	O
out	O
period	O
,	O
one	O
dose	O
of	O
indomethacin	B-CHEMICAL
50	O
mg	O
was	O
given	O
as	O
a	O
positive	O
control	O
to	O
check	O
for	O
NSAID	O
induced	O
inhibition	O
of	O
platelet	O
function	O
.	O

COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibition	O
was	O
measured	O
as	O
percentage	O
inhibition	O
of	O
serum	O
TXB2	B-CHEMICAL
generation	O
in	O
clotting	O
whole	O
blood	O
,	O
and	O
as	O
closure	O
time	O
with	O
use	O
of	O
the	O
platelet	O
function	O
analyser	O
PFA	O
-	O
100	O
.	O

Data	O
are	O
reported	O
as	O
median	O
with	O
range	O
.	O

Paired	O
variables	O
were	O
analysed	O
using	O
Wilcoxons	O
signed	O
rank	O
test	O
.	O

RESULTS	O
:	O
TXB2	B-CHEMICAL
levels	O
decreased	O
significantly	O
after	O
all	O
three	O
medications	O
,	O
but	O
percentage	O
inhibition	O
after	O
nabumetone	B-CHEMICAL
and	O
indomethacin	B-CHEMICAL
(	O
88	O
%	O
and	O
97	O
%	O
,	O
respectively	O
)	O
was	O
significantly	O
higher	O
than	O
after	O
meloxicam	B-CHEMICAL
(	O
63	O
%	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Closure	O
times	O
increased	O
significantly	O
after	O
administration	O
of	O
all	O
three	O
medications	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Increases	O
in	O
closure	O
time	O
after	O
administration	O
did	O
not	O
differ	O
between	O
nabumetone	B-CHEMICAL
and	O
meloxicam	B-CHEMICAL
(	O
24	O
%	O
and	O
14	O
%	O
,	O
respectively	O
)	O
,	O
but	O
were	O
significantly	O
larger	O
after	O
indomethacin	B-CHEMICAL
administration	O
(	O
63	O
%	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
maximum	O
registered	O
dosage	O
,	O
nabumetone	B-CHEMICAL
inhibits	O
thromboxane	B-CHEMICAL
production	O
much	O
more	O
than	O
meloxicam	O
,	O
signifying	O
less	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selectivity	O
of	O
the	O
former	O
.	O

However	O
,	O
both	O
nabumetone	B-CHEMICAL
and	O
meloxicam	B-CHEMICAL
cause	O
only	O
minor	O
impairment	O
in	O
platelet	O
function	O
in	O
comparison	O
with	O
indomethacin	B-CHEMICAL
and	O
the	O
difference	O
between	O
them	O
is	O
not	O
significant	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
induce	O
apoptosis	O
in	O
association	O
with	O
activation	O
of	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
in	O
rheumatoid	O
synovial	O
cells	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
have	O
been	O
reported	O
to	O
induce	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
lines	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
NSAIDs	O
on	O
the	O
growth	O
and	O
apoptosis	O
of	O
synovial	O
cells	O
from	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
analyzed	O
the	O
activation	O
of	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
PPARgamma	B-GENE-Y
)	O
as	O
a	O
possible	O
mechanism	O
of	O
action	O
of	O
NSAIDs	O
.	O

Cell	O
proliferation	O
and	O
viability	O
were	O
assessed	O
from	O
5	B-CHEMICAL
-	I-CHEMICAL
bromo	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxyuridine	I-CHEMICAL
incorporation	O
and	O
by	O
4	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
iodophenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
nitrophenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2H	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
tetrazolio	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
benzene	I-CHEMICAL
disulfonate	I-CHEMICAL
(	O
WST	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
)	O
assay	O
,	O
respectively	O
.	O

The	O
apoptosis	O
of	O
synovial	O
cells	O
was	O
identified	O
by	O
DNA	O
fragmentation	O
assay	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
-	O
end	O
labeling	O
assay	O
.	O

Indometacin	B-CHEMICAL
,	O
diclofenac	B-CHEMICAL
,	O
oxaprozin	B-CHEMICAL
,	O
and	O
zaltoprofen	B-CHEMICAL
reduced	O
cell	O
proliferation	O
and	O
induced	O
apoptotic	O
cell	O
death	O
in	O
synovial	O
cells	O
,	O
whereas	O
ketoprofen	B-CHEMICAL
and	O
acetaminophen	B-CHEMICAL
did	O
not	O
.	O

N	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
cyclohexyloxyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
nitrophenyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
methanesulfonamide	I-CHEMICAL
(	O
NS	B-CHEMICAL
-	I-CHEMICAL
398	I-CHEMICAL
)	O
,	O
a	O
selective	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
also	O
inhibited	O
cell	O
proliferation	O
,	O
whereas	O
it	O
did	O
not	O
cause	O
apoptosis	O
.	O

Rheumatoid	O
synovial	O
cells	O
expressed	O
PPARgamma	B-GENE-Y
mRNA	O
,	O
and	O
the	O
PPARgamma	B-GENE-Y
ligands	O
15	B-CHEMICAL
-	I-CHEMICAL
deoxy	I-CHEMICAL
-	I-CHEMICAL
Delta	I-CHEMICAL
(	I-CHEMICAL
12	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
prostaglandin	I-CHEMICAL
J	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
and	O
troglitazone	B-CHEMICAL
reduced	O
the	O
proliferation	O
and	O
induced	O
apoptosis	O
in	O
synovial	O
cells	O
.	O

Luciferase	O
reporter	O
assay	O
demonstrated	O
that	O
not	O
only	O
PPARgamma	B-GENE-Y
ligands	O
but	O
also	O
NSAIDs	O
,	O
which	O
could	O
induce	O
apoptosis	O
,	O
increased	O
the	O
activation	O
of	O
PPARgamma	B-GENE-Y
in	O
synovial	O
cells	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
NSAIDs	O
and	O
PPARgamma	B-GENE-Y
ligands	O
to	O
stimulate	O
the	O
activation	O
of	O
PPARgamma	B-GENE-Y
correlated	O
with	O
their	O
ability	O
to	O
decrease	O
cell	O
viability	O
(	O
r	O
=	O
0	O
.	O
92	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
ability	O
to	O
induce	O
DNA	O
fragmentation	O
(	O
r	O
=	O
0	O
.	O
97	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
synovial	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PPARgamma	B-GENE-Y
is	O
an	O
attractive	O
target	O
for	O
induction	O
of	O
apoptosis	O
in	O
rheumatoid	O
synovial	O
cells	O
and	O
that	O
the	O
activation	O
of	O
the	O
PPARgamma	B-GENE-Y
pathway	O
is	O
associated	O
with	O
the	O
apoptotic	O
action	O
of	O
NSAIDs	O
.	O

Enzymatic	O
characterization	O
of	O
a	O
recombinant	O
isoform	O
hybrid	O
of	O
glutamic	B-GENE-N
acid	I-GENE-N
decarboxylase	I-GENE-N
(	O
rGAD67	B-GENE-N
/	I-GENE-N
65	I-GENE-N
)	O
expressed	O
in	O
yeast	O
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
Glutamic	B-GENE-N
acid	I-GENE-N
decarboxylase	I-GENE-N
(	O
GAD	B-GENE-N
,	O
EC	B-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
15	I-GENE-Y
)	O
catalyses	O
the	O
conversion	O
of	O
glutamate	B-CHEMICAL
to	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	B-CHEMICAL
)	O
.	O

The	O
65	O
kDa	O
isoform	O
,	O
GAD65	B-GENE-Y
is	O
a	O
potent	O
autoantigen	O
in	O
type	O
1	O
diabetes	O
,	O
whereas	O
GAD67	B-GENE-Y
is	O
not	O
.	O

A	O
hybrid	O
cDNA	O
was	O
created	O
by	O
fusing	O
a	O
human	O
cDNA	O
for	O
amino	B-CHEMICAL
acids	I-CHEMICAL
1	O
-	O
101	O
of	O
GAD67	B-GENE-Y
to	O
a	O
human	O
cDNA	O
for	O
amino	B-CHEMICAL
acids	I-CHEMICAL
96	O
-	O
585	O
of	O
GAD65	B-GENE-Y
;	O
the	O
recombinant	O
(	O
r	O
)	O
protein	O
was	O
expressed	O
in	O
yeast	O
and	O
was	O
shown	O
to	O
have	O
equivalent	O
immunoreactivity	O
to	O
mammalian	B-GENE-N
brain	I-GENE-N
GAD	I-GENE-N
with	O
diabetes	O
sera	O
.	O

We	O
here	O
report	O
on	O
enzymatic	O
and	O
molecular	O
properties	O
of	O
rGAD67	B-GENE-N
/	I-GENE-N
65	I-GENE-N
.	O

METHODS	O
:	O
Studies	O
were	O
performed	O
on	O
enzymatic	O
activity	O
of	O
rGAD67	B-GENE-N
/	I-GENE-N
65	I-GENE-N
by	O
production	O
of	O
3H	B-CHEMICAL
-	I-CHEMICAL
GABA	I-CHEMICAL
from	O
3H	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
,	O
enzyme	O
kinetics	O
,	O
binding	O
to	O
the	O
enzyme	O
cofactor	O
pyridoxal	B-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
,	O
stability	O
according	O
to	O
differences	O
in	O
pH	O
,	O
temperature	O
and	O
duration	O
of	O
storage	O
,	O
and	O
antigenic	O
reactivity	O
with	O
various	O
GAD	B-GENE-N
-	O
specific	O
antisera	O
.	O

RESULTS	O
:	O
The	O
properties	O
of	O
rGAD67	B-GENE-N
/	I-GENE-N
65	I-GENE-N
were	O
compared	O
with	O
published	O
data	O
for	O
mammalian	B-GENE-N
brain	I-GENE-N
GAD	I-GENE-N
(	O
brackets	O
)	O
.	O

These	O
included	O
a	O
specific	O
enzyme	O
activity	O
of	O
22	O
.	O
7	O
(	O
16	O
.	O
7	O
)	O
nKat	O
,	O
optimal	O
pH	O
for	O
enzymatic	O
activity	O
7	O
.	O
4	O
(	O
6	O
.	O
8	O
)	O
,	O
K	O
(	O
m	O
)	O
of	O
1	O
.	O
3	O
(	O
1	O
.	O
3	O
)	O
mM	O
,	O
efficient	O
non	O
-	O
covalent	O
binding	O
to	O
the	O
cofactor	O
PLP	B-CHEMICAL
,	O
and	O
high	O
autoantigenic	O
potency	O
.	O

The	O
stability	O
of	O
rGAD67	B-GENE-N
/	I-GENE-N
65	I-GENE-N
was	O
optimal	O
over	O
3	O
months	O
at	O
-	O
80	O
degrees	O
C	O
,	O
or	O
in	O
lyophilized	O
form	O
at	O
-	O
20	O
degrees	O
C	O
.	O

CONCLUSIONS	O
:	O
Hybrid	O
rGAD67	B-GENE-N
/	I-GENE-N
65	I-GENE-N
has	O
enzymatic	O
and	O
other	O
properties	O
similar	O
to	O
those	O
of	O
the	O
mixed	O
isoforms	O
of	O
GAD	B-GENE-N
in	O
preparations	O
from	O
mammalian	O
brain	O
as	O
described	O
elsewhere	O
,	O
in	O
addition	O
to	O
its	O
previously	O
described	O
similar	O
immunoreactivity	O
.	O

Renal	O
failure	O
associated	O
with	O
the	O
use	O
of	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
.	O

OBJECTIVE	O
:	O
Celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
are	O
two	O
relatively	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
that	O
selectively	O
inhibit	O
the	O
cyclo	B-GENE-Y
-	I-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
isoenzyme	O
at	O
therapeutic	O
concentrations	O
.	O

The	O
nephrotoxic	O
potential	O
of	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
has	O
not	O
been	O
clearly	O
established	O
.	O

This	O
study	O
was	O
conducted	O
in	O
order	O
to	O
understand	O
the	O
association	O
between	O
acute	O
renal	O
failure	O
and	O
the	O
two	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
.	O

METHODS	O
:	O
A	O
search	O
was	O
performed	O
in	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
'	O
s	O
(	O
FDA	O
)	O
Adverse	O
Event	O
Reporting	O
System	O
(	O
AERS	O
)	O
to	O
identify	O
cases	O
of	O
renal	O
failure	O
submitted	O
to	O
the	O
FDA	O
.	O

A	O
MEDLINE	O
search	O
of	O
the	O
English	O
language	O
literature	O
was	O
also	O
performed	O
to	O
identify	O
published	O
cases	O
of	O
renal	O
failure	O
associated	O
with	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
.	O

RESULTS	O
:	O
One	O
hundred	O
twenty	O
-	O
two	O
and	O
142	O
domestic	O
US	O
cases	O
of	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
-	O
associated	O
renal	O
failure	O
,	O
respectively	O
,	O
were	O
identified	O
in	O
the	O
AERS	O
database	O
.	O

The	O
literature	O
search	O
identified	O
19	O
cases	O
of	O
acute	O
renal	O
impairment	O
in	O
association	O
with	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
.	O

In	O
addition	O
,	O
drug	O
regulatory	O
authorities	O
in	O
the	O
UK	O
,	O
Canada	O
,	O
and	O
Australia	O
have	O
received	O
about	O
50	O
reports	O
of	O
renal	O
failure	O
with	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
.	O

Descriptive	O
statistics	O
of	O
the	O
AERS	O
cases	O
have	O
been	O
summarised	O
in	O
this	O
report	O
.	O

CONCLUSIONS	O
:	O
Data	O
from	O
AERS	O
and	O
published	O
case	O
reports	O
suggest	O
that	O
use	O
of	O
both	O
these	O
drugs	O
is	O
associated	O
with	O
renal	O
effects	O
similar	O
to	O
that	O
of	O
conventional	O
nonselective	O
NSAIDs	O
.	O

Physicians	O
should	O
be	O
aware	O
that	O
serious	O
or	O
life	O
-	O
threatening	O
renal	O
failure	O
has	O
been	O
reported	O
in	O
patients	O
with	O
normal	O
or	O
impaired	O
renal	O
function	O
after	O
short	O
-	O
term	O
therapy	O
with	O
celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
.	O

Patients	O
at	O
greatest	O
risk	O
for	O
renal	O
injury	O
are	O
those	O
with	O
pre	O
-	O
existing	O
renal	O
impairment	O
,	O
heart	O
failure	O
,	O
liver	O
dysfunction	O
,	O
those	O
taking	O
diuretics	O
and	O
/	O
or	O
ACE	B-GENE-Y
inhibitors	O
,	O
and	O
the	O
elderly	O
.	O

Kidney	O
function	O
should	O
be	O
monitored	O
closely	O
for	O
any	O
signs	O
of	O
potential	O
renal	O
injuries	O
soon	O
after	O
initiating	O
treatment	O
with	O
these	O
agents	O
,	O
especially	O
in	O
high	O
-	O
risk	O
populations	O
.	O

In	O
addition	O
,	O
healthcare	O
practitioners	O
should	O
adequately	O
warn	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
serious	O
renal	O
toxicity	O
,	O
and	O
of	O
the	O
need	O
for	O
them	O
to	O
see	O
their	O
physician	O
promptly	O
if	O
they	O
occur	O
.	O

Celecoxib	B-CHEMICAL
and	O
rofecoxib	B-CHEMICAL
are	O
not	O
recommended	O
for	O
use	O
in	O
patients	O
with	O
advanced	O
renal	O
disease	O
.	O

Dopamine	B-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
-	O
induced	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
mediated	O
production	O
of	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
in	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	O
transfected	O
Chinese	O
hamster	O
ovary	O
cells	O
without	O
simultaneous	O
administration	O
of	O
a	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
mobilizing	O
agent	O
.	O

We	O
have	O
earlier	O
demonstrated	O
that	O
dopamine	O
stimulates	O
the	O
liberation	O
of	O
the	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
precursor	O
,	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
,	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
transfected	O
with	O
the	O
rat	B-GENE-Y
dopamine	I-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
(	I-GENE-Y
long	I-GENE-Y
isoform	I-GENE-Y
)	I-GENE-Y
,	O
also	O
without	O
concomitant	O
administration	O
of	O
a	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
releasing	O
agent	O
[	O
Nilsson	O
et	O
al	O
.	O
,	O
Br	O
J	O
Pharmacol	O
1998	O
;	O
124	O
:	O
1651	O
-	O
8	O
]	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
dopamine	B-CHEMICAL
,	O
under	O
the	O
same	O
conditions	O
,	O
also	O
induces	O
a	O
concentration	O
-	O
dependent	O
increase	O
in	O
the	O
production	O
of	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
,	O
with	O
a	O
maximal	O
effect	O
of	O
235	O
%	O
at	O
approximately	O
100	O
microM	O
,	O
and	O
with	O
an	O
EC	O
(	O
50	O
)	O
of	O
794	O
nM	O
.	O

The	O
effect	O
was	O
counteracted	O
by	O
the	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
antagonist	O
eticlopride	B-CHEMICAL
,	O
pertussis	B-GENE-N
toxin	I-GENE-N
,	O
the	O
inhibitor	O
of	O
intracellular	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
release	O
TMB	O
-	O
8	O
,	O
incubation	O
in	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
free	O
experimental	O
medium	O
,	O
and	O
PKC	B-GENE-N
desensitization	O
obtained	O
by	O
chronic	O
pretreatment	O
with	O
the	O
phorbol	O
ester	O
TPA	O
.	O

It	O
was	O
also	O
antagonized	O
by	O
the	O
non	O
-	O
specific	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
inhibitor	O
,	O
indomethacin	B-CHEMICAL
,	O
and	O
by	O
the	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
NS	B-CHEMICAL
-	I-CHEMICAL
398	I-CHEMICAL
,	O
but	O
not	O
by	O
the	O
specific	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitor	O
,	O
valeryl	B-CHEMICAL
salicylate	I-CHEMICAL
.	O

Both	O
the	O
non	O
-	O
specific	O
phospholipase	B-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
inhibitor	O
,	O
quinacrine	B-CHEMICAL
,	O
and	O
an	O
inhibitor	O
of	O
cPLA	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
and	O
iPLA	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
,	O
AACOF3	O
,	O
counteracted	O
the	O
effect	O
;	O
in	O
contrast	O
,	O
a	O
selective	O
iPLA	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
inhibitor	O
,	O
BEL	O
,	O
and	O
a	O
selective	O
sPLA	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
inhibitor	O
,	O
TAPC	O
,	O
were	O
ineffective	O
.	O

No	O
effects	O
of	O
dopamine	B-CHEMICAL
were	O
obtained	O
in	O
control	O
cells	O
mock	O
-	O
transfected	O
with	O
the	O
p3C	O
vector	O
only	O
.	O

The	O
results	O
reinforce	O
previous	O
assumptions	O
that	O
dopamine	B-CHEMICAL
may	O
interact	O
with	O
eicosanoid	B-CHEMICAL
metabolism	O
by	O
means	O
of	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
activation	O
,	O
and	O
implicate	O
an	O
involvement	O
of	O
cPLA	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
this	O
effect	O
.	O

It	O
is	O
suggested	O
that	O
measurement	O
of	O
dopamine	B-CHEMICAL
-	O
induced	O
PGE	O
(	O
2	O
)	O
production	O
may	O
serve	O
as	O
a	O
convenient	O
way	O
to	O
study	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
function	O
in	O
vitro	O
.	O

Minocycline	B-CHEMICAL
markedly	O
protects	O
the	O
neonatal	O
brain	O
against	O
hypoxic	O
-	O
ischemic	O
injury	O
.	O

Hypoxic	O
-	O
ischemic	O
brain	O
injury	O
in	O
the	O
perinatal	O
period	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Presently	O
,	O
there	O
are	O
no	O
proven	O
effective	O
therapies	O
with	O
which	O
to	O
safeguard	O
the	O
human	O
neonatal	O
brain	O
against	O
this	O
type	O
of	O
injury	O
.	O

Minocycline	B-CHEMICAL
,	O
a	O
semisynthetic	O
tetracycline	B-CHEMICAL
,	O
has	O
been	O
shown	O
to	O
be	O
neuroprotective	O
in	O
certain	O
adult	O
ischemic	O
injury	O
/	O
stroke	O
and	O
neurodegenerative	O
disease	O
models	O
.	O

However	O
,	O
minocycline	O
'	O
s	O
neuroprotective	O
effects	O
have	O
not	O
been	O
assessed	O
after	O
insults	O
to	O
the	O
neonatal	O
brain	O
.	O

We	O
now	O
report	O
that	O
minocycline	B-CHEMICAL
administered	O
either	O
immediately	O
before	O
or	O
immediately	O
after	O
a	O
hypoxic	O
-	O
ischemic	O
insult	O
substantially	O
blocks	O
tissue	O
damage	O
in	O
a	O
rodent	O
model	O
of	O
neonatal	O
hypoxic	O
-	O
ischemic	O
brain	O
injury	O
.	O

Minocycline	B-CHEMICAL
treatment	O
prevents	O
the	O
formation	O
of	O
activated	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
a	O
known	O
effector	O
of	O
apoptosis	O
,	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
calpain	B-GENE-N
cleaved	O
substrate	O
,	O
a	O
marker	O
of	O
excitotoxic	O
/	O
necrotic	O
cell	O
death	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
a	O
systemic	O
treatment	O
that	O
can	O
be	O
administered	O
after	O
a	O
hypoxic	O
-	O
ischemic	O
insult	O
,	O
which	O
provides	O
robust	O
,	O
nearly	O
complete	O
neuroprotection	O
to	O
the	O
developing	O
brain	O
.	O

Our	O
data	O
suggest	O
that	O
minocycline	B-CHEMICAL
or	O
a	O
related	O
neuroprotective	O
tetracycline	B-CHEMICAL
may	O
be	O
a	O
candidate	O
to	O
consider	O
in	O
human	O
clinical	O
trials	O
to	O
protect	O
the	O
developing	O
brain	O
against	O
hypoxic	O
-	O
ischemic	O
-	O
induced	O
damage	O
.	O

A	O
novel	O
SCN5A	B-GENE-Y
arrhythmia	O
mutation	O
,	O
M1766L	B-GENE-N
,	O
with	O
expression	O
defect	O
rescued	O
by	O
mexiletine	B-CHEMICAL
.	O

OBJECTIVE	O
:	O
Mutations	O
in	O
the	O
cardiac	O
sodium	B-CHEMICAL
channel	O
gene	O
,	O
SCN5A	B-GENE-Y
,	O
cause	O
congenital	O
long	O
QT	O
syndrome	O
(	O
LQT3	O
)	O
,	O
Brugada	O
syndrome	O
,	O
idiopathic	O
ventricular	O
fibrillation	O
,	O
and	O
conduction	O
disease	O
by	O
distinct	O
cellular	O
and	O
clinical	O
electrophysiological	O
phenotypes	O
.	O

METHODS	O
:	O
Postmortem	O
molecular	O
analysis	O
of	O
SCN5A	B-GENE-Y
was	O
conducted	O
on	O
an	O
infant	O
who	O
presented	O
shortly	O
after	O
birth	O
with	O
self	O
-	O
terminating	O
torsades	O
de	O
pointes	O
.	O

The	O
infant	O
was	O
treated	O
with	O
lidocaine	B-CHEMICAL
,	O
propranolol	B-CHEMICAL
,	O
and	O
mexiletine	B-CHEMICAL
and	O
was	O
stable	O
for	O
16	O
months	O
manifesting	O
only	O
a	O
prolonged	O
QT	O
interval	O
.	O

The	O
infant	O
collapsed	O
suddenly	O
following	O
presumed	O
viral	O
gastroenteritis	O
,	O
was	O
found	O
in	O
2	O
:	O
1	O
AV	O
block	O
,	O
and	O
was	O
subsequently	O
declared	O
brain	O
dead	O
.	O

Genomic	O
DNA	O
was	O
subjected	O
to	O
SCN5A	B-GENE-Y
mutational	O
analyses	O
and	O
DNA	O
sequencing	O
revealing	O
a	O
novel	O
,	O
spontaneous	O
germline	O
missense	O
mutation	O
,	O
M1766L	B-GENE-N
.	O

The	O
M1766L	B-GENE-N
mutation	O
was	O
engineered	O
into	O
the	O
hH1a	O
clone	O
by	O
site	O
-	O
directed	O
mutagenesis	O
,	O
transfected	O
into	O
embryonic	O
kidney	O
cells	O
(	O
HEK	O
-	O
293	O
)	O
,	O
and	O
studied	O
by	O
voltage	O
clamp	O
.	O

RESULTS	O
:	O
The	O
M1766L	B-GENE-N
mutation	O
caused	O
a	O
significant	O
decrease	O
in	O
the	O
sodium	B-CHEMICAL
channel	O
expression	O
.	O

Co	O
-	O
expression	O
with	O
beta1	O
subunit	O
,	O
incubation	O
at	O
low	O
temperature	O
,	O
and	O
most	O
effectively	O
incubation	O
with	O
mexiletine	B-CHEMICAL
partially	O
'	O
rescued	O
'	O
the	O
defective	O
expression	O
.	O

In	O
addition	O
to	O
this	O
pronounced	O
loss	O
of	O
function	O
,	O
M1766L	B-GENE-N
also	O
showed	O
a	O
10	O
-	O
fold	O
increase	O
in	O
the	O
persistent	O
late	O
sodium	B-CHEMICAL
current	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
suggest	O
that	O
M1766L	B-GENE-N
-	O
SCN5A	B-GENE-Y
channel	O
dysfunction	O
may	O
contribute	O
to	O
the	O
basis	O
of	O
lethal	O
arrhythmias	O
,	O
displays	O
an	O
overlapping	O
electrophysiological	O
phenotype	O
,	O
and	O
represents	O
the	O
first	O
sodium	B-CHEMICAL
channelopathy	O
rescued	O
by	O
drug	O
.	O

Disposition	O
of	O
a	O
specific	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
valdecoxib	B-CHEMICAL
,	O
in	O
human	O
.	O

Valdecoxib	B-CHEMICAL
is	O
a	O
potent	O
and	O
specific	O
inhibitor	O
of	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
which	O
is	O
used	O
for	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
,	O
and	O
the	O
dysmenorrhea	O
pain	O
.	O

Eight	O
male	O
human	O
subjects	O
each	O
received	O
a	O
single	O
50	O
-	O
mg	O
oral	O
dose	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
valdecoxib	I-CHEMICAL
.	O

Urine	O
,	O
feces	O
,	O
and	O
blood	O
samples	O
were	O
collected	O
after	O
administration	O
of	O
the	O
radioactive	O
dose	O
.	O

Most	O
of	O
the	O
radioactivity	O
in	O
plasma	O
was	O
associated	O
with	O
valdecoxib	B-CHEMICAL
and	O
the	O
hydroxylated	O
metabolite	O
of	O
valdecoxib	B-CHEMICAL
(	O
M1	O
)	O
.	O

The	O
estimated	O
terminal	O
half	O
-	O
life	O
for	O
valdecoxib	B-CHEMICAL
was	O
about	O
7	O
h	O
.	O

About	O
76	O
.	O
1	O
%	O
of	O
the	O
radioactive	O
dose	O
was	O
recovered	O
in	O
urine	O
and	O
18	O
%	O
of	O
the	O
radioactive	O
dose	O
was	O
recovered	O
in	O
feces	O
.	O

Valdecoxib	B-CHEMICAL
was	O
extensively	O
metabolized	O
in	O
human	O
,	O
and	O
nine	O
phase	O
I	O
metabolites	O
were	O
identified	O
.	O

The	O
primary	O
oxidative	O
metabolic	O
pathways	O
of	O
valdecoxib	B-CHEMICAL
involved	O
hydroxylation	O
at	O
either	O
the	O
methyl	B-CHEMICAL
group	O
to	O
form	O
M1	O
or	O
N	B-CHEMICAL
-	O
hydroxylation	O
at	O
the	O
sulfonamide	B-CHEMICAL
moiety	O
to	O
form	O
M2	O
.	O

Further	O
oxidation	O
of	O
M1	O
led	O
to	O
the	O
formation	O
of	O
several	O
other	O
phase	O
I	O
metabolites	O
.	O

Oxidative	O
breakdown	O
of	O
the	O
N	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
sulfonamide	I-CHEMICAL
function	O
group	O
in	O
M2	O
led	O
to	O
the	O
formation	O
of	O
corresponding	O
sulfinic	B-CHEMICAL
acid	I-CHEMICAL
and	O
sulfonic	B-CHEMICAL
acid	I-CHEMICAL
metabolites	O
.	O

The	O
O	B-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
conjugate	O
of	O
M1	O
and	O
N	B-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
conjugate	O
of	O
valdecoxib	B-CHEMICAL
were	O
the	O
major	O
urinary	O
metabolites	O
,	O
which	O
accounted	O
for	O
23	O
.	O
3	O
and	O
19	O
.	O
5	O
%	O
of	O
the	O
total	O
administered	O
dose	O
,	O
respectively	O
.	O

The	O
remaining	O
urinary	O
metabolites	O
were	O
glucuronide	O
conjugates	O
of	O
other	O
phase	O
I	O
metabolites	O
.	O

Only	O
3	O
%	O
of	O
the	O
administered	O
dose	O
was	O
recovered	O
in	O
urine	O
as	O
unchanged	O
parent	O
,	O
suggesting	O
that	O
renal	O
clearance	O
is	O
insignificant	O
for	O
valdecoxib	B-CHEMICAL
.	O

Absorption	O
of	O
valdecoxib	B-CHEMICAL
was	O
excellent	O
since	O
the	O
recovery	O
of	O
unchanged	O
valdecoxib	B-CHEMICAL
in	O
feces	O
was	O
<	O
1	O
%	O
of	O
the	O
administered	O
dose	O
.	O

Bupropion	B-CHEMICAL
inhibits	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	O
overflow	O
from	O
rat	O
striatal	O
slices	O
preloaded	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
and	O
from	O
rat	O
hippocampal	O
slices	O
preloaded	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
norepinephrine	I-CHEMICAL
.	O

Bupropion	B-CHEMICAL
,	O
an	O
efficacious	O
antidepressant	O
and	O
smoking	O
cessation	O
agent	O
,	O
inhibits	O
dopamine	B-GENE-N
and	I-GENE-N
norepinephrine	I-GENE-N
transporters	I-GENE-N
(	O
DAT	B-GENE-Y
and	O
NET	B-GENE-Y
,	O
respectively	O
)	O
.	O

Recently	O
,	O
bupropion	B-CHEMICAL
has	O
been	O
reported	O
to	O
noncompetitively	O
inhibit	O
alpha3beta2	B-GENE-N
,	I-GENE-N
alpha3beta4	I-GENE-N
,	I-GENE-N
and	I-GENE-N
alpha4beta2	I-GENE-N
nicotinic	I-GENE-N
acetylcholine	I-GENE-N
receptors	I-GENE-N
(	I-GENE-N
nAChRs	I-GENE-N
)	I-GENE-N
expressed	O
in	O
Xenopus	O
oocytes	O
or	O
established	O
cell	O
lines	O
.	O

The	O
present	O
study	O
evaluated	O
bupropion	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
native	O
alpha3beta2	B-GENE-N
*	I-GENE-N
and	I-GENE-N
alpha3beta4	I-GENE-N
*	I-GENE-N
nAChRs	I-GENE-N
using	O
functional	O
neurotransmitter	O
release	O
assays	O
,	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	O
overflow	O
from	O
superfused	O
rat	O
striatal	O
slices	O
preloaded	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
(	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
DA	I-CHEMICAL
)	O
,	O
and	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	O
overflow	O
from	O
hippocampal	O
slices	O
preloaded	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
norepinephrine	I-CHEMICAL
(	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
NE	I-CHEMICAL
)	O
.	O

The	O
mechanism	O
of	O
inhibition	O
was	O
evaluated	O
using	O
Schild	O
analysis	O
.	O

To	O
eliminate	O
the	O
interaction	O
of	O
bupropion	B-CHEMICAL
with	O
DAT	B-GENE-Y
or	O
NET	B-GENE-Y
,	O
nomifensine	B-CHEMICAL
or	O
desipramine	B-CHEMICAL
,	O
respectively	O
,	O
was	O
included	O
in	O
the	O
superfusion	O
buffer	O
.	O

A	O
high	O
bupropion	B-CHEMICAL
concentration	O
(	O
100	O
microM	O
)	O
elicited	O
intrinsic	O
activity	O
in	O
the	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
DA	I-CHEMICAL
release	O
assay	O
.	O

However	O
,	O
none	O
of	O
the	O
concentrations	O
(	O
1	O
nM	O
-	O
100	O
microM	O
)	O
examined	O
evoked	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
NE	I-CHEMICAL
overflow	O
and	O
,	O
thus	O
,	O
were	O
without	O
intrinsic	O
activity	O
in	O
this	O
assay	O
.	O

Moreover	O
,	O
bupropion	B-CHEMICAL
inhibited	O
both	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
DA	I-CHEMICAL
overflow	O
(	O
IC	O
(	O
50	O
)	O
=	O
1	O
.	O
27	O
microM	O
)	O
and	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
NE	I-CHEMICAL
overflow	O
(	O
IC	O
(	O
50	O
)	O
=	O
323	O
nM	O
)	O
at	O
bupropion	B-CHEMICAL
concentrations	O
well	O
below	O
those	O
eliciting	O
intrinsic	O
activity	O
.	O

Results	O
from	O
Schild	O
analyses	O
suggest	O
that	O
bupropion	B-CHEMICAL
competitively	O
inhibits	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
DA	I-CHEMICAL
overflow	O
,	O
whereas	O
evidence	O
for	O
receptor	O
reserve	O
was	O
obtained	O
upon	O
assessment	O
of	O
bupropion	B-CHEMICAL
inhibition	O
of	O
nicotine	B-CHEMICAL
-	O
evoked	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
NE	I-CHEMICAL
overflow	O
.	O

Thus	O
,	O
bupropion	B-CHEMICAL
acts	O
as	O
an	O
antagonist	O
at	O
alpha3beta2	B-GENE-N
*	I-GENE-N
and	I-GENE-N
alpha3beta4	I-GENE-N
*	I-GENE-N
nAChRs	I-GENE-N
in	O
rat	O
striatum	O
and	O
hippocampus	O
,	O
respectively	O
,	O
across	O
the	O
same	O
concentration	O
range	O
that	O
inhibits	O
DAT	B-GENE-Y
and	O
NET	B-GENE-Y
function	O
.	O

The	O
combination	O
of	O
nAChR	B-GENE-N
and	O
transporter	O
inhibition	O
produced	O
by	O
bupropion	B-CHEMICAL
may	O
contribute	O
to	O
its	O
clinical	O
efficacy	O
as	O
a	O
smoking	O
cessation	O
agent	O
.	O

The	O
clinical	O
profile	O
of	O
the	O
angiotensin	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
blocker	O
eprosartan	B-CHEMICAL
.	O

Angiotensin	B-GENE-N
II	I-GENE-N
receptor	I-GENE-N
antagonists	O
block	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
AT1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
and	O
reduce	O
the	O
pressor	O
effects	O
of	O
angiotensin	B-CHEMICAL
in	O
the	O
vasculature	O
.	O

By	O
this	O
mechanism	O
,	O
they	O
induce	O
similar	O
pharmacological	O
effects	O
to	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
(	O
ACE	B-GENE-Y
)	O
inhibitors	O
,	O
resulting	O
in	O
a	O
lowering	O
of	O
blood	O
pressure	O
(	O
BP	O
)	O
.	O

However	O
,	O
AT1	B-GENE-Y
antagonists	O
differ	O
from	O
ACE	B-GENE-Y
inhibitors	O
with	O
respect	O
to	O
side	O
effects	O
,	O
and	O
induce	O
less	O
cough	O
,	O
which	O
is	O
related	O
to	O
bradykinin	B-GENE-Y
activation	O
.	O

Within	O
the	O
class	O
of	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
antagonists	O
,	O
eprosartan	O
differs	O
from	O
other	O
currently	O
clinically	O
available	O
agents	O
in	O
terms	O
of	O
its	O
chemical	O
structure	O
and	O
its	O
dual	O
pharmacological	O
mode	O
of	O
action	O
.	O

Eprosartan	B-CHEMICAL
acts	O
not	O
only	O
at	O
vascular	O
AT1	B-GENE-Y
receptors	O
but	O
also	O
at	O
presynaptic	O
AT1	B-GENE-Y
receptors	O
,	O
causing	O
inhibition	O
of	O
sympathetically	O
stimulated	O
noradrenaline	B-CHEMICAL
release	O
.	O

Eprosartan	B-CHEMICAL
is	O
not	O
metabolized	O
by	O
cytochrome	B-GENE-N
P450	I-GENE-N
enzymes	O
and	O
therefore	O
has	O
a	O
low	O
potential	O
for	O
metabolic	O
drug	O
interactions	O
,	O
which	O
may	O
be	O
of	O
importance	O
when	O
treating	O
the	O
elderly	O
and	O
patients	O
on	O
multiple	O
drugs	O
.	O

In	O
clinical	O
trials	O
eprosartan	B-CHEMICAL
has	O
proven	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
the	O
ACE	B-GENE-Y
inhibitor	O
enalapril	O
in	O
reducing	O
BP	O
,	O
but	O
with	O
a	O
significantly	O
lower	O
incidence	O
of	O
side	O
effects	O
.	O

Eprosartan	B-CHEMICAL
is	O
safe	O
,	O
effective	O
and	O
well	O
tolerated	O
in	O
long	O
-	O
term	O
treatment	O
,	O
either	O
as	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
antihypertensive	O
drugs	O
such	O
as	O
hydrochlorothiazide	B-CHEMICAL
.	O

Species	O
-	O
specific	O
differences	O
in	O
the	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
transactivation	O
function	O
upon	O
binding	O
with	O
betamethasone	B-CHEMICAL
-	I-CHEMICAL
esters	I-CHEMICAL
.	O

Glucocorticoids	O
(	O
GCs	O
)	O
are	O
the	O
most	O
effective	O
drugs	O
for	O
anti	O
-	O
inflammatory	O
diseases	O
.	O

A	O
number	O
of	O
adverse	O
side	O
effects	O
,	O
however	O
,	O
limit	O
chronic	O
treatment	O
with	O
GCs	O
.	O

To	O
improve	O
their	O
therapeutic	O
usefulness	O
,	O
attempts	O
have	O
been	O
made	O
to	O
dissociate	O
the	O
two	O
main	O
actions	O
of	O
the	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
,	O
transactivation	O
and	O
transrepression	O
,	O
which	O
are	O
believed	O
to	O
be	O
responsible	O
for	O
the	O
side	O
effects	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
respectively	O
.	O

We	O
report	O
here	O
species	O
-	O
specific	O
differences	O
in	O
the	O
transactivation	O
response	O
mediated	O
by	O
GR	B-GENE-Y
.	O

Dexamethasone	B-CHEMICAL
(	O
DEX	B-CHEMICAL
)	O
,	O
betamethasone	B-CHEMICAL
(	O
BM	B-CHEMICAL
)	O
,	O
and	O
their	O
esterified	O
-	O
derivatives	O
had	O
full	O
transrepression	O
agonistic	O
activity	O
in	O
a	O
reporter	O
assay	O
using	O
CV	O
-	O
1	O
cells	O
transfected	O
with	O
either	O
human	B-GENE-N
or	I-GENE-N
rat	I-GENE-N
GR	I-GENE-N
.	O

These	O
GCs	O
also	O
had	O
full	O
transactivation	O
agonistic	O
activity	O
in	O
CV	O
-	O
1	O
cells	O
transfected	O
with	O
human	B-GENE-Y
GR	I-GENE-Y
.	O

The	O
esterified	O
-	O
BM	B-CHEMICAL
,	O
however	O
,	O
had	O
only	O
partial	O
transactivation	O
agonistic	O
activity	O
in	O
cells	O
transfected	O
with	O
rat	B-GENE-Y
GR	I-GENE-Y
,	O
whereas	O
BM	B-CHEMICAL
and	O
esterified	O
-	O
DEX	B-CHEMICAL
had	O
full	O
transactivation	O
agonistic	O
activity	O
.	O

Moreover	O
,	O
in	O
rat	O
hepatoma	O
H4	O
-	O
II	O
-	O
E	O
cells	O
,	O
the	O
esterified	O
-	O
BM	B-CHEMICAL
failed	O
to	O
induce	O
tyrosine	B-GENE-Y
aminotransferase	I-GENE-Y
,	O
which	O
is	O
regulated	O
by	O
GR	B-GENE-Y
-	O
mediated	O
transactivation	O
activity	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
binding	O
affinity	O
of	O
these	O
GCs	O
to	O
human	B-GENE-N
and	I-GENE-N
rat	I-GENE-N
GR	I-GENE-N
.	O

Consistent	O
with	O
the	O
weak	O
transactivation	O
activity	O
of	O
esterified	O
-	O
BM	B-CHEMICAL
mediated	O
by	O
rat	B-GENE-Y
GR	I-GENE-Y
,	O
there	O
were	O
few	O
side	O
effects	O
,	O
evaluated	O
by	O
thymus	O
involution	O
and	O
body	O
weight	O
loss	O
,	O
in	O
an	O
antigen	O
-	O
induced	O
asthmatic	O
model	O
in	O
rats	O
.	O

These	O
results	O
suggest	O
that	O
the	O
potency	O
of	O
esterified	O
-	O
BM	B-CHEMICAL
to	O
induce	O
transactivation	O
activity	O
is	O
different	O
between	O
species	O
and	O
that	O
this	O
difference	O
is	O
not	O
due	O
to	O
differences	O
in	O
receptor	O
binding	O
.	O

Biosynthesis	O
of	O
iron	B-CHEMICAL
-	O
sulphur	B-CHEMICAL
clusters	O
is	O
a	O
complex	O
and	O
highly	O
conserved	O
process	O
.	O

Iron	B-CHEMICAL
-	O
sulphur	B-CHEMICAL
(	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
)	O
clusters	O
are	O
simple	O
inorganic	O
prosthetic	O
groups	O
that	O
are	O
contained	O
in	O
a	O
variety	O
of	O
proteins	O
having	O
functions	O
related	O
to	O
electron	O
transfer	O
,	O
gene	O
regulation	O
,	O
environmental	O
sensing	O
and	O
substrate	O
activation	O
.	O

In	O
spite	O
of	O
their	O
simple	O
structures	O
,	O
biological	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
clusters	O
are	O
not	O
formed	O
spontaneously	O
.	O

Rather	O
,	O
a	O
consortium	O
of	O
highly	O
conserved	O
proteins	O
is	O
required	O
for	O
both	O
the	O
formation	O
of	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
clusters	O
and	O
their	O
insertion	O
into	O
various	O
protein	O
partners	O
.	O

Among	O
the	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
cluster	O
biosynthetic	O
proteins	O
are	O
included	O
a	O
pyridoxal	B-CHEMICAL
phosphate	I-CHEMICAL
-	O
dependent	O
enzyme	O
(	O
NifS	B-GENE-Y
)	O
that	O
is	O
involved	O
in	O
the	O
activation	O
of	O
sulphur	B-CHEMICAL
from	O
l	B-CHEMICAL
-	I-CHEMICAL
cysteine	I-CHEMICAL
,	O
and	O
a	O
molecular	O
scaffold	O
protein	O
(	O
NifU	B-GENE-N
)	O
upon	O
which	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
cluster	O
precursors	O
are	O
formed	O
.	O

The	O
formation	O
or	O
transfer	O
of	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
clusters	O
appears	O
to	O
require	O
an	O
electron	O
-	O
transfer	O
step	O
.	O

Another	O
complexity	O
is	O
that	O
molecular	O
chaperones	O
homologous	O
to	O
DnaJ	O
and	O
DnaK	O
are	O
involved	O
in	O
some	O
aspect	O
of	O
the	O
maturation	O
of	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
-	O
cluster	O
-	O
containing	O
proteins	O
.	O

It	O
appears	O
that	O
the	O
basic	O
biochemical	O
features	O
of	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
cluster	O
formation	O
are	O
strongly	O
conserved	O
in	O
Nature	O
,	O
since	O
organisms	O
from	O
all	O
three	O
life	O
Kingdoms	O
contain	O
the	O
same	O
consortium	O
of	O
homologous	O
proteins	O
required	O
for	O
[	O
Fe	B-CHEMICAL
-	I-CHEMICAL
S	I-CHEMICAL
]	O
cluster	O
formation	O
that	O
were	O
discovered	O
in	O
the	O
eubacteria	O
.	O

Mazindol	B-CHEMICAL
analogues	O
as	O
potential	O
inhibitors	O
of	O
the	O
cocaine	B-GENE-N
binding	I-GENE-N
site	I-GENE-N
at	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
.	O

A	O
series	O
of	O
mazindol	B-CHEMICAL
(	O
2	O
)	O
and	O
homomazindol	B-CHEMICAL
(	O
3	O
)	O
analogues	O
with	O
a	O
variety	O
of	O
electron	O
-	O
donating	O
and	O
electron	O
-	O
withdrawing	O
groups	O
in	O
the	O
pendant	O
aryl	B-CHEMICAL
group	O
and	O
the	O
benzo	B-CHEMICAL
ring	O
C	O
,	O
as	O
well	O
as	O
H	O
,	O
methoxy	B-CHEMICAL
,	O
and	O
alkyl	B-CHEMICAL
groups	O
replacing	O
the	O
hydroxyl	B-CHEMICAL
group	O
were	O
synthesized	O
,	O
and	O
their	O
binding	O
affinities	O
at	O
the	O
dopamine	B-GENE-N
transporter	I-GENE-N
(	O
DAT	B-GENE-N
)	O
on	O
rat	O
or	O
guinea	O
pig	O
striatal	O
membranes	O
were	O
determined	O
.	O

Several	O
active	O
analogues	O
were	O
also	O
evaluated	O
for	O
their	O
ability	O
to	O
block	O
uptake	O
of	O
DA	B-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
,	O
and	O
NE	B-CHEMICAL
and	O
inhibit	O
binding	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
]	I-CHEMICAL
RTI	I-CHEMICAL
-	I-CHEMICAL
55	I-CHEMICAL
at	O
HEK	O
-	O
hDAT	B-GENE-Y
,	O
HEK	O
-	O
hSERT	B-GENE-Y
,	O
and	O
HEK	O
-	O
hNET	B-GENE-Y
cells	O
.	O

Mazindane	B-CHEMICAL
(	O
26	O
)	O
was	O
found	O
to	O
be	O
a	O
pro	O
-	O
drug	O
,	O
oxidizing	O
(	O
5	B-CHEMICAL
-	I-CHEMICAL
H	I-CHEMICAL
-	O
-	O
>	O
5	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
)	O
to	O
mazindol	B-CHEMICAL
on	O
rat	O
striatal	O
membranes	O
and	O
HEK	O
-	O
hDAT	B-GENE-Y
cells	O
.	O

The	O
4	B-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
trichloro	I-CHEMICAL
analogue	O
(	O
38	O
)	O
of	O
mazindol	B-CHEMICAL
was	O
the	O
most	O
potent	O
and	O
selective	O
ligand	O
for	O
HEK	O
-	O
hDAT	B-GENE-Y
cells	O
(	O
DAT	B-GENE-Y
K	O
(	O
i	O
)	O
=	O
1	O
.	O
1	O
nM	O
;	O
SERT	B-GENE-Y
/	O
DAT	B-GENE-Y
=	O
1283	O
and	O
NET	B-GENE-Y
/	O
DAT	B-GENE-Y
=	O
38	O
)	O
.	O

Experimental	O
results	O
strongly	O
favor	O
the	O
cyclic	O
or	O
ol	O
tautomers	O
of	O
2	O
and	O
3	O
to	O
bind	O
more	O
tightly	O
at	O
the	O
DAT	B-GENE-Y
than	O
the	O
corresponding	O
keto	O
tautomers	O
.	O

SUR	B-GENE-Y
-	O
dependent	O
modulation	O
of	O
KATP	B-GENE-N
channels	I-GENE-N
by	O
an	O
N	B-CHEMICAL
-	O
terminal	O
KIR6	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
peptide	O
.	O

Defining	O
intersubunit	O
gating	O
interactions	O
.	O

Ntp	O
and	O
Ctp	O
,	O
synthetic	O
peptides	O
based	O
on	O
the	O
N	B-CHEMICAL
-	O
and	O
C	B-CHEMICAL
-	O
terminal	O
sequences	O
of	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
0	I-GENE-Y
,	O
respectively	O
,	O
were	O
used	O
to	O
probe	O
gating	O
of	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
0	I-GENE-Y
/	O
SUR	B-GENE-Y
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
.	O

Micromolar	O
Ntp	O
dose	O
-	O
dependently	O
increased	O
the	O
mean	O
open	O
channel	O
probability	O
in	O
ligand	O
-	O
free	O
solution	O
(	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
)	O
and	O
attenuated	O
the	O
ATP	B-CHEMICAL
inhibition	O
of	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR1	B-GENE-Y
,	O
but	O
had	O
no	O
effect	O
on	O
homomeric	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
channels	O
.	O

Ntp	O
(	O
up	O
to	O
approximately	O
10	O
(	O
-	O
4	O
)	O
m	O
)	O
did	O
not	O
affect	O
significantly	O
the	O
mean	O
open	O
or	O
"	O
fast	O
,	O
"	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
driving	O
force	O
-	O
dependent	O
,	O
intraburst	O
closed	O
times	O
,	O
verifying	O
that	O
Ntp	O
selectively	O
modulates	O
the	O
ratio	O
of	O
mean	O
burst	O
to	O
interburst	O
times	O
.	O

Ctp	O
and	O
Rnp	O
,	O
a	O
randomized	O
Ntp	O
,	O
had	O
no	O
effect	O
,	O
indicating	O
that	O
the	O
effects	O
of	O
Ntp	O
are	O
structure	O
specific	O
.	O

Ntp	O
opened	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
/	O
SUR1	B-GENE-Y
channels	O
normally	O
silent	O
in	O
the	O
absence	O
of	O
stimulatory	O
Mg	O
(	O
-	O
)	O
nucleotide	B-CHEMICAL
(	I-CHEMICAL
s	I-CHEMICAL
)	I-CHEMICAL
and	O
attenuated	O
the	O
coupling	O
of	O
high	O
-	O
affinity	O
sulfonylurea	B-CHEMICAL
binding	O
with	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
pore	O
closure	O
.	O

These	O
effects	O
resemble	O
those	O
seen	O
with	O
N	B-CHEMICAL
-	O
terminal	O
deletions	O
(	O
DeltaN	O
)	O
of	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
0	I-GENE-Y
,	O
and	O
application	O
of	O
Ntp	O
to	O
DeltaNK	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
decreased	O
their	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
and	O
apparent	O
IC	O
(	O
50	O
)	O
for	O
ATP	B-CHEMICAL
in	O
the	O
absence	O
of	O
Mg	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
.	O

The	O
results	O
are	O
consistent	O
with	O
a	O
competition	O
between	O
Ntp	O
and	O
the	O
endogenous	O
N	B-CHEMICAL
terminus	O
for	O
a	O
site	O
of	O
interaction	O
on	O
the	O
cytoplasmic	O
face	O
of	O
the	O
channel	O
or	O
with	O
partial	O
replacement	O
of	O
the	O
deleted	O
N	B-CHEMICAL
terminus	O
by	O
Ntp	O
,	O
respectively	O
.	O

The	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
N	B-CHEMICAL
terminus	O
and	O
the	O
TMD0	O
-	O
L0	O
segment	O
of	O
SUR1	B-GENE-Y
are	O
known	O
to	O
control	O
the	O
P	O
(	O
O	O
(	O
max	O
)	O
)	O
.	O

The	O
L0	O
linker	O
has	O
been	O
reported	O
to	O
be	O
required	O
for	O
glibenclamide	B-CHEMICAL
binding	O
,	O
and	O
DeltaNK	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
SUR1	B-GENE-Y
channels	O
exhibit	O
reduced	O
labeling	O
of	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
with	O
(	B-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	I-CHEMICAL
azidoglibenclamide	I-CHEMICAL
,	O
implying	O
that	O
the	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
N	B-CHEMICAL
terminus	O
and	O
L0	O
of	O
SUR1	B-GENE-Y
are	O
in	O
proximity	O
.	O

We	O
hypothesize	O
that	O
L0	O
interacts	O
with	O
the	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
N	B-CHEMICAL
terminus	O
in	O
ligand	O
-	O
inhibited	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
and	O
put	O
forward	O
a	O
model	O
,	O
based	O
on	O
the	O
architecture	O
of	O
BtuCD	B-GENE-N
,	O
MsbA	B-GENE-N
,	O
and	O
the	O
KcsA	B-GENE-N
channel	O
,	O
in	O
which	O
TMD0	O
-	O
L0	O
links	O
the	O
MDR	B-GENE-N
-	O
like	O
core	O
of	O
SUR	B-GENE-Y
with	O
the	O
K	B-GENE-Y
(	I-GENE-Y
IR	I-GENE-Y
)	I-GENE-Y
pore	O
.	O

Gemfibrozil	B-CHEMICAL
,	O
a	O
lipid	O
-	O
lowering	O
drug	O
,	O
inhibits	O
the	O
induction	O
of	O
nitric	B-GENE-N
-	I-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
in	O
human	O
astrocytes	O
.	O

Gemfibrozil	B-CHEMICAL
,	O
a	O
lipid	O
-	O
lowering	O
drug	O
,	O
inhibited	O
cytokine	B-GENE-N
-	O
induced	O
production	O
of	O
NO	B-CHEMICAL
and	O
the	O
expression	O
of	O
inducible	B-GENE-Y
nitric	I-GENE-Y
-	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
in	O
human	O
U373MG	O
astroglial	O
cells	O
and	O
primary	O
astrocytes	O
.	O

Similar	O
to	O
gemfibrozil	B-CHEMICAL
,	O
clofibrate	B-CHEMICAL
,	O
another	O
fibrate	B-CHEMICAL
drug	O
,	O
also	O
inhibited	O
the	O
expression	O
of	O
iNOS	B-GENE-Y
.	O

Inhibition	O
of	O
human	B-GENE-N
iNOS	I-GENE-N
promoter	I-GENE-N
-	O
driven	O
luciferase	O
activity	O
by	O
gemfibrozil	B-CHEMICAL
in	O
cytokine	B-GENE-N
-	O
stimulated	O
U373MG	O
astroglial	O
cells	O
suggests	O
that	O
this	O
compound	O
inhibits	O
the	O
transcription	O
of	O
iNOS	B-GENE-Y
.	O

Since	O
gemfibrozil	B-CHEMICAL
is	O
known	O
to	O
activate	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
PPAR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
)	O
,	O
we	O
investigated	O
the	O
role	O
of	O
PPAR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
in	O
gemfibrozil	B-CHEMICAL
-	O
mediated	O
inhibition	O
of	O
iNOS	B-GENE-Y
.	O

Gemfibrozil	B-CHEMICAL
induced	O
peroxisome	B-GENE-N
proliferator	I-GENE-N
-	I-GENE-N
responsive	I-GENE-N
element	I-GENE-N
(	O
PPRE	B-GENE-N
)	O
-	O
dependent	O
luciferase	O
activity	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
expression	O
of	O
DeltahPPAR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
the	O
dominant	O
-	O
negative	O
mutant	O
of	O
human	B-GENE-Y
PPAR	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
.	O

However	O
,	O
DeltahPPAR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
was	O
unable	O
to	O
abrogate	O
gemfibrozil	B-CHEMICAL
-	O
mediated	O
inhibition	O
of	O
iNOS	B-GENE-Y
suggesting	O
that	O
gemfibrozil	B-CHEMICAL
inhibits	O
iNOS	B-GENE-Y
independent	O
of	O
PPAR	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
.	O

The	O
human	B-GENE-N
iNOS	I-GENE-N
promoter	I-GENE-N
contains	O
consensus	O
sequences	O
for	O
the	O
binding	O
of	O
transcription	O
factors	O
,	O
including	O
interferon	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
(	I-GENE-Y
IFN	I-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
)	I-GENE-Y
regulatory	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IRF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
binding	O
to	O
interferon	B-GENE-N
-	I-GENE-N
stimulated	I-GENE-N
responsive	I-GENE-N
element	I-GENE-N
(	O
ISRE	B-GENE-N
)	O
,	O
signal	B-GENE-N
transducer	I-GENE-N
and	I-GENE-N
activator	I-GENE-N
of	I-GENE-N
transcription	I-GENE-N
(	O
STAT	B-GENE-N
)	O
binding	O
to	O
gamma	O
-	O
activation	O
site	O
(	O
GAS	O
)	O
,	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
)	O
,	O
activator	B-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
and	O
CCAAT	B-GENE-Y
/	I-GENE-Y
enhancer	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
beta	I-GENE-Y
(	O
C	B-GENE-Y
/	I-GENE-Y
EBPbeta	I-GENE-Y
)	O
;	O
therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
gemfibrozil	B-CHEMICAL
on	O
the	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

The	O
combination	O
of	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1beta	I-GENE-Y
and	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
induced	O
the	O
activation	O
of	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
,	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
C	B-GENE-Y
/	I-GENE-Y
EBPbeta	I-GENE-Y
,	O
and	O
GAS	O
but	O
not	O
that	O
of	O
ISRE	B-GENE-N
,	O
suggesting	O
that	O
IRF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
may	O
not	O
be	O
involved	O
in	O
cytokine	B-GENE-N
-	O
induced	O
expression	O
of	O
iNOS	B-GENE-Y
in	O
human	O
astrocytes	O
.	O

Interestingly	O
,	O
gemfibrozil	B-CHEMICAL
strongly	O
inhibited	O
the	O
activation	O
of	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
,	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
C	B-GENE-Y
/	I-GENE-Y
EBPbeta	I-GENE-Y
but	O
not	O
that	O
of	O
GAS	O
in	O
cytokine	B-GENE-N
-	O
stimulated	O
astroglial	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
gemfibrozil	B-CHEMICAL
inhibits	O
the	O
induction	O
of	O
iNOS	B-GENE-Y
probably	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
,	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
C	B-GENE-Y
/	I-GENE-Y
EBPbeta	I-GENE-Y
and	O
that	O
gemfibrozil	B-CHEMICAL
,	O
a	O
prescribed	O
drug	O
for	O
humans	O
,	O
may	O
further	O
find	O
its	O
therapeutic	O
use	O
in	O
neuroinflammatory	O
diseases	O
.	O

Re	O
-	O
evaluation	O
of	O
lisuride	B-CHEMICAL
pharmacology	O
:	O
5	B-GENE-Y
-	I-GENE-Y
hydroxytryptamine1A	I-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
behavioral	O
effects	O
overlap	O
its	O
other	O
properties	O
in	O
rats	O
.	O

RATIONALE	O
:	O
There	O
is	O
substantial	O
evidence	O
that	O
lisuride	B-CHEMICAL
can	O
produce	O
effects	O
linked	O
to	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptor	O
occupancy	O
.	O

Nevertheless	O
,	O
this	O
action	O
has	O
generally	O
been	O
ignored	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
lisuride	B-CHEMICAL
,	O
in	O
favor	O
of	O
an	O
exclusive	O
role	O
for	O
dopamine	B-GENE-N
receptors	I-GENE-N
in	O
considering	O
its	O
antiparkinsonian	O
effects	O
,	O
or	O
an	O
exclusive	O
role	O
of	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2A	I-GENE-N
/	I-GENE-N
2C	I-GENE-N
)	I-GENE-N
receptor	O
activation	O
in	O
hallucinogenesis	O
.	O

These	O
conclusions	O
are	O
surprising	O
when	O
one	O
considers	O
that	O
the	O
potent	O
interaction	O
of	O
lisuride	B-CHEMICAL
with	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptors	O
has	O
been	O
demonstrated	O
in	O
several	O
different	O
laboratories	O
and	O
that	O
activation	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
receptors	O
can	O
modulate	O
dopaminergically	O
mediated	O
responses	O
.	O

OBJECTIVE	O
:	O
The	O
lack	O
of	O
full	O
substitution	O
of	O
lisuride	B-CHEMICAL
for	O
lysergic	B-CHEMICAL
acid	I-CHEMICAL
diethylamide	I-CHEMICAL
(	O
LSD	B-CHEMICAL
)	O
in	O
drug	O
discrimination	O
experiments	O
and	O
induction	O
of	O
a	O
pronounced	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
syndrome	O
by	O
this	O
compound	O
at	O
relatively	O
low	O
doses	O
convinced	O
us	O
to	O
execute	O
two	O
series	O
of	O
experiments	O
that	O
might	O
explain	O
the	O
primary	O
mechanism	O
responsible	O
for	O
lisuride	B-CHEMICAL
-	O
mediated	O
biological	O
effects	O
and	O
its	O
paradoxical	O
classification	O
as	O
a	O
dopamine	B-CHEMICAL
agonist	O
in	O
the	O
literature	O
.	O

RESULTS	O
:	O
In	O
drug	O
discrimination	O
studies	O
,	O
lisuride	B-CHEMICAL
fully	O
mimicked	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
agonist	O
LY	B-CHEMICAL
293284	I-CHEMICAL
,	O
only	O
partially	O
substituted	O
for	O
LSD	B-CHEMICAL
and	O
DOI	B-CHEMICAL
,	O
and	O
failed	O
to	O
substitute	O
for	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
.	O

Lisuride	B-CHEMICAL
produced	O
a	O
significant	O
dose	O
-	O
related	O
increase	O
in	O
flat	O
body	O
posture	O
,	O
forepaw	O
treading	O
,	O
and	O
lower	O
-	O
lip	O
retraction	O
which	O
reflect	O
a	O
modulation	O
of	O
behavior	O
by	O
action	O
at	O
central	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptors	O
.	O

Only	O
pMPPI	O
[	O
4	B-CHEMICAL
-	I-CHEMICAL
iodo	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
piperazinyl	I-CHEMICAL
]	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyridynyl	I-CHEMICAL
-	I-CHEMICAL
benzamide	I-CHEMICAL
hydrochloride	I-CHEMICAL
]	O
,	O
a	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
antagonist	O
,	O
was	O
effective	O
in	O
inhibiting	O
all	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
syndrome	O
behaviors	O
produced	O
by	O
lisuride	B-CHEMICAL
,	O
whereas	O
pMPPI	O
was	O
without	O
effect	O
on	O
any	O
behavior	O
induced	O
by	O
LSD	B-CHEMICAL
.	O

Lisuride	O
dose	O
dependently	O
decreased	O
body	O
temperature	O
in	O
rats	O
with	O
a	O
potency	O
similar	O
to	O
that	O
of	O
the	O
selective	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
agonist	O
LY	B-CHEMICAL
293284	I-CHEMICAL
.	O

The	O
hypothermic	O
effect	O
of	O
lisuride	B-CHEMICAL
was	O
prevented	O
by	O
pre	O
-	O
injection	O
of	O
pMPPI	O
,	O
but	O
not	O
by	O
ketanserin	B-CHEMICAL
or	O
haloperidol	B-CHEMICAL
.	O

CONCLUSION	O
:	O
We	O
have	O
demonstrated	O
that	O
the	O
behavioral	O
effects	O
of	O
low	O
doses	O
of	O
lisuride	B-CHEMICAL
are	O
clearly	O
mediated	O
by	O
stimulation	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptors	O
.	O

Stereospecific	O
inhibition	O
of	O
monoamine	B-GENE-N
uptake	I-GENE-N
transporters	I-GENE-N
by	O
meta	B-CHEMICAL
-	I-CHEMICAL
hydroxyephedrine	I-CHEMICAL
isomers	O
.	O

Meta	B-CHEMICAL
-	I-CHEMICAL
hydroxyephedrine	I-CHEMICAL
(	O
HED	B-CHEMICAL
)	O
comprises	O
four	O
stereoisomers	O
consisting	O
of	O
two	O
enantiomeric	O
pairs	O
related	O
to	O
ephedrine	B-CHEMICAL
and	O
pseudoephedrine	B-CHEMICAL
.	O

HED	B-CHEMICAL
is	O
transported	O
into	O
adrenergic	O
neurons	O
and	O
radiolabeled	O
HED	B-CHEMICAL
has	O
been	O
employed	O
in	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
to	O
image	O
adrenergic	O
neurons	O
in	O
vivo	O
.	O

To	O
extend	O
structure	O
-	O
activity	O
analyses	O
of	O
binding	O
sites	O
within	O
monoamine	B-GENE-N
transporters	I-GENE-N
and	O
to	O
determine	O
which	O
stereoisomer	O
displayed	O
the	O
best	O
selectivity	O
for	O
PET	O
imaging	O
applications	O
,	O
we	O
tested	O
the	O
HED	B-CHEMICAL
compounds	O
for	O
their	O
abilities	O
to	O
inhibit	O
[	O
(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	O
neurotransmitter	O
uptake	O
into	O
platelets	O
,	O
transfected	O
cells	O
,	O
and	O
chromaffin	O
vesicles	O
.	O

We	O
hypothesized	O
that	O
the	O
HED	B-CHEMICAL
compounds	O
would	O
be	O
most	O
potent	O
at	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
(	O
NET	B-GENE-Y
)	O
compared	O
to	O
the	O
serotonin	B-GENE-N
or	I-GENE-N
dopamine	I-GENE-N
transporters	I-GENE-N
and	O
that	O
the	O
1R	O
diastereomers	O
would	O
be	O
more	O
effective	O
than	O
1S	O
diastereomers	O
.	O

Supporting	O
the	O
hypotheses	O
,	O
all	O
stereoisomers	O
were	O
most	O
potent	O
at	O
the	O
NET	B-GENE-Y
and	O
the	O
1R	O
,	O
2S	O
stereoisomer	O
was	O
the	O
most	O
potent	O
inhibitor	O
overall	O
.	O

However	O
,	O
the	O
1S	O
,	O
2R	O
isomer	O
may	O
be	O
preferred	O
for	O
PET	O
applications	O
because	O
of	O
better	O
selectivity	O
among	O
the	O
transporters	O
and	O
reduced	O
neuronal	O
recycling	O
.	O

Escitalopram	B-CHEMICAL
.	O

Escitalopram	B-CHEMICAL
oxalate	I-CHEMICAL
(	O
S	B-CHEMICAL
-	I-CHEMICAL
citalopram	I-CHEMICAL
,	O
Lexapro	B-CHEMICAL
)	O
,	O
a	O
selective	O
serotonin	B-CHEMICAL
re	O
-	O
uptake	O
inhibitor	O
antidepressant	O
which	O
is	O
the	O
S	B-CHEMICAL
-	I-CHEMICAL
enantiomer	I-CHEMICAL
of	I-CHEMICAL
citalopram	I-CHEMICAL
,	O
is	O
in	O
clinical	O
development	O
worldwide	O
for	O
the	O
treatment	O
of	O
depression	O
and	O
anxiety	O
disorders	O
.	O

Preclinical	O
studies	O
demonstrate	O
that	O
the	O
therapeutic	O
activity	O
of	O
citalopram	B-CHEMICAL
resides	O
in	O
the	O
S	O
-	O
isomer	O
and	O
that	O
escitalopram	B-CHEMICAL
binds	O
with	O
high	O
affinity	O
to	O
the	O
human	B-GENE-Y
serotonin	I-GENE-Y
transporter	I-GENE-Y
.	O

Conversely	O
,	O
R	B-CHEMICAL
-	I-CHEMICAL
citalopram	I-CHEMICAL
is	O
approximately	O
30	O
-	O
fold	O
less	O
potent	O
than	O
escitalopram	B-CHEMICAL
at	O
this	O
transporter	O
.	O

Escitalopram	B-CHEMICAL
has	O
linear	O
pharmacokinetics	O
,	O
so	O
that	O
plasma	O
levels	O
increase	O
proportionately	O
and	O
predictably	O
with	O
increased	O
doses	O
and	O
its	O
half	O
-	O
life	O
of	O
27	O
-	O
32	O
h	O
is	O
consistent	O
with	O
once	O
-	O
daily	O
dosing	O
.	O

In	O
addition	O
,	O
escitalopram	B-CHEMICAL
has	O
negligible	O
effects	O
on	O
cytochrome	B-GENE-N
P450	I-GENE-N
drug	O
-	O
metabolising	O
enzymes	O
in	O
vitro	O
,	O
suggesting	O
a	O
low	O
potential	O
for	O
drug	O
-	O
drug	O
interactions	O
.	O

The	O
efficacy	O
of	O
escitalopram	B-CHEMICAL
in	O
patients	O
with	O
major	O
depressive	O
disorder	O
has	O
been	O
demonstrated	O
in	O
multiple	O
short	O
-	O
term	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trials	O
,	O
three	O
of	O
which	O
included	O
citalopram	B-CHEMICAL
as	O
an	O
active	O
control	O
,	O
as	O
well	O
as	O
in	O
a	O
36	O
-	O
week	O
study	O
evaluating	O
efficacy	O
in	O
the	O
prevention	O
of	O
depression	O
relapse	O
.	O

In	O
these	O
studies	O
,	O
escitalopram	B-CHEMICAL
was	O
shown	O
to	O
have	O
robust	O
efficacy	O
in	O
the	O
treatment	O
of	O
depression	O
and	O
associated	O
symptoms	O
of	O
anxiety	O
relative	O
to	O
placebo	O
.	O

Efficacy	O
has	O
also	O
been	O
shown	O
in	O
treating	O
generalised	O
anxiety	O
disorder	O
,	O
panic	O
disorder	O
and	O
social	O
anxiety	O
disorder	O
.	O

Results	O
also	O
suggest	O
that	O
,	O
at	O
comparable	O
doses	O
,	O
escitalopram	B-CHEMICAL
demonstrates	O
clinically	O
relevant	O
and	O
statistically	O
significant	O
superiority	O
to	O
placebo	O
treatment	O
earlier	O
than	O
citalopram	B-CHEMICAL
.	O

Analysis	O
of	O
the	O
safety	O
database	O
shows	O
a	O
low	O
rate	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
,	O
and	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
escitalopram	B-CHEMICAL
10	O
mg	O
/	O
day	O
and	O
placebo	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
early	O
because	O
of	O
adverse	O
events	O
.	O

The	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
escitalopram	B-CHEMICAL
which	O
occurred	O
at	O
a	O
rate	O
greater	O
than	O
placebo	O
include	O
nausea	O
,	O
insomnia	O
,	O
ejaculation	O
disorder	O
,	O
diarrhoea	O
,	O
dry	O
mouth	O
and	O
somnolence	O
.	O

Only	O
nausea	O
occurred	O
in	O
>	O
10	O
%	O
of	O
escitalopram	B-CHEMICAL
-	O
treated	O
patients	O
.	O

Formation	O
of	O
Mallory	O
body	O
-	O
like	O
inclusions	O
and	O
cell	O
death	O
induced	O
by	O
deregulated	O
expression	O
of	O
keratin	B-GENE-Y
18	I-GENE-Y
.	O

Mallory	O
bodies	O
(	O
MBs	O
)	O
are	O
cytoplasmic	O
inclusions	O
that	O
contain	O
keratin	B-GENE-Y
8	I-GENE-Y
(	O
K8	B-GENE-Y
)	O
and	O
K18	B-GENE-Y
and	O
are	O
present	O
in	O
hepatocytes	O
of	O
individuals	O
with	O
alcoholic	B-CHEMICAL
liver	O
disease	O
,	O
nonalcoholic	B-CHEMICAL
steatohepatitis	O
,	O
or	O
benign	O
or	O
malignant	O
hepatocellular	O
neoplasia	O
.	O

Mice	O
fed	O
long	O
term	O
with	O
griseofulvin	B-CHEMICAL
are	O
an	O
animal	O
model	O
of	O
MB	O
formation	O
.	O

However	O
,	O
the	O
lack	O
of	O
a	O
cellular	O
model	O
has	O
impeded	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
this	O
process	O
.	O

Culture	O
of	O
HepG2	O
cells	O
with	O
griseofulvin	B-CHEMICAL
has	O
now	O
been	O
shown	O
to	O
induce	O
both	O
the	O
formation	O
of	O
intracellular	O
aggregates	O
containing	O
K18	B-GENE-Y
as	O
well	O
as	O
an	O
increase	O
in	O
the	O
abundance	O
of	O
K18	B-GENE-Y
mRNA	O
.	O

Overexpression	O
of	O
K18	B-GENE-Y
in	O
HepG2	O
,	O
HeLa	O
,	O
or	O
COS	O
-	O
7	O
cells	O
also	O
induced	O
the	O
formation	O
of	O
intracellular	O
aggregates	O
that	O
stained	O
with	O
antibodies	O
to	O
ubiquitin	B-GENE-N
and	O
with	O
rhodamine	B-CHEMICAL
B	I-CHEMICAL
(	O
characteristics	O
of	O
MBs	O
formed	O
in	O
vivo	O
)	O
,	O
eventually	O
leading	O
to	O
cell	O
death	O
.	O

The	O
MB	O
-	O
like	O
aggregates	O
were	O
deposited	O
around	O
centrosomes	O
and	O
disrupted	O
the	O
microtubular	O
array	O
.	O

Coexpression	O
of	O
K8	B-GENE-Y
with	O
K18	B-GENE-Y
restored	O
the	O
normal	O
fibrous	O
pattern	O
of	O
keratin	B-GENE-N
distribution	O
and	O
reduced	O
the	O
toxicity	O
of	O
K18	B-GENE-Y
.	O

In	O
contrast	O
,	O
an	O
NH	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	O
terminal	O
deletion	O
mutant	O
of	O
K8	B-GENE-Y
promoted	O
the	O
formation	O
of	O
intracellular	O
aggregates	O
even	O
in	O
the	O
absence	O
of	O
K18	B-GENE-Y
overexpression	O
.	O

Deregulated	O
expression	O
of	O
K18	B-GENE-Y
,	O
or	O
an	O
imbalance	O
between	O
K8	B-GENE-Y
and	O
K18	B-GENE-Y
,	O
may	O
thus	O
be	O
an	O
important	O
determinant	O
of	O
MB	O
formation	O
,	O
which	O
compromises	O
the	O
function	O
of	O
centrosomes	O
and	O
the	O
microtubule	O
network	O
and	O
leads	O
to	O
cell	O
death	O
.	O

Cyclooxygenase	B-GENE-N
and	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
inhibitors	O
protect	O
against	O
mononuclear	O
phagocyte	O
neurotoxicity	O
.	O

Neuroinflammation	O
and	O
oxidative	O
stress	O
are	O
believed	O
to	O
be	O
contributing	O
factors	O
to	O
neurodegeneration	O
in	O
normal	O
aging	O
,	O
as	O
well	O
as	O
in	O
age	O
-	O
related	O
neurological	O
disorders	O
.	O

Reactive	O
microglia	O
are	O
found	O
in	O
increased	O
numbers	O
in	O
aging	O
brain	O
and	O
are	O
prominently	O
associated	O
with	O
lesions	O
in	O
such	O
age	O
-	O
related	O
degenerative	O
conditions	O
as	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
.	O

In	O
vitro	O
,	O
stimulated	O
microglia	O
or	O
microglial	O
-	O
like	O
cells	O
secrete	O
neurotoxic	O
materials	O
and	O
are	O
generators	O
of	O
free	O
radicals	O
through	O
their	O
respiratory	O
burst	O
system	O
.	O

Agents	O
that	O
suppress	O
microglial	O
activation	O
are	O
therefore	O
candidates	O
for	O
neuroprotection	O
.	O

We	O
have	O
developed	O
quantitative	O
in	O
vitro	O
assays	O
for	O
measuring	O
neurotoxicity	O
of	O
microglia	O
or	O
other	O
mononuclear	O
phagocytes	O
.	O

Neuronal	O
like	O
SH	O
-	O
SY5Y	O
cells	O
are	O
cultured	O
in	O
supernatants	O
from	O
activated	O
cells	O
of	O
the	O
human	O
monocytic	O
THP	O
-	O
1	O
line	O
and	O
their	O
survival	O
is	O
followed	O
.	O

Respiratory	O
burst	O
is	O
directly	O
measured	O
on	O
the	O
activated	O
cells	O
.	O

We	O
tested	O
inhibitors	O
of	O
the	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
or	O
the	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
(	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
)	O
pathways	O
as	O
possible	O
neuroprotective	O
agents	O
.	O

The	O
COX	B-GENE-N
pathway	O
generates	O
inflammatory	O
prostaglandins	B-CHEMICAL
,	O
while	O
the	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
pathway	O
generates	O
inflammatory	O
leukotrienes	B-CHEMICAL
.	O

We	O
found	O
that	O
inhibitors	O
of	O
both	O
these	O
pathways	O
suppressed	O
neurotoxicity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

They	O
included	O
the	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitor	O
indomethacin	O
;	O
the	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
NS	B-CHEMICAL
-	I-CHEMICAL
398	I-CHEMICAL
;	O
the	O
mixed	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
ibuprofen	B-CHEMICAL
;	O
the	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
derivatives	O
of	O
indomethacin	B-CHEMICAL
,	O
ibuprofen	B-CHEMICAL
and	O
flurbiprofen	B-CHEMICAL
;	O
the	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
inhibitor	O
REV	B-CHEMICAL
5901	I-CHEMICAL
;	O
and	O
the	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
activating	I-GENE-Y
protein	I-GENE-Y
(	O
FLAP	B-GENE-Y
)	O
inhibitor	O
MK	B-CHEMICAL
-	I-CHEMICAL
886	I-CHEMICAL
.	O

The	O
FLAP	B-GENE-Y
inhibitor	O
also	O
reduced	O
respiratory	O
burst	O
activity	O
in	O
a	O
more	O
potent	O
manner	O
than	O
indomethacin	O
.	O

Combinations	O
of	O
COX	B-GENE-N
and	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
inhibitors	O
were	O
more	O
effective	O
than	O
single	O
inhibitors	O
.	O

The	O
data	O
suggest	O
that	O
both	O
COX	B-GENE-N
inhibitors	O
and	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
inhibitors	O
may	O
be	O
neuroprotective	O
in	O
vivo	O
by	O
suppressing	O
toxic	O
actions	O
of	O
microglia	O
/	O
macrophages	O
,	O
and	O
that	O
combinations	O
of	O
the	O
two	O
might	O
have	O
greater	O
therapeutic	O
potential	O
than	O
single	O
inhibitors	O
of	O
either	O
class	O
.	O

MDMA	B-CHEMICAL
-	O
and	O
p	B-CHEMICAL
-	I-CHEMICAL
chlorophenylalanine	I-CHEMICAL
-	O
induced	O
reduction	O
in	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
concentrations	O
:	O
effects	O
on	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
densities	O
.	O

Low	O
levels	O
of	O
serotonin	B-CHEMICAL
may	O
reduce	O
the	O
density	O
of	O
the	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
(	O
SERT	B-GENE-Y
)	O
by	O
either	O
increasing	O
trafficking	O
or	O
reducing	O
synthesis	O
;	O
a	O
"	O
neuroadaptive	O
response	O
"	O
.	O

To	O
determine	O
whether	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
)	O
-	O
induced	O
reductions	O
in	O
SERT	B-GENE-Y
density	O
could	O
be	O
related	O
to	O
such	O
a	O
mechanism	O
,	O
p	B-CHEMICAL
-	I-CHEMICAL
chlorophenylalanine	I-CHEMICAL
or	O
MDMA	B-CHEMICAL
was	O
administered	O
to	O
rats	O
,	O
and	O
brain	O
serotonin	B-CHEMICAL
and	O
SERT	B-GENE-Y
density	O
were	O
measured	O
.	O

As	O
expected	O
,	O
both	O
treatments	O
led	O
to	O
serotonin	B-CHEMICAL
depletion	O
1	O
,	O
7	O
and	O
14	O
days	O
later	O
.	O

However	O
,	O
only	O
MDMA	B-CHEMICAL
reduced	O
SERT	B-GENE-Y
density	O
.	O

This	O
observation	O
suggests	O
that	O
MDMA	B-CHEMICAL
-	O
induced	O
reductions	O
in	O
SERT	B-GENE-Y
density	O
do	O
not	O
represent	O
neuroadaptive	O
responses	O
to	O
decreased	O
levels	O
of	O
brain	O
serotonin	B-CHEMICAL
,	O
but	O
may	O
occur	O
in	O
response	O
to	O
some	O
other	O
stimulus	O
or	O
to	O
the	O
neurotoxic	O
effects	O
of	O
MDMA	B-CHEMICAL
.	O

Atomoxetine	B-CHEMICAL
increases	O
extracellular	O
levels	O
of	O
norepinephrine	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
in	O
prefrontal	O
cortex	O
of	O
rat	O
:	O
a	O
potential	O
mechanism	O
for	O
efficacy	O
in	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
.	O

The	O
selective	O
norepinephrine	B-GENE-Y
(	I-GENE-Y
NE	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
inhibitor	O
atomoxetine	B-CHEMICAL
(	O
formerly	O
called	O
tomoxetine	B-CHEMICAL
or	O
LY139603	B-CHEMICAL
)	O
has	O
been	O
shown	O
to	O
alleviate	O
symptoms	O
in	O
Attention	O
Deficit	O
/	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O

We	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
atomoxetine	B-CHEMICAL
in	O
ADHD	O
by	O
evaluating	O
the	O
interaction	O
of	O
atomoxetine	B-CHEMICAL
with	O
monoamine	B-GENE-N
transporters	I-GENE-N
,	O
the	O
effects	O
on	O
extracellular	O
levels	O
of	O
monoamines	B-CHEMICAL
,	O
and	O
the	O
expression	O
of	O
the	O
neuronal	O
activity	O
marker	O
Fos	B-GENE-Y
in	O
brain	O
regions	O
.	O

Atomoxetine	B-CHEMICAL
inhibited	O
binding	O
of	O
radioligands	O
to	O
clonal	O
cell	O
lines	O
transfected	O
with	O
human	B-GENE-N
NE	I-GENE-N
,	I-GENE-N
serotonin	I-GENE-N
(	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
)	I-GENE-N
and	I-GENE-N
dopamine	I-GENE-N
(	I-GENE-N
DA	I-GENE-N
)	I-GENE-N
transporters	I-GENE-N
with	O
dissociation	O
constants	O
(	O
K	O
(	O
i	O
)	O
)	O
values	O
of	O
5	O
,	O
77	O
and	O
1451	O
nM	O
,	O
respectively	O
,	O
demonstrating	O
selectivity	O
for	O
NE	B-GENE-Y
transporters	I-GENE-Y
.	O

In	O
microdialysis	O
studies	O
,	O
atomoxetine	B-CHEMICAL
increased	O
extracellular	O
(	O
EX	O
)	O
levels	O
of	O
NE	B-CHEMICAL
in	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
3	O
-	O
fold	O
,	O
but	O
did	O
not	O
alter	O
5	O
-	O
HT	O
(	O
EX	O
)	O
levels	O
.	O

Atomoxetine	B-CHEMICAL
also	O
increased	O
DA	O
(	O
EX	O
)	O
concentrations	O
in	O
PFC	O
3	O
-	O
fold	O
,	O
but	O
did	O
not	O
alter	O
DA	O
(	O
EX	O
)	O
in	O
striatum	O
or	O
nucleus	O
accumbens	O
.	O

In	O
contrast	O
,	O
the	O
psychostimulant	O
methylphenidate	B-CHEMICAL
,	O
which	O
is	O
used	O
in	O
ADHD	O
therapy	O
,	O
increased	O
NE	O
(	O
EX	O
)	O
and	O
DA	O
(	O
EX	O
)	O
equally	O
in	O
PFC	O
,	O
but	O
also	O
increased	O
DA	O
(	O
EX	O
)	O
in	O
the	O
striatum	O
and	O
nucleus	O
accumbens	O
to	O
the	O
same	O
level	O
.	O

The	O
expression	O
of	O
the	O
neuronal	O
activity	O
marker	O
Fos	B-GENE-Y
was	O
increased	O
3	O
.	O
7	O
-	O
fold	O
in	O
PFC	O
by	O
atomoxetine	B-CHEMICAL
administration	O
,	O
but	O
was	O
not	O
increased	O
in	O
the	O
striatum	O
or	O
nucleus	O
accumbens	O
,	O
consistent	O
with	O
the	O
regional	O
distribution	O
of	O
increased	O
DA	O
(	O
EX	O
)	O
.	O

We	O
hypothesize	O
that	O
the	O
atomoxetine	B-CHEMICAL
-	O
induced	O
increase	O
of	O
catecholamines	B-CHEMICAL
in	O
PFC	O
,	O
a	O
region	O
involved	O
in	O
attention	O
and	O
memory	O
,	O
mediates	O
the	O
therapeutic	O
effects	O
of	O
atomoxetine	B-CHEMICAL
in	O
ADHD	O
.	O

In	O
contrast	O
to	O
methylphenidate	B-CHEMICAL
,	O
atomoxetine	B-CHEMICAL
did	O
not	O
increase	O
DA	B-CHEMICAL
in	O
striatum	O
or	O
nucleus	O
accumbens	O
,	O
suggesting	O
it	O
would	O
not	O
have	O
motoric	O
or	O
drug	O
abuse	O
liabilities	O
.	O

Pharmacological	O
properties	O
of	O
the	O
anti	O
-	O
Parkinson	O
drug	O
rasagiline	B-CHEMICAL
;	O
modification	O
of	O
endogenous	O
brain	O
amines	B-CHEMICAL
,	O
reserpine	B-CHEMICAL
reversal	O
,	O
serotonergic	O
and	O
dopaminergic	O
behaviours	O
.	O

Rasagiline	B-CHEMICAL
[	O
N	B-CHEMICAL
-	I-CHEMICAL
propargyl	I-CHEMICAL
-	I-CHEMICAL
1R	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
aminoindan	I-CHEMICAL
;	O
TVP1012	B-CHEMICAL
]	O
is	O
a	O
potent	O
irreversible	O
monoamine	B-GENE-N
oxidase	I-GENE-N
(	O
MAO	B-GENE-N
)	O
inhibitor	O
with	O
selectivity	O
for	O
type	O
B	O
of	O
the	O
enzyme	O
,	O
which	O
is	O
being	O
developed	O
for	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

In	O
this	O
study	O
we	O
examined	O
effects	O
of	O
rasagiline	B-CHEMICAL
on	O
CNS	O
monoamine	B-CHEMICAL
levels	O
,	O
modification	O
of	O
behavioural	O
response	O
to	O
L	B-CHEMICAL
-	I-CHEMICAL
tryptophan	I-CHEMICAL
,	O
fluoxetine	B-CHEMICAL
and	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
,	O
and	O
reversal	O
of	O
reserpine	B-CHEMICAL
syndrome	O
.	O

Reserpine	B-CHEMICAL
-	O
induced	O
ptosis	O
was	O
reversed	O
by	O
rasagiline	B-CHEMICAL
at	O
doses	O
above	O
2	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
i	O
.	O
p	O
.	O
,	O
which	O
inhibit	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
as	O
well	O
as	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
,	O
but	O
not	O
at	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
-	O
selective	O
doses	O
.	O

However	O
,	O
combination	O
of	O
rasagiline	B-CHEMICAL
(	O
10	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
i	O
.	O
p	O
.	O
)	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
DOPA	I-CHEMICAL
or	O
L	B-CHEMICAL
-	I-CHEMICAL
tryptophan	I-CHEMICAL
(	O
50	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
i	O
.	O
p	O
.	O
)	O
,	O
or	O
rasagiline	B-CHEMICAL
(	O
10	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
p	O
.	O
o	O
.	O
)	O
with	O
fluoxetine	B-CHEMICAL
(	O
10	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
p	O
.	O
o	O
.	O
)	O
,	O
did	O
not	O
induce	O
the	O
behavioural	O
hyperactivity	O
syndrome	O
which	O
is	O
seen	O
following	O
inhibition	O
of	O
both	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
by	O
tranylcypromine	B-CHEMICAL
together	O
with	O
the	O
monoamine	B-CHEMICAL
precursors	O
.	O

Following	O
oral	O
administration	O
,	O
levels	O
of	O
noradrenaline	B-CHEMICAL
(	O
NA	B-CHEMICAL
)	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
and	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
were	O
unaffected	O
in	O
hippocampus	O
and	O
striatum	O
after	O
single	O
doses	O
of	O
rasagiline	B-CHEMICAL
up	O
to	O
2	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
.	O

Following	O
chronic	O
oral	O
administration	O
(	O
21	O
days	O
,	O
one	O
dose	O
daily	O
)	O
,	O
levels	O
of	O
NA	B-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
DA	B-CHEMICAL
in	O
hippocampus	O
and	O
striatum	O
were	O
unaffected	O
by	O
rasagiline	B-CHEMICAL
at	O
doses	O
up	O
to	O
1	O
mg	O
x	O
kg	O
(	O
-	O
1	O
)	O
.	O

Rasagiline	B-CHEMICAL
does	O
not	O
modify	O
CNS	O
monoamine	B-CHEMICAL
tissue	O
levels	O
or	O
monoamine	B-CHEMICAL
-	O
induced	O
behavioural	O
syndromes	O
at	O
doses	O
which	O
selectively	O
inhibit	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
but	O
not	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
.	O

L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
accumulation	O
and	O
freeze	O
tolerance	O
of	O
Saccharomyces	O
cerevisiae	O
are	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
PRO1	B-GENE-Y
gene	O
encoding	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
kinase	I-GENE-Y
.	O

We	O
previously	O
isolated	O
a	O
mutant	O
which	O
showed	O
a	O
high	O
tolerance	O
to	O
freezing	O
that	O
correlated	O
with	O
higher	O
levels	O
of	O
intracellular	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
derived	O
from	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
analogue	O
-	O
resistant	O
mutants	O
.	O

The	O
mutation	O
responsible	O
for	O
the	O
analogue	O
resistance	O
and	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
accumulation	O
was	O
a	O
single	O
nuclear	O
dominant	O
mutation	O
.	O

By	O
introducing	O
the	O
mutant	O
-	O
derived	O
genomic	O
library	O
into	O
a	O
non	O
-	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
-	O
utilizing	O
strain	O
,	O
the	O
mutant	O
was	O
found	O
to	O
carry	O
an	O
allele	O
of	O
the	O
wild	O
-	O
type	O
PRO1	B-GENE-Y
gene	O
encoding	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
kinase	I-GENE-Y
,	O
which	O
resulted	O
in	O
a	O
single	O
amino	B-CHEMICAL
acid	I-CHEMICAL
replacement	O
;	O
Asp	B-CHEMICAL
(	O
GAC	B-GENE-N
)	O
at	O
position	O
154	O
was	O
replaced	O
by	O
Asn	B-CHEMICAL
(	O
AAC	B-GENE-N
)	O
.	O

Interestingly	O
,	O
the	O
allele	O
of	O
PRO1	B-GENE-Y
was	O
shown	O
to	O
enhance	O
the	O
activities	O
of	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
kinase	I-GENE-Y
and	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
phosphate	I-GENE-Y
reductase	I-GENE-Y
,	O
both	O
of	O
which	O
catalyze	O
the	O
first	O
two	O
steps	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
synthesis	O
from	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
and	O
which	O
together	O
may	O
form	O
a	O
complex	O
in	O
vivo	O
.	O

When	O
cultured	O
in	O
liquid	O
minimal	O
medium	O
,	O
yeast	O
cells	O
expressing	O
the	O
mutated	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
kinase	I-GENE-Y
were	O
found	O
to	O
accumulate	O
intracellular	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
and	O
showed	O
a	O
prominent	O
increase	O
in	O
cell	O
viability	O
after	O
freezing	O
at	O
-	O
20	O
degrees	O
C	O
compared	O
to	O
the	O
viability	O
of	O
cells	O
harboring	O
the	O
wild	O
-	O
type	O
PRO1	B-GENE-Y
gene	O
.	O

These	O
results	O
suggest	O
that	O
the	O
altered	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
kinase	I-GENE-Y
results	O
in	O
stabilization	O
of	O
the	O
complex	O
or	O
has	O
an	O
indirect	O
effect	O
on	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
phosphate	I-GENE-Y
reductase	I-GENE-Y
activity	O
,	O
which	O
leads	O
to	O
an	O
increase	O
in	O
L	B-CHEMICAL
-	I-CHEMICAL
proline	I-CHEMICAL
production	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
approach	O
described	O
in	O
this	O
paper	O
could	O
be	O
a	O
practical	O
method	O
for	O
breeding	O
novel	O
freeze	O
-	O
tolerant	O
yeast	O
strains	O
.	O

Eprosartan	B-CHEMICAL
for	O
the	O
treatment	O
of	O
hypertension	O
.	O

Antihypertensive	O
agents	O
are	O
proven	O
to	O
reduce	O
the	O
cardiovascular	O
risk	O
of	O
stroke	O
,	O
coronary	O
heart	O
disease	O
and	O
cardiac	O
failure	O
.	O

The	O
ideal	O
antihypertensive	O
agent	O
should	O
control	O
all	O
grades	O
of	O
hypertension	O
and	O
have	O
a	O
placebo	O
-	O
like	O
side	O
effect	O
profile	O
.	O

Angiotensin	B-GENE-N
II	I-GENE-N
(	I-GENE-N
AII	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
antagonists	O
are	O
a	O
relatively	O
new	O
class	O
of	O
antihypertensive	O
agent	O
that	O
block	O
AII	B-GENE-Y
Type	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
AT	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
,	O
and	O
reduce	O
the	O
pressor	O
effects	O
of	O
AII	B-CHEMICAL
in	O
the	O
vasculature	O
.	O

By	O
this	O
mechanism	O
,	O
they	O
induce	O
similar	O
pharmacological	O
effects	O
compared	O
with	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
(	O
ACE	B-GENE-Y
)	O
inhibitors	O
,	O
resulting	O
in	O
a	O
lowering	O
of	O
blood	O
pressure	O
.	O

However	O
,	O
AII	B-GENE-N
receptor	I-GENE-N
blockers	O
differ	O
from	O
ACE	B-GENE-Y
inhibitors	O
with	O
respect	O
to	O
side	O
effects	O
,	O
and	O
induce	O
less	O
cough	O
,	O
a	O
side	O
effect	O
which	O
may	O
be	O
related	O
to	O
bradykinin	B-CHEMICAL
or	O
other	O
mediators	O
such	O
as	O
substance	B-CHEMICAL
P	I-CHEMICAL
.	O

Within	O
the	O
class	O
of	O
AII	B-CHEMICAL
blockers	O
,	O
eprosartan	B-CHEMICAL
differs	O
from	O
other	O
currently	O
available	O
agents	O
in	O
terms	O
of	O
chemical	O
structure	O
,	O
as	O
it	O
is	O
a	O
non	O
-	O
biphenyl	B-CHEMICAL
,	O
non	O
-	O
tetrazole	B-CHEMICAL
,	O
non	O
-	O
peptide	O
antagonist	O
with	O
a	O
dual	O
pharmacological	O
mode	O
of	O
action	O
.	O

Eprosartan	B-CHEMICAL
acts	O
at	O
vascular	O
AT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
(	O
postsynaptically	O
)	O
and	O
at	O
presynaptic	O
AT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
,	O
where	O
it	O
inhibits	O
sympathetically	O
stimulated	O
noradrenaline	B-CHEMICAL
release	O
.	O

Its	O
lack	O
of	O
metabolism	O
by	O
cytochrome	B-GENE-N
P450	I-GENE-N
enzymes	O
confers	O
a	O
low	O
potential	O
for	O
metabolic	O
drug	O
interactions	O
and	O
may	O
be	O
of	O
importance	O
when	O
treating	O
elderly	O
patients	O
and	O
those	O
on	O
multiple	O
drugs	O
.	O

In	O
clinical	O
trials	O
,	O
eprosartan	B-CHEMICAL
has	O
been	O
demonstrated	O
to	O
be	O
at	O
least	O
as	O
effective	O
in	O
reducing	O
blood	O
pressure	O
as	O
the	O
ACE	B-GENE-Y
inhibitor	O
enalapril	B-CHEMICAL
,	O
and	O
has	O
significantly	O
lower	O
side	O
effects	O
.	O

Eprosartan	B-CHEMICAL
is	O
safe	O
,	O
effective	O
and	O
well	O
-	O
tolerated	O
in	O
long	O
-	O
term	O
treatment	O
,	O
either	O
as	O
a	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
antihypertensive	O
drugs	O
such	O
as	O
hydrochlorothiazide	B-CHEMICAL
.	O

Mouse	B-GENE-Y
brain	I-GENE-Y
serine	I-GENE-Y
racemase	I-GENE-Y
catalyzes	O
specific	O
elimination	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
serine	I-CHEMICAL
to	O
pyruvate	B-CHEMICAL
.	O

D	B-CHEMICAL
-	I-CHEMICAL
Serine	I-CHEMICAL
was	O
previously	O
identified	O
in	O
mammalian	O
brain	O
and	O
was	O
shown	O
to	O
be	O
a	O
co	O
-	O
agonist	O
at	O
the	O
'	O
glycine	B-CHEMICAL
'	O
site	O
of	O
the	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
-	I-GENE-N
type	I-GENE-N
receptors	I-GENE-N
.	O

Racemization	O
of	O
serine	B-CHEMICAL
is	O
catalyzed	O
by	O
serine	B-GENE-Y
racemase	I-GENE-Y
,	O
a	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
-	O
dependent	O
enzyme	O
expressed	O
mainly	O
in	O
brain	O
and	O
liver	O
.	O

NMDA	B-GENE-N
receptor	I-GENE-N
overactivation	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
pathological	O
conditions	O
and	O
inhibitors	O
of	O
serine	B-GENE-Y
racemase	I-GENE-Y
are	O
thus	O
potentially	O
interesting	O
targets	O
for	O
therapy	O
.	O

We	O
expressed	O
recombinant	O
mouse	B-GENE-Y
serine	I-GENE-Y
racemase	I-GENE-Y
in	O
insect	O
cells	O
and	O
purified	O
it	O
to	O
near	O
homogeneity	O
.	O

The	O
enzyme	O
is	O
a	O
non	O
-	O
covalent	O
homodimer	O
in	O
solution	O
and	O
requires	O
divalent	O
cations	O
Mg	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
or	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
for	O
activity	O
but	O
not	O
for	O
dimerization	O
.	O

In	O
addition	O
to	O
the	O
racemization	O
it	O
also	O
catalyzes	O
specific	O
elimination	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
Ser	I-CHEMICAL
to	O
pyruvate	B-CHEMICAL
.	O

D	B-CHEMICAL
-	I-CHEMICAL
Serine	I-CHEMICAL
is	O
eliminated	O
much	O
less	O
efficiently	O
.	O

Both	O
L	B-CHEMICAL
-	I-CHEMICAL
serine	I-CHEMICAL
racemization	O
and	O
elimination	O
activities	O
of	O
serine	B-CHEMICAL
racemase	O
are	O
of	O
comparable	O
magnitude	O
,	O
display	O
alkaline	B-CHEMICAL
pH	O
optimum	O
and	O
are	O
negligible	O
below	O
pH	O
6	O
.	O
5	O
.	O

Sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
inhibits	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	O
induced	O
phosphorylation	O
of	O
extracellular	B-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
Bad	B-GENE-Y
in	O
human	O
colon	O
cancer	O
cells	O
.	O

Colorectal	O
cancer	O
is	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
death	O
in	O
the	O
United	O
States	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
including	O
sulindac	B-CHEMICAL
are	O
promising	O
chemopreventive	O
agents	O
for	O
colorectal	O
cancer	O
.	O

Sulindac	B-CHEMICAL
and	O
selective	O
cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
cause	O
regression	O
of	O
colonic	O
polyps	O
in	O
familial	O
polyposis	O
patients	O
.	O

Sulindac	B-CHEMICAL
induces	O
apoptotic	O
cell	O
death	O
in	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
tumor	O
cells	O
,	O
activation	O
of	O
extracellular	B-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	I-GENE-N
ERK	I-GENE-N
)	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
results	O
in	O
phosphorylation	O
of	O
several	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
effectors	O
,	O
including	O
the	O
proapoptotic	O
protein	O
Bad	B-GENE-Y
.	O

Phosphorylation	O
of	O
Ser112	B-CHEMICAL
by	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
inactivates	O
Bad	B-GENE-Y
and	O
protects	O
the	O
tumor	O
cell	O
from	O
apoptosis	O
.	O

Sulindac	B-CHEMICAL
metabolites	O
and	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
selectively	O
inhibit	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
phosphorylation	O
in	O
human	O
colon	O
cancer	O
cells	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
EGF	B-GENE-Y
)	O
strongly	O
induces	O
phosphorylation	O
of	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
Bad	B-GENE-Y
in	O
HT29	O
colon	O
cancer	O
cells	O
.	O

EGF	B-GENE-Y
-	O
stimulated	O
phosphorylation	O
of	O
ERK	B-GENE-N
and	O
Bad	B-GENE-Y
is	O
blocked	O
by	O
pretreatment	O
with	O
U0126	B-CHEMICAL
,	O
a	O
selective	O
MAP	B-GENE-N
kinase	I-GENE-N
kinase	I-GENE-N
(	I-GENE-N
MKK	I-GENE-N
)	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
inhibitor	O
.	O

Similarly	O
,	O
pretreatment	O
with	O
sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
blocks	O
the	O
ability	O
of	O
EGF	B-GENE-Y
to	O
induce	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
Bad	B-GENE-Y
phosphorylation	O
,	O
but	O
also	O
down	O
-	O
regulates	O
total	O
Bad	B-GENE-Y
but	O
not	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
protein	O
levels	O
.	O

The	O
ability	O
of	O
sulindac	B-CHEMICAL
to	O
block	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
signaling	O
by	O
the	O
EGF	B-GENE-Y
receptor	I-GENE-Y
may	O
account	O
for	O
at	O
least	O
part	O
of	O
its	O
potent	O
growth	O
-	O
inhibitory	O
effects	O
against	O
cancer	O
cells	O
.	O

DRF	B-CHEMICAL
2655	I-CHEMICAL
:	O
a	O
unique	O
molecule	O
that	O
reduces	O
body	O
weight	O
and	O
ameliorates	O
metabolic	O
abnormalities	O
.	O

OBJECTIVE	O
:	O
Preclinical	O
evaluation	O
of	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
,	O
a	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
(	O
PPARalpha	B-GENE-Y
)	O
and	O
PPARgamma	B-GENE-Y
agonist	O
,	O
as	O
a	O
body	O
-	O
weight	O
lowering	O
,	O
hypolipidemic	O
and	O
euglycemic	O
agent	O
.	O

RESEARCH	O
METHODS	O
AND	O
PROCEDURES	O
:	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
was	O
studied	O
in	O
different	O
genetic	O
,	O
normal	O
,	O
and	O
hyperlipidemic	O
animal	O
models	O
.	O

HEK	O
293	O
cells	O
were	O
used	O
to	O
conduct	O
the	O
reporter	O
-	O
based	O
transactivation	O
of	O
PPARalpha	B-GENE-Y
and	O
PPARgamma	B-GENE-Y
.	O

To	O
understand	O
the	O
biochemical	O
mechanism	O
of	O
lipid	O
-	O
,	O
body	O
-	O
weight	O
-	O
,	O
and	O
glucose	B-CHEMICAL
-	O
lowering	O
effects	O
,	O
activities	O
of	O
key	O
beta	O
-	O
oxidation	O
and	O
lipid	O
catabolism	O
enzymes	O
and	O
gluconeogenic	O
enzymes	O
were	O
studied	O
in	O
db	O
/	O
db	O
mice	O
treated	O
with	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
.	O

3T3L1	O
cells	O
were	O
used	O
for	O
adipogenesis	O
study	O
,	O
and	O
HepG2	O
cells	O
were	O
used	O
to	O
study	O
the	O
effect	O
of	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
on	O
total	O
cholesterol	B-CHEMICAL
and	O
triglyceride	B-CHEMICAL
synthesis	O
using	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
acetate	I-CHEMICAL
and	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
glycerol	I-CHEMICAL
.	O

RESULTS	O
:	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
showed	O
concentration	O
-	O
dependent	O
transactivation	O
of	O
PPARalpha	B-GENE-Y
and	O
PPARgamma	B-GENE-Y
.	O

In	O
the	O
3T3L1	O
cell	O
-	O
differentiation	O
study	O
,	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
and	O
rosiglitazone	B-CHEMICAL
showed	O
369	O
%	O
and	O
471	O
%	O
increases	O
,	O
respectively	O
,	O
in	O
triglyceride	B-CHEMICAL
accumulation	O
.	O

DRF	B-CHEMICAL
2655	I-CHEMICAL
showed	O
body	O
-	O
weight	O
lowering	O
and	O
euglycemic	O
and	O
hypolipidemic	O
effects	O
in	O
various	O
animal	O
models	O
.	O

db	O
/	O
db	O
mice	O
treated	O
with	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
showed	O
5	O
-	O
and	O
3	O
.	O
6	O
-	O
fold	O
inhibition	O
in	O
phosphoenolpyruvate	B-GENE-Y
carboxykinase	I-GENE-Y
and	O
glucose	B-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphatase	I-GENE-Y
activity	O
and	O
651	O
%	O
and	O
77	O
%	O
increases	O
in	O
the	O
beta	O
-	O
oxidation	O
enzymes	O
carnitine	B-GENE-N
palmitoyltransferase	I-GENE-N
and	O
carnitine	B-GENE-Y
acetyltransferase	I-GENE-Y
,	O
respectively	O
.	O

HepG2	O
cells	O
treated	O
with	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
showed	O
significant	O
reduction	O
in	O
lipid	O
synthesis	O
.	O

DISCUSSION	O
:	O
DRF	B-CHEMICAL
2655	I-CHEMICAL
showed	O
excellent	O
euglycemic	O
and	O
hypolipidemic	O
activities	O
in	O
different	O
animal	O
models	O
.	O

An	O
exciting	O
finding	O
is	O
its	O
body	O
-	O
weight	O
lowering	O
effect	O
in	O
these	O
models	O
,	O
which	O
might	O
be	O
mediated	O
by	O
the	O
induction	O
of	O
target	O
enzymes	O
involved	O
in	O
hepatic	O
lipid	O
catabolism	O
through	O
PPARalpha	B-GENE-Y
activation	O
.	O

Gonadotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
receptor	I-GENE-Y
gene	O
expression	O
during	O
pubertal	O
development	O
of	O
male	O
rats	O
.	O

Appropriate	O
expression	O
of	O
the	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
(	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
)	O
in	O
gonadotropes	O
is	O
critical	O
for	O
GnRH	B-CHEMICAL
signaling	O
and	O
hence	O
for	O
gonadotropin	B-GENE-N
secretion	O
and	O
sexual	O
development	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
the	O
ontogeny	O
of	O
the	O
steady	O
-	O
state	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
mRNA	O
levels	O
in	O
pituitaries	O
of	O
male	O
rats	O
from	O
Day	O
5	O
to	O
Day	O
55	O
,	O
when	O
sexual	O
maturity	O
is	O
attained	O
.	O

Developmental	O
changes	O
of	O
gonadotropin	B-GENE-N
subunit	O
(	O
alpha	O
,	O
FSHbeta	B-GENE-Y
,	O
and	O
LHbeta	B-GENE-Y
)	O
mRNA	O
levels	O
were	O
also	O
assessed	O
.	O

In	O
addition	O
,	O
the	O
role	O
of	O
the	O
endogenous	O
GnRH	B-CHEMICAL
on	O
the	O
maturational	O
changes	O
of	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
and	O
gonadotropin	B-GENE-N
subunit	O
gene	O
expression	O
was	O
investigated	O
.	O

Messenger	O
RNA	O
levels	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
of	O
total	O
RNA	O
from	O
anterior	O
pituitaries	O
.	O

Amounts	O
of	O
the	O
most	O
abundant	O
(	O
5	O
.	O
0	O
kb	O
)	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
mRNA	O
increased	O
slowly	O
from	O
Day	O
5	O
through	O
the	O
infantile	O
and	O
the	O
juvenile	O
periods	O
,	O
to	O
peak	O
at	O
Day	O
35	O
(	O
12	O
-	O
fold	O
increase	O
vs	O
.	O
Day	O
5	O
)	O
.	O

Thereafter	O
,	O
the	O
levels	O
of	O
the	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
mRNA	O
decline	O
slightly	O
until	O
Day	O
55	O
(	O
33	O
%	O
decrease	O
vs	O
.	O
Day	O
35	O
)	O
.	O

Parallel	O
changes	O
were	O
observed	O
on	O
the	O
4	O
.	O
5	O
-	O
kb	O
transcript	O
of	O
the	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
gene	O
.	O

Alpha	O
subunit	O
mRNA	O
was	O
easily	O
detected	O
at	O
Day	O
5	O
,	O
and	O
its	O
levels	O
increased	O
progressively	O
through	O
the	O
infantile	O
period	O
(	O
2	O
.	O
5	O
-	O
fold	O
increase	O
)	O
and	O
peaked	O
at	O
Day	O
25	O
(	O
3	O
.	O
3	O
-	O
fold	O
increase	O
vs	O
.	O
Day	O
5	O
)	O
with	O
a	O
smooth	O
nonstatistically	O
significant	O
increment	O
until	O
Day	O
35	O
;	O
then	O
it	O
decreased	O
by	O
41	O
.	O
5	O
%	O
at	O
Day	O
55	O
.	O

FSHbeta	B-GENE-Y
and	O
LHbeta	B-GENE-Y
mRNA	O
levels	O
rose	O
slowly	O
until	O
Day	O
25	O
.	O

A	O
sharp	O
rise	O
occurred	O
thereafter	O
to	O
reach	O
maximum	O
levels	O
at	O
Day	O
35	O
(	O
5	O
.	O
8	O
-	O
fold	O
for	O
FSHbeta	B-GENE-Y
and	O
3	O
.	O
8	O
-	O
fold	O
for	O
LHbeta	B-GENE-Y
vs	O
.	O
Day	O
25	O
)	O
.	O

Thereafter	O
,	O
the	O
levels	O
of	O
both	O
mRNAs	O
fell	O
until	O
Day	O
55	O
(	O
44	O
.	O
1	O
%	O
decrease	O
for	O
FSHbeta	B-GENE-Y
and	O
37	O
.	O
1	O
%	O
decrease	O
for	O
LHbeta	B-GENE-Y
vs	O
.	O
Day	O
35	O
)	O
.	O

To	O
ascertain	O
whether	O
developmental	O
activation	O
of	O
the	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
and	O
gonadotropin	B-GENE-N
subunit	O
gene	O
expression	O
is	O
GnRH	B-CHEMICAL
dependent	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
blocking	O
the	O
endogenous	O
GnRH	B-CHEMICAL
action	O
by	O
treating	O
developing	O
male	O
rats	O
with	O
the	O
specific	O
GnRH	B-CHEMICAL
antagonist	O
cetrorelix	O
(	O
1	O
.	O
5	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
week	O
,	O
s	O
.	O
c	O
.	O
)	O
through	O
the	O
infantile	O
(	O
Days	O
5	O
-	O
20	O
)	O
and	O
the	O
juvenile	O
periods	O
(	O
Days	O
20	O
-	O
35	O
)	O
.	O

Cetrorelix	B-CHEMICAL
completely	O
blocked	O
the	O
rise	O
of	O
levels	O
of	O
the	O
two	O
most	O
abundant	O
species	O
,	O
5	O
.	O
0	O
kb	O
and	O
4	O
.	O
5	O
kb	O
,	O
of	O
the	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
mRNA	O
,	O
during	O
both	O
the	O
infantile	O
and	O
the	O
juvenile	O
periods	O
.	O

Cetrorelix	B-CHEMICAL
also	O
abolished	O
the	O
developmental	O
rise	O
of	O
the	O
gonadotropin	B-GENE-N
beta	I-GENE-N
subunit	O
mRNAs	O
during	O
the	O
two	O
periods	O
of	O
the	O
study	O
.	O

In	O
contrast	O
,	O
the	O
alpha	O
subunit	O
gene	O
expression	O
was	O
not	O
altered	O
by	O
cetrorelix	O
treatment	O
during	O
any	O
of	O
the	O
two	O
periods	O
.	O

These	O
data	O
demonstrate	O
that	O
sexual	O
maturation	O
of	O
male	O
rats	O
is	O
accompanied	O
by	O
a	O
progressive	O
and	O
concerted	O
induction	O
of	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
and	O
gonadotropin	B-GENE-N
subunit	O
gene	O
expression	O
.	O

Developmental	O
activation	O
of	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
and	O
gonadotropin	B-GENE-N
beta	I-GENE-N
subunit	O
genes	O
is	O
GnRH	B-CHEMICAL
dependent	O
.	O

The	O
apparent	O
GnRH	B-CHEMICAL
-	O
independent	O
regulation	O
of	O
the	O
alpha	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
subunit	O
mRNA	O
levels	O
may	O
be	O
due	O
to	O
the	O
contribution	O
of	O
thyrotropes	O
and	O
perhaps	O
to	O
the	O
presence	O
of	O
exclusive	O
regulatory	O
signals	O
for	O
this	O
gene	O
.	O

Long	O
-	O
term	O
use	O
of	O
sildenafil	B-CHEMICAL
.	O

The	O
treatment	O
of	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
has	O
been	O
revolutionised	O
by	O
new	O
agents	O
to	O
inhibit	O
the	O
enzyme	O
PDE5	B-GENE-Y
.	O

The	O
scientific	O
basis	O
of	O
this	O
treatment	O
of	O
ED	O
includes	O
relaxation	O
of	O
the	O
corpus	O
cavernosum	O
smooth	O
muscle	O
tissue	O
by	O
inhibition	O
of	O
PDE5	B-GENE-Y
that	O
breaks	O
down	O
cGMP	B-CHEMICAL
,	O
the	O
key	O
pathway	O
for	O
the	O
production	O
of	O
erectile	O
function	O
in	O
humans	O
.	O

Many	O
clinical	O
studies	O
,	O
both	O
pre	O
-	O
and	O
post	O
-	O
marketing	O
,	O
have	O
demonstrated	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
sildenafil	B-CHEMICAL
(	O
Viagra	B-CHEMICAL
,	O
Pfizer	O
)	O
-	O
the	O
first	O
approved	O
selective	O
PDE	B-GENE-N
inhibitor	O
for	O
the	O
treatment	O
of	O
ED	O
.	O

Sildenafil	B-CHEMICAL
is	O
inhibitory	O
of	O
PDE5	B-GENE-Y
at	O
a	O
rate	O
tenfold	O
higher	O
than	O
for	O
the	O
next	O
PDE	B-GENE-N
(	O
PDE6	B-GENE-N
)	O
,	O
which	O
produces	O
visual	O
changes	O
through	O
the	O
retinal	O
rods	O
.	O

Its	O
clinical	O
effectiveness	O
has	O
been	O
well	O
documented	O
in	O
the	O
majority	O
of	O
men	O
with	O
ED	O
irrespective	O
of	O
aetiology	O
.	O

The	O
aetiology	O
of	O
ED	O
,	O
also	O
,	O
does	O
not	O
appear	O
to	O
effect	O
the	O
function	O
of	O
sildenafil	B-CHEMICAL
in	O
relaxing	O
corpus	O
cavernosum	O
smooth	O
muscle	O
tissue	O
.	O

Adverse	O
events	O
are	O
usually	O
associated	O
with	O
the	O
vascular	O
changes	O
from	O
PDE5	B-GENE-Y
inhibition	O
.	O

These	O
include	O
headache	O
and	O
flushing	O
.	O

Each	O
of	O
these	O
adverse	O
events	O
,	O
however	O
,	O
declines	O
with	O
medication	O
use	O
.	O

With	O
the	O
use	O
of	O
sildenafil	B-CHEMICAL
,	O
it	O
has	O
been	O
clearly	O
,	O
clinically	O
demonstrated	O
that	O
the	O
selective	O
inhibition	O
of	O
PDE5	B-GENE-Y
is	O
an	O
appropriate	O
,	O
effective	O
,	O
safe	O
method	O
for	O
the	O
treatment	O
of	O
ED	O
of	O
all	O
aetiologies	O
and	O
severities	O
.	O

Effects	O
of	O
serine	B-GENE-N
/	I-GENE-N
threonine	I-GENE-N
protein	I-GENE-N
phosphatase	I-GENE-N
inhibitors	O
on	O
morphine	B-CHEMICAL
-	O
induced	O
antinociception	O
in	O
the	O
tail	O
flick	O
test	O
in	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
serine	B-GENE-N
/	I-GENE-N
threonine	I-GENE-N
protein	I-GENE-N
phosphatase	I-GENE-N
(	O
PP	B-GENE-N
)	O
inhibitors	O
on	O
morphine	B-CHEMICAL
-	O
induced	O
antinociception	O
in	O
the	O
tail	O
flick	O
test	O
in	O
mice	O
,	O
and	O
on	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
naloxone	I-CHEMICAL
binding	O
to	O
the	O
forebrain	O
crude	O
synaptosome	O
fraction	O
.	O

Neither	O
okadaic	B-CHEMICAL
acid	I-CHEMICAL
nor	O
cantharidin	B-CHEMICAL
(	O
1	O
-	O
10000	O
nM	O
)	O
displaced	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
naloxone	I-CHEMICAL
from	O
its	O
specific	O
binding	O
sites	O
,	O
which	O
indicates	O
that	O
they	O
do	O
not	O
interact	O
at	O
the	O
opioid	B-GENE-N
receptor	I-GENE-N
level	O
.	O

The	O
i	O
.	O
c	O
.	O
v	O
.	O
administration	O
of	O
very	O
low	O
doses	O
of	O
okadaic	B-CHEMICAL
acid	I-CHEMICAL
(	O
0	O
.	O
001	O
-	O
1	O
pg	O
/	O
mouse	O
)	O
and	O
cantharidin	B-CHEMICAL
(	O
0	O
.	O
001	O
-	O
1	O
ng	O
/	O
mouse	O
)	O
,	O
which	O
inhibit	O
PP2A	B-GENE-N
,	O
produced	O
a	O
dose	O
-	O
dependent	O
antagonism	O
of	O
the	O
antinociception	O
induced	O
by	O
morphine	B-CHEMICAL
(	O
s	O
.	O
c	O
.	O
)	O
.	O

However	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
nor	I-CHEMICAL
-	I-CHEMICAL
okadaone	I-CHEMICAL
(	O
0	O
.	O
001	O
pg	O
/	O
mouse	O
-	O
1	O
ng	O
/	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
,	O
an	O
analogue	O
of	O
okadaic	B-CHEMICAL
acid	I-CHEMICAL
lacking	O
activity	O
against	O
protein	B-GENE-N
phosphatases	I-GENE-N
,	O
did	O
not	O
affect	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B-CHEMICAL
.	O

On	O
the	O
other	O
hand	O
,	O
high	O
doses	O
of	O
okadaic	B-CHEMICAL
acid	I-CHEMICAL
(	O
10	O
ng	O
/	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
and	O
cantharidin	B-CHEMICAL
(	O
1	O
microg	O
/	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
,	O
which	O
also	O
block	O
PP1	B-GENE-N
,	O
and	O
calyculin	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
(	O
0	O
.	O
1	O
fg	O
/	O
mouse	O
-	O
1	O
ng	O
/	O
mouse	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
,	O
which	O
inhibits	O
equally	O
both	O
PP1	B-GENE-N
and	O
PP2A	B-GENE-N
,	O
did	O
not	O
modify	O
the	O
morphine	B-CHEMICAL
-	O
induced	O
antinociception	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
type	B-GENE-N
2A	I-GENE-N
serine	I-GENE-N
/	I-GENE-N
threonine	I-GENE-N
protein	I-GENE-N
phosphatases	I-GENE-N
may	O
play	O
a	O
role	O
in	O
the	O
antinociceptive	O
effect	O
of	O
morphine	B-CHEMICAL
,	O
and	O
that	O
PP1	B-GENE-N
might	O
counterbalace	O
this	O
activity	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
liver	O
and	O
muscle	O
isoforms	O
of	O
ovine	B-GENE-Y
carnitine	I-GENE-Y
palmitoyltransferase	I-GENE-Y
1	I-GENE-Y
:	O
residues	O
within	O
the	O
N	B-CHEMICAL
-	O
terminus	O
of	O
the	O
muscle	O
isoform	O
influence	O
the	O
kinetic	O
properties	O
of	O
the	O
enzyme	O
.	O

The	O
nucleotide	B-CHEMICAL
sequence	O
data	O
reported	O
will	O
appear	O
in	O
DDBJ	O
,	O
EMBL	O
,	O
GenBank	O
(	O
R	O
)	O
and	O
GSDB	O
Nucleotide	B-CHEMICAL
Sequence	O
Databases	O
;	O
the	O
sequences	O
of	O
ovine	B-GENE-Y
CPT1A	I-GENE-Y
and	O
CPT1B	B-GENE-Y
cDNAs	O
have	O
the	O
accession	O
numbers	O
Y18387	B-GENE-Y
and	O
AJ272435	B-GENE-Y
respectively	O
and	O
the	O
partial	O
adipose	O
tissue	O
and	O
liver	O
CPT1A	B-GENE-Y
clones	O
have	O
the	O
accession	O
numbers	O
Y18830	B-GENE-Y
and	O
Y18829	B-GENE-Y
respectively	O
.	O

Fatty	B-CHEMICAL
acid	I-CHEMICAL
and	O
ketone	B-CHEMICAL
body	O
metabolism	O
differ	O
considerably	O
between	O
monogastric	O
and	O
ruminant	O
species	O
.	O

The	O
regulation	O
of	O
the	O
key	O
enzymes	O
involved	O
may	O
differ	O
accordingly	O
.	O

Carnitine	B-GENE-Y
palmitoyltransferase	I-GENE-Y
1	I-GENE-Y
(	O
CPT	B-GENE-Y
1	I-GENE-Y
)	O
is	O
the	O
key	O
locus	O
for	O
the	O
control	O
of	O
long	O
-	O
chain	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
beta	O
-	O
oxidation	O
and	O
liver	O
ketogenesis	O
.	O

Previously	O
we	O
showed	O
that	O
CPT	B-GENE-N
1	I-GENE-N
kinetics	O
in	O
sheep	O
and	O
rat	O
liver	O
mitochondria	O
differ	O
.	O

We	O
cloned	O
cDNAs	O
for	O
both	O
isoforms	O
[	O
liver	O
-	O
(	O
L	O
-	O
)	O
and	O
muscle	O
-	O
(	O
M	O
-	O
)	O
]	O
of	O
ovine	B-GENE-Y
CPT	I-GENE-Y
1	I-GENE-Y
in	O
order	O
to	O
elucidate	O
the	O
structural	O
features	O
of	O
these	O
proteins	O
and	O
their	O
genes	O
(	O
CPT1A	B-GENE-Y
and	O
CPT1B	B-GENE-Y
)	O
.	O

Their	O
deduced	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequences	O
show	O
a	O
high	O
degree	O
of	O
conservation	O
compared	O
with	O
orthologues	O
from	O
other	O
mammalian	O
species	O
,	O
with	O
the	O
notable	O
exception	O
of	O
the	O
N	B-CHEMICAL
-	O
terminus	O
of	O
ovine	B-GENE-Y
M	I-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
1	I-GENE-Y
.	O

These	O
differences	O
were	O
also	O
present	O
in	O
bovine	B-GENE-Y
M	I-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
1	I-GENE-Y
,	O
whose	O
N	B-CHEMICAL
-	O
terminal	O
sequence	O
we	O
determined	O
.	O

In	O
addition	O
,	O
the	O
5	O
'	O
-	O
end	O
of	O
the	O
sheep	B-GENE-Y
CPT1B	I-GENE-Y
cDNA	O
suggested	O
a	O
different	O
promoter	O
architecture	O
when	O
compared	O
with	O
previously	O
characterized	O
CPT1B	B-GENE-Y
genes	O
.	O

Northern	O
blotting	O
revealed	O
differences	O
in	O
tissue	O
distribution	O
for	O
both	O
CPT1A	B-GENE-Y
and	O
CPT1B	B-GENE-Y
transcripts	O
compared	O
with	O
other	O
species	O
.	O

In	O
particular	O
,	O
ovine	B-GENE-Y
CPT1B	I-GENE-Y
mRNA	O
was	O
less	O
tissue	O
restricted	O
,	O
and	O
the	O
predominant	O
transcript	O
in	O
the	O
pancreas	O
was	O
CPT1B	B-GENE-Y
.	O

Expression	O
in	O
yeast	O
allowed	O
kinetic	O
characterization	O
of	O
the	O
two	O
native	O
enzymes	O
,	O
and	O
of	O
a	O
chimaera	O
in	O
which	O
the	O
distinctive	O
N	B-CHEMICAL
-	O
terminal	O
segment	O
of	O
ovine	B-GENE-Y
M	I-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
1	I-GENE-Y
was	O
replaced	O
with	O
that	O
from	O
rat	B-GENE-Y
M	I-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
1	I-GENE-Y
.	O

The	O
ovine	O
N	B-CHEMICAL
-	O
terminal	O
segment	O
influences	O
the	O
kinetics	O
of	O
the	O
enzyme	O
for	O
both	O
its	O
substrates	O
,	O
such	O
that	O
the	O
K	O
(	O
m	O
)	O
for	O
palmitoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
is	O
decreased	O
and	O
that	O
for	O
carnitine	B-CHEMICAL
is	O
increased	O
for	O
the	O
chimaera	O
,	O
relative	O
to	O
the	O
parental	O
ovine	B-GENE-Y
M	I-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
1	I-GENE-Y
.	O

Thyroid	B-GENE-N
hormone	I-GENE-N
receptors	I-GENE-N
/	O
THR	B-GENE-N
genes	O
in	O
human	O
cancer	O
.	O

Thyroid	B-CHEMICAL
hormone	I-CHEMICAL
(	O
triiodothyronine	B-CHEMICAL
,	O
T3	O
)	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
growth	O
,	O
differentiation	O
and	O
tissue	O
homeostasis	O
in	O
higher	O
organisms	O
that	O
acts	O
through	O
the	O
control	O
of	O
target	O
gene	O
expression	O
.	O

Most	O
,	O
if	O
not	O
all	O
,	O
major	O
T3	O
actions	O
are	O
mediated	O
by	O
specific	O
high	O
affinity	O
nuclear	B-GENE-N
receptors	I-GENE-N
(	O
TR	B-GENE-N
)	O
which	O
are	O
encoded	O
by	O
two	O
genes	O
,	O
THRA	B-GENE-Y
and	O
THRB	B-GENE-Y
.	O

Several	O
TRalpha	B-GENE-Y
and	O
TRbeta	B-GENE-Y
receptor	O
isoforms	O
are	O
expressed	O
.	O

Abundant	O
and	O
contradictory	O
literature	O
exists	O
on	O
the	O
relationship	O
between	O
circulating	O
thyroid	B-CHEMICAL
hormone	I-CHEMICAL
levels	O
,	O
thyroid	O
diseases	O
and	O
human	O
cancer	O
.	O

In	O
1986	O
,	O
a	O
connection	O
between	O
TR	B-GENE-N
and	O
cancer	O
became	O
evident	O
when	O
the	O
chicken	B-GENE-Y
TRalpha1	I-GENE-Y
was	O
characterized	O
as	O
the	O
c	B-GENE-Y
-	I-GENE-Y
erbA	I-GENE-Y
proto	O
-	O
oncogene	O
,	O
the	O
cellular	O
counterpart	O
of	O
the	O
retroviral	O
v	B-GENE-N
-	I-GENE-N
erbA	I-GENE-N
oncogene	O
.	O

V	B-GENE-N
-	I-GENE-N
erbA	I-GENE-N
causes	O
erythroleukemias	O
and	O
sarcomas	O
in	O
birds	O
,	O
and	O
hepatocellular	O
carcinomas	O
in	O
transgenic	O
mice	O
.	O

In	O
recent	O
years	O
,	O
many	O
studies	O
have	O
analyzed	O
the	O
presence	O
of	O
quantitative	O
(	O
abnormal	O
levels	O
)	O
or	O
qualitative	O
(	O
mutations	O
)	O
alterations	O
in	O
the	O
expression	O
of	O
THR	B-GENE-N
genes	O
in	O
different	O
types	O
of	O
human	O
neoplasias	O
.	O

While	O
their	O
role	O
in	O
tumor	O
generation	O
or	O
progression	O
is	O
currently	O
unclear	O
,	O
both	O
gross	O
chromosomal	O
and	O
minor	O
mutations	O
(	O
deletions	O
,	O
aberrant	O
splicing	O
,	O
point	O
mutations	O
)	O
and	O
changes	O
in	O
the	O
level	O
of	O
expression	O
of	O
THRA	B-GENE-Y
and	O
THRB	B-GENE-Y
genes	O
have	O
been	O
found	O
.	O

Together	O
with	O
other	O
in	O
vitro	O
data	O
indicating	O
connections	O
between	O
TR	B-GENE-N
and	O
p53	B-GENE-Y
,	O
Rb	B-GENE-Y
,	O
cyclin	B-GENE-N
D	I-GENE-N
and	O
other	O
cell	O
cycle	O
regulators	O
and	O
oncogenes	O
,	O
these	O
results	O
suggest	O
that	O
THRA	B-GENE-Y
and	O
THRB	B-GENE-Y
may	O
be	O
involved	O
in	O
human	O
cancer	O
.	O

Investigating	O
the	O
regulation	O
of	O
one	O
-	O
carbon	B-CHEMICAL
metabolism	O
in	O
Arabidopsis	O
thaliana	O
.	O

Serine	B-CHEMICAL
(	O
Ser	B-CHEMICAL
)	O
biosynthesis	O
in	O
C	O
(	O
3	O
)	O
plants	O
can	O
occur	O
via	O
several	O
pathways	O
.	O

One	O
major	O
route	O
involves	O
the	O
tetrahydrofolate	B-CHEMICAL
(	O
THF	B-CHEMICAL
)	O
-	O
dependent	O
activities	O
of	O
the	O
glycine	B-GENE-N
decarboxylase	I-GENE-N
complex	I-GENE-N
(	O
GDC	B-GENE-N
,	O
EC	B-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
10	I-GENE-Y
)	O
and	O
serine	B-GENE-N
hydroxymethyltransferase	I-GENE-N
(	O
SHMT	B-GENE-N
,	O
EC	B-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
with	O
glycine	B-CHEMICAL
(	O
Gly	B-CHEMICAL
)	O
as	O
one	O
-	O
carbon	B-CHEMICAL
(	O
1	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
)	O
source	O
.	O

An	O
alternative	O
THF	B-CHEMICAL
-	O
dependent	O
pathway	O
involves	O
the	O
C1	B-GENE-Y
-	I-GENE-Y
THF	I-GENE-Y
synthase	I-GENE-Y
/	O
SHMT	B-GENE-N
activities	O
with	O
formate	B-CHEMICAL
as	O
1	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
source	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
aspects	O
of	O
the	O
regulation	O
of	O
these	O
two	O
folate	O
-	O
mediated	O
pathways	O
in	O
Arabidopsis	O
thaliana	O
(	O
L	O
.	O
)	O
Heynh	O
.	O

Columbia	O
using	O
two	O
approaches	O
.	O

Firstly	O
,	O
transgenic	O
plants	O
overexpressing	O
formate	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
FDH	B-GENE-Y
,	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
)	O
were	O
used	O
to	O
continue	O
our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
FDH	B-GENE-Y
in	O
formate	B-CHEMICAL
metabolism	O
.	O

The	O
formate	B-CHEMICAL
pool	O
size	O
was	O
approximately	O
73	O
nmol	O
(	O
g	O
FW	O
)	O
(	O
-	O
1	O
)	O
in	O
wild	O
type	O
(	O
WT	O
)	O
Arabidopsis	O
plants	O
;	O
three	O
independent	O
transgenic	O
lines	O
had	O
similar	O
-	O
sized	O
pools	O
of	O
formate	B-CHEMICAL
.	O

Transgenic	O
plants	O
produced	O
more	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
CO	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
from	O
supplied	O
[	B-CHEMICAL
(	I-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
formate	I-CHEMICAL
than	O
did	O
WT	O
plants	O
but	O
were	O
not	O
significantly	O
different	O
from	O
WT	O
plants	O
in	O
their	O
synthesis	O
of	O
Ser	B-CHEMICAL
.	O

We	O
concluded	O
that	O
FDH	B-GENE-Y
has	O
no	O
direct	O
role	O
in	O
the	O
regulation	O
of	O
the	O
above	O
two	O
pathways	O
of	O
Ser	B-CHEMICAL
synthesis	O
;	O
the	O
breakdown	O
of	O
formate	B-CHEMICAL
to	O
CO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
by	O
the	O
FDH	B-GENE-Y
reaction	O
is	O
the	O
primary	O
and	O
preferred	O
fate	O
of	O
the	O
organic	O
acid	O
in	O
Arabidopsis	O
.	O

The	O
ratio	O
between	O
the	O
GDC	B-GENE-N
/	O
SHMT	B-GENE-N
and	O
C1	B-GENE-Y
-	I-GENE-Y
THF	I-GENE-Y
synthase	I-GENE-Y
/	O
SHMT	B-GENE-N
pathways	O
of	O
Ser	B-CHEMICAL
synthesis	O
from	O
[	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
Gly	I-CHEMICAL
and	O
[	B-CHEMICAL
(	I-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
formate	I-CHEMICAL
,	O
respectively	O
,	O
in	O
Arabidopsis	O
shoots	O
was	O
21	O
:	O
1	O
;	O
in	O
roots	O
,	O
9	O
:	O
1	O
.	O

In	O
shoots	O
,	O
therefore	O
,	O
the	O
pathway	O
from	O
formate	B-CHEMICAL
plays	O
only	O
a	O
small	O
role	O
in	O
Ser	B-CHEMICAL
synthesis	O
;	O
in	O
the	O
case	O
of	O
roots	O
,	O
results	O
indicated	O
that	O
the	O
9	O
:	O
1	O
ratio	O
was	O
as	O
a	O
result	O
of	O
greater	O
fluxes	O
of	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
through	O
both	O
pathways	O
together	O
with	O
a	O
relatively	O
higher	O
contribution	O
from	O
the	O
C1	B-GENE-Y
-	I-GENE-Y
THF	I-GENE-Y
synthase	I-GENE-Y
/	O
SHMT	B-GENE-N
route	O
than	O
in	O
shoots	O
.	O

We	O
also	O
examined	O
the	O
synthesis	O
of	O
Ser	B-CHEMICAL
in	O
a	O
GDC	B-GENE-N
-	O
deficient	O
mutant	O
of	O
Arabidopsis	O
(	O
glyD	B-CHEMICAL
)	O
where	O
the	O
GDC	B-GENE-N
/	O
SHMT	B-GENE-N
pathway	O
was	O
impaired	O
.	O

Compared	O
with	O
WT	O
,	O
glyD	B-CHEMICAL
plants	O
accumulated	O
5	O
-	O
fold	O
more	O
Gly	B-CHEMICAL
than	O
WT	O
after	O
supplying	O
[	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
Gly	I-CHEMICAL
for	O
24	O
h	O
;	O
the	O
accumulation	O
of	O
Ser	B-CHEMICAL
from	O
[	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
Gly	I-CHEMICAL
was	O
reduced	O
by	O
25	O
%	O
in	O
the	O
same	O
time	O
period	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
accumulation	O
of	O
Ser	B-CHEMICAL
through	O
the	O
C1	B-GENE-Y
-	I-GENE-Y
THF	I-GENE-Y
synthase	I-GENE-Y
/	O
SHMT	B-GENE-N
pathway	O
in	O
glyD	B-CHEMICAL
plants	O
was	O
2	O
.	O
5	O
-	O
fold	O
greater	O
than	O
that	O
in	O
WT	O
plants	O
.	O

Our	O
experiments	O
confirmed	O
that	O
the	O
GDC	B-GENE-N
/	O
SHMT	B-GENE-N
and	O
C1	B-GENE-Y
-	I-GENE-Y
THF	I-GENE-Y
synthase	I-GENE-Y
/	O
SHMT	B-GENE-N
pathways	O
normally	O
operate	O
independently	O
in	O
Arabidopsis	O
plants	O
but	O
that	O
when	O
the	O
primary	O
GDC	B-GENE-N
/	O
SHMT	B-GENE-N
pathway	O
is	O
impaired	O
the	O
alternative	O
C1	B-GENE-Y
-	I-GENE-Y
THF	I-GENE-Y
synthase	I-GENE-Y
/	O
SHMT	B-GENE-N
pathway	O
can	O
partially	O
compensate	O
for	O
deficiencies	O
in	O
the	O
synthesis	O
of	O
Ser	B-CHEMICAL
.	O

Methionine	B-GENE-Y
adenosyltransferase	I-GENE-Y
II	I-GENE-Y
beta	I-GENE-Y
subunit	O
gene	O
expression	O
provides	O
a	O
proliferative	O
advantage	O
in	O
human	O
hepatoma	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Of	O
the	O
2	O
genes	O
(	O
MAT1A	B-GENE-Y
,	O
MAT2A	B-GENE-Y
)	O
encoding	O
methionine	B-GENE-N
adenosyltransferase	I-GENE-N
,	O
the	O
enzyme	O
that	O
synthesizes	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosylmethionine	I-CHEMICAL
,	O
MAT1A	B-GENE-Y
,	O
is	O
expressed	O
in	O
liver	O
,	O
whereas	O
MAT2A	B-GENE-Y
is	O
expressed	O
in	O
extrahepatic	O
tissues	O
.	O

In	O
liver	O
,	O
MAT2A	B-GENE-Y
expression	O
associates	O
with	O
growth	O
,	O
dedifferentiation	O
,	O
and	O
cancer	O
.	O

Here	O
,	O
we	O
identified	O
the	O
beta	O
subunit	O
as	O
a	O
regulator	O
of	O
proliferation	O
in	O
human	O
hepatoma	O
cell	O
lines	O
.	O

The	O
beta	O
subunit	O
has	O
been	O
cloned	O
and	O
shown	O
to	O
lower	O
the	O
K	O
(	O
m	O
)	O
of	O
methionine	B-GENE-Y
adenosyltransferase	I-GENE-Y
II	I-GENE-Y
alpha2	I-GENE-Y
(	O
the	O
MAT2A	B-GENE-Y
product	O
)	O
for	O
methionine	B-CHEMICAL
and	O
to	O
render	O
the	O
enzyme	O
more	O
susceptible	O
to	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosylmethionine	I-CHEMICAL
inhibition	O
.	O

METHODS	O
:	O
Methionine	B-GENE-N
adenosyltransferase	I-GENE-N
II	I-GENE-N
alpha2	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
subunit	O
expression	O
was	O
analyzed	O
in	O
human	O
and	O
rat	O
liver	O
and	O
hepatoma	O
cell	O
lines	O
and	O
their	O
interaction	O
studied	O
in	O
HuH7	O
cells	O
.	O
beta	O
Subunit	O
expression	O
was	O
up	O
-	O
and	O
down	O
-	O
regulated	O
in	O
human	O
hepatoma	O
cell	O
lines	O
and	O
the	O
effect	O
on	O
DNA	O
synthesis	O
determined	O
.	O

RESULTS	O
:	O
We	O
found	O
that	O
beta	O
subunit	O
is	O
expressed	O
in	O
rat	O
extrahepatic	O
tissues	O
but	O
not	O
in	O
normal	O
liver	O
.	O

In	O
human	O
liver	O
,	O
beta	O
subunit	O
expression	O
associates	O
with	O
cirrhosis	O
and	O
hepatoma	O
.	O
beta	O
Subunit	O
is	O
expressed	O
in	O
most	O
(	O
HepG2	O
,	O
PLC	O
,	O
and	O
Hep3B	O
)	O
but	O
not	O
all	O
(	O
HuH7	O
)	O
hepatoma	O
cell	O
lines	O
.	O

Transfection	O
of	O
beta	O
subunit	O
reduced	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosylmethionine	I-CHEMICAL
content	O
and	O
stimulated	O
DNA	O
synthesis	O
in	O
HuH7	O
cells	O
,	O
whereas	O
down	O
-	O
regulation	O
of	O
beta	O
subunit	O
expression	O
diminished	O
DNA	O
synthesis	O
in	O
HepG2	O
.	O

The	O
interaction	O
between	O
methionine	B-GENE-N
adenosyltransferase	I-GENE-N
II	I-GENE-N
alpha2	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
subunit	O
was	O
demonstrated	O
in	O
HuH7	O
cells	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
indicate	O
that	O
beta	O
subunit	O
associates	O
with	O
cirrhosis	O
and	O
cancer	O
providing	O
a	O
proliferative	O
advantage	O
in	O
hepatoma	O
cells	O
through	O
its	O
interaction	O
with	O
methionine	B-GENE-Y
adenosyltransferase	I-GENE-Y
II	I-GENE-Y
alpha2	I-GENE-Y
and	O
down	O
-	O
regulation	O
of	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosylmethionine	I-CHEMICAL
levels	O
.	O

Cloning	O
and	O
expression	O
of	O
a	O
heme	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
from	O
the	O
genome	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
YLR205c	B-GENE-Y
gene	O
of	O
Saccharomyces	O
cerevisiae	O
does	O
not	O
show	O
significant	O
sequence	O
identity	O
to	O
any	O
known	O
gene	O
,	O
except	O
for	O
heme	B-GENE-N
oxygenase	I-GENE-N
(	O
22	O
%	O
to	O
human	B-GENE-Y
HO	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
.	O

The	O
YLR205	B-GENE-N
ORF	I-GENE-N
was	O
cloned	O
and	O
overexpressed	O
in	O
both	O
Escherichia	O
coli	O
and	O
S	O
.	O
cerevisiae	O
.	O

Both	O
expression	O
systems	O
yielded	O
proteins	O
that	O
bound	O
heme	O
tightly	O
.	O

The	O
isolated	O
YLR205c	B-GENE-Y
protein	O
underwent	O
reduction	O
in	O
the	O
presence	O
of	O
either	O
NADPH	B-GENE-Y
-	I-GENE-Y
cytochrome	I-GENE-Y
P450	I-GENE-Y
reductase	I-GENE-Y
or	O
NADH	B-GENE-N
-	I-GENE-N
putidaredoxin	I-GENE-N
-	I-GENE-N
putidaredoxin	I-GENE-N
reductase	I-GENE-N
but	O
did	O
not	O
exhibit	O
heme	B-GENE-N
oxygenase	I-GENE-N
activity	O
.	O

The	O
protein	O
exhibited	O
modest	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
peroxidase	B-GENE-N
activities	O
with	O
guaiacol	B-CHEMICAL
,	O
potassium	B-CHEMICAL
iodide	I-CHEMICAL
,	O
and	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
'	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
azino	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
ethylbenzothiazoline	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
sulfonic	I-CHEMICAL
acid	I-CHEMICAL
(	O
ABTS	B-CHEMICAL
)	O
.	O

Thus	O
,	O
YLR205c	B-GENE-Y
codes	O
for	O
a	O
hemoprotein	B-GENE-N
of	O
unknown	O
physiological	O
function	O
that	O
exhibits	O
peroxidase	B-GENE-N
activity	O
.	O

GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
,	O
seizures	O
,	O
and	O
the	O
amygdala	O
.	O

The	O
amygdala	O
is	O
a	O
critical	O
brain	O
region	O
for	O
limbic	O
seizure	O
activity	O
,	O
but	O
the	O
mechanisms	O
underlying	O
its	O
epileptic	O
susceptibility	O
are	O
obscure	O
.	O

Several	O
lines	O
of	O
evidence	O
implicate	O
GluR5	B-GENE-Y
(	O
GLU	B-GENE-Y
(	I-GENE-Y
K5	I-GENE-Y
)	I-GENE-Y
)	O
kainate	B-GENE-N
receptors	I-GENE-N
,	O
a	O
type	O
of	O
ionotropic	B-GENE-N
glutamate	I-GENE-N
receptor	I-GENE-N
,	O
in	O
the	O
amygdala	O
'	O
s	O
vulnerability	O
to	O
seizures	O
and	O
epileptogenesis	O
.	O

GluR5	B-GENE-Y
mRNA	O
is	O
abundant	O
in	O
temporal	O
lobe	O
structures	O
including	O
the	O
amygdala	O
.	O

Brain	O
slice	O
recordings	O
indicate	O
that	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
mediate	O
a	O
portion	O
of	O
the	O
synaptic	O
excitation	O
of	O
neurons	O
in	O
the	O
rat	O
basolateral	O
amygdala	O
.	O

Whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
studies	O
demonstrate	O
that	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptor	I-GENE-N
-	O
mediated	O
synaptic	O
currents	O
are	O
inwardly	O
rectifying	O
and	O
are	O
likely	O
to	O
be	O
calcium	B-CHEMICAL
permeable	O
.	O

Prolonged	O
activation	O
of	O
basolateral	O
amygdala	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
results	O
in	O
enduring	O
synaptic	O
facilitation	O
through	O
a	O
calcium	B-CHEMICAL
-	O
dependent	O
process	O
.	O

The	O
selective	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptor	I-GENE-N
agonist	O
ATPA	O
induces	O
spontaneous	O
epileptiform	O
bursting	O
that	O
is	O
sensitive	O
to	O
the	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptor	I-GENE-N
antagonist	O
LY293558	B-CHEMICAL
.	O

Intra	O
-	O
amygdala	O
infusion	O
of	O
ATPA	O
in	O
the	O
rat	O
induces	O
limbic	O
status	O
epilepticus	O
;	O
in	O
some	O
animals	O
,	O
recurrent	O
spontaneous	O
seizures	O
occur	O
for	O
months	O
after	O
the	O
ATPA	O
treatment	O
.	O

Together	O
,	O
these	O
observations	O
indicate	O
that	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
have	O
a	O
unique	O
role	O
in	O
triggering	O
epileptiform	O
activity	O
in	O
the	O
amygdala	O
and	O
could	O
participate	O
in	O
long	O
-	O
term	O
plasticity	O
mechanisms	O
that	O
underlie	O
some	O
forms	O
of	O
epileptogenesis	O
.	O

Accordingly	O
,	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
represent	O
a	O
potential	O
target	O
for	O
antiepileptic	O
and	O
antiepileptogenic	O
drug	O
treatments	O
.	O

Most	O
antiepileptic	O
drugs	O
do	O
not	O
act	O
through	O
effects	O
on	O
glutamate	B-GENE-N
receptors	I-GENE-N
.	O

However	O
,	O
topiramate	B-CHEMICAL
at	O
low	O
concentrations	O
causes	O
slow	O
inhibition	O
of	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptor	I-GENE-N
-	O
mediated	O
synaptic	O
currents	O
in	O
the	O
basolateral	O
amygdala	O
,	O
indicating	O
that	O
it	O
may	O
protect	O
against	O
seizures	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
suppression	O
of	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptor	I-GENE-N
responses	O
.	O

Properties	O
of	O
purified	O
recombinant	O
human	B-GENE-N
polyamine	I-GENE-N
oxidase	I-GENE-N
,	O
PAOh1	B-GENE-Y
/	O
SMO	B-GENE-Y
.	O

The	O
discovery	O
of	O
an	O
inducible	O
oxidase	B-GENE-N
whose	O
apparent	O
substrate	O
preference	O
is	O
spermine	B-CHEMICAL
indicates	O
that	O
polyamine	B-CHEMICAL
catabolism	O
is	O
more	O
complex	O
than	O
that	O
originally	O
proposed	O
.	O

To	O
facilitate	O
the	O
study	O
of	O
this	O
enzyme	O
,	O
the	O
purification	O
and	O
characterization	O
of	O
the	O
recombinant	O
human	B-GENE-Y
PAOh1	I-GENE-Y
/	O
SMO	B-GENE-Y
polyamine	B-GENE-N
oxidase	I-GENE-N
are	O
reported	O
.	O

Purified	O
PAOh1	B-GENE-Y
/	O
SMO	B-GENE-Y
oxidizes	O
both	O
spermine	B-CHEMICAL
(	O
K	O
(	O
m	O
)	O
=	O
1	O
.	O
6	O
microM	O
)	O
and	O
N	B-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
acetylspermine	I-CHEMICAL
(	O
K	O
(	O
m	O
)	O
=	O
51	O
microM	O
)	O
,	O
but	O
does	O
not	O
oxidize	O
spermidine	B-CHEMICAL
.	O

The	O
purified	O
human	O
enzyme	O
also	O
does	O
not	O
oxidize	O
eight	O
representative	O
antitumor	O
polyamine	B-CHEMICAL
analogues	O
;	O
however	O
,	O
specific	O
oligamine	O
analogues	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
oxidation	O
of	O
spermine	B-CHEMICAL
by	O
PAOh1	B-GENE-Y
/	O
SMO	B-GENE-Y
.	O

The	O
results	O
of	O
these	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
PAOh1	B-GENE-Y
/	O
SMO	B-GENE-Y
represents	O
a	O
new	O
addition	O
to	O
the	O
polyamine	B-CHEMICAL
metabolic	O
pathway	O
that	O
may	O
represent	O
a	O
new	O
target	O
for	O
antineoplastic	O
drug	O
development	O
.	O

Altered	O
methionine	B-CHEMICAL
metabolism	O
in	O
long	O
living	O
Ames	O
dwarf	O
mice	O
.	O

Ames	O
dwarf	O
mice	O
(	O
df	O
/	O
df	O
)	O
are	O
deficient	O
in	O
growth	B-GENE-Y
hormone	I-GENE-Y
,	O
prolactin	B-GENE-Y
,	O
and	O
thyroid	B-GENE-N
-	I-GENE-N
stimulating	I-GENE-N
hormone	I-GENE-N
and	O
live	O
significantly	O
longer	O
than	O
their	O
normal	O
siblings	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
found	O
that	O
the	O
hormone	O
deficiencies	O
affect	O
methionine	B-CHEMICAL
metabolism	O
.	O

We	O
previously	O
reported	O
that	O
the	O
dwarf	O
mice	O
exhibit	O
enzyme	O
activities	O
and	O
levels	O
that	O
combat	O
oxidative	O
stress	O
more	O
efficiently	O
than	O
those	O
of	O
normal	O
mice	O
.	O

Moreover	O
,	O
methionine	B-CHEMICAL
or	O
metabolites	O
of	O
methionine	B-CHEMICAL
are	O
involved	O
in	O
antioxidative	O
processes	O
.	O

Thus	O
,	O
we	O
performed	O
an	O
experiment	O
that	O
compared	O
various	O
parameters	O
of	O
methionine	B-CHEMICAL
metabolism	O
between	O
18	O
-	O
month	O
old	O
male	O
dwarf	O
(	O
N	O
=	O
6	O
)	O
and	O
wild	O
type	O
(	O
N	O
=	O
5	O
)	O
mice	O
.	O

The	O
specific	O
activity	O
of	O
liver	B-GENE-N
methionine	I-GENE-N
adenosyltransferase	I-GENE-N
(	O
MAT	B-GENE-N
)	O
was	O
significantly	O
elevated	O
(	O
205	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
in	O
the	O
dwarf	O
mice	O
,	O
as	O
were	O
cystathionine	B-GENE-N
synthase	I-GENE-N
(	O
50	O
%	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
cystathionase	B-GENE-Y
(	O
83	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
glycine	B-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
methyltransferase	I-GENE-Y
(	O
GNMT	B-GENE-Y
,	O
91	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
activities	O
.	O

Even	O
though	O
the	O
activities	O
of	O
MAT	B-GENE-N
and	O
GNMT	B-GENE-Y
were	O
elevated	O
,	O
the	O
concentration	O
of	O
liver	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosylmethionine	I-CHEMICAL
was	O
decreased	O
(	O
24	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosylhomocysteine	I-CHEMICAL
increased	O
(	O
113	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
the	O
dwarf	O
mice	O
.	O

These	O
data	O
indicate	O
that	O
dwarf	O
mice	O
,	O
compared	O
to	O
wild	O
type	O
mice	O
,	O
have	O
a	O
markedly	O
different	O
metabolism	O
of	O
methionine	B-CHEMICAL
.	O

Altered	O
methionine	B-CHEMICAL
metabolism	O
may	O
partially	O
explain	O
earlier	O
reports	O
indicating	O
less	O
oxidative	O
damage	O
to	O
proteins	O
in	O
dwarf	O
mice	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
methionine	B-CHEMICAL
metabolism	O
may	O
play	O
a	O
role	O
in	O
oxidative	O
defense	O
in	O
the	O
dwarf	O
mouse	O
and	O
should	O
be	O
studied	O
as	O
a	O
potential	O
mechanism	O
of	O
extended	O
lifespan	O
.	O

Biosynthetic	O
regulation	O
and	O
intracellular	O
transport	O
of	O
phosphatidylserine	B-CHEMICAL
in	O
mammalian	O
cells	O
.	O

In	O
mammalian	O
cells	O
,	O
phosphatidylserine	B-CHEMICAL
(	O
PtdSer	B-CHEMICAL
)	O
is	O
synthesized	O
through	O
the	O
action	O
of	O
the	O
endoplasmic	O
reticulum	O
enzymes	O
,	O
PtdSer	B-GENE-N
synthase	I-GENE-N
1	I-GENE-N
and	I-GENE-N
2	I-GENE-N
,	O
and	O
the	O
decarboxylation	O
of	O
PtdSer	O
accounts	O
for	O
the	O
majority	O
of	O
phosphatidylethanolamine	B-CHEMICAL
(	O
PtdEtn	B-CHEMICAL
)	O
synthesis	O
.	O

PtdSer	B-CHEMICAL
decarboxylation	O
for	O
PtdEtn	B-CHEMICAL
formation	O
occurs	O
in	O
the	O
mitochondria	O
.	O

In	O
addition	O
,	O
the	O
transport	O
of	O
PtdSer	B-CHEMICAL
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
mitochondria	O
is	O
probably	O
a	O
rate	O
limiting	O
step	O
for	O
PtdEtn	B-CHEMICAL
synthesis	O
through	O
the	O
decarboxylation	O
pathway	O
.	O

Therefore	O
,	O
the	O
regulation	O
of	O
PtdSer	B-CHEMICAL
synthesis	O
and	O
its	O
intracellular	O
transport	O
appear	O
to	O
be	O
essential	O
events	O
for	O
the	O
maintenance	O
of	O
normal	O
cellular	O
PtdSer	B-CHEMICAL
and	O
PtdEtn	B-CHEMICAL
levels	O
.	O

Here	O
we	O
describe	O
the	O
current	O
understanding	O
of	O
the	O
regulation	O
of	O
PtdSer	B-CHEMICAL
biosynthesis	O
and	O
the	O
transport	O
of	O
PtdSer	B-CHEMICAL
from	O
the	O
ER	O
to	O
the	O
mitochondria	O
in	O
mammalian	O
cells	O
.	O

Diclofenac	B-CHEMICAL
inhibits	O
proliferation	O
and	O
differentiation	O
of	O
neural	O
stem	O
cells	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
are	O
widely	O
used	O
in	O
clinical	O
situations	O
as	O
anti	O
-	O
inflammatory	O
,	O
analgesic	O
and	O
antipyretic	O
drugs	O
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
whether	O
NSAIDs	O
have	O
effects	O
on	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
NSAIDs	O
on	O
neural	O
stem	O
cell	O
(	O
NSC	O
)	O
proliferation	O
and	O
differentiation	O
into	O
neurons	O
.	O

In	O
contrast	O
to	O
aspirin	B-CHEMICAL
,	O
naproxen	B-CHEMICAL
,	O
indomethacin	B-CHEMICAL
and	O
ibuprofen	B-CHEMICAL
,	O
treatment	O
with	O
diclofenac	B-CHEMICAL
(	O
10	O
microM	O
)	O
for	O
2	O
days	O
induced	O
the	O
death	O
of	O
NSCs	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Diclofenac	B-CHEMICAL
also	O
inhibited	O
the	O
proliferation	O
of	O
NSCs	O
and	O
their	O
differentiation	O
into	O
neurons	O
.	O

Treatment	O
with	O
diclofenac	B-CHEMICAL
resulted	O
in	O
nuclear	O
condensation	O
(	O
a	O
morphological	O
change	O
due	O
to	O
apoptosis	O
of	O
NSCs	O
)	O
24hr	O
after	O
the	O
treatment	O
and	O
activated	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
after	O
6	O
hr	O
,	O
indicating	O
that	O
diclofenac	B-CHEMICAL
may	O
cause	O
apoptosis	O
of	O
neuronal	O
cells	O
via	O
activation	O
of	O
the	O
caspase	B-GENE-N
cascade	O
.	O

These	O
results	O
suggest	O
that	O
diclofenac	B-CHEMICAL
may	O
affect	O
the	O
development	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Tissue	O
expression	O
and	O
translational	O
control	O
of	O
rat	B-GENE-Y
kynurenine	I-GENE-Y
aminotransferase	I-GENE-Y
/	O
glutamine	B-GENE-Y
transaminase	I-GENE-Y
K	I-GENE-Y
mRNAs	O
.	O

Kynurenic	B-CHEMICAL
acid	I-CHEMICAL
(	O
KA	B-CHEMICAL
)	O
is	O
an	O
endogenous	O
glutamate	B-GENE-N
receptor	I-GENE-N
antagonist	O
at	O
the	O
level	O
of	O
the	O
different	O
ionotropic	B-GENE-N
glutamate	I-GENE-N
receptors	I-GENE-N
.	O

One	O
of	O
the	O
enzymes	O
responsible	O
for	O
the	O
production	O
of	O
KA	B-CHEMICAL
,	O
kynurenine	B-GENE-Y
aminotransferase	I-GENE-Y
I	I-GENE-Y
(	O
KATI	B-GENE-Y
)	O
,	O
also	O
catalyses	O
the	O
reversible	O
transamination	O
of	O
glutamine	B-CHEMICAL
to	O
oxoglutaramic	B-CHEMICAL
acid	I-CHEMICAL
(	O
GTK	B-GENE-Y
,	O
EC	B-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
15	I-GENE-Y
)	O
.	O

The	O
enzyme	O
exists	O
in	O
a	O
cytosolic	O
and	O
in	O
a	O
mitochondrial	O
form	O
because	O
of	O
the	O
presence	O
of	O
two	O
different	O
KATI	B-GENE-Y
mRNAs	O
coding	O
for	O
a	O
protein	O
respectively	O
with	O
and	O
without	O
leader	B-GENE-N
sequence	I-GENE-N
targeting	O
the	O
protein	O
into	O
mitochondria	O
.	O

We	O
have	O
cloned	O
from	O
a	O
phage	O
library	O
of	O
rat	O
kidney	O
cDNA	O
four	O
new	O
KATI	B-GENE-Y
cDNAs	O
containing	O
different	O
5	B-GENE-N
'	I-GENE-N
untranslated	I-GENE-N
regions	I-GENE-N
(	O
UTRs	B-GENE-N
)	O
.	O

One	O
of	O
the	O
transcripts	O
(	O
+	O
14KATI	B-GENE-Y
cDNA	O
)	O
contains	O
an	O
alternative	O
site	O
of	O
initiation	O
of	O
translation	O
.	O

The	O
tissue	O
distribution	O
of	O
the	O
different	O
transcripts	O
was	O
studied	O
by	O
RT	O
-	O
PCR	O
.	O

The	O
study	O
demonstrated	O
that	O
several	O
KATI	B-GENE-Y
mRNAs	O
are	O
constitutively	O
expressed	O
in	O
ubiquitous	O
manner	O
,	O
while	O
+	O
14KATI	B-GENE-Y
mRNA	O
is	O
present	O
only	O
in	O
kidney	O
.	O

The	O
translational	O
efficiency	O
of	O
the	O
different	O
transcripts	O
was	O
studied	O
in	O
vitro	O
and	O
enzymatic	O
activities	O
were	O
measured	O
in	O
transiently	O
transfected	O
Cos	O
-	O
1	O
cells	O
.	O

Each	O
KATI	B-GENE-Y
mRNA	O
exhibits	O
a	O
different	O
in	O
vitro	O
translational	O
efficiency	O
,	O
which	O
corresponds	O
to	O
different	O
levels	O
of	O
KAT	B-GENE-Y
enzymatic	O
activity	O
in	O
transfected	O
cells	O
.	O

Both	O
findings	O
correlate	O
with	O
the	O
predicted	O
accessibility	O
of	O
the	O
ribosomal	O
binding	O
sites	O
of	O
the	O
different	O
mRNAs	O
.	O

The	O
structure	O
of	O
the	O
rat	B-GENE-Y
KATI	I-GENE-Y
/	O
GTK	B-GENE-Y
gene	O
was	O
also	O
studied	O
.	O

The	O
expression	O
of	O
several	O
KATI	B-GENE-Y
mRNAs	O
with	O
different	O
5	B-GENE-N
'	I-GENE-N
UTRs	I-GENE-N
represents	O
an	O
interesting	O
example	O
of	O
transcriptional	O
/	O
translational	O
control	O
on	O
the	O
expression	O
of	O
pyridoxal	B-GENE-N
phosphate	I-GENE-N
(	I-GENE-N
PLP	I-GENE-N
)	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
aminotransferases	I-GENE-N
.	O

Recent	O
developments	O
in	O
the	O
synthesis	O
of	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
.	O

The	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
and	O
butyrylcholinesterase	B-GENE-Y
(	O
BuChE	B-GENE-Y
)	O
inhibitory	O
activities	O
of	O
a	O
series	O
of	O
pyrano	B-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
quinolines	I-CHEMICAL
(	O
2	O
,	O
3	O
)	O
,	O
[	B-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
]	I-CHEMICAL
naphthyridines	I-CHEMICAL
(	O
5	O
,	O
6	O
)	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diaryl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydrofuro	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
quinolines	I-CHEMICAL
(	O
11	O
-	O
13	O
)	O
/	O
4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
,	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diphenyl	I-CHEMICAL
-	I-CHEMICAL
5H	I-CHEMICAL
-	I-CHEMICAL
cyclohepta	I-CHEMICAL
[	I-CHEMICAL
e	I-CHEMICAL
]	I-CHEMICAL
furo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
14	O
)	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diphenylthieno	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
quinoline	I-CHEMICAL
(	O
15	O
)	O
/	O
4	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
,	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diphenyl	I-CHEMICAL
-	I-CHEMICAL
5H	I-CHEMICAL
-	I-CHEMICAL
cyclohepta	I-CHEMICAL
[	I-CHEMICAL
e	I-CHEMICAL
]	I-CHEMICAL
thieno	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
16	O
)	O
are	O
described	O
.	O

These	O
compounds	O
are	O
tacrine	B-CHEMICAL
analogues	O
that	O
have	O
been	O
prepared	O
from	O
readily	O
available	O
polyfunctionalized	O
ethyl	B-CHEMICAL
[	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
cyano	I-CHEMICAL
-	I-CHEMICAL
4H	I-CHEMICAL
-	I-CHEMICAL
pyran	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
carboxylates	I-CHEMICAL
(	O
9	O
,	O
10	O
)	O
,	O
ethyl	B-CHEMICAL
[	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
cyanopyridine	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
carboxylates	I-CHEMICAL
(	O
7	O
,	O
8	O
)	O
,	O
2	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
cyano	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diarylfurans	I-CHEMICAL
(	O
17	O
-	O
19	O
)	O
and	O
2	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
cyano	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diphenylthiophene	I-CHEMICAL
(	O
20	O
)	O
via	O
Friedlander	O
condensation	O
with	O
selected	O
ketones	B-CHEMICAL
.	O

These	O
compounds	O
are	O
competitive	O
and	O
,	O
in	O
a	O
few	O
cases	O
,	O
non	O
-	O
competitive	O
inhibitors	O
for	O
AChE	B-GENE-Y
,	O
the	O
most	O
potent	O
being	O
compound	O
(	O
14	O
)	O
,	O
though	O
three	O
-	O
fold	O
less	O
active	O
than	O
tacrine	B-CHEMICAL
.	O

The	O
BuChE	B-GENE-Y
inhibitory	O
activity	O
is	O
only	O
significant	O
in	O
compounds	O
11	O
and	O
14	O
,	O
ten	O
-	O
fold	O
less	O
active	O
than	O
tacrine	B-CHEMICAL
.	O

Furthermore	O
,	O
the	O
products	O
12	O
and	O
13	O
are	O
selective	O
and	O
moderate	O
AChE	B-GENE-Y
inhibitors	O
.	O

NHE3	B-GENE-Y
inhibition	O
activates	O
duodenal	O
bicarbonate	O
secretion	O
in	O
the	O
rat	O
.	O

We	O
examined	O
the	O
effect	O
of	O
inhibition	O
of	O
Na	B-GENE-N
+	I-GENE-N
/	I-GENE-N
H	I-GENE-N
+	I-GENE-N
exchange	I-GENE-N
(	O
NHE	B-GENE-N
)	O
on	O
duodenal	O
bicarbonate	O
secretion	O
(	O
DBS	O
)	O
in	O
rats	O
to	O
further	O
understand	O
DBS	O
regulation	O
.	O

DBS	O
was	O
measured	O
by	O
using	O
the	O
pH	O
-	O
stat	O
method	O
and	O
by	O
using	O
CO2	B-CHEMICAL
-	O
sensitive	O
electrodes	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
dimethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
amiloride	I-CHEMICAL
(	O
50	O
microM	O
;	O
DMA	B-CHEMICAL
)	O
,	O
a	O
concentration	O
that	O
selectively	O
inhibits	O
the	O
NHE	B-GENE-N
isoforms	O
NHE1	B-GENE-Y
and	O
NHE2	B-GENE-Y
,	O
but	O
not	O
NHE3	B-GENE-Y
,	O
did	O
not	O
affect	O
DBS	O
.	O

Nevertheless	O
,	O
3	O
mM	O
DMA	B-CHEMICAL
,	O
a	O
higher	O
concentration	O
that	O
inhibits	O
NHE1	B-GENE-Y
,	O
NHE2	B-GENE-Y
,	O
and	O
NHE3	B-GENE-Y
,	O
significantly	O
increased	O
DBS	O
.	O

Moreover	O
,	O
S1611	B-CHEMICAL
and	O
S3226	B-CHEMICAL
,	O
both	O
specific	O
inhibitors	O
of	O
NHE3	B-GENE-Y
only	O
,	O
or	O
perfusion	O
with	O
Na	B-CHEMICAL
+	I-CHEMICAL
-	O
free	O
solutions	O
,	O
dose	O
dependently	O
increased	O
DBS	O
,	O
as	O
measured	O
by	O
pH	O
-	O
stat	O
and	O
CO2	B-CHEMICAL
-	O
sensitive	O
electrode	O
,	O
without	O
affecting	O
intracellular	O
pH	O
.	O

Coperfusion	O
with	O
0	O
.	O
1	O
microM	O
indomethacin	B-CHEMICAL
,	O
0	O
.	O
5	O
mM	O
DIDS	O
,	O
or	O
1	O
mM	O
methazolamide	B-CHEMICAL
did	O
not	O
affect	O
S3226	B-CHEMICAL
-	O
induced	O
DBS	O
.	O

Nevertheless	O
,	O
coperfusion	O
with	O
0	O
.	O
1	O
and	O
0	O
.	O
3	O
mM	O
5	B-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
phenylpropylamino	I-CHEMICAL
)	I-CHEMICAL
benzoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
which	O
inhibits	O
the	O
cystic	B-GENE-Y
fibrosis	I-GENE-Y
transmembrane	I-GENE-Y
conductor	I-GENE-Y
regulator	I-GENE-Y
(	O
CFTR	B-GENE-Y
)	O
,	O
dose	O
dependently	O
inhibited	O
S3226	B-CHEMICAL
-	O
induced	O
DBS	O
.	O

In	O
conclusion	O
,	O
only	O
specific	O
apical	O
NHE3	B-GENE-Y
inhibition	O
increased	O
DBS	O
,	O
whereas	O
prostaglandin	B-CHEMICAL
synthesis	O
,	O
Na	B-GENE-Y
+	I-GENE-Y
-	I-GENE-Y
HCO3	I-GENE-Y
-	I-GENE-Y
cotransporter	I-GENE-Y
activation	O
,	O
or	O
intracellular	O
HCO3	B-CHEMICAL
-	O
formation	O
by	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
was	O
not	O
involved	O
.	O

Because	O
NHE3	B-GENE-Y
inhibition	O
-	O
increased	O
DBS	O
was	O
inhibited	O
by	O
an	O
anion	B-GENE-N
channel	I-GENE-N
inhibitor	O
and	O
because	O
reciprocal	O
CFTR	B-GENE-Y
regulation	O
has	O
been	O
previously	O
shown	O
between	O
NHE3	B-GENE-Y
and	O
apical	B-GENE-N
membrane	I-GENE-N
anion	I-GENE-N
transporters	I-GENE-N
,	O
we	O
speculate	O
that	O
NHE3	B-GENE-Y
inhibition	O
increased	O
DBS	O
by	O
altering	O
anion	B-GENE-N
transporter	I-GENE-N
function	O
.	O

Selective	O
antagonism	O
of	O
GluR5	B-GENE-Y
kainate	B-GENE-N
-	I-GENE-N
receptor	I-GENE-N
-	O
mediated	O
synaptic	O
currents	O
by	O
topiramate	B-CHEMICAL
in	O
rat	O
basolateral	O
amygdala	O
neurons	O
.	O

Topiramate	B-CHEMICAL
is	O
a	O
widely	O
used	O
antiepileptic	O
agent	O
whose	O
mechanism	O
of	O
action	O
is	O
poorly	O
understood	O
.	O

The	O
drug	O
has	O
been	O
reported	O
to	O
interact	O
with	O
various	O
ion	B-GENE-N
channel	I-GENE-N
types	O
,	O
including	O
AMPA	B-GENE-N
/	I-GENE-N
kainate	I-GENE-N
receptors	I-GENE-N
.	O

In	O
whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
recordings	O
from	O
principal	O
neurons	O
of	O
the	O
rat	O
basolateral	O
amygdala	O
,	O
topiramate	B-CHEMICAL
at	O
low	O
concentrations	O
(	O
IC50	O
,	O
approximately	O
0	O
.	O
5	O
microm	O
)	O
selectively	O
inhibited	O
pharmacologically	O
isolated	O
excitatory	O
synaptic	O
currents	O
mediated	O
by	O
kainate	B-GENE-N
receptors	I-GENE-N
containing	O
the	O
GluR5	B-GENE-Y
subunit	O
.	O

Topiramate	B-CHEMICAL
also	O
partially	O
depressed	O
predominantly	O
AMPA	B-GENE-N
-	I-GENE-N
receptor	I-GENE-N
-	O
mediated	O
EPSCs	O
,	O
but	O
with	O
lower	O
efficacy	O
.	O

Topiramate	B-CHEMICAL
did	O
not	O
alter	O
the	O
degree	O
of	O
facilitation	O
in	O
paired	O
-	O
pulse	O
experiments	O
,	O
and	O
it	O
reduced	O
the	O
amplitude	O
of	O
miniature	O
EPSCs	O
without	O
affecting	O
their	O
frequency	O
,	O
demonstrating	O
that	O
the	O
block	O
of	O
synaptic	O
responses	O
occurs	O
postsynaptically	O
.	O

Inhibition	O
of	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
could	O
represent	O
a	O
key	O
mechanism	O
underlying	O
the	O
anticonvulsant	O
activity	O
of	O
topiramate	B-CHEMICAL
.	O

Moreover	O
,	O
these	O
results	O
support	O
the	O
concept	O
that	O
GluR5	B-GENE-Y
kainate	B-GENE-N
receptors	I-GENE-N
represent	O
a	O
novel	O
target	O
for	O
antiepileptic	O
drug	O
development	O
.	O

Effects	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
aza	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxycytidine	I-CHEMICAL
on	O
fetal	B-GENE-N
hemoglobin	I-GENE-N
levels	O
,	O
red	O
cell	O
adhesion	O
,	O
and	O
hematopoietic	O
differentiation	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O

Fetal	B-GENE-N
hemoglobin	I-GENE-N
(	O
HbF	B-GENE-N
)	O
decreases	O
polymerization	O
of	O
sickle	B-GENE-N
hemoglobin	I-GENE-N
(	O
HbS	B-GENE-N
)	O
and	O
improves	O
outcomes	O
in	O
sickle	O
cell	O
disease	O
(	O
SSD	O
)	O
.	O

Therefore	O
,	O
a	O
therapeutic	O
goal	O
in	O
SSD	O
is	O
pharmacologic	O
reactivation	O
of	O
HbF	B-GENE-N
.	O

Silencing	O
of	O
the	O
gamma	B-GENE-N
-	I-GENE-N
globin	I-GENE-N
(	O
HbF	B-GENE-N
)	O
gene	O
is	O
associated	O
with	O
DNA	O
methylation	O
.	O

The	O
cytosine	B-CHEMICAL
analog	O
5	B-CHEMICAL
-	I-CHEMICAL
aza	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxycytidine	I-CHEMICAL
(	O
decitabine	B-CHEMICAL
)	O
hypomethylates	O
DNA	O
by	O
inhibiting	O
DNA	B-GENE-N
methyltransferase	I-GENE-N
.	O

We	O
examined	O
if	O
subcutaneous	O
decitabine	B-CHEMICAL
could	O
increase	O
HbF	B-GENE-N
levels	O
and	O
improve	O
SSD	O
pathophysiology	O
without	O
cytotoxicity	O
.	O

Eight	O
symptomatic	O
SSD	O
patients	O
resistant	O
or	O
intolerant	O
of	O
standard	O
treatment	O
with	O
hydroxyurea	B-CHEMICAL
received	O
decitabine	B-CHEMICAL
0	O
.	O
2	O
mg	O
/	O
kg	O
subcutaneously	O
1	O
to	O
3	O
times	O
per	O
week	O
in	O
2	O
cycles	O
of	O
6	O
-	O
week	O
duration	O
.	O

Treatment	O
decreased	O
neutrophils	O
and	O
increased	O
mean	O
HbF	B-GENE-N
(	O
6	O
.	O
5	O
%	O
to	O
20	O
.	O
4	O
%	O
,	O
P	O
<	O
.	O
0001	O
)	O
and	O
mean	O
total	O
hemoglobin	B-GENE-N
(	O
76	O
to	O
96	O
g	O
/	O
L	O
[	O
7	O
.	O
6	O
to	O
9	O
.	O
6	O
g	O
/	O
dL	O
]	O
,	O
P	O
<	O
.	O
001	O
)	O
.	O

Features	O
of	O
vaso	O
-	O
occlusive	O
crisis	O
pathophysiology	O
such	O
as	O
red	O
cell	O
adhesion	O
,	O
endothelial	O
damage	O
,	O
and	O
coagulation	O
pathway	O
activity	O
significantly	O
improved	O
.	O

gamma	B-GENE-N
-	I-GENE-N
Globin	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
methylation	O
decreased	O
,	O
and	O
platelets	O
and	O
the	O
proportion	O
of	O
megakaryocytes	O
and	O
erythroid	O
cells	O
in	O
the	O
marrow	O
increased	O
without	O
a	O
decrease	O
in	O
marrow	O
cellularity	O
,	O
consistent	O
with	O
a	O
DNA	O
hypomethylating	O
,	O
noncytotoxic	O
mechanism	O
of	O
action	O
.	O

Weekly	O
subcutaneous	O
decitabine	B-CHEMICAL
produces	O
cumulative	O
increases	O
in	O
HbF	B-GENE-N
and	O
total	O
hemoglobin	B-GENE-N
through	O
a	O
noncytotoxic	O
mechanism	O
of	O
action	O
.	O

Chronic	O
dosing	O
and	O
sustained	O
increases	O
in	O
hemoglobin	B-GENE-N
F	I-GENE-N
and	O
total	O
hemoglobin	B-GENE-N
levels	O
may	O
be	O
possible	O
.	O

Further	O
studies	O
in	O
SSD	O
and	O
thalassemia	O
are	O
indicated	O
.	O

Structure	O
-	O
based	O
design	O
of	O
aliskiren	B-CHEMICAL
,	O
a	O
novel	O
orally	O
effective	O
renin	B-GENE-Y
inhibitor	O
.	O

Hypertension	O
is	O
a	O
major	O
risk	O
factor	O
for	O
cardiovascular	O
diseases	O
such	O
as	O
stroke	O
,	O
myocardial	O
infarction	O
,	O
and	O
heart	O
failure	O
,	O
the	O
leading	O
causes	O
of	O
death	O
in	O
the	O
Western	O
world	O
.	O

Inhibitors	O
of	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
system	O
(	O
RAS	O
)	O
have	O
proven	O
to	O
be	O
successful	O
treatments	O
for	O
hypertension	O
.	O

As	O
renin	B-GENE-Y
specifically	O
catalyses	O
the	O
rate	O
-	O
limiting	O
step	O
of	O
the	O
RAS	O
,	O
it	O
represents	O
the	O
optimal	O
target	O
for	O
RAS	O
inhibition	O
.	O

Several	O
peptide	O
-	O
like	O
renin	B-GENE-Y
inhibitors	O
have	O
been	O
synthesized	O
previously	O
,	O
but	O
poor	O
pharmacokinetic	O
properties	O
meant	O
that	O
these	O
compounds	O
were	O
not	O
clinically	O
useful	O
.	O

We	O
employed	O
a	O
combination	O
of	O
molecular	O
modelling	O
and	O
crystallographic	O
structure	O
analysis	O
to	O
design	O
renin	B-GENE-Y
inhibitors	O
lacking	O
the	O
extended	O
peptide	O
-	O
like	O
backbone	O
of	O
earlier	O
inhibitors	O
,	O
for	O
improved	O
pharmacokinetic	O
properties	O
.	O

This	O
led	O
to	O
the	O
discovery	O
of	O
aliskiren	B-CHEMICAL
,	O
a	O
highly	O
potent	O
and	O
selective	O
inhibitor	O
of	O
human	B-GENE-Y
renin	I-GENE-Y
in	O
vitro	O
,	O
and	O
in	O
vivo	O
;	O
once	O
-	O
daily	O
oral	O
doses	O
of	O
aliskiren	B-CHEMICAL
inhibit	O
renin	B-GENE-Y
and	O
lower	O
blood	O
pressure	O
in	O
sodium	B-CHEMICAL
-	O
depleted	O
marmosets	O
and	O
hypertensive	O
human	O
patients	O
.	O

Aliskiren	B-CHEMICAL
represents	O
the	O
first	O
in	O
a	O
novel	O
class	O
of	O
renin	B-GENE-Y
inhibitors	O
with	O
the	O
potential	O
for	O
treatment	O
of	O
hypertension	O
and	O
related	O
cardiovascular	O
diseases	O
.	O

The	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
polymorphism	O
,	O
5HTTLPR	B-GENE-Y
,	O
is	O
associated	O
with	O
a	O
faster	O
response	O
time	O
to	O
sertraline	B-CHEMICAL
in	O
an	O
elderly	O
population	O
with	O
major	O
depressive	O
disorder	O
.	O

RATIONALE	O
:	O
A	O
common	O
polymorphism	O
(	O
5HTTLPR	B-GENE-Y
)	O
within	O
the	O
promoter	O
region	O
of	O
the	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
gene	O
(	O
LSC6A4	B-GENE-Y
)	O
has	O
been	O
shown	O
to	O
influence	O
response	O
time	O
as	O
well	O
as	O
overall	O
response	O
to	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
in	O
subjects	O
with	O
major	O
depressive	O
disorder	O
.	O

We	O
hypothesized	O
that	O
a	O
similar	O
effect	O
in	O
response	O
time	O
to	O
sertraline	B-CHEMICAL
would	O
be	O
observed	O
and	O
that	O
no	O
effect	O
on	O
response	O
time	O
would	O
be	O
seen	O
in	O
a	O
placebo	O
arm	O
.	O

OBJECTIVES	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
subjects	O
homozygous	O
for	O
the	O
long	O
allele	O
at	O
the	O
5HTTLPR	B-GENE-Y
polymorphism	O
would	O
respond	O
more	O
rapidly	O
to	O
sertraline	B-CHEMICAL
than	O
subjects	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
short	O
allele	O
.	O

METHODS	O
:	O
HAM	O
-	O
D	O
and	O
CGI	O
-	O
I	O
responses	O
to	O
sertraline	B-CHEMICAL
and	O
placebo	O
were	O
measured	O
weekly	O
in	O
the	O
context	O
of	O
an	O
8	O
-	O
week	O
,	O
placebo	O
-	O
controlled	O
study	O
in	O
elderly	O
depressed	O
subjects	O
.	O

Genotyping	O
of	O
the	O
5HTTLPR	B-GENE-Y
polymorphism	O
was	O
performed	O
to	O
test	O
for	O
correlations	O
with	O
response	O
at	O
each	O
week	O
in	O
the	O
sertraline	B-CHEMICAL
and	O
placebo	O
groups	O
(	O
n	O
=	O
206	O
)	O
.	O

RESULTS	O
:	O
Subjects	O
homozygous	O
for	O
the	O
long	O
allele	O
of	O
5HTTLPR	B-GENE-Y
showed	O
a	O
significant	O
increase	O
in	O
response	O
at	O
week	O
1	O
and	O
week	O
2	O
,	O
as	O
assessed	O
by	O
the	O
CGI	O
-	O
I	O
scale	O
compared	O
with	O
subjects	O
carrying	O
one	O
or	O
two	O
copies	O
of	O
the	O
short	O
allele	O
(	O
P	O
=	O
0	O
.	O
01	O
at	O
both	O
weeks	O
)	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
placebo	O
group	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
genetic	O
variation	O
in	O
the	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
gene	O
effects	O
the	O
response	O
time	O
to	O
sertraline	B-CHEMICAL
and	O
provides	O
complementing	O
evidence	O
to	O
previous	O
reports	O
that	O
this	O
polymorphism	O
affects	O
response	O
time	O
to	O
other	O
SSRIs	O
.	O

Changes	O
of	O
phosphorylation	O
of	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
in	O
rat	O
nucleus	O
accumbens	O
after	O
chronic	O
ethanol	B-CHEMICAL
intake	O
:	O
naloxone	B-CHEMICAL
reversal	O
.	O

AIM	O
:	O
To	O
study	O
the	O
changes	O
in	O
the	O
expression	O
and	O
phosphorylation	O
of	O
cAMP	B-GENE-N
response	I-GENE-N
element	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
in	O
the	O
rat	O
nucleus	O
accumbens	O
after	O
chronic	O
ethanol	B-CHEMICAL
intake	O
and	O
its	O
withdrawal	O
.	O

METHODS	O
:	O
Ethanol	B-CHEMICAL
was	O
given	O
in	O
drinking	O
water	O
at	O
the	O
concentration	O
of	O
6	O
%	O
(	O
v	O
/	O
v	O
)	O
,	O
for	O
one	O
month	O
.	O

Changes	O
in	O
the	O
levels	O
of	O
CREB	B-GENE-N
and	O
phospho	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
(	O
p	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
)	O
protein	O
in	O
the	O
nucleus	O
accumbens	O
were	O
measured	O
by	O
immunohistochemistry	O
methods	O
.	O

RESULTS	O
:	O
Ethanol	B-CHEMICAL
given	O
to	O
rats	O
in	O
drinking	O
water	O
decreased	O
the	O
level	O
of	O
p	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
protein	O
in	O
the	O
nucleus	O
accumbens	O
(	O
-	O
75	O
%	O
)	O
at	O
the	O
time	O
of	O
exposure	O
to	O
ethanol	B-CHEMICAL
.	O

The	O
decrement	O
of	O
p	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
protein	O
in	O
the	O
nucleus	O
accumbens	O
remained	O
at	O
24	O
h	O
(	O
-	O
35	O
%	O
)	O
and	O
72	O
h	O
(	O
-	O
28	O
%	O
)	O
of	O
ethanol	B-CHEMICAL
withdrawal	O
,	O
which	O
recovered	O
toward	O
control	O
level	O
after	O
7	O
d	O
of	O
ethanol	B-CHEMICAL
withdrawal	O
.	O

However	O
,	O
chronic	O
ethanol	B-CHEMICAL
,	O
as	O
well	O
as	O
ethanol	B-CHEMICAL
withdrawal	O
failed	O
to	O
produce	O
any	O
significant	O
alteration	O
in	O
the	O
level	O
of	O
CREB	B-GENE-N
protein	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Naloxone	B-CHEMICAL
(	O
alone	O
)	O
treatment	O
of	O
rats	O
had	O
no	O
effect	O
on	O
the	O
levels	O
of	O
CREB	B-GENE-N
and	O
p	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
protein	O
in	O
the	O
nucleus	O
accumbens	O
.	O

However	O
,	O
when	O
naloxone	O
was	O
administered	O
concurrently	O
with	O
ethanol	B-CHEMICAL
treatment	O
,	O
it	O
antagonized	O
the	O
down	O
-	O
regulation	O
of	O
p	B-GENE-N
-	I-GENE-N
CREB	I-GENE-N
protein	O
in	O
the	O
nucleus	O
accumbens	O
(	O
142	O
%	O
)	O
of	O
rats	O
exposed	O
to	O
ethanol	B-CHEMICAL
.	O

CONCLUSION	O
:	O
A	O
long	O
-	O
term	O
intake	O
of	O
ethanol	B-CHEMICAL
solution	O
down	O
-	O
regulates	O
the	O
phosphorylation	O
of	O
CREB	B-GENE-N
in	O
the	O
nucleus	O
accumbens	O
,	O
and	O
those	O
changes	O
can	O
be	O
reversed	O
by	O
naloxone	B-CHEMICAL
,	O
which	O
may	O
be	O
one	O
kind	O
of	O
the	O
molecular	O
mechanisms	O
associated	O
with	O
ethanol	B-CHEMICAL
dependence	O
.	O

Zuclopenthixol	B-CHEMICAL
facilitates	O
memory	O
retrieval	O
in	O
rats	O
:	O
possible	O
involvement	O
of	O
noradrenergic	O
and	O
serotonergic	O
mechanisms	O
.	O

Although	O
disturbed	O
memory	O
function	O
often	O
coexists	O
with	O
psychosis	O
,	O
the	O
cognitive	O
effects	O
of	O
antipsychotic	O
medications	O
with	O
diverse	O
pharmacodynamic	O
properties	O
are	O
rarely	O
investigated	O
.	O

The	O
neurocognitive	O
profile	O
of	O
zuclopenthixol	B-CHEMICAL
,	O
a	O
thioxanthene	B-CHEMICAL
dopaminergic	O
antagonist	O
and	O
a	O
conventional	O
neuroleptic	O
agent	O
,	O
has	O
yet	O
to	O
be	O
investigated	O
despite	O
the	O
effect	O
of	O
the	O
drug	O
on	O
a	O
variety	O
of	O
neurotransmitter	O
systems	O
involved	O
in	O
mediation	O
of	O
learning	O
and	O
memory	O
processes	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
zuclopenthixol	B-CHEMICAL
was	O
tested	O
on	O
memory	O
retrieval	O
24	O
h	O
after	O
training	O
using	O
an	O
inhibitory	O
avoidance	O
task	O
in	O
rats	O
.	O

Acute	O
administration	O
of	O
zuclopenthixol	B-CHEMICAL
(	O
0	O
.	O
7	O
and	O
1	O
.	O
4	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
before	O
retrieval	O
testing	O
increased	O
step	O
-	O
through	O
latency	O
during	O
the	O
test	O
session	O
.	O

The	O
same	O
doses	O
of	O
zuclopenthixol	B-CHEMICAL
did	O
not	O
affect	O
the	O
ambulatory	O
activity	O
of	O
rats	O
in	O
the	O
openfield	O
test	O
and	O
therefore	O
the	O
facilitatory	O
effect	O
of	O
the	O
drug	O
on	O
memory	O
function	O
could	O
not	O
be	O
confounded	O
with	O
any	O
motoric	O
properties	O
.	O

This	O
study	O
also	O
investigated	O
the	O
effect	O
of	O
zuclopenthixol	B-CHEMICAL
on	O
cortical	O
and	O
hippocampal	O
monoaminergic	O
neurotransmitters	O
'	O
levels	O
together	O
with	O
acetylcholinesterase	B-GENE-Y
enzyme	O
(	O
AChE	B-GENE-Y
)	O
activity	O
,	O
both	O
of	O
which	O
are	O
known	O
to	O
be	O
important	O
in	O
control	O
of	O
cognitive	O
function	O
.	O

Administration	O
of	O
zuclopenthixol	B-CHEMICAL
(	O
0	O
.	O
7	O
and	O
1	O
.	O
4	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
neither	O
affected	O
dopamine	B-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
level	O
nor	O
AChE	B-GENE-Y
activity	O
in	O
rat	O
cortex	O
and	O
hippocampus	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
lower	O
dose	O
of	O
zuclopenthixol	B-CHEMICAL
elevated	O
cortical	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
level	O
,	O
while	O
the	O
higher	O
dose	O
elevated	O
both	O
cortical	O
and	O
hippocampal	O
NE	B-CHEMICAL
level	O
together	O
with	O
hippocampal	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
level	O
.	O

These	O
results	O
may	O
suggest	O
the	O
involvement	O
of	O
adrenergic	O
and	O
serotonergic	O
mechanisms	O
in	O
the	O
facilitatory	O
effect	O
of	O
zuclopenthixol	B-CHEMICAL
on	O
retrieval	O
memory	O
.	O

Zuclopenthixol	B-CHEMICAL
may	O
therefore	O
be	O
a	O
better	O
alternative	O
than	O
other	O
commonly	O
used	O
antipsychotic	O
medications	O
reported	O
to	O
impair	O
cognitive	O
function	O
of	O
schizophrenic	O
patients	O
.	O

Synthesis	O
and	O
in	O
vitro	O
pharmacology	O
at	O
AMPA	B-CHEMICAL
and	O
kainate	B-CHEMICAL
preferring	O
glutamate	B-GENE-N
receptors	I-GENE-N
of	O
4	B-CHEMICAL
-	I-CHEMICAL
heteroarylmethylidene	I-CHEMICAL
glutamate	I-CHEMICAL
analogues	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
Amino	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
thiazolyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
isoxazolyl	I-CHEMICAL
]	I-CHEMICAL
propionic	I-CHEMICAL
acid	I-CHEMICAL
(	O
1	O
)	O
is	O
a	O
potent	O
AMPA	B-GENE-N
receptor	I-GENE-N
agonist	O
with	O
moderate	O
affinity	O
for	O
native	O
kainic	B-GENE-N
acid	I-GENE-N
(	I-GENE-N
KA	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
,	O
whereas	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
E	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
dimethylpropylidene	I-CHEMICAL
)	I-CHEMICAL
glutamic	I-CHEMICAL
acid	I-CHEMICAL
(	O
3	O
)	O
show	O
high	O
affinity	O
for	O
the	O
GluR5	B-GENE-Y
subtype	O
of	O
KA	B-GENE-N
receptors	I-GENE-N
and	O
much	O
lower	O
affinity	O
for	O
the	O
GluR2	B-GENE-Y
subtype	O
of	O
AMPA	B-GENE-N
receptors	I-GENE-N
.	O

As	O
an	O
attempt	O
to	O
develop	O
new	O
pharmacological	O
tools	O
for	O
studies	O
of	O
GluR5	B-GENE-Y
receptors	O
,	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
E	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
thiazolylmethylene	I-CHEMICAL
)	I-CHEMICAL
glutamic	I-CHEMICAL
acid	I-CHEMICAL
(	O
4a	O
)	O
was	O
designed	O
as	O
a	O
structural	O
hybrid	O
between	O
1	O
and	O
3	O
.	O

4a	O
was	O
shown	O
to	O
be	O
a	O
potent	O
GluR5	B-GENE-Y
agonist	O
and	O
a	O
high	O
affinity	O
ligand	O
and	O
to	O
indiscriminately	O
bind	O
to	O
the	O
AMPA	B-GENE-N
receptor	I-GENE-N
subtypes	O
GluR1	B-GENE-N
-	I-GENE-N
4	I-GENE-N
with	O
lower	O
affinities	O
.	O

Compounds	O
4b	O
-	O
h	O
,	O
in	O
which	O
the	O
2	B-CHEMICAL
-	I-CHEMICAL
thiazolyl	I-CHEMICAL
substituent	O
of	O
4a	O
was	O
replaced	O
by	O
other	O
heterocyclic	B-CHEMICAL
rings	O
,	O
which	O
have	O
previously	O
been	O
incorporated	O
as	O
5	O
-	O
substituents	O
in	O
AMPA	B-CHEMICAL
analogues	O
,	O
as	O
exemplified	O
by	O
1	O
were	O
also	O
synthesized	O
.	O

Compounds	O
4b	O
-	O
h	O
were	O
either	O
inactive	O
(	O
4e	O
,	O
f	O
)	O
or	O
weaker	O
than	O
4a	O
as	O
affinity	O
ligands	O
for	O
GluR1	B-GENE-N
-	I-GENE-N
4	I-GENE-N
and	O
GluR5	B-GENE-Y
with	O
relative	O
potencies	O
comparable	O
with	O
those	O
of	O
the	O
corresponding	O
AMPA	B-CHEMICAL
analogues	O
as	O
AMPA	B-GENE-N
receptor	I-GENE-N
agonists	O
.	O

Compounds	O
4a	O
-	O
h	O
may	O
be	O
useful	O
tools	O
for	O
the	O
progressing	O
pharmacophore	O
mapping	O
of	O
the	O
GluR5	B-GENE-Y
agonist	O
binding	O
site	O
.	O

Amsacrine	B-CHEMICAL
and	O
etoposide	B-CHEMICAL
hypersensitivity	O
of	O
yeast	O
cells	O
overexpressing	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
.	O

Increasing	O
the	O
cellular	O
concentration	O
of	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
in	O
yeast	O
by	O
expressing	O
constitutively	O
a	O
plasmid	O
-	O
borne	O
TOP2	B-GENE-Y
gene	O
encoding	O
the	O
enzyme	O
greatly	O
increases	O
the	O
sensitivity	O
of	O
the	O
cells	O
to	O
amsacrine	B-CHEMICAL
and	O
etoposide	B-CHEMICAL
(	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
)	O
.	O

This	O
increased	O
drug	O
sensitivity	O
at	O
a	O
higher	O
intracellular	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
level	O
is	O
observed	O
in	O
both	O
RAD52	B-GENE-Y
+	O
repair	O
-	O
proficient	O
strains	O
and	O
rad52	B-GENE-Y
mutants	O
that	O
are	O
defective	O
in	O
the	O
repair	O
of	O
double	O
-	O
stranded	O
breaks	O
.	O

These	O
results	O
provide	O
strong	O
support	O
of	O
the	O
hypothesis	O
that	O
the	O
cellular	O
target	O
of	O
these	O
drugs	O
is	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
,	O
and	O
that	O
these	O
drugs	O
kill	O
cells	O
by	O
converting	O
DNA	B-GENE-Y
topoisomerase	I-GENE-Y
II	I-GENE-Y
into	O
a	O
DNA	O
damaging	O
agent	O
.	O

Failure	O
of	O
ritodrine	B-CHEMICAL
to	O
prevent	O
preterm	O
labor	O
in	O
the	O
sheep	O
.	O

OBJECTIVES	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
continuous	O
infusion	O
of	O
ritodrine	B-CHEMICAL
could	O
prevent	O
preterm	O
delivery	O
in	O
sheep	O
.	O

STUDY	O
DESIGN	O
:	O
Sheep	O
in	O
preterm	O
labor	O
induced	O
by	O
RU	B-CHEMICAL
486	I-CHEMICAL
(	O
mifepristone	B-CHEMICAL
)	O
received	O
infusions	O
of	O
either	O
ritodrine	B-CHEMICAL
(	O
n	O
=	O
5	O
)	O
or	O
saline	O
solution	O
(	O
n	O
=	O
5	O
)	O
,	O
and	O
the	O
progress	O
of	O
labor	O
was	O
monitored	O
.	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
Adrenergic	I-GENE-Y
receptor	I-GENE-Y
density	O
and	O
function	O
(	O
agonist	O
-	O
induced	O
cyclic	B-CHEMICAL
adenosine	I-CHEMICAL
monophosphate	I-CHEMICAL
production	O
)	O
was	O
measured	O
in	O
myometrial	O
samples	O
from	O
both	O
groups	O
.	O

RESULTS	O
:	O
Ritodrine	B-CHEMICAL
initially	O
inhibited	O
labor	O
contractions	O
.	O

This	O
inhibition	O
was	O
only	O
maintained	O
for	O
16	O
hours	O
,	O
after	O
which	O
both	O
the	O
amplitude	O
and	O
frequency	O
of	O
electromyographic	O
bursts	O
and	O
contractions	O
returned	O
.	O

The	O
failure	O
of	O
the	O
myometrium	O
to	O
respond	O
to	O
ritodrine	B-CHEMICAL
(	O
desensitization	O
)	O
was	O
associated	O
with	O
significant	O
reductions	O
in	O
agonist	O
-	O
induced	O
cyclic	B-CHEMICAL
adenosine	I-CHEMICAL
monophosphate	I-CHEMICAL
production	O
and	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
concentration	O
in	O
myometrial	O
tissue	O
collected	O
from	O
these	O
animals	O
compared	O
with	O
the	O
saline	O
solution	O
-	O
treated	O
controls	O
.	O

CONCLUSIONS	O
:	O
Continuous	O
infusion	O
of	O
ritodrine	B-CHEMICAL
to	O
sheep	O
in	O
preterm	O
labor	O
produces	O
only	O
a	O
transient	O
inhibition	O
of	O
contractions	O
.	O

This	O
desensitization	O
is	O
caused	O
by	O
a	O
down	O
-	O
regulation	O
of	O
myometrial	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptors	I-GENE-Y
.	O

Different	O
neuroleptics	O
show	O
common	O
dose	O
and	O
time	O
dependent	O
effects	O
in	O
quantitative	O
field	O
potential	O
analysis	O
in	O
freely	O
moving	O
rats	O
.	O

Under	O
the	O
assumption	O
that	O
field	O
potentials	O
recorded	O
from	O
particular	O
brain	O
areas	O
reflect	O
the	O
net	O
balance	O
of	O
neurotransmitter	O
activities	O
,	O
the	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
responses	O
induced	O
by	O
intraperitoneal	O
application	O
of	O
different	O
neuroleptic	O
drugs	O
are	O
quantified	O
by	O
spectral	O
analysis	O
of	O
the	O
electroencephalogram	O
recorded	O
from	O
frontal	O
cortex	O
,	O
hippocampus	O
,	O
striatum	O
and	O
reticular	O
formation	O
.	O

The	O
actions	O
of	O
haloperidol	B-CHEMICAL
,	O
chlorpromazine	B-CHEMICAL
,	O
clozapine	B-CHEMICAL
,	O
prothipendyl	B-CHEMICAL
and	O
thioridazine	B-CHEMICAL
in	O
general	O
were	O
characterized	O
by	O
increases	O
of	O
the	O
spectral	O
power	O
in	O
the	O
alpha	O
1	O
and	O
beta	O
range	O
,	O
at	O
higher	O
dosages	O
also	O
in	O
the	O
theta	O
range	O
.	O

This	O
observed	O
pattern	O
of	O
changes	O
is	O
in	O
line	O
with	O
the	O
neuroleptic	O
induced	O
spectral	O
changes	O
reported	O
in	O
the	O
literature	O
for	O
other	O
animals	O
and	O
man	O
.	O

In	O
the	O
light	O
of	O
the	O
already	O
known	O
effects	O
of	O
other	O
psychoactive	O
drugs	O
on	O
the	O
frequency	O
content	O
of	O
field	O
potentials	O
in	O
the	O
rat	O
,	O
it	O
should	O
now	O
be	O
possible	O
to	O
classify	O
different	O
drugs	O
in	O
terms	O
of	O
their	O
clinical	O
indication	O
.	O

With	O
respect	O
to	O
the	O
type	O
of	O
neurotransmitter	O
control	O
underlying	O
the	O
changes	O
produced	O
by	O
various	O
neuroleptics	O
,	O
it	O
is	O
quite	O
obvious	O
from	O
the	O
comparisons	O
with	O
the	O
respective	O
drug	O
effects	O
that	O
dopamine	B-GENE-Y
-	I-GENE-Y
D1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
controlled	O
transmission	O
is	O
not	O
responsible	O
for	O
this	O
action	O
.	O

On	O
the	O
basis	O
of	O
earlier	O
findings	O
a	O
possible	O
interaction	O
between	O
dopamine	B-GENE-Y
-	I-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
or	O
glutamatergic	O
transmitter	O
control	O
is	O
discussed	O
.	O

The	O
effects	O
of	O
labetalol	B-CHEMICAL
and	O
dilevalol	B-CHEMICAL
on	O
isolated	O
cardiovascular	O
preparations	O
of	O
the	O
guinea	O
-	O
pig	O
and	O
rat	O
.	O

Differing	O
effects	O
of	O
labetalol	B-CHEMICAL
and	O
dilevalol	B-CHEMICAL
on	O
cardiovascular	O
preparations	O
have	O
been	O
reported	O
.	O

I	O
have	O
studied	O
the	O
effects	O
of	O
labetalol	B-CHEMICAL
and	O
dilevalol	B-CHEMICAL
on	O
the	O
contractile	O
responses	O
of	O
the	O
rat	O
and	O
guinea	O
-	O
pig	O
left	O
atria	O
and	O
rat	O
portal	O
vein	O
.	O

On	O
the	O
guinea	O
-	O
pig	O
left	O
atria	O
low	O
concentrations	O
of	O
labetalol	B-CHEMICAL
(	O
>	O
or	O
=	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
and	O
of	O
dilevalol	B-CHEMICAL
(	O
>	O
or	O
=	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
inhibited	O
to	O
a	O
small	O
extent	O
the	O
responses	O
to	O
electrical	O
cardiac	O
stimulation	O
,	O
which	O
is	O
indicative	O
of	O
membrane	O
stabilizing	O
activity	O
.	O

Labetalol	B-CHEMICAL
(	O
>	O
or	O
=	O
3	O
x	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
and	O
dilevalol	B-CHEMICAL
(	O
>	O
or	O
=	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
caused	O
surmountable	O
antagonism	O
of	O
the	O
isoprenaline	B-CHEMICAL
responses	O
of	O
the	O
atria	O
and	O
the	O
pA2	O
values	O
were	O
8	O
.	O
60	O
and	O
8	O
.	O
98	O
at	O
the	O
beta	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
of	O
the	O
rat	O
left	O
atria	O
and	O
7	O
.	O
90	O
and	O
8	O
.	O
31	O
,	O
respectively	O
,	O
on	O
the	O
guinea	O
-	O
pig	O
left	O
atria	O
which	O
has	O
functional	O
beta	B-GENE-N
1	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

Labetalol	B-CHEMICAL
and	O
dilevalol	B-CHEMICAL
(	O
both	O
at	O
>	O
or	O
=	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
attenuated	O
the	O
spontaneous	O
contractile	O
activity	O
of	O
the	O
rat	O
portal	O
vein	O
and	O
the	O
attenuation	O
to	O
labetalol	B-CHEMICAL
at	O
10	O
(	O
-	O
6	O
)	O
M	O
was	O
abolished	O
by	O
ICI	B-CHEMICAL
118	I-CHEMICAL
,	I-CHEMICAL
551	I-CHEMICAL
which	O
illustrates	O
that	O
the	O
labetalol	B-CHEMICAL
-	O
induced	O
attenuation	O
is	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
mediated	O
.	O

The	O
isoprenaline	B-CHEMICAL
attenuation	O
responses	O
of	O
the	O
portal	O
vein	O
were	O
inhibited	O
by	O
labetalol	B-CHEMICAL
and	O
dilevalol	B-CHEMICAL
(	O
both	O
at	O
>	O
or	O
=	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
and	O
the	O
pA2	O
value	O
for	O
the	O
labetalol	B-CHEMICAL
at	O
beta	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
was	O
7	O
.	O
59	O
.	O

It	O
is	O
concluded	O
that	O
labetalol	B-CHEMICAL
and	O
dilevalol	B-CHEMICAL
are	O
beta	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
selective	O
antagonists	O
.	O

Prostacyclin	B-CHEMICAL
analogues	O
inhibit	O
tissue	B-GENE-Y
factor	I-GENE-Y
expression	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
via	O
a	O
cyclic	B-CHEMICAL
AMP	I-CHEMICAL
-	O
dependent	O
mechanism	O
.	O

Increased	O
expression	O
of	O
tissue	B-GENE-Y
factor	I-GENE-Y
procoagulant	O
by	O
peripheral	O
blood	O
monocytes	O
has	O
been	O
implicated	O
in	O
a	O
number	O
of	O
thrombotic	O
disorders	O
.	O

The	O
present	O
studies	O
were	O
undertaken	O
to	O
determine	O
whether	O
stable	O
analogues	O
of	O
prostacyclin	B-CHEMICAL
,	O
a	O
potent	O
endothelium	O
-	O
derived	O
platelet	O
inhibitor	O
and	O
vasodilator	O
,	O
could	O
inhibit	O
tissue	B-GENE-Y
factor	I-GENE-Y
expression	O
by	O
human	O
monocytic	O
cells	O
.	O

Exposure	O
of	O
monocytic	O
tumor	O
THP	O
-	O
1	O
cells	O
to	O
100	O
ng	O
/	O
ml	O
endotoxin	O
,	O
2	O
units	O
/	O
ml	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
,	O
or	O
5	O
ng	O
/	O
ml	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
for	O
4	O
hours	O
led	O
to	O
increased	O
tissue	B-GENE-Y
factor	I-GENE-Y
procoagulant	O
activity	O
.	O

Preincubation	O
for	O
30	O
minutes	O
with	O
iloprost	B-CHEMICAL
,	O
ciprostene	B-CHEMICAL
,	O
and	O
carbacyclin	B-CHEMICAL
led	O
to	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
tissue	B-GENE-Y
factor	I-GENE-Y
expression	O
induced	O
by	O
all	O
three	O
challenging	O
agents	O
.	O

Iloprost	B-CHEMICAL
was	O
the	O
most	O
potent	O
:	O
50	O
%	O
inhibition	O
occurred	O
at	O
5	O
nM	O
,	O
a	O
concentration	O
close	O
to	O
the	O
reported	O
dissociation	O
constant	O
for	O
iloprost	B-CHEMICAL
binding	O
to	O
the	O
platelet	O
prostacyclin	B-GENE-Y
receptor	I-GENE-Y
.	O

An	O
orally	O
active	O
analogue	O
,	O
cicaprost	B-CHEMICAL
,	O
was	O
equally	O
effective	O
against	O
endotoxin	O
-	O
induced	O
tissue	B-GENE-Y
factor	I-GENE-Y
expression	O
.	O

Carbacyclin	B-CHEMICAL
and	O
ciprostene	B-CHEMICAL
were	O
100	O
times	O
less	O
potent	O
.	O

Iloprost	O
prevented	O
the	O
endotoxin	O
-	O
induced	O
expression	O
of	O
tissue	B-GENE-Y
factor	I-GENE-Y
antigen	O
on	O
the	O
surface	O
of	O
THP	O
-	O
1	O
cells	O
,	O
as	O
determined	O
by	O
flow	O
cytometry	O
.	O

Iloprost	B-CHEMICAL
(	O
500	O
pM	O
-	O
50	O
nM	O
)	O
increased	O
intracellular	O
levels	O
of	O
cyclic	B-CHEMICAL
AMP	I-CHEMICAL
.	O

This	O
effect	O
was	O
potentiated	O
by	O
isobutylmethylxanthine	B-CHEMICAL
,	O
an	O
inhibitor	O
of	O
phosphodiesterase	B-GENE-N
.	O

The	O
inhibitory	O
effects	O
of	O
iloprost	O
on	O
tissue	B-GENE-Y
factor	I-GENE-Y
expression	O
were	O
also	O
potentiated	O
by	O
isobutylmethylxanthine	B-CHEMICAL
and	O
mimicked	O
by	O
forskolin	B-CHEMICAL
and	O
dibutyryl	B-CHEMICAL
cyclic	I-CHEMICAL
AMP	I-CHEMICAL
but	O
not	O
dibutyryl	B-CHEMICAL
cyclic	I-CHEMICAL
GMP	I-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
prostacyclin	B-CHEMICAL
may	O
play	O
a	O
role	O
in	O
downregulating	O
tissue	B-GENE-Y
factor	I-GENE-Y
expression	O
in	O
monocytes	O
,	O
at	O
least	O
in	O
part	O
via	O
elevation	O
of	O
intracellular	O
levels	O
of	O
cyclic	B-CHEMICAL
AMP	I-CHEMICAL
.	O

Effectiveness	O
of	O
endopeptidase	B-GENE-N
inhibition	O
(	O
candoxatril	B-CHEMICAL
)	O
in	O
congestive	O
heart	O
failure	O
.	O

Candoxatril	B-CHEMICAL
is	O
a	O
novel	O
,	O
orally	O
active	O
inhibitor	O
of	O
neutral	B-GENE-Y
endopeptidase	I-GENE-Y
EC	B-GENE-Y
3	I-GENE-Y
.	I-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
24	I-GENE-Y
.	I-GENE-Y
11	I-GENE-Y
,	O
the	O
enzyme	O
that	O
degrades	O
atrial	B-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
(	O
ANP	B-GENE-Y
)	O
.	O

The	O
acute	O
and	O
chronic	O
(	O
10	O
days	O
treatment	O
)	O
hemodynamic	O
and	O
hormonal	O
effects	O
of	O
candoxatril	B-CHEMICAL
(	O
150	O
mg	O
twice	O
daily	O
)	O
in	O
12	O
patients	O
with	O
moderately	O
severe	O
congestive	O
heart	O
failure	O
were	O
investigated	O
in	O
a	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
study	O
.	O

On	O
study	O
day	O
1	O
,	O
candoxatril	B-CHEMICAL
acutely	O
increased	O
plasma	O
ANP	B-GENE-Y
levels	O
,	O
suppressed	O
aldosterone	B-CHEMICAL
and	O
decreased	O
right	O
atrial	O
and	O
pulmonary	O
capillary	O
wedge	O
pressures	O
.	O

After	O
10	O
days	O
of	O
treatment	O
,	O
basal	O
ANP	B-GENE-Y
was	O
increased	O
and	O
basal	O
aldosterone	B-CHEMICAL
was	O
decreased	O
.	O

Body	O
weight	O
was	O
reduced	O
,	O
most	O
likely	O
reflecting	O
chronic	O
natriuretic	O
or	O
diuretic	O
effects	O
,	O
or	O
both	O
,	O
and	O
there	O
was	O
a	O
trend	O
toward	O
increased	O
cardiac	O
index	O
and	O
reduced	O
preload	O
values	O
.	O

On	O
study	O
day	O
10	O
,	O
the	O
acute	O
effects	O
of	O
candoxatril	B-CHEMICAL
were	O
similar	O
to	O
those	O
on	O
day	O
1	O
(	O
i	O
.	O
e	O
.	O
,	O
ANP	B-GENE-Y
was	O
further	O
increased	O
,	O
aldosterone	B-CHEMICAL
was	O
suppressed	O
,	O
and	O
right	O
and	O
left	O
ventricular	O
filling	O
pressures	O
were	O
decreased	O
)	O
.	O

Thus	O
,	O
candoxatril	B-CHEMICAL
may	O
offer	O
a	O
new	O
and	O
effective	O
therapeutic	O
approach	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
.	O

Prohormone	B-GENE-Y
convertase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
will	O
process	O
prorelaxin	B-GENE-N
,	O
a	O
member	O
of	O
the	O
insulin	B-GENE-Y
family	O
of	O
hormones	O
.	O

Relaxin	B-GENE-N
is	O
a	O
polypeptide	O
hormone	O
involved	O
in	O
remodeling	O
of	O
the	O
birth	O
canal	O
during	O
parturition	O
.	O

It	O
is	O
synthesized	O
as	O
a	O
preprohormone	O
precursor	O
,	O
which	O
undergoes	O
specific	O
processing	O
to	O
form	O
the	O
mature	O
two	O
-	O
chain	O
disulfide	B-CHEMICAL
-	O
linked	O
active	O
species	O
that	O
is	O
secreted	O
by	O
the	O
cell	O
.	O

A	O
major	O
part	O
of	O
this	O
processing	O
requires	O
endoproteolytic	O
cleavage	O
at	O
specific	O
pairs	O
of	O
basic	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
,	O
an	O
event	O
necessary	O
for	O
the	O
maturation	O
of	O
a	O
variety	O
of	O
important	O
biologically	O
active	O
proteins	O
,	O
such	O
as	O
insulin	B-GENE-Y
and	O
nerve	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
.	O

Human	B-GENE-Y
type	I-GENE-Y
2	I-GENE-Y
preprorelaxin	I-GENE-Y
was	O
coexpressed	O
in	O
human	O
kidney	O
293	O
cells	O
with	O
the	O
candidate	O
prohormone	B-GENE-N
convertase	I-GENE-N
-	I-GENE-N
processing	I-GENE-N
enzymes	I-GENE-N
mPC1	B-GENE-Y
or	O
mPC2	B-GENE-Y
,	O
both	O
cloned	O
from	O
the	O
mouse	O
pituitary	O
tumor	O
AtT	O
-	O
20	O
cell	O
line	O
,	O
or	O
with	O
the	O
yeast	B-GENE-Y
kex2	I-GENE-Y
alpha	B-GENE-Y
-	I-GENE-Y
mating	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
from	O
Saccharomyces	O
cerevisiae	O
.	O

Prorelaxin	B-GENE-N
expressed	O
alone	O
in	O
293	O
cells	O
was	O
secreted	O
into	O
the	O
culture	O
medium	O
unprocessed	O
.	O

Transient	O
coexpression	O
with	O
mPC1	B-GENE-Y
or	O
kex2	B-GENE-Y
,	O
but	O
not	O
with	O
mPC2	B-GENE-Y
,	O
resulted	O
in	O
the	O
secretion	O
of	O
a	O
low	O
mol	O
wt	O
species	O
with	O
an	O
electrophoretic	O
mobility	O
very	O
similar	O
,	O
if	O
not	O
identical	O
,	O
to	O
that	O
of	O
authentic	O
mature	O
relaxin	B-GENE-N
purified	O
from	O
human	O
placenta	O
.	O

This	O
species	O
was	O
precipitable	O
by	O
monoclonal	O
antibodies	O
specific	O
for	O
relaxin	B-GENE-N
and	O
had	O
a	O
retention	O
time	O
on	O
reverse	O
phase	O
HPLC	O
comparable	O
to	O
that	O
of	O
relaxin	B-GENE-N
.	O

Its	O
analysis	O
by	O
both	O
electrospray	O
and	O
fast	O
atom	O
bombardment	O
mass	O
spectrometry	O
generated	O
mass	O
data	O
that	O
were	O
consistent	O
only	O
with	O
mature	O
relaxin	B-GENE-N
.	O

The	O
basic	O
residues	O
required	O
for	O
mPC1	B-GENE-Y
-	O
dependent	O
cleavage	O
of	O
prorelaxin	B-GENE-N
are	O
defined	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

The	O
tricyclic	B-CHEMICAL
antidepressant	O
clomipramine	B-CHEMICAL
increases	O
plasma	O
glucose	B-CHEMICAL
levels	O
of	O
mice	O
.	O

Effects	O
of	O
the	O
tricyclic	B-CHEMICAL
antidepressant	O
clomipramine	B-CHEMICAL
on	O
plasma	O
glucose	B-CHEMICAL
levels	O
in	O
mice	O
were	O
studied	O
.	O

Clomipramine	B-CHEMICAL
at	O
doses	O
ranging	O
5	O
-	O
20	O
mg	O
/	O
kg	O
elicited	O
significant	O
hyperglycemia	O
in	O
mice	O
.	O

Hyperglycemia	O
elicited	O
by	O
clomipramine	B-CHEMICAL
was	O
not	O
reduced	O
by	O
pretreatment	O
with	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
depleter	O
p	B-CHEMICAL
-	I-CHEMICAL
chlorophenylalanine	I-CHEMICAL
.	O

The	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
/	I-GENE-N
5	I-GENE-N
/	I-GENE-N
7	I-GENE-N
)	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
methysergide	O
and	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2A	I-GENE-N
/	I-GENE-N
2B	I-GENE-N
/	I-GENE-N
2C	I-GENE-N
)	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
LY	B-CHEMICAL
53857	I-CHEMICAL
enhanced	O
clomipramine	B-CHEMICAL
-	O
induced	O
hyperglycemia	O
,	O
while	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
1A	I-GENE-N
/	I-GENE-N
1B	I-GENE-N
)	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
propranolol	I-CHEMICAL
and	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
3	I-GENE-N
/	I-GENE-N
4	I-GENE-N
)	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
tropisetron	B-CHEMICAL
did	O
not	O
affect	O
it	O
.	O

The	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2B	I-GENE-N
/	I-GENE-N
2C	I-GENE-N
)	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
SB	B-CHEMICAL
206553	I-CHEMICAL
facilitated	O
hyperglycemia	O
induced	O
by	O
clomipramine	B-CHEMICAL
,	O
although	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
-	O
receptor	O
antagonist	O
ketanserin	B-CHEMICAL
was	O
without	O
effect	O
.	O

Clomipramine	B-CHEMICAL
-	O
induced	O
hyperglycemia	O
was	O
reduced	O
by	O
prior	O
adrenalectomy	O
.	O

These	O
results	O
suggest	O
that	O
clomipramine	B-CHEMICAL
induces	O
hyperglycemia	O
in	O
mice	O
by	O
blocking	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2B	I-GENE-Y
)	I-GENE-Y
and	O
/	O
or	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2C	I-GENE-Y
)	I-GENE-Y
receptors	O
,	O
which	O
results	O
in	O
facilitation	O
of	O
adrenaline	B-CHEMICAL
release	O
.	O

Compared	O
pharmacological	O
characteristics	O
in	O
humans	O
of	O
racemic	O
cetirizine	B-CHEMICAL
and	O
levocetirizine	B-CHEMICAL
,	O
two	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
.	O

The	O
potent	O
histamine	B-GENE-Y
H	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
cetirizine	B-CHEMICAL
(	O
Zyrtec	B-CHEMICAL
)	O
is	O
a	O
racemic	O
mixture	O
of	O
levocetirizine	B-CHEMICAL
(	O
now	O
available	O
under	O
the	O
trademark	O
Xyzal	B-CHEMICAL
and	O
dextrocetirizine	B-CHEMICAL
.	O

In	O
this	O
Commentary	O
,	O
we	O
examine	O
some	O
biological	O
properties	O
of	O
cetirizine	B-CHEMICAL
and	O
levocetirizine	B-CHEMICAL
,	O
namely	O
enantioselectivity	O
in	O
pharmacological	O
activity	O
and	O
pharmacokinetic	O
properties	O
,	O
with	O
emphasis	O
on	O
the	O
possibility	O
of	O
racemization	O
,	O
the	O
compared	O
behavior	O
of	O
the	O
two	O
enantiomers	O
,	O
and	O
the	O
potential	O
for	O
interactions	O
with	O
other	O
drugs	O
.	O

Recent	O
data	O
demonstrate	O
that	O
the	O
antihistaminergic	O
activity	O
of	O
the	O
racemate	O
is	O
primarily	O
due	O
to	O
levocetirizine	B-CHEMICAL
.	O

Levocetirizine	B-CHEMICAL
is	O
rapidly	O
and	O
extensively	O
absorbed	O
,	O
poorly	O
metabolized	O
,	O
and	O
not	O
subject	O
to	O
racemization	O
.	O

Its	O
pharmacokinetic	O
characteristics	O
are	O
comparable	O
after	O
administration	O
alone	O
or	O
in	O
the	O
racemate	O
.	O

Its	O
apparent	O
volume	O
of	O
distribution	O
is	O
smaller	O
than	O
that	O
of	O
dextrocetirizine	B-CHEMICAL
(	O
0	O
.	O
41	O
L	O
kg	O
(	O
-	O
1	O
)	O
vs	O
.	O
0	O
.	O
60	O
L	O
kg	O
(	O
-	O
1	O
)	O
)	O
.	O

Moreover	O
,	O
the	O
non	O
-	O
renal	O
(	O
mostly	O
hepatic	O
)	O
clearance	O
of	O
levocetirizine	B-CHEMICAL
is	O
also	O
significantly	O
lower	O
than	O
that	O
of	O
dextrocetirizine	B-CHEMICAL
(	O
11	O
.	O
8	O
mL	O
min	O
(	O
-	O
1	O
)	O
vs	O
.	O
29	O
.	O
2	O
mL	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

Our	O
conclusion	O
is	O
that	O
levocetirizine	B-CHEMICAL
is	O
indeed	O
the	O
eutomer	O
of	O
cetirizine	B-CHEMICAL
.	O

The	O
evidence	O
reviewed	O
here	O
confirms	O
preclinical	O
findings	O
and	O
offers	O
a	O
rationale	O
for	O
the	O
chiral	O
switch	O
from	O
the	O
racemate	O
to	O
levocetirizine	B-CHEMICAL
.	O

In	O
vitro	O
simulation	O
of	O
therapeutic	O
plasmatic	O
fibrinolysis	O
.	O

One	O
type	O
of	O
therapy	O
for	O
thromboembolism	O
is	O
plasmatic	O
thrombolysis	O
.	O

Several	O
plasminogen	B-GENE-N
activators	I-GENE-N
(	O
PA	B-GENE-N
)	O
are	O
clinically	O
available	O
,	O
including	O
urokinase	B-GENE-N
(	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
,	O
tissue	B-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
,	O
streptokinase	B-GENE-N
(	O
SK	B-GENE-N
)	O
,	O
plasminogen	B-GENE-N
-	I-GENE-N
streptokinase	I-GENE-N
-	I-GENE-N
activator	I-GENE-N
-	I-GENE-N
complex	I-GENE-N
(	O
PSAC	B-GENE-N
)	O
,	O
or	O
mutants	O
of	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
such	O
as	O
reteplase	O
(	O
RP	O
)	O
or	O
tenecteplase	O
(	O
TP	O
)	O
.	O

Therapeutic	O
plasmatic	O
fibrinolysis	O
was	O
simulated	O
,	O
using	O
the	O
PA	B-GENE-N
at	O
relevant	O
plasma	O
concentrations	O
,	O
and	O
plasmin	B-GENE-Y
(	O
Pli	B-GENE-Y
)	O
and	O
PA	B-GENE-N
activities	O
were	O
determined	O
.	O

Normal	O
citrated	O
plasma	O
was	O
supplemented	O
with	O
31	O
to	O
1	O
,	O
000	O
IU	O
/	O
mL	O
u	O
-	O
PA	O
,	O
0	O
.	O
31	O
to	O
20	O
microg	O
/	O
mL	O
t	B-GENE-N
-	I-GENE-N
PA	I-GENE-N
,	O
125	O
to	O
4	O
,	O
000	O
IU	O
/	O
mL	O
SK	B-GENE-N
,	O
12	O
.	O
5	O
to	O
400	O
U	O
/	O
mL	O
PSAC	B-GENE-N
,	O
125	O
to	O
4	O
,	O
000	O
U	O
/	O
mL	O
RP	O
,	O
or	O
0	O
.	O
31	O
to	O
10	O
microg	O
/	O
mL	O
TP	O
.	O

Ten	O
IU	O
/	O
mL	O
urokinase	B-GENE-N
was	O
also	O
incubated	O
with	O
pooled	O
plasma	O
of	O
stroke	O
patients	O
,	O
that	O
was	O
previously	O
oxidized	O
with	O
the	O
singlet	B-CHEMICAL
oxygen	I-CHEMICAL
(	O
1O2	B-CHEMICAL
)	O
donor	O
chloramine	B-CHEMICAL
T	I-CHEMICAL
(	O
CT	B-CHEMICAL
)	O
,	O
to	O
destroy	O
plasmatic	B-GENE-Y
PAI	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
alpha2	O
-	O
antiplasmin	B-GENE-Y
.	O

After	O
0	O
to	O
80	O
minutes	O
(	O
37	O
degrees	O
C	O
)	O
,	O
50	O
-	O
microL	O
samples	O
were	O
withdrawn	O
and	O
added	O
to	O
100	O
microL	O
1	O
.	O
5	O
M	O
arginine	B-CHEMICAL
,	O
pH	O
8	O
.	O
7	O
,	O
and	O
oxidized	O
with	O
50	O
microL	O
of	O
20	O
mM	O
CT	B-CHEMICAL
.	O

For	O
determination	O
of	O
plasmin	B-GENE-Y
activity	O
,	O
10	O
microL	O
thereof	O
was	O
incubated	O
with	O
150	O
microL	O
1	O
.	O
5	O
M	O
arginine	B-CHEMICAL
,	O
pH	O
8	O
.	O
7	O
,	O
and	O
100	O
microL	O
20	O
mM	O
CT	B-CHEMICAL
preoxidized	O
(	O
15	O
minutes	O
37	O
degrees	O
C	O
)	O
pooled	O
normal	O
citrate	B-CHEMICAL
buffered	O
EDTA	B-CHEMICAL
-	O
plasma	O
for	O
30	O
minutes	O
(	O
37	O
degrees	O
C	O
)	O
.	O

For	O
determination	O
of	O
[	O
PA	B-GENE-N
+	O
Pli	B-GENE-Y
]	O
-	O
activity	O
,	O
arginine	B-CHEMICAL
was	O
added	O
after	O
this	O
incubation	O
.	O

25	O
-	O
microL	O
6	O
mM	O
Val	B-CHEMICAL
-	I-CHEMICAL
Leu	I-CHEMICAL
-	I-CHEMICAL
Lys	I-CHEMICAL
-	O
pNA	O
were	O
added	O
and	O
deltaA	O
/	O
h	O
at	O
room	O
temperature	O
(	O
RT	O
)	O
was	O
monitored	O
,	O
using	O
a	O
microtiterplate	O
reader	O
.	O

[	O
PA	B-GENE-N
+	O
Pli	B-GENE-Y
]	O
-	O
Pli	B-GENE-Y
=	O
PA	B-GENE-N
.	O

The	O
PA	B-GENE-N
concentration	O
required	O
to	O
induce	O
25	O
%	O
[	O
ED25	O
]	O
of	O
the	O
maximally	O
inducible	O
Pli	B-GENE-Y
-	O
activity	O
in	O
plasma	O
(	O
=	O
1	O
U	O
/	O
mL	O
=	O
45	O
mg	O
/	O
L	O
=	O
0	O
.	O
53	O
micromol	O
/	O
L	O
active	O
Pli	B-GENE-Y
;	O
deltaA	O
=	O
363	O
+	O
/	O
-	O
8	O
mA	O
/	O
h	O
RT	O
)	O
after	O
10	O
minutes	O
(	O
37	O
degrees	O
C	O
)	O
were	O
320	O
IU	O
/	O
mL	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
,	O
8	O
microg	O
/	O
mL	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
,	O
140	O
U	O
/	O
mL	O
PSAC	O
,	O
6	O
,	O
000	O
IU	O
/	O
mL	O
SK	O
,	O
720	O
U	O
/	O
mL	O
RP	O
,	O
and	O
approximately	O
150	O
microg	O
/	O
mL	O
TP	O
.	O

The	O
approximate	O
activity	O
half	O
-	O
lives	O
of	O
the	O
PA	B-GENE-N
in	O
plasma	O
were	O
30	O
minutes	O
for	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
,	O
30	O
minutes	O
for	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
,	O
greater	O
than	O
80	O
minutes	O
for	O
SK	B-GENE-N
,	O
greater	O
than	O
80	O
minutes	O
for	O
PSAC	B-GENE-N
,	O
50	O
minutes	O
for	O
RP	O
,	O
and	O
80	O
minutes	O
for	O
TP	O
.	O

The	O
present	O
study	O
shows	O
-	O
-	O
for	O
the	O
first	O
time	O
-	O
-	O
a	O
combined	O
kinetic	O
in	O
vitro	O
simulation	O
of	O
the	O
plasmatic	O
activity	O
of	O
six	O
different	O
PAs	B-GENE-N
.	O

At	O
clinically	O
used	O
concentrations	O
,	O
RP	O
induces	O
the	O
highest	O
plasmatic	B-GENE-Y
Pli	I-GENE-Y
activity	O
.	O

Due	O
to	O
unselective	O
generation	O
of	O
plasmin	B-GENE-Y
in	O
plasma	O
,	O
all	O
PA	B-GENE-N
are	O
of	O
some	O
danger	O
in	O
inducing	O
severe	O
hemorrhagias	O
.	O

Clinical	O
thrombolysis	O
might	O
be	O
improved	O
by	O
usage	O
of	O
more	O
physiologic	O
activators	O
of	O
thrombolysis	O
,	O
such	O
as	O
activators	O
of	O
polymorphonuclear	O
neutrophils	O
.	O

P2Y	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
agonist	O
INS37217	B-CHEMICAL
enhances	O
functional	O
recovery	O
after	O
detachment	O
caused	O
by	O
subretinal	O
injection	O
in	O
normal	O
and	O
rds	O
mice	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
the	O
effects	O
of	O
INS37217	B-CHEMICAL
on	O
the	O
recovery	O
of	O
retinal	B-CHEMICAL
function	O
after	O
experimental	O
retinal	B-CHEMICAL
detachment	O
induced	O
by	O
subretinal	O
injection	O
.	O

METHODS	O
:	O
Subretinal	O
injections	O
of	O
1	O
micro	O
L	O
of	O
fluorescent	O
microbeads	O
,	O
saline	O
,	O
or	O
INS37217	B-CHEMICAL
(	O
1	O
-	O
200	O
micro	O
M	O
)	O
were	O
made	O
by	O
the	O
transvitreal	O
method	O
in	O
normal	O
(	O
C57BL	O
/	O
6	O
)	O
mice	O
and	O
in	O
mice	O
heterozygous	O
for	O
the	O
retinal	B-CHEMICAL
degeneration	O
slow	O
(	O
rds	O
)	O
gene	O
.	O

Control	O
,	O
mock	O
-	O
injected	O
animals	O
underwent	O
corneal	O
puncture	O
without	O
injection	O
.	O

Histologic	O
and	O
ERG	O
evaluations	O
were	O
made	O
at	O
0	O
to	O
1	O
and	O
8	O
hours	O
,	O
and	O
1	O
,	O
3	O
,	O
7	O
,	O
10	O
,	O
14	O
,	O
and	O
60	O
days	O
post	O
injection	O
(	O
PI	O
)	O
.	O

DNA	O
fragmentation	O
was	O
evaluated	O
by	O
terminal	O
deoxynucleotidyl	B-CHEMICAL
transferase	O
-	O
mediated	O
uridine	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
triphosphate	I-CHEMICAL
-	I-CHEMICAL
biotin	I-CHEMICAL
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
.	O

RESULTS	O
:	O
A	O
single	O
subretinal	O
injection	O
of	O
saline	O
solution	O
containing	O
fluorescent	O
beads	O
caused	O
a	O
histologically	O
evident	O
retinal	O
detachment	O
and	O
distributed	O
the	O
microbeads	O
to	O
almost	O
all	O
the	O
subretinal	O
space	O
.	O

Spontaneous	O
reattachment	O
occurred	O
within	O
24	O
hours	O
after	O
injection	O
and	O
was	O
accompanied	O
by	O
evident	O
retinal	B-CHEMICAL
folding	O
that	O
appeared	O
largely	O
resolved	O
by	O
6	O
days	O
later	O
.	O

Relative	O
to	O
controls	O
,	O
injection	O
of	O
saline	O
resulted	O
in	O
approximately	O
40	O
%	O
recovery	O
of	O
dark	O
-	O
adapted	O
a	O
-	O
wave	O
amplitude	O
at	O
24	O
hours	O
PI	O
and	O
gradually	O
improved	O
to	O
approximately	O
90	O
%	O
of	O
controls	O
at	O
2	O
months	O
PI	O
.	O

Subretinal	O
injection	O
of	O
saline	O
containing	O
INS37217	B-CHEMICAL
(	O
10	O
micro	O
M	O
)	O
significantly	O
increased	O
rod	O
and	O
cone	O
ERG	O
of	O
normal	O
and	O
rds	O
(	O
+	O
/	O
-	O
)	O
mice	O
at	O
1	O
and	O
10	O
days	O
PI	O
,	O
when	O
compared	O
with	O
injection	O
of	O
saline	O
alone	O
.	O

Additionally	O
,	O
INS37217	B-CHEMICAL
reduced	O
the	O
number	O
of	O
TUNEL	O
-	O
positive	O
photoreceptors	O
and	O
the	O
enhanced	O
rate	O
of	O
reattachment	O
.	O

CONCLUSIONS	O
:	O
Enhancement	O
of	O
ERG	O
recovery	O
by	O
INS37217	B-CHEMICAL
is	O
likely	O
due	O
to	O
reduced	O
retinal	B-CHEMICAL
folding	O
and	O
cell	O
death	O
associated	O
with	O
detachment	O
.	O

These	O
results	O
support	O
the	O
use	O
of	O
INS37217	B-CHEMICAL
to	O
help	O
restore	O
function	O
after	O
therapies	O
that	O
involve	O
subretinal	O
administration	O
of	O
drugs	O
in	O
animal	O
models	O
of	O
retinal	B-CHEMICAL
diseases	O
.	O

Activation	O
of	O
alpha	B-GENE-Y
2B	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
mediates	O
the	O
cardiovascular	O
effects	O
of	O
etomidate	B-CHEMICAL
.	O

BACKGROUND	O
:	O
The	O
intravenous	O
anesthetic	O
etomidate	B-CHEMICAL
exhibits	O
structural	O
similarities	O
to	O
specific	O
alpha2	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonists	O
of	O
the	O
type	O
such	O
as	O
dexmedetomidine	B-CHEMICAL
.	O

The	O
current	O
study	O
was	O
performed	O
to	O
elucidate	O
the	O
possible	O
interaction	O
of	O
etomidate	B-CHEMICAL
with	O
alpha2	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
mice	O
lacking	O
individual	O
alpha2	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtypes	O
(	O
alpha2	O
-	O
KO	O
)	O
.	O

METHODS	O
:	O
Sedative	O
and	O
cardiovascular	O
responses	O
to	O
etomidate	B-CHEMICAL
and	O
the	O
alpha2	O
-	O
agonist	O
,	O
dexmedetomidine	B-CHEMICAL
,	O
were	O
determined	O
in	O
mice	O
deficient	O
in	O
alpha2	B-GENE-N
-	I-GENE-N
receptor	I-GENE-N
subtypes	O
.	O

Inhibition	O
of	O
binding	O
of	O
the	O
alpha2	B-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
RX821002	I-CHEMICAL
to	O
recombinant	O
alpha2	B-GENE-N
-	I-GENE-N
receptors	I-GENE-N
by	O
etomidate	B-CHEMICAL
was	O
tested	O
in	O
human	O
embryonic	O
kidney	O
(	O
HEK293	O
)	O
cells	O
in	O
vitro	O
.	O

RESULTS	O
:	O
In	O
vivo	O
,	O
loss	O
and	O
recovery	O
of	O
the	O
righting	O
reflex	O
required	O
similar	O
times	O
after	O
intraperitoneal	O
injection	O
of	O
etomidate	B-CHEMICAL
in	O
wild	O
-	O
type	O
and	O
in	O
alpha2A	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
-	O
deficient	O
mice	O
,	O
indicating	O
that	O
the	O
hypnotic	O
effect	O
of	O
etomidate	B-CHEMICAL
in	O
mice	O
does	O
not	O
require	O
the	O
alpha2A	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
subtype	O
.	O

Intravenous	O
injection	O
of	O
etomidate	B-CHEMICAL
resulted	O
in	O
a	O
transient	O
increase	O
(	O
duration	O
2	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
2	O
min	O
)	O
in	O
arterial	O
blood	O
pressure	O
in	O
wild	O
-	O
type	O
mice	O
(	O
17	O
+	O
/	O
-	O
3	O
mmHg	O
)	O
.	O

Etomidate	B-CHEMICAL
did	O
not	O
affect	O
blood	O
pressure	O
in	O
alpha2B	O
-	O
KO	O
or	O
alpha2AB	O
-	O
KO	O
mice	O
.	O

In	O
membranes	O
from	O
HEK293	O
cells	O
transfected	O
with	O
alpha2	B-GENE-N
-	I-GENE-N
receptors	I-GENE-N
,	O
etomidate	B-CHEMICAL
inhibited	O
binding	O
of	O
the	O
alpha2	O
-	O
antagonist	O
,	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
RX821002	I-CHEMICAL
,	O
with	O
higher	O
potency	O
from	O
alpha2B	B-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha2C	I-GENE-N
-	I-GENE-N
receptors	I-GENE-N
than	O
from	O
alpha2A	B-GENE-Y
-	I-GENE-Y
receptors	I-GENE-Y
(	O
Ki	O
alpha2A	O
208	O
microm	O
,	O
alpha2B	O
26	O
microm	O
,	O
alpha2C	O
56	O
microm	O
)	O
.	O

In	O
alpha2B	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
-	O
expressing	O
HEK293	O
cells	O
,	O
etomidate	B-CHEMICAL
rapidly	O
increased	O
phosphorylation	O
of	O
the	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
related	I-GENE-N
kinases	I-GENE-N
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
.	O

CONCLUSIONS	O
:	O
These	O
results	O
indicate	O
that	O
etomidate	B-CHEMICAL
acts	O
as	O
an	O
agonist	O
at	O
alpha2	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
which	O
appears	O
in	O
vivo	O
primarily	O
as	O
an	O
alpha2B	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
increase	O
in	O
blood	O
pressure	O
.	O

This	O
effect	O
of	O
etomidate	B-CHEMICAL
may	O
contribute	O
to	O
the	O
cardiovascular	O
stability	O
of	O
patients	O
after	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B-CHEMICAL
.	O

Transcriptional	O
control	O
of	O
the	O
arginine	B-GENE-N
/	I-GENE-N
lysine	I-GENE-N
transporter	I-GENE-N
,	O
cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
by	O
physiological	O
stress	O
.	O

Cells	O
respond	O
to	O
physiological	O
stress	O
by	O
phosphorylating	O
the	O
alpha	O
subunit	O
of	O
the	O
translation	O
initiation	O
factor	O
eIF2	B-GENE-N
.	O

This	O
adaptive	O
response	O
inhibits	O
protein	O
synthesis	O
and	O
up	O
-	O
regulates	O
genes	O
essential	O
for	O
cell	O
survival	O
.	O

Cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
the	O
transporter	O
for	O
the	O
essential	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
arginine	B-CHEMICAL
and	O
lysine	B-CHEMICAL
,	O
is	O
one	O
of	O
the	O
up	O
-	O
regulated	O
genes	O
.	O

We	O
previously	O
showed	O
that	O
stress	O
increases	O
cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
by	O
coordinated	O
stabilization	O
of	O
the	O
mRNA	O
and	O
increased	O
mRNA	O
translation	O
.	O

This	O
induction	O
is	O
triggered	O
by	O
amino	B-CHEMICAL
acid	I-CHEMICAL
depletion	O
and	O
the	O
unfolded	B-GENE-N
protein	I-GENE-N
response	I-GENE-N
(	O
UPR	B-GENE-N
)	O
,	O
which	O
is	O
caused	O
by	O
unfolded	O
proteins	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

We	O
show	O
here	O
that	O
cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
transcription	O
is	O
also	O
increased	O
by	O
cellular	O
stress	O
.	O

Our	O
studies	O
demonstrate	O
that	O
the	O
cat	B-GENE-N
-	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
/	O
regulatory	O
region	O
is	O
TATA	B-GENE-N
-	O
less	O
and	O
is	O
located	O
in	O
a	O
region	O
that	O
includes	O
94	O
bases	O
of	O
the	O
first	O
exon	O
.	O

Transcription	O
from	O
this	O
promoter	O
is	O
stimulated	O
8	O
-	O
fold	O
by	O
cellular	O
stress	O
.	O

An	O
amino	B-CHEMICAL
acid	I-CHEMICAL
response	O
element	O
within	O
the	O
first	O
exon	O
is	O
shown	O
to	O
be	O
required	O
for	O
the	O
response	O
to	O
amino	B-CHEMICAL
acid	I-CHEMICAL
depletion	O
but	O
not	O
to	O
the	O
UPR	O
.	O

The	O
stimulation	O
of	O
transcription	O
by	O
amino	B-CHEMICAL
acid	I-CHEMICAL
depletion	O
requires	O
activation	O
of	O
GCN2	B-GENE-Y
kinase	B-GENE-N
,	O
which	O
phosphorylates	O
eIF2alpha	B-GENE-Y
.	O

This	O
phosphorylation	O
also	O
induces	O
translation	O
of	O
the	O
cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
,	O
demonstrating	O
that	O
stress	O
-	O
induced	O
transcriptional	O
and	O
translational	O
control	O
of	O
cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
are	O
downstream	O
targets	O
of	O
a	O
signaling	O
pathway	O
initiating	O
with	O
eIF2alpha	B-GENE-Y
phosphorylation	O
.	O

Our	O
studies	O
show	O
that	O
the	O
increase	O
in	O
cat	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
expression	O
by	O
cellular	O
stress	O
involves	O
at	O
least	O
three	O
types	O
of	O
coordinate	O
regulation	O
:	O
regulation	O
of	O
transcription	O
,	O
regulation	O
of	O
mRNA	O
stability	O
,	O
and	O
regulation	O
of	O
mRNA	O
translation	O
.	O

Mechanism	O
of	O
organophosphates	B-CHEMICAL
(	O
nerve	O
gases	O
and	O
pesticides	O
)	O
and	O
antidotes	O
:	O
electron	O
transfer	O
and	O
oxidative	O
stress	O
.	O

Evidence	O
indicates	O
that	O
nerve	O
gas	O
toxins	O
operate	O
in	O
ways	O
in	O
addition	O
to	O
inhibition	O
of	O
acetylcholine	B-GENE-Y
esterase	I-GENE-Y
.	O

Alternative	O
bioactivities	O
are	O
discussed	O
with	O
focus	O
on	O
electron	O
transfer	O
.	O

The	O
main	O
class	O
,	O
including	O
pralidoxime	B-CHEMICAL
(	O
2	B-CHEMICAL
-	I-CHEMICAL
PAM	I-CHEMICAL
)	O
,	O
incorporates	O
conjugated	O
iminium	B-CHEMICAL
and	O
oxime	B-CHEMICAL
moieties	O
that	O
are	O
electron	O
affinic	O
.	O

Various	O
physiological	O
properties	O
of	O
iminium	B-CHEMICAL
and	O
oxime	B-CHEMICAL
species	O
are	O
reviewed	O
.	O

The	O
organophosphates	B-CHEMICAL
encompass	O
both	O
nerve	O
gases	O
and	O
insecticides	O
,	O
possessing	O
similar	O
properties	O
,	O
but	O
different	O
activities	O
.	O

Toxic	O
manifestations	O
are	O
apparently	O
due	O
,	O
in	O
part	O
,	O
to	O
oxidative	O
stress	O
.	O

Alkylation	O
of	O
DNA	O
takes	O
place	O
which	O
may	O
lead	O
to	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
.	O

Structure	O
-	O
activity	O
relationships	O
are	O
examined	O
,	O
including	O
reduction	O
potentials	O
and	O
the	O
captodative	O
effect	O
.	O

The	O
neuropharmacological	O
basis	O
for	O
the	O
use	O
of	O
memantine	B-CHEMICAL
in	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Memantine	B-CHEMICAL
has	O
been	O
demonstrated	O
to	O
be	O
safe	O
and	O
effective	O
in	O
the	O
symptomatic	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

While	O
the	O
neurobiological	O
basis	O
for	O
the	O
therapeutic	O
activity	O
of	O
memantine	B-CHEMICAL
is	O
not	O
fully	O
understood	O
,	O
the	O
drug	O
is	O
not	O
a	O
cholinesterase	B-GENE-Y
inhibitor	O
and	O
,	O
therefore	O
,	O
acts	O
differently	O
from	O
current	O
AD	O
therapies	O
.	O

Memantine	B-CHEMICAL
can	O
interact	O
with	O
a	O
variety	O
of	O
ligand	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
ion	I-GENE-N
channels	I-GENE-N
.	O

However	O
,	O
NMDA	B-GENE-N
receptors	I-GENE-N
appear	O
to	O
be	O
a	O
key	O
target	O
of	O
memantine	B-CHEMICAL
at	O
therapeutic	O
concentrations	O
.	O

Memantine	B-CHEMICAL
is	O
an	O
uncompetitive	O
(	O
channel	O
blocking	O
)	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonist	O
.	O

Like	O
other	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonists	O
,	O
memantine	B-CHEMICAL
at	O
high	O
concentrations	O
can	O
inhibit	O
mechanisms	O
of	O
synaptic	O
plasticity	O
that	O
are	O
believed	O
to	O
underlie	O
learning	O
and	O
memory	O
.	O

However	O
,	O
at	O
lower	O
,	O
clinically	O
relevant	O
concentrations	O
memantine	B-CHEMICAL
can	O
under	O
some	O
circumstances	O
promote	O
synaptic	O
plasticity	O
and	O
preserve	O
or	O
enhance	O
memory	O
in	O
animal	O
models	O
of	O
AD	O
.	O

In	O
addition	O
,	O
memantine	B-CHEMICAL
can	O
protect	O
against	O
the	O
excitotoxic	O
destruction	O
of	O
cholinergic	O
neurons	O
.	O

Blockade	O
of	O
NMDA	B-GENE-N
receptors	I-GENE-N
by	O
memantine	B-CHEMICAL
could	O
theoretically	O
confer	O
disease	O
-	O
modifying	O
activity	O
in	O
AD	O
by	O
inhibiting	O
the	O
"	O
weak	O
"	O
NMDA	B-GENE-N
receptor	I-GENE-N
-	O
dependent	O
excitotoxicity	O
that	O
has	O
been	O
hypothesized	O
to	O
play	O
a	O
role	O
in	O
the	O
progressive	O
neuronal	O
loss	O
that	O
underlies	O
the	O
evolving	O
dementia	O
.	O

Moreover	O
,	O
recent	O
in	O
vitro	O
studies	O
suggest	O
that	O
memantine	B-CHEMICAL
abrogates	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
(	O
Abeta	B-GENE-Y
)	O
toxicity	O
and	O
possibly	O
inhibits	O
Abeta	B-GENE-Y
production	O
.	O

Considerable	O
attention	O
has	O
focused	O
on	O
the	O
investigation	O
of	O
theories	O
to	O
explain	O
the	O
better	O
tolerability	O
of	O
memantine	B-CHEMICAL
over	O
other	O
NMDA	B-GENE-N
receptor	I-GENE-N
antagonists	O
,	O
particularly	O
those	O
that	O
act	O
by	O
a	O
similar	O
channel	O
blocking	O
mechanism	O
such	O
as	O
dissociative	O
anesthetic	O
-	O
like	O
agents	O
(	O
phencyclidine	B-CHEMICAL
,	O
ketamine	B-CHEMICAL
,	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
)	O
.	O

A	O
variety	O
of	O
channel	O
-	O
level	O
factors	O
could	O
be	O
relevant	O
,	O
including	O
fast	O
channel	O
-	O
blocking	O
kinetics	O
and	O
strong	O
voltage	O
-	O
dependence	O
(	O
allowing	O
rapid	O
relief	O
of	O
block	O
during	O
synaptic	O
activity	O
)	O
,	O
as	O
well	O
as	O
reduced	O
trapping	O
(	O
permitting	O
egress	O
from	O
closed	O
channels	O
)	O
.	O

These	O
factors	O
may	O
allow	O
memantine	B-CHEMICAL
to	O
block	O
channel	O
activity	O
induced	O
by	O
low	O
,	O
tonic	O
levels	O
of	O
glutamate	B-CHEMICAL
-	O
-	O
an	O
action	O
that	O
might	O
contribute	O
to	O
symptomatic	O
improvement	O
and	O
could	O
theoretically	O
protect	O
against	O
weak	O
excitotoxicity	O
-	O
-	O
while	O
sparing	O
synaptic	O
responses	O
required	O
for	O
normal	O
behavioral	O
functioning	O
,	O
cognition	O
and	O
memory	O
.	O

Update	O
on	O
rivastigmine	B-CHEMICAL
.	O

BACKGROUND	O
:	O
Rivastigmine	B-CHEMICAL
is	O
a	O
carbamate	B-CHEMICAL
drug	O
designed	O
to	O
inhibit	O
both	O
acetylcholinesterase	B-GENE-Y
and	O
butyrylcholinesterase	B-GENE-Y
by	O
reversibly	O
covalently	O
bonding	O
to	O
these	O
enzymes	O
.	O

Butyrylcholinesterase	B-GENE-Y
in	O
-	O
creases	O
as	O
Alzheimer	O
disease	O
progresses	O
,	O
so	O
its	O
inhibition	O
may	O
become	O
more	O
important	O
as	O
the	O
disease	O
worsens	O
.	O

Metabolism	O
of	O
rivastigmine	B-CHEMICAL
occurs	O
at	O
the	O
synapse	O
rather	O
than	O
at	O
the	O
liver	O
and	O
previous	O
studies	O
have	O
demonstrated	O
no	O
drug	O
-	O
drug	O
interactions	O
.	O

Rivastigmine	B-CHEMICAL
has	O
a	O
half	O
-	O
life	O
at	O
the	O
synapse	O
of	O
9	O
hours	O
allowing	O
for	O
bid	O
dosing	O
.	O

REVIEW	O
SUMMARY	O
:	O
Effective	O
therapy	O
requires	O
up	O
-	O
titration	O
from	O
initial	O
dosage	O
of	O
3	O
mg	O
/	O
d	O
to	O
6	O
mg	O
/	O
d	O
with	O
additional	O
increases	O
to	O
9	O
mg	O
or	O
12	O
mg	O
/	O
d	O
giving	O
additional	O
benefits	O
in	O
some	O
patients	O
.	O

Beneficial	O
effects	O
with	O
rivastigmine	B-CHEMICAL
therapy	O
in	O
the	O
functioning	O
of	O
activities	O
of	O
daily	O
living	O
,	O
behavior	O
,	O
cognition	O
,	O
and	O
global	O
functioning	O
have	O
been	O
demonstrated	O
in	O
patients	O
with	O
mild	O
to	O
moderate	O
Alzheimer	O
disease	O
in	O
4	O
large	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
multicenter	O
clinical	O
trials	O
.	O

Potential	O
adverse	O
effects	O
of	O
nausea	O
,	O
vomiting	O
,	O
or	O
diarrhea	O
in	O
these	O
original	O
Alzheimer	O
trials	O
with	O
rapid	O
(	O
every	O
week	O
)	O
dosage	O
increases	O
occurred	O
in	O
up	O
to	O
34	O
%	O
of	O
patients	O
and	O
can	O
be	O
minimized	O
by	O
slower	O
monthly	O
up	O
-	O
titrations	O
.	O

Rivastigmine	B-CHEMICAL
also	O
was	O
proven	O
effective	O
in	O
decreasing	O
psychiatric	O
symptoms	O
and	O
cognitive	O
deficits	O
in	O
a	O
large	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
patients	O
with	O
diffuse	O
Lewy	O
body	O
disease	O
.	O

Other	O
studies	O
have	O
suggested	O
that	O
rivastigmine	B-CHEMICAL
improves	O
symptoms	O
in	O
nursing	O
home	O
patients	O
with	O
more	O
severe	O
stage	O
Alzheimer	O
disease	O
,	O
Parkinson	O
dementia	O
,	O
and	O
subcortical	O
dementia	O
.	O

Follow	O
-	O
up	O
studies	O
have	O
suggested	O
that	O
rivastigmine	B-CHEMICAL
may	O
delay	O
disease	O
progression	O
and	O
,	O
in	O
patients	O
discontinuing	O
the	O
drug	O
,	O
no	O
withdrawal	O
effects	O
were	O
seen	O
.	O

CONCLUSION	O
:	O
Rivastigmine	B-CHEMICAL
is	O
an	O
effective	O
therapeutic	O
agent	O
for	O
treating	O
cognitive	O
and	O
behavioral	O
symptoms	O
in	O
Alzheimer	O
disease	O
and	O
diffuse	O
Lewy	O
body	O
disease	O
and	O
may	O
also	O
have	O
beneficial	O
effects	O
in	O
vascular	O
and	O
Parkinson	O
dementias	O
.	O

Mechanisms	O
of	O
cefadroxil	B-CHEMICAL
uptake	O
in	O
the	O
choroid	O
plexus	O
:	O
studies	O
in	O
wild	O
-	O
type	O
and	O
PEPT2	B-GENE-Y
knockout	O
mice	O
.	O

The	O
choroid	O
plexus	O
uptake	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
cefadroxil	I-CHEMICAL
was	O
studied	O
in	O
peptide	B-GENE-Y
transporter	I-GENE-Y
2	I-GENE-Y
(	O
PEPT2	B-GENE-Y
)	O
wild	O
-	O
type	O
and	O
null	O
mice	O
as	O
a	O
function	O
of	O
temperature	O
,	O
transport	O
inhibitors	O
,	O
pH	O
,	O
and	O
saturability	O
.	O

At	O
normal	O
pH	O
(	O
7	O
.	O
4	O
)	O
and	O
temperature	O
(	O
37	O
degrees	O
C	O
)	O
,	O
the	O
uptake	O
of	O
1	O
microM	O
cefadroxil	B-CHEMICAL
was	O
reduced	O
by	O
83	O
%	O
in	O
PEPT2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
as	O
compared	O
with	O
PEPT2	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

A	O
further	O
reduction	O
was	O
achieved	O
in	O
null	O
animals	O
by	O
reducing	O
the	O
temperature	O
to	O
4	O
degrees	O
C	O
,	O
or	O
by	O
adding	O
saturating	O
concentrations	O
of	O
unlabeled	O
cefadroxil	B-CHEMICAL
or	O
p	B-CHEMICAL
-	I-CHEMICAL
aminohippurate	I-CHEMICAL
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Glycylsarcosine	B-CHEMICAL
coadministration	O
could	O
inhibit	O
the	O
uptake	O
of	O
cefadroxil	B-CHEMICAL
in	O
PEPT2	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
but	O
not	O
PEPT2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Although	O
a	O
proton	O
-	O
stimulated	O
uptake	O
of	O
cefadroxil	B-CHEMICAL
was	O
demonstrated	O
in	O
PEPT2	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
mice	O
(	O
pH	O
6	O
.	O
5	O
versus	O
pH	O
7	O
.	O
4	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
no	O
pH	O
dependence	O
was	O
observed	O
in	O
PEPT2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Kinetic	O
parameters	O
for	O
cefadroxil	B-CHEMICAL
(	O
without	O
p	B-CHEMICAL
-	I-CHEMICAL
aminohippurate	I-CHEMICAL
)	O
in	O
wild	O
-	O
type	O
mice	O
were	O
:	O
V	O
(	O
max	O
)	O
=	O
5	O
.	O
4	O
pmol	O
/	O
mg	O
/	O
min	O
,	O
K	O
(	O
m	O
)	O
=	O
34	O
microM	O
,	O
and	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
0069	O
microl	O
/	O
mg	O
/	O
min	O
;	O
in	O
the	O
presence	O
of	O
p	B-CHEMICAL
-	I-CHEMICAL
aminohippurate	I-CHEMICAL
,	O
the	O
parameters	O
were	O
:	O
V	O
(	O
max	O
)	O
=	O
4	O
.	O
1	O
pmol	O
/	O
mg	O
/	O
min	O
,	O
K	O
(	O
m	O
)	O
=	O
27	O
microM	O
,	O
and	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
0064	O
microl	O
/	O
mg	O
/	O
min	O
.	O

In	O
null	O
animals	O
,	O
the	O
kinetic	O
parameters	O
of	O
cefadroxil	B-CHEMICAL
(	O
without	O
p	B-CHEMICAL
-	I-CHEMICAL
aminohippurate	I-CHEMICAL
)	O
were	O
:	O
V	O
(	O
max	O
)	O
=	O
2	O
.	O
7	O
pmol	O
/	O
mg	O
/	O
min	O
,	O
K	O
(	O
m	O
)	O
=	O
110	O
microM	O
,	O
and	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
0084	O
microl	O
/	O
mg	O
/	O
min	O
;	O
in	O
the	O
presence	O
of	O
p	B-CHEMICAL
-	I-CHEMICAL
aminohippurate	I-CHEMICAL
,	O
only	O
a	O
K	O
(	O
d	O
)	O
=	O
0	O
.	O
010	O
microl	O
/	O
mg	O
/	O
min	O
was	O
observed	O
.	O

Based	O
on	O
kinetic	O
and	O
inhibitor	O
analyses	O
,	O
it	O
was	O
determined	O
that	O
(	O
under	O
linear	O
conditions	O
)	O
,	O
80	O
to	O
85	O
%	O
of	O
cefadroxil	O
'	O
s	O
uptake	O
in	O
choroid	O
plexus	O
is	O
mediated	O
by	O
PEPT2	B-GENE-Y
,	O
10	O
to	O
15	O
%	O
by	O
organic	B-GENE-Y
anion	I-GENE-Y
transporter	I-GENE-Y
(	I-GENE-Y
s	I-GENE-Y
)	I-GENE-Y
,	O
and	O
5	O
%	O
by	O
nonspecific	O
mechanisms	O
.	O

These	O
findings	O
demonstrate	O
that	O
PEPT2	B-GENE-Y
is	O
the	O
primary	O
transporter	O
responsible	O
for	O
cefadroxil	B-CHEMICAL
uptake	O
in	O
the	O
choroid	O
plexus	O
.	O

Moreover	O
,	O
the	O
data	O
suggest	O
a	O
role	O
for	O
PEPT2	B-GENE-Y
in	O
the	O
clearance	O
of	O
peptidomimetics	O
from	O
cerebrospinal	O
fluid	O
.	O

Turnover	O
of	O
type	B-GENE-N
II	I-GENE-N
collagen	I-GENE-N
and	O
aggrecan	B-GENE-Y
in	O
cartilage	O
matrix	O
at	O
the	O
onset	O
of	O
inflammatory	O
arthritis	O
in	O
humans	O
:	O
relationship	O
to	O
mediators	O
of	O
systemic	O
and	O
local	O
inflammation	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
in	O
vivo	O
the	O
extent	O
of	O
damage	O
to	O
,	O
and	O
changes	O
in	O
turnover	O
of	O
,	O
articular	O
cartilage	O
type	B-GENE-N
II	I-GENE-N
collagen	I-GENE-N
(	O
CII	B-GENE-N
)	O
and	O
the	O
proteoglycan	B-GENE-N
aggrecan	B-GENE-Y
following	O
the	O
onset	O
of	O
inflammatory	O
arthritis	O
in	O
humans	O
,	O
and	O
to	O
examine	O
the	O
hypothesis	O
that	O
there	O
are	O
direct	O
relationships	O
between	O
cartilage	O
biomarkers	O
of	O
damage	O
/	O
turnover	O
and	O
clinical	O
,	O
histologic	O
,	O
and	O
molecular	O
markers	O
of	O
inflammation	O
.	O

METHODS	O
:	O
Synovial	O
fluid	O
(	O
SF	O
)	O
and	O
synovial	O
membrane	O
(	O
SM	O
)	O
were	O
obtained	O
by	O
arthroscopy	O
,	O
and	O
a	O
synovitis	O
score	O
was	O
determined	O
,	O
in	O
32	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
(	O
13	O
with	O
early	O
untreated	O
disease	O
,	O
19	O
with	O
established	O
disease	O
)	O
,	O
18	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
and	O
10	O
with	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Systemic	O
disease	O
activity	O
markers	O
were	O
recorded	O
,	O
and	O
SM	O
CD3	O
+	O
T	O
cells	O
,	O
CD4	O
+	O
T	O
cells	O
,	O
CD68	O
+	O
macrophages	O
,	O
and	O
lining	O
layer	O
hyperplasia	O
were	O
quantified	O
.	O

SF	O
levels	O
of	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
alpha	I-GENE-Y
(	O
TNFalpha	B-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
)	O
,	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
1	I-GENE-Y
(	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
MMP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
Col2	B-GENE-N
-	I-GENE-N
3	I-GENE-N
/	I-GENE-N
4C	I-GENE-N
(	I-GENE-N
Long	I-GENE-N
mono	I-GENE-N
)	I-GENE-N
neoepitope	I-GENE-N
(	O
C2C	B-GENE-N
)	O
(	O
reflecting	O
collagenase	B-GENE-N
cleavage	O
of	O
cartilage	O
CII	B-GENE-N
)	O
,	O
C	B-GENE-N
-	I-GENE-N
propeptide	I-GENE-N
of	I-GENE-N
type	I-GENE-N
II	I-GENE-N
procollagen	I-GENE-N
(	O
PIICP	B-GENE-N
)	O
(	O
a	O
biosynthesis	O
marker	O
)	O
,	O
keratan	O
sulfate	B-CHEMICAL
(	O
KS	O
)	O
,	O
and	O
the	O
846	O
epitope	O
of	O
aggrecan	B-GENE-Y
(	O
turnover	O
)	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
or	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Levels	O
of	O
cartilage	O
degradation	O
products	O
in	O
early	O
RA	O
or	O
early	O
PsA	O
were	O
not	O
elevated	O
above	O
levels	O
in	O
OA	O
,	O
although	O
in	O
early	O
inflammatory	O
arthritis	O
,	O
TNFalpha	B-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
were	O
similar	O
to	O
those	O
observed	O
in	O
late	O
inflammatory	O
disease	O
and	O
higher	O
than	O
those	O
in	O
OA	O
.	O

PIICP	B-GENE-N
was	O
reduced	O
in	O
early	O
RA	O
.	O

Correlations	O
were	O
observed	O
between	O
the	O
SF	O
C2C	B-GENE-N
neoepitope	I-GENE-N
level	O
and	O
the	O
Health	O
Assessment	O
Questionnaire	O
score	O
,	O
C	B-GENE-Y
-	I-GENE-Y
reactive	I-GENE-Y
protein	I-GENE-Y
level	O
,	O
plasma	O
viscosity	O
,	O
synovitis	O
score	O
,	O
and	O
SF	O
TNFalpha	B-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
.	O

KS	O
epitope	O
content	O
was	O
reduced	O
in	O
direct	O
relation	O
to	O
SM	O
macrophage	O
infiltration	O
in	O
the	O
sublining	O
and	O
lining	O
layers	O
and	O
in	O
the	O
presence	O
of	O
elevated	O
SF	O
MMP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
.	O

Both	O
SF	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
SF	O
MMP	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
levels	O
correlated	O
with	O
CD4	O
+	O
T	O
cell	O
infiltration	O
and	O
lining	O
layer	O
hyperplasia	O
in	O
the	O
SM	O
,	O
and	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
correlated	O
with	O
lining	O
layer	O
CD68	B-GENE-Y
levels	O
,	O
but	O
TNFalpha	B-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
levels	O
did	O
not	O
.	O

CONCLUSION	O
:	O
Except	O
for	O
CII	B-GENE-N
synthesis	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
extracellular	O
matrix	O
turnover	O
of	O
aggrecan	B-GENE-Y
or	O
CII	B-GENE-N
in	O
the	O
early	O
stages	O
of	O
human	O
inflammatory	O
arthritis	O
.	O

However	O
,	O
the	O
direct	O
correlation	O
between	O
the	O
increases	O
in	O
TNFalpha	B-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
production	O
and	O
collagen	B-GENE-N
degradation	O
suggests	O
that	O
collagenase	B-GENE-N
cleavage	O
of	O
cartilage	O
collagen	B-GENE-N
is	O
related	O
to	O
the	O
activities	O
of	O
TNFalpha	B-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

The	O
reduction	O
in	O
CII	B-GENE-N
synthesis	O
in	O
early	O
RA	O
may	O
contribute	O
to	O
the	O
developing	O
pathology	O
,	O
since	O
a	O
lack	O
of	O
synthesis	O
of	O
this	O
molecule	O
would	O
inhibit	O
maintenance	O
of	O
cartilage	O
matrix	O
.	O

Molecular	O
mechanism	O
of	O
terbinafine	B-CHEMICAL
resistance	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Ten	O
mutants	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
resistant	O
to	O
the	O
antimycotic	O
terbinafine	B-CHEMICAL
were	O
isolated	O
after	O
chemical	O
or	O
UV	O
mutagenesis	O
.	O

Molecular	O
analysis	O
of	O
these	O
mutants	O
revealed	O
single	O
base	O
pair	O
exchanges	O
in	O
the	O
ERG1	B-GENE-Y
gene	O
coding	O
for	O
squalene	B-GENE-Y
epoxidase	I-GENE-Y
,	O
the	O
target	O
of	O
terbinafine	B-CHEMICAL
.	O

The	O
mutants	O
did	O
not	O
show	O
cross	O
-	O
resistance	O
to	O
any	O
of	O
the	O
substrates	O
of	O
various	O
pleiotropic	O
drug	O
resistance	O
efflux	O
pumps	O
tested	O
.	O

The	O
ERG1	B-GENE-Y
mRNA	O
levels	O
in	O
the	O
mutants	O
did	O
not	O
differ	O
from	O
those	O
in	O
the	O
wild	O
-	O
type	O
parent	O
strains	O
.	O

Terbinafine	B-CHEMICAL
resistance	O
was	O
transmitted	O
with	O
the	O
mutated	O
alleles	O
in	O
gene	O
replacement	O
experiments	O
,	O
proving	O
that	O
single	O
amino	B-CHEMICAL
acid	I-CHEMICAL
substitutions	O
in	O
the	O
Erg1	B-GENE-Y
protein	O
were	O
sufficient	O
to	O
confer	O
the	O
resistance	O
phenotype	O
.	O

The	O
amino	B-CHEMICAL
acid	I-CHEMICAL
changes	O
caused	O
by	O
the	O
point	O
mutations	O
were	O
clustered	O
in	O
two	O
regions	O
of	O
the	O
Erg1	B-GENE-Y
protein	O
.	O

Seven	O
mutants	O
carried	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
substitutions	O
F402L	B-GENE-N
(	O
one	O
mutant	O
)	O
,	O
F420L	B-GENE-N
(	O
one	O
mutant	O
)	O
,	O
and	O
P430S	B-GENE-N
(	O
five	O
mutants	O
)	O
in	O
the	O
C	B-CHEMICAL
-	O
terminal	O
part	O
of	O
the	O
protein	O
;	O
and	O
three	O
mutants	O
carried	O
an	O
L251F	B-GENE-N
exchange	O
in	O
the	O
central	O
part	O
of	O
the	O
protein	O
.	O

Interestingly	O
,	O
all	O
exchanges	O
identified	O
involved	O
amino	B-CHEMICAL
acids	I-CHEMICAL
which	O
are	O
conserved	O
in	O
the	O
squalene	B-GENE-N
epoxidases	I-GENE-N
of	O
yeasts	O
and	O
mammals	O
.	O

Two	O
mutations	O
that	O
were	O
generated	O
by	O
PCR	O
mutagenesis	O
of	O
the	O
ERG1	B-GENE-Y
gene	O
and	O
that	O
conferred	O
terbinafine	B-CHEMICAL
resistance	O
mapped	O
in	O
the	O
same	O
regions	O
of	O
the	O
Erg1	B-GENE-Y
protein	O
,	O
with	O
one	O
resulting	O
in	O
an	O
L251F	B-GENE-N
exchange	O
and	O
the	O
other	O
resulting	O
in	O
an	O
F433S	B-GENE-N
exchange	O
.	O

The	O
results	O
strongly	O
indicate	O
that	O
these	O
regions	O
are	O
responsible	O
for	O
the	O
interaction	O
of	O
yeast	B-GENE-Y
squalene	I-GENE-Y
epoxidase	I-GENE-Y
with	O
terbinafine	B-CHEMICAL
.	O

The	O
inhibitory	O
effect	O
of	O
ginseng	B-CHEMICAL
saponins	I-CHEMICAL
on	O
the	O
stress	O
-	O
induced	O
plasma	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
level	O
in	O
mice	O
.	O

The	O
effect	O
of	O
ginseng	B-CHEMICAL
saponins	I-CHEMICAL
on	O
plasma	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
)	O
in	O
non	O
-	O
stressed	O
and	O
immobilization	O
-	O
stressed	O
mice	O
were	O
investigated	O
.	O

Ginseng	O
total	O
saponins	B-CHEMICAL
,	O
ginsenosides	B-CHEMICAL
Rb2	I-CHEMICAL
,	I-CHEMICAL
Rg1	I-CHEMICAL
and	I-CHEMICAL
Rd	I-CHEMICAL
administered	O
intraperitoneally	O
attenuated	O
the	O
immobilization	O
stress	O
-	O
induced	O
increase	O
in	O
plasma	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
level	O
.	O

But	O
,	O
intracerebroventricular	O
injection	O
of	O
each	O
ginsenoside	B-CHEMICAL
did	O
not	O
affect	O
plasma	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
level	O
induced	O
by	O
immobilization	O
stress	O
.	O

Ginsenosides	B-CHEMICAL
Rb2	I-CHEMICAL
,	I-CHEMICAL
Rd	I-CHEMICAL
and	I-CHEMICAL
Rg1	I-CHEMICAL
significantly	O
decreased	O
norepinephrine	B-CHEMICAL
and	O
/	O
or	O
epinephrine	B-CHEMICAL
-	O
induced	O
increase	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
level	O
in	O
macrophage	O
cell	O
line	O
(	O
RAW	O
264	O
.	O
7	O
)	O
.	O

Thus	O
,	O
it	O
can	O
be	O
suggested	O
that	O
the	O
inhibitory	O
action	O
of	O
ginseng	B-CHEMICAL
saponins	I-CHEMICAL
against	O
the	O
immobilization	O
stress	O
-	O
induced	O
increase	O
of	O
plasma	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
level	O
would	O
be	O
in	O
periphery	O
;	O
at	O
least	O
in	O
part	O
,	O
mediated	O
by	O
blocking	O
norepinephrine	B-CHEMICAL
-	O
and	O
/	O
or	O
epinephrine	B-CHEMICAL
-	O
induced	O
increase	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
level	O
in	O
macrophage	O
rather	O
than	O
in	O
the	O
brain	O
.	O

Ginseng	B-CHEMICAL
saponins	I-CHEMICAL
might	O
be	O
proposed	O
as	O
a	O
possible	O
candidate	O
in	O
the	O
research	O
or	O
therapeutic	O
modulation	O
of	O
stress	O
-	O
related	O
disorders	O
.	O

Enhanced	O
beta2	B-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
(	O
beta2AR	B-GENE-Y
)	O
signaling	O
by	O
adeno	O
-	O
associated	O
viral	O
(	O
AAV	O
)	O
-	O
mediated	O
gene	O
transfer	O
.	O

BACKGROUND	O
:	O
Beta2	B-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptors	I-GENE-Y
(	O
beta2AR	B-GENE-Y
)	O
play	O
important	O
regulatory	O
roles	O
in	O
a	O
variety	O
of	O
cells	O
and	O
organ	O
systems	O
and	O
are	O
important	O
therapeutic	O
targets	O
in	O
the	O
treatment	O
of	O
airway	O
and	O
cardiovascular	O
disease	O
.	O

Prolonged	O
use	O
of	O
beta	O
-	O
agonists	O
results	O
in	O
tolerance	O
secondary	O
to	O
receptor	O
down	O
-	O
regulation	O
resulting	O
in	O
reduced	O
therapeutic	O
efficiency	O
.	O

The	O
purpose	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
the	O
signaling	O
capabilities	O
of	O
the	O
beta2AR	B-GENE-Y
expressed	O
by	O
a	O
recombinant	O
adeno	O
-	O
associated	O
viral	O
(	O
AAV	O
)	O
vector	O
that	O
also	O
included	O
an	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
gene	O
(	O
AAV	O
-	O
beta2AR	B-GENE-Y
/	O
EGFP	O
)	O
.	O

RESULTS	O
:	O
By	O
epifluorescence	O
microscopy	O
,	O
approximately	O
40	O
%	O
of	O
infected	O
HEK	O
293	O
cells	O
demonstrated	O
EGFP	O
expression	O
.	O

beta2AR	B-GENE-Y
density	O
measured	O
with	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
dihydroalprenolol	I-CHEMICAL
(	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
DHA	I-CHEMICAL
)	O
increased	O
either	O
13	O
-	O
or	O
77	O
-	O
fold	O
in	O
infected	O
cells	O
compared	O
to	O
mock	O
infected	O
controls	O
depending	O
on	O
the	O
culture	O
conditions	O
used	O
.	O

The	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
DHA	I-CHEMICAL
binding	O
was	O
to	O
a	O
single	O
receptor	O
population	O
with	O
a	O
dissociation	O
constant	O
of	O
0	O
.	O
42	O
nM	O
,	O
as	O
would	O
be	O
expected	O
for	O
wild	O
-	O
type	O
beta2AR	B-GENE-Y
.	O

Agonist	O
competition	O
assays	O
with	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
DHA	I-CHEMICAL
showed	O
the	O
following	O
rank	O
order	O
of	O
potency	O
:	O
isoproterenol	B-CHEMICAL
>	O
epinephrine	B-CHEMICAL
>	O
norepinephrine	B-CHEMICAL
,	O
consistent	O
with	O
beta2AR	B-GENE-Y
interaction	O
.	O

Isoproterenol	B-CHEMICAL
-	O
stimulated	O
cyclic	B-CHEMICAL
AMP	I-CHEMICAL
levels	O
were	O
5	O
-	O
fold	O
higher	O
in	O
infected	O
cells	O
compared	O
to	O
controls	O
(	O
314	O
+	O
/	O
-	O
43	O
vs	O
.	O
63	O
.	O
4	O
+	O
/	O
-	O
9	O
.	O
6	O
nmol	O
/	O
dish	O
;	O
n	O
=	O
3	O
)	O
.	O

Receptor	O
trafficking	O
demonstrated	O
surface	O
expression	O
of	O
beta2AR	B-GENE-Y
with	O
vehicle	O
treatment	O
and	O
internalization	O
following	O
isoproterenol	B-CHEMICAL
treatment	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
HEK	O
293	O
cells	O
infected	O
with	O
AAV	O
-	O
beta2AR	B-GENE-Y
/	O
EGFP	O
effectively	O
express	O
beta2AR	B-GENE-Y
and	O
that	O
increased	O
expression	O
of	O
these	O
receptors	O
results	O
in	O
enhanced	O
beta2AR	B-GENE-Y
signaling	O
.	O

This	O
method	O
of	O
gene	O
transfer	O
may	O
provide	O
an	O
important	O
means	O
to	O
enhance	O
function	O
in	O
in	O
vivo	O
systems	O
.	O

Structure	O
of	O
human	B-GENE-Y
microsomal	I-GENE-Y
cytochrome	I-GENE-Y
P450	I-GENE-Y
2C8	I-GENE-Y
.	O

Evidence	O
for	O
a	O
peripheral	B-GENE-N
fatty	I-GENE-N
acid	I-GENE-N
binding	I-GENE-N
site	I-GENE-N
.	O

A	O
2	O
.	O
7	O
-	O
Angstrom	O
molecular	O
structure	O
of	O
human	B-GENE-Y
microsomal	I-GENE-Y
cytochrome	I-GENE-Y
P450	I-GENE-Y
2C8	I-GENE-Y
(	O
CYP2C8	B-GENE-Y
)	O
was	O
determined	O
by	O
x	O
-	O
ray	O
crystallography	O
.	O

The	O
membrane	O
protein	O
was	O
modified	O
for	O
crystallization	O
by	O
replacement	O
of	O
the	O
hydrophobic	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
with	O
a	O
short	O
hydrophilic	O
sequence	O
before	O
residue	O
28	O
.	O

The	O
structure	O
of	O
the	O
native	O
sequence	O
is	O
complete	O
from	O
residue	O
28	O
to	O
the	O
beginning	O
of	O
a	O
C	B-CHEMICAL
-	O
terminal	O
histidine	B-CHEMICAL
tag	O
used	O
for	O
purification	O
.	O

CYP2C8	B-GENE-Y
is	O
one	O
of	O
the	O
principal	O
hepatic	O
drug	O
-	O
metabolizing	O
enzymes	O
that	O
oxidizes	O
therapeutic	O
drugs	O
such	O
as	O
taxol	O
and	O
cerivastatin	O
and	O
endobiotics	O
such	O
as	O
retinoic	O
acid	O
and	O
arachidonic	O
acid	O
.	O

Consistent	O
with	O
the	O
relatively	O
large	O
size	O
of	O
its	O
preferred	O
substrates	O
,	O
the	O
active	O
site	O
volume	O
is	O
twice	O
that	O
observed	O
for	O
the	O
structure	O
of	O
CYP2C5	B-GENE-Y
.	O

The	O
extended	O
active	O
site	O
cavity	O
is	O
bounded	O
by	O
the	O
beta1	B-GENE-N
sheet	I-GENE-N
and	O
helix	B-GENE-N
F	I-GENE-N
'	I-GENE-N
that	O
have	O
not	O
previously	O
been	O
implicated	O
in	O
substrate	O
recognition	O
by	O
mammalian	B-GENE-N
P450s	I-GENE-N
.	O

CYP2C8	B-GENE-Y
crystallized	O
as	O
a	O
symmetric	O
dimer	O
formed	O
by	O
the	O
interaction	O
of	O
helices	B-GENE-N
F	I-GENE-N
,	I-GENE-N
F	I-GENE-N
'	I-GENE-N
,	I-GENE-N
G	I-GENE-N
'	I-GENE-N
,	I-GENE-N
and	I-GENE-N
G	I-GENE-N
.	O

Two	O
molecules	O
of	O
palmitic	B-CHEMICAL
acid	I-CHEMICAL
are	O
bound	O
in	O
the	O
dimer	O
interface	O
.	O

The	O
dimer	O
is	O
observed	O
in	O
solution	O
,	O
and	O
mass	O
spectrometry	O
confirmed	O
the	O
association	O
of	O
palmitic	B-CHEMICAL
acid	I-CHEMICAL
with	O
the	O
enzyme	O
.	O

This	O
novel	O
finding	O
identifies	O
a	O
peripheral	O
binding	O
site	O
in	O
P450s	B-GENE-N
that	O
may	O
contribute	O
to	O
drug	O
-	O
drug	O
interactions	O
in	O
P450	B-GENE-N
metabolism	O
.	O

Efficacy	O
and	O
safety	O
of	O
tamsulosin	B-CHEMICAL
in	O
the	O
treatment	O
of	O
urological	O
diseases	O
.	O

The	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
,	O
tamsulosin	B-CHEMICAL
,	O
is	O
selective	O
for	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
-	I-GENE-N
over	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

Both	O
placebo	O
-	O
controlled	O
and	O
comparative	O
studies	O
with	O
other	O
agents	O
have	O
demonstrated	O
tamsulosin	B-CHEMICAL
to	O
be	O
an	O
effective	O
treatment	O
for	O
patients	O
with	O
lower	O
urinary	O
symptoms	O
suggestive	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

Its	O
effectiveness	O
appears	O
to	O
be	O
maintained	O
over	O
many	O
years	O
.	O

Tamsulosin	B-CHEMICAL
may	O
also	O
effectively	O
reduce	O
lower	O
urinary	O
tract	O
symptoms	O
in	O
other	O
urological	O
diseases	O
.	O

A	O
dose	O
of	O
tamsulosin	B-CHEMICAL
0	O
.	O
4	O
mg	O
/	O
day	O
has	O
a	O
tolerability	O
close	O
to	O
that	O
of	O
placebo	O
and	O
has	O
little	O
,	O
if	O
any	O
,	O
blood	O
pressure	O
lowering	O
effects	O
.	O

Tolerability	O
and	O
lack	O
of	O
blood	O
pressure	O
lowering	O
are	O
maintained	O
even	O
in	O
high	O
-	O
risk	O
patients	O
such	O
as	O
those	O
with	O
cardiovascular	O
comorbidity	O
and	O
/	O
or	O
comedication	O
.	O

Apart	O
from	O
adrenoceptor	B-GENE-N
subtype	O
-	O
selectivity	O
,	O
a	O
smooth	O
pharmacokinetic	O
profile	O
of	O
its	O
modified	O
-	O
release	O
formulation	O
and	O
a	O
selective	O
accumulation	O
in	O
target	O
tissues	O
may	O
contribute	O
to	O
an	O
excellent	O
efficacy	O
:	O
tolerability	O
ratio	O
.	O

Serum	O
carvedilol	B-CHEMICAL
concentration	O
and	O
its	O
relation	O
to	O
change	O
in	O
plasma	O
brain	B-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
level	O
in	O
the	O
treatment	O
of	O
heart	O
failure	O
:	O
a	O
preliminary	O
study	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
influence	O
of	O
carvedilol	B-CHEMICAL
dose	O
and	O
concentration	O
in	O
serum	O
on	O
plasma	O
brain	B-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
(	O
BNP	B-GENE-Y
)	O
,	O
a	O
measure	O
of	O
heart	O
failure	O
progression	O
.	O

METHODS	O
:	O
12	O
patients	O
with	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
functional	O
class	O
II	O
-	O
III	O
chronic	O
heart	O
failure	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

They	O
received	O
carvedilol	B-CHEMICAL
at	O
daily	O
doses	O
of	O
1	O
-	O
20	O
mg	O
with	O
a	O
1	O
-	O
2	O
weekly	O
adjustment	O
.	O

Serum	O
carvedilol	B-CHEMICAL
trough	O
concentrations	O
were	O
measured	O
in	O
steady	O
-	O
state	O
using	O
a	O
specific	O
fluorescence	O
HPLC	O
method	O
.	O

The	O
degree	O
of	O
improvement	O
in	O
heart	O
failure	O
was	O
assessed	O
from	O
the	O
ratio	O
of	O
change	O
in	O
the	O
plasma	O
BNP	B-GENE-Y
concentration	O
,	O
2	O
weeks	O
,	O
1	O
month	O
and	O
3	O
months	O
after	O
the	O
commencement	O
of	O
carvedilol	B-CHEMICAL
administration	O
.	O

RESULTS	O
:	O
From	O
the	O
pharmacokinetic	O
aspect	O
,	O
there	O
was	O
no	O
valid	O
correlation	O
between	O
the	O
trough	O
serum	O
carvedilol	B-CHEMICAL
concentration	O
(	O
Cmin	O
)	O
and	O
daily	O
dose	O
per	O
body	O
weight	O
(	O
Dd	O
/	O
BW	O
)	O
,	O
indicating	O
that	O
there	O
was	O
a	O
wide	O
difference	O
in	O
the	O
carvedilol	B-CHEMICAL
elimination	O
capacity	O
among	O
individuals	O
.	O

A	O
significant	O
decrease	O
in	O
the	O
BNP	B-GENE-Y
was	O
observed	O
at	O
the	O
3rd	O
month	O
in	O
patients	O
treated	O
with	O
the	O
high	O
dose	O
(	O
>	O
750	O
mg	O
/	O
3	O
months	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
patients	O
with	O
a	O
mean	O
serum	O
carvedilol	B-CHEMICAL
level	O
(	O
Cmin	O
)	O
of	O
less	O
than	O
2	O
.	O
5	O
nmol	O
/	O
l	O
up	O
to	O
2	O
weeks	O
after	O
the	O
start	O
ofcarvedilol	B-CHEMICAL
therapy	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
the	O
BNP	B-GENE-Y
value	O
after	O
the	O
3rd	O
month	O
was	O
significantly	O
larger	O
,	O
relative	O
to	O
the	O
patient	O
group	O
with	O
Cmin	O
over	O
2	O
.	O
5	O
nmol	O
/	O
l	O
.	O

CONCLUSIONS	O
:	O
The	O
total	O
carvedilol	B-CHEMICAL
dose	O
was	O
confirmed	O
to	O
be	O
one	O
of	O
the	O
determinants	O
for	O
improvement	O
in	O
heart	O
failure	O
,	O
and	O
it	O
was	O
suggested	O
that	O
the	O
initial	O
serum	O
level	O
also	O
plays	O
an	O
important	O
role	O
in	O
therapeutic	O
outcome	O
.	O

Therefore	O
,	O
it	O
may	O
be	O
important	O
to	O
monitor	O
the	O
serum	O
carvedilol	B-CHEMICAL
level	O
at	O
the	O
introductory	O
period	O
to	O
determine	O
the	O
daily	O
dose	O
requirements	O
because	O
of	O
the	O
wide	O
inter	O
-	O
individual	O
variability	O
in	O
its	O
metabolic	O
clearance	O
.	O

Structural	O
model	O
of	O
carnitine	B-GENE-Y
palmitoyltransferase	I-GENE-Y
I	I-GENE-Y
based	O
on	O
the	O
carnitine	B-GENE-Y
acetyltransferase	I-GENE-Y
crystal	O
.	O

CPT	B-GENE-Y
I	I-GENE-Y
(	O
carnitine	B-GENE-Y
palmitoyltransferase	I-GENE-Y
I	I-GENE-Y
)	O
catalyses	O
the	O
conversion	O
of	O
palmitoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
into	O
palmitoylcarnitine	B-CHEMICAL
in	O
the	O
presence	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
carnitine	I-CHEMICAL
,	O
facilitating	O
the	O
entry	O
of	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
into	O
mitochondria	O
.	O

We	O
propose	O
a	O
3	O
-	O
D	O
(	O
three	O
-	O
dimensional	O
)	O
structural	O
model	O
for	O
L	B-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
I	I-GENE-Y
(	O
liver	B-GENE-Y
CPT	I-GENE-Y
I	I-GENE-Y
)	O
,	O
based	O
on	O
the	O
similarity	O
of	O
this	O
enzyme	O
to	O
the	O
recently	O
crystallized	O
mouse	B-GENE-Y
carnitine	I-GENE-Y
acetyltransferase	I-GENE-Y
.	O

The	O
model	O
includes	O
607	O
of	O
the	O
773	O
amino	B-CHEMICAL
acids	I-CHEMICAL
of	O
L	B-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
I	I-GENE-Y
,	O
and	O
the	O
positions	O
of	O
carnitine	B-CHEMICAL
,	O
CoA	B-CHEMICAL
and	O
the	O
palmitoyl	B-CHEMICAL
group	O
were	O
assigned	O
by	O
superposition	O
and	O
docking	O
analysis	O
.	O

Functional	O
analysis	O
of	O
this	O
3	O
-	O
D	O
model	O
included	O
the	O
mutagenesis	O
of	O
several	O
amino	B-CHEMICAL
acids	I-CHEMICAL
in	O
order	O
to	O
identify	O
putative	O
catalytic	O
residues	O
.	O

Mutants	O
D477A	B-GENE-N
,	O
D567A	B-GENE-N
and	O
E590D	B-GENE-N
showed	O
reduced	O
L	B-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
I	I-GENE-Y
activity	O
.	O

In	O
addition	O
,	O
individual	O
mutation	O
of	O
amino	B-CHEMICAL
acids	I-CHEMICAL
forming	O
the	O
conserved	O
Ser685	O
-	O
Thr686	O
-	O
Ser687	O
motif	O
abolished	O
enzyme	O
activity	O
in	O
mutants	O
T686A	B-GENE-N
and	O
S687A	B-GENE-N
and	O
altered	O
K	O
(	O
m	O
)	O
and	O
the	O
catalytic	O
efficiency	O
for	O
carnitine	B-CHEMICAL
in	O
mutant	O
S685A	B-GENE-N
.	O

We	O
conclude	O
that	O
the	O
catalytic	O
residues	O
are	O
His473	O
and	O
Asp477	O
,	O
while	O
Ser687	O
probably	O
stabilizes	O
the	O
transition	O
state	O
.	O

Several	O
conserved	O
lysines	O
,	O
i	O
.	O
e	O
.	O
Lys455	O
,	O
Lys505	O
,	O
Lys560	O
and	O
Lys561	O
,	O
were	O
also	O
mutated	O
.	O

Only	O
mutants	O
K455A	B-GENE-N
and	O
K560A	B-GENE-N
showed	O
decreases	O
in	O
activity	O
of	O
50	O
%	O
.	O

The	O
model	O
rationalizes	O
the	O
finding	O
of	O
nine	O
natural	O
mutations	O
in	O
patients	O
with	O
hereditary	O
L	B-GENE-Y
-	I-GENE-Y
CPT	I-GENE-Y
I	I-GENE-Y
deficiencies	O
.	O

Thymidine	B-GENE-N
kinase	I-GENE-N
and	O
thymidine	B-GENE-Y
phosphorylase	I-GENE-Y
level	O
as	O
the	O
main	O
predictive	O
parameter	O
for	O
sensitivity	O
to	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
in	O
a	O
mouse	O
model	O
.	O

TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
is	O
a	O
new	O
oral	O
anti	O
-	O
cancer	O
drug	O
preparation	O
,	O
composed	O
of	O
a	O
1	O
:	O
0	O
.	O
5	O
mixture	O
(	O
on	O
a	O
molar	O
basis	O
)	O
of	O
alpha	B-CHEMICAL
,	I-CHEMICAL
alpha	I-CHEMICAL
,	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
trifluorothymidine	I-CHEMICAL
(	O
FTD	B-CHEMICAL
)	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
iminopyrrolidinyl	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
,	I-CHEMICAL
3H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pyrimidinedione	I-CHEMICAL
hydrochloride	I-CHEMICAL
(	O
TPI	B-CHEMICAL
)	O
.	O

TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
currently	O
undergoing	O
clinical	O
trials	O
,	O
has	O
been	O
demonstrated	O
to	O
have	O
at	O
least	O
two	O
mechanisms	O
,	O
inhibition	O
of	O
TS	B-GENE-Y
and	O
incorporation	O
into	O
DNA	O
.	O

We	O
hypothesized	O
that	O
the	O
thymidine	B-CHEMICAL
metabolism	O
enzyme	O
may	O
be	O
a	O
crucial	O
factor	O
that	O
affects	O
the	O
antitumor	O
activity	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
.	O

In	O
the	O
present	O
study	O
,	O
we	O
measured	O
the	O
enzyme	O
activity	O
of	O
thymidine	B-GENE-N
kinase	I-GENE-N
(	O
TK	B-GENE-N
)	O
,	O
thymidine	B-GENE-Y
phosphorylase	I-GENE-Y
(	O
TP	B-GENE-Y
)	O
and	O
thymidilate	B-GENE-Y
synthase	I-GENE-Y
(	O
TS	B-GENE-Y
)	O
in	O
human	O
cancer	O
xenografts	O
to	O
investigate	O
the	O
contribution	O
of	O
these	O
enzymes	O
to	O
the	O
sensitivity	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
.	O

Antitumor	O
activity	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
appears	O
to	O
be	O
associated	O
with	O
TK	B-GENE-N
,	O
tumor	O
growth	O
and	O
TS	B-GENE-Y
.	O

However	O
,	O
the	O
most	O
related	O
factors	O
in	O
this	O
study	O
were	O
the	O
TK	B-GENE-N
and	O
TP	B-GENE-Y
ratio	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
between	O
tumor	O
growth	O
inhibition	O
and	O
this	O
ratio	O
.	O

These	O
results	O
suggested	O
that	O
the	O
activation	O
and	O
degradation	O
pattern	O
of	O
FTD	B-CHEMICAL
plays	O
an	O
important	O
role	O
in	O
the	O
efficacy	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
and	O
that	O
it	O
is	O
possible	O
to	O
use	O
the	O
TK	B-GENE-N
/	O
TP	B-GENE-Y
ratio	O
to	O
predict	O
response	O
to	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
therapy	O
.	O

We	O
also	O
studied	O
the	O
influence	O
of	O
TPI	B-CHEMICAL
on	O
the	O
capacity	O
of	O
exogenous	O
dThd	O
to	O
reverse	O
FTD	B-CHEMICAL
-	O
dependent	O
growth	O
inhibition	O
.	O

Thymidine	B-CHEMICAL
(	O
dThd	O
)	O
levels	O
rescued	O
the	O
effect	O
of	O
FTD	B-CHEMICAL
in	O
vitro	O
and	O
significantly	O
increased	O
in	O
serum	O
after	O
administration	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
or	O
TPI	B-CHEMICAL
alone	O
but	O
not	O
FTD	B-CHEMICAL
alone	O
.	O

This	O
may	O
suggest	O
the	O
possibility	O
of	O
a	O
decrease	O
in	O
antitumor	O
effect	O
.	O

However	O
,	O
our	O
study	O
indicated	O
that	O
the	O
therapeutic	O
index	O
was	O
clearly	O
increased	O
by	O
FTD	B-CHEMICAL
combined	O
with	O
TPI	B-CHEMICAL
,	O
compared	O
with	O
FTD	B-CHEMICAL
alone	O
,	O
suggesting	O
FTD	B-CHEMICAL
-	O
induced	O
toxicity	O
to	O
sensitive	O
host	O
tissue	O
can	O
be	O
selectively	O
reversed	O
with	O
dThd	O
.	O

In	O
conclusion	O
,	O
TK	B-GENE-N
and	O
TPI	B-CHEMICAL
effects	O
on	O
TP	B-GENE-Y
play	O
important	O
roles	O
in	O
the	O
cytotoxic	O
action	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
,	O
and	O
it	O
is	O
possible	O
to	O
use	O
the	O
TK	B-GENE-N
/	O
TP	B-GENE-Y
ratio	O
to	O
predict	O
more	O
precisely	O
individual	O
resistance	O
or	O
sensitivity	O
.	O

Arformoterol	B-CHEMICAL
:	O
(	B-CHEMICAL
R	I-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
eformoterol	I-CHEMICAL
,	O
(	B-CHEMICAL
R	I-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
formoterol	I-CHEMICAL
,	O
arformoterol	B-CHEMICAL
tartrate	I-CHEMICAL
,	O
eformoterol	B-CHEMICAL
-	O
sepracor	O
,	O
formoterol	B-CHEMICAL
-	O
sepracor	O
,	O
R	B-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
-	I-CHEMICAL
eformoterol	I-CHEMICAL
,	O
R	B-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
-	I-CHEMICAL
formoterol	I-CHEMICAL
.	O

Sepracor	O
in	O
the	O
US	O
is	O
developing	O
arformoterol	B-CHEMICAL
[	O
R	B-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
-	I-CHEMICAL
formoterol	I-CHEMICAL
]	O
,	O
a	O
single	O
isomer	O
form	O
of	O
the	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
formoterol	B-CHEMICAL
[	O
eformoterol	B-CHEMICAL
]	O
.	O

This	O
isomer	O
contains	O
two	O
chiral	O
centres	O
and	O
is	O
being	O
developed	O
as	O
an	O
inhaled	O
preparation	O
for	O
the	O
treatment	O
of	O
respiratory	O
disorders	O
.	O

Sepracor	O
believes	O
that	O
arformoterol	B-CHEMICAL
has	O
the	O
potential	O
to	O
be	O
a	O
once	O
-	O
daily	O
therapy	O
with	O
a	O
rapid	O
onset	O
of	O
action	O
and	O
a	O
duration	O
of	O
effect	O
exceeding	O
12	O
hours	O
.	O

In	O
1995	O
,	O
Sepracor	O
acquired	O
New	O
England	O
Pharmaceuticals	O
,	O
a	O
manufacturer	O
of	O
metered	O
-	O
dose	O
and	O
dry	O
powder	O
inhalers	O
,	O
for	O
the	O
purpose	O
of	O
preparing	O
formulations	O
of	O
levosalbutamol	B-CHEMICAL
and	O
arformoterol	B-CHEMICAL
.	O

Phase	O
II	O
dose	O
-	O
ranging	O
clinical	O
studies	O
of	O
arformoterol	B-CHEMICAL
as	O
a	O
longer	O
-	O
acting	O
,	O
complementary	O
bronchodilator	O
were	O
completed	O
successfully	O
in	O
the	O
fourth	O
quarter	O
of	O
2000	O
.	O

Phase	O
III	O
trials	O
of	O
arformoterol	B-CHEMICAL
began	O
in	O
September	O
2001	O
.	O

The	O
indications	O
for	O
the	O
drug	O
appeared	O
to	O
be	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

However	O
,	O
an	O
update	O
of	O
the	O
pharmaceutical	O
product	O
information	O
on	O
the	O
Sepracor	O
website	O
in	O
September	O
2003	O
listed	O
COPD	O
maintenance	O
therapy	O
as	O
the	O
only	O
indication	O
for	O
arformoterol	B-CHEMICAL
.	O

In	O
October	O
2002	O
,	O
Sepracor	O
stated	O
that	O
two	O
pivotal	O
phase	O
III	O
studies	O
were	O
ongoing	O
in	O
1600	O
patients	O
.	O

Sepracor	O
estimates	O
that	O
its	O
NDA	O
submission	O
for	O
arformoterol	B-CHEMICAL
,	O
which	O
is	O
projected	O
for	O
the	O
first	O
half	O
of	O
2004	O
,	O
will	O
include	O
approximately	O
3000	O
adult	O
subjects	O
.	O

Sepracor	O
stated	O
in	O
July	O
2003	O
that	O
it	O
had	O
completed	O
more	O
than	O
100	O
preclinical	O
studies	O
and	O
initiated	O
or	O
completed	O
15	O
clinical	O
studies	O
for	O
arformoterol	B-CHEMICAL
inhalation	O
solution	O
for	O
the	O
treatment	O
of	O
bronchospasm	O
in	O
patients	O
with	O
COPD	O
.	O

In	O
addition	O
,	O
Sepracor	O
stated	O
that	O
the	O
two	O
pivotal	O
phase	O
III	O
studies	O
in	O
1600	O
patients	O
were	O
still	O
progressing	O
.	O

In	O
1995	O
,	O
European	O
patents	O
were	O
granted	O
to	O
Sepracor	O
for	O
the	O
use	O
of	O
arformoterol	B-CHEMICAL
in	O
the	O
treatment	O
of	O
asthma	O
,	O
and	O
the	O
US	O
patent	O
application	O
was	O
pending	O
.	O

Truncated	O
ErbB2	B-GENE-Y
receptor	O
(	O
p95ErbB2	B-GENE-Y
)	O
is	O
regulated	O
by	O
heregulin	B-GENE-Y
through	O
heterodimer	O
formation	O
with	O
ErbB3	B-GENE-Y
yet	O
remains	O
sensitive	O
to	O
the	O
dual	O
EGFR	B-GENE-Y
/	O
ErbB2	B-GENE-Y
kinase	O
inhibitor	O
GW572016	B-CHEMICAL
.	O

The	O
expression	O
of	O
the	O
NH2	B-CHEMICAL
terminally	O
truncated	O
ErbB2	B-GENE-Y
receptor	O
(	O
p95ErbB2	B-GENE-Y
)	O
in	O
breast	O
cancer	O
correlates	O
with	O
metastatic	O
disease	O
progression	O
compared	O
with	O
the	O
expression	O
of	O
full	O
-	O
length	O
p185ErbB2	B-GENE-Y
.	O

We	O
now	O
show	O
that	O
heregulin	B-GENE-Y
(	O
HRG	B-GENE-Y
)	O
,	O
but	O
not	O
EGF	B-GENE-Y
,	O
stimulates	O
p95ErbB2	B-GENE-Y
phosphorylation	O
in	O
BT474	O
breast	O
cancer	O
cells	O
.	O

Furthermore	O
,	O
phospho	B-GENE-Y
-	I-GENE-Y
p95ErbB2	I-GENE-Y
forms	O
heterodimers	O
with	O
ErbB3	B-GENE-Y
,	O
but	O
not	O
EGFR	B-GENE-Y
,	O
while	O
p185ErbB2	B-GENE-Y
heterodimerizes	O
with	O
both	O
EGFR	B-GENE-Y
and	O
ErbB3	B-GENE-Y
.	O

The	O
predilection	O
of	O
p95ErbB2	B-GENE-Y
to	O
heterodimerize	O
with	O
ErbB3	B-GENE-Y
provides	O
an	O
explanation	O
for	O
its	O
regulation	O
by	O
HRG	B-GENE-Y
,	O
an	O
ErbB3	B-GENE-Y
ligand	O
.	O

GW572016	B-CHEMICAL
,	O
a	O
reversible	O
small	O
molecule	O
inhibitor	O
of	O
EGFR	B-GENE-Y
and	O
ErbB2	B-GENE-Y
tyrosine	B-GENE-N
kinases	I-GENE-N
,	O
inhibits	O
baseline	O
p95ErbB2	B-GENE-Y
phosphorylation	O
in	O
BT474	O
cells	O
and	O
tumor	O
xenografts	O
.	O

Inhibition	O
of	O
p95ErbB2	B-GENE-Y
,	O
p185ErbB2	B-GENE-Y
,	O
and	O
EGFR	B-GENE-Y
phosphorylation	O
by	O
GW572016	B-CHEMICAL
resulted	O
in	O
the	O
inhibition	O
of	O
downstream	O
phospho	O
-	O
Erk1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
phospho	O
-	O
AKT	B-GENE-N
,	O
and	O
cyclin	B-GENE-N
D	I-GENE-N
steady	O
-	O
state	O
protein	O
levels	O
.	O

Increased	O
phosphorylation	O
of	O
p95ErbB2	B-GENE-Y
and	O
AKT	B-GENE-N
in	O
response	O
to	O
HRG	B-GENE-N
was	O
abrogated	O
to	O
varying	O
degrees	O
by	O
GW572016	B-CHEMICAL
.	O

In	O
contrast	O
,	O
trastuzumab	O
did	O
not	O
inhibit	O
p95ErbB2	B-GENE-Y
phosphorylation	O
or	O
the	O
expression	O
of	O
downstream	O
phospho	O
-	O
Erk1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
phospho	B-GENE-N
-	I-GENE-N
AKT	I-GENE-N
,	O
or	O
cyclin	B-GENE-N
D	I-GENE-N
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
trastuzumab	O
resistance	O
may	O
be	O
mediated	O
in	O
part	O
by	O
the	O
selection	O
of	O
p95ErbB2	B-GENE-Y
-	O
expressing	O
breast	O
cancer	O
cells	O
capable	O
of	O
exerting	O
potent	O
growth	O
and	O
prosurvival	O
signals	O
through	O
p95ErbB2	B-GENE-Y
-	O
ErbB3	B-GENE-Y
heterodimers	O
.	O

Thus	O
,	O
p95ErbB2	B-GENE-Y
represents	O
a	O
target	O
for	O
therapeutic	O
intervention	O
,	O
and	O
one	O
that	O
is	O
sensitive	O
to	O
GW572016	B-CHEMICAL
therapy	O
.	O

Overexpression	O
of	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
in	O
adult	O
rat	O
ventricular	O
myocytes	O
enhances	O
CGP	B-CHEMICAL
12177A	I-CHEMICAL
cardiostimulation	O
:	O
implications	O
for	O
'	O
putative	O
'	O
beta	B-GENE-N
4	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
pharmacology	O
.	O

1	O
.	O

CGP	B-CHEMICAL
12177A	I-CHEMICAL
mediates	O
cardiostimulation	O
by	O
activation	O
of	O
the	O
'	O
putative	O
'	O
beta	B-GENE-N
(	I-GENE-N
4	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
;	O
however	O
,	O
it	O
has	O
recently	O
been	O
reported	O
that	O
disruption	O
of	O
the	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
gene	O
abolishes	O
this	O
effect	O
.	O

We	O
have	O
adenovirally	O
overexpressed	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
in	O
isolated	O
,	O
cultured	O
adult	O
rat	O
ventricular	O
cardiomyocytes	O
and	O
observed	O
the	O
inotropic	O
potency	O
of	O
isoprenaline	B-CHEMICAL
and	O
CGP	B-CHEMICAL
12177A	I-CHEMICAL
(	O
in	O
the	O
presence	O
of	O
1	O
microm	O
propranolol	B-CHEMICAL
)	O
.	O

2	O
.	O

Isoprenaline	B-CHEMICAL
was	O
a	O
full	O
inotropic	O
agonist	O
at	O
rat	O
ventricular	O
myocytes	O
(	O
pD	O
(	O
2	O
)	O
7	O
.	O
69	O
+	O
/	O
-	O
0	O
.	O
12	O
)	O
.	O

CGP	B-CHEMICAL
12177A	I-CHEMICAL
was	O
a	O
nonconventional	O
partial	O
agonist	O
(	O
pD	O
(	O
2	O
)	O
6	O
.	O
34	O
+	O
/	O
-	O
0	O
.	O
09	O
)	O
,	O
increasing	O
inotropy	O
and	O
lusitropy	O
,	O
with	O
an	O
intrinsic	O
activity	O
of	O
0	O
.	O
34	O
and	O
antagonised	O
by	O
bupranolol	B-CHEMICAL
.	O

3	O
.	O

beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
overexpression	O
enhanced	O
the	O
inotropic	O
potency	O
of	O
isoprenaline	B-CHEMICAL
by	O
11	O
.	O
7	O
-	O
fold	O
(	O
pD	O
(	O
2	O
)	O
8	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
14	O
)	O
and	O
CGP	O
12177A	O
by	O
5	O
.	O
9	O
-	O
fold	O
(	O
7	O
.	O
11	O
+	O
/	O
-	O
0	O
.	O
10	O
)	O
,	O
respectively	O
.	O

Green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
overexpression	O
did	O
not	O
alter	O
the	O
potency	O
of	O
isoprenaline	B-CHEMICAL
or	O
CGP	O
12177A	O
(	O
pD	O
(	O
2	O
)	O
7	O
.	O
41	O
+	O
/	O
-	O
0	O
.	O
24	O
and	O
pD	O
(	O
2	O
)	O
6	O
.	O
60	O
+	O
/	O
-	O
0	O
.	O
50	O
,	O
respectively	O
)	O
.	O

4	O
.	O

The	O
cardiostimulant	O
effects	O
of	O
CGP	B-CHEMICAL
12177A	I-CHEMICAL
were	O
enhanced	O
by	O
IBMX	O
(	O
phosphodiesterase	B-GENE-N
inhibitor	O
)	O
and	O
decreased	O
by	O
Rp	B-CHEMICAL
-	I-CHEMICAL
cAMPS	I-CHEMICAL
(	O
cAMP	B-CHEMICAL
antagonist	O
)	O
.	O

CGP	B-CHEMICAL
12177A	I-CHEMICAL
also	O
increased	O
cAMP	B-CHEMICAL
levels	O
.	O

CGP	B-CHEMICAL
12177A	I-CHEMICAL
but	O
not	O
isoprenaline	B-CHEMICAL
initiated	O
arrhythmias	O
at	O
lower	O
concentrations	O
following	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
overexpression	O
.	O

5	O
.	O

(	B-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	I-CHEMICAL
Cyanopindolol	I-CHEMICAL
saturation	O
binding	O
in	O
Adv	O
.	O
beta	O
(	O
1	O
)	O
myocytes	O
demonstrated	O
approximately	O
18	O
-	O
fold	O
increase	O
in	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

(	B-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
CGP	I-CHEMICAL
12177A	I-CHEMICAL
saturation	O
binding	O
,	O
in	O
the	O
presence	O
of	O
propranolol	B-CHEMICAL
,	O
increased	O
approximately	O
5	O
-	O
fold	O
following	O
overexpression	O
of	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

6	O
.	O

This	O
study	O
demonstrates	O
enhanced	O
cardiostimulation	O
by	O
CGP	B-CHEMICAL
12177A	I-CHEMICAL
(	O
in	O
the	O
presence	O
of	O
propranolol	B-CHEMICAL
)	O
in	O
rat	O
ventricular	O
myocytes	O
overexpressing	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
,	O
mediated	O
by	O
a	O
Gs	B-GENE-N
/	O
cAMP	B-CHEMICAL
signalling	O
pathway	O
.	O

'	O
Putative	O
'	O
beta	B-GENE-N
(	I-GENE-N
4	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
pharmacology	O
appears	O
to	O
be	O
mediated	O
by	O
activation	O
of	O
a	O
novel	O
affinity	O
state	O
of	O
the	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
.	O

Alpha1	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
and	O
their	O
inhibitors	O
in	O
lower	O
urinary	O
tract	O
symptoms	O
and	O
benign	O
prostatic	O
hyperplasia	O
.	O

PURPOSE	O
:	O
We	O
provide	O
a	O
comprehensive	O
overview	O
of	O
the	O
role	O
of	O
alpha1	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
(	O
alpha1ARs	B-GENE-N
)	O
as	O
critical	O
mediators	O
of	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
and	O
pathophysiology	O
in	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
,	O
and	O
we	O
review	O
the	O
pharmacological	O
antagonists	O
of	O
alpha1ARs	B-GENE-N
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
A	O
review	O
was	O
performed	O
of	O
pertinent	O
studies	O
in	O
the	O
literature	O
relating	O
to	O
the	O
pathophysiology	O
of	O
LUTS	O
and	O
BPH	O
,	O
focusing	O
on	O
the	O
role	O
of	O
alpha1ARs	B-GENE-N
,	O
and	O
of	O
clinical	O
trial	O
and	O
practice	O
data	O
evaluating	O
the	O
different	O
agents	O
that	O
inhibit	O
these	O
receptors	O
.	O

RESULTS	O
:	O
Further	O
characterization	O
of	O
the	O
alpha1AR	B-GENE-N
gene	O
family	O
indicates	O
that	O
3	O
receptor	O
subtypes	O
exist	O
in	O
humans	O
.	O

Their	O
different	O
distribution	O
between	O
urinary	O
tract	O
and	O
cardiovascular	O
tissues	O
has	O
provided	O
a	O
strategy	O
for	O
the	O
development	O
of	O
improved	O
therapeutic	O
agents	O
.	O

Since	O
excessive	O
activity	O
of	O
the	O
alpha1aAR	B-GENE-Y
and	O
alpha1dAR	B-GENE-Y
subtypes	O
appears	O
to	O
be	O
a	O
common	O
feature	O
in	O
symptomatic	O
BPH	O
and	O
alpha1aARs	B-GENE-Y
are	O
enriched	O
in	O
prostatic	O
tissue	O
,	O
drugs	O
that	O
demonstrate	O
high	O
alpha1aAR	B-GENE-Y
selectivity	O
have	O
attracted	O
attention	O
.	O

Tamsulosin	B-CHEMICAL
,	O
which	O
has	O
high	O
affinity	O
for	O
alpha1aAR	B-GENE-Y
and	O
alpha1dAR	B-GENE-Y
subtypes	O
but	O
not	O
for	O
alpha1bAR	B-GENE-Y
,	O
shows	O
efficacy	O
similar	O
to	O
the	O
nonsubtype	O
selective	O
agents	O
terazosin	B-CHEMICAL
and	O
doxazosin	B-CHEMICAL
.	O

It	O
is	O
associated	O
with	O
fewer	O
cardiovascular	O
side	O
effects	O
,	O
although	O
it	O
has	O
some	O
ejaculatory	O
side	O
effects	O
.	O

The	O
nonsubtype	O
selective	O
agent	O
alfuzosin	B-CHEMICAL
also	O
demonstrates	O
efficacy	O
and	O
offers	O
an	O
enhanced	O
side	O
effect	O
profile	O
,	O
particularly	O
minimizing	O
hypotension	O
.	O

Other	O
agents	O
with	O
super	O
selective	O
specificity	O
for	O
the	O
alpha1aAR	B-GENE-Y
subtype	O
are	O
under	O
investigation	O
.	O

CONCLUSIONS	O
:	O
Further	O
advances	O
in	O
the	O
treatment	O
of	O
LUTS	O
associated	O
with	O
BPH	O
may	O
depend	O
not	O
only	O
on	O
receptor	O
subtype	O
selectivity	O
,	O
but	O
also	O
on	O
other	O
pharmacokinetic	O
and	O
pharmacodynamic	O
factors	O
.	O

Ornithine	B-CHEMICAL
metabolism	O
in	O
male	O
and	O
female	O
rat	O
kidney	O
:	O
mitochondrial	O
expression	O
of	O
ornithine	B-GENE-Y
aminotransferase	I-GENE-Y
and	O
arginase	B-GENE-Y
II	I-GENE-Y
.	O

In	O
the	O
kidney	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
ornithine	I-CHEMICAL
is	O
reabsorbed	O
along	O
the	O
proximal	O
convoluted	O
tubule	O
(	O
PCT	O
)	O
,	O
transported	O
by	O
basolateral	O
carriers	O
,	O
and	O
produced	O
by	O
arginase	B-GENE-Y
II	I-GENE-Y
(	O
AII	B-GENE-Y
)	O
.	O

Here	O
,	O
the	O
renal	O
metabolic	O
fate	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
ornithine	I-CHEMICAL
was	O
analyzed	O
in	O
male	O
and	O
female	O
rats	O
.	O

Kidneys	O
and	O
renal	O
zones	O
were	O
dissected	O
and	O
used	O
for	O
Western	O
blot	O
analysis	O
,	O
immunofluorescence	O
,	O
and	O
electron	O
microscopic	O
studies	O
.	O

Ornithine	B-GENE-Y
aminotransferase	I-GENE-Y
(	O
OAT	B-GENE-Y
)	O
and	O
AII	B-GENE-Y
were	O
localized	O
using	O
specific	O
antibodies	O
.	O

Ornithine	B-CHEMICAL
oxidation	O
was	O
determined	O
by	O
incubating	O
microdissected	O
tubules	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
or	O
L	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
U	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
ornithine	I-CHEMICAL
in	O
the	O
presence	O
or	O
absence	O
of	O
energy	O
-	O
providing	O
substrates	O
.	O

Ornithine	B-GENE-Y
decarboxylase	I-GENE-Y
(	O
ODC	B-GENE-Y
)	O
mRNAs	O
were	O
localized	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
48	O
-	O
kDa	O
OAT	B-GENE-Y
protein	O
was	O
detected	O
in	O
male	O
and	O
female	O
kidneys	O
,	O
but	O
its	O
level	O
was	O
fourfold	O
higher	O
in	O
the	O
latter	O
.	O

OAT	B-GENE-Y
relative	O
distribution	O
increased	O
from	O
the	O
superficial	O
cortex	O
toward	O
the	O
outer	O
medulla	O
to	O
reach	O
its	O
highest	O
level	O
.	O

Almost	O
all	O
OAT	B-GENE-Y
protein	O
was	O
localized	O
in	O
cortical	O
and	O
medullary	O
proximal	O
straight	O
tubules	O
(	O
CPST	O
and	O
OSPST	O
,	O
respectively	O
)	O
.	O

In	O
proximal	O
straight	O
tubule	O
(	O
PST	O
)	O
,	O
AII	B-GENE-Y
protein	O
distribution	O
overlapped	O
that	O
of	O
OAT	B-GENE-Y
.	O

No	O
gender	O
difference	O
in	O
AII	B-GENE-Y
protein	O
level	O
was	O
found	O
.	O

OAT	B-GENE-Y
and	O
AII	B-GENE-Y
were	O
colocalized	O
within	O
PST	O
mitochondria	O
.	O

L	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
ornithine	I-CHEMICAL
decarboxylation	O
occurred	O
in	O
all	O
tubules	O
,	O
but	O
predominantly	O
in	O
proximal	O
tubules	O
.	O

L	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
ornithine	I-CHEMICAL
decarboxylation	O
was	O
enhanced	O
when	O
L	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
ornithine	I-CHEMICAL
was	O
given	O
to	O
tubules	O
as	O
the	O
sole	O
substrate	O
.	O

The	O
use	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
U	I-CHEMICAL
-	I-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
ornithine	I-CHEMICAL
demonstrated	O
the	O
complete	O
oxidation	O
of	O
ornithine	B-CHEMICAL
.	O

In	O
conclusion	O
,	O
the	O
OAT	B-GENE-Y
gene	O
was	O
expressed	O
more	O
in	O
female	O
rat	O
proximal	O
tubules	O
than	O
in	O
male	O
.	O

Because	O
OAT	B-GENE-Y
and	O
AII	B-GENE-Y
proteins	O
overlapped	O
in	O
PST	O
mitochondria	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
-	O
derived	O
ornithine	B-CHEMICAL
may	O
be	O
preferentially	O
converted	O
to	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
,	O
as	O
proven	O
by	O
ornithine	B-CHEMICAL
oxidation	O
.	O

However	O
,	O
the	O
coexpression	O
of	O
ODC	B-GENE-Y
,	O
glutamate	B-GENE-N
decarboxylase	I-GENE-N
,	O
and	O
glutamine	B-GENE-Y
synthetase	I-GENE-Y
in	O
PST	O
suggests	O
that	O
L	B-CHEMICAL
-	I-CHEMICAL
ornithine	I-CHEMICAL
can	O
also	O
be	O
metabolized	O
to	O
putrescine	B-CHEMICAL
,	O
GABA	B-CHEMICAL
,	O
and	O
L	B-CHEMICAL
-	I-CHEMICAL
glutamine	I-CHEMICAL
.	O

The	O
fate	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
ornithine	I-CHEMICAL
may	O
depend	O
on	O
the	O
cellular	O
context	O
.	O

Emerging	O
role	O
of	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
inhibition	O
in	O
therapy	O
for	O
advanced	O
malignancy	O
:	O
focus	O
on	O
NSCLC	O
.	O

Combination	O
chemotherapy	O
regimens	O
have	O
emerged	O
as	O
the	O
standard	O
approach	O
in	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O

Meta	O
-	O
analyses	O
have	O
demonstrated	O
a	O
2	O
-	O
month	O
increase	O
in	O
median	O
survival	O
after	O
platinum	B-CHEMICAL
-	O
based	O
therapy	O
vs	O
.	O
best	O
supportive	O
care	O
,	O
and	O
an	O
absolute	O
10	O
%	O
improvement	O
in	O
the	O
1	O
-	O
year	O
survival	O
rate	O
.	O

Just	O
as	O
importantly	O
,	O
cytotoxic	O
therapy	O
has	O
produced	O
benefits	O
in	O
symptom	O
control	O
and	O
quality	O
of	O
life	O
.	O

Newer	O
agents	O
,	O
including	O
the	O
taxanes	B-CHEMICAL
,	O
vinorelbine	B-CHEMICAL
,	O
gemcitabine	B-CHEMICAL
,	O
and	O
irinotecan	B-CHEMICAL
,	O
have	O
expanded	O
our	O
therapeutic	O
options	O
in	O
the	O
treatment	O
of	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
.	O

Despite	O
their	O
contributions	O
,	O
we	O
have	O
reached	O
a	O
therapeutic	O
plateau	O
,	O
with	O
response	O
rates	O
seldom	O
exceeding	O
30	O
-	O
40	O
%	O
in	O
cooperative	O
group	O
studies	O
and	O
1	O
-	O
year	O
survival	O
rates	O
stable	O
between	O
30	O
%	O
and	O
40	O
%	O
.	O

It	O
is	O
doubtful	O
that	O
substituting	O
one	O
agent	O
for	O
another	O
in	O
various	O
combinations	O
will	O
lead	O
to	O
any	O
further	O
improvement	O
in	O
these	O
rates	O
.	O

The	O
thrust	O
of	O
current	O
research	O
has	O
focused	O
on	O
targeted	O
therapy	O
,	O
and	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
inhibition	O
is	O
one	O
of	O
the	O
most	O
promising	O
clinical	O
strategies	O
.	O

Epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
inhibitors	O
currently	O
under	O
investigation	O
include	O
the	O
small	O
molecules	O
gefitinib	B-CHEMICAL
(	O
Iressa	B-CHEMICAL
,	O
ZD1839	B-CHEMICAL
)	O
and	O
erlotinib	B-CHEMICAL
(	O
Tarceva	B-CHEMICAL
,	O
OSI	B-CHEMICAL
-	I-CHEMICAL
774	I-CHEMICAL
)	O
,	O
as	O
well	O
as	O
monoclonal	O
antibodies	O
such	O
as	O
cetuximab	B-CHEMICAL
(	O
IMC	B-CHEMICAL
-	I-CHEMICAL
225	I-CHEMICAL
,	O
Erbitux	B-CHEMICAL
)	O
.	O

Agents	O
that	O
have	O
only	O
begun	O
to	O
undergo	O
clinical	O
evaluation	O
include	O
CI	B-CHEMICAL
-	I-CHEMICAL
1033	I-CHEMICAL
,	O
an	O
irreversible	O
pan	O
-	O
erbB	B-GENE-Y
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
,	O
and	O
PKI166	B-CHEMICAL
and	O
GW572016	B-CHEMICAL
,	O
both	O
examples	O
of	O
dual	O
kinase	B-GENE-N
inhibitors	O
(	O
inhibiting	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
and	O
Her2	B-GENE-Y
)	O
.	O

Preclinical	O
models	O
have	O
demonstrated	O
synergy	O
for	O
all	O
these	O
agents	O
in	O
combination	O
with	O
either	O
chemotherapy	O
or	O
radiotherapy	O
,	O
leading	O
to	O
great	O
enthusiasm	O
regarding	O
their	O
ultimate	O
contribution	O
to	O
lung	O
cancer	O
therapy	O
.	O

However	O
,	O
serious	O
clinical	O
challenges	O
persist	O
.	O

These	O
include	O
the	O
identification	O
of	O
the	O
optimal	O
dose	O
(	O
s	O
)	O
;	O
the	O
proper	O
integration	O
of	O
these	O
agents	O
into	O
popular	O
,	O
established	O
cytotoxic	O
regimens	O
;	O
and	O
the	O
selection	O
of	O
the	O
optimal	O
setting	O
(	O
s	O
)	O
in	O
which	O
to	O
test	O
these	O
compounds	O
.	O

Both	O
gefitinib	B-CHEMICAL
and	O
erlotinib	B-CHEMICAL
have	O
shown	O
clinical	O
activity	O
in	O
pretreated	O
,	O
advanced	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
but	O
placebo	O
-	O
controlled	O
randomized	O
Phase	O
III	O
studies	O
evaluating	O
gefitinib	B-CHEMICAL
in	O
combination	O
with	O
standard	O
cytotoxic	O
therapy	O
,	O
to	O
our	O
chagrin	O
,	O
have	O
failed	O
to	O
demonstrate	O
a	O
survival	O
advantage	O
compared	O
with	O
chemotherapy	O
alone	O
.	O

Externalization	O
of	O
phosphatidylserine	B-CHEMICAL
during	O
apoptosis	O
does	O
not	O
specifically	O
require	O
either	O
isoform	O
of	O
phosphatidylserine	B-GENE-N
synthase	I-GENE-N
.	O

Phosphatidylserine	B-CHEMICAL
(	O
PtdSer	B-CHEMICAL
)	O
is	O
made	O
in	O
mammalian	O
cells	O
by	O
two	O
PtdSer	B-GENE-N
synthases	I-GENE-N
,	O
PSS1	B-GENE-N
and	O
PSS2	B-GENE-N
.	O

In	O
the	O
plasma	O
membrane	O
PtdSer	B-CHEMICAL
is	O
normally	O
localized	O
on	O
the	O
inner	O
leaflet	O
but	O
undergoes	O
transbilayer	O
movement	O
during	O
apoptosis	O
and	O
becomes	O
exposed	O
on	O
the	O
cell	O
surface	O
.	O

We	O
induced	O
apoptosis	O
with	O
staurosporine	B-CHEMICAL
in	O
four	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cell	O
lines	O
that	O
are	O
deficient	O
in	O
PSS1	B-GENE-Y
and	O
/	O
or	O
PSS2	B-GENE-Y
to	O
determine	O
if	O
PtdSer	B-CHEMICAL
generated	O
by	O
either	O
of	O
these	O
enzymes	O
is	O
required	O
for	O
externalization	O
on	O
the	O
cell	O
surface	O
during	O
apoptosis	O
.	O

The	O
onset	O
of	O
apoptosis	O
was	O
confirmed	O
by	O
the	O
appearance	O
of	O
morphological	O
changes	O
and	O
DNA	O
fragmentation	O
while	O
the	O
plasma	O
membrane	O
remained	O
largely	O
intact	O
.	O

In	O
all	O
cell	O
lines	O
,	O
regardless	O
of	O
their	O
content	O
of	O
PSS1	B-GENE-Y
and	O
/	O
or	O
PSS2	B-GENE-Y
,	O
apoptosis	O
occurred	O
to	O
approximately	O
the	O
same	O
extent	O
,	O
and	O
within	O
approximately	O
the	O
same	O
time	O
frame	O
,	O
as	O
in	O
parental	O
CHO	O
-	O
K1	O
cells	O
.	O

The	O
exposure	O
of	O
PtdSer	B-CHEMICAL
on	O
the	O
cell	O
surface	O
was	O
assessed	O
by	O
annexin	O
V	O
labeling	O
and	O
flow	O
cytometry	O
.	O

Cells	O
that	O
were	O
deficient	O
in	O
either	O
PSS1	B-GENE-Y
or	O
PSS2	B-GENE-Y
,	O
as	O
well	O
as	O
cells	O
that	O
were	O
deficient	O
in	O
both	O
PSS1	B-GENE-Y
and	O
PSS2	B-GENE-Y
,	O
externalized	O
normal	O
amounts	O
of	O
PtdSer	B-CHEMICAL
.	O

Our	O
study	O
demonstrates	O
,	O
that	O
reduction	O
of	O
in	O
vitro	O
serine	B-CHEMICAL
-	O
exchange	O
activity	O
,	O
even	O
by	O
97	O
%	O
,	O
does	O
not	O
restrict	O
the	O
externalization	O
of	O
PtdSer	B-CHEMICAL
during	O
apoptosis	O
.	O

Moreover	O
,	O
a	O
normal	O
level	O
of	O
expression	O
of	O
PSS1	B-GENE-Y
and	O
/	O
or	O
PSS2	B-GENE-Y
is	O
not	O
required	O
for	O
generating	O
the	O
pool	O
of	O
PtdSer	B-CHEMICAL
externalized	O
during	O
apoptosis	O
.	O

Block	O
of	O
human	B-GENE-Y
NaV1	I-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
sodium	B-GENE-N
channels	I-GENE-N
by	O
novel	O
alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxyphenylamide	I-CHEMICAL
analogues	O
of	O
phenytoin	B-CHEMICAL
.	O

Voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
(	I-GENE-N
Na	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
are	O
a	O
critical	O
component	O
of	O
electrically	O
excitable	O
cells	O
.	O

Phenytoin	B-CHEMICAL
(	O
diphenylhydantoin	B-CHEMICAL
,	O
DPH	B-CHEMICAL
)	O
is	O
an	O
established	O
sodium	B-GENE-N
channel	I-GENE-N
blocker	O
and	O
is	O
a	O
useful	O
anticonvulsant	O
and	O
class	O
1b	O
antiarrhythmic	O
,	O
and	O
has	O
been	O
effectively	O
used	O
in	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
synthesized	O
novel	O
alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxyphenylamide	I-CHEMICAL
analogues	O
of	O
diphenylhydantoin	B-CHEMICAL
and	O
examined	O
their	O
ability	O
to	O
inhibit	O
human	B-GENE-Y
Na	I-GENE-Y
(	I-GENE-Y
V	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
sodium	B-GENE-N
channels	I-GENE-N
expressed	O
in	O
Chinese	O
Hamster	O
Ovary	O
(	O
CHO	O
-	O
K1	O
)	O
cells	O
.	O

Phenyl	B-CHEMICAL
ring	O
substitutions	O
were	O
examined	O
including	O
para	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
,	O
para	B-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
,	O
para	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
,	O
ortho	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
and	O
meta	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
.	O

We	O
have	O
found	O
that	O
phenyl	B-CHEMICAL
ring	O
substitutions	O
with	O
electron	O
withdrawing	O
properties	O
resulted	O
in	O
compounds	O
with	O
greater	O
activity	O
.	O

In	O
comparison	O
to	O
diphenylhydantoin	B-CHEMICAL
,	O
the	O
novel	O
chloro	B-CHEMICAL
-	O
substituted	O
alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxyphenylamide	I-CHEMICAL
compounds	O
produced	O
as	O
much	O
as	O
a	O
20	O
-	O
fold	O
greater	O
tonic	O
and	O
frequency	O
-	O
dependent	O
blockade	O
of	O
Na	B-GENE-Y
(	I-GENE-Y
V	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
channels	O
with	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
14	O
.	O
5	O
microM	O
.	O

In	O
addition	O
,	O
the	O
chloro	B-CHEMICAL
-	O
substitutions	O
have	O
position	O
specific	O
state	O
dependent	O
blocking	O
properties	O
.	O

The	O
ortho	B-CHEMICAL
-	I-CHEMICAL
,	I-CHEMICAL
meta	I-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
para	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
substitutions	O
have	O
an	O
8	O
-	O
,	O
13	O
-	O
and	O
3	O
-	O
fold	O
increased	O
affinity	O
for	O
the	O
inactivated	O
state	O
,	O
respectively	O
.	O

Molecular	O
modeling	O
suggests	O
that	O
these	O
differences	O
in	O
affinity	O
are	O
due	O
to	O
a	O
direct	O
interaction	O
with	O
the	O
receptor	O
.	O

Comparing	O
models	O
of	O
diphenylhydantoin	B-CHEMICAL
to	O
the	O
novel	O
alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxyphenlyamide	I-CHEMICAL
compound	O
suggests	O
that	O
the	O
increased	O
activity	O
may	O
be	O
due	O
to	O
an	O
optimized	O
phenyl	B-CHEMICAL
ring	O
position	O
and	O
increased	O
molecular	O
volume	O
.	O

This	O
information	O
may	O
be	O
useful	O
in	O
the	O
development	O
of	O
more	O
potent	O
sodium	B-GENE-N
channel	I-GENE-N
blockers	O
.	O

Effects	O
of	O
an	O
ethanolic	O
salix	O
extract	O
on	O
the	O
release	O
of	O
selected	O
inflammatory	O
mediators	O
in	O
vitro	O
.	O

Salix	O
extracts	O
are	O
in	O
current	O
use	O
for	O
the	O
treatment	O
of	O
pain	O
and	O
inflammation	O
.	O

In	O
order	O
to	O
obtain	O
an	O
insight	O
into	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
the	O
ethanolic	O
Salix	O
extract	O
1520L	O
-	O
-	O
which	O
is	O
essentially	O
similar	O
to	O
an	O
extract	O
for	O
which	O
clinical	O
studies	O
have	O
demonstrated	O
analgesic	O
effectiveness	O
-	O
-	O
its	O
effects	O
were	O
evaluated	O
in	O
an	O
established	O
in	O
vitro	O
assay	O
test	O
system	O
using	O
primary	O
human	O
monocytes	O
.	O

The	O
IC50	O
-	O
values	O
obtained	O
for	O
the	O
inhibition	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
release	O
of	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
PGE2	B-CHEMICAL
)	O
reflecting	O
cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
mediated	O
PGE2	B-CHEMICAL
release	O
were	O
47	O
microg	O
/	O
ml	O
and	O
0	O
.	O
6	O
microg	O
/	O
ml	O
,	O
for	O
the	O
Salix	O
extract	O
1520L	O
and	O
rofecoxib	B-CHEMICAL
-	O
like	O
research	O
compound	O
L745337	B-CHEMICAL
,	O
respectively	O
.	O

There	O
was	O
no	O
effect	O
on	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
activity	O
.	O

The	O
Salix	O
extract	O
inhibited	O
the	O
LPS	O
-	O
induced	O
release	O
of	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
1beta	I-GENE-Y
and	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
with	O
IC50	O
-	O
values	O
of	O
180	O
.	O
0	O
,	O
33	O
.	O
0	O
and	O
86	O
.	O
0	O
microg	O
/	O
ml	O
,	O
respectively	O
.	O

Both	O
,	O
salicin	B-CHEMICAL
and	O
salicylate	B-CHEMICAL
,	O
had	O
no	O
effect	O
in	O
any	O
of	O
the	O
parameters	O
.	O

Our	O
results	O
indicate	O
that	O
Salix	O
extract	O
1520L	O
inhibits	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
mediated	O
PGE2	B-CHEMICAL
release	O
through	O
compounds	O
other	O
than	O
salicin	B-CHEMICAL
or	O
salicylate	B-CHEMICAL
.	O

Our	O
data	O
further	O
suggest	O
that	O
the	O
proprietary	O
Salix	O
extract	O
is	O
a	O
weak	O
inhibitor	O
of	O
proinflammatory	O
cytokines	B-GENE-N
.	O

Kinetic	O
mechanism	O
of	O
quinone	B-GENE-Y
oxidoreductase	I-GENE-Y
2	I-GENE-Y
and	O
its	O
inhibition	O
by	O
the	O
antimalarial	O
quinolines	B-CHEMICAL
.	O

Quinone	B-GENE-Y
oxidoreductase	I-GENE-Y
2	I-GENE-Y
(	O
QR2	B-GENE-Y
)	O
purified	O
from	O
human	O
red	O
blood	O
cells	O
was	O
recently	O
shown	O
to	O
be	O
a	O
potential	O
target	O
of	O
the	O
quinoline	B-CHEMICAL
antimalarial	O
compounds	O
[	O
Graves	O
et	O
al	O
.	O
,	O
(	O
2002	O
)	O
Mol	O
.	O
Pharmacol	O
.	O
62	O
,	O
1364	O
]	O
.	O

QR2	B-GENE-Y
catalyzes	O
the	O
two	O
-	O
electron	O
reduction	O
of	O
menadione	B-CHEMICAL
via	O
the	O
oxidation	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
alkylated	I-CHEMICAL
or	O
N	B-CHEMICAL
-	I-CHEMICAL
ribosylated	I-CHEMICAL
nicotinamides	I-CHEMICAL
.	O

To	O
investigate	O
the	O
mechanism	O
and	O
consequences	O
of	O
inhibition	O
of	O
QR2	B-GENE-Y
by	O
the	O
quinolines	B-CHEMICAL
further	O
,	O
we	O
have	O
used	O
steady	O
-	O
state	O
and	O
transient	O
-	O
state	O
kinetics	O
to	O
define	O
the	O
mechanism	O
of	O
QR2	B-GENE-Y
.	O

Importantly	O
,	O
we	O
have	O
shown	O
that	O
QR2	B-GENE-Y
when	O
isolated	O
from	O
an	O
overproducing	O
strain	O
of	O
E	O
.	O
coli	O
is	O
kinetically	O
equivalent	O
to	O
the	O
enzyme	O
from	O
the	O
native	O
human	O
red	O
blood	O
cell	O
source	O
.	O

We	O
observe	O
ping	O
-	O
pong	O
kinetics	O
consistent	O
with	O
one	O
substrate	O
/	O
inhibitor	O
binding	O
site	O
that	O
shows	O
selectivity	O
for	O
the	O
oxidation	O
state	O
of	O
the	O
FAD	O
cofactor	O
,	O
suggesting	O
that	O
selective	O
inhibition	O
of	O
the	O
liver	O
versus	O
red	O
blood	O
cell	O
forms	O
of	O
malaria	O
may	O
be	O
possible	O
.	O

The	O
reductant	O
N	B-CHEMICAL
-	I-CHEMICAL
methyldihydronicotinamide	I-CHEMICAL
and	O
the	O
inhibitor	O
primaquine	B-CHEMICAL
bind	O
exclusively	O
to	O
the	O
oxidized	O
enzyme	O
.	O

In	O
contrast	O
,	O
the	O
inhibitors	O
quinacrine	B-CHEMICAL
and	O
chloroquine	B-CHEMICAL
bind	O
exclusively	O
to	O
the	O
reduced	O
enzyme	O
.	O

The	O
quinone	B-CHEMICAL
substrate	O
menadione	B-CHEMICAL
,	O
on	O
the	O
other	O
hand	O
,	O
binds	O
nonspecifically	O
to	O
both	O
forms	O
of	O
the	O
enzyme	O
.	O

Single	O
-	O
turnover	O
kinetics	O
of	O
the	O
reductive	O
half	O
-	O
reaction	O
are	O
chemically	O
and	O
kinetically	O
competent	O
and	O
confirm	O
the	O
inhibitor	O
selectivity	O
seen	O
in	O
the	O
steady	O
-	O
state	O
experiments	O
.	O

Our	O
studies	O
shed	O
light	O
on	O
the	O
possible	O
in	O
vivo	O
potency	O
of	O
the	O
quinolines	B-CHEMICAL
and	O
provide	O
a	O
foundation	O
for	O
future	O
studies	O
aimed	O
at	O
creating	O
more	O
potent	O
QR2	B-GENE-Y
inhibitors	O
and	O
at	O
understanding	O
the	O
physiological	O
significance	O
of	O
QR2	B-GENE-Y
.	O

Evidence	O
that	O
the	O
granulocyte	B-GENE-Y
colony	I-GENE-Y
-	I-GENE-Y
stimulating	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
G	I-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
plays	O
a	O
role	O
in	O
the	O
pharmacokinetics	O
of	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
and	O
PegG	O
-	O
CSF	O
using	O
a	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
KO	O
model	O
.	O

The	O
covalent	O
attachment	O
of	O
polyethylene	O
glycol	O
to	O
filgrastim	O
results	O
in	O
a	O
new	O
molecule	O
pegfilgrastim	O
,	O
which	O
has	O
a	O
significantly	O
longer	O
half	O
-	O
life	O
than	O
filgrastim	O
.	O

It	O
is	O
likely	O
that	O
the	O
clearance	O
of	O
both	O
filgrastim	O
and	O
pegfilgrastim	O
involves	O
granulocyte	B-GENE-Y
colony	I-GENE-Y
simulating	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
G	I-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
binding	O
,	O
but	O
the	O
pharmacokinetics	O
of	O
these	O
drugs	O
have	O
not	O
been	O
compared	O
in	O
mice	O
with	O
and	O
without	O
a	O
functional	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
receptor	I-GENE-Y
.	O

We	O
sought	O
to	O
clarify	O
the	O
role	O
of	O
receptor	O
-	O
mediated	O
clearance	O
of	O
filgrastim	O
and	O
pegfilgrastim	O
using	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
or	O
mice	O
with	O
a	O
non	O
-	O
functional	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
(	O
knockout	O
,	O
KO	O
)	O
.	O

We	O
administered	O
single	O
doses	O
of	O
filgrastim	O
or	O
pegfilgrastim	O
(	O
10	O
or	O
100	O
microg	O
kg	O
(	O
-	O
1	O
)	O
)	O
intravenously	O
to	O
WT	O
and	O
KO	O
mice	O
.	O

Plasma	O
levels	O
of	O
protein	O
were	O
measured	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
at	O
preset	O
time	O
points	O
,	O
and	O
AUC	O
,	O
MRT	O
,	O
CL	O
,	O
V	O
(	O
d	O
)	O
,	O
and	O
T	O
(	O
1	O
/	O
2	O
)	O
were	O
calculated	O
.	O

When	O
compared	O
with	O
WT	O
mice	O
,	O
the	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
KO	O
mice	O
had	O
significantly	O
greater	O
AUC	O
,	O
longer	O
MRT	O
,	O
longer	O
T	O
(	O
1	O
/	O
2	O
)	O
,	O
and	O
lower	O
clearance	O
.	O

This	O
was	O
the	O
case	O
whether	O
animals	O
received	O
10	O
or	O
100	O
microg	O
kg	O
(	O
-	O
1	O
)	O
and	O
whether	O
they	O
received	O
filgrastim	O
or	O
pegfilgrastim	O
.	O

The	O
volume	O
of	O
protein	O
distribution	O
was	O
identical	O
among	O
WT	O
and	O
KO	O
mice	O
.	O

However	O
,	O
the	O
V	O
(	O
d	O
)	O
was	O
larger	O
after	O
pegfilgrastim	O
dosing	O
than	O
after	O
filgrastim	O
dosing	O
.	O

In	O
both	O
WT	O
and	O
KO	O
mice	O
,	O
increasing	O
the	O
dose	O
of	O
figrastim	O
or	O
pegfilgrastim	O
resulted	O
in	O
a	O
proportional	O
increase	O
in	O
the	O
AUC	O
.	O

A	O
functional	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
is	O
an	O
important	O
mechanism	O
in	O
the	O
plasma	O
clearance	O
of	O
both	O
filgrastim	O
and	O
pegfilgrastim	O
.	O

Cross	O
-	O
inhibition	O
of	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
-	O
and	O
ABCA1	B-GENE-Y
-	O
mediated	O
cholesterol	B-CHEMICAL
transport	O
by	O
the	O
small	O
molecules	O
BLT	O
-	O
4	O
and	O
glyburide	B-CHEMICAL
.	O

Scavenger	B-GENE-Y
receptor	I-GENE-Y
class	I-GENE-Y
B	I-GENE-Y
type	I-GENE-Y
I	I-GENE-Y
(	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
)	O
and	O
ABCA1	B-GENE-N
are	O
structurally	O
dissimilar	O
cell	O
surface	O
proteins	O
that	O
play	O
key	O
roles	O
in	O
HDL	B-GENE-N
metabolism	O
.	O

SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
is	O
a	O
receptor	O
that	O
binds	O
HDL	B-GENE-N
with	O
high	O
affinity	O
and	O
mediates	O
both	O
the	O
selective	O
lipid	O
uptake	O
of	O
cholesteryl	B-CHEMICAL
esters	I-CHEMICAL
from	O
lipid	O
-	O
rich	O
HDL	B-GENE-N
to	O
cells	O
and	O
the	O
efflux	O
of	O
unesterified	O
cholesterol	B-CHEMICAL
from	O
cells	O
to	O
HDL	B-GENE-N
.	O

ABCA1	B-GENE-Y
mediates	O
the	O
efflux	O
of	O
unesterified	O
cholesterol	B-CHEMICAL
and	O
phospholipids	O
from	O
cells	O
to	O
lipid	O
-	O
poor	O
apolipoprotein	B-GENE-Y
A	I-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
(	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
)	O
.	O

The	O
activities	O
of	O
ABCA1	B-GENE-Y
and	O
other	O
ATP	B-GENE-N
binding	I-GENE-N
cassette	I-GENE-N
superfamily	I-GENE-N
members	O
are	O
inhibited	O
by	O
the	O
drug	O
glyburide	B-CHEMICAL
,	O
and	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
-	O
mediated	O
lipid	O
transport	O
is	O
blocked	O
by	O
small	O
molecule	O
inhibitors	O
called	O
BLTs	O
.	O

Here	O
,	O
we	O
show	O
that	O
one	O
BLT	B-CHEMICAL
,	O
[	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methoxy	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
naphthalen	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
-	I-CHEMICAL
urea	I-CHEMICAL
]	O
(	O
BLT	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
)	O
,	O
blocked	O
ABCA1	B-GENE-Y
-	O
mediated	O
cholesterol	B-CHEMICAL
efflux	O
to	O
lipid	O
-	O
poor	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
at	O
a	O
potency	O
similar	O
to	O
that	O
for	O
its	O
inhibition	O
of	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
approximately	O
55	O
-	O
60	O
microM	O
)	O
.	O

Reciprocally	O
,	O
glyburide	B-CHEMICAL
blocked	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
-	O
mediated	O
selective	O
lipid	O
uptake	O
and	O
efflux	O
at	O
a	O
potency	O
similar	O
to	O
that	O
for	O
its	O
inhibition	O
of	O
ABCA1	B-GENE-Y
(	O
IC	O
(	O
50	O
)	O
approximately	O
275	O
-	O
300	O
microM	O
)	O
.	O

As	O
is	O
the	O
case	O
with	O
BLTs	O
,	O
glyburide	B-CHEMICAL
increased	O
the	O
apparent	O
affinity	O
of	O
HDL	B-GENE-N
binding	O
to	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
.	O

The	O
reciprocal	O
inhibition	O
of	O
SR	B-GENE-Y
-	I-GENE-Y
BI	I-GENE-Y
and	O
ABCA1	B-GENE-Y
by	O
BLT	O
-	O
4	O
and	O
glyburide	B-CHEMICAL
raises	O
the	O
possibility	O
that	O
these	O
proteins	O
may	O
share	O
similar	O
or	O
common	O
steps	O
in	O
their	O
mechanisms	O
of	O
lipid	O
transport	O
.	O

Carbonic	B-GENE-N
anhydrase	I-GENE-N
inhibitors	O
:	O
aromatic	B-CHEMICAL
and	I-CHEMICAL
heterocyclic	I-CHEMICAL
sulfonamides	I-CHEMICAL
incorporating	O
adamantyl	B-CHEMICAL
moieties	O
with	O
strong	O
anticonvulsant	O
activity	O
.	O

A	O
series	O
of	O
aromatic	B-CHEMICAL
/	I-CHEMICAL
heterocyclic	I-CHEMICAL
sulfonamides	I-CHEMICAL
incorporating	O
adamantyl	B-CHEMICAL
moieties	O
were	O
prepared	O
by	O
reaction	O
of	O
aromatic	B-CHEMICAL
/	I-CHEMICAL
heterocyclic	I-CHEMICAL
aminosulfonamides	I-CHEMICAL
with	O
the	O
acyl	B-CHEMICAL
chlorides	I-CHEMICAL
derived	O
from	O
adamantyl	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
and	O
1	B-CHEMICAL
-	I-CHEMICAL
adamantyl	I-CHEMICAL
-	I-CHEMICAL
acetic	I-CHEMICAL
acid	I-CHEMICAL
.	O

Related	O
derivatives	O
were	O
obtained	O
from	O
the	O
above	O
-	O
mentioned	O
aminosulfonamides	B-CHEMICAL
with	O
adamantyl	B-CHEMICAL
isocyanate	I-CHEMICAL
and	O
adamantyl	B-CHEMICAL
isothiocyanate	I-CHEMICAL
,	O
respectively	O
.	O

Some	O
of	O
these	O
derivatives	O
showed	O
good	O
inhibitory	O
potency	O
against	O
two	O
human	B-GENE-N
CA	I-GENE-N
isozymes	O
involved	O
in	O
important	O
physiological	O
processes	O
,	O
CA	B-GENE-Y
I	I-GENE-Y
,	O
and	O
CA	B-GENE-Y
II	I-GENE-Y
,	O
of	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
the	O
clinically	O
used	O
drugs	O
acetazolamide	B-CHEMICAL
and	O
methazolamide	B-CHEMICAL
.	O

The	O
lipophilicity	O
of	O
the	O
best	O
CA	B-GENE-N
inhibitors	O
was	O
determined	O
and	O
expressed	O
as	O
their	O
experimental	O
log	O
k	O
'	O
IAM	O
and	O
theoretical	O
ClogP	O
value	O
.	O

Their	O
lipophilicity	O
was	O
propitious	O
with	O
the	O
crossing	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
log	O
k	O
'	O
>	O
IAM	O
>	O
1	O
.	O
35	O
)	O
.	O

The	O
anticonvulsant	O
activity	O
of	O
some	O
of	O
the	O
best	O
CA	B-GENE-N
inhibitors	O
reported	O
here	O
has	O
been	O
evaluated	O
in	O
a	O
MES	O
test	O
in	O
mice	O
.	O

After	O
intraperitoneal	O
injection	O
(	O
30	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
compounds	O
A8	O
and	O
A9	O
exhibited	O
a	O
high	O
protection	O
against	O
electrically	O
induced	O
convulsions	O
(	O
>	O
90	O
%	O
)	O
.	O

Their	O
ED50	O
was	O
3	O
.	O
5	O
and	O
2	O
.	O
6	O
mg	O
kg	O
(	O
-	O
1	O
)	O
,	O
respectively	O
.	O

In	O
vitro	O
inhibition	O
of	O
diacylglycerol	B-GENE-Y
acyltransferase	I-GENE-Y
by	O
prenylflavonoids	B-CHEMICAL
from	O
Sophora	O
flavescens	O
.	O

Four	O
prenylflavonoids	B-CHEMICAL
,	O
kurarinone	B-CHEMICAL
(	O
1	O
)	O
,	O
a	O
chalcone	B-CHEMICAL
of	O
1	O
,	O
kuraridin	B-CHEMICAL
(	O
2	O
)	O
,	O
kurarinol	B-CHEMICAL
(	O
3	O
)	O
,	O
kushenol	B-CHEMICAL
H	I-CHEMICAL
(	O
4	O
)	O
and	O
kushenol	B-CHEMICAL
K	I-CHEMICAL
(	O
5	O
)	O
isolated	O
from	O
the	O
roots	O
of	O
Sophora	O
flavescens	O
were	O
investigated	O
for	O
their	O
inhibitory	O
effects	O
on	O
diacylglycerol	B-GENE-Y
acyltransferase	I-GENE-Y
(	O
DGAT	B-GENE-Y
)	O
.	O

The	O
flavonoids	B-CHEMICAL
inhibited	O
DGAT	B-GENE-Y
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
IC50	O
values	O
of	O
10	O
.	O
9	O
microM	O
(	O
1	O
)	O
,	O
9	O
.	O
8	O
microM	O
(	O
2	O
)	O
,	O
8	O
.	O
6	O
microM	O
(	O
3	O
)	O
,	O
142	O
.	O
0	O
microM	O
(	O
4	O
)	O
and	O
250	O
microM	O
(	O
5	O
)	O
.	O

The	O
prenylflavonoids	B-CHEMICAL
without	O
C3	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
(	O
1	O
,	O
2	O
,	O
3	O
)	O
showed	O
stronger	O
inhibition	O
than	O
those	O
with	O
C3	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
(	O
4	O
,	O
5	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
flavonoids	B-CHEMICAL
without	O
side	O
chains	O
(	O
hesperetin	B-CHEMICAL
,	O
naringenin	B-CHEMICAL
,	O
quercetin	B-CHEMICAL
and	O
kaempferol	B-CHEMICAL
)	O
did	O
not	O
inhibit	O
the	O
enzyme	O
activity	O
at	O
a	O
final	O
concentration	O
of	O
800	O
microM	O
.	O

These	O
data	O
suggest	O
that	O
the	O
lavandulyl	B-CHEMICAL
side	O
chain	O
and	O
the	O
position	O
of	O
the	O
hydroxy	B-CHEMICAL
group	O
are	O
important	O
for	O
high	O
DGAT	B-GENE-Y
inhibitory	O
activity	O
.	O

Compound	O
1	O
also	O
inhibited	O
de	O
novo	O
synthesis	O
of	O
triacylglycerol	B-CHEMICAL
(	O
TG	B-CHEMICAL
)	O
in	O
Raji	O
cells	O
.	O

In	O
vitro	O
antiprogestational	O
/	O
antiglucocorticoid	O
activity	O
and	O
progestin	B-CHEMICAL
and	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
binding	O
of	O
the	O
putative	O
metabolites	O
and	O
synthetic	O
derivatives	O
of	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
,	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
,	O
and	O
mifepristone	B-CHEMICAL
.	O

In	O
determining	O
the	O
biological	O
profiles	O
of	O
various	O
antiprogestins	O
,	O
it	O
is	O
important	O
to	O
assess	O
the	O
hormonal	O
and	O
antihormonal	O
activity	O
,	O
selectivity	O
,	O
and	O
potency	O
of	O
their	O
proximal	O
metabolites	O
.	O

The	O
early	O
metabolism	O
of	O
mifepristone	B-CHEMICAL
is	O
characterized	O
by	O
rapid	O
demethylation	O
and	O
hydroxylation	O
.	O

Similar	O
initial	O
metabolic	O
pathways	O
have	O
been	O
proposed	O
for	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
(	O
CDB	O
:	O
Contraceptive	O
Development	O
Branch	O
of	O
NICHD	O
)	O
and	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
,	O
and	O
their	O
putative	O
metabolites	O
have	O
been	O
synthesized	O
.	O

We	O
have	O
examined	O
the	O
functional	O
activities	O
and	O
potencies	O
,	O
in	O
various	O
cell	O
-	O
based	O
assays	O
,	O
and	O
relative	O
binding	O
affinities	O
(	O
RBAs	O
)	O
for	O
progesterone	B-GENE-N
receptors	I-GENE-N
(	O
PR	B-GENE-N
)	O
and	O
glucocorticoid	B-GENE-Y
receptors	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
of	O
the	O
putative	O
mono	O
-	O
and	O
didemethylated	O
metabolites	O
of	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
,	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
,	O
and	O
mifepristone	B-CHEMICAL
and	O
of	O
the	O
17alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
and	O
aromatic	O
A	O
-	O
ring	O
derivatives	O
of	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
and	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
.	O

The	O
binding	O
affinities	O
of	O
the	O
monodemethylated	O
metabolites	O
for	O
rabbit	B-GENE-Y
uterine	I-GENE-Y
PR	I-GENE-Y
and	O
human	B-GENE-Y
PR	I-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
PR	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
were	O
similar	O
to	O
those	O
of	O
the	O
parent	O
compounds	O
.	O

Monodemethylated	O
mifepristone	B-CHEMICAL
bound	O
to	O
rabbit	B-GENE-Y
thymic	I-GENE-Y
GR	I-GENE-Y
with	O
higher	O
affinity	O
than	O
monodemethylated	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
or	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
.	O

T47D	O
-	O
CO	O
cells	O
were	O
used	O
to	O
assess	O
inhibition	O
of	O
R5020	O
-	O
stimulated	O
endogenous	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
activity	O
and	O
transactivation	O
of	O
the	O
PRE	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	O
thymidine	B-GENE-N
kinase	I-GENE-N
(	O
tk	B-GENE-N
)	O
-	O
luciferase	O
(	O
LUC	O
)	O
reporter	O
plasmid	O
in	O
transient	O
transfections	O
.	O

The	O
antiprogestational	O
potency	O
was	O
as	O
follows	O
:	O
mifepristone	B-CHEMICAL
/	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
/	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
/	O
monodemethylated	O
metabolites	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
9	O
)	O
M	O
)	O
>	O
aromatic	O
A	O
-	O
ring	O
derivatives	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
>	O
didemethylated	O
/	O
17alpha	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
derivatives	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
.	O

Antiglucocorticoid	O
activity	O
was	O
determined	O
by	O
inhibition	O
of	O
dexamethasone	B-CHEMICAL
-	O
stimulated	O
transcriptional	O
activity	O
in	O
HepG2	O
cells	O
.	O

The	O
mono	O
-	O
and	O
didemethylated	O
metabolites	O
of	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
and	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
had	O
less	O
antiglucocorticoid	O
activity	O
(	O
IC	O
(	O
50	O
)	O
'	O
s	O
approximately	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
than	O
monodemethylated	O
mifepristone	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
approximately	O
10	O
(	O
-	O
8	O
)	O
M	O
)	O
or	O
the	O
other	O
test	O
compounds	O
.	O

At	O
10	O
(	O
-	O
6	O
)	O
M	O
in	O
transcription	O
assays	O
,	O
none	O
of	O
these	O
compounds	O
showed	O
progestin	B-CHEMICAL
agonist	O
activity	O
,	O
whereas	O
mifepristone	B-CHEMICAL
and	O
its	O
monodemethylated	O
metabolite	O
manifested	O
slight	O
glucocorticoid	B-GENE-Y
agonist	O
activity	O
.	O

The	O
reduced	O
antiglucocorticoid	O
activity	O
of	O
monodemethylated	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
and	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
was	O
confirmed	O
in	O
vivo	O
by	O
the	O
thymus	O
involution	O
assay	O
in	O
adrenalectomized	O
male	O
rats	O
.	O

The	O
aromatic	O
A	O
-	O
ring	O
derivatives	O
-	O
stimulated	O
transcription	O
of	O
an	O
estrogen	B-CHEMICAL
-	O
responsive	O
reporter	O
plasmid	O
in	O
MCF	O
-	O
7	O
and	O
T47D	O
-	O
CO	O
human	O
breast	O
cancer	O
cells	O
but	O
were	O
much	O
less	O
potent	O
than	O
estradiol	B-CHEMICAL
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
proximal	O
metabolites	O
of	O
mifepristone	B-CHEMICAL
,	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
,	O
and	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
contribute	O
significantly	O
to	O
the	O
antiprogestational	O
activity	O
of	O
the	O
parent	O
compounds	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
reduced	O
antiglucocorticoid	O
activity	O
of	O
CDB	B-CHEMICAL
-	I-CHEMICAL
2914	I-CHEMICAL
and	O
CDB	B-CHEMICAL
-	I-CHEMICAL
4124	I-CHEMICAL
compared	O
to	O
mifepristone	B-CHEMICAL
in	O
vivo	O
may	O
be	O
due	O
in	O
part	O
to	O
decreased	O
activity	O
of	O
their	O
putative	O
proximal	O
metabolites	O
.	O

A	O
PET	O
study	O
of	O
dopamine	B-GENE-N
D2	I-GENE-N
and	I-GENE-N
serotonin	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
occupancy	O
in	O
patients	O
with	O
schizophrenia	O
treated	O
with	O
therapeutic	O
doses	O
of	O
ziprasidone	B-CHEMICAL
.	O

OBJECTIVE	O
:	O
Ziprasidone	B-CHEMICAL
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
shows	O
a	O
higher	O
affinity	O
for	O
serotonin	B-CHEMICAL
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
compared	O
with	O
dopamine	B-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
in	O
vitro	O
.	O

The	O
affinity	O
of	O
ziprasidone	B-CHEMICAL
for	O
these	O
receptors	O
in	O
vivo	O
in	O
patients	O
was	O
examined	O
in	O
a	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
.	O

METHOD	O
:	O
The	O
authors	O
conducted	O
a	O
PET	O
study	O
to	O
evaluate	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
occupancy	O
(	O
using	O
[	B-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
raclopride	I-CHEMICAL
)	O
and	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
occupancy	O
(	O
using	O
[	B-CHEMICAL
(	I-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
]	I-CHEMICAL
setoperone	I-CHEMICAL
)	O
in	O
brain	O
regions	O
of	O
interest	O
in	O
16	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
randomly	O
assigned	O
to	O
receive	O
40	O
,	O
80	O
,	O
120	O
,	O
or	O
160	O
mg	O
/	O
day	O
of	O
ziprasidone	B-CHEMICAL
,	O
which	O
reflected	O
the	O
recommended	O
dose	O
range	O
.	O

PET	O
scanning	O
was	O
done	O
after	O
3	O
weeks	O
of	O
administration	O
and	O
at	O
trough	O
plasma	O
levels	O
,	O
i	O
.	O
e	O
.	O
,	O
12	O
-	O
16	O
hours	O
after	O
the	O
last	O
dose	O
.	O

RESULTS	O
:	O
The	O
mean	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	O
occupancy	O
was	O
significantly	O
higher	O
than	O
the	O
mean	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
(	O
mean	O
=	O
76	O
%	O
,	O
SD	O
=	O
15	O
%	O
,	O
and	O
mean	O
=	O
56	O
%	O
,	O
SD	O
=	O
18	O
%	O
,	O
respectively	O
)	O
.	O

The	O
estimated	O
plasma	O
ziprasidone	B-CHEMICAL
concentration	O
associated	O
with	O
50	O
%	O
maximal	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	O
occupancy	O
was	O
almost	O
four	O
times	O
lower	O
than	O
that	O
for	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
affirm	O
that	O
ziprasidone	B-CHEMICAL
is	O
similar	O
to	O
other	O
novel	O
antipsychotics	O
in	O
having	O
greater	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
than	O
D	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
occupancy	O
at	O
therapeutic	O
doses	O
and	O
suggest	O
that	O
the	O
optimal	O
effective	O
dose	O
of	O
ziprasidone	B-CHEMICAL
is	O
closer	O
to	O
120	O
mg	O
/	O
day	O
than	O
to	O
the	O
lower	O
doses	O
suggested	O
by	O
previous	O
PET	O
studies	O
.	O

The	O
relatively	O
high	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
,	O
even	O
at	O
trough	O
plasma	O
levels	O
,	O
suggests	O
that	O
ziprasidone	B-CHEMICAL
is	O
more	O
similar	O
to	O
risperidone	B-CHEMICAL
and	O
olanzapine	O
in	O
receptor	O
occupancy	O
profile	O
than	O
to	O
clozapine	B-CHEMICAL
and	O
quetiapine	B-CHEMICAL
.	O

Since	O
ziprasidone	B-CHEMICAL
plasma	O
levels	O
show	O
significant	O
(	O
more	O
than	O
twofold	O
)	O
variation	O
within	O
a	O
single	O
dose	O
cycle	O
,	O
studies	O
that	O
are	O
aimed	O
at	O
peak	O
plasma	O
levels	O
(	O
6	O
hours	O
after	O
the	O
last	O
dose	O
)	O
and	O
that	O
examine	O
extrastriatal	O
regions	O
are	O
required	O
to	O
fully	O
characterize	O
the	O
in	O
vivo	O
occupancy	O
profile	O
of	O
ziprasidone	B-CHEMICAL
.	O

Characterization	O
of	O
the	O
interaction	O
of	O
ingenol	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
angelate	I-CHEMICAL
with	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
.	O

Ingenol	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
angelate	I-CHEMICAL
(	O
I3A	B-CHEMICAL
)	O
is	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
Euphorbia	O
peplus	O
,	O
which	O
has	O
been	O
used	O
in	O
traditional	O
medicine	O
.	O

Here	O
,	O
we	O
report	O
the	O
initial	O
characterization	O
of	O
I3A	B-CHEMICAL
as	O
a	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	O
PKC	B-GENE-N
)	O
ligand	O
.	O

I3A	B-CHEMICAL
bound	O
to	O
PKC	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
in	O
the	O
presence	O
of	O
phosphatidylserine	B-CHEMICAL
with	O
high	O
affinity	O
;	O
however	O
,	O
under	O
these	O
assay	O
conditions	O
,	O
little	O
PKC	B-GENE-N
isoform	O
selectivity	O
was	O
observed	O
.	O

PKC	B-GENE-N
isoforms	O
did	O
show	O
different	O
sensitivity	O
and	O
selectivity	O
for	O
down	O
-	O
regulation	O
by	O
I3A	B-CHEMICAL
and	O
phorbol	B-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
myristate	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
(	O
PMA	B-CHEMICAL
)	O
in	O
WEHI	O
-	O
231	O
,	O
HOP	O
-	O
92	O
,	O
and	O
Colo	O
-	O
205	O
cells	O
.	O

In	O
all	O
of	O
the	O
three	O
cell	O
types	O
,	O
I3A	B-CHEMICAL
inhibited	O
cell	O
proliferation	O
with	O
somewhat	O
lower	O
potency	O
than	O
did	O
PMA	B-CHEMICAL
.	O

In	O
intact	O
CHO	O
-	O
K1	O
cells	O
,	O
I3A	B-CHEMICAL
was	O
able	O
to	O
translocate	O
different	O
green	B-GENE-Y
fluorescent	I-GENE-Y
protein	I-GENE-Y
-	O
tagged	O
PKC	B-GENE-N
isoforms	O
,	O
visualized	O
by	O
confocal	O
microscopy	O
,	O
with	O
equal	O
or	O
higher	O
potency	O
than	O
PMA	B-CHEMICAL
.	O

PKC	B-GENE-Y
-	I-GENE-Y
delta	I-GENE-Y
in	O
particular	O
showed	O
a	O
different	O
pattern	O
of	O
translocation	O
in	O
response	O
to	O
I3A	B-CHEMICAL
and	O
PMA	B-CHEMICAL
.	O

I3A	B-CHEMICAL
induced	O
a	O
higher	O
level	O
of	O
secretion	O
of	O
the	O
inflammatory	O
cytokine	B-GENE-N
interleukin	B-GENE-Y
6	I-GENE-Y
compared	O
with	O
PMA	B-CHEMICAL
in	O
the	O
WEHI	O
-	O
231	O
cells	O
and	O
displayed	O
a	O
marked	O
biphasic	O
dose	O
-	O
response	O
curve	O
for	O
the	O
induction	O
.	O

I3A	B-CHEMICAL
was	O
unable	O
to	O
cause	O
the	O
same	O
extent	O
of	O
association	O
of	O
the	O
C1b	B-GENE-N
domain	I-GENE-N
of	O
PKC	B-GENE-Y
-	I-GENE-Y
delta	I-GENE-Y
with	O
lipids	O
,	O
compared	O
with	O
PMA	B-CHEMICAL
or	O
the	O
physiological	O
regulator	O
diacylglycerol	B-CHEMICAL
,	O
and	O
was	O
able	O
to	O
partially	O
block	O
the	O
association	O
induced	O
by	O
these	O
agents	O
,	O
measured	O
by	O
surface	O
plasmon	O
resonance	O
.	O

The	O
in	O
vitro	O
kinase	O
activity	O
of	O
PKC	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
induced	O
by	O
I3A	B-CHEMICAL
was	O
lower	O
than	O
that	O
induced	O
by	O
PMA	B-CHEMICAL
.	O

The	O
novel	O
pattern	O
of	O
behavior	O
of	O
I3A	B-CHEMICAL
makes	O
it	O
of	O
great	O
interest	O
for	O
further	O
evaluation	O
.	O

Enzyme	O
expression	O
profiles	O
suggest	O
the	O
novel	O
tumor	O
-	O
activated	O
fluoropyrimidine	B-CHEMICAL
carbamate	I-CHEMICAL
capecitabine	B-CHEMICAL
(	O
Xeloda	B-CHEMICAL
)	O
might	O
be	O
effective	O
against	O
papillary	O
thyroid	O
cancers	O
of	O
children	O
and	O
young	O
adults	O
.	O

PURPOSE	O
:	O
The	O
fluoropyrimidine	B-CHEMICAL
carbamate	I-CHEMICAL
(	O
capecitabine	B-CHEMICAL
)	O
is	O
converted	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
)	O
by	O
thymidine	B-GENE-Y
phosphorylase	I-GENE-Y
(	O
TP	B-GENE-Y
)	O
inside	O
target	O
tissues	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
interferes	O
with	O
DNA	O
synthesis	O
by	O
blocking	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
(	O
TS	B-GENE-Y
)	O
but	O
is	O
inactivated	O
by	O
dihydropyrimidine	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
DPD	B-GENE-Y
)	O
.	O

Favorable	O
enzyme	O
profiles	O
(	O
high	O
TP	B-GENE-Y
and	O
low	O
DPD	B-GENE-Y
)	O
generate	O
high	O
intratumor	O
levels	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
that	O
are	O
effective	O
against	O
many	O
tumors	O
,	O
especially	O
those	O
with	O
low	O
TS	B-GENE-Y
.	O

Capecitabine	B-CHEMICAL
has	O
not	O
been	O
tested	O
against	O
thyroid	O
cancers	O
,	O
and	O
it	O
is	O
not	O
known	O
to	O
what	O
extent	O
thyroid	O
cancers	O
express	O
TP	B-GENE-Y
,	O
TS	B-GENE-Y
or	O
DPD	B-GENE-Y
.	O

METHODS	O
:	O
To	O
test	O
this	O
,	O
we	O
determined	O
TP	B-GENE-Y
,	O
TS	B-GENE-Y
and	O
DPD	B-GENE-Y
in	O
19	O
thyroid	O
cancers	O
from	O
young	O
patients	O
(	O
14	O
papillary	O
,	O
4	O
follicular	O
,	O
1	O
medullary	O
)	O
by	O
immunohistochemistry	O
.	O

After	O
approval	O
by	O
the	O
Human	O
Use	O
Committee	O
,	O
the	O
intensity	O
of	O
TP	B-GENE-Y
,	O
TS	B-GENE-Y
,	O
and	O
DPD	B-GENE-Y
staining	O
was	O
determined	O
by	O
two	O
independent	O
examiners	O
and	O
graded	O
(	O
absent	O
=	O
0	O
to	O
intense	O
=	O
3	O
)	O
with	O
>	O
90	O
%	O
concordance	O
.	O

RESULTS	O
:	O
TS	B-GENE-Y
was	O
detected	O
in	O
7	O
/	O
19	O
cancers	O
(	O
37	O
%	O
)	O
,	O
TP	B-GENE-Y
in	O
14	O
/	O
19	O
cancers	O
(	O
74	O
%	O
)	O
and	O
DPD	B-GENE-Y
in	O
14	O
/	O
19	O
cancers	O
(	O
74	O
%	O
)	O
.	O

In	O
six	O
tumors	O
,	O
TP	B-GENE-Y
was	O
more	O
intense	O
that	O
DPD	B-GENE-Y
,	O
suggesting	O
capecitabine	O
sensitivity	O
.	O

Only	O
five	O
tumors	O
failed	O
to	O
express	O
TP	B-GENE-Y
but	O
four	O
of	O
these	O
expressed	O
DPD	B-GENE-Y
,	O
suggesting	O
capecitabine	B-CHEMICAL
resistance	O
.	O

Overall	O
,	O
6	O
/	O
19	O
tumors	O
(	O
32	O
%	O
of	O
the	O
total	O
)	O
had	O
a	O
favorable	O
expression	O
profile	O
,	O
and	O
all	O
of	O
them	O
were	O
papillary	O
cancers	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
the	O
majority	O
of	O
differentiated	O
thyroid	O
cancers	O
(	O
74	O
%	O
)	O
express	O
TP	B-GENE-Y
and	O
low	O
levels	O
of	O
TS	B-GENE-Y
(	O
63	O
%	O
undetectable	O
)	O
.	O

The	O
results	O
support	O
the	O
hypothesis	O
that	O
capecitabine	B-CHEMICAL
is	O
activated	O
in	O
the	O
majority	O
of	O
differentiated	O
thyroid	O
cancers	O
and	O
that	O
32	O
%	O
have	O
favorable	O
expression	O
of	O
all	O
three	O
enzymes	O
(	O
TP	B-GENE-Y
,	O
TS	B-GENE-Y
,	O
and	O
DPD	B-GENE-Y
)	O
.	O

Polyamine	B-CHEMICAL
metabolism	O
in	O
a	O
member	O
of	O
the	O
phylum	O
Microspora	O
(	O
Encephalitozoon	O
cuniculi	O
)	O
:	O
effects	O
of	O
polyamine	B-CHEMICAL
analogues	O
.	O

The	O
uptake	O
,	O
biosynthesis	O
and	O
catabolism	O
of	O
polyamines	B-CHEMICAL
in	O
the	O
microsporidian	O
parasite	O
Encephalitozoon	O
cuniculi	O
are	O
detailed	O
with	O
reference	O
to	O
the	O
effects	O
of	O
oligoamine	B-CHEMICAL
and	O
arylamine	B-CHEMICAL
analogues	O
of	O
polyamines	B-CHEMICAL
.	O

Enc	O
.	O
cuniculi	O
,	O
an	O
intracellular	O
parasite	O
of	O
mammalian	O
cells	O
,	O
has	O
both	O
biosynthetic	O
and	O
catabolic	O
enzymes	O
of	O
polyamine	B-CHEMICAL
metabolism	O
,	O
as	O
demonstrated	O
in	O
cell	O
-	O
free	O
extracts	O
of	O
mature	O
spores	O
.	O

The	O
uptake	O
of	O
polyamines	B-CHEMICAL
was	O
measured	O
in	O
immature	O
,	O
pre	O
-	O
emergent	O
spores	O
isolated	O
from	O
host	O
cells	O
by	O
Percoll	O
gradient	O
.	O

Spermine	O
was	O
rapidly	O
taken	O
up	O
and	O
metabolized	O
to	O
spermidine	O
and	O
an	O
unknown	O
,	O
possibly	O
acetamidopropanal	O
,	O
by	O
spermidine	B-GENE-N
/	I-GENE-N
spermine	I-GENE-N
N	I-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
acetyltransferase	I-GENE-N
(	O
SSAT	B-GENE-N
)	O
and	O
polyamine	B-GENE-N
oxidase	I-GENE-N
(	O
PAO	B-GENE-N
)	O
.	O

Most	O
of	O
the	O
spermidine	B-CHEMICAL
and	O
the	O
unknown	O
product	O
were	O
found	O
in	O
the	O
cell	O
incubation	O
medium	O
,	O
indicating	O
they	O
were	O
released	O
from	O
the	O
cell	O
.	O

bis	B-CHEMICAL
(	I-CHEMICAL
Ethyl	I-CHEMICAL
)	I-CHEMICAL
oligoamine	I-CHEMICAL
analogues	O
of	O
polyamines	B-CHEMICAL
,	O
such	O
as	O
SL	B-CHEMICAL
-	I-CHEMICAL
11144	I-CHEMICAL
and	O
SL	B-CHEMICAL
-	I-CHEMICAL
11158	I-CHEMICAL
,	O
as	O
well	O
as	O
arylamine	B-CHEMICAL
analogues	O
[	O
BW	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	O
a	O
bis	B-CHEMICAL
(	I-CHEMICAL
phenylbenzyl	I-CHEMICAL
)	I-CHEMICAL
3	O
-	O
7	O
-	O
3	O
analogue	O
]	O
blocked	O
uptake	O
and	O
interconversion	O
of	O
spermine	B-CHEMICAL
at	O
micromolar	O
levels	O
and	O
,	O
in	O
the	O
case	O
of	O
BW	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	O
acted	O
as	O
substrate	O
for	O
PAO	B-GENE-N
.	O

The	O
Enc	B-GENE-N
.	I-GENE-N
cuniculi	I-GENE-N
PAO	I-GENE-N
activity	O
differed	O
from	O
that	O
found	O
in	O
mammalian	O
cells	O
with	O
respect	O
to	O
pH	O
optimum	O
,	O
substrate	O
specificity	O
and	O
sensitivity	O
to	O
known	O
PAO	B-GENE-N
inhibitors	O
.	O

SL	B-CHEMICAL
-	I-CHEMICAL
11158	I-CHEMICAL
inhibited	O
SSAT	B-GENE-N
activity	O
with	O
a	O
mixed	O
type	O
of	O
inhibition	O
in	O
which	O
the	O
analogue	O
had	O
a	O
70	O
-	O
fold	O
higher	O
affinity	O
for	O
the	O
enzyme	O
than	O
the	O
natural	O
substrate	O
,	O
spermine	B-CHEMICAL
.	O

The	O
interest	O
in	O
Enc	O
.	O
cuniculi	O
polyamine	O
metabolism	O
and	O
the	O
biochemical	O
effects	O
of	O
these	O
polyamine	B-CHEMICAL
analogues	O
is	O
warranted	O
since	O
they	O
cure	O
model	O
infections	O
of	O
Enc	O
.	O
cuniculi	O
in	O
mice	O
and	O
are	O
potential	O
candidates	O
for	O
human	O
clinical	O
trials	O
.	O

Redesign	O
of	O
carnitine	B-GENE-Y
acetyltransferase	I-GENE-Y
specificity	O
by	O
protein	O
engineering	O
.	O

In	O
eukaryotes	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
carnitine	I-CHEMICAL
is	O
involved	O
in	O
energy	O
metabolism	O
by	O
facilitating	O
beta	O
-	O
oxidation	O
of	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
.	O

Carnitine	B-GENE-Y
acetyltransferases	I-GENE-Y
(	O
CrAT	B-GENE-Y
)	O
catalyze	O
the	O
reversible	O
conversion	O
of	O
acetyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
and	O
carnitine	B-CHEMICAL
to	O
acetylcarnitine	B-CHEMICAL
and	O
free	O
CoA	O
.	O

To	O
redesign	O
the	O
specificity	O
of	O
rat	B-GENE-Y
CrAT	I-GENE-Y
toward	O
its	O
substrates	O
,	O
we	O
mutated	O
Met564	O
.	O

The	O
M564G	B-GENE-N
mutated	O
CrAT	B-GENE-Y
showed	O
higher	O
activity	O
toward	O
longer	O
chain	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
:	O
activity	O
toward	O
myristoyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
was	O
1250	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
CrAT	B-GENE-Y
,	O
and	O
lower	O
activity	O
toward	O
its	O
natural	O
substrate	O
,	O
acetyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
.	O

Kinetic	O
constants	O
of	O
the	O
mutant	O
CrAT	B-GENE-Y
showed	O
modification	O
in	O
favor	O
of	O
longer	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
as	O
substrates	O
.	O

In	O
the	O
reverse	O
case	O
,	O
mutation	O
of	O
the	O
orthologous	O
glycine	B-GENE-N
(	I-GENE-N
Gly553	I-GENE-N
)	I-GENE-N
to	I-GENE-N
methionine	I-GENE-N
in	O
carnitine	B-GENE-Y
octanoyltransferase	I-GENE-Y
(	O
COT	B-GENE-Y
)	O
decreased	O
activity	O
toward	O
its	O
natural	O
substrates	O
,	O
medium	O
-	O
and	O
long	O
-	O
chain	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
,	O
and	O
increased	O
activity	O
toward	O
short	O
-	O
chain	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
.	O

Another	O
CrAT	B-GENE-Y
mutant	O
,	O
M564A	B-GENE-N
,	O
was	O
prepared	O
and	O
tested	O
in	O
the	O
same	O
way	O
,	O
with	O
similar	O
results	O
.	O

We	O
conclude	O
that	O
Met564	O
blocks	O
the	O
entry	O
of	O
medium	O
-	O
and	O
long	O
-	O
chain	O
acyl	B-CHEMICAL
-	I-CHEMICAL
CoAs	I-CHEMICAL
to	O
the	O
catalytic	O
site	O
of	O
CrAT	B-GENE-Y
.	O

Three	O
-	O
dimensional	O
models	O
of	O
wild	O
-	O
type	O
and	O
mutated	O
CrAT	B-GENE-Y
and	O
COT	B-GENE-Y
support	O
this	O
hypothesis	O
.	O

We	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
amino	B-CHEMICAL
acid	I-CHEMICAL
is	O
able	O
to	O
determine	O
the	O
substrate	O
specificity	O
of	O
CrAT	B-GENE-Y
and	O
COT	B-GENE-Y
.	O

No	O
influence	O
of	O
moderate	O
hepatic	O
impairment	O
on	O
the	O
pharmacokinetics	O
of	O
lumiracoxib	B-CHEMICAL
,	O
an	O
oral	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selective	O
inhibitor	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
influence	O
of	O
hepatic	O
impairment	O
on	O
the	O
pharmacokinetics	O
(	O
PK	O
)	O
of	O
the	O
novel	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
selective	O
inhibitor	O
lumiracoxib	B-CHEMICAL
(	O
Prexige	B-CHEMICAL
)	O
,	O
so	O
that	O
dose	O
recommendations	O
for	O
clinical	O
use	O
can	O
be	O
provided	O
.	O

This	O
was	O
an	O
open	O
-	O
label	O
,	O
single	O
dose	O
,	O
case	O
-	O
controlled	O
study	O
in	O
which	O
eight	O
subjects	O
with	O
liver	O
cirrhosis	O
classed	O
as	O
moderate	O
hepatic	O
impairment	O
(	O
Child	O
-	O
Pugh	O
score	O
:	O
7	O
-	O
9	O
)	O
and	O
eight	O
demographically	O
-	O
matched	O
healthy	O
subjects	O
received	O
a	O
single	O
oral	O
400	O
mg	O
dose	O
of	O
lumiracoxib	B-CHEMICAL
.	O

Routine	O
safety	O
assessments	O
were	O
made	O
and	O
blood	O
samples	O
were	O
taken	O
for	O
determination	O
of	O
lumiracoxib	B-CHEMICAL
concentrations	O
for	O
96	O
h	O
post	O
dose	O
.	O

The	O
ex	O
vivo	O
binding	O
of	O
lumiracoxib	B-CHEMICAL
to	O
plasma	O
proteins	O
was	O
determined	O
pre	O
dose	O
and	O
at	O
2	O
and	O
12	O
h	O
post	O
dose	O
.	O

An	O
analysis	O
of	O
variance	O
was	O
used	O
to	O
detect	O
differences	O
in	O
PK	O
parameters	O
(	O
AUC	O
,	O
Cmax	O
and	O
Tmax	O
)	O
between	O
the	O
treatment	O
groups	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
subjects	O
with	O
moderate	O
hepatic	O
insufficiency	O
and	O
healthy	O
subjects	O
in	O
the	O
area	O
under	O
the	O
lumiracoxib	B-CHEMICAL
plasma	O
concentration	O
-	O
time	O
curves	O
(	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
)	O
:	O
29	O
.	O
2	O
+	O
/	O
-	O
6	O
.	O
7	O
microg	O
h	O
ml	O
(	O
-	O
1	O
)	O
versus	O
28	O
.	O
7	O
+	O
/	O
-	O
6	O
.	O
3	O
mircrog	O
h	O
ml	O
(	O
-	O
1	O
)	O
.	O

The	O
rate	O
of	O
absorption	O
of	O
lumiracoxib	B-CHEMICAL
was	O
not	O
significantly	O
altered	O
by	O
hepatic	O
impairment	O
based	O
on	O
Cmax	O
and	O
Tmax	O
.	O

The	O
protein	O
-	O
bound	O
fraction	O
of	O
lumiracoxib	B-CHEMICAL
exceeded	O
98	O
%	O
both	O
in	O
healthy	O
control	O
subjects	O
and	O
in	O
those	O
with	O
moderate	O
hepatic	O
insufficiency	O
.	O

A	O
single	O
dose	O
of	O
400	O
mg	O
lumiracoxib	B-CHEMICAL
was	O
well	O
tolerated	O
.	O

In	O
conclusion	O
,	O
no	O
dose	O
adjustments	O
appear	O
to	O
be	O
required	O
when	O
lumiracoxib	B-CHEMICAL
is	O
administered	O
to	O
patients	O
with	O
either	O
mild	O
or	O
moderate	O
hepatic	O
impairment	O
.	O

P2Y12	B-GENE-Y
,	O
a	O
new	O
platelet	O
ADP	B-GENE-N
receptor	I-GENE-N
,	O
target	O
of	O
clopidogrel	B-CHEMICAL
.	O

Clopidogrel	B-CHEMICAL
is	O
a	O
potent	O
antithrombotic	O
drug	O
that	O
inhibits	O
ADP	B-CHEMICAL
-	O
induced	O
platelet	O
aggregation	O
.	O

The	O
results	O
of	O
large	O
clinical	O
trials	O
have	O
demonstrated	O
an	O
overall	O
benefit	O
of	O
clopidogrel	B-CHEMICAL
over	O
aspirin	B-CHEMICAL
in	O
the	O
prevention	O
of	O
vascular	O
ischemic	O
events	O
(	O
myocardial	O
infarction	O
,	O
stroke	O
,	O
vascular	O
death	O
)	O
in	O
patients	O
with	O
a	O
history	O
of	O
symptomatic	O
atherosclerotic	O
disease	O
.	O

The	O
antiaggregating	O
effect	O
of	O
clopidogrel	B-CHEMICAL
is	O
attributed	O
to	O
an	O
irreversible	O
inhibition	O
of	O
ADP	B-CHEMICAL
binding	O
to	O
a	O
purinergic	B-GENE-N
receptor	I-GENE-N
present	O
at	O
the	O
platelet	O
surface	O
.	O

Clopidogrel	B-CHEMICAL
is	O
not	O
active	O
in	O
vitro	O
and	O
can	O
be	O
considered	O
a	O
precursor	O
of	O
an	O
active	O
metabolite	O
formed	O
in	O
the	O
liver	O
.	O

The	O
chemical	O
structure	O
of	O
this	O
active	O
metabolite	O
and	O
its	O
biological	O
activity	O
have	O
been	O
described	O
recently	O
.	O

Several	O
purinergic	B-GENE-N
receptors	I-GENE-N
have	O
been	O
described	O
on	O
platelets	O
;	O
P2X	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
,	O
a	O
calcium	B-GENE-N
channel	I-GENE-N
,	O
and	O
P2Y1	B-GENE-Y
a	O
Gq	B-GENE-N
-	I-GENE-N
coupled	I-GENE-N
seven	I-GENE-N
-	I-GENE-N
transmembrane	I-GENE-N
domain	I-GENE-N
receptor	I-GENE-N
,	O
have	O
been	O
found	O
not	O
to	O
be	O
antagonized	O
by	O
clopidogrel	B-CHEMICAL
.	O

Another	O
Gi	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
(	O
named	O
P2Y12	B-GENE-Y
)	O
has	O
been	O
recently	O
cloned	O
and	O
stably	O
expressed	O
in	O
CHO	O
cells	O
.	O

These	O
cells	O
displayed	O
a	O
strong	O
affinity	O
for	O
(	B-CHEMICAL
33	I-CHEMICAL
)	I-CHEMICAL
P	I-CHEMICAL
-	I-CHEMICAL
2MeS	I-CHEMICAL
-	I-CHEMICAL
ADP	I-CHEMICAL
,	O
a	O
stable	O
analogue	O
of	O
ADP	B-CHEMICAL
,	O
the	O
binding	O
characteristics	O
of	O
which	O
corresponded	O
in	O
all	O
points	O
to	O
those	O
observed	O
on	O
platelets	O
.	O

The	O
binding	O
of	O
(	B-CHEMICAL
33	I-CHEMICAL
)	I-CHEMICAL
P	I-CHEMICAL
-	I-CHEMICAL
2MeS	I-CHEMICAL
-	I-CHEMICAL
ADP	I-CHEMICAL
to	O
these	O
cells	O
was	O
strongly	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
clopidogrel	B-CHEMICAL
with	O
a	O
potency	O
that	O
was	O
consistent	O
with	O
that	O
observed	O
for	O
this	O
compound	O
on	O
platelets	O
.	O

In	O
these	O
transfected	O
CHO	O
cells	O
,	O
as	O
in	O
platelets	O
,	O
ADP	B-CHEMICAL
and	O
2MeS	B-CHEMICAL
-	I-CHEMICAL
ADP	I-CHEMICAL
induced	O
adenylyl	B-CHEMICAL
cyclase	O
downregulation	O
,	O
an	O
effect	O
that	O
was	O
inhibited	O
by	O
the	O
active	O
metabolite	O
of	O
clopidogrel	B-CHEMICAL
.	O

These	O
results	O
demonstrate	O
that	O
this	O
receptor	O
corresponds	O
to	O
the	O
previously	O
called	O
"	O
P2t	B-GENE-Y
"	O
platelet	B-GENE-N
receptor	I-GENE-N
and	O
show	O
that	O
the	O
active	O
metabolite	O
of	O
clopidogrel	B-CHEMICAL
binds	O
in	O
a	O
covalent	O
manner	O
to	O
this	O
receptor	O
,	O
thus	O
explaining	O
how	O
it	O
blocks	O
the	O
aggregating	O
effect	O
of	O
ADP	B-CHEMICAL
on	O
platelets	O
.	O

5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
,	O
alpha2A	O
/	O
2C	O
-	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
alpha1	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
mediate	O
the	O
external	O
carotid	O
vasoconstriction	O
to	O
ergotamine	B-CHEMICAL
in	O
vagosympathectomised	O
dogs	O
.	O

It	O
has	O
previously	O
been	O
suggested	O
that	O
ergotamine	B-CHEMICAL
produces	O
external	O
carotid	O
vasoconstriction	O
in	O
vagosympathectomised	O
dogs	O
via	O
5	B-GENE-N
-	I-GENE-N
HT1B	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
receptors	O
and	O
alpha2	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

The	O
present	O
study	O
has	O
reanalysed	O
this	O
suggestion	O
by	O
using	O
more	O
selective	O
antagonists	O
alone	O
and	O
in	O
combination	O
.	O

Fifty	O
-	O
two	O
anaesthetised	O
dogs	O
were	O
prepared	O
for	O
ultrasonic	O
measurements	O
of	O
external	O
carotid	O
blood	O
flow	O
.	O

The	O
animals	O
were	O
divided	O
into	O
thirteen	O
groups	O
(	O
n	O
=	O
4	O
each	O
)	O
receiving	O
an	O
i	O
.	O
v	O
.	O
bolus	O
injection	O
of	O
,	O
either	O
physiological	O
saline	O
(	O
0	O
.	O
3	O
ml	O
/	O
kg	O
;	O
control	O
)	O
,	O
or	O
the	O
antagonists	O
SB224289	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
;	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
)	O
,	O
BRL15572	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
;	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
)	O
,	O
rauwolscine	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
;	O
alpha2	O
)	O
,	O
SB224289	B-CHEMICAL
+	O
BRL15572	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
each	O
)	O
,	O
SB224289	B-CHEMICAL
+	O
rauwolscine	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
each	O
)	O
,	O
BRL15572	B-CHEMICAL
+	O
rauwolscine	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
each	O
)	O
,	O
rauwolscine	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	B-CHEMICAL
(	O
100	O
microg	O
/	O
kg	O
;	O
alpha1	O
)	O
,	O
SB224289	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	B-CHEMICAL
(	O
100	O
microg	O
/	O
kg	O
)	O
,	O
SB224289	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
rauwolscine	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	B-CHEMICAL
(	O
100	O
microg	O
/	O
kg	O
)	O
,	O
SB224289	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	B-CHEMICAL
(	O
100	O
microg	O
/	O
kg	O
)	O
+	O
BRL44408	B-CHEMICAL
(	O
1	O
,	O
000	O
microg	O
/	O
kg	O
;	O
alpha2A	O
)	O
,	O
SB224289	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	B-CHEMICAL
(	O
100	O
microg	O
/	O
kg	O
)	O
+	O
imiloxan	B-CHEMICAL
(	O
1	O
,	O
000	O
microg	O
/	O
kg	O
;	O
alpha2B	O
)	O
,	O
or	O
SB224289	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
)	O
+	O
prazosin	B-CHEMICAL
(	O
100	O
microg	O
/	O
kg	O
)	O
+	O
MK912	B-CHEMICAL
(	O
300	O
microg	O
/	O
kg	O
;	O
alpha2C	O
)	O
.	O

Each	O
group	O
received	O
consecutive	O
1	O
-	O
min	O
intracarotid	O
infusions	O
of	O
ergotamine	B-CHEMICAL
(	O
0	O
.	O
56	O
,	O
1	O
,	O
1	O
.	O
8	O
,	O
3	O
.	O
1	O
,	O
5	O
.	O
6	O
,	O
10	O
and	O
18	O
microg	O
/	O
min	O
)	O
,	O
following	O
a	O
cumulative	O
schedule	O
.	O

In	O
saline	O
-	O
pretreated	O
animals	O
,	O
ergotamine	B-CHEMICAL
induced	O
dose	O
-	O
dependent	O
decreases	O
in	O
external	O
carotid	O
blood	O
flow	O
without	O
affecting	O
arterial	O
blood	O
pressure	O
or	O
heart	O
rate	O
.	O

These	O
control	O
responses	O
were	O
:	O
unaffected	O
by	O
SB224289	B-CHEMICAL
,	O
BRL15572	B-CHEMICAL
,	O
rauwolscine	B-CHEMICAL
or	O
the	O
combinations	O
of	O
SB224289	B-CHEMICAL
+	O
BRL15572	B-CHEMICAL
,	O
BRL15572	B-CHEMICAL
+	O
rauwolscine	B-CHEMICAL
,	O
rauwolscine	B-CHEMICAL
+	O
prazosin	B-CHEMICAL
,	O
SB224289	B-CHEMICAL
+	O
prazosin	B-CHEMICAL
,	O
or	O
SB224289	B-CHEMICAL
+	O
prazosin	B-CHEMICAL
+	O
imiloxan	B-CHEMICAL
;	O
slightly	O
blocked	O
by	O
SB224289	B-CHEMICAL
+	O
rauwolscine	B-CHEMICAL
;	O
and	O
markedly	O
blocked	O
by	O
SB224289	B-CHEMICAL
+	O
rauwolscine	B-CHEMICAL
+	O
prazosin	B-CHEMICAL
,	O
SB224289	B-CHEMICAL
+	O
prazosin	B-CHEMICAL
+	O
BRL44408	B-CHEMICAL
or	O
SB224289	B-CHEMICAL
+	O
prazosin	B-CHEMICAL
+	O
MK912	B-CHEMICAL
.	O

Thus	O
,	O
the	O
cranio	O
-	O
selective	O
vasoconstriction	O
elicited	O
by	O
ergotamine	B-CHEMICAL
in	O
dogs	O
is	O
predominantly	O
mediated	O
by	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptors	O
as	O
well	O
as	O
alpha2A	B-GENE-N
/	I-GENE-N
2C	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtypes	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
by	O
alpha1	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

Significant	O
receptor	O
affinities	O
of	O
metabolites	O
and	O
a	O
degradation	O
product	O
of	O
mometasone	B-CHEMICAL
furoate	I-CHEMICAL
.	O

Mometasone	B-CHEMICAL
furoate	I-CHEMICAL
(	O
MF	B-CHEMICAL
)	O
is	O
a	O
highly	O
potent	O
glucocorticoid	O
used	O
topically	O
to	O
treat	O
inflammation	O
in	O
the	O
lung	O
,	O
nose	O
and	O
on	O
the	O
skin	O
.	O

However	O
,	O
so	O
far	O
no	O
information	O
has	O
been	O
published	O
on	O
the	O
human	B-GENE-Y
glucocorticoid	I-GENE-Y
receptor	I-GENE-Y
activity	O
of	O
the	O
metabolites	O
or	O
degradation	O
products	O
of	O
MF	B-CHEMICAL
.	O

We	O
have	O
now	O
determined	O
the	O
relative	O
receptor	O
binding	O
affinities	O
of	O
the	O
known	O
metabolite	O
6beta	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
MF	I-CHEMICAL
and	O
the	O
degradation	O
product	O
9	B-CHEMICAL
,	I-CHEMICAL
11	I-CHEMICAL
-	I-CHEMICAL
epoxy	I-CHEMICAL
MF	I-CHEMICAL
to	O
understand	O
their	O
possible	O
contribution	O
to	O
undesirable	O
systemic	O
side	O
effects	O
.	O

In	O
competition	O
experiments	O
with	O
human	B-GENE-Y
lung	I-GENE-Y
glucocorticoid	I-GENE-Y
receptors	I-GENE-Y
we	O
have	O
determined	O
the	O
relative	O
receptor	O
affinities	O
(	O
RRA	O
)	O
of	O
these	O
substances	O
with	O
reference	O
to	O
dexamethasone	B-CHEMICAL
(	O
RRA	O
=	O
100	O
)	O
.	O

We	O
have	O
discovered	O
that	O
6beta	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
MF	I-CHEMICAL
and	O
9	B-CHEMICAL
,	I-CHEMICAL
11	I-CHEMICAL
-	I-CHEMICAL
epoxy	I-CHEMICAL
MF	I-CHEMICAL
display	O
RRAs	O
of	O
206	O
+	O
/	O
-	O
15	O
and	O
220	O
+	O
/	O
-	O
22	O
,	O
respectively	O
.	O

This	O
level	O
of	O
activity	O
is	O
similar	O
to	O
that	O
of	O
the	O
clinically	O
used	O
inhaled	O
corticosteroid	B-CHEMICAL
flunisolide	B-CHEMICAL
(	O
RRA	O
180	O
+	O
/	O
-	O
11	O
)	O
.	O

Furthermore	O
we	O
observed	O
that	O
9	B-CHEMICAL
,	I-CHEMICAL
11	I-CHEMICAL
-	I-CHEMICAL
epoxy	I-CHEMICAL
MF	I-CHEMICAL
is	O
a	O
chemically	O
reactive	O
metabolite	O
.	O

In	O
recovery	O
experiments	O
with	O
human	O
plasma	O
and	O
lung	O
tissue	O
we	O
found	O
a	O
time	O
dependent	O
decrease	O
in	O
extractability	O
of	O
the	O
compound	O
.	O

Hence	O
,	O
we	O
provide	O
data	O
that	O
might	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
pharmacokinetics	O
as	O
well	O
as	O
the	O
clinical	O
effects	O
of	O
MF	B-CHEMICAL
.	O

Probing	O
for	O
a	O
hydrophobic	O
a	O
binding	O
register	O
in	O
prostate	B-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
membrane	I-GENE-Y
antigen	I-GENE-Y
with	O
phenylalkylphosphonamidates	B-CHEMICAL
.	O

To	O
explore	O
for	O
the	O
existence	O
of	O
an	O
auxiliary	O
hydrophobic	O
binding	O
register	O
remote	O
from	O
the	O
active	O
site	O
of	O
PSMA	B-GENE-Y
a	O
series	O
of	O
phenylalkylphosphonamidate	B-CHEMICAL
derivatives	O
of	O
glutamic	B-CHEMICAL
acid	I-CHEMICAL
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
potencies	O
against	O
PSMA	B-GENE-Y
.	O

Both	O
the	O
phenyl	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
benzylphosphonamidates	I-CHEMICAL
(	O
1a	O
and	O
1b	O
)	O
exhibited	O
only	O
modest	O
inhibitory	O
potency	O
against	O
.	O

The	O
phenethyl	B-CHEMICAL
analog	O
1c	O
was	O
intermediate	O
in	O
inhibitory	O
potency	O
while	O
inhibitors	O
possessing	O
a	O
longer	O
alkyl	B-CHEMICAL
tether	O
from	O
the	O
phenyl	O
ring	O
,	O
resulted	O
in	O
markedly	O
improved	O
K	O
(	O
i	O
)	O
values	O
.	O

The	O
greatest	O
inhibitory	O
potency	O
was	O
obtained	O
for	O
the	O
inhibitors	O
in	O
which	O
the	O
phenyl	O
ring	O
was	O
extended	O
furthest	O
from	O
the	O
central	O
phosphorus	B-CHEMICAL
(	O
1f	O
,	O
n	O
=	O
5	O
and	O
1g	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
slightly	O
serrated	O
pattern	O
that	O
emerged	O
as	O
the	O
alkyl	B-CHEMICAL
tether	O
increased	O
from	O
three	O
to	O
six	O
methylene	O
units	O
suggests	O
that	O
inhibitory	O
potency	O
is	O
not	O
simply	O
correlated	O
to	O
increased	O
hydrophobicity	O
imparted	O
by	O
the	O
phenylalkyl	B-CHEMICAL
chain	O
,	O
but	O
rather	O
that	O
one	O
or	O
more	O
hydrophobic	O
binding	O
registers	O
may	O
exist	O
remote	O
from	O
the	O
substrate	O
recognition	O
architecture	O
in	O
the	O
active	O
site	O
of	O
PSMA	B-GENE-Y
.	O

Synthesis	O
,	O
receptor	O
binding	O
and	O
functional	O
studies	O
of	O
mesoridazine	B-CHEMICAL
stereoisomers	O
.	O

The	O
four	O
stereoisomers	O
of	O
mesoridazine	B-CHEMICAL
were	O
synthesized	O
and	O
evaluated	O
in	O
D2	B-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
,	O
D1	B-GENE-Y
,	O
and	O
D3	B-GENE-Y
receptor	I-GENE-Y
binding	O
and	O
functional	O
assays	O
.	O

Two	O
isomers	O
demonstrated	O
potent	O
D2	O
receptor	O
binding	O
(	O
Ki	O
<	O
3	O
nM	O
)	O
and	O
functional	O
antagonism	O
(	O
IC50	O
<	O
or	O
=	O
10	O
nM	O
)	O
activities	O
.	O

These	O
two	O
isomers	O
also	O
showed	O
moderate	O
affinity	O
for	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
and	O
D3	B-GENE-Y
receptors	I-GENE-Y
.	O

A	O
third	O
isomer	O
was	O
devoid	O
of	O
significant	O
D2	B-GENE-Y
receptor	I-GENE-Y
binding	O
,	O
but	O
did	O
have	O
moderate	O
affinity	O
for	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
and	O
D3	B-GENE-Y
receptors	I-GENE-Y
.	O

The	O
fourth	O
isomer	O
demonstrated	O
poor	O
affinity	O
for	O
all	O
the	O
receptors	O
tested	O
.	O

Most	O
significantly	O
,	O
the	O
stereochemistry	O
of	O
the	O
sulfoxide	B-CHEMICAL
moiety	O
played	O
a	O
dominant	O
role	O
in	O
the	O
observed	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
.	O

Cerebral	O
D2	B-GENE-N
and	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
occupancy	O
in	O
Schizophrenic	O
patients	O
treated	O
with	O
olanzapine	B-CHEMICAL
or	O
clozapine	B-CHEMICAL
.	O

We	O
report	O
the	O
results	O
of	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
prospective	O
trial	O
on	O
D2	B-GENE-N
and	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
occupancy	O
and	O
the	O
clinical	O
effects	O
of	O
olanzapine	B-CHEMICAL
versus	O
clozapine	B-CHEMICAL
in	O
a	O
sample	O
of	O
neuroleptic	O
-	O
refractory	O
schizophrenic	O
patients	O
.	O

Receptor	O
occupancy	O
was	O
evaluated	O
in	O
different	O
cortical	O
areas	O
and	O
in	O
basal	O
ganglia	O
using	O
[	B-CHEMICAL
18F	I-CHEMICAL
]	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
ethyl	I-CHEMICAL
-	I-CHEMICAL
spiperone	I-CHEMICAL
(	O
[	B-CHEMICAL
18F	I-CHEMICAL
]	I-CHEMICAL
FESP	I-CHEMICAL
)	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

A	O
total	O
of	O
15	O
neuroleptic	O
-	O
free	O
patients	O
completed	O
the	O
study	O
undergoing	O
a	O
baseline	O
and	O
a	O
post	O
-	O
treatment	O
PET	O
scan	O
(	O
olanzapine	B-CHEMICAL
,	O
nine	O
patients	O
,	O
one	O
female	O
;	O
clozapine	B-CHEMICAL
,	O
six	O
patients	O
,	O
three	O
female	O
)	O
8	O
weeks	O
after	O
starting	O
treatment	O
.	O

PET	O
data	O
were	O
analysed	O
both	O
by	O
regions	O
of	O
interest	O
and	O
on	O
a	O
voxel	O
-	O
by	O
-	O
voxel	O
basis	O
using	O
Statistical	O
Parametric	O
Mapping	O
(	O
SPM96	O
)	O
.	O

Olanzapine	B-CHEMICAL
and	O
clozapine	B-CHEMICAL
induced	O
a	O
similar	O
and	O
significant	O
inhibition	O
of	O
[	B-CHEMICAL
18F	I-CHEMICAL
]	I-CHEMICAL
FESP	I-CHEMICAL
binding	O
index	O
in	O
the	O
cortex	O
.	O

In	O
the	O
basal	O
ganglia	O
,	O
receptor	O
occupancy	O
was	O
significantly	O
higher	O
with	O
olanzapine	B-CHEMICAL
than	O
with	O
clozapine	B-CHEMICAL
(	O
p	O
=	O
0	O
.	O
0018	O
)	O
.	O

By	O
contrast	O
,	O
no	O
differences	O
in	O
receptor	O
occupancy	O
were	O
detected	O
at	O
the	O
level	O
of	O
the	O
pituitary	O
gland	O
.	O

Clinical	O
outcomes	O
,	O
in	O
particular	O
a	O
full	O
extra	O
pyramidal	O
tolerability	O
,	O
were	O
similar	O
.	O

In	O
this	O
sample	O
of	O
neuroleptic	O
-	O
refractory	O
schizophrenic	O
patients	O
,	O
olanzapine	B-CHEMICAL
and	O
clozapine	B-CHEMICAL
showed	O
a	O
different	O
pattern	O
of	O
occupancy	O
of	O
D2	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
receptor	I-GENE-Y
despite	O
a	O
common	O
lack	O
of	O
extrapyramidal	O
side	O
-	O
effects	O
.	O

Brain	O
but	O
not	O
spinal	O
NR2B	B-GENE-Y
receptor	O
is	O
responsible	O
for	O
the	O
anti	O
-	O
allodynic	O
effect	O
of	O
an	O
NR2B	B-GENE-Y
subunit	O
-	O
selective	O
antagonist	O
CP	B-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
in	O
a	O
rat	O
chronic	O
constriction	O
injury	O
model	O
.	O

In	O
order	O
to	O
examine	O
the	O
site	O
of	O
action	O
of	O
an	O
NR2B	B-GENE-Y
subtype	O
-	O
selective	O
NMDA	B-CHEMICAL
antagonist	O
CP	B-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
,	O
we	O
investigated	O
its	O
analgesic	O
effect	O
in	O
a	O
rat	O
model	O
of	O
neuropathic	O
pain	O
at	O
various	O
routes	O
of	O
administration	O
.	O

Mechanical	O
allodynia	O
was	O
induced	O
by	O
chronic	O
constriction	O
injury	O
(	O
CCI	O
)	O
of	O
the	O
sciatic	O
nerve	O
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

Subcutaneous	O
treatment	O
of	O
the	O
animals	O
with	O
CP	B-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
at	O
10	O
mg	O
/	O
kg	O
significantly	O
inhibited	O
CCI	O
-	O
induced	O
mechanical	O
allodynia	O
.	O

Intracerebroventricular	O
injection	O
of	O
CP	B-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
at	O
10	O
,	O
30	O
and	O
100	O
nmol	O
also	O
inhibited	O
the	O
mechanical	O
allodynia	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
the	O
statistically	O
significant	O
effect	O
being	O
achieved	O
at	O
the	O
highest	O
dose	O
tested	O
(	O
100	O
nmol	O
)	O
without	O
producing	O
any	O
behavioral	O
abnormalities	O
.	O

However	O
,	O
intrathecal	O
injection	O
of	O
CP	B-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
at	O
a	O
dose	O
of	O
300	O
nmol	O
failed	O
to	O
inhibit	O
CCI	O
-	O
induced	O
allodynia	O
.	O

A	O
receptor	O
binding	O
assay	O
using	O
rat	O
forebrain	O
and	O
spinal	O
cord	O
membrane	O
preparations	O
demonstrated	O
that	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
CP	I-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
bound	O
to	O
the	O
brain	O
NR2B	B-GENE-Y
receptor	O
with	O
a	O
greater	O
extent	O
compared	O
to	O
the	O
spinal	O
cord	O
one	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
anti	O
-	O
allodynia	O
effect	O
of	O
CP	B-CHEMICAL
-	I-CHEMICAL
101	I-CHEMICAL
,	I-CHEMICAL
606	I-CHEMICAL
is	O
ascribable	O
to	O
blockade	O
of	O
NR2B	B-GENE-Y
receptors	O
at	O
the	O
brain	O
,	O
but	O
not	O
at	O
the	O
spinal	O
cord	O
.	O

In	O
contrast	O
,	O
intrathecal	O
injection	O
of	O
a	O
non	O
-	O
selective	O
NMDA	B-CHEMICAL
antagonist	O
,	O
memantine	B-CHEMICAL
,	O
significantly	O
inhibited	O
CCI	O
-	O
induced	O
mechanical	O
allodynia	O
at	O
a	O
dose	O
of	O
300	O
nmol	O
,	O
indicating	O
the	O
difference	O
in	O
the	O
site	O
of	O
action	O
between	O
the	O
non	O
-	O
selective	O
NMDA	B-CHEMICAL
antagonist	O
and	O
the	O
NR2B	B-GENE-Y
-	O
specific	O
NMDA	B-CHEMICAL
antagonist	O
.	O

The	O
inhibitory	O
effect	O
of	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
on	O
HIF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
activation	O
is	O
not	O
dependent	O
on	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
-	O
soluble	B-GENE-N
guanylyl	I-GENE-N
cyclase	I-GENE-N
pathway	O
.	O

Adaptation	O
to	O
hypoxia	O
and	O
maintenance	O
of	O
O	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
homeostasis	O
involve	O
a	O
wide	O
range	O
of	O
responses	O
that	O
occur	O
at	O
different	O
organizational	O
levels	O
in	O
the	O
body	O
.	O

One	O
of	O
the	O
most	O
important	O
transcription	O
factors	O
that	O
activate	O
the	O
expression	O
of	O
O	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	O
regulated	O
genes	O
is	O
hypoxia	B-GENE-N
-	I-GENE-N
inducible	I-GENE-N
factor	I-GENE-N
1	I-GENE-N
(	O
HIF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
)	O
.	O

Nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
mediates	O
a	O
variety	O
of	O
biological	O
effects	O
including	O
relaxation	O
of	O
blood	O
vessels	O
and	O
cytotoxicity	O
of	O
activated	O
macrophages	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
clinically	O
used	O
nitrates	O
nitroglycerin	B-CHEMICAL
(	O
NTG	B-CHEMICAL
)	O
,	O
isosorbide	B-CHEMICAL
dinitrate	I-CHEMICAL
(	O
ISDN	B-CHEMICAL
)	O
,	O
and	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SNP	B-CHEMICAL
)	O
on	O
HIF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
-	O
mediated	O
transcriptional	O
responses	O
to	O
hypoxia	O
.	O

We	O
demonstrate	O
that	O
among	O
the	O
three	O
nitrates	O
,	O
only	O
SNP	B-CHEMICAL
inhibits	O
HIF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
activation	O
in	O
response	O
to	O
hypoxia	O
.	O

In	O
contrast	O
,	O
NTG	B-CHEMICAL
or	O
ISDN	B-CHEMICAL
does	O
not	O
affect	O
HIF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
activity	O
.	O

SNP	B-CHEMICAL
inhibits	O
the	O
accumulation	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
the	O
regulatory	O
subunit	O
of	O
HIF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
,	O
and	O
the	O
transcriptional	O
activation	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
via	O
a	O
mechanism	O
that	O
is	O
not	O
dependent	O
on	O
either	O
NO	B-CHEMICAL
or	O
soluble	B-GENE-N
guanylate	I-GENE-N
cyclase	I-GENE-N
.	O

Amylin	B-GENE-Y
receptors	O
:	O
molecular	O
composition	O
and	O
pharmacology	O
.	O

Several	O
receptors	O
which	O
bind	O
the	O
hormone	O
AMY	B-GENE-Y
(	O
amylin	B-GENE-Y
)	O
with	O
high	O
affinity	O
have	O
now	O
been	O
identified	O
.	O

The	O
minimum	O
binding	O
unit	O
is	O
composed	O
of	O
the	O
CT	B-GENE-Y
(	I-GENE-Y
calcitonin	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
at	O
its	O
core	O
,	O
plus	O
a	O
RAMP	B-GENE-N
(	O
receptor	B-GENE-N
activity	I-GENE-N
modifying	I-GENE-N
protein	I-GENE-N
)	O
.	O

The	O
receptors	O
have	O
been	O
named	O
AMY	B-GENE-N
(	I-GENE-N
1	I-GENE-N
(	I-GENE-N
a	I-GENE-N
)	I-GENE-N
)	I-GENE-N
,	O
AMY	B-GENE-N
(	I-GENE-N
2	I-GENE-N
(	I-GENE-N
a	I-GENE-N
)	I-GENE-N
)	I-GENE-N
and	O
AMY	B-GENE-N
(	I-GENE-N
3	I-GENE-N
(	I-GENE-N
a	I-GENE-N
)	I-GENE-N
)	I-GENE-N
in	O
accordance	O
with	O
the	O
association	O
of	O
the	O
CT	B-GENE-Y
receptor	I-GENE-Y
(	B-GENE-Y
CT	I-GENE-Y
(	I-GENE-Y
(	I-GENE-Y
a	I-GENE-Y
)	I-GENE-Y
)	I-GENE-Y
)	I-GENE-Y
with	O
RAMP1	B-GENE-Y
,	O
RAMP2	B-GENE-Y
and	O
RAMP3	B-GENE-Y
respectively	O
.	O

The	O
challenge	O
is	O
now	O
to	O
determine	O
the	O
localization	O
and	O
pharmacological	O
nature	O
of	O
each	O
of	O
these	O
receptors	O
.	O

Recent	O
attempts	O
to	O
achieve	O
these	O
aims	O
will	O
be	O
briefly	O
discussed	O
.	O

Genetic	O
risk	O
factors	O
for	O
infection	O
in	O
patients	O
with	O
early	O
rheumatoid	O
arthritis	O
.	O

We	O
analyzed	O
clinical	O
and	O
genetic	O
factors	O
contributing	O
to	O
infections	O
in	O
457	O
subjects	O
with	O
early	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
enrolled	O
in	O
a	O
prospective	O
,	O
1	O
-	O
year	O
clinical	O
trial	O
of	O
methotrexate	B-CHEMICAL
and	O
the	O
TNF	B-GENE-Y
inhibitor	O
etanercept	O
.	O

Subjects	O
were	O
genotyped	O
for	O
the	O
following	O
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
:	O
(	O
TNF	B-GENE-Y
-	O
308	O
,	O
-	O
238	O
,	O
and	O
+	O
488	O
)	O
;	O
lymphotoxin	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
LTA	B-GENE-Y
)	O
(	O
LTA	B-GENE-Y
+	O
249	O
,	O
+	O
365	O
,	O
and	O
+	O
720	O
)	O
;	O
and	O
Fc	B-GENE-N
gamma	I-GENE-N
receptors	I-GENE-N
FCGR2A	B-GENE-Y
131	O
H	O
/	O
R	O
;	O
FCGR3A	B-GENE-Y
176	O
F	O
/	O
V	O
;	O
and	O
FCGR3B	B-GENE-Y
NA	O
1	O
/	O
2	O
and	O
genotypes	O
were	O
correlated	O
with	O
infections	O
.	O

At	O
least	O
one	O
URI	O
was	O
noted	O
in	O
52	O
%	O
of	O
subjects	O
(	O
99	O
/	O
191	O
)	O
with	O
the	O
NA2	O
/	O
NA2	O
genotype	O
of	O
the	O
neutrophil	O
-	O
specific	O
FCGR3B	B-GENE-Y
gene	O
,	O
compared	O
to	O
42	O
%	O
(	O
77	O
/	O
181	O
)	O
of	O
those	O
with	O
the	O
NA1	O
/	O
NA2	O
genotype	O
and	O
39	O
%	O
(	O
23	O
/	O
59	O
)	O
of	O
those	O
with	O
the	O
NA1	O
/	O
NA1	O
genotype	O
(	O
P	O
=	O
0	O
.	O
038	O
)	O
.	O

Urinary	O
tract	O
infection	O
(	O
UTI	O
)	O
was	O
associated	O
with	O
the	O
TNF	B-GENE-Y
-	O
238	O
A	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
2	O
.	O
56	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
05	O
-	O
6	O
.	O
25	O
)	O
and	O
LTA	B-GENE-Y
+	O
365	O
C	O
(	O
OR	O
1	O
.	O
73	O
,	O
95	O
%	O
CI	O
1	O
.	O
07	O
-	O
2	O
.	O
79	O
)	O
alleles	O
,	O
and	O
marginally	O
with	O
the	O
FCGR3A	B-GENE-Y
F	O
allele	O
(	O
OR	O
1	O
.	O
72	O
,	O
95	O
%	O
CI	O
0	O
.	O
99	O
-	O
3	O
.	O
00	O
)	O
.	O

There	O
was	O
a	O
striking	O
linear	O
correlation	O
between	O
UTI	O
and	O
the	O
number	O
of	O
risk	O
alleles	O
defined	O
by	O
these	O
three	O
SNPs	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
suggesting	O
an	O
additive	O
effect	O
on	O
susceptibility	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
the	O
role	O
of	O
genetics	O
in	O
susceptibility	O
to	O
bacterial	O
and	O
viral	O
infections	O
.	O

Pseudohypoaldosteronism	O
type	O
1	O
and	O
the	O
genes	O
encoding	O
prostasin	B-GENE-Y
,	O
alpha	B-GENE-Y
-	I-GENE-Y
spectrin	I-GENE-Y
,	O
and	O
Nedd4	B-GENE-Y
.	O

Pseudohypoaldosteronism	O
type	O
1	O
(	O
PHA1	O
)	O
,	O
a	O
rare	O
disorder	O
of	O
infancy	O
,	O
presents	O
with	O
potential	O
life	O
-	O
threatening	O
salt	O
wasting	O
and	O
failure	O
to	O
thrive	O
.	O

Thus	O
far	O
,	O
PHA1	O
has	O
been	O
attributed	O
to	O
mutations	O
affecting	O
the	O
mineralocorticoid	B-GENE-Y
receptor	I-GENE-Y
or	O
any	O
of	O
the	O
three	O
subunits	O
assembling	O
the	O
amiloride	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
epithelial	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
(	O
ENaC	B-GENE-N
)	O
.	O

However	O
,	O
a	O
lot	O
of	O
patients	O
with	O
a	O
phenotype	O
resembling	O
PHA1	O
,	O
show	O
no	O
defects	O
in	O
these	O
proteins	O
,	O
making	O
it	O
likely	O
that	O
further	O
genes	O
are	O
involved	O
in	O
the	O
aetiology	O
of	O
this	O
disease	O
.	O

Recent	O
studies	O
have	O
elucidated	O
additional	O
participants	O
(	O
alpha	B-GENE-Y
-	I-GENE-Y
spectrin	I-GENE-Y
and	O
members	O
of	O
the	O
families	O
of	O
transmembrane	B-GENE-N
serine	I-GENE-N
proteases	I-GENE-N
,	O
ubiquitin	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
ligases	I-GENE-N
,	O
and	O
serum	B-GENE-N
-	I-GENE-N
and	I-GENE-N
glucocorticoid	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinases	I-GENE-N
,	O
respectively	O
)	O
regulating	O
and	O
/	O
or	O
interacting	O
in	O
the	O
complex	O
pathway	O
of	O
sodium	B-CHEMICAL
retention	O
in	O
the	O
amiloride	B-CHEMICAL
-	O
sensitive	O
distal	O
nephron	O
.	O

This	O
led	O
us	O
to	O
investigate	O
whether	O
PHA1	O
can	O
also	O
be	O
associated	O
with	O
mutations	O
in	O
some	O
of	O
these	O
genes	O
.	O

Our	O
data	O
suggest	O
that	O
at	O
least	O
the	O
prostasin	B-GENE-Y
gene	O
might	O
be	O
excluded	O
as	O
a	O
causative	O
locus	O
.	O

Substrate	O
specificity	O
of	O
the	O
human	B-GENE-N
renal	I-GENE-N
sodium	I-GENE-N
dicarboxylate	I-GENE-N
cotransporter	I-GENE-N
,	O
hNaDC	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
under	O
voltage	O
-	O
clamp	O
conditions	O
.	O

Proximal	O
tubule	O
cells	O
extract	O
dicarboxylates	O
from	O
filtrate	O
and	O
blood	O
,	O
using	O
cotransporters	O
located	O
in	O
the	O
brush	O
border	O
[	O
sodium	B-GENE-N
dicarboxylate	I-GENE-N
cotransporter	I-GENE-N
(	O
NaDC	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
]	O
and	O
basolateral	O
cell	O
membrane	O
(	O
NaDC	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
)	O
.	O

We	O
expressed	O
the	O
human	B-GENE-Y
NaDC	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
(	O
hNaDC	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
)	O
in	O
Xenopus	O
laevis	O
oocytes	O
and	O
characterized	O
it	O
by	O
the	O
two	O
-	O
electrode	O
voltage	O
-	O
clamp	O
technique	O
.	O

At	O
-	O
60	O
mV	O
,	O
succinate	B-CHEMICAL
(	O
4	O
carbons	B-CHEMICAL
)	O
and	O
glutarate	B-CHEMICAL
(	O
5	O
carbons	B-CHEMICAL
)	O
generated	O
inward	O
currents	O
due	O
to	O
translocation	O
of	O
three	O
sodium	B-CHEMICAL
ions	O
and	O
one	O
divalent	O
dicarboxylate	O
,	O
whereas	O
oxalate	B-CHEMICAL
(	O
2	O
carbons	B-CHEMICAL
)	O
and	O
malonate	B-CHEMICAL
(	O
3	O
carbons	B-CHEMICAL
)	O
did	O
not	O
.	O

The	O
cis	B-CHEMICAL
-	I-CHEMICAL
dicarboxylate	I-CHEMICAL
maleate	I-CHEMICAL
produced	O
currents	O
smaller	O
in	O
magnitude	O
,	O
whereas	O
the	O
trans	B-CHEMICAL
-	I-CHEMICAL
dicarboxylate	I-CHEMICAL
fumarate	I-CHEMICAL
generated	O
currents	O
similar	O
to	O
succinate	B-CHEMICAL
.	O

The	O
substituted	O
succinate	B-CHEMICAL
derivatives	O
,	O
malate	B-CHEMICAL
,	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dimethylsuccinate	I-CHEMICAL
,	O
and	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dimercaptosuccinate	I-CHEMICAL
elicited	O
inward	O
currents	O
,	O
whereas	O
aspartate	B-CHEMICAL
and	O
guanidinosuccinate	B-CHEMICAL
showed	O
hardly	O
detectable	O
currents	O
.	O

The	O
C	B-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
dicarboxylates	I-CHEMICAL
glutarate	I-CHEMICAL
and	O
alpha	B-CHEMICAL
-	I-CHEMICAL
ketoglutarate	I-CHEMICAL
produced	O
larger	O
currents	O
than	O
succinate	B-CHEMICAL
;	O
glutamate	B-CHEMICAL
and	O
folate	B-CHEMICAL
failed	O
to	O
cause	O
inward	O
currents	O
.	O

Kinetic	O
analysis	O
revealed	O
,	O
at	O
-	O
60	O
mV	O
,	O
K	O
(	O
0	O
.	O
5	O
)	O
values	O
of	O
25	O
+	O
/	O
-	O
12	O
microM	O
for	O
succinate	B-CHEMICAL
and	O
45	O
+	O
/	O
-	O
13	O
microM	O
for	O
alpha	B-CHEMICAL
-	I-CHEMICAL
ketoglutarate	I-CHEMICAL
,	O
values	O
close	O
to	O
the	O
plasma	O
concentration	O
of	O
these	O
compounds	O
.	O

For	O
both	O
compounds	O
,	O
the	O
K	O
(	O
0	O
.	O
5	O
)	O
was	O
independent	O
of	O
voltage	O
,	O
whereas	O
the	O
maximal	O
current	O
increased	O
with	O
hyperpolarization	O
.	O

As	O
opposed	O
to	O
the	O
rat	O
and	O
flounder	O
orthologs	O
,	O
hNaDC	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
was	O
hardly	O
inhibited	O
by	O
lithium	B-CHEMICAL
concentrations	O
up	O
to	O
5	O
mM	O
.	O

In	O
the	O
absence	O
of	O
sodium	B-CHEMICAL
,	O
however	O
,	O
lithium	B-CHEMICAL
can	O
mediate	O
succinate	B-CHEMICAL
-	O
dependent	O
currents	O
.	O

The	O
narrow	O
substrate	O
specificity	O
prevents	O
interaction	O
of	O
drugs	O
with	O
dicarboxylate	O
-	O
like	O
structure	O
with	O
hNaDC	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
ensures	O
sufficient	O
support	O
of	O
the	O
proximal	O
tubule	O
cells	O
with	O
alpha	B-CHEMICAL
-	I-CHEMICAL
ketoglutarate	I-CHEMICAL
for	O
anion	O
secretion	O
via	O
organic	B-GENE-N
anion	I-GENE-N
transporter	I-GENE-N
1	I-GENE-N
or	I-GENE-N
3	I-GENE-N
.	O

State	O
-	O
dependent	O
mibefradil	B-CHEMICAL
block	O
of	O
Na	B-GENE-N
+	I-GENE-N
channels	I-GENE-N
.	O

Mibefradil	B-CHEMICAL
is	O
a	O
T	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca2	I-GENE-N
+	I-GENE-N
channel	I-GENE-N
antagonist	O
with	O
reported	O
cross	O
-	O
reactivity	O
with	O
other	O
classes	O
of	O
ion	O
channels	O
,	O
including	O
K	B-GENE-N
+	I-GENE-N
,	I-GENE-N
Cl	I-GENE-N
-	I-GENE-N
,	I-GENE-N
and	I-GENE-N
Na	I-GENE-N
+	I-GENE-N
channels	I-GENE-N
.	O

Using	O
whole	O
-	O
cell	O
voltage	O
clamp	O
,	O
we	O
examined	O
mibefradil	B-CHEMICAL
block	O
of	O
four	O
Na	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
isoforms	O
expressed	O
in	O
human	O
embryonic	O
kidney	O
cells	O
:	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
(	O
cardiac	O
)	O
,	O
Nav1	B-GENE-Y
.	I-GENE-Y
4	I-GENE-Y
(	O
skeletal	O
muscle	O
)	O
,	O
Nav1	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
(	O
brain	O
)	O
,	O
and	O
Nav1	B-GENE-Y
.	I-GENE-Y
7	I-GENE-Y
(	O
peripheral	O
nerve	O
)	O
.	O

Mibefradil	B-CHEMICAL
blocked	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
in	O
a	O
use	O
/	O
frequency	O
-	O
dependent	O
manner	O
,	O
indicating	O
preferential	O
binding	O
to	O
states	O
visited	O
during	O
depolarization	O
.	O

Mibefradil	B-CHEMICAL
blocked	O
currents	O
of	O
all	O
Na	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
isoforms	O
with	O
similar	O
affinity	O
and	O
a	O
dependence	O
on	O
holding	O
potential	O
,	O
and	O
drug	O
off	O
-	O
rate	O
was	O
slowed	O
at	O
depolarized	O
potentials	O
(	O
k	O
(	O
off	O
)	O
was	O
0	O
.	O
024	O
/	O
s	O
at	O
-	O
130	O
mV	O
and	O
0	O
.	O
007	O
/	O
s	O
at	O
-	O
100	O
mV	O
for	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
)	O
.	O

We	O
further	O
probed	O
the	O
interaction	O
of	O
mibefradil	B-CHEMICAL
with	O
inactivated	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
channels	O
.	O

Neither	O
the	O
degree	O
nor	O
the	O
time	O
course	O
of	O
block	O
was	O
dependent	O
on	O
the	O
stimulus	O
duration	O
,	O
which	O
dramatically	O
changed	O
the	O
residency	O
time	O
of	O
channels	O
in	O
the	O
fast	O
-	O
inactivated	O
state	O
.	O

In	O
addition	O
,	O
inhibiting	O
the	O
binding	O
of	O
the	O
fast	O
inactivation	O
lid	O
(	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
ICM	O
+	O
MTSET	O
)	O
did	O
not	O
alter	O
mibefradil	B-CHEMICAL
block	O
,	O
confirming	O
that	O
the	O
drug	O
does	O
not	O
preferentially	O
interact	O
with	O
the	O
fast	O
-	O
inactivated	O
state	O
.	O

We	O
also	O
tested	O
whether	O
mibefradil	B-CHEMICAL
interacted	O
with	O
slow	O
-	O
inactivated	O
state	O
(	O
s	O
)	O
.	O

When	O
selectively	O
applied	O
to	O
channels	O
after	O
inducing	O
slow	O
inactivation	O
with	O
a	O
60	O
-	O
s	O
pulse	O
to	O
-	O
10	O
mV	O
,	O
mibefradil	B-CHEMICAL
(	O
1	O
microM	O
)	O
produced	O
45	O
%	O
fractional	O
block	O
in	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
and	O
greater	O
block	O
(	O
88	O
%	O
)	O
in	O
an	O
isoform	O
(	O
Nav1	B-GENE-Y
.	I-GENE-Y
4	I-GENE-Y
)	O
that	O
slow	O
-	O
inactivates	O
more	O
completely	O
.	O

Our	O
results	O
suggest	O
that	O
mibefradil	B-CHEMICAL
blocks	O
Na	B-GENE-N
+	I-GENE-N
channels	I-GENE-N
in	O
a	O
state	O
-	O
dependent	O
manner	O
that	O
does	O
not	O
depend	O
on	O
fast	O
inactivation	O
but	O
probably	O
involves	O
interaction	O
with	O
one	O
or	O
more	O
slow	O
-	O
inactivated	O
state	O
(	O
s	O
)	O
.	O

Meclofenamic	B-CHEMICAL
acid	I-CHEMICAL
and	O
diclofenac	B-CHEMICAL
,	O
novel	O
templates	O
of	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
potassium	B-GENE-N
channel	I-GENE-N
openers	O
,	O
depress	O
cortical	O
neuron	O
activity	O
and	O
exhibit	O
anticonvulsant	O
properties	O
.	O

The	O
voltage	O
-	O
dependent	O
M	O
-	O
type	O
potassium	B-CHEMICAL
current	O
(	O
M	O
-	O
current	O
)	O
plays	O
a	O
major	O
role	O
in	O
controlling	O
brain	O
excitability	O
by	O
stabilizing	O
the	O
membrane	O
potential	O
and	O
acting	O
as	O
a	O
brake	O
for	O
neuronal	O
firing	O
.	O

The	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
heteromeric	O
channel	O
complex	O
was	O
identified	O
as	O
the	O
molecular	O
correlate	O
of	O
the	O
M	O
-	O
current	O
.	O

Furthermore	O
,	O
the	O
KCNQ2	B-GENE-Y
and	O
KCNQ3	B-GENE-Y
channel	I-GENE-Y
alpha	I-GENE-Y
subunits	I-GENE-Y
are	O
mutated	O
in	O
families	O
with	O
benign	O
familial	O
neonatal	O
convulsions	O
,	O
a	O
neonatal	O
form	O
of	O
epilepsy	O
.	O

Enhancement	O
of	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
potassium	B-CHEMICAL
currents	O
may	O
provide	O
an	O
important	O
target	O
for	O
antiepileptic	O
drug	O
development	O
.	O

Here	O
,	O
we	O
show	O
that	O
meclofenamic	B-CHEMICAL
acid	I-CHEMICAL
(	O
meclofenamate	B-CHEMICAL
)	O
and	O
diclofenac	B-CHEMICAL
,	O
two	O
related	O
molecules	O
previously	O
used	O
as	O
anti	O
-	O
inflammatory	O
drugs	O
,	O
act	O
as	O
novel	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
channel	O
openers	O
.	O

Extracellular	O
application	O
of	O
meclofenamate	B-CHEMICAL
(	O
EC	O
(	O
50	O
)	O
=	O
25	O
microM	O
)	O
and	O
diclofenac	B-CHEMICAL
(	O
EC	O
(	O
50	O
)	O
=	O
2	O
.	O
6	O
microM	O
)	O
resulted	O
in	O
the	O
activation	O
of	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
K	O
(	O
+	O
)	O
currents	O
,	O
heterologously	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Both	O
openers	O
activated	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
channels	O
by	O
causing	O
a	O
hyperpolarizing	O
shift	O
of	O
the	O
voltage	O
activation	O
curve	O
(	O
-	O
23	O
and	O
-	O
15	O
mV	O
,	O
respectively	O
)	O
and	O
by	O
markedly	O
slowing	O
the	O
deactivation	O
kinetics	O
.	O

The	O
effects	O
of	O
the	O
drugs	O
were	O
stronger	O
on	O
KCNQ2	B-GENE-Y
than	O
on	O
KCNQ3	B-GENE-Y
channel	I-GENE-Y
alpha	I-GENE-Y
subunits	I-GENE-Y
.	O

In	O
contrast	O
,	O
they	O
did	O
not	O
enhance	O
KCNQ1	B-GENE-Y
K	O
(	O
+	O
)	O
currents	O
.	O

Both	O
openers	O
increased	O
KCNQ2	B-GENE-N
/	I-GENE-N
Q3	I-GENE-N
current	O
amplitude	O
at	O
physiologically	O
relevant	O
potentials	O
and	O
led	O
to	O
hyperpolarization	O
of	O
the	O
resting	O
membrane	O
potential	O
.	O

In	O
cultured	O
cortical	O
neurons	O
,	O
meclofenamate	B-CHEMICAL
and	O
diclofenac	B-CHEMICAL
enhanced	O
the	O
M	O
-	O
current	O
and	O
reduced	O
evoked	O
and	O
spontaneous	O
action	O
potentials	O
,	O
whereas	O
in	O
vivo	O
diclofenac	B-CHEMICAL
exhibited	O
an	O
anticonvulsant	O
activity	O
(	O
ED	O
(	O
50	O
)	O
=	O
43	O
mg	O
/	O
kg	O
)	O
.	O

These	O
compounds	O
potentially	O
constitute	O
novel	O
drug	O
templates	O
for	O
the	O
treatment	O
of	O
neuronal	O
hyperexcitability	O
including	O
epilepsy	O
,	O
migraine	O
,	O
or	O
neuropathic	O
pain	O
.	O

Extracellular	B-GENE-N
loop	I-GENE-N
3	I-GENE-N
(	O
EL3	B-GENE-N
)	O
and	O
EL3	B-GENE-N
-	I-GENE-N
proximal	I-GENE-N
transmembrane	I-GENE-N
helix	I-GENE-N
7	I-GENE-N
of	O
the	O
mammalian	B-GENE-N
type	I-GENE-N
I	I-GENE-N
and	I-GENE-N
type	I-GENE-N
II	I-GENE-N
gonadotropin	I-GENE-N
-	I-GENE-N
releasing	I-GENE-N
hormone	I-GENE-N
(	I-GENE-N
GnRH	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
determine	O
differential	O
ligand	O
selectivity	O
to	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
and	O
GnRH	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
.	O

Mammalian	B-GENE-N
type	I-GENE-N
I	I-GENE-N
and	I-GENE-N
II	I-GENE-N
gonadotropin	I-GENE-N
-	I-GENE-N
releasing	I-GENE-N
hormone	I-GENE-N
(	I-GENE-N
GnRH	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
(	O
GnRHRs	B-GENE-N
)	O
show	O
differential	O
ligand	O
preference	O
for	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
and	O
GnRH	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
,	O
respectively	O
.	O

Using	O
a	O
variety	O
of	O
chimeric	O
receptors	O
based	O
on	O
green	B-GENE-Y
monkey	I-GENE-Y
GnRHR	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
gmGnRHR	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
a	O
representative	O
type	B-GENE-Y
II	I-GENE-Y
GnRHR	I-GENE-Y
,	O
and	O
rat	B-GENE-Y
GnRHR	I-GENE-Y
,	O
a	O
representative	O
type	B-GENE-Y
I	I-GENE-Y
GnRHR	I-GENE-Y
,	O
this	O
study	O
elucidated	O
specific	O
domains	O
responsible	O
for	O
this	O
ligand	O
selectivity	O
.	O

A	O
chimeric	O
gmGnRHR	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
with	O
the	O
extracellular	B-GENE-N
loop	I-GENE-N
3	I-GENE-N
(	O
EL3	B-GENE-N
)	O
and	O
EL3	B-GENE-N
-	I-GENE-N
proximal	I-GENE-N
transmembrane	I-GENE-N
helix	I-GENE-N
7	I-GENE-N
(	O
TMH7	B-GENE-N
)	O
of	O
rat	B-GENE-Y
GnRHR	I-GENE-Y
showed	O
a	O
great	O
increase	O
in	O
ligand	O
sensitivity	O
to	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
but	O
not	O
to	O
GnRH	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
.	O

Point	O
-	O
mutation	O
studies	O
indicate	O
that	O
four	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
Leu	B-CHEMICAL
/	O
Phe	B-CHEMICAL
(	O
7	O
.	O
38	O
)	O
,	O
Leu	B-CHEMICAL
/	O
Phe	B-CHEMICAL
(	O
7	O
.	O
43	O
)	O
,	O
Ala	B-CHEMICAL
/	O
Pro	B-CHEMICAL
(	O
7	O
.	O
46	O
)	O
,	O
and	O
Pro	B-CHEMICAL
/	O
Cys	B-CHEMICAL
(	O
7	O
.	O
47	O
)	O
in	O
TMH7	B-GENE-N
are	O
critical	O
for	O
ligand	O
selectivity	O
as	O
well	O
as	O
receptor	O
conformation	O
.	O

Furthermore	O
,	O
a	O
combinatory	O
mutation	O
(	O
Pro	B-CHEMICAL
(	O
7	O
.	O
31	O
)	O
-	O
Pro	B-CHEMICAL
(	O
7	O
.	O
32	O
)	O
-	O
Ser	B-CHEMICAL
(	O
7	O
.	O
33	O
)	O
motif	O
to	O
Ser	B-CHEMICAL
-	I-CHEMICAL
Glu	I-CHEMICAL
-	I-CHEMICAL
Pro	I-CHEMICAL
in	O
EL3	B-GENE-N
and	O
Leu	B-CHEMICAL
(	O
7	O
.	O
38	O
)	O
,	O
Leu	B-CHEMICAL
(	O
7	O
.	O
43	O
)	O
,	O
Ala	B-CHEMICAL
(	O
7	O
.	O
46	O
)	O
,	O
and	O
Pro	B-CHEMICAL
(	O
7	O
.	O
47	O
)	O
to	O
those	O
of	O
rat	B-GENE-Y
GnRHR	I-GENE-Y
)	O
in	O
gmGnRH	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
exhibited	O
an	O
approximately	O
500	O
-	O
fold	O
increased	O
sensitivity	O
to	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
,	O
indicating	O
that	O
these	O
residues	O
are	O
critical	O
for	O
discriminating	O
GnRH	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
from	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
.	O

[	O
Trp	O
(	O
7	O
)	O
]	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
and	O
[	O
Trp	O
(	O
8	O
)	O
]	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
but	O
not	O
[	O
His	O
(	O
5	O
)	O
]	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
exhibit	O
a	O
higher	O
potency	O
in	O
activating	O
wild	O
-	O
type	O
gmGnRHR	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
than	O
native	O
GnRH	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
,	O
indicating	O
that	O
amino	B-CHEMICAL
acids	I-CHEMICAL
at	O
positions	O
7	O
and	O
8	O
of	O
GnRHs	B-GENE-N
are	O
more	O
important	O
than	O
position	O
5	O
for	O
differential	O
recognition	O
by	O
type	B-GENE-N
I	I-GENE-N
and	I-GENE-N
type	I-GENE-N
II	I-GENE-N
GnRHRs	I-GENE-N
.	O

As	O
a	O
whole	O
,	O
these	O
data	O
suggest	O
a	O
molecular	O
coevolution	O
of	O
ligands	O
and	O
their	O
receptors	O
and	O
facilitate	O
the	O
understanding	O
of	O
the	O
molecular	O
interaction	O
between	O
GnRHs	B-GENE-N
and	O
their	O
cognate	O
receptors	O
.	O

Pranlukast	B-CHEMICAL
,	O
a	O
leukotriene	B-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
inhibits	O
interleukin	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
production	O
via	O
a	O
mechanism	O
distinct	O
from	O
leukotriene	B-GENE-N
receptor	I-GENE-N
antagonism	O
.	O

BACKGROUND	O
:	O
Pranlukast	B-CHEMICAL
,	O
a	O
cysteinyl	B-GENE-Y
leukotriene	I-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
(	O
CysLTR1	B-GENE-Y
)	O
antagonist	O
,	O
inhibits	O
not	O
only	O
airway	O
smooth	O
muscle	O
contraction	O
,	O
but	O
also	O
allergic	O
inflammation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
mechanism	O
of	O
pranlukast	B-CHEMICAL
-	O
induced	O
interleukin	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
)	O
inhibition	O
in	O
allergic	O
inflammation	O
.	O

METHODS	O
:	O
Surgically	O
resected	O
human	O
lung	O
tissue	O
was	O
passively	O
sensitized	O
in	O
vitro	O
with	O
mite	O
-	O
allergen	O
-	O
sensitized	O
sera	O
,	O
followed	O
by	O
stimulation	O
with	O
mite	O
allergen	O
after	O
pretreatment	O
of	O
the	O
tissue	O
with	O
pranlukast	B-CHEMICAL
,	O
dexamethasone	B-CHEMICAL
,	O
or	O
both	O
.	O

The	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
protein	O
level	O
in	O
the	O
culture	O
medium	O
was	O
measured	O
,	O
and	O
in	O
situ	O
hybridization	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
and	O
CysLTR1	B-GENE-Y
mRNA	O
was	O
performed	O
using	O
lung	O
tissues	O
.	O

RESULTS	O
:	O
Pretreatment	O
of	O
lung	O
tissues	O
with	O
pranlukast	B-CHEMICAL
alone	O
significantly	O
decreased	O
the	O
amount	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
protein	O
in	O
the	O
culture	O
medium	O
by	O
40	O
%	O
.	O

The	O
combination	O
of	O
pranlukast	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
synergistically	O
enhanced	O
this	O
effect	O
.	O

Quantitative	O
in	O
situ	O
hybridization	O
with	O
image	O
analysis	O
revealed	O
abundant	O
expression	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
mRNA	O
in	O
eosinophils	O
,	O
lymphocytes	O
,	O
and	O
mast	O
cells	O
in	O
sensitized	O
and	O
allergen	O
-	O
stimulated	O
lung	O
tissues	O
.	O

CysLTR1	B-GENE-Y
mRNA	O
was	O
detected	O
in	O
macrophages	O
,	O
smooth	O
muscle	O
cells	O
,	O
eosinophils	O
,	O
and	O
mast	O
cells	O
,	O
but	O
was	O
less	O
expressed	O
in	O
lymphocytes	O
.	O

Pranlukast	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
mRNA	O
expression	O
was	O
noted	O
in	O
various	O
cells	O
,	O
irrespective	O
of	O
their	O
CysLTR1	B-GENE-Y
mRNA	O
expression	O
status	O
.	O

In	O
addition	O
,	O
cysteinyl	B-CHEMICAL
leukotrienes	I-CHEMICAL
per	O
se	O
failed	O
to	O
upregulate	O
the	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
production	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
indicate	O
that	O
pranlukast	B-CHEMICAL
inhibits	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
synthesis	O
via	O
a	O
mechanism	O
distinct	O
from	O
CysLTR1	B-GENE-Y
antagonism	O
.	O

Further	O
insights	O
into	O
the	O
effect	O
of	O
quinidine	B-CHEMICAL
in	O
short	O
QT	O
syndrome	O
caused	O
by	O
a	O
mutation	O
in	O
HERG	B-GENE-Y
.	O

INTRODUCTION	O
:	O
The	O
principal	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
quinidine	B-CHEMICAL
in	O
suppressing	O
IKr	B-GENE-N
in	O
vitro	O
and	O
in	O
modulating	O
the	O
rate	O
dependence	O
of	O
the	O
QT	O
interval	O
in	O
the	O
"	O
SQT1	O
"	O
form	O
of	O
the	O
short	O
QT	O
syndrome	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Graded	O
-	O
intensity	O
bicycle	O
exercise	O
testing	O
was	O
performed	O
off	O
drug	O
in	O
three	O
patients	O
and	O
during	O
oral	O
quinidine	B-CHEMICAL
in	O
two	O
patients	O
with	O
short	O
QT	O
syndrome	O
and	O
compared	O
to	O
a	O
control	O
group	O
of	O
healthy	O
normal	O
subjects	O
.	O

The	O
in	O
vitro	O
effects	O
of	O
quinidine	B-CHEMICAL
on	O
currents	O
in	O
patch	O
clamp	O
technique	O
were	O
investigated	O
.	O

Off	O
drugs	O
QTpV3	O
/	O
heart	O
rate	O
correlation	O
is	O
much	O
weaker	O
in	O
patients	O
with	O
short	O
QT	O
syndrome	O
,	O
and	O
QTpV3	O
shortens	O
less	O
with	O
heart	O
rate	O
increase	O
compared	O
to	O
normal	O
subjects	O
.	O

In	O
addition	O
to	O
prolonging	O
the	O
QT	O
interval	O
into	O
the	O
normal	O
range	O
,	O
quinidine	B-CHEMICAL
restored	O
the	O
heart	O
rate	O
dependence	O
of	O
the	O
QT	O
interval	O
toward	O
a	O
range	O
of	O
adaptation	O
reported	O
for	O
normal	O
subjects	O
.	O

Data	O
from	O
heterologous	O
expression	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
HERG	B-GENE-Y
genes	O
indicate	O
the	O
mutation	O
causes	O
a	O
20	O
-	O
fold	O
increase	O
in	O
IC50	O
of	O
d	O
-	O
sotalol	O
but	O
only	O
a	O
5	O
.	O
8	O
-	O
fold	O
increase	O
in	O
IC50	O
of	O
quinidine	B-CHEMICAL
.	O

CONCLUSION	O
:	O
Oral	O
quinidine	B-CHEMICAL
is	O
effective	O
in	O
suppressing	O
the	O
gain	O
of	O
function	O
in	O
IKr	B-GENE-N
responsible	O
for	O
some	O
cases	O
of	O
short	O
QT	O
syndrome	O
with	O
a	O
mutation	O
in	O
HERG	B-GENE-Y
and	O
thus	O
restoring	O
normal	O
rate	O
dependence	O
of	O
the	O
QT	O
interval	O
and	O
rendering	O
ventricular	O
tachycardia	O
/	O
ventricular	O
fibrillation	O
noninducible	O
.	O

Effect	O
of	O
apocalmodulin	B-GENE-Y
on	O
recombinant	O
human	B-GENE-Y
brain	I-GENE-Y
glutamic	I-GENE-Y
acid	I-GENE-Y
decarboxylase	I-GENE-Y
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
the	O
recombinant	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
(	O
GST	B-GENE-N
)	O
-	O
human	B-GENE-Y
L	I-GENE-Y
-	I-GENE-Y
glutamic	I-GENE-Y
acid	I-GENE-Y
decarboxylase	I-GENE-Y
(	O
HGAD	B-GENE-Y
)	O
isoforms	O
,	O
65	B-GENE-Y
-	I-GENE-Y
kDa	I-GENE-Y
L	I-GENE-Y
-	I-GENE-Y
glutamic	I-GENE-Y
acid	I-GENE-Y
decarboxylase	I-GENE-Y
(	O
GAD	B-GENE-Y
)	O
(	O
GST	B-GENE-N
-	O
HGAD65	B-GENE-Y
)	O
fusion	O
protein	O
or	O
free	O
truncated	O
HGAD65	B-GENE-Y
,	O
were	O
activated	O
by	O
apocalmodulin	B-GENE-Y
(	O
ApoCaM	B-GENE-Y
)	O
to	O
an	O
extent	O
of	O
60	O
%	O
.	O

Both	O
truncated	O
forms	O
of	O
GAD67	B-GENE-Y
(	O
tGAD67	B-GENE-Y
)	O
,	O
HGAD67	B-GENE-Y
(	I-GENE-Y
Delta1	I-GENE-Y
-	I-GENE-Y
70	I-GENE-Y
)	I-GENE-Y
and	O
HGAD67	B-GENE-Y
(	I-GENE-Y
Delta1	I-GENE-Y
-	I-GENE-Y
90	I-GENE-Y
)	I-GENE-Y
,	O
were	O
markedly	O
activated	O
by	O
ApoCaM	B-GENE-Y
to	O
an	O
extent	O
of	O
141	O
and	O
85	O
%	O
,	O
respectively	O
,	O
while	O
GST	B-GENE-N
-	O
HGAD67	B-GENE-Y
was	O
not	O
significantly	O
affected	O
.	O

The	O
activation	O
appears	O
to	O
be	O
due	O
to	O
an	O
increase	O
of	O
GAD	B-GENE-Y
affinity	O
for	O
its	O
cofactor	O
,	O
pyridoxal	B-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
.	O

This	O
conclusion	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

Firstly	O
,	O
the	O
V	O
(	O
max	O
)	O
of	O
GAD	B-GENE-Y
was	O
increased	O
when	O
ApoCaM	B-GENE-Y
was	O
present	O
whereas	O
the	O
affinity	O
for	O
the	O
substrate	O
,	O
glutamate	B-CHEMICAL
,	O
was	O
not	O
affected	O
.	O

Secondly	O
,	O
the	O
affinity	O
of	O
GAD	B-GENE-Y
for	O
PLP	B-CHEMICAL
was	O
increased	O
in	O
the	O
presence	O
of	O
ApoCaM	B-GENE-Y
.	O

Thirdly	O
,	O
results	O
from	O
calmodulin	B-GENE-Y
-	O
agarose	O
affinity	O
column	O
chromatography	O
studies	O
indicated	O
a	O
direct	O
interaction	O
or	O
binding	O
between	O
ApoCaM	B-GENE-Y
and	O
GAD	B-GENE-Y
.	O

Fourthly	O
,	O
ApoCaM	B-GENE-Y
was	O
found	O
to	O
be	O
copurified	O
with	O
GAD65	B-GENE-Y
/	O
GAD67	B-GENE-Y
by	O
anti	O
-	O
GAD65	B-GENE-N
/	I-GENE-N
67	I-GENE-N
immunoaffinity	O
column	O
using	O
rat	O
brain	O
extract	O
.	O

Hence	O
,	O
it	O
is	O
proposed	O
that	O
a	O
conformational	O
change	O
is	O
induced	O
when	O
ApoCaM	B-GENE-Y
interacts	O
with	O
GAD65	B-GENE-Y
or	O
tGAD67	B-GENE-Y
,	O
resulting	O
in	O
an	O
increase	O
of	O
GAD	B-GENE-Y
affinity	O
for	O
PLP	B-CHEMICAL
and	O
the	O
activation	O
of	O
GAD	B-GENE-Y
.	O

The	O
physiological	O
significance	O
of	O
the	O
interaction	O
between	O
GAD	B-GENE-Y
and	O
ApoCaM	B-GENE-Y
is	O
discussed	O
.	O

Crystal	O
structure	O
of	O
the	O
pyridoxal	B-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
-	O
dependent	O
serine	B-GENE-Y
dehydratase	I-GENE-Y
from	O
human	O
liver	O
.	O

L	B-GENE-Y
-	I-GENE-Y
serine	I-GENE-Y
dehydratase	I-GENE-Y
(	O
SDH	B-GENE-Y
)	O
,	O
a	O
member	O
of	O
the	O
beta	O
-	O
family	O
of	O
pyridoxal	B-CHEMICAL
phosphate	I-CHEMICAL
-	O
dependent	O
(	O
PLP	O
)	O
enzymes	O
,	O
catalyzes	O
the	O
deamination	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
serine	I-CHEMICAL
and	O
L	B-CHEMICAL
-	I-CHEMICAL
threonine	I-CHEMICAL
to	O
yield	O
pyruvate	B-CHEMICAL
or	O
2	B-CHEMICAL
-	I-CHEMICAL
oxobutyrate	I-CHEMICAL
.	O

The	O
crystal	O
structure	O
of	O
L	B-GENE-Y
-	I-GENE-Y
serine	I-GENE-Y
dehydratase	I-GENE-Y
from	O
human	O
liver	O
(	O
hSDH	B-GENE-Y
)	O
has	O
been	O
solved	O
at	O
2	O
.	O
5	O
A	O
-	O
resolution	O
by	O
molecular	O
replacement	O
.	O

The	O
structure	O
is	O
a	O
homodimer	O
and	O
reveals	O
a	O
fold	O
typical	O
for	O
beta	O
-	O
family	O
PLP	O
-	O
dependent	O
enzymes	O
.	O

Each	O
monomer	O
serves	O
as	O
an	O
active	O
unit	O
and	O
is	O
subdivided	O
into	O
two	O
distinct	O
domains	O
:	O
a	O
small	O
domain	O
and	O
a	O
PLP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
that	O
covalently	O
anchors	O
the	O
cofactor	O
.	O

Both	O
domains	O
show	O
the	O
typical	O
open	O
alpha	O
/	O
beta	O
architecture	O
of	O
PLP	O
enzymes	O
.	O

Comparison	O
with	O
the	O
rSDH	B-GENE-Y
-	O
(	O
PLP	O
-	O
OMS	O
)	O
holo	O
-	O
enzyme	O
reveals	O
a	O
large	O
structural	O
difference	O
in	O
active	O
sites	O
caused	O
by	O
the	O
artifical	O
O	B-CHEMICAL
-	I-CHEMICAL
methylserine	I-CHEMICAL
.	O

Furthermore	O
,	O
the	O
activity	O
of	O
hSDH	B-GENE-Y
-	O
PLP	O
was	O
assayed	O
and	O
it	O
proved	O
to	O
show	O
catalytic	O
activity	O
.	O

That	O
suggests	O
that	O
the	O
structure	O
of	O
hSDH	B-GENE-Y
-	O
PLP	O
is	O
the	O
first	O
structure	O
of	O
the	O
active	O
natural	O
holo	O
-	O
SDH	B-GENE-Y
.	O

[	O
Treatment	O
of	O
androgen	B-CHEMICAL
-	O
independent	O
hormone	O
refractory	O
prostate	O
cancer	O
using	O
docetaxel	B-CHEMICAL
]	O
.	O

Although	O
prostate	O
cancer	O
patients	O
with	O
metastatic	O
lesion	O
initially	O
respond	O
to	O
androgen	B-CHEMICAL
ablation	O
therapy	O
,	O
almost	O
patients	O
develop	O
to	O
hormone	O
-	O
refractory	O
states	O
.	O

The	O
optimal	O
treatment	O
for	O
men	O
with	O
hormone	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
has	O
not	O
been	O
established	O
.	O

Docetaxel	B-CHEMICAL
is	O
a	O
semisynthetic	O
taxane	B-CHEMICAL
that	O
inhibit	O
tumor	O
growth	O
by	O
induction	O
of	O
microtubule	O
stabilization	O
and	O
promotion	O
of	O
bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inactivation	O
,	O
which	O
induce	O
apoptosis	O
.	O

Docetaxel	B-CHEMICAL
as	O
single	O
agent	O
has	O
significant	O
anti	O
-	O
tumor	O
effect	O
in	O
HRPC	O
patients	O
.	O

Docetaxel	B-CHEMICAL
combined	O
with	O
estramustine	B-CHEMICAL
or	O
other	O
antimicrotubular	O
agents	O
have	O
shown	O
further	O
significant	O
cytotoxicity	O
in	O
HRPC	O
patients	O
.	O

In	O
the	O
United	O
States	O
,	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approved	O
docetaxel	B-CHEMICAL
,	O
injection	O
in	O
combination	O
with	O
prednisone	B-CHEMICAL
for	O
the	O
treatment	O
of	O
patients	O
with	O
advanced	O
metastatic	O
prostate	O
cancer	O
in	O
2004	O
.	O

Carvedilol	B-CHEMICAL
modulates	O
the	O
expression	O
of	O
hypoxia	B-GENE-Y
-	I-GENE-Y
inducible	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
and	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
in	O
a	O
rat	O
model	O
of	O
volume	O
-	O
overload	O
heart	O
failure	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
beta	O
-	O
blockers	O
has	O
emerged	O
as	O
a	O
beneficial	O
treatment	O
for	O
congestive	O
heart	O
failure	O
.	O

Hypoxia	B-GENE-Y
-	I-GENE-Y
inducible	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
(	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
)	O
is	O
tightly	O
regulated	O
in	O
the	O
ventricular	O
myocardium	O
.	O

However	O
,	O
the	O
expression	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
in	O
chronic	O
heart	O
failure	O
resulting	O
from	O
volume	O
overload	O
and	O
after	O
treatment	O
with	O
beta	O
-	O
blocker	O
is	O
little	O
known	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
test	O
the	O
hypothesis	O
that	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
plays	O
a	O
role	O
in	O
the	O
failing	O
myocardium	O
because	O
of	O
volume	O
overload	O
,	O
an	O
aorta	O
-	O
caval	O
shunt	O
was	O
created	O
for	O
4	O
weeks	O
in	O
adult	O
Sprague	O
-	O
Dawley	O
rats	O
to	O
induce	O
volume	O
-	O
overload	O
heart	O
failure	O
.	O

Carvedilol	B-CHEMICAL
at	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
per	O
day	O
after	O
surgery	O
was	O
given	O
.	O

The	O
heart	O
weight	O
and	O
body	O
weight	O
ratio	O
increased	O
from	O
2	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
3	O
in	O
the	O
sham	O
group	O
to	O
3	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
7	O
(	O
P	O
<	O
.	O
001	O
)	O
in	O
the	O
shunt	O
group	O
.	O

Left	O
ventricular	O
end	O
-	O
diastolic	O
dimension	O
increased	O
from	O
6	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
5	O
mm	O
to	O
8	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
mm	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Treatment	O
with	O
carvedilol	B-CHEMICAL
in	O
the	O
shunt	O
group	O
reversed	O
the	O
heart	O
weight	O
and	O
ventricular	O
dimension	O
to	O
the	O
baseline	O
values	O
.	O

Western	O
blot	O
showed	O
that	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
,	O
and	O
brain	B-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
(	O
BNP	B-GENE-Y
)	O
proteins	O
were	O
upregulated	O
and	O
nerve	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
(	O
NGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
)	O
downregulated	O
in	O
the	O
shunt	O
group	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
showed	O
that	O
mRNA	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
and	O
BNP	B-GENE-Y
increased	O
and	O
mRNA	O
of	O
NGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
decreased	O
in	O
the	O
shunt	O
group	O
.	O

Treatment	O
with	O
carvedilol	B-CHEMICAL
reversed	O
both	O
protein	O
and	O
mRNA	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
BNP	B-GENE-Y
,	O
and	O
NGF	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
to	O
the	O
baseline	O
values	O
.	O

Increased	O
immunohistochemical	O
labeling	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
and	O
BNP	B-GENE-Y
in	O
the	O
ventricular	O
myocardium	O
was	O
observed	O
in	O
the	O
shunt	O
group	O
and	O
carvedilol	B-CHEMICAL
again	O
normalized	O
the	O
labeling	O
.	O

CONCLUSION	O
:	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
and	O
VEGF	B-GENE-Y
mRNA	O
and	O
protein	O
expression	O
were	O
upregulated	O
in	O
the	O
rat	O
model	O
of	O
volume	O
-	O
overload	O
heart	O
failure	O
.	O

Treatment	O
with	O
carvedilol	B-CHEMICAL
is	O
associated	O
with	O
a	O
reversal	O
of	O
abnormal	O
regulation	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
and	O
VEGF	B-GENE-Y
in	O
the	O
failing	O
ventricular	O
myocardium	O
.	O

Mutation	O
of	O
arginine	B-CHEMICAL
228	O
to	O
lysine	B-CHEMICAL
enhances	O
the	O
glucosyltransferase	B-GENE-N
activity	O
of	O
bovine	B-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	I-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
galactosyltransferase	I-GENE-Y
I	I-GENE-Y
.	O

Beta	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	I-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
galactosyltransferase	I-GENE-Y
I	I-GENE-Y
(	O
beta4Gal	B-GENE-Y
-	I-GENE-Y
T1	I-GENE-Y
)	O
normally	O
transfers	O
Gal	B-CHEMICAL
from	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Gal	I-CHEMICAL
to	O
GlcNAc	B-CHEMICAL
in	O
the	O
presence	O
of	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
ion	O
(	O
Gal	B-GENE-N
-	I-GENE-N
T	I-GENE-N
activity	O
)	O
and	O
also	O
transfers	O
Glc	B-CHEMICAL
from	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Glc	I-CHEMICAL
to	O
GlcNAc	B-CHEMICAL
(	O
Glc	B-GENE-N
-	I-GENE-N
T	I-GENE-N
activity	O
)	O
,	O
albeit	O
at	O
only	O
0	O
.	O
3	O
%	O
efficiency	O
.	O

In	O
addition	O
,	O
alpha	B-GENE-Y
-	I-GENE-Y
lactalbumin	I-GENE-Y
(	O
LA	B-GENE-Y
)	O
enhances	O
this	O
Glc	B-GENE-N
-	I-GENE-N
T	I-GENE-N
activity	O
more	O
than	O
25	O
times	O
.	O

Comparison	O
of	O
the	O
crystal	O
structures	O
of	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Gal	I-CHEMICAL
-	O
and	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Glc	I-CHEMICAL
-	O
bound	O
beta4Gal	B-GENE-Y
-	I-GENE-Y
T1	I-GENE-Y
reveals	O
that	O
the	O
O4	B-CHEMICAL
hydroxyl	I-CHEMICAL
group	O
in	O
both	O
Gal	B-CHEMICAL
and	O
Glc	B-CHEMICAL
moieties	O
forms	O
a	O
hydrogen	B-CHEMICAL
bond	O
with	O
the	O
side	O
chain	O
carboxylate	B-CHEMICAL
group	O
of	O
Glu317	O
.	O

The	O
orientation	O
of	O
the	O
O4	B-CHEMICAL
hydroxyl	I-CHEMICAL
of	I-CHEMICAL
glucose	I-CHEMICAL
causes	O
a	O
steric	O
hindrance	O
to	O
the	O
side	O
chain	O
carboxylate	B-CHEMICAL
group	O
of	O
Glu317	O
,	O
accounting	O
for	O
the	O
enzyme	O
'	O
s	O
low	O
Glc	B-GENE-N
-	I-GENE-N
T	I-GENE-N
activity	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
mutation	O
of	O
Arg228	O
,	O
a	O
residue	O
in	O
the	O
vicinity	O
of	O
Glu317	O
,	O
to	O
lysine	B-CHEMICAL
(	O
R228K	B-GENE-N
-	O
Gal	B-GENE-N
-	I-GENE-N
T1	I-GENE-N
)	O
results	O
in	O
a	O
15	O
-	O
fold	O
higher	O
Glc	B-GENE-N
-	I-GENE-N
T	I-GENE-N
activity	O
,	O
which	O
is	O
further	O
enhanced	O
by	O
LA	O
to	O
nearly	O
25	O
%	O
of	O
the	O
Gal	B-GENE-N
-	I-GENE-N
T	I-GENE-N
activity	O
of	O
the	O
wild	O
type	O
.	O

The	O
kinetic	O
parameters	O
indicate	O
that	O
the	O
main	O
effect	O
of	O
the	O
mutation	O
of	O
Arg228	O
to	O
lysine	B-CHEMICAL
is	O
on	O
the	O
k	O
(	O
cat	O
)	O
of	O
Glc	B-GENE-N
-	I-GENE-N
T	I-GENE-N
,	O
which	O
increases	O
3	O
-	O
4	O
-	O
fold	O
,	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
LA	O
;	O
simultaneously	O
,	O
the	O
k	O
(	O
cat	O
)	O
for	O
the	O
Gal	B-GENE-N
-	I-GENE-N
T	I-GENE-N
reaction	O
is	O
reduced	O
30	O
-	O
fold	O
.	O

The	O
crystal	O
structure	O
of	O
R228K	B-GENE-N
-	O
Gal	B-GENE-N
-	I-GENE-N
T1	I-GENE-N
complexed	O
with	O
LA	O
,	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Gal	I-CHEMICAL
,	O
and	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
determined	O
at	O
1	O
.	O
9	O
A	O
resolution	O
shows	O
that	O
the	O
Asp318	O
side	O
chain	O
exhibits	O
a	O
minor	O
alternate	O
conformation	O
,	O
compared	O
to	O
that	O
in	O
the	O
wild	O
type	O
.	O

This	O
alternate	O
conformation	O
now	O
causes	O
a	O
steric	O
hindrance	O
to	O
the	O
O4	B-CHEMICAL
hydroxyl	I-CHEMICAL
group	O
of	O
the	O
Gal	B-CHEMICAL
moiety	O
of	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Gal	I-CHEMICAL
,	O
probably	O
causing	O
the	O
dissociation	O
of	O
UDP	B-CHEMICAL
-	I-CHEMICAL
Gal	I-CHEMICAL
and	O
the	O
reduced	O
k	O
(	O
cat	O
)	O
of	O
the	O
Gal	B-GENE-N
-	I-GENE-N
T	I-GENE-N
reaction	O
.	O

Apolipoprotein	B-GENE-Y
E3	I-GENE-Y
(	O
apoE3	B-GENE-Y
)	O
safeguards	O
pig	O
proximal	O
tubular	O
LLC	O
-	O
PK1	O
cells	O
against	O
reduction	O
in	O
SGLT1	B-GENE-Y
activity	O
induced	O
by	O
gentamicin	B-CHEMICAL
C	I-CHEMICAL
.	O

Megalin	O
,	O
a	O
family	O
of	O
endocytic	B-GENE-N
receptors	I-GENE-N
related	O
to	O
the	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
(	I-GENE-N
LDL	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
,	O
is	O
a	O
major	O
pathway	O
for	O
proximal	O
tubular	O
aminoglycoside	B-CHEMICAL
accumulation	O
.	O

We	O
previously	O
reported	O
that	O
aminoglycoside	B-CHEMICAL
antibiotics	O
reduce	O
SGLT1	B-GENE-Y
-	O
dependent	O
glucose	B-CHEMICAL
transport	O
in	O
pig	O
proximal	O
tubular	O
epithelial	O
LLC	O
-	O
PK1	O
cells	O
in	O
parallel	O
with	O
the	O
order	O
of	O
their	O
nephrotoxicity	O
.	O

In	O
this	O
study	O
,	O
using	O
a	O
model	O
of	O
gentamicin	B-CHEMICAL
C	I-CHEMICAL
(	O
GMC	B-CHEMICAL
)	O
-	O
induced	O
reduction	O
in	O
SGLT1	B-GENE-Y
activity	O
,	O
we	O
examined	O
whether	O
ligands	O
for	O
megalin	O
protect	O
LLC	O
-	O
PK1	O
cells	O
from	O
the	O
GMC	B-CHEMICAL
-	O
induced	O
reduction	O
in	O
SGLT1	B-GENE-Y
activity	O
.	O

We	O
employed	O
apolipoprotein	B-GENE-Y
E3	I-GENE-Y
(	O
apoE3	B-GENE-Y
)	O
and	O
lactoferrin	B-GENE-Y
as	O
ligands	O
for	O
megalin	O
.	O

Then	O
the	O
cells	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
apoE3	B-GENE-Y
,	O
lactoferrin	B-GENE-Y
and	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
with	O
or	O
without	O
100	O
microg	O
/	O
ml	O
of	O
GMC	B-CHEMICAL
,	O
and	O
the	O
SGLT1	B-GENE-Y
-	O
dependent	O
methyl	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
glucopyranoside	I-CHEMICAL
(	O
AMG	B-CHEMICAL
)	O
uptake	O
and	O
levels	O
of	O
SGLT1	B-GENE-Y
expression	O
were	O
determined	O
.	O

As	O
a	O
result	O
,	O
we	O
demonstrated	O
that	O
the	O
apoE3	B-GENE-Y
significantly	O
protects	O
these	O
cells	O
from	O
GMC	B-CHEMICAL
-	O
induced	O
reduction	O
in	O
AMG	B-CHEMICAL
uptake	O
,	O
but	O
neither	O
lactoferrin	B-GENE-Y
nor	O
albumin	B-GENE-Y
does	O
.	O

In	O
accord	O
with	O
a	O
rise	O
in	O
AMG	B-CHEMICAL
uptake	O
activity	O
,	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
SGLT1	B-GENE-Y
were	O
apparently	O
up	O
-	O
regulated	O
in	O
the	O
presence	O
of	O
apoE3	B-GENE-Y
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
uptake	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
gentamicin	I-CHEMICAL
is	O
decreased	O
by	O
apoE3	B-GENE-Y
,	O
and	O
that	O
apoE3	B-GENE-Y
showed	O
obvious	O
protection	O
against	O
the	O
GMC	B-CHEMICAL
-	O
dependent	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
glucosamidase	I-CHEMICAL
(	O
NAG	B-CHEMICAL
)	O
release	O
from	O
LLC	O
-	O
PK1	O
cells	O
.	O

Thus	O
,	O
these	O
results	O
indicate	O
that	O
apoE3	B-GENE-Y
could	O
be	O
a	O
valuable	O
tool	O
for	O
the	O
prevention	O
of	O
aminoglycoside	B-CHEMICAL
nephrotoxicity	O
.	O

Cellular	O
and	O
pharmacogenetics	O
foundation	O
of	O
synergistic	O
interaction	O
of	O
pemetrexed	B-CHEMICAL
and	O
gemcitabine	B-CHEMICAL
in	O
human	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
cells	O
.	O

Gemcitabine	B-CHEMICAL
and	O
pemetrexed	B-CHEMICAL
are	O
effective	O
agents	O
in	O
the	O
treatment	O
of	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
,	O
and	O
the	O
present	O
study	O
investigates	O
cellular	O
and	O
genetic	O
aspects	O
of	O
their	O
interaction	O
against	O
A549	O
,	O
Calu	O
-	O
1	O
,	O
and	O
Calu	O
-	O
6	O
cells	O
.	O

Cells	O
were	O
treated	O
with	O
pemetrexed	B-CHEMICAL
and	O
gemcitabine	B-CHEMICAL
,	O
and	O
their	O
interaction	O
was	O
assessed	O
using	O
the	O
combination	O
index	O
.	O

The	O
role	O
of	O
drug	O
metabolism	O
in	O
gemcitabine	B-CHEMICAL
cytotoxicity	O
was	O
examined	O
with	O
inhibitors	O
of	O
deoxycytidine	B-GENE-Y
kinase	I-GENE-Y
(	O
dCK	B-GENE-Y
)	O
,	O
5	B-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
nucleotidase	I-GENE-Y
,	O
and	O
cytidine	B-GENE-Y
deaminase	I-GENE-Y
,	O
whereas	O
the	O
role	O
of	O
pemetrexed	O
targets	O
,	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
(	O
TS	B-GENE-Y
)	O
,	O
dihydrofolate	B-GENE-Y
reductase	I-GENE-Y
(	O
DHFR	B-GENE-Y
)	O
,	O
and	O
glycinamide	B-GENE-Y
ribonucleotide	I-GENE-Y
formyltransferase	I-GENE-Y
(	O
GARFT	B-GENE-Y
)	O
in	O
drug	O
chemosensitivity	O
was	O
analyzed	O
in	O
cytotoxicity	O
rescue	O
studies	O
.	O

The	O
effect	O
of	O
gemcitabine	B-CHEMICAL
and	O
pemetrexed	O
on	O
Akt	B-GENE-N
phosphorylation	O
was	O
investigated	O
with	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
whereas	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
was	O
used	O
to	O
study	O
target	O
gene	O
-	O
expression	O
profiles	O
and	O
its	O
modulation	O
by	O
each	O
drug	O
.	O

Synergistic	O
cytotoxicity	O
was	O
demonstrated	O
,	O
and	O
pemetrexed	B-CHEMICAL
significantly	O
decreased	O
the	O
amount	O
of	O
phosphorylated	B-GENE-N
Akt	I-GENE-N
,	O
enhanced	O
apoptosis	O
,	O
and	O
increased	O
the	O
expression	O
of	O
dCK	B-GENE-Y
in	O
A549	O
and	O
Calu	O
-	O
6	O
cells	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
human	B-GENE-Y
nucleoside	I-GENE-Y
equilibrative	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
hENT1	B-GENE-Y
)	O
in	O
all	O
cell	O
lines	O
.	O

PCR	O
demonstrated	O
a	O
correlation	O
between	O
dCK	B-GENE-Y
expression	O
and	O
gemcitabine	B-CHEMICAL
sensitivity	O
,	O
whereas	O
expression	O
of	O
TS	B-GENE-Y
,	O
DHFR	B-GENE-Y
,	O
and	O
GARFT	B-GENE-Y
was	O
predictive	O
of	O
pemetrexed	B-CHEMICAL
chemosensitivity	O
.	O

These	O
data	O
demonstrated	O
that	O
1	O
)	O
gemcitabine	B-CHEMICAL
and	O
pemetrexed	B-CHEMICAL
synergistically	O
interact	O
against	O
NSCLC	O
cells	O
through	O
the	O
suppression	O
of	O
Akt	B-GENE-N
phosphorylation	O
and	O
induction	O
of	O
apoptosis	O
;	O
2	O
)	O
the	O
gene	O
expression	O
profile	O
of	O
critical	O
genes	O
may	O
predict	O
for	O
drug	O
chemosensitivity	O
;	O
and	O
3	O
)	O
pemetrexed	B-CHEMICAL
enhances	O
dCK	B-GENE-Y
and	O
hENT1	B-GENE-Y
expression	O
,	O
thus	O
suggesting	O
the	O
role	O
of	O
gene	O
-	O
expression	O
modulation	O
for	O
rational	O
development	O
of	O
chemotherapy	O
combinations	O
.	O

Genetic	O
predictors	O
of	O
the	O
maximum	O
doses	O
patients	O
receive	O
during	O
clinical	O
use	O
of	O
the	O
anti	O
-	O
epileptic	O
drugs	O
carbamazepine	B-CHEMICAL
and	O
phenytoin	B-CHEMICAL
.	O

Phenytoin	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
are	O
effective	O
and	O
inexpensive	O
anti	O
-	O
epileptic	O
drugs	O
(	O
AEDs	O
)	O
.	O

As	O
with	O
many	O
AEDs	O
,	O
a	O
broad	O
range	O
of	O
doses	O
is	O
used	O
,	O
with	O
the	O
final	O
"	O
maintenance	O
"	O
dose	O
normally	O
determined	O
by	O
trial	O
and	O
error	O
.	O

Although	O
many	O
genes	O
could	O
influence	O
response	O
to	O
these	O
medicines	O
,	O
there	O
are	O
obvious	O
candidates	O
.	O

Both	O
drugs	O
target	O
the	O
alpha	B-GENE-N
-	I-GENE-N
subunit	I-GENE-N
of	I-GENE-N
the	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
,	O
encoded	O
by	O
the	O
SCN	B-GENE-N
family	O
of	O
genes	O
.	O

Phenytoin	B-CHEMICAL
is	O
principally	O
metabolized	O
by	O
CYP2C9	B-GENE-Y
,	O
and	O
both	O
are	O
probable	O
substrates	O
of	O
the	O
drug	B-GENE-N
transporter	I-GENE-N
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
.	O

We	O
therefore	O
assessed	O
whether	O
variation	O
in	O
these	O
genes	O
associates	O
with	O
the	O
clinical	O
use	O
of	O
carbamazepine	B-CHEMICAL
and	O
phenytoin	B-CHEMICAL
in	O
cohorts	O
of	O
425	O
and	O
281	O
patients	O
,	O
respectively	O
.	O

We	O
report	O
that	O
a	O
known	O
functional	O
polymorphism	O
in	O
CYP2C9	B-GENE-Y
is	O
highly	O
associated	O
with	O
the	O
maximum	O
dose	O
of	O
phenytoin	B-CHEMICAL
(	O
P	O
=	O
0	O
.	O
0066	O
)	O
.	O

We	O
also	O
show	O
that	O
an	O
intronic	O
polymorphism	O
in	O
the	O
SCN1A	B-GENE-Y
gene	O
shows	O
significant	O
association	O
with	O
maximum	O
doses	O
in	O
regular	O
usage	O
of	O
both	O
carbamazepine	B-CHEMICAL
and	O
phenytoin	B-CHEMICAL
(	O
P	O
=	O
0	O
.	O
0051	O
and	O
P	O
=	O
0	O
.	O
014	O
,	O
respectively	O
)	O
.	O

This	O
polymorphism	O
disrupts	O
the	O
consensus	O
sequence	O
of	O
the	O
5	O
'	O
splice	O
donor	O
site	O
of	O
a	O
highly	O
conserved	O
alternative	O
exon	O
(	O
5N	O
)	O
,	O
and	O
it	O
significantly	O
affects	O
the	O
proportions	O
of	O
the	O
alternative	O
transcripts	O
in	O
individuals	O
with	O
a	O
history	O
of	O
epilepsy	O
.	O

These	O
results	O
provide	O
evidence	O
of	O
a	O
drug	O
target	O
polymorphism	O
associated	O
with	O
the	O
clinical	O
use	O
of	O
AEDs	O
and	O
set	O
the	O
stage	O
for	O
a	O
prospective	O
evaluation	O
of	O
how	O
pharmacogenetic	O
diagnostics	O
can	O
be	O
used	O
to	O
improve	O
dosing	O
decisions	O
in	O
the	O
use	O
of	O
phenytoin	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
.	O

Although	O
the	O
case	O
made	O
here	O
is	O
compelling	O
,	O
our	O
results	O
cannot	O
be	O
considered	O
definitive	O
or	O
ready	O
for	O
clinical	O
application	O
until	O
they	O
are	O
confirmed	O
by	O
independent	O
replication	O
.	O

Antimyeloma	O
effects	O
of	O
a	O
novel	O
synthetic	O
retinoid	B-CHEMICAL
Am80	B-CHEMICAL
(	O
Tamibarotene	B-CHEMICAL
)	O
through	O
inhibition	O
of	O
angiogenesis	O
.	O

In	O
multiple	O
myeloma	O
(	O
MM	O
)	O
,	O
the	O
interaction	O
between	O
myeloma	O
cells	O
and	O
bone	O
marrow	O
microenvironment	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
MM	O
.	O

We	O
first	O
examined	O
the	O
inducing	O
effect	O
of	O
myeloma	O
cells	O
on	O
migration	O
of	O
human	O
umbilical	O
vein	O
vascular	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

Five	O
myeloma	O
cell	O
lines	O
produced	O
varying	O
amounts	O
of	O
VEGF	B-GENE-Y
,	O
and	O
migration	O
of	O
HUVECs	O
was	O
induced	O
by	O
coculture	O
with	O
myeloma	O
cells	O
.	O

We	O
next	O
examined	O
the	O
inhibitory	O
effect	O
of	O
a	O
novel	O
synthetic	O
retinoid	B-CHEMICAL
Am80	B-CHEMICAL
(	O
Tamibarotene	B-CHEMICAL
)	O
on	O
both	O
myeloma	O
cells	O
and	O
HUVECs	O
.	O

Am80	B-CHEMICAL
is	O
specific	O
for	O
the	O
retinoic	B-GENE-N
-	I-GENE-N
acid	I-GENE-N
receptor	I-GENE-N
-	I-GENE-N
alpha	I-GENE-N
/	I-GENE-N
beta	I-GENE-N
,	O
and	O
has	O
therapeutic	O
effects	O
in	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
resistant	O
acute	O
promyelocytic	O
leukemia	O
.	O

Am80	B-CHEMICAL
slightly	O
inhibited	O
the	O
growth	O
of	O
both	O
myeloma	O
cells	O
and	O
HUVECs	O
,	O
and	O
remarkably	O
inhibited	O
the	O
growth	O
of	O
HUVECs	O
stimulated	O
by	O
VEGF	B-GENE-Y
.	O

Am80	B-CHEMICAL
showed	O
little	O
growth	O
inhibition	O
of	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSCs	O
)	O
,	O
but	O
it	O
markedly	O
inhibited	O
migration	O
of	O
HUVECs	O
by	O
cocultured	O
myeloma	O
cells	O
.	O

Am80	B-CHEMICAL
inhibited	O
VEGF	B-GENE-Y
-	O
induced	O
phosphorylation	O
of	O
VEGF	B-GENE-N
receptor	I-GENE-N
.	O

In	O
addition	O
,	O
VEGF	B-GENE-Y
-	O
induced	O
formation	O
of	O
tube	O
-	O
like	O
structures	O
in	O
vitro	O
and	O
neovascularization	O
in	O
mouse	O
corneas	O
were	O
significantly	O
inhibited	O
by	O
Am80	B-CHEMICAL
.	O

These	O
findings	O
clearly	O
demonstrate	O
that	O
Am80	B-CHEMICAL
is	O
a	O
potential	O
inhibitor	O
of	O
angiogenesis	O
caused	O
by	O
the	O
interaction	O
between	O
vascular	O
endothelial	O
cells	O
and	O
myeloma	O
cells	O
,	O
and	O
might	O
be	O
a	O
useful	O
therapeutic	O
agent	O
against	O
MM	O
.	O

Effects	O
of	O
inhibition	O
of	O
urokinase	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
by	O
amiloride	B-CHEMICAL
in	O
the	O
cornea	O
and	O
tear	O
fluid	O
of	O
eyes	O
irradiated	O
with	O
UVB	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
our	O
hypothesis	O
that	O
amiloride	B-CHEMICAL
,	O
a	O
specific	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
inhibitor	O
,	O
effectively	O
decreases	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
activity	O
in	O
cornea	O
as	O
well	O
as	O
in	O
tear	O
fluid	O
and	O
favourably	O
affects	O
corneal	O
healing	O
.	O

Therefore	O
,	O
comparative	O
histochemical	O
and	O
biochemical	O
studies	O
of	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
and	O
the	O
effects	O
of	O
amiloride	B-CHEMICAL
were	O
performed	O
on	O
rabbit	O
corneas	O
and	O
tear	O
fluid	O
using	O
the	O
sensitive	O
fluorogenic	O
substrate	O
Z	B-CHEMICAL
-	I-CHEMICAL
Gly	I-CHEMICAL
-	I-CHEMICAL
Gly	I-CHEMICAL
-	I-CHEMICAL
Arg	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
trifluoromethylcoumarin	I-CHEMICAL
.	O

Rabbit	O
eyes	O
were	O
repeatedly	O
irradiated	O
with	O
UVB	O
for	O
9	O
days	O
and	O
during	O
the	O
irradiation	O
topically	O
treated	O
with	O
amiloride	B-CHEMICAL
(	O
1	O
mg	O
/	O
ml	O
saline	O
)	O
or	O
placebo	O
(	O
saline	O
)	O
(	O
dropwise	O
,	O
5	O
times	O
daily	O
)	O
.	O

Results	O
show	O
that	O
in	O
placebo	O
-	O
treated	O
eyes	O
,	O
UVB	O
evoked	O
the	O
appearance	O
of	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
activity	O
in	O
cornea	O
and	O
tear	O
fluid	O
in	O
early	O
stages	O
of	O
irradiation	O
,	O
and	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
levels	O
increased	O
during	O
irradiation	O
.	O

Corneal	O
epithelium	O
was	O
gradually	O
lost	O
and	O
remnants	O
of	O
the	O
epithelium	O
as	O
well	O
as	O
keratocytes	O
in	O
the	O
upper	O
part	O
of	O
corneal	O
stroma	O
showed	O
high	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
activity	O
.	O

Finally	O
,	O
corneas	O
lost	O
their	O
epithelium	O
completely	O
.	O

In	O
corneal	O
stroma	O
,	O
numerous	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
-	O
containing	O
inflammatory	O
cells	O
were	O
present	O
.	O

Corneas	O
were	O
vascularized	O
.	O

When	O
amiloride	B-CHEMICAL
was	O
dropped	O
on	O
the	O
eye	O
surface	O
on	O
the	O
first	O
day	O
of	O
irradiation	O
and	O
subsequently	O
daily	O
until	O
the	O
end	O
of	O
the	O
experiment	O
,	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
activity	O
in	O
both	O
cornea	O
and	O
tear	O
fluid	O
was	O
strongly	O
inhibited	O
.	O

Corneas	O
were	O
covered	O
with	O
a	O
continuous	O
epithelium	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

The	O
number	O
of	O
inflammatory	O
cells	O
was	O
significantly	O
decreased	O
.	O

Corneal	O
vascularization	O
was	O
reduced	O
by	O
50	O
%	O
.	O

In	O
conclusion	O
,	O
early	O
application	O
of	O
amiloride	B-CHEMICAL
inhibited	O
u	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
activity	O
in	O
UVB	O
-	O
irradiated	O
corneas	O
as	O
well	O
as	O
in	O
tear	O
fluid	O
and	O
diminished	O
the	O
development	O
of	O
corneal	O
pathology	O
.	O

Structural	O
,	O
kinetic	O
,	O
and	O
thermodynamic	O
analysis	O
of	O
the	O
binding	O
of	O
the	O
40	O
kDa	O
PEG	B-CHEMICAL
-	O
interferon	B-GENE-Y
-	I-GENE-Y
alpha2a	I-GENE-Y
and	O
its	O
individual	O
positional	O
isomers	O
to	O
the	O
extracellular	O
domain	O
of	O
the	O
receptor	O
IFNAR2	B-GENE-Y
.	O

Type	B-GENE-N
-	I-GENE-N
I	I-GENE-N
Interferons	I-GENE-N
exert	O
antiviral	O
and	O
antiproliferative	O
activities	O
through	O
the	O
binding	O
to	O
a	O
common	O
cell	O
surface	O
receptor	O
comprising	O
two	O
subunits	O
,	O
IFNAR1	B-GENE-Y
and	O
IFNAR2	B-GENE-Y
.	O

Human	B-GENE-Y
recombinant	I-GENE-Y
Interferon	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
(	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
)	O
is	O
a	O
potent	O
drug	O
(	O
Roferon	O
-	O
A	O
)	O
used	O
to	O
treat	O
various	O
cancers	O
and	O
viral	O
diseases	O
including	O
Hepatitis	O
B	O
/	O
C	O
infections	O
.	O

To	O
significantly	O
improve	O
the	O
pharmacological	O
properties	O
of	O
the	O
drug	O
,	O
a	O
pegylated	O
form	O
of	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
was	O
developed	O
(	O
PEGASYS	O
)	O
.	O

This	O
40	O
kDa	O
PEG	B-CHEMICAL
-	O
conjugated	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
(	O
(	O
40	O
)	O
PEG	O
-	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
)	O
is	O
obtained	O
by	O
the	O
covalent	O
binding	O
of	O
one	O
40	O
kDa	O
branched	O
PEG	O
-	O
polymer	O
to	O
a	O
lysine	B-CHEMICAL
side	O
-	O
chain	O
of	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
.	O

Here	O
,	O
we	O
report	O
the	O
detailed	O
structural	O
,	O
kinetic	O
,	O
and	O
thermodynamic	O
analysis	O
of	O
the	O
binding	O
to	O
the	O
extracellular	O
domain	O
of	O
the	O
receptor	O
IFNAR2	B-GENE-Y
of	O
(	O
40	O
)	O
PEG	O
-	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
and	O
its	O
isolated	O
positional	O
isomers	O
modified	O
at	O
K31	O
,	O
K134	O
,	O
K131	O
,	O
K121	O
,	O
K164	O
,	O
and	O
K70	O
,	O
respectively	O
,	O
in	O
comparison	O
with	O
unmodified	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
.	O

Our	O
binding	O
studies	O
,	O
using	O
the	O
surface	O
plasmon	O
resonance	O
technique	O
,	O
show	O
that	O
the	O
pegylation	O
does	O
not	O
abolish	O
the	O
binding	O
to	O
the	O
receptor	O
,	O
but	O
significantly	O
reduces	O
the	O
affinity	O
mainly	O
due	O
to	O
a	O
change	O
of	O
the	O
association	O
rate	O
.	O

The	O
results	O
are	O
supported	O
by	O
modeling	O
and	O
simulation	O
of	O
the	O
binding	O
,	O
using	O
Self	O
-	O
Avoiding	O
-	O
Walk	O
calculations	O
for	O
the	O
polymer	O
conformations	O
.	O

A	O
correlation	O
between	O
the	O
structural	O
parameters	O
and	O
the	O
kinetic	O
and	O
thermodynamic	O
parameters	O
of	O
the	O
binding	O
of	O
the	O
positional	O
isomers	O
could	O
be	O
established	O
.	O

For	O
the	O
Isomer	O
-	O
K31	O
and	O
-	O
K164	O
,	O
the	O
PEG	O
-	O
polymer	O
attachment	O
point	O
is	O
located	O
in	O
proximity	O
to	O
the	O
binding	O
interface	O
,	O
and	O
the	O
isomers	O
display	O
affinity	O
in	O
the	O
range	O
150	O
-	O
520	O
nM	O
in	O
an	O
enthalpy	O
-	O
driven	O
binding	O
process	O
.	O

In	O
contrast	O
for	O
the	O
Isomer	O
-	O
K134	O
,	O
-	O
K131	O
,	O
-	O
K121	O
,	O
and	O
-	O
K70	O
,	O
the	O
PEG	B-CHEMICAL
-	O
polymer	O
is	O
attached	O
remotely	O
from	O
the	O
binding	O
interface	O
,	O
and	O
the	O
isomers	O
exhibit	O
a	O
higher	O
affinity	O
(	O
32	O
-	O
76	O
nM	O
)	O
in	O
an	O
entropy	O
-	O
driven	O
binding	O
process	O
.	O

This	O
study	O
constitutes	O
an	O
essential	O
collection	O
of	O
knowledge	O
on	O
which	O
the	O
interaction	O
of	O
(	O
40	O
)	O
PEG	O
-	O
IFNalpha	B-GENE-Y
(	I-GENE-Y
2a	I-GENE-Y
)	I-GENE-Y
and	O
its	O
positional	O
isomers	O
with	O
its	O
cellular	O
receptors	O
can	O
be	O
better	O
understood	O
.	O

Beta1	B-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
enhancement	O
of	O
hippocampal	O
CA3	O
network	O
activity	O
.	O

Norepinephrine	B-CHEMICAL
is	O
an	O
endogenous	O
neurotransmitter	O
distributed	O
throughout	O
the	O
mammalian	O
brain	O
.	O

In	O
higher	O
cortical	O
structures	O
such	O
as	O
the	O
hippocampus	O
,	O
norepinephrine	B-CHEMICAL
,	O
via	O
beta	B-GENE-N
adrenergic	I-GENE-N
receptor	I-GENE-N
(	O
AR	B-GENE-N
)	O
activation	O
,	O
has	O
been	O
shown	O
to	O
reinforce	O
the	O
cognitive	O
processes	O
of	O
attention	O
and	O
memory	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
beta1AR	B-GENE-Y
activation	O
on	O
hippocampal	O
cornu	O
ammonis	O
3	O
(	O
CA3	O
)	O
network	O
activity	O
.	O

AR	B-GENE-N
expression	O
was	O
first	O
determined	O
using	O
immunocytochemistry	O
with	O
antibodies	O
against	O
beta1ARs	B-GENE-Y
,	O
which	O
were	O
found	O
to	O
be	O
exceptionally	O
dense	O
in	O
hippocampal	O
CA3	O
pyramidal	O
neurons	O
.	O

CA3	O
network	O
activity	O
was	O
then	O
examined	O
in	O
vitro	O
using	O
field	O
potential	O
recordings	O
in	O
rat	O
brain	O
slices	O
.	O

The	O
selective	O
betaAR	B-GENE-N
agonist	O
isoproterenol	B-CHEMICAL
caused	O
an	O
enhancement	O
of	O
hippocampal	O
CA3	O
network	O
activity	O
,	O
as	O
measured	O
by	O
an	O
increase	O
in	O
frequency	O
of	O
spontaneous	O
burst	O
discharges	O
recorded	O
in	O
the	O
CA3	O
region	O
.	O

In	O
the	O
presence	O
of	O
alphaAR	B-GENE-N
blockade	O
,	O
concentration	O
-	O
response	O
curves	O
for	O
isoproterenol	B-CHEMICAL
,	O
norepinephrine	B-CHEMICAL
,	O
and	O
epinephrine	B-CHEMICAL
suggested	O
that	O
a	O
beta1AR	B-GENE-Y
was	O
involved	O
in	O
this	O
response	O
,	O
and	O
the	O
rank	O
order	O
of	O
potency	O
was	O
isoproterenol	B-CHEMICAL
>	O
norepinephrine	B-CHEMICAL
=	O
epinephrine	B-CHEMICAL
.	O

Finally	O
,	O
equilibrium	O
dissociation	O
constants	O
(	O
pK	O
(	O
b	O
)	O
)	O
of	O
subtype	O
-	O
selective	O
betaAR	B-GENE-N
antagonists	O
were	O
functionally	O
determined	O
to	O
characterize	O
the	O
AR	B-GENE-N
subtype	O
modulating	O
hippocampal	O
CA3	O
activity	O
.	O

The	O
selective	O
beta1AR	B-GENE-Y
antagonists	O
atenolol	B-CHEMICAL
and	O
metoprolol	B-CHEMICAL
blocked	O
isoproterenol	B-CHEMICAL
-	O
induced	O
enhancement	O
,	O
with	O
apparent	O
K	O
(	O
b	O
)	O
values	O
of	O
85	O
+	O
/	O
-	O
36	O
and	O
3	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
7	O
nM	O
,	O
respectively	O
.	O

In	O
contrast	O
,	O
the	O
selective	O
beta2AR	B-GENE-Y
antagonists	O
ICI	B-CHEMICAL
-	I-CHEMICAL
118	I-CHEMICAL
,	I-CHEMICAL
551	I-CHEMICAL
and	O
butoxamine	B-CHEMICAL
inhibited	O
isoproterenol	B-CHEMICAL
-	O
mediated	O
enhancement	O
with	O
apparent	O
low	O
affinities	O
(	O
K	O
(	O
b	O
)	O
of	O
222	O
+	O
/	O
-	O
61	O
and	O
9268	O
+	O
/	O
-	O
512	O
nM	O
,	O
respectively	O
)	O
.	O

Together	O
,	O
this	O
pharmacological	O
profile	O
of	O
subtype	O
-	O
selective	O
betaAR	B-GENE-N
antagonists	O
indicates	O
that	O
in	O
this	O
model	O
,	O
beta1AR	B-GENE-Y
activation	O
is	O
responsible	O
for	O
the	O
enhanced	O
hippocampal	O
CA3	O
network	O
activity	O
initiated	O
by	O
isoproterenol	B-CHEMICAL
.	O

[	O
Disorders	O
with	O
eosinophilia	O
,	O
treatment	O
of	O
hypereosinophilic	O
syndrome	O
]	O
.	O

Eosinophilia	O
may	O
be	O
associated	O
with	O
reactive	O
conditions	O
and	O
with	O
clonal	O
disorders	O
of	O
the	O
hematopoietic	O
cells	O
.	O

The	O
hypereosinophilic	O
syndrome	O
takes	O
an	O
intermedier	O
place	O
in	O
this	O
group	O
.	O

In	O
this	O
disease	O
a	O
sustained	O
eosinophilia	O
with	O
end	O
organ	O
damage	O
can	O
occur	O
.	O

The	O
author	O
summarized	O
the	O
diagnostic	O
procedures	O
and	O
differential	O
diagnosis	O
in	O
the	O
group	O
of	O
these	O
diseases	O
focusing	O
on	O
characteristics	O
and	O
treatment	O
of	O
hypereosinophilic	O
syndrome	O
.	O

The	O
treatment	O
has	O
been	O
varied	O
and	O
included	O
steroids	B-CHEMICAL
,	O
hydroxyurea	B-CHEMICAL
,	O
interferon	B-GENE-N
-	I-GENE-N
alpha	I-GENE-N
,	O
and	O
in	O
some	O
cases	O
chemotherapy	O
.	O

On	O
the	O
basis	O
of	O
FIP1L1	B-GENE-Y
-	O
PDGFRa	B-GENE-Y
fusion	O
gene	O
hypereosinophilic	O
syndrome	O
would	O
be	O
classified	O
as	O
a	O
clonal	O
disease	O
and	O
in	O
the	O
FIP1L1	B-GENE-Y
-	O
PDGFRa	B-GENE-Y
positive	O
cases	O
the	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
imatinib	B-CHEMICAL
mesylate	I-CHEMICAL
(	O
Glivec	O
)	O
would	O
be	O
effective	O
.	O

Use	O
of	O
nitisinone	B-CHEMICAL
in	O
patients	O
with	O
alkaptonuria	O
.	O

Alkaptonuria	O
,	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
HGD	B-GENE-Y
gene	O
and	O
deficiency	O
of	O
homogentisate	B-GENE-Y
1	I-GENE-Y
,	I-GENE-Y
2	I-GENE-Y
dioxygenase	I-GENE-Y
,	O
is	O
characterized	O
by	O
ochronosis	O
,	O
arthritis	O
,	O
and	O
daily	O
excretion	O
of	O
gram	O
quantities	O
of	O
homogentisic	B-CHEMICAL
acid	I-CHEMICAL
(	O
HGA	B-CHEMICAL
)	O
.	O

Nitisinone	O
,	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
4	B-GENE-Y
-	I-GENE-Y
hydroxyphenylpyruvate	I-GENE-Y
dioxygenase	I-GENE-Y
,	O
can	O
drastically	O
reduce	O
urinary	O
excretion	O
of	O
HGA	B-CHEMICAL
in	O
individuals	O
with	O
alkaptonuria	O
.	O

We	O
investigated	O
the	O
safety	O
and	O
the	O
HGA	B-CHEMICAL
-	O
depleting	O
efficacy	O
of	O
nitisinone	B-CHEMICAL
in	O
an	O
open	O
-	O
label	O
,	O
single	O
-	O
center	O
study	O
of	O
9	O
alkaptonuria	O
patients	O
(	O
5	O
women	O
,	O
4	O
men	O
;	O
35	O
-	O
69	O
years	O
of	O
age	O
)	O
over	O
the	O
course	O
of	O
3	O
to	O
4	O
months	O
.	O

Each	O
patient	O
received	O
nitisinone	B-CHEMICAL
in	O
incremental	O
doses	O
,	O
0	O
.	O
35	O
mg	O
bid	O
followed	O
by	O
1	O
.	O
05	O
mg	O
bid	O
,	O
and	O
remained	O
on	O
this	O
dosage	O
and	O
a	O
regular	O
diet	O
for	O
3	O
months	O
.	O

Nitisinone	B-CHEMICAL
reduced	O
urinary	O
HGA	B-CHEMICAL
levels	O
from	O
an	O
average	O
of	O
4	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
8	O
(	O
SD	O
)	O
g	O
/	O
day	O
to	O
0	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
2	O
g	O
/	O
day	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

The	O
average	O
plasma	O
tyrosine	B-CHEMICAL
concentration	O
,	O
initially	O
68	O
+	O
/	O
-	O
18	O
mmicro	O
mol	O
/	O
L	O
,	O
rose	O
to	O
760	O
+	O
/	O
-	O
181	O
micro	O
mol	O
/	O
L	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

During	O
the	O
final	O
week	O
of	O
the	O
study	O
,	O
5	O
patients	O
adhered	O
to	O
a	O
protein	O
-	O
restricted	O
diet	O
(	O
40	O
g	O
/	O
day	O
)	O
,	O
and	O
their	O
mean	O
plasma	O
tyrosine	B-CHEMICAL
level	O
fell	O
from	O
755	O
+	O
/	O
-	O
167	O
to	O
603	O
+	O
/	O
-	O
114	O
mu	O
mol	O
/	O
L	O
.	O

Six	O
of	O
the	O
7	O
patients	O
who	O
received	O
nitisinone	B-CHEMICAL
for	O
more	O
than	O
1	O
week	O
reported	O
decreased	O
pain	O
in	O
their	O
affected	O
joints	O
.	O

Weekly	O
ophthalmologic	O
examinations	O
showed	O
no	O
signs	O
of	O
corneal	O
toxicity	O
.	O

Adverse	O
events	O
included	O
the	O
passing	O
of	O
kidney	O
stones	O
,	O
the	O
recognition	O
of	O
symptoms	O
related	O
to	O
aortic	O
stenosis	O
,	O
and	O
elevation	O
of	O
liver	O
transaminase	B-GENE-N
levels	O
.	O

We	O
conclude	O
that	O
low	O
-	O
dose	O
nitisinone	B-CHEMICAL
effectively	O
reduced	O
urinary	O
HGA	B-CHEMICAL
levels	O
in	O
patients	O
with	O
alkaptonuria	O
.	O

Future	O
long	O
-	O
term	O
clinical	O
trials	O
are	O
planned	O
to	O
determine	O
the	O
benefits	O
of	O
nitisinone	B-CHEMICAL
in	O
preventing	O
joint	O
deterioration	O
and	O
providing	O
pain	O
relief	O
,	O
and	O
its	O
long	O
-	O
term	O
side	O
effects	O
.	O

Diethylcarbamazine	B-CHEMICAL
activity	O
against	O
Brugia	O
malayi	O
microfilariae	O
is	O
dependent	O
on	O
inducible	B-GENE-Y
nitric	I-GENE-Y
-	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
and	O
the	O
cyclooxygenase	B-GENE-N
pathway	O
.	O

BACKGROUND	O
:	O
Diethylcarbamazine	B-CHEMICAL
(	O
DEC	B-CHEMICAL
)	O
has	O
been	O
used	O
for	O
many	O
years	O
in	O
the	O
treatment	O
of	O
human	O
lymphatic	O
filariasis	O
.	O

Its	O
mode	O
of	O
action	O
is	O
not	O
well	O
understood	O
,	O
but	O
it	O
is	O
known	O
to	O
interact	O
with	O
the	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
pathway	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
contribution	O
of	O
the	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
and	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
pathways	O
to	O
the	O
activity	O
of	O
DEC	B-CHEMICAL
against	O
B	O
.	O
malayi	O
microfilariae	O
in	O
mice	O
.	O

METHODS	O
:	O
B	O
.	O
malayi	O
microfilariae	O
were	O
injected	O
intravenously	O
into	O
mice	O
and	O
parasitaemia	O
was	O
measured	O
24	O
hours	O
later	O
.	O

DEC	B-CHEMICAL
was	O
then	O
administered	O
to	O
BALB	O
/	O
c	O
mice	O
with	O
and	O
without	O
pre	O
-	O
treatment	O
with	O
indomethacin	B-CHEMICAL
or	O
dexamethasone	B-CHEMICAL
and	O
the	O
parasitaemia	O
monitored	O
.	O

To	O
investigate	O
a	O
role	O
for	O
inducible	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
in	O
DEC	O
'	O
s	O
activity	O
,	O
DEC	B-CHEMICAL
and	O
ivermectin	B-CHEMICAL
were	O
administered	O
to	O
microfilaraemic	O
iNOS	B-GENE-Y
-	O
/	O
-	O
mice	O
and	O
their	O
background	O
strain	O
(	O
129	O
/	O
SV	O
)	O
.	O

Western	O
blot	O
analysis	O
was	O
used	O
to	O
determine	O
any	O
effect	O
of	O
DEC	B-CHEMICAL
on	O
the	O
production	O
of	O
COX	B-GENE-N
and	O
inducible	O
nitric	B-GENE-Y
-	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
proteins	O
.	O

RESULTS	O
:	O
DEC	O
administered	O
alone	O
to	O
BALB	O
/	O
c	O
mice	O
resulted	O
in	O
a	O
rapid	O
and	O
profound	O
reduction	O
in	O
circulating	O
microfilariae	O
within	O
five	O
minutes	O
of	O
treatment	O
.	O

Microfilarial	O
levels	O
began	O
to	O
recover	O
after	O
24	O
hours	O
and	O
returned	O
to	O
near	O
pre	O
-	O
treatment	O
levels	O
two	O
weeks	O
later	O
,	O
suggesting	O
that	O
the	O
sequestration	O
of	O
microfilariae	O
occurs	O
independently	O
of	O
parasite	O
killing	O
.	O

Pre	O
-	O
treatment	O
of	O
animals	O
with	O
dexamethasone	B-CHEMICAL
or	O
indomethacin	B-CHEMICAL
reduced	O
DEC	O
'	O
s	O
efficacy	O
by	O
almost	O
90	O
%	O
or	O
56	O
%	O
,	O
respectively	O
,	O
supporting	O
a	O
role	O
for	O
the	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
and	O
cyclooxygenase	B-GENE-N
pathways	O
in	O
vivo	O
.	O

Furthermore	O
,	O
experiments	O
showed	O
that	O
treatment	O
with	O
DEC	B-CHEMICAL
results	O
in	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
protein	O
in	O
peritoneal	O
exudate	O
cells	O
.	O

Additionally	O
,	O
in	O
iNOS	B-GENE-Y
-	O
/	O
-	O
mice	O
infected	O
with	O
B	O
.	O
malayi	O
microfilariae	O
,	O
DEC	B-CHEMICAL
showed	O
no	O
activity	O
,	O
whereas	O
the	O
efficacy	O
of	O
another	O
antifilarial	O
drug	O
,	O
ivermectin	B-CHEMICAL
,	O
was	O
unaffected	O
.	O

CONCLUSION	O
:	O
These	O
results	O
confirm	O
the	O
important	O
role	O
of	O
the	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
metabolic	O
pathway	O
in	O
DEC	O
'	O
s	O
mechanism	O
of	O
action	O
in	O
vivo	O
and	O
show	O
that	O
in	O
addition	O
to	O
its	O
effects	O
on	O
the	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
pathway	O
,	O
it	O
targets	O
the	O
cyclooxygenase	B-GENE-N
pathway	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Moreover	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
inducible	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
is	O
essential	O
for	O
the	O
rapid	O
sequestration	O
of	O
microfilariae	O
by	O
DEC	B-CHEMICAL
.	O

Verapamil	B-CHEMICAL
prevents	O
torsade	O
de	O
pointes	O
by	O
reduction	O
of	O
transmural	O
dispersion	O
of	O
repolarization	O
and	O
suppression	O
of	O
early	O
afterdepolarizations	O
in	O
an	O
intact	O
heart	O
model	O
of	O
LQT3	O
.	O

BACKGROUND	O
:	O
In	O
long	O
QT	O
syndrome	O
(	O
LQTS	O
)	O
,	O
prolongation	O
of	O
the	O
QT	O
-	O
interval	O
is	O
associated	O
with	O
sudden	O
cardiac	O
death	O
resulting	O
from	O
potentially	O
life	O
-	O
threatening	O
polymorphic	O
tachycardia	O
of	O
the	O
torsade	O
de	O
pointes	O
(	O
TdP	O
)	O
type	O
.	O

Experimental	O
as	O
well	O
as	O
clinical	O
reports	O
support	O
the	O
hypothesis	O
that	O
calcium	B-GENE-N
channel	I-GENE-N
blockers	O
such	O
as	O
verapamil	B-CHEMICAL
may	O
be	O
an	O
appropriate	O
therapeutic	O
approach	O
in	O
LQTS	O
.	O

We	O
investigated	O
the	O
electrophysiologic	O
mechanism	O
by	O
which	O
verapamil	O
suppresses	O
TdP	O
,	O
in	O
a	O
recently	O
developed	O
intact	O
heart	O
model	O
of	O
LQT3	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
In	O
8	O
Langendorff	O
-	O
perfused	O
rabbit	O
hearts	O
,	O
veratridine	B-CHEMICAL
(	O
0	O
.	O
1	O
microM	O
)	O
,	O
an	O
inhibitor	O
of	O
sodium	B-GENE-N
channel	I-GENE-N
inactivation	O
,	O
led	O
to	O
a	O
marked	O
increase	O
in	O
QT	O
-	O
interval	O
and	O
simultaneously	O
recorded	O
monophasic	O
ventricular	O
action	O
potentials	O
(	O
MAPs	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
thereby	O
mimicking	O
LQT3	O
.	O

In	O
bradycardic	O
(	O
AV	O
-	O
blocked	O
)	O
hearts	O
,	O
simultaneous	O
recording	O
of	O
up	O
to	O
eight	O
epi	O
-	O
and	O
endocardial	O
MAPs	O
demonstrated	O
a	O
significant	O
increase	O
in	O
total	O
dispersion	O
of	O
repolarization	O
(	O
56	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
reverse	O
frequency	O
-	O
dependence	O
.	O

After	O
lowering	O
potassium	B-CHEMICAL
concentration	O
,	O
veratridine	B-CHEMICAL
reproducibly	O
led	O
to	O
early	O
afterdepolarizations	O
(	O
EADs	O
)	O
and	O
TdP	O
in	O
6	O
of	O
8	O
(	O
75	O
%	O
)	O
hearts	O
.	O

Additional	O
infusion	O
of	O
verapamil	B-CHEMICAL
(	O
0	O
.	O
75	O
microM	O
)	O
suppressed	O
EADs	O
and	O
consecutively	O
TdP	O
in	O
all	O
hearts	O
.	O

Verapamil	B-CHEMICAL
significantly	O
shortened	O
endocardial	O
but	O
not	O
epicardial	O
MAPs	O
which	O
resulted	O
in	O
significant	O
reduction	O
of	O
ventricular	O
transmural	O
dispersion	O
of	O
repolarization	O
.	O

CONCLUSIONS	O
:	O
Verapamil	B-CHEMICAL
is	O
highly	O
effective	O
in	O
preventing	O
TdP	O
via	O
shortening	O
of	O
endocardial	O
MAPs	O
,	O
reduction	O
of	O
left	O
ventricular	O
transmural	O
dispersion	O
of	O
repolarization	O
and	O
suppression	O
of	O
EADs	O
in	O
an	O
intact	O
heart	O
model	O
of	O
LQT3	O
.	O

These	O
data	O
suggest	O
a	O
possible	O
therapeutic	O
role	O
of	O
verapamil	B-CHEMICAL
in	O
the	O
treatment	O
of	O
LQT3	O
patients	O
.	O

[	O
Protein	O
profile	O
and	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
in	O
children	O
of	O
school	O
age	O
in	O
Ivory	O
Coast	O
]	O
.	O

The	O
purpose	O
of	O
this	O
transverse	O
prospective	O
study	O
was	O
to	O
determine	O
blood	O
nutritional	O
,	O
immunity	O
and	O
inflammatory	O
proteins	O
change	O
in	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
in	O
children	O
of	O
school	O
-	O
age	O
(	O
262	O
children	O
,	O
aged	O
7	O
to	O
15	O
years	O
)	O
.	O

Blood	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
has	O
been	O
determined	O
by	O
HPLC	O
with	O
UV	O
detection	O
.	O

Proteins	O
have	O
been	O
measured	O
by	O
radial	O
immunodiffusion	O
according	O
to	O
Mancini	O
.	O

Results	O
showed	O
that	O
96	O
children	O
(	O
36	O
.	O
6	O
%	O
)	O
presented	O
a	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
(	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
<	O
200	O
microg	O
/	O
L	O
with	O
a	O
retinol	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
/	O
transthyretin	B-GENE-Y
molar	O
ratio	O
=	O
0	O
.	O
29	O
+	O
/	O
-	O
0	O
.	O
06	O
)	O
while	O
166	O
(	O
63	O
.	O
3	O
%	O
)	O
children	O
presented	O
normal	O
blood	O
concentrations	O
of	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
(	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
>	O
or	O
=	O
200	O
microg	O
/	O
L	O
with	O
a	O
Retinol	B-GENE-N
Binding	I-GENE-N
Protein	I-GENE-N
/	O
Transthyretin	B-GENE-Y
molar	O
ratio	O
=	O
0	O
.	O
40	O
+	O
/	O
-	O
0	O
.	O
08	O
)	O
.	O

This	O
study	O
showed	O
that	O
the	O
retinol	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
and	O
the	O
immunoglobulin	B-GENE-N
A	I-GENE-N
are	O
lower	O
in	O
children	O
with	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
isolated	O
increase	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
glycoprotein	I-GENE-Y
acid	I-GENE-Y
has	O
been	O
observed	O
in	O
boys	O
with	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
.	O

The	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
observed	O
in	O
this	O
survey	O
is	O
due	O
to	O
a	O
micronutrients	O
deficiency	O
in	O
the	O
diet	O
which	O
is	O
essentially	O
based	O
on	O
glucides	O
.	O

The	O
positive	O
correlation	O
between	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
and	O
immunoglobulin	B-GENE-N
A	I-GENE-N
concentrations	O
might	O
be	O
the	O
result	O
of	O
the	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
inductive	O
effect	O
during	O
immunoglobulins	B-GENE-N
A	I-GENE-N
synthesis	O
.	O

The	O
isolated	O
increasing	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
glycoprotein	I-GENE-Y
acid	I-GENE-Y
in	O
boys	O
with	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
has	O
been	O
assigned	O
to	O
the	O
ecosensitiveness	O
of	O
the	O
unfavourable	O
environment	O
.	O

We	O
therefore	O
concluded	O
that	O
,	O
in	O
Ivorian	O
primary	O
-	O
school	O
-	O
aged	O
children	O
with	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
deficiency	O
,	O
nutritional	O
,	O
immunity	O
and	O
inflammatory	O
proteins	O
which	O
are	O
modified	O
are	O
respectively	O
retinol	B-GENE-N
binding	I-GENE-N
protein	I-GENE-N
,	O
immunoglobulin	B-GENE-N
A	I-GENE-N
and	O
alpha	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
glycoprotein	I-GENE-Y
acid	I-GENE-Y
.	O

Monocarboxylate	B-GENE-N
transporters	I-GENE-N
in	O
the	O
central	O
nervous	O
system	O
:	O
distribution	O
,	O
regulation	O
and	O
function	O
.	O

Monocarboxylate	B-GENE-N
transporters	I-GENE-N
(	O
MCTs	B-GENE-N
)	O
are	O
proton	O
-	O
linked	O
membrane	O
carriers	O
involved	O
in	O
the	O
transport	O
of	O
monocarboxylates	B-CHEMICAL
such	O
as	O
lactate	B-CHEMICAL
,	O
pyruvate	B-CHEMICAL
,	O
as	O
well	O
as	O
ketone	B-CHEMICAL
bodies	O
.	O

They	O
belong	O
to	O
a	O
larger	O
family	O
of	O
transporters	O
composed	O
of	O
14	O
members	O
in	O
mammals	O
based	O
on	O
sequence	O
homologies	O
.	O

MCTs	B-GENE-N
are	O
found	O
in	O
various	O
tissues	O
including	O
the	O
brain	O
where	O
three	O
isoforms	O
,	O
MCT1	B-GENE-Y
,	O
MCT2	B-GENE-Y
and	O
MCT4	B-GENE-Y
,	O
have	O
been	O
described	O
.	O

Each	O
of	O
these	O
isoforms	O
exhibits	O
a	O
distinct	O
regional	O
and	O
cellular	O
distribution	O
in	O
rodent	O
brain	O
.	O

At	O
the	O
cellular	O
level	O
,	O
MCT1	B-GENE-Y
is	O
expressed	O
by	O
endothelial	O
cells	O
of	O
microvessels	O
,	O
by	O
ependymocytes	O
as	O
well	O
as	O
by	O
astrocytes	O
.	O

MCT4	B-GENE-Y
expression	O
appears	O
to	O
be	O
specific	O
for	O
astrocytes	O
.	O

By	O
contrast	O
,	O
the	O
predominant	O
neuronal	O
monocarboxylate	B-GENE-N
transporter	I-GENE-N
is	O
MCT2	B-GENE-Y
.	O

Interestingly	O
,	O
part	O
of	O
MCT2	B-GENE-Y
immunoreactivity	O
is	O
located	O
at	O
postsynaptic	O
sites	O
,	O
suggesting	O
a	O
particular	O
role	O
of	O
monocarboxylates	B-CHEMICAL
and	O
their	O
transporters	O
in	O
synaptic	O
transmission	O
.	O

In	O
addition	O
to	O
variation	O
in	O
expression	O
during	O
development	O
and	O
upon	O
nutritional	O
modifications	O
,	O
new	O
data	O
indicate	O
that	O
MCT	B-GENE-N
expression	O
is	O
regulated	O
at	O
the	O
translational	O
level	O
by	O
neurotransmitters	O
.	O

Understanding	O
how	O
transport	O
of	O
monocarboxylates	B-CHEMICAL
is	O
regulated	O
could	O
be	O
of	O
particular	O
importance	O
not	O
only	O
for	O
neuroenergetics	O
but	O
also	O
for	O
areas	O
such	O
as	O
functional	O
brain	O
imaging	O
,	O
regulation	O
of	O
food	O
intake	O
and	O
glucose	B-CHEMICAL
homeostasis	O
,	O
or	O
for	O
central	O
nervous	O
system	O
disorders	O
such	O
as	O
ischaemia	O
and	O
neurodegenerative	O
diseases	O
.	O

The	O
platelet	B-GENE-N
P2	I-GENE-N
receptors	I-GENE-N
as	O
molecular	O
targets	O
for	O
old	O
and	O
new	O
antiplatelet	O
drugs	O
.	O

Platelet	O
activation	O
by	O
ADP	B-CHEMICAL
and	O
ATP	B-CHEMICAL
plays	O
a	O
crucial	O
role	O
in	O
haemostasis	O
and	O
thrombosis	O
,	O
and	O
their	O
so	O
-	O
called	O
P2	B-GENE-N
receptors	I-GENE-N
are	O
potential	O
targets	O
for	O
antithrombotic	O
drugs	O
.	O

The	O
ATP	B-GENE-Y
-	I-GENE-Y
gated	I-GENE-Y
channel	I-GENE-Y
P2X1	I-GENE-Y
and	O
the	O
2	O
G	B-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
coupled	I-GENE-Y
P2Y1	I-GENE-Y
and	O
P2Y12	B-GENE-Y
ADP	B-GENE-N
receptors	I-GENE-N
selectively	O
contribute	O
to	O
platelet	O
aggregation	O
.	O

The	O
P2Y1	B-GENE-Y
receptor	O
is	O
responsible	O
for	O
ADP	B-CHEMICAL
-	O
induced	O
shape	O
change	O
and	O
weak	O
and	O
transient	O
aggregation	O
,	O
while	O
the	O
P2Y12	B-GENE-Y
receptor	O
is	O
responsible	O
for	O
the	O
completion	O
and	O
amplification	O
of	O
the	O
response	O
to	O
ADP	B-CHEMICAL
and	O
to	O
all	O
platelet	O
agonists	O
,	O
including	O
thromboxane	B-CHEMICAL
A2	I-CHEMICAL
(	O
TXA2	B-CHEMICAL
)	O
,	O
thrombin	B-GENE-Y
,	O
and	O
collagen	B-GENE-N
.	O

The	O
P2X1	B-GENE-Y
receptor	O
is	O
involved	O
in	O
platelet	O
shape	O
change	O
and	O
in	O
activation	O
by	O
collagen	B-GENE-N
under	O
shear	O
conditions	O
.	O

Due	O
to	O
its	O
central	O
role	O
in	O
the	O
formation	O
and	O
stabilization	O
of	O
a	O
thrombus	O
,	O
the	O
P2Y12	B-GENE-Y
receptor	O
is	O
a	O
well	O
-	O
established	O
target	O
of	O
antithrombotic	O
drugs	O
like	O
ticlopidine	B-CHEMICAL
or	O
clopidogrel	B-CHEMICAL
,	O
which	O
have	O
proved	O
efficacy	O
in	O
many	O
clinical	O
trials	O
and	O
experimental	O
models	O
of	O
thrombosis	O
.	O

Competitive	O
P2Y12	B-GENE-Y
antagonists	O
have	O
also	O
been	O
shown	O
to	O
be	O
effective	O
in	O
experimental	O
thrombosis	O
as	O
well	O
as	O
in	O
several	O
clinical	O
trials	O
.	O

Studies	O
in	O
P2Y1	B-GENE-Y
and	O
P2X1	B-GENE-Y
knockout	O
mice	O
and	O
experimental	O
thrombosis	O
models	O
using	O
selective	O
P2Y1	B-GENE-Y
and	O
P2X1	B-GENE-Y
antagonists	O
have	O
shown	O
that	O
,	O
depending	O
on	O
the	O
conditions	O
,	O
these	O
receptors	O
could	O
also	O
be	O
potential	O
targets	O
for	O
new	O
antithrombotic	O
drugs	O
.	O

Improving	O
the	O
tolerability	O
of	O
anticholinergic	O
agents	O
in	O
the	O
treatment	O
of	O
overactive	O
bladder	O
.	O

Pharmacological	O
treatment	O
for	O
overactive	O
bladder	O
has	O
centred	O
around	O
the	O
interruption	O
of	O
the	O
detrusor	O
activity	O
that	O
is	O
central	O
to	O
urge	O
and	O
incontinence	O
symptoms	O
.	O

The	O
majority	O
of	O
patients	O
with	O
this	O
disorder	O
are	O
treated	O
with	O
antimuscarinic	O
agents	O
.	O

These	O
drugs	O
have	O
been	O
demonstrated	O
to	O
improve	O
urgency	O
,	O
frequency	O
of	O
micturition	O
and	O
urge	O
incontinence	O
,	O
all	O
of	O
which	O
are	O
primary	O
symptoms	O
of	O
overactive	O
bladder	O
;	O
however	O
,	O
they	O
are	O
also	O
commonly	O
associated	O
with	O
anticholinergic	O
adverse	O
effects	O
,	O
most	O
notably	O
dry	O
mouth	O
.	O

Attempts	O
to	O
increase	O
tolerability	O
have	O
included	O
the	O
development	O
of	O
advanced	O
formulations	O
that	O
regulate	O
release	O
of	O
the	O
active	O
ingredient	O
and	O
the	O
development	O
of	O
pharmacological	O
agents	O
that	O
target	O
the	O
desired	O
bladder	O
receptors	O
more	O
specifically	O
and	O
accurately	O
.	O

Although	O
all	O
agents	O
provide	O
good	O
efficacy	O
,	O
tolerability	O
is	O
greatly	O
affected	O
by	O
the	O
formulation	O
used	O
to	O
deliver	O
the	O
active	O
pharmacological	O
agent	O
,	O
as	O
well	O
as	O
the	O
specificity	O
of	O
the	O
targeted	O
receptors	O
.	O

Clinical	O
trials	O
involving	O
a	O
transdermal	O
formulation	O
of	O
oxybutynin	B-CHEMICAL
have	O
shown	O
that	O
this	O
delivery	O
method	O
may	O
be	O
associated	O
with	O
a	O
lower	O
incidence	O
of	O
anticholinergic	O
adverse	O
events	O
compared	O
with	O
both	O
the	O
immediate	O
-	O
release	O
and	O
the	O
extended	O
-	O
release	O
oral	O
formulations	O
of	O
traditional	O
agents	O
,	O
as	O
well	O
as	O
the	O
most	O
recently	O
approved	O
agents	O
-	O
trospium	B-CHEMICAL
chloride	I-CHEMICAL
,	O
solifenacin	B-CHEMICAL
and	O
darifenacin	B-CHEMICAL
.	O

Much	O
is	O
still	O
being	O
learned	O
about	O
the	O
function	O
and	O
specificity	O
of	O
muscarinic	B-GENE-N
receptors	I-GENE-N
,	O
which	O
will	O
support	O
the	O
development	O
of	O
agents	O
with	O
sustained	O
efficacy	O
and	O
enhanced	O
tolerability	O
compared	O
with	O
the	O
available	O
formulations	O
to	O
date	O
.	O

These	O
include	O
the	O
S	B-CHEMICAL
-	I-CHEMICAL
isomer	I-CHEMICAL
of	I-CHEMICAL
oxybutynin	I-CHEMICAL
,	O
as	O
well	O
as	O
selective	O
muscarinic	B-GENE-Y
M2	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
.	O

Effect	O
of	O
thiazolidinediones	B-CHEMICAL
on	O
equilibrative	B-GENE-Y
nucleoside	I-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
in	O
human	O
aortic	O
smooth	O
muscle	O
cells	O
.	O

Thiazolidinediones	B-CHEMICAL
are	O
a	O
new	O
class	O
of	O
anti	O
-	O
diabetic	O
agents	O
which	O
increase	O
insulin	B-GENE-Y
sensitivity	O
by	O
binding	O
to	O
the	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
PPAR	B-GENE-Y
(	I-GENE-Y
gamma	I-GENE-Y
)	I-GENE-Y
)	O
and	O
stimulating	O
the	O
expression	O
of	O
insulin	B-GENE-Y
-	O
responsive	O
genes	O
involved	O
in	O
glucose	B-CHEMICAL
and	O
lipid	O
metabolism	O
.	O

These	O
drugs	O
also	O
have	O
vasodilatory	O
and	O
anti	O
-	O
proliferative	O
effects	O
on	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

However	O
the	O
mechanisms	O
for	O
these	O
actions	O
are	O
not	O
fully	O
understood	O
.	O

Adenosine	O
is	O
a	O
vasodilator	O
and	O
a	O
substrate	O
of	O
equilibrative	B-GENE-N
nucleoside	I-GENE-N
transporters	I-GENE-N
(	O
ENT	B-GENE-N
)	O
.	O

The	O
present	O
study	O
studied	O
the	O
effects	O
of	O
three	O
thiazolidinediones	B-CHEMICAL
,	O
troglitazone	B-CHEMICAL
,	O
pioglitazone	B-CHEMICAL
and	O
ciglitazone	B-CHEMICAL
,	O
on	O
ENT1	B-GENE-Y
in	O
the	O
human	O
aortic	O
smooth	O
muscle	O
cells	O
(	O
HASMCs	O
)	O
.	O

Although	O
incubating	O
HASMCs	O
for	O
48h	O
with	O
thiazolidinediones	B-CHEMICAL
had	O
no	O
effect	O
on	O
ENT1	B-GENE-Y
mRNA	O
and	O
protein	O
levels	O
,	O
troglitazone	B-CHEMICAL
acutely	O
inhibited	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
adenosine	I-CHEMICAL
uptake	O
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
NBMPR	I-CHEMICAL
binding	O
of	O
HASMCs	O
with	O
IC50	O
values	O
of	O
2	O
.	O
35	O
+	O
/	O
-	O
0	O
.	O
35	O
and	O
3	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
57microM	O
,	O
respectively	O
.	O

The	O
effect	O
of	O
troglitazone	B-CHEMICAL
on	O
ENT1	B-GENE-Y
was	O
PPAR	B-GENE-Y
(	I-GENE-Y
gamma	I-GENE-Y
)	I-GENE-Y
-	O
independent	O
and	O
kinetic	O
studies	O
revealed	O
that	O
troglitazone	B-CHEMICAL
was	O
a	O
competitive	O
inhibitor	O
of	O
ENT1	B-GENE-Y
.	O

In	O
contrast	O
,	O
pioglitazone	B-CHEMICAL
and	O
ciglitazone	B-CHEMICAL
had	O
minimal	O
effects	O
on	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
adenosine	I-CHEMICAL
uptake	O
by	O
HASMCs	O
.	O

Troglitazone	B-CHEMICAL
differs	O
from	O
pioglitazone	B-CHEMICAL
and	O
ciglitazone	B-CHEMICAL
in	O
that	O
its	O
side	O
-	O
chain	O
contains	O
a	O
Vitamin	B-CHEMICAL
E	I-CHEMICAL
moiety	O
.	O

The	O
difference	O
in	O
structure	O
of	O
troglitazone	B-CHEMICAL
did	O
not	O
account	O
for	O
its	O
inhibitory	O
effect	O
on	O
ENT1	B-GENE-Y
because	O
Vitamin	B-CHEMICAL
E	I-CHEMICAL
did	O
not	O
inhibit	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
adenosine	I-CHEMICAL
uptake	O
by	O
HASMCs	O
.	O

Using	O
the	O
nucleoside	B-GENE-N
transporter	I-GENE-N
deficient	O
PK15NTD	O
cells	O
stably	O
expressing	O
ENT1	B-GENE-Y
and	O
ENT2	B-GENE-Y
,	O
it	O
was	O
found	O
that	O
troglitazone	B-CHEMICAL
inhibited	O
ENT1	B-GENE-Y
but	O
had	O
no	O
effect	O
on	O
ENT2	B-GENE-Y
.	O

From	O
these	O
results	O
,	O
it	O
is	O
suggested	O
that	O
troglitazone	B-CHEMICAL
may	O
enhance	O
the	O
vasodilatory	O
effect	O
of	O
adenosine	B-CHEMICAL
by	O
inhibiting	O
ENT1	B-GENE-Y
.	O

Pharmacologically	O
,	O
troglitazone	B-CHEMICAL
is	O
a	O
novel	O
inhibitor	O
of	O
ENT1	B-GENE-Y
.	O

2	B-CHEMICAL
-	I-CHEMICAL
Arylpropionic	I-CHEMICAL
CXC	B-GENE-Y
chemokine	I-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
(	O
CXCR1	B-GENE-Y
)	O
ligands	O
as	O
novel	O
noncompetitive	O
CXCL8	B-GENE-Y
inhibitors	O
.	O

The	O
CXC	B-GENE-N
chemokine	I-GENE-N
CXCL8	B-GENE-Y
/	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
plays	O
a	O
major	O
role	O
in	O
the	O
activation	O
and	O
recruitment	O
of	O
polymorphonuclear	O
(	O
PMN	O
)	O
cells	O
at	O
inflammatory	O
sites	O
.	O

CXCL8	B-GENE-Y
activates	O
PMNs	O
by	O
binding	O
the	O
seven	B-GENE-N
-	I-GENE-N
transmembrane	I-GENE-N
(	I-GENE-N
7	I-GENE-N
-	I-GENE-N
TM	I-GENE-N
)	I-GENE-N
G	I-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
CXC	B-GENE-Y
chemokine	I-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
(	O
CXCR1	B-GENE-Y
)	O
and	O
CXC	B-GENE-Y
chemokine	I-GENE-Y
receptor	I-GENE-Y
2	I-GENE-Y
(	O
CXCR2	B-GENE-Y
)	O
.	O

(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Ketoprofen	I-CHEMICAL
(	O
1	O
)	O
was	O
previously	O
reported	O
to	O
be	O
a	O
potent	O
and	O
specific	O
noncompetitive	O
inhibitor	O
of	O
CXCL8	B-GENE-Y
-	O
induced	O
human	O
PMNs	O
chemotaxis	O
.	O

We	O
report	O
here	O
molecular	O
modeling	O
studies	O
showing	O
a	O
putative	O
interaction	O
site	O
of	O
1	O
in	O
the	O
TM	O
region	O
of	O
CXCR1	B-GENE-Y
.	O

The	O
binding	O
model	O
was	O
confirmed	O
by	O
alanine	B-CHEMICAL
scanning	O
mutagenesis	O
and	O
photoaffinity	O
labeling	O
experiments	O
.	O

The	O
molecular	O
model	O
driven	O
medicinal	O
chemistry	O
optimization	O
of	O
1	O
led	O
to	O
a	O
new	O
class	O
of	O
potent	O
and	O
specific	O
inhibitors	O
of	O
CXCL8	B-GENE-Y
biological	O
activity	O
.	O

Among	O
these	O
,	O
repertaxin	B-CHEMICAL
(	O
13	O
)	O
was	O
selected	O
as	O
a	O
clinical	O
candidate	O
drug	O
for	O
prevention	O
of	O
post	O
-	O
ischemia	O
reperfusion	O
injury	O
.	O

Thalidomide	B-CHEMICAL
inhibits	O
growth	O
of	O
tumors	O
through	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
degradation	O
independent	O
of	O
antiangiogenesis	O
.	O

Thalidomide	B-CHEMICAL
is	O
an	O
antiangiogenic	O
drug	O
and	O
is	O
clinically	O
useful	O
in	O
a	O
number	O
of	O
cancers	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
by	O
which	O
thalidomide	B-CHEMICAL
exerts	O
its	O
antitumor	O
effects	O
is	O
poorly	O
understood	O
.	O

This	O
study	O
was	O
designed	O
to	O
clarify	O
the	O
relationship	O
between	O
antiangiogenesis	O
and	O
antitumor	O
effects	O
of	O
thalidomide	B-CHEMICAL
and	O
to	O
explore	O
the	O
molecular	O
mechanism	O
for	O
its	O
antitumor	O
activity	O
.	O

We	O
evaluated	O
the	O
effects	O
of	O
thalidomide	B-CHEMICAL
on	O
the	O
growth	O
of	O
human	O
tumor	O
cells	O
expressing	O
(	O
MCF	O
-	O
7	O
and	O
HL	O
-	O
60	O
)	O
or	O
not	O
expressing	O
(	O
HeLa	O
and	O
K562	O
)	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
vitro	O
.	O

We	O
also	O
studied	O
the	O
effects	O
of	O
thalidomide	B-CHEMICAL
on	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
or	O
bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
,	O
TNFalpha	B-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
GSH	O
and	O
cytochrome	B-GENE-Y
c	I-GENE-Y
in	O
these	O
cells	O
.	O

Thalidomide	B-CHEMICAL
could	O
inhibit	O
tumor	O
growth	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
MCF	O
-	O
7	O
and	O
HL	O
-	O
60	O
;	O
its	O
IC50s	O
for	O
them	O
were	O
18	O
.	O
36	O
+	O
/	O
-	O
2	O
.	O
34	O
and	O
22	O
.	O
14	O
+	O
/	O
-	O
2	O
.	O
15	O
microM	O
,	O
respectively	O
,	O
while	O
this	O
effect	O
was	O
not	O
observed	O
in	O
HeLa	O
and	O
K562	O
.	O

Thalidomide	B-CHEMICAL
reduced	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
accompanied	O
by	O
a	O
decrease	O
of	O
bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
protein	O
,	O
TNFalpha	B-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
GSH	O
and	O
an	O
increased	O
cytochrome	B-GENE-Y
c	I-GENE-Y
,	O
but	O
had	O
no	O
effect	O
on	O
that	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
in	O
MCF	O
-	O
7	O
and	O
HL	O
-	O
60	O
.	O

Moreover	O
,	O
cells	O
not	O
expressing	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
were	O
insensitive	O
to	O
the	O
growth	O
-	O
inhibitory	O
and	O
effects	O
on	O
cytokines	B-GENE-N
of	O
thalidomide	B-CHEMICAL
.	O

In	O
our	O
mouse	O
xenograft	O
model	O
of	O
OVCAR	O
-	O
3	O
and	O
HCT	O
-	O
8	O
,	O
we	O
found	O
that	O
thalidomide	B-CHEMICAL
could	O
decrease	O
intratumoral	O
microvessel	O
density	O
in	O
both	O
tumors	O
;	O
it	O
exerted	O
antitumor	O
effects	O
only	O
on	O
OVCAR	O
-	O
3	O
expressing	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
but	O
did	O
not	O
on	O
HCT	O
-	O
8	O
not	O
expressing	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Effect	O
of	O
thalidomide	B-CHEMICAL
on	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
vivo	O
was	O
consistent	O
with	O
that	O
of	O
in	O
vitro	O
.	O

These	O
results	O
demonstrated	O
that	O
thalidomide	B-CHEMICAL
might	O
inhibit	O
growth	O
of	O
tumors	O
through	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
degradation	O
independent	O
of	O
antiangiogenesis	O
.	O

Duloxetine	B-CHEMICAL
hydrochloride	I-CHEMICAL
:	O
a	O
new	O
dual	O
-	O
acting	O
medication	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
.	O

BACKGROUND	O
:	O
Duloxetine	B-CHEMICAL
hydrochloride	I-CHEMICAL
has	O
recently	O
been	O
approved	O
by	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Duloxetine	B-CHEMICAL
is	O
a	O
potent	O
inhibitor	O
of	O
serotonin	B-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
reuptake	O
,	O
with	O
weak	O
effects	O
on	O
dopamine	B-CHEMICAL
reuptake	O
.	O

OBJECTIVE	O
:	O
This	O
article	O
reviews	O
the	O
literature	O
on	O
duloxetine	B-CHEMICAL
with	O
regard	O
to	O
its	O
pharmacodynamics	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
and	O
tolerability	O
.	O

METHODS	O
:	O
A	O
comprehensive	O
search	O
of	O
MEDLINE	O
was	O
performed	O
using	O
the	O
terms	O
duloxetine	B-CHEMICAL
,	O
Cymbalta	B-CHEMICAL
,	O
and	O
major	O
depressive	O
disorder	O
,	O
with	O
no	O
restriction	O
on	O
year	O
.	O

The	O
Eli	O
Lilly	O
and	O
Company	O
clinical	O
trial	O
registry	O
,	O
and	O
abstracts	O
and	O
posters	O
from	O
recent	O
American	O
Psychiatric	O
Association	O
meetings	O
were	O
also	O
reviewed	O
.	O

RESULTS	O
:	O
Duloxetine	B-CHEMICAL
exhibits	O
linear	O
,	O
dose	O
-	O
dependent	O
pharmacokinetics	O
across	O
the	O
approved	O
oral	O
dosage	O
range	O
of	O
40	O
to	O
60	O
mg	O
/	O
d	O
.	O

No	O
dose	O
adjustment	O
appears	O
to	O
be	O
needed	O
based	O
on	O
age	O
.	O

Duloxetine	B-CHEMICAL
has	O
shown	O
efficacy	O
in	O
reducing	O
depressive	O
symptoms	O
compared	O
with	O
placebo	O
,	O
and	O
duloxetine	O
recipients	O
have	O
shown	O
significant	O
improvements	O
in	O
global	O
functioning	O
compared	O
with	O
placebo	O
(	O
both	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Response	O
and	O
remission	O
rates	O
have	O
been	O
comparable	O
to	O
or	O
greater	O
than	O
those	O
seen	O
with	O
fluoxetine	B-CHEMICAL
or	O
paroxetine	B-CHEMICAL
.	O

Duloxetine	B-CHEMICAL
is	O
generally	O
well	O
tolerated	O
,	O
with	O
nausea	O
,	O
dry	O
mouth	O
,	O
and	O
fatigue	O
being	O
the	O
most	O
common	O
treatment	O
-	O
emergent	O
adverse	O
effects	O
.	O

Cardiovascular	O
adverse	O
effects	O
do	O
not	O
appear	O
to	O
result	O
in	O
sustained	O
blood	O
pressure	O
elevations	O
,	O
QTc	O
-	O
interval	O
prolongation	O
,	O
or	O
other	O
electrocardiographic	O
changes	O
.	O

CONCLUSIONS	O
:	O
Based	O
on	O
the	O
available	O
evidence	O
,	O
duloxetine	B-CHEMICAL
is	O
a	O
well	O
-	O
tolerated	O
and	O
effective	O
treatment	O
for	O
MDD	O
in	O
adults	O
.	O

Randomized	O
head	O
-	O
to	O
-	O
head	O
comparisons	O
against	O
established	O
antidepressants	O
are	O
needed	O
to	O
determine	O
the	O
relative	O
safety	O
and	O
efficacy	O
of	O
duloxetine	B-CHEMICAL
.	O

In	O
vivo	O
comparison	O
of	O
the	O
reinforcing	O
and	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
effects	O
of	O
local	O
anesthetics	O
in	O
rhesus	O
monkeys	O
.	O

Dopaminergic	O
mechanisms	O
are	O
thought	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
reinforcing	O
effects	O
of	O
cocaine	B-CHEMICAL
.	O

Similar	O
to	O
cocaine	B-CHEMICAL
,	O
other	O
local	O
anesthetics	O
bind	O
to	O
the	O
dopamine	B-GENE-N
transporter	I-GENE-N
(	O
DAT	B-GENE-N
)	O
and	O
inhibit	O
DA	B-CHEMICAL
uptake	O
in	O
rodent	O
and	O
monkey	O
brain	O
.	O

Additionally	O
,	O
local	O
anesthetics	O
are	O
self	O
-	O
administered	O
in	O
rhesus	O
monkeys	O
,	O
indicative	O
of	O
abuse	O
liability	O
.	O

The	O
present	O
study	O
examined	O
the	O
reinforcing	O
and	O
DAT	B-GENE-Y
effects	O
of	O
the	O
local	O
anesthetics	O
dimethocaine	B-CHEMICAL
,	O
procaine	B-CHEMICAL
and	O
cocaine	B-CHEMICAL
using	O
in	O
vivo	O
techniques	O
.	O

Monkeys	O
were	O
trained	O
to	O
respond	O
under	O
a	O
second	O
-	O
order	O
schedule	O
for	O
i	O
.	O
v	O
.	O
cocaine	B-CHEMICAL
administration	O
(	O
0	O
.	O
10	O
or	O
0	O
.	O
30	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
.	O

When	O
responding	O
was	O
stable	O
,	O
dimethocaine	B-CHEMICAL
(	O
0	O
.	O
030	O
-	O
1	O
.	O
7	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
or	O
procaine	B-CHEMICAL
(	O
0	O
.	O
10	O
-	O
10	O
mg	O
/	O
kg	O
/	O
infusion	O
)	O
was	O
substituted	O
for	O
the	O
cocaine	B-CHEMICAL
training	O
dose	O
.	O

Dimethocaine	B-CHEMICAL
administration	O
produced	O
higher	O
response	O
rates	O
compared	O
with	O
that	O
of	O
procaine	B-CHEMICAL
,	O
and	O
was	O
a	O
more	O
potent	O
reinforcer	O
.	O

Drug	O
effects	O
on	O
behavior	O
were	O
related	O
to	O
DAT	B-GENE-Y
occupancy	O
in	O
monkey	O
striatum	O
during	O
neuroimaging	O
with	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
.	O

DAT	B-GENE-Y
occupancy	O
was	O
determined	O
by	O
displacement	O
of	O
8	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
]	I-CHEMICAL
fluroethyl	I-CHEMICAL
)	I-CHEMICAL
2beta	I-CHEMICAL
-	I-CHEMICAL
carbomethoxy	I-CHEMICAL
-	I-CHEMICAL
3beta	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chlorophenyl	I-CHEMICAL
)	I-CHEMICAL
nortropane	I-CHEMICAL
(	O
FECNT	B-CHEMICAL
)	O
.	O

DAT	B-GENE-Y
occupancy	O
was	O
between	O
66	O
and	O
82	O
%	O
and	O
<	O
10	O
-	O
41	O
%	O
for	O
doses	O
of	O
dimethocaine	B-CHEMICAL
and	O
procaine	B-CHEMICAL
that	O
maintained	O
maximum	O
response	O
rates	O
,	O
respectively	O
.	O

Finally	O
,	O
in	O
vivo	O
microdialysis	O
in	O
awake	O
subjects	O
determined	O
drug	O
-	O
induced	O
changes	O
in	O
extracellular	O
DA	B-CHEMICAL
in	O
the	O
caudate	O
nucleus	O
.	O

There	O
was	O
close	O
correspondence	O
between	O
peak	O
increases	O
in	O
DA	B-CHEMICAL
and	O
DAT	B-GENE-Y
occupancy	O
.	O

Overall	O
,	O
reinforcing	O
effects	O
were	O
consistent	O
with	O
DAT	B-GENE-Y
effects	O
determined	O
with	O
in	O
vivo	O
techniques	O
.	O

The	O
results	O
further	O
support	O
a	O
role	O
for	O
the	O
DAT	B-GENE-Y
in	O
the	O
abuse	O
liability	O
of	O
local	O
anesthetics	O
.	O

In	O
vitro	O
inhibitory	O
effects	O
of	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drugs	O
on	O
4	B-CHEMICAL
-	I-CHEMICAL
methylumbelliferone	I-CHEMICAL
glucuronidation	O
in	O
recombinant	O
human	B-GENE-Y
UDP	I-GENE-Y
-	I-GENE-Y
glucuronosyltransferase	I-GENE-Y
1A9	I-GENE-Y
-	O
-	O
potent	O
inhibition	O
by	O
niflumic	B-CHEMICAL
acid	I-CHEMICAL
.	O

The	O
inhibitory	O
potencies	O
of	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
on	O
UDP	B-GENE-Y
-	I-GENE-Y
glucuronosyltransferase	I-GENE-Y
(	I-GENE-Y
UGT	I-GENE-Y
)	I-GENE-Y
1A9	I-GENE-Y
activity	O
were	O
investigated	O
in	O
recombinant	O
human	B-GENE-Y
UGT1A9	I-GENE-Y
using	O
4	B-CHEMICAL
-	I-CHEMICAL
methylumbelliferone	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
MU	I-CHEMICAL
)	O
as	O
a	O
substrate	O
for	O
glucuronidation	O
.	O

4	B-CHEMICAL
-	I-CHEMICAL
MU	I-CHEMICAL
glucuronidation	O
(	O
4	O
-	O
MUG	O
)	O
showed	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
a	O
Km	O
value	O
of	O
6	O
.	O
7	O
microM	O
.	O

The	O
inhibitory	O
effects	O
of	O
the	O
following	O
seven	O
NSAIDs	O
were	O
investigated	O
:	O
acetaminophen	B-CHEMICAL
,	O
diclofenac	B-CHEMICAL
,	O
diflunisal	B-CHEMICAL
,	O
indomethacin	B-CHEMICAL
,	O
ketoprofen	B-CHEMICAL
,	O
naproxen	B-CHEMICAL
and	O
niflumic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Niflumic	B-CHEMICAL
acid	I-CHEMICAL
had	O
the	O
most	O
potent	O
inhibitory	O
effect	O
on	O
4	O
-	O
MUG	O
with	O
an	O
IC50	O
value	O
of	O
0	O
.	O
0341	O
microM	O
.	O

The	O
IC50	O
values	O
of	O
diflunisal	B-CHEMICAL
,	O
diclofenac	B-CHEMICAL
and	O
indomethacin	B-CHEMICAL
were	O
1	O
.	O
31	O
,	O
24	O
.	O
2	O
,	O
and	O
34	O
.	O
1	O
microM	O
,	O
respectively	O
,	O
while	O
acetaminophen	B-CHEMICAL
,	O
ketoprofen	B-CHEMICAL
and	O
naproxen	B-CHEMICAL
showed	O
less	O
potent	O
inhibition	O
.	O

Niflumic	B-CHEMICAL
acid	I-CHEMICAL
,	O
diflunisal	B-CHEMICAL
,	O
diclofenac	B-CHEMICAL
and	O
indomethacin	B-CHEMICAL
inhibited	O
4	O
-	O
MUG	O
competitively	O
with	O
Ki	O
values	O
of	O
0	O
.	O
0275	O
,	O
0	O
.	O
710	O
,	O
53	O
.	O
3	O
and	O
69	O
.	O
9	O
microM	O
,	O
respectively	O
,	O
being	O
similar	O
to	O
each	O
IC50	O
value	O
.	O

In	O
conclusion	O
,	O
of	O
the	O
seven	O
NSAIDs	O
investigated	O
,	O
niflumic	B-CHEMICAL
acid	I-CHEMICAL
was	O
the	O
most	O
potent	O
inhibitor	O
of	O
recombinant	O
UGT1A9	B-GENE-Y
via	O
4	O
-	O
MUG	O
in	O
a	O
competitive	O
manner	O
.	O

Spectrum	O
of	O
mutations	O
in	O
mut	B-GENE-Y
methylmalonic	O
acidemia	O
and	O
identification	O
of	O
a	O
common	O
Hispanic	O
mutation	O
and	O
haplotype	O
.	O

Cobalamin	B-CHEMICAL
nonresponsive	O
methylmalonic	O
acidemia	O
(	O
MMA	O
,	O
mut	O
complementation	O
class	O
)	O
results	O
from	O
mutations	O
in	O
the	O
nuclear	O
gene	O
MUT	B-GENE-Y
,	O
which	O
codes	O
for	O
the	O
mitochondrial	O
enzyme	O
methylmalonyl	B-GENE-Y
CoA	I-GENE-Y
mutase	I-GENE-Y
(	O
MCM	B-GENE-Y
)	O
.	O

To	O
better	O
elucidate	O
the	O
spectrum	O
of	O
mutations	O
that	O
cause	O
MMA	O
,	O
the	O
MUT	B-GENE-Y
gene	O
was	O
sequenced	O
in	O
160	O
patients	O
with	O
mut	B-GENE-Y
MMA	O
.	O

Sequence	O
analysis	O
identified	O
mutations	O
in	O
96	O
%	O
of	O
disease	O
alleles	O
.	O

Mutations	O
were	O
found	O
in	O
all	O
coding	O
exons	O
,	O
but	O
predominantly	O
in	O
exons	O
2	O
,	O
3	O
,	O
6	O
,	O
and	O
11	O
.	O

A	O
total	O
of	O
116	O
different	O
mutations	O
,	O
68	O
of	O
which	O
were	O
novel	O
,	O
were	O
identified	O
.	O

Of	O
the	O
116	O
different	O
mutations	O
,	O
53	O
%	O
were	O
missense	O
mutations	O
,	O
22	O
%	O
were	O
deletions	O
,	O
duplications	O
or	O
insertions	O
,	O
16	O
%	O
were	O
nonsense	O
mutations	O
,	O
and	O
9	O
%	O
were	O
splice	O
-	O
site	O
mutations	O
.	O

Sixty	O
-	O
one	O
of	O
the	O
mutations	O
have	O
only	O
been	O
identified	O
in	O
one	O
family	O
.	O

A	O
novel	O
mutation	O
in	O
exon	O
2	O
,	O
c	O
.	O
322C	B-GENE-N
>	I-GENE-N
T	I-GENE-N
(	O
p	O
.	O
R108C	B-GENE-N
)	O
,	O
was	O
identified	O
in	O
16	O
of	O
27	O
Hispanic	O
patients	O
.	O

SNP	O
genotyping	O
data	O
demonstrated	O
that	O
Hispanic	O
patients	O
with	O
this	O
mutation	O
share	O
a	O
common	O
haplotype	O
.	O

Three	O
other	O
mutations	O
were	O
seen	O
exclusively	O
in	O
Hispanic	O
patients	O
:	O
c	O
.	O
280G	B-GENE-N
>	I-GENE-N
A	I-GENE-N
(	O
p	O
.	O
G94R	B-GENE-N
)	O
,	O
c	O
.	O
1022dupA	O
,	O
and	O
c	O
.	O
970G	B-GENE-N
>	I-GENE-N
A	I-GENE-N
(	O
p	O
.	O
A324T	B-GENE-N
)	O
.	O

Seven	O
mutations	O
were	O
seen	O
almost	O
exclusively	O
in	O
black	O
patients	O
,	O
including	O
the	O
previously	O
reported	O
c	O
.	O
2150G	B-GENE-N
>	I-GENE-N
T	I-GENE-N
(	O
p	O
.	O
G717V	B-GENE-N
)	O
mutation	O
,	O
which	O
was	O
identified	O
in	O
12	O
of	O
29	O
black	O
patients	O
.	O

Two	O
mutations	O
were	O
seen	O
only	O
in	O
Asian	O
patients	O
.	O

Some	O
frequently	O
identified	O
mutations	O
were	O
not	O
population	O
-	O
specific	O
and	O
were	O
identified	O
in	O
patients	O
of	O
various	O
ethnic	O
backgrounds	O
.	O

Some	O
of	O
these	O
mutations	O
were	O
found	O
in	O
mutation	O
clusters	O
in	O
exons	O
2	O
,	O
3	O
,	O
6	O
,	O
and	O
11	O
,	O
suggesting	O
a	O
recurrent	O
mutation	O
.	O

New	O
progestagens	B-CHEMICAL
for	O
contraceptive	O
use	O
.	O

The	O
progestins	B-CHEMICAL
have	O
different	O
pharmacologic	O
properties	O
depending	O
upon	O
the	O
parent	O
molecule	O
,	O
usually	O
testosterone	B-CHEMICAL
or	O
progesterone	B-CHEMICAL
(	O
P	O
)	O
,	O
from	O
which	O
they	O
are	O
derived	O
.	O

Very	O
small	O
structural	O
changes	O
in	O
the	O
parent	O
molecule	O
may	O
induce	O
considerable	O
differences	O
in	O
the	O
activity	O
of	O
the	O
derivative	O
.	O

In	O
hormonal	O
contraceptives	O
,	O
progestins	O
represent	O
the	O
major	O
agent	O
designed	O
for	O
suppressing	O
ovulation	O
and	O
are	O
used	O
in	O
combination	O
with	O
estrogen	B-CHEMICAL
(	O
E	O
)	O
usually	O
ethinyl	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
(	O
EE	B-CHEMICAL
)	O
.	O

The	O
development	O
of	O
new	O
generations	O
of	O
progestins	B-CHEMICAL
with	O
improved	O
selectivity	O
profiles	O
has	O
been	O
a	O
great	O
challenge	O
.	O

Steroidal	B-CHEMICAL
and	O
nonsteroidal	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
(	O
PR	B-GENE-Y
)	O
agonists	O
have	O
been	O
synthesized	O
as	O
well	O
,	O
although	O
the	O
latter	O
are	O
still	O
in	O
a	O
very	O
early	O
stage	O
of	O
development	O
.	O

Several	O
new	O
progestins	B-CHEMICAL
,	O
have	O
been	O
synthesized	O
in	O
the	O
last	O
two	O
decades	O
.	O

These	O
include	O
dienogest	B-CHEMICAL
(	O
DNG	B-CHEMICAL
)	O
,	O
drospirenone	B-CHEMICAL
(	O
DRSP	B-CHEMICAL
)	O
,	O
Nestorone	B-CHEMICAL
(	O
NES	B-CHEMICAL
)	O
,	O
nomegestrol	B-CHEMICAL
acetate	I-CHEMICAL
(	O
NOMAc	B-CHEMICAL
)	O
and	O
trimegestone	B-CHEMICAL
(	O
TMG	B-CHEMICAL
)	O
.	O

These	O
new	O
progestins	B-CHEMICAL
have	O
been	O
designed	O
to	O
have	O
no	O
androgenic	O
or	O
estrogenic	O
actions	O
and	O
to	O
be	O
closer	O
in	O
activity	O
to	O
the	O
physiological	O
hormone	O
P	O
.	O

DRSP	B-CHEMICAL
differs	O
from	O
the	O
classic	O
progestins	B-CHEMICAL
as	O
it	O
is	O
derived	O
from	O
spirolactone	B-CHEMICAL
.	O

It	O
is	O
essentially	O
an	O
antimineralocorticoid	O
steroid	B-CHEMICAL
with	O
no	O
androgenic	O
effect	O
but	O
a	O
partial	O
antiandrogenic	O
effect	O
.	O

The	O
antiovulatory	O
potency	O
of	O
the	O
different	O
progestins	B-CHEMICAL
varies	O
.	O

TMG	B-CHEMICAL
and	O
NES	B-CHEMICAL
are	O
the	O
most	O
potent	O
progestins	B-CHEMICAL
synthesized	O
to	O
date	O
,	O
followed	O
by	O
two	O
of	O
the	O
older	O
progestins	B-CHEMICAL
,	O
keto	B-CHEMICAL
-	I-CHEMICAL
desogestrel	I-CHEMICAL
(	O
keto	B-CHEMICAL
-	I-CHEMICAL
DSG	I-CHEMICAL
)	O
and	O
levonorgestrel	B-CHEMICAL
(	O
LNG	B-CHEMICAL
)	O
.	O

The	O
new	O
molecules	O
TMG	B-CHEMICAL
,	O
DRSP	B-CHEMICAL
and	O
DNG	B-CHEMICAL
also	O
have	O
antiandrogenic	O
activity	O
.	O

Striking	O
differences	O
exist	O
regarding	O
the	O
side	O
effects	O
among	O
the	O
progestins	B-CHEMICAL
and	O
the	O
combination	O
with	O
EE	B-CHEMICAL
leads	O
to	O
other	O
reactions	O
related	O
to	O
the	O
E	O
itself	O
and	O
whether	O
the	O
associated	O
progestin	B-CHEMICAL
counterbalances	O
,	O
more	O
or	O
less	O
,	O
the	O
estrogenic	O
action	O
.	O

The	O
19	B-CHEMICAL
-	I-CHEMICAL
norprogesterone	I-CHEMICAL
molecules	O
and	O
the	O
new	O
molecules	O
DRSP	B-CHEMICAL
and	O
DNG	B-CHEMICAL
are	O
not	O
androgenic	O
and	O
,	O
therefore	O
,	O
have	O
no	O
negative	O
effect	O
on	O
the	O
lipid	O
profile	O
.	O

Given	O
their	O
pharmacological	O
properties	O
,	O
it	O
is	O
likely	O
that	O
the	O
new	O
progestins	B-CHEMICAL
may	O
have	O
neutral	O
effects	O
on	O
metabolic	O
or	O
vascular	O
risks	O
.	O

However	O
,	O
this	O
hypothesis	O
must	O
be	O
confirmed	O
in	O
large	O
clinical	O
trials	O
.	O

Drug	O
binding	O
interactions	O
in	O
the	O
inner	O
cavity	O
of	O
HERG	B-GENE-Y
channels	O
:	O
molecular	O
insights	O
from	O
structure	O
-	O
activity	O
relationships	O
of	O
clofilium	B-CHEMICAL
and	O
ibutilide	B-CHEMICAL
analogs	O
.	O

Block	O
of	O
human	B-GENE-Y
ether	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
related	I-GENE-Y
gene	I-GENE-Y
(	I-GENE-Y
hERG	I-GENE-Y
)	I-GENE-Y
K	I-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
channels	I-GENE-Y
by	O
otherwise	O
useful	O
drugs	O
is	O
the	O
most	O
common	O
cause	O
of	O
long	O
QT	O
syndrome	O
,	O
a	O
disorder	O
of	O
cardiac	O
repolarization	O
that	O
predisposes	O
patients	O
to	O
potentially	O
fatal	O
arrhythmias	O
.	O

This	O
undesirable	O
long	O
QT	O
side	O
effect	O
has	O
been	O
a	O
major	O
reason	O
for	O
the	O
withdrawal	O
of	O
medications	O
from	O
the	O
pharmaceutical	O
market	O
.	O

Understanding	O
the	O
molecular	O
basis	O
of	O
hERG	B-GENE-Y
block	O
is	O
therefore	O
essential	O
to	O
facilitate	O
the	O
design	O
of	O
safe	O
drugs	O
.	O

Binding	O
sites	O
for	O
hERG	B-GENE-Y
blockers	O
have	O
been	O
mapped	O
within	O
the	O
inner	O
cavity	O
of	O
the	O
channel	O
and	O
include	O
aromatic	O
residues	O
in	O
the	O
S6	O
helix	O
(	O
Tyr	B-CHEMICAL
-	O
652	O
,	O
Phe	B-CHEMICAL
-	O
656	O
)	O
and	O
residues	O
in	O
the	O
pore	O
helix	O
(	O
Thr	B-CHEMICAL
-	O
623	O
,	O
Ser	B-CHEMICAL
-	O
624	O
,	O
Val	B-CHEMICAL
-	O
625	O
)	O
.	O

We	O
used	O
mutagenesis	O
of	O
these	O
residues	O
,	O
combined	O
with	O
an	O
investigation	O
of	O
hERG	B-GENE-Y
block	O
by	O
close	O
analogs	O
of	O
clofilium	B-CHEMICAL
and	O
ibutilide	B-CHEMICAL
,	O
to	O
assess	O
how	O
specific	O
alterations	O
in	O
drug	O
structure	O
affected	O
potency	O
and	O
binding	O
interactions	O
.	O

Although	O
changing	O
the	O
basic	O
nitrogen	B-CHEMICAL
from	O
quaternary	O
to	O
tertiary	O
accelerated	O
the	O
onset	O
of	O
block	O
,	O
the	O
IC	O
(	O
50	O
)	O
and	O
kinetics	O
for	O
recovery	O
from	O
block	O
were	O
similar	O
.	O

In	O
contrast	O
,	O
analogs	O
with	O
different	O
para	O
-	O
substituents	O
on	O
the	O
phenyl	B-CHEMICAL
ring	O
had	O
significantly	O
different	O
potencies	O
for	O
wild	O
-	O
type	O
hERG	B-GENE-Y
block	O
.	O

The	O
highest	O
potency	O
was	O
achieved	O
with	O
polar	O
or	O
electronegative	O
para	O
-	O
substituents	O
,	O
whereas	O
neutral	O
para	O
-	O
substituents	O
had	O
potencies	O
more	O
than	O
100	O
-	O
fold	O
lower	O
.	O

Results	O
from	O
mutagenesis	O
and	O
molecular	O
modeling	O
studies	O
suggest	O
that	O
phenyl	B-CHEMICAL
ring	O
para	O
-	O
substituents	O
influence	O
drug	O
interactions	O
with	O
Thr	B-CHEMICAL
-	O
623	O
,	O
Ser	B-CHEMICAL
-	O
624	O
,	O
and	O
Tyr	B-CHEMICAL
-	O
652	O
and	O
strongly	O
affect	O
binding	O
affinity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
modifying	O
the	O
para	O
-	O
substituent	O
could	O
be	O
a	O
useful	O
strategy	O
for	O
reducing	O
hERG	O
potency	O
and	O
increasing	O
the	O
safety	O
margin	O
of	O
compounds	O
in	O
development	O
.	O

Effect	O
of	O
MELANOTAN	B-CHEMICAL
,	O
[	B-CHEMICAL
Nle	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Phe	I-CHEMICAL
(	I-CHEMICAL
7	I-CHEMICAL
)	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
MSH	I-CHEMICAL
,	O
on	O
melanin	O
synthesis	O
in	O
humans	O
with	O
MC1R	B-GENE-Y
variant	O
alleles	O
.	O

MELANOTAN	B-CHEMICAL
(	O
NDP	B-CHEMICAL
-	I-CHEMICAL
MSH	I-CHEMICAL
)	O
binds	O
the	O
MC1	B-GENE-Y
receptor	I-GENE-Y
to	O
significantly	O
increase	O
the	O
eumelanin	O
content	O
of	O
human	O
skin	O
cells	O
.	O

In	O
this	O
study	O
of	O
77	O
Caucasian	O
individuals	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
MELANOTAN	B-CHEMICAL
in	O
individuals	O
with	O
variant	O
MC1R	B-GENE-Y
genotypes	O
,	O
as	O
it	O
has	O
been	O
suggested	O
through	O
in	O
vitro	O
studies	O
that	O
variant	O
alleles	O
decrease	O
MELANOTAN	B-CHEMICAL
binding	O
efficacy	O
,	O
which	O
would	O
subsequently	O
affect	O
the	O
synthesis	O
of	O
melanin	O
.	O

Administration	O
of	O
MELANOTAN	B-CHEMICAL
produced	O
a	O
significant	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
increase	O
in	O
melanin	O
density	O
in	O
treated	O
,	O
compared	O
to	O
placebo	O
,	O
individuals	O
.	O

Importantly	O
,	O
MELANOTAN	B-CHEMICAL
increased	O
the	O
melanin	O
density	O
to	O
a	O
greater	O
extent	O
in	O
individuals	O
carrying	O
the	O
variant	O
alleles	O
Val60Leu	O
,	O
Asp84Glu	O
,	O
Val92Met	O
,	O
Arg142His	O
,	O
Arg151Cys	O
,	O
and	O
Arg160Trp	O
than	O
in	O
individuals	O
with	O
no	O
variant	O
alleles	O
.	O

This	O
study	O
demonstrates	O
that	O
MELANOTAN	B-CHEMICAL
effectively	O
increases	O
the	O
melanin	O
content	O
of	O
skin	O
in	O
those	O
individuals	O
with	O
MC1R	B-GENE-Y
variant	O
alleles	O
and	O
therefore	O
,	O
those	O
most	O
in	O
need	O
of	O
photoprotection	O
.	O

Tissue	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
acts	O
as	O
a	O
cytokine	B-GENE-N
that	O
triggers	O
intracellular	O
signal	O
transduction	O
and	O
induces	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
gene	O
expression	O
.	O

Tissue	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
tPA	B-GENE-Y
)	O
,	O
a	O
serine	B-GENE-N
protease	I-GENE-N
well	O
known	O
for	O
generating	O
plasmin	B-GENE-Y
,	O
has	O
been	O
demonstrated	O
to	O
induce	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
(	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
)	O
gene	O
expression	O
and	O
protein	O
secretion	O
in	O
renal	O
interstitial	O
fibroblasts	O
.	O

However	O
,	O
exactly	O
how	O
tPA	B-GENE-Y
transduces	O
its	O
signal	O
into	O
the	O
nucleus	O
to	O
control	O
gene	O
expression	O
is	O
unknown	O
.	O

This	O
study	O
investigated	O
the	O
mechanism	O
by	O
which	O
tPA	B-GENE-Y
induces	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
gene	O
expression	O
.	O

Both	O
wild	O
-	O
type	O
and	O
non	O
-	O
enzymatic	O
mutant	O
tPA	B-GENE-Y
were	O
found	O
to	O
induce	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
expression	O
in	O
rat	O
kidney	O
interstitial	O
fibroblasts	O
(	O
NRK	O
-	O
49F	O
)	O
,	O
indicating	O
that	O
the	O
actions	O
of	O
tPA	B-GENE-Y
are	O
independent	O
of	O
its	O
proteolytic	O
activity	O
.	O

tPA	B-GENE-Y
bound	O
to	O
the	O
low	B-GENE-Y
density	I-GENE-Y
lipoprotein	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
LRP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
in	O
NRK	O
-	O
49F	O
cells	O
,	O
and	O
this	O
binding	O
was	O
competitively	O
abrogated	O
by	O
the	O
LRP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
antagonist	O
,	O
the	O
receptor	O
-	O
associated	O
protein	O
.	O

In	O
mouse	O
embryonic	O
fibroblasts	O
(	O
PEA	O
-	O
13	O
)	O
lacking	O
LRP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
tPA	B-GENE-Y
failed	O
to	O
induce	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
expression	O
.	O

Furthermore	O
,	O
tPA	B-GENE-Y
induced	O
rapid	O
tyrosine	B-CHEMICAL
phosphorylation	O
on	O
the	O
beta	O
subunit	O
of	O
LRP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
which	O
was	O
followed	O
by	O
the	O
activation	O
of	O
Mek1	B-GENE-Y
and	O
its	O
downstream	O
Erk	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	I-GENE-N
-	I-GENE-N
2	I-GENE-N
.	O

Blockade	O
of	O
Erk	B-GENE-N
-	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
activation	O
by	O
the	O
Mek1	B-GENE-Y
inhibitor	O
abolished	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
induction	O
by	O
tPA	B-GENE-Y
in	O
NRK	O
-	O
49F	O
cells	O
.	O

Conversely	O
,	O
overexpression	O
of	O
constitutively	B-GENE-Y
activated	I-GENE-Y
Mek1	I-GENE-Y
induced	O
Erk	B-GENE-N
-	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
phosphorylation	O
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
expression	O
.	O

In	O
mouse	O
obstructed	O
kidney	O
,	O
tPA	B-GENE-Y
,	O
LRP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
were	O
concomitantly	O
induced	O
in	O
the	O
renal	O
interstitium	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
besides	O
its	O
classical	O
proteolytic	O
activity	O
,	O
tPA	B-GENE-Y
acts	O
as	O
a	O
cytokine	B-GENE-N
that	O
binds	O
to	O
the	O
cell	O
membrane	O
receptor	O
LRP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
induces	O
its	O
tyrosine	B-CHEMICAL
phosphorylation	O
,	O
and	O
triggers	O
intracellular	O
signal	O
transduction	O
,	O
thereby	O
inducing	O
specific	O
gene	O
expression	O
in	O
renal	O
interstitial	O
fibroblasts	O
.	O

Co	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
bond	O
activation	O
in	O
methylmalonyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
mutase	I-GENE-Y
by	O
stabilization	O
of	O
the	O
post	O
-	O
homolysis	O
product	O
Co2	B-CHEMICAL
+	I-CHEMICAL
cobalamin	B-CHEMICAL
.	O

Despite	O
decades	O
of	O
research	O
,	O
the	O
mechanism	O
by	O
which	O
coenzyme	B-CHEMICAL
B12	I-CHEMICAL
(	O
adenosylcobalamin	B-CHEMICAL
,	O
AdoCbl	B-CHEMICAL
)	O
-	O
dependent	O
enzymes	O
promote	O
homolytic	O
cleavage	O
of	O
the	O
cofactor	O
'	O
s	O
Co	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
bond	O
to	O
initiate	O
catalysis	O
has	O
continued	O
to	O
elude	O
researchers	O
.	O

In	O
this	O
work	O
,	O
we	O
utilized	O
magnetic	O
circular	O
dichroism	O
spectroscopy	O
to	O
explore	O
how	O
the	O
electronic	O
structure	O
of	O
the	O
reduced	O
B12	O
cofactor	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
post	O
-	O
homolysis	O
product	O
Co2	B-CHEMICAL
+	I-CHEMICAL
Cbl	I-CHEMICAL
)	O
is	O
modulated	O
by	O
the	O
enzyme	O
methylmalonyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
mutase	I-GENE-Y
.	O

Our	O
data	O
reveal	O
a	O
fairly	O
uniform	O
stabilization	O
of	O
the	O
Co	O
3d	O
orbitals	O
relative	O
to	O
the	O
corrin	O
pi	O
/	O
pi	O
*	O
-	O
based	O
molecular	O
orbitals	O
when	O
Co2	B-CHEMICAL
+	I-CHEMICAL
Cbl	I-CHEMICAL
is	O
bound	O
to	O
the	O
enzyme	O
active	O
site	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
substrate	O
.	O

Contrastingly	O
,	O
our	O
previous	O
studies	O
(	O
Brooks	O
,	O
A	O
.	O
J	O
.	O
;	O
Vlasie	O
,	O
M	O
.	O
;	O
Banerjee	O
,	O
R	O
.	O
;	O
Brunold	O
,	O
T	O
.	O
C	O
.	O
J	O
.	O
Am	O
.	O
Chem	O
.	O
Soc	O
.	O
2004	O
,	O
126	O
,	O
8167	O
-	O
8180	O
.	O
)	O
showed	O
that	O
when	O
AdoCbl	B-CHEMICAL
is	O
bound	O
to	O
the	O
MMCM	B-GENE-Y
active	O
site	O
,	O
no	O
enzymatic	O
perturbation	O
of	O
the	O
Co3	B-CHEMICAL
+	I-CHEMICAL
Cbl	I-CHEMICAL
electronic	O
structure	O
occurs	O
,	O
even	O
in	O
the	O
presence	O
of	O
substrate	O
(	O
analogues	O
)	O
.	O

Collectively	O
,	O
these	O
observations	O
provide	O
direct	O
evidence	O
that	O
enzymatic	O
Co	B-CHEMICAL
-	I-CHEMICAL
C	I-CHEMICAL
bond	O
activation	O
involves	O
stabilization	O
of	O
the	O
post	O
-	O
homolysis	O
product	O
,	O
Co2	B-CHEMICAL
+	I-CHEMICAL
Cbl	I-CHEMICAL
,	O
rather	O
than	O
destabilization	O
of	O
the	O
Co3	B-CHEMICAL
+	I-CHEMICAL
Cbl	I-CHEMICAL
"	O
ground	O
"	O
state	O
.	O

Crystal	O
structures	O
of	O
protein	B-GENE-N
phosphatase	I-GENE-N
-	I-GENE-N
1	I-GENE-N
bound	O
to	O
motuporin	B-CHEMICAL
and	O
dihydromicrocystin	B-CHEMICAL
-	I-CHEMICAL
LA	I-CHEMICAL
:	O
elucidation	O
of	O
the	O
mechanism	O
of	O
enzyme	O
inhibition	O
by	O
cyanobacterial	O
toxins	O
.	O

The	O
microcystins	B-CHEMICAL
and	O
nodularins	B-CHEMICAL
are	O
tumour	O
promoting	O
hepatotoxins	O
that	O
are	O
responsible	O
for	O
global	O
adverse	O
human	O
health	O
effects	O
and	O
wildlife	O
fatalities	O
in	O
countries	O
where	O
drinking	O
water	O
supplies	O
contain	O
cyanobacteria	O
.	O

The	O
toxins	O
function	O
by	O
inhibiting	O
broad	O
specificity	O
Ser	B-GENE-N
/	I-GENE-N
Thr	I-GENE-N
protein	I-GENE-N
phosphatases	I-GENE-N
in	O
the	O
host	O
cells	O
,	O
thereby	O
disrupting	O
signal	O
transduction	O
pathways	O
.	O

A	O
previous	O
crystal	O
structure	O
of	O
a	O
microcystin	B-CHEMICAL
bound	O
to	O
the	O
catalytic	O
subunit	O
of	O
protein	B-GENE-N
phosphatase	I-GENE-N
-	I-GENE-N
1	I-GENE-N
(	O
PP	B-GENE-N
-	I-GENE-N
1c	I-GENE-N
)	O
showed	O
distinct	O
changes	O
in	O
the	O
active	O
site	O
region	O
when	O
compared	O
with	O
protein	B-GENE-N
phosphatase	I-GENE-N
-	I-GENE-N
1	I-GENE-N
structures	O
bound	O
to	O
other	O
toxins	O
.	O

We	O
have	O
elucidated	O
the	O
crystal	O
structures	O
of	O
the	O
cyanotoxins	B-GENE-N
,	O
motuporin	B-CHEMICAL
(	O
nodularin	B-CHEMICAL
-	I-CHEMICAL
V	I-CHEMICAL
)	O
and	O
dihydromicrocystin	B-CHEMICAL
-	I-CHEMICAL
LA	I-CHEMICAL
bound	O
to	O
human	B-GENE-Y
protein	I-GENE-Y
phosphatase	I-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
(	I-GENE-Y
gamma	I-GENE-Y
isoform	I-GENE-Y
)	I-GENE-Y
.	O

The	O
atomic	O
structures	O
of	O
these	O
complexes	O
reveal	O
the	O
structural	O
basis	O
for	O
inhibition	O
of	O
protein	B-GENE-N
phosphatases	I-GENE-N
by	O
these	O
toxins	O
.	O

Comparisons	O
of	O
the	O
structures	O
of	O
the	O
cyanobacterial	B-GENE-N
toxin	I-GENE-N
:	O
phosphatase	B-GENE-N
complexes	O
explain	O
the	O
biochemical	O
mechanism	O
by	O
which	O
microcystins	B-CHEMICAL
but	O
not	O
nodularins	B-CHEMICAL
permanently	O
modify	O
their	O
protein	B-GENE-N
phosphatase	I-GENE-N
targets	O
by	O
covalent	O
addition	O
to	O
an	O
active	O
site	O
cysteine	B-CHEMICAL
residue	O
.	O

Selective	O
costimulation	O
modulators	O
:	O
a	O
novel	O
approach	O
for	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

T	O
cells	O
have	O
a	O
central	O
role	O
in	O
the	O
orchestration	O
of	O
the	O
immune	O
pathways	O
that	O
contribute	O
to	O
the	O
inflammation	O
and	O
joint	O
destruction	O
characteristic	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

The	O
requirement	O
for	O
a	O
dual	O
signal	O
for	O
T	O
-	O
cell	O
activation	O
and	O
the	O
construction	O
of	O
a	O
fusion	O
protein	O
that	O
prevents	O
engagement	O
of	O
the	O
costimulatory	O
molecules	O
required	O
for	O
this	O
activation	O
has	O
led	O
to	O
a	O
new	O
approach	O
to	O
RA	O
therapy	O
.	O

This	O
approach	O
is	O
mechanistically	O
distinct	O
from	O
other	O
currently	O
used	O
therapies	O
;	O
it	O
targets	O
events	O
early	O
rather	O
than	O
late	O
in	O
the	O
immune	O
cascade	O
,	O
and	O
it	O
results	O
in	O
immunomodulation	O
rather	O
than	O
complete	O
immunosuppression	O
.	O

The	O
fusion	O
protein	O
abatacept	O
is	O
a	O
selective	O
costimulation	O
modulator	O
that	O
avidly	O
binds	O
to	O
the	O
CD80	B-GENE-Y
/	O
CD86	B-GENE-Y
ligands	O
on	O
an	O
antigen	O
-	O
presenting	O
cell	O
,	O
resulting	O
in	O
the	O
inability	O
of	O
these	O
ligands	O
to	O
engage	O
the	O
CD28	B-GENE-N
receptor	I-GENE-N
on	O
the	O
T	O
cell	O
.	O

Abatacept	O
dose	O
-	O
dependently	O
reduces	O
T	O
-	O
cell	O
proliferation	O
,	O
serum	O
concentrations	O
of	O
acute	O
-	O
phase	O
reactants	O
,	O
and	O
other	O
markers	O
of	O
inflammation	O
,	O
including	O
the	O
production	O
of	O
rheumatoid	O
factor	O
by	O
B	O
cells	O
.	O

Recent	O
studies	O
have	O
provided	O
consistent	O
evidence	O
that	O
treatment	O
with	O
abatacept	O
results	O
in	O
a	O
rapid	O
onset	O
of	O
efficacy	O
that	O
is	O
maintained	O
over	O
the	O
course	O
of	O
treatment	O
in	O
patients	O
with	O
inadequate	O
response	O
to	O
methotrexate	B-CHEMICAL
and	O
anti	O
-	O
tumor	B-GENE-N
necrosis	I-GENE-N
factor	I-GENE-N
therapies	O
.	O

This	O
efficacy	O
includes	O
patient	O
-	O
centered	O
outcomes	O
and	O
radiographic	O
measurement	O
of	O
disease	O
progression	O
.	O

Abatacept	O
has	O
also	O
demonstrated	O
a	O
very	O
favorable	O
safety	O
profile	O
to	O
date	O
.	O

This	O
article	O
reviews	O
the	O
rationale	O
for	O
this	O
therapeutic	O
approach	O
and	O
highlights	O
some	O
of	O
the	O
recent	O
studies	O
that	O
demonstrate	O
the	O
benefits	O
obtained	O
by	O
using	O
abatacept	O
.	O

This	O
clinical	O
experience	O
indicates	O
that	O
abatacept	O
is	O
a	O
significant	O
addition	O
to	O
the	O
therapeutic	O
armamentarium	O
for	O
the	O
management	O
of	O
patients	O
with	O
RA	O
.	O

Identification	O
of	O
the	O
regulatory	O
region	O
of	O
the	O
L	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
pyruvate	I-GENE-Y
kinase	I-GENE-Y
gene	O
in	O
mouse	O
liver	O
by	O
hydrodynamics	O
-	O
based	O
gene	O
transfection	O
.	O

Expression	O
of	O
L	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
pyruvate	I-GENE-Y
kinase	I-GENE-Y
(	O
L	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
)	O
is	O
upregulated	O
in	O
the	O
liver	O
by	O
dietary	O
carbohydrate	B-CHEMICAL
.	O

Previously	O
,	O
3	O
carbohydrate	B-GENE-N
/	I-GENE-N
insulin	I-GENE-N
response	I-GENE-N
elements	I-GENE-N
were	O
identified	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
L	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
gene	O
up	O
to	O
bp	O
-	O
170	O
.	O

Studies	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
beyond	O
bp	O
-	O
183	O
in	O
transgenic	O
mice	O
suggested	O
that	O
other	O
regulatory	O
elements	O
may	O
be	O
present	O
upstream	O
of	O
bp	O
-	O
183	O
,	O
but	O
the	O
positions	O
of	O
these	O
elements	O
were	O
uncertain	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
existence	O
of	O
regulatory	O
regions	O
of	O
the	O
L	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
gene	O
responding	O
to	O
stimulation	O
by	O
feeding	O
was	O
examined	O
using	O
in	O
vivo	O
hydrodynamics	O
-	O
based	O
gene	O
transfection	O
(	O
HT	O
)	O
in	O
mouse	O
liver	O
.	O

The	O
firefly	O
-	O
luciferase	O
(	O
FL	O
)	O
gene	O
,	O
fused	O
with	O
various	O
lengths	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
L	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
gene	O
,	O
was	O
introduced	O
into	O
mouse	O
liver	O
by	O
HT	O
.	O

The	O
mice	O
had	O
free	O
access	O
to	O
a	O
high	O
-	O
carbohydrate	B-CHEMICAL
diet	O
.	O

In	O
liver	O
homogenate	O
,	O
luciferase	O
activity	O
of	O
pL	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
(	O
-	O
1467	O
)	O
-	O
FL	O
(	O
which	O
included	O
the	O
5	O
'	O
-	O
flanking	O
region	O
from	O
bp	O
-	O
1467	O
to	O
+	O
17	O
)	O
,	O
was	O
markedly	O
stimulated	O
by	O
feeding	O
.	O

5	O
'	O
-	O
Deletion	O
up	O
to	O
bp	O
-	O
1065	O
caused	O
only	O
minor	O
changes	O
in	O
luciferase	O
activity	O
,	O
but	O
further	O
deletion	O
up	O
to	O
bp	O
-	O
690	O
and	O
bp	O
-	O
203	O
caused	O
significant	O
,	O
gradual	O
decreases	O
in	O
activity	O
.	O

Further	O
analyses	O
utilizing	O
5	O
'	O
-	O
deletion	O
mutants	O
indicated	O
the	O
existence	O
of	O
positive	O
regulatory	O
regions	O
that	O
respond	O
to	O
stimulation	O
by	O
feeding	O
between	O
bp	O
-	O
1065	O
and	O
-	O
945	O
,	O
and	O
between	O
-	O
300	O
and	O
-	O
203	O
on	O
the	O
L	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
gene	O
.	O

These	O
results	O
suggest	O
that	O
unidentified	O
cis	B-GENE-N
-	I-GENE-N
acting	I-GENE-N
DNA	I-GENE-N
elements	I-GENE-N
exist	O
in	O
the	O
upstream	O
region	O
of	O
the	O
L	B-GENE-Y
-	I-GENE-Y
PK	I-GENE-Y
gene	O
,	O
and	O
that	O
HT	O
is	O
a	O
useful	O
approach	O
for	O
detecting	O
regulatory	O
regions	O
of	O
genes	O
expressed	O
in	O
the	O
liver	O
.	O

Dose	O
-	O
response	O
effect	O
of	O
tetracyclines	B-CHEMICAL
on	O
cerebral	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
after	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
hyperstimulation	O
.	O

Brain	O
arteriovenous	O
malformations	O
(	O
BAVMs	O
)	O
are	O
a	O
potentially	O
life	O
-	O
threatening	O
disorder	O
.	O

Matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
(	I-GENE-Y
MMP	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
activity	O
was	O
greatly	O
increased	O
in	O
BAVM	O
tissue	O
specimens	O
.	O

Doxycycline	B-CHEMICAL
was	O
shown	O
to	O
decrease	O
cerebral	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
activities	O
and	O
angiogenesis	O
induced	O
by	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
dose	O
-	O
response	O
effects	O
of	O
doxycycline	B-CHEMICAL
and	O
minocycline	B-CHEMICAL
on	O
cerebral	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
using	O
our	O
mouse	O
model	O
with	O
VEGF	B-GENE-Y
focal	O
hyperstimulation	O
delivered	O
with	O
adenoviral	O
vector	O
(	O
AdVEGF	B-GENE-Y
)	O
in	O
the	O
brain	O
.	O

Mice	O
were	O
treated	O
with	O
doxycycline	B-CHEMICAL
or	O
minocycline	B-CHEMICAL
,	O
respectively	O
,	O
at	O
1	O
,	O
5	O
,	O
10	O
,	O
30	O
,	O
50	O
,	O
or	O
100	O
mg	O
/	O
kg	O
/	O
day	O
through	O
drinking	O
water	O
for	O
1	O
week	O
.	O

Our	O
results	O
have	O
shown	O
that	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
messenger	O
ribonucleic	O
acid	O
(	O
mRNA	O
)	O
expression	O
was	O
inhibited	O
by	O
doxycycline	B-CHEMICAL
starting	O
at	O
10	O
mg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Minocycline	B-CHEMICAL
showed	O
more	O
potent	O
inhibition	O
on	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
mRNA	O
expression	O
,	O
starting	O
at	O
1	O
(	O
P	O
<	O
0	O
.	O
005	O
)	O
and	O
further	O
at	O
more	O
than	O
30	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
mg	O
/	O
kg	O
/	O
day	O
.	O

At	O
the	O
enzymatic	O
activity	O
level	O
,	O
doxycycline	B-CHEMICAL
started	O
to	O
suppress	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
activity	O
at	O
5	O
mg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
minocycline	B-CHEMICAL
had	O
an	O
effect	O
at	O
a	O
lower	O
dose	O
,	O
1	O
mg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

The	O
inhibition	O
of	O
cerebral	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
mRNA	O
and	O
activity	O
were	O
highly	O
correlated	O
with	O
drug	O
levels	O
in	O
the	O
brain	O
tissue	O
.	O

We	O
also	O
assessed	O
the	O
potential	O
relevant	O
signaling	O
pathway	O
in	O
vitro	O
to	O
elucidate	O
the	O
mechanisms	O
underlying	O
the	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
inhibition	O
by	O
tetracyclines	B-CHEMICAL
.	O

In	O
vitro	O
,	O
minocycline	B-CHEMICAL
,	O
but	O
not	O
doxycycline	B-CHEMICAL
,	O
inhibits	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
,	O
at	O
least	O
in	O
part	O
,	O
via	O
the	O
extracellular	B-GENE-N
signaling	I-GENE-N
-	I-GENE-N
related	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
-	O
mediated	O
pathway	O
.	O

This	O
study	O
provided	O
the	O
evidence	O
that	O
the	O
tetracyclines	B-CHEMICAL
inhibit	O
stimulated	O
cerebral	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
at	O
multiple	O
levels	O
and	O
are	O
effective	O
at	O
very	O
low	O
doses	O
,	O
offering	O
great	O
potential	O
for	O
therapeutic	O
use	O
.	O

Characterization	O
of	O
the	O
omega	B-GENE-N
class	I-GENE-N
of	I-GENE-N
glutathione	I-GENE-N
transferases	I-GENE-N
.	O

The	O
Omega	B-GENE-N
class	I-GENE-N
of	I-GENE-N
cytosolic	I-GENE-N
glutathione	I-GENE-N
transferases	I-GENE-N
was	O
initially	O
recognized	O
by	O
bioinformatic	O
analysis	O
of	O
human	O
sequence	O
databases	O
,	O
and	O
orthologous	O
sequences	O
were	O
subsequently	O
discovered	O
in	O
mouse	O
,	O
rat	O
,	O
pig	O
,	O
Caenorhabditis	O
elegans	O
,	O
Schistosoma	O
mansoni	O
,	O
and	O
Drosophila	O
melanogaster	O
.	O

In	O
humans	O
and	O
mice	O
,	O
two	O
GSTO	B-GENE-N
genes	O
have	O
been	O
recognized	O
and	O
their	O
genetic	O
structures	O
and	O
expression	O
patterns	O
identified	O
.	O

In	O
both	O
species	O
,	O
GSTO1	B-GENE-Y
mRNA	O
is	O
expressed	O
in	O
liver	O
and	O
heart	O
as	O
well	O
as	O
a	O
range	O
of	O
other	O
tissues	O
.	O

GSTO2	B-GENE-Y
is	O
expressed	O
predominantly	O
in	O
the	O
testis	O
,	O
although	O
moderate	O
levels	O
of	O
expression	O
are	O
seen	O
in	O
other	O
tissues	O
.	O

Extensive	O
immunohistochemistry	O
of	O
rat	O
and	O
human	O
tissue	O
sections	O
has	O
demonstrated	O
cellular	O
and	O
subcellular	O
specificity	O
in	O
the	O
expression	O
of	O
GSTO1	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

The	O
crystal	O
structure	O
of	O
recombinant	O
human	B-GENE-Y
GSTO1	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
has	O
been	O
determined	O
,	O
and	O
it	O
adopts	O
the	O
canonical	O
GST	B-GENE-N
fold	I-GENE-N
.	O

A	O
cysteine	B-CHEMICAL
residue	O
in	O
place	O
of	O
the	O
catalytic	O
tyrosine	B-CHEMICAL
or	O
serine	B-CHEMICAL
residues	O
found	O
in	O
other	O
GSTs	B-GENE-N
was	O
shown	O
to	O
form	O
a	O
mixed	O
disulfide	B-CHEMICAL
with	O
glutathione	B-CHEMICAL
.	O

Omega	B-GENE-N
class	I-GENE-N
GSTs	I-GENE-N
have	O
dehydroascorbate	B-GENE-N
reductase	I-GENE-N
and	O
thioltransferase	B-GENE-N
activities	O
and	O
also	O
catalyze	O
the	O
reduction	O
of	O
monomethylarsonate	B-CHEMICAL
,	O
an	O
intermediate	O
in	O
the	O
pathway	O
of	O
arsenic	B-CHEMICAL
biotransformation	O
.	O

Other	O
diverse	O
actions	O
of	O
human	B-GENE-Y
GSTO1	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
include	O
modulation	O
of	O
ryanodine	B-GENE-N
receptors	I-GENE-N
and	O
interaction	O
with	O
cytokine	B-GENE-N
release	O
inhibitory	O
drugs	O
.	O

In	O
addition	O
,	O
GSTO1	B-GENE-Y
has	O
been	O
linked	O
to	O
the	O
age	O
at	O
onset	O
of	O
both	O
Alzheimer	O
'	O
s	O
and	O
Parkinson	O
'	O
s	O
diseases	O
.	O

Several	O
polymorphisms	O
have	O
been	O
identified	O
in	O
the	O
coding	O
regions	O
of	O
the	O
human	B-GENE-Y
GSTO1	I-GENE-Y
and	O
GSTO2	B-GENE-Y
genes	O
.	O

Our	O
laboratory	O
has	O
expressed	O
recombinant	O
human	B-GENE-Y
GSTO1	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
GSTO2	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
proteins	O
,	O
as	O
well	O
as	O
a	O
number	O
of	O
polymorphic	O
variants	O
.	O

The	O
expression	O
and	O
purification	O
of	O
these	O
proteins	O
and	O
determination	O
of	O
their	O
enzymatic	O
activity	O
is	O
described	O
.	O

Galanin	B-GENE-Y
attenuates	O
cyclic	B-GENE-N
AMP	I-GENE-N
regulatory	I-GENE-N
element	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
phosphorylation	O
induced	O
by	O
chronic	O
morphine	B-CHEMICAL
and	O
naloxone	B-CHEMICAL
challenge	O
in	O
Cath	O
.	O
a	O
cells	O
and	O
primary	O
striatal	O
cultures	O
.	O

Repeated	O
morphine	B-CHEMICAL
administration	O
leads	O
to	O
molecular	O
alterations	O
of	O
the	O
neural	O
circuitry	O
in	O
the	O
locus	O
coeruleus	O
and	O
nucleus	O
accumbens	O
.	O

These	O
changes	O
include	O
increased	O
activity	O
of	O
several	O
components	O
of	O
the	O
cAMP	B-CHEMICAL
signaling	O
pathway	O
that	O
are	O
thought	O
to	O
be	O
associated	O
with	O
psychological	O
and	O
somatic	O
signs	O
of	O
opiate	O
withdrawal	O
.	O

The	O
neuropeptide	O
galanin	B-GENE-Y
has	O
been	O
shown	O
to	O
attenuate	O
cAMP	B-CHEMICAL
signaling	O
in	O
multiple	O
cell	O
types	O
.	O

The	O
current	O
study	O
demonstrates	O
that	O
acute	O
galanin	B-GENE-Y
treatment	O
blocks	O
the	O
consequences	O
of	O
increased	O
cAMP	B-CHEMICAL
signaling	O
following	O
chronic	O
opiate	O
administration	O
and	O
withdrawal	O
in	O
Cath	O
.	O
a	O
cells	O
and	O
primary	O
cultures	O
of	O
striatal	O
neurons	O
as	O
measured	O
by	O
phosphorylation	O
of	O
the	O
transcription	O
factor	O
cAMP	B-GENE-N
regulatory	I-GENE-N
element	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
(	O
CREB	B-GENE-N
)	O
.	O

In	O
addition	O
,	O
galanin	B-GENE-Y
-	O
mediated	O
attenuation	O
of	O
CREB	B-GENE-N
phosphorylation	O
is	O
independent	O
of	O
galanin	B-GENE-Y
-	O
induced	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	I-GENE-N
ERK	I-GENE-N
)	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
phosphorylation	O
in	O
Cath	O
.	O
a	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
galanin	B-GENE-N
receptors	I-GENE-N
may	O
serve	O
as	O
an	O
additional	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
opiate	O
withdrawal	O
.	O

Systemic	O
administration	O
of	O
beta2	B-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonists	O
,	O
formoterol	B-CHEMICAL
and	O
salmeterol	B-CHEMICAL
,	O
elicit	O
skeletal	O
muscle	O
hypertrophy	O
in	O
rats	O
at	O
micromolar	O
doses	O
.	O

beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
Adrenoceptor	I-GENE-Y
agonists	O
provide	O
a	O
potential	O
therapy	O
for	O
muscle	O
wasting	O
and	O
weakness	O
,	O
but	O
their	O
use	O
may	O
be	O
limited	O
by	O
adverse	O
effects	O
on	O
the	O
heart	O
,	O
mediated	O
in	O
part	O
,	O
by	O
beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
activation	O
.	O

Two	O
beta	O
(	O
2	O
)	O
-	O
agonists	O
,	O
formoterol	B-CHEMICAL
and	O
salmeterol	B-CHEMICAL
,	O
are	O
approved	O
for	O
treating	O
asthma	O
and	O
have	O
an	O
extended	O
duration	O
of	O
action	O
and	O
increased	O
safety	O
,	O
associated	O
with	O
greater	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
selectivity	O
.	O

The	O
pharmacological	O
profiles	O
of	O
formoterol	B-CHEMICAL
and	O
salmeterol	B-CHEMICAL
and	O
their	O
effects	O
on	O
skeletal	O
and	O
cardiac	O
muscle	O
mass	O
were	O
investigated	O
in	O
12	O
-	O
week	O
-	O
old	O
,	O
male	O
F344	O
rats	O
.	O

Formoterol	B-CHEMICAL
and	O
salmeterol	B-CHEMICAL
were	O
each	O
administered	O
via	O
daily	O
i	O
.	O
p	O
.	O
injection	O
at	O
one	O
of	O
seven	O
doses	O
(	O
ranging	O
from	O
1	O
to	O
2	O
,	O
000	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
)	O
,	O
for	O
4	O
weeks	O
.	O

Rats	O
were	O
anaesthetised	O
and	O
the	O
EDL	O
and	O
soleus	O
muscles	O
and	O
the	O
heart	O
were	O
excised	O
and	O
weighed	O
.	O

Dose	O
-	O
response	O
curves	O
were	O
constructed	O
based	O
on	O
skeletal	O
and	O
cardiac	O
muscle	O
hypertrophy	O
.	O

Formoterol	B-CHEMICAL
was	O
more	O
potent	O
than	O
salmeterol	B-CHEMICAL
,	O
with	O
a	O
significantly	O
lower	O
ED	O
(	O
50	O
)	O
in	O
EDL	O
muscles	O
(	O
1	O
and	O
130	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
salmeterol	B-CHEMICAL
had	O
greater	O
intrinsic	O
activity	O
than	O
formoterol	B-CHEMICAL
in	O
both	O
EDL	O
and	O
soleus	O
muscles	O
(	O
12	O
%	O
greater	O
hypertrophy	O
than	O
formoterol	B-CHEMICAL
)	O
.	O

The	O
drugs	O
had	O
similar	O
potency	O
and	O
intrinsic	O
activity	O
in	O
the	O
heart	O
,	O
with	O
a	O
smaller	O
leftward	O
shift	O
for	O
formoterol	B-CHEMICAL
than	O
seen	O
in	O
skeletal	O
muscle	O
.	O

A	O
dose	O
of	O
25	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
of	O
formoterol	B-CHEMICAL
elicited	O
greater	O
EDL	O
and	O
soleus	O
hypertrophy	O
than	O
salmeterol	B-CHEMICAL
,	O
but	O
resulted	O
in	O
similar	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
downregulation	O
.	O

These	O
results	O
show	O
that	O
doses	O
as	O
low	O
as	O
1	O
microg	O
kg	O
(	O
-	O
1	O
)	O
day	O
(	O
-	O
1	O
)	O
of	O
formoterol	B-CHEMICAL
can	O
elicit	O
significant	O
muscle	O
hypertrophy	O
with	O
minimal	O
cardiac	O
hypertrophy	O
and	O
provide	O
important	O
information	O
regarding	O
the	O
potential	O
therapeutic	O
use	O
of	O
formoterol	B-CHEMICAL
and	O
salmeterol	B-CHEMICAL
for	O
muscle	O
wasting	O
.	O

Dasatinib	B-CHEMICAL
(	O
BMS	B-CHEMICAL
-	I-CHEMICAL
354825	I-CHEMICAL
)	O
inhibits	O
KITD816V	B-GENE-Y
,	O
an	O
imatinib	B-CHEMICAL
-	O
resistant	O
activating	O
mutation	O
that	O
triggers	O
neoplastic	O
growth	O
in	O
most	O
patients	O
with	O
systemic	O
mastocytosis	O
.	O

Mastocytosis	O
is	O
associated	O
with	O
an	O
activating	O
mutation	O
in	O
the	O
KIT	B-GENE-Y
oncoprotein	O
(	O
KITD816V	B-GENE-Y
)	O
that	O
results	O
in	O
autophosphorylation	O
of	O
the	O
KIT	B-GENE-Y
receptor	O
in	O
a	O
ligand	O
-	O
independent	O
manner	O
.	O

This	O
mutation	O
is	O
inherently	O
resistant	O
to	O
imatinib	B-CHEMICAL
and	O
,	O
to	O
date	O
,	O
there	O
remains	O
no	O
effective	O
curative	O
therapy	O
for	O
systemic	O
mastocytosis	O
associated	O
with	O
KITD816V	B-GENE-Y
.	O

Dasatinib	B-CHEMICAL
(	O
BMS	B-CHEMICAL
-	I-CHEMICAL
354825	I-CHEMICAL
)	O
is	O
a	O
novel	O
orally	O
bioavailable	O
SRC	B-GENE-Y
/	O
ABL	B-GENE-Y
inhibitor	O
that	O
has	O
activity	O
against	O
multiple	O
imatinib	B-CHEMICAL
-	O
resistant	O
BCR	B-GENE-Y
-	O
ABL	B-GENE-Y
isoforms	O
in	O
vitro	O
that	O
is	O
presently	O
showing	O
considerable	O
promise	O
in	O
early	O
-	O
phase	O
clinical	O
trials	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

Pharmacokinetic	O
analysis	O
suggests	O
that	O
high	O
nanomolar	O
concentrations	O
of	O
dasatinib	B-CHEMICAL
can	O
be	O
achieved	O
safely	O
in	O
humans	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
significant	O
inhibitory	O
activity	O
of	O
dasatinib	B-CHEMICAL
against	O
both	O
wild	O
-	O
type	O
KIT	B-GENE-Y
and	O
the	O
KITD816V	B-GENE-Y
mutation	O
in	O
the	O
nanomolar	O
range	O
in	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
kinase	B-GENE-N
assays	O
.	O

Additionally	O
,	O
dasatinib	B-CHEMICAL
leads	O
to	O
growth	O
inhibition	O
of	O
a	O
KITD816V	B-GENE-Y
-	O
harboring	O
human	O
masto	O
-	O
cytosis	O
cell	O
line	O
.	O

Significantly	O
,	O
dasatinib	B-CHEMICAL
selectively	O
kills	O
primary	O
neoplastic	O
bone	O
marrow	O
mast	O
cells	O
from	O
patients	O
with	O
systemic	O
mastocytosis	O
while	O
sparing	O
other	O
hematopoietic	O
cells	O
.	O

Computer	O
modeling	O
suggests	O
that	O
the	O
KITD816V	B-GENE-Y
mutation	O
destabilizes	O
the	O
inactive	O
conformation	O
of	O
the	O
KIT	B-GENE-N
activation	I-GENE-N
loop	I-GENE-N
to	O
which	O
imatinib	B-CHEMICAL
binds	O
,	O
but	O
it	O
is	O
not	O
predicted	O
to	O
impair	O
binding	O
of	O
KIT	B-GENE-Y
by	O
dasatinib	B-CHEMICAL
.	O

Based	O
upon	O
our	O
results	O
,	O
further	O
evaluation	O
of	O
dasatinib	B-CHEMICAL
for	O
the	O
treatment	O
of	O
systemic	O
masto	O
-	O
cytosis	O
in	O
clinical	O
trials	O
is	O
warranted	O
.	O

Moreover	O
,	O
dasatinib	B-CHEMICAL
may	O
be	O
of	O
clinical	O
utility	O
in	O
other	O
disease	O
settings	O
driven	O
by	O
activating	O
KIT	B-GENE-Y
mutations	O
.	O

Cholinesterase	B-GENE-Y
inhibitors	O
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O

BACKGROUND	O
:	O
Since	O
the	O
introduction	O
of	O
the	O
first	O
cholinesterase	B-GENE-Y
inhibitor	O
(	O
ChEI	O
)	O
in	O
1997	O
,	O
most	O
clinicians	O
and	O
probably	O
most	O
patients	O
would	O
consider	O
the	O
cholinergic	O
drugs	O
,	O
donepezil	B-CHEMICAL
,	O
galantamine	B-CHEMICAL
and	O
rivastigmine	B-CHEMICAL
,	O
to	O
be	O
the	O
first	O
line	O
pharmacotherapy	O
for	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
.	O
The	O
drugs	O
have	O
slightly	O
different	O
pharmacological	O
properties	O
,	O
but	O
they	O
all	O
work	O
by	O
inhibiting	O
the	O
breakdown	O
of	O
acetylcholine	B-CHEMICAL
,	O
an	O
important	O
neurotransmitter	O
associated	O
with	O
memory	O
,	O
by	O
blocking	O
the	O
enzyme	O
acetylcholinesterase	B-GENE-Y
.	O

The	O
most	O
that	O
these	O
drugs	O
could	O
achieve	O
is	O
to	O
modify	O
the	O
manifestations	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Cochrane	O
reviews	O
of	O
each	O
ChEI	O
for	O
Alzheimer	O
'	O
s	O
disease	O
have	O
been	O
completed	O
(	O
Birks	O
2005	O
,	O
Birks	O
2005b	O
and	O
Loy	O
2005	O
)	O
.	O

Despite	O
the	O
evidence	O
from	O
the	O
clinical	O
studies	O
and	O
the	O
intervening	O
clinical	O
experience	O
the	O
debate	O
on	O
whether	O
ChEIs	O
are	O
effective	O
continues	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effects	O
of	O
donepezil	B-CHEMICAL
,	O
galantamine	B-CHEMICAL
and	O
rivastigmine	B-CHEMICAL
in	O
people	O
with	O
mild	O
,	O
moderate	O
or	O
severe	O
dementia	O
due	O
to	O
Alzheimer	O
'	O
s	O
disease	O
.	O

SEARCH	O
STRATEGY	O
:	O
The	O
Cochrane	O
Dementia	O
and	O
Cognitive	O
Improvement	O
Group	O
'	O
s	O
Specialized	O
Register	O
was	O
searched	O
using	O
the	O
terms	O
'	O
donepezil	B-CHEMICAL
'	O
,	O
'	O
E2020	B-CHEMICAL
'	O
,	O
'	O
Aricept	B-CHEMICAL
'	O
,	O
galanthamin	B-CHEMICAL
*	O
galantamin	B-CHEMICAL
*	O
reminyl	B-CHEMICAL
,	O
rivastigmine	B-CHEMICAL
,	O
exelon	B-CHEMICAL
,	O
"	O
ENA	B-CHEMICAL
713	I-CHEMICAL
"	O
and	O
ENA	B-CHEMICAL
-	I-CHEMICAL
713	I-CHEMICAL
on	O
12	O
June	O
2005	O
.	O

This	O
Register	O
contains	O
up	O
-	O
to	O
-	O
date	O
records	O
of	O
all	O
major	O
health	O
care	O
databases	O
and	O
many	O
ongoing	O
trial	O
databases	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
unconfounded	O
,	O
blinded	O
,	O
randomized	O
trials	O
in	O
which	O
treatment	O
with	O
a	O
ChEI	O
was	O
compared	O
with	O
placebo	O
or	O
another	O
ChEI	O
for	O
patients	O
with	O
mild	O
,	O
moderate	O
or	O
severe	O
dementia	O
due	O
to	O
Alzheimer	O
'	O
s	O
disease	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
Data	O
were	O
extracted	O
by	O
one	O
reviewer	O
(	O
JSB	O
)	O
,	O
pooled	O
where	O
appropriate	O
and	O
possible	O
,	O
and	O
the	O
pooled	O
treatment	O
effects	O
,	O
or	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
estimated	O
.	O

MAIN	O
RESULTS	O
:	O
The	O
results	O
of	O
13	O
randomized	O
,	O
double	O
blind	O
,	O
placebo	O
controlled	O
trials	O
demonstrate	O
that	O
treatment	O
for	O
periods	O
of	O
6	O
months	O
and	O
one	O
year	O
,	O
with	O
donepezil	B-CHEMICAL
,	O
galantamine	B-CHEMICAL
or	O
rivastigmine	B-CHEMICAL
at	O
the	O
recommended	O
dose	O
for	O
people	O
with	O
mild	O
,	O
moderate	O
or	O
severe	O
dementia	O
due	O
to	O
Alzheimer	O
'	O
s	O
disease	O
produced	O
improvements	O
in	O
cognitive	O
function	O
,	O
on	O
average	O
-	O
2	O
.	O
7	O
points	O
(	O
95	O
%	O
CI	O
-	O
3	O
.	O
0	O
to	O
-	O
2	O
.	O
3	O
)	O
,	O
in	O
the	O
midrange	O
of	O
the	O
70	O
point	O
ADAS	O
-	O
Cog	O
Scale	O
.	O

Study	O
clinicians	O
blind	O
to	O
other	O
measures	O
rated	O
global	O
clinical	O
state	O
more	O
positively	O
in	O
treated	O
patients	O
.	O

Benefits	O
of	O
treatment	O
were	O
also	O
seen	O
on	O
measures	O
of	O
activities	O
of	O
daily	O
living	O
and	O
behaviour	O
.	O

None	O
of	O
these	O
treatment	O
effects	O
are	O
large	O
.	O

There	O
is	O
nothing	O
to	O
suggest	O
the	O
effects	O
are	O
less	O
for	O
patients	O
with	O
severe	O
dementia	O
or	O
mild	O
dementia	O
,	O
although	O
there	O
is	O
very	O
little	O
evidence	O
for	O
other	O
than	O
mild	O
to	O
moderate	O
dementia	O
.	O
More	O
patients	O
leave	O
ChEI	O
treatment	O
groups	O
,	O
approximately	O
29	O
%	O
,	O
on	O
account	O
of	O
adverse	O
events	O
than	O
leave	O
the	O
placebo	O
groups	O
(	O
18	O
%	O
)	O
.	O

There	O
is	O
evidence	O
of	O
more	O
adverse	O
events	O
in	O
total	O
in	O
the	O
patients	O
treated	O
with	O
a	O
ChEI	O
than	O
with	O
placebo	O
.	O

Although	O
many	O
types	O
of	O
adverse	O
event	O
were	O
reported	O
,	O
nausea	O
,	O
vomiting	O
,	O
diarrhoea	O
,	O
were	O
significantly	O
more	O
frequent	O
in	O
the	O
ChEI	O
groups	O
than	O
in	O
placebo	O
.	O

There	O
are	O
four	O
studies	O
,	O
all	O
supported	O
by	O
one	O
of	O
the	O
pharmaceutical	O
companies	O
,	O
in	O
which	O
two	O
ChEIs	O
were	O
compared	O
,	O
two	O
studies	O
of	O
donepezil	B-CHEMICAL
compared	O
with	O
galantamine	B-CHEMICAL
,	O
and	O
two	O
of	O
donepezil	B-CHEMICAL
compared	O
with	O
rivastigmine	B-CHEMICAL
.	O

In	O
three	O
studies	O
the	O
patients	O
were	O
not	O
blinded	O
to	O
treatment	O
,	O
only	O
the	O
fourth	O
,	O
DON	O
vs	O
RIV	O
/	O
Bullock	O
is	O
double	O
blind	O
.	O

Two	O
of	O
the	O
studies	O
provide	O
little	O
evidence	O
,	O
they	O
are	O
of	O
12	O
weeks	O
duration	O
,	O
which	O
is	O
barely	O
long	O
enough	O
to	O
complete	O
the	O
drug	O
titration	O
.	O

There	O
is	O
no	O
evidence	O
from	O
DON	O
vs	O
GAL	O
/	O
Wilcock	O
of	O
a	O
treatment	O
difference	O
between	O
donepezil	B-CHEMICAL
and	O
galantamine	B-CHEMICAL
at	O
52	O
weeks	O
for	O
cognition	O
,	O
activities	O
of	O
daily	O
living	O
,	O
the	O
numbers	O
who	O
leave	O
the	O
trial	O
before	O
the	O
end	O
of	O
treatment	O
,	O
the	O
number	O
who	O
suffer	O
any	O
adverse	O
event	O
,	O
or	O
any	O
specific	O
adverse	O
event	O
.	O

There	O
is	O
no	O
evidence	O
from	O
DON	O
vs	O
RIV	O
/	O
Bullock	O
of	O
a	O
difference	O
between	O
donepezil	B-CHEMICAL
and	O
rivastigmine	B-CHEMICAL
for	O
cognitive	O
function	O
,	O
activities	O
of	O
daily	O
living	O
and	O
behavioural	O
disturbance	O
at	O
two	O
years	O
.	O

Fewer	O
patients	O
suffer	O
adverse	O
events	O
on	O
donepezil	B-CHEMICAL
than	O
rivastigmine	B-CHEMICAL
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
The	O
three	O
cholinesterase	B-GENE-Y
inhibitors	O
are	O
efficacious	O
for	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
.	O

It	O
is	O
not	O
possible	O
to	O
identify	O
those	O
who	O
will	O
respond	O
to	O
treatment	O
prior	O
to	O
treatment	O
.	O

There	O
is	O
no	O
evidence	O
that	O
treatment	O
with	O
a	O
ChEI	O
is	O
not	O
cost	O
effective	O
.	O

Despite	O
the	O
slight	O
variations	O
in	O
the	O
mode	O
of	O
action	O
of	O
the	O
three	O
cholinesterase	B-GENE-Y
inhibitors	O
there	O
is	O
no	O
evidence	O
of	O
any	O
differences	O
between	O
them	O
with	O
respect	O
to	O
efficacy	O
.	O

There	O
appears	O
to	O
be	O
less	O
adverse	O
effects	O
associated	O
with	O
donepezil	B-CHEMICAL
compared	O
with	O
rivastigmine	B-CHEMICAL
.	O

It	O
may	O
be	O
that	O
galantamine	B-CHEMICAL
and	O
rivastigmine	B-CHEMICAL
match	O
donepezil	B-CHEMICAL
in	O
tolerability	O
if	O
a	O
careful	O
and	O
gradual	O
titration	O
routine	O
over	O
more	O
than	O
three	O
months	O
is	O
used	O
.	O

Titration	O
with	O
donepezil	B-CHEMICAL
is	O
more	O
straightforward	O
and	O
the	O
lower	O
dose	O
may	O
be	O
worth	O
consideration	O
.	O

Intradialytic	O
parenteral	O
nutrition	O
:	O
comparison	O
of	O
olive	O
oil	O
versus	O
soybean	O
oil	O
-	O
based	O
lipid	O
emulsions	O
.	O

Lipid	O
,	O
oxidative	O
and	O
inflammatory	O
parameters	O
are	O
frequently	O
altered	O
in	O
dialysis	O
patients	O
and	O
may	O
be	O
worsened	O
by	O
intravenous	O
lipid	O
emulsions	O
(	O
ILE	O
)	O
.	O

We	O
assessed	O
the	O
efficacy	O
and	O
tolerance	O
of	O
olive	O
as	O
compared	O
with	O
standard	O
soybean	O
oil	O
-	O
based	O
ILE	O
during	O
intradialytic	O
parenteral	O
nutrition	O
(	O
IDPN	O
)	O
.	O

IDPN	O
mixtures	O
containing	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
glucose	B-CHEMICAL
,	O
and	O
either	O
olive	O
oil	O
(	O
OO	O
group	O
,	O
n	O
17	O
)	O
or	O
soybean	O
oil	O
-	O
based	O
ILE	O
(	O
SO	O
group	O
,	O
n	O
18	O
)	O
were	O
administered	O
in	O
a	O
5	O
-	O
week	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
.	O

On	O
days	O
0	O
and	O
35	O
,	O
patients	O
'	O
nutritional	O
status	O
was	O
assessed	O
by	O
BMI	O
,	O
normalized	O
protein	O
catabolic	O
rate	O
,	O
predialytic	O
creatinine	B-CHEMICAL
,	O
serum	B-GENE-Y
albumin	I-GENE-Y
and	O
transthyretin	B-GENE-Y
;	O
lipid	O
metabolism	O
by	O
plasma	O
LDL	B-GENE-N
-	O
and	O
HDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
,	O
triacylglycerols	B-CHEMICAL
,	O
phospholipids	O
,	O
apo	B-GENE-N
A	I-GENE-N
-	I-GENE-N
I	I-GENE-N
,	I-GENE-N
A	I-GENE-N
-	I-GENE-N
II	I-GENE-N
,	I-GENE-N
B	I-GENE-N
,	I-GENE-N
C	I-GENE-N
-	I-GENE-N
II	I-GENE-N
,	I-GENE-N
C	I-GENE-N
-	I-GENE-N
III	I-GENE-N
,	I-GENE-N
E	I-GENE-N
and	O
lipoprotein	B-GENE-Y
(	I-GENE-Y
a	I-GENE-Y
)	I-GENE-Y
;	O
oxidative	O
status	O
by	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
,	O
retinol	B-CHEMICAL
,	O
selenium	B-CHEMICAL
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
,	O
malondialdehyde	B-CHEMICAL
and	O
advanced	O
oxidized	O
protein	O
products	O
;	O
inflammatory	O
status	O
by	O
serum	O
C	B-GENE-Y
-	I-GENE-Y
reactive	I-GENE-Y
protein	I-GENE-Y
,	O
orosomucoid	B-GENE-N
,	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

No	O
serious	O
adverse	O
event	O
was	O
observed	O
.	O

Significant	O
changes	O
were	O
observed	O
from	O
day	O
0	O
to	O
day	O
35	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
:	O
nutritional	O
criteria	O
improved	O
(	O
albumin	B-GENE-Y
in	O
OO	O
;	O
albumin	B-GENE-Y
,	O
transthyretin	B-GENE-Y
and	O
creatinine	B-CHEMICAL
in	O
SO	O
)	O
;	O
LDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
,	O
apo	B-GENE-N
B	I-GENE-N
,	I-GENE-N
C	I-GENE-N
-	I-GENE-N
II	I-GENE-N
,	I-GENE-N
C	I-GENE-N
-	I-GENE-N
III	I-GENE-N
and	O
apo	B-GENE-N
A	I-GENE-N
-	I-GENE-N
I	I-GENE-N
/	I-GENE-N
A	I-GENE-N
-	I-GENE-N
II	I-GENE-N
ratio	O
increased	O
in	O
both	O
groups	O
.	O

HDL	B-GENE-N
-	O
cholesterol	B-CHEMICAL
decreased	O
in	O
OO	O
;	O
apo	B-GENE-Y
E	I-GENE-Y
increased	O
and	O
lipoprotein	B-GENE-Y
(	I-GENE-Y
a	I-GENE-Y
)	I-GENE-Y
decreased	O
in	O
SO	O
;	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
/	O
cholesterol	B-CHEMICAL
ratio	O
increased	O
in	O
OO	O
;	O
malondialdehyde	B-CHEMICAL
decreased	O
in	O
both	O
groups	O
;	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
increased	O
in	O
both	O
groups	O
.	O

The	O
between	O
-	O
group	O
comparison	O
only	O
showed	O
the	O
following	O
differences	O
:	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
/	O
cholesterol	B-CHEMICAL
increased	O
in	O
OO	O
;	O
lipoprotein	B-GENE-Y
(	I-GENE-Y
a	I-GENE-Y
)	I-GENE-Y
decreased	O
in	O
SO	O
.	O

From	O
these	O
data	O
,	O
it	O
was	O
concluded	O
that	O
OO	O
-	O
and	O
SO	O
-	O
based	O
IDPNs	O
similarly	O
improved	O
nutritional	O
status	O
and	O
influenced	O
plasma	O
lipid	O
,	O
oxidative	O
,	O
inflammatory	O
and	O
immune	O
parameters	O
.	O

Structures	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
human	B-GENE-Y
spermidine	I-GENE-Y
/	I-GENE-Y
spermine	I-GENE-Y
N1	I-GENE-Y
-	I-GENE-Y
acetyltransferase	I-GENE-Y
,	O
a	O
potential	O
therapeutic	O
drug	O
target	O
.	O

Spermidine	B-GENE-Y
/	I-GENE-Y
spermine	I-GENE-Y
N1	I-GENE-Y
-	I-GENE-Y
acetyltransferase	I-GENE-Y
(	O
SSAT	B-GENE-Y
)	O
is	O
a	O
key	O
enzyme	O
in	O
the	O
control	O
of	O
polyamine	B-CHEMICAL
levels	O
in	O
human	O
cells	O
,	O
as	O
acetylation	O
of	O
spermidine	B-CHEMICAL
and	O
spermine	B-CHEMICAL
triggers	O
export	O
or	O
degradation	O
.	O

Increased	O
intracellular	O
polyamine	B-CHEMICAL
levels	O
accompany	O
several	O
types	O
of	O
cancers	O
as	O
well	O
as	O
other	O
human	O
diseases	O
,	O
and	O
compounds	O
that	O
affect	O
the	O
expression	O
,	O
activity	O
,	O
or	O
stability	O
of	O
SSAT	B-GENE-Y
are	O
being	O
explored	O
as	O
potential	O
therapeutic	O
drugs	O
.	O

We	O
have	O
expressed	O
human	B-GENE-Y
SSAT	I-GENE-Y
from	O
the	O
cloned	O
cDNA	O
in	O
Escherichia	O
coli	O
and	O
have	O
determined	O
high	O
-	O
resolution	O
structures	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
SSAT	B-GENE-Y
,	O
as	O
the	O
free	O
dimer	O
and	O
in	O
binary	O
and	O
ternary	O
complexes	O
with	O
CoA	B-CHEMICAL
,	O
acetyl	B-CHEMICAL
-	I-CHEMICAL
CoA	I-CHEMICAL
(	O
AcCoA	B-CHEMICAL
)	O
,	O
spermine	B-CHEMICAL
,	O
and	O
the	O
inhibitor	O
N1	B-CHEMICAL
,	I-CHEMICAL
N11bis	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
ethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
norspermine	I-CHEMICAL
(	O
BE	O
-	O
3	O
-	O
3	O
-	O
3	O
)	O
.	O

These	O
structures	O
show	O
details	O
of	O
binding	O
sites	O
for	O
cofactor	O
,	O
substrates	O
,	O
and	O
inhibitor	O
and	O
provide	O
a	O
framework	O
to	O
understand	O
enzymatic	O
activity	O
,	O
mutations	O
,	O
and	O
the	O
action	O
of	O
potential	O
drugs	O
.	O

Two	O
dimer	O
conformations	O
were	O
observed	O
:	O
a	O
symmetric	O
form	O
with	O
two	O
open	O
surface	O
channels	O
capable	O
of	O
binding	O
substrate	O
or	O
cofactor	O
,	O
and	O
an	O
asymmetric	O
form	O
in	O
which	O
only	O
one	O
of	O
the	O
surface	O
channels	O
appears	O
capable	O
of	O
binding	O
and	O
acetylating	O
polyamines	B-CHEMICAL
.	O

SSAT	B-GENE-Y
was	O
found	O
to	O
self	O
-	O
acetylate	B-CHEMICAL
lysine	B-CHEMICAL
-	O
26	O
in	O
the	O
presence	O
of	O
AcCoA	B-CHEMICAL
and	O
absence	O
of	O
substrate	O
,	O
a	O
reaction	O
apparently	O
catalzyed	O
by	O
AcCoA	B-CHEMICAL
bound	O
in	O
the	O
second	O
channel	O
of	O
the	O
asymmetric	O
dimer	O
.	O

These	O
unexpected	O
and	O
intriguing	O
complexities	O
seem	O
likely	O
to	O
have	O
some	O
as	O
yet	O
undefined	O
role	O
in	O
regulating	O
SSAT	B-GENE-Y
activity	O
or	O
stability	O
as	O
a	O
part	O
of	O
polyamine	B-CHEMICAL
homeostasis	O
.	O

Sequence	O
signatures	O
group	O
SSAT	B-GENE-Y
with	O
proteins	O
that	O
appear	O
to	O
have	O
thialysine	B-GENE-Y
Nepsilon	I-GENE-Y
-	I-GENE-Y
acetyltransferase	I-GENE-Y
activity	O
.	O

Crystal	O
structure	O
of	O
the	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
signaling	O
complex	O
:	O
paradigm	O
for	O
a	O
heterotrimeric	O
cytokine	B-GENE-N
receptor	I-GENE-N
.	O

IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
is	O
a	O
cytokine	B-GENE-N
that	O
functions	O
as	O
a	O
growth	O
factor	O
and	O
central	O
regulator	O
in	O
the	O
immune	O
system	O
and	O
mediates	O
its	O
effects	O
through	O
ligand	O
-	O
induced	O
hetero	O
-	O
trimerization	O
of	O
the	O
receptor	O
subunits	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
,	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
beta	I-GENE-N
,	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
(	I-GENE-N
c	I-GENE-N
)	I-GENE-N
.	O

Here	O
,	O
we	O
describe	O
the	O
crystal	O
structure	O
of	O
the	O
trimeric	O
assembly	O
of	O
the	O
human	B-GENE-N
IL	I-GENE-N
-	I-GENE-N
2	I-GENE-N
receptor	I-GENE-N
ectodomains	O
in	O
complex	O
with	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
at	O
3	O
.	O
0	O
A	O
resolution	O
.	O

The	O
quaternary	O
structure	O
is	O
consistent	O
with	O
a	O
stepwise	O
assembly	O
from	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
to	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
/	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
beta	I-GENE-Y
to	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
/	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
beta	I-GENE-N
/	I-GENE-N
gamma	I-GENE-N
(	I-GENE-N
c	I-GENE-N
)	I-GENE-N
.	O

The	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
subunit	O
forms	O
the	O
largest	O
of	O
the	O
three	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
interfaces	O
,	O
which	O
,	O
together	O
with	O
the	O
high	O
abundance	O
of	O
charge	O
-	O
charge	O
interactions	O
,	O
correlates	O
well	O
with	O
the	O
rapid	O
association	O
rate	O
and	O
high	O
-	O
affinity	O
interaction	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
with	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
at	O
the	O
cell	O
surface	O
.	O

Surprisingly	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
makes	O
no	O
contacts	O
with	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
beta	I-GENE-N
or	I-GENE-N
gamma	I-GENE-N
(	I-GENE-N
c	I-GENE-N
)	I-GENE-N
,	O
and	O
only	O
minor	O
changes	O
are	O
observed	O
in	O
the	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
structure	O
in	O
response	O
to	O
receptor	O
binding	O
.	O

These	O
findings	O
support	O
the	O
principal	O
role	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
to	O
deliver	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
to	O
the	O
signaling	O
complex	O
and	O
act	O
as	O
regulator	O
of	O
signal	O
transduction	O
.	O

Cooperativity	O
in	O
assembly	O
of	O
the	O
final	O
quaternary	O
complex	O
is	O
easily	O
explained	O
by	O
the	O
extraordinarily	O
extensive	O
set	O
of	O
interfaces	O
found	O
within	O
the	O
fully	O
assembled	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
signaling	O
complex	O
,	O
which	O
nearly	O
span	O
the	O
entire	O
length	O
of	O
the	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
beta	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
(	I-GENE-N
c	I-GENE-N
)	I-GENE-N
subunits	O
.	O

Helix	O
A	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
wedges	O
tightly	O
between	O
IL	B-GENE-N
-	I-GENE-N
2R	I-GENE-N
beta	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
(	I-GENE-N
c	I-GENE-N
)	I-GENE-N
to	O
form	O
a	O
three	O
-	O
way	O
junction	O
that	O
coalesces	O
into	O
a	O
composite	O
binding	O
site	O
for	O
the	O
final	O
gamma	O
(	O
c	O
)	O
recruitment	O
.	O

The	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
gamma	O
(	O
c	O
)	O
interface	O
itself	O
exhibits	O
the	O
smallest	O
buried	O
surface	O
and	O
the	O
fewest	O
hydrogen	B-CHEMICAL
bonds	O
in	O
the	O
complex	O
,	O
which	O
is	O
consistent	O
with	O
its	O
promiscuous	O
use	O
in	O
other	O
cytokine	B-GENE-N
receptor	I-GENE-N
complexes	O
.	O

Roles	O
of	O
rifampicin	B-CHEMICAL
in	O
drug	O
-	O
drug	O
interactions	O
:	O
underlying	O
molecular	O
mechanisms	O
involving	O
the	O
nuclear	B-GENE-Y
pregnane	I-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
.	O

Rifampicin	B-CHEMICAL
,	O
an	O
important	O
drug	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
is	O
used	O
extensively	O
despite	O
its	O
broad	O
effects	O
on	O
drug	O
-	O
drug	O
interactions	O
,	O
creating	O
serious	O
problems	O
.	O

The	O
clinical	O
importance	O
of	O
such	O
interactions	O
includes	O
autoinduction	O
leading	O
to	O
suboptimal	O
or	O
failed	O
treatment	O
.	O

The	O
concomitantly	O
administered	O
effects	O
of	O
rifampicin	B-CHEMICAL
on	O
other	O
drugs	O
can	O
result	O
in	O
their	O
altered	O
metabolism	O
or	O
transportation	O
that	O
are	O
metabolised	O
by	O
cytochromes	B-GENE-N
P450	I-GENE-N
or	O
transported	O
by	O
p	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
in	O
the	O
gastrointestinal	O
tract	O
and	O
liver	O
.	O

This	O
review	O
paper	O
summarises	O
recent	O
findings	O
with	O
emphases	O
on	O
the	O
molecular	O
mechanisms	O
used	O
to	O
explain	O
these	O
broad	O
drug	O
-	O
drug	O
interactions	O
.	O

In	O
general	O
,	O
rifampicin	B-CHEMICAL
can	O
act	O
on	O
a	O
pattern	O
:	O
rifampicin	B-CHEMICAL
activates	O
the	O
nuclear	B-GENE-Y
pregnane	I-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
that	O
in	O
turn	O
affects	O
cytochromes	B-GENE-N
P450	I-GENE-N
,	O
glucuronosyltransferases	B-GENE-N
and	O
p	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
activities	O
.	O

This	O
pattern	O
of	O
action	O
may	O
explain	O
many	O
of	O
the	O
rifampicin	B-CHEMICAL
inducing	O
drug	O
-	O
drug	O
interactions	O
.	O

However	O
,	O
effects	O
through	O
other	O
mechanisms	O
have	O
also	O
been	O
reported	O
and	O
these	O
make	O
any	O
explanation	O
of	O
such	O
drug	O
-	O
drug	O
interactions	O
more	O
complex	O
.	O

Withdrawal	O
from	O
free	O
-	O
choice	O
ethanol	B-CHEMICAL
consumption	O
results	O
in	O
increased	O
packing	O
density	O
of	O
glutamine	B-GENE-Y
synthetase	I-GENE-Y
-	O
immunoreactive	O
astrocytes	O
in	O
the	O
prelimbic	O
cortex	O
of	O
alcohol	B-CHEMICAL
-	O
preferring	O
rats	O
.	O

Excess	O
activation	O
of	O
glutamatergic	O
neurotransmission	O
in	O
the	O
cerebral	O
cortex	O
following	O
ethanol	B-CHEMICAL
withdrawal	O
is	O
considered	O
to	O
contribute	O
to	O
significant	O
behavioural	O
disturbances	O
,	O
and	O
to	O
alcohol	B-CHEMICAL
craving	O
.	O

Astrocytes	O
may	O
play	O
a	O
role	O
in	O
these	O
manifestations	O
because	O
astrocytes	O
are	O
essential	O
in	O
the	O
regulation	O
of	O
released	O
glutamate	B-CHEMICAL
and	O
its	O
conversion	O
to	O
glutamine	B-CHEMICAL
through	O
the	O
enzyme	O
glutamine	B-GENE-Y
synthetase	I-GENE-Y
(	O
GS	B-GENE-Y
)	O
.	O

However	O
,	O
it	O
is	O
unclear	O
if	O
withdrawal	O
from	O
free	O
-	O
choice	O
ethanol	B-CHEMICAL
drinking	O
causes	O
changes	O
in	O
the	O
numbers	O
of	O
astrocytes	O
expressing	O
GS	B-GENE-Y
or	O
the	O
cytoskeletal	O
protein	O
of	O
astrocytes	O
glial	B-GENE-Y
fibrillary	I-GENE-Y
acidic	I-GENE-Y
protein	I-GENE-Y
(	O
GFAP	B-GENE-Y
)	O
.	O

Alcohol	B-CHEMICAL
-	O
preferring	O
(	O
P	O
)	O
rats	O
exposed	O
to	O
free	O
-	O
choice	O
ethanol	B-CHEMICAL
drinking	O
were	O
either	O
maintained	O
without	O
forced	O
interruption	O
of	O
ethanol	B-CHEMICAL
drinking	O
,	O
subjected	O
to	O
a	O
3	O
-	O
day	O
withdrawal	O
period	O
at	O
the	O
end	O
of	O
2	O
months	O
,	O
or	O
subjected	O
to	O
three	O
3	O
-	O
day	O
withdrawal	O
periods	O
along	O
6	O
months	O
.	O

At	O
2	O
months	O
,	O
P	O
rats	O
were	O
also	O
compared	O
with	O
alcohol	B-CHEMICAL
-	O
naive	O
alcohol	B-CHEMICAL
non	O
-	O
preferring	O
rats	O
(	O
NP	O
)	O
rats	O
.	O

Packing	O
density	O
of	O
GS	B-GENE-Y
and	O
GFAP	B-GENE-Y
-	O
immunoreactive	O
(	O
IR	O
)	O
astrocytes	O
was	O
measured	O
in	O
sections	O
from	O
the	O
prelimbic	O
cortex	O
(	O
PLC	O
)	O
using	O
the	O
optical	O
disector	O
probe	O
.	O

An	O
alcohol	B-CHEMICAL
deprivation	O
effect	O
was	O
observed	O
in	O
P	O
rats	O
with	O
withdrawals	O
during	O
a	O
6	O
-	O
month	O
ethanol	O
drinking	O
period	O
.	O

Ethanol	B-CHEMICAL
withdrawal	O
significantly	O
increased	O
the	O
packing	O
density	O
of	O
GS	B-GENE-Y
-	O
and	O
GFAP	B-GENE-Y
-	O
IR	O
astrocytes	O
in	O
the	O
PLC	O
of	O
P	O
rats	O
as	O
compared	O
with	O
P	O
rats	O
with	O
continuous	O
access	O
to	O
ethanol	O
.	O

In	O
addition	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
the	O
pre	O
-	O
withdrawal	O
ethanol	B-CHEMICAL
consumption	O
and	O
the	O
packing	O
density	O
of	O
GS	B-GENE-Y
-	O
IR	O
astrocytes	O
.	O

The	O
present	O
results	O
suggest	O
the	O
involvement	O
of	O
astrocytes	O
in	O
the	O
regulation	O
of	O
the	O
glutamatergic	O
activation	O
associated	O
with	O
withdrawal	O
from	O
free	O
-	O
choice	O
ethanol	B-CHEMICAL
consumption	O
and	O
point	O
to	O
differential	O
adaptations	O
of	O
GS	B-GENE-Y
and	O
GFAP	B-GENE-Y
to	O
prolonged	O
alcohol	B-CHEMICAL
drinking	O
in	O
the	O
PLC	O
of	O
P	O
rats	O
.	O

Abnormally	O
high	O
plasma	O
levels	O
of	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
in	O
children	O
with	O
autism	O
not	O
taking	O
supplements	O
compared	O
to	O
controls	O
not	O
taking	O
supplements	O
.	O

BACKGROUND	O
:	O
There	O
have	O
been	O
many	O
studies	O
of	O
the	O
effect	O
of	O
high	O
-	O
dose	O
supplementation	O
of	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
on	O
children	O
and	O
adults	O
with	O
autism	O
,	O
with	O
all	O
but	O
one	O
reporting	O
benefits	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
biochemical	O
basis	O
for	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
therapy	O
by	O
measuring	O
the	O
level	O
of	O
total	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
in	O
the	O
plasma	O
of	O
unsupplemented	O
children	O
with	O
autism	O
spectrum	O
disorder	O
compared	O
to	O
unsupplemented	O
control	O
subjects	O
.	O

PARTICIPANTS	O
:	O
Children	O
with	O
autism	O
spectrum	O
disorders	O
(	O
n	O
=	O
35	O
,	O
age	O
3	O
-	O
9	O
years	O
)	O
and	O
unrelated	O
typical	O
children	O
(	O
n	O
=	O
11	O
,	O
age	O
6	O
-	O
9	O
years	O
)	O
,	O
all	O
from	O
Arizona	O
,	O
were	O
studied	O
.	O

(	O
This	O
includes	O
the	O
data	O
from	O
24	O
children	O
with	O
autism	O
from	O
our	O
previous	O
study	O
.	O
)	O
METHODOLOGY	O
:	O
A	O
microbiologic	O
assay	O
was	O
used	O
to	O
measure	O
the	O
level	O
of	O
total	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
(	O
including	O
phosphorylated	O
and	O
unphosphorylated	O
forms	O
)	O
,	O
in	O
a	O
blinded	O
fashion	O
.	O

RESULTS	O
:	O
Children	O
with	O
autism	O
had	O
a	O
75	O
%	O
higher	O
level	O
of	O
total	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
than	O
the	O
controls	O
(	O
medians	O
of	O
56	O
versus	O
32	O
ng	O
/	O
mL	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
00002	O
)	O
.	O

Most	O
of	O
the	O
autistic	O
children	O
(	O
77	O
%	O
)	O
had	O
levels	O
that	O
were	O
more	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
median	O
value	O
of	O
the	O
controls	O
.	O

The	O
autistic	O
girls	O
(	O
n	O
=	O
5	O
)	O
also	O
had	O
elevated	O
levels	O
(	O
mean	O
of	O
54	O
.	O
6	O
ng	O
/	O
mL	O
,	O
median	O
of	O
60	O
ng	O
/	O
mL	O
)	O
.	O

DISCUSSION	O
:	O
These	O
results	O
are	O
consistent	O
with	O
previous	O
studies	O
that	O
found	O
that	O
:	O
(	O
1	O
)	O
pyridoxal	B-GENE-Y
kinase	I-GENE-Y
had	O
a	O
very	O
low	O
activity	O
in	O
children	O
with	O
autism	O
and	O
(	O
2	O
)	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
levels	O
are	O
unusually	O
low	O
in	O
children	O
with	O
autism	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
low	O
conversion	O
of	O
pyridoxal	B-CHEMICAL
and	O
pyridoxine	B-CHEMICAL
to	O
PLP	B-CHEMICAL
results	O
in	O
low	O
levels	O
of	O
PLP	B-CHEMICAL
,	O
which	O
is	O
the	O
active	O
cofactor	O
for	O
113	O
known	O
enzymatic	O
reactions	O
,	O
including	O
the	O
formation	O
of	O
many	O
key	O
neurotransmitters	O
.	O

CONCLUSIONS	O
:	O
Total	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
is	O
abnormally	O
high	O
in	O
autism	O
,	O
consistent	O
with	O
previous	O
reports	O
of	O
an	O
impaired	O
pyridoxal	B-GENE-Y
kinase	I-GENE-Y
for	O
the	O
conversion	O
of	O
pyridoxine	B-CHEMICAL
and	O
pyridoxal	B-CHEMICAL
to	O
PLP	B-CHEMICAL
.	O

This	O
may	O
explain	O
the	O
many	O
published	O
studies	O
of	O
benefits	O
of	O
high	O
-	O
dose	O
vitamin	B-CHEMICAL
B6	I-CHEMICAL
supplementation	O
in	O
some	O
children	O
and	O
adults	O
with	O
autism	O
.	O

New	O
assignments	O
for	O
multitasking	O
signal	O
transduction	O
inhibitors	O
.	O

An	O
article	O
presented	O
in	O
this	O
issue	O
of	O
Molecular	O
Pharmacology	O
(	O
p	O
.	O
1527	O
)	O
provides	O
an	O
intriguing	O
example	O
of	O
how	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitors	O
can	O
be	O
put	O
to	O
many	O
uses	O
.	O

In	O
this	O
article	O
,	O
the	O
action	O
of	O
dasatinib	B-CHEMICAL
(	O
BMS	B-CHEMICAL
-	I-CHEMICAL
354825	I-CHEMICAL
)	O
is	O
contrasted	O
with	O
that	O
of	O
imatinib	B-CHEMICAL
,	O
a	O
kinase	B-GENE-N
inhibitor	O
that	O
is	O
currently	O
being	O
used	O
to	O
treat	O
chronic	O
myelogenous	O
leukemia	O
and	O
other	O
disorders	O
.	O

Both	O
pharmacologic	O
inhibitors	O
target	O
several	O
tyrosine	B-GENE-N
kinases	I-GENE-N
,	O
including	O
Bcr	B-GENE-Y
-	O
Abl	B-GENE-Y
and	O
the	O
platelet	B-GENE-N
-	I-GENE-N
derived	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
(	O
PDGFR	B-GENE-N
)	O
.	O

Up	O
to	O
this	O
point	O
,	O
the	O
PDGFR	B-GENE-N
has	O
not	O
been	O
a	O
primary	O
therapeutic	O
target	O
for	O
this	O
class	O
of	O
agents	O
.	O

The	O
work	O
of	O
Chen	O
and	O
colleagues	O
shows	O
that	O
dasatinib	B-CHEMICAL
is	O
a	O
particularly	O
potent	O
inhibitor	O
of	O
PDGFR	B-GENE-N
and	O
that	O
the	O
compound	O
also	O
targets	O
Src	B-GENE-Y
kinase	I-GENE-Y
.	O

The	O
authors	O
suggest	O
that	O
this	O
combination	O
of	O
activities	O
could	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
vascular	O
obstructive	O
diseases	O
.	O

Although	O
a	O
lack	O
of	O
absolute	O
specificity	O
has	O
typically	O
been	O
regarded	O
as	O
a	O
pharmacologic	O
drawback	O
,	O
this	O
study	O
exemplifies	O
how	O
drugs	O
with	O
multiple	O
molecular	O
targets	O
can	O
potentially	O
provide	O
a	O
very	O
beneficial	O
spectrum	O
of	O
therapeutic	O
activities	O
in	O
multiple	O
disease	O
states	O
.	O

Involvement	O
of	O
EP1	B-GENE-Y
and	O
EP2	B-GENE-Y
receptors	I-GENE-Y
in	O
the	O
regulation	O
of	O
the	O
Na	B-GENE-N
,	I-GENE-N
K	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
by	O
prostaglandins	B-CHEMICAL
in	O
MDCK	O
cells	O
.	O

Prostaglandins	B-CHEMICAL
are	O
key	O
regulators	O
of	O
ion	O
transport	O
in	O
the	O
kidney	O
.	O

In	O
MDCK	O
cells	O
,	O
which	O
model	O
distal	O
tubule	O
cells	O
,	O
the	O
transcription	O
of	O
the	O
Na	B-GENE-N
,	I-GENE-N
K	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
beta1	I-GENE-N
subunit	O
is	O
regulated	O
by	O
PGE1	O
and	O
PGE2	O
.	O

To	O
identify	O
the	O
EP	B-GENE-N
receptors	I-GENE-N
that	O
mediate	O
transcriptional	O
regulation	O
,	O
transient	O
transfection	O
studies	O
are	O
conducted	O
using	O
the	O
human	O
beta1promoter	O
/	O
luciferase	O
construct	O
,	O
pHbeta1	O
-	O
1141	O
Luc	O
.	O

The	O
involvement	O
of	O
EP1	B-GENE-Y
and	O
EP2	B-GENE-Y
receptors	I-GENE-Y
is	O
indicated	O
by	O
studies	O
with	O
the	O
EP1	B-GENE-Y
selective	O
agonist	O
17	B-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
trinor	I-CHEMICAL
PGE2	I-CHEMICAL
,	O
and	O
the	O
EP2	B-GENE-Y
selective	O
agonist	O
butaprost	B-CHEMICAL
(	O
which	O
stimulate	O
)	O
,	O
as	O
well	O
as	O
by	O
studies	O
with	O
the	O
antagonists	O
SC	B-CHEMICAL
-	I-CHEMICAL
51089	I-CHEMICAL
(	O
EP1	O
specific	O
)	O
and	O
AH	B-CHEMICAL
6809	I-CHEMICAL
(	O
EP1	B-GENE-Y
and	O
EP2	B-GENE-Y
specific	O
)	O
.	O

Consistent	O
with	O
the	O
involvement	O
of	O
Gs	B-GENE-N
coupled	O
EP2	B-GENE-Y
receptors	I-GENE-Y
,	O
is	O
that	O
the	O
PGE1	B-CHEMICAL
stimulation	O
is	O
inhibited	O
by	O
the	O
PKAI	B-GENE-N
expression	O
vector	O
(	O
encoding	O
the	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
(	I-GENE-N
PKA	I-GENE-N
)	I-GENE-N
inhibitory	I-GENE-N
protein	I-GENE-N
)	O
,	O
as	O
well	O
as	O
by	O
the	O
myristolated	B-GENE-N
PKA	I-GENE-N
inhibitory	I-GENE-N
peptide	I-GENE-N
PKI	O
.	O

In	O
addition	O
to	O
this	O
evidence	O
(	O
for	O
the	O
involvement	O
of	O
EP2	B-GENE-Y
receptors	I-GENE-Y
)	O
,	O
evidence	O
for	O
the	O
involvement	O
of	O
EP1	B-GENE-Y
receptors	I-GENE-Y
in	O
the	O
PGE1	B-CHEMICAL
mediated	O
stimulation	O
of	O
Na	B-GENE-N
,	I-GENE-N
K	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
beta	I-GENE-N
subunit	O
gene	O
transcription	O
includes	O
the	O
stimulatory	O
effect	O
of	O
17	B-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
trinor	I-CHEMICAL
PGE2	I-CHEMICAL
,	O
as	O
well	O
as	O
the	O
inhibitory	O
effects	O
of	O
SC	B-CHEMICAL
-	I-CHEMICAL
51089	I-CHEMICAL
.	O

Also	O
consistent	O
with	O
the	O
involvement	O
of	O
Gq	B-GENE-N
coupled	O
EP1	B-GENE-Y
receptors	I-GENE-Y
,	O
the	O
PGE1	B-CHEMICAL
stimulation	O
is	O
inhibited	O
by	O
the	O
PKCI	B-GENE-N
vector	O
(	O
encoding	O
the	O
PKC	B-GENE-N
inhibitory	I-GENE-N
domain	I-GENE-N
)	O
,	O
the	O
PKC	B-GENE-N
inhibitor	O
Go	B-CHEMICAL
6976	I-CHEMICAL
,	O
thapsigargin	B-CHEMICAL
,	O
as	O
well	O
as	O
the	O
calmodulin	B-GENE-N
antagonists	O
W7	B-CHEMICAL
and	O
W13	B-CHEMICAL
.	O

Corticotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
reduces	O
pressure	O
pain	O
sensitivity	O
in	O
humans	O
without	O
involvement	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
endorphin	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
31	I-GENE-Y
)	I-GENE-Y
,	O
but	O
does	O
not	O
reduce	O
heat	O
pain	O
sensitivity	O
.	O

In	O
the	O
present	O
study	O
the	O
effects	O
of	O
intravenously	O
administered	O
corticotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	O
CRH	B-GENE-Y
)	O
on	O
the	O
release	O
of	O
proopiomelanocortin	B-GENE-Y
(	O
POMC	B-GENE-Y
)	O
derivatives	O
such	O
as	O
adrenocorticotropic	B-GENE-Y
hormone	I-GENE-Y
(	O
ACTH	B-GENE-Y
)	O
,	O
beta	B-GENE-Y
-	I-GENE-Y
lipotropin	I-GENE-Y
(	O
beta	B-GENE-Y
-	I-GENE-Y
LPH	I-GENE-Y
)	O
and	O
beta	B-GENE-Y
-	I-GENE-Y
endorphin	I-GENE-Y
(	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
)	O
as	O
well	O
as	O
direct	O
effects	O
of	O
CRH	B-GENE-Y
on	O
pain	O
sensitivity	O
were	O
examined	O
.	O

In	O
16	O
healthy	O
volunteers	O
we	O
studied	O
the	O
effects	O
of	O
100	O
microg	O
intravenously	O
administered	O
CRH	B-GENE-Y
in	O
absence	O
or	O
presence	O
of	O
12	O
mg	O
naloxone	B-CHEMICAL
on	O
heat	O
or	O
pressure	O
pain	O
sensitivity	O
,	O
using	O
a	O
double	O
-	O
blind	O
,	O
cross	O
-	O
over	O
and	O
placebo	O
-	O
controlled	O
design	O
.	O

To	O
evaluate	O
analgesic	O
effects	O
of	O
CRH	B-GENE-Y
via	O
release	O
of	O
POMC	B-GENE-Y
derivatives	O
,	O
we	O
determined	O
plasma	O
concentrations	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
-	O
immunoreactive	O
material	O
(	O
IRM	O
)	O
,	O
authentic	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
(	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
31	I-GENE-Y
)	I-GENE-Y
)	O
and	O
beta	B-GENE-Y
-	I-GENE-Y
LPH	I-GENE-Y
IRM	O
,	O
in	O
parallel	O
with	O
heat	O
and	O
pressure	O
pain	O
tolerance	O
thresholds	O
before	O
and	O
15	O
and	O
30	O
min	O
after	O
treatment	O
with	O
CRH	B-GENE-Y
(	O
or	O
placebo	O
)	O
,	O
and	O
5	O
min	O
after	O
naloxone	B-CHEMICAL
(	O
or	O
placebo	O
)	O
administration	O
which	O
was	O
administered	O
40	O
min	O
after	O
CRH	B-GENE-Y
(	O
or	O
placebo	O
)	O
injection	O
.	O

CRH	B-GENE-Y
increased	O
levels	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
IRM	O
,	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
31	I-GENE-Y
)	I-GENE-Y
and	O
beta	B-GENE-Y
-	I-GENE-Y
LPH	I-GENE-Y
IRM	O
.	O

As	O
compared	O
to	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
IRM	O
levels	O
measured	O
by	O
a	O
commercial	O
RIA	O
kit	O
,	O
the	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
31	I-GENE-Y
)	I-GENE-Y
levels	O
determined	O
by	O
a	O
highly	O
specific	O
two	O
-	O
site	O
RIA	O
,	O
proved	O
to	O
be	O
remarkably	O
small	O
.	O

Furthermore	O
,	O
CRH	B-GENE-Y
did	O
not	O
induce	O
increases	O
of	O
heat	O
pain	O
tolerance	O
thresholds	O
,	O
but	O
of	O
pressure	O
pain	O
tolerance	O
thresholds	O
,	O
which	O
,	O
however	O
,	O
were	O
not	O
reversible	O
by	O
naloxone	B-CHEMICAL
.	O

Neither	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
nor	O
beta	B-GENE-Y
-	I-GENE-Y
LPH	I-GENE-Y
IRM	O
nor	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
31	I-GENE-Y
)	I-GENE-Y
levels	O
correlated	O
with	O
heat	O
or	O
pressure	O
pain	O
tolerance	O
thresholds	O
.	O

We	O
conclude	O
that	O
CRH	B-GENE-N
does	O
not	O
modulate	O
heat	O
,	O
but	O
pressure	O
pain	O
;	O
POMC	B-GENE-Y
derivatives	O
like	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
IRM	O
,	O
beta	B-GENE-Y
-	I-GENE-Y
END	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
31	I-GENE-Y
)	I-GENE-Y
or	O
beta	B-GENE-Y
-	I-GENE-Y
LPH	I-GENE-Y
do	O
not	O
mediate	O
this	O
effect	O
.	O

Antiobesity	O
action	O
of	O
peripheral	O
exenatide	O
(	O
exendin	O
-	O
4	O
)	O
in	O
rodents	O
:	O
effects	O
on	O
food	O
intake	O
,	O
body	O
weight	O
,	O
metabolic	O
status	O
and	O
side	O
-	O
effect	O
measures	O
.	O

BACKGROUND	O
:	O
Exenatide	O
(	O
exendin	O
-	O
4	O
)	O
is	O
an	O
incretin	B-GENE-Y
mimetic	O
currently	O
marketed	O
as	O
an	O
antidiabetic	O
agent	O
for	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

In	O
preclinical	O
models	O
,	O
a	O
reduction	O
in	O
body	O
weight	O
has	O
also	O
been	O
shown	O
in	O
low	O
-	O
fat	O
-	O
fed	O
,	O
leptin	B-GENE-N
receptor	I-GENE-N
-	O
deficient	O
rodents	O
.	O

OBJECTIVE	O
:	O
To	O
more	O
closely	O
model	O
the	O
polygenic	O
and	O
environmental	O
state	O
of	O
human	O
obesity	O
,	O
we	O
characterized	O
the	O
effect	O
of	O
exenatide	O
on	O
food	O
intake	O
and	O
body	O
weight	O
in	O
high	O
-	O
fat	O
-	O
fed	O
,	O
normal	O
(	O
those	O
with	O
an	O
intact	O
leptin	B-GENE-N
signaling	O
system	O
)	O
rodents	O
.	O

As	O
glucagon	B-GENE-N
-	I-GENE-N
like	I-GENE-N
peptide	I-GENE-N
-	I-GENE-N
1	I-GENE-N
receptor	I-GENE-N
agonism	O
has	O
been	O
found	O
to	O
elicit	O
behaviors	O
associated	O
with	O
visceral	O
illness	O
in	O
rodents	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
peripheral	O
exenatide	O
on	O
kaolin	B-CHEMICAL
consumption	O
and	O
locomotor	O
activity	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
High	O
-	O
fat	O
-	O
fed	O
C57BL	O
/	O
6	O
mice	O
and	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
treated	O
with	O
exenatide	O
(	O
3	O
,	O
10	O
and	O
30	O
microg	O
/	O
kg	O
/	O
day	O
)	O
for	O
4	O
weeks	O
via	O
subcutaneously	O
implanted	O
osmotic	O
pumps	O
.	O

Food	O
intake	O
and	O
body	O
weight	O
were	O
assessed	O
weekly	O
.	O

At	O
4	O
weeks	O
,	O
body	O
composition	O
and	O
plasma	O
metabolic	O
profiles	O
were	O
measured	O
.	O

Kaolin	B-CHEMICAL
consumption	O
and	O
locomotor	O
activity	O
were	O
measured	O
in	O
fasted	O
Sprague	O
-	O
Dawley	O
rats	O
following	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
exenatide	O
(	O
0	O
.	O
1	O
-	O
10	O
microg	O
/	O
kg	O
)	O
.	O

Exenatide	O
treatment	O
in	O
mice	O
and	O
rats	O
dose	O
-	O
dependently	O
decreased	O
food	O
intake	O
and	O
body	O
weight	O
;	O
significant	O
reductions	O
in	O
body	O
weight	O
gain	O
were	O
observed	O
throughout	O
treatment	O
at	O
10	O
and	O
30	O
microg	O
/	O
kg	O
/	O
day	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Decreased	O
body	O
weight	O
gain	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
fat	O
mass	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
sparing	O
of	O
lean	O
tissue	O
.	O

Plasma	O
cholesterol	B-CHEMICAL
,	O
triglycerides	B-CHEMICAL
and	O
insulin	B-GENE-N
were	O
also	O
significantly	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Exenatide	O
at	O
10	O
microg	O
/	O
kg	O
significantly	O
reduced	O
food	O
intake	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
failed	O
to	O
induce	O
kaolin	B-CHEMICAL
intake	O
.	O

In	O
general	O
,	O
locomotor	O
activity	O
was	O
reduced	O
at	O
doses	O
of	O
exenatide	O
that	O
decreased	O
food	O
intake	O
,	O
although	O
a	O
slightly	O
higher	O
dose	O
was	O
required	O
to	O
produce	O
significant	O
changes	O
in	O
activity	O
.	O

CONCLUSION	O
:	O
Systemic	O
exenatide	O
reduces	O
body	O
weight	O
gain	O
in	O
normal	O
,	O
high	O
-	O
fat	O
-	O
fed	O
rodents	O
,	O
a	O
model	O
that	O
parallels	O
human	O
genetic	O
variation	O
and	O
food	O
consumption	O
patterns	O
,	O
and	O
may	O
play	O
a	O
role	O
in	O
metabolic	O
pathways	O
mediating	O
food	O
intake	O
.	O

Sulindac	B-CHEMICAL
independently	O
modulates	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
cyclic	B-GENE-N
GMP	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
signaling	O
pathways	O
.	O

Colorectal	O
cancer	O
is	O
the	O
second	O
leading	O
cause	O
of	O
cancer	O
mortality	O
in	O
the	O
United	O
States	O
.	O

Substantial	O
human	O
and	O
animal	O
data	O
support	O
the	O
ability	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
to	O
cause	O
regression	O
of	O
existing	O
colon	O
tumors	O
and	O
prevent	O
new	O
tumor	O
formation	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
sulindac	B-CHEMICAL
prevents	O
tumor	O
growth	O
is	O
poorly	O
understood	O
and	O
seems	O
complex	O
as	O
sulindac	B-CHEMICAL
can	O
modulate	O
several	O
growth	O
-	O
related	O
signaling	O
pathways	O
.	O

Sulindac	B-CHEMICAL
metabolites	O
simultaneously	O
(	O
a	O
)	O
increase	O
cellular	O
cyclic	B-CHEMICAL
GMP	I-CHEMICAL
and	O
subsequently	O
activate	O
cyclic	B-GENE-N
GMP	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
PKG	B-GENE-N
)	O
;	O
(	O
b	O
)	O
activate	O
c	B-GENE-N
-	I-GENE-N
jun	I-GENE-N
NH2	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
(	O
JNK	B-GENE-N
)	O
;	O
(	O
c	O
)	O
inhibit	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
;	O
and	O
(	O
d	O
)	O
decrease	O
beta	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
protein	O
expression	O
at	O
times	O
and	O
doses	O
consistent	O
with	O
apoptosis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
PKG	B-GENE-N
,	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
JNK	B-GENE-N
,	O
and	O
beta	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
are	O
independent	O
targets	O
for	O
sulindac	B-CHEMICAL
in	O
vitro	O
.	O

Pharmacologic	O
activation	O
of	O
PKG	B-GENE-N
with	O
YC	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
increases	O
JNK	B-GENE-N
phosphorylation	O
and	O
induces	O
apoptosis	O
in	O
colon	O
cancer	O
cells	O
without	O
modulating	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
phosphorylation	O
or	O
beta	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
protein	O
expression	O
.	O

Inhibition	O
of	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
with	O
U0126	B-CHEMICAL
induces	O
apoptosis	O
but	O
fails	O
to	O
activate	O
JNK	B-GENE-N
phosphorylation	O
or	O
down	O
-	O
regulate	O
beta	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
protein	O
expression	O
.	O

Cotreatment	O
with	O
U0126	B-CHEMICAL
and	O
YC	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
synergistically	O
increases	O
apoptosis	O
in	O
colorectal	O
cancer	O
cells	O
and	O
recapitulates	O
the	O
effects	O
of	O
sulindac	B-CHEMICAL
treatment	O
on	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
JNK	B-GENE-N
,	O
and	O
beta	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
.	O

These	O
results	O
indicate	O
that	O
sulindac	B-CHEMICAL
metabolites	O
modulate	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
PKG	B-GENE-N
pathways	O
independently	O
in	O
colon	O
cancer	O
cells	O
and	O
suggest	O
that	O
the	O
full	O
apoptotic	O
effect	O
of	O
sulindac	B-CHEMICAL
is	O
mediated	O
by	O
more	O
than	O
one	O
pathway	O
.	O

Using	O
similar	O
combinatorial	O
approaches	O
in	O
vivo	O
may	O
provide	O
more	O
effective	O
,	O
less	O
toxic	O
chemopreventive	O
and	O
chemotherapeutic	O
strategies	O
.	O

Such	O
therapies	O
could	O
dramatically	O
reduce	O
the	O
incidence	O
and	O
death	O
rate	O
from	O
colorectal	O
cancer	O
.	O

Herbicidal	O
inhibitors	O
of	O
amino	B-CHEMICAL
acid	I-CHEMICAL
biosynthesis	O
and	O
herbicide	O
-	O
tolerant	O
crops	O
.	O

Acetohydroxyacid	B-GENE-N
synthase	I-GENE-N
(	O
AHAS	B-GENE-N
)	O
inhibitors	O
interfere	O
with	O
branched	B-CHEMICAL
-	I-CHEMICAL
chain	I-CHEMICAL
amino	I-CHEMICAL
acid	I-CHEMICAL
biosynthesis	O
by	O
inhibiting	O
AHAS	B-GENE-N
.	O

Glyphosate	B-CHEMICAL
affects	O
aromatic	B-CHEMICAL
amino	I-CHEMICAL
acid	I-CHEMICAL
biosynthesis	O
by	O
inhibiting	O
5	B-GENE-N
-	I-GENE-N
enolpyruvylshikimate	I-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
phosphate	I-GENE-N
synthase	I-GENE-N
(	O
EPSPS	B-GENE-N
)	O
.	O

Glufosinate	B-CHEMICAL
inhibits	O
glutamine	B-GENE-N
synthetase	I-GENE-N
and	O
blocks	O
biosynthesis	O
of	O
glutamine	B-CHEMICAL
.	O

AHAS	B-GENE-N
gene	O
variants	O
that	O
confer	O
tolerance	O
to	O
AHAS	B-GENE-N
inhibitors	O
have	O
been	O
discovered	O
in	O
plants	O
through	O
selection	O
or	O
mutagenesis	O
.	O

Imidazolinone	B-CHEMICAL
-	O
tolerant	O
crops	O
have	O
been	O
commercialized	O
based	O
on	O
these	O
AHAS	B-GENE-N
gene	O
variants	O
.	O

A	O
modified	O
maize	B-GENE-Y
EPSPS	I-GENE-Y
gene	O
and	O
CP4	O
-	O
EPSPS	B-GENE-Y
gene	O
from	O
Agrobacterium	O
sp	O
.	O
have	O
been	O
used	O
to	O
transform	O
plants	O
for	O
target	O
-	O
based	O
tolerance	O
to	O
glyphosate	B-CHEMICAL
.	O

A	O
gox	B-GENE-N
gene	O
isolated	O
from	O
Ochrobactrum	O
anthropi	O
has	O
also	O
been	O
employed	O
to	O
encode	O
glyphosate	B-GENE-N
oxidoreductase	I-GENE-N
to	O
detoxify	O
glyphosate	B-CHEMICAL
in	O
plants	O
.	O

Glyphosate	B-CHEMICAL
-	O
tolerant	O
crops	O
with	O
EPSPS	B-GENE-N
transgene	O
alone	O
or	O
both	O
EPSPS	B-GENE-N
and	O
gox	B-GENE-N
transgenes	O
have	O
been	O
commercialized	O
.	O

Similarly	O
,	O
bar	B-GENE-Y
and	O
pat	B-GENE-Y
genes	O
isolated	O
from	O
Streptomyces	O
hygroscopicus	O
and	O
S	O
.	O
viridochromogenes	O
,	O
respectively	O
,	O
have	O
been	O
inserted	O
into	O
plants	O
to	O
encode	O
phosphinothricin	B-GENE-N
N	I-GENE-N
-	I-GENE-N
acetyltransferase	I-GENE-N
to	O
detoxify	O
glufosinate	B-CHEMICAL
.	O

Glufosinate	B-CHEMICAL
-	O
tolerant	O
crops	O
have	O
been	O
commercialized	O
using	O
one	O
of	O
these	O
two	O
transgenes	O
.	O

Covalent	O
linkage	O
of	O
apolipoprotein	B-GENE-Y
e	I-GENE-Y
to	O
albumin	B-GENE-Y
nanoparticles	O
strongly	O
enhances	O
drug	O
transport	O
into	O
the	O
brain	O
.	O

Drug	O
delivery	O
to	O
the	O
brain	O
is	O
becoming	O
more	O
and	O
more	O
important	O
but	O
is	O
severely	O
restricted	O
by	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Nanoparticles	O
coated	O
with	O
polysorbates	B-CHEMICAL
have	O
previously	O
been	O
shown	O
to	O
enable	O
the	O
transport	O
of	O
several	O
drugs	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
which	O
under	O
normal	O
circumstances	O
is	O
impermeable	O
to	O
these	O
compounds	O
.	O

Apolipoprotein	B-GENE-Y
E	I-GENE-Y
was	O
suggested	O
to	O
mediate	O
this	O
drug	O
transport	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

In	O
the	O
present	O
study	O
,	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
was	O
coupled	O
by	O
chemical	O
methods	O
to	O
nanoparticles	O
made	O
of	O
human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
HSA	B-GENE-Y
-	O
NP	O
)	O
.	O

Loperamide	B-CHEMICAL
,	O
which	O
does	O
not	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
but	O
exerts	O
antinociceptive	O
effects	O
after	O
direct	O
injection	O
into	O
the	O
brain	O
,	O
was	O
used	O
as	O
model	O
drug	O
.	O

Apolipoprotein	B-GENE-Y
E	I-GENE-Y
was	O
chemically	O
bound	O
via	O
linkers	O
to	O
loperamide	B-CHEMICAL
-	O
loaded	O
HSA	B-GENE-Y
-	O
NP	O
.	O

This	O
preparation	O
induced	O
antinociceptive	O
effects	O
in	O
the	O
tail	O
-	O
flick	O
test	O
in	O
ICR	O
mice	O
after	O
i	O
.	O
v	O
.	O
injection	O
.	O

In	O
contrast	O
,	O
nanoparticles	O
linked	O
to	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
variants	O
that	O
do	O
not	O
recognize	O
lipoprotein	B-GENE-N
receptors	I-GENE-N
failed	O
to	O
induce	O
these	O
effects	O
.	O

These	O
results	O
indicate	O
that	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
attached	O
to	O
the	O
surface	O
of	O
nanoparticles	O
facilitates	O
transport	O
of	O
drugs	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
probably	O
after	O
interaction	O
with	O
lipoprotein	B-GENE-N
receptors	I-GENE-N
on	O
the	O
brain	O
capillary	O
endothelial	O
cell	O
membranes	O
.	O

Effect	O
of	O
antidepressant	O
drugs	O
in	O
mice	O
lacking	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
.	O

One	O
of	O
the	O
main	O
theories	O
concerning	O
the	O
mechanism	O
of	O
action	O
of	O
antidepressant	O
drugs	O
(	O
ADs	O
)	O
is	O
based	O
on	O
the	O
notion	O
that	O
the	O
neurochemical	O
background	O
of	O
depression	O
involves	O
an	O
impairment	O
of	O
central	O
noradrenergic	O
transmission	O
with	O
a	O
concomitant	O
decrease	O
of	O
the	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
in	O
the	O
synaptic	O
gap	O
.	O

Many	O
ADs	O
increase	O
synaptic	O
NE	B-CHEMICAL
availability	O
by	O
inhibition	O
of	O
the	O
reuptake	O
of	O
NE	B-CHEMICAL
.	O

Using	O
mice	O
lacking	O
NE	B-GENE-Y
transporter	I-GENE-Y
(	O
NET	B-GENE-Y
-	O
/	O
-	O
)	O
we	O
examined	O
their	O
baseline	O
phenotype	O
as	O
well	O
as	O
the	O
response	O
in	O
the	O
forced	O
swim	O
test	O
(	O
FST	O
)	O
and	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
upon	O
treatment	O
with	O
ADs	O
that	O
display	O
different	O
pharmacological	O
profiles	O
.	O

In	O
both	O
tests	O
,	O
the	O
NET	B-GENE-Y
-	O
/	O
-	O
mice	O
behaved	O
like	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
acutely	O
treated	O
with	O
ADs	O
.	O

Autoradiographic	O
studies	O
showed	O
decreased	O
binding	O
of	O
the	O
beta	O
-	O
adrenergic	O
ligand	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
CGP12177	I-CHEMICAL
in	O
the	O
cerebral	O
cortex	O
of	O
NET	B-GENE-Y
-	O
/	O
-	O
mice	O
,	O
indicating	O
the	O
changes	O
at	O
the	O
level	O
of	O
beta	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
similar	O
to	O
those	O
obtained	O
with	O
ADs	O
treatment	O
.	O

The	O
binding	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
prazosin	I-CHEMICAL
to	O
alpha1	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
in	O
the	O
cerebral	O
cortex	O
of	O
NET	B-GENE-Y
-	O
/	O
-	O
mice	O
was	O
also	O
decreased	O
,	O
most	O
probably	O
as	O
an	O
adaptive	O
response	O
to	O
the	O
sustained	O
elevation	O
of	O
extracellular	O
NE	B-CHEMICAL
levels	O
observed	O
in	O
these	O
mice	O
.	O

A	O
pronounced	O
NET	B-GENE-Y
knockout	O
-	O
induced	O
shortening	O
of	O
the	O
immobility	O
time	O
in	O
the	O
TST	O
(	O
by	O
ca	O
50	O
%	O
)	O
compared	O
to	O
WT	O
mice	O
was	O
not	O
reduced	O
any	O
further	O
by	O
NET	B-GENE-Y
-	O
inhibiting	O
ADs	O
such	O
as	O
reboxetine	B-CHEMICAL
,	O
desipramine	B-CHEMICAL
,	O
and	O
imipramine	B-CHEMICAL
.	O

Citalopram	B-CHEMICAL
,	O
which	O
is	O
devoid	O
of	O
affinity	O
for	O
the	O
NET	B-GENE-Y
,	O
exerted	O
a	O
significant	O
reduction	O
of	O
immobility	O
time	O
in	O
the	O
NET	B-GENE-Y
-	O
/	O
-	O
mice	O
.	O

In	O
the	O
FST	O
,	O
reboxetine	B-CHEMICAL
,	O
desipramine	B-CHEMICAL
,	O
imipramine	B-CHEMICAL
,	O
and	O
citalopram	B-CHEMICAL
administered	O
acutely	O
did	O
not	O
reduce	O
any	O
further	O
the	O
immobility	O
time	O
shortened	O
by	O
NET	B-GENE-Y
knockout	O
itself	O
(	O
ca	O
25	O
%	O
)	O
;	O
however	O
,	O
antidepressant	O
-	O
like	O
action	O
of	O
repeatedly	O
(	O
7	O
days	O
)	O
administered	O
desipramine	B-CHEMICAL
was	O
observed	O
in	O
NET	B-GENE-Y
-	O
/	O
-	O
mice	O
,	O
indicating	O
that	O
the	O
chronic	O
presence	O
of	O
this	O
drug	O
may	O
also	O
affect	O
other	O
neurochemical	O
targets	O
involved	O
in	O
the	O
behavioral	O
reactions	O
monitored	O
by	O
this	O
test	O
.	O

From	O
the	O
present	O
study	O
,	O
it	O
may	O
be	O
concluded	O
that	O
mice	O
lacking	O
the	O
NET	B-GENE-Y
may	O
represent	O
a	O
good	O
model	O
of	O
some	O
aspects	O
of	O
depression	O
-	O
resistant	O
behavior	O
,	O
paralleled	O
with	O
alterations	O
in	O
the	O
expression	O
of	O
adrenergic	B-GENE-N
receptors	I-GENE-N
,	O
which	O
result	O
as	O
an	O
adaptation	O
to	O
elevated	O
levels	O
of	O
extracellular	O
NE	B-CHEMICAL
.	O

Physiological	O
oxygenation	O
status	O
is	O
required	O
for	O
fully	O
differentiated	O
phenotype	O
in	O
kidney	O
cortex	O
proximal	O
tubules	O
.	O

Hypoxia	O
has	O
been	O
suspected	O
to	O
trigger	O
transdifferentiation	O
of	O
renal	O
tubular	O
cells	O
into	O
myofibroblasts	O
in	O
an	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
process	O
.	O

To	O
determine	O
the	O
functional	O
networks	O
potentially	O
altered	O
by	O
hypoxia	O
,	O
rat	O
renal	O
tubule	O
suspensions	O
were	O
incubated	O
under	O
three	O
conditions	O
of	O
oxygenation	O
ranging	O
from	O
normoxia	O
(	O
lactate	O
uptake	O
)	O
to	O
severe	O
hypoxia	O
(	O
lactate	O
production	O
)	O
.	O

Transcriptome	O
changes	O
after	O
4	O
h	O
were	O
analyzed	O
on	O
a	O
high	O
scale	O
by	O
restriction	O
fragment	O
differential	O
display	O
.	O

Among	O
1	O
,	O
533	O
transcripts	O
found	O
,	O
42	O
%	O
were	O
maximally	O
expressed	O
under	O
severe	O
hypoxia	O
and	O
8	O
%	O
under	O
mild	O
hypoxia	O
(	O
Po	O
(	O
2	O
)	O
=	O
48	O
mmHg	O
)	O
,	O
suggesting	O
two	O
different	O
levels	O
of	O
oxygen	B-CHEMICAL
sensing	O
.	O

Normoxia	O
was	O
required	O
for	O
full	O
expression	O
of	O
the	O
proximal	O
tubule	O
-	O
specific	O
transcripts	O
25	B-GENE-Y
-	I-GENE-Y
hydroxyvitamin	I-GENE-Y
D	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
(	O
Cyp27b1	B-GENE-Y
)	O
and	O
l	B-GENE-Y
-	I-GENE-Y
pyruvate	I-GENE-Y
kinase	I-GENE-Y
(	O
Pklr	B-GENE-Y
)	O
,	O
transcripts	O
involved	O
in	O
tissue	O
cohesion	O
such	O
as	O
fibronectin	B-GENE-Y
(	O
Fn1	B-GENE-Y
)	O
and	O
N	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
(	O
Cdh2	B-GENE-Y
)	O
,	O
and	O
non	B-GENE-N
-	I-GENE-N
muscle	I-GENE-N
-	I-GENE-N
type	I-GENE-N
myosin	I-GENE-N
transcripts	O
.	O

Mild	O
hypoxia	O
increased	O
myogenin	B-GENE-Y
transcript	O
level	O
.	O

Conversely	O
,	O
severe	O
hypoxia	O
increased	O
transcripts	O
involved	O
in	O
extracellular	O
matrix	O
remodeling	O
,	O
those	O
of	O
muscle	B-GENE-N
-	I-GENE-N
type	I-GENE-N
myosins	I-GENE-N
,	O
and	O
others	O
involved	O
in	O
creatine	O
phosphate	B-CHEMICAL
synthesis	O
and	O
lactate	O
transport	O
(	O
Slc16a7	B-GENE-Y
)	O
.	O

Accordingly	O
,	O
microscopy	O
showed	O
loss	O
of	O
tubule	O
aggregation	O
under	O
hypoxia	O
,	O
without	O
tubular	O
disruption	O
.	O

Hypoxia	O
also	O
increased	O
the	O
levels	O
of	O
kidney	O
-	O
specific	O
transcripts	O
normally	O
restricted	O
to	O
the	O
less	O
oxygenated	O
medullary	O
zone	O
and	O
others	O
specific	O
for	O
the	O
distal	O
part	O
of	O
the	O
nephron	O
.	O

We	O
conclude	O
that	O
extensive	O
oxygen	B-CHEMICAL
supply	O
to	O
the	O
kidney	O
tubule	O
favors	O
expression	O
of	O
its	O
differentiated	O
functions	O
specifically	O
in	O
the	O
proximal	O
tubule	O
,	O
whose	O
embryonic	O
origin	O
is	O
mesenchymal	O
.	O

The	O
phenotype	O
changes	O
could	O
potentially	O
permit	O
transient	O
adaptation	O
to	O
hypoxia	O
but	O
also	O
favor	O
pathological	O
processes	O
such	O
as	O
tissue	O
invasion	O
.	O

Reboxetine	B-CHEMICAL
versus	O
fluvoxamine	B-CHEMICAL
in	O
the	O
treatment	O
of	O
motor	O
vehicle	O
accident	O
-	O
related	O
posttraumatic	O
stress	O
disorder	O
:	O
a	O
double	O
-	O
blind	O
,	O
fixed	O
-	O
dosage	O
,	O
controlled	O
trial	O
.	O

BACKGROUND	O
:	O
Motor	O
vehicle	O
accidents	O
(	O
MVAs	O
)	O
are	O
a	O
leading	O
cause	O
of	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
in	O
the	O
general	O
population	O
.	O

Alterations	O
in	O
norepinephrine	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
systems	O
have	O
been	O
proposed	O
as	O
mechanisms	O
involved	O
in	O
the	O
pathophysiology	O
of	O
the	O
condition	O
,	O
with	O
treatment	O
directed	O
at	O
these	O
neurotransmitter	O
systems	O
.	O

Reboxetine	B-CHEMICAL
,	O
a	O
selective	O
norepinephrine	B-CHEMICAL
reuptake	O
inhibitor	O
,	O
exhibits	O
high	O
affinity	O
and	O
selectivity	O
for	O
the	O
human	B-GENE-Y
norepinephrine	I-GENE-Y
transporter	I-GENE-Y
.	O

Inasmuch	O
as	O
PTSD	O
may	O
be	O
associated	O
with	O
dysregulation	O
of	O
noradrenergic	O
activity	O
,	O
the	O
present	O
double	O
-	O
blind	O
randomized	O
clinical	O
trial	O
intended	O
to	O
evaluate	O
reboxetine	O
'	O
s	O
efficacy	O
in	O
the	O
management	O
of	O
MVA	O
-	O
related	O
PTSD	O
and	O
to	O
compare	O
its	O
efficacy	O
with	O
a	O
medication	O
commonly	O
used	O
in	O
PTSD	O
,	O
the	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
fluvoxamine	B-CHEMICAL
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
MVA	O
-	O
related	O
PTSD	O
attending	O
a	O
local	O
community	O
mental	O
health	O
outpatient	O
clinic	O
were	O
randomized	O
to	O
receive	O
a	O
fixed	O
dose	O
of	O
either	O
reboxetine	B-CHEMICAL
(	O
8	O
mg	O
/	O
d	O
)	O
or	O
fluvoxamine	B-CHEMICAL
(	O
150	O
mg	O
/	O
d	O
)	O
in	O
a	O
double	O
-	O
blind	O
fashion	O
for	O
a	O
period	O
of	O
8	O
weeks	O
.	O

RESULTS	O
:	O
At	O
baseline	O
and	O
at	O
study	O
end	O
point	O
,	O
the	O
2	O
subgroups	O
demonstrated	O
no	O
statistical	O
differences	O
in	O
scores	O
on	O
PTSD	O
,	O
depression	O
,	O
and	O
anxiety	O
rating	O
scales	O
.	O

Both	O
medications	O
led	O
to	O
significant	O
improvements	O
in	O
all	O
clinical	O
scales	O
measured	O
.	O

Nine	O
patients	O
receiving	O
reboxetine	B-CHEMICAL
and	O
3	O
receiving	O
fluvoxamine	B-CHEMICAL
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

CONCLUSIONS	O
:	O
Study	O
observations	O
indicate	O
comparable	O
efficacy	O
of	O
reboxetine	B-CHEMICAL
and	O
fluvoxamine	B-CHEMICAL
in	O
the	O
management	O
of	O
MVA	O
-	O
related	O
PTSD	O
despite	O
reboxetine	O
'	O
s	O
selective	O
noradrenergic	O
activity	O
.	O

Reboxetine	B-CHEMICAL
appears	O
to	O
be	O
at	O
least	O
as	O
effective	O
as	O
fluvoxamine	B-CHEMICAL
and	O
may	O
offer	O
an	O
alternative	O
management	O
option	O
in	O
this	O
often	O
difficult	O
-	O
to	O
-	O
treat	O
and	O
disabling	O
condition	O
.	O

A	O
lower	O
and	O
flexible	O
reboxetine	B-CHEMICAL
dosing	O
schedule	O
will	O
be	O
recommended	O
for	O
future	O
research	O
to	O
improve	O
its	O
tolerability	O
in	O
PTSD	O
patients	O
.	O

The	O
microsomal	B-GENE-Y
/	I-GENE-Y
peroxidase	I-GENE-Y
antigen	I-GENE-Y
:	O
modulation	O
of	O
its	O
expression	O
in	O
thyroid	O
cells	O
.	O

Evidence	O
has	O
accumulated	O
in	O
the	O
last	O
few	O
years	O
that	O
the	O
expression	O
of	O
the	O
microsomal	B-GENE-Y
/	I-GENE-Y
peroxidase	I-GENE-Y
antigen	I-GENE-Y
(	O
M	B-GENE-Y
/	I-GENE-Y
TPO	I-GENE-Y
-	I-GENE-Y
Ag	I-GENE-Y
)	O
in	O
thyroid	O
cells	O
is	O
induced	O
by	O
TSH	B-GENE-N
,	O
through	O
pathways	O
which	O
involve	O
intracellular	O
cAMP	B-CHEMICAL
accumulation	O
and	O
protein	O
synthesis	O
.	O

These	O
data	O
have	O
been	O
found	O
true	O
in	O
any	O
thyroid	O
system	O
studied	O
so	O
far	O
,	O
both	O
in	O
terms	O
of	O
immunologic	O
and	O
enzymatic	O
activity	O
of	O
TPO	B-GENE-Y
.	O

TSH	B-GENE-N
and	O
cAMP	B-CHEMICAL
also	O
increase	O
the	O
levels	O
of	O
the	O
specific	O
mRNA	O
for	O
TPO	B-GENE-Y
in	O
thyroid	O
cells	O
from	O
different	O
species	O
.	O

Whether	O
this	O
phenomenon	O
is	O
due	O
to	O
a	O
direct	O
transcriptional	O
regulation	O
of	O
the	O
TPO	B-GENE-Y
gene	O
,	O
as	O
shown	O
in	O
dog	O
thyroid	O
cells	O
,	O
or	O
to	O
posttranscriptional	O
effects	O
,	O
as	O
it	O
would	O
appear	O
in	O
FRTL	O
-	O
5	O
cells	O
,	O
remains	O
to	O
be	O
clarified	O
by	O
future	O
experiments	O
.	O

Thyroid	B-GENE-N
stimulating	I-GENE-N
antibody	I-GENE-N
(	O
TSAb	B-GENE-N
)	O
of	O
Graves	O
'	O
disease	O
also	O
stimulates	O
the	O
expression	O
of	O
M	B-GENE-Y
/	I-GENE-Y
TPO	I-GENE-Y
-	I-GENE-Y
Ag	I-GENE-Y
.	O

This	O
finding	O
gives	O
further	O
support	O
to	O
the	O
relevance	O
of	O
TSAb	B-GENE-N
in	O
the	O
pathogenesis	O
of	O
hyperthyroidism	O
and	O
explains	O
the	O
well	O
known	O
observation	O
that	O
the	O
"	O
microsomal	O
"	O
antigen	O
is	O
particularly	O
abundant	O
in	O
glands	O
of	O
Graves	O
'	O
patients	O
.	O

The	O
modulation	O
of	O
M	B-GENE-Y
/	I-GENE-Y
TPO	I-GENE-Y
-	I-GENE-Y
Ag	I-GENE-Y
surface	O
expression	O
by	O
TSH	B-GENE-N
can	O
explain	O
the	O
decrease	O
of	O
circulating	O
anti	O
-	O
MAb	O
observed	O
during	O
L	B-CHEMICAL
-	I-CHEMICAL
thyroxine	I-CHEMICAL
therapy	O
in	O
hypothyroid	O
patients	O
with	O
Hashimoto	O
'	O
s	O
thyroiditis	O
.	O

Other	O
agents	O
,	O
such	O
as	O
methimazole	B-CHEMICAL
and	O
sodium	B-CHEMICAL
iodide	I-CHEMICAL
,	O
which	O
influence	O
thyroid	O
cell	O
function	O
,	O
do	O
not	O
directly	O
interfere	O
with	O
the	O
expression	O
of	O
M	B-GENE-Y
/	I-GENE-Y
TPO	I-GENE-Y
-	I-GENE-Y
Ag	I-GENE-Y
.	O

Cytokines	B-GENE-N
,	O
such	O
as	O
gamma	B-GENE-Y
-	I-GENE-Y
interferon	I-GENE-Y
,	O
interleukin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
,	O
and	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
have	O
been	O
shown	O
to	O
inhibit	O
the	O
TSH	B-GENE-N
-	O
induced	O
increase	O
of	O
TPO	B-GENE-Y
mRNA	O
,	O
but	O
further	O
investigations	O
are	O
required	O
to	O
elucidate	O
the	O
exact	O
role	O
of	O
cytokines	B-GENE-N
in	O
the	O
regulation	O
of	O
M	B-GENE-Y
/	I-GENE-Y
TPO	I-GENE-Y
-	I-GENE-Y
Ag	I-GENE-Y
expression	O
.	O

Soy	O
protein	O
suppresses	O
gene	O
expression	O
of	O
acetyl	B-GENE-Y
-	I-GENE-Y
coA	I-GENE-Y
carboxylase	I-GENE-Y
alpha	I-GENE-Y
from	O
promoter	B-GENE-N
PI	I-GENE-N
in	O
rat	O
liver	O
.	O

Dietary	O
soy	O
protein	O
isolate	O
(	O
SPI	O
)	O
reduces	O
hepatic	O
lipogenesis	O
by	O
suppressing	O
gene	O
expression	O
of	O
lipogenic	O
enzymes	O
,	O
including	O
acetyl	B-GENE-N
-	I-GENE-N
CoA	I-GENE-N
carboxylase	I-GENE-N
(	O
ACC	B-GENE-N
)	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
mechanism	O
of	O
this	O
regulation	O
,	O
the	O
effect	O
of	O
dietary	O
SPI	O
on	O
promoter	B-GENE-N
(	I-GENE-N
PI	I-GENE-N
and	I-GENE-N
PII	I-GENE-N
)	I-GENE-N
specific	O
gene	O
expression	O
of	O
ACC	B-GENE-Y
alpha	I-GENE-Y
was	O
investigated	O
.	O

Rats	O
were	O
fed	O
experimental	O
diets	O
containing	O
SPI	O
or	O
casein	B-GENE-N
as	O
a	O
nitrogen	B-CHEMICAL
source	O
.	O

SPI	O
feeding	O
decreased	O
the	O
hepatic	O
contents	O
of	O
total	O
ACC	B-GENE-N
mRNA	O
as	O
well	O
as	O
triglyceride	B-CHEMICAL
(	O
TG	B-CHEMICAL
)	O
content	O
,	O
but	O
dietary	O
SPI	O
affected	O
the	O
amount	O
of	O
sterol	B-GENE-Y
-	I-GENE-Y
regulatory	I-GENE-Y
element	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
SREBP	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
and	O
protein	O
very	O
little	O
.	O

The	O
amount	O
of	O
ACC	B-GENE-N
mRNA	O
transcribed	O
from	O
PII	B-GENE-N
promoter	I-GENE-N
containing	O
SRE	B-GENE-N
was	O
not	O
significantly	O
affected	O
by	O
dietary	O
protein	O
,	O
while	O
a	O
significant	O
decrease	O
in	O
PI	B-GENE-N
-	O
generated	O
ACC	B-GENE-N
mRNA	O
content	O
was	O
observed	O
in	O
rats	O
fed	O
the	O
SPI	O
diet	O
.	O

These	O
data	O
suggest	O
that	O
SPI	O
feeding	O
decreased	O
the	O
hepatic	O
contents	O
of	O
ACC	B-GENE-Y
alpha	I-GENE-Y
mRNA	O
mainly	O
by	O
regulating	O
PI	B-GENE-N
promoter	I-GENE-N
via	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
other	O
than	O
SREBP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Changes	O
in	O
submaxillary	O
gland	O
gene	O
expression	O
in	O
F344	O
rats	O
by	O
multiple	O
dosing	O
of	O
theophylline	B-CHEMICAL
.	O

Multiple	O
exposure	O
to	O
theophylline	B-CHEMICAL
,	O
a	O
phosphodiesterase	B-GENE-N
(	O
PDE	B-GENE-N
)	O
inhibitor	O
,	O
induces	O
acinar	O
hypertrophy	O
in	O
the	O
salivary	O
gland	O
.	O

This	O
study	O
examined	O
the	O
effect	O
of	O
theophylline	B-CHEMICAL
on	O
the	O
gene	O
expression	O
of	O
secretory	O
proteins	O
and	O
phosphodiesterases	B-GENE-N
in	O
the	O
submaxillary	O
gland	O
.	O

Male	O
F344	O
rats	O
received	O
saline	O
or	O
theophylline	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
)	O
intraperitoneally	O
for	O
4	O
days	O
.	O

The	O
gene	O
expressions	O
for	O
the	O
secretory	O
protein	O
,	O
cystatin	B-GENE-Y
S	I-GENE-Y
(	O
CysS	B-GENE-Y
)	O
,	O
and	O
PDE	B-GENE-N
subfamilies	I-GENE-N
3A	I-GENE-N
and	I-GENE-N
4D	I-GENE-N
in	O
the	O
submaxillary	O
gland	O
were	O
quantified	O
using	O
RT	O
-	O
PCR	O
.	O

Theophylline	B-CHEMICAL
exposure	O
resulted	O
in	O
a	O
sustained	O
increase	O
in	O
mRNA	O
expression	O
for	O
CysS	B-GENE-Y
and	O
PDE3A	B-GENE-Y
,	O
but	O
PDE4D	B-GENE-Y
gene	O
expression	O
was	O
unchanged	O
.	O

Our	O
results	O
suggest	O
that	O
submaxillary	O
hypertrophy	O
is	O
primarily	O
caused	O
by	O
the	O
enhanced	O
transcription	O
of	O
CysS	B-GENE-Y
,	O
and	O
that	O
the	O
transcription	O
of	O
each	O
PDE	B-GENE-N
subfamily	O
gene	O
is	O
regulated	O
differently	O
.	O

Comparative	O
proteomics	O
of	O
ovarian	O
epithelial	O
tumors	O
.	O

We	O
analyzed	O
12	O
ovarian	O
epithelial	O
tumors	O
using	O
2D	O
PAGE	O
-	O
based	O
comparative	O
proteomics	O
to	O
construct	O
intra	O
-	O
and	O
inter	O
-	O
tumoral	O
distance	O
map	O
trees	O
and	O
to	O
discover	O
surrogate	O
biomarkers	O
indicative	O
of	O
an	O
ovarian	O
tumor	O
.	O

The	O
analysis	O
was	O
performed	O
after	O
laser	O
microdissection	O
of	O
12	O
fresh	O
-	O
frozen	O
tissue	O
samples	O
,	O
including	O
4	O
serous	O
,	O
5	O
mucinous	O
,	O
and	O
3	O
endometrioid	O
tumors	O
,	O
with	O
correlation	O
with	O
their	O
histopathological	O
characteristics	O
.	O

Ovarian	O
epithelial	O
tumors	O
and	O
normal	O
tissues	O
showed	O
an	O
apparent	O
separation	O
on	O
the	O
distance	O
map	O
tree	O
.	O

Mucinous	O
carcinomas	O
were	O
closest	O
to	O
the	O
normal	O
group	O
,	O
whereas	O
serous	O
carcinomas	O
were	O
located	O
furthest	O
from	O
the	O
normal	O
group	O
.	O

All	O
mucinous	O
tumors	O
with	O
aggressive	O
histology	O
were	O
separated	O
from	O
the	O
low	O
malignant	O
potential	O
(	O
LMP	O
)	O
group	O
.	O

The	O
benign	O
-	O
looking	O
cysts	O
adjacent	O
to	O
the	O
intraepithelial	O
carcinoma	O
(	O
IEC	O
)	O
showed	O
an	O
expression	O
pattern	O
identical	O
to	O
that	O
of	O
the	O
IEC	O
area	O
.	O

The	O
extent	O
of	O
change	O
on	O
the	O
lineages	O
leading	O
to	O
the	O
mucinous	O
and	O
serous	O
carcinoma	O
was	O
1	O
.	O
98	O
-	O
fold	O
different	O
.	O

The	O
overall	O
gene	O
expression	O
profiles	O
of	O
serous	O
or	O
endometrioid	O
carcinomas	O
appeared	O
to	O
be	O
less	O
affected	O
by	O
grade	O
or	O
stage	O
than	O
by	O
histologic	O
type	O
.	O

The	O
potential	O
candidate	O
biomarkers	O
screened	O
in	O
ovarian	O
tumors	O
and	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
in	O
comparison	O
to	O
normal	O
tissues	O
were	O
as	O
follows	O
:	O
NM23	B-GENE-Y
,	O
annexin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
protein	B-GENE-N
phosphatase	I-GENE-N
-	I-GENE-N
1	I-GENE-N
,	O
ferritin	B-GENE-Y
light	I-GENE-Y
chain	I-GENE-Y
,	O
proteasome	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
and	O
NAGK	B-GENE-Y
(	O
N	B-GENE-Y
-	I-GENE-Y
acetyl	I-GENE-Y
glucosamine	I-GENE-Y
kinase	I-GENE-Y
)	O
.	O

In	O
conclusion	O
,	O
ovarian	O
mucinous	O
tumors	O
are	O
distinct	O
from	O
other	O
ovarian	O
epithelial	O
tumors	O
.	O

LMP	O
mucinous	O
tumors	O
showing	O
histologically	O
aggressive	O
features	O
belong	O
to	O
mucinous	O
carcinoma	O
on	O
the	O
proteomic	O
basis	O
.	O

The	O
role	O
of	O
late	O
I	O
and	O
antiarrhythmic	O
drugs	O
in	O
EAD	O
formation	O
and	O
termination	O
in	O
Purkinje	O
fibers	O
.	O

Multiple	O
components	O
of	O
cardiac	O
Na	B-CHEMICAL
current	O
play	O
a	O
role	O
in	O
determining	O
electrical	O
excitation	O
in	O
the	O
heart	O
.	O

Recently	O
,	O
the	O
role	O
of	O
nonequilibrium	O
components	O
in	O
controlling	O
cardiac	O
action	O
potential	O
plateau	O
duration	O
,	O
and	O
their	O
importance	O
in	O
regulating	O
the	O
occurrence	O
of	O
afterdepolarizations	O
and	O
arrhythmias	O
have	O
garnered	O
more	O
attention	O
.	O

In	O
particular	O
,	O
late	O
Na	B-CHEMICAL
current	O
(	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
)	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
LQT2	O
and	O
LQT3	O
arrhythmias	O
.	O

Class	O
III	O
agents	O
like	O
dofetilide	B-CHEMICAL
,	O
clofilium	B-CHEMICAL
,	O
and	O
sotalol	B-CHEMICAL
,	O
which	O
can	O
all	O
cause	O
a	O
drug	O
-	O
induced	O
form	O
of	O
LQT2	O
,	O
significantly	O
lengthen	O
action	O
potential	O
duration	O
at	O
50	O
%	O
and	O
90	O
%	O
repolarization	O
in	O
isolated	O
rabbit	O
Purkinje	O
fibers	O
,	O
and	O
can	O
initiate	O
the	O
formation	O
of	O
early	O
afterdepolarizations	O
,	O
and	O
extra	O
beats	O
.	O

These	O
actions	O
can	O
lead	O
to	O
the	O
development	O
of	O
a	O
serious	O
ventricular	O
tachycardia	O
,	O
torsades	O
de	O
pointes	O
,	O
in	O
animal	O
models	O
and	O
patients	O
.	O

However	O
,	O
pretreatment	O
with	O
agents	O
that	O
block	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
,	O
like	O
lidocaine	B-CHEMICAL
,	O
mexiletine	B-CHEMICAL
,	O
and	O
RSD1235	B-CHEMICAL
,	O
a	O
novel	O
mixed	O
ion	B-GENE-N
channel	I-GENE-N
blocker	O
for	O
the	O
rapid	O
pharmacologic	O
conversion	O
of	O
atrial	O
fibrillation	O
,	O
significantly	O
attenuates	O
the	O
prolonging	O
effects	O
of	O
Class	O
III	O
agents	O
or	O
those	O
induced	O
by	O
ATX	O
-	O
II	O
,	O
a	O
specific	O
toxin	O
that	O
delays	O
Na	B-GENE-N
channel	I-GENE-N
inactivation	O
and	O
amplifies	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
greatly	O
,	O
mimicking	O
LQT3	O
.	O

The	O
Na	B-GENE-N
channel	I-GENE-N
block	O
caused	O
by	O
lidocaine	B-CHEMICAL
and	O
RSD1235	B-CHEMICAL
can	O
be	O
through	O
the	O
open	O
or	O
inactivated	O
states	O
of	O
the	O
channel	O
,	O
but	O
both	O
equivalently	O
inhibit	O
a	O
late	O
component	O
of	O
Na	B-CHEMICAL
current	O
(	O
I	O
(	O
Na	B-CHEMICAL
)	O
)	O
,	O
recorded	O
at	O
22	O
degrees	O
C	O
using	O
whole	O
-	O
cell	O
patch	O
clamp	O
of	O
Nav	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
expressed	O
in	O
HEK	O
cells	O
.	O

These	O
protective	O
actions	O
of	O
lidocaine	B-CHEMICAL
,	O
mexiletine	B-CHEMICAL
,	O
and	O
RSD1235	B-CHEMICAL
may	O
result	O
,	O
at	O
least	O
in	O
part	O
,	O
from	O
their	O
ability	O
to	O
inhibit	O
late	O
I	O
(	O
Na	B-CHEMICAL
)	O
during	O
action	O
potential	O
repolarization	O
,	O
and	O
inhibition	O
of	O
the	O
inward	O
currents	O
contributing	O
to	O
EAD	O
and	O
arrhythmia	O
formation	O
.	O

Dynamics	O
of	O
NO	B-CHEMICAL
rebinding	O
to	O
the	O
heme	B-GENE-N
domain	I-GENE-N
of	I-GENE-N
NO	I-GENE-N
synthase	I-GENE-N
-	I-GENE-N
like	I-GENE-N
proteins	I-GENE-N
from	O
bacterial	O
pathogens	O
.	O

Some	O
Gram	O
-	O
positive	O
bacterial	O
pathogens	O
harbor	O
a	O
gene	O
that	O
encodes	O
a	O
protein	O
(	O
HNS	B-GENE-N
,	O
Heme	B-GENE-N
domain	I-GENE-N
of	I-GENE-N
NO	I-GENE-N
Synthase	I-GENE-N
-	I-GENE-N
like	I-GENE-N
proteins	I-GENE-N
)	O
with	O
striking	O
sequence	O
identity	O
to	O
the	O
oxygenase	B-GENE-N
domain	I-GENE-N
of	O
mammalian	B-GENE-N
NO	I-GENE-N
synthases	I-GENE-N
(	O
NOS	B-GENE-N
)	O
.	O

However	O
,	O
they	O
lack	O
the	O
N	B-GENE-N
-	I-GENE-N
terminal	I-GENE-N
and	I-GENE-N
the	I-GENE-N
Zn	I-GENE-N
-	I-GENE-N
cysteine	I-GENE-N
motif	I-GENE-N
participating	O
to	O
the	O
stability	O
of	O
an	O
active	O
dimer	O
in	O
the	O
mammalian	O
isoforms	O
.	O

The	O
unique	O
properties	O
of	O
HNS	B-GENE-N
make	O
it	O
an	O
excellent	O
model	O
system	O
for	O
probing	O
how	O
the	O
heme	O
environment	O
tunes	O
NO	B-CHEMICAL
dynamics	O
and	O
for	O
comparing	O
it	O
to	O
the	O
endothelial	B-GENE-N
NO	I-GENE-N
synthase	I-GENE-N
heme	I-GENE-N
domain	I-GENE-N
(	O
eNOS	B-GENE-N
(	I-GENE-N
HD	I-GENE-N
)	I-GENE-N
)	O
using	O
ultrafast	O
transient	O
spectroscopy	O
.	O

NO	B-CHEMICAL
rebinding	O
in	O
HNS	B-GENE-N
from	O
Staphylococcus	O
aureus	O
(	O
SA	B-GENE-N
-	I-GENE-N
HNS	I-GENE-N
)	O
is	O
faster	O
than	O
that	O
measured	O
for	O
either	O
Bacillus	O
anthracis	O
(	O
BA	B-GENE-N
-	I-GENE-N
HNS	I-GENE-N
)	O
or	O
for	O
eNOS	B-GENE-N
(	I-GENE-N
HD	I-GENE-N
)	I-GENE-N
in	O
both	O
oxidized	O
and	O
reduced	O
forms	O
in	O
the	O
presence	O
of	O
arginine	B-CHEMICAL
.	O

To	O
test	O
whether	O
these	O
distinct	O
rates	O
arise	O
from	O
different	O
energy	O
barriers	O
for	O
NO	B-CHEMICAL
recombination	O
,	O
we	O
measured	O
rebinding	O
kinetics	O
at	O
several	O
temperatures	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
different	O
barriers	O
for	O
NO	B-CHEMICAL
recombination	O
in	O
SA	B-GENE-N
-	I-GENE-N
HNS	I-GENE-N
and	O
BA	B-GENE-N
-	I-GENE-N
HNS	I-GENE-N
and	O
the	O
presence	O
of	O
a	O
second	O
NO	B-CHEMICAL
-	O
binding	O
site	O
.	O

The	O
hypothesis	O
that	O
an	O
additional	O
NO	B-CHEMICAL
-	O
binding	O
cavity	O
is	O
present	O
in	O
BA	B-GENE-N
-	I-GENE-N
HNS	I-GENE-N
is	O
also	O
consistent	O
with	O
the	O
effect	O
of	O
the	O
NO	B-CHEMICAL
concentration	O
on	O
its	O
rebinding	O
.	O

The	O
lack	O
of	O
the	O
effect	O
of	O
NO	B-CHEMICAL
concentration	O
on	O
the	O
geminate	O
rebinding	O
in	O
SA	B-GENE-N
-	I-GENE-N
HNS	I-GENE-N
could	O
be	O
due	O
to	O
an	O
isolated	O
second	O
site	O
.	O

We	O
confirm	O
the	O
existence	O
of	O
a	O
second	O
NO	B-CHEMICAL
site	O
in	O
the	O
oxygenase	B-GENE-N
domain	I-GENE-N
of	O
the	O
reduced	B-GENE-Y
eNOS	I-GENE-Y
as	O
previously	O
hypothesized	O
[	O
A	O
.	O
Slama	O
-	O
Schwok	O
,	O
M	O
.	O
Negrerie	O
,	O
V	O
.	O
Berka	O
,	O
J	O
.	O
C	O
.	O
Lambry	O
,	O
A	O
.	O
L	O
.	O
Tsai	O
,	O
M	O
.	O
H	O
.	O
Vos	O
,	O
J	O
.	O
L	O
.	O
Martin	O
,	O
Nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
traffic	O
in	O
endothelial	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
.	O
Evidence	O
for	O
a	O
new	O
NO	B-CHEMICAL
binding	O
site	O
dependent	O
on	O
tetrahydrobiopterin	B-CHEMICAL
?	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
277	O
(	O
2002	O
)	O
7581	O
-	O
7586	O
]	O
.	O

This	O
site	O
requires	O
the	O
presence	O
of	O
arginine	B-CHEMICAL
and	O
BH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
;	O
and	O
we	O
propose	O
that	O
NO	B-CHEMICAL
dynamic	O
and	O
escape	O
from	O
eNOS	B-GENE-Y
is	O
regulated	O
by	O
the	O
active	O
site	O
H	B-CHEMICAL
-	O
bonding	O
network	O
connecting	O
between	O
the	O
heme	O
,	O
the	O
substrate	O
,	O
and	O
cofactor	O
.	O

Lutein	O
and	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
interact	O
to	O
modify	O
iNOS	B-GENE-Y
mRNA	O
levels	O
through	O
the	O
PPARgamma	B-GENE-Y
/	O
RXR	B-GENE-N
pathway	O
in	O
chickens	O
and	O
HD11	O
cell	O
lines	O
.	O

Two	O
experiments	O
were	O
conducted	O
to	O
investigate	O
the	O
effect	O
of	O
lutein	O
and	O
fat	O
or	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
EPA	B-CHEMICAL
)	O
interaction	O
on	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
,	O
PPARs	B-GENE-N
alpha	I-GENE-N
,	I-GENE-N
beta	I-GENE-N
,	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
,	O
and	O
retinoic	B-GENE-N
acid	I-GENE-N
X	I-GENE-N
receptor	I-GENE-N
(	I-GENE-N
RXR	I-GENE-N
)	I-GENE-N
alpha	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
mRNA	O
levels	O
.	O

In	O
Expt	O
.	O

1	O
,	O
macrophages	O
were	O
collected	O
from	O
broiler	O
chicks	O
fed	O
3	O
or	O
6	O
%	O
dietary	O
fat	O
(	O
g	O
/	O
100	O
g	O
)	O
with	O
0	O
,	O
25	O
,	O
and	O
50	O
mg	O
lutein	O
/	O
kg	O
feed	O
for	O
23	O
d	O
.	O

In	O
Expt	O
.	O

2	O
,	O
using	O
a	O
3	O
x	O
3	O
factorial	O
,	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
EPA	B-CHEMICAL
)	O
at	O
0	O
,	O
15	O
and	O
50	O
micromol	O
/	O
L	O
and	O
lutein	O
at	O
0	O
,	O
10	O
and	O
100	O
micromol	O
/	O
L	O
were	O
applied	O
to	O
HD11	O
cell	O
culture	O
for	O
24	O
h	O
.	O

In	O
both	O
experiments	O
,	O
cells	O
were	O
stimulated	O
with	O
lipopolysaccharide	O
before	O
RNA	O
isolation	O
.	O

Lutein	O
interacted	O
with	O
fat	O
in	O
Expt	O
.	O

1	O
and	O
with	O
EPA	O
in	O
Expt	O
.	O

2	O
to	O
affect	O
mRNA	O
levels	O
of	O
iNOS	B-GENE-Y
,	O
PPARgamma	B-GENE-Y
,	O
and	O
RXRalpha	B-GENE-Y
in	O
chicken	O
macrophages	O
and	O
HD11	O
cells	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
3	O
%	O
dietary	O
fat	O
or	O
up	O
to	O
15	O
micromol	O
/	O
L	O
EPA	O
in	O
the	O
medium	O
,	O
increasing	O
lutein	O
increased	O
the	O
iNOS	B-GENE-Y
mRNA	O
.	O

However	O
,	O
at	O
6	O
%	O
dietary	O
fat	O
or	O
50	O
micromol	O
/	O
L	O
EPA	O
,	O
lutein	O
did	O
not	O
cause	O
a	O
rise	O
in	O
iNOS	B-GENE-Y
mRNA	O
.	O

Increasing	O
lutein	O
in	O
the	O
medium	O
from	O
0	O
to	O
100	O
micromol	O
/	O
L	O
decreased	O
iNOS	B-GENE-Y
mRNA	O
.	O

Increasing	O
lutein	O
with	O
high	O
fat	O
(	O
6	O
%	O
)	O
or	O
EPA	O
(	O
15	O
micromol	O
/	O
L	O
EPA	O
)	O
increased	O
PPARgamma	B-GENE-Y
and	O
RXRalpha	B-GENE-Y
mRNA	O
levels	O
.	O

Lutein	O
increased	O
PPARalpha	B-GENE-Y
mRNA	O
levels	O
in	O
both	O
macrophages	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
HD11	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
cells	O
and	O
RXRgamma	B-GENE-Y
(	O
P	O
<	O
0	O
.	O
01	O
)	O
mRNA	O
levels	O
in	O
macrophages	O
.	O

GW9662	B-CHEMICAL
,	O
a	O
PPARgamma	B-GENE-Y
antagonist	O
,	O
prevented	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
the	O
lutein	O
-	O
induced	O
iNOS	B-GENE-Y
mRNA	O
downregulation	O
in	O
HD11	O
cells	O
.	O

LG101208	O
,	O
a	O
RXR	B-GENE-N
antagonist	O
,	O
prevented	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
iNOS	B-GENE-Y
upregulation	O
induced	O
by	O
10	O
micromol	O
/	O
L	O
lutein	O
and	O
iNOS	B-GENE-Y
mRNA	O
downregulation	O
induced	O
by	O
100	O
micromol	O
/	O
L	O
lutein	O
.	O

We	O
conclude	O
that	O
lutein	O
and	O
EPA	B-CHEMICAL
interact	O
through	O
the	O
PPARgamma	B-GENE-Y
and	O
RXR	B-GENE-N
pathways	O
to	O
modulate	O
iNOS	B-GENE-Y
mRNA	O
.	O

Effect	O
of	O
ramelteon	B-CHEMICAL
(	O
TAK	B-CHEMICAL
-	I-CHEMICAL
375	I-CHEMICAL
)	O
,	O
a	O
selective	O
MT1	B-GENE-N
/	I-GENE-N
MT2	I-GENE-N
receptor	I-GENE-N
agonist	O
,	O
on	O
motor	O
performance	O
in	O
mice	O
.	O

Effect	O
of	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrahydro	I-CHEMICAL
-	I-CHEMICAL
2H	I-CHEMICAL
-	I-CHEMICAL
indeno	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
5	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
furan	I-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
propionamide	I-CHEMICAL
(	O
ramelteon	B-CHEMICAL
,	O
TAK	B-CHEMICAL
-	I-CHEMICAL
375	I-CHEMICAL
)	O
,	O
a	O
selective	O
MT1	B-GENE-N
/	I-GENE-N
MT2	I-GENE-N
receptor	I-GENE-N
agonist	O
,	O
on	O
motor	O
coordination	O
was	O
studied	O
using	O
rota	O
-	O
rod	O
performance	O
in	O
mice	O
.	O

Ramelteon	B-CHEMICAL
did	O
not	O
impair	O
rota	O
-	O
rod	O
performance	O
at	O
doses	O
of	O
3	O
,	O
10	O
and	O
30	O
mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O

Melatonin	B-CHEMICAL
and	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
,	O
a	O
ligand	O
of	O
MT3	B-GENE-N
biding	O
site	O
,	O
also	O
had	O
no	O
impairment	O
on	O
the	O
performance	O
,	O
per	O
se	O
.	O

However	O
,	O
in	O
combination	O
with	O
a	O
low	O
dose	O
of	O
diazepam	B-CHEMICAL
(	O
3mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
,	O
treatment	O
with	O
melatonin	B-CHEMICAL
and	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
exacerbated	O
the	O
impairment	O
by	O
diazepam	B-CHEMICAL
.	O

Ramelteon	B-CHEMICAL
had	O
no	O
significant	O
effect	O
on	O
the	O
diazepam	B-CHEMICAL
-	O
induced	O
impairment	O
of	O
motor	O
coordination	O
.	O

Sorafenib	B-CHEMICAL
(	O
BAY	B-CHEMICAL
43	I-CHEMICAL
-	I-CHEMICAL
9006	I-CHEMICAL
,	O
Nexavar	B-CHEMICAL
)	O
,	O
a	O
dual	O
-	O
action	O
inhibitor	O
that	O
targets	O
RAF	B-GENE-N
/	O
MEK	B-GENE-N
/	O
ERK	B-GENE-N
pathway	O
in	O
tumor	O
cells	O
and	O
tyrosine	B-GENE-N
kinases	I-GENE-N
VEGFR	B-GENE-N
/	O
PDGFR	B-GENE-N
in	O
tumor	O
vasculature	O
.	O

Activating	O
mutations	O
in	O
Ras	B-GENE-N
and	O
B	B-GENE-Y
-	I-GENE-Y
RAF	I-GENE-Y
were	O
identified	O
in	O
several	O
human	O
cancers	O
.	O

In	O
addition	O
,	O
several	O
receptor	B-GENE-N
tyrosine	I-GENE-N
kinases	I-GENE-N
,	O
acting	O
upstream	O
of	O
Ras	B-GENE-N
,	O
were	O
found	O
either	O
mutated	O
or	O
overexpressed	O
in	O
human	O
tumors	O
.	O

Because	O
oncogenic	O
activation	O
of	O
the	O
Ras	B-GENE-N
/	O
RAF	B-GENE-N
pathway	O
may	O
lead	O
to	O
a	O
sustained	O
proliferative	O
signal	O
resulting	O
in	O
tumor	O
growth	O
and	O
progression	O
,	O
inhibition	O
of	O
this	O
pathway	O
represents	O
an	O
attractive	O
approach	O
for	O
cancer	O
drug	O
discovery	O
.	O

A	O
novel	O
class	O
of	O
biaryl	B-CHEMICAL
urea	I-CHEMICAL
that	O
inhibits	O
C	B-GENE-Y
-	I-GENE-Y
RAF	I-GENE-Y
kinase	B-GENE-N
was	O
discovered	O
using	O
a	O
combination	O
of	O
medicinal	O
and	O
combinatorial	O
chemistry	O
approaches	O
.	O

This	O
effort	O
culminated	O
in	O
the	O
identification	O
of	O
the	O
clinical	O
candidate	O
BAY	B-CHEMICAL
43	I-CHEMICAL
-	I-CHEMICAL
9006	I-CHEMICAL
(	O
Sorafenib	B-CHEMICAL
,	O
Nexavar	B-CHEMICAL
)	O
,	O
which	O
has	O
recently	O
been	O
approved	O
by	O
the	O
FDA	O
for	O
advanced	O
renal	O
cell	O
carcinoma	O
in	O
phase	O
III	O
clinical	O
trials	O
.	O

Sorafenib	B-CHEMICAL
inhibited	O
the	O
kinase	B-GENE-N
activity	O
of	O
both	O
C	B-GENE-Y
-	I-GENE-Y
RAF	I-GENE-Y
and	O
B	B-GENE-Y
-	I-GENE-Y
RAF	I-GENE-Y
(	O
wild	O
type	O
and	O
V600E	B-GENE-N
mutant	O
)	O
.	O

It	O
inhibited	O
MEK	B-GENE-N
and	O
ERK	B-GENE-N
phosphorylation	O
in	O
various	O
cancer	O
cell	O
lines	O
and	O
tumor	O
xenografts	O
and	O
exhibited	O
potent	O
oral	O
antitumor	O
activity	O
in	O
a	O
broad	O
spectrum	O
of	O
human	O
tumor	O
xenograft	O
models	O
.	O

Further	O
characterization	O
of	O
sorafenib	B-CHEMICAL
revealed	O
that	O
this	O
molecule	O
was	O
a	O
multikinase	O
inhibitor	O
that	O
targeted	O
the	O
vascular	B-GENE-N
endothelial	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
family	O
(	O
VEGFR	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
VEGFR	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
)	O
and	O
platelet	B-GENE-N
-	I-GENE-N
derived	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
family	O
(	O
PDGFR	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
and	O
Kit	B-GENE-Y
)	O
,	O
which	O
play	O
key	O
roles	O
in	O
tumor	O
progression	O
and	O
angiogenesis	O
.	O

Thus	O
,	O
sorafenib	B-CHEMICAL
may	O
inhibit	O
tumor	O
growth	O
by	O
a	O
dual	O
mechanism	O
,	O
acting	O
either	O
directly	O
on	O
the	O
tumor	O
(	O
through	O
inhibition	O
of	O
Raf	B-GENE-N
and	O
Kit	B-GENE-Y
signaling	O
)	O
and	O
/	O
or	O
on	O
tumor	O
angiogenesis	O
(	O
through	O
inhibition	O
of	O
VEGFR	B-GENE-N
and	O
PDGFR	B-GENE-N
signaling	O
)	O
.	O

In	O
phase	O
I	O
and	O
phase	O
II	O
clinical	O
trials	O
,	O
sorafenib	B-CHEMICAL
showed	O
limited	O
side	O
effects	O
and	O
,	O
more	O
importantly	O
,	O
disease	O
stabilization	O
.	O

This	O
agent	O
is	O
currently	O
being	O
evaluated	O
in	O
phase	O
III	O
clinical	O
trials	O
in	O
renal	O
cell	O
and	O
hepatocellular	O
carcinomas	O
.	O

A	O
molecular	O
mechanism	O
of	O
pyruvate	B-CHEMICAL
protection	O
against	O
cytotoxicity	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
in	O
osteoblasts	O
.	O

We	O
demonstrated	O
previously	O
that	O
exogenous	O
pyruvate	B-CHEMICAL
has	O
a	O
protective	O
action	O
against	O
cell	O
death	O
by	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
in	O
cultured	O
osteoblasts	O
through	O
a	O
mechanism	O
associated	O
with	O
its	O
antioxidative	O
property	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
evaluated	O
possible	O
participation	O
of	O
monocarboxylate	B-GENE-N
transporters	I-GENE-N
(	O
MCTs	B-GENE-N
)	O
responsible	O
for	O
the	O
bidirectional	O
membrane	O
transport	O
of	O
pyruvate	B-CHEMICAL
in	O
the	O
cytoprotective	O
property	O
in	O
osteoblasts	O
.	O

Expression	O
of	O
the	O
MCT2	B-GENE-Y
isoform	O
was	O
found	O
in	O
cultured	O
rat	O
calvarial	O
osteoblasts	O
and	O
in	O
osteoblasts	O
located	O
on	O
mouse	O
tibia	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

The	O
accumulation	O
of	O
[	B-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
pyruvate	I-CHEMICAL
occurred	O
in	O
a	O
temperature	O
-	O
and	O
pH	O
-	O
dependent	O
manner	O
in	O
osteoblasts	O
cultured	O
for	O
7	O
days	O
with	O
high	O
sensitivity	O
to	O
a	O
specific	O
MCT	B-GENE-N
inhibitor	O
,	O
whereas	O
pyruvate	B-CHEMICAL
was	O
released	O
into	O
extracellular	O
spaces	O
from	O
cultured	O
osteoblasts	O
in	O
a	O
fashion	O
sensitive	O
to	O
the	O
MCT	B-GENE-N
inhibitor	O
.	O

Transient	O
overexpression	O
of	O
the	O
MCT2	B-GENE-Y
isoform	O
led	O
to	O
reduced	O
vulnerability	O
to	O
the	O
cytotoxicity	O
of	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
with	O
an	O
increased	O
activity	O
of	O
[	B-CHEMICAL
14C	I-CHEMICAL
]	I-CHEMICAL
pyruvate	I-CHEMICAL
accumulation	O
in	O
murine	O
osteoblastic	O
MC3T3	O
-	O
E1	O
cells	O
.	O

Ovariectomy	O
significantly	O
decreased	O
the	O
content	O
of	O
pyruvate	B-CHEMICAL
in	O
femoral	O
bone	O
marrows	O
in	O
mice	O
in	O
vivo	O
,	O
whereas	O
daily	O
i	O
.	O
p	O
.	O
administration	O
of	O
pyruvate	B-CHEMICAL
at	O
0	O
.	O
25	O
g	O
/	O
kg	O
significantly	O
prevented	O
alterations	O
of	O
several	O
histomorphometric	O
parameters	O
as	O
well	O
as	O
cancellous	O
bone	O
loss	O
in	O
femurs	O
by	O
ovariectomy	O
on	O
28	O
days	O
after	O
the	O
operation	O
.	O

These	O
results	O
suggest	O
that	O
MCTs	B-GENE-N
may	O
be	O
functionally	O
expressed	O
by	O
osteoblasts	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
mechanisms	O
related	O
to	O
the	O
cytoprotective	O
property	O
of	O
pyruvate	B-CHEMICAL
.	O

Functional	O
divergence	O
of	O
a	O
unique	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
of	O
leucyl	B-GENE-N
-	I-GENE-N
tRNA	I-GENE-N
synthetase	I-GENE-N
to	O
accommodate	O
its	O
splicing	O
and	O
aminoacylation	O
roles	O
.	O

Leucyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
(	O
LeuRS	B-GENE-Y
)	O
performs	O
dual	O
essential	O
roles	O
in	O
group	O
I	O
intron	O
RNA	O
splicing	O
as	O
well	O
as	O
protein	O
synthesis	O
within	O
the	O
yeast	O
mitochondria	O
.	O

Deletions	O
of	O
the	O
C	B-CHEMICAL
terminus	O
differentially	O
impact	O
the	O
two	O
functions	O
of	O
the	O
enzyme	O
in	O
splicing	O
and	O
aminoacylation	O
in	O
vivo	O
.	O

Herein	O
,	O
we	O
determined	O
that	O
a	O
fiveamino	B-CHEMICAL
acid	I-CHEMICAL
C	B-CHEMICAL
-	O
terminal	O
deletion	O
of	O
LeuRS	B-GENE-Y
,	O
which	O
does	O
not	O
complement	O
a	O
null	O
strain	O
,	O
can	O
form	O
a	O
ternary	O
complex	O
with	O
the	O
bI4	O
intron	O
and	O
its	O
maturase	O
splicing	O
partner	O
.	O

However	O
,	O
the	O
complex	O
fails	O
to	O
stimulate	O
splicing	O
activity	O
.	O

The	O
x	O
-	O
ray	O
co	O
-	O
crystal	O
structure	O
of	O
LeuRS	B-GENE-Y
showed	O
that	O
a	O
C	B-CHEMICAL
-	O
terminal	O
extension	O
of	O
about	O
60	O
amino	B-CHEMICAL
acids	I-CHEMICAL
forms	O
a	O
discrete	O
domain	O
,	O
which	O
is	O
unique	O
among	O
the	O
LeuRSs	B-GENE-Y
and	O
interacts	O
with	O
the	O
corner	O
of	O
the	O
L	O
-	O
shaped	O
tRNALeu	O
.	O

Interestingly	O
,	O
deletion	O
of	O
the	O
entire	O
yeast	B-GENE-Y
mitochondrial	I-GENE-Y
LeuRS	I-GENE-Y
C	B-CHEMICAL
-	O
terminal	O
domain	O
enhanced	O
its	O
aminoacylation	O
and	O
amino	B-CHEMICAL
acid	I-CHEMICAL
editing	O
activities	O
.	O

In	O
striking	O
contrast	O
,	O
deletion	O
of	O
the	O
corresponding	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
of	O
Escherichia	B-GENE-Y
coli	I-GENE-Y
LeuRS	I-GENE-Y
abolished	O
aminoacylation	O
of	O
tRNALeu	O
and	O
also	O
amino	B-CHEMICAL
acid	I-CHEMICAL
editing	O
of	O
mischarged	O
tRNA	O
molecules	O
.	O

These	O
results	O
suggest	O
that	O
the	O
role	O
of	O
the	O
leucine	B-CHEMICAL
-	O
specific	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
in	O
tRNA	O
recognition	O
for	O
aminoacylation	O
and	O
amino	B-CHEMICAL
acid	I-CHEMICAL
editing	O
has	O
adapted	O
differentially	O
and	O
with	O
surprisingly	O
opposite	O
effects	O
.	O

We	O
propose	O
that	O
the	O
secondary	O
role	O
of	O
yeast	B-GENE-Y
mitochondrial	I-GENE-Y
LeuRS	I-GENE-Y
in	O
RNA	O
splicing	O
has	O
impacted	O
the	O
functional	O
evolution	O
of	O
this	O
critical	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
.	O

Discovery	O
and	O
optimization	O
of	O
anthranilic	B-CHEMICAL
acid	I-CHEMICAL
sulfonamides	I-CHEMICAL
as	O
inhibitors	O
of	O
methionine	B-GENE-Y
aminopeptidase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
:	O
a	O
structural	O
basis	O
for	O
the	O
reduction	O
of	O
albumin	B-GENE-Y
binding	O
.	O

Methionine	B-GENE-Y
aminopeptidase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
MetAP2	B-GENE-Y
)	O
is	O
a	O
novel	O
target	O
for	O
cancer	O
therapy	O
.	O

As	O
part	O
of	O
an	O
effort	O
to	O
discover	O
orally	O
active	O
reversible	O
inhibitors	O
of	O
MetAP2	B-GENE-Y
,	O
a	O
series	O
of	O
anthranilic	B-CHEMICAL
acid	I-CHEMICAL
sulfonamides	I-CHEMICAL
with	O
micromolar	O
affinities	O
for	O
human	B-GENE-Y
MetAP2	I-GENE-Y
were	O
identified	O
using	O
affinity	O
selection	O
by	O
mass	O
spectrometry	O
(	O
ASMS	O
)	O
screening	O
.	O

These	O
micromolar	O
hits	O
were	O
rapidly	O
improved	O
to	O
nanomolar	O
leads	O
on	O
the	O
basis	O
of	O
insights	O
from	O
protein	O
crystallography	O
;	O
however	O
,	O
the	O
compounds	O
displayed	O
extensive	O
binding	O
to	O
human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
and	O
had	O
limited	O
activity	O
in	O
cellular	O
assays	O
.	O

Modifications	O
based	O
on	O
structural	O
information	O
on	O
the	O
binding	O
of	O
lead	O
compounds	O
to	O
both	O
MetAP2	B-GENE-Y
and	O
domain	B-GENE-N
III	I-GENE-N
of	I-GENE-N
albumin	I-GENE-N
allowed	O
the	O
identification	O
of	O
compounds	O
with	O
significant	O
improvements	O
in	O
both	O
parameters	O
,	O
which	O
showed	O
good	O
cellular	O
activity	O
in	O
both	O
proliferation	O
and	O
methionine	B-CHEMICAL
processing	O
assays	O
.	O

Mitochondrial	B-GENE-Y
arginase	I-GENE-Y
II	I-GENE-Y
modulates	O
nitric	B-CHEMICAL
-	I-CHEMICAL
oxide	I-CHEMICAL
synthesis	O
through	O
nonfreely	O
exchangeable	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
pools	O
in	O
human	O
endothelial	O
cells	O
.	O

Reduced	O
synthesis	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
contributes	O
to	O
the	O
endothelial	O
dysfunction	O
and	O
may	O
be	O
related	O
to	O
limited	O
availability	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
,	O
the	O
common	O
substrate	O
of	O
constitutive	B-GENE-Y
nitric	I-GENE-Y
-	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
NOS	B-GENE-N
)	O
and	O
cytosolic	O
arginase	B-GENE-Y
I	I-GENE-Y
and	O
mitochondrial	B-GENE-Y
arginase	I-GENE-Y
II	I-GENE-Y
.	O

To	O
determine	O
whether	O
arginases	B-GENE-N
modulate	O
the	O
endothelial	O
NO	B-CHEMICAL
synthesis	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
the	O
competitive	O
arginase	B-GENE-N
inhibitor	O
N	B-CHEMICAL
(	I-CHEMICAL
omega	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
nor	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
(	O
Nor	B-CHEMICAL
-	I-CHEMICAL
NOHA	I-CHEMICAL
)	O
on	O
the	O
activity	O
of	O
NOS	B-GENE-N
,	O
arginases	B-GENE-N
,	O
and	O
L	B-GENE-N
-	I-GENE-N
arginine	I-GENE-N
transporter	I-GENE-N
and	O
on	O
NO	B-CHEMICAL
release	O
at	O
surface	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

In	O
unstimulated	O
cells	O
,	O
Nor	B-CHEMICAL
-	I-CHEMICAL
NOHA	I-CHEMICAL
dose	O
-	O
dependently	O
reduced	O
the	O
arginase	B-GENE-N
activity	O
with	O
maximal	O
inhibition	O
at	O
20	O
microM	O
.	O

When	O
HUVECs	O
were	O
stimulated	O
by	O
thrombin	B-GENE-Y
without	O
extracellular	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
,	O
Nor	B-CHEMICAL
-	I-CHEMICAL
NOHA	I-CHEMICAL
dose	O
-	O
dependently	O
increased	O
the	O
NOS	B-GENE-N
activity	O
and	O
the	O
NO	B-CHEMICAL
release	O
with	O
maximal	O
effects	O
at	O
20	O
microM	O
.	O

Extracellular	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
also	O
dose	O
-	O
dependently	O
increased	O
NO	B-CHEMICAL
release	O
and	O
arginase	B-GENE-N
activity	O
.	O

When	O
HUVECs	O
were	O
stimulated	O
by	O
thrombin	B-GENE-Y
in	O
the	O
presence	O
of	O
100	O
microM	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
,	O
NOS	B-GENE-N
activity	O
and	O
NO	B-CHEMICAL
release	O
were	O
similar	O
in	O
untreated	O
and	O
Nor	B-CHEMICAL
-	I-CHEMICAL
NOHA	I-CHEMICAL
-	O
treated	O
cells	O
.	O

However	O
,	O
despite	O
activation	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
uptake	O
,	O
the	O
inhibition	O
of	O
arginase	B-GENE-N
activity	O
by	O
Nor	B-CHEMICAL
-	I-CHEMICAL
NOHA	I-CHEMICAL
was	O
still	O
significant	O
.	O

The	O
depletion	O
of	O
freely	O
exchangeable	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
pools	O
with	O
extracellular	O
L	B-CHEMICAL
-	I-CHEMICAL
lysine	I-CHEMICAL
did	O
not	O
prevent	O
Nor	B-CHEMICAL
-	I-CHEMICAL
NOHA	I-CHEMICAL
from	O
increasing	O
the	O
NO	B-CHEMICAL
release	O
.	O

This	O
indicates	O
the	O
presence	O
of	O
pools	O
,	O
which	O
are	O
accessible	O
to	O
NOS	B-GENE-N
and	O
arginase	B-GENE-N
,	O
but	O
not	O
exchangeable	O
.	O

Interestingly	O
,	O
the	O
mitochondrial	B-GENE-Y
arginase	I-GENE-Y
II	I-GENE-Y
was	O
constitutively	O
expressed	O
,	O
whereas	O
the	O
cytosolic	O
arginase	B-GENE-Y
I	I-GENE-Y
was	O
barely	O
detectable	O
in	O
HUVECs	O
.	O

These	O
data	O
suggest	O
that	O
endothelial	O
NO	B-CHEMICAL
synthesis	O
depends	O
on	O
the	O
activity	O
of	O
arginase	B-GENE-Y
II	I-GENE-Y
in	O
mitochondria	O
and	O
l	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
carriers	O
in	O
cell	O
membrane	O
.	O

Involvement	O
of	O
pertussis	B-GENE-N
toxin	I-GENE-N
-	O
sensitive	O
G	B-GENE-N
-	I-GENE-N
proteins	I-GENE-N
in	O
the	O
hormonal	O
inhibition	O
of	O
dihydropyridine	B-CHEMICAL
-	O
sensitive	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
in	O
an	O
insulin	B-GENE-Y
-	O
secreting	O
cell	O
line	O
(	O
RINm5F	O
)	O
.	O

Adrenaline	B-CHEMICAL
inhibits	O
insulin	B-GENE-Y
secretion	O
via	O
pertussis	O
toxin	O
-	O
sensitive	O
mechanisms	O
.	O

Since	O
voltage	O
-	O
dependent	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
play	O
a	O
key	O
role	O
in	O
insulin	B-GENE-Y
secretion	O
,	O
we	O
examined	O
whether	O
adrenaline	B-CHEMICAL
modulates	O
voltage	O
-	O
dependent	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
of	O
the	O
rat	O
insulinoma	O
cell	O
line	O
,	O
RINm5F	O
.	O

In	O
the	O
whole	O
-	O
cell	O
configuration	O
of	O
the	O
patch	O
-	O
clamp	O
technique	O
,	O
dihydropyridine	B-CHEMICAL
-	O
but	O
not	O
omega	O
-	O
conotoxin	O
-	O
sensitive	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
were	O
identified	O
.	O

Adrenaline	B-CHEMICAL
via	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
inhibited	O
the	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
by	O
about	O
50	O
%	O
.	O

Somatostatin	B-CHEMICAL
which	O
also	O
inhibits	O
insulin	B-GENE-Y
secretion	O
was	O
less	O
efficient	O
(	O
inhibition	O
by	O
20	O
%	O
)	O
.	O

The	O
hormonal	O
inhibition	O
of	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
was	O
not	O
affected	O
by	O
intracellularly	O
applied	O
cAMP	B-CHEMICAL
but	O
blocked	O
by	O
the	O
intracellularly	O
applied	O
GDP	B-CHEMICAL
analog	O
guanosine	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
thiodiphosphate	I-CHEMICAL
)	I-CHEMICAL
and	O
by	O
pretreatment	O
of	O
cells	O
with	O
pertussis	B-GENE-N
toxin	I-GENE-N
.	O

In	O
contrast	O
to	O
adrenaline	B-CHEMICAL
and	O
somatostatin	B-CHEMICAL
,	O
galanin	B-GENE-Y
,	O
another	O
inhibitor	O
of	O
insulin	B-GENE-Y
secretion	O
,	O
reduced	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
by	O
about	O
40	O
%	O
in	O
a	O
pertussis	B-GENE-N
toxin	I-GENE-N
-	O
insensitive	O
manner	O
.	O

Immunoblot	O
experiments	O
performed	O
with	O
antibodies	O
generated	O
against	O
synthetic	O
peptides	O
revealed	O
that	O
membranes	O
of	O
RINm5F	O
cells	O
possess	O
four	O
pertussis	B-GENE-N
toxin	I-GENE-N
-	O
sensitive	O
G	B-GENE-N
-	I-GENE-N
proteins	I-GENE-N
including	O
Gi1	B-GENE-Y
,	O
Gi2	B-GENE-Y
,	O
Go2	B-GENE-Y
,	O
and	O
another	O
Go	B-GENE-N
subtype	O
,	O
most	O
likely	O
representing	O
Go1	B-GENE-Y
.	O

In	O
membranes	O
of	O
control	O
but	O
not	O
of	O
pertussis	B-GENE-N
toxin	I-GENE-N
-	O
treated	O
cells	O
,	O
adrenaline	B-CHEMICAL
via	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
stimulated	O
incorporation	O
of	O
the	O
photo	O
-	O
reactive	O
GTP	B-CHEMICAL
analog	O
[	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
32P	I-CHEMICAL
]	I-CHEMICAL
GTP	I-CHEMICAL
azidoanilide	I-CHEMICAL
into	O
pertussis	O
toxin	O
substrates	O
comigrating	O
with	O
the	O
alpha	O
-	O
subunits	O
of	O
Gi2	B-GENE-Y
,	O
Go2	B-GENE-Y
,	O
and	O
the	O
not	O
further	O
identified	O
Go	B-GENE-N
subtype	O
.	O

The	O
present	O
findings	O
indicate	O
that	O
activated	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
of	O
RINm5F	O
cells	O
interact	O
with	O
multiple	O
G	B-GENE-N
-	I-GENE-N
proteins	I-GENE-N
,	O
i	O
.	O
e	O
.	O
two	O
forms	O
of	O
Go	B-GENE-N
and	O
with	O
Gi2	B-GENE-Y
.	O

These	O
G	B-GENE-N
-	I-GENE-N
proteins	I-GENE-N
are	O
likely	O
to	O
be	O
involved	O
in	O
the	O
adrenaline	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
dihydropyridine	B-CHEMICAL
-	O
sensitive	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
currents	O
and	O
in	O
other	O
signal	O
transduction	O
pathways	O
contributing	O
to	O
the	O
adrenaline	B-CHEMICAL
-	O
induced	O
inhibition	O
of	O
insulin	B-GENE-Y
secretion	O
.	O

Acromegaly	O
:	O
molecular	O
expression	O
of	O
somatostatin	B-GENE-N
receptor	I-GENE-N
subtypes	O
and	O
treatment	O
outcome	O
.	O

About	O
a	O
third	O
of	O
acromegalic	O
patients	O
are	O
resistant	O
to	O
the	O
currently	O
commercially	O
available	O
somatostatin	B-CHEMICAL
analogs	O
(	O
SA	O
)	O
octreotide	B-CHEMICAL
and	O
lanreotide	B-CHEMICAL
.	O

Such	O
resistance	O
is	O
related	O
to	O
an	O
overall	O
reduction	O
of	O
somatostatin	B-GENE-N
receptor	I-GENE-N
(	O
SSTR	B-GENE-N
)	O
density	O
or	O
to	O
a	O
differentiated	O
expression	O
of	O
SSTR	B-GENE-N
subtypes	O
.	O

There	O
are	O
five	O
known	O
SSTR	B-GENE-N
subtypes	O
.	O

SSTR2	B-GENE-Y
and	O
SSTR5	B-GENE-Y
are	O
usually	O
expressed	O
in	O
GH	B-GENE-Y
-	O
secreting	O
pituitary	O
tumors	O
,	O
and	O
both	O
octreotide	B-CHEMICAL
and	O
lanreotide	B-CHEMICAL
bind	O
preferentially	O
to	O
SSTR2	B-GENE-Y
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
SSTR5	B-GENE-Y
.	O

SA	O
inhibitory	O
effects	O
on	O
GH	B-GENE-Y
secretion	O
and	O
tumor	O
cell	O
proliferation	O
can	O
occur	O
together	O
or	O
be	O
dissociated	O
events	O
,	O
depending	O
on	O
the	O
tumor	O
expression	O
of	O
SSTR	B-GENE-N
subtypes	O
involved	O
in	O
each	O
mechanism	O
.	O

The	O
development	O
of	O
specific	O
somatostatin	B-CHEMICAL
subtypes	O
analogs	O
,	O
mainly	O
for	O
SSTR5	B-GENE-Y
,	O
of	O
a	O
SSTR2	B-GENE-Y
-	O
SSTR5	B-GENE-Y
bispecific	O
compound	O
,	O
and	O
of	O
a	O
"	O
universal	O
"	O
analog	O
with	O
high	O
affinity	O
to	O
SSTR1	B-GENE-N
,	I-GENE-N
2	I-GENE-N
,	I-GENE-N
3	I-GENE-N
,	I-GENE-N
and	I-GENE-N
5	I-GENE-N
showed	O
preliminary	O
,	O
albeit	O
promising	O
results	O
for	O
the	O
treatment	O
of	O
resistant	O
somatotropic	O
adenomas	O
.	O

Gene	O
deletion	O
reveals	O
roles	O
for	O
annexin	B-GENE-Y
A1	I-GENE-Y
in	O
the	O
regulation	O
of	O
lipolysis	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
release	O
in	O
epididymal	O
adipose	O
tissue	O
.	O

In	O
this	O
study	O
,	O
epididymal	O
adipose	O
tissue	O
from	O
male	O
annexin	B-GENE-Y
1	I-GENE-Y
(	O
ANXA1	B-GENE-Y
)	O
-	O
null	O
and	O
wild	O
-	O
type	O
control	O
mice	O
were	O
used	O
to	O
explore	O
the	O
potential	O
role	O
of	O
ANXA1	B-GENE-Y
in	O
adipocyte	O
biology	O
.	O

ANXA1	B-GENE-Y
was	O
detected	O
by	O
Western	O
blot	O
analysis	O
in	O
wild	O
-	O
type	O
tissue	O
and	O
localized	O
predominantly	O
to	O
the	O
stromal	O
-	O
vascular	O
compartment	O
.	O

Epididymal	O
fat	O
pad	O
mass	O
was	O
reduced	O
by	O
ANXA1	B-GENE-Y
gene	O
deletion	O
,	O
but	O
adipocyte	O
size	O
was	O
unchanged	O
,	O
suggesting	O
that	O
ANXA1	B-GENE-Y
is	O
required	O
for	O
the	O
maintenance	O
of	O
adipocyte	O
and	O
/	O
or	O
preadipocyte	O
cell	O
number	O
.	O

Epididymal	O
tissue	O
from	O
wild	O
-	O
type	O
mice	O
responded	O
in	O
vitro	O
to	O
noradrenaline	B-CHEMICAL
and	O
isoprenaline	B-CHEMICAL
with	O
increased	O
glycerol	B-CHEMICAL
release	O
,	O
reduced	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
release	O
,	O
and	O
increased	O
cAMP	B-CHEMICAL
accumulation	O
.	O

Qualitatively	O
similar	O
but	O
significantly	O
attenuated	O
responses	O
to	O
the	O
catecholamines	B-CHEMICAL
were	O
observed	O
in	O
tissue	O
from	O
ANXA1	B-GENE-Y
-	O
null	O
mice	O
,	O
an	O
effect	O
that	O
was	O
not	O
associated	O
with	O
changes	O
in	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
mRNA	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
also	O
stimulated	O
lipolysis	O
in	O
vitro	O
,	O
but	O
its	O
effects	O
were	O
muted	O
by	O
ANXA1	B-GENE-Y
gene	O
deletion	O
.	O

By	O
contrast	O
,	O
LPS	O
failed	O
to	O
influence	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
release	O
from	O
wild	O
-	O
type	O
tissue	O
but	O
stimulated	O
the	O
release	O
of	O
the	O
cytokine	B-GENE-N
from	O
tissue	O
from	O
ANXA1	B-GENE-Y
-	O
null	O
mice	O
.	O

ANXA1	B-GENE-Y
gene	O
deletion	O
did	O
not	O
affect	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
expression	O
or	O
the	O
ability	O
of	O
dexamethasone	B-CHEMICAL
to	O
suppress	O
catecholamine	B-CHEMICAL
-	O
induced	O
lipolysis	O
.	O

It	O
did	O
,	O
however	O
,	O
augment	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
expression	O
and	O
modify	O
the	O
inhibitory	O
effects	O
of	O
glucocorticoids	O
on	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
release	O
.	O

Collectively	O
,	O
these	O
studies	O
suggest	O
that	O
ANXA1	B-GENE-Y
supports	O
aspects	O
of	O
adipose	O
tissue	O
mass	O
and	O
alters	O
the	O
sensitivity	O
of	O
epididymal	O
adipose	O
tissue	O
to	O
catecholamines	B-CHEMICAL
,	O
glucocorticoids	O
,	O
and	O
LPS	O
,	O
thereby	O
modulating	O
lipolysis	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
release	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
MEN1	B-GENE-Y
gene	O
in	O
subjects	O
with	O
multiple	O
endocrine	O
neoplasia	O
-	O
1	O
.	O

Multiple	O
endocrine	O
neoplasia	O
type	O
1	O
(	O
MEN1	B-GENE-Y
)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	O
endocrine	O
and	O
pituitary	O
adenomas	O
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	B-GENE-Y
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	B-GENE-Y
with	O
novel	O
mutations	O
in	O
the	O
MEN1	B-GENE-Y
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	O
had	O
primary	O
hyperparathyroidism	O
(	O
PHPT	O
)	O
plus	O
a	O
prolactinoma	O
;	O
three	O
relatives	O
had	O
PHPT	O
only	O
.	O

The	O
index	O
patient	O
in	O
the	O
second	O
family	O
was	O
a	O
46	O
-	O
yr	O
-	O
old	O
woman	O
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	O
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	O
and	O
watery	O
diarrhea	O
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	O
islet	O
cell	O
tumor	O
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	O
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	B-GENE-Y
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	O
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	B-GENE-N
to	I-GENE-N
G	I-GENE-N
transition	I-GENE-N
at	I-GENE-N
codon	I-GENE-N
557	I-GENE-N
(	O
AAG	B-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
GAG	I-GENE-N
)	O
of	O
exon	O
10	O
of	O
MEN1	B-GENE-Y
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	B-CHEMICAL
by	O
glutamic	B-CHEMICAL
acid	I-CHEMICAL
.	O

The	O
Chinese	O
index	O
patient	O
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	O
at	O
codon	O
418	O
of	O
exon	O
9	O
(	O
GAC	B-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
TAT	I-GENE-N
)	O
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	B-CHEMICAL
acid	I-CHEMICAL
by	O
tyrosine	B-CHEMICAL
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	B-GENE-Y
gene	O
.	O

Comparison	O
of	O
cyclooxygenase	B-GENE-N
inhibitory	O
activity	O
and	O
ocular	O
anti	O
-	O
inflammatory	O
effects	O
of	O
ketorolac	B-CHEMICAL
tromethamine	I-CHEMICAL
and	O
bromfenac	B-CHEMICAL
sodium	I-CHEMICAL
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
activity	O
and	O
anti	O
-	O
inflammatory	O
effects	O
of	O
the	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
ketorolac	B-CHEMICAL
tromethamine	I-CHEMICAL
(	O
ketorolac	B-CHEMICAL
)	O
and	O
bromfenac	B-CHEMICAL
sodium	I-CHEMICAL
(	O
bromfenac	B-CHEMICAL
)	O
.	O

METHODS	O
:	O
Cyclooxygenase	B-GENE-N
activity	O
and	O
selectivity	O
was	O
determined	O
in	O
vitro	O
by	O
measuring	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
production	O
following	O
incubation	O
of	O
varying	O
concentrations	O
of	O
NSAID	O
with	O
human	B-GENE-Y
recombinant	I-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
or	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Anti	O
-	O
inflammatory	O
effects	O
were	O
evaluated	O
in	O
a	O
rabbit	O
model	O
in	O
which	O
an	O
ocular	O
inflammatory	O
response	O
was	O
induced	O
by	O
intravenous	O
injection	O
of	O
10	O
microg	O
/	O
kg	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
study	O
animals	O
,	O
one	O
eye	O
was	O
treated	O
with	O
50	O
microL	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
ketorolac	I-CHEMICAL
0	O
.	O
4	O
%	O
(	O
Acular	B-CHEMICAL
LS	I-CHEMICAL
)	O
or	O
bromfenac	B-CHEMICAL
0	O
.	O
09	O
%	O
(	O
Xibrom	B-CHEMICAL
)	O
and	O
the	O
other	O
eye	O
with	O
50	O
microL	O
buffered	O
saline	O
.	O

In	O
control	O
animals	O
,	O
both	O
eyes	O
were	O
treated	O
with	O
vehicle	O
.	O

All	O
animals	O
were	O
treated	O
twice	O
:	O
2	O
hours	O
and	O
1	O
hour	O
before	O
LPS	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
production	O
in	O
vitro	O
,	O
measured	O
by	O
enzyme	O
immunoassay	O
;	O
fluorescein	B-CHEMICAL
isothiocyanate	I-CHEMICAL
(	O
FITC	B-CHEMICAL
)	O
-	O
dextran	O
leakage	O
into	O
the	O
anterior	O
chamber	O
,	O
measured	O
by	O
fluorophotometry	O
;	O
aqueous	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
levels	O
in	O
vivo	O
,	O
measured	O
by	O
ELISA	O
immunoassay	O
.	O

RESULTS	O
:	O
Ketorolac	B-CHEMICAL
was	O
six	O
times	O
more	O
active	O
against	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
02	O
microM	O
)	O
than	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
12	O
microM	O
)	O
while	O
bromfenac	B-CHEMICAL
was	O
approximately	O
32	O
times	O
more	O
active	O
against	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
0066	O
microM	O
)	O
than	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
210	O
microM	O
)	O
.	O

In	O
the	O
animal	O
model	O
,	O
both	O
drugs	O
resulted	O
in	O
nearly	O
complete	O
inhibition	O
of	O
FITC	B-CHEMICAL
-	O
dextran	O
leakage	O
and	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
production	O
in	O
the	O
anterior	O
chamber	O
of	O
treated	O
eyes	O
.	O

There	O
was	O
also	O
a	O
79	O
%	O
inhibition	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
of	O
FITC	B-CHEMICAL
-	O
dextran	O
leakage	O
in	O
the	O
contralateral	O
eyes	O
of	O
bromfenac	B-CHEMICAL
-	O
treated	O
rabbits	O
,	O
and	O
a	O
22	O
.	O
5	O
%	O
inhibition	O
(	O
not	O
statistically	O
significant	O
)	O
in	O
the	O
contralateral	O
eyes	O
of	O
ketorolac	B-CHEMICAL
-	O
treated	O
rabbits	O
.	O

CONCLUSIONS	O
:	O
Ketorolac	B-CHEMICAL
is	O
relatively	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
selective	O
while	O
bromfenac	B-CHEMICAL
is	O
potently	O
selective	O
for	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
over	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

In	O
the	O
animal	O
model	O
,	O
both	O
ketorolac	B-CHEMICAL
0	O
.	O
4	O
%	O
and	O
bromfenac	B-CHEMICAL
0	O
.	O
09	O
%	O
demonstrated	O
maximal	O
anti	O
-	O
inflammatory	O
activity	O
in	O
treated	O
eyes	O
.	O

Only	O
bromfenac	B-CHEMICAL
0	O
.	O
09	O
%	O
had	O
a	O
significant	O
effect	O
on	O
the	O
contralateral	O
eye	O
,	O
suggesting	O
possible	O
systemic	O
absorption	O
of	O
this	O
drug	O
.	O

Methyl	B-CHEMICAL
transfer	O
in	O
glycine	B-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
methyltransferase	I-GENE-Y
.	O

A	O
theoretical	O
study	O
.	O

Density	O
functional	O
theory	O
calculations	O
using	O
the	O
hybrid	O
functional	O
B3LYP	O
have	O
been	O
performed	O
to	O
study	O
the	O
methyl	B-CHEMICAL
transfer	O
step	O
in	O
glycine	B-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
methyltransferase	I-GENE-Y
(	O
GNMT	B-GENE-Y
)	O
.	O

This	O
enzyme	O
catalyzes	O
the	O
S	B-CHEMICAL
-	I-CHEMICAL
adenosyl	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
methionine	I-CHEMICAL
(	O
SAM	B-CHEMICAL
)	O
-	O
dependent	O
methylation	O
of	O
glycine	B-CHEMICAL
to	O
form	O
sarcosine	B-CHEMICAL
.	O

The	O
starting	O
point	O
for	O
the	O
calculations	O
is	O
the	O
recent	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
GNMT	B-GENE-Y
complexed	O
with	O
SAM	B-CHEMICAL
and	O
acetate	O
.	O

Several	O
quantum	O
chemical	O
models	O
with	O
different	O
sizes	O
,	O
employing	O
up	O
to	O
98	O
atoms	O
,	O
were	O
used	O
.	O

The	O
calculations	O
demonstrate	O
that	O
the	O
suggested	O
mechanism	O
,	O
where	O
the	O
methyl	O
group	O
is	O
transferred	O
in	O
a	O
single	O
S	O
(	O
N	O
)	O
2	O
step	O
,	O
is	O
thermodynamically	O
plausible	O
.	O

By	O
adding	O
or	O
eliminating	O
various	O
groups	O
at	O
the	O
active	O
site	O
,	O
it	O
was	O
furthermore	O
demonstrated	O
that	O
hydrogen	B-CHEMICAL
bonds	O
to	O
the	O
amino	B-CHEMICAL
group	O
of	O
the	O
glycine	B-CHEMICAL
substrate	O
lower	O
the	O
reaction	O
barrier	O
,	O
while	O
hydrogen	B-CHEMICAL
bonds	O
to	O
the	O
carboxylate	B-CHEMICAL
group	O
raise	O
the	O
barrier	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Amino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxybenzoic	I-CHEMICAL
acid	I-CHEMICAL
4	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
thioxo	I-CHEMICAL
-	I-CHEMICAL
5H	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
]	I-CHEMICAL
dithiol	I-CHEMICAL
-	I-CHEMICAL
3yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
)	O
,	O
a	O
hydrogen	B-CHEMICAL
sulfide	I-CHEMICAL
-	O
releasing	O
derivative	O
of	O
mesalamine	B-CHEMICAL
,	O
exerts	O
antinociceptive	O
effects	O
in	O
a	O
model	O
of	O
postinflammatory	O
hypersensitivity	O
.	O

H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
functions	O
as	O
a	O
neuromodulator	O
and	O
exerts	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Recent	O
data	O
indicate	O
that	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
is	O
linked	O
to	O
inflammation	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
a	O
novel	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
-	O
releasing	O
derivative	O
of	O
mesalamine	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxybenzoic	I-CHEMICAL
acid	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
thioxo	I-CHEMICAL
-	I-CHEMICAL
5H	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
]	I-CHEMICAL
dithiol	I-CHEMICAL
-	I-CHEMICAL
3yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
ester	I-CHEMICAL
,	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
)	O
in	O
modulating	O
nociception	O
to	O
colorectal	O
distension	O
(	O
CRD	O
)	O
,	O
a	O
model	O
that	O
mimics	O
some	O
features	O
of	O
IBS	O
,	O
in	O
healthy	O
and	O
postcolitic	O
rats	O
.	O

Four	O
graded	O
(	O
0	O
.	O
4	O
-	O
1	O
.	O
6	O
ml	O
of	O
water	O
)	O
CRDs	O
were	O
produced	O
in	O
conscious	O
rats	O
,	O
and	O
colorectal	O
sensitivity	O
and	O
pain	O
were	O
assessed	O
by	O
measuring	O
the	O
abdominal	O
withdrawal	O
response	O
and	O
spinal	O
c	B-GENE-Y
-	I-GENE-Y
Fos	I-GENE-Y
expression	O
.	O

In	O
healthy	O
rats	O
,	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
dose	O
dependently	O
(	O
25	O
,	O
50	O
,	O
or	O
100	O
mg	O
/	O
kg	O
)	O
attenuated	O
CRD	O
-	O
induced	O
hypersensitivity	O
and	O
significantly	O
inhibited	O
CRD	O
-	O
induced	O
overexpression	O
of	O
spinal	O
c	B-GENE-Y
-	I-GENE-Y
FOS	I-GENE-Y
mRNA	O
,	O
whereas	O
mesalamine	B-CHEMICAL
had	O
no	O
effect	O
.	O

ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
-	O
induced	O
antinociception	O
was	O
reversed	O
by	O
glibenclamide	B-CHEMICAL
,	O
a	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
(	I-GENE-N
K	I-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
inhibitor	O
.	O

The	O
antinociceptive	O
effect	O
of	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
was	O
maintained	O
in	O
a	O
rodent	O
model	O
of	O
postinflammatory	O
hypersensitivity	O
(	O
4	O
weeks	O
after	O
colitis	O
induction	O
)	O
.	O

At	O
a	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
,	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
reversed	O
the	O
allodynic	O
response	O
caused	O
by	O
CRD	O
in	O
postcolitic	O
rats	O
.	O

Colonic	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
interkeukin	B-GENE-Y
-	I-GENE-Y
1beta	I-GENE-Y
mRNA	O
and	O
spinal	O
c	B-GENE-Y
-	I-GENE-Y
FOS	I-GENE-Y
mRNA	O
expression	O
were	O
significantly	O
down	O
-	O
regulated	O
by	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
,	O
but	O
not	O
by	O
mesalamine	B-CHEMICAL
.	O

ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
,	O
but	O
not	O
mesalamine	B-CHEMICAL
,	O
increased	O
blood	O
concentrations	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
in	O
both	O
healthy	O
and	O
postcolitic	O
rats	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
ATB	B-CHEMICAL
-	I-CHEMICAL
429	I-CHEMICAL
inhibits	O
hypersensitivity	O
induced	O
by	O
CRD	O
in	O
both	O
healthy	O
and	O
postcolitic	O
,	O
allodynic	O
rats	O
by	O
a	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
-	O
mediated	O
mechanism	O
.	O

This	O
study	O
provides	O
evidence	O
that	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
-	O
releasing	O
drugs	O
might	O
have	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
painful	O
intestinal	O
disorders	O
.	O

[	O
Screening	O
of	O
short	O
peptides	O
binding	O
to	O
cell	O
surface	O
interleukin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
chain	I-GENE-Y
]	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
and	O
characterize	O
the	O
short	O
peptides	O
which	O
bind	O
specifically	O
to	O
interleukin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
chain	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
2Ralpha	I-GENE-Y
)	O
for	O
acquisition	O
of	O
small	O
antagonists	O
for	O
blocking	O
the	O
binding	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
with	O
IL	B-GENE-Y
-	I-GENE-Y
2Ralpha	I-GENE-Y
.	O

METHODS	O
:	O
12	O
-	O
mer	O
phage	O
displayed	O
peptide	O
library	O
was	O
screened	O
with	O
the	O
target	O
cells	O
of	O
MT	O
-	O
2	O
cells	O
which	O
expressed	O
IL	B-GENE-Y
-	I-GENE-Y
2Ralpha	I-GENE-Y
at	O
high	O
levels	O
.	O

The	O
binding	O
phage	O
clones	O
were	O
eluted	O
by	O
anti	O
-	O
IL	B-GENE-Y
-	I-GENE-Y
2Ralpha	I-GENE-Y
monoclonal	O
antibody	O
.	O

After	O
3	O
rounds	O
of	O
screening	O
,	O
the	O
positive	O
phage	O
clones	O
were	O
identified	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
immunohistochemistry	O
,	O
and	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequences	O
of	O
the	O
positive	O
clones	O
were	O
deduced	O
from	O
the	O
DNA	O
sequences	O
.	O

RESULTS	O
:	O
Seven	O
positive	O
clones	O
were	O
screened	O
out	O
of	O
the	O
17	O
phage	O
clones	O
bound	O
to	O
MT	O
-	O
2	O
cells	O
.	O

The	O
positive	O
clone	O
M15	O
could	O
bind	O
specifically	O
to	O
MT	O
-	O
2	O
cell	O
and	O
PHA	O
-	O
activated	O
peripheral	O
blood	O
monouclear	O
cells	O
.	O

Amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
analysis	O
identified	O
6	O
sequences	O
,	O
all	O
of	O
which	O
contained	O
hydrophilic	O
residues	O
,	O
and	O
5	O
of	O
these	O
6	O
sequences	O
included	O
Tyr	B-CHEMICAL
,	O
Phe	B-CHEMICAL
and	O
Leu	B-CHEMICAL
conservative	O
residues	O
.	O

CONCLUSION	O
:	O
The	O
peptide	O
sequences	O
containing	O
Tyr	B-CHEMICAL
,	O
Phe	B-CHEMICAL
conservative	O
residues	O
identified	O
in	O
this	O
study	O
can	O
bind	O
to	O
cell	O
surface	O
IL	B-GENE-Y
-	I-GENE-Y
2Ralpha	I-GENE-Y
.	O

RNA	O
interference	O
-	O
triggered	O
reversal	O
of	O
ABCC2	B-GENE-Y
-	O
dependent	O
cisplatin	B-CHEMICAL
resistance	O
in	O
human	O
cancer	O
cells	O
.	O

The	O
adenosine	B-GENE-N
triphosphate	I-GENE-N
binding	I-GENE-N
cassette	I-GENE-N
(	I-GENE-N
ABC	I-GENE-N
)	I-GENE-N
-	I-GENE-N
transporter	I-GENE-N
ABCC2	B-GENE-Y
(	O
MRP2	B-GENE-Y
/	O
cMOAT	B-GENE-Y
)	O
can	O
mediate	O
resistance	O
against	O
the	O
commonly	O
used	O
anticancer	O
drugs	O
cisplatin	B-CHEMICAL
and	O
paclitaxel	B-CHEMICAL
.	O

To	O
overcome	O
the	O
ABCC2	B-GENE-Y
-	O
depending	O
drug	O
resistance	O
,	O
two	O
specific	O
anti	O
-	O
ABCC2	B-GENE-Y
small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
were	O
designed	O
for	O
transient	O
triggering	O
of	O
the	O
gene	O
-	O
silencing	O
RNA	O
interference	O
(	O
RNAi	O
)	O
pathway	O
in	O
the	O
cisplatin	B-CHEMICAL
-	O
resistant	O
human	O
ovarian	O
carcinoma	O
cell	O
line	O
A2780RCIS	O
.	O

Since	O
both	O
siRNAs	O
showed	O
biological	O
activity	O
,	O
for	O
stable	O
inhibition	O
of	O
ABCC2	B-GENE-Y
a	O
corresponding	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
-	O
encoding	O
expression	O
vector	O
was	O
designed	O
.	O

By	O
treatment	O
of	O
A2780RCIS	O
cells	O
with	O
this	O
construct	O
,	O
the	O
expressions	O
of	O
the	O
targeted	O
ABCC2	B-GENE-Y
encoding	O
mRNA	O
and	O
transport	O
protein	O
were	O
inhibited	O
.	O

These	O
effects	O
were	O
accompanied	O
by	O
reversal	O
of	O
resistance	O
against	O
cisplatin	B-CHEMICAL
and	O
paclitaxel	B-CHEMICAL
.	O

Thus	O
,	O
the	O
data	O
demonstrate	O
the	O
utility	O
of	O
the	O
analyzed	O
RNAs	O
as	O
powerful	O
laboratory	O
tools	O
and	O
indicate	O
that	O
siRNA	O
-	O
and	O
shRNA	O
-	O
mediated	O
RNAi	O
-	O
based	O
gene	O
therapeutic	O
approaches	O
may	O
be	O
applicable	O
in	O
preventing	O
and	O
reversing	O
ABCC2	B-GENE-Y
-	O
depending	O
drug	O
resistance	O
.	O

Mutations	O
within	O
the	O
human	B-GENE-Y
GLYT2	I-GENE-Y
(	O
SLC6A5	B-GENE-Y
)	O
gene	O
associated	O
with	O
hyperekplexia	O
.	O

Hereditary	O
hyperekplexia	O
is	O
a	O
neuromotor	O
disorder	O
characterized	O
by	O
exaggerated	O
startle	O
reflexes	O
and	O
muscle	O
stiffness	O
in	O
the	O
neonate	O
.	O

The	O
disease	O
has	O
been	O
associated	O
with	O
mutations	O
in	O
the	O
glycine	B-GENE-N
receptor	I-GENE-N
subunit	O
genes	O
GLRA1	B-GENE-Y
and	O
GLRB	B-GENE-Y
.	O

Here	O
,	O
we	O
describe	O
mutations	O
within	O
the	O
neuronal	O
glycine	B-GENE-Y
transporter	I-GENE-Y
2	I-GENE-Y
gene	O
(	O
GLYT2	B-GENE-Y
,	O
or	O
SLC6A5	B-GENE-Y
,	O
)	O
of	O
hyperekplexia	O
patients	O
,	O
whose	O
symptoms	O
cannot	O
be	O
attributed	O
to	O
glycine	B-GENE-N
receptor	I-GENE-N
mutations	O
.	O

One	O
of	O
the	O
GLYT2	B-GENE-Y
mutations	O
identified	O
causes	O
truncation	O
of	O
the	O
transporter	B-GENE-N
protein	I-GENE-N
and	O
a	O
complete	O
loss	O
of	O
transport	O
function	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
GLYT2	B-GENE-Y
being	O
a	O
disease	O
gene	O
in	O
human	O
hyperekplexia	O
.	O

Bovine	B-GENE-N
and	I-GENE-N
ovine	I-GENE-N
gonadotropin	I-GENE-N
-	I-GENE-N
releasing	I-GENE-N
hormone	I-GENE-N
(	I-GENE-N
GnRH	I-GENE-N
)	I-GENE-N
-	I-GENE-N
II	I-GENE-N
ligand	O
precursors	O
and	O
type	B-GENE-N
II	I-GENE-N
GnRH	I-GENE-N
receptor	I-GENE-N
genes	O
are	O
functionally	O
inactivated	O
.	O

The	O
decapeptide	O
sequence	O
of	O
GnRH	B-CHEMICAL
-	I-CHEMICAL
II	I-CHEMICAL
is	O
conserved	O
in	O
all	O
jawed	O
vertebrate	O
species	O
studied	O
to	O
date	O
.	O

New	O
data	O
for	O
cattle	O
(	O
Bos	O
taurus	O
)	O
indicates	O
a	O
gene	O
encoding	O
GnRH	B-CHEMICAL
-	I-CHEMICAL
II	I-CHEMICAL
decapeptide	O
possessing	O
arginine	B-CHEMICAL
(	O
codon	O
:	O
CGG	B-CHEMICAL
)	O
rather	O
than	O
tryptophan	B-CHEMICAL
(	O
TGG	B-CHEMICAL
)	O
at	O
position	O
three	O
in	O
the	O
mature	O
peptide	O
.	O

This	O
substitution	O
is	O
unique	O
.	O

We	O
confirmed	O
the	O
DNA	O
sequence	O
after	O
cloning	O
part	O
of	O
the	O
bovine	B-GENE-Y
prepro	I-GENE-Y
-	I-GENE-Y
GnRH	I-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
gene	O
.	O

Bovine	B-GENE-Y
GnRH	I-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
peptide	O
was	O
synthesized	O
and	O
pharmacologically	O
characterized	O
.	O

It	O
did	O
not	O
bind	O
to	O
mammalian	O
GnRH	B-GENE-N
receptors	I-GENE-N
expressed	O
in	O
different	O
types	O
of	O
cell	O
nor	O
did	O
it	O
exhibit	O
agonist	O
or	O
antagonist	O
properties	O
on	O
types	B-GENE-N
I	I-GENE-N
or	I-GENE-N
II	I-GENE-N
GnRH	I-GENE-N
receptors	I-GENE-N
expressed	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Bovine	O
primers	O
facilitated	O
cloning	O
of	O
ovine	B-GENE-Y
GnRH	I-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
DNA	O
.	O

A	O
premature	O
stop	O
codon	O
(	O
TGA	O
)	O
replaces	O
the	O
expected	O
tryptophan	B-CHEMICAL
codon	O
at	O
position	O
seven	O
of	O
GnRH	B-CHEMICAL
-	I-CHEMICAL
II	I-CHEMICAL
in	O
sheep	O
DNA	O
.	O

Thus	O
,	O
both	O
species	O
possess	O
prepro	B-GENE-N
-	I-GENE-N
GnRH	I-GENE-N
-	I-GENE-N
II	I-GENE-N
genes	O
encoding	O
inactive	O
peptides	O
,	O
as	O
previously	O
described	O
for	O
chimpanzee	B-GENE-Y
GnRH	I-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
.	O

The	O
updated	O
bovine	B-GENE-Y
type	I-GENE-Y
II	I-GENE-Y
GnRH	I-GENE-Y
receptor	I-GENE-Y
gene	O
sequence	O
revealed	O
inactivation	O
by	O
frame	O
shifts	O
,	O
premature	O
stop	O
codons	O
,	O
and	O
nucleotide	B-CHEMICAL
changes	O
specifying	O
nonconservative	O
replacement	O
of	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
,	O
similar	O
to	O
inactivation	O
of	O
sheep	B-GENE-Y
type	I-GENE-Y
II	I-GENE-Y
GnRH	I-GENE-Y
receptor	I-GENE-Y
.	O

Spliced	O
RNA	O
transcripts	O
from	O
the	O
disrupted	O
receptor	O
gene	O
were	O
not	O
detected	O
in	O
bovine	O
pituitary	O
.	O

In	O
contrast	O
,	O
bovine	B-GENE-Y
prepro	I-GENE-Y
-	I-GENE-Y
GnRH	I-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
and	O
type	B-GENE-Y
I	I-GENE-Y
GnRH	I-GENE-Y
receptor	I-GENE-Y
genes	O
are	O
intact	O
,	O
encoding	O
well	O
-	O
conserved	O
protein	O
sequences	O
.	O

These	O
findings	O
,	O
and	O
previous	O
descriptions	O
of	O
inactivation	O
of	O
the	O
human	B-GENE-Y
type	I-GENE-Y
II	I-GENE-Y
GnRH	I-GENE-Y
receptor	I-GENE-Y
and	O
deletions	O
of	O
prepro	B-GENE-N
-	I-GENE-N
GnRH	I-GENE-N
-	I-GENE-N
II	I-GENE-N
and	O
type	B-GENE-N
II	I-GENE-N
GnRH	I-GENE-N
receptor	I-GENE-N
in	O
laboratory	O
rodents	O
,	O
suggest	O
the	O
GnRH	B-CHEMICAL
-	I-CHEMICAL
II	I-CHEMICAL
system	O
has	O
been	O
replaced	O
by	O
the	O
GnRH	B-GENE-N
-	I-GENE-N
I	I-GENE-N
system	O
or	O
is	O
redundant	O
in	O
certain	O
mammals	O
.	O

Liver	O
choline	B-GENE-Y
dehydrogenase	I-GENE-Y
and	O
kidney	O
betaine	B-GENE-N
-	I-GENE-N
homocysteine	I-GENE-N
methyltransferase	I-GENE-N
expression	O
are	O
not	O
affected	O
by	O
methionine	B-CHEMICAL
or	O
choline	B-CHEMICAL
intake	O
in	O
growing	O
rats	O
.	O

Choline	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
CHDH	B-GENE-Y
)	O
and	O
betaine	B-GENE-N
-	I-GENE-N
homocysteine	I-GENE-N
methyltransferase	I-GENE-N
(	O
BHMT	B-GENE-N
)	O
are	O
2	O
enzymes	O
involved	O
in	O
choline	B-CHEMICAL
oxidation	O
.	O

BHMT	B-GENE-N
is	O
expressed	O
at	O
high	O
levels	O
in	O
rat	O
liver	O
and	O
its	O
expression	O
is	O
regulated	O
by	O
dietary	O
Met	B-CHEMICAL
and	O
choline	B-CHEMICAL
.	O

BHMT	B-GENE-N
is	O
also	O
found	O
in	O
rat	O
kidney	O
,	O
albeit	O
in	O
substantially	O
lower	O
amounts	O
,	O
but	O
it	O
is	O
not	O
known	O
whether	O
kidney	O
BHMT	B-GENE-N
expression	O
is	O
regulated	O
by	O
dietary	O
Met	B-CHEMICAL
or	O
choline	B-CHEMICAL
.	O

Similarly	O
,	O
CHDH	B-GENE-Y
activity	O
is	O
highest	O
in	O
the	O
liver	O
and	O
kidney	O
,	O
but	O
the	O
regulation	O
of	O
its	O
expression	O
by	O
diet	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

Sprague	O
Dawley	O
rats	O
(	O
approximately	O
50	O
g	O
)	O
were	O
fed	O
,	O
for	O
9	O
d	O
in	O
2	O
x	O
3	O
factorial	O
design	O
(	O
n	O
=	O
8	O
)	O
,	O
an	O
l	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
acid	I-CHEMICAL
-	O
defined	O
diet	O
varying	O
in	O
l	B-CHEMICAL
-	I-CHEMICAL
Met	I-CHEMICAL
(	O
0	O
.	O
125	O
,	O
0	O
.	O
3	O
,	O
or	O
0	O
.	O
8	O
%	O
)	O
and	O
choline	B-CHEMICAL
(	O
0	O
or	O
25	O
mmol	O
/	O
kg	O
diet	O
)	O
.	O

Liver	O
and	O
kidney	O
BHMT	B-GENE-N
and	O
CHDH	B-GENE-Y
were	O
assessed	O
using	O
enzymatic	O
,	O
Western	O
blot	O
,	O
and	O
real	O
-	O
time	O
PCR	O
analyses	O
.	O

Liver	O
samples	O
were	O
also	O
fixed	O
for	O
histological	O
analysis	O
.	O

Liver	O
BHMT	B-GENE-N
activity	O
was	O
1	O
.	O
3	O
-	O
fold	O
higher	O
in	O
rats	O
fed	O
the	O
Met	B-CHEMICAL
deficient	O
diet	O
containing	O
choline	B-CHEMICAL
,	O
which	O
was	O
reflected	O
in	O
corresponding	O
increases	O
in	O
mRNA	O
content	O
and	O
immunodetectable	O
protein	O
.	O

Independent	O
of	O
dietary	O
choline	B-CHEMICAL
,	O
supplemental	O
Met	B-CHEMICAL
increased	O
hepatic	O
BHMT	B-GENE-N
activity	O
approximately	O
30	O
%	O
.	O

Kidney	O
BHMT	B-GENE-N
and	O
liver	O
CHDH	B-GENE-Y
expression	O
were	O
refractory	O
to	O
these	O
diets	O
.	O

Some	O
degree	O
of	O
fatty	O
liver	O
developed	O
in	O
all	O
rats	O
fed	O
a	O
choline	B-CHEMICAL
-	O
devoid	O
diet	O
,	O
indicating	O
that	O
supplemental	O
Met	B-CHEMICAL
cannot	O
completely	O
compensate	O
for	O
the	O
lack	O
of	O
dietary	O
choline	B-CHEMICAL
in	O
growing	O
rats	O
.	O

Temporal	O
profile	O
of	O
brain	O
and	O
pituitary	O
GnRHs	B-GENE-N
,	O
GnRH	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
and	O
gonadotropin	B-GENE-N
mRNA	O
expression	O
and	O
content	O
during	O
early	O
development	O
in	O
European	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
L	O
.	O
)	O
.	O

A	O
likely	O
endocrine	O
control	O
mechanism	O
for	O
sexual	O
differentiation	O
in	O
size	O
-	O
graded	O
populations	O
of	O
European	O
sea	O
bass	O
(	O
Dicentrarchus	O
labrax	O
)	O
is	O
proposed	O
by	O
evaluating	O
the	O
brain	O
expression	O
and	O
pituitary	O
content	O
of	O
two	O
forms	O
of	O
gonadotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
(	O
GnRH	B-CHEMICAL
)	O
,	O
namely	O
sea	O
bream	O
(	O
sbGnRH	B-GENE-N
)	O
and	O
salmon	O
(	O
sGnRH	B-GENE-N
)	O
,	O
the	O
pituitary	O
expression	O
of	O
one	O
subtype	O
of	O
GnRH	B-GENE-Y
receptor	I-GENE-Y
(	O
dlGnRH	B-GENE-N
-	I-GENE-N
R	I-GENE-N
-	I-GENE-N
2A	I-GENE-N
)	O
and	O
the	O
three	O
gonadotropin	B-GENE-N
(	O
GtH	B-GENE-N
)	O
subunits	O
,	O
namely	O
glycoprotein	B-GENE-N
alpha	I-GENE-N
(	O
GPalpha	B-GENE-N
)	O
,	O
follicle	B-GENE-N
-	I-GENE-N
stimulating	I-GENE-N
hormone	I-GENE-N
beta	I-GENE-N
(	O
FSHbeta	B-GENE-N
)	O
and	O
luteinizing	B-GENE-N
hormone	I-GENE-N
beta	I-GENE-N
(	O
LHbeta	B-GENE-N
)	O
,	O
as	O
well	O
as	O
the	O
pituitary	O
and	O
plasma	O
LH	B-GENE-N
levels	O
between	O
50	O
and	O
300	O
days	O
post	O
-	O
hatching	O
(	O
dph	O
)	O
.	O

Four	O
gradings	O
were	O
conducted	O
between	O
2	O
and	O
8	O
months	O
after	O
hatching	O
,	O
resulting	O
in	O
a	O
population	O
of	O
large	O
and	O
small	O
individuals	O
,	O
having	O
96	O
.	O
5	O
%	O
females	O
(	O
female	O
-	O
dominant	O
population	O
)	O
and	O
69	O
.	O
2	O
%	O
males	O
(	O
male	O
-	O
dominant	O
population	O
)	O
,	O
respectively	O
,	O
after	O
the	O
last	O
grading	O
.	O

The	O
onset	O
of	O
gonadal	O
differentiation	O
was	O
different	O
in	O
the	O
two	O
sexes	O
,	O
and	O
coincided	O
with	O
a	O
peak	O
of	O
expression	O
of	O
sbGnRH	B-GENE-N
or	O
sGnRH	B-GENE-N
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
these	O
GnRHs	B-CHEMICAL
was	O
correlated	O
with	O
the	O
expression	O
of	O
dlGnRH	B-GENE-N
-	I-GENE-N
R	I-GENE-N
-	I-GENE-N
2A	I-GENE-N
.	O

Sex	O
-	O
related	O
differences	O
in	O
the	O
brain	O
and	O
pituitary	O
content	O
of	O
sbGnRH	B-GENE-N
were	O
also	O
found	O
at	O
the	O
time	O
of	O
sexual	O
differentiation	O
.	O

Moreover	O
,	O
the	O
observed	O
sexual	O
dimorphism	O
at	O
the	O
transcriptional	O
or	O
synthesis	O
level	O
of	O
these	O
GnRH	B-CHEMICAL
forms	O
suggests	O
that	O
a	O
different	O
neuro	O
-	O
hormonal	O
regulation	O
is	O
operating	O
according	O
to	O
sex	O
.	O

At	O
the	O
onset	O
of	O
sex	O
differentiation	O
,	O
FSHbeta	B-GENE-N
transcriptional	O
activity	O
reached	O
maximal	O
values	O
,	O
which	O
were	O
maintained	O
until	O
the	O
completion	O
of	O
the	O
process	O
.	O

The	O
present	O
study	O
suggests	O
a	O
role	O
for	O
sbGnRH	B-GENE-N
,	O
sGnRH	B-GENE-N
and	O
the	O
dlGnRH	B-GENE-N
-	I-GENE-N
R	I-GENE-N
-	I-GENE-N
2A	I-GENE-N
during	O
gonadal	O
differentiation	O
,	O
possibly	O
through	O
enhancement	O
of	O
FSHbeta	B-GENE-N
gene	O
expression	O
.	O

In	O
males	O
,	O
a	O
different	O
endocrine	O
regulation	O
seems	O
to	O
exist	O
also	O
during	O
spermiogenesis	O
and	O
spermiation	O
,	O
when	O
gene	O
transcription	O
,	O
peptide	O
synthesis	O
and	O
release	O
of	O
LH	B-GENE-N
are	O
of	O
greater	O
importance	O
.	O

Brugada	O
syndrome	O
.	O

A	O
novel	O
clinical	O
entity	O
characterized	O
by	O
ST	O
segment	O
elevation	O
in	O
right	O
precordial	O
leads	O
(	O
V1	O
to	O
V3	O
)	O
,	O
incomplete	O
or	O
complete	O
right	O
bundle	O
branch	O
block	O
,	O
and	O
susceptibility	O
to	O
ventricular	O
tachyarrhythmia	O
and	O
sudden	O
cardiac	O
death	O
has	O
been	O
described	O
by	O
Brugada	O
et	O
al	O
.	O
in	O
1992	O
.	O

This	O
disease	O
is	O
now	O
frequently	O
called	O
"	O
Brugada	O
syndrome	O
"	O
(	O
BrS	O
)	O
.	O

The	O
prevalence	O
of	O
BrS	O
in	O
the	O
general	O
population	O
is	O
unknown	O
.	O

The	O
suggested	O
prevalence	O
ranges	O
from	O
5	O
/	O
1	O
,	O
000	O
(	O
Caucasians	O
)	O
to	O
14	O
/	O
1	O
,	O
000	O
(	O
Japanese	O
)	O
.	O

Syncope	O
,	O
typically	O
occurring	O
at	O
rest	O
or	O
during	O
sleep	O
(	O
in	O
individuals	O
in	O
their	O
third	O
or	O
fourth	O
decades	O
of	O
life	O
)	O
is	O
a	O
common	O
presentation	O
of	O
BrS	O
.	O

In	O
some	O
cases	O
,	O
tachycardia	O
does	O
not	O
terminate	O
spontaneously	O
and	O
it	O
may	O
degenerate	O
into	O
ventricular	O
fibrillation	O
and	O
lead	O
to	O
sudden	O
death	O
.	O

Both	O
sporadic	O
and	O
familial	O
cases	O
have	O
been	O
reported	O
and	O
pedigree	O
analysis	O
suggests	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
.	O

In	O
approximately	O
20	O
%	O
of	O
the	O
cases	O
BrS	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
SCN5A	B-GENE-Y
gene	O
on	O
chromosome	O
3p21	O
-	O
23	O
,	O
encoding	O
the	O
cardiac	O
sodium	B-GENE-N
channel	I-GENE-N
,	O
a	O
protein	O
involved	O
in	O
the	O
control	O
of	O
myocardial	O
excitability	O
.	O

Since	O
the	O
use	O
of	O
the	O
implantable	O
cardioverter	O
defibrillator	O
(	O
ICD	O
)	O
is	O
the	O
only	O
therapeutic	O
option	O
of	O
proven	O
efficacy	O
for	O
primary	O
and	O
secondary	O
prophylaxis	O
of	O
cardiac	O
arrest	O
,	O
the	O
identification	O
of	O
high	O
-	O
risk	O
subjects	O
is	O
one	O
of	O
the	O
major	O
goals	O
in	O
the	O
clinical	O
decision	O
-	O
making	O
process	O
.	O

Quinidine	B-CHEMICAL
may	O
be	O
regarded	O
as	O
an	O
adjunctive	O
therapy	O
for	O
patients	O
at	O
higher	O
risk	O
and	O
may	O
reduce	O
the	O
number	O
of	O
cases	O
of	O
ICD	O
shock	O
in	O
patients	O
with	O
multiple	O
recurrences	O
.	O

Relative	O
myotoxic	O
and	O
haemodynamic	O
effects	O
of	O
the	O
beta	O
-	O
agonists	O
fenoterol	B-CHEMICAL
and	O
clenbuterol	B-CHEMICAL
measured	O
in	O
conscious	O
unrestrained	O
rats	O
.	O

The	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
(	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
AR	I-GENE-Y
)	O
agonists	O
clenbuterol	B-CHEMICAL
and	O
fenoterol	B-CHEMICAL
have	O
similar	O
beneficial	O
effects	O
in	O
animal	O
models	O
of	O
heart	O
failure	O
.	O

However	O
,	O
large	O
doses	O
of	O
clenbuterol	B-CHEMICAL
can	O
induce	O
cardiomyocyte	O
death	O
,	O
and	O
it	O
is	O
not	O
known	O
which	O
of	O
these	O
agents	O
has	O
the	O
most	O
favourable	O
therapeutic	O
profile	O
.	O

We	O
have	O
investigated	O
the	O
cardiotoxicity	O
of	O
clenbuterol	B-CHEMICAL
and	O
fenoterol	B-CHEMICAL
alongside	O
that	O
of	O
isoprenaline	B-CHEMICAL
,	O
and	O
compared	O
their	O
haemodynamic	O
effects	O
.	O

Wistar	O
rats	O
(	O
n	O
=	O
6	O
per	O
group	O
)	O
were	O
subcutaneously	O
injected	O
with	O
each	O
beta	O
-	O
agonist	O
(	O
0	O
.	O
003	O
-	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
)	O
or	O
saline	O
,	O
and	O
cardiomyocyte	O
apoptosis	O
was	O
detected	O
by	O
caspase	B-GENE-Y
3	I-GENE-Y
immunohistochemistry	O
.	O

In	O
a	O
separate	O
experiment	O
,	O
rats	O
(	O
n	O
=	O
4	O
)	O
were	O
given	O
equivalent	O
doses	O
to	O
those	O
used	O
in	O
the	O
myotoxicity	O
studies	O
,	O
in	O
a	O
randomized	O
cross	O
-	O
over	O
design	O
,	O
and	O
their	O
blood	O
pressure	O
recorded	O
via	O
radiotelemetry	O
.	O

Injection	O
of	O
0	O
.	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
fenoterol	B-CHEMICAL
or	O
isoprenaline	B-CHEMICAL
,	O
but	O
not	O
clenbuterol	B-CHEMICAL
,	O
induced	O
significant	O
cardiomyocyte	O
apoptosis	O
(	O
0	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
05	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

At	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
,	O
all	O
agonists	O
induced	O
apoptosis	O
(	O
fenoterol	B-CHEMICAL
,	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
%	O
;	O
isoprenaline	B-CHEMICAL
,	O
0	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
8	O
%	O
;	O
and	O
clenbuterol	B-CHEMICAL
,	O
0	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
07	O
%	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

beta	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
Adrenoceptor	I-GENE-Y
antagonism	O
(	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
bisoprolol	B-CHEMICAL
)	O
prevented	O
92	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
of	O
apoptosis	O
induced	O
by	O
all	O
three	O
agonists	O
,	O
but	O
clenbuterol	B-CHEMICAL
-	O
induced	O
apoptosis	O
could	O
also	O
be	O
prevented	O
by	O
96	O
%	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
by	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
AR	I-GENE-Y
antagonism	O
(	O
10	O
mg	O
kg	O
(	O
-	O
1	O
)	O
ICI	O
118	O
551	O
)	O
.	O

Clenbuterol	B-CHEMICAL
decreased	O
diastolic	O
(	O
1	O
.	O
3	O
-	O
to	O
1	O
.	O
6	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
systolic	O
blood	O
pressure	O
(	O
1	O
.	O
3	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
doses	O
>	O
0	O
.	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
increased	O
heart	O
rate	O
(	O
1	O
.	O
4	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Fenoterol	B-CHEMICAL
increased	O
heart	O
rate	O
(	O
1	O
.	O
2	O
-	O
to	O
1	O
.	O
4	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
doses	O
>	O
0	O
.	O
3	O
mmol	O
kg	O
(	O
-	O
1	O
)	O
decreased	O
diastolic	O
blood	O
pressure	O
(	O
1	O
.	O
3	O
-	O
fold	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
cardiotoxicity	O
of	O
fenoterol	B-CHEMICAL
was	O
similar	O
to	O
isoprenaline	B-CHEMICAL
and	O
greater	O
than	O
clenbuterol	B-CHEMICAL
,	O
and	O
fenoterol	B-CHEMICAL
had	O
less	O
desirable	O
haemodynamic	O
effects	O
.	O

Immunotherapy	O
for	O
De	O
Novo	O
renal	O
transplantation	O
:	O
what	O
'	O
s	O
in	O
the	O
pipeline	O
?	O

Immunosuppressive	O
drugs	O
have	O
been	O
traditionally	O
developed	O
to	O
prevent	O
acute	O
rejection	O
and	O
to	O
improve	O
short	O
-	O
term	O
kidney	O
transplant	O
outcomes	O
.	O

There	O
is	O
still	O
a	O
medical	O
need	O
to	O
improve	O
outcomes	O
among	O
subgroups	O
of	O
patients	O
at	O
higher	O
risk	O
for	O
graft	O
loss	O
and	O
to	O
reduce	O
cardiovascular	O
,	O
infectious	O
and	O
malignancy	O
-	O
associated	O
morbidity	O
and	O
mortality	O
,	O
and	O
improve	O
long	O
-	O
term	O
adherence	O
.	O

Several	O
new	O
immunosuppressive	O
agents	O
and	O
formulations	O
are	O
undergoing	O
clinical	O
investigation	O
and	O
are	O
discussed	O
in	O
this	O
review	O
.	O
A	O
modified	O
release	O
tacrolimus	B-CHEMICAL
formulation	O
(	O
MR4	O
)	O
for	O
once	O
-	O
daily	O
administration	O
is	O
undergoing	O
phase	O
III	O
trials	O
.	O

It	O
has	O
been	O
developed	O
to	O
be	O
administered	O
de	O
novo	O
or	O
for	O
maintenance	O
using	O
the	O
same	O
therapeutic	O
target	O
tacrolimus	B-CHEMICAL
trough	O
concentrations	O
as	O
for	O
the	O
original	O
formulation	O
.	O

Belatacept	O
(	O
LEA29Y	O
)	O
,	O
a	O
second	O
generation	O
cytotoxic	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
-	I-GENE-Y
lymphocyte	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
antigen	I-GENE-Y
immunoglobulin	B-GENE-N
(	O
CTLA4	B-GENE-Y
-	O
Ig	B-GENE-N
)	O
,	O
blocks	O
the	O
interaction	O
between	O
CD80	B-GENE-N
/	I-GENE-N
86	I-GENE-N
and	O
CD28	B-GENE-Y
costimulatory	O
pathways	O
.	O

In	O
phase	O
II	O
trials	O
,	O
belatacept	O
was	O
as	O
effective	O
as	O
ciclosporin	B-CHEMICAL
(	O
cyclosporine	B-CHEMICAL
)	O
when	O
administered	O
in	O
combination	O
with	O
basiliximab	O
,	O
mycophenolate	B-CHEMICAL
mofetil	I-CHEMICAL
(	O
MMF	B-CHEMICAL
)	O
and	O
corticosteroids	O
.	O

Currently	O
,	O
belatacept	O
is	O
undergoing	O
phase	O
III	O
trials	O
including	O
one	O
study	O
in	O
recipients	O
of	O
organs	O
from	O
expanded	O
criteria	O
donors	O
.	O

Inhibitors	O
of	O
the	O
Janus	B-GENE-Y
protein	I-GENE-Y
tyrosine	I-GENE-Y
kinase	I-GENE-Y
(	I-GENE-Y
JAK	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
show	O
some	O
selectivity	O
for	O
cells	O
of	O
the	O
lymphoid	O
lineage	O
and	O
have	O
been	O
shown	O
to	O
be	O
effective	O
in	O
late	O
preclinical	O
transplant	O
models	O
.	O

The	O
most	O
frequent	O
adverse	O
effects	O
have	O
been	O
related	O
to	O
nonspecific	O
binding	O
to	O
JAK2	B-GENE-Y
kinases	B-GENE-N
.	O

CP	B-CHEMICAL
-	I-CHEMICAL
690550	I-CHEMICAL
,	O
a	O
JAK3	B-GENE-Y
inhibitor	O
is	O
currently	O
in	O
phase	O
II	O
clinical	O
trials	O
.	O
FK778	B-CHEMICAL
,	O
is	O
a	O
synthetic	O
malononitrilamide	B-CHEMICAL
that	O
targets	O
the	O
critical	O
enzyme	O
of	O
the	O
de	O
novo	O
pyrimidine	B-CHEMICAL
synthesis	O
,	O
dihydroorotic	B-GENE-Y
acid	I-GENE-Y
dehydrogenase	I-GENE-Y
,	O
and	O
receptor	B-GENE-N
-	I-GENE-N
associated	I-GENE-N
tyrosine	I-GENE-N
kinases	I-GENE-N
has	O
completed	O
phase	O
II	O
trials	O
.	O

FK778	B-CHEMICAL
also	O
shows	O
antiviral	O
activities	O
that	O
have	O
been	O
tested	O
in	O
patients	O
with	O
polyomavirus	O
nephropathy	O
.	O

Fingolimod	B-CHEMICAL
(	O
FTY720	B-CHEMICAL
)	O
,	O
a	O
synthetic	O
sphingosine	B-GENE-N
phosphate	I-GENE-N
receptor	I-GENE-N
modulator	O
that	O
reduces	O
the	O
recirculation	O
of	O
lymphocytes	O
to	O
blood	O
and	O
peripheral	O
tissues	O
including	O
inflammatory	O
lesions	O
and	O
graft	O
sites	O
is	O
undergoing	O
phase	O
III	O
trials	O
.	O

Although	O
the	O
efficacy	O
of	O
fingolimod	B-CHEMICAL
is	O
similar	O
to	O
MMF	B-CHEMICAL
in	O
patients	O
receiving	O
full	O
doses	O
of	O
ciclosporin	B-CHEMICAL
,	O
safety	O
issues	O
such	O
as	O
a	O
negative	O
chronotropic	O
effect	O
,	O
macular	O
oedema	O
,	O
pulmonary	O
adverse	O
reactions	O
and	O
graft	O
function	O
resulted	O
in	O
premature	O
discontinuation	O
of	O
the	O
development	O
programme	O
for	O
kidney	O
transplantation	O
.	O

Because	O
there	O
was	O
no	O
clear	O
clinical	O
benefit	O
over	O
treatment	O
options	O
,	O
the	O
clinical	O
development	O
programme	O
of	O
FK778	B-CHEMICAL
was	O
discontinued	O
.	O
Finally	O
,	O
a	O
new	O
evolving	O
strategy	O
with	O
powerful	O
induction	O
-	O
induced	O
prolonged	O
T	O
-	O
cell	O
depletion	O
followed	O
by	O
low	O
-	O
dose	O
immunosuppressive	O
monotherapy	O
is	O
showing	O
promising	O
results	O
.	O

Medroxyprogesterone	B-CHEMICAL
acetate	I-CHEMICAL
but	O
not	O
drospirenone	B-CHEMICAL
ablates	O
the	O
protective	O
function	O
of	O
17	B-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
in	O
aldosterone	B-CHEMICAL
salt	O
-	O
treated	O
rats	O
.	O

Controversial	O
results	O
obtained	O
from	O
human	O
and	O
animal	O
studies	O
on	O
the	O
prevention	O
of	O
heart	O
disease	O
by	O
estrogens	B-CHEMICAL
and	O
progestins	B-CHEMICAL
warrant	O
a	O
better	O
understanding	O
of	O
nuclear	B-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
function	O
and	O
interaction	O
.	O

To	O
address	O
this	O
issue	O
and	O
taking	O
into	O
account	O
that	O
effects	O
of	O
synthetic	O
progestins	B-CHEMICAL
are	O
not	O
only	O
referable	O
to	O
action	O
through	O
the	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
but	O
may	O
also	O
be	O
mediated	O
by	O
other	O
steroid	B-GENE-N
receptors	I-GENE-N
,	O
we	O
characterized	O
cardiovascular	O
function	O
and	O
inflammatory	O
gene	O
expression	O
in	O
aldosterone	B-CHEMICAL
salt	O
-	O
treated	O
rats	O
on	O
long	O
-	O
term	O
administration	O
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
,	O
medroxyprogesterone	B-CHEMICAL
acetate	I-CHEMICAL
,	O
and	O
drospirenone	B-CHEMICAL
,	O
a	O
new	O
progestogen	B-CHEMICAL
exhibiting	O
antimineralocorticoid	O
activity	O
.	O

The	O
complex	O
pattern	O
of	O
cardiovascular	O
injury	O
in	O
ovariectomized	O
Wistar	O
rats	O
induced	O
by	O
chronic	O
aldosterone	B-CHEMICAL
infusion	O
plus	O
a	O
high	O
-	O
salt	O
diet	O
was	O
significantly	O
attenuated	O
in	O
sham	O
-	O
ovariectomized	O
rats	O
and	O
by	O
coadministration	O
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
in	O
ovariectomized	O
animals	O
after	O
8	O
weeks	O
of	O
continuous	O
treatment	O
.	O

The	O
beneficial	O
role	O
of	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
on	O
blood	O
pressure	O
,	O
cardiac	O
hypertrophy	O
,	O
vascular	O
osteopontin	B-GENE-Y
expression	O
,	O
perivascular	O
fibrosis	O
,	O
and	O
impaired	O
NO	B-CHEMICAL
-	O
dependent	O
relaxation	O
of	O
isolated	O
aortic	O
rings	O
was	O
completely	O
abrogated	O
by	O
coadministration	O
of	O
medroxyprogesterone	B-CHEMICAL
acetate	I-CHEMICAL
.	O

In	O
contrast	O
,	O
drospirenone	B-CHEMICAL
was	O
either	O
neutral	O
or	O
additive	O
to	O
17beta	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
in	O
protecting	O
against	O
aldosterone	B-CHEMICAL
salt	O
-	O
induced	O
cardiovascular	O
injury	O
and	O
inflammation	O
.	O

The	O
current	O
results	O
support	O
the	O
hypothesis	O
of	O
complex	O
interactions	O
among	O
estrogen	B-GENE-N
,	I-GENE-N
progesterone	I-GENE-N
,	I-GENE-N
glucocorticoid	I-GENE-N
,	I-GENE-N
androgen	I-GENE-N
,	I-GENE-N
and	I-GENE-N
mineralocorticoid	I-GENE-N
receptor	I-GENE-N
signaling	O
in	O
cardiovascular	O
injury	O
and	O
inflammation	O
.	O

Novel	O
progestins	B-CHEMICAL
,	O
such	O
as	O
drospirenone	B-CHEMICAL
,	O
confer	O
superior	O
effects	O
compared	O
with	O
medroxyprogesterone	B-CHEMICAL
acetate	I-CHEMICAL
in	O
a	O
model	O
of	O
aldosterone	B-CHEMICAL
-	O
induced	O
heart	O
disease	O
because	O
of	O
its	O
antimineralocorticoid	O
properties	O
.	O

Licofelone	B-CHEMICAL
,	O
a	O
balanced	O
inhibitor	O
of	O
cyclooxygenase	B-GENE-N
and	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
,	O
reduces	O
inflammation	O
in	O
a	O
rabbit	O
model	O
of	O
atherosclerosis	O
.	O

Licofelone	B-CHEMICAL
,	O
a	O
dual	O
anti	O
-	O
inflammatory	O
drug	O
that	O
inhibits	O
5	B-GENE-Y
-	I-GENE-Y
lipoxygenase	I-GENE-Y
(	O
LOX	B-GENE-N
)	O
and	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
enzymes	O
,	O
may	O
have	O
a	O
better	O
cardiovascular	O
profile	O
that	O
cycloxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
due	O
to	O
cycloxygenase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
blockade	O
-	O
mediated	O
antithrombotic	O
effect	O
and	O
a	O
better	O
gastrointestinal	O
tolerability	O
.	O

We	O
examined	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
licofelone	B-CHEMICAL
on	O
atherosclerotic	O
lesions	O
as	O
well	O
as	O
in	O
isolated	O
neutrophils	O
from	O
whole	O
blood	O
of	O
rabbits	O
compared	O
with	O
a	O
selective	O
inhibitor	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
rofecoxib	B-CHEMICAL
.	O

We	O
also	O
assessed	O
the	O
antithrombotic	O
effect	O
of	O
licofelone	B-CHEMICAL
in	O
rabbit	O
platelet	O
-	O
rich	O
plasma	O
.	O

For	O
this	O
purpose	O
,	O
30	O
rabbits	O
underwent	O
injury	O
of	O
femoral	O
arteries	O
,	O
and	O
they	O
were	O
randomized	O
to	O
receive	O
10	O
mg	O
/	O
kg	O
/	O
day	O
licofelone	B-CHEMICAL
or	O
5	O
mg	O
/	O
kg	O
/	O
day	O
rofecoxib	B-CHEMICAL
or	O
no	O
treatment	O
during	O
4	O
weeks	O
with	O
atherogenic	O
diet	O
in	O
all	O
cases	O
.	O

Ten	O
healthy	O
rabbits	O
were	O
used	O
as	O
controls	O
.	O

Neutrophils	O
and	O
platelets	O
were	O
isolated	O
from	O
peripheral	O
blood	O
of	O
rabbits	O
for	O
ex	O
vivo	O
studies	O
.	O

Licofelone	B-CHEMICAL
reduced	O
intima	O
/	O
media	O
ratio	O
in	O
injured	O
arteries	O
,	O
the	O
macrophages	O
infiltration	O
in	O
the	O
neointimal	O
area	O
,	O
monocyte	B-GENE-Y
chemoattractant	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
gene	O
expression	O
,	O
and	O
the	O
activation	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
in	O
rabbit	O
atheroma	O
.	O

Moreover	O
,	O
licofelone	B-CHEMICAL
inhibited	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
protein	O
expression	O
in	O
vascular	O
lesions	O
.	O

Rofecoxib	B-CHEMICAL
only	O
diminished	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
protein	O
expression	O
and	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
expression	O
in	O
vascular	O
atheroma	O
.	O

Prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
in	O
rabbit	O
plasma	O
was	O
attenuated	O
by	O
both	O
drugs	O
.	O

Licofelone	B-CHEMICAL
almost	O
abolished	O
5	B-GENE-Y
-	I-GENE-Y
LOX	I-GENE-Y
activity	O
by	O
inhibiting	O
leukotriene	B-CHEMICAL
B4	I-CHEMICAL
generation	O
in	O
rabbit	O
neutrophils	O
and	O
prevented	O
platelet	O
thromboxane	B-CHEMICAL
B2	I-CHEMICAL
production	O
from	O
whole	O
blood	O
.	O

Licofelone	B-CHEMICAL
reduces	O
neointimal	O
formation	O
and	O
inflammation	O
in	O
an	O
atherosclerotic	O
rabbit	O
model	O
more	O
markedly	O
than	O
rofecoxib	B-CHEMICAL
.	O

This	O
effect	O
,	O
together	O
with	O
the	O
antiplatelet	O
activity	O
of	O
licofelone	B-CHEMICAL
,	O
suggests	O
that	O
this	O
drug	O
may	O
have	O
a	O
favorable	O
cardiovascular	O
profile	O
.	O

Different	O
responses	O
to	O
dexamethasone	B-CHEMICAL
and	O
prednisolone	B-CHEMICAL
in	O
the	O
same	O
depressed	O
patients	O
.	O

RATIONALE	O
:	O
Patients	O
with	O
major	O
depression	O
show	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
hyperactivity	O
,	O
but	O
the	O
mechanisms	O
underlying	O
this	O
abnormality	O
are	O
still	O
unclear	O
.	O

OBJECTIVES	O
:	O
We	O
have	O
compared	O
two	O
synthetic	O
glucorticoids	O
,	O
dexamethasone	B-CHEMICAL
and	O
prednisolone	B-CHEMICAL
,	O
in	O
their	O
ability	O
to	O
suppress	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
depressed	O
patients	O
.	O

Dexamethasone	B-CHEMICAL
probes	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
function	O
,	O
while	O
prednisolone	B-CHEMICAL
probes	O
both	O
GR	B-GENE-Y
and	O
mineralocorticoid	B-GENE-Y
receptor	I-GENE-Y
(	O
MR	B-GENE-Y
)	O
function	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
We	O
used	O
a	O
single	O
-	O
blind	O
,	O
repeated	O
-	O
measure	O
design	O
.	O

We	O
administered	O
placebo	O
,	O
prednisolone	B-CHEMICAL
(	O
5	O
mg	O
)	O
or	O
dexamethasone	B-CHEMICAL
(	O
0	O
.	O
5	O
mg	O
)	O
,	O
at	O
22	O
:	O
00	O
,	O
to	O
18	O
severe	O
,	O
treatment	O
-	O
resistant	O
depressed	O
inpatients	O
(	O
15	O
of	O
them	O
with	O
a	O
history	O
of	O
childhood	O
trauma	O
)	O
and	O
14	O
healthy	O
volunteers	O
.	O

On	O
the	O
following	O
days	O
,	O
we	O
collected	O
salivary	O
cortisol	B-CHEMICAL
from	O
9	O
:	O
00	O
to	O
22	O
:	O
00	O
.	O

RESULTS	O
:	O
Depressed	O
patients	O
had	O
higher	O
salivary	O
cortisol	B-CHEMICAL
levels	O
compared	O
with	O
controls	O
,	O
at	O
baseline	O
and	O
after	O
both	O
prednisolone	B-CHEMICAL
and	O
dexamethasone	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Consistent	O
with	O
previous	O
studies	O
,	O
depressed	O
inpatients	O
showed	O
impaired	O
suppression	O
by	O
dexamethasone	B-CHEMICAL
:	O
based	O
on	O
the	O
analysis	O
of	O
the	O
areas	O
under	O
the	O
curve	O
(	O
AUCs	O
)	O
,	O
suppression	O
by	O
dexamethasone	B-CHEMICAL
(	O
0	O
.	O
5	O
mg	O
)	O
was	O
-	O
85	O
%	O
in	O
controls	O
vs	O
-	O
46	O
%	O
in	O
depressed	O
patients	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
.	O

However	O
,	O
the	O
same	O
depressed	O
patients	O
showed	O
normal	O
suppression	O
by	O
prednisolone	B-CHEMICAL
(	O
5	O
mg	O
)	O
:	O
suppression	O
was	O
-	O
41	O
%	O
in	O
controls	O
and	O
-	O
36	O
%	O
in	O
depressed	O
patients	O
(	O
p	O
=	O
0	O
.	O
6	O
)	O
.	O

CONCLUSIONS	O
:	O
We	O
suggest	O
that	O
the	O
additional	O
effects	O
of	O
prednisolone	B-CHEMICAL
on	O
the	O
MR	B-GENE-Y
explain	O
the	O
different	O
responses	O
to	O
these	O
glucocorticoids	O
in	O
the	O
same	O
depressed	O
patients	O
.	O

Characterization	O
of	O
the	O
regulation	O
of	O
renal	B-GENE-N
Na	I-GENE-N
+	I-GENE-N
/	I-GENE-N
H	I-GENE-N
+	I-GENE-N
exchanger	I-GENE-N
NHE3	B-GENE-Y
by	O
insulin	B-GENE-Y
.	O

Insulin	B-GENE-Y
receptors	I-GENE-Y
are	O
widely	O
distributed	O
in	O
the	O
kidney	O
and	O
affect	O
multiple	O
aspects	O
of	O
renal	O
function	O
.	O

In	O
the	O
proximal	O
tubule	O
,	O
insulin	B-GENE-Y
regulates	O
volume	O
and	O
acid	O
-	O
base	O
regulation	O
through	O
stimulation	O
of	O
the	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
/	I-GENE-N
H	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
exchanger	I-GENE-N
NHE3	B-GENE-Y
.	O

This	O
paper	O
characterizes	O
the	O
signaling	O
pathway	O
by	O
which	O
insulin	B-GENE-Y
stimulates	O
NHE3	B-GENE-Y
in	O
a	O
cell	O
culture	O
model	O
[	O
opossum	O
kidney	O
(	O
OK	O
)	O
cell	O
]	O
.	O

Insulin	B-GENE-Y
has	O
two	O
distinct	O
phases	O
of	O
action	O
on	O
NHE3	B-GENE-Y
.	O

Chronic	O
insulin	B-GENE-Y
(	O
24	O
h	O
)	O
activates	O
NHE3	B-GENE-Y
through	O
the	O
classic	O
phosphatidylinositol	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
-	O
serum	B-GENE-N
-	I-GENE-N
and	I-GENE-N
glucocorticoid	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
kinase	I-GENE-N
1	I-GENE-N
(	O
PI3K	B-GENE-N
-	O
SGK1	B-GENE-N
)	O
pathway	O
as	O
insulin	B-GENE-Y
stimulates	O
SGK1	B-GENE-N
phosphorylation	O
and	O
the	O
insulin	B-GENE-Y
effect	O
can	O
be	O
blocked	O
by	O
the	O
PI3K	B-GENE-N
inhibitor	O
wortmannin	B-CHEMICAL
or	O
a	O
dominant	O
-	O
negative	O
SGK1	B-GENE-N
.	O

We	O
showed	O
that	O
SGK1	B-GENE-N
transcript	O
and	O
protein	O
are	O
expressed	O
in	O
rat	O
proximal	O
tubule	O
and	O
OK	O
cells	O
.	O

We	O
previously	O
showed	O
that	O
glucocorticoids	O
augment	O
the	O
effect	O
of	O
insulin	B-GENE-Y
on	O
NHE3	B-GENE-Y
(	O
Klisic	O
J	O
,	O
Hu	O
MC	O
,	O
Nief	O
V	O
,	O
Reyes	O
L	O
,	O
Fuster	O
D	O
,	O
Moe	O
OW	O
,	O
Ambuhl	O
PM	O
.	O
Am	O
J	O
Physiol	O
Renal	O
Physiol	O
283	O
:	O
F532	O
-	O
F539	O
,	O
2002	O
)	O
.	O

Part	O
of	O
this	O
can	O
be	O
mediated	O
via	O
induction	O
of	O
SGK1	B-GENE-Y
by	O
glucocorticoids	O
,	O
and	O
indeed	O
the	O
insulin	B-GENE-Y
effect	O
on	O
NHE3	B-GENE-Y
can	O
also	O
be	O
amplified	O
by	O
overexpression	O
of	O
SGK1	B-GENE-Y
.	O

We	O
next	O
addressed	O
the	O
acute	O
effect	O
of	O
insulin	B-GENE-Y
(	O
1	O
-	O
2	O
h	O
)	O
on	O
NHE3	B-GENE-Y
by	O
systematically	O
examining	O
the	O
candidate	O
signaling	O
cascades	O
and	O
activation	O
mechanisms	O
of	O
NHE3	B-GENE-Y
.	O

We	O
ruled	O
out	O
the	O
PI3K	B-GENE-N
-	O
SGK1	B-GENE-N
-	O
Akt	B-GENE-N
and	O
TC10	B-GENE-N
pathways	O
,	O
increased	O
surface	O
NHE3	B-GENE-Y
,	O
NHE3	B-GENE-Y
phosphorylation	O
,	O
NHE3	B-GENE-Y
association	O
with	O
calcineurin	B-GENE-N
homologous	I-GENE-N
protein	I-GENE-N
1	I-GENE-N
or	O
megalin	B-GENE-Y
as	O
mechanisms	O
of	O
acute	O
activation	O
of	O
NHE3	B-GENE-Y
by	O
insulin	B-GENE-Y
.	O

In	O
summary	O
,	O
insulin	B-GENE-Y
stimulates	O
NHE3	B-GENE-Y
acutely	O
via	O
yet	O
undefined	O
pathways	O
and	O
mechanisms	O
.	O

The	O
chronic	O
effect	O
of	O
insulin	B-GENE-Y
is	O
mediated	O
by	O
the	O
classic	O
PI3K	B-GENE-N
-	O
SGK1	B-GENE-N
route	O
.	O

Update	O
on	O
the	O
use	O
of	O
aromatase	B-GENE-Y
inhibitors	O
in	O
breast	O
cancer	O
.	O

Estrogens	B-CHEMICAL
are	O
biosynthesised	O
from	O
androgens	B-CHEMICAL
by	O
the	O
CYP450	B-GENE-N
enzyme	O
complex	O
called	O
aromatase	B-GENE-Y
.	O

Aromatase	B-GENE-Y
is	O
expressed	O
in	O
the	O
ovary	O
,	O
placenta	O
,	O
brain	O
,	O
bone	O
,	O
adipose	O
tissue	O
and	O
breast	O
tissue	O
.	O

In	O
breast	O
cancer	O
,	O
intratumoural	O
aromatase	B-GENE-Y
is	O
the	O
source	O
for	O
local	O
estrogen	B-CHEMICAL
production	O
in	O
the	O
tissue	O
.	O

Inhibition	O
of	O
aromatase	B-GENE-Y
is	O
an	O
important	O
approach	O
for	O
reducing	O
growth	O
stimulatory	O
effects	O
of	O
estrogens	B-CHEMICAL
in	O
estrogen	B-CHEMICAL
-	O
dependent	O
breast	O
cancer	O
.	O

The	O
potent	O
and	O
selective	O
third	O
-	O
generation	O
aromatase	B-GENE-Y
inhibitors	O
anastrozole	B-CHEMICAL
,	O
letrozole	B-CHEMICAL
and	O
exemestane	O
were	O
introduced	O
to	O
the	O
market	O
as	O
endocrine	O
therapy	O
in	O
postmenopausal	O
patients	O
failing	O
anti	O
-	O
estrogen	B-CHEMICAL
therapy	O
alone	O
,	O
or	O
multiple	O
hormonal	O
therapies	O
.	O

Anastrozole	B-CHEMICAL
and	O
letrozole	B-CHEMICAL
are	O
both	O
non	O
-	O
steroidal	B-CHEMICAL
aromatase	B-GENE-Y
inhibitors	O
that	O
compete	O
with	O
the	O
substrate	O
for	O
binding	O
to	O
the	O
enzyme	O
active	O
site	O
.	O

Exemestane	O
is	O
a	O
mechanism	O
-	O
based	O
steroidal	B-CHEMICAL
inhibitor	O
that	O
mimics	O
the	O
substrate	O
,	O
is	O
converted	O
by	O
the	O
enzyme	O
to	O
a	O
reactive	O
intermediate	O
,	O
and	O
results	O
in	O
inactivation	O
of	O
aromatase	B-GENE-Y
.	O

These	O
third	O
-	O
generation	O
aromatase	B-GENE-Y
inhibitors	O
are	O
currently	O
approved	O
as	O
first	O
-	O
line	O
therapy	O
for	O
the	O
treatment	O
of	O
postmenopausal	O
women	O
with	O
metastatic	O
estrogen	B-CHEMICAL
-	O
dependent	O
breast	O
cancer	O
.	O

The	O
use	O
of	O
an	O
aromatase	B-GENE-Y
inhibitor	O
as	O
initial	O
therapy	O
,	O
or	O
after	O
treatment	O
with	O
tamoxifen	B-CHEMICAL
,	O
is	O
now	O
recommended	O
as	O
adjuvant	O
hormonal	O
therapy	O
for	O
postmenopausal	O
women	O
with	O
hormone	O
-	O
dependent	O
breast	O
cancer	O
.	O

Several	O
clinical	O
studies	O
of	O
aromatase	B-GENE-Y
inhibitors	O
focus	O
on	O
the	O
use	O
of	O
these	O
agents	O
in	O
the	O
adjuvant	O
setting	O
,	O
for	O
the	O
treatment	O
of	O
early	O
breast	O
cancer	O
.	O

Recently	O
published	O
results	O
show	O
improved	O
responses	O
with	O
these	O
agents	O
compared	O
with	O
tamoxifen	B-CHEMICAL
.	O

Interferon	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
is	O
causatively	O
involved	O
in	O
experimental	O
inflammatory	O
bowel	O
disease	O
in	O
mice	O
.	O

Cytokines	B-GENE-N
may	O
be	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
bowel	O
diseases	O
(	O
IBD	O
)	O
,	O
but	O
it	O
remains	O
controversial	O
whether	O
interferon	B-GENE-Y
(	I-GENE-Y
IFN	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
,	O
a	O
typical	O
proinflammatory	O
cytokine	B-GENE-N
,	O
is	O
an	O
essential	O
mediator	O
to	O
cause	O
the	O
disorders	O
.	O

In	O
the	O
present	O
study	O
,	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
-	O
type	O
(	O
WT	O
)	O
C57BL	O
/	O
6	O
mice	O
were	O
fed	O
2	O
.	O
5	O
%	O
dextran	O
sodium	O
sulphate	O
(	O
DSS	O
)	O
in	O
drinking	O
water	O
for	O
7	O
days	O
,	O
in	O
order	O
to	O
investigate	O
DSS	O
-	O
induced	O
intestinal	O
inflammation	O
.	O

The	O
DSS	O
-	O
treated	O
WT	O
mice	O
exhibited	O
a	O
robust	O
production	O
of	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
in	O
the	O
gut	O
,	O
a	O
remarkable	O
loss	O
of	O
body	O
weight	O
,	O
as	O
well	O
as	O
high	O
rate	O
of	O
mortality	O
(	O
60	O
%	O
)	O
.	O

In	O
striking	O
contrast	O
,	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
deficient	O
mice	O
did	O
not	O
develop	O
DSS	O
-	O
induced	O
colitis	O
,	O
as	O
indicated	O
by	O
the	O
maintenance	O
of	O
body	O
weight	O
and	O
survival	O
rate	O
of	O
100	O
%	O
.	O

Severe	O
intestinal	O
inflammation	O
was	O
demonstrated	O
exclusively	O
in	O
WT	O
animals	O
in	O
terms	O
of	O
the	O
shortening	O
of	O
the	O
bowel	O
as	O
well	O
as	O
the	O
elevation	O
of	O
the	O
disease	O
activity	O
index	O
,	O
myeloperoxidase	B-GENE-Y
(	O
MPO	B-GENE-Y
)	O
activity	O
and	O
serum	B-GENE-Y
haptoglobin	I-GENE-Y
level	O
.	O

Histological	O
study	O
of	O
DSS	O
-	O
treated	O
WT	O
intestine	O
revealed	O
disruption	O
of	O
mucosal	O
epithelium	O
and	O
massive	O
infiltration	O
of	O
inflammatory	O
cells	O
,	O
while	O
the	O
organ	O
from	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
remained	O
virtually	O
normal	O
in	O
appearance	O
.	O

Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
analyses	O
indicated	O
abundant	O
production	O
of	O
three	O
chemokines	B-GENE-N
,	O
i	O
.	O
e	O
.	O
monokine	B-GENE-Y
induced	I-GENE-Y
by	I-GENE-Y
interferon	I-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
(	O
MIG	B-GENE-Y
)	O
,	O
interferon	B-GENE-Y
-	I-GENE-Y
inducible	I-GENE-Y
protein	I-GENE-Y
10	I-GENE-Y
(	O
IP	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
)	O
and	O
monocyte	B-GENE-Y
chemoattractant	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
in	O
the	O
DSS	O
-	O
irritated	O
intestine	O
of	O
WT	O
but	O
not	O
of	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

The	O
present	O
results	O
demonstrate	O
clearly	O
that	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
plays	O
indispensable	O
roles	O
in	O
the	O
initiation	O
of	O
DSS	O
colitis	O
,	O
and	O
some	O
chemokines	B-GENE-N
are	O
produced	O
in	O
an	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
-	O
dependent	O
fashion	O
.	O

Auranofin	B-CHEMICAL
,	O
as	O
an	O
anti	O
-	O
rheumatic	O
gold	O
compound	O
,	O
suppresses	O
LPS	O
-	O
induced	O
homodimerization	O
of	O
TLR4	B-GENE-Y
.	O

Toll	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
(	I-GENE-N
TLRs	I-GENE-N
)	I-GENE-N
,	O
which	O
are	O
activated	O
by	O
invading	O
microorganisms	O
or	O
endogenous	O
molecules	O
,	O
evoke	O
immune	O
and	O
inflammatory	O
responses	O
.	O

TLR	B-GENE-N
activation	O
is	O
closely	O
linked	O
to	O
the	O
development	O
of	O
many	O
chronic	O
inflammatory	O
diseases	O
including	O
rheumatoid	O
arthritis	O
.	O

Auranofin	B-CHEMICAL
,	O
an	O
Au	B-CHEMICAL
(	I-CHEMICAL
I	I-CHEMICAL
)	I-CHEMICAL
compound	O
,	O
is	O
a	O
well	O
-	O
known	O
and	O
long	O
-	O
used	O
anti	O
-	O
rheumatic	O
drug	O
.	O

However	O
,	O
the	O
mechanism	O
as	O
to	O
how	O
auranofin	B-CHEMICAL
relieves	O
the	O
symptom	O
of	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
fully	O
clarified	O
.	O

Our	O
results	O
demonstrated	O
that	O
auranofin	B-CHEMICAL
suppressed	O
TLR4	B-GENE-Y
-	O
mediated	O
activation	O
of	O
transcription	O
factors	O
,	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
and	O
IRF3	B-GENE-Y
,	O
and	O
expression	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
a	O
pro	O
-	O
inflammatory	O
enzyme	O
.	O

This	O
suppression	O
was	O
well	O
correlated	O
with	O
the	O
inhibitory	O
effect	O
of	O
auranofin	B-CHEMICAL
on	O
the	O
homodimerization	O
of	O
TLR4	B-GENE-Y
induced	O
by	O
an	O
agonist	O
.	O

Furthermore	O
,	O
auranofin	B-CHEMICAL
inhibited	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
activation	O
induced	O
by	O
MyD88	B-GENE-Y
-	O
dependent	O
downstream	O
signaling	O
components	O
of	O
TLR4	B-GENE-Y
,	O
MyD88	B-GENE-Y
,	O
IKKbeta	B-GENE-Y
,	O
and	O
p65	B-GENE-Y
.	O

IRF3	B-GENE-Y
activation	O
induced	O
by	O
MyD88	B-GENE-Y
-	O
independent	O
signaling	O
components	O
,	O
TRIF	B-GENE-Y
and	O
TBK1	B-GENE-Y
,	O
was	O
also	O
downregulated	O
by	O
auranofin	B-CHEMICAL
.	O

Our	O
results	O
first	O
demonstrate	O
that	O
auranofin	B-CHEMICAL
suppresses	O
the	O
multiple	O
steps	O
in	O
TLR4	B-GENE-Y
signaling	O
,	O
especially	O
the	O
homodimerization	O
of	O
TLR4	B-GENE-Y
.	O

The	O
results	O
suggest	O
that	O
the	O
suppression	O
of	O
TLR4	B-GENE-Y
activity	O
by	O
auranofin	B-CHEMICAL
may	O
be	O
the	O
molecular	O
mechanism	O
through	O
which	O
auranofin	B-CHEMICAL
exerts	O
anti	O
-	O
rheumatic	O
activity	O
.	O

Neural	O
tube	O
defects	O
and	O
folate	B-CHEMICAL
pathway	O
genes	O
:	O
family	O
-	O
based	O
association	O
tests	O
of	O
gene	O
-	O
gene	O
and	O
gene	O
-	O
environment	O
interactions	O
.	O

BACKGROUND	O
:	O
Folate	B-CHEMICAL
metabolism	O
pathway	O
genes	O
have	O
been	O
examined	O
for	O
association	O
with	O
neural	O
tube	O
defects	O
(	O
NTDs	O
)	O
because	O
folic	B-CHEMICAL
acid	I-CHEMICAL
supplementation	O
reduces	O
the	O
risk	O
of	O
this	O
debilitating	O
birth	O
defect	O
.	O

Most	O
studies	O
addressed	O
these	O
genes	O
individually	O
,	O
often	O
with	O
different	O
populations	O
providing	O
conflicting	O
results	O
.	O

OBJECTIVES	O
:	O
Our	O
study	O
evaluates	O
several	O
folate	B-CHEMICAL
pathway	O
genes	O
for	O
association	O
with	O
human	O
NTDs	O
,	O
incorporating	O
an	O
environmental	O
cofactor	O
:	O
maternal	O
folate	B-CHEMICAL
supplementation	O
.	O

METHODS	O
:	O
In	O
304	O
Caucasian	O
American	O
NTD	O
families	O
with	O
myelomeningocele	O
or	O
anencephaly	O
,	O
we	O
examined	O
28	O
polymorphisms	O
in	O
11	O
genes	O
:	O
folate	B-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
,	O
folate	B-GENE-Y
receptor	I-GENE-Y
2	I-GENE-Y
,	O
solute	B-GENE-Y
carrier	I-GENE-Y
family	I-GENE-Y
19	I-GENE-Y
member	I-GENE-Y
1	I-GENE-Y
,	O
transcobalamin	B-GENE-Y
II	I-GENE-Y
,	O
methylenetetrahydrofolate	B-GENE-Y
dehydrogenase	I-GENE-Y
1	I-GENE-Y
,	O
serine	B-GENE-Y
hydroxymethyl	I-GENE-Y
-	I-GENE-Y
transferase	I-GENE-Y
1	I-GENE-Y
,	O
5	B-GENE-Y
,	I-GENE-Y
10	I-GENE-Y
-	I-GENE-Y
methylenetetrahydrofolate	I-GENE-Y
reductase	I-GENE-Y
(	O
MTHFR	B-GENE-Y
)	O
,	O
5	B-GENE-Y
-	I-GENE-Y
methyltetrahydrofolate	I-GENE-Y
-	I-GENE-Y
homo	I-GENE-Y
-	I-GENE-Y
cysteine	I-GENE-Y
methyltransferase	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
methyltetrahydrofolate	I-GENE-Y
-	I-GENE-Y
homocysteine	I-GENE-Y
methyltransferase	I-GENE-Y
reductase	I-GENE-Y
,	O
betaine	B-GENE-Y
-	I-GENE-Y
homocysteine	I-GENE-Y
methyltransferase	I-GENE-Y
(	O
BHMT	B-GENE-Y
)	O
,	O
and	O
cystathionine	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
synthase	I-GENE-Y
.	O

RESULTS	O
:	O
Only	O
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
in	O
BHMT	B-GENE-Y
were	O
significantly	O
associated	O
in	O
the	O
overall	O
data	O
set	O
;	O
this	O
significance	O
was	O
strongest	O
when	O
mothers	O
took	O
folate	B-CHEMICAL
-	O
containing	O
nutritional	O
supplements	O
before	O
conception	O
.	O

The	O
BHMT	B-GENE-Y
SNP	O
rs3733890	O
was	O
more	O
significant	O
when	O
the	O
data	O
were	O
stratified	O
by	O
preferential	O
transmission	O
of	O
the	O
MTHFR	B-GENE-Y
rs1801133	O
thermolabile	O
T	O
allele	O
from	O
parent	O
to	O
offspring	O
.	O

Other	O
SNPs	O
in	O
folate	B-CHEMICAL
pathway	O
genes	O
were	O
marginally	O
significant	O
in	O
some	O
analyses	O
when	O
stratified	O
by	O
maternal	O
supplementation	O
,	O
MTHFR	B-GENE-Y
,	O
or	O
BHMT	B-GENE-Y
allele	O
transmission	O
.	O

CONCLUSIONS	O
:	O
BHMT	B-GENE-Y
rs3733890	O
is	O
significantly	O
associated	O
in	O
our	O
data	O
set	O
,	O
whereas	O
MTHFR	B-GENE-Y
rs1801133	O
is	O
not	O
a	O
major	O
risk	O
factor	O
.	O

Further	O
investigation	O
of	O
folate	B-CHEMICAL
and	O
methionine	B-CHEMICAL
cycle	O
genes	O
will	O
require	O
extensive	O
SNP	O
genotyping	O
and	O
/	O
or	O
resequencing	O
to	O
identify	O
novel	O
variants	O
,	O
inclusion	O
of	O
environmental	O
factors	O
,	O
and	O
investigation	O
of	O
gene	O
-	O
gene	O
interactions	O
in	O
large	O
data	O
sets	O
.	O

Functional	O
analyses	O
of	O
glycyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
mutations	O
suggest	O
a	O
key	O
role	O
for	O
tRNA	B-GENE-N
-	I-GENE-N
charging	I-GENE-N
enzymes	I-GENE-N
in	O
peripheral	O
axons	O
.	O

Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
type	O
2D	O
(	O
CMT2D	O
)	O
and	O
distal	O
spinal	O
muscular	O
atrophy	O
type	O
V	O
(	O
dSMA	O
-	O
V	O
)	O
are	O
axonal	O
neuropathies	O
characterized	O
by	O
a	O
phenotype	O
that	O
is	O
more	O
severe	O
in	O
the	O
upper	O
extremities	O
.	O

We	O
previously	O
implicated	O
mutations	O
in	O
the	O
gene	O
encoding	O
glycyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
(	O
GARS	B-GENE-Y
)	O
as	O
the	O
cause	O
of	O
CMT2D	O
and	O
dSMA	O
-	O
V	O
.	O

GARS	B-GENE-Y
is	O
a	O
member	O
of	O
the	O
family	O
of	O
aminoacyl	B-GENE-N
-	I-GENE-N
tRNA	I-GENE-N
synthetases	I-GENE-N
responsible	O
for	O
charging	O
tRNA	O
with	O
cognate	O
amino	B-CHEMICAL
acids	I-CHEMICAL
;	O
GARS	B-GENE-Y
ligates	O
glycine	B-CHEMICAL
to	O
tRNA	O
(	O
Gly	O
)	O
.	O

Here	O
,	O
we	O
present	O
functional	O
analyses	O
of	O
disease	O
-	O
associated	O
GARS	B-GENE-Y
mutations	O
and	O
show	O
that	O
there	O
are	O
not	O
any	O
significant	O
mutation	O
-	O
associated	O
changes	O
in	O
GARS	B-GENE-Y
expression	O
levels	O
;	O
that	O
the	O
majority	O
of	O
identified	O
GARS	B-GENE-Y
mutations	O
modeled	O
in	O
yeast	O
severely	O
impair	O
viability	O
;	O
and	O
that	O
,	O
in	O
most	O
cases	O
,	O
mutant	O
GARS	B-GENE-Y
protein	O
mislocalizes	O
in	O
neuronal	O
cells	O
.	O

Indeed	O
,	O
four	O
of	O
the	O
five	O
mutations	O
studied	O
show	O
loss	O
-	O
of	O
-	O
function	O
features	O
in	O
at	O
least	O
one	O
assay	O
,	O
suggesting	O
that	O
tRNA	O
-	O
charging	O
deficits	O
play	O
a	O
role	O
in	O
disease	O
pathogenesis	O
.	O

Finally	O
,	O
we	O
detected	O
endogenous	O
GARS	B-GENE-Y
-	O
associated	O
granules	O
in	O
the	O
neurite	O
projections	O
of	O
cultured	O
neurons	O
and	O
in	O
the	O
peripheral	O
nerve	O
axons	O
of	O
normal	O
human	O
tissue	O
.	O

These	O
data	O
are	O
particularly	O
important	O
in	O
light	O
of	O
the	O
recent	O
identification	O
of	O
CMT	O
-	O
associated	O
mutations	O
in	O
another	O
tRNA	B-GENE-N
synthetase	I-GENE-N
gene	O
[	O
YARS	B-GENE-Y
(	O
tyrosyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
gene	O
)	O
]	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
tRNA	B-GENE-N
-	I-GENE-N
charging	I-GENE-N
enzymes	I-GENE-N
play	O
a	O
key	O
role	O
in	O
maintaining	O
peripheral	O
axons	O
.	O

Reductive	O
detoxification	O
of	O
arylhydroxylamine	B-CHEMICAL
carcinogens	O
by	O
human	B-GENE-Y
NADH	I-GENE-Y
cytochrome	I-GENE-Y
b5	I-GENE-Y
reductase	I-GENE-Y
and	O
cytochrome	B-GENE-Y
b5	I-GENE-Y
.	O

Heterocyclic	B-CHEMICAL
and	I-CHEMICAL
aromatic	I-CHEMICAL
amine	I-CHEMICAL
carcinogens	O
are	O
thought	O
to	O
lead	O
to	O
tumor	O
initiation	O
via	O
the	O
formation	O
of	O
DNA	O
adducts	O
,	O
and	O
bioactivation	O
to	O
arylhydroxylamine	B-CHEMICAL
metabolites	O
is	O
necessary	O
for	O
reactivity	O
with	O
DNA	O
.	O

Carcinogenic	O
arylhydroxylamine	B-CHEMICAL
metabolites	O
are	O
cleared	O
by	O
a	O
microsomal	O
,	O
NADH	B-CHEMICAL
-	O
dependent	O
,	O
oxygen	B-CHEMICAL
-	O
insensitive	O
reduction	O
pathway	O
in	O
humans	O
,	O
which	O
may	O
be	O
a	O
source	O
of	O
interindividual	O
variability	O
in	O
response	O
to	O
aromatic	B-CHEMICAL
amine	I-CHEMICAL
carcinogens	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
identity	O
of	O
this	O
reduction	O
pathway	O
in	O
human	O
liver	O
.	O

On	O
the	O
basis	O
of	O
our	O
findings	O
with	O
structurally	O
similar	O
arylhydroxylamine	B-CHEMICAL
metabolites	O
of	O
therapeutic	O
drugs	O
,	O
we	O
hypothesized	O
that	O
the	O
reductive	O
detoxification	O
of	O
arylhydroxylamine	B-CHEMICAL
carcinogens	O
was	O
catalyzed	O
by	O
NADH	B-GENE-Y
cytochrome	I-GENE-Y
b5	I-GENE-Y
reductase	I-GENE-Y
(	O
b5R	B-GENE-Y
)	O
and	O
cytochrome	B-GENE-Y
b5	I-GENE-Y
(	O
cyt	B-GENE-Y
b5	I-GENE-Y
)	O
.	O

We	O
found	O
that	O
reduction	O
of	O
the	O
carcinogenic	O
hydroxylamines	B-CHEMICAL
of	O
the	O
aromatic	B-CHEMICAL
amine	I-CHEMICAL
4	B-CHEMICAL
-	I-CHEMICAL
aminobiphenyl	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
ABP	I-CHEMICAL
;	O
found	O
in	O
cigarette	O
smoke	O
)	O
and	O
the	O
heterocyclic	B-CHEMICAL
amine	I-CHEMICAL
2	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenylimidazo	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
PhIP	B-CHEMICAL
;	O
found	O
in	O
grilled	O
meats	O
)	O
was	O
indeed	O
catalyzed	O
by	O
a	O
purified	O
system	O
containing	O
only	O
human	B-GENE-Y
b5R	I-GENE-Y
and	O
cyt	B-GENE-Y
b5	I-GENE-Y
.	O

Specific	O
activities	O
were	O
56	O
-	O
346	O
-	O
fold	O
higher	O
in	O
the	O
purified	O
system	O
as	O
compared	O
to	O
human	O
liver	O
microsomes	O
(	O
HLM	O
)	O
,	O
with	O
similar	O
Michaelis	O
-	O
Menten	O
constants	O
(	O
K	O
(	O
m	O
)	O
values	O
)	O
in	O
both	O
systems	O
.	O

The	O
stoichiometry	O
for	O
b5R	B-GENE-Y
and	O
cyt	B-GENE-Y
b5	I-GENE-Y
that	O
yielded	O
the	O
highest	O
activity	O
in	O
the	O
purified	O
system	O
was	O
also	O
similar	O
to	O
that	O
found	O
in	O
native	O
HLM	O
(	O
approximately	O
1	O
:	O
8	O
to	O
1	O
:	O
10	O
)	O
.	O

Polyclonal	O
antisera	O
to	O
either	O
b5R	B-GENE-Y
or	O
cyt	B-GENE-Y
b5	I-GENE-Y
significantly	O
inhibited	O
N	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
aminobiphenyl	I-CHEMICAL
(	O
NHOH	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ABP	I-CHEMICAL
)	O
reduction	O
by	O
95	O
and	O
89	O
%	O
,	O
respectively	O
,	O
and	O
immunoreactive	O
cyt	O
b5	O
protein	O
content	O
in	O
individual	O
HLM	O
was	O
significantly	O
correlated	O
with	O
individual	O
reduction	O
of	O
both	O
NHOH	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ABP	I-CHEMICAL
and	O
N	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
PhIP	I-CHEMICAL
(	O
NHOH	B-CHEMICAL
-	I-CHEMICAL
PhIP	I-CHEMICAL
)	O
.	O

Finally	O
,	O
titration	O
of	O
HLM	O
into	O
the	O
purified	O
b5R	B-GENE-Y
/	O
cyt	B-GENE-Y
b5	I-GENE-Y
system	O
did	O
not	O
enhance	O
the	O
efficiency	O
of	O
reduction	O
activity	O
.	O

We	O
conclude	O
that	O
b5R	B-GENE-Y
and	O
cyt	B-GENE-Y
b5	I-GENE-Y
are	O
together	O
solely	O
capable	O
of	O
the	O
reduction	O
of	O
arylhydroxylamine	B-CHEMICAL
carcinogens	O
,	O
and	O
we	O
further	O
hypothesize	O
that	O
this	O
pathway	O
may	O
be	O
a	O
source	O
of	O
individual	O
variability	O
with	O
respect	O
to	O
cancer	O
susceptibility	O
following	O
4	B-CHEMICAL
-	I-CHEMICAL
ABP	I-CHEMICAL
or	O
PhIP	B-CHEMICAL
exposure	O
.	O

Imatinib	B-CHEMICAL
mesylate	I-CHEMICAL
(	O
Gleevec	B-CHEMICAL
)	O
enhances	O
mature	O
osteoclast	O
apoptosis	O
and	O
suppresses	O
osteoclast	O
bone	O
resorbing	O
activity	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
imatinib	B-CHEMICAL
mesylate	I-CHEMICAL
,	O
a	O
kinase	B-GENE-N
inhibitor	O
that	O
targets	O
the	O
intracellular	O
tyrosine	B-GENE-N
kinase	I-GENE-N
BCR	B-GENE-Y
-	O
ABL	B-GENE-Y
and	O
the	O
platelet	B-GENE-N
derived	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
(	I-GENE-N
PDGF	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
,	O
is	O
an	O
effective	O
inhibitor	O
of	O
the	O
macrophage	B-GENE-Y
colony	I-GENE-Y
stimulating	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
M	I-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
FMS	I-GENE-Y
.	O

Given	O
that	O
M	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
signalling	O
through	O
c	B-GENE-Y
-	I-GENE-Y
FMS	I-GENE-Y
plays	O
an	O
important	O
role	O
in	O
osteoclast	O
biology	O
,	O
we	O
speculated	O
that	O
blocking	O
such	O
a	O
pathway	O
with	O
imatinib	B-CHEMICAL
may	O
modulate	O
osteoclast	O
activity	O
.	O

Using	O
a	O
cell	O
model	O
of	O
mature	O
rabbit	O
osteoclasts	O
,	O
we	O
thus	O
investigated	O
the	O
effect	O
of	O
imatinib	B-CHEMICAL
on	O
in	O
vitro	O
osteoclast	O
apoptosis	O
and	O
bone	O
resorbing	O
activity	O
.	O

Our	O
findings	O
demonstrate	O
that	O
imatinib	B-CHEMICAL
dose	O
-	O
dependently	O
stimulates	O
osteoclast	O
apoptosis	O
,	O
a	O
phenomenon	O
which	O
is	O
blocked	O
by	O
the	O
caspase	B-GENE-Y
I	I-GENE-Y
inhibitor	O
Z	O
-	O
VAD	O
-	O
fmk	O
.	O

The	O
ability	O
of	O
imatinib	B-CHEMICAL
to	O
enhance	O
osteoclast	O
cell	O
death	O
was	O
accompanied	O
by	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
osteoclast	O
bone	O
resorbing	O
activity	O
.	O

Imatinib	B-CHEMICAL
was	O
also	O
found	O
to	O
inhibit	O
M	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
-	O
induced	O
osteoclast	O
survival	O
as	O
well	O
as	O
M	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
-	O
induced	O
osteoclast	O
bone	O
resorbing	O
activity	O
,	O
but	O
was	O
without	O
effect	O
on	O
interleukin	B-GENE-Y
1alpha	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
)	O
and	O
receptor	B-GENE-Y
activator	I-GENE-Y
of	I-GENE-Y
nuclear	I-GENE-Y
factor	I-GENE-Y
kappa	I-GENE-Y
B	I-GENE-Y
ligand	I-GENE-Y
(	O
RANKL	B-GENE-Y
)	O
-	O
induced	O
inhibition	O
of	O
osteoclasts	O
apoptosis	O
,	O
further	O
supporting	O
the	O
hypothesis	O
that	O
imatinib	B-CHEMICAL
may	O
affect	O
mature	O
osteoclasts	O
through	O
the	O
inhibition	O
of	O
c	B-GENE-Y
-	I-GENE-Y
FMS	I-GENE-Y
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
imatinib	B-CHEMICAL
could	O
be	O
of	O
clinical	O
value	O
in	O
treating	O
diseases	O
where	O
bone	O
destruction	O
can	O
occur	O
due	O
to	O
excessive	O
M	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
production	O
such	O
as	O
osteoporosis	O
,	O
inflammatory	O
-	O
and	O
tumor	O
-	O
induced	O
osteolysis	O
.	O

Comparison	O
of	O
the	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibiting	O
properties	O
of	O
two	O
reversible	O
and	O
selective	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
inhibitors	O
moclobemide	B-CHEMICAL
and	O
toloxatone	B-CHEMICAL
,	O
and	O
assessment	O
of	O
their	O
effect	O
on	O
psychometric	O
performance	O
in	O
healthy	O
subjects	O
.	O

1	O
.	O

The	O
effects	O
of	O
two	O
reversible	O
,	O
predominantly	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
(	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
)	O
inhibitors	O
,	O
moclobemide	B-CHEMICAL
(	O
150	O
mg	O
three	O
times	O
daily	O
)	O
and	O
toloxatone	B-CHEMICAL
(	O
400	O
-	O
200	O
-	O
400	O
mg	O
day	O
-	O
1	O
)	O
on	O
monoamine	B-CHEMICAL
metabolites	O
and	O
psychometric	O
performance	O
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
controlled	O
crossover	O
study	O
in	O
12	O
healthy	O
subjects	O
.	O

2	O
.	O

After	O
7	O
days	O
of	O
moclobemide	B-CHEMICAL
/	O
toloxatone	B-CHEMICAL
/	O
placebo	O
administration	O
subjects	O
were	O
hospitalized	O
for	O
24	O
h	O
on	O
day	O
8	O
.	O

Blood	O
samples	O
were	O
drawn	O
every	O
2	O
h	O
for	O
determination	O
of	O
plasma	O
noradrenaline	B-CHEMICAL
(	O
NA	B-CHEMICAL
)	O
,	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroxyphenylglycol	I-CHEMICAL
(	O
DHPG	B-CHEMICAL
)	O
,	O
homovanillic	B-CHEMICAL
acid	I-CHEMICAL
(	O
HVA	B-CHEMICAL
)	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxyindolacetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HIAA	I-CHEMICAL
)	O
.	O

Urine	O
was	O
collected	O
for	O
measurements	O
of	O
normetanephrine	B-CHEMICAL
and	O
3	B-CHEMICAL
-	I-CHEMICAL
methoxytyramine	I-CHEMICAL
excretion	O
.	O

Psychometric	O
performance	O
(	O
short	O
-	O
and	O
long	O
-	O
term	O
memory	O
,	O
critical	O
flicker	O
fusion	O
frequency	O
,	O
choice	O
reaction	O
time	O
)	O
and	O
subjective	O
feelings	O
were	O
assessed	O
before	O
each	O
drug	O
intake	O
(	O
in	O
the	O
morning	O
,	O
at	O
noon	O
,	O
in	O
the	O
evening	O
)	O
.	O

3	O
.	O

Compared	O
with	O
placebo	O
,	O
both	O
reversible	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibitors	O
decreased	O
the	O
plasma	O
concentration	O
of	O
DHPG	B-CHEMICAL
and	O
HVA	B-CHEMICAL
.	O

The	O
overall	O
fall	O
in	O
DHPG	B-CHEMICAL
(	O
AUC	O
from	O
0	O
to	O
24	O
h	O
)	O
was	O
44	O
%	O
during	O
moclobemide	B-CHEMICAL
and	O
12	O
%	O
during	O
toloxatone	B-CHEMICAL
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
the	O
overall	O
decrease	O
in	O
HVA	B-CHEMICAL
was	O
38	O
%	O
and	O
20	O
%	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
on	O
moclobemide	B-CHEMICAL
and	O
toloxatone	B-CHEMICAL
,	O
respectively	O
.	O

4	O
.	O

Before	O
the	O
next	O
drug	O
intake	O
,	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
inhibition	O
,	O
as	O
judged	O
by	O
the	O
decrease	O
of	O
plasma	O
DHPG	B-CHEMICAL
concentration	O
,	O
was	O
significantly	O
different	O
from	O
placebo	O
with	O
moclobemide	B-CHEMICAL
but	O
not	O
with	O
toloxatone	B-CHEMICAL
.	O

5	O
.	O

Moclobemide	B-CHEMICAL
,	O
but	O
not	O
toloxatone	B-CHEMICAL
,	O
exerted	O
a	O
moderate	O
,	O
but	O
significant	O
inhibition	O
of	O
the	O
deamination	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
as	O
judged	O
by	O
the	O
fall	O
in	O
plasma	O
5	B-CHEMICAL
-	I-CHEMICAL
HIAA	I-CHEMICAL
concentration	O
.	O

Neither	O
drug	O
influenced	O
plasma	O
NA	B-CHEMICAL
concentration	O
.	O

6	O
.	O

A	O
significant	O
rise	O
in	O
urinary	O
excretion	O
of	O
normetanephrine	B-CHEMICAL
was	O
observed	O
on	O
moclobemide	B-CHEMICAL
and	O
to	O
a	O
lesser	O
extent	O
on	O
toloxatone	B-CHEMICAL
.	O

The	O
urinary	O
excretion	O
of	O
3	B-CHEMICAL
-	I-CHEMICAL
methoxytyramine	I-CHEMICAL
was	O
significantly	O
raised	O
by	O
moclobemide	B-CHEMICAL
but	O
not	O
by	O
toloxatone	B-CHEMICAL
.	O

7	O
.	O

Neither	O
moclobemide	B-CHEMICAL
nor	O
toloxatone	B-CHEMICAL
altered	O
memory	O
function	O
,	O
vigilance	O
,	O
subjective	O
feelings	O
or	O
sleep	O
characteristics	O
of	O
the	O
subjects	O
.	O

Clinical	O
pharmacology	O
of	O
enalkiren	B-CHEMICAL
,	O
a	O
novel	O
,	O
dipeptide	B-CHEMICAL
renin	B-GENE-Y
inhibitor	O
.	O

Enalkiren	B-CHEMICAL
(	O
A	B-CHEMICAL
-	I-CHEMICAL
64662	I-CHEMICAL
)	O
,	O
a	O
potent	O
,	O
dipeptide	B-CHEMICAL
renin	B-GENE-Y
inhibitor	O
,	O
mimics	O
the	O
transition	O
state	O
of	O
the	O
human	B-GENE-Y
renin	I-GENE-Y
substrate	O
,	O
angiotensinogen	B-GENE-Y
.	O

Enalkiren	B-CHEMICAL
has	O
been	O
shown	O
to	O
produce	O
dose	O
-	O
related	O
suppression	O
of	O
plasma	O
renin	B-GENE-Y
activity	O
(	O
PRA	O
)	O
and	O
angiotensin	B-CHEMICAL
II	I-CHEMICAL
when	O
administered	O
intravenously	O
.	O

Doses	O
of	O
enalkiren	B-CHEMICAL
of	O
less	O
than	O
0	O
.	O
1	O
mg	O
/	O
kg	O
induced	O
little	O
hemodynamic	O
response	O
in	O
normotensive	O
and	O
hypertensive	O
volunteers	O
despite	O
marked	O
suppression	O
of	O
PRA	O
.	O

However	O
,	O
at	O
doses	O
of	O
0	O
.	O
3	O
and	O
1	O
.	O
2	O
mg	O
/	O
kg	O
,	O
enalkiren	B-CHEMICAL
produced	O
significant	O
,	O
dose	O
-	O
related	O
decreases	O
in	O
systolic	O
and	O
diastolic	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
hypertensive	O
patients	O
,	O
and	O
the	O
BP	O
response	O
was	O
enhanced	O
by	O
pretreatment	O
with	O
hydrochlorothiazide	B-CHEMICAL
.	O

The	O
effects	O
of	O
enalkiren	B-CHEMICAL
on	O
PRA	O
and	O
BP	O
are	O
prolonged	O
despite	O
its	O
relatively	O
short	O
elimination	O
phase	O
plasma	O
half	O
-	O
life	O
(	O
1	O
.	O
6	O
h	O
)	O
.	O

Persistent	O
pharmacologic	O
activity	O
without	O
evidence	O
of	O
tachyphylaxis	O
was	O
demonstrated	O
during	O
1	O
week	O
of	O
treatment	O
in	O
hypertensive	O
patients	O
.	O

The	O
observed	O
dissociation	O
between	O
suppression	O
of	O
PRA	O
and	O
BP	O
response	O
and	O
the	O
recruitment	O
of	O
dose	O
-	O
related	O
BP	O
decrements	O
,	O
despite	O
complete	O
suppression	O
of	O
PRA	O
,	O
are	O
unexplained	O
phenomena	O
.	O

The	O
results	O
of	O
clinical	O
trials	O
with	O
enalkiren	B-CHEMICAL
are	O
encouraging	O
,	O
and	O
suggest	O
that	O
renin	B-GENE-Y
inhibitors	O
may	O
be	O
safe	O
,	O
useful	O
therapeutic	O
agents	O
in	O
the	O
management	O
of	O
hypertension	O
.	O

Dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
by	O
risperidone	B-CHEMICAL
:	O
implications	O
for	O
the	O
timing	O
and	O
magnitude	O
of	O
clinical	O
response	O
.	O

The	O
objective	O
of	O
the	O
study	O
is	O
to	O
investigate	O
whether	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
occupancy	O
by	O
risperidone	B-CHEMICAL
and	O
plasma	O
levels	O
over	O
time	O
can	O
account	O
for	O
therapeutic	O
efficacy	O
and	O
the	O
latency	O
period	O
to	O
response	O
.	O

Thirty	O
-	O
eight	O
examinations	O
with	O
(	B-CHEMICAL
123	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	I-CHEMICAL
IBZM	I-CHEMICAL
single	O
photon	O
emission	O
computed	O
tomography	O
were	O
performed	O
on	O
22	O
patients	O
with	O
schizophrenia	O
,	O
at	O
diagnosis	O
,	O
48	O
h	O
after	O
starting	O
risperidone	B-CHEMICAL
treatment	O
and	O
at	O
a	O
stable	O
dose	O
.	O

Risperidone	B-CHEMICAL
plasma	O
levels	O
were	O
determined	O
and	O
psychopathologic	O
evaluations	O
(	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
,	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
)	O
were	O
carried	O
out	O
.	O

No	O
differences	O
in	O
the	O
striatal	O
/	O
occipital	O
(	O
S	O
/	O
O	O
)	O
ratio	O
or	O
plasma	O
levels	O
were	O
found	O
between	O
examinations	O
at	O
the	O
48	O
-	O
h	O
time	O
point	O
and	O
when	O
a	O
stable	O
dose	O
level	O
had	O
been	O
established	O
,	O
so	O
these	O
parameters	O
could	O
not	O
account	O
for	O
the	O
latency	O
period	O
required	O
for	O
clinical	O
response	O
.	O

D2	B-GENE-Y
receptor	I-GENE-Y
occupancy	O
at	O
48	O
h	O
correlated	O
positively	O
with	O
clinical	O
improvement	O
after	O
2	O
weeks	O
of	O
treatment	O
.	O

Therefore	O
,	O
if	O
these	O
results	O
are	O
confirmed	O
,	O
D2	B-GENE-Y
receptor	I-GENE-Y
occupancy	O
at	O
the	O
beginning	O
of	O
treatment	O
with	O
risperidone	B-CHEMICAL
may	O
be	O
a	O
predictor	O
of	O
subsequent	O
clinical	O
response	O
.	O

Treatment	O
-	O
related	O
osteoporosis	O
in	O
men	O
with	O
prostate	O
cancer	O
.	O

The	O
intended	O
therapeutic	O
effect	O
of	O
gonadotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	O
GnRH	B-GENE-Y
)	O
agonists	O
is	O
hypogonadism	O
,	O
a	O
major	O
cause	O
of	O
acquired	O
osteoporosis	O
in	O
men	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
GnRH	B-GENE-Y
agonists	O
increase	O
bone	O
turnover	O
and	O
decrease	O
bone	O
mineral	O
density	O
,	O
a	O
surrogate	O
for	O
fracture	O
risk	O
.	O

Large	O
claims	O
-	O
based	O
analyses	O
and	O
other	O
retrospective	O
studies	O
provide	O
compelling	O
evidence	O
that	O
GnRH	B-GENE-Y
agonists	O
increase	O
risk	O
of	O
clinical	O
fractures	O
.	O

Estrogens	B-CHEMICAL
play	O
a	O
central	O
role	O
in	O
homeostasis	O
of	O
the	O
normal	O
male	O
skeleton	O
,	O
and	O
estrogen	B-CHEMICAL
deficiency	O
rather	O
than	O
testosterone	B-CHEMICAL
deficiency	O
seems	O
to	O
be	O
primarily	O
responsible	O
for	O
the	O
adverse	O
skeletal	O
effects	O
of	O
GnRH	B-GENE-Y
agonists	O
.	O

In	O
randomized	O
controlled	O
trials	O
,	O
bisphosphonates	B-CHEMICAL
(	O
pamidronate	B-CHEMICAL
and	O
zoledronic	B-CHEMICAL
acid	I-CHEMICAL
)	O
and	O
selective	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
modulators	O
(	O
raloxifene	B-CHEMICAL
and	O
toremifene	B-CHEMICAL
)	O
increased	O
bone	O
mineral	O
density	O
in	O
GnRH	B-GENE-Y
agonist	O
-	O
treated	O
men	O
.	O

Two	O
ongoing	O
large	O
randomized	O
placebo	O
-	O
controlled	O
studies	O
will	O
prospectively	O
define	O
fracture	O
outcomes	O
in	O
men	O
with	O
prostate	O
cancer	O
and	O
assess	O
the	O
efficacy	O
of	O
novel	O
pharmacologic	O
interventions	O
(	O
AMG162	O
,	O
toremifene	B-CHEMICAL
)	O
during	O
GnRH	B-GENE-Y
agonist	O
treatment	O
.	O

The	O
effects	O
of	O
adulthood	O
olanzapine	B-CHEMICAL
treatment	O
on	O
cognitive	O
performance	O
and	O
neurotrophic	B-GENE-N
factor	I-GENE-N
content	O
in	O
male	O
and	O
female	O
rats	O
neonatally	O
treated	O
with	O
quinpirole	B-CHEMICAL
.	O

Male	O
and	O
female	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
administered	O
quinpirole	B-CHEMICAL
(	O
1	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
or	O
saline	O
once	O
daily	O
from	O
postnatal	O
day	O
(	O
P	O
)	O
1	O
to	O
P21	O
.	O

This	O
drug	O
treatment	O
has	O
been	O
shown	O
to	O
produce	O
long	O
-	O
term	O
priming	O
of	O
the	O
D2	B-GENE-Y
receptor	I-GENE-Y
.	O

Beginning	O
on	O
P62	O
,	O
rats	O
were	O
administered	O
the	O
atypical	O
antipsychotic	O
olanzapine	B-CHEMICAL
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
twice	O
daily	O
(	O
i	O
.	O
p	O
.	O
)	O
for	O
28	O
days	O
.	O

One	O
day	O
after	O
olanzapine	B-CHEMICAL
treatment	O
ceased	O
,	O
rats	O
were	O
tested	O
on	O
the	O
place	O
and	O
match	O
-	O
to	O
-	O
place	O
versions	O
of	O
the	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
for	O
seven	O
consecutive	O
days	O
.	O

Dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
priming	O
was	O
verified	O
through	O
a	O
yawning	O
behavioural	O
test	O
,	O
a	O
D2	B-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
event	O
,	O
before	O
olanzapine	B-CHEMICAL
was	O
administered	O
as	O
well	O
as	O
after	O
olanzapine	B-CHEMICAL
treatment	O
and	O
behavioural	O
testing	O
were	O
complete	O
.	O

Results	O
showed	O
that	O
neonatal	O
quinpirole	B-CHEMICAL
treatment	O
induced	O
D2	B-GENE-Y
priming	O
that	O
was	O
eliminated	O
by	O
olanzapine	B-CHEMICAL
treatment	O
.	O

On	O
the	O
MWM	O
place	O
version	O
,	O
D2	B-GENE-Y
-	O
primed	O
rats	O
demonstrated	O
a	O
significant	O
impairment	O
that	O
was	O
eliminated	O
by	O
olanzapine	B-CHEMICAL
treatment	O
,	O
but	O
olanzapine	B-CHEMICAL
treatment	O
to	O
animals	O
neonatally	O
treated	O
with	O
saline	O
produced	O
a	O
significant	O
deficit	O
on	O
the	O
place	O
version	O
of	O
the	O
MWM	O
.	O

There	O
were	O
no	O
significant	O
deficits	O
on	O
the	O
match	O
-	O
to	O
-	O
place	O
version	O
.	O

Brain	O
tissue	O
analyses	O
revealed	O
that	O
neonatal	O
quinpirole	B-CHEMICAL
treatment	O
produced	O
a	O
significant	O
decrease	O
in	O
hippocampal	O
NGF	B-GENE-Y
,	O
BDNF	B-GENE-Y
and	O
ChAT	B-GENE-Y
that	O
was	O
eliminated	O
by	O
olanzapine	B-CHEMICAL
treatment	O
.	O

Neonatal	O
quinpirole	B-CHEMICAL
treatment	O
produced	O
a	O
significant	O
decrease	O
in	O
BDNF	B-GENE-Y
and	O
ChAT	B-GENE-Y
in	O
the	O
frontal	O
cortex	O
that	O
was	O
unaffected	O
by	O
olanzapine	B-CHEMICAL
treatment	O
.	O

These	O
results	O
show	O
that	O
olanzapine	B-CHEMICAL
eliminates	O
D2	B-GENE-Y
receptor	I-GENE-Y
priming	O
and	O
cognitive	O
impairment	O
and	O
also	O
alleviates	O
decreases	O
in	O
neurotrophins	O
and	O
acetylcholinergic	O
markers	O
produced	O
by	O
D2	B-GENE-Y
priming	O
in	O
the	O
hippocampus	O
.	O

Dexamethasone	B-CHEMICAL
suppresses	O
histamine	B-CHEMICAL
synthesis	O
by	O
repressing	O
both	O
transcription	O
and	O
activity	O
of	O
HDC	B-GENE-Y
in	O
allergic	O
rats	O
.	O

BACKGROUND	O
:	O
Histamine	B-CHEMICAL
synthesized	O
by	O
histidine	B-GENE-Y
decarboxylase	I-GENE-Y
(	O
HDC	B-GENE-Y
)	O
from	O
L	B-CHEMICAL
-	I-CHEMICAL
histidine	I-CHEMICAL
is	O
a	O
major	O
chemical	O
mediator	O
in	O
the	O
development	O
of	O
nasal	O
allergy	O
which	O
is	O
characterized	O
by	O
nasal	O
hypersensitivity	O
.	O

However	O
the	O
regulatory	O
mechanism	O
of	O
histamine	B-CHEMICAL
synthesis	O
by	O
HDC	B-GENE-Y
remains	O
to	O
be	O
elucidated	O
.	O

The	O
objectives	O
of	O
the	O
present	O
study	O
were	O
to	O
examine	O
the	O
changes	O
of	O
histamine	B-CHEMICAL
content	O
,	O
HDC	B-GENE-Y
activity	O
and	O
HDC	B-GENE-Y
mRNA	O
expression	O
in	O
the	O
nasal	O
mucosa	O
of	O
allergy	O
model	O
rats	O
sensitized	O
by	O
the	O
exposure	O
to	O
toluene	B-CHEMICAL
diisocyanate	I-CHEMICAL
(	O
TDI	B-CHEMICAL
)	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
dexamethasone	B-CHEMICAL
on	O
the	O
above	O
mentioned	O
allergic	O
parameters	O
.	O

METHODS	O
:	O
Rats	O
were	O
sensitized	O
and	O
provocated	O
by	O
TDI	B-CHEMICAL
and	O
the	O
nasal	O
allergy	O
-	O
like	O
behaviors	O
were	O
scored	O
during	O
a	O
10	O
minute	O
period	O
after	O
provocation	O
.	O

Histamine	B-CHEMICAL
content	O
and	O
HDC	B-GENE-Y
activity	O
in	O
the	O
nasal	O
mucosa	O
were	O
determined	O
using	O
fluorometric	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
expression	O
of	O
HDC	B-GENE-N
mRNA	O
in	O
nasal	O
mucosa	O
was	O
determined	O
using	O
real	O
-	O
time	O
quantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

RESULTS	O
:	O
In	O
TDI	B-CHEMICAL
-	O
sensitized	O
rats	O
,	O
nasal	O
allergy	O
-	O
like	O
behaviors	O
such	O
as	O
sneezing	O
and	O
watery	O
rhinorrhea	O
were	O
induced	O
.	O

Histamine	B-CHEMICAL
content	O
,	O
HDC	B-GENE-Y
activity	O
and	O
HDC	B-GENE-Y
mRNA	O
expression	O
in	O
nasal	O
mucosa	O
were	O
also	O
significantly	O
increased	O
after	O
TDI	B-CHEMICAL
provocation	O
.	O

Pretreatment	O
with	O
dexamethasone	B-CHEMICAL
significantly	O
suppressed	O
nasal	O
allergy	O
-	O
like	O
behaviors	O
,	O
up	O
-	O
regulation	O
of	O
histamine	B-CHEMICAL
content	O
,	O
HDC	B-GENE-Y
activity	O
and	O
HDC	B-GENE-Y
mRNA	O
induced	O
by	O
TDI	B-CHEMICAL
in	O
TDI	B-CHEMICAL
-	O
sensitized	O
rats	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
indicate	O
that	O
increased	O
synthesis	O
of	O
histamine	B-CHEMICAL
through	O
up	O
-	O
regulation	O
of	O
HDC	B-GENE-Y
gene	O
expression	O
and	O
HDC	B-GENE-Y
activity	O
in	O
nasal	O
mucosa	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
nasal	O
hypersensitivity	O
.	O

Repression	O
of	O
HDC	B-GENE-Y
gene	O
expression	O
and	O
HDC	B-GENE-Y
activity	O
by	O
dexamethasone	B-CHEMICAL
may	O
underlie	O
its	O
therapeutic	O
effect	O
in	O
the	O
treatment	O
of	O
allergy	O
.	O

Methionine	B-GENE-Y
synthase	I-GENE-Y
reductase	I-GENE-Y
polymorphisms	O
are	O
associated	O
with	O
serum	O
osteocalcin	B-GENE-Y
levels	O
in	O
postmenopausal	O
women	O
.	O

Homocysteine	B-CHEMICAL
(	O
Hcy	B-CHEMICAL
)	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
osteoporosis	O
and	O
fracture	O
.	O

Methionine	B-GENE-Y
synthase	I-GENE-Y
reductase	I-GENE-Y
(	O
MTRR	B-GENE-Y
)	O
is	O
an	O
enzyme	O
involved	O
in	O
the	O
conversion	O
of	O
Hcy	B-CHEMICAL
to	O
methionine	B-CHEMICAL
.	O

We	O
hypothesized	O
that	O
certain	O
genetic	O
polymorphisms	O
of	O
MTRR	B-GENE-Y
leading	O
to	O
reduced	O
enzyme	O
activity	O
may	O
cause	O
hyperhomocysteinemia	O
and	O
affect	O
bone	O
metabolism	O
.	O

We	O
therefore	O
examined	O
the	O
associations	O
of	O
the	O
A66G	B-GENE-N
and	O
C524T	B-GENE-N
polymorphisms	O
of	O
the	O
MTRR	B-GENE-Y
gene	O
with	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
and	O
serum	O
osteocalcin	B-GENE-Y
levels	O
in	O
postmenopausal	O
women	O
.	O

Although	O
we	O
did	O
not	O
detect	O
any	O
significant	O
associations	O
between	O
MTRR	B-GENE-Y
polymorphisms	O
and	O
BMD	O
or	O
serum	O
osteocalcin	B-GENE-Y
levels	O
,	O
we	O
found	O
that	O
the	O
66G	O
/	O
524C	O
haplotype	O
,	O
which	O
has	O
reduced	O
enzyme	O
activity	O
,	O
was	O
significantly	O
associated	O
with	O
serum	O
osteocalcin	B-GENE-Y
levels	O
in	O
a	O
gene	O
-	O
dose	O
dependent	O
manner	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

That	O
is	O
,	O
the	O
highest	O
osteocalcin	B-GENE-Y
levels	O
(	O
34	O
.	O
5	O
+	O
/	O
-	O
16	O
.	O
8	O
ng	O
/	O
ml	O
)	O
were	O
observed	O
in	O
subjects	O
bearing	O
two	O
copies	O
,	O
intermediate	O
osteocalcin	B-GENE-Y
levels	O
(	O
32	O
.	O
6	O
+	O
/	O
-	O
14	O
.	O
4	O
ng	O
/	O
ml	O
)	O
were	O
observed	O
in	O
subjects	O
bearing	O
one	O
copy	O
,	O
and	O
the	O
lowest	O
levels	O
of	O
osteocalcin	B-GENE-Y
(	O
28	O
.	O
8	O
+	O
/	O
-	O
10	O
.	O
9	O
ng	O
/	O
ml	O
)	O
were	O
observed	O
in	O
subjects	O
bearing	O
no	O
copies	O
.	O

These	O
results	O
suggest	O
that	O
the	O
66G	O
/	O
524C	O
haplotype	O
of	O
the	O
MTRR	B-GENE-Y
gene	O
affect	O
bone	O
turn	O
over	O
rate	O
.	O

Glutathione	B-GENE-N
peroxidases	I-GENE-N
and	O
redox	O
-	O
regulated	O
transcription	O
factors	O
.	O

Analysis	O
of	O
the	O
selenoproteome	O
identified	O
five	O
glutathione	B-GENE-N
peroxidases	I-GENE-N
(	O
GPxs	B-GENE-N
)	O
in	O
mammals	O
:	O
cytosolic	B-GENE-N
GPx	I-GENE-N
(	O
cGPx	B-GENE-N
,	O
GPx1	B-GENE-N
)	O
,	O
phospholipid	B-GENE-N
hydroperoxide	I-GENE-N
GPx	I-GENE-N
(	O
PHGPX	B-GENE-N
,	O
GPx4	B-GENE-N
)	O
,	O
plasma	B-GENE-N
GPx	I-GENE-N
(	O
pGPX	B-GENE-N
,	O
GPx3	B-GENE-N
)	O
,	O
gastrointestinal	B-GENE-N
GPx	I-GENE-N
(	O
GI	B-GENE-N
-	I-GENE-N
GPx	I-GENE-N
,	O
GPx2	B-GENE-N
)	O
and	O
,	O
in	O
humans	B-GENE-Y
,	I-GENE-Y
GPx6	I-GENE-Y
,	O
which	O
is	O
restricted	O
to	O
the	O
olfactory	O
system	O
.	O

GPxs	B-GENE-N
reduce	O
hydroperoxides	O
to	O
the	O
corresponding	O
alcohols	B-CHEMICAL
by	O
means	O
of	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
.	O

They	O
have	O
long	O
been	O
considered	O
to	O
only	O
act	O
as	O
antioxidant	O
enzymes	O
.	O

Increasing	O
evidence	O
,	O
however	O
,	O
suggests	O
that	O
nature	O
has	O
not	O
created	O
redundant	O
GPxs	B-GENE-N
just	O
to	O
detoxify	O
hydroperoxides	O
.	O

cGPx	B-GENE-Y
clearly	O
acts	O
as	O
an	O
antioxidant	O
,	O
as	O
convincingly	O
demonstrated	O
in	O
GPx1	B-GENE-Y
-	O
knockout	O
mice	O
.	O

PHGPx	B-GENE-N
specifically	O
interferes	O
with	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
activation	O
by	O
interleukin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
,	O
reduces	O
leukotriene	B-CHEMICAL
and	O
prostanoid	B-CHEMICAL
biosynthesis	O
,	O
prevents	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
,	O
and	O
is	O
indispensable	O
for	O
sperm	O
maturation	O
and	O
embryogenesis	O
.	O

GI	B-GENE-N
-	I-GENE-N
GPx	I-GENE-N
,	O
which	O
is	O
not	O
exclusively	O
expressed	O
in	O
the	O
gastrointestinal	O
system	O
,	O
is	O
upregulated	O
in	O
colon	O
and	O
skin	O
cancers	O
and	O
in	O
certain	O
cultured	O
cancer	O
cells	O
.	O

GI	B-GENE-N
-	I-GENE-N
GPx	I-GENE-N
is	O
a	O
target	O
for	O
Nrf2	B-GENE-Y
,	O
and	O
thus	O
is	O
part	O
of	O
the	O
adaptive	O
response	O
by	O
itself	O
,	O
while	O
PHGPx	B-GENE-N
might	O
prevent	O
cancer	O
by	O
interfering	O
with	O
inflammatory	O
pathways	O
.	O

In	O
conclusion	O
,	O
cGPx	B-GENE-Y
,	O
PHGPx	B-GENE-N
and	O
GI	B-GENE-N
-	I-GENE-N
GPx	I-GENE-N
have	O
distinct	O
roles	O
,	O
particularly	O
in	O
cellular	O
defence	O
mechanisms	O
.	O

Redox	O
sensing	O
and	O
redox	O
regulation	O
of	O
metabolic	O
events	O
have	O
become	O
attractive	O
paradigms	O
to	O
unravel	O
the	O
specific	O
and	O
in	O
part	O
still	O
enigmatic	O
roles	O
of	O
GPxs	B-GENE-N
.	O

Adenosine	B-GENE-N
receptor	I-GENE-N
antagonists	O
intensify	O
the	O
benzodiazepine	B-CHEMICAL
withdrawal	O
signs	O
in	O
mice	O
.	O

The	O
aim	O
of	O
the	O
present	O
experiment	O
was	O
to	O
assess	O
the	O
involvement	O
of	O
adenosine	B-GENE-N
receptor	I-GENE-N
antagonists	O
in	O
benzodiazepine	B-CHEMICAL
(	O
BDZ	B-CHEMICAL
)	O
withdrawal	O
signs	O
,	O
observed	O
as	O
the	O
seizure	O
susceptibility	O
in	O
mice	O
.	O

The	O
discontinuation	O
of	O
chronic	O
treatment	O
with	O
temazepam	B-CHEMICAL
or	O
diazepam	B-CHEMICAL
decreased	O
seizure	O
threshold	O
(	O
one	O
of	O
BDZ	B-CHEMICAL
withdrawal	O
signs	O
)	O
.	O

The	O
concomitant	O
application	O
of	O
subconvulsive	O
dose	O
of	O
pentetrazole	B-CHEMICAL
(	O
55	O
.	O
0	O
mg	O
/	O
kg	O
)	O
with	O
low	O
dose	O
of	O
flumazenil	B-CHEMICAL
(	O
5	O
.	O
0	O
mg	O
/	O
kg	O
)	O
-	O
a	O
BDZ	B-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
immediately	O
induced	O
BDZ	B-CHEMICAL
withdrawal	O
signs	O
in	O
these	O
animals	O
.	O

The	O
non	O
-	O
selective	O
adenosine	B-GENE-N
receptor	I-GENE-N
antagonist	O
(	O
caffeine	B-CHEMICAL
)	O
,	O
and	O
the	O
selective	O
adenosine	B-GENE-Y
A1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
(	O
DPCPX	B-CHEMICAL
)	O
,	O
injected	O
15	O
min	O
before	O
the	O
application	O
of	O
pentetrazole	B-CHEMICAL
and	O
flumazenil	B-CHEMICAL
,	O
were	O
able	O
to	O
intensify	O
BDZ	B-CHEMICAL
withdrawal	O
signs	O
in	O
mice	O
.	O

The	O
most	O
apparent	O
effects	O
were	O
observed	O
after	O
administration	O
of	O
DPCPX	B-CHEMICAL
,	O
indicating	O
that	O
the	O
adenosine	B-GENE-Y
A1	I-GENE-Y
receptor	I-GENE-Y
may	O
play	O
a	O
more	O
important	O
role	O
in	O
these	O
effects	O
.	O

The	O
obtained	O
data	O
demonstrate	O
that	O
the	O
adenosinergic	O
system	O
is	O
involved	O
in	O
BDZ	B-CHEMICAL
withdrawal	O
signs	O
in	O
mice	O
,	O
and	O
adenosine	B-GENE-Y
A1	I-GENE-Y
receptor	I-GENE-Y
plays	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

Occupancy	O
of	O
dopamine	B-CHEMICAL
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
,	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
and	O
serotonin	B-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
in	O
schizophrenic	O
patients	O
treated	O
with	O
flupentixol	B-CHEMICAL
in	O
comparison	O
with	O
risperidone	B-CHEMICAL
and	O
haloperidol	B-CHEMICAL
.	O

RATIONALE	O
:	O
Flupentixol	B-CHEMICAL
(	O
FLX	B-CHEMICAL
)	O
has	O
been	O
used	O
as	O
a	O
neuroleptic	O
for	O
nearly	O
4	O
decades	O
.	O

In	O
vitro	O
data	O
show	O
comparable	O
affinity	O
to	O
dopamine	B-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
,	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
and	O
recently	O
,	O
FLX	B-CHEMICAL
showed	O
to	O
be	O
not	O
inferior	O
to	O
risperidone	B-CHEMICAL
in	O
schizophrenic	O
patients	O
with	O
predominant	O
negative	O
symptomatology	O
,	O
which	O
was	O
implicated	O
with	O
flupentixol	O
'	O
s	O
interaction	O
with	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
and	O
/	O
or	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
.	O

OBJECTIVES	O
:	O
To	O
assess	O
in	O
vivo	O
receptor	O
occupancy	O
(	O
RO	O
)	O
in	O
patients	O
clinically	O
treated	O
with	O
FLX	O
(	O
n	O
=	O
13	O
,	O
5	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
4	O
mg	O
/	O
day	O
)	O
in	O
comparison	O
with	O
risperidone	B-CHEMICAL
(	O
RIS	O
,	O
n	O
=	O
11	O
,	O
3	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
3	O
mg	O
/	O
day	O
)	O
and	O
haloperidol	B-CHEMICAL
(	O
HAL	O
,	O
n	O
=	O
11	O
,	O
8	O
.	O
5	O
+	O
/	O
-	O
5	O
.	O
5	O
mg	O
/	O
day	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Each	O
patient	O
underwent	O
two	O
PET	O
scans	O
with	O
3	B-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
methylspiperone	I-CHEMICAL
(	O
target	O
:	O
frontal	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
)	O
,	O
[	B-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
SCH23390	I-CHEMICAL
(	O
striatal	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
)	O
or	O
[	B-CHEMICAL
(	I-CHEMICAL
11	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
raclopride	I-CHEMICAL
(	O
striatal	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
)	O
.	O

RO	O
was	O
calculated	O
as	O
the	O
percentage	O
reduction	O
of	O
specific	O
binding	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

RESULTS	O
:	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	O
RO	O
under	O
FLX	O
was	O
between	O
50	O
%	O
and	O
70	O
%	O
,	O
indicating	O
an	O
ED	O
(	O
50	O
)	O
of	O
about	O
0	O
.	O
7	O
ng	O
/	O
ml	O
serum	O
.	O

5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
and	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	O
RO	O
was	O
20	O
+	O
/	O
-	O
10	O
%	O
and	O
20	O
+	O
/	O
-	O
5	O
%	O
(	O
mean	O
,	O
SEM	O
)	O
.	O

Under	O
HAL	O
,	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	O
RO	O
was	O
14	O
+	O
/	O
-	O
6	O
%	O
and	O
under	O
RIS	O
not	O
significantly	O
different	O
from	O
zero	O
.	O

CONCLUSIONS	O
:	O
We	O
were	O
able	O
to	O
demonstrate	O
a	O
moderate	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
and	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
occupancy	O
under	O
clinically	O
relevant	O
doses	O
of	O
flupentixol	B-CHEMICAL
,	O
albeit	O
lower	O
than	O
expected	O
from	O
in	O
vitro	O
data	O
and	O
clearly	O
below	O
saturation	O
.	O

Therefore	O
,	O
if	O
flupentixol	O
'	O
s	O
efficacy	O
on	O
negative	O
symptoms	O
is	O
based	O
on	O
its	O
interaction	O
with	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
and	O
/	O
or	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
,	O
it	O
should	O
be	O
highly	O
dependent	O
on	O
serum	O
concentration	O
and	O
thus	O
on	O
dosage	O
and	O
metabolism	O
.	O

However	O
,	O
these	O
data	O
suggest	O
that	O
mechanisms	O
other	O
than	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
antagonism	O
may	O
contribute	O
to	O
flupentixol	O
'	O
s	O
efficacy	O
on	O
negative	O
symptoms	O
.	O

ABCA1	B-GENE-Y
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
on	O
high	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
-	O
cholesterol	B-CHEMICAL
and	O
overweight	O
:	O
the	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O
study	O
.	O

The	O
adenosine	B-GENE-Y
triphosphate	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
cassette	I-GENE-Y
A1	I-GENE-Y
(	O
ABCA1	B-GENE-Y
)	O
gene	O
plays	O
a	O
key	O
role	O
in	O
reverse	O
cholesterol	B-CHEMICAL
transport	O
.	O

Some	O
ABCA1	B-GENE-Y
gene	O
polymorphisms	O
have	O
been	O
associated	O
with	O
high	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
-	O
cholesterol	B-CHEMICAL
(	O
HDL	B-GENE-N
-	O
C	O
)	O
concentrations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
three	O
polymorphisms	O
,	O
C69T	B-GENE-N
,	O
G378C	B-GENE-N
,	O
and	O
G1051A	B-GENE-N
(	O
R219K	B-GENE-N
)	O
,	O
on	O
HDL	B-GENE-N
-	O
C	O
levels	O
and	O
their	O
interaction	O
with	O
BMI	O
in	O
more	O
than	O
5000	O
French	O
whites	O
from	O
the	O
D	O
.	O
E	O
.	O
S	O
.	O
I	O
.	O
R	O
.	O

(	O
Data	O
from	O
an	O
Epidemiological	O
Study	O
on	O
the	O
Insulin	B-GENE-Y
Resistance	O
syndrome	O
)	O
cohort	O
study	O
.	O

The	O
T	O
allele	O
of	O
the	O
C69T	B-GENE-N
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
was	O
associated	O
with	O
higher	O
HDL	B-GENE-N
-	O
C	O
levels	O
in	O
normal	O
-	O
weight	O
men	O
(	O
BMI	O
<	O
25	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

The	O
C	O
allele	O
of	O
the	O
G378C	B-GENE-N
SNP	O
was	O
associated	O
with	O
lower	O
HDL	B-GENE-N
-	O
C	O
in	O
overweight	O
subjects	O
(	O
BMI	O
>	O
or	O
=	O
25	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
.	O

For	O
the	O
G1051A	B-GENE-N
SNP	O
,	O
in	O
the	O
normal	O
-	O
weight	O
group	O
,	O
the	O
minor	O
A	O
allele	O
was	O
significantly	O
associated	O
with	O
higher	O
HDL	B-GENE-N
-	O
C	O
levels	O
.	O

In	O
contrast	O
,	O
in	O
overweight	O
people	O
,	O
the	O
minor	O
allele	O
was	O
associated	O
with	O
lower	O
HDL	B-GENE-N
-	O
C	O
levels	O
.	O

After	O
accounting	O
for	O
multiple	O
testing	O
,	O
empiric	O
p	O
values	O
remained	O
significant	O
for	O
the	O
associations	O
between	O
G378C	B-GENE-N
SNP	O
and	O
HDL	B-GENE-N
-	O
C	O
in	O
the	O
overweight	O
group	O
and	O
between	O
G1051A	B-GENE-N
SNP	O
and	O
HDL	B-GENE-N
-	O
C	O
in	O
the	O
normal	O
-	O
weight	O
group	O
.	O

This	O
study	O
suggests	O
that	O
ABCA1	B-GENE-Y
gene	O
polymorphisms	O
modulate	O
HDL	B-GENE-N
-	O
C	O
concentrations	O
,	O
in	O
interaction	O
with	O
BMI	O
,	O
and	O
,	O
thus	O
,	O
they	O
might	O
influence	O
cardiovascular	O
risk	O
in	O
the	O
general	O
population	O
.	O

Ankyrin	B-GENE-N
repeat	O
and	O
suppressors	O
of	O
cytokine	B-GENE-N
signaling	I-GENE-N
box	I-GENE-N
protein	I-GENE-N
asb	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
targets	O
creatine	B-GENE-Y
kinase	I-GENE-Y
B	I-GENE-Y
for	O
degradation	O
.	O

The	O
suppressors	B-GENE-N
of	I-GENE-N
cytokine	I-GENE-N
signaling	I-GENE-N
(	I-GENE-N
SOCS	I-GENE-N
)	I-GENE-N
proteins	I-GENE-N
inhibit	O
cytokine	B-GENE-N
action	O
by	O
direct	O
interaction	O
with	O
Janus	B-GENE-N
kinases	I-GENE-N
or	O
activated	O
cytokine	B-GENE-N
receptors	I-GENE-N
.	O

In	O
addition	O
to	O
the	O
N	B-CHEMICAL
-	O
terminal	O
and	O
Src	B-GENE-N
homology	I-GENE-N
2	I-GENE-N
domains	I-GENE-N
that	O
mediate	O
these	O
interactions	O
,	O
SOCS	B-GENE-N
proteins	O
contain	O
a	O
C	B-CHEMICAL
-	O
terminal	O
SOCS	B-GENE-N
box	I-GENE-N
.	O

DNA	O
data	O
base	O
searches	O
have	O
identified	O
a	O
number	O
of	O
other	O
protein	O
families	O
that	O
possess	O
a	O
SOCS	B-GENE-N
box	I-GENE-N
,	O
of	O
which	O
the	O
ankyrin	B-GENE-N
repeat	O
and	O
SOCS	B-GENE-N
box	I-GENE-N
-	O
containing	O
(	O
Asb	B-GENE-N
)	O
proteins	O
constitute	O
the	O
largest	O
.	O

Although	O
it	O
is	O
known	O
that	O
the	O
SOCS	B-GENE-N
proteins	O
are	O
involved	O
in	O
the	O
negative	O
regulation	O
of	O
cytokine	B-GENE-N
signaling	O
,	O
the	O
biological	O
and	O
biochemical	O
functions	O
of	O
the	O
Asbs	B-GENE-N
are	O
largely	O
undefined	O
.	O

Using	O
a	O
proteomics	O
approach	O
,	O
we	O
demonstrate	O
that	O
creatine	B-GENE-Y
kinase	I-GENE-Y
B	I-GENE-Y
(	O
CKB	B-GENE-Y
)	O
interacts	O
with	O
Asb	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
in	O
a	O
specific	O
,	O
SOCS	B-GENE-N
box	I-GENE-N
-	O
independent	O
manner	O
.	O

This	O
interaction	O
increases	O
the	O
polyubiquitylation	O
of	O
CKB	B-GENE-Y
and	O
decreases	O
total	O
CKB	B-GENE-Y
levels	O
within	O
the	O
cell	O
.	O

The	O
targeting	O
of	O
CKB	B-GENE-Y
for	O
degradation	O
by	O
Asb	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
was	O
primarily	O
SOCS	B-GENE-N
box	I-GENE-N
-	O
dependent	O
and	O
suggests	O
that	O
Asb	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
acts	O
as	O
a	O
specific	O
ubiquitin	B-GENE-N
ligase	I-GENE-N
regulating	O
levels	O
of	O
this	O
evolutionarily	O
conserved	O
enzyme	O
.	O

Effect	O
of	O
galantamine	B-CHEMICAL
on	O
acetylcholinesterase	B-GENE-Y
and	O
butyrylcholinesterase	B-GENE-Y
activities	O
in	O
the	O
presence	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
carnitine	I-CHEMICAL
in	O
rat	O
selected	O
brain	O
and	O
peripheral	O
tissues	O
.	O

OBJECTIVES	O
:	O
The	O
alkaloid	O
galantamine	B-CHEMICAL
(	O
GAL	B-CHEMICAL
)	O
,	O
which	O
exhibits	O
a	O
combined	O
anticholinesterase	B-GENE-Y
and	O
direct	O
parasympathomimetic	O
mechanism	O
of	O
action	O
,	O
is	O
employed	O
in	O
conjunction	O
with	O
therapeutic	O
interventions	O
in	O
the	O
stimulation	O
of	O
central	O
cholinergic	O
transfer	O
in	O
cognitive	O
diseases	O
.	O

We	O
attempted	O
to	O
achieve	O
pharmacologically	O
-	O
induced	O
enhancement	O
of	O
the	O
parasympathomimetic	O
activity	O
of	O
GAL	B-CHEMICAL
in	O
the	O
key	O
areas	O
of	O
rat	O
brain	O
,	O
using	O
an	O
interactive	O
combination	O
of	O
the	O
alkaloid	O
with	O
the	O
transmembrane	O
enhancer	O
L	B-CHEMICAL
-	I-CHEMICAL
carnitine	I-CHEMICAL
(	O
CAR	B-CHEMICAL
)	O
.	O

METHODS	O
:	O
We	O
investigated	O
activities	O
of	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
in	O
brain	O
areas	O
(	O
frontal	O
cortex	O
,	O
basal	O
ganglia	O
,	O
septum	O
and	O
hippocampus	O
)	O
and	O
the	O
hypophysis	O
,	O
and	O
that	O
of	O
butyrylcholinesterase	B-GENE-Y
(	O
BuChE	B-GENE-Y
)	O
in	O
plasma	O
and	O
liver	O
.	O

RESULTS	O
:	O
Following	O
administration	O
of	O
the	O
highest	O
of	O
the	O
GAL	B-CHEMICAL
doses	O
used	O
(	O
2	O
.	O
5	O
;	O
5	O
;	O
10	O
mg	O
/	O
kg	O
i	O
.	O
m	O
.	O
)	O
,	O
AChE	B-GENE-Y
activity	O
decreased	O
mainly	O
in	O
the	O
frontal	O
cortex	O
,	O
hippocampus	O
and	O
hypophysis	O
.	O

In	O
the	O
interaction	O
of	O
GAL	B-CHEMICAL
and	O
CAR	B-CHEMICAL
,	O
AChE	B-GENE-Y
inhibition	O
was	O
stronger	O
but	O
without	O
any	O
statistical	O
significance	O
.	O

The	O
peripheral	O
inhibition	O
of	O
BuChE	B-GENE-Y
was	O
found	O
to	O
be	O
dose	O
-	O
dependent	O
.	O

Premedication	O
by	O
CAR	B-CHEMICAL
led	O
to	O
a	O
slight	O
change	O
in	O
the	O
values	O
of	O
the	O
activities	O
monitored	O
.	O

CONCLUSIONS	O
:	O
CAR	B-CHEMICAL
in	O
terms	O
of	O
positive	O
modulation	O
of	O
GAL	B-CHEMICAL
targeting	O
to	O
the	O
central	O
nervous	O
system	O
had	O
no	O
statistically	O
significant	O
effect	O
.	O

Warfarin	B-CHEMICAL
dose	O
and	O
the	O
pharmacogenomics	O
of	O
CYP2C9	B-GENE-Y
and	O
VKORC1	B-GENE-Y
-	O
rationale	O
and	O
perspectives	O
.	O

Warfarin	B-CHEMICAL
is	O
the	O
most	O
widely	O
prescribed	O
oral	O
anticoagulant	O
,	O
but	O
there	O
is	O
greater	O
than	O
10	O
-	O
fold	O
interindividual	O
variability	O
in	O
the	O
dose	O
required	O
to	O
attain	O
a	O
therapeutic	O
response	O
.	O

Information	O
from	O
pharmacogenomics	O
,	O
the	O
study	O
of	O
the	O
interaction	O
of	O
an	O
individual	O
'	O
s	O
genotype	O
and	O
drug	O
response	O
,	O
can	O
help	O
optimize	O
drug	O
efficacy	O
while	O
minimizing	O
adverse	O
drug	O
reactions	O
.	O

Pharmacogenetic	O
analysis	O
of	O
two	O
genes	O
,	O
the	O
warfarin	B-CHEMICAL
metabolic	O
enzyme	O
CYP2C9	B-GENE-Y
and	O
warfarin	B-CHEMICAL
target	O
enzyme	O
,	O
vitamin	B-GENE-Y
K	I-GENE-Y
epoxide	I-GENE-Y
reductase	I-GENE-Y
complex	I-GENE-Y
1	I-GENE-Y
VKORC1	B-GENE-Y
,	O
confirmed	O
their	O
influence	O
on	O
warfarin	B-CHEMICAL
maintenance	O
dose	O
.	O

Possession	O
of	O
CYP2C9	B-GENE-Y
*	O
2	O
or	O
CYP2C9	B-GENE-Y
*	O
3	O
variant	O
alleles	O
,	O
which	O
result	O
in	O
decreased	O
enzyme	O
activity	O
,	O
is	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
mean	O
warfarin	B-CHEMICAL
dose	O
.	O

Several	O
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
in	O
VKORC1	B-GENE-Y
are	O
associated	O
with	O
warfarin	B-CHEMICAL
dose	O
across	O
the	O
normal	O
dose	O
range	O
.	O

Haplotypes	O
based	O
on	O
these	O
SNPs	O
explain	O
a	O
large	O
fraction	O
of	O
the	O
interindividual	O
variation	O
in	O
warfarin	B-CHEMICAL
dose	O
,	O
and	O
VKORC1	B-GENE-Y
has	O
an	O
approximately	O
three	O
-	O
fold	O
greater	O
effect	O
than	O
CYP2C9	B-GENE-Y
.	O

Algorithms	O
incorporating	O
genetic	O
(	O
CYP2C9	B-GENE-Y
and	O
VKORC1	B-GENE-Y
)	O
,	O
demographic	O
,	O
and	O
clinical	O
factors	O
to	O
estimate	O
the	O
warfarin	B-CHEMICAL
dosage	O
,	O
could	O
potentially	O
minimize	O
the	O
risk	O
of	O
over	O
dose	O
during	O
warfarin	B-CHEMICAL
induction	O
.	O

Comparative	O
gene	O
expression	O
profiling	O
of	O
in	O
vitro	O
differentiated	O
megakaryocytes	O
and	O
erythroblasts	O
identifies	O
novel	O
activatory	O
and	O
inhibitory	O
platelet	O
membrane	O
proteins	O
.	O

To	O
identify	O
previously	O
unknown	O
platelet	B-GENE-N
receptors	I-GENE-N
we	O
compared	O
the	O
transcriptomes	O
of	O
in	O
vitro	O
differentiated	O
megakaryocytes	O
(	O
MKs	O
)	O
and	O
erythroblasts	O
(	O
EBs	O
)	O
.	O

RNA	O
was	O
obtained	O
from	O
purified	O
,	O
biologically	O
paired	O
MK	O
and	O
EB	O
cultures	O
and	O
compared	O
using	O
cDNA	O
microarrays	O
.	O

Bioinformatical	O
analysis	O
of	O
MK	O
-	O
up	O
-	O
regulated	O
genes	O
identified	O
151	O
transcripts	O
encoding	O
transmembrane	O
domain	O
-	O
containing	O
proteins	O
.	O

Although	O
many	O
of	O
these	O
were	O
known	O
platelet	O
genes	O
,	O
a	O
number	O
of	O
previously	O
unidentified	O
or	O
poorly	O
characterized	O
transcripts	O
were	O
also	O
detected	O
.	O

Many	O
of	O
these	O
transcripts	O
,	O
including	O
G6b	B-GENE-Y
,	O
G6f	B-GENE-Y
,	O
LRRC32	B-GENE-Y
,	O
LAT2	B-GENE-Y
,	O
and	O
the	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
SUCNR1	B-GENE-Y
,	O
encode	O
proteins	O
with	O
structural	O
features	O
or	O
functions	O
that	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
the	O
modulation	O
of	O
platelet	O
function	O
.	O

Immunoblotting	O
on	O
platelets	O
confirmed	O
the	O
presence	O
of	O
the	O
encoded	O
proteins	O
,	O
and	O
flow	O
cytometric	O
analysis	O
confirmed	O
the	O
expression	O
of	O
G6b	B-GENE-Y
,	O
G6f	B-GENE-Y
,	O
and	O
LRRC32	B-GENE-Y
on	O
the	O
surface	O
of	O
platelets	O
.	O

Through	O
comparative	O
analysis	O
of	O
expression	O
in	O
platelets	O
and	O
other	O
blood	O
cells	O
we	O
demonstrated	O
that	O
G6b	B-GENE-Y
,	O
G6f	B-GENE-Y
,	O
and	O
LRRC32	B-GENE-Y
are	O
restricted	O
to	O
the	O
platelet	O
lineage	O
,	O
whereas	O
LAT2	B-GENE-Y
and	O
SUCNR1	B-GENE-Y
were	O
also	O
detected	O
in	O
other	O
blood	O
cells	O
.	O

The	O
identification	O
of	O
the	O
succinate	B-GENE-N
receptor	I-GENE-N
SUCNR1	B-GENE-Y
in	O
platelets	O
is	O
of	O
particular	O
interest	O
,	O
because	O
physiologically	O
relevant	O
concentrations	O
of	O
succinate	B-CHEMICAL
were	O
shown	O
to	O
potentiate	O
the	O
effect	O
of	O
low	O
doses	O
of	O
a	O
variety	O
of	O
platelet	O
agonists	O
.	O

Development	O
and	O
validation	O
of	O
a	O
non	O
-	O
radioactive	O
DNA	B-GENE-N
polymerase	I-GENE-N
assay	O
for	O
studying	O
cytomegalovirus	O
resistance	O
to	O
foscarnet	B-CHEMICAL
.	O

Phenotypic	O
characterisation	O
of	O
the	O
human	B-GENE-Y
cytomegalovirus	I-GENE-Y
(	I-GENE-Y
HCMV	I-GENE-Y
)	I-GENE-Y
pUL54	I-GENE-Y
DNA	B-GENE-N
polymerase	I-GENE-N
is	O
a	O
useful	O
tool	O
for	O
testing	O
for	O
mutations	O
in	O
the	O
UL54	B-GENE-Y
gene	O
thought	O
to	O
render	O
HCMV	O
resistant	O
to	O
foscarnet	B-CHEMICAL
.	O

In	O
this	O
study	O
,	O
an	O
in	O
-	O
house	O
non	O
-	O
isotopic	O
method	O
for	O
assessing	O
polymerase	O
enzymatic	O
activity	O
in	O
the	O
presence	O
and	O
absence	O
of	O
foscarnet	B-CHEMICAL
was	O
developed	O
and	O
its	O
utility	O
for	O
HCMV	B-GENE-N
polymerase	I-GENE-N
phenotyping	O
evaluated	O
.	O

Polymerase	B-GENE-N
activity	O
was	O
assessed	O
by	O
monitoring	O
the	O
incorporation	O
of	O
digoxigenin	B-CHEMICAL
-	O
labelled	O
nucleotides	O
into	O
the	O
growing	O
DNA	O
chain	O
and	O
foscarnet	B-CHEMICAL
concentrations	O
inhibiting	O
enzymatic	O
activity	O
by	O
50	O
%	O
were	O
determined	O
.	O

HCMV	B-GENE-N
DNA	I-GENE-N
polymerases	I-GENE-N
were	O
synthesised	O
in	O
vitro	O
by	O
expression	O
of	O
UL54	B-GENE-Y
under	O
the	O
control	O
of	O
the	O
T7	B-GENE-N
promoter	I-GENE-N
.	O

Mutations	O
of	O
interest	O
were	O
introduced	O
into	O
the	O
wild	O
-	O
type	O
UL54	B-GENE-Y
gene	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Mutated	O
polymerases	B-GENE-N
and	O
polymerases	B-GENE-N
from	O
HCMV	O
reference	O
strains	O
were	O
studied	O
.	O

The	O
activity	O
of	O
polymerases	B-GENE-N
containing	O
mutations	O
known	O
to	O
confer	O
resistance	O
to	O
foscarnet	B-CHEMICAL
(	O
V715M	B-GENE-N
,	O
T700A	B-GENE-N
and	O
N495K	B-GENE-N
)	O
was	O
inhibited	O
by	O
concentrations	O
of	O
foscarnet	B-CHEMICAL
eight	O
to	O
14	O
times	O
higher	O
than	O
those	O
required	O
to	O
inhibit	O
wild	O
-	O
type	O
polymerases	B-GENE-N
.	O

Our	O
in	O
-	O
house	O
non	O
-	O
radioactive	O
phenotypic	O
assay	O
was	O
sensitive	O
and	O
reproducible	O
.	O

It	O
is	O
also	O
easy	O
to	O
perform	O
and	O
could	O
provide	O
a	O
convenient	O
method	O
for	O
characterising	O
mutations	O
conferring	O
resistance	O
to	O
foscarnet	B-CHEMICAL
in	O
HCMV	O
.	O

Configuration	O
of	O
a	O
scintillation	O
proximity	O
assay	O
for	O
the	O
activity	O
assessment	O
of	O
recombinant	O
human	B-GENE-Y
adenine	I-GENE-Y
phosphoribosyltransferase	I-GENE-Y
.	O

Adenine	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
plays	O
a	O
role	O
in	O
purine	B-CHEMICAL
salvage	O
by	O
catalyzing	O
the	O
direct	O
conversion	O
of	O
adenine	B-CHEMICAL
to	O
adenosine	B-CHEMICAL
monophosphate	I-CHEMICAL
.	O

The	O
involvement	O
of	O
the	O
purine	B-CHEMICAL
salvage	O
pathway	O
in	O
tumor	O
proliferation	O
and	O
angiogenesis	O
makes	O
adenine	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
a	O
potential	O
target	O
for	O
oncology	O
drug	O
discovery	O
.	O

We	O
have	O
expressed	O
and	O
characterized	O
recombinant	O
,	O
N	B-CHEMICAL
-	O
terminally	O
His	B-CHEMICAL
-	O
tagged	O
human	B-GENE-Y
adenine	I-GENE-Y
phosphoribosyltransferase	I-GENE-Y
.	O

Two	O
assay	O
formats	O
were	O
assessed	O
for	O
use	O
in	O
a	O
high	O
throughput	O
screen	O
:	O
a	O
spectrophotometric	O
-	O
based	O
enzyme	O
-	O
coupled	O
assay	O
system	O
and	O
a	O
radiometric	O
ionic	O
capture	O
scintillation	O
proximity	O
bead	O
assay	O
format	O
.	O

Ultimately	O
,	O
the	O
scintillation	O
proximity	O
assay	O
format	O
was	O
chosen	O
because	O
of	O
automated	O
screening	O
compatibility	O
limitations	O
of	O
the	O
coupled	O
assay	O
.	O

We	O
describe	O
here	O
the	O
biochemical	O
characterization	O
of	O
adenine	B-GENE-Y
phosphoribosyltransferase	I-GENE-Y
and	O
the	O
development	O
of	O
a	O
robust	O
,	O
homogeneous	O
,	O
384	O
-	O
well	O
assay	O
suitable	O
for	O
high	O
throughput	O
screening	O
.	O

Antitumor	O
activity	O
of	O
sorafenib	B-CHEMICAL
in	O
FLT3	B-GENE-Y
-	O
driven	O
leukemic	O
cells	O
.	O

Activating	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
insertions	O
in	O
the	O
juxtamembrane	B-GENE-N
domain	I-GENE-N
of	O
the	O
FLT3	B-GENE-Y
tyrosine	B-GENE-N
kinase	I-GENE-N
are	O
found	O
in	O
about	O
one	O
fourth	O
of	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
and	O
have	O
been	O
shown	O
to	O
be	O
an	O
independent	O
negative	O
prognostic	O
factor	O
for	O
survival	O
.	O

We	O
show	O
that	O
sorafenib	B-CHEMICAL
(	O
BAY	B-CHEMICAL
43	I-CHEMICAL
-	I-CHEMICAL
9006	I-CHEMICAL
,	O
Nexavar	B-CHEMICAL
)	O
potently	O
inhibits	O
FLT3	B-GENE-Y
enzymatic	O
and	O
signaling	O
activities	O
.	O

In	O
HEK293	O
cells	O
stably	O
transfected	O
with	O
FLT3	B-GENE-Y
-	O
WT	O
or	O
FLT3	B-GENE-Y
-	O
ITD	O
,	O
sorafenib	B-CHEMICAL
blocked	O
basal	O
and	O
ligand	O
dependent	O
FLT3	B-GENE-Y
-	O
mediated	O
tyrosine	B-CHEMICAL
autophosphorylation	O
as	O
well	O
as	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
Stat5	B-GENE-Y
phosphorylation	O
.	O

In	O
leukemia	O
cell	O
lines	O
MV4	O
-	O
11	O
and	O
EOL	O
-	O
1	O
,	O
sorafenib	B-CHEMICAL
treatment	O
resulted	O
in	O
decreased	O
cell	O
proliferation	O
and	O
inhibition	O
of	O
FLT3	B-GENE-Y
signaling	O
.	O

The	O
growth	O
of	O
the	O
FLT3	B-GENE-Y
-	O
independent	O
RS4	O
-	O
11	O
cell	O
line	O
was	O
only	O
weakly	O
inhibited	O
by	O
sorafenib	B-CHEMICAL
.	O

Cell	O
cycle	O
arrest	O
and	O
induction	O
of	O
apoptosis	O
were	O
observed	O
upon	O
treatment	O
with	O
sorafenib	B-CHEMICAL
in	O
MV4	O
-	O
11	O
and	O
EOL	O
-	O
1	O
cells	O
.	O

The	O
antitumor	O
efficacy	O
of	O
sorafenib	B-CHEMICAL
was	O
evaluated	O
against	O
the	O
MV4	O
-	O
11	O
leukemia	O
grown	O
subcutaneously	O
in	O
NCr	O
nu	O
/	O
nu	O
mice	O
.	O

Doses	O
of	O
3	O
and	O
10	O
mg	O
/	O
kg	O
administered	O
orally	O
for	O
14	O
days	O
resulted	O
in	O
six	O
and	O
nine	O
out	O
of	O
10	O
animals	O
with	O
complete	O
responses	O
,	O
respectively	O
.	O

The	O
demonstration	O
that	O
sorafenib	B-CHEMICAL
exhibits	O
potent	O
target	O
inhibition	O
and	O
efficacy	O
in	O
FLT3	B-GENE-Y
-	O
driven	O
models	O
suggests	O
that	O
this	O
compound	O
may	O
have	O
a	O
therapeutic	O
benefit	O
for	O
patients	O
with	O
FLT3	B-GENE-Y
-	O
driven	O
leukemias	O
.	O

Pegylated	B-GENE-N
recombinant	I-GENE-N
human	I-GENE-N
arginase	I-GENE-N
(	O
rhArg	B-GENE-N
-	O
peg5	O
,	O
000mw	O
)	O
inhibits	O
the	O
in	O
vitro	O
and	O
in	O
vivo	O
proliferation	O
of	O
human	O
hepatocellular	O
carcinoma	O
through	O
arginine	B-CHEMICAL
depletion	O
.	O

Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
is	O
believed	O
to	O
be	O
auxotrophic	O
for	O
arginine	B-CHEMICAL
through	O
the	O
lack	O
of	O
expression	O
of	O
argininosuccinate	B-GENE-Y
synthetase	I-GENE-Y
(	O
ASS	B-GENE-Y
)	O
.	O

The	O
successful	O
use	O
of	O
the	O
arginine	B-GENE-N
-	I-GENE-N
depleting	I-GENE-N
enzyme	I-GENE-N
arginine	B-GENE-N
deiminase	I-GENE-N
(	O
ADI	B-GENE-N
)	O
to	O
treat	O
ASS	B-GENE-Y
-	O
deficient	O
tumors	O
has	O
opened	O
up	O
new	O
possibilities	O
for	O
effective	O
cancer	O
therapy	O
.	O

Nevertheless	O
,	O
many	O
ASS	B-GENE-Y
-	O
positive	O
HCC	O
cell	O
lines	O
are	O
found	O
to	O
be	O
resistant	O
to	O
ADI	B-GENE-N
treatment	O
,	O
although	O
most	O
require	O
arginine	B-CHEMICAL
for	O
proliferation	O
.	O

Thus	O
far	O
,	O
an	O
arginine	B-GENE-N
-	I-GENE-N
depleting	I-GENE-N
enzyme	I-GENE-N
for	O
killing	O
ASS	B-GENE-Y
-	O
positive	O
tumors	O
has	O
not	O
been	O
reported	O
.	O

Here	O
,	O
we	O
provide	O
direct	O
evidence	O
that	O
recombinant	O
human	B-GENE-N
arginase	I-GENE-N
(	O
rhArg	B-GENE-N
)	O
inhibits	O
ASS	B-GENE-Y
-	O
positive	O
HCCs	O
.	O

All	O
the	O
five	O
human	O
HCC	O
cell	O
lines	O
we	O
used	O
were	O
sensitive	O
to	O
rhArg	B-GENE-N
but	O
ADI	B-GENE-N
had	O
virtually	O
no	O
effect	O
on	O
these	O
cells	O
.	O

They	O
all	O
expressed	O
ASS	B-GENE-Y
,	O
but	O
not	O
ornithine	B-GENE-Y
transcarbamylase	I-GENE-Y
(	O
OTC	B-GENE-Y
)	O
,	O
the	O
enzyme	O
that	O
converts	O
ornithine	B-CHEMICAL
,	O
the	O
product	O
of	O
degradation	O
of	O
arginine	B-CHEMICAL
with	O
rhArg	B-GENE-N
,	O
to	O
citrulline	B-CHEMICAL
,	O
which	O
is	O
converted	O
back	O
to	O
arginine	B-CHEMICAL
via	O
ASS	B-GENE-Y
.	O

Transfection	O
of	O
HCC	O
cells	O
with	O
OTC	B-GENE-Y
resulted	O
in	O
resistance	O
to	O
rhArg	B-GENE-N
.	O

Thus	O
,	O
OTC	B-GENE-Y
expression	O
alone	O
may	O
be	O
sufficient	O
to	O
induce	O
rhArg	B-GENE-N
resistance	O
in	O
ASS	B-GENE-Y
-	O
positive	O
HCC	O
cells	O
.	O

This	O
surprising	O
correlation	O
between	O
the	O
lack	O
of	O
OTC	B-GENE-Y
expression	O
and	O
sensitivity	O
of	O
ASS	B-GENE-Y
-	O
positive	O
HCC	O
cells	O
shows	O
that	O
OTC	B-GENE-Y
-	O
deficient	O
HCCs	O
are	O
sensitive	O
to	O
rhArg	B-GENE-N
-	O
mediated	O
arginine	B-CHEMICAL
depletion	O
.	O

Therefore	O
,	O
pretreatment	O
tumor	O
gene	O
expression	O
profiling	O
of	O
ASS	B-GENE-Y
and	O
OTC	B-GENE-Y
could	O
aid	O
in	O
predicting	O
tumor	O
response	O
to	O
arginine	B-CHEMICAL
depletion	O
with	O
arginine	B-GENE-N
-	I-GENE-N
depleting	I-GENE-N
enzymes	I-GENE-N
.	O

We	O
have	O
also	O
shown	O
that	O
the	O
rhArg	B-GENE-N
native	O
enzyme	O
and	O
the	O
pegylated	B-GENE-N
rhArg	I-GENE-N
(	O
rhArg	B-GENE-N
-	O
peg	O
(	O
5	O
,	O
000mw	O
)	O
)	O
gave	O
similar	O
anticancer	O
efficacy	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
growth	O
of	O
the	O
OTC	B-GENE-Y
-	O
deficient	O
Hep3B	O
tumor	O
cells	O
(	O
ASS	B-GENE-Y
-	O
positive	O
and	O
ADI	B-GENE-N
-	O
resistant	O
)	O
in	O
mice	O
was	O
inhibited	O
by	O
treatment	O
with	O
rhArg	B-GENE-N
-	O
peg	O
(	O
5	O
,	O
000mw	O
)	O
,	O
which	O
is	O
active	O
alone	O
and	O
is	O
synergistic	O
in	O
combination	O
with	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
rhArg	B-GENE-N
-	O
peg	O
(	O
5	O
,	O
000mw	O
)	O
is	O
a	O
novel	O
agent	O
for	O
effective	O
cancer	O
therapy	O
.	O

Pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
may	O
be	O
curative	O
in	O
early	O
-	O
onset	O
epileptic	O
encephalopathy	O
.	O

Neonatal	O
epileptic	O
encephalopathy	O
can	O
be	O
caused	O
by	O
inborn	O
errors	O
of	O
metabolism	O
.	O

These	O
conditions	O
are	O
often	O
unresponsive	O
to	O
treatment	O
with	O
conventional	O
antiepileptic	O
drugs	O
.	O

Six	O
children	O
with	O
pyridox	B-GENE-Y
(	I-GENE-Y
am	I-GENE-Y
)	I-GENE-Y
ine	I-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
phosphate	I-GENE-Y
oxidase	I-GENE-Y
(	O
PNPO	B-GENE-Y
)	O
deficiency	O
presented	O
with	O
neonatal	O
epileptic	O
encephalopathy	O
.	O

Two	O
were	O
treated	O
with	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
within	O
the	O
first	O
month	O
of	O
life	O
and	O
showed	O
normal	O
development	O
or	O
moderate	O
psychomotor	O
retardation	O
thereafter	O
.	O

Four	O
children	O
with	O
late	O
or	O
no	O
treatment	O
died	O
or	O
showed	O
severe	O
mental	O
handicap	O
.	O

All	O
of	O
the	O
children	O
showed	O
atypical	O
biochemical	O
findings	O
.	O

Prompt	O
treatment	O
with	O
PLP	B-CHEMICAL
in	O
all	O
neonates	O
and	O
infants	O
with	O
epileptic	O
encephalopathy	O
should	O
become	O
mandatory	O
,	O
permitting	O
normal	O
development	O
in	O
at	O
least	O
some	O
of	O
those	O
affected	O
with	O
PNPO	B-GENE-Y
deficiency	O
.	O

Specificity	O
of	O
zebrafish	B-GENE-Y
retinol	I-GENE-Y
saturase	I-GENE-Y
:	O
formation	O
of	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
and	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
.	O

Metabolism	O
of	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
,	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinol	I-CHEMICAL
,	O
leads	O
to	O
the	O
formation	O
of	O
11	B-CHEMICAL
-	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
retinaldehyde	I-CHEMICAL
,	O
the	O
visual	O
chromophore	O
,	O
and	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
which	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
through	O
the	O
retinoic	B-GENE-N
acid	I-GENE-N
receptor	I-GENE-N
.	O

Enzymes	O
and	O
binding	O
proteins	O
involved	O
in	O
retinoid	B-CHEMICAL
metabolism	O
are	O
highly	O
conserved	O
across	O
species	O
.	O

We	O
previously	O
described	O
a	O
novel	O
mammalian	O
enzyme	O
that	O
saturates	O
the	O
13	O
-	O
14	O
double	O
bond	O
of	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinol	I-CHEMICAL
to	O
produce	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
,	O
which	O
then	O
follows	O
the	O
same	O
metabolic	O
fate	O
as	O
that	O
of	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinol	I-CHEMICAL
.	O

Specifically	O
,	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
is	O
transiently	O
oxidized	O
to	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
dihydroretinoic	I-CHEMICAL
acid	I-CHEMICAL
before	O
being	O
oxidized	O
further	O
by	O
Cyp26	B-GENE-Y
enzymes	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
two	O
putative	O
RetSat	B-GENE-Y
homologues	O
in	O
zebrafish	O
,	O
one	O
of	O
which	O
,	O
zebrafish	B-GENE-Y
RetSat	I-GENE-Y
A	I-GENE-Y
(	O
zRetSat	B-GENE-Y
A	I-GENE-Y
)	O
,	O
also	O
had	O
retinol	B-GENE-Y
saturase	I-GENE-Y
activity	O
,	O
whereas	O
zebrafish	B-GENE-Y
RetSat	I-GENE-Y
B	I-GENE-Y
(	O
zRetSat	B-GENE-Y
B	I-GENE-Y
)	O
was	O
inactive	O
under	O
similar	O
conditions	O
.	O

Unlike	O
mouse	B-GENE-Y
RetSat	I-GENE-Y
(	O
mRetSat	B-GENE-Y
)	O
,	O
zRetSat	B-GENE-Y
A	I-GENE-Y
had	O
an	O
altered	O
bond	O
specificity	O
saturating	O
either	O
the	O
13	O
-	O
14	O
or	O
7	O
-	O
8	O
double	O
bonds	O
of	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinol	I-CHEMICAL
to	O
produce	O
either	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
or	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
,	O
respectively	O
.	O

zRetSat	B-GENE-Y
A	I-GENE-Y
also	O
saturated	O
the	O
13	O
-	O
14	O
or	O
7	O
-	O
8	O
double	O
bonds	O
of	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
didehydroretinol	I-CHEMICAL
(	O
vitamin	B-CHEMICAL
A2	I-CHEMICAL
)	O
,	O
a	O
second	O
endogenous	O
form	O
of	O
vitamin	B-CHEMICAL
A	I-CHEMICAL
in	O
zebrafish	O
.	O

The	O
dual	O
enzymatic	O
activity	O
of	O
zRetSat	B-GENE-Y
A	I-GENE-Y
displays	O
a	O
newly	O
acquired	O
specificity	O
for	O
the	O
13	O
-	O
14	O
double	O
bond	O
retained	O
in	O
higher	O
vertebrates	O
and	O
also	O
the	O
evolutionarily	O
preserved	O
activity	O
of	O
bacterial	B-GENE-N
phytoene	I-GENE-N
desaturases	I-GENE-N
and	O
plant	B-GENE-N
carotenoid	I-GENE-N
isomerases	I-GENE-N
.	O

Expression	O
of	O
zRetSat	B-GENE-Y
A	I-GENE-Y
was	O
restricted	O
to	O
the	O
liver	O
and	O
intestine	O
of	O
hatchlings	O
and	O
adult	O
zebrafish	O
,	O
whereas	O
zRetSat	B-GENE-Y
B	I-GENE-Y
was	O
expressed	O
in	O
the	O
same	O
tissues	O
but	O
at	O
earlier	O
developmental	O
stages	O
.	O

Exogenous	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
retinol	I-CHEMICAL
,	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
,	I-CHEMICAL
14	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
,	O
or	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydroretinol	I-CHEMICAL
led	O
to	O
the	O
strong	O
induction	O
of	O
the	O
expression	O
of	O
the	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
-	O
metabolizing	O
enzyme	O
,	O
Cyp26A1	B-GENE-Y
,	O
arguing	O
for	O
an	O
active	O
signaling	O
function	O
of	O
dihydroretinoid	B-CHEMICAL
metabolites	O
in	O
zebrafish	O
.	O

These	O
findings	O
point	O
to	O
a	O
conserved	O
function	O
but	O
altered	O
specificity	O
of	O
RetSat	B-GENE-Y
in	O
vertebrates	O
,	O
leading	O
to	O
the	O
generation	O
of	O
various	O
dihydroretinoid	B-CHEMICAL
compounds	O
,	O
some	O
of	O
which	O
could	O
have	O
signaling	O
functions	O
.	O

Bimodal	O
occurrence	O
of	O
aspartoacylase	B-GENE-Y
in	O
myelin	O
and	O
cytosol	O
of	O
brain	O
.	O

The	O
growing	O
use	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylaspartate	I-CHEMICAL
as	O
an	O
indicator	O
of	O
neuronal	O
viability	O
has	O
fostered	O
interest	O
in	O
the	O
biological	O
function	O
(	O
s	O
)	O
of	O
this	O
unusual	O
amino	B-CHEMICAL
acid	I-CHEMICAL
derivative	O
.	O

In	O
considering	O
the	O
various	O
physiological	O
roles	O
that	O
have	O
been	O
proposed	O
for	O
this	O
relatively	O
abundant	O
molecule	O
one	O
is	O
obliged	O
to	O
take	O
into	O
account	O
its	O
unusual	O
metabolic	O
compartmentalization	O
,	O
according	O
to	O
which	O
synthesis	O
and	O
storage	O
occur	O
in	O
the	O
neuron	O
and	O
hydrolytic	O
cleavage	O
in	O
the	O
oligodendrocyte	O
.	O

The	O
latter	O
reaction	O
,	O
catalyzed	O
by	O
aspartoacylase	B-GENE-Y
(	O
ASPA	B-GENE-Y
)	O
,	O
produces	O
acetyl	B-CHEMICAL
groups	O
plus	O
aspartate	B-CHEMICAL
and	O
has	O
been	O
proposed	O
to	O
occur	O
in	O
both	O
soluble	O
and	O
membranous	O
subfractions	O
of	O
white	O
matter	O
.	O

Our	O
study	O
supports	O
such	O
bimodal	O
occurrence	O
and	O
we	O
now	O
present	O
immunoblot	O
,	O
proteomic	O
,	O
and	O
biochemical	O
evidence	O
that	O
the	O
membrane	O
-	O
bound	O
form	O
of	O
ASPA	B-GENE-Y
is	O
intrinsic	O
to	O
purified	O
myelin	O
membranes	O
.	O

This	O
was	O
supported	O
by	O
a	O
novel	O
TLC	O
-	O
based	O
method	O
for	O
the	O
assay	O
of	O
ASPA	B-GENE-Y
.	O

That	O
observation	O
,	O
together	O
with	O
previous	O
demonstrations	O
of	O
numerous	O
lipid	O
-	O
synthesizing	O
enzymes	O
in	O
myelin	O
,	O
suggests	O
utilization	O
of	O
acetyl	B-CHEMICAL
groups	O
liberated	O
by	O
myelin	O
-	O
localized	O
ASPA	B-GENE-Y
for	O
lipid	O
synthesis	O
within	O
the	O
myelin	O
sheath	O
.	O

Such	O
synthesis	O
might	O
be	O
selective	O
and	O
could	O
explain	O
the	O
deficit	O
of	O
myelin	O
lipids	O
in	O
animals	O
lacking	O
ASPA	B-GENE-N
.	O

Hypoxia	O
and	O
lactate	B-CHEMICAL
production	O
in	O
trophoblast	O
cells	O
.	O

The	O
etiology	O
of	O
preeclampsia	O
is	O
unknown	O
but	O
is	O
thought	O
to	O
be	O
related	O
to	O
hypoxia	O
in	O
the	O
placenta	O
.	O

We	O
previously	O
reported	O
that	O
the	O
enzyme	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
(	O
LDH	B-GENE-N
)	O
has	O
increased	O
activity	O
and	O
gene	O
expression	O
in	O
placentas	O
from	O
preeclamptic	O
pregnancies	O
[	O
Tsoi	O
SCM	O
,	O
Zheng	O
J	O
,	O
Xu	O
F	O
,	O
Kay	O
HH	O
.	O
Differential	O
expression	O
of	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
isozymes	O
(	O
LDH	B-GENE-N
)	O
in	O
human	O
placenta	O
with	O
high	O
expression	O
of	O
LDH	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
isozyme	O
in	O
the	O
endothelial	O
cells	O
of	O
pre	O
-	O
eclampsia	O
villi	O
.	O
Placenta	O
2001	O
;	O
22	O
:	O
317	O
-	O
22	O
]	O
.	O

LDH	B-GENE-N
is	O
responsible	O
for	O
pyruvate	B-CHEMICAL
conversion	O
to	O
lactate	B-CHEMICAL
through	O
glycolysis	O
.	O

In	O
this	O
study	O
,	O
we	O
further	O
investigated	O
the	O
role	O
of	O
hypoxia	O
in	O
primary	O
trophoblast	O
cells	O
and	O
a	O
cultured	O
cell	O
line	O
,	O
JEG3	O
cells	O
,	O
to	O
obtain	O
a	O
better	O
understanding	O
of	O
how	O
it	O
affects	O
the	O
activities	O
of	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
,	O
lactate	B-CHEMICAL
production	O
and	O
regulatory	O
genes	O
,	O
as	O
a	O
possible	O
model	O
for	O
preeclampsia	O
.	O

Primary	O
trophoblast	O
cells	O
and	O
JEG3	O
cells	O
were	O
cultured	O
under	O
1	O
%	O
oxygen	B-CHEMICAL
.	O

At	O
6	O
,	O
12	O
and	O
24h	O
,	O
cells	O
were	O
analyzed	O
for	O
LDHA	B-GENE-Y
and	O
LDHB	B-GENE-Y
isozyme	O
activities	O
,	O
mRNA	O
and	O
protein	O
expression	O
compared	O
to	O
standard	O
culture	O
conditions	O
.	O

Lactate	B-CHEMICAL
was	O
measured	O
from	O
cell	O
medium	O
.	O

The	O
hypoxia	B-GENE-N
inducible	I-GENE-N
transcription	I-GENE-N
factor	I-GENE-N
(	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
)	O
protein	O
expression	O
was	O
confirmed	O
by	O
western	O
blot	O
.	O

Two	O
lactate	B-GENE-N
transporters	I-GENE-N
(	O
MCT1	B-GENE-Y
and	O
MCT4	B-GENE-Y
)	O
mRNA	O
and	O
protein	O
expression	O
were	O
also	O
studied	O
under	O
hypoxia	O
.	O

Finally	O
,	O
lactate	B-CHEMICAL
was	O
measured	O
in	O
plasma	O
obtained	O
from	O
patients	O
with	O
severe	O
preeclampsia	O
.	O

Under	O
hypoxic	O
conditions	O
,	O
LDHA	B-GENE-Y
mRNA	O
is	O
increased	O
in	O
primary	O
trophoblast	O
cells	O
and	O
JEG3	O
cells	O
.	O

The	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
protein	O
expression	O
is	O
higher	O
in	O
hypoxia	O
-	O
treated	O
JEG3	O
cells	O
than	O
control	O
.	O

LDHA	B-GENE-Y
isozyme	O
activity	O
and	O
its	O
protein	O
expression	O
are	O
increased	O
most	O
significantly	O
at	O
24h	O
of	O
culture	O
under	O
hypoxia	O
.	O

However	O
,	O
LDHB	B-GENE-Y
protein	O
is	O
unchanged	O
while	O
its	O
mRNA	O
is	O
decreased	O
.	O

Lactate	B-CHEMICAL
secretion	O
from	O
JEG3	O
cells	O
under	O
hypoxia	O
is	O
increased	O
,	O
as	O
is	O
the	O
lactate	B-CHEMICAL
levels	O
in	O
the	O
plasma	O
from	O
preeclampsia	O
patients	O
.	O

Of	O
the	O
two	O
lactate	B-CHEMICAL
transporters	O
studied	O
,	O
MCT4	B-GENE-Y
mRNA	O
and	O
protein	O
level	O
are	O
increased	O
under	O
hypoxia	O
.	O

Our	O
findings	O
support	O
the	O
role	O
of	O
hypoxia	O
in	O
inducing	O
HIF	B-GENE-Y
-	I-GENE-Y
1alpha	I-GENE-Y
activity	O
in	O
trophoblasts	O
and	O
increasing	O
LDH	B-GENE-N
transcription	O
as	O
well	O
as	O
its	O
activity	O
.	O

Higher	O
levels	O
of	O
lactate	B-CHEMICAL
are	O
produced	O
and	O
secreted	O
which	O
may	O
contribute	O
to	O
the	O
higher	O
lactate	B-CHEMICAL
levels	O
in	O
plasma	O
of	O
preeclamptic	O
patients	O
.	O

These	O
mechanisms	O
may	O
be	O
important	O
in	O
the	O
pathophysiology	O
of	O
preeclampsia	O
.	O

alpha	B-CHEMICAL
-	I-CHEMICAL
Linolenic	I-CHEMICAL
acid	I-CHEMICAL
,	O
Delta6	B-GENE-Y
-	I-GENE-Y
desaturase	I-GENE-Y
gene	O
polymorphism	O
,	O
and	O
the	O
risk	O
of	O
nonfatal	O
myocardial	O
infarction	O
.	O

BACKGROUND	O
:	O
Delta	B-GENE-Y
(	I-GENE-Y
6	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
Desaturase	I-GENE-Y
(	O
FADS2	B-GENE-Y
)	O
is	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
polyunsaturated	B-CHEMICAL
fatty	I-CHEMICAL
acid	I-CHEMICAL
(	O
PUFA	B-CHEMICAL
)	O
biosynthetic	O
pathway	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
test	O
whether	O
the	O
common	O
deletion	O
[	O
T	O
/	O
-	O
]	O
in	O
the	O
promoter	O
of	O
FADS2	B-GENE-Y
affects	O
the	O
PUFA	B-CHEMICAL
biosynthetic	O
pathway	O
and	O
consequently	O
modifies	O
the	O
effect	O
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
(	O
ALA	B-CHEMICAL
)	O
on	O
myocardial	O
infarction	O
(	O
MI	O
)	O
.	O

DESIGN	O
:	O
Case	O
subjects	O
(	O
n	O
=	O
1694	O
)	O
with	O
a	O
first	O
nonfatal	O
acute	O
MI	O
were	O
matched	O
by	O
age	O
,	O
sex	O
,	O
and	O
area	O
of	O
residence	O
to	O
1694	O
population	O
-	O
based	O
control	O
subjects	O
in	O
Costa	O
Rica	O
.	O

PUFAs	B-CHEMICAL
were	O
quantified	O
by	O
gas	O
-	O
liquid	O
chromatography	O
from	O
plasma	O
and	O
adipose	O
tissue	O
samples	O
.	O

Least	O
-	O
squares	O
means	O
from	O
generalized	O
linear	O
models	O
and	O
odds	O
ratios	O
(	O
ORs	O
)	O
and	O
95	O
%	O
CIs	O
from	O
multiple	O
conditional	O
logistic	O
regression	O
models	O
were	O
estimated	O
.	O

RESULTS	O
:	O
The	O
prevalence	O
of	O
the	O
variant	O
T	O
/	O
-	O
allele	O
was	O
48	O
%	O
.	O

Eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
,	O
gamma	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
,	O
and	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
decreased	O
in	O
adipose	O
tissue	O
and	O
plasma	O
with	O
increasing	O
number	O
of	O
copies	O
of	O
the	O
variant	O
allele	O
with	O
a	O
monotonic	O
trend	O
(	O
P	O
<	O
0	O
.	O
05	O
for	O
all	O
)	O
.	O

Fasting	O
plasma	O
triacylglycerols	B-CHEMICAL
by	O
genotype	O
were	O
2	O
.	O
08	O
mmol	O
/	O
L	O
for	O
TT	O
,	O
2	O
.	O
16	O
mmol	O
/	O
L	O
for	O
T	O
-	O
,	O
and	O
2	O
.	O
26	O
mmol	O
/	O
L	O
for	O
-	O
-	O
[	O
ie	O
,	O
homozygous	O
for	O
the	O
variant	O
(	O
deletion	O
)	O
allele	O
]	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
FADS2	B-GENE-Y
deletion	O
was	O
not	O
associated	O
with	O
MI	O
and	O
did	O
not	O
significantly	O
modify	O
the	O
association	O
between	O
adipose	O
tissue	O
ALA	B-CHEMICAL
and	O
the	O
risk	O
of	O
MI	O
.	O

CONCLUSIONS	O
:	O
The	O
FADS2	B-GENE-Y
deletion	O
may	O
prevent	O
the	O
conversion	O
of	O
ALA	B-CHEMICAL
into	O
very	B-CHEMICAL
-	I-CHEMICAL
long	I-CHEMICAL
-	I-CHEMICAL
chain	I-CHEMICAL
PUFAs	I-CHEMICAL
.	O

However	O
,	O
this	O
metabolic	O
effect	O
is	O
not	O
translated	O
into	O
an	O
attenuated	O
risk	O
between	O
ALA	B-CHEMICAL
and	O
MI	O
among	O
carriers	O
of	O
the	O
variant	O
.	O

It	O
is	O
possible	O
that	O
,	O
at	O
current	O
intakes	O
of	O
ALA	B-CHEMICAL
,	O
any	O
potential	O
defect	O
in	O
the	O
transcription	O
of	O
the	O
gene	O
is	O
masked	O
by	O
the	O
availability	O
of	O
substrate	O
.	O

Further	O
research	O
in	O
populations	O
deficient	O
in	O
ALA	B-CHEMICAL
intake	O
is	O
warranted	O
.	O

Characterization	O
of	O
renal	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
.	O

In	O
kidneys	O
,	O
stimulation	O
of	O
adenylyl	B-GENE-N
cyclase	I-GENE-N
causes	O
egress	O
of	O
cAMP	B-CHEMICAL
,	O
conversion	O
of	O
cAMP	B-CHEMICAL
to	O
AMP	B-CHEMICAL
by	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
,	O
and	O
metabolism	O
of	O
AMP	B-CHEMICAL
to	O
adenosine	B-CHEMICAL
by	O
ecto	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
nucleotidase	I-GENE-Y
.	O

Although	O
much	O
is	O
known	O
about	O
ecto	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
'	I-GENE-Y
-	I-GENE-Y
nucleotidase	I-GENE-Y
,	O
the	O
renal	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
remains	O
uncharacterized	O
.	O

We	O
administered	O
cAMP	B-CHEMICAL
(	O
10	O
microM	O
in	O
the	O
perfusate	O
)	O
to	O
12	O
different	O
groups	O
of	O
perfused	O
kidneys	O
.	O

AMP	B-CHEMICAL
was	O
measured	O
in	O
perfusate	O
using	O
ion	O
trap	O
mass	O
spectrometry	O
.	O

In	O
control	O
kidneys	O
(	O
n	O
=	O
19	O
)	O
,	O
basal	O
renal	O
secretion	O
rate	O
of	O
AMP	B-CHEMICAL
was	O
0	O
.	O
49	O
+	O
/	O
-	O
0	O
.	O
08	O
and	O
increased	O
to	O
3	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
nmol	O
AMP	B-CHEMICAL
/	O
g	O
kidney	O
weight	O
/	O
min	O
during	O
administration	O
of	O
cAMP	B-CHEMICAL
.	O

A	O
broad	O
-	O
spectrum	O
phosphodiesterase	B-GENE-N
(	O
PDE	B-GENE-N
)	O
inhibitor	O
(	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
isobutyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methylxanthine	I-CHEMICAL
,	O
300	O
microM	O
,	O
n	O
=	O
6	O
)	O
and	O
an	O
ecto	O
-	O
phosphodiesterase	O
inhibitor	O
(	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dipropyl	I-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
sulfophenylxanthine	I-CHEMICAL
,	O
1	O
mM	O
,	O
n	O
=	O
6	O
)	O
significantly	O
attenuated	O
cAMP	B-CHEMICAL
-	O
induced	O
AMP	B-CHEMICAL
secretion	O
by	O
60	O
and	O
74	O
%	O
,	O
respectively	O
.	O

Blockade	O
of	O
PDE1	B-GENE-N
(	O
8	B-CHEMICAL
-	I-CHEMICAL
methoxymethyl	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
isobutyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methylxanthine	I-CHEMICAL
,	O
100	O
microM	O
)	O
,	O
PDE2	B-GENE-N
[	O
erythro	B-CHEMICAL
-	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
nonyl	I-CHEMICAL
)	I-CHEMICAL
adenine	I-CHEMICAL
,	O
30	O
microM	O
]	O
,	O
PDE3	B-GENE-N
(	O
milrinone	B-CHEMICAL
,	O
10	O
microM	O
;	O
cGMP	O
,	O
10	O
microM	O
)	O
,	O
PDE4	B-GENE-N
(	O
Ro	O
20	O
-	O
1724	O
[	O
4	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
butoxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methoxybenzyl	I-CHEMICAL
)	I-CHEMICAL
imidazolidin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
]	O
,	O
100	O
microM	O
)	O
,	O
PDE5	B-GENE-Y
and	O
PDE6	B-GENE-N
(	O
zaprinast	B-CHEMICAL
,	O
30	O
microM	O
)	O
,	O
and	O
PDE7	B-GENE-N
[	O
BRL	B-CHEMICAL
-	I-CHEMICAL
50481	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
trimethylbenzenesulfonamide	I-CHEMICAL
)	O
,	O
10	O
microM	O
]	O
did	O
not	O
alter	O
renal	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
activity	O
.	O

Administration	O
of	O
a	O
concentration	O
(	O
100	O
microM	O
)	O
of	O
dipyridamole	B-CHEMICAL
that	O
blocks	O
PDE8	B-GENE-N
inhibited	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
activity	O
(	O
by	O
44	O
%	O
)	O
.	O

However	O
,	O
a	O
lower	O
concentration	O
of	O
dipyridamole	B-CHEMICAL
(	O
3	O
microM	O
)	O
that	O
blocks	O
PDE9	B-GENE-N
,	O
PDE10	B-GENE-Y
,	O
and	O
PDE11	B-GENE-Y
,	O
but	O
not	O
PDE8	B-GENE-N
,	O
did	O
not	O
inhibit	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
activity	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
renal	O
ecto	O
-	O
phosphodiesterase	B-GENE-N
activity	O
is	O
not	O
mediated	O
by	O
PDE1	B-GENE-N
,	O
PDE2	B-GENE-N
,	O
PDE3	B-GENE-N
,	O
PDE4	B-GENE-N
,	O
PDE5	B-GENE-Y
,	O
PDE6	B-GENE-N
,	O
PDE7	B-GENE-N
,	O
PDE9	B-GENE-N
,	O
PDE10	B-GENE-Y
,	O
or	O
PDE11	B-GENE-Y
and	O
is	O
inhibited	O
by	O
high	O
concentrations	O
of	O
dipyridamole	B-CHEMICAL
.	O

Ecto	O
-	O
phosphodiesterase	B-GENE-N
has	O
some	O
pharmacological	O
characteristics	O
similar	O
to	O
PDE8	O
.	O

Genetic	O
linkage	O
of	O
Fc	B-GENE-Y
gamma	I-GENE-Y
RIIa	I-GENE-Y
and	O
Fc	B-GENE-Y
gamma	I-GENE-Y
RIIIa	I-GENE-Y
and	O
implications	O
for	O
their	O
use	O
in	O
predicting	O
clinical	O
responses	O
to	O
CD20	B-GENE-Y
-	O
directed	O
monoclonal	O
antibody	O
therapy	O
.	O

BACKGROUND	O
:	O
Polymorphisms	O
in	O
FcgammaRIIa	B-GENE-Y
and	O
FcgammaRIIIa	B-GENE-Y
receptors	O
are	O
associated	O
with	O
responses	O
to	O
the	O
CD20	B-GENE-Y
-	O
directed	O
immunoglobulin	B-GENE-Y
G1	I-GENE-Y
(	O
IgG1	B-GENE-Y
)	O
monoclonal	O
antibody	O
rituximab	O
among	O
patients	O
with	O
indolent	O
lymphoma	O
.	O

At	O
odds	O
with	O
the	O
aforementioned	O
clinical	O
observations	O
has	O
been	O
the	O
finding	O
that	O
IgG1	B-GENE-Y
binding	O
is	O
impacted	O
by	O
polymorphisms	O
in	O
FcgammaRIIIa	B-GENE-Y
but	O
not	O
FcgammaRIIa	B-GENE-Y
.	O

One	O
possibility	O
for	O
this	O
discrepancy	O
might	O
involve	O
linkage	O
of	O
polymorphisms	O
between	O
FcgammaRIIa	B-GENE-Y
and	O
FcgammaRIIIa	B-GENE-Y
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
As	O
such	O
,	O
we	O
performed	O
allelespecific	O
polymerase	O
chain	O
reaction	O
and	O
directed	O
sequencing	O
of	O
the	O
genomic	O
DNA	O
coding	O
region	O
of	O
FcgammaRIIA	B-GENE-Y
and	O
FcgammaRIIIA	B-GENE-Y
for	O
52	O
healthy	O
individuals	O
.	O

RESULTS	O
:	O
Two	O
common	O
polymorphisms	O
were	O
observed	O
for	O
FcgammaRIIA	B-GENE-Y
(	O
at	O
positions	O
27	O
and	O
131	O
)	O
and	O
FcgammaRIIIA	B-GENE-Y
(	O
at	O
positions	O
48	O
and	O
158	O
)	O
.	O

Importantly	O
,	O
we	O
observed	O
linkage	O
among	O
polymorphisms	O
within	O
and	O
between	O
FcgammaRIIa	B-GENE-Y
and	O
FcgammaRIIIa	B-GENE-Y
,	O
including	O
the	O
expression	O
of	O
histidine	O
at	O
FcgammaRIIa	B-GENE-Y
-	O
131	O
and	O
valine	O
at	O
FcgammaRIIIa	B-GENE-Y
,	O
both	O
of	O
which	O
are	O
associated	O
with	O
enhanced	O
responses	O
to	O
rituximab	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrate	O
that	O
there	O
is	O
wide	O
linkage	O
within	O
and	O
between	O
polymorphisms	O
in	O
FcgammaRIIa	B-GENE-Y
and	O
FcgammaRIIIa	B-GENE-Y
and	O
might	O
provide	O
an	O
explanation	O
for	O
why	O
polymorphisms	O
at	O
FcgammaRIIa	B-GENE-Y
are	O
associated	O
with	O
rituximab	O
responses	O
despite	O
a	O
lack	O
of	O
impact	O
on	O
IgG1	B-GENE-Y
binding	O
.	O

CONCLUSION	O
:	O
Knowledge	O
of	O
such	O
linkages	O
could	O
facilitate	O
the	O
development	O
of	O
diagnostic	O
tests	O
aimed	O
at	O
identifying	O
patients	O
who	O
might	O
be	O
more	O
suitable	O
for	O
treatment	O
with	O
rituximab	O
and	O
possibly	O
other	O
therapeutic	O
antibodies	O
.	O

Identification	O
of	O
a	O
novel	O
polymorphism	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
L	B-GENE-N
-	I-GENE-N
arginine	I-GENE-N
transporter	I-GENE-N
gene	O
SLC7A1	B-GENE-Y
:	O
contribution	O
to	O
hypertension	O
and	O
endothelial	O
dysfunction	O
.	O

BACKGROUND	O
:	O
Endothelial	O
dysfunction	O
because	O
of	O
reduced	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
bioavailability	O
is	O
a	O
key	O
feature	O
of	O
essential	O
hypertension	O
.	O

We	O
have	O
found	O
that	O
normotensive	O
siblings	O
of	O
subjects	O
with	O
essential	O
hypertension	O
have	O
impaired	O
endothelial	O
function	O
accompanied	O
by	O
altered	O
arginine	B-CHEMICAL
metabolism	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
have	O
identified	O
a	O
novel	O
C	O
/	O
T	O
polymorphism	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
principal	O
arginine	B-GENE-N
transporter	I-GENE-N
,	I-GENE-N
solute	I-GENE-N
carrier	I-GENE-N
family	I-GENE-N
7	I-GENE-N
(	I-GENE-N
cationic	I-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporter	I-GENE-N
,	I-GENE-N
y	I-GENE-N
+	I-GENE-N
system	I-GENE-N
)	I-GENE-N
,	I-GENE-N
member	I-GENE-N
1	I-GENE-N
gene	I-GENE-N
(	O
SLC7A1	B-GENE-Y
)	O
.	O

The	O
minor	O
T	O
allele	O
significantly	O
attenuates	O
reporter	O
gene	O
expression	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
is	O
impaired	O
in	O
its	O
capacity	O
to	O
form	O
DNA	O
-	O
protein	O
complexes	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
278	O
hypertensive	O
subjects	O
the	O
frequency	O
of	O
the	O
T	O
allele	O
was	O
13	O
.	O
3	O
%	O
compared	O
with	O
7	O
.	O
6	O
%	O
in	O
498	O
normotensive	O
subjects	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
the	O
overall	O
genotype	O
distribution	O
observed	O
in	O
hypertensives	O
differed	O
significantly	O
from	O
that	O
in	O
normotensives	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

To	O
complement	O
these	O
studies	O
,	O
we	O
generated	O
an	O
endothelial	O
-	O
specific	O
transgenic	O
mouse	O
overexpressing	O
L	B-GENE-N
-	I-GENE-N
arginine	I-GENE-N
transporter	I-GENE-N
SLC7A1	B-GENE-Y
.	O

The	O
Slc7A1	B-GENE-Y
transgenic	O
mice	O
exhibited	O
significantly	O
enhanced	O
responses	O
to	O
the	O
endothelium	O
-	O
dependent	O
vasodilator	O
acetylcholine	B-CHEMICAL
(	O
-	O
log	O
EC50	O
for	O
wild	O
-	O
type	O
versus	O
Slc7A1	B-GENE-Y
transgenic	O
:	O
6	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
10	O
versus	O
7	O
.	O
56	O
+	O
/	O
-	O
0	O
.	O
13	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
was	O
accompanied	O
by	O
elevated	O
production	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
by	O
isolated	O
aortic	O
endothelial	O
cells	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
identifies	O
a	O
key	O
,	O
functionally	O
active	O
polymorphism	O
in	O
the	O
3	O
'	O
UTR	O
of	O
SLC7A1	B-GENE-Y
.	O

As	O
such	O
,	O
this	O
polymorphism	O
may	O
account	O
for	O
the	O
apparent	O
link	O
between	O
altered	O
endothelial	O
function	O
,	O
L	B-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
,	O
and	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
metabolism	O
and	O
predisposition	O
to	O
essential	O
hypertension	O
.	O

A	O
novel	O
tyrosine	B-GENE-N
kinase	I-GENE-N
switch	O
is	O
a	O
mechanism	O
of	O
imatinib	B-CHEMICAL
resistance	O
in	O
gastrointestinal	O
stromal	O
tumors	O
.	O

KIT	B-GENE-Y
or	O
alpha	B-GENE-Y
-	I-GENE-Y
platelet	I-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
alpha	B-GENE-Y
-	I-GENE-Y
PDGFR	I-GENE-Y
)	O
activating	O
mutations	O
are	O
the	O
pathogenic	O
mechanisms	O
that	O
characterize	O
gastrointestinal	O
stromal	O
tumors	O
(	O
GIST	O
)	O
.	O

Despite	O
excellent	O
responses	O
to	O
imatinib	B-CHEMICAL
mesylate	I-CHEMICAL
(	O
IM	B-CHEMICAL
)	O
,	O
patients	O
are	O
relapsing	O
.	O

We	O
developed	O
an	O
IM	B-CHEMICAL
-	O
resistant	O
GIST	O
cell	O
line	O
(	O
GIST	O
-	O
R	O
)	O
from	O
the	O
IM	B-CHEMICAL
-	O
sensitive	O
GIST882	O
cell	O
line	O
(	O
GIST	O
-	O
S	O
)	O
by	O
growing	O
these	O
cells	O
in	O
IM	B-CHEMICAL
.	O

Gene	O
expression	O
profiling	O
(	O
GEP	O
)	O
of	O
GIST	O
-	O
S	O
,	O
GIST	O
-	O
R	O
cells	O
and	O
two	O
IM	B-CHEMICAL
resistant	O
GIST	O
patients	O
demonstrated	O
that	O
KIT	B-GENE-Y
is	O
downregulated	O
implying	O
a	O
major	O
role	O
in	O
IM	B-CHEMICAL
resistance	O
.	O

Instead	O
,	O
GIST	O
-	O
R	O
cells	O
have	O
acquired	O
IM	B-CHEMICAL
resistance	O
by	O
overexpressing	O
the	O
oncogenic	B-GENE-N
receptor	I-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
-	O
AXL	B-GENE-Y
-	O
in	O
a	O
'	O
kinase	B-GENE-N
switch	O
'	O
.	O

Further	O
,	O
the	O
two	O
IM	B-CHEMICAL
resistant	O
GIST	O
patients	O
express	O
AXL	B-GENE-Y
and	O
not	O
c	B-GENE-Y
-	I-GENE-Y
Kit	I-GENE-Y
,	O
seen	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Real	O
time	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
Western	O
blotting	O
of	O
the	O
GIST	O
-	O
S	O
and	O
GIST	O
-	O
R	O
cells	O
confirmed	O
the	O
switch	O
from	O
Kit	B-GENE-Y
to	O
AXL	B-GENE-Y
.	O

In	O
GIST	O
-	O
R	O
,	O
AXL	B-GENE-Y
is	O
tyrosine	B-CHEMICAL
phosphorylated	O
and	O
its	O
ligand	O
growth	B-GENE-Y
-	I-GENE-Y
arrest	I-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
gene	I-GENE-Y
6	I-GENE-Y
is	O
overexpressed	O
implying	O
autocrine	O
activation	O
.	O

The	O
kinase	B-GENE-N
switch	O
is	O
associated	O
with	O
a	O
morphological	O
change	O
from	O
spindle	O
to	O
epithelioid	O
.	O

Molecular	O
modeling	O
of	O
the	O
kinase	B-GENE-N
domain	I-GENE-N
of	O
mutant	O
c	B-GENE-Y
-	I-GENE-Y
Kit	I-GENE-Y
(	O
V654A	B-GENE-N
)	O
and	O
AXL	B-GENE-Y
showed	O
no	O
binding	O
to	O
IM	B-CHEMICAL
but	O
efficient	O
binding	O
to	O
MP470	B-CHEMICAL
,	O
a	O
novel	O
c	B-GENE-Y
-	I-GENE-Y
Kit	I-GENE-Y
/	O
AXL	B-GENE-Y
kinase	B-GENE-N
inhibitor	O
.	O

MP470	B-CHEMICAL
synergizes	O
with	O
docetaxel	B-CHEMICAL
(	O
taxotere	B-CHEMICAL
)	O
and	O
is	O
cytotoxic	O
to	O
GIST	O
cells	O
.	O

Induction	O
of	O
cyp1a1	B-GENE-Y
is	O
a	O
nonspecific	O
biomarker	O
of	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
activation	O
:	O
results	O
of	O
large	O
scale	O
screening	O
of	O
pharmaceuticals	O
and	O
toxicants	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Expression	O
of	O
Cyp1a1	B-GENE-Y
and	O
its	O
related	O
enzyme	O
activity	O
have	O
long	O
been	O
used	O
as	O
a	O
biomarker	O
for	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AhR	B-GENE-Y
)	O
activation	O
and	O
a	O
warning	O
of	O
dioxin	B-CHEMICAL
-	O
like	O
toxicity	O
.	O

As	O
a	O
result	O
,	O
induction	O
of	O
Cyp1a1	B-GENE-Y
by	O
pharmaceutical	O
drug	O
candidates	O
or	O
environmental	O
contaminants	O
raises	O
significant	O
concern	O
in	O
risk	O
assessment	O
.	O

The	O
current	O
study	O
evaluates	O
the	O
specificity	O
of	O
Cyp1a1	B-GENE-Y
induction	O
as	O
a	O
marker	O
for	O
AhR	B-GENE-Y
affinity	O
and	O
activation	O
and	O
provides	O
context	O
to	O
assess	O
the	O
relevancy	O
of	O
AhR	B-GENE-Y
activation	O
to	O
risk	O
assessment	O
.	O

In	O
vivo	O
experiments	O
examined	O
the	O
expression	O
of	O
Cyp1a1	B-GENE-Y
and	O
other	O
AhR	B-GENE-Y
-	O
regulated	O
genes	O
in	O
liver	O
,	O
kidney	O
,	O
and	O
heart	O
in	O
response	O
to	O
596	O
compounds	O
.	O

From	O
this	O
data	O
set	O
,	O
a	O
subset	O
of	O
147	O
compounds	O
was	O
then	O
evaluated	O
for	O
their	O
ability	O
to	O
activate	O
or	O
bind	O
to	O
the	O
AhR	B-GENE-Y
using	O
a	O
combination	O
of	O
gel	O
shift	O
,	O
reporter	O
gene	O
,	O
and	O
competitive	O
receptor	O
binding	O
assays	O
.	O

Whereas	O
in	O
vivo	O
Cyp1a1	B-GENE-Y
mRNA	O
expression	O
is	O
a	O
sensitive	O
marker	O
for	O
AhR	B-GENE-Y
activation	O
,	O
it	O
lacks	O
specificity	O
,	O
because	O
81	O
(	O
59	O
%	O
)	O
of	O
137	O
compounds	O
were	O
found	O
to	O
significantly	O
induce	O
Cyp1a1	B-GENE-Y
in	O
vivo	O
but	O
were	O
not	O
verified	O
to	O
bind	O
or	O
activate	O
the	O
AhR	B-GENE-Y
in	O
vitro	O
.	O

Combining	O
in	O
vivo	O
and	O
in	O
vitro	O
findings	O
,	O
we	O
identified	O
nine	O
AhR	B-GENE-Y
agonists	O
,	O
six	O
of	O
which	O
are	O
marketed	O
therapeutics	O
and	O
have	O
been	O
approved	O
by	O
the	O
U	O
.	O
S	O
.	O

Food	O
and	O
Drug	O
Administration	O
,	O
including	O
leflunomide	B-CHEMICAL
,	O
flutamide	B-CHEMICAL
,	O
and	O
nimodipine	B-CHEMICAL
.	O

These	O
drugs	O
do	O
not	O
produce	O
dioxin	B-CHEMICAL
-	O
like	O
toxicity	O
in	O
rats	O
or	O
in	O
humans	O
.	O

These	O
data	O
demonstrate	O
that	O
induction	O
of	O
Cyp1a1	B-GENE-Y
is	O
a	O
nonspecific	O
biomarker	O
of	O
direct	O
AhR	B-GENE-Y
affinity	O
and	O
activation	O
and	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
Cyp1a1	B-GENE-Y
induction	O
and	O
/	O
or	O
AhR	B-GENE-Y
activation	O
is	O
not	O
synonymous	O
with	O
dioxin	B-CHEMICAL
-	O
like	O
toxicity	O
.	O

Antipsychotic	O
profile	O
of	O
rolipram	B-CHEMICAL
:	O
efficacy	O
in	O
rats	O
and	O
reduced	O
sensitivity	O
in	O
mice	O
deficient	O
in	O
the	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
4B	I-GENE-Y
(	O
PDE4B	B-GENE-Y
)	O
enzyme	O
.	O

RATIONALE	O
:	O
Recent	O
studies	O
provide	O
evidence	O
for	O
reduced	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
4B	I-GENE-Y
(	O
PDE4B	B-GENE-Y
)	O
as	O
a	O
genetic	O
susceptibility	O
factor	O
as	O
well	O
as	O
suggesting	O
an	O
association	O
of	O
several	O
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
in	O
PDE4B	B-GENE-Y
that	O
are	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
schizophrenia	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
activity	O
of	O
rolipram	B-CHEMICAL
,	O
a	O
nonsubtype	O
-	O
selective	O
PDE4	B-GENE-N
inhibitor	O
,	O
in	O
several	O
animal	O
models	O
predictive	O
of	O
antipsychotic	O
-	O
like	O
efficacy	O
and	O
side	O
-	O
effect	O
liability	O
and	O
to	O
use	O
PDE4B	B-GENE-Y
wild	O
-	O
type	O
and	O
knockout	O
mice	O
to	O
begin	O
to	O
understand	O
the	O
subtypes	O
involved	O
in	O
the	O
activity	O
of	O
rolipram	B-CHEMICAL
.	O

RESULTS	O
:	O
In	O
rats	O
,	O
rolipram	B-CHEMICAL
antagonized	O
both	O
phencyclidine	B-CHEMICAL
hydrochloride	I-CHEMICAL
-	O
and	O
D	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
-	O
induced	O
hyperactivity	O
and	O
inhibited	O
conditioned	O
avoidance	O
responding	O
(	O
CAR	O
)	O
.	O

In	O
PDE4B	B-GENE-Y
wild	O
-	O
type	O
mice	O
,	O
rolipram	B-CHEMICAL
dose	O
-	O
dependently	O
suppressed	O
CAR	O
(	O
ED	O
(	O
50	O
)	O
=	O
2	O
.	O
4	O
mg	O
/	O
kg	O
)	O
;	O
however	O
,	O
in	O
knockout	O
mice	O
,	O
their	O
sensitivity	O
to	O
rolipram	B-CHEMICAL
at	O
the	O
higher	O
doses	O
(	O
1	O
.	O
0	O
and	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
was	O
reduced	O
,	O
resulting	O
in	O
a	O
threefold	O
shift	O
in	O
the	O
ED	O
(	O
50	O
)	O
(	O
7	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
suggesting	O
PDE4B	B-GENE-Y
is	O
involved	O
,	O
at	O
least	O
in	O
part	O
,	O
with	O
the	O
activity	O
of	O
rolipram	B-CHEMICAL
.	O

Only	O
the	O
highest	O
dose	O
of	O
rolipram	B-CHEMICAL
(	O
3	O
.	O
2	O
mg	O
/	O
kg	O
)	O
produced	O
a	O
modest	O
but	O
significant	O
degree	O
of	O
catalepsy	O
.	O

CONCLUSIONS	O
:	O
Rolipram	B-CHEMICAL
has	O
a	O
pharmacologic	O
profile	O
similar	O
to	O
that	O
of	O
the	O
atypical	O
antipsychotics	O
and	O
has	O
low	O
extrapyramidal	O
symptom	O
liability	O
.	O

These	O
results	O
suggest	O
that	O
PDE4B	B-GENE-Y
mediates	O
the	O
antipsychotic	O
effects	O
of	O
rolipram	B-CHEMICAL
in	O
CAR	O
and	O
that	O
the	O
PDE4B	B-GENE-Y
-	O
regulated	O
cyclic	B-CHEMICAL
adenosine	I-CHEMICAL
monophosphate	I-CHEMICAL
signaling	O
pathway	O
may	O
play	O
a	O
role	O
in	O
the	O
pathophysiology	O
and	O
pharmacotherapy	O
of	O
psychosis	O
.	O

Xanthurenic	O
aciduria	O
due	O
to	O
a	O
mutation	O
in	O
KYNU	B-GENE-Y
encoding	O
kynureninase	B-GENE-Y
.	O

Massive	O
urinary	O
excretion	O
of	O
xanthurenic	B-CHEMICAL
acid	I-CHEMICAL
,	O
3	B-CHEMICAL
-	I-CHEMICAL
hydroxykynurenine	I-CHEMICAL
and	O
kynurenine	B-CHEMICAL
,	O
known	O
as	O
xanthurenic	O
aciduria	O
or	O
hydroxykynureninuria	O
,	O
in	O
a	O
young	O
Somali	O
boy	O
suggested	O
kynureninase	B-GENE-Y
deficiency	O
.	O

Mutation	O
analysis	O
of	O
KYNU	B-GENE-Y
encoding	O
kynureninase	B-GENE-Y
of	O
the	O
index	O
case	O
revealed	O
homozygosity	O
for	O
a	O
c	O
.	O
593	O
A	B-GENE-N
>	I-GENE-N
G	I-GENE-N
substitution	O
leading	O
to	O
a	O
threonine	B-GENE-N
-	I-GENE-N
to	I-GENE-N
-	I-GENE-N
alanine	I-GENE-N
(	O
T198A	B-GENE-N
)	O
shift	O
.	O

A	O
younger	O
brother	O
was	O
found	O
to	O
have	O
a	O
similar	O
excretion	O
pattern	O
and	O
the	O
same	O
genotype	O
.	O

At	O
present	O
,	O
neither	O
of	O
the	O
two	O
boys	O
has	O
symptoms	O
of	O
niacin	O
deficiency	O
.	O

This	O
is	O
the	O
first	O
report	O
linking	O
xanthurenic	O
aciduria	O
to	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
kynureninase	B-GENE-Y
.	O

Sitagliptin	B-CHEMICAL
.	O

Sitagliptin	B-CHEMICAL
,	O
an	O
oral	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
DPP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
inhibitor	O
,	O
improves	O
glycaemic	O
control	O
by	O
inhibiting	O
DPP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
inactivation	O
of	O
the	O
incretin	B-GENE-N
hormones	I-GENE-N
glucagon	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
glucose	B-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
insulinotropic	I-GENE-Y
polypeptide	I-GENE-Y
.	O

This	O
increases	O
active	O
incretin	B-GENE-N
and	O
insulin	B-GENE-Y
levels	O
,	O
and	O
decreases	O
glucagon	B-GENE-Y
levels	O
and	O
post	O
-	O
glucose	B-CHEMICAL
-	O
load	O
glucose	B-CHEMICAL
excursion	O
.	O

In	O
large	O
,	O
well	O
designed	O
phase	O
III	O
trials	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
,	O
sitagliptin	B-CHEMICAL
100	O
or	O
200mg	O
once	O
daily	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antihyperglycaemics	O
was	O
associated	O
with	O
significant	O
improvements	O
relative	O
to	O
placebo	O
in	O
overall	O
glycaemic	O
control	O
and	O
indices	O
for	O
insulin	B-GENE-Y
response	O
and	O
beta	O
-	O
cell	O
function	O
.	O

Improvements	O
from	O
baseline	O
in	O
mean	O
glycosylated	B-GENE-Y
haemoglobin	I-GENE-Y
(	O
HbA	B-GENE-Y
(	I-GENE-Y
1c	I-GENE-Y
)	I-GENE-Y
)	O
were	O
significantly	O
greater	O
with	O
sitagliptin	B-CHEMICAL
monotherapy	O
than	O
with	O
placebo	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

As	O
add	O
-	O
on	O
therapy	O
in	O
patients	O
with	O
suboptimal	O
glycaemic	O
control	O
despite	O
oral	O
antihyperglycaemic	O
treatment	O
,	O
sitagliptin	B-CHEMICAL
improved	O
HbA	B-GENE-Y
(	I-GENE-Y
1c	I-GENE-Y
)	I-GENE-Y
to	O
a	O
significantly	O
greater	O
extent	O
than	O
placebo	O
when	O
added	O
to	O
metformin	B-CHEMICAL
or	O
pioglitazone	B-CHEMICAL
and	O
was	O
noninferior	O
to	O
glipizide	B-CHEMICAL
when	O
added	O
to	O
metformin	B-CHEMICAL
.	O

Sitagliptin	B-CHEMICAL
was	O
well	O
tolerated	O
when	O
administered	O
alone	O
or	O
in	O
combination	O
with	O
other	O
antihyperglycaemics	O
,	O
with	O
an	O
adverse	O
event	O
profile	O
similar	O
to	O
that	O
shown	O
with	O
placebo	O
.	O

The	O
incidence	O
of	O
hypoglycaemia	O
with	O
sitagliptin	B-CHEMICAL
was	O
similar	O
to	O
that	O
with	O
placebo	O
and	O
,	O
in	O
combination	O
with	O
metformin	B-CHEMICAL
,	O
lower	O
than	O
that	O
with	O
glipizide	B-CHEMICAL
.	O

Sitagliptin	B-CHEMICAL
had	O
a	O
generally	O
neutral	O
effect	O
on	O
bodyweight	O
.	O

alpha7	B-GENE-N
nicotinic	I-GENE-N
receptor	I-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
polymorphisms	O
in	O
inbred	O
mice	O
affect	O
expression	O
in	O
a	O
cell	O
type	O
-	O
specific	O
fashion	O
.	O

Inbred	O
mouse	O
strains	O
display	O
significant	O
differences	O
in	O
their	O
levels	O
of	O
brain	O
alpha7	B-GENE-Y
nicotinic	I-GENE-Y
acetylcholine	I-GENE-Y
receptor	I-GENE-Y
(	O
alpha7	B-GENE-Y
nAChR	I-GENE-Y
)	O
expression	O
,	O
as	O
measured	O
by	O
binding	O
of	O
the	O
alpha7	O
-	O
selective	O
antagonist	O
alpha	O
-	O
bungarotoxin	O
.	O

Variations	O
in	O
alpha	B-GENE-Y
-	I-GENE-Y
bungarotoxin	I-GENE-Y
binding	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
an	O
animal	O
'	O
s	O
sensitivity	O
to	O
nicotine	B-CHEMICAL
-	O
induced	O
seizures	O
and	O
sensory	O
gating	O
.	O

In	O
two	O
inbred	O
mouse	O
strains	O
,	O
C3H	O
/	O
2Ibg	O
(	O
C3H	O
)	O
and	O
DBA	O
/	O
2Ibg	O
(	O
DBA	O
/	O
2	O
)	O
,	O
the	O
inter	O
-	O
strain	O
binding	O
differences	O
are	O
linked	O
to	O
a	O
restriction	O
length	O
polymorphism	O
in	O
the	O
alpha7	B-GENE-Y
nAChR	I-GENE-Y
gene	O
,	O
Chrna7	B-GENE-Y
.	O

Despite	O
this	O
finding	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
through	O
which	O
genetic	O
variability	O
in	O
Chrna7	B-GENE-Y
may	O
contribute	O
to	O
alpha7	B-GENE-Y
nAChR	I-GENE-Y
expression	O
differences	O
remains	O
unknown	O
.	O

However	O
,	O
studies	O
of	O
the	O
human	B-GENE-Y
alpha7	I-GENE-Y
nAChR	I-GENE-Y
gene	O
(	O
CHRNA7	B-GENE-Y
)	O
previously	O
have	O
demonstrated	O
that	O
CHRNA7	B-GENE-N
promoter	I-GENE-N
polymorphisms	O
are	O
associated	O
with	O
differences	O
in	O
promoter	O
activity	O
as	O
well	O
as	O
differences	O
in	O
sensory	O
processing	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
947	O
-	O
base	O
pair	O
region	O
of	O
the	O
Chrna7	B-GENE-N
promoter	I-GENE-N
was	O
cloned	O
from	O
both	O
the	O
C3H	O
and	O
DBA	O
/	O
2	O
inbred	O
mouse	O
strains	O
in	O
an	O
attempt	O
to	O
identify	O
polymorphisms	O
that	O
may	O
underlie	O
alpha7	B-GENE-Y
nAChR	I-GENE-Y
differential	O
expression	O
.	O

Sequence	O
analysis	O
of	O
these	O
fragments	O
identified	O
14	O
single	O
nucleotide	B-CHEMICAL
polymorphisms	O
(	O
SNPs	O
)	O
.	O

A	O
combination	O
of	O
two	O
of	O
these	O
SNPs	O
affects	O
promoter	O
activity	O
in	O
an	O
in	O
vitro	O
luciferase	O
reporter	O
assay	O
.	O

These	O
results	O
suggest	O
a	O
mechanism	O
through	O
which	O
the	O
Chrna7	B-GENE-N
promoter	I-GENE-N
genotype	O
may	O
influence	O
interstrain	O
variations	O
in	O
alpha7	B-GENE-Y
nAChR	I-GENE-Y
expression	O
.	O

A	O
single	O
residue	O
in	O
leucyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
affecting	O
amino	B-CHEMICAL
acid	I-CHEMICAL
specificity	O
and	O
tRNA	O
aminoacylation	O
.	O

Human	B-GENE-Y
mitochondrial	I-GENE-Y
leucyl	I-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
(	O
hs	B-GENE-Y
mt	I-GENE-Y
LeuRS	I-GENE-Y
)	O
achieves	O
high	O
aminoacylation	O
fidelity	O
without	O
a	O
functional	O
editing	O
active	O
site	O
,	O
representing	O
a	O
rare	O
example	O
of	O
a	O
class	B-GENE-N
I	I-GENE-N
aminoacyl	I-GENE-N
-	I-GENE-N
tRNA	I-GENE-N
synthetase	I-GENE-N
(	O
aaRS	B-GENE-N
)	O
that	O
does	O
not	O
proofread	O
its	O
products	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
enzyme	O
achieves	O
high	O
selectivity	O
by	O
using	O
a	O
more	O
specific	O
synthetic	O
active	O
site	O
that	O
is	O
not	O
prone	O
to	O
errors	O
under	O
physiological	O
conditions	O
.	O

Interestingly	O
,	O
the	O
synthetic	O
active	O
site	O
of	O
hs	B-GENE-Y
mt	I-GENE-Y
LeuRS	I-GENE-Y
displays	O
a	O
high	O
degree	O
of	O
homology	O
with	O
prokaryotic	O
,	O
lower	O
eukaryotic	O
,	O
and	O
other	O
mitochondrial	O
LeuRSs	B-GENE-Y
that	O
are	O
less	O
specific	O
.	O

However	O
,	O
there	O
is	O
one	O
residue	O
that	O
differs	O
between	O
hs	B-GENE-N
mt	I-GENE-N
and	I-GENE-N
Escherichia	I-GENE-N
coli	I-GENE-N
LeuRSs	I-GENE-N
located	O
on	O
a	O
flexible	O
closing	O
loop	O
near	O
the	O
signature	O
KMSKS	B-GENE-N
motif	I-GENE-N
.	O

Here	O
we	O
describe	O
studies	O
indicating	O
that	O
this	O
particular	O
residue	O
(	O
K600	O
in	O
hs	B-GENE-Y
mt	I-GENE-Y
LeuRS	I-GENE-Y
and	O
L570	O
in	O
E	B-GENE-Y
.	I-GENE-Y
coli	I-GENE-Y
LeuRS	I-GENE-Y
)	O
strongly	O
impacts	O
aminoacylation	O
in	O
two	O
ways	O
:	O
it	O
affects	O
both	O
amino	B-CHEMICAL
acid	I-CHEMICAL
discrimination	O
and	O
transfer	O
RNA	O
(	O
tRNA	O
)	O
binding	O
.	O

While	O
this	O
residue	O
may	O
not	O
be	O
in	O
direct	O
contact	O
with	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
or	O
tRNA	O
substrate	O
,	O
substitutions	O
of	O
this	O
position	O
in	O
both	O
enzymes	O
lead	O
to	O
altered	O
catalytic	O
efficiency	O
and	O
perturbations	O
to	O
the	O
discrimination	O
of	O
leucine	B-CHEMICAL
and	O
isoleucine	B-CHEMICAL
.	O

In	O
addition	O
,	O
tRNA	O
recognition	O
and	O
aminoacylation	O
is	O
affected	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
conformation	O
of	O
the	O
synthetic	O
active	O
site	O
,	O
modulated	O
by	O
this	O
residue	O
,	O
may	O
be	O
coupled	O
to	O
specificity	O
and	O
provide	O
new	O
insights	O
into	O
the	O
origins	O
of	O
selectivity	O
without	O
editing	O
.	O

Gene	O
expression	O
signature	O
of	O
parathion	B-CHEMICAL
-	O
transformed	O
human	O
breast	O
epithelial	O
cells	O
.	O

Environmental	O
substances	O
seem	O
to	O
be	O
involved	O
in	O
the	O
etiology	O
of	O
breast	O
cancers	O
.	O

Many	O
studies	O
have	O
found	O
an	O
association	O
between	O
human	O
cancer	O
and	O
exposure	O
to	O
agricultural	O
pesticides	O
such	O
as	O
the	O
organophosphorous	B-CHEMICAL
pesticides	O
.	O

Parathion	B-CHEMICAL
is	O
a	O
cholinesterase	B-GENE-N
inhibitor	O
that	O
induces	O
the	O
hydrolysis	O
of	O
body	O
choline	B-CHEMICAL
esters	I-CHEMICAL
,	O
including	O
acetylcholine	B-CHEMICAL
at	O
cholinergic	O
synapses	O
.	O

The	O
primary	O
target	O
of	O
action	O
in	O
insects	O
is	O
the	O
nervous	O
system	O
whereby	O
pesticides	O
inhibit	O
the	O
release	O
of	O
the	O
enzyme	O
acetylcholinesterase	B-GENE-N
at	O
the	O
synaptic	O
junction	O
.	O

Atropine	O
is	O
a	O
parasympatholytic	O
alkaloid	O
used	O
as	O
an	O
antidote	O
to	O
acetylcholinesterase	B-GENE-N
inhibitors	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
parathion	B-CHEMICAL
and	O
atropine	B-CHEMICAL
on	O
cell	O
transformation	O
of	O
human	O
breast	O
epithelial	O
cells	O
in	O
vitro	O
.	O

These	O
studies	O
showed	O
that	O
parathion	B-CHEMICAL
alone	O
was	O
able	O
to	O
induce	O
malignant	O
transformation	O
of	O
an	O
immortalized	O
human	O
breast	O
epithelial	O
cell	O
line	O
,	O
MCF	O
-	O
10F	O
as	O
indicated	O
by	O
increased	O
cell	O
proliferation	O
,	O
anchorage	O
independency	O
and	O
invasive	O
capabilities	O
.	O

There	O
was	O
also	O
an	O
increase	O
in	O
c	B-GENE-Y
-	I-GENE-Y
kit	I-GENE-Y
,	O
Trio	B-GENE-Y
,	O
Rho	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
,	O
Rac	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
EGFR	B-GENE-Y
,	O
Notch	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
Dvl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
Ezrin	B-GENE-Y
,	O
beta	B-GENE-Y
catenin	I-GENE-Y
and	O
mutant	O
p53	B-GENE-Y
protein	O
expression	O
in	O
the	O
parathion	B-CHEMICAL
-	O
treated	O
cells	O
.	O

However	O
,	O
atropine	B-CHEMICAL
significantly	O
inhibited	O
this	O
increase	O
.	O

In	O
a	O
human	O
cell	O
cycle	O
array	O
of	O
96	O
genes	O
,	O
13	O
of	O
them	O
were	O
altered	O
by	O
parathion	B-CHEMICAL
treatment	O
.	O

Among	O
the	O
genes	O
affected	O
were	O
the	O
cyclins	B-GENE-N
,	O
such	O
as	O
cyclin	B-GENE-Y
D3	I-GENE-Y
,	O
the	O
cyclin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
kinases	I-GENE-N
(	O
CDKs	B-GENE-N
)	O
such	O
as	O
CDK41	B-GENE-Y
and	O
the	O
minichromosome	B-GENE-Y
maintenance	I-GENE-Y
deficient	I-GENE-Y
(	I-GENE-Y
MCM	I-GENE-Y
)	I-GENE-Y
MCM2	I-GENE-Y
and	O
MCM3	B-GENE-Y
.	O

It	O
is	O
suggested	O
that	O
parathion	B-CHEMICAL
influences	O
human	O
breast	O
epithelial	O
cell	O
transformation	O
and	O
is	O
an	O
initiator	O
factor	O
in	O
the	O
transformation	O
process	O
in	O
breast	O
cancer	O
.	O

In	O
vivo	O
effects	O
of	O
amtolmetin	B-CHEMICAL
guacyl	I-CHEMICAL
on	O
lipid	O
peroxidation	O
and	O
antioxidant	O
defence	O
systems	O
.	O

Comparison	O
with	O
non	O
-	O
selective	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selective	O
NSAIDs	O
.	O

1	O
.	O

The	O
in	O
vivo	O
effects	O
of	O
the	O
non	O
-	O
steroid	B-CHEMICAL
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
amtolmetin	B-CHEMICAL
guacyl	I-CHEMICAL
,	O
a	O
pro	O
-	O
drug	O
of	O
the	O
NSAID	O
tolmetin	B-CHEMICAL
,	O
on	O
lipid	O
peroxidation	O
,	O
glutathione	B-CHEMICAL
levels	O
and	O
activity	O
of	O
antioxidant	O
enzymes	O
(	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
catalase	B-GENE-Y
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
and	O
glutathione	B-GENE-N
reductase	I-GENE-N
)	O
in	O
rat	O
gastric	O
mucosa	O
,	O
colon	O
mucosa	O
and	O
liver	O
,	O
were	O
compared	O
with	O
the	O
effects	O
of	O
non	O
-	O
selective	O
(	O
indomethacin	B-CHEMICAL
,	O
diclofenac	B-CHEMICAL
)	O
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selective	O
(	O
celecoxib	B-CHEMICAL
)	O
NSAIDs	O
.	O

2	O
.	O

Indomethacin	B-CHEMICAL
treatment	O
led	O
to	O
an	O
increase	O
in	O
lipid	O
peroxidation	O
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
and	O
glucose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphate	I-GENE-Y
dehydrogenase	I-GENE-Y
activities	O
and	O
to	O
a	O
decrease	O
in	O
catalase	B-GENE-Y
activity	O
and	O
glutathione	B-CHEMICAL
levels	O
in	O
gastric	O
mucosa	O
.	O

In	O
contrast	O
,	O
amtolmetin	B-CHEMICAL
guacyl	I-CHEMICAL
treatment	O
was	O
without	O
effects	O
in	O
gastric	O
and	O
colon	O
mucosa	O
,	O
or	O
liver	O
from	O
control	O
animals	O
.	O

Like	O
amtolmetin	B-CHEMICAL
guacyl	I-CHEMICAL
,	O
celecoxib	B-CHEMICAL
had	O
no	O
effect	O
on	O
the	O
lipid	O
peroxidation	O
,	O
or	O
on	O
enzyme	O
and	O
non	O
-	O
enzyme	O
antioxidant	O
defence	O
systems	O
in	O
gastric	O
mucosa	O
.	O

3	O
.	O

It	O
is	O
suggested	O
that	O
the	O
lack	O
of	O
pro	O
-	O
oxidant	O
effects	O
in	O
vivo	O
associated	O
with	O
amtolmetin	B-CHEMICAL
guacyl	I-CHEMICAL
treatment	O
contribute	O
improved	O
gastric	O
tolerability	O
.	O

Inborn	O
errors	O
in	O
the	O
metabolism	O
of	O
glutathione	B-CHEMICAL
.	O

Glutathione	B-CHEMICAL
is	O
a	O
tripeptide	B-CHEMICAL
composed	O
of	O
glutamate	B-CHEMICAL
,	O
cysteine	B-CHEMICAL
and	O
glycine	B-CHEMICAL
.	O

Glutathione	B-CHEMICAL
is	O
present	O
in	O
millimolar	O
concentrations	O
in	O
most	O
mammalian	O
cells	O
and	O
it	O
is	O
involved	O
in	O
several	O
fundamental	O
biological	O
functions	O
,	O
including	O
free	O
radical	O
scavenging	O
,	O
detoxification	O
of	O
xenobiotics	O
and	O
carcinogens	O
,	O
redox	O
reactions	O
,	O
biosynthesis	O
of	O
DNA	O
,	O
proteins	O
and	O
leukotrienes	B-CHEMICAL
,	O
as	O
well	O
as	O
neurotransmission	O
/	O
neuromodulation	O
.	O

Glutathione	B-CHEMICAL
is	O
metabolised	O
via	O
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
glutamyl	I-CHEMICAL
cycle	O
,	O
which	O
is	O
catalyzed	O
by	O
six	O
enzymes	O
.	O

In	O
man	O
,	O
hereditary	O
deficiencies	O
have	O
been	O
found	O
in	O
five	O
of	O
the	O
six	O
enzymes	O
.	O

Glutathione	B-GENE-Y
synthetase	I-GENE-Y
deficiency	O
is	O
the	O
most	O
frequently	O
recognized	O
disorder	O
and	O
,	O
in	O
its	O
severe	O
form	O
,	O
it	O
is	O
associated	O
with	O
hemolytic	O
anemia	O
,	O
metabolic	O
acidosis	O
,	O
5	O
-	O
oxoprolinuria	O
,	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
damage	O
and	O
recurrent	O
bacterial	O
infections	O
.	O

Gamma	B-GENE-Y
-	I-GENE-Y
glutamylcysteine	I-GENE-Y
synthetase	I-GENE-Y
deficiency	O
is	O
also	O
associated	O
with	O
hemolytic	O
anemia	O
,	O
and	O
some	O
patients	O
with	O
this	O
disorder	O
show	O
defects	O
of	O
neuromuscular	O
function	O
and	O
generalized	O
aminoaciduria	O
.	O

Gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
transpeptidase	I-GENE-Y
deficiency	O
has	O
been	O
found	O
in	O
patients	O
with	O
CNS	O
involvement	O
and	O
glutathionuria	O
.	O

5	B-GENE-Y
-	I-GENE-Y
Oxoprolinase	I-GENE-Y
deficiency	O
is	O
associated	O
with	O
5	O
-	O
oxoprolinuria	O
but	O
without	O
a	O
clear	O
association	O
with	O
other	O
symptoms	O
.	O

Dipeptidase	B-GENE-N
deficiency	O
has	O
been	O
described	O
in	O
one	O
patient	O
.	O

All	O
disorders	O
are	O
very	O
rare	O
and	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
.	O

Most	O
of	O
the	O
mutations	O
are	O
leaky	O
so	O
that	O
many	O
patients	O
have	O
residual	O
enzyme	O
activity	O
.	O

Diagnosis	O
is	O
made	O
by	O
measuring	O
the	O
concentration	O
of	O
different	O
metabolites	O
in	O
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
glutamyl	I-CHEMICAL
cycle	O
,	O
enzyme	O
activity	O
and	O
in	O
glutathione	B-GENE-Y
synthetase	I-GENE-Y
and	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamylcysteine	I-GENE-Y
synthetase	I-GENE-Y
deficiency	O
,	O
also	O
by	O
mutation	O
analysis	O
.	O

Prenatal	O
diagnosis	O
has	O
been	O
preformed	O
in	O
glutathione	B-CHEMICAL
synthetase	O
deficiency	O
.	O

The	O
prognosis	O
is	O
difficult	O
to	O
predict	O
,	O
as	O
few	O
patients	O
are	O
known	O
,	O
but	O
seems	O
to	O
vary	O
significantly	O
between	O
different	O
patients	O
.	O

The	O
aims	O
of	O
the	O
treatment	O
of	O
glutathione	B-CHEMICAL
synthesis	O
defects	O
are	O
to	O
avoid	O
hemolytic	O
crises	O
and	O
to	O
increase	O
the	O
defense	O
against	O
reactive	O
oxygen	B-CHEMICAL
species	O
.	O

No	O
treatment	O
has	O
been	O
recommended	O
for	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyl	I-GENE-Y
transpeptidase	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
oxoprolinase	I-GENE-Y
and	O
dipeptidase	B-GENE-N
deficiency	O
.	O

Application	O
of	O
the	O
bradford	O
hill	O
criteria	O
to	O
assess	O
the	O
causality	O
of	O
cisapride	B-CHEMICAL
-	O
induced	O
arrhythmia	O
:	O
a	O
model	O
for	O
assessing	O
causal	O
association	O
in	O
pharmacovigilance	O
.	O

INTRODUCTION	O
:	O
The	O
Bradford	O
Hill	O
criteria	O
are	O
a	O
widely	O
used	O
,	O
useful	O
tool	O
for	O
the	O
assessment	O
of	O
biomedical	O
causation	O
.	O

We	O
have	O
examined	O
their	O
application	O
to	O
pharmacovigilance	O
using	O
the	O
example	O
of	O
cisapride	B-CHEMICAL
-	O
induced	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
.	O

METHODS	O
:	O
A	O
literature	O
search	O
was	O
conducted	O
using	O
MEDLINE	O
,	O
EMBASE	O
,	O
Reactions	O
Weekly	O
and	O
regulatory	O
websites	O
to	O
identify	O
evidence	O
for	O
the	O
association	O
between	O
cisapride	B-CHEMICAL
and	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
that	O
had	O
been	O
published	O
in	O
the	O
English	O
language	O
.	O

Two	O
hundred	O
and	O
five	O
publications	O
were	O
identified	O
as	O
being	O
potentially	O
suitable	O
for	O
the	O
study	O
.	O

After	O
excluding	O
irrelevant	O
articles	O
,	O
studies	O
on	O
high	O
-	O
risk	O
populations	O
and	O
review	O
articles	O
,	O
70	O
publications	O
were	O
assessed	O
using	O
the	O
Bradford	O
Hill	O
criteria	O
.	O

These	O
included	O
24	O
case	O
reports	O
,	O
case	O
series	O
or	O
spontaneous	O
report	O
summaries	O
;	O
eight	O
epidemiological	O
studies	O
;	O
22	O
clinical	O
studies	O
;	O
and	O
16	O
experimental	O
(	O
in	O
vivo	O
and	O
in	O
vitro	O
)	O
publications	O
.	O

RESULTS	O
:	O
The	O
most	O
compelling	O
evidence	O
for	O
an	O
association	O
between	O
cisapride	B-CHEMICAL
use	O
and	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
came	O
from	O
case	O
/	O
spontaneous	O
reports	O
and	O
biological	O
plausibility	O
.	O

Considering	O
the	O
rare	O
incidence	O
of	O
serious	O
cardiac	O
events	O
,	O
these	O
criteria	O
formed	O
the	O
basis	O
for	O
the	O
strength	O
of	O
the	O
association	O
.	O

The	O
number	O
of	O
reports	O
from	O
different	O
populations	O
showed	O
consistency	O
.	O

Specificity	O
was	O
supported	O
by	O
clinical	O
and	O
cardiographic	O
characterisation	O
of	O
the	O
events	O
.	O

There	O
were	O
temporal	O
relationships	O
between	O
the	O
events	O
and	O
the	O
initiation	O
of	O
cisapride	B-CHEMICAL
treatment	O
,	O
increases	O
in	O
the	O
dosage	O
and	O
the	O
receipt	O
of	O
interacting	O
medications	O
.	O

The	O
relationships	O
between	O
the	O
adverse	O
events	O
and	O
the	O
latter	O
two	O
factors	O
exhibited	O
biological	O
gradients	O
.	O

Experimental	O
evidence	O
could	O
be	O
found	O
from	O
biological	O
models	O
,	O
as	O
well	O
as	O
reports	O
of	O
positive	O
dechallenge	O
and	O
/	O
or	O
rechallenge	O
found	O
in	O
individual	O
patients	O
.	O

Cisapride	B-CHEMICAL
was	O
found	O
to	O
bind	O
the	O
human	B-GENE-Y
ether	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
go	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
gene	I-GENE-Y
(	I-GENE-Y
HERG	I-GENE-Y
)	I-GENE-Y
potassium	I-GENE-Y
channel	I-GENE-Y
,	O
which	O
provides	O
a	O
plausible	O
mechanism	O
for	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
.	O

Other	O
QTc	O
interval	O
-	O
prolonging	O
/	O
arrhythmic	O
drugs	O
that	O
also	O
bind	O
to	O
HERG	B-GENE-Y
provided	O
an	O
analogy	O
for	O
cisapride	B-CHEMICAL
causing	O
QTc	O
interval	O
prolongation	O
/	O
arrhythmia	O
via	O
this	O
mechanism	O
.	O

The	O
evidence	O
provided	O
by	O
clinical	O
studies	O
was	O
inconsistent	O
,	O
and	O
epidemiological	O
studies	O
failed	O
to	O
demonstrate	O
an	O
association	O
.	O

Nevertheless	O
,	O
this	O
did	O
not	O
prevent	O
the	O
assessment	O
of	O
causation	O
.	O

DISCUSSION	O
:	O
This	O
study	O
showed	O
how	O
different	O
types	O
of	O
evidence	O
found	O
in	O
pharmacovigilance	O
can	O
be	O
evaluated	O
using	O
the	O
Bradford	O
Hill	O
criteria	O
.	O

Further	O
work	O
is	O
required	O
to	O
examine	O
how	O
the	O
criteria	O
can	O
be	O
applied	O
to	O
different	O
types	O
of	O
adverse	O
events	O
and	O
how	O
they	O
may	O
be	O
applied	O
to	O
pharmacovigilance	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
induce	O
colorectal	O
cancer	O
cell	O
apoptosis	O
by	O
suppressing	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
.	O

To	O
determine	O
the	O
role	O
of	O
14	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
3	I-GENE-N
in	O
colorectal	O
cancer	O
apoptosis	O
induced	O
by	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
we	O
evaluated	O
the	O
effects	O
of	O
sulindac	B-CHEMICAL
on	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
protein	I-GENE-Y
expression	O
in	O
colorectal	O
cancer	O
cells	O
.	O

Sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
inhibited	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
proteins	I-GENE-Y
in	O
HT	O
-	O
29	O
and	O
DLD	O
-	O
1	O
cells	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

Sulindac	B-CHEMICAL
sulfone	I-CHEMICAL
at	O
600	O
mumol	O
/	O
L	O
inhibited	O
14	O
-	O
3	O
-	O
3epsilon	O
protein	O
expression	O
in	O
HT	O
-	O
29	O
.	O

Indomethacin	B-CHEMICAL
and	O
SC	B-CHEMICAL
-	I-CHEMICAL
236	I-CHEMICAL
,	O
a	O
selective	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
inhibitor	O
,	O
exerted	O
a	O
similar	O
effect	O
as	O
sulindac	B-CHEMICAL
.	O

Sulindac	B-CHEMICAL
suppressed	O
14	O
-	O
3	O
-	O
3epsilon	O
promoter	O
activity	O
.	O

As	O
14	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
3epsilon	I-GENE-N
promoter	I-GENE-N
activation	O
is	O
mediated	O
by	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
delta	I-GENE-Y
(	O
PPARdelta	B-GENE-Y
)	O
,	O
we	O
determined	O
the	O
correlation	O
between	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
inhibition	O
and	O
PPARdelta	B-GENE-Y
suppression	O
by	O
NSAIDs	O
.	O

Sulindac	B-CHEMICAL
sulfide	I-CHEMICAL
inhibited	O
PPARdelta	B-GENE-Y
protein	O
expression	O
and	O
PPARdelta	B-GENE-Y
transcriptional	O
activity	O
.	O

Overexpression	O
of	O
PPARdelta	B-GENE-Y
by	O
adenoviral	O
transfer	O
rescued	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
proteins	O
from	O
elimination	O
by	O
sulindac	B-CHEMICAL
or	O
indomethacin	B-CHEMICAL
.	O

NSAID	O
-	O
induced	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
suppression	O
was	O
associated	O
with	O
reduced	O
cytosolic	B-GENE-Y
Bad	I-GENE-Y
with	O
elevation	O
of	O
mitochondrial	B-GENE-Y
Bad	I-GENE-Y
and	O
increase	O
in	O
apoptosis	O
which	O
was	O
rescued	O
by	O
Ad	O
-	O
PPARdelta	B-GENE-Y
transduction	O
.	O

Stable	O
expression	O
of	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
in	O
HT	O
-	O
29	O
significantly	O
protected	O
cells	O
from	O
apoptosis	O
.	O

Our	O
findings	O
shed	O
light	O
on	O
a	O
novel	O
mechanism	O
by	O
which	O
NSAIDs	O
induce	O
colorectal	O
cancer	O
apoptosis	O
via	O
the	O
PPARdelta	B-GENE-Y
/	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
transcriptional	O
pathway	O
.	O

These	O
results	O
suggest	O
that	O
14	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
3epsilon	I-GENE-Y
is	O
a	O
target	O
for	O
the	O
prevention	O
and	O
therapy	O
of	O
colorectal	O
cancer	O
.	O

Functional	O
and	O
molecular	O
characterization	O
of	O
multiple	O
K	B-GENE-N
-	I-GENE-N
Cl	I-GENE-N
cotransporter	I-GENE-N
isoforms	O
in	O
corneal	O
epithelial	O
cells	O
.	O

The	O
dependence	O
of	O
regulatory	O
volume	O
decrease	O
(	O
RVD	O
)	O
activity	O
on	O
potassium	B-GENE-N
-	I-GENE-N
chloride	I-GENE-N
cotransporter	I-GENE-N
(	O
KCC	B-GENE-N
)	O
isoform	O
expression	O
was	O
characterized	O
in	O
corneal	O
epithelial	O
cells	O
(	O
CEC	O
)	O
.	O

During	O
exposure	O
to	O
a	O
50	O
%	O
hypotonic	O
challenge	O
,	O
the	O
RVD	O
response	O
was	O
larger	O
in	O
SV40	O
-	O
immortalized	O
human	O
CEC	O
(	O
HCEC	O
)	O
than	O
in	O
SV40	O
-	O
immortalized	O
rabbit	O
CEC	O
(	O
RCEC	O
)	O
.	O

A	O
KCC	B-GENE-N
inhibitor	O
-	O
[	B-CHEMICAL
(	I-CHEMICAL
dihydroindenyl	I-CHEMICAL
)	I-CHEMICAL
oxy	I-CHEMICAL
]	I-CHEMICAL
alkanoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
DIOA	B-CHEMICAL
)	O
-	O
blocked	O
RVD	O
more	O
in	O
HCEC	O
than	O
RCEC	O
.	O

Under	O
isotonic	O
conditions	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
ethylmaleimide	I-CHEMICAL
(	O
NEM	B-CHEMICAL
)	O
produced	O
KCC	B-GENE-N
activation	O
and	O
transient	O
cell	O
shrinkage	O
.	O

Both	O
of	O
these	O
changes	O
were	O
greater	O
in	O
HCEC	O
than	O
in	O
RCEC	O
.	O

Immunoblot	O
analysis	O
of	O
HCEC	O
,	O
RCEC	O
,	O
primary	O
human	O
CEC	O
(	O
pHCEC	O
)	O
,	O
and	O
primary	O
bovine	O
CEC	O
(	O
BCEC	O
)	O
plasma	O
membrane	O
enriched	O
fractions	O
revealed	O
KCC1	B-GENE-N
,	O
KCC3	B-GENE-N
,	O
and	O
KCC4	B-GENE-N
isoform	O
expression	O
,	O
whereas	O
KCC2	B-GENE-N
was	O
undetectable	O
.	O

During	O
a	O
hypotonic	O
challenge	O
,	O
KCC1	B-GENE-N
membrane	O
content	O
increased	O
more	O
rapidly	O
in	O
HCEC	O
than	O
in	O
RCEC	O
.	O

Such	O
a	O
challenge	O
induced	O
a	O
larger	O
increase	O
and	O
more	O
transient	O
p44	B-GENE-N
/	I-GENE-N
42MAPK	I-GENE-N
activation	O
in	O
HCEC	O
than	O
RCEC	O
.	O

On	O
the	O
other	O
hand	O
,	O
HCEC	O
and	O
RCEC	O
p38MAPK	B-GENE-N
phosphorylation	O
reached	O
peak	O
activations	O
at	O
2	O
.	O
5	O
and	O
15	O
min	O
,	O
respectively	O
.	O

Only	O
in	O
HCEC	O
,	O
pharmacological	O
manipulation	O
of	O
KCC	B-GENE-N
activity	O
modified	O
the	O
hypotonicity	O
-	O
induced	O
activation	O
of	O
p44	B-GENE-N
/	I-GENE-N
42MAPK	I-GENE-N
,	O
whereas	O
p38MAPK	B-GENE-N
phosphorylation	O
was	O
insensitive	O
to	O
such	O
procedures	O
in	O
both	O
cell	O
lines	O
.	O

Larger	O
increases	O
in	O
HCEC	O
KCC1	B-GENE-Y
membrane	O
protein	O
content	O
correlated	O
with	O
their	O
ability	O
to	O
undergo	O
faster	O
and	O
more	O
complete	O
RVD	O
.	O

Furthermore	O
,	O
pharmacological	O
activation	O
of	O
KCC	B-GENE-N
increased	O
p44	B-GENE-N
/	I-GENE-N
42MAPK	I-GENE-N
phosphorylation	O
in	O
HCEC	O
but	O
not	O
in	O
RCEC	O
,	O
presumably	O
a	O
reflection	O
of	O
low	O
KCC1	B-GENE-Y
membrane	O
expression	O
in	O
RCEC	O
.	O

These	O
findings	O
suggest	O
that	O
KCC1	B-GENE-N
plays	O
a	O
role	O
in	O
(	O
i	O
)	O
maintaining	O
isotonic	O
steady	O
-	O
state	O
cell	O
volume	O
homeostasis	O
,	O
(	O
ii	O
)	O
recovery	O
of	O
isotonic	O
cell	O
volume	O
after	O
a	O
hypotonic	O
challenge	O
through	O
RVD	O
,	O
and	O
(	O
iii	O
)	O
regulating	O
hypotonicity	O
-	O
induced	O
activation	O
of	O
the	O
p44	B-GENE-N
/	I-GENE-N
42MAPK	I-GENE-N
signaling	O
pathway	O
required	O
for	O
cell	O
proliferation	O
.	O

Preclinical	O
pharmacokinetics	O
and	O
in	O
vitro	O
metabolism	O
of	O
dasatinib	B-CHEMICAL
(	O
BMS	B-CHEMICAL
-	I-CHEMICAL
354825	I-CHEMICAL
)	O
:	O
a	O
potent	O
oral	O
multi	O
-	O
targeted	O
kinase	B-GENE-N
inhibitor	O
against	O
SRC	B-GENE-Y
and	O
BCR	B-GENE-Y
-	O
ABL	B-GENE-Y
.	O

PURPOSE	O
:	O
Dasatinib	B-CHEMICAL
(	O
BMS	B-CHEMICAL
-	I-CHEMICAL
354825	I-CHEMICAL
)	O
,	O
a	O
potent	O
oral	O
multi	O
-	O
targeted	O
kinase	B-GENE-N
inhibitor	O
against	O
SRC	B-GENE-Y
and	O
BCR	B-GENE-Y
-	O
ABL	B-GENE-Y
,	O
has	O
recently	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
in	O
imatinib	B-CHEMICAL
-	O
acquired	O
resistance	O
and	O
intolerance	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
were	O
conducted	O
to	O
characterize	O
the	O
pharmacokinetics	O
and	O
metabolism	O
of	O
dasatinib	B-CHEMICAL
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
and	O
monkey	O
.	O

Possible	O
mechanisms	O
contributing	O
to	O
the	O
incomplete	O
oral	O
bioavailability	O
of	O
dasatinib	B-CHEMICAL
in	O
animals	O
were	O
investigated	O
.	O

METHODS	O
:	O
Metabolic	O
stability	O
of	O
dasatinib	B-CHEMICAL
was	O
measured	O
after	O
incubation	O
with	O
liver	O
microsomes	O
(	O
either	O
NADPH	B-CHEMICAL
-	O
or	O
UDPGA	B-CHEMICAL
-	O
fortified	O
)	O
and	O
isolated	O
hepatocytes	O
obtained	O
from	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
monkey	O
,	O
and	O
human	O
.	O

In	O
all	O
cases	O
,	O
substrate	O
depletion	O
over	O
time	O
was	O
measured	O
,	O
and	O
appropriate	O
scaling	O
factors	O
were	O
used	O
to	O
predict	O
in	O
vivo	O
clearance	O
.	O

Pharmacokinetics	O
of	O
dasatinib	B-CHEMICAL
were	O
determined	O
in	O
mice	O
,	O
rats	O
,	O
dogs	O
,	O
and	O
monkeys	O
after	O
administration	O
of	O
single	O
intravenous	O
or	O
oral	O
doses	O
.	O

In	O
addition	O
,	O
the	O
routes	O
of	O
excretion	O
were	O
investigated	O
after	O
administration	O
of	O
dasatinib	B-CHEMICAL
to	O
bile	O
duct	O
cannulated	O
(	O
BDC	O
)	O
rats	O
.	O

Absorption	O
and	O
first	O
-	O
pass	O
metabolism	O
were	O
evaluated	O
as	O
possible	O
reasons	O
for	O
the	O
incomplete	O
oral	O
bioavailability	O
using	O
various	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
like	O
Caco	O
-	O
2	O
cells	O
,	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
knockout	O
mice	O
,	O
and	O
intra	O
-	O
portal	O
dosing	O
in	O
rats	O
.	O

RESULTS	O
:	O
In	O
vivo	O
systemic	O
plasma	O
clearance	O
values	O
of	O
dasatinib	B-CHEMICAL
were	O
62	O
,	O
26	O
,	O
25	O
,	O
and	O
34	O
ml	O
/	O
min	O
/	O
kg	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
and	O
monkey	O
,	O
respectively	O
.	O

Scaling	O
of	O
in	O
vitro	O
hepatocyte	O
and	O
liver	O
microsomal	O
data	O
gave	O
reasonably	O
good	O
predictions	O
of	O
in	O
vivo	O
clearances	O
across	O
all	O
species	O
.	O

Percent	O
distribution	O
in	O
blood	O
cells	O
ranged	O
from	O
43	O
%	O
in	O
mouse	O
to	O
57	O
%	O
in	O
dog	O
.	O

Dasatinib	B-CHEMICAL
showed	O
high	O
volumes	O
of	O
distribution	O
(	O
>	O
3	O
l	O
/	O
kg	O
)	O
and	O
high	O
serum	O
protein	O
binding	O
values	O
(	O
>	O
90	O
%	O
)	O
in	O
all	O
four	O
species	O
tested	O
.	O

Oral	O
bioavailability	O
of	O
dasatinib	B-CHEMICAL
ranged	O
from	O
14	O
%	O
in	O
the	O
mouse	O
to	O
34	O
%	O
in	O
the	O
dog	O
.	O

In	O
rats	O
,	O
bioavailability	O
after	O
an	O
intraportal	O
dose	O
was	O
comparable	O
to	O
that	O
after	O
intra	O
-	O
arterial	O
administration	O
.	O

In	O
BDC	O
rats	O
,	O
less	O
than	O
15	O
%	O
of	O
an	O
intravenous	O
dose	O
was	O
excreted	O
unchanged	O
in	O
urine	O
,	O
bile	O
,	O
and	O
the	O
gastrointestinal	O
tract	O
,	O
suggesting	O
that	O
dasatinib	B-CHEMICAL
is	O
cleared	O
primarily	O
via	O
metabolism	O
.	O

Dasatinib	B-CHEMICAL
has	O
high	O
intrinsic	O
permeability	O
in	O
Caco	O
-	O
2	O
cells	O
,	O
however	O
,	O
the	O
efflux	O
ratio	O
was	O
approximately	O
two	O
-	O
fold	O
indicating	O
that	O
it	O
may	O
be	O
a	O
substrate	O
for	O
an	O
intestinal	O
efflux	O
transporter	O
.	O

However	O
,	O
in	O
vivo	O
studies	O
in	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
knockout	O
mice	O
versus	O
wild	O
-	O
type	O
mice	O
showed	O
no	O
difference	O
in	O
the	O
amount	O
of	O
dasatinib	B-CHEMICAL
remaining	O
unabsorbed	O
in	O
the	O
gastrointestinal	O
tract	O
,	O
suggesting	O
that	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
may	O
not	O
be	O
responsible	O
for	O
the	O
incomplete	O
bioavailability	O
.	O

CONCLUSIONS	O
:	O
Dasatinib	B-CHEMICAL
shows	O
intermediate	O
clearance	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
and	O
monkey	O
,	O
and	O
distributes	O
extensively	O
in	O
those	O
species	O
.	O

Oxidative	O
metabolism	O
appears	O
to	O
be	O
the	O
predominant	O
clearance	O
pathway	O
.	O

The	O
incomplete	O
oral	O
bioavailability	O
may	O
be	O
due	O
to	O
both	O
incomplete	O
absorption	O
and	O
high	O
first	O
-	O
pass	O
metabolism	O
.	O

However	O
,	O
the	O
efflux	B-GENE-N
transporter	I-GENE-N
,	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
does	O
not	O
appear	O
to	O
be	O
limiting	O
oral	O
absorption	O
.	O

Molecular	O
determinants	O
for	O
the	O
selective	O
inhibition	O
of	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
by	O
lumiracoxib	B-CHEMICAL
.	O

Lumiracoxib	B-CHEMICAL
is	O
the	O
first	O
example	O
of	O
a	O
marketed	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
of	O
the	O
arylacetic	B-CHEMICAL
acid	I-CHEMICAL
class	O
,	O
and	O
it	O
is	O
reported	O
to	O
be	O
the	O
most	O
selective	O
COXIB	O
in	O
vivo	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
of	O
its	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
has	O
not	O
been	O
completely	O
defined	O
.	O

Using	O
standard	O
assays	O
,	O
lumiracoxib	B-CHEMICAL
was	O
found	O
to	O
be	O
a	O
poor	O
inhibitor	O
of	O
purified	O
ovine	B-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
a	O
relatively	O
weak	O
inhibitor	O
of	O
purified	O
human	B-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

The	O
extent	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
plateaued	O
at	O
around	O
50	O
%	O
and	O
suggested	O
that	O
the	O
inhibitor	O
may	O
be	O
reversibly	O
bound	O
to	O
the	O
enzyme	O
.	O

Kinetic	O
studies	O
with	O
lumiracoxib	B-CHEMICAL
demonstrated	O
that	O
it	O
was	O
a	O
time	O
-	O
dependent	O
and	O
slowly	O
reversible	O
inhibitor	O
of	O
human	B-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
that	O
exhibited	O
at	O
least	O
two	O
binding	O
steps	O
during	O
inhibition	O
.	O

Derivatives	O
of	O
lumiracoxib	B-CHEMICAL
were	O
synthesized	O
with	O
or	O
without	O
the	O
methyl	B-CHEMICAL
group	O
on	O
the	O
phenylacetic	B-CHEMICAL
acid	I-CHEMICAL
ring	O
and	O
with	O
various	O
substitutions	O
on	O
the	O
lower	O
aniline	B-CHEMICAL
ring	O
.	O

Inhibition	O
studies	O
demonstrated	O
that	O
the	O
methyl	B-CHEMICAL
group	O
on	O
the	O
phenylacetic	B-CHEMICAL
acid	I-CHEMICAL
ring	O
is	O
required	O
for	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selectivity	O
.	O

The	O
chemical	O
identity	O
and	O
position	O
of	O
the	O
substituents	O
on	O
the	O
lower	O
aniline	B-CHEMICAL
ring	O
were	O
important	O
in	O
determining	O
the	O
potency	O
and	O
extent	O
of	O
COX	B-GENE-N
inhibition	O
as	O
well	O
as	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selectivity	O
.	O

Mutation	O
of	O
Ser	B-GENE-N
-	I-GENE-N
530	I-GENE-N
to	I-GENE-N
Ala	I-GENE-N
or	O
Val	B-GENE-N
-	I-GENE-N
349	I-GENE-N
to	I-GENE-N
Ala	I-GENE-N
or	I-GENE-N
Leu	I-GENE-N
abolished	O
the	O
potent	O
inhibition	O
observed	O
with	O
wild	O
-	O
type	O
human	B-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
key	O
lumiracoxib	B-CHEMICAL
analogs	O
.	O

Interestingly	O
,	O
a	O
Val	B-GENE-N
-	I-GENE-N
349	I-GENE-N
to	I-GENE-N
Ile	I-GENE-N
mutant	O
was	O
inhibited	O
with	O
equal	O
potency	O
to	O
human	B-GENE-Y
COX	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
with	O
2	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dichloro	I-CHEMICAL
-	O
,	O
2	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dimethyl	I-CHEMICAL
-	O
,	O
or	O
2	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	O
substituted	O
inhibitors	O
and	O
,	O
in	O
the	O
case	O
of	O
lumiracoxib	B-CHEMICAL
,	O
actually	O
showed	O
an	O
increase	O
in	O
potency	O
.	O

Taken	O
together	O
with	O
a	O
recent	O
crystal	O
structure	O
of	O
a	O
lumiracoxib	B-CHEMICAL
-	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
complex	O
,	O
the	O
kinetic	O
analyses	O
presented	O
herein	O
of	O
the	O
inhibition	O
of	O
mutant	O
COX	B-GENE-Y
-	I-GENE-Y
2s	I-GENE-Y
by	O
lumiracoxib	B-CHEMICAL
allows	O
the	O
definition	O
of	O
the	O
molecular	O
basis	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
.	O

Underexpression	O
of	O
the	O
Na	B-GENE-N
+	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
neutral	I-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporter	I-GENE-N
ASCT2	B-GENE-Y
in	O
the	O
spontaneously	O
hypertensive	O
rat	O
kidney	O
.	O

This	O
study	O
examined	O
the	O
inward	O
transport	O
of	O
l	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
alanine	I-CHEMICAL
,	O
an	O
ASCT2	B-GENE-Y
preferential	O
substrate	O
,	O
in	O
monolayers	O
of	O
immortalized	O
renal	O
proximal	O
tubular	O
epithelial	O
(	O
PTE	O
)	O
cells	O
from	O
Wistar	O
-	O
Kyoto	O
(	O
WKY	O
)	O
and	O
spontaneously	O
hypertensive	O
(	O
SHR	O
)	O
rats	O
.	O

The	O
expression	O
of	O
ASCT2	B-GENE-Y
in	O
WKY	O
and	O
SHR	O
PTE	O
cells	O
and	O
kidney	O
cortices	O
from	O
WKY	O
and	O
SHR	O
was	O
also	O
evaluated	O
.	O

l	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
alanine	I-CHEMICAL
uptake	O
was	O
highly	O
dependent	O
on	O
extracellular	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
.	O

Replacement	O
of	O
NaCl	B-CHEMICAL
by	O
LiCl	B-CHEMICAL
or	O
choline	B-CHEMICAL
chloride	I-CHEMICAL
abolished	O
transport	O
activity	O
in	O
SHR	O
and	O
WKY	O
PTE	O
cells	O
.	O

In	O
the	O
presence	O
of	O
the	O
system	O
L	O
inhibitor	O
BCH	O
,	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
l	B-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
uptake	O
in	O
WKY	O
and	O
SHR	O
PTE	O
cells	O
was	O
inhibited	O
by	O
alanine	B-CHEMICAL
,	O
serine	B-CHEMICAL
,	O
and	O
cysteine	B-CHEMICAL
,	O
which	O
is	O
consistent	O
with	O
amino	B-CHEMICAL
acid	I-CHEMICAL
transport	O
through	O
ASCT2	B-GENE-Y
.	O

The	O
saturable	O
component	O
of	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
l	B-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
transport	O
under	O
V	O
(	O
max	O
)	O
conditions	O
in	O
SHR	O
PTE	O
cells	O
was	O
one	O
-	O
half	O
of	O
that	O
in	O
WKY	O
PTE	O
cells	O
,	O
with	O
similar	O
K	O
(	O
m	O
)	O
values	O
.	O

Differences	O
in	O
magnitude	O
of	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
l	B-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
uptake	O
through	O
ASCT2	B-GENE-Y
between	O
WKY	O
and	O
SHR	O
PTE	O
cells	O
correlated	O
positively	O
with	O
differences	O
in	O
ASCT2	B-GENE-Y
protein	O
expression	O
,	O
this	O
being	O
more	O
abundant	O
in	O
WKY	O
PTE	O
cells	O
.	O

Abundance	O
of	O
ASCT2	B-GENE-Y
transcript	O
and	O
protein	O
in	O
kidney	O
cortices	O
of	O
SHR	O
rats	O
was	O
also	O
lower	O
than	O
that	O
in	O
normotensive	O
WKY	O
rats	O
.	O

In	O
conclusion	O
,	O
immortalized	O
SHR	O
and	O
WKY	O
PTE	O
cells	O
take	O
up	O
l	B-CHEMICAL
-	I-CHEMICAL
alanine	I-CHEMICAL
mainly	O
through	O
a	O
high	O
-	O
affinity	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
amino	I-GENE-N
acid	I-GENE-N
transporter	I-GENE-N
,	O
with	O
functional	O
features	O
of	O
ASCT2	B-GENE-Y
transport	O
.	O

The	O
activity	O
and	O
expression	O
of	O
the	O
ASCT2	B-GENE-Y
transporter	O
were	O
considerably	O
lower	O
in	O
the	O
SHR	O
cells	O
.	O

Glucagon	B-GENE-Y
receptor	I-GENE-Y
antagonism	O
improves	O
islet	O
function	O
in	O
mice	O
with	O
insulin	B-GENE-N
resistance	O
induced	O
by	O
a	O
high	O
-	O
fat	O
diet	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Increased	O
glucagon	B-GENE-Y
secretion	O
predicts	O
deterioration	O
of	O
glucose	B-CHEMICAL
tolerance	O
,	O
and	O
high	O
glucagon	B-GENE-Y
levels	O
contribute	O
to	O
hyperglycaemia	O
in	O
type	O
2	O
diabetes	O
.	O

Inhibition	O
of	O
glucagon	O
action	O
may	O
therefore	O
be	O
a	O
potential	O
novel	O
target	O
to	O
reduce	O
hyperglycaemia	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
chronic	O
treatment	O
with	O
a	O
glucagon	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
(	O
GRA	O
)	O
improves	O
islet	O
dysfunction	O
in	O
female	O
mice	O
on	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
8	O
weeks	O
of	O
HFD	O
,	O
mice	O
were	O
treated	O
with	O
a	O
small	O
molecule	O
GRA	O
(	O
300	O
mg	O
/	O
kg	O
,	O
gavage	O
once	O
daily	O
)	O
for	O
up	O
to	O
30	O
days	O
.	O

Insulin	B-GENE-N
secretion	O
was	O
studied	O
after	O
oral	O
and	O
intravenous	O
administration	O
of	O
glucose	B-CHEMICAL
and	O
glucagon	B-GENE-Y
secretion	O
after	O
intravenous	O
arginine	B-CHEMICAL
.	O

Islet	O
morphology	O
was	O
examined	O
and	O
insulin	B-GENE-N
secretion	O
and	O
glucose	B-CHEMICAL
oxidation	O
were	O
measured	O
in	O
isolated	O
islets	O
.	O

RESULTS	O
:	O
Fasting	O
plasma	O
glucose	B-CHEMICAL
levels	O
were	O
reduced	O
by	O
GRA	O
(	O
6	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
2	O
vs	O
7	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
mmol	O
/	O
l	O
;	O
p	O
=	O
0	O
.	O
017	O
)	O
.	O

The	O
acute	O
insulin	B-GENE-N
response	O
to	O
intravenous	O
glucose	B-CHEMICAL
was	O
augmented	O
(	O
1	O
,	O
300	O
+	O
/	O
-	O
110	O
vs	O
790	O
+	O
/	O
-	O
64	O
pmol	O
/	O
l	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
early	O
insulin	B-GENE-N
response	O
to	O
oral	O
glucose	B-CHEMICAL
was	O
reduced	O
in	O
mice	O
on	O
HFD	O
+	O
GRA	O
(	O
1	O
,	O
890	O
+	O
/	O
-	O
160	O
vs	O
3	O
,	O
040	O
+	O
/	O
-	O
420	O
pmol	O
/	O
l	O
;	O
p	O
=	O
0	O
.	O
012	O
)	O
,	O
but	O
glucose	B-CHEMICAL
excursions	O
were	O
improved	O
.	O

Intravenous	O
arginine	B-CHEMICAL
significantly	O
increased	O
the	O
acute	O
glucagon	B-GENE-Y
response	O
(	O
129	O
+	O
/	O
-	O
12	O
vs	O
36	O
+	O
/	O
-	O
6	O
ng	O
/	O
l	O
in	O
controls	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
notably	O
without	O
affecting	O
plasma	O
glucose	B-CHEMICAL
.	O

GRA	O
caused	O
a	O
modest	O
increase	O
in	O
alpha	O
cell	O
mass	O
,	O
while	O
beta	O
cell	O
mass	O
was	O
similar	O
to	O
that	O
in	O
mice	O
on	O
HFD	O
+	O
vehicle	O
.	O

Isolated	O
islets	O
displayed	O
improved	O
glucose	B-CHEMICAL
-	O
stimulated	O
insulin	B-GENE-N
secretion	O
after	O
GRA	O
treatment	O
(	O
0	O
.	O
061	O
+	O
/	O
-	O
0	O
.	O
007	O
vs	O
0	O
.	O
030	O
+	O
/	O
-	O
0	O
.	O
004	O
pmol	O
islet	O
(	O
-	O
1	O
)	O
h	O
(	O
-	O
1	O
)	O
at	O
16	O
.	O
7	O
mmol	O
/	O
l	O
glucose	B-CHEMICAL
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
without	O
affecting	O
islet	O
glucose	B-CHEMICAL
oxidation	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Chronic	O
glucagon	B-GENE-Y
receptor	I-GENE-Y
antagonism	O
in	O
HFD	O
-	O
fed	O
mice	O
improves	O
islet	O
sensitivity	O
to	O
glucose	B-CHEMICAL
and	O
increases	O
insulin	B-GENE-N
secretion	O
,	O
suggesting	O
improvement	O
of	O
key	O
defects	O
underlying	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
and	O
type	O
2	O
diabetes	O
.	O

Hydrogen	B-CHEMICAL
sulfide	I-CHEMICAL
acts	O
as	O
a	O
mediator	O
of	O
inflammation	O
in	O
acute	O
pancreatitis	O
:	O
in	O
vitro	O
studies	O
using	O
isolated	O
mouse	O
pancreatic	O
acinar	O
cells	O
.	O

Hydrogen	B-CHEMICAL
sulphide	I-CHEMICAL
(	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
)	O
is	O
synthesized	O
from	O
L	B-CHEMICAL
-	I-CHEMICAL
cysteine	I-CHEMICAL
via	O
the	O
action	O
of	O
cystathionine	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
-	I-GENE-Y
lyase	I-GENE-Y
(	O
CSE	B-GENE-Y
)	O
and	O
cystathionine	B-GENE-Y
-	I-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
synthase	I-GENE-Y
(	O
CBS	B-GENE-Y
)	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
acts	O
as	O
a	O
mediator	O
of	O
inflammation	O
.	O

However	O
the	O
mechanism	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
presence	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
and	O
the	O
expression	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
synthesizing	O
enzymes	O
,	O
CSE	B-GENE-Y
and	O
CBS	B-GENE-Y
,	O
in	O
isolated	O
mouse	O
pancreatic	O
acini	O
.	O

Pancreatic	O
acinar	O
cells	O
from	O
mice	O
were	O
incubated	O
with	O
or	O
without	O
caerulein	B-CHEMICAL
(	O
10	O
(	O
-	O
7	O
)	O
M	O
for	O
30	O
and	O
60	O
min	O
)	O
.	O

Caerulein	B-CHEMICAL
increased	O
the	O
levels	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
and	O
CSE	B-GENE-Y
mRNA	O
expression	O
while	O
CBS	B-GENE-Y
mRNA	O
expression	O
was	O
decreased	O
.	O

In	O
addition	O
,	O
cells	O
pre	O
-	O
treated	O
with	O
DL	B-CHEMICAL
-	I-CHEMICAL
propargylglycine	I-CHEMICAL
(	O
PAG	B-CHEMICAL
,	O
3	O
mM	O
)	O
,	O
a	O
CSE	B-GENE-Y
inhibitor	O
,	O
reduced	O
the	O
formation	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
in	O
caerulein	B-CHEMICAL
treated	O
cells	O
,	O
suggesting	O
that	O
CSE	B-GENE-Y
may	O
be	O
the	O
main	O
enzyme	O
involved	O
in	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
formation	O
in	O
mouse	O
acinar	O
cells	O
.	O

Furthermore	O
,	O
substance	B-CHEMICAL
P	I-CHEMICAL
(	O
SP	B-CHEMICAL
)	O
concentration	O
in	O
the	O
acini	O
and	O
expression	O
of	O
SP	B-CHEMICAL
gene	O
(	O
preprotachykinin	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
,	O
PPT	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
)	O
and	O
neurokinin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
NK	B-GENE-Y
-	I-GENE-Y
1R	I-GENE-Y
)	O
,	O
the	O
primary	O
receptor	O
for	O
SP	B-CHEMICAL
,	O
are	O
increased	O
in	O
secretagogue	O
caerulein	B-CHEMICAL
-	O
treated	O
acinar	O
cells	O
.	O

Inhibition	O
of	O
endogenous	O
production	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
by	O
PAG	B-CHEMICAL
significantly	O
suppressed	O
SP	B-CHEMICAL
concentration	O
,	O
PPT	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
expression	O
and	O
NK1	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
expression	O
in	O
the	O
acini	O
.	O

To	O
determine	O
whether	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
itself	O
provoked	O
inflammation	O
in	O
acinar	O
cells	O
,	O
the	O
cells	O
were	O
treated	O
with	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
donor	O
drug	O
,	O
sodium	B-CHEMICAL
hydrosulphide	I-CHEMICAL
(	O
NaHS	B-CHEMICAL
)	O
,	O
(	O
10	O
,	O
50	O
and	O
100	O
muM	O
)	O
,	O
that	O
resulted	O
in	O
a	O
significant	O
increase	O
in	O
SP	B-CHEMICAL
concentration	O
and	O
expression	O
of	O
PPT	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
NK1	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
in	O
acinar	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
pro	O
-	O
inflammatory	O
effect	O
of	O
H	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
may	O
be	O
mediated	O
by	O
SP	B-GENE-Y
-	O
NK	B-GENE-Y
-	I-GENE-Y
1R	I-GENE-Y
related	O
pathway	O
in	O
mouse	O
pancreatic	O
acinar	O
cells	O
.	O

IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
stimulates	O
the	O
expression	O
of	O
CXCL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
and	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
mRNA	O
by	O
equine	O
pulmonary	O
artery	O
endothelial	O
cells	O
.	O

Little	O
is	O
known	O
concerning	O
the	O
possible	O
contribution	O
of	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
-	O
type	O
cytokines	B-GENE-N
to	O
the	O
recruitment	O
of	O
neutrophils	O
into	O
the	O
lung	O
tissue	O
.	O

In	O
the	O
present	O
study	O
,	O
endothelial	O
cells	O
from	O
equine	O
pulmonary	O
arteries	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
recombinant	O
equine	B-GENE-Y
(	I-GENE-Y
re	I-GENE-Y
)	I-GENE-Y
IL	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
reIL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
,	O
and	O
the	O
cytokine	B-GENE-N
mRNA	O
expression	O
of	O
molecules	O
implicated	O
in	O
the	O
chemotaxis	O
and	O
migration	O
of	O
neutrophils	O
was	O
studied	O
using	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

The	O
functional	O
response	O
of	O
reIL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
-	O
induced	O
endothelial	O
cell	O
stimulation	O
on	O
neutrophil	O
migration	O
was	O
also	O
studied	O
using	O
a	O
chemotaxis	O
chamber	O
.	O

ReIL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
either	O
increased	O
the	O
expression	O
of	O
CXCL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
,	O
and	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
,	O
or	O
potentiated	O
the	O
coeffects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
)	O
on	O
CXCL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
.	O

Supernatants	O
collected	O
from	O
cultured	O
endothelial	O
cells	O
stimulated	O
with	O
reIL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
significantly	O
promoted	O
neutrophil	O
migration	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Dexamethasone	B-CHEMICAL
(	O
DXM	B-CHEMICAL
)	O
decreased	O
the	O
expression	O
of	O
CXCL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
and	O
iNOS	B-GENE-Y
induced	O
by	O
reIL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
while	O
1400W	B-CHEMICAL
dihydrochloride	I-CHEMICAL
(	O
1400W	B-CHEMICAL
)	O
,	O
a	O
selective	O
inhibitor	O
of	O
iNOS	B-GENE-Y
,	O
decreased	O
the	O
expression	O
of	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
VEGF	B-GENE-Y
,	O
and	O
iNOS	B-GENE-Y
.	O

DXM	B-CHEMICAL
and	O
1400W	B-CHEMICAL
attenuated	O
the	O
mRNA	O
expression	O
of	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
and	O
iNOS	B-GENE-Y
induced	O
by	O
the	O
costimulation	O
of	O
reIL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
reTNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
,	O
and	O
LPS	O
.	O

Neither	O
equine	B-GENE-N
nor	I-GENE-N
human	I-GENE-N
recombinant	I-GENE-N
IL	I-GENE-N
-	I-GENE-N
5	I-GENE-N
influenced	O
the	O
mRNA	O
expression	O
of	O
CXCL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
or	O
VEGF	B-GENE-Y
.	O

These	O
findings	O
suggest	O
that	O
Th2	O
-	O
type	O
cytokines	B-GENE-N
may	O
contribute	O
to	O
pulmonary	O
neutrophilia	O
during	O
allergic	O
inflammation	O
by	O
the	O
increased	O
expression	O
of	O
neutrophil	O
chemokines	B-GENE-N
and	O
adhesion	B-GENE-N
molecules	I-GENE-N
by	O
endothelial	O
cells	O
.	O

DXM	B-CHEMICAL
and	O
the	O
iNOS	B-GENE-Y
inhibitors	O
may	O
decrease	O
pulmonary	O
neutrophilia	O
due	O
,	O
in	O
part	O
,	O
to	O
a	O
direct	O
inhibition	O
of	O
some	O
of	O
these	O
factors	O
.	O

[	O
Short	O
QT	O
syndrome	O
]	O
.	O

Short	O
QT	O
syndrome	O
is	O
a	O
new	O
genetic	O
disorder	O
associated	O
with	O
familial	O
atrial	O
fibrillation	O
and	O
/	O
or	O
sudden	O
death	O
or	O
syncope	O
.	O

To	O
date	O
,	O
different	O
mutations	O
in	O
genes	O
encoding	O
for	O
cardiac	B-GENE-N
ion	I-GENE-N
channels	I-GENE-N
(	O
KCNH2	B-GENE-Y
,	O
KCNQ1	B-GENE-Y
,	O
and	O
KCNJ2	B-GENE-Y
)	O
have	O
been	O
identified	O
to	O
cause	O
the	O
short	O
QT	O
syndrome	O
.	O

The	O
mutations	O
lead	O
to	O
a	O
gain	O
of	O
function	O
of	O
the	O
affected	O
current	O
(	O
IKr	B-GENE-Y
,	O
IKs	B-GENE-Y
,	O
and	O
IK1	B-GENE-Y
)	O
.	O

The	O
phenotype	O
is	O
characterized	O
by	O
a	O
shortened	O
QT	O
interval	O
<	O
335	O
ms	O
after	O
correction	O
for	O
heart	O
rate	O
at	O
rates	O
<	O
80	O
beats	O
/	O
min	O
.	O

Furthermore	O
,	O
the	O
QT	O
interval	O
poorly	O
adapts	O
to	O
heart	O
rate	O
.	O

Patients	O
exhibit	O
shortened	O
atrial	O
and	O
ventricular	O
effective	O
refractory	O
periods	O
and	O
,	O
in	O
the	O
majority	O
,	O
inducibility	O
of	O
ventricular	O
fibrillation	O
.	O

Death	O
occurs	O
already	O
in	O
newborns	O
.	O

Therapy	O
of	O
choice	O
seems	O
to	O
be	O
the	O
implantable	O
cardioverter	O
defibrillator	O
because	O
of	O
the	O
high	O
incidence	O
of	O
sudden	O
death	O
.	O

Pharmacological	O
treatment	O
has	O
been	O
studied	O
and	O
it	O
could	O
be	O
demonstrated	O
,	O
that	O
some	O
mutant	O
currents	O
may	O
be	O
insufficiently	O
suppressed	O
by	O
drugs	O
targeted	O
to	O
block	O
the	O
specific	O
current	O
such	O
as	O
,	O
e	O
.	O
g	O
.	O
,	O
sotalol	B-CHEMICAL
or	O
ibutilide	B-CHEMICAL
in	O
patients	O
with	O
a	O
mutation	O
in	O
the	O
IKr	B-GENE-Y
-	O
coding	O
gene	O
KCNH2	B-GENE-Y
(	O
HERG	B-GENE-Y
)	O
.	O

Quinidine	B-CHEMICAL
proved	O
to	O
be	O
efficient	O
in	O
prolonging	O
the	O
QT	O
interval	O
and	O
normalizing	O
the	O
effective	O
refractory	O
periods	O
in	O
some	O
patients	O
.	O

Serine	B-GENE-N
racemases	I-GENE-N
from	O
barley	O
,	O
Hordeum	O
vulgare	O
L	O
.	O
,	O
and	O
other	O
plant	O
species	O
represent	O
a	O
distinct	O
eukaryotic	O
group	O
:	O
gene	O
cloning	O
and	O
recombinant	O
protein	O
characterization	O
.	O

Several	O
d	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
acids	I-CHEMICAL
have	O
been	O
identified	O
in	O
plants	O
.	O

However	O
,	O
the	O
biosynthetic	O
pathway	O
to	O
them	O
is	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
cloned	O
and	O
sequenced	O
a	O
cDNA	O
encoding	O
a	O
serine	B-GENE-Y
racemase	I-GENE-Y
from	O
barley	O
which	O
contained	O
an	O
open	O
reading	O
frame	O
encoding	O
337	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
.	O

The	O
deduced	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
showed	O
significant	O
identity	O
to	O
plant	O
and	O
mammalian	O
serine	B-GENE-N
racemases	I-GENE-N
and	O
contained	O
conserved	O
pyridoxal	B-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
PLP	B-CHEMICAL
)	O
-	O
binding	O
lysine	B-CHEMICAL
and	O
PLP	B-CHEMICAL
-	O
interacting	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
.	O

The	O
purified	O
gene	O
product	O
catalyzed	O
not	O
only	O
racemization	O
of	O
serine	B-CHEMICAL
but	O
also	O
dehydration	O
of	O
serine	B-CHEMICAL
to	O
pyruvate	B-CHEMICAL
.	O

The	O
enzyme	O
requires	O
PLP	B-CHEMICAL
and	O
divalent	O
cations	O
such	O
as	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
Mg	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
or	O
Mn	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
but	O
not	O
ATP	B-CHEMICAL
,	O
whereas	O
mammalian	O
serine	B-GENE-N
racemase	I-GENE-N
activity	O
is	O
increased	O
by	O
ATP	B-CHEMICAL
.	O

In	O
addition	O
to	O
the	O
results	O
regarding	O
the	O
effect	O
of	O
ATP	B-CHEMICAL
on	O
enzyme	O
activity	O
and	O
the	O
phylogenetic	O
analysis	O
of	O
eukaryotic	O
serine	B-GENE-N
racemases	I-GENE-N
,	O
the	O
antiserum	O
against	O
Arabidopsis	B-GENE-Y
serine	I-GENE-Y
racemase	I-GENE-Y
did	O
not	O
form	O
a	O
precipitate	O
with	O
barley	O
and	O
rice	O
serine	B-GENE-N
racemases	I-GENE-N
.	O

This	O
suggests	O
that	O
plant	O
serine	B-GENE-N
racemases	I-GENE-N
represent	O
a	O
distinct	O
group	O
in	O
the	O
eukaryotic	O
serine	B-GENE-N
racemase	I-GENE-N
family	O
and	O
can	O
be	O
clustered	O
into	O
monocot	O
and	O
dicot	O
types	O
.	O

Estimation	O
of	O
warfarin	B-CHEMICAL
maintenance	O
dose	O
based	O
on	O
VKORC1	B-GENE-Y
(	O
-	B-GENE-N
1639	I-GENE-N
G	I-GENE-N
>	I-GENE-N
A	I-GENE-N
)	O
and	O
CYP2C9	B-GENE-Y
genotypes	O
.	O

BACKGROUND	O
:	O
CYP2C9	B-GENE-Y
polymorphisms	O
are	O
associated	O
with	O
decreased	O
S	B-CHEMICAL
-	I-CHEMICAL
warfarin	I-CHEMICAL
clearance	O
and	O
lower	O
maintenance	O
dosage	O
.	O

Decreased	O
expression	O
of	O
VKORC1	B-GENE-Y
resulting	O
from	O
the	O
-	B-GENE-N
1639G	I-GENE-N
>	I-GENE-N
A	I-GENE-N
substitution	O
has	O
also	O
been	O
implicated	O
in	O
lower	O
warfarin	B-CHEMICAL
dose	O
requirements	O
.	O

We	O
investigated	O
the	O
additional	O
contribution	O
of	O
this	O
polymorphism	O
to	O
the	O
variance	O
in	O
warfarin	B-CHEMICAL
dose	O
.	O

METHODS	O
:	O
Sixty	O
-	O
five	O
patients	O
with	O
stable	O
anticoagulation	O
were	O
genotyped	O
for	O
CYP2C9	B-GENE-Y
and	O
VKORC1	B-GENE-Y
with	O
Tag	O
-	O
It	O
allele	O
-	O
specific	O
primer	O
extension	O
technology	O
.	O

Plasma	O
S	B-CHEMICAL
-	I-CHEMICAL
warfarin	I-CHEMICAL
concentrations	O
and	O
warfarin	B-CHEMICAL
maintenance	O
dose	O
were	O
compared	O
among	O
patients	O
on	O
the	O
basis	O
of	O
the	O
VKORC1	B-GENE-Y
-	B-GENE-N
1639G	I-GENE-N
>	I-GENE-N
A	I-GENE-N
genotype	O
.	O

RESULTS	O
:	O
Eighty	O
percent	O
of	O
CYP2C9	B-GENE-Y
*	O
1	O
/	O
*	O
1	O
patients	O
stabilized	O
on	O
<	O
4	O
.	O
0	O
mg	O
/	O
day	O
warfarin	B-CHEMICAL
had	O
at	O
least	O
1	O
VKORC1	B-GENE-Y
-	O
1639A	O
allele	O
.	O

Mean	O
warfarin	B-CHEMICAL
doses	O
(	O
SD	O
)	O
were	O
6	O
.	O
7	O
(	O
3	O
.	O
3	O
)	O
,	O
4	O
.	O
3	O
(	O
2	O
.	O
2	O
)	O
,	O
and	O
2	O
.	O
7	O
(	O
1	O
.	O
2	O
)	O
mg	O
/	O
day	O
for	O
patients	O
with	O
the	O
VKORC1	B-GENE-Y
-	O
1639GG	O
,	O
GA	O
,	O
and	O
AA	O
genotypes	O
,	O
respectively	O
.	O

Steady	O
-	O
state	O
plasma	O
concentrations	O
of	O
S	B-CHEMICAL
-	I-CHEMICAL
warfarin	I-CHEMICAL
were	O
lowest	O
in	O
patients	O
with	O
the	O
VKORC1	B-GENE-Y
-	O
1639AA	O
genotype	O
and	O
demonstrated	O
a	O
positive	O
association	O
with	O
the	O
VKORC1	B-GENE-Y
-	O
1639G	O
allele	O
copy	O
number	O
(	O
trend	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

A	O
model	O
including	O
VKORC1	B-GENE-Y
and	O
CYP2C9	B-GENE-Y
genotypes	O
,	O
age	O
,	O
sex	O
,	O
and	O
body	O
weight	O
accounted	O
for	O
61	O
%	O
of	O
the	O
variance	O
in	O
warfarin	B-CHEMICAL
daily	O
maintenance	O
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
VKORC1	B-GENE-Y
-	O
1639A	O
allele	O
accounts	O
for	O
low	O
dosage	O
requirements	O
of	O
most	O
patients	O
without	O
a	O
CYP2C9	B-GENE-Y
variant	O
.	O

Higher	O
plasma	O
S	B-CHEMICAL
-	I-CHEMICAL
warfarin	I-CHEMICAL
concentrations	O
corresponding	O
to	O
increased	O
warfarin	B-CHEMICAL
maintenance	O
dosages	O
support	O
a	O
hypothesis	O
for	O
increased	O
expression	O
of	O
the	O
VKORC1	B-GENE-Y
-	O
1639G	O
allele	O
.	O

VKORC1	B-GENE-Y
and	O
CYP2C9	B-GENE-Y
genotypes	O
,	O
age	O
,	O
sex	O
,	O
and	O
body	O
weight	O
account	O
for	O
the	O
majority	O
of	O
variance	O
in	O
warfarin	B-CHEMICAL
dose	O
among	O
our	O
study	O
population	O
.	O

Cytosolic	B-GENE-Y
aspartate	I-GENE-Y
aminotransferase	I-GENE-Y
,	O
a	O
new	O
partner	O
in	O
adipocyte	O
glyceroneogenesis	O
and	O
an	O
atypical	O
target	O
of	O
thiazolidinedione	B-CHEMICAL
.	O

We	O
show	O
that	O
cytosolic	B-GENE-Y
aspartate	I-GENE-Y
aminotransferase	I-GENE-Y
(	O
cAspAT	B-GENE-Y
)	O
is	O
involved	O
in	O
adipocyte	O
glyceroneogenesis	O
,	O
a	O
regulated	O
pathway	O
that	O
controls	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
homeostasis	O
by	O
promoting	O
glycerol	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
formation	O
for	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
re	O
-	O
esterification	O
during	O
fasting	O
.	O

cAspAT	B-GENE-Y
activity	O
,	O
as	O
well	O
as	O
the	O
incorporation	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
aspartate	I-CHEMICAL
into	O
the	O
neutral	O
lipid	O
fraction	O
of	O
3T3	O
-	O
F442A	B-GENE-N
adipocytes	O
was	O
stimulated	O
by	O
the	O
thiazolidinedione	B-CHEMICAL
(	O
TZD	B-CHEMICAL
)	O
rosiglitazone	B-CHEMICAL
.	O

Conversely	O
,	O
the	O
ratio	O
of	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
to	O
glycerol	B-CHEMICAL
released	O
into	O
the	O
medium	O
decreased	O
.	O

Regulation	O
of	O
cAspAT	B-GENE-Y
gene	O
expression	O
was	O
specific	O
to	O
differentiated	O
adipocytes	O
and	O
did	O
not	O
require	O
any	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
PPARgamma	B-GENE-Y
)	O
/	O
retinoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
direct	O
binding	O
.	O

Nevertheless	O
,	O
PPARgamma	B-GENE-Y
is	O
indirectly	O
necessary	O
for	O
both	O
cAspAT	B-GENE-Y
basal	O
expression	O
and	O
TZD	B-CHEMICAL
responsiveness	O
because	O
they	O
are	O
,	O
respectively	O
,	O
diminished	O
and	O
abolished	O
by	O
ectopic	O
overexpression	O
of	O
a	O
dominant	O
negative	O
PPARgamma	B-GENE-Y
.	O

The	O
cAspAT	B-GENE-Y
TZD	B-CHEMICAL
-	O
responsive	O
site	O
was	O
restricted	O
to	O
a	O
single	O
AGGACA	B-CHEMICAL
hexanucleotide	B-CHEMICAL
located	O
at	O
-	O
381	O
to	O
-	O
376	O
bp	O
whose	O
mutation	O
impaired	O
the	O
specific	O
RORalpha	B-GENE-Y
binding	O
.	O

RORalpha	B-GENE-Y
ectopic	O
expression	O
activated	O
the	O
cAspAT	B-GENE-Y
gene	O
transcription	O
in	O
absence	O
of	O
rosiglitazone	B-CHEMICAL
,	O
and	O
its	O
protein	O
amount	O
in	O
nuclear	O
extracts	O
is	O
1	O
.	O
8	O
-	O
fold	O
increased	O
by	O
rosiglitazone	B-CHEMICAL
treatment	O
of	O
adipocytes	O
.	O

Finally	O
,	O
the	O
amounts	O
of	O
RORalpha	B-GENE-Y
and	O
cAspAT	B-GENE-Y
mRNAs	O
were	O
similarly	O
increased	O
by	O
TZD	B-CHEMICAL
treatment	O
of	O
human	O
adipose	O
tissue	O
explants	O
,	O
confirming	O
coordinated	O
regulation	O
.	O

Our	O
data	O
identify	O
cAspAT	B-GENE-Y
as	O
a	O
new	O
member	O
of	O
glyceroneogenesis	O
,	O
transcriptionally	O
regulated	O
by	O
TZD	B-CHEMICAL
via	O
the	O
control	O
of	O
RORalpha	B-GENE-Y
expression	O
by	O
PPARgamma	B-GENE-Y
in	O
adipocytes	O
.	O

Parnaparin	O
,	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
,	O
prevents	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
-	O
dependent	O
formation	O
of	O
platelet	O
-	O
leukocyte	O
aggregates	O
in	O
human	O
whole	O
blood	O
.	O

Parnaparin	O
,	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
(	O
LMWH	O
)	O
,	O
prevents	O
platelet	O
activation	O
and	O
interaction	O
with	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
in	O
a	O
washed	O
cell	O
system	O
.	O

The	O
in	O
-	O
vitro	O
effect	O
of	O
parnaparin	O
was	O
studied	O
here	O
on	O
platelet	O
-	O
PMN	O
aggregates	O
formed	O
with	O
more	O
physiologic	O
approaches	O
in	O
whole	O
blood	O
,	O
in	O
parallel	O
with	O
unfractionated	O
heparin	O
and	O
enoxaparin	O
,	O
another	O
LMWH	O
.	O

Citrated	O
blood	O
from	O
healthy	O
subjects	O
was	O
stimulated	O
:	O
i	O
)	O
from	O
passage	O
through	O
the	O
"	O
Platelet	O
Function	O
Analyzer	O
"	O
(	O
PFA	O
-	O
100	O
)	O
,	O
a	O
device	O
that	O
exposes	O
blood	O
to	O
standardized	O
high	O
shear	O
flow	O
through	O
collagen	B-GENE-N
/	O
ADP	B-CHEMICAL
cartridges	O
;	O
ii	O
)	O
by	O
collagen	O
and	O
ADP	B-CHEMICAL
(	O
2	O
and	O
50	O
mug	O
/	O
ml	O
,	O
respectively	O
)	O
added	O
in	O
combination	O
under	O
stirring	O
in	O
an	O
aggregometer	O
cuvette	O
;	O
iii	O
)	O
with	O
recombinant	O
Tissue	B-GENE-Y
Factor	I-GENE-Y
,	O
to	O
generate	O
thrombin	B-GENE-Y
concentrations	O
able	O
to	O
activate	O
platelets	O
without	O
inducing	O
blood	O
clotting	O
,	O
or	O
iv	O
)	O
the	O
Thrombin	O
Receptor	O
Activating	O
Peptide	O
-	O
6	O
(	O
TRAP	O
-	O
6	O
)	O
.	O

Platelet	B-GENE-Y
P	I-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
and	O
platelet	O
-	O
PMN	O
aggregates	O
were	O
measured	O
by	O
flow	O
cytometry	O
upon	O
stimulation	O
of	O
blood	O
.	O

Fibrinogen	B-GENE-N
binding	O
to	O
platelets	O
and	O
markers	O
of	O
PMN	O
activation	O
were	O
also	O
detected	O
.	O

Platelet	B-GENE-Y
P	I-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
expression	O
and	O
platelet	O
-	O
PMN	O
aggregate	O
formation	O
were	O
induced	O
in	O
all	O
four	O
activation	O
conditions	O
tested	O
.	O

Parnaparin	O
prevented	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
0	O
.	O
3	O
-	O
0	O
.	O
8	O
IUaXa	O
/	O
ml	O
)	O
the	O
expression	O
of	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
and	O
the	O
formation	O
of	O
mixed	O
aggregates	O
,	O
while	O
the	O
two	O
reference	O
heparin	O
preparations	O
had	O
a	O
much	O
weaker	O
effect	O
.	O

Platelet	B-GENE-N
fibrinogen	I-GENE-N
binding	O
and	O
PMN	O
activation	O
markers	O
(	O
fibrinogen	B-GENE-N
binding	O
,	O
CD11b	B-GENE-Y
and	O
CD40	B-GENE-Y
)	O
were	O
also	O
prevented	O
by	O
parnaparin	O
.	O

These	O
data	O
extend	O
in	O
more	O
physiological	O
systems	O
of	O
platelet	O
activation	O
,	O
the	O
anti	O
-	O
inflammatory	O
profile	O
of	O
parnaparin	O
,	O
previously	O
reported	O
in	O
washed	O
cells	O
.	O

The	O
greater	O
effect	O
of	O
parnaparin	O
,	O
as	O
compared	O
to	O
the	O
reference	O
heparins	O
,	O
could	O
be	O
due	O
to	O
chemico	O
-	O
physical	O
differences	O
possibly	O
unrelated	O
to	O
their	O
anticoagulant	O
effect	O
.	O

Transfection	O
of	O
HepG2	O
cells	O
with	O
hGSTA4	B-GENE-Y
provides	O
protection	O
against	O
4	B-CHEMICAL
-	I-CHEMICAL
hydroxynonenal	I-CHEMICAL
-	O
mediated	O
oxidative	O
injury	O
.	O

4	B-CHEMICAL
-	I-CHEMICAL
Hydroxynonenal	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
)	O
is	O
a	O
mutagenic	O
alpha	B-CHEMICAL
,	I-CHEMICAL
beta	I-CHEMICAL
-	I-CHEMICAL
unsaturated	I-CHEMICAL
aldehyde	I-CHEMICAL
produced	O
during	O
oxidative	O
injury	O
that	O
is	O
conjugated	O
by	O
several	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
(	O
GST	B-GENE-N
)	O
isoforms	O
.	O

The	O
alpha	O
class	O
human	B-GENE-Y
GSTA4	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
enzyme	O
(	O
hGSTA4	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
has	O
a	O
particularly	O
high	O
catalytic	O
efficiency	O
toward	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
conjugation	O
.	O

However	O
,	O
hGST4	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
expression	O
is	O
low	O
in	O
most	O
human	O
cells	O
and	O
there	O
are	O
other	O
aldehyde	B-CHEMICAL
metabolizing	O
enzymes	O
that	O
detoxify	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
.	O

In	O
the	O
current	O
study	O
,	O
we	O
determined	O
the	O
effect	O
of	O
over	O
-	O
expression	O
of	O
hGSTA4	B-GENE-Y
mRNA	O
on	O
the	O
sensitivity	O
of	O
HepG2	O
cells	O
to	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
injury	O
.	O

HepG2	O
cells	O
transfected	O
with	O
an	O
hGSTA4	B-GENE-Y
vector	O
construct	O
exhibited	O
high	O
steady	O
-	O
state	O
hGSTA4	B-GENE-Y
mRNA	O
,	O
high	O
GST	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
-	O
HNE	O
catalytic	O
activities	O
,	O
but	O
lower	O
basal	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
concentrations	O
relative	O
to	O
insert	O
-	O
free	O
vector	O
(	O
control	O
)	O
cells	O
.	O

Exposure	O
to	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
elicited	O
an	O
increase	O
in	O
GSH	B-CHEMICAL
concentrations	O
in	O
the	O
control	O
and	O
hGSTA4	B-GENE-Y
cells	O
,	O
although	O
the	O
dose	O
-	O
response	O
of	O
GSH	B-CHEMICAL
induction	O
differed	O
among	O
the	O
two	O
cell	O
types	O
.	O

Specifically	O
,	O
hGSTA4	B-GENE-Y
cells	O
had	O
significantly	O
higher	O
GSH	B-CHEMICAL
concentrations	O
when	O
exposed	O
to	O
5	O
-	O
15	O
microM	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
,	O
but	O
not	O
at	O
20	O
microM	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
,	O
suggesting	O
extensive	O
GSH	B-CHEMICAL
utilization	O
at	O
high	O
concentrations	O
of	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
.	O

The	O
hGSTA4	B-GENE-Y
cells	O
exhibited	O
a	O
significant	O
growth	O
advantage	O
relative	O
to	O
control	O
cells	O
in	O
the	O
absence	O
of	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
,	O
and	O
a	O
trend	O
towards	O
increased	O
growth	O
at	O
low	O
dose	O
exposures	O
to	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
.	O

However	O
,	O
the	O
hGSTA4	B-GENE-Y
cells	O
did	O
not	O
exhibit	O
a	O
growth	O
advantage	O
relative	O
to	O
control	O
cells	O
at	O
higher	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
exposures	O
associated	O
with	O
increased	O
GSH	B-CHEMICAL
utilization	O
.	O

As	O
expected	O
,	O
the	O
hGSTA4	B-GENE-Y
cells	O
showed	O
resistance	O
to	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
stimulated	O
lipid	O
peroxidation	O
at	O
all	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
doses	O
.	O

In	O
summary	O
,	O
our	O
data	O
indicates	O
that	O
over	O
-	O
expression	O
of	O
hGSTA4	B-GENE-Y
at	O
levels	O
conferring	O
high	O
GST	B-GENE-N
-	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
conjugating	O
activity	O
confers	O
a	O
partial	O
growth	O
advantage	O
to	O
HepG2	O
cells	O
and	O
protects	O
against	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
oxidative	O
injury	O
.	O

However	O
,	O
the	O
loss	O
of	O
proliferative	O
capacity	O
of	O
hGSTA4	B-GENE-Y
cells	O
challenged	O
with	O
levels	O
of	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
associated	O
with	O
severe	O
oxidative	O
stress	O
indicates	O
a	O
role	O
of	O
other	O
aldehyde	B-CHEMICAL
metabolizing	O
enzymes	O
,	O
and	O
/	O
or	O
GSH	B-CHEMICAL
-	O
electrophile	O
transporter	O
proteins	O
,	O
in	O
providing	O
full	O
cellular	O
protection	O
against	O
4	B-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
toxicity	O
.	O

EphB1	B-GENE-Y
null	O
mice	O
exhibit	O
neuronal	O
loss	O
in	O
substantia	O
nigra	O
pars	O
reticulata	O
and	O
spontaneous	O
locomotor	O
hyperactivity	O
.	O

The	O
molecular	O
mechanisms	O
that	O
regulate	O
basal	O
ganglia	O
development	O
are	O
largely	O
unknown	O
.	O

Eph	B-GENE-N
receptor	I-GENE-N
tyrosine	B-GENE-N
kinases	I-GENE-N
are	O
potential	O
participants	O
in	O
this	O
process	O
as	O
they	O
regulate	O
development	O
of	O
other	O
CNS	O
regions	O
and	O
are	O
expressed	O
in	O
basal	O
ganglia	O
nuclei	O
,	O
such	O
as	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
and	O
striatum	O
.	O

To	O
address	O
the	O
role	O
of	O
Eph	B-GENE-N
receptors	I-GENE-N
in	O
the	O
development	O
of	O
these	O
nuclei	O
,	O
we	O
analysed	O
anatomical	O
changes	O
in	O
the	O
SN	O
and	O
striatum	O
of	O
mice	O
with	O
null	O
mutations	O
for	O
EphB1	B-GENE-Y
.	O

These	O
mice	O
express	O
beta	O
-	O
galactosidase	O
as	O
a	O
marker	O
for	O
cells	O
normally	O
expressing	O
EphB1	B-GENE-Y
.	O

In	O
situ	O
hybridization	O
data	O
and	O
a	O
direct	O
comparison	O
of	O
SN	O
neurons	O
expressing	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
TH	B-GENE-Y
)	O
and	O
/	O
or	O
the	O
beta	O
-	O
gal	O
marker	O
for	O
EphB1	B-GENE-Y
revealed	O
that	O
EphB1	B-GENE-Y
is	O
not	O
expressed	O
in	O
TH	B-GENE-Y
+	O
neurons	O
of	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
but	O
is	O
restricted	O
to	O
neurons	O
in	O
pars	O
reticulata	O
(	O
SNr	O
)	O
.	O

Consistent	O
with	O
this	O
,	O
we	O
find	O
that	O
EphB1	B-GENE-Y
null	O
mice	O
exhibit	O
a	O
significant	O
decrease	O
in	O
the	O
volume	O
and	O
number	O
of	O
neurons	O
(	O
40	O
%	O
decrease	O
)	O
in	O
SNr	O
,	O
whereas	O
the	O
volume	O
and	O
number	O
of	O
TH	B-GENE-Y
+	O
neurons	O
in	O
SNc	O
is	O
not	O
significantly	O
affected	O
nor	O
are	O
there	O
changes	O
in	O
the	O
distribution	O
of	O
nigrostriatal	O
dopamine	B-CHEMICAL
neurons	O
.	O

Although	O
EphB1	B-GENE-Y
is	O
expressed	O
in	O
the	O
striatum	O
,	O
EphB1	B-GENE-Y
-	O
/	O
-	O
mice	O
exhibit	O
no	O
significant	O
changes	O
in	O
striatal	O
volume	O
and	O
TH	B-GENE-Y
fiber	O
density	O
,	O
and	O
have	O
no	O
obvious	O
alterations	O
in	O
striatal	O
patch	O
/	O
matrix	O
organization	O
.	O

Behavioral	O
evaluation	O
of	O
EphB1	B-GENE-Y
null	O
mice	O
in	O
an	O
open	O
-	O
field	O
environment	O
revealed	O
that	O
these	O
mice	O
exhibited	O
spontaneous	O
locomotor	O
hyperactivity	O
.	O

These	O
results	O
suggest	O
that	O
EphB1	B-GENE-Y
is	O
necessary	O
for	O
the	O
proper	O
formation	O
of	O
SNr	O
,	O
and	O
that	O
neuronal	O
loss	O
in	O
SNr	O
is	O
associated	O
with	O
altered	O
locomotor	O
functions	O
.	O

Artificial	O
sweeteners	O
and	O
salts	O
producing	O
a	O
metallic	O
taste	O
sensation	O
activate	O
TRPV1	B-GENE-Y
receptors	O
.	O

Throughout	O
the	O
world	O
many	O
people	O
use	O
artificial	O
sweeteners	O
(	O
AS	O
)	O
for	O
the	O
purpose	O
of	O
reducing	O
caloric	O
intake	O
.	O

The	O
most	O
prominently	O
used	O
of	O
these	O
molecules	O
include	O
saccharin	B-CHEMICAL
,	O
aspartame	B-CHEMICAL
(	O
Nutrasweet	B-CHEMICAL
)	O
,	O
acesulfame	B-CHEMICAL
-	I-CHEMICAL
K	I-CHEMICAL
,	O
and	O
cyclamate	B-CHEMICAL
.	O

Despite	O
the	O
caloric	O
advantage	O
they	O
provide	O
,	O
one	O
key	O
concern	O
in	O
their	O
use	O
is	O
their	O
aversive	O
aftertaste	O
that	O
has	O
been	O
characterized	O
on	O
a	O
sensory	O
level	O
as	O
bitter	O
and	O
/	O
or	O
metallic	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
activation	O
of	O
particular	O
T2R	B-GENE-N
bitter	O
taste	O
receptors	O
is	O
partially	O
involved	O
with	O
the	O
bitter	O
aftertaste	O
sensation	O
of	O
saccharin	B-CHEMICAL
and	O
acesulfame	B-CHEMICAL
-	I-CHEMICAL
K	I-CHEMICAL
.	O

To	O
more	O
fully	O
understand	O
the	O
biology	O
behind	O
these	O
phenomena	O
we	O
have	O
addressed	O
the	O
question	O
of	O
whether	O
AS	O
could	O
stimulate	O
transient	B-GENE-Y
receptor	I-GENE-Y
potential	I-GENE-Y
vanilloid	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	I-GENE-Y
TRPV1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
,	O
as	O
these	O
receptors	O
are	O
activated	O
by	O
a	O
large	O
range	O
of	O
structurally	O
different	O
chemicals	O
.	O

Moreover	O
,	O
TRPV1	B-GENE-Y
receptors	O
and	O
/	O
or	O
their	O
variants	O
are	O
found	O
in	O
taste	O
receptor	O
cells	O
and	O
in	O
nerve	O
terminals	O
throughout	O
the	O
oral	O
cavity	O
.	O

Hence	O
,	O
TRPV1	B-GENE-Y
activation	O
could	O
be	O
involved	O
in	O
the	O
AS	O
aftertaste	O
or	O
even	O
contribute	O
to	O
the	O
poorly	O
understood	O
metallic	O
taste	O
sensation	O
.	O

Using	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
imaging	O
on	O
TRPV1	B-GENE-Y
receptors	O
heterologously	O
expressed	O
in	O
the	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
293	O
cells	O
and	O
on	O
dissociated	O
primary	O
sensory	O
neurons	O
,	O
we	O
find	O
that	O
in	O
both	O
systems	O
,	O
AS	O
activate	O
TRPV1	B-GENE-Y
receptors	O
,	O
and	O
,	O
moreover	O
,	O
they	O
sensitize	O
these	O
channels	O
to	O
acid	O
and	O
heat	O
.	O

We	O
also	O
found	O
that	O
TRPV1	B-GENE-Y
receptors	O
are	O
activated	O
by	O
CuSO	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	O
ZnSO	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	O
and	O
FeSO	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
,	O
three	O
salts	O
known	O
to	O
produce	O
a	O
metallic	O
taste	O
sensation	O
.	O

In	O
summary	O
,	O
our	O
results	O
identify	O
a	O
novel	O
group	O
of	O
compounds	O
that	O
activate	O
TRPV1	B-GENE-Y
and	O
,	O
consequently	O
,	O
provide	O
a	O
molecular	O
mechanism	O
that	O
may	O
account	O
for	O
off	O
tastes	O
of	O
sweeteners	O
and	O
metallic	O
tasting	O
salts	O
.	O

Anthocyanin	B-CHEMICAL
,	O
antioxidant	O
activity	O
and	O
stress	O
-	O
induced	O
gene	O
expression	O
in	O
high	O
CO2	B-CHEMICAL
-	O
treated	O
table	O
grapes	O
stored	O
at	O
low	O
temperature	O
.	O

A	O
pretreatment	O
with	O
20kPa	O
CO2	B-CHEMICAL
+	O
20	O
kPa	O
O2	O
+	O
60	O
kPa	O
N2	B-CHEMICAL
for	O
3	O
days	O
proved	O
effective	O
in	O
maintaining	O
the	O
fruit	O
quality	O
and	O
controlling	O
decay	O
in	O
table	O
grapes	O
(	O
Vitis	O
vinifera	O
cv	O
.	O
Cardinal	O
)	O
stored	O
at	O
0	O
degrees	O
C	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
analyzed	O
whether	O
total	O
anthocyanin	B-CHEMICAL
content	O
,	O
the	O
molecular	O
mechanism	O
implicated	O
in	O
their	O
biosynthesis	O
and	O
antioxidant	O
activity	O
is	O
related	O
to	O
the	O
beneficial	O
effect	O
of	O
this	O
gaseous	O
treatment	O
.	O

We	O
isolated	O
partial	O
cDNAs	O
that	O
codified	O
for	O
enzymes	O
implicated	O
in	O
the	O
anthocyanin	B-CHEMICAL
biosynthesis	O
such	O
as	O
l	B-GENE-Y
-	I-GENE-Y
phenylalanine	I-GENE-Y
ammonia	I-GENE-Y
-	I-GENE-Y
lyase	I-GENE-Y
(	O
PAL	B-GENE-Y
)	O
and	O
chalcone	B-GENE-Y
synthase	I-GENE-Y
(	O
CHS	B-GENE-Y
)	O
,	O
and	O
an	O
antioxidant	O
enzyme	O
such	O
as	O
ascorbate	B-GENE-Y
peroxidase	I-GENE-Y
(	O
APX	B-GENE-Y
)	O
.	O

Low	O
temperatures	O
induced	O
an	O
accumulation	O
of	O
total	O
anthocyanin	B-CHEMICAL
content	O
in	O
the	O
skin	O
of	O
both	O
treated	O
and	O
non	O
-	O
treated	O
grapes	O
,	O
although	O
levels	O
were	O
lower	O
in	O
CO2	B-CHEMICAL
-	O
treated	O
fruit	O
.	O

By	O
contrast	O
,	O
antioxidant	O
activity	O
decreased	O
during	O
storage	O
at	O
0	O
degrees	O
C	O
in	O
non	O
-	O
treated	O
grapes	O
but	O
did	O
not	O
change	O
in	O
CO2	B-CHEMICAL
-	O
treated	O
grapes	O
.	O

The	O
up	O
-	O
regulation	O
of	O
anthocyanin	B-CHEMICAL
biosynthesis	O
gene	O
expression	O
and	O
VcAPX	B-GENE-Y
mRNA	O
observed	O
in	O
non	O
-	O
treated	O
grape	O
is	O
not	O
enhanced	O
in	O
CO2	B-CHEMICAL
-	O
treated	O
grapes	O
,	O
which	O
presented	O
low	O
total	O
decay	O
.	O

These	O
results	O
point	O
out	O
the	O
ability	O
of	O
CO2	B-CHEMICAL
-	O
treated	O
grapes	O
to	O
prevent	O
the	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
rather	O
than	O
their	O
inactivation	O
by	O
means	O
of	O
induction	O
of	O
studied	O
defense	O
systems	O
.	O

Candesartan	B-CHEMICAL
cilexetil	I-CHEMICAL
-	O
-	O
a	O
review	O
of	O
effects	O
on	O
cardiovascular	O
complications	O
in	O
hypertension	O
and	O
chronic	O
heart	O
failure	O
.	O

UNLABELLED	O
:	O
Therapeutic	O
interventions	O
that	O
block	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
-	O
aldosterone	B-CHEMICAL
system	O
(	O
RAAS	O
)	O
have	O
an	O
important	O
role	O
in	O
slowing	O
the	O
progression	O
of	O
cardiovascular	O
risk	O
actors	O
to	O
established	O
cardiovascular	O
diseases	O
.	O

In	O
recent	O
years	O
,	O
angiotensin	B-GENE-N
receptor	I-GENE-N
blockers	O
(	O
ARBs	O
)	O
have	O
emerged	O
as	O
effective	O
and	O
well	O
-	O
tolerated	O
alternatives	O
to	O
an	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitor	O
(	O
ACEi	O
)	O
for	O
RAAS	O
blockade	O
.	O

The	O
ARB	O
candesartan	B-CHEMICAL
was	O
initially	O
established	O
as	O
an	O
effective	O
once	O
-	O
daily	O
antihypertensive	O
treatment	O
,	O
providing	O
24	O
-	O
h	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
with	O
a	O
trough	O
:	O
peak	O
ratio	O
close	O
to	O
100	O
%	O
.	O

SCOPE	O
:	O
A	O
Medline	O
literature	O
search	O
was	O
undertaken	O
to	O
identify	O
randomised	O
,	O
controlled	O
trials	O
that	O
examined	O
the	O
efficacy	O
and	O
cardiovascular	O
outcomes	O
associated	O
with	O
candesartan	B-CHEMICAL
cilexetil	I-CHEMICAL
in	O
hypertension	O
and	O
chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

FINDINGS	O
:	O
Compared	O
with	O
other	O
ARBs	O
,	O
candesartan	B-CHEMICAL
demonstrates	O
the	O
strongest	O
binding	O
affinity	O
to	O
the	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
.	O

Clinical	O
trials	O
have	O
demonstrated	O
that	O
candesartan	B-CHEMICAL
is	O
well	O
tolerated	O
in	O
combination	O
with	O
diuretics	O
or	O
calcium	B-GENE-N
channel	I-GENE-N
blockers	O
(	O
CCBs	O
)	O
,	O
making	O
it	O
a	O
suitable	O
treatment	O
option	O
for	O
patients	O
whose	O
hypertension	O
is	O
not	O
adequately	O
controlled	O
by	O
monotherapy	O
.	O

Subsequently	O
,	O
candesartan	B-CHEMICAL
became	O
the	O
only	O
ARB	O
licensed	O
in	O
the	O
UK	O
to	O
treat	O
patients	O
with	O
CHF	O
and	O
left	O
ventricular	O
ejection	O
fraction	O
<	O
or	O
=	O
40	O
%	O
as	O
add	O
-	O
on	O
therapy	O
to	O
an	O
ACEi	O
or	O
when	O
an	O
ACEi	O
is	O
not	O
tolerated	O
.	O

Studies	O
in	O
patients	O
with	O
symptomatic	O
HF	O
have	O
indicated	O
that	O
candesartan	B-CHEMICAL
treatment	O
was	O
associated	O
with	O
significant	O
relative	O
risk	O
reductions	O
in	O
cardiovascular	O
mortality	O
and	O
hospitalisation	O
due	O
to	O
CHF	O
.	O

CONCLUSIONS	O
:	O
There	O
are	O
clear	O
indications	O
that	O
the	O
clinical	O
benefits	O
of	O
candesartan	B-CHEMICAL
may	O
extend	O
beyond	O
its	O
proven	O
antihypertensive	O
effects	O
to	O
a	O
wider	O
range	O
of	O
complications	O
across	O
the	O
cardiovascular	O
continuum	O
,	O
including	O
diabetes	O
,	O
left	O
ventricular	O
hypertrophy	O
,	O
atherosclerosis	O
and	O
stroke	O
.	O

Such	O
results	O
suggest	O
that	O
candesartan	B-CHEMICAL
treatment	O
may	O
offer	O
significant	O
patient	O
benefits	O
as	O
well	O
as	O
practical	O
advantages	O
over	O
conventional	O
treatment	O
.	O

Apoptosis	O
induced	O
by	O
oxidized	O
lipids	O
is	O
associated	O
with	O
up	O
-	O
regulation	O
of	O
p66Shc	B-GENE-Y
in	O
intestinal	O
Caco	O
-	O
2	O
cells	O
:	O
protective	O
effects	O
of	O
phenolic	B-CHEMICAL
compounds	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
alterations	O
of	O
the	O
redox	O
balance	O
induced	O
by	O
the	O
lipid	O
fraction	O
of	O
oxLDL	B-GENE-N
in	O
Caco	O
-	O
2	O
intestinal	O
cells	O
,	O
and	O
the	O
effects	O
of	O
tyrosol	B-CHEMICAL
and	O
protocatechuic	B-CHEMICAL
acid	I-CHEMICAL
,	O
two	O
dietary	O
phenolic	B-CHEMICAL
compounds	O
.	O

We	O
found	O
that	O
oxidized	O
lipids	O
extracted	O
from	O
oxLDL	B-GENE-N
(	O
LipE	B-GENE-Y
)	O
induced	O
oxidative	O
stress	O
by	O
determining	O
,	O
6	O
h	O
after	O
treatment	O
,	O
ROS	O
overproduction	O
(	O
about	O
a	O
100	O
%	O
and	O
a	O
43	O
%	O
increase	O
of	O
O	B-CHEMICAL
*	I-CHEMICAL
2	I-CHEMICAL
and	O
H2O2	B-CHEMICAL
production	O
,	O
respectively	O
,	O
P	O
<	O
.	O
05	O
:	O
LipE	B-GENE-Y
vs	O
.	O
control	O
)	O
and	O
,	O
12	O
h	O
after	O
treatment	O
,	O
GSH	O
depletion	O
(	O
about	O
a	O
26	O
%	O
decrease	O
,	O
P	O
<	O
.	O
05	O
:	O
LipE	B-GENE-Y
vs	O
.	O
control	O
)	O
,	O
and	O
by	O
impairing	O
the	O
activities	O
of	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
catalase	B-GENE-Y
and	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
.	O

In	O
response	O
to	O
the	O
induced	O
oxidative	O
stress	O
,	O
we	O
observed	O
significant	O
overexpression	O
of	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
6	O
h	O
after	O
treatment	O
:	O
P	O
<	O
.	O
05	O
)	O
,	O
glutathione	B-GENE-N
reductase	I-GENE-N
and	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamylcysteine	I-GENE-Y
synthetase	I-GENE-Y
(	O
12	O
h	O
after	O
treatment	O
:	O
P	O
<	O
.	O
05	O
)	O
.	O

Notably	O
,	O
when	O
GSH	O
depletion	O
occurred	O
,	O
p66Shc	B-GENE-Y
protein	O
expression	O
increased	O
by	O
about	O
300	O
%	O
with	O
respect	O
to	O
control	O
(	O
P	O
<	O
.	O
001	O
;	O
LipE	B-GENE-Y
vs	O
.	O
control	O
)	O
.	O

These	O
effects	O
were	O
fully	O
counteracted	O
by	O
dietary	O
phenolics	B-CHEMICAL
which	O
inhibited	O
ROS	O
overproduction	O
and	O
GSH	O
consumption	O
,	O
rendered	O
the	O
reactive	O
transcription	O
of	O
glutathione	B-CHEMICAL
-	O
associated	O
enzymes	O
unnecessary	O
and	O
blocked	O
the	O
intracellular	O
signals	O
leading	O
to	O
the	O
overexpression	O
and	O
rearrangement	O
of	O
p66Shc	B-GENE-Y
signalling	O
molecule	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
the	O
impairment	O
of	O
the	O
antioxidant	O
system	O
hijacks	O
intestinal	O
cells	O
towards	O
an	O
apoptotic	O
-	O
prone	O
phenotype	O
via	O
the	O
activation	O
of	O
p66Shc	B-GENE-Y
molecule	O
.	O

They	O
also	O
propose	O
a	O
reappraisal	O
of	O
dietary	O
polyphenols	B-CHEMICAL
as	O
intestinal	O
protecting	O
agents	O
,	O
indicating	O
the	O
antiapoptotic	O
effect	O
as	O
a	O
further	O
mechanism	O
of	O
action	O
of	O
these	O
antioxidant	O
compounds	O
.	O

Efficacy	O
and	O
safety	O
of	O
the	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
inhibitor	O
,	O
sitagliptin	B-CHEMICAL
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
inadequately	O
controlled	O
on	O
glimepiride	B-CHEMICAL
alone	O
or	O
on	O
glimepiride	B-CHEMICAL
and	O
metformin	B-CHEMICAL
.	O

AIM	O
:	O
To	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
24	O
-	O
week	O
treatment	O
with	O
sitagliptin	B-CHEMICAL
,	O
a	O
highly	O
selective	O
once	O
-	O
daily	O
oral	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
DPP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
inhibitor	O
,	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
had	O
inadequate	O
glycaemic	O
control	O
[	O
glycosylated	B-GENE-Y
haemoglobin	I-GENE-Y
(	O
HbA	B-GENE-Y
(	I-GENE-Y
1c	I-GENE-Y
)	I-GENE-Y
)	O
>	O
or	O
=	O
7	O
.	O
5	O
%	O
and	O
<	O
or	O
=	O
10	O
.	O
5	O
%	O
]	O
while	O
on	O
glimepiride	O
alone	O
or	O
in	O
combination	O
with	O
metformin	O
.	O

METHODS	O
:	O
After	O
a	O
screening	O
,	O
diet	O
/	O
exercise	O
run	O
-	O
in	O
and	O
drug	O
wash	O
-	O
off	O
period	O
,	O
a	O
glimepiride	O
+	O
/	O
-	O
metformin	O
dose	O
titration	O
/	O
stabilization	O
period	O
and	O
a	O
2	O
-	O
week	O
,	O
single	O
-	O
blind	O
placebo	O
run	O
-	O
in	O
,	O
441	O
patients	O
(	O
of	O
ages	O
18	O
-	O
75	O
years	O
)	O
were	O
randomized	O
to	O
receive	O
the	O
addition	O
of	O
sitagliptin	O
100	O
mg	O
once	O
daily	O
or	O
placebo	O
in	O
a	O
1	O
:	O
1	O
ratio	O
for	O
24	O
weeks	O
.	O

Of	O
these	O
patients	O
,	O
212	O
were	O
on	O
glimepiride	O
(	O
>	O
or	O
=	O
4	O
mg	O
/	O
day	O
)	O
monotherapy	O
and	O
229	O
were	O
on	O
glimepiride	O
(	O
>	O
or	O
=	O
4	O
mg	O
/	O
day	O
)	O
plus	O
metformin	O
(	O
>	O
or	O
=	O
1	O
,	O
500	O
mg	O
/	O
day	O
)	O
combination	O
therapy	O
.	O

Patients	O
exceeding	O
pre	O
-	O
specified	O
glycaemic	O
thresholds	O
during	O
the	O
double	O
-	O
blind	O
treatment	O
period	O
were	O
provided	O
open	O
-	O
label	O
rescue	O
therapy	O
(	O
pioglitazone	O
)	O
until	O
study	O
end	O
.	O

The	O
primary	O
efficacy	O
analysis	O
evaluated	O
the	O
change	O
in	O
HbA	O
(	O
1c	O
)	O
from	O
baseline	O
to	O
Week	O
24	O
.	O

Secondary	O
efficacy	O
endpoints	O
included	O
fasting	O
plasma	O
glucose	O
(	O
FPG	O
)	O
,	O
2	O
-	O
h	O
post	O
-	O
meal	O
glucose	O
and	O
lipid	O
measurements	O
.	O

RESULTS	O
:	O
Mean	O
baseline	O
HbA	O
(	O
1c	O
)	O
was	O
8	O
.	O
34	O
%	O
in	O
the	O
sitagliptin	O
and	O
placebo	O
groups	O
.	O

After	O
24	O
weeks	O
,	O
sitagliptin	O
reduced	O
HbA	O
(	O
1c	O
)	O
by	O
0	O
.	O
74	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
relative	O
to	O
placebo	O
.	O

In	O
the	O
subset	O
of	O
patients	O
on	O
glimepiride	O
plus	O
metformin	O
,	O
sitagliptin	O
reduced	O
HbA	O
(	O
1c	O
)	O
by	O
0	O
.	O
89	O
%	O
relative	O
to	O
placebo	O
,	O
compared	O
with	O
a	O
reduction	O
of	O
0	O
.	O
57	O
%	O
in	O
the	O
subset	O
of	O
patients	O
on	O
glimepiride	O
alone	O
.	O

The	O
addition	O
of	O
sitagliptin	O
reduced	O
FPG	O
by	O
20	O
.	O
1	O
mg	O
/	O
dl	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
increased	O
homeostasis	O
model	O
assessment	O
-	O
beta	O
,	O
a	O
marker	O
of	O
beta	O
-	O
cell	O
function	O
,	O
by	O
12	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
relative	O
to	O
placebo	O
.	O

In	O
patients	O
who	O
underwent	O
a	O
meal	O
tolerance	O
test	O
(	O
n	O
=	O
134	O
)	O
,	O
sitagliptin	O
decreased	O
2	O
-	O
h	O
post	O
-	O
prandial	O
glucose	O
(	O
PPG	O
)	O
by	O
36	O
.	O
1	O
mg	O
/	O
dl	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
relative	O
to	O
placebo	O
.	O

The	O
addition	O
of	O
sitagliptin	O
was	O
generally	O
well	O
tolerated	O
,	O
although	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
overall	O
(	O
60	O
vs	O
.	O
47	O
%	O
)	O
and	O
drug	O
-	O
related	O
adverse	O
experiences	O
(	O
AEs	O
)	O
(	O
15	O
vs	O
.	O
7	O
%	O
)	O
in	O
the	O
sitagliptin	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O

This	O
was	O
largely	O
because	O
of	O
a	O
higher	O
incidence	O
of	O
hypoglycaemia	O
AEs	O
(	O
12	O
vs	O
.	O
2	O
%	O
,	O
respectively	O
)	O
in	O
the	O
sitagliptin	O
group	O
compared	O
with	O
the	O
placebo	O
group	O
.	O

Body	O
weight	O
modestly	O
increased	O
with	O
sitagliptin	O
relative	O
to	O
placebo	O
(	O
+	O
0	O
.	O
8	O
vs	O
.	O
-	O
0	O
.	O
4	O
kg	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Sitagliptin	O
100	O
mg	O
once	O
daily	O
significantly	O
improved	O
glycaemic	O
control	O
and	O
beta	O
-	O
cell	O
function	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
had	O
inadequate	O
glycaemic	O
control	O
with	O
glimepiride	O
or	O
glimepiride	O
plus	O
metformin	O
therapy	O
.	O

The	O
addition	O
of	O
sitagliptin	O
was	O
generally	O
well	O
tolerated	O
,	O
with	O
a	O
modest	O
increase	O
in	O
hypoglycaemia	O
and	O
body	O
weight	O
,	O
consistent	O
with	O
glimepiride	O
therapy	O
and	O
the	O
observed	O
degree	O
of	O
glycaemic	O
improvement	O
.	O

Impaired	O
antibody	O
synthesis	O
after	O
spinal	O
cord	O
injury	O
is	O
level	O
dependent	O
and	O
is	O
due	O
to	O
sympathetic	O
nervous	O
system	O
dysregulation	O
.	O

Individuals	O
with	O
spinal	O
cord	O
injury	O
(	O
SCI	O
)	O
are	O
highly	O
susceptible	O
to	O
infection	O
.	O

This	O
post	O
-	O
traumatic	O
immune	O
suppression	O
is	O
thought	O
to	O
occur	O
via	O
alterations	O
in	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
or	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
function	O
.	O

Normally	O
,	O
the	O
HPA	O
axis	O
and	O
SNS	O
help	O
coordinate	O
proper	O
immune	O
function	O
.	O

After	O
SCI	O
,	O
the	O
HPA	O
axis	O
becomes	O
activated	O
and	O
descending	O
input	O
to	O
sympathetic	O
preganglionic	O
neurons	O
(	O
SPNs	O
)	O
is	O
impaired	O
.	O

Because	O
lymphoid	O
organs	O
are	O
innervated	O
by	O
SPNs	O
distributed	O
throughout	O
the	O
thoracolumbar	O
spinal	O
cord	O
,	O
we	O
predicted	O
level	O
-	O
dependent	O
immune	O
suppression	O
after	O
SCI	O
due	O
to	O
activation	O
of	O
the	O
HPA	O
axis	O
and	O
loss	O
of	O
descending	O
input	O
to	O
SPNs	O
.	O

We	O
tested	O
this	O
hypothesis	O
by	O
measuring	O
indices	O
of	O
HPA	O
(	O
circulating	O
corticosterone	B-CHEMICAL
;	O
CORT	B-CHEMICAL
)	O
and	O
SNS	O
function	O
(	O
norepinephrine	B-CHEMICAL
(	O
NE	B-CHEMICAL
)	O
in	O
spleen	O
)	O
as	O
well	O
as	O
antigen	O
-	O
specific	O
antibody	O
synthesis	O
against	O
an	O
exogenous	O
non	O
-	O
self	O
protein	O
following	O
high	O
-	O
or	O
low	O
-	O
level	O
SCI	O
.	O

Using	O
a	O
mid	O
-	O
thoracic	O
(	O
T9	O
)	O
spinal	O
contusion	O
injury	O
model	O
,	O
we	O
found	O
that	O
CORT	B-CHEMICAL
was	O
elevated	O
after	O
SCI	O
with	O
aberrant	O
patterns	O
of	O
diurnal	O
CORT	B-CHEMICAL
synthesis	O
evident	O
through	O
at	O
least	O
the	O
first	O
24	O
h	O
post	O
-	O
injury	O
.	O

However	O
,	O
splenic	O
NE	B-CHEMICAL
and	O
antibody	O
synthesis	O
were	O
similar	O
to	O
uninjured	O
controls	O
.	O

Injury	O
severity	O
did	O
not	O
change	O
these	O
parameters	O
.	O

Indeed	O
,	O
CORT	B-CHEMICAL
,	O
NE	B-CHEMICAL
and	O
antibody	O
synthesis	O
were	O
similar	O
after	O
T9	O
contusion	O
or	O
transection	O
SCI	O
.	O

In	O
contrast	O
,	O
high	O
-	O
level	O
SCI	O
(	O
T3	O
)	O
caused	O
sustained	O
increases	O
in	O
CORT	B-CHEMICAL
and	O
splenic	O
NE	B-CHEMICAL
along	O
with	O
impaired	O
antibody	O
synthesis	O
and	O
elevated	O
splenocyte	O
apoptosis	O
.	O

The	O
immunosuppressive	O
effects	O
of	O
T3	O
SCI	O
were	O
caused	O
by	O
NE	B-CHEMICAL
acting	O
at	O
beta2	B-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptors	I-GENE-Y
(	O
beta2AR	B-GENE-Y
)	O
and	O
could	O
be	O
reversed	O
using	O
beta2AR	B-GENE-Y
blockers	O
.	O

Interestingly	O
,	O
impaired	O
antibody	O
after	O
T3	O
SCI	O
could	O
be	O
mimicked	O
after	O
T9	O
SCI	O
with	O
a	O
beta2AR	B-GENE-Y
agonist	O
.	O

These	O
data	O
illustrate	O
the	O
immunosuppressive	O
effects	O
of	O
the	O
SNS	O
after	O
high	O
-	O
level	O
SCI	O
and	O
indicate	O
that	O
immune	O
deficits	O
may	O
be	O
overcome	O
using	O
beta	O
-	O
blockers	O
.	O

A	O
fluorescent	O
polymeric	O
heparin	O
sensor	O
.	O

Linear	O
copolymers	O
have	O
been	O
developed	O
which	O
carry	O
binding	O
sites	O
tailored	O
for	O
sulfated	O
sugars	O
.	O

All	O
binding	O
monomers	O
are	O
based	O
on	O
the	O
methacrylamide	B-CHEMICAL
skeleton	O
and	O
ensure	O
statistical	O
radical	O
copolymerization	O
.	O

They	O
are	O
decorated	O
with	O
o	B-CHEMICAL
-	I-CHEMICAL
aminomethylphenylboronates	I-CHEMICAL
for	O
covalent	O
ester	O
formation	O
and	O
/	O
or	O
alkylammonium	B-CHEMICAL
ions	O
for	O
noncovalent	O
Coulomb	O
attraction	O
.	O

Alcohol	B-CHEMICAL
sidechains	O
maintain	O
a	O
high	O
water	O
solubility	O
;	O
a	O
dansyl	B-CHEMICAL
monomer	O
was	O
constructed	O
as	O
a	O
fluorescence	O
label	O
.	O

Statistical	O
copolymerization	O
of	O
comonomer	O
mixtures	O
with	O
optimized	O
ratios	O
was	O
started	O
by	O
AIBN	B-CHEMICAL
(	O
AIBN	B-CHEMICAL
=	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
azoisobutyronitrile	I-CHEMICAL
)	O
and	O
furnished	O
water	O
-	O
soluble	O
comonomers	O
with	O
an	O
exceptionally	O
high	O
affinity	O
for	O
glucosaminoglucans	O
.	O

Heparin	O
can	O
be	O
quantitatively	O
detected	O
with	O
an	O
unprecedented	O
30	O
nM	O
sensitivity	O
,	O
and	O
a	O
neutral	O
polymer	O
without	O
any	O
ammonium	B-CHEMICAL
cation	I-CHEMICAL
is	O
still	O
able	O
to	O
bind	O
the	O
target	O
with	O
almost	O
micromolar	O
affinity	O
.	O

From	O
this	O
unexpected	O
result	O
,	O
we	O
propose	O
a	O
new	O
binding	O
scheme	O
between	O
the	O
boronate	B-CHEMICAL
and	O
a	O
sulfated	O
ethylene	B-CHEMICAL
glycol	I-CHEMICAL
or	O
aminoethanol	B-CHEMICAL
unit	O
.	O

Although	O
the	O
mechanism	O
of	O
heparin	O
binding	O
involves	O
covalent	O
boronate	B-CHEMICAL
ester	I-CHEMICAL
formation	O
,	O
it	O
can	O
be	O
completely	O
reversed	O
by	O
protamine	O
addition	O
,	O
similar	O
to	O
heparin	O
'	O
s	O
complex	O
formation	O
with	O
antithrombin	B-GENE-Y
III	I-GENE-Y
.	O

Treatment	O
of	O
Niemann	O
-	O
Pick	O
disease	O
type	O
C	O
in	O
two	O
children	O
with	O
miglustat	B-CHEMICAL
:	O
initial	O
responses	O
and	O
maintenance	O
of	O
effects	O
over	O
1	O
year	O
.	O

Niemann	O
-	O
Pick	O
disease	O
type	O
C	O
(	O
NP	O
-	O
C	O
)	O
is	O
a	O
lipid	O
storage	O
disorder	O
characterized	O
by	O
the	O
accumulation	O
of	O
unesterified	O
cholesterol	B-CHEMICAL
and	O
glycolipids	O
in	O
the	O
lysosomal	O
/	O
late	O
endosomal	O
system	O
of	O
certain	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
visceral	O
organs	O
.	O

Clinical	O
symptoms	O
include	O
progressive	O
neurological	O
deterioration	O
and	O
visceral	O
organomegaly	O
.	O

Miglustat	B-CHEMICAL
,	O
a	O
small	O
iminosugar	O
molecule	O
approved	O
for	O
the	O
treatment	O
of	O
Gaucher	O
disease	O
,	O
reversibly	O
inhibits	O
glucosylceramide	B-GENE-Y
synthase	I-GENE-Y
,	O
which	O
catalyses	O
the	O
first	O
committed	O
step	O
in	O
glycosphingolipid	O
synthesis	O
.	O

The	O
physicochemical	O
properties	O
of	O
miglustat	O
allow	O
it	O
to	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
suggest	O
possible	O
benefits	O
in	O
lysosomal	O
storage	O
diseases	O
affecting	O
the	O
CNS	O
.	O

Here	O
,	O
we	O
present	O
findings	O
in	O
two	O
children	O
with	O
NP	O
-	O
C	O
,	O
aged	O
14	O
years	O
(	O
patient	O
1	O
)	O
and	O
9	O
years	O
(	O
patient	O
2	O
)	O
,	O
treated	O
with	O
miglustat	B-CHEMICAL
for	O
1	O
year	O
.	O

Before	O
treatment	O
,	O
patient	O
1	O
presented	O
with	O
severe	O
difficulties	O
in	O
swallowing	O
and	O
walking	O
,	O
and	O
patient	O
2	O
with	O
problems	O
mostly	O
affecting	O
communication	O
and	O
social	O
interaction	O
.	O

Videofluoroscopic	O
studies	O
in	O
patient	O
1	O
demonstrated	O
a	O
substantial	O
improvement	O
in	O
swallowing	O
by	O
month	O
6	O
of	O
treatment	O
,	O
and	O
ambulation	O
index	O
measurements	O
indicated	O
improved	O
walking	O
.	O

Mini	O
Mental	O
-	O
State	O
Examination	O
(	O
MMSE	O
)	O
assessments	O
in	O
patient	O
2	O
showed	O
cognitive	O
improvement	O
by	O
month	O
6	O
,	O
which	O
was	O
sustained	O
up	O
to	O
month	O
12	O
.	O

Liver	O
/	O
spleen	O
volume	O
and	O
plasma	O
chitotriosidase	B-GENE-Y
activities	O
were	O
stabilized	O
in	O
both	O
cases	O
.	O

There	O
was	O
no	O
weight	O
loss	O
during	O
treatment	O
.	O

Patient	O
1	O
experienced	O
severe	O
but	O
self	O
-	O
limiting	O
paresthesia	O
,	O
which	O
was	O
not	O
associated	O
with	O
peripheral	O
neuropathy	O
.	O

We	O
conclude	O
that	O
miglustat	B-CHEMICAL
can	O
provide	O
therapeutic	O
benefits	O
in	O
CNS	O
symptoms	O
and	O
allows	O
stabilization	O
of	O
systemic	O
disease	O
in	O
childhood	O
-	O
onset	O
NP	O
-	O
C	O
.	O

Further	O
follow	O
-	O
up	O
is	O
crucial	O
to	O
determine	O
the	O
long	O
-	O
term	O
maintenance	O
of	O
these	O
effects	O
.	O

Methylphenidate	B-CHEMICAL
administration	O
to	O
juvenile	O
rats	O
alters	O
brain	O
areas	O
involved	O
in	O
cognition	O
,	O
motivated	O
behaviors	O
,	O
appetite	O
,	O
and	O
stress	O
.	O

Thousands	O
of	O
children	O
receive	O
methylphenidate	B-CHEMICAL
(	O
MPH	B-CHEMICAL
;	O
Ritalin	B-CHEMICAL
)	O
for	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
yet	O
the	O
long	O
-	O
term	O
neurochemical	O
consequences	O
of	O
MPH	B-CHEMICAL
treatment	O
are	O
unknown	O
.	O

To	O
mimic	O
clinical	O
Ritalin	B-CHEMICAL
treatment	O
in	O
children	O
,	O
male	O
rats	O
were	O
injected	O
with	O
MPH	B-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
or	O
vehicle	O
twice	O
daily	O
from	O
postnatal	O
day	O
7	O
(	O
PND7	O
)	O
-	O
PND35	O
.	O

At	O
the	O
end	O
of	O
administration	O
(	O
PND35	O
)	O
or	O
in	O
adulthood	O
(	O
PND135	O
)	O
,	O
brain	O
sections	O
from	O
littermate	O
pairs	O
were	O
immunocytochemically	O
labeled	O
for	O
neurotransmitters	O
and	O
cytological	O
markers	O
in	O
16	O
regions	O
implicated	O
in	O
MPH	B-CHEMICAL
effects	O
and	O
/	O
or	O
ADHD	O
etiology	O
.	O

At	O
PND35	O
,	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
of	O
rats	O
given	O
MPH	B-CHEMICAL
showed	O
55	O
%	O
greater	O
immunoreactivity	O
(	O
-	O
ir	O
)	O
for	O
the	O
catecholamine	B-CHEMICAL
marker	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
TH	B-GENE-Y
)	O
,	O
60	O
%	O
more	O
Nissl	O
-	O
stained	O
cells	O
,	O
and	O
40	O
%	O
less	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
(	O
NET	B-GENE-Y
)	O
-	O
ir	O
density	O
.	O

In	O
hippocampal	O
dentate	O
gyrus	O
,	O
MPH	B-CHEMICAL
-	O
receiving	O
rats	O
showed	O
a	O
51	O
%	O
decrease	O
in	O
NET	B-GENE-Y
-	O
ir	O
density	O
and	O
a	O
61	O
%	O
expanded	O
distribution	O
of	O
the	O
new	O
-	O
cell	O
marker	O
PSA	O
-	O
NCAM	B-GENE-Y
(	O
polysialylated	O
form	O
of	O
neural	B-GENE-Y
cell	I-GENE-Y
adhesion	I-GENE-Y
molecule	I-GENE-Y
)	O
.	O

In	O
medial	O
striatum	O
,	O
TH	B-GENE-Y
-	O
ir	O
decreased	O
by	O
21	O
%	O
,	O
and	O
in	O
hypothalamus	O
neuropeptide	B-GENE-Y
Y	I-GENE-Y
-	O
ir	O
increased	O
by	O
10	O
%	O
in	O
MPH	B-CHEMICAL
-	O
exposed	O
rats	O
.	O

At	O
PND135	O
,	O
MPH	O
-	O
exposed	O
rats	O
exhibited	O
decreased	O
anxiety	O
in	O
the	O
elevated	O
plus	O
-	O
maze	O
and	O
a	O
trend	O
for	O
decreased	O
TH	B-GENE-Y
-	O
ir	O
in	O
the	O
mPFC	O
.	O

Neither	O
PND35	O
nor	O
PND135	O
rats	O
showed	O
major	O
structural	O
differences	O
with	O
MPH	B-CHEMICAL
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
developmental	O
exposure	O
to	O
high	O
therapeutic	O
doses	O
of	O
MPH	B-CHEMICAL
has	O
short	O
-	O
term	O
effects	O
on	O
select	O
neurotransmitters	O
in	O
brain	O
regions	O
involved	O
in	O
motivated	O
behaviors	O
,	O
cognition	O
,	O
appetite	O
,	O
and	O
stress	O
.	O

Although	O
the	O
observed	O
neuroanatomical	O
changes	O
largely	O
resolve	O
with	O
time	O
,	O
chronic	O
modulation	O
of	O
young	O
brains	O
with	O
MPH	B-CHEMICAL
may	O
exert	O
effects	O
on	O
brain	O
neurochemistry	O
that	O
modify	O
some	O
behaviors	O
even	O
in	O
adulthood	O
.	O

Analgesic	O
and	O
anti	O
-	O
inflammatory	O
activities	O
of	O
aqueous	O
extract	O
from	O
Glycine	B-CHEMICAL
tomentella	O
root	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
analgesic	O
effect	O
of	O
the	O
aqueous	O
extract	O
of	O
the	O
root	O
of	O
Glycine	B-CHEMICAL
tomentella	O
(	O
AGT	O
)	O
using	O
models	O
of	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
writhing	O
response	O
and	O
formalin	B-CHEMICAL
test	O
,	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
AGT	O
using	O
model	O
of	O
lambda	O
-	O
carrageenan	O
-	O
induced	O
paw	O
edema	O
.	O

In	O
order	O
to	O
investigate	O
the	O
anti	O
-	O
inflammatory	O
mechanism	O
of	O
AGT	O
,	O
we	O
have	O
detected	O
the	O
activities	O
of	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GPx	B-GENE-N
)	O
and	O
glutathione	B-GENE-Y
reductase	I-GENE-Y
(	O
GRx	B-GENE-Y
)	O
in	O
the	O
liver	O
and	O
the	O
levels	O
of	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
and	O
NO	B-CHEMICAL
in	O
the	O
edema	O
paw	O
.	O

In	O
the	O
analgesic	O
test	O
,	O
AGT	O
(	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
g	O
/	O
kg	O
)	O
decreased	O
the	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
writhing	O
response	O
and	O
the	O
licking	O
time	O
on	O
the	O
late	O
phase	O
in	O
the	O
formalin	B-CHEMICAL
test	O
.	O

In	O
the	O
anti	O
-	O
inflammatory	O
test	O
,	O
AGT	O
(	O
0	O
.	O
5	O
and	O
1	O
.	O
0	O
g	O
/	O
kg	O
)	O
decreased	O
the	O
paw	O
edema	O
at	O
the	O
third	O
,	O
fourth	O
,	O
fifth	O
and	O
sixth	O
hour	O
after	O
lambda	O
-	O
carrageenan	O
administration	O
,	O
and	O
increased	O
the	O
activities	O
of	O
SOD	B-GENE-N
,	O
GPx	B-GENE-N
and	O
GRx	B-GENE-Y
in	O
the	O
liver	O
tissue	O
and	O
decreased	O
the	O
MDA	B-CHEMICAL
level	O
in	O
the	O
edema	O
paw	O
at	O
the	O
third	O
hour	O
after	O
lambda	O
-	O
carrageenan	O
injection	O
.	O

However	O
,	O
AGT	O
could	O
not	O
affect	O
the	O
NO	B-CHEMICAL
level	O
which	O
induced	O
by	O
lambda	O
-	O
carrageenan	O
.	O

These	O
results	O
suggested	O
that	O
AGT	O
possessed	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

The	O
anti	O
-	O
inflammatory	O
mechanism	O
of	O
AGT	O
might	O
be	O
related	O
to	O
the	O
decrease	O
in	O
the	O
level	O
of	O
MDA	B-CHEMICAL
in	O
the	O
edema	O
paw	O
via	O
increasing	O
the	O
activities	O
of	O
SOD	B-GENE-N
,	O
GPx	B-GENE-N
and	O
GRx	B-GENE-Y
in	O
the	O
liver	O
.	O

Thermodynamic	O
determination	O
of	O
the	O
binding	O
constants	O
of	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitors	O
by	O
a	O
displacement	O
method	O
.	O

Somatic	O
angiotensin	B-GENE-Y
I	I-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
(	O
s	O
-	O
ACE	B-GENE-Y
)	O
plays	O
a	O
central	O
role	O
in	O
blood	O
pressure	O
regulation	O
and	O
has	O
been	O
the	O
target	O
of	O
most	O
antihypertensive	O
drugs	O
.	O

A	O
displacement	O
isothermal	O
titration	O
calorimetry	O
method	O
has	O
been	O
used	O
to	O
accurately	O
determine	O
the	O
binding	O
constant	O
of	O
three	O
strong	O
s	O
-	O
ACE	B-GENE-Y
inhibitors	O
.	O

Under	O
the	O
experimental	O
conditions	O
studied	O
in	O
this	O
work	O
,	O
the	O
relative	O
potency	O
of	O
the	O
inhibitors	O
was	O
determined	O
to	O
be	O
enalaprilat	B-CHEMICAL
>	O
lisinopril	B-CHEMICAL
>	O
captopril	B-CHEMICAL
.	O

We	O
analyze	O
the	O
thermodynamic	O
behaviour	O
of	O
the	O
binding	O
process	O
using	O
the	O
new	O
structural	O
information	O
provided	O
by	O
the	O
ACE	B-GENE-Y
structures	O
,	O
as	O
well	O
as	O
the	O
conformational	O
changes	O
that	O
occur	O
upon	O
binding	O
.	O

Glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
M1	I-GENE-N
and	I-GENE-N
P1	I-GENE-N
polymorphisms	O
and	O
risk	O
of	O
breast	O
cancer	O
and	O
fibrocystic	O
breast	O
conditions	O
in	O
Chinese	O
women	O
.	O

Enzymes	O
encoded	O
by	O
the	O
glutathione	B-GENE-Y
S	I-GENE-Y
-	I-GENE-Y
tranferase	I-GENE-Y
mu	I-GENE-Y
1	I-GENE-Y
(	O
GSTM1	B-GENE-Y
)	O
and	O
pi	B-GENE-Y
1	I-GENE-Y
(	O
GSTP1	B-GENE-Y
)	O
genes	O
,	O
which	O
are	O
expressed	O
in	O
breast	O
tissue	O
,	O
catalyze	O
the	O
detoxification	O
of	O
endogenous	O
and	O
exogenous	O
electrophiles	O
.	O

Reduced	O
enzyme	O
activity	O
,	O
due	O
to	O
carriage	O
of	O
the	O
GSTM1	B-GENE-Y
deletion	O
or	O
the	O
GSTP1	B-GENE-Y
Ile105Val	O
Val	O
allele	O
,	O
may	O
therefore	O
affect	O
susceptibility	O
to	O
breast	O
cancer	O
and	O
related	O
conditions	O
.	O

In	O
a	O
case	O
-	O
control	O
study	O
of	O
Chinese	O
women	O
,	O
we	O
examined	O
whether	O
these	O
polymorphisms	O
were	O
associated	O
with	O
risk	O
of	O
breast	O
cancer	O
and	O
fibrocystic	O
breast	O
conditions	O
.	O

Women	O
diagnosed	O
with	O
breast	O
cancer	O
(	O
n	O
=	O
615	O
)	O
or	O
fibrocystic	O
breast	O
conditions	O
(	O
n	O
=	O
467	O
)	O
were	O
compared	O
to	O
women	O
without	O
clinical	O
breast	O
disease	O
(	O
n	O
=	O
878	O
)	O
.	O

We	O
also	O
examined	O
whether	O
these	O
associations	O
differed	O
by	O
menopausal	O
status	O
or	O
by	O
presence	O
of	O
proliferation	O
in	O
the	O
extra	O
-	O
tumoral	O
epithelium	O
among	O
women	O
with	O
breast	O
cancer	O
and	O
in	O
lesions	O
among	O
women	O
with	O
fibrocystic	O
conditions	O
.	O

No	O
overall	O
association	O
of	O
either	O
GST	B-GENE-N
polymorphism	O
with	O
risk	O
of	O
breast	O
cancer	O
or	O
fibrocystic	O
breast	O
conditions	O
was	O
observed	O
.	O

There	O
was	O
some	O
evidence	O
of	O
slightly	O
elevated	O
cancer	O
risk	O
associated	O
with	O
carriage	O
of	O
the	O
GSTM1	B-GENE-Y
null	O
genotype	O
and	O
at	O
least	O
one	O
GSTP1	B-GENE-Y
105	O
-	O
Val	O
allele	O
(	O
OR	O
=	O
1	O
.	O
33	O
,	O
95	O
%	O
CI	O
,	O
0	O
.	O
99	O
-	O
1	O
.	O
80	O
)	O
,	O
compared	O
to	O
carriage	O
of	O
the	O
GSTM1	B-GENE-Y
non	O
-	O
null	O
and	O
GSTP1	B-GENE-Y
Ile	O
/	O
Ile	O
genotypes	O
.	O

This	O
relationship	O
was	O
stronger	O
in	O
women	O
who	O
had	O
breast	O
cancer	O
with	O
extra	O
-	O
tumoral	O
tissue	O
proliferation	O
(	O
OR	O
=	O
1	O
.	O
77	O
,	O
95	O
%	O
CI	O
,	O
1	O
.	O
03	O
-	O
3	O
.	O
04	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
GSTM1	B-GENE-Y
and	O
GSTP1	B-GENE-Y
genotypes	O
do	O
not	O
individually	O
influence	O
susceptibility	O
to	O
breast	O
cancer	O
or	O
fibrocystic	O
breast	O
conditions	O
.	O

The	O
observed	O
increased	O
risk	O
of	O
breast	O
cancer	O
associated	O
with	O
joint	O
carriage	O
of	O
the	O
GSTM1	B-GENE-Y
null	O
genotype	O
and	O
GSTP1	B-GENE-Y
105	O
-	O
Val	O
allele	O
needs	O
confirmation	O
in	O
other	O
studies	O
.	O

Inhibition	O
of	O
platelet	B-GENE-N
receptors	I-GENE-N
involved	O
in	O
neutrophil	O
-	O
platelet	O
interaction	O
in	O
model	O
cardiopulmonary	O
bypass	O
.	O

We	O
investigated	O
the	O
interactions	O
between	O
neutrophils	O
,	O
platelets	O
,	O
and	O
artificial	O
surfaces	O
,	O
and	O
whether	O
blocking	O
of	O
relevant	O
receptors	O
on	O
platelets	O
reduced	O
unwanted	O
activation	O
responses	O
in	O
model	O
cardiopulmonary	O
bypass	O
.	O

Isolated	O
neutrophils	O
and	O
platelets	O
resuspended	O
in	O
heparin	O
-	O
anticoagulated	O
plasma	O
were	O
recirculated	O
with	O
and	O
without	O
blocking	O
antibodies	O
to	O
CD62P	B-GENE-Y
,	O
CD42b	B-GENE-Y
,	O
or	O
junctional	B-GENE-Y
adhesion	I-GENE-Y
molecule	I-GENE-Y
C	I-GENE-Y
(	O
JAM	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
)	O
in	O
polyvinyl	B-CHEMICAL
chloride	I-CHEMICAL
tubing	O
using	O
a	O
roller	O
pump	O
.	O

Platelet	O
adhesion	O
to	O
the	O
tubing	O
was	O
inhibited	O
by	O
anti	O
-	O
CD42b	B-GENE-Y
and	O
anti	O
-	O
CD62P	B-GENE-Y
,	O
and	O
adhesion	O
of	O
neutrophils	O
by	O
anti	O
-	O
JAM	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
.	O

Formation	O
of	O
platelet	O
-	O
neutrophil	O
and	O
platelet	O
aggregates	O
was	O
reduced	O
by	O
anti	O
-	O
CD62P	B-GENE-Y
.	O

Anti	O
-	O
JAM	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
decreased	O
platelet	O
-	O
neutrophil	O
aggregation	O
at	O
low	O
concentrations	O
and	O
platelet	O
macroaggregates	O
at	O
high	O
concentrations	O
.	O

Anti	O
-	O
CD62P	B-GENE-Y
increased	O
neutrophil	O
CD11b	B-GENE-Y
expression	O
but	O
not	O
degranulation	O
.	O

Anti	O
-	O
JAM	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
substantially	O
increased	O
neutrophil	O
degranulation	O
and	O
slightly	O
increased	O
CD11b	B-GENE-Y
expression	O
.	O

Platelet	O
activation	O
increased	O
when	O
CD62P	B-GENE-Y
was	O
blocked	O
and	O
decreased	O
with	O
anti	O
-	O
CD42b	B-GENE-Y
antibody	O
.	O

High	O
-	O
dose	O
anti	O
-	O
JAM	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
reduced	O
platelet	O
activation	O
.	O

In	O
conclusion	O
,	O
inhibiting	O
platelet	O
and	O
neutrophil	O
-	O
platelet	O
interactions	O
had	O
useful	O
effects	O
but	O
no	O
single	O
blocking	O
antibody	O
seemed	O
capable	O
of	O
inducing	O
only	O
beneficial	O
effects	O
.	O

Bone	O
growth	O
retardation	O
in	O
mouse	O
embryos	O
expressing	O
human	B-GENE-Y
collagenase	I-GENE-Y
1	I-GENE-Y
.	O

Cellular	O
growth	O
and	O
differentiation	O
are	O
readouts	O
of	O
multiple	O
signaling	O
pathways	O
from	O
the	O
intercellular	O
and	O
/	O
or	O
extracellular	O
milieu	O
.	O

The	O
extracellular	O
matrix	O
through	O
the	O
activation	O
of	O
cellular	O
receptors	O
transmits	O
these	O
signals	O
.	O

Therefore	O
,	O
extracellular	O
matrix	O
proteolysis	O
could	O
affect	O
cell	O
fate	O
in	O
a	O
variety	O
of	O
biological	O
events	O
.	O

However	O
,	O
the	O
biological	O
consequence	O
of	O
inadequate	O
extracellular	O
matrix	O
degradation	O
in	O
vivo	O
is	O
not	O
clear	O
.	O

We	O
developed	O
a	O
mouse	O
model	O
expressing	O
human	B-GENE-Y
collagenase	I-GENE-Y
(	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
MMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
under	O
the	O
control	O
of	O
Col2a1	B-GENE-N
promoter	I-GENE-N
.	O

The	O
mice	O
showed	O
significant	O
growth	O
retardation	O
during	O
embryogenesis	O
and	O
a	O
loss	O
of	O
the	O
demarcation	O
of	O
zonal	O
structure	O
and	O
columnar	O
array	O
of	O
the	O
cartilage	O
.	O

Immunological	O
examination	O
revealed	O
increased	O
degradation	O
of	O
type	B-GENE-N
II	I-GENE-N
collagen	I-GENE-N
and	O
upregulation	O
of	O
fibronectin	B-GENE-Y
and	O
alpha	B-GENE-Y
(	I-GENE-Y
5	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
integrin	I-GENE-Y
subunit	O
in	O
the	O
transgenic	O
cartilage	O
.	O

The	O
resting	O
zone	O
and	O
proliferating	O
zone	O
of	O
the	O
growth	O
plate	O
cartilage	O
exhibited	O
a	O
simultaneous	O
increase	O
in	O
bromodeoxyuridine	B-CHEMICAL
(	O
BrdU	B-CHEMICAL
)	O
-	O
incorporated	O
proliferating	O
cells	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
X	O
-	O
dUTP	O
nick	O
-	O
end	O
labeling	O
-	O
positive	O
apoptotic	O
cells	O
,	O
respectively	O
.	O

Chondrocyte	O
differentiation	O
was	O
not	O
disturbed	O
in	O
the	O
transgenic	O
mice	O
as	O
evidenced	O
by	O
normal	O
expression	O
of	O
the	O
Ihh	O
and	O
type	B-GENE-N
X	I-GENE-N
collagen	I-GENE-N
expression	O
.	O

These	O
data	O
demonstrate	O
that	O
type	B-GENE-N
II	I-GENE-N
collagen	I-GENE-N
proteolysis	O
is	O
an	O
important	O
determinant	O
for	O
the	O
skeletal	O
outgrowth	O
through	O
modulation	O
of	O
chondrocyte	O
survival	O
and	O
cartilagenous	O
growth	O
.	O

Expressions	O
and	O
mechanical	O
functions	O
of	O
alpha1	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtypes	O
in	O
hamster	O
ureter	O
.	O

We	O
characterized	O
the	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtypes	O
in	O
hamster	O
ureters	O
according	O
to	O
gene	O
and	O
protein	O
expressions	O
and	O
contractile	O
function	O
.	O

Real	O
-	O
time	O
quantitative	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
and	O
immunohistochemical	O
analysis	O
were	O
performed	O
to	O
determine	O
mRNA	O
levels	O
and	O
receptor	O
protein	O
expressions	O
respectively	O
,	O
for	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
,	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1B	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
hamster	O
ureteral	O
smooth	O
muscle	O
.	O

alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
Adrenoceptor	I-GENE-N
antagonists	O
were	O
tested	O
against	O
the	O
phenylephrine	B-CHEMICAL
(	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonist	O
)	O
-	O
induced	O
contraction	O
in	O
isolated	O
hamster	O
ureteral	O
preparations	O
using	O
a	O
functional	O
experimental	O
approach	O
.	O

In	O
the	O
smooth	O
muscle	O
,	O
relative	O
mRNA	O
expression	O
levels	O
for	O
alpha	B-GENE-N
(	I-GENE-N
1a	I-GENE-N
)	I-GENE-N
-	I-GENE-N
,	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1b	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1d	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
were	O
10	O
.	O
7	O
%	O
,	O
1	O
.	O
2	O
%	O
and	O
88	O
.	O
1	O
%	O
,	O
respectively	O
,	O
and	O
protein	O
expressions	O
were	O
identified	O
for	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
immunohistochemically	O
.	O

Noradrenaline	B-CHEMICAL
and	O
phenylephrine	B-CHEMICAL
(	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
agonist	O
)	O
each	O
produced	O
a	O
concentration	O
-	O
dependent	O
tonic	O
contraction	O
,	O
their	O
pD	O
(	O
2	O
)	O
values	O
being	O
6	O
.	O
87	O
+	O
/	O
-	O
0	O
.	O
08	O
and	O
6	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
05	O
,	O
respectively	O
.	O

Prazosin	B-CHEMICAL
(	O
nonselective	O
alpha	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
)	O
,	O
silodosin	B-CHEMICAL
(	O
selective	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
)	O
and	O
BMY	B-CHEMICAL
-	I-CHEMICAL
7378	I-CHEMICAL
(	O
8	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
piperazinyl	I-CHEMICAL
]	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
azaspiro	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
.	I-CHEMICAL
5	I-CHEMICAL
]	I-CHEMICAL
decane	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
dihydrochloride	I-CHEMICAL
)	O
(	O
selective	O
alpha	B-GENE-N
(	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
)	O
competitively	O
antagonized	O
the	O
phenylephrine	B-CHEMICAL
-	O
induced	O
contraction	O
(	O
pA	O
(	O
2	O
)	O
values	O
,	O
8	O
.	O
60	O
+	O
/	O
-	O
0	O
.	O
07	O
,	O
9	O
.	O
44	O
+	O
/	O
-	O
0	O
.	O
06	O
and	O
5	O
.	O
75	O
+	O
/	O
-	O
0	O
.	O
07	O
,	O
respectively	O
)	O
.	O

Chloroethylclonidine	B-CHEMICAL
(	O
3x10	O
(	O
-	O
6	O
)	O
mol	O
/	O
L	O
or	O
more	O
)	O
produced	O
a	O
rightward	O
shift	O
in	O
the	O
concentration	O
-	O
response	O
curve	O
for	O
phenylephrine	B-CHEMICAL
.	O

Thus	O
,	O
in	O
hamster	O
ureters	O
,	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
(	I-GENE-N
1D	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
were	O
more	O
prevalent	O
than	O
the	O
alpha	B-GENE-Y
(	I-GENE-Y
1B	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
,	O
with	O
contraction	O
being	O
mediated	O
mainly	O
via	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

If	O
these	O
findings	O
hold	O
true	O
for	O
humans	O
,	O
alpha	B-GENE-N
(	I-GENE-N
1A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
could	O
become	O
useful	O
medication	O
for	O
stone	O
passage	O
in	O
urolithiasis	O
patients	O
.	O

IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
-	O
induced	O
IDO	B-GENE-Y
and	O
WRS	B-GENE-Y
expression	O
in	O
microglia	O
is	O
differentially	O
regulated	O
by	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
.	O

Indoleamine	B-GENE-Y
2	I-GENE-Y
,	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
dioxygenase	I-GENE-Y
(	O
IDO	B-GENE-Y
)	O
,	O
a	O
tryptophan	B-CHEMICAL
catabolizing	O
enzyme	O
,	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
various	O
neurological	O
disorders	O
.	O

IDO	B-GENE-Y
expression	O
is	O
induced	O
by	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
and	O
leads	O
to	O
neurotoxicity	O
by	O
generating	O
quinolinic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Additionally	O
,	O
it	O
inhibits	O
the	O
immune	O
response	O
through	O
both	O
tryptophan	B-CHEMICAL
depletion	O
and	O
generating	O
other	O
tryptophan	B-CHEMICAL
catabolites	O
.	O

IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
have	O
been	O
shown	O
to	O
control	O
IDO	B-GENE-Y
expression	O
by	O
antagonizing	O
the	O
effects	O
of	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
in	O
different	O
cell	O
types	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
these	O
cytokines	B-GENE-N
on	O
IDO	B-GENE-Y
expression	O
in	O
microglia	O
.	O

Interestingly	O
,	O
we	O
observed	O
that	O
both	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
greatly	O
enhanced	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
-	O
induced	O
IDO	B-GENE-Y
expression	O
.	O

However	O
,	O
tryptophanyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
(	O
WRS	B-GENE-Y
)	O
,	O
which	O
is	O
coinduced	O
with	O
IDO	B-GENE-Y
by	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
,	O
is	O
downregulated	O
by	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
.	O

The	O
effect	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
was	O
independent	O
of	O
STAT	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

Modulation	O
of	O
IDO	B-GENE-Y
but	O
not	O
WRS	B-GENE-Y
was	O
eliminated	O
by	O
inhibition	O
of	O
protein	B-GENE-N
phosphatase	I-GENE-N
2A	I-GENE-N
(	O
PP2A	B-GENE-N
)	O
activity	O
.	O

The	O
phosphatidylinositol	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
(	O
PI3K	B-GENE-N
)	O
pathway	O
further	O
differentiated	O
the	O
regulation	O
of	O
these	O
two	O
enzymes	O
,	O
as	O
inhibiting	O
the	O
PI3K	B-GENE-N
pathway	O
eliminated	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
induction	O
of	O
IDO	B-GENE-Y
,	O
whereas	O
such	O
inhibition	O
greatly	O
enhanced	O
WRS	B-GENE-Y
expression	O
.	O

These	O
findings	O
show	O
discordance	O
between	O
modulations	O
of	O
expression	O
of	O
two	O
distinct	O
enzymes	O
utilizing	O
tryptophan	B-CHEMICAL
as	O
a	O
common	O
substrate	O
,	O
and	O
raise	O
the	O
possibility	O
of	O
their	O
involvement	O
in	O
regulating	O
immune	O
responses	O
in	O
various	O
neurological	O
disorders	O
.	O

Central	O
sympatholysis	O
as	O
a	O
novel	O
countermeasure	O
for	O
cocaine	B-CHEMICAL
-	O
induced	O
sympathetic	O
activation	O
and	O
vasoconstriction	O
in	O
humans	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
cocaine	O
'	O
s	O
sympathomimetic	O
actions	O
can	O
be	O
reversed	O
by	O
a	O
potent	O
centrally	O
acting	O
alpha2	B-GENE-N
adrenergic	I-GENE-N
receptor	I-GENE-N
(	O
AR	B-GENE-N
)	O
agonist	O
(	O
dexmedetomidine	B-CHEMICAL
)	O
.	O

BACKGROUND	O
:	O
We	O
recently	O
showed	O
that	O
cocaine	B-CHEMICAL
stimulates	O
the	O
human	O
cardiovascular	O
system	O
primarily	O
by	O
acting	O
in	O
the	O
brain	O
to	O
increase	O
sympathetic	O
nerve	O
activity	O
(	O
SNA	O
)	O
,	O
the	O
neural	O
stimulus	O
to	O
norepinephrine	B-CHEMICAL
release	O
.	O

Thus	O
,	O
SNA	O
constitutes	O
a	O
putative	O
new	O
drug	O
target	O
to	O
block	O
cocaine	O
'	O
s	O
adverse	O
cardiovascular	O
effects	O
at	O
their	O
origin	O
.	O

METHODS	O
:	O
In	O
22	O
healthy	O
cocaine	B-CHEMICAL
-	O
naive	O
humans	O
,	O
we	O
measured	O
skin	O
SNA	O
(	O
microneurography	O
)	O
and	O
skin	O
blood	O
flow	O
(	O
laser	O
Doppler	O
velocimetry	O
)	O
as	O
well	O
as	O
heart	O
rate	O
and	O
blood	O
pressure	O
before	O
and	O
after	O
intranasal	O
cocaine	B-CHEMICAL
(	O
2	O
mg	O
/	O
kg	O
)	O
alone	O
and	O
in	O
combination	O
with	O
dexmedetomidine	B-CHEMICAL
or	O
saline	O
.	O

RESULTS	O
:	O
During	O
intranasal	O
cocaine	B-CHEMICAL
alone	O
,	O
SNA	O
increased	O
by	O
2	O
-	O
fold	O
and	O
skin	O
vascular	O
resistance	O
increased	O
from	O
13	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
3	O
to	O
20	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
2	O
resistance	O
units	O
while	O
mean	O
arterial	O
pressure	O
increased	O
by	O
14	O
+	O
/	O
-	O
3	O
mm	O
Hg	O
and	O
heart	O
rate	O
by	O
18	O
+	O
/	O
-	O
3	O
beats	O
/	O
min	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Dexmedetomidine	B-CHEMICAL
abolished	O
these	O
increases	O
,	O
whereas	O
intravenous	O
saline	O
was	O
without	O
effect	O
.	O

Dexmedetomidine	B-CHEMICAL
was	O
effective	O
in	O
blocking	O
these	O
sympathomimetic	O
actions	O
of	O
cocaine	B-CHEMICAL
even	O
in	O
all	O
7	O
subjects	O
who	O
were	O
homozygous	O
for	O
the	O
Del322	O
-	O
325	O
polymorphism	O
in	O
the	O
alpha2C	B-GENE-Y
AR	I-GENE-Y
,	O
a	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
that	O
is	O
highly	O
enriched	O
in	O
blacks	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
advance	O
the	O
novel	O
hypothesis	O
that	O
central	O
sympatholysis	O
with	O
dexmedetomidine	B-CHEMICAL
constitutes	O
a	O
highly	O
effective	O
countermeasure	O
for	O
cocaine	O
'	O
s	O
sympathomimetic	O
actions	O
on	O
the	O
human	O
cardiovascular	O
system	O
,	O
even	O
in	O
individuals	O
carrying	O
the	O
alpha2CDel322	B-GENE-Y
-	O
325	O
polymorphism	O
.	O

(	O
Study	O
to	O
Improve	O
Scientific	O
Understanding	O
of	O
the	O
Cardiovascular	O
Actions	O
of	O
Cocaine	B-CHEMICAL
;	O
http	O
:	O
/	O
/	O
clinicaltrials	O
.	O
gov	O
/	O
ct	O
/	O
show	O
/	O
NCT00338546	O
?	O
order	O
=	O
1	O
;	O
NCT00338546	O
)	O
.	O

Acetaminophen	B-CHEMICAL
(	O
paracetamol	B-CHEMICAL
)	O
is	O
a	O
selective	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
in	O
man	O
.	O

For	O
more	O
than	O
three	O
decades	O
,	O
acetaminophen	B-CHEMICAL
(	O
INN	B-CHEMICAL
,	O
paracetamol	B-CHEMICAL
)	O
has	O
been	O
claimed	O
to	O
be	O
devoid	O
of	O
significant	O
inhibition	O
of	O
peripheral	O
prostanoids	B-CHEMICAL
.	O

Meanwhile	O
,	O
attempts	O
to	O
explain	O
its	O
action	O
by	O
inhibition	O
of	O
a	O
central	O
cyclooxygenase	B-GENE-N
(	I-GENE-N
COX	I-GENE-N
)	I-GENE-N
-	I-GENE-N
3	I-GENE-N
have	O
been	O
rejected	O
.	O

The	O
fact	O
that	O
acetaminophen	B-CHEMICAL
acts	O
functionally	O
as	O
a	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
led	O
us	O
to	O
investigate	O
the	O
hypothesis	O
of	O
whether	O
it	O
works	O
via	O
preferential	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
blockade	O
.	O

Ex	O
vivo	O
COX	B-GENE-N
inhibition	O
and	O
pharmacokinetics	O
of	O
acetaminophen	B-CHEMICAL
were	O
assessed	O
in	O
5	O
volunteers	O
receiving	O
single	O
1000	O
mg	O
doses	O
orally	O
.	O

Coagulation	O
-	O
induced	O
thromboxane	B-CHEMICAL
B	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
and	O
lipopolysaccharide	O
-	O
induced	O
prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
were	O
measured	O
ex	O
vivo	O
and	O
in	O
vitro	O
in	O
human	O
whole	O
blood	O
as	O
indices	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
activity	O
.	O

In	O
vitro	O
,	O
acetaminophen	B-CHEMICAL
elicited	O
a	O
4	O
.	O
4	O
-	O
fold	O
selectivity	O
toward	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
(	O
IC	O
(	O
50	O
)	O
=	O
113	O
.	O
7	O
micromol	O
/	O
L	O
for	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
;	O
IC	O
(	O
50	O
)	O
=	O
25	O
.	O
8	O
micromol	O
/	O
L	O
for	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

Following	O
oral	O
administration	O
of	O
the	O
drug	O
,	O
maximal	O
ex	O
vivo	O
inhibitions	O
were	O
56	O
%	O
(	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
83	O
%	O
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

Acetaminophen	B-CHEMICAL
plasma	O
concentrations	O
remained	O
above	O
the	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
for	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
for	O
at	O
least	O
5	O
h	O
postadministration	O
.	O

Ex	O
vivo	O
IC	O
(	O
50	O
)	O
values	O
(	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
:	O
105	O
.	O
2	O
micromol	O
/	O
L	O
;	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
:	O
26	O
.	O
3	O
micromol	O
/	O
L	O
)	O
of	O
acetaminophen	B-CHEMICAL
compared	O
favorably	O
with	O
its	O
in	O
vitro	O
IC	O
(	O
50	O
)	O
values	O
.	O

In	O
contrast	O
to	O
previous	O
concepts	O
,	O
acetaminophen	B-CHEMICAL
inhibited	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
by	O
more	O
than	O
80	O
%	O
,	O
i	O
.	O
e	O
.	O
,	O
to	O
a	O
degree	O
comparable	O
to	O
nonsteroidal	O
antiinflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
and	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
.	O

However	O
,	O
a	O
>	O
95	O
%	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
blockade	O
relevant	O
for	O
suppression	O
of	O
platelet	O
function	O
was	O
not	O
achieved	O
.	O

Our	O
data	O
may	O
explain	O
acetaminophen	O
'	O
s	O
analgesic	O
and	O
antiinflammatory	O
action	O
as	O
well	O
as	O
its	O
superior	O
overall	O
gastrointestinal	O
safety	O
profile	O
compared	O
with	O
NSAIDs	O
.	O

In	O
view	O
of	O
its	O
substantial	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibition	O
,	O
recently	O
defined	O
cardiovascular	O
warnings	O
for	O
use	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
should	O
also	O
be	O
considered	O
for	O
acetaminophen	B-CHEMICAL
.	O

Na	B-CHEMICAL
+	I-CHEMICAL
/	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
exchange	O
inhibitors	O
:	O
a	O
new	O
class	O
of	O
calcium	B-CHEMICAL
regulators	O
.	O

The	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
/	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
exchanger	I-GENE-N
(	O
NCX	B-GENE-N
)	O
is	O
a	O
bidirectional	O
transporter	O
that	O
normally	O
extrudes	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
from	O
the	O
cell	O
(	O
forward	O
mode	O
)	O
,	O
but	O
also	O
brings	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
into	O
the	O
cell	O
(	O
reverse	O
mode	O
)	O
under	O
special	O
conditions	O
such	O
as	O
intracellular	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
i	O
)	O
)	O
accumulation	O
or	O
membrane	O
depolarization	O
.	O

There	O
are	O
three	O
mammalian	B-GENE-N
NCX	I-GENE-N
isoforms	O
:	O
NCX1	B-GENE-Y
is	O
widely	O
expressed	O
in	O
the	O
heart	O
,	O
kidney	O
,	O
brain	O
,	O
blood	O
vessels	O
,	O
and	O
so	O
on	O
;	O
whereas	O
the	O
expression	O
of	O
NCX2	B-GENE-Y
and	O
NCX3	B-GENE-Y
is	O
limited	O
mainly	O
to	O
the	O
brain	O
and	O
skeletal	O
muscle	O
.	O

The	O
pharmacology	O
of	O
NCX	B-GENE-N
inhibitors	O
has	O
been	O
studied	O
extensively	O
since	O
the	O
development	O
of	O
KB	B-CHEMICAL
-	I-CHEMICAL
R7943	I-CHEMICAL
,	O
a	O
prototype	O
benzyloxyphenyl	B-CHEMICAL
NCX	B-GENE-N
inhibitor	O
,	O
in	O
1996	O
.	O

Currently	O
,	O
experiments	O
are	O
actively	O
progressing	O
with	O
more	O
selective	O
inhibitors	O
:	O
SEA0400	B-CHEMICAL
,	O
SN	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
,	O
and	O
YM	B-CHEMICAL
-	I-CHEMICAL
244769	I-CHEMICAL
.	O

Intriguingly	O
,	O
the	O
inhibitory	O
potency	O
of	O
benzyloxyphenyl	B-CHEMICAL
NCX	B-GENE-N
inhibitors	O
is	O
directly	O
coupled	O
to	O
the	O
rate	O
of	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
i	O
)	O
-	O
dependent	O
inactivation	O
.	O

Therefore	O
,	O
the	O
benzyloxyphenyl	B-CHEMICAL
inhibitors	O
are	O
apparently	O
dormant	O
during	O
the	O
forward	O
mode	O
under	O
normal	O
conditions	O
(	O
low	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
i	O
)	O
)	O
,	O
but	O
become	O
effective	O
during	O
the	O
reverse	O
mode	O
under	O
pathological	O
conditions	O
(	O
high	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
i	O
)	O
)	O
.	O

This	O
should	O
be	O
an	O
ideal	O
profile	O
for	O
calcium	B-CHEMICAL
regulators	O
against	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
i	O
)	O
-	O
related	O
diseases	O
,	O
such	O
as	O
ischemia	O
/	O
reperfusion	O
injuries	O
,	O
salt	O
-	O
dependent	O
hypertension	O
,	O
and	O
digitalis	O
arrhythmia	O
.	O

Existing	O
ion	B-GENE-N
channel	I-GENE-N
blockers	O
,	O
such	O
as	O
amiodarone	B-CHEMICAL
,	O
dronedarone	B-CHEMICAL
,	O
bepridil	B-CHEMICAL
,	O
aprindine	B-CHEMICAL
,	O
and	O
cibenzoline	B-CHEMICAL
,	O
have	O
been	O
found	O
to	O
have	O
an	O
NCX	B-GENE-N
inhibitory	O
action	O
.	O

It	O
is	O
possible	O
that	O
this	O
property	O
is	O
partly	O
responsible	O
for	O
their	O
antiarrhythmic	O
and	O
cardioprotective	O
effects	O
.	O

This	O
article	O
presents	O
the	O
characteristics	O
of	O
selective	O
and	O
non	O
-	O
selective	O
NCX	B-GENE-N
inhibitors	O
and	O
their	O
therapeutic	O
potential	O
as	O
a	O
new	O
calcium	B-CHEMICAL
regulator	O
.	O

Conivaptan	B-CHEMICAL
:	O
a	O
dual	O
vasopressin	B-GENE-N
receptor	I-GENE-N
v1a	I-GENE-N
/	I-GENE-N
v2	I-GENE-N
antagonist	O
[	O
corrected	O
]	O
.	O

Several	O
fluid	O
retentive	O
states	O
such	O
as	O
heart	O
failure	O
,	O
cirrhosis	O
of	O
the	O
liver	O
,	O
and	O
syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
secretion	O
are	O
associated	O
with	O
inappropriate	O
elevation	O
in	O
plasma	O
levels	O
of	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
(	O
AVP	B-CHEMICAL
)	O
,	O
a	O
neuropeptide	O
that	O
is	O
secreted	O
by	O
the	O
hypothalamus	O
and	O
plays	O
a	O
critical	O
role	O
in	O
the	O
regulation	O
of	O
serum	O
osmolality	O
and	O
in	O
circulatory	O
homeostasis	O
.	O

The	O
actions	O
of	O
AVP	B-CHEMICAL
are	O
mediated	O
by	O
three	O
receptor	O
subtypes	O
V1a	O
,	O
V2	O
,	O
and	O
V1b	O
.	O

The	O
V1a	B-GENE-Y
receptor	I-GENE-Y
regulates	O
vasodilation	O
and	O
cellular	O
hypertrophy	O
while	O
the	O
V2	B-GENE-Y
receptor	I-GENE-Y
regulates	O
free	O
water	O
excretion	O
.	O

The	O
V1b	B-GENE-Y
receptor	I-GENE-Y
regulates	O
adrenocorticotropin	B-GENE-Y
hormone	I-GENE-Y
release	O
.	O

Conivaptan	B-CHEMICAL
is	O
a	O
nonpeptide	O
dual	O
V1a	B-GENE-N
/	I-GENE-N
V2	I-GENE-N
AVP	I-GENE-N
receptor	I-GENE-N
antagonist	O
.	O

It	O
binds	O
with	O
high	O
affinity	O
,	O
competitively	O
,	O
and	O
reversibly	O
to	O
the	O
V1a	B-GENE-N
/	I-GENE-N
V2	I-GENE-N
receptor	I-GENE-N
subtypes	O
;	O
its	O
antagonistic	O
effect	O
is	O
concentration	O
dependent	O
.	O

It	O
inhibits	O
CYP3A4	B-GENE-Y
liver	O
enzyme	O
and	O
elevates	O
plasma	O
levels	O
of	O
other	O
drugs	O
metabolized	O
by	O
this	O
enzyme	O
.	O

It	O
is	O
approved	O
only	O
for	O
short	O
-	O
term	O
intravenous	O
use	O
.	O

Infusion	O
site	O
reaction	O
is	O
the	O
most	O
common	O
reason	O
for	O
discontinuation	O
of	O
the	O
drug	O
.	O

In	O
animals	O
conivaptan	O
increased	O
urine	O
volume	O
and	O
free	O
water	O
clearance	O
.	O

In	O
heart	O
failure	O
models	O
it	O
improved	O
hemodynamic	O
parameters	O
and	O
free	O
water	O
excretion	O
.	O

Conivaptan	B-CHEMICAL
has	O
been	O
shown	O
to	O
correct	O
hyponatremia	O
in	O
euvolemic	O
or	O
hypervolemic	O
patients	O
.	O

Its	O
efficacy	O
and	O
safety	O
for	O
short	O
-	O
term	O
use	O
have	O
led	O
to	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approval	O
of	O
its	O
intravenous	O
form	O
for	O
the	O
correction	O
of	O
hyponatremia	O
in	O
euvolemic	O
and	O
hypervolemic	O
states	O
.	O

Despite	O
its	O
ability	O
to	O
block	O
the	O
action	O
of	O
AVP	B-CHEMICAL
on	O
V1a	B-GENE-Y
receptors	I-GENE-Y
,	O
no	O
demonstrable	O
benefit	O
from	O
this	O
action	O
was	O
noted	O
in	O
patients	O
with	O
chronic	O
compensated	O
heart	O
failure	O
and	O
it	O
is	O
not	O
approved	O
for	O
this	O
indication	O
.	O

Consideration	O
should	O
be	O
given	O
to	O
further	O
evaluation	O
of	O
its	O
potential	O
benefits	O
in	O
patients	O
with	O
acute	O
decompensated	O
heart	O
failure	O
.	O

Kinetic	O
characterization	O
of	O
adenylosuccinate	B-GENE-Y
synthetase	I-GENE-Y
from	O
the	O
thermophilic	O
archaea	O
Methanocaldococcus	O
jannaschii	O
.	O

Adenylosuccinate	B-GENE-Y
synthetase	I-GENE-Y
(	O
AdSS	B-GENE-Y
)	O
catalyzes	O
the	O
Mg2	B-CHEMICAL
+	I-CHEMICAL
dependent	O
condensation	O
of	O
a	O
molecule	O
of	O
IMP	O
with	O
aspartate	B-CHEMICAL
to	O
form	O
adenylosuccinate	B-CHEMICAL
,	O
in	O
a	O
reaction	O
driven	O
by	O
the	O
hydrolysis	O
of	O
GTP	B-CHEMICAL
to	O
GDP	B-CHEMICAL
.	O

AdSS	B-GENE-Y
from	O
the	O
thermophilic	O
archaea	O
,	O
Methanocaldococcus	O
jannaschii	O
(	O
MjAdSS	B-GENE-Y
)	O
is	O
345	O
amino	B-CHEMICAL
acids	I-CHEMICAL
long	O
against	O
an	O
average	O
length	O
of	O
430	O
-	O
457	O
amino	B-CHEMICAL
acids	I-CHEMICAL
for	O
most	O
mesophilic	O
AdSS	B-GENE-Y
.	O

This	O
short	O
AdSS	B-GENE-Y
has	O
two	O
large	O
deletions	O
that	O
map	O
to	O
the	O
middle	O
and	O
C	B-CHEMICAL
-	O
terminus	O
of	O
the	O
protein	O
.	O

This	O
article	O
discusses	O
the	O
detailed	O
kinetic	O
characterization	O
of	O
MjAdSS	B-GENE-Y
.	O

Initial	O
velocity	O
and	O
product	O
inhibition	O
studies	O
,	O
carried	O
out	O
at	O
70	O
degrees	O
C	O
,	O
suggest	O
a	O
rapid	O
equilibrium	O
random	O
AB	O
steady	O
-	O
state	O
ordered	O
C	O
kinetic	O
mechanism	O
for	O
the	O
MjAdSS	B-GENE-Y
catalyzed	O
reaction	O
.	O

AdSS	B-GENE-Y
are	O
known	O
to	O
exhibit	O
monomer	O
-	O
dimer	O
equilibrium	O
with	O
the	O
dimer	O
being	O
implicated	O
in	O
catalysis	O
.	O

In	O
contrast	O
,	O
our	O
studies	O
show	O
that	O
MjAdSS	B-GENE-Y
is	O
an	O
equilibrium	O
mixture	O
of	O
dimers	O
and	O
tetramers	O
with	O
the	O
tetramer	O
being	O
the	O
catalytically	O
active	O
form	O
.	O

The	O
tetramer	O
dissociates	O
into	O
dimers	O
with	O
a	O
minor	O
increase	O
in	O
ionic	O
strength	O
of	O
the	O
buffer	O
,	O
while	O
the	O
dimer	O
is	O
extremely	O
stable	O
and	O
does	O
not	O
dissociate	O
even	O
at	O
1	O
.	O
2	O
M	O
NaCl	B-CHEMICAL
.	O

Phosphate	B-CHEMICAL
,	O
a	O
product	O
of	O
the	O
reaction	O
,	O
was	O
found	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
MjAdSS	B-GENE-Y
showing	O
biphasic	O
inhibition	O
of	O
enzyme	O
activity	O
.	O

The	O
inhibition	O
was	O
competitive	O
with	O
IMP	O
and	O
noncompetitive	O
with	O
GTP	B-CHEMICAL
.	O

MjAdSS	B-GENE-Y
,	O
like	O
the	O
mouse	B-GENE-N
acidic	I-GENE-N
isozyme	I-GENE-N
,	O
exhibits	O
substrate	O
inhibition	O
,	O
with	O
IMP	O
inhibiting	O
enzyme	O
activity	O
at	O
subsaturating	O
GTP	B-CHEMICAL
concentrations	O
.	O

Regulation	O
of	O
enzyme	O
activity	O
by	O
the	O
glycolytic	O
intermediate	O
,	O
fructose	B-CHEMICAL
1	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
bisphosphate	I-CHEMICAL
,	O
was	O
also	O
observed	O
with	O
the	O
inhibition	O
being	O
competitive	O
with	O
IMP	O
and	O
noncompetitive	O
against	O
GTP	B-CHEMICAL
.	O

Conformational	O
variations	O
of	O
both	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
and	O
inhibitors	O
provide	O
the	O
structural	O
basis	O
for	O
the	O
physiological	O
effects	O
of	O
vardenafil	B-CHEMICAL
and	O
sildenafil	B-CHEMICAL
.	O

Vardenafil	B-CHEMICAL
has	O
higher	O
affinity	O
to	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
(	O
PDE5	B-GENE-Y
)	O
than	O
sildenafil	B-CHEMICAL
and	O
lower	O
administered	O
dosage	O
for	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
these	O
differences	O
is	O
puzzling	O
because	O
two	O
drugs	O
have	O
similar	O
chemical	O
structures	O
.	O

Reported	O
here	O
is	O
a	O
crystal	O
structure	O
of	O
the	O
fully	O
active	O
and	O
nonmutated	O
PDE5A1	B-GENE-N
catalytic	I-GENE-N
domain	I-GENE-N
in	O
complex	O
with	O
vardenafil	B-CHEMICAL
.	O

The	O
structure	O
shows	O
that	O
the	O
conformation	O
of	O
the	O
H	O
-	O
loop	O
in	O
the	O
PDE5A1	B-GENE-Y
-	O
vardenafil	B-CHEMICAL
complex	O
is	O
different	O
from	O
those	O
of	O
any	O
known	O
structures	O
of	O
the	O
unliganded	O
PDE5	B-GENE-Y
and	O
its	O
complexes	O
with	O
the	O
inhibitors	O
.	O

In	O
addition	O
,	O
the	O
molecular	O
configuration	O
of	O
vardenafil	B-CHEMICAL
differs	O
from	O
that	O
of	O
sildenafil	B-CHEMICAL
when	O
bound	O
to	O
PDE5	B-GENE-Y
.	O

It	O
is	O
noteworthy	O
that	O
the	O
binding	O
of	O
vardenafil	B-CHEMICAL
causes	O
loss	O
of	O
the	O
divalent	O
metal	O
ions	O
that	O
have	O
been	O
observed	O
in	O
all	O
the	O
previously	O
published	O
PDE	B-GENE-N
structures	O
.	O

The	O
conformational	O
variation	O
of	O
both	O
PDE5	B-GENE-Y
and	O
the	O
inhibitors	O
provides	O
structural	O
insight	O
into	O
the	O
different	O
potencies	O
of	O
the	O
drugs	O
.	O

Critical	O
amino	B-CHEMICAL
acids	I-CHEMICAL
in	O
phosphodiesterase	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
catalytic	O
site	O
that	O
provide	O
for	O
high	O
-	O
affinity	O
interaction	O
with	O
cyclic	B-CHEMICAL
guanosine	I-CHEMICAL
monophosphate	I-CHEMICAL
and	O
inhibitors	O
.	O

The	O
molecular	O
bases	O
for	O
phosphodiesterase	B-GENE-Y
5	I-GENE-Y
(	O
PDE5	B-GENE-Y
)	O
catalytic	O
-	O
site	O
affinity	O
for	O
cyclic	B-CHEMICAL
guanosine	I-CHEMICAL
monophosphate	I-CHEMICAL
(	O
cGMP	B-CHEMICAL
)	O
and	O
potency	O
of	O
inhibitors	O
are	O
poorly	O
understood	O
.	O

Cocrystal	O
structures	O
of	O
PDE5	B-GENE-N
catalytic	I-GENE-N
(	I-GENE-N
C	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
with	O
inhibitors	O
reveal	O
a	O
hydrogen	B-CHEMICAL
bond	O
and	O
hydrophobic	O
interactions	O
with	O
Tyr	B-CHEMICAL
-	O
612	O
,	O
hydrogen	B-CHEMICAL
bonds	O
with	O
Gln	B-CHEMICAL
-	O
817	O
,	O
a	O
hydrophobic	O
clamp	O
formed	O
by	O
Phe	B-CHEMICAL
-	O
820	O
and	O
Val	B-CHEMICAL
-	O
782	O
,	O
and	O
contacts	O
with	O
His	B-CHEMICAL
-	O
613	O
,	O
Leu	B-CHEMICAL
-	O
765	O
,	O
and	O
Phe	B-CHEMICAL
-	O
786	O
[	O
Sung	O
et	O
al	O
.	O
(	O
2003	O
)	O
Nature	O
425	O
,	O
98	O
-	O
102	O
;	O
Huai	O
et	O
al	O
.	O
(	O
2004	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
279	O
,	O
13095	O
-	O
13101	O
]	O
.	O

Present	O
results	O
of	O
point	O
mutations	O
of	O
full	O
-	O
length	O
PDE5	B-GENE-Y
showed	O
that	O
maximum	O
catalysis	O
was	O
decreased	O
2650	O
-	O
fold	O
in	O
H613A	B-GENE-N
and	O
55	O
-	O
fold	O
in	O
F820A	B-GENE-N
.	O

Catalytic	O
-	O
site	O
affinities	O
for	O
cGMP	B-CHEMICAL
,	O
vardenafil	B-CHEMICAL
,	O
sildenafil	B-CHEMICAL
,	O
tadalafil	B-CHEMICAL
,	O
or	O
3	B-CHEMICAL
-	I-CHEMICAL
isobutyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methylxanthine	I-CHEMICAL
(	O
IBMX	B-CHEMICAL
)	O
were	O
respectively	O
weakened	O
14	O
-	O
,	O
123	O
-	O
,	O
30	O
-	O
,	O
51	O
-	O
,	O
and	O
43	O
-	O
fold	O
for	O
Y612A	B-GENE-N
;	O
63	O
-	O
,	O
511	O
-	O
,	O
43	O
-	O
,	O
95	O
-	O
and	O
61	O
-	O
fold	O
for	O
Q817A	B-GENE-N
;	O
and	O
59	O
-	O
,	O
448	O
-	O
,	O
71	O
-	O
,	O
137	O
-	O
,	O
and	O
93	O
-	O
fold	O
for	O
F820A	B-GENE-N
.	O

The	O
data	O
indicate	O
that	O
these	O
three	O
amino	B-CHEMICAL
acids	I-CHEMICAL
are	O
major	O
determinants	O
of	O
affinity	O
for	O
cGMP	B-CHEMICAL
and	O
potency	O
of	O
selective	O
and	O
nonselective	O
inhibitors	O
,	O
and	O
that	O
higher	O
vardenafil	B-CHEMICAL
potency	O
over	O
sildenafil	B-CHEMICAL
and	O
tadalafil	B-CHEMICAL
results	O
from	O
stronger	O
contacts	O
with	O
Tyr	B-CHEMICAL
-	O
612	O
,	O
Gln	B-CHEMICAL
-	O
817	O
,	O
and	O
Phe	B-CHEMICAL
-	O
820	O
.	O

Affinity	O
of	O
V782A	B-GENE-N
for	O
cGMP	B-CHEMICAL
,	O
vardenafil	B-CHEMICAL
,	O
sildenafil	B-CHEMICAL
,	O
tadalafil	B-CHEMICAL
,	O
or	O
IBMX	B-CHEMICAL
was	O
reduced	O
5	O
.	O
5	O
-	O
,	O
23	O
-	O
,	O
10	O
-	O
,	O
3	O
-	O
,	O
and	O
12	O
-	O
fold	O
,	O
respectively	O
.	O

Change	O
in	O
affinity	O
for	O
cGMP	B-CHEMICAL
,	O
vardenafil	B-CHEMICAL
,	O
sildenafil	B-CHEMICAL
,	O
or	O
IBMX	B-CHEMICAL
in	O
Y612F	B-GENE-N
,	O
H613A	B-GENE-N
,	O
L765A	B-GENE-N
,	O
or	O
F786A	B-GENE-N
was	O
less	O
,	O
but	O
affinity	O
of	O
H613A	B-GENE-N
or	O
F786A	B-GENE-N
for	O
tadalafil	B-CHEMICAL
was	O
weakened	O
37	O
-	O
and	O
17	O
-	O
fold	O
,	O
respectively	O
.	O

The	O
results	O
quantify	O
the	O
role	O
of	O
PDE5	B-GENE-Y
catalytic	O
-	O
site	O
residues	O
for	O
cGMP	B-CHEMICAL
and	O
inhibitors	O
,	O
indicate	O
that	O
Tyr	B-CHEMICAL
-	O
612	O
,	O
Gln	B-CHEMICAL
-	O
817	O
,	O
and	O
Phe	B-CHEMICAL
-	O
820	O
are	O
the	O
most	O
important	O
cGMP	B-CHEMICAL
or	O
inhibitor	O
contacts	O
studied	O
,	O
and	O
identify	O
residues	O
that	O
contribute	O
to	O
selectivity	O
among	O
different	O
classes	O
of	O
inhibitors	O
.	O

MORAb	O
-	O
003	O
,	O
a	O
fully	O
humanized	O
monoclonal	O
antibody	O
against	O
the	O
folate	B-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
,	O
for	O
the	O
potential	O
treatment	O
of	O
epithelial	O
ovarian	O
cancer	O
.	O

Morphotek	O
Inc	O
is	O
developing	O
MORAb	O
-	O
003	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
directed	O
against	O
folate	B-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
,	O
for	O
the	O
potential	O
treatment	O
of	O
ovarian	O
cancer	O
.	O

Phase	O
II	O
clinical	O
trialsof	O
MORAb	O
-	O
003	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
platinum	B-CHEMICAL
/	O
taxane	B-CHEMICAL
chemotherapy	O
,	O
are	O
underway	O
in	O
ovarian	O
cancer	O
patients	O
experiencing	O
their	O
first	O
disease	O
recurrence	O
.	O

Inhibition	O
of	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
(	O
DPP	B-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
)	O
by	O
atorvastatin	B-CHEMICAL
.	O

Dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
(	O
DPP	B-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
)	O
is	O
an	O
enzyme	O
responsible	O
for	O
the	O
inactivation	O
of	O
the	O
glucoregulatory	O
incretin	B-GENE-N
hormones	I-GENE-N
glucagon	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
glucose	B-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
insulinotropic	I-GENE-Y
polypeptide	I-GENE-Y
(	O
GIP	B-GENE-Y
)	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
hypolipidemic	O
agent	O
atorvastatin	B-CHEMICAL
is	O
a	O
competitive	O
inhibitor	O
of	O
porcine	B-GENE-Y
DPP	I-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
in	O
vitro	O
,	O
with	O
K	O
(	O
i	O
)	O
=	O
57	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
3	O
microM	O
.	O

These	O
results	O
may	O
have	O
implications	O
in	O
the	O
development	O
of	O
novel	O
DPP	B-GENE-Y
-	I-GENE-Y
IV	I-GENE-Y
inhibitors	O
based	O
on	O
the	O
use	O
of	O
atorvastatin	B-CHEMICAL
as	O
a	O
lead	O
compound	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

Introduction	O
:	O
The	O
pharmacological	O
profile	O
of	O
eprosartan	B-CHEMICAL
-	O
-	O
implications	O
for	O
cerebrovascular	O
and	O
cardiovascular	O
risk	O
reduction	O
.	O

Moderate	O
elevations	O
in	O
blood	O
pressure	O
translate	O
to	O
significant	O
increases	O
in	O
cardiovascular	O
and	O
cerebro	O
vascular	O
risk	O
.	O

Beneficially	O
,	O
this	O
relationship	O
allows	O
small	O
decreases	O
in	O
blood	O
pressure	O
to	O
be	O
associated	O
with	O
risk	O
reduction	O
.	O

Both	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-CHEMICAL
system	O
and	O
the	O
sympathetic	O
nervous	O
system	O
are	O
involved	O
in	O
hypertension	O
,	O
hence	O
targeting	O
these	O
systems	O
is	O
likely	O
to	O
be	O
of	O
benefit	O
in	O
the	O
treatment	O
of	O
hypertension	O
.	O

Angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
blockers	O
(	O
ARBs	O
)	O
are	O
used	O
for	O
controlling	O
blood	O
pressure	O
and	O
treating	O
heart	O
failure	O
in	O
a	O
broad	O
range	O
of	O
patients	O
,	O
including	O
those	O
with	O
diabetes	O
and	O
the	O
elderly	O
.	O

Not	O
only	O
have	O
ARBs	O
shown	O
good	O
efficacy	O
and	O
tolerability	O
,	O
they	O
also	O
appear	O
to	O
have	O
a	O
protective	O
effect	O
that	O
goes	O
beyond	O
that	O
expected	O
from	O
the	O
reduction	O
of	O
blood	O
pressure	O
.	O

The	O
ARB	O
eprosartan	B-CHEMICAL
is	O
a	O
nonbiphenyl	O
nontetrazole	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
AT1	B-GENE-Y
)	O
antagonist	O
,	O
which	O
acts	O
to	O
decrease	O
total	O
peripheral	O
resistance	O
.	O

Eprosartan	B-CHEMICAL
acts	O
at	O
vascular	O
AT1	B-GENE-Y
receptors	I-GENE-Y
(	O
postsynaptically	O
)	O
and	O
at	O
presynaptic	O
AT1	B-GENE-Y
receptors	I-GENE-Y
,	O
where	O
it	O
inhibits	O
noradrenaline	B-CHEMICAL
release	O
.	O

In	O
clinical	O
studies	O
,	O
eprosartan	B-CHEMICAL
has	O
been	O
shown	O
to	O
significantly	O
reduce	O
cardiovascular	O
and	O
cerebrovascular	O
events	O
,	O
whilst	O
avoiding	O
the	O
persistent	O
cough	O
that	O
commonly	O
occurs	O
with	O
the	O
use	O
of	O
angiotensin	B-GENE-Y
-	I-GENE-Y
converting	I-GENE-Y
enzyme	I-GENE-Y
inhibitors	O
.	O

Eprosartan	B-CHEMICAL
can	O
also	O
be	O
differentiated	O
from	O
other	O
ARBs	O
due	O
to	O
its	O
noradrenergic	O
effects	O
,	O
which	O
other	O
ARBs	O
used	O
at	O
therapeutic	O
doses	O
do	O
not	O
possess	O
.	O

Eprosartan	B-CHEMICAL
,	O
therefore	O
,	O
represents	O
a	O
useful	O
therapeutic	O
option	O
in	O
the	O
management	O
of	O
patients	O
with	O
hypertension	O
,	O
including	O
those	O
with	O
a	O
history	O
of	O
stroke	O
or	O
with	O
co	O
-	O
morbid	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Covalent	O
modification	O
of	O
stathmin	B-GENE-Y
by	O
CCNU	O
determined	O
by	O
FTMS	O
analysis	O
of	O
modified	O
proteins	O
and	O
tryptic	O
peptides	O
.	O

Chemical	O
modification	O
of	O
proteins	O
is	O
often	O
carried	O
out	O
to	O
generate	O
protein	O
-	O
small	O
molecule	O
conjugates	O
for	O
various	O
applications	O
.	O

The	O
high	O
resolution	O
and	O
mass	O
accuracy	O
of	O
a	O
Fourier	O
transform	O
mass	O
spectrometer	O
is	O
particularly	O
useful	O
for	O
assessing	O
the	O
extent	O
or	O
sites	O
of	O
covalent	O
modifications	O
.	O

As	O
protein	O
-	O
small	O
molecule	O
reactions	O
often	O
produce	O
products	O
with	O
variable	O
numbers	O
of	O
the	O
compound	O
incorporated	O
at	O
different	O
sites	O
,	O
a	O
direct	O
mass	O
analysis	O
of	O
the	O
reaction	O
products	O
at	O
times	O
yields	O
mass	O
spectra	O
hard	O
to	O
interpret	O
.	O

Chromatographic	O
separation	O
at	O
protein	O
level	O
could	O
reduce	O
the	O
complexity	O
of	O
a	O
sample	O
,	O
thus	O
allowing	O
more	O
accurate	O
mass	O
spectrometric	O
analysis	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
the	O
utility	O
of	O
reversed	O
-	O
phase	O
protein	O
chromatography	O
and	O
FT	O
-	O
ICR	O
mass	O
spectrometry	O
in	O
analyzing	O
CCNU	O
(	O
lomustine	B-CHEMICAL
,	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
chloroethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
cyclohexyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
nitroso	I-CHEMICAL
-	I-CHEMICAL
urea	I-CHEMICAL
,	O
MW	O
:	O
233	O
.	O
7Da	O
)	O
modification	O
of	O
stathmin	B-GENE-Y
.	O

With	O
this	O
combined	O
approach	O
,	O
we	O
determined	O
the	O
stoichiometry	O
as	O
well	O
as	O
sites	O
of	O
CCNU	O
incorporation	O
into	O
the	O
protein	O
,	O
demonstrating	O
differential	O
reactivity	O
of	O
several	O
lysyl	O
residues	O
to	O
CCNU	O
alkylation	O
.	O

Phosphodiesterase	B-GENE-N
4	I-GENE-N
inhibitors	O
delay	O
human	O
eosinophil	O
and	O
neutrophil	O
apoptosis	O
in	O
the	O
absence	O
and	O
presence	O
of	O
salbutamol	B-CHEMICAL
.	O

In	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
the	O
number	O
of	O
eosinophils	O
and	O
neutrophils	O
in	O
the	O
lung	O
is	O
increased	O
.	O

One	O
described	O
mechanism	O
leading	O
to	O
the	O
impaired	O
clearance	O
of	O
these	O
cells	O
from	O
the	O
lung	O
is	O
the	O
delay	O
in	O
their	O
programmed	O
cell	O
death	O
(	O
apoptosis	O
)	O
.	O

Selective	O
inhibitors	O
of	O
phosphodiesterases	B-GENE-N
(	O
PDEs	B-GENE-N
)	O
are	O
under	O
development	O
for	O
the	O
treatment	O
of	O
lung	O
diseases	O
because	O
of	O
their	O
anti	O
-	O
inflammatory	O
and	O
bronchodilator	O
activity	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
establish	O
whether	O
inhibitors	O
of	O
PDE3	B-GENE-N
,	O
PDE4	B-GENE-N
and	O
PDE5	B-GENE-Y
modulate	O
human	O
eosinophil	O
or	O
neutrophil	O
apoptosis	O
or	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
-	O
or	O
cytokine	B-GENE-N
-	O
afforded	O
survival	O
.	O

We	O
also	O
evaluated	O
whether	O
a	O
PDE4	B-GENE-N
inhibitor	O
could	O
modulate	O
the	O
effect	O
of	O
a	O
corticosteroid	B-CHEMICAL
on	O
eosinophil	O
and	O
neutrophil	O
apoptosis	O
.	O

Apoptosis	O
was	O
measured	O
by	O
using	O
the	O
relative	O
DNA	O
fragmentation	O
assay	O
and	O
Annexin	O
-	O
V	O
binding	O
.	O

Inhibitors	O
of	O
PDE4	B-GENE-N
(	O
rolipram	B-CHEMICAL
;	O
0	O
.	O
1	O
-	O
10	O
microM	O
)	O
and	O
PDE3	B-GENE-N
(	O
cilostazol	B-CHEMICAL
;	O
0	O
.	O
1	O
-	O
10	O
microM	O
)	O
delayed	O
spontaneous	O
eosinophil	O
apoptosis	O
maximally	O
by	O
25	O
%	O
and	O
15	O
%	O
,	O
respectively	O
.	O

A	O
combination	O
of	O
a	O
PDE4	B-GENE-N
or	O
PDE3	B-GENE-N
inhibitor	O
(	O
10	O
microM	O
)	O
with	O
salbutamol	B-CHEMICAL
(	O
100	O
nM	O
)	O
further	O
delayed	O
eosinophil	O
apoptosis	O
maximally	O
by	O
42	O
-	O
49	O
%	O
.	O

In	O
neutrophils	O
,	O
rolipram	B-CHEMICAL
(	O
10	O
microM	O
)	O
also	O
decreased	O
apoptosis	O
with	O
a	O
maximal	O
inhibition	O
of	O
13	O
%	O
.	O

The	O
combination	O
of	O
rolipram	B-CHEMICAL
(	O
10	O
microM	O
)	O
and	O
salbutamol	B-CHEMICAL
(	O
100	O
nM	O
)	O
produced	O
a	O
27	O
%	O
inhibition	O
of	O
neutrophil	O
apoptosis	O
.	O

Inhibitor	O
of	O
cGMP	B-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
PDE5	I-GENE-Y
(	O
zaprinast	B-CHEMICAL
;	O
0	O
.	O
1	O
-	O
10	O
microM	O
)	O
did	O
not	O
affect	O
eosinophil	O
apoptosis	O
and	O
only	O
slightly	O
increased	O
spontaneous	O
neutrophil	O
apoptosis	O
.	O

The	O
effect	O
of	O
budesonide	B-CHEMICAL
on	O
apoptosis	O
was	O
not	O
significantly	O
modulated	O
by	O
a	O
PDE4	B-GENE-N
inhibitor	O
in	O
eosinophils	O
or	O
neutrophils	O
.	O

The	O
present	O
results	O
show	O
that	O
selective	O
inhibitors	O
of	O
cAMP	B-GENE-N
-	I-GENE-N
hydrolyzing	I-GENE-N
PDEs	I-GENE-N
(	O
PDE3	B-GENE-N
and	O
PDE4	B-GENE-N
)	O
delay	O
eosinophil	O
apoptosis	O
and	O
,	O
thus	O
,	O
increase	O
their	O
survival	O
in	O
vitro	O
.	O

Furthermore	O
,	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonists	O
enhance	O
the	O
anti	O
-	O
apoptotic	O
effects	O
of	O
PDE3	B-GENE-N
and	O
PDE4	B-GENE-N
inhibitors	O
,	O
suggesting	O
that	O
such	O
drug	O
combinations	O
may	O
prolong	O
eosinophil	O
and	O
neutrophil	O
longevity	O
in	O
the	O
lung	O
.	O

Statins	B-CHEMICAL
increase	O
p21	B-GENE-Y
through	O
inhibition	O
of	O
histone	B-GENE-N
deacetylase	I-GENE-N
activity	O
and	O
release	O
of	O
promoter	O
-	O
associated	O
HDAC1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
.	O

Statins	B-CHEMICAL
are	O
3	B-GENE-Y
-	I-GENE-Y
hydroxy	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
methylglutaryl	I-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibitors	O
broadly	O
used	O
for	O
the	O
control	O
of	O
hypercholesterolemia	O
.	O

Recently	O
,	O
they	O
are	O
reported	O
to	O
have	O
beneficial	O
effects	O
on	O
certain	O
cancers	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
statins	O
inhibited	O
the	O
histone	B-GENE-N
deacetylase	I-GENE-N
(	O
HDAC	B-GENE-N
)	O
activity	O
and	O
increased	O
the	O
accumulation	O
of	O
acetylated	B-GENE-N
histone	I-GENE-N
-	I-GENE-N
H3	I-GENE-N
and	O
the	O
expression	O
of	O
p21	B-GENE-Y
(	O
WAF	B-GENE-Y
/	O
CIP	B-GENE-Y
)	O
in	O
human	O
cancer	O
cells	O
.	O

Computational	O
modeling	O
showed	O
the	O
direct	O
interaction	O
of	O
the	O
carboxylic	B-CHEMICAL
acid	I-CHEMICAL
moiety	O
of	O
statins	O
with	O
the	O
catalytic	O
site	O
of	O
HDAC2	B-GENE-Y
.	O

In	O
the	O
subsequent	O
enzymatic	O
assay	O
,	O
it	O
was	O
shown	O
that	O
lovastatin	B-CHEMICAL
inhibited	O
HDAC2	B-GENE-Y
activity	O
competitively	O
with	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
31	O
.	O
6	O
micromol	O
/	O
L	O
.	O

Sp1	B-GENE-Y
but	O
not	O
p53	B-GENE-Y
sites	O
were	O
found	O
to	O
be	O
the	O
statins	B-GENE-N
-	I-GENE-N
responsive	I-GENE-N
element	I-GENE-N
shown	O
by	O
p21	B-GENE-Y
luciferase	O
-	O
promoter	O
assays	O
.	O

DNA	O
affinity	O
protein	O
binding	O
assay	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
showed	O
the	O
dissociation	O
of	O
HDAC1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
association	O
of	O
CBP	B-GENE-Y
,	O
leading	O
to	O
the	O
histone	B-GENE-N
-	I-GENE-N
H3	I-GENE-N
acetylation	O
on	O
the	O
Sp1	B-GENE-Y
sites	O
of	O
p21	B-GENE-N
promoter	I-GENE-N
.	O

In	O
vitro	O
cell	O
proliferation	O
and	O
in	O
vivo	O
tumor	O
growth	O
were	O
both	O
inhibited	O
by	O
statins	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
for	O
statins	O
through	O
abrogation	O
of	O
the	O
HDAC	B-GENE-N
activity	O
and	O
promoter	O
histone	B-GENE-N
-	I-GENE-N
H3	I-GENE-N
acetylation	O
to	O
regulate	O
p21	B-GENE-Y
expression	O
.	O

Therefore	O
,	O
statins	O
might	O
serve	O
as	O
novel	O
HDAC	B-GENE-N
inhibitors	O
for	O
cancer	O
therapy	O
and	O
chemoprevention	O
.	O

Flavopiridol	B-CHEMICAL
Hoechst	O
AG	O
.	O

Hoechst	O
is	O
developing	O
flavopiridol	B-CHEMICAL
,	O
a	O
synthetic	O
flavonoid	B-CHEMICAL
based	O
on	O
an	O
extract	O
from	O
an	O
Indian	O
plant	O
,	O
for	O
the	O
potential	O
treatment	O
of	O
cancer	O
.	O

Flavopiridol	B-CHEMICAL
,	O
a	O
cyclin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
kinase	I-GENE-N
inhibitor	O
,	O
arrests	O
cell	O
division	O
and	O
causes	O
apoptosis	O
in	O
non	O
-	O
small	O
lung	O
cancer	O
cells	O
[	O
283660	O
]	O
.	O

A	O
phase	O
II	O
trial	O
,	O
in	O
collaboration	O
with	O
the	O
National	O
Cancer	O
Institute	O
,	O
has	O
commenced	O
at	O
the	O
University	O
of	O
Chicago	O
Medical	O
Center	O
,	O
which	O
involves	O
patients	O
with	O
high	O
or	O
intermediate	O
-	O
grade	O
lymphoma	O
or	O
multiple	O
myeloma	O
[	O
272937	O
]	O
,	O
[	O
277372	O
]	O
.	O

In	O
ex	O
vivo	O
experiments	O
with	O
tumor	O
cells	O
from	O
refractory	O
chronic	O
lymphoblastic	O
leukemia	O
,	O
dose	O
-	O
dependent	O
CDK2	B-GENE-Y
inhibition	O
associated	O
with	O
apoptotic	O
changes	O
was	O
seen	O
at	O
concentrations	O
greater	O
than	O
100	O
nM	O
of	O
flavopiridol	B-CHEMICAL
.	O

In	O
vitro	O
pharmacokinetic	O
studies	O
have	O
shown	O
that	O
flavopiridol	B-CHEMICAL
undergoes	O
hepatic	O
biotransformation	O
to	O
its	O
corresponding	O
glucoronide	B-CHEMICAL
by	O
uridine	B-CHEMICAL
diphosphate	I-CHEMICAL
glucoronosyltransferases	O
[	O
283791	O
]	O
.	O

Flavopiridol	B-CHEMICAL
inhibits	O
CDK	B-GENE-N
with	O
an	O
IC50	O
value	O
of	O
0	O
.	O
4	O
mM	O
[	O
285707	O
]	O
.	O

Preclinical	O
toxicology	O
studies	O
in	O
rats	O
and	O
dogs	O
demonstrated	O
dose	O
-	O
related	O
leukopenia	O
and	O
drug	O
-	O
related	O
lesions	O
in	O
the	O
thymus	O
,	O
spleen	O
and	O
bone	O
marrow	O
.	O

The	O
gastrointestinal	O
and	O
bone	O
marrow	O
toxicity	O
was	O
dose	O
-	O
limiting	O
[	O
178579	O
]	O
.	O

Hoechst	O
Marion	O
Roussel	O
expects	O
to	O
launch	O
flavopiridol	B-CHEMICAL
in	O
the	O
year	O
2001	O
,	O
with	O
potential	O
sales	O
in	O
excess	O
of	O
DM	O
750	O
million	O
[	O
288651	O
]	O
.	O

Optimization	O
of	O
taxane	B-CHEMICAL
binding	O
to	O
microtubules	B-GENE-N
:	O
binding	O
affinity	O
dissection	O
and	O
incremental	O
construction	O
of	O
a	O
high	O
-	O
affinity	O
analog	O
of	O
paclitaxel	B-CHEMICAL
.	O

The	O
microtubule	B-GENE-N
binding	O
affinities	O
of	O
a	O
series	O
of	O
synthetic	O
taxanes	B-CHEMICAL
have	O
been	O
measured	O
with	O
the	O
aims	O
of	O
dissecting	O
individual	O
group	O
contributions	O
and	O
obtaining	O
a	O
rationale	O
for	O
the	O
design	O
of	O
novel	O
compounds	O
with	O
the	O
ability	O
to	O
overcome	O
drug	O
resistance	O
.	O

As	O
previously	O
observed	O
for	O
epothilones	B-CHEMICAL
,	O
the	O
positive	O
and	O
negative	O
contributions	O
of	O
the	O
different	O
substituents	O
to	O
the	O
binding	O
free	O
energies	O
are	O
cumulative	O
.	O

By	O
combining	O
the	O
most	O
favorable	O
substitutions	O
we	O
increased	O
the	O
binding	O
affinity	O
of	O
paclitaxel	B-CHEMICAL
500	O
-	O
fold	O
.	O

Insight	O
into	O
the	O
structural	O
basis	O
for	O
this	O
improvement	O
was	O
gained	O
with	O
molecular	O
modeling	O
and	O
NMR	O
data	O
obtained	O
for	O
microtubule	B-GENE-N
-	O
bound	O
docetaxel	B-CHEMICAL
.	O

Taxanes	B-CHEMICAL
with	O
affinities	O
for	O
microtubules	B-GENE-N
well	O
above	O
their	O
affinities	O
for	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
are	O
shown	O
not	O
to	O
be	O
affected	O
by	O
multidrug	O
resistance	O
.	O

This	O
finding	O
strongly	O
indicates	O
that	O
optimization	O
of	O
the	O
ligand	O
-	O
target	O
interaction	O
is	O
a	O
good	O
strategy	O
to	O
overcome	O
multidrug	O
resistance	O
mediated	O
by	O
efflux	B-GENE-N
pumps	I-GENE-N
.	O

Synergy	O
between	O
pairs	O
of	O
competitive	O
antagonists	O
at	O
adult	O
human	B-GENE-N
muscle	I-GENE-N
acetylcholine	I-GENE-N
receptors	I-GENE-N
.	O

BACKGROUND	O
:	O
Synergistic	O
neuromuscular	O
blocking	O
effects	O
have	O
been	O
observed	O
clinically	O
with	O
certain	O
pairs	O
of	O
nicotinic	B-GENE-N
acetylcholine	I-GENE-N
receptor	I-GENE-N
(	O
nAChR	B-GENE-N
)	O
competitive	O
antagonists	O
.	O

The	O
mechanism	O
for	O
synergy	O
has	O
not	O
been	O
elucidated	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
synergy	O
arises	O
from	O
a	O
differential	O
selectivity	O
of	O
antagonists	O
for	O
the	O
two	O
ligand	O
binding	O
sites	O
on	O
adult	O
human	B-GENE-N
nAChR	I-GENE-N
.	O

METHODS	O
:	O
We	O
expressed	O
nAChR	B-GENE-N
in	O
BOSC23	O
cells	O
.	O

We	O
applied	O
ACh	O
with	O
or	O
without	O
antagonists	O
to	O
outside	O
-	O
out	O
patches	O
and	O
measured	O
macroscopic	O
currents	O
at	O
room	O
temperature	O
.	O

We	O
determined	O
the	O
IC	O
(	O
90	O
)	O
for	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tubocurarine	I-CHEMICAL
,	O
metocurine	B-CHEMICAL
,	O
pancuronium	B-CHEMICAL
,	O
vecuronium	B-CHEMICAL
,	O
cisatracurium	B-CHEMICAL
,	O
rocuronium	B-CHEMICAL
,	O
and	O
atracurium	B-CHEMICAL
.	O

For	O
15	O
combinations	O
of	O
two	O
antagonists	O
,	O
we	O
determined	O
the	O
IC	O
(	O
90	O
)	O
for	O
one	O
antagonist	O
in	O
the	O
presence	O
of	O
the	O
IC	O
(	O
70	O
)	O
of	O
a	O
second	O
antagonist	O
.	O

We	O
constructed	O
isobolograms	O
for	O
90	O
%	O
inhibition	O
.	O

For	O
single	O
antagonists	O
,	O
we	O
measured	O
inhibition	O
of	O
receptors	O
containing	O
mutations	O
in	O
the	O
epsilon	O
-	O
and	O
delta	O
-	O
subunits	O
to	O
determine	O
site	O
selectivity	O
.	O

RESULTS	O
:	O
Two	O
pairs	O
of	O
antagonists	O
,	O
metocurine	B-CHEMICAL
+	O
cisatracurium	B-CHEMICAL
and	O
cisatracurium	B-CHEMICAL
+	O
atracurium	B-CHEMICAL
exhibited	O
additive	O
inhibition	O
.	O

Ten	O
combinations	O
,	O
including	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tubocurarine	I-CHEMICAL
+	O
pancuronium	B-CHEMICAL
and	O
pancuronium	B-CHEMICAL
+	O
vecuronium	B-CHEMICAL
,	O
were	O
highly	O
synergistic	O
such	O
that	O
the	O
combination	O
was	O
two	O
to	O
three	O
times	O
more	O
effective	O
than	O
expected	O
for	O
additivity	O
.	O

Three	O
combinations	O
were	O
1	O
.	O
5	O
-	O
1	O
.	O
6	O
times	O
more	O
effective	O
than	O
expected	O
for	O
additivity	O
.	O

Inhibition	O
by	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tubocurarine	I-CHEMICAL
and	O
metocurine	B-CHEMICAL
was	O
sensitive	O
to	O
mutations	O
in	O
the	O
epsilon	O
-	O
subunit	O
only	O
.	O

Vecuronium	B-CHEMICAL
was	O
affected	O
by	O
the	O
delta	O
-	O
subunit	O
mutation	O
only	O
.	O

Inhibition	O
by	O
other	O
antagonists	O
was	O
decreased	O
by	O
mutations	O
in	O
either	O
subunit	O
.	O

CONCLUSIONS	O
:	O
Many	O
combinations	O
of	O
antagonists	O
exhibited	O
synergistic	O
effects	O
on	O
adult	O
human	B-GENE-N
nAChR	I-GENE-N
.	O

Synergy	O
was	O
observed	O
with	O
structurally	O
similar	O
and	O
dissimilar	O
antagonists	O
.	O

The	O
degree	O
of	O
synergy	O
did	O
not	O
always	O
correlate	O
well	O
with	O
site	O
specificity	O
assayed	O
with	O
mutants	O
.	O

In	O
some	O
,	O
but	O
not	O
all	O
cases	O
,	O
the	O
synergy	O
at	O
the	O
receptor	O
level	O
correlated	O
with	O
clinical	O
determinations	O
of	O
synergy	O
.	O

We	O
conclude	O
that	O
the	O
synergistic	O
actions	O
of	O
muscle	O
relaxants	O
can	O
be	O
partially	O
explained	O
by	O
direct	O
interactions	O
with	O
adult	O
human	B-GENE-N
nAChR	I-GENE-N
.	O

Formoterol	B-CHEMICAL
in	O
the	O
management	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O

Bronchodilators	O
represent	O
the	O
hallmark	O
of	O
symptomatic	O
treatment	O
of	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
(	O
COPD	O
)	O
.	O

There	O
are	O
four	O
categories	O
of	O
bronchodilators	O
:	O
anticholinergics	O
,	O
methylxanthines	B-CHEMICAL
,	O
short	O
-	O
acting	O
beta2	O
-	O
agonists	O
,	O
and	O
long	O
-	O
acting	O
beta2	O
-	O
agonists	O
such	O
as	O
formoterol	B-CHEMICAL
.	O

Significant	O
research	O
has	O
been	O
performed	O
to	O
investigate	O
the	O
efficacy	O
,	O
safety	O
and	O
tolerability	O
of	O
formoterol	B-CHEMICAL
in	O
the	O
therapeutic	O
field	O
of	O
COPD	O
.	O

Formoterol	B-CHEMICAL
exhibits	O
a	O
rapid	O
onset	O
of	O
bronchodilation	O
similar	O
to	O
that	O
observed	O
with	O
salbutamol	B-CHEMICAL
,	O
yet	O
its	O
long	O
bronchodilatory	O
duration	O
is	O
comparable	O
to	O
salmeterol	B-CHEMICAL
.	O

In	O
addition	O
,	O
formoterol	B-CHEMICAL
presents	O
with	O
a	O
clear	O
superiority	O
in	O
lung	O
function	O
improvement	O
compared	O
with	O
either	O
ipratropium	B-CHEMICAL
bromide	I-CHEMICAL
or	O
oral	O
theophylline	B-CHEMICAL
,	O
while	O
its	O
efficacy	O
improves	O
when	O
administered	O
in	O
combination	O
with	O
ipratropium	B-CHEMICAL
.	O

Formoterol	B-CHEMICAL
has	O
been	O
shown	O
to	O
better	O
reduce	O
dynamic	O
hyperinflation	O
,	O
which	O
is	O
responsible	O
for	O
exercise	O
intolerance	O
and	O
dyspnea	O
in	O
COPD	O
patients	O
,	O
compared	O
with	O
other	O
bronchodilators	O
,	O
whereas	O
it	O
exerts	O
synergistic	O
effect	O
with	O
tiotropium	O
.	O

Moreover	O
,	O
formoterol	B-CHEMICAL
reduces	O
exacerbations	O
,	O
increases	O
days	O
free	O
of	O
use	O
of	O
rescue	O
medication	O
and	O
improves	O
patients	O
'	O
quality	O
of	O
life	O
and	O
disease	O
symptoms	O
.	O

Formoterol	B-CHEMICAL
has	O
a	O
favorable	O
safety	O
profile	O
and	O
is	O
better	O
tolerated	O
than	O
theophylline	B-CHEMICAL
.	O

Collectively	O
,	O
data	O
extracted	O
from	O
multicenter	O
clinical	O
trials	O
support	O
formoterol	B-CHEMICAL
as	O
a	O
valid	O
therapeutic	O
option	O
in	O
the	O
treatment	O
of	O
COPD	O
.	O

ABCB1	B-GENE-Y
polymorphisms	O
influence	O
steady	O
-	O
state	O
plasma	O
levels	O
of	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
and	O
risperidone	B-CHEMICAL
active	O
moiety	O
.	O

Risperidone	B-CHEMICAL
is	O
metabolized	O
to	O
its	O
active	O
metabolite	O
,	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
,	O
mainly	O
by	O
the	O
cytochrome	B-GENE-N
P450	I-GENE-N
enzymes	O
CYP2D6	B-GENE-N
and	I-GENE-N
3A4	I-GENE-N
.	O

Its	O
antipsychotic	O
effect	O
is	O
assumed	O
to	O
be	O
related	O
to	O
the	O
active	O
moiety	O
,	O
that	O
is	O
,	O
the	O
sum	O
of	O
risperidone	B-CHEMICAL
and	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
.	O

Both	O
risperidone	B-CHEMICAL
and	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
are	O
substrates	O
of	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
,	O
a	O
transport	O
protein	O
involved	O
in	O
drug	O
absorption	O
,	O
distribution	O
,	O
and	O
elimination	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
influence	O
of	O
polymorphisms	O
in	O
genes	O
encoding	O
CYP3A5	B-GENE-Y
and	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
(	O
ABCB1	B-GENE-Y
)	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
levels	O
of	O
risperidone	B-CHEMICAL
,	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
,	O
and	O
the	O
active	O
moiety	O
,	O
taking	O
CYP2D6	B-GENE-Y
genotype	O
status	O
into	O
account	O
.	O

Forty	O
-	O
six	O
white	O
patients	O
with	O
schizophrenia	O
treated	O
with	O
risperidone	B-CHEMICAL
(	O
1	O
-	O
10	O
mg	O
/	O
d	O
)	O
in	O
monotherapy	O
for	O
4	O
-	O
6	O
weeks	O
were	O
genotyped	O
,	O
and	O
their	O
plasma	O
concentrations	O
of	O
risperidone	B-CHEMICAL
and	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
were	O
measured	O
.	O

Dose	O
-	O
corrected	O
plasma	O
concentrations	O
(	O
C	O
/	O
D	O
)	O
of	O
risperidone	B-CHEMICAL
,	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
,	O
and	O
active	O
moiety	O
showed	O
up	O
to	O
68	O
-	O
,	O
9	O
-	O
,	O
and	O
10	O
-	O
fold	O
interindividual	O
variation	O
,	O
respectively	O
.	O

Six	O
patients	O
carried	O
1	O
CYP3A5	B-GENE-Y
*	O
1	O
allele	O
and	O
therefore	O
were	O
likely	O
to	O
express	O
the	O
CYP3A5	B-GENE-Y
enzyme	O
.	O

The	O
CYP3A5	B-GENE-Y
genotype	O
did	O
not	O
influence	O
risperidone	B-CHEMICAL
,	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
,	O
or	O
active	O
moiety	O
C	O
/	O
Ds	O
.	O

The	O
CYP2D6	B-GENE-Y
genotype	O
in	O
these	O
46	O
patients	O
was	O
again	O
associated	O
with	O
risperidone	B-CHEMICAL
C	O
/	O
D	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
but	O
not	O
with	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
C	O
/	O
D	O
or	O
active	O
moiety	O
C	O
/	O
D	O
,	O
as	O
previously	O
shown	O
by	O
our	O
group	O
in	O
37	O
of	O
these	O
patients	O
.	O

Patients	O
homozygous	O
for	O
the	O
ABCB1	B-GENE-Y
3435T	O
/	O
2677T	O
/	O
1236T	O
haplotype	O
had	O
significantly	O
lower	O
C	O
/	O
Ds	O
of	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
(	O
P	O
=	O
0	O
.	O
026	O
)	O
and	O
active	O
moiety	O
(	O
P	O
=	O
0	O
.	O
028	O
)	O
than	O
patients	O
carrying	O
other	O
ABCB1	B-GENE-Y
genotypes	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
confirmed	O
the	O
significant	O
effect	O
of	O
CYP2D6	B-GENE-Y
genotype	O
on	O
the	O
steady	O
-	O
state	O
plasma	O
levels	O
of	O
risperidone	B-CHEMICAL
and	O
showed	O
that	O
ABCB1	B-GENE-Y
polymorphisms	O
have	O
a	O
moderate	O
effect	O
on	O
those	O
of	O
9	B-CHEMICAL
-	I-CHEMICAL
hydroxyrisperidone	I-CHEMICAL
and	O
the	O
active	O
moiety	O
.	O

Tumor	O
-	O
growth	O
-	O
promoting	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
pathway	O
provides	O
medulloblastoma	O
therapeutic	O
targets	O
.	O

Prostaglandin	B-CHEMICAL
E	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
(	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
)	O
has	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
several	O
aspects	O
of	O
tumor	O
development	O
and	O
progression	O
.	O

PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
is	O
synthesized	O
from	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
by	O
cyclooxygenases	B-GENE-N
(	O
COX	B-GENE-N
)	O
and	O
prostaglandin	B-GENE-N
E	I-GENE-N
synthases	I-GENE-N
(	O
PGES	B-GENE-N
)	O
and	O
mediates	O
its	O
biological	O
activity	O
through	O
binding	O
to	O
the	O
four	O
prostanoid	B-GENE-Y
receptors	I-GENE-Y
EP	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
through	O
EP	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
.	O

In	O
this	O
study	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
medulloblastoma	O
(	O
MB	O
)	O
,	O
the	O
most	O
common	O
malignant	O
childhood	O
brain	O
tumor	O
,	O
expresses	O
high	O
levels	O
of	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
microsomal	B-GENE-Y
prostaglandin	I-GENE-Y
E	I-GENE-Y
synthase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
EP	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
through	O
EP	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
and	O
secretes	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
.	O

PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
and	O
the	O
EP	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
agonist	O
butaprost	O
stimulated	O
MB	O
cell	O
proliferation	O
.	O

Treatment	O
of	O
MB	O
cells	O
with	O
COX	B-GENE-N
inhibitors	O
suppressed	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
production	O
and	O
induced	O
caspase	B-GENE-N
-	O
dependent	O
apoptosis	O
.	O

Similarly	O
,	O
specific	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
silencing	O
by	O
small	O
interfering	O
RNA	O
inhibited	O
MB	O
cell	O
growth	O
.	O

EP	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
and	O
EP	B-GENE-Y
(	I-GENE-Y
3	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
ONO	B-CHEMICAL
-	I-CHEMICAL
8713	I-CHEMICAL
and	O
ONO	B-CHEMICAL
-	I-CHEMICAL
AE3	I-CHEMICAL
-	I-CHEMICAL
240	I-CHEMICAL
,	O
but	O
not	O
the	O
EP	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
antagonists	O
ONO	B-CHEMICAL
-	I-CHEMICAL
AE3	I-CHEMICAL
-	I-CHEMICAL
208	I-CHEMICAL
and	O
AH	B-CHEMICAL
23848	I-CHEMICAL
,	O
inhibited	O
tumor	O
cell	O
proliferation	O
,	O
indicating	O
the	O
significance	O
of	O
EP	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
and	O
EP	B-GENE-Y
(	I-GENE-Y
3	I-GENE-Y
)	I-GENE-Y
but	O
not	O
EP	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
for	O
MB	O
growth	O
.	O

Administration	O
of	O
COX	B-GENE-N
inhibitors	O
at	O
clinically	O
achievable	O
nontoxic	O
concentrations	O
significantly	O
inhibited	O
growth	O
of	O
established	O
human	O
MB	O
xenografts	O
.	O

Apoptosis	O
was	O
increased	O
,	O
proliferation	O
was	O
reduced	O
,	O
and	O
angiogenesis	O
was	O
inhibited	O
in	O
MBs	O
treated	O
with	O
COX	B-GENE-N
inhibitors	O
.	O

This	O
study	O
suggests	O
that	O
PGE	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
is	O
important	O
for	O
MB	O
growth	O
and	O
that	O
therapies	O
targeting	O
the	O
prostanoid	O
metabolic	O
pathway	O
are	O
potentially	O
beneficial	O
and	O
should	O
be	O
tested	O
in	O
clinical	O
settings	O
for	O
treatment	O
of	O
children	O
with	O
MB	O
.	O

Plerixafor	B-CHEMICAL
,	O
a	O
CXCR4	B-GENE-Y
antagonist	O
for	O
the	O
mobilization	O
of	O
hematopoietic	O
stem	O
cells	O
.	O

Stem	O
cells	O
harvested	O
from	O
peripheral	O
blood	O
are	O
the	O
most	O
commonly	O
used	O
graft	O
source	O
in	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

While	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
is	O
the	O
most	O
frequently	O
used	O
agent	O
for	O
stem	O
cell	O
mobilization	O
,	O
the	O
use	O
of	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
alone	O
results	O
in	O
suboptimal	O
stem	O
cell	O
yields	O
in	O
a	O
significant	O
proportion	O
of	O
patients	O
undergoing	O
autologous	O
transplantation	O
.	O

Plerixafor	B-CHEMICAL
(	O
AMD3100	B-CHEMICAL
,	O
Genzyme	O
Corporation	O
)	O
is	O
a	O
bicyclam	B-CHEMICAL
molecule	O
that	O
antagonizes	O
the	O
binding	O
of	O
the	O
chemokine	B-GENE-N
stromal	B-GENE-Y
cell	I-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
SDF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
to	O
its	O
cognate	O
receptor	O
CXCR4	B-GENE-Y
.	O

Plerixafor	B-CHEMICAL
results	O
in	O
the	O
rapid	O
and	O
reversible	O
mobilization	O
of	O
hematopoietic	O
stem	O
cells	O
into	O
the	O
peripheral	O
circulation	O
and	O
is	O
synergistic	O
when	O
combined	O
with	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
.	O

In	O
clinical	O
studies	O
of	O
autologous	O
stem	O
cell	O
transplantation	O
,	O
the	O
combination	O
of	O
plerixafor	B-CHEMICAL
and	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
allows	O
the	O
collection	O
of	O
large	O
numbers	O
of	O
stem	O
cells	O
in	O
fewer	O
apheresis	O
sessions	O
and	O
can	O
salvage	O
those	O
who	O
fail	O
G	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
mobilization	O
alone	O
.	O

[	O
Pharmacological	O
effects	O
of	O
a	O
mu	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
naltrexone	B-CHEMICAL
on	O
alcohol	B-CHEMICAL
dependence	O
]	O
.	O

Alcohol	B-CHEMICAL
is	O
one	O
of	O
the	O
most	O
commonly	O
abused	O
substances	O
,	O
and	O
its	O
chronic	O
intake	O
leads	O
to	O
the	O
development	O
of	O
ethanol	B-CHEMICAL
dependence	O
in	O
both	O
humans	O
and	O
laboratory	O
animals	O
.	O

In	O
many	O
countries	O
,	O
a	O
mu	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
naltrexone	B-CHEMICAL
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
alcohol	B-CHEMICAL
dependence	O
.	O

The	O
introduction	O
of	O
naltrexone	B-CHEMICAL
for	O
the	O
treatment	O
of	O
alcohol	B-CHEMICAL
dependence	O
has	O
been	O
mainly	O
based	O
on	O
behavioral	O
animal	O
models	O
that	O
provide	O
evidence	O
of	O
the	O
involvement	O
of	O
the	O
endogenous	O
opioid	O
system	O
in	O
alcohol	B-CHEMICAL
drinking	O
and	O
dependence	O
.	O

It	O
has	O
been	O
well	O
known	O
that	O
alcohol	B-CHEMICAL
leads	O
to	O
the	O
activation	O
of	O
the	O
endogenous	O
opioid	O
system	O
.	O

The	O
endogenous	O
opioid	O
agonists	O
,	O
such	O
as	O
beta	B-GENE-Y
-	I-GENE-Y
endorphin	I-GENE-Y
,	O
increase	O
the	O
activity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
through	O
the	O
inhibition	O
of	O
the	O
gamma	B-CHEMICAL
-	I-CHEMICAL
aminobutyric	I-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	B-CHEMICAL
)	O
-	O
containing	O
inhibitory	O
interneurons	O
in	O
the	O
ventral	O
tegmental	O
area	O
,	O
resulting	O
in	O
the	O
expression	O
of	O
alcohol	B-CHEMICAL
reinforcement	O
and	O
/	O
or	O
rewarding	O
effect	O
.	O

Therefore	O
,	O
naltrexone	B-CHEMICAL
,	O
which	O
is	O
useful	O
for	O
alcohol	B-CHEMICAL
dependence	O
therapy	O
,	O
may	O
attenuate	O
the	O
rewarding	O
effect	O
of	O
ethanol	B-CHEMICAL
by	O
interfering	O
with	O
the	O
ethanol	B-CHEMICAL
-	O
induced	O
stimulation	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
.	O

The	O
following	O
review	O
provides	O
a	O
summary	O
of	O
the	O
interactions	O
between	O
endogenous	O
opioid	O
system	O
and	O
mesolimbic	O
dopaminergic	O
system	O
in	O
alcohol	B-CHEMICAL
dependence	O
.	O

Neurochemical	O
effects	O
of	O
the	O
monoamine	B-GENE-N
oxidase	I-GENE-N
inhibitor	O
phenelzine	B-CHEMICAL
on	O
brain	O
GABA	B-CHEMICAL
and	O
alanine	B-CHEMICAL
:	O
A	O
comparison	O
with	O
vigabatrin	B-CHEMICAL
.	O

PURPOSE	O
:	O
To	O
compare	O
phenelzine	B-CHEMICAL
(	O
PLZ	B-CHEMICAL
)	O
,	O
an	O
antidepressant	O
drug	O
with	O
anxiolytic	O
properties	O
which	O
inhibits	O
monoamine	B-GENE-N
oxidase	I-GENE-N
(	O
MAO	B-GENE-N
)	O
but	O
also	O
elevates	O
rat	O
brain	O
levels	O
of	O
the	O
amino	B-CHEMICAL
acids	I-CHEMICAL
?	O
-	O
aminobutyric	B-CHEMICAL
acid	I-CHEMICAL
(	O
GABA	B-CHEMICAL
)	O
and	O
alanine	B-CHEMICAL
(	O
ALA	B-CHEMICAL
)	O
,	O
with	O
vigabatrin	B-CHEMICAL
(	O
VIG	B-CHEMICAL
)	O
,	O
an	O
anticonvulsant	O
which	O
elevates	O
brain	O
GABA	B-CHEMICAL
by	O
inhibition	O
of	O
GABA	B-GENE-Y
transaminase	I-GENE-Y
(	O
GABA	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
)	O
,	O
with	O
regard	O
to	O
their	O
actions	O
on	O
brain	O
levels	O
of	O
GABA	B-CHEMICAL
and	O
ALA	B-CHEMICAL
and	O
on	O
activities	O
of	O
MAO	B-GENE-N
,	O
GABA	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
and	O
ALA	B-GENE-N
transaminase	I-GENE-N
(	O
ALA	B-GENE-N
-	I-GENE-N
T	I-GENE-N
)	O
.	O

METHODS	O
:	O
Male	O
rats	O
were	O
administered	O
PLZ	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
or	O
VIG	B-CHEMICAL
(	O
1	O
,	O
000	O
mg	O
/	O
kg	O
)	O
i	O
.	O
p	O
.	O
,	O
and	O
the	O
rats	O
were	O
euthanized	O
4	O
hours	O
later	O
and	O
the	O
brains	O
removed	O
for	O
analysis	O
of	O
levels	O
of	O
GABA	B-CHEMICAL
and	O
ALA	B-CHEMICAL
(	O
by	O
electron	O
capture	O
gas	O
chromatography	O
after	O
derivatization	O
)	O
and	O
activities	O
of	O
MAO	B-GENE-N
,	O
GABA	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
and	O
ALA	B-GENE-N
-	I-GENE-N
T	I-GENE-N
(	O
radiochemical	O
assays	O
)	O
.	O

RESULTS	O
:	O
Both	O
PLZ	B-CHEMICAL
and	O
VIG	B-CHEMICAL
inhibited	O
GABA	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
and	O
elevated	O
GABA	B-CHEMICAL
levels	O
.	O

Only	O
PLZ	B-CHEMICAL
inhibited	O
MAO	B-GENE-N
and	O
ALA	B-GENE-N
-	I-GENE-N
T	I-GENE-N
and	O
elevated	O
ALA	B-CHEMICAL
levels	O
.	O

The	O
effects	O
of	O
PLZ	B-CHEMICAL
on	O
both	O
amino	B-CHEMICAL
acids	I-CHEMICAL
and	O
their	O
transaminases	B-GENE-N
were	O
blocked	O
by	O
pre	O
-	O
treatment	O
with	O
the	O
MAO	B-GENE-N
inhibitor	O
tranylcypromine	B-CHEMICAL
.	O

This	O
pretreament	O
had	O
no	O
effect	O
on	O
the	O
inhibition	O
of	O
GABA	B-GENE-Y
-	I-GENE-Y
T	I-GENE-Y
or	O
the	O
elevation	O
of	O
brain	O
GABA	B-CHEMICAL
levels	O
produced	O
by	O
VIG	B-CHEMICAL
.	O

CONCLUSIONS	O
:	O
At	O
the	O
doses	O
studied	O
,	O
PLZ	B-CHEMICAL
was	O
as	O
effective	O
as	O
VIG	B-CHEMICAL
at	O
elevating	O
brain	O
GABA	B-CHEMICAL
levels	O
,	O
but	O
,	O
unlike	O
VIG	B-CHEMICAL
,	O
also	O
inhibited	O
MAO	B-GENE-N
and	O
ALA	B-GENE-N
-	I-GENE-N
T	I-GENE-N
(	O
and	O
increased	O
brain	O
ALA	B-CHEMICAL
levels	O
)	O
.	O

Pretreatment	O
of	O
rats	O
with	O
the	O
MAO	B-GENE-N
inhibitor	O
tranylcypromine	B-CHEMICAL
prevented	O
the	O
increase	O
in	O
brain	O
GABA	B-CHEMICAL
and	O
ALA	B-CHEMICAL
levels	O
with	O
PLZ	B-CHEMICAL
,	O
but	O
did	O
not	O
block	O
the	O
effect	O
of	O
VIG	B-CHEMICAL
on	O
GABA	B-CHEMICAL
.	O

These	O
observations	O
with	O
tranylcypromine	B-CHEMICAL
and	O
PLZ	B-CHEMICAL
support	O
the	O
hypothesis	O
that	O
an	O
active	O
metabolite	O
of	O
PLZ	B-CHEMICAL
produced	O
by	O
the	O
actions	O
of	O
MAO	B-GENE-N
on	O
this	O
drug	O
plays	O
a	O
major	O
role	O
in	O
its	O
GABA	B-CHEMICAL
-	O
and	O
ALA	B-CHEMICAL
-	O
elevating	O
actions	O
.	O

Pharmacology	O
of	O
ramelteon	B-CHEMICAL
,	O
a	O
selective	O
MT1	B-GENE-Y
/	O
MT2	B-GENE-Y
receptor	O
agonist	O
:	O
a	O
novel	O
therapeutic	O
drug	O
for	O
sleep	O
disorders	O
.	O

An	O
estimated	O
one	O
-	O
third	O
of	O
the	O
general	O
population	O
is	O
affected	O
by	O
insomnia	O
,	O
and	O
this	O
number	O
is	O
increasing	O
due	O
to	O
more	O
stressful	O
working	O
conditions	O
and	O
the	O
progressive	O
aging	O
of	O
society	O
.	O

However	O
,	O
current	O
treatment	O
of	O
insomnia	O
with	O
hypnotics	O
,	O
gamma	B-GENE-N
-	I-GENE-N
aminobutyric	I-GENE-N
acid	I-GENE-N
A	I-GENE-N
(	I-GENE-N
GABA	I-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
modulators	O
,	O
induces	O
various	O
side	O
effects	O
,	O
including	O
cognitive	O
impairment	O
,	O
motor	O
disturbance	O
,	O
dependence	O
,	O
tolerance	O
,	O
hangover	O
,	O
and	O
rebound	O
insomnia	O
.	O

Ramelteon	B-CHEMICAL
(	O
Rozerem	B-CHEMICAL
;	O
Takeda	O
Pharmaceutical	O
Company	O
Limited	O
,	O
Osaka	O
,	O
Japan	O
)	O
is	O
an	O
orally	O
active	O
,	O
highly	O
selective	O
melatonin	B-CHEMICAL
MT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
/	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	O
agonist	O
.	O

Unlike	O
the	O
sedative	O
hypnotics	O
that	O
target	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
complexes	O
,	O
ramelteon	B-CHEMICAL
is	O
a	O
chronohypnotic	O
that	O
acts	O
on	O
the	O
melatonin	B-CHEMICAL
MT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
and	O
MT	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptors	O
,	O
which	O
are	O
primarily	O
located	O
in	O
the	O
suprachiasmatic	O
nucleus	O
,	O
the	O
body	O
'	O
s	O
"	O
master	O
clock	O
.	O
"	O
As	O
such	O
,	O
ramelteon	B-CHEMICAL
possesses	O
the	O
first	O
new	O
therapeutic	O
mechanism	O
of	O
action	O
for	O
a	O
prescription	O
insomnia	O
medication	O
in	O
over	O
three	O
decades	O
.	O

Ramelteon	B-CHEMICAL
has	O
demonstrated	O
sleep	O
-	O
promoting	O
effects	O
in	O
clinical	O
trials	O
,	O
and	O
coupled	O
with	O
its	O
favorable	O
safety	O
profile	O
and	O
lack	O
of	O
abuse	O
potential	O
or	O
dependence	O
,	O
this	O
chronohypnotic	O
provides	O
an	O
important	O
treatment	O
option	O
for	O
insomnia	O
.	O

Studies	O
of	O
the	O
biogenic	B-GENE-N
amine	I-GENE-N
transporters	I-GENE-N
.	O

13	O
.	O

Identification	O
of	O
"	O
agonist	O
"	O
and	O
"	O
antagonist	O
"	O
allosteric	O
modulators	O
of	O
amphetamine	B-CHEMICAL
-	O
induced	O
dopamine	B-CHEMICAL
release	O
.	O

Recent	O
studies	O
identified	O
novel	O
allosteric	O
modulators	O
of	O
the	O
dopamine	B-GENE-Y
(	I-GENE-Y
DA	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
(	O
DAT	B-GENE-Y
)	O
.	O

N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
Diphenylmethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
quinazolinamine	I-CHEMICAL
(	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
9804	I-CHEMICAL
)	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
diphenylethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
quinazolinamine	I-CHEMICAL
(	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20040	I-CHEMICAL
)	O
,	O
and	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diphenylpropyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
quinazolinamine	I-CHEMICAL
(	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20041	I-CHEMICAL
)	O
partially	O
inhibited	O
[	B-CHEMICAL
(	I-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
]	I-CHEMICAL
3beta	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
iodophenyl	I-CHEMICAL
)	I-CHEMICAL
tropan	I-CHEMICAL
-	I-CHEMICAL
2beta	I-CHEMICAL
-	I-CHEMICAL
carboxylic	I-CHEMICAL
acid	I-CHEMICAL
methyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
RTI	B-CHEMICAL
-	I-CHEMICAL
55	I-CHEMICAL
)	O
binding	O
,	O
slowed	O
the	O
dissociation	O
rate	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
125	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
]	I-CHEMICAL
RTI	I-CHEMICAL
-	I-CHEMICAL
55	I-CHEMICAL
from	O
the	O
DAT	B-GENE-Y
,	O
and	O
partially	O
inhibited	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
uptake	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
that	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
9804	I-CHEMICAL
and	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20040	I-CHEMICAL
,	O
at	O
doses	O
that	O
do	O
not	O
alter	O
release	O
,	O
partially	O
inhibited	O
d	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
-	O
induced	O
DAT	B-GENE-Y
-	O
mediated	O
release	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenylpyridinium	I-CHEMICAL
(	O
MPP	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
)	O
or	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
from	O
striatal	O
synaptosomes	O
(	O
"	O
DAT	B-GENE-Y
-	O
mediated	O
DA	B-CHEMICAL
release	O
"	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

SoRI	B-CHEMICAL
-	I-CHEMICAL
20041	I-CHEMICAL
,	O
which	O
does	O
not	O
alter	O
DAT	B-GENE-Y
-	O
mediated	O
DA	B-CHEMICAL
release	O
measured	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
DA	I-CHEMICAL
,	O
reversed	O
the	O
effect	O
of	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20040	I-CHEMICAL
.	O

SoRI	B-CHEMICAL
-	I-CHEMICAL
20040	I-CHEMICAL
and	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
9804	I-CHEMICAL
also	O
partially	O
inhibited	O
DAT	B-GENE-Y
-	O
mediated	O
DA	B-CHEMICAL
release	O
induced	O
by	O
DA	B-CHEMICAL
or	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxyamphetamine	I-CHEMICAL
,	O
demonstrating	O
that	O
the	O
observed	O
partial	O
inhibition	O
is	O
not	O
specific	O
for	O
a	O
particular	O
DAT	B-GENE-Y
substrate	O
.	O

SoRI	B-CHEMICAL
-	I-CHEMICAL
9804	I-CHEMICAL
and	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20040	I-CHEMICAL
did	O
not	O
attenuate	O
D	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
-	O
induced	O
release	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
from	O
serotonergic	O
,	O
or	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
MPP	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
from	O
noradrenergic	O
,	O
nerve	O
terminals	O
.	O

Kinetic	O
experiments	O
demonstrated	O
that	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
9804	I-CHEMICAL
,	O
in	O
contrast	O
to	O
cocaine	B-CHEMICAL
,	O
slowed	O
D	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
-	O
induced	O
release	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
MPP	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
from	O
dopaminergic	O
nerve	O
terminals	O
without	O
altering	O
the	O
apparent	O
rate	O
constants	O
.	O

The	O
two	O
major	O
findings	O
of	O
this	O
study	O
are	O
1	O
)	O
the	O
identification	O
of	O
both	O
"	O
agonist	O
"	O
(	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
9804	I-CHEMICAL
and	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20040	I-CHEMICAL
)	O
and	O
"	O
antagonist	O
"	O
(	O
SoRI	B-CHEMICAL
-	I-CHEMICAL
20041	I-CHEMICAL
)	O
allosteric	O
modulators	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
-	O
induced	O
DAT	B-GENE-Y
-	O
mediated	O
DA	B-CHEMICAL
release	O
and	O
2	O
)	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
DA	I-CHEMICAL
uptake	O
and	O
d	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
-	O
induced	O
DAT	B-GENE-Y
-	O
mediated	O
efflux	O
can	O
be	O
separately	O
modulated	O
.	O

Such	O
agents	O
may	O
have	O
therapeutic	O
potential	O
for	O
the	O
treatment	O
of	O
stimulant	O
addiction	O
,	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
other	O
psychiatric	O
disorders	O
.	O

Clinical	O
utility	O
of	O
acarbose	B-CHEMICAL
,	O
an	O
alpha	B-GENE-Y
-	I-GENE-Y
glucosidase	I-GENE-Y
inhibitor	O
in	O
cardiometabolic	O
disorders	O
.	O

Diabetes	O
is	O
associated	O
with	O
an	O
increase	O
risk	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

Recently	O
,	O
macrovascular	O
complications	O
of	O
diabetes	O
have	O
been	O
shown	O
to	O
start	O
before	O
the	O
development	O
of	O
diabetes	O
.	O

Indeed	O
,	O
several	O
clinical	O
studies	O
have	O
confirmed	O
the	O
increased	O
risk	O
of	O
CVD	O
in	O
patients	O
with	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
(	O
IGT	O
)	O
.	O

Since	O
postprandial	O
hyperglycemia	O
and	O
insulin	B-GENE-Y
resistance	O
are	O
thought	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
CVD	O
in	O
patients	O
with	O
IGT	O
,	O
amelioration	O
of	O
postprandial	O
hyperglycemia	O
as	O
well	O
as	O
insulin	B-GENE-Y
resistance	O
is	O
a	O
therapeutic	O
target	O
for	O
the	O
prevention	O
of	O
CVD	O
in	O
these	O
high	O
-	O
risk	O
patients	O
.	O

Acarbose	B-CHEMICAL
,	O
an	O
alpha	B-GENE-Y
-	I-GENE-Y
glucosidase	I-GENE-Y
inhibitor	O
,	O
delays	O
the	O
absorption	O
of	O
carbohydrate	B-CHEMICAL
from	O
the	O
small	O
intestine	O
,	O
thereby	O
reducing	O
postprandial	O
hyperglycemia	O
.	O

Further	O
,	O
recently	O
,	O
acarbose	B-CHEMICAL
has	I-CHEMICAL
been	I-CHEMICAL
shown	I-CHEMICAL
to	I-CHEMICAL
improve	I-CHEMICAL
insulin	I-CHEMICAL
resistance	I-CHEMICAL
in	I-CHEMICAL
vivo	I-CHEMICAL
.	O

These	O
findings	O
suggest	O
that	O
acarbose	B-CHEMICAL
is	O
a	O
promising	O
metabolic	O
modifier	O
that	O
could	O
reduce	O
the	O
risk	O
of	O
CVD	O
in	O
patients	O
with	O
the	O
metabolic	O
syndrome	O
.	O

In	O
this	O
paper	O
,	O
we	O
review	O
the	O
clinical	O
utility	O
of	O
acarbose	B-CHEMICAL
in	O
various	O
cardiometabolic	O
disorders	O
.	O

Tolvaptan	B-CHEMICAL
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
hyponatremia	O
.	O

Tolvaptan	B-CHEMICAL
is	O
a	O
selective	O
arginine	B-GENE-Y
vasopressin	I-GENE-Y
(	I-GENE-Y
AVP	I-GENE-Y
)	I-GENE-Y
V	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
blocker	O
used	O
to	O
induce	O
free	O
water	O
diuresis	O
in	O
the	O
treatment	O
of	O
euvolemic	O
or	O
hypervolemic	O
hyponatremia	O
.	O

Currently	O
the	O
orally	O
active	O
medication	O
is	O
in	O
the	O
final	O
stages	O
prior	O
to	O
approval	O
by	O
the	O
FDA	O
for	O
outpatient	O
therapy	O
.	O

It	O
appears	O
to	O
be	O
safe	O
and	O
effective	O
at	O
promoting	O
aquaresis	O
and	O
raising	O
serum	O
sodium	B-CHEMICAL
levels	O
in	O
both	O
short	O
-	O
and	O
long	O
-	O
term	O
studies	O
.	O

Tolvaptan	B-CHEMICAL
is	O
also	O
effective	O
for	O
treatment	O
of	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
exacerbation	O
,	O
but	O
whether	O
there	O
are	O
long	O
standing	O
beneficial	O
effects	O
on	O
CHF	O
is	O
still	O
controversial	O
.	O

Prolonged	O
use	O
of	O
tolvaptan	B-CHEMICAL
leads	O
to	O
increased	O
endogenous	O
levels	O
of	O
AVP	B-CHEMICAL
and	O
perhaps	O
over	O
-	O
stimulation	O
of	O
V	B-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
.	O

Theoretically	O
this	O
activation	O
could	O
lead	O
to	O
increased	O
afterload	O
and	O
cardiac	O
myocyte	O
fibrosis	O
,	O
causing	O
progression	O
of	O
CHF	O
.	O

However	O
,	O
after	O
52	O
weeks	O
of	O
tolvaptan	B-CHEMICAL
therapy	O
there	O
was	O
no	O
worsening	O
of	O
left	O
ventricular	O
dilatation	O
.	O

In	O
addition	O
,	O
tolvaptan	B-CHEMICAL
is	O
metabolized	O
by	O
the	O
CYP3A4	B-GENE-Y
system	O
;	O
thus	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
increased	O
interactions	O
with	O
other	O
medications	O
.	O

Tolvaptan	B-CHEMICAL
is	O
a	O
breakthrough	O
in	O
the	O
therapy	O
of	O
hyponatremia	O
as	O
it	O
directly	O
combats	O
elevated	O
AVP	B-CHEMICAL
levels	O
associated	O
with	O
the	O
syndrome	O
of	O
inappropriate	O
secretion	O
of	O
antidiuretic	B-GENE-Y
hormone	I-GENE-Y
,	O
congestive	O
heart	O
failure	O
,	O
and	O
cirrhosis	O
of	O
the	O
liver	O
.	O

Rivastigmine	B-CHEMICAL
for	O
Alzheimer	O
'	O
s	O
disease	O
.	O

BACKGROUND	O
:	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
is	O
the	O
commonest	O
cause	O
of	O
dementia	O
affecting	O
older	O
people	O
.	O

One	O
of	O
the	O
therapeutic	O
strategies	O
aimed	O
at	O
ameliorating	O
the	O
clinical	O
manifestations	O
of	O
Alzheimer	O
'	O
s	O
disease	O
is	O
to	O
enhance	O
cholinergic	O
neurotransmission	O
in	O
relevant	O
parts	O
of	O
the	O
brain	O
by	O
the	O
use	O
of	O
cholinesterase	B-GENE-Y
inhibitors	O
to	O
delay	O
the	O
breakdown	O
of	O
acetylcholine	B-CHEMICAL
released	O
into	O
synaptic	O
clefts	O
.	O

Tacrine	B-CHEMICAL
,	O
the	O
first	O
of	O
the	O
cholinesterase	B-GENE-Y
inhibitors	O
to	O
undergo	O
extensive	O
trials	O
for	O
this	O
purpose	O
,	O
was	O
associated	O
with	O
significant	O
adverse	O
effects	O
including	O
hepatotoxicity	O
.	O

Other	O
cholinesterase	B-GENE-Y
inhibitors	O
,	O
including	O
rivastigmine	B-CHEMICAL
,	O
with	O
superior	O
properties	O
in	O
terms	O
of	O
specificity	O
of	O
action	O
and	O
low	O
risk	O
of	O
adverse	O
effects	O
,	O
have	O
now	O
been	O
introduced	O
.	O

Rivastigmine	B-CHEMICAL
has	O
received	O
approval	O
for	O
use	O
in	O
60	O
countries	O
including	O
all	O
member	O
states	O
of	O
the	O
European	O
Union	O
and	O
the	O
USA	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
clinical	O
efficacy	O
and	O
safety	O
of	O
rivastigmine	B-CHEMICAL
for	O
patients	O
with	O
dementia	O
of	O
Alzheimer	O
'	O
s	O
type	O
.	O

SEARCH	O
STRATEGY	O
:	O
The	O
Specialized	O
Register	O
of	O
the	O
Cochrane	O
Dementia	O
and	O
Cognitive	O
Improvement	O
Group	O
(	O
CDCIG	O
)	O
,	O
The	O
Cochrane	O
Library	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
CINAHL	O
and	O
LILACS	O
were	O
searched	O
on	O
27	O
March	O
2008	O
using	O
the	O
terms	O
:	O
Rivastigmine	B-CHEMICAL
OR	O
exelon	B-CHEMICAL
OR	O
ENA	B-CHEMICAL
OR	O
"	O
SDZ	B-CHEMICAL
ENA	I-CHEMICAL
713	I-CHEMICAL
"	O
.	O

The	O
CDCIG	O
Specialized	O
Register	O
contains	O
records	O
from	O
all	O
major	O
health	O
care	O
databases	O
(	O
The	O
Cochrane	O
Library	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
PsycINFO	O
,	O
CINAHL	O
,	O
LILACS	O
)	O
as	O
well	O
as	O
from	O
many	O
clinical	O
trials	O
registries	O
and	O
grey	O
literature	O
sources	O
.	O

SELECTION	O
CRITERIA	O
:	O
All	O
unconfounded	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
trials	O
in	O
which	O
treatment	O
with	O
rivastigmine	B-CHEMICAL
was	O
administered	O
to	O
patients	O
with	O
dementia	O
of	O
the	O
Alzheimer	O
'	O
s	O
type	O
for	O
more	O
than	O
two	O
weeks	O
and	O
its	O
effects	O
compared	O
with	O
those	O
of	O
placebo	O
in	O
a	O
parallel	O
group	O
of	O
patients	O
.	O

DATA	O
COLLECTION	O
AND	O
ANALYSIS	O
:	O
One	O
reviewer	O
(	O
JSB	O
)	O
applied	O
study	O
selection	O
criteria	O
,	O
assessed	O
the	O
quality	O
of	O
studies	O
and	O
extracted	O
data	O
.	O

MAIN	O
RESULTS	O
:	O
Nine	O
trials	O
,	O
involving	O
4775	O
participants	O
,	O
were	O
included	O
in	O
the	O
analyses	O
.	O

Use	O
of	O
rivastigmine	B-CHEMICAL
in	O
high	O
doses	O
was	O
associated	O
with	O
statistically	O
significant	O
benefits	O
on	O
several	O
measures	O
.	O

High	O
-	O
dose	O
rivastigmine	B-CHEMICAL
(	O
6	O
to	O
12	O
mg	O
daily	O
)	O
was	O
associated	O
with	O
a	O
two	O
-	O
point	O
improvement	O
in	O
cognitive	O
function	O
on	O
the	O
ADAS	O
-	O
Cog	O
score	O
compared	O
with	O
placebo	O
(	O
weighted	O
mean	O
difference	O
-	O
1	O
.	O
99	O
,	O
95	O
%	O
confidence	O
interval	O
-	O
2	O
.	O
49	O
to	O
-	O
1	O
.	O
50	O
,	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
)	O
and	O
a	O
2	O
.	O
2	O
point	O
improvement	O
in	O
activities	O
of	O
daily	O
living	O
assessed	O
on	O
the	O
Progressive	O
Deterioration	O
Scale	O
(	O
weighted	O
mean	O
difference	O
-	O
2	O
.	O
15	O
,	O
95	O
%	O
confidence	O
interval	O
-	O
3	O
.	O
16	O
to	O
-	O
1	O
.	O
13	O
,	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
)	O
at	O
26	O
weeks	O
.	O

At	O
lower	O
doses	O
(	O
4	O
mg	O
daily	O
or	O
lower	O
)	O
differences	O
were	O
in	O
the	O
same	O
direction	O
but	O
were	O
statistically	O
significant	O
only	O
for	O
cognitive	O
function	O
.	O

There	O
were	O
statistically	O
significantly	O
higher	O
numbers	O
of	O
events	O
of	O
nausea	O
,	O
vomiting	O
,	O
diarrhoea	O
,	O
anorexia	O
,	O
headache	O
,	O
syncope	O
,	O
abdominal	O
pain	O
and	O
dizziness	O
among	O
patients	O
taking	O
high	O
-	O
dose	O
rivastigmine	B-CHEMICAL
than	O
among	O
those	O
taking	O
placebo	O
.	O

There	O
was	O
some	O
evidence	O
that	O
adverse	O
events	O
might	O
be	O
less	O
common	O
with	O
more	O
frequent	O
,	O
smaller	O
doses	O
of	O
rivastigmine	B-CHEMICAL
.	O

The	O
2008	O
update	O
includes	O
a	O
new	O
study	O
testing	O
two	O
types	O
of	O
rivastigmine	B-CHEMICAL
transdermal	O
patch	O
,	O
one	O
delivering	O
a	O
higher	O
dose	O
than	O
previously	O
tested	O
(	O
17	O
.	O
4	O
mg	O
/	O
day	O
)	O
and	O
a	O
smaller	O
patch	O
delivering	O
9	O
.	O
6	O
mg	O
/	O
day	O
.	O

The	O
efficacy	O
of	O
the	O
smaller	O
patch	O
was	O
not	O
significantly	O
different	O
compared	O
with	O
the	O
capsules	O
of	O
similar	O
daily	O
dose	O
,	O
but	O
was	O
associated	O
with	O
significantly	O
fewer	O
adverse	O
events	O
of	O
nausea	O
,	O
vomiting	O
,	O
dizziness	O
and	O
asthenia	O
.	O

The	O
efficacy	O
of	O
the	O
larger	O
patch	O
was	O
not	O
significantly	O
different	O
compared	O
with	O
the	O
smaller	O
patch	O
,	O
but	O
the	O
smaller	O
patch	O
was	O
associated	O
with	O
significantly	O
fewer	O
adverse	O
events	O
of	O
nausea	O
,	O
vomiting	O
,	O
weight	O
loss	O
and	O
dizziness	O
.	O

There	O
appears	O
to	O
be	O
advantages	O
associated	O
with	O
the	O
smaller	O
patch	O
compared	O
with	O
both	O
the	O
higher	O
dose	O
patch	O
and	O
the	O
6	O
-	O
12	O
mg	O
/	O
day	O
capsules	O
.	O

AUTHORS	O
'	O
CONCLUSIONS	O
:	O
Rivastigmine	B-CHEMICAL
appears	O
to	O
be	O
beneficial	O
for	O
people	O
with	O
mild	O
to	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
.	O

In	O
comparisons	O
with	O
placebo	O
,	O
improvements	O
were	O
seen	O
in	O
the	O
rate	O
of	O
decline	O
of	O
cognitive	O
function	O
,	O
activities	O
of	O
daily	O
living	O
,	O
and	O
severity	O
of	O
dementia	O
with	O
daily	O
doses	O
of	O
6	O
to	O
12	O
mg	O
.	O

Adverse	O
events	O
were	O
consistent	O
with	O
the	O
cholinergic	O
actions	O
of	O
the	O
drug	O
.	O

A	O
transdermal	O
patch	O
has	O
been	O
tested	O
in	O
one	O
trial	O
,	O
and	O
there	O
is	O
evidence	O
that	O
the	O
lower	O
dose	O
smaller	O
patch	O
is	O
associated	O
with	O
fewer	O
side	O
effects	O
than	O
the	O
capsules	O
or	O
the	O
higher	O
dose	O
larger	O
patch	O
and	O
has	O
comparable	O
efficacy	O
to	O
both	O
.	O

This	O
review	O
has	O
not	O
examined	O
economic	O
data	O
.	O

Effect	O
of	O
ketoconazole	B-CHEMICAL
on	O
the	O
pharmacokinetic	O
profile	O
of	O
ambrisentan	B-CHEMICAL
.	O

Ambrisentan	B-CHEMICAL
is	O
an	O
endothelin	B-GENE-Y
type	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
ET	I-GENE-Y
(	I-GENE-Y
A	I-GENE-Y
)	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
selective	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
that	O
is	O
metabolized	O
primarily	O
by	O
glucuronidation	O
but	O
also	O
undergoes	O
oxidative	O
metabolism	O
by	O
CYP3A4	B-GENE-Y
.	O

The	O
potential	O
for	O
ketoconazole	B-CHEMICAL
,	O
the	O
archetypal	O
strong	O
inhibitor	O
of	O
CYP3A4	B-GENE-Y
,	O
to	O
alter	O
the	O
pharmacokinetic	O
profile	O
of	O
ambrisentan	B-CHEMICAL
and	O
its	O
oxidative	O
metabolite	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
hydroxymethyl	I-CHEMICAL
ambrisentan	I-CHEMICAL
,	O
was	O
assessed	O
in	O
an	O
open	O
-	O
label	O
,	O
nonrandomized	O
,	O
2	O
-	O
period	O
,	O
single	O
-	O
sequence	O
study	O
in	O
16	O
healthy	O
men	O
.	O

Participants	O
received	O
a	O
single	O
dose	O
of	O
ambrisentan	B-CHEMICAL
10	O
mg	O
alone	O
and	O
after	O
4	O
days	O
of	O
ketoconazole	B-CHEMICAL
400	O
mg	O
administered	O
once	O
daily	O
.	O

In	O
the	O
presence	O
of	O
multiple	O
doses	O
of	O
ketoconazole	B-CHEMICAL
,	O
single	O
-	O
dose	O
ambrisentan	B-CHEMICAL
AUC	O
(	O
0	O
-	O
infinity	O
)	O
estimate	O
was	O
increased	O
by	O
35	O
.	O
3	O
%	O
,	O
whereas	O
C	O
(	O
max	O
)	O
was	O
increased	O
by	O
20	O
.	O
0	O
%	O
.	O

For	O
the	O
4	B-CHEMICAL
-	I-CHEMICAL
hydroxymethyl	I-CHEMICAL
ambrisentan	I-CHEMICAL
metabolite	O
,	O
AUC	O
(	O
0	O
-	O
infinity	O
)	O
estimate	O
was	O
decreased	O
by	O
4	O
.	O
0	O
%	O
,	O
whereas	O
C	O
(	O
max	O
)	O
was	O
decreased	O
by	O
16	O
.	O
5	O
%	O
.	O

Concomitant	O
administration	O
of	O
ambrisentan	B-CHEMICAL
and	O
ketoconazole	B-CHEMICAL
was	O
well	O
tolerated	O
.	O

In	O
summary	O
,	O
ketoconazole	B-CHEMICAL
had	O
no	O
clinically	O
significant	O
effect	O
on	O
the	O
pharmacokinetics	O
or	O
safety	O
profile	O
of	O
ambrisentan	B-CHEMICAL
;	O
therefore	O
,	O
no	O
changes	O
in	O
ambrisentan	B-CHEMICAL
dose	O
should	O
be	O
necessary	O
when	O
the	O
drug	O
is	O
administered	O
concomitantly	O
with	O
known	O
CYP3A4	B-GENE-Y
inhibitors	O
.	O

ATP	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
cassette	I-GENE-Y
transporter	I-GENE-Y
A1	I-GENE-Y
is	O
involved	O
in	O
hepatic	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
secretion	O
.	O

Vitamin	B-CHEMICAL
E	I-CHEMICAL
(	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
)	O
is	O
an	O
essential	O
fat	O
-	O
soluble	O
nutrient	O
with	O
antioxidant	O
properties	O
.	O

alpha	B-GENE-Y
-	I-GENE-Y
Tocopherol	I-GENE-Y
transfer	I-GENE-Y
protein	I-GENE-Y
(	O
alpha	B-GENE-Y
-	I-GENE-Y
TTP	I-GENE-Y
)	O
,	O
the	O
product	O
of	O
the	O
gene	O
responsible	O
for	O
familial	O
isolated	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
deficiency	O
,	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
the	O
plasma	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
level	O
by	O
mediating	O
the	O
secretion	O
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
by	O
the	O
liver	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
hepatic	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
secretion	O
are	O
not	O
fully	O
understood	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
elucidate	O
the	O
mechanism	O
of	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
re	O
-	O
efflux	O
from	O
hepatocytes	O
,	O
the	O
cells	O
that	O
have	O
the	O
most	O
important	O
role	O
in	O
regulating	O
plasma	O
-	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
concentrations	O
.	O

From	O
in	O
vitro	O
experiments	O
using	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
tocopheryl	I-CHEMICAL
acetate	I-CHEMICAL
and	O
McARH7777	O
cells	O
that	O
stably	O
express	O
alpha	B-GENE-Y
-	I-GENE-Y
tocopherol	I-GENE-Y
transfer	I-GENE-Y
protein	I-GENE-Y
(	O
alpha	B-GENE-Y
-	I-GENE-Y
TTP	I-GENE-Y
)	O
,	O
the	O
following	O
results	O
were	O
obtained	O
.	O

First	O
,	O
addition	O
of	O
apolipoprotein	B-GENE-Y
A	I-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
(	O
apoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
)	O
,	O
a	O
direct	O
acceptor	O
of	O
the	O
ATP	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
cassette	I-GENE-Y
transporter	I-GENE-Y
A1	I-GENE-Y
(	O
ABCA1	B-GENE-Y
)	O
-	O
secreted	O
lipids	O
,	O
increased	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
secretion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Second	O
,	O
probucol	B-CHEMICAL
,	O
an	O
antiatherogenic	O
compound	O
reported	O
to	O
be	O
an	O
inactivator	O
of	O
ABCA1	B-GENE-Y
reduced	O
hepatic	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
secretion	O
.	O

Third	O
,	O
ABCA1	B-GENE-Y
-	O
RNAi	O
suppressed	O
hepatic	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
secretion	O
.	O

In	O
a	O
mouse	O
in	O
vivo	O
experiment	O
,	O
addition	O
of	O
1	O
%	O
probucol	B-CHEMICAL
to	O
the	O
diet	O
decreased	O
plasma	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
concentrations	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
ABCA1	B-GENE-Y
is	O
substantially	O
involved	O
in	O
hepatic	O
alpha	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
secretion	O
.	O

AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
-	O
dependent	O
and	O
-	O
independent	O
mechanisms	O
underlying	O
in	O
vitro	O
antiglioma	O
action	O
of	O
compound	O
C	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
compound	O
C	O
,	O
a	O
well	O
-	O
known	O
inhibitor	O
of	O
the	O
intracellular	O
energy	O
sensor	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
AMPK	B-GENE-N
)	O
,	O
on	O
proliferation	O
and	O
viability	O
of	O
human	O
U251	O
and	O
rat	O
C6	O
glioma	O
cell	O
lines	O
.	O

Compound	O
C	O
caused	O
G	O
(	O
2	O
)	O
/	O
M	O
cell	O
cycle	O
block	O
,	O
accompanied	O
by	O
apoptotic	O
glioma	O
cell	O
death	O
characterized	O
by	O
caspase	B-GENE-N
activation	O
,	O
phosphatidylserine	B-CHEMICAL
exposure	O
and	O
DNA	O
fragmentation	O
.	O

The	O
mechanisms	O
underlying	O
the	O
pro	O
-	O
apoptotic	O
action	O
of	O
compound	O
C	O
involved	O
induction	O
of	O
oxidative	O
stress	O
and	O
downregulation	O
of	O
antiapoptotic	O
molecule	O
Bcl	B-GENE-N
-	I-GENE-N
2	I-GENE-N
,	O
while	O
no	O
alteration	O
of	O
pro	O
-	O
apoptotic	O
Bax	B-GENE-N
was	O
observed	O
.	O

Compound	O
C	O
diminished	O
AMPK	B-GENE-N
phosphorylation	O
and	O
enzymatic	O
activity	O
,	O
resulting	O
in	O
reduced	O
phosphorylation	O
of	O
its	O
target	O
acetyl	B-GENE-N
CoA	I-GENE-N
carboxylase	I-GENE-N
.	O

AMPK	B-GENE-N
activators	O
metformin	B-CHEMICAL
and	O
AICAR	B-CHEMICAL
partly	O
prevented	O
the	O
cell	O
cycle	O
block	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
induced	O
by	O
compound	O
C	O
.	O

The	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
targeting	O
of	O
human	B-GENE-Y
AMPK	I-GENE-Y
mimicked	O
compound	O
C	O
-	O
induced	O
G	O
(	O
2	O
)	O
/	O
M	O
cell	O
cycle	O
arrest	O
,	O
but	O
failed	O
to	O
induce	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
U251	O
glioma	O
cells	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
indicate	O
that	O
AMPK	B-GENE-N
inhibition	O
is	O
required	O
,	O
but	O
not	O
sufficient	O
for	O
compound	O
C	O
-	O
mediated	O
apoptotic	O
death	O
of	O
glioma	O
cells	O
.	O

Inhibitory	O
effect	O
of	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
on	O
the	O
vesicular	B-GENE-Y
monoamine	I-GENE-Y
transporter	I-GENE-Y
2	I-GENE-Y
.	O

The	O
neuronal	B-GENE-Y
vesicular	I-GENE-Y
monoamine	I-GENE-Y
transporter	I-GENE-Y
(	O
VMAT2	B-GENE-Y
)	O
is	O
the	O
target	O
molecule	O
of	O
action	O
of	O
some	O
psychostimulants	O
,	O
such	O
as	O
methamphetamine	B-CHEMICAL
and	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
)	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
antidepressants	O
,	O
such	O
as	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
on	O
VMAT2	B-GENE-Y
activity	O
by	O
measuring	O
adenosine	B-CHEMICAL
triphosphate	I-CHEMICAL
-	O
dependent	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
uptake	O
into	O
synaptic	O
vesicles	O
prepared	O
from	O
rat	O
striatum	O
.	O

SSRIs	O
,	O
fluoxetine	B-CHEMICAL
,	O
paroxetine	B-CHEMICAL
,	O
and	O
fluvoxamine	B-CHEMICAL
,	O
inhibited	O
vesicular	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
uptake	O
in	O
vitro	O
.	O

The	O
rank	O
order	O
of	O
potency	O
was	O
reserpine	B-CHEMICAL
>	O
>	O
fluoxetine	B-CHEMICAL
,	O
paroxetine	B-CHEMICAL
>	O
fluvoxamine	B-CHEMICAL
,	O
methamphetamine	B-CHEMICAL
>	O
MDMA	B-CHEMICAL
.	O

Moreover	O
,	O
kinetic	O
analysis	O
revealed	O
that	O
inhibition	O
by	O
reserpine	B-CHEMICAL
,	O
a	O
typical	O
VMAT2	B-GENE-Y
inhibitor	O
,	O
was	O
uncompetitive	O
,	O
decreasing	O
maximum	O
velocity	O
and	O
affinity	O
for	O
dopamine	B-CHEMICAL
.	O

Inhibition	O
by	O
fluoxetine	B-CHEMICAL
was	O
noncompetitive	O
,	O
only	O
decreasing	O
maximum	O
velocity	O
for	O
dopamine	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
fluoxetine	B-CHEMICAL
inhibited	O
the	O
activity	O
of	O
VMAT2	B-GENE-Y
by	O
a	O
mechanism	O
different	O
from	O
that	O
of	O
reserpine	B-CHEMICAL
and	O
did	O
not	O
directly	O
interact	O
with	O
the	O
active	O
site	O
of	O
VMAT2	B-GENE-Y
.	O

Lowering	O
interleukin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
activity	O
with	O
anakinra	O
improves	O
myocardial	O
deformation	O
in	O
rheumatoid	O
arthritis	O
.	O

OBJECTIVE	O
:	O
Inhibition	O
of	O
interleukin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
activity	O
improves	O
nitro	B-CHEMICAL
-	O
oxidative	O
stress	O
,	O
endothelial	O
and	O
coronary	O
function	O
.	O

The	O
authors	O
investigated	O
(	O
a	O
)	O
the	O
association	O
of	O
nitro	B-CHEMICAL
-	O
oxidative	O
stress	O
and	O
endothelial	O
function	O
with	O
myocardial	O
deformation	O
,	O
(	O
b	O
)	O
the	O
effects	O
of	O
anakinra	O
,	O
an	O
interleukin	B-GENE-Y
-	I-GENE-Y
1a	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
on	O
myocardial	O
deformation	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

METHODS	O
:	O
The	O
authors	O
compared	O
46	O
RA	O
patients	O
to	O
23	O
normal	O
controls	O
.	O

23	O
patients	O
received	O
anakinra	O
(	O
150	O
mg	O
subcutaneously	O
once	O
daily	O
)	O
and	O
23	O
patients	O
a	O
5	O
-	O
mg	O
increase	O
of	O
prednisolone	B-CHEMICAL
dose	O
for	O
30	O
days	O
.	O

At	O
baseline	O
and	O
post	O
-	O
treatment	O
this	O
study	O
assessed	O
(	O
a	O
)	O
the	O
left	O
ventricular	O
(	O
LV	O
)	O
longitudinal	O
,	O
circumferential	O
and	O
radial	O
strain	O
and	O
strain	O
rate	O
,	O
using	O
speckle	O
tracking	O
echocardiography	O
,	O
(	O
b	O
)	O
the	O
coronary	O
flow	O
reserve	O
(	O
CFR	O
)	O
,	O
(	O
c	O
)	O
the	O
flow	O
-	O
mediated	O
endothelial	O
-	O
dependent	O
dilation	O
of	O
the	O
brachial	O
artery	O
(	O
FMD	O
)	O
and	O
(	O
d	O
)	O
nitrotyrosine	B-CHEMICAL
(	O
NT	B-CHEMICAL
)	O
and	O
malondialdehyde	B-CHEMICAL
blood	O
levels	O
.	O

RESULTS	O
:	O
Patients	O
had	O
impaired	O
baseline	O
myocardial	O
deformation	O
indices	O
compared	O
to	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

CFR	O
and	O
NT	B-CHEMICAL
levels	O
were	O
related	O
to	O
longitudinal	O
strain	O
,	O
systolic	O
and	O
diastolic	O
strain	O
rate	O
,	O
circumferential	O
strain	O
and	O
systolic	O
strain	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

FMD	O
was	O
related	O
to	O
longitudinal	O
and	O
circumferential	O
diastolic	O
strain	O
rate	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Compared	O
to	O
baseline	O
,	O
anakinra	O
-	O
treated	O
patients	O
increased	O
the	O
longitudinal	O
strain	O
(	O
-	O
17	O
.	O
8	O
%	O
(	O
3	O
.	O
7	O
%	O
)	O
vs	O
-	O
22	O
.	O
1	O
%	O
(	O
3	O
.	O
5	O
%	O
)	O
)	O
,	O
systolic	O
(	O
-	O
1	O
.	O
02	O
(	O
0	O
.	O
23	O
)	O
l	O
/	O
s	O
vs	O
-	O
1	O
.	O
25	O
(	O
0	O
.	O
23	O
)	O
l	O
/	O
s	O
)	O
and	O
diastolic	O
(	O
0	O
.	O
96	O
(	O
0	O
.	O
37	O
)	O
l	O
/	O
s	O
vs	O
1	O
.	O
20	O
(	O
0	O
.	O
39	O
)	O
l	O
/	O
s	O
)	O
longitudinal	O
strain	O
rate	O
,	O
circumferential	O
strain	O
and	O
strain	O
rate	O
(	O
p	O
<	O
0	O
.	O
05	O
for	O
all	O
comparisons	O
)	O
.	O

No	O
significant	O
changes	O
were	O
observed	O
among	O
prednisolone	B-CHEMICAL
-	O
treated	O
patients	O
CONCLUSIONS	O
:	O
Myocardial	O
deformation	O
is	O
impaired	O
in	O
RA	O
patients	O
and	O
is	O
related	O
to	O
nitro	B-CHEMICAL
-	O
oxidative	O
stress	O
and	O
endothelial	O
dysfunction	O
.	O

Chronic	O
inhibition	O
of	O
IL	B-GENE-N
-	I-GENE-N
1	I-GENE-N
improves	O
LV	O
deformation	O
in	O
parallel	O
with	O
endothelial	O
function	O
and	O
nitro	B-CHEMICAL
-	O
oxidative	O
stress	O
.	O

Amitriptyline	B-CHEMICAL
is	O
a	O
TrkA	B-GENE-Y
and	O
TrkB	B-GENE-Y
receptor	O
agonist	O
that	O
promotes	O
TrkA	B-GENE-Y
/	O
TrkB	B-GENE-Y
heterodimerization	O
and	O
has	O
potent	O
neurotrophic	O
activity	O
.	O

Neurotrophins	B-GENE-N
,	O
the	O
cognate	O
ligands	O
for	O
the	O
Trk	B-GENE-N
receptors	I-GENE-N
,	O
are	O
homodimers	O
and	O
induce	O
Trk	B-GENE-N
dimerization	O
through	O
a	O
symmetric	O
bivalent	O
mechanism	O
.	O

We	O
report	O
here	O
that	O
amitriptyline	B-CHEMICAL
,	O
an	O
antidepressant	O
drug	O
,	O
directly	O
binds	O
TrkA	B-GENE-Y
and	O
TrkB	B-GENE-Y
and	O
triggers	O
their	O
dimerization	O
and	O
activation	O
.	O

Amitriptyline	B-CHEMICAL
,	O
but	O
not	O
any	O
other	O
tricyclic	B-CHEMICAL
or	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
antidepressants	O
,	O
promotes	O
TrkA	B-GENE-Y
autophosphorylation	O
in	O
primary	O
neurons	O
and	O
induces	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Amitriptyline	B-CHEMICAL
binds	O
the	O
extracellular	O
domain	O
of	O
both	O
TrkA	B-GENE-Y
and	O
TrkB	B-GENE-Y
and	O
promotes	O
TrkA	B-GENE-Y
-	O
TrkB	B-GENE-Y
receptor	O
heterodimerization	O
.	O

Truncation	O
of	O
amitriptyline	B-CHEMICAL
binding	O
motif	O
on	O
TrkA	B-GENE-Y
abrogates	O
the	O
receptor	O
dimerization	O
by	O
amitriptyline	B-CHEMICAL
.	O

Administration	O
of	O
amitriptyline	B-CHEMICAL
to	O
mice	O
activates	O
both	O
receptors	O
and	O
significantly	O
reduces	O
kainic	B-CHEMICAL
acid	I-CHEMICAL
-	O
triggered	O
neuronal	O
cell	O
death	O
.	O

Inhibition	O
of	O
TrkA	B-GENE-Y
,	O
but	O
not	O
TrkB	B-GENE-Y
,	O
abolishes	O
amitriptyline	O
'	O
s	O
neuroprotective	O
effect	O
without	O
impairing	O
its	O
antidepressant	O
activity	O
.	O

Thus	O
,	O
amitriptyline	B-CHEMICAL
acts	O
as	O
a	O
TrkA	B-GENE-Y
and	O
TrkB	B-GENE-Y
agonist	O
and	O
possesses	O
marked	O
neurotrophic	O
activity	O
.	O

Effects	O
of	O
changeover	O
from	O
voglibose	B-CHEMICAL
to	O
acarbose	B-CHEMICAL
on	O
postprandial	O
triglycerides	B-CHEMICAL
in	O
type	O
2	O
diabetes	O
mellitus	O
patients	O
.	O

INTRODUCTION	O
:	O
In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
the	O
alpha	B-GENE-N
-	I-GENE-N
glucosidase	I-GENE-N
inhibitors	O
acarbose	B-CHEMICAL
and	O
voglibose	B-CHEMICAL
on	O
postprandial	O
plasma	O
glucose	B-CHEMICAL
and	O
serum	O
triglyceride	O
levels	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

METHODS	O
:	O
Twenty	O
-	O
one	O
Japanese	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

Subjects	O
had	O
been	O
treated	O
with	O
voglibose	B-CHEMICAL
for	O
at	O
least	O
3	O
months	O
.	O

They	O
underwent	O
a	O
400	O
kcal	O
balanced	O
food	O
meal	O
tolerance	O
test	O
before	O
and	O
8	O
weeks	O
after	O
the	O
changeover	O
from	O
voglibose	B-CHEMICAL
to	O
acarbose	B-CHEMICAL
.	O

Subjects	O
were	O
divided	O
into	O
two	O
groups	O
:	O
the	O
first	O
group	O
(	O
low	O
-	O
dose	O
group	O
;	O
n	O
=	O
11	O
)	O
was	O
changed	O
over	O
from	O
0	O
.	O
6	O
mg	O
/	O
day	O
voglibose	B-CHEMICAL
to	O
150	O
mg	O
/	O
day	O
acarbose	B-CHEMICAL
,	O
and	O
the	O
other	O
(	O
high	O
-	O
dose	O
group	O
;	O
n	O
=	O
10	O
)	O
from	O
0	O
.	O
9	O
mg	O
/	O
day	O
voglibose	B-CHEMICAL
to	O
300	O
mg	O
/	O
day	O
acarbose	O
.	O

RESULTS	O
:	O
The	O
increment	O
rate	O
of	O
postprandial	O
plasma	O
glucose	B-CHEMICAL
(	O
[	O
plasma	O
glucose	B-CHEMICAL
2	O
hours	O
after	O
test	O
meal	O
-	O
fasting	O
glucose	B-CHEMICAL
]	O
/	O
fasting	O
glucose	B-CHEMICAL
)	O
decreased	O
from	O
34	O
.	O
7	O
%	O
+	O
/	O
-	O
23	O
.	O
9	O
%	O
to	O
25	O
.	O
0	O
%	O
+	O
/	O
-	O
24	O
.	O
6	O
%	O
(	O
P	O
=	O
0	O
.	O
13	O
)	O
in	O
the	O
low	O
-	O
dose	O
group	O
,	O
and	O
decreased	O
significantly	O
from	O
56	O
.	O
1	O
%	O
+	O
/	O
-	O
53	O
.	O
1	O
%	O
to	O
31	O
.	O
5	O
%	O
+	O
/	O
-	O
36	O
.	O
0	O
%	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
in	O
the	O
high	O
-	O
dose	O
group	O
after	O
changeover	O
.	O

However	O
,	O
there	O
were	O
no	O
significant	O
changes	O
in	O
blood	O
glycated	B-GENE-Y
hemoglobin	I-GENE-Y
(	O
HbA	B-GENE-Y
(	I-GENE-Y
1c	I-GENE-Y
)	I-GENE-Y
)	O
levels	O
before	O
and	O
after	O
changeover	O
in	O
either	O
group	O
.	O

The	O
increment	O
rate	O
of	O
postprandial	O
serum	O
triglyceride	B-CHEMICAL
(	O
TG	B-CHEMICAL
)	O
(	O
[	O
serum	O
TG	B-CHEMICAL
2	O
hours	O
after	O
test	O
meal	O
-	O
fasting	O
TG	B-CHEMICAL
]	O
/	O
fasting	O
TG	B-CHEMICAL
)	O
decreased	O
significantly	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
(	O
52	O
.	O
4	O
%	O
+	O
/	O
-	O
60	O
.	O
0	O
%	O
to	O
24	O
.	O
3	O
%	O
+	O
/	O
-	O
16	O
.	O
6	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
changes	O
in	O
serum	O
high	O
-	O
density	O
lipoprotein	O
cholesterol	B-CHEMICAL
levels	O
were	O
observed	O
in	O
either	O
group	O
,	O
whereas	O
serum	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
cholesterol	B-CHEMICAL
levels	O
decreased	O
significantly	O
from	O
3	O
.	O
20	O
+	O
/	O
-	O
0	O
.	O
25	O
to	O
2	O
.	O
65	O
+	O
/	O
-	O
0	O
.	O
18	O
mmol	O
/	O
L	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
,	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
type	O
2	O
diabetes	O
our	O
findings	O
suggest	O
that	O
acarbose	B-CHEMICAL
300	O
mg	O
/	O
day	O
is	O
superior	O
to	O
voglibose	B-CHEMICAL
0	O
.	O
9	O
mg	O
/	O
day	O
in	O
improving	O
postprandial	O
hyperglycemia	O
and	O
hypertriglyceridemia	O
.	O

Cellular	O
mechanisms	O
of	O
insulin	B-GENE-Y
resistance	O
:	O
role	O
of	O
stress	B-GENE-N
-	I-GENE-N
regulated	I-GENE-N
serine	I-GENE-N
kinases	I-GENE-N
and	O
insulin	B-GENE-N
receptor	I-GENE-N
substrates	I-GENE-N
(	O
IRS	B-GENE-N
)	O
serine	B-CHEMICAL
phosphorylation	O
.	O

Insulin	B-GENE-N
receptor	I-GENE-N
substrates	I-GENE-N
(	O
IRS	B-GENE-N
)	O
serine	B-CHEMICAL
phosphorylation	O
is	O
a	O
time	O
-	O
controlled	O
physiological	O
feedback	O
mechanism	O
in	O
insulin	B-GENE-Y
signaling	O
that	O
is	O
hijacked	O
by	O
metabolic	O
and	O
inflammatory	O
stresses	O
to	O
promote	O
insulin	B-GENE-Y
resistance	O
.	O

Kinases	B-GENE-N
,	O
including	O
IKKbeta	B-GENE-Y
,	O
JNK	B-GENE-N
,	O
ERK	B-GENE-N
,	O
mTOR	B-GENE-Y
,	O
and	O
S6K	B-GENE-N
,	O
activated	O
by	O
the	O
inducers	O
of	O
insulin	B-GENE-Y
resistance	O
induce	O
uncontrolled	O
IRS	B-GENE-N
serine	B-CHEMICAL
phosphorylation	O
.	O

Studies	O
with	O
genetically	O
modified	O
mice	O
reveal	O
that	O
these	O
kinases	B-GENE-N
integrate	O
signals	O
from	O
metabolic	O
and	O
inflammatory	O
stresses	O
in	O
adipose	O
tissue	O
,	O
liver	O
,	O
and	O
hypothalamus	O
leading	O
to	O
peripheral	O
and	O
central	O
insulin	B-GENE-N
resistance	O
.	O

Moreover	O
,	O
IKKbeta	B-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
and	O
JNK1	B-GENE-Y
pathways	O
in	O
myeloid	O
cells	O
represent	O
a	O
core	O
mechanism	O
involved	O
in	O
inflammation	O
linked	O
to	O
obesity	O
.	O

These	O
kinases	B-GENE-N
are	O
thus	O
potential	O
drug	O
targets	O
against	O
insulin	B-GENE-N
resistance	O
and	O
the	O
targeting	O
of	O
the	O
IKKbeta	B-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
or	O
the	O
JNK	B-GENE-N
pathway	O
may	O
evolve	O
into	O
future	O
diabetes	O
medication	O
.	O

Vapreotide	B-CHEMICAL
:	O
a	O
somatostatin	B-CHEMICAL
analog	O
for	O
the	O
treatment	O
of	O
acute	O
variceal	O
bleeding	O
.	O

BACKGROUND	O
:	O
Portal	O
hypertension	O
is	O
a	O
clinically	O
important	O
consequence	O
of	O
cirrhosis	O
that	O
can	O
lead	O
to	O
morbidities	O
such	O
as	O
variceal	O
bleeding	O
,	O
hepatic	O
encephalopathy	O
and	O
ascites	O
.	O

All	O
of	O
these	O
outcomes	O
carry	O
high	O
mortality	O
rates	O
.	O

There	O
have	O
been	O
several	O
drugs	O
created	O
to	O
assist	O
with	O
endoscopic	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
variceal	O
bleeding	O
.	O

Recently	O
,	O
vapreotide	B-CHEMICAL
has	O
been	O
studied	O
in	O
patients	O
to	O
evaluate	O
its	O
efficacy	O
as	O
treatment	O
for	O
acute	O
variceal	O
hemorrhage	O
.	O

Although	O
no	O
comparisons	O
have	O
been	O
made	O
between	O
vapreotide	B-CHEMICAL
and	O
other	O
somatostatin	B-CHEMICAL
analogues	O
,	O
this	O
drug	O
has	O
been	O
shown	O
to	O
have	O
efficacy	O
in	O
the	O
control	O
of	O
acute	O
variceal	O
bleeding	O
as	O
well	O
as	O
reducing	O
the	O
risk	O
of	O
recurrent	O
bleeding	O
and	O
death	O
,	O
especially	O
when	O
started	O
prior	O
to	O
endoscopy	O
.	O

OBJECTIVE	O
:	O
This	O
paper	O
reviews	O
the	O
literature	O
regarding	O
the	O
basic	O
science	O
and	O
clinical	O
efficacy	O
of	O
vapreotide	B-CHEMICAL
in	O
acute	O
variceal	O
bleeding	O
.	O

METHODS	O
:	O
We	O
used	O
a	O
PubMed	O
/	O
Medline	O
search	O
in	O
order	O
to	O
review	O
the	O
literature	O
regarding	O
the	O
drug	O
,	O
vapreotide	B-CHEMICAL
.	O

RESULTS	O
/	O
CONCLUSIONS	O
:	O
Vapreotide	B-CHEMICAL
appears	O
to	O
have	O
benefit	O
in	O
the	O
control	O
of	O
acute	O
variceal	O
bleeding	O
.	O

It	O
is	O
easy	O
to	O
administer	O
and	O
has	O
few	O
side	O
effects	O
,	O
which	O
are	O
minor	O
.	O

These	O
findings	O
endorse	O
the	O
need	O
for	O
future	O
trials	O
to	O
evaluate	O
vapreotide	B-CHEMICAL
and	O
its	O
use	O
in	O
acute	O
variceal	O
hemorrhage	O
,	O
a	O
morbidity	O
among	O
patients	O
with	O
cirrhosis	O
.	O

Esmolol	B-CHEMICAL
reduces	O
autonomic	O
hypersensitivity	O
and	O
length	O
of	O
seizures	O
induced	O
by	O
electroconvulsive	O
therapy	O
.	O

We	O
evaluated	O
the	O
clinical	O
effectiveness	O
of	O
esmolol	B-CHEMICAL
,	O
an	O
ultra	O
-	O
short	O
-	O
acting	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
blocking	O
drug	O
,	O
to	O
control	O
the	O
sinus	O
tachycardia	O
and	O
increase	O
in	O
arterial	O
blood	O
pressures	O
induced	O
by	O
electroconvulsive	O
therapy	O
(	O
ECT	O
)	O
.	O

Each	O
of	O
20	O
patients	O
,	O
ASA	O
physical	O
status	O
I	O
-	O
III	O
,	O
participated	O
in	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
study	O
,	O
involving	O
four	O
match	O
-	O
pair	O
trials	O
(	O
placebo	O
versus	O
esmolol	B-CHEMICAL
)	O
during	O
ECT	O
.	O

Each	O
patient	O
acted	O
as	O
his	O
or	O
her	O
own	O
control	O
(	O
total	O
number	O
of	O
ECT	O
procedures	O
,	O
160	O
)	O
.	O

We	O
administered	O
a	O
4	O
-	O
min	O
infusion	O
of	O
either	O
placebo	O
or	O
esmolol	B-CHEMICAL
at	O
the	O
rate	O
of	O
500	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
.	O

We	O
then	O
induced	O
anesthesia	O
with	O
methohexital	B-CHEMICAL
and	O
succinylcholine	B-CHEMICAL
.	O

After	O
administration	O
of	O
electrical	O
stimulation	O
for	O
ECT	O
,	O
the	O
rate	O
of	O
infusion	O
decreased	O
to	O
300	O
micrograms	O
.	O
kg	O
-	O
1	O
.	O
min	O
-	O
1	O
for	O
three	O
additional	O
minutes	O
and	O
was	O
then	O
discontinued	O
.	O

Statistically	O
significant	O
reductions	O
in	O
mean	O
heart	O
rate	O
from	O
minute	O
2	O
until	O
minute	O
15	O
and	O
in	O
maximum	O
heart	O
rate	O
(	O
the	O
mean	O
of	O
each	O
patient	O
'	O
s	O
maximum	O
heart	O
rate	O
after	O
seizure	O
changed	O
from	O
152	O
+	O
/	O
-	O
23	O
to	O
115	O
+	O
/	O
-	O
24	O
beats	O
/	O
min	O
)	O
occurred	O
in	O
patients	O
given	O
esmolol	B-CHEMICAL
.	O

During	O
and	O
immediately	O
after	O
infusion	O
,	O
arterial	O
blood	O
pressure	O
also	O
decreased	O
.	O

Finally	O
,	O
the	O
length	O
of	O
seizures	O
decreased	O
,	O
as	O
manifested	O
clinically	O
from	O
48	O
+	O
/	O
-	O
18	O
to	O
39	O
+	O
/	O
-	O
14	O
s	O
and	O
on	O
electroencephalogram	O
from	O
86	O
+	O
/	O
-	O
41	O
to	O
67	O
+	O
/	O
-	O
28	O
s	O
.	O

We	O
conclude	O
that	O
esmolol	B-CHEMICAL
effectively	O
controls	O
the	O
hyperdynamic	O
response	O
to	O
ECT	O
and	O
reduces	O
the	O
length	O
of	O
seizures	O
.	O

The	O
significance	O
of	O
the	O
latter	O
to	O
the	O
overall	O
effectiveness	O
of	O
ECT	O
is	O
not	O
known	O
.	O

Histamine	B-CHEMICAL
and	O
asthma	O
:	O
an	O
appraisal	O
based	O
on	O
specific	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonism	O
.	O

H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
have	O
been	O
utilized	O
,	O
following	O
their	O
initial	O
chemical	O
synthesis	O
in	O
1933	O
,	O
both	O
in	O
the	O
treatment	O
of	O
conditions	O
in	O
which	O
histamine	B-CHEMICAL
is	O
considered	O
to	O
be	O
of	O
pathogenic	O
importance	O
and	O
conversely	O
to	O
help	O
elucidate	O
the	O
role	O
of	O
histamine	B-CHEMICAL
in	O
disease	O
,	O
through	O
an	O
evaluation	O
of	O
their	O
influence	O
on	O
disease	O
expression	O
.	O

While	O
there	O
is	O
considerable	O
indirect	O
evidence	O
to	O
implicate	O
histamine	B-CHEMICAL
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
a	O
critical	O
evaluation	O
of	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonism	O
in	O
this	O
condition	O
has	O
,	O
until	O
recently	O
,	O
proved	O
difficult	O
,	O
as	O
many	O
of	O
the	O
early	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
possessed	O
additional	O
actions	O
,	O
such	O
as	O
anti	O
-	O
cholinergic	O
,	O
local	O
anaesthetic	O
,	O
alpha	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonistic	O
and	O
anti	O
-	O
serotonin	O
activity	O
.	O

In	O
addition	O
,	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
have	O
been	O
shown	O
to	O
have	O
effects	O
on	O
mast	O
cell	O
function	O
.	O

In	O
low	O
concentrations	O
in	O
vitro	O
,	O
antihistamines	O
have	O
been	O
found	O
to	O
inhibit	O
immunologically	O
stimulated	O
mast	O
cell	O
mediator	O
release	O
,	O
with	O
the	O
IC50	O
in	O
the	O
nanomolar	O
to	O
micromolar	O
range	O
,	O
while	O
at	O
higher	O
concentrations	O
they	O
induce	O
histamine	B-CHEMICAL
release	O
.	O

The	O
potency	O
of	O
these	O
drugs	O
in	O
producing	O
such	O
effects	O
is	O
unrelated	O
to	O
their	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
blocking	O
activity	O
.	O

Furthermore	O
the	O
sedative	O
effects	O
of	O
these	O
therapeutic	O
agents	O
limit	O
the	O
tolerable	O
administrable	O
dose	O
and	O
thus	O
the	O
degree	O
of	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
blockade	O
achievable	O
within	O
the	O
airways	O
.	O

The	O
recent	O
development	O
of	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
devoid	O
of	O
clinical	O
sedative	O
effects	O
has	O
enabled	O
the	O
administration	O
of	O
doses	O
of	O
H1	B-GENE-Y
-	O
antihistamines	O
which	O
achieve	O
a	O
greater	O
degree	O
of	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
blockade	O
within	O
the	O
airways	O
,	O
thus	O
permitting	O
a	O
better	O
appraisal	O
of	O
the	O
role	O
of	O
histamine	B-CHEMICAL
in	O
this	O
condition	O
.	O

Furthermore	O
,	O
the	O
receptor	O
specificity	O
of	O
many	O
of	O
these	O
agents	O
has	O
been	O
focused	O
such	O
that	O
terfenadine	B-CHEMICAL
,	O
astemizole	B-CHEMICAL
,	O
loratadine	B-CHEMICAL
and	O
cetirizine	B-CHEMICAL
are	O
devoid	O
of	O
anticholinergic	O
activity	O
and	O
exhibit	O
little	O
alpha	O
-	O
antagonistic	O
or	O
anti	O
-	O
serotonin	B-CHEMICAL
activity	O
of	O
clinical	O
relevance	O
.	O

However	O
,	O
of	O
these	O
agents	O
both	O
loratadine	B-CHEMICAL
and	O
cetirizine	B-CHEMICAL
possess	O
additional	O
actions	O
likely	O
to	O
be	O
of	O
relevance	O
to	O
asthma	O
.	O

Pretreatment	O
with	O
loratadine	B-CHEMICAL
has	O
been	O
shown	O
to	O
reduce	O
the	O
recovery	O
of	O
both	O
histamine	B-CHEMICAL
and	O
prostaglandin	B-CHEMICAL
D2	I-CHEMICAL
(	O
PGD2	B-CHEMICAL
)	O
in	O
nasal	O
lavage	O
fluid	O
following	O
nasal	O
allergen	O
challenge	O
,	O
a	O
finding	O
interpreted	O
as	O
indicative	O
of	O
in	O
vivo	O
mast	O
cell	O
stabilization	O
,	O
and	O
cetirizine	B-CHEMICAL
has	O
been	O
shown	O
in	O
vivo	O
at	O
therapeutic	O
doses	O
to	O
inhibit	O
allergen	O
-	O
induced	O
eosinophil	O
chemotaxis	O
.	O

Thus	O
while	O
both	O
these	O
agents	O
offer	O
the	O
potential	O
of	O
an	O
oral	O
therapy	O
for	O
asthma	O
based	O
on	O
an	O
H1	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
their	O
additional	O
actions	O
do	O
not	O
make	O
them	O
ideally	O
suited	O
to	O
the	O
exploration	O
of	O
the	O
role	O
of	O
histamine	B-CHEMICAL
in	O
asthma	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

The	O
potassium	B-GENE-Y
channel	I-GENE-Y
subunit	I-GENE-Y
Kvbeta3	I-GENE-Y
interacts	O
with	O
pannexin	B-GENE-Y
1	I-GENE-Y
and	O
attenuates	O
its	O
sensitivity	O
to	O
changes	O
in	O
redox	O
potentials	O
.	O

Pannexin	B-GENE-Y
1	I-GENE-Y
(	O
Panx1	B-GENE-Y
)	O
,	O
a	O
member	O
of	O
the	O
second	O
gap	B-GENE-N
junction	I-GENE-N
protein	I-GENE-N
family	O
identified	O
in	O
vertebrates	O
,	O
appears	O
to	O
preferentially	O
form	O
non	O
-	O
junctional	O
membrane	O
channels	O
.	O

A	O
candidate	O
regulatory	O
protein	O
of	O
Panx1	B-GENE-Y
is	O
the	O
potassium	B-GENE-Y
channel	I-GENE-Y
subunit	I-GENE-Y
Kvbeta3	I-GENE-Y
,	O
previously	O
identified	O
by	O
bacterial	O
two	O
-	O
hybrid	O
strategies	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
physical	O
association	O
of	O
Panx1	B-GENE-Y
with	O
Kvbeta3	B-GENE-Y
by	O
immunoprecipitation	O
when	O
co	O
-	O
expressed	O
in	O
a	O
neuroblastoma	O
cell	O
line	O
(	O
Neuro2A	O
)	O
.	O

Furthermore	O
,	O
in	O
vivo	O
co	O
-	O
expression	O
of	O
Panx1	B-GENE-Y
and	O
Kvbeta3	B-GENE-Y
was	O
shown	O
to	O
occur	O
in	O
murine	O
hippocampus	O
and	O
cerebellum	O
.	O

Kvbeta3	B-GENE-Y
is	O
known	O
to	O
accelerate	O
inactivation	O
of	O
otherwise	O
slowly	O
inactivating	O
potassium	B-GENE-N
channels	I-GENE-N
under	O
reducing	O
conditions	O
.	O

We	O
subsequently	O
found	O
that	O
Panx1	B-GENE-Y
channel	O
currents	O
exhibit	O
a	O
significant	O
reduction	O
when	O
exposed	O
to	O
reducing	O
agents	O
,	O
and	O
that	O
this	O
effect	O
is	O
attenuated	O
in	O
the	O
presence	O
of	O
Kvbeta3	B-GENE-Y
.	O

Apparently	O
,	O
Kvbeta3	B-GENE-Y
is	O
involved	O
in	O
regulating	O
the	O
susceptibility	O
of	O
Panx1	B-GENE-Y
channels	O
to	O
redox	O
potential	O
.	O

Furthermore	O
,	O
the	O
Panx1	B-GENE-Y
channel	O
blockers	O
carbenoxolone	B-CHEMICAL
and	O
Probenecid	B-CHEMICAL
were	O
less	O
effective	O
in	O
inhibiting	O
Panx1	B-GENE-Y
currents	O
when	O
Kvbeta3	B-GENE-Y
was	O
co	O
-	O
expressed	O
.	O

The	O
influence	O
of	O
Kvbeta3	B-GENE-Y
on	O
Panx1	B-GENE-Y
is	O
the	O
first	O
example	O
of	O
modulation	O
of	O
Panx1	B-GENE-Y
channel	O
function	O
(	O
s	O
)	O
by	O
interacting	O
proteins	O
,	O
and	O
suggests	O
the	O
physiological	O
importance	O
of	O
sensing	O
changes	O
in	O
redox	O
potentials	O
.	O

Screening	O
for	O
(	O
anti	O
)	O
androgenic	O
properties	O
using	O
a	O
standard	O
operation	O
protocol	O
based	O
on	O
the	O
human	O
stably	O
transfected	O
androgen	B-CHEMICAL
sensitive	O
PALM	O
cell	O
line	O
.	O

First	O
steps	O
towards	O
validation	O
.	O

Despite	O
more	O
than	O
a	O
decade	O
of	O
research	O
in	O
the	O
field	O
of	O
endocrine	O
active	O
compounds	O
targeting	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
,	O
and	O
although	O
suitable	O
cell	O
lines	O
can	O
be	O
obtained	O
,	O
no	O
validated	O
human	O
stably	O
transfected	O
androgen	B-CHEMICAL
sensitive	O
transactivation	O
assay	O
is	O
available	O
.	O

Bayer	O
Schering	O
Pharma	O
(	O
BSP	O
)	O
and	O
the	O
Flemish	O
Institute	O
for	O
Technological	O
Research	O
(	O
VITO	O
)	O
,	O
partners	O
within	O
the	O
EU	O
-	O
sponsored	O
6th	O
framework	O
project	O
ReProTect	O
,	O
made	O
first	O
steps	O
towards	O
such	O
a	O
validation	O
.	O

A	O
standard	O
operation	O
protocol	O
(	O
SOP	O
)	O
developed	O
at	O
BSP	O
based	O
on	O
the	O
androgen	B-CHEMICAL
sensitive	O
PALM	O
cell	O
line	O
was	O
transferred	O
to	O
VITO	O
and	O
its	O
performance	O
and	O
transferability	O
were	O
thoroughly	O
studied	O
.	O

The	O
investigation	O
followed	O
a	O
generic	O
protocol	O
prepared	O
for	O
all	O
reporter	O
gene	O
assays	O
evaluated	O
within	O
ReProTect	O
,	O
and	O
in	O
both	O
laboratories	O
at	O
least	O
three	O
independent	O
experiments	O
were	O
performed	O
.	O

The	O
highest	O
concentration	O
to	O
be	O
tested	O
was	O
limited	O
to	O
10	O
microM	O
,	O
if	O
needed	O
.	O

A	O
few	O
compounds	O
,	O
17alpha	B-CHEMICAL
-	I-CHEMICAL
methyltestosterone	I-CHEMICAL
(	O
17alpha	B-CHEMICAL
-	I-CHEMICAL
MT	I-CHEMICAL
)	O
,	O
vinclozolin	B-CHEMICAL
and	O
linuron	B-CHEMICAL
,	O
were	O
studied	O
using	O
a	O
real	O
world	O
scenario	O
,	O
i	O
.	O
e	O
.	O
,	O
assuming	O
that	O
their	O
interaction	O
with	O
the	O
AR	B-GENE-Y
was	O
not	O
known	O
:	O
A	O
prescreening	O
for	O
agonism	O
and	O
true	O
,	O
competitive	O
antagonism	O
was	O
used	O
to	O
select	O
conditions	O
such	O
as	O
the	O
appropriate	O
mode	O
of	O
action	O
,	O
and	O
the	O
working	O
range	O
excluding	O
cytotoxicity	O
for	O
the	O
final	O
screening	O
.	O

All	O
other	O
compounds	O
were	O
tested	O
according	O
to	O
the	O
generic	O
protocol	O
:	O
Compounds	O
screened	O
for	O
agonism	O
were	O
the	O
reference	O
androgen	B-CHEMICAL
17alpha	B-CHEMICAL
-	I-CHEMICAL
methyldihydrotestosterone	I-CHEMICAL
(	O
MDHT	B-CHEMICAL
)	O
,	O
levonorgestrel	B-CHEMICAL
,	O
norethynodrel	B-CHEMICAL
,	O
progesterone	B-CHEMICAL
,	O
o	B-CHEMICAL
,	I-CHEMICAL
p	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
DDT	I-CHEMICAL
,	O
and	O
dibutylphthalate	B-CHEMICAL
(	O
DBP	B-CHEMICAL
)	O
,	O
while	O
compounds	O
screened	O
for	O
antagonism	O
were	O
the	O
reference	O
anti	B-CHEMICAL
-	I-CHEMICAL
androgen	I-CHEMICAL
flutamide	B-CHEMICAL
,	O
prochloraz	B-CHEMICAL
,	O
o	B-CHEMICAL
,	I-CHEMICAL
p	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
DDT	I-CHEMICAL
,	O
progesterone	B-CHEMICAL
,	O
norethynodrel	B-CHEMICAL
,	O
and	O
DBP	B-CHEMICAL
.	O

Cytotoxicity	O
was	O
assessed	O
in	O
parallel	O
as	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
release	O
.	O

The	O
prescreen	O
classified	O
17alpha	B-CHEMICAL
-	I-CHEMICAL
MT	I-CHEMICAL
as	O
androgenic	O
,	O
vinclozolin	B-CHEMICAL
and	O
linuron	O
as	O
anti	O
-	O
androgenic	O
and	O
compounds	O
were	O
tested	O
accordingly	O
.	O

In	O
the	O
absence	O
of	O
cytotoxicity	O
,	O
appropriate	O
androgenic	O
properties	O
of	O
reference	O
and	O
test	O
compounds	O
were	O
detected	O
by	O
both	O
laboratories	O
,	O
o	B-CHEMICAL
,	I-CHEMICAL
p	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
DDT	I-CHEMICAL
and	O
DBP	B-CHEMICAL
had	O
no	O
androgenic	O
activity	O
.	O

Across	O
the	O
two	O
laboratories	O
EC	O
(	O
50	O
)	O
-	O
values	O
for	O
MDHT	B-CHEMICAL
,	O
17alpha	B-CHEMICAL
-	I-CHEMICAL
MT	I-CHEMICAL
,	O
and	O
levonorgestrel	B-CHEMICAL
varied	O
by	O
not	O
more	O
than	O
a	O
factor	O
of	O
3	O
.	O
4	O
,	O
for	O
norethynodrel	B-CHEMICAL
by	O
a	O
factor	O
of	O
9	O
.	O
7	O
.	O

Progesterone	B-CHEMICAL
effects	O
could	O
not	O
fully	O
be	O
evaluated	O
,	O
as	O
frequently	O
concentration	O
response	O
curves	O
were	O
incomplete	O
.	O

In	O
the	O
absence	O
of	O
cytotoxicity	O
anti	O
-	O
androgenic	O
properties	O
of	O
reference	O
and	O
test	O
compounds	O
were	O
also	O
detected	O
in	O
both	O
laboratories	O
.	O

DBP	B-CHEMICAL
,	O
the	O
putative	O
negative	O
reference	O
compound	O
,	O
was	O
inactive	O
,	O
norethynodrel	B-CHEMICAL
rather	O
showed	O
agonistic	O
properties	O
.	O

Progesterone	B-CHEMICAL
was	O
an	O
antagonist	O
at	O
low	O
concentrations	O
,	O
but	O
agonistic	O
properties	O
were	O
observed	O
in	O
one	O
laboratory	O
at	O
high	O
concentrations	O
.	O

Since	O
the	O
highest	O
test	O
concentration	O
was	O
limited	O
to	O
10	O
microM	O
,	O
for	O
some	O
compounds	O
no	O
complete	O
concentration	O
response	O
curves	O
were	O
obtained	O
and	O
estimation	O
of	O
EC	O
(	O
50	O
)	O
-	O
values	O
was	O
less	O
robust	O
.	O

Our	O
data	O
demonstrated	O
that	O
the	O
SOP	O
was	O
transferable	O
,	O
and	O
that	O
the	O
assay	O
was	O
able	O
to	O
rank	O
compounds	O
with	O
strong	O
,	O
weak	O
,	O
and	O
without	O
affinity	O
for	O
the	O
AR	B-GENE-Y
and	O
to	O
discriminate	O
agonists	O
and	O
antagonists	O
.	O

The	O
sensitivity	O
of	O
the	O
assay	O
could	O
be	O
improved	O
further	O
,	O
if	O
the	O
limit	O
of	O
solubility	O
or	O
beginning	O
cytotoxicity	O
was	O
chosen	O
as	O
the	O
highest	O
test	O
concentration	O
.	O

The	O
assay	O
avoids	O
the	O
use	O
of	O
tissues	O
from	O
laboratory	O
animals	O
,	O
and	O
thus	O
contributes	O
to	O
the	O
3R	O
concept	O
.	O

Furthermore	O
,	O
it	O
could	O
be	O
adjusted	O
to	O
an	O
intermediate	O
/	O
high	O
throughput	O
format	O
.	O

On	O
the	O
whole	O
,	O
this	O
PALM	O
assay	O
is	O
a	O
promising	O
candidate	O
for	O
further	O
validation	O
.	O

Binding	O
between	O
heparin	O
and	O
the	O
integrin	B-GENE-N
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
.	O

Heparin	O
possesses	O
antimetastatic	O
effects	O
that	O
were	O
related	O
to	O
various	O
molecular	O
mechanisms	O
beyond	O
anticoagulant	O
activities	O
.	O

The	O
ability	O
of	O
heparin	O
to	O
interfere	O
with	O
the	O
function	O
of	O
adhesion	B-GENE-N
receptors	I-GENE-N
in	O
the	O
metastatic	O
course	O
appears	O
as	O
a	O
promising	O
therapeutic	O
approach	O
.	O

This	O
refers	O
to	O
numerous	O
findings	O
that	O
heparin	O
attenuates	O
metastasis	O
in	O
a	O
selectin	O
-	O
dependent	O
manner	O
.	O

We	O
recently	O
demonstrated	O
that	O
heparin	O
interferes	O
with	O
the	O
integrin	B-GENE-N
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
on	O
murine	O
melanoma	O
cells	O
binding	O
to	O
VCAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

To	O
confirm	O
this	O
activity	O
and	O
to	O
obtain	O
further	O
insight	O
into	O
molecular	O
recognition	O
of	O
heparin	O
by	O
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
we	O
investigated	O
the	O
inhibition	O
of	O
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
mediated	O
binding	O
of	O
human	O
melanoma	O
MV3	O
cells	O
to	O
immobilised	O
VCAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
by	O
different	O
heparins	O
.	O

The	O
size	O
of	O
heparin	O
has	O
an	O
important	O
impact	O
on	O
inhibition	O
.	O

Unfractionated	O
heparin	O
(	O
UFH	O
)	O
and	O
tinzaparin	B-CHEMICAL
,	O
a	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
(	O
LMWH	O
)	O
representing	O
a	O
mean	O
of	O
about	O
18	O
-	O
20	O
monomers	O
,	O
displayed	O
high	O
inhibitory	O
activity	O
.	O

Fractionating	O
tinzaparin	B-CHEMICAL
to	O
14	O
-	O
18	O
monomers	O
reduced	O
inhibition	O
slightly	O
,	O
while	O
the	O
pentasaccharide	B-CHEMICAL
fondaparinux	I-CHEMICAL
was	O
without	O
effects	O
.	O

To	O
confirm	O
molecular	O
recognition	O
of	O
tinzaparin	B-CHEMICAL
by	O
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
a	O
surface	O
acoustic	O
wave	O
-	O
biosensor	O
was	O
applied	O
.	O

A	O
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
containing	O
membrane	O
preparation	O
of	O
MV3	O
cells	O
was	O
immobilised	O
at	O
the	O
sensors	O
to	O
allow	O
for	O
detection	O
of	O
kinetic	O
binding	O
constants	O
of	O
tinzaparin	B-CHEMICAL
compared	O
to	O
VCAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Tinzaparin	B-CHEMICAL
binds	O
to	O
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
with	O
affinity	O
in	O
the	O
low	O
micromolar	O
range	O
(	O
4	O
.	O
61	O
x	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
which	O
clearly	O
indicates	O
specific	O
molecular	O
recognition	O
.	O

Furthermore	O
,	O
tinzaparin	B-CHEMICAL
displays	O
a	O
nearly	O
identical	O
k	O
(	O
off	O
)	O
compared	O
to	O
VCAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
5	O
.	O
13	O
x	O
10	O
(	O
-	O
3	O
)	O
s	O
(	O
-	O
1	O
)	O
versus	O
3	O
.	O
44	O
x	O
10	O
(	O
-	O
3	O
)	O
s	O
(	O
-	O
1	O
)	O
)	O
which	O
is	O
evident	O
for	O
interference	O
with	O
the	O
ligand	O
binding	O
.	O

The	O
data	O
provide	O
evidence	O
for	O
a	O
direct	O
confirmation	O
of	O
heparin	O
binding	O
to	O
VLA	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
thus	O
,	O
contribute	O
to	O
understand	O
the	O
antimetastatic	O
activity	O
of	O
heparin	O
.	O

Effects	O
of	O
bambuterol	B-CHEMICAL
and	O
terbutaline	B-CHEMICAL
on	O
isolated	O
rat	O
'	O
s	O
tracheal	O
smooth	O
muscle	O
.	O

Terbutaline	B-CHEMICAL
(	O
Bricanyl	B-CHEMICAL
)	O
and	O
its	O
prodrug	O
Bambuterol	B-CHEMICAL
(	O
Bambec	B-CHEMICAL
)	O
are	O
highly	O
potent	O
beta	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonists	O
often	O
used	O
in	O
asthma	O
patients	O
.	O

Terbutaline	B-CHEMICAL
in	O
the	O
form	O
of	O
inhaled	O
short	O
-	O
acting	O
bronchodilator	O
relieves	O
asthmatic	O
symptoms	O
.	O

However	O
,	O
the	O
effects	O
of	O
bambuterol	B-CHEMICAL
given	O
intratracheally	O
have	O
rarely	O
been	O
explored	O
.	O

To	O
verify	O
the	O
effect	O
of	O
bambuterol	B-CHEMICAL
and	O
terbutaline	B-CHEMICAL
,	O
which	O
act	O
on	O
the	O
tracheal	O
smooth	O
muscle	O
directly	O
in	O
vitro	O
,	O
we	O
used	O
our	O
preparation	O
to	O
test	O
the	O
effects	O
of	O
bambuterol	B-CHEMICAL
on	O
isolated	O
rat	O
'	O
s	O
tracheal	O
smooth	O
muscle	O
compared	O
with	O
terbutaline	B-CHEMICAL
.	O

The	O
following	O
assessments	O
of	O
bambuterol	B-CHEMICAL
and	O
terbutaline	B-CHEMICAL
were	O
performed	O
:	O
(	O
1	O
)	O
effect	O
on	O
tracheal	O
smooth	O
muscle	O
resting	O
tension	O
;	O
(	O
2	O
)	O
effect	O
on	O
contraction	O
caused	O
by	O
10	O
(	O
-	O
6	O
)	O
M	O
methacholine	B-CHEMICAL
as	O
a	O
parasympathetic	O
mimetic	O
;	O
(	O
3	O
)	O
effect	O
of	O
the	O
drugs	O
on	O
electrically	O
induced	O
tracheal	O
smooth	O
muscle	O
contractions	O
.	O

The	O
results	O
indicated	O
that	O
adding	O
bambuterol	B-CHEMICAL
induced	O
a	O
significant	O
further	O
contraction	O
to	O
10	O
(	O
-	O
6	O
)	O
M	O
methacholine	B-CHEMICAL
-	O
induced	O
contraction	O
when	O
the	O
preparation	O
was	O
increased	O
to	O
10	O
(	O
-	O
4	O
)	O
M	O
.	O

But	O
terbutaline	B-CHEMICAL
elicited	O
a	O
relaxation	O
response	O
at	O
a	O
dose	O
of	O
10	O
(	O
-	O
6	O
)	O
M	O
or	O
more	O
.	O

Both	O
bambuterol	B-CHEMICAL
and	O
terbutaline	B-CHEMICAL
could	O
inhibit	O
electrical	O
field	O
stimulation	O
(	O
EFS	O
)	O
induced	O
spike	O
contraction	O
.	O

Terbutaline	B-CHEMICAL
had	O
an	O
anti	O
-	O
cholinergic	O
effect	O
that	O
could	O
relieve	O
asthmatic	O
symptoms	O
.	O

But	O
the	O
effect	O
of	O
bambuterol	O
acting	O
on	O
tracheal	O
smooth	O
muscle	O
directly	O
was	O
controversial	O
.	O

Polymorphisms	O
in	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
(	O
SLC6A3	B-GENE-Y
)	O
are	O
associated	O
with	O
stimulant	O
effects	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
:	O
an	O
exploratory	O
pharmacogenetic	O
study	O
using	O
healthy	O
volunteers	O
.	O

Individuals	O
vary	O
in	O
their	O
subjective	O
responses	O
to	O
stimulant	O
drugs	O
,	O
and	O
these	O
differences	O
are	O
believed	O
to	O
be	O
partially	O
genetic	O
in	O
origin	O
.	O

We	O
evaluated	O
associations	O
between	O
mood	O
,	O
cognitive	O
and	O
cardiovascular	O
responses	O
to	O
d	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
and	O
four	O
polymorphisms	O
in	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
(	O
SLC6A3	B-GENE-Y
)	O
:	O
rs460000	O
,	O
rs3756450	O
,	O
rs37022	O
and	O
rs6869645	O
.	O

Healthy	O
Caucasian	O
male	O
and	O
female	O
volunteers	O
(	O
N	O
=	O
152	O
)	O
participated	O
in	O
a	O
double	O
-	O
blind	O
,	O
crossover	O
design	O
study	O
in	O
which	O
they	O
received	O
placebo	O
,	O
10	O
and	O
20	O
mg	O
of	O
d	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
.	O

We	O
measured	O
self	O
-	O
reported	O
rating	O
of	O
mood	O
,	O
performance	O
on	O
the	O
Digit	O
Symbol	O
Substitution	O
Task	O
,	O
blood	O
pressure	O
and	O
heart	O
rate	O
.	O

Individuals	O
with	O
the	O
C	O
/	O
C	O
genotype	O
at	O
rs460000	O
(	O
N	O
=	O
83	O
)	O
reported	O
approximately	O
twofold	O
higher	O
ratings	O
of	O
stimulation	O
and	O
euphoria	O
relative	O
to	O
the	O
A	O
/	O
A	O
+	O
A	O
/	O
C	O
(	O
N	O
=	O
69	O
)	O
genotype	O
group	O
,	O
at	O
both	O
the	O
10	O
and	O
20	O
mg	O
doses	O
.	O

No	O
other	O
responses	O
or	O
SNPs	O
showed	O
significant	O
effects	O
.	O

rs460000	O
is	O
in	O
perfect	O
LD	O
with	O
rs463379	O
(	O
CEU	O
:	O
D	O
'	O
=	O
1	O
;	O
r	O
(	O
2	O
)	O
=	O
1	O
)	O
,	O
which	O
was	O
not	O
studied	O
here	O
,	O
but	O
has	O
been	O
associated	O
with	O
etiology	O
of	O
Attention	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O

These	O
findings	O
suggest	O
a	O
pleiotropic	O
effect	O
of	O
this	O
polymorphic	O
locus	O
on	O
both	O
ADHD	O
and	O
sensitivity	O
to	O
the	O
subjective	O
effects	O
of	O
amphetamine	B-CHEMICAL
.	O

Bile	O
acids	O
induce	O
cdx2	B-GENE-Y
expression	O
through	O
the	O
farnesoid	B-GENE-Y
x	I-GENE-Y
receptor	I-GENE-Y
in	O
gastric	O
epithelial	O
cells	O
.	O

Clinical	O
and	O
experimental	O
studies	O
showed	O
that	O
the	O
reflux	O
of	O
bile	O
into	O
the	O
stomach	O
contributes	O
to	O
the	O
induction	O
of	O
intestinal	O
metaplasia	O
of	O
the	O
stomach	O
and	O
gastric	O
carcinogenesis	O
.	O

Caudal	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
homeobox	I-GENE-Y
2	I-GENE-Y
(	O
Cdx2	B-GENE-Y
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
exhibition	O
of	O
intestinal	O
phenotypes	O
by	O
regulating	O
the	O
expression	O
of	O
intestine	O
-	O
specific	O
genes	O
such	O
as	O
goblet	O
-	O
specific	O
gene	O
mucin	B-GENE-Y
2	I-GENE-Y
(	O
MUC2	B-GENE-Y
)	O
.	O

We	O
investigated	O
the	O
involvement	O
of	O
the	O
farnesoid	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
(	O
FXR	B-GENE-Y
)	O
,	O
a	O
nuclear	B-GENE-N
receptor	I-GENE-N
for	O
bile	O
acids	O
,	O
in	O
the	O
chenodeoxycholic	B-CHEMICAL
acid	I-CHEMICAL
(	O
CDCA	B-CHEMICAL
)	O
-	O
induced	O
expression	O
of	O
Cdx2	B-GENE-Y
and	O
MUC2	B-GENE-Y
in	O
normal	O
rat	O
gastric	O
epithelial	O
cells	O
(	O
RGM	O
-	O
1	O
cells	O
)	O
.	O

RGM	O
-	O
1	O
cells	O
were	O
treated	O
with	O
CDCA	B-CHEMICAL
or	O
GW4064	B-CHEMICAL
,	O
an	O
FXR	B-GENE-Y
agonist	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
guggulsterone	B-CHEMICAL
,	O
an	O
FXR	B-GENE-Y
antagonist	O
.	O

CDCA	B-CHEMICAL
induced	O
dose	O
-	O
dependent	O
expression	O
of	O
Cdx2	B-GENE-Y
and	O
MUC2	B-GENE-Y
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

The	O
maximum	O
stimulation	O
of	O
Cdx2	B-GENE-Y
and	O
MUC2	B-GENE-Y
mRNA	O
induced	O
by	O
CDCA	B-CHEMICAL
was	O
observed	O
at	O
3	O
h	O
and	O
by	O
6	O
h	O
,	O
respectively	O
.	O

GW4064	B-CHEMICAL
also	O
induced	O
expression	O
of	O
these	O
molecules	O
.	O

The	O
effects	O
of	O
CDCA	B-CHEMICAL
and	O
GW4064	B-CHEMICAL
on	O
expression	O
of	O
Cdx2	B-GENE-Y
and	O
MUC2	B-GENE-Y
were	O
abolished	O
by	O
guggulsterone	B-CHEMICAL
.	O

These	O
findings	O
suggest	O
that	O
bile	O
acids	O
may	O
induce	O
gastric	O
intestinal	O
metaplasia	O
and	O
carcinogenesis	O
through	O
the	O
FXR	B-GENE-Y
.	O

Carbonic	B-GENE-N
anhydrase	I-GENE-N
inhibitors	O
.	O

Inhibition	O
of	O
mammalian	B-GENE-N
isoforms	I-GENE-N
I	I-GENE-N
-	I-GENE-N
XIV	I-GENE-N
with	O
a	O
series	O
of	O
natural	O
product	O
polyphenols	B-CHEMICAL
and	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
.	O

A	O
series	O
of	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
and	O
phenol	B-CHEMICAL
natural	O
products	O
,	O
such	O
as	O
p	B-CHEMICAL
-	I-CHEMICAL
hydroxybenzoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
p	B-CHEMICAL
-	I-CHEMICAL
coumaric	I-CHEMICAL
acid	I-CHEMICAL
,	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
,	O
ferulic	B-CHEMICAL
acid	I-CHEMICAL
,	O
gallic	B-CHEMICAL
acid	I-CHEMICAL
,	O
syringic	B-CHEMICAL
acid	I-CHEMICAL
,	O
quercetin	B-CHEMICAL
,	O
and	O
ellagic	B-CHEMICAL
acid	I-CHEMICAL
,	O
were	O
investigated	O
for	O
their	O
inhibitory	O
effects	O
against	O
the	O
metalloenzyme	B-GENE-N
carbonic	B-GENE-N
anhydrase	I-GENE-N
(	O
CA	B-GENE-N
,	O
EC	B-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
.	O

All	O
mammalian	O
isozymes	O
of	O
human	O
(	O
h	O
)	O
or	O
murine	O
(	O
m	O
)	O
origin	O
hCA	B-GENE-Y
I	I-GENE-Y
-	O
hCA	B-GENE-Y
XII	I-GENE-Y
,	O
mCA	B-GENE-Y
XIII	I-GENE-Y
and	O
hCA	B-GENE-Y
XIV	I-GENE-Y
were	O
inhibited	O
in	O
the	O
low	O
micromolar	O
or	O
submicromolar	O
range	O
by	O
these	O
(	O
poly	O
)	O
phenols	O
(	O
K	O
(	O
I	O
)	O
s	O
in	O
the	O
range	O
of	O
0	O
.	O
87	O
-	O
7	O
.	O
79	O
microM	O
)	O
.	O

p	B-CHEMICAL
-	I-CHEMICAL
Hydroxybenzoic	I-CHEMICAL
acid	I-CHEMICAL
was	O
the	O
best	O
inhibitor	O
of	O
all	O
isozymes	O
(	O
K	O
(	O
I	O
)	O
s	O
of	O
0	O
.	O
87	O
-	O
35	O
.	O
4	O
microM	O
)	O
and	O
the	O
different	O
isozymes	O
showed	O
very	O
variable	O
inhibition	O
profiles	O
with	O
these	O
derivatives	O
.	O

Phenols	B-CHEMICAL
like	O
the	O
ones	O
investigated	O
here	O
possess	O
a	O
CA	B-GENE-N
inhibition	O
mechanism	O
distinct	O
of	O
that	O
of	O
the	O
sulfonamides	B-CHEMICAL
/	O
sulfamates	B-CHEMICAL
used	O
clinically	O
or	O
the	O
coumarins	B-CHEMICAL
.	O

Unlike	O
the	O
sulfonamides	B-CHEMICAL
,	O
which	O
bind	O
to	O
the	O
catalytic	O
zinc	B-CHEMICAL
ion	O
,	O
phenols	B-CHEMICAL
are	O
anchored	O
at	O
the	O
Zn	B-CHEMICAL
(	I-CHEMICAL
II	I-CHEMICAL
)	I-CHEMICAL
-	O
coordinated	O
water	O
molecule	O
and	O
bind	O
more	O
externally	O
within	O
the	O
active	O
site	O
cavity	O
,	O
making	O
contacts	O
with	O
various	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
.	O

As	O
this	O
is	O
the	O
region	O
with	O
the	O
highest	O
variability	O
between	O
the	O
many	O
CA	B-GENE-N
isozymes	O
found	O
in	O
mammals	O
,	O
this	O
class	O
of	O
compounds	O
may	O
lead	O
to	O
isoform	O
-	O
selective	O
inhibitors	O
targeting	O
just	O
one	O
or	O
few	O
of	O
the	O
medicinally	O
relevant	O
CAs	B-GENE-N
.	O

Autoradiographic	O
study	O
of	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
during	O
memory	O
formation	O
.	O

Serotonin	B-GENE-Y
transporter	I-GENE-Y
(	O
SERT	B-GENE-Y
)	O
has	O
been	O
associated	O
with	O
drugs	O
of	O
abuse	O
like	O
d	B-CHEMICAL
-	I-CHEMICAL
methamphetamine	I-CHEMICAL
(	O
METH	B-CHEMICAL
)	O
.	O

METH	B-CHEMICAL
is	O
well	O
known	O
to	O
produce	O
effects	O
on	O
the	O
monoamine	B-CHEMICAL
systems	O
but	O
it	O
is	O
unclear	O
how	O
METH	B-CHEMICAL
affects	O
SERT	B-GENE-Y
and	O
memory	O
.	O

Here	O
the	O
effects	O
of	O
METH	B-CHEMICAL
and	O
the	O
serotonin	B-CHEMICAL
reuptake	O
inhibitor	O
fluoxetine	B-CHEMICAL
(	O
FLX	B-CHEMICAL
)	O
on	O
autoshaping	O
and	O
novel	O
object	O
recognition	O
(	O
NOR	O
)	O
were	O
investigated	O
.	O

Notably	O
,	O
both	O
memory	O
tasks	O
recruit	O
different	O
behavioral	O
,	O
neural	O
and	O
cognitive	O
demand	O
.	O

In	O
autoshaping	O
task	O
a	O
dose	O
-	O
response	O
curve	O
for	O
METH	B-CHEMICAL
was	O
determined	O
.	O

METH	B-CHEMICAL
(	O
1	O
.	O
0mg	O
/	O
kg	O
)	O
impaired	O
short	O
-	O
term	O
memory	O
(	O
STM	O
;	O
lasting	O
less	O
of	O
90min	O
)	O
in	O
NOR	O
and	O
impaired	O
both	O
STM	O
and	O
long	O
-	O
term	O
memory	O
(	O
LTM	O
;	O
lasting	O
24	O
and	O
48h	O
)	O
in	O
autoshaping	O
,	O
indicating	O
that	O
METH	B-CHEMICAL
had	O
long	O
-	O
lasting	O
effects	O
in	O
the	O
latter	O
task	O
.	O

A	O
comparative	O
autoradiography	O
study	O
of	O
the	O
relationship	O
between	O
the	O
binding	O
pattern	O
of	O
SERT	B-GENE-Y
in	O
autoshaping	O
new	O
untrained	O
vs	O
.	O
trained	O
treated	O
(	O
METH	B-CHEMICAL
,	O
FLX	B-CHEMICAL
,	O
or	O
both	O
)	O
animals	O
was	O
made	O
.	O

Considering	O
that	O
hemispheric	O
dominance	O
is	O
important	O
for	O
LTM	O
,	O
hence	O
right	O
vs	O
.	O
left	O
hemisphere	O
of	O
the	O
brain	O
was	O
compared	O
.	O

Results	O
showed	O
that	O
trained	O
animals	O
decreased	O
cortical	O
SERT	B-GENE-Y
binding	O
relative	O
to	O
untrained	O
ones	O
.	O

In	O
untrained	O
and	O
trained	O
treated	O
animals	O
with	O
the	O
amnesic	O
dose	O
(	O
1	O
.	O
0mg	O
/	O
kg	O
)	O
of	O
METH	B-CHEMICAL
SERT	B-GENE-Y
binding	O
in	O
several	O
areas	O
including	O
hippocampus	O
and	O
cortex	O
decreased	O
,	O
more	O
remarkably	O
in	O
the	O
trained	O
animals	O
.	O

In	O
contrast	O
,	O
FLX	O
improved	O
memory	O
,	O
increased	O
SERT	B-GENE-Y
binding	O
,	O
prevented	O
the	O
METH	B-CHEMICAL
amnesic	O
effect	O
and	O
re	O
-	O
established	O
the	O
SERT	B-GENE-Y
binding	O
.	O

In	O
general	O
,	O
memory	O
and	O
amnesia	O
seemed	O
to	O
make	O
SERT	B-GENE-Y
more	O
vulnerable	O
to	O
drugs	O
effects	O
.	O

Effect	O
of	O
anabolic	O
-	O
androgenic	O
steroids	B-CHEMICAL
and	O
glucocorticoids	O
on	O
the	O
kinetics	O
of	O
hAR	B-GENE-Y
and	O
hGR	B-GENE-Y
nucleocytoplasmic	O
translocation	O
.	O

Although	O
the	O
qualitative	O
nucleocytoplasmic	O
transport	O
of	O
nuclear	B-GENE-N
hormone	I-GENE-N
receptors	I-GENE-N
(	O
NHRs	B-GENE-N
)	O
has	O
been	O
studied	O
,	O
there	O
is	O
little	O
documentation	O
of	O
the	O
cellular	O
kinetics	O
of	O
this	O
transport	O
.	O

Here	O
,	O
translocation	O
studies	O
using	O
the	O
human	B-GENE-Y
androgen	I-GENE-Y
receptor	I-GENE-Y
(	O
hAR	B-GENE-Y
)	O
and	O
the	O
human	B-GENE-Y
glucocorticoid	I-GENE-Y
receptor	I-GENE-Y
(	O
hGR	B-GENE-Y
)	O
were	O
performed	O
to	O
aid	O
in	O
identifying	O
the	O
mechanism	O
by	O
which	O
anabolic	O
-	O
androgenic	O
steroids	B-CHEMICAL
(	O
AAS	O
)	O
were	O
activating	O
hAR	B-GENE-Y
and	O
potentially	O
interacting	O
with	O
hGR	B-GENE-Y
and	O
how	O
glucocorticoid	O
ligands	O
were	O
interacting	O
with	O
the	O
hGR	B-GENE-Y
and	O
hAR	B-GENE-Y
.	O

The	O
real	O
-	O
time	O
analysis	O
of	O
EGFP	O
-	O
labeled	O
hAR	B-GENE-Y
and	O
hGR	B-GENE-Y
ligand	O
-	O
induced	O
cytoplasm	O
-	O
to	O
-	O
nucleus	O
translocation	O
was	O
performed	O
using	O
fluorescence	O
microscopy	O
to	O
better	O
understand	O
the	O
action	O
of	O
these	O
NHRs	B-GENE-N
in	O
a	O
physiologically	O
relevant	O
cell	O
-	O
based	O
model	O
.	O

After	O
transient	O
transfection	O
,	O
the	O
hAR	B-GENE-Y
and	O
hGR	B-GENE-Y
individually	O
translocate	O
as	O
expected	O
(	O
i	O
.	O
e	O
.	O
,	O
transport	O
is	O
ligand	O
-	O
induced	O
and	O
dose	O
-	O
dependent	O
)	O
in	O
this	O
model	O
biological	O
system	O
.	O

Testosterone	B-CHEMICAL
(	O
TEST	B-CHEMICAL
)	O
had	O
the	O
fastest	O
translocation	O
rate	O
for	O
the	O
hAR	B-GENE-Y
of	O
0	O
.	O
0525	O
min	O
(	O
-	O
1	O
)	O
.	O

The	O
other	O
endogenous	O
steroids	B-CHEMICAL
,	O
androstenedione	B-CHEMICAL
(	O
ANE	B-CHEMICAL
)	O
and	O
dihydrotestosterone	B-CHEMICAL
(	O
DHT	B-CHEMICAL
)	O
,	O
had	O
considerably	O
lower	O
hAR	B-GENE-Y
transport	O
rates	O
.	O

The	O
rates	O
of	O
hAR	B-GENE-Y
transport	O
for	O
the	O
exogenous	O
steroids	B-CHEMICAL
methyltrienelone	B-CHEMICAL
(	O
MET	B-CHEMICAL
)	O
,	O
nandrolone	B-CHEMICAL
(	O
NAN	B-CHEMICAL
)	O
,	O
and	O
oxandrolone	B-CHEMICAL
(	O
OXA	B-CHEMICAL
)	O
are	O
lower	O
than	O
that	O
of	O
testosterone	B-CHEMICAL
and	O
similar	O
to	O
those	O
of	O
the	O
endogenous	O
steroids	B-CHEMICAL
ANE	B-CHEMICAL
and	O
DHT	B-CHEMICAL
.	O

The	O
hGR	B-GENE-Y
transport	O
rates	O
for	O
cortisol	O
(	O
COR	O
)	O
and	O
dexamethasone	O
(	O
DEX	O
)	O
are	O
also	O
presented	O
.	O

The	O
synthetic	O
GC	O
,	O
DEX	O
,	O
had	O
a	O
more	O
rapid	O
translocation	O
rate	O
(	O
0	O
.	O
1599	O
min	O
(	O
-	O
1	O
)	O
)	O
at	O
the	O
highest	O
dose	O
of	O
100	O
nM	O
compared	O
to	O
the	O
endogenous	O
GC	O
COR	O
(	O
0	O
.	O
0431	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
data	O
obtained	O
agrees	O
with	O
the	O
existing	O
qualitative	O
data	O
and	O
adds	O
an	O
important	O
ligand	O
-	O
dependent	O
kinetic	O
component	O
to	O
hAR	B-GENE-Y
and	O
hGR	B-GENE-Y
transport	O
.	O

These	O
kinetic	O
data	O
can	O
aid	O
our	O
understanding	O
of	O
NHR	B-CHEMICAL
action	O
and	O
interaction	O
with	O
other	O
regulatory	O
proteins	O
,	O
and	O
can	O
be	O
useful	O
in	O
the	O
development	O
of	O
new	O
therapies	O
.	O

Increased	O
muscarinic	B-GENE-N
receptor	I-GENE-N
activity	O
of	O
airway	O
smooth	O
muscle	O
isolated	O
from	O
a	O
mouse	O
model	O
of	O
allergic	O
asthma	O
.	O

The	O
mechanisms	O
leading	O
to	O
airway	O
hyper	O
-	O
responsiveness	O
(	O
AHR	O
)	O
in	O
asthma	O
are	O
still	O
not	O
fully	O
understood	O
.	O

AHR	O
could	O
be	O
produced	O
by	O
hypersensitivity	O
of	O
the	O
airway	O
smooth	O
muscle	O
or	O
hyperreactivity	O
of	O
the	O
airways	O
.	O

This	O
study	O
was	O
conducted	O
to	O
ascertain	O
whether	O
AHR	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
is	O
produced	O
by	O
changes	O
at	O
the	O
level	O
of	O
the	O
airway	O
smooth	O
muscle	O
.	O

Airway	O
smooth	O
muscle	O
responses	O
were	O
characterised	O
in	O
vitro	O
in	O
isolated	O
trachea	O
spirals	O
from	O
naive	O
mice	O
and	O
from	O
an	O
acute	O
ovalbumin	B-GENE-Y
(	O
OVA	B-GENE-Y
)	O
challenge	O
model	O
of	O
allergic	O
asthma	O
.	O

AHR	O
was	O
investigated	O
in	O
vivo	O
in	O
conscious	O
,	O
freely	O
moving	O
mice	O
.	O

Inflammatory	O
cell	O
influx	O
into	O
the	O
lungs	O
and	O
antibody	O
responses	O
to	O
the	O
antigen	O
were	O
also	O
measured	O
.	O

In	O
vitro	O
study	O
of	O
tracheal	O
airway	O
smooth	O
muscle	O
from	O
naive	O
mice	O
demonstrated	O
concentration	O
-	O
related	O
contractions	O
to	O
methacholine	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
,	O
but	O
no	O
responses	O
to	O
histamine	B-CHEMICAL
or	O
adenosine	B-CHEMICAL
or	O
its	O
stable	O
analogue	O
,	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
ethyl	I-CHEMICAL
-	I-CHEMICAL
carboxamidoadenosine	I-CHEMICAL
.	O

The	O
contractions	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
were	O
inhibited	O
by	O
ketanserin	B-CHEMICAL
and	O
alosetron	B-CHEMICAL
indicating	O
involvement	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
3	I-GENE-Y
)	I-GENE-Y
receptors	O
,	O
respectively	O
.	O

In	O
an	O
acute	O
model	O
of	O
allergic	O
asthma	O
,	O
OVA	B-GENE-Y
-	O
treated	O
mice	O
were	O
shown	O
to	O
be	O
atopic	O
by	O
inflammatory	O
cell	O
influx	O
to	O
the	O
lungs	O
after	O
OVA	B-GENE-Y
challenge	O
,	O
increases	O
in	O
total	O
IgE	B-GENE-N
and	O
OVA	B-GENE-Y
-	O
specific	O
IgG	B-GENE-N
levels	O
and	O
contractions	O
to	O
OVA	B-GENE-Y
in	O
isolated	O
trachea	O
.	O

In	O
the	O
asthmatic	O
model	O
,	O
AHR	O
to	O
methacholine	B-CHEMICAL
was	O
demonstrated	O
in	O
conscious	O
,	O
freely	O
moving	O
mice	O
in	O
vivo	O
and	O
in	O
isolated	O
trachea	O
in	O
vitro	O
24	O
and	O
72h	O
after	O
OVA	B-GENE-Y
challenge	O
.	O

No	O
AHR	O
in	O
vitro	O
was	O
seen	O
for	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
,	O
histamine	B-CHEMICAL
or	O
adenosine	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
,	O
in	O
our	O
mouse	O
model	O
of	O
asthma	O
,	O
changes	O
occur	O
at	O
the	O
level	O
of	O
the	O
muscarinic	B-GENE-N
receptor	I-GENE-N
transduction	O
pathway	O
of	O
coupling	O
to	O
airway	O
smooth	O
muscle	O
contraction	O
.	O

These	O
changes	O
are	O
maintained	O
when	O
tissues	O
are	O
removed	O
from	O
the	O
inflammatory	O
environment	O
and	O
for	O
at	O
least	O
3	O
days	O
.	O

Immunohistochemical	O
characterization	O
of	O
pyrimidine	B-CHEMICAL
synthetic	O
enzymes	O
,	O
thymidine	B-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
,	O
in	O
various	O
types	O
of	O
cancer	O
.	O

Thymidine	B-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
and	O
thymidylate	B-GENE-Y
synthase	I-GENE-Y
(	O
TS	B-GENE-Y
)	O
are	O
key	O
enzymes	O
for	O
salvage	O
and	O
de	O
novo	O
pyrimidine	B-CHEMICAL
synthesis	O
,	O
respectively	O
.	O

Numerous	O
studies	O
have	O
suggested	O
that	O
increased	O
TS	B-GENE-Y
levels	O
are	O
associated	O
closely	O
with	O
resistance	O
to	O
fluoropyrimidine	B-CHEMICAL
-	O
based	O
chemotherapy	O
.	O

TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
is	O
a	O
novel	O
drug	O
containing	O
trifluorothymidine	B-CHEMICAL
,	O
which	O
is	O
phosphorylated	O
by	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
to	O
its	O
active	O
monophosphated	O
form	O
,	O
that	O
in	O
turn	O
can	O
inhibit	O
TS	B-GENE-Y
.	O

TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
has	O
been	O
shown	O
to	O
exhibit	O
antitumor	O
activity	O
in	O
fluoropyrimidine	B-CHEMICAL
-	O
resistant	O
human	O
cancer	O
cells	O
.	O

TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
is	O
currently	O
undergoing	O
clinical	O
trials	O
for	O
use	O
in	O
gastrointestinal	O
cancers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
immunohistochemistry	O
to	O
investigate	O
the	O
expression	O
of	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
TS	B-GENE-Y
in	O
various	O
types	O
of	O
cancer	O
.	O

TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
TS	B-GENE-Y
expression	O
was	O
markedly	O
different	O
between	O
cancer	O
types	O
.	O

High	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
was	O
detected	O
prominently	O
in	O
gastrointestinal	O
adenocarcinomas	O
and	O
esophageal	O
and	O
uterine	O
squamous	O
cell	O
carcinomas	O
.	O

Gastrointestinal	O
adenocarcinomas	O
and	O
squamous	O
cell	O
uterine	O
carcinomas	O
were	O
often	O
accompanied	O
by	O
high	O
TS	B-GENE-Y
expression	O
,	O
indicating	O
activation	O
of	O
pyrimidine	B-CHEMICAL
synthesis	O
through	O
both	O
the	O
salvage	O
and	O
de	O
novo	O
pathways	O
.	O

These	O
results	O
led	O
us	O
to	O
consider	O
that	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
may	O
also	O
be	O
effective	O
for	O
esophageal	O
and	O
uterine	O
squamous	O
cell	O
carcinomas	O
,	O
as	O
well	O
as	O
for	O
gastrointestinal	O
adenocarcinomas	O
,	O
even	O
in	O
fluoropyrimidine	B-CHEMICAL
-	O
resistant	O
cases	O
with	O
high	O
TS	B-GENE-Y
expression	O
.	O

In	O
contrast	O
,	O
thyroid	O
papillary	O
carcinomas	O
,	O
lung	O
adenocarcinomas	O
,	O
hepatocellular	O
carcinomas	O
,	O
pancreatic	O
ductal	O
carcinomas	O
,	O
and	O
renal	O
cell	O
carcinomas	O
,	O
which	O
exhibit	O
low	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
,	O
may	O
be	O
resistant	O
to	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
.	O

In	O
non	O
-	O
small	O
cell	O
lung	O
cancers	O
,	O
high	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
was	O
demonstrated	O
in	O
squamous	O
cell	O
carcinomas	O
,	O
but	O
not	O
in	O
adenocarcinomas	O
.	O

This	O
result	O
suggests	O
that	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
efficacy	O
and	O
the	O
pyrimidine	B-CHEMICAL
synthetic	O
pathway	O
may	O
differ	O
depending	O
on	O
histological	O
type	O
.	O

Our	O
results	O
indicate	O
that	O
administration	O
of	O
TAS	B-CHEMICAL
-	I-CHEMICAL
102	I-CHEMICAL
could	O
be	O
selected	O
on	O
the	O
basis	O
of	O
the	O
immunohistochemical	O
evaluation	O
of	O
TK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
TS	B-GENE-Y
.	O

Phenothiazines	B-CHEMICAL
inhibit	O
S100A4	B-GENE-Y
function	O
by	O
inducing	O
protein	O
oligomerization	O
.	O

S100A4	B-GENE-Y
,	O
a	O
member	O
of	O
the	O
S100	B-GENE-N
family	O
of	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
binding	O
proteins	O
,	O
regulates	O
carcinoma	O
cell	O
motility	O
via	O
interactions	O
with	O
myosin	B-GENE-Y
-	I-GENE-Y
IIA	I-GENE-Y
.	O

Numerous	O
studies	O
indicate	O
that	O
S100A4	B-GENE-Y
is	O
not	O
simply	O
a	O
marker	O
for	O
metastatic	O
disease	O
,	O
but	O
rather	O
has	O
a	O
direct	O
role	O
in	O
metastatic	O
progression	O
.	O

These	O
observations	O
suggest	O
that	O
S100A4	B-GENE-Y
is	O
an	O
excellent	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Using	O
a	O
unique	O
biosensor	O
-	O
based	O
assay	O
,	O
trifluoperazine	B-CHEMICAL
(	O
TFP	B-CHEMICAL
)	O
was	O
identified	O
as	O
an	O
inhibitor	O
that	O
disrupts	O
the	O
S100A4	B-GENE-Y
/	O
myosin	B-GENE-Y
-	I-GENE-Y
IIA	I-GENE-Y
interaction	O
.	O

To	O
examine	O
the	O
interaction	O
of	O
S100A4	B-GENE-Y
with	O
TFP	B-CHEMICAL
,	O
we	O
determined	O
the	O
2	O
.	O
3	O
A	O
crystal	O
structure	O
of	O
human	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
S100A4	B-GENE-Y
bound	O
to	O
TFP	B-CHEMICAL
.	O

Two	O
TFP	B-CHEMICAL
molecules	O
bind	O
within	O
the	O
hydrophobic	O
target	O
binding	O
pocket	O
of	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
S100A4	B-GENE-Y
with	O
no	O
significant	O
conformational	O
changes	O
observed	O
in	O
the	O
protein	O
upon	O
complex	O
formation	O
.	O

NMR	O
chemical	O
shift	O
perturbations	O
are	O
consistent	O
with	O
the	O
crystal	O
structure	O
and	O
demonstrate	O
that	O
TFP	B-CHEMICAL
binds	O
to	O
the	O
target	O
binding	O
cleft	O
of	O
S100A4	B-GENE-Y
in	O
solution	O
.	O

Remarkably	O
,	O
TFP	B-CHEMICAL
binding	O
results	O
in	O
the	O
assembly	O
of	O
five	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
S100A4	B-GENE-Y
/	O
TFP	O
dimers	O
into	O
a	O
tightly	O
packed	O
pentameric	O
ring	O
.	O

Within	O
each	O
pentamer	O
most	O
of	O
the	O
contacts	O
between	O
S100A4	B-GENE-Y
dimers	O
occurs	O
through	O
the	O
TFP	B-CHEMICAL
moieties	O
.	O

The	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
S100A4	B-GENE-Y
/	O
prochlorperazine	B-CHEMICAL
(	O
PCP	B-CHEMICAL
)	O
complex	O
exhibits	O
a	O
similar	O
pentameric	O
assembly	O
.	O

Equilibrium	O
sedimentation	O
and	O
cross	O
-	O
linking	O
studies	O
demonstrate	O
the	O
cooperative	O
formation	O
of	O
a	O
similarly	O
sized	O
S100A4	B-GENE-Y
/	O
TFP	B-CHEMICAL
oligomer	O
in	O
solution	O
.	O

Assays	O
examining	O
the	O
ability	O
of	O
TFP	B-CHEMICAL
to	O
block	O
S100A4	B-GENE-Y
-	O
mediated	O
disassembly	O
of	O
myosin	B-GENE-Y
-	I-GENE-Y
IIA	I-GENE-Y
filaments	O
demonstrate	O
that	O
significant	O
inhibition	O
of	O
S100A4	B-GENE-Y
function	O
occurs	O
only	O
at	O
TFP	B-CHEMICAL
concentrations	O
that	O
promote	O
S100A4	B-GENE-Y
oligomerization	O
.	O

Together	O
these	O
studies	O
support	O
a	O
unique	O
mode	O
of	O
inhibition	O
in	O
which	O
phenothiazines	B-CHEMICAL
disrupt	O
the	O
S100A4	B-GENE-Y
/	O
myosin	B-GENE-Y
-	I-GENE-Y
IIA	I-GENE-Y
interaction	O
by	O
sequestering	O
S100A4	B-GENE-Y
via	O
small	O
molecule	O
-	O
induced	O
oligomerization	O
.	O

Rapid	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
inhibition	O
of	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
ultradian	O
activity	O
in	O
healthy	O
males	O
.	O

A	O
complex	O
dynamic	O
ultradian	O
rhythm	O
underlies	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
circadian	O
rhythm	O
.	O

We	O
have	O
investigated	O
in	O
normal	O
human	O
male	O
subjects	O
the	O
importance	O
,	O
site	O
of	O
action	O
,	O
and	O
receptor	O
-	O
mediated	O
processes	O
involved	O
in	O
rapid	O
basal	O
corticosteroid	B-CHEMICAL
feedback	O
and	O
its	O
interaction	O
with	O
corticotrophin	B-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	O
CRH	B-GENE-Y
)	O
drive	O
.	O

Pro	B-GENE-Y
-	I-GENE-Y
opiomelanocortin	I-GENE-Y
(	O
POMC	B-GENE-Y
)	O
,	O
ACTH	O
,	O
and	O
cortisol	O
were	O
measured	O
every	O
10	O
min	O
from	O
healthy	O
males	O
during	O
the	O
awakening	O
period	O
or	O
late	O
afternoon	O
using	O
an	O
automated	O
blood	O
sampling	O
system	O
.	O

Mathematical	O
modeling	O
into	O
discrete	O
pulses	O
of	O
activity	O
revealed	O
that	O
intravenous	O
infusion	O
of	O
the	O
synthetic	O
mixed	O
glucocorticoid	O
/	O
mineralocorticoid	O
agonist	O
prednisolone	B-CHEMICAL
produced	O
rapid	O
inhibition	O
of	O
ACTH	O
and	O
cortisol	B-CHEMICAL
pulsatility	O
within	O
30	O
min	O
in	O
the	O
morning	O
and	O
afternoon	O
.	O

Any	O
pulse	O
that	O
had	O
commenced	O
at	O
the	O
time	O
of	O
injection	O
was	O
unaffected	O
,	O
and	O
subsequent	O
pulsatility	O
was	O
inhibited	O
.	O

Prednisolone	B-CHEMICAL
also	O
inhibited	O
ACTH	O
and	O
cortisol	B-CHEMICAL
secretion	O
in	O
response	O
to	O
exogenous	O
CRH	B-GENE-Y
stimulation	O
,	O
inferring	O
rapid	O
feedback	O
inhibition	O
at	O
the	O
anterior	O
pituitary	O
.	O

Circulating	O
POMC	B-GENE-Y
peptide	O
concentrations	O
were	O
unaffected	O
,	O
suggesting	O
that	O
the	O
rapid	O
corticosteroid	B-CHEMICAL
inhibitory	O
effect	O
specifically	O
targeted	O
ACTH	O
secretion	O
from	O
pituitary	O
corticotrophs	O
.	O

Prednisolone	B-CHEMICAL
fast	O
feedback	O
was	O
only	O
reduced	O
by	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
pretreatment	O
and	O
not	O
by	O
mineralocorticoid	B-GENE-Y
receptor	I-GENE-Y
antagonism	O
,	O
suggesting	O
a	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
pathway	O
.	O

The	O
intravenous	O
prednisolone	B-CHEMICAL
suppression	O
test	O
provides	O
a	O
powerful	O
new	O
tool	O
to	O
investigate	O
HPA	O
abnormalities	O
underlying	O
metabolic	O
and	O
psychiatric	O
disease	O
states	O
.	O

The	O
role	O
of	O
rasagiline	B-CHEMICAL
in	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
.	O

Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
is	O
the	O
second	O
most	O
common	O
neurodegenerative	O
disorder	O
,	O
affecting	O
1	O
%	O
to	O
2	O
%	O
of	O
people	O
older	O
than	O
60	O
years	O
.	O

Treatment	O
of	O
PD	O
consists	O
of	O
symptomatic	O
therapies	O
while	O
neuroprotective	O
strategies	O
have	O
remained	O
elusive	O
.	O

Rasagiline	B-CHEMICAL
is	O
a	O
novel	O
,	O
potent	O
,	O
and	O
irreversible	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
type	I-GENE-Y
B	I-GENE-Y
(	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
)	O
inhibitor	O
which	O
has	O
been	O
approved	O
for	O
treatment	O
of	O
PD	O
.	O

Rasagiline	B-CHEMICAL
inhibits	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
more	O
potently	O
than	O
selegiline	O
and	O
has	O
the	O
advantage	O
of	O
once	O
-	O
daily	O
dosing	O
.	O

In	O
several	O
large	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trials	O
,	O
rasagiline	B-CHEMICAL
has	O
demonstrated	O
efficacy	O
as	O
monotherapy	O
in	O
early	O
PD	O
and	O
as	O
adjunctive	O
therapy	O
in	O
advanced	O
PD	O
.	O

In	O
addition	O
,	O
rasagiline	B-CHEMICAL
has	O
been	O
shown	O
to	O
have	O
neuroprotective	O
effects	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
.	O

The	O
recently	O
completed	O
delayed	O
-	O
start	O
ADAGIO	O
(	O
Attenuation	O
of	O
Disease	O
Progression	O
with	O
Azilect	O
Given	O
Once	O
-	O
daily	O
)	O
trial	O
suggests	O
a	O
potential	O
disease	O
-	O
modifying	O
effect	O
for	O
rasagiline	B-CHEMICAL
1	O
mg	O
/	O
day	O
,	O
though	O
the	O
clinical	O
import	O
of	O
this	O
finding	O
has	O
yet	O
to	O
be	O
established	O
.	O

Everolimus	B-CHEMICAL
:	O
the	O
first	O
approved	O
product	O
for	O
patients	O
with	O
advanced	O
renal	O
cell	O
cancer	O
after	O
sunitinib	B-CHEMICAL
and	O
/	O
or	O
sorafenib	B-CHEMICAL
.	O

Everolimus	B-CHEMICAL
(	O
RAD001	B-CHEMICAL
,	O
Afinitor	B-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
)	I-CHEMICAL
Novartis	I-CHEMICAL
)	O
is	O
the	O
first	O
oral	O
inhibitor	O
of	O
mTOR	B-GENE-Y
(	O
mammalian	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
)	O
to	O
reach	O
the	O
oncology	O
clinic	O
.	O

Everolimus	B-CHEMICAL
10	O
mg	O
daily	O
achieves	O
complete	O
inhibition	O
of	O
its	O
target	O
at	O
below	O
the	O
maximum	O
tolerable	O
dose	O
for	O
most	O
patients	O
.	O

A	O
phase	O
III	O
randomized	O
placebo	O
-	O
controlled	O
trial	O
has	O
examined	O
the	O
impact	O
of	O
everolimus	B-CHEMICAL
in	O
patients	O
with	O
clear	O
cell	O
renal	O
cancers	O
and	O
progressive	O
disease	O
on	O
or	O
within	O
6	O
months	O
of	O
the	O
VEGFR	B-GENE-N
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitors	O
sunitinib	B-CHEMICAL
and	O
/	O
or	O
sorafenib	B-CHEMICAL
.	O

The	O
primary	O
endpoint	O
of	O
progression	O
-	O
free	O
survival	O
was	O
increased	O
from	O
median	O
1	O
.	O
9	O
to	O
4	O
.	O
9	O
months	O
(	O
hazard	O
ratio	O
0	O
.	O
33	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
25	O
%	O
were	O
still	O
progression	O
-	O
free	O
after	O
10	O
months	O
of	O
everolimus	B-CHEMICAL
therapy	O
.	O

There	O
was	O
a	O
delay	O
in	O
time	O
to	O
decline	O
of	O
performance	O
status	O
and	O
trends	O
to	O
improvement	O
in	O
quality	O
of	O
life	O
,	O
disease	O
-	O
related	O
symptoms	O
,	O
and	O
overall	O
survival	O
despite	O
crossover	O
of	O
the	O
majority	O
of	O
patients	O
assigned	O
to	O
placebo	O
.	O

In	O
2009	O
,	O
everolimus	B-CHEMICAL
was	O
approved	O
in	O
the	O
US	O
and	O
Europe	O
as	O
the	O
only	O
validated	O
option	O
for	O
this	O
indication	O
.	O

Toxicities	O
are	O
usually	O
mild	O
to	O
moderate	O
and	O
can	O
be	O
managed	O
with	O
dose	O
reduction	O
or	O
interruption	O
if	O
necessary	O
.	O

Opportunistic	O
infections	O
and	O
non	O
-	O
infectious	O
pneumonitis	O
are	O
seen	O
as	O
a	O
class	O
effect	O
.	O

Management	O
of	O
common	O
practical	O
management	O
issues	O
are	O
discussed	O
.	O

Clinical	O
trials	O
are	O
in	O
progress	O
to	O
examine	O
additional	O
roles	O
for	O
everolimus	B-CHEMICAL
in	O
renal	O
cancer	O
,	O
alone	O
and	O
in	O
combination	O
with	O
other	O
agents	O
.	O

Hormonal	O
therapy	O
of	O
prostate	O
cancer	O
.	O

Of	O
all	O
cancers	O
,	O
prostate	O
cancer	O
is	O
the	O
most	O
sensitive	O
to	O
hormones	O
:	O
it	O
is	O
thus	O
very	O
important	O
to	O
take	O
advantage	O
of	O
this	O
unique	O
property	O
and	O
to	O
always	O
use	O
optimal	O
androgen	B-CHEMICAL
blockade	O
when	O
hormone	O
therapy	O
is	O
the	O
appropriate	O
treatment	O
.	O

A	O
fundamental	O
observation	O
is	O
that	O
the	O
serum	O
testosterone	B-CHEMICAL
concentration	O
only	O
reflects	O
the	O
amount	O
of	O
testosterone	B-CHEMICAL
of	O
testicular	O
origin	O
which	O
is	O
released	O
in	O
the	O
blood	O
from	O
which	O
it	O
reaches	O
all	O
tissues	O
.	O

Recent	O
data	O
show	O
,	O
however	O
,	O
that	O
an	O
approximately	O
equal	O
amount	O
of	O
testosterone	B-CHEMICAL
is	O
made	O
from	O
dehydroepiandrosterone	B-CHEMICAL
(	O
DHEA	B-CHEMICAL
)	O
directly	O
in	O
the	O
peripheral	O
tissues	O
,	O
including	O
the	O
prostate	O
,	O
and	O
does	O
not	O
appear	O
in	O
the	O
blood	O
.	O

Consequently	O
,	O
after	O
castration	O
,	O
the	O
95	O
-	O
97	O
%	O
fall	O
in	O
serum	O
testosterone	B-CHEMICAL
does	O
not	O
reflect	O
the	O
40	O
-	O
50	O
%	O
testosterone	B-CHEMICAL
(	O
testo	B-CHEMICAL
)	O
and	O
dihydrotestosterone	B-CHEMICAL
(	O
DHT	B-CHEMICAL
)	O
made	O
locally	O
in	O
the	O
prostate	O
from	O
DHEA	B-CHEMICAL
of	O
adrenal	O
origin	O
.	O

In	O
fact	O
,	O
while	O
elimination	O
of	O
testicular	O
androgens	B-CHEMICAL
by	O
castration	O
alone	O
has	O
never	O
been	O
shown	O
to	O
prolong	O
life	O
in	O
metastatic	O
prostate	O
cancer	O
,	O
combination	O
of	O
castration	O
(	O
surgical	O
or	O
medical	O
with	O
a	O
gonadotropin	B-CHEMICAL
-	I-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
(	O
GnRH	B-CHEMICAL
)	O
agonist	O
)	O
with	O
a	O
pure	O
anti	O
-	O
androgen	B-CHEMICAL
has	O
been	O
the	O
first	O
treatment	O
shown	O
to	O
prolong	O
life	O
.	O

Most	O
importantly	O
,	O
when	O
applied	O
at	O
the	O
localized	O
stage	O
,	O
the	O
same	O
combined	O
androgen	B-CHEMICAL
blockade	O
(	O
CAB	O
)	O
can	O
provide	O
long	O
-	O
term	O
control	O
or	O
cure	O
of	O
the	O
disease	O
in	O
more	O
than	O
90	O
%	O
of	O
cases	O
.	O

Obviously	O
,	O
since	O
prostate	O
cancer	O
usually	O
grows	O
and	O
metastasizes	O
without	O
signs	O
or	O
symptoms	O
,	O
screening	O
with	O
prostate	B-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
antigen	I-GENE-Y
(	O
PSA	B-GENE-Y
)	O
is	O
absolutely	O
needed	O
to	O
diagnose	O
prostate	O
cancer	O
at	O
an	O
'	O
early	O
'	O
stage	O
before	O
metastasis	O
occurs	O
and	O
the	O
cancer	O
becomes	O
non	O
-	O
curable	O
.	O

While	O
the	O
role	O
of	O
androgens	B-CHEMICAL
was	O
believed	O
to	O
have	O
become	O
non	O
-	O
significant	O
in	O
cancer	O
progressing	O
under	O
any	O
form	O
of	O
androgen	B-CHEMICAL
blockade	O
,	O
recent	O
data	O
have	O
shown	O
increased	O
expression	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
in	O
treatment	O
-	O
resistant	O
disease	O
with	O
a	O
benefit	O
of	O
further	O
androgen	B-CHEMICAL
blockade	O
.	O

Since	O
the	O
available	O
anti	O
-	O
androgens	B-CHEMICAL
have	O
low	O
affinity	O
for	O
AR	B-GENE-Y
and	O
cannot	O
block	O
androgen	B-CHEMICAL
action	O
completely	O
,	O
especially	O
in	O
the	O
presence	O
of	O
increased	O
AR	B-GENE-Y
levels	O
,	O
it	O
becomes	O
important	O
to	O
discover	O
more	O
potent	O
and	O
purely	O
antagonistic	O
blockers	O
of	O
AR	B-GENE-Y
.	O

The	O
data	O
obtained	O
with	O
compounds	O
under	O
development	O
are	O
promising	O
.	O

While	O
waiting	O
for	O
this	O
(	O
these	O
)	O
new	O
anti	O
-	O
androgen	B-CHEMICAL
(	I-CHEMICAL
s	I-CHEMICAL
)	I-CHEMICAL
,	O
combined	O
treatment	O
with	O
castration	O
and	O
a	O
pure	O
anti	O
-	O
androgen	B-CHEMICAL
(	O
bicalutamide	B-CHEMICAL
,	O
flutamide	B-CHEMICAL
or	O
nilutamide	B-CHEMICAL
)	O
is	O
the	O
only	O
available	O
and	O
the	O
best	O
scientifically	O
based	O
means	O
of	O
treating	O
prostate	O
cancer	O
by	O
hormone	O
therapy	O
at	O
any	O
stage	O
of	O
the	O
disease	O
with	O
the	O
optimal	O
chance	O
of	O
success	O
and	O
even	O
cure	O
in	O
localized	O
disease	O
.	O

Predicting	O
cardiomyopathic	O
phenotypes	O
by	O
altering	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
affinity	O
of	O
cardiac	B-GENE-Y
troponin	I-GENE-Y
C	I-GENE-Y
.	O

Cardiac	O
diseases	O
associated	O
with	O
mutations	O
in	O
troponin	B-GENE-N
subunits	O
include	O
hypertrophic	O
cardiomyopathy	O
(	O
HCM	O
)	O
,	O
dilated	O
cardiomyopathy	O
(	O
DCM	O
)	O
,	O
and	O
restrictive	O
cardiomyopathy	O
(	O
RCM	O
)	O
.	O

Altered	O
calcium	O
handling	O
in	O
these	O
diseases	O
is	O
evidenced	O
by	O
changes	O
in	O
the	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
of	O
contraction	O
.	O

Mutations	O
in	O
the	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensor	O
,	O
troponin	B-GENE-Y
C	I-GENE-Y
(	O
TnC	B-GENE-Y
)	O
,	O
were	O
generated	O
to	O
increase	O
/	O
decrease	O
the	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
of	O
cardiac	O
skinned	O
fibers	O
to	O
create	O
the	O
characteristic	O
effects	O
of	O
DCM	O
,	O
HCM	O
,	O
and	O
RCM	O
.	O

We	O
also	O
used	O
a	O
reconstituted	O
assay	O
to	O
determine	O
the	O
mutation	O
effects	O
on	O
ATPase	B-GENE-N
activation	O
and	O
inhibition	O
.	O

One	O
mutant	O
(	O
A23Q	B-GENE-N
)	O
was	O
found	O
with	O
HCM	O
-	O
like	O
properties	O
(	O
increased	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
of	O
force	O
and	O
normal	O
levels	O
of	O
ATPase	B-GENE-N
inhibition	O
)	O
.	O

Three	O
mutants	O
(	O
S37G	B-GENE-N
,	O
V44Q	B-GENE-N
,	O
and	O
L48Q	B-GENE-N
)	O
were	O
identified	O
with	O
RCM	O
-	O
like	O
properties	O
(	O
a	O
large	O
increase	O
in	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
,	O
partial	O
loss	O
of	O
ATPase	B-GENE-N
inhibition	O
,	O
and	O
increased	O
basal	O
force	O
)	O
.	O

Two	O
mutations	O
were	O
identified	O
(	O
E40A	B-GENE-N
and	O
I61Q	B-GENE-N
)	O
with	O
DCM	O
properties	O
(	O
decreased	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
,	O
maximal	O
force	O
recovery	O
,	O
and	O
activation	O
of	O
the	O
ATPase	B-GENE-N
at	O
high	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
)	O
.	O

Steady	O
-	O
state	O
fluorescence	O
was	O
utilized	O
to	O
assess	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
affinity	O
in	O
isolated	O
cardiac	B-GENE-Y
(	I-GENE-Y
c	I-GENE-Y
)	I-GENE-Y
TnCs	I-GENE-Y
containing	O
F27W	B-GENE-N
and	O
did	O
not	O
necessarily	O
mirror	O
the	O
fiber	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
.	O

Circular	O
dichroism	O
of	O
mutant	O
cTnCs	B-GENE-Y
revealed	O
a	O
trend	O
where	O
increased	O
alpha	O
-	O
helical	O
content	O
correlated	O
with	O
increased	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
in	O
skinned	O
fibers	O
and	O
vice	O
versa	O
.	O

The	O
main	O
findings	O
from	O
this	O
study	O
were	O
as	O
follows	O
:	O
1	O
)	O
cTnC	B-GENE-Y
mutants	O
demonstrated	O
distinct	O
functional	O
phenotypes	O
reminiscent	O
of	O
bona	O
fide	O
HCM	O
,	O
RCM	O
,	O
and	O
DCM	O
mutations	O
;	O
2	O
)	O
a	O
region	O
in	O
cTnC	B-GENE-Y
associated	O
with	O
increased	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
in	O
skinned	O
fibers	O
was	O
identified	O
;	O
and	O
3	O
)	O
the	O
F27W	B-GENE-N
reporter	O
mutation	O
affected	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
sensitivity	O
,	O
maximal	O
force	O
,	O
and	O
ATPase	B-GENE-N
activation	O
of	O
some	O
mutants	O
.	O

Histamine	B-GENE-Y
H4	I-GENE-Y
receptor	I-GENE-Y
antagonism	O
diminishes	O
existing	O
airway	O
inflammation	O
and	O
dysfunction	O
via	O
modulation	O
of	O
Th2	B-GENE-N
cytokines	I-GENE-N
.	O

BACKGROUND	O
:	O
Airway	O
remodeling	O
and	O
dysfunction	O
are	O
characteristic	O
features	O
of	O
asthma	O
thought	O
to	O
be	O
caused	O
by	O
aberrant	O
production	O
of	O
Th2	B-GENE-N
cytokines	I-GENE-N
.	O

Histamine	B-GENE-Y
H4	I-GENE-Y
receptor	I-GENE-Y
(	O
H4R	B-GENE-Y
)	O
perturbation	O
has	O
previously	O
been	O
shown	O
to	O
modify	O
acute	O
inflammation	O
and	O
Th2	B-GENE-N
cytokine	I-GENE-N
production	O
in	O
a	O
murine	O
model	O
of	O
asthma	O
.	O

We	O
examined	O
the	O
ability	O
of	O
H4R	B-GENE-Y
antagonists	O
to	O
therapeutically	O
modify	O
the	O
effects	O
of	O
Th2	B-GENE-N
cytokine	I-GENE-N
production	O
such	O
as	O
goblet	O
cell	O
hyperplasia	O
(	O
GCH	O
)	O
,	O
and	O
collagen	B-GENE-N
deposition	O
in	O
a	O
sub	O
-	O
chronic	O
model	O
of	O
asthma	O
.	O

In	O
addition	O
,	O
effects	O
on	O
Th2	O
mediated	O
lung	O
dysfunction	O
were	O
also	O
determined	O
.	O

METHODS	O
:	O
Mice	O
were	O
sensitized	O
to	O
ovalbumin	B-GENE-Y
(	O
OVA	B-GENE-Y
)	O
followed	O
by	O
repeated	O
airway	O
challenge	O
with	O
OVA	B-GENE-Y
.	O

After	O
inflammation	O
was	O
established	O
mice	O
were	O
dosed	O
with	O
the	O
H4R	B-GENE-Y
antagonist	O
,	O
JNJ	B-CHEMICAL
7777120	I-CHEMICAL
,	O
or	O
anti	O
-	O
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
antibody	O
for	O
comparison	O
.	O

Airway	O
hyperreactivity	O
(	O
AHR	O
)	O
was	O
measured	O
,	O
lungs	O
lavaged	O
and	O
tissues	O
collected	O
for	O
analysis	O
.	O

RESULTS	O
:	O
Therapeutic	O
H4R	B-GENE-Y
antagonism	O
inhibited	O
T	O
cell	O
infiltration	O
in	O
to	O
the	O
lung	O
and	O
decreased	O
Th2	B-GENE-N
cytokines	I-GENE-N
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
.	O

IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
dependent	O
remodeling	O
parameters	O
such	O
as	O
GCH	O
and	O
lung	O
collagen	B-GENE-N
were	O
reduced	O
.	O

Intervention	O
with	O
H4R	B-GENE-Y
antagonist	O
also	O
improved	O
measures	O
of	O
central	O
and	O
peripheral	O
airway	O
dysfunction	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
demonstrate	O
that	O
therapeutic	O
H4R	B-GENE-Y
antagonism	O
can	O
significantly	O
ameliorate	O
allergen	O
induced	O
,	O
Th2	B-GENE-N
cytokine	I-GENE-N
driven	O
pathologies	O
such	O
as	O
lung	O
remodeling	O
and	O
airway	O
dysfunction	O
.	O

The	O
ability	O
of	O
H4R	B-GENE-Y
antagonists	O
to	O
affect	O
these	O
key	O
manifestations	O
of	O
asthma	O
suggests	O
their	O
potential	O
as	O
novel	O
human	O
therapeutics	O
.	O

Moxifloxacin	B-CHEMICAL
enhances	O
etoposide	B-CHEMICAL
-	O
induced	O
cytotoxic	O
,	O
apoptotic	O
and	O
anti	O
-	O
topoisomerase	B-GENE-Y
II	I-GENE-Y
effects	O
in	O
a	O
human	O
colon	O
carcinoma	O
cell	O
line	O
.	O

Etoposide	B-CHEMICAL
(	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
)	O
is	O
a	O
topoisomerase	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
(	O
topo	B-GENE-Y
II	I-GENE-Y
)	O
inhibitor	O
chemotherapeutic	O
agent	O
.	O

Studies	O
have	O
shown	O
that	O
a	O
combination	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
with	O
other	O
drugs	O
demonstrates	O
better	O
clinical	O
responses	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moxifloxacin	B-CHEMICAL
(	O
MXF	B-CHEMICAL
)	O
and	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
on	O
cellular	O
topo	B-GENE-Y
II	I-GENE-Y
activity	O
in	O
drug	O
-	O
treated	O
cells	O
and	O
evaluate	O
the	O
influence	O
of	O
MXF	B-CHEMICAL
on	O
the	O
mode	O
of	O
action	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
,	O
on	O
proliferation	O
and	O
apoptosis	O
of	O
HT	O
-	O
29	O
cells	O
.	O

Decatenation	O
assay	O
,	O
band	O
depletion	O
and	O
Western	O
blot	O
analysis	O
,	O
cytotoxic	O
assay	O
(	O
MTT	B-CHEMICAL
)	O
,	O
flow	O
cytometric	O
studies	O
(	O
cell	O
cycle	O
and	O
survivin	O
expression	O
)	O
,	O
apoptosis	O
(	O
DAPI	B-CHEMICAL
-	O
sulforhodamine	B-CHEMICAL
staining	O
and	O
caspase	B-GENE-Y
3	I-GENE-Y
activity	O
)	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
and	O
VEGF	B-GENE-Y
secretion	O
were	O
determined	O
.	O

MXF	B-CHEMICAL
or	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
slightly	O
affected	O
cellular	O
topo	B-GENE-Y
II	I-GENE-Y
activity	O
in	O
nuclear	O
extracts	O
derived	O
from	O
drug	O
-	O
treated	O
cells	O
while	O
the	O
combination	O
enhanced	O
inhibitory	O
activity	O
and	O
the	O
reduction	O
in	O
band	O
depletion	O
of	O
topo	B-GENE-Y
II	I-GENE-Y
.	O

VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
induced	O
cell	O
cycle	O
arrest	O
at	O
G2	O
/	O
M	O
and	O
the	O
appearance	O
of	O
the	O
subG1	O
peak	O
which	O
was	O
increased	O
by	O
the	O
addition	O
of	O
MXF	B-CHEMICAL
.	O

Apoptosis	O
studies	O
(	O
DAPI	B-CHEMICAL
staining	O
and	O
caspase	B-GENE-Y
3	I-GENE-Y
activity	O
)	O
showed	O
a	O
marked	O
increase	O
in	O
the	O
presence	O
of	O
MXF	B-CHEMICAL
and	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
compared	O
to	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
alone	O
.	O

VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
induced	O
the	O
release	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
and	O
addition	O
of	O
MXF	B-CHEMICAL
reduced	O
enhanced	O
release	O
and	O
the	O
spontaneous	O
release	O
of	O
VEGF	B-GENE-Y
from	O
the	O
cells	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
suggest	O
that	O
the	O
enhancement	O
in	O
the	O
reduction	O
of	O
topo	B-GENE-Y
II	I-GENE-Y
activity	O
by	O
the	O
combined	O
MXF	B-CHEMICAL
/	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
treatments	O
was	O
probably	O
due	O
to	O
the	O
increase	O
in	O
the	O
level	O
of	O
the	O
DNA	O
-	O
enzyme	O
cleavable	O
complexes	O
formed	O
by	O
both	O
drugs	O
.	O

The	O
unique	O
combination	O
of	O
MXF	B-CHEMICAL
/	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
may	O
have	O
clinical	O
benefits	O
and	O
a	O
cytotoxic	O
drug	O
'	O
sparing	O
effect	O
'	O
and	O
should	O
be	O
further	O
studied	O
in	O
vivo	O
.	O

Copy	O
number	O
variations	O
of	O
the	O
human	B-GENE-Y
histamine	I-GENE-Y
H4	I-GENE-Y
receptor	I-GENE-Y
gene	O
are	O
associated	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

BACKGROUND	O
:	O
Systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
is	O
a	O
complex	O
genetic	O
disease	O
;	O
the	O
histamine	B-GENE-Y
H4	I-GENE-Y
receptor	I-GENE-Y
(	O
HRH4	B-GENE-Y
)	O
has	O
been	O
shown	O
to	O
be	O
related	O
to	O
different	O
kinds	O
of	O
autoimmune	O
disorders	O
;	O
and	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
have	O
been	O
found	O
to	O
be	O
associated	O
with	O
various	O
types	O
of	O
diseases	O
.	O

OBJECTIVES	O
:	O
To	O
explore	O
a	O
possible	O
association	O
between	O
HRH4	B-GENE-Y
(	O
formerly	O
H4R	B-GENE-Y
)	O
CNVs	O
and	O
the	O
risk	O
of	O
SLE	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
and	O
RNA	O
from	O
340	O
patients	O
with	O
SLE	O
and	O
392	O
healthy	O
controls	O
were	O
extracted	O
,	O
and	O
CNVs	O
and	O
mRNA	O
levels	O
of	O
HRH4	B-GENE-Y
were	O
examined	O
.	O

RESULTS	O
:	O
The	O
expression	O
of	O
HRH4	B-GENE-Y
mRNA	O
was	O
significantly	O
increased	O
in	O
patients	O
with	O
SLE	O
compared	O
with	O
controls	O
.	O

Amplification	O
of	O
HRH4	B-GENE-Y
copy	O
numbers	O
significantly	O
increased	O
the	O
risk	O
of	O
SLE	O
[	O
P	O
<	O
0	O
.	O
001	O
,	O
odds	O
ratio	O
(	O
OR	O
)	O
2	O
.	O
26	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
50	O
-	O
3	O
.	O
40	O
]	O
.	O

HRH4	B-GENE-Y
amplifications	O
also	O
positively	O
correlated	O
with	O
the	O
incidence	O
of	O
arthritis	O
(	O
P	O
=	O
0	O
.	O
019	O
,	O
OR	O
1	O
.	O
96	O
,	O
95	O
%	O
CI	O
1	O
.	O
11	O
-	O
3	O
.	O
47	O
)	O
,	O
and	O
proteinuria	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
OR	O
2	O
.	O
95	O
,	O
95	O
%	O
CI	O
1	O
.	O
73	O
-	O
5	O
.	O
00	O
)	O
and	O
antinuclear	O
antibody	O
abnormalities	O
(	O
P	O
<	O
0	O
.	O
001	O
,	O
OR	O
2	O
.	O
97	O
,	O
95	O
%	O
CI	O
1	O
.	O
66	O
-	O
5	O
.	O
33	O
)	O
.	O

Deletions	O
of	O
HRH4	B-GENE-Y
copy	O
numbers	O
were	O
protective	O
against	O
proteinuria	O
(	O
P	O
=	O
0	O
.	O
03	O
,	O
OR	O
0	O
.	O
50	O
,	O
95	O
%	O
CI	O
0	O
.	O
26	O
-	O
0	O
.	O
94	O
)	O
.	O

CONCLUSION	O
:	O
CNVs	O
of	O
the	O
HRH4	B-GENE-Y
gene	O
are	O
associated	O
with	O
SLE	O
.	O

Rasagiline	B-CHEMICAL
protects	O
against	O
alpha	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
induced	O
sensitivity	O
to	O
oxidative	O
stress	O
in	O
dopaminergic	O
cells	O
.	O

Rasagiline	B-CHEMICAL
is	O
a	O
propargylamine	B-CHEMICAL
and	O
irreversible	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
(	I-GENE-Y
MAO	I-GENE-Y
)	I-GENE-Y
B	I-GENE-Y
inhibitor	O
used	O
for	O
the	O
treatment	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

It	O
has	O
demonstrated	O
neuroprotective	O
properties	O
in	O
laboratory	O
studies	O
.	O

Current	O
concepts	O
of	O
PD	O
aetiopathogenesis	O
include	O
the	O
role	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
,	O
protein	O
aggregation	O
,	O
free	O
radical	O
metabolism	O
and	O
mitochondrial	O
dysfunction	O
in	O
contributing	O
to	O
cell	O
death	O
.	O

We	O
have	O
used	O
a	O
combination	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
and	O
free	O
radical	O
mediated	O
toxicity	O
in	O
a	O
dopaminergic	O
cell	O
line	O
to	O
provide	O
a	O
model	O
of	O
nigral	O
toxicity	O
in	O
order	O
to	O
investigate	O
the	O
potential	O
molecular	O
mechanisms	O
that	O
mediate	O
rasagiline	B-CHEMICAL
protection	O
.	O

We	O
demonstrate	O
that	O
rasagiline	B-CHEMICAL
protects	O
against	O
cell	O
death	O
induced	O
by	O
the	O
combination	O
of	O
free	O
radicals	O
generated	O
by	O
paraquat	B-CHEMICAL
and	O
either	O
wild	O
-	O
type	O
or	O
A53T	B-GENE-N
mutant	O
alpha	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
over	O
-	O
expression	O
.	O

This	O
protection	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
caspase	B-GENE-Y
3	I-GENE-Y
activation	O
,	O
a	O
reduction	O
in	O
superoxide	B-CHEMICAL
generation	O
and	O
a	O
trend	O
to	O
ameliorate	O
the	O
fall	O
in	O
mitochondrial	O
membrane	O
potential	O
.	O

Rasagiline	B-CHEMICAL
induced	O
an	O
increase	O
in	O
cellular	O
glutathione	B-CHEMICAL
levels	O
.	O

The	O
results	O
support	O
a	O
role	O
for	O
rasagiline	B-CHEMICAL
in	O
protecting	O
dopaminergic	O
cells	O
against	O
free	O
radical	O
mediated	O
damage	O
and	O
apoptosis	O
in	O
the	O
presence	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
over	O
-	O
expression	O
.	O

The	O
data	O
are	O
of	O
relevance	O
to	O
the	O
interpretation	O
of	O
the	O
potential	O
mechanisms	O
of	O
action	O
of	O
rasagiline	B-CHEMICAL
in	O
explaining	O
the	O
results	O
of	O
disease	O
modification	O
trials	O
in	O
PD	O
.	O

A	O
structural	O
and	O
functional	O
perspective	O
into	O
the	O
mechanism	O
of	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
sensitizers	O
that	O
target	O
the	O
cardiac	O
troponin	B-GENE-N
complex	I-GENE-N
.	O

The	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
dependent	O
interaction	O
between	O
troponin	B-GENE-N
I	I-GENE-N
(	O
cTnI	B-GENE-N
)	O
and	O
troponin	B-GENE-N
C	I-GENE-N
(	O
cTnC	B-GENE-N
)	O
triggers	O
contraction	O
in	O
heart	O
muscle	O
.	O

Heart	O
failure	O
is	O
characterized	O
by	O
a	O
decrease	O
in	O
cardiac	O
output	O
,	O
and	O
compounds	O
that	O
increase	O
the	O
sensitivity	O
of	O
cardiac	O
muscle	O
to	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
have	O
therapeutic	O
potential	O
.	O

The	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
sensitizer	O
,	O
levosimendan	B-CHEMICAL
,	O
targets	O
cTnC	O
;	O
however	O
,	O
detailed	O
understanding	O
of	O
its	O
mechanism	O
has	O
been	O
obscured	O
by	O
its	O
instability	O
.	O

In	O
order	O
to	O
understand	O
how	O
this	O
class	O
of	O
positive	O
inotropes	O
function	O
,	O
we	O
investigated	O
the	O
mode	O
of	O
action	O
of	O
two	O
fluorine	B-CHEMICAL
containing	O
novel	O
analogs	O
of	O
levosimendan	B-CHEMICAL
;	O
2	B-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
difluoro	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
biphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yloxy	I-CHEMICAL
acetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
)	O
and	O
2	B-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
difluoro	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
biphenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
acetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
dfbp	B-CHEMICAL
)	O
.	O

The	O
affinities	O
of	O
dfbp	B-CHEMICAL
and	O
dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
for	O
the	O
regulatory	O
domain	O
of	O
cTnC	B-GENE-N
were	O
measured	O
in	O
the	O
absence	O
and	O
presence	O
of	O
cTnI	O
by	O
NMR	O
spectroscopy	O
,	O
and	O
dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
was	O
found	O
to	O
bind	O
more	O
strongly	O
than	O
dfbp	B-CHEMICAL
.	O

Dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
also	O
increased	O
the	O
affinity	O
of	O
cTnI	B-GENE-N
for	O
cTnC	B-GENE-N
.	O

Dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
increased	O
the	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
sensitivity	O
of	O
demembranated	O
cardiac	O
trabeculae	O
in	O
a	O
manner	O
similar	O
to	O
levosimendan	B-CHEMICAL
.	O

The	O
high	O
resolution	O
NMR	O
solution	O
structure	O
of	O
the	O
cTnC	B-GENE-N
-	O
cTnI	B-GENE-N
-	O
dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
ternary	O
complex	O
showed	O
that	O
dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
bound	O
at	O
the	O
hydrophobic	O
interface	O
formed	O
by	O
cTnC	B-GENE-N
and	O
cTnI	B-GENE-N
making	O
critical	O
interactions	O
with	O
residues	O
such	O
as	O
Arg147	O
of	O
cTnI	B-GENE-N
.	O

In	O
the	O
absence	O
of	O
cTnI	B-GENE-N
,	O
docking	O
localized	O
dfbp	B-CHEMICAL
-	I-CHEMICAL
o	I-CHEMICAL
to	O
the	O
same	O
position	O
in	O
the	O
hydrophobic	O
groove	O
of	O
cTnC	B-GENE-N
.	O

The	O
structural	O
and	O
functional	O
data	O
reveal	O
that	O
the	O
levosimendan	B-CHEMICAL
class	O
of	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
sensitizers	O
work	O
by	O
binding	O
to	O
the	O
regulatory	O
domain	O
of	O
cTnC	B-GENE-N
and	O
stabilizing	O
the	O
pivotal	O
cTnC	B-GENE-N
-	O
cTnI	B-GENE-N
regulatory	O
unit	O
via	O
a	O
network	O
of	O
hydrophobic	O
and	O
electrostatic	O
interactions	O
,	O
in	O
contrast	O
to	O
the	O
destabilizing	O
effects	O
of	O
antagonists	O
such	O
as	O
W7	O
at	O
the	O
same	O
interface	O
.	O

Salicylate	B-CHEMICAL
pre	O
-	O
treatment	O
attenuates	O
intensity	O
of	O
bronchial	O
and	O
nasal	O
symptoms	O
precipitated	O
by	O
aspirin	B-CHEMICAL
in	O
aspirin	B-CHEMICAL
-	O
intolerant	O
patients	O
.	O

Aspirin	B-CHEMICAL
(	O
ASA	B-CHEMICAL
)	O
and	O
other	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drugs	O
,	O
which	O
are	O
cyclooxygenase	B-GENE-N
(	O
COX	B-GENE-N
)	O
inhibitors	O
,	O
precipitate	O
asthmatic	O
attacks	O
in	O
ASA	B-CHEMICAL
-	O
intolerant	O
patients	O
,	O
while	O
sodium	B-CHEMICAL
salicylate	I-CHEMICAL
,	O
hardly	O
active	O
on	O
COX	B-GENE-N
by	O
itself	O
,	O
is	O
well	O
tolerated	O
by	O
these	O
patients	O
.	O

However	O
,	O
salicylate	B-CHEMICAL
moiety	O
appears	O
to	O
interfere	O
with	O
aspirin	B-CHEMICAL
inhibitory	O
action	O
on	O
platelets	O
and	O
vascular	O
COX	B-GENE-N
.	O

Such	O
interaction	O
,	O
if	O
present	O
at	O
the	O
level	O
of	O
respiratory	O
tract	O
,	O
may	O
be	O
of	O
interest	O
to	O
pathogenesis	O
of	O
ASA	B-CHEMICAL
-	O
induced	O
asthma	O
.	O

We	O
performed	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
cross	O
-	O
over	O
study	O
on	O
the	O
effect	O
of	O
choline	B-CHEMICAL
magnesium	I-CHEMICAL
trisalicylate	I-CHEMICAL
(	O
CMT	B-CHEMICAL
,	O
trilisate	B-CHEMICAL
)	O
pre	O
-	O
treatment	O
on	O
ASA	B-CHEMICAL
-	O
induced	O
adverse	O
reactions	O
in	O
nine	O
patients	O
.	O

Pulmonary	O
function	O
tests	O
,	O
nasal	O
symptoms	O
score	O
,	O
PNIF	O
and	O
serum	O
salicylate	B-CHEMICAL
levels	O
were	O
monitored	O
following	O
challenges	O
with	O
threshold	O
doses	O
of	O
ASA	B-CHEMICAL
.	O

Trilisate	B-CHEMICAL
administered	O
at	O
a	O
dose	O
of	O
3000	O
mg	O
daily	O
for	O
3	O
days	O
,	O
offered	O
a	O
moderate	O
protection	O
against	O
ASA	B-CHEMICAL
-	O
induced	O
symptoms	O
;	O
it	O
diminished	O
the	O
severity	O
and	O
/	O
or	O
delayed	O
the	O
appearance	O
of	O
FEV1	O
fall	O
.	O

Maximal	O
decreases	O
in	O
FEV1	O
as	O
well	O
as	O
reaction	O
intensity	O
indexes	O
were	O
significantly	O
lower	O
(	O
P	O
less	O
than	O
0	O
.	O
02	O
and	O
P	O
less	O
than	O
0	O
.	O
002	O
,	O
respectively	O
)	O
after	O
trilisate	B-CHEMICAL
pre	O
-	O
treatment	O
as	O
compared	O
to	O
placebo	O
.	O

Trilisate	B-CHEMICAL
also	O
attenuated	O
nasal	O
symptoms	O
in	O
three	O
out	O
of	O
five	O
patients	O
.	O

Although	O
the	O
precise	O
mechanism	O
of	O
the	O
protective	O
action	O
of	O
trilisate	B-CHEMICAL
is	O
unknown	O
,	O
our	O
data	O
support	O
the	O
possibility	O
of	O
interaction	O
between	O
salicylate	B-CHEMICAL
and	O
ASA	B-CHEMICAL
on	O
cyclo	B-GENE-N
-	I-GENE-N
oxygenase	I-GENE-N
locus	O
in	O
the	O
respiratory	O
tract	O
in	O
ASA	B-CHEMICAL
-	O
intolerant	O
patients	O
.	O

Inhibition	O
of	O
recombinant	O
L	B-GENE-N
-	I-GENE-N
type	I-GENE-N
voltage	I-GENE-N
-	I-GENE-N
gated	I-GENE-N
calcium	I-GENE-N
channels	I-GENE-N
by	O
positive	O
allosteric	O
modulators	O
of	O
GABAA	B-GENE-N
receptors	I-GENE-N
.	O

Benzodiazepines	B-CHEMICAL
(	O
BDZs	B-CHEMICAL
)	O
depress	O
neuronal	O
excitability	O
via	O
positive	O
allosteric	O
modulation	O
of	O
inhibitory	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
(	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
R	I-GENE-N
)	O
.	O

BDZs	B-CHEMICAL
and	O
other	O
positive	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
R	I-GENE-N
modulators	O
,	O
including	O
barbiturates	B-CHEMICAL
,	O
ethanol	B-CHEMICAL
,	O
and	O
neurosteroids	B-CHEMICAL
,	O
can	O
also	O
inhibit	O
L	B-GENE-N
-	I-GENE-N
type	I-GENE-N
voltage	I-GENE-N
-	I-GENE-N
gated	I-GENE-N
calcium	I-GENE-N
channels	I-GENE-N
(	O
L	B-GENE-N
-	I-GENE-N
VGCCs	I-GENE-N
)	O
,	O
which	O
could	O
contribute	O
to	O
reduced	O
neuronal	O
excitability	O
.	O

Because	O
neuronal	O
L	B-GENE-N
-	I-GENE-N
VGCC	I-GENE-N
function	O
is	O
up	O
-	O
regulated	O
after	O
long	O
-	O
term	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
R	I-GENE-N
modulator	O
exposure	O
,	O
an	O
interaction	O
with	O
L	B-GENE-N
-	I-GENE-N
VGCCs	I-GENE-N
may	O
also	O
play	O
a	O
role	O
in	O
physical	O
dependence	O
.	O

The	O
current	O
studies	O
assessed	O
the	O
effects	O
of	O
BDZs	B-CHEMICAL
(	O
diazepam	B-CHEMICAL
,	O
flurazepam	B-CHEMICAL
,	O
and	O
desalkylflurazepam	B-CHEMICAL
)	O
,	O
allopregnanolone	B-CHEMICAL
,	O
pentobarbital	B-CHEMICAL
,	O
and	O
ethanol	B-CHEMICAL
on	O
whole	O
-	O
cell	O
Ba	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
currents	O
through	O
recombinant	O
neuronal	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
and	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
L	B-GENE-N
-	I-GENE-N
VGCCs	I-GENE-N
expressed	O
with	O
beta	O
(	O
3	O
)	O
and	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
1	O
in	O
HEK293T	O
cells	O
.	O

Allopregnanolone	B-CHEMICAL
was	O
the	O
most	O
potent	O
inhibitor	O
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
10	O
muM	O
)	O
,	O
followed	O
by	O
BDZs	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
50	O
muM	O
)	O
,	O
pentobarbital	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
,	O
0	O
.	O
3	O
-	O
1	O
mM	O
)	O
,	O
and	O
ethanol	B-CHEMICAL
(	O
IC	O
(	O
50	O
)	O
,	O
approximately	O
300	O
mM	O
)	O
.	O

Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
channels	O
were	O
less	O
sensitive	O
to	O
pentobarbital	B-CHEMICAL
inhibition	O
than	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
channels	O
,	O
similar	O
to	O
dihydropyridine	B-CHEMICAL
(	O
DHP	B-CHEMICAL
)	O
L	B-GENE-N
-	I-GENE-N
VGCC	I-GENE-N
antagonists	O
.	O

All	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
R	I-GENE-N
modulators	O
induced	O
a	O
negative	O
shift	O
in	O
the	O
steady	O
-	O
state	O
inactivation	O
curve	O
of	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
3	I-GENE-Y
channels	O
,	O
but	O
only	O
BDZs	B-CHEMICAL
and	O
pentobarbital	B-CHEMICAL
induced	O
a	O
negative	O
shift	O
in	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
channel	O
inactivation	O
.	O

Mutation	O
of	O
the	O
high	B-GENE-N
-	I-GENE-N
affinity	I-GENE-N
DHP	I-GENE-N
binding	I-GENE-N
site	I-GENE-N
(	O
T1039Y	B-GENE-N
and	O
Q1043M	B-GENE-N
)	O
in	O
Ca	B-GENE-Y
(	I-GENE-Y
v	I-GENE-Y
)	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
channels	O
reduced	O
pentobarbital	B-CHEMICAL
potency	O
.	O

Despite	O
the	O
structural	O
similarity	O
between	O
benzothiazepines	B-CHEMICAL
and	O
BDZs	B-CHEMICAL
,	O
mutation	O
of	O
an	O
amino	B-CHEMICAL
acid	I-CHEMICAL
important	O
for	O
diltiazem	B-CHEMICAL
potency	O
(	O
I1150A	B-GENE-N
)	O
did	O
not	O
affect	O
diazepam	B-CHEMICAL
potency	O
.	O

Although	O
L	B-GENE-N
-	I-GENE-N
VGCC	I-GENE-N
inhibition	O
by	O
BDZs	B-CHEMICAL
occurred	O
at	O
concentrations	O
that	O
are	O
possibly	O
too	O
high	O
to	O
be	O
clinically	O
relevant	O
and	O
is	O
not	O
likely	O
to	O
play	O
a	O
role	O
in	O
the	O
up	O
-	O
regulation	O
of	O
L	B-GENE-N
-	I-GENE-N
VGCCs	I-GENE-N
during	O
long	O
-	O
term	O
treatment	O
,	O
pentobarbital	B-CHEMICAL
and	O
ethanol	O
inhibited	O
L	B-GENE-N
-	I-GENE-N
VGCCs	I-GENE-N
at	O
clinically	O
relevant	O
concentrations	O
.	O

VMAT2	B-GENE-Y
:	O
a	O
dynamic	O
regulator	O
of	O
brain	O
monoaminergic	O
neuronal	O
function	O
interacting	O
with	O
drugs	O
of	O
abuse	O
.	O

The	O
monoaminergic	O
neuron	O
,	O
in	O
particular	O
the	O
dopaminergic	O
neuron	O
,	O
is	O
central	O
to	O
mediating	O
the	O
hedonic	O
and	O
addictive	O
properties	O
of	O
drugs	O
of	O
abuse	O
.	O

The	O
effects	O
of	O
amphetamine	B-CHEMICAL
(	O
AMPH	B-CHEMICAL
)	O
and	O
cocaine	B-CHEMICAL
(	O
COC	B-CHEMICAL
)	O
,	O
for	O
example	O
,	O
depend	O
on	O
the	O
ability	O
to	O
increase	O
dopamine	B-CHEMICAL
in	O
the	O
synapse	O
,	O
by	O
effects	O
on	O
either	O
the	O
plasma	O
membrane	O
transporter	O
DAT	B-GENE-Y
or	O
the	O
vesicular	O
transporter	O
for	O
monoamine	B-CHEMICAL
storage	O
,	O
VMAT2	B-GENE-Y
.	O

The	O
potential	O
role	O
of	O
DAT	B-GENE-Y
as	O
a	O
target	O
for	O
AMPH	B-CHEMICAL
and	O
COC	B-CHEMICAL
has	O
been	O
reviewed	O
extensively	O
.	O

Here	O
,	O
we	O
present	O
VMAT2	B-GENE-Y
as	O
a	O
target	O
that	O
enables	O
the	O
rewarding	O
and	O
addictive	O
actions	O
of	O
these	O
drugs	O
,	O
based	O
on	O
imaging	O
,	O
neurochemical	O
,	O
biochemical	O
,	O
cell	O
biological	O
,	O
genetic	O
,	O
and	O
immunohistochemical	O
evidence	O
.	O

The	O
presence	O
of	O
VMAT2	B-GENE-Y
in	O
noradrenergic	O
,	O
serotoninergic	O
,	O
histaminergic	O
,	O
and	O
potentially	O
trace	O
aminergic	O
neurons	O
invites	O
consideration	O
of	O
a	O
wider	O
role	O
for	O
aminergic	O
neurotransmission	O
in	O
AMPH	B-CHEMICAL
and	O
COC	B-CHEMICAL
abuse	O
and	O
addiction	O
.	O

Does	O
aspirin	B-CHEMICAL
acetylate	O
multiple	O
cellular	O
proteins	O
?	O

(	O
Review	O
)	O
.	O

Aspirin	B-CHEMICAL
is	O
a	O
salicylate	B-CHEMICAL
drug	O
that	O
is	O
extensively	O
used	O
for	O
its	O
anti	O
-	O
inflammatory	O
,	O
antipyretic	O
,	O
analgesic	O
and	O
anti	O
-	O
thrombotic	O
effects	O
.	O

More	O
recently	O
,	O
it	O
has	O
been	O
shown	O
to	O
decrease	O
the	O
incidence	O
of	O
cancers	O
of	O
epithelial	O
origin	O
.	O

In	O
most	O
cases	O
,	O
aspirin	B-CHEMICAL
is	O
relatively	O
safe	O
.	O

However	O
,	O
it	O
does	O
cause	O
a	O
host	O
of	O
adverse	O
effects	O
and	O
toxicities	O
,	O
including	O
gastrointestinal	O
bleeding	O
,	O
ulcerations	O
,	O
nephrotoxicity	O
and	O
hypersensitivity	O
reactions	O
.	O

Although	O
the	O
inhibition	O
of	O
cyclooxygenases	B-GENE-N
by	O
aspirin	B-CHEMICAL
,	O
which	O
leads	O
to	O
its	O
anti	O
-	O
inflammatory	O
/	O
analgesic	O
properties	O
,	O
has	O
been	O
well	O
studied	O
,	O
the	O
mechanisms	O
involved	O
in	O
its	O
chemopreventive	O
effects	O
as	O
well	O
as	O
some	O
of	O
its	O
adverse	O
effects	O
are	O
as	O
yet	O
ill	O
-	O
defined	O
.	O

Studies	O
over	O
the	O
past	O
decades	O
suggest	O
that	O
,	O
besides	O
cyclooxygenases	B-GENE-N
,	O
aspirin	B-CHEMICAL
acetylates	O
other	O
cellular	O
proteins	O
.	O

These	O
studies	O
used	O
radiolabeled	O
3H	B-CHEMICAL
or	O
14C	B-CHEMICAL
aspirin	B-CHEMICAL
,	O
the	O
only	O
approach	O
used	O
to	O
date	O
for	O
the	O
detection	O
of	O
proteins	O
acetylated	O
by	O
aspirin	B-CHEMICAL
.	O

In	O
a	O
recent	O
study	O
using	O
protein	O
-	O
specific	O
anti	O
-	O
acetyl	O
lysine	B-CHEMICAL
antibodies	O
and	O
immunological	O
methods	O
,	O
we	O
demonstrated	O
the	O
ability	O
of	O
aspirin	B-CHEMICAL
to	O
acetylate	O
the	O
tumor	B-GENE-Y
suppressor	I-GENE-Y
protein	I-GENE-Y
p53	I-GENE-Y
.	O

In	O
this	O
review	O
,	O
we	O
present	O
current	O
research	O
from	O
the	O
literature	O
on	O
the	O
aspirin	B-CHEMICAL
-	O
induced	O
acetylation	O
of	O
proteins	O
.	O

We	O
also	O
describe	O
an	O
immunological	O
approach	O
to	O
detecting	O
acetylated	O
proteins	O
in	O
aspirin	B-CHEMICAL
-	O
treated	O
cells	O
,	O
and	O
demonstrate	O
that	O
multiple	O
proteins	O
are	O
acetylated	O
.	O

Since	O
post	O
-	O
translational	O
modification	O
of	O
proteins	O
,	O
such	O
as	O
acetylation	O
,	O
may	O
lead	O
to	O
the	O
alteration	O
of	O
their	O
function	O
,	O
it	O
is	O
possible	O
that	O
some	O
of	O
the	O
hitherto	O
unexplained	O
beneficial	O
or	O
adverse	O
effects	O
of	O
aspirin	B-CHEMICAL
could	O
occur	O
as	O
a	O
result	O
of	O
these	O
modifications	O
.	O

The	O
identification	O
of	O
these	O
novel	O
acetylation	O
targets	O
of	O
aspirin	B-CHEMICAL
represents	O
a	O
new	O
area	O
for	O
investigation	O
.	O

Pseudoephedrine	B-CHEMICAL
inhibits	O
T	O
-	O
cell	O
activation	O
by	O
targeting	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
,	O
NFAT	B-GENE-N
and	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
signaling	O
pathways	O
.	O

Pseudoephedrine	B-CHEMICAL
(	O
PSE	B-CHEMICAL
)	O
is	O
a	O
stereoisomer	O
of	O
ephedrine	B-CHEMICAL
that	O
is	O
commonly	O
used	O
as	O
a	O
nasal	O
decongestant	O
in	O
combination	O
with	O
other	O
anti	O
-	O
inflammatory	O
drugs	O
for	O
the	O
symptomatic	O
treatment	O
of	O
some	O
common	O
pathologies	O
such	O
as	O
common	O
cold	O
.	O

Herein	O
,	O
we	O
describe	O
for	O
the	O
first	O
time	O
the	O
effects	O
of	O
PSE	B-CHEMICAL
on	O
T	O
-	O
cell	O
activation	O
events	O
.	O

We	O
found	O
that	O
PSE	B-CHEMICAL
inhibits	O
interleukin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
and	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
TNF	I-GENE-Y
)	I-GENE-Y
alpha	I-GENE-Y
-	O
gene	O
transcription	O
in	O
stimulated	O
Jurkat	O
cells	O
,	O
a	O
human	O
T	O
-	O
cell	O
leukemia	O
cell	O
line	O
.	O

To	O
further	O
characterize	O
the	O
inhibitory	O
mechanisms	O
of	O
PSE	B-CHEMICAL
at	O
the	O
transcriptional	O
level	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
)	O
,	O
nuclear	B-GENE-N
factor	I-GENE-N
of	I-GENE-N
activated	I-GENE-N
T	I-GENE-N
cells	I-GENE-N
(	O
NFAT	B-GENE-N
)	O
,	O
and	O
activator	B-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
transcription	O
factors	O
and	O
found	O
that	O
PSE	B-CHEMICAL
inhibited	O
NF	B-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
-	O
dependent	O
transcriptional	O
activity	O
without	O
affecting	O
either	O
the	O
phosphorylation	O
,	O
the	O
degradation	O
of	O
the	O
cytoplasmic	O
NF	B-GENE-Y
-	I-GENE-Y
kappaB	I-GENE-Y
inhibitory	I-GENE-Y
protein	I-GENE-Y
,	O
IkappaBalpha	B-GENE-Y
or	O
the	O
DNA	O
-	O
binding	O
activity	O
.	O

However	O
,	O
phosphorylation	O
of	O
the	O
p65	B-GENE-Y
/	O
RelA	B-GENE-Y
subunit	O
was	O
clearly	O
inhibited	O
by	O
PSE	B-CHEMICAL
in	O
stimulated	O
cells	O
.	O

In	O
addition	O
,	O
PSE	B-CHEMICAL
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NFAT	B-GENE-N
without	O
interfering	O
with	O
the	O
calcium	B-CHEMICAL
-	O
induced	O
NFAT	B-GENE-N
dephosphorylation	O
event	O
,	O
which	O
represents	O
the	O
major	O
signaling	O
pathway	O
for	O
its	O
activation	O
.	O

NFAT	B-GENE-N
cooperates	O
with	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
,	O
a	O
compound	O
of	O
the	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
complex	O
,	O
to	O
activate	O
target	O
genes	O
,	O
and	O
we	O
also	O
found	O
that	O
PSE	B-CHEMICAL
inhibited	O
both	O
JNK	B-GENE-N
activation	O
and	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
transcriptional	O
activity	O
.	O

These	O
findings	O
provide	O
new	O
mechanistic	O
insights	O
into	O
the	O
potential	O
immunomodulatory	O
activities	O
of	O
PSE	B-CHEMICAL
and	O
highlight	O
their	O
potential	O
in	O
designing	O
novel	O
therapeutic	O
strategies	O
to	O
manage	O
inflammatory	O
diseases	O
.	O

Vesicular	B-GENE-Y
monoamine	I-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
mRNA	O
and	O
immunoreactive	O
proteins	O
in	O
mouse	O
brain	O
.	O

OBJECTIVE	O
:	O
Vesicular	B-GENE-Y
monoamine	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
mRNA	O
and	O
protein	O
were	O
examined	O
(	O
1	O
)	O
to	O
determine	O
whether	O
adult	O
mouse	O
brain	O
expresses	O
full	O
-	O
length	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
that	O
can	O
be	O
translated	O
to	O
functional	O
transporter	O
protein	O
and	O
(	O
2	O
)	O
to	O
compare	O
immunoreactive	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
proteins	O
in	O
brain	O
and	O
adrenal	O
.	O

METHODS	O
:	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
was	O
detected	O
in	O
mouse	O
brain	O
with	O
RT	O
-	O
PCR	O
.	O

The	O
cDNA	O
was	O
sequenced	O
,	O
cloned	O
into	O
an	O
expression	O
vector	O
,	O
transfected	O
into	O
COS	O
-	O
1	O
cells	O
,	O
and	O
cell	O
protein	O
was	O
assayed	O
for	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
.	O

Immunoreactive	O
proteins	O
were	O
examined	O
on	O
western	O
blots	O
probed	O
with	O
four	O
different	O
antibodies	O
to	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

RESULTS	O
:	O
Sequencing	O
confirmed	O
identity	O
of	O
the	O
entire	O
coding	O
sequences	O
of	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
cDNA	O
from	O
mouse	O
medulla	O
oblongata	O
/	O
pons	O
and	O
adrenal	O
to	O
a	O
Gen	O
-	O
Bank	O
reference	O
sequence	O
.	O

Transfection	O
of	O
the	O
brain	O
cDNA	O
into	O
COS	O
-	O
1	O
cells	O
resulted	O
in	O
transporter	O
activity	O
that	O
was	O
blocked	O
by	O
the	O
VMAT	B-GENE-N
inhibitor	O
reserpine	B-CHEMICAL
and	O
a	O
proton	O
ionophore	O
,	O
but	O
not	O
by	O
tetrabenazine	B-CHEMICAL
,	O
which	O
has	O
a	O
high	O
affinity	O
for	O
VMAT	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Antibodies	O
to	O
either	O
the	O
C	B-CHEMICAL
-	O
or	O
N	B-CHEMICAL
-	O
terminus	O
of	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
detected	O
two	O
proteins	O
(	O
73	O
and	O
55	O
kD	O
)	O
in	O
transfected	O
COS	O
-	O
1	O
cells	O
.	O

The	O
C	B-CHEMICAL
-	O
terminal	O
antibodies	O
detected	O
both	O
proteins	O
in	O
extracts	O
of	O
mouse	O
medulla	O
/	O
pons	O
,	O
cortex	O
,	O
hypothalamus	O
,	O
and	O
cerebellum	O
but	O
only	O
the	O
73	O
kD	O
protein	O
and	O
higher	O
molecular	O
weight	O
immunoreactive	O
proteins	O
in	O
mouse	O
adrenal	O
and	O
rat	O
PC12	O
cells	O
,	O
which	O
are	O
positive	O
controls	O
for	O
rodent	B-GENE-Y
VMAT	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
demonstrate	O
that	O
a	O
functional	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
coding	O
sequence	O
is	O
expressed	O
in	O
mouse	O
brain	O
and	O
suggest	O
processing	O
of	O
VMAT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
protein	O
differs	O
in	O
mouse	O
adrenal	O
and	O
brain	O
.	O

The	O
mechanisms	O
responsible	O
for	O
garlic	O
-	O
drug	O
interactions	O
and	O
their	O
in	O
vivo	O
relevance	O
.	O

Garlic	O
phytochemicals	O
and	O
garlic	O
supplements	O
influence	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
behavior	O
of	O
concomitantly	O
ingested	O
drugs	O
.	O

In	O
this	O
paper	O
we	O
have	O
summarized	O
the	O
mechanisms	O
responsible	O
for	O
first	O
-	O
pass	O
intestinal	O
pharmacokinetic	O
interactions	O
by	O
investigating	O
the	O
intestinal	O
permeability	O
of	O
some	O
cardiovascular	O
,	O
antiviral	O
drugs	O
,	O
their	O
transport	O
with	O
hepatic	O
transporters	O
and	O
CYP3A4	B-GENE-Y
metabolism	O
.	O

Transporter	O
-	O
enzyme	O
interplay	O
was	O
studied	O
with	O
several	O
in	O
vitro	O
models	O
of	O
varying	O
complexity	O
:	O
rat	O
small	O
intestine	O
and	O
Caco	O
-	O
2	O
cell	O
monolayers	O
were	O
used	O
in	O
studies	O
of	O
intestinal	O
processes	O
,	O
and	O
hepatic	O
pharmacokinetics	O
was	O
monitored	O
in	O
HepG2	O
cells	O
,	O
isolated	O
rat	O
hepatocytes	O
and	O
rat	O
liver	O
slices	O
.	O

Garlic	O
phytochemicals	O
from	O
aged	O
garlic	O
extract	O
modified	O
the	O
activities	O
of	O
secretory	O
and	O
absorptive	O
transporters	O
in	O
both	O
intestine	O
and	O
liver	O
and	O
competitively	O
inhibited	O
CYP3A4	B-GENE-Y
enzyme	O
.	O

The	O
increased	O
activities	O
of	O
the	O
most	O
important	O
intestinal	O
efflux	O
(	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
-	O
Pgp	B-GENE-N
,	O
Multidrug	B-GENE-Y
Resistance	I-GENE-Y
Associated	I-GENE-Y
Protein	I-GENE-Y
2	I-GENE-Y
-	O
MRP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
Breast	B-GENE-Y
Cancer	I-GENE-Y
Resistance	I-GENE-Y
Protein	I-GENE-Y
-	O
BCRP	B-GENE-Y
)	O
and	O
uptake	O
(	O
MonoCarboxylate	B-GENE-Y
Transporter	I-GENE-Y
1	I-GENE-Y
-	O
MCT1	B-GENE-Y
,	O
Organic	B-GENE-N
Anion	I-GENE-N
Transporting	I-GENE-N
Polypeptide	I-GENE-N
-	O
OATP	B-GENE-N
,	O
Peptide	B-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
-	O
PepT1	B-GENE-Y
)	O
transporters	O
were	O
caused	O
by	O
changes	O
in	O
electrophysiological	O
membrane	O
properties	O
and	O
by	O
allosteric	O
modifications	O
.	O

Because	O
clinical	O
studies	O
investigating	O
interactions	O
between	O
garlic	O
and	O
human	B-GENE-N
immunodeficiency	I-GENE-N
virus	I-GENE-N
protease	I-GENE-N
inhibitors	O
saquinavir	B-CHEMICAL
and	O
ritonavir	B-CHEMICAL
have	O
already	O
been	O
performed	O
,	O
we	O
used	O
these	O
in	O
vivo	O
data	O
to	O
evaluate	O
the	O
in	O
vitro	O
results	O
and	O
the	O
reliability	O
of	O
the	O
models	O
employed	O
as	O
screening	O
tools	O
for	O
forecasting	O
the	O
potential	O
of	O
first	O
-	O
pass	O
intestinal	O
metabolism	O
changes	O
.	O

We	O
also	O
assessed	O
the	O
probability	O
of	O
pharmacokinetic	O
interactions	O
with	O
garlic	O
of	O
the	O
novel	O
drug	O
darunavir	B-CHEMICAL
and	O
other	O
cardiovascular	O
drugs	O
.	O

Finally	O
,	O
selected	O
garlic	O
phytochemicals	O
were	O
tested	O
for	O
their	O
ability	O
to	O
influence	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
and	O
CYP3A4	B-GENE-Y
activities	O
.	O

Cooperative	O
homotropic	O
interaction	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
with	O
the	O
catalytic	O
site	O
of	O
phenylalanine	B-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
monooxygenase	I-GENE-Y
.	O

Catecholamines	B-CHEMICAL
(	O
adrenaline	B-CHEMICAL
,	O
noradrenaline	B-CHEMICAL
and	O
dopamine	B-CHEMICAL
)	O
are	O
potent	O
inhibitors	O
of	O
phenylalanine	B-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
monooxygenase	I-GENE-Y
(	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
EC	B-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
14	I-GENE-Y
.	I-GENE-Y
16	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
.	O

The	O
amines	O
bind	O
to	O
the	O
enzyme	O
by	O
a	O
direct	O
coordination	O
to	O
the	O
high	O
-	O
spin	O
(	O
S	O
=	O
5	O
/	O
2	O
)	O
Fe	O
(	O
III	O
)	O
at	O
the	O
active	O
site	O
(	O
charge	O
transfer	O
interaction	O
)	O
,	O
as	O
seen	O
by	O
resonance	O
Raman	O
and	O
EPR	O
spectroscopy	O
.	O

Experimental	O
evidence	O
is	O
presented	O
that	O
a	O
group	O
with	O
an	O
apparent	O
pKa	O
value	O
of	O
about	O
5	O
.	O
1	O
(	O
20	O
degrees	O
C	O
)	O
is	O
involved	O
in	O
the	O
interaction	O
between	O
the	O
catecholamine	B-CHEMICAL
and	O
the	O
enzyme	O
.	O

The	O
high	O
-	O
affinity	O
binding	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
to	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
as	O
studied	O
by	O
equilibrium	O
microdialysis	O
(	O
anaerobically	O
)	O
and	O
ultrafiltration	O
(	O
aerobically	O
)	O
,	O
shows	O
positive	O
cooperativity	O
(	O
h	O
=	O
1	O
.	O
9	O
)	O
;	O
at	O
pH	O
7	O
.	O
2	O
and	O
20	O
degrees	O
C	O
the	O
rat	O
enzyme	O
binds	O
about	O
0	O
.	O
5	O
mol	O
L	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
/	O
mol	O
subunit	O
with	O
a	O
half	O
-	O
maximal	O
binding	O
(	O
S50	O
)	O
at	O
0	O
.	O
25	O
microM	O
L	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
.	O

No	O
binding	O
to	O
the	O
ferrous	O
form	O
of	O
the	O
enzyme	O
was	O
observed	O
.	O

The	O
affinity	O
decreases	O
with	O
decreasing	O
pH	O
,	O
by	O
phosphorylation	O
and	O
by	O
preincubation	O
of	O
the	O
enzyme	O
with	O
the	O
substrate	O
L	B-CHEMICAL
-	I-CHEMICAL
phenylalanine	I-CHEMICAL
,	O
while	O
it	O
increases	O
after	O
alkylation	O
of	O
the	O
enzyme	O
with	O
the	O
activator	O
N	B-CHEMICAL
-	I-CHEMICAL
ethylmaleimide	I-CHEMICAL
.	O

Preincubation	O
of	O
the	O
enzyme	O
with	O
L	B-CHEMICAL
-	I-CHEMICAL
phenylalanine	I-CHEMICAL
also	O
leads	O
to	O
a	O
complete	O
loss	O
of	O
the	O
cooperativity	O
of	O
L	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
binding	O
(	O
h	O
=	O
1	O
.	O
0	O
)	O
.	O

The	O
many	O
similarities	O
in	O
binding	O
properties	O
of	O
the	O
inhibitor	O
L	B-CHEMICAL
-	I-CHEMICAL
noradrenaline	I-CHEMICAL
and	O
the	O
activator	O
/	O
substrate	O
L	B-CHEMICAL
-	I-CHEMICAL
phenylalanine	I-CHEMICAL
makes	O
it	O
likely	O
that	O
the	O
cooperative	O
interactions	O
of	O
these	O
effectors	O
are	O
due	O
to	O
their	O
binding	O
to	O
the	O
same	O
site	O
.	O

The	O
high	O
-	O
affinity	O
of	O
catecholamines	B-CHEMICAL
to	O
phenylalanine	B-GENE-Y
hydroxylase	I-GENE-Y
is	O
a	O
valuable	O
probe	O
to	O
study	O
the	O
active	O
site	O
of	O
this	O
enzyme	O
and	O
is	O
also	O
relevant	O
for	O
the	O
homologous	O
enzyme	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
which	O
is	O
purified	O
as	O
a	O
stable	O
catecholamine	B-CHEMICAL
-	O
Fe	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
complex	O
.	O

Allelopathic	O
activity	O
studies	O
of	O
Mikania	O
scandens	O
.	O

Preliminary	O
investigation	O
of	O
a	O
number	O
of	O
plant	O
extracts	O
for	O
allelopathic	O
activity	O
using	O
seed	O
germination	O
inhibition	O
bioassay	O
showed	O
a	O
promising	O
activity	O
of	O
the	O
water	O
extract	O
of	O
the	O
aerial	O
parts	O
of	O
Mikania	O
scandens	O
.	O

Activity	O
-	O
guided	O
fractionation	O
of	O
the	O
M	O
.	O
scandens	O
extract	O
led	O
to	O
the	O
isolation	O
of	O
the	O
highly	O
allelopathic	O
active	O
compound	O
mikanolide	B-CHEMICAL
,	O
with	O
minimum	O
inhibitory	O
concentration	O
of	O
0	O
.	O
083	O
µM	O
mL	O
(	O
-	O
1	O
)	O
.	O

As	O
M	O
.	O
scandens	O
is	O
a	O
highly	O
abundant	O
invasive	O
plant	O
in	O
Sri	O
Lanka	O
and	O
other	O
South	O
Asian	O
countries	O
,	O
this	O
plant	O
could	O
be	O
developed	O
as	O
an	O
environment	O
friendly	O
natural	O
herbicide	O
,	O
either	O
in	O
crude	O
form	O
as	O
shredded	O
plant	O
material	O
or	O
as	O
pure	O
mikanolide	B-CHEMICAL
,	O
which	O
is	O
the	O
major	O
constituent	O
(	O
∼	O
0	O
.	O
02	O
%	O
)	O
in	O
the	O
plant	O
.	O

Green	O
tea	O
extract	O
alleviates	O
arsenic	B-CHEMICAL
-	O
induced	O
biochemical	O
toxicity	O
and	O
lipid	O
peroxidation	O
in	O
rats	O
.	O

The	O
present	O
work	O
was	O
undertaken	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
an	O
aqueous	O
extract	O
of	O
green	O
tea	O
(	O
GT	O
,	O
Camellia	O
sinensis	O
)	O
leaves	O
against	O
arsenic	B-CHEMICAL
(	O
NaAsO2	B-CHEMICAL
)	O
-	O
induced	O
biochemical	O
toxicity	O
and	O
lipid	O
peroxidation	O
production	O
in	O
experimental	O
rats	O
.	O

The	O
treatment	O
with	O
arsenic	B-CHEMICAL
exhibited	O
a	O
significant	O
increase	O
in	O
some	O
serum	O
hepatic	O
and	O
renal	O
biochemical	O
parameters	O
(	O
alanine	B-GENE-N
aminotransferase	I-GENE-N
,	O
aspartate	B-GENE-N
aminotransferase	I-GENE-N
,	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
,	O
total	O
protein	O
,	O
albumin	B-GENE-Y
,	O
bilirubin	B-CHEMICAL
,	O
cholesterol	B-CHEMICAL
,	O
urea	B-CHEMICAL
and	O
creatinine	B-CHEMICAL
)	O
.	O

But	O
the	O
co	O
-	O
administration	O
of	O
GT	O
has	O
increased	O
the	O
level	O
of	O
plasmatic	O
concentration	O
of	O
biochemical	O
parameters	O
.	O

Exposure	O
of	O
rats	O
to	O
arsenic	B-CHEMICAL
caused	O
also	O
a	O
significant	O
increase	O
in	O
liver	O
,	O
kidney	O
and	O
testicular	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	O
substances	O
compared	O
to	O
control	O
.	O

However	O
,	O
the	O
co	O
-	O
administration	O
of	O
GT	O
was	O
effective	O
in	O
reducing	O
its	O
level	O
.	O

To	O
conclude	O
,	O
our	O
data	O
suggest	O
that	O
arsenic	B-CHEMICAL
exposure	O
enhanced	O
an	O
oxidative	O
stress	O
by	O
disturbing	O
the	O
tissue	O
antioxidant	O
defense	O
system	O
,	O
but	O
the	O
GT	O
co	O
-	O
administration	O
alleviates	O
the	O
toxicity	O
induced	O
by	O
arsenic	B-CHEMICAL
exposure	O
.	O

Structural	O
basis	O
for	O
the	O
altered	O
drug	O
sensitivities	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
-	O
associated	O
mutants	O
of	O
human	B-GENE-Y
epidermal	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
.	O

The	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
has	O
an	O
essential	O
role	O
in	O
multiple	O
signaling	O
pathways	O
,	O
including	O
cell	O
proliferation	O
and	O
migration	O
,	O
through	O
extracellular	O
ligand	O
binding	O
and	O
subsequent	O
activation	O
of	O
its	O
intracellular	O
tyrosine	B-GENE-N
kinase	I-GENE-N
(	I-GENE-N
TK	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
.	O

The	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
(	O
NSCLC	O
)	O
-	O
associated	O
EGFR	B-GENE-Y
mutants	O
,	O
L858R	B-GENE-N
and	O
G719S	B-GENE-N
,	O
are	O
constitutively	O
active	O
and	O
oncogenic	O
.	O

They	O
display	O
sensitivity	O
to	O
TK	B-GENE-N
inhibitors	O
,	O
including	O
gefitinib	B-CHEMICAL
and	O
erlotinib	B-CHEMICAL
.	O

In	O
contrast	O
,	O
the	O
secondary	O
mutation	O
of	O
the	O
gatekeeper	O
residue	O
,	O
T790M	B-GENE-N
,	O
reportedly	O
confers	O
inhibitor	O
resistance	O
on	O
the	O
oncogenic	O
EGFR	B-GENE-Y
mutants	O
.	O

In	O
this	O
study	O
,	O
our	O
biochemical	O
analyses	O
revealed	O
that	O
the	O
introduction	O
of	O
the	O
T790M	B-GENE-N
mutation	O
confers	O
gefitinib	B-CHEMICAL
resistance	O
on	O
the	O
G719S	B-GENE-N
mutant	O
.	O

The	O
G719S	B-GENE-N
/	O
T790M	B-GENE-N
double	O
mutant	O
has	O
enhanced	O
activity	O
and	O
retains	O
high	O
gefitinib	B-CHEMICAL
-	O
binding	O
affinity	O
.	O

The	O
T790M	B-GENE-N
mutation	O
increases	O
the	O
ATP	B-CHEMICAL
affinity	O
of	O
the	O
G719S	B-GENE-N
mutant	O
,	O
explaining	O
the	O
acquired	O
drug	O
resistance	O
of	O
the	O
double	O
mutant	O
.	O

Structural	O
analyses	O
of	O
the	O
G719S	B-GENE-N
/	O
T790M	B-GENE-N
double	O
mutant	O
,	O
as	O
well	O
as	O
the	O
wild	O
type	O
and	O
the	O
G719S	B-GENE-N
and	O
L858R	B-GENE-N
mutants	O
,	O
revealed	O
that	O
the	O
T790M	B-GENE-N
mutation	O
stabilizes	O
the	O
hydrophobic	O
spine	O
of	O
the	O
active	O
EGFR	B-GENE-Y
-	O
TK	B-GENE-N
conformation	O
.	O

The	O
Met790	B-CHEMICAL
side	O
chain	O
of	O
the	O
G719S	B-GENE-N
/	O
T790M	B-GENE-N
double	O
mutant	O
,	O
in	O
the	O
apo	O
form	O
and	O
gefitinib	B-CHEMICAL
-	O
and	O
AMPPNP	O
-	O
bound	O
forms	O
,	O
adopts	O
different	O
conformations	O
that	O
explain	O
the	O
accommodation	O
of	O
these	O
ligands	O
.	O

In	O
the	O
L858R	B-GENE-N
mutant	O
structure	O
,	O
the	O
active	O
-	O
site	O
cleft	O
is	O
expanded	O
by	O
the	O
repositioning	O
of	O
Phe723	B-CHEMICAL
within	O
the	O
P	O
-	O
loop	O
.	O

Notably	O
,	O
the	O
introduction	O
of	O
the	O
F723A	B-GENE-N
mutation	O
greatly	O
enhanced	O
the	O
gefitinib	B-CHEMICAL
sensitivity	O
of	O
the	O
wild	O
-	O
type	O
EGFR	B-GENE-Y
in	O
vivo	O
,	O
supporting	O
our	O
hypothesis	O
that	O
the	O
expansion	O
of	O
the	O
active	O
-	O
site	O
cleft	O
results	O
in	O
enhanced	O
gefitinib	B-CHEMICAL
sensitivity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
altered	O
drug	O
sensitivities	O
caused	O
by	O
distinct	O
NSCLC	O
-	O
associated	O
EGFR	B-GENE-Y
mutations	O
.	O

WNT6	B-GENE-Y
is	O
a	O
novel	O
target	O
gene	O
of	O
caveolin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
promoting	O
chemoresistance	O
to	O
epirubicin	B-CHEMICAL
in	O
human	O
gastric	O
cancer	O
cells	O
.	O

Resistance	O
to	O
chemotherapy	O
is	O
a	O
major	O
obstacle	O
for	O
curative	O
treatment	O
of	O
human	O
gastric	O
cancer	O
(	O
GC	O
)	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
are	O
largely	O
unknown	O
.	O

Wingless	B-GENE-N
-	I-GENE-N
type	I-GENE-N
MMTV	I-GENE-N
integration	I-GENE-N
site	I-GENE-N
family	I-GENE-N
members	I-GENE-N
(	O
WNTs	B-GENE-N
)	O
are	O
secreted	O
glycoproteins	O
involved	O
in	O
embryogenesis	O
and	O
,	O
on	O
inappropriate	O
expression	O
in	O
the	O
adult	O
,	O
in	O
cancer	O
.	O

Here	O
,	O
we	O
show	O
expression	O
of	O
WNT6	B-GENE-Y
in	O
GC	O
patient	O
specimens	O
,	O
human	O
GC	O
cell	O
lines	O
and	O
in	O
a	O
mouse	O
model	O
of	O
GC	O
.	O

In	O
human	O
GC	O
cells	O
,	O
WNT6	B-GENE-Y
expression	O
was	O
enhanced	O
by	O
caveolin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
Cav1	B-GENE-Y
)	O
,	O
a	O
scaffold	O
protein	O
of	O
plasma	O
membrane	O
caveolae	O
.	O

WNT6	B-GENE-Y
knock	O
-	O
down	O
and	O
overexpression	O
experiments	O
demonstrated	O
that	O
WNT6	B-GENE-Y
increased	O
the	O
resistance	O
to	O
apoptotic	O
cell	O
death	O
induced	O
by	O
the	O
anthracycline	B-CHEMICAL
chemotherapeutics	O
epirubicin	B-CHEMICAL
(	O
Epi	B-CHEMICAL
)	O
and	O
doxorubicin	B-CHEMICAL
(	O
Dox	B-CHEMICAL
)	O
.	O

Epi	B-CHEMICAL
increased	O
the	O
activity	O
of	O
the	O
human	B-GENE-N
WNT6	I-GENE-N
promoter	I-GENE-N
through	O
Cav1	B-GENE-Y
-	O
dependent	O
binding	O
of	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
to	O
the	O
proximal	O
WNT6	B-GENE-N
promoter	I-GENE-N
.	O

Epi	B-CHEMICAL
increased	O
both	O
WNT6	B-GENE-Y
/	O
Wnt6	B-GENE-Y
and	O
Cav1	B-GENE-Y
expression	O
in	O
human	O
GC	O
cells	O
and	O
within	O
the	O
tumor	O
area	O
of	O
a	O
murine	O
model	O
of	O
GC	O
(	O
CEA424	O
-	O
SV40	O
TAg	O
)	O
.	O

In	O
GC	O
patients	O
,	O
WNT6	B-GENE-Y
expression	O
was	O
positively	O
associated	O
with	O
the	O
tumor	O
stage	O
and	O
the	O
nodal	O
status	O
,	O
and	O
inversely	O
correlated	O
with	O
the	O
response	O
to	O
ECF	O
(	O
Epi	B-CHEMICAL
,	O
cisplatin	B-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
fluorouracil	I-CHEMICAL
)	O
chemotherapy	O
.	O

These	O
results	O
showed	O
that	O
WNT6	B-GENE-Y
and	O
Cav1	B-GENE-Y
are	O
upregulated	O
by	O
chemotherapeutics	O
and	O
enhance	O
the	O
resistance	O
of	O
GC	O
cells	O
to	O
anthracycline	B-CHEMICAL
drugs	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
driving	O
WNT6	B-GENE-Y
/	O
Cav1	B-GENE-Y
-	O
induced	O
drug	O
resistance	O
will	O
provide	O
benefits	O
in	O
developing	O
new	O
therapies	O
for	O
GC	O
.	O

Differentiating	O
the	O
roles	O
of	O
mGlu2	B-GENE-Y
and	O
mGlu3	B-GENE-Y
receptors	O
using	O
LY541850	B-CHEMICAL
,	O
an	O
mGlu2	B-GENE-Y
agonist	O
/	O
mGlu3	B-GENE-Y
antagonist	O
.	O

Despite	O
the	O
potential	O
therapeutic	O
relevance	O
of	O
group	B-GENE-N
II	I-GENE-N
metabotropic	I-GENE-N
glutamate	I-GENE-N
(	I-GENE-N
mGlu	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
,	O
there	O
has	O
been	O
a	O
lack	O
of	O
pharmacological	O
tools	O
for	O
separating	O
the	O
roles	O
of	O
mGlu2	B-GENE-Y
and	O
mGlu3	B-GENE-Y
receptor	O
subtypes	O
.	O

LY541850	B-CHEMICAL
was	O
claimed	O
from	O
human	B-GENE-N
mGlu	I-GENE-N
receptors	I-GENE-N
expressed	O
in	O
non	O
-	O
neuronal	O
cells	O
to	O
be	O
a	O
selective	O
orthosteric	O
mGlu2	B-GENE-Y
agonist	O
and	O
mGlu3	B-GENE-Y
antagonist	O
.	O

We	O
have	O
verified	O
this	O
pharmacological	O
profile	O
of	O
LY541850	B-CHEMICAL
in	O
hippocampal	O
slices	O
.	O

Field	O
excitatory	O
post	O
-	O
synaptic	O
potentials	O
(	O
fEPSPs	O
)	O
evoked	O
by	O
stimulation	O
of	O
the	O
temporo	O
-	O
ammonic	O
path	O
(	O
TAP	O
)	O
input	O
to	O
CA1	O
stratum	O
lacunosum	O
moleculare	O
(	O
SLM	O
)	O
were	O
inhibited	O
by	O
LY541850	B-CHEMICAL
in	O
mGlu3	B-GENE-Y
-	O
/	O
-	O
mice	O
(	O
EC	O
(	O
50	O
)	O
38	O
nM	O
)	O
and	O
wild	O
-	O
type	O
littermates	O
(	O
EC	O
(	O
50	O
)	O
42	O
nM	O
)	O
to	O
a	O
similar	O
extent	O
but	O
were	O
not	O
significantly	O
affected	O
in	O
mGlu2	B-GENE-Y
-	O
/	O
-	O
mice	O
.	O

The	O
group	O
II	O
agonist	O
,	O
DCG	O
-	O
IV	O
,	O
inhibited	O
the	O
fEPSP	O
in	O
all	O
three	O
genotypes	O
.	O

Co	O
-	O
application	O
of	O
DCG	O
-	O
IV	O
and	O
LY541850	B-CHEMICAL
in	O
mGlu3	B-GENE-Y
-	O
/	O
-	O
and	O
wild	O
-	O
type	O
littermates	O
resulted	O
in	O
an	O
additive	O
effect	O
,	O
whereas	O
in	O
mGlu2	B-GENE-Y
-	O
/	O
-	O
mice	O
,	O
LY541850	B-CHEMICAL
reversed	O
the	O
inhibitory	O
action	O
of	O
DCG	O
-	O
IV	O
.	O

These	O
results	O
confirm	O
the	O
selective	O
mGlu2	B-GENE-Y
agonist	O
and	O
mGlu3	B-GENE-Y
antagonist	O
actions	O
of	O
LY541850	B-CHEMICAL
.	O

A	O
similar	O
profile	O
of	O
activity	O
was	O
seen	O
in	O
medial	O
perforant	O
path	O
synapse	O
to	O
the	O
dentate	O
gyrus	O
.	O

Systemic	O
administration	O
of	O
LY541850	B-CHEMICAL
to	O
wild	O
-	O
type	O
mice	O
,	O
reduced	O
the	O
increase	O
in	O
locomotor	O
activity	O
following	O
both	O
phencyclidine	B-CHEMICAL
and	O
amphetamine	B-CHEMICAL
administration	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
mGlu2	B-GENE-Y
receptors	O
mediate	O
the	O
antipsychotic	O
effects	O
of	O
mixed	O
group	O
II	O
agonists	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-GENE-N
Glutamate	I-GENE-N
Receptors	I-GENE-N
'	O
.	O

eIF4F	B-GENE-Y
suppression	O
in	O
breast	O
cancer	O
affects	O
maintenance	O
and	O
progression	O
.	O

Levels	O
of	O
eukaryotic	B-GENE-Y
initiation	I-GENE-Y
factor	I-GENE-Y
4E	I-GENE-Y
(	O
eIF4E	B-GENE-Y
)	O
are	O
frequently	O
elevated	O
in	O
human	O
cancers	O
and	O
in	O
some	O
instances	O
have	O
been	O
associated	O
with	O
poor	O
prognosis	O
and	O
outcome	O
.	O

Here	O
we	O
utilize	O
transgenic	O
and	O
allograft	O
breast	O
cancer	O
models	O
to	O
demonstrate	O
that	O
increased	O
mammalian	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
(	O
mTOR	B-GENE-Y
)	O
signalling	O
can	O
be	O
a	O
significant	O
contributor	O
to	O
breast	O
cancer	O
progression	O
in	O
vivo	O
.	O

Suppressing	O
mTOR	B-GENE-Y
activity	O
,	O
as	O
well	O
as	O
levels	O
and	O
activity	O
of	O
the	O
downstream	O
translation	O
regulators	O
,	O
eIF4E	B-GENE-Y
and	O
eIF4A	B-GENE-Y
,	O
delayed	O
breast	O
cancer	O
progression	O
,	O
onset	O
of	O
associated	O
pulmonary	O
metastasis	O
in	O
vivo	O
and	O
breast	O
cancer	O
cell	O
invasion	O
and	O
migration	O
in	O
vitro	O
.	O

Translation	O
of	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
,	O
matrix	B-GENE-Y
metallopeptidase	I-GENE-Y
9	I-GENE-Y
(	O
MMP9	B-GENE-Y
)	O
and	O
cyclin	B-GENE-Y
D1	I-GENE-Y
mRNAs	O
,	O
which	O
encode	O
products	O
associated	O
with	O
the	O
metastatic	O
phenotype	O
,	O
is	O
inhibited	O
upon	O
eIF4E	B-GENE-Y
suppression	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
mTOR	B-GENE-Y
/	O
eIF4F	B-GENE-Y
axis	O
is	O
an	O
important	O
contributor	O
to	O
tumor	O
maintenance	O
and	O
progression	O
programs	O
in	O
breast	O
cancer	O
.	O

Targeting	O
this	O
pathway	O
may	O
be	O
of	O
therapeutic	O
benefit	O
.	O

Effect	O
of	O
water	O
extracts	O
from	O
edible	O
myrtaceae	O
plants	O
on	O
uptake	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
nitrobenz	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
oxa	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diazol	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
amino	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
deoxyglucose	I-CHEMICAL
in	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
-	O
treated	O
FL83B	O
mouse	O
hepatocytes	O
.	O

This	O
study	O
investigated	O
the	O
glucose	B-CHEMICAL
uptake	O
activity	O
of	O
the	O
water	O
extracts	O
from	O
the	O
leaves	O
and	O
fruit	O
of	O
edible	O
Myrtaceae	O
plants	O
,	O
including	O
guava	O
(	O
Psidium	O
guajava	O
Linn	O
.	O
)	O
,	O
wax	O
apples	O
[	O
Syzygium	O
samarangense	O
(	O
Blume	O
)	O
Merr	O
.	O
and	O
L	O
.	O
M	O
.	O
Perry	O
]	O
,	O
Pu	O
-	O
Tau	O
[	O
Syzygium	O
jambo	O
(	O
L	O
.	O
)	O
Alston	O
]	O
,	O
and	O
Kan	O
-	O
Shi	O
Pu	O
-	O
Tau	O
(	O
Syzygium	O
cumini	O
Linn	O
.	O
)	O
in	O
FL83B	O
mouse	O
hepatocytes	O
.	O

The	O
fluorescent	O
dye	O
2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
nitrobenz	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
oxa	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
diazol	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
amino	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
deoxyglucose	I-CHEMICAL
was	O
used	O
to	O
estimate	O
the	O
uptake	O
ability	O
of	O
the	O
cells	O
.	O

Glucose	B-CHEMICAL
uptake	O
test	O
showed	O
that	O
pink	O
wax	O
apple	O
fruit	O
extract	O
(	O
PWFE	O
)	O
exhibits	O
the	O
highest	O
glucose	B-CHEMICAL
uptake	O
activity	O
,	O
at	O
an	O
increment	O
of	O
21	O
%	O
in	O
the	O
insulin	B-GENE-N
-	O
resistant	O
FL83B	O
mouse	O
hepatocytes	O
as	O
compared	O
with	O
the	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
-	O
treated	O
control	O
group	O
.	O

Vescalagin	B-CHEMICAL
was	O
isolated	O
using	O
column	O
chromatography	O
of	O
PWFE	O
.	O

This	O
compound	O
,	O
at	O
the	O
concentration	O
of	O
6	O
.	O
25	O
µg	O
/	O
mL	O
,	O
exhibits	O
the	O
same	O
glucose	B-CHEMICAL
uptake	O
improvement	O
in	O
insulin	B-GENE-N
-	O
resistant	O
cells	O
as	O
PWFE	O
at	O
a	O
100	O
-	O
µg	O
/	O
mL	O
dose	O
.	O

We	O
postulate	O
that	O
vescalagin	B-CHEMICAL
is	O
an	O
active	O
component	O
in	O
PWFE	O
that	O
may	O
alleviate	O
the	O
insulin	B-GENE-N
resistance	O
in	O
mouse	O
hepatocytes	O
.	O

Extracts	O
of	O
Scutellaria	O
baicalensis	O
reduced	O
body	O
weight	O
and	O
blood	O
triglyceride	B-CHEMICAL
in	O
db	O
/	O
db	O
Mice	O
.	O

Scutellaria	O
baicalensis	O
has	O
been	O
extensively	O
employed	O
for	O
the	O
clinical	O
treatment	O
of	O
hyperlipidemia	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
dysentery	O
,	O
inflammatory	O
diseases	O
,	O
and	O
the	O
common	O
cold	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
investigate	O
the	O
anti	O
-	O
obesity	O
and	O
anti	O
-	O
dyslipidemia	O
effect	O
of	O
Scutellaria	O
baicalensis	O
extracts	O
(	O
SBE	O
)	O
in	O
type	O
2	O
diabetic	O
db	O
/	O
db	O
mice	O
.	O

Male	O
db	O
/	O
db	O
mice	O
were	O
divided	O
into	O
three	O
groups	O
(	O
n	O
=	O
5	O
)	O
and	O
orally	O
administrated	O
vehicle	O
(	O
control	O
)	O
,	O
SBE	O
10	O
,	O
and	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
for	O
4	O
weeks	O
everyday	O
.	O

Administration	O
of	O
SBE	O
improves	O
weight	O
gain	O
,	O
hypertriglyceridemia	O
,	O
and	O
hyperinsulinemia	O
in	O
db	O
/	O
db	O
mice	O
.	O

In	O
obese	O
db	O
/	O
db	O
mice	O
,	O
SBE	O
treatment	O
also	O
reduced	O
plasma	O
alanine	B-GENE-N
aminotransferase	I-GENE-N
levels	O
.	O

In	O
the	O
livers	O
of	O
db	O
/	O
db	O
mice	O
,	O
SBE	O
promoted	O
5	B-GENE-N
'	I-GENE-N
AMP	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
activity	O
and	O
restored	O
metabolic	O
process	O
and	O
insulin	B-GENE-N
signaling	O
pathways	O
.	O

Our	O
data	O
demonstrate	O
that	O
SBE	O
exerts	O
potent	O
anti	O
-	O
obesity	O
and	O
anti	O
-	O
hypertriglyceride	O
effects	O
suggesting	O
its	O
useful	O
potential	O
function	O
as	O
adjuvant	O
therapeutic	O
agent	O
for	O
the	O
treatment	O
of	O
weight	O
gain	O
and	O
hypertriglyceridemia	O
.	O

R	B-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
(	O
armodafinil	B-CHEMICAL
)	O
:	O
a	O
unique	O
dopamine	B-CHEMICAL
uptake	O
inhibitor	O
and	O
potential	O
medication	O
for	O
psychostimulant	O
abuse	O
.	O

BACKGROUND	O
:	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Modafinil	I-CHEMICAL
has	O
piqued	O
interest	O
as	O
a	O
treatment	O
for	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
and	O
stimulant	O
dependence	O
.	O

The	O
R	B-CHEMICAL
-	I-CHEMICAL
enantiomer	I-CHEMICAL
of	I-CHEMICAL
modafinil	I-CHEMICAL
might	O
have	O
unique	O
pharmacological	O
properties	O
that	O
should	O
be	O
further	O
investigated	O
.	O

METHODS	O
:	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Modafinil	I-CHEMICAL
and	O
its	O
R	O
-	O
(	O
-	O
)	O
-	O
and	O
S	O
-	O
(	O
+	O
)	O
-	O
enantiomers	O
were	O
synthesized	O
and	O
tested	O
for	O
inhibition	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
dopamine	I-CHEMICAL
(	O
DA	B-CHEMICAL
)	O
uptake	O
and	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
WIN	I-CHEMICAL
35428	I-CHEMICAL
binding	O
in	O
human	B-GENE-Y
dopamine	I-GENE-Y
transporter	I-GENE-Y
(	O
DAT	B-GENE-Y
)	O
wild	O
-	O
type	O
and	O
mutants	O
with	O
altered	O
conformational	O
equilibria	O
.	O

Data	O
were	O
compared	O
with	O
cocaine	B-CHEMICAL
and	O
the	O
atypical	O
DA	B-CHEMICAL
uptake	O
inhibitor	O
,	O
JHW	B-CHEMICAL
007	I-CHEMICAL
.	O

R	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
were	O
also	O
evaluated	O
in	O
microdialysis	O
studies	O
in	O
the	O
mouse	O
nucleus	O
accumbens	O
shell	O
and	O
in	O
a	O
cocaine	B-CHEMICAL
discrimination	O
procedure	O
.	O

RESULTS	O
:	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
,	I-CHEMICAL
R	I-CHEMICAL
-	I-CHEMICAL
,	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
bind	O
to	O
the	O
DAT	B-GENE-Y
and	O
inhibit	O
DA	B-CHEMICAL
uptake	O
less	O
potently	O
than	O
cocaine	B-CHEMICAL
,	O
with	O
R	B-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
having	O
approximately	O
threefold	O
higher	O
affinity	O
than	O
its	O
S	O
-	O
enantiomer	O
.	O

Molecular	O
docking	O
studies	O
revealed	O
subtle	O
differences	O
in	O
binding	O
modes	O
for	O
the	O
enantiomers	O
.	O

R	B-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
was	O
significantly	O
less	O
potent	O
in	O
the	O
DAT	B-GENE-Y
Y156F	B-GENE-N
mutant	O
compared	O
with	O
wild	O
-	O
type	O
DAT	B-GENE-Y
,	O
whereas	O
S	B-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
was	O
affected	O
less	O
.	O

Studies	O
with	O
the	O
Y335A	B-GENE-N
DAT	B-GENE-Y
mutant	O
showed	O
that	O
the	O
R	O
-	O
and	O
S	O
-	O
enantiomers	O
tolerated	O
the	O
inward	O
-	O
facing	O
conformation	O
better	O
than	O
cocaine	B-CHEMICAL
,	O
which	O
was	O
further	O
supported	O
by	O
[	B-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
trimethylammonium	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
methanethiosulfonate	I-CHEMICAL
reactivity	O
on	O
the	O
DAT	B-GENE-Y
E2C	B-GENE-N
I159C	B-GENE-N
.	O

Microdialysis	O
studies	O
demonstrated	O
that	O
both	O
R	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
produced	O
increases	O
in	O
extracellular	O
DA	B-CHEMICAL
concentrations	O
in	O
the	O
nucleus	O
accumbens	O
shell	O
less	O
efficaciously	O
than	O
cocaine	B-CHEMICAL
and	O
with	O
a	O
longer	O
duration	O
of	O
action	O
.	O

Both	O
enantiomers	O
fully	O
substituted	O
in	O
mice	O
trained	O
to	O
discriminate	O
cocaine	B-CHEMICAL
from	O
saline	O
.	O

CONCLUSIONS	O
:	O
R	B-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
displays	O
an	O
in	O
vitro	O
profile	O
different	O
from	O
cocaine	B-CHEMICAL
.	O

Future	O
trials	O
with	O
R	B-CHEMICAL
-	I-CHEMICAL
modafinil	I-CHEMICAL
as	O
a	O
substitute	O
therapy	O
with	O
the	O
potential	O
benefit	O
of	O
cognitive	O
enhancement	O
for	O
psychostimulant	O
addiction	O
are	O
warranted	O
.	O

MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
oncoprotein	O
as	O
a	O
target	O
in	O
breast	O
cancer	O
:	O
activation	O
of	O
signaling	O
pathways	O
and	O
therapeutic	O
approaches	O
.	O

Mucin	B-GENE-Y
1	I-GENE-Y
(	O
MUC1	B-GENE-Y
)	O
is	O
a	O
heterodimeric	O
protein	O
formed	O
by	O
two	O
subunits	O
that	O
is	O
aberrantly	O
overexpressed	O
in	O
human	O
breast	O
cancer	O
and	O
other	O
cancers	O
.	O

Historically	O
,	O
much	O
of	O
the	O
early	O
work	O
on	O
MUC1	B-GENE-Y
focused	O
on	O
the	O
shed	O
mucin	B-GENE-N
subunit	O
.	O

However	O
,	O
more	O
recent	O
studies	O
have	O
been	O
directed	O
at	O
the	O
transmembrane	O
MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
subunit	I-GENE-Y
(	O
MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
)	O
that	O
functions	O
as	O
an	O
oncoprotein	O
.	O

MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
interacts	O
with	O
EGFR	B-GENE-Y
(	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
)	O
,	O
ErbB2	B-GENE-Y
and	O
other	O
receptor	B-GENE-N
tyrosine	I-GENE-N
kinases	I-GENE-N
at	O
the	O
cell	O
membrane	O
and	O
contributes	O
to	O
activation	O
of	O
the	O
PI3K	B-GENE-N
	O
AKT	B-GENE-N
and	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
kinase	I-GENE-N
(	O
MEK	B-GENE-N
)	O
	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
pathways	O
.	O

MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
also	O
localizes	O
to	O
the	O
nucleus	O
where	O
it	O
activates	O
the	O
Wnt	B-GENE-N
/	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
,	O
signal	B-GENE-N
transducer	I-GENE-N
and	I-GENE-N
activator	I-GENE-N
of	I-GENE-N
transcription	I-GENE-N
(	O
STAT	B-GENE-N
)	O
and	O
NF	B-GENE-N
(	B-GENE-N
nuclear	I-GENE-N
factor	I-GENE-N
)	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
RelA	B-GENE-Y
pathways	O
.	O

These	O
findings	O
and	O
the	O
demonstration	O
that	O
MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
is	O
a	O
druggable	O
target	O
have	O
provided	O
the	O
experimental	O
basis	O
for	O
designing	O
agents	O
that	O
block	O
MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
function	O
.	O

Notably	O
,	O
inhibitors	O
of	O
the	O
MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
subunit	O
have	O
been	O
developed	O
that	O
directly	O
block	O
its	O
oncogenic	O
function	O
and	O
induce	O
death	O
of	O
breast	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
xenograft	O
models	O
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
a	O
first	O
-	O
in	O
-	O
class	O
MUC1	B-GENE-Y
-	I-GENE-Y
C	I-GENE-Y
inhibitor	O
has	O
entered	O
phase	O
I	O
evaluation	O
as	O
a	O
potential	O
agent	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
breast	O
cancers	O
who	O
express	O
this	O
oncoprotein	O
.	O

Silibinin	B-CHEMICAL
triggers	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
arrest	O
of	O
SGC7901	O
cells	O
.	O

Silibinin	B-CHEMICAL
,	O
a	O
flavonoid	B-CHEMICAL
compound	O
,	O
has	O
shown	O
to	O
be	O
of	O
chemopreventive	O
potential	O
against	O
many	O
cancers	O
.	O

However	O
,	O
its	O
efficacy	O
against	O
gastric	O
cancer	O
has	O
not	O
been	O
well	O
elucidated	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
activity	O
of	O
Silibinin	B-CHEMICAL
on	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
arrest	O
in	O
human	O
gastric	O
cells	O
culture	O
system	O
using	O
SGC	O
-	O
7901	O
as	O
the	O
model	O
.	O

Silibinin	B-CHEMICAL
treatment	O
could	O
inhibit	O
the	O
cell	O
growth	O
and	O
cause	O
a	O
prominent	O
G2	O
phase	O
arrest	O
and	O
apoptosis	O
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

In	O
mechanistic	O
studies	O
,	O
Silibinin	B-CHEMICAL
decreased	O
the	O
protein	O
level	O
of	O
p34cdc2	B-GENE-Y
,	O
which	O
might	O
be	O
the	O
possible	O
molecular	O
mechanism	O
of	O
Silibinin	B-CHEMICAL
efficacy	O
on	O
the	O
growth	O
inhibition	O
in	O
SGC	O
-	O
7901	O
cells	O
.	O

In	O
addition	O
,	O
Silibinin	B-CHEMICAL
caused	O
an	O
increase	O
in	O
p53	B-GENE-Y
and	O
p21	B-GENE-Y
protein	O
level	O
as	O
well	O
as	O
mRNA	O
levels	O
.	O

Interestingly	O
,	O
Silibinin	B-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
SGC	O
-	O
7901	O
cells	O
was	O
independent	O
of	O
caspases	O
activation	O
.	O

These	O
results	O
indicated	O
that	O
Silibinin	B-CHEMICAL
is	O
a	O
cell	O
-	O
cycle	O
regulator	O
and	O
apoptosis	O
inducer	O
in	O
human	O
gastric	O
carcinoma	O
SGC	O
-	O
7901	O
cells	O
and	O
might	O
be	O
used	O
as	O
a	O
candidate	O
chemopreventive	O
agent	O
for	O
gastric	O
carcinoma	O
prevention	O
and	O
intervention	O
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Anxiolytic	O
-	O
but	O
not	O
antidepressant	O
-	O
like	O
activity	O
of	O
Lu	B-CHEMICAL
AF21934	I-CHEMICAL
,	O
a	O
novel	O
,	O
selective	O
positive	O
allosteric	O
modulator	O
of	O
the	O
mGlu₄	B-GENE-Y
receptor	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
the	O
Group	B-GENE-N
III	I-GENE-N
mGlu	I-GENE-N
receptor	I-GENE-N
-	O
selective	O
orthosteric	O
agonist	O
,	O
LSP1	B-CHEMICAL
-	I-CHEMICAL
2111	I-CHEMICAL
produced	O
anxiolytic	O
-	O
but	O
not	O
antidepressant	O
-	O
like	O
effects	O
upon	O
peripheral	O
administration	O
.	O

Herein	O
,	O
we	O
report	O
the	O
pharmacological	O
actions	O
of	O
Lu	B-CHEMICAL
AF21934	I-CHEMICAL
,	O
a	O
novel	O
,	O
selective	O
,	O
and	O
brain	O
-	O
penetrant	O
positive	O
allosteric	O
modulator	O
(	O
PAM	O
)	O
of	O
the	O
mGlu	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
receptor	O
in	O
the	O
stress	O
-	O
induced	O
hyperthermia	O
(	O
SIH	O
)	O
,	O
four	O
-	O
plate	O
,	O
marble	O
-	O
burying	O
and	O
Vogel	O
'	O
s	O
conflict	O
tests	O
.	O

In	O
all	O
models	O
,	O
except	O
Vogel	O
'	O
s	O
conflict	O
test	O
,	O
a	O
dose	O
-	O
dependent	O
anxiolytic	O
-	O
like	O
effect	O
was	O
seen	O
.	O

The	O
anti	O
-	O
hyperthermic	O
effect	O
of	O
Lu	B-CHEMICAL
AF21934	I-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
in	O
the	O
SIH	O
test	O
was	O
inhibited	O
by	O
the	O
benzodiazepine	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
flumazenil	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
and	O
was	O
not	O
serotonin	B-CHEMICAL
-	O
dependent	O
,	O
as	O
it	O
persisted	O
in	O
serotonin	B-CHEMICAL
-	O
deficient	O
mice	O
and	O
upon	O
blockade	O
of	O
either	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptors	O
by	O
WAY100635	B-CHEMICAL
,	O
or	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2A	I-GENE-N
/	I-GENE-N
2C	I-GENE-N
)	I-GENE-N
receptors	O
by	O
ritanserin	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
the	O
GABAergic	O
system	O
,	O
but	O
not	O
the	O
serotonergic	O
system	O
,	O
is	O
involved	O
in	O
the	O
mechanism	O
of	O
the	O
anxiolytic	O
-	O
like	O
phenotype	O
of	O
Lu	B-CHEMICAL
AF21934	I-CHEMICAL
in	O
rodents	O
.	O

Lu	B-CHEMICAL
AF21934	I-CHEMICAL
did	O
not	O
produce	O
antidepressant	O
-	O
like	O
effects	O
in	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
in	O
mice	O
;	O
however	O
,	O
it	O
decreased	O
the	O
basal	O
locomotor	O
activity	O
of	O
mice	O
that	O
were	O
not	O
habituated	O
to	O
activity	O
cages	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-GENE-N
Glutamate	I-GENE-N
Receptors	I-GENE-N
'	O
.	O

The	O
interaction	O
between	O
mGluR1	B-GENE-Y
and	O
the	O
calcium	B-GENE-N
channel	I-GENE-N
Cav₂	B-GENE-Y
.	I-GENE-Y
₁	I-GENE-Y
preserves	O
coupling	O
in	O
the	O
presence	O
of	O
long	B-GENE-N
Homer	I-GENE-N
proteins	I-GENE-N
.	O

Group	B-GENE-N
I	I-GENE-N
metabotropic	I-GENE-N
glutamate	I-GENE-N
receptors	I-GENE-N
(	O
mGluR1	B-GENE-N
and	I-GENE-N
5	I-GENE-N
)	O
are	O
G	B-GENE-N
protein	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
that	O
regulate	O
neuronal	O
activity	O
in	O
a	O
number	O
of	O
ways	O
.	O

Some	O
of	O
the	O
most	O
well	O
studied	O
functions	O
of	O
group	B-GENE-N
I	I-GENE-N
mGluRs	I-GENE-N
,	O
such	O
as	O
initiation	O
of	O
multiple	O
forms	O
of	O
mGluR	B-GENE-N
-	O
dependent	O
long	O
-	O
term	O
depression	O
,	O
require	O
receptor	O
localization	O
near	O
the	O
post	O
-	O
synaptic	O
density	O
(	O
PSD	O
)	O
.	O

This	O
localization	O
is	O
in	O
turn	O
dependent	O
on	O
the	O
Homer	B-GENE-N
family	O
of	O
scaffolding	O
proteins	O
which	O
bind	O
to	O
a	O
small	O
motif	O
on	O
the	O
distal	O
C	B-CHEMICAL
-	O
termini	O
of	O
mGluR1	B-GENE-N
and	I-GENE-N
5	I-GENE-N
,	O
localize	O
the	O
receptors	O
near	O
the	O
PSD	O
,	O
strengthen	O
coupling	O
to	O
post	O
-	O
synaptic	O
effectors	O
and	O
simultaneously	O
uncouple	O
the	O
mGluRs	B-GENE-N
from	O
extra	O
-	O
synaptic	O
effectors	O
such	O
as	O
voltage	B-GENE-N
dependent	I-GENE-N
ion	I-GENE-N
channels	I-GENE-N
.	O

Here	O
the	O
selectivity	O
of	O
this	O
uncoupling	O
process	O
was	O
examined	O
by	O
testing	O
the	O
ability	O
of	O
Homer	B-GENE-Y
-	I-GENE-Y
2b	I-GENE-Y
to	O
uncouple	O
mGluR1	B-GENE-Y
from	O
multiple	O
voltage	B-GENE-N
dependent	I-GENE-N
calcium	I-GENE-N
channels	I-GENE-N
including	O
Ca	B-GENE-Y
(	I-GENE-Y
V2	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
(	O
N	B-GENE-N
-	I-GENE-N
type	I-GENE-N
)	O
,	O
Ca	B-GENE-Y
(	I-GENE-Y
V3	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
(	O
T	B-GENE-N
-	I-GENE-N
type	I-GENE-N
)	I-GENE-N
,	O
and	O
Ca	B-GENE-Y
(	I-GENE-Y
V2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
(	O
P	B-GENE-N
/	I-GENE-N
Q	I-GENE-N
-	I-GENE-N
type	I-GENE-N
)	O
expressed	O
in	O
rat	O
sympathetic	O
neurons	O
from	O
the	O
superior	O
cervical	O
ganglion	O
(	O
SCG	O
)	O
.	O

Of	O
these	O
,	O
only	O
the	O
mGluR1	B-GENE-Y
-	O
Ca	B-GENE-Y
(	I-GENE-Y
V2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
modulatory	O
pathway	O
was	O
insensitive	O
to	O
Homer	B-GENE-Y
-	I-GENE-Y
2b	I-GENE-Y
expression	O
.	O

Uncoupling	O
from	O
this	O
channel	O
was	O
achieved	O
by	O
co	O
-	O
expression	O
of	O
an	O
mGluR1	B-GENE-Y
C	B-CHEMICAL
-	O
terminal	O
protein	O
designed	O
to	O
disrupt	O
a	O
previously	O
described	O
direct	O
interaction	O
between	O
these	O
two	O
proteins	O
,	O
suggesting	O
that	O
this	O
interaction	O
allows	O
incorporation	O
of	O
Ca	B-GENE-Y
(	I-GENE-Y
V2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
into	O
the	O
mGluR1	B-GENE-Y
/	O
Homer	B-GENE-N
signaling	O
complex	O
,	O
thereby	O
preserving	O
modulation	O
in	O
the	O
presence	O
of	O
scaffolding	O
Homer	B-GENE-N
proteins	I-GENE-N
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	B-GENE-N
Glutamate	I-GENE-N
Receptors	I-GENE-N
'	O
.	O

The	O
potential	O
of	O
nicotinic	O
enhancement	O
of	O
cognitive	O
remediation	O
training	O
in	O
schizophrenia	O
.	O

Cognitive	O
deficits	O
in	O
schizophrenia	O
are	O
critically	O
important	O
predictors	O
of	O
long	O
-	O
term	O
psychosocial	O
outcome	O
and	O
are	O
not	O
significantly	O
ameliorated	O
by	O
currently	O
available	O
medications	O
.	O

Cognitive	O
remediation	O
training	O
has	O
shown	O
promise	O
for	O
alleviating	O
cognitive	O
symptoms	O
of	O
schizophrenia	O
,	O
but	O
the	O
clinical	O
significance	O
has	O
often	O
been	O
limited	O
by	O
small	O
effect	O
sizes	O
.	O

Approaches	O
that	O
achieve	O
larger	O
improvement	O
involve	O
time	O
requirements	O
that	O
can	O
be	O
cost	O
-	O
prohibitive	O
within	O
the	O
current	O
clinical	O
care	O
system	O
.	O

This	O
mini	O
-	O
review	O
evaluates	O
the	O
theoretical	O
potential	O
of	O
a	O
pharmacological	O
enhancement	O
strategy	O
of	O
cognitive	O
remediation	O
training	O
with	O
nicotinic	B-GENE-N
acetylcholine	I-GENE-N
receptor	I-GENE-N
(	O
nAChR	B-GENE-N
)	O
agonists	O
.	O

nAChR	B-GENE-N
agonists	O
can	O
facilitate	O
sensory	O
processing	O
,	O
alertness	O
,	O
attention	O
,	O
learning	O
and	O
memory	O
.	O

While	O
these	O
effects	O
may	O
be	O
too	O
subtle	O
and	O
short	O
-	O
lasting	O
to	O
be	O
of	O
clinical	O
relevance	O
as	O
a	O
primary	O
treatment	O
of	O
cognitive	O
deficits	O
,	O
they	O
constitute	O
an	O
ideal	O
effects	O
profile	O
for	O
enhancing	O
training	O
benefits	O
.	O

Several	O
mechanisms	O
are	O
described	O
through	O
which	O
repeated	O
coupling	O
of	O
cognitive	O
training	O
challenges	O
with	O
nAChR	B-GENE-N
stimulation	O
may	O
enhance	O
and	O
accelerate	O
cognitive	O
remediation	O
training	O
effects	O
,	O
advancing	O
such	O
interventions	O
into	O
more	O
effective	O
and	O
practicable	O
treatments	O
of	O
some	O
of	O
the	O
most	O
debilitating	O
symptoms	O
of	O
schizophrenia	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Efficacy	O
and	O
long	O
-	O
term	O
safety	O
of	O
alipogene	O
tiparvovec	O
(	O
AAV1	O
-	O
LPL	B-GENE-Y
(	O
S447X	B-GENE-N
)	O
)	O
gene	O
therapy	O
for	O
lipoprotein	B-GENE-Y
lipase	I-GENE-Y
deficiency	O
:	O
an	O
open	O
-	O
label	O
trial	O
.	O

We	O
describe	O
the	O
2	O
-	O
year	O
follow	O
-	O
up	O
of	O
an	O
open	O
-	O
label	O
trial	O
(	O
CT	O
-	O
AMT	O
-	O
011	O
-	O
01	O
)	O
of	O
AAV1	O
-	O
LPL	B-GENE-Y
(	O
S447X	B-GENE-N
)	O
gene	O
therapy	O
for	O
lipoprotein	B-GENE-Y
lipase	I-GENE-Y
(	O
LPL	B-GENE-Y
)	O
deficiency	O
(	O
LPLD	O
)	O
,	O
an	O
orphan	O
disease	O
associated	O
with	O
chylomicronemia	O
,	O
severe	O
hypertriglyceridemia	O
,	O
metabolic	O
complications	O
and	O
potentially	O
life	O
-	O
threatening	O
pancreatitis	O
.	O

The	O
LPL	B-GENE-Y
(	O
S447X	B-GENE-N
)	O
gene	O
variant	O
,	O
in	O
an	O
adeno	O
-	O
associated	O
viral	O
vector	O
of	O
serotype	O
1	O
(	O
alipogene	O
tiparvovec	O
)	O
,	O
was	O
administered	O
to	O
14	O
adult	O
LPLD	O
patients	O
with	O
a	O
prior	O
history	O
of	O
pancreatitis	O
.	O

Primary	O
objectives	O
were	O
to	O
assess	O
the	O
long	O
-	O
term	O
safety	O
of	O
alipogene	O
tiparvovec	O
and	O
achieve	O
a	O
	O
40	O
%	O
reduction	O
in	O
fasting	O
median	O
plasma	O
triglyceride	B-CHEMICAL
(	O
TG	O
)	O
at	O
3	O
-	O
12	O
weeks	O
compared	O
with	O
baseline	O
.	O

Cohorts	O
1	O
(	O
n	O
=	O
2	O
)	O
and	O
2	O
(	O
n	O
=	O
4	O
)	O
received	O
3	O
×	O
10	O
(	O
11	O
)	O
gc	O
kg	O
(	O
-	O
1	O
)	O
,	O
and	O
cohort	O
3	O
(	O
n	O
=	O
8	O
)	O
received	O
1	O
×	O
10	O
(	O
12	O
)	O
gc	O
kg	O
(	O
-	O
1	O
)	O
.	O

Cohorts	O
2	O
and	O
3	O
also	O
received	O
immunosuppressants	O
from	O
the	O
time	O
of	O
alipogene	O
tiparvovec	O
administration	O
and	O
continued	O
for	O
12	O
weeks	O
.	O

Alipogene	O
tiparvovec	O
was	O
well	O
tolerated	O
,	O
without	O
emerging	O
safety	O
concerns	O
for	O
2	O
years	O
.	O

Half	O
of	O
the	O
patients	O
demonstrated	O
a	O
	O
40	O
%	O
reduction	O
in	O
fasting	O
TG	O
between	O
3	O
and	O
12	O
weeks	O
.	O

TG	O
subsequently	O
returned	O
to	O
baseline	O
,	O
although	O
sustained	O
LPL	B-GENE-Y
(	O
S447X	B-GENE-N
)	O
expression	O
and	O
long	O
-	O
term	O
changes	O
in	O
TG	O
-	O
rich	O
lipoprotein	O
characteristics	O
were	O
noted	O
independently	O
of	O
the	O
effect	O
on	O
fasting	O
plasma	O
TG	O
.	O

Anti	O
-	O
diabetic	O
Activity	O
of	O
Swertiamarin	B-CHEMICAL
is	O
due	O
to	O
an	O
Active	O
Metabolite	O
,	O
Gentianine	B-CHEMICAL
,	O
that	O
Upregulates	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
Gene	O
Expression	O
in	O
3T3	O
-	O
L1	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
the	O
anti	O
-	O
diabetic	O
effects	O
of	O
swertiamarin	B-CHEMICAL
;	O
however	O
,	O
pharmacokinetic	O
analysis	O
showed	O
that	O
swertiamarin	B-CHEMICAL
had	O
a	O
plasma	O
half	O
-	O
life	O
of	O
1	O
.	O
3	O
h	O
.	O

Gentianine	B-CHEMICAL
is	O
an	O
active	O
metabolite	O
of	O
swertiamarin	B-CHEMICAL
that	O
possesses	O
a	O
pharmacophoric	O
moiety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
possibility	O
whether	O
the	O
anti	O
-	O
diabetic	O
effect	O
of	O
swertiamarin	B-CHEMICAL
is	O
due	O
to	O
gentianine	B-CHEMICAL
.	O

Swertiamarin	B-CHEMICAL
treatment	O
had	O
no	O
significant	O
effect	O
on	O
adipogenesis	O
,	O
or	O
the	O
mRNA	O
expression	O
of	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
and	O
GLUT	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
adiponectin	B-GENE-Y
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
gentianine	B-CHEMICAL
significantly	O
increased	O
adipogenesis	O
,	O
which	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
,	O
GLUT	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
adiponectin	B-GENE-Y
.	O

These	O
findings	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
anti	O
-	O
diabetic	O
effect	O
of	O
swertiamarin	B-CHEMICAL
is	O
due	O
to	O
gentianine	B-CHEMICAL
,	O
an	O
active	O
metabolite	O
of	O
swertiamarin	B-CHEMICAL
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Dual	O
inhibitor	O
of	O
PDE7	B-GENE-N
and	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	O
VP1	O
.	O
15	O
acts	O
as	O
antipsychotic	O
and	O
cognitive	O
enhancer	O
in	O
C57BL	O
/	O
6J	O
mice	O
.	O

Cognitive	O
deficit	O
is	O
a	O
core	O
of	O
schizophrenia	O
and	O
it	O
is	O
not	O
effectively	O
treated	O
by	O
the	O
available	O
antipsychotic	O
drugs	O
,	O
hence	O
new	O
and	O
more	O
effective	O
therapy	O
is	O
needed	O
.	O

Schizophrenia	O
is	O
considered	O
as	O
a	O
pathway	O
disorder	O
where	O
Disrupted	B-GENE-Y
-	I-GENE-Y
In	I-GENE-Y
-	I-GENE-Y
Schizophrenia	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
DISC1	B-GENE-Y
)	O
is	O
important	O
molecular	O
player	O
that	O
regulates	O
multiple	O
cellular	O
cascades	O
.	O

We	O
recently	O
reported	O
synergistic	O
action	O
between	O
phosphodiesterase	B-GENE-N
-	I-GENE-N
4	I-GENE-N
(	O
PDE4	B-GENE-N
)	O
and	O
glycogen	B-GENE-N
synthase	I-GENE-N
kinase	I-GENE-N
-	I-GENE-N
3	I-GENE-N
(	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
)	O
as	O
DISC1	B-GENE-Y
interacting	O
proteins	O
.	O

In	O
the	O
current	O
study	O
we	O
characterized	O
behavioural	O
effects	O
of	O
a	O
newly	O
developed	O
compound	O
,	O
VP1	O
.	O
15	O
that	O
inhibits	O
both	O
PDE7	B-GENE-N
and	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
with	O
main	O
focus	O
on	O
its	O
antipsychotic	O
and	O
cognitive	O
capacities	O
.	O

VP1	O
.	O
15	O
reduced	O
ambulation	O
in	O
C57BL	O
/	O
6J	O
mice	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
7	O
.	O
5	O
mg	O
/	O
kg	O
and	O
3	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
and	O
,	O
hence	O
,	O
lower	O
dose	O
was	O
chosen	O
for	O
the	O
further	O
analysis	O
.	O

VP1	O
.	O
1	O
.	O
5	O
facilitated	O
pre	O
-	O
pulse	O
inhibition	O
(	O
PPI	O
)	O
,	O
reversed	O
amphetamine	B-CHEMICAL
-	O
but	O
not	O
MK	B-CHEMICAL
-	I-CHEMICAL
801	I-CHEMICAL
-	O
induced	O
PPI	O
deficit	O
.	O

The	O
drug	O
was	O
able	O
to	O
ameliorate	O
the	O
disrupted	O
latent	O
inhibition	O
(	O
LI	O
)	O
induced	O
by	O
the	O
increased	O
number	O
of	O
conditioning	O
trials	O
and	O
reversed	O
amphetamine	B-CHEMICAL
-	O
induced	O
LI	O
deficit	O
,	O
supporting	O
further	O
its	O
antipsychotic	O
effects	O
.	O

The	O
drug	O
also	O
significantly	O
improved	O
episodic	O
memory	O
in	O
the	O
spatial	O
object	O
recognition	O
test	O
,	O
facilitated	O
working	O
memory	O
in	O
Y	O
-	O
maze	O
and	O
enhanced	O
cued	O
fear	O
memory	O
,	O
but	O
had	O
no	O
effect	O
on	O
executive	O
function	O
in	O
the	O
Puzzle	O
box	O
and	O
contextual	O
fear	O
conditioning	O
.	O

Taken	O
together	O
,	O
VP1	O
.	O
15	O
elicited	O
antipsychotic	O
effects	O
and	O
also	O
facilitated	O
cognitive	O
domains	O
in	O
mice	O
,	O
suggesting	O
that	O
multitarget	O
drugs	O
,	O
affecting	O
molecular	O
substrates	O
from	O
the	O
same	O
pathway	O
,	O
perhaps	O
could	O
be	O
antipsychotics	O
of	O
new	O
-	O
generation	O
that	O
open	O
a	O
new	O
possibilities	O
in	O
drug	O
discoveries	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Passive	O
stiffness	O
of	O
airway	O
smooth	O
muscle	O
:	O
the	O
next	O
target	O
for	O
improving	O
airway	O
distensibility	O
and	O
treatment	O
for	O
asthma	O
?	O

Reduced	O
airway	O
distensibility	O
due	O
to	O
increased	O
airway	O
stiffness	O
is	O
a	O
characteristic	O
of	O
asthma	O
.	O

Airway	O
stiffness	O
is	O
determined	O
by	O
the	O
property	O
and	O
structural	O
organization	O
of	O
the	O
various	O
elements	O
of	O
the	O
airway	O
wall	O
,	O
and	O
is	O
often	O
divided	O
into	O
active	O
and	O
passive	O
components	O
.	O

Active	O
stiffness	O
is	O
thought	O
to	O
be	O
associated	O
with	O
activation	O
of	O
muscle	O
cells	O
in	O
the	O
airway	O
wall	O
.	O

This	O
component	O
of	O
stiffness	O
can	O
be	O
inhibited	O
when	O
active	O
force	O
produced	O
by	O
the	O
muscle	O
is	O
abolished	O
.	O

Passive	O
stiffness	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
thought	O
to	O
stem	O
from	O
non	O
-	O
muscle	O
component	O
of	O
the	O
airway	O
wall	O
,	O
especially	O
the	O
collagen	B-GENE-N
/	O
elastin	B-GENE-Y
fibrous	O
network	O
of	O
the	O
extracellular	O
matrix	O
within	O
which	O
the	O
muscle	O
cells	O
are	O
embedded	O
.	O

In	O
this	O
brief	O
review	O
,	O
the	O
notion	O
that	O
passive	O
stiffness	O
is	O
exclusively	O
extracellular	O
in	O
origin	O
is	O
challenged	O
.	O

Recent	O
evidence	O
suggests	O
that	O
a	O
substantial	O
portion	O
of	O
the	O
passive	O
stiffness	O
of	O
an	O
in	O
vitro	O
preparation	O
of	O
tracheal	O
smooth	O
muscle	O
is	O
calcium	B-CHEMICAL
sensitive	O
and	O
is	O
regulated	O
by	O
Rho	B-GENE-N
-	I-GENE-N
kinase	I-GENE-N
,	O
although	O
the	O
underlying	O
mechanism	O
and	O
the	O
details	O
of	O
regulation	O
for	O
the	O
development	O
of	O
this	O
intracellular	O
passive	O
stiffness	O
are	O
still	O
largely	O
unknown	O
.	O

To	O
reduce	O
airway	O
stiffness	O
different	O
lines	O
of	O
attack	O
must	O
be	O
tailored	O
to	O
different	O
components	O
of	O
the	O
stiffness	O
.	O

The	O
regulatable	O
passive	O
stiffness	O
is	O
distinct	O
from	O
the	O
relatively	O
permanent	O
stiffness	O
of	O
the	O
extracellular	O
matrix	O
and	O
the	O
stiffness	O
associated	O
with	O
active	O
muscle	O
contraction	O
.	O

To	O
improve	O
airway	O
distensibility	O
during	O
asthma	O
exacerbation	O
,	O
a	O
comprehensive	O
approach	O
to	O
reduce	O
overall	O
airway	O
stiffness	O
should	O
therefore	O
include	O
a	O
strategy	O
for	O
targeting	O
the	O
regulatable	O
passive	O
stiffness	O
.	O

Protective	O
Effects	O
of	O
a	O
Purified	O
Saponin	B-CHEMICAL
Mixture	O
from	O
Astragalus	O
corniculatus	O
Bieb	O
.	O
,	O
in	O
vivo	O
Hepatotoxicity	O
Models	O
.	O

In	O
this	O
study	O
,	O
the	O
in	O
vivo	O
effects	O
of	O
a	O
purified	O
saponin	B-CHEMICAL
mixture	O
(	O
PSM	O
)	O
,	O
obtained	O
from	O
Astragalus	O
corniculatus	O
Bieb	O
.	O
,	O
were	O
investigated	O
using	O
two	O
in	O
vivo	O
hepatotoxicity	O
models	O
based	O
on	O
liver	O
damage	O
caused	O
by	O
paracetamol	B-CHEMICAL
(	O
PC	O
)	O
and	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
(	O
CCl4	B-CHEMICAL
)	O
.	O

The	O
effects	O
of	O
PSM	O
were	O
compared	O
with	O
silymarin	B-CHEMICAL
.	O

Male	O
Wistar	O
rats	O
were	O
challenged	O
orally	O
with	O
20	O
%	O
CCl4	B-CHEMICAL
or	O
PC	O
(	O
2	O
g	O
/	O
kg	O
)	O
four	O
days	O
after	O
being	O
pre	O
-	O
treated	O
with	O
PSM	O
(	O
100	O
mg	O
/	O
kg	O
)	O
or	O
silymarin	B-CHEMICAL
(	O
200	O
mg	O
/	O
kg	O
)	O
.	O

A	O
significant	O
decrease	O
of	O
aspartate	B-GENE-Y
aminotransferase	I-GENE-Y
,	O
alanine	B-GENE-N
aminotransferase	I-GENE-N
,	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
(	O
LDH	B-GENE-N
)	O
activities	O
and	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
levels	O
and	O
an	O
increase	O
of	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
quantity	O
was	O
observed	O
after	O
CCl4	B-CHEMICAL
and	O
PC	O
administration	O
alone	O
.	O

PSM	O
pre	O
-	O
treatment	O
decreased	O
serum	B-GENE-N
transaminases	I-GENE-N
and	O
LDH	B-GENE-N
activities	O
and	O
MDA	B-CHEMICAL
levels	O
and	O
increased	O
the	O
levels	O
of	O
cell	O
protector	O
GSH	B-CHEMICAL
.	O

Biotransformation	O
phase	O
I	O
enzymes	O
were	O
also	O
assessed	O
in	O
both	O
models	O
.	O

In	O
the	O
CCl4	B-CHEMICAL
hepatotoxicity	O
model	O
,	O
pre	O
-	O
treatment	O
with	O
PSM	O
or	O
silymarin	B-CHEMICAL
resulted	O
in	O
significantly	O
increased	O
activities	O
of	O
ethylmorphine	B-GENE-N
-	I-GENE-N
N	I-GENE-N
-	I-GENE-N
demethylase	I-GENE-N
and	O
aniline	B-GENE-N
4	I-GENE-N
-	I-GENE-N
hydroxylase	I-GENE-N
activity	O
and	O
cytochrome	B-GENE-N
P450	I-GENE-N
,	O
compared	O
to	O
the	O
CCl4	B-CHEMICAL
only	O
group	O
.	O

Neither	O
silymarin	B-CHEMICAL
nor	O
PSM	O
influenced	O
PC	O
biotransformation	O
.	O

Our	O
results	O
suggest	O
that	O
PSM	O
,	O
obtained	O
from	O
A	O
.	O
corniculatus	O
,	O
Bieb	O
.	O
showed	O
in	O
vivo	O
hepatoprotective	O
and	O
antioxidant	O
activities	O
against	O
CCl4	B-CHEMICAL
and	O
PC	O
-	O
induced	O
liver	O
damage	O
comparable	O
to	O
that	O
of	O
silymarin	B-CHEMICAL
.	O

Copyright	O
©	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Current	O
understanding	O
of	O
TRPM7	B-GENE-Y
pharmacology	O
and	O
drug	O
development	O
for	O
stroke	O
.	O

The	O
initial	O
excitement	O
and	O
countless	O
efforts	O
to	O
find	O
a	O
pharmacological	O
agent	O
that	O
disrupts	O
the	O
excitotoxic	O
pathway	O
of	O
ischemic	O
neuronal	O
death	O
have	O
only	O
led	O
to	O
disappointing	O
clinical	O
trials	O
.	O

Currently	O
,	O
a	O
thrombolytic	O
agent	O
called	O
recombinant	B-GENE-Y
tissue	I-GENE-Y
plasminogen	I-GENE-Y
activator	I-GENE-Y
(	O
rt	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
is	O
the	O
only	O
pharmacological	O
treatment	O
available	O
for	O
patients	O
with	O
acute	O
ischemic	O
stroke	O
in	O
most	O
countries	O
.	O

Even	O
though	O
its	O
efficacy	O
has	O
been	O
confirmed	O
repeatedly	O
,	O
rt	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
is	O
considerably	O
underused	O
due	O
to	O
reasons	O
including	O
a	O
short	O
therapeutic	O
window	O
and	O
repeated	O
complications	O
associated	O
with	O
its	O
use	O
.	O

A	O
search	O
for	O
alternative	O
mechanisms	O
that	O
may	O
operate	O
dependently	O
or	O
independently	O
with	O
the	O
well	O
-	O
established	O
excitotoxic	O
mechanism	O
has	O
led	O
researchers	O
to	O
the	O
discovery	O
of	O
newly	O
described	O
non	O
-	O
glutamate	B-CHEMICAL
mechanisms	O
.	O

Among	O
the	O
latter	O
,	O
transient	B-GENE-Y
receptor	I-GENE-Y
potential	I-GENE-Y
melastatin	I-GENE-Y
7	I-GENE-Y
(	O
TRPM7	B-GENE-Y
)	O
is	O
one	O
of	O
the	O
important	O
nonglutamate	O
mechanisms	O
in	O
stroke	O
,	O
which	O
has	O
been	O
evaluated	O
in	O
both	O
in	O
-	O
vitro	O
and	O
in	O
-	O
vivo	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
the	O
current	O
state	O
of	O
pharmacological	O
treatments	O
of	O
ischemic	O
stroke	O
and	O
provide	O
evidence	O
that	O
TRPM7	B-GENE-Y
is	O
a	O
promising	O
therapeutic	O
target	O
of	O
stroke	O
.	O

Hospitalized	O
osteoporotic	O
vertebral	O
fracture	O
increases	O
the	O
risk	O
of	O
stroke	O
:	O
a	O
population	O
-	O
based	O
cohort	O
study	O
.	O

The	O
association	O
between	O
osteoporosis	O
and	O
cardiovascular	O
diseases	O
has	O
been	O
demonstrated	O
.	O

Higher	O
cardiovascular	O
risk	O
has	O
also	O
been	O
correlated	O
with	O
vertebral	O
fractures	O
.	O

However	O
,	O
the	O
association	O
between	O
osteoporotic	O
vertebral	O
fracture	O
and	O
the	O
possibly	O
higher	O
risk	O
of	O
stroke	O
remains	O
uncertain	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
the	O
incidence	O
,	O
risk	O
,	O
and	O
type	O
of	O
stroke	O
in	O
patients	O
with	O
osteoporotic	O
vertebral	O
fracture	O
.	O

Patients	O
with	O
osteoporotic	O
vertebral	O
fracture	O
were	O
identified	O
(	O
n	O
=	O
380	O
)	O
and	O
10	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
per	O
case	O
(	O
comparison	O
group	O
,	O
n	O
=	O
3795	O
)	O
were	O
chosen	O
from	O
a	O
nationwide	O
representative	O
cohort	O
of	O
999	O
,	O
997	O
people	O
from	O
1998	O
to	O
2005	O
.	O

Both	O
groups	O
were	O
followed	O
-	O
up	O
for	O
stroke	O
events	O
for	O
3	O
years	O
,	O
matched	O
by	O
propensity	O
scores	O
with	O
adjustments	O
for	O
covariates	O
such	O
as	O
comorbidities	O
(	O
ie	O
,	O
hypertension	O
,	O
diabetes	O
,	O
arrhythmia	O
,	O
or	O
coronary	O
heart	O
diseases	O
)	O
and	O
exposure	O
to	O
medications	O
(	O
ie	O
,	O
aspirin	B-CHEMICAL
,	O
lipid	O
lowering	O
drug	O
,	O
or	O
nitrates	B-CHEMICAL
)	O
,	O
and	O
assessed	O
by	O
Kaplan	O
-	O
Meier	O
and	O
Cox	O
regression	O
analyses	O
.	O

The	O
incidence	O
rate	O
of	O
stroke	O
in	O
the	O
osteoporotic	O
vertebral	O
fracture	O
group	O
(	O
37	O
.	O
5	O
per	O
1000	O
person	O
-	O
years	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
27	O
.	O
5	O
-	O
51	O
.	O
2	O
)	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
comparison	O
group	O
(	O
14	O
.	O
0	O
per	O
1000	O
person	O
-	O
years	O
;	O
95	O
%	O
CI	O
,	O
12	O
.	O
0	O
-	O
16	O
.	O
4	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Stroke	O
was	O
more	O
likely	O
to	O
occur	O
in	O
the	O
osteoporotic	O
vertebral	O
fracture	O
patients	O
than	O
in	O
the	O
normal	O
controls	O
(	O
crude	O
hazard	O
ratio	O
[	O
HR	O
]	O
2	O
.	O
68	O
,	O
95	O
%	O
CI	O
1	O
.	O
89	O
-	O
3	O
.	O
79	O
,	O
p	O
<	O
0	O
.	O
001	O
;	O
adjusted	O
HR	O
2	O
.	O
71	O
,	O
95	O
%	O
CI	O
1	O
.	O
90	O
-	O
3	O
.	O
86	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
conclusion	O
,	O
patients	O
with	O
osteoporotic	O
vertebral	O
fracture	O
have	O
a	O
higher	O
risk	O
of	O
stroke	O
(	O
ie	O
,	O
both	O
ischemic	O
and	O
hemorrhagic	O
)	O
and	O
require	O
stroke	O
prevention	O
strategies	O
.	O

Effects	O
of	O
fenofibrate	B-CHEMICAL
,	O
a	O
PPAR	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
ligand	O
,	O
on	O
the	O
haemodynamics	O
of	O
glycerol	B-CHEMICAL
-	O
induced	O
renal	O
failure	O
in	O
rats	O
.	O

The	O
modulating	O
effect	O
of	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
α	I-GENE-Y
ligand	O
on	O
haemodynamic	O
effects	O
of	O
phenylepherine	B-CHEMICAL
(	O
PE	O
)	O
,	O
angiotensin	B-GENE-Y
II	I-GENE-Y
(	O
AII	B-GENE-Y
)	O
,	O
endothelin	B-GENE-Y
1	I-GENE-Y
(	O
ET1	B-GENE-Y
)	O
,	O
acetylcholine	B-CHEMICAL
(	O
Ach	B-CHEMICAL
)	O
,	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
(	O
SNP	B-CHEMICAL
)	O
and	O
isoproterenol	B-CHEMICAL
(	O
ISO	B-CHEMICAL
)	O
were	O
evaluated	O
in	O
glycerol	B-CHEMICAL
-	O
induced	O
acute	O
kidney	O
injury	O
in	O
rats	O
.	O

The	O
effect	O
of	O
PE	O
on	O
fenofibrate	B-CHEMICAL
-	O
treated	O
animals	O
was	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MAP	O
)	O
.	O

For	O
AII	B-GENE-Y
and	O
ET1	B-GENE-Y
,	O
MAP	O
was	O
also	O
increased	O
for	O
the	O
fenofibrate	B-CHEMICAL
group	O
but	O
not	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

On	O
the	O
medullary	O
blood	O
flow	O
(	O
MBF	O
)	O
,	O
while	O
the	O
lower	O
doses	O
of	O
PE	O
and	O
AII	B-GENE-Y
increased	O
the	O
perfusion	O
unit	O
on	O
the	O
fenofibrate	B-CHEMICAL
-	O
treated	O
group	O
,	O
the	O
higher	O
doses	O
decreased	O
the	O
perfusion	O
unit	O
.	O

The	O
ET1	B-GENE-Y
increased	O
the	O
perfusion	O
unit	O
on	O
this	O
group	O
but	O
not	O
in	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
effects	O
of	O
PE	O
and	O
AII	B-GENE-Y
on	O
the	O
cortical	O
blood	O
flow	O
(	O
CBF	O
)	O
of	O
fenofibrate	B-CHEMICAL
-	O
treated	O
group	O
is	O
similar	O
to	O
that	O
of	O
MBF	O
for	O
the	O
same	O
group	O
but	O
not	O
for	O
ET1	B-GENE-Y
.	O

The	O
effect	O
of	O
Ach	B-CHEMICAL
,	O
SNP	B-CHEMICAL
and	O
ISO	B-CHEMICAL
in	O
all	O
the	O
groups	O
was	O
the	O
decrease	O
in	O
MAP	O
.	O

ISO	B-CHEMICAL
caused	O
dose	O
-	O
dependent	O
increase	O
in	O
MBF	O
of	O
fenofibrate	B-CHEMICAL
-	O
treated	O
group	O
.	O

The	O
effect	O
of	O
Ach	B-CHEMICAL
,	O
SNP	B-CHEMICAL
and	O
ISO	B-CHEMICAL
on	O
the	O
CBF	O
perfusion	O
unit	O
was	O
that	O
of	O
the	O
increase	O
for	O
the	O
fenofibrate	B-CHEMICAL
-	O
treated	O
group	O
.	O

The	O
study	O
showed	O
that	O
fenofibrate	B-CHEMICAL
did	O
not	O
attenuate	O
increased	O
blood	O
pressure	O
induced	O
by	O
PE	O
,	O
AII	B-GENE-Y
and	O
ET1	B-GENE-Y
but	O
caused	O
enhanced	O
vasodilation	O
by	O
Ach	B-CHEMICAL
,	O
SNP	B-CHEMICAL
and	O
ISO	B-CHEMICAL
.	O

The	O
R740S	B-GENE-N
mutation	O
in	O
the	O
V	B-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
a3	I-GENE-N
subunit	O
increases	O
lysosomal	O
pH	O
,	O
impairs	O
NFATc1	B-GENE-Y
translocation	O
,	O
and	O
decreases	O
in	O
vitro	O
osteoclastogenesis	O
.	O

Vacuolar	B-GENE-N
H	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
(	O
V	B-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
)	O
,	O
a	O
multisubunit	O
enzyme	O
located	O
at	O
the	O
ruffled	O
border	O
and	O
in	O
lysosomes	O
of	O
osteoclasts	O
,	O
is	O
necessary	O
for	O
bone	O
resorption	O
.	O

We	O
previously	O
showed	O
that	O
heterozygous	O
mice	O
with	O
an	O
R740S	B-GENE-N
mutation	O
in	O
the	O
a3	O
subunit	O
of	O
V	B-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
(	O
+	O
/	O
R740S	O
)	O
have	O
mild	O
osteopetrosis	O
resulting	O
from	O
an	O
∼	O
90	O
%	O
reduction	O
in	O
proton	O
translocation	O
across	O
osteoclast	O
membranes	O
.	O

Here	O
we	O
show	O
that	O
lysosomal	O
pH	O
is	O
also	O
higher	O
in	O
+	O
/	O
R740S	B-GENE-N
compared	O
with	O
wild	O
-	O
type	O
(	O
+	O
/	O
+	O
)	O
osteoclasts	O
.	O

Both	O
osteoclast	O
number	O
and	O
size	O
were	O
decreased	O
in	O
cultures	O
of	O
+	O
/	O
R740S	B-GENE-N
compared	O
with	O
+	O
/	O
+	O
bone	O
marrow	O
cells	O
,	O
with	O
concomitant	O
decreased	O
expression	O
of	O
key	O
osteoclast	O
markers	O
(	O
TRAP	B-GENE-N
,	O
cathepsin	B-GENE-N
K	I-GENE-N
,	O
OSCAR	B-GENE-N
,	O
DC	B-GENE-N
-	I-GENE-N
STAMP	I-GENE-N
,	O
and	O
NFATc1	B-GENE-N
)	O
,	O
suggesting	O
that	O
low	O
lysosomal	O
pH	O
plays	O
an	O
important	O
role	O
in	O
osteoclastogenesis	O
.	O

To	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
,	O
NFATc1	B-GENE-N
activation	O
was	O
assessed	O
.	O

NFATc1	B-GENE-N
nuclear	O
translocation	O
was	O
significantly	O
reduced	O
in	O
+	O
/	O
R740S	B-GENE-N
compared	O
with	O
+	O
/	O
+	O
cells	O
;	O
however	O
,	O
this	O
was	O
not	O
because	O
of	O
impaired	O
enzymatic	O
activity	O
of	O
calcineurin	O
,	O
the	O
phosphatase	O
responsible	O
for	O
NFATc1	B-GENE-N
dephosphorylation	O
.	O

Protein	O
and	O
RNA	O
expression	O
levels	O
of	O
regulator	O
of	O
calcineurin	B-GENE-N
1	I-GENE-N
(	O
RCAN1	B-GENE-N
)	O
,	O
an	O
endogenous	O
inhibitor	O
of	O
NFATc1	B-GENE-N
activation	O
and	O
a	O
protein	O
degraded	O
in	O
lysosomes	O
,	O
were	O
not	O
significantly	O
different	O
between	O
+	O
/	O
R740S	B-GENE-N
and	O
+	O
/	O
+	O
osteoclasts	O
,	O
but	O
the	O
RCAN1	B-GENE-N
/	O
NFATc1	B-GENE-N
ratio	O
was	O
significantly	O
higher	O
in	O
+	O
/	O
R740S	B-GENE-N
versus	O
+	O
/	O
+	O
cells	O
.	O

The	O
lysosomal	O
inhibitor	O
chloroquine	B-CHEMICAL
significantly	O
increased	O
RCAN1	B-GENE-N
accumulation	O
in	O
+	O
/	O
+	O
cells	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
higher	O
lysosomal	O
pH	O
impairs	O
RCAN1	B-GENE-N
degradation	O
,	O
leading	O
to	O
a	O
higher	O
RCAN1	B-GENE-N
/	O
NFATc1	B-GENE-N
ratio	O
and	O
consequently	O
NFATc1	B-GENE-N
inhibition	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
lysosomal	O
pH	O
in	O
osteoclasts	O
leads	O
to	O
decreased	O
NFATc1	B-GENE-N
signaling	O
and	O
nuclear	O
translocation	O
,	O
resulting	O
in	O
a	O
cell	O
autonomous	O
impairment	O
of	O
osteoclastogenesis	O
in	O
vitro	O
.	O

AKRs	B-GENE-N
expression	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
smokers	O
:	O
The	O
role	O
of	O
body	O
mass	O
index	O
.	O

Aldo	B-GENE-N
-	I-GENE-N
keto	I-GENE-N
reductases	I-GENE-N
(	O
AKRs	B-GENE-N
)	O
metabolize	O
a	O
wide	O
range	O
of	O
substrates	O
,	O
including	O
polycyclic	B-CHEMICAL
aromatic	I-CHEMICAL
hydrocarbons	I-CHEMICAL
(	O
PAHs	B-CHEMICAL
)	O
,	O
generating	O
metabolites	O
(	O
o	B-CHEMICAL
-	I-CHEMICAL
quinones	I-CHEMICAL
)	O
and	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
,	O
which	O
are	O
capable	O
of	O
initiating	O
and	O
promoting	O
carcinogenesis	O
.	O

Exposure	O
to	O
PAHs	B-CHEMICAL
,	O
their	O
metabolites	O
,	O
and	O
ROS	O
further	O
increase	O
AKRs	B-GENE-N
isoform	O
expression	O
that	O
may	O
amplify	O
oxidative	O
damage	O
.	O

Human	B-GENE-N
AKR	I-GENE-N
enzymes	O
are	O
highly	O
polymorphic	O
,	O
and	O
allelic	O
variants	O
may	O
contribute	O
to	O
different	O
AKRs	B-GENE-N
expression	O
in	O
individuals	O
.	O

Despite	O
the	O
importance	O
of	O
AKRs	B-GENE-N
in	O
PAHs	B-CHEMICAL
metabolism	O
,	O
there	O
are	O
no	O
studies	O
that	O
evaluate	O
,	O
in	O
general	O
human	O
populations	O
,	O
the	O
effect	O
of	O
PAHs	B-CHEMICAL
on	O
AKRs	B-GENE-N
expression	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
tobacco	O
smoke	O
exposure	O
,	O
and	O
AKR1A1	B-GENE-Y
*	I-GENE-Y
2	I-GENE-Y
and	O
AKR1C3	B-GENE-Y
*	I-GENE-Y
2	I-GENE-Y
polymorphisms	O
,	O
on	O
AKR1A1	B-GENE-Y
and	O
AKR1C1	B-GENE-Y
-	O
AKR1C3	B-GENE-Y
messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
in	O
PBLs	O
from	O
smokers	O
.	O

In	O
the	O
smoker	O
group	O
,	O
there	O
is	O
a	O
statistically	O
significant	O
positive	O
association	O
between	O
AKR1A1	B-GENE-Y
,	O
AKR1C1	B-GENE-Y
,	O
and	O
AKR1C3	B-GENE-Y
mRNA	O
induction	O
and	O
urine	O
cotinine	B-CHEMICAL
levels	O
in	O
individuals	O
with	O
a	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
less	O
than	O
25	O
.	O

However	O
,	O
AKR1A1	B-GENE-Y
*	I-GENE-Y
2	I-GENE-Y
and	O
AKR1C3	B-GENE-Y
*	I-GENE-Y
2	I-GENE-Y
alleles	O
did	O
not	O
influence	O
AKR1A1	B-GENE-Y
and	O
AKR1C1	B-GENE-Y
-	O
AKR1C3	B-GENE-Y
mRNA	O
levels	O
.	O

These	O
results	O
suggest	O
that	O
AKRs	B-GENE-N
induction	O
by	O
PAHs	B-CHEMICAL
in	O
smokers	O
'	O
PBLs	O
is	O
associated	O
with	O
BMI	O
;	O
therefore	O
,	O
the	O
role	O
of	O
adipose	O
tissue	O
accumulation	O
in	O
PAHs	B-CHEMICAL
'	O
effects	O
needs	O
further	O
investigation	O
.	O

Novel	O
non	O
-	O
canonical	O
TGF	B-GENE-N
-	I-GENE-N
β	I-GENE-N
signaling	O
networks	O
:	O
emerging	O
roles	O
in	O
airway	O
smooth	O
muscle	O
phenotype	O
and	O
function	O
.	O

The	O
airway	O
smooth	O
muscle	O
(	O
ASM	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

ASM	O
cells	O
express	O
a	O
wide	O
range	O
of	O
receptors	O
involved	O
in	O
contraction	O
,	O
growth	O
,	O
matrix	O
protein	O
production	O
and	O
the	O
secretion	O
of	O
cytokines	B-GENE-N
and	O
chemokines	B-GENE-N
.	O

Transforming	B-GENE-N
growth	I-GENE-N
factor	I-GENE-N
beta	I-GENE-N
(	O
TGF	B-GENE-N
-	I-GENE-N
β	I-GENE-N
)	O
is	O
one	O
of	O
the	O
major	O
players	O
in	O
determining	O
the	O
structural	O
and	O
functional	O
abnormalities	O
of	O
the	O
ASM	O
in	O
asthma	O
and	O
COPD	O
.	O

It	O
is	O
increasingly	O
evident	O
that	O
TGF	B-GENE-N
-	I-GENE-N
β	I-GENE-N
functions	O
as	O
a	O
master	O
switch	O
,	O
controlling	O
a	O
network	O
of	O
intracellular	O
and	O
autocrine	O
signaling	O
loops	O
that	O
effect	O
ASM	O
phenotype	O
and	O
function	O
.	O

In	O
this	O
review	O
,	O
the	O
various	O
elements	O
that	O
participate	O
in	O
non	O
-	O
canonical	O
TGF	B-GENE-N
-	I-GENE-N
β	I-GENE-N
signaling	O
,	O
including	O
MAPK	B-GENE-N
,	O
PI3K	B-GENE-N
,	O
WNT	B-GENE-N
/	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
,	O
and	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
are	O
discussed	O
,	O
focusing	O
on	O
their	O
effect	O
on	O
ASM	O
phenotype	O
and	O
function	O
.	O

In	O
addition	O
,	O
new	O
aspects	O
of	O
ASM	O
biology	O
and	O
their	O
possible	O
association	O
with	O
non	O
-	O
canonical	O
TGF	B-GENE-N
-	I-GENE-N
β	I-GENE-N
signaling	O
will	O
be	O
discussed	O
.	O

Thiazolidinediones	B-CHEMICAL
(	O
TZDs	B-CHEMICAL
)	O
affect	O
osteoblast	O
viability	O
and	O
biomarkers	O
independently	O
of	O
the	O
TZD	B-CHEMICAL
effects	O
on	O
aromatase	B-GENE-Y
.	O

Thiazolidinediones	B-CHEMICAL
(	O
TZDs	B-CHEMICAL
)	O
are	O
insulin	B-GENE-Y
sensitizers	O
used	O
for	O
treatment	O
of	O
diabetes	O
.	O

We	O
have	O
previously	O
reported	O
that	O
TZDs	B-CHEMICAL
reduce	O
estrogen	B-CHEMICAL
synthesis	O
by	O
inhibiting	O
aromatase	B-GENE-Y
activity	O
in	O
human	O
granulosa	O
cells	O
(	O
HGC	O
)	O
.	O

Multiple	O
clinical	O
trials	O
demonstrated	O
that	O
TZDs	B-CHEMICAL
increase	O
the	O
risk	O
of	O
fractures	O
in	O
postmenopausal	O
women	O
with	O
type	O
2	O
diabetes	O
.	O

We	O
studied	O
mouse	O
osteoblasts	O
alone	O
or	O
in	O
a	O
co	O
-	O
culture	O
with	O
HGC	O
to	O
determine	O
whether	O
TZD	B-CHEMICAL
inhibition	O
of	O
aromatase	B-GENE-Y
plays	O
a	O
role	O
in	O
their	O
effects	O
on	O
bone	O
metabolism	O
.	O

Mouse	O
osteoblasts	O
were	O
cultured	O
with	O
and	O
without	O
HGC	O
,	O
and	O
incubated	O
in	O
a	O
medium	O
with	O
or	O
without	O
testosterone	B-CHEMICAL
,	O
pioglitazone	B-CHEMICAL
or	O
rosiglitazone	B-CHEMICAL
.	O

Cell	O
growth	O
,	O
oleic	O
acid	O
uptake	O
,	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
activity	O
,	O
and	O
osteocalcin	B-GENE-Y
production	O
were	O
measured	O
.	O

TZDs	B-CHEMICAL
inhibited	O
estradiol	B-CHEMICAL
production	O
by	O
up	O
to	O
84	O
%	O
in	O
HGC	O
/	O
mouse	O
osteoblast	O
co	O
-	O
cultures	O
.	O

TZDs	B-CHEMICAL
induced	O
mouse	O
osteoblast	O
death	O
and	O
increased	O
oleic	B-CHEMICAL
acid	I-CHEMICAL
uptake	O
.	O

TZDs	B-CHEMICAL
also	O
inhibited	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
activity	O
(	O
58	O
-	O
75	O
%	O
,	O
p	O
<	O
0	O
.	O
046	O
)	O
and	O
osteocalcin	B-GENE-Y
production	O
(	O
52	O
-	O
75	O
%	O
,	O
p	O
<	O
0	O
.	O
031	O
)	O
.	O

For	O
all	O
the	O
parameters	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
osteoblast	O
cultures	O
alone	O
and	O
the	O
HCG	O
/	O
osteoblast	O
co	O
-	O
cultures	O
.	O

TZD	B-CHEMICAL
effects	O
on	O
osteoblast	O
viability	O
,	O
oleic	O
acid	O
uptake	O
,	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
and	O
osteocalcin	B-GENE-Y
production	O
are	O
independent	O
of	O
their	O
effects	O
on	O
aromatase	B-GENE-Y
.	O

Theoretical	O
study	O
of	O
the	O
decomposition	O
of	O
ethyl	B-CHEMICAL
and	I-CHEMICAL
ethyl	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
glycidate	I-CHEMICAL
.	O

The	O
mechanism	O
of	O
the	O
decomposition	O
of	O
ethyl	B-CHEMICAL
and	I-CHEMICAL
ethyl	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
glycidate	I-CHEMICAL
in	O
gas	O
phase	O
was	O
studied	O
by	O
density	O
functional	O
theory	O
(	O
DFT	O
)	O
and	O
MP2	O
methods	O
.	O

A	O
proposed	O
mechanism	O
for	O
the	O
reaction	O
indicates	O
that	O
the	O
ethyl	B-CHEMICAL
side	O
of	O
the	O
ester	O
is	O
eliminated	O
as	O
ethylene	B-CHEMICAL
through	O
a	O
concerted	O
six	O
-	O
membered	O
cyclic	O
transition	O
state	O
,	O
and	O
the	O
unstable	O
intermediate	O
glycidic	B-CHEMICAL
acid	I-CHEMICAL
decarboxylates	O
rapidly	O
to	O
give	O
the	O
corresponding	O
aldehyde	B-CHEMICAL
.	O

Two	O
possible	O
pathways	O
for	O
glycidic	B-CHEMICAL
acid	I-CHEMICAL
decarboxylation	O
were	O
studied	O
:	O
one	O
via	O
a	O
five	O
-	O
membered	O
cyclic	O
transition	O
state	O
,	O
and	O
the	O
other	O
via	O
a	O
four	O
-	O
membered	O
cyclic	O
transition	O
state	O
.	O

The	O
results	O
of	O
the	O
calculations	O
indicate	O
that	O
the	O
decarboxylation	O
reaction	O
occurs	O
via	O
a	O
mechanism	O
with	O
five	O
-	O
membered	O
cyclic	O
transition	O
state	O
.	O

Multidrug	B-GENE-N
resistance	I-GENE-N
-	I-GENE-N
associated	I-GENE-N
proteins	I-GENE-N
are	O
involved	O
in	O
the	O
transport	O
of	O
the	O
glutathione	B-CHEMICAL
conjugates	O
of	O
the	O
ultimate	O
carcinogen	O
of	O
benzo	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyrene	I-CHEMICAL
in	O
human	O
Caco	O
-	O
2	O
cells	O
.	O

A	O
wide	O
variety	O
of	O
contaminants	O
are	O
ingested	O
through	O
food	O
,	O
among	O
them	O
the	O
pro	O
-	O
carcinogenic	O
polycyclic	O
aromatic	O
hydrocarbon	O
benzo	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyrene	I-CHEMICAL
(	O
BP	O
)	O
that	O
is	O
resorbed	O
and	O
partially	O
metabolized	O
in	O
the	O
enterocytes	O
of	O
the	O
small	O
intestine	O
.	O

Previous	O
in	O
vitro	O
studies	O
have	O
revealed	O
that	O
BP	B-CHEMICAL
phenols	I-CHEMICAL
are	O
excreted	O
as	O
Phase	O
II	O
metabolites	O
including	O
glucuronides	O
and	O
sulfates	B-CHEMICAL
.	O

This	O
export	O
is	O
mediated	O
by	O
the	O
breast	B-GENE-Y
cancer	I-GENE-Y
resistance	I-GENE-Y
protein	I-GENE-Y
(	O
ABCG2	B-GENE-Y
)	O
.	O

The	O
ultimate	O
carcinogenic	O
Phase	O
I	O
BP	O
metabolite	O
anti	O
-	O
BP	B-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
dihydrodiol	I-CHEMICAL
-	I-CHEMICAL
9	I-CHEMICAL
,	I-CHEMICAL
10	I-CHEMICAL
-	I-CHEMICAL
epoxide	I-CHEMICAL
(	O
BPDE	B-CHEMICAL
)	O
can	O
be	O
detoxified	O
by	O
glutathione	B-CHEMICAL
conjugate	O
formation	O
catalyzed	O
by	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferases	I-GENE-N
.	O

In	O
the	O
present	O
study	O
,	O
differentiated	O
human	O
intestinal	O
Caco	O
-	O
2	O
cells	O
were	O
used	O
as	O
a	O
model	O
for	O
the	O
human	O
small	O
intestine	O
to	O
investigate	O
the	O
detoxification	O
of	O
BPDE	B-CHEMICAL
and	O
excretion	O
of	O
stereoisomeric	O
glutathione	B-CHEMICAL
conjugates	O
in	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
the	O
glutathione	B-GENE-N
-	I-GENE-N
cleaving	I-GENE-N
enzyme	I-GENE-N
γ	B-GENE-N
-	I-GENE-N
glutamyl	I-GENE-N
transpeptidase	I-GENE-N
at	O
the	O
cell	O
surface	O
.	O

The	O
results	O
indicate	O
that	O
the	O
glutathione	B-CHEMICAL
conjugates	O
of	O
BPDE	B-CHEMICAL
are	O
formed	O
and	O
excreted	O
mainly	O
to	O
the	O
apical	O
and	O
to	O
a	O
minor	O
extent	O
to	O
the	O
basolateral	O
side	O
of	O
polarized	O
Caco	O
-	O
2	O
monolayers	O
.	O

Inhibition	O
studies	O
revealed	O
that	O
the	O
multidrug	B-GENE-N
resistance	I-GENE-N
-	I-GENE-N
associated	I-GENE-N
proteins	I-GENE-N
(	O
ABCCs	B-GENE-N
)	O
are	O
involved	O
in	O
the	O
transport	O
of	O
BPDE	B-CHEMICAL
glutathione	I-CHEMICAL
conjugates	O
.	O

Stable	O
ABCC1	B-GENE-Y
,	O
ABCC2	B-GENE-Y
and	O
ABCC3	B-GENE-Y
knockdown	O
cell	O
lines	O
were	O
generated	O
,	O
thus	O
making	O
it	O
possible	O
to	O
demonstrate	O
that	O
ABCC1	B-GENE-Y
mediates	O
the	O
basolateral	O
and	O
ABCC2	B-GENE-Y
the	O
apical	O
excretion	O
of	O
BPDE	B-CHEMICAL
glutathione	I-CHEMICAL
conjugates	O
.	O

In	O
conclusion	O
,	O
the	O
ultimate	O
carcinogen	O
BPDE	B-CHEMICAL
is	O
detoxified	O
via	O
glutathione	B-CHEMICAL
conjugation	O
and	O
subsequently	O
excreted	O
by	O
Caco	O
-	O
2	O
cells	O
in	O
both	O
apical	O
and	O
basolateral	O
directions	O
.	O

This	O
finding	O
is	O
equivalent	O
to	O
a	O
transport	O
into	O
feces	O
as	O
well	O
as	O
blood	O
system	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

A	O
human	O
hemi	O
-	O
cornea	O
model	O
for	O
eye	O
irritation	O
testing	O
:	O
quality	O
control	O
of	O
production	O
,	O
reliability	O
and	O
predictive	O
capacity	O
.	O

We	O
have	O
developed	O
a	O
3	O
-	O
dimensional	O
human	O
hemi	O
-	O
cornea	O
which	O
comprises	O
an	O
immortalized	O
epithelial	O
cell	O
line	O
and	O
keratocytes	O
embedded	O
in	O
a	O
collagen	B-GENE-N
stroma	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
used	O
MTT	B-CHEMICAL
reduction	O
of	O
the	O
whole	O
tissue	O
to	O
clarify	O
whether	O
the	O
production	O
of	O
this	O
complex	O
3	O
-	O
D	O
-	O
model	O
is	O
transferable	O
into	O
other	O
laboratories	O
and	O
whether	O
these	O
tissues	O
can	O
be	O
constructed	O
reproducibly	O
.	O

Our	O
results	O
demonstrate	O
the	O
reproducible	O
production	O
of	O
the	O
hemi	O
-	O
cornea	O
model	O
according	O
to	O
standard	O
operation	O
procedures	O
using	O
15	O
independent	O
batches	O
of	O
reconstructed	O
hemi	O
-	O
cornea	O
models	O
in	O
two	O
independent	O
laboratories	O
each	O
.	O

Furthermore	O
,	O
the	O
hemi	O
-	O
cornea	O
tissues	O
have	O
been	O
treated	O
with	O
20	O
chemicals	O
of	O
different	O
eye	O
-	O
irritating	O
potential	O
under	O
blind	O
conditions	O
to	O
assess	O
the	O
performance	O
and	O
limitations	O
of	O
our	O
test	O
system	O
comparing	O
three	O
different	O
prediction	O
models	O
.	O

The	O
most	O
suitable	O
prediction	O
model	O
revealed	O
an	O
overall	O
in	O
vitro	O
-	O
in	O
vivo	O
concordance	O
of	O
80	O
%	O
and	O
70	O
%	O
in	O
the	O
participating	O
laboratories	O
,	O
respectively	O
,	O
and	O
an	O
inter	O
-	O
laboratory	O
concordance	O
of	O
80	O
%	O
.	O

Sensitivity	O
of	O
the	O
test	O
was	O
77	O
%	O
and	O
specificity	O
was	O
between	O
57	O
%	O
and	O
86	O
%	O
to	O
discriminate	O
classified	O
from	O
non	O
-	O
classified	O
chemicals	O
.	O

We	O
conclude	O
that	O
additional	O
physiologically	O
relevant	O
endpoints	O
in	O
both	O
epithelium	O
and	O
stroma	O
have	O
to	O
be	O
developed	O
for	O
the	O
reliable	O
prediction	O
of	O
all	O
GHS	O
classes	O
of	O
eye	O
irritation	O
in	O
one	O
stand	O
alone	O
test	O
system	O
.	O

Lead	O
-	O
induced	O
ER	O
calcium	B-CHEMICAL
release	O
and	O
inhibitory	O
effects	O
of	O
methionine	B-CHEMICAL
choline	I-CHEMICAL
in	O
cultured	O
rat	O
hippocampal	O
neurons	O
.	O

Lead	O
,	O
a	O
ubiquitous	O
neurotoxicant	O
,	O
can	O
result	O
in	O
learning	O
and	O
memory	O
dysfunction	O
.	O

Long	O
term	O
potentiation	O
in	O
the	O
hippocampus	O
,	O
a	O
potential	O
neural	O
substrate	O
for	O
learning	O
and	O
memory	O
,	O
is	O
thought	O
to	O
be	O
linked	O
to	O
calcium	B-CHEMICAL
-	O
triggered	O
intracellular	O
events	O
.	O

In	O
this	O
study	O
,	O
laser	O
scanning	O
confocal	O
microscopy	O
was	O
used	O
to	O
examine	O
the	O
effects	O
of	O
Pb	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
on	O
intracellular	O
and	O
endoplasmic	O
reticulum	O
free	O
calcium	B-CHEMICAL
concentration	O
(	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
and	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
ER	O
)	O
)	O
in	O
cultured	O
neonatal	O
rat	O
hippocampal	O
neurons	O
and	O
their	O
possible	O
antagonism	O
by	O
methionine	B-CHEMICAL
choline	I-CHEMICAL
;	O
understanding	O
these	O
effects	O
would	O
help	O
explain	O
the	O
lead	O
-	O
induced	O
cognitive	O
and	O
learning	O
dysfunction	O
and	O
explore	O
efficient	O
safety	O
and	O
relief	O
strategies	O
.	O

The	O
results	O
showed	O
that	O
Pb	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
increased	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
and	O
decreased	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
ER	O
)	O
linearly	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependant	O
manner	O
,	O
and	O
Pb	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
addition	O
after	O
the	O
applying	O
of	O
a	O
ryanodine	B-GENE-N
receptor	I-GENE-N
(	O
RyR	B-GENE-N
)	O
antagonist	O
and	O
an	O
inositol	B-GENE-N
-	I-GENE-N
1	I-GENE-N
,	I-GENE-N
4	I-GENE-N
,	I-GENE-N
5	I-GENE-N
-	I-GENE-N
triphosphate	I-GENE-N
receptor	I-GENE-N
(	O
IP	B-GENE-N
(	I-GENE-N
3	I-GENE-N
)	I-GENE-N
R	I-GENE-N
)	O
antagonist	O
did	O
not	O
increase	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
.	O

The	O
addition	O
of	O
10	O
,	O
20	O
,	O
or	O
40	O
mmol	O
/	O
L	O
methionine	B-CHEMICAL
choline	I-CHEMICAL
simultaneously	O
with	O
addition	O
of	O
10	O
μmol	O
/	O
L	O
Pb	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
decreased	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
in	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
free	O
culture	O
medium	O
by	O
39	O
.	O
0	O
%	O
,	O
66	O
.	O
0	O
%	O
,	O
and	O
61	O
.	O
6	O
%	O
,	O
respectively	O
,	O
in	O
a	O
concentration	O
-	O
dependant	O
manner	O
in	O
a	O
certain	O
dose	O
range	O
.	O

Our	O
results	O
suggest	O
that	O
Pb	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
induces	O
ER	O
calcium	B-CHEMICAL
release	O
to	O
increase	O
the	O
resting	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
;	O
and	O
methionine	B-CHEMICAL
choline	I-CHEMICAL
inhibit	O
this	O
increase	O
in	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
.	O

α	B-CHEMICAL
-	I-CHEMICAL
Amino	I-CHEMICAL
-	I-CHEMICAL
α	I-CHEMICAL
´	I-CHEMICAL
-	I-CHEMICAL
Halomethylketones	I-CHEMICAL
:	O
Synthetic	O
Methodologies	O
and	O
Pharmaceutical	O
Applications	O
as	O
Serine	B-GENE-N
and	I-GENE-N
Cysteine	I-GENE-N
Protease	I-GENE-N
Inhibitors	O
.	O

α	B-CHEMICAL
-	I-CHEMICAL
Amino	I-CHEMICAL
-	I-CHEMICAL
α	I-CHEMICAL
´	I-CHEMICAL
-	I-CHEMICAL
halomethylketones	I-CHEMICAL
are	O
interesting	O
scaffolds	O
bearing	O
(	O
at	O
least	O
)	O
two	O
sequential	O
electrophilic	O
carbons	B-CHEMICAL
that	O
by	O
interacting	O
with	O
the	O
nucleophilic	O
moieties	O
of	O
several	O
enzymes	O
,	O
represent	O
the	O
ideal	O
candidates	O
for	O
in	O
vivo	O
and	O
in	O
vitro	O
inhibition	O
studies	O
.	O

In	O
this	O
work	O
a	O
summary	O
of	O
their	O
use	O
as	O
optimal	O
inhibitors	O
of	O
physiologically	O
relevant	O
serine	B-GENE-N
and	I-GENE-N
cysteine	I-GENE-N
proteases	I-GENE-N
is	O
given	O
with	O
a	O
particular	O
emphasis	O
on	O
recently	O
established	O
SAR	O
studies	O
.	O

A	O
brief	O
survey	O
of	O
the	O
most	O
relevant	O
synthetic	O
processes	O
for	O
their	O
obtainment	O
and	O
the	O
importance	O
they	O
possess	O
in	O
synthetic	O
medicinal	O
chemistry	O
is	O
reported	O
.	O

Noncanonical	O
control	O
of	O
C	O
.	O
elegans	O
germline	O
apoptosis	O
by	O
the	O
insulin	B-GENE-N
/	O
IGF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	O
Ras	B-GENE-N
/	O
MAPK	B-GENE-N
signaling	O
pathways	O
.	O

The	O
insulin	B-GENE-N
/	O
IGF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
pathway	O
controls	O
a	O
number	O
of	O
physiological	O
processes	O
in	O
the	O
nematode	O
worm	O
Caenorhabditis	O
elegans	O
,	O
including	O
development	O
,	O
aging	O
and	O
stress	O
response	O
.	O

We	O
previously	O
found	O
that	O
the	O
Akt	B-GENE-Y
/	O
PKB	B-GENE-Y
ortholog	O
AKT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
dampens	O
the	O
apoptotic	O
response	O
to	O
genotoxic	O
stress	O
in	O
the	O
germline	O
by	O
negatively	O
regulating	O
the	O
p53	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
CEP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Here	O
,	O
we	O
report	O
unexpected	O
rearrangements	O
to	O
the	O
insulin	B-GENE-N
/	O
IGF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
pathway	O
,	O
whereby	O
the	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
receptor	I-GENE-Y
DAF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
3	B-GENE-Y
-	I-GENE-Y
phosphoinositide	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
PDK	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
oppose	O
AKT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
to	O
promote	O
DNA	O
damage	O
-	O
induced	O
apoptosis	O
.	O

While	O
DNA	O
damage	O
does	O
not	O
affect	O
phosphorylation	O
at	O
the	O
PDK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
site	O
Thr350	B-GENE-N
/	I-GENE-N
Thr308	I-GENE-N
of	O
AKT	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
it	O
increased	O
phosphorylation	O
at	O
Ser517	B-GENE-N
/	I-GENE-N
Ser473	I-GENE-N
.	O

Although	O
ablation	O
of	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
or	O
pdk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
completely	O
suppressed	O
akt	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
dependent	O
apoptosis	O
,	O
the	O
transcriptional	O
activation	O
of	O
CEP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
unaffected	O
,	O
suggesting	O
that	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
pdk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
act	O
independently	O
or	O
downstream	O
of	O
cep	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
akt	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Ablation	O
of	O
the	O
akt	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
paralog	O
akt	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
or	O
the	O
downstream	O
target	O
of	O
the	O
insulin	B-GENE-N
/	O
IGF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
pathway	O
daf	B-GENE-Y
-	I-GENE-Y
16	I-GENE-Y
(	O
a	O
FOXO	B-GENE-Y
transcription	O
factor	O
)	O
restored	O
sensitivity	O
to	O
damage	O
-	O
induced	O
apoptosis	O
in	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
pdk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mutants	O
.	O

In	O
addition	O
,	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
pdk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mutants	O
have	O
reduced	O
levels	O
of	O
phospho	B-GENE-Y
-	I-GENE-Y
MPK	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	O
ERK	B-GENE-N
in	O
their	O
germ	O
cells	O
,	O
indicating	O
that	O
the	O
insulin	B-GENE-N
/	O
IGF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
pathway	O
promotes	O
Ras	B-GENE-N
signaling	O
in	O
the	O
germline	O
.	O

Ablation	O
of	O
the	O
Ras	B-GENE-N
effector	O
gla	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
a	O
negative	O
regulator	O
of	O
mpk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
restored	O
sensitivity	O
to	O
apoptosis	O
in	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mutants	O
,	O
suggesting	O
that	O
gla	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
acts	O
downstream	O
of	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

In	O
addition	O
,	O
the	O
hypersensitivity	O
of	O
let	B-GENE-Y
-	I-GENE-Y
60	I-GENE-Y
/	O
Ras	B-GENE-N
gain	O
-	O
of	O
-	O
function	O
mutants	O
to	O
damage	O
-	O
induced	O
apoptosis	O
was	O
suppressed	O
to	O
wild	O
-	O
type	O
levels	O
by	O
ablation	O
of	O
daf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Thus	O
,	O
insulin	B-GENE-N
/	O
IGF	B-GENE-N
-	I-GENE-N
1	I-GENE-N
signaling	O
selectively	O
engages	O
AKT	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
DAF	B-GENE-Y
-	I-GENE-Y
16	I-GENE-Y
to	O
promote	O
DNA	O
damage	O
-	O
induced	O
germ	O
cell	O
apoptosis	O
downstream	O
of	O
CEP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
through	O
the	O
Ras	B-GENE-N
pathway	O
.	O

Influence	O
of	O
stimulant	O
-	O
induced	O
hyperactivity	O
on	O
social	O
approach	O
in	O
the	O
BTBR	O
mouse	O
model	O
of	O
autism	O
.	O

Translational	O
research	O
is	O
needed	O
to	O
discover	O
pharmacological	O
targets	O
and	O
treatments	O
for	O
the	O
diagnostic	O
behavioral	O
domains	O
of	O
autism	O
spectrum	O
disorders	O
.	O

Animal	O
models	O
with	O
phenotypic	O
relevance	O
to	O
diagnostic	O
criteria	O
offer	O
clear	O
experimental	O
strategies	O
to	O
test	O
the	O
efficacy	O
and	O
safety	O
of	O
novel	O
treatments	O
.	O

Antagonists	O
of	O
mGluR5	B-GENE-Y
receptors	O
are	O
in	O
clinical	O
trials	O
for	O
Fragile	O
X	O
syndrome	O
and	O
under	O
investigation	O
for	O
the	O
treatment	O
of	O
autism	O
spectrum	O
disorders	O
.	O

However	O
,	O
in	O
preclinical	O
studies	O
of	O
mGluR5	B-GENE-Y
compounds	O
tested	O
in	O
our	O
laboratory	O
and	O
others	O
,	O
increased	O
locomotion	O
following	O
mGluR5	B-GENE-Y
modulation	O
has	O
been	O
observed	O
.	O

Understanding	O
the	O
influence	O
of	O
general	O
activity	O
on	O
sociability	O
and	O
repetitive	O
behaviors	O
will	O
increase	O
the	O
accuracy	O
of	O
interpretations	O
of	O
positive	O
outcomes	O
measured	O
from	O
pharmacological	O
treatment	O
that	O
produces	O
locomotor	O
activating	O
or	O
sedating	O
effects	O
.	O

In	O
the	O
present	O
studies	O
,	O
dose	O
-	O
response	O
curves	O
for	O
d	B-CHEMICAL
-	I-CHEMICAL
amphetamine	I-CHEMICAL
(	O
AMPH	B-CHEMICAL
)	O
-	O
induced	O
hyperlocomotion	O
were	O
similar	O
in	O
standard	O
B6	O
mice	O
and	O
in	O
the	O
BTBR	O
mouse	O
model	O
of	O
autism	O
.	O

AMPH	B-CHEMICAL
produced	O
significant	O
,	O
robust	O
reductions	O
in	O
the	O
high	O
level	O
of	O
repetitive	O
self	O
-	O
grooming	O
that	O
characterizes	O
BTBR	O
,	O
and	O
also	O
reduced	O
the	O
low	O
baseline	O
grooming	O
in	O
B6	O
,	O
indicating	O
that	O
AMPH	B-CHEMICAL
-	O
induced	O
hyperlocomotion	O
competes	O
with	O
time	O
spent	O
engaged	O
in	O
self	O
-	O
grooming	O
.	O

We	O
then	O
tested	O
AMPH	B-CHEMICAL
in	O
B6	O
and	O
BTBR	O
on	O
the	O
3	O
-	O
chambered	O
social	O
approach	O
task	O
.	O

One	O
component	O
of	O
sociability	O
,	O
the	O
time	O
spent	O
in	O
the	O
chamber	O
with	O
the	O
novel	O
mouse	O
,	O
in	O
B6	O
mice	O
was	O
reduced	O
,	O
while	O
the	O
sniffing	O
time	O
component	O
of	O
sociability	O
in	O
BTBR	O
mice	O
was	O
enhanced	O
.	O

This	O
finding	O
replicated	O
across	O
multiple	O
cohorts	O
treated	O
with	O
AMPH	B-CHEMICAL
and	O
saline	O
vehicle	O
.	O

In	O
-	O
depth	O
analysis	O
revealed	O
that	O
AMPH	B-CHEMICAL
increased	O
the	O
number	O
and	O
decreased	O
the	O
duration	O
of	O
sniffing	O
bouts	O
in	O
BTBR	O
,	O
suggesting	O
BTBR	O
treated	O
with	O
AMPH	B-CHEMICAL
mostly	O
engaged	O
in	O
brief	O
sniffs	O
rather	O
than	O
true	O
social	O
interactions	O
with	O
the	O
novel	O
mouse	O
during	O
the	O
social	O
approach	O
task	O
.	O

Our	O
data	O
suggest	O
that	O
compounds	O
with	O
stimulant	O
properties	O
may	O
have	O
some	O
direct	O
benefits	O
on	O
reducing	O
repetitive	O
behaviors	O
in	O
autism	O
spectrum	O
disorders	O
,	O
particularly	O
in	O
the	O
subset	O
of	O
autistic	O
individuals	O
with	O
hyperactivity	O
.	O

This	O
article	O
is	O
part	O
of	O
the	O
Special	O
Issue	O
entitled	O
'	O
Neurodevelopmental	O
Disorders	O
'	O
.	O

Energy	O
depletion	O
of	O
bovine	O
mammary	O
epithelial	O
cells	O
activates	O
AMPK	B-GENE-N
and	O
suppresses	O
protein	O
synthesis	O
through	O
inhibition	O
of	O
mTORC1	B-GENE-N
signaling	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
cellular	O
energy	O
status	O
regulates	O
global	O
protein	O
synthesis	O
in	O
mammary	O
epithelial	O
cells	O
have	O
not	O
been	O
characterized	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effect	O
of	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
AMPK	B-GENE-N
)	O
activation	O
by	O
2	B-CHEMICAL
-	I-CHEMICAL
deoxyglucose	I-CHEMICAL
on	O
protein	O
synthesis	O
and	O
the	O
mammalian	B-GENE-N
target	I-GENE-N
of	I-GENE-N
rapamycin	I-GENE-N
complex	I-GENE-N
1	I-GENE-N
(	O
mTORC1	B-GENE-N
)	O
signaling	O
pathway	O
in	O
bovine	O
mammary	O
epithelial	O
cells	O
.	O

Phosphorylation	O
of	O
AMPK	B-GENE-N
at	O
Thr172	B-CHEMICAL
increased	O
by	O
1	O
.	O
4	O
-	O
fold	O
within	O
5	O
min	O
,	O
and	O
remained	O
elevated	O
throughout	O
a	O
30	O
-	O
min	O
time	O
course	O
,	O
in	O
response	O
to	O
2	B-CHEMICAL
-	I-CHEMICAL
deoxyglucose	I-CHEMICAL
.	O

Global	O
rates	O
of	O
protein	O
synthesis	O
declined	O
by	O
78	O
%	O
of	O
control	O
values	O
.	O

The	O
decline	O
in	O
protein	O
synthesis	O
was	O
associated	O
with	O
repression	O
of	O
mTORC1	B-GENE-N
signaling	O
,	O
as	O
indicated	O
by	O
reduced	O
phosphorylation	O
of	O
ribosomal	B-GENE-Y
protein	I-GENE-Y
S6	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
and	O
eIF4E	B-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
4E	B-GENE-Y
-	I-GENE-Y
BP1	I-GENE-Y
)	O
.	O

Phosphorylation	O
of	O
ER	O
-	O
stress	O
marker	O
eIF2α	B-GENE-Y
was	O
also	O
increased	O
but	O
only	O
at	O
30	O
min	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
deoxyglucose	I-CHEMICAL
exposure	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
Deoxyglucose	I-CHEMICAL
increased	O
phosphorylation	O
of	O
tuberous	B-GENE-Y
sclerosis	I-GENE-Y
complex	I-GENE-Y
2	I-GENE-Y
(	O
TSC2	B-GENE-Y
)	O
on	O
AMPK	B-GENE-N
consensus	O
sites	O
but	O
did	O
not	O
change	O
the	O
amount	O
of	O
TSC1	B-GENE-Y
bound	O
to	O
TSC2	B-GENE-Y
.	O

Activation	O
of	O
AMPK	B-GENE-N
did	O
not	O
result	O
in	O
changes	O
in	O
the	O
amount	O
of	O
raptor	O
bound	O
to	O
mTOR	B-GENE-Y
.	O

The	O
inhibitory	O
effects	O
of	O
AMPK	B-GENE-N
activation	O
on	O
mTORC1	B-GENE-N
signaling	O
were	O
associated	O
with	O
a	O
marked	O
increase	O
in	O
Ser792	B-CHEMICAL
phosphorylation	O
on	O
raptor	O
.	O

Collectively	O
,	O
the	O
results	O
suggest	O
that	O
activation	O
of	O
AMPK	B-GENE-N
represses	O
global	O
protein	O
synthesis	O
in	O
mammary	O
epithelial	O
cells	O
through	O
inhibition	O
of	O
mTORC1	B-GENE-N
signaling	O
.	O

Validation	O
of	O
an	O
in	O
vitro	O
exposure	O
system	O
for	O
toxicity	O
assessment	O
of	O
air	O
-	O
delivered	O
nanomaterials	O
.	O

To	O
overcome	O
the	O
limitations	O
of	O
in	O
vitro	O
exposure	O
of	O
submerged	O
lung	O
cells	O
to	O
nanoparticles	O
(	O
NPs	O
)	O
,	O
we	O
validated	O
an	O
integrated	O
low	O
flow	O
system	O
capable	O
of	O
generating	O
and	O
depositing	O
airborne	O
NPs	O
directly	O
onto	O
cells	O
at	O
an	O
air	O
-	O
liquid	O
interface	O
(	O
ALI	O
)	O
.	O

The	O
in	O
vitro	O
exposure	O
system	O
was	O
shown	O
to	O
provide	O
uniform	O
and	O
controlled	O
dosing	O
of	O
particles	O
with	O
70	O
.	O
3	O
%	O
efficiency	O
to	O
epithelial	O
cells	O
grown	O
on	O
transwells	O
.	O

This	O
system	O
delivered	O
a	O
continuous	O
airborne	O
exposure	O
of	O
NPs	O
to	O
lung	O
cells	O
without	O
loss	O
of	O
cell	O
viability	O
in	O
repeated	O
4h	O
exposure	O
periods	O
.	O

We	O
sequentially	O
exposed	O
cells	O
to	O
air	O
-	O
delivered	O
copper	B-CHEMICAL
(	O
Cu	B-CHEMICAL
)	O
NPs	O
in	O
vitro	O
to	O
compare	O
toxicity	O
results	O
to	O
our	O
prior	O
in	O
vivo	O
inhalation	O
studies	O
.	O

The	O
evaluation	O
of	O
cellular	O
dosimetry	O
indicated	O
that	O
a	O
large	O
amount	O
of	O
Cu	B-CHEMICAL
was	O
taken	O
up	O
,	O
dissolved	O
and	O
released	O
into	O
the	O
basolateral	O
medium	O
(	O
62	O
%	O
of	O
total	O
mass	O
)	O
.	O

Exposure	O
to	O
Cu	B-CHEMICAL
NPs	O
decreased	O
cell	O
viability	O
to	O
73	O
%	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
elevated	O
levels	O
of	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
,	O
intracellular	O
reactive	O
oxygen	B-CHEMICAL
species	O
and	O
interleukin	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
that	O
mirrored	O
our	O
findings	O
from	O
subacute	O
in	O
vivo	O
inhalation	O
studies	O
in	O
mice	O
.	O

Our	O
results	O
show	O
that	O
this	O
exposure	O
system	O
is	O
useful	O
for	O
screening	O
of	O
NP	O
toxicity	O
in	O
a	O
manner	O
that	O
represents	O
cellular	O
responses	O
of	O
the	O
pulmonary	O
epithelium	O
in	O
vivo	O
.	O

Leukotriene	B-CHEMICAL
D4	I-CHEMICAL
induces	O
cognitive	O
impairment	O
through	O
enhancement	O
of	O
CysLT₁	B-GENE-Y
R	I-GENE-Y
-	O
mediated	O
amyloid	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
generation	O
in	O
mice	O
.	O

Amyloid	B-GENE-Y
plaques	O
in	O
the	O
extracellular	O
parenchyma	O
mainly	O
consist	O
of	O
amyloid	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
peptides	I-GENE-Y
(	O
Aβ	B-GENE-Y
)	O
,	O
one	O
of	O
the	O
pathological	O
hallmarks	O
in	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
neuroinflammation	O
,	O
amyloidogenesis	O
,	O
and	O
memory	O
performance	O
following	O
intracerebral	O
infusions	O
of	O
leukotriene	B-CHEMICAL
D4	I-CHEMICAL
(	O
LTD4	B-CHEMICAL
)	O
in	O
mice	O
.	O

The	O
results	O
demonstrated	O
that	O
intracerebral	O
infusions	O
of	O
LTD4	B-CHEMICAL
(	O
1	O
ng	O
/	O
mouse	O
)	O
produced	O
memory	O
impairment	O
as	O
determined	O
by	O
Morris	O
water	O
maze	O
test	O
and	O
Y	O
-	O
maze	O
test	O
in	O
mice	O
,	O
and	O
caused	O
the	O
accumulation	O
of	O
Aβ1	B-GENE-Y
-	I-GENE-Y
40	I-GENE-Y
and	O
Aβ1	B-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
in	O
the	O
hippocampus	O
and	O
cortex	O
through	O
increased	O
activity	O
of	O
β	O
-	O
and	O
γ	O
-	O
secretases	O
accompanied	O
with	O
increased	O
expression	O
of	O
amyloid	B-GENE-Y
precursor	I-GENE-Y
protein	I-GENE-Y
(	O
APP	B-GENE-Y
)	O
.	O

LTD4	B-CHEMICAL
also	O
induced	O
expression	O
of	O
cysteinyl	B-GENE-Y
leukotriene	I-GENE-Y
receptor	I-GENE-Y
1	I-GENE-Y
(	O
CysLT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
)	O
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
p65	B-GENE-Y
in	O
the	O
hippocampus	O
and	O
cortex	O
.	O

Pretreatment	O
with	O
pranlukast	B-CHEMICAL
(	O
1	O
.	O
5	O
ng	O
/	O
mouse	O
,	O
intracerebroventricularly	O
)	O
,	O
a	O
CysLT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
antagonist	O
,	O
blocked	O
LTD4	B-CHEMICAL
-	O
induced	O
amyloidogenesis	O
,	O
memory	O
deficits	O
.	O

Pranlukast	B-CHEMICAL
(	O
0	O
.	O
6	O
μM	O
)	O
also	O
prevented	O
LTD4	B-CHEMICAL
(	O
20	O
nM	O
)	O
-	O
induced	O
amyloidogenesis	O
in	O
the	O
cultured	O
neurons	O
in	O
vitro	O
.	O

Moreover	O
,	O
LTD4	B-CHEMICAL
-	O
induced	O
increases	O
in	O
CysLT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
p65	B-GENE-Y
in	O
the	O
brain	O
were	O
also	O
attenuated	O
by	O
pranlukast	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
LTD4	B-CHEMICAL
increases	O
Aβ	B-GENE-Y
peptide	I-GENE-Y
burden	O
via	O
activation	O
of	O
CysLT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
,	O
which	O
further	O
affects	O
APP	B-GENE-Y
levels	O
and	O
activity	O
of	O
β	O
-	O
and	O
γ	O
-	O
secretases	O
via	O
the	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
pathway	O
.	O

Our	O
findings	O
identify	O
CysLT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
signaling	O
as	O
a	O
novel	O
proinflammatory	O
and	O
proamyloidogenic	O
pathway	O
,	O
and	O
suggest	O
a	O
rationale	O
for	O
development	O
of	O
therapeutics	O
targeting	O
the	O
CysLT	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
R	I-GENE-Y
in	O
neuroinflammatory	O
diseases	O
such	O
as	O
AD	O
.	O

Swim	O
training	O
of	O
monosodium	B-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
glutamate	I-CHEMICAL
-	O
obese	O
mice	O
improves	O
the	O
impaired	O
insulin	B-GENE-Y
receptor	I-GENE-Y
tyrosine	B-CHEMICAL
phosphorylation	O
in	O
pancreatic	O
islets	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
changes	O
on	O
glucose	B-CHEMICAL
homoeostasis	O
and	O
of	O
the	O
insulin	B-GENE-Y
receptor	I-GENE-Y
(	O
IR	B-GENE-Y
)	O
and	O
insulin	B-GENE-Y
receptor	I-GENE-Y
substrate	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
signalling	O
in	O
pancreatic	O
islets	O
from	O
MSG	B-CHEMICAL
-	O
obese	O
mice	O
submitted	O
to	O
or	O
not	O
submitted	O
to	O
swim	O
training	O
.	O

Swim	O
training	O
of	O
90	O
-	O
day	O
-	O
old	O
MSG	B-CHEMICAL
mice	O
was	O
used	O
to	O
evaluate	O
whether	O
signalling	O
pathways	O
of	O
the	O
IR	B-GENE-Y
and	O
IRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
in	O
islets	O
are	O
involved	O
with	O
the	O
insulin	B-GENE-N
resistance	O
and	O
glucose	B-CHEMICAL
intolerance	O
observed	O
in	O
this	O
obese	O
animal	O
model	O
.	O

The	O
results	O
showed	O
that	O
IR	B-GENE-Y
tyrosine	B-CHEMICAL
phosphorylation	O
(	O
pIR	B-GENE-Y
)	O
was	O
reduced	O
by	O
42	O
%	O
in	O
MSG	B-CHEMICAL
-	O
obese	O
mice	O
(	O
MSG	B-CHEMICAL
,	O
6	O
.	O
7	O
±	O
0	O
.	O
2	O
arbitrary	O
units	O
(	O
a	O
.	O
u	O
.	O
)	O
;	O
control	O
,	O
11	O
.	O
5	O
±	O
0	O
.	O
4	O
a	O
.	O
u	O
.	O
)	O
;	O
on	O
the	O
other	O
hand	O
,	O
exercise	O
training	O
increased	O
pIR	B-GENE-Y
by	O
76	O
%	O
in	O
MSG	B-CHEMICAL
mice	O
without	O
affecting	O
control	O
mice	O
(	O
MSG	B-CHEMICAL
,	O
11	O
.	O
8	O
±	O
0	O
.	O
3	O
;	O
control	O
,	O
12	O
.	O
8	O
±	O
0	O
.	O
2	O
a	O
.	O
u	O
.	O
)	O
.	O

Although	O
the	O
treatment	O
with	O
MSG	B-CHEMICAL
increased	O
IRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
tyrosine	B-CHEMICAL
phosphorylation	O
(	O
pIRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
by	O
96	O
%	O
(	O
MSG	B-CHEMICAL
,	O
17	O
.	O
02	O
±	O
0	O
.	O
6	O
;	O
control	O
,	O
8	O
.	O
7	O
±	O
0	O
.	O
2	O
a	O
.	O
u	O
.	O
)	O
,	O
exercise	O
training	O
also	O
increased	O
it	O
in	O
both	O
groups	O
(	O
control	O
,	O
13	O
.	O
6	O
±	O
0	O
.	O
1	O
;	O
MSG	B-CHEMICAL
,	O
22	O
.	O
2	O
±	O
1	O
.	O
1	O
a	O
.	O
u	O
.	O
)	O
.	O

Current	O
research	O
shows	O
that	O
the	O
practice	O
of	O
swim	O
training	O
increases	O
the	O
tyrosine	B-CHEMICAL
phosphorylation	O
of	O
IRS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
which	O
can	O
modulate	O
the	O
effect	O
caused	O
by	O
obesity	O
in	O
insulin	B-GENE-Y
receptors	I-GENE-Y
.	O

Pioglitazone	B-CHEMICAL
protects	O
against	O
cisplatin	B-CHEMICAL
induced	O
nephrotoxicity	O
in	O
rats	O
and	O
potentiates	O
its	O
anticancer	O
activity	O
against	O
human	O
renal	O
adenocarcinoma	O
cell	O
lines	O
.	O

Cisplatin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	O
is	O
a	O
serious	O
problem	O
that	O
limits	O
its	O
use	O
in	O
cancer	O
treatment	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
renal	O
protective	O
capacity	O
of	O
pioglitazone	B-CHEMICAL
to	O
reduce	O
the	O
cisplatin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	O
.	O

The	O
underlying	O
suggested	O
mechanism	O
(	O
s	O
)	O
and	O
whether	O
this	O
nephroprotective	O
effect	O
(	O
if	O
any	O
)	O
interferes	O
with	O
the	O
cytotoxic	O
effect	O
of	O
cisplatin	B-CHEMICAL
on	O
cancer	O
cells	O
were	O
also	O
investigated	O
.	O

Pioglitazone	B-CHEMICAL
,	O
Bisphenol	B-CHEMICAL
A	I-CHEMICAL
diglycidyl	I-CHEMICAL
ether	I-CHEMICAL
,	O
BADGE	B-CHEMICAL
,	O
IP	O
injected	O
(	O
Peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
gamma	I-GENE-Y
(	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
)	O
antagonist	O
)	O
,	O
or	O
their	O
combination	O
were	O
administered	O
to	O
rats	O
one	O
hour	O
before	O
cisplatin	B-CHEMICAL
injection	O
.	O

Moreover	O
,	O
their	O
effects	O
on	O
the	O
cell	O
viability	O
of	O
human	O
renal	O
adenocarcinoma	O
cell	O
models	O
(	O
ACHN	O
)	O
were	O
studied	O
.	O

The	O
obtained	O
results	O
showed	O
that	O
pioglitazone	B-CHEMICAL
improved	O
the	O
renal	O
function	O
,	O
structural	O
changes	O
,	O
renal	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
,	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
nuclear	B-GENE-N
factor	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
genes	O
expression	O
in	O
cisplatin	B-CHEMICAL
injected	O
rats	O
.	O

It	O
increased	O
both	O
renal	O
reduced	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
content	O
and	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
gene	O
expression	O
.	O

In	O
contrast	O
to	O
the	O
data	O
obtained	O
by	O
prior	O
administration	O
of	O
BADGE	B-CHEMICAL
.	O

Pioglitazone	B-CHEMICAL
also	O
potentiated	O
the	O
cytotoxic	O
effect	O
of	O
cisplatin	B-CHEMICAL
on	O
human	O
renal	O
adenocarcinoma	O
cells	O
and	O
this	O
effect	O
was	O
abolished	O
by	O
BADGE	B-CHEMICAL
co	O
administration	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
suggested	O
that	O
pioglitazone	B-CHEMICAL
protected	O
against	O
cisplatin	B-CHEMICAL
-	O
induced	O
nephrotoxicity	O
through	O
its	O
interaction	O
with	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
receptors	O
and	O
antioxidant	O
effects	O
.	O

Furthermore	O
,	O
pioglitazone	B-CHEMICAL
did	O
not	O
interfere	O
but	O
rather	O
potentiated	O
the	O
cytotoxic	O
effects	O
of	O
cisplatin	B-CHEMICAL
on	O
human	O
renal	O
adenocarcinoma	O
cells	O
.	O

Can	O
peripheral	O
blood	O
γδ	O
T	O
cells	O
predict	O
osteonecrosis	O
of	O
the	O
jaw	O
?	O

An	O
immunological	O
perspective	O
on	O
the	O
adverse	O
drug	O
effects	O
of	O
aminobisphosphonate	B-CHEMICAL
therapy	O
.	O

Nitrogen	B-CHEMICAL
-	I-CHEMICAL
bisphosphonates	I-CHEMICAL
(	O
n	B-CHEMICAL
-	I-CHEMICAL
BP	I-CHEMICAL
)	O
,	O
often	O
referred	O
to	O
as	O
aminobisphosphonates	B-CHEMICAL
,	O
are	O
the	O
most	O
commonly	O
prescribed	O
drugs	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
bone	O
fragility	O
.	O

However	O
,	O
long	O
-	O
term	O
continuous	O
treatment	O
predisposes	O
certain	O
individuals	O
to	O
serious	O
rare	O
side	O
effects	O
,	O
such	O
as	O
bisphosphonate	B-CHEMICAL
-	O
associated	O
osteonecrosis	O
of	O
the	O
jaw	O
(	O
BAONJ	O
)	O
.	O

n	B-CHEMICAL
-	I-CHEMICAL
BP	I-CHEMICAL
use	O
is	O
known	O
to	O
unintentionally	O
activate	O
a	O
subset	O
of	O
innate	O
T	O
cells	O
called	O
Vγ9Vδ2	O
T	O
cells	O
,	O
but	O
the	O
consequence	O
of	O
this	O
chronic	O
immune	O
stimulation	O
has	O
remained	O
unexplored	O
.	O

The	O
primary	O
objectives	O
of	O
this	O
study	O
were	O
to	O
1	O
)	O
determine	O
the	O
fate	O
of	O
Vγ9Vδ2	O
T	O
cells	O
in	O
osteoporotic	O
patients	O
on	O
n	B-CHEMICAL
-	I-CHEMICAL
BP	I-CHEMICAL
therapy	O
as	O
a	O
function	O
of	O
time	O
and	O
type	O
of	O
therapy	O
;	O
2	O
)	O
evaluate	O
the	O
proportion	O
of	O
Vγ9Vδ2	O
T	O
cells	O
in	O
patients	O
who	O
had	O
recently	O
experienced	O
n	B-CHEMICAL
-	I-CHEMICAL
BP	I-CHEMICAL
-	O
associated	O
ONJ	O
.	O

We	O
found	O
there	O
is	O
a	O
notable	O
loss	O
of	O
Vγ9Vδ2	O
T	O
cells	O
over	O
time	O
in	O
osteoporotic	O
patients	O
on	O
n	B-CHEMICAL
-	I-CHEMICAL
BP	I-CHEMICAL
therapy	O
,	O
particularly	O
those	O
on	O
intravenous	O
(	O
iv	O
)	O
therapy	O
(	O
Spearman	O
r	O
=	O
-	O
0	O
.	O
55	O
,	O
p	O
<	O
0	O
.	O
0001	O
iv	O
;	O
r	O
=	O
-	O
0	O
.	O
3	O
,	O
p	O
<	O
0	O
.	O
03	O
oral	O
)	O
(	O
n	O
=	O
68	O
)	O
;	O
no	O
difference	O
was	O
observed	O
in	O
total	O
T	O
cells	O
,	O
monocytes	O
,	O
or	O
granulocytes	O
.	O

Importantly	O
,	O
the	O
observed	O
negative	O
effect	O
on	O
Vγ9Vδ2	O
T	O
cells	O
coincides	O
with	O
the	O
reported	O
route	O
of	O
administration	O
and	O
timing	O
of	O
the	O
rare	O
occurrence	O
of	O
BAONJ	O
.	O

Patients	O
(	O
n	O
=	O
6	O
)	O
who	O
had	O
experienced	O
BAONJ	O
were	O
all	O
found	O
to	O
be	O
significantly	O
deficient	O
in	O
Vγ9Vδ2	O
T	O
cells	O
(	O
median	O
=	O
0	O
.	O
07	O
%	O
)	O
in	O
comparison	O
to	O
age	O
-	O
and	O
sex	O
-	O
matched	O
treatment	O
-	O
naïve	O
controls	O
(	O
N	O
=	O
11	O
;	O
median	O
=	O
2	O
.	O
40	O
%	O
)	O
,	O
U	O
=	O
0	O
,	O
p	O
=	O
0	O
.	O
001	O
;	O
this	O
was	O
the	O
only	O
consistent	O
difference	O
in	O
the	O
leukocytes	O
assessed	O
.	O

All	O
BAONJ	O
cases	O
had	O
an	O
underlying	O
condition	O
that	O
further	O
contributed	O
to	O
impaired	O
immunity	O
.	O

We	O
propose	O
Vγ9Vδ2	O
T	O
cells	O
show	O
a	O
strong	O
potential	O
to	O
serve	O
as	O
harbingers	O
of	O
possible	O
adverse	O
immune	O
effects	O
of	O
n	B-CHEMICAL
-	I-CHEMICAL
BP	I-CHEMICAL
therapy	O
,	O
particularly	O
in	O
those	O
patients	O
already	O
having	O
a	O
compromised	O
immune	O
system	O
as	O
they	O
may	O
be	O
most	O
vulnerable	O
to	O
the	O
development	O
of	O
conditions	O
such	O
as	O
BAONJ	O
.	O

Snake	B-GENE-N
venom	I-GENE-N
metalloproteinases	I-GENE-N
.	O

Recent	O
proteomic	O
analyses	O
of	O
snake	O
venoms	O
show	O
that	O
metalloproteinases	B-GENE-N
represent	O
major	O
components	O
in	O
most	O
of	O
the	O
Crotalid	O
and	O
Viperid	O
venoms	O
.	O

In	O
this	O
chapter	O
we	O
discuss	O
the	O
multiple	O
activities	O
of	O
the	O
SVMPs	B-GENE-N
.	O

In	O
addition	O
to	O
hemorrhagic	O
activity	O
,	O
members	O
of	O
the	O
SVMP	B-GENE-N
family	O
also	O
have	O
fibrin	O
(	O
ogen	O
)	O
olytic	O
activity	O
,	O
act	O
as	O
prothrombin	B-GENE-Y
activators	O
,	O
activate	O
blood	O
coagulation	B-GENE-Y
factor	I-GENE-Y
X	I-GENE-Y
,	O
possess	O
apoptotic	O
activity	O
,	O
inhibit	O
platelet	O
aggregation	O
,	O
are	O
pro	O
-	O
inflammatory	O
and	O
inactivate	O
blood	O
serine	B-GENE-N
proteinase	I-GENE-N
inhibitors	O
.	O

Clearly	O
the	O
SVMPs	B-GENE-N
have	O
multiple	O
functions	O
in	O
addition	O
to	O
their	O
well	O
-	O
known	O
hemorrhagic	O
activity	O
.	O

The	O
realization	O
that	O
there	O
are	O
structural	O
variations	O
in	O
the	O
SVMPs	B-GENE-N
and	O
the	O
early	O
studies	O
that	O
led	O
to	O
their	O
classification	O
represents	O
an	O
important	O
event	O
in	O
our	O
understanding	O
of	O
the	O
structural	O
forms	O
of	O
the	O
SVMPs	B-GENE-N
.	O

The	O
SVMPs	B-GENE-N
were	O
subdivided	O
into	O
the	O
P	O
-	O
I	O
,	O
P	O
-	O
II	O
and	O
P	O
-	O
III	O
protein	O
classes	O
.	O

The	O
noticeable	O
characteristic	O
that	O
distinguished	O
the	O
different	O
classes	O
was	O
their	O
size	O
(	O
molecular	O
weight	O
)	O
differences	O
and	O
domain	O
structure	O
:	O
Class	O
I	O
(	O
P	O
-	O
I	O
)	O
,	O
the	O
small	O
SVMPs	B-GENE-N
,	O
have	O
molecular	O
masses	O
of	O
20	O
-	O
30	O
kDa	O
,	O
contain	O
only	O
a	O
pro	B-GENE-N
domain	I-GENE-N
and	O
the	O
proteinase	B-GENE-N
domain	I-GENE-N
;	O
Class	O
II	O
(	O
P	O
-	O
II	O
)	O
,	O
the	O
medium	O
size	O
SVMPs	B-GENE-N
,	O
molecular	O
masses	O
of	O
30	O
-	O
60	O
kDa	O
,	O
contain	O
the	O
pro	B-GENE-N
domain	I-GENE-N
,	O
proteinase	B-GENE-N
domain	I-GENE-N
and	O
disintegrin	B-GENE-N
domain	I-GENE-N
;	O
Class	O
III	O
(	O
P	O
-	O
III	O
)	O
,	O
the	O
large	O
SVMPs	B-GENE-N
,	O
have	O
molecular	O
masses	O
of	O
60	O
-	O
100	O
kDa	O
,	O
contain	O
pro	B-GENE-N
,	O
proteinase	B-GENE-N
,	O
disintegrin	B-GENE-N
-	I-GENE-N
like	I-GENE-N
and	O
cysteine	B-GENE-N
-	I-GENE-N
rich	I-GENE-N
domain	I-GENE-N
structure	O
.	O

Another	O
significant	O
advance	O
in	O
the	O
SVMP	B-GENE-N
field	O
was	O
the	O
characterization	O
of	O
the	O
crystal	O
structure	O
of	O
the	O
first	O
P	B-GENE-N
-	I-GENE-N
I	I-GENE-N
class	I-GENE-N
SVMP	I-GENE-N
.	O

The	O
structures	O
of	O
other	O
P	B-GENE-N
-	I-GENE-N
I	I-GENE-N
SVMPs	I-GENE-N
soon	O
followed	O
and	O
the	O
structures	O
of	O
P	B-GENE-N
-	I-GENE-N
III	I-GENE-N
SVMPs	I-GENE-N
have	O
also	O
been	O
determined	O
.	O

The	O
active	O
site	O
of	O
the	O
metalloproteinase	B-GENE-N
domain	I-GENE-N
has	O
a	O
consensus	O
HEXXHXXGXXHD	B-GENE-N
sequence	O
and	O
a	O
Met	B-CHEMICAL
-	O
turn	O
.	O

The	O
"	O
Met	B-CHEMICAL
-	O
turn	O
"	O
structure	O
contains	O
a	O
conserved	O
Met	B-CHEMICAL
residue	O
that	O
forms	O
a	O
hydrophobic	O
basement	O
for	O
the	O
three	O
zinc	B-CHEMICAL
-	O
binding	O
histidines	B-CHEMICAL
in	O
the	O
consensus	O
sequence	O
.	O

Wogonoside	B-CHEMICAL
induces	O
autophagy	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
by	O
regulating	O
MAPK	B-GENE-N
-	O
mTOR	B-GENE-Y
pathway	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
wogonoside	B-CHEMICAL
,	O
a	O
bioactive	O
flavonoid	B-CHEMICAL
extracted	O
from	O
the	O
root	O
of	O
Scutellaria	O
baicalensis	O
Gerogi	O
,	O
has	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
angiogenic	O
activities	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
wogonoside	B-CHEMICAL
-	O
induced	O
autophagy	O
on	O
human	O
breast	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

We	O
report	O
that	O
wogonoside	B-CHEMICAL
triggered	O
the	O
formation	O
of	O
microtubule	B-GENE-N
-	I-GENE-N
associated	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
light	I-GENE-N
chain	I-GENE-N
3	I-GENE-N
(	O
MAP	B-GENE-N
-	I-GENE-N
LC3	I-GENE-N
)	O
positive	O
autophagosomes	O
and	O
the	O
accumulation	O
of	O
acidic	O
vesicular	O
and	O
autolysosomes	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

In	O
addition	O
,	O
cells	O
treated	O
by	O
wogonoside	B-CHEMICAL
developed	O
autophagosome	O
-	O
like	O
characteristics	O
,	O
including	O
single	O
and	O
double	O
membrane	O
vacuoles	O
containing	O
intact	O
and	O
degraded	O
cellular	O
debris	O
.	O

The	O
results	O
showed	O
that	O
wogonoside	B-CHEMICAL
promotes	O
the	O
expression	O
of	O
LC3	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
and	O
Beclin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Furthermore	O
,	O
wogonoside	B-CHEMICAL
inhibited	O
cell	O
growth	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
which	O
was	O
associated	O
with	O
wogonoside	B-CHEMICAL
-	O
induced	O
autophagy	O
.	O

Wogonoside	B-CHEMICAL
also	O
suppressed	O
the	O
activation	O
of	O
mammalian	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
(	O
mTOR	B-GENE-Y
)	O
and	O
p70	B-GENE-N
-	I-GENE-N
S6	I-GENE-N
kinase	I-GENE-N
(	O
p70S6K	B-GENE-N
)	I-GENE-N
by	O
regulating	O
the	O
expression	O
of	O
the	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
and	O
p38	B-GENE-N
involved	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
wogonoside	B-CHEMICAL
partially	O
inhibits	O
MDA	O
-	O
MB	O
-	O
231	O
cell	O
growth	O
by	O
inducing	O
autophagy	O
through	O
the	O
MAPK	B-GENE-N
-	O
mTOR	B-GENE-Y
pathway	O
and	O
may	O
be	O
a	O
promising	O
anti	O
-	O
tumor	O
agent	O
.	O

Effect	O
of	O
ifenprodil	B-CHEMICAL
on	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptor	I-GENE-N
gating	O
.	O

Ifenprodil	B-CHEMICAL
is	O
an	O
allosteric	O
inhibitor	O
of	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptors	I-GENE-N
.	O

Despite	O
its	O
widespread	O
use	O
as	O
a	O
prototype	O
for	O
drug	O
development	O
and	O
a	O
subtype	O
-	O
selective	O
tool	O
for	O
physiologic	O
experiments	O
,	O
its	O
precise	O
effect	O
on	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
gating	O
is	O
yet	O
to	O
be	O
fully	O
understood	O
.	O

Interestingly	O
,	O
recent	O
crystallographic	O
evidence	O
identified	O
that	O
ifenprodil	B-CHEMICAL
,	I-CHEMICAL
unlike	O
zinc	B-CHEMICAL
,	O
binds	O
at	O
the	O
interface	O
of	O
the	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
amino	B-CHEMICAL
terminal	O
domain	O
dimer	O
by	O
an	O
induced	O
-	O
fit	O
mechanism	O
.	O

To	O
delineate	O
the	O
effect	O
of	O
this	O
unique	O
binding	O
on	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
receptor	O
gating	O
,	O
we	O
recorded	O
steady	O
-	O
state	O
currents	O
from	O
cell	O
-	O
attached	O
and	O
outside	O
-	O
out	O
patches	O
.	O

At	O
pH	O
7	O
.	O
9	O
in	O
cell	O
-	O
attached	O
patches	O
,	O
ifenprodil	B-CHEMICAL
increased	O
the	O
occupancy	O
of	O
the	O
long	O
-	O
lived	O
shut	O
conformations	O
,	O
thereby	O
reducing	O
the	O
open	O
probability	O
of	O
the	O
receptor	O
with	O
no	O
change	O
in	O
the	O
mean	O
open	O
time	O
.	O

In	O
addition	O
,	O
ifenprodil	B-CHEMICAL
selectively	O
affected	O
the	O
area	O
of	O
shut	O
time	O
constants	O
,	O
but	O
not	O
the	O
time	O
constants	O
themselves	O
.	O

Kinetic	O
analyses	O
suggested	O
that	O
ifenprodil	B-CHEMICAL
prevents	O
the	O
transition	O
of	O
the	O
receptor	O
to	O
an	O
open	O
state	O
and	O
increases	O
its	O
dwell	O
time	O
in	O
an	O
intrinsically	O
occurring	O
closed	O
conformation	O
or	O
desensitized	O
state	O
.	O

We	O
found	O
distinct	O
differences	O
in	O
the	O
action	O
of	O
ifenprodil	B-CHEMICAL
at	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
in	O
comparison	O
with	O
previous	O
studies	O
on	O
the	O
effect	O
of	O
zinc	B-CHEMICAL
on	O
GluN1	B-GENE-Y
/	O
GluN2A	B-GENE-Y
gating	O
,	O
which	O
may	O
arise	O
due	O
to	O
their	O
unique	O
binding	O
sites	O
.	O

Our	O
data	O
also	O
uncover	O
the	O
potential	O
pH	O
-	O
dependent	O
action	O
of	O
ifenprodil	B-CHEMICAL
on	O
gating	O
.	O

At	O
a	O
low	O
pH	O
(	O
pH	O
7	O
.	O
4	O
)	O
,	O
but	O
not	O
pH	O
7	O
.	O
9	O
,	O
ifenprodil	B-CHEMICAL
reduces	O
the	O
mean	O
open	O
time	O
of	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
receptors	O
,	O
which	O
may	O
be	O
responsible	O
for	O
its	O
usefulness	O
as	O
a	O
context	O
-	O
dependent	O
inhibitor	O
in	O
conditions	O
like	O
ischemia	O
and	O
stroke	O
,	O
when	O
the	O
pH	O
of	O
the	O
extracellular	O
milieu	O
becomes	O
acidic	O
.	O

SB365	B-CHEMICAL
,	O
Pulsatilla	B-CHEMICAL
saponin	I-CHEMICAL
D	I-CHEMICAL
suppresses	O
the	O
proliferation	O
of	O
human	O
colon	O
cancer	O
cells	O
and	O
induces	O
apoptosis	O
by	O
modulating	O
the	O
AKT	B-GENE-N
/	O
mTOR	B-GENE-Y
signalling	O
pathway	O
.	O

Pulsatilla	O
koreana	O
has	O
been	O
used	O
as	O
a	O
traditional	O
medicine	O
for	O
the	O
treatment	O
of	O
several	O
diseases	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
SB365	B-CHEMICAL
,	O
Pulsatilla	B-CHEMICAL
saponin	I-CHEMICAL
D	I-CHEMICAL
isolated	O
from	O
the	O
root	O
of	O
P	O
.	O
koreana	O
inhibits	O
the	O
progression	O
of	O
colon	O
cancer	O
.	O

We	O
found	O
that	O
SB365	B-CHEMICAL
strongly	O
suppressed	O
the	O
growth	O
and	O
proliferation	O
of	O
colon	O
cancer	O
cells	O
and	O
induced	O
their	O
apoptosis	O
.	O

Also	O
,	O
SB365	B-CHEMICAL
showed	O
anti	O
-	O
angiogenic	O
activity	O
by	O
decreasing	O
the	O
expression	O
of	O
HIF	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
and	O
VEGF	B-GENE-Y
.	O

These	O
results	O
were	O
confirmed	O
by	O
an	O
in	O
vivo	O
study	O
showing	O
that	O
SB365	B-CHEMICAL
significantly	O
inhibited	O
tumor	O
growth	O
by	O
the	O
induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
angiogenesis	O
with	O
stronger	O
anticancer	O
activity	O
than	O
5	B-CHEMICAL
-	I-CHEMICAL
FU	I-CHEMICAL
.	O

When	O
further	O
examined	O
for	O
its	O
anticancer	O
mechanism	O
,	O
SB365	B-CHEMICAL
effectively	O
suppressed	O
the	O
AKT	B-GENE-N
/	O
mTOR	B-GENE-Y
pathway	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Taken	O
together	O
,	O
our	O
study	O
demonstrated	O
that	O
SB365	B-CHEMICAL
inhibits	O
the	O
AKT	B-GENE-N
/	O
mTOR	B-GENE-Y
pathway	O
,	O
leading	O
to	O
the	O
suppression	O
of	O
tumor	O
growth	O
and	O
angiogenesis	O
together	O
with	O
induction	O
of	O
apoptosis	O
.	O

Therefore	O
,	O
SB365	B-CHEMICAL
is	O
a	O
good	O
candidate	O
as	O
a	O
natural	O
product	O
for	O
use	O
in	O
the	O
treatment	O
of	O
colon	O
cancer	O
.	O

Optimization	O
of	O
frozen	O
sour	O
cherries	O
vacuum	O
drying	O
process	O
.	O

The	O
objective	O
of	O
this	O
research	O
was	O
to	O
optimize	O
the	O
vacuum	O
-	O
drying	O
of	O
frozen	O
sour	O
cherries	O
in	O
order	O
to	O
preserve	O
health	O
-	O
beneficial	O
phytochemicals	O
,	O
as	O
well	O
as	O
textural	O
characteristics	O
.	O

Investigated	O
range	O
of	O
temperature	O
was	O
46	O
-	O
74	O
°	O
C	O
and	O
,	O
of	O
pressure	O
,	O
17	O
-	O
583mbar	O
,	O
in	O
a	O
new	O
design	O
of	O
vacuum	O
-	O
dryer	O
equipment	O
.	O

The	O
total	O
solids	O
,	O
a	O
(	O
w	O
)	O
value	O
,	O
total	O
phenolics	B-CHEMICAL
,	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
,	O
antioxidant	O
activity	O
,	O
anthocyanin	B-CHEMICAL
content	O
,	O
total	O
colour	O
change	O
and	O
firmness	O
were	O
used	O
as	O
quality	O
indicators	O
of	O
dried	O
sour	O
cherry	O
.	O

Within	O
the	O
experimental	O
range	O
of	O
studied	O
variables	O
,	O
the	O
optimum	O
conditions	O
of	O
54	O
.	O
03	O
°	O
C	O
and	O
148	O
.	O
16mbar	O
were	O
established	O
for	O
vacuum	O
drying	O
of	O
sour	O
cherry	O
.	O

Separate	O
validation	O
experiments	O
were	O
conducted	O
,	O
under	O
optimum	O
conditions	O
,	O
to	O
verify	O
predictions	O
and	O
adequacy	O
of	O
the	O
second	O
-	O
order	O
polynomial	O
models	O
.	O

Under	O
these	O
optimal	O
conditions	O
,	O
the	O
predicted	O
amount	O
of	O
total	O
phenolics	B-CHEMICAL
was	O
744mg	O
CAE	O
/	O
100	O
dw	O
,	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
1	O
.	O
44mg	O
/	O
100g	O
per	O
dry	O
weight	O
(	O
g	O
dw	O
)	O
,	O
anthocyanin	B-CHEMICAL
content	O
125mg	O
/	O
100g	O
dw	O
,	O
IC	O
(	O
50	O
)	O
3	O
.	O
23mg	O
/	O
ml	O
,	O
total	O
solids	O
70	O
.	O
72	O
%	O
,	O
a	O
(	O
w	O
)	O
value	O
0	O
.	O
646	O
,	O
total	O
colour	O
change	O
52	O
.	O
61	O
and	O
firmness	O
3395	O
.	O
4g	O
.	O

The	O
investigated	O
parameters	O
had	O
a	O
significant	O
effect	O
on	O
the	O
quality	O
of	O
the	O
dried	O
sour	O
cherries	O
.	O

Diuretic	O
effects	O
of	O
cannabinoids	O
.	O

In	O
vivo	O
effects	O
of	O
cannabinoid	O
(	O
CB	O
)	O
agonists	O
are	O
often	O
assessed	O
using	O
four	O
well	O
-	O
established	O
measures	O
:	O
locomotor	O
activity	O
,	O
hypothermia	O
,	O
cataleptic	O
-	O
like	O
effects	O
,	O
and	O
analgesia	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
doses	O
of	O
CB	O
agonists	O
that	O
produce	O
these	O
effects	O
also	O
reliably	O
increase	O
diuresis	O
.	O

Diuretic	O
effects	O
of	O
several	O
CB	O
agonists	O
were	O
measured	O
in	O
female	O
rats	O
over	O
2	O
hours	O
immediately	O
after	O
drug	O
injection	O
,	O
and	O
results	O
were	O
compared	O
with	O
hypothermic	O
effects	O
.	O

Direct	O
-	O
acting	O
CB1	B-GENE-Y
agonists	O
,	O
including	O
Δ	B-CHEMICAL
(	I-CHEMICAL
9	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tetrahydrocannabinol	I-CHEMICAL
,	O
WIN	B-CHEMICAL
55	I-CHEMICAL
,	I-CHEMICAL
212	I-CHEMICAL
[	O
R	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
morpholinyl	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
]	I-CHEMICAL
pyrrolo	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
de	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
benzoxazinyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
naphthalenyl	I-CHEMICAL
)	I-CHEMICAL
methanone	I-CHEMICAL
mesylate	I-CHEMICAL
]	O
,	O
AM2389	B-CHEMICAL
[	O
9β	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
hexyl	I-CHEMICAL
-	I-CHEMICAL
cyclobut	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hexahydrocannabinol	I-CHEMICAL
]	O
,	O
and	O
AM4054	B-CHEMICAL
[	O
9β	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
hydroxymethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
adamantyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
hexahydrocannabinol	I-CHEMICAL
]	O
,	O
produced	O
dose	O
-	O
dependent	O
increases	O
in	O
diuresis	O
and	O
decreases	O
in	O
colonic	O
temperature	O
,	O
with	O
slightly	O
lower	O
ED	O
(	O
50	O
)	O
values	O
for	O
diuresis	O
than	O
for	O
hypothermia	O
.	O

The	O
highest	O
doses	O
of	O
cannabinoid	O
drugs	O
yielded	O
,	O
on	O
average	O
,	O
26	O
-	O
32	O
g	O
/	O
kg	O
urine	O
;	O
comparable	O
effects	O
were	O
obtained	O
with	O
10	O
mg	O
/	O
kg	O
furosemide	B-CHEMICAL
and	O
3	O
.	O
0	O
mg	O
/	O
kg	O
trans	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dichloro	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
pyrrolidinyl	I-CHEMICAL
)	I-CHEMICAL
cyclohexyl	I-CHEMICAL
]	I-CHEMICAL
benzeneacetamide	I-CHEMICAL
(	O
U50	B-CHEMICAL
-	I-CHEMICAL
488	I-CHEMICAL
)	O
.	O

Methanandamide	B-CHEMICAL
(	O
10	O
.	O
0	O
mg	O
/	O
kg	O
)	O
had	O
lesser	O
effect	O
than	O
other	O
CB	O
agonists	O
,	O
and	O
the	O
CB2	B-GENE-Y
agonist	O
AM1241	B-CHEMICAL
[	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
methylpiperidin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
ylmethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
iodo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
nitrobenzoyl	I-CHEMICAL
)	I-CHEMICAL
indole	I-CHEMICAL
]	O
,	O
the	O
anandamide	B-CHEMICAL
transport	O
inhibitor	O
AM404	B-CHEMICAL
,	O
and	O
the	O
CB	O
antagonist	O
rimonabant	B-CHEMICAL
did	O
not	O
have	O
diuretic	O
effects	O
.	O

In	O
further	O
studies	O
,	O
the	O
diuretic	O
effects	O
of	O
the	O
CB1	B-GENE-Y
agonist	O
AM4054	B-CHEMICAL
were	O
similar	O
in	O
male	O
and	O
female	O
rats	O
,	O
displayed	O
a	O
relatively	O
rapid	O
onset	O
to	O
action	O
,	O
and	O
were	O
dose	O
-	O
dependently	O
antagonized	O
by	O
30	O
minutes	O
pretreatment	O
with	O
rimonabant	B-CHEMICAL
,	O
but	O
not	O
by	O
the	O
vanilloid	B-GENE-Y
receptor	I-GENE-Y
type	I-GENE-Y
I	I-GENE-Y
antagonist	O
capsazepine	B-CHEMICAL
,	O
nor	O
were	O
the	O
effects	O
of	O
WIN	B-CHEMICAL
55	I-CHEMICAL
,	I-CHEMICAL
212	I-CHEMICAL
antagonized	O
by	O
the	O
CB2	B-GENE-Y
antagonist	O
AM630	B-CHEMICAL
[	O
(	B-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
iodo	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
morpholinyl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
indol	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
]	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methoxyphenyl	I-CHEMICAL
)	I-CHEMICAL
methanone	I-CHEMICAL
)	I-CHEMICAL
]	O
.	O

These	O
data	O
indicate	O
that	O
cannabinoids	O
have	O
robust	O
diuretic	O
effects	O
in	O
rats	O
that	O
are	O
mediated	O
via	O
CB1	B-GENE-Y
receptor	O
mechanisms	O
.	O

Novel	O
assays	O
for	O
detection	O
of	O
urinary	O
KIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
in	O
mouse	O
models	O
of	O
kidney	O
injury	O
.	O

Kidney	B-GENE-Y
injury	I-GENE-Y
molecule	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
KIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
has	O
been	O
qualified	O
by	O
the	O
Food	O
and	O
Drug	O
Administration	O
and	O
European	O
Medicines	O
Agency	O
as	O
a	O
urinary	O
biomarker	O
to	O
monitor	O
preclinical	O
nephrotoxicity	O
in	O
rats	O
and	O
on	O
a	O
case	O
-	O
by	O
-	O
case	O
basis	O
for	O
the	O
translation	O
of	O
potentially	O
nephrotoxic	O
drugs	O
into	O
first	O
-	O
in	O
human	O
studies	O
.	O

Although	O
mouse	O
models	O
are	O
widely	O
employed	O
in	O
preclinical	O
studies	O
,	O
few	O
urinary	O
biomarker	O
studies	O
have	O
been	O
performed	O
in	O
mice	O
due	O
to	O
limited	O
urine	O
availability	O
and	O
lack	O
of	O
sensitive	O
assays	O
.	O

Here	O
,	O
we	O
report	O
the	O
development	O
and	O
validation	O
of	O
two	O
different	O
assays	O
for	O
quantitative	O
assessment	O
of	O
mouse	B-GENE-Y
urinary	I-GENE-Y
KIM	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
uKIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
compare	O
the	O
sensitivity	O
of	O
KIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
relative	O
to	O
other	O
standard	O
markers	O
in	O
ischemia	O
reperfusion	O
and	O
aristolochic	B-CHEMICAL
acid	I-CHEMICAL
(	O
AA	O
)	O
-	O
induced	O
kidney	O
injury	O
in	O
mice	O
.	O

A	O
sensitive	O
,	O
reproducible	O
,	O
and	O
quantitative	O
microbead	O
-	O
based	O
KIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
ELISA	O
was	O
established	O
,	O
which	O
requires	O
only	O
10	O
μl	O
urine	O
for	O
triplicate	O
determination	O
with	O
an	O
assay	O
range	O
of	O
12	O
.	O
21	O
pg	O
/	O
ml	O
to	O
50	O
ng	O
/	O
ml	O
.	O

The	O
second	O
assay	O
is	O
a	O
laminar	O
flow	O
dipstick	O
assay	O
,	O
which	O
has	O
an	O
assay	O
range	O
of	O
195	O
pg	O
/	O
ml	O
to	O
50	O
ng	O
/	O
ml	O
and	O
provides	O
quantitative	O
assessment	O
of	O
KIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
in	O
15	O
min	O
.	O

uKIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
increased	O
with	O
increasing	O
time	O
of	O
ischemia	O
or	O
time	O
after	O
AA	O
administration	O
.	O

After	O
only	O
10	O
-	O
min	O
ischemia	O
followed	O
by	O
24	O
-	O
h	O
reperfusion	O
,	O
uKIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
significantly	O
elevated	O
by	O
13	O
-	O
fold	O
,	O
whereas	O
serum	O
creatinine	B-CHEMICAL
(	O
sCr	O
)	O
,	O
blood	O
urea	B-CHEMICAL
nitrogen	B-CHEMICAL
,	O
N	B-GENE-Y
-	I-GENE-Y
acetyl	I-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
-	I-GENE-Y
glucosaminidase	I-GENE-Y
(	O
NAG	B-GENE-Y
)	O
,	O
and	O
proteinuria	O
levels	O
did	O
not	O
change	O
.	O

After	O
AA	O
administration	O
,	O
uKIM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
were	O
significantly	O
upregulated	O
by	O
greater	O
than	O
threefold	O
within	O
12	O
h	O
,	O
whereas	O
sCr	O
and	O
NAG	B-GENE-Y
levels	O
were	O
unchanged	O
.	O

Mouse	B-GENE-Y
KIM	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
stable	O
for	O
multiple	O
freeze	O
-	O
thaw	O
cycles	O
,	O
for	O
up	O
to	O
5	O
days	O
at	O
room	O
temperature	O
and	O
up	O
to	O
at	O
least	O
an	O
year	O
when	O
stored	O
at	O
-	O
80	O
°	O
C	O
.	O

Inhibition	O
of	O
neurite	O
outgrowth	O
and	O
alteration	O
of	O
cytoskeletal	O
gene	O
expression	O
by	O
sodium	B-CHEMICAL
arsenite	I-CHEMICAL
.	O

Arsenic	B-CHEMICAL
compounds	O
that	O
are	O
often	O
found	O
in	O
drinking	O
water	O
increase	O
the	O
risk	O
of	O
developmental	O
brain	O
disorders	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
live	O
imaging	O
analyses	O
of	O
Neuro	O
-	O
2a	O
cells	O
expressing	O
SCAT3	O
,	O
a	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
cleavage	O
peptide	O
sequence	O
linking	O
two	O
fluorescent	O
proteins	O
;	O
enhanced	O
cyan	O
fluorescence	O
protein	O
(	O
ECFP	O
)	O
and	O
Venus	O
,	O
to	O
determine	O
whether	O
sodium	B-CHEMICAL
arsenite	I-CHEMICAL
(	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
;	O
0	O
,	O
1	O
,	O
5	O
,	O
or	O
10	O
μM	O
)	O
affects	O
both	O
neurite	O
outgrowth	O
and	O
/	O
or	O
induces	O
apoptosis	O
with	O
the	O
same	O
doses	O
and	O
in	O
the	O
same	O
cell	O
cultures	O
.	O

We	O
observed	O
that	O
the	O
area	O
ratio	O
of	O
neurite	O
to	O
cell	O
body	O
in	O
SCAT3	O
-	O
expressing	O
cells	O
was	O
significantly	O
reduced	O
by	O
5	O
and	O
10	O
μM	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
,	O
but	O
not	O
by	O
1	O
μM	O
,	O
although	O
the	O
emission	O
ratio	O
of	O
ECFP	O
to	O
Venus	O
,	O
an	O
endpoint	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
,	O
was	O
not	O
changed	O
.	O

However	O
,	O
cytological	O
assay	O
using	O
apoptotic	O
and	O
necrotic	O
markers	O
resulted	O
in	O
that	O
apoptosis	O
,	O
but	O
not	O
necrosis	O
,	O
was	O
significantly	O
induced	O
in	O
Neuro	O
-	O
2a	O
cells	O
when	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
exposure	O
continued	O
after	O
the	O
significant	O
effects	O
of	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
on	O
neurite	O
outgrowth	O
were	O
found	O
by	O
live	O
imaging	O
.	O

These	O
results	O
suggested	O
that	O
neurite	O
outgrowth	O
was	O
suppressed	O
by	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
prior	O
to	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
apoptosis	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
on	O
cytoskeletal	O
gene	O
expression	O
in	O
Neuro	O
-	O
2a	O
cells	O
.	O

NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
increased	O
the	O
mRNA	O
levels	O
of	O
the	O
light	B-GENE-N
and	I-GENE-N
medium	I-GENE-N
subunits	I-GENE-N
of	I-GENE-N
neurofilament	I-GENE-N
and	O
decreased	O
the	O
mRNA	O
levels	O
of	O
tau	B-GENE-Y
and	O
tubulin	B-GENE-N
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
no	O
significant	O
effect	O
was	O
found	O
in	O
the	O
mRNA	O
levels	O
of	O
the	O
heavy	B-GENE-Y
subunit	I-GENE-Y
of	I-GENE-Y
neurofilament	I-GENE-Y
,	O
microtubule	B-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
protein	I-GENE-Y
2	I-GENE-Y
,	O
or	O
actin	B-GENE-N
.	O

The	O
changes	O
in	O
cytoskeletal	O
gene	O
expression	O
are	O
likely	O
responsible	O
for	O
the	O
inhibitory	O
effects	O
of	O
NaAsO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
on	O
neurite	O
outgrowth	O
.	O

Resveratrol	B-CHEMICAL
attenuates	O
hepatotoxicity	O
of	O
rats	O
exposed	O
to	O
arsenic	B-CHEMICAL
trioxide	I-CHEMICAL
.	O

Arsenic	B-CHEMICAL
trioxide	I-CHEMICAL
(	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
)	O
is	O
an	O
environmental	O
pollutant	O
and	O
potent	O
toxicant	O
to	O
humans	O
.	O

However	O
,	O
it	O
also	O
shows	O
substantial	O
anti	O
-	O
cancer	O
activity	O
in	O
individuals	O
with	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Unfortunately	O
,	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
-	O
treated	O
leukemia	O
patients	O
suffer	O
hepatotoxicity	O
.	O

Resveratrol	B-CHEMICAL
has	O
been	O
demonstrated	O
to	O
have	O
efficient	O
antioxidant	O
and	O
antineoplastic	O
activities	O
.	O

The	O
study	O
that	O
how	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
in	O
combination	O
with	O
resveratrol	B-CHEMICAL
affects	O
hepatotoxicity	O
and	O
arsenic	B-CHEMICAL
accumulation	O
in	O
the	O
liver	O
is	O
lacking	O
,	O
and	O
the	O
present	O
study	O
tackles	O
this	O
question	O
.	O

Wistar	O
rats	O
were	O
injected	O
with	O
3mg	O
/	O
kg	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
on	O
alternate	O
days	O
;	O
resveratrol	B-CHEMICAL
(	O
8mg	O
/	O
kg	O
)	O
was	O
administered	O
1h	O
before	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
.	O

Rats	O
were	O
killed	O
on	O
the	O
8th	O
day	O
to	O
determine	O
histological	O
liver	O
damage	O
,	O
the	O
antioxidant	O
enzymes	O
in	O
serum	O
,	O
the	O
ratio	O
of	O
reduced	B-CHEMICAL
glutathione	I-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
to	O
oxidized	B-CHEMICAL
glutathione	I-CHEMICAL
(	O
GSSG	B-CHEMICAL
)	O
,	O
and	O
arsenic	B-CHEMICAL
accumulation	O
in	O
the	O
liver	O
.	O

In	O
the	O
resveratrol	B-CHEMICAL
+	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
group	O
,	O
activities	O
of	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
catalase	B-GENE-Y
in	O
serum	O
and	O
GSH	B-CHEMICAL
/	O
GSSG	B-CHEMICAL
were	O
significantly	O
increased	O
,	O
histopathological	O
effects	O
were	O
reduced	O
,	O
and	O
arsenic	B-CHEMICAL
accumulation	O
markedly	O
decreased	O
in	O
the	O
liver	O
,	O
compared	O
with	O
the	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
-	O
treated	O
group	O
.	O

Thus	O
,	O
resveratrol	B-CHEMICAL
attenuated	O
As	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
O	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
hepatotoxicity	O
by	O
decreasing	O
oxidative	O
stress	O
and	O
arsenic	B-CHEMICAL
accumulation	O
in	O
the	O
liver	O
.	O

These	O
data	O
suggest	O
that	O
use	O
of	O
resveratrol	B-CHEMICAL
as	O
post	O
-	O
remission	O
therapy	O
of	O
APL	O
and	O
adjunctive	O
therapy	O
in	O
patients	O
with	O
chronic	O
exposure	O
to	O
arsenic	B-CHEMICAL
may	O
decrease	O
arsenic	B-CHEMICAL
hepatotoxicity	O
.	O

DNA	O
methylation	O
and	O
histone	B-GENE-N
modification	O
profiles	O
of	O
mouse	B-GENE-N
organic	I-GENE-N
anion	I-GENE-N
transporting	I-GENE-N
polypeptides	I-GENE-N
.	O

Organic	B-GENE-N
anion	I-GENE-N
transporting	I-GENE-N
polypeptides	I-GENE-N
(	O
rodents	O
,	O
Oatps	B-GENE-N
;	O
human	O
,	O
OATPs	B-GENE-N
)	O
are	O
primarily	O
involved	O
in	O
the	O
transmembrane	O
transportation	O
of	O
a	O
wide	O
range	O
of	O
endogenous	O
and	O
exogenous	O
compounds	O
.	O

Multiple	O
mouse	B-GENE-Y
Oatp1	I-GENE-Y
isoforms	O
are	O
closely	O
located	O
on	O
chromosome	O
6	O
,	O
where	O
each	O
isoform	O
shows	O
distinct	O
tissue	O
distribution	O
;	O
Oatp1b2	B-GENE-Y
,	O
Oatp1a6	B-GENE-N
,	O
and	O
Oatp1c1	B-GENE-Y
are	O
expressed	O
exclusively	O
in	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
cerebrum	O
,	O
respectively	O
;	O
Oatp1a1	B-GENE-Y
in	O
the	O
liver	O
and	O
kidney	O
;	O
and	O
Oatp1a4	B-GENE-Y
in	O
the	O
liver	O
and	O
cerebrum	O
.	O

We	O
have	O
identified	O
tissue	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
differentially	I-GENE-N
methylated	I-GENE-N
region	I-GENE-N
(	O
T	B-GENE-N
-	I-GENE-N
DMR	I-GENE-N
)	O
around	O
the	O
transcriptional	B-GENE-N
start	I-GENE-N
site	I-GENE-N
(	O
TSS	B-GENE-N
)	O
of	O
Oatp1b2	B-GENE-Y
,	O
which	O
correlates	O
with	O
its	O
liver	O
-	O
specific	O
expression	O
.	O

Bisulfite	B-CHEMICAL
sequencing	O
also	O
demonstrated	O
the	O
presence	O
of	O
T	B-GENE-N
-	I-GENE-N
DMRs	I-GENE-N
around	O
the	O
TSS	B-GENE-N
in	O
other	O
Oatp1	B-GENE-Y
genes	O
:	O
CpG	O
dinucleotides	O
at	O
+	O
149	O
relative	O
to	O
the	O
TSS	B-GENE-N
for	O
Oatp1c1	B-GENE-Y
;	O
-	O
48	O
,	O
+	O
101	O
,	O
and	O
+	O
356	O
for	O
Oatp1a4	B-GENE-Y
;	O
-	O
572	O
and	O
-	O
550	O
for	O
Oatp1a1	B-GENE-Y
;	O
and	O
-	O
122	O
and	O
+	O
216	O
for	O
Oatp1a6	B-GENE-N
were	O
differentially	O
methylated	O
among	O
the	O
liver	O
,	O
kidney	O
,	O
and	O
cerebrum	O
.	O

These	O
methylation	O
profiles	O
were	O
largely	O
consistent	O
with	O
the	O
tissue	O
distribution	O
of	O
Oatp1	B-GENE-Y
mRNAs	O
.	O

Chromatin	O
immunoprecipitation	O
assay	O
revealed	O
that	O
the	O
mRNA	O
expression	O
of	O
Oatp1	B-GENE-Y
genes	O
was	O
accompanied	O
by	O
acetylated	O
histone	B-GENE-N
H3	I-GENE-N
.	O

Human	B-GENE-Y
OATP1B1	I-GENE-Y
and	O
OATP1B3	B-GENE-Y
are	O
located	O
on	O
chromosome	O
12p12	O
in	O
the	O
OATP1	B-GENE-Y
cluster	O
;	O
both	O
show	O
predominant	O
expression	O
in	O
the	O
liver	O
.	O

These	O
genes	O
also	O
contained	O
T	B-GENE-N
-	I-GENE-N
DMRs	I-GENE-N
that	O
were	O
hypomethylated	O
in	O
the	O
liver	O
,	O
compared	O
with	O
kidney	O
cortex	O
:	O
-	O
511	O
,	O
-	O
411	O
,	O
and	O
+	O
92	O
relative	O
to	O
the	O
TSS	B-GENE-N
for	O
OATP1B1	B-GENE-Y
and	O
-	O
331	O
,	O
+	O
70	O
,	O
and	O
+	O
73	O
for	O
OATP1B3	B-GENE-Y
.	O

These	O
results	O
suggest	O
that	O
the	O
difference	O
in	O
epigenetic	O
profiles	O
comprising	O
DNA	O
methylation	O
and	O
histone	B-GENE-N
acetylation	O
determines	O
the	O
distinct	O
tissue	O
distribution	O
of	O
Oatp	B-GENE-N
/	O
OATP	B-GENE-N
mRNAs	O
.	O

Apoptosis	O
induced	O
neurotoxicity	O
of	O
Di	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
-	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chlorobenzohydroxamato	I-CHEMICAL
)	I-CHEMICAL
Tin	I-CHEMICAL
(	I-CHEMICAL
IV	I-CHEMICAL
)	I-CHEMICAL
via	O
mitochondria	O
-	O
mediated	O
pathway	O
in	O
PC12	O
cells	O
.	O

The	O
severe	O
toxicity	O
of	O
antitumor	O
organotin	B-CHEMICAL
(	I-CHEMICAL
IV	I-CHEMICAL
)	I-CHEMICAL
compounds	O
limits	O
their	O
application	O
in	O
clinic	O
,	O
however	O
,	O
the	O
toxic	O
mechanism	O
is	O
still	O
unclear	O
.	O

Di	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
-	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chlorobenzohydroxamato	I-CHEMICAL
)	I-CHEMICAL
Tin	I-CHEMICAL
(	I-CHEMICAL
IV	I-CHEMICAL
)	I-CHEMICAL
(	O
DBDCT	B-CHEMICAL
)	O
,	O
an	O
antitumor	O
agent	O
with	O
high	O
activity	O
and	O
obvious	O
neurotoxicity	O
was	O
chosen	O
as	O
a	O
typical	O
diorganotin	B-CHEMICAL
(	I-CHEMICAL
IV	I-CHEMICAL
)	I-CHEMICAL
compound	O
to	O
investigate	O
its	O
neurotoxic	O
mechanism	O
using	O
PC12	O
cells	O
and	O
comprehensive	O
methods	O
.	O

Treatment	O
with	O
DBDCT	B-CHEMICAL
resulted	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
growth	O
inhibition	O
of	O
PC12	O
cells	O
.	O

The	O
changes	O
in	O
cell	O
morphology	O
were	O
observed	O
using	O
light	O
microscopy	O
,	O
fluorescence	O
microscopy	O
and	O
transmission	O
electron	O
microscopy	O
.	O

PC12	O
cell	O
apoptosis	O
induced	O
by	O
DBDCT	B-CHEMICAL
was	O
confirmed	O
by	O
annexin	O
V	O
/	O
propidium	B-CHEMICAL
iodide	I-CHEMICAL
staining	O
,	O
and	O
characterized	O
by	O
cleavage	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
proteins	O
.	O

DBDCT	B-CHEMICAL
induced	O
the	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
from	O
the	O
mitochondria	O
to	O
the	O
cytosol	O
and	O
the	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
.	O

DBDCT	B-CHEMICAL
up	O
-	O
regulated	O
the	O
expression	O
of	O
Bax	B-GENE-Y
,	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
and	O
significantly	O
increased	O
the	O
ratio	O
of	O
Bax	B-GENE-Y
/	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

DBDCT	B-CHEMICAL
also	O
caused	O
the	O
phosphorylation	O
of	O
JNK	B-GENE-N
and	O
p38	B-GENE-N
(	O
MAPK	B-GENE-N
)	O
.	O

In	O
rats	O
exposed	O
to	O
DBDCT	B-CHEMICAL
,	O
apoptosis	O
was	O
also	O
observed	O
in	O
brain	O
,	O
as	O
shown	O
by	O
the	O
detection	O
of	O
cleaved	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
proteins	O
and	O
increased	O
TUNEL	O
positive	O
staining	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
demonstrated	O
that	O
DBDCT	B-CHEMICAL
caused	O
the	O
neurotoxicity	O
by	O
inducing	O
apoptosis	O
via	O
mitochondria	O
-	O
mediated	O
pathway	O
.	O

Interactions	O
between	O
CYP2E1	B-GENE-Y
and	O
CYP2B4	B-GENE-Y
:	O
effects	O
on	O
affinity	O
for	O
NADPH	B-GENE-Y
-	I-GENE-Y
cytochrome	I-GENE-Y
P450	I-GENE-Y
reductase	I-GENE-Y
and	O
substrate	O
metabolism	O
.	O

Studies	O
in	O
microsomal	O
and	O
reconstituted	O
systems	O
have	O
shown	O
that	O
the	O
presence	O
of	O
one	O
cytochrome	B-GENE-N
P450	I-GENE-N
isoform	O
can	O
significantly	O
influence	O
the	O
catalytic	O
activity	O
of	O
another	O
isoform	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
whether	O
CYP2E1	B-GENE-Y
could	O
influence	O
the	O
catalytic	O
activity	O
of	O
CYP2B4	B-GENE-Y
under	O
steady	O
-	O
state	O
turnover	O
conditions	O
.	O

The	O
results	O
show	O
that	O
CYP2E1	B-GENE-Y
inhibits	O
CYP2B4	B-GENE-Y
-	O
mediated	O
metabolism	O
of	O
benzphetamine	B-CHEMICAL
(	O
BNZ	B-CHEMICAL
)	O
with	O
a	O
K	O
(	O
i	O
)	O
of	O
0	O
.	O
04	O
µM	O
.	O

However	O
,	O
CYP2B4	B-GENE-Y
is	O
not	O
an	O
inhibitor	O
of	O
CYP2E1	B-GENE-Y
-	O
mediated	O
p	B-CHEMICAL
-	I-CHEMICAL
nitrophenol	I-CHEMICAL
hydroxylation	O
.	O

When	O
these	O
inhibition	O
studies	O
were	O
performed	O
with	O
the	O
artificial	O
oxidant	O
tert	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
hydroperoxide	I-CHEMICAL
,	O
CYP2E1	B-GENE-Y
did	O
not	O
significantly	O
inhibit	O
CYP2B4	B-GENE-Y
activity	O
.	O

Determinations	O
of	O
the	O
apparent	O
K	O
(	O
M	O
)	O
and	O
k	O
(	O
cat	O
)	O
of	O
CYP2B4	B-GENE-Y
for	O
CPR	B-GENE-Y
in	O
the	O
presence	O
of	O
increasing	O
concentrations	O
of	O
CYP2E1	B-GENE-Y
revealed	O
a	O
mixed	O
inhibition	O
of	O
CYP2B4	B-GENE-Y
by	O
CYP2E1	B-GENE-Y
.	O

At	O
low	O
concentrations	O
of	O
CYP2E1	B-GENE-Y
,	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2B4	B-GENE-Y
for	O
CPR	B-GENE-Y
increased	O
up	O
to	O
23	O
-	O
fold	O
with	O
virtually	O
no	O
change	O
in	O
the	O
k	O
(	O
cat	O
)	O
for	O
the	O
reaction	O
,	O
however	O
,	O
at	O
higher	O
concentrations	O
of	O
CYP2E1	B-GENE-Y
,	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2B4	B-GENE-Y
for	O
CPR	B-GENE-Y
decreased	O
to	O
levels	O
similar	O
to	O
those	O
observed	O
in	O
the	O
absence	O
of	O
CYP2E1	B-GENE-Y
and	O
the	O
k	O
(	O
cat	O
)	O
also	O
decreased	O
by	O
11	O
-	O
fold	O
.	O

Additionally	O
,	O
CYP2E1	B-GENE-Y
increased	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2B4	B-GENE-Y
for	O
BNZ	B-CHEMICAL
by	O
8	O
-	O
fold	O
and	O
the	O
apparent	O
K	O
(	O
M	O
)	O
did	O
not	O
decrease	O
to	O
its	O
original	O
value	O
when	O
saturating	O
concentrations	O
of	O
CPR	B-GENE-Y
were	O
used	O
.	O

While	O
the	O
individual	O
apparent	O
K	O
(	O
M	O
)	O
values	O
of	O
CYP2B4	B-GENE-Y
and	O
CYP2E1	B-GENE-Y
for	O
CPR	B-GENE-Y
are	O
similar	O
,	O
the	O
apparent	O
K	O
(	O
M	O
)	O
of	O
CYP2E1	B-GENE-Y
for	O
CPR	B-GENE-Y
in	O
the	O
presence	O
of	O
CYP2B4	B-GENE-N
decreased	O
significantly	O
,	O
thus	O
suggesting	O
that	O
CYP2B4	B-GENE-Y
enhances	O
the	O
affinity	O
of	O
CYP2E1	B-GENE-Y
for	O
CPR	B-GENE-Y
and	O
this	O
may	O
allow	O
CYP2E1	B-GENE-Y
to	O
out	O
-	O
compete	O
CYP2B4	B-GENE-Y
for	O
CPR	B-GENE-Y
.	O

Adverse	O
outcome	O
pathways	O
during	O
zebrafish	O
embryogenesis	O
:	O
a	O
case	O
study	O
with	O
paraoxon	B-CHEMICAL
.	O

Using	O
paraoxon	B-CHEMICAL
as	O
a	O
reference	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
inhibitor	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
adverse	O
outcome	O
pathway	O
(	O
AOP	O
)	O
that	O
provided	O
quantitative	O
linkages	O
across	O
levels	O
of	O
biological	O
organization	O
during	O
zebrafish	O
embryogenesis	O
.	O

Within	O
normal	O
zebrafish	O
embryos	O
,	O
we	O
first	O
demonstrated	O
that	O
ache	B-GENE-Y
transcripts	O
and	O
AChE	B-GENE-Y
activity	O
increased	O
in	O
a	O
stage	O
-	O
dependent	O
manner	O
following	O
segmentation	O
.	O

We	O
then	O
showed	O
that	O
static	O
exposure	O
of	O
embryos	O
to	O
paraoxon	B-CHEMICAL
(	O
31	O
.	O
2	O
-	O
500	O
nM	O
)	O
from	O
5	O
to	O
96	O
hpf	O
resulted	O
in	O
significant	O
stage	O
-	O
and	O
concentration	O
-	O
dependent	O
AChE	B-GENE-Y
inhibition	O
,	O
albeit	O
these	O
effects	O
were	O
fully	O
reversible	O
within	O
48	O
h	O
following	O
transfer	O
to	O
clean	O
water	O
.	O

However	O
,	O
even	O
in	O
the	O
presence	O
of	O
significant	O
AChE	B-GENE-Y
inhibition	O
,	O
exposure	O
to	O
non	O
-	O
teratogenic	O
paraoxon	B-CHEMICAL
concentrations	O
(	O
≤	O
250	O
nM	O
)	O
did	O
not	O
adversely	O
impact	O
secondary	O
motoneuron	O
development	O
at	O
96	O
hpf	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
potential	O
effects	O
of	O
paraoxon	B-CHEMICAL
exposure	O
on	O
spontaneous	O
tail	O
contractions	O
at	O
26	O
hpf	O
-	O
an	O
early	O
locomotor	O
behavior	O
that	O
results	O
from	O
innervation	O
of	O
primary	O
(	O
not	O
secondary	O
)	O
motoneuron	O
axons	O
to	O
target	O
axial	O
muscles	O
.	O

Based	O
on	O
these	O
studies	O
,	O
the	O
frequency	O
of	O
spontaneous	O
tail	O
contractions	O
at	O
26	O
hpf	O
-	O
a	O
developmental	O
stage	O
with	O
minimal	O
AChE	B-GENE-Y
expression	O
and	O
activity	O
-	O
was	O
significantly	O
higher	O
following	O
exposure	O
to	O
paraoxon	B-CHEMICAL
concentrations	O
as	O
low	O
as	O
31	O
.	O
2	O
nM	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
(	O
1	O
)	O
normal	O
AChE	B-GENE-Y
activity	O
is	O
not	O
required	O
for	O
secondary	O
motoneuron	O
development	O
and	O
(	O
2	O
)	O
spontaneous	O
tail	O
contractions	O
at	O
26	O
hpf	O
are	O
sensitive	O
to	O
paraoxon	B-CHEMICAL
exposure	O
,	O
an	O
effect	O
that	O
may	O
be	O
independent	O
of	O
AChE	B-GENE-Y
inhibition	O
.	O

Using	O
a	O
well	O
-	O
studied	O
reference	O
chemical	O
,	O
this	O
study	O
highlights	O
the	O
potential	O
challenges	O
in	O
developing	O
quantitative	O
AOPs	O
to	O
support	O
chemical	O
screening	O
and	O
prioritization	O
strategies	O
.	O

TLR4	B-GENE-Y
antagonist	O
reduces	O
early	O
-	O
stage	O
atherosclerosis	O
in	O
diabetic	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
-	O
deficient	O
mice	O
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
deficiency	O
of	O
toll	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
receptor	I-GENE-Y
4	I-GENE-Y
(	O
TLR4	B-GENE-Y
)	O
is	O
associated	O
with	O
reduced	O
atherosclerosis	O
in	O
atherosclerosis	O
-	O
prone	O
mice	O
and	O
attenuated	O
pro	O
-	O
inflammatory	O
state	O
in	O
diabetic	O
mice	O
,	O
it	O
remains	O
undetermined	O
whether	O
treatment	O
with	O
a	O
TLR4	B-GENE-Y
antagonist	O
reduces	O
atherosclerosis	O
in	O
nondiabetic	O
or	O
diabetic	O
mice	O
that	O
have	O
TLR4	B-GENE-Y
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effect	O
of	O
Rhodobacter	O
sphaeroides	O
lipopolysaccharide	O
(	O
Rs	O
-	O
LPS	O
)	O
,	O
an	O
established	O
TLR4	B-GENE-Y
antagonist	O
,	O
on	O
early	O
-	O
stage	O
atherosclerosis	O
in	O
nondiabetic	O
and	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
-	O
deficient	O
(	O
Apoe	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
.	O

Analysis	O
of	O
atherosclerotic	O
lesions	O
of	O
both	O
en	O
face	O
aortas	O
and	O
cross	O
sections	O
of	O
aortic	O
roots	O
showed	O
that	O
administration	O
of	O
Rs	O
-	O
LPS	O
in	O
14	O
-	O
week	O
-	O
old	O
diabetic	O
Apoe	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
for	O
10	O
weeks	O
significantly	O
reduced	O
atherosclerotic	O
lesions	O
.	O

Although	O
atherosclerotic	O
lesions	O
in	O
nondiabetic	O
Apoe	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
appeared	O
to	O
be	O
decreased	O
by	O
Rs	O
-	O
LPS	O
treatment	O
,	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Metabolic	O
study	O
showed	O
that	O
Rs	O
-	O
LPS	O
significantly	O
lowered	O
serum	O
levels	O
of	O
cholesterol	B-CHEMICAL
and	O
triglycerides	B-CHEMICAL
in	O
nondiabetic	O
mice	O
but	O
not	O
in	O
diabetic	O
mice	O
.	O

Furthermore	O
,	O
immunohistochemistry	O
studies	O
showed	O
that	O
Rs	O
-	O
LPS	O
inhibited	O
the	O
expression	O
of	O
interleukin	B-GENE-Y
6	I-GENE-Y
and	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
reduced	O
the	O
content	O
of	O
monocytes	O
and	O
macrophages	O
in	O
atherosclerotic	O
plaques	O
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
TLR4	B-GENE-Y
antagonist	O
inhibited	O
vascular	O
inflammation	O
and	O
atherogenesis	O
in	O
diabetic	O
Apoe	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
lowered	O
serum	O
cholesterol	B-CHEMICAL
and	O
triglyceride	B-CHEMICAL
levels	O
in	O
nondiabetic	O
Apoe	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Parental	O
exposure	O
to	O
natural	O
mixtures	O
of	O
POPs	O
reduced	O
embryo	O
production	O
and	O
altered	O
gene	O
transcription	O
in	O
zebrafish	O
embryos	O
.	O

Determination	O
of	O
toxicity	O
of	O
complex	O
mixtures	O
has	O
been	O
proposed	O
to	O
be	O
one	O
of	O
the	O
most	O
important	O
challenges	O
for	O
modern	O
toxicology	O
.	O

In	O
this	O
study	O
we	O
performed	O
genome	O
wide	O
transcriptome	O
profiling	O
to	O
assess	O
potential	O
toxicant	O
induced	O
changes	O
in	O
gene	O
regulation	O
in	O
zebrafish	O
embryos	O
following	O
parental	O
exposure	O
to	O
two	O
natural	O
mixtures	O
of	O
persistent	O
organic	O
pollutants	O
(	O
POPs	O
)	O
.	O

The	O
mixtures	O
used	O
were	O
extracted	O
from	O
burbot	O
(	O
Lota	O
lota	O
)	O
liver	O
originating	O
from	O
two	O
lakes	O
(	O
Lake	O
Mjøsa	O
and	O
Lake	O
Losna	O
)	O
belonging	O
to	O
the	O
same	O
freshwater	O
system	O
in	O
Norway	O
.	O

The	O
dominating	O
groups	O
of	O
contaminants	O
were	O
polybrominated	B-CHEMICAL
diphenyl	I-CHEMICAL
ethers	I-CHEMICAL
(	O
PBDEs	B-CHEMICAL
)	O
,	O
polychlorinated	B-CHEMICAL
biphenyls	I-CHEMICAL
(	O
PCBs	B-CHEMICAL
)	O
and	O
dichlorodiphenyltrichloroethane	B-CHEMICAL
metabolites	O
(	O
DDTs	O
)	O
.	O

Because	O
both	O
mixtures	O
used	O
in	O
the	O
present	O
study	O
induced	O
similar	O
effects	O
,	O
it	O
is	O
likely	O
that	O
the	O
same	O
toxicants	O
are	O
involved	O
.	O

The	O
Mjøsa	O
mixture	O
contains	O
high	O
levels	O
of	O
PBDEs	B-CHEMICAL
while	O
this	O
group	O
of	O
pollutants	O
is	O
low	O
in	O
the	O
Losna	O
mixture	O
.	O

However	O
,	O
both	O
mixtures	O
contain	O
substantial	O
concentrations	O
of	O
PCB	B-CHEMICAL
and	O
DDT	B-CHEMICAL
suggesting	O
these	O
contaminants	O
as	O
the	O
predominant	O
contributors	O
to	O
the	O
toxicity	O
observed	O
.	O

The	O
observed	O
effects	O
included	O
phenotypic	O
traits	O
,	O
like	O
embryo	O
production	O
and	O
survival	O
,	O
and	O
gene	O
transcription	O
changes	O
corresponding	O
with	O
disease	O
and	O
biological	O
functions	O
such	O
as	O
cancer	O
,	O
reproductive	O
system	O
disease	O
,	O
cardiovascular	O
disease	O
,	O
lipid	O
and	O
protein	O
metabolism	O
,	O
small	O
molecule	O
biochemistry	O
and	O
cell	O
cycle	O
.	O

The	O
changes	O
in	O
gene	O
transcription	O
included	O
genes	O
regulated	O
by	O
HNF4A	B-GENE-Y
,	O
insulin	B-GENE-Y
,	O
LH	B-GENE-N
,	O
FSH	B-GENE-N
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
which	O
are	O
known	O
to	O
be	O
central	O
regulators	O
of	O
endocrine	O
signaling	O
,	O
metabolism	O
,	O
metabolic	O
homeostasis	O
,	O
immune	O
functions	O
,	O
cancer	O
development	O
and	O
reproduction	O
.	O

The	O
results	O
suggest	O
that	O
relative	O
low	O
concentrations	O
of	O
the	O
natural	O
mixtures	O
of	O
POPs	O
used	O
in	O
the	O
present	O
study	O
might	O
pose	O
a	O
threat	O
to	O
wild	O
freshwater	O
fish	O
living	O
in	O
the	O
lakes	O
from	O
which	O
the	O
POPs	O
mixtures	O
originated	O
.	O

Artemisinic	B-CHEMICAL
acid	I-CHEMICAL
inhibits	O
melanogenesis	O
through	O
downregulation	O
of	O
C	B-GENE-Y
/	I-GENE-Y
EBP	I-GENE-Y
α	I-GENE-Y
-	O
dependent	O
expression	O
of	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
gene	O
.	O

Cholesterol	B-CHEMICAL
is	O
associated	O
with	O
the	O
regulation	O
of	O
melanogenesis	O
which	O
is	O
the	O
major	O
physiological	O
defense	O
against	O
solar	O
irradiation	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
determine	O
the	O
effects	O
of	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
on	O
melanogenesis	O
and	O
its	O
mechanisms	O
of	O
action	O
in	O
human	O
epidermal	O
melanocytes	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
inhibited	O
melanin	O
content	O
.	O

The	O
mRNA	O
levels	O
of	O
microphthalmia	B-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
transcription	I-GENE-Y
factor	I-GENE-Y
(	O
MITF	B-GENE-Y
)	O
and	O
its	O
downstream	O
genes	O
tyrosinase	B-GENE-Y
,	O
tyrosinase	B-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
TRP	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
TRP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
were	O
reduced	O
by	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
treatment	O
.	O

Additionally	O
,	O
the	O
mRNA	O
levels	O
of	O
melanogenesis	O
-	O
related	O
genes	O
(	O
c	B-GENE-Y
-	I-GENE-Y
KIT	I-GENE-Y
,	O
stem	B-GENE-Y
cell	I-GENE-Y
factor	I-GENE-Y
(	O
SCF	B-GENE-Y
)	O
,	O
and	O
macrophage	B-GENE-Y
migration	I-GENE-Y
inhibitory	I-GENE-Y
factor	I-GENE-Y
(	O
MIF	B-GENE-Y
)	O
)	O
were	O
down	O
-	O
regulated	O
by	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Furthermore	O
,	O
cAMP	B-CHEMICAL
production	O
and	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
(	O
PKA	B-GENE-N
)	O
activity	O
were	O
suppressed	O
by	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Moreover	O
,	O
attempts	O
to	O
elucidate	O
a	O
possible	O
mechanism	O
underlying	O
the	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
-	O
mediated	O
effects	O
revealed	O
that	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
regulated	O
melanogenesis	O
by	O
inhibiting	O
cholesterol	B-CHEMICAL
synthesis	O
through	O
downregulation	O
of	O
the	O
hydroxymethylglutaryl	B-GENE-Y
CoA	I-GENE-Y
(	I-GENE-Y
HMG	I-GENE-Y
CoA	I-GENE-Y
)	I-GENE-Y
reductase	I-GENE-Y
gene	O
,	O
which	O
was	O
mediated	O
through	O
reduced	O
expression	O
of	O
the	O
CCAAT	B-GENE-Y
/	I-GENE-Y
enhancer	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
/	I-GENE-Y
EBP	I-GENE-Y
)	I-GENE-Y
α	I-GENE-Y
gene	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
inhibition	O
of	O
melanogenesis	O
by	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
occurs	O
through	O
reduced	O
expression	O
of	O
the	O
HMG	B-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
gene	O
,	O
which	O
is	O
mediated	O
by	O
C	B-GENE-Y
/	I-GENE-Y
EBP	I-GENE-Y
α	I-GENE-Y
inhibition	O
and	O
suggest	O
that	O
artemisinic	B-CHEMICAL
acid	I-CHEMICAL
may	O
be	O
useful	O
as	O
a	O
hyperpigmentation	O
inhibitor	O
.	O

Potentiation	O
of	O
sulfonylurea	B-CHEMICAL
action	O
by	O
an	O
EPAC	B-GENE-Y
-	O
selective	O
cAMP	B-CHEMICAL
analog	O
in	O
INS	O
-	O
1	O
cells	O
:	O
comparison	O
of	O
tolbutamide	B-CHEMICAL
and	O
gliclazide	B-CHEMICAL
and	O
a	O
potential	O
role	O
for	O
EPAC	B-GENE-Y
activation	O
of	O
a	O
2	O
-	O
APB	O
-	O
sensitive	O
Ca2	O
+	O
influx	O
.	O

Tolbutamide	B-CHEMICAL
and	O
gliclazide	O
block	O
the	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
K	B-GENE-Y
(	I-GENE-Y
ir	I-GENE-Y
)	I-GENE-Y
6	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
/	O
Sur1	B-GENE-Y
,	O
causing	O
membrane	O
depolarization	O
and	O
stimulating	O
insulin	B-GENE-Y
secretion	O
in	O
pancreatic	O
beta	O
cells	O
.	O

We	O
examined	O
the	O
ability	O
of	O
the	O
EPAC	B-GENE-Y
-	O
selective	O
cAMP	B-CHEMICAL
analog	O
8	B-CHEMICAL
-	I-CHEMICAL
pCPT	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
to	O
potentiate	O
the	O
action	O
of	O
these	O
drugs	O
and	O
the	O
mechanism	O
that	O
might	O
account	O
for	O
it	O
.	O

Insulin	B-GENE-N
secretion	O
stimulated	O
by	O
both	O
200	O
μM	O
tolbutamide	B-CHEMICAL
and	O
20	O
μM	O
gliclazide	B-CHEMICAL
,	O
concentrations	O
that	O
had	O
equivalent	O
effects	O
on	O
membrane	O
potential	O
,	O
was	O
inhibited	O
by	O
thapsigargin	B-CHEMICAL
(	O
1	O
μM	O
)	O
or	O
the	O
L	B-GENE-N
-	I-GENE-N
type	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
blocker	O
nicardipine	B-CHEMICAL
(	O
2	O
μM	O
)	O
and	O
was	O
potentiated	O
by	O
8	B-CHEMICAL
-	I-CHEMICAL
pCPT	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
at	O
concentrations	O
≥	O
2	O
μM	O
in	O
INS	O
-	O
1	O
cells	O
.	O

Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
transients	O
stimulated	O
by	O
either	O
tolbutamide	B-CHEMICAL
or	O
gliclazide	B-CHEMICAL
were	O
inhibited	O
by	O
thapsigargin	B-CHEMICAL
or	O
nicardipine	B-CHEMICAL
and	O
were	O
significantly	O
potentiated	O
by	O
8	O
-	O
pCPT	O
-	O
2	O
'	O
-	O
O	O
-	O
Me	O
-	O
cAMP	O
-	O
AM	O
at	O
5	O
μM	O
but	O
not	O
1	O
μM	O
.	O

Both	O
tolbutamide	B-CHEMICAL
and	O
gliclazide	B-CHEMICAL
stimulated	O
phospholipase	B-GENE-N
C	I-GENE-N
activity	O
;	O
however	O
,	O
only	O
gliclazide	B-CHEMICAL
did	O
so	O
independently	O
of	O
its	O
activity	O
at	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
,	O
and	O
this	O
activity	O
was	O
partially	O
inhibited	O
by	O
pertussis	B-GENE-N
toxin	I-GENE-N
.	O

8	B-CHEMICAL
-	I-CHEMICAL
pCPT	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
alone	O
(	O
5	O
μM	O
)	O
did	O
not	O
stimulate	O
insulin	B-GENE-N
secretion	O
,	O
but	O
did	O
increase	O
intracellular	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
concentration	O
significantly	O
,	O
and	O
this	O
activity	O
was	O
inhibited	O
by	O
25	O
μM	O
2	B-CHEMICAL
-	I-CHEMICAL
aminoethoxydiphenylborate	I-CHEMICAL
(	O
2	B-CHEMICAL
-	I-CHEMICAL
APB	I-CHEMICAL
)	O
or	O
the	O
removal	O
of	O
extracellular	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
.	O

8	B-CHEMICAL
-	I-CHEMICAL
pCPT	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
potentiation	O
of	O
insulin	B-GENE-N
secretion	O
stimulated	O
by	O
tolbutamide	B-CHEMICAL
was	O
markedly	O
inhibited	O
by	O
2	B-CHEMICAL
-	I-CHEMICAL
APB	I-CHEMICAL
(	O
25	O
μM	O
)	O
and	O
enhanced	O
by	O
the	O
PKC	B-GENE-N
inhibitor	O
bisindolylmaleimide	B-CHEMICAL
I	I-CHEMICAL
(	O
1	O
μM	O
)	O
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
actions	O
of	O
both	O
tolbutamide	B-CHEMICAL
and	O
gliclazide	B-CHEMICAL
are	O
strongly	O
potentiated	O
by	O
8	B-CHEMICAL
-	I-CHEMICAL
pCPT	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
,	O
that	O
gliclazide	B-CHEMICAL
can	O
stimulate	O
phospholipase	B-GENE-N
C	I-GENE-N
activity	O
via	O
a	O
partially	O
pertussis	B-GENE-N
toxin	I-GENE-N
-	O
sensitive	O
mechanism	O
,	O
and	O
that	O
8	B-CHEMICAL
-	I-CHEMICAL
pCPT	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
potentiation	O
of	O
tolbutamide	O
action	O
may	O
involve	O
activation	O
of	O
a	O
2	B-CHEMICAL
-	I-CHEMICAL
APB	I-CHEMICAL
-	O
sensitive	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
.	O

In	O
vivo	O
genotoxicity	O
of	O
methyleugenol	B-CHEMICAL
in	O
gpt	B-GENE-Y
delta	O
transgenic	O
rats	O
following	O
medium	O
-	O
term	O
exposure	O
.	O

Methyleugenol	B-CHEMICAL
(	O
MEG	B-CHEMICAL
)	O
,	O
which	O
is	O
commonly	O
used	O
as	O
a	O
fragrance	O
and	O
flavoring	O
agent	O
,	O
has	O
been	O
shown	O
to	O
induce	O
hepatocellular	O
tumors	O
in	O
rodents	O
.	O

However	O
,	O
the	O
role	O
of	O
genotoxicity	O
as	O
a	O
possible	O
mechanism	O
of	O
action	O
is	O
not	O
fully	O
understood	O
even	O
though	O
the	O
DNA	O
-	O
reactive	O
metabolite	O
of	O
MEG	B-CHEMICAL
has	O
been	O
identified	O
.	O

In	O
this	O
study	O
,	O
a	O
gpt	B-GENE-Y
delta	O
transgenic	O
rat	O
model	O
was	O
used	O
to	O
clarify	O
whether	O
genotoxic	O
mechanisms	O
are	O
involved	O
in	O
MEG	B-CHEMICAL
-	O
induced	O
hepatocarcinogenesis	O
following	O
medium	O
-	O
term	O
exposure	O
.	O

F344	O
gpt	B-GENE-Y
delta	O
rats	O
were	O
subjected	O
to	O
repeated	O
oral	O
administration	O
of	O
MEG	B-CHEMICAL
at	O
dosages	O
of	O
0	O
,	O
10	O
,	O
30	O
,	O
or	O
100mg	O
/	O
kg	O
(	O
a	O
carcinogenic	O
dose	O
)	O
for	O
13	O
weeks	O
.	O

The	O
relative	O
weight	O
of	O
the	O
liver	O
of	O
the	O
male	O
and	O
female	O
rats	O
that	O
were	O
administered	O
100mg	O
/	O
kg	O
MEG	B-CHEMICAL
and	O
the	O
absolute	O
weight	O
of	O
the	O
liver	O
of	O
the	O
male	O
rats	O
that	O
were	O
administered	O
100mg	O
/	O
kg	O
MEG	B-CHEMICAL
were	O
significantly	O
increased	O
.	O

In	O
addition	O
,	O
the	O
number	O
and	O
area	O
of	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
placental	I-GENE-N
form	I-GENE-N
(	O
GST	B-GENE-N
-	I-GENE-N
P	I-GENE-N
)	O
positive	O
foci	O
and	O
proliferating	B-GENE-Y
cell	I-GENE-Y
nuclear	I-GENE-Y
antigen	I-GENE-Y
(	O
PCNA	B-GENE-Y
)	O
positive	O
cell	O
ratios	O
in	O
the	O
hepatocytes	O
were	O
significantly	O
increased	O
in	O
the	O
male	O
and	O
female	O
rats	O
that	O
were	O
administered	O
100mg	O
/	O
kg	O
MEG	B-CHEMICAL
compared	O
with	O
the	O
control	O
animals	O
.	O

In	O
the	O
in	O
vivo	O
mutation	O
assays	O
,	O
a	O
significant	O
increase	O
in	O
the	O
gpt	B-GENE-Y
and	O
Spi	B-GENE-N
(	O
-	O
)	O
mutant	O
frequencies	O
was	O
observed	O
in	O
both	O
sexes	O
at	O
the	O
carcinogenic	O
dose	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
participation	O
of	O
genotoxic	O
mechanisms	O
in	O
MEG	B-CHEMICAL
-	O
induced	O
hepatocarcinogenesis	O
.	O

Histone	B-GENE-Y
deacetylase	I-GENE-Y
3	I-GENE-Y
is	O
required	O
for	O
maintenance	O
of	O
bone	O
mass	O
during	O
aging	O
.	O

Histone	B-GENE-Y
deacetylase	I-GENE-Y
3	I-GENE-Y
(	O
Hdac3	B-GENE-Y
)	O
is	O
a	O
nuclear	O
enzyme	O
that	O
removes	O
acetyl	B-CHEMICAL
groups	O
from	O
lysine	B-CHEMICAL
residues	O
in	O
histones	B-GENE-N
and	O
other	O
proteins	O
to	O
epigenetically	O
regulate	O
gene	O
expression	O
.	O

Hdac3	B-GENE-Y
interacts	O
with	O
bone	O
-	O
related	O
transcription	O
factors	O
and	O
co	O
-	O
factors	O
such	O
as	O
Runx2	B-GENE-Y
and	O
Zfp521	B-GENE-Y
,	O
and	O
thus	O
is	O
poised	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
skeletal	O
system	O
.	O

To	O
understand	O
the	O
role	O
of	O
Hdac3	B-GENE-Y
in	O
osteoblasts	O
and	O
osteocytes	O
,	O
Hdac3	B-GENE-Y
conditional	O
knockout	O
(	O
CKO	O
)	O
mice	O
were	O
created	O
with	O
the	O
osteocalcin	B-GENE-N
(	I-GENE-N
OCN	I-GENE-N
)	I-GENE-N
promoter	I-GENE-N
driving	O
Cre	B-GENE-N
expression	O
.	O

Hdac3	B-GENE-Y
CKO	O
(	O
OCN	B-GENE-Y
)	O
mice	O
were	O
of	O
normal	O
size	O
and	O
weight	O
,	O
but	O
progressively	O
lost	O
trabecular	O
and	O
cortical	O
bone	O
mass	O
with	O
age	O
.	O

The	O
Hdac3	B-GENE-Y
CKO	O
(	O
OCN	B-GENE-Y
)	O
mice	O
exhibited	O
reduced	O
cortical	O
bone	O
mineralization	O
and	O
material	O
properties	O
and	O
suffered	O
frequent	O
fractures	O
.	O

Bone	O
resorption	O
was	O
lower	O
,	O
not	O
higher	O
,	O
in	O
the	O
Hdac3	B-GENE-Y
CKO	O
(	O
OCN	B-GENE-Y
)	O
mice	O
,	O
suggesting	O
that	O
primary	O
defects	O
in	O
osteoblasts	O
caused	O
the	O
reduced	O
bone	O
mass	O
.	O

Indeed	O
,	O
reductions	O
in	O
bone	O
formation	O
were	O
observed	O
.	O

Osteoblasts	O
and	O
osteocytes	O
from	O
Hdac3	B-GENE-Y
CKO	O
(	O
OCN	B-GENE-Y
)	O
mice	O
showed	O
increased	O
DNA	O
damage	O
and	O
reduced	O
functional	O
activity	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Thus	O
,	O
Hdac3	B-GENE-Y
expression	O
in	O
osteoblasts	O
and	O
osteocytes	O
is	O
essential	O
for	O
bone	O
maintenance	O
during	O
aging	O
.	O

The	O
exposure	O
of	O
highly	O
toxic	O
aconitine	B-CHEMICAL
does	O
not	O
significantly	O
impact	O
the	O
activity	O
and	O
expression	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
in	O
rats	O
determined	O
by	O
a	O
novel	O
ultra	O
performance	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometric	O
method	O
of	O
a	O
specific	O
probe	O
buspirone	B-CHEMICAL
.	O

Aconitum	O
species	O
are	O
widely	O
used	O
to	O
treat	O
rheumatism	O
,	O
cardiovascular	O
diseases	O
,	O
and	O
tumors	O
in	O
China	O
and	O
other	O
Asian	O
countries	O
.	O

The	O
herbs	O
are	O
always	O
used	O
with	O
drugs	O
such	O
as	O
paclitaxel	B-CHEMICAL
.	O

Aconitine	B-CHEMICAL
(	O
AC	O
)	O
is	O
one	O
of	O
the	O
main	O
bioactive	O
/	O
high	O
-	O
toxic	O
alkaloids	O
of	O
Aconitum	O
roots	O
.	O

AC	O
is	O
metabolized	O
by	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	I-GENE-N
CYP	I-GENE-N
)	I-GENE-N
3A	I-GENE-N
.	O

However	O
,	O
whether	O
AC	O
inhibits	O
/	O
induces	O
CYP3A	B-GENE-N
,	O
which	O
causes	O
drug	O
-	O
drug	O
interaction	O
(	O
DDI	O
)	O
is	O
unclear	O
.	O

Our	O
study	O
aims	O
to	O
explore	O
the	O
potent	O
effects	O
of	O
AC	O
,	O
as	O
a	O
marker	O
component	O
of	O
Aconitum	O
,	O
on	O
CYP3A	B-GENE-N
using	O
the	O
probe	O
buspirone	B-CHEMICAL
in	O
rats	O
.	O

The	O
effects	O
of	O
oral	O
AC	O
on	O
pharmacokinetics	O
of	O
buspirone	B-CHEMICAL
were	O
evaluated	O
.	O

CYP3A	B-GENE-N
activity	O
and	O
protein	O
levels	O
in	O
rat	O
liver	O
microsomes	O
pretreated	O
with	O
oral	O
AC	O
were	O
also	O
measured	O
using	O
in	O
vitro	O
buspirone	B-CHEMICAL
metabolism	O
and	O
Western	O
blot	O
.	O

Buspirone	B-CHEMICAL
and	O
its	O
major	O
metabolites	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyrimidinyl	I-CHEMICAL
)	I-CHEMICAL
piperazine	I-CHEMICAL
and	O
6	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
hydroxybuspirone	I-CHEMICAL
were	O
determined	O
using	O
a	O
newly	O
validated	O
UPLC	O
-	O
MS	O
/	O
MS	O
method	O
.	O

Single	O
dose	O
and	O
7	O
-	O
day	O
AC	O
administration	O
at	O
0	O
.	O
125mg	O
/	O
kg	O
had	O
no	O
effect	O
on	O
CYP3A	B-GENE-N
activity	O
since	O
no	O
change	O
in	O
the	O
formation	O
of	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
pyrimidinyl	I-CHEMICAL
)	I-CHEMICAL
piperazine	I-CHEMICAL
and	O
6	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
hydroxybuspirone	I-CHEMICAL
.	O

CYP3A	B-GENE-N
activity	O
and	O
protein	O
levels	O
in	O
liver	O
microsomes	O
were	O
also	O
not	O
affected	O
by	O
7	O
-	O
day	O
AC	O
pretreatment	O
at	O
0	O
.	O
125mg	O
/	O
kg	O
.	O

Therefore	O
,	O
AC	O
neither	O
inhibits	O
nor	O
induces	O
CYP3A	B-GENE-N
in	O
rats	O
,	O
indicating	O
AC	O
does	O
not	O
cause	O
CYP3A	B-GENE-N
-	O
related	O
DDI	O
in	O
the	O
liver	O
.	O

Nitrogen	B-CHEMICAL
-	O
containing	O
bisphosphonates	B-CHEMICAL
induce	O
apoptosis	O
of	O
hematopoietic	O
tumor	O
cells	O
via	O
inhibition	O
of	O
Ras	B-GENE-N
signaling	O
pathways	O
and	O
Bim	B-GENE-Y
-	O
mediated	O
activation	O
of	O
the	O
intrinsic	O
apoptotic	O
pathway	O
.	O

Nitrogen	B-CHEMICAL
-	O
containing	O
bisphosphonates	B-CHEMICAL
(	O
N	B-CHEMICAL
-	O
BPs	B-CHEMICAL
)	O
induce	O
apoptosis	O
in	O
tumor	O
cells	O
by	O
inhibiting	O
the	O
prenylation	O
of	O
small	O
G	B-GENE-N
-	I-GENE-N
proteins	I-GENE-N
.	O

However	O
,	O
the	O
details	O
of	O
the	O
apoptosis	O
-	O
inducing	O
mechanism	O
remain	O
obscure	O
.	O

The	O
present	O
study	O
showed	O
that	O
the	O
induction	O
of	O
apoptosis	O
by	O
N	B-CHEMICAL
-	O
BPs	B-CHEMICAL
in	O
hematopoietic	O
tumor	O
cells	O
is	O
mediated	O
by	O
mitochondrial	O
apoptotic	O
signaling	O
pathways	O
,	O
which	O
are	O
activated	O
by	O
the	O
suppression	O
of	O
geranylgeranyl	B-CHEMICAL
pyrophosphate	I-CHEMICAL
(	O
GGPP	B-CHEMICAL
)	O
biosynthesis	O
.	O

Furthermore	O
,	O
N	B-CHEMICAL
-	O
BPs	B-CHEMICAL
decreased	O
the	O
levels	O
of	O
phosphorylated	B-GENE-N
extracellular	I-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
and	O
mTOR	B-GENE-Y
via	O
suppression	O
of	O
Ras	B-GENE-N
prenylation	O
and	O
enhanced	O
Bim	B-GENE-Y
expression	O
.	O

The	O
present	O
results	O
indicated	O
that	O
N	B-CHEMICAL
-	O
BPs	B-CHEMICAL
induce	O
apoptosis	O
by	O
decreasing	O
the	O
mitochondrial	O
transmembrane	O
potential	O
,	O
increasing	O
the	O
activation	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
and	O
enhancing	O
Bim	B-GENE-Y
expression	O
through	O
inhibition	O
of	O
the	O
Ras	B-GENE-N
/	O
MEK	B-GENE-N
/	O
ERK	B-GENE-N
and	O
Ras	B-GENE-N
/	O
mTOR	B-GENE-Y
pathways	O
.	O

The	O
accumulation	O
of	O
N	B-CHEMICAL
-	O
BPs	B-CHEMICAL
in	O
bones	O
suggests	O
that	O
they	O
may	O
act	O
more	O
effectively	O
on	O
tumors	O
that	O
have	O
spread	O
to	O
bones	O
or	O
on	O
Ras	B-GENE-N
-	O
variable	O
tumors	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
show	O
that	O
the	O
specific	O
molecular	O
pathways	O
of	O
N	B-CHEMICAL
-	O
BP	O
-	O
induced	O
apoptosis	O
.	O

Aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
disruption	O
of	O
contact	O
inhibition	O
is	O
associated	O
with	O
connexin43	B-GENE-Y
downregulation	O
and	O
inhibition	O
of	O
gap	O
junctional	O
intercellular	O
communication	O
.	O

The	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AhR	B-GENE-Y
)	O
contributes	O
to	O
the	O
control	O
of	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
,	O
cell	O
adhesion	O
,	O
migration	O
or	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
regulation	O
of	O
connexin43	B-GENE-Y
(	O
Cx43	B-GENE-Y
)	O
and	O
Cx43	B-GENE-Y
-	O
mediated	O
gap	O
junctional	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
during	O
the	O
AhR	B-GENE-Y
-	O
dependent	O
disruption	O
of	O
contact	O
inhibition	O
in	O
non	O
-	O
tumorigenic	O
liver	O
epithelial	O
cells	O
.	O

The	O
contact	O
inhibition	O
of	O
cell	O
proliferation	O
is	O
a	O
process	O
restricting	O
the	O
cell	O
division	O
of	O
confluent	O
non	O
-	O
transformed	O
cells	O
,	O
which	O
is	O
frequently	O
abolished	O
in	O
cancer	O
cells	O
;	O
however	O
,	O
the	O
mechanisms	O
contributing	O
to	O
its	O
disruption	O
are	O
still	O
only	O
partially	O
understood	O
.	O

Disruption	O
of	O
contact	O
inhibition	O
,	O
which	O
was	O
induced	O
by	O
toxic	O
AhR	B-GENE-Y
ligands	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
or	O
polycyclic	B-CHEMICAL
aromatic	I-CHEMICAL
hydrocarbons	I-CHEMICAL
in	O
epithelial	O
WB	O
-	O
F344	O
cells	O
,	O
reduced	O
Cx43	B-GENE-Y
protein	O
levels	O
,	O
possibly	O
via	O
enhanced	O
proteasomal	O
degradation	O
,	O
significantly	O
decreased	O
the	O
amount	O
of	O
gap	O
junction	O
plaques	O
and	O
downregulated	O
GJIC	O
,	O
in	O
an	O
AhR	B-GENE-Y
-	O
dependent	O
manner	O
.	O

Although	O
both	O
intracellular	O
and	O
membrane	O
Cx43	B-GENE-Y
pools	O
were	O
markedly	O
reduced	O
in	O
cells	O
released	O
from	O
contact	O
inhibition	O
by	O
TCDD	B-CHEMICAL
,	O
siRNA	O
-	O
mediated	O
Cx43	B-GENE-Y
knock	O
-	O
down	O
was	O
not	O
sufficient	O
to	O
stimulate	O
proliferation	O
in	O
contact	O
-	O
inhibited	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
downregulation	O
of	O
Cx43	B-GENE-Y
/	O
GJIC	O
in	O
non	O
-	O
transformed	O
epithelial	O
cells	O
is	O
an	O
inherent	O
part	O
of	O
disruption	O
of	O
contact	O
inhibition	O
,	O
which	O
occurs	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

This	O
process	O
runs	O
in	O
parallel	O
with	O
alterations	O
of	O
other	O
forms	O
of	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
,	O
thus	O
suggesting	O
that	O
toxic	O
AhR	B-GENE-Y
agonists	O
may	O
simultaneously	O
abrogate	O
contact	O
inhibition	O
and	O
reduce	O
GJIC	O
,	O
two	O
essential	O
mechanisms	O
linked	O
to	O
deregulation	O
of	O
cell	O
-	O
to	O
-	O
cell	O
communication	O
during	O
tumor	O
promotion	O
and	O
progression	O
.	O

Lysine	B-CHEMICAL
48	O
-	O
linked	O
polyubiquitination	O
of	O
organic	B-GENE-Y
anion	I-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
is	O
essential	O
for	O
its	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
-	O
regulated	O
endocytosis	O
.	O

Organic	B-GENE-Y
anion	I-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
OAT1	B-GENE-Y
)	O
mediates	O
the	O
body	O
'	O
s	O
disposition	O
of	O
a	O
diverse	O
array	O
of	O
environmental	O
toxins	O
and	O
clinically	O
important	O
drugs	O
.	O

Therefore	O
,	O
understanding	O
the	O
regulation	O
of	O
this	O
transporter	O
has	O
profound	O
clinical	O
significance	O
.	O

We	O
had	O
previously	O
established	O
that	O
OAT1	B-GENE-Y
undergoes	O
constitutive	O
internalization	O
from	O
and	O
recycling	O
back	O
to	O
the	O
cell	O
surface	O
and	O
that	O
acute	O
activation	O
of	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	O
PKC	B-GENE-N
)	O
inhibits	O
OAT1	B-GENE-Y
activity	O
by	O
reducing	O
OAT1	B-GENE-Y
cell	O
-	O
surface	O
expression	O
through	O
accelerating	O
its	O
internalization	O
from	O
cell	O
surface	O
to	O
intracellular	O
compartments	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
provide	O
novel	O
evidence	O
that	O
acute	O
activation	O
of	O
PKC	B-GENE-N
significantly	O
enhances	O
OAT1	B-GENE-Y
ubiquitination	O
both	O
in	O
vitro	O
and	O
ex	O
vivo	O
.	O

We	O
further	O
show	O
that	O
ubiquitination	O
of	O
cell	O
-	O
surface	O
OAT1	B-GENE-Y
increases	O
in	O
cells	O
transfected	O
with	O
dominant	O
negative	O
mutant	O
of	O
dynamin	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
a	O
maneuver	O
blocking	O
OAT1	B-GENE-Y
internalization	O
,	O
which	O
suggests	O
that	O
OAT1	B-GENE-Y
ubiquitination	O
proceeds	O
before	O
OAT1	B-GENE-Y
internalization	O
.	O

Mass	O
spectroscopy	O
has	O
revealed	O
that	O
ubiquitination	O
of	O
OAT1	B-GENE-Y
consists	O
of	O
polyubiquitin	O
chains	O
,	O
primarily	O
through	O
lysine	B-CHEMICAL
48	O
linkage	O
.	O

Transfection	O
of	O
cells	O
with	O
the	O
dominant	O
negative	O
mutant	O
of	O
ubiquitin	O
Ub	O
-	O
K48R	O
,	O
which	O
prevents	O
the	O
formation	O
of	O
Lys48	B-CHEMICAL
-	O
linked	O
polyubiquitin	O
chains	O
,	O
abolishes	O
PKC	B-GENE-N
-	O
stimulated	O
OAT1	B-GENE-Y
ubiquitination	O
and	O
internalization	O
.	O

Together	O
,	O
our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Lys48	B-CHEMICAL
-	O
linked	O
polyubiquitination	O
is	O
essential	O
for	O
PKC	B-GENE-N
-	O
regulated	O
OAT1	B-GENE-Y
trafficking	O
.	O

Lanthanum	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
regulates	O
the	O
nitrogen	B-CHEMICAL
assimilation	O
in	O
soybean	O
seedlings	O
under	O
ultraviolet	O
-	O
B	O
radiation	O
.	O

Ultraviolet	O
-	O
B	O
(	O
UV	O
-	O
B	O
,	O
280	O
-	O
320	O
nm	O
)	O
radiation	O
has	O
seriously	O
affected	O
the	O
growth	O
of	O
plants	O
.	O

Finding	O
the	O
technology	O
/	O
method	O
to	O
alleviate	O
the	O
damage	O
of	O
UV	O
-	O
B	O
radiation	O
has	O
become	O
a	O
frontal	O
topic	O
in	O
the	O
field	O
of	O
environmental	O
science	O
.	O

The	O
pretreatment	O
with	O
rare	O
earth	O
elements	O
(	O
REEs	O
)	O
is	O
an	O
effective	O
method	O
,	O
but	O
the	O
regulation	O
mechanism	O
of	O
REEs	O
is	O
unknown	O
.	O

Here	O
,	O
the	O
regulation	O
effects	O
of	O
lanthanum	B-CHEMICAL
(	O
La	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
)	O
on	O
nitrogen	B-CHEMICAL
assimilation	O
in	O
soybean	O
seedlings	O
(	O
Glycine	O
max	O
L	O
.	O
)	O
under	O
ultraviolet	O
-	O
B	O
radiation	O
were	O
investigated	O
to	O
elucidate	O
the	O
regulation	O
mechanism	O
of	O
REEs	O
on	O
plants	O
under	O
UV	O
-	O
B	O
radiation	O
.	O

UV	O
-	O
B	O
radiation	O
led	O
to	O
the	O
inhibition	O
in	O
the	O
activities	O
of	O
the	O
key	O
enzymes	O
(	O
nitrate	B-GENE-N
reductase	I-GENE-N
,	O
glutamine	B-GENE-N
synthetase	I-GENE-N
,	O
glutamate	B-GENE-N
synthase	I-GENE-N
)	O
in	O
the	O
nitrogen	B-CHEMICAL
assimilation	O
,	O
the	O
decrease	O
in	O
the	O
contents	O
of	O
nitrate	B-CHEMICAL
and	O
soluble	O
proteins	O
,	O
as	O
well	O
as	O
the	O
increase	O
in	O
the	O
content	O
of	O
amino	B-CHEMICAL
acid	I-CHEMICAL
in	O
soybean	O
seedlings	O
.	O

The	O
change	O
degree	O
of	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
high	O
level	O
(	O
0	O
.	O
45	O
W	O
m	O
(	O
-	O
2	O
)	O
)	O
was	O
higher	O
than	O
that	O
of	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
low	O
level	O
(	O
0	O
.	O
15	O
W	O
m	O
(	O
-	O
2	O
)	O
)	O
.	O

The	O
pretreatment	O
with	O
20	O
mg	O
L	O
(	O
-	O
1	O
)	O
La	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
could	O
alleviate	O
the	O
effects	O
of	O
UV	O
-	O
B	O
radiation	O
on	O
the	O
activities	O
of	O
nitrate	B-GENE-N
reductase	I-GENE-N
,	O
glutamine	B-GENE-N
synthetase	I-GENE-N
,	O
glutamate	B-GENE-N
synthase	I-GENE-N
,	O
and	O
glutamate	B-GENE-N
dehydrogenase	I-GENE-N
,	O
promoting	O
amino	B-CHEMICAL
acid	I-CHEMICAL
conversion	O
and	O
protein	O
synthesis	O
in	O
soybean	O
seedlings	O
.	O

The	O
regulation	O
effect	O
of	O
La	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
under	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
low	O
level	O
was	O
better	O
than	O
that	O
of	O
UV	O
-	O
B	O
radiation	O
at	O
the	O
high	O
level	O
.	O

The	O
results	O
indicated	O
that	O
the	O
pretreatment	O
with	O
20	O
mg	O
L	O
(	O
-	O
1	O
)	O
La	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
could	O
alleviate	O
the	O
inhibition	O
of	O
UV	O
-	O
B	O
radiation	O
on	O
nitrogen	B-CHEMICAL
assimilation	O
in	O
soybean	O
seedlings	O
.	O

Apoptosis	O
initiation	O
of	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
in	O
SGC	O
-	O
7901	O
gastric	O
carcinoma	O
cancer	O
cells	O
via	O
a	O
PI3K	B-GENE-N
-	O
AKT	B-GENE-N
pathway	O
.	O

β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
has	O
been	O
shown	O
to	O
hold	O
potent	O
anti	O
-	O
proliferative	O
and	O
apoptosis	O
induction	O
properties	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
on	O
apoptosis	O
initiation	O
and	O
its	O
possible	O
mechanisms	O
of	O
action	O
,	O
we	O
qualified	O
cell	O
apoptosis	O
,	O
proteins	O
related	O
to	O
apoptosis	O
and	O
a	O
phosphatidylinositol	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
(	O
PI3K	B-GENE-N
)	O
-	O
AKT	B-GENE-N
pathway	O
in	O
human	O
gastric	O
adenocarcinoma	O
cancer	O
SGC	O
-	O
7901	O
cells	O
.	O

The	O
results	O
demonstrated	O
that	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
SGC	O
-	O
7901	O
cells	O
treated	O
with	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
(	O
25	O
,	O
50	O
,	O
100	O
and	O
200	O
μmol	O
/	O
L	O
)	O
for	O
24	O
h	O
.	O

β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
was	O
also	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
cleaved	O
-	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
inhibit	O
bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
in	O
SGC	O
-	O
7901	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
significantly	O
decreased	O
levels	O
of	O
p	B-GENE-N
-	I-GENE-N
PI3K	I-GENE-N
and	O
p	B-GENE-N
-	I-GENE-N
AKT	I-GENE-N
expression	O
were	O
observed	O
in	O
SGC	O
-	O
7901	O
cells	O
after	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
treatments	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Thus	O
,	O
the	O
apoptosis	O
induction	O
in	O
SGC	O
-	O
7901	O
cells	O
by	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
may	O
be	O
regulated	O
through	O
a	O
PI3K	B-GENE-N
-	O
AKT	B-GENE-N
pathway	O
.	O

These	O
results	O
demonstrate	O
a	O
potential	O
mechanism	O
by	O
which	O
β	B-CHEMICAL
-	I-CHEMICAL
ionone	I-CHEMICAL
to	O
induce	O
apoptosis	O
initiation	O
in	O
SGC	O
-	O
7901	O
cells	O
.	O

Cytochrome	B-GENE-N
P450	I-GENE-N
-	O
mediated	O
herb	O
-	O
drug	O
interaction	O
potential	O
of	O
Galgeun	O
-	O
tang	O
.	O

We	O
evaluated	O
the	O
herb	O
-	O
drug	O
interaction	O
potential	O
of	O
Galgeun	O
-	O
tang	O
(	O
GGT	O
)	O
extracts	O
,	O
mediated	O
by	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	O
CYP	B-GENE-N
)	O
inhibition	O
/	O
induction	O
.	O

Further	O
,	O
the	O
effects	O
of	O
fermentation	O
on	O
the	O
CYP	B-GENE-N
-	O
mediated	O
herb	O
-	O
drug	O
interaction	O
potential	O
of	O
GGT	O
extracts	O
were	O
determined	O
.	O

As	O
measured	O
by	O
LC	O
-	O
ESI	O
/	O
MS	O
/	O
MS	O
,	O
GGT	O
extracts	O
(	O
0	O
-	O
300μg	O
/	O
mL	O
)	O
showed	O
no	O
inhibitory	O
activity	O
toward	O
eight	O
CYP	B-GENE-N
isoforms	O
(	O
1A2	B-GENE-N
,	I-GENE-N
2A6	I-GENE-N
,	I-GENE-N
2B6	I-GENE-N
,	I-GENE-N
2C9	I-GENE-N
,	I-GENE-N
2C19	I-GENE-N
,	I-GENE-N
2D6	I-GENE-N
,	I-GENE-N
2E1	I-GENE-N
,	I-GENE-N
and	I-GENE-N
3A4	I-GENE-N
)	O
in	O
pooled	O
human	O
liver	O
microsomes	O
,	O
suggesting	O
that	O
GGT	O
may	O
have	O
low	O
potential	O
for	O
herb	O
-	O
drug	O
interactions	O
mediated	O
by	O
CYP	B-GENE-N
inhibition	O
.	O

Hepatic	O
CYP	B-GENE-N
expression	O
and	O
activity	O
in	O
rats	O
treated	O
with	O
GGT	O
extracts	O
twice	O
per	O
day	O
for	O
1week	O
was	O
examined	O
.	O

Among	O
the	O
tested	O
CYP	B-GENE-N
isoforms	O
(	O
1A1	B-GENE-N
,	I-GENE-N
1A2	I-GENE-N
,	I-GENE-N
1B1	I-GENE-N
,	I-GENE-N
2B1	I-GENE-N
,	I-GENE-N
2C11	I-GENE-N
,	I-GENE-N
2E1	I-GENE-N
,	I-GENE-N
3A1	I-GENE-N
,	I-GENE-N
3A2	I-GENE-N
,	I-GENE-N
and	I-GENE-N
4A1	I-GENE-N
)	O
,	O
CYP1B1	B-GENE-N
and	I-GENE-N
4A1	I-GENE-N
were	O
increased	O
by	O
GGT	O
extracts	O
.	O

Hepatic	O
activities	O
of	O
7	B-GENE-Y
-	I-GENE-Y
ethoxyresorufin	I-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
deethylase	I-GENE-Y
,	O
7	B-GENE-Y
-	I-GENE-Y
pentoxyresorufin	I-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
depentylase	I-GENE-Y
,	O
and	O
chlorzoxazone	B-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
,	O
but	O
not	O
midazolam	B-GENE-N
hydroxylase	I-GENE-N
were	O
also	O
elevated	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
GGT	O
extracts	O
may	O
increase	O
the	O
toxicity	O
of	O
environmental	O
toxicants	O
through	O
the	O
elevating	O
CYP	B-GENE-N
-	O
dependent	O
metabolic	O
activation	O
.	O

Interestingly	O
,	O
the	O
increases	O
in	O
CYP1B1	B-GENE-Y
and	O
CYP4A1	B-GENE-Y
levels	O
,	O
and	O
7	B-GENE-Y
-	I-GENE-Y
ethoxyresorufin	I-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
deethylase	I-GENE-Y
,	O
7	B-GENE-Y
-	I-GENE-Y
pentoxyresorufin	I-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
depentylase	I-GENE-Y
,	O
and	O
chlorzoxazone	B-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
hydroxylase	I-GENE-Y
activities	O
were	O
attenuated	O
by	O
fermentation	O
of	O
GGT	O
extract	O
using	O
Lactobacillus	O
plantarum	O
KFRI	O
402	O
,	O
but	O
not	O
144	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
CYP	B-GENE-N
regulatory	O
component	O
(	O
s	O
)	O
from	O
GGT	O
and	O
determination	O
its	O
metabolism	O
.	O

Hydrogen	B-CHEMICAL
sulfide	I-CHEMICAL
as	O
an	O
allosteric	O
modulator	O
of	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
potassium	I-GENE-N
channels	I-GENE-N
in	O
colonic	O
inflammation	O
.	O

The	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
potassium	I-GENE-N
channel	I-GENE-N
(	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
)	O
in	O
mouse	O
colonic	O
smooth	O
muscle	O
cell	O
is	O
a	O
complex	O
containing	O
a	O
pore	O
-	O
forming	O
subunit	O
(	O
Kir6	B-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
and	O
a	O
sulfonylurea	B-GENE-N
receptor	I-GENE-N
subunit	O
(	O
SUR2B	B-GENE-Y
)	O
.	O

These	O
channels	O
contribute	O
to	O
the	O
cellular	O
excitability	O
of	O
smooth	O
muscle	O
cells	O
and	O
hence	O
regulate	O
the	O
motility	O
patterns	O
in	O
the	O
colon	O
.	O

Whole	O
-	O
cell	O
voltage	O
-	O
clamp	O
techniques	O
were	O
used	O
to	O
study	O
the	O
alterations	O
in	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
in	O
smooth	O
muscle	O
cells	O
in	O
experimental	O
colitis	O
.	O

Colonic	O
inflammation	O
was	O
induced	O
in	O
BALB	O
/	O
C	O
mice	O
after	O
intracolonic	O
administration	O
of	O
trinitrobenzene	B-CHEMICAL
sulfonic	I-CHEMICAL
acid	I-CHEMICAL
.	O

K	B-CHEMICAL
(	O
ATP	B-CHEMICAL
)	O
currents	O
were	O
measured	O
at	O
a	O
holding	O
potential	O
of	O
-	O
60	O
mV	O
in	O
high	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
external	O
solution	O
.	O

The	O
concentration	O
response	O
to	O
levcromakalim	B-CHEMICAL
(	O
LEVC	B-CHEMICAL
)	O
,	O
a	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
opener	O
,	O
was	O
significantly	O
shifted	O
to	O
the	O
left	O
in	O
the	O
inflamed	O
smooth	O
-	O
muscle	O
cells	O
.	O

Both	O
the	O
potency	O
and	O
maximal	O
currents	O
induced	O
by	O
LEVC	B-CHEMICAL
were	O
enhanced	O
in	O
inflammation	O
.	O

The	O
EC	O
(	O
50	O
)	O
values	O
in	O
control	O
were	O
6259	O
nM	O
(	O
n	O
=	O
10	O
)	O
and	O
422	O
nM	O
(	O
n	O
=	O
8	O
)	O
in	O
inflamed	O
colon	O
,	O
and	O
the	O
maximal	O
currents	O
were	O
9	O
.	O
9	O
±	O
0	O
.	O
71	O
pA	O
/	O
pF	O
(	O
60	O
μM	O
)	O
in	O
control	O
and	O
39	O
.	O
7	O
±	O
8	O
.	O
8	O
pA	O
/	O
pF	O
(	O
3	O
μM	O
)	O
after	O
inflammation	O
.	O

As	O
was	O
seen	O
with	O
LEVC	B-CHEMICAL
,	O
the	O
potency	O
and	O
efficacy	O
of	O
sodium	B-CHEMICAL
hydrogen	I-CHEMICAL
sulfide	I-CHEMICAL
(	O
NaHS	B-CHEMICAL
)	O
(	O
10	O
-	O
1000	O
μM	O
)	O
on	O
K	B-CHEMICAL
(	O
ATP	B-CHEMICAL
)	O
currents	O
were	O
significantly	O
greater	O
in	O
inflamed	O
colon	O
compared	O
with	O
controls	O
.	O

In	O
control	O
cells	O
,	O
pretreatment	O
with	O
100	O
µM	O
NaHS	B-CHEMICAL
shifted	O
the	O
EC	O
(	O
50	O
)	O
for	O
LEV	O
-	O
induced	O
currents	O
from	O
2838	O
(	O
n	O
=	O
6	O
)	O
to	O
154	O
(	O
n	O
=	O
8	O
)	O
nM	O
.	O

Sulfhydration	O
of	O
sulfonylurea	B-GENE-Y
receptor	I-GENE-Y
2B	I-GENE-Y
(	O
SUR2B	B-GENE-Y
)	O
was	O
induced	O
by	O
NaHS	B-CHEMICAL
and	O
colonic	O
inflammation	O
.	O

These	O
data	O
suggest	O
that	O
sulfhydration	O
of	O
SUR2B	B-GENE-Y
induces	O
allosteric	O
modulation	O
of	O
K	B-CHEMICAL
(	O
ATP	B-CHEMICAL
)	O
currents	O
in	O
colonic	O
inflammation	O
.	O

Rosmarinic	B-CHEMICAL
acid	I-CHEMICAL
ameliorates	O
acute	O
liver	O
damage	O
and	O
fibrogenesis	O
in	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
-	O
intoxicated	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
of	O
rosmarinic	B-CHEMICAL
acid	I-CHEMICAL
(	O
RA	O
)	O
,	O
a	O
natural	O
phenolic	O
,	O
in	O
the	O
treatment	O
of	O
acute	O
liver	O
toxicity	O
.	O

RA	O
at	O
10	O
,	O
25	O
and	O
50mg	O
/	O
kg	O
was	O
administered	O
by	O
gavage	O
once	O
daily	O
for	O
2	O
consecutive	O
days	O
,	O
6h	O
after	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
intoxication	O
.	O

CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
intoxication	O
caused	O
hepatic	O
necrosis	O
and	O
increased	O
serum	O
ALT	B-GENE-N
activity	O
.	O

In	O
the	O
livers	O
,	O
oxidative	O
/	O
nitrosative	O
stress	O
was	O
evidenced	O
by	O
increased	O
3	B-CHEMICAL
-	I-CHEMICAL
nitrotyrosine	I-CHEMICAL
(	O
3	B-CHEMICAL
-	I-CHEMICAL
NT	I-CHEMICAL
)	O
and	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
reactive	O
substances	O
(	O
TBARS	O
)	O
formation	O
and	O
a	O
significant	O
decrease	O
in	O
Cu	B-GENE-Y
/	I-GENE-Y
Zn	I-GENE-Y
superoxide	I-GENE-Y
dismutase	I-GENE-Y
(	O
SOD	B-GENE-N
)	O
activity	O
.	O

CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
administration	O
triggered	O
inflammatory	O
response	O
in	O
mice	O
livers	O
by	O
activating	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappaB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
,	O
which	O
coincided	O
with	O
the	O
induction	O
of	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
and	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

RA	O
improved	O
histological	O
and	O
serum	O
markers	O
of	O
liver	O
damage	O
and	O
significantly	O
ameliorated	O
oxidative	O
/	O
nitrosative	O
stress	O
and	O
inflammatory	O
response	O
in	O
liver	O
tissue	O
.	O

Additionally	O
,	O
RA	O
prevented	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
beta1	I-GENE-Y
(	O
TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
)	O
and	O
alpha	B-GENE-Y
-	I-GENE-Y
smooth	I-GENE-Y
muscle	I-GENE-Y
actin	I-GENE-Y
(	O
α	B-GENE-Y
-	I-GENE-Y
SMA	I-GENE-Y
)	O
expression	O
,	O
suggesting	O
suppression	O
of	O
profibrotic	O
response	O
.	O

Furthermore	O
,	O
RA	O
significantly	O
inhibited	O
the	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
apoptosis	O
,	O
which	O
was	O
evident	O
from	O
decreased	O
cleavage	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
.	O

The	O
hepatoprotective	O
activity	O
of	O
RA	O
coincided	O
with	O
enhanced	O
NF	B-GENE-Y
-	I-GENE-Y
E2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
Nrf2	B-GENE-Y
)	O
and	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
expression	O
.	O

The	O
results	O
of	O
this	O
study	O
indicates	O
that	O
RA	O
possesses	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
,	O
antiapoptotic	O
and	O
antifibrotic	O
activity	O
against	O
acute	O
liver	O
toxicity	O
.	O

Antiarrhythmic	O
effects	O
of	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
epicatechin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
gallate	I-CHEMICAL
,	O
a	O
novel	O
sodium	B-GENE-N
channel	I-GENE-N
agonist	O
in	O
cultured	O
neonatal	O
rat	O
ventricular	O
myocytes	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Epicatechin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
gallate	I-CHEMICAL
(	O
ECG	B-CHEMICAL
)	O
,	O
a	O
polyphenol	B-CHEMICAL
extracted	O
from	O
green	O
tea	O
,	O
has	O
been	O
proposed	O
as	O
an	O
effective	O
compound	O
for	O
improving	O
cardiac	O
contractility	O
.	O

However	O
,	O
the	O
therapeutic	O
potential	O
of	O
ECG	B-CHEMICAL
on	O
the	O
treatment	O
of	O
arrhythmia	O
remains	O
unknown	O
.	O

We	O
investigated	O
the	O
direct	O
actions	O
of	O
ECG	B-CHEMICAL
on	O
the	O
modulation	O
of	O
ion	O
currents	O
and	O
cardiac	O
cell	O
excitability	O
in	O
the	O
primary	O
culture	O
of	O
neonatal	O
rat	O
ventricular	O
myocyte	O
(	O
NRVM	O
)	O
,	O
which	O
is	O
considered	O
a	O
hypertrophic	O
model	O
for	O
analysis	O
of	O
myocardial	O
arrhythmias	O
.	O

By	O
using	O
the	O
whole	O
-	O
cell	O
patch	O
-	O
clamp	O
configurations	O
,	O
we	O
found	O
ECG	B-CHEMICAL
enhanced	O
the	O
slowly	O
inactivating	O
component	O
of	O
voltage	O
-	O
gated	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
currents	O
(	O
I	O
(	O
Na	B-CHEMICAL
)	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
0	O
.	O
1	O
-	O
100	O
μM	O
)	O
with	O
an	O
EC	O
(	O
50	O
)	O
value	O
of	O
3	O
.	O
8	O
μM	O
.	O

ECG	B-CHEMICAL
not	O
only	O
shifted	O
the	O
current	O
-	O
voltage	O
relationship	O
of	O
peak	O
I	O
(	O
Na	B-CHEMICAL
)	O
to	O
the	O
hyperpolarizing	O
direction	O
but	O
also	O
accelerated	O
I	O
(	O
Na	B-CHEMICAL
)	O
recovery	O
kinetics	O
.	O

Working	O
at	O
a	O
concentration	O
level	O
of	O
I	O
(	O
Na	B-CHEMICAL
)	O
enhancement	O
,	O
ECG	B-CHEMICAL
has	O
no	O
notable	O
effect	O
on	O
voltage	O
-	O
gated	O
K	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
currents	O
and	O
L	O
-	O
type	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
currents	O
.	O

With	O
culture	O
time	O
increment	O
,	O
the	O
firing	O
rate	O
of	O
spontaneous	O
action	O
potential	O
(	O
sAP	O
)	O
in	O
NRVMs	O
was	O
gradually	O
decreased	O
until	O
spontaneous	O
early	O
after	O
-	O
depolarization	O
(	O
EAD	O
)	O
was	O
observed	O
after	O
about	O
one	O
week	O
culture	O
.	O

ECG	B-CHEMICAL
increased	O
the	O
firing	O
rate	O
of	O
normal	O
sAP	O
about	O
two	O
-	O
fold	O
without	O
waveform	O
alteration	O
.	O

Interestingly	O
,	O
the	O
bradycardia	O
-	O
dependent	O
EAD	O
could	O
be	O
significantly	O
restored	O
by	O
ECG	B-CHEMICAL
in	O
fast	O
firing	O
rate	O
to	O
normal	O
sAP	O
waveform	O
.	O

The	O
expression	O
of	O
dominant	O
cardiac	O
sodium	B-GENE-N
channel	I-GENE-N
subunit	O
,	O
Nav1	B-GENE-Y
.	I-GENE-Y
5	I-GENE-Y
,	O
was	O
consistently	O
detected	O
throughout	O
the	O
culture	O
periods	O
.	O

Our	O
results	O
reveal	O
how	O
ECG	B-CHEMICAL
,	O
the	O
novel	O
I	O
(	O
Na	B-CHEMICAL
)	O
agonist	O
,	O
may	O
act	O
as	O
a	O
promising	O
candidate	O
in	O
clinical	O
applications	O
on	O
cardiac	O
arrhythmias	O
.	O

In	O
vivo	O
and	O
in	O
vitro	O
characterization	O
of	O
naltrindole	B-CHEMICAL
-	O
derived	O
ligands	O
at	O
the	O
κ	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
.	O

Accumulating	O
evidence	O
supports	O
a	O
role	O
for	O
κ	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
in	O
the	O
treatment	O
of	O
mood	O
disorders	O
.	O

Standard	O
κ	O
-	O
antagonists	O
have	O
an	O
unusual	O
pharmacodynamic	O
action	O
,	O
with	O
a	O
single	O
injection	O
blocking	O
receptor	O
signaling	O
for	O
several	O
weeks	O
.	O

Here	O
,	O
we	O
have	O
characterized	O
the	O
κ	O
-	O
selective	O
properties	O
of	O
two	O
ligands	O
,	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminomethyl	I-CHEMICAL
)	I-CHEMICAL
naltrindole	I-CHEMICAL
(	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
AMN	I-CHEMICAL
)	O
and	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
Naltrindol	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
)	I-CHEMICAL
pentanimidamide	I-CHEMICAL
(	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
MABN	I-CHEMICAL
)	O
,	O
to	O
identify	O
whether	O
modifications	O
of	O
the	O
naltrindole	B-CHEMICAL
side	O
chain	O
produces	O
short	O
-	O
acting	O
κ	O
-	O
antagonists	O
.	O

Opioid	B-GENE-N
receptor	I-GENE-N
binding	O
affinity	O
and	O
activity	O
were	O
assessed	O
using	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
diprenorphine	I-CHEMICAL
binding	O
,	O
guanosine	B-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
35S	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
thio	I-CHEMICAL
)	I-CHEMICAL
triphosphate	I-CHEMICAL
(	O
[	B-CHEMICAL
(	I-CHEMICAL
35	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
GTPγS	I-CHEMICAL
)	O
binding	O
and	O
isolated	O
guinea	O
-	O
pig	O
ileum	O
.	O

Pharmacodynamic	O
profiles	O
of	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
AMN	I-CHEMICAL
and	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
MABN	I-CHEMICAL
(	O
1	O
-	O
10	O
mg	O
/	O
kg	O
)	O
were	O
investigated	O
using	O
the	O
tail	O
-	O
withdrawal	O
assay	O
and	O
diuresis	O
.	O

Efficacy	O
was	O
also	O
determined	O
in	O
depression	O
-	O
and	O
anxiety	O
-	O
related	O
behavioral	O
paradigms	O
in	O
CD	O
-	O
1	O
mice	O
.	O

Both	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
AMN	I-CHEMICAL
and	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
MABN	I-CHEMICAL
had	O
high	O
affinity	O
for	O
κ	B-GENE-Y
-	I-GENE-Y
receptors	I-GENE-Y
(	O
K	O
(	O
i	O
)	O
1	O
.	O
36	O
±	O
0	O
.	O
98	O
and	O
0	O
.	O
27	O
±	O
0	O
.	O
08	O
,	O
respectively	O
)	O
and	O
were	O
revealed	O
as	O
potent	O
κ	O
-	O
antagonists	O
(	O
pA	O
(	O
2	O
)	O
7	O
.	O
43	O
and	O
8	O
.	O
18	O
,	O
respectively	O
)	O
and	O
μ	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
(	O
pA	O
(	O
2	O
)	O
7	O
.	O
62	O
and	O
7	O
.	O
85	O
,	O
respectively	O
)	O
in	O
the	O
ileum	O
.	O

Contrary	O
to	O
our	O
hypothesis	O
,	O
in	O
vivo	O
,	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
AMN	I-CHEMICAL
and	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
MABN	I-CHEMICAL
displayed	O
long	O
-	O
lasting	O
antagonist	O
effects	O
in	O
mice	O
,	O
reducing	O
the	O
antinociceptive	O
actions	O
of	O
U50	B-CHEMICAL
,	I-CHEMICAL
488	I-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
at	O
28	O
and	O
21	O
days	O
post	O
-	O
injection	O
,	O
respectively	O
.	O

Interestingly	O
,	O
while	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
AMN	I-CHEMICAL
and	O
5	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
MABN	I-CHEMICAL
were	O
not	O
κ	O
-	O
selective	O
,	O
both	O
compounds	O
did	O
show	O
significant	O
antidepressant	O
-	O
and	O
anxiolytic	O
-	O
like	O
effects	O
at	O
7	O
-	O
14	O
days	O
post	O
-	O
injection	O
in	O
mice	O
.	O

Phillyrin	B-CHEMICAL
attenuates	O
high	O
glucose	B-CHEMICAL
-	O
induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
through	O
the	O
activation	O
of	O
LKB1	B-GENE-Y
/	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
-	O
dependent	O
signalling	O
.	O

Phillyrin	B-CHEMICAL
,	O
an	O
active	O
constituent	O
found	O
in	O
many	O
medicinal	O
plants	O
and	O
certain	O
functional	O
foods	O
,	O
has	O
anti	O
-	O
obesity	O
activity	O
in	O
vivo	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
provide	O
new	O
data	O
on	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
the	O
role	O
of	O
phillyrin	B-CHEMICAL
in	O
the	O
prevention	O
of	O
high	O
glucose	B-CHEMICAL
-	O
induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
.	O

We	O
found	O
that	O
phillyrin	B-CHEMICAL
suppressed	O
high	O
glucose	B-CHEMICAL
-	O
induced	O
lipid	O
accumulation	O
in	O
HepG2	O
cells	O
.	O

Phillyrin	B-CHEMICAL
strongly	O
inhibited	O
high	O
glucose	B-CHEMICAL
-	O
induced	O
fatty	B-GENE-Y
acid	I-GENE-Y
synthase	I-GENE-Y
(	O
FAS	B-GENE-Y
)	O
expression	O
by	O
modulating	O
sterol	B-GENE-Y
regulatory	I-GENE-Y
element	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
(	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
)	O
activation	O
.	O

Moreover	O
,	O
use	O
of	O
the	O
pharmacological	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
AMPK	B-GENE-N
)	O
inhibitor	O
compound	B-CHEMICAL
C	I-CHEMICAL
revealed	O
that	O
AMPK	B-GENE-N
is	O
essential	O
for	O
suppressing	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
expression	O
in	O
phillyrin	B-CHEMICAL
-	O
treated	O
cells	O
.	O

Finally	O
,	O
we	O
found	O
that	O
liver	B-GENE-Y
kinase	I-GENE-Y
B1	I-GENE-Y
(	O
LKB1	B-GENE-Y
)	O
phosphorylation	O
is	O
required	O
for	O
the	O
phillyrin	B-CHEMICAL
-	O
enhanced	O
activation	O
of	O
AMPK	B-GENE-N
in	O
HepG2	O
hepatocytes	O
.	O

These	O
results	O
indicate	O
that	O
phillyrin	B-CHEMICAL
prevents	O
lipid	O
accumulation	O
in	O
HepG2	O
cells	O
by	O
blocking	O
the	O
expression	O
of	O
SREBP	B-GENE-Y
-	I-GENE-Y
1c	I-GENE-Y
and	O
FAS	B-GENE-Y
through	O
LKB1	B-GENE-Y
/	O
AMPK	B-GENE-N
activation	O
,	O
suggesting	O
that	O
phillyrin	B-CHEMICAL
is	O
a	O
novel	O
AMPK	B-GENE-N
activator	O
with	O
a	O
role	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
obesity	O
.	O

Physicochemical	O
parameters	O
that	O
influence	O
carotenoids	O
bioaccessibility	O
from	O
a	O
tomato	O
juice	O
.	O

In	O
vitro	O
digestion	O
models	O
have	O
been	O
developed	O
to	O
estimate	O
carotenoid	O
bioavailability	O
but	O
most	O
do	O
not	O
consider	O
that	O
their	O
diffusion	O
from	O
fruit	O
matrix	O
to	O
the	O
lipid	O
phase	O
of	O
the	O
bolus	O
could	O
be	O
a	O
limiting	O
step	O
.	O

Therefore	O
we	O
designed	O
a	O
model	O
in	O
which	O
tomato	O
juice	O
is	O
mixed	O
with	O
oil	O
or	O
oil	O
/	O
water	O
emulsions	O
,	O
and	O
the	O
carotenoids	O
diffusing	O
to	O
oil	O
are	O
measured	O
by	O
spectrometry	O
.	O

Temperature	O
,	O
pH	O
and	O
tomato	O
juice	O
/	O
peanut	O
oil	O
ratio	O
were	O
evaluated	O
for	O
their	O
influence	O
on	O
carotenoid	O
diffusion	O
.	O

When	O
oil	O
/	O
tomato	O
ratio	O
was	O
between	O
0	O
.	O
11	O
and	O
1	O
,	O
extraction	O
of	O
lycopene	B-CHEMICAL
was	O
limited	O
by	O
the	O
saturation	O
of	O
the	O
oil	O
phase	O
.	O

With	O
a	O
large	O
excess	O
of	O
oil	O
,	O
diffusion	O
was	O
also	O
limited	O
,	O
as	O
only	O
31	O
±	O
1	O
%	O
of	O
lycopene	B-CHEMICAL
could	O
be	O
extracted	O
from	O
the	O
juice	O
.	O

Diffusion	O
did	O
not	O
vary	O
significantly	O
with	O
pH	O
but	O
doubled	O
when	O
temperature	O
rose	O
from	O
10	O
°	O
C	O
to	O
37	O
°	O
C	O
.	O

When	O
the	O
juice	O
was	O
mixed	O
in	O
an	O
emulsion	O
stabilised	O
with	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
or	O
phospholipids	O
the	O
maximum	O
extraction	O
decreased	O
to	O
14	O
.	O
5	O
±	O
0	O
.	O
2	O
%	O
and	O
18	O
.	O
5	O
±	O
1	O
.	O
5	O
%	O
respectively	O
,	O
indicating	O
that	O
in	O
addition	O
to	O
the	O
saturation	O
of	O
the	O
oil	O
phase	O
at	O
low	O
oil	O
/	O
tomato	O
ratio	O
and	O
in	O
addition	O
to	O
intrinsic	O
properties	O
of	O
the	O
tomato	O
juice	O
in	O
non	O
-	O
saturating	O
conditions	O
,	O
lycopene	B-CHEMICAL
diffusion	O
was	O
limited	O
by	O
the	O
structure	O
of	O
the	O
interface	O
in	O
emulsions	O
.	O

Quantitative	O
determination	O
of	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
chain	O
composition	O
in	O
pork	O
meat	O
products	O
by	O
high	O
resolution	O
1H	B-CHEMICAL
NMR	O
spectroscopy	O
.	O

High	O
resolution	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
NMR	O
spectroscopy	O
was	O
proposed	O
for	O
the	O
determination	O
of	O
the	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
chain	O
profile	O
of	O
lipids	O
in	O
pork	O
meat	O
products	O
during	O
ripening	O
.	O

Two	O
typical	O
Mediterranean	O
PDO	O
salami	O
produced	O
in	O
Calabria	O
,	O
a	O
region	O
in	O
the	O
Southern	O
Italy	O
,	O
were	O
chosen	O
as	O
a	O
case	O
of	O
study	O
.	O

Quantitative	O
NMR	O
analysis	O
provided	O
the	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
chain	O
profiles	O
of	O
total	O
lipid	O
extracts	O
.	O

The	O
transesterification	O
of	O
total	O
lipid	O
extracts	O
furnished	O
FAME	B-CHEMICAL
mixtures	O
that	O
enabled	O
quantitation	O
of	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
acyl	I-CHEMICAL
chains	O
in	O
the	O
acylglycerol	B-CHEMICAL
and	O
FFA	O
portions	O
.	O

In	O
all	O
cases	O
,	O
oleyl	B-CHEMICAL
chains	O
were	O
predominant	O
,	O
and	O
high	O
amounts	O
of	O
polyunsaturated	B-CHEMICAL
fatty	I-CHEMICAL
acid	I-CHEMICAL
chains	O
were	O
observed	O
.	O

The	O
proposed	O
spectroscopic	O
method	O
allowed	O
also	O
the	O
estimation	O
of	O
the	O
most	O
important	O
nutritional	O
parameters	O
of	O
dry	O
fermented	O
meat	O
products	O
.	O

A	O
combination	O
of	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
and	I-CHEMICAL
[	I-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Huperzine	I-CHEMICAL
A	I-CHEMICAL
improves	O
protection	O
against	O
soman	O
toxicity	O
compared	O
to	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Huperzine	I-CHEMICAL
A	I-CHEMICAL
in	O
guinea	O
pigs	O
.	O

The	O
neuropathologic	O
mechanisms	O
after	O
exposure	O
to	O
lethal	O
doses	O
of	O
nerve	O
agent	O
are	O
complex	O
and	O
involve	O
multiple	O
biochemical	O
pathways	O
.	O

Effective	O
treatment	O
requires	O
drugs	O
that	O
can	O
simultaneously	O
protect	O
by	O
reversible	O
binding	O
to	O
the	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
and	O
blocking	O
cascades	O
of	O
seizure	O
related	O
brain	O
damage	O
,	O
inflammation	O
,	O
neuronal	O
degeneration	O
as	O
well	O
as	O
promoting	O
induction	O
of	O
neuroregeneration	O
.	O

[	B-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Huperzine	I-CHEMICAL
A	I-CHEMICAL
(	O
[	B-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
)	O
,	O
is	O
a	O
naturally	O
occurring	O
potent	O
reversible	O
AChE	B-GENE-Y
inhibitor	O
that	O
penetrates	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

It	O
also	O
has	O
several	O
neuroprotective	O
effects	O
including	O
modification	O
of	O
beta	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
peptide	I-GENE-Y
,	O
reduction	O
of	O
oxidative	O
stress	O
,	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
apoptotic	O
and	O
induction	O
and	O
regulation	O
of	O
nerve	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
.	O

Toxicities	O
at	O
higher	O
doses	O
restrict	O
the	O
neuroporotective	O
ability	O
of	O
[	B-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
for	O
treatment	O
.	O

The	O
synthetic	O
stereoisomer	O
,	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
,	O
is	O
less	O
toxic	O
due	O
to	O
poor	O
AChE	B-GENE-Y
inhibition	O
and	O
is	O
suitable	O
for	O
both	O
pre	O
-	O
/	O
post	O
-	O
exposure	O
treatments	O
of	O
nerve	O
agent	O
toxicity	O
.	O

[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
block	O
the	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
(	O
NMDA	B-CHEMICAL
)	O
-	O
induced	O
seizure	O
in	O
rats	O
,	O
reduce	O
excitatory	O
amino	B-CHEMICAL
acid	I-CHEMICAL
induced	O
neurotoxicity	O
and	O
also	O
prevent	O
soman	O
induced	O
toxicity	O
with	O
minimum	O
performance	O
decrement	O
.	O

Unique	O
combinations	O
of	O
two	O
stereo	O
-	O
isomers	O
of	O
Hup	B-CHEMICAL
A	I-CHEMICAL
may	O
provide	O
an	O
excellent	O
pre	O
/	O
post	O
-	O
treatment	O
drug	O
for	O
the	O
nerve	O
agent	O
induced	O
seizure	O
/	O
status	O
epilepticus	O
.	O

We	O
investigated	O
a	O
combination	O
of	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
with	O
a	O
small	O
dose	O
of	O
[	B-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
(	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
and	I-CHEMICAL
[	I-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
)	O
against	O
soman	B-CHEMICAL
toxicity	O
.	O

Our	O
data	O
showed	O
that	O
pretreatment	O
with	O
a	O
combination	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
and	I-CHEMICAL
[	I-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
significantly	O
increased	O
the	O
survival	O
rate	O
and	O
reduced	O
behavioral	O
abnormalities	O
after	O
exposure	O
to	O
1	O
.	O
2	O
×	O
LD50	O
soman	O
compared	O
to	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
in	O
guinea	O
pigs	O
.	O

In	O
addition	O
,	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
and	I-CHEMICAL
[	I-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
pretreatment	O
inhibited	O
the	O
development	O
of	O
high	O
power	O
of	O
EEG	O
better	O
than	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
pretreatment	O
alone	O
.	O

These	O
data	O
suggest	O
that	O
a	O
combination	O
of	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
and	I-CHEMICAL
[	I-CHEMICAL
-	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
offers	O
better	O
protection	O
than	O
[	B-CHEMICAL
+	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Hup	I-CHEMICAL
A	I-CHEMICAL
and	O
serves	O
as	O
a	O
potent	O
medical	O
countermeasure	O
against	O
lethal	O
dose	O
nerve	O
agent	O
toxicity	O
in	O
guinea	O
pigs	O
.	O

Neuroprotective	O
role	O
of	O
ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
potassium	I-GENE-N
channels	I-GENE-N
in	O
cerebral	O
ischemia	O
.	O

ATP	B-GENE-N
-	I-GENE-N
sensitive	I-GENE-N
potassium	I-GENE-N
(	I-GENE-N
K	I-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
are	O
weak	O
,	O
inward	O
rectifiers	O
that	O
couple	O
metabolic	O
status	O
to	O
cell	O
membrane	O
electrical	O
activity	O
,	O
thus	O
modulating	O
many	O
cellular	O
functions	O
.	O

An	O
increase	O
in	O
the	O
ADP	B-CHEMICAL
/	O
ATP	B-CHEMICAL
ratio	O
opens	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
,	O
leading	O
to	O
membrane	O
hyperpolarization	O
.	O

K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
are	O
ubiquitously	O
expressed	O
in	O
neurons	O
located	O
in	O
different	O
regions	O
of	O
the	O
brain	O
,	O
including	O
the	O
hippocampus	O
and	O
cortex	O
.	O

Brief	O
hypoxia	O
triggers	O
membrane	O
hyperpolarization	O
in	O
these	O
central	O
neurons	O
.	O

In	O
vivo	O
animal	O
studies	O
confirmed	O
that	O
knocking	O
out	O
the	O
Kir6	B-GENE-N
.	I-GENE-N
2	I-GENE-N
subunit	O
of	O
the	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
increases	O
ischemic	O
infarction	O
,	O
and	O
overexpression	O
of	O
the	O
Kir6	B-GENE-N
.	I-GENE-N
2	I-GENE-N
subunit	O
reduces	O
neuronal	O
injury	O
from	O
ischemic	O
insults	O
.	O

These	O
findings	O
provide	O
the	O
basis	O
for	O
a	O
practical	O
strategy	O
whereby	O
activation	O
of	O
endogenous	O
K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
reduces	O
cellular	O
damage	O
resulting	O
from	O
cerebral	O
ischemic	O
stroke	O
.	O

K	B-GENE-N
(	I-GENE-N
ATP	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
modulators	O
may	O
prove	O
to	O
be	O
clinically	O
useful	O
as	O
part	O
of	O
a	O
combination	O
therapy	O
for	O
stroke	O
management	O
in	O
the	O
future	O
.	O

An	O
Indian	O
butyrylcholinesterase	B-GENE-Y
variant	O
L307P	B-GENE-N
is	O
not	O
structurally	O
stable	O
:	O
A	O
molecular	O
dynamics	O
simulation	O
study	O
.	O

The	O
human	B-GENE-Y
butyrylcholinesterase	I-GENE-Y
(	O
BChE	B-GENE-Y
)	O
activity	O
is	O
less	O
than	O
1	O
%	O
in	O
the	O
serum	O
of	O
silent	O
variant	O
individuals	O
of	O
Vysya	O
community	O
in	O
India	O
.	O

They	O
are	O
homozygous	O
for	O
a	O
point	O
mutation	O
at	O
codon	O
307	O
(	O
CTT	B-GENE-N
→	O
CCT	B-GENE-N
)	O
resulting	O
in	O
the	O
substitution	O
of	O
leucine	B-GENE-N
307	I-GENE-N
by	I-GENE-N
proline	I-GENE-N
.	O

The	O
reason	O
for	O
the	O
disappearance	O
of	O
the	O
protein	O
in	O
the	O
serum	O
has	O
not	O
been	O
explicated	O
till	O
date	O
.	O

Based	O
on	O
this	O
background	O
,	O
we	O
performed	O
molecular	O
dynamics	O
simulation	O
to	O
probe	O
the	O
structural	O
stability	O
of	O
Indian	O
variant	O
(	O
L307P	B-GENE-N
)	O
in	O
comparison	O
with	O
wild	O
and	O
other	O
BChE	B-GENE-Y
variants	O
(	O
D70G	B-GENE-N
,	O
E497V	B-GENE-N
,	O
V142M	B-GENE-N
)	O
having	O
differential	O
esterase	B-GENE-N
activity	O
.	O

The	O
simulation	O
of	O
all	O
the	O
mutants	O
except	O
D70G	B-GENE-N
showed	O
a	O
much	O
larger	O
Cα	O
root	O
mean	O
square	O
deviation	O
from	O
the	O
wild	O
BChE	B-GENE-Y
crystal	O
structure	O
,	O
showing	O
the	O
overall	O
conformational	O
disturbance	O
.	O

Further	O
analysis	O
revealed	O
that	O
secondary	O
structure	O
of	O
the	O
mutant	O
proteins	O
was	O
not	O
stable	O
.	O

The	O
orientation	O
of	O
the	O
catalytic	O
triad	O
is	O
also	O
distorted	O
in	O
all	O
the	O
mutants	O
.	O

The	O
distance	O
between	O
δ	O
nitrogen	B-CHEMICAL
of	O
His438	B-CHEMICAL
to	O
ε	O
oxygen	B-CHEMICAL
of	O
Glu325	B-CHEMICAL
and	O
ε	O
nitrogen	B-CHEMICAL
of	O
His438	B-CHEMICAL
to	O
γ	O
oxygen	B-CHEMICAL
of	O
Ser198	B-CHEMICAL
were	O
highly	O
altered	O
in	O
L307P	B-GENE-N
mutant	O
than	O
the	O
wild	O
and	O
other	O
three	O
variants	O
throughout	O
the	O
simulation	O
.	O

Such	O
disparity	O
of	O
distances	O
between	O
the	O
catalytic	O
residues	O
may	O
be	O
due	O
to	O
the	O
change	O
in	O
the	O
protein	O
conformation	O
attributing	O
to	O
their	O
differential	O
catalytic	O
activity	O
.	O

Our	O
studies	O
thus	O
prove	O
that	O
the	O
Indian	O
BChE	B-GENE-Y
L307P	B-GENE-N
mutant	O
with	O
negligible	O
activity	O
is	O
possibly	O
due	O
to	O
its	O
structural	O
instability	O
when	O
compared	O
to	O
other	O
BChE	B-GENE-Y
variants	O
.	O

A	O
mutation	O
in	O
the	O
FAM36A	B-GENE-Y
gene	O
,	O
the	O
human	O
ortholog	O
of	O
COX20	B-GENE-N
,	O
impairs	O
cytochrome	B-GENE-N
c	I-GENE-N
oxidase	I-GENE-N
assembly	O
and	O
is	O
associated	O
with	O
ataxia	O
and	O
muscle	O
hypotonia	O
.	O

The	O
mitochondrial	B-GENE-N
respiratory	I-GENE-N
chain	I-GENE-N
complex	I-GENE-N
IV	I-GENE-N
(	O
cytochrome	B-GENE-N
c	I-GENE-N
oxidase	I-GENE-N
)	O
is	O
a	O
multi	O
-	O
subunit	O
enzyme	O
that	O
transfers	O
electrons	O
from	O
cytochrome	B-GENE-Y
c	I-GENE-Y
to	O
molecular	O
oxygen	B-CHEMICAL
,	O
yielding	O
water	O
.	O

Its	O
biogenesis	O
requires	O
concerted	O
expression	O
of	O
mitochondria	O
-	O
and	O
nuclear	O
-	O
encoded	O
subunits	O
and	O
assembly	O
factors	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
homozygous	O
missense	O
mutation	O
in	O
FAM36A	B-GENE-Y
from	O
a	O
patient	O
who	O
displays	O
ataxia	O
and	O
muscle	O
hypotonia	O
.	O

The	O
FAM36A	B-GENE-Y
gene	O
is	O
a	O
remote	O
,	O
putative	O
ortholog	O
of	O
the	O
fungal	B-GENE-N
complex	I-GENE-N
IV	I-GENE-N
assembly	I-GENE-N
factor	I-GENE-N
COX20	B-GENE-N
.	O

Messenger	O
RNA	O
(	O
mRNA	O
)	O
and	O
protein	O
co	O
-	O
expression	O
analyses	O
support	O
the	O
involvement	O
of	O
FAM36A	B-GENE-Y
in	O
complex	B-GENE-N
IV	I-GENE-N
function	O
in	O
mammals	O
.	O

The	O
c	B-GENE-N
.	I-GENE-N
154A	I-GENE-N
>	I-GENE-N
C	I-GENE-N
mutation	O
in	O
the	O
FAM36A	B-GENE-Y
gene	O
,	O
a	O
mutation	O
that	O
is	O
absent	O
in	O
sequenced	O
exomes	O
,	O
leads	O
to	O
a	O
reduced	O
activity	O
and	O
lower	O
levels	O
of	O
complex	B-GENE-N
IV	I-GENE-N
and	O
its	O
protein	O
subunits	O
.	O

The	O
FAM36A	B-GENE-Y
protein	O
is	O
nearly	O
absent	O
in	O
patient	O
'	O
s	O
fibroblasts	O
.	O

Cells	O
affected	O
by	O
the	O
mutation	O
accumulate	O
subassemblies	O
of	O
complex	B-GENE-N
IV	I-GENE-N
that	O
contain	O
COX1	B-GENE-Y
but	O
are	O
almost	O
devoid	O
of	O
COX2	B-GENE-Y
protein	O
.	O

We	O
observe	O
co	O
-	O
purification	O
of	O
FAM36A	B-GENE-Y
and	O
COX2	B-GENE-Y
proteins	O
,	O
supporting	O
that	O
the	O
FAM36A	B-GENE-Y
defect	O
hampers	O
the	O
early	O
step	O
of	O
complex	B-GENE-N
IV	I-GENE-N
assembly	O
at	O
the	O
incorporation	O
of	O
the	O
COX2	B-GENE-Y
subunit	O
.	O

Lentiviral	O
complementation	O
of	O
patient	O
'	O
s	O
fibroblasts	O
with	O
wild	O
-	O
type	O
FAM36A	B-GENE-Y
increases	O
the	O
complex	B-GENE-N
IV	I-GENE-N
activity	O
as	O
well	O
as	O
the	O
amount	O
of	O
holocomplex	B-GENE-N
IV	I-GENE-N
and	O
of	O
individual	O
subunits	O
.	O

These	O
results	O
establish	O
the	O
function	O
of	O
the	O
human	B-GENE-Y
gene	I-GENE-Y
FAM36A	I-GENE-Y
/	O
COX20	B-GENE-Y
in	O
complex	B-GENE-N
IV	I-GENE-N
assembly	O
and	O
support	O
a	O
causal	O
role	O
of	O
the	O
gene	O
in	O
complex	B-GENE-N
IV	I-GENE-N
deficiency	O
.	O

Protective	O
effect	O
of	O
cinnamon	O
polyphenols	B-CHEMICAL
against	O
STZ	B-CHEMICAL
-	O
diabetic	O
mice	O
fed	O
high	O
-	O
sugar	O
,	O
high	O
-	O
fat	O
diet	O
and	O
its	O
underlying	O
mechanism	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
potential	O
effects	O
of	O
14days	O
'	O
intragastrically	O
given	O
of	O
cinnamon	O
polyphenols	B-CHEMICAL
(	O
CPS	O
)	O
in	O
treating	O
diabetic	O
mice	O
induced	O
by	O
intraperitoneal	O
injection	O
of	O
streptozotocin	B-CHEMICAL
(	O
150mgkg	O
(	O
-	O
1	O
)	O
)	O
and	O
fed	O
high	O
-	O
sugar	B-CHEMICAL
,	O
high	O
-	O
fat	O
diet	O
.	O

The	O
diabetic	O
mice	O
model	O
was	O
successfully	O
established	O
through	O
determining	O
on	O
fasting	O
blood	O
-	O
glucose	B-CHEMICAL
(	O
FBG	O
)	O
test	O
.	O

As	O
revealed	O
by	O
glucose	B-GENE-N
oxidase	I-GENE-N
(	O
GOD	O
)	O
and	O
radioimmunoassay	O
(	O
RIA	O
)	O
,	O
both	O
dimethyldiguanide	B-CHEMICAL
(	O
DC	O
,	O
0	O
.	O
6gkg	O
(	O
-	O
1	O
)	O
d	O
(	O
-	O
1	O
)	O
)	O
and	O
CPS	O
(	O
0	O
.	O
3	O
,	O
0	O
.	O
6	O
,	O
1	O
.	O
2gkg	O
(	O
-	O
1	O
)	O
d	O
(	O
-	O
1	O
)	O
)	O
treatments	O
significantly	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
blood	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-N
levels	O
in	O
serum	O
,	O
while	O
the	O
levels	O
of	O
oxidative	O
stress	O
markers	O
were	O
markedly	O
lowered	O
through	O
ELISA	O
assay	O
.	O

Meanwhile	O
,	O
the	O
pathological	O
damage	O
in	O
islet	O
with	O
pancreatic	O
beta	O
cells	O
was	O
ameliorated	O
by	O
treatment	O
of	O
CPS	O
at	O
different	O
doses	O
,	O
as	O
shown	O
in	O
HE	O
stain	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
treatments	O
also	O
caused	O
notable	O
reduction	O
of	O
iNOS	B-GENE-Y
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
expressions	O
showing	O
in	O
Western	O
blot	O
analysis	O
.	O

These	O
findings	O
demonstrate	O
that	O
cinnamon	O
polyphenols	B-CHEMICAL
can	O
exert	O
the	O
hypoglycemic	O
and	O
hypolipidemic	O
effects	O
through	O
the	O
mechanisms	O
that	O
may	O
be	O
associated	O
with	O
repairing	O
pancreatic	O
beta	O
cells	O
in	O
diabetic	O
mice	O
and	O
improving	O
its	O
anti	O
-	O
oxidative	O
capacity	O
,	O
as	O
well	O
as	O
attenuating	O
cytotoxicity	O
via	O
inhibition	O
of	O
iNOS	B-GENE-Y
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
.	O

Polymorphisms	O
in	O
OCTN1	B-GENE-Y
and	O
OCTN2	B-GENE-Y
transporters	O
genes	O
are	O
associated	O
with	O
prolonged	O
time	O
to	O
progression	O
in	O
unresectable	O
gastrointestinal	O
stromal	O
tumours	O
treated	O
with	O
imatinib	B-CHEMICAL
therapy	O
.	O

The	O
two	O
basic	O
mainstays	O
of	O
gastrointestinal	O
stromal	O
tumours	O
(	O
GIST	O
)	O
treatment	O
are	O
surgery	O
and	O
imatinib	B-CHEMICAL
,	O
a	O
selective	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
that	O
allows	O
achieving	O
a	O
stable	O
or	O
responding	O
disease	O
in	O
about	O
80	O
%	O
of	O
patients	O
with	O
unresectable	O
/	O
metastatic	O
GIST	O
.	O

Response	O
to	O
imatinib	B-CHEMICAL
mainly	O
depends	O
from	O
KIT	B-GENE-Y
and	O
PDGFRα	B-GENE-Y
mutational	O
status	O
.	O

Nevertheless	O
,	O
some	O
patients	O
with	O
a	O
potentially	O
responsive	O
genotype	O
do	O
not	O
respond	O
,	O
and	O
others	O
develop	O
a	O
pattern	O
of	O
resistance	O
to	O
imatinib	B-CHEMICAL
which	O
is	O
not	O
associated	O
with	O
secondary	O
mutations	O
.	O

This	O
emphasizes	O
the	O
presence	O
of	O
mechanisms	O
of	O
resistance	O
other	O
than	O
the	O
receptor	O
-	O
related	O
genotype	O
,	O
and	O
the	O
need	O
of	O
biological	O
predictors	O
to	O
select	O
the	O
optimal	O
therapeutic	O
strategy	O
,	O
particularly	O
now	O
that	O
other	O
potent	O
inhibitors	O
are	O
available	O
.	O

We	O
investigated	O
a	O
panel	O
of	O
31	O
polymorphisms	O
in	O
11	O
genes	O
,	O
potentially	O
associated	O
with	O
the	O
pharmacogenetics	O
of	O
imatinib	B-CHEMICAL
,	O
in	O
a	O
group	O
of	O
54	O
unresectable	O
/	O
metastatic	O
GISTs	O
treated	O
with	O
imatinib	B-CHEMICAL
400mg	O
daily	O
as	O
first	O
line	O
therapy	O
.	O

Included	O
in	O
this	O
analysis	O
were	O
polymorphisms	O
in	O
the	O
transporters	O
'	O
family	O
SLC22	B-GENE-N
,	O
SLCO	B-GENE-N
,	O
ABC	B-GENE-N
,	O
and	O
in	O
the	O
metabolizing	O
genes	O
CYP	B-GENE-N
-	I-GENE-N
3A4	I-GENE-N
and	I-GENE-N
-	I-GENE-N
3A5	I-GENE-N
.	O

Time	O
to	O
progression	O
was	O
significantly	O
improved	O
in	O
presence	O
of	O
the	O
C	O
allele	O
in	O
SLC22A4	B-GENE-Y
(	O
OCTN1	B-GENE-Y
rs1050152	O
)	O
,	O
and	O
the	O
two	O
minor	O
alleles	O
(	O
G	O
)	O
in	O
SLC22A5	B-GENE-Y
(	O
OCTN2	B-GENE-Y
rs2631367	O
and	O
rs2631372	O
)	O
.	O

Importantly	O
,	O
multivariate	O
analysis	O
,	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
KIT	B-GENE-Y
/	O
PDGFRα	B-GENE-Y
mutational	O
status	O
,	O
and	O
tumour	O
size	O
,	O
revealed	O
that	O
all	O
the	O
three	O
genotypes	O
maintained	O
independent	O
predictive	O
significance	O
.	O

In	O
conclusion	O
,	O
in	O
this	O
study	O
we	O
showed	O
that	O
SLC22A4	B-GENE-Y
and	O
SLC22A5	B-GENE-Y
genotypes	O
may	O
be	O
an	O
important	O
predictor	O
of	O
time	O
to	O
progression	O
in	O
GIST	O
patients	O
receiving	O
imatinib	B-CHEMICAL
therapy	O
.	O

Further	O
investigations	O
are	O
required	O
in	O
an	O
attempt	O
to	O
further	O
personalize	O
GIST	O
therapy	O
.	O

Discovery	O
of	O
novel	O
cannabinoid	B-GENE-N
receptor	I-GENE-N
ligands	O
by	O
a	O
virtual	O
screening	O
approach	O
:	O
further	O
development	O
of	O
2	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
trisubstituted	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazines	I-CHEMICAL
as	O
CB2	B-GENE-Y
agonists	O
.	O

3D	O
ligand	O
-	O
based	O
virtual	O
screening	O
was	O
employed	O
to	O
identify	O
novel	O
scaffolds	O
for	O
cannabinoid	B-GENE-N
receptor	I-GENE-N
ligand	O
development	O
.	O

A	O
total	O
of	O
112	O
compounds	O
with	O
diverse	O
structures	O
were	O
purchased	O
from	O
commercial	O
vendors	O
.	O

12	O
CB1	B-GENE-Y
receptor	O
antagonists	O
/	O
inverse	O
agonists	O
and	O
10	O
CB2	B-GENE-Y
receptor	O
agonists	O
were	O
identified	O
in	O
vitro	O
.	O

One	O
of	O
the	O
CB2	B-GENE-Y
agonists	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
cyclopentyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ethoxy	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylpiperidin	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
amine	I-CHEMICAL
(	O
19	O
,	O
-	O
logEC	O
(	O
50	O
)	O
=	O
7	O
.	O
5	O
,	O
E	O
(	O
max	O
)	O
=	O
255	O
%	O
)	O
was	O
selected	O
for	O
further	O
development	O
.	O

As	O
far	O
as	O
we	O
are	O
aware	O
,	O
the	O
compound	O
'	O
s	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazine	I-CHEMICAL
scaffold	O
represents	O
a	O
new	O
core	O
structure	O
for	O
CB2	B-GENE-Y
agonists	O
.	O

A	O
library	O
of	O
fifty	O
-	O
seven	O
2	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
trisubstituted	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
triazines	I-CHEMICAL
was	O
created	O
to	O
clarify	O
the	O
structure	O
-	O
activity	O
relationship	O
study	O
of	O
the	O
analogs	O
.	O

Long	O
range	O
effect	O
of	O
mutations	O
on	O
specific	O
conformational	O
changes	O
in	O
the	O
extracellular	O
loop	O
2	O
of	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
.	O

The	O
topology	O
of	O
the	O
second	O
extracellular	O
loop	O
(	O
ECL2	O
)	O
and	O
its	O
interaction	O
with	O
ligands	O
is	O
unique	O
in	O
each	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
.	O

When	O
the	O
orthosteric	O
ligand	O
pocket	O
located	O
in	O
the	O
transmembrane	O
(	O
TM	O
)	O
domain	O
is	O
occupied	O
,	O
ligand	O
-	O
specific	O
conformational	O
changes	O
occur	O
in	O
the	O
ECL2	O
.	O

In	O
more	O
than	O
90	O
%	O
of	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
,	O
ECL2	O
is	O
tethered	O
to	O
the	O
third	O
TM	O
helix	O
via	O
a	O
disulfide	O
bond	O
.	O

Therefore	O
,	O
understanding	O
the	O
extent	O
to	O
which	O
the	O
TM	O
domain	O
and	O
ECL2	O
conformations	O
are	O
coupled	O
is	O
useful	O
.	O

To	O
investigate	O
this	O
,	O
we	O
examined	O
conformational	O
changes	O
in	O
ECL2	O
of	O
the	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
AT1R	B-GENE-Y
)	O
by	O
introducing	O
mutations	O
in	O
distant	O
sites	O
that	O
alter	O
the	O
activation	O
state	O
equilibrium	O
of	O
the	O
AT1R	B-GENE-Y
.	O

Differential	O
accessibility	O
of	O
reporter	O
cysteines	B-CHEMICAL
introduced	O
at	O
four	O
conformation	O
-	O
sensitive	O
sites	O
in	O
ECL2	O
of	O
these	O
mutants	O
was	O
measured	O
.	O

Binding	O
of	O
the	O
agonist	O
angiotensin	B-GENE-Y
II	I-GENE-Y
(	O
AngII	B-GENE-Y
)	O
and	O
inverse	O
agonist	O
losartan	B-CHEMICAL
in	O
wild	O
-	O
type	O
AT1R	B-GENE-Y
changed	O
the	O
accessibility	O
of	O
reporter	O
cysteines	B-CHEMICAL
,	O
and	O
the	O
pattern	O
was	O
consistent	O
with	O
ligand	O
-	O
specific	O
"	O
lid	O
"	O
conformations	O
of	O
ECL2	O
.	O

Without	O
agonist	O
stimulation	O
,	O
the	O
ECL2	O
in	O
the	O
gain	O
of	O
function	O
mutant	O
N111G	B-GENE-N
assumed	O
a	O
lid	O
conformation	O
similar	O
to	O
AngII	B-GENE-Y
-	O
bound	O
wild	O
-	O
type	O
AT1R	B-GENE-Y
.	O

In	O
the	O
presence	O
of	O
inverse	O
agonists	O
,	O
the	O
conformation	O
of	O
ECL2	O
in	O
the	O
N111G	B-GENE-N
mutant	O
was	O
similar	O
to	O
the	O
inactive	O
state	O
of	O
wild	O
-	O
type	O
AT1R	B-GENE-Y
.	O

In	O
contrast	O
,	O
AngII	B-GENE-Y
did	O
not	O
induce	O
a	O
lid	O
conformation	O
in	O
ECL2	O
in	O
the	O
loss	O
of	O
function	O
D281A	B-GENE-N
mutant	O
,	O
which	O
is	O
consistent	O
with	O
the	O
reduced	O
AngII	B-GENE-Y
binding	O
affinity	O
in	O
this	O
mutant	O
.	O

However	O
,	O
a	O
lid	O
conformation	O
was	O
induced	O
by	O
[	O
Sar	B-CHEMICAL
(	O
1	O
)	O
,	O
Gln	B-CHEMICAL
(	O
2	O
)	O
,	O
Ile	B-CHEMICAL
(	O
8	O
)	O
]	O
AngII	B-GENE-Y
,	O
a	O
specific	O
analog	O
that	O
binds	O
to	O
the	O
D281A	B-GENE-N
mutant	O
with	O
better	O
affinity	O
than	O
AngII	B-GENE-Y
.	O

These	O
results	O
provide	O
evidence	O
for	O
the	O
emerging	O
paradigm	O
of	O
domain	O
coupling	O
facilitated	O
by	O
long	O
range	O
interactions	O
at	O
distant	O
sites	O
on	O
the	O
same	O
receptor	O
.	O

Heteromtoxin	B-GENE-Y
(	O
HmTx	B-GENE-Y
)	O
,	O
a	O
novel	O
heterodimeric	O
phospholipase	B-GENE-N
A	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
from	O
Heterometrus	O
laoticus	O
scorpion	O
venom	O
.	O

Heteromtoxin	B-GENE-Y
(	O
HmTx	B-GENE-Y
)	O
is	O
a	O
group	B-GENE-N
III	I-GENE-N
phospholipase	I-GENE-N
A	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
produced	O
in	O
Heterometrus	O
laoticus	O
,	O
in	O
Thailand	O
.	O

In	O
this	O
study	O
,	O
HmTx	B-GENE-Y
was	O
purified	O
from	O
venom	O
by	O
separation	O
chromatography	O
,	O
and	O
the	O
PLA	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
activity	O
of	O
the	O
fractions	O
was	O
determined	O
by	O
lecithin	O
agar	O
assay	O
.	O

The	O
enzyme	O
is	O
an	O
acidic	O
protein	O
with	O
a	O
pI	O
of	O
5	O
.	O
6	O
and	O
an	O
apparent	O
molecular	O
weight	O
of	O
14018	O
.	O
4	O
Da	O
.	O

The	O
nucleotide	B-CHEMICAL
sequence	O
of	O
HmTx	B-GENE-Y
contains	O
649	O
bp	O
,	O
and	O
the	O
mature	O
protein	O
is	O
predicted	O
to	O
have	O
131	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
-	O
104	O
of	O
which	O
make	O
up	O
the	O
large	O
subunit	O
,	O
and	O
27	O
of	O
which	O
make	O
up	O
the	O
small	O
subunit	O
.	O

The	O
subunit	O
structure	O
of	O
HmTx	B-GENE-Y
is	O
highly	O
similar	O
to	O
that	O
of	O
the	O
other	O
toxin	O
,	O
Pandinus	O
imperator	O
imperatoxin	O
I	O
(	O
IpTx	O
(	O
i	O
)	O
)	O
and	O
to	O
Mesobuthus	B-GENE-N
tamulus	I-GENE-N
phospholipase	I-GENE-N
A	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
(	O
MtPLA	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
)	O
.	O

The	O
3D	O
-	O
structure	O
of	O
HmTx	B-GENE-Y
consists	O
of	O
three	O
conserved	O
alpha	O
-	O
helices	O
:	O
h1	O
(	O
Lys24	B-CHEMICAL
-	O
His34	B-CHEMICAL
)	O
,	O
h2	O
(	O
Cys59	B-CHEMICAL
-	O
Asp71	B-CHEMICAL
)	O
,	O
and	O
h3	O
(	O
Ala80	B-CHEMICAL
-	O
Phe89	B-CHEMICAL
)	O
.	O

The	O
beta	O
-	O
sheet	O
consisted	O
of	O
a	O
single	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
(	O
b1	O
.	O
1	O
at	O
Glu43	B-CHEMICAL
-	O
Lys45	B-CHEMICAL
and	O
b1	O
.	O
2	O
at	O
Lys48	B-CHEMICAL
-	O
Asn50	B-CHEMICAL
)	O
that	O
was	O
highly	O
similar	O
to	O
the	O
conserved	O
sequences	O
(	O
-	O
CGXG	O
-	O
,	O
-	O
CCXXHDXC	O
-	O
and	O
CXCEXXXXXC	O
-	O
)	O
of	O
Apis	O
mellifera	O
(	O
bee	O
)	O
phospholipases	B-GENE-N
.	O

Effect	O
of	O
developmental	O
dioxin	B-CHEMICAL
exposure	O
on	O
methylation	O
and	O
expression	O
of	O
specific	O
imprinted	O
genes	O
in	O
mice	O
.	O

2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
Tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
is	O
an	O
endocrine	O
disruptor	O
affecting	O
the	O
reproductive	O
system	O
in	O
humans	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effects	O
of	O
TCDD	B-CHEMICAL
administered	O
to	O
pregnant	O
mice	O
at	O
two	O
different	O
doses	O
(	O
2	O
-	O
10	O
ng	O
/	O
kg	O
/	O
day	O
)	O
,	O
on	O
imprinted	O
genes	O
in	O
the	O
male	O
offspring	O
.	O

The	O
degree	O
of	O
methylation	O
and	O
the	O
mRNA	O
expression	O
of	O
Snrpn	B-GENE-Y
,	O
Peg3	B-GENE-Y
and	O
Igf2r	B-GENE-Y
were	O
analyzed	O
in	O
the	O
sperm	O
,	O
skeletal	O
muscle	O
and	O
liver	O
.	O

TCDD	B-CHEMICAL
administration	O
(	O
10	O
ng	O
/	O
kg	O
/	O
day	O
)	O
decreased	O
the	O
sperm	O
count	O
in	O
the	O
male	O
offspring	O
.	O

It	O
did	O
not	O
affect	O
methylation	O
but	O
increased	O
mRNA	O
expression	O
of	O
Snrpn	B-GENE-Y
,	O
Peg3	B-GENE-Y
,	O
Igf2r	B-GENE-Y
and	O
Air	B-GENE-Y
ncRNA	I-GENE-Y
.	O

In	O
muscle	O
and	O
liver	O
,	O
TCDD	B-CHEMICAL
(	O
10	O
ng	O
/	O
kg	O
/	O
day	O
)	O
induced	O
increases	O
in	O
methylation	O
and	O
decreases	O
in	O
mRNA	O
expression	O
of	O
Igf2r	B-GENE-Y
.	O

These	O
results	O
show	O
that	O
the	O
robust	O
effects	O
of	O
TCDD	B-CHEMICAL
on	O
the	O
mRNA	O
expression	O
of	O
Snrpn	B-GENE-Y
,	O
Peg3	B-GENE-Y
and	O
Igf2r	B-GENE-Y
genes	O
in	O
the	O
sperm	O
and	O
of	O
Igf2r	B-GENE-Y
in	O
the	O
muscle	O
and	O
liver	O
are	O
unrelated	O
to	O
changes	O
in	O
methylation	O
in	O
their	O
respective	O
genes	O
.	O

Structural	O
optimization	O
of	O
2	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
thiophene	I-CHEMICAL
amides	I-CHEMICAL
as	O
highly	O
potent	O
and	O
selective	O
17β	B-GENE-Y
-	I-GENE-Y
hydroxysteroid	I-GENE-Y
dehydrogenase	I-GENE-Y
type	I-GENE-Y
2	I-GENE-Y
inhibitors	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

Inhibition	O
of	O
17β	B-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
is	O
an	O
attractive	O
mechanism	O
for	O
the	O
treatment	O
of	O
osteoporosis	O
.	O

We	O
report	O
here	O
the	O
optimization	O
of	O
human	B-GENE-Y
17β	I-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
inhibitors	O
in	O
the	O
2	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
thiophene	I-CHEMICAL
amide	I-CHEMICAL
class	O
by	O
varying	O
the	O
size	O
of	O
the	O
linker	O
(	O
n	O
equals	O
0	O
and	O
2	O
)	O
between	O
the	O
amide	B-CHEMICAL
moiety	O
and	O
the	O
phenyl	B-CHEMICAL
group	O
.	O

While	O
none	O
of	O
the	O
phenethylamides	B-CHEMICAL
(	O
n	O
=	O
2	O
)	O
were	O
active	O
,	O
most	O
of	O
the	O
anilides	B-CHEMICAL
(	O
n	O
=	O
0	O
)	O
turned	O
out	O
to	O
moderately	O
or	O
strongly	O
inhibit	O
17β	B-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
.	O

The	O
four	O
most	O
active	O
compounds	O
showed	O
an	O
IC₅₀	O
of	O
around	O
60	O
nM	O
and	O
a	O
very	O
good	O
selectivity	O
toward	O
17β	B-GENE-Y
-	I-GENE-Y
HSD1	I-GENE-Y
,	O
17β	B-GENE-Y
-	I-GENE-Y
HSD4	I-GENE-Y
,	O
17β	B-GENE-Y
-	I-GENE-Y
HSD5	I-GENE-Y
,	O
11β	B-GENE-Y
-	I-GENE-Y
HSD1	I-GENE-Y
,	O
11β	B-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
and	O
the	O
estrogen	B-GENE-N
receptors	I-GENE-N
α	I-GENE-N
and	I-GENE-N
β	I-GENE-N
.	O

The	O
investigated	O
compounds	O
inhibited	O
monkey	O
17β	B-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
moderately	O
,	O
and	O
one	O
of	O
them	O
showed	O
good	O
inhibitory	O
activity	O
on	O
mouse	B-GENE-Y
17β	I-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
.	O

SAR	O
studies	O
allowed	O
a	O
first	O
characterization	O
of	O
the	O
human	B-GENE-Y
17β	I-GENE-Y
-	I-GENE-Y
HSD2	I-GENE-Y
active	O
site	O
,	O
which	O
is	O
predicted	O
to	O
be	O
considerably	O
larger	O
than	O
that	O
of	O
17β	B-GENE-Y
-	I-GENE-Y
HSD1	I-GENE-Y
.	O

Synergistic	O
anti	O
-	O
cancer	O
effects	O
of	O
resveratrol	B-CHEMICAL
and	O
chemotherapeutic	O
agent	O
clofarabine	B-CHEMICAL
against	O
human	O
malignant	O
mesothelioma	O
MSTO	O
-	O
211H	O
cells	O
.	O

Dietary	O
phytochemicals	O
as	O
adjuvants	O
have	O
been	O
suggested	O
to	O
play	O
important	O
roles	O
in	O
enhancing	O
chemotherapeutic	O
potential	O
owing	O
to	O
multitargeted	O
chemopreventive	O
properties	O
and	O
lack	O
of	O
substantial	O
toxicity	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
efficacy	O
of	O
the	O
combined	O
treatment	O
of	O
various	O
phytochemicals	O
with	O
the	O
anticancer	O
drug	O
clofarabine	B-CHEMICAL
in	O
malignant	O
mesothelioma	O
MSTO	O
-	O
211H	O
cells	O
and	O
normal	O
mesothelial	O
MeT	O
-	O
5A	O
cells	O
.	O

The	O
combined	O
treatment	O
of	O
resveratrol	B-CHEMICAL
and	O
clofarabine	B-CHEMICAL
produced	O
a	O
synergistic	O
antiproliferative	O
effect	O
in	O
MSTO	O
-	O
211H	O
cells	O
,	O
but	O
not	O
in	O
MeT	O
-	O
5A	O
cells	O
.	O

In	O
MSTO	O
-	O
211H	O
cells	O
,	O
the	O
nuclear	O
accumulation	O
of	O
Sp1	B-GENE-Y
and	O
the	O
levels	O
of	O
p	B-GENE-N
-	I-GENE-N
Akt	I-GENE-N
,	O
Sp1	B-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
Met	I-GENE-Y
,	O
cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
and	O
p21	B-GENE-Y
were	O
effectively	O
decreased	O
by	O
the	O
combined	O
treatment	O
of	O
them	O
.	O

In	O
combination	O
with	O
clofarabine	B-CHEMICAL
,	O
the	O
ability	O
of	O
resveratrol	B-CHEMICAL
to	O
reduce	O
the	O
contents	O
of	O
Sp1	B-GENE-Y
and	O
its	O
target	O
gene	O
products	O
was	O
also	O
evident	O
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
experiment	O
.	O

The	O
inhibition	O
of	O
phosphoinositide	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
using	O
Ly294002	B-CHEMICAL
augmented	O
a	O
decrease	O
in	O
the	O
p21	B-GENE-Y
level	O
induced	O
by	O
their	O
combination	O
,	O
but	O
it	O
showed	O
no	O
significant	O
effects	O
on	O
expression	O
of	O
Sp1	B-GENE-Y
and	O
cyclin	B-GENE-Y
D1	I-GENE-Y
.	O

Taken	O
together	O
,	O
the	O
data	O
provide	O
evidence	O
that	O
the	O
synergistic	O
antiproliferative	O
effect	O
of	O
resveratrol	B-CHEMICAL
and	O
clofarabine	B-CHEMICAL
is	O
linked	O
to	O
the	O
inhibition	O
of	O
Akt	B-GENE-N
and	O
Sp1	B-GENE-Y
activities	O
,	O
and	O
suggest	O
that	O
this	O
combination	O
may	O
have	O
therapeutic	O
value	O
in	O
treatment	O
of	O
malignant	O
mesothelioma	O
.	O

Emodin	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
glucoside	I-CHEMICAL
inhibits	O
HMGB1	B-GENE-Y
-	O
induced	O
inflammatory	O
responses	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

High	B-GENE-Y
mobility	I-GENE-Y
group	I-GENE-Y
box	I-GENE-Y
1	I-GENE-Y
(	O
HMGB1	B-GENE-Y
)	O
protein	O
acts	O
as	O
a	O
potent	O
proinflammatory	O
cytokine	B-GENE-N
and	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
several	O
vascular	O
diseases	O
,	O
such	O
as	O
,	O
systemic	O
vasculitis	O
and	O
sepsis	O
.	O

Emodin	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
glucoside	I-CHEMICAL
(	O
EG	O
)	O
is	O
a	O
new	O
active	O
compound	O
from	O
Reynoutria	O
japonica	O
,	O
and	O
its	O
biologic	O
activities	O
have	O
not	O
been	O
previously	O
investigated	O
.	O

In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
the	O
antiinflammatory	O
activities	O
of	O
EG	O
on	O
HMGB1	B-GENE-Y
-	O
mediated	O
proinflammatory	O
responses	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
and	O
in	O
a	O
murine	O
cecal	O
ligation	O
and	O
puncture	O
(	O
CLP	O
)	O
-	O
model	O
of	O
sepsis	O
in	O
mice	O
.	O

EG	O
was	O
found	O
to	O
suppress	O
the	O
release	O
of	O
HMGB1	B-GENE-Y
,	O
the	O
production	O
of	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
TNF	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
and	O
the	O
activation	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
by	O
HMGB1	B-GENE-Y
in	O
HUVECs	O
,	O
and	O
to	O
inhibit	O
HMGB1	B-GENE-Y
-	O
mediated	O
hyperpermeability	O
and	O
leukocyte	O
migration	O
in	O
mice	O
.	O

In	O
the	O
CLP	O
model	O
,	O
HMGB1	B-GENE-Y
was	O
highly	O
released	O
,	O
but	O
this	O
release	O
was	O
prevented	O
by	O
EG	O
.	O

Furthermore	O
,	O
EG	O
also	O
increased	O
the	O
survival	O
times	O
of	O
CLP	O
administered	O
mice	O
.	O

Collectively	O
,	O
this	O
study	O
shows	O
EG	O
can	O
protect	O
barrier	O
integrity	O
and	O
inhibit	O
HMGB1	B-GENE-Y
-	O
mediated	O
inflammatory	O
responses	O
,	O
which	O
suggests	O
a	O
potential	O
use	O
as	O
a	O
therapy	O
for	O
sepsis	O
or	O
septic	O
shock	O
.	O

Linking	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
subunits	O
to	O
alcohol	B-CHEMICAL
-	O
induced	O
conditioned	O
taste	O
aversion	O
and	O
recovery	O
from	O
acute	O
alcohol	B-CHEMICAL
intoxication	O
.	O

GABA	B-GENE-N
type	I-GENE-N
A	I-GENE-N
receptors	I-GENE-N
(	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
R	I-GENE-N
)	O
are	O
important	O
for	O
ethanol	B-CHEMICAL
actions	O
and	O
it	O
is	O
of	O
interest	O
to	O
link	O
individual	O
subunits	O
with	O
specific	O
ethanol	B-CHEMICAL
behaviors	O
.	O

We	O
studied	O
null	O
mutant	O
mice	O
for	O
six	O
different	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
R	I-GENE-N
subunits	I-GENE-N
(	I-GENE-N
α1	I-GENE-N
,	I-GENE-N
α2	I-GENE-N
,	I-GENE-N
α3	I-GENE-N
,	I-GENE-N
α4	I-GENE-N
,	I-GENE-N
α5	I-GENE-N
and	I-GENE-N
δ	I-GENE-N
)	O
.	O

Only	O
mice	O
lacking	O
the	O
α2	O
subunit	O
showed	O
reduction	O
of	O
conditioned	O
taste	O
aversion	O
(	O
CTA	O
)	O
to	O
ethanol	B-CHEMICAL
.	O

These	O
results	O
are	O
in	O
agreement	O
with	O
data	O
from	O
knock	O
-	O
in	O
mice	O
with	O
mutation	O
of	O
the	O
ethanol	B-CHEMICAL
-	O
sensitive	O
site	O
in	O
the	O
α2	O
-	O
subunit	O
(	O
Blednov	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

All	O
together	O
,	O
they	O
indicate	O
that	O
aversive	O
property	O
of	O
ethanol	B-CHEMICAL
is	O
dependent	O
on	O
ethanol	B-CHEMICAL
action	O
on	O
α2	B-GENE-Y
-	I-GENE-Y
containing	I-GENE-Y
GABA	I-GENE-Y
(	I-GENE-Y
A	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
.	O

Deletion	O
of	O
the	O
α2	O
-	O
subunit	O
led	O
to	O
faster	O
recovery	O
whereas	O
absence	O
of	O
the	O
α3	O
-	O
subunit	O
slowed	O
recovery	O
from	O
ethanol	B-CHEMICAL
-	O
induced	O
incoordination	O
(	O
rotarod	O
)	O
.	O

Deletion	O
of	O
the	O
other	O
four	O
subunits	O
did	O
not	O
affect	O
this	O
behavior	O
.	O

Similar	O
changes	O
in	O
this	O
behavior	O
for	O
the	O
α2	O
and	O
α3	O
null	O
mutants	O
were	O
found	O
for	O
flurazepam	B-CHEMICAL
motor	O
incoordination	O
.	O

However	O
,	O
no	O
differences	O
in	O
recovery	O
were	O
found	O
in	O
motor	O
-	O
incoordinating	O
effects	O
of	O
an	O
α1	O
-	O
selective	O
modulator	O
(	O
zolpidem	B-CHEMICAL
)	O
or	O
an	O
α4	O
-	O
selective	O
agonist	O
(	O
gaboxadol	B-CHEMICAL
)	O
.	O

Therefore	O
,	O
recovery	O
of	O
rotarod	O
incoordination	O
is	O
under	O
control	O
of	O
two	O
GABA	B-GENE-N
(	I-GENE-N
A	I-GENE-N
)	I-GENE-N
-	I-GENE-N
R	I-GENE-N
subunits	I-GENE-N
:	I-GENE-N
α2	I-GENE-N
and	I-GENE-N
α3	I-GENE-N
.	O

For	O
motor	O
activity	O
,	O
α3	O
null	O
mice	O
demonstrated	O
higher	O
activation	O
by	O
ethanol	B-CHEMICAL
(	O
1	O
g	O
/	O
kg	O
)	O
whereas	O
both	O
α2	O
(	O
-	O
/	O
-	O
)	O
and	O
α3	O
(	O
-	O
/	O
Y	O
)	O
knockout	O
mice	O
were	O
less	O
sensitive	O
to	O
ethanol	B-CHEMICAL
-	O
induced	O
reduction	O
of	O
motor	O
activity	O
(	O
1	O
.	O
5	O
g	O
/	O
kg	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
the	O
effects	O
of	O
ethanol	B-CHEMICAL
at	O
GABAergic	O
synapses	O
containing	O
α2	O
subunit	O
are	O
important	O
for	O
specific	O
behavioral	O
effects	O
of	O
ethanol	B-CHEMICAL
which	O
may	O
be	O
relevant	O
to	O
the	O
genetic	O
linkage	O
of	O
the	O
α2	O
subunit	O
with	O
human	O
alcoholism	O
.	O

Arsenic	B-CHEMICAL
activates	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
Gi	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
signaling	O
to	O
inhibit	O
stem	O
cell	O
differentiation	O
in	O
adipogenesis	O
.	O

Dysfunctional	O
lipid	O
and	O
glucose	B-CHEMICAL
metabolism	O
contribute	O
to	O
metabolic	O
syndrome	O
-	O
a	O
major	O
public	O
health	O
concern	O
that	O
enhances	O
cardiovascular	O
disease	O
risk	O
.	O

Arsenic	B-CHEMICAL
(	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
)	O
exposure	O
may	O
increase	O
metabolic	O
syndrome	O
and	O
cardiovascular	O
disease	O
risk	O
by	O
impairing	O
adipose	O
tissue	O
differentiation	O
,	O
function	O
,	O
and	O
insulin	O
sensitivity	O
through	O
pathogenic	O
mechanisms	O
that	O
remain	O
unclear	O
.	O

We	O
hypothesized	O
that	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
signals	O
through	O
the	O
Pertussis	B-GENE-N
toxin	I-GENE-N
(	O
Ptx	B-GENE-N
)	O
sensitive	O
,	O
Gi	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
(	O
GPCR	B-GENE-N
)	O
to	O
impair	O
adipogenesis	O
,	O
as	O
previously	O
demonstrated	O
for	O
its	O
stimulation	O
of	O
vascular	O
oxidant	O
generation	O
,	O
angiogenesis	O
,	O
and	O
remodeling	O
.	O

Because	O
both	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
and	O
GPCR	B-GENE-N
ligands	O
inhibit	O
progenitor	O
cell	O
differentiation	O
into	O
adipocytes	O
,	O
we	O
investigated	O
the	O
hypothesis	O
in	O
a	O
model	O
of	O
low	O
-	O
passage	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSC	O
)	O
.	O

As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
(	O
0	O
.	O
1	O
-	O
1	O
.	O
0	O
µM	O
)	O
suppressed	O
dexamethasone	B-CHEMICAL
/	O
insulin	O
-	O
induced	O
hMSC	O
adipogenesis	O
,	O
as	O
indicated	O
by	O
decreased	O
transcriptional	O
promoters	O
of	O
differentiation	O
,	O
decreased	O
fat	O
droplet	O
formation	O
,	O
and	O
decreased	O
expression	O
of	O
differentiated	O
adipocyte	O
markers	O
,	O
such	O
as	O
adiponectin	B-GENE-Y
and	O
perilipin	B-GENE-Y
.	O

Preincubating	O
hMSC	O
with	O
Ptx	B-GENE-N
prevented	O
90	O
%	O
of	O
the	O
suppressive	O
effect	O
of	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
.	O

Selective	O
competitive	O
antagonists	O
of	O
Gi	B-GENE-N
-	O
coupled	O
endothelin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
type	I-GENE-N
A	I-GENE-N
and	I-GENE-N
B	I-GENE-N
receptors	I-GENE-N
were	O
~	O
60	O
%	O
effective	O
in	O
blocking	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
inhibition	O
and	O
combination	O
of	O
antagonists	O
to	O
both	O
receptors	O
were	O
85	O
%	O
effective	O
.	O

In	O
contrast	O
,	O
antagonists	O
to	O
the	O
sphingosine	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
phosphate	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
previously	O
shown	O
to	O
mediate	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
vascular	O
effects	O
)	O
or	O
the	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
were	O
ineffective	O
in	O
blocking	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
effects	O
.	O

These	O
studies	O
suggest	O
a	O
majority	O
of	O
arsenic	B-CHEMICAL
-	O
inhibited	O
adipocyte	O
differentiation	O
,	O
and	O
metabolism	O
requires	O
endothelin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
GPCRs	B-GENE-N
and	O
that	O
As	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
effects	O
on	O
GPCR	B-GENE-N
signaling	O
are	O
tissue	O
and	O
context	O
specific	O
.	O

This	O
may	O
represent	O
a	O
significant	O
mechanism	O
for	O
the	O
contribution	O
of	O
arsenic	B-CHEMICAL
exposure	O
to	O
increased	O
metabolic	O
and	O
cardiovascular	O
diseases	O
.	O

2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
Tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
-	O
mediated	O
production	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
is	O
an	O
essential	O
step	O
in	O
the	O
mechanism	O
of	O
action	O
to	O
accelerate	O
human	O
keratinocyte	O
differentiation	O
.	O

Chloracne	O
is	O
commonly	O
observed	O
in	O
humans	O
exposed	O
to	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
;	O
yet	O
,	O
the	O
mechanism	O
of	O
toxicity	O
is	O
not	O
well	O
understood	O
.	O

Using	O
normal	O
human	O
epidermal	O
keratinocytes	O
,	O
we	O
investigated	O
the	O
mechanism	O
of	O
TCDD	B-CHEMICAL
-	O
mediated	O
enhancement	O
of	O
epidermal	O
differentiation	O
by	O
integrating	O
functional	O
genomic	O
,	O
metabolomic	O
,	O
and	O
biochemical	O
analyses	O
.	O

TCDD	B-CHEMICAL
increased	O
the	O
expression	O
of	O
40	O
%	O
of	O
the	O
genes	O
of	O
the	O
epidermal	O
differentiation	O
complex	O
found	O
on	O
chromosome	O
1q21	O
and	O
75	O
%	O
of	O
the	O
genes	O
required	O
for	O
de	O
novo	O
ceramide	B-CHEMICAL
biosynthesis	O
.	O

Lipid	O
analysis	O
demonstrated	O
that	O
eight	O
of	O
the	O
nine	O
classes	O
of	O
ceramides	B-CHEMICAL
were	O
increased	O
by	O
TCDD	B-CHEMICAL
,	O
altering	O
the	O
ratio	O
of	O
ceramides	B-CHEMICAL
to	O
free	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
.	O

TCDD	B-CHEMICAL
decreased	O
the	O
expression	O
of	O
the	O
glucose	B-GENE-N
transporter	I-GENE-N
,	O
SLC2A1	B-GENE-Y
,	O
and	O
most	O
of	O
the	O
glycolytic	O
transcripts	O
,	O
followed	O
by	O
decreases	O
in	O
glycolytic	O
intermediates	O
,	O
including	O
pyruvate	B-CHEMICAL
.	O

NADH	B-CHEMICAL
and	O
Krebs	O
cycle	O
intermediates	O
were	O
decreased	O
,	O
whereas	O
NAD	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
was	O
increased	O
.	O

Mitochondrial	O
glutathione	B-GENE-N
(	I-GENE-N
GSH	I-GENE-N
)	I-GENE-N
reductase	I-GENE-N
activity	O
and	O
the	O
GSH	B-CHEMICAL
/	O
glutathione	B-CHEMICAL
disulfide	I-CHEMICAL
ratio	O
were	O
decreased	O
by	O
TCDD	B-CHEMICAL
,	O
ultimately	O
leading	O
to	O
mitochondrial	O
dysfunction	O
,	O
characterized	O
by	O
decreased	O
inner	O
mitochondrial	O
membrane	O
potential	O
and	O
ATP	B-CHEMICAL
production	O
,	O
and	O
increased	O
production	O
of	O
the	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
,	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
.	O

Aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AHR	B-GENE-Y
)	O
antagonists	O
blocked	O
the	O
response	O
of	O
many	O
transcripts	O
to	O
TCDD	B-CHEMICAL
,	O
and	O
the	O
endpoints	O
of	O
decreased	O
ATP	B-CHEMICAL
production	O
and	O
differentiation	O
,	O
suggesting	O
regulation	O
by	O
the	O
AHR	B-GENE-Y
.	O

Cotreatment	O
of	O
cells	O
with	O
chemical	O
antioxidants	O
or	O
the	O
enzyme	O
catalase	B-GENE-Y
blocked	O
the	O
TCDD	B-CHEMICAL
-	O
mediated	O
acceleration	O
of	O
keratinocyte	O
cornified	O
envelope	O
formation	O
,	O
an	O
endpoint	O
of	O
terminal	O
differentiation	O
.	O

Thus	O
,	O
TCDD	B-CHEMICAL
-	O
mediated	O
ROS	O
production	O
is	O
a	O
critical	O
step	O
in	O
the	O
mechanism	O
of	O
this	O
chemical	O
to	O
accelerate	O
keratinocyte	O
differentiation	O
.	O

IFNα	B-GENE-N
converts	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
into	O
a	O
cytokine	B-GENE-N
efficiently	O
activating	O
STAT1	B-GENE-Y
and	O
its	O
downstream	O
targets	O
.	O

Besides	O
their	O
antiviral	O
activity	O
,	O
type	B-GENE-N
I	I-GENE-N
Interferons	I-GENE-N
(	O
IFN	B-GENE-N
)	O
display	O
context	O
-	O
specific	O
immunomodulation	O
.	O

In	O
contrast	O
to	O
long	O
-	O
known	O
IFNα	B-GENE-N
/	I-GENE-N
β	I-GENE-N
,	O
Interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
is	O
an	O
anti	O
-	O
bacterial	O
,	O
largely	O
tissue	O
protective	O
cytokine	B-GENE-N
that	O
recently	O
gained	O
attention	O
.	O

Herein	O
,	O
cellular	O
IFNα	B-GENE-N
/	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
interactions	O
are	O
investigated	O
.	O

We	O
report	O
that	O
pre	O
-	O
conditioning	O
of	O
epithelial	O
cells	O
with	O
IFNα	B-GENE-N
initiated	O
dramatic	O
changes	O
in	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
signaling	O
normally	O
dominated	O
by	O
signal	B-GENE-Y
transducer	I-GENE-Y
and	I-GENE-Y
activator	I-GENE-Y
of	I-GENE-Y
transcription	I-GENE-Y
(	I-GENE-Y
STAT	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
.	O

Specifically	O
,	O
by	O
using	O
human	O
DLD1	O
colon	O
epithelial	O
/	O
carcinoma	O
cells	O
we	O
demonstrate	O
that	O
,	O
upon	O
IFNα	B-GENE-N
,	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
converts	O
into	O
a	O
cytokine	B-GENE-N
robustly	O
activating	O
STAT1	B-GENE-Y
and	O
its	O
downstream	O
pro	O
-	O
inflammatory	O
targets	O
CXCL9	B-GENE-Y
,	O
CXCL10	B-GENE-Y
,	O
and	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
.	O

Accordingly	O
,	O
only	O
after	O
IFNα	B-GENE-N
pre	O
-	O
incubation	O
was	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
-	O
induced	O
STAT1	B-GENE-Y
binding	O
to	O
the	O
CXCL10	B-GENE-N
promoter	I-GENE-N
detectable	O
.	O

Using	O
the	O
viral	O
mimic	O
polyinosinic	B-CHEMICAL
:	I-CHEMICAL
polycytidylic	I-CHEMICAL
acid	I-CHEMICAL
and	O
the	O
IFNα	B-GENE-N
/	I-GENE-N
β	I-GENE-N
antagonist	O
B18R	O
we	O
furthermore	O
demonstrate	O
the	O
capability	O
of	O
endogenous	O
IFN	B-GENE-N
to	O
promote	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
-	O
induced	O
STAT1	B-GENE-Y
activation	O
and	O
expression	O
of	O
CXCL10	B-GENE-Y
.	O

IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
-	O
induced	O
STAT1	B-GENE-Y
activation	O
subsequent	O
to	O
IFNα	B-GENE-N
priming	O
became	O
likewise	O
apparent	O
in	O
human	O
Caco2	O
colon	O
epithelial	O
/	O
carcinoma	O
cells	O
,	O
HepG2	O
hepatoma	O
cells	O
,	O
and	O
primary	O
keratinocytes	O
.	O

Current	O
observations	O
may	O
relate	O
to	O
characteristics	O
of	O
IFNα	B-GENE-N
/	I-GENE-N
β	I-GENE-N
in	O
clinical	O
therapy	O
and	O
expose	O
margins	O
of	O
tissue	O
protection	O
by	O
IL	B-GENE-Y
-	I-GENE-Y
22	I-GENE-Y
application	O
.	O

Enhanced	O
heterodimerization	O
of	O
Bax	B-GENE-Y
by	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mutants	O
improves	O
irradiated	O
cell	O
survival	O
.	O

B	B-GENE-Y
Cell	I-GENE-Y
Lymphoma	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
protein	O
suppresses	O
ionizing	O
radiation	O
-	O
induced	O
apoptosis	O
in	O
hemato	O
-	O
lymphoid	O
system	O
.	O

To	O
enhance	O
the	O
survival	O
of	O
irradiated	O
cells	O
,	O
we	O
have	O
compared	O
the	O
effects	O
and	O
mechanism	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
its	O
functional	O
variants	O
,	O
D34A	B-GENE-N
(	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
resistant	O
)	O
and	O
S70E	B-GENE-N
(	O
mimics	O
phosphorylation	O
on	O
S70	O
)	O
.	O

Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
its	O
mutants	O
were	O
transfected	O
into	O
hematopoietic	O
cell	O
line	O
and	O
assessed	O
for	O
cell	O
survival	O
,	O
clonogenicity	O
and	O
cell	O
cycle	O
perturbations	O
upon	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
electrostatic	O
potential	O
of	O
BH3	B-GENE-N
cleft	I-GENE-N
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
mutants	O
and	O
their	O
heterodimerization	O
with	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
associated	I-GENE-Y
X	I-GENE-Y
protein	I-GENE-Y
(	O
Bax	B-GENE-Y
)	O
were	O
computationally	O
evaluated	O
.	O

Correspondingly	O
,	O
these	O
results	O
were	O
verified	O
by	O
co	O
-	O
immunoprecipitation	O
and	O
western	O
blotting	O
.	O

The	O
mutants	O
afford	O
higher	O
radioprotective	O
effect	O
than	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
apoptotic	O
and	O
clonogenic	O
assays	O
at	O
D	O
(	O
0	O
)	O
(	O
radiation	O
dose	O
at	O
which	O
37	O
%	O
cell	O
survival	O
was	O
observed	O
)	O
.	O

The	O
computational	O
and	O
functional	O
analysis	O
indicates	O
that	O
mutants	O
have	O
higher	O
propensity	O
to	O
neutralize	O
Bax	B-GENE-Y
protein	O
by	O
heterodimerization	O
and	O
have	O
increased	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
suppression	O
capability	O
,	O
which	O
is	O
responsible	O
for	O
enhanced	O
survival	O
.	O

This	O
study	O
implies	O
potential	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mutants	O
or	O
their	O
chemical	O
/	O
peptide	O
mimics	O
to	O
elicit	O
radioprotective	O
effect	O
in	O
cells	O
exposed	O
to	O
radiation	O
.	O

Nanobody	O
-	O
albumin	B-GENE-Y
nanoparticles	O
(	O
NANAPs	O
)	O
for	O
the	O
delivery	O
of	O
a	O
multikinase	B-GENE-N
inhibitor	O
17864	B-CHEMICAL
to	O
EGFR	B-GENE-Y
overexpressing	O
tumor	O
cells	O
.	O

A	O
novel	O
,	O
EGFR	B-GENE-Y
-	O
targeted	O
nanomedicine	O
has	O
been	O
developed	O
in	O
the	O
current	O
study	O
.	O

Glutaraldehyde	B-CHEMICAL
crosslinked	O
albumin	B-GENE-Y
nanoparticles	O
with	O
a	O
size	O
of	O
approximately	O
100nm	O
were	O
loaded	O
with	O
the	O
multikinase	B-GENE-N
inhibitor	O
17864	B-CHEMICAL
-	O
L	O
(	O
x	O
)	O
-	O
a	O
platinum	B-CHEMICAL
-	O
bound	O
sunitinib	B-CHEMICAL
analogue	O
-	O
which	O
couples	O
the	O
drug	O
to	O
methionine	B-CHEMICAL
residues	O
of	O
albumin	B-GENE-Y
and	O
is	O
released	O
in	O
a	O
reductive	O
environment	O
.	O

Albumin	B-GENE-Y
nanoparticles	O
were	O
surface	O
-	O
coated	O
with	O
bifunctional	O
polyethylene	B-CHEMICAL
glycol	I-CHEMICAL
3500	O
(	O
PEG	B-CHEMICAL
)	O
and	O
a	O
nanobody	O
-	O
the	O
single	O
variable	O
domain	O
of	O
an	O
antibody	O
-	O
(	O
Ega1	O
)	O
against	O
the	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
.	O

EGa1	O
-	O
PEG	B-CHEMICAL
functionalized	O
nanoparticles	O
showed	O
a	O
40	O
-	O
fold	O
higher	O
binding	O
to	O
EGFR	B-GENE-Y
-	O
positive	O
14C	B-CHEMICAL
squamous	O
head	O
and	O
neck	O
cancer	O
cells	O
in	O
comparison	O
to	O
PEGylated	O
nanoparticles	O
.	O

17864	B-CHEMICAL
-	O
L	O
(	O
x	O
)	O
loaded	O
EGa1	O
-	O
PEG	B-CHEMICAL
nanoparticles	O
were	O
internalized	O
by	O
clathrin	B-GENE-N
-	O
mediated	O
endocytosis	O
and	O
ultimately	O
digested	O
in	O
lysosomes	O
.	O

The	O
intracellular	O
routing	O
of	O
EGa1	O
targeted	O
nanoparticles	O
leads	O
to	O
a	O
successful	O
release	O
of	O
the	O
kinase	B-GENE-N
inhibitor	O
in	O
the	O
cell	O
and	O
inhibition	O
of	O
proliferation	O
whereas	O
the	O
non	O
-	O
targeted	O
formulations	O
had	O
no	O
antiproliferative	O
effects	O
on	O
14C	B-CHEMICAL
cells	O
.	O

The	O
drug	O
loaded	O
targeted	O
nanoparticles	O
were	O
as	O
effective	O
as	O
the	O
free	O
drug	O
in	O
vitro	O
.	O

These	O
results	O
demonstrate	O
that	O
multikinase	B-GENE-N
inhibitor	O
loaded	O
nanoparticles	O
are	O
interesting	O
nanomedicines	O
for	O
the	O
treatment	O
of	O
EGFR	B-GENE-Y
-	O
positive	O
cancers	O
.	O

Purification	O
and	O
structural	O
characterisation	O
of	O
phospholipase	B-GENE-N
A1	I-GENE-N
(	O
Vespapase	B-GENE-N
,	O
Ves	B-GENE-N
a	I-GENE-N
1	I-GENE-N
)	O
from	O
Thai	O
banded	O
tiger	O
wasp	O
(	O
Vespa	O
affinis	O
)	O
venom	O
.	O

The	O
Thai	O
banded	O
tiger	O
wasp	O
(	O
Vespa	O
affinis	O
)	O
is	O
one	O
of	O
the	O
most	O
dangerous	O
vespid	O
species	O
in	O
Southeast	O
Asia	O
,	O
and	O
stinging	O
accidents	O
involving	O
this	O
species	O
still	O
cause	O
fatalities	O
.	O

In	O
the	O
present	O
study	O
,	O
four	O
forms	O
of	O
V	B-GENE-N
.	I-GENE-N
affinis	I-GENE-N
phospholipase	I-GENE-N
A	I-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
were	O
identified	O
through	O
a	O
proteomics	O
approach	O
.	O

Two	O
of	O
these	O
enzymes	O
were	O
purified	O
by	O
reverse	O
-	O
phase	O
chromatography	O
,	O
and	O
their	O
biochemical	O
properties	O
were	O
characterised	O
.	O

These	O
enzymes	O
,	O
designated	O
Ves	B-GENE-N
a	I-GENE-N
1s	I-GENE-N
,	O
are	O
not	O
glycoproteins	O
and	O
exist	O
as	O
33441	O
.	O
5	O
and	O
33474	O
.	O
4	O
Da	O
proteins	O
,	O
which	O
corresponded	O
with	O
the	O
34	O
-	O
kDa	O
band	O
observed	O
via	O
SDS	O
-	O
PAGE	O
.	O

The	O
thermal	O
stabilities	O
of	O
these	O
enzymes	O
were	O
stronger	O
than	O
snake	O
venom	O
.	O

Using	O
an	O
in	O
vivo	O
assay	O
,	O
no	O
difference	O
was	O
found	O
in	O
the	O
toxicities	O
of	O
the	O
different	O
isoforms	O
.	O

Furthermore	O
,	O
the	O
toxicity	O
of	O
these	O
enzymes	O
does	O
not	O
appear	O
to	O
be	O
correlated	O
with	O
their	O
PLA	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
activity	O
.	O

The	O
cDNAs	O
of	O
the	O
full	O
-	O
length	O
version	O
of	O
Ves	B-GENE-N
a	I-GENE-N
1s	I-GENE-N
revealed	O
that	O
the	O
Ves	B-GENE-N
a	I-GENE-N
1	I-GENE-N
gene	O
consists	O
of	O
a	O
1005	O
-	O
bp	O
ORF	O
,	O
which	O
encodes	O
334	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
,	O
and	O
67	O
-	O
and	O
227	O
-	O
bp	O
5	O
'	O
and	O
3	O
'	O
UTRs	O
,	O
respectively	O
.	O

The	O
two	O
isoforms	O
are	O
different	O
by	O
three	O
nucleotide	B-CHEMICAL
substitutions	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
two	O
amino	B-CHEMICAL
acids	I-CHEMICAL
.	O

Through	O
sequence	O
alignment	O
,	O
these	O
enzymes	O
were	O
classified	O
as	O
members	O
of	O
the	O
pancreatic	B-GENE-N
lipase	I-GENE-N
family	O
.	O

The	O
structural	O
modelling	O
of	O
Ves	B-GENE-N
a	I-GENE-N
1	I-GENE-N
used	O
the	O
rat	B-GENE-Y
pancreatic	I-GENE-Y
lipase	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
protein	I-GENE-Y
2	I-GENE-Y
(	O
1bu8A	B-GENE-Y
)	O
as	O
a	O
template	O
because	O
it	O
has	O
PLA	B-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
activity	O
,	O
which	O
demonstrated	O
that	O
this	O
enzyme	O
belongs	O
to	O
the	O
α	B-GENE-N
/	I-GENE-N
β	I-GENE-N
hydrolase	I-GENE-N
fold	O
family	O
.	O

The	O
Ves	B-GENE-N
a	I-GENE-N
1	I-GENE-N
structure	O
,	O
which	O
is	O
composed	O
of	O
seven	O
α	O
-	O
helixes	O
and	O
eleven	O
β	O
-	O
strands	O
,	O
contains	O
the	O
β	O
-	O
strand	O
/	O
ɛSer	O
/	O
α	O
-	O
helix	O
structural	O
motif	O
,	O
which	O
contains	O
the	O
Gly	B-GENE-N
-	I-GENE-N
X	I-GENE-N
-	I-GENE-N
Ser	I-GENE-N
-	I-GENE-N
X	I-GENE-N
-	I-GENE-N
Gly	I-GENE-N
consensus	O
sequence	O
.	O

The	O
typical	O
surface	O
structures	O
that	O
play	O
important	O
roles	O
in	O
substrate	O
selectivity	O
(	O
the	O
lid	O
domain	O
and	O
the	O
β9	O
loop	O
)	O
were	O
shortened	O
in	O
the	O
Ves	B-GENE-N
a	I-GENE-N
1	I-GENE-N
structure	O
,	O
which	O
suggests	O
that	O
this	O
enzyme	O
may	O
only	O
exhibit	O
phospholipase	B-GENE-N
activity	O
.	O

Moreover	O
,	O
the	O
observed	O
insertion	O
of	O
proline	B-CHEMICAL
into	O
the	O
lid	O
domain	O
of	O
the	O
Ves	B-GENE-N
a	I-GENE-N
1	I-GENE-N
structure	O
is	O
rare	O
.	O

We	O
therefore	O
propose	O
that	O
this	O
proline	B-CHEMICAL
residue	O
might	O
be	O
involved	O
in	O
the	O
stability	O
and	O
activity	O
of	O
Ves	B-GENE-N
a	I-GENE-N
1s	I-GENE-N
.	O

Hydroxysafflor	B-CHEMICAL
yellow	I-CHEMICAL
a	I-CHEMICAL
inhibits	O
lipopolysaccharide	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

Hydroxysafflor	B-CHEMICAL
yellow	I-CHEMICAL
A	I-CHEMICAL
(	O
HSYA	B-CHEMICAL
)	O
is	O
an	O
active	O
ingredient	O
obtained	O
from	O
the	O
flower	O
of	O
Carthamus	O
tinctorius	O
L	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
HSYA	B-CHEMICAL
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
human	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

A549	O
cells	O
stimulated	O
with	O
LPS	O
were	O
incubated	O
with	O
three	O
doses	O
of	O
HSYA	B-CHEMICAL
(	O
1	O
,	O
4	O
and	O
16μmol	O
/	O
L	O
)	O
.	O

HSYA	B-CHEMICAL
suppressed	O
the	O
expression	O
of	O
TLR	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
Myd88	B-GENE-Y
,	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
TNFα	B-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
at	O
the	O
mRNA	O
and	O
protein	O
level	O
,	O
and	O
inhibited	O
the	O
adhesion	O
of	O
leukocytes	O
to	O
A549	O
cells	O
.	O

HSYA	B-CHEMICAL
treatment	O
also	O
decreased	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
p65	B-GENE-Y
nuclear	O
translocation	O
and	O
inhibited	O
the	O
phosphorylation	O
of	O
p38	B-GENE-N
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
p38	B-GENE-N
MAPK	B-GENE-N
)	O
.	O

These	O
findings	O
suggest	O
that	O
HSYA	B-CHEMICAL
effectively	O
inhibits	O
LPS	O
-	O
induced	O
inflammatory	O
signal	O
transduction	O
in	O
A549	O
cells	O
.	O

Gliotransmission	O
and	O
brain	O
glucose	B-CHEMICAL
sensing	O
:	O
critical	O
role	O
of	O
endozepines	B-GENE-N
.	O

Hypothalamic	O
glucose	B-CHEMICAL
sensing	O
is	O
involved	O
in	O
the	O
control	O
of	O
feeding	O
behavior	O
and	O
peripheral	O
glucose	B-CHEMICAL
homeostasis	O
,	O
and	O
glial	O
cells	O
are	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
this	O
process	O
.	O

Diazepam	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
inhibitor	I-GENE-Y
(	O
DBI	B-GENE-Y
)	O
and	O
its	O
processing	O
product	O
the	O
octadecaneuropeptide	B-GENE-N
(	O
ODN	B-GENE-N
)	O
,	O
collectively	O
named	O
endozepines	B-GENE-N
,	O
are	O
secreted	O
by	O
astroglia	O
,	O
and	O
ODN	B-GENE-N
is	O
a	O
potent	O
anorexigenic	O
factor	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
involvement	O
of	O
endozepines	O
in	O
brain	O
glucose	B-CHEMICAL
sensing	O
.	O

First	O
,	O
we	O
showed	O
that	O
intracerebroventricular	O
administration	O
of	O
glucose	B-CHEMICAL
in	O
rats	O
increases	O
DBI	B-GENE-Y
expression	O
in	O
hypothalamic	O
glial	O
-	O
like	O
tanycytes	O
.	O

We	O
then	O
demonstrated	O
that	O
glucose	B-CHEMICAL
stimulates	O
endozepine	O
secretion	O
from	O
hypothalamic	O
explants	O
.	O

Feeding	O
experiments	O
indicate	O
that	O
the	O
anorexigenic	O
effect	O
of	O
central	O
administration	O
of	O
glucose	B-CHEMICAL
was	O
blunted	O
by	O
coinjection	O
of	O
an	O
ODN	B-GENE-N
antagonist	O
.	O

Conversely	O
,	O
the	O
hyperphagic	O
response	O
elicited	O
by	O
central	O
glucoprivation	O
was	O
suppressed	O
by	O
an	O
ODN	B-GENE-N
agonist	O
.	O

The	O
anorexigenic	O
effects	O
of	O
centrally	O
injected	O
glucose	B-CHEMICAL
or	O
ODN	B-GENE-N
agonist	O
were	O
suppressed	O
by	O
blockade	O
of	O
the	O
melanocortin	B-GENE-N
-	I-GENE-N
3	I-GENE-N
/	I-GENE-N
4	I-GENE-N
receptors	I-GENE-N
,	O
suggesting	O
that	O
glucose	B-CHEMICAL
sensing	O
involves	O
endozepinergic	O
control	O
of	O
the	O
melanocortin	B-GENE-N
pathway	O
.	O

Finally	O
,	O
we	O
found	O
that	O
brain	O
endozepines	B-GENE-N
modulate	O
blood	O
glucose	B-CHEMICAL
levels	O
,	O
suggesting	O
their	O
involvement	O
in	O
a	O
feedback	O
loop	O
controlling	O
whole	O
-	O
body	O
glucose	B-CHEMICAL
homeostasis	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
endozepines	B-GENE-N
are	O
a	O
critical	O
relay	O
in	O
brain	O
glucose	B-CHEMICAL
sensing	O
and	O
potentially	O
new	O
targets	O
in	O
treatment	O
of	O
metabolic	O
disorders	O
.	O

The	O
structure	O
and	O
properties	O
of	O
septin	B-GENE-Y
3	I-GENE-Y
:	O
a	O
possible	O
missing	O
link	O
in	O
septin	B-GENE-N
filament	O
formation	O
.	O

The	O
human	O
genome	O
codes	O
for	O
13	O
members	O
of	O
a	O
family	O
of	O
filament	O
-	O
forming	O
GTP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
known	O
as	O
septins	B-GENE-N
.	O

These	O
have	O
been	O
divided	O
into	O
four	O
different	O
subgroups	O
on	O
the	O
basis	O
of	O
sequence	O
similarity	O
.	O

The	O
differences	O
between	O
the	O
subgroups	O
are	O
believed	O
to	O
control	O
their	O
correct	O
assembly	O
into	O
heterofilaments	O
which	O
have	O
specific	O
roles	O
in	O
membrane	O
remodelling	O
events	O
.	O

Many	O
different	O
combinations	O
of	O
the	O
13	O
proteins	O
are	O
theoretically	O
possible	O
and	O
it	O
is	O
therefore	O
important	O
to	O
understand	O
the	O
structural	O
basis	O
of	O
specific	O
filament	O
assembly	O
.	O

However	O
,	O
three	O
-	O
dimensional	O
structures	O
are	O
currently	O
available	O
for	O
only	O
three	O
of	O
the	O
four	O
subgroups	O
.	O

In	O
the	O
present	O
study	O
we	O
describe	O
the	O
crystal	O
structure	O
of	O
a	O
construct	O
of	O
human	B-GENE-Y
SEPT3	I-GENE-Y
which	O
belongs	O
to	O
the	O
outstanding	O
subgroup	O
.	O

This	O
construct	O
(	O
SEPT3	B-GENE-Y
-	O
GC	O
)	O
,	O
which	O
includes	O
the	O
GTP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
and	I-GENE-N
C	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
domains	I-GENE-N
,	O
purifies	O
as	O
a	O
nucleotide	B-CHEMICAL
-	O
free	O
monomer	O
,	O
allowing	O
for	O
its	O
characterization	O
in	O
terms	O
of	O
GTP	B-CHEMICAL
-	O
binding	O
and	O
hydrolysis	O
.	O

In	O
the	O
crystal	O
structure	O
,	O
SEPT3	B-GENE-Y
-	O
GC	O
forms	O
foreshortened	O
filaments	O
which	O
employ	O
the	O
same	O
NC	O
and	O
G	O
interfaces	O
observed	O
in	O
the	O
heterotrimeric	O
complex	O
of	O
human	B-GENE-N
septins	I-GENE-N
2	I-GENE-N
,	I-GENE-N
6	I-GENE-N
and	I-GENE-N
7	I-GENE-N
,	O
reinforcing	O
the	O
notion	O
of	O
'	O
promiscuous	O
'	O
interactions	O
described	O
previously	O
.	O

In	O
the	O
present	O
study	O
we	O
describe	O
these	O
two	O
interfaces	O
and	O
relate	O
the	O
structure	O
to	O
its	O
tendency	O
to	O
form	O
monomers	O
and	O
its	O
efficiency	O
in	O
the	O
hydrolysis	O
of	O
GTP	B-CHEMICAL
.	O

The	O
relevance	O
of	O
these	O
results	O
is	O
emphasized	O
by	O
the	O
fact	O
that	O
septins	O
from	O
the	O
SEPT3	B-GENE-Y
subgroup	O
may	O
be	O
important	O
determinants	O
of	O
polymerization	O
by	O
occupying	O
the	O
terminal	O
position	O
in	O
octameric	O
units	O
which	O
themselves	O
form	O
the	O
building	O
blocks	O
of	O
at	O
least	O
some	O
heterofilaments	O
.	O

Supra	O
-	O
normal	O
stimulation	O
of	O
dopamine	B-GENE-Y
D1	I-GENE-Y
receptors	I-GENE-Y
in	O
the	O
prelimbic	O
cortex	O
blocks	O
behavioral	O
expression	O
of	O
both	O
aversive	O
and	O
rewarding	O
associative	O
memories	O
through	O
a	O
cyclic	B-CHEMICAL
-	I-CHEMICAL
AMP	I-CHEMICAL
-	O
dependent	O
signaling	O
pathway	O
.	O

Dopamine	B-GENE-N
(	I-GENE-N
DA	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
transmission	O
through	O
either	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
or	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	O
like	O
subtypes	O
is	O
involved	O
critically	O
in	O
the	O
processing	O
of	O
emotional	O
information	O
within	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
.	O

However	O
the	O
functional	O
role	O
of	O
specific	O
DA	B-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
receptor	I-GENE-Y
transmission	O
in	O
the	O
expression	O
of	O
emotionally	O
salient	O
associative	O
memories	O
(	O
either	O
aversive	O
or	O
rewarding	O
)	O
is	O
not	O
currently	O
understood	O
.	O

Here	O
we	O
demonstrate	O
that	O
specific	O
activation	O
of	O
DA	B-GENE-Y
D	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptors	I-GENE-Y
in	O
the	O
prelimbic	O
(	O
PLC	O
)	O
division	O
of	O
the	O
mPFC	O
causes	O
a	O
transient	O
block	O
in	O
the	O
behavioral	O
expression	O
of	O
both	O
aversive	O
and	O
rewarding	O
associative	O
memories	O
.	O

We	O
report	O
that	O
intra	O
-	O
PLC	O
microinfusions	O
of	O
a	O
selective	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
agonist	O
block	O
the	O
spontaneous	O
expression	O
of	O
an	O
associative	O
olfactory	O
fear	O
memory	O
,	O
without	O
altering	O
the	O
stability	O
of	O
the	O
original	O
memory	O
trace	O
.	O

Furthermore	O
,	O
using	O
an	O
unbiased	O
place	O
conditioning	O
procedure	O
(	O
CPP	O
)	O
,	O
intra	O
-	O
PLC	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
receptor	I-GENE-Y
activation	O
blocks	O
the	O
spontaneous	O
expression	O
of	O
an	O
associative	O
morphine	B-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
;	O
i	O
.	O
p	O
.	O
)	O
reward	O
memory	O
,	O
while	O
leaving	O
morphine	B-CHEMICAL
-	O
primed	O
memory	O
expression	O
intact	O
.	O

Interestingly	O
,	O
both	O
intra	O
-	O
PLC	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
mediated	O
block	O
of	O
either	O
fear	O
-	O
related	O
or	O
reward	O
-	O
related	O
associative	O
memories	O
were	O
dependent	O
upon	O
downstream	O
cyclic	B-CHEMICAL
-	I-CHEMICAL
AMP	I-CHEMICAL
(	O
cAMP	B-CHEMICAL
)	O
signaling	O
as	O
both	O
effects	O
were	O
rescued	O
by	O
co	O
-	O
administration	O
of	O
a	O
cAMP	B-CHEMICAL
signaling	O
inhibitor	O
.	O

The	O
blockade	O
of	O
both	O
rewarding	O
and	O
aversive	O
associative	O
memories	O
is	O
mediated	O
through	O
a	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	O
specific	O
signaling	O
pathway	O
,	O
as	O
neither	O
forms	O
of	O
spontaneous	O
memory	O
expression	O
were	O
blocked	O
by	O
intra	O
-	O
PLC	O
microinfusions	O
of	O
a	O
D	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
receptor	I-GENE-Y
agonist	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
spontaneous	O
expression	O
of	O
either	O
rewarding	O
or	O
aversive	O
emotionally	O
salient	O
memories	O
shares	O
a	O
common	O
,	O
D	B-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
mediated	O
substrate	O
within	O
the	O
mPFC	O
.	O

The	O
glycogen	B-GENE-Y
synthase	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
/	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
pathway	O
is	O
involved	O
in	O
cinobufagin	B-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
cultured	O
osteosarcoma	O
cells	O
.	O

Cinobufagin	B-CHEMICAL
,	O
a	O
major	O
component	O
of	O
cinobufacini	O
(	O
huachansu	O
)	O
,	O
is	O
an	O
important	O
cardenolidal	B-CHEMICAL
steroid	I-CHEMICAL
.	O

Several	O
studies	O
have	O
suggested	O
that	O
cinobufagin	B-CHEMICAL
has	O
potent	O
anti	O
-	O
cancer	O
effects	O
.	O

The	O
present	O
study	O
examines	O
the	O
apoptosis	O
-	O
inducing	O
activity	O
and	O
the	O
underlying	O
mechanism	O
of	O
action	O
of	O
cinobufagin	B-CHEMICAL
in	O
osteosarcoma	O
(	O
OS	O
)	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
cinobufagin	B-CHEMICAL
potently	O
inhibited	O
the	O
proliferation	O
of	O
U2OS	O
,	O
MG63	O
and	O
SaOS	O
-	O
2	O
cells	O
.	O

Significant	O
increases	O
in	O
G2	O
/	O
M	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
OS	O
cells	O
were	O
also	O
observed	O
.	O

The	O
expression	O
levels	O
of	O
several	O
apoptotic	O
proteins	O
were	O
assessed	O
after	O
cinobufagin	B-CHEMICAL
treatment	O
in	O
U2OS	O
cells	O
.	O

Among	O
them	O
,	O
xIAP	B-GENE-Y
,	O
cIAP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
survivin	B-GENE-Y
and	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
levels	O
decreased	O
remarkably	O
,	O
while	O
the	O
levels	O
of	O
Bax	B-GENE-Y
and	O
cleaved	O
-	O
PARP	B-GENE-N
increased	O
.	O

Furthermore	O
,	O
we	O
validated	O
the	O
inhibition	O
of	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
following	O
cinobufagin	B-CHEMICAL
treatment	O
.	O

Western	O
blots	O
showed	O
a	O
decrease	O
in	O
nuclear	O
p65	B-GENE-Y
protein	O
expression	O
after	O
exposure	O
to	O
different	O
concentrations	O
of	O
cinobufagin	B-CHEMICAL
,	O
while	O
the	O
phosphorylation	O
of	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
was	O
simultaneously	O
increased	O
.	O

Transduction	O
with	O
constitutively	O
active	O
forms	O
of	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
could	O
protect	O
against	O
the	O
downregulation	O
of	O
p65	B-GENE-Y
and	O
upregulation	O
of	O
cleaved	O
-	O
PARP	B-GENE-N
that	O
are	O
induced	O
by	O
cinobufagin	B-CHEMICAL
treatment	O
.	O

However	O
,	O
combined	O
treatment	O
with	O
cinobufagin	B-CHEMICAL
and	O
SB216367	B-CHEMICAL
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
p65	B-GENE-Y
and	O
an	O
increase	O
in	O
cleaved	O
-	O
PARP	B-GENE-N
in	O
U2OS	O
cells	O
.	O

Altogether	O
,	O
these	O
results	O
show	O
that	O
cinobufagin	B-CHEMICAL
is	O
a	O
promising	O
agent	O
for	O
the	O
treatment	O
of	O
OS	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
reveal	O
the	O
involvement	O
of	O
the	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
pathway	O
in	O
cinobufagin	B-CHEMICAL
-	O
induced	O
apoptosis	O
.	O

EphB4	B-GENE-Y
enhances	O
the	O
process	O
of	O
endochondral	O
ossification	O
and	O
inhibits	O
remodeling	O
during	O
bone	O
fracture	O
repair	O
.	O

Previous	O
reports	O
have	O
identified	O
a	O
role	O
for	O
the	O
tyrosine	B-GENE-N
kinase	I-GENE-N
receptor	I-GENE-N
EphB4	B-GENE-Y
and	O
its	O
ligand	O
,	O
ephrinB2	B-GENE-Y
,	O
as	O
potential	O
mediators	O
of	O
both	O
bone	O
formation	O
by	O
osteoblasts	O
and	O
bone	O
resorption	O
by	O
osteoclasts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
role	O
of	O
EphB4	B-GENE-Y
during	O
bone	O
repair	O
after	O
traumatic	O
injury	O
.	O

We	O
performed	O
femoral	O
fractures	O
with	O
internal	O
fixation	O
in	O
transgenic	O
mice	O
that	O
overexpress	O
EphB4	B-GENE-Y
under	O
the	O
collagen	B-GENE-N
type	I-GENE-N
1	I-GENE-N
promoter	I-GENE-N
(	O
Col1	B-GENE-N
-	O
EphB4	B-GENE-Y
)	O
and	O
investigated	O
the	O
bone	O
repair	O
process	O
up	O
to	O
12	O
weeks	O
postfracture	O
.	O

The	O
data	O
indicated	O
that	O
Col1	B-GENE-N
-	O
EphB4	B-GENE-Y
mice	O
exhibited	O
stiffer	O
and	O
stronger	O
bones	O
after	O
fracture	O
compared	O
with	O
wild	O
-	O
type	O
mice	O
.	O

The	O
fractured	O
bones	O
of	O
Col1	B-GENE-N
-	O
EphB4	B-GENE-Y
transgenic	O
mice	O
displayed	O
significantly	O
greater	O
tissue	O
and	O
bone	O
volume	O
2	O
weeks	O
postfracture	O
compared	O
with	O
that	O
of	O
wild	O
-	O
type	O
mice	O
.	O

These	O
findings	O
correlated	O
with	O
increased	O
chondrogenesis	O
and	O
mineral	O
formation	O
within	O
the	O
callus	O
site	O
at	O
2	O
weeks	O
postfracture	O
,	O
as	O
demonstrated	O
by	O
increased	O
safranin	B-CHEMICAL
O	I-CHEMICAL
and	O
von	O
Kossa	O
staining	O
,	O
respectively	O
.	O

Interestingly	O
,	O
Col1	B-GENE-N
-	O
EphB4	B-GENE-Y
mice	O
were	O
found	O
to	O
possess	O
significantly	O
greater	O
numbers	O
of	O
clonogenic	O
mesenchymal	O
stromal	O
progenitor	O
cells	O
(	O
CFU	O
-	O
F	O
)	O
,	O
with	O
an	O
increased	O
capacity	O
to	O
form	O
mineralized	O
nodules	O
in	O
vitro	O
under	O
osteogenic	O
conditions	O
,	O
when	O
compared	O
with	O
those	O
of	O
the	O
wild	O
-	O
type	O
control	O
mice	O
.	O

Furthermore	O
,	O
Col1	B-GENE-N
-	O
EphB4	B-GENE-Y
mice	O
had	O
significantly	O
lower	O
numbers	O
of	O
TRAP	B-GENE-Y
-	O
positive	O
multinucleated	O
osteoclasts	O
within	O
the	O
callus	O
site	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
EphB4	B-GENE-Y
promotes	O
endochondral	O
ossification	O
while	O
inhibiting	O
osteoclast	O
development	O
during	O
callus	O
formation	O
and	O
may	O
represent	O
a	O
novel	O
drug	O
target	O
for	O
the	O
repair	O
of	O
fractured	O
bones	O
.	O

3D	O
-	O
QSAR	O
-	O
assisted	O
drug	O
design	O
:	O
identification	O
of	O
a	O
potent	O
quinazoline	B-CHEMICAL
-	O
based	O
Aurora	B-GENE-N
kinase	I-GENE-N
inhibitor	O
.	O

We	O
describe	O
the	O
3D	O
-	O
QSAR	O
-	O
assisted	O
design	O
of	O
an	O
Aurora	B-GENE-Y
kinase	I-GENE-Y
A	I-GENE-Y
inhibitor	O
with	O
improved	O
physicochemical	O
properties	O
,	O
in	O
vitro	O
activity	O
,	O
and	O
in	O
vivo	O
pharmacokinetic	O
profiles	O
over	O
those	O
of	O
the	O
initial	O
lead	O
.	O

Three	O
different	O
3D	O
-	O
QSAR	O
models	O
were	O
built	O
and	O
validated	O
by	O
using	O
a	O
set	O
of	O
66	O
pyrazole	B-CHEMICAL
(	O
Model	O
I	O
)	O
and	O
furanopyrimidine	B-CHEMICAL
(	O
Model	O
II	O
)	O
compounds	O
with	O
IC	O
(	O
50	O
)	O
values	O
toward	O
Aurora	B-GENE-Y
kinase	I-GENE-Y
A	I-GENE-Y
ranging	O
from	O
33	O
nM	O
to	O
10	O
.	O
5	O
μM	O
.	O

The	O
best	O
3D	O
-	O
QSAR	O
model	O
,	O
Model	O
III	O
,	O
constructed	O
with	O
24	O
training	O
set	O
compounds	O
from	O
both	O
series	O
,	O
showed	O
robustness	O
(	O
r	O
(	O
2	O
)	O
(	O
CV	O
)	O
=	O
0	O
.	O
54	O
and	O
0	O
.	O
52	O
for	O
CoMFA	O
and	O
CoMSIA	O
,	O
respectively	O
)	O
and	O
superior	O
predictive	O
capacity	O
for	O
42	O
test	O
set	O
compounds	O
(	O
R	O
(	O
2	O
)	O
(	O
pred	O
)	O
=	O
0	O
.	O
52	O
and	O
0	O
.	O
67	O
,	O
CoMFA	O
and	O
CoMSIA	O
)	O
.	O

Superimposition	O
of	O
CoMFA	O
and	O
CoMSIA	O
Model	O
III	O
over	O
the	O
crystal	O
structure	O
of	O
Aurora	B-GENE-Y
kinase	I-GENE-Y
A	I-GENE-Y
suggests	O
the	O
potential	O
to	O
improve	O
the	O
activity	O
of	O
the	O
ligands	O
by	O
decreasing	O
the	O
steric	O
clash	O
with	O
Val147	O
and	O
Leu139	O
and	O
by	O
increasing	O
hydrophobic	O
contact	O
with	O
Leu139	O
and	O
Gly216	O
residues	O
in	O
the	O
solvent	O
-	O
exposed	O
region	O
of	O
the	O
enzyme	O
.	O

Based	O
on	O
these	O
suggestions	O
,	O
the	O
rational	O
redesign	O
of	O
furanopyrimidine	B-CHEMICAL
24	O
(	O
clog	O
P	O
=	O
7	O
.	O
41	O
;	O
Aurora	B-GENE-Y
A	I-GENE-Y
IC	O
(	O
50	O
)	O
=	O
43	O
nM	O
;	O
HCT	O
-	O
116	O
IC	O
(	O
50	O
)	O
=	O
400	O
nM	O
)	O
led	O
to	O
the	O
identification	O
of	O
quinazoline	B-CHEMICAL
67	O
(	O
clog	O
P	O
=	O
5	O
.	O
28	O
;	O
Aurora	B-GENE-Y
A	I-GENE-Y
IC	O
(	O
50	O
)	O
=	O
25	O
nM	O
;	O
HCT	O
-	O
116	O
IC	O
(	O
50	O
)	O
=	O
23	O
nM	O
)	O
.	O

Rat	O
in	O
vivo	O
pharmacokinetic	O
studies	O
showed	O
that	O
67	O
has	O
better	O
systemic	O
exposure	O
after	O
i	O
.	O
v	O
.	O
administration	O
than	O
24	O
,	O
and	O
holds	O
potential	O
for	O
further	O
development	O
.	O

Deficits	O
in	O
male	O
sexual	O
behavior	O
in	O
adulthood	O
after	O
social	O
instability	O
stress	O
in	O
adolescence	O
in	O
rats	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
exposure	O
to	O
stressors	O
in	O
adolescence	O
has	O
long	O
-	O
lasting	O
effects	O
on	O
emotional	O
and	O
cognitive	O
behavior	O
,	O
but	O
little	O
is	O
known	O
as	O
to	O
whether	O
reproductive	O
functions	O
are	O
affected	O
.	O

We	O
investigated	O
appetitive	O
and	O
consummatory	O
aspects	O
of	O
sexual	O
behavior	O
in	O
male	O
rats	O
that	O
were	O
exposed	O
to	O
chronic	O
social	O
instability	O
stress	O
(	O
SS	O
,	O
n	O
=	O
24	O
)	O
for	O
16	O
days	O
in	O
mid	O
-	O
adolescence	O
compared	O
to	O
control	O
rats	O
(	O
CTL	O
,	O
n	O
=	O
24	O
)	O
.	O

Over	O
five	O
sexual	O
behavior	O
test	O
sessions	O
with	O
a	O
receptive	O
female	O
,	O
SS	O
rats	O
made	O
fewer	O
ejaculations	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
and	O
had	O
longer	O
latencies	O
to	O
ejaculation	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

When	O
only	O
data	O
from	O
rats	O
that	O
ejaculated	O
in	O
the	O
fifth	O
session	O
were	O
analyzed	O
,	O
SS	O
rats	O
(	O
n	O
=	O
18	O
)	O
had	O
reduced	O
copulatory	O
efficiency	O
(	O
more	O
mounts	O
and	O
intromissions	O
before	O
ejaculation	O
)	O
compared	O
to	O
CTL	O
rats	O
(	O
n	O
=	O
19	O
)	O
(	O
p	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
CTL	O
rats	O
were	O
twice	O
as	O
likely	O
as	O
SS	O
rats	O
to	O
make	O
more	O
than	O
one	O
ejaculation	O
in	O
the	O
fifth	O
session	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O

Further	O
,	O
more	O
CTL	O
(	O
14	O
/	O
24	O
)	O
than	O
SS	O
(	O
5	O
/	O
25	O
)	O
rats	O
ejaculated	O
in	O
four	O
or	O
more	O
sessions	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O

SS	O
rats	O
had	O
lower	O
plasma	O
testosterone	B-CHEMICAL
concentrations	O
than	O
CTL	O
rats	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
but	O
did	O
not	O
differ	O
in	O
androgen	B-GENE-Y
receptor	I-GENE-Y
,	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
alpha	I-GENE-Y
,	O
or	O
Fos	B-GENE-Y
immunoreactive	O
cell	O
counts	O
in	O
the	O
medial	O
preoptic	O
area	O
.	O

The	O
groups	O
did	O
not	O
differ	O
in	O
a	O
partner	O
preference	O
test	O
administered	O
between	O
the	O
fourth	O
and	O
fifth	O
sexual	O
behavior	O
session	O
.	O

The	O
results	O
suggest	O
that	O
developmental	O
history	O
contributes	O
to	O
individual	O
differences	O
in	O
reproductive	O
behavior	O
,	O
and	O
that	O
stress	O
exposures	O
in	O
adolescence	O
may	O
be	O
a	O
factor	O
in	O
sexual	O
sluggishness	O
.	O

Pharmacophore	O
identification	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
inhibitor	O
10074	B-CHEMICAL
-	I-CHEMICAL
G5	I-CHEMICAL
.	O

A	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
study	O
of	O
the	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
(	O
Myc	B-GENE-Y
)	O
inhibitor	O
10074	B-CHEMICAL
-	I-CHEMICAL
G5	I-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
biphenyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
nitrobenzo	I-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
]	I-CHEMICAL
oxadiazol	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
amine	I-CHEMICAL
,	O
1	O
)	O
-	O
which	O
targets	O
a	O
hydrophobic	O
domain	O
of	O
the	O
Myc	B-GENE-Y
oncoprotein	O
that	O
is	O
flanked	O
by	O
arginine	B-CHEMICAL
residues	O
-	O
was	O
executed	O
in	O
order	O
to	O
determine	O
its	O
pharmacophore	O
.	O

Whilst	O
the	O
7	B-CHEMICAL
-	I-CHEMICAL
nitrobenzofurazan	I-CHEMICAL
was	O
found	O
to	O
be	O
critical	O
for	O
inhibitory	O
activity	O
,	O
the	O
ortho	B-CHEMICAL
-	I-CHEMICAL
biphenyl	I-CHEMICAL
could	O
be	O
replaced	O
with	O
a	O
para	B-CHEMICAL
-	I-CHEMICAL
carboxyphenyl	I-CHEMICAL
group	O
to	O
furnish	O
the	O
new	O
inhibitor	O
JY	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
094	I-CHEMICAL
(	O
3q	O
)	O
.	O

Around	O
five	O
times	O
as	O
potent	O
as	O
the	O
lead	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
33	O
μM	O
for	O
disruption	O
of	O
the	O
Myc	B-GENE-Y
-	O
Max	B-GENE-Y
heterodimer	O
,	O
JY	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
094	I-CHEMICAL
demonstrated	O
excellent	O
selectivity	O
over	O
Max	B-GENE-Y
-	O
Max	B-GENE-Y
homodimers	O
,	O
with	O
no	O
apparent	O
effect	O
at	O
100	O
μM	O
.	O

Importantly	O
,	O
the	O
carboxylic	O
acid	O
of	O
JY	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
094	I-CHEMICAL
improves	O
the	O
physicochemical	O
properties	O
of	O
the	O
lead	O
compound	O
,	O
which	O
will	O
facilitate	O
the	O
incorporation	O
of	O
additional	O
hydrophobicity	O
that	O
might	O
enhance	O
Myc	B-GENE-Y
inhibitory	O
activity	O
further	O
still	O
.	O

Pulmonary	O
delivery	O
of	O
an	O
aerosolized	O
recombinant	O
human	B-GENE-Y
butyrylcholinesterase	I-GENE-Y
pretreatment	O
protects	O
against	O
aerosolized	O
paraoxon	B-CHEMICAL
in	O
macaques	O
.	O

Butyrylcholinesterase	B-GENE-Y
(	O
BChE	B-GENE-Y
)	O
is	O
the	O
leading	O
pretreatment	O
candidate	O
against	O
exposure	O
to	O
organophosphates	B-CHEMICAL
(	O
OPs	O
)	O
,	O
which	O
pose	O
an	O
ever	O
increasing	O
public	O
and	O
military	O
health	O
.	O

Since	O
respiratory	O
failure	O
is	O
the	O
primary	O
cause	O
of	O
death	O
following	O
acute	O
OP	O
poisoning	O
,	O
an	O
inhaled	O
BChE	B-GENE-Y
therapeutic	O
could	O
prove	O
highly	O
efficacious	O
in	O
preventing	O
acute	O
toxicity	O
as	O
well	O
as	O
the	O
associated	O
delayed	O
neuropathy	O
.	O

To	O
address	O
this	O
,	O
studies	O
have	O
been	O
performed	O
in	O
mice	O
and	O
macaques	O
using	O
Chinese	O
Hamster	O
Ovary	O
cells	O
(	O
CHO	O
)	O
-	O
derived	O
recombinant	O
(	O
r	O
)	O
BChE	B-GENE-Y
delivered	O
by	O
the	O
pulmonary	O
route	O
,	O
to	O
examine	O
whether	O
the	O
deposition	O
of	O
both	O
macaque	O
(	O
Ma	O
)	O
and	O
human	O
(	O
Hu	O
)	O
rBChE	B-GENE-Y
administered	O
as	O
aerosols	O
(	O
aer	O
)	O
favored	O
the	O
creation	O
and	O
retention	O
of	O
an	O
efficient	O
protective	O
"	O
pulmonary	O
bioshield	O
"	O
that	O
could	O
scavenge	O
incoming	O
(	O
inhaled	O
)	O
OPs	O
in	O
situ	O
thereby	O
preventing	O
entry	O
into	O
the	O
circulation	O
and	O
inhibition	O
of	O
plasma	O
BChE	B-GENE-Y
and	O
AChE	B-GENE-Y
on	O
red	O
blood	O
cells	O
(	O
RBC	O
-	O
AChE	B-GENE-Y
)	O
and	O
in	O
cholinergic	O
synapses	O
.	O

In	O
contrast	O
to	O
parenteral	O
delivery	O
of	O
rBChE	B-GENE-Y
,	O
which	O
currently	O
requires	O
posttranslational	O
modification	O
for	O
good	O
plasma	O
stability	O
,	O
an	O
unmodified	O
aer	O
-	O
rBChE	B-GENE-Y
pretreatment	O
given	O
1	O
-	O
40h	O
prior	O
to	O
>	O
1	O
LD50	O
of	O
aer	O
-	O
paraoxon	B-CHEMICAL
(	O
Px	O
)	O
was	O
able	O
to	O
prevent	O
inhibition	O
of	O
circulating	O
cholinesterase	B-GENE-Y
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
show	O
protection	O
by	O
rBChE	B-GENE-Y
against	O
a	O
pesticide	O
such	O
as	O
paraoxon	B-CHEMICAL
when	O
delivered	O
directly	O
into	O
the	O
lung	O
and	O
bode	O
well	O
for	O
the	O
use	O
of	O
a	O
non	O
-	O
invasive	O
and	O
consumer	O
friendly	O
method	O
of	O
rHuBChE	B-GENE-Y
delivery	O
as	O
a	O
human	O
treatment	O
to	O
counteract	O
OP	O
toxicity	O
.	O

Serotonin	B-CHEMICAL
-	O
glutamate	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
-	O
dopamine	B-CHEMICAL
reciprocal	O
interactions	O
as	O
putative	O
molecular	O
targets	O
for	O
novel	O
antipsychotic	O
treatments	O
:	O
from	O
receptor	O
heterodimers	O
to	O
postsynaptic	O
scaffolding	O
and	O
effector	O
proteins	O
.	O

The	O
physical	O
and	O
functional	O
interactions	O
between	O
serotonin	B-CHEMICAL
-	O
glutamate	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
-	O
dopamine	B-CHEMICAL
signaling	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
psychosis	O
pathophysiology	O
and	O
are	O
supposed	O
to	O
be	O
relevant	O
for	O
antipsychotic	O
treatment	O
.	O

Type	B-GENE-Y
II	I-GENE-Y
metabotropic	I-GENE-Y
glutamate	I-GENE-Y
receptors	I-GENE-Y
(	O
mGluRs	B-GENE-N
)	O
and	O
serotonin	B-CHEMICAL
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
receptors	O
have	O
been	O
reported	O
to	O
form	O
heterodimers	O
that	O
modulate	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	O
mediated	O
intracellular	O
signaling	O
differentially	O
compared	O
to	O
mGluR2	B-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
2A	I-GENE-Y
)	I-GENE-Y
homomers	O
.	O

Additionally	O
,	O
direct	O
evidence	O
has	O
been	O
provided	O
that	O
D	B-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
and	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2A	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
form	O
physical	O
heterocomplexes	O
which	O
exert	O
a	O
functional	O
cross	O
-	O
talk	O
,	O
as	O
demonstrated	O
by	O
studies	O
on	O
hallucinogen	O
-	O
induced	O
signaling	O
.	O

Moving	O
from	O
receptors	O
to	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
scenario	O
,	O
the	O
scaffolding	O
protein	O
PSD	O
-	O
95	O
is	O
known	O
to	O
interact	O
with	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
,	I-GENE-N
D	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
and	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
(	I-GENE-N
2	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
,	O
regulating	O
their	O
activation	O
state	O
.	O

Homer1a	O
,	O
the	O
inducible	O
member	O
of	O
the	O
Homer	B-GENE-N
family	O
of	O
PSD	O
proteins	O
that	O
is	O
implicated	O
in	O
glutamatergic	O
signal	O
transduction	O
,	O
is	O
induced	O
in	O
striatum	O
by	O
antipsychotics	O
with	O
high	O
dopamine	B-CHEMICAL
receptor	O
affinity	O
and	O
in	O
the	O
cortex	O
by	O
antipsychotics	O
with	O
mixed	O
serotonergic	O
/	O
dopaminergic	O
profile	O
.	O

Signaling	O
molecules	O
,	O
such	O
as	O
Akt	B-GENE-N
and	O
glycogen	B-GENE-N
-	I-GENE-N
synthase	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
-	I-GENE-N
3	I-GENE-N
(	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
)	O
,	O
could	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
antipsychotics	O
,	O
targeting	O
dopamine	B-CHEMICAL
,	O
serotonin	B-CHEMICAL
,	O
and	O
glutamate	B-CHEMICAL
neurotransmission	O
.	O

Altogether	O
,	O
these	O
proteins	O
stand	O
at	O
the	O
crossroad	O
of	O
glutamate	B-CHEMICAL
-	O
dopamine	B-CHEMICAL
-	O
serotonin	B-CHEMICAL
signaling	O
pathways	O
and	O
may	O
be	O
considered	O
as	O
valuable	O
molecular	O
targets	O
for	O
current	O
and	O
new	O
antipsychotics	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
provide	O
a	O
critical	O
appraisal	O
on	O
serotonin	B-CHEMICAL
-	O
glutamate	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
-	O
dopamine	B-CHEMICAL
interplay	O
to	O
support	O
the	O
idea	O
that	O
next	O
generation	O
schizophrenia	O
pharmacotherapy	O
should	O
not	O
exclusively	O
rely	O
on	O
receptor	O
targeting	O
strategies	O
.	O

Effects	O
of	O
ozone	B-CHEMICAL
and	O
fine	O
particulate	O
matter	O
(	O
PM	O
(	O
2	O
.	O
5	O
)	O
)	O
on	O
rat	O
system	O
inflammation	O
and	O
cardiac	O
function	O
.	O

In	O
order	O
to	O
understand	O
the	O
toxic	O
mechanisms	O
of	O
cardiovascular	O
system	O
injuries	O
induced	O
by	O
ambient	O
PM	O
(	O
2	O
.	O
5	O
)	O
and	O
/	O
or	O
ozone	B-CHEMICAL
,	O
a	O
subacute	O
toxicological	O
animal	O
experiment	O
was	O
designed	O
with	O
exposure	O
twice	O
a	O
week	O
for	O
3	O
continuous	O
weeks	O
.	O

Wistar	O
rats	O
were	O
randomly	O
categorized	O
into	O
8	O
groups	O
(	O
n	O
=	O
6	O
)	O
:	O
1	O
control	O
group	O
,	O
3	O
groups	O
exposed	O
to	O
fine	O
particulate	O
matters	O
(	O
PM	O
(	O
2	O
.	O
5	O
)	O
)	O
alone	O
at	O
3	O
doses	O
(	O
0	O
.	O
2	O
,	O
0	O
.	O
8	O
,	O
or	O
3	O
.	O
2	O
mg	O
/	O
rat	O
)	O
,	O
1	O
group	O
to	O
ozone	B-CHEMICAL
(	O
0	O
.	O
81	O
ppm	O
)	O
alone	O
and	O
3	O
groups	O
to	O
ozone	B-CHEMICAL
plus	O
PM	O
(	O
2	O
.	O
5	O
)	O
at	O
3	O
doses	O
(	O
0	O
.	O
2	O
,	O
0	O
.	O
8	O
,	O
or	O
3	O
.	O
2	O
mg	O
/	O
rat	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
at	O
approximately	O
24	O
-	O
h	O
both	O
after	O
the	O
3rd	O
exposure	O
and	O
the	O
last	O
(	O
6th	O
)	O
exposure	O
,	O
and	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
monitored	O
at	O
approximately	O
24	O
-	O
h	O
after	O
the	O
6th	O
exposure	O
.	O

Biomarkers	O
of	O
systemic	O
inflammation	O
and	O
injuries	O
(	O
CRP	B-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
LDH	B-GENE-N
,	O
CK	B-GENE-N
)	O
,	O
heart	O
oxidative	O
stress	O
(	O
MDA	B-CHEMICAL
,	O
SOD	B-GENE-N
)	O
and	O
endothelial	O
function	O
(	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
VEGF	B-GENE-Y
)	O
were	O
analyzed	O
after	O
the	O
6th	O
exposure	O
.	O

Additionally	O
,	O
myocardial	O
ultrastructural	O
alterations	O
were	O
observed	O
under	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
for	O
histopathological	O
analyses	O
.	O

Results	O
showed	O
that	O
PM	O
(	O
2	O
.	O
5	O
)	O
alone	O
exposure	O
could	O
trigger	O
the	O
significant	O
increase	O
of	O
CRP	B-GENE-Y
,	O
MDA	B-CHEMICAL
,	O
CK	B-GENE-N
,	O
ET	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
SBP	O
and	O
decrease	O
of	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
,	O
a	O
marker	O
of	O
cardiac	O
autonomic	O
nervous	O
system	O
(	O
ANS	O
)	O
function	O
.	O

Ozone	B-CHEMICAL
alone	O
exposure	O
in	O
rats	O
did	O
not	O
show	O
significant	O
alterations	O
in	O
any	O
indicators	O
.	O

Ozone	B-CHEMICAL
plus	O
PM	O
(	O
2	O
.	O
5	O
)	O
exposure	O
,	O
however	O
,	O
induced	O
CRP	B-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
CK	B-GENE-N
,	O
LDH	B-GENE-N
and	O
MDA	B-CHEMICAL
increase	O
,	O
SOD	B-GENE-N
and	O
HRV	O
decrease	O
significantly	O
in	O
a	O
dose	O
-	O
response	O
way	O
.	O

Meanwhile	O
,	O
abnormal	O
ECG	O
types	O
were	O
monitored	O
in	O
rats	O
exposed	O
to	O
PM	O
(	O
2	O
.	O
5	O
)	O
with	O
and	O
without	O
ozone	B-CHEMICAL
and	O
obvious	O
myocardial	O
ultrastructural	O
changes	O
were	O
observed	O
by	O
TEM	O
.	O

In	O
conclusion	O
,	O
PM	O
(	O
2	O
.	O
5	O
)	O
alone	O
exposure	O
could	O
cause	O
inflammation	O
,	O
endothelial	O
function	O
and	O
ANS	O
injuries	O
,	O
and	O
ozone	B-CHEMICAL
potentiated	O
these	O
effects	O
induced	O
by	O
PM	O
(	O
2	O
.	O
5	O
)	O
.	O

P21	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
(	O
Pak1	B-GENE-Y
)	O
mediates	O
the	O
cross	O
talk	O
between	O
insulin	B-GENE-N
and	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
on	O
proglucagon	B-GENE-N
gene	O
expression	O
and	O
its	O
ablation	O
affects	O
glucose	B-CHEMICAL
homeostasis	O
in	O
male	O
C57BL	O
/	O
6	O
mice	O
.	O

In	O
gut	O
endocrine	O
L	O
cells	O
,	O
the	O
Wnt	B-GENE-N
signaling	O
pathway	O
effector	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
(	O
β	B-GENE-Y
-	I-GENE-Y
cat	I-GENE-Y
)	O
/	O
transcription	B-GENE-Y
factor	I-GENE-Y
7	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
2	I-GENE-Y
mediates	O
the	O
stimulatory	O
effect	O
of	O
insulin	B-GENE-Y
on	O
proglucagon	B-GENE-N
(	O
gcg	B-GENE-Y
)	O
expression	O
and	O
glucagon	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
production	O
.	O

In	O
several	O
other	O
cell	O
lineages	O
,	O
insulin	B-GENE-N
is	O
able	O
to	O
stimulate	O
p21	B-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
(	O
Pak1	B-GENE-Y
)	O
.	O

Here	O
we	O
determined	O
the	O
role	O
of	O
Pak1	B-GENE-Y
in	O
gcg	B-GENE-Y
expression	O
and	O
the	O
effect	O
of	O
Pak1	B-GENE-Y
deletion	O
on	O
glucose	B-CHEMICAL
homeostasis	O
.	O

Insulin	B-GENE-N
stimulated	O
Pak1	B-GENE-Y
activation	O
through	O
increasing	O
its	O
Thr423	B-CHEMICAL
phosphorylation	O
in	O
gut	O
gcg	B-GENE-Y
-	O
expressing	O
cell	O
lines	O
,	O
associated	O
with	O
increased	O
gcg	B-GENE-Y
mRNA	O
levels	O
.	O

This	O
stimulation	O
was	O
attenuated	O
by	O
the	O
Pak	B-GENE-N
inhibitor	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
dihydroxy	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
dinaphthyldisulfide	I-CHEMICAL
(	O
IPA3	B-CHEMICAL
)	O
or	O
dominant	O
-	O
negative	O
Pak1	B-GENE-Y
.	O

Both	O
insulin	B-GENE-N
and	O
cAMP	B-CHEMICAL
-	O
promoting	O
agents	O
activated	O
β	O
-	O
cat	O
Ser675	B-CHEMICAL
phosphorylation	O
,	O
which	O
was	O
attenuated	O
by	O
IPA3	O
or	O
protein	B-GENE-N
kinase	I-GENE-N
A	I-GENE-N
inhibition	O
,	O
respectively	O
.	O

Gut	O
gcg	B-GENE-Y
levels	O
were	O
reduced	O
in	O
male	O
Pak1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
associated	O
with	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
after	O
an	O
ip	O
or	O
oral	O
glucose	B-CHEMICAL
challenge	O
.	O

These	O
mice	O
had	O
lower	O
circulating	O
active	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
levels	O
after	O
a	O
glucose	B-CHEMICAL
challenge	O
as	O
well	O
as	O
reduced	O
distal	O
ileum	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
content	O
after	O
insulin	O
treatment	O
.	O

Finally	O
,	O
the	O
Pak1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
exhibited	O
reduced	O
brainstem	O
gcg	O
level	O
and	O
abolished	O
β	B-GENE-Y
-	I-GENE-Y
cat	I-GENE-Y
Ser675	B-CHEMICAL
phosphorylation	O
in	O
brain	O
neurons	O
after	O
insulin	B-GENE-N
treatment	O
.	O

We	O
suggest	O
that	O
Pak1	B-GENE-Y
mediates	O
the	O
cross	O
talk	O
between	O
insulin	B-GENE-N
and	O
Wnt	B-GENE-N
signaling	O
pathways	O
on	O
gut	O
and	O
brain	O
gcg	B-GENE-Y
expression	O
,	O
and	O
its	O
ablation	O
impairs	O
glucose	B-CHEMICAL
homeostasis	O
.	O

Insulin	B-GENE-Y
-	I-GENE-Y
degrading	I-GENE-Y
enzyme	I-GENE-Y
(	O
IDE	B-GENE-Y
)	O
:	O
a	O
novel	O
heat	B-GENE-N
shock	I-GENE-N
-	I-GENE-N
like	I-GENE-N
protein	I-GENE-N
.	O

Insulin	B-GENE-Y
-	I-GENE-Y
degrading	I-GENE-Y
enzyme	I-GENE-Y
(	O
IDE	B-GENE-Y
)	O
is	O
a	O
highly	O
conserved	O
zinc	B-GENE-N
metallopeptidase	I-GENE-N
that	O
is	O
ubiquitously	O
distributed	O
in	O
human	O
tissues	O
,	O
and	O
particularly	O
abundant	O
in	O
the	O
brain	O
,	O
liver	O
,	O
and	O
muscles	O
.	O

IDE	B-GENE-Y
activity	O
has	O
been	O
historically	O
associated	O
with	O
insulin	B-GENE-Y
and	O
β	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
catabolism	O
.	O

However	O
,	O
over	O
the	O
last	O
decade	O
,	O
several	O
experimental	O
findings	O
have	O
established	O
that	O
IDE	B-GENE-Y
is	O
also	O
involved	O
in	O
a	O
wide	O
variety	O
of	O
physiopathological	O
processes	O
,	O
including	O
ubiquitin	B-GENE-N
clearance	O
and	O
Varicella	O
Zoster	O
Virus	O
infection	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
normal	O
and	O
malignant	O
cells	O
exposed	O
to	O
different	O
stresses	O
markedly	O
up	O
-	O
regulate	O
IDE	B-GENE-Y
in	O
a	O
heat	B-GENE-N
shock	I-GENE-N
protein	I-GENE-N
(	O
HSP	B-GENE-N
)	O
-	O
like	O
fashion	O
.	O

Additionally	O
,	O
we	O
focused	O
our	O
attention	O
on	O
tumor	O
cells	O
and	O
report	O
that	O
(	O
i	O
)	O
IDE	B-GENE-Y
is	O
overexpressed	O
in	O
vivo	O
in	O
tumors	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
;	O
(	O
ii	O
)	O
IDE	B-GENE-Y
-	O
silencing	O
inhibits	O
neuroblastoma	O
(	O
SHSY5Y	O
)	O
cell	O
proliferation	O
and	O
triggers	O
cell	O
death	O
;	O
(	O
iii	O
)	O
IDE	B-GENE-Y
inhibition	O
is	O
accompanied	O
by	O
a	O
decrease	O
of	O
the	O
poly	O
-	O
ubiquitinated	O
protein	O
content	O
and	O
co	O
-	O
immunoprecipitates	O
with	O
proteasome	O
and	O
ubiquitin	O
in	O
SHSY5Y	O
cells	O
.	O

In	O
this	O
work	O
,	O
we	O
propose	O
a	O
novel	O
role	O
for	O
IDE	B-GENE-Y
as	O
a	O
heat	B-GENE-N
shock	I-GENE-N
protein	I-GENE-N
with	O
implications	O
in	O
cell	O
growth	O
regulation	O
and	O
cancer	O
progression	O
,	O
thus	O
opening	O
up	O
an	O
intriguing	O
hypothesis	O
of	O
IDE	B-GENE-Y
as	O
an	O
anticancer	O
target	O
.	O

Silencing	O
α1	B-GENE-N
,	I-GENE-N
3	I-GENE-N
-	I-GENE-N
fucosyltransferases	I-GENE-N
in	O
human	O
leukocytes	O
reveals	O
a	O
role	O
for	O
FUT9	B-GENE-Y
enzyme	O
during	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
-	O
mediated	O
cell	O
adhesion	O
.	O

Leukocyte	O
adhesion	O
during	O
inflammation	O
is	O
initiated	O
by	O
the	O
binding	O
of	O
sialofucosylated	O
carbohydrates	B-CHEMICAL
expressed	O
on	O
leukocytes	O
to	O
endothelial	O
E	B-GENE-N
/	I-GENE-N
P	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
.	O

Although	O
the	O
glycosyltransferases	B-GENE-N
(	O
glycoTs	B-GENE-N
)	O
constructing	O
selectin	B-GENE-N
-	O
ligands	O
have	O
largely	O
been	O
identified	O
using	O
knock	O
-	O
out	O
mice	O
,	O
important	O
differences	O
may	O
exist	O
between	O
humans	O
and	O
mice	O
.	O

To	O
address	O
this	O
,	O
we	O
developed	O
a	O
systematic	O
lentivirus	O
-	O
based	O
shRNA	O
delivery	O
workflow	O
to	O
create	O
human	O
leukocytic	O
HL	O
-	O
60	O
cell	O
lines	O
that	O
lack	O
up	O
to	O
three	O
glycoTs	B-GENE-N
.	O

Using	O
this	O
,	O
the	O
contributions	O
of	O
all	O
three	O
myeloid	O
α1	B-GENE-N
,	I-GENE-N
3	I-GENE-N
-	I-GENE-N
fucosyltransferases	I-GENE-N
(	O
FUT4	B-GENE-Y
,	O
FUT7	B-GENE-Y
,	O
and	O
FUT9	B-GENE-Y
)	O
to	O
selectin	B-GENE-N
-	O
ligand	O
biosynthesis	O
were	O
evaluated	O
.	O

The	O
cell	O
adhesion	O
properties	O
of	O
these	O
modified	O
cells	O
to	O
L	B-GENE-N
-	I-GENE-N
,	I-GENE-N
E	I-GENE-N
-	I-GENE-N
,	I-GENE-N
and	I-GENE-N
P	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
under	O
hydrodynamic	O
shear	O
were	O
compared	O
with	O
bone	O
marrow	O
-	O
derived	O
neutrophils	O
from	O
Fut4	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
Fut7	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
dual	O
knock	O
-	O
out	O
mice	O
.	O

Results	O
demonstrate	O
that	O
predominantly	O
FUT7	B-GENE-Y
,	O
and	O
to	O
a	O
lesser	O
extent	O
FUT4	B-GENE-Y
,	O
forms	O
the	O
selectin	B-GENE-N
-	O
ligand	O
at	O
the	O
N	B-CHEMICAL
terminus	O
of	O
leukocyte	O
P	B-GENE-N
-	I-GENE-N
selectin	I-GENE-N
glycoprotein	I-GENE-N
ligand	I-GENE-N
-	I-GENE-N
1	I-GENE-N
(	O
PSGL	B-GENE-N
-	I-GENE-N
1	I-GENE-N
)	O
in	O
humans	O
and	O
mice	O
.	O

Here	O
,	O
85	O
%	O
reduction	O
in	O
leukocyte	O
interaction	O
was	O
observed	O
in	O
human	B-GENE-N
FUT4	I-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
7	I-GENE-N
(	O
-	O
)	O
dual	O
knockdowns	O
on	O
P	B-GENE-N
/	I-GENE-N
L	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
substrates	O
.	O

Unlike	O
Fut4	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
Fut7	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mouse	O
neutrophils	O
,	O
however	O
,	O
human	O
knockdowns	O
lacking	O
FUT4	B-GENE-Y
and	O
FUT7	B-GENE-Y
only	O
exhibited	O
partial	O
reduction	O
in	O
rolling	O
interaction	O
on	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
.	O

In	O
this	O
case	O
,	O
the	O
third	O
α1	B-GENE-N
,	I-GENE-N
3	I-GENE-N
-	I-GENE-N
fucosyltransferase	I-GENE-N
FUT9	B-GENE-Y
played	O
an	O
important	O
role	O
because	O
leukocyte	O
adhesion	O
was	O
reduced	O
by	O
50	O
-	O
60	O
%	O
in	O
FUT9	B-GENE-Y
-	O
HL	O
-	O
60	O
,	O
70	O
-	O
80	O
%	O
in	O
dual	O
knockdown	O
FUT7	B-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
9	I-GENE-N
(	O
-	O
)	O
cells	O
,	O
and	O
∼	O
85	O
%	O
in	O
FUT4	B-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
7	I-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
9	I-GENE-N
(	O
-	O
)	O
triple	O
knockdowns	O
.	O

Gene	O
silencing	O
results	O
are	O
in	O
agreement	O
with	O
gain	O
-	O
of	O
-	O
function	O
experiments	O
where	O
all	O
three	O
fucosyltransferases	B-GENE-N
conferred	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
-	O
mediated	O
rolling	O
in	O
HEK293T	O
cells	O
.	O

This	O
study	O
advances	O
new	O
tools	O
to	O
study	O
human	B-GENE-N
glycoT	I-GENE-N
function	O
.	O

It	O
suggests	O
a	O
species	O
-	O
specific	O
role	O
for	O
FUT9	B-GENE-Y
during	O
the	O
biosynthesis	O
of	O
human	B-GENE-Y
E	I-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
ligands	O
.	O

Hyperglycemia	O
slows	O
embryonic	O
growth	O
and	O
suppresses	O
cell	O
cycle	O
via	O
cyclin	B-GENE-Y
D1	I-GENE-Y
and	O
p21	B-GENE-Y
.	O

In	O
pregnant	O
women	O
,	O
the	O
diabetic	O
condition	O
results	O
in	O
a	O
three	O
-	O
to	O
fivefold	O
increased	O
risk	O
for	O
fetal	O
cardiac	O
malformations	O
as	O
a	O
result	O
of	O
elevated	O
glucose	B-CHEMICAL
concentrations	O
and	O
the	O
resultant	O
osmotic	O
stress	O
in	O
the	O
developing	O
embryo	O
and	O
fetus	O
.	O

Heart	O
development	O
before	O
septation	O
in	O
the	O
chick	O
embryo	O
was	O
studied	O
under	O
two	O
hyperglycemic	O
conditions	O
.	O

Pulsed	O
hyperglycemia	O
induced	O
by	O
daily	O
administration	O
of	O
glucose	B-CHEMICAL
during	O
3	O
days	O
of	O
development	O
caused	O
daily	O
spikes	O
in	O
plasma	O
glucose	B-CHEMICAL
concentration	O
.	O

In	O
a	O
second	O
model	O
,	O
sustained	O
hyperglycemia	O
was	O
induced	O
with	O
a	O
single	O
injection	O
of	O
glucose	B-CHEMICAL
into	O
the	O
yolk	O
on	O
day	O
0	O
.	O

The	O
sustained	O
model	O
raised	O
the	O
average	O
plasma	O
glucose	B-CHEMICAL
concentration	O
from	O
70	O
mg	O
/	O
dL	O
to	O
180	O
mg	O
/	O
dL	O
and	O
led	O
to	O
decreased	O
gene	O
expression	O
of	O
glucose	B-GENE-N
transporter	I-GENE-N
GLUT1	B-GENE-Y
.	O

Both	O
models	O
of	O
hyperglycemia	O
reduced	O
embryo	O
size	O
,	O
increased	O
mortality	O
,	O
and	O
delayed	O
development	O
.	O

Within	O
the	O
heart	O
outflow	O
tract	O
,	O
reduced	O
proliferation	O
of	O
myocardial	O
and	O
endocardial	O
cells	O
resulted	O
from	O
the	O
sustained	O
hyperglycemia	O
and	O
hyperosmolarity	O
.	O

The	O
cell	O
cycle	O
inhibitor	O
p21	B-GENE-Y
was	O
significantly	O
increased	O
,	O
whereas	O
cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
a	O
cell	O
cycle	O
promoter	O
,	O
decreased	O
in	O
sustained	O
hyperglycemia	O
compared	O
with	O
controls	O
.	O

The	O
evidence	O
suggests	O
that	O
hyperglycemia	O
-	O
induced	O
developmental	O
delays	O
are	O
associated	O
with	O
slowed	O
cell	O
cycle	O
progression	O
,	O
leading	O
to	O
reduced	O
cellular	O
proliferation	O
.	O

The	O
suppression	O
of	O
critical	O
developmental	O
steps	O
may	O
underlie	O
the	O
cardiac	O
defects	O
observed	O
during	O
late	O
gestation	O
under	O
hyperglycemic	O
conditions	O
.	O

The	O
in	O
vivo	O
antioxidant	O
and	O
antifibrotic	O
properties	O
of	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
,	O
Theaceae	O
)	O
.	O

The	O
in	O
vivo	O
antioxidant	O
and	O
antifibrotic	O
properties	O
of	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
,	O
Theaceae	O
)	O
were	O
investigated	O
with	O
a	O
study	O
of	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
(	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
)	O
-	O
induced	O
oxidative	O
stress	O
and	O
hepatic	O
fibrosis	O
in	O
male	O
ICR	O
mice	O
.	O

Oral	O
administration	O
of	O
green	O
tea	O
extract	O
at	O
doses	O
of	O
125	O
,	O
625	O
and	O
1250	O
mg	O
/	O
kg	O
for	O
8	O
weeks	O
significantly	O
reduced	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
the	O
levels	O
of	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
protein	O
carbonyls	B-CHEMICAL
in	O
the	O
liver	O
by	O
at	O
least	O
28	O
%	O
compared	O
with	O
that	O
was	O
induced	O
by	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
(	O
1	O
mL	O
/	O
kg	O
)	O
in	O
mice	O
.	O

Moreover	O
,	O
green	O
tea	O
extract	O
administration	O
significantly	O
increased	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
the	O
activities	O
of	O
catalase	B-GENE-Y
,	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GSH	B-GENE-N
-	I-GENE-N
Px	I-GENE-N
)	O
and	O
glutathione	B-GENE-Y
reductase	I-GENE-Y
(	O
GSH	B-GENE-Y
-	I-GENE-Y
Rd	I-GENE-Y
)	O
in	O
the	O
liver	O
.	O

Our	O
study	O
found	O
that	O
oral	O
administration	O
of	O
green	O
tea	O
extract	O
prevented	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
hepatic	O
fibrosis	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
hydroxyproline	B-CHEMICAL
level	O
in	O
the	O
liver	O
and	O
a	O
reduced	O
incidence	O
of	O
hepatic	O
fibrosis	O
by	O
histological	O
observations	O
.	O

These	O
results	O
indicate	O
that	O
green	O
tea	O
exhibits	O
potent	O
protective	O
effects	O
against	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
oxidative	O
stress	O
and	O
hepatic	O
fibrosis	O
in	O
mice	O
by	O
inhibiting	O
oxidative	O
damage	O
and	O
increasing	O
antioxidant	O
enzyme	O
activities	O
.	O

Neurotoxicity	O
of	O
"	O
ecstasy	B-CHEMICAL
"	O
and	O
its	O
metabolites	O
in	O
human	O
dopaminergic	O
differentiated	O
SH	O
-	O
SY5Y	O
cells	O
.	O

"	O
Ecstasy	B-CHEMICAL
"	O
(	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
or	O
MDMA	B-CHEMICAL
)	O
is	O
a	O
widely	O
abused	O
recreational	O
drug	O
,	O
reported	O
to	O
produce	O
neurotoxic	O
effects	O
,	O
both	O
in	O
laboratory	O
animals	O
and	O
in	O
humans	O
.	O

MDMA	B-CHEMICAL
metabolites	O
can	O
be	O
major	O
contributors	O
for	O
MDMA	B-CHEMICAL
neurotoxicity	O
.	O

This	O
work	O
studied	O
the	O
neurotoxicity	O
of	O
MDMA	B-CHEMICAL
and	O
its	O
catechol	B-CHEMICAL
metabolites	O
,	O
α	B-CHEMICAL
-	I-CHEMICAL
methyldopamine	I-CHEMICAL
(	O
α	B-CHEMICAL
-	I-CHEMICAL
MeDA	I-CHEMICAL
)	O
and	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
α	I-CHEMICAL
-	I-CHEMICAL
methyldopamine	I-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
α	I-CHEMICAL
-	I-CHEMICAL
MeDA	I-CHEMICAL
)	O
in	O
human	O
dopaminergic	O
SH	O
-	O
SY5Y	O
cells	O
differentiated	O
with	O
retinoic	B-CHEMICAL
acid	I-CHEMICAL
and	O
12	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
tetradecanoyl	I-CHEMICAL
-	I-CHEMICAL
phorbol	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
-	I-CHEMICAL
acetate	I-CHEMICAL
.	O

Differentiation	O
led	O
to	O
SH	O
-	O
SY5Y	O
neurons	O
with	O
higher	O
ability	O
to	O
accumulate	O
dopamine	B-CHEMICAL
and	O
higher	O
resistance	O
towards	O
dopamine	B-CHEMICAL
neurotoxicity	O
.	O

MDMA	B-CHEMICAL
catechol	B-CHEMICAL
metabolites	O
were	O
neurotoxic	O
to	O
SH	O
-	O
SY5Y	O
neurons	O
,	O
leading	O
to	O
caspase	B-GENE-Y
3	I-GENE-Y
-	O
independent	O
cell	O
death	O
in	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

MDMA	B-CHEMICAL
did	O
not	O
show	O
a	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
death	O
.	O

Pre	O
-	O
treatment	O
with	O
the	O
antioxidant	O
and	O
glutathione	B-CHEMICAL
precursor	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
acetylcysteine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
)	O
,	O
resulted	O
in	O
strong	O
protection	O
against	O
the	O
MDMA	B-CHEMICAL
metabolites	O
'	O
neurotoxicity	O
.	O

Neither	O
the	O
superoxide	B-CHEMICAL
radical	O
scavenger	O
,	O
tiron	O
,	O
nor	O
the	O
inhibitor	O
of	O
the	O
dopamine	B-GENE-Y
(	I-GENE-Y
DA	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
,	O
GBR	B-CHEMICAL
12909	I-CHEMICAL
,	O
prevented	O
the	O
metabolites	O
'	O
toxicity	O
.	O

Cells	O
exposed	O
to	O
α	B-CHEMICAL
-	I-CHEMICAL
MeDA	I-CHEMICAL
showed	O
an	O
increase	O
in	O
intracellular	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
levels	O
,	O
which	O
,	O
at	O
the	O
48	O
h	O
time	O
-	O
point	O
,	O
was	O
not	O
dependent	O
in	O
the	O
activity	O
increase	O
of	O
γ	B-GENE-Y
-	I-GENE-Y
glutamylcysteine	I-GENE-Y
synthetase	I-GENE-Y
(	O
γ	B-GENE-Y
-	I-GENE-Y
GCS	I-GENE-Y
)	O
,	O
revealing	O
a	O
possible	O
transient	O
effect	O
.	O

Importantly	O
,	O
pre	O
-	O
treatment	O
with	O
buthionine	B-CHEMICAL
sulfoximine	I-CHEMICAL
(	O
BSO	B-CHEMICAL
)	O
,	O
an	O
inhibitor	O
of	O
γ	B-GENE-Y
-	I-GENE-Y
GCS	I-GENE-Y
,	O
prevented	O
α	B-CHEMICAL
-	I-CHEMICAL
MeDA	I-CHEMICAL
induced	O
increase	O
in	O
GSH	B-CHEMICAL
levels	O
,	O
but	O
did	O
not	O
augment	O
this	O
metabolite	O
cytotoxicity	O
.	O

Even	O
so	O
,	O
BSO	B-CHEMICAL
pre	O
-	O
treatment	O
abolished	O
NAC	B-CHEMICAL
protective	O
effects	O
against	O
α	B-CHEMICAL
-	I-CHEMICAL
MeDA	I-CHEMICAL
neurotoxicity	O
,	O
which	O
were	O
,	O
at	O
least	O
partially	O
,	O
due	O
to	O
GSH	B-CHEMICAL
de	O
novo	O
synthesis	O
.	O

Inversely	O
,	O
pre	O
-	O
treatment	O
of	O
cells	O
with	O
BSO	B-CHEMICAL
augmented	O
N	B-CHEMICAL
-	I-CHEMICAL
Me	I-CHEMICAL
-	I-CHEMICAL
α	I-CHEMICAL
-	I-CHEMICAL
MeDA	I-CHEMICAL
-	O
induced	O
neurotoxicity	O
,	O
but	O
only	O
slightly	O
affected	O
NAC	B-CHEMICAL
neuroprotection	O
.	O

In	O
conclusion	O
,	O
MDMA	B-CHEMICAL
catechol	B-CHEMICAL
metabolites	O
promote	O
differential	O
toxic	O
effects	O
to	O
differentiated	O
dopaminergic	O
human	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Effect	O
of	O
blood	O
-	O
retinal	O
barrier	O
development	O
on	O
formation	O
of	O
selenite	B-CHEMICAL
nuclear	O
cataract	O
in	O
rat	O
.	O

Selenite	B-CHEMICAL
cataract	O
,	O
as	O
an	O
experimental	O
animal	O
model	O
of	O
nuclear	O
cataract	O
to	O
mimic	O
human	O
senile	O
cataract	O
,	O
is	O
produced	O
only	O
when	O
overdose	O
selenite	B-CHEMICAL
is	O
injected	O
to	O
neonatal	O
rats	O
before	O
eyelid	O
opening	O
.	O

To	O
clarify	O
the	O
cause	O
of	O
age	O
differences	O
on	O
selenite	B-CHEMICAL
cataract	O
formation	O
in	O
rats	O
,	O
mRNA	O
expression	O
of	O
GPx1	B-GENE-Y
,	O
MsrA	B-GENE-Y
and	O
MsrB1	B-GENE-Y
,	O
as	O
well	O
as	O
GPx	B-GENE-N
activity	O
in	O
Wistar	O
rat	O
lens	O
at	O
different	O
ages	O
were	O
assayed	O
,	O
level	O
of	O
lipid	O
peroxidation	O
,	O
extent	O
of	O
lens	O
damage	O
induced	O
by	O
sodium	B-CHEMICAL
selenite	I-CHEMICAL
and	O
barricade	O
function	O
of	O
blood	O
-	O
retinal	O
barrier	O
(	O
BRB	O
)	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
mRNA	O
expressions	O
and	O
activity	O
of	O
antioxidant	O
enzymes	O
in	O
neonatal	O
rat	O
lens	O
before	O
eyelid	O
opening	O
were	O
the	O
highest	O
and	O
then	O
decreased	O
with	O
age	O
,	O
and	O
revealed	O
by	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
using	O
lanthanum	B-CHEMICAL
hydroxide	I-CHEMICAL
as	O
tracer	O
that	O
higher	O
selenite	B-CHEMICAL
content	O
entering	O
eyes	O
injured	O
lens	O
and	O
resulted	O
in	O
cataract	O
formation	O
for	O
immature	O
BRB	O
before	O
eyelid	O
opening	O
,	O
moreover	O
,	O
a	O
little	O
selenite	B-CHEMICAL
content	O
entering	O
eyes	O
was	O
not	O
enough	O
to	O
induce	O
cataract	O
formation	O
after	O
eyelid	O
opening	O
because	O
of	O
mature	O
BRB	O
.	O

Polymethoxyflavones	B-CHEMICAL
as	O
agents	O
that	O
prevent	O
formation	O
of	O
cataract	O
:	O
nobiletin	B-CHEMICAL
congeners	O
show	O
potent	O
growth	O
inhibitory	O
effects	O
in	O
human	O
lens	O
epithelial	O
cells	O
.	O

Posterior	O
capsular	O
opacification	O
(	O
PCO	O
)	O
is	O
the	O
most	O
frequent	O
complication	O
and	O
the	O
primary	O
reason	O
for	O
visual	O
decrease	O
after	O
extracapsular	O
cataract	O
surgery	O
.	O

The	O
proliferation	O
and	O
migration	O
of	O
leftover	O
lens	O
epithelial	O
cells	O
(	O
LECs	O
)	O
after	O
surgery	O
may	O
contribute	O
to	O
the	O
development	O
of	O
PCO	O
.	O

To	O
prevent	O
PCO	O
,	O
a	O
rational	O
approach	O
would	O
be	O
to	O
inhibit	O
both	O
the	O
proliferation	O
and	O
the	O
migration	O
of	O
LECs	O
using	O
nontoxic	O
xenobiotics	O
.	O

Nobiletin	B-CHEMICAL
,	O
one	O
of	O
the	O
most	O
abundant	O
polymethoxyflavones	B-CHEMICAL
(	O
PMFs	B-CHEMICAL
)	O
in	O
citrus	O
peel	O
,	O
and	O
its	O
synthetic	O
congeners	O
displayed	O
a	O
potent	O
inhibition	O
of	O
LEC	O
proliferation	O
.	O

Structural	O
features	O
which	O
enhance	O
anti	O
-	O
proliferative	O
activity	O
have	O
also	O
been	O
discussed	O
.	O

Determination	O
of	O
paralytic	O
shellfish	O
poisoning	O
toxins	O
by	O
HILIC	O
-	O
MS	O
/	O
MS	O
coupled	O
with	O
dispersive	O
solid	O
phase	O
extraction	O
.	O

This	O
paper	O
describes	O
the	O
use	O
of	O
QuEChERS	O
(	O
Quick	O
,	O
Easy	O
,	O
Cheap	O
,	O
Effective	O
,	O
Rugged	O
and	O
Safe	O
)	O
for	O
the	O
extraction	O
,	O
cleanup	O
and	O
detection	O
of	O
10	O
paralytic	O
shellfish	O
toxins	O
(	O
PSP	O
)	O
in	O
sea	O
food	O
by	O
HILIC	O
-	O
MS	O
/	O
MS	O
with	O
positive	O
ESI	O
.	O

Matrix	O
matched	O
calibration	O
standards	O
were	O
used	O
to	O
compensate	O
for	O
matrix	O
effects	O
.	O

The	O
toxins	O
were	O
extracted	O
with	O
acetonitrile	B-CHEMICAL
/	O
water	O
(	O
90	O
:	O
10	O
,	O
v	O
/	O
v	O
)	O
containing	O
0	O
.	O
1	O
%	O
formic	B-CHEMICAL
acid	I-CHEMICAL
and	O
cleaned	O
by	O
HLB	O
and	O
GCB	B-CHEMICAL
sorbents	O
.	O

Qualitative	O
and	O
quantitative	O
detection	O
for	O
the	O
analytes	O
were	O
carried	O
out	O
under	O
the	O
multiple	O
reaction	O
monitoring	O
(	O
MRM	O
)	O
in	O
positive	O
ionization	O
mode	O
after	O
chromatography	O
separation	O
on	O
a	O
TSK	O
-	O
gel	O
Amide	B-CHEMICAL
-	O
80	O
®	O
column	O
(	O
150	O
mm	O
×	O
2	O
.	O
0	O
mm	O
×	O
3	O
μm	O
)	O
.	O

Studies	O
at	O
three	O
fortification	O
levels	O
for	O
the	O
toxins	O
in	O
the	O
range	O
of	O
8	O
.	O
1	O
-	O
225	O
.	O
5	O
μg	O
/	O
kg	O
gave	O
mean	O
recoveries	O
from	O
71	O
.	O
3	O
%	O
to	O
104	O
.	O
6	O
%	O
with	O
relative	O
standard	O
deviation	O
(	O
RSD	O
)	O
≤	O
15	O
.	O
8	O
%	O
.	O

The	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
was	O
below	O
the	O
recommended	O
regulatory	O
limit	O
of	O
170	O
μgSTX	B-CHEMICAL
(	O
equ	O
.	O
)	O
/	O
kg	O
and	O
the	O
proposed	O
method	O
fully	O
meets	O
the	O
needs	O
of	O
daily	O
monitoring	O
.	O

Phosphodiesterase	B-GENE-N
inhibitors	O
.	O

Part	O
5	O
:	O
hybrid	O
PDE3	B-GENE-N
/	I-GENE-N
4	I-GENE-N
inhibitors	O
as	O
dual	O
bronchorelaxant	O
/	O
anti	O
-	O
inflammatory	O
agents	O
for	O
inhaled	O
administration	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
Methoxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
trifluoromethyl	I-CHEMICAL
)	I-CHEMICAL
pyrazolo	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dihydropyridazin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
(	I-CHEMICAL
2H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
(	O
KCA	B-CHEMICAL
-	I-CHEMICAL
1490	I-CHEMICAL
)	O
exhibits	O
moderate	O
dual	O
PDE3	B-GENE-N
/	I-GENE-N
4	I-GENE-N
-	O
inhibitory	O
activity	O
and	O
promises	O
as	O
a	O
combined	O
bronchodilatory	O
/	O
anti	O
-	O
inflammatory	O
agent	O
.	O

N	B-CHEMICAL
-	O
alkylation	O
of	O
the	O
pyridazinone	B-CHEMICAL
ring	O
markedly	O
enhances	O
potency	O
against	O
PDE4	B-GENE-N
but	O
suppresses	O
PDE3	B-GENE-N
inhibition	O
.	O

Addition	O
of	O
a	O
6	B-CHEMICAL
-	I-CHEMICAL
aryl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dihydropyridazin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
(	I-CHEMICAL
2H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
extension	O
to	O
the	O
N	B-CHEMICAL
-	O
alkyl	O
group	O
facilitates	O
both	O
enhancement	O
of	O
PDE4	B-GENE-N
-	O
inhibitory	O
activity	O
and	O
restoration	O
of	O
potent	O
PDE3	B-GENE-N
inhibition	O
.	O

Both	O
dihydropyridazinone	B-CHEMICAL
rings	O
,	O
in	O
the	O
core	O
and	O
extension	O
,	O
can	O
be	O
replaced	O
by	O
achiral	O
4	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dimethylpyrazolone	I-CHEMICAL
subunits	O
and	O
the	O
core	O
pyrazolopyridine	B-CHEMICAL
by	O
isosteric	O
bicyclic	O
heteroaromatics	O
.	O

In	O
combination	O
,	O
these	O
modifications	O
afford	O
potent	O
dual	O
PDE3	B-GENE-N
/	I-GENE-N
4	I-GENE-N
inhibitors	O
that	O
suppress	O
histamine	B-CHEMICAL
-	O
induced	O
bronchoconstriction	O
in	O
vivo	O
and	O
exhibit	O
promising	O
anti	O
-	O
inflammatory	O
activity	O
via	O
intratracheal	O
administration	O
.	O

Substrates	O
of	O
IAP	B-GENE-N
ubiquitin	B-GENE-N
ligases	I-GENE-N
identified	O
with	O
a	O
designed	O
orthogonal	O
E3	B-GENE-N
ligase	I-GENE-N
,	O
the	O
NEDDylator	O
.	O

Inhibitors	B-GENE-N
of	I-GENE-N
Apoptosis	I-GENE-N
Protein	I-GENE-N
(	O
IAPs	B-GENE-N
)	O
are	O
guardian	O
ubiquitin	B-GENE-N
ligases	I-GENE-N
that	O
keep	O
classic	O
proapoptotic	O
proteins	O
in	O
check	O
.	O

Systematic	O
identification	O
of	O
additional	O
IAP	O
substrates	O
is	O
challenged	O
by	O
the	O
heterogeneity	O
and	O
sheer	O
number	O
of	O
ubiquitinated	O
proteins	O
(	O
>	O
5	O
,	O
000	O
)	O
.	O

Here	O
we	O
report	O
a	O
powerful	O
catalytic	O
tagging	O
tool	O
,	O
the	O
NEDDylator	O
,	O
which	O
fuses	O
a	O
NEDD8	B-GENE-Y
E2	B-GENE-N
-	I-GENE-N
conjugating	I-GENE-N
enzyme	I-GENE-N
,	O
Ubc12	B-GENE-Y
,	O
to	O
the	O
ubiquitin	B-GENE-N
ligase	I-GENE-N
,	O
XIAP	B-GENE-Y
or	O
cIAP1	B-GENE-Y
.	O

This	O
permits	O
transfer	O
of	O
the	O
rare	O
ubiquitin	B-GENE-N
homolog	O
NEDD8	B-GENE-Y
to	O
the	O
ubiquitin	B-GENE-N
E3	I-GENE-N
substrates	O
,	O
allowing	O
them	O
to	O
be	O
efficiently	O
purified	O
for	O
LC	O
-	O
MS	O
/	O
MS	O
identification	O
.	O

We	O
have	O
identified	O
>	O
50	O
potential	O
IAP	B-GENE-N
substrates	O
of	O
both	O
cytosolic	O
and	O
mitochondrial	O
origin	O
that	O
bear	O
hallmark	O
N	B-CHEMICAL
-	O
terminal	O
IAP	B-GENE-N
binding	O
motifs	O
.	O

These	O
substrates	O
include	O
the	O
recently	O
discovered	O
protein	B-GENE-N
phosphatase	I-GENE-N
PGAM5	B-GENE-Y
,	O
which	O
we	O
show	O
is	O
proteolytically	O
processed	O
,	O
accumulates	O
in	O
cytosol	O
during	O
apoptosis	O
,	O
and	O
sensitizes	O
cells	O
to	O
death	O
.	O

These	O
studies	O
reveal	O
mechanisms	O
and	O
antagonistic	O
partners	O
for	O
specific	O
IAPs	B-GENE-N
,	O
and	O
provide	O
a	O
powerful	O
technology	O
for	O
labeling	O
binding	O
partners	O
in	O
transient	O
protein	O
-	O
protein	O
complexes	O
.	O

Reduced	O
plasma	O
oxytocin	B-CHEMICAL
levels	O
in	O
female	O
patients	O
with	O
borderline	O
personality	O
disorder	O
.	O

The	O
neuropeptide	O
oxytocin	B-CHEMICAL
is	O
involved	O
in	O
social	O
cognition	O
and	O
interaction	O
across	O
species	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
affiliative	O
behaviors	O
.	O

Oxytocin	B-CHEMICAL
levels	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
,	O
but	O
also	O
in	O
plasma	O
or	O
urine	O
,	O
have	O
been	O
shown	O
to	O
be	O
negatively	O
associated	O
with	O
childhood	O
traumata	O
,	O
aggressive	O
behavior	O
,	O
and	O
suicide	O
attempts	O
.	O

Recently	O
,	O
an	O
altered	O
activity	O
of	O
the	O
oxytocin	B-CHEMICAL
system	O
has	O
been	O
discussed	O
to	O
play	O
a	O
prominent	O
role	O
in	O
borderline	O
personality	O
disorder	O
(	O
BPD	O
)	O
,	O
which	O
is	O
thought	O
to	O
be	O
closely	O
related	O
to	O
traumatic	O
experiences	O
in	O
childhood	O
and	O
is	O
characterized	O
by	O
(	O
para	O
)	O
suicidal	O
behaviors	O
as	O
well	O
as	O
aggressive	O
outbursts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
plasma	O
oxytocin	B-CHEMICAL
levels	O
of	O
women	O
with	O
and	O
without	O
BPD	O
in	O
the	O
follicular	O
phase	O
and	O
assessed	O
the	O
relationship	O
between	O
oxytocin	B-CHEMICAL
concentrations	O
and	O
childhood	O
traumata	O
.	O

Women	O
diagnosed	O
with	O
BPD	O
had	O
significantly	O
reduced	O
oxytocin	B-CHEMICAL
concentrations	O
,	O
even	O
after	O
controlling	O
for	O
estrogen	B-CHEMICAL
,	O
progesterone	B-CHEMICAL
,	O
and	O
contraceptive	O
intake	O
.	O

In	O
addition	O
,	O
plasma	O
oxytocin	B-CHEMICAL
correlated	O
negatively	O
with	O
experiences	O
of	O
childhood	O
traumata	O
,	O
in	O
particular	O
with	O
emotional	O
neglect	O
and	O
abuse	O
.	O

The	O
results	O
of	O
mediation	O
analyses	O
do	O
not	O
support	O
a	O
model	O
of	O
oxytocin	B-CHEMICAL
being	O
a	O
prominent	O
mediator	O
in	O
the	O
link	O
between	O
childhood	O
trauma	O
and	O
BPD	O
.	O

Thus	O
,	O
the	O
findings	O
indicate	O
dysregulations	O
in	O
the	O
oxytocin	B-CHEMICAL
system	O
of	O
patients	O
diagnosed	O
with	O
BPD	O
with	O
more	O
longitudinal	O
research	O
being	O
necessary	O
to	O
disentangle	O
the	O
relationship	O
between	O
childhood	O
adversities	O
,	O
oxytocin	B-CHEMICAL
system	O
,	O
and	O
psychopathology	O
.	O

Identification	O
of	O
a	O
novel	O
benzimidazole	B-CHEMICAL
derivative	O
as	O
a	O
highly	O
potent	O
NPY	B-GENE-Y
Y5	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
with	O
an	O
anti	O
-	O
obesity	O
profile	O
.	O

Optimization	O
of	O
HTS	O
hit	O
1	O
for	O
NPY	B-GENE-Y
Y5	I-GENE-Y
receptor	I-GENE-Y
binding	O
affinity	O
,	O
CYP450	B-GENE-N
inhibition	O
,	O
solubility	O
and	O
metabolic	O
stability	O
led	O
to	O
the	O
identification	O
of	O
some	O
orally	O
available	O
oxygen	B-CHEMICAL
-	O
linker	O
derivatives	O
for	O
in	O
vivo	O
study	O
.	O

Among	O
them	O
,	O
derivative	O
4i	O
inhibited	O
food	O
intake	O
induced	O
by	O
the	O
NPY	B-GENE-Y
Y5	I-GENE-Y
selective	O
agonist	O
,	O
and	O
chronic	O
oral	O
administration	O
of	O
4i	O
in	O
DIO	O
mice	O
caused	O
a	O
dose	O
-	O
dependent	O
reduction	O
of	O
body	O
weight	O
gain	O
.	O

pH	O
-	O
responsive	O
composite	O
microspheres	O
based	O
on	O
magnetic	O
mesoporous	O
silica	B-CHEMICAL
nanoparticle	O
for	O
drug	O
delivery	O
.	O

pH	O
-	O
responsive	O
composite	O
microspheres	O
,	O
consisting	O
of	O
a	O
core	O
of	O
Fe3O4	B-CHEMICAL
nanoparticle	O
,	O
a	O
sandwiched	O
layer	O
of	O
mesoporous	O
silica	B-CHEMICAL
and	O
a	O
shell	O
of	O
crosslinked	O
poly	B-CHEMICAL
(	I-CHEMICAL
methacrylic	I-CHEMICAL
acid	I-CHEMICAL
)	I-CHEMICAL
(	O
PMAA	B-CHEMICAL
)	O
,	O
were	O
successfully	O
synthesized	O
via	O
distillation	O
precipitation	O
polymerization	O
.	O

The	O
pKa	O
of	O
the	O
composite	O
microsphere	O
increased	O
with	O
the	O
increase	O
in	O
the	O
crosslinking	O
density	O
.	O

Doxorubicin	B-CHEMICAL
hydrochloride	I-CHEMICAL
(	O
DOX	B-CHEMICAL
)	O
was	O
applied	O
as	O
a	O
model	O
drug	O
,	O
and	O
the	O
behavior	O
of	O
drug	O
storage	O
/	O
release	O
was	O
investigated	O
.	O

The	O
cumulative	O
release	O
of	O
DOX	B-CHEMICAL
-	O
loaded	O
composite	O
microsphere	O
in	O
vitro	O
showed	O
that	O
the	O
drug	O
release	O
rate	O
was	O
much	O
faster	O
below	O
its	O
pKa	O
than	O
that	O
of	O
above	O
its	O
pKa	O
.	O

Because	O
pH	O
of	O
most	O
tumor	O
tissues	O
was	O
lower	O
than	O
that	O
of	O
normal	O
tissues	O
,	O
the	O
pH	O
-	O
responsive	O
composite	O
microspheres	O
are	O
promising	O
drug	O
delivery	O
system	O
especially	O
for	O
cancer	O
therapy	O
.	O

Combining	O
QSAR	O
classification	O
models	O
for	O
predictive	O
modeling	O
of	O
human	B-GENE-N
monoamine	I-GENE-N
oxidase	I-GENE-N
inhibitors	O
.	O

Due	O
to	O
their	O
role	O
in	O
the	O
metabolism	O
of	O
monoamine	O
neurotransmitters	O
,	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
and	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
present	O
a	O
significant	O
pharmacological	O
interest	O
.	O

For	O
instance	O
the	O
inhibitors	O
of	O
human	B-GENE-Y
MAO	I-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
are	O
considered	O
useful	O
tools	O
for	O
the	O
treatment	O
of	O
Parkinson	O
Disease	O
.	O

Therefore	O
,	O
the	O
rational	O
design	O
and	O
synthesis	O
of	O
new	O
MAOs	B-GENE-N
inhibitors	O
is	O
considered	O
of	O
great	O
importance	O
for	O
the	O
development	O
of	O
new	O
and	O
more	O
effective	O
treatments	O
of	O
Parkinson	O
Disease	O
.	O

In	O
this	O
work	O
,	O
Quantitative	O
Structure	O
Activity	O
Relationships	O
(	O
QSAR	O
)	O
has	O
been	O
developed	O
to	O
predict	O
the	O
human	B-GENE-N
MAO	I-GENE-N
inhibitory	O
activity	O
and	O
selectivity	O
.	O

The	O
first	O
step	O
was	O
the	O
selection	O
of	O
a	O
suitable	O
dataset	O
of	O
heterocyclic	O
compounds	O
that	O
include	O
chromones	B-CHEMICAL
,	O
coumarins	B-CHEMICAL
,	O
chalcones	B-CHEMICAL
,	O
thiazolylhydrazones	B-CHEMICAL
,	O
etc	O
.	O

These	O
compounds	O
were	O
previously	O
synthesized	O
in	O
one	O
of	O
our	O
laboratories	O
,	O
or	O
elsewhere	O
,	O
and	O
their	O
activities	O
measured	O
by	O
the	O
same	O
assays	O
and	O
for	O
the	O
same	O
laboratory	O
staff	O
.	O

Applying	O
linear	O
discriminant	O
analysis	O
to	O
data	O
derived	O
from	O
a	O
variety	O
of	O
molecular	O
representations	O
and	O
feature	O
selection	O
algorithms	O
,	O
reliable	O
QSAR	O
models	O
were	O
built	O
which	O
could	O
be	O
used	O
to	O
predict	O
for	O
test	O
compounds	O
the	O
inhibitory	O
activity	O
and	O
selectivity	O
toward	O
human	B-GENE-N
MAO	I-GENE-N
.	O

This	O
work	O
also	O
showed	O
how	O
several	O
QSAR	O
models	O
can	O
be	O
combined	O
to	O
make	O
better	O
predictions	O
.	O

The	O
final	O
models	O
exhibit	O
significant	O
statistics	O
,	O
interpretability	O
,	O
as	O
well	O
as	O
displaying	O
predictive	O
power	O
on	O
an	O
external	O
validation	O
set	O
made	O
up	O
of	O
chromone	O
derivatives	O
with	O
unknown	O
activity	O
(	O
that	O
are	O
being	O
reported	O
here	O
for	O
first	O
time	O
)	O
synthesized	O
by	O
our	O
group	O
,	O
and	O
coumarins	B-CHEMICAL
recently	O
reported	O
in	O
the	O
literature	O
.	O

From	O
traditional	O
European	O
medicine	O
to	O
discovery	O
of	O
new	O
drug	O
candidates	O
for	O
the	O
treatment	O
of	O
dementia	O
and	O
Alzheimer	O
'	O
s	O
disease	O
:	O
acetylcholinesterase	B-GENE-Y
inhibitors	O
.	O

The	O
leading	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
therapeutics	O
to	O
date	O
involves	O
inhibitors	O
of	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
,	O
which	O
should	O
,	O
in	O
principle	O
,	O
elevate	O
cholinergic	O
signaling	O
and	O
limit	O
inflammation	O
.	O

In	O
spite	O
of	O
the	O
effectiveness	O
in	O
20	O
%	O
-	O
30	O
%	O
of	O
AD	O
patients	O
,	O
more	O
attention	O
has	O
been	O
paid	O
to	O
find	O
new	O
anti	O
-	O
AChE	B-GENE-Y
agents	O
from	O
medicinal	O
plants	O
.	O

Galanthamine	B-CHEMICAL
,	O
contained	O
in	O
the	O
bulbs	O
and	O
flowers	O
of	O
Galanthus	O
and	O
related	O
genera	O
like	O
Narcissus	O
,	O
represents	O
a	O
good	O
example	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
review	O
the	O
role	O
of	O
possible	O
AChE	B-GENE-Y
inhibitors	O
(	O
AChEI	O
)	O
present	O
in	O
plants	O
traditionally	O
used	O
in	O
European	O
medicine	O
for	O
improving	O
memory	O
.	O

Starting	O
from	O
Galanthamine	B-CHEMICAL
,	O
properties	O
of	O
Melissa	O
species	O
,	O
Salvia	O
officinalis	O
,	O
Arnica	O
chamissonis	O
and	O
Ruta	O
graveolens	O
are	O
discussed	O
to	O
point	O
to	O
the	O
role	O
of	O
these	O
plants	O
as	O
potential	O
sources	O
for	O
the	O
development	O
of	O
therapeutic	O
agents	O
for	O
AD	O
.	O

Anisotropy	O
of	O
chemical	O
bonding	O
in	O
semifluorinated	O
graphite	B-CHEMICAL
C2F	B-CHEMICAL
revealed	O
with	O
angle	O
-	O
resolved	O
X	O
-	O
ray	O
absorption	O
spectroscopy	O
.	O

Highly	O
oriented	O
pyrolytic	O
graphite	B-CHEMICAL
characterized	O
by	O
a	O
low	O
misorientation	O
of	O
crystallites	O
is	O
fluorinated	O
using	O
a	O
gaseous	O
mixture	O
of	O
BrF	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
with	O
Br	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
at	O
room	O
temperature	O
.	O

The	O
golden	O
-	O
colored	O
product	O
,	O
easily	O
delaminating	O
into	O
micrometer	O
-	O
size	O
transparent	O
flakes	O
,	O
is	O
an	O
intercalation	O
compound	O
where	O
Br	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
molecules	O
are	O
hosted	O
between	O
fluorinated	O
graphene	B-CHEMICAL
layers	O
of	O
approximate	O
C	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
composition	O
.	O

To	O
unravel	O
the	O
chemical	O
bonding	O
in	O
semifluorinated	O
graphite	B-CHEMICAL
,	O
we	O
apply	O
angle	O
-	O
resolved	O
near	O
-	O
edge	O
X	O
-	O
ray	O
absorption	O
fine	O
structure	O
(	O
NEXAFS	O
)	O
spectroscopy	O
and	O
quantum	O
-	O
chemical	O
modeling	O
.	O

The	O
strong	O
angular	O
dependence	O
of	O
the	O
CK	O
and	O
FK	O
edge	O
NEXAFS	O
spectra	O
on	O
the	O
incident	O
radiation	O
indicates	O
that	O
room	O
-	O
temperature	O
-	O
produced	O
graphite	B-CHEMICAL
fluoride	I-CHEMICAL
is	O
a	O
highly	O
anisotropic	O
material	O
,	O
where	O
half	O
of	O
the	O
carbon	B-CHEMICAL
atoms	O
are	O
covalently	O
bonded	O
with	O
fluorine	B-CHEMICAL
,	O
while	O
the	O
rest	O
of	O
the	O
carbon	O
atoms	O
preserve	O
π	O
electrons	O
.	O

Comparison	O
of	O
the	O
experimental	O
CK	O
edge	O
spectrum	O
with	O
theoretical	O
spectra	O
plotted	O
for	O
C	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
F	I-CHEMICAL
models	O
reveals	O
that	O
fluorine	B-CHEMICAL
atoms	O
are	O
more	O
likely	O
to	O
form	O
chains	O
.	O

This	O
conclusion	O
agrees	O
with	O
the	O
atomic	O
force	O
microscopy	O
observation	O
of	O
a	O
chain	O
-	O
like	O
pattern	O
on	O
the	O
surface	O
of	O
graphite	B-CHEMICAL
fluoride	I-CHEMICAL
layers	O
.	O

Platelet	O
-	O
derived	O
microparticles	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
the	O
polycystic	O
ovary	O
syndrome	O
.	O

A	O
substantial	O
proportion	O
of	O
women	O
with	O
the	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
are	O
obese	O
and	O
obesity	O
is	O
considered	O
as	O
a	O
prothrombotic	O
state	O
.	O

Platelet	O
-	O
derived	O
microparticles	O
(	O
PMPs	O
)	O
might	O
be	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
coagulation	O
cascade	O
.	O

We	O
aimed	O
to	O
assess	O
plasma	O
PMPs	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
.	O

We	O
measured	O
plasma	O
PMPs	O
and	O
determined	O
anthropometric	O
,	O
metabolic	O
,	O
hormonal	O
and	O
ultrasonographic	O
features	O
of	O
PCOS	O
in	O
67	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
(	O
with	O
body	O
mass	O
index	O
[	O
BMI	O
]	O
>	O
25	O
.	O
0	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
in	O
21	O
BMI	O
-	O
matched	O
healthy	O
women	O
.	O

Circulating	O
androgens	B-CHEMICAL
and	O
markers	O
of	O
insulin	B-GENE-Y
resistance	O
(	O
IR	O
)	O
were	O
higher	O
in	O
women	O
with	O
PCOS	O
than	O
in	O
controls	O
.	O

Plasma	O
PMPs	O
were	O
also	O
higher	O
in	O
women	O
with	O
PCOS	O
than	O
in	O
controls	O
(	O
p	O
=	O
0	O
.	O
046	O
)	O
.	O

In	O
women	O
with	O
PCOS	O
,	O
plasma	O
PMPs	O
correlated	O
with	O
the	O
mean	O
number	O
of	O
follicles	O
in	O
the	O
ovaries	O
(	O
r	O
=	O
0	O
.	O
343	O
;	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
controls	O
,	O
plasma	O
PMPs	O
did	O
not	O
correlate	O
with	O
any	O
of	O
the	O
studied	O
parameters	O
.	O

In	O
conclusion	O
,	O
plasma	O
PMPs	O
are	O
elevated	O
in	O
overweight	O
/	O
obese	O
women	O
with	O
PCOS	O
compared	O
with	O
BMI	O
-	O
matched	O
controls	O
.	O

The	O
cause	O
of	O
this	O
increase	O
is	O
unclear	O
but	O
both	O
IR	O
and	O
hyperandrogenemia	O
might	O
be	O
implicated	O
.	O

More	O
studies	O
are	O
required	O
to	O
elucidate	O
the	O
pathogenesis	O
of	O
the	O
elevation	O
of	O
PMPs	O
in	O
PCOS	O
and	O
to	O
assess	O
its	O
implications	O
on	O
the	O
cardiovascular	O
risk	O
of	O
these	O
patients	O
.	O

DNA	B-GENE-Y
polymerase	I-GENE-Y
POLQ	I-GENE-Y
and	O
cellular	O
defense	O
against	O
DNA	O
damage	O
.	O

In	O
mammalian	O
cells	O
,	O
POLQ	B-GENE-Y
(	O
pol	B-GENE-Y
θ	I-GENE-Y
)	O
is	O
an	O
unusual	O
specialized	O
DNA	B-GENE-N
polymerase	I-GENE-N
whose	O
in	O
vivo	O
function	O
is	O
under	O
active	O
investigation	O
.	O

POLQ	B-GENE-Y
has	O
been	O
implicated	O
by	O
different	O
experiments	O
to	O
play	O
a	O
role	O
in	O
resistance	O
to	O
ionizing	O
radiation	O
and	O
defense	O
against	O
genomic	O
instability	O
,	O
in	O
base	O
excision	O
repair	O
,	O
and	O
in	O
immunological	O
diversification	O
.	O

The	O
protein	O
is	O
formed	O
by	O
an	O
N	B-GENE-N
-	I-GENE-N
terminal	I-GENE-N
helicase	I-GENE-N
-	I-GENE-N
like	I-GENE-N
domain	I-GENE-N
,	O
a	O
C	B-GENE-N
-	I-GENE-N
terminal	I-GENE-N
DNA	I-GENE-N
polymerase	I-GENE-N
domain	I-GENE-N
,	O
and	O
a	O
large	B-GENE-N
central	I-GENE-N
domain	I-GENE-N
that	O
spans	O
between	O
the	O
two	O
.	O

This	O
arrangement	O
is	O
also	O
found	O
in	O
the	O
Drosophila	B-GENE-Y
Mus308	I-GENE-Y
protein	O
,	O
which	O
functions	O
in	O
resistance	O
to	O
DNA	O
interstrand	O
crosslinking	O
agents	O
.	O

Homologs	O
of	O
POLQ	B-GENE-Y
and	O
Mus308	B-GENE-Y
are	O
found	O
in	O
multicellular	O
eukaryotes	O
,	O
including	O
plants	O
,	O
but	O
a	O
comparison	O
of	O
phenotypes	O
suggests	O
that	O
not	O
all	O
of	O
these	O
genes	O
are	O
functional	O
orthologs	O
.	O

Flies	O
defective	O
in	O
Mus308	B-GENE-Y
are	O
sensitive	O
to	O
DNA	O
interstrand	O
crosslinking	O
agents	O
,	O
while	O
mammalian	O
cells	O
defective	O
in	O
POLQ	B-GENE-Y
are	O
primarily	O
sensitive	O
to	O
DNA	O
double	O
-	O
strand	O
breaking	O
agents	O
.	O

Cells	O
from	O
Polq	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
are	O
hypersensitive	O
to	O
radiation	O
and	O
peripheral	O
blood	O
cells	O
display	O
increased	O
spontaneous	O
and	O
ionizing	O
radiation	O
-	O
induced	O
levels	O
of	O
micronuclei	O
(	O
a	O
hallmark	O
of	O
gross	O
chromosomal	O
aberrations	O
)	O
,	O
though	O
mice	O
apparently	O
develop	O
normally	O
.	O

Loss	O
of	O
POLQ	B-GENE-N
in	O
human	O
and	O
mouse	O
cells	O
causes	O
sensitivity	O
to	O
ionizing	O
radiation	O
and	O
other	O
double	O
strand	O
breaking	O
agents	O
and	O
increased	O
DNA	O
damage	O
signaling	O
.	O

Retrospective	O
studies	O
of	O
clinical	O
samples	O
show	O
that	O
higher	O
levels	O
of	O
POLQ	B-GENE-Y
gene	O
expression	O
in	O
breast	O
and	O
colorectal	O
cancer	O
are	O
correlated	O
with	O
poorer	O
outcomes	O
for	O
patients	O
.	O

A	O
clear	O
understanding	O
of	O
the	O
mechanism	O
of	O
action	O
and	O
physiologic	O
function	O
of	O
POLQ	B-GENE-Y
in	O
the	O
cell	O
is	O
likely	O
to	O
bear	O
clinical	O
relevance	O
.	O

Neuroprotective	O
effects	O
of	O
oxymatrine	B-CHEMICAL
against	O
excitotoxicity	O
partially	O
through	O
down	O
-	O
regulation	O
of	O
NR2B	B-GENE-Y
-	O
containing	O
NMDA	B-GENE-N
receptors	I-GENE-N
.	O

Oxymatrine	B-CHEMICAL
(	O
OMT	B-CHEMICAL
)	O
is	O
a	O
major	O
bioactive	O
component	O
derived	O
from	O
Sophora	O
flavescens	O
Ait	O
(	O
kushen	O
)	O
,	O
which	O
is	O
widely	O
used	O
in	O
Chinese	O
medicine	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
it	O
has	O
neuroprotective	O
effects	O
;	O
however	O
,	O
its	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

We	O
focus	O
on	O
the	O
mechanisms	O
of	O
pharmacologic	O
action	O
in	O
OMT	B-CHEMICAL
by	O
detecting	O
its	O
pharmacological	O
properties	O
against	O
focal	O
cerebral	O
ischemia	O
in	O
vivo	O
and	O
NMDA	B-CHEMICAL
-	O
induced	O
neurotoxicity	O
in	O
vitro	O
.	O

OMT	B-CHEMICAL
prevented	O
cerebral	O
ischemic	O
injury	O
in	O
mice	O
induced	O
via	O
a	O
2	O
h	O
middle	O
cerebral	O
artery	O
occlusion	O
and	O
a	O
24	O
h	O
reperfusion	O
,	O
in	O
vivo	O
.	O

In	O
vitro	O
cultured	O
neurons	O
challenged	O
with	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
aspartate	I-CHEMICAL
(	O
NMDA	B-CHEMICAL
,	O
200	O
μM	O
)	O
for	O
30	O
min	O
showed	O
significant	O
decrease	O
in	O
the	O
viability	O
of	O
neurons	O
;	O
however	O
,	O
OMT	B-CHEMICAL
was	O
able	O
to	O
protect	O
neurons	O
against	O
induced	O
neurotoxicity	O
via	O
NMDA	B-CHEMICAL
exposure	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
OMT	B-CHEMICAL
decreased	O
the	O
expression	O
of	O
Bax	B-GENE-Y
and	O
repaired	O
the	O
balance	O
of	O
pro	O
-	O
and	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

Furthermore	O
,	O
OMT	B-CHEMICAL
significantly	O
reversed	O
the	O
up	O
-	O
regulation	O
of	O
NR2B	B-GENE-Y
and	O
inhibited	O
the	O
calcium	B-CHEMICAL
overload	O
in	O
the	O
cultured	O
neurons	O
after	O
challenging	O
the	O
NMDA	B-CHEMICAL
.	O

OMT	B-CHEMICAL
showed	O
partial	O
protection	O
in	O
the	O
cortical	O
neurons	O
via	O
down	O
-	O
regulation	O
of	O
NR2B	B-GENE-Y
containing	O
NMDA	B-GENE-N
receptors	I-GENE-N
and	O
up	O
-	O
regulation	O
of	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
family	O
.	O

Our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
development	O
of	O
natural	O
therapeutic	O
anti	O
-	O
oxidants	O
against	O
ischemia	O
.	O

In	O
vitro	O
investigation	O
of	O
efficacy	O
of	O
new	O
reactivators	O
on	O
OPC	O
inhibited	O
rat	B-GENE-Y
brain	I-GENE-Y
acetylcholinesterase	I-GENE-Y
.	O

Organophosphorus	B-CHEMICAL
compounds	O
(	O
OPC	O
)	O
were	O
developed	O
as	O
warfare	O
nerve	O
agents	O
.	O

They	O
are	O
also	O
widely	O
used	O
as	O
pesticides	O
.	O

The	O
drug	O
therapy	O
of	O
intoxication	O
with	O
OPC	O
includes	O
mainly	O
combination	O
of	O
cholinesterase	B-GENE-Y
(	O
ChE	B-GENE-Y
)	O
reactivators	O
and	O
cholinolytics	O
.	O

There	O
is	O
no	O
single	O
ChE	B-GENE-Y
reactivator	O
having	O
an	O
ability	O
to	O
reactivate	O
sufficiently	O
the	O
inhibited	O
enzyme	O
due	O
to	O
the	O
high	O
variability	O
of	O
chemical	O
structure	O
of	O
the	O
inhibitors	O
.	O

The	O
difficulties	O
in	O
reactivation	O
of	O
ChE	B-GENE-Y
activity	O
and	O
slight	O
antidote	O
effect	O
regarding	O
intoxication	O
with	O
some	O
OPC	O
are	O
some	O
of	O
the	O
reasons	O
for	O
continuous	O
efforts	O
to	O
obtain	O
new	O
reactivators	O
of	O
ChE	B-GENE-Y
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
some	O
ChE	B-GENE-Y
reactivators	O
against	O
OPC	O
intoxication	O
(	O
tabun	B-CHEMICAL
,	O
paraoxon	B-CHEMICAL
and	O
dichlorvos	B-CHEMICAL
)	O
in	O
in	O
vitro	O
experiments	O
and	O
to	O
compare	O
their	O
activity	O
to	O
that	O
known	O
for	O
some	O
currently	O
used	O
oximes	B-CHEMICAL
(	O
obidoxime	B-CHEMICAL
,	O
HI	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
,	O
2	B-CHEMICAL
-	I-CHEMICAL
PAM	I-CHEMICAL
)	O
.	O

Experiments	O
were	O
carried	O
out	O
using	O
rat	B-GENE-Y
brain	I-GENE-Y
acetylcholinesterase	I-GENE-Y
(	O
AChE	B-GENE-Y
)	O
.	O

Reactivators	O
showed	O
different	O
activity	O
in	O
the	O
reactivation	O
of	O
rat	B-GENE-Y
brain	I-GENE-Y
AChE	I-GENE-Y
after	O
dichlorvos	B-CHEMICAL
,	O
paraoxon	B-CHEMICAL
and	O
tabun	B-CHEMICAL
inhibition	O
.	O

AChE	B-GENE-Y
was	O
easier	O
reactivated	O
after	O
paraoxon	B-CHEMICAL
treatment	O
.	O

The	O
best	O
effect	O
showed	O
BT	B-CHEMICAL
-	I-CHEMICAL
07	I-CHEMICAL
-	I-CHEMICAL
4M	I-CHEMICAL
,	O
obidoxime	B-CHEMICAL
,	O
TMB	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
and	O
BT	B-CHEMICAL
-	I-CHEMICAL
08	I-CHEMICAL
from	O
the	O
group	O
of	O
symmetric	O
oximes	B-CHEMICAL
,	O
and	O
Toxidin	B-CHEMICAL
,	O
BT	B-CHEMICAL
-	I-CHEMICAL
05	I-CHEMICAL
and	O
BT	B-CHEMICAL
-	I-CHEMICAL
03	I-CHEMICAL
from	O
asymmetric	O
compounds	O
.	O

The	O
reactivation	O
of	O
brain	O
AChE	B-GENE-Y
inhibited	O
with	O
tabun	O
demonstrated	O
better	O
activity	O
of	O
new	O
compound	O
BT	B-CHEMICAL
-	I-CHEMICAL
07	I-CHEMICAL
-	I-CHEMICAL
4M	I-CHEMICAL
,	O
TMB	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
and	O
obidoxime	B-CHEMICAL
from	O
symmetric	O
oximes	B-CHEMICAL
,	O
and	O
BT	B-CHEMICAL
-	I-CHEMICAL
05	I-CHEMICAL
and	O
BT	B-CHEMICAL
-	I-CHEMICAL
03	I-CHEMICAL
possessing	O
asymmetric	O
structure	O
.	O

All	O
compounds	O
showed	O
low	O
activity	O
toward	O
inhibition	O
of	O
AChE	B-GENE-Y
caused	O
by	O
dichlorvos	B-CHEMICAL
.	O

Comparison	O
of	O
two	O
main	O
structure	O
types	O
(	O
symmetric	O
/	O
asymmetric	O
)	O
showed	O
that	O
the	O
symmetric	O
compounds	O
reactivated	O
better	O
AChE	B-GENE-Y
,	O
inhibited	O
with	O
this	O
OPC	O
,	O
than	O
asymmetric	O
ones	O
.	O

Role	O
of	O
organic	B-GENE-Y
cation	I-GENE-Y
/	I-GENE-Y
carnitine	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
in	O
uptake	O
of	O
phenformin	B-CHEMICAL
and	O
inhibitory	O
effect	O
on	O
complex	B-GENE-N
I	I-GENE-N
respiration	O
in	O
mitochondria	O
.	O

Phenformin	B-CHEMICAL
causes	O
lactic	O
acidosis	O
in	O
clinical	O
situations	O
due	O
to	O
inhibition	O
of	O
mitochondrial	B-GENE-N
respiratory	I-GENE-N
chain	I-GENE-N
complex	I-GENE-N
I	I-GENE-N
.	O

It	O
is	O
reportedly	O
taken	O
up	O
by	O
hepatocytes	O
and	O
exhibits	O
mitochondrial	O
toxicity	O
in	O
the	O
liver	O
.	O

In	O
this	O
study	O
,	O
uptake	O
of	O
phenformin	B-CHEMICAL
and	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
tetraethylammonium	I-CHEMICAL
(	O
TEA	B-CHEMICAL
)	O
and	O
complex	B-GENE-N
I	I-GENE-N
inhibition	O
by	O
phenformin	B-CHEMICAL
were	O
examined	O
in	O
isolated	O
liver	O
and	O
heart	O
mitochondria	O
.	O

Uptake	O
of	O
phenformin	B-CHEMICAL
into	O
isolated	O
rat	O
liver	O
mitochondria	O
was	O
higher	O
than	O
that	O
into	O
heart	O
mitochondria	O
.	O

It	O
was	O
inhibited	O
by	O
several	O
cat	O
ionic	O
compounds	O
,	O
which	O
suggests	O
the	O
involvement	O
of	O
multispecific	O
transport	O
system	O
(	O
s	O
)	O
.	O

Similar	O
characteristics	O
were	O
also	O
observed	O
for	O
uptake	O
of	O
TEA	B-CHEMICAL
;	O
however	O
,	O
uptake	O
of	O
phenformin	B-CHEMICAL
into	O
mitochondria	O
of	O
organic	B-GENE-Y
cation	I-GENE-Y
/	I-GENE-Y
carnitine	I-GENE-Y
transporter	I-GENE-Y
1	I-GENE-Y
(	O
OCTN1	B-GENE-Y
)	O
knockout	O
mice	O
was	O
lower	O
than	O
that	O
in	O
wild	O
-	O
type	O
mice	O
,	O
whereas	O
uptake	O
of	O
TEA	B-CHEMICAL
was	O
comparable	O
between	O
the	O
two	O
strains	O
,	O
suggesting	O
the	O
involvement	O
of	O
distinct	O
transport	O
mechanisms	O
for	O
these	O
two	O
cations	O
in	O
mitochondria	O
.	O

Inhibition	O
by	O
phenformin	B-CHEMICAL
of	O
oxygen	B-CHEMICAL
consumption	O
via	O
complex	B-GENE-N
I	I-GENE-N
respiration	O
in	O
isolated	O
rat	O
liver	O
mitochondria	O
was	O
greater	O
than	O
that	O
in	O
heart	O
mitochondria	O
,	O
whereas	O
inhibitory	O
effect	O
of	O
phenformin	B-CHEMICAL
on	O
complex	B-GENE-N
I	I-GENE-N
respiration	O
was	O
similar	O
in	O
inside	O
-	O
out	O
structured	O
submitochondrial	O
particles	O
prepared	O
from	O
rat	O
livers	O
and	O
hearts	O
.	O

Lactic	O
acidosis	O
provoked	O
by	O
iv	O
infusion	O
of	O
phenformin	B-CHEMICAL
was	O
weaker	O
in	O
octn1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
than	O
that	O
in	O
wild	O
-	O
type	O
mice	O
.	O

These	O
observations	O
suggest	O
that	O
uptake	O
of	O
phenformin	B-CHEMICAL
into	O
liver	O
mitochondria	O
is	O
at	O
least	O
partly	O
mediated	O
by	O
OCTN1	B-GENE-Y
and	O
functionally	O
relevant	O
to	O
its	O
inhibition	O
potential	O
of	O
complex	B-GENE-N
I	I-GENE-N
respiration	O
.	O

This	O
study	O
was	O
,	O
thus	O
,	O
the	O
first	O
to	O
demonstrate	O
OCTN1	B-GENE-Y
-	O
mediated	O
mitochondrial	O
transport	O
and	O
toxicity	O
of	O
biguanide	O
in	O
vivo	O
in	O
rodents	O
.	O

Rufinamide	B-CHEMICAL
attenuates	O
mechanical	O
allodynia	O
in	O
a	O
model	O
of	O
neuropathic	O
pain	O
in	O
the	O
mouse	O
and	O
stabilizes	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
inactivated	O
state	O
.	O

BACKGROUND	O
:	O
Voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
channels	I-GENE-N
dysregulation	O
is	O
important	O
for	O
hyperexcitability	O
leading	O
to	O
pain	O
persistence	O
.	O

Sodium	B-GENE-N
channel	I-GENE-N
blockers	O
currently	O
used	O
to	O
treat	O
neuropathic	O
pain	O
are	O
poorly	O
tolerated	O
.	O

Getting	O
new	O
molecules	O
to	O
clinical	O
use	O
is	O
laborious	O
.	O

We	O
here	O
propose	O
a	O
drug	O
already	O
marketed	O
as	O
anticonvulsant	O
,	O
rufinamide	B-CHEMICAL
.	O

METHODS	O
:	O
We	O
compared	O
the	O
behavioral	O
effect	O
of	O
rufinamide	B-CHEMICAL
to	O
amitriptyline	B-CHEMICAL
using	O
the	O
Spared	O
Nerve	O
Injury	O
neuropathic	O
pain	O
model	O
in	O
mice	O
.	O

We	O
compared	O
the	O
effect	O
of	O
rufinamide	B-CHEMICAL
on	O
sodium	B-CHEMICAL
currents	O
using	O
in	O
vitro	O
patch	O
clamp	O
in	O
cells	O
expressing	O
the	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
Nav1	B-GENE-Y
.	I-GENE-Y
7	I-GENE-Y
isoform	O
and	O
on	O
dissociated	O
dorsal	O
root	O
ganglion	O
neurons	O
to	O
amitriptyline	B-CHEMICAL
and	O
mexiletine	B-CHEMICAL
.	O

RESULTS	O
:	O
In	O
naive	O
mice	O
,	O
amitriptyline	B-CHEMICAL
(	O
20	O
mg	O
/	O
kg	O
)	O
increased	O
withdrawal	O
threshold	O
to	O
mechanical	O
stimulation	O
from	O
1	O
.	O
3	O
(	O
0	O
.	O
6	O
-	O
1	O
.	O
9	O
)	O
(	O
median	O
[	O
95	O
%	O
CI	O
]	O
)	O
to	O
2	O
.	O
3	O
g	O
(	O
2	O
.	O
2	O
-	O
2	O
.	O
5	O
)	O
and	O
latency	O
of	O
withdrawal	O
to	O
heat	O
stimulation	O
from	O
13	O
.	O
1	O
(	O
10	O
.	O
4	O
-	O
15	O
.	O
5	O
)	O
to	O
30	O
.	O
0	O
s	O
(	O
21	O
.	O
8	O
-	O
31	O
.	O
9	O
)	O
,	O
whereas	O
rufinamide	B-CHEMICAL
had	O
no	O
effect	O
.	O

Rufinamide	B-CHEMICAL
and	O
amitriptyline	B-CHEMICAL
alleviated	O
injury	O
-	O
induced	O
mechanical	O
allodynia	O
for	O
4	O
h	O
(	O
maximal	O
effect	O
:	O
0	O
.	O
10	O
+	O
/	O
-	O
0	O
.	O
03	O
g	O
(	O
mean	O
+	O
/	O
-	O
SD	O
)	O
to	O
1	O
.	O
99	O
+	O
/	O
-	O
0	O
.	O
26	O
g	O
for	O
rufinamide	B-CHEMICAL
and	O
0	O
.	O
25	O
+	O
/	O
-	O
0	O
.	O
22	O
g	O
to	O
1	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
85	O
g	O
for	O
amitriptyline	B-CHEMICAL
)	O
.	O

All	O
drugs	O
reduced	O
peak	O
current	O
and	O
stabilized	O
the	O
inactivated	O
state	O
of	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
Nav1	B-GENE-Y
.	I-GENE-Y
7	I-GENE-Y
,	O
with	O
similar	O
effects	O
in	O
dorsal	O
root	O
ganglion	O
neurons	O
.	O

CONCLUSIONS	O
:	O
At	O
doses	O
alleviating	O
neuropathic	O
pain	O
,	O
amitriptyline	B-CHEMICAL
showed	O
alteration	O
of	O
behavioral	O
response	O
possibly	O
related	O
to	O
either	O
alteration	O
of	O
basal	O
pain	O
sensitivity	O
or	O
sedative	O
effect	O
or	O
both	O
.	O

Side	O
-	O
effects	O
and	O
drug	O
tolerance	O
/	O
compliance	O
are	O
major	O
problems	O
with	O
drugs	O
such	O
as	O
amitriptyline	B-CHEMICAL
.	O

Rufinamide	B-CHEMICAL
seems	O
to	O
have	O
a	O
better	O
tolerability	O
profile	O
and	O
could	O
be	O
a	O
new	O
alternative	O
to	O
explore	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
.	O

The	O
Effects	O
of	O
Carbohydrate	B-CHEMICAL
,	O
Unsaturated	O
Fat	O
,	O
and	O
Protein	O
Intake	O
on	O
Measures	O
of	O
Insulin	B-GENE-Y
Sensitivity	O
:	O
Results	O
from	O
the	O
OmniHeart	O
Trial	O
.	O

OBJECTIVE	O
Impaired	O
insulin	B-GENE-Y
sensitivity	O
increases	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
.	O

Although	O
calorie	O
restriction	O
and	O
weight	O
loss	O
increase	O
insulin	B-GENE-Y
sensitivity	O
,	O
the	O
effects	O
of	O
modifying	O
macronutrient	O
composition	O
on	O
insulin	B-GENE-Y
sensitivity	O
are	O
uncertain	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
effects	O
on	O
insulin	B-GENE-Y
sensitivity	O
of	O
a	O
carbohydrate	B-CHEMICAL
-	O
rich	O
diet	O
(	O
CARB	B-CHEMICAL
;	O
similar	O
to	O
the	O
Dietary	O
Approaches	O
to	O
Stop	O
Hypertension	O
[	O
DASH	O
]	O
diet	O
)	O
,	O
a	O
protein	O
-	O
rich	O
diet	O
(	O
PROT	O
;	O
protein	O
predominantly	O
from	O
plant	O
sources	O
)	O
,	O
and	O
an	O
unsaturated	O
fat	O
-	O
rich	O
diet	O
(	O
UNSAT	O
;	O
predominantly	O
monounsaturated	O
)	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
This	O
study	O
was	O
a	O
randomized	O
,	O
controlled	O
,	O
three	O
-	O
period	O
,	O
crossover	O
feeding	O
study	O
.	O

The	O
study	O
participants	O
were	O
164	O
individuals	O
with	O
prehypertension	O
or	O
stage	O
1	O
hypertension	O
without	O
diabetes	O
.	O

Diets	O
were	O
administered	O
for	O
6	O
weeks	O
each	O
,	O
with	O
a	O
washout	O
period	O
between	O
diets	O
of	O
2	O
-	O
4	O
weeks	O
.	O

Weight	O
was	O
held	O
constant	O
throughout	O
the	O
study	O
.	O

For	O
our	O
primary	O
outcome	O
,	O
we	O
calculated	O
the	O
quantitative	O
insulin	B-GENE-Y
sensitivity	O
check	O
index	O
(	O
QUICKI	O
)	O
using	O
the	O
end	O
-	O
of	O
-	O
period	O
fasting	O
serum	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-Y
.	O

QUICKI	O
is	O
a	O
validated	O
measure	O
of	O
insulin	B-GENE-Y
sensitivity	O
.	O

The	O
primary	O
analyses	O
used	O
generalized	O
estimating	O
equations	O
.	O

RESULTS	O
At	O
baseline	O
,	O
mean	O
(	O
SD	O
)	O
BMI	O
was	O
30	O
.	O
2	O
(	O
6	O
.	O
1	O
)	O
kg	O
/	O
m	O
(	O
2	O
)	O
,	O
and	O
mean	O
(	O
SD	O
)	O
QUICKI	O
was	O
0	O
.	O
35	O
(	O
0	O
.	O
04	O
)	O
.	O

The	O
UNSAT	O
diet	O
increased	O
QUICKI	O
by	O
0	O
.	O
005	O
,	O
more	O
than	O
the	O
CARB	B-CHEMICAL
diet	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

PROT	O
had	O
no	O
significant	O
effect	O
compared	O
with	O
CARB	B-CHEMICAL
.	O

CONCLUSIONS	O
A	O
diet	O
that	O
partially	O
replaces	O
carbohydrate	B-CHEMICAL
with	O
unsaturated	O
fat	O
may	O
improve	O
insulin	B-GENE-Y
sensitivity	O
in	O
a	O
population	O
at	O
risk	O
for	O
cardiovascular	O
disease	O
.	O

Given	O
the	O
well	O
-	O
recognized	O
challenges	O
of	O
sustaining	O
weight	O
loss	O
,	O
our	O
results	O
suggest	O
an	O
alternative	O
approach	O
for	O
improving	O
insulin	B-GENE-Y
sensitivity	O
.	O

Vitamin	B-CHEMICAL
K2	I-CHEMICAL
covalently	O
binds	O
to	O
Bak	B-GENE-Y
and	O
induces	O
Bak	B-GENE-Y
-	O
mediated	O
apoptosis	O
.	O

Vitamin	B-CHEMICAL
K2	I-CHEMICAL
(	O
VK2	B-CHEMICAL
,	O
menaquinone	B-CHEMICAL
)	O
is	O
known	O
to	O
have	O
anticancer	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Although	O
its	O
effect	O
is	O
thought	O
to	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
induction	O
of	O
apoptosis	O
,	O
the	O
underlying	O
molecular	O
mechanism	O
remains	O
elusive	O
.	O

Here	O
,	O
we	O
identified	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
antagonist	O
killer	O
1	O
(	O
Bak	B-GENE-Y
)	O
as	O
a	O
molecular	O
target	O
of	O
VK2	B-CHEMICAL
-	O
induced	O
apoptosis	O
.	O

VK2	B-CHEMICAL
directly	O
interacts	O
with	O
Bak	B-GENE-Y
and	O
induces	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
.	O

Although	O
Bak	B-GENE-Y
and	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
X	I-GENE-Y
protein	I-GENE-Y
(	O
Bax	B-GENE-Y
)	O
,	O
another	O
member	O
of	O
the	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
family	O
,	O
are	O
generally	O
thought	O
to	O
be	O
functionally	O
redundant	O
,	O
only	O
Bak	B-GENE-Y
is	O
necessary	O
and	O
sufficient	O
for	O
VK2	B-CHEMICAL
-	O
induced	O
cytochrome	B-GENE-Y
c	I-GENE-Y
(	O
cyt	B-GENE-Y
c	I-GENE-Y
)	O
release	O
and	O
cell	O
death	O
.	O

Moreover	O
,	O
VK2	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
epoxide	I-CHEMICAL
,	O
an	O
intracellular	O
metabolite	O
of	O
VK2	B-CHEMICAL
,	O
was	O
shown	O
to	O
covalently	O
bind	O
to	O
the	O
cysteine	B-CHEMICAL
-	O
166	O
residue	O
of	O
Bak	B-GENE-Y
.	O

Several	O
lines	O
of	O
evidence	O
suggested	O
that	O
the	O
covalent	O
attachment	O
of	O
VK2	B-CHEMICAL
is	O
critical	O
for	O
apoptosis	O
induction	O
.	O

Thus	O
this	O
study	O
reveals	O
a	O
specific	O
role	O
for	O
Bak	B-GENE-Y
in	O
mitochondria	O
-	O
mediated	O
apoptosis	O
.	O

This	O
study	O
also	O
provides	O
insight	O
into	O
the	O
anticancer	O
effects	O
of	O
VK2	B-CHEMICAL
and	O
suggests	O
that	O
Bak	B-GENE-Y
may	O
be	O
a	O
potential	O
target	O
of	O
cancer	O
therapy	O
.	O

The	O
yeast	B-GENE-N
cap	I-GENE-N
binding	I-GENE-N
complex	I-GENE-N
modulates	O
transcription	O
factor	O
recruitment	O
and	O
establishes	O
proper	O
histone	B-GENE-N
H3K36	I-GENE-N
trimethylation	O
during	O
active	O
transcription	O
.	O

Recent	O
studies	O
have	O
revealed	O
a	O
close	O
relationship	O
between	O
transcription	O
,	O
histone	B-GENE-N
modification	O
,	O
and	O
RNA	O
processing	O
.	O

In	O
fact	O
,	O
genome	O
-	O
wide	O
analyses	O
that	O
correlate	O
histone	O
marks	O
with	O
RNA	O
processing	O
signals	O
raise	O
the	O
possibility	O
that	O
specific	O
RNA	O
processing	O
factors	O
may	O
modulate	O
transcription	O
and	O
help	O
to	O
"	O
write	O
"	O
chromatin	O
marks	O
.	O

Here	O
we	O
show	O
that	O
the	O
nuclear	B-GENE-N
cap	I-GENE-N
binding	I-GENE-N
complex	I-GENE-N
(	O
CBC	B-GENE-N
)	O
directs	O
recruitment	O
of	O
transcription	O
elongation	O
factors	O
and	O
establishes	O
proper	O
histone	B-GENE-N
marks	O
during	O
active	O
transcription	O
.	O

A	O
directed	O
genetic	O
screen	O
revealed	O
that	O
deletion	O
of	O
either	O
subunit	O
of	O
the	O
CBC	B-GENE-N
confers	O
a	O
synthetic	O
growth	O
defect	O
when	O
combined	O
with	O
deletion	O
of	O
genes	O
encoding	O
either	O
Ctk2	B-GENE-Y
or	O
Bur2	B-GENE-Y
,	O
a	O
component	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
ortholog	O
of	O
P	B-GENE-N
-	I-GENE-N
TEFb	I-GENE-N
.	O

The	O
CBC	B-GENE-N
physically	O
associates	O
with	O
these	O
complexes	O
to	O
recruit	O
them	O
during	O
transcription	O
and	O
mediates	O
phosphorylation	O
at	O
Ser	B-CHEMICAL
-	O
2	O
of	O
the	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
of	O
RNA	B-GENE-N
polymerase	I-GENE-N
II	I-GENE-N
.	O

To	O
understand	O
how	O
these	O
interactions	O
influence	O
downstream	O
events	O
,	O
histone	B-GENE-N
H3K36me3	I-GENE-N
was	O
examined	O
,	O
and	O
we	O
demonstrate	O
that	O
CBCΔ	B-GENE-N
affects	O
proper	O
Set2	B-GENE-Y
-	O
dependent	O
H3K36me3	B-GENE-N
.	O

Consistent	O
with	O
this	O
,	O
the	O
CBC	B-GENE-N
and	O
Set2	B-GENE-Y
have	O
similar	O
effects	O
on	O
the	O
ability	O
to	O
rapidly	O
induce	O
and	O
sustain	O
activated	O
gene	O
expression	O
,	O
and	O
these	O
effects	O
are	O
distinct	O
from	O
other	O
histone	B-GENE-N
methyltransferases	O
.	O

This	O
work	O
provides	O
evidence	O
for	O
an	O
emerging	O
model	O
that	O
RNA	O
processing	O
factors	O
can	O
modulate	O
the	O
recruitment	O
of	O
transcription	O
factors	O
and	O
influence	O
histone	B-GENE-N
modification	O
during	O
elongation	O
.	O

Peptidyl	B-GENE-Y
-	I-GENE-Y
prolyl	I-GENE-Y
cis	I-GENE-Y
/	I-GENE-Y
trans	I-GENE-Y
-	I-GENE-Y
isomerase	I-GENE-Y
A1	I-GENE-Y
(	O
Pin1	B-GENE-Y
)	O
is	O
a	O
target	O
for	O
modification	O
by	O
lipid	O
electrophiles	O
.	O

Oxidation	O
of	O
membrane	O
phospholipids	O
is	O
associated	O
with	O
inflammation	O
,	O
neurodegenerative	O
disease	O
,	O
and	O
cancer	O
.	O

Oxyradical	O
damage	O
to	O
phospholipids	O
results	O
in	O
the	O
production	O
of	O
reactive	O
aldehydes	B-CHEMICAL
that	O
adduct	O
proteins	O
and	O
modulate	O
their	O
function	O
.	O

4	B-CHEMICAL
-	I-CHEMICAL
Hydroxynonenal	I-CHEMICAL
(	O
HNE	B-CHEMICAL
)	O
,	O
a	O
common	O
product	O
of	O
oxidative	O
damage	O
to	O
lipids	O
,	O
adducts	O
proteins	O
at	O
exposed	O
Cys	B-CHEMICAL
,	O
His	B-CHEMICAL
,	O
or	O
Lys	B-CHEMICAL
residues	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
peptidyl	B-GENE-Y
-	I-GENE-Y
prolyl	I-GENE-Y
cis	I-GENE-Y
/	I-GENE-Y
trans	I-GENE-Y
-	I-GENE-Y
isomerase	I-GENE-Y
A1	I-GENE-Y
(	O
Pin1	B-GENE-Y
)	O
,	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
conversion	O
of	O
the	O
peptide	O
bond	O
of	O
pSer	B-CHEMICAL
/	O
pThr	B-CHEMICAL
-	O
Pro	B-CHEMICAL
moieties	O
in	O
signaling	O
proteins	O
from	O
cis	O
to	O
trans	O
,	O
is	O
highly	O
susceptible	O
to	O
HNE	B-CHEMICAL
modification	O
.	O

Incubation	O
of	O
purified	O
Pin1	B-GENE-Y
with	O
HNE	B-CHEMICAL
followed	O
by	O
MALDI	O
-	O
TOF	O
/	O
TOF	O
mass	O
spectrometry	O
resulted	O
in	O
detection	O
of	O
Michael	O
adducts	O
at	O
the	O
active	O
site	O
residues	O
His	B-CHEMICAL
-	O
157	O
and	O
Cys	B-CHEMICAL
-	O
113	O
.	O

Time	O
and	O
concentration	O
dependencies	O
indicate	O
that	O
Cys	B-CHEMICAL
-	O
113	O
is	O
the	O
primary	O
site	O
of	O
HNE	B-CHEMICAL
modification	O
.	O

Pin1	B-GENE-Y
was	O
adducted	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
treated	O
with	O
8	B-CHEMICAL
-	I-CHEMICAL
alkynyl	I-CHEMICAL
-	I-CHEMICAL
HNE	I-CHEMICAL
as	O
judged	O
by	O
click	O
chemistry	O
conjugation	O
with	O
biotin	B-CHEMICAL
followed	O
by	O
streptavidin	O
-	O
based	O
pulldown	O
and	O
Western	O
blotting	O
with	O
anti	O
-	O
Pin1	B-GENE-Y
antibody	O
.	O

Furthermore	O
,	O
orbitrap	O
MS	O
data	O
support	O
the	O
adduction	O
of	O
Cys	B-CHEMICAL
-	O
113	O
in	O
the	O
Pin1	B-GENE-Y
active	O
site	O
upon	O
HNE	B-CHEMICAL
treatment	O
of	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

siRNA	O
knockdown	O
of	O
Pin1	B-GENE-Y
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
partially	O
protected	O
the	O
cells	O
from	O
HNE	B-CHEMICAL
-	O
induced	O
toxicity	O
.	O

Recent	O
studies	O
indicate	O
that	O
Pin1	B-GENE-Y
is	O
an	O
important	O
molecular	O
target	O
for	O
the	O
chemopreventive	O
effects	O
of	O
green	O
tea	O
polyphenols	B-CHEMICAL
.	O

The	O
present	O
study	O
establishes	O
that	O
it	O
is	O
also	O
a	O
target	O
for	O
electrophilic	O
modification	O
by	O
products	O
of	O
lipid	O
peroxidation	O
.	O

Aberrant	O
transcription	O
of	O
the	O
LHCGR	B-GENE-Y
gene	O
caused	O
by	O
a	O
mutation	O
in	O
exon	O
6A	O
leads	O
to	O
Leydig	O
cell	O
hypoplasia	O
type	O
II	O
.	O

The	O
luteinizing	B-GENE-Y
hormone	I-GENE-Y
/	I-GENE-Y
chorionic	I-GENE-Y
gonadotropin	I-GENE-Y
receptor	I-GENE-Y
(	O
LHCGR	B-GENE-Y
)	O
is	O
essential	O
for	O
normal	O
male	O
sex	O
differentiation	O
.	O

Recently	O
,	O
the	O
additional	O
primate	O
-	O
specific	O
exon	O
6A	O
of	O
the	O
LHCGR	B-GENE-Y
was	O
discovered	O
and	O
it	O
was	O
shown	O
to	O
act	O
as	O
regulatory	O
element	O
at	O
the	O
transcriptional	O
level	O
.	O

Compound	O
heterozygous	O
mutations	O
in	O
exon	O
6A	O
(	O
c	B-GENE-N
.	I-GENE-N
580	I-GENE-N
A	I-GENE-N
>	I-GENE-N
G	I-GENE-N
)	O
and	O
exon	O
11	O
(	O
c	B-GENE-N
.	I-GENE-N
1244T	I-GENE-N
>	I-GENE-N
C	I-GENE-N
)	O
were	O
identified	O
in	O
the	O
LHCGR	B-GENE-Y
of	O
a	O
male	O
46	O
,	O
XY	O
patient	O
with	O
genital	O
malformation	O
.	O

Analysis	O
revealed	O
that	O
mutation	O
c	B-GENE-N
.	I-GENE-N
580A	I-GENE-N
>	I-GENE-N
G	I-GENE-N
in	O
exon	O
6A	O
affects	O
the	O
splicing	O
pattern	O
resulting	O
in	O
an	O
increase	O
of	O
transcripts	O
containing	O
the	O
internal	O
variants	O
of	O
exon	O
6A	O
prone	O
to	O
nonsense	O
-	O
mediated	O
decay	O
.	O

In	O
contrast	O
,	O
mutation	O
c	B-GENE-N
.	I-GENE-N
1244T	I-GENE-N
>	I-GENE-N
C	I-GENE-N
results	O
in	O
an	O
amino	B-CHEMICAL
acid	I-CHEMICAL
substitution	O
(	O
Ile415Thr	B-GENE-N
)	O
,	O
which	O
abolishes	O
signal	O
transduction	O
due	O
to	O
structural	O
changes	O
.	O

When	O
inherited	O
in	O
a	O
compound	O
heterozygous	O
fashion	O
these	O
mutations	O
result	O
in	O
Leydig	O
cell	O
hypoplasia	O
(	O
LCH	O
)	O
type	O
II	O
.	O

Thus	O
this	O
study	O
provides	O
proof	O
that	O
mutations	O
causing	O
aberrant	O
transcription	O
can	O
impair	O
receptor	O
function	O
and	O
thereby	O
be	O
causative	O
of	O
LCH	O
.	O

Age	O
dependent	O
differences	O
in	O
the	O
regulation	O
of	O
hippocampal	O
steroid	B-CHEMICAL
hormones	O
and	O
receptor	O
genes	O
:	O
relations	O
to	O
motivation	O
and	O
cognition	O
in	O
male	O
rats	O
.	O

Estrogen	B-CHEMICAL
and	O
estrogenic	O
functions	O
are	O
age	O
-	O
dependently	O
involved	O
in	O
the	O
modulation	O
of	O
learning	O
,	O
memory	O
and	O
mood	O
in	O
female	O
humans	O
and	O
animals	O
.	O

However	O
,	O
the	O
investigation	O
of	O
estrogenic	O
effects	O
in	O
males	O
has	O
been	O
largely	O
neglected	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
hippocampal	O
gene	O
expression	O
of	O
estrogen	B-GENE-N
receptors	I-GENE-N
α	I-GENE-N
and	I-GENE-N
β	I-GENE-N
(	O
ERα	B-GENE-N
,	I-GENE-N
β	I-GENE-N
)	O
in	O
8	O
-	O
week	O
-	O
old	O
,	O
12	O
-	O
week	O
-	O
old	O
and	O
24	O
-	O
week	O
-	O
old	O
male	O
rats	O
.	O

To	O
control	O
for	O
possible	O
interactions	O
between	O
the	O
expression	O
of	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
genes	O
and	O
other	O
learning	O
-	O
related	O
steroid	B-GENE-N
receptors	I-GENE-N
,	O
androgen	B-GENE-Y
receptors	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
,	O
corticosterone	B-CHEMICAL
-	O
binding	O
glucocorticoid	B-GENE-Y
receptors	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
and	O
mineralocorticoid	B-GENE-Y
receptors	I-GENE-Y
(	O
MR	B-GENE-Y
)	O
were	O
also	O
measured	O
.	O

Furthermore	O
,	O
the	O
concentrations	O
of	O
the	O
ligands	O
17β	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
,	O
testosterone	B-CHEMICAL
and	O
corticosterone	B-CHEMICAL
were	O
measured	O
.	O

The	O
spatial	O
training	O
was	O
conducted	O
in	O
a	O
hole	O
-	O
board	O
.	O

The	O
8	O
-	O
week	O
-	O
old	O
rats	O
exhibited	O
higher	O
levels	O
of	O
general	O
activity	O
and	O
exploration	O
during	O
the	O
training	O
and	O
performed	O
best	O
with	O
respect	O
to	O
spatial	O
learning	O
and	O
memory	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
between	O
the	O
12	O
-	O
week	O
-	O
old	O
and	O
24	O
-	O
week	O
-	O
old	O
rats	O
.	O

The	O
trained	O
8	O
-	O
week	O
-	O
old	O
rats	O
exhibited	O
increased	O
gene	O
expression	O
of	O
ERα	B-GENE-Y
compared	O
with	O
the	O
untrained	O
rats	O
in	O
this	O
age	O
group	O
as	O
well	O
as	O
the	O
trained	O
12	O
-	O
week	O
-	O
old	O
and	O
24	O
-	O
week	O
-	O
old	O
rats	O
.	O

The	O
concentrations	O
of	O
estradiol	B-CHEMICAL
and	O
testosterone	B-CHEMICAL
,	O
however	O
,	O
were	O
generally	O
higher	O
in	O
the	O
24	O
-	O
week	O
-	O
old	O
rats	O
than	O
in	O
the	O
8	O
-	O
week	O
-	O
old	O
and	O
12	O
-	O
week	O
-	O
old	O
rats	O
.	O

The	O
ERα	B-GENE-Y
mRNA	O
concentrations	O
correlated	O
positively	O
with	O
behavior	O
that	O
indicate	O
general	O
learning	O
motivation	O
.	O

These	O
results	O
suggest	O
a	O
specific	O
role	O
of	O
ERα	B-GENE-Y
in	O
the	O
age	O
-	O
related	O
differences	O
in	O
motivation	O
and	O
subsequent	O
success	O
in	O
the	O
task	O
.	O

Thus	O
,	O
estrogen	B-CHEMICAL
and	O
estrogenic	O
functions	O
may	O
play	O
a	O
more	O
prominent	O
role	O
in	O
young	O
male	O
behavior	O
and	O
development	O
than	O
has	O
been	O
previously	O
assumed	O
.	O

Acute	O
Macrovascular	O
Dysfunction	O
in	O
Patients	O
With	O
Type	O
2	O
Diabetes	O
Induced	O
by	O
Ingestion	O
of	O
Advanced	O
Glycated	B-GENE-N
β	I-GENE-N
-	I-GENE-N
Lactoglobulins	I-GENE-N
.	O

OBJECTIVE	O
Recent	O
evidence	O
indicates	O
that	O
heat	O
-	O
enhanced	O
food	O
advanced	O
glycation	O
end	O
products	O
(	O
AGEs	O
)	O
adversely	O
affect	O
vascular	O
function	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
acute	O
effects	O
of	O
an	O
oral	O
load	O
of	O
heat	O
-	O
treated	O
,	O
AGE	O
-	O
modified	O
β	B-GENE-N
-	I-GENE-N
lactoglobulins	I-GENE-N
(	O
AGE	O
-	O
BLG	B-GENE-N
)	O
compared	O
with	O
heat	O
-	O
treated	O
,	O
nonglycated	B-GENE-N
BLG	I-GENE-N
(	O
C	B-GENE-N
-	I-GENE-N
BLG	I-GENE-N
)	O
on	O
vascular	O
function	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
a	O
double	O
-	O
blind	O
,	O
controlled	O
,	O
randomized	O
,	O
crossover	O
study	O
,	O
19	O
patients	O
with	O
T2DM	O
received	O
,	O
on	O
two	O
different	O
occasions	O
,	O
beverages	O
containing	O
either	O
AGE	O
-	O
BLG	B-GENE-N
or	O
C	B-GENE-N
-	I-GENE-N
BLG	I-GENE-N
.	O

We	O
measured	O
macrovascular	O
[	O
brachial	O
ultrasound	O
of	O
flow	O
-	O
mediated	O
dilatation	O
(	O
FMD	O
)	O
]	O
and	O
microvascular	O
(	O
laser	O
-	O
Doppler	O
measurements	O
of	O
reactive	O
hyperemia	O
in	O
the	O
hand	O
)	O
functions	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
90	O
(	O
T90	O
)	O
,	O
and	O
180	O
(	O
T180	O
)	O
min	O
.	O

RESULTS	O
Following	O
the	O
AGE	O
-	O
BLG	B-GENE-N
,	O
FMD	O
decreased	O
at	O
T90	O
by	O
80	O
%	O
from	O
baseline	O
and	O
remained	O
decreased	O
by	O
42	O
%	O
at	O
T180	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
baseline	O
,	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
C	B-GENE-N
-	I-GENE-N
BLG	I-GENE-N
at	O
T90	O
)	O
.	O

By	O
comparison	O
,	O
following	O
C	B-GENE-N
-	I-GENE-N
BLG	I-GENE-N
,	O
FMD	O
decreased	O
by	O
27	O
%	O
at	O
T90	O
and	O
51	O
%	O
at	O
T180	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
baseline	O
at	O
T180	O
)	O
.	O

A	O
significant	O
decrease	O
in	O
nitrite	B-CHEMICAL
(	O
T180	O
)	O
and	O
nitrate	B-CHEMICAL
(	O
T90	O
and	O
T180	O
)	O
,	O
as	O
well	O
as	O
a	O
significant	O
increase	O
in	O
N	B-CHEMICAL
(	I-CHEMICAL
ε	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
carboxymethyllisine	I-CHEMICAL
,	O
accompanied	O
intake	O
of	O
AGE	O
-	O
BLG	B-GENE-N
.	O

There	O
was	O
no	O
change	O
in	O
microvascular	O
function	O
caused	O
by	O
either	O
beverage	O
.	O

CONCLUSIONS	O
In	O
patients	O
with	O
T2DM	O
,	O
acute	O
oral	O
administration	O
of	O
a	O
single	O
AGE	O
-	O
modified	O
protein	O
class	O
significantly	O
though	O
transiently	O
impaired	O
macrovascular	O
function	O
in	O
concert	O
with	O
decreased	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
bioavailability	O
.	O

These	O
AGE	O
-	O
related	O
changes	O
were	O
independent	O
of	O
heat	O
treatment	O
.	O

The	O
influence	O
of	O
sex	O
,	O
ethnicity	O
,	O
and	O
CYP2B6	B-GENE-Y
genotype	O
on	O
bupropion	B-CHEMICAL
metabolism	O
as	O
an	O
index	O
of	O
hepatic	O
CYP2B6	B-GENE-Y
activity	O
in	O
humans	O
.	O

The	O
effects	O
of	O
sex	O
,	O
ethnicity	O
,	O
and	O
genetic	O
polymorphism	O
on	O
hepatic	O
CYP2B6	B-GENE-Y
(	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
2B6	I-GENE-Y
)	O
expression	O
and	O
activity	O
were	O
previously	O
demonstrated	O
in	O
vitro	O
.	O

Race	O
/	O
ethnic	O
differences	O
in	O
CYP2B6	B-GENE-Y
genotype	O
and	O
phenotype	O
were	O
observed	O
only	O
in	O
women	O
.	O

To	O
identify	O
important	O
covariates	O
associated	O
with	O
interindividual	O
variation	O
in	O
CYP2B6	B-GENE-Y
activity	O
in	O
vivo	O
,	O
we	O
evaluated	O
these	O
effects	O
in	O
healthy	O
volunteers	O
using	O
bupropion	B-CHEMICAL
(	O
Wellbutrin	B-CHEMICAL
SR	I-CHEMICAL
GlaxoSmithKline	O
,	O
Research	O
Triangle	O
Park	O
,	O
NC	O
)	O
as	O
a	O
CYP2B6	B-GENE-Y
probe	O
substrate	O
.	O

A	O
fixed	O
150	O
-	O
mg	O
oral	O
sustained	O
-	O
release	O
dose	O
of	O
bupropion	B-CHEMICAL
was	O
administered	O
to	O
100	O
healthy	O
volunteers	O
comprising	O
four	O
sex	O
/	O
ethnicity	O
cohorts	O
(	O
n	O
=	O
25	O
each	O
)	O
:	O
Caucasian	O
men	O
and	O
Caucasian	O
,	O
African	O
American	O
,	O
and	O
Hispanic	O
women	O
.	O

Blood	O
samples	O
were	O
obtained	O
at	O
0	O
and	O
6	O
hours	O
postdose	O
for	O
the	O
measurement	O
of	O
serum	O
bupropion	B-CHEMICAL
(	O
BU	O
)	O
and	O
hydroxybupropion	B-CHEMICAL
(	O
HB	O
)	O
concentrations	O
.	O

Whole	O
blood	O
was	O
obtained	O
at	O
baseline	O
for	O
CYP2B6	B-GENE-Y
genotyping	O
.	O

To	O
characterize	O
the	O
relationship	O
between	O
CYP2B6	B-GENE-Y
activity	O
and	O
ethnicity	O
,	O
sex	O
,	O
and	O
genotype	O
when	O
accounting	O
for	O
serum	O
BU	O
concentrations	O
(	O
dose	O
-	O
adjusted	O
log	O
(	O
10	O
)	O
-	O
transformed	O
)	O
,	O
analysis	O
of	O
covariance	O
model	O
was	O
fitted	O
in	O
which	O
the	O
dependent	O
variable	O
was	O
CYP2B6	B-GENE-Y
activity	O
represented	O
as	O
the	O
log	O
(	O
10	O
)	O
-	O
transformed	O
,	O
metabolic	O
ratio	O
of	O
HB	O
to	O
BU	O
concentrations	O
.	O

Several	O
CYP2B6	B-GENE-Y
polymorphisms	O
were	O
associated	O
with	O
CYP2B6	B-GENE-Y
activity	O
.	O

Evidence	O
of	O
dependence	O
of	O
CYP2B6	B-GENE-Y
activity	O
on	O
ethnicity	O
or	O
genotype	O
-	O
by	O
-	O
ethnicity	O
interactions	O
was	O
not	O
detected	O
in	O
women	O
.	O

These	O
results	O
suggest	O
that	O
CYP2B6	B-GENE-Y
genotype	O
is	O
the	O
most	O
important	O
patient	O
variable	O
for	O
predicting	O
the	O
level	O
of	O
CYP2B6	B-GENE-Y
activity	O
in	O
women	O
,	O
when	O
measured	O
by	O
the	O
metabolism	O
of	O
bupropion	B-CHEMICAL
.	O

The	O
bupropion	B-CHEMICAL
metabolic	O
ratio	O
appears	O
to	O
detect	O
known	O
differences	O
in	O
CYP2B6	B-GENE-Y
activity	O
associated	O
with	O
genetic	O
polymorphism	O
,	O
across	O
different	O
ethnic	O
groups	O
.	O

Prospective	O
studies	O
will	O
be	O
needed	O
to	O
validate	O
the	O
use	O
of	O
bupropion	B-CHEMICAL
as	O
a	O
probe	O
substrate	O
for	O
clinical	O
use	O
.	O

Phase	O
1	O
and	O
phase	O
2	O
drug	O
metabolism	O
and	O
bile	B-CHEMICAL
acid	I-CHEMICAL
production	O
of	O
HepaRG	O
cells	O
in	O
a	O
bioartificial	O
liver	O
in	O
absence	O
of	O
dimethyl	B-CHEMICAL
sulfoxide	I-CHEMICAL
.	O

The	O
human	O
liver	O
cell	O
line	O
HepaRG	O
has	O
been	O
recognized	O
as	O
a	O
promising	O
source	O
for	O
in	O
vitro	O
testing	O
of	O
metabolism	O
and	O
toxicity	O
of	O
compounds	O
.	O

However	O
,	O
currently	O
the	O
hepatic	O
differentiation	O
of	O
these	O
cells	O
relies	O
on	O
exposure	O
to	O
dimethylsulfoxide	B-CHEMICAL
(	O
DMSO	B-CHEMICAL
)	O
,	O
which	O
,	O
as	O
a	O
side	O
effect	O
,	O
has	O
a	O
cytotoxic	O
effect	O
and	O
represses	O
an	O
all	O
-	O
round	O
hepatic	O
functionality	O
.	O

The	O
AMC	O
-	O
bioartificial	O
liver	O
(	O
AMC	O
-	O
BAL	O
)	O
is	O
a	O
three	O
-	O
dimensional	O
bioreactor	O
that	O
has	O
previously	O
been	O
shown	O
to	O
upregulate	O
various	O
liver	O
functions	O
of	O
cultured	O
cells	O
.	O

We	O
therefore	O
cultured	O
HepaRG	O
cells	O
in	O
the	O
AMC	O
-	O
BAL	O
without	O
DMSO	B-CHEMICAL
and	O
characterized	O
the	O
drug	O
metabolism	O
.	O

Within	O
14	O
days	O
of	O
culture	O
,	O
the	O
HepaRG	O
-	O
AMC	O
-	O
BALs	O
contained	O
highly	O
polarized	O
viable	O
liver	O
-	O
like	O
tissue	O
with	O
heterogeneous	O
expression	O
of	O
CYP3A4	B-GENE-Y
.	O

We	O
found	O
a	O
substantial	O
metabolism	O
of	O
the	O
tested	O
substrates	O
,	O
ranging	O
from	O
26	O
%	O
(	O
UDP	B-GENE-Y
-	I-GENE-Y
glucuronosyltransferase	I-GENE-Y
1A1	I-GENE-Y
)	O
,	O
47	O
%	O
(	O
CYP3A4	B-GENE-Y
)	O
,	O
to	O
240	O
%	O
(	O
CYP2C9	B-GENE-Y
)	O
of	O
primary	O
human	O
hepatocytes	O
.	O

The	O
CYP3A4	B-GENE-Y
activity	O
could	O
be	O
induced	O
2	O
-	O
fold	O
by	O
rifampicin	B-CHEMICAL
,	O
whereas	O
CYP2C9	B-GENE-Y
activity	O
remained	O
equally	O
high	O
.	O

The	O
HepaRG	O
-	O
AMC	O
-	O
BAL	O
secreted	O
bile	B-CHEMICAL
acids	I-CHEMICAL
at	O
43	O
%	O
the	O
rate	O
of	O
primary	O
human	O
hepatocytes	O
and	O
demonstrated	O
hydroxylation	O
,	O
conjugation	O
,	O
and	O
transport	O
of	O
bile	B-CHEMICAL
salts	I-CHEMICAL
.	O

Concluding	O
,	O
culturing	O
HepaRG	O
cells	O
in	O
the	O
AMC	O
-	O
BAL	O
yields	O
substantial	O
phase	O
1	O
and	O
phase	O
2	O
drug	O
metabolism	O
,	O
while	O
maintaining	O
high	O
viability	O
,	O
rendering	O
DMSO	B-CHEMICAL
addition	O
superfluous	O
for	O
the	O
promotion	O
of	O
drug	O
metabolism	O
.	O

Therefore	O
,	O
AMC	O
-	O
BAL	O
culturing	O
makes	O
the	O
HepaRG	O
cells	O
more	O
suitable	O
for	O
testing	O
metabolism	O
and	O
toxicity	O
of	O
drugs	O
.	O

Differentiation	O
of	O
opioid	O
drug	O
effects	O
by	O
hierarchical	O
multi	O
-	O
site	O
phosphorylation	O
.	O

Differences	O
in	O
the	O
ability	O
of	O
opioid	O
drugs	O
to	O
promote	O
regulated	O
endocytosis	O
of	O
μ	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptors	I-GENE-Y
are	O
related	O
to	O
their	O
tendency	O
to	O
produce	O
drug	O
tolerance	O
and	O
dependence	O
.	O

Here	O
we	O
show	O
that	O
drug	O
-	O
specific	O
differences	O
in	O
receptor	O
internalization	O
are	O
determined	O
by	O
a	O
conserved	O
,	O
10	O
-	O
residue	O
sequence	O
in	O
the	O
receptor	O
'	O
s	O
carboxyl	B-GENE-N
-	I-GENE-N
terminal	I-GENE-N
cytoplasmic	I-GENE-N
tail	I-GENE-N
.	O

Diverse	O
opioids	O
induce	O
receptor	O
phosphorylation	O
at	O
serine	B-CHEMICAL
(	O
S	O
)	O
375	O
,	O
present	O
in	O
the	O
middle	O
of	O
this	O
sequence	O
,	O
but	O
opioids	O
differ	O
markedly	O
in	O
their	O
ability	O
to	O
drive	O
higher	O
-	O
order	O
phosphorylation	O
on	O
flanking	O
residues	O
[	O
threonine	B-CHEMICAL
(	O
T	O
)	O
370	O
,	O
T376	O
,	O
and	O
T379	O
]	O
.	O

Multi	O
-	O
phosphorylation	O
is	O
required	O
for	O
the	O
endocytosis	O
-	O
promoting	O
activity	O
of	O
this	O
sequence	O
and	O
occurs	O
both	O
sequentially	O
and	O
hierarchically	O
,	O
with	O
S375	O
representing	O
the	O
initiating	O
site	O
.	O

Higher	O
-	O
order	O
phosphorylation	O
involving	O
T370	O
,	O
T376	O
,	O
and	O
T379	O
specifically	O
requires	O
GRK2	B-GENE-N
/	I-GENE-N
3	I-GENE-N
isoforms	O
,	O
and	O
the	O
same	O
sequence	O
controls	O
opioid	B-GENE-N
receptor	I-GENE-N
internalization	O
in	O
neurons	O
.	O

These	O
results	O
reveal	O
a	O
biochemical	O
mechanism	O
differentiating	O
the	O
endocytic	O
activity	O
of	O
opioid	O
drugs	O
.	O

Influence	O
of	O
developmental	O
lead	O
exposure	O
on	O
expression	O
of	O
DNA	B-GENE-N
methyltransferases	I-GENE-N
and	O
methyl	B-GENE-N
cytosine	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
in	O
hippocampus	O
.	O

Developmental	O
exposure	O
to	O
lead	O
(	O
Pb	B-CHEMICAL
)	O
has	O
adverse	O
effects	O
on	O
cognitive	O
functioning	O
and	O
behavior	O
that	O
can	O
persist	O
into	O
adulthood	O
.	O

Exposures	O
that	O
occur	O
during	O
fetal	O
or	O
early	O
life	O
periods	O
may	O
produce	O
changes	O
in	O
brain	O
related	O
to	O
physiological	O
re	O
-	O
programming	O
from	O
an	O
epigenetic	O
influence	O
such	O
as	O
altered	O
DNA	O
methylation	O
status	O
.	O

Since	O
DNA	O
methylation	O
is	O
regulated	O
by	O
DNA	B-GENE-N
methyltransferases	I-GENE-N
and	O
methyl	B-GENE-N
cytosine	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
,	O
this	O
study	O
assessed	O
the	O
extent	O
to	O
which	O
developmental	O
Pb	B-CHEMICAL
exposure	O
might	O
affect	O
expression	O
of	O
these	O
proteins	O
in	O
the	O
hippocampus	O
.	O

Long	O
Evans	O
dams	O
were	O
fed	O
chow	O
with	O
or	O
without	O
added	O
Pb	B-CHEMICAL
acetate	I-CHEMICAL
(	O
0	O
,	O
150	O
,	O
375	O
,	O
750	O
ppm	O
)	O
prior	O
to	O
breeding	O
and	O
remained	O
on	O
the	O
same	O
diet	O
through	O
weaning	O
(	O
perinatal	O
exposure	O
group	O
)	O
.	O

Other	O
animals	O
were	O
exposed	O
to	O
the	O
same	O
doses	O
of	O
Pb	B-CHEMICAL
but	O
exposure	O
started	O
on	O
postnatal	O
day	O
1	O
and	O
continued	O
through	O
weaning	O
(	O
early	O
postnatal	O
exposure	O
group	O
)	O
.	O

All	O
animals	O
were	O
euthanized	O
on	O
day	O
55	O
and	O
hippocampi	O
were	O
removed	O
.	O

Western	O
blot	O
analyses	O
showed	O
significant	O
effects	O
of	O
Pb	B-CHEMICAL
exposure	O
on	O
DNMT1	B-GENE-Y
,	O
DNMT3a	B-GENE-Y
,	O
and	O
MeCP2	B-GENE-Y
expression	O
,	O
with	O
effects	O
often	O
seen	O
at	O
the	O
lowest	O
level	O
of	O
exposure	O
and	O
modified	O
by	O
sex	O
and	O
developmental	O
window	O
of	O
Pb	B-CHEMICAL
exposure	O
.	O

These	O
data	O
suggest	O
potential	O
epigenetic	O
effects	O
of	O
developmental	O
Pb	B-CHEMICAL
exposure	O
on	O
DNA	O
methylation	O
mediated	O
at	O
least	O
in	O
part	O
through	O
dysregulation	O
of	O
methyltransferases	B-GENE-N
.	O

Comparative	O
genomics	O
,	O
molecular	O
evolution	O
and	O
computational	O
modeling	O
of	O
ALDH1B1	B-GENE-Y
and	O
ALDH2	B-GENE-Y
.	O

Vertebrate	B-GENE-Y
ALDH2	I-GENE-Y
genes	O
encode	O
mitochondrial	O
enzymes	O
capable	O
of	O
metabolizing	O
acetaldehyde	B-CHEMICAL
and	O
other	O
biological	O
aldehydes	B-CHEMICAL
in	O
the	O
body	O
.	O

Mammalian	B-GENE-Y
ALDH1B1	I-GENE-Y
,	O
another	O
mitochondrial	O
enzyme	O
sharing	O
72	O
%	O
identity	O
with	O
ALDH2	B-GENE-Y
,	O
is	O
also	O
capable	O
of	O
metabolizing	O
acetaldehyde	B-CHEMICAL
but	O
has	O
a	O
tissue	O
distribution	O
and	O
pattern	O
of	O
activity	O
distinct	O
from	O
that	O
of	O
ALDH2	B-GENE-Y
.	O

Bioinformatic	O
analyses	O
of	O
several	O
vertebrate	O
genomes	O
were	O
undertaken	O
using	O
known	O
ALDH2	B-GENE-Y
and	O
ALDH1B1	B-GENE-Y
amino	B-CHEMICAL
acid	I-CHEMICAL
sequences	O
.	O

Phylogenetic	O
analysis	O
of	O
many	O
representative	O
vertebrate	O
species	O
(	O
including	O
fish	O
,	O
amphibians	O
,	O
birds	O
and	O
mammals	O
)	O
indicated	O
the	O
presence	O
of	O
ALDH1B1	B-GENE-Y
in	O
many	O
mammalian	O
species	O
and	O
in	O
frogs	O
(	O
Xenopus	O
tropicalis	O
)	O
;	O
no	O
evidence	O
was	O
found	O
for	O
ALDH1B1	B-GENE-Y
in	O
the	O
genomes	O
of	O
birds	O
,	O
reptiles	O
or	O
fish	O
.	O

Predicted	O
vertebrate	B-GENE-Y
ALDH2	I-GENE-Y
and	O
ALDH1B1	B-GENE-Y
subunit	O
sequences	O
and	O
structures	O
were	O
highly	O
conserved	O
,	O
including	O
residues	O
previously	O
shown	O
to	O
be	O
involved	O
in	O
catalysis	O
and	O
coenzyme	O
binding	O
for	O
human	B-GENE-Y
ALDH2	I-GENE-Y
.	O

Studies	O
of	O
ALDH1B1	B-GENE-Y
sequences	O
supported	O
the	O
hypothesis	O
that	O
the	O
ALDH1B1	B-GENE-N
gene	O
originated	O
in	O
early	O
vertebrates	O
from	O
a	O
retrotransposition	O
of	O
the	O
vertebrate	O
ALDH2	B-GENE-Y
gene	O
.	O

Given	O
the	O
high	O
degree	O
of	O
similarity	O
between	O
ALDH2	B-GENE-Y
and	O
ALDH1B1	B-GENE-Y
,	O
it	O
is	O
surprising	O
that	O
individuals	O
with	O
an	O
inactivating	O
mutation	O
in	O
ALDH2	B-GENE-Y
(	O
ALDH2	B-GENE-Y
*	O
2	O
)	O
do	O
not	O
exhibit	O
a	O
compensatory	O
increase	O
in	O
ALDH1B1	B-GENE-Y
activity	O
.	O

We	O
hypothesized	O
that	O
the	O
similarity	O
between	O
the	O
two	O
ALDHs	B-GENE-N
would	O
allow	O
for	O
dominant	O
negative	O
heterotetramerization	O
between	O
the	O
inactive	O
ALDH2	B-GENE-Y
mutants	O
and	O
ALDH1B1	B-GENE-Y
.	O

Computational	O
-	O
based	O
molecular	O
modeling	O
studies	O
examining	O
predicted	O
protein	O
-	O
protein	O
interactions	O
indicated	O
that	O
heterotetramerization	O
between	O
ALDH2	B-GENE-Y
and	O
ALDH1B1	B-GENE-Y
subunits	O
was	O
highly	O
probable	O
and	O
may	O
partially	O
explain	O
a	O
lack	O
of	O
compensation	O
by	O
ALDH1B1	B-GENE-Y
in	O
ALDH2	B-GENE-Y
(	O
∗	O
)	O
2	O
individuals	O
.	O

Beta	B-CHEMICAL
-	I-CHEMICAL
glucogallin	I-CHEMICAL
reduces	O
the	O
expression	O
of	O
lipopolysaccharide	O
-	O
induced	O
inflammatory	O
markers	O
by	O
inhibition	O
of	O
aldose	B-GENE-Y
reductase	I-GENE-Y
in	O
murine	O
macrophages	O
and	O
ocular	O
tissues	O
.	O

Aldose	B-GENE-Y
reductase	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
catalyzes	O
the	O
reduction	O
of	O
toxic	O
lipid	O
aldehydes	B-CHEMICAL
to	O
their	O
alcohol	B-CHEMICAL
products	O
and	O
mediates	O
inflammatory	O
signals	O
triggered	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Beta	B-CHEMICAL
-	I-CHEMICAL
glucogallin	I-CHEMICAL
(	O
BGG	B-CHEMICAL
)	O
,	O
a	O
recently	O
described	O
AR	B-GENE-Y
inhibitor	O
,	O
was	O
purified	O
from	O
extracts	O
of	O
the	O
Indian	O
gooseberry	O
(	O
Emblica	O
officinalis	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
BGG	B-CHEMICAL
showed	O
low	O
cytotoxicity	O
in	O
Raw264	O
.	O
7	O
murine	O
macrophages	O
and	O
effectively	O
inhibited	O
AR	B-GENE-Y
activity	O
as	O
measured	O
by	O
a	O
decrease	O
in	O
sorbitol	B-CHEMICAL
accumulation	O
.	O

In	O
addition	O
,	O
BGG	B-CHEMICAL
-	O
mediated	O
inhibition	O
of	O
AR	B-GENE-Y
prevented	O
LPS	O
-	O
induced	O
activation	O
of	O
JNK	B-GENE-N
and	O
p38	B-GENE-N
and	O
lowered	O
ROS	O
levels	O
,	O
which	O
could	O
inhibit	O
LPS	O
-	O
induced	O
apoptosis	O
.	O

Uveitis	O
is	O
a	O
disease	O
of	O
the	O
eye	O
associated	O
with	O
chronic	O
inflammation	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
demonstrated	O
that	O
treatment	O
with	O
BGG	B-CHEMICAL
decreased	O
the	O
number	O
of	O
inflammatory	O
cells	O
that	O
infiltrate	O
the	O
ocular	O
media	O
of	O
mice	O
with	O
experimental	O
uveitis	O
.	O

Accordingly	O
,	O
these	O
results	O
suggest	O
BGG	B-CHEMICAL
is	O
a	O
potential	O
therapy	O
for	O
inflammatory	O
diseases	O
.	O

Mechanisms	O
limiting	O
distribution	O
of	O
the	O
threonine	B-GENE-Y
-	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
B	I-GENE-Y
-	I-GENE-Y
RaF	I-GENE-Y
(	O
V600E	B-GENE-N
)	O
inhibitor	O
dabrafenib	B-CHEMICAL
to	O
the	O
brain	O
:	O
implications	O
for	O
the	O
treatment	O
of	O
melanoma	O
brain	O
metastases	O
.	O

Brain	O
metastases	O
are	O
a	O
common	O
cause	O
of	O
death	O
in	O
stage	O
IV	O
metastatic	O
melanoma	O
.	O

Dabrafenib	O
is	O
a	O
BRAF	B-GENE-Y
(	O
gene	O
encoding	O
serine	B-GENE-Y
/	I-GENE-Y
threonine	I-GENE-Y
-	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
B	I-GENE-Y
-	I-GENE-Y
Raf	I-GENE-Y
)	O
inhibitor	O
that	O
has	O
been	O
developed	O
to	O
selectively	O
target	O
the	O
valine	B-GENE-N
600	I-GENE-N
to	I-GENE-N
glutamic	I-GENE-N
acid	I-GENE-N
substitution	O
(	O
BRAF	B-GENE-Y
(	O
V600E	B-GENE-N
)	O
)	O
,	O
which	O
is	O
commonly	O
found	O
in	O
metastatic	O
melanoma	O
.	O

Clinical	O
trials	O
with	O
dabrafenib	B-CHEMICAL
have	O
shown	O
encouraging	O
results	O
;	O
however	O
,	O
the	O
central	O
nervous	O
system	O
distribution	O
of	O
dabrafenib	B-CHEMICAL
remains	O
unknown	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
evaluate	O
the	O
brain	O
distribution	O
of	O
dabrafenib	B-CHEMICAL
in	O
mice	O
,	O
and	O
to	O
see	O
whether	O
active	O
efflux	O
by	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
and	O
breast	B-GENE-Y
cancer	I-GENE-Y
resistance	I-GENE-Y
protein	I-GENE-Y
(	O
BCRP	B-GENE-Y
)	O
restricts	O
its	O
delivery	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
.	O

In	O
vitro	O
accumulation	O
studies	O
conducted	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
II	O
cells	O
indicate	O
that	O
dabrafenib	B-CHEMICAL
is	O
an	O
avid	O
substrate	O
for	O
both	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
and	O
BCRP	B-GENE-Y
.	O

Directional	O
flux	O
studies	O
revealed	O
greater	O
transport	O
in	O
the	O
basolateral	O
to	O
apical	O
direction	O
with	O
corrected	O
efflux	O
ratios	O
greater	O
than	O
2	O
for	O
both	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
and	O
Bcrp1	B-GENE-Y
transfected	O
cell	O
lines	O
.	O

In	O
vivo	O
,	O
the	O
ratio	O
of	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
(	O
brain	O
)	O
to	O
AUC	O
(	O
plasma	O
)	O
(	O
K	O
(	O
p	O
)	O
)	O
of	O
dabrafenib	B-CHEMICAL
after	O
an	O
i	O
.	O
v	O
.	O
dose	O
(	O
2	O
.	O
5	O
mg	O
/	O
kg	O
)	O
was	O
0	O
.	O
023	O
,	O
which	O
increased	O
by	O
18	O
-	O
fold	O
in	O
Mdr1	B-GENE-N
a	I-GENE-N
/	I-GENE-N
b	I-GENE-N
(	O
-	O
/	O
-	O
)	O
Bcrp1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
to	O
0	O
.	O
42	O
.	O

Dabrafenib	B-CHEMICAL
plasma	O
exposure	O
was	O
∼	O
2	O
-	O
fold	O
greater	O
in	O
Mdr1	B-GENE-N
a	I-GENE-N
/	I-GENE-N
b	I-GENE-N
(	O
-	O
/	O
-	O
)	O
Bcrp1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
as	O
compared	O
with	O
wild	O
-	O
type	O
with	O
an	O
oral	O
dose	O
(	O
25	O
mg	O
/	O
kg	O
)	O
;	O
however	O
,	O
the	O
brain	O
distribution	O
was	O
increased	O
by	O
~	O
10	O
-	O
fold	O
with	O
a	O
resulting	O
K	O
(	O
p	O
)	O
of	O
0	O
.	O
25	O
.	O

Further	O
,	O
compared	O
with	O
vemurafenib	B-CHEMICAL
,	O
another	O
BRAF	B-GENE-Y
(	O
V600E	B-GENE-N
)	O
inhibitor	O
,	O
dabrafenib	B-CHEMICAL
showed	O
greater	O
brain	O
penetration	O
with	O
a	O
similar	O
dose	O
.	O

In	O
conclusion	O
,	O
the	O
dabrafenib	B-CHEMICAL
brain	O
distribution	O
is	O
limited	O
in	O
an	O
intact	O
BBB	O
model	O
,	O
and	O
the	O
data	O
presented	O
herein	O
may	O
have	O
clinical	O
implications	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
melanoma	O
brain	O
metastases	O
.	O

An	O
engineered	O
human	B-GENE-Y
follistatin	I-GENE-Y
variant	O
:	O
insights	O
into	O
the	O
pharmacokinetic	O
and	O
pharmocodynamic	O
relationships	O
of	O
a	O
novel	O
molecule	O
with	O
broad	O
therapeutic	O
potential	O
.	O

Human	B-GENE-Y
follistatin	I-GENE-Y
is	O
a	O
regulatory	O
glycoprotein	O
with	O
widespread	O
biologic	O
functions	O
,	O
including	O
antiinflammatory	O
activities	O
,	O
wound	O
-	O
healing	O
properties	O
,	O
and	O
muscle	O
-	O
stimulating	O
effects	O
.	O

The	O
role	O
of	O
follistatin	B-GENE-Y
in	O
a	O
wide	O
range	O
of	O
biologic	O
activities	O
shows	O
promise	O
for	O
potential	O
clinical	O
application	O
,	O
which	O
has	O
prompted	O
considerable	O
interest	O
in	O
the	O
investigation	O
of	O
the	O
protein	O
as	O
a	O
potential	O
disease	O
-	O
modifying	O
agent	O
.	O

In	O
spite	O
of	O
this	O
potential	O
,	O
the	O
development	O
of	O
follistatin	B-GENE-Y
as	O
a	O
broad	O
use	O
biotherapeutic	O
has	O
been	O
severely	O
hindered	O
by	O
a	O
poor	O
understanding	O
and	O
characterization	O
of	O
its	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PK	O
/	O
PD	O
)	O
relationships	O
.	O

Therefore	O
,	O
to	O
better	O
define	O
these	O
relationships	O
,	O
we	O
performed	O
in	O
-	O
depth	O
analyses	O
of	O
the	O
PK	O
/	O
PD	O
relationships	O
of	O
native	O
follistatin	B-GENE-Y
-	I-GENE-Y
315	I-GENE-Y
(	O
FST315	B-GENE-Y
)	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
intrinsic	O
PK	O
/	O
PD	O
properties	O
of	O
native	O
FST315	B-GENE-Y
are	O
poorly	O
suited	O
for	O
acting	O
as	O
a	O
parentally	O
administered	O
biotherapeutic	O
with	O
broad	O
systemic	O
effects	O
.	O

Here	O
,	O
we	O
leveraged	O
protein	O
engineering	O
to	O
modify	O
the	O
PK	O
characteristics	O
of	O
the	O
native	O
molecule	O
by	O
fusing	O
FST315	B-GENE-Y
to	O
a	O
murine	B-GENE-N
IgG	I-GENE-N
(	I-GENE-N
1	I-GENE-N
)	I-GENE-N
Fc	I-GENE-N
and	O
removing	O
the	O
intrinsic	O
heparan	O
sulfate	B-CHEMICAL
-	O
binding	O
activity	O
of	O
follistatin	B-GENE-Y
.	O

The	O
engineered	O
variant	O
molecule	O
had	O
~	O
100	O
-	O
and	O
~	O
1600	O
-	O
fold	O
improvements	O
in	O
terminal	O
half	O
-	O
life	O
and	O
exposure	O
,	O
respectively	O
.	O

In	O
contrast	O
to	O
the	O
native	O
FST315	B-GENE-Y
,	O
the	O
variant	O
showed	O
a	O
robust	O
,	O
dose	O
-	O
dependent	O
pharmacological	O
effect	O
when	O
administered	O
subcutaneously	O
on	O
a	O
weekly	O
basis	O
in	O
mouse	O
models	O
of	O
muscle	O
atrophy	O
and	O
degeneration	O
.	O

These	O
studies	O
highlight	O
the	O
underappreciated	O
and	O
critical	O
relationship	O
between	O
optimizing	O
multiple	O
physical	O
and	O
chemical	O
properties	O
of	O
follistatin	B-GENE-Y
on	O
its	O
overall	O
PK	O
/	O
PD	O
profile	O
.	O

Moreover	O
,	O
our	O
findings	O
provide	O
the	O
first	O
documented	O
strategy	O
toward	O
the	O
development	O
of	O
a	O
follistatin	B-GENE-Y
therapeutic	O
with	O
potential	O
use	O
in	O
patients	O
affected	O
with	O
skeletal	O
muscle	O
diseases	O
.	O

Rapid	O
and	O
specific	O
purification	O
of	O
Argonaute	B-GENE-N
-	O
small	O
RNA	O
complexes	O
from	O
crude	O
cell	O
lysates	O
.	O

Small	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
direct	O
Argonaute	B-GENE-N
proteins	O
,	O
the	O
core	O
components	O
of	O
the	O
RNA	B-GENE-N
-	I-GENE-N
induced	I-GENE-N
silencing	I-GENE-N
complex	I-GENE-N
(	O
RISC	B-GENE-N
)	O
,	O
to	O
cleave	O
complementary	O
target	O
RNAs	O
.	O

Here	O
,	O
we	O
describe	O
a	O
method	O
to	O
purify	O
active	O
RISC	B-GENE-N
containing	O
a	O
single	O
,	O
unique	O
small	O
RNA	O
guide	O
sequence	O
.	O

We	O
begin	O
by	O
capturing	O
RISC	B-GENE-N
using	O
a	O
complementary	O
2	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
oligonucleotide	O
tethered	O
to	O
beads	O
.	O

Unlike	O
other	O
methods	O
that	O
capture	O
RISC	B-GENE-N
but	O
do	O
not	O
allow	O
its	O
recovery	O
,	O
our	O
strategy	O
purifies	O
active	O
,	O
soluble	O
RISC	B-GENE-N
in	O
good	O
yield	O
.	O

The	O
method	O
takes	O
advantage	O
of	O
the	O
finding	O
that	O
RISC	O
partially	O
paired	O
to	O
a	O
target	O
through	O
its	O
siRNA	O
guide	O
dissociates	O
more	O
than	O
300	O
times	O
faster	O
than	O
a	O
fully	O
paired	O
siRNA	O
in	O
RISC	B-GENE-N
.	O

We	O
use	O
this	O
strategy	O
to	O
purify	O
fly	B-GENE-Y
Ago1	I-GENE-Y
-	O
and	O
Ago2	B-GENE-Y
-	I-GENE-Y
RISC	I-GENE-Y
,	O
as	O
well	O
as	O
mouse	B-GENE-Y
AGO2	I-GENE-Y
-	I-GENE-Y
RISC	I-GENE-Y
.	O

The	O
method	O
can	O
discriminate	O
among	O
RISCs	B-GENE-N
programmed	O
with	O
different	O
guide	O
strands	O
,	O
making	O
it	O
possible	O
to	O
deplete	O
and	O
recover	O
specific	O
RISC	B-GENE-N
populations	O
.	O

Endogenous	O
microRNA	O
:	O
Argonaute	B-GENE-N
complexes	O
can	O
also	O
be	O
purified	O
from	O
cell	O
lysates	O
.	O

Our	O
method	O
scales	O
readily	O
and	O
takes	O
less	O
than	O
a	O
day	O
to	O
complete	O
.	O

Curcumin	B-CHEMICAL
improves	O
TNBS	O
-	O
induced	O
colitis	O
in	O
rats	O
by	O
inhibiting	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
expression	O
via	O
the	O
TLR4	B-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
pathway	O
.	O

Curcumin	B-CHEMICAL
is	O
a	O
widely	O
used	O
spice	O
with	O
anti	O
-	O
inflammatory	O
and	O
anticancer	O
properties	O
.	O

It	O
has	O
been	O
reported	O
to	O
have	O
beneficial	O
effects	O
in	O
experimental	O
colitis	O
.	O

This	O
study	O
explored	O
whether	O
curcumin	B-CHEMICAL
improves	O
colonic	O
inflammation	O
in	O
a	O
rat	O
colitis	O
model	O
through	O
inhibition	O
of	O
the	O
TLR4	B-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
pathway	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
expression	O
.	O

After	O
induction	O
of	O
colitis	O
with	O
2	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
trinitrobenzene	I-CHEMICAL
sulfonic	I-CHEMICAL
acid	I-CHEMICAL
,	O
rats	O
were	O
intragastrically	O
administered	O
with	O
curcumin	B-CHEMICAL
or	O
sulfasalazine	B-CHEMICAL
daily	O
for	O
one	O
week	O
.	O

Rat	O
intestinal	O
mucosa	O
was	O
collected	O
for	O
evaluation	O
of	O
the	O
disease	O
activity	O
index	O
,	O
colonic	O
mucosa	O
damage	O
index	O
,	O
and	O
histological	O
score	O
.	O

Myeloperoxidase	B-GENE-Y
activity	O
was	O
detected	O
by	O
immunohistochemistry	O
,	O
and	O
mRNA	O
and	O
protein	O
expression	O
levels	O
of	O
TLR4	B-GENE-Y
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
in	O
colonic	O
mucosa	O
were	O
detected	O
by	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
.	O

Compared	O
with	O
the	O
untreated	O
colitis	O
group	O
,	O
the	O
curcumin	B-CHEMICAL
-	O
treated	O
group	O
showed	O
significant	O
decreases	O
in	O
the	O
disease	O
activity	O
index	O
,	O
colonic	O
mucosa	O
damage	O
index	O
,	O
histological	O
score	O
,	O
myeloperoxidase	B-GENE-Y
activity	O
,	O
and	O
expressions	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
mRNA	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
mRNA	O
,	O
TLR4	B-GENE-Y
protein	O
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
p65	B-GENE-Y
protein	O
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
p28	B-GENE-Y
protein	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

TLR4	B-GENE-Y
mRNA	O
expression	O
did	O
not	O
differ	O
between	O
groups	O
.	O

Disease	O
activity	O
index	O
decreased	O
more	O
rapidly	O
in	O
the	O
curcumin	B-CHEMICAL
-	O
treated	O
group	O
than	O
in	O
the	O
sulfasalazine	B-CHEMICAL
-	O
treated	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
TLR4	B-GENE-Y
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
mRNA	O
and	O
proteins	O
between	O
curcumin	B-CHEMICAL
-	O
treated	O
and	O
sulfasalazine	B-CHEMICAL
-	O
treated	O
groups	O
.	O

Curcumin	B-CHEMICAL
shows	O
significant	O
therapeutic	O
effects	O
on	O
2	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
trinitrobenzene	I-CHEMICAL
sulfonic	I-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
colitis	O
that	O
are	O
comparable	O
to	O
sulfasalazine	B-CHEMICAL
.	O

The	O
anti	O
-	O
inflammatory	O
actions	O
of	O
curcumin	B-CHEMICAL
on	O
colitis	O
may	O
involve	O
inhibition	O
of	O
the	O
TLR4	B-GENE-Y
/	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
pathway	O
and	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
27	I-GENE-Y
expression	O
.	O

Neurochemical	O
control	O
of	O
rapid	O
stress	O
-	O
induced	O
changes	O
in	O
brain	O
aromatase	B-GENE-Y
activity	O
.	O

In	O
the	O
male	O
brain	O
,	O
the	O
medial	O
preoptic	O
nucleus	O
(	O
POM	O
)	O
is	O
known	O
to	O
be	O
a	O
critical	O
relay	O
for	O
the	O
activation	O
of	O
sexual	O
behaviour	O
,	O
with	O
the	O
aromatisation	O
of	O
testosterone	B-CHEMICAL
into	O
17β	B-CHEMICAL
-	I-CHEMICAL
oestradiol	I-CHEMICAL
(	O
E2	O
)	O
playing	O
a	O
key	O
role	O
.	O

Acute	O
stress	O
has	O
been	O
shown	O
to	O
differentially	O
modulate	O
the	O
aromatase	B-GENE-Y
enzyme	O
in	O
this	O
and	O
other	O
brain	O
nuclei	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
.	O

In	O
POM	O
specifically	O
,	O
stress	O
induces	O
increases	O
in	O
aromatase	B-GENE-Y
activity	O
(	O
AA	O
)	O
that	O
are	O
both	O
rapid	O
and	O
reversible	O
.	O

How	O
the	O
physiological	O
processes	O
initiated	O
during	O
an	O
acute	O
stress	O
response	O
mediate	O
sex	O
-	O
and	O
nuclei	O
-	O
specific	O
changes	O
in	O
AA	O
and	O
which	O
stress	O
response	O
hormones	O
are	O
involved	O
remains	O
to	O
be	O
determined	O
.	O

By	O
examining	O
the	O
relative	O
effects	O
of	O
corticosterone	B-CHEMICAL
(	O
CORT	B-CHEMICAL
)	O
,	O
arginine	B-CHEMICAL
vasotocin	I-CHEMICAL
(	O
AVT	B-CHEMICAL
,	O
the	O
avian	O
homologue	O
to	O
arginine	B-CHEMICAL
vasopressin	I-CHEMICAL
)	O
and	O
corticotrophin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
factor	I-GENE-Y
(	O
CRF	B-GENE-Y
)	O
,	O
the	O
present	O
study	O
aimed	O
to	O
define	O
the	O
hormone	O
profile	O
regulating	O
stress	O
-	O
induced	O
increases	O
in	O
AA	O
in	O
the	O
POM	O
.	O

We	O
found	O
that	O
CORT	B-CHEMICAL
,	O
AVT	B-CHEMICAL
and	O
CRF	B-GENE-Y
all	O
appear	O
to	O
play	O
some	O
role	O
in	O
these	O
changes	O
in	O
the	O
male	O
brain	O
.	O

In	O
addition	O
,	O
these	O
effects	O
occur	O
in	O
a	O
targeted	O
manner	O
,	O
such	O
that	O
modulation	O
of	O
the	O
enzyme	O
by	O
these	O
hormones	O
only	O
occurs	O
in	O
the	O
POM	O
rather	O
than	O
in	O
all	O
aromatase	B-GENE-Y
-	O
expressing	O
nuclei	O
.	O

Similarly	O
,	O
in	O
the	O
female	O
brain	O
,	O
the	O
experimental	O
effects	O
were	O
restricted	O
to	O
the	O
POM	O
but	O
only	O
CRF	B-GENE-Y
was	O
capable	O
of	O
inducing	O
the	O
stress	O
-	O
like	O
increases	O
in	O
AA	O
.	O

These	O
data	O
further	O
demonstrate	O
the	O
high	O
degree	O
of	O
specificity	O
(	O
nuclei	O
-	O
,	O
sex	O
-	O
and	O
hormone	O
-	O
specific	O
effects	O
)	O
in	O
this	O
system	O
,	O
highlighting	O
the	O
complexity	O
of	O
the	O
stress	O
-	O
aromatase	B-GENE-Y
link	O
and	O
suggesting	O
modes	O
through	O
which	O
the	O
nongenomic	O
modulation	O
of	O
this	O
enzyme	O
can	O
result	O
in	O
targeted	O
,	O
rapid	O
changes	O
in	O
local	O
oestrogen	B-CHEMICAL
concentrations	O
.	O

Dandelion	O
leaf	O
extract	O
protects	O
against	O
liver	O
injury	O
induced	O
by	O
methionine	B-CHEMICAL
-	O
and	O
choline	B-CHEMICAL
-	O
deficient	O
diet	O
in	O
mice	O
.	O

We	O
investigated	O
the	O
hepatoprotective	O
effects	O
of	O
the	O
extract	O
of	O
dandelion	O
leaves	O
(	O
EDL	O
)	O
on	O
a	O
murine	O
model	O
of	O
methionine	B-CHEMICAL
-	O
and	O
choline	B-CHEMICAL
-	O
deficient	O
(	O
MCD	O
)	O
diet	O
-	O
induced	O
nonalcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
.	O

C57BL	O
/	O
6	O
mice	O
were	O
fed	O
for	O
4	O
weeks	O
with	O
one	O
of	O
the	O
following	O
diets	O
:	O
control	O
diet	O
(	O
Cont	O
)	O
,	O
MCD	O
diet	O
(	O
MCD	O
)	O
,	O
MCD	O
diet	O
supplemented	O
with	O
EDL	O
at	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
·	O
daily	O
(	O
MCD	O
+	O
D200	O
)	O
,	O
and	O
MCD	O
diet	O
supplemented	O
with	O
EDL	O
at	O
500	O
mg	O
/	O
kg	O
body	O
weight	O
·	O
daily	O
(	O
MCD	O
+	O
D500	O
)	O
.	O

Hepatic	O
function	O
was	O
assessed	O
by	O
evaluating	O
the	O
following	O
parameters	O
:	O
liver	O
histology	O
;	O
plasma	O
levels	O
of	O
alanine	B-GENE-N
aminotransferase	I-GENE-N
(	O
ALT	B-GENE-N
)	O
,	O
triglyceride	B-CHEMICAL
(	O
TG	O
)	O
,	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
,	O
and	O
reduced	B-CHEMICAL
glutathione	I-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
;	O
expression	O
levels	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
;	O
and	O
levels	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
pJNK	B-GENE-N
/	O
JNK	B-GENE-N
protein	O
.	O

Histopathological	O
evaluations	O
revealed	O
that	O
addition	O
of	O
EDL	O
to	O
the	O
MCD	O
diet	O
dampens	O
the	O
severity	O
of	O
the	O
clinical	O
signs	O
of	O
NASH	O
.	O

Moreover	O
,	O
EDL	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
serum	O
levels	O
of	O
ALT	B-GENE-N
,	O
hepatic	O
TG	O
,	O
and	O
MDA	B-CHEMICAL
,	O
and	O
in	O
the	O
expression	O
levels	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
;	O
on	O
the	O
contrary	O
,	O
the	O
levels	O
of	O
reduced	B-CHEMICAL
GSH	I-CHEMICAL
increased	O
.	O

At	O
the	O
post	O
-	O
transcriptional	O
level	O
,	O
EDL	O
significantly	O
decreased	O
the	O
activation	O
of	O
procaspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
to	O
active	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
and	O
the	O
phosphorylation	O
of	O
JNK	B-GENE-N
.	O

These	O
results	O
suggest	O
that	O
the	O
beneficial	O
effects	O
of	O
EDL	O
on	O
NASH	O
are	O
mainly	O
due	O
to	O
its	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Iodine	B-CHEMICAL
-	I-CHEMICAL
129	I-CHEMICAL
microdosing	O
for	O
protein	O
and	O
peptide	O
drug	O
development	O
:	O
erythropoietin	B-GENE-Y
as	O
a	O
case	O
study	O
.	O

BACKGROUND	O
:	O
Microdosing	O
is	O
a	O
technique	O
for	O
studying	O
the	O
behavior	O
of	O
compounds	O
in	O
vivo	O
at	O
1	O
/	O
100th	O
of	O
the	O
dose	O
of	O
a	O
test	O
substance	O
calculated	O
,	O
based	O
on	O
animal	O
data	O
,	O
to	O
yield	O
a	O
pharmacologic	O
effect	O
.	O

In	O
microdosing	O
,	O
use	O
is	O
made	O
of	O
accelerator	O
MS	O
(	O
AMS	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
(	B-CHEMICAL
129	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	O
labeling	O
of	O
proteins	O
with	O
subsequent	O
AMS	O
measurements	O
is	O
a	O
suitable	O
method	O
to	O
perform	O
microdose	O
studies	O
with	O
therapeutic	O
proteins	O
.	O

We	O
used	O
erythropoietin	B-GENE-Y
(	O
EPO	B-GENE-Y
)	O
as	O
a	O
case	O
study	O
.	O

RESULTS	O
:	O
In	O
an	O
animal	O
study	O
with	O
(	B-CHEMICAL
129	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	O
labeled	O
EPO	B-GENE-Y
in	O
Han	O
-	O
Wistar	O
rats	O
,	O
an	O
increase	O
of	O
(	B-CHEMICAL
129	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	O
EPO	B-GENE-Y
is	O
observed	O
after	O
dose	O
administration	O
.	O

The	O
half	O
-	O
life	O
was	O
found	O
to	O
be	O
2	O
and	O
5	O
.	O
5	O
h	O
for	O
two	O
different	O
EPOs	B-GENE-Y
.	O

These	O
results	O
are	O
in	O
accordance	O
with	O
expected	O
values	O
.	O

CoNCLUSION	O
:	O
Although	O
further	O
research	O
is	O
required	O
,	O
(	B-CHEMICAL
129	I-CHEMICAL
)	I-CHEMICAL
I	I-CHEMICAL
-	O
labeling	O
of	O
proteins	O
seems	O
a	O
feasible	O
method	O
for	O
AMS	O
microdose	O
studies	O
with	O
peptide	O
and	O
protein	O
drugs	O
,	O
such	O
as	O
biosimilars	O
.	O

The	O
effects	O
of	O
kisspeptin	B-GENE-N
in	O
human	O
reproductive	O
function	O
-	O
therapeutic	O
implications	O
.	O

Kisspeptin	B-GENE-N
is	O
a	O
54	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
peptide	O
which	O
is	O
encoded	O
by	O
the	O
KiSS	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
and	O
activates	O
the	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
GPR54	B-GENE-Y
.	O

Evidence	O
suggests	O
that	O
this	O
system	O
is	O
a	O
key	O
regulator	O
of	O
mammalian	O
and	O
human	O
reproduction	O
.	O

Animal	O
studies	O
have	O
shown	O
that	O
GPR54	B-GENE-Y
-	O
deficient	O
mice	O
have	O
abnormal	O
sexual	O
development	O
.	O

Central	O
and	O
peripheral	O
administration	O
of	O
kisspeptin	B-GENE-N
stimulates	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
gonadal	O
(	O
HPG	O
)	O
axis	O
whilst	O
pre	O
-	O
administration	O
of	O
a	O
gonadotrophin	B-CHEMICAL
releasing	I-CHEMICAL
hormone	I-CHEMICAL
(	O
GnRH	B-CHEMICAL
)	O
antagonist	O
abolishes	O
this	O
effect	O
.	O

In	O
humans	O
,	O
inactivating	O
GPR54	B-GENE-Y
mutations	O
cause	O
normosmic	O
hypogonadotrophic	O
hypogonadism	O
whilst	O
activation	O
of	O
GPR54	B-GENE-Y
signalling	O
is	O
associated	O
with	O
premature	O
puberty	O
.	O

In	O
healthy	O
human	O
volunteers	O
,	O
the	O
acute	O
intravenous	O
administration	O
of	O
kisspeptin	O
potently	O
increases	O
plasma	O
luteinising	B-GENE-N
hormone	I-GENE-N
(	O
LH	B-GENE-N
)	O
levels	O
and	O
significantly	O
increases	O
plasma	O
follicle	B-GENE-N
stimulating	I-GENE-N
hormone	I-GENE-N
(	O
FSH	B-GENE-N
)	O
and	O
testosterone	B-CHEMICAL
without	O
side	O
effects	O
in	O
both	O
males	O
and	O
in	O
females	O
particularly	O
in	O
the	O
preovulatatory	O
phase	O
of	O
the	O
menstrual	O
cycle	O
.	O

In	O
infertility	O
due	O
to	O
hypothalamic	O
amenorrhoea	O
acute	O
administration	O
of	O
kisspeptin	B-GENE-N
results	O
in	O
stimulation	O
of	O
reproductive	O
hormones	O
.	O

The	O
kisspeptin	B-GENE-N
/	O
GPR54	B-GENE-Y
system	O
therefore	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
reproduction	O
in	O
humans	O
.	O

Hence	O
kisspeptin	B-GENE-N
has	O
potential	O
as	O
a	O
novel	O
tool	O
for	O
the	O
manipulation	O
of	O
the	O
HPG	O
axis	O
and	O
treatment	O
of	O
infertility	O
in	O
humans	O
.	O

This	O
review	O
discusses	O
the	O
evidence	O
highlighting	O
kisspeptin	B-GENE-N
'	I-GENE-N
s	I-GENE-N
key	O
role	O
in	O
human	O
reproduction	O
.	O

Super	O
-	O
stable	O
ultrafine	O
beta	B-CHEMICAL
-	I-CHEMICAL
tungsten	I-CHEMICAL
nanocrystals	O
with	O
metastable	O
phase	O
and	O
related	O
magnetism	O
.	O

Ultrafine	O
tungsten	B-CHEMICAL
nanocrystals	O
(	O
average	O
size	O
of	O
3	O
nm	O
)	O
with	O
a	O
metastable	O
phase	O
(	O
beta	B-CHEMICAL
-	I-CHEMICAL
tungsten	I-CHEMICAL
with	O
A15	O
structure	O
,	O
β	O
-	O
W	B-CHEMICAL
)	O
have	O
been	O
prepared	O
by	O
laser	O
ablation	O
of	O
tungsten	B-CHEMICAL
in	O
liquid	O
nitrogen	B-CHEMICAL
.	O

The	O
as	O
-	O
prepared	O
metastable	O
nanocrystals	O
exhibited	O
super	O
-	O
stablity	O
,	O
and	O
can	O
keep	O
the	O
same	O
metastable	O
structure	O
over	O
a	O
period	O
of	O
6	O
months	O
at	O
room	O
temperature	O
.	O

This	O
super	O
-	O
stability	O
is	O
attributed	O
to	O
the	O
nanosized	O
confinement	O
effect	O
of	O
ultrafine	O
nanocrystals	O
.	O

The	O
magnetism	O
measurements	O
showed	O
that	O
the	O
β	O
-	O
W	B-CHEMICAL
nanocrystals	O
have	O
weak	O
ferromagnetic	O
properties	O
at	O
2	O
K	O
,	O
which	O
may	O
arise	O
from	O
surface	O
defects	O
and	O
unpaired	O
electrons	O
on	O
the	O
surface	O
of	O
the	O
ultrafine	O
nanocrystals	O
.	O

These	O
findings	O
provided	O
useful	O
information	O
for	O
the	O
application	O
of	O
ultrafine	O
β	O
-	O
W	B-CHEMICAL
nanocrystals	O
in	O
microelectronics	O
and	O
spintronics	O
.	O

Visualization	O
and	O
virtual	O
screening	O
of	O
the	O
chemical	O
universe	O
database	O
GDB	O
-	O
17	O
.	O

The	O
chemical	O
universe	O
database	O
GDB	O
-	O
17	O
contains	O
166	O
.	O
4	O
billion	O
molecules	O
of	O
up	O
to	O
17	O
atoms	O
of	O
C	B-CHEMICAL
,	O
N	B-CHEMICAL
,	O
O	B-CHEMICAL
,	O
S	B-CHEMICAL
,	O
and	O
halogens	B-CHEMICAL
obeying	O
rules	O
for	O
chemical	O
stability	O
,	O
synthetic	O
feasibility	O
,	O
and	O
medicinal	O
chemistry	O
.	O

GDB	O
-	O
17	O
was	O
analyzed	O
using	O
42	O
integer	O
value	O
descriptors	O
of	O
molecular	O
structure	O
which	O
we	O
term	O
"	O
Molecular	O
Quantum	O
Numbers	O
"	O
(	O
MQN	O
)	O
.	O

Principal	O
component	O
analysis	O
and	O
representation	O
of	O
the	O
(	O
PC1	O
,	O
PC2	O
)	O
-	O
plane	O
provided	O
a	O
graphical	O
overview	O
of	O
the	O
GDB	O
-	O
17	O
chemical	O
space	O
.	O

Rapid	O
ligand	O
-	O
based	O
virtual	O
screening	O
(	O
LBVS	O
)	O
of	O
GDB	O
-	O
17	O
using	O
the	O
city	O
-	O
block	O
distance	O
CBD	O
(	O
MQN	O
)	O
as	O
a	O
similarity	O
search	O
measure	O
was	O
enabled	O
by	O
a	O
hashed	O
MQN	O
-	O
fingerprint	O
.	O

LBVS	O
of	O
the	O
entire	O
GDB	O
-	O
17	O
and	O
of	O
selected	O
subsets	O
identified	O
shape	O
similar	O
,	O
scaffold	O
hopping	O
analogs	O
(	O
ROCS	O
>	O
1	O
.	O
6	O
and	O
T	O
(	O
SF	O
)	O
<	O
0	O
.	O
5	O
)	O
of	O
15	O
drugs	O
.	O

Over	O
97	O
%	O
of	O
these	O
analogs	O
occurred	O
within	O
CBD	O
(	O
MQN	O
)	O
≤	O
12	O
from	O
each	O
drug	O
,	O
a	O
constraint	O
which	O
might	O
help	O
focus	O
advanced	O
virtual	O
screening	O
.	O

An	O
MQN	O
-	O
searchable	O
50	O
million	O
subset	O
of	O
GDB	O
-	O
17	O
is	O
publicly	O
available	O
at	O
www	O
.	O
gdb	O
.	O
unibe	O
.	O
ch	O
.	O

Bioreducible	O
polymers	O
as	O
a	O
determining	O
factor	O
for	O
polyplex	B-CHEMICAL
decomplexation	O
rate	O
and	O
transfection	O
.	O

Polyplex	B-CHEMICAL
formation	O
(	O
complexation	O
)	O
and	O
gene	O
release	O
from	O
the	O
polyplexes	B-CHEMICAL
(	O
decomplexation	O
)	O
are	O
major	O
events	O
in	O
polymeric	O
gene	O
delivery	O
;	O
however	O
,	O
the	O
effect	O
of	O
the	O
decomplexation	O
rate	O
on	O
transfection	O
has	O
been	O
rarely	O
investigated	O
.	O

This	O
study	O
employed	O
mixed	O
polymers	O
of	O
poly	B-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
L	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
lysine	I-CHEMICAL
)	I-CHEMICAL
(	O
PLL	B-CHEMICAL
:	O
MW	O
~	O
7	O
.	O
4	O
kDa	O
)	O
and	O
reducible	O
PLL	B-CHEMICAL
(	O
RPLL	O
)	O
(	O
MW	O
~	O
6	O
.	O
7	O
kDa	O
)	O
to	O
design	O
decomplexation	O
rate	O
-	O
controllable	O
PLL	B-CHEMICAL
(	O
100	O
-	O
x	O
)	O
RPLL	O
(	O
x	O
)	O
/	O
pDNA	O
complexes	O
(	O
PRL	O
(	O
x	O
)	O
polyplexes	B-CHEMICAL
)	O
.	O

The	O
transfection	O
efficiency	O
of	O
a	O
model	O
gene	O
(	O
luciferase	O
)	O
in	O
MCF7	O
and	O
HEK293	O
cell	O
lines	O
increased	O
with	O
increasing	O
x	O
(	O
RPLL	O
content	O
)	O
in	O
the	O
PRL	O
(	O
x	O
)	O
polyplexes	B-CHEMICAL
until	O
peaking	O
at	O
x	O
=	O
2	O
.	O
5	O
and	O
10	O
,	O
respectively	O
,	O
after	O
which	O
point	O
transfection	O
efficiency	O
declined	O
rapidly	O
.	O

In	O
MCF7	O
cells	O
,	O
PRL	O
(	O
2	O
.	O
5	O
)	O
polyplex	B-CHEMICAL
produced	O
3	O
or	O
223	O
times	O
higher	O
gene	O
expression	O
than	O
PLL	B-CHEMICAL
or	O
RPLL	O
polyplexes	B-CHEMICAL
,	O
respectively	O
.	O

Similarly	O
,	O
the	O
transfection	O
efficiency	O
of	O
PRL	O
(	O
10	O
)	O
polyplex	B-CHEMICAL
-	O
transfected	O
HEK293	O
cells	O
was	O
3	O
.	O
8	O
or	O
67	O
times	O
higher	O
than	O
that	O
of	O
PLL	B-CHEMICAL
or	O
RPLL	O
polyplexes	B-CHEMICAL
,	O
respectively	O
.	O

The	O
transfection	O
results	O
were	O
not	O
apparently	O
related	O
to	O
the	O
particle	O
size	O
,	O
surface	O
charge	O
,	O
complexation	O
/	O
compactness	O
,	O
cellular	O
uptake	O
,	O
or	O
cytotoxicity	O
of	O
the	O
tested	O
polyplexes	B-CHEMICAL
.	O

However	O
,	O
the	O
decomplexation	O
rate	O
varied	O
by	O
RPLL	O
content	O
in	O
the	O
polyplexes	B-CHEMICAL
,	O
which	O
in	O
turn	O
influenced	O
the	O
gene	O
transfection	O
.	O

The	O
nuclear	O
localization	O
of	O
pDNA	O
delivered	O
by	O
PRL	O
(	O
x	O
)	O
polyplexes	B-CHEMICAL
showed	O
a	O
similar	O
trend	O
to	O
their	O
transfection	O
efficiencies	O
.	O

This	O
study	O
suggests	O
that	O
an	O
optimum	O
decomplexation	O
rate	O
may	O
result	O
in	O
high	O
nuclear	O
localization	O
of	O
pDNA	O
and	O
transfection	O
.	O

Understanding	O
in	O
decomplexation	O
and	O
intracellular	O
localization	O
of	O
pDNA	O
may	O
help	O
develop	O
more	O
effective	O
polyplexes	B-CHEMICAL
.	O

Selective	O
inhibitors	O
and	O
tailored	O
activity	O
probes	O
for	O
lipoprotein	B-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
phospholipase	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
.	O

Lipoprotein	B-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
phospholipase	I-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
(	O
Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
or	O
PLA	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
G7	I-GENE-Y
)	I-GENE-Y
binds	O
to	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
(	O
LDL	B-GENE-N
)	O
particles	O
,	O
where	O
it	O
is	O
thought	O
to	O
hydrolyze	O
oxidatively	O
truncated	O
phospholipids	O
.	O

Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
has	O
also	O
been	O
implicated	O
as	O
a	O
pro	O
-	O
tumorigenic	O
enzyme	O
in	O
human	O
prostate	O
cancer	O
.	O

Several	O
inhibitors	O
of	O
Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
have	O
been	O
described	O
,	O
including	O
darapladib	B-CHEMICAL
,	O
which	O
is	O
currently	O
in	O
phase	O
3	O
clinical	O
development	O
for	O
the	O
treatment	O
of	O
atherosclerosis	O
.	O

The	O
selectivity	O
that	O
darapladib	B-CHEMICAL
and	O
other	O
Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
inhibitors	O
display	O
across	O
the	O
larger	O
serine	B-GENE-N
hydrolase	I-GENE-N
family	O
has	O
not	O
,	O
however	O
,	O
been	O
reported	O
.	O

Here	O
,	O
we	O
describe	O
the	O
use	O
of	O
both	O
general	O
and	O
tailored	O
activity	O
-	O
based	O
probes	O
for	O
profiling	O
Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
and	O
inhibitors	O
of	O
this	O
enzyme	O
in	O
native	O
biological	O
systems	O
.	O

We	O
show	O
that	O
both	O
darapladib	B-CHEMICAL
and	O
a	O
novel	O
class	O
of	O
structurally	O
distinct	O
carbamate	B-CHEMICAL
inhibitors	O
inactivate	O
Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
in	O
mouse	O
tissues	O
and	O
human	O
cell	O
lines	O
with	O
high	O
selectivity	O
.	O

Our	O
findings	O
thus	O
identify	O
both	O
inhibitors	O
and	O
chemoproteomic	O
probes	O
that	O
are	O
suitable	O
for	O
investigating	O
Lp	B-GENE-Y
-	I-GENE-Y
PLA	I-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
)	I-GENE-Y
function	O
in	O
biological	O
systems	O
.	O

Identification	O
of	O
benzofuran	B-CHEMICAL
central	O
cores	O
for	O
the	O
inhibition	O
of	O
leukotriene	B-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
hydrolase	I-GENE-Y
.	O

Leukotrienes	B-CHEMICAL
(	O
LT	O
'	O
s	O
)	O
are	O
known	O
to	O
play	O
a	O
physiological	O
role	O
in	O
inflammatory	O
immune	O
response	O
.	O

Leukotriene	B-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
hydrolase	I-GENE-Y
(	O
LTA	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
)	O
is	O
a	O
cystolic	O
enzyme	O
that	O
stereospecifically	O
catalyzes	O
the	O
transformation	O
of	O
LTA	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
to	O
LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
.	O

LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
is	O
a	O
known	O
pro	O
-	O
inflammatory	O
mediator	O
.	O

This	O
paper	O
describes	O
the	O
identification	O
and	O
synthesis	O
of	O
substituted	O
benzofurans	B-CHEMICAL
as	O
LTH	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
inhibitors	O
.	O

The	O
benzofuran	B-CHEMICAL
series	O
demonstrated	O
reduced	O
mouse	O
and	O
human	O
whole	O
blood	O
LTB	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
levels	O
in	O
vitro	O
and	O
led	O
to	O
the	O
identification	O
one	O
analog	O
for	O
advanced	O
profiling	O
.	O

Benzofuran	B-CHEMICAL
28	O
showed	O
dose	O
responsive	O
target	O
engagement	O
and	O
provides	O
a	O
useful	O
tool	O
to	O
explore	O
a	O
LTA	B-GENE-Y
(	I-GENE-Y
4	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
inhibitor	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
asthma	O
and	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Neoechinulin	B-CHEMICAL
A	I-CHEMICAL
suppresses	O
amyloid	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
oligomer	O
-	O
induced	O
microglia	O
activation	O
and	O
thereby	O
protects	O
PC	O
-	O
12	O
cells	O
from	O
inflammation	O
-	O
mediated	O
toxicity	O
.	O

A	O
pathological	O
hallmark	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
,	O
aggregation	O
and	O
deposition	O
of	O
amyloid	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
peptides	I-GENE-Y
,	O
has	O
been	O
recognized	O
as	O
a	O
potent	O
activator	O
of	O
microglia	O
-	O
mediated	O
neuroinflammation	O
and	O
neuronal	O
dysfunction	O
.	O

Therefore	O
,	O
downregulation	O
of	O
microglial	O
activation	O
has	O
a	O
significant	O
therapeutic	O
demand	O
.	O

In	O
this	O
study	O
,	O
focus	O
was	O
given	O
to	O
evaluate	O
the	O
ability	O
of	O
neoechinulin	B-CHEMICAL
A	I-CHEMICAL
,	O
an	O
indole	B-CHEMICAL
alkaloid	O
isolated	O
from	O
marine	O
-	O
derived	O
Microsporum	O
sp	O
.	O
,	O
to	O
attenuate	O
microglial	O
activation	O
by	O
oligomeric	O
amyloid	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
(	O
Aβ42	B-GENE-Y
)	O
.	O

Neoechinulin	B-CHEMICAL
A	I-CHEMICAL
treatment	O
significantly	O
inhibited	O
the	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
and	O
nitrogen	B-CHEMICAL
species	O
in	O
Aβ42	B-GENE-Y
-	O
activated	O
BV	O
-	O
2	O
microglia	O
cells	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
neoechinulin	B-CHEMICAL
A	I-CHEMICAL
significantly	O
suppressed	O
the	O
production	O
of	O
neurotoxic	O
inflammatory	O
mediator	O
tumour	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
)	O
,	O
and	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
PGE2	B-CHEMICAL
)	O
in	O
activated	O
BV	O
-	O
2	O
cells	O
.	O

Moreover	O
,	O
the	O
treatment	O
downregulated	O
the	O
protein	O
and	O
gene	O
expressions	O
of	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
,	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

Further	O
,	O
activated	O
microglia	O
-	O
mediated	O
apoptosis	O
of	O
PC	O
-	O
12	O
pheochromocytoma	O
cells	O
was	O
significantly	O
repressed	O
by	O
neoechinulin	B-CHEMICAL
A	I-CHEMICAL
.	O

The	O
molecular	O
mechanism	O
studies	O
suggested	O
that	O
neoechinulin	B-CHEMICAL
A	I-CHEMICAL
may	O
block	O
the	O
phosphorylation	O
of	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
molecule	O
p38	B-GENE-N
,	O
apoptosis	B-GENE-Y
signal	I-GENE-Y
-	I-GENE-Y
regulating	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
(	O
ASK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
nuclear	O
translocation	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
p65	B-GENE-Y
and	O
p50	B-GENE-Y
subunits	O
.	O

Regulation	O
of	O
these	O
signalling	O
pathways	O
have	O
most	O
probably	O
contributed	O
to	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
neoechinulin	B-CHEMICAL
A	I-CHEMICAL
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
with	O
further	O
studies	O
neoechinulin	B-CHEMICAL
A	I-CHEMICAL
have	O
a	O
potential	O
to	O
be	O
developed	O
as	O
a	O
modulator	O
of	O
neuroinflammatory	O
process	O
in	O
AD	O
.	O

The	O
effects	O
of	O
jaspamide	B-CHEMICAL
on	O
human	O
cardiomyocyte	O
function	O
and	O
cardiac	B-GENE-N
ion	I-GENE-N
channel	I-GENE-N
activity	O
.	O

Jaspamide	B-CHEMICAL
(	O
jasplakinolide	B-CHEMICAL
;	O
NSC	B-CHEMICAL
-	I-CHEMICAL
613009	I-CHEMICAL
)	O
is	O
a	O
cyclodepsipeptide	B-CHEMICAL
that	O
has	O
antitumor	O
activity	O
.	O

A	O
narrow	O
margin	O
of	O
safety	O
was	O
observed	O
between	O
doses	O
required	O
for	O
efficacy	O
in	O
mouse	O
tumor	O
models	O
and	O
doses	O
that	O
caused	O
severe	O
acute	O
toxicity	O
in	O
rats	O
and	O
dogs	O
.	O

We	O
explored	O
the	O
hypothesis	O
that	O
the	O
observed	O
toxicity	O
was	O
due	O
to	O
cardiotoxicity	O
.	O

Jaspamide	B-CHEMICAL
was	O
tested	O
in	O
a	O
patch	O
clamp	O
assay	O
to	O
determine	O
its	O
effect	O
on	O
selected	O
cardiac	B-GENE-N
ion	I-GENE-N
channels	I-GENE-N
.	O

Jaspamide	B-CHEMICAL
(	O
10	O
μM	O
)	O
inhibited	O
Kv1	O
.	O
5	O
activity	O
by	O
98	O
.	O
5	O
%	O
.	O

Jaspamide	B-CHEMICAL
also	O
inhibited	O
other	O
channels	O
including	O
Cav1	B-GENE-N
.	I-GENE-N
2	I-GENE-N
,	O
Cav3	B-GENE-N
.	I-GENE-N
2	I-GENE-N
,	O
and	O
HCN2	B-GENE-N
;	O
however	O
,	O
the	O
Kv11	B-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
(	O
hERG	B-GENE-Y
)	O
channel	O
was	O
minimally	O
affected	O
.	O

Using	O
spontaneously	O
contracting	O
human	O
cardiomyocytes	O
derived	O
from	O
induced	O
pluripotent	O
stem	O
cells	O
,	O
effects	O
on	O
cardiomyocyte	O
contraction	O
and	O
viability	O
were	O
also	O
examined	O
.	O

Jaspamide	B-CHEMICAL
(	O
30	O
nM	O
to	O
30	O
μM	O
)	O
decreased	O
cardiomyocyte	O
cell	O
indices	O
and	O
beat	O
amplitude	O
,	O
putative	O
measurements	O
of	O
cell	O
viability	O
and	O
cardiac	O
contractility	O
,	O
respectively	O
.	O

Concentration	O
-	O
dependent	O
increases	O
in	O
rhythmic	O
beating	O
rate	O
were	O
noted	O
at	O
≤	O
6	O
h	O
of	O
treatment	O
,	O
followed	O
by	O
dose	O
-	O
dependent	O
decreases	O
after	O
6	O
and	O
72	O
h	O
exposure	O
.	O

The	O
toxic	O
effects	O
of	O
jaspamide	B-CHEMICAL
were	O
compared	O
with	O
that	O
of	O
the	O
known	O
cardiotoxicant	O
mitoxantrone	B-CHEMICAL
,	O
and	O
confirmed	O
by	O
multiparameter	O
fluorescence	O
imaging	O
analysis	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
toxicity	O
observed	O
in	O
rats	O
and	O
dogs	O
is	O
due	O
to	O
toxic	O
effects	O
of	O
jaspamide	B-CHEMICAL
on	O
cardiomyocytes	O
.	O

Chemokine	B-GENE-N
expression	O
is	O
upregulated	O
in	O
chondrocytes	O
in	O
diabetic	O
fracture	O
healing	O
.	O

Chemokines	B-GENE-N
are	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
several	O
aspects	O
of	O
bone	O
metabolism	O
including	O
the	O
recruitment	O
of	O
leukocytes	O
and	O
the	O
formation	O
of	O
osteoclasts	O
.	O

We	O
investigated	O
the	O
impact	O
of	O
diabetes	O
on	O
chemokine	B-GENE-N
expression	O
in	O
normal	O
and	O
diabetic	O
fracture	O
healing	O
.	O

Fracture	O
of	O
the	O
femur	O
was	O
performed	O
in	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	O
and	O
matched	O
normoglycemic	O
control	O
mice	O
.	O

Microarray	O
analysis	O
was	O
carried	O
out	O
and	O
chemokine	B-GENE-N
mRNA	O
levels	O
in	O
vivo	O
were	O
assessed	O
.	O

CCL4	B-GENE-Y
were	O
examined	O
in	O
fracture	O
calluses	O
by	O
immunohistochemistry	O
and	O
the	O
role	O
of	O
TNF	B-GENE-N
in	O
diabetes	O
-	O
enhanced	O
expression	O
was	O
investigated	O
by	O
treatment	O
of	O
animals	O
with	O
the	O
TNF	B-GENE-N
-	O
specific	O
inhibitor	O
,	O
pegsunercept	O
.	O

In	O
vitro	O
studies	O
were	O
conducted	O
with	O
ATDC5	O
chondrocytes	O
.	O

Diabetes	O
significantly	O
upregulated	O
mRNA	O
levels	O
of	O
several	O
chemokines	B-GENE-N
in	O
vivo	O
including	O
CCL4	B-GENE-Y
,	O
CCL8	B-GENE-Y
,	O
CCL6	B-GENE-Y
,	O
CCL11	B-GENE-Y
,	O
CCL20	B-GENE-Y
,	O
CCL24	B-GENE-Y
,	O
CXCL2	B-GENE-Y
,	O
CXCL5	B-GENE-Y
and	O
chemokine	B-GENE-N
receptors	I-GENE-N
CCR5	B-GENE-Y
and	O
CXCR4	B-GENE-Y
.	O

Chondrocytes	O
were	O
identified	O
as	O
a	O
significant	O
source	O
of	O
CCL4	B-GENE-Y
and	O
its	O
expression	O
in	O
diabetic	O
fractures	O
was	O
dependent	O
on	O
TNF	B-GENE-N
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
significantly	O
increased	O
mRNA	O
levels	O
of	O
several	O
chemokines	B-GENE-N
in	O
vitro	O
which	O
were	O
knocked	O
down	O
with	O
FOXO1	B-GENE-Y
siRNA	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CCL4	B-GENE-Y
expression	O
at	O
the	O
mRNA	O
and	O
proteins	O
levels	O
was	O
induced	O
by	O
FOXO1	B-GENE-Y
over	O
-	O
expression	O
and	O
reduced	O
by	O
FOXO1	B-GENE-Y
knockdown	O
.	O

The	O
current	O
studies	O
point	O
to	O
the	O
importance	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
as	O
a	O
mechanism	O
for	O
diabetes	O
enhanced	O
chemokine	B-GENE-N
expression	O
by	O
chondrocytes	O
,	O
which	O
may	O
contribute	O
to	O
the	O
accelerated	O
loss	O
of	O
cartilage	O
observed	O
in	O
diabetic	O
fracture	O
healing	O
.	O

Moreover	O
,	O
in	O
vitro	O
results	O
point	O
to	O
FOXO1	B-GENE-Y
as	O
a	O
potentially	O
important	O
transcription	O
factor	O
in	O
mediating	O
this	O
effect	O
.	O

Synthesis	O
,	O
crystal	O
structure	O
and	O
antidiabetic	O
activity	O
of	O
substituted	O
(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
Benzo	I-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
thiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
ylamino	I-CHEMICAL
)	I-CHEMICAL
phenylprop	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
.	O

A	O
novel	O
series	O
of	O
substituted	O
(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
Benzo	I-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
thiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
ylamino	I-CHEMICAL
)	I-CHEMICAL
phenylprop	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
onewere	I-CHEMICAL
synthesized	O
starting	O
from	O
2	B-CHEMICAL
-	I-CHEMICAL
aminobenzothiazole	I-CHEMICAL
and	O
1	B-CHEMICAL
-	I-CHEMICAL
aryl	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
methylsulfanyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
propen	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
onesin	I-CHEMICAL
the	O
presence	O
of	O
a	O
catalytic	O
amount	O
of	O
sodium	B-CHEMICAL
hydride	I-CHEMICAL
in	O
THF	B-CHEMICAL
.	O

The	O
synthesised	O
compounds	O
'	O
structures	O
were	O
confirmed	O
by	O
IR	O
,	O
Mass	O
spectrometry	O
,	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
NMR	O
,	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
NMR	O
and	O
HRMS	O
spectral	O
data	O
.	O

These	O
compounds	O
were	O
evaluated	O
for	O
their	O
antidiabetic	O
activity	O
,	O
and	O
most	O
of	O
the	O
derivatives	O
of	O
(	B-CHEMICAL
E	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
Benzo	I-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
thiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
ylamino	I-CHEMICAL
)	I-CHEMICAL
phenylprop	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
displayed	O
significant	O
antidiabetic	O
activity	O
.	O

Characterization	O
of	O
tyrosinase	B-GENE-Y
inhibitors	O
in	O
the	O
twigs	O
of	O
Cudrania	O
tricuspidata	O
and	O
their	O
structure	O
-	O
activity	O
relationship	O
study	O
.	O

The	O
twigs	O
of	O
Cudrania	O
tricuspidata	O
were	O
found	O
to	O
show	O
strong	O
tyrosinase	B-GENE-Y
inhibitory	O
activity	O
,	O
and	O
further	O
detailed	O
component	O
analysis	O
resulted	O
in	O
the	O
isolation	O
of	O
a	O
new	O
flavanol	B-CHEMICAL
glucoside	I-CHEMICAL
,	O
(	B-CHEMICAL
2S	I-CHEMICAL
,	I-CHEMICAL
3S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
dihydromorin	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucoside	I-CHEMICAL
(	O
1	O
)	O
,	O
plus	O
twenty	O
-	O
seven	O
known	O
compounds	O
(	O
2	O
-	O
28	O
)	O
.	O

Their	O
structures	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
ESI	O
-	O
MS	O
and	O
NMR	O
spectral	O
data	O
.	O

Among	O
the	O
isolated	O
compounds	O
,	O
trans	B-CHEMICAL
-	I-CHEMICAL
dihydromorin	I-CHEMICAL
(	O
8	O
)	O
,	O
oxyresveratrol	B-CHEMICAL
(	O
9	O
)	O
,	O
and	O
steppogenin	B-CHEMICAL
(	O
12	O
)	O
were	O
found	O
to	O
exhibit	O
significant	O
tyrosinase	B-GENE-Y
inhibition	O
activities	O
.	O

Moreover	O
,	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
these	O
isolated	O
compounds	O
was	O
also	O
discussed	O
.	O

Cortisol	B-CHEMICAL
and	O
interferon	O
tau	O
regulation	O
of	O
endometrial	O
function	O
and	O
conceptus	O
development	O
in	O
female	O
sheep	O
.	O

During	O
early	O
pregnancy	O
in	O
sheep	O
,	O
the	O
elongating	O
conceptus	O
secretes	O
interferon	B-GENE-N
-	I-GENE-N
τ	I-GENE-N
(	O
IFNT	B-GENE-N
)	O
and	O
the	O
conceptus	O
as	O
well	O
as	O
endometrial	O
epithelia	O
produce	O
prostaglandins	B-CHEMICAL
(	O
PG	O
)	O
via	O
PG	B-GENE-Y
synthase	I-GENE-Y
2	I-GENE-Y
(	O
PTGS2	B-GENE-Y
)	O
and	O
cortisol	B-CHEMICAL
via	O
hydroxysteroid	B-GENE-Y
(	I-GENE-Y
11	I-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
)	I-GENE-Y
dehydrogenase	I-GENE-Y
1	I-GENE-Y
(	O
HSD11B1	B-GENE-Y
)	O
.	O

Ovarian	O
progesterone	B-CHEMICAL
induces	O
and	O
PG	O
and	O
IFNT	B-GENE-N
stimulates	O
endometrial	O
HSD11B1	B-GENE-Y
expression	O
and	O
keto	B-GENE-N
-	I-GENE-N
reductase	I-GENE-N
activity	O
as	O
well	O
as	O
many	O
epithelial	O
genes	O
that	O
govern	O
trophectoderm	O
proliferation	O
,	O
migration	O
,	O
and	O
attachment	O
during	O
elongation	O
.	O

The	O
primary	O
aim	O
of	O
these	O
studies	O
was	O
to	O
test	O
the	O
hypothesis	O
that	O
HSD11B1	B-GENE-Y
-	O
derived	O
cortisol	B-CHEMICAL
has	O
a	O
biological	O
role	O
in	O
endometrial	O
function	O
and	O
conceptus	O
development	O
during	O
early	O
pregnancy	O
in	O
sheep	O
.	O

In	O
study	O
1	O
,	O
cyclic	O
ewes	O
received	O
vehicle	O
,	O
cortisol	B-CHEMICAL
,	O
PF	B-CHEMICAL
915275	I-CHEMICAL
(	O
PF	O
;	O
a	O
selective	O
inhibitor	O
of	O
HSD11B1	B-GENE-Y
)	O
,	O
cortisol	B-CHEMICAL
and	O
PF	O
,	O
meloxicam	B-CHEMICAL
(	O
a	O
selective	O
inhibitor	O
of	O
PTGS2	B-GENE-Y
)	O
,	O
cortisol	B-CHEMICAL
and	O
meloxicam	B-CHEMICAL
,	O
recombinant	O
ovine	B-GENE-N
IFNT	I-GENE-N
,	O
or	O
IFNT	B-GENE-N
and	O
PF	O
into	O
the	O
uterus	O
from	O
day	O
10	O
to	O
day14	O
after	O
estrus	O
.	O

Cortisol	B-CHEMICAL
and	O
IFNT	B-GENE-N
stimulated	O
endometrial	O
HSD11B1	B-GENE-Y
expression	O
and	O
activity	O
,	O
increased	O
endometrial	O
PTGS2	B-GENE-Y
activity	O
and	O
the	O
amount	O
of	O
PG	O
in	O
the	O
uterine	O
lumen	O
,	O
and	O
up	O
-	O
regulated	O
many	O
conceptus	O
elongation	O
-	O
related	O
genes	O
in	O
the	O
endometrium	O
.	O

Some	O
effects	O
of	O
cortisol	B-CHEMICAL
and	O
IFNT	B-GENE-N
were	O
mediated	O
by	O
PTGS2	B-GENE-Y
-	O
derived	O
PG	O
.	O

In	O
study	O
2	O
,	O
bred	O
ewes	O
received	O
PF	B-CHEMICAL
915275	I-CHEMICAL
or	O
recombinant	O
ovine	B-GENE-N
IFNT	I-GENE-N
and	O
into	O
the	O
uterus	O
from	O
day	O
10	O
to	O
day	O
14	O
after	O
mating	O
.	O

Inhibition	O
of	O
HSD11B1	B-GENE-Y
activity	O
in	O
utero	O
prevented	O
conceptus	O
elongation	O
,	O
whereas	O
IFNT	B-GENE-N
rescued	O
conceptus	O
elongation	O
in	O
PF	O
-	O
infused	O
ewes	O
.	O

These	O
results	O
suggest	O
that	O
HSD11B1	B-GENE-Y
-	O
derived	O
cortisol	B-CHEMICAL
mediates	O
,	O
in	O
part	O
,	O
actions	O
of	O
ovarian	O
progesterone	B-CHEMICAL
and	O
the	O
conceptus	O
on	O
endometrial	O
function	O
and	O
support	O
the	O
hypothesis	O
that	O
IFNT	B-GENE-N
,	O
PG	O
,	O
and	O
cortisol	B-CHEMICAL
coordinately	O
regulate	O
endometrial	O
functions	O
important	O
for	O
conceptus	O
elongation	O
and	O
implantation	O
during	O
early	O
pregnancy	O
in	O
sheep	O
.	O

Comparative	O
formation	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenylimidazo	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
PhIP	B-CHEMICAL
)	O
in	O
creatinine	B-CHEMICAL
/	O
phenylalanine	B-CHEMICAL
and	O
creatinine	B-CHEMICAL
/	O
phenylalanine	B-CHEMICAL
/	O
4	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
nonenal	I-CHEMICAL
reaction	O
mixtures	O
.	O

The	O
comparative	O
formation	O
of	O
the	O
heterocyclic	O
aromatic	O
amine	O
2	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenylimidazo	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
PhIP	B-CHEMICAL
)	O
in	O
both	O
creatinine	B-CHEMICAL
/	O
phenylalanine	B-CHEMICAL
(	O
CRN	B-CHEMICAL
/	O
Phe	B-CHEMICAL
)	O
and	O
creatinine	B-CHEMICAL
/	O
phenylalanine	B-CHEMICAL
/	O
4	B-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
nonenal	I-CHEMICAL
(	O
CRN	B-CHEMICAL
/	O
Phe	B-CHEMICAL
/	O
ON	O
)	O
systems	O
was	O
studied	O
to	O
analyse	O
the	O
ability	O
of	O
lipid	O
-	O
derived	O
reactive	O
carbonyls	B-CHEMICAL
to	O
promote	O
PhIP	B-CHEMICAL
formation	O
.	O

Although	O
PhIP	B-CHEMICAL
was	O
produced	O
to	O
some	O
extent	O
in	O
the	O
CRN	B-CHEMICAL
/	O
Phe	B-CHEMICAL
system	O
,	O
the	O
presence	O
of	O
the	O
oxidized	O
lipid	O
increased	O
considerably	O
the	O
amount	O
of	O
PhIP	B-CHEMICAL
produced	O
.	O

This	O
increase	O
seemed	O
to	O
be	O
a	O
consequence	O
of	O
the	O
decrease	O
in	O
the	O
E	O
(	O
a	O
)	O
of	O
the	O
reaction	O
when	O
the	O
lipid	O
was	O
present	O
,	O
which	O
diminished	O
from	O
112	O
.	O
9	O
to	O
80	O
.	O
9	O
kJ	O
/	O
mol	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
addition	O
of	O
the	O
lipid	O
did	O
not	O
seem	O
to	O
produce	O
PhIP	B-CHEMICAL
by	O
an	O
alternative	O
mechanism	O
because	O
PhIP	B-CHEMICAL
was	O
formed	O
analogously	O
in	O
both	O
CRN	B-CHEMICAL
/	O
Phe	B-CHEMICAL
and	O
CRN	B-CHEMICAL
/	O
Phe	B-CHEMICAL
/	O
ON	O
systems	O
as	O
a	O
function	O
of	O
pH	O
,	O
creatinine	B-CHEMICAL
concentration	O
,	O
phenylalanine	B-CHEMICAL
concentration	O
,	O
time	O
,	O
temperature	O
,	O
oxygen	B-CHEMICAL
concentration	O
in	O
the	O
reaction	O
atmosphere	O
,	O
and	O
the	O
addition	O
of	O
different	O
amounts	O
of	O
ammonia	B-CHEMICAL
.	O

All	O
these	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
lipid	O
oxidation	O
products	O
to	O
produce	O
PhIP	B-CHEMICAL
is	O
related	O
to	O
their	O
capacity	O
to	O
induce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	B-CHEMICAL
to	O
phenylacetaldehyde	B-CHEMICAL
.	O

Therefore	O
,	O
any	O
other	O
reactive	O
carbonyl	B-CHEMICAL
compound	O
that	O
can	O
produce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	B-CHEMICAL
should	O
also	O
be	O
considered	O
as	O
a	O
potential	O
inducer	O
of	O
PhIP	B-CHEMICAL
formation	O
under	O
appropriate	O
conditions	O
.	O

Evaluation	O
of	O
biological	O
activities	O
of	O
a	O
groundnut	O
(	O
Apios	O
americana	O
Medik	O
)	O
extract	O
containing	O
a	O
novel	O
isoflavone	B-CHEMICAL
.	O

Groundnut	O
(	O
Apios	O
americana	O
Medik	O
)	O
contains	O
a	O
novel	O
isoflavone	B-CHEMICAL
,	O
genistein	B-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
gentiobioside	I-CHEMICAL
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
biological	O
activities	O
of	O
an	O
alcohol	B-CHEMICAL
extract	O
of	O
groundnut	O
containing	O
genistein	B-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
gentiobioside	I-CHEMICAL
as	O
the	O
main	O
component	O
.	O

Although	O
the	O
groundnut	O
extract	O
by	O
itself	O
did	O
not	O
show	O
antioxidative	O
activity	O
,	O
it	O
drove	O
the	O
antioxidative	O
system	O
in	O
cells	O
.	O

Pretreatment	O
of	O
human	O
breast	O
carcinoma	O
MCF	O
-	O
7	O
cells	O
for	O
24	O
h	O
with	O
the	O
groundnut	O
extract	O
and	O
soybean	O
isoflavone	B-CHEMICAL
increased	O
gene	O
expression	O
of	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
a	O
major	O
antioxidative	O
stress	O
enzyme	O
.	O

These	O
groundnut	O
extract	O
-	O
treated	O
cells	O
showed	O
antioxidative	O
activity	O
against	O
free	O
radicals	O
derived	O
from	O
a	O
radical	O
initiator	O
.	O

Pretreatment	O
of	O
cells	O
with	O
100	O
μg	O
/	O
mL	O
groundnut	O
extract	O
prevented	O
the	O
depletion	O
of	O
glutathione	B-CHEMICAL
by	O
the	O
radical	O
initiator	O
;	O
however	O
,	O
treatment	O
with	O
100	O
μg	O
/	O
mL	O
of	O
soybean	O
isoflavone	B-CHEMICAL
injured	O
the	O
cell	O
membrane	O
,	O
indicating	O
that	O
glutathione	B-CHEMICAL
might	O
be	O
released	O
to	O
the	O
extracellular	O
environment	O
.	O

These	O
results	O
suggest	O
that	O
the	O
groundnut	O
extract	O
had	O
isoflavone	B-CHEMICAL
-	O
like	O
activity	O
.	O

Like	O
soybean	O
,	O
groundnuts	O
are	O
a	O
good	O
source	O
of	O
isoflavones	B-CHEMICAL
.	O

Influence	O
of	O
nitrogen	B-CHEMICAL
supply	O
on	O
the	O
production	O
of	O
higher	O
alcohols	B-CHEMICAL
/	O
esters	B-CHEMICAL
and	O
expression	O
of	O
flavour	O
-	O
related	O
genes	O
in	O
cachaça	O
fermentation	O
.	O

This	O
study	O
provides	O
the	O
first	O
attempt	O
to	O
analyse	O
the	O
influence	O
of	O
ammonium	B-CHEMICAL
supplements	O
on	O
sugar	B-CHEMICAL
-	O
cane	O
juice	O
fermentation	O
and	O
the	O
flavour	O
profile	O
in	O
a	O
cachaça	O
industrial	O
process	O
.	O

The	O
objective	O
was	O
to	O
find	O
a	O
relationship	O
between	O
higher	O
alcohol	B-CHEMICAL
/	O
ester	B-CHEMICAL
content	O
and	O
the	O
transcription	O
levels	O
of	O
the	O
main	O
genes	O
involved	O
in	O
production	O
of	O
these	O
compounds	O
under	O
cachaça	O
fermentation	O
.	O

Sugar	B-CHEMICAL
-	O
cane	O
juice	O
with	O
a	O
low	O
amount	O
of	O
assimilable	O
nitrogen	B-CHEMICAL
(	O
81	O
mg	O
N	O
/	O
L	O
)	O
,	O
was	O
further	O
supplemented	O
with	O
mid	O
-	O
range	O
or	O
high	O
concentrations	O
of	O
ammonium	B-CHEMICAL
sulfate	I-CHEMICAL
.	O

Overall	O
,	O
higher	O
alcohol	B-CHEMICAL
production	O
was	O
reduced	O
by	O
ammonium	B-CHEMICAL
supplementation	O
,	O
and	O
this	O
can	O
be	O
correlated	O
with	O
a	O
general	O
downregulation	O
of	O
genes	O
encoding	O
decarboxylases	B-GENE-N
and	O
dehydrogenases	B-GENE-N
of	O
the	O
Ehrlich	B-GENE-N
pathway	I-GENE-N
.	O

The	O
production	O
of	O
acetate	B-CHEMICAL
esters	I-CHEMICAL
was	O
enhanced	O
by	O
mid	O
-	O
range	O
ammonium	B-CHEMICAL
supplementation	O
and	O
the	O
production	O
of	O
acyl	B-CHEMICAL
esters	I-CHEMICAL
by	O
high	O
ammonium	B-CHEMICAL
supplementation	O
.	O

The	O
acyl	B-CHEMICAL
esters	I-CHEMICAL
could	O
be	O
correlated	O
with	O
expression	O
of	O
alcohol	B-GENE-Y
acyl	I-GENE-Y
-	I-GENE-Y
transferase	I-GENE-Y
EEB1	I-GENE-Y
and	O
the	O
acyl	B-GENE-Y
esterase	I-GENE-Y
IAH1	I-GENE-Y
.	O

Structure	O
activity	O
relationship	O
studies	O
of	O
tricyclic	B-CHEMICAL
bispyran	I-CHEMICAL
sulfone	I-CHEMICAL
γ	B-GENE-N
-	I-GENE-N
secretase	I-GENE-N
inhibitors	O
.	O

An	O
investigation	O
is	O
detailed	O
of	O
the	O
structure	O
activity	O
relationships	O
(	O
SAR	O
)	O
of	O
two	O
sulfone	B-CHEMICAL
side	O
chains	O
of	O
compound	O
(	O
-	O
)	O
-	O
1a	O
(	O
SCH	B-CHEMICAL
900229	I-CHEMICAL
)	O
,	O
a	O
potent	O
,	O
PS1	B-GENE-Y
-	O
selective	O
γ	B-GENE-N
-	I-GENE-N
secretase	I-GENE-N
inhibitor	O
and	O
clinical	O
candidate	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Specifically	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
CF	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
and	O
4	B-CHEMICAL
-	I-CHEMICAL
Br	I-CHEMICAL
substituted	O
arylsulfone	B-CHEMICAL
analogs	O
,	O
(	O
-	O
)	O
-	O
1b	O
and	O
(	O
-	O
)	O
-	O
1c	O
,	O
are	O
equipotent	O
to	O
compound	O
(	O
-	O
)	O
-	O
1a	O
.	O

On	O
the	O
right	O
hand	O
side	O
chain	O
,	O
linker	O
size	O
and	O
terminal	O
substituents	O
of	O
the	O
pendant	O
sulfone	B-CHEMICAL
group	O
are	O
also	O
investigated	O
.	O

Heterobivalent	O
dual	O
-	O
target	O
probe	O
for	O
targeting	O
GRP	B-GENE-Y
and	O
Y1	B-GENE-Y
receptors	I-GENE-Y
on	O
tumor	O
cells	O
.	O

Receptor	O
targeting	O
ligands	O
for	O
imaging	O
and	O
/	O
or	O
therapy	O
of	O
cancer	O
are	O
limited	O
by	O
heterogeneity	O
of	O
receptor	O
expression	O
by	O
tumor	O
cells	O
,	O
both	O
inter	O
-	O
patient	O
and	O
intra	O
-	O
patient	O
.	O

It	O
is	O
often	O
more	O
important	O
for	O
imaging	O
agents	O
to	O
identify	O
local	O
and	O
distant	O
spread	O
of	O
disease	O
than	O
it	O
is	O
to	O
identify	O
a	O
specific	O
receptor	O
presence	O
.	O

Two	O
natural	O
hormone	O
peptide	O
receptors	O
,	O
GRPR	B-GENE-Y
and	O
Y1	B-GENE-Y
,	O
are	O
specifically	O
interesting	O
because	O
expression	O
of	O
GRPR	B-GENE-Y
,	O
Y1	B-GENE-Y
or	O
both	O
is	O
up	O
-	O
regulated	O
in	O
most	O
breast	O
cancers	O
.	O

We	O
describe	O
here	O
the	O
design	O
and	O
development	O
of	O
a	O
new	O
heterobivalent	O
peptide	O
ligand	O
,	O
truncated	B-GENE-N
bombesin	I-GENE-N
(	O
t	B-GENE-N
-	I-GENE-N
BBN	I-GENE-N
)	O
/	O
BVD15	O
-	O
DO3A	O
,	O
for	O
dual	O
-	O
targeting	O
of	O
GRPR	B-GENE-Y
and	O
Y1	B-GENE-Y
,	O
and	O
validation	O
of	O
its	O
dual	O
binding	O
capability	O
.	O

Such	O
a	O
probe	O
should	O
be	O
useful	O
in	O
imaging	O
cells	O
,	O
tissues	O
and	O
tumors	O
that	O
are	O
GRPR	B-GENE-Y
and	O
/	O
or	O
Y1	B-GENE-Y
positive	O
and	O
should	O
target	O
radioisotopes	O
,	O
for	O
example	O
,	O
(	O
68	O
)	O
Ga	O
and	O
/	O
or	O
(	O
177	O
)	O
Lu	O
,	O
to	O
more	O
tumors	O
cells	O
than	O
single	O
GRPR	B-GENE-Y
or	O
Y1	B-GENE-Y
targeted	O
probes	O
.	O

A	O
GRP	B-GENE-Y
targeting	O
ligand	O
,	O
J	O
-	O
G	O
-	O
Abz4	O
-	O
QWAVGHLM	O
-	O
NH	O
(	O
2	O
)	O
(	O
J	O
-	O
G	O
-	O
Abz4	O
-	O
t	O
-	O
BBN	O
)	O
,	O
and	O
an	O
Y1	B-GENE-Y
targeting	O
ligand	O
,	O
INP	O
-	O
K	O
[	O
ε	O
-	O
J	O
-	O
(	O
α	O
-	O
DO3A	O
-	O
ε	O
-	O
DGa	O
)	O
-	O
K	O
]	O
-	O
YRLRY	O
-	O
NH	O
(	O
2	O
)	O
(	O
[	O
ε	O
-	O
J	O
-	O
(	O
α	O
-	O
DO3A	O
-	O
ε	O
-	O
DGa	O
)	O
-	O
K	O
]	O
-	O
BVD	O
-	O
15	O
)	O
,	O
were	O
synthesized	O
and	O
coupled	O
to	O
produce	O
the	O
heterobivalent	O
ligand	O
,	O
t	B-GENE-N
-	I-GENE-N
BBN	I-GENE-N
/	O
BVD15	O
-	O
DO3A	O
.	O

Competitive	O
displacement	O
binding	O
assays	O
using	O
t	B-GENE-N
-	I-GENE-N
BBN	I-GENE-N
/	O
BVD15	O
-	O
DO3A	O
against	O
(	B-GENE-N
125	I-GENE-N
)	I-GENE-N
I	I-GENE-N
-	I-GENE-N
Tyr	I-GENE-N
(	I-GENE-N
4	I-GENE-N
)	I-GENE-N
-	I-GENE-N
BBN	I-GENE-N
yielded	O
an	O
IC	O
(	O
50	O
)	O
value	O
of	O
18	O
±	O
0	O
.	O
7	O
nM	O
for	O
GRPR	B-GENE-Y
in	O
T	O
-	O
47D	O
cells	O
,	O
a	O
human	O
breast	O
cancer	O
cell	O
line	O
.	O

A	O
similar	O
assay	O
using	O
t	B-GENE-N
-	I-GENE-N
BBN	I-GENE-N
/	O
BVD15	O
-	O
DO3A	O
against	O
porcine	B-GENE-Y
(	I-GENE-Y
125	I-GENE-Y
)	I-GENE-Y
I	I-GENE-Y
-	I-GENE-Y
NPY	I-GENE-Y
showed	O
IC	O
(	O
50	O
)	O
values	O
of	O
80	O
±	O
11	O
nM	O
for	O
Y1	B-GENE-Y
receptor	I-GENE-Y
in	O
MCF7	O
cells	O
,	O
another	O
human	O
breast	O
cancer	O
cell	O
line	O
.	O

In	O
conclusion	O
,	O
it	O
is	O
possible	O
to	O
construct	O
a	O
single	O
DO3A	O
chelate	O
containing	O
probe	O
that	O
can	O
target	O
both	O
GRPR	B-GENE-Y
and	O
Y1	B-GENE-Y
on	O
human	O
tumor	O
cells	O
.	O

Activation	O
of	O
an	O
apoptotic	O
signal	O
transduction	O
pathway	O
involved	O
in	O
the	O
upregulation	O
of	O
calpain	B-GENE-N
and	O
apoptosis	B-GENE-Y
-	I-GENE-Y
inducing	I-GENE-Y
factor	I-GENE-Y
in	O
aldosterone	B-CHEMICAL
-	O
induced	O
primary	O
cultured	O
cardiomyocytes	O
.	O

In	O
this	O
study	O
,	O
aldosterone	B-CHEMICAL
(	O
ALD	B-CHEMICAL
)	O
-	O
induced	O
apoptosis	O
of	O
cardiomyocyte	O
was	O
evaluated	O
based	O
on	O
the	O
previous	O
studies	O
,	O
and	O
the	O
roles	O
of	O
calpain	B-GENE-N
signaling	O
were	O
clarified	O
.	O

Primary	O
cultured	O
rat	O
cardiomyocytes	O
were	O
injured	O
by	O
ALD	B-CHEMICAL
(	O
0	O
.	O
01	O
-	O
10	O
μM	O
)	O
for	O
varying	O
time	O
periods	O
.	O

Then	O
,	O
the	O
effects	O
of	O
ethylene	B-CHEMICAL
glycol	I-CHEMICAL
tetraacetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
EGTA	B-CHEMICAL
)	O
(	O
0	O
.	O
5	O
mM	O
)	O
,	O
calpeptin	B-CHEMICAL
(	O
2	O
.	O
5	O
μM	O
)	O
,	O
and	O
spironoclactone	B-CHEMICAL
(	O
10	O
μM	O
)	O
were	O
evaluated	O
on	O
cardiomyocytes	O
activated	O
by	O
ALD	B-CHEMICAL
.	O

Cardiomyocytes	O
that	O
were	O
injured	O
by	O
ALD	B-CHEMICAL
were	O
assayed	O
by	O
the	O
MTT	B-CHEMICAL
and	O
LDH	B-GENE-N
leakage	O
ratio	O
.	O

Apoptosis	O
was	O
evaluated	O
by	O
a	O
TUNEL	O
assay	O
,	O
annexin	O
V	O
/	O
PI	O
staining	O
,	O
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
.	O

The	O
expression	O
of	O
cleavage	O
of	O
Bid	B-GENE-Y
(	O
tBid	B-GENE-Y
)	O
,	O
calpain	B-GENE-N
and	O
apoptosis	B-GENE-Y
-	I-GENE-Y
inducing	I-GENE-Y
factor	I-GENE-Y
(	O
AIF	B-GENE-Y
)	O
was	O
evaluated	O
by	O
western	O
blot	O
analysis	O
.	O

ALD	B-CHEMICAL
increased	O
calpain	B-GENE-N
expression	O
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
and	O
promoted	O
Bid	O
cleavage	O
.	O

It	O
also	O
induced	O
the	O
release	O
of	O
AIF	B-GENE-Y
from	O
mitochondria	O
into	O
the	O
cytosol	O
.	O

The	O
upregulation	O
of	O
calpain	B-GENE-N
,	O
tBid	B-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activity	O
were	O
further	O
inhibited	O
by	O
treatment	O
with	O
EGTA	B-CHEMICAL
in	O
the	O
presence	O
of	O
ALD	B-CHEMICAL
.	O

Additionally	O
,	O
AIF	B-GENE-Y
levels	O
in	O
the	O
cytosol	O
decreased	O
due	O
to	O
EGTA	B-CHEMICAL
but	O
not	O
due	O
to	O
calpeptin	B-CHEMICAL
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
significant	O
decrease	O
in	O
apoptosis	O
.	O

Furthermore	O
,	O
treatment	O
with	O
spironoclactone	B-CHEMICAL
not	O
only	O
attenuated	O
the	O
pro	O
-	O
apoptotic	O
effect	O
of	O
ALD	B-CHEMICAL
but	O
reversed	O
the	O
ALD	B-CHEMICAL
-	O
induced	O
increase	O
of	O
calpain	B-GENE-N
and	O
AIF	B-GENE-Y
levels	O
.	O

Immunomodulatory	O
properties	O
of	O
multi	O
-	O
walled	O
carbon	B-CHEMICAL
nanotubes	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
healthy	O
subjects	O
and	O
allergic	O
patients	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
immunomodulatory	O
activity	O
of	O
multi	O
-	O
walled	O
carbon	B-CHEMICAL
nanotubes	O
(	O
MWCNTs	O
)	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
from	O
healthy	O
donors	O
and	O
mite	O
-	O
allergic	O
subjects	O
.	O

Freshly	O
prepared	O
PBMCs	O
,	O
stimulated	O
or	O
not	O
with	O
Toll	B-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
(	I-GENE-N
TLR	I-GENE-N
)	I-GENE-N
1	I-GENE-N
-	I-GENE-N
9	I-GENE-N
agonists	O
,	O
a	O
T	B-GENE-N
cell	I-GENE-N
mitogen	I-GENE-N
(	O
phytohemagglutinin	B-GENE-N
A	I-GENE-N
)	O
or	O
mite	O
allergen	O
extract	O
were	O
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
MWCNTs	O
.	O

Secretion	O
of	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
IL	B-GENE-N
-	I-GENE-N
12	I-GENE-N
/	I-GENE-N
23p40	I-GENE-N
or	O
IFN	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
was	O
quantified	O
in	O
the	O
culture	O
supernatants	O
by	O
ELISA	O
.	O

Basal	O
secretion	O
of	O
all	O
the	O
cytokines	B-GENE-N
was	O
not	O
altered	O
by	O
MWCNTs	O
in	O
PBMCs	O
from	O
both	O
healthy	O
donors	O
and	O
allergic	O
subjects	O
.	O

In	O
PBMCs	O
from	O
healthy	O
donors	O
,	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
and	O
IL	B-GENE-N
-	I-GENE-N
12	I-GENE-N
/	I-GENE-N
23p40	I-GENE-N
secretion	O
in	O
response	O
to	O
the	O
TLR4	B-GENE-Y
agonist	O
,	O
lipopolysaccharide	O
was	O
however	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
MWCNTs	O
.	O

Significant	O
increases	O
in	O
the	O
release	O
of	O
these	O
cytokines	B-GENE-N
were	O
also	O
observed	O
in	O
PBMCs	O
stimulated	O
with	O
a	O
TLR2	B-GENE-Y
or	O
TLR3	B-GENE-Y
agonist	O
.	O

MWCNTs	O
also	O
increased	O
the	O
release	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
IFN	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
by	O
PBMCs	O
stimulated	O
with	O
a	O
T	B-GENE-N
cell	I-GENE-N
mitogen	I-GENE-N
.	O

In	O
contrast	O
,	O
MWCNTs	O
inhibited	O
allergen	O
-	O
induced	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
secretion	O
by	O
PBMCs	O
from	O
mite	O
-	O
allergic	O
subjects	O
.	O

As	O
well	O
,	O
MWCNTs	O
altered	O
the	O
capacity	O
of	O
PBMC	O
-	O
derived	O
monocytes	O
to	O
differentiate	O
into	O
functional	O
dendritic	O
cells	O
.	O

All	O
together	O
,	O
our	O
data	O
suggest	O
that	O
according	O
to	O
its	O
immune	O
cell	O
target	O
,	O
MWCNTs	O
may	O
either	O
promote	O
or	O
suppress	O
immune	O
responses	O
in	O
humans	O
.	O

Further	O
investigations	O
are	O
necessary	O
to	O
fully	O
understand	O
the	O
complexity	O
behind	O
interactions	O
of	O
engineered	O
nanoparticles	O
with	O
the	O
immune	O
system	O
.	O

Safrole	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
oxide	I-CHEMICAL
induces	O
atherosclerotic	O
plaque	O
vulnerability	O
in	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
-	O
knockout	O
mice	O
.	O

Safrole	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
oxide	I-CHEMICAL
(	O
SFO	B-CHEMICAL
)	O
is	O
the	O
major	O
electrophilic	O
metabolite	O
of	O
safrole	B-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
allyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
methylenedioxybenzene	I-CHEMICAL
)	O
,	O
a	O
natural	O
plant	O
constituent	O
found	O
in	O
essential	O
oils	O
of	O
numerous	O
edible	O
herbs	O
and	O
spices	O
and	O
in	O
food	O
containing	O
these	O
herbs	O
,	O
such	O
as	O
pesto	O
sauce	O
,	O
cola	O
beverages	O
and	O
bologna	O
sausages	O
.	O

The	O
effects	O
of	O
SFO	B-CHEMICAL
in	O
mammalian	O
systems	O
,	O
especially	O
the	O
cardiovascular	O
system	O
,	O
are	O
little	O
known	O
.	O

Disruption	O
of	O
vulnerable	O
atherosclerotic	O
plaques	O
in	O
atherosclerosis	O
,	O
a	O
chronic	O
inflammatory	O
disease	O
,	O
is	O
the	O
main	O
cause	O
of	O
cardiovascular	O
events	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
SFO	B-CHEMICAL
-	O
induced	O
atherosclerotic	O
plaque	O
vulnerability	O
(	O
possibility	O
of	O
rupture	O
)	O
in	O
apolipoprotein	B-GENE-Y
E	I-GENE-Y
-	O
knockout	O
(	O
apoE	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
.	O

Lipid	O
area	O
in	O
vessel	O
wall	O
reached	O
59	O
.	O
8	O
%	O
in	O
high	O
dose	O
SFO	B-CHEMICAL
(	O
SFO	B-CHEMICAL
-	O
HD	O
)	O
treated	O
group	O
,	O
which	O
is	O
only	O
31	O
.	O
2	O
%	O
in	O
control	O
group	O
.	O

SFO	B-CHEMICAL
treatment	O
changed	O
the	O
lesion	O
composition	O
to	O
an	O
unstable	O
phenotype	O
,	O
increased	O
the	O
number	O
of	O
apoptotic	O
cells	O
in	O
plaque	O
and	O
the	O
endothelium	O
in	O
plaques	O
was	O
damaged	O
after	O
SFO	B-CHEMICAL
treatment	O
.	O

Furthermore	O
,	O
compared	O
with	O
control	O
groups	O
,	O
the	O
plaque	O
endothelium	O
level	O
of	O
p75	B-GENE-Y
(	I-GENE-Y
NTR	I-GENE-Y
)	I-GENE-Y
was	O
3	O
-	O
fold	O
increased	O
and	O
the	O
liver	O
level	O
of	O
p75	B-GENE-Y
(	I-GENE-Y
NTR	I-GENE-Y
)	I-GENE-Y
was	O
17	O
.	O
4	O
-	O
fold	O
increased	O
by	O
SFO	B-CHEMICAL
-	O
HD	O
.	O

Meanwhile	O
,	O
the	O
serum	O
level	O
of	O
KC	O
(	O
a	O
functional	O
homolog	O
of	O
IL	B-GENE-N
-	I-GENE-N
8	I-GENE-N
and	O
the	O
main	O
proinflammatory	O
alpha	B-GENE-N
chemokine	I-GENE-N
in	O
mice	O
)	O
in	O
apoE	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
up	O
to	O
357pg	O
/	O
ml	O
in	O
SFO	B-CHEMICAL
-	O
HD	O
treated	O
group	O
.	O

Thus	O
,	O
SFO	B-CHEMICAL
contributes	O
to	O
the	O
instability	O
of	O
atherosclerotic	O
plaque	O
in	O
apoE	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
through	O
activating	O
p75	B-GENE-Y
(	I-GENE-Y
NTR	I-GENE-Y
)	I-GENE-Y
and	O
IL	B-GENE-N
-	I-GENE-N
8	I-GENE-N
and	O
cell	O
apoptosis	O
in	O
plaque	O
.	O

Synthesis	O
,	O
molecular	O
modeling	O
and	O
evaluation	O
of	O
novel	O
N	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
benzylpiperidin	I-CHEMICAL
-	I-CHEMICAL
/	I-CHEMICAL
piperazin	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
acylhydrazone	I-CHEMICAL
derivatives	O
as	O
dual	O
inhibitors	O
for	O
cholinesterases	B-GENE-Y
and	O
Aβ	B-GENE-Y
aggregation	O
.	O

To	O
develop	O
new	O
drugs	O
for	O
treatment	O
of	O
Alzheimer	O
'	O
s	O
disease	O
,	O
a	O
group	O
of	O
N	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Benzylpiperidin	I-CHEMICAL
-	I-CHEMICAL
/	I-CHEMICAL
piperazin	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
acylhydrazones	I-CHEMICAL
was	O
designed	O
,	O
synthesized	O
and	O
tested	O
for	O
their	O
ability	O
to	O
inhibit	O
acetylcholinesterase	B-GENE-Y
,	O
butyrylcholinesterase	B-GENE-Y
and	O
aggregation	O
of	O
amyloid	B-GENE-N
beta	I-GENE-N
peptides	I-GENE-N
(	I-GENE-N
1	I-GENE-N
-	I-GENE-N
40	I-GENE-N
,	I-GENE-N
1	I-GENE-N
-	I-GENE-N
42	I-GENE-N
and	I-GENE-N
1	I-GENE-N
-	I-GENE-N
40	I-GENE-N
_	I-GENE-N
1	I-GENE-N
-	I-GENE-N
42	I-GENE-N
)	I-GENE-N
.	O

The	O
enzyme	O
inhibition	O
assay	O
results	O
indicated	O
that	O
compounds	O
moderately	O
inhibit	O
both	O
acetylcholinesterase	B-GENE-Y
and	O
butyrylcholinesterase	B-GENE-Y
.	O

β	B-GENE-Y
-	I-GENE-Y
Amyloid	I-GENE-Y
aggregation	O
results	O
showed	O
that	O
all	O
compounds	O
exhibited	O
remarkable	O
Aβ	B-GENE-Y
fibril	O
aggregation	O
inhibition	O
activity	O
with	O
a	O
nearly	O
similar	O
potential	O
as	O
the	O
reference	O
compound	O
rifampicin	B-CHEMICAL
,	O
which	O
makes	O
them	O
promising	O
anti	O
-	O
Alzheimer	O
drug	O
candidates	O
.	O

Docking	O
experiments	O
were	O
carried	O
out	O
with	O
the	O
aim	O
to	O
understand	O
the	O
interactions	O
of	O
the	O
most	O
active	O
compounds	O
with	O
the	O
active	O
site	O
of	O
the	O
cholinesterase	B-GENE-Y
enzymes	O
.	O

NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
-	O
associated	O
mechanisms	O
underlying	O
the	O
response	O
of	O
embryonic	O
cells	O
to	O
Doxorubicin	B-CHEMICAL
.	O

The	O
involvement	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
in	O
the	O
regulation	O
of	O
teratogen	O
-	O
induced	O
apoptosis	O
has	O
not	O
been	O
established	O
yet	O
.	O

Therefore	O
,	O
we	O
tried	O
to	O
assess	O
the	O
involvement	O
of	O
the	O
p65	B-GENE-Y
subunit	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
in	O
the	O
embryonic	O
response	O
to	O
the	O
anti	O
-	O
cancer	O
drug	O
Doxorubicin	B-CHEMICAL
(	O
DOX	B-CHEMICAL
)	O
.	O

Thus	O
,	O
exposure	O
of	O
p65	B-GENE-Y
knockout	O
(	O
p65	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
)	O
or	O
wild	O
type	O
(	O
WT	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
to	O
DOX	B-CHEMICAL
resulted	O
in	O
a	O
decrease	O
in	O
cell	O
survival	O
,	O
culture	O
density	O
and	O
cell	O
proliferation	O
,	O
which	O
was	O
found	O
to	O
be	O
more	O
prominent	O
in	O
p65	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
MEFs	O
.	O

Those	O
phenomena	O
were	O
accompanied	O
by	O
a	O
DOX	B-CHEMICAL
-	O
induced	O
increase	O
in	O
the	O
proportion	O
of	O
apoptotic	O
cells	O
,	O
which	O
was	O
demonstrated	O
only	O
in	O
p65	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
cells	O
and	O
a	O
G2	O
/	O
M	O
arrest	O
,	O
which	O
was	O
found	O
to	O
be	O
more	O
prominent	O
in	O
WT	O
cells	O
.	O

Furthermore	O
,	O
DOX	B-CHEMICAL
-	O
treated	O
WT	O
and	O
p65	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
MEFs	O
differed	O
in	O
their	O
expression	O
of	O
various	O
apoptosis	O
-	O
associated	O
molecules	O
,	O
when	O
the	O
former	O
demonstrated	O
a	O
decrease	O
in	O
the	O
percentage	O
of	O
p65	B-GENE-Y
-	O
positive	O
and	O
a	O
more	O
prominent	O
decrease	O
in	O
the	O
percentage	O
of	O
p53	B-GENE-Y
-	O
positive	O
cells	O
,	O
while	O
a	O
decreased	O
percentage	O
of	O
IκBα	B-GENE-Y
-	O
positive	O
and	O
a	O
more	O
prominent	O
decrease	O
in	O
the	O
percentage	O
of	O
bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
positive	O
cells	O
was	O
detected	O
among	O
the	O
latter	O
.	O

The	O
fact	O
that	O
the	O
response	O
of	O
the	O
cells	O
to	O
the	O
teratogen	O
was	O
clearly	O
p65	B-GENE-Y
-	O
dependent	O
implicates	O
this	O
molecule	O
to	O
be	O
involved	O
in	O
the	O
response	O
of	O
the	O
embryonic	O
cells	O
to	O
DOX	B-CHEMICAL
.	O

Fetal	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
overexpression	O
programs	O
adult	O
pancreatic	O
β	O
-	O
cell	O
dysfunction	O
.	O

Adult	O
β	O
-	O
cell	O
dysfunction	O
,	O
a	O
hallmark	O
of	O
type	O
2	O
diabetes	O
,	O
can	O
be	O
programmed	O
by	O
adverse	O
fetal	O
environment	O
.	O

We	O
have	O
shown	O
that	O
fetal	O
glucocorticoids	O
(	O
GCs	O
)	O
participate	O
in	O
this	O
programming	O
through	O
inhibition	O
of	O
β	O
-	O
cell	O
development	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
regulation	O
.	O

We	O
showed	O
that	O
GCs	O
stimulate	O
the	O
expression	O
of	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
coactivator	I-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
(	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
)	O
,	O
a	O
coregulator	O
of	O
the	O
GCs	B-GENE-Y
receptor	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
,	O
and	O
that	O
the	O
overexpression	O
of	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
represses	O
genes	O
important	O
for	O
β	O
-	O
cell	O
development	O
and	O
function	O
.	O

More	O
precisely	O
,	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
inhibited	O
the	O
expression	O
of	O
the	O
key	O
β	O
-	O
cell	O
transcription	O
factor	O
pancreatic	B-GENE-Y
duodenal	I-GENE-Y
homeobox	I-GENE-Y
1	I-GENE-Y
(	O
Pdx1	B-GENE-Y
)	O
.	O

This	O
repression	O
required	O
the	O
GR	B-GENE-Y
and	O
was	O
mediated	O
through	O
binding	O
of	O
a	O
GR	B-GENE-Y
/	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
complex	O
to	O
the	O
Pdx1	B-GENE-N
promoter	I-GENE-N
.	O

To	O
explore	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
function	O
,	O
we	O
generated	O
mice	O
with	O
inducible	O
β	O
-	O
cell	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
overexpression	O
.	O

Mice	O
overexpressing	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
exhibited	O
at	O
adult	O
age	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
associated	O
with	O
reduced	O
insulin	O
secretion	O
,	O
decreased	O
β	O
-	O
cell	O
mass	O
,	O
and	O
β	O
-	O
cell	O
hypotrophy	O
.	O

Interestingly	O
,	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
expression	O
in	O
fetal	O
life	O
only	O
was	O
sufficient	O
to	O
impair	O
adult	O
β	O
-	O
cell	O
function	O
whereas	O
β	O
-	O
cell	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
overexpression	O
from	O
adult	O
age	O
had	O
no	O
consequence	O
on	O
β	O
-	O
cell	O
function	O
.	O

Altogether	O
,	O
our	O
results	O
demonstrate	O
that	O
the	O
GR	B-GENE-Y
and	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
participate	O
in	O
the	O
fetal	O
programming	O
of	O
adult	O
β	O
-	O
cell	O
function	O
through	O
inhibition	O
of	O
Pdx1	B-GENE-Y
expression	O
.	O

G6PC2	B-GENE-Y
:	O
A	O
Negative	O
Regulator	O
of	O
Basal	O
Glucose	B-CHEMICAL
-	O
Stimulated	O
Insulin	B-GENE-Y
Secretion	O
.	O

Elevated	O
fasting	O
blood	O
glucose	B-CHEMICAL
(	O
FBG	O
)	O
is	O
associated	O
with	O
increased	O
risk	O
for	O
the	O
development	O
of	O
type	O
2	O
diabetes	O
and	O
cardiovascular	O
-	O
associated	O
mortality	O
.	O

Genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
have	O
linked	O
polymorphisms	O
in	O
G6PC2	B-GENE-Y
with	O
variations	O
in	O
FBG	O
and	O
body	O
fat	O
,	O
although	O
not	O
insulin	B-GENE-Y
sensitivity	O
or	O
glucose	B-CHEMICAL
tolerance	O
.	O

G6PC2	B-GENE-Y
encodes	O
an	O
islet	O
-	O
specific	O
,	O
endoplasmic	O
reticulum	O
-	O
resident	O
glucose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphatase	I-GENE-Y
catalytic	I-GENE-Y
subunit	I-GENE-Y
.	O

A	O
combination	O
of	O
in	O
situ	O
perfused	O
pancreas	O
,	O
in	O
vitro	O
isolated	O
islet	O
,	O
and	O
in	O
vivo	O
analyses	O
were	O
used	O
to	O
explore	O
the	O
function	O
of	O
G6pc2	B-GENE-Y
in	O
mice	O
.	O

G6pc2	B-GENE-Y
deletion	O
had	O
little	O
effect	O
on	O
insulin	B-GENE-N
sensitivity	O
and	O
glucose	B-CHEMICAL
tolerance	O
,	O
whereas	O
body	O
fat	O
was	O
reduced	O
in	O
female	O
G6pc2	B-GENE-Y
knockout	O
(	O
KO	O
)	O
mice	O
on	O
both	O
a	O
chow	O
and	O
high	O
-	O
fat	O
diet	O
,	O
observations	O
that	O
are	O
all	O
consistent	O
with	O
human	O
GWAS	O
data	O
.	O

G6pc2	B-GENE-Y
deletion	O
resulted	O
in	O
a	O
leftward	O
shift	O
in	O
the	O
dose	O
-	O
response	O
curve	O
for	O
glucose	B-CHEMICAL
-	O
stimulated	O
insulin	B-GENE-N
secretion	O
(	O
GSIS	O
)	O
.	O

As	O
a	O
consequence	O
,	O
under	O
fasting	O
conditions	O
in	O
which	O
plasma	O
insulin	B-GENE-N
levels	O
were	O
identical	O
,	O
blood	O
glucose	B-CHEMICAL
levels	O
were	O
reduced	O
in	O
G6pc2	B-GENE-Y
KO	O
mice	O
,	O
again	O
consistent	O
with	O
human	O
GWAS	O
data	O
.	O

Glucose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphatase	I-GENE-Y
activity	O
was	O
reduced	O
,	O
whereas	O
basal	O
cytoplasmic	O
calcium	B-CHEMICAL
levels	O
were	O
elevated	O
in	O
islets	O
isolated	O
from	O
G6pc2	B-GENE-Y
KO	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
G6pc2	B-GENE-Y
represents	O
a	O
novel	O
,	O
negative	O
regulator	O
of	O
basal	O
GSIS	O
that	O
acts	O
by	O
hydrolyzing	O
glucose	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
,	O
thereby	O
reducing	O
glycolytic	O
flux	O
.	O

Display	O
of	O
amino	B-CHEMICAL
groups	O
on	O
substrate	O
surfaces	O
by	O
simple	O
dip	O
-	O
coating	O
of	O
methacrylate	B-CHEMICAL
-	O
based	O
polymers	O
and	O
its	O
application	O
to	O
DNA	O
immobilization	O
.	O

The	O
implementation	O
of	O
a	O
reactive	O
functional	O
group	O
onto	O
a	O
material	O
surface	O
is	O
of	O
great	O
importance	O
.	O

Reactive	O
functional	O
groups	O
(	O
e	O
.	O
g	O
.	O
,	O
an	O
amino	B-CHEMICAL
group	O
and	O
a	O
hydroxyl	B-CHEMICAL
group	O
)	O
are	O
usually	O
hydrophilic	O
,	O
which	O
makes	O
it	O
difficult	O
to	O
display	O
them	O
on	O
a	O
dry	O
polymer	O
surface	O
.	O

We	O
here	O
propose	O
a	O
novel	O
method	O
for	O
displaying	O
amino	B-CHEMICAL
groups	O
on	O
the	O
surfaces	O
of	O
polymeric	O
substrates	O
through	O
dip	O
-	O
coating	O
of	O
a	O
methacrylate	B-CHEMICAL
-	O
based	O
copolymer	O
.	O

We	O
synthesized	O
copolymers	O
composed	O
of	O
methyl	B-CHEMICAL
methacrylate	I-CHEMICAL
and	O
2	B-CHEMICAL
-	I-CHEMICAL
aminoethyl	I-CHEMICAL
methacrylate	I-CHEMICAL
with	O
different	O
protecting	O
groups	O
or	O
ion	O
-	O
complexes	O
on	O
their	O
amino	B-CHEMICAL
groups	O
,	O
then	O
dip	O
-	O
coated	O
the	O
copolymers	O
onto	O
a	O
poly	B-CHEMICAL
(	I-CHEMICAL
methyl	I-CHEMICAL
methacrylate	I-CHEMICAL
)	I-CHEMICAL
(	O
PMMA	B-CHEMICAL
)	O
substrate	O
.	O

Evaluation	O
using	O
a	O
cleavable	O
fluorescent	O
compound	O
,	O
which	O
was	O
synthesized	O
in	O
the	O
present	O
study	O
to	O
quantify	O
a	O
small	O
amount	O
(	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
of	O
amino	B-CHEMICAL
groups	O
on	O
a	O
solid	O
surface	O
,	O
revealed	O
that	O
the	O
protection	O
of	O
amino	B-CHEMICAL
groups	O
affected	O
their	O
surface	O
segregation	O
in	O
the	O
copolymer	O
coating	O
.	O

p	B-CHEMICAL
-	I-CHEMICAL
Toluenesulfonate	I-CHEMICAL
ion	O
-	O
complex	O
and	O
tert	B-CHEMICAL
-	I-CHEMICAL
butoxycarbonyl	I-CHEMICAL
(	O
Boc	B-CHEMICAL
)	O
protection	O
of	O
amino	B-CHEMICAL
groups	O
were	O
found	O
to	O
effectively	O
display	O
amino	B-CHEMICAL
groups	O
on	O
the	O
surface	O
(	O
more	O
than	O
70	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
.	O

The	O
density	O
of	O
amino	B-CHEMICAL
groups	O
displayed	O
on	O
a	O
surface	O
can	O
be	O
easily	O
controlled	O
by	O
mixing	O
the	O
copolymer	O
and	O
PMMA	B-CHEMICAL
before	O
dip	O
-	O
coating	O
.	O

Dip	O
-	O
coating	O
of	O
the	O
copolymer	O
with	O
Boc	B-CHEMICAL
protection	O
on	O
various	O
polymeric	O
substrates	O
also	O
successfully	O
displayed	O
amino	B-CHEMICAL
groups	O
on	O
their	O
surfaces	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
amino	B-CHEMICAL
groups	O
displayed	O
can	O
be	O
utilized	O
for	O
the	O
immobilization	O
of	O
a	O
DNA	O
oligonucleotide	O
on	O
a	O
substrate	O
surface	O
.	O

Methylation	O
damage	O
to	O
RNA	O
induced	O
in	O
vivo	O
in	O
Escherichia	O
coli	O
is	O
repaired	O
by	O
endogenous	O
AlkB	B-GENE-Y
as	O
part	O
of	O
the	O
adaptive	O
response	O
.	O

Cytotoxic	O
1	B-CHEMICAL
-	I-CHEMICAL
methyladenine	I-CHEMICAL
(	O
1	B-CHEMICAL
-	I-CHEMICAL
meA	I-CHEMICAL
)	O
and	O
3	B-CHEMICAL
-	I-CHEMICAL
methylcytosine	I-CHEMICAL
(	O
3	B-CHEMICAL
-	I-CHEMICAL
meC	I-CHEMICAL
)	O
lesions	O
induced	O
in	O
DNA	O
and	O
RNA	O
in	O
vitro	O
and	O
in	O
pre	O
-	O
damaged	O
DNA	O
and	O
RNA	O
bacteriophages	O
in	O
vivo	O
are	O
repaired	O
by	O
the	O
Escherichia	B-GENE-Y
coli	I-GENE-Y
(	I-GENE-Y
E	I-GENE-Y
.	I-GENE-Y
coli	I-GENE-Y
)	I-GENE-Y
protein	I-GENE-Y
AlkB	I-GENE-Y
and	O
a	O
human	B-GENE-Y
homolog	I-GENE-Y
,	I-GENE-Y
ALKBH3	I-GENE-Y
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
endogenous	O
RNA	O
is	O
repaired	O
in	O
vivo	O
by	O
repair	O
proteins	O
present	O
at	O
physiological	O
concentrations	O
.	O

The	O
concept	O
of	O
RNA	O
repair	O
as	O
a	O
biologically	O
relevant	O
process	O
has	O
therefore	O
remained	O
elusive	O
.	O

Here	O
,	O
we	O
demonstrate	O
AlkB	B-GENE-Y
-	O
mediated	O
repair	O
of	O
endogenous	O
RNA	O
in	O
vivo	O
by	O
measuring	O
differences	O
in	O
lesion	O
-	O
accumulation	O
in	O
two	O
independent	O
AlkB	B-GENE-Y
-	O
proficient	O
and	O
deficient	O
E	O
.	O
coli	O
strains	O
during	O
exposure	O
to	O
methyl	B-CHEMICAL
methanesulfonate	I-CHEMICAL
(	O
MMS	B-CHEMICAL
)	O
.	O

Repair	O
was	O
observed	O
both	O
in	O
AlkB	B-GENE-Y
-	O
overproducing	O
strains	O
and	O
in	O
the	O
wild	O
-	O
type	O
strains	O
after	O
AlkB	B-GENE-Y
induction	O
.	O

RNA	O
repair	O
appeared	O
to	O
be	O
highest	O
in	O
RNA	O
species	O
below	O
200	O
nucleotides	B-CHEMICAL
in	O
size	O
,	O
mainly	O
comprising	O
tRNAs	O
.	O

Strikingly	O
,	O
at	O
least	O
10	O
-	O
fold	O
more	O
lesions	O
were	O
repaired	O
in	O
RNA	O
than	O
in	O
DNA	O
.	O

This	O
may	O
be	O
a	O
consequence	O
of	O
some	O
30	O
-	O
fold	O
higher	O
levels	O
of	O
aberrant	O
methylation	O
in	O
RNA	O
than	O
in	O
DNA	O
after	O
exposure	O
to	O
MMS	B-CHEMICAL
.	O

A	O
high	O
primary	O
kinetic	O
isotope	O
effect	O
(	O
>	O
10	O
)	O
was	O
measured	O
using	O
a	O
deuterated	O
methylated	O
RNA	O
substrate	O
,	O
D3	O
-	O
1me	O
(	O
rA	O
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
catalytic	O
step	O
,	O
and	O
not	O
the	O
search	O
step	O
that	O
is	O
rate	O
-	O
limiting	O
.	O

Our	O
results	O
demonstrate	O
that	O
RNA	O
repair	O
by	O
AlkB	B-GENE-Y
takes	O
place	O
in	O
endogenous	O
RNA	O
as	O
part	O
of	O
an	O
adaptive	O
response	O
in	O
wild	O
-	O
type	O
E	O
.	O
coli	O
cells	O
.	O

Fisetin	B-CHEMICAL
averts	O
oxidative	O
stress	O
in	O
pancreatic	O
tissues	O
of	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetic	O
rats	O
.	O

Persistent	O
hyperglycemia	O
is	O
associated	O
with	O
chronic	O
oxidative	O
stress	O
which	O
contributes	O
to	O
the	O
development	O
and	O
progression	O
of	O
diabetes	O
-	O
associated	O
complications	O
.	O

The	O
sensitivity	O
of	O
pancreatic	O
β	O
-	O
cells	O
to	O
oxidative	O
stress	O
has	O
been	O
attributed	O
to	O
their	O
low	O
content	O
of	O
antioxidants	O
compared	O
with	O
other	O
tissues	O
.	O

Bioactive	O
compounds	O
with	O
potent	O
antidiabetic	O
properties	O
have	O
been	O
shown	O
to	O
ameliorate	O
hyperglycemia	O
mediated	O
oxidative	O
stress	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
oral	O
administration	O
of	O
fisetin	B-CHEMICAL
(	O
10	O
mg	O
/	O
Kg	O
b	O
.	O
w	O
.	O
)	O
,	O
a	O
bioflavonoid	B-CHEMICAL
found	O
to	O
be	O
present	O
in	O
strawberries	O
,	O
persimmon	O
,	O
to	O
STZ	B-CHEMICAL
-	O
induced	O
experimental	O
diabetic	O
rats	O
significantly	O
improved	O
normoglycemia	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
evaluate	O
the	O
antioxidant	O
potential	O
of	O
fisetin	B-CHEMICAL
in	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Diabetes	O
was	O
induced	O
by	O
single	O
intraperitoneal	O
injection	O
of	O
streptozotocin	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Fisetin	B-CHEMICAL
was	O
administered	O
orally	O
for	O
30	O
days	O
.	O

At	O
the	O
end	O
of	O
the	O
study	O
,	O
all	O
animals	O
were	O
killed	O
.	O

Blood	O
samples	O
were	O
collected	O
for	O
the	O
biochemical	O
estimations	O
.	O

The	O
antioxidant	O
status	O
was	O
evaluated	O
.	O

Histological	O
examinations	O
were	O
performed	O
on	O
pancreatic	O
tissues	O
.	O

Fisetin	B-CHEMICAL
treatment	O
showed	O
a	O
significant	O
decline	O
in	O
the	O
levels	O
of	O
blood	O
glucose	B-CHEMICAL
,	O
glycosylated	B-GENE-N
hemoglobin	I-GENE-N
(	O
HbA1c	B-GENE-N
)	O
,	O
NF	B-GENE-N
-	I-GENE-N
kB	I-GENE-N
p65	B-GENE-Y
unit	O
(	O
in	O
pancreas	O
)	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
(	O
plasma	O
)	O
,	O
serum	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
with	O
an	O
elevation	O
in	O
plasma	O
insulin	B-GENE-N
.	O

The	O
treatment	O
also	O
improved	O
the	O
antioxidant	O
status	O
in	O
pancreas	O
as	O
well	O
as	O
plasma	O
of	O
diabetic	O
rats	O
indicating	O
the	O
antioxidant	O
potential	O
of	O
fisetin	B-CHEMICAL
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
DPPH	B-CHEMICAL
and	O
ABTS	B-CHEMICAL
assays	O
substantiate	O
the	O
free	O
radical	O
scavenging	O
activity	O
of	O
fisetin	B-CHEMICAL
.	O

Histological	O
studies	O
of	O
the	O
pancreas	O
also	O
evidenced	O
the	O
tissue	O
protective	O
nature	O
of	O
fisetin	B-CHEMICAL
.	O

It	O
is	O
concluded	O
that	O
,	O
fisetin	B-CHEMICAL
possesses	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
property	O
and	O
may	O
be	O
considered	O
as	O
an	O
adjunct	O
for	O
the	O
treatment	O
of	O
diabetes	O
.	O

Alcohol	O
intoxications	O
during	O
adolescence	O
increase	O
motivation	O
for	O
alcohol	O
in	O
adult	O
rats	O
and	O
induce	O
neuroadaptations	O
in	O
the	O
nucleus	O
accumbens	O
.	O

Adolescent	O
alcohol	O
binge	O
drinking	O
constitutes	O
a	O
major	O
vulnerability	O
factor	O
to	O
develop	O
alcoholism	O
.	O

However	O
,	O
mechanisms	O
underlying	O
this	O
susceptibility	O
remain	O
unknown	O
.	O

We	O
evaluated	O
the	O
effect	O
of	O
adolescent	O
binge	O
-	O
like	O
ethanol	B-CHEMICAL
intoxication	O
on	O
vulnerability	O
to	O
alcohol	O
abuse	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

To	O
model	O
binge	O
-	O
like	O
ethanol	B-CHEMICAL
intoxication	O
,	O
every	O
2	O
days	O
,	O
rats	O
received	O
an	O
ethanol	B-CHEMICAL
injection	O
(	O
3	O
.	O
0	O
g	O
/	O
kg	O
)	O
for	O
2	O
consecutive	O
days	O
across	O
14	O
days	O
either	O
from	O
postnatal	O
day	O
30	O
(	O
PND30	O
)	O
to	O
43	O
(	O
early	O
adolescence	O
)	O
or	O
from	O
PND	O
45	O
to	O
PND	O
58	O
(	O
late	O
adolescence	O
)	O
.	O

In	O
young	O
adult	O
animals	O
,	O
we	O
measured	O
free	O
ethanol	B-CHEMICAL
consumption	O
in	O
the	O
two	O
-	O
bottle	O
choice	O
paradigm	O
,	O
motivation	O
for	O
ethanol	B-CHEMICAL
in	O
the	O
operant	O
self	O
-	O
administration	O
task	O
and	O
both	O
ethanol	B-CHEMICAL
'	O
s	O
rewarding	O
and	O
aversive	O
properties	O
in	O
the	O
conditioned	O
place	O
preference	O
(	O
CPP	O
)	O
and	O
taste	O
aversion	O
(	O
CTA	O
)	O
paradigms	O
.	O

While	O
intermittent	O
ethanol	B-CHEMICAL
intoxications	O
(	O
IEI	O
)	O
during	O
late	O
adolescence	O
had	O
no	O
effect	O
on	O
free	O
-	O
choice	O
10	O
%	O
ethanol	B-CHEMICAL
consumption	O
,	O
we	O
found	O
that	O
IEI	O
during	O
early	O
adolescence	O
promoted	O
free	O
-	O
choice	O
10	O
%	O
ethanol	B-CHEMICAL
consumption	O
,	O
enhanced	O
motivation	O
for	O
ethanol	B-CHEMICAL
in	O
the	O
self	O
-	O
administration	O
paradigm	O
and	O
induced	O
a	O
loss	O
of	O
both	O
ethanol	B-CHEMICAL
-	O
induced	O
CPP	O
and	O
CTA	O
in	O
young	O
adults	O
.	O

No	O
modification	O
in	O
either	O
sucrose	B-CHEMICAL
self	O
-	O
administration	O
or	O
amphetamine	B-CHEMICAL
-	O
induced	O
CPP	O
was	O
observed	O
.	O

As	O
the	O
nucleus	O
accumbens	O
(	O
Nac	O
)	O
is	O
particularly	O
involved	O
in	O
addictive	O
behavior	O
,	O
we	O
analyzed	O
IEI	O
-	O
induced	O
long	O
-	O
term	O
neuroadaptations	O
in	O
the	O
Nac	O
using	O
c	B-GENE-Y
-	I-GENE-Y
Fos	I-GENE-Y
immunohistochemistry	O
and	O
an	O
array	O
of	O
neurotransmission	O
-	O
related	O
genes	O
.	O

This	O
vulnerability	O
to	O
ethanol	B-CHEMICAL
abuse	O
was	O
associated	O
with	O
a	O
lower	O
c	B-GENE-Y
-	I-GENE-Y
Fos	I-GENE-Y
immunoreactivity	O
in	O
the	O
Nac	O
and	O
enduring	O
alterations	O
of	O
the	O
expression	O
of	O
Penk	B-GENE-Y
and	O
Slc6a4	B-GENE-Y
,	O
2	O
neurotransmission	O
-	O
related	O
genes	O
that	O
have	O
been	O
shown	O
to	O
play	O
critical	O
roles	O
in	O
the	O
behavioral	O
effects	O
of	O
ethanol	B-CHEMICAL
and	O
alcoholism	O
.	O

Toxicity	O
of	O
the	O
flame	O
-	O
retardant	O
BDE	B-CHEMICAL
-	I-CHEMICAL
49	I-CHEMICAL
on	O
brain	O
mitochondria	O
and	O
neuronal	O
progenitor	O
striatal	O
cells	O
enhanced	O
by	O
a	O
PTEN	B-GENE-Y
-	O
deficient	O
background	O
.	O

Polybrominated	B-CHEMICAL
diphenyl	I-CHEMICAL
ethers	I-CHEMICAL
(	O
PBDEs	B-CHEMICAL
)	O
represent	O
an	O
important	O
group	O
of	O
flame	O
retardants	O
extensively	O
used	O
,	O
tonnage	O
of	O
which	O
in	O
the	O
environment	O
has	O
been	O
steadily	O
increasing	O
over	O
the	O
past	O
25	O
years	O
.	O

PBDEs	B-CHEMICAL
or	O
metabolites	O
can	O
induce	O
neurotoxicity	O
and	O
mitochondrial	O
dysfunction	O
(	O
MD	O
)	O
through	O
a	O
variety	O
of	O
mechanisms	O
.	O

Recently	O
,	O
PBDEs	B-CHEMICAL
with	O
<	O
5	O
Br	B-CHEMICAL
substitutions	O
(	O
i	O
.	O
e	O
.	O
,	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetrabromodiphenyl	I-CHEMICAL
ether	I-CHEMICAL
[	O
BDE	B-CHEMICAL
-	I-CHEMICAL
47	I-CHEMICAL
]	O
and	O
2	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetrabromodiphenyl	I-CHEMICAL
ether	I-CHEMICAL
[	O
BDE	B-CHEMICAL
-	I-CHEMICAL
49	I-CHEMICAL
]	O
)	O
have	O
gained	O
interest	O
because	O
of	O
their	O
high	O
bioaccumulation	O
.	O

In	O
particular	O
,	O
congeners	O
such	O
as	O
BDE	B-CHEMICAL
-	I-CHEMICAL
49	I-CHEMICAL
arise	O
as	O
one	O
of	O
the	O
most	O
biologically	O
active	O
,	O
with	O
concentrations	O
typically	O
lower	O
than	O
those	O
observed	O
for	O
BDE	B-CHEMICAL
-	I-CHEMICAL
47	I-CHEMICAL
in	O
biological	O
tissues	O
;	O
however	O
,	O
its	O
potential	O
to	O
cause	O
MD	O
at	O
biologically	O
relevant	O
concentrations	O
is	O
unknown	O
.	O

To	O
this	O
end	O
,	O
the	O
effect	O
of	O
BDE	B-CHEMICAL
-	I-CHEMICAL
49	I-CHEMICAL
was	O
studied	O
in	O
brain	O
mitochondria	O
and	O
neuronal	O
progenitor	O
striatal	O
cells	O
(	O
NPC	O
)	O
.	O

BDE	B-CHEMICAL
-	I-CHEMICAL
49	I-CHEMICAL
uncoupled	O
mitochondria	O
at	O
concentrations	O
<	O
0	O
.	O
1	O
nM	O
,	O
whereas	O
at	O
>	O
1	O
nM	O
,	O
it	O
inhibited	O
the	O
electron	O
transport	O
at	O
Complex	O
V	O
(	O
mixed	O
type	O
inhibition	O
;	O
IC	O
(	O
50	O
)	O
=	O
6	O
nM	O
)	O
and	O
Complex	O
IV	O
(	O
noncompetitive	O
inhibition	O
;	O
IC	O
(	O
50	O
)	O
=	O
40	O
nM	O
)	O
.	O

These	O
concentrations	O
are	O
easily	O
achieved	O
in	O
plasma	O
concentrations	O
considering	O
that	O
BDE	B-CHEMICAL
-	I-CHEMICAL
49	I-CHEMICAL
(	O
this	O
study	O
,	O
400	O
-	O
fold	O
)	O
and	O
other	O
PBDEs	B-CHEMICAL
accumulate	O
1	O
-	O
3	O
orders	O
of	O
magnitude	O
in	O
the	O
cells	O
,	O
particularly	O
in	O
mitochondria	O
and	O
microsomes	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
NPC	O
and	O
exacerbated	O
with	O
PTEN	B-GENE-Y
(	O
negative	O
modulator	O
of	O
the	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
pathway	O
)	O
deficiency	O
,	O
background	O
associated	O
with	O
autism	O
-	O
like	O
behavior	O
,	O
schizophrenia	O
,	O
and	O
epilepsy	O
.	O

PBDE	B-CHEMICAL
-	O
mediated	O
MD	O
per	O
se	O
or	O
enhanced	O
by	O
a	O
background	O
that	O
confers	O
susceptibility	O
to	O
this	O
exposure	O
may	O
have	O
profound	O
implications	O
in	O
the	O
energy	O
balance	O
of	O
brain	O
.	O

Molecular	O
mechanisms	O
of	O
fibrosis	O
-	O
associated	O
promotion	O
of	O
liver	O
carcinogenesis	O
.	O

Hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
mostly	O
develops	O
in	O
patients	O
with	O
advanced	O
fibrosis	O
;	O
however	O
,	O
the	O
mechanisms	O
of	O
interaction	O
between	O
a	O
genotoxic	O
insult	O
and	O
fibrogenesis	O
are	O
not	O
well	O
understood	O
.	O

This	O
study	O
tested	O
a	O
hypothesis	O
that	O
fibrosis	O
promotes	O
HCC	O
via	O
a	O
mechanism	O
that	O
involves	O
activation	O
of	O
liver	O
stem	O
cells	O
.	O

First	O
,	O
B6C3F1	O
mice	O
were	O
administered	O
diethylnitrosamine	B-CHEMICAL
(	O
DEN	B-CHEMICAL
;	O
single	O
ip	O
injection	O
of	O
1mg	O
/	O
kg	O
at	O
14	O
days	O
of	O
age	O
)	O
.	O

Second	O
,	O
carbon	B-CHEMICAL
tetrachloride	I-CHEMICAL
(	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
;	O
0	O
.	O
2ml	O
/	O
kg	O
,	O
2	O
/	O
week	O
ip	O
starting	O
at	O
8	O
weeks	O
of	O
age	O
)	O
was	O
administered	O
for	O
9	O
or	O
14	O
weeks	O
to	O
develop	O
advanced	O
liver	O
fibrosis	O
.	O

In	O
animals	O
treated	O
with	O
DEN	B-CHEMICAL
as	O
neonates	O
,	O
presence	O
of	O
liver	O
fibrosis	O
led	O
to	O
more	O
than	O
doubling	O
(	O
to	O
100	O
%	O
)	O
of	O
the	O
liver	O
tumor	O
incidence	O
as	O
early	O
as	O
5	O
months	O
of	O
age	O
.	O

This	O
effect	O
was	O
associated	O
with	O
activation	O
of	O
cells	O
with	O
progenitor	O
features	O
in	O
noncancerous	O
liver	O
tissue	O
,	O
including	O
markers	O
of	O
replicative	O
senescence	O
(	O
p16	B-GENE-Y
)	O
,	O
oncofetal	O
transformation	O
(	O
Afp	B-GENE-Y
,	O
H19	B-GENE-Y
,	O
and	O
Bex1	B-GENE-Y
)	O
,	O
and	O
increased	O
"	O
stemness	O
"	O
(	O
Prom1	B-GENE-Y
and	O
Epcam	B-GENE-Y
)	O
.	O

In	O
contrast	O
,	O
the	O
dose	O
of	O
DEN	B-CHEMICAL
used	O
did	O
not	O
modify	O
the	O
extent	O
of	O
liver	O
inflammation	O
,	O
fibrogenesis	O
,	O
oxidative	O
stress	O
,	O
proliferation	O
,	O
or	O
apoptosis	O
induced	O
by	O
subchronic	O
CCl	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
administration	O
.	O

This	O
study	O
demonstrates	O
the	O
potential	O
role	O
of	O
liver	O
stem	O
-	O
like	O
cells	O
in	O
the	O
mechanisms	O
of	O
chemical	O
-	O
induced	O
,	O
fibrosis	O
-	O
promoted	O
HCC	O
.	O

We	O
posit	O
that	O
the	O
combination	O
of	O
genotoxic	O
and	O
fibrogenic	O
insults	O
is	O
a	O
sensible	O
approach	O
to	O
model	O
liver	O
carcinogenesis	O
in	O
experimental	O
animals	O
.	O

These	O
results	O
may	O
contribute	O
to	O
identification	O
of	O
cirrhotic	O
patients	O
predisposed	O
to	O
HCC	O
by	O
analyzing	O
the	O
expression	O
of	O
hepatic	O
progenitor	O
cell	O
markers	O
in	O
the	O
noncancerous	O
liver	O
tissue	O
.	O

Anti	O
-	O
diabetic	O
property	O
of	O
Tinospora	O
cordifolia	O
and	O
its	O
active	O
compound	O
is	O
mediated	O
through	O
the	O
expression	O
of	O
Glut	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
in	O
L6	O
myotubes	O
.	O

Tinospora	O
cordifolia	O
is	O
a	O
well	O
reported	O
plant	O
possessing	O
numerous	O
medicinal	O
values	O
including	O
anti	O
-	O
diabetic	O
property	O
.	O

Aim	O
of	O
the	O
present	O
study	O
is	O
to	O
study	O
the	O
mechanism	O
of	O
action	O
of	O
Tinospora	O
cordifolia	O
and	O
its	O
active	O
compound	O
in	O
differentiated	O
myocytes	O
,	O
L6	O
cells	O
.	O

Key	O
marker	O
of	O
diabetes	O
in	O
cells	O
is	O
the	O
insulin	B-GENE-Y
dependent	I-GENE-Y
glucose	I-GENE-Y
transporter	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
Glut	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
which	O
also	O
responds	O
to	O
exogenous	O
chemicals	O
,	O
and	O
is	O
over	O
expressed	O
up	O
to	O
5	O
-	O
and	O
4	O
-	O
fold	O
,	O
by	O
Tinospora	O
cordifolia	O
and	O
palmatine	B-CHEMICAL
,	O
respectively	O
.	O

Next	O
to	O
Glut	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
the	O
predominant	O
protein	O
influencing	O
glucose	B-CHEMICAL
metabolism	O
is	O
PPARα	B-GENE-N
and	I-GENE-N
γ	I-GENE-N
whose	O
expressions	O
were	O
also	O
positively	O
modulated	O
.	O

Further	O
,	O
the	O
inhibitors	O
of	O
insulin	B-GENE-N
pathway	O
prevented	O
glucose	B-CHEMICAL
uptake	O
mediated	O
by	O
Tinospora	O
cordifolia	O
and	O
palmatine	B-CHEMICAL
which	O
shows	O
that	O
the	O
activity	O
is	O
majorly	O
mediated	O
through	O
insulin	B-GENE-N
pathway	O
.	O

Zinc	B-CHEMICAL
drives	O
a	O
tertiary	O
fold	O
in	O
the	O
prion	B-GENE-N
protein	I-GENE-N
with	O
familial	O
disease	O
mutation	O
sites	O
at	O
the	O
interface	O
.	O

The	O
cellular	O
prion	B-GENE-Y
protein	I-GENE-Y
PrP	I-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
)	I-GENE-Y
consists	O
of	O
two	O
domains	O
-	O
-	O
a	O
flexible	O
N	B-CHEMICAL
-	O
terminal	O
domain	O
,	O
which	O
participates	O
in	O
copper	B-CHEMICAL
and	O
zinc	B-CHEMICAL
regulation	O
,	O
and	O
a	O
largely	O
helical	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
that	O
converts	O
to	O
β	O
sheet	O
in	O
the	O
course	O
of	O
prion	O
disease	O
.	O

These	O
two	O
domains	O
are	O
thought	O
to	O
be	O
fully	O
independent	O
and	O
noninteracting	O
.	O

Compelling	O
cellular	O
and	O
biophysical	O
studies	O
,	O
however	O
,	O
suggest	O
a	O
higher	O
order	O
structure	O
that	O
is	O
relevant	O
to	O
both	O
PrP	B-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
)	I-GENE-Y
function	O
and	O
misfolding	O
in	O
disease	O
.	O

Here	O
,	O
we	O
identify	O
a	O
Zn²	B-CHEMICAL
⁺	I-CHEMICAL
-	O
driven	O
N	B-CHEMICAL
-	O
terminal	O
to	O
C	B-CHEMICAL
-	O
terminal	O
tertiary	O
interaction	O
in	O
PrP	B-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
)	I-GENE-Y
.	O

The	O
C	B-CHEMICAL
-	O
terminal	O
surface	O
participating	O
in	O
this	O
interaction	O
carries	O
the	O
majority	O
of	O
the	O
point	O
mutations	O
that	O
confer	O
familial	O
prion	O
disease	O
.	O

Investigation	O
of	O
mutant	O
PrPs	B-GENE-N
finds	O
a	O
systematic	O
relationship	O
between	O
the	O
type	O
of	O
mutation	O
and	O
the	O
apparent	O
strength	O
of	O
this	O
domain	O
structure	O
.	O

The	O
structural	O
features	O
identified	O
here	O
suggest	O
mechanisms	O
by	O
which	O
physiologic	O
metal	O
ions	O
trigger	O
PrP	B-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
)	I-GENE-Y
trafficking	O
and	O
control	O
prion	O
disease	O
.	O

Cerebral	O
and	O
extracerebral	O
cholesterol	B-CHEMICAL
metabolism	O
and	O
CSF	O
markers	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

The	O
disturbances	O
of	O
the	O
cholesterol	B-CHEMICAL
synthesis	O
and	O
metabolism	O
described	O
in	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
may	O
be	O
both	O
a	O
consequence	O
of	O
the	O
neurodegenerative	O
process	O
and	O
a	O
contributor	O
to	O
the	O
pathogenesis	O
.	O

These	O
putative	O
relationships	O
and	O
their	O
underlying	O
mechanisms	O
are	O
not	O
well	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
relationship	O
between	O
the	O
cerebral	O
and	O
extracerebral	O
cholesterol	B-CHEMICAL
synthesis	O
and	O
metabolism	O
,	O
and	O
the	O
AD	O
pathology	O
as	O
reflected	O
by	O
CSF	O
markers	O
in	O
humans	O
.	O

We	O
evaluated	O
the	O
relationships	O
between	O
the	O
plasma	O
and	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
concentrations	O
of	O
cholesterol	B-CHEMICAL
,	O
the	O
cholesterol	B-CHEMICAL
precursors	O
lanosterol	B-CHEMICAL
,	O
lathosterol	B-CHEMICAL
and	O
desmosterol	B-CHEMICAL
,	O
and	O
the	O
cholesterol	B-CHEMICAL
elimination	O
products	O
24S	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
and	O
27	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
,	O
and	O
the	O
CSF	O
markers	O
for	O
AD	O
pathology	O
Aβ1	B-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
and	O
p	B-GENE-Y
-	I-GENE-Y
tau181	I-GENE-Y
in	O
86	O
subjects	O
with	O
normal	O
cognition	O
and	O
in	O
107	O
AD	O
patients	O
.	O

CSF	O
desmosterol	B-CHEMICAL
,	O
cholesterol	B-CHEMICAL
and	O
24S	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
in	O
the	O
AD	O
group	O
,	O
and	O
CSF	O
24S	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
in	O
the	O
control	O
group	O
correlated	O
with	O
the	O
p	B-GENE-Y
-	I-GENE-Y
tau181	I-GENE-Y
levels	O
.	O

Neither	O
CSF	O
nor	O
plasma	O
concentrations	O
of	O
the	O
included	O
compounds	O
correlated	O
with	O
the	O
CSF	O
Aβ1	B-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
levels	O
.	O

In	O
multivariate	O
regression	O
tests	O
including	O
age	O
,	O
gender	O
,	O
albumin	O
ratio	O
,	O
number	O
of	O
the	O
APOEɛ4	B-GENE-Y
alleles	O
,	O
and	O
diagnosis	O
,	O
p	B-GENE-Y
-	I-GENE-Y
tau181	I-GENE-Y
levels	O
independently	O
predicted	O
the	O
CSF	O
desmosterol	B-CHEMICAL
,	O
cholesterol	B-CHEMICAL
and	O
24S	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
concentrations	O
.	O

The	O
associations	O
remained	O
significant	O
for	O
CSF	O
cholesterol	B-CHEMICAL
and	O
24S	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
when	O
analyses	O
were	O
separately	O
performed	O
in	O
the	O
AD	O
group	O
.	O

The	O
results	O
suggest	O
that	O
alterations	O
of	O
CNS	O
cholesterol	B-CHEMICAL
de	O
novo	O
genesis	O
and	O
metabolism	O
are	O
related	O
to	O
neurodegeneration	O
and	O
in	O
particular	O
to	O
the	O
cerebral	O
accumulation	O
of	O
phosphorylated	B-GENE-Y
tau	I-GENE-Y
.	O

In	O
vitro	O
study	O
of	O
intestinal	O
transport	O
of	O
fluoride	B-CHEMICAL
using	O
the	O
Caco	O
-	O
2	O
cell	O
line	O
.	O

Water	O
and	O
food	O
are	O
the	O
main	O
sources	O
of	O
fluoride	B-CHEMICAL
exposure	O
and	O
therefore	O
it	O
is	O
necessary	O
to	O
study	O
intestinal	O
absorption	O
in	O
order	O
to	O
make	O
a	O
correct	O
evaluation	O
of	O
the	O
risk	O
/	O
benefit	O
associated	O
with	O
exposure	O
to	O
fluoride	B-CHEMICAL
.	O

The	O
present	O
study	O
characterizes	O
intestinal	O
transport	O
of	O
fluoride	B-CHEMICAL
,	O
using	O
the	O
Caco	O
-	O
2	O
cell	O
line	O
as	O
a	O
model	O
of	O
the	O
intestinal	O
epithelium	O
,	O
and	O
evaluates	O
the	O
coefficients	O
of	O
apparent	O
permeability	O
and	O
intracellular	O
accumulation	O
in	O
various	O
conditions	O
(	O
pH	O
,	O
temperature	O
,	O
opening	O
of	O
cell	O
junctions	O
,	O
presence	O
of	O
anions	O
)	O
.	O

The	O
results	O
indicate	O
that	O
fluoride	B-CHEMICAL
is	O
an	O
element	O
with	O
moderate	O
absorption	O
(	O
<	O
70	O
%	O
)	O
in	O
both	O
directions	O
(	O
absorptive	O
and	O
secretory	O
)	O
.	O

Both	O
in	O
absorption	O
(	O
apical	O
-	O
basolateral	O
)	O
and	O
in	O
secretion	O
(	O
basolateral	O
-	O
apical	O
)	O
there	O
is	O
transport	O
by	O
the	O
paracellular	O
pathway	O
,	O
which	O
may	O
be	O
considered	O
predominant	O
.	O

Absorption	O
and	O
secretion	O
of	O
fluoride	B-CHEMICAL
increase	O
at	O
acid	O
pH	O
levels	O
,	O
possibly	O
because	O
of	O
its	O
non	O
-	O
ionized	O
state	O
at	O
these	O
pHs	O
and	O
/	O
or	O
because	O
of	O
participation	O
of	O
a	O
F	B-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
/	I-GENE-N
H	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
cotransporter	I-GENE-N
or	O
a	O
F	B-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
/	I-GENE-N
OH	I-GENE-N
(	I-GENE-N
-	I-GENE-N
)	I-GENE-N
antiporter	I-GENE-N
.	O

The	O
results	O
also	O
suggest	O
transcellular	O
participation	O
of	O
mechanisms	O
involved	O
in	O
transport	O
of	O
Cl	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
and	O
of	O
an	O
active	O
transport	O
in	O
the	O
secretory	O
direction	O
.	O

The	O
present	O
study	O
extend	O
the	O
knowledge	O
on	O
the	O
cellular	O
transport	O
of	O
fluoride	B-CHEMICAL
and	O
provide	O
the	O
basis	O
for	O
future	O
studies	O
aimed	O
at	O
identifying	O
potential	O
transporters	O
involved	O
in	O
human	O
fluoride	B-CHEMICAL
absorption	O
.	O

Nuclear	B-GENE-N
receptor	I-GENE-N
CAR	B-GENE-Y
specifically	O
activates	O
the	O
two	O
-	O
pore	O
K	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
Kcnk1	B-GENE-Y
gene	O
in	O
male	O
mouse	O
livers	O
,	O
which	O
attenuates	O
phenobarbital	B-CHEMICAL
-	O
induced	O
hepatic	O
hyperplasia	O
.	O

KCNK1	B-GENE-Y
,	O
a	O
member	O
of	O
the	O
family	O
of	O
two	O
-	O
pore	O
K	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
ion	I-GENE-N
channels	I-GENE-N
,	O
is	O
specifically	O
induced	O
in	O
the	O
livers	O
of	O
male	O
mice	O
after	O
phenobarbital	B-CHEMICAL
treatment	O
.	O

Here	O
,	O
we	O
have	O
determined	O
the	O
molecular	O
mechanism	O
of	O
this	O
male	O
-	O
specific	O
activation	O
of	O
the	O
Kcnk1	B-GENE-Y
gene	O
and	O
characterized	O
KCNK1	B-GENE-Y
as	O
a	O
phenobarbital	B-CHEMICAL
-	O
inducible	O
antihyperplasia	O
factor	O
.	O

Upon	O
activation	O
by	O
phenobarbital	B-CHEMICAL
,	O
nuclear	B-GENE-N
receptor	I-GENE-N
CAR	B-GENE-Y
binds	O
the	O
97	O
-	O
bp	O
response	O
element	O
(	O
-	O
2441	O
/	O
-	O
2345	O
)	O
within	O
the	O
Kcnk1	B-GENE-N
promoter	I-GENE-N
.	O

This	O
binding	O
is	O
observed	O
in	O
the	O
livers	O
of	O
male	O
mice	O
,	O
but	O
not	O
in	O
the	O
livers	O
of	O
female	O
mice	O
and	O
requires	O
the	O
pituitary	O
gland	O
,	O
because	O
hypophysectomy	O
abrogates	O
it	O
.	O

Hyperplasia	O
further	O
progressed	O
in	O
the	O
livers	O
of	O
Kcnk1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
male	O
mice	O
compared	O
with	O
those	O
of	O
Kcnk1	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
males	O
after	O
phenobarbital	B-CHEMICAL
treatment	O
.	O

Thus	O
,	O
KCNK1	B-GENE-Y
suppresses	O
phenobarbital	B-CHEMICAL
-	O
induced	O
hyperplasia	O
.	O

These	O
results	O
indicate	O
that	O
phenobarbital	B-CHEMICAL
treatment	O
induces	O
KCNK1	B-GENE-Y
to	O
elicit	O
a	O
male	O
-	O
specific	O
and	O
growth	O
-	O
suppressing	O
signal	O
.	O

Thus	O
,	O
KCNK1	B-GENE-Y
and	O
Kcnk1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
provide	O
an	O
experimental	O
tool	O
for	O
further	O
investigation	O
into	O
the	O
molecular	O
mechanism	O
of	O
CAR	B-GENE-Y
-	O
mediated	O
promotion	O
of	O
the	O
development	O
of	O
hepatocellular	O
carcinoma	O
in	O
mice	O
.	O

ABT	B-CHEMICAL
-	I-CHEMICAL
199	I-CHEMICAL
,	O
a	O
potent	O
and	O
selective	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
,	O
achieves	O
antitumor	O
activity	O
while	O
sparing	O
platelets	O
.	O

Proteins	O
in	O
the	O
B	B-GENE-Y
cell	I-GENE-Y
CLL	I-GENE-Y
/	I-GENE-Y
lymphoma	I-GENE-Y
2	I-GENE-Y
(	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
family	O
are	O
key	O
regulators	O
of	O
the	O
apoptotic	O
process	O
.	O

This	O
family	O
comprises	O
proapoptotic	O
and	O
prosurvival	O
proteins	O
,	O
and	O
shifting	O
the	O
balance	O
toward	O
the	O
latter	O
is	O
an	O
established	O
mechanism	O
whereby	O
cancer	O
cells	O
evade	O
apoptosis	O
.	O

The	O
therapeutic	O
potential	O
of	O
directly	O
inhibiting	O
prosurvival	O
proteins	O
was	O
unveiled	O
with	O
the	O
development	O
of	O
navitoclax	B-CHEMICAL
,	O
a	O
selective	O
inhibitor	O
of	O
both	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
1	I-GENE-Y
(	O
BCL	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
(	I-GENE-Y
L	I-GENE-Y
)	I-GENE-Y
)	O
,	O
which	O
has	O
shown	O
clinical	O
efficacy	O
in	O
some	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
dependent	O
hematological	O
cancers	O
.	O

However	O
,	O
concomitant	O
on	O
-	O
target	O
thrombocytopenia	O
caused	O
by	O
BCL	B-GENE-Y
-	I-GENE-Y
X	I-GENE-Y
(	I-GENE-Y
L	I-GENE-Y
)	I-GENE-Y
inhibition	O
limits	O
the	O
efficacy	O
achievable	O
with	O
this	O
agent	O
.	O

Here	O
we	O
report	O
the	O
re	O
-	O
engineering	O
of	O
navitoclax	B-CHEMICAL
to	O
create	O
a	O
highly	O
potent	O
,	O
orally	O
bioavailable	O
and	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
selective	O
inhibitor	O
,	O
ABT	B-CHEMICAL
-	I-CHEMICAL
199	I-CHEMICAL
.	O

This	O
compound	O
inhibits	O
the	O
growth	O
of	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
dependent	O
tumors	O
in	O
vivo	O
and	O
spares	O
human	O
platelets	O
.	O

A	O
single	O
dose	O
of	O
ABT	B-CHEMICAL
-	I-CHEMICAL
199	I-CHEMICAL
in	O
three	O
patients	O
with	O
refractory	O
chronic	O
lymphocytic	O
leukemia	O
resulted	O
in	O
tumor	O
lysis	O
within	O
24	O
h	O
.	O

These	O
data	O
indicate	O
that	O
selective	O
pharmacological	O
inhibition	O
of	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
shows	O
promise	O
for	O
the	O
treatment	O
of	O
BCL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
dependent	O
hematological	O
cancers	O
.	O

Smoothened	B-GENE-Y
is	O
a	O
fully	O
competent	O
activator	O
of	O
the	O
heterotrimeric	O
G	B-GENE-N
protein	I-GENE-N
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
.	O

Smoothened	B-GENE-Y
(	O
Smo	B-GENE-Y
)	O
is	O
a	O
7	O
-	O
transmembrane	O
protein	O
essential	O
to	O
the	O
activation	O
of	O
Gli	B-GENE-Y
transcription	O
factors	O
(	O
Gli	B-GENE-Y
)	O
by	O
hedgehog	O
morphogens	O
.	O

The	O
structure	O
of	O
Smo	B-GENE-Y
implies	O
interactions	O
with	O
heterotrimeric	O
G	B-GENE-N
proteins	I-GENE-N
,	O
but	O
the	O
degree	O
to	O
which	O
G	B-GENE-N
proteins	I-GENE-N
participate	O
in	O
the	O
actions	O
of	O
hedgehogs	O
remains	O
controversial	O
.	O

We	O
posit	O
that	O
the	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
family	O
of	O
G	B-GENE-N
proteins	I-GENE-N
provides	O
to	O
hedgehogs	O
the	O
ability	O
to	O
expand	O
well	O
beyond	O
the	O
bounds	O
of	O
Gli	B-GENE-Y
.	O

In	O
this	O
regard	O
,	O
we	O
evaluate	O
here	O
the	O
efficacy	O
of	O
Smo	B-GENE-Y
as	O
it	O
relates	O
to	O
the	O
activation	O
of	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
,	O
by	O
comparing	O
Smo	B-GENE-Y
with	O
the	O
5	B-GENE-Y
-	I-GENE-Y
hydroxytryptamine	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
(	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
)	O
receptor	O
,	O
a	O
quintessential	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
.	O

We	O
find	O
that	O
with	O
use	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
35	I-CHEMICAL
)	I-CHEMICAL
S	I-CHEMICAL
]	I-CHEMICAL
guanosine	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
thio	I-CHEMICAL
)	I-CHEMICAL
triphosphate	I-CHEMICAL
,	O
first	O
,	O
with	O
forms	O
of	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
endogenous	O
to	O
human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
-	O
293	O
cells	O
made	O
to	O
express	O
epitope	O
-	O
tagged	O
receptors	O
and	O
,	O
second	O
,	O
with	O
individual	O
forms	O
of	O
Gα	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
fused	O
to	O
the	O
C	O
terminus	O
of	O
each	O
receptor	O
,	O
Smo	B-GENE-Y
is	O
equivalent	O
to	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
(	I-GENE-Y
1A	I-GENE-Y
)	I-GENE-Y
receptor	O
in	O
the	O
assay	O
as	O
it	O
relates	O
to	O
capacity	O
to	O
activate	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
.	O

This	O
finding	O
is	O
true	O
regardless	O
of	O
subtype	O
of	O
G	B-GENE-N
(	I-GENE-N
i	I-GENE-N
)	I-GENE-N
(	O
e	O
.	O
g	O
.	O
,	O
G	B-GENE-Y
(	I-GENE-Y
i2	I-GENE-Y
)	I-GENE-Y
,	O
G	B-GENE-Y
(	I-GENE-Y
o	I-GENE-Y
)	I-GENE-Y
,	O
and	O
G	B-GENE-Y
(	I-GENE-Y
z	I-GENE-Y
)	I-GENE-Y
)	O
tested	O
.	O

We	O
also	O
find	O
that	O
Smo	B-GENE-Y
endogenous	O
to	O
HEK	O
-	O
293	O
cells	O
,	O
ostensibly	O
through	O
inhibition	O
of	O
adenylyl	B-GENE-N
cyclase	I-GENE-N
,	O
decreases	O
intracellular	O
levels	O
of	O
cAMP	B-CHEMICAL
.	O

The	O
results	O
indicate	O
that	O
Smo	B-GENE-Y
is	O
a	O
receptor	O
that	O
can	O
engage	O
not	O
only	O
Gli	B-GENE-Y
but	O
also	O
other	O
more	O
immediate	O
effectors	O
.	O

Antigenotoxic	O
potencies	O
of	O
a	O
lichen	O
species	O
,	O
Evernia	O
prunastri	O
.	O

In	O
this	O
article	O
,	O
the	O
genotoxic	O
and	O
antigenotoxic	O
effects	O
of	O
methanol	B-CHEMICAL
extract	O
of	O
Evernia	O
prunastri	O
(	O
Huds	O
.	O
)	O
Willd	O
.	O

(	O
MEP	O
)	O
were	O
studied	O
using	O
WP2	O
,	O
Ames	O
(	O
TA1535	O
and	O
TA1537	O
)	O
and	O
sister	O
chromatid	O
exchange	O
(	O
SCE	O
)	O
test	O
systems	O
.	O

The	O
results	O
obtained	O
from	O
bacterial	O
test	O
systems	O
demonstrated	O
that	O
MEP	O
has	O
strong	O
antimutagenic	O
potencies	O
on	O
TA1537	O
and	O
WP2	O
strains	O
.	O

The	O
highest	O
inhibition	O
rates	O
for	O
MEP	O
on	O
TA1537	O
and	O
WP2	O
strains	O
were	O
37	O
.	O
70	O
%	O
and	O
69	O
.	O
70	O
%	O
,	O
respectively	O
.	O

According	O
to	O
the	O
SCE	O
test	O
system	O
,	O
MEP	O
reduced	O
the	O
genotoxic	O
effects	O
of	O
aflatoxin	B-CHEMICAL
.	O

In	O
order	O
to	O
clarify	O
the	O
mechanism	O
underlying	O
the	O
antigenotoxic	O
effects	O
of	O
MEP	O
,	O
the	O
antioxidants	O
were	O
determined	O
.	O

Cotreatments	O
of	O
5	O
,	O
10	O
and	O
20	O
µg	O
/	O
mL	O
concentrations	O
of	O
MEP	O
with	O
aflatoxin	B-CHEMICAL
B	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
decreased	O
the	O
frequencies	O
of	O
SCE	O
and	O
the	O
malondialdehyde	B-CHEMICAL
level	O
and	O
increased	O
amount	O
of	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
glutathione	B-CHEMICAL
and	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
which	O
were	O
decreased	O
by	O
aflatoxin	B-CHEMICAL
.	O

The	O
data	O
obtained	O
from	O
this	O
work	O
have	O
clearly	O
shown	O
that	O
MEP	O
has	O
significant	O
antigenotoxic	O
effects	O
which	O
are	O
thought	O
to	O
be	O
partly	O
due	O
to	O
the	O
antioxidant	O
activities	O
and	O
antioxidant	O
inducing	O
capability	O
of	O
MEP	O
.	O

This	O
is	O
the	O
first	O
report	O
indicating	O
the	O
antigenotoxic	O
activities	O
of	O
MEP	O
against	O
several	O
mutagen	O
agents	O
such	O
as	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
nitrosoguanidine	I-CHEMICAL
,	O
acridin	B-CHEMICAL
and	O
aflatoxin	B-CHEMICAL
.	O

Hepatocyte	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
activator	I-GENE-Y
inhibitor	I-GENE-Y
type	I-GENE-Y
2	I-GENE-Y
(	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
modulates	O
hepcidin	B-GENE-Y
expression	O
by	O
inhibiting	O
the	O
cell	O
surface	O
protease	B-GENE-N
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
a	O
recently	O
identified	O
cell	O
surface	O
protease	B-GENE-N
,	O
is	O
the	O
key	O
enzyme	O
of	O
iron	B-CHEMICAL
homoeostasis	O
modulating	O
the	O
expression	O
of	O
the	O
liver	O
peptide	O
hormone	O
hepcidin	B-GENE-Y
.	O

HAI	B-GENE-N
(	B-GENE-N
hepatocyte	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
activator	I-GENE-N
inhibitor	I-GENE-N
)	I-GENE-N
types	I-GENE-N
1	I-GENE-N
and	I-GENE-N
2	I-GENE-N
(	O
HAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
respectively	O
)	O
have	O
been	O
shown	O
to	O
inhibit	O
the	O
close	O
homologue	O
,	O
i	O
.	O
e	O
.	O
matriptase	B-GENE-N
.	O

By	O
co	O
-	O
expressing	O
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
the	O
inhibitor	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
we	O
have	O
identified	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
displaying	O
high	O
inhibitory	O
potential	O
against	O
matriptase	B-GENE-N
-	I-GENE-N
2	I-GENE-N
at	O
the	O
cell	O
surface	O
as	O
well	O
as	O
in	O
conditioned	O
medium	O
.	O

Accordingly	O
,	O
complex	O
formation	O
between	O
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
was	O
demonstrated	O
by	O
isolation	O
of	O
the	O
complex	O
via	O
immobilizing	O
either	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
or	O
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
from	O
lysates	O
and	O
conditioned	O
medium	O
of	O
co	O
-	O
expressing	O
cells	O
.	O

Furthermore	O
,	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
indirectly	O
influences	O
the	O
expression	O
of	O
the	O
hepcidin	B-GENE-Y
-	O
encoding	O
gene	O
HAMP	B-GENE-Y
.	O

The	O
inhibitor	O
abrogates	O
the	O
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
mediated	O
suppression	O
of	O
HAMP	B-GENE-Y
expression	O
,	O
presumably	O
by	O
inhibiting	O
the	O
supposed	O
potential	O
of	O
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
to	O
cleave	O
membrane	O
-	O
bound	O
HJV	O
(	O
haemojuvelin	O
)	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
the	O
present	O
study	O
have	O
characterized	O
HAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
as	O
an	O
inhibitor	O
of	O
matriptase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
that	O
modulates	O
the	O
synthesis	O
of	O
hepcidin	B-GENE-Y
and	O
provides	O
new	O
insights	O
into	O
the	O
regulatory	O
mechanism	O
of	O
iron	B-CHEMICAL
homoeostasis	O
,	O
with	O
clinical	O
importance	O
for	O
a	O
treatment	O
of	O
iron	B-CHEMICAL
overload	O
diseases	O
.	O

Development	O
of	O
new	O
cyclic	O
plasmin	B-GENE-Y
inhibitors	O
with	O
excellent	O
potency	O
and	O
selectivity	O
.	O

The	O
trypsin	B-GENE-N
-	O
like	O
serine	B-GENE-N
protease	I-GENE-N
plasmin	B-GENE-Y
is	O
a	O
target	O
for	O
the	O
development	O
of	O
antifibrinolytic	O
drugs	O
for	O
use	O
in	O
cardiac	O
surgery	O
with	O
cardiopulmonary	O
bypass	O
or	O
organ	O
transplantations	O
to	O
reduce	O
excessive	O
blood	O
loss	O
.	O

The	O
optimization	O
of	O
our	O
recently	O
described	O
substrate	O
-	O
analogue	O
plasmin	B-GENE-Y
inhibitors	O
,	O
which	O
were	O
cyclized	O
between	O
their	O
P3	O
and	O
P2	O
side	O
chains	O
,	O
provided	O
a	O
new	O
series	O
with	O
improved	O
efficacy	O
and	O
excellent	O
selectivity	O
.	O

The	O
most	O
potent	O
inhibitor	O
8	O
binds	O
to	O
plasmin	B-GENE-Y
with	O
an	O
inhibition	O
constant	O
of	O
0	O
.	O
2	O
nM	O
,	O
whereas	O
K	O
(	O
i	O
)	O
values	O
>	O
1	O
μM	O
were	O
determined	O
for	O
nearly	O
all	O
other	O
tested	O
trypsin	B-GENE-N
-	I-GENE-N
like	I-GENE-N
serine	I-GENE-N
proteases	I-GENE-N
,	O
with	O
the	O
exception	O
of	O
trypsin	B-GENE-N
,	O
which	O
is	O
also	O
inhibited	O
in	O
the	O
nanomolar	O
range	O
.	O

Docking	O
studies	O
revealed	O
a	O
potential	O
binding	O
mode	O
in	O
the	O
widely	O
open	O
active	O
site	O
of	O
plasmin	B-GENE-Y
that	O
explains	O
the	O
strong	O
potency	O
and	O
selectivity	O
profile	O
of	O
these	O
inhibitors	O
.	O

The	O
dialkylated	O
piperazine	B-CHEMICAL
-	O
linker	O
segment	O
contributes	O
to	O
an	O
excellent	O
solubility	O
of	O
all	O
analogues	O
.	O

Based	O
on	O
their	O
overall	O
profile	O
the	O
presented	O
inhibitors	O
are	O
well	O
suited	O
for	O
further	O
development	O
as	O
injectable	O
antifibrinolytic	O
drugs	O
.	O

Tunable	O
morphology	O
and	O
mesophase	O
formation	O
by	O
naphthalene	B-CHEMICAL
-	O
containing	O
poly	B-CHEMICAL
(	I-CHEMICAL
aryl	I-CHEMICAL
ether	I-CHEMICAL
)	I-CHEMICAL
dendron	O
-	O
based	O
low	O
-	O
molecular	O
-	O
weight	O
fluorescent	O
gels	O
.	O

Novel	O
poly	B-CHEMICAL
(	I-CHEMICAL
aryl	I-CHEMICAL
ether	I-CHEMICAL
)	I-CHEMICAL
dendron	O
-	O
based	O
low	O
-	O
molecular	O
-	O
weight	O
organogelaters	O
(	O
LMWG	O
)	O
containing	O
naphthalene	B-CHEMICAL
units	O
at	O
the	O
core	O
have	O
been	O
synthesized	O
,	O
and	O
the	O
self	O
-	O
assembly	O
of	O
the	O
system	O
has	O
been	O
examined	O
in	O
a	O
variety	O
of	O
solvents	O
and	O
solvent	O
mixtures	O
.	O

The	O
compounds	O
readily	O
form	O
gels	O
with	O
attractive	O
critical	O
gel	O
concentration	O
values	O
associated	O
with	O
gelation	O
-	O
induced	O
enhanced	O
emission	O
(	O
GIEE	O
)	O
.	O

In	O
addition	O
to	O
the	O
remarkable	O
properties	O
of	O
the	O
previously	O
reported	O
anthracene	B-CHEMICAL
and	O
pyrene	B-CHEMICAL
analogues	O
(	O
Rajamalli	O
,	O
P	O
.	O
;	O
Prasad	O
,	O
E	O
.	O
Org	O
.	O
Lett	O
.	O
2011	O
,	O
13	O
,	O
3714	O
and	O
Rajamalli	O
,	O
P	O
.	O
;	O
Prasad	O
,	O
E	O
.	O
Soft	O
Matter2012	O
,	O
8	O
,	O
8896	O
)	O
,	O
the	O
self	O
-	O
assembled	O
systems	O
exhibit	O
distinctly	O
different	O
structure	O
-	O
property	O
relationships	O
.	O

Unlike	O
the	O
reported	O
ones	O
,	O
the	O
present	O
system	O
forms	O
sheetlike	O
morphology	O
in	O
nonpolar	O
solvent	O
mixtures	O
,	O
giant	O
vesicles	O
in	O
polar	O
solvent	O
mixtures	O
,	O
and	O
lamellar	O
or	O
hexagonal	O
columnar	O
phases	O
in	O
single	O
solvents	O
.	O

The	O
unique	O
properties	O
of	O
the	O
self	O
-	O
assembled	O
systems	O
,	O
which	O
were	O
analyzed	O
through	O
electron	O
microscopic	O
(	O
SEM	O
,	O
TEM	O
,	O
AFM	O
)	O
and	O
spectroscopic	O
techniques	O
(	O
POM	O
,	O
fluorescence	O
)	O
,	O
are	O
attributed	O
to	O
the	O
replacement	O
of	O
anthracene	B-CHEMICAL
/	O
pyrene	B-CHEMICAL
units	O
by	O
naphthalene	B-CHEMICAL
units	O
.	O

The	O
present	O
work	O
unravels	O
the	O
subtle	O
role	O
of	O
minute	O
structural	O
change	O
in	O
altering	O
the	O
properties	O
of	O
LMWGs	O
based	O
on	O
poly	B-CHEMICAL
(	I-CHEMICAL
aryl	I-CHEMICAL
ether	I-CHEMICAL
)	I-CHEMICAL
dendrons	O
.	O

All	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
protects	O
hepatocellular	O
carcinoma	O
cells	O
against	O
serum	O
-	O
starvation	O
-	O
induced	O
cell	O
death	O
by	O
upregulating	O
collagen	B-GENE-Y
8A2	I-GENE-Y
.	O

As	O
a	O
therapeutic	O
or	O
chemopreventative	O
agent	O
for	O
various	O
cancers	O
,	O
all	B-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
retinoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
atRA	B-CHEMICAL
)	O
has	O
been	O
reported	O
to	O
inhibit	O
growth	O
,	O
induce	O
apoptosis	O
or	O
cause	O
differentiation	O
.	O

It	O
was	O
found	O
that	O
atRA	B-CHEMICAL
could	O
protect	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cells	O
against	O
cell	O
death	O
induced	O
by	O
serum	O
starvation	O
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
atRA	B-CHEMICAL
could	O
enhance	O
cell	O
adhesion	O
,	O
but	O
had	O
no	O
effect	O
on	O
the	O
cell	O
cycle	O
and	O
apoptosis	O
.	O

Using	O
an	O
Illumina	O
Human	O
HT	O
-	O
12	O
v4	O
expression	O
microarray	O
,	O
207	O
upregulated	O
and	O
173	O
downregulated	O
genes	O
were	O
identified	O
in	O
HepG2	O
cells	O
treated	O
with	O
atRA	B-CHEMICAL
.	O

The	O
most	O
upregulated	O
genes	O
are	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
family	I-GENE-Y
26	I-GENE-Y
subfamily	I-GENE-Y
A	I-GENE-Y
polypeptide	I-GENE-Y
1	I-GENE-Y
(	O
CYP26A1	B-GENE-Y
)	O
,	O
histidine	B-GENE-Y
triad	I-GENE-Y
nucleotide	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
3	I-GENE-Y
(	O
HINT3	B-GENE-Y
)	O
,	O
miR	B-GENE-Y
-	I-GENE-Y
1282	I-GENE-Y
and	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
family	I-GENE-Y
26	I-GENE-Y
subfamily	I-GENE-Y
B	I-GENE-Y
polypeptide	I-GENE-Y
1	I-GENE-Y
(	O
CYP26B1	B-GENE-Y
)	O
,	O
which	O
showed	O
more	O
than	O
fivefold	O
greater	O
expression	O
.	O

Using	O
Gene	O
Ontology	O
analysis	O
,	O
the	O
greatest	O
significance	O
was	O
found	O
in	O
extracellular	O
-	O
matrix	O
-	O
related	O
molecular	O
functions	O
and	O
the	O
cellular	O
component	O
in	O
upregulated	O
genes	O
.	O

The	O
upregulation	O
of	O
collagen	B-GENE-Y
8A2	I-GENE-Y
(	O
COL8A2	B-GENE-Y
)	O
was	O
further	O
confirmed	O
using	O
quantitative	O
RT	O
-	O
PCR	O
and	O
western	O
blotting	O
.	O

Knockdown	O
of	O
COL8A2	B-GENE-Y
blocked	O
enhancement	O
in	O
the	O
early	O
stage	O
of	O
cell	O
adhesion	O
by	O
atRA	B-CHEMICAL
treatment	O
.	O

Re	O
-	O
expression	O
of	O
COL8A2	B-GENE-Y
in	O
COL8A2	B-GENE-Y
-	O
knocked	O
-	O
down	O
HCC	O
cells	O
reversed	O
the	O
effect	O
of	O
small	O
interfering	O
RNA	O
-	O
COL8A2	B-GENE-Y
.	O

In	O
addition	O
,	O
COL8A2	B-GENE-Y
could	O
increase	O
HCC	O
cell	O
migration	O
and	O
invasion	O
.	O

Thus	O
,	O
COL8A2	B-GENE-Y
was	O
identified	O
as	O
the	O
key	O
protein	O
involved	O
in	O
the	O
enhancement	O
of	O
cell	O
adhesion	O
of	O
atRA	B-CHEMICAL
under	O
serum	O
-	O
free	O
conditions	O
.	O

In	O
conclusion	O
,	O
atRA	B-CHEMICAL
protects	O
HCC	O
cells	O
against	O
serum	O
-	O
starvation	O
-	O
induced	O
cell	O
death	O
by	O
enhancing	O
cell	O
adhesion	O
,	O
and	O
COL8A2	B-GENE-Y
plays	O
an	O
important	O
role	O
in	O
HCC	O
cell	O
migration	O
and	O
invasion	O
.	O

Locally	O
administered	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
prevents	O
aeroallergen	O
-	O
induced	O
airway	O
sensitization	O
in	O
mice	O
through	O
immunomodulatory	O
mechanisms	O
.	O

Prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
attenuates	O
airway	O
pathology	O
in	O
asthmatic	O
patients	O
and	O
exerts	O
a	O
protective	O
effect	O
in	O
antigen	O
-	O
sensitized	O
mice	O
when	O
administered	O
systemically	O
.	O

We	O
aimed	O
to	O
establish	O
the	O
consequences	O
of	O
intranasal	O
PGE2	B-CHEMICAL
administration	O
on	O
airway	O
reactivity	O
to	O
aeroallergens	O
in	O
mice	O
and	O
reveal	O
the	O
underlying	O
immunoinflammatory	O
mechanisms	O
.	O

PGE2	B-CHEMICAL
was	O
administered	O
either	O
daily	O
during	O
a	O
10	O
-	O
day	O
exposure	O
to	O
house	O
dust	O
mite	O
(	O
HDM	O
)	O
extracts	O
or	O
for	O
limited	O
intervals	O
.	O

Airway	O
hyperreactivity	O
was	O
measured	O
by	O
whole	O
-	O
body	O
and	O
invasive	O
plethysmography	O
.	O

The	O
phenotypes	O
of	O
lung	O
immune	O
cells	O
and	O
cytokine	B-GENE-N
production	O
were	O
analysed	O
by	O
flow	O
cytometry	O
and	O
ELISA	O
,	O
respectively	O
.	O

Airway	O
hyperreactivity	O
was	O
sustainably	O
reduced	O
only	O
when	O
PGE2	B-CHEMICAL
administration	O
was	O
restricted	O
to	O
the	O
initial	O
5	O
days	O
of	O
exposure	O
to	O
HDM	O
.	O

Lung	O
inflammation	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
production	O
,	O
and	O
airway	O
mast	O
cell	O
activity	O
were	O
also	O
prevented	O
under	O
this	O
early	O
short	O
-	O
term	O
treatment	O
with	O
PGE2	B-CHEMICAL
.	O

Interestingly	O
,	O
a	O
Th2	O
response	O
was	O
already	O
committed	O
on	O
day	O
5	O
of	O
exposure	O
to	O
HDM	O
.	O

This	O
was	O
paralleled	O
by	O
GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
and	O
osteopontin	B-GENE-Y
upregulation	O
and	O
a	O
decreased	O
number	O
of	O
plasmacytoid	O
dendritic	O
and	O
T	O
regulatory	O
cells	O
,	O
as	O
well	O
as	O
a	O
trend	O
towards	O
reduced	O
IL	B-GENE-Y
-	I-GENE-Y
10	I-GENE-Y
expression	O
.	O

Local	O
PGE2	B-CHEMICAL
administration	O
prevented	O
the	O
increase	O
of	O
airway	O
IL	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
and	O
osteopontin	B-GENE-Y
and	O
kept	O
lung	O
plasmacytoid	O
dendritic	O
cell	O
counts	O
close	O
to	O
baseline	O
.	O

GM	B-GENE-Y
-	I-GENE-Y
CSF	I-GENE-Y
and	O
Tregs	O
were	O
unaffected	O
by	O
the	O
treatment	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
protection	O
provided	O
by	O
PGE2	B-CHEMICAL
is	O
a	O
result	O
of	O
the	O
modulation	O
of	O
early	O
lung	O
immunomodulatory	O
mechanisms	O
,	O
and	O
possibly	O
a	O
shift	O
in	O
the	O
balance	O
of	O
dendritic	O
cells	O
towards	O
a	O
tolerogenic	O
profile	O
.	O

Pharmacokinetic	O
and	O
pharmacodynamic	O
modeling	O
of	O
hedgehog	B-GENE-N
inhibitor	O
TAK	B-CHEMICAL
-	I-CHEMICAL
441	I-CHEMICAL
for	O
the	O
inhibition	O
of	O
Gli1	B-GENE-Y
messenger	O
RNA	O
expression	O
and	O
antitumor	O
efficacy	O
in	O
xenografted	O
tumor	O
model	O
mice	O
.	O

6	B-CHEMICAL
-	I-CHEMICAL
Ethyl	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
hydroxyacetyl	I-CHEMICAL
)	I-CHEMICAL
piperidin	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenylethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
trifluoroethoxy	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
pyrrolo	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
carboxamide	I-CHEMICAL
(	O
TAK	B-CHEMICAL
-	I-CHEMICAL
441	I-CHEMICAL
)	O
is	O
a	O
potent	O
,	O
selective	O
hedgehog	B-GENE-N
signaling	O
pathway	O
inhibitor	O
that	O
binds	O
to	O
Smo	B-GENE-Y
and	O
is	O
being	O
developed	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

The	O
objectives	O
of	O
these	O
studies	O
were	O
to	O
explore	O
the	O
possibility	O
of	O
establishing	O
of	O
a	O
link	O
between	O
the	O
pharmacokinetics	O
of	O
TAK	B-CHEMICAL
-	I-CHEMICAL
441	I-CHEMICAL
and	O
the	O
responses	O
of	O
Gli1	B-GENE-Y
mRNA	O
in	O
tumor	O
-	O
associated	O
stromal	O
or	O
skin	O
cells	O
and	O
the	O
antitumor	O
effect	O
of	O
hedgehog	B-GENE-N
inhibition	O
.	O

To	O
this	O
end	O
,	O
we	O
built	O
pharmacokinetic	O
and	O
pharmacodynamic	O
models	O
that	O
describe	O
the	O
relationship	O
of	O
the	O
concentrations	O
of	O
TAK	B-CHEMICAL
-	I-CHEMICAL
441	I-CHEMICAL
plasma	O
to	O
the	O
responses	O
of	O
Gli1	B-GENE-Y
mRNA	O
in	O
the	O
tumor	O
(	O
target	O
)	O
and	O
skin	O
(	O
surrogate	O
)	O
and	O
to	O
tumor	O
growth	O
inhibition	O
in	O
mice	O
bearing	O
xenografts	O
of	O
human	O
pancreatic	O
tumors	O
(	O
PAN	O
-	O
04	O
)	O
.	O

The	O
responses	O
of	O
Gli1	B-GENE-Y
mRNA	O
and	O
tumor	O
growth	O
were	O
described	O
by	O
an	O
indirect	O
response	O
model	O
and	O
an	O
exponential	O
tumor	O
growth	O
model	O
,	O
respectively	O
.	O

The	O
IC50	O
values	O
for	O
Gli1	B-GENE-Y
mRNA	O
inhibition	O
in	O
the	O
tumor	O
and	O
skin	O
by	O
TAK	B-CHEMICAL
-	I-CHEMICAL
441	I-CHEMICAL
were	O
estimated	O
to	O
be	O
0	O
.	O
0457	O
and	O
0	O
.	O
113	O
μg	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
IC90	O
value	O
for	O
tumor	O
growth	O
inhibition	O
was	O
estimated	O
to	O
be	O
0	O
.	O
68	O
μg	O
/	O
ml	O
.	O

These	O
results	O
suggest	O
that	O
a	O
>	O
83	O
%	O
inhibition	O
of	O
Gli1	B-GENE-Y
mRNA	O
expression	O
in	O
the	O
skin	O
or	O
a	O
>	O
94	O
%	O
inhibition	O
of	O
Gli1	B-GENE-Y
mRNA	O
expression	O
in	O
the	O
tumor	O
would	O
be	O
required	O
to	O
sufficiently	O
inhibit	O
(	O
>	O
90	O
%	O
)	O
hedgehog	B-GENE-N
-	O
related	O
tumor	O
growth	O
in	O
the	O
xenografted	O
model	O
mice	O
.	O

We	O
conclude	O
that	O
Gli1	B-GENE-Y
mRNA	O
expression	O
in	O
the	O
tumor	O
and	O
skin	O
could	O
be	O
a	O
useful	O
biomarker	O
for	O
predicting	O
the	O
antitumor	O
effect	O
of	O
hedgehog	B-GENE-N
inhibitors	O
.	O

Lower	O
Adiponectin	B-GENE-Y
Levels	O
at	O
First	O
Trimester	O
of	O
Pregnancy	O
Are	O
Associated	O
With	O
Increased	O
Insulin	B-GENE-Y
Resistance	O
and	O
Higher	O
Risk	O
of	O
Developing	O
Gestational	O
Diabetes	O
Mellitus	O
.	O

OBJECTIVETo	O
evaluate	O
the	O
associations	O
between	O
adiponectin	B-GENE-Y
levels	O
and	O
1	O
)	O
the	O
risk	O
of	O
developing	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
,	O
and	O
2	O
)	O
insulin	B-GENE-Y
resistance	O
/	O
sensitivity	O
,	O
β	O
-	O
cell	O
function	O
,	O
and	O
compensation	O
indices	O
in	O
a	O
prospective	O
cohort	O
representative	O
of	O
the	O
general	O
population	O
of	O
pregnant	O
women	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
performed	O
anthropometric	O
measurements	O
and	O
collected	O
blood	O
samples	O
at	O
1st	O
(	O
6	O
-	O
13	O
weeks	O
)	O
and	O
2nd	O
(	O
24	O
-	O
28	O
weeks	O
)	O
trimesters	O
.	O

Diagnosis	O
of	O
GDM	O
was	O
made	O
at	O
2nd	O
trimester	O
,	O
based	O
on	O
a	O
75	O
-	O
g	O
oral	O
glucose	B-CHEMICAL
tolerance	O
test	O
(	O
International	O
Association	O
of	O
Diabetes	O
and	O
Pregnancy	O
Study	O
Group	O
criteria	O
)	O
.	O

Insulin	B-GENE-Y
was	O
measured	O
(	O
ELISA	O
;	O
Luminex	O
)	O
to	O
estimate	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-GENE-Y
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
,	O
β	O
-	O
cell	O
function	O
(	O
HOMA	O
-	O
B	O
)	O
,	O
insulin	B-GENE-Y
sensitivity	O
(	O
Matsuda	O
index	O
)	O
,	O
insulin	B-GENE-Y
secretion	O
(	O
AUC	O
(	O
insulin	B-GENE-Y
/	O
glucose	B-CHEMICAL
)	O
)	O
,	O
and	O
β	O
-	O
cell	O
compensation	O
(	O
insulin	B-GENE-Y
secretion	O
sensitivity	O
index	O
-	O
2	O
)	O
.	O

Adiponectin	B-GENE-Y
was	O
measured	O
by	O
radioimmunoassay	O
.	O
RESULTSAmong	O
the	O
445	O
participants	O
included	O
in	O
this	O
study	O
,	O
38	O
women	O
developed	O
GDM	O
.	O

Women	O
who	O
developed	O
GDM	O
had	O
lower	O
1st	O
-	O
trimester	O
adiponectin	B-GENE-Y
levels	O
(	O
9	O
.	O
67	O
±	O
3	O
.	O
84	O
vs	O
.	O
11	O
.	O
92	O
±	O
4	O
.	O
59	O
µg	O
/	O
mL	O
in	O
women	O
with	O
normal	O
glucose	B-CHEMICAL
tolerance	O
)	O
.	O

Lower	O
adiponectin	B-GENE-Y
levels	O
were	O
associated	O
with	O
higher	O
risk	O
of	O
developing	O
GDM	O
(	O
OR	O
,	O
1	O
.	O
12	O
per	O
1	O
µg	O
/	O
mL	O
decrease	O
of	O
adiponectin	B-GENE-Y
levels	O
;	O
P	O
=	O
0	O
.	O
02	O
,	O
adjusted	O
for	O
BMI	O
and	O
HbA	O
(	O
1c	O
)	O
at	O
1st	O
trimester	O
)	O
.	O

Adiponectin	B-GENE-Y
levels	O
at	O
1st	O
and	O
2nd	O
trimesters	O
were	O
associated	O
with	O
HOMA	O
-	O
IR	O
(	O
both	O
:	O
r	O
=	O
-	O
0	O
.	O
22	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
Matsuda	O
index	O
(	O
r	O
=	O
0	O
.	O
28	O
,	O
P	O
<	O
0	O
.	O
0001	O
,	O
and	O
r	O
=	O
0	O
.	O
29	O
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

After	O
adjustment	O
for	O
confounding	O
factors	O
,	O
we	O
found	O
no	O
significant	O
association	O
with	O
HOMA	O
-	O
B	O
and	O
AUC	O
(	O
insulin	B-GENE-Y
/	O
glucose	B-CHEMICAL
)	O
.	O
CONCLUSIONSPregnant	O
women	O
with	O
lower	O
adiponectin	B-GENE-Y
levels	O
at	O
1st	O
trimester	O
have	O
higher	O
levels	O
of	O
insulin	B-GENE-Y
resistance	O
and	O
are	O
more	O
likely	O
to	O
develop	O
GDM	O
independently	O
of	O
adiposity	O
or	O
glycemic	O
measurements	O
.	O

Single	O
-	O
walled	O
carbon	B-CHEMICAL
nanotube	O
surface	O
control	O
of	O
complement	O
recognition	O
and	O
activation	O
.	O

Carbon	B-CHEMICAL
nanotubes	O
(	O
CNTs	O
)	O
are	O
receiving	O
considerable	O
attention	O
in	O
site	O
-	O
specific	O
drug	O
and	O
nucleic	O
acid	O
delivery	O
,	O
photodynamic	O
therapy	O
,	O
and	O
photoacoustic	O
molecular	O
imaging	O
.	O

Despite	O
these	O
advances	O
,	O
nanotubes	O
may	O
activate	O
the	O
complement	O
system	O
(	O
an	O
integral	O
part	O
of	O
innate	O
immunity	O
)	O
,	O
which	O
can	O
induce	O
clinically	O
significant	O
anaphylaxis	O
.	O

We	O
demonstrate	O
that	O
single	O
-	O
walled	O
CNTs	O
coated	O
with	O
human	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
activate	O
the	O
complement	O
system	O
through	O
C1q	O
-	O
mediated	O
classical	O
and	O
the	O
alternative	O
pathways	O
.	O

Surface	O
coating	O
with	O
methoxypoly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
glycol	I-CHEMICAL
)	I-CHEMICAL
-	O
based	O
amphiphiles	O
,	O
which	O
confers	O
solubility	O
and	O
prolongs	O
circulation	O
profiles	O
of	O
CNTs	O
,	O
activates	O
the	O
complement	O
system	O
differently	O
,	O
depending	O
on	O
the	O
amphiphile	O
structure	O
.	O

CNTs	O
with	O
linear	O
poly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
glycol	I-CHEMICAL
)	I-CHEMICAL
amphiphiles	O
trigger	O
the	O
lectin	B-GENE-N
pathway	O
of	O
the	O
complement	O
through	O
both	O
L	O
-	O
ficolin	O
and	O
mannan	O
-	O
binding	O
lectin	B-GENE-N
recognition	O
.	O

The	O
lectin	B-GENE-N
pathway	O
activation	O
,	O
however	O
,	O
did	O
not	O
trigger	O
the	O
amplification	O
loop	O
of	O
the	O
alternative	O
pathway	O
.	O

An	O
amphiphile	O
with	O
branched	O
poly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
glycol	I-CHEMICAL
)	I-CHEMICAL
architecture	O
also	O
activated	O
the	O
lectin	B-GENE-N
pathway	O
but	O
only	O
through	O
L	O
-	O
ficolin	O
recognition	O
.	O

Importantly	O
,	O
this	O
mode	O
of	O
activation	O
neither	O
generated	O
anaphylatoxins	O
nor	O
induced	O
triggering	O
of	O
the	O
effector	O
arm	O
of	O
the	O
complement	O
system	O
.	O

These	O
observations	O
provide	O
a	O
major	O
step	O
toward	O
nanomaterial	O
surface	O
modification	O
with	O
polymers	O
that	O
have	O
the	O
properties	O
to	O
significantly	O
improve	O
innate	O
immunocompatibility	O
by	O
limiting	O
the	O
formation	O
of	O
complement	O
C3	B-GENE-N
and	I-GENE-N
C5	I-GENE-N
convertases	I-GENE-N
.	O

Bioactive	O
flavaglines	B-CHEMICAL
and	O
other	O
constituents	O
isolated	O
from	O
Aglaia	O
perviridis	O
.	O

Eight	O
new	O
compounds	O
,	O
including	O
two	O
cyclopenta	B-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
benzopyran	I-CHEMICAL
derivatives	O
(	O
1	O
,	O
2	O
)	O
,	O
two	O
cyclopenta	B-CHEMICAL
[	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
benzofuran	I-CHEMICAL
derivatives	O
(	O
3	O
,	O
4	O
)	O
,	O
three	O
cycloartane	B-CHEMICAL
triterpenoids	I-CHEMICAL
(	O
5	O
-	O
7	O
)	O
,	O
and	O
an	O
apocarotenoid	O
(	O
8	O
)	O
,	O
together	O
with	O
16	O
known	O
compounds	O
,	O
were	O
isolated	O
from	O
the	O
chloroform	B-CHEMICAL
-	O
soluble	O
partitions	O
of	O
separate	O
methanol	B-CHEMICAL
extracts	O
of	O
a	O
combination	O
of	O
the	O
fruits	O
,	O
leaves	O
,	O
and	O
twigs	O
and	O
of	O
the	O
roots	O
of	O
Aglaia	O
perviridis	O
collected	O
in	O
Vietnam	O
.	O

Isolation	O
work	O
was	O
monitored	O
using	O
human	O
colon	O
cancer	O
cells	O
(	O
HT	O
-	O
29	O
)	O
and	O
facilitated	O
with	O
an	O
LC	O
/	O
MS	O
dereplication	O
procedure	O
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
(	O
1	O
-	O
8	O
)	O
were	O
determined	O
on	O
the	O
basis	O
of	O
spectroscopic	O
data	O
interpretation	O
.	O

The	O
Mosher	O
ester	O
method	O
was	O
employed	O
to	O
determine	O
the	O
absolute	O
configurations	O
of	O
5	O
-	O
7	O
,	O
and	O
the	O
absolute	O
configuration	O
of	O
the	O
9	O
,	O
10	O
-	O
diol	B-CHEMICAL
unit	O
of	O
compound	O
8	O
was	O
established	O
by	O
a	O
dimolybdenum	B-CHEMICAL
tetraacetate	I-CHEMICAL
[	O
Mo2	B-CHEMICAL
(	I-CHEMICAL
AcO	I-CHEMICAL
)	I-CHEMICAL
4	I-CHEMICAL
]	O
induced	O
circular	O
dichroism	O
procedure	O
.	O

Seven	O
known	O
rocaglate	B-CHEMICAL
derivatives	O
(	O
9	O
-	O
15	O
)	O
exhibited	O
significant	O
cytotoxicity	O
against	O
the	O
HT	O
-	O
29	O
cell	O
line	O
,	O
with	O
rocaglaol	B-CHEMICAL
(	O
9	O
)	O
being	O
the	O
most	O
potent	O
(	O
ED50	O
0	O
.	O
0007	O
μM	O
)	O
.	O

The	O
new	O
compounds	O
2	O
-	O
4	O
were	O
also	O
active	O
against	O
this	O
cell	O
line	O
,	O
with	O
ED50	O
values	O
ranging	O
from	O
0	O
.	O
46	O
to	O
4	O
.	O
7	O
μM	O
.	O

The	O
cytotoxic	O
compounds	O
were	O
evaluated	O
against	O
a	O
normal	O
colon	O
cell	O
line	O
,	O
CCD	O
-	O
112CoN	O
.	O

In	O
addition	O
,	O
the	O
new	O
compound	O
perviridicin	B-CHEMICAL
B	I-CHEMICAL
(	O
2	O
)	O
,	O
three	O
known	O
rocaglate	B-CHEMICAL
derivatives	O
(	O
9	O
,	O
11	O
,	O
12	O
)	O
,	O
and	O
a	O
known	O
sesquiterpene	B-CHEMICAL
,	O
2	B-CHEMICAL
-	I-CHEMICAL
oxaisodauc	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
-	I-CHEMICAL
al	I-CHEMICAL
(	O
17	O
)	O
,	O
showed	O
significant	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
(	O
p65	B-GENE-Y
)	O
inhibitory	O
activity	O
in	O
an	O
ELISA	O
assay	O
.	O

Identification	O
of	O
aldo	B-GENE-N
-	I-GENE-N
keto	I-GENE-N
reductases	I-GENE-N
as	O
NRF2	B-GENE-Y
-	O
target	O
marker	O
genes	O
in	O
human	O
cells	O
.	O

Transcription	O
factor	O
NF	B-GENE-Y
-	I-GENE-Y
E2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
NRF2	B-GENE-Y
)	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
cellular	O
defense	O
against	O
oxidative	O
/	O
electrophilic	O
stress	O
by	O
up	O
-	O
regulating	O
multiple	O
antioxidant	O
genes	O
.	O

Numerous	O
studies	O
with	O
genetically	O
modified	O
animals	O
have	O
demonstrated	O
that	O
Nrf2	B-GENE-Y
is	O
a	O
sensitivity	O
determining	O
factor	O
upon	O
the	O
exposure	O
to	O
environmental	O
chemicals	O
including	O
carcinogens	O
.	O

Moreover	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
polymorphism	O
in	O
the	O
human	B-GENE-N
NRF2	I-GENE-N
promoter	I-GENE-N
is	O
associated	O
with	O
higher	O
risks	O
for	O
developing	O
acute	O
lung	O
injury	O
,	O
gastric	O
mucosal	O
inflammation	O
,	O
and	O
nephritis	O
.	O

Therefore	O
,	O
the	O
identification	O
of	O
reliable	O
and	O
effective	O
human	O
target	O
genes	O
of	O
NRF2	B-GENE-Y
may	O
allow	O
the	O
monitoring	O
of	O
NRF2	B-GENE-Y
activity	O
and	O
to	O
predict	O
individual	O
sensitivity	O
to	O
environmental	O
stress	O
-	O
induced	O
damage	O
.	O

For	O
this	O
purpose	O
,	O
we	O
investigated	O
genes	O
that	O
are	O
tightly	O
controlled	O
by	O
NRF2	B-GENE-Y
to	O
establish	O
markers	O
for	O
NRF2	B-GENE-Y
activity	O
in	O
human	O
cells	O
.	O

Firstly	O
,	O
in	O
the	O
normal	O
human	O
renal	O
epithelial	O
HK	O
-	O
2	O
cells	O
,	O
the	O
measurement	O
of	O
the	O
expression	O
of	O
30	O
previously	O
reported	O
NRF2	B-GENE-Y
target	O
genes	O
in	O
response	O
to	O
NRF2	B-GENE-Y
inducers	O
(	O
sulforaphane	B-CHEMICAL
,	O
tert	B-CHEMICAL
-	I-CHEMICAL
butylhydroquinone	I-CHEMICAL
,	O
cinnamic	B-CHEMICAL
aldehyde	I-CHEMICAL
,	O
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
)	O
showed	O
that	O
the	O
aldo	B-GENE-Y
-	I-GENE-Y
keto	I-GENE-Y
reductase	I-GENE-Y
(	I-GENE-Y
AKR	I-GENE-Y
)	I-GENE-Y
1C1	I-GENE-Y
is	O
highly	O
inducible	O
by	O
all	O
treatments	O
.	O

Accordantly	O
,	O
the	O
basal	O
and	O
inducible	O
expressions	O
of	O
AKRs	B-GENE-N
were	O
significantly	O
attenuated	O
in	O
NRF2	B-GENE-Y
-	O
silenced	O
HK	O
-	O
2	O
cells	O
.	O

Whereas	O
,	O
cells	O
with	O
stable	O
KEAP1	B-GENE-Y
knockdown	O
,	O
which	O
causes	O
a	O
modest	O
NRF2	B-GENE-Y
activation	O
,	O
demonstrated	O
substantially	O
increased	O
levels	O
of	O
AKR1A1	B-GENE-N
,	I-GENE-N
1B1	I-GENE-N
,	I-GENE-N
1B10	I-GENE-N
,	I-GENE-N
1C1	I-GENE-N
,	I-GENE-N
1C2	I-GENE-N
,	I-GENE-N
and	I-GENE-N
1C3	I-GENE-N
.	O

Secondly	O
,	O
the	O
linkage	O
between	O
NRF2	B-GENE-Y
and	O
the	O
AKRs	B-GENE-N
was	O
confirmed	O
in	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
U937	O
,	O
which	O
can	O
be	O
a	O
model	O
of	O
peripherally	O
available	O
blood	O
cells	O
.	O

The	O
treatment	O
of	O
U937	O
cells	O
with	O
NRF2	B-GENE-Y
inducers	O
including	O
sulforaphane	B-CHEMICAL
effectively	O
elevated	O
the	O
expression	O
of	O
AKR1B1	B-GENE-N
,	I-GENE-N
1B10	I-GENE-N
,	I-GENE-N
1C1	I-GENE-N
,	I-GENE-N
1C2	I-GENE-N
,	I-GENE-N
and	I-GENE-N
1C3	I-GENE-N
.	O

Whereas	O
,	O
the	O
levels	O
of	O
both	O
the	O
basal	O
and	O
sulforaphane	B-CHEMICAL
-	O
inducible	O
expression	O
of	O
AKR1C1	B-GENE-Y
were	O
significantly	O
reduced	O
in	O
NRF2	B-GENE-Y
-	O
silenced	O
stable	O
U937	O
cells	O
compared	O
to	O
the	O
control	O
cells	O
.	O

Similarly	O
,	O
the	O
inducible	O
expression	O
of	O
AKR1C1	B-GENE-Y
was	O
observed	O
in	O
another	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP	O
-	O
1	O
as	O
well	O
as	O
in	O
human	O
primary	O
blood	O
CD14	O
(	O
+	O
)	O
monocytes	O
.	O

In	O
conclusion	O
,	O
together	O
with	O
the	O
high	O
inducibility	O
and	O
NRF2	B-GENE-Y
dependency	O
shown	O
in	O
renal	O
epithelial	O
cells	O
as	O
well	O
as	O
in	O
peripherally	O
available	O
blood	O
cells	O
,	O
current	O
findings	O
suggest	O
that	O
AKRs	B-GENE-N
can	O
be	O
utilized	O
as	O
a	O
marker	O
of	O
NRF2	B-GENE-Y
activity	O
in	O
human	O
cells	O
.	O

Two	O
distinct	O
mechanisms	O
of	O
Topoisomerase	B-GENE-Y
1	I-GENE-Y
-	O
dependent	O
mutagenesis	O
in	O
yeast	O
.	O

Topoisomerase	B-GENE-Y
1	I-GENE-Y
(	O
Top1	B-GENE-Y
)	O
resolves	O
transcription	O
-	O
associated	O
supercoils	O
by	O
generating	O
transient	O
single	O
-	O
strand	O
breaks	O
in	O
DNA	O
.	O

Top1	B-GENE-Y
activity	O
in	O
yeast	O
is	O
a	O
major	O
source	O
of	O
transcription	O
-	O
associated	O
mutagenesis	O
,	O
generating	O
a	O
distinctive	O
mutation	O
signature	O
characterized	O
by	O
deletions	O
in	O
short	O
,	O
tandem	O
repeats	O
.	O

A	O
similar	O
signature	O
is	O
associated	O
with	O
the	O
persistence	O
of	O
ribonucleoside	B-CHEMICAL
monophosphates	I-CHEMICAL
(	O
rNMPs	B-CHEMICAL
)	O
in	O
DNA	O
,	O
and	O
it	O
also	O
depends	O
on	O
Top1	B-GENE-Y
activity	O
.	O

There	O
is	O
only	O
partial	O
overlap	O
,	O
however	O
,	O
between	O
Top1	B-GENE-Y
-	O
dependent	O
deletion	O
hotspots	O
identified	O
in	O
highly	O
transcribed	O
DNA	O
and	O
those	O
associated	O
with	O
rNMPs	B-CHEMICAL
,	O
suggesting	O
the	O
existence	O
of	O
both	O
rNMP	B-CHEMICAL
-	O
dependent	O
and	O
rNMP	B-CHEMICAL
-	O
independent	O
events	O
.	O

Here	O
,	O
we	O
present	O
genetic	O
studies	O
confirming	O
that	O
there	O
are	O
two	O
distinct	O
types	O
of	O
hotspots	O
.	O

Data	O
suggest	O
a	O
novel	O
model	O
in	O
which	O
rNMP	B-CHEMICAL
-	O
dependent	O
hotspots	O
are	O
generated	O
by	O
sequential	O
Top1	B-GENE-Y
reactions	O
and	O
are	O
consistent	O
with	O
rNMP	B-CHEMICAL
-	O
independent	O
hotspots	O
reflecting	O
processing	O
of	O
a	O
trapped	O
Top1	B-GENE-Y
cleavage	O
complex	O
.	O

p300	B-GENE-Y
-	O
mediated	O
acetylation	O
of	O
TRF2	B-GENE-Y
is	O
required	O
for	O
maintaining	O
functional	O
telomeres	O
.	O

The	O
human	B-GENE-Y
telomeric	I-GENE-Y
protein	I-GENE-Y
TRF2	I-GENE-Y
is	O
required	O
to	O
protect	O
chromosome	O
ends	O
by	O
facilitating	O
their	O
organization	O
into	O
the	O
protective	O
capping	O
structure	O
.	O

Post	O
-	O
translational	O
modifications	O
of	O
TRF2	B-GENE-Y
such	O
as	O
phosphorylation	O
,	O
ubiquitination	O
,	O
SUMOylation	O
,	O
methylation	O
and	O
poly	O
(	O
ADP	B-CHEMICAL
-	O
ribosyl	O
)	O
ation	O
have	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
telomere	O
function	O
.	O

Here	O
we	O
show	O
that	O
TRF2	B-GENE-Y
specifically	O
interacts	O
with	O
the	O
histone	B-GENE-Y
acetyltransferase	I-GENE-Y
p300	I-GENE-Y
,	O
and	O
that	O
p300	B-GENE-Y
acetylates	O
the	O
lysine	B-CHEMICAL
residue	O
at	O
position	O
293	O
of	O
TRF2	B-GENE-Y
.	O

We	O
also	O
report	O
that	O
p300	B-GENE-Y
-	O
mediated	O
acetylation	O
stabilizes	O
the	O
TRF2	B-GENE-Y
protein	O
by	O
inhibiting	O
its	O
ubiquitin	B-GENE-N
-	O
dependent	O
proteolysis	O
and	O
is	O
required	O
for	O
efficient	O
telomere	O
binding	O
of	O
TRF2	B-GENE-Y
.	O

Furthermore	O
,	O
overexpression	O
of	O
the	O
acetylation	O
-	O
deficient	O
mutant	O
,	O
K293R	B-GENE-N
,	O
induces	O
DNA	O
-	O
damage	O
response	O
foci	O
at	O
telomeres	O
,	O
thereby	O
leading	O
to	O
induction	O
of	O
impaired	O
cell	O
growth	O
,	O
cellular	O
senescence	O
and	O
altered	O
cell	O
cycle	O
distribution	O
.	O

A	O
small	O
but	O
significant	O
number	O
of	O
metaphase	O
chromosomes	O
show	O
no	O
telomeric	O
signals	O
at	O
chromatid	O
ends	O
,	O
suggesting	O
an	O
aberrant	O
telomere	O
structure	O
.	O

These	O
findings	O
demonstrate	O
that	O
acetylation	O
of	O
TRF2	B-GENE-Y
by	O
p300	B-GENE-Y
plays	O
a	O
crucial	O
role	O
in	O
the	O
maintenance	O
of	O
functional	O
telomeres	O
as	O
well	O
as	O
in	O
the	O
regulation	O
of	O
the	O
telomere	O
-	O
associated	O
DNA	O
-	O
damage	O
response	O
,	O
thus	O
providing	O
a	O
new	O
route	O
for	O
modulating	O
telomere	O
protection	O
function	O
.	O

Pterostilbene	B-CHEMICAL
exerts	O
antitumor	O
activity	O
against	O
human	O
osteosarcoma	O
cells	O
by	O
inhibiting	O
the	O
JAK2	B-GENE-Y
/	O
STAT3	B-GENE-Y
signaling	O
pathway	O
.	O

Osteosarcoma	O
is	O
a	O
high	O
-	O
grade	O
malignant	O
bone	O
tumor	O
.	O

Pterostilbene	B-CHEMICAL
(	O
PTE	B-CHEMICAL
)	O
is	O
a	O
natural	O
,	O
dimethylated	O
analog	O
of	O
resveratrol	B-CHEMICAL
with	O
higher	O
bioavailability	O
.	O

While	O
PTE	B-CHEMICAL
has	O
been	O
shown	O
to	O
have	O
potent	O
antitumor	O
activity	O
against	O
various	O
types	O
of	O
cancer	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
effects	O
of	O
PTE	B-CHEMICAL
remain	O
largely	O
unknown	O
.	O

The	O
Janus	B-GENE-Y
kinase	I-GENE-Y
2	I-GENE-Y
/	O
Signal	B-GENE-Y
Transducer	I-GENE-Y
and	I-GENE-Y
Activator	I-GENE-Y
of	I-GENE-Y
Transcription	I-GENE-Y
3	I-GENE-Y
(	O
JAK2	B-GENE-Y
/	O
STAT3	B-GENE-Y
)	O
signaling	O
pathway	O
plays	O
a	O
crucial	O
role	O
in	O
tumorigenesis	O
and	O
immune	O
development	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
antitumor	O
activity	O
of	O
PTE	B-CHEMICAL
against	O
human	O
osteosarcoma	O
cells	O
and	O
explored	O
the	O
role	O
of	O
JAK2	B-GENE-Y
/	O
STAT3	B-GENE-Y
and	O
apoptosis	O
-	O
related	O
signaling	O
pathways	O
on	O
the	O
activity	O
of	O
PTE	B-CHEMICAL
.	O

PTE	B-CHEMICAL
treatment	O
resulted	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
osteosarcoma	O
cell	O
viability	O
.	O

Additionally	O
,	O
PTE	B-CHEMICAL
exhibited	O
strong	O
antitumor	O
activity	O
,	O
as	O
evidenced	O
not	O
only	O
by	O
reductions	O
in	O
tumor	O
cell	O
adhesion	O
,	O
migration	O
and	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
but	O
also	O
by	O
increases	O
in	O
the	O
apoptotic	O
index	O
,	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
and	O
several	O
biochemical	O
parameters	O
.	O

Furthermore	O
,	O
PTE	B-CHEMICAL
treatment	O
directly	O
inhibited	O
the	O
phosphorylation	O
of	O
JAK2	B-GENE-Y
at	O
Tyr	B-CHEMICAL
1007	O
and	O
the	O
downstream	O
activation	O
of	O
STAT3	B-GENE-Y
.	O

PTE	B-CHEMICAL
also	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
STAT3	B-GENE-Y
target	O
genes	O
,	O
including	O
the	O
anti	O
-	O
apoptotic	O
proteins	O
Bcl	B-GENE-Y
-	I-GENE-Y
xL	I-GENE-Y
and	O
Mcl	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
leading	O
to	O
the	O
up	O
-	O
regulation	O
of	O
mitochondrial	O
apoptosis	O
pathway	O
-	O
related	O
proteins	O
(	O
Bax	B-GENE-Y
,	O
Bak	B-GENE-Y
,	O
cytosolic	O
Cytochrome	B-GENE-Y
c	I-GENE-Y
,	O
and	O
cleaved	O
Caspase3	B-GENE-Y
)	O
and	O
cyclin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
kinase	I-GENE-N
inhibitors	O
such	O
as	O
p21	B-GENE-Y
and	O
p27	B-GENE-Y
.	O

PTE	B-CHEMICAL
,	O
used	O
in	O
combination	O
with	O
a	O
known	O
JAK2	B-GENE-Y
/	O
STAT3	B-GENE-Y
inhibitor	O
,	O
AG490	B-CHEMICAL
,	O
further	O
decreased	O
the	O
viability	O
of	O
osteosarcoma	O
cells	O
.	O

Taken	O
together	O
,	O
PTE	B-CHEMICAL
is	O
a	O
potent	O
inhibitor	O
of	O
osteosarcoma	O
cell	O
growth	O
that	O
targets	O
the	O
JAK2	B-GENE-Y
/	O
STAT3	B-GENE-Y
signaling	O
pathway	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
JAK2	B-GENE-Y
/	O
STAT3	B-GENE-Y
signaling	O
is	O
a	O
novel	O
mechanism	O
of	O
action	O
for	O
PTE	B-CHEMICAL
during	O
therapeutic	O
intervention	O
in	O
osteosarcoma	O
cancers	O
.	O

FXR	B-GENE-Y
-	O
dependent	O
and	O
-	O
independent	O
interaction	O
of	O
glucocorticoids	O
with	O
the	O
regulatory	O
pathways	O
involved	O
in	O
the	O
control	O
of	O
bile	B-CHEMICAL
acid	I-CHEMICAL
handling	O
by	O
the	O
liver	O
.	O

Treatment	O
with	O
glucocorticoids	O
(	O
GCs	O
)	O
may	O
cause	O
adverse	O
effects	O
,	O
including	O
cholestasis	O
.	O

The	O
ability	O
of	O
dexamethasone	B-CHEMICAL
,	O
prednisolone	B-CHEMICAL
and	O
budesonide	B-CHEMICAL
to	O
affect	O
the	O
liver	O
handling	O
of	O
bile	B-CHEMICAL
acids	I-CHEMICAL
(	O
BAs	O
)	O
has	O
been	O
investigated	O
.	O

In	O
rats	O
treated	O
with	O
GCs	O
for	O
4	O
days	O
,	O
altered	O
serum	O
and	O
bile	O
BA	O
levels	O
,	O
changed	O
conjugation	O
pattern	O
,	O
and	O
delayed	O
and	O
decreased	O
ability	O
to	O
conjugate	O
/	O
secrete	O
exogenously	O
administered	O
deoxycholate	B-CHEMICAL
,	O
were	O
found	O
using	O
HPLC	O
-	O
MS	O
/	O
MS	O
.	O

RT	O
-	O
QPCR	O
analyses	O
revealed	O
that	O
GC	O
treatment	O
also	O
induced	O
a	O
down	O
-	O
regulation	O
of	O
liver	B-GENE-N
nuclear	I-GENE-N
receptors	I-GENE-N
(	O
Fxr	B-GENE-Y
,	O
Gr	B-GENE-Y
and	O
Shp	B-GENE-Y
)	O
,	O
transporters	O
(	O
Ntcp	B-GENE-Y
,	O
Mrp4	B-GENE-Y
and	O
Bcrp	B-GENE-Y
)	O
and	O
enzymes	O
(	O
Cyp7a1	B-GENE-Y
and	O
Baat	B-GENE-Y
)	O
,	O
whereas	O
Bsep	B-GENE-Y
,	O
Mrp2	B-GENE-Y
and	O
Cyp27a1	B-GENE-Y
were	O
up	O
-	O
regulated	O
.	O

Human	O
HepG2	O
and	O
Alexander	O
cell	O
lines	O
were	O
used	O
as	O
in	O
vitro	O
models	O
of	O
liver	O
cells	O
with	O
and	O
without	O
constitutive	O
FXR	B-GENE-Y
expression	O
,	O
respectively	O
.	O

In	O
HepG2	O
cells	O
,	O
GCs	O
induced	O
a	O
decreased	O
expression	O
of	O
FXR	B-GENE-Y
and	O
SHP	B-GENE-Y
,	O
and	O
inhibited	O
the	O
regulatory	O
effect	O
of	O
GW4064	B-CHEMICAL
on	O
FXR	B-GENE-Y
-	O
target	O
genes	O
.	O

In	O
Alexander	O
cells	O
,	O
only	O
when	O
they	O
were	O
transfected	O
with	O
FXR	B-GENE-Y
+	O
RXR	B-GENE-N
,	O
GW4064	B-CHEMICAL
caused	O
up	O
-	O
regulation	O
of	O
SHP	B-GENE-Y
and	O
OSTβ	B-GENE-Y
,	O
and	O
a	O
down	O
-	O
regulation	O
of	O
CYP27A1	B-GENE-Y
.	O

GCs	O
had	O
the	O
opposite	O
effect	O
on	O
these	O
genes	O
,	O
both	O
in	O
the	O
absence	O
and	O
in	O
the	O
presence	O
of	O
FXR	B-GENE-Y
expression	O
.	O

Co	O
-	O
transfection	O
of	O
Alexander	O
cells	O
with	O
IR	O
-	O
1	O
-	O
Luc	O
and	O
FXR	B-GENE-Y
+	O
RXR	B-GENE-N
revealed	O
that	O
GCs	O
did	O
not	O
inhibit	O
but	O
moderately	O
enhanced	O
FXR	B-GENE-Y
activity	O
.	O

Moreover	O
,	O
GCs	O
have	O
a	O
synergistic	O
effect	O
on	O
GW4064	B-CHEMICAL
-	O
induced	O
FXR	B-GENE-Y
activation	O
,	O
whereas	O
chenodeoxycholate	B-CHEMICAL
and	O
GW4064	B-CHEMICAL
have	O
an	O
additive	O
effect	O
.	O

In	O
conclusion	O
,	O
GCs	O
are	O
able	O
to	O
directly	O
or	O
indirectly	O
activate	O
FXR	B-GENE-Y
but	O
they	O
also	O
antagonize	O
,	O
through	O
FXR	B-GENE-Y
-	O
independent	O
mechanisms	O
,	O
the	O
expression	O
of	O
FXR	B-GENE-Y
and	O
FXR	B-GENE-Y
target	O
genes	O
involved	O
in	O
the	O
hepatic	O
handling	O
of	O
BAs	O
.	O

Predictive	O
modeling	O
of	O
insulin	B-GENE-Y
release	O
profile	O
from	O
cross	O
-	O
linked	O
chitosan	O
microspheres	O
.	O

Insulin	B-GENE-Y
-	O
loaded	O
microspheres	O
composed	O
of	O
chitosan	O
3	O
%	O
(	O
w	O
/	O
v	O
)	O
,	O
and	O
loading	O
120	O
IU	O
insulin	B-GENE-Y
were	O
produced	O
by	O
emulsion	O
cross	O
-	O
linking	O
method	O
.	O

Cross	O
-	O
linking	O
time	O
was	O
5	O
h	O
and	O
glutaraldehyde	B-CHEMICAL
3	O
.	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
was	O
used	O
as	O
cross	O
-	O
linker	O
.	O

Swelling	O
ratio	O
studies	O
were	O
evaluated	O
to	O
predict	O
release	O
of	O
insulin	B-GENE-Y
from	O
chitosan	O
microspheres	O
.	O

Bacitracin	B-CHEMICAL
and	O
sodium	B-CHEMICAL
taurocholate	I-CHEMICAL
were	O
incorporated	O
in	O
the	O
formulations	O
as	O
proteolytic	O
enzyme	O
inhibitor	O
and	O
absorption	O
enhancer	O
,	O
respectively	O
.	O

In	O
vitro	O
insulin	B-GENE-Y
release	O
studies	O
were	O
performed	O
in	O
phosphate	B-CHEMICAL
buffer	O
pH	O
7	O
.	O
4	O
and	O
also	O
in	O
HCl	B-CHEMICAL
pH	O
2	O
with	O
and	O
without	O
trypsin	B-GENE-N
.	O

Activity	O
of	O
bacitracin	B-CHEMICAL
was	O
also	O
evaluated	O
.	O

In	O
vitro	O
release	O
showed	O
a	O
controlled	O
profile	O
up	O
to	O
12	O
h	O
and	O
the	O
formulation	O
containing	O
0	O
.	O
15	O
%	O
(	O
w	O
/	O
v	O
)	O
of	O
bacitracin	B-CHEMICAL
revealed	O
a	O
maximum	O
biological	O
activity	O
of	O
about	O
49	O
.	O
1	O
±	O
4	O
.	O
1	O
%	O
.	O

Mathematical	O
modeling	O
using	O
Higuchi	O
and	O
Korsmeyer	O
-	O
Peppas	O
suggested	O
a	O
non	O
-	O
Fickian	O
diffusion	O
as	O
the	O
mechanism	O
of	O
insulin	B-GENE-Y
release	O
.	O

Insulin	B-GENE-Y
-	O
loaded	O
chitosan	O
microspheres	O
for	O
oral	O
delivery	O
showed	O
to	O
be	O
an	O
innovative	O
and	O
reliable	O
delivery	O
system	O
to	O
overcome	O
conventional	O
insulin	B-GENE-Y
therapy	O
.	O

The	O
effect	O
of	O
manganese	B-CHEMICAL
on	O
dopamine	B-CHEMICAL
toxicity	O
and	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
(	O
DAT	B-GENE-Y
)	O
in	O
control	O
and	O
DAT	B-GENE-Y
transfected	O
HEK	O
cells	O
.	O

Chronic	O
exposure	O
to	O
Mn	B-CHEMICAL
results	O
in	O
the	O
development	O
of	O
a	O
neurological	O
disorder	O
known	O
as	O
manganism	O
characterized	O
by	O
neurological	O
deficits	O
resembling	O
that	O
seen	O
in	O
Parkinsonism	O
.	O

Although	O
dopaminergic	O
neurons	O
within	O
the	O
nigrostriatal	O
pathway	O
appear	O
intact	O
,	O
Mn	B-CHEMICAL
-	O
induced	O
irregularities	O
in	O
DA	O
transmission	O
have	O
been	O
observed	O
including	O
decreased	O
amphetamine	B-CHEMICAL
-	O
induced	O
DA	O
release	O
and	O
loss	O
of	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
(	O
DAT	B-GENE-Y
)	O
.	O

Results	O
of	O
studies	O
to	O
evaluate	O
the	O
effect	O
of	O
Mn	B-CHEMICAL
and	O
DA	O
on	O
cell	O
viability	O
in	O
control	O
and	O
DAT	B-GENE-Y
-	O
transfected	O
HEK	O
cells	O
reveal	O
that	O
Mn	B-CHEMICAL
is	O
equally	O
toxic	O
to	O
both	O
cell	O
lines	O
whereas	O
DA	O
was	O
only	O
toxic	O
to	O
cells	O
containing	O
DAT	B-GENE-Y
.	O

DA	O
toxicity	O
was	O
saturable	O
suggesting	O
that	O
transport	O
may	O
be	O
rate	O
limiting	O
.	O

When	O
Mn	B-CHEMICAL
and	O
DA	O
were	O
added	O
simultaneously	O
to	O
the	O
media	O
,	O
cell	O
toxicity	O
was	O
similar	O
to	O
that	O
produced	O
by	O
Mn	B-CHEMICAL
alone	O
suggesting	O
that	O
Mn	B-CHEMICAL
may	O
suppress	O
DA	O
uptake	O
in	O
the	O
DAT	B-GENE-Y
containing	O
cells	O
.	O

Preincubation	O
of	O
DA	O
prior	O
to	O
the	O
addition	O
of	O
Mn	B-CHEMICAL
resulted	O
in	O
cell	O
death	O
which	O
was	O
essentially	O
additive	O
with	O
that	O
produced	O
independently	O
by	O
the	O
two	O
agents	O
.	O

Mn	B-CHEMICAL
was	O
also	O
shown	O
to	O
decrease	O
DA	O
uptake	O
and	O
amphetamine	B-CHEMICAL
-	O
induced	O
DA	O
efflux	O
in	O
DAT	B-GENE-Y
containing	O
cells	O
.	O

Time	O
-	O
lapsed	O
confocal	O
microscopy	O
indicates	O
that	O
Mn	B-CHEMICAL
can	O
promote	O
trafficking	O
of	O
cell	O
surface	O
DAT	B-GENE-Y
into	O
intracellular	O
compartments	O
which	O
may	O
account	O
for	O
the	O
decrease	O
in	O
DA	O
uptake	O
and	O
DA	O
efflux	O
in	O
these	O
cells	O
.	O

Mn	B-CHEMICAL
-	O
induced	O
internalization	O
of	O
DAT	B-GENE-Y
may	O
provide	O
an	O
explanation	O
for	O
disruption	O
in	O
DA	O
transmission	O
previously	O
reported	O
in	O
the	O
striatum	O
.	O

Effects	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
amino	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenylimidazo	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
PhIP	B-CHEMICAL
)	O
on	O
histopathology	O
,	O
oxidative	O
stress	O
,	O
and	O
expression	O
of	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
jun	I-GENE-Y
and	O
p16	B-GENE-Y
in	O
rat	O
stomachs	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
Amino	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phenylimidazo	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyridine	I-CHEMICAL
(	O
PhIP	B-CHEMICAL
)	O
is	O
one	O
of	O
the	O
most	O
abundant	O
heterocyclic	B-CHEMICAL
amines	I-CHEMICAL
(	O
HCAs	B-CHEMICAL
)	O
generated	O
from	O
overcooking	O
meat	O
at	O
high	O
temperatures	O
.	O

To	O
understand	O
the	O
possible	O
mechanism	O
of	O
PhIP	B-CHEMICAL
-	O
associated	O
stomach	O
cancer	O
,	O
the	O
effects	O
of	O
PhIP	B-CHEMICAL
on	O
morphology	O
,	O
oxidative	O
stress	O
,	O
gene	O
expression	O
of	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
jun	I-GENE-Y
and	O
p16	B-GENE-Y
in	O
rat	O
stomachs	O
were	O
investigated	O
.	O

The	O
results	O
showed	O
that	O
(	O
1	O
)	O
15mg	O
/	O
kg	O
body	O
weight	O
PhIP	B-CHEMICAL
induced	O
obvious	O
histopathological	O
changes	O
in	O
gastric	O
mucosa	O
;	O
(	O
2	O
)	O
PhIP	B-CHEMICAL
(	O
10	O
and	O
/	O
or	O
15mg	O
/	O
kg	O
)	O
significantly	O
decreased	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
and	O
glutathioneperoxidase	B-GENE-N
(	O
GPx	B-GENE-N
)	O
activities	O
,	O
while	O
increased	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
activity	O
compared	O
with	O
the	O
control	O
.	O

With	O
the	O
elevated	O
doses	O
of	O
PhIP	B-CHEMICAL
,	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
contents	O
,	O
protein	O
carbonyl	B-CHEMICAL
(	O
PCO	O
)	O
contents	O
and	O
DNA	O
-	O
protein	O
crosslinks	O
(	O
DPC	O
)	O
coefficients	O
were	O
significantly	O
raised	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
(	O
3	O
)	O
PhIP	B-CHEMICAL
at	O
the	O
doses	O
of	O
10mg	O
/	O
kg	O
and	O
/	O
or	O
15mg	O
/	O
kg	O
significantly	O
inhibited	O
p16	B-GENE-Y
mRNA	O
and	O
protein	O
expression	O
,	O
whereas	O
enhanced	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
and	O
c	B-GENE-Y
-	I-GENE-Y
jun	I-GENE-Y
expression	O
relative	O
to	O
control	O
.	O

The	O
data	O
indicated	O
that	O
PhIP	B-CHEMICAL
could	O
cause	O
stomach	O
injury	O
,	O
oxidative	O
stress	O
in	O
rat	O
stomachs	O
as	O
well	O
as	O
the	O
activation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
fos	I-GENE-Y
and	O
c	B-GENE-Y
-	I-GENE-Y
jun	I-GENE-Y
and	O
inactivation	O
of	O
p16	B-GENE-Y
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
PhIP	B-CHEMICAL
-	O
associated	O
stomach	O
cancer	O
.	O

A	O
physiologically	O
based	O
pharmacokinetic	O
model	O
for	O
the	O
oxime	B-CHEMICAL
TMB	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
:	O
simulation	O
of	O
rodent	O
and	O
human	O
data	O
.	O

Multiple	O
oximes	B-CHEMICAL
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
use	O
as	O
countermeasures	O
against	O
chemical	O
warfare	O
nerve	O
agents	O
.	O

The	O
current	O
U	O
.	O
S	O
.	O
military	O
and	O
civilian	O
oxime	B-CHEMICAL
countermeasure	O
,	O
2	B-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
hydroxyimino	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
methylpyridin	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
ium	I-CHEMICAL
chloride	I-CHEMICAL
(	O
2	B-CHEMICAL
-	I-CHEMICAL
PAM	I-CHEMICAL
)	O
,	O
is	O
under	O
consideration	O
for	O
replacement	O
with	O
a	O
more	O
effective	O
acetylcholinesterase	B-GENE-Y
reactivator	O
,	O
1	B-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
methylenebis	I-CHEMICAL
{	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
hydroxyiminomethyl	I-CHEMICAL
}	I-CHEMICAL
pyridinium	I-CHEMICAL
dimethanesulfonate	I-CHEMICAL
(	O
MMB	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
)	O
.	O

Kinetic	O
data	O
in	O
the	O
scientific	O
literature	O
for	O
MMB	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
are	O
limited	O
;	O
therefore	O
,	O
a	O
physiologically	O
based	O
pharmacokinetic	O
(	O
PBPK	O
)	O
model	O
was	O
developed	O
for	O
a	O
structurally	O
related	O
oxime	B-CHEMICAL
,	O
1	B-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
trimethylenebis	I-CHEMICAL
{	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
hydroximinomethyl	I-CHEMICAL
}	I-CHEMICAL
pyridinium	I-CHEMICAL
dibromide	I-CHEMICAL
.	O

Based	O
on	O
a	O
previous	O
model	O
structure	O
for	O
the	O
organophosphate	B-CHEMICAL
diisopropylfluorophosphate	B-CHEMICAL
,	O
the	O
model	O
includes	O
key	O
sites	O
of	O
acetylcholinesterase	B-GENE-Y
inhibition	O
(	O
brain	O
and	O
diaphragm	O
)	O
,	O
as	O
well	O
as	O
fat	O
,	O
kidney	O
,	O
liver	O
,	O
rapidly	O
perfused	O
tissues	O
and	O
slowly	O
perfused	O
tissues	O
.	O

All	O
tissue	O
compartments	O
are	O
diffusion	O
limited	O
.	O

Model	O
parameters	O
were	O
collected	O
from	O
the	O
literature	O
,	O
predicted	O
using	O
quantitative	O
structure	O
-	O
property	O
relationships	O
or	O
,	O
when	O
necessary	O
,	O
fit	O
to	O
available	O
pharmacokinetic	O
data	O
from	O
the	O
literature	O
.	O

The	O
model	O
was	O
parameterized	O
using	O
rat	O
plasma	O
,	O
tissue	O
and	O
urine	O
time	O
course	O
data	O
from	O
intramuscular	O
administration	O
,	O
as	O
well	O
as	O
human	O
blood	O
and	O
urine	O
data	O
from	O
intravenous	O
and	O
intramuscular	O
administration	O
;	O
sensitivity	O
analyses	O
were	O
performed	O
.	O

The	O
PBPK	O
model	O
successfully	O
simulates	O
rat	O
and	O
human	O
data	O
sets	O
and	O
has	O
been	O
evaluated	O
by	O
predicting	O
intravenous	O
mouse	O
and	O
intramuscular	O
human	O
data	O
not	O
used	O
in	O
the	O
development	O
of	O
the	O
model	O
.	O

Monte	O
Carlo	O
analyses	O
were	O
performed	O
to	O
quantify	O
human	O
population	O
kinetic	O
variability	O
in	O
the	O
human	O
evaluation	O
data	O
set	O
.	O

The	O
model	O
identifies	O
potential	O
pharmacokinetic	O
differences	O
between	O
rodents	O
and	O
humans	O
,	O
indicated	O
by	O
differences	O
in	O
model	O
parameters	O
between	O
species	O
.	O

The	O
PBPK	O
model	O
can	O
be	O
used	O
to	O
optimize	O
the	O
dosing	O
regimen	O
to	O
improve	O
oxime	B-CHEMICAL
therapeutic	O
efficacy	O
in	O
a	O
human	O
population	O
.	O

Copper	B-CHEMICAL
induced	O
upregulation	O
of	O
apoptosis	O
related	O
genes	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
gill	O
.	O

Copper	B-CHEMICAL
(	O
Cu	B-CHEMICAL
)	O
is	O
an	O
essential	O
micronutrient	O
that	O
,	O
when	O
present	O
in	O
high	O
concentrations	O
,	O
becomes	O
toxic	O
to	O
aquatic	O
organisms	O
.	O

It	O
is	O
known	O
that	O
Cu	B-CHEMICAL
toxicity	O
may	O
induce	O
apoptotic	O
cell	O
death	O
.	O

However	O
,	O
the	O
precise	O
mechanism	O
and	O
the	O
pathways	O
that	O
are	O
activated	O
,	O
in	O
fish	O
,	O
are	O
still	O
unclear	O
.	O

Thus	O
,	O
this	O
study	O
aimed	O
to	O
assess	O
which	O
apoptotic	O
pathways	O
are	O
triggered	O
by	O
Cu	B-CHEMICAL
,	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
gill	O
,	O
the	O
main	O
target	O
of	O
waterborne	O
pollutants	O
.	O

Fish	O
where	O
exposed	O
to	O
12	O
.	O
5	O
and	O
100	O
μg	O
/	O
L	O
of	O
Cu	B-CHEMICAL
during	O
6	O
,	O
12	O
,	O
24	O
and	O
48	O
h	O
.	O

Fish	O
gills	O
were	O
collected	O
to	O
TUNEL	O
assay	O
and	O
mRNA	O
expression	O
analysis	O
of	O
selected	O
genes	O
by	O
real	O
time	O
PCR	O
.	O

An	O
approach	O
to	O
different	O
apoptosis	O
pathways	O
was	O
done	O
selecting	O
p53	B-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
,	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
and	O
apoptosis	B-GENE-Y
inducing	I-GENE-Y
factor	I-GENE-Y
(	O
AIF	B-GENE-Y
)	O
genes	O
.	O

The	O
higher	O
incidence	O
of	O
TUNEL	O
-	O
positive	O
cells	O
,	O
in	O
gill	O
epithelia	O
of	O
the	O
exposed	O
fish	O
,	O
proved	O
that	O
Cu	B-CHEMICAL
induced	O
apoptosis	O
.	O

The	O
results	O
suggest	O
that	O
different	O
apoptosis	O
pathways	O
are	O
triggered	O
by	O
Cu	B-CHEMICAL
at	O
different	O
time	O
points	O
of	O
the	O
exposure	O
period	O
,	O
as	O
the	O
increase	O
in	O
transcripts	O
was	O
sequential	O
,	O
instead	O
of	O
simultaneous	O
.	O

Apoptosis	O
seems	O
to	O
be	O
initiated	O
via	O
intrinsic	O
pathway	O
(	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
)	O
,	O
through	O
p53	B-GENE-Y
activation	O
;	O
then	O
followed	O
by	O
the	O
extrinsic	O
pathway	O
(	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
)	O
and	O
finally	O
by	O
the	O
caspase	B-GENE-N
-	O
independent	O
pathway	O
(	O
AIF	B-GENE-Y
)	O
.	O

A	O
possible	O
model	O
for	O
Cu	B-CHEMICAL
-	O
induce	O
apoptosis	O
pathways	O
is	O
proposed	O
.	O

Silica	B-CHEMICAL
nanoparticles	O
-	O
induced	O
cytotoxicity	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
cultured	O
A431	O
and	O
A549	O
cells	O
.	O

In	O
medicine	O
,	O
the	O
use	O
of	O
silica	B-CHEMICAL
nanoparticles	O
(	O
SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
)	O
offers	O
new	O
perspectives	O
in	O
biosensor	O
,	O
drug	O
delivery	O
and	O
cancer	O
therapy	O
.	O

However	O
,	O
questions	O
about	O
potential	O
toxic	O
and	O
deleterious	O
effects	O
of	O
SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
have	O
also	O
been	O
raised	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
induction	O
of	O
cytotoxicity	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
by	O
SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
(	O
size	O
15	O
nm	O
)	O
in	O
human	O
skin	O
epithelial	O
(	O
A431	O
)	O
and	O
human	O
lung	O
epithelial	O
(	O
A549	O
)	O
cells	O
.	O

SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
(	O
concentration	O
range	O
25	O
-	O
200	O
µg	O
/	O
ml	O
)	O
induced	O
dose	O
-	O
dependent	O
cytotoxicity	O
in	O
both	O
types	O
of	O
cells	O
,	O
which	O
was	O
demonstrated	O
by	O
cell	O
viability	O
(	O
3	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dimethylthiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diphenyltetrazoliumbromide	I-CHEMICAL
)	O
and	O
lactate	B-GENE-N
dehydrogenase	I-GENE-N
leakage	O
assays	O
.	O

SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
were	O
also	O
found	O
to	O
induce	O
oxidative	O
stress	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
indicated	O
by	O
depletion	O
of	O
glutathione	B-CHEMICAL
and	O
induction	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
generation	O
and	O
lipid	O
peroxidation	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
that	O
following	O
the	O
exposure	O
of	O
cells	O
to	O
SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
,	O
the	O
messenger	O
RNA	O
level	O
of	O
apoptotic	O
genes	O
(	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
)	O
were	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
activities	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
enzymes	O
were	O
also	O
significantly	O
higher	O
in	O
both	O
kinds	O
of	O
cells	O
exposed	O
to	O
SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
.	O

This	O
study	O
suggested	O
that	O
SiO	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
)	I-CHEMICAL
NPs	O
induce	O
cytotoxicity	O
and	O
apoptosis	O
in	O
A431	O
and	O
A549	O
cells	O
,	O
which	O
is	O
likely	O
to	O
be	O
mediated	O
through	O
ROS	O
generation	O
and	O
oxidative	O
stress	O
.	O

Characterization	O
of	O
four	O
new	O
mouse	B-GENE-N
cytochrome	I-GENE-N
P450	I-GENE-N
enzymes	O
of	O
the	O
CYP2J	B-GENE-N
subfamily	O
.	O

The	O
cytochrome	B-GENE-N
P450	I-GENE-N
superfamily	O
encompasses	O
a	O
diverse	O
group	O
of	O
enzymes	O
that	O
catalyze	O
the	O
oxidation	O
of	O
various	O
substrates	O
.	O

The	O
mouse	O
CYP2J	B-GENE-N
subfamily	O
includes	O
members	O
that	O
have	O
wide	O
tissue	O
distribution	O
and	O
are	O
active	O
in	O
the	O
metabolism	O
of	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
(	O
AA	O
)	O
,	O
linoleic	B-CHEMICAL
acid	I-CHEMICAL
(	O
LA	O
)	O
,	O
and	O
other	O
lipids	O
and	O
xenobiotics	O
.	O

The	O
mouse	B-GENE-N
Cyp2j	I-GENE-N
locus	O
contains	O
seven	O
genes	O
and	O
three	O
pseudogenes	O
located	O
in	O
a	O
contiguous	O
0	O
.	O
62	O
megabase	O
cluster	O
on	O
chromosome	O
4	O
.	O

We	O
describe	O
four	O
new	O
mouse	B-GENE-N
CYP2J	I-GENE-N
isoforms	O
(	O
designated	O
CYP2J8	B-GENE-Y
,	O
CYP2J11	B-GENE-Y
,	O
CYP2J12	B-GENE-Y
,	O
and	O
CYP2J13	B-GENE-Y
)	O
.	O

The	O
four	O
cDNAs	O
contain	O
open	O
reading	O
frames	O
that	O
encode	O
polypeptides	O
with	O
62	O
-	O
84	O
%	O
identity	O
with	O
the	O
three	O
previously	O
identified	O
mouse	B-GENE-N
CYP2Js	I-GENE-N
.	O

All	O
four	O
new	O
CYP2J	B-GENE-N
proteins	O
were	O
expressed	O
in	O
Sf21	O
insect	O
cells	O
.	O

Each	O
recombinant	O
protein	O
metabolized	O
AA	O
and	O
LA	O
to	O
epoxides	B-CHEMICAL
and	O
hydroxy	B-CHEMICAL
derivatives	O
.	O

Specific	O
antibodies	O
,	O
mRNA	O
probes	O
,	O
and	O
polymerase	O
chain	O
reaction	O
primer	O
sets	O
were	O
developed	O
for	O
each	O
mouse	O
CYP2J	B-GENE-N
to	O
examine	O
their	O
tissue	O
distribution	O
.	O

CYP2J8	B-GENE-Y
transcripts	O
were	O
found	O
in	O
the	O
kidney	O
,	O
liver	O
,	O
and	O
brain	O
,	O
and	O
protein	O
expression	O
was	O
confirmed	O
in	O
the	O
kidney	O
and	O
brain	O
(	O
neuropil	O
)	O
.	O

CYP2J11	B-GENE-Y
transcripts	O
were	O
most	O
abundant	O
in	O
the	O
kidney	O
and	O
heart	O
,	O
with	O
protein	O
detected	O
primarily	O
in	O
the	O
kidney	O
(	O
proximal	O
convoluted	O
tubules	O
)	O
,	O
liver	O
,	O
and	O
heart	O
(	O
cardiomyocytes	O
)	O
.	O

CYP2J12	B-GENE-Y
transcripts	O
were	O
prominently	O
present	O
in	O
the	O
brain	O
,	O
and	O
CYP2J13	B-GENE-Y
transcripts	O
were	O
detected	O
in	O
multiple	O
tissues	O
,	O
with	O
the	O
highest	O
expression	O
in	O
the	O
kidney	O
.	O

CYP2J12	B-GENE-Y
and	O
CYP2J13	B-GENE-Y
protein	O
expression	O
could	O
not	O
be	O
determined	O
because	O
the	O
antibodies	O
developed	O
were	O
not	O
immunospecific	O
.	O

We	O
conclude	O
that	O
the	O
four	O
new	O
CYP2J	B-GENE-N
isoforms	O
might	O
be	O
involved	O
in	O
the	O
metabolism	O
of	O
AA	O
and	O
LA	O
to	O
bioactive	O
lipids	O
in	O
mouse	O
hepatic	O
and	O
extrahepatic	O
tissues	O
.	O

Inhibition	O
of	O
matrix	B-GENE-N
metalloproteinases	I-GENE-N
(	O
MMPs	B-GENE-N
)	O
as	O
a	O
potential	O
strategy	O
to	O
ameliorate	O
hypertension	O
-	O
induced	O
cardiovascular	O
alterations	O
.	O

A	O
group	O
of	O
proteases	O
,	O
the	O
matrix	B-GENE-N
metalloproteinases	I-GENE-N
(	O
MMPs	B-GENE-N
)	O
are	O
well	O
known	O
for	O
their	O
capacity	O
to	O
degrade	O
extracellular	B-GENE-N
matrix	I-GENE-N
(	I-GENE-N
ECM	I-GENE-N
)	I-GENE-N
proteins	I-GENE-N
.	O

Particularly	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
contribute	O
to	O
the	O
degradation	O
and	O
reorganization	O
of	O
the	O
ECM	O
components	O
and	O
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
cardiovascular	O
remodeling	O
.	O

Imbalanced	O
MMP	B-GENE-N
activity	O
promotes	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
migration	O
and	O
proliferation	O
and	O
endothelial	O
dysfunction	O
,	O
thus	O
resulting	O
in	O
increased	O
cardiovascular	O
stiffness	O
and	O
hypertrophy	O
.	O

Furthermore	O
,	O
MMP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
cleaves	O
non	O
-	O
ECM	O
protein	O
substrates	O
including	O
cellular	O
receptors	O
and	O
intracellular	O
proteins	O
,	O
thus	O
causing	O
cardiac	O
and	O
vascular	O
dysfunction	O
.	O

It	O
is	O
now	O
becoming	O
clear	O
that	O
increased	O
MMP	B-GENE-N
activity	O
promotes	O
long	O
-	O
lasting	O
cardiovascular	O
structural	O
and	O
functional	O
alterations	O
in	O
both	O
experimental	O
and	O
clinical	O
hypertension	O
,	O
and	O
this	O
alteration	O
may	O
contribute	O
to	O
sustained	O
hypertension	O
and	O
its	O
complications	O
.	O

Other	O
pathogenic	O
mechanisms	O
including	O
activation	O
of	O
the	O
renin	B-GENE-Y
-	O
angiotensin	B-GENE-Y
-	O
aldosterone	O
system	O
and	O
oxidative	O
stress	O
activate	O
and	O
upregulate	O
MMPs	B-GENE-N
.	O

Therefore	O
,	O
MMP	B-GENE-N
inhibition	O
may	O
prevent	O
the	O
deleterious	O
consequences	O
of	O
hypertension	O
to	O
the	O
cardiovascular	O
system	O
.	O

This	O
review	O
article	O
will	O
focus	O
on	O
growing	O
evidence	O
supporting	O
the	O
relevance	O
of	O
MMPs	B-GENE-N
in	O
hypertension	O
and	O
the	O
effects	O
of	O
MMP	B-GENE-N
inhibitors	O
.	O

Particularly	O
,	O
the	O
effects	O
of	O
doxycycline	B-CHEMICAL
used	O
as	O
a	O
non	O
selective	O
MMP	B-GENE-N
inhibitor	O
in	O
experimental	O
and	O
clinical	O
studies	O
will	O
be	O
discussed	O
.	O

Peroxynitrite	B-CHEMICAL
mediates	O
testosterone	B-CHEMICAL
-	O
induced	O
vasodilation	O
of	O
microvascular	O
resistance	O
vessels	O
.	O

Our	O
knowledge	O
of	O
how	O
androgens	B-CHEMICAL
influence	O
the	O
cardiovascular	O
system	O
is	O
far	O
from	O
complete	O
,	O
and	O
this	O
lack	O
of	O
understanding	O
is	O
especially	O
true	O
of	O
how	O
androgens	B-CHEMICAL
affect	O
resistance	O
vessels	O
.	O

Our	O
aim	O
was	O
to	O
identify	O
the	O
signaling	O
mechanisms	O
stimulated	O
by	O
testosterone	B-CHEMICAL
(	O
TES	B-CHEMICAL
)	O
in	O
microvascular	O
arteries	O
and	O
to	O
understand	O
how	O
these	O
mechanisms	O
mediate	O
TES	B-CHEMICAL
-	O
induced	O
vasodilation	O
.	O

Mesenteric	O
microvessels	O
were	O
isolated	O
from	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

Tension	O
studies	O
demonstrated	O
a	O
rapid	O
,	O
concentration	O
-	O
dependent	O
,	O
vasodilatory	O
response	O
to	O
TES	B-CHEMICAL
that	O
did	O
not	O
involve	O
protein	O
synthesis	O
or	O
aromatization	O
to	O
17β	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
.	O

Dichlorofluorescein	B-CHEMICAL
fluorescence	O
and	O
nitrotyrosine	B-CHEMICAL
immunoblot	O
experiments	O
indicated	O
that	O
TES	B-CHEMICAL
stimulated	O
peroxynitrite	B-CHEMICAL
formation	O
in	O
microvessels	O
,	O
and	O
functional	O
studies	O
demonstrated	O
that	O
TES	B-CHEMICAL
-	O
induced	O
vasodilation	O
was	O
inhibited	O
by	O
scavenging	O
peroxynitrite	B-CHEMICAL
.	O

As	O
predicted	O
,	O
TES	B-CHEMICAL
enhanced	O
the	O
production	O
of	O
both	O
peroxynitrite	B-CHEMICAL
precursors	O
(	O
i	O
.	O
e	O
.	O
,	O
superoxide	B-CHEMICAL
and	O
nitic	B-CHEMICAL
oxide	I-CHEMICAL
)	O
,	O
and	O
xanthine	B-GENE-Y
oxidase	I-GENE-Y
was	O
identified	O
as	O
the	O
likely	O
source	O
of	O
TES	B-CHEMICAL
-	O
stimulated	O
superoxide	B-CHEMICAL
production	O
.	O

Functional	O
and	O
biochemical	O
studies	O
indicated	O
that	O
TES	B-CHEMICAL
signaling	O
involved	O
activity	O
of	O
the	O
phosphoinositide	B-GENE-N
3	I-GENE-N
(	I-GENE-N
PI3	I-GENE-N
)	I-GENE-N
kinase	I-GENE-N
-	O
protein	B-GENE-Y
kinase	I-GENE-Y
B	I-GENE-Y
(	O
Akt	B-GENE-Y
)	O
cascade	O
initiated	O
by	O
activation	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
and	O
culminated	O
in	O
enhanced	O
production	O
of	O
cGMP	B-CHEMICAL
and	O
microvascular	O
vasodilation	O
.	O

These	O
findings	O
,	O
derived	O
from	O
a	O
variety	O
of	O
analytical	O
and	O
functional	O
approaches	O
,	O
provide	O
evidence	O
for	O
a	O
novel	O
nongenomic	O
signaling	O
mechanism	O
for	O
androgen	B-CHEMICAL
action	O
in	O
the	O
microvasculature	O
:	O
TES	B-CHEMICAL
-	O
stimulated	O
vasodilation	O
mediated	O
primarily	O
by	O
peroxynitrite	B-CHEMICAL
formed	O
from	O
xanthine	B-GENE-Y
oxidase	I-GENE-Y
-	O
generated	O
superoxide	B-CHEMICAL
and	O
NO	B-CHEMICAL
.	O

This	O
response	O
was	O
associated	O
with	O
activation	O
of	O
the	O
PI3	B-GENE-N
kinase	I-GENE-N
-	O
Akt	B-GENE-Y
signaling	O
cascade	O
initiated	O
by	O
activation	O
of	O
the	O
androgen	B-GENE-Y
receptor	I-GENE-Y
.	O

We	O
propose	O
this	O
mechanism	O
could	O
account	O
for	O
TES	B-CHEMICAL
-	O
stimulated	O
cGMP	B-CHEMICAL
production	O
in	O
microvessels	O
and	O
,	O
ultimately	O
,	O
vasodilation	O
.	O

Butein	B-CHEMICAL
protects	O
human	O
dental	O
pulp	O
cells	O
from	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
-	O
induced	O
oxidative	O
toxicity	O
via	O
Nrf2	B-GENE-Y
pathway	O
-	O
dependent	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expressions	O
.	O

Rhus	O
verniciflua	O
Stokes	O
is	O
a	O
plant	O
that	O
is	O
native	O
to	O
East	O
Asian	O
countries	O
,	O
such	O
as	O
Korea	O
,	O
China	O
,	O
and	O
Japan	O
.	O

Butein	B-CHEMICAL
,	O
a	O
plant	O
polyphenol	B-CHEMICAL
,	O
is	O
one	O
of	O
the	O
major	O
active	O
components	O
of	O
R	O
.	O
verniciflua	O
.	O

Reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
,	O
produced	O
via	O
dental	O
adhesive	O
bleaching	O
agents	O
and	O
pulpal	O
disease	O
,	O
can	O
cause	O
oxidative	O
stress	O
.	O

Here	O
,	O
we	O
found	O
that	O
butein	B-CHEMICAL
possesses	O
cytoprotective	O
effects	O
on	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
(	O
H2O2	B-CHEMICAL
)	O
-	O
induced	O
dental	O
cell	O
death	O
.	O

H2O2	B-CHEMICAL
is	O
a	O
representative	O
ROS	O
and	O
causes	O
cell	O
death	O
through	O
necrosis	O
in	O
human	O
dental	O
pulp	O
(	O
HDP	O
)	O
cells	O
.	O

H2O2	B-CHEMICAL
-	O
induced	O
cytotoxicity	O
and	O
production	O
of	O
ROS	O
were	O
blocked	O
in	O
the	O
presence	O
of	O
butein	B-CHEMICAL
,	O
and	O
these	O
effects	O
were	O
dose	O
dependent	O
.	O

Butein	B-CHEMICAL
also	O
increased	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
protein	O
expression	O
and	O
HO	B-GENE-Y
activity	O
.	O

In	O
addition	O
,	O
butein	B-CHEMICAL
-	O
dependent	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
was	O
required	O
for	O
the	O
inhibition	O
of	O
H2O2	B-CHEMICAL
-	O
induced	O
cell	O
death	O
and	O
ROS	O
generation	O
.	O

Furthermore	O
,	O
butein	B-CHEMICAL
treatment	O
caused	O
nuclear	O
accumulation	O
of	O
nuclear	B-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
E2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
Nrf2	B-GENE-Y
)	O
and	O
increased	O
the	O
promoter	O
activity	O
of	O
antioxidant	B-GENE-N
response	I-GENE-N
elements	I-GENE-N
(	O
AREs	B-GENE-N
)	O
.	O

Treatment	O
of	O
HDP	O
cells	O
with	O
a	O
c	B-GENE-N
-	I-GENE-N
Jun	I-GENE-N
NH2	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
(	O
JNK	B-GENE-N
)	O
inhibitor	O
also	O
reduced	O
butein	B-CHEMICAL
-	O
induced	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
,	O
and	O
butein	B-CHEMICAL
treatment	O
led	O
to	O
increased	O
JNK	B-GENE-N
phosphorylation	O
.	O

These	O
results	O
indicate	O
that	O
butein	B-CHEMICAL
may	O
be	O
used	O
to	O
prevent	O
functional	O
dental	O
cell	O
death	O
and	O
thus	O
may	O
be	O
useful	O
as	O
a	O
pulpal	O
disease	O
agent	O
.	O

Genome	O
-	O
wide	O
screen	O
for	O
modulation	O
of	O
hepatic	O
apolipoprotein	B-GENE-Y
A	I-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
(	O
ApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
)	O
secretion	O
.	O

Control	O
of	O
plasma	O
cholesterol	B-CHEMICAL
levels	O
is	O
a	O
major	O
therapeutic	O
strategy	O
for	O
management	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
.	O

Although	O
reducing	O
LDL	B-GENE-N
cholesterol	B-CHEMICAL
(	O
LDL	B-GENE-N
-	O
c	O
)	O
levels	O
decreases	O
morbidity	O
and	O
mortality	O
,	O
this	O
therapeutic	O
intervention	O
only	O
translates	O
into	O
a	O
25	O
-	O
40	O
%	O
reduction	O
in	O
cardiovascular	O
events	O
.	O

Epidemiological	O
studies	O
have	O
shown	O
that	O
a	O
high	O
LDL	B-GENE-N
-	O
c	O
level	O
is	O
not	O
the	O
only	O
risk	O
factor	O
for	O
CAD	O
;	O
low	O
HDL	B-GENE-N
cholesterol	B-CHEMICAL
(	O
HDL	B-GENE-N
-	O
c	O
)	O
is	O
an	O
independent	O
risk	O
factor	O
for	O
CAD	O
.	O

Apolipoprotein	B-GENE-Y
A	I-GENE-Y
-	I-GENE-Y
I	O
(	O
ApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
)	O
is	O
the	O
major	O
protein	O
component	O
of	O
HDL	B-GENE-N
-	O
c	O
that	O
mediates	O
reverse	O
cholesterol	B-CHEMICAL
transport	O
from	O
tissues	O
to	O
the	O
liver	O
for	O
excretion	O
.	O

Therefore	O
,	O
increasing	O
ApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
levels	O
is	O
an	O
attractive	O
strategy	O
for	O
HDL	B-GENE-N
-	O
c	O
elevation	O
.	O

Using	O
genome	O
-	O
wide	O
siRNA	O
screening	O
,	O
targets	O
that	O
regulate	O
hepatocyte	O
ApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
secretion	O
were	O
identified	O
through	O
transfection	O
of	O
21	O
,	O
789	O
siRNAs	O
into	O
hepatocytes	O
whereby	O
cell	O
supernatants	O
were	O
assayed	O
for	O
ApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
.	O

Approximately	O
800	O
genes	O
were	O
identified	O
and	O
triaged	O
using	O
a	O
convergence	O
of	O
information	O
,	O
including	O
genetic	O
associations	O
with	O
HDL	B-GENE-N
-	O
c	O
levels	O
,	O
tissue	O
-	O
specific	O
gene	O
expression	O
,	O
druggability	O
assessments	O
,	O
and	O
pathway	O
analysis	O
.	O

Fifty	O
-	O
nine	O
genes	O
were	O
selected	O
for	O
reconfirmation	O
;	O
40	O
genes	O
were	O
confirmed	O
.	O

Here	O
we	O
describe	O
the	O
siRNA	O
screening	O
strategy	O
,	O
assay	O
implementation	O
and	O
validation	O
,	O
data	O
triaging	O
,	O
and	O
example	O
genes	O
of	O
interest	O
.	O

The	O
genes	O
of	O
interest	O
include	O
known	O
and	O
novel	O
genes	O
encoding	O
secreted	O
enzymes	O
,	O
proteases	O
,	O
G	B-GENE-N
-	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
,	O
metabolic	O
enzymes	O
,	O
ion	B-GENE-N
transporters	I-GENE-N
,	O
and	O
proteins	O
of	O
unknown	O
function	O
.	O

Repression	O
of	O
farnesyltransferase	B-GENE-Y
(	O
FNTA	B-GENE-Y
)	O
by	O
siRNA	O
and	O
the	O
enzyme	O
inhibitor	O
manumycin	B-CHEMICAL
A	I-CHEMICAL
caused	O
elevation	O
of	O
ApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
secretion	O
from	O
hepatocytes	O
and	O
from	O
transgenic	O
mice	O
expressing	O
hApoA	B-GENE-Y
-	I-GENE-Y
I	I-GENE-Y
and	O
cholesterol	B-CHEMICAL
ester	I-CHEMICAL
transfer	O
protein	O
transgenes	O
.	O

In	O
total	O
,	O
this	O
work	O
underscores	O
the	O
power	O
of	O
functional	O
genetic	O
assessment	O
to	O
identify	O
new	O
therapeutic	O
targets	O
.	O

Activation	O
of	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
Protein	I-GENE-N
Kinase	I-GENE-N
and	O
Phosphorylation	O
of	O
Glycogen	B-GENE-Y
Synthase	I-GENE-Y
Kinase3	I-GENE-Y
β	I-GENE-Y
Mediate	O
Ursolic	B-CHEMICAL
Acid	I-CHEMICAL
Induced	O
Apoptosis	O
in	O
HepG2	O
Liver	O
Cancer	O
Cells	O
.	O

Despite	O
the	O
antitumour	O
effect	O
of	O
ursolic	B-CHEMICAL
acid	I-CHEMICAL
observed	O
in	O
several	O
cancers	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
roles	O
of	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
AMPK	B-GENE-N
)	O
and	O
glycogen	B-GENE-Y
synthase	I-GENE-Y
kinase	I-GENE-Y
3	I-GENE-Y
beta	I-GENE-Y
(	O
GSK3β	B-GENE-Y
)	O
were	O
examined	O
in	O
ursolic	O
acid	O
induced	O
apoptosis	O
in	O
HepG2	O
hepatocellular	O
carcinoma	O
cells	O
.	O

Ursolic	B-CHEMICAL
acid	I-CHEMICAL
significantly	O
exerted	O
cytotoxicity	O
,	O
increased	O
the	O
sub	O
-	O
G1	O
population	O
and	O
the	O
number	O
of	O
ethidium	B-CHEMICAL
homodimer	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)	O
mediated	O
dUTP	B-CHEMICAL
nick	O
end	O
labeling	O
positive	O
cells	O
in	O
HepG2	O
cells	O
.	O

Also	O
,	O
ursolic	O
acid	O
enhanced	O
the	O
cleavages	O
of	O
poly	B-GENE-N
-	I-GENE-N
ADP	I-GENE-N
-	I-GENE-N
ribose	I-GENE-N
polymerase	I-GENE-N
(	O
PARP	B-GENE-N
)	O
and	O
caspase3	B-GENE-Y
,	O
attenuated	O
the	O
expression	O
of	O
astrocyte	B-GENE-Y
elevated	I-GENE-Y
gene	I-GENE-Y
(	O
AEG1	B-GENE-Y
)	O
and	O
survivin	B-GENE-Y
in	O
HepG2	O
cells	O
.	O

Interestingly	O
,	O
ursolic	B-CHEMICAL
acid	I-CHEMICAL
increased	O
the	O
phosphorylation	O
of	O
AMPK	B-GENE-N
and	O
coenzyme	B-GENE-N
A	I-GENE-N
carboxylase	I-GENE-N
and	O
also	O
enhanced	O
phosphorylation	O
of	O
GSK3β	B-GENE-Y
at	O
inactive	O
form	O
serine	B-CHEMICAL
9	O
,	O
whereas	O
ursolic	B-CHEMICAL
acid	I-CHEMICAL
attenuated	O
the	O
phosphorylation	O
of	O
AKT	B-GENE-N
and	O
mTOR	B-GENE-Y
in	O
HepG2	O
cells	O
.	O

Conversely	O
,	O
AMPK	B-GENE-N
inhibitor	O
compound	B-CHEMICAL
C	I-CHEMICAL
or	O
GSK3β	B-GENE-Y
inhibitor	O
SB216763	B-CHEMICAL
blocked	O
the	O
cleavages	O
of	O
PARP	B-GENE-N
and	O
caspase	B-GENE-Y
3	I-GENE-Y
induced	O
by	O
ursolic	B-CHEMICAL
acid	I-CHEMICAL
in	O
HepG2	O
cells	O
.	O

Furthermore	O
,	O
proteosomal	O
inhibitor	O
MG132	B-CHEMICAL
suppressed	O
AMPK	B-GENE-N
activation	O
,	O
GSK3β	B-GENE-Y
phosphorylation	O
,	O
cleaved	O
PARP	B-GENE-N
and	O
deceased	O
AEG	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
induced	O
by	O
ursolic	B-CHEMICAL
acid	I-CHEMICAL
in	O
HepG2	O
cells	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
ursolic	B-CHEMICAL
acid	I-CHEMICAL
induced	O
apoptosis	O
in	O
HepG2	O
cells	O
via	O
AMPK	B-GENE-N
activation	O
and	O
GSK3β	B-GENE-Y
phosphorylation	O
as	O
a	O
potent	O
chemopreventive	O
agent	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Transport	O
by	O
OATP1B1	B-GENE-Y
and	O
OATP1B3	B-GENE-Y
enhances	O
the	O
cytotoxicity	O
of	O
epigallocatechin	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
gallate	I-CHEMICAL
and	O
several	O
quercetin	B-CHEMICAL
derivatives	O
.	O

Organic	B-GENE-N
anion	I-GENE-N
transporting	I-GENE-N
polypeptides	I-GENE-N
(	I-GENE-N
OATPs	I-GENE-N
)	I-GENE-N
1B1	I-GENE-N
and	I-GENE-N
1B3	I-GENE-N
are	O
transporters	O
that	O
are	O
expressed	O
selectively	O
in	O
human	O
hepatocytes	O
under	O
normal	O
conditions	O
.	O

OATP1B3	B-GENE-Y
is	O
also	O
expressed	O
in	O
certain	O
cancers	O
.	O

Flavonoids	B-CHEMICAL
such	O
as	O
green	O
tea	O
catechins	B-CHEMICAL
and	O
quercetin	B-CHEMICAL
glycosides	I-CHEMICAL
have	O
been	O
shown	O
to	O
modulate	O
the	O
function	O
of	O
some	O
OATPs	B-GENE-N
.	O

In	O
the	O
present	O
study	O
,	O
the	O
extent	O
to	O
which	O
six	O
substituted	O
quercetin	B-CHEMICAL
derivatives	O
(	O
1	O
-	O
6	O
)	O
affected	O
the	O
function	O
of	O
OATP1B1	B-GENE-Y
and	O
OATP1B3	B-GENE-Y
was	O
investigated	O
.	O

Uptake	O
of	O
the	O
radiolabeled	O
model	O
substrates	O
estradiol	B-CHEMICAL
17β	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
estrone	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
sulfate	I-CHEMICAL
,	O
and	O
dehydroepiandrosterone	B-CHEMICAL
sulfate	I-CHEMICAL
(	O
DHEAS	B-CHEMICAL
)	O
was	O
determined	O
in	O
the	O
absence	O
and	O
presence	O
of	O
compounds	O
1	O
-	O
6	O
using	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
stably	O
expressing	O
either	O
OATP1B1	B-GENE-Y
or	O
OATP1B3	B-GENE-Y
.	O

Several	O
of	O
compounds	O
1	O
-	O
6	O
inhibited	O
OATP	B-GENE-N
-	O
mediated	O
uptake	O
of	O
all	O
three	O
model	O
substrates	O
,	O
suggesting	O
that	O
they	O
could	O
also	O
be	O
potential	O
substrates	O
.	O

Compound	O
6	O
stimulated	O
OATP1B3	B-GENE-Y
-	O
mediated	O
estradiol	B-CHEMICAL
17β	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
uptake	O
by	O
increasing	O
the	O
apparent	O
affinity	O
of	O
OATP1B3	B-GENE-Y
for	O
its	O
substrate	O
.	O

Cytotoxicity	O
assays	O
demonstrated	O
that	O
epigallocatechin	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
gallate	I-CHEMICAL
(	O
EGCG	B-CHEMICAL
)	O
and	O
most	O
of	O
compounds	O
1	O
-	O
6	O
killed	O
preferentially	O
OATP	B-GENE-N
-	O
expressing	O
CHO	O
cells	O
.	O

EGCG	B-CHEMICAL
,	O
1	O
,	O
and	O
3	O
were	O
the	O
most	O
potent	O
cytotoxic	O
compounds	O
,	O
with	O
EGCG	B-CHEMICAL
and	O
3	O
selectively	O
killing	O
OATP1B3	B-GENE-Y
-	O
expressing	O
cells	O
.	O

Given	O
that	O
OATP1B3	B-GENE-Y
is	O
expressed	O
in	O
several	O
cancers	O
,	O
EGCG	B-CHEMICAL
and	O
some	O
of	O
the	O
quercetin	B-CHEMICAL
derivatives	O
studied	O
might	O
be	O
promising	O
lead	O
compounds	O
for	O
the	O
development	O
of	O
novel	O
anticancer	O
drugs	O
.	O

Thioredoxin	B-GENE-Y
-	O
mimetic	O
peptides	O
(	O
TXM	O
)	O
reverse	O
auranofin	B-CHEMICAL
induced	O
apoptosis	O
and	O
restore	O
insulin	B-GENE-N
secretion	O
in	O
insulinoma	O
cells	O
.	O

The	O
thioredoxin	B-GENE-N
reductase	I-GENE-N
/	O
thioredoxin	B-GENE-Y
system	O
(	O
TrxR	B-GENE-N
/	O
Trx1	B-GENE-Y
)	O
plays	O
a	O
major	O
role	O
in	O
protecting	O
cells	O
from	O
oxidative	O
stress	O
.	O

Disruption	O
of	O
the	O
TrxR	B-GENE-N
-	O
Trx1	B-GENE-Y
system	O
keeps	O
Trx1	B-GENE-Y
in	O
the	O
oxidized	O
state	O
leading	O
to	O
cell	O
death	O
through	O
activation	O
of	O
the	O
ASK1	B-GENE-Y
-	O
Trx1	B-GENE-Y
apoptotic	O
pathway	O
.	O

The	O
potential	O
mechanism	O
and	O
ability	O
of	O
tri	O
-	O
and	O
tetra	O
-	O
oligopeptides	O
derived	O
from	O
the	O
canonical	O
-	O
CxxC	B-GENE-N
-	I-GENE-N
motif	I-GENE-N
of	O
the	O
Trx1	B-GENE-Y
-	O
active	O
site	O
to	O
mimic	O
and	O
enhance	O
Trx1	B-GENE-Y
cellular	O
activity	O
was	O
examined	O
.	O

The	O
Trx	B-GENE-Y
mimetics	O
peptides	O
(	O
TXM	O
)	O
protected	O
insulinoma	O
INS	O
832	O
/	O
13	O
cells	O
from	O
oxidative	O
stress	O
induced	O
by	O
selectively	O
inhibiting	O
TrxR	B-GENE-N
with	O
auranofin	B-CHEMICAL
(	O
AuF	B-CHEMICAL
)	O
.	O

TXM	O
reversed	O
the	O
AuF	B-CHEMICAL
-	O
effects	O
preventing	O
apoptosis	O
,	O
and	O
increasing	O
cell	O
-	O
viability	O
.	O

The	O
TXM	O
peptides	O
were	O
effective	O
in	O
inhibiting	O
AuF	B-CHEMICAL
-	O
induced	O
MAPK	B-GENE-N
,	O
JNK	B-GENE-N
and	O
p38	B-GENE-N
(	O
MAPK	B-GENE-N
)	O
phosphorylation	O
,	O
in	O
correlation	O
with	O
preventing	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
cleavage	O
and	O
thereby	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
dissociation	O
.	O

The	O
ability	O
to	O
form	O
a	O
disulfide	B-CHEMICAL
-	O
bridge	O
-	O
like	O
conformation	O
was	O
estimated	O
from	O
molecular	O
dynamics	O
simulations	O
.	O

The	O
TXM	O
peptides	O
restored	O
insulin	B-GENE-N
secretion	O
and	O
displayed	O
Trx1	B-GENE-Y
denitrosylase	B-GENE-N
activity	O
.	O

Their	O
potency	O
was	O
10	O
-	O
100	O
-	O
fold	O
higher	O
than	O
redox	O
reagents	O
like	O
NAC	B-CHEMICAL
,	O
AD4	B-CHEMICAL
,	O
or	O
ascorbic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Unable	O
to	O
reverse	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
phosphorylation	O
,	O
TXM	O
-	O
CB3	O
(	O
NAc	B-CHEMICAL
-	I-CHEMICAL
Cys	I-CHEMICAL
-	I-CHEMICAL
Pro	I-CHEMICAL
-	I-CHEMICAL
Cys	I-CHEMICAL
amide	I-CHEMICAL
)	O
appeared	O
to	O
function	O
in	O
part	O
,	O
through	O
inhibiting	O
ASK1	B-GENE-Y
-	O
Trx	B-GENE-Y
dissociation	O
.	O

These	O
highly	O
effective	O
anti	O
-	O
apoptotic	O
effects	O
of	O
Trx1	B-GENE-Y
mimetic	O
peptides	O
exhibited	O
in	O
INS	O
832	O
/	O
13	O
cells	O
could	O
become	O
valuable	O
in	O
treating	O
adverse	O
oxidative	O
-	O
stress	O
related	O
disorders	O
such	O
as	O
diabetes	O
.	O

Dose	O
-	O
dependent	O
effects	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
on	O
transdifferentiation	O
of	O
skeletal	O
muscle	O
cells	O
to	O
adipose	O
cells	O
.	O

Fat	O
infiltration	O
within	O
muscle	O
is	O
one	O
of	O
a	O
number	O
of	O
features	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
deficiency	O
,	O
which	O
leads	O
to	O
a	O
decline	O
in	O
muscle	O
functionality	O
.	O

The	O
origin	O
of	O
this	O
fat	O
is	O
unclear	O
,	O
but	O
one	O
possibility	O
is	O
that	O
it	O
forms	O
from	O
myogenic	O
precursor	O
cells	O
present	O
in	O
the	O
muscle	O
,	O
which	O
transdifferentiate	O
into	O
mature	O
adipocytes	O
.	O

The	O
current	O
study	O
examined	O
the	O
effect	O
of	O
the	O
active	O
form	O
of	O
vitamin	B-CHEMICAL
D₃	I-CHEMICAL
,	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
-	I-CHEMICAL
dihydroxyvitamin	I-CHEMICAL
D₃	I-CHEMICAL
(	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
₂D₃	I-CHEMICAL
)	O
,	O
on	O
the	O
capacity	O
of	O
the	O
C2C12	O
muscle	O
cell	O
line	O
to	O
differentiate	O
towards	O
the	O
myogenic	O
and	O
adipogenic	O
lineages	O
.	O

Cells	O
were	O
cultured	O
in	O
myogenic	O
or	O
adipogenic	O
differentiation	O
media	O
containing	O
increasing	O
concentrations	O
(	O
0	O
,	O
10	O
⁻	O
¹³	O
,	O
10	O
⁻	O
¹¹	O
,	O
10	O
⁻	O
⁹	O
,	O
10	O
⁻	O
⁷	O
or	O
10	O
⁻	O
⁵	O
M	O
)	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
₂D₃	I-CHEMICAL
for	O
up	O
to	O
6	O
days	O
and	O
markers	O
of	O
muscle	O
and	O
fat	O
development	O
measured	O
.	O

Mature	O
myofibres	O
were	O
formed	O
in	O
both	O
adipogenic	O
and	O
myogenic	O
media	O
,	O
but	O
fat	O
droplets	O
were	O
only	O
observed	O
in	O
adipogenic	O
media	O
.	O

Relative	O
to	O
controls	O
,	O
low	O
physiological	O
concentrations	O
(	O
10	O
⁻	O
¹³	O
and	O
10	O
⁻	O
¹¹	O
M	O
)	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
₂D3	I-CHEMICAL
increased	O
fat	O
droplet	O
accumulation	O
,	O
whereas	O
high	O
physiological	O
(	O
10	O
⁻	O
⁹	O
M	O
)	O
and	O
supraphysiological	O
concentrations	O
(	O
≥	O
10	O
⁻	O
⁷	O
M	O
)	O
inhibited	O
fat	O
accumulation	O
.	O

This	O
increased	O
accumulation	O
of	O
fat	O
with	O
low	O
physiological	O
concentrations	O
(	O
10	O
⁻	O
¹³	O
and	O
10	O
⁻	O
¹¹	O
M	O
)	O
was	O
associated	O
with	O
a	O
sequential	O
up	O
-	O
regulation	O
of	O
PPARγ2	B-GENE-Y
(	O
PPARG	B-GENE-Y
)	O
and	O
FABP4	B-GENE-Y
mRNA	O
,	O
indicating	O
formation	O
of	O
adipocytes	O
,	O
whereas	O
higher	O
concentrations	O
(	O
≥	O
10	O
⁻	O
⁹	O
M	O
)	O
reduced	O
all	O
these	O
effects	O
,	O
and	O
the	O
highest	O
concentration	O
(	O
10	O
⁻	O
⁵	O
M	O
)	O
appeared	O
to	O
have	O
toxic	O
effects	O
.	O

This	O
is	O
the	O
first	O
study	O
to	O
demonstrate	O
dose	O
-	O
dependent	O
effects	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
(	I-CHEMICAL
OH	I-CHEMICAL
)	I-CHEMICAL
₂D₃	I-CHEMICAL
on	O
the	O
transdifferentiation	O
of	O
muscle	O
cells	O
into	O
adipose	O
cells	O
.	O

Low	O
physiological	O
concentrations	O
(	O
possibly	O
mimicking	O
a	O
deficient	O
state	O
)	O
induced	O
adipogenesis	O
,	O
whereas	O
higher	O
(	O
physiological	O
and	O
supraphysiological	O
)	O
concentrations	O
attenuated	O
this	O
effect	O
.	O

PXR	B-GENE-Y
antagonists	O
and	O
implication	O
in	O
drug	O
metabolism	O
.	O

Adopted	O
orphan	B-GENE-N
nuclear	I-GENE-N
receptor	I-GENE-N
(	O
NR	B-GENE-N
)	O
,	O
pregnane	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
(	O
PXR	B-GENE-Y
)	O
,	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
xeno	O
-	O
and	O
endobiotic	O
metabolism	O
.	O

Since	O
the	O
discovery	O
of	O
the	O
functional	O
role	O
of	O
PXR	B-GENE-Y
in	O
1998	O
,	O
there	O
is	O
evolving	O
evidence	O
for	O
the	O
role	O
of	O
PXR	B-GENE-Y
agonists	O
in	O
abrogating	O
metabolic	O
pathophysiology	O
(	O
e	O
.	O
g	O
.	O
,	O
cholestasis	O
,	O
hypercholesterolemia	O
,	O
and	O
inflammation	O
)	O
.	O

However	O
,	O
more	O
recently	O
,	O
it	O
is	O
clear	O
that	O
PXR	B-GENE-Y
is	O
also	O
an	O
important	O
mediator	O
of	O
adverse	O
xeno	O
-	O
(	O
e	O
.	O
g	O
.	O
,	O
enhances	O
acetaminophen	B-CHEMICAL
toxicity	O
)	O
and	O
endobiotic	O
(	O
e	O
.	O
g	O
.	O
,	O
hepatic	O
steatosis	O
)	O
metabolic	O
phenotypes	O
.	O

Moreover	O
,	O
in	O
cancer	O
therapeutics	O
,	O
PXR	B-GENE-Y
activation	O
can	O
induce	O
drug	O
resistance	O
,	O
and	O
there	O
is	O
growing	O
evidence	O
for	O
tissue	O
-	O
specific	O
enhancement	O
of	O
the	O
malignant	O
phenotype	O
.	O

Thus	O
,	O
in	O
these	O
instances	O
,	O
there	O
may	O
be	O
a	O
role	O
for	O
PXR	B-GENE-Y
antagonists	O
.	O

However	O
,	O
as	O
opposed	O
to	O
the	O
discovery	O
efforts	O
for	O
PXR	B-GENE-Y
agonists	O
,	O
there	O
are	O
only	O
a	O
few	O
antagonists	O
described	O
.	O

The	O
mode	O
of	O
action	O
of	O
these	O
antagonists	O
(	O
e	O
.	O
g	O
.	O
,	O
sulforaphane	B-CHEMICAL
)	O
remains	O
less	O
clear	O
.	O

Our	O
laboratory	O
efforts	O
have	O
focused	O
on	O
this	O
question	O
.	O

Since	O
the	O
original	O
discovery	O
of	O
azoles	B-CHEMICAL
analogs	O
as	O
PXR	B-GENE-Y
antagonists	O
,	O
we	O
have	O
preliminarily	O
defined	O
an	O
important	O
PXR	B-GENE-Y
antagonist	O
pharmacophore	O
and	O
developed	O
less	O
-	O
toxic	O
PXR	B-GENE-Y
antagonists	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
our	O
published	O
and	O
unpublished	O
findings	O
on	O
recent	O
structure	O
-	O
function	O
studies	O
involving	O
the	O
azole	B-CHEMICAL
chemical	O
scaffold	O
.	O

Further	O
work	O
in	O
the	O
future	O
is	O
needed	O
to	O
fully	O
define	O
potent	O
,	O
more	O
-	O
selective	O
PXR	B-GENE-Y
antagonists	O
that	O
may	O
be	O
useful	O
in	O
clinical	O
application	O
.	O

Hydroxy	B-CHEMICAL
-	O
terminated	O
conjugated	O
polymer	O
nanoparticles	O
have	O
near	O
-	O
unity	O
bright	O
fraction	O
and	O
reveal	O
cholesterol	B-CHEMICAL
-	O
dependence	O
of	O
IGF1R	B-GENE-N
nanodomains	I-GENE-N
.	O

Fluorescent	O
nanoparticles	O
have	O
enabled	O
many	O
discoveries	O
regarding	O
how	O
molecular	O
machines	O
function	O
.	O

Quantum	O
dots	O
have	O
been	O
the	O
dominant	O
class	O
of	O
fluorescent	O
nanoparticles	O
but	O
suffer	O
from	O
blinking	O
and	O
from	O
a	O
substantial	O
dark	O
fraction	O
-	O
-	O
particles	O
where	O
the	O
fluorescence	O
is	O
never	O
seen	O
-	O
-	O
complicating	O
any	O
analysis	O
of	O
biological	O
function	O
.	O

Nanoparticles	O
composed	O
of	O
conjugated	O
fluorescent	O
polymers	O
(	O
Pdots	O
)	O
have	O
recently	O
been	O
shown	O
to	O
have	O
high	O
brightness	O
and	O
no	O
blinking	O
.	O

Here	O
we	O
develop	O
a	O
robust	O
and	O
efficient	O
means	O
to	O
measure	O
the	O
dark	O
fraction	O
of	O
Pdots	O
,	O
conjugating	O
Atto	O
dyes	O
to	O
the	O
nanoparticles	O
and	O
testing	O
fluorescence	O
colocalization	O
of	O
dye	O
and	O
Pdot	O
puncta	O
.	O

This	O
established	O
that	O
the	O
Pdots	O
we	O
generated	O
had	O
minimal	O
dark	O
fraction	O
:	O
∼	O
3	O
%	O
.	O

The	O
application	O
of	O
nanoparticles	O
in	O
biological	O
environments	O
is	O
highly	O
sensitive	O
to	O
surface	O
functionalization	O
.	O

For	O
Pdots	O
we	O
found	O
that	O
passivation	O
with	O
uncharged	O
hydroxy	B-CHEMICAL
-	O
terminated	O
polyethylene	B-CHEMICAL
glycol	I-CHEMICAL
caused	O
a	O
dramatic	O
reduction	O
in	O
nonspecific	O
cell	O
binding	O
and	O
aggregation	O
compared	O
to	O
a	O
charged	O
coating	O
.	O

Using	O
carbonyl	B-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
imidazole	I-CHEMICAL
the	O
hydroxy	B-CHEMICAL
-	O
Pdots	O
were	O
functionalized	O
efficiently	O
with	O
streptavidin	O
for	O
high	O
stability	O
targeting	O
,	O
allowing	O
specific	O
labeling	O
of	O
mammalian	O
cells	O
.	O

Type	B-GENE-Y
I	I-GENE-Y
insulin	I-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
IGF1R	B-GENE-Y
)	O
regulates	O
cell	O
survival	O
and	O
development	O
,	O
with	O
roles	O
in	O
aging	O
,	O
heart	O
disease	O
,	O
and	O
cancer	O
.	O

We	O
used	O
hydroxy	B-CHEMICAL
-	O
Pdots	O
to	O
track	O
the	O
dynamics	O
of	O
IGF1R	B-GENE-Y
on	O
a	O
breast	O
cancer	O
cell	O
-	O
line	O
,	O
determining	O
the	O
diffusion	O
characteristics	O
and	O
showing	O
cholesterol	B-CHEMICAL
-	O
containing	O
membrane	O
nanodomains	O
were	O
important	O
for	O
receptor	O
mobility	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
near	O
-	O
unity	O
bright	O
fraction	O
and	O
low	O
nonspecific	O
binding	O
of	O
hydroxy	B-CHEMICAL
-	O
Pdots	O
,	O
combined	O
with	O
Pdot	O
photostability	O
and	O
lack	O
of	O
blinking	O
,	O
provides	O
many	O
advantages	O
for	O
investigations	O
at	O
the	O
single	O
molecule	O
level	O
.	O

Testosterone	B-CHEMICAL
deficiency	O
induces	O
markedly	O
decreased	O
serum	O
triglycerides	B-CHEMICAL
,	O
increased	O
small	O
dense	O
LDL	B-GENE-N
,	O
and	O
hepatic	O
steatosis	O
mediated	O
by	O
dysregulation	O
of	O
lipid	O
assembly	O
and	O
secretion	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
.	O

OBJECTIVE	O
:	O
Although	O
low	O
serum	O
testosterone	B-CHEMICAL
(	O
T	O
)	O
is	O
associated	O
with	O
metabolic	O
disorders	O
,	O
the	O
mechanism	O
of	O
this	O
association	O
is	O
unclear	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
combined	O
effects	O
of	O
T	O
deficiency	O
and	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
on	O
hepatic	O
lipid	O
homeostasis	O
in	O
mice	O
.	O

MATERIALS	O
/	O
METHODS	O
:	O
Orchiectomized	O
(	O
ORX	O
)	O
mice	O
and	O
sham	O
-	O
operated	O
(	O
SHAM	O
)	O
mice	O
were	O
randomly	O
divided	O
into	O
five	O
groups	O
:	O
SHAM	O
mice	O
fed	O
a	O
standard	O
diet	O
(	O
SD	O
)	O
,	O
SHAM	O
mice	O
fed	O
HFD	O
,	O
ORX	O
mice	O
fed	O
SD	O
,	O
ORX	O
mice	O
fed	O
HFD	O
,	O
and	O
ORX	O
mice	O
fed	O
HFD	O
with	O
T	O
supplementation	O
.	O

After	O
4weeks	O
of	O
treatment	O
,	O
we	O
investigated	O
the	O
synthesis	O
and	O
secretion	O
of	O
lipids	O
in	O
the	O
liver	O
and	O
detailed	O
serum	O
lipoprotein	O
profiles	O
in	O
each	O
group	O
.	O

RESULTS	O
:	O
ORX	O
mice	O
fed	O
HFD	O
showed	O
increased	O
hepatic	O
steatosis	O
,	O
markedly	O
decreased	O
serum	O
triglyceride	B-CHEMICAL
(	O
TG	O
)	O
and	O
TG	O
-	O
VLDL	B-GENE-N
content	O
,	O
and	O
increased	O
serum	O
very	O
small	O
-	O
LDL	B-GENE-N
content	O
.	O

Gene	O
expression	O
analysis	O
revealed	O
that	O
ORX	O
mice	O
fed	O
HFD	O
showed	O
significantly	O
decreased	O
expression	O
of	O
microsomal	B-GENE-Y
triglyceride	I-GENE-Y
transfer	I-GENE-Y
protein	I-GENE-Y
,	O
lipin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
(	I-GENE-Y
PPAR	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
and	O
PPAR	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
coactivator	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
and	O
significantly	O
increased	O
sterol	B-GENE-Y
regulatory	I-GENE-Y
element	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
diacylglycerol	B-GENE-Y
acyltransferase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
fatty	B-GENE-Y
acid	I-GENE-Y
synthase	I-GENE-Y
.	O

Reduction	O
of	O
hepatic	O
AMPK	B-GENE-N
phosphorylation	O
was	O
observed	O
in	O
ORX	O
mice	O
fed	O
HFD	O
.	O

These	O
perturbations	O
in	O
ORX	O
mice	O
fed	O
HFD	O
were	O
normalized	O
to	O
the	O
levels	O
of	O
SHAM	O
mice	O
fed	O
HFD	O
by	O
T	O
supplementation	O
.	O

CONCLUSION	O
:	O
T	O
deficiency	O
is	O
associated	O
with	O
failure	O
of	O
lipid	O
homeostasis	O
mediated	O
by	O
altered	O
expression	O
of	O
genes	O
involved	O
in	O
hepatic	O
assembly	O
and	O
secretion	O
of	O
lipids	O
.	O

Contribution	O
of	O
single	B-GENE-Y
-	I-GENE-Y
minded	I-GENE-Y
2	I-GENE-Y
to	O
hyperglycaemia	O
-	O
induced	O
neurotoxicity	O
.	O

Diabetes	O
mellitus	O
is	O
associated	O
to	O
central	O
nervous	O
system	O
damage	O
,	O
which	O
results	O
in	O
impairment	O
of	O
brain	O
functions	O
and	O
cognitive	O
deficits	O
and	O
decline	O
in	O
memory	O
.	O

However	O
,	O
the	O
mechanisms	O
mediating	O
the	O
actions	O
of	O
glucose	B-CHEMICAL
on	O
the	O
neurons	O
remained	O
elusive	O
.	O

Single	B-GENE-Y
-	I-GENE-Y
minded	I-GENE-Y
2	I-GENE-Y
(	O
Sim2	B-GENE-Y
)	O
,	O
a	O
basic	B-GENE-N
helix	I-GENE-N
-	I-GENE-N
loop	I-GENE-N
-	I-GENE-N
helix	I-GENE-N
(	O
bHLH	B-GENE-N
)	O
-	O
PAS	B-GENE-N
transcriptional	O
repressor	O
,	O
is	O
thought	O
to	O
be	O
involved	O
in	O
some	O
symptoms	O
of	O
Down	O
syndrome	O
.	O

We	O
hypothesized	O
that	O
Sim2	B-GENE-Y
mediated	O
hyperglycaemia	O
-	O
induced	O
neuronal	O
injury	O
and	O
impairment	O
of	O
learning	O
and	O
memory	O
.	O

It	O
was	O
found	O
that	O
expression	O
of	O
Sim2	B-GENE-Y
protein	O
in	O
cortical	O
neurons	O
was	O
increased	O
in	O
streptozotocin	B-CHEMICAL
-	O
induced	O
diabetes	O
mellitus	O
rat	O
model	O
.	O

Drebrin	B-GENE-Y
,	O
down	O
-	O
regulated	O
by	O
Sim2	B-GENE-Y
,	O
was	O
subsequently	O
decreased	O
as	O
detected	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
and	O
Western	O
blot	O
analysis	O
.	O

The	O
expression	O
pattern	O
of	O
Sim2	B-GENE-Y
and	O
Drebrin	B-GENE-Y
correspond	O
to	O
50mmol	O
/	O
L	O
glucose	B-CHEMICAL
(	O
hyperglycaemia	O
)	O
was	O
also	O
found	O
in	O
primary	O
cultured	O
neurons	O
.	O

Curcumin	B-CHEMICAL
,	O
one	O
neuroprotective	O
agent	O
,	O
inhibited	O
hyperglycaemia	O
-	O
induced	O
neurotoxicity	O
.	O

Moreover	O
,	O
curcumin	B-CHEMICAL
alleviated	O
Sim2	B-GENE-Y
expression	O
,	O
and	O
reversely	O
raised	O
Drebrin	B-GENE-Y
expression	O
in	O
neurons	O
treated	O
with	O
hyperglycaemia	O
.	O

Finally	O
,	O
we	O
found	O
that	O
silencing	O
Sim2	B-GENE-Y
expression	O
decreased	O
hyperglycaemia	O
-	O
induced	O
neuronal	O
injury	O
.	O

In	O
conclusion	O
,	O
Sim2	B-GENE-Y
may	O
mediate	O
neurotoxicity	O
during	O
hyperglycaemia	O
and	O
thereby	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
hyperglycaemia	O
-	O
induced	O
cognitive	O
deficits	O
.	O

Suppression	O
of	O
Src	B-GENE-Y
/	O
ERK	B-GENE-N
and	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
/	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
signaling	O
by	O
pinosylvin	B-CHEMICAL
inhibits	O
the	O
growth	O
of	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Pinosylvin	B-CHEMICAL
,	O
a	O
naturally	O
occurring	O
trans	B-CHEMICAL
-	I-CHEMICAL
stilbenoid	I-CHEMICAL
mainly	O
found	O
in	O
Pinus	O
species	O
,	O
has	O
exhibited	O
a	O
potential	O
cancer	O
chemopreventive	O
activity	O
.	O

However	O
,	O
the	O
growth	O
inhibitory	O
activity	O
against	O
cancer	O
cells	O
and	O
the	O
underlying	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
elucidated	O
.	O

Therefore	O
,	O
the	O
anti	O
-	O
proliferative	O
activity	O
of	O
pinosylvin	B-CHEMICAL
was	O
investigated	O
in	O
human	O
colorectal	O
HCT	O
116	O
cancer	O
cells	O
.	O

Pinosylvin	B-CHEMICAL
inhibited	O
the	O
proliferation	O
of	O
HCT	O
116	O
cells	O
by	O
arresting	O
transition	O
of	O
cell	O
cycle	O
from	O
G1	O
to	O
S	O
phase	O
along	O
with	O
the	O
downregulation	O
of	O
cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
cyclin	B-GENE-Y
E	I-GENE-Y
,	O
cyclin	B-GENE-Y
A	I-GENE-Y
,	O
cyclin	B-GENE-Y
dependent	I-GENE-Y
kinase	I-GENE-Y
2	I-GENE-Y
(	O
CDK2	B-GENE-Y
)	O
,	O
CDK4	B-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
,	O
and	O
retinoblastoma	B-GENE-Y
protein	I-GENE-Y
(	O
pRb	B-GENE-Y
)	O
,	O
and	O
the	O
upregulation	O
of	O
p21	B-GENE-Y
(	O
WAF1	B-GENE-Y
/	O
CIP1	B-GENE-Y
)	O
and	O
p53	B-GENE-Y
.	O

Pinosylvin	B-CHEMICAL
was	O
also	O
found	O
to	O
attenuate	O
the	O
activation	O
of	O
proteins	O
involved	O
in	O
focal	B-GENE-Y
adhesion	I-GENE-Y
kinase	I-GENE-Y
(	O
FAK	B-GENE-Y
)	O
/	O
c	B-GENE-Y
-	I-GENE-Y
Src	I-GENE-Y
/	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
signaling	O
,	O
and	O
phosphoinositide	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
(	O
PI3K	B-GENE-N
)	O
/	O
Akt	B-GENE-N
/	O
glycogen	B-GENE-Y
synthase	I-GENE-Y
kinase	I-GENE-Y
3β	I-GENE-Y
(	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
)	O
signaling	O
pathway	O
.	O

Subsequently	O
,	O
pinosylvin	B-CHEMICAL
suppressed	O
the	O
nuclear	O
translocation	O
of	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
,	O
one	O
of	O
downstream	O
molecules	O
of	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
/	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
signaling	O
,	O
and	O
these	O
events	O
led	O
to	O
the	O
sequential	O
downregulation	O
of	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
-	O
mediated	O
transcription	O
of	O
target	O
genes	O
including	O
BMP4	B-GENE-Y
,	O
ID2	B-GENE-Y
,	O
survivin	B-GENE-Y
,	O
cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
MMP7	B-GENE-Y
,	O
and	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
anti	O
-	O
proliferative	O
activity	O
of	O
pinosylvin	B-CHEMICAL
might	O
be	O
associated	O
with	O
the	O
cell	O
cycle	O
arrest	O
and	O
downregulation	O
of	O
cell	O
proliferation	O
regulating	O
signaling	O
pathways	O
in	O
human	O
colorectal	O
cancer	O
cells	O
.	O

Administration	O
of	O
the	O
optimized	O
β	B-CHEMICAL
-	I-CHEMICAL
Lapachone	I-CHEMICAL
-	O
poloxamer	B-CHEMICAL
-	O
cyclodextrin	O
ternary	O
system	O
induces	O
apoptosis	O
,	O
DNA	O
damage	O
and	O
reduces	O
tumor	O
growth	O
in	O
a	O
human	O
breast	O
adenocarcinoma	O
xenograft	O
mouse	O
model	O
.	O

β	B-CHEMICAL
-	I-CHEMICAL
Lapachone	I-CHEMICAL
(	O
β	B-CHEMICAL
-	I-CHEMICAL
Lap	I-CHEMICAL
)	O
is	O
a	O
1	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
orthonaphthoquinone	I-CHEMICAL
that	O
selectively	O
induces	O
cell	O
death	O
in	O
human	O
cancer	O
cells	O
through	O
NAD	B-GENE-Y
(	I-GENE-Y
P	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
:	I-GENE-Y
quinone	I-GENE-Y
oxidoreductase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
NQO1	B-GENE-Y
)	O
.	O

NQO1	B-GENE-Y
is	O
overexpressed	O
in	O
a	O
variety	O
of	O
tumors	O
,	O
as	O
compared	O
to	O
normal	O
adjacent	O
tissue	O
.	O

However	O
,	O
the	O
low	O
solubility	O
and	O
non	O
-	O
specific	O
distribution	O
of	O
β	B-CHEMICAL
-	I-CHEMICAL
Lap	I-CHEMICAL
limit	O
its	O
suitability	O
for	O
clinical	O
assays	O
.	O

We	O
formulated	O
β	B-CHEMICAL
-	I-CHEMICAL
Lap	I-CHEMICAL
in	O
an	O
optimal	O
random	O
methylated	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
cyclodextrin	I-CHEMICAL
/	O
poloxamer	B-CHEMICAL
407	I-CHEMICAL
mixture	O
(	O
i	O
.	O
e	O
.	O
,	O
β	B-CHEMICAL
-	I-CHEMICAL
Lap	I-CHEMICAL
ternary	O
system	O
)	O
and	O
,	O
using	O
human	O
breast	O
adenocarcinoma	O
MCF	O
-	O
7	O
cells	O
and	O
immunodeficient	O
mice	O
,	O
performed	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
its	O
anti	O
-	O
tumor	O
effects	O
on	O
proliferation	O
,	O
cell	O
cycle	O
,	O
apoptosis	O
,	O
DNA	O
damage	O
,	O
and	O
tumor	O
growth	O
.	O

This	O
ternary	O
system	O
is	O
fluid	O
at	O
room	O
temperature	O
,	O
gels	O
over	O
29	O
°	O
C	O
,	O
and	O
provides	O
a	O
significant	O
amount	O
of	O
drug	O
,	O
thus	O
facilitating	O
intratumoral	O
delivery	O
,	O
in	O
situ	O
gelation	O
,	O
and	O
the	O
formation	O
of	O
a	O
depot	O
for	O
time	O
-	O
release	O
.	O

Administration	O
of	O
β	B-CHEMICAL
-	I-CHEMICAL
Lap	I-CHEMICAL
ternary	O
system	O
to	O
MCF	O
-	O
7	O
cells	O
induces	O
an	O
increase	O
in	O
apoptosis	O
and	O
DNA	O
damage	O
,	O
while	O
producing	O
no	O
changes	O
in	O
cell	O
cycle	O
.	O

Moreover	O
,	O
in	O
a	O
mouse	O
xenograft	O
tumor	O
model	O
,	O
intratumoral	O
injection	O
of	O
the	O
system	O
significantly	O
reduces	O
tumor	O
volume	O
,	O
while	O
increasing	O
apoptosis	O
and	O
DNA	O
damage	O
without	O
visible	O
toxicity	O
to	O
liver	O
or	O
kidney	O
.	O

These	O
anti	O
-	O
tumoral	O
effects	O
and	O
lack	O
of	O
visible	O
toxicity	O
make	O
this	O
system	O
a	O
promising	O
new	O
therapeutic	O
agent	O
for	O
breast	O
cancer	O
treatment	O
.	O

Antidepressant	O
use	O
and	O
glycemic	O
control	O
.	O

RATIONALE	O
:	O
Past	O
research	O
on	O
the	O
association	O
of	O
antidepressant	O
medication	O
use	O
with	O
glycemic	O
control	O
abnormalities	O
has	O
produced	O
mixed	O
results	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
association	O
of	O
antidepressant	O
use	O
with	O
glycemic	O
control	O
abnormalities	O
and	O
screen	O
-	O
positive	O
diabetes	O
in	O
a	O
representative	O
population	O
sample	O
of	O
US	O
adults	O
without	O
a	O
diagnosis	O
of	O
diabetes	O
.	O

METHODS	O
:	O
Using	O
data	O
from	O
adult	O
participants	O
of	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Survey	O
(	O
NHANES	O
,	O
2005	O
-	O
2010	O
)	O
,	O
the	O
association	O
of	O
antidepressant	O
use	O
with	O
continuous	O
measures	O
of	O
HbA1c	B-GENE-Y
,	O
fasting	O
blood	O
sugar	B-CHEMICAL
,	O
2	O
-	O
h	O
oral	O
glucose	B-CHEMICAL
tolerance	O
test	O
,	O
insulin	B-GENE-Y
sensitivity	O
and	O
screen	O
-	O
positive	O
diabetes	O
according	O
to	O
HbA1c	B-GENE-Y
,	O
fasting	O
blood	O
sugar	O
and	O
2	O
-	O
h	O
oral	O
glucose	B-CHEMICAL
tolerance	O
test	O
were	O
assessed	O
.	O

RESULTS	O
:	O
Antidepressant	O
use	O
was	O
not	O
associated	O
with	O
increased	O
levels	O
of	O
HbA1c	B-GENE-Y
,	O
fasting	O
blood	O
sugar	B-CHEMICAL
,	O
2	O
-	O
h	O
oral	O
glucose	B-CHEMICAL
tolerance	O
test	O
,	O
reduced	O
insulin	B-GENE-Y
sensitivity	O
or	O
increased	O
prevalence	O
of	O
screen	O
-	O
positive	O
diabetes	O
.	O

Results	O
were	O
mostly	O
consistent	O
across	O
sociodemographic	O
groups	O
and	O
across	O
different	O
lengths	O
of	O
exposure	O
,	O
different	O
classes	O
of	O
antidepressants	O
and	O
levels	O
of	O
body	O
mass	O
index	O
.	O

CONCLUSIONS	O
:	O
In	O
this	O
representative	O
population	O
sample	O
,	O
antidepressant	O
use	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
abnormalities	O
in	O
glycemic	O
control	O
or	O
undetected	O
diabetes	O
.	O

Positive	O
findings	O
from	O
past	O
research	O
may	O
be	O
attributable	O
to	O
detection	O
bias	O
,	O
in	O
that	O
individuals	O
prescribed	O
antidepressants	O
may	O
be	O
more	O
likely	O
to	O
be	O
tested	O
and	O
diagnosed	O
with	O
diabetes	O
.	O

Iron	B-CHEMICAL
overload	O
inhibits	O
osteoblast	O
biological	O
activity	O
through	O
oxidative	O
stress	O
.	O

Iron	B-CHEMICAL
overload	O
has	O
recently	O
been	O
connected	O
with	O
bone	O
mineral	O
density	O
in	O
osteoporosis	O
.	O

However	O
,	O
to	O
date	O
,	O
the	O
effect	O
of	O
iron	B-CHEMICAL
overload	O
on	O
osteoblasts	O
remains	O
poorly	O
understood	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
examine	O
osteoblast	O
biological	O
activity	O
under	O
iron	B-CHEMICAL
overload	O
.	O

The	O
osteoblast	O
cells	O
(	O
hFOB1	O
.	O
19	O
)	O
were	O
cultured	O
in	O
a	O
medium	O
supplemented	O
with	O
different	O
concentrations	O
(	O
50	O
,	O
100	O
,	O
and	O
200	O
μM	O
)	O
of	O
ferric	B-CHEMICAL
ammonium	I-CHEMICAL
citrate	I-CHEMICAL
as	O
a	O
donor	O
of	O
ferric	B-CHEMICAL
ion	O
.	O

Intracellular	O
iron	B-CHEMICAL
was	O
measured	O
with	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

Reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
were	O
detected	O
by	O
2	B-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
dichlorofluorescin	I-CHEMICAL
diacetate	I-CHEMICAL
fluorophotometry	O
.	O

Osteoblast	O
biological	O
activities	O
were	O
evaluated	O
by	O
measuring	O
the	O
activity	O
of	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
(	O
ALP	B-GENE-N
)	O
and	O
mineralization	O
function	O
.	O

Results	O
indicated	O
that	O
iron	B-CHEMICAL
overload	O
could	O
consequently	O
increase	O
intracellular	O
iron	B-CHEMICAL
concentration	O
and	O
intracellular	O
ROS	O
levels	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Additionally	O
,	O
ALP	B-GENE-N
activity	O
was	O
suppressed	O
,	O
and	O
a	O
decline	O
in	O
the	O
number	O
of	O
mineralized	O
nodules	O
was	O
observed	O
in	O
in	O
vitro	O
cultured	O
osteoblast	O
cells	O
.	O

According	O
to	O
these	O
results	O
,	O
it	O
seems	O
that	O
iron	B-CHEMICAL
overload	O
probably	O
inhibits	O
osteoblast	O
function	O
through	O
higher	O
oxidative	O
stress	O
following	O
increased	O
intracellular	O
iron	B-CHEMICAL
concentrations	O
.	O

Chemopreventive	O
effects	O
of	O
Ginkgo	O
biloba	O
extract	O
in	O
estrogen	B-CHEMICAL
-	O
negative	O
human	O
breast	O
cancer	O
cells	O
.	O

Excessive	O
level	O
of	O
estrogen	B-CHEMICAL
is	O
considered	O
as	O
a	O
main	O
cause	O
of	O
breast	O
cancer	O
,	O
therefore	O
,	O
many	O
studies	O
have	O
focused	O
on	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
-	O
positive	O
breast	O
cancer	O
,	O
even	O
though	O
ER	B-GENE-Y
-	O
negative	O
cancer	O
has	O
a	O
poor	O
prognosis	O
than	O
ER	B-GENE-Y
-	O
positive	O
breast	O
cancer	O
.	O

We	O
evaluated	O
the	O
anti	O
-	O
cancer	O
effects	O
of	O
Ginkgo	O
biloba	O
extract	O
(	O
GBE	O
)	O
in	O
estrogen	B-CHEMICAL
-	O
independent	O
breast	O
cancer	O
.	O

GBE	O
has	O
been	O
traditionally	O
used	O
as	O
a	O
platelet	O
activating	O
factor	O
,	O
a	O
circulatory	O
stimulant	O
,	O
a	O
tonic	O
,	O
and	O
anti	O
-	O
asthmatic	O
drug	O
,	O
and	O
anti	O
-	O
cancer	O
agent	O
.	O

However	O
,	O
anti	O
-	O
cancer	O
effects	O
of	O
GBE	O
on	O
ER	B-GENE-Y
-	O
negative	O
breast	O
cancer	O
have	O
not	O
been	O
proved	O
yet	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
chemotherapeutic	O
potential	O
of	O
GBE	O
in	O
the	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
ER	B-GENE-Y
-	O
negative	O
)	O
human	O
breast	O
cancer	O
cell	O
line	O
.	O

Our	O
results	O
showed	O
that	O
cytotoxicity	O
effects	O
of	O
GBE	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
lead	O
to	O
DNA	O
fragmentation	O
at	O
high	O
concentrations	O
(	O
500	O
and	O
1	O
,	O
000	O
μg	O
/	O
ml	O
)	O
.	O

Caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
was	O
significantly	O
activated	O
and	O
mRNA	O
levels	O
of	O
apoptosis	O
-	O
related	O
genes	O
(	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
Bax	B-GENE-Y
)	O
were	O
altered	O
.	O

These	O
results	O
indicate	O
that	O
GBE	O
induces	O
apoptosis	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
.	O

It	O
is	O
presumed	O
that	O
GBE	O
has	O
chemopreventive	O
effects	O
in	O
ER	B-GENE-Y
-	O
independent	O
breast	O
cancer	O
through	O
anti	O
-	O
proliferation	O
and	O
apoptosis	O
-	O
inducing	O
activities	O
.	O

Sex	O
differences	O
in	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
ketamine	B-CHEMICAL
.	O

Current	O
medications	O
for	O
major	O
depression	O
suffer	O
from	O
numerous	O
limitations	O
.	O

Once	O
the	O
right	O
drug	O
for	O
treatment	O
has	O
been	O
determined	O
,	O
it	O
still	O
takes	O
several	O
weeks	O
for	O
it	O
to	O
take	O
effect	O
and	O
improve	O
mood	O
.	O

This	O
time	O
lag	O
is	O
a	O
serious	O
concern	O
for	O
the	O
healthcare	O
community	O
when	O
dealing	O
with	O
patients	O
with	O
suicidal	O
thoughts	O
.	O

However	O
,	O
recent	O
clinical	O
studies	O
have	O
shown	O
that	O
a	O
single	O
low	O
-	O
dose	O
injection	O
of	O
ketamine	B-CHEMICAL
,	O
an	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
d	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptor	I-GENE-N
(	O
NMDAR	B-GENE-N
)	O
antagonist	O
,	O
has	O
rapid	O
antidepressant	O
effects	O
that	O
are	O
observed	O
within	O
hours	O
and	O
are	O
long	O
lasting	O
.	O

Although	O
major	O
depression	O
affects	O
twice	O
as	O
many	O
women	O
as	O
men	O
,	O
all	O
studies	O
examining	O
the	O
rapid	O
antidepressant	O
effects	O
of	O
ketamine	B-CHEMICAL
have	O
focused	O
on	O
male	O
subjects	O
.	O

Thus	O
,	O
we	O
have	O
investigated	O
the	O
behavioral	O
and	O
molecular	O
effects	O
of	O
ketamine	B-CHEMICAL
in	O
both	O
male	O
and	O
female	O
rats	O
and	O
demonstrated	O
greater	O
sensitivity	O
in	O
female	O
rats	O
at	O
a	O
low	O
dose	O
of	O
ketamine	B-CHEMICAL
,	O
a	O
dose	O
does	O
not	O
have	O
antidepressant	O
-	O
like	O
effects	O
in	O
male	O
rats	O
.	O

The	O
antidepressant	O
-	O
like	O
effects	O
of	O
this	O
low	O
dose	O
of	O
ketamine	B-CHEMICAL
were	O
completely	O
abolished	O
when	O
female	O
rats	O
were	O
ovariectomized	O
(	O
OVX	O
)	O
,	O
and	O
restored	O
when	O
physiological	O
levels	O
of	O
estrogen	B-CHEMICAL
and	O
progesterone	B-CHEMICAL
were	O
supplemented	O
,	O
suggesting	O
a	O
critical	O
role	O
for	O
gonadal	O
hormones	O
in	O
enhancing	O
the	O
antidepressant	O
-	O
like	O
effects	O
of	O
ketamine	B-CHEMICAL
in	O
female	O
rats	O
.	O

In	O
preclinical	O
studies	O
,	O
the	O
mammalian	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
(	O
mTOR	B-GENE-Y
)	O
in	O
the	O
medial	O
prefrontal	O
cortex	O
and	O
the	O
eukaryotic	B-GENE-N
elongation	I-GENE-N
factor	I-GENE-N
(	O
eEF2	B-GENE-Y
)	O
in	O
the	O
hippocampus	O
have	O
been	O
proposed	O
as	O
critical	O
mediators	O
of	O
ketamine	B-CHEMICAL
'	O
s	O
rapid	O
antidepressant	O
actions	O
.	O

In	O
our	O
hands	O
,	O
the	O
increased	O
sensitivity	O
of	O
female	O
rats	O
to	O
a	O
low	O
dose	O
of	O
ketamine	B-CHEMICAL
was	O
not	O
mediated	O
through	O
phosphorylation	O
of	O
mTOR	B-GENE-Y
or	O
eEF2	B-GENE-Y
.	O

Prenatal	O
exposure	O
to	O
bisphenol	B-CHEMICAL
A	I-CHEMICAL
impacts	O
midbrain	O
dopamine	B-CHEMICAL
neurons	O
and	O
hippocampal	O
spine	O
synapses	O
in	O
non	O
-	O
human	O
primates	O
.	O

Prevalent	O
use	O
of	O
bisphenol	B-CHEMICAL
-	I-CHEMICAL
A	I-CHEMICAL
(	O
BPA	B-CHEMICAL
)	O
in	O
the	O
manufacture	O
of	O
resins	O
,	O
plastics	O
and	O
paper	O
products	O
has	O
led	O
to	O
frequent	O
exposure	O
of	O
most	O
people	O
to	O
this	O
endocrine	O
disruptor	O
.	O

Some	O
rodent	O
studies	O
have	O
suggested	O
that	O
BPA	B-CHEMICAL
can	O
exert	O
detrimental	O
effects	O
on	O
brain	O
development	O
.	O

However	O
as	O
rodent	O
models	O
cannot	O
be	O
relied	O
on	O
to	O
predict	O
consequences	O
of	O
human	O
exposure	O
to	O
BPA	B-CHEMICAL
during	O
development	O
,	O
it	O
is	O
important	O
to	O
investigate	O
the	O
effects	O
of	O
BPA	B-CHEMICAL
on	O
non	O
-	O
human	O
primate	O
brain	O
development	O
.	O

Previous	O
research	O
suggests	O
that	O
BPA	B-CHEMICAL
preferentially	O
targets	O
dopamine	B-CHEMICAL
neurons	O
in	O
ventral	O
mesencephalon	O
and	O
glutamatergic	O
neurons	O
in	O
hippocampus	O
,	O
so	O
the	O
present	O
work	O
examined	O
the	O
susceptibility	O
of	O
these	O
systems	O
to	O
low	O
dose	O
BPA	B-CHEMICAL
exposure	O
at	O
the	O
fetal	O
and	O
juvenile	O
stages	O
of	O
development	O
in	O
non	O
-	O
human	O
primates	O
.	O

Exposure	O
of	O
pregnant	O
rhesus	O
monkeys	O
to	O
relatively	O
low	O
levels	O
of	O
BPA	B-CHEMICAL
during	O
the	O
final	O
2	O
months	O
of	O
gestation	O
,	O
induced	O
abnormalities	O
in	O
fetal	O
ventral	O
mesencephalon	O
and	O
hippocampus	O
.	O

Specifically	O
,	O
light	O
microscopy	O
revealed	O
a	O
decrease	O
in	O
tyrosine	B-GENE-N
hydroxylase	I-GENE-N
-	O
expressing	O
(	O
dopamine	B-CHEMICAL
)	O
neurons	O
in	O
the	O
midbrain	O
of	O
BPA	B-CHEMICAL
-	O
exposed	O
fetuses	O
and	O
electron	O
microscopy	O
identified	O
a	O
reduction	O
in	O
spine	O
synapses	O
in	O
the	O
CA1	O
region	O
of	O
hippocampus	O
.	O

In	O
contrast	O
,	O
administration	O
of	O
BPA	B-CHEMICAL
to	O
juvenile	O
vervet	O
monkeys	O
(	O
14	O
-	O
18	O
months	O
of	O
age	O
)	O
was	O
without	O
effect	O
on	O
these	O
indices	O
,	O
or	O
on	O
dopamine	B-CHEMICAL
and	O
serotonin	B-CHEMICAL
concentrations	O
in	O
striatum	O
and	O
prefrontal	O
cortex	O
,	O
or	O
on	O
performance	O
of	O
a	O
cognitive	O
task	O
that	O
tests	O
working	O
memory	O
capacity	O
.	O

These	O
data	O
indicate	O
that	O
BPA	B-CHEMICAL
exerts	O
an	O
age	O
-	O
dependent	O
detrimental	O
impact	O
on	O
primate	O
brain	O
development	O
,	O
at	O
blood	O
levels	O
within	O
the	O
range	O
measured	O
in	O
humans	O
having	O
only	O
environmental	O
contact	O
with	O
BPA	B-CHEMICAL
.	O

Time	O
-	O
dependent	O
changes	O
in	O
hepatic	O
and	O
intestinal	O
induction	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
after	O
administration	O
of	O
dexamethasone	B-CHEMICAL
to	O
rats	O
.	O

Abstract	O
1	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
the	O
dose	O
of	O
and	O
the	O
number	O
of	O
times	O
an	O
inducer	O
was	O
administered	O
and	O
the	O
duration	O
of	O
induction	O
of	O
hepatic	O
and	O
intestinal	O
cytochrome	B-GENE-N
P450	I-GENE-N
3A	I-GENE-N
(	O
CYP3A	B-GENE-N
)	O
in	O
rats	O
using	O
dexamethasone	B-CHEMICAL
21	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
)	O
and	O
midazolam	B-CHEMICAL
(	O
MDZ	B-CHEMICAL
)	O
as	O
an	O
inducer	O
and	O
a	O
substrate	O
to	O
CYP3A	B-GENE-N
,	O
respectively	O
.	O

2	O
.	O

The	O
number	O
of	O
times	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
was	O
administered	O
was	O
not	O
a	O
significant	O
factor	O
in	O
the	O
induction	O
of	O
either	O
hepatic	O
or	O
intestinal	O
CYP3A	B-GENE-N
;	O
however	O
,	O
administration	O
of	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
multiple	O
times	O
markedly	O
decreased	O
the	O
bioavailability	O
of	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
by	O
self	O
-	O
induction	O
of	O
CYP3A	B-GENE-N
.	O

3	O
.	O

CYP3A	B-GENE-N
induction	O
in	O
the	O
liver	O
increased	O
depending	O
on	O
the	O
dose	O
of	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
,	O
whereas	O
that	O
in	O
intestine	O
showed	O
a	O
mild	O
increase	O
,	O
but	O
the	O
induction	O
level	O
was	O
almost	O
constant	O
regardless	O
of	O
the	O
dose	O
of	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
.	O

4	O
.	O

Administration	O
of	O
a	O
single	O
dose	O
of	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
showed	O
a	O
temporal	O
increase	O
in	O
CYP3A	B-GENE-N
activity	O
in	O
both	O
tissues	O
and	O
the	O
induction	O
ratios	O
reached	O
maximum	O
values	O
at	O
12	O
h	O
after	O
DEX	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
administration	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
mild	O
increase	O
of	O
CYP3A	B-GENE-N
activity	O
,	O
which	O
lasted	O
for	O
at	O
least	O
48	O
h	O
,	O
was	O
observed	O
in	O
both	O
tissues	O
after	O
administration	O
of	O
multiple	O
doses	O
.	O

5	O
.	O

Some	O
physiological	O
compounds	O
such	O
as	O
cytokines	B-GENE-N
might	O
be	O
involved	O
in	O
decreasing	O
the	O
CYP3A	B-GENE-N
activity	O
to	O
maintain	O
homeostasis	O
of	O
the	O
body	O
.	O

Impact	O
of	O
ketorolac	B-CHEMICAL
administration	O
around	O
ovarian	O
stimulation	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
fertilization	O
and	O
subsequent	O
embryo	O
development	O
.	O

Abstract	O
We	O
performed	O
this	O
study	O
to	O
investigate	O
the	O
effect	O
of	O
ketorolac	B-CHEMICAL
(	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
)	O
administration	O
around	O
ovarian	O
stimulation	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
fertilization	O
process	O
.	O

Sixty	O
-	O
four	O
female	O
mice	O
(	O
ICR	O
)	O
were	O
injected	O
with	O
ketorolac	B-CHEMICAL
(	O
0	O
,	O
7	O
.	O
5	O
,	O
15	O
and	O
30	O
µg	O
/	O
d	O
)	O
for	O
3	O
d	O
starting	O
from	O
the	O
day	O
of	O
eCG	B-GENE-N
treatment	O
.	O

In	O
experiment	O
1	O
,	O
41	O
mice	O
were	O
triggered	O
by	O
hCG	B-GENE-N
and	O
then	O
mated	O
;	O
two	O
-	O
cell	O
embryos	O
were	O
obtained	O
and	O
in	O
vitro	O
development	O
up	O
to	O
blastocyst	O
was	O
observed	O
.	O

In	O
experiment	O
2	O
,	O
23	O
mice	O
were	O
triggered	O
by	O
hCG	B-GENE-N
and	O
mature	O
oocytes	O
were	O
collected	O
;	O
in	O
vitro	O
fertilization	O
rate	O
and	O
subsequent	O
embryo	O
development	O
up	O
to	O
blastocyst	O
was	O
recorded	O
.	O

In	O
experiment	O
1	O
,	O
the	O
blastocyst	O
-	O
forming	O
rates	O
per	O
in	O
vivo	O
fertilized	O
two	O
-	O
cell	O
embryo	O
showed	O
an	O
inverse	O
relationship	O
with	O
a	O
dosage	O
of	O
ketorolac	B-CHEMICAL
(	O
97	O
.	O
6	O
%	O
,	O
64	O
.	O
2	O
%	O
,	O
35	O
.	O
4	O
%	O
and	O
25	O
.	O
9	O
%	O
)	O
.	O

In	O
experiment	O
2	O
,	O
degenerated	O
oocytes	O
were	O
frequently	O
observed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
4	O
.	O
3	O
%	O
,	O
22	O
.	O
9	O
%	O
,	O
22	O
.	O
4	O
%	O
and	O
75	O
.	O
0	O
%	O
)	O
.	O

Lower	O
fertilization	O
rates	O
were	O
noted	O
in	O
all	O
the	O
three	O
ketorolac	B-CHEMICAL
-	O
treating	O
groups	O
;	O
blastocyst	O
-	O
forming	O
rate	O
was	O
significantly	O
lower	O
in	O
30	O
-	O
µg	O
-	O
treating	O
group	O
when	O
compared	O
with	O
the	O
control	O
group	O
.	O

Administration	O
of	O
ketorolac	B-CHEMICAL
around	O
ovarian	O
stimulation	O
significantly	O
affects	O
the	O
development	O
of	O
in	O
vivo	O
fertilized	O
embryo	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

High	O
-	O
dose	O
ketorolac	B-CHEMICAL
could	O
result	O
in	O
a	O
poor	O
oocyte	O
quality	O
and	O
decreased	O
embryo	O
developmental	O
competence	O
.	O

Depletion	O
of	O
molecular	O
chaperones	O
from	O
the	O
endoplasmic	O
reticulum	O
and	O
fragmentation	O
of	O
the	O
Golgi	O
apparatus	O
associated	O
with	O
pathogenesis	O
in	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
.	O

Missense	O
mutations	O
in	O
the	O
proteolipid	B-GENE-Y
protein	I-GENE-Y
1	I-GENE-Y
(	O
PLP1	B-GENE-Y
)	O
gene	O
cause	O
a	O
wide	O
spectrum	O
of	O
hypomyelinating	O
disorders	O
,	O
from	O
mild	O
spastic	O
paraplegia	O
type	O
2	O
to	O
severe	O
Pelizaeus	O
-	O
Merzbacher	O
disease	O
(	O
PMD	O
)	O
.	O

Mutant	O
PLP1	B-GENE-Y
accumulates	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
induces	O
ER	O
stress	O
.	O

However	O
,	O
the	O
link	O
between	O
the	O
clinical	O
severity	O
of	O
PMD	O
and	O
the	O
cellular	O
response	O
induced	O
by	O
mutant	O
PLP1	B-GENE-Y
remains	O
largely	O
unknown	O
.	O

Accumulation	O
of	O
misfolded	O
proteins	O
in	O
the	O
ER	O
generally	O
leads	O
to	O
up	O
-	O
regulation	O
of	O
ER	O
chaperones	O
to	O
alleviate	O
ER	O
stress	O
.	O

Here	O
,	O
we	O
found	O
that	O
expression	O
of	O
the	O
PLP1	B-GENE-Y
-	O
A243V	B-GENE-N
mutant	O
,	O
which	O
causes	O
severe	O
disease	O
,	O
depletes	O
some	O
ER	O
chaperones	O
with	O
a	O
KDEL	B-GENE-N
(	O
Lys	B-CHEMICAL
-	I-CHEMICAL
Asp	I-CHEMICAL
-	I-CHEMICAL
Glu	I-CHEMICAL
-	I-CHEMICAL
Leu	I-CHEMICAL
)	O
motif	O
,	O
in	O
HeLa	O
cells	O
,	O
MO3	O
.	O
13	O
oligodendrocytic	O
cells	O
,	O
and	O
primary	O
oligodendrocytes	O
.	O

The	O
same	O
PLP1	B-GENE-Y
mutant	O
also	O
induces	O
fragmentation	O
of	O
the	O
Golgi	O
apparatus	O
(	O
GA	O
)	O
.	O

These	O
organelle	O
changes	O
are	O
less	O
prominent	O
in	O
cells	O
with	O
milder	O
disease	O
-	O
associated	O
PLP1	B-GENE-Y
mutants	O
.	O

Similar	O
changes	O
are	O
also	O
observed	O
in	O
cells	O
expressing	O
another	O
disease	O
-	O
causing	O
gene	O
that	O
triggers	O
ER	O
stress	O
,	O
as	O
well	O
as	O
in	O
cells	O
treated	O
with	O
brefeldin	B-CHEMICAL
A	I-CHEMICAL
,	O
which	O
induces	O
ER	O
stress	O
and	O
GA	O
fragmentation	O
by	O
inhibiting	O
GA	O
to	O
ER	O
trafficking	O
.	O

We	O
also	O
found	O
that	O
mutant	O
PLP1	B-GENE-Y
disturbs	O
localization	O
of	O
the	O
KDEL	B-GENE-N
receptor	O
,	O
which	O
transports	O
the	O
chaperones	O
with	O
the	O
KDEL	B-GENE-N
motif	I-GENE-N
from	O
the	O
GA	O
to	O
the	O
ER	O
.	O

These	O
data	O
show	O
that	O
PLP1	B-GENE-Y
mutants	O
inhibit	O
GA	O
to	O
ER	O
trafficking	O
,	O
which	O
reduces	O
the	O
supply	O
of	O
ER	O
chaperones	O
and	O
induces	O
GA	O
fragmentation	O
.	O

We	O
propose	O
that	O
depletion	O
of	O
ER	O
chaperones	O
and	O
GA	O
fragmentation	O
induced	O
by	O
mutant	O
misfolded	O
proteins	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
inherited	O
ER	O
stress	O
-	O
related	O
diseases	O
and	O
affect	O
the	O
disease	O
severity	O
.	O

Topoisomerase	B-GENE-Y
IIβ	I-GENE-Y
deficiency	O
enhances	O
camptothecin	B-CHEMICAL
-	O
induced	O
apoptosis	O
.	O

Camptothecin	B-CHEMICAL
(	O
CPT	B-CHEMICAL
)	O
,	O
a	O
topoisomerase	B-GENE-Y
(	I-GENE-Y
Top	I-GENE-Y
)	I-GENE-Y
I	I-GENE-Y
-	O
targeting	O
drug	O
that	O
stabilizes	O
Top1	B-GENE-Y
-	O
DNA	O
covalent	O
adducts	O
,	O
can	O
induce	O
S	O
-	O
phase	O
-	O
specific	O
cytotoxicity	O
due	O
to	O
the	O
arrest	O
of	O
progressing	O
replication	O
forks	O
.	O

However	O
,	O
CPT	B-CHEMICAL
-	O
induced	O
non	O
-	O
S	O
-	O
phase	O
cytotoxicity	O
is	O
less	O
well	O
characterized	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
topoisomerase	B-GENE-Y
IIβ	I-GENE-Y
(	O
Top2β	B-GENE-Y
)	O
as	O
a	O
specific	O
determinant	O
for	O
CPT	B-CHEMICAL
sensitivity	O
,	O
but	O
not	O
for	O
many	O
other	O
cytotoxic	O
agents	O
,	O
in	O
non	O
-	O
S	O
-	O
phase	O
cells	O
.	O

First	O
,	O
quiescent	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
lacking	O
Top2β	B-GENE-Y
were	O
shown	O
to	O
be	O
hypersensitive	O
to	O
CPT	B-CHEMICAL
with	O
prominent	O
induction	O
of	O
apoptosis	O
.	O

Second	O
,	O
ICRF	B-CHEMICAL
-	I-CHEMICAL
187	I-CHEMICAL
,	O
a	O
Top2	B-GENE-Y
catalytic	O
inhibitor	O
known	O
to	O
deplete	O
Top2β	B-GENE-Y
,	O
specifically	O
sensitized	O
MEFs	O
to	O
CPT	B-CHEMICAL
.	O

To	O
explore	O
the	O
molecular	O
basis	O
for	O
CPT	B-CHEMICAL
hypersensitivity	O
in	O
Top2β	B-GENE-Y
-	O
deficient	O
cells	O
,	O
we	O
found	O
that	O
upon	O
CPT	B-CHEMICAL
exposure	O
,	O
the	O
RNA	B-GENE-N
polymerase	I-GENE-N
II	I-GENE-N
large	I-GENE-N
subunit	I-GENE-N
(	O
RNAP	B-GENE-N
LS	I-GENE-N
)	O
became	O
progressively	O
depleted	O
,	O
followed	O
by	O
recovery	O
to	O
nearly	O
the	O
original	O
level	O
in	O
wild	O
-	O
type	O
MEFs	O
,	O
whereas	O
RNAP	B-GENE-N
LS	I-GENE-N
remained	O
depleted	O
without	O
recovery	O
in	O
Top2β	B-GENE-Y
-	O
deficient	O
cells	O
.	O

Concomitant	O
with	O
the	O
reduction	O
of	O
the	O
RNAP	B-GENE-N
LS	I-GENE-N
level	O
,	O
the	O
p53	B-GENE-Y
protein	O
level	O
was	O
greatly	O
induced	O
.	O

Interestingly	O
,	O
RNAP	B-GENE-N
LS	I-GENE-N
depletion	O
has	O
been	O
well	O
documented	O
to	O
lead	O
to	O
p53	B-GENE-Y
-	O
dependent	O
apoptosis	O
.	O

Altogether	O
,	O
our	O
findings	O
support	O
a	O
model	O
in	O
which	O
Top2β	B-GENE-Y
deficiency	O
promotes	O
CPT	B-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
quiescent	O
non	O
-	O
S	O
-	O
phase	O
cells	O
,	O
possibly	O
due	O
to	O
RNAP	B-GENE-N
LS	I-GENE-N
depletion	O
and	O
p53	B-GENE-Y
accumulation	O
.	O

Using	O
a	O
fragment	O
-	O
based	O
approach	O
to	O
target	O
protein	O
-	O
protein	O
interactions	O
.	O

The	O
ability	O
to	O
identify	O
inhibitors	O
of	O
protein	O
-	O
protein	O
interactions	O
represents	O
a	O
major	O
challenge	O
in	O
modern	O
drug	O
discovery	O
and	O
in	O
the	O
development	O
of	O
tools	O
for	O
chemical	O
biology	O
.	O

In	O
recent	O
years	O
,	O
fragment	O
-	O
based	O
approaches	O
have	O
emerged	O
as	O
a	O
new	O
methodology	O
in	O
drug	O
discovery	O
;	O
however	O
,	O
few	O
examples	O
of	O
small	O
molecules	O
that	O
are	O
active	O
against	O
chemotherapeutic	O
targets	O
have	O
been	O
published	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
fragment	O
-	O
based	O
approach	O
of	O
targeting	O
the	O
interaction	O
between	O
the	O
tumour	O
suppressor	O
BRCA2	B-GENE-Y
and	O
the	O
recombination	O
enzyme	O
RAD51	B-GENE-Y
;	O
it	O
makes	O
use	O
of	O
a	O
screening	O
pipeline	O
of	O
biophysical	O
techniques	O
that	O
we	O
expect	O
to	O
be	O
more	O
generally	O
applicable	O
to	O
similar	O
targets	O
.	O

Disruption	O
of	O
this	O
interaction	O
in	O
vivo	O
is	O
hypothesised	O
to	O
give	O
rise	O
to	O
cellular	O
hypersensitivity	O
to	O
radiation	O
and	O
genotoxic	O
drugs	O
.	O

We	O
have	O
used	O
protein	O
engineering	O
to	O
create	O
a	O
monomeric	O
form	O
of	O
RAD51	B-GENE-Y
by	O
humanising	O
a	O
thermostable	O
archaeal	O
orthologue	O
,	O
RadA	B-GENE-N
,	O
and	O
used	O
this	O
protein	O
for	O
fragment	O
screening	O
.	O

The	O
initial	O
fragment	O
hits	O
were	O
thoroughly	O
validated	O
biophysically	O
by	O
isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
and	O
NMR	O
techniques	O
and	O
observed	O
by	O
X	O
-	O
ray	O
crystallography	O
to	O
bind	O
in	O
a	O
shallow	O
surface	O
pocket	O
that	O
is	O
occupied	O
in	O
the	O
native	O
complex	O
by	O
the	O
side	O
chain	O
of	O
a	O
phenylalanine	B-CHEMICAL
from	O
the	O
conserved	O
FxxA	B-GENE-N
interaction	I-GENE-N
motif	I-GENE-N
found	O
in	O
BRCA2	B-GENE-Y
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
fragments	O
or	O
any	O
small	O
molecule	O
binding	O
at	O
this	O
protein	O
-	O
protein	O
interaction	O
site	O
.	O

The	O
mannose	B-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
-	O
binding	O
sites	O
of	O
M6P	B-CHEMICAL
/	O
IGF2R	B-GENE-Y
determine	O
its	O
capacity	O
to	O
suppress	O
matrix	O
invasion	O
by	O
squamous	O
cell	O
carcinoma	O
cells	O
.	O

The	O
M6P	B-CHEMICAL
(	O
mannose	B-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
)	O
/	O
IGF2R	B-GENE-Y
(	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
II	I-GENE-Y
receptor	I-GENE-Y
)	O
interacts	O
with	O
a	O
variety	O
of	O
factors	O
that	O
impinge	O
on	O
tumour	O
invasion	O
and	O
metastasis	O
.	O

It	O
has	O
been	O
shown	O
that	O
expression	O
of	O
wild	O
-	O
type	O
M6P	B-CHEMICAL
/	O
IGF2R	B-GENE-Y
reduces	O
the	O
tumorigenic	O
and	O
invasive	O
properties	O
of	O
receptor	O
-	O
deficient	O
SCC	O
-	O
VII	O
squamous	O
cell	O
carcinoma	O
cells	O
.	O

We	O
have	O
now	O
used	O
mutant	O
forms	O
of	O
M6P	B-CHEMICAL
/	O
IGF2R	B-GENE-Y
to	O
assess	O
the	O
relevance	O
of	O
the	O
different	O
ligand	O
-	O
binding	O
sites	O
of	O
the	O
receptor	O
for	O
its	O
biological	O
activities	O
in	O
this	O
cellular	O
system	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
M6P	B-CHEMICAL
/	O
IGF2R	B-GENE-Y
does	O
not	O
require	O
a	O
functional	O
binding	O
site	O
for	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
II	I-GENE-Y
for	O
inhibition	O
of	O
anchorage	O
-	O
independent	O
growth	O
and	O
matrix	O
invasion	O
by	O
SCC	O
-	O
VII	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
simultaneous	O
mutation	O
of	O
both	O
M6P	B-CHEMICAL
-	O
binding	O
sites	O
is	O
sufficient	O
to	O
impair	O
all	O
cellular	O
functions	O
of	O
the	O
receptor	O
tested	O
.	O

These	O
findings	O
highlight	O
that	O
the	O
interaction	O
between	O
M6P	B-CHEMICAL
/	O
IGF2R	B-GENE-Y
and	O
M6P	B-CHEMICAL
-	O
modified	O
ligands	O
is	O
not	O
only	O
important	O
for	O
intracellular	O
accumulation	O
of	O
lysosomal	O
enzymes	O
and	O
formation	O
of	O
dense	O
lysosomes	O
,	O
but	O
is	O
also	O
crucial	O
for	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
suppress	O
SCC	O
-	O
VII	O
growth	O
and	O
invasion	O
.	O

The	O
present	O
study	O
also	O
shows	O
that	O
some	O
of	O
the	O
biological	O
activities	O
of	O
M6P	B-CHEMICAL
/	O
IGF2R	B-GENE-Y
in	O
SCC	O
-	O
VII	O
cells	O
strongly	O
depend	O
on	O
a	O
functional	O
M6P	B-CHEMICAL
-	O
binding	O
site	O
within	O
domain	O
3	O
,	O
thus	O
providing	O
further	O
evidence	O
for	O
the	O
non	O
-	O
redundant	O
cellular	O
functions	O
of	O
the	O
individual	O
carbohydrate	B-CHEMICAL
-	O
binding	O
domains	O
of	O
the	O
receptor	O
.	O

Synthesis	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
aminomethyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
azabicyclo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
.	I-CHEMICAL
2	I-CHEMICAL
.	I-CHEMICAL
1	I-CHEMICAL
]	I-CHEMICAL
heptanes	I-CHEMICAL
via	O
LiAlH₄	B-CHEMICAL
-	O
induced	O
reductive	O
cyclization	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
cyano	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenylbutyl	I-CHEMICAL
)	I-CHEMICAL
aziridines	I-CHEMICAL
and	O
evaluation	O
of	O
their	O
antimalarial	O
activity	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
cyano	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenylbutyl	I-CHEMICAL
)	I-CHEMICAL
aziridines	I-CHEMICAL
were	O
employed	O
for	O
the	O
one	O
-	O
step	O
stereoselective	O
construction	O
of	O
both	O
endo	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
exo	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminomethyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
azabicyclo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
.	I-CHEMICAL
2	I-CHEMICAL
.	I-CHEMICAL
1	I-CHEMICAL
]	I-CHEMICAL
heptanes	I-CHEMICAL
as	O
new	O
azaheterobicyclic	B-CHEMICAL
scaffolds	O
via	O
a	O
double	O
LiAlH	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
-	O
induced	O
reductive	O
cyclization	O
protocol	O
.	O

Antiplasmodial	O
assessment	O
of	O
these	O
1	B-CHEMICAL
-	I-CHEMICAL
azabicyclo	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
.	I-CHEMICAL
2	I-CHEMICAL
.	I-CHEMICAL
1	I-CHEMICAL
]	I-CHEMICAL
heptanes	I-CHEMICAL
revealed	O
moderate	O
to	O
good	O
activities	O
in	O
the	O
micromolar	O
range	O
,	O
with	O
the	O
exo	O
-	O
isomers	O
being	O
the	O
most	O
promising	O
structures	O
.	O

Furthermore	O
,	O
the	O
proposed	O
mode	O
of	O
action	O
was	O
supported	O
by	O
ligand	O
docking	O
studies	O
,	O
pointing	O
to	O
a	O
strong	O
binding	O
interaction	O
with	O
the	O
enzyme	O
plasmepsin	B-GENE-Y
II	I-GENE-Y
.	O

A	O
novel	O
metabotropic	B-GENE-Y
glutamate	I-GENE-Y
receptor	I-GENE-Y
5	I-GENE-Y
positive	O
allosteric	O
modulator	O
acts	O
at	O
a	O
unique	O
site	O
and	O
confers	O
stimulus	O
bias	O
to	O
mGlu5	B-GENE-Y
signaling	O
.	O

Metabotropic	B-GENE-Y
glutamate	I-GENE-Y
receptor	I-GENE-Y
5	I-GENE-Y
(	O
mGlu5	B-GENE-Y
)	O
is	O
a	O
target	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
,	O
such	O
as	O
schizophrenia	O
and	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Furthermore	O
,	O
mGlu5	B-GENE-Y
has	O
been	O
shown	O
to	O
play	O
an	O
important	O
role	O
in	O
hippocampal	O
synaptic	O
plasticity	O
,	O
specifically	O
in	O
long	O
-	O
term	O
depression	O
(	O
LTD	O
)	O
and	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
,	O
which	O
is	O
thought	O
to	O
be	O
involved	O
in	O
cognition	O
.	O

Multiple	O
mGlu5	B-GENE-Y
-	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
have	O
been	O
developed	O
from	O
a	O
variety	O
of	O
different	O
scaffolds	O
.	O

Previous	O
work	O
has	O
extensively	O
characterized	O
a	O
common	O
allosteric	O
site	O
on	O
mGlu5	B-GENE-Y
,	O
termed	O
the	O
MPEP	B-CHEMICAL
(	O
2	B-CHEMICAL
-	I-CHEMICAL
Methyl	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
phenylethynyl	I-CHEMICAL
)	I-CHEMICAL
pyridine	I-CHEMICAL
)	O
binding	O
site	O
.	O

However	O
,	O
one	O
mGlu5	B-GENE-Y
PAM	O
,	O
CPPHA	B-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dioxo	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2H	I-CHEMICAL
-	I-CHEMICAL
isoindol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
]	I-CHEMICAL
phenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxybenzamide	I-CHEMICAL
)	O
,	O
interacts	O
with	O
a	O
separate	O
allosteric	O
site	O
on	O
mGlu5	B-GENE-Y
.	O

Using	O
cell	O
-	O
based	O
assays	O
and	O
brain	O
slice	O
preparations	O
,	O
we	O
characterized	O
the	O
interaction	O
of	O
a	O
potent	O
and	O
efficacious	O
mGlu5	B-GENE-Y
PAM	O
from	O
the	O
CPPHA	B-CHEMICAL
series	O
termed	O
NCFP	B-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
fluoro	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dioxoisoindolin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
)	I-CHEMICAL
phenyl	I-CHEMICAL
)	I-CHEMICAL
picolinamide	I-CHEMICAL
)	O
.	O

NCFP	B-CHEMICAL
binds	O
to	O
the	O
CPPHA	B-CHEMICAL
site	O
on	O
mGlu5	B-GENE-Y
and	O
potentiates	O
mGlu5	B-GENE-Y
-	O
mediated	O
responses	O
in	O
both	O
recombinant	O
and	O
native	O
systems	O
.	O

However	O
,	O
NCFP	B-CHEMICAL
provides	O
greater	O
mGlu5	B-GENE-Y
subtype	O
selectivity	O
than	O
does	O
CPPHA	B-CHEMICAL
,	O
making	O
it	O
more	O
suitable	O
for	O
studies	O
of	O
effects	O
on	O
mGlu5	B-GENE-Y
in	O
CNS	O
preparations	O
.	O

Of	O
interest	O
,	O
NCFP	B-CHEMICAL
does	O
not	O
potentiate	O
responses	O
involved	O
in	O
hippocampal	O
synaptic	O
plasticity	O
(	O
LTD	O
/	O
LTP	O
)	O
,	O
setting	O
it	O
apart	O
from	O
other	O
previously	O
characterized	O
MPEP	B-CHEMICAL
site	O
PAMs	O
.	O

This	O
suggests	O
that	O
although	O
mGlu5	B-GENE-Y
PAMs	O
may	O
have	O
similar	O
responses	O
in	O
some	O
systems	O
,	O
they	O
can	O
induce	O
differential	O
effects	O
on	O
mGlu5	B-GENE-Y
-	O
mediated	O
physiologic	O
responses	O
in	O
the	O
CNS	O
.	O

Such	O
stimulus	O
bias	O
by	O
mGlu5	B-GENE-Y
PAMs	O
may	O
complicate	O
drug	O
discovery	O
efforts	O
but	O
would	O
also	O
allow	O
for	O
specifically	O
tailored	O
therapies	O
,	O
if	O
pharmacological	O
biases	O
can	O
be	O
attributed	O
to	O
different	O
therapeutic	O
outcomes	O
.	O

Disruption	O
of	O
the	O
cereblon	B-GENE-Y
gene	O
enhances	O
hepatic	O
AMPK	B-GENE-N
activity	O
and	O
prevents	O
high	O
fat	O
diet	O
-	O
induced	O
obesity	O
and	O
insulin	B-GENE-N
resistance	O
in	O
mice	O
.	O

A	O
nonsense	O
mutation	O
in	O
cereblon	B-GENE-Y
(	O
CRBN	B-GENE-Y
)	O
causes	O
a	O
mild	O
type	O
of	O
mental	O
retardation	O
in	O
humans	O
.	O

An	O
earlier	O
study	O
showed	O
that	O
CRBN	B-GENE-Y
negatively	O
regulates	O
the	O
functional	O
activity	O
of	O
AMP	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
AMPK	B-GENE-N
)	O
in	O
vitro	O
by	O
binding	O
directly	O
to	O
the	O
α1	B-GENE-Y
subunit	I-GENE-Y
of	I-GENE-Y
the	I-GENE-Y
AMPK	I-GENE-Y
complex	O
.	O

However	O
,	O
the	O
in	O
vivo	O
role	O
of	O
CRBN	B-GENE-Y
was	O
not	O
studied	O
.	O

To	O
elucidate	O
the	O
physiological	O
functions	O
of	O
Crbn	B-GENE-Y
,	O
a	O
mouse	O
strain	O
was	O
generated	O
in	O
which	O
the	O
Crbn	B-GENE-Y
gene	O
was	O
deleted	O
throughout	O
the	O
whole	O
body	O
.	O

In	O
Crbn	B-GENE-Y
-	O
deficient	O
mice	O
fed	O
a	O
normal	O
diet	O
,	O
AMPK	B-GENE-N
in	O
the	O
liver	O
showed	O
hyper	O
-	O
phosphorylation	O
,	O
which	O
indicated	O
the	O
constitutive	O
activation	O
of	O
AMPK	B-GENE-N
.	O

Since	O
Crbn	B-GENE-Y
-	O
deficient	O
mice	O
showed	O
significantly	O
less	O
weight	O
gain	O
when	O
fed	O
a	O
high	O
fat	O
diet	O
and	O
their	O
insulin	O
sensitivity	O
was	O
considerably	O
improved	O
,	O
the	O
functions	O
of	O
Crbn	B-GENE-Y
in	O
the	O
liver	O
were	O
primarily	O
investigated	O
.	O

These	O
results	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
that	O
Crbn	B-GENE-Y
is	O
a	O
negative	O
modulator	O
of	O
AMPK	B-GENE-N
,	O
which	O
suggests	O
that	O
Crbn	B-GENE-Y
may	O
be	O
a	O
potential	O
target	O
for	O
metabolic	O
disorders	O
of	O
the	O
liver	O
.	O

Impaired	O
local	O
production	O
of	O
pro	O
-	O
resolving	O
lipid	O
mediators	O
in	O
obesity	O
and	O
17	B-CHEMICAL
-	I-CHEMICAL
HDHA	I-CHEMICAL
as	O
a	O
potential	O
treatment	O
for	O
obesity	O
-	O
associated	O
inflammation	O
.	O

Obesity	O
-	O
induced	O
chronic	O
low	O
-	O
grade	O
inflammation	O
originates	O
from	O
adipose	O
tissue	O
and	O
is	O
crucial	O
for	O
obesity	O
-	O
driven	O
metabolic	O
deterioration	O
including	O
insulin	B-GENE-Y
resistance	O
and	O
type	O
2	O
diabetes	O
.	O
Chronic	O
inflammation	O
may	O
be	O
a	O
consequence	O
of	O
a	O
failure	O
to	O
actively	O
resolve	O
inflammation	O
,	O
and	O
could	O
result	O
from	O
a	O
lack	O
of	O
local	O
specialized	O
pro	O
-	O
resolving	O
lipid	O
mediators	O
(	O
SPM	O
)	O
such	O
as	O
resolvins	B-CHEMICAL
and	O
protectins	O
,	O
which	O
derive	O
from	O
the	O
n	O
-	O
3	O
polyunsaturated	B-CHEMICAL
fatty	I-CHEMICAL
acids	I-CHEMICAL
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
EPA	B-CHEMICAL
)	O
and	O
docosahexaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
DHA	B-CHEMICAL
)	O
.	O

We	O
assessed	O
obesity	O
-	O
induced	O
changes	O
of	O
n	O
-	O
3	O
-	O
derived	O
SPM	O
in	O
adipose	O
tissue	O
and	O
effects	O
of	O
dietary	O
EPA	B-CHEMICAL
/	O
DHA	B-CHEMICAL
thereon	O
.	O
Moreover	O
,	O
we	O
treated	O
obese	O
mice	O
with	O
SPM	O
precursors	O
and	O
investigated	O
effects	O
on	O
inflammation	O
and	O
metabolic	O
dysregulation	O
.	O

Obesity	O
significantly	O
decreased	O
DHA	B-CHEMICAL
-	O
derived	O
17	B-CHEMICAL
-	I-CHEMICAL
hydroxydocosahexaenoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
17	B-CHEMICAL
-	I-CHEMICAL
HDHA	I-CHEMICAL
,	O
resolvin	B-CHEMICAL
D1	I-CHEMICAL
precursor	O
)	O
and	O
protectin	B-CHEMICAL
D1	I-CHEMICAL
levels	O
in	O
murine	O
adipose	O
tissue	O
.	O

Dietary	O
EPA	B-CHEMICAL
/	O
DHA	B-CHEMICAL
treatment	O
restored	O
endogenous	O
biosynthesis	O
of	O
n	O
-	O
3	O
derived	O
lipid	O
mediators	O
in	O
obesity	O
while	O
attenuating	O
adipose	O
tissue	O
inflammation	O
and	O
improving	O
insulin	B-GENE-N
sensitivity	O
.	O

Notably	O
,	O
17	B-CHEMICAL
-	I-CHEMICAL
HDHA	I-CHEMICAL
treatment	O
reduced	O
adipose	O
tissue	O
expression	O
of	O
inflammatory	O
cytokines	B-GENE-N
,	O
increased	O
adiponectin	B-GENE-Y
expression	O
and	O
improved	O
glucose	B-CHEMICAL
tolerance	O
parallel	O
to	O
insulin	B-GENE-N
sensitivity	O
in	O
obese	O
mice	O
.	O

These	O
findings	O
indicate	O
that	O
impaired	O
biosynthesis	O
of	O
certain	O
SPM	O
and	O
SPM	O
precursors	O
including	O
17	B-CHEMICAL
-	I-CHEMICAL
HDHA	I-CHEMICAL
and	O
protectin	B-CHEMICAL
D1	I-CHEMICAL
contributes	O
to	O
adipose	O
tissue	O
inflammation	O
in	O
obesity	O
and	O
suggest	O
17	B-CHEMICAL
-	I-CHEMICAL
HDHA	I-CHEMICAL
as	O
a	O
novel	O
treatment	O
option	O
for	O
obesity	O
-	O
associated	O
complications	O
.	O

Pyrrolopyrazines	B-CHEMICAL
as	O
Selective	O
Spleen	B-GENE-Y
Tyrosine	I-GENE-Y
Kinase	I-GENE-Y
Inhibitors	O
.	O

We	O
describe	O
the	O
discovery	O
of	O
several	O
pyrrolopyrazines	B-CHEMICAL
as	O
potent	O
and	O
selective	O
Syk	B-GENE-Y
inhibitors	O
and	O
the	O
efforts	O
that	O
eventually	O
led	O
to	O
the	O
desired	O
improvements	O
in	O
physicochemical	O
properties	O
and	O
human	O
whole	O
blood	O
potencies	O
.	O

Ultimately	O
,	O
our	O
mouse	O
model	O
revealed	O
unexpected	O
toxicity	O
that	O
precluded	O
us	O
from	O
further	O
advancing	O
this	O
series	O
.	O

Design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
novel	O
hybrid	O
compounds	O
of	O
imidazole	B-CHEMICAL
scaffold	O
-	O
based	O
2	B-CHEMICAL
-	I-CHEMICAL
benzylbenzofuran	I-CHEMICAL
as	O
potent	O
anticancer	O
agents	O
.	O

A	O
series	O
of	O
novel	O
hybrid	O
compounds	O
between	O
2	B-CHEMICAL
-	I-CHEMICAL
benzylbenzofuran	I-CHEMICAL
and	O
imidazole	B-CHEMICAL
has	O
been	O
prepared	O
and	O
evaluated	O
in	O
vitro	O
against	O
a	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
benzimidazole	B-CHEMICAL
ring	O
and	O
substitution	O
of	O
the	O
imidazolyl	B-CHEMICAL
-	O
3	O
-	O
position	O
with	O
a	O
naphthylacyl	B-CHEMICAL
or	O
4	B-CHEMICAL
-	I-CHEMICAL
methoxyphenacyl	I-CHEMICAL
group	O
were	O
vital	O
for	O
modulating	O
cytotoxic	O
activity	O
.	O

In	O
particular	O
,	O
hybrid	O
compounds	O
46	O
and	O
47	O
were	O
found	O
to	O
be	O
the	O
most	O
potent	O
derivatives	O
against	O
5	O
strains	O
human	O
tumor	O
cell	O
lines	O
and	O
more	O
active	O
than	O
cisplatin	B-CHEMICAL
(	O
DDP	B-CHEMICAL
)	O
,	O
and	O
exhibited	O
cytotoxic	O
activities	O
selectively	O
against	O
breast	O
carcinoma	O
(	O
MCF	O
-	O
7	O
)	O
and	O
myeloid	O
liver	O
carcinoma	O
(	O
SMMC	O
-	O
7721	O
)	O
,	O
respectively	O
.	O

Evidence	O
for	O
a	O
new	O
binding	O
mode	O
to	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
:	O
allosteric	O
regulation	O
by	O
the	O
marine	O
compound	O
palinurin	B-CHEMICAL
.	O

Glycogen	B-GENE-Y
synthase	I-GENE-Y
kinase	I-GENE-Y
3β	I-GENE-Y
(	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
)	O
is	O
widely	O
recognised	O
as	O
a	O
relevant	O
player	O
in	O
the	O
pathogenesis	O
of	O
several	O
highly	O
prevalent	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
,	O
mood	O
disorders	O
,	O
diabetes	O
and	O
cancer	O
.	O

Therefore	O
,	O
this	O
enzyme	O
constitutes	O
a	O
highly	O
attractive	O
therapeutic	O
target	O
for	O
the	O
development	O
of	O
selective	O
inhibitors	O
as	O
new	O
promising	O
drugs	O
for	O
the	O
treatment	O
of	O
these	O
pathologies	O
.	O

We	O
describe	O
here	O
the	O
isolation	O
and	O
biochemical	O
characterization	O
of	O
the	O
marine	O
natural	O
sesquiterpene	B-CHEMICAL
palinurin	B-CHEMICAL
as	O
a	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
inhibitor	O
.	O

Experimental	O
studies	O
performed	O
for	O
characterizing	O
the	O
inhibitory	O
mechanism	O
indicate	O
that	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
inhibition	O
by	O
palinurin	B-CHEMICAL
cannot	O
be	O
competed	O
out	O
by	O
ATP	B-CHEMICAL
nor	O
peptide	O
substrate	O
.	O

Molecular	O
modelling	O
techniques	O
have	O
enabled	O
us	O
to	O
propose	O
an	O
unconventional	O
binding	O
mode	O
to	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
.	O

Moreover	O
,	O
molecular	O
dynamics	O
simulations	O
have	O
identified	O
an	O
allosteric	O
mechanism	O
by	O
which	O
binding	O
of	O
palinurin	B-CHEMICAL
leads	O
to	O
GSK	B-GENE-Y
-	I-GENE-Y
3β	I-GENE-Y
inhibition	O
.	O

The	O
inhibitory	O
activities	O
determined	O
for	O
a	O
series	O
of	O
structurally	O
related	O
analogues	O
support	O
the	O
proposed	O
binding	O
mode	O
of	O
palinurin	B-CHEMICAL
,	O
which	O
is	O
the	O
first	O
compound	O
described	O
to	O
target	O
this	O
allosteric	O
site	O
.	O

The	O
results	O
offer	O
new	O
opportunities	O
for	O
designing	O
and	O
developing	O
selective	O
inhibitors	O
with	O
novel	O
mechanisms	O
of	O
action	O
.	O

Bioactive	O
microconstituents	O
and	O
antioxidant	O
properties	O
of	O
wild	O
edible	O
mushrooms	O
from	O
the	O
island	O
of	O
Lesvos	O
,	O
Greece	O
.	O

Crude	O
composition	O
,	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
,	O
sterols	B-CHEMICAL
,	O
total	O
phenolic	O
content	O
(	O
TPC	O
)	O
,	O
individual	O
polyphenols	B-CHEMICAL
and	O
terpenic	B-CHEMICAL
acids	I-CHEMICAL
were	O
determined	O
in	O
five	O
wild	O
edible	O
mushrooms	O
species	O
(	O
Lactarius	O
deliciosus	O
,	O
Lactarius	O
sanguifluus	O
,	O
Lactarius	O
semisanguifluus	O
,	O
Russula	O
delica	O
,	O
Suillus	O
bellinii	O
)	O
from	O
Lesvos	O
Island	O
,	O
Greece	O
.	O

In	O
addition	O
,	O
the	O
DPPH	B-CHEMICAL
scavenging	O
capacity	O
,	O
the	O
ferric	B-CHEMICAL
ion	O
reducing	O
power	O
(	O
FRAP	O
)	O
and	O
the	O
ferrous	B-CHEMICAL
ion	O
chelating	O
activity	O
of	O
mushroom	O
methanolic	O
extracts	O
were	O
assessed	O
.	O

Among	O
sterols	B-CHEMICAL
,	O
ergosterol	B-CHEMICAL
predominated	O
at	O
concentrations	O
9	O
.	O
2	O
-	O
18	O
.	O
0mg	O
/	O
100g	O
fw	O
.	O

Total	O
phenolic	O
content	O
of	O
mushroom	O
extracts	O
ranged	O
from	O
6	O
.	O
0	O
to	O
20	O
.	O
8mg	O
GAE	O
/	O
100g	O
fw	O
.	O

Up	O
to	O
19	O
simple	O
polyphenols	B-CHEMICAL
were	O
determined	O
in	O
mushrooms	O
extracts	O
,	O
the	O
more	O
abundant	O
being	O
p	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
benzoic	I-CHEMICAL
acid	I-CHEMICAL
,	O
p	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
phenylacetic	I-CHEMICAL
acid	I-CHEMICAL
,	O
o	B-CHEMICAL
-	I-CHEMICAL
coumaric	I-CHEMICAL
acid	I-CHEMICAL
,	O
ferulic	B-CHEMICAL
acid	I-CHEMICAL
and	O
chrysin	B-CHEMICAL
.	O

In	O
addition	O
,	O
the	O
triterpenic	B-CHEMICAL
acids	I-CHEMICAL
oleanolic	B-CHEMICAL
and	O
ursolic	B-CHEMICAL
were	O
detected	O
for	O
the	O
first	O
time	O
in	O
mushrooms	O
.	O

All	O
species	O
exerted	O
antioxidant	O
activity	O
and	O
ferrous	B-CHEMICAL
ion	O
chelating	O
capacity	O
.	O

Principal	O
component	O
analysis	O
revealed	O
good	O
correlations	O
between	O
TPC	O
,	O
DPPH	B-CHEMICAL
and	O
FRAP	O
but	O
not	O
with	O
metal	O
chelating	O
activity	O
.	O

It	O
seems	O
that	O
mushrooms	O
polyphenols	B-CHEMICAL
exert	O
antiradical	O
and	O
reducing	O
activities	O
,	O
but	O
they	O
are	O
not	O
strong	O
metal	O
chelators	O
,	O
the	O
observed	O
chelating	O
ability	O
being	O
probably	O
due	O
to	O
other	O
classes	O
of	O
compounds	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
the	O
bioactive	O
microconstituents	O
and	O
antioxidant	O
activity	O
of	O
wild	O
Greek	O
edible	O
mushrooms	O
.	O

Formation	O
of	O
mainstream	O
cigarette	O
smoke	O
constituents	O
prioritized	O
by	O
the	O
World	O
Health	O
Organization	O
-	O
-	O
yield	O
patterns	O
observed	O
in	O
market	O
surveys	O
,	O
clustering	O
and	O
inverse	O
correlations	O
.	O

The	O
WHO	O
TobReg	O
proposed	O
mandating	O
ceilings	O
on	O
selected	O
smoke	O
constituents	O
determined	O
from	O
the	O
market	O
-	O
specific	O
median	O
of	O
nicotine	B-CHEMICAL
-	O
normalized	O
yield	O
distributions	O
.	O

Data	O
validating	O
this	O
regulatory	O
concept	O
were	O
obtained	O
from	O
essentially	O
single	O
-	O
blend	O
surveys	O
.	O

This	O
process	O
is	O
strongly	O
impacted	O
by	O
inverse	O
correlations	O
among	O
yields	O
.	O

In	O
the	O
present	O
study	O
,	O
18	O
priority	O
WHO	O
smoke	O
constituent	O
yields	O
(	O
nicotine	B-CHEMICAL
-	O
normalized	O
)	O
were	O
determined	O
(	O
using	O
two	O
smoking	O
regimens	O
)	O
from	O
262	O
commercial	O
brands	O
including	O
American	O
,	O
Virginia	O
and	O
local	O
blends	O
from	O
13	O
countries	O
.	O

Principal	O
Component	O
Analysis	O
was	O
used	O
to	O
identify	O
yields	O
patterns	O
,	O
clustering	O
of	O
blend	O
types	O
and	O
the	O
inverse	O
correlations	O
causing	O
these	O
clusters	O
.	O

Three	O
principal	O
components	O
explain	O
about	O
75	O
%	O
of	O
total	O
data	O
variability	O
.	O

PC1	O
was	O
sensitive	O
to	O
the	O
relative	O
levels	O
of	O
gas	O
-	O
and	O
particle	O
-	O
phase	O
compounds	O
.	O

PC2	O
and	O
PC3	O
cluster	O
American	O
-	O
and	O
Virginia	O
-	O
blends	O
,	O
revealing	O
inverse	O
correlations	O
:	O
Nitrogen	B-CHEMICAL
oxides	I-CHEMICAL
and	O
amino	B-CHEMICAL
-	O
or	O
nitroso	B-CHEMICAL
-	O
aromatic	O
compounds	O
inversely	O
correlate	O
to	O
either	O
formaldehyde	B-CHEMICAL
and	O
acrolein	B-CHEMICAL
,	O
or	O
benzo	B-CHEMICAL
(	I-CHEMICAL
a	I-CHEMICAL
)	I-CHEMICAL
pyrene	I-CHEMICAL
and	O
di	B-CHEMICAL
-	I-CHEMICAL
hydroxybenzenes	I-CHEMICAL
.	O

These	O
results	O
can	O
be	O
explained	O
by	O
reviewing	O
the	O
processes	O
determining	O
each	O
components	O
smoke	O
delivery	O
.	O

Regulatory	O
initiatives	O
simultaneously	O
targeting	O
selected	O
smoke	O
constituents	O
in	O
markets	O
with	O
mixed	O
blend	O
styles	O
will	O
be	O
strongly	O
impacted	O
by	O
the	O
inverse	O
correlations	O
described	O
.	O

It	O
is	O
difficult	O
to	O
predict	O
the	O
ultimate	O
impact	O
of	O
such	O
regulations	O
on	O
public	O
health	O
,	O
considering	O
the	O
complex	O
chemistry	O
of	O
cigarette	O
smoke	O
formation	O
.	O

Design	O
,	O
synthesis	O
,	O
characterization	O
and	O
anti	O
-	O
inflammatory	O
evaluation	O
of	O
novel	O
pyrazole	B-CHEMICAL
amalgamated	O
flavones	B-CHEMICAL
.	O

A	O
series	O
of	O
novel	O
pyrazole	B-CHEMICAL
amalgamated	O
flavones	B-CHEMICAL
has	O
been	O
designed	O
and	O
synthesized	O
from	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
trimethoxy	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
pyrazole	I-CHEMICAL
6	O
.	O

The	O
structures	O
of	O
regioisomers	O
6	O
and	O
7	O
were	O
resolved	O
by	O
2D	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
COSY	O
,	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
HSQC	O
and	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
HMBC	O
experiments	O
.	O

The	O
newly	O
synthesized	O
compounds	O
were	O
tested	O
for	O
their	O
in	O
vitro	O
COX	B-GENE-N
inhibition	O
and	O
in	O
vivo	O
carrageenan	O
induced	O
hind	O
paw	O
edema	O
in	O
rats	O
and	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
induced	O
vascular	O
permeability	O
in	O
mice	O
.	O

Although	O
the	O
compounds	O
have	O
inhibitory	O
profile	O
against	O
both	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
some	O
of	O
the	O
compounds	O
are	O
found	O
to	O
be	O
selective	O
against	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
supported	O
by	O
inhibition	O
of	O
paw	O
edema	O
and	O
vascular	O
permeability	O
.	O

Docking	O
studies	O
were	O
also	O
carried	O
out	O
to	O
determine	O
the	O
structural	O
features	O
which	O
sway	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
the	O
tested	O
compounds	O
.	O

The	O
keto	B-CHEMICAL
and	O
phenolic	B-CHEMICAL
-	O
OH	B-CHEMICAL
are	O
major	O
factors	O
that	O
are	O
prominently	O
involved	O
in	O
interaction	O
with	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
active	O
site	O
.	O

Longer	O
HSD11B2	B-GENE-Y
CA	B-GENE-N
-	I-GENE-N
repeat	I-GENE-N
in	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
and	O
type	O
2	O
diabetes	O
.	O

Type	B-GENE-Y
2	I-GENE-Y
11β	I-GENE-Y
-	I-GENE-Y
hydroxysteroid	I-GENE-Y
dehydrogenase	I-GENE-Y
encoded	O
by	O
the	O
HSD11B2	B-GENE-Y
gene	O
converts	O
cortisol	B-CHEMICAL
to	O
inactive	O
cortisone	B-CHEMICAL
,	O
and	O
alteration	O
in	O
this	O
enzymatic	O
activity	O
might	O
affect	O
glucose	B-CHEMICAL
homeostasis	O
by	O
affecting	O
circulating	O
levels	O
or	O
tissue	O
availability	O
of	O
glucocorticoids	O
.	O

We	O
investigated	O
the	O
association	O
of	O
HSD11B2	B-GENE-Y
variant	O
with	O
glucose	B-CHEMICAL
homeostasis	O
.	O

Subjects	O
with	O
normal	O
glucose	B-CHEMICAL
tolerance	O
(	O
n	O
=	O
585	O
)	O
,	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
(	O
n	O
=	O
202	O
)	O
and	O
type	O
2	O
diabetes	O
(	O
n	O
=	O
355	O
)	O
were	O
genotyped	O
for	O
a	O
highly	O
polymorphic	O
CA	B-GENE-N
-	I-GENE-N
repeat	I-GENE-N
polymorphism	O
in	O
the	O
first	O
intron	O
of	O
HSD11B2	B-GENE-Y
.	O

Allele	O
and	O
genotype	O
frequencies	O
differed	O
between	O
normal	O
and	O
impaired	O
glucose	B-CHEMICAL
tolerance	O
(	O
P	O
=	O
0	O
.	O
0014	O
and	O
0	O
.	O
0407	O
,	O
respectively	O
;	O
4DF	O
)	O
or	O
type	O
2	O
diabetes	O
(	O
P	O
=	O
0	O
.	O
0053	O
and	O
0	O
.	O
0078	O
)	O
,	O
with	O
significant	O
linear	O
trends	O
between	O
the	O
repeat	O
length	O
and	O
the	O
phenotype	O
fraction	O
.	O

In	O
normal	O
subjects	O
,	O
total	O
CA	B-GENE-N
-	I-GENE-N
repeat	I-GENE-N
length	O
was	O
negatively	O
correlated	O
with	O
fasting	O
insulin	B-GENE-Y
and	O
HOMA	O
-	O
β	O
.	O

Thus	O
,	O
subjects	O
having	O
more	O
CA	B-GENE-N
repeats	I-GENE-N
are	O
susceptible	O
to	O
developing	O
abnormal	O
glucose	B-CHEMICAL
tolerance	O
,	O
whereas	O
normal	O
subjects	O
carrying	O
more	O
CA	B-GENE-N
repeats	I-GENE-N
appeared	O
to	O
have	O
frugal	O
characteristics	O
in	O
insulin	B-GENE-Y
secretion	O
.	O

Transcriptome	O
alterations	O
following	O
developmental	O
atrazine	B-CHEMICAL
exposure	O
in	O
zebrafish	O
are	O
associated	O
with	O
disruption	O
of	O
neuroendocrine	O
and	O
reproductive	O
system	O
function	O
,	O
cell	O
cycle	O
,	O
and	O
carcinogenesis	O
.	O

Atrazine	B-CHEMICAL
,	O
a	O
herbicide	O
commonly	O
applied	O
to	O
agricultural	O
areas	O
and	O
a	O
common	O
contaminant	O
of	O
potable	O
water	O
supplies	O
,	O
is	O
implicated	O
as	O
an	O
endocrine	O
-	O
disrupting	O
chemical	O
(	O
EDC	O
)	O
and	O
potential	O
carcinogen	O
.	O

Studies	O
show	O
that	O
EDCs	O
can	O
cause	O
irreversible	O
changes	O
in	O
tissue	O
formation	O
,	O
decreased	O
reproductive	O
potential	O
,	O
obesity	O
,	O
and	O
cancer	O
.	O

The	O
U	O
.	O
S	O
.	O

Environmental	O
Protection	O
Agency	O
considers	O
an	O
atrazine	B-CHEMICAL
concentration	O
of	O
≤	O
3	O
ppb	O
in	O
drinking	O
water	O
safe	O
for	O
consumption	O
.	O

The	O
specific	O
adverse	O
human	O
health	O
effects	O
associated	O
with	O
a	O
developmental	O
atrazine	B-CHEMICAL
exposure	O
and	O
the	O
underlying	O
genetic	O
mechanisms	O
of	O
these	O
effects	O
are	O
not	O
well	O
defined	O
.	O

In	O
this	O
study	O
,	O
zebrafish	O
embryos	O
were	O
exposed	O
to	O
a	O
range	O
of	O
atrazine	B-CHEMICAL
concentrations	O
to	O
establish	O
toxicity	O
.	O

Morphological	O
,	O
transcriptomic	O
,	O
and	O
protein	O
alterations	O
were	O
then	O
assessed	O
at	O
72h	O
postfertilization	O
following	O
developmental	O
atrazine	B-CHEMICAL
exposure	O
at	O
0	O
,	O
0	O
.	O
3	O
,	O
3	O
,	O
or	O
30	O
ppb	O
.	O

A	O
significant	O
increase	O
in	O
head	O
length	O
was	O
observed	O
in	O
all	O
three	O
atrazine	B-CHEMICAL
treatments	O
.	O

Transcriptomic	O
profiles	O
revealed	O
21	O
,	O
62	O
,	O
and	O
64	O
genes	O
with	O
altered	O
expression	O
in	O
the	O
0	O
.	O
3	O
,	O
3	O
,	O
and	O
30	O
ppb	O
atrazine	B-CHEMICAL
treatments	O
,	O
respectively	O
.	O

Altered	O
genes	O
were	O
associated	O
with	O
neuroendocrine	O
and	O
reproductive	O
system	O
development	O
,	O
function	O
,	O
and	O
disease	O
;	O
cell	O
cycle	O
control	O
;	O
and	O
carcinogenesis	O
.	O

There	O
was	O
a	O
significant	O
overlap	O
(	O
42	O
genes	O
)	O
between	O
the	O
3	O
and	O
30	O
ppb	O
differentially	O
expressed	O
gene	O
lists	O
,	O
with	O
two	O
of	O
these	O
genes	O
(	O
CYP17A1	B-GENE-Y
and	O
SAMHD1	B-GENE-Y
)	O
present	O
in	O
all	O
three	O
atrazine	B-CHEMICAL
treatments	O
.	O

Increased	O
transcript	O
levels	O
were	O
translated	O
to	O
significant	O
upregulation	O
in	O
protein	O
expression	O
.	O

Overall	O
,	O
this	O
study	O
identifies	O
genetic	O
and	O
molecular	O
targets	O
altered	O
in	O
response	O
to	O
a	O
developmental	O
atrazine	B-CHEMICAL
exposure	O
to	O
further	O
define	O
the	O
biological	O
pathways	O
and	O
mechanisms	O
of	O
toxicity	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
xanthine	B-CHEMICAL
derivatives	O
on	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
4	I-GENE-Y
.	O

A	O
series	O
of	O
xanthine	B-CHEMICAL
derivatives	O
in	O
which	O
a	O
methylene	B-CHEMICAL
was	O
inserted	O
at	O
position	O
8	O
of	O
xanthine	B-CHEMICAL
scaffold	O
was	O
synthesized	O
and	O
evaluated	O
as	O
inhibitors	O
of	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
4	I-GENE-Y
(	O
DPP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

As	O
the	O
results	O
of	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
study	O
of	O
the	O
series	O
,	O
the	O
compounds	O
with	O
4	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
quinazoline	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
group	O
at	O
N	O
-	O
1	O
position	O
and	O
2	B-CHEMICAL
-	I-CHEMICAL
aminoethylaminomethyl	I-CHEMICAL
group	O
gave	O
better	O
activities	O
.	O

Compounds	O
H4	O
and	O
H9	O
showed	O
good	O
DPP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
inhibition	O
and	O
more	O
than	O
100	O
-	O
fold	O
selectivity	O
over	O
DPP	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
and	O
DPP	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
.	O

Surface	O
-	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
with	O
enhanced	O
pharmacokinetics	O
and	O
tumor	O
growth	O
inhibition	O
.	O

We	O
characterized	O
in	O
this	O
study	O
the	O
pharmacokinetics	O
and	O
antitumor	O
efficacy	O
of	O
histidine	B-CHEMICAL
-	O
lysine	B-CHEMICAL
(	O
HK	O
)	O
:	O
siRNA	O
nanoplexes	O
modified	O
with	O
PEG	B-CHEMICAL
and	O
a	O
cyclic	O
RGD	B-GENE-N
(	O
cRGD	B-GENE-N
)	O
ligand	O
targeting	O
αvβ3	B-GENE-Y
and	O
αvβ5	B-GENE-Y
integrins	I-GENE-Y
.	O

With	O
noninvasive	O
imaging	O
,	O
systemically	O
administered	O
surface	O
-	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
showed	O
nearly	O
4	O
-	O
fold	O
greater	O
blood	O
levels	O
,	O
40	O
%	O
higher	O
accumulation	O
in	O
tumor	O
tissue	O
,	O
and	O
60	O
%	O
lower	O
luciferase	O
activity	O
than	O
unmodified	O
HK	O
:	O
siRNA	O
nanoplexes	O
.	O

We	O
then	O
determined	O
whether	O
the	O
surface	O
-	O
modified	O
HK	O
:	O
siRNA	O
nanoplex	O
carrier	O
was	O
more	O
effective	O
in	O
reducing	O
MDA	O
-	O
MB	O
-	O
435	O
tumor	O
growth	O
with	O
an	O
siRNA	O
targeting	O
Raf	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Repeated	O
systemic	O
administration	O
of	O
the	O
selected	O
surface	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
targeting	O
Raf	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
showed	O
35	O
%	O
greater	O
inhibition	O
of	O
tumor	O
growth	O
than	O
unmodified	O
HK	O
:	O
siRNA	O
nanoplexes	O
and	O
60	O
%	O
greater	O
inhibition	O
of	O
tumor	O
growth	O
than	O
untreated	O
mice	O
.	O

The	O
improved	O
blood	O
pharmacokinetic	O
results	O
and	O
tumor	O
localization	O
observed	O
with	O
the	O
integrin	B-GENE-N
-	O
targeting	O
surface	O
modification	O
of	O
HK	O
:	O
siRNA	O
nanoplexes	O
correlated	O
with	O
greater	O
tumor	O
growth	O
inhibition	O
.	O

This	O
investigation	O
reveals	O
that	O
through	O
control	O
of	O
targeting	O
ligand	O
surface	O
display	O
in	O
association	O
with	O
a	O
steric	O
PEG	B-CHEMICAL
layer	O
,	O
modified	O
HK	O
:	O
siRNA	O
nanoplexes	O
show	O
promise	O
to	O
advance	O
RNAi	O
therapeutics	O
in	O
oncology	O
and	O
potentially	O
other	O
critical	O
diseases	O
.	O

Bioactivation	O
of	O
the	O
nasal	O
toxicant	O
2	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dichlorobenzonitrile	I-CHEMICAL
:	O
an	O
assessment	O
of	O
metabolic	O
activity	O
in	O
human	O
nasal	O
mucosa	O
and	O
identification	O
of	O
indicators	O
of	O
exposure	O
and	O
potential	O
toxicity	O
.	O

The	O
herbicide	O
2	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dichlorobenzonitrile	I-CHEMICAL
(	O
DCBN	B-CHEMICAL
)	O
is	O
a	O
potent	O
nasal	O
toxicant	O
in	O
rodents	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
DCBN	B-CHEMICAL
causes	O
similar	O
nasal	O
toxicity	O
in	O
humans	O
.	O

The	O
tissue	O
-	O
selective	O
toxicity	O
of	O
DCBN	B-CHEMICAL
in	O
mouse	O
nasal	O
mucosa	O
is	O
largely	O
dependent	O
on	O
target	O
tissue	O
bioactivation	O
by	O
CYP2A5	B-GENE-Y
.	O

The	O
human	O
orthologues	O
of	O
CYP2A5	B-GENE-Y
,	O
CYP2A6	B-GENE-Y
and	O
CYP2A13	B-GENE-Y
,	O
are	O
both	O
expressed	O
in	O
nasal	O
mucosa	O
and	O
are	O
capable	O
of	O
activating	O
DCBN	B-CHEMICAL
.	O

In	O
this	O
study	O
,	O
we	O
directly	O
determined	O
the	O
ability	O
of	O
human	O
nasal	O
mucosa	O
to	O
bioactivate	O
DCBN	B-CHEMICAL
.	O

We	O
also	O
tested	O
the	O
suitability	O
of	O
a	O
glutathione	B-CHEMICAL
conjugate	O
of	O
DCBN	B-CHEMICAL
(	O
GS	O
-	O
DCBN	B-CHEMICAL
)	O
or	O
its	O
derivatives	O
as	O
biomarkers	O
of	O
DCBN	B-CHEMICAL
exposure	O
and	O
nasal	O
toxicity	O
in	O
mouse	O
models	O
.	O

We	O
found	O
that	O
human	O
fetal	O
nasal	O
mucosa	O
microsomes	O
catalyze	O
the	O
formation	O
of	O
GS	O
-	O
DCBN	B-CHEMICAL
,	O
with	O
a	O
Km	O
value	O
comparable	O
to	O
that	O
of	O
adult	O
mouse	O
nasal	O
mucosa	O
microsomes	O
.	O

The	O
activity	O
of	O
the	O
human	O
nasal	O
mucosa	O
microsomes	O
was	O
inhibited	O
by	O
8	B-CHEMICAL
-	I-CHEMICAL
methoxypsoralen	I-CHEMICAL
,	O
a	O
known	O
CYP2A	B-GENE-N
inhibitor	O
.	O

GS	O
-	O
DCBN	B-CHEMICAL
and	O
its	O
metabolites	O
were	O
detected	O
in	O
the	O
nasal	O
mucosa	O
and	O
nasal	O
-	O
wash	O
fluid	O
obtained	O
from	O
DCBN	B-CHEMICAL
-	O
treated	O
mice	O
,	O
in	O
amounts	O
that	O
increased	O
with	O
escalations	O
in	O
DCBN	B-CHEMICAL
dose	O
,	O
and	O
they	O
were	O
all	O
still	O
detectable	O
at	O
24	O
h	O
after	O
a	O
DCBN	B-CHEMICAL
treatment	O
(	O
at	O
10	O
mg	O
/	O
kg	O
)	O
.	O

Further	O
studies	O
in	O
Cyp2a5	B-GENE-Y
-	O
null	O
mice	O
indicated	O
that	O
GS	O
-	O
DCBN	B-CHEMICAL
and	O
its	O
metabolites	O
in	O
nasal	O
-	O
wash	O
fluid	O
were	O
generated	O
in	O
the	O
nasal	O
mucosa	O
,	O
rather	O
than	O
in	O
other	O
organs	O
.	O

Thus	O
,	O
our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
the	O
human	O
nasal	O
mucosa	O
is	O
capable	O
of	O
bioactivating	O
DCBN	B-CHEMICAL
and	O
that	O
GS	O
-	O
DCBN	B-CHEMICAL
and	O
its	O
metabolites	O
in	O
nasal	O
-	O
wash	O
fluid	O
may	O
collectively	O
serve	O
as	O
indicators	O
of	O
DCBN	B-CHEMICAL
exposure	O
and	O
potential	O
nasal	O
toxicity	O
in	O
humans	O
.	O

Design	O
,	O
synthesis	O
,	O
and	O
structure	O
-	O
activity	O
relationship	O
studies	O
of	O
tryptanthrins	B-CHEMICAL
as	O
antitubercular	O
agents	O
.	O

The	O
natural	O
product	O
tryptanthrin	B-CHEMICAL
(	O
1a	O
)	O
represents	O
a	O
potential	O
lead	O
for	O
new	O
tuberculosis	O
(	O
TB	O
)	O
drugs	O
since	O
tryptanthrin	B-CHEMICAL
and	O
its	O
synthetic	O
analogues	O
possess	O
potent	O
in	O
vitro	O
activity	O
against	O
Mycobacterium	O
tuberculosis	O
(	O
Mtb	O
)	O
.	O

However	O
,	O
in	O
spite	O
of	O
their	O
in	O
vitro	O
activity	O
,	O
none	O
of	O
these	O
agents	O
have	O
been	O
shown	O
to	O
be	O
efficacious	O
in	O
vivo	O
against	O
animal	O
models	O
of	O
TB	O
.	O

Described	O
herein	O
are	O
syntheses	O
of	O
new	O
tryptanthrin	B-CHEMICAL
analogues	O
together	O
with	O
a	O
systematic	O
investigation	O
of	O
their	O
in	O
vitro	O
antitubercular	O
activity	O
and	O
ADME	O
properties	O
followed	O
by	O
pharmacokinetic	O
characterization	O
in	O
rodents	O
for	O
the	O
most	O
promising	O
compounds	O
.	O

Those	O
with	O
the	O
best	O
potency	O
and	O
oral	O
bioavailability	O
were	O
progressed	O
to	O
evaluations	O
of	O
efficacy	O
against	O
acute	O
murine	O
TB	O
.	O

The	O
work	O
aimed	O
to	O
prove	O
the	O
concept	O
that	O
this	O
compound	O
class	O
can	O
limit	O
growth	O
of	O
Mtb	O
during	O
infection	O
as	O
well	O
as	O
to	O
establish	O
the	O
SAR	O
for	O
in	O
vitro	O
activity	O
against	O
Mtb	O
and	O
the	O
range	O
of	O
in	O
vitro	O
ADME	O
parameters	O
for	O
this	O
class	O
of	O
natural	O
products	O
.	O

Novel	O
C	O
-	O
11	O
-	O
deoxy	O
(	O
5b	O
)	O
and	O
A	O
-	O
ring	O
-	O
saturated	O
(	O
6	O
)	O
tryptanthrin	B-CHEMICAL
analogues	O
were	O
discovered	O
that	O
maintained	O
activity	O
against	O
Mtb	O
and	O
showed	O
improved	O
solubility	O
compared	O
to	O
tryptanthrin	B-CHEMICAL
as	O
well	O
as	O
evidence	O
of	O
oral	O
bioavailability	O
in	O
rodents	O
.	O

However	O
,	O
neither	O
5b	O
nor	O
6	O
demonstrated	O
efficacy	O
against	O
acute	O
murine	O
TB	O
following	O
administration	O
at	O
doses	O
up	O
to	O
400	O
mg	O
/	O
kg	O
daily	O
for	O
4	O
weeks	O
.	O

Although	O
5b	O
and	O
6	O
failed	O
to	O
inhibit	O
replication	O
or	O
kill	O
Mtb	O
in	O
vivo	O
,	O
they	O
illuminate	O
a	O
path	O
to	O
new	O
structural	O
variations	O
of	O
the	O
tryptanthrin	B-CHEMICAL
scaffold	O
that	O
may	O
maximize	O
the	O
potential	O
of	O
this	O
class	O
of	O
compounds	O
against	O
TB	O
.	O

Anti	O
-	O
aging	O
molecule	O
,	O
Sirt1	B-GENE-Y
:	O
a	O
novel	O
therapeutic	O
target	O
for	O
diabetic	O
nephropathy	O
.	O

Caloric	O
restriction	O
prolongs	O
the	O
lifespan	O
of	O
many	O
species	O
.	O

Therefore	O
,	O
investigators	O
have	O
researched	O
the	O
usefulness	O
of	O
caloric	O
restriction	O
for	O
healthy	O
lifespan	O
extension	O
.	O

Sirt1	B-GENE-Y
,	O
an	O
NAD	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
dependent	I-GENE-N
deacetylase	I-GENE-N
,	O
was	O
identified	O
as	O
a	O
molecule	O
necessary	O
for	O
caloric	O
restriction	O
-	O
related	O
anti	O
-	O
aging	O
strategies	O
.	O

Sirt1	B-GENE-Y
functions	O
as	O
an	O
intracellular	O
energy	O
sensor	O
to	O
detect	O
the	O
concentration	O
of	O
NAD	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
and	O
controls	O
in	O
vivo	O
metabolic	O
changes	O
under	O
caloric	O
restriction	O
and	O
starvation	O
through	O
its	O
deacetylase	B-GENE-N
activity	O
to	O
many	O
targets	O
including	O
histones	B-GENE-N
,	O
nuclear	O
transcriptional	O
factors	O
,	O
and	O
enzymes	O
.	O

During	O
the	O
past	O
decade	O
,	O
investigators	O
have	O
reported	O
the	O
relationship	O
between	O
disturbance	O
of	O
Sirt1	B-GENE-Y
activation	O
and	O
the	O
onset	O
of	O
aging	O
-	O
and	O
obesity	O
-	O
associated	O
diseases	O
such	O
as	O
diabetes	O
,	O
cardiovascular	O
disease	O
and	O
neurodegenerative	O
disorders	O
.	O

Consequently	O
,	O
a	O
calorie	O
restriction	O
-	O
mimetic	O
action	O
of	O
Sirt1	B-GENE-Y
is	O
now	O
expected	O
as	O
a	O
new	O
therapy	O
for	O
these	O
diseases	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
gradually	O
clarified	O
the	O
role	O
of	O
Sirt1	B-GENE-Y
in	O
the	O
onset	O
of	O
kidney	O
disease	O
.	O

Its	O
activation	O
may	O
also	O
become	O
a	O
new	O
target	O
of	O
treatment	O
in	O
the	O
patients	O
with	O
chronic	O
kidney	O
disease	O
including	O
diabetic	O
nephropathy	O
.	O

In	O
this	O
article	O
,	O
we	O
would	O
like	O
to	O
review	O
the	O
role	O
of	O
Sirt1	B-GENE-Y
in	O
the	O
onset	O
of	O
kidney	O
disease	O
based	O
on	O
previous	O
studies	O
,	O
and	O
discuss	O
its	O
possibility	O
as	O
the	O
target	O
of	O
treatment	O
in	O
diabetic	O
nephropathy	O
.	O

Transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
β	I-GENE-Y
integrates	O
Smad	B-GENE-Y
3	I-GENE-Y
to	O
mechanistic	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
complexes	O
to	O
arrest	O
deptor	B-GENE-Y
abundance	O
for	O
glomerular	O
mesangial	O
cell	O
hypertrophy	O
.	O

In	O
many	O
renal	O
diseases	O
,	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
β	I-GENE-Y
(	O
TGFβ	B-GENE-Y
)	O
-	O
stimulated	O
canonical	O
Smad	B-GENE-Y
3	I-GENE-Y
and	O
noncanonical	O
mechanistic	B-GENE-Y
target	I-GENE-Y
of	I-GENE-Y
rapamycin	I-GENE-Y
(	O
mTOR	B-GENE-Y
)	O
promote	O
increased	O
protein	O
synthesis	O
and	O
mesangial	O
cell	O
hypertrophy	O
.	O

The	O
cellular	O
underpinnings	O
involving	O
these	O
signaling	O
molecules	O
to	O
regulate	O
mesangial	O
cell	O
hypertrophy	O
are	O
not	O
fully	O
understood	O
.	O

Deptor	B-GENE-Y
has	O
recently	O
been	O
identified	O
as	O
an	O
mTOR	B-GENE-Y
interacting	O
protein	O
and	O
functions	O
as	O
an	O
endogenous	O
inhibitor	O
of	O
the	O
kinase	B-GENE-N
activity	O
for	O
both	O
TORC1	B-GENE-Y
and	O
TORC2	B-GENE-Y
.	O

Prolonged	O
incubation	O
of	O
mesangial	O
cells	O
with	O
TGFβ	B-GENE-Y
reduced	O
the	O
levels	O
of	O
deptor	B-GENE-Y
concomitant	O
with	O
an	O
increase	O
in	O
TORC1	B-GENE-Y
and	O
TORC2	B-GENE-Y
activity	O
.	O

Sustained	O
TGFβ	B-GENE-Y
activation	O
was	O
required	O
to	O
inhibit	O
association	O
of	O
deptor	B-GENE-Y
with	O
mTOR	B-GENE-N
,	O
whereas	O
rapid	O
activation	O
had	O
no	O
effect	O
.	O

Using	O
the	O
mTOR	B-GENE-Y
inhibitor	O
PP242	B-CHEMICAL
,	I-CHEMICAL
we	O
found	O
that	O
TGFβ	B-GENE-Y
-	O
induced	O
both	O
early	O
and	O
sustained	O
activation	O
of	O
TORC1	B-GENE-Y
and	O
TORC2	B-GENE-Y
was	O
necessary	O
for	O
deptor	B-GENE-Y
suppression	O
.	O

PP242	B-CHEMICAL
-	O
induced	O
reversal	O
of	O
deptor	B-GENE-Y
suppression	O
by	O
TGFβ	B-GENE-Y
was	O
associated	O
with	O
a	O
significant	O
inhibition	O
of	O
TGFβ	B-GENE-Y
-	O
stimulated	O
protein	O
synthesis	O
and	O
hypertrophy	O
.	O

Interestingly	O
,	O
expression	O
of	O
siRNA	O
against	O
Smad	B-GENE-Y
3	I-GENE-Y
or	O
Smad	B-GENE-Y
7	I-GENE-Y
,	O
which	O
blocks	O
TGFβ	B-GENE-N
receptor	I-GENE-N
-	O
specific	O
Smad	B-GENE-Y
3	I-GENE-Y
signaling	O
,	O
prevented	O
TGFβ	B-GENE-Y
-	O
induced	O
suppression	O
of	O
deptor	B-GENE-Y
abundance	O
and	O
TORC1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activities	O
.	O

Furthermore	O
,	O
overexpression	O
of	O
Smad	B-GENE-Y
3	I-GENE-Y
decreased	O
deptor	B-GENE-Y
expression	O
similar	O
to	O
TGFβ	B-GENE-Y
stimulation	O
concomitant	O
with	O
increased	O
TORC1	B-GENE-Y
and	O
TORC2	B-GENE-Y
activities	O
.	O

Finally	O
,	O
knockdown	O
of	O
deptor	B-GENE-Y
reversed	O
Smad	B-GENE-Y
7	I-GENE-Y
-	O
mediated	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
mesangial	O
cell	O
hypertrophy	O
induced	O
by	O
TGFβ	B-GENE-Y
.	O

These	O
data	O
reveal	O
the	O
requirement	O
of	O
both	O
early	O
and	O
late	O
activation	O
of	O
mTOR	B-GENE-Y
for	O
TGFβ	B-GENE-Y
-	O
induced	O
protein	O
synthesis	O
.	O

Our	O
results	O
support	O
that	O
TGFβ	B-GENE-Y
-	O
stimulated	O
Smad	B-GENE-Y
3	I-GENE-Y
acts	O
as	O
a	O
key	O
node	O
to	O
instill	O
a	O
feedback	O
loop	O
between	O
deptor	B-GENE-Y
down	O
-	O
regulation	O
and	O
TORC1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activation	O
in	O
driving	O
mesangial	O
cell	O
hypertrophy	O
.	O

Influence	O
of	O
chain	O
length	O
and	O
double	O
bond	O
on	O
the	O
aqueous	O
behavior	O
of	O
choline	B-CHEMICAL
carboxylate	I-CHEMICAL
soaps	O
.	O

In	O
preceding	O
studies	O
,	O
we	O
demonstrated	O
that	O
choline	B-CHEMICAL
carboxylates	I-CHEMICAL
ChC	B-CHEMICAL
(	I-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
with	O
alkyl	B-CHEMICAL
chain	O
lengths	O
of	O
m	O
=	O
12	O
-	O
18	O
are	O
highly	O
water	O
-	O
soluble	O
(	O
for	O
m	O
=	O
12	O
,	O
soluble	O
up	O
to	O
93	O
wt	O
%	O
soap	O
and	O
0	O
°	O
C	O
)	O
.	O

In	O
addition	O
,	O
choline	B-CHEMICAL
soaps	O
are	O
featured	O
by	O
an	O
extraordinary	O
lyotropic	O
phase	O
behavior	O
.	O

With	O
decreasing	O
water	O
concentration	O
,	O
the	O
following	O
phases	O
were	O
found	O
:	O
micellar	O
phase	O
(	O
L	O
(	O
1	O
)	O
)	O
,	O
discontinuous	O
cubic	O
phase	O
(	O
I	O
(	O
1	O
)	O
'	O
and	O
I	O
(	O
1	O
)	O
"	O
)	O
,	O
hexagonal	O
phase	O
(	O
H	O
(	O
1	O
)	O
)	O
,	O
bicontinuous	O
cubic	O
phase	O
(	O
V	O
(	O
1	O
)	O
)	O
,	O
and	O
lamellar	O
phase	O
(	O
L	O
(	O
α	O
)	O
)	O
.	O

The	O
present	O
work	O
is	O
also	O
focused	O
on	O
the	O
lyotropic	O
phase	O
behavior	O
of	O
choline	B-CHEMICAL
soaps	O
but	O
with	O
shorter	O
alkyl	B-CHEMICAL
chains	O
or	O
different	O
alkyl	B-CHEMICAL
chain	O
properties	O
.	O

We	O
have	O
investigated	O
the	O
aqueous	O
phase	O
behavior	O
of	O
choline	B-CHEMICAL
soaps	O
with	O
C	B-CHEMICAL
(	I-CHEMICAL
8	I-CHEMICAL
)	I-CHEMICAL
and	O
C	B-CHEMICAL
(	I-CHEMICAL
10	I-CHEMICAL
)	I-CHEMICAL
chain	O
-	O
lengths	O
(	O
choline	B-CHEMICAL
octanoate	I-CHEMICAL
and	O
choline	B-CHEMICAL
decanoate	I-CHEMICAL
)	O
and	O
with	O
a	O
C	B-CHEMICAL
(	I-CHEMICAL
18	I-CHEMICAL
)	I-CHEMICAL
chain	O
-	O
length	O
with	O
a	O
cis	O
-	O
double	O
bond	O
(	O
choline	B-CHEMICAL
oleate	I-CHEMICAL
)	O
.	O

We	O
found	O
that	O
choline	B-CHEMICAL
decanoate	I-CHEMICAL
follows	O
the	O
lyotropic	O
phase	O
behavior	O
of	O
the	O
longer	O
-	O
chain	O
homologues	O
mentioned	O
above	O
.	O

Choline	B-CHEMICAL
octanoate	I-CHEMICAL
in	O
water	O
shows	O
no	O
discontinuous	O
cubic	O
phases	O
,	O
but	O
an	O
extended	O
,	O
isotropic	O
micellar	O
solution	O
phase	O
.	O

In	O
addition	O
,	O
choline	B-CHEMICAL
octanoate	I-CHEMICAL
is	O
at	O
the	O
limit	O
between	O
a	O
surfactant	O
and	O
a	O
hydrotrope	O
.	O

The	O
double	O
bond	O
in	O
choline	B-CHEMICAL
oleate	I-CHEMICAL
leads	O
also	O
to	O
a	O
better	O
solubility	O
in	O
water	O
and	O
a	O
decrease	O
of	O
the	O
solubilization	O
temperature	O
.	O

It	O
also	O
influences	O
the	O
Gaussian	O
curvature	O
of	O
the	O
aggregates	O
which	O
results	O
in	O
a	O
loss	O
of	O
discontinuous	O
cubic	O
phases	O
in	O
the	O
binary	O
phase	O
diagram	O
.	O

The	O
different	O
lyotropic	O
mesophases	O
were	O
identified	O
by	O
the	O
penetration	O
scan	O
technique	O
with	O
polarizing	O
light	O
microscope	O
and	O
visual	O
observations	O
.	O

To	O
clarify	O
the	O
structural	O
behavior	O
small	O
(	O
SAXS	O
)	O
and	O
wide	O
(	O
WAXS	O
)	O
angle	O
X	O
-	O
ray	O
scattering	O
were	O
performed	O
.	O

To	O
further	O
characterize	O
the	O
extended	O
,	O
isotropic	O
micellar	O
solution	O
phase	O
in	O
the	O
binary	O
phase	O
diagram	O
of	O
choline	B-CHEMICAL
octanoate	I-CHEMICAL
viscosity	O
and	O
conductivity	O
measurements	O
were	O
also	O
carried	O
out	O
.	O

Resistance	O
to	O
conventional	O
insecticides	O
in	O
Pakistani	O
populations	O
of	O
Musca	O
domestica	O
L	O
.	O

(	O
Diptera	O
:	O
Muscidae	O
)	O
:	O
a	O
potential	O
ectoparasite	O
of	O
dairy	O
animals	O
.	O

The	O
house	O
fly	O
,	O
Musca	O
domestica	O
L	O
.	O
,	O
is	O
an	O
important	O
hygienic	O
pest	O
of	O
humans	O
and	O
dairy	O
animals	O
with	O
the	O
potential	O
to	O
develop	O
resistance	O
to	O
most	O
chemical	O
classes	O
of	O
insecticides	O
.	O

Six	O
adult	O
house	O
fly	O
strains	O
from	O
dairy	O
farms	O
in	O
Punjab	O
,	O
Pakistan	O
were	O
evaluated	O
for	O
resistance	O
to	O
selected	O
insecticides	O
from	O
organochlorine	B-CHEMICAL
,	O
organophosphate	B-CHEMICAL
,	O
carbamate	B-CHEMICAL
and	O
pyrethroid	B-CHEMICAL
classes	O
.	O

For	O
a	O
chlorocyclodiene	B-CHEMICAL
and	O
two	O
organophosphates	B-CHEMICAL
tested	O
,	O
the	O
resistance	O
ratios	O
(	O
RR	O
)	O
at	O
LC50	O
were	O
in	O
the	O
range	O
of	O
5	O
.	O
60	O
-	O
22	O
.	O
02	O
fold	O
for	O
endosulfan	B-CHEMICAL
,	O
7	O
.	O
66	O
-	O
23	O
.	O
24	O
fold	O
for	O
profenofos	O
and	O
2	O
.	O
47	O
-	O
7	O
.	O
44	O
fold	O
for	O
chlorpyrifos	B-CHEMICAL
.	O

For	O
two	O
pyrethroids	B-CHEMICAL
and	O
one	O
carbamate	B-CHEMICAL
,	O
the	O
RR	O
values	O
at	O
LC50	O
were	O
30	O
.	O
22	O
-	O
70	O
.	O
02	O
for	O
cypermethrin	B-CHEMICAL
,	O
5	O
.	O
73	O
-	O
18	O
.	O
31	O
for	O
deltamethrin	B-CHEMICAL
,	O
and	O
4	O
.	O
39	O
-	O
15	O
.	O
50	O
for	O
methomyl	B-CHEMICAL
.	O

This	O
is	O
the	O
first	O
report	O
of	O
resistance	O
to	O
different	O
classes	O
of	O
insecticides	O
in	O
Pakistani	O
dairy	O
populations	O
of	O
house	O
flies	O
.	O

Regular	O
insecticide	O
resistance	O
monitoring	O
programs	O
on	O
dairy	O
farms	O
are	O
needed	O
to	O
prevent	O
field	O
control	O
failures	O
.	O

Moreover	O
,	O
integrated	O
approaches	O
including	O
the	O
judicious	O
use	O
of	O
insecticides	O
are	O
needed	O
to	O
delay	O
the	O
development	O
of	O
insecticide	O
resistance	O
in	O
house	O
flies	O
.	O

REMNANT	O
UPTAKE	O
AS	O
A	O
POSTOPERATIVE	O
ONCOLOGIC	O
QUALITY	O
INDICATOR	O
.	O

BACKGROUND	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
utility	O
of	O
remnant	O
uptake	O
on	O
postoperative	O
radioiodine	B-CHEMICAL
scans	O
as	O
an	O
oncologic	O
indicator	O
after	O
thyroidectomy	O
for	O
differentiated	O
thyroid	O
cancer	O
(	O
DTC	O
)	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
review	O
of	O
patients	O
undergoing	O
total	O
thyroidectomy	O
for	O
DTC	O
and	O
subsequent	O
radioactive	O
iodine	B-CHEMICAL
(	O
RAI	O
)	O
treatment	O
.	O

Of	O
the	O
eight	O
surgeons	O
included	O
,	O
three	O
were	O
considered	O
high	O
volume	O
,	O
performing	O
at	O
least	O
20	O
thyroidectomies	O
per	O
year	O
.	O

Patients	O
with	O
distant	O
metastases	O
at	O
diagnosis	O
or	O
poorly	O
differentiated	O
variants	O
were	O
excluded	O
.	O

To	O
control	O
for	O
the	O
effect	O
of	O
varying	O
RAI	O
doses	O
,	O
the	O
remnant	O
uptake	O
was	O
analyzed	O
as	O
a	O
ratio	O
of	O
the	O
percentage	O
uptake	O
to	O
the	O
dose	O
received	O
(	O
uptake	O
to	O
dose	O
ratio	O
,	O
UDR	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
was	O
used	O
to	O
determine	O
the	O
influence	O
of	O
UDR	O
on	O
recurrence	O
.	O

RESULTS	O
:	O
Of	O
the	O
223	O
patients	O
who	O
met	O
inclusion	O
criteria	O
,	O
21	O
patients	O
(	O
9	O
.	O
42	O
%	O
)	O
experienced	O
a	O
recurrence	O
.	O

Those	O
who	O
recurred	O
had	O
a	O
ten	O
-	O
fold	O
higher	O
UDR	O
compared	O
to	O
those	O
who	O
did	O
not	O
recur	O
(	O
0	O
.	O
030	O
vs	O
.	O
0	O
.	O
003	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
.	O

Similarly	O
,	O
patients	O
with	O
increasing	O
postoperative	O
thyroglobulin	B-GENE-Y
measurements	O
(	O
0	O
.	O
339	O
vs	O
.	O
0	O
.	O
003	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
also	O
had	O
significantly	O
greater	O
UDRs	O
compared	O
to	O
those	O
with	O
stable	O
thyroglobulin	B-GENE-Y
.	O

The	O
UDRs	O
of	O
high	O
volume	O
surgeons	O
were	O
significantly	O
smaller	O
than	O
low	O
volume	O
surgeons	O
(	O
0	O
.	O
003	O
vs	O
.	O
0	O
.	O
025	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

When	O
combined	O
with	O
other	O
known	O
predictors	O
for	O
recurrence	O
,	O
UDR	O
(	O
OR	O
3	O
.	O
71	O
,	O
C	O
.	O
I	O
1	O
.	O
05	O
-	O
13	O
.	O
10	O
,	O
p	O
=	O
0	O
.	O
041	O
)	O
was	O
significantly	O
associated	O
with	O
recurrence	O
.	O

High	O
volume	O
surgeons	O
maintained	O
a	O
low	O
level	O
of	O
permanent	O
complications	O
across	O
all	O
UDRs	O
whereas	O
low	O
volume	O
surgeons	O
had	O
greater	O
permanent	O
complications	O
associated	O
with	O
higher	O
uptake	O
.	O

Inhibition	O
of	O
monoamine	B-GENE-N
oxidase	I-GENE-N
by	O
phthalide	B-CHEMICAL
analogues	O
.	O

Based	O
on	O
recent	O
reports	O
that	O
the	O
small	O
molecules	O
,	O
isatin	B-CHEMICAL
and	O
phthalimide	B-CHEMICAL
,	O
are	O
suitable	O
scaffolds	O
for	O
the	O
design	O
of	O
high	O
potency	O
monoamine	B-GENE-N
oxidase	I-GENE-N
(	O
MAO	B-GENE-N
)	O
inhibitors	O
,	O
the	O
present	O
study	O
examines	O
the	O
MAO	B-GENE-N
inhibitory	O
properties	O
of	O
a	O
series	O
of	O
phthalide	B-CHEMICAL
[	O
2	B-CHEMICAL
-	I-CHEMICAL
benzofuran	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
(	I-CHEMICAL
3H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
]	O
analogues	O
.	O

Phthalide	B-CHEMICAL
is	O
structurally	O
related	O
to	O
isatin	B-CHEMICAL
and	O
phthalimide	B-CHEMICAL
and	O
it	O
is	O
demonstrated	O
here	O
that	O
substitution	O
at	O
C6	O
of	O
the	O
phthalide	B-CHEMICAL
moiety	O
yields	O
compounds	O
endowed	O
with	O
high	O
binding	O
affinities	O
to	O
both	O
human	B-GENE-N
MAO	I-GENE-N
isoforms	O
.	O

Among	O
the	O
nineteen	O
homologues	O
evaluated	O
,	O
the	O
lowest	O
IC	O
(	O
50	O
)	O
values	O
recorded	O
for	O
the	O
inhibition	O
of	O
MAO	B-GENE-N
-	I-GENE-N
A	I-GENE-N
and	I-GENE-N
-	I-GENE-N
B	I-GENE-N
were	O
0	O
.	O
096	O
and	O
0	O
.	O
0014	O
μM	O
,	O
respectively	O
.	O

In	O
most	O
instances	O
,	O
C6	O
-	O
substituted	O
phthalides	B-CHEMICAL
exhibit	O
MAO	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
specific	O
inhibition	O
.	O

Among	O
a	O
series	O
of	O
6	B-CHEMICAL
-	I-CHEMICAL
benzyloxyphthalides	I-CHEMICAL
bearing	O
substituents	O
on	O
the	O
para	O
position	O
of	O
the	O
phenyl	B-CHEMICAL
ring	O
the	O
general	O
order	O
of	O
potency	O
was	O
CF	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
>	O
I	B-CHEMICAL
>	O
Br	B-CHEMICAL
>	O
Cl	B-CHEMICAL
>	O
F	B-CHEMICAL
>	O
CH	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
>	O
H	B-CHEMICAL
.	O

The	O
results	O
also	O
show	O
that	O
the	O
binding	O
modes	O
of	O
representative	O
phthalides	B-CHEMICAL
are	O
reversible	O
and	O
competitive	O
at	O
both	O
MAO	B-GENE-N
isoforms	O
.	O

Based	O
on	O
these	O
data	O
,	O
C6	B-CHEMICAL
-	O
substituted	O
phthalides	B-CHEMICAL
may	O
serve	O
as	O
leads	O
for	O
the	O
development	O
of	O
therapies	O
for	O
neurodegenerative	O
disorders	O
such	O
as	O
Parkinson	O
'	O
s	O
disease	O
.	O

Discovery	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
small	O
molecules	O
that	O
block	O
the	O
human	B-GENE-N
immunoglobulin	I-GENE-N
G	I-GENE-N
-	O
human	B-GENE-Y
neonatal	I-GENE-Y
Fc	I-GENE-Y
receptor	I-GENE-Y
(	O
hIgG	B-GENE-N
-	O
hFcRn	B-GENE-Y
)	O
protein	O
-	O
protein	O
interaction	O
.	O

The	O
neonatal	B-GENE-Y
Fc	I-GENE-Y
receptor	I-GENE-Y
,	O
FcRn	B-GENE-Y
,	O
prolongs	O
the	O
half	O
-	O
life	O
of	O
IgG	B-GENE-N
in	O
the	O
serum	O
and	O
represents	O
a	O
potential	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmune	O
disease	O
.	O

Small	O
molecules	O
that	O
block	O
the	O
protein	O
-	O
protein	O
interactions	O
of	O
human	B-GENE-N
IgG	I-GENE-N
-	O
human	B-GENE-Y
FcRn	I-GENE-Y
may	O
lower	O
pathogenic	O
autoantibodies	O
and	O
provide	O
effective	O
treatment	O
.	O

A	O
novel	O
class	O
of	O
quinoxalines	B-CHEMICAL
has	O
been	O
discovered	O
as	O
antagonists	O
of	O
the	O
IgG	B-GENE-N
:	O
FcRn	B-GENE-Y
protein	O
-	O
protein	O
interaction	O
through	O
optimization	O
of	O
a	O
hit	O
derived	O
from	O
a	O
virtual	O
ligand	O
-	O
based	O
screen	O
.	O

3	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
R	I-CHEMICAL
/	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
Hydroxyvoacamine	I-CHEMICAL
,	O
a	O
potent	O
acetylcholinesterase	B-GENE-Y
inhibitor	O
from	O
Tabernaemontana	O
divaricata	O
.	O

Guided	O
by	O
the	O
acetylcholinesterase	B-GENE-Y
inhibiting	O
activity	O
,	O
the	O
bisindole	B-CHEMICAL
alkaloid	I-CHEMICAL
3	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
R	I-CHEMICAL
/	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
hydroxyvoacamine	I-CHEMICAL
was	O
isolated	O
from	O
a	O
stem	O
extract	O
of	O
Tabernaemontana	O
divaricata	O
,	O
a	O
plant	O
used	O
in	O
Thailand	O
in	O
traditional	O
rejuvenation	O
remedies	O
for	O
improving	O
the	O
memory	O
.	O

The	O
structure	O
of	O
the	O
alkaloid	O
was	O
elucidated	O
by	O
extensive	O
use	O
of	O
NMR	O
spectroscopy	O
and	O
the	O
complete	O
assignment	O
of	O
the	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
and	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
NMR	O
spectra	O
is	O
reported	O
.	O

The	O
alkaloid	O
acted	O
as	O
a	O
non	O
-	O
competitive	O
inhibitor	O
against	O
AChE	B-GENE-Y
with	O
an	O
IC50	O
value	O
of	O
7	O
.	O
00	O
±	O
1	O
.	O
99μM	O
.	O

An	O
HPLC	O
method	O
was	O
developed	O
for	O
the	O
quantitative	O
analysis	O
of	O
the	O
AChE	B-GENE-Y
inhibitor	O
.	O

It	O
suggested	O
that	O
there	O
was	O
12	O
.	O
4	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
3	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
R	I-CHEMICAL
/	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
hydroxyvoacamine	I-CHEMICAL
in	O
the	O
alkaloid	O
enriched	O
fraction	O
of	O
T	O
.	O
divaricata	O
stem	O
.	O

Hepatocytes	O
display	O
a	O
compensatory	O
survival	O
response	O
against	O
cadmium	B-CHEMICAL
toxicity	O
by	O
a	O
mechanism	O
mediated	O
by	O
EGFR	B-GENE-Y
and	O
Src	B-GENE-Y
.	O

Although	O
the	O
liver	O
is	O
a	O
cadmium	B-CHEMICAL
-	O
target	O
organ	O
,	O
hepatocyte	O
response	O
involved	O
in	O
its	O
toxicity	O
is	O
not	O
yet	O
elucidated	O
.	O

A	O
link	O
between	O
this	O
heavy	O
metal	O
treatment	O
and	O
Stat3	B-GENE-Y
signaling	O
pathways	O
was	O
examined	O
in	O
primary	O
mouse	O
hepatocytes	O
.	O

We	O
provided	O
evidence	O
of	O
a	O
novel	O
link	O
among	O
NADPH	B-GENE-N
oxidase	I-GENE-N
and	O
Stat3	B-GENE-Y
signaling	O
,	O
mediated	O
by	O
Src	B-GENE-Y
,	O
EGFR	B-GENE-Y
,	O
and	O
Erk1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
.	O

Cadmium	B-CHEMICAL
activates	O
NADPH	B-GENE-N
oxidase	I-GENE-N
.	O

ROS	O
produced	O
by	O
this	O
oxidase	B-GENE-N
activates	O
Src	B-GENE-Y
,	O
enable	O
that	O
in	O
turn	O
,	O
transactivates	O
EGFR	B-GENE-Y
that	O
activates	O
Stat3	B-GENE-Y
in	O
tyrosine	B-CHEMICAL
,	O
allowing	O
its	O
dimerization	O
.	O

Also	O
,	O
ROS	O
from	O
NADPH	B-GENE-N
oxidase	I-GENE-N
favors	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activation	O
that	O
phosphorylates	O
Stat3	B-GENE-Y
in	O
serine	B-CHEMICAL
,	O
resulting	O
in	O
a	O
compensatory	O
or	O
adaptive	O
survival	O
response	O
such	O
as	O
production	O
of	O
metallothionein	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
in	O
short	O
Cd	B-CHEMICAL
exposure	O
times	O
.	O

However	O
,	O
after	O
12h	O
CdCl2	B-CHEMICAL
treatment	O
,	O
cell	O
viability	O
diminished	O
in	O
50	O
%	O
,	O
accompanied	O
by	O
a	O
drastic	O
decrease	O
of	O
metallothionein	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
production	O
,	O
and	O
an	O
increase	O
in	O
p53	B-GENE-Y
activation	O
and	O
the	O
pro	O
-	O
apoptotic	O
protein	O
Bax	B-GENE-Y
.	O

Catalpol	B-CHEMICAL
suppresses	O
advanced	O
glycation	O
end	O
-	O
products	O
-	O
induced	O
inflammatory	O
responses	O
through	O
inhibition	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
in	O
human	O
monocytic	O
THP	O
-	O
1	O
cells	O
.	O

Advanced	O
glycation	O
end	O
-	O
products	O
(	O
AGEs	O
)	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
development	O
of	O
diabetic	O
complications	O
by	O
inducing	O
inflammation	O
.	O

We	O
previously	O
reported	O
that	O
the	O
fresh	O
roots	O
of	O
Rehmannia	O
glutinosa	O
Libosch	O
.	O
,	O
which	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
in	O
traditional	O
Korean	O
medicine	O
,	O
also	O
have	O
the	O
potential	O
to	O
suppress	O
AGE	O
-	O
mediated	O
inflammatory	O
response	O
in	O
THP	O
-	O
1	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
isolated	O
catalpol	B-CHEMICAL
from	O
R	O
.	O
glutinosa	O
,	O
and	O
examined	O
whether	O
it	O
has	O
anti	O
-	O
inflammatory	O
effects	O
on	O
AGE	O
-	O
stimulated	O
THP	O
-	O
1	O
cells	O
.	O

Catalpol	B-CHEMICAL
reduced	O
the	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediates	O
,	O
such	O
as	O
monocyte	B-GENE-Y
chemotactic	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
inducible	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
,	O
and	O
receptor	B-GENE-Y
for	I-GENE-Y
AGE	I-GENE-Y
(	O
RAGE	B-GENE-Y
)	O
.	O

Promoter	O
and	O
electromobility	O
shift	O
assays	O
showed	O
that	O
transcriptional	O
activation	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
was	O
significantly	O
reduced	O
by	O
catalpol	B-CHEMICAL
treatment	O
,	O
while	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
was	O
not	O
.	O

Catalpol	B-CHEMICAL
also	O
suppressed	O
AGE	O
-	O
induced	O
phosphorylation	O
of	O
mitogen	B-GENE-N
activated	I-GENE-N
protein	I-GENE-N
(	I-GENE-N
MAP	I-GENE-N
)	I-GENE-N
kinases	I-GENE-N
,	O
degradation	O
of	O
IκBα	B-GENE-Y
and	O
the	O
nuclear	O
localization	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
.	O

Moreover	O
,	O
the	O
production	O
of	O
intracellular	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
elicited	O
by	O
AGE	O
was	O
also	O
suppressed	O
by	O
catalpol	B-CHEMICAL
treatment	O
,	O
through	O
dual	O
action	O
of	O
reducing	O
ROS	O
itself	O
and	O
inhibiting	O
NADPH	B-GENE-N
oxidase	I-GENE-N
activity	O
.	O

Our	O
findings	O
indicate	O
that	O
catalpol	B-CHEMICAL
suppresses	O
AGE	O
-	O
mediated	O
inflammation	O
by	O
inhibiting	O
ROS	O
production	O
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activity	O
.	O

We	O
suggest	O
that	O
catalpol	B-CHEMICAL
,	O
a	O
major	O
constituent	O
of	O
the	O
fresh	O
roots	O
of	O
R	O
.	O
glutinosa	O
,	O
contributes	O
to	O
the	O
prevention	O
of	O
AGE	O
-	O
mediated	O
diabetic	O
complications	O
.	O

3D	O
Organotypic	O
Cultures	O
of	O
Human	O
HepaRG	O
Cells	O
:	O
A	O
Tool	O
for	O
In	O
Vitro	O
Toxicity	O
Studies	O
.	O

Drug	O
-	O
induced	O
human	O
hepatotoxicity	O
is	O
difficult	O
to	O
predict	O
using	O
the	O
current	O
in	O
vitro	O
systems	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
3D	O
organotypic	O
cultures	O
of	O
the	O
human	O
hepatoma	O
HepaRG	O
cell	O
line	O
were	O
prepared	O
using	O
a	O
high	O
-	O
throughput	O
hanging	O
drop	O
method	O
.	O

The	O
organotypic	O
cultures	O
were	O
maintained	O
for	O
3	O
weeks	O
and	O
assessed	O
for	O
(	O
1	O
)	O
liver	O
specific	O
functions	O
,	O
including	O
phase	O
I	O
enzyme	O
and	O
transporter	O
activities	O
,	O
(	O
2	O
)	O
expression	O
of	O
liver	O
-	O
specific	O
proteins	O
,	O
and	O
(	O
3	O
)	O
responses	O
to	O
three	O
drugs	O
(	O
acetaminophen	B-CHEMICAL
,	O
troglitazone	B-CHEMICAL
,	O
and	O
rosiglitazone	B-CHEMICAL
)	O
.	O

Our	O
results	O
show	O
that	O
the	O
organotypic	O
cultures	O
maintain	O
high	O
liver	O
-	O
specific	O
functionality	O
during	O
3	O
weeks	O
of	O
culture	O
.	O

The	O
immunohistochemistry	O
analyses	O
illustrate	O
that	O
the	O
organotypic	O
cultures	O
express	O
liver	O
-	O
specific	O
markers	O
such	O
as	O
albumin	B-GENE-Y
,	O
CYP3A4	B-GENE-Y
,	O
CYP2E1	B-GENE-Y
,	O
and	O
MRP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
throughout	O
the	O
cultivation	O
period	O
.	O

Accordingly	O
,	O
the	O
production	O
rates	O
of	O
albumin	B-GENE-Y
and	O
glucose	B-CHEMICAL
,	O
as	O
well	O
as	O
CYP2E1	B-GENE-Y
activity	O
,	O
were	O
significantly	O
higher	O
in	O
the	O
3D	O
versus	O
the	O
2D	O
cultures	O
.	O

Toxicity	O
studies	O
show	O
that	O
the	O
organotypic	O
cultures	O
are	O
more	O
sensitive	O
to	O
acetaminophen	B-CHEMICAL
-	O
and	O
rosiglitazone	B-CHEMICAL
-	O
induced	O
toxicity	O
but	O
less	O
sensitive	O
to	O
troglitazone	B-CHEMICAL
-	O
induced	O
toxicity	O
than	O
the	O
2D	O
cultures	O
.	O

Furthermore	O
,	O
the	O
EC50	O
value	O
(	O
2	O
.	O
7mM	O
)	O
for	O
acetaminophen	B-CHEMICAL
on	O
the	O
3D	O
cultures	O
was	O
similar	O
to	O
in	O
vivo	O
toxicity	O
.	O

In	O
summary	O
,	O
the	O
results	O
from	O
our	O
study	O
suggest	O
that	O
the	O
3D	O
organotypic	O
HepaRG	O
culture	O
is	O
a	O
promising	O
in	O
vitro	O
tool	O
for	O
more	O
accurate	O
assessment	O
of	O
acute	O
and	O
also	O
possibly	O
for	O
chronic	O
drug	O
-	O
induced	O
hepatotoxicity	O
.	O

Pancreatic	O
β	O
-	O
Cell	O
Dysfunction	O
and	O
Risk	O
of	O
New	O
-	O
Onset	O
Diabetes	O
After	O
Kidney	O
Transplantation	O
.	O

OBJECTIVEChronic	O
exposure	O
to	O
calcineurin	B-GENE-N
inhibitors	O
and	O
corticosteroids	O
poses	O
renal	O
transplant	O
recipients	O
(	O
RTR	O
)	O
at	O
high	O
risk	O
for	O
development	O
of	O
new	O
-	O
onset	O
diabetes	O
after	O
transplantation	O
(	O
NODAT	O
)	O
.	O

Pancreatic	O
β	O
-	O
cell	O
dysfunction	O
may	O
be	O
crucial	O
to	O
the	O
pathophysiology	O
of	O
NODAT	O
and	O
specific	O
markers	O
for	O
β	O
-	O
cell	O
dysfunction	O
may	O
have	O
additive	O
value	O
for	O
predicting	O
NODAT	O
in	O
this	O
population	O
.	O

Therefore	O
,	O
we	O
prospectively	O
investigated	O
whether	O
proinsulin	B-GENE-Y
,	O
as	O
a	O
marker	O
of	O
pancreatic	O
β	O
-	O
cell	O
dysfunction	O
,	O
is	O
associated	O
with	O
future	O
development	O
of	O
NODAT	O
and	O
improves	O
prediction	O
of	O
it	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODSAll	O
RTR	O
between	O
2001	O
and	O
2003	O
with	O
a	O
functioning	O
graft	O
for	O
≥	O
1	O
year	O
were	O
considered	O
eligible	O
for	O
inclusion	O
,	O
except	O
for	O
subjects	O
with	O
diabetes	O
at	O
baseline	O
who	O
were	O
excluded	O
.	O

We	O
recorded	O
incidence	O
of	O
NODAT	O
until	O
April	O
2012	O
.	O
RESULTSA	O
total	O
of	O
487	O
RTR	O
(	O
age	O
50	O
±	O
12	O
years	O
,	O
55	O
%	O
men	O
)	O
participated	O
at	O
a	O
median	O
time	O
of	O
6	O
.	O
0	O
(	O
interquartile	O
range	O
[	O
IQR	O
]	O
,	O
2	O
.	O
6	O
-	O
11	O
.	O
5	O
)	O
years	O
after	O
transplantation	O
.	O

Median	O
fasting	O
proinsulin	B-GENE-Y
levels	O
were	O
16	O
.	O
6	O
(	O
IQR	O
,	O
11	O
.	O
0	O
-	O
24	O
.	O
2	O
)	O
pmol	O
/	O
L	O
.	O

During	O
median	O
follow	O
-	O
up	O
for	O
10	O
.	O
1	O
(	O
IQR	O
,	O
9	O
.	O
1	O
-	O
10	O
.	O
4	O
)	O
years	O
,	O
42	O
(	O
35	O
%	O
)	O
RTR	O
had	O
development	O
of	O
NODAT	O
in	O
the	O
highest	O
quartile	O
of	O
the	O
distribution	O
of	O
proinsulin	B-GENE-Y
versus	O
34	O
(	O
9	O
%	O
)	O
in	O
the	O
lowest	O
three	O
quartiles	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
Cox	O
regression	O
analyses	O
,	O
proinsulin	B-GENE-Y
(	O
hazard	O
ratio	O
,	O
2	O
.	O
29	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
85	O
-	O
2	O
.	O
83	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
was	O
strongly	O
associated	O
with	O
NODAT	O
development	O
.	O

This	O
was	O
independent	O
of	O
age	O
,	O
sex	O
,	O
calcineurine	B-GENE-N
inhibitors	O
,	O
prednisolone	B-CHEMICAL
use	O
,	O
components	O
of	O
the	O
metabolic	O
syndrome	O
,	O
or	O
homeostasis	O
model	O
assessment	O
.	O
CONCLUSIONSIn	O
conclusion	O
,	O
fasting	O
proinsulin	B-GENE-Y
is	O
strongly	O
associated	O
with	O
NODAT	O
development	O
in	O
RTR	O
.	O

Our	O
results	O
highlight	O
the	O
role	O
of	O
β	O
-	O
cell	O
dysfunction	O
in	O
the	O
pathophysiology	O
of	O
NODAT	O
and	O
indicate	O
the	O
potential	O
value	O
of	O
proinsulin	B-GENE-Y
for	O
identification	O
of	O
RTR	O
at	O
increased	O
risk	O
for	O
NODAT	O
.	O

Use	O
of	O
the	O
Combination	O
Index	O
to	O
determine	O
interactions	O
between	O
plant	O
-	O
derived	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
on	O
hepatotoxicity	O
endpoints	O
in	O
human	O
and	O
rat	O
hepatoma	O
cells	O
.	O

The	O
beneficial	O
or	O
adverse	O
effects	O
of	O
isolated	O
phytochemicals	O
are	O
not	O
always	O
concordant	O
with	O
effects	O
of	O
the	O
botanical	O
dietary	O
supplements	O
from	O
which	O
they	O
were	O
derived	O
.	O

This	O
disparity	O
could	O
be	O
due	O
to	O
interactions	O
between	O
the	O
various	O
phytochemicals	O
present	O
in	O
the	O
whole	O
plant	O
.	O

The	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
,	O
rosmarinic	B-CHEMICAL
acid	I-CHEMICAL
(	O
RA	O
)	O
,	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
(	O
CA	O
)	O
and	O
ferulic	B-CHEMICAL
acid	I-CHEMICAL
(	O
FA	O
)	O
are	O
widely	O
present	O
in	O
foods	O
and	O
dietary	O
supplements	O
,	O
and	O
they	O
are	O
assumed	O
to	O
exert	O
various	O
beneficial	O
biological	O
effects	O
.	O

However	O
,	O
there	O
is	O
little	O
data	O
on	O
the	O
potential	O
biological	O
interactions	O
of	O
these	O
three	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
which	O
commonly	O
occur	O
together	O
and	O
are	O
linked	O
metabolically	O
.	O

In	O
the	O
present	O
study	O
,	O
liver	O
toxicity	O
of	O
the	O
three	O
phenolic	B-CHEMICAL
acids	I-CHEMICAL
was	O
assessed	O
on	O
the	O
three	O
compounds	O
singly	O
and	O
in	O
various	O
binary	O
and	O
one	O
ternary	O
combinations	O
.	O

A	O
series	O
of	O
in	O
vitro	O
endpoints	O
relevant	O
to	O
liver	O
toxicity	O
were	O
evaluated	O
in	O
both	O
a	O
human	O
(	O
HepG2	O
/	O
C3A	O
)	O
and	O
rat	O
(	O
MH1C1	O
)	O
hepatocyte	O
cell	O
line	O
.	O

The	O
Combination	O
Index	O
(	O
CI	O
)	O
was	O
calculated	O
for	O
each	O
endpoint	O
from	O
both	O
the	O
concentration	O
responses	O
of	O
the	O
single	O
compounds	O
and	O
the	O
responses	O
of	O
the	O
various	O
binary	O
and	O
ternary	O
mixtures	O
.	O

Both	O
synergistic	O
and	O
antagonistic	O
interactions	O
were	O
observed	O
for	O
some	O
endpoints	O
and	O
some	O
combinations	O
of	O
test	O
agents	O
.	O

Interactions	O
were	O
most	O
prevalent	O
in	O
measures	O
of	O
oxidative	O
stress	O
and	O
cytochrome	B-GENE-N
P450	I-GENE-N
activities	O
in	O
both	O
cell	O
types	O
.	O

There	O
was	O
only	O
a	O
53	O
%	O
concordance	O
between	O
the	O
rat	O
and	O
human	O
cells	O
which	O
may	O
be	O
suggestive	O
of	O
species	O
differences	O
.	O

The	O
data	O
suggest	O
an	O
approach	O
for	O
better	O
characterizing	O
the	O
beneficial	O
or	O
adverse	O
effects	O
of	O
complex	O
botanical	O
products	O
through	O
evaluation	O
of	O
interactions	O
between	O
individual	O
phytochemical	O
components	O
.	O

Association	O
of	O
serum	B-GENE-Y
proprotein	I-GENE-Y
convertase	I-GENE-Y
subtilisin	I-GENE-Y
/	I-GENE-Y
kexin	I-GENE-Y
type	I-GENE-Y
9	I-GENE-Y
with	O
carotid	O
intima	O
media	O
thickness	O
in	O
hypertensive	O
subjects	O
.	O

OBJECTIVE	O
:	O
The	O
clinical	O
significance	O
of	O
the	O
measurement	O
of	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
(	O
proprotein	B-GENE-Y
subtilisin	I-GENE-Y
kexin	I-GENE-Y
type	I-GENE-Y
9	I-GENE-Y
)	O
is	O
not	O
well	O
defined	O
.	O

This	O
study	O
investigated	O
the	O
association	O
between	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
levels	O
and	O
atherosclerosis	O
assessed	O
by	O
carotid	O
intima	O
media	O
thickness	O
(	O
IMT	O
)	O
in	O
hypertensive	O
patients	O
.	O

METHODS	O
:	O
A	O
total	O
of	O
126	O
hypertensive	O
patients	O
over	O
the	O
age	O
of	O
45	O
were	O
enrolled	O
.	O

The	O
maximum	O
carotid	O
IMT	O
(	O
max	O
-	O
IMT	O
)	O
and	O
the	O
mean	O
carotid	O
IMT	O
(	O
mean	O
-	O
IMT	O
)	O
were	O
measured	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Clinical	O
and	O
laboratory	O
parameters	O
including	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
were	O
analyzed	O
.	O

RESULTS	O
:	O
Patients	O
were	O
divided	O
into	O
tertiles	O
based	O
on	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
levels	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
total	O
cholesterol	B-CHEMICAL
,	O
HDL	B-GENE-N
-	O
cholesterol	O
and	O
triglyceride	B-CHEMICAL
,	O
max	O
-	O
IMT	O
was	O
significantly	O
increased	O
in	O
the	O
highest	O
tertile	O
of	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
(	O
0	O
.	O
969	O
±	O
0	O
.	O
033	O
vs	O
0	O
.	O
959	O
±	O
0	O
.	O
033	O
vs	O
1	O
.	O
077	O
±	O
0	O
.	O
033mm	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
026	O
)	O
.	O

Mean	O
-	O
IMT	O
showed	O
a	O
tendency	O
to	O
increase	O
across	O
the	O
tertile	O
groups	O
(	O
0	O
.	O
773	O
±	O
0	O
.	O
025	O
vs	O
0	O
.	O
790	O
±	O
0	O
.	O
026	O
vs	O
0	O
.	O
856	O
±	O
0	O
.	O
025mm	O
,	O
respectively	O
;	O
P	O
=	O
0	O
.	O
059	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
revealed	O
that	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
was	O
independently	O
associated	O
with	O
carotid	O
IMT	O
(	O
max	O
-	O
IMT	O
:	O
β	O
=	O
0	O
.	O
212	O
,	O
P	O
=	O
0	O
.	O
016	O
;	O
mean	O
-	O
IMT	O
:	O
β	O
=	O
0	O
.	O
184	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

CONCLUSION	O
:	O
The	O
present	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
association	O
between	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
levels	O
and	O
carotid	O
IMT	O
in	O
hypertensive	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
serum	B-GENE-Y
PCSK9	I-GENE-Y
may	O
have	O
a	O
certain	O
role	O
in	O
early	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

Pharmacogenetics	O
of	O
Allopurinol	B-CHEMICAL
-	O
Making	O
an	O
Old	O
Drug	O
Safer	O
.	O

Allopurinol	B-CHEMICAL
is	O
a	O
drug	O
that	O
has	O
been	O
used	O
for	O
decades	O
to	O
lower	O
serum	O
urate	O
levels	O
in	O
patients	O
with	O
gout	O
or	O
chronic	O
renal	O
failure	O
and	O
in	O
cancer	O
patients	O
undergoing	O
chemotherapy	O
at	O
risk	O
of	O
tumor	O
lysis	O
syndrome	O
.	O

Patients	O
may	O
develop	O
cutaneous	O
hypersensitivity	O
reactions	O
,	O
ranging	O
from	O
mild	O
rashes	O
to	O
potentially	O
fatal	O
severe	O
cutaneous	O
adverse	O
reactions	O
(	O
SCARs	O
)	O
namely	O
drug	O
hypersensitivity	O
syndrome	O
,	O
Stevens	O
-	O
Johnson	O
syndrome	O
(	O
SJS	O
)	O
,	O
and	O
toxic	O
epidermal	O
necrolysis	O
(	O
TEN	O
)	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
the	O
association	O
between	O
human	B-GENE-Y
leukocyte	I-GENE-Y
antigen	I-GENE-Y
(	I-GENE-Y
HLA	I-GENE-Y
)	I-GENE-Y
B	I-GENE-Y
*	O
58	O
:	O
01	O
allele	O
and	O
allopurinol	B-CHEMICAL
-	O
induced	O
SCARs	O
,	O
which	O
might	O
explain	O
ethnic	O
differences	O
in	O
their	O
incidences	O
.	O

Genotyping	O
is	O
now	O
required	O
before	O
starting	O
abacavir	B-CHEMICAL
and	O
carbamazepine	B-CHEMICAL
so	O
as	O
to	O
identify	O
individuals	O
susceptible	O
to	O
SJS	O
.	O

However	O
,	O
no	O
genetic	O
screening	O
is	O
advocated	O
before	O
commencement	O
of	O
allopurinol	B-CHEMICAL
.	O

The	O
lack	O
of	O
availability	O
of	O
a	O
rapid	O
and	O
inexpensive	O
screening	O
test	O
for	O
the	O
HLA	B-GENE-Y
-	I-GENE-Y
B	I-GENE-Y
*	O
58	O
:	O
01	O
allele	O
is	O
one	O
of	O
the	O
obstacles	O
to	O
such	O
screening	O
.	O

Development	O
of	O
a	O
test	O
that	O
is	O
quick	O
,	O
accurate	O
,	O
and	O
cost	O
-	O
effective	O
is	O
warranted	O
.	O

Different	O
effects	O
of	O
clopidogrel	B-CHEMICAL
and	O
clarithromycin	B-CHEMICAL
on	O
the	O
enantioselective	O
pharmacokinetics	O
of	O
sibutramine	B-CHEMICAL
and	O
its	O
active	O
metabolites	O
in	O
healthy	O
subjects	O
.	O

In	O
this	O
study	O
,	O
we	O
assessed	O
the	O
effects	O
of	O
clopidogrel	B-CHEMICAL
and	O
clarithromycin	B-CHEMICAL
,	O
known	O
CYP2B6	B-GENE-Y
and	O
CYP3A	B-GENE-N
inhibitors	O
,	O
respectively	O
,	O
on	O
the	O
enantioselective	O
disposition	O
of	O
racemic	B-CHEMICAL
sibutramine	I-CHEMICAL
in	O
conjunction	O
with	O
CYP2B6	B-GENE-Y
polymorphisms	O
in	O
humans	O
.	O

Sibutramine	B-CHEMICAL
showed	O
enantioselective	O
plasma	O
profiles	O
with	O
consistently	O
higher	O
concentrations	O
of	O
R	O
-	O
enantiomers	O
.	O

Clopidogrel	B-CHEMICAL
and	O
clarithromycin	B-CHEMICAL
significantly	O
increased	O
the	O
sibutramine	B-CHEMICAL
plasma	O
concentration	O
,	O
but	O
their	O
effects	O
differed	O
between	O
enantiomers	O
;	O
a	O
2	O
.	O
2	O
-	O
fold	O
versus	O
4	O
.	O
1	O
-	O
fold	O
increase	O
in	O
the	O
AUC	O
in	O
S	O
-	O
enantiomer	O
and	O
1	O
.	O
8	O
-	O
fold	O
versus	O
2	O
.	O
0	O
-	O
fold	O
for	O
the	O
R	O
-	O
enantiomer	O
,	O
respectively	O
.	O

The	O
AUCs	O
of	O
S	O
-	O
and	O
R	O
-	O
desmethyl	O
metabolites	O
changed	O
significantly	O
during	O
the	O
clopidogrel	B-CHEMICAL
phase	O
(	O
P	O
<	O
.	O
001	O
and	O
P	O
<	O
.	O
001	O
,	O
respectively	O
)	O
but	O
not	O
during	O
the	O
clarithromycin	B-CHEMICAL
phase	O
(	O
P	O
=	O
.	O
099	O
and	O
P	O
=	O
.	O
090	O
,	O
respectively	O
)	O
.	O

Exposure	O
to	O
sibutramine	B-CHEMICAL
was	O
higher	O
in	O
subjects	O
with	O
the	O
CYP2B6	B-GENE-Y
*	O
6	O
/	O
*	O
6	O
genotype	O
,	O
but	O
no	O
statistical	O
difference	O
was	O
observed	O
among	O
the	O
CYP2B6	B-GENE-Y
genotypes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
enantioselective	O
disposition	O
of	O
sibutramine	B-CHEMICAL
and	O
its	O
active	O
metabolites	O
are	O
influenced	O
by	O
the	O
altered	O
genetic	O
and	O
environmental	O
factors	O
of	O
CYP2B6	B-GENE-Y
and	O
CYP3A	B-GENE-N
activity	O
in	O
vivo	O
.	O

International	O
Union	O
of	O
Pharmacology	O
.	O

LXXXVII	O
.	O

Complement	B-GENE-N
peptide	I-GENE-N
C5a	I-GENE-N
,	I-GENE-N
C4a	I-GENE-N
,	I-GENE-N
and	I-GENE-N
C3a	I-GENE-N
receptors	I-GENE-N
.	O

The	O
activation	O
of	O
the	O
complement	B-GENE-N
cascade	O
,	O
a	O
cornerstone	O
of	O
the	O
innate	O
immune	O
response	O
,	O
produces	O
a	O
number	O
of	O
small	O
(	O
74	O
-	O
77	O
amino	B-CHEMICAL
acid	I-CHEMICAL
)	O
fragments	O
,	O
originally	O
termed	O
anaphylatoxins	B-GENE-N
,	O
that	O
are	O
potent	O
chemoattractants	O
and	O
secretagogues	O
that	O
act	O
on	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

These	O
fragments	O
,	O
C5a	B-GENE-Y
,	O
C4a	B-GENE-Y
,	O
and	O
C3a	B-GENE-Y
,	O
participate	O
at	O
all	O
levels	O
of	O
the	O
immune	O
response	O
and	O
are	O
also	O
involved	O
in	O
other	O
processes	O
such	O
as	O
neural	O
development	O
and	O
organ	O
regeneration	O
.	O

Their	O
primary	O
function	O
,	O
however	O
,	O
is	O
in	O
inflammation	O
,	O
so	O
they	O
are	O
important	O
targets	O
for	O
the	O
development	O
of	O
antiinflammatory	O
therapies	O
.	O

Only	O
three	O
receptors	O
for	O
complement	O
peptides	O
have	O
been	O
found	O
,	O
but	O
there	O
are	O
no	O
satisfactory	O
antagonists	O
as	O
yet	O
,	O
despite	O
intensive	O
investigation	O
.	O

In	O
humans	O
,	O
there	O
is	O
a	O
single	O
receptor	O
for	O
C3a	B-GENE-Y
(	O
C3a	B-GENE-Y
receptor	I-GENE-Y
)	O
,	O
no	O
known	O
receptor	O
for	O
C4a	B-GENE-Y
,	O
and	O
two	O
receptors	O
for	O
C5a	B-GENE-Y
(	O
C5a₁	B-GENE-Y
receptor	I-GENE-Y
and	O
C5a₂	B-GENE-Y
receptor	I-GENE-Y
)	O
.	O

The	O
most	O
recently	O
characterized	O
receptor	O
,	O
the	O
C5a₂	B-GENE-Y
receptor	O
(	O
previously	O
known	O
as	O
C5L2	B-GENE-Y
or	O
GPR77	B-GENE-Y
)	O
,	O
has	O
been	O
regarded	O
as	O
a	O
passive	O
binding	O
protein	O
,	O
but	O
signaling	O
activities	O
are	O
now	O
ascribed	O
to	O
it	O
,	O
so	O
we	O
propose	O
that	O
it	O
be	O
formally	O
identified	O
as	O
a	O
receptor	O
and	O
be	O
given	O
a	O
name	O
to	O
reflect	O
this	O
.	O

Here	O
,	O
we	O
describe	O
the	O
complex	O
biology	O
of	O
the	O
complement	O
peptides	O
,	O
introduce	O
a	O
new	O
suggested	O
nomenclature	O
,	O
and	O
review	O
our	O
current	O
knowledge	O
of	O
receptor	O
pharmacology	O
.	O

Robust	O
array	O
-	O
based	O
coregulator	O
binding	O
assay	O
predicting	O
ERα	B-GENE-Y
-	O
agonist	O
potency	O
and	O
generating	O
binding	O
profiles	O
reflecting	O
ligand	O
structure	O
.	O

Testing	O
chemicals	O
for	O
their	O
endocrine	O
-	O
disrupting	O
potential	O
,	O
including	O
interference	O
with	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
(	O
ER	B-GENE-Y
)	O
signaling	O
,	O
is	O
an	O
important	O
aspect	O
of	O
chemical	O
safety	O
testing	O
.	O

Because	O
of	O
the	O
practical	O
drawbacks	O
of	O
animal	O
testing	O
,	O
the	O
development	O
of	O
in	O
vitro	O
alternatives	O
for	O
the	O
uterotrophic	O
assay	O
and	O
other	O
in	O
vivo	O
(	O
anti	O
)	O
estrogenicity	O
tests	O
has	O
high	O
priority	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
an	O
in	O
vitro	O
assay	O
that	O
profiles	O
ligand	O
-	O
induced	O
binding	O
of	O
ERα	B-GENE-Y
to	O
a	O
microarray	O
of	O
coregulator	O
-	O
derived	O
peptides	O
might	O
be	O
a	O
valuable	O
candidate	O
for	O
a	O
panel	O
of	O
in	O
vitro	O
assays	O
aiming	O
at	O
an	O
ultimate	O
replacement	O
of	O
the	O
uterotrophic	O
assay	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
reproducibility	O
and	O
robustness	O
of	O
this	O
coregulator	O
binding	O
assay	O
was	O
determined	O
by	O
measuring	O
the	O
binding	O
profiles	O
of	O
14	O
model	O
compounds	O
that	O
are	O
recommended	O
by	O
the	O
Office	O
of	O
Prevention	O
,	O
Pesticides	O
and	O
Toxic	O
Substances	O
for	O
testing	O
laboratory	O
proficiency	O
in	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
transactivation	O
assays	O
.	O

With	O
a	O
median	O
coefficient	O
of	O
variation	O
of	O
5	O
.	O
0	O
%	O
and	O
excellent	O
correlation	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
993	O
)	O
between	O
duplicate	O
measurements	O
,	O
the	O
reproducibility	O
of	O
the	O
ERα	B-GENE-Y
-	O
coregulator	O
binding	O
assay	O
was	O
better	O
than	O
the	O
reproducibility	O
of	O
other	O
commonly	O
used	O
in	O
vitro	O
ER	B-GENE-Y
functional	O
assays	O
.	O

In	O
addition	O
,	O
the	O
coregulator	O
binding	O
assay	O
is	O
correctly	O
predicting	O
the	O
estrogenicity	O
for	O
13	O
out	O
of	O
14	O
compounds	O
tested	O
.	O

When	O
the	O
potency	O
of	O
the	O
ER	B-GENE-Y
-	O
agonists	O
to	O
induce	O
ERα	B-GENE-Y
-	O
coregulator	O
binding	O
was	O
compared	O
to	O
their	O
ER	B-GENE-Y
binding	O
affinity	O
,	O
their	O
ranking	O
was	O
similar	O
,	O
and	O
the	O
correlation	O
between	O
the	O
EC50	O
values	O
was	O
excellent	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
96	O
)	O
,	O
as	O
was	O
the	O
correlation	O
with	O
their	O
potency	O
in	O
a	O
transactivation	O
assay	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
94	O
)	O
.	O

Moreover	O
,	O
when	O
the	O
ERα	B-GENE-Y
-	O
coregulator	O
binding	O
profiles	O
were	O
hierarchically	O
clustered	O
using	O
Euclidian	O
cluster	O
distance	O
,	O
the	O
structurally	O
related	O
compounds	O
were	O
found	O
to	O
cluster	O
together	O
,	O
whereas	O
the	O
steroid	B-CHEMICAL
test	O
compounds	O
having	O
an	O
aromatic	O
A	O
-	O
ring	O
were	O
separated	O
from	O
those	O
with	O
a	O
cyclohexene	B-CHEMICAL
A	O
-	O
ring	O
.	O

We	O
concluded	O
that	O
this	O
assay	O
is	O
capable	O
of	O
distinguishing	O
ERα	B-GENE-Y
agonists	O
and	O
antagonists	O
and	O
that	O
it	O
even	O
reflects	O
the	O
structural	O
similarity	O
of	O
ERα	B-GENE-Y
agonists	O
,	O
indicating	O
a	O
potential	O
to	O
achieve	O
identification	O
and	O
classification	O
of	O
ERα	B-GENE-Y
endocrine	O
disruptors	O
with	O
high	O
fidelity	O
.	O

The	O
effect	O
of	O
inorganic	O
arsenic	B-CHEMICAL
on	O
endothelium	O
-	O
dependent	O
relaxation	O
:	O
Role	O
of	O
NADPH	B-GENE-N
oxidase	I-GENE-N
and	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
.	O

Chronic	O
arsenic	B-CHEMICAL
ingestion	O
predisposes	O
to	O
vascular	O
disease	O
,	O
but	O
underlying	O
mechanisms	O
are	O
poorly	O
understood	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
analyzed	O
the	O
effects	O
of	O
short	O
-	O
term	O
arsenite	B-CHEMICAL
exposure	O
on	O
vascular	O
function	O
and	O
endothelium	O
-	O
dependent	O
relaxation	O
.	O

Endothelium	O
-	O
dependent	O
relaxations	O
,	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
and	O
endothelium	O
derived	O
hyperpolarizing	O
factor	O
(	O
EDHF	O
)	O
-	O
type	O
,	O
were	O
studied	O
in	O
rabbit	O
iliac	O
artery	O
and	O
aortic	O
rings	O
using	O
the	O
G	B-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
agonist	O
acetylcholine	B-CHEMICAL
(	O
ACh	B-CHEMICAL
)	O
and	O
by	O
cyclopiazonic	B-CHEMICAL
acid	I-CHEMICAL
(	O
CPA	B-CHEMICAL
)	O
,	O
which	O
promotes	O
store	O
-	O
operated	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
entry	O
by	O
inhibiting	O
the	O
endothelial	O
SERCA	B-GENE-N
pump	O
.	O

Production	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
in	O
the	O
endothelium	O
of	O
rabbit	O
aortic	O
valve	O
leaflets	O
and	O
endothelium	O
-	O
denuded	O
RIA	O
and	O
aortic	O
rings	O
was	O
assessed	O
by	O
imaging	O
of	O
dihydroethidium	B-CHEMICAL
.	O

In	O
the	O
iliac	O
artery	O
,	O
exposure	O
to	O
100μM	O
arsenite	B-CHEMICAL
for	O
30min	O
potentiated	O
EDHF	O
-	O
type	O
relaxations	O
evoked	O
by	O
both	O
CPA	B-CHEMICAL
and	O
ACh	B-CHEMICAL
.	O

Potentiation	O
was	O
prevented	O
by	O
catalase	B-GENE-Y
,	O
the	O
catalase	B-GENE-Y
/	O
superoxide	B-GENE-N
dismutase	I-GENE-N
mimetic	O
manganese	B-CHEMICAL
porphyrin	I-CHEMICAL
and	O
the	O
NADPH	B-GENE-N
oxidase	I-GENE-N
inhibitor	O
apocynin	B-CHEMICAL
.	O

By	O
contrast	O
in	O
aortic	O
rings	O
,	O
that	O
exhibited	O
negligible	O
EDHF	O
-	O
type	O
responses	O
,	O
endothelium	O
-	O
dependent	O
NO	B-CHEMICAL
-	O
mediated	O
relaxations	O
evoked	O
by	O
CPA	B-CHEMICAL
and	O
ACh	B-CHEMICAL
were	O
unaffected	O
by	O
arsenite	B-CHEMICAL
.	O

Arsenite	B-CHEMICAL
induced	O
apocynin	B-CHEMICAL
-	O
sensitive	O
increases	O
in	O
ROS	O
production	O
in	O
the	O
aortic	O
valve	O
endothelium	O
,	O
but	O
not	O
in	O
the	O
media	O
and	O
adventitia	O
of	O
the	O
iliac	O
artery	O
and	O
aorta	O
.	O

Our	O
results	O
suggest	O
that	O
arsenite	B-CHEMICAL
can	O
potentiate	O
EDHF	O
-	O
type	O
relaxations	O
via	O
a	O
mechanism	O
that	O
is	O
dependent	O
on	O
hydrogen	B-CHEMICAL
peroxide	I-CHEMICAL
,	O
thus	O
demonstrating	O
that	O
dismutation	O
of	O
the	O
superoxide	B-CHEMICAL
anion	O
generated	O
by	O
NADPH	B-GENE-N
oxidase	I-GENE-N
can	O
potentially	O
offset	O
loss	O
of	O
NO	B-CHEMICAL
bioavailability	O
under	O
conditions	O
of	O
reduced	O
eNOS	B-GENE-Y
activity	O
.	O

By	O
contrast	O
,	O
selective	O
increases	O
in	O
endothelial	O
ROS	O
production	O
following	O
exposure	O
to	O
arsenite	B-CHEMICAL
failed	O
to	O
modify	O
relaxations	O
mediated	O
by	O
endogenous	O
NO	B-CHEMICAL
.	O

Add	O
-	O
on	O
therapy	O
with	O
the	O
DPP	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
inhibitor	O
sitagliptin	B-CHEMICAL
improves	O
glycemic	O
control	O
in	O
insulin	B-GENE-Y
-	O
treated	O
Japanese	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

The	O
effect	O
of	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	B-CHEMICAL
on	O
glycemic	O
control	O
was	O
prospectively	O
investigated	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
receiving	O
insulin	B-GENE-Y
alone	O
or	O
insulin	B-GENE-N
combined	O
with	O
oral	O
antidiabetic	O
drugs	O
.	O

Seventy	O
-	O
one	O
patients	O
were	O
evaluated	O
(	O
38	O
men	O
and	O
33	O
women	O
aged	O
63	O
.	O
9	O
±	O
10	O
.	O
2	O
years	O
)	O
.	O

They	O
were	O
divided	O
into	O
three	O
groups	O
,	O
which	O
were	O
45	O
patients	O
receiving	O
premixed	O
insulin	B-GENE-Y
twice	O
daily	O
,	O
15	O
patients	O
receiving	O
multiple	O
daily	O
insulin	B-GENE-Y
injections	O
,	O
and	O
11	O
patients	O
receiving	O
basal	O
insulin	B-GENE-Y
with	O
oral	O
antidiabetic	O
drugs	O
(	O
basal	O
insulin	B-GENE-Y
therapy	O
)	O
.	O

Concomitant	O
oral	O
drugs	O
included	O
sulfonylureas	B-CHEMICAL
,	O
α	B-GENE-N
-	I-GENE-N
glucosidase	I-GENE-N
inhibitors	O
and	O
metformin	B-CHEMICAL
.	O

The	O
hemoglobin	B-GENE-Y
A1c	I-GENE-Y
(	O
HbA1c	B-GENE-Y
)	O
of	O
all	O
patients	O
improved	O
significantly	O
from	O
8	O
.	O
1	O
±	O
1	O
.	O
2	O
%	O
to	O
7	O
.	O
6	O
±	O
1	O
.	O
1	O
%	O
after	O
12	O
weeks	O
of	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	B-CHEMICAL
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
the	O
insulin	B-GENE-Y
dosage	O
was	O
reduced	O
from	O
27	O
.	O
3	O
±	O
15	O
.	O
8	O
U	O
/	O
day	O
to	O
24	O
.	O
5	O
±	O
16	O
.	O
5	O
U	O
/	O
day	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Body	O
weight	O
did	O
not	O
change	O
after	O
the	O
start	O
of	O
concomitant	O
therapy	O
and	O
severe	O
hypoglycemia	O
was	O
not	O
observed	O
.	O

The	O
baseline	O
HbA1c	B-GENE-Y
and	O
glycated	B-GENE-Y
albumin	I-GENE-Y
levels	O
were	O
identified	O
as	O
factors	O
that	O
predicted	O
the	O
response	O
to	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	B-CHEMICAL
.	O

These	O
findings	O
suggest	O
that	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	B-CHEMICAL
can	O
be	O
expected	O
to	O
achieve	O
improvement	O
of	O
poor	O
glycemic	O
control	O
irrespective	O
of	O
a	O
patient	O
'	O
s	O
demographic	O
profile	O
.	O

Stratified	O
analysis	O
based	O
on	O
the	O
insulin	B-GENE-Y
regimen	O
revealed	O
a	O
stronger	O
antidiabetic	O
effect	O
and	O
a	O
high	O
efficacy	O
of	O
sitagliptin	B-CHEMICAL
when	O
it	O
was	O
added	O
to	O
basal	O
insulin	B-GENE-Y
therapy	O
.	O

The	O
results	O
of	O
this	O
investigation	O
confirmed	O
that	O
add	O
-	O
on	O
therapy	O
with	O
sitagliptin	B-CHEMICAL
to	O
various	O
insulin	B-GENE-Y
regimens	O
could	O
improve	O
glycemic	O
control	O
without	O
severe	O
hypoglycemia	O
and	O
/	O
or	O
weight	O
gain	O
.	O

Reversible	O
inhibition	O
of	O
human	B-GENE-N
carboxylesterases	I-GENE-N
by	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
.	O

Carboxylesterases	B-GENE-N
hydrolyze	O
esters	B-CHEMICAL
,	O
amides	B-CHEMICAL
,	O
and	O
thioesters	B-CHEMICAL
to	O
produce	O
carboxylic	B-CHEMICAL
acids	I-CHEMICAL
and	O
resulting	O
alcohols	B-CHEMICAL
,	O
amines	B-CHEMICAL
,	O
and	O
thiols	B-CHEMICAL
,	O
respectively	O
.	O

Uridine	B-GENE-N
5	I-GENE-N
'	I-GENE-N
-	I-GENE-N
diphosphate	I-GENE-N
-	I-GENE-N
glucuronosyltransferases	I-GENE-N
are	O
colocalized	O
with	O
carboxylesterases	B-GENE-N
and	O
have	O
the	O
potential	O
to	O
further	O
metabolize	O
carboxylic	B-CHEMICAL
acids	I-CHEMICAL
to	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
,	O
but	O
it	O
is	O
currently	O
unknown	O
if	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
,	O
being	O
esters	B-CHEMICAL
,	O
also	O
interact	O
with	O
carboxylesterases	B-GENE-N
.	O

Objective	O
:	O
This	O
study	O
explores	O
the	O
ability	O
of	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
to	O
act	O
as	O
substrates	O
or	O
inhibitors	O
of	O
human	B-GENE-Y
carboxylesterases	I-GENE-Y
1	I-GENE-Y
(	O
hCES1	B-GENE-Y
)	O
and	O
2	O
(	O
hCES2	B-GENE-Y
)	O
.	O

Methods	O
:	O
The	O
stability	O
of	O
six	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
in	O
the	O
presence	O
of	O
hCES1	B-GENE-Y
,	O
hCES2	B-GENE-Y
,	O
and	O
buffer	O
alone	O
(	O
100	O
mM	O
potassium	B-CHEMICAL
phosphate	I-CHEMICAL
,	O
pH	O
7	O
.	O
4	O
,	O
37	O
°	O
C	O
)	O
were	O
investigated	O
.	O

Reversible	O
inhibition	O
of	O
4	B-CHEMICAL
-	I-CHEMICAL
nitrophenyl	I-CHEMICAL
acetate	I-CHEMICAL
hydrolysis	O
by	O
the	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
was	O
also	O
studied	O
.	O

Diclofenac	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
was	O
used	O
to	O
explore	O
potential	O
time	O
-	O
dependent	O
inactivation	O
.	O

Results	O
:	O
The	O
chemical	O
stability	O
half	O
-	O
life	O
values	O
for	O
CGP	B-CHEMICAL
47292	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
diclofenac	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
naproxen	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
naproxen	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
ibuprofen	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
(	I-CHEMICAL
racemic	I-CHEMICAL
)	I-CHEMICAL
,	O
clopidogrel	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
and	O
valproate	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
were	O
found	O
to	O
be	O
0	O
.	O
252	O
,	O
0	O
.	O
537	O
,	O
0	O
.	O
996	O
,	O
1	O
.	O
77	O
,	O
3	O
.	O
67	O
,	O
5	O
.	O
02	O
,	O
and	O
15	O
.	O
2	O
hours	O
,	O
respectively	O
.	O

Diclofenac	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
clopidogrel	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
ibuprofen	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
(	B-CHEMICAL
R	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
naproxen	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
,	O
and	O
(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
naproxen	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
selectively	O
inhibited	O
hCES1	B-GENE-Y
,	O
with	O
Ki	O
values	O
of	O
4	O
.	O
32	O
±	O
0	O
.	O
47	O
,	O
24	O
.	O
8	O
±	O
4	O
.	O
2	O
,	O
355	O
±	O
38	O
,	O
468	O
±	O
21	O
,	O
707	O
±	O
64	O
µM	O
,	O
respectively	O
,	O
but	O
did	O
not	O
significantly	O
inhibit	O
hCES2	B-GENE-Y
.	O

Valproate	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
and	O
CGP	B-CHEMICAL
47292	I-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
did	O
not	O
inhibit	O
either	O
hCES	B-GENE-N
.	O

Time	O
-	O
dependent	O
inactivation	O
of	O
hCES1	B-GENE-Y
by	O
diclofenac	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
glucuronide	I-CHEMICAL
was	O
not	O
observed	O
.	O

Lastly	O
,	O
both	O
hCES1	B-GENE-Y
and	O
hCES2	B-GENE-Y
were	O
shown	O
not	O
to	O
catalyze	O
the	O
hydrolysis	O
of	O
the	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
studied	O
.	O

Conclusion	O
:	O
Drug	O
-	O
drug	O
interaction	O
studies	O
may	O
be	O
warranted	O
for	O
drugs	O
that	O
metabolize	O
to	O
acyl	B-CHEMICAL
glucuronides	I-CHEMICAL
due	O
to	O
the	O
potential	O
inhibition	O
of	O
hCESs	B-GENE-N
.	O

Apoptotic	O
cell	O
death	O
in	O
rat	O
epididymis	O
following	O
epichlorohydrin	B-CHEMICAL
treatment	O
.	O

Epichlorohydrin	B-CHEMICAL
(	O
ECH	B-CHEMICAL
)	O
is	O
an	O
antifertility	O
agent	O
that	O
acts	O
both	O
as	O
an	O
epididymal	O
toxicant	O
and	O
an	O
agent	O
capable	O
of	O
directly	O
affecting	O
sperm	O
motility	O
.	O

This	O
study	O
identified	O
the	O
time	O
course	O
of	O
apoptotic	O
cell	O
death	O
in	O
rat	O
epididymides	O
after	O
ECH	O
treatment	O
.	O

Rats	O
were	O
administrated	O
with	O
a	O
single	O
oral	O
dose	O
of	O
ECH	B-CHEMICAL
(	O
50	O
mg	O
/	O
kg	O
)	O
.	O

ECH	B-CHEMICAL
-	O
induced	O
apoptotic	O
changes	O
were	O
evaluated	O
by	O
terminal	B-GENE-Y
deoxynucleotidyl	I-GENE-Y
transferase	I-GENE-Y
dUTP	B-CHEMICAL
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
assay	O
and	O
its	O
related	O
mechanism	O
was	O
confirmed	O
by	O
Western	O
blot	O
analysis	O
and	O
colorimetric	O
assay	O
.	O

The	O
TUNEL	O
assay	O
showed	O
that	O
the	O
number	O
of	O
apoptotic	O
cells	O
increased	O
at	O
8	O
h	O
,	O
reached	O
a	O
maximum	O
level	O
at	O
12	O
h	O
,	O
and	O
then	O
decreased	O
progressively	O
.	O

The	O
Western	O
blot	O
analysis	O
demonstrated	O
no	O
significant	O
changes	O
in	O
proapoptotic	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
X	I-GENE-Y
(	O
Bax	B-GENE-Y
)	O
and	O
anti	O
-	O
apoptotic	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
during	O
the	O
time	O
course	O
of	O
the	O
study	O
.	O

However	O
,	O
phospho	B-GENE-N
-	I-GENE-N
p38	I-GENE-N
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
p	B-GENE-N
-	I-GENE-N
p38	I-GENE-N
MAPK	B-GENE-N
)	O
and	O
phospho	B-GENE-N
-	I-GENE-N
c	I-GENE-N
-	I-GENE-N
Jun	I-GENE-N
amino	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
(	O
p	B-GENE-N
-	I-GENE-N
JNK	I-GENE-N
)	O
expression	O
increased	O
at	O
8	O
-	O
24	O
h	O
.	O

Caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
activities	O
also	O
increased	O
at	O
8	O
-	O
48	O
h	O
and	O
12	O
-	O
48	O
h	O
,	O
respectively	O
,	O
in	O
the	O
same	O
manner	O
as	O
p	B-GENE-N
-	I-GENE-N
p38	I-GENE-N
MAPK	B-GENE-N
and	O
p	B-GENE-N
-	I-GENE-N
JNK	I-GENE-N
expression	O
.	O

These	O
results	O
indicate	O
that	O
ECH	O
induced	O
apoptotic	O
changes	O
in	O
rat	O
epididymides	O
and	O
that	O
the	O
apoptotic	O
cell	O
death	O
may	O
be	O
related	O
more	O
to	O
the	O
MAPK	B-GENE-N
pathway	O
than	O
to	O
the	O
mitochondrial	O
pathway	O
.	O

Protective	O
effects	O
of	O
protein	O
transduction	O
domain	O
-	O
metallothionein	B-GENE-N
fusion	O
proteins	O
against	O
hypoxia	O
-	O
and	O
oxidative	O
stress	O
-	O
induced	O
apoptosis	O
in	O
an	O
ischemia	O
/	O
reperfusion	O
rat	O
model	O
.	O

Ischemic	O
heart	O
diseases	O
caused	O
by	O
insufficient	O
oxygen	B-CHEMICAL
supply	O
to	O
the	O
cardiac	O
muscle	O
require	O
pharmaceutical	O
agents	O
for	O
the	O
prevention	O
of	O
the	O
progress	O
and	O
recurrence	O
.	O

Metallothionein	B-GENE-N
(	O
MT	B-GENE-N
)	O
has	O
a	O
potential	O
as	O
a	O
protein	O
therapeutic	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
due	O
to	O
its	O
anti	O
-	O
oxidative	O
effects	O
under	O
stressful	O
conditions	O
.	O

In	O
spite	O
of	O
its	O
therapeutic	O
potential	O
,	O
efficient	O
delivery	O
systems	O
need	O
to	O
be	O
developed	O
to	O
overcome	O
limitations	O
such	O
as	O
low	O
transduction	O
efficiency	O
,	O
instability	O
and	O
short	O
half	O
-	O
life	O
in	O
the	O
body	O
.	O

To	O
enhance	O
intra	O
-	O
cellular	O
transduction	O
efficiency	O
,	O
Tat	O
sequence	O
as	O
a	O
protein	O
transduction	O
domain	O
(	O
PTD	O
)	O
was	O
fused	O
with	O
MT	B-GENE-N
in	O
a	O
recombinant	O
method	O
.	O

Anti	O
-	O
apoptotic	O
and	O
anti	O
-	O
oxidative	O
effects	O
of	O
Tat	O
-	O
MT	B-GENE-N
fusion	O
protein	O
were	O
evaluated	O
under	O
hyperglycemia	O
and	O
hypoxia	O
stress	O
conditions	O
in	O
cultured	O
H9c2	O
cells	O
.	O

Recovery	O
of	O
cardiac	O
functions	O
by	O
anti	O
-	O
apoptotic	O
and	O
anti	O
-	O
fibrotic	O
effects	O
of	O
Tat	O
-	O
MT	B-GENE-N
was	O
confirmed	O
in	O
an	O
ischemia	O
/	O
reperfusion	O
(	O
I	O
/	O
R	O
)	O
rat	O
myocardial	O
infarction	O
model	O
.	O

Tat	O
-	O
MT	B-GENE-N
fusion	O
protein	O
effectively	O
protected	O
H9c2	O
cells	O
under	O
stressful	O
conditions	O
by	O
reducing	O
intracellular	O
ROS	O
production	O
and	O
inhibiting	O
caspase	O
-	O
3	O
activation	O
.	O

Tat	O
-	O
MT	B-GENE-N
fusion	O
protein	O
inhibited	O
apoptosis	O
,	O
reduced	O
fibrosis	O
area	O
and	O
enhanced	O
cardiac	O
functions	O
in	O
I	O
/	O
R	O
.	O

Tat	O
-	O
MT	B-GENE-N
fusion	O
protein	O
could	O
be	O
a	O
promising	O
therapeutic	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
diseases	O
.	O

Effect	O
of	O
low	O
dose	O
Bisphenol	B-CHEMICAL
A	I-CHEMICAL
on	O
the	O
early	O
differentiation	O
of	O
human	O
embryonic	O
stem	O
cells	O
into	O
mammary	O
epithelial	O
cells	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
Bisphenol	B-CHEMICAL
A	I-CHEMICAL
(	O
BPA	B-CHEMICAL
)	O
can	O
disturb	O
the	O
development	O
of	O
mammary	O
structure	O
and	O
increase	O
the	O
risk	O
of	O
breast	O
cancer	O
in	O
experimental	O
animals	O
.	O

In	O
this	O
study	O
,	O
an	O
in	O
vitro	O
model	O
of	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
differentiation	O
into	O
mammary	O
epithelial	O
cells	O
was	O
applied	O
to	O
investigate	O
the	O
effect	O
of	O
low	O
dose	O
BPA	B-CHEMICAL
on	O
the	O
early	O
stages	O
of	O
mammogenesis	O
.	O

A	O
newly	O
established	O
hESC	O
line	O
was	O
directionally	O
differentiated	O
into	O
mammary	O
epithelial	O
cells	O
by	O
a	O
well	O
-	O
established	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
culture	O
system	O
.	O

The	O
differentiated	O
mammary	O
epithelial	O
cells	O
were	O
characterized	O
by	O
immunofluorescence	O
and	O
western	O
blotting	O
assay	O
,	O
and	O
were	O
called	O
induced	O
differentiated	O
mammary	O
epithelial	O
cells	O
(	O
iDMECs	O
)	O
based	O
on	O
these	O
data	O
.	O

The	O
hESCs	O
were	O
treated	O
with	O
low	O
doses	O
of	O
BPA	B-CHEMICAL
range	O
10	O
(	O
-	O
9	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
during	O
the	O
differentiation	O
process	O
,	O
with	O
DMSO	B-CHEMICAL
as	O
the	O
solvent	O
control	O
and	O
17	B-CHEMICAL
-	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
estrodiol	I-CHEMICAL
(	O
E2	O
)	O
as	O
the	O
estrogen	O
-	O
positive	O
control	O
.	O

Our	O
results	O
showed	O
that	O
low	O
dose	O
BPA	B-CHEMICAL
and	O
E2	O
could	O
influence	O
the	O
mammosphere	O
area	O
of	O
iDMECs	O
and	O
upregulate	O
the	O
expression	O
level	O
of	O
Oct4	B-GENE-Y
and	O
Nanog	B-GENE-Y
proteins	O
,	O
while	O
only	O
BPA	B-CHEMICAL
could	O
downregulate	O
the	O
expression	O
of	O
E	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
protein	O
.	O

Taken	O
together	O
,	O
this	O
study	O
provides	O
some	O
insights	O
into	O
the	O
effects	O
of	O
low	O
dose	O
BPA	B-CHEMICAL
on	O
the	O
early	O
differentiation	O
stage	O
of	O
mammary	O
epithelial	O
cells	O
and	O
suggests	O
an	O
easier	O
canceration	O
status	O
of	O
iDMECs	O
under	O
the	O
effect	O
of	O
low	O
dose	O
BPA	B-CHEMICAL
during	O
its	O
early	O
differentiation	O
stage	O
.	O

Decreased	O
serum	O
concentrations	O
of	O
25	B-CHEMICAL
-	I-CHEMICAL
hydroxycholecalciferol	I-CHEMICAL
are	O
associated	O
with	O
increased	O
risk	O
of	O
progression	O
to	O
impaired	O
fasting	O
glucose	B-CHEMICAL
and	O
diabetes	O
.	O

OBJECTIVE	O
To	O
study	O
the	O
association	O
between	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
status	O
and	O
the	O
risk	O
of	O
incident	O
impaired	O
fasting	O
glucose	B-CHEMICAL
(	O
IFG	O
)	O
and	O
diabetes	O
in	O
a	O
population	O
-	O
based	O
cohort	O
of	O
diabetes	O
-	O
free	O
subjects	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O
In	O
a	O
historical	O
prospective	O
cohort	O
study	O
of	O
subjects	O
from	O
the	O
Clalit	O
Health	O
Services	O
database	O
,	O
which	O
includes	O
information	O
on	O
nearly	O
4	O
million	O
people	O
,	O
diabetes	O
-	O
free	O
subjects	O
aged	O
40	O
-	O
70	O
years	O
with	O
serum	O
25	B-CHEMICAL
-	I-CHEMICAL
hydroxycholecalciferol	I-CHEMICAL
(	O
25	B-CHEMICAL
-	I-CHEMICAL
OHD	I-CHEMICAL
)	O
measurements	O
available	O
were	O
followed	O
for	O
2	O
years	O
to	O
assess	O
the	O
development	O
of	O
IFG	O
and	O
diabetes	O
in	O
five	O
25	B-CHEMICAL
-	I-CHEMICAL
OHD	I-CHEMICAL
subgroups	O
:	O
≥	O
25	O
,	O
25	O
.	O
1	O
-	O
37	O
.	O
5	O
,	O
37	O
.	O
6	O
-	O
50	O
,	O
50	O
.	O
1	O
-	O
75	O
,	O
and	O
>	O
75	O
nmol	O
/	O
L	O
.	O

RESULTS	O
The	O
baseline	O
cohort	O
included	O
117	O
,	O
960	O
adults	O
:	O
83	O
,	O
526	O
normoglycemic	O
subjects	O
and	O
34	O
,	O
434	O
subjects	O
with	O
IFG	O
.	O

During	O
follow	O
-	O
up	O
,	O
8	O
,	O
629	O
subjects	O
(	O
10	O
.	O
3	O
%	O
of	O
the	O
normoglycemic	O
group	O
)	O
developed	O
IFG	O
,	O
and	O
2	O
,	O
162	O
subjects	O
(	O
1	O
.	O
8	O
%	O
of	O
the	O
total	O
cohort	O
)	O
progressed	O
to	O
diabetes	O
.	O

A	O
multivariable	O
model	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
population	O
group	O
,	O
immigrant	O
status	O
,	O
BMI	O
,	O
season	O
of	O
vitamin	B-CHEMICAL
D	I-CHEMICAL
measurement	O
,	O
LDL	B-GENE-N
and	O
HDL	B-GENE-N
cholesterol	B-CHEMICAL
,	O
triglycerides	B-CHEMICAL
,	O
estimated	O
glomerular	O
filtration	O
rate	O
,	O
history	O
of	O
hypertension	O
or	O
cardiovascular	O
disease	O
,	O
Charlson	O
comorbidity	O
index	O
,	O
smoking	O
,	O
and	O
socioeconomic	O
status	O
revealed	O
an	O
inverse	O
association	O
between	O
25	B-CHEMICAL
-	I-CHEMICAL
OHD	I-CHEMICAL
and	O
the	O
risk	O
of	O
progression	O
to	O
IFG	O
and	O
diabetes	O
.	O

The	O
odds	O
of	O
transitioning	O
from	O
normoglycemia	O
to	O
IFG	O
,	O
from	O
normoglycemia	O
to	O
diabetes	O
,	O
and	O
from	O
IFG	O
to	O
diabetes	O
in	O
subjects	O
with	O
a	O
25	B-CHEMICAL
-	I-CHEMICAL
OHD	I-CHEMICAL
level	O
≤	O
25	O
nmol	O
/	O
L	O
were	O
greater	O
than	O
those	O
of	O
subjects	O
with	O
a	O
25	B-CHEMICAL
-	I-CHEMICAL
OHD	I-CHEMICAL
level	O
>	O
75	O
nmol	O
/	O
L	O
[	O
odds	O
ratio	O
1	O
.	O
13	O
(	O
95	O
%	O
CI	O
1	O
.	O
03	O
-	O
1	O
.	O
24	O
)	O
,	O
1	O
.	O
77	O
(	O
1	O
.	O
11	O
-	O
2	O
.	O
83	O
)	O
,	O
and	O
1	O
.	O
43	O
(	O
1	O
.	O
16	O
-	O
1	O
.	O
76	O
)	O
,	O
respectively	O
]	O
.	O

CONCLUSIONS	O
Vitamin	B-CHEMICAL
D	I-CHEMICAL
deficiency	O
appears	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
the	O
development	O
of	O
IFG	O
and	O
diabetes	O
.	O

Pharmacokinetic	O
Interactions	O
between	O
Monoamine	B-GENE-Y
Oxidase	I-GENE-Y
A	I-GENE-Y
Inhibitor	O
Harmaline	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
Methoxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
Dimethyltryptamine	I-CHEMICAL
,	O
and	O
the	O
Impact	O
of	O
CYP2D6	B-GENE-Y
Status	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Methoxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
dimethyltryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
or	O
street	O
name	O
"	O
5	B-CHEMICAL
-	I-CHEMICAL
MEO	I-CHEMICAL
"	O
)	O
is	O
a	O
newer	O
designer	O
drug	O
belonging	O
to	O
a	O
group	O
of	O
naturally	O
occurring	O
indolealkylamines	B-CHEMICAL
.	O

Our	O
recent	O
study	O
has	O
demonstrated	O
that	O
coadministration	O
of	O
monoamine	B-GENE-Y
oxidase	I-GENE-Y
A	I-GENE-Y
(	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
)	O
inhibitor	O
harmaline	B-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
increases	O
systemic	O
exposure	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
(	O
2	O
mg	O
/	O
kg	O
)	O
and	O
active	O
metabolite	O
bufotenine	O
.	O

This	O
study	O
is	O
aimed	O
at	O
delineating	O
harmaline	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
pharmacokinetic	O
(	O
PK	O
)	O
interactions	O
at	O
multiple	O
dose	O
levels	O
,	O
as	O
well	O
as	O
the	O
impact	O
of	O
CYP2D6	B-GENE-Y
that	O
affects	O
harmaline	B-CHEMICAL
PK	O
and	O
determines	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
O	B-CHEMICAL
-	O
demethylation	O
to	O
produce	O
bufotenine	B-CHEMICAL
.	O

Our	O
data	O
revealed	O
that	O
inhibition	O
of	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
-	O
mediated	O
metabolic	O
elimination	O
by	O
harmaline	B-CHEMICAL
(	O
2	O
,	O
5	O
,	O
and	O
15	O
mg	O
/	O
kg	O
)	O
led	O
to	O
a	O
sharp	O
increase	O
in	O
systemic	O
and	O
cerebral	O
exposure	O
to	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
(	O
2	O
and	O
10	O
mg	O
/	O
kg	O
)	O
at	O
all	O
dose	O
combinations	O
.	O

A	O
more	O
pronounced	O
effect	O
on	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
PK	O
was	O
associated	O
with	O
greater	O
exposure	O
to	O
harmaline	B-CHEMICAL
in	O
wild	O
-	O
type	O
mice	O
than	O
CYP2D6	B-GENE-Y
-	O
humanized	O
(	O
Tg	O
-	O
CYP2D6	B-GENE-Y
)	O
mice	O
.	O

Harmaline	B-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
also	O
increased	O
blood	O
and	O
brain	O
bufotenine	B-CHEMICAL
concentrations	O
that	O
were	O
generally	O
higher	O
in	O
Tg	O
-	O
CYP2D6	B-GENE-Y
mice	O
.	O

Surprisingly	O
,	O
greater	O
harmaline	B-CHEMICAL
dose	O
(	O
15	O
mg	O
/	O
kg	O
)	O
reduced	O
bufotenine	B-CHEMICAL
levels	O
.	O

The	O
in	O
vivo	O
inhibitory	O
effect	O
of	O
harmaline	B-CHEMICAL
on	O
CYP2D6	B-GENE-Y
-	O
catalyzed	O
bufotenine	B-CHEMICAL
formation	O
was	O
confirmed	O
by	O
in	O
vitro	O
study	O
using	O
purified	O
CYP2D6	B-GENE-Y
.	O

Given	O
these	O
findings	O
,	O
a	O
unified	O
PK	O
model	O
including	O
the	O
inhibition	O
of	O
MAO	B-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
-	O
and	O
CYP2D6	B-GENE-Y
-	O
catalyzed	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
metabolism	O
by	O
harmaline	B-CHEMICAL
was	O
developed	O
to	O
describe	O
blood	O
harmaline	B-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
,	O
and	O
bufotenine	B-CHEMICAL
PK	O
profiles	O
in	O
both	O
wild	O
-	O
type	O
and	O
Tg	O
-	O
CYP2D6	B-GENE-Y
mouse	O
models	O
.	O

This	O
PK	O
model	O
may	O
be	O
further	O
employed	O
to	O
predict	O
harmaline	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
PK	O
interactions	O
at	O
various	O
doses	O
,	O
define	O
the	O
impact	O
of	O
CYP2D6	B-GENE-Y
status	O
,	O
and	O
drive	O
harmaline	B-CHEMICAL
-	O
5	B-CHEMICAL
-	I-CHEMICAL
MeO	I-CHEMICAL
-	I-CHEMICAL
DMT	I-CHEMICAL
pharmacodynamics	O
.	O

Tmem64	B-GENE-Y
modulates	O
calcium	B-CHEMICAL
signaling	O
during	O
RANKL	B-GENE-Y
-	O
mediated	O
osteoclast	O
differentiation	O
.	O

Osteoclast	O
maturation	O
and	O
function	O
primarily	O
depend	O
on	O
receptor	B-GENE-Y
activator	I-GENE-Y
of	I-GENE-Y
NF	I-GENE-Y
-	I-GENE-Y
κB	I-GENE-Y
ligand	I-GENE-Y
(	O
RANKL	B-GENE-Y
)	O
-	O
mediated	O
induction	O
of	O
nuclear	B-GENE-Y
factor	I-GENE-Y
of	I-GENE-Y
activated	I-GENE-Y
T	I-GENE-Y
cells	I-GENE-Y
c1	I-GENE-Y
(	O
NFATc1	B-GENE-Y
)	O
,	O
which	O
is	O
further	O
activated	O
via	O
increased	O
intracellular	O
calcium	B-CHEMICAL
(	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
)	O
oscillation	O
.	O

However	O
,	O
the	O
coordination	O
mechanism	O
that	O
mediates	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
oscillation	O
during	O
osteoclastogenesis	O
remains	O
ill	O
defined	O
.	O

Here	O
,	O
we	O
identified	O
transmembrane	B-GENE-Y
protein	I-GENE-Y
64	I-GENE-Y
(	O
Tmem64	B-GENE-Y
)	O
as	O
a	O
regulator	O
of	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
oscillation	O
during	O
osteoclastogenesis	O
.	O

We	O
found	O
that	O
Tmem64	B-GENE-Y
-	O
deficient	O
mice	O
exhibit	O
increased	O
bone	O
mass	O
due	O
in	O
part	O
to	O
impaired	O
osteoclast	O
formation	O
.	O

Using	O
in	O
vitro	O
osteoclast	O
culture	O
systems	O
,	O
we	O
show	O
here	O
that	O
Tmem64	O
interacts	O
with	O
sarcoplasmic	O
endoplasmic	O
reticulum	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
ATPase	O
2	O
(	O
SERCA2	O
)	O
and	O
modulates	O
its	O
activity	O
.	O

Consequently	O
,	O
Tmem64	B-GENE-Y
deficiency	O
significantly	O
diminishes	O
RANKL	B-GENE-Y
-	O
induced	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
(	O
i	O
)	O
oscillation	O
,	O
which	O
results	O
in	O
reduced	O
Ca	B-GENE-Y
(	I-GENE-Y
2	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
/	I-GENE-Y
calmodulin	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
protein	I-GENE-Y
kinases	I-GENE-Y
(	I-GENE-Y
CaMK	I-GENE-Y
)	I-GENE-Y
IV	I-GENE-Y
and	O
mitochondrial	O
ROS	O
,	O
both	O
of	O
which	O
contribute	O
to	O
achieving	O
the	O
CREB	B-GENE-N
activity	O
necessary	O
for	O
osteoclast	O
formation	O
.	O

These	O
data	O
demonstrate	O
that	O
Tmem64	B-GENE-Y
is	O
a	O
positive	O
modulator	O
of	O
osteoclast	O
differentiation	O
via	O
SERCA2	B-GENE-Y
-	O
dependent	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
signaling	O
.	O

Alcohol	B-CHEMICAL
modulates	O
expression	O
of	O
DNA	B-GENE-N
methyltranferases	I-GENE-N
and	O
methyl	B-GENE-N
CpG	I-GENE-N
-	I-GENE-N
/	I-GENE-N
CpG	I-GENE-N
domain	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
in	O
murine	O
embryonic	O
fibroblasts	O
.	O

Fetal	O
alcohol	B-CHEMICAL
syndrome	O
(	O
FAS	O
)	O
,	O
presenting	O
with	O
a	O
constellation	O
of	O
neuro	O
-	O
/	O
psychological	O
,	O
craniofacial	O
and	O
cardiac	O
abnormalities	O
,	O
occurs	O
frequently	O
in	O
offspring	O
of	O
women	O
who	O
consume	O
alcohol	B-CHEMICAL
during	O
pregnancy	O
,	O
with	O
a	O
prevalence	O
of	O
1	O
-	O
3	O
per	O
1000	O
livebirths	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
alcohol	B-CHEMICAL
alters	O
global	O
DNA	O
methylation	O
,	O
and	O
modulates	O
expression	O
of	O
the	O
DNA	B-GENE-N
methyltransferases	I-GENE-N
(	O
DNMTs	B-GENE-N
)	O
and	O
various	O
methyl	O
CpG	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
.	O

Murine	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
,	O
utilized	O
as	O
an	O
in	O
vitro	O
embryonic	O
model	O
system	O
,	O
demonstrated	O
∼	O
5	O
%	O
reduction	O
in	O
global	O
DNA	O
methylation	O
following	O
exposure	O
to	O
200mM	O
ethanol	B-CHEMICAL
.	O

In	O
addition	O
,	O
ethanol	B-CHEMICAL
induced	O
degradation	O
of	O
DNA	B-GENE-N
methyltransferases	I-GENE-N
(	O
DNMT	B-GENE-Y
-	I-GENE-Y
1	O
,	O
DNMT	B-GENE-Y
-	I-GENE-Y
3a	I-GENE-Y
,	O
and	O
DNMT	B-GENE-Y
-	I-GENE-Y
3b	I-GENE-Y
)	O
,	O
as	O
well	O
as	O
the	O
methyl	B-GENE-N
CpG	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
(	O
MeCP	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
MBD	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
MBD	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
)	O
,	O
in	O
MEF	O
cells	O
by	O
the	O
proteasomal	O
pathway	O
.	O

Such	O
degradation	O
could	O
be	O
completely	O
rescued	O
by	O
pretreatment	O
of	O
MEF	O
cells	O
with	O
the	O
proteasomal	O
inhibitor	O
,	O
MG	B-CHEMICAL
-	I-CHEMICAL
132	I-CHEMICAL
.	O

These	O
data	O
support	O
a	O
potential	O
epigenetic	O
molecular	O
mechanism	O
underlying	O
the	O
pathogenesis	O
of	O
FAS	O
during	O
mammalian	O
development	O
.	O

Impaired	O
cliff	O
avoidance	O
reaction	O
in	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
knockout	O
mice	O
.	O

RATIONALE	O
:	O
Impulsivity	O
is	O
a	O
key	O
feature	O
of	O
disorders	O
that	O
include	O
attention	O
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O

The	O
cliff	O
avoidance	O
reaction	O
(	O
CAR	O
)	O
assesses	O
maladaptive	O
impulsive	O
rodent	O
behavior	O
.	O

Dopamine	B-GENE-Y
transporter	I-GENE-Y
knockout	O
(	O
DAT	B-GENE-Y
-	O
KO	O
)	O
mice	O
display	O
features	O
of	O
ADHD	O
and	O
are	O
candidates	O
in	O
which	O
to	O
test	O
other	O
impulsive	O
phenotypes	O
.	O

OBJECTIVES	O
:	O
Impulsivity	O
of	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
was	O
assessed	O
in	O
the	O
CAR	O
paradigm	O
.	O

For	O
comparison	O
,	O
attentional	O
deficits	O
were	O
also	O
assessed	O
in	O
prepulse	O
inhibition	O
(	O
PPI	O
)	O
in	O
which	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
have	O
been	O
shown	O
to	O
exhibit	O
impaired	O
sensorimotor	O
gating	O
.	O

RESULTS	O
:	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
exhibited	O
a	O
profound	O
CAR	O
impairment	O
compared	O
to	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
.	O

As	O
expected	O
,	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
showed	O
PPI	O
deficits	O
compared	O
to	O
WT	O
mice	O
.	O

Furthermore	O
,	O
the	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
with	O
the	O
most	O
impaired	O
CAR	O
exhibited	O
the	O
most	O
severe	O
PPI	O
deficits	O
.	O

Treatment	O
with	O
methylphenidate	B-CHEMICAL
or	O
nisoxetine	B-CHEMICAL
ameliorated	O
CAR	O
impairments	O
in	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
DAT	B-GENE-Y
-	O
KO	O
mice	O
exhibit	O
impulsive	O
CAR	O
behavior	O
that	O
correlates	O
with	O
their	O
PPI	O
deficits	O
.	O

Blockade	O
of	O
monoamine	B-GENE-N
transporters	I-GENE-N
,	O
especially	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
(	O
NET	B-GENE-Y
)	O
in	O
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
,	O
may	O
contribute	O
to	O
pharmacological	O
improvement	O
of	O
impulsivity	O
in	O
these	O
mice	O
.	O

Impaired	O
function	O
of	O
prejunctional	O
adenosine	B-GENE-Y
A1	I-GENE-Y
receptors	I-GENE-Y
expressed	O
by	O
perivascular	O
sympathetic	O
nerves	O
in	O
DOCA	B-CHEMICAL
-	O
salt	O
hypertensive	O
rats	O
.	O

Increased	O
sympathetic	O
nervous	O
system	O
activity	O
contributes	O
to	O
deoxycorticosterone	B-CHEMICAL
acetate	I-CHEMICAL
(	O
DOCA	B-CHEMICAL
)	O
-	O
salt	O
hypertension	O
in	O
rats	O
.	O

ATP	B-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
(	O
NE	O
)	O
are	O
coreleased	O
from	O
perivascular	O
sympathetic	O
nerves	O
.	O

NE	O
acts	O
at	O
prejunctional	O
α2	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
(	O
α2ARs	B-GENE-N
)	O
to	O
inhibit	O
NE	O
release	O
,	O
and	O
α2AR	B-GENE-N
function	O
is	O
impaired	O
in	O
DOCA	B-CHEMICAL
-	O
salt	O
rats	O
.	O

Adenosine	B-CHEMICAL
,	O
an	O
enzymatic	O
ATP	B-CHEMICAL
degradation	O
product	O
,	O
acts	O
at	O
prejunctional	O
A1	B-GENE-Y
adenosine	I-GENE-Y
receptors	I-GENE-Y
(	O
A1Rs	B-GENE-Y
)	O
to	O
inhibit	O
NE	O
release	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
prejunctional	O
A1R	B-GENE-Y
function	O
is	O
impaired	O
in	O
sympathetic	O
nerves	O
supplying	O
mesenteric	O
arteries	O
(	O
MAs	O
)	O
and	O
veins	O
(	O
MVs	O
)	O
of	O
DOCA	B-CHEMICAL
-	O
salt	O
rats	O
.	O

Electrically	O
evoked	O
NE	O
release	O
and	O
constrictions	O
of	O
blood	O
vessels	O
were	O
studied	O
in	O
vitro	O
with	O
use	O
of	O
amperometry	O
to	O
measure	O
NE	O
oxidation	O
currents	O
and	O
video	O
microscopy	O
,	O
respectively	O
.	O

Immunohistochemical	O
methods	O
were	O
used	O
to	O
localize	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
TH	B-GENE-Y
)	O
and	O
A1Rs	B-GENE-Y
in	O
perivascular	O
sympathetic	O
nerves	O
.	O

TH	B-GENE-Y
and	O
A1Rs	B-GENE-Y
colocalized	O
to	O
perivascular	O
sympathetic	O
nerves	O
.	O

Adenosine	B-CHEMICAL
and	O
N	B-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
cyclopentyl	I-CHEMICAL
-	I-CHEMICAL
adenosine	I-CHEMICAL
(	O
CPA	B-CHEMICAL
,	O
A1R	B-GENE-Y
agonist	O
)	O
constricted	O
MVs	O
but	O
not	O
MAs	O
.	O

Adenosine	B-CHEMICAL
and	O
CPA	B-CHEMICAL
(	O
0	O
.	O
001	O
-	O
10	O
µM	O
)	O
inhibited	O
neurogenic	O
constrictions	O
and	O
NE	O
release	O
in	O
MAs	O
and	O
MVs	O
.	O

DOCA	B-CHEMICAL
-	O
salt	O
arteries	O
were	O
resistant	O
to	O
adenosine	B-CHEMICAL
and	O
CPA	B-CHEMICAL
-	O
mediated	O
inhibition	O
of	O
NE	O
release	O
and	O
constriction	O
.	O

The	O
A2A	B-GENE-Y
adenosine	I-GENE-Y
receptor	I-GENE-Y
agonist	O
CGS21680	B-CHEMICAL
(	O
C23H29N7O6	B-CHEMICAL
.	I-CHEMICAL
HCl	I-CHEMICAL
.	I-CHEMICAL
xH2O	I-CHEMICAL
)	O
(	O
0	O
.	O
001	O
-	O
0	O
.	O
1	O
μM	O
)	O
did	O
not	O
alter	O
NE	O
oxidation	O
currents	O
.	O

We	O
conclude	O
that	O
there	O
are	O
prejunctional	O
A1Rs	B-GENE-Y
in	O
arteries	O
and	O
both	O
pre	O
-	O
and	O
postjunctional	O
A1Rs	B-GENE-Y
in	O
veins	O
;	O
thus	O
,	O
adenosine	B-CHEMICAL
selectively	O
constricts	O
the	O
veins	O
.	O

Prejunctional	O
A1R	B-GENE-Y
function	O
is	O
impaired	O
in	O
arteries	O
,	O
but	O
not	O
veins	O
,	O
from	O
DOCA	B-CHEMICAL
-	O
salt	O
rats	O
.	O

Sympathetic	O
autoreceptor	O
dysfunction	O
is	O
not	O
specific	O
to	O
α2ARs	B-GENE-N
,	O
but	O
there	O
is	O
a	O
more	O
general	O
disruption	O
of	O
prejunctional	O
mechanisms	O
controlling	O
sympathetic	O
neurotransmitter	O
release	O
in	O
DOCA	B-CHEMICAL
-	O
salt	O
hypertension	O
.	O

Temperature	O
Effects	O
of	O
Sputtering	O
of	O
Langmuir	O
-	O
Blodgett	O
Multilayers	O
.	O

Time	O
-	O
of	O
-	O
flight	O
secondary	O
ion	O
mass	O
spectrometry	O
(	O
TOF	O
-	O
SIMS	O
)	O
and	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
are	O
employed	O
to	O
characterize	O
a	O
wedge	O
-	O
shaped	O
crater	O
eroded	O
by	O
a	O
40	O
keV	O
C	B-CHEMICAL
(	I-CHEMICAL
60	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
cluster	O
ion	O
beam	O
on	O
an	O
organic	O
thin	O
film	O
of	O
402	O
nm	O
of	O
barium	B-CHEMICAL
arachidate	I-CHEMICAL
(	O
AA	O
)	O
multilayers	O
prepared	O
by	O
the	O
Langmuir	O
-	O
Blodgett	O
(	O
LB	O
)	O
technique	O
.	O

Sample	O
cooling	O
to	O
90	O
K	O
was	O
used	O
to	O
help	O
reduce	O
chemical	O
damage	O
,	O
improve	O
depth	O
resolution	O
and	O
maintain	O
constant	O
erosion	O
rate	O
during	O
depth	O
profiling	O
.	O

The	O
film	O
was	O
characterized	O
at	O
90	O
K	O
,	O
135	O
K	O
,	O
165	O
K	O
,	O
205	O
K	O
,	O
265	O
K	O
and	O
300	O
K	O
.	O

It	O
is	O
shown	O
that	O
sample	O
cooling	O
to	O
205	O
K	O
or	O
lower	O
helps	O
to	O
inhibit	O
erosion	O
rate	O
decay	O
,	O
whereas	O
at	O
300	O
K	O
and	O
265	O
K	O
the	O
erosion	O
rate	O
continues	O
to	O
drop	O
after	O
250	O
nm	O
of	O
erosion	O
,	O
reaching	O
about	O
half	O
of	O
the	O
initial	O
value	O
after	O
removal	O
of	O
the	O
entire	O
film	O
.	O

Depth	O
profiles	O
are	O
acquired	O
from	O
the	O
SIMS	O
images	O
of	O
the	O
eroded	O
wedge	O
crater	O
.	O

The	O
results	O
suggest	O
that	O
sample	O
cooling	O
only	O
slightly	O
improves	O
the	O
altered	O
layer	O
thickness	O
,	O
but	O
eliminates	O
the	O
decrease	O
in	O
erosion	O
rate	O
observed	O
above	O
265	O
K	O
.	O

Toxicity	O
and	O
toxicokinetics	O
of	O
binary	O
combinations	O
of	O
petroleum	B-CHEMICAL
hydrocarbon	I-CHEMICAL
distillates	O
with	O
the	O
earthworm	O
Eisenia	O
andrei	O
.	O

Petroleum	B-CHEMICAL
hydrocarbons	I-CHEMICAL
(	O
PHCs	B-CHEMICAL
)	O
act	O
via	O
narcosis	O
and	O
are	O
expected	O
to	O
have	O
additive	O
toxicity	O
.	O

However	O
,	O
previous	O
work	O
has	O
demonstrated	O
less	O
-	O
than	O
-	O
additive	O
toxicity	O
with	O
PHC	B-CHEMICAL
distillates	O
and	O
earthworms	O
.	O

A	O
study	O
was	O
initiated	O
to	O
investigate	O
this	O
through	O
toxicity	O
and	O
toxicokinetic	O
studies	O
with	O
the	O
earthworm	O
Eisenia	O
andrei	O
.	O

Three	O
petroleum	O
distillate	O
fractions	O
,	O
F2	O
(	O
>	O
C10	B-CHEMICAL
-	I-CHEMICAL
C16	I-CHEMICAL
)	O
,	O
F3a	O
(	O
>	O
C16	B-CHEMICAL
-	I-CHEMICAL
C23	I-CHEMICAL
)	O
,	O
and	O
F3b	O
(	O
>	O
C23	B-CHEMICAL
-	I-CHEMICAL
C34	I-CHEMICAL
)	O
,	O
were	O
used	O
in	O
two	O
binary	O
combinations	O
,	O
F2F3a	O
and	O
F3aF3b	O
.	O

In	O
the	O
toxicity	O
study	O
,	O
clean	O
soil	O
was	O
spiked	O
with	O
equitoxic	O
combinations	O
of	O
the	O
two	O
distillates	O
ranging	O
from	O
0	O
.	O
5	O
to	O
2	O
.	O
5	O
toxic	O
units	O
.	O

In	O
the	O
toxicokinetic	O
study	O
,	O
a	O
binary	O
combination	O
consisting	O
of	O
one	O
concentration	O
of	O
each	O
distillate	O
was	O
used	O
.	O

On	O
a	O
soil	O
concentration	O
basis	O
,	O
the	O
toxicity	O
of	O
the	O
binary	O
combinations	O
of	O
distillates	O
was	O
less	O
than	O
additive	O
.	O

Accumulation	O
of	O
the	O
individual	O
distillates	O
,	O
however	O
,	O
was	O
generally	O
reduced	O
when	O
a	O
second	O
distillate	O
was	O
present	O
,	O
resulting	O
in	O
lower	O
body	O
burden	O
.	O

This	O
is	O
thought	O
to	O
be	O
due	O
to	O
the	O
presence	O
of	O
a	O
nonaqueous	O
-	O
phase	O
liquid	O
at	O
the	O
soil	O
concentrations	O
used	O
.	O

On	O
a	O
tissue	O
concentration	O
basis	O
,	O
toxicity	O
was	O
closer	O
to	O
additive	O
.	O

The	O
results	O
demonstrate	O
that	O
tissue	O
concentrations	O
are	O
the	O
preferred	O
metric	O
for	O
toxicity	O
for	O
earthworms	O
.	O

They	O
also	O
demonstrate	O
that	O
the	O
Canada	O
-	O
wide	O
soil	O
standards	O
based	O
on	O
individual	O
distillates	O
are	O
likely	O
protective	O
.	O

Environ	O
.	O

Toxicol	O
.	O

Chem	O
.	O

2013	O
;	O
32	O
:	O
1016	O
-	O
1026	O
.	O

©	O
2013	O
SETAC	O
.	O

Drug	O
cocktail	O
interaction	O
study	O
on	O
the	O
effect	O
of	O
the	O
orally	O
administered	O
lavender	O
oil	O
preparation	O
silexan	O
on	O
cytochrome	B-GENE-N
p450	I-GENE-N
enzymes	O
in	O
healthy	O
volunteers	O
.	O

This	O
cocktail	O
study	O
evaluated	O
the	O
interaction	O
potential	O
of	O
the	O
oral	O
lavender	O
oil	O
preparation	O
silexan	O
with	O
major	O
P450	B-GENE-N
(	O
cytochrome	B-GENE-N
P450	I-GENE-N
)	O
enzymes	O
.	O

Subjects	O
and	O
Methods	O
:	O
Sixteen	O
healthy	O
male	O
or	O
female	O
Caucasians	O
completed	O
this	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
2	O
-	O
fold	O
crossover	O
study	O
.	O

Silexan	O
(	O
160	O
mg	O
)	O
or	O
placebo	O
were	O
administered	O
once	O
daily	O
for	O
11	O
days	O
.	O

Additionally	O
,	O
on	O
day	O
11	O
of	O
both	O
study	O
periods	O
,	O
150	O
mg	O
caffeine	B-CHEMICAL
(	O
CYP1A2	B-GENE-Y
)	O
,	O
125	O
mg	O
tolbutamide	B-CHEMICAL
(	O
CYP2C9	B-GENE-Y
)	O
,	O
20	O
mg	O
omeprazole	B-CHEMICAL
(	O
CYP2C19	B-GENE-Y
)	O
,	O
30	O
mg	O
dextromethorphan	B-CHEMICAL
-	I-CHEMICAL
HBr	I-CHEMICAL
(	O
CYP2D6	B-GENE-Y
)	O
,	O
and	O
2	O
mg	O
midazolam	B-CHEMICAL
(	O
CYP3A4	B-GENE-Y
)	O
were	O
administered	O
orally	O
.	O

Formal	O
interaction	O
was	O
excluded	O
if	O
the	O
90	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
for	O
the	O
silexan	O
over	O
placebo	O
ratios	O
for	O
phenotyping	O
metrics	O
(	O
primary	O
:	O
AUC0	O
-	O
t	O
)	O
was	O
within	O
a	O
0	O
.	O
70	O
-	O
1	O
.	O
43	O
range	O
.	O

Results	O
:	O
According	O
to	O
the	O
AUC0	O
-	O
t	O
comparisons	O
,	O
silexan	O
had	O
no	O
relevant	O
effect	O
on	O
CYP1A2	B-GENE-N
,	I-GENE-N
2C9	I-GENE-N
,	I-GENE-N
2D6	I-GENE-N
,	I-GENE-N
and	I-GENE-N
3A4	I-GENE-N
activity	O
.	O

Secondary	O
phenotyping	O
metrics	O
confirmed	O
this	O
result	O
.	O

Mean	O
ratios	O
for	O
all	O
omeprazole	B-CHEMICAL
-	O
derived	O
metrics	O
were	O
close	O
to	O
unity	O
.	O

The	O
90	O
%	O
CI	O
for	O
the	O
AUC0	O
-	O
t	O
ratio	O
of	O
omeprazole	B-CHEMICAL
but	O
not	O
for	O
omeprazole	B-CHEMICAL
/	O
5	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
omeprazole	I-CHEMICAL
plasma	O
ratio	O
3	O
hours	O
post	O
-	O
dose	O
or	O
omeprazole	B-CHEMICAL
/	O
5	B-CHEMICAL
-	I-CHEMICAL
OH	I-CHEMICAL
-	I-CHEMICAL
omeprazole	I-CHEMICAL
AUC0	O
-	O
t	O
ratio	O
(	O
secondary	O
CYP2C19	B-GENE-Y
metrics	O
)	O
was	O
above	O
the	O
predefined	O
threshold	O
of	O
1	O
.	O
43	O
,	O
probably	O
caused	O
by	O
the	O
inherent	O
high	O
variability	O
of	O
omeprazole	B-CHEMICAL
pharmacokinetics	O
.	O

Silexan	O
and	O
the	O
phenotyping	O
drugs	O
were	O
well	O
tolerated	O
.	O

Repeated	O
silexan	O
(	O
160	O
mg	O
/	O
day	O
)	O
administration	O
has	O
no	O
clinically	O
relevant	O
inhibitory	O
or	O
inducing	O
effects	O
on	O
the	O
CYP1A2	B-GENE-N
,	I-GENE-N
2C9	I-GENE-N
,	I-GENE-N
2C19	I-GENE-N
,	I-GENE-N
2D6	I-GENE-N
,	I-GENE-N
and	I-GENE-N
3A4	I-GENE-N
enzymes	O
in	O
vivo	O
.	O

Role	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
in	O
the	O
chemistry	O
and	O
anticancer	O
activity	O
of	O
etoposide	B-CHEMICAL
(	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
,	I-CHEMICAL
213	I-CHEMICAL
)	O
.	O

Originally	O
identified	O
as	O
an	O
innate	O
cytotoxin	O
,	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
(	B-CHEMICAL
·	I-CHEMICAL
)	I-CHEMICAL
NO	I-CHEMICAL
)	O
formation	O
in	O
tumors	O
can	O
influence	O
chemotherapy	O
and	O
exacerbate	O
cancer	O
progression	O
.	O

Here	O
,	O
we	O
examined	O
the	O
hypothesis	O
that	O
(	B-CHEMICAL
·	I-CHEMICAL
)	I-CHEMICAL
NO	I-CHEMICAL
generation	O
contributes	O
to	O
cancer	O
cell	O
drug	O
resistance	O
toward	O
the	O
widely	O
used	O
anticancer	O
drug	O
Etoposide	B-CHEMICAL
(	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
)	O
.	O

The	O
UV	O
-	O
vis	O
spectrum	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
was	O
not	O
changed	O
by	O
exposure	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
to	O
(	B-CHEMICAL
·	I-CHEMICAL
)	I-CHEMICAL
NO	I-CHEMICAL
in	O
aqueous	O
buffer	O
.	O

In	O
contrast	O
,	O
reddish	O
-	O
orange	O
compound	O
(	O
s	O
)	O
characteristic	O
of	O
o	B-CHEMICAL
-	I-CHEMICAL
quinone	I-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
nitroso	I-CHEMICAL
-	I-CHEMICAL
VP	I-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
were	O
readily	O
generated	O
in	O
a	O
hydrophobic	O
medium	O
(	O
chloroform	B-CHEMICAL
)	O
in	O
an	O
oxygen	B-CHEMICAL
-	O
dependent	O
manner	O
.	O

Similar	O
products	O
were	O
also	O
formed	O
when	O
the	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
radical	O
,	O
generated	O
from	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
and	O
horseradish	O
peroxidase	O
/	O
H2O2	B-CHEMICAL
,	O
was	O
exposed	O
directly	O
to	O
(	B-CHEMICAL
·	I-CHEMICAL
)	I-CHEMICAL
NO	I-CHEMICAL
in	O
chloroform	B-CHEMICAL
in	O
the	O
presence	O
of	O
oxygen	B-CHEMICAL
.	O

Separation	O
and	O
spectral	O
analysis	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
reaction	O
extracts	O
by	O
electron	O
spin	O
resonance	O
and	O
UV	O
-	O
vis	O
indicated	O
the	O
generation	O
of	O
the	O
phenoxy	B-CHEMICAL
radical	O
and	O
the	O
o	B-CHEMICAL
-	I-CHEMICAL
quinone	I-CHEMICAL
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
,	O
as	O
well	O
as	O
putative	O
nitroxide	B-CHEMICAL
,	O
iminoxyl	B-CHEMICAL
,	O
and	O
other	O
nitrogen	B-CHEMICAL
oxide	I-CHEMICAL
intermediates	O
.	O

Nitric	B-CHEMICAL
oxide	I-CHEMICAL
products	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
displayed	O
significantly	O
diminished	O
topoisomerase	B-GENE-Y
II	I-GENE-Y
-	O
dependent	O
cleavage	O
of	O
DNA	O
and	O
cytotoxicity	O
to	O
human	O
HL	O
-	O
60	O
leukemia	O
cells	O
.	O

LPS	O
-	O
mediated	O
induction	O
of	O
nitric	B-GENE-N
oxide	I-GENE-N
synthase	I-GENE-N
in	O
murine	O
macrophages	O
resulted	O
in	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
resistance	O
compared	O
to	O
Raw	O
cells	O
.	O

Furthermore	O
,	O
(	B-CHEMICAL
·	I-CHEMICAL
)	I-CHEMICAL
NO	I-CHEMICAL
products	O
derived	O
from	O
iNOS	B-GENE-Y
rapidly	O
reacted	O
with	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
leading	O
to	O
decreased	O
DNA	O
damage	O
and	O
cytotoxicity	O
.	O

Together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
formation	O
of	O
(	B-CHEMICAL
·	I-CHEMICAL
)	I-CHEMICAL
NO	I-CHEMICAL
in	O
tumors	O
(	O
associated	O
macrophages	O
)	O
can	O
contribute	O
to	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
resistance	O
via	O
the	O
detoxification	O
of	O
VP	B-CHEMICAL
-	I-CHEMICAL
16	I-CHEMICAL
.	O

Hematologic	O
and	O
hepatic	O
responses	O
of	O
the	O
freshwater	O
fish	O
Hoplias	O
malabaricus	O
after	O
saxitoxin	B-CHEMICAL
exposure	O
.	O

The	O
bioaccumulation	O
of	O
saxitoxins	B-CHEMICAL
(	O
STX	B-CHEMICAL
)	O
in	O
the	O
trophic	O
chain	O
,	O
mainly	O
in	O
freshwater	O
,	O
are	O
not	O
completely	O
known	O
.	O

This	O
work	O
aimed	O
to	O
elucidate	O
the	O
effects	O
of	O
STX	B-CHEMICAL
on	O
Hoplias	O
malabaricus	O
through	O
trophic	O
bioassay	O
.	O

The	O
fish	O
were	O
fed	O
once	O
every	O
five	O
days	O
with	O
Astyanax	O
sp	O
.	O
before	O
being	O
subjected	O
to	O
an	O
intraperitoneal	O
inoculation	O
with	O
the	O
lysate	O
of	O
Cylindrospermopsis	O
raciborskii	O
culture	O
containing	O
97	O
%	O
STX	B-CHEMICAL
and	O
3	O
%	O
by	O
neosaxitoxin	B-CHEMICAL
and	O
gonyautoxin	B-CHEMICAL
during	O
20	O
days	O
.	O

The	O
animal	O
'	O
s	O
liver	O
was	O
assessed	O
using	O
biomarkers	O
as	O
activities	O
of	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
,	O
catalase	B-GENE-N
(	O
CAT	B-GENE-N
)	O
,	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
(	O
GST	B-GENE-N
)	O
,	O
and	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GPx	B-GENE-N
)	O
,	O
and	O
concentrations	O
of	O
reduced	B-CHEMICAL
glutathione	I-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
and	O
lipoperoxidation	O
(	O
LPO	O
)	O
and	O
protein	O
carbonylation	O
(	O
PCO	O
)	O
.	O

In	O
the	O
blood	O
was	O
analyzed	O
the	O
genotoxic	O
and	O
hematological	O
parameters	O
.	O

The	O
hepatosomatic	O
index	O
and	O
the	O
relative	O
condition	O
factor	O
did	O
not	O
show	O
a	O
significant	O
difference	O
between	O
the	O
exposed	O
and	O
control	O
groups	O
.	O

The	O
values	O
of	O
mean	O
corpuscular	O
hemoglobin	B-GENE-N
concentration	O
and	O
mean	O
corpuscular	O
hemoglobin	B-GENE-N
increased	O
in	O
the	O
STX	B-CHEMICAL
group	O
.	O

The	O
hepatic	O
tissue	O
from	O
both	O
groups	O
exhibited	O
a	O
typical	O
pattern	O
that	O
have	O
been	O
already	O
described	O
for	O
most	O
teleost	O
fish	O
.	O

The	O
results	O
suggested	O
the	O
generation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
,	O
with	O
increased	O
activity	O
of	O
GPx	B-GENE-N
and	O
concentrations	O
of	O
LPO	O
and	O
GSH	B-CHEMICAL
;	O
whereas	O
the	O
specific	O
activity	O
of	O
SOD	B-GENE-N
decreased	O
.	O

However	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
CAT	B-GENE-N
,	O
PCO	O
,	O
and	O
DNA	O
damage	O
.	O

Although	O
the	O
STX	B-CHEMICAL
effects	O
are	O
known	O
as	O
neurotoxic	O
,	O
this	O
cyanotoxin	O
caused	O
liver	O
biochemical	O
alterations	O
that	O
can	O
be	O
considered	O
ecologically	O
relevant	O
.	O

Antofine	B-CHEMICAL
-	O
induced	O
connexin43	B-GENE-Y
gap	O
junction	O
disassembly	O
in	O
rat	O
astrocytes	O
involves	O
protein	B-GENE-Y
kinase	I-GENE-Y
Cβ	I-GENE-Y
.	O

Antofine	B-CHEMICAL
,	O
a	O
phenanthroindolizidine	B-CHEMICAL
alkaloid	I-CHEMICAL
derived	O
from	O
Cryptocaryachinensis	O
and	O
Ficusseptica	O
in	O
the	O
Asclepiadaceae	O
milkweed	O
family	O
,	O
is	O
cytotoxic	O
for	O
various	O
cancer	O
cell	O
lines	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
treatment	O
of	O
rat	O
primary	O
astrocytes	O
with	O
antofine	B-CHEMICAL
induced	O
dose	O
-	O
dependent	O
inhibition	O
of	O
gap	O
junction	O
intercellular	O
communication	O
(	O
GJIC	O
)	O
,	O
as	O
assessed	O
by	O
scrape	O
-	O
loading	O
6	B-CHEMICAL
-	I-CHEMICAL
carboxyfluorescein	I-CHEMICAL
dye	O
transfer	O
.	O

Levels	O
of	O
Cx43	B-GENE-Y
protein	O
were	O
also	O
decreased	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
following	O
antofine	B-CHEMICAL
treatment	O
.	O

Double	O
-	O
labeling	O
immunofluorescence	O
microscopy	O
showed	O
that	O
antofine	B-CHEMICAL
(	O
10ng	O
/	O
ml	O
)	O
induced	O
endocytosis	O
of	O
surface	O
gap	O
junctions	O
into	O
the	O
cytoplasm	O
,	O
where	O
Cx43	B-GENE-Y
was	O
co	O
-	O
localized	O
with	O
the	O
early	O
endosome	O
marker	O
EEA1	B-GENE-N
.	O

Inhibition	O
of	O
lysosomes	O
or	O
proteasomes	O
by	O
co	O
-	O
treatment	O
with	O
antofine	B-CHEMICAL
and	O
their	O
respective	O
specific	O
inhibitors	O
,	O
NH4Cl	B-CHEMICAL
or	O
MG132	B-CHEMICAL
,	O
partially	O
inhibited	O
the	O
antofine	O
-	O
induced	O
decrease	O
in	O
Cx43	B-GENE-Y
protein	O
levels	O
,	O
but	O
did	O
not	O
inhibit	O
the	O
antofine	O
-	O
induced	O
inhibition	O
of	O
GJIC	O
.	O

After	O
30min	O
of	O
treatment	O
,	O
antofine	O
induced	O
a	O
rapid	O
increase	O
in	O
the	O
intracellular	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
concentration	O
and	O
activation	O
of	O
protein	B-GENE-N
kinase	I-GENE-N
C	I-GENE-N
(	I-GENE-N
PKC	I-GENE-N
)	I-GENE-N
α	I-GENE-N
/	I-GENE-N
βII	I-GENE-N
,	O
which	O
was	O
maintained	O
for	O
at	O
least	O
6h	O
.	O

Co	O
-	O
treatment	O
of	O
astrocytes	O
with	O
antofine	B-CHEMICAL
and	O
the	O
intracellular	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
chelator	O
BAPTA	B-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
prevented	O
downregulation	O
of	O
Cx43	B-GENE-Y
and	O
inhibition	O
of	O
GJIC	O
.	O

Moreover	O
,	O
co	O
-	O
treatment	O
with	O
antofine	B-CHEMICAL
and	O
a	O
specific	O
PKCβ	B-GENE-Y
inhibitor	O
prevented	O
endocytosis	O
of	O
gap	O
junctions	O
,	O
downregulation	O
of	O
Cx43	B-GENE-Y
,	O
and	O
inhibition	O
of	O
GJIC	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
antofine	B-CHEMICAL
induces	O
Cx43	B-GENE-Y
gap	O
junction	O
disassembly	O
by	O
the	O
PKCβ	B-GENE-Y
signaling	O
pathway	O
.	O

Inhibition	O
of	O
GJIC	O
by	O
antofine	B-CHEMICAL
may	O
undermine	O
the	O
neuroprotective	O
effect	O
of	O
astrocytes	O
in	O
CNS	O
.	O

A	O
genetically	O
encoded	O
and	O
gate	O
for	O
cell	O
-	O
targeted	O
metabolic	O
labeling	O
of	O
proteins	O
.	O

We	O
describe	O
a	O
genetic	O
AND	O
gate	O
for	O
cell	O
-	O
targeted	O
metabolic	O
labeling	O
and	O
proteomic	O
analysis	O
in	O
complex	O
cellular	O
systems	O
.	O

The	O
centerpiece	O
of	O
the	O
AND	O
gate	O
is	O
a	O
bisected	O
methionyl	B-GENE-Y
-	I-GENE-Y
tRNA	I-GENE-Y
synthetase	I-GENE-Y
(	O
MetRS	B-GENE-Y
)	O
that	O
charges	O
the	O
Met	B-CHEMICAL
surrogate	O
azidonorleucine	B-CHEMICAL
(	O
Anl	B-CHEMICAL
)	O
to	O
tRNA	O
(	O
Met	B-CHEMICAL
)	O
.	O

Cellular	O
protein	O
labeling	O
occurs	O
only	O
upon	O
activation	O
of	O
two	O
different	O
promoters	O
that	O
drive	O
expression	O
of	O
the	O
N	B-CHEMICAL
-	O
and	O
C	B-CHEMICAL
-	O
terminal	O
fragments	O
of	O
the	O
bisected	O
MetRS	B-GENE-Y
.	O

Anl	B-CHEMICAL
-	O
labeled	O
proteins	O
can	O
be	O
tagged	O
with	O
fluorescent	O
dyes	O
or	O
affinity	O
reagents	O
via	O
either	O
copper	B-CHEMICAL
-	O
catalyzed	O
or	O
strain	O
-	O
promoted	O
azide	O
-	O
alkyne	O
cycloaddition	O
.	O

Protein	O
labeling	O
is	O
apparent	O
within	O
5	O
min	O
after	O
addition	O
of	O
Anl	B-CHEMICAL
to	O
bacterial	O
cells	O
in	O
which	O
the	O
AND	O
gate	O
has	O
been	O
activated	O
.	O

This	O
method	O
allows	O
spatial	O
and	O
temporal	O
control	O
of	O
proteomic	O
labeling	O
and	O
identification	O
of	O
proteins	O
made	O
in	O
specific	O
cellular	O
subpopulations	O
.	O

The	O
approach	O
is	O
demonstrated	O
by	O
selective	O
labeling	O
of	O
proteins	O
in	O
bacterial	O
cells	O
immobilized	O
in	O
the	O
center	O
of	O
a	O
laminar	O
-	O
flow	O
microfluidic	O
channel	O
,	O
where	O
they	O
are	O
exposed	O
to	O
overlapping	O
,	O
opposed	O
gradients	O
of	O
inducers	O
of	O
the	O
N	B-CHEMICAL
-	O
and	O
C	B-CHEMICAL
-	O
terminal	O
MetRS	B-GENE-Y
fragments	O
.	O

The	O
observed	O
labeling	O
profile	O
is	O
predicted	O
accurately	O
from	O
the	O
strengths	O
of	O
the	O
individual	O
input	O
signals	O
.	O

The	O
therapeutic	O
potential	O
of	O
allosteric	O
ligands	O
for	O
free	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
sensitive	O
GPCRs	B-GENE-N
.	O

G	B-GENE-N
protein	I-GENE-N
coupled	I-GENE-N
receptors	I-GENE-N
(	O
GPCRs	B-GENE-N
)	O
are	O
the	O
most	O
historically	O
successful	O
therapeutic	O
targets	O
.	O

Despite	O
this	O
success	O
there	O
are	O
many	O
important	O
aspects	O
of	O
GPCR	B-GENE-N
pharmacology	O
and	O
function	O
that	O
have	O
yet	O
to	O
be	O
exploited	O
to	O
their	O
full	O
therapeutic	O
potential	O
.	O

One	O
in	O
particular	O
that	O
has	O
been	O
gaining	O
attention	O
in	O
recent	O
times	O
is	O
that	O
of	O
GPCR	B-GENE-N
ligands	O
that	O
bind	O
to	O
allosteric	O
sites	O
on	O
the	O
receptor	O
distinct	O
from	O
the	O
orthosteric	O
site	O
of	O
the	O
endogenous	O
ligand	O
.	O

As	O
therapeutics	O
,	O
allosteric	O
ligands	O
possess	O
many	O
theoretical	O
advantages	O
over	O
their	O
orthosteric	O
counterparts	O
,	O
including	O
more	O
complex	O
modes	O
of	O
action	O
,	O
improved	O
safety	O
,	O
more	O
physiologically	O
appropriate	O
responses	O
,	O
better	O
target	O
selectivity	O
,	O
and	O
reduced	O
likelihood	O
of	O
desensitisation	O
and	O
tachyphylaxis	O
.	O

Despite	O
these	O
advantages	O
,	O
the	O
development	O
of	O
allosteric	O
ligands	O
is	O
often	O
difficult	O
from	O
a	O
medicinal	O
chemistry	O
standpoint	O
due	O
to	O
the	O
more	O
complex	O
challenge	O
of	O
identifying	O
allosteric	O
leads	O
and	O
their	O
often	O
flat	O
or	O
confusing	O
SAR	O
.	O

The	O
present	O
review	O
will	O
consider	O
the	O
advantages	O
and	O
challenges	O
associated	O
with	O
allosteric	O
GPCR	B-GENE-N
ligands	O
,	O
and	O
examine	O
how	O
the	O
particular	O
properties	O
of	O
these	O
ligands	O
may	O
be	O
exploited	O
to	O
uncover	O
the	O
therapeutic	O
potential	O
for	O
free	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
sensitive	O
GPCRs	B-GENE-N
.	O

Compound	O
and	O
compositions	O
as	O
TGR5	B-GENE-Y
agonists	O
:	O
WO2012082947	O
.	O

The	O
patent	O
application	O
WO2012082947	O
claims	O
novel	O
compounds	O
as	O
agonists	O
of	O
a	O
plasma	B-GENE-Y
membrane	I-GENE-Y
-	I-GENE-Y
bound	I-GENE-Y
bile	I-GENE-Y
acid	I-GENE-Y
receptor	I-GENE-Y
TGR5	B-GENE-Y
.	O

By	O
activating	O
TGR5	B-GENE-Y
,	O
the	O
agonists	O
improve	O
glycemic	O
control	O
and	O
enhance	O
energy	O
expenditure	O
.	O

The	O
basic	O
generic	O
claim	O
of	O
the	O
patent	O
covers	O
pyrazole	B-CHEMICAL
derivatives	O
,	O
different	O
permutations	O
on	O
the	O
core	O
pyrazole	B-CHEMICAL
ring	O
are	O
covered	O
in	O
the	O
subsidiary	O
claims	O
.	O

The	O
claimed	O
compounds	O
are	O
human	B-GENE-Y
TGR5	I-GENE-Y
agonists	O
having	O
potency	O
in	O
the	O
nM	O
range	O
.	O

Synthesis	O
and	O
cancer	O
stem	O
cell	O
-	O
based	O
activity	O
of	O
substituted	O
5	B-CHEMICAL
-	I-CHEMICAL
morpholino	I-CHEMICAL
-	I-CHEMICAL
7H	I-CHEMICAL
-	I-CHEMICAL
thieno	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyran	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
ones	I-CHEMICAL
designed	O
as	O
next	O
generation	O
PI3K	B-GENE-N
inhibitors	O
.	O

Dysregulation	O
of	O
the	O
phosphatidylinositol	B-GENE-N
-	I-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
(	O
PI3K	B-GENE-N
)	O
pathway	O
in	O
a	O
wide	O
range	O
of	O
tumors	O
has	O
made	O
PI3K	B-GENE-N
a	O
consensus	O
target	O
to	O
inhibit	O
as	O
illustrated	O
by	O
more	O
than	O
15	O
inhibitors	O
now	O
in	O
clinical	O
trials	O
.	O

Our	O
previous	O
work	O
,	O
built	O
on	O
the	O
early	O
pioneering	O
multikinase	O
inhibitor	O
LY294002	B-CHEMICAL
,	O
resulted	O
in	O
the	O
only	O
PI3K	B-GENE-N
vascular	O
-	O
targeted	O
PI3K	B-GENE-N
inhibitor	O
prodrug	O
,	O
SF1126	B-CHEMICAL
,	O
which	O
has	O
now	O
completed	O
Phase	O
I	O
clinical	O
trials	O
.	O

This	O
inhibitor	O
has	O
properties	O
that	O
impart	O
more	O
in	O
vivo	O
activity	O
than	O
should	O
be	O
warranted	O
by	O
its	O
enzymatic	O
potency	O
,	O
which	O
in	O
general	O
is	O
much	O
lower	O
than	O
other	O
clinical	O
stage	O
PI3K	B-GENE-N
inhibitors	O
.	O

We	O
embarked	O
on	O
the	O
exploration	O
of	O
scaffolds	O
that	O
retained	O
such	O
properties	O
while	O
simultaneously	O
exhibiting	O
an	O
increased	O
potency	O
toward	O
PI3K	B-GENE-N
.	O

This	O
work	O
resulted	O
in	O
the	O
discovery	O
of	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
morpholino	I-CHEMICAL
-	I-CHEMICAL
7H	I-CHEMICAL
-	I-CHEMICAL
thieno	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
pyran	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
system	O
as	O
the	O
foundation	O
of	O
a	O
new	O
compound	O
class	O
of	O
potential	O
PI3K	B-GENE-N
inhibitors	O
having	O
improved	O
potency	O
toward	O
PI3K	B-GENE-N
.	O

The	O
synthesis	O
and	O
cancer	O
stem	O
cell	O
-	O
based	O
activity	O
of	O
these	O
compounds	O
are	O
reported	O
herein	O
.	O

Genome	O
-	O
wide	O
integrated	O
analyses	O
of	O
androgen	B-GENE-Y
receptor	I-GENE-Y
signaling	O
in	O
prostate	O
cancer	O
based	O
on	O
high	O
-	O
throughput	O
technology	O
.	O

The	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
is	O
a	O
steroid	B-GENE-N
hormone	I-GENE-N
receptor	I-GENE-N
that	O
functions	O
as	O
a	O
ligand	O
-	O
dependent	O
transcriptional	O
factor	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
prostate	O
cancer	O
.	O

Recent	O
advancement	O
in	O
high	O
throughput	O
technologies	O
including	O
microarrays	O
and	O
deep	O
-	O
sequencing	O
provides	O
unbiased	O
genome	O
-	O
wide	O
knowledge	O
on	O
the	O
AR	B-GENE-Y
signaling	O
including	O
datasets	O
for	O
androgen	B-CHEMICAL
-	O
regulated	O
gene	O
expression	O
and	O
genomic	O
binding	O
sites	O
for	O
AR	B-GENE-Y
.	O

In	O
the	O
present	O
review	O
,	O
we	O
will	O
briefly	O
summarize	O
the	O
main	O
features	O
of	O
the	O
AR	B-GENE-Y
signaling	O
as	O
well	O
as	O
the	O
individual	O
AR	B-GENE-Y
target	O
genes	O
identified	O
by	O
the	O
integration	O
of	O
multiple	O
datasets	O
in	O
prostate	O
cancer	O
.	O

Cap	O
analysis	O
gene	O
expression	O
(	O
CAGE	O
)	O
is	O
also	O
featured	O
as	O
a	O
unique	O
transcriptome	O
method	O
,	O
which	O
particularly	O
determines	O
the	O
androgen	B-CHEMICAL
-	O
dependent	O
transcription	O
start	O
points	O
in	O
prostate	O
cancer	O
.	O

Spiro	O
heterocycles	O
as	O
potential	O
inhibitors	O
of	O
SIRT1	B-GENE-Y
:	O
Pd	B-CHEMICAL
/	O
C	B-CHEMICAL
-	O
mediated	O
synthesis	O
of	O
novel	O
N	B-CHEMICAL
-	I-CHEMICAL
indolylmethyl	I-CHEMICAL
spiroindoline	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
quinazolines	I-CHEMICAL
.	O

Novel	O
N	B-CHEMICAL
-	I-CHEMICAL
indolylmethyl	I-CHEMICAL
substituted	I-CHEMICAL
spiroindoline	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
quinazolines	I-CHEMICAL
were	O
designed	O
as	O
potential	O
inhibitiors	O
of	O
SIRT1	B-GENE-Y
.	O

These	O
compounds	O
were	O
synthesized	O
in	O
good	O
yields	O
by	O
using	O
Pd	B-CHEMICAL
/	O
C	B-CHEMICAL
-	I-CHEMICAL
Cu	I-CHEMICAL
mediated	O
coupling	O
-	O
cyclization	O
strategy	O
as	O
a	O
key	O
step	O
involving	O
the	O
reaction	O
of	O
1	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
prop	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
ynyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
'	I-CHEMICAL
H	I-CHEMICAL
-	I-CHEMICAL
spiro	I-CHEMICAL
[	I-CHEMICAL
indoline	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
quinazoline	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
with	O
2	B-CHEMICAL
-	I-CHEMICAL
iodoanilides	I-CHEMICAL
.	O

Some	O
of	O
the	O
compounds	O
synthesized	O
have	O
shown	O
encouraging	O
inhibition	O
of	O
Sir	B-GENE-Y
2	I-GENE-Y
protein	O
(	O
a	O
yeast	O
homologue	O
of	O
mammalian	B-GENE-N
SIRT1	I-GENE-N
)	O
in	O
vitro	O
and	O
three	O
of	O
them	O
showed	O
dose	O
dependent	O
inhibition	O
of	O
Sir	B-GENE-Y
2	I-GENE-Y
.	O

The	O
docking	O
results	O
suggested	O
that	O
the	O
benzene	B-CHEMICAL
ring	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
tetrahydroquinazolin	I-CHEMICAL
ring	O
system	O
of	O
these	O
molecules	O
occupied	O
the	O
deep	O
hydrophobic	O
pocket	O
of	O
the	O
protein	O
and	O
one	O
of	O
the	O
NH	B-CHEMICAL
along	O
with	O
the	O
sulfonyl	B-CHEMICAL
group	O
participated	O
in	O
strong	O
H	B-CHEMICAL
-	O
bonding	O
interaction	O
with	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
.	O

Anti	O
-	O
inflammatory	O
effects	O
of	O
an	O
aqueous	O
extract	O
of	O
Welsh	O
onion	O
green	O
leaves	O
in	O
mice	O
.	O

The	O
anti	O
-	O
inflammatory	O
effects	O
of	O
an	O
aqueous	O
extract	O
of	O
Welsh	O
onion	O
green	O
leaves	O
(	O
WOE	O
)	O
in	O
mice	O
was	O
investigated	O
.	O

Administration	O
of	O
WOE	O
,	O
in	O
the	O
range	O
of	O
0	O
.	O
25	O
-	O
1g	O
/	O
kg	O
,	O
showed	O
a	O
concentration	O
dependent	O
inhibition	O
on	O
paw	O
edema	O
development	O
after	O
carrageenan	O
treatment	O
in	O
mice	O
.	O

The	O
anti	O
-	O
inflammatory	O
effects	O
of	O
WOE	O
were	O
closely	O
attributed	O
to	O
decreased	O
levels	O
of	O
tissue	O
NO	B-CHEMICAL
and	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
.	O

Further	O
evidence	O
for	O
WOE	O
'	O
s	O
protection	O
is	O
shown	O
in	O
the	O
reduction	O
of	O
lipid	O
oxidation	O
and	O
the	O
increase	O
of	O
antioxidant	O
enzyme	O
activities	O
,	O
including	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
,	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
,	O
and	O
glutathione	B-GENE-N
peroxidase	I-GENE-N
(	O
GPX	B-GENE-N
)	O
in	O
vivo	O
.	O

Further	O
,	O
WOE	O
also	O
decreased	O
the	O
number	O
of	O
acetic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
writhing	O
responses	O
and	O
formalin	B-CHEMICAL
-	O
induced	O
pain	O
in	O
the	O
late	O
phase	O
in	O
mice	O
.	O

Overall	O
,	O
the	O
results	O
showed	O
that	O
WOE	O
might	O
serve	O
as	O
a	O
natural	O
source	O
of	O
anti	O
-	O
inflammatory	O
compounds	O
.	O

Apple	O
polyphenols	B-CHEMICAL
suppress	O
antigen	O
presentation	O
of	O
ovalbumin	B-GENE-N
by	O
THP	O
-	O
1	O
-	O
derived	O
dendritic	O
cells	O
.	O

Apple	O
polyphenol	B-CHEMICAL
extract	O
(	O
AP	O
)	O
and	O
procyanidin	B-CHEMICAL
contained	O
in	O
AP	O
were	O
investigated	O
for	O
their	O
immunomodulatory	O
effects	O
using	O
THP	O
-	O
1	O
-	O
derived	O
human	O
dendritic	O
cells	O
(	O
TDDCs	O
)	O
.	O

The	O
expression	O
levels	O
of	O
HLA	B-GENE-N
-	I-GENE-N
DR	I-GENE-N
(	O
MHC	B-GENE-N
class	I-GENE-N
II	I-GENE-N
)	O
and	O
CD86	B-GENE-N
(	O
costimulatory	O
molecule	O
)	O
were	O
measured	O
as	O
an	O
indicator	O
of	O
antigen	O
presentation	O
in	O
TDDCs	O
.	O

A	O
significant	O
decrease	O
in	O
HLA	B-GENE-N
-	I-GENE-N
DR	I-GENE-N
expression	O
was	O
observed	O
in	O
the	O
AP	O
and	O
fractionated	O
procyanidin	B-CHEMICAL
-	O
treated	O
cells	O
in	O
the	O
presence	O
of	O
ovalbumin	B-GENE-N
(	O
OVA	B-GENE-N
)	O
,	O
but	O
no	O
effect	O
on	O
CD86	B-GENE-N
expression	O
was	O
observed	O
.	O

The	O
uptake	O
of	O
OVA	B-GENE-N
was	O
not	O
inhibited	O
by	O
AP	O
treatment	O
,	O
and	O
the	O
gene	O
expression	O
of	O
membrane	O
-	O
associated	O
RING	B-GENE-N
-	I-GENE-N
CH	I-GENE-N
ubiquitin	B-GENE-N
E3	I-GENE-N
ligase	I-GENE-N
,	O
MARCH1	B-GENE-N
,	O
was	O
up	O
-	O
regulated	O
by	O
AP	O
treatment	O
.	O

It	O
can	O
therefore	O
be	O
presumed	O
that	O
AP	O
suppresses	O
HLA	B-GENE-N
-	I-GENE-N
DR	I-GENE-N
expression	O
via	O
the	O
ubiquitin	B-GENE-N
-	O
proteasome	B-GENE-N
pathway	O
.	O

Furthermore	O
,	O
the	O
up	O
-	O
regulation	O
of	O
IL	B-GENE-N
-	I-GENE-N
12	I-GENE-N
and	O
TNF	B-GENE-N
-	I-GENE-N
α	I-GENE-N
was	O
found	O
in	O
the	O
procyanidin	B-CHEMICAL
trimers	O
-	O
treated	O
cells	O
in	O
the	O
presence	O
of	O
OVA	B-GENE-N
.	O

These	O
results	O
suggest	O
that	O
apple	O
polyphenols	B-CHEMICAL
would	O
be	O
an	O
effective	O
factor	O
for	O
the	O
development	O
of	O
immunomodulatory	O
agents	O
with	O
suppressive	O
effects	O
of	O
antigen	O
presentation	O
.	O

Alteration	O
of	O
α	B-GENE-Y
-	I-GENE-Y
tocopherol	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
protein	I-GENE-Y
(	O
TAP	B-GENE-Y
)	O
expression	O
in	O
human	O
breast	O
epithelial	O
cells	O
during	O
breast	O
cancer	O
development	O
.	O

Breast	O
cancer	O
is	O
the	O
most	O
common	O
malignancy	O
among	O
women	O
and	O
has	O
an	O
age	O
-	O
specific	O
incidence	O
profile	O
.	O

Over	O
the	O
last	O
decade	O
,	O
many	O
studies	O
have	O
demonstrated	O
the	O
anticancer	O
activity	O
of	O
α	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
,	O
the	O
main	O
and	O
most	O
active	O
form	O
of	O
natural	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
.	O

α	B-GENE-Y
-	I-GENE-Y
Tocopherol	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
protein	I-GENE-Y
(	O
TAP	B-GENE-Y
)	O
was	O
found	O
to	O
be	O
one	O
of	O
the	O
major	O
α	B-GENE-N
-	I-GENE-N
tocopherol	I-GENE-N
binding	I-GENE-N
proteins	I-GENE-N
in	O
human	O
serum	O
and	O
in	O
liver	O
,	O
brain	O
,	O
and	O
prostate	O
tissues	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
reduced	O
TAP	B-GENE-Y
expression	O
was	O
significantly	O
correlated	O
with	O
Her2	B-GENE-Y
/	O
neu	B-GENE-Y
receptor	O
expression	O
,	O
breast	O
cancer	O
stage	O
and	O
nodal	O
stage	O
in	O
paired	O
normal	O
and	O
cancerous	O
breast	O
tissue	O
samples	O
from	O
93	O
patients	O
using	O
real	O
-	O
time	O
PCR	O
analysis	O
.	O

A	O
cell	O
viability	O
assay	O
showed	O
that	O
α	B-CHEMICAL
-	I-CHEMICAL
tocopheryl	I-CHEMICAL
succinate	I-CHEMICAL
(	O
α	B-CHEMICAL
-	I-CHEMICAL
TOS	I-CHEMICAL
)	O
,	O
a	O
synthetic	O
derivative	O
of	O
α	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
,	O
enhanced	O
the	O
cells	O
'	O
sensitivity	O
to	O
doxorubicin	B-CHEMICAL
and	O
resulted	O
in	O
a	O
reduction	O
in	O
cell	O
viability	O
in	O
breast	O
cancers	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
use	O
of	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
or	O
its	O
analogue	O
as	O
a	O
dietary	O
supplement	O
may	O
be	O
beneficial	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Peyer	O
'	O
s	O
patch	O
-	O
mediated	O
intestinal	O
immune	O
system	O
modulating	O
activity	O
of	O
pectic	O
-	O
type	O
polysaccharide	O
from	O
peel	O
of	O
Citrus	O
unshiu	O
.	O

An	O
intestinal	O
immune	O
system	O
modulating	O
polysaccharide	O
(	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
,	O
18kDa	O
)	O
was	O
purified	O
from	O
Citrus	O
unshiu	O
peel	O
.	O

CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
mainly	O
comprised	O
GalA	B-CHEMICAL
,	O
GlcA	B-CHEMICAL
,	O
Ara	B-CHEMICAL
,	O
Gal	B-CHEMICAL
and	O
Rha	B-CHEMICAL
,	O
and	O
it	O
consisted	O
of	O
4	O
-	O
linked	O
GalA	B-CHEMICAL
,	O
terminal	O
Araf	B-CHEMICAL
,	O
4	O
-	O
or	O
5	O
-	O
linked	O
/	O
3	O
,	O
4	O
-	O
or	O
3	O
,	O
5	O
-	O
branched	O
Ara	B-CHEMICAL
,	O
terminal	O
Gal	B-CHEMICAL
,	O
and	O
2	O
-	O
linked	O
/	O
2	O
,	O
4	O
-	O
branched	O
Rha	B-CHEMICAL
.	O

After	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
digestion	O
by	O
endo	O
-	O
α	O
-	O
d	O
-	O
(	O
1	O
→	O
4	O
)	O
-	O
polygalacturonase	B-GENE-N
,	O
its	O
hydrolysate	O
was	O
fractionated	O
into	O
PG	O
-	O
1	O
and	O
PG	O
-	O
2	O
.	O

Methylation	O
analyses	O
of	O
PG	O
-	O
1	O
and	O
PG	O
-	O
2	O
using	O
base	O
-	O
catalysed	O
β	O
-	O
elimination	O
suggested	O
that	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
be	O
assumed	O
as	O
pectic	O
-	O
type	O
polysaccharide	O
.	O

Since	O
the	O
activities	O
of	O
PG	O
-	O
1	O
and	O
PG	O
-	O
2	O
were	O
potently	O
decreased	O
,	O
the	O
whole	O
polysaccharide	O
structure	O
of	O
CUI	O
-	O
3IIb	O
-	O
3	O
-	O
2	O
would	O
be	O
essential	O
to	O
maintain	O
the	O
activity	O
.	O

Meanwhile	O
,	O
when	O
CUI	O
-	O
3IIb	O
was	O
orally	O
administered	O
in	O
mice	O
,	O
bone	O
marrow	O
cell	O
proliferation	O
and	O
GM	O
-	O
CSF	O
/	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
production	O
from	O
Peyer	O
'	O
s	O
patch	O
cell	O
were	O
significantly	O
higher	O
(	O
1	O
.	O
76	O
-	O
and	O
2	O
.	O
03	O
/	O
2	O
.	O
51	O
-	O
fold	O
,	O
respectively	O
)	O
than	O
a	O
saline	O
.	O

Therefore	O
,	O
a	O
pectic	O
-	O
type	O
polysaccharide	O
from	O
citrus	O
peel	O
could	O
stimulate	O
Peyer	O
'	O
s	O
patches	O
and	O
produce	O
hematopoietic	O
growth	O
factors	O
resulted	O
in	O
bone	O
marrow	O
cell	O
proliferation	O
.	O

Iron	B-CHEMICAL
and	O
zinc	B-CHEMICAL
bioavailability	O
in	O
Caco	O
-	O
2	O
cells	O
:	O
influence	O
of	O
caseinophosphopeptides	B-GENE-N
.	O

A	O
study	O
has	O
been	O
made	O
of	O
the	O
influence	O
of	O
two	O
pools	O
of	O
caseinophosphopeptides	B-GENE-N
(	O
CPPs	B-GENE-N
)	O
obtained	O
from	O
α	B-GENE-N
(	I-GENE-N
s	I-GENE-N
)	I-GENE-N
-	I-GENE-N
and	I-GENE-N
β	I-GENE-N
-	I-GENE-N
casein	I-GENE-N
(	O
CN	B-GENE-N
)	O
fractions	O
,	O
and	O
of	O
three	O
specific	O
CPPs	B-GENE-N
(	O
β	B-GENE-Y
-	I-GENE-Y
CN	I-GENE-Y
(	O
1	O
-	O
25	O
)	O
4P	O
,	O
α	B-GENE-Y
(	I-GENE-Y
s1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CN	I-GENE-Y
(	O
64	O
-	O
74	O
)	O
4P	O
and	O
α	B-GENE-N
(	I-GENE-N
s2	I-GENE-N
)	I-GENE-N
-	I-GENE-N
CN	I-GENE-N
(	O
1	O
-	O
19	O
)	O
4P	O
)	O
,	O
on	O
iron	B-CHEMICAL
bioavailability	O
(	O
ferritin	B-GENE-Y
synthesis	O
)	O
and	O
zinc	B-CHEMICAL
bioavailability	O
(	O
retention	O
,	O
transport	O
and	O
uptake	O
of	O
zinc	B-CHEMICAL
)	O
in	O
Caco	O
-	O
2	O
cells	O
.	O

α	B-GENE-N
-	I-GENE-N
CPP	I-GENE-N
and	O
β	B-GENE-N
-	I-GENE-N
CPP	I-GENE-N
pools	O
did	O
not	O
improve	O
ferritin	B-GENE-Y
synthesis	O
,	O
but	O
the	O
three	O
specific	O
CPPs	B-GENE-N
showed	O
an	O
increase	O
in	O
ferritin	B-GENE-Y
synthesis	O
in	O
Caco	O
-	O
2	O
cells	O
versus	O
iron	B-CHEMICAL
sulphate	I-CHEMICAL
,	O
β	B-GENE-Y
-	I-GENE-Y
CN	I-GENE-Y
(	O
1	O
-	O
25	O
)	O
4P	O
being	O
the	O
most	O
effective	O
.	O

In	O
relation	O
to	O
zinc	B-CHEMICAL
bioavailability	O
,	O
α	B-GENE-N
-	I-GENE-N
CPPs	I-GENE-N
,	O
β	B-GENE-N
-	I-GENE-N
CPPs	I-GENE-N
,	O
α	B-GENE-Y
(	I-GENE-Y
s1	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
CN	I-GENE-Y
(	O
64	O
-	O
74	O
)	O
4P	O
and	O
β	B-GENE-Y
-	I-GENE-Y
CN	I-GENE-Y
(	O
1	O
-	O
25	O
)	O
4P	O
increased	O
zinc	B-CHEMICAL
uptake	O
.	O

However	O
,	O
this	O
increase	O
was	O
of	O
the	O
same	O
order	O
as	O
the	O
increase	O
due	O
to	O
the	O
presence	O
of	O
zinc	B-CHEMICAL
sulphate	I-CHEMICAL
.	O

A	O
water	O
-	O
alcohol	B-CHEMICAL
extract	O
of	O
Citrus	O
grandis	O
whole	O
fruits	O
has	O
beneficial	O
metabolic	O
effects	O
in	O
the	O
obese	O
Zucker	O
rats	O
fed	O
with	O
high	O
fat	O
/	O
high	O
cholesterol	B-CHEMICAL
diet	O
.	O

Epidemiological	O
studies	O
suggest	O
that	O
citrus	O
fruits	O
and	O
compounds	O
such	O
as	O
flavonoids	B-CHEMICAL
,	O
limonoids	O
and	O
pectins	O
have	O
health	O
promoting	O
effects	O
.	O

Our	O
aim	O
was	O
to	O
study	O
the	O
effects	O
of	O
Citrus	O
grandis	O
(	O
L	O
.	O
)	O
Osbeck	O
var	O
.	O
tomentosa	O
hort	O
.	O
fruit	O
extract	O
on	O
the	O
energy	O
metabolism	O
.	O

A	O
whole	O
fruit	O
powder	O
from	O
dry	O
water	O
and	O
alcohol	B-CHEMICAL
extracts	O
of	O
C	O
.	O
grandis	O
containing	O
19	O
%	O
naringin	B-CHEMICAL
flavonoid	O
was	O
prepared	O
.	O

The	O
effects	O
of	O
the	O
citrus	O
extract	O
were	O
followed	O
in	O
the	O
obese	O
Zucker	O
rats	O
fed	O
with	O
the	O
HFD	O
.	O

The	O
circulatory	O
levels	O
of	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
decreased	O
significantly	O
by	O
the	O
extract	O
in	O
comparison	O
to	O
the	O
HFD	O
group	O
,	O
whereas	O
the	O
decreased	O
ghrelin	B-GENE-Y
levels	O
were	O
reversed	O
.	O

The	O
levels	O
of	O
PYY	B-GENE-Y
were	O
decreased	O
in	O
all	O
HFD	O
groups	O
.	O

The	O
leptin	B-GENE-Y
amounts	O
decreased	O
but	O
not	O
significantly	O
whereas	O
insulin	B-GENE-N
and	O
amylin	B-GENE-Y
were	O
unchanged	O
.	O

The	O
cholesterol	B-CHEMICAL
and	O
glucose	B-CHEMICAL
levels	O
were	O
somewhat	O
but	O
not	O
systematically	O
improved	O
in	O
the	O
HFD	O
fed	O
rats	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
active	O
compounds	O
and	O
their	O
mechanisms	O
.	O

Oligomeric	O
procyanidins	B-CHEMICAL
of	O
lotus	O
seedpod	O
inhibits	O
the	O
formation	O
of	O
advanced	O
glycation	O
end	O
-	O
products	O
by	O
scavenging	O
reactive	O
carbonyls	B-CHEMICAL
.	O

It	O
has	O
been	O
reported	O
that	O
oligomeric	O
procyanidins	B-CHEMICAL
of	O
lotus	O
seedpod	O
(	O
LSOPC	O
)	O
is	O
effective	O
in	O
the	O
alleviation	O
of	O
Alzheimer	O
'	O
s	O
disease	O
and	O
diabetes	O
through	O
its	O
antioxidant	O
and	O
insulin	B-GENE-Y
-	O
potentiating	O
activities	O
.	O

This	O
study	O
investigated	O
the	O
anti	O
-	O
glycative	O
activity	O
of	O
LSOPC	O
in	O
a	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
BSA	B-GENE-Y
)	O
-	O
glucose	B-CHEMICAL
model	O
.	O

The	O
level	O
of	O
glycation	O
and	O
conformational	O
alterations	O
were	O
assessed	O
by	O
specific	O
fluorescence	O
,	O
Congo	O
red	O
binding	O
assay	O
and	O
circular	O
dichroism	O
.	O

The	O
results	O
show	O
that	O
LSOPC	O
has	O
a	O
significant	O
anti	O
-	O
glycative	O
activity	O
in	O
vitro	O
and	O
it	O
can	O
also	O
effectively	O
protect	O
the	O
secondary	O
structure	O
of	O
BSA	B-GENE-Y
during	O
glycation	O
.	O

LSOPC	O
or	O
catechin	B-CHEMICAL
(	O
a	O
major	O
constituent	O
unit	O
of	O
LSOPC	O
)	O
,	O
were	O
used	O
to	O
react	O
with	O
methylglyoxal	B-CHEMICAL
.	O

The	O
structures	O
of	O
their	O
carbonyl	B-CHEMICAL
adducts	O
were	O
tentatively	O
identified	O
using	O
HPLC	O
-	O
MS	O
(	O
2	O
)	O
.	O

Their	O
capacity	O
to	O
scavenge	O
methylglyoxal	B-CHEMICAL
suggested	O
carbonyl	B-CHEMICAL
scavenging	O
as	O
a	O
major	O
mechanism	O
of	O
antiglycation	O
.	O

Therefore	O
,	O
LSOPC	O
could	O
be	O
helpful	O
to	O
prevent	O
AGEs	O
-	O
associated	O
diseases	O
,	O
and	O
with	O
the	O
potential	O
to	O
be	O
used	O
as	O
functional	O
food	O
ingredients	O
.	O

Vegfrecine	B-CHEMICAL
,	O
an	O
Inhibitor	O
of	O
VEGF	B-GENE-N
Receptor	I-GENE-N
Tyrosine	I-GENE-N
Kinases	I-GENE-N
Isolated	O
from	O
the	O
Culture	O
Broth	O
of	O
Streptomyces	O
sp	O
.	O

A	O
new	O
inhibitor	O
of	O
VEGF	B-GENE-N
receptor	I-GENE-N
tyrosine	I-GENE-N
kinases	I-GENE-N
,	O
vegfrecine	B-CHEMICAL
(	O
1	O
)	O
,	O
was	O
isolated	O
from	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
sp	O
.	O

MK931	O
-	O
CF8	O
.	O

The	O
molecular	O
structure	O
of	O
1	O
was	O
determined	O
by	O
NMR	O
and	O
MS	O
analysis	O
combined	O
with	O
synthesis	O
.	O

Compound	O
1	O
showed	O
potent	O
inhibitory	O
activity	O
against	O
vascular	B-GENE-N
endothelial	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
(	O
VEGFR	B-GENE-N
)	O
tyrosine	B-GENE-N
kinases	I-GENE-N
in	O
in	O
vitro	O
enzyme	O
assays	O
,	O
but	O
platelet	B-GENE-N
-	I-GENE-N
derived	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptors	I-GENE-N
(	O
PDGFRs	B-GENE-N
)	O
,	O
fibroblast	B-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
(	O
FGFR	B-GENE-N
)	O
,	O
and	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
responded	O
only	O
weakly	O
.	O

Compound	O
1	O
is	O
a	O
promising	O
new	O
selective	O
VEGFR	B-GENE-N
inhibitor	O
for	O
investigating	O
new	O
treatments	O
of	O
cancer	O
and	O
inflammatory	O
diseases	O
.	O

Reduction	O
of	O
dimethylarsinic	B-CHEMICAL
acid	I-CHEMICAL
to	O
the	O
highly	O
toxic	O
dimethylarsinous	B-CHEMICAL
acid	I-CHEMICAL
by	O
rats	O
and	O
rat	O
liver	O
cytosol	O
.	O

Dimethylarsinic	B-CHEMICAL
acid	I-CHEMICAL
(	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
)	O
,	O
the	O
major	O
urinary	O
metabolite	O
of	O
inorganic	O
arsenic	B-CHEMICAL
,	O
is	O
weakly	O
cytotoxic	O
,	O
whereas	O
its	O
reduced	O
form	O
,	O
dimethylarsinous	B-CHEMICAL
acid	I-CHEMICAL
(	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
)	O
,	O
is	O
highly	O
toxic	O
.	O

Although	O
glutathione	B-GENE-Y
S	I-GENE-Y
-	I-GENE-Y
transferase	I-GENE-Y
omega	I-GENE-Y
1	I-GENE-Y
(	O
GSTO1	B-GENE-Y
)	O
and	O
arsenic	B-GENE-Y
methyltransferase	I-GENE-Y
have	O
been	O
shown	O
or	O
thought	O
to	O
catalyze	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
reduction	O
,	O
their	O
role	O
in	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
reduction	O
in	O
vivo	O
,	O
or	O
in	O
cell	O
extracts	O
is	O
uncertain	O
.	O

Therefore	O
,	O
the	O
reduction	O
of	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
to	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
in	O
rats	O
and	O
in	O
rat	O
liver	O
cytosol	O
was	O
studied	O
to	O
better	O
understand	O
its	O
mechanism	O
.	O

To	O
assess	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
reduction	O
in	O
rats	O
,	O
a	O
novel	O
procedure	O
was	O
devised	O
based	O
on	O
following	O
the	O
accumulation	O
of	O
red	O
blood	O
cell	O
(	O
RBC	O
)	O
-	O
bound	O
dimethylarsenic	B-CHEMICAL
(	O
DMAs	B-CHEMICAL
)	O
,	O
which	O
represents	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
,	O
in	O
the	O
blood	O
of	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
-	O
injected	O
anesthetized	O
rats	O
.	O

These	O
studies	O
indicated	O
that	O
rats	O
reduced	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
to	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
to	O
a	O
significant	O
extent	O
,	O
as	O
in	O
90	O
min	O
31	O
%	O
of	O
the	O
injected	O
50	O
μmol	O
/	O
kg	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
dose	O
was	O
converted	O
to	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
that	O
was	O
sequestered	O
by	O
the	O
circulating	O
erythrocytes	O
.	O

Pretreatment	O
of	O
rats	O
with	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
depletors	O
(	O
phorone	B-CHEMICAL
or	O
BSO	B-CHEMICAL
)	O
delayed	O
the	O
elimination	O
of	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
and	O
the	O
accumulation	O
of	O
RBC	O
-	O
bound	O
DMAs	B-CHEMICAL
,	O
whereas	O
the	O
indirect	O
methyltransferase	B-GENE-N
inhibitor	O
periodate	B-CHEMICAL
-	O
oxidized	O
adenosine	B-CHEMICAL
was	O
without	O
effect	O
.	O

Assessment	O
of	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
-	O
reducing	O
activity	O
of	O
rat	O
liver	O
cytosol	O
revealed	O
that	O
reduction	O
of	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
required	O
cytosolic	O
protein	O
and	O
GSH	B-CHEMICAL
and	O
was	O
inhibited	O
by	O
thiol	B-CHEMICAL
reagents	O
,	O
GSSG	B-CHEMICAL
and	O
dehydroascorbate	B-CHEMICAL
.	O

Although	O
thioredoxin	B-GENE-N
reductase	I-GENE-N
(	O
TRR	B-GENE-N
)	O
inhibitors	O
(	O
aurothioglucose	B-CHEMICAL
and	O
Sb	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
)	O
inhibited	O
cytosolic	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
reduction	O
,	O
recombinant	O
rat	B-GENE-N
TRR	I-GENE-N
plus	O
NADPH	B-CHEMICAL
,	O
alone	O
or	O
when	O
added	O
to	O
the	O
cytosol	O
,	O
failed	O
to	O
support	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
reduction	O
.	O

On	O
ultrafiltration	O
of	O
the	O
cytosol	O
through	O
a	O
3	O
kDa	O
filter	O
,	O
the	O
reducing	O
activity	O
in	O
the	O
retentate	O
was	O
lost	O
but	O
was	O
largely	O
restored	O
by	O
NADPH	B-CHEMICAL
.	O

Such	O
experiments	O
also	O
suggested	O
that	O
the	O
reducing	O
enzyme	O
was	O
larger	O
than	O
100	O
kDa	O
and	O
was	O
not	O
GSTO1	B-GENE-Y
.	O

In	O
summary	O
,	O
reduction	O
of	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
V	I-CHEMICAL
)	I-CHEMICAL
to	O
the	O
highly	O
toxic	O
DMAs	B-CHEMICAL
(	I-CHEMICAL
III	I-CHEMICAL
)	I-CHEMICAL
in	O
rats	O
and	O
rat	O
liver	O
cytosol	O
is	O
a	O
GSH	B-CHEMICAL
-	O
dependent	O
enzymatic	O
process	O
,	O
yet	O
its	O
mechanism	O
remains	O
uncertain	O
.	O

Discovery	O
of	O
novel	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxydiarylamide	I-CHEMICAL
derivatives	O
as	O
TMPRSS4	B-GENE-Y
inhibitors	O
.	O

TMPRSS4	B-GENE-Y
is	O
a	O
novel	O
type	B-GENE-N
II	I-GENE-N
transmembrane	I-GENE-N
serine	I-GENE-N
protease	I-GENE-N
that	O
has	O
been	O
implicated	O
in	O
the	O
invasion	O
and	O
metastasis	O
of	O
colon	O
cancer	O
cells	O
.	O

In	O
this	O
study	O
,	O
a	O
novel	O
series	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxydiarylamide	I-CHEMICAL
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibiting	O
TMPRSS4	B-GENE-Y
serine	B-GENE-N
protease	I-GENE-N
activity	O
and	O
suppressing	O
cancer	O
cell	O
invasion	O
.	O

These	O
derivatives	O
demonstrated	O
good	O
inhibitory	O
activity	O
against	O
TMPRSS4	B-GENE-Y
serine	B-GENE-N
protease	I-GENE-N
,	O
which	O
correlated	O
with	O
the	O
promising	O
anti	O
-	O
invasive	O
activity	O
of	O
colon	O
cancer	O
cells	O
overexpressing	O
TMPRSS4	B-GENE-Y
.	O

A	O
genetic	O
program	O
promotes	O
C	O
.	O
elegans	O
longevity	O
at	O
cold	O
temperatures	O
via	O
a	O
thermosensitive	O
TRP	B-GENE-N
channel	I-GENE-N
.	O

Both	O
poikilotherms	O
and	O
homeotherms	O
live	O
longer	O
at	O
lower	O
body	O
temperatures	O
,	O
highlighting	O
a	O
general	O
role	O
of	O
temperature	O
reduction	O
in	O
lifespan	O
extension	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
remain	O
unclear	O
.	O

One	O
prominent	O
model	O
is	O
that	O
cold	O
temperatures	O
reduce	O
the	O
rate	O
of	O
chemical	O
reactions	O
,	O
thereby	O
slowing	O
the	O
rate	O
of	O
aging	O
.	O

This	O
view	O
suggests	O
that	O
cold	O
-	O
dependent	O
lifespan	O
extension	O
is	O
simply	O
a	O
passive	O
thermodynamic	O
process	O
.	O

Here	O
,	O
we	O
challenge	O
this	O
view	O
in	O
C	O
.	O
elegans	O
by	O
showing	O
that	O
genetic	O
programs	O
actively	O
promote	O
longevity	O
at	O
cold	O
temperatures	O
.	O

We	O
find	O
that	O
TRPA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
a	O
cold	O
-	O
sensitive	O
TRP	B-GENE-N
channel	I-GENE-N
,	O
detects	O
temperature	O
drop	O
in	O
the	O
environment	O
to	O
extend	O
lifespan	O
.	O

This	O
effect	O
requires	O
cold	O
-	O
induced	O
,	O
TRPA	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	O
mediated	O
calcium	B-CHEMICAL
influx	O
and	O
a	O
calcium	B-CHEMICAL
-	O
sensitive	O
PKC	B-GENE-N
that	O
signals	O
to	O
the	O
transcription	O
factor	O
DAF	B-GENE-Y
-	I-GENE-Y
16	I-GENE-Y
/	O
FOXO	B-GENE-Y
.	O

Human	B-GENE-Y
TRPA1	I-GENE-Y
can	O
functionally	O
substitute	O
for	O
worm	B-GENE-N
TRPA	I-GENE-N
-	I-GENE-N
1	I-GENE-N
in	O
promoting	O
longevity	O
.	O

Our	O
results	O
reveal	O
a	O
previously	O
unrecognized	O
function	O
for	O
TRP	B-GENE-N
channels	I-GENE-N
,	O
link	O
calcium	B-CHEMICAL
signaling	O
to	O
longevity	O
,	O
and	O
,	O
importantly	O
,	O
demonstrate	O
that	O
genetic	O
programs	O
contribute	O
to	O
lifespan	O
extension	O
at	O
cold	O
temperatures	O
.	O

Narirutin	B-CHEMICAL
fraction	O
from	O
citrus	O
peels	O
attenuates	O
alcoholic	O
liver	O
disease	O
in	O
mice	O
.	O

This	O
study	O
aimed	O
to	O
demonstrate	O
protective	O
activities	O
of	O
the	O
narirutin	B-CHEMICAL
fraction	O
from	O
peels	O
of	O
Citrus	O
unshiu	O
against	O
ethanol	B-CHEMICAL
-	O
induced	O
hepatic	O
damage	O
through	O
an	O
animal	O
study	O
.	O

Citrus	O
narirutin	B-CHEMICAL
fraction	O
(	O
CNF	O
)	O
,	O
contained	O
75	O
%	O
of	O
narirutin	B-CHEMICAL
,	O
was	O
obtained	O
by	O
an	O
ultra	O
-	O
sonicated	O
extraction	O
and	O
further	O
purification	O
.	O

ICR	O
mice	O
were	O
divided	O
into	O
four	O
groups	O
;	O
normaldiet	O
control	O
,	O
ethanol	B-CHEMICAL
control	O
(	O
6	O
.	O
5g	O
ethanol	B-CHEMICAL
/	O
kg	O
)	O
,	O
low	O
-	O
CNF	O
(	O
ethanol	B-CHEMICAL
+	O
150mg	O
CNF	O
/	O
kg	O
)	O
and	O
high	O
-	O
CNF	O
(	O
ethanol	B-CHEMICAL
+	O
300mg	O
CNF	O
/	O
kg	O
)	O
groups	O
.	O

Consumption	O
of	O
alcohol	B-CHEMICAL
for	O
8weeks	O
induced	O
severe	O
liver	O
damage	O
with	O
increases	O
in	O
prognostic	O
indicators	O
such	O
as	O
aspartate	B-GENE-N
transaminase	I-GENE-N
,	O
alanine	B-GENE-N
transaminase	I-GENE-N
in	O
serum	O
whereas	O
co	O
-	O
administration	O
of	O
CNF	O
suppressed	O
their	O
increases	O
.	O

Excessive	O
accumulations	O
in	O
liver	O
TG	O
and	O
TC	O
in	O
ethanol	B-CHEMICAL
control	O
group	O
were	O
also	O
suppressed	O
by	O
co	O
-	O
administration	O
of	O
CNF	O
.	O

Co	O
-	O
administration	O
of	O
CNF	O
maintained	O
SOD	B-GENE-N
activity	O
,	O
GSH	B-CHEMICAL
and	O
malondialdehyde	B-CHEMICAL
levels	O
close	O
to	O
those	O
of	O
the	O
normal	O
diet	O
group	O
.	O

Chronic	O
consumption	O
of	O
alcohol	B-CHEMICAL
also	O
stimulated	O
abrupt	O
increases	O
in	O
pro	O
-	O
inflammatory	O
cytokines	O
such	O
as	O
nuclear	B-GENE-N
factor	I-GENE-N
(	I-GENE-N
NF	I-GENE-N
)	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
(	I-GENE-Y
TNF	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
and	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
in	O
liver	O
otherwise	O
co	O
-	O
administration	O
of	O
CNF	O
effectively	O
suppressed	O
production	O
of	O
these	O
cytokines	B-GENE-N
dose	O
-	O
dependently	O
.	O

These	O
results	O
indicate	O
that	O
co	O
-	O
administration	O
of	O
CNF	O
with	O
alcohol	B-CHEMICAL
can	O
alleviate	O
alcohol	B-CHEMICAL
induced	O
liver	O
damage	O
through	O
preventing	O
lipid	O
formation	O
,	O
protecting	O
antioxidant	O
system	O
and	O
suppressing	O
productions	O
of	O
pro	O
-	O
inflammatory	O
cytokines	B-GENE-N
.	O

Lifelong	O
exposure	O
to	O
bisphenol	B-CHEMICAL
a	I-CHEMICAL
alters	O
cardiac	O
structure	O
/	O
function	O
,	O
protein	O
expression	O
,	O
and	O
DNA	O
methylation	O
in	O
adult	O
mice	O
.	O

Bisphenol	B-CHEMICAL
A	I-CHEMICAL
(	O
BPA	B-CHEMICAL
)	O
is	O
an	O
estrogenizing	O
endocrine	O
disruptor	O
compound	O
of	O
concern	O
.	O

Our	O
objective	O
was	O
to	O
test	O
whether	O
lifelong	O
BPA	B-CHEMICAL
would	O
impact	O
cardiac	O
structure	O
/	O
function	O
,	O
calcium	B-CHEMICAL
homeostasis	O
protein	O
expression	O
,	O
and	O
the	O
DNA	O
methylation	O
of	O
cardiac	O
genes	O
.	O

We	O
delivered	O
0	O
.	O
5	O
and	O
5	O
.	O
0	O
µg	O
/	O
kg	O
/	O
day	O
BPA	B-CHEMICAL
lifelong	O
from	O
gestation	O
day	O
11	O
or	O
200	O
µg	O
/	O
kg	O
/	O
day	O
from	O
gestation	O
day	O
11	O
to	O
postnatal	O
day	O
21	O
via	O
the	O
drinking	O
water	O
to	O
C57bl	O
/	O
6n	O
mice	O
.	O

BPA	B-CHEMICAL
5	O
.	O
0	O
males	O
and	O
females	O
had	O
increased	O
body	O
weight	O
,	O
body	O
mass	O
index	O
,	O
body	O
surface	O
area	O
,	O
and	O
adiposity	O
.	O

Echocardiography	O
identified	O
concentric	O
remodeling	O
in	O
all	O
BPA	B-CHEMICAL
-	O
treated	O
males	O
.	O

Systolic	O
and	O
diastolic	O
cardiac	O
functions	O
were	O
essentially	O
similar	O
,	O
but	O
lifelong	O
BPA	B-CHEMICAL
enhanced	O
male	O
and	O
reduced	O
female	O
sex	O
-	O
specific	O
differences	O
in	O
velocity	O
of	O
circumferential	O
shortening	O
and	O
ascending	O
aorta	O
velocity	O
time	O
integral	O
.	O

Diastolic	O
blood	O
pressure	O
was	O
increased	O
in	O
all	O
BPA	B-CHEMICAL
females	O
.	O

The	O
calcium	B-CHEMICAL
homeostasis	O
proteins	O
sarcoendoplasmic	B-GENE-Y
reticulum	I-GENE-Y
ATPase	I-GENE-Y
2a	I-GENE-Y
(	O
SERCA2a	B-GENE-Y
)	O
,	O
sodium	B-GENE-Y
calcium	I-GENE-Y
exchanger	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
phospholamban	B-GENE-Y
(	O
PLB	B-GENE-Y
)	O
,	O
phospho	B-GENE-Y
-	I-GENE-Y
PLB	I-GENE-Y
,	O
and	O
calsequestrin	B-GENE-Y
2	I-GENE-Y
are	O
important	O
for	O
contraction	O
and	O
relaxation	O
.	O

Changes	O
in	O
their	O
expression	O
suggest	O
increased	O
calcium	B-CHEMICAL
mobility	O
in	O
males	O
and	O
reduced	O
calcium	B-CHEMICAL
mobility	O
in	O
females	O
supporting	O
the	O
cardiac	O
function	O
changes	O
.	O

DNA	B-GENE-Y
methyltransferase	I-GENE-Y
3a	I-GENE-Y
expression	O
was	O
increased	O
in	O
all	O
BPA	B-CHEMICAL
males	O
and	O
BPA	B-CHEMICAL
0	O
.	O
5	O
females	O
and	O
reduced	O
in	O
BPA	B-CHEMICAL
200	O
females	O
.	O

Global	O
DNA	O
methylation	O
was	O
increased	O
in	O
BPA	B-CHEMICAL
0	O
.	O
5	O
males	O
and	O
reduced	O
in	O
BPA	B-CHEMICAL
0	O
.	O
5	O
females	O
.	O

BPA	B-CHEMICAL
induced	O
sex	O
-	O
specific	O
altered	O
DNA	O
methylation	O
in	O
specific	O
CpG	B-CHEMICAL
pairs	O
in	O
the	O
calsequestrin	B-GENE-Y
2	I-GENE-Y
CpG	O
island	O
.	O

These	O
results	O
suggest	O
that	O
continual	O
exposure	O
to	O
BPA	B-CHEMICAL
impacts	O
cardiac	O
structure	O
/	O
function	O
,	O
protein	O
expression	O
,	O
and	O
epigenetic	O
DNA	O
methylation	O
marks	O
in	O
males	O
and	O
females	O
.	O

The	O
Prevalence	O
of	O
Meeting	O
A1C	B-GENE-Y
,	O
Blood	O
Pressure	O
,	O
and	O
LDL	B-GENE-N
Goals	O
Among	O
People	O
With	O
Diabetes	O
,	O
1988	O
-	O
2010	O
.	O

OBJECTIVETo	O
determine	O
the	O
prevalence	O
of	O
people	O
with	O
diabetes	O
who	O
meet	O
hemoglobin	B-GENE-Y
A	I-GENE-Y
(	I-GENE-Y
1c	I-GENE-Y
)	I-GENE-Y
(	O
A1C	B-GENE-Y
)	O
,	O
blood	O
pressure	O
(	O
BP	O
)	O
,	O
and	O
LDL	B-GENE-N
cholesterol	B-CHEMICAL
(	O
ABC	O
)	O
recommendations	O
,	O
and	O
their	O
current	O
statin	O
use	O
,	O
factors	O
associated	O
with	O
goal	O
achievement	O
,	O
and	O
changes	O
in	O
the	O
proportion	O
achieving	O
goals	O
between	O
1988	O
and	O
2010	O
.	O
RESEARCH	O
AND	O
DESIGN	O
METHODSData	O
were	O
cross	O
-	O
sectional	O
from	O
the	O
National	O
Health	O
and	O
Nutrition	O
Examination	O
Surveys	O
(	O
NHANES	O
)	O
from	O
1988	O
-	O
1994	O
,	O
1999	O
-	O
2002	O
,	O
2003	O
-	O
2006	O
,	O
and	O
2007	O
-	O
2010	O
.	O

Participants	O
were	O
4	O
,	O
926	O
adults	O
aged	O
≥	O
20	O
years	O
who	O
self	O
-	O
reported	O
a	O
previous	O
diagnosis	O
of	O
diabetes	O
and	O
completed	O
the	O
household	O
interview	O
and	O
physical	O
examination	O
(	O
n	O
=	O
1	O
,	O
558	O
for	O
valid	O
LDL	O
levels	O
)	O
.	O

Main	O
outcome	O
measures	O
were	O
A1C	B-GENE-Y
,	O
BP	O
,	O
and	O
LDL	B-GENE-N
cholesterol	B-CHEMICAL
,	O
in	O
accordance	O
with	O
the	O
American	O
Diabetes	O
Association	O
recommendations	O
,	O
and	O
current	O
use	O
of	O
statins	O
.	O
RESULTSIn	O
2007	O
-	O
2010	O
,	O
52	O
.	O
5	O
%	O
of	O
people	O
with	O
diabetes	O
achieved	O
A1C	B-GENE-Y
<	O
7	O
.	O
0	O
%	O
(	O
<	O
53	O
mmol	O
/	O
mol	O
)	O
,	O
51	O
.	O
1	O
%	O
achieved	O
BP	O
<	O
130	O
/	O
80	O
mmHg	O
,	O
56	O
.	O
2	O
%	O
achieved	O
LDL	B-GENE-N
<	O
100	O
mg	O
/	O
dL	O
,	O
and	O
18	O
.	O
8	O
%	O
achieved	O
all	O
three	O
ABCs	O
.	O

These	O
levels	O
of	O
control	O
were	O
significant	O
improvements	O
from	O
1988	O
to	O
1994	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Statin	O
use	O
significantly	O
increased	O
between	O
1988	O
-	O
1994	O
(	O
4	O
.	O
2	O
%	O
)	O
and	O
2007	O
-	O
2010	O
(	O
51	O
.	O
4	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Compared	O
with	O
non	O
-	O
Hispanic	O
whites	O
,	O
Mexican	O
Americans	O
were	O
less	O
likely	O
to	O
meet	O
A1C	B-GENE-Y
and	O
LDL	B-GENE-N
goals	O
(	O
P	O
<	O
0	O
.	O
03	O
)	O
,	O
and	O
non	O
-	O
Hispanic	O
blacks	O
were	O
less	O
likely	O
to	O
meet	O
BP	O
and	O
LDL	B-GENE-N
goals	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
.	O

Compared	O
with	O
non	O
-	O
Hispanic	O
blacks	O
,	O
Mexican	O
Americans	O
were	O
less	O
likely	O
to	O
meet	O
A1C	B-GENE-Y
goals	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Younger	O
individuals	O
were	O
less	O
likely	O
to	O
meet	O
A1C	B-GENE-Y
and	O
LDL	B-GENE-N
goals	O
.	O
CONCLUSIONSDespite	O
significant	O
improvement	O
during	O
the	O
past	O
decade	O
,	O
achieving	O
the	O
ABC	O
goals	O
remains	O
suboptimal	O
among	O
adults	O
with	O
diabetes	O
,	O
particularly	O
in	O
some	O
minority	O
groups	O
.	O

Substantial	O
opportunity	O
exists	O
to	O
further	O
improve	O
diabetes	O
control	O
and	O
,	O
thus	O
,	O
to	O
reduce	O
diabetes	O
-	O
related	O
morbidity	O
and	O
mortality	O
.	O

Development	O
of	O
a	O
cell	O
-	O
based	O
high	O
-	O
throughput	O
peroxisome	B-GENE-N
proliferator	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
receptors	I-GENE-N
(	O
PPARs	B-GENE-N
)	O
screening	O
model	O
and	O
its	O
application	O
for	O
evaluation	O
of	O
the	O
extracts	O
from	O
Rhizoma	O
Coptis	O
.	O

To	O
date	O
,	O
peroxisome	B-GENE-N
proliferator	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
receptors	I-GENE-N
(	O
PPARs	B-GENE-N
)	O
are	O
becoming	O
the	O
new	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
metabolic	O
diseases	O
,	O
such	O
as	O
Type	O
2	O
diabetes	O
,	O
obesity	O
,	O
and	O
cardiovascular	O
disease	O
.	O

In	O
this	O
study	O
,	O
a	O
cell	O
-	O
based	O
high	O
-	O
throughput	O
PPARs	B-GENE-N
(	O
PPARα	B-GENE-N
/	I-GENE-N
β	I-GENE-N
/	I-GENE-N
γ	I-GENE-N
)	O
model	O
was	O
developed	O
for	O
the	O
screening	O
of	O
PPARs	B-GENE-N
agonists	O
.	O

The	O
screening	O
conditions	O
were	O
evaluated	O
through	O
analyzing	O
the	O
expression	O
value	O
of	O
luciferase	O
.	O

Finally	O
,	O
24	O
h	O
of	O
drug	O
acting	O
time	O
,	O
5	O
times	O
of	O
the	O
dilution	O
factor	O
of	O
luciferase	O
zymolyte	O
,	O
and	O
about	O
2	O
×	O
10	O
(	O
4	O
)	O
cells	O
/	O
well	O
on	O
HeLa	O
cells	O
in	O
96	O
-	O
well	O
plates	O
were	O
used	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
quality	O
of	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
in	O
stability	O
and	O
reliability	O
was	O
evaluated	O
by	O
the	O
Z	O
'	O
-	O
factor	O
.	O

Additionally	O
,	O
different	O
extracts	O
of	O
Rhizoma	O
Coptis	O
and	O
berberine	B-CHEMICAL
were	O
tested	O
by	O
the	O
developed	O
method	O
.	O

The	O
results	O
suggested	O
that	O
both	O
the	O
EtOAc	B-CHEMICAL
extract	O
and	O
berberine	B-CHEMICAL
were	O
able	O
to	O
activate	O
PPARα	B-GENE-N
/	I-GENE-N
β	I-GENE-N
/	I-GENE-N
γ	I-GENE-N
,	O
and	O
Rhizoma	O
Coptis	O
contains	O
potential	O
natural	O
agonists	O
of	O
PPARs	B-GENE-N
besides	O
berberine	B-CHEMICAL
.	O

In	O
conclusion	O
,	O
the	O
developed	O
HTS	O
assay	O
is	O
a	O
simple	O
,	O
rapid	O
,	O
stable	O
,	O
and	O
specific	O
method	O
for	O
the	O
screening	O
of	O
PPARs	B-GENE-N
natural	O
agonists	O
.	O

Charge	O
screening	O
between	O
anionic	O
and	O
cationic	O
surfactants	O
in	O
ionic	O
liquids	O
.	O

The	O
aggregation	O
and	O
interfacial	O
behavior	O
of	O
mixtures	O
of	O
anionic	O
(	O
sodium	B-CHEMICAL
dodecylsulfate	I-CHEMICAL
,	O
SDS	B-CHEMICAL
)	O
and	O
cationic	O
(	O
dodecylammonium	B-CHEMICAL
bromide	I-CHEMICAL
,	O
DTAB	B-CHEMICAL
)	O
surfactants	O
were	O
investigated	O
.	O

A	O
room	O
-	O
temperature	O
ionic	O
liquid	O
(	O
IL	O
)	O
was	O
explored	O
as	O
a	O
solvent	O
for	O
the	O
SDS	B-CHEMICAL
/	O
DTAB	B-CHEMICAL
system	O
and	O
compared	O
to	O
water	O
.	O

The	O
critical	O
micelle	O
concentration	O
(	O
cmc	O
)	O
and	O
composition	O
in	O
mixed	O
micelles	O
were	O
determined	O
for	O
both	O
solvents	O
.	O

Our	O
experiments	O
showed	O
nearly	O
ideal	O
mixing	O
of	O
SDS	B-CHEMICAL
/	O
DTAB	B-CHEMICAL
over	O
the	O
entire	O
composition	O
range	O
and	O
suggest	O
that	O
charge	O
screening	O
is	O
prominent	O
in	O
ILs	O
.	O

This	O
behavior	O
is	O
in	O
sharp	O
contrast	O
to	O
the	O
strong	O
electrostatic	O
attraction	O
and	O
a	O
multiphase	O
composition	O
gap	O
in	O
water	O
.	O

Two	O
models	O
by	O
Clint	O
and	O
Rubingh	O
,	O
which	O
describe	O
ideal	O
and	O
nonideal	O
micellar	O
behavior	O
,	O
respectively	O
,	O
are	O
discussed	O
on	O
the	O
basis	O
of	O
our	O
results	O
.	O

According	O
to	O
Rubingh	O
'	O
s	O
model	O
,	O
the	O
composition	O
of	O
mixed	O
micelles	O
is	O
gradually	O
changing	O
with	O
the	O
bulk	O
composition	O
in	O
ILs	O
but	O
tends	O
to	O
be	O
a	O
1	O
:	O
1	O
ratio	O
in	O
water	O
.	O

The	O
results	O
here	O
are	O
further	O
support	O
of	O
the	O
strong	O
charge	O
screening	O
in	O
ionic	O
liquids	O
.	O

Pelargonidin	B-CHEMICAL
activates	O
the	O
AhR	B-GENE-Y
and	O
induces	O
CYP1A1	B-GENE-Y
in	O
primary	O
human	O
hepatocytes	O
and	O
human	O
cancer	O
cell	O
lines	O
HepG2	O
and	O
LS174T	O
.	O

We	O
examined	O
the	O
effects	O
of	O
anthocyanidins	B-CHEMICAL
(	O
cyanidin	B-CHEMICAL
,	O
delphinidin	B-CHEMICAL
,	O
malvidin	B-CHEMICAL
,	O
peonidin	B-CHEMICAL
,	O
petunidin	B-CHEMICAL
,	O
pelargonidin	B-CHEMICAL
)	O
on	O
the	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AhR	B-GENE-Y
)	O
-	O
CYP1A1	B-GENE-Y
signaling	O
pathway	O
in	O
human	O
hepatocytes	O
,	O
hepatic	O
HepG2	O
and	O
intestinal	O
LS174T	O
cancer	O
cells	O
.	O

AhR	B-GENE-Y
-	O
dependent	O
reporter	O
gene	O
expression	O
in	O
transfected	O
HepG2	O
cells	O
was	O
increased	O
by	O
pelargonidin	B-CHEMICAL
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
at	O
24h	O
.	O

Similarly	O
,	O
pelargonidin	B-CHEMICAL
induced	O
the	O
expression	O
of	O
CYP1A1	B-GENE-Y
mRNA	O
up	O
to	O
5	O
-	O
fold	O
in	O
HepG2	O
and	O
LS174T	O
cells	O
relative	O
to	O
the	O
induction	O
by	O
5	O
nM	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzodioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
,	O
the	O
most	O
potent	O
activator	O
of	O
AhR	B-GENE-Y
.	O

CYP1A1	B-GENE-Y
and	O
CYP1A2	B-GENE-Y
mRNAs	O
were	O
also	O
increased	O
by	O
pelargonidin	B-CHEMICAL
in	O
three	O
primary	O
human	O
hepatocytes	O
cultures	O
(	O
approximately	O
5	O
%	O
of	O
TCDD	B-CHEMICAL
potency	O
)	O
and	O
the	O
increase	O
in	O
CYP1A1	B-GENE-Y
protein	O
in	O
HepG2	O
and	O
LS174T	O
cells	O
was	O
comparable	O
to	O
the	O
increase	O
in	O
catalytic	O
activity	O
of	O
CYP1A1	B-GENE-Y
enzyme	O
.	O

Ligand	O
binding	O
analysis	O
demonstrated	O
that	O
pelargonidin	B-CHEMICAL
was	O
a	O
weak	O
ligand	O
of	O
AhR	B-GENE-Y
.	O

Enzyme	O
kinetic	O
analyses	O
using	O
human	O
liver	O
microsomes	O
revealed	O
inhibition	O
of	O
CYP1A1	B-GENE-Y
activity	O
by	O
delphinidin	B-CHEMICAL
(	O
IC50	O
78	O
μM	O
)	O
and	O
pelargonidin	B-CHEMICAL
(	O
IC50	O
33	O
μM	O
)	O
.	O

Overall	O
,	O
although	O
most	O
anthocyanidins	B-CHEMICAL
had	O
no	O
effects	O
on	O
AhR	B-GENE-Y
-	O
CYP1A1	B-GENE-Y
signaling	O
,	O
pelargonidin	B-CHEMICAL
can	O
bind	O
to	O
and	O
activate	O
the	O
AhR	B-GENE-Y
and	O
AhR	B-GENE-Y
-	O
dependent	O
gene	O
expression	O
,	O
and	O
pelargonidin	B-CHEMICAL
and	O
delphinidin	B-CHEMICAL
inhibit	O
the	O
CYP1A1	B-GENE-Y
catalytic	O
activity	O
.	O

Metformin	B-CHEMICAL
and	O
Sulfonylureas	B-CHEMICAL
in	O
Relation	O
to	O
Cancer	O
Risk	O
in	O
Type	O
II	O
Diabetes	O
Patients	O
:	O
A	O
Meta	O
-	O
analysis	O
using	O
primary	O
data	O
of	O
published	O
studies	O
.	O

INTRODUCTION	O
:	O
Accumulating	O
evidence	O
suggests	O
that	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
hyperinsulinemia	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
malignancies	O
.	O

It	O
remains	O
to	O
be	O
fully	O
elucidated	O
whether	O
use	O
of	O
metformin	B-CHEMICAL
,	O
an	O
insulin	B-GENE-Y
sensitizer	O
,	O
and	O
/	O
or	O
sulfonylureas	B-CHEMICAL
,	O
insulin	B-GENE-Y
secretagogues	O
,	O
affect	O
cancer	O
incidence	O
in	O
subjects	O
with	O
T2DM	O
.	O

MATERIAL	O
&	O
METHODS	O
:	O
We	O
performed	O
a	O
meta	O
-	O
analysis	O
using	O
PubMed	O
,	O
of	O
randomized	O
control	O
trials	O
(	O
RCTs	O
)	O
,	O
cohorts	O
,	O
and	O
case	O
-	O
control	O
studies	O
published	O
through	O
July	O
2012	O
that	O
assess	O
effects	O
of	O
metformin	B-CHEMICAL
and	O
/	O
or	O
sulfonylurea	B-CHEMICAL
sulfonylureas	B-CHEMICAL
on	O
cancer	O
risk	O
at	O
any	O
site	O
,	O
in	O
subjects	O
with	O
T2DM	O
.	O

Fixed	O
and	O
random	O
effects	O
meta	O
-	O
analysis	O
models	O
were	O
used	O
,	O
and	O
the	O
effect	O
size	O
was	O
summarized	O
as	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
RCTs	O
/	O
cohorts	O
and	O
as	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
the	O
case	O
-	O
control	O
studies	O
.	O

RESULTS	O
:	O
Analysis	O
of	O
24	O
metformin	B-CHEMICAL
studies	O
in	O
subjects	O
with	O
T2DM	O
showed	O
that	O
metformin	B-CHEMICAL
use	O
is	O
associated	O
with	O
reduced	O
risk	O
for	O
the	O
development	O
of	O
cancer	O
,	O
in	O
both	O
cohort	O
(	O
RR	O
=	O
0	O
.	O
70	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
67	O
-	O
0	O
.	O
73	O
]	O
)	O
and	O
case	O
-	O
control	O
studies	O
(	O
OR	O
=	O
0	O
.	O
90	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
84	O
-	O
0	O
.	O
98	O
]	O
)	O
,	O
but	O
this	O
finding	O
was	O
not	O
supported	O
by	O
RCTs	O
(	O
RR	O
=	O
1	O
.	O
01	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
81	O
-	O
1	O
.	O
26	O
]	O
)	O
.	O

Data	O
from	O
18	O
sulfonylurea	B-CHEMICAL
studies	O
in	O
subjects	O
with	O
T2DM	O
showed	O
that	O
sulfonylurea	B-CHEMICAL
use	O
is	O
associated	O
with	O
an	O
increase	O
in	O
all	O
-	O
cancer	O
risk	O
,	O
in	O
cohort	O
studies	O
(	O
RR	O
=	O
1	O
.	O
55	O
[	O
95	O
%	O
CI	O
=	O
1	O
.	O
48	O
-	O
1	O
.	O
63	O
]	O
)	O
,	O
though	O
data	O
from	O
RCTs	O
(	O
RR	O
=	O
1	O
.	O
17	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
95	O
-	O
1	O
.	O
45	O
]	O
)	O
and	O
case	O
-	O
control	O
studies	O
(	O
OR	O
=	O
1	O
.	O
02	O
[	O
95	O
%	O
CI	O
=	O
0	O
.	O
93	O
-	O
1	O
.	O
13	O
]	O
)	O
failed	O
to	O
demonstrate	O
a	O
statistically	O
significant	O
effect	O
.	O

CONCLUSIONS	O
:	O
This	O
analysis	O
using	O
pooled	O
primary	O
data	O
demonstrates	O
that	O
metformin	B-CHEMICAL
use	O
reduces	O
,	O
while	O
sulfonylurea	B-CHEMICAL
use	O
may	O
be	O
associated	O
with	O
an	O
increased	O
cancer	O
risk	O
in	O
subjects	O
with	O
T2DM	O
.	O

These	O
findings	O
need	O
to	O
be	O
confirmed	O
in	O
large	O
-	O
scale	O
RCTs	O
before	O
they	O
are	O
translated	O
into	O
clinical	O
practice	O
.	O

Bioactive	O
phenolics	B-CHEMICAL
from	O
Seriphidium	O
stenocephalum	O
.	O

Chromatographic	O
separation	O
of	O
the	O
ethyl	B-CHEMICAL
acetate	I-CHEMICAL
soluble	O
part	O
of	O
the	O
methanolic	O
extract	O
from	O
Seriphidium	O
stenocephalum	O
yielded	O
three	O
new	O
compounds	O
:	O
stenocepflavone	B-CHEMICAL
(	O
1	O
)	O
,	O
stenocepflavan	B-CHEMICAL
(	O
2	O
)	O
,	O
and	O
stenocephol	B-CHEMICAL
(	O
3	O
)	O
,	O
together	O
with	O
cirsimaritin	B-CHEMICAL
(	O
4	O
)	O
,	O
5	B-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
trihydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
trimethoxyflavone	I-CHEMICAL
(	O
5	O
)	O
,	O
5	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetrahydroxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
methoxyflavone	I-CHEMICAL
(	O
6	O
)	O
,	O
and	O
axillaroside	B-CHEMICAL
(	O
7	O
)	O
.	O

All	O
isolates	O
were	O
characterized	O
with	O
the	O
help	O
of	O
spectroscopic	O
data	O
including	O
1D	O
,	O
2D	O
NMR	O
,	O
and	O
high	O
resolution	O
mass	O
spectrometry	O
and	O
/	O
or	O
in	O
comparison	O
with	O
the	O
related	O
compounds	O
in	O
literature	O
.	O

All	O
compounds	O
were	O
tested	O
for	O
in	O
vitro	O
enzyme	O
inhibitory	O
activities	O
against	O
acetylcholinesterase	B-GENE-Y
,	O
butyrylcholinesterase	B-GENE-Y
,	O
and	O
lipoxygenase	B-GENE-N
.	O

Compounds	O
1	O
and	O
4	O
-	O
7	O
exhibited	O
significant	O
activity	O
against	O
all	O
the	O
tested	O
enzymes	O
,	O
whereas	O
compounds	O
2	O
and	O
3	O
were	O
found	O
inactive	O
.	O

SIRT1	B-GENE-Y
inhibits	O
NADPH	B-GENE-N
oxidase	I-GENE-N
activation	O
and	O
protects	O
endothelial	O
function	O
in	O
the	O
rat	O
aorta	O
:	O
Implications	O
for	O
vascular	O
aging	O
.	O

Vascular	O
aging	O
is	O
characterized	O
by	O
up	O
-	O
regulation	O
of	O
NADPH	B-GENE-N
oxidase	I-GENE-N
,	O
oxidative	O
stress	O
and	O
endothelial	O
dysfunction	O
.	O

Previous	O
studies	O
demonstrate	O
that	O
the	O
activity	O
of	O
the	O
evolutionarily	O
conserved	O
NAD	B-GENE-Y
(	I-GENE-Y
+	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
deacetylase	I-GENE-Y
SIRT1	I-GENE-Y
declines	O
with	O
age	O
and	O
that	O
pharmacological	O
activators	O
of	O
SIRT1	B-GENE-Y
confer	O
significant	O
anti	O
-	O
aging	O
cardiovascular	O
effects	O
.	O

To	O
determine	O
whether	O
dysregulation	O
of	O
SIRT1	B-GENE-Y
promotes	O
NADPH	B-GENE-N
oxidase	I-GENE-N
-	O
dependent	O
production	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
and	O
impairs	O
endothelial	O
function	O
we	O
assessed	O
the	O
effects	O
of	O
three	O
structurally	O
different	O
inhibitors	O
of	O
SIRT1	B-GENE-Y
(	O
nicotinamide	B-CHEMICAL
,	O
sirtinol	B-CHEMICAL
,	O
EX527	B-CHEMICAL
)	O
in	O
aorta	O
segments	O
isolated	O
from	O
young	O
Wistar	O
rats	O
.	O

Inhibition	O
of	O
SIRT1	B-GENE-Y
induced	O
endothelial	O
dysfunction	O
,	O
as	O
shown	O
by	O
the	O
significantly	O
reduced	O
relaxation	O
to	O
the	O
endothelium	O
-	O
dependent	O
vasodilators	O
acetylcholine	B-CHEMICAL
and	O
the	O
calcium	B-CHEMICAL
ionophore	O
A23187	B-CHEMICAL
.	O

Endothelial	O
dysfunction	O
induced	O
by	O
SIRT1	B-GENE-Y
inhibition	O
was	O
prevented	O
by	O
treatment	O
of	O
the	O
vessels	O
with	O
the	O
NADPH	B-GENE-N
oxidase	I-GENE-N
inhibitor	O
apocynin	B-CHEMICAL
or	O
superoxide	B-GENE-N
dismutase	I-GENE-N
.	O

Inhibition	O
of	O
SIRT1	B-GENE-Y
significantly	O
increased	O
vascular	O
superoxide	B-CHEMICAL
production	O
,	O
enhanced	O
NADPH	B-GENE-N
oxidase	I-GENE-N
activity	O
,	O
and	O
mRNA	O
expression	O
of	O
its	O
subunits	O
p22	B-GENE-Y
(	I-GENE-Y
phox	I-GENE-Y
)	I-GENE-Y
and	O
NOX4	B-GENE-Y
,	O
which	O
were	O
prevented	O
by	O
resveratrol	B-CHEMICAL
.	O

Peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
PPARα	B-GENE-Y
)	O
activation	O
mimicked	O
the	O
effects	O
of	O
resveratrol	B-CHEMICAL
while	O
PPARα	B-GENE-Y
inhibition	O
prevented	O
the	O
effects	O
of	O
this	O
SIRT1	B-GENE-Y
activator	O
.	O

SIRT1	B-GENE-Y
co	O
-	O
precipitated	O
with	O
PPARα	B-GENE-Y
and	O
nicotinamide	B-CHEMICAL
increased	O
the	O
acetylation	O
of	O
the	O
PPARα	B-GENE-Y
coactivator	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
,	O
which	O
was	O
suppressed	O
by	O
resveratrol	B-CHEMICAL
.	O

In	O
conclusion	O
,	O
impaired	O
activity	O
of	O
SIRT1	B-GENE-Y
induces	O
endothelial	O
dysfunction	O
and	O
up	O
-	O
regulates	O
NADPH	B-GENE-N
oxidase	I-GENE-N
-	O
derived	O
ROS	O
production	O
in	O
the	O
vascular	O
wall	O
,	O
mimicking	O
the	O
vascular	O
aging	O
phenotype	O
.	O

Moreover	O
,	O
a	O
new	O
mechanism	O
for	O
controlling	O
endothelial	O
function	O
after	O
SIRT1	B-GENE-Y
activation	O
involves	O
a	O
decreased	O
PGC	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
acetylation	O
and	O
the	O
subsequent	O
PPARα	B-GENE-Y
activation	O
,	O
resulting	O
in	O
both	O
decreased	O
NADPH	B-GENE-N
oxidase	I-GENE-N
-	O
driven	O
ROS	O
production	O
and	O
NO	B-CHEMICAL
inactivation	O
.	O

Balancing	O
societal	O
needs	O
and	O
regulatory	O
certainty	O
:	O
the	O
case	O
study	O
of	O
peramivir	B-CHEMICAL
in	O
Japan	O
.	O

Regulators	O
must	O
balance	O
societal	O
and	O
medical	O
requirements	O
against	O
the	O
need	O
for	O
certainty	O
about	O
benefit	O
and	O
risk	O
for	O
new	O
medicines	O
.	O

This	O
is	O
described	O
in	O
a	O
case	O
study	O
of	O
the	O
expedited	O
review	O
and	O
approval	O
of	O
peramivir	B-CHEMICAL
,	O
a	O
novel	O
neuraminidase	B-GENE-N
inhibitor	O
,	O
in	O
Japan	O
in	O
the	O
context	O
of	O
the	O
emergence	O
of	O
new	O
strain	O
of	O
influenza	O
in	O
2009	O
.	O

The	O
case	O
illustrates	O
the	O
importance	O
of	O
regulatory	O
science	O
and	O
transparency	O
in	O
supporting	O
such	O
decision	O
making	O
.	O

High	O
-	O
glucose	B-CHEMICAL
environment	O
enhanced	O
oxidative	O
stress	O
and	O
increased	O
interleukin	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
secretion	O
from	O
keratinocytes	O
:	O
New	O
insights	O
on	O
impaired	O
diabetic	O
wound	O
healing	O
.	O

Impaired	O
wound	O
healing	O
frequently	O
occurs	O
in	O
patients	O
with	O
diabetes	O
.	O

Interluekin	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
)	O
production	O
by	O
keratinocyte	O
is	O
responsible	O
for	O
recruiting	O
neutrophils	O
during	O
healing	O
.	O

Intense	O
inflammation	O
is	O
associated	O
with	O
diabetic	O
wounds	O
while	O
reduction	O
of	O
neutrophil	O
infiltration	O
is	O
associated	O
with	O
enhanced	O
healing	O
.	O

We	O
hypothesized	O
that	O
increased	O
neutrophil	O
recruitment	O
by	O
keratinocytes	O
may	O
contribute	O
to	O
the	O
delayed	O
healing	O
of	O
diabetic	O
wound	O
.	O

Using	O
cultured	O
human	O
keratinocytes	O
and	O
diabetic	O
rat	O
model	O
,	O
the	O
current	O
study	O
showed	O
that	O
high	O
-	O
glucose	B-CHEMICAL
environment	O
enhanced	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
production	O
via	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
-	O
extracelluar	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
pathway	O
in	O
a	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
-	O
dependent	O
manner	O
in	O
keratinocytes	O
.	O

In	O
addition	O
,	O
diabetic	O
rat	O
skin	O
showed	O
enhanced	O
EGFR	B-GENE-Y
,	O
ERK	B-GENE-N
and	O
IL	B-GENE-N
-	I-GENE-N
8	I-GENE-N
expression	O
as	O
compared	O
to	O
control	O
rats	O
.	O

The	O
dermal	O
neutrophil	O
infiltration	O
of	O
the	O
wound	O
,	O
as	O
represented	O
by	O
expression	O
of	O
myeloperoxidase	B-GENE-Y
level	O
,	O
was	O
also	O
significantly	O
higher	O
in	O
diabetic	O
rats	O
.	O

Treating	O
diabetic	O
rats	O
with	O
dapsone	B-CHEMICAL
,	O
an	O
agent	O
known	O
to	O
inhibit	O
neutrophil	O
function	O
,	O
was	O
associated	O
with	O
improved	O
healing	O
.	O

In	O
conclusion	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
production	O
and	O
neutrophil	O
infiltration	O
are	O
increased	O
in	O
high	O
-	O
glucose	B-CHEMICAL
environment	O
due	O
to	O
elevated	O
ROS	O
level	O
and	O
contributed	O
to	O
impaired	O
wound	O
healing	O
in	O
diabetic	O
skin	O
.	O

Targeting	O
these	O
dysfunctions	O
may	O
present	O
novel	O
therapeutic	O
approaches	O
.	O

Modulation	O
of	O
cytochrome	B-GENE-N
P450	I-GENE-N
1	I-GENE-N
(	O
Cyp1	B-GENE-N
)	O
by	O
vanadium	B-CHEMICAL
in	O
hepatic	O
tissue	O
and	O
isolated	O
hepatocyte	O
of	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
vanadium	B-CHEMICAL
(	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
)	O
on	O
Cyp1	B-GENE-N
expression	O
and	O
activity	O
in	O
C57BL	O
/	O
6	O
mice	O
liver	O
and	O
isolated	O
hepatocytes	O
.	O

For	O
this	O
purpose	O
,	O
C57BL6	O
mice	O
were	O
injected	O
intraperitoneally	O
with	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
5	O
mg	O
/	O
kg	O
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
(	O
15	O
μg	O
/	O
kg	O
)	O
for	O
6	O
and	O
24	O
h	O
.	O

Furthermore	O
,	O
isolated	O
hepatocytes	O
from	O
C57BL6	O
mice	O
were	O
treated	O
with	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
5	O
,	O
10	O
,	O
and	O
20	O
μM	O
)	O
in	O
the	O
absence	O
and	O
presence	O
of	O
TCDD	B-CHEMICAL
(	O
1	O
nM	O
)	O
for	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
24	O
h	O
.	O

In	O
vivo	O
,	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
alone	O
did	O
not	O
significantly	O
alter	O
Cyp1a1	B-GENE-Y
,	O
Cyp1a2	B-GENE-Y
,	O
or	O
Cyp1b1	B-GENE-Y
mRNA	O
,	O
protein	O
,	O
or	O
catalytic	O
activity	O
levels	O
.	O

Upon	O
co	O
-	O
exposure	O
to	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
and	O
TCDD	B-CHEMICAL
,	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
significantly	O
potentiated	O
the	O
TCDD	B-CHEMICAL
-	O
mediated	O
induction	O
of	O
the	O
Cyp1a1	B-GENE-Y
,	O
Cyp1a2	B-GENE-Y
,	O
and	O
Cyp1b1	B-GENE-Y
mRNA	O
,	O
protein	O
,	O
and	O
catalytic	O
activity	O
levels	O
at	O
24	O
h	O
.	O

In	O
vitro	O
,	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
decreased	O
the	O
TCDD	B-CHEMICAL
-	O
mediated	O
induction	O
of	O
Cyp1a1	B-GENE-Y
mRNA	O
,	O
protein	O
,	O
and	O
catalytic	O
activity	O
levels	O
.	O

Furthermore	O
,	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
significantly	O
inhibited	O
the	O
TCDD	B-CHEMICAL
-	O
induced	O
AhR	B-GENE-Y
-	O
dependent	O
luciferase	O
activity	O
.	O

V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
also	O
increased	O
serum	B-GENE-N
hemoglobin	I-GENE-N
(	O
Hb	B-GENE-N
)	O
levels	O
in	O
animals	O
treated	O
for	O
24	O
h	O
.	O

Upon	O
treatment	O
of	O
isolated	O
hepatocytes	O
with	O
Hb	B-GENE-N
alone	O
or	O
in	O
the	O
presence	O
of	O
TCDD	B-CHEMICAL
,	O
there	O
was	O
an	O
increase	O
in	O
the	O
AhR	B-GENE-Y
-	O
dependent	O
luciferase	O
activity	O
.	O

When	O
isolated	O
hepatocytes	O
were	O
treated	O
for	O
2	O
h	O
with	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
in	O
the	O
presence	O
of	O
TCDD	B-CHEMICAL
,	O
followed	O
by	O
replacement	O
of	O
the	O
medium	O
with	O
new	O
medium	O
containing	O
Hb	B-GENE-N
,	O
there	O
was	O
further	O
potentiation	O
to	O
the	O
TCDD	B-CHEMICAL
-	O
mediated	O
effect	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
there	O
is	O
a	O
differential	O
modulation	O
of	O
Cyp1a1	B-GENE-Y
by	O
V	B-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
in	O
C57BL	O
/	O
6	O
mice	O
livers	O
and	O
isolated	O
hepatocytes	O
and	O
demonstrates	O
Hb	B-GENE-N
as	O
an	O
in	O
vivo	O
specific	O
modulator	O
.	O

TCDD	B-CHEMICAL
inhibition	O
of	O
canonical	O
wnt	B-GENE-N
signaling	O
disrupts	O
prostatic	O
bud	O
formation	O
in	O
mouse	O
urogenital	O
sinus	O
.	O

In	O
mice	O
,	O
in	O
utero	O
exposure	O
to	O
2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
reduces	O
the	O
number	O
of	O
dorsolateral	O
prostatic	O
buds	O
resulting	O
in	O
a	O
smaller	O
dorsolateral	O
prostate	O
and	O
prevents	O
formation	O
of	O
ventral	O
buds	O
culminating	O
in	O
ventral	O
prostate	O
agenesis	O
.	O

The	O
genes	O
and	O
signaling	O
pathways	O
affected	O
by	O
TCDD	B-CHEMICAL
that	O
are	O
responsible	O
for	O
disrupting	O
prostate	O
development	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
treatment	O
of	O
urogenital	O
sinus	O
(	O
UGS	O
)	O
organ	O
cultures	O
with	O
known	O
inhibitors	O
of	O
canonical	O
Wnt	B-GENE-N
signaling	O
also	O
inhibits	O
prostatic	O
bud	O
formation	O
.	O

In	O
support	O
of	O
the	O
hypothesis	O
that	O
TCDD	B-CHEMICAL
decreases	O
canonical	O
Wnt	B-GENE-N
signaling	O
,	O
we	O
identify	O
inhibitory	O
effects	O
of	O
TCDD	B-CHEMICAL
on	O
multiple	O
components	O
of	O
the	O
canonical	O
Wnt	B-GENE-N
signaling	O
pathway	O
in	O
the	O
UGS	O
that	O
temporally	O
coincide	O
with	O
the	O
inhibitory	O
effect	O
of	O
TCDD	B-CHEMICAL
on	O
prostatic	O
bud	O
formation	O
:	O
(	O
1	O
)	O
expression	O
of	O
R	B-GENE-N
-	I-GENE-N
spondins	I-GENE-N
(	O
Rspo2	B-GENE-Y
and	O
Rspo3	B-GENE-Y
)	O
that	O
promote	O
canonical	O
Wnt	B-GENE-N
signaling	O
is	O
reduced	O
;	O
(	O
2	O
)	O
expression	O
of	O
Lef1	B-GENE-Y
,	O
Tcf1	B-GENE-Y
,	O
and	O
Wif1	B-GENE-Y
,	O
established	O
canonical	O
Wnt	B-GENE-N
target	O
genes	O
,	O
is	O
decreased	O
;	O
(	O
3	O
)	O
expression	O
of	O
Lgr5	B-GENE-Y
,	O
a	O
RSPO	B-GENE-Y
receptor	I-GENE-Y
that	O
activates	O
canonical	O
Wnt	B-GENE-N
signaling	O
,	O
is	O
reduced	O
;	O
and	O
(	O
4	O
)	O
expression	O
of	O
Dickkopfs	B-GENE-N
(	O
Dkks	B-GENE-N
)	O
,	O
inhibitors	O
of	O
canonical	O
Wnt	B-GENE-N
signaling	O
,	O
is	O
not	O
increased	O
by	O
TCDD	B-CHEMICAL
.	O

Thus	O
,	O
the	O
TCDD	B-CHEMICAL
-	O
induced	O
reduction	O
in	O
canonical	O
Wnt	B-GENE-N
signaling	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
activators	O
(	O
Rspo2	B-GENE-Y
and	O
Rspo3	B-GENE-Y
)	O
rather	O
than	O
an	O
increase	O
in	O
inhibitors	O
(	O
Dkk1	B-GENE-Y
and	O
Dkk2	B-GENE-Y
)	O
of	O
the	O
pathway	O
.	O

This	O
study	O
focuses	O
on	O
determining	O
whether	O
treatment	O
of	O
TCDD	B-CHEMICAL
-	O
exposed	O
UGS	O
organ	O
cultures	O
with	O
RSPO2	B-GENE-Y
and	O
/	O
or	O
RSPO3	B-GENE-Y
is	O
capable	O
of	O
rescuing	O
the	O
inhibitory	O
effects	O
of	O
TCDD	B-CHEMICAL
on	O
canonical	O
Wnt	B-GENE-N
signaling	O
and	O
prostatic	O
bud	O
formation	O
.	O

We	O
discovered	O
that	O
each	O
RSPO	B-GENE-N
alone	O
or	O
in	O
combination	O
partially	O
rescues	O
TCDD	B-CHEMICAL
inhibition	O
of	O
both	O
canonical	O
Wnt	B-GENE-N
signaling	O
and	O
prostatic	O
bud	O
formation	O
.	O

The	O
Interaction	O
of	O
Adrenomedullin	B-GENE-Y
and	O
Macrophages	O
Induces	O
Ovarian	O
Cancer	O
Cell	O
Migration	O
via	O
Activation	O
of	O
RhoA	B-GENE-Y
Signaling	O
Pathway	O
.	O

Tumor	O
-	O
associated	O
macrophages	O
(	O
TAMs	O
)	O
are	O
correlated	O
with	O
poor	O
prognosis	O
in	O
many	O
human	O
cancers	O
;	O
however	O
,	O
the	O
mechanism	O
by	O
which	O
TAMs	O
facilitate	O
ovarian	O
cancer	O
cell	O
migration	O
and	O
invasion	O
remains	O
unknown	O
.	O

This	O
study	O
was	O
aimed	O
to	O
examine	O
the	O
function	O
of	O
adrenomedullin	B-GENE-Y
(	O
ADM	B-GENE-Y
)	O
in	O
macrophage	O
polarization	O
and	O
their	O
further	O
effects	O
on	O
the	O
migration	O
of	O
ovarian	O
cancer	O
cells	O
.	O

Exogenous	O
ADM	B-GENE-Y
antagonist	O
and	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
specific	O
for	O
ADM	B-GENE-Y
expression	O
were	O
treated	O
to	O
macrophages	O
and	O
EOC	O
cell	O
line	O
HO8910	O
,	O
respectively	O
.	O

Then	O
macrophages	O
were	O
cocultured	O
with	O
HO8910	O
cells	O
without	O
direct	O
contact	O
.	O

Flow	O
cytometry	O
,	O
Western	O
blot	O
and	O
real	O
-	O
time	O
PCR	O
were	O
used	O
to	O
detect	O
macrophage	O
phenotype	O
and	O
cytokine	B-GENE-N
production	O
.	O

The	O
migration	O
ability	O
and	O
cytoskeleton	O
rearrangement	O
of	O
ovarian	O
cancer	O
cells	O
were	O
determined	O
by	O
Transwell	O
migration	O
assay	O
and	O
phalloidin	B-CHEMICAL
staining	O
.	O

Western	O
blot	O
was	O
performed	O
to	O
evaluate	O
the	O
activity	O
status	O
of	O
signaling	O
molecules	O
in	O
the	O
process	O
of	O
ovarian	O
cancer	O
cell	O
migration	O
.	O

The	O
results	O
showed	O
that	O
ADM	B-GENE-Y
induced	O
macrophage	O
phenotype	O
and	O
cytokine	B-GENE-N
production	O
similar	O
to	O
TAMs	O
.	O

Macrophages	O
polarized	O
by	O
ADM	B-GENE-Y
promoted	O
the	O
migration	O
and	O
cytoskeleton	O
rearrangement	O
of	O
HO8910	O
cells	O
.	O

The	O
expression	O
of	O
RhoA	B-GENE-Y
and	O
its	O
downstream	O
effector	O
,	O
cofilin	B-GENE-N
,	O
were	O
upregulated	O
in	O
macrophage	O
-	O
induced	O
migration	O
of	O
HO8910	O
cells	O
.	O

In	O
conclusion	O
,	O
ADM	B-GENE-Y
could	O
polarize	O
macrophages	O
similar	O
to	O
TAMs	O
,	O
and	O
then	O
polarized	O
macrophages	O
promote	O
the	O
migration	O
of	O
ovarian	O
cancer	O
cells	O
via	O
activation	O
of	O
RhoA	B-GENE-Y
signaling	O
pathway	O
in	O
vitro	O
.	O

TCF7L2	B-GENE-Y
Variation	O
and	O
Proliferative	O
Diabetic	O
Retinopathy	O
.	O

Proliferative	O
diabetic	O
retinopathy	O
(	O
PDR	O
)	O
is	O
the	O
most	O
severe	O
vision	O
-	O
threatening	O
complication	O
of	O
diabetes	O
.	O

To	O
investigated	O
genetic	O
association	O
between	O
TCF7L2	B-GENE-Y
and	O
PDR	O
in	O
Caucasian	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
and	O
its	O
functional	O
consequences	O
,	O
383	O
T2DM	O
patients	O
with	O
PDR	O
(	O
T2DM	O
-	O
PDR	O
)	O
and	O
756	O
T2DM	O
patients	O
without	O
diabetic	O
retinopathy	O
(	O
T2DM	O
-	O
no	O
DR	O
)	O
were	O
genotyped	O
with	O
rs7903146	O
in	O
TCF7L2	B-GENE-Y
.	O

We	O
found	O
that	O
risk	O
allele	O
(	O
T	O
)	O
frequency	O
of	O
rs7903146	O
was	O
significantly	O
higher	O
in	O
T2DM	O
-	O
PDR	O
patients	O
(	O
allelic	O
P	O
=	O
2	O
.	O
52E	O
-	O
04	O
)	O
.	O

In	O
lymphoblastoid	O
cells	O
induced	O
to	O
undergo	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
by	O
treatment	O
of	O
tunicamycin	B-CHEMICAL
,	O
higher	O
fold	O
change	O
of	O
TCF7L2	B-GENE-Y
and	O
VEGFA	B-GENE-Y
mRNA	O
levels	O
were	O
observed	O
in	O
rs7903146	O
-	O
TT	O
cells	O
than	O
that	O
in	O
rs7903146	O
-	O
CC	O
cells	O
(	O
P	O
=	O
0	O
.	O
02	O
for	O
TCF7L2	B-GENE-Y
;	O
P	O
=	O
0	O
.	O
004	O
for	O
VEGFA	B-GENE-Y
)	O
,	O
suggesting	O
ER	O
stress	O
plays	O
a	O
role	O
in	O
PDR	O
pathogenesis	O
.	O

Silencing	O
TCF7L2	B-GENE-Y
resulted	O
in	O
decreased	O
mRNA	O
levels	O
of	O
both	O
TCF7L2	B-GENE-Y
and	O
VEGFA	B-GENE-Y
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Retinas	O
of	O
oxygen	B-CHEMICAL
-	O
induced	O
retinopathy	O
(	O
OIR	O
)	O
mice	O
(	O
a	O
model	O
for	O
PDR	O
)	O
had	O
higher	O
TCF7L2	B-GENE-Y
and	O
VEGFA	B-GENE-Y
mRNA	O
levels	O
than	O
controls	O
(	O
P	O
=	O
2	O
.	O
9E	O
-	O
04	O
for	O
TCF7L2	B-GENE-Y
;	O
P	O
=	O
1	O
.	O
9E	O
-	O
07	O
for	O
VEGFA	B-GENE-Y
)	O
.	O

Together	O
,	O
our	O
study	O
showed	O
that	O
TCF7L2	B-GENE-Y
-	O
rs7903146	O
is	O
associated	O
with	O
PDR	O
in	O
Caucasian	O
T2DM	O
and	O
suggested	O
TCF7L2	B-GENE-Y
promoted	O
pathological	O
retinal	O
neovascularization	O
via	O
ER	O
stress	O
-	O
dependent	O
upregulation	O
of	O
VEGFA	B-GENE-Y
.	O

Changes	O
in	O
A1C	B-GENE-Y
Levels	O
Are	O
Significantly	O
Associated	O
With	O
Changes	O
in	O
Levels	O
of	O
the	O
Cardiovascular	O
Risk	O
Biomarker	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
:	O
Results	O
from	O
SteP	O
Study	O
.	O

OBJECTIVEThe	O
effect	O
of	O
therapeutic	O
strategies	O
on	O
cardiovascular	O
(	O
CV	O
)	O
disease	O
can	O
be	O
evaluated	O
by	O
monitoring	O
changes	O
in	O
CV	O
risk	O
biomarkers	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
a	O
structured	O
self	O
-	O
monitoring	O
of	O
blood	O
glucose	B-CHEMICAL
(	O
SMBG	O
)	O
protocol	O
and	O
the	O
resulting	O
improvements	O
in	O
glycemic	O
control	O
on	O
changes	O
in	O
high	O
-	O
sensitivity	O
C	B-GENE-Y
-	I-GENE-Y
reactive	I-GENE-Y
protein	I-GENE-Y
(	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
)	O
in	O
insulin	B-GENE-Y
-	O
naïve	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODSThe	O
Structured	O
Testing	O
Program	O
(	O
STeP	O
)	O
study	O
was	O
a	O
prospective	O
,	O
cluster	O
-	O
randomized	O
,	O
multicenter	O
trial	O
in	O
which	O
483	O
poorly	O
controlled	O
,	O
insulin	B-GENE-Y
-	O
naïve	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
randomized	O
to	O
active	O
control	O
(	O
ACG	O
)	O
or	O
structured	O
testing	O
(	O
STG	O
)	O
that	O
included	O
quarterly	O
structured	O
SMBG	O
.	O

Changes	O
in	O
A1C	B-GENE-Y
,	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
,	O
and	O
glycemic	O
variability	O
(	O
STG	O
subjects	O
only	O
)	O
were	O
measured	O
at	O
baseline	O
and	O
quarterly	O
.	O
RESULTSReductions	O
in	O
geometric	O
mean	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
values	O
were	O
significantly	O
greater	O
in	O
the	O
STG	O
group	O
at	O
months	O
3	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
,	O
6	O
(	O
P	O
=	O
0	O
.	O
0003	O
)	O
,	O
and	O
12	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
than	O
in	O
the	O
ACG	O
group	O
.	O

STG	O
patients	O
at	O
high	O
CV	O
risk	O
(	O
>	O
3	O
mg	O
/	O
L	O
)	O
showed	O
significantly	O
greater	O
reductions	O
in	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
levels	O
than	O
ACG	O
patients	O
at	O
high	O
CV	O
risk	O
:	O
-	O
3	O
.	O
64	O
mg	O
/	O
dL	O
(	O
95	O
%	O
CI	O
-	O
4	O
.	O
21	O
to	O
-	O
3	O
.	O
06	O
)	O
versus	O
-	O
2	O
.	O
18	O
mg	O
/	O
dL	O
(	O
-	O
2	O
.	O
93	O
to	O
-	O
1	O
.	O
43	O
)	O
,	O
respectively	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
reductions	O
in	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
and	O
A1C	B-GENE-Y
in	O
both	O
groups	O
:	O
standardized	O
coefficient	O
(	O
β	O
)	O
was	O
0	O
.	O
25	O
for	O
the	O
entire	O
cohort	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
0	O
.	O
31	O
for	O
STG	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
0	O
.	O
16	O
for	O
ACG	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
CONCLUSIONSReductions	O
in	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
level	O
are	O
associated	O
with	O
reductions	O
in	O
A1C	B-GENE-Y
but	O
not	O
reductions	O
in	O
lipids	O
or	O
glycemic	O
variability	O
.	O

Comprehensive	O
structured	O
SMBG	O
-	O
based	O
interventions	O
that	O
lower	O
A1C	B-GENE-Y
may	O
translate	O
into	O
improvements	O
in	O
CV	O
risk	O
,	O
as	O
evidenced	O
by	O
levels	O
of	O
the	O
biomarker	O
hs	B-GENE-Y
-	I-GENE-Y
CRP	I-GENE-Y
.	O

Changes	O
in	O
morphometry	O
and	O
association	O
between	O
whole	O
-	O
body	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
and	O
steroid	B-CHEMICAL
hormone	O
profiles	O
in	O
relation	O
to	O
bioaccumulation	O
patterns	O
in	O
salmon	O
larvae	O
exposed	O
to	O
perfluorooctane	B-CHEMICAL
sulfonic	I-CHEMICAL
or	I-CHEMICAL
perfluorooctane	I-CHEMICAL
carboxylic	I-CHEMICAL
acids	I-CHEMICAL
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
used	O
salmon	O
embryos	O
whose	O
continuous	O
exposure	O
to	O
waterborne	O
PFOA	B-CHEMICAL
or	O
PFOS	B-CHEMICAL
at	O
100	O
μg	O
/	O
L	O
started	O
as	O
freshly	O
fertilized	O
eggs	O
,	O
and	O
lasted	O
for	O
a	O
total	O
of	O
52	O
days	O
.	O

PFOS	B-CHEMICAL
and	O
PFOA	B-CHEMICAL
were	O
dissolved	O
in	O
methanol	B-CHEMICAL
(	O
carrier	O
vehicle	O
)	O
whose	O
concentration	O
never	O
exceeded	O
0	O
.	O
01	O
%	O
of	O
total	O
tank	O
volume	O
.	O

Samples	O
were	O
collected	O
at	O
day	O
21	O
,	O
28	O
,	O
35	O
,	O
52	O
,	O
49	O
and	O
56	O
after	O
the	O
start	O
of	O
the	O
exposure	O
.	O

Note	O
that	O
days	O
49	O
and	O
56	O
represent	O
end	O
of	O
exposure	O
and	O
1	O
week	O
after	O
a	O
recovery	O
period	O
,	O
respectively	O
.	O

Tissue	O
bioaccumulations	O
were	O
determined	O
by	O
HPLC	O
/	O
MS	O
/	O
MS	O
,	O
steroid	B-CHEMICAL
hormones	O
,	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
(	O
FAs	B-CHEMICAL
)	O
and	O
lipids	O
were	O
determined	O
by	O
GC	O
-	O
MS	O
,	O
while	O
mRNA	O
expression	O
levels	O
of	O
genes	O
were	O
determined	O
by	O
qPCR	O
in	O
whole	O
body	O
homogenate	O
.	O

We	O
observed	O
that	O
PFOS	B-CHEMICAL
and	O
PFOA	B-CHEMICAL
showed	O
a	O
steady	O
increase	O
in	O
whole	O
body	O
burden	O
during	O
the	O
exposure	O
period	O
,	O
with	O
a	O
slight	O
decrease	O
after	O
the	O
recovery	O
period	O
.	O

Calculated	O
somatic	O
indexes	O
showed	O
that	O
PFOA	B-CHEMICAL
produced	O
increases	O
in	O
heart	O
-	O
,	O
thymus	O
-	O
,	O
liver	O
-	O
and	O
kidney	O
somatic	O
indexes	O
(	O
HSI	O
,	O
TSI	O
,	O
LSI	O
and	O
KSI	O
)	O
.	O

PFOA	B-CHEMICAL
and	O
PFOS	B-CHEMICAL
exposure	O
produced	O
significant	O
decreases	O
in	O
whole	O
body	O
dehydroepiandrosterone	B-CHEMICAL
(	O
DHEA	B-CHEMICAL
)	O
,	O
estrone	O
and	O
testosterone	B-CHEMICAL
at	O
sampling	O
day	O
21	O
and	O
a	O
strong	O
increase	O
of	O
cortisol	B-CHEMICAL
and	O
cholesterol	B-CHEMICAL
at	O
the	O
end	O
of	O
recovery	O
period	O
(	O
day	O
56	O
)	O
.	O

PFOA	B-CHEMICAL
and	O
PFOS	B-CHEMICAL
effects	O
differed	O
with	O
DHEA	B-CHEMICAL
and	O
estrone	B-CHEMICAL
.	O

While	O
PFOS	B-CHEMICAL
decreased	O
DHEA	B-CHEMICAL
levels	O
,	O
PFOA	B-CHEMICAL
produced	O
an	O
increase	O
at	O
day	O
49	O
,	O
and	O
while	O
PFOS	B-CHEMICAL
decreased	O
estrone	B-CHEMICAL
,	O
PFOA	B-CHEMICAL
produced	O
a	O
slight	O
increase	O
at	O
day	O
56	O
.	O

We	O
observed	O
changes	O
in	O
FA	O
composition	O
that	O
predominantly	O
involved	O
increases	O
in	O
FA	B-CHEMICAL
methyl	I-CHEMICAL
esters	I-CHEMICAL
(	O
FAMEs	B-CHEMICAL
)	O
,	O
mono	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
poly	I-CHEMICAL
-	I-CHEMICAL
unsaturated	I-CHEMICAL
FA	I-CHEMICAL
(	O
MUFA	B-CHEMICAL
and	O
PUFA	B-CHEMICAL
)	O
and	O
a	O
decrease	O
in	O
n	O
-	O
3	O
/	O
n	O
-	O
6	O
PUFA	B-CHEMICAL
ratio	O
by	O
both	O
PFOA	B-CHEMICAL
and	O
PFOS	B-CHEMICAL
.	O

Particularly	O
,	O
an	O
increase	O
in	O
-	O
pentadecenoic	B-CHEMICAL
MUFA	I-CHEMICAL
(	O
15	O
:	O
1	O
)	O
,	O
two	O
n	O
-	O
3	O
PUFAs	B-CHEMICAL
α	B-CHEMICAL
-	I-CHEMICAL
linolenic	I-CHEMICAL
acid	I-CHEMICAL
[	O
ALA	B-CHEMICAL
:	O
18	O
:	O
3	O
n3	O
]	O
and	O
eicosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
[	O
EPA	B-CHEMICAL
:	O
20	O
:	O
5	O
n	O
-	O
3	O
]	O
and	O
n	O
-	O
6	O
PUFA	B-CHEMICAL
:	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
[	O
ARA	B-CHEMICAL
:	O
20	O
:	O
4	O
n6	O
]	O
,	O
docosapentaenoic	B-CHEMICAL
acid	I-CHEMICAL
(	O
DPA	B-CHEMICAL
)	O
by	O
PFOA	B-CHEMICAL
and	O
PFOS	B-CHEMICAL
were	O
observed	O
.	O

These	O
effects	O
were	O
associated	O
with	O
changes	O
in	O
mRNA	O
expression	O
of	O
FA	B-GENE-N
elongase	I-GENE-N
(	O
FAE	B-GENE-N
)	O
,	O
Δ5	B-GENE-Y
-	I-GENE-Y
desaturase	I-GENE-Y
(	O
FAD5	B-GENE-Y
)	O
and	O
Δ6	B-GENE-Y
-	I-GENE-Y
desaturase	I-GENE-Y
(	O
FAD6	B-GENE-Y
)	O
genes	O
.	O

In	O
summary	O
,	O
the	O
changes	O
in	O
hormonal	O
and	O
FA	O
profiles	O
may	O
represent	O
cellular	O
and	O
/	O
or	O
physiological	O
adaptation	O
to	O
continuous	O
PFOS	B-CHEMICAL
and	O
PFOA	B-CHEMICAL
exposure	O
by	O
increasing	O
membrane	O
fluidity	O
,	O
and	O
/	O
or	O
overt	O
developmental	O
effects	O
.	O

The	O
present	O
findings	O
provide	O
some	O
potential	O
insights	O
and	O
basis	O
for	O
a	O
better	O
understanding	O
on	O
the	O
possible	O
mechanisms	O
of	O
PFCs	O
toxicity	O
in	O
fish	O
.	O

Transcriptional	O
regulation	O
of	O
human	B-GENE-Y
ferredoxin	I-GENE-Y
1	I-GENE-Y
in	O
ovarian	O
granulosa	O
cells	O
.	O

Ferredoxin	B-GENE-Y
1	I-GENE-Y
(	O
FDX1	B-GENE-Y
;	O
adrenodoxin	B-GENE-Y
)	O
is	O
an	O
iron	B-CHEMICAL
-	O
sulfur	B-CHEMICAL
protein	O
that	O
is	O
involved	O
in	O
various	O
metabolic	O
processes	O
,	O
including	O
steroid	B-CHEMICAL
hormone	I-CHEMICAL
synthesis	O
in	O
mammalian	O
tissues	O
.	O

We	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
FDX1	B-GENE-Y
in	O
ovarian	O
granulosa	O
cells	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
the	O
NR5A	B-GENE-N
family	O
,	O
including	O
steroidogenic	B-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
SF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
liver	B-GENE-Y
receptor	I-GENE-Y
homolog	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
could	O
induce	O
differentiation	O
of	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
hMSCs	O
)	O
into	O
steroidogenic	O
cells	O
.	O

A	O
ChIP	O
assay	O
showed	O
that	O
SF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
could	O
bind	O
to	O
the	O
FDX1	B-GENE-N
promoter	I-GENE-N
in	O
differentiated	O
hMSCs	O
.	O

Luciferase	O
reporter	O
assays	O
showed	O
that	O
transcription	O
of	O
FDX1	B-GENE-Y
was	O
synergistically	O
activated	O
by	O
the	O
NR5A	B-GENE-N
family	O
and	O
8Br	B-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
treatment	O
through	O
two	O
SF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
binding	O
sites	O
and	O
a	O
CRE	B-GENE-N
-	O
like	O
sequence	O
in	O
a	O
human	O
ovarian	O
granulosa	O
cell	O
line	O
,	O
KGN	O
.	O

Knockdown	O
of	O
FDX1	B-GENE-Y
attenuated	O
progesterone	B-CHEMICAL
production	O
in	O
KGN	O
cells	O
.	O

These	O
results	O
indicate	O
transcription	O
of	O
FDX1	B-GENE-Y
is	O
regulated	O
by	O
the	O
NR5A	B-GENE-N
family	O
and	O
cAMP	B-CHEMICAL
signaling	O
,	O
and	O
participates	O
in	O
steroid	B-CHEMICAL
hormone	O
production	O
in	O
ovarian	O
granulosa	O
cells	O
.	O

Effect	O
of	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
against	O
dimethylnitrosamine	B-CHEMICAL
-	O
induced	O
hepatic	O
fibrosis	O
in	O
rats	O
.	O

Sinapic	B-CHEMICAL
acid	I-CHEMICAL
is	O
a	O
member	O
of	O
the	O
phenylpropanoid	B-CHEMICAL
family	O
and	O
is	O
abundant	O
in	O
cereals	O
,	O
nuts	O
,	O
oil	O
seeds	O
,	O
and	O
berries	O
.	O

It	O
exhibits	O
a	O
wide	O
range	O
of	O
pharmacological	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
hepatoprotective	O
and	O
antifibrotic	O
effects	O
of	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
on	O
dimethylnitrosamine	B-CHEMICAL
(	O
DMN	B-CHEMICAL
)	O
-	O
induced	O
chronic	O
liver	O
injury	O
in	O
rats	O
.	O

Sinapic	B-CHEMICAL
acid	I-CHEMICAL
remarkably	O
prevented	O
DMN	B-CHEMICAL
-	O
induced	O
loss	O
of	O
body	O
weight	O
.	O

This	O
was	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
levels	O
of	O
serum	O
alanine	B-GENE-N
transaminase	I-GENE-N
,	O
aspartate	B-GENE-Y
transaminase	I-GENE-Y
,	O
and	O
liver	O
malondialdehyde	B-CHEMICAL
content	O
.	O

Furthermore	O
,	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
reduced	O
hepatic	O
hydroxyproline	B-CHEMICAL
content	O
,	O
which	O
correlated	O
with	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
type	B-GENE-N
I	I-GENE-N
collagen	I-GENE-N
mRNA	O
and	O
histological	O
analysis	O
of	O
collagen	B-GENE-N
in	O
liver	O
tissue	O
.	O

Additionally	O
,	O
the	O
expression	O
of	O
hepatic	O
fibrosis	O
-	O
related	O
factors	O
such	O
as	O
α	B-GENE-Y
-	I-GENE-Y
smooth	I-GENE-Y
muscle	I-GENE-Y
actin	I-GENE-Y
and	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
(	O
TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
)	O
,	O
were	O
reduced	O
in	O
rats	O
treated	O
with	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
.	O

Sinapic	B-CHEMICAL
acid	I-CHEMICAL
exhibited	O
strong	O
scavenging	O
activity	O
.	O

In	O
conclusion	O
,	O
we	O
find	O
that	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
exhibits	O
hepatoprotective	O
and	O
antifibrotic	O
effects	O
against	O
DMN	B-CHEMICAL
-	O
induced	O
liver	O
injury	O
,	O
most	O
likely	O
due	O
to	O
its	O
antioxidant	O
activities	O
of	O
scavenging	O
radicals	O
,	O
its	O
capacity	O
to	O
suppress	O
TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
and	O
its	O
ability	O
to	O
attenuate	O
activation	O
of	O
hepatic	O
stellate	O
cells	O
.	O

This	O
suggests	O
that	O
sinapic	B-CHEMICAL
acid	I-CHEMICAL
is	O
a	O
potentially	O
useful	O
agent	O
for	O
the	O
protection	O
against	O
liver	O
fibrosis	O
and	O
cirrhosis	O
.	O

The	O
characteristics	O
of	O
genistin	B-CHEMICAL
-	O
induced	O
inhibitory	O
effects	O
on	O
intestinal	O
motility	O
.	O

Genistin	B-CHEMICAL
belongs	O
to	O
isoflavones	B-CHEMICAL
.	O

Based	O
on	O
the	O
facts	O
that	O
genistin	B-CHEMICAL
exerts	O
inhibitory	O
effects	O
on	O
the	O
contractility	O
of	O
vascular	O
smooth	O
muscle	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
effects	O
of	O
genistin	B-CHEMICAL
on	O
intestinal	O
contractility	O
and	O
evaluate	O
its	O
potential	O
clinical	O
implication	O
.	O

Ex	O
vivo	O
[	O
isolated	O
jejunal	O
segment	O
(	O
IJS	O
)	O
of	O
rat	O
]	O
,	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
assays	O
were	O
used	O
in	O
the	O
study	O
.	O

The	O
results	O
indicated	O
that	O
genistin	B-CHEMICAL
(	O
5	O
-	O
80	O
μmol	O
/	O
L	O
)	O
inhibited	O
the	O
contraction	O
of	O
IJS	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
inhibited	O
the	O
increased	O
-	O
contractility	O
of	O
IJS	O
induced	O
by	O
acetylcholine	B-CHEMICAL
(	O
ACh	B-CHEMICAL
)	O
,	O
histamine	B-CHEMICAL
,	O
high	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
and	O
erythromycin	B-CHEMICAL
,	O
respectively	O
.	O

The	O
inhibitory	O
effects	O
of	O
genistin	B-CHEMICAL
were	O
correlated	O
with	O
the	O
stimulation	O
of	O
alpha	B-GENE-N
adrenergic	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
since	O
these	O
inhibitory	O
effects	O
were	O
significantly	O
blocked	O
in	O
the	O
presence	O
of	O
phentolamine	B-CHEMICAL
and	O
propranolol	B-CHEMICAL
respectively	O
.	O

No	O
further	O
inhibitory	O
effects	O
of	O
genistin	B-CHEMICAL
were	O
observed	O
in	O
the	O
presence	O
of	O
verapamil	B-CHEMICAL
or	O
in	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
free	O
condition	O
,	O
indicating	O
genistin	B-CHEMICAL
-	O
induced	O
inhibitory	O
effects	O
are	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
dependent	O
.	O

Genistin	B-CHEMICAL
decreased	O
myosin	B-GENE-Y
light	I-GENE-Y
chain	I-GENE-Y
kinase	I-GENE-Y
(	O
MLCK	B-GENE-Y
)	O
protein	O
contents	O
and	O
MLCK	B-GENE-Y
mRNA	O
expression	O
in	O
IJS	O
,	O
and	O
inhibited	O
both	O
phosphorylation	O
and	O
Mg	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	O
ATPase	B-GENE-N
activity	O
of	O
purified	O
myosin	O
,	O
implicating	O
that	O
the	O
decrease	O
of	O
MLCK	B-GENE-Y
contents	O
and	O
inhibition	O
of	O
MLCK	B-GENE-Y
activity	O
are	O
involved	O
in	O
the	O
genistin	B-CHEMICAL
-	O
induced	O
inhibitory	O
effects	O
.	O

The	O
study	O
suggests	O
the	O
potential	O
clinical	O
implications	O
of	O
genistin	B-CHEMICAL
in	O
relieving	O
intestinal	O
hypercontractility	O
.	O

The	O
circadian	O
clock	O
circuitry	O
and	O
the	O
AHR	B-GENE-Y
signaling	O
pathway	O
in	O
physiology	O
and	O
pathology	O
.	O

Life	O
forms	O
populating	O
the	O
Earth	O
must	O
face	O
environmental	O
challenges	O
to	O
assure	O
individual	O
and	O
species	O
survival	O
.	O

The	O
strategies	O
predisposed	O
to	O
maintain	O
organismal	O
homeostasis	O
and	O
grant	O
selective	O
advantage	O
rely	O
on	O
anticipatory	O
phenomena	O
facing	O
periodic	O
modifications	O
,	O
and	O
compensatory	O
phenomena	O
facing	O
unpredictable	O
changes	O
.	O

Biological	O
processes	O
bringing	O
about	O
these	O
responses	O
are	O
respectively	O
driven	O
by	O
the	O
circadian	O
timing	O
system	O
,	O
a	O
complex	O
of	O
biological	O
oscillators	O
entrained	O
to	O
the	O
environmental	O
light	O
/	O
dark	O
cycle	O
,	O
and	O
by	O
regulatory	O
and	O
metabolic	O
networks	O
that	O
precisely	O
direct	O
the	O
body	O
'	O
s	O
adjustments	O
to	O
variations	O
of	O
external	O
conditions	O
and	O
internal	O
milieu	O
.	O

A	O
critical	O
role	O
in	O
organismal	O
homeostatic	O
functions	O
is	O
played	O
by	O
the	O
aryl	B-GENE-Y
hydrocarbon	I-GENE-Y
receptor	I-GENE-Y
(	O
AHR	B-GENE-Y
)	O
complex	O
,	O
which	O
senses	O
environmental	O
and	O
endogenous	O
compounds	O
,	O
influences	O
metabolic	O
responses	O
controlling	O
phase	O
I	O
/	O
II	O
gene	O
expression	O
,	O
and	O
modulates	O
vital	O
phenomena	O
such	O
as	O
development	O
,	O
inflammation	O
and	O
adaptive	O
immunity	O
.	O

A	O
physiological	O
cross	O
-	O
talk	O
between	O
circadian	O
and	O
AHR	B-GENE-Y
signaling	O
pathways	O
has	O
been	O
evidenced	O
.	O

The	O
alteration	O
of	O
AHR	B-GENE-Y
signaling	O
pathway	O
deriving	O
from	O
genetic	O
damage	O
with	O
polymorphisms	O
or	O
mutations	O
,	O
or	O
produced	O
by	O
exogenous	O
or	O
endogenous	O
AHR	B-GENE-Y
activation	O
,	O
and	O
chronodisruption	O
caused	O
by	O
mismatch	O
between	O
the	O
body	O
'	O
s	O
internal	O
clock	O
and	O
geophysical	O
time	O
/	O
social	O
schedules	O
,	O
are	O
capable	O
of	O
triggering	O
pathological	O
mechanisms	O
involved	O
in	O
metabolic	O
,	O
immune	O
-	O
related	O
and	O
neoplastic	O
diseases	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
molecular	O
components	O
of	O
the	O
circadian	O
clock	O
circuitry	O
and	O
AHR	B-GENE-Y
signaling	O
pathway	O
may	O
represent	O
useful	O
tools	O
for	O
preventive	O
interventions	O
and	O
valuable	O
targets	O
of	O
therapeutic	O
approaches	O
.	O

NADPH	B-GENE-Y
Oxidase	I-GENE-Y
NOX5	I-GENE-Y
-	I-GENE-Y
S	I-GENE-Y
and	O
Nuclear	B-GENE-Y
Factor	I-GENE-Y
κB1	I-GENE-Y
Mediate	O
Acid	O
-	O
Induced	O
Microsomal	B-GENE-Y
Prostaglandin	I-GENE-Y
E	I-GENE-Y
Synthase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
Expression	O
in	O
Barrett	O
'	O
s	O
Esophageal	O
Adenocarcinoma	O
Cells	O
.	O

The	O
mechanisms	O
of	O
progression	O
from	O
Barrett	O
'	O
s	O
esophagus	O
(	O
BE	O
)	O
to	O
esophageal	O
adenocarcinoma	O
(	O
EA	O
)	O
are	O
not	O
known	O
.	O

Cycloxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
-	O
derived	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
PGE2	B-CHEMICAL
)	O
has	O
been	O
shown	O
to	O
be	O
important	O
in	O
esophageal	O
tumorigenesis	O
.	O

We	O
have	O
shown	O
that	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mediates	O
acid	O
-	O
induced	O
PGE2	B-CHEMICAL
production	O
.	O

The	O
prostaglandin	B-GENE-Y
E	I-GENE-Y
synthase	I-GENE-Y
(	O
PGES	B-GENE-Y
)	O
responsible	O
for	O
acid	O
-	O
induced	O
PGE2	B-CHEMICAL
production	O
in	O
BE	O
,	O
however	O
,	O
is	O
not	O
known	O
.	O

We	O
found	O
that	O
microsomal	B-GENE-Y
PGES1	I-GENE-Y
(	O
mPGES1	B-GENE-Y
)	O
,	O
mPGES2	B-GENE-Y
,	O
and	O
cytosolic	B-GENE-Y
PGES	I-GENE-Y
(	O
cPGES	B-GENE-Y
)	O
were	O
present	O
in	O
FLO	O
EA	O
cells	O
.	O

Pulsed	O
acid	O
treatment	O
significantly	O
increased	O
mPGES1	B-GENE-Y
mRNA	O
and	O
protein	O
levels	O
but	O
had	O
little	O
or	O
no	O
effect	O
on	O
mPGES2	B-GENE-Y
or	O
cPGES	B-GENE-Y
mRNA	O
.	O

Knockdown	O
of	O
mPGES1	B-GENE-Y
by	O
mPGES1	B-GENE-Y
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
blocked	O
acid	O
-	O
induced	O
increase	O
in	O
PGE2	B-CHEMICAL
production	O
and	O
thymidine	B-CHEMICAL
incorporation	O
.	O

Knockdown	O
of	O
NADPH	B-GENE-N
oxidase	I-GENE-N
,	O
NOX5	B-GENE-Y
-	I-GENE-Y
S	I-GENE-Y
,	O
a	O
variant	O
lacking	O
calcium	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
domains	I-GENE-N
,	O
by	O
NOX5	B-GENE-Y
siRNA	O
significantly	O
inhibited	O
acid	O
-	O
induced	O
increase	O
in	O
mPGES1	B-GENE-Y
expression	O
,	O
thymidine	B-CHEMICAL
incorporation	O
,	O
and	O
PGE2	B-CHEMICAL
production	O
.	O

Overexpression	O
of	O
NOX5	B-GENE-Y
-	I-GENE-Y
S	I-GENE-Y
significantly	O
increased	O
the	O
luciferase	O
activity	O
in	O
FLO	O
cells	O
transfected	O
with	O
a	O
nuclear	B-GENE-N
factor	I-GENE-N
κB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
in	O
vivo	O
activation	O
reporter	O
plasmid	O
pNF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
-	O
Luc	O
.	O

Knockdown	O
of	O
NF	B-GENE-Y
-	I-GENE-Y
κB1	I-GENE-Y
p50	B-GENE-Y
by	O
p50	B-GENE-Y
siRNA	O
significantly	O
decreased	O
acid	O
-	O
induced	O
increase	O
in	O
mPGES1	B-GENE-Y
expression	O
,	O
thymidine	B-CHEMICAL
incorporation	O
,	O
and	O
PGE2	B-CHEMICAL
production	O
.	O

Two	O
novel	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
binding	I-GENE-N
elements	I-GENE-N
,	O
GGAGTCTCCC	B-GENE-N
and	O
CGGGACACCC	B-GENE-N
,	O
were	O
identified	O
in	O
the	O
mPGES1	B-GENE-N
gene	I-GENE-N
promoter	I-GENE-N
.	O

We	O
conclude	O
that	O
mPGES1	B-GENE-Y
mediates	O
acid	O
-	O
induced	O
increase	O
in	O
PGE2	B-CHEMICAL
production	O
and	O
cell	O
proliferation	O
.	O

Acid	O
-	O
induced	O
mPGES1	B-GENE-Y
expression	O
depends	O
on	O
activation	O
of	O
NOX5	B-GENE-Y
-	I-GENE-Y
S	I-GENE-Y
and	O
NF	B-GENE-Y
-	I-GENE-Y
κB1	I-GENE-Y
p50	B-GENE-Y
.	O

Microsomal	B-GENE-Y
PGES1	I-GENE-Y
may	O
be	O
a	O
potential	O
target	O
to	O
prevent	O
or	O
treat	O
EA	O
.	O

Disposition	O
and	O
Metabolism	O
of	O
GSK2251052	B-CHEMICAL
in	O
Humans	O
:	O
A	O
Novel	O
Boron	B-CHEMICAL
-	O
Containing	O
Antibiotic	O
.	O

(	B-CHEMICAL
S	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
Aminomethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
hydroxypropoxy	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
benzoxaborole	I-CHEMICAL
(	O
GSK2251052	B-CHEMICAL
)	O
is	O
a	O
novel	O
boron	B-CHEMICAL
-	O
containing	O
antibiotic	O
that	O
inhibits	O
bacterial	B-GENE-N
leucyl	I-GENE-N
tRNA	I-GENE-N
synthetase	I-GENE-N
,	O
and	O
that	O
has	O
been	O
in	O
development	O
for	O
the	O
treatment	O
of	O
serious	O
Gram	O
-	O
negative	O
infections	O
.	O

In	O
this	O
study	O
,	O
six	O
healthy	O
adult	O
male	O
subjects	O
received	O
a	O
single	O
i	O
.	O
v	O
.	O
dose	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
GSK2251052	I-CHEMICAL
,	O
1500	O
mg	O
infused	O
over	O
1	O
hour	O
.	O

Blood	O
,	O
urine	O
,	O
and	O
feces	O
were	O
collected	O
over	O
an	O
extended	O
period	O
of	O
14	O
days	O
,	O
and	O
accelerator	O
mass	O
spectrometry	O
was	O
used	O
to	O
quantify	O
low	O
levels	O
of	O
radioactivity	O
in	O
plasma	O
at	O
later	O
time	O
points	O
to	O
supplement	O
the	O
less	O
-	O
sensitive	O
liquid	O
scintillation	O
counting	O
technique	O
.	O

An	O
excellent	O
mass	O
balance	O
recovery	O
was	O
achieved	O
representing	O
a	O
mean	O
total	O
of	O
98	O
.	O
2	O
%	O
of	O
the	O
dose	O
,	O
including	O
90	O
.	O
5	O
%	O
recovered	O
in	O
the	O
urine	O
.	O

Pharmacokinetic	O
analysis	O
demonstrated	O
that	O
radioactivity	O
was	O
moderately	O
associated	O
with	O
the	O
blood	O
cellular	O
components	O
,	O
and	O
together	O
with	O
GSK2251052	B-CHEMICAL
,	O
both	O
were	O
highly	O
distributed	O
into	O
tissues	O
.	O

The	O
parent	O
compound	O
had	O
a	O
much	O
shorter	O
half	O
-	O
life	O
than	O
total	O
radioactivity	O
in	O
plasma	O
,	O
approximately	O
11	O
.	O
6	O
hours	O
compared	O
with	O
96	O
hours	O
.	O

GSK2251052	B-CHEMICAL
and	O
its	O
major	O
metabolite	O
M3	O
,	O
which	O
resulted	O
from	O
oxidation	O
of	O
the	O
propanol	B-CHEMICAL
side	O
chain	O
to	O
the	O
corresponding	O
carboxylic	B-CHEMICAL
acid	I-CHEMICAL
,	O
comprised	O
the	O
majority	O
of	O
the	O
plasma	O
radioactivity	O
,	O
37	O
and	O
53	O
%	O
of	O
the	O
area	O
under	O
the	O
plasma	O
versus	O
time	O
concentration	O
curve	O
from	O
time	O
zero	O
to	O
infinity	O
,	O
respectively	O
.	O

Additionally	O
,	O
M3	O
was	O
eliminated	O
renally	O
,	O
and	O
was	O
demonstrated	O
to	O
be	O
responsible	O
for	O
the	O
long	O
plasma	O
radioactivity	O
elimination	O
half	O
-	O
life	O
.	O

A	O
combination	O
of	O
in	O
vitro	O
metabolism	O
experiments	O
and	O
a	O
pharmacokinetic	O
study	O
in	O
monkeys	O
with	O
the	O
inhibitor	O
4	B-CHEMICAL
-	I-CHEMICAL
methylpyrazole	I-CHEMICAL
provided	O
strong	O
evidence	O
that	O
alcohol	B-GENE-N
dehydrogenase	I-GENE-N
,	O
potentially	O
in	O
association	O
with	O
aldehyde	B-GENE-N
dehydrogenase	I-GENE-N
,	O
is	O
the	O
primary	O
enzyme	O
involved	O
in	O
the	O
formation	O
of	O
the	O
M3	O
metabolite	O
.	O

Protective	O
effect	O
of	O
butylated	B-CHEMICAL
hydroxytoluene	I-CHEMICAL
on	O
ferric	B-CHEMICAL
nitrilotriacetate	I-CHEMICAL
induced	O
hepatotoxicity	O
and	O
oxidative	O
stress	O
in	O
mice	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
evaluate	O
the	O
possible	O
ameliorating	O
effect	O
of	O
butylated	B-CHEMICAL
hydroxyl	I-CHEMICAL
toluene	I-CHEMICAL
(	O
BHT	B-CHEMICAL
)	O
,	O
associated	O
with	O
ferric	B-CHEMICAL
nitrilotriacetate	I-CHEMICAL
(	O
Fe	B-CHEMICAL
-	I-CHEMICAL
NTA	I-CHEMICAL
)	O
-	O
induced	O
oxidative	O
stress	O
and	O
liver	O
injury	O
in	O
mice	O
.	O

The	O
treatment	O
of	O
mice	O
with	O
Fe	B-CHEMICAL
-	I-CHEMICAL
NTA	I-CHEMICAL
alone	O
enhances	O
ornithine	B-GENE-Y
decarboxylase	I-GENE-Y
activity	O
to	O
4	O
.	O
6	O
folds	O
,	O
protein	O
carbonyl	B-CHEMICAL
formation	O
increased	O
up	O
to	O
2	O
.	O
9	O
folds	O
and	O
DNA	O
synthesis	O
expressed	O
in	O
terms	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
thymidine	I-CHEMICAL
incorporation	O
increased	O
to	O
3	O
.	O
2	O
folds	O
,	O
and	O
antioxidants	O
and	O
antioxidant	O
enzymes	O
decreased	O
to	O
1	O
.	O
8	O
-	O
2	O
.	O
5	O
folds	O
,	O
compared	O
with	O
the	O
corresponding	O
saline	O
-	O
treated	O
controls	O
.	O

These	O
changes	O
were	O
reversed	O
significantly	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
in	O
animals	O
receiving	O
a	O
pretreatment	O
of	O
BHT	B-CHEMICAL
.	O

Our	O
data	O
show	O
that	O
BHT	B-CHEMICAL
can	O
reciprocate	O
the	O
toxic	O
effects	O
of	O
Fe	B-CHEMICAL
-	I-CHEMICAL
NTA	I-CHEMICAL
and	O
can	O
serve	O
as	O
a	O
potent	O
chemopreventive	O
agent	O
.	O

Defective	O
DNA	O
damage	O
response	O
and	O
repair	O
in	O
liver	O
cells	O
expressing	O
hepatitis	B-GENE-Y
B	I-GENE-Y
virus	I-GENE-Y
surface	I-GENE-Y
antigen	I-GENE-Y
.	O

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
is	O
implicated	O
in	O
liver	O
cancer	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
out	O
whether	O
HBV	O
or	O
its	O
components	O
[	O
HBV	B-GENE-Y
surface	I-GENE-Y
antigen	I-GENE-Y
(	O
HBsAg	B-GENE-Y
)	O
,	O
HBV	B-GENE-Y
core	I-GENE-Y
protein	I-GENE-Y
(	O
HBc	B-GENE-Y
)	O
,	O
and	O
HBV	B-GENE-Y
X	I-GENE-Y
protein	I-GENE-Y
(	O
HBx	B-GENE-Y
)	O
]	O
could	O
interfere	O
with	O
the	O
host	O
DNA	O
damage	O
response	O
and	O
repair	O
pathway	O
.	O

The	O
full	O
HBV	O
genome	O
or	O
individual	O
HBV	B-GENE-N
open	I-GENE-N
-	I-GENE-N
reading	I-GENE-N
frame	I-GENE-N
(	O
ORF	B-GENE-N
)	O
was	O
introduced	O
into	O
HepG2	O
cells	O
to	O
examine	O
the	O
effect	O
on	O
host	O
genomic	O
stability	O
,	O
DNA	O
repair	O
efficacy	O
in	O
response	O
to	O
double	O
-	O
strand	O
DNA	O
damage	O
,	O
and	O
DNA	O
damage	O
-	O
induced	O
cell	O
death	O
.	O

Responses	O
to	O
apoptosis	O
induction	O
in	O
the	O
HBV	B-GENE-N
ORF	I-GENE-N
-	O
transfected	O
HepG2	O
cells	O
were	O
also	O
compared	O
with	O
those	O
in	O
HBV	O
-	O
positive	O
and	O
HBV	O
-	O
negative	O
human	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cells	O
.	O

In	O
the	O
absence	O
of	O
HBV	O
replication	O
,	O
accumulation	O
of	O
HBsAg	B-GENE-Y
in	O
liver	O
cells	O
without	O
other	O
HBV	O
proteins	O
enhanced	O
DNA	O
repair	O
protein	O
and	O
tumor	O
suppressor	O
promyelocytic	B-GENE-Y
leukemia	I-GENE-Y
(	O
PML	B-GENE-Y
)	O
degradation	O
,	O
which	O
resulted	O
in	O
resistance	O
to	O
apoptosis	O
induction	O
and	O
deficient	O
double	O
-	O
strand	O
DNA	O
repair	O
.	O

However	O
,	O
HBsAg	B-GENE-Y
-	O
positive	O
cells	O
exhibited	O
increased	O
cell	O
death	O
with	O
exposure	O
to	O
the	O
poly	B-GENE-N
(	I-GENE-N
ADP	I-GENE-N
-	I-GENE-N
ribose	I-GENE-N
)	I-GENE-N
polymerase	I-GENE-N
inhibitor	O
that	O
blocks	O
single	O
-	O
strand	O
DNA	O
repair	O
.	O

These	O
results	O
indicate	O
that	O
suppression	O
of	O
PML	B-GENE-Y
by	O
HBsAg	B-GENE-Y
disrupts	O
cellular	O
mechanisms	O
that	O
respond	O
to	O
double	O
-	O
strand	O
DNA	O
damage	O
for	O
DNA	O
repair	O
or	O
apoptosis	O
induction	O
,	O
which	O
may	O
facilitate	O
hepatocarcinogenesis	O
and	O
open	O
up	O
a	O
synthetic	O
lethality	O
strategy	O
for	O
HBsAg	B-GENE-Y
-	O
positive	O
HCC	O
treatment	O
.	O
-	O
Chung	O
,	O
Y	O
.	O
-	O
L	O
.	O

Defective	O
DNA	O
damage	O
response	O
and	O
repair	O
in	O
liver	O
cells	O
expressing	O
hepatitis	B-GENE-Y
B	I-GENE-Y
virus	I-GENE-Y
surface	I-GENE-Y
antigen	I-GENE-Y
.	O

CYP2J2	B-GENE-Y
overexpression	O
increases	O
EETs	B-CHEMICAL
and	O
protects	O
against	O
angiotensin	B-GENE-Y
II	I-GENE-Y
-	O
induced	O
abdominal	O
aortic	O
aneurysm	O
in	O
mice	O
.	O

Cytochrome	B-GENE-Y
P450	I-GENE-Y
epoxygenase	I-GENE-Y
2J2	I-GENE-Y
(	O
CYP2J2	B-GENE-Y
)	O
metabolizes	O
arachidonic	B-CHEMICAL
acids	I-CHEMICAL
to	O
form	O
epoxyeicosatrienoic	B-CHEMICAL
acids	I-CHEMICAL
(	O
EETs	B-CHEMICAL
)	O
,	O
which	O
possess	O
various	O
beneficial	O
effects	O
on	O
the	O
cardiovascular	O
system	O
.	O

However	O
,	O
whether	O
increasing	O
EETs	B-CHEMICAL
production	O
by	O
CYP2J2	B-GENE-Y
overexpression	O
in	O
vivo	O
could	O
prevent	O
abdominal	O
aortic	O
aneurysm	O
(	O
AAA	O
)	O
remains	O
unknown	O
.	O

Here	O
we	O
investigated	O
the	O
effects	O
of	O
recombinant	O
adeno	O
-	O
associated	O
virus	O
(	O
rAAV	O
)	O
-	O
mediated	O
CYP2J2	B-GENE-Y
overexpression	O
on	O
angiotensin	B-GENE-Y
(	I-GENE-Y
Ang	I-GENE-Y
)	I-GENE-Y
II	I-GENE-Y
-	O
induced	O
AAA	O
in	O
apoE	O
-	O
deficient	O
mice	O
.	O

rAAV	O
-	O
CYP2J2	B-GENE-Y
delivery	O
led	O
to	O
an	O
abundant	O
aortic	O
CYP2J2	B-GENE-Y
expression	O
and	O
increased	O
EETs	B-CHEMICAL
generation	O
.	O

It	O
was	O
shown	O
that	O
CYP2J2	B-GENE-Y
overexpression	O
attenuated	O
matrix	B-GENE-N
metalloproteinase	I-GENE-N
expression	O
and	O
activity	O
,	O
elastin	B-GENE-Y
degradation	O
,	O
and	O
AAA	O
formation	O
,	O
which	O
was	O
associated	O
with	O
reduced	O
aortic	O
inflammation	O
and	O
macrophage	O
infiltration	O
.	O

In	O
cultured	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
VSMCs	O
)	O
,	O
rAAV	O
-	O
mediated	O
CYP2J2	B-GENE-Y
overexpression	O
and	O
EETs	B-CHEMICAL
markedly	O
suppressed	O
Ang	B-GENE-Y
II	I-GENE-Y
-	O
induced	O
inflammatory	O
cytokine	B-GENE-N
expression	O
.	O

Moreover	O
,	O
overexpressed	O
CYP2J2	B-GENE-Y
and	O
EETs	B-CHEMICAL
inhibited	O
Ang	B-GENE-Y
II	I-GENE-Y
-	O
induced	O
macrophage	O
migration	O
in	O
a	O
VSMC	O
-	O
macrophage	O
coculture	O
system	O
.	O

We	O
further	O
indicated	O
that	O
these	O
protective	O
effects	O
were	O
mediated	O
by	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
(	I-GENE-Y
PPAR	I-GENE-Y
)	I-GENE-Y
γ	I-GENE-Y
activation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
rAAV	O
-	O
mediated	O
CYP2J2	B-GENE-Y
overexpression	O
prevents	O
AAA	O
development	O
which	O
is	O
likely	O
via	O
PPARγ	B-GENE-Y
activation	O
and	O
anti	O
-	O
inflammatory	O
action	O
,	O
suggesting	O
that	O
increasing	O
EETs	B-CHEMICAL
levels	O
could	O
be	O
considered	O
as	O
a	O
potential	O
strategy	O
to	O
prevent	O
and	O
treat	O
AAA	O
.	O

Structural	O
Investigation	O
and	O
Biological	O
Activity	O
of	O
Sesquiterpene	B-CHEMICAL
Lactones	I-CHEMICAL
from	O
the	O
Traditional	O
Chinese	O
Herb	O
Inula	O
racemosa	O
.	O

Five	O
new	O
sesquiterpene	B-CHEMICAL
lactones	I-CHEMICAL
,	O
racemosalactones	B-CHEMICAL
A	I-CHEMICAL
-	I-CHEMICAL
E	I-CHEMICAL
(	O
1	O
-	O
5	O
)	O
,	O
along	O
with	O
19	O
known	O
sesquiterpene	B-CHEMICAL
latones	I-CHEMICAL
(	O
6	O
-	O
24	O
)	O
,	O
were	O
isolated	O
from	O
the	O
roots	O
of	O
Inula	O
racemosa	O
.	O

Their	O
structures	O
were	O
elucidated	O
by	O
extensive	O
spectroscopic	O
analysis	O
,	O
and	O
the	O
absolute	O
configuration	O
of	O
2	O
was	O
deduced	O
from	O
X	O
-	O
ray	O
diffraction	O
analysis	O
.	O

Compounds	O
1	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
12	O
,	O
14	O
,	O
and	O
17	O
exhibited	O
antiproliferative	O
activities	O
with	O
IC50	O
values	O
ranging	O
from	O
0	O
.	O
38	O
to	O
4	O
.	O
19	O
μg	O
/	O
mL	O
against	O
human	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
A549	O
,	O
hepatocellular	O
carcinoma	O
HepG2	O
,	O
and	O
human	O
fibrosarcoma	O
HT1080	O
cells	O
.	O

Compounds	O
6	O
and	O
8	O
exhibited	O
antiproliferative	O
activities	O
against	O
endothelial	O
cells	O
with	O
IC50	O
values	O
of	O
2	O
.	O
4	O
and	O
2	O
.	O
5	O
μg	O
/	O
mL	O
,	O
respectively	O
.	O

Furthermore	O
,	O
compounds	O
6	O
and	O
8	O
both	O
inhibited	O
endothelial	O
cell	O
tube	O
formation	O
at	O
1	O
.	O
0	O
μg	O
/	O
mL	O
.	O

A	O
method	O
for	O
the	O
rapid	O
and	O
straightforward	O
preparative	O
-	O
scale	O
isolation	O
of	O
compound	O
6	O
from	O
alantolides	B-CHEMICAL
is	O
described	O
.	O

Involvement	O
of	O
regucalcin	B-GENE-Y
in	O
lipid	O
metabolism	O
and	O
diabetes	O
.	O

Regucalcin	B-GENE-Y
(	O
RGN	B-GENE-Y
/	O
SMP30	B-GENE-Y
)	O
was	O
originally	O
discovered	O
in	O
1978	O
as	O
a	O
unique	O
calcium	B-CHEMICAL
-	O
binding	O
protein	O
that	O
does	O
not	O
contain	O
the	O
EF	B-GENE-N
-	I-GENE-N
hand	I-GENE-N
motif	I-GENE-N
of	O
calcium	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
.	O

The	O
regucalcin	B-GENE-Y
gene	O
(	O
rgn	B-GENE-Y
)	O
is	O
localized	O
on	O
the	O
X	O
chromosome	O
and	O
is	O
identified	O
in	O
over	O
15	O
species	O
consisting	O
the	O
regucalcin	B-GENE-Y
family	O
.	O

Regucalcin	B-GENE-Y
has	O
been	O
shown	O
to	O
play	O
a	O
multifunctional	O
role	O
in	O
cell	O
regulation	O
;	O
maintaining	O
of	O
intracellular	O
calcium	B-CHEMICAL
homeostasis	O
and	O
suppressing	O
of	O
signal	O
transduction	O
,	O
translational	O
protein	O
synthesis	O
,	O
nuclear	O
deoxyribonucleic	O
acid	O
(	O
DNA	O
)	O
and	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
synthesis	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

Moreover	O
,	O
regucalcin	B-GENE-Y
may	O
play	O
a	O
pathophysiological	O
role	O
in	O
metabolic	O
disorder	O
.	O

The	O
expression	O
of	O
regucalcin	B-GENE-Y
is	O
stimulated	O
through	O
the	O
action	O
of	O
insulin	B-GENE-Y
in	O
liver	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
it	O
is	O
decreased	O
in	O
the	O
liver	O
of	O
rats	O
with	O
type	O
I	O
diabetes	O
induced	O
by	O
streptozotocin	B-CHEMICAL
administration	O
in	O
vivo	O
.	O

Overexpression	O
of	O
endogenous	O
regucalcin	B-GENE-Y
stimulates	O
glucose	B-CHEMICAL
utilization	O
and	O
lipid	O
production	O
in	O
liver	O
cells	O
with	O
glucose	B-CHEMICAL
supplementation	O
in	O
vitro	O
.	O

Regucalcin	B-GENE-Y
reveals	O
insulin	B-GENE-Y
resistance	O
in	O
liver	O
cells	O
.	O

Deficiency	O
of	O
regucalcin	B-GENE-Y
induces	O
an	O
impairment	O
of	O
glucose	B-CHEMICAL
tolerance	O
and	O
lipid	O
accumulation	O
in	O
the	O
liver	O
of	O
mice	O
in	O
vivo	O
.	O

Overexpression	O
of	O
endogenous	O
regucalcin	B-GENE-Y
has	O
been	O
shown	O
to	O
decrease	O
triglyceride	B-CHEMICAL
,	O
total	O
cholesterol	B-CHEMICAL
and	O
glycogen	O
contents	O
in	O
the	O
liver	O
of	O
rats	O
,	O
inducing	O
hyperlipidemia	O
.	O

Leptin	B-GENE-Y
and	O
adiponectin	B-GENE-Y
mRNA	O
expressions	O
in	O
the	O
liver	O
tissues	O
are	O
decreased	O
in	O
regucalcin	B-GENE-Y
transgenic	O
rats	O
.	O

Decrease	O
in	O
hepatic	O
regucalcin	B-GENE-Y
is	O
associated	O
with	O
the	O
development	O
and	O
progression	O
of	O
nonalcoholic	O
fatty	O
liver	O
disease	O
and	O
fibrosis	O
in	O
human	O
patients	O
.	O

Regucalcin	O
may	O
be	O
a	O
key	O
molecule	O
in	O
lipid	O
metabolic	O
disorder	O
and	O
diabetes	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
nicotinamide	B-CHEMICAL
derivative	O
as	O
anti	O
-	O
angiogenic	O
agents	O
.	O

Previously	O
,	O
we	O
have	O
found	O
that	O
BRN	B-CHEMICAL
-	I-CHEMICAL
103	I-CHEMICAL
,	O
a	O
nicotinamide	B-CHEMICAL
derivative	O
,	O
inhibits	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
-	O
mediated	O
angiogenesis	O
signaling	O
in	O
human	O
endothelial	O
cells	O
.	O

During	O
our	O
continuous	O
efforts	O
to	O
identify	O
more	O
potent	O
anti	O
-	O
angiogenic	O
agents	O
,	O
we	O
synthesized	O
various	O
nicotinamide	B-CHEMICAL
derivatives	O
and	O
evaluated	O
their	O
anti	O
-	O
angiogenic	O
effects	O
.	O

We	O
found	O
that	O
2	B-CHEMICAL
-	I-CHEMICAL
{	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
fluoropyrimidin	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
]	I-CHEMICAL
piperidin	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ylamino	I-CHEMICAL
}	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
chlorophenyl	I-CHEMICAL
)	I-CHEMICAL
pyridine	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
carboxamide	I-CHEMICAL
(	O
BRN	B-CHEMICAL
-	I-CHEMICAL
250	I-CHEMICAL
)	O
significantly	O
inhibited	O
human	O
umbilical	O
vascular	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
proliferation	O
,	O
migration	O
,	O
tube	O
formation	O
,	O
and	O
microvessel	O
growth	O
in	O
a	O
concentration	O
range	O
of	O
10	O
-	O
100	O
nM	O
.	O

Furthermore	O
,	O
BRN	B-CHEMICAL
-	I-CHEMICAL
250	I-CHEMICAL
inhibited	O
the	O
VEGF	B-GENE-Y
-	O
induced	O
phosphorylation	O
and	O
intracellular	O
tyrosine	B-GENE-N
kinase	I-GENE-N
activity	O
of	O
VEGF	B-GENE-Y
receptor	I-GENE-Y
2	I-GENE-Y
(	O
VEGFR2	B-GENE-Y
)	O
and	O
the	O
activation	O
of	O
its	O
downstream	O
AKT	B-GENE-N
pathway	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
BRN	B-CHEMICAL
-	I-CHEMICAL
250	I-CHEMICAL
be	O
considered	O
a	O
potential	O
lead	O
compound	O
for	O
cancer	O
therapy	O
.	O

Inhibition	O
of	O
angiogenesis	O
and	O
invasion	O
by	O
DMBT	B-CHEMICAL
is	O
mediated	O
by	O
downregulation	O
of	O
VEGF	B-GENE-N
and	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
through	O
Akt	B-GENE-N
pathway	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	O
cancer	O
cells	O
.	O

Invasion	O
,	O
either	O
directly	O
or	O
via	O
metastasis	O
formation	O
,	O
is	O
the	O
main	O
cause	O
of	O
death	O
in	O
cancer	O
patients	O
,	O
development	O
of	O
efficient	O
anti	O
-	O
invasive	O
agents	O
is	O
an	O
important	O
research	O
challenge	O
.	O

In	O
order	O
to	O
obtain	O
more	O
potent	O
inhibitors	O
,	O
a	O
series	O
of	O
brartemicin	B-CHEMICAL
analogs	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
inhibitory	O
activity	O
against	O
invasion	O
.	O

Among	O
the	O
synthetic	O
analogs	O
tested	O
,	O
DMBT	B-CHEMICAL
,	O
6	B-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dimethoxybenzoyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
a	I-CHEMICAL
,	I-CHEMICAL
a	I-CHEMICAL
-	I-CHEMICAL
d	I-CHEMICAL
-	I-CHEMICAL
trehalose	I-CHEMICAL
,	O
was	O
found	O
to	O
be	O
the	O
most	O
potent	O
anti	O
-	O
invasive	O
agent	O
.	O

But	O
the	O
effects	O
of	O
DMBT	B-CHEMICAL
on	O
breast	O
cancer	O
cells	O
were	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
DMBT	B-CHEMICAL
on	O
invasion	O
and	O
metastasis	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
were	O
investigated	O
.	O

MTT	B-CHEMICAL
assay	O
showed	O
that	O
no	O
obvious	O
inhibitory	O
or	O
cytotoxic	O
effect	O
of	O
DMBT	B-CHEMICAL
was	O
found	O
.	O

DMBT	B-CHEMICAL
could	O
inhibit	O
invasion	O
,	O
migration	O
and	O
tube	O
formation	O
of	O
HUVECs	O
.	O

Gelatin	O
zymography	O
showed	O
that	O
DMBT	B-CHEMICAL
inhibited	O
secretion	O
and	O
activity	O
of	O
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
.	O

Western	O
blotting	O
demonstrated	O
that	O
DMBT	B-CHEMICAL
effectively	O
suppressed	O
the	O
expression	O
of	O
VEGF	B-GENE-N
,	O
p	B-GENE-Y
-	I-GENE-Y
VEGFR	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
p	B-GENE-Y
-	I-GENE-Y
EGFR	I-GENE-Y
,	O
and	O
p	B-GENE-N
-	I-GENE-N
Akt	I-GENE-N
.	O

These	O
results	O
suggested	O
that	O
DMBT	B-CHEMICAL
could	O
inhibit	O
invasion	O
and	O
angiogenesis	O
by	O
downregulation	O
of	O
VEGFand	B-GENE-N
MMP	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
,	O
resulting	O
from	O
the	O
inhibition	O
of	O
Akt	B-GENE-N
pathway	O
.	O

DMBT	B-CHEMICAL
might	O
be	O
a	O
promising	O
lead	O
molecule	O
for	O
the	O
anti	O
-	O
metastasis	O
and	O
serve	O
as	O
a	O
therapeutic	O
agent	O
to	O
inhibit	O
breast	O
cancer	O
cell	O
invasion	O
and	O
metastasis	O
.	O

Phenotypic	O
analysis	O
of	O
ovine	O
antigen	O
presenting	O
cells	O
loaded	O
with	O
nanoparticles	O
migrating	O
from	O
the	O
site	O
of	O
vaccination	O
.	O

Virus	O
-	O
sized	O
particulate	O
adjuvants	O
such	O
as	O
ISCOMs	O
,	O
polystyrene	B-CHEMICAL
nanoparticles	O
and	O
virus	O
-	O
like	O
particles	O
have	O
been	O
shown	O
to	O
target	O
dendritic	O
cells	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
T	O
and	O
B	O
cells	O
in	O
vivo	O
.	O

Using	O
an	O
ovine	O
pseudo	O
-	O
afferent	O
lymph	O
cannulation	O
model	O
to	O
capture	O
APC	O
that	O
traffic	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
,	O
we	O
show	O
that	O
40	O
-	O
50nm	O
nanoparticles	O
are	O
taken	O
up	O
at	O
the	O
site	O
of	O
injection	O
by	O
dendritic	O
cells	O
(	O
DCs	O
)	O
migrating	O
to	O
the	O
draining	O
lymph	O
node	O
.	O

These	O
DCs	O
can	O
express	O
CD11c	B-GENE-Y
,	O
CD1b	B-GENE-Y
,	O
CD5	B-GENE-Y
,	O
MHC	B-GENE-N
class	I-GENE-N
II	I-GENE-N
and	O
CD8	B-GENE-N
.	O

Nanoparticles	O
transported	O
by	O
DCs	O
migrating	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
therefore	O
needs	O
to	O
be	O
considered	O
as	O
a	O
new	O
mechanism	O
underlying	O
the	O
immunogenicity	O
of	O
virus	O
-	O
sized	O
vaccine	O
delivery	O
systems	O
.	O

Alternariol	B-CHEMICAL
induces	O
abnormal	O
nuclear	O
morphology	O
and	O
cell	O
cycle	O
arrest	O
in	O
murine	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

The	O
mycotoxin	O
alternariol	B-CHEMICAL
(	O
AOH	B-CHEMICAL
)	O
,	O
a	O
frequent	O
contaminant	O
in	O
fruit	O
and	O
cereal	O
products	O
,	O
is	O
known	O
to	O
induce	O
DNA	O
damage	O
with	O
subsequent	O
cell	O
cycle	O
arrest	O
.	O

Here	O
we	O
elucidated	O
the	O
effects	O
of	O
AOH	B-CHEMICAL
on	O
stages	O
of	O
cell	O
cycle	O
progression	O
using	O
the	O
RAW	O
264	O
.	O
7	O
macrophage	O
model	O
.	O

AOH	B-CHEMICAL
resulted	O
in	O
an	O
accumulation	O
of	O
cells	O
in	O
the	O
G2	O
/	O
M	O
-	O
phase	O
(	O
4N	O
)	O
.	O

Most	O
cells	O
exhibited	O
a	O
large	O
G2	O
nucleus	O
whereas	O
numbers	O
of	O
true	O
mitotic	O
cells	O
were	O
reduced	O
relative	O
to	O
control	O
.	O

Both	O
cyclin	B-GENE-Y
B1	I-GENE-Y
and	O
p	B-GENE-Y
-	I-GENE-Y
cdc2	I-GENE-Y
levels	O
increased	O
,	O
while	O
cyclin	B-GENE-Y
B1	I-GENE-Y
remained	O
in	O
the	O
cytoplasm	O
;	O
suggesting	O
arrest	O
in	O
the	O
G2	O
/	O
M	O
transition	O
point	O
.	O

Remarkably	O
,	O
after	O
exposure	O
to	O
AOH	B-CHEMICAL
for	O
24h	O
,	O
most	O
of	O
the	O
cells	O
exhibited	O
abnormally	O
shaped	O
nuclei	O
,	O
as	O
evidenced	O
by	O
partly	O
divided	O
nuclei	O
,	O
nuclear	O
blebs	O
,	O
polyploidy	O
and	O
micronuclei	O
(	O
MN	O
)	O
.	O

AOH	B-CHEMICAL
treatment	O
also	O
induced	O
abnormal	O
Aurora	B-GENE-Y
B	I-GENE-Y
bridges	O
,	O
suggesting	O
that	O
cytokinesis	O
was	O
interfered	O
within	O
cells	O
undergoing	O
karyokinesis	O
.	O

A	O
minor	O
part	O
of	O
the	O
resultant	O
G1	O
tetraploid	O
(	O
4N	O
)	O
cells	O
re	O
-	O
entered	O
the	O
S	O
-	O
phase	O
and	O
progressed	O
to	O
8N	O
cells	O
.	O

Contribution	O
of	O
the	O
m1	O
transmembrane	O
helix	O
and	O
pre	O
-	O
m1	O
region	O
to	O
positive	O
allosteric	O
modulation	O
and	O
gating	O
of	O
N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
d	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
receptors	I-GENE-N
.	O

N	B-GENE-N
-	I-GENE-N
methyl	I-GENE-N
-	I-GENE-N
d	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
(	I-GENE-N
NMDA	I-GENE-N
)	I-GENE-N
receptors	I-GENE-N
are	O
glutamate	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
ion	I-GENE-N
channels	I-GENE-N
whose	O
function	O
is	O
critical	O
for	O
normal	O
excitatory	O
synaptic	O
transmission	O
in	O
the	O
brain	O
and	O
whose	O
dysfunction	O
has	O
been	O
implicated	O
in	O
several	O
neurologic	O
conditions	O
.	O

NMDA	B-GENE-N
receptor	I-GENE-N
function	O
is	O
subject	O
to	O
extensive	O
allosteric	O
regulation	O
both	O
by	O
endogenous	O
compounds	O
and	O
by	O
exogenous	O
small	O
molecules	O
.	O

Elucidating	O
the	O
structural	O
determinants	O
and	O
mechanism	O
of	O
action	O
by	O
which	O
allosteric	O
regulators	O
control	O
gating	O
will	O
enhance	O
our	O
understanding	O
of	O
NMDA	B-GENE-N
receptor	I-GENE-N
activation	O
and	O
facilitate	O
the	O
development	O
of	O
novel	O
therapeutics	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
structural	O
determinants	O
for	O
(	B-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
chlorophenyl	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
dimethoxy	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methoxyphenoxy	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dihydroisoquinolin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
(	I-CHEMICAL
1H	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
methanone	I-CHEMICAL
(	O
CIQ	B-CHEMICAL
)	O
,	O
a	O
GluN2C	O
/	O
2D	O
-	O
selective	O
positive	O
allosteric	O
modulator	O
.	O

We	O
show	O
that	O
CIQ	B-CHEMICAL
does	O
not	O
bind	O
to	O
the	O
amino	B-CHEMICAL
-	O
terminal	O
domain	O
of	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
and	O
does	O
not	O
share	O
structural	O
determinants	O
with	O
modulators	O
acting	O
at	O
the	O
agonist	O
-	O
binding	O
domain	O
dimer	O
interface	O
or	O
ion	B-GENE-N
channel	I-GENE-N
pore	O
.	O

Rather	O
,	O
we	O
identified	O
critical	O
determinants	O
of	O
CIQ	B-CHEMICAL
modulation	O
in	O
the	O
region	O
near	O
the	O
first	O
transmembrane	O
helix	O
of	O
GluN2D	O
,	O
including	O
in	O
a	O
putative	O
pre	O
-	O
M1	O
cuff	O
helix	O
that	O
may	O
influence	O
channel	O
gating	O
.	O

We	O
also	O
show	O
that	O
mutations	O
within	O
the	O
GluN2D	O
pre	O
-	O
M1	O
region	O
alter	O
open	O
probability	O
of	O
the	O
NMDA	B-GENE-N
receptor	I-GENE-N
.	O

These	O
results	O
suggest	O
a	O
novel	O
site	O
of	O
action	O
for	O
potentiation	O
of	O
NMDA	B-GENE-N
receptors	I-GENE-N
by	O
small	O
molecules	O
and	O
implicate	O
the	O
pre	O
-	O
M1	O
region	O
in	O
NMDA	B-GENE-N
receptor	I-GENE-N
gating	O
.	O

Life	O
-	O
threatening	O
hypoglycemia	O
associated	O
with	O
intentional	O
insulin	B-GENE-Y
ingestion	O
.	O

There	O
are	O
reports	O
of	O
insulin	B-GENE-Y
overdose	O
by	O
injection	O
,	O
yet	O
little	O
is	O
known	O
regarding	O
the	O
potential	O
harms	O
of	O
intentional	O
oral	O
ingestion	O
of	O
insulin	B-GENE-Y
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
case	O
of	O
massive	O
insulin	B-GENE-Y
ingestion	O
and	O
ensuing	O
hypoglycemia	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
are	O
no	O
previously	O
published	O
cases	O
of	O
hypoglycemia	O
caused	O
by	O
intentional	O
insulin	B-GENE-Y
ingestion	O
.	O

A	O
51	O
-	O
year	O
-	O
old	O
man	O
intentionally	O
ingested	O
three	O
10	O
-	O
ml	O
vials	O
(	O
total	O
of	O
3000	O
units	O
)	O
of	O
various	O
insulins	B-GENE-Y
:	O
one	O
vial	O
each	O
of	O
insulin	B-GENE-Y
aspart	O
,	O
lispro	O
,	O
and	O
glargine	O
.	O

Four	O
symptomatic	O
hypoglycemic	O
episodes	O
,	O
with	O
blood	O
glucose	B-CHEMICAL
levels	O
of	O
48	O
,	O
25	O
,	O
34	O
,	O
and	O
40	O
mg	O
/	O
dl	O
,	O
occurred	O
approximately	O
1	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
hours	O
,	O
respectively	O
,	O
after	O
ingestion	O
.	O

The	O
hypoglycemia	O
could	O
not	O
be	O
explained	O
other	O
than	O
the	O
ingestion	O
of	O
the	O
insulins	B-GENE-Y
.	O

The	O
patient	O
was	O
admitted	O
for	O
observation	O
,	O
and	O
euglycemia	O
occurred	O
within	O
24	O
hours	O
without	O
any	O
additional	O
hypoglycemic	O
episodes	O
.	O

Hypoglycemia	O
treatment	O
is	O
reviewed	O
in	O
this	O
case	O
report	O
,	O
and	O
factors	O
that	O
may	O
affect	O
systemic	O
response	O
of	O
orally	O
ingested	O
insulin	B-GENE-Y
,	O
including	O
gastrointestinal	O
absorption	O
and	O
insulin	B-GENE-Y
sensitivity	O
,	O
are	O
discussed	O
.	O

In	O
addition	O
,	O
the	O
findings	O
of	O
our	O
case	O
report	O
may	O
provide	O
useful	O
insight	O
into	O
the	O
development	O
of	O
novel	O
oral	O
insulin	B-GENE-Y
products	O
that	O
are	O
currently	O
in	O
research	O
.	O

Despite	O
poor	O
bioavailability	O
(	O
1	O
%	O
)	O
when	O
taken	O
orally	O
,	O
insulin	B-GENE-Y
may	O
produce	O
symptomatic	O
hypoglycemia	O
with	O
a	O
massive	O
ingestion	O
.	O

Vigilant	O
blood	O
glucose	B-CHEMICAL
monitoring	O
,	O
supportive	O
care	O
with	O
glucose	B-CHEMICAL
replacement	O
therapy	O
,	O
and	O
admission	O
to	O
the	O
hospital	O
for	O
observation	O
may	O
be	O
required	O
.	O

Concentration	O
-	O
dependent	O
inhibitory	O
effects	O
of	O
baicalin	B-CHEMICAL
on	O
the	O
metabolism	O
of	O
dextromethorphan	B-CHEMICAL
,	O
a	O
dual	O
probe	O
of	O
CYP2D	B-GENE-N
and	O
CYP3A	B-GENE-N
,	O
in	O
rats	O
.	O

Baicalin	B-CHEMICAL
has	O
been	O
shown	O
to	O
possess	O
many	O
pharmacological	O
effects	O
,	O
including	O
antiviral	O
,	O
antioxidant	O
,	O
anti	O
-	O
cancer	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
reveal	O
the	O
inhibitory	O
effects	O
of	O
baicalin	B-CHEMICAL
on	O
the	O
metabolism	O
of	O
dextromethorphan	B-CHEMICAL
(	O
DXM	B-CHEMICAL
)	O
,	O
a	O
dual	O
probe	O
substrate	O
of	O
CYP2D	B-GENE-N
and	O
CYP3A	B-GENE-N
,	O
in	O
rats	O
.	O

Lineweaver	O
-	O
Burk	O
plots	O
demonstrated	O
that	O
baicalin	B-CHEMICAL
inhibited	O
the	O
activities	O
of	O
CYP2D	B-GENE-N
and	O
CYP3A	B-GENE-N
in	O
a	O
non	O
-	O
competitive	O
manner	O
in	O
rat	O
liver	O
microsomes	O
(	O
RLMs	O
)	O
.	O

Concomitant	O
administration	O
of	O
baicalin	B-CHEMICAL
(	O
0	O
.	O
90g	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
and	O
DXM	B-CHEMICAL
(	O
10mg	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
)	O
increased	O
the	O
maximum	O
drug	O
concentration	O
(	O
Cmax	O
)	O
(	O
37	O
%	O
)	O
and	O
the	O
area	O
under	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
(	O
42	O
%	O
)	O
and	O
decreased	O
the	O
clearance	O
(	O
CL	O
)	O
(	O
27	O
%	O
)	O
of	O
DXM	B-CHEMICAL
in	O
a	O
randomised	O
,	O
crossover	O
study	O
in	O
rats	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
change	O
in	O
the	O
AUC	O
of	O
DXM	B-CHEMICAL
was	O
significantly	O
correlated	O
with	O
the	O
Cmax	O
and	O
AUC	O
of	O
baicalin	B-CHEMICAL
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
inhibitory	O
effects	O
of	O
multiple	O
doses	O
of	O
baicalin	B-CHEMICAL
(	O
0	O
.	O
90g	O
/	O
kg	O
,	O
i	O
.	O
v	O
.	O
,	O
12days	O
)	O
on	O
the	O
metabolism	O
of	O
DXM	B-CHEMICAL
were	O
similar	O
to	O
those	O
observed	O
following	O
a	O
single	O
dose	O
in	O
rats	O
.	O

The	O
activity	O
of	O
CYP3A	B-GENE-N
in	O
excised	O
liver	O
samples	O
from	O
rats	O
following	O
multiple	O
baicalin	B-CHEMICAL
treatment	O
was	O
significantly	O
decreased	O
compared	O
to	O
that	O
of	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
multiple	O
doses	O
of	O
baicalin	B-CHEMICAL
had	O
no	O
obvious	O
effect	O
on	O
the	O
activity	O
of	O
CYP2D	B-GENE-N
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
baicalin	B-CHEMICAL
inhibits	O
the	O
metabolism	O
of	O
DXM	B-CHEMICAL
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
rats	O
,	O
possibly	O
through	O
inhibiting	O
hepatic	O
CYP2D	B-GENE-N
and	O
CYP3A	B-GENE-N
activities	O
.	O

Differential	O
phosphoproteome	O
of	O
the	O
striatum	O
from	O
pleiotrophin	B-GENE-Y
knockout	O
and	O
midkine	B-GENE-Y
knockout	O
mice	O
treated	O
with	O
amphetamine	B-CHEMICAL
:	O
Correlations	O
with	O
amphetamine	B-CHEMICAL
-	O
induced	O
neurotoxicity	O
.	O

The	O
neurotrophic	O
factors	O
pleiotrophin	B-GENE-Y
(	O
PTN	B-GENE-Y
)	O
and	O
midkine	B-GENE-Y
(	O
MK	B-GENE-Y
)	O
have	O
been	O
shown	O
to	O
modulate	O
amphetamine	B-CHEMICAL
-	O
induced	O
neurotoxicity	O
.	O

Accordingly	O
,	O
PTN	B-GENE-Y
-	O
/	O
-	O
and	O
MK	B-GENE-Y
-	O
/	O
-	O
mice	O
show	O
an	O
increased	O
vulnerability	O
to	O
amphetamine	B-CHEMICAL
-	O
induced	O
neurotoxic	O
effects	O
.	O

In	O
an	O
effort	O
to	O
uncover	O
new	O
pharmacological	O
targets	O
to	O
prevent	O
amphetamine	B-CHEMICAL
neurotoxic	O
effects	O
,	O
we	O
have	O
now	O
used	O
a	O
proteomic	O
approach	O
to	O
study	O
protein	O
phosphorylation	O
,	O
in	O
which	O
we	O
combined	O
phosphoprotein	O
enrichment	O
,	O
by	O
immobilized	O
metal	O
affinity	O
chromatography	O
(	O
IMAC	O
)	O
,	O
with	O
two	O
-	O
dimensional	O
gel	O
electrophoresis	O
and	O
mass	O
spectrometry	O
,	O
in	O
order	O
to	O
identify	O
the	O
phosphoproteins	O
regulated	O
in	O
the	O
striatum	O
of	O
PTN	B-GENE-Y
-	O
/	O
-	O
,	O
MK	B-GENE-Y
-	O
/	O
-	O
and	O
wild	O
type	O
(	O
WT	O
)	O
mice	O
treated	O
with	O
amphetamine	B-CHEMICAL
.	O

We	O
identified	O
13	O
differentially	O
expressed	O
phosphoproteins	O
that	O
are	O
judged	O
to	O
be	O
relevant	O
in	O
the	O
neuroprotective	O
roles	O
of	O
PTN	B-GENE-Y
and	O
MK	B-GENE-Y
against	O
amphetamine	B-CHEMICAL
-	O
induced	O
neurotoxicity	O
.	O

It	O
is	O
very	O
interesting	O
to	O
note	O
that	O
4	O
of	O
these	O
phosphoproteins	O
,	O
annexin	B-GENE-Y
A7	I-GENE-Y
(	O
ANXA7	B-GENE-Y
)	O
,	O
COP9	B-GENE-Y
signalosome	I-GENE-Y
subunit	I-GENE-Y
5	I-GENE-Y
(	O
COPS5	B-GENE-Y
)	O
,	O
aldehyde	B-GENE-Y
dehydrogenase	I-GENE-Y
family	I-GENE-Y
1	I-GENE-Y
member	I-GENE-Y
A1	I-GENE-Y
(	O
ALDH1A1	B-GENE-Y
)	O
and	O
creatine	B-GENE-Y
kinase	I-GENE-Y
U	I-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
(	O
CKMT1	B-GENE-Y
)	O
,	O
are	O
known	O
to	O
be	O
involved	O
in	O
Parkinson	O
'	O
s	O
disease	O
,	O
a	O
result	O
of	O
significant	O
importance	O
since	O
PTN	B-GENE-Y
and	O
MK	B-GENE-Y
have	O
been	O
also	O
demonstrated	O
to	O
limit	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
progress	O
and	O
have	O
been	O
suggested	O
to	O
be	O
among	O
the	O
important	O
genetic	O
factors	O
possibly	O
preventing	O
the	O
development	O
of	O
PD	O
in	O
methamphetamine	B-CHEMICAL
abusers	O
.	O

The	O
data	O
identify	O
phosphoproteins	O
differentially	O
regulated	O
by	O
amphetamine	B-CHEMICAL
treatment	O
and	O
/	O
or	O
the	O
presence	O
of	O
endogenous	O
PTN	B-GENE-Y
/	O
MK	B-GENE-Y
which	O
may	O
be	O
relevant	O
mediators	O
of	O
PTN	B-GENE-Y
/	O
MK	B-GENE-Y
neuroprotective	O
effects	O
against	O
amphetamine	B-CHEMICAL
-	O
induced	O
neurotoxicity	O
.	O

The	O
data	O
support	O
further	O
studies	O
to	O
validate	O
the	O
phosphoproteins	O
here	O
identified	O
as	O
possible	O
new	O
pharmacological	O
targets	O
to	O
prevent	O
amphetamine	B-CHEMICAL
neurotoxic	O
effects	O
.	O

Structure	O
-	O
based	O
design	O
of	O
novel	O
dihydroisoquinoline	B-CHEMICAL
BACE	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
that	O
do	O
not	O
engage	O
the	O
catalytic	O
aspartates	B-CHEMICAL
.	O

The	O
structure	O
-	O
activity	O
relationship	O
of	O
a	O
series	O
of	O
dihydroisoquinoline	B-CHEMICAL
BACE	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
is	O
described	O
.	O

Application	O
of	O
structure	O
-	O
based	O
design	O
to	O
screening	O
hit	O
1	O
yielded	O
sub	O
-	O
micromolar	O
inhibitors	O
.	O

Replacement	O
of	O
the	O
carboxylic	B-CHEMICAL
acid	I-CHEMICAL
of	O
1	O
was	O
guided	O
by	O
X	O
-	O
ray	O
crystallography	O
,	O
which	O
allowed	O
the	O
replacement	O
of	O
a	O
key	O
water	O
-	O
mediated	O
hydrogen	B-CHEMICAL
bond	O
.	O

This	O
work	O
culminated	O
in	O
compounds	O
such	O
as	O
31	O
,	O
which	O
possess	O
good	O
BACE	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
potency	O
,	O
excellent	O
permeability	O
and	O
a	O
low	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
efflux	O
ratio	O
.	O

PF	B-CHEMICAL
-	I-CHEMICAL
04859989	I-CHEMICAL
as	O
a	O
template	O
for	O
structure	O
-	O
based	O
drug	O
design	O
:	O
identification	O
of	O
new	O
pyrazole	B-CHEMICAL
series	O
of	O
irreversible	O
KAT	B-GENE-Y
II	I-GENE-Y
inhibitors	O
with	O
improved	O
lipophilic	O
efficiency	O
.	O

The	O
structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
new	O
pyrazole	B-CHEMICAL
series	O
of	O
irreversible	O
KAT	B-GENE-Y
II	I-GENE-Y
inhibitors	O
are	O
described	O
herein	O
.	O

The	O
modification	O
of	O
the	O
inhibitor	O
scaffold	O
of	O
1	O
and	O
2	O
from	O
a	O
dihydroquinolinone	B-CHEMICAL
core	O
to	O
a	O
tetrahydropyrazolopyridinone	B-CHEMICAL
core	O
led	O
to	O
discovery	O
of	O
a	O
new	O
series	O
of	O
potent	O
KAT	B-GENE-Y
II	I-GENE-Y
inhibitors	O
with	O
excellent	O
physicochemical	O
properties	O
.	O

Compound	O
20	O
is	O
the	O
most	O
potent	O
and	O
lipophilically	O
efficient	O
of	O
these	O
new	O
pyrazole	B-CHEMICAL
analogs	O
,	O
with	O
a	O
k	O
(	O
inact	O
)	O
/	O
K	O
(	O
i	O
)	O
value	O
of	O
112	O
,	O
000	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
and	O
lipophilic	O
efficiency	O
(	O
LipE	O
)	O
of	O
8	O
.	O
53	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
20	O
with	O
KAT	B-GENE-Y
II	I-GENE-Y
demonstrates	O
key	O
features	O
that	O
contribute	O
to	O
this	O
remarkable	O
potency	O
and	O
binding	O
efficiency	O
.	O

A	O
new	O
series	O
of	O
N2	B-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
toluenesulfonylamino	I-CHEMICAL
)	I-CHEMICAL
phthalimide	I-CHEMICAL
analogues	O
as	O
α	B-GENE-N
-	I-GENE-N
glucosidase	I-GENE-N
inhibitors	O
.	O

Several	O
members	O
of	O
a	O
new	O
family	O
of	O
non	O
-	O
sugar	B-CHEMICAL
-	O
type	O
α	B-GENE-N
-	I-GENE-N
glycosidase	I-GENE-N
inhibitors	O
,	O
bearing	O
a	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
toluenesulfonylamino	I-CHEMICAL
)	I-CHEMICAL
phthalimide	I-CHEMICAL
moiety	O
and	O
various	O
substituent	O
at	O
the	O
N2	O
position	O
,	O
were	O
synthesized	O
and	O
their	O
activities	O
were	O
investigated	O
.	O

The	O
newly	O
synthesized	O
compounds	O
displayed	O
different	O
inhibition	O
profile	O
towards	O
yeast	B-GENE-Y
α	I-GENE-Y
-	I-GENE-Y
glycosidase	I-GENE-Y
and	O
rat	B-GENE-N
intestinal	I-GENE-N
α	I-GENE-N
-	I-GENE-N
glycosidase	I-GENE-N
.	O

Almost	O
all	O
the	O
compounds	O
had	O
strong	O
inhibitory	O
activities	O
against	O
yeast	B-GENE-Y
α	I-GENE-Y
-	I-GENE-Y
glycosidase	I-GENE-Y
.	O

Regarding	O
rat	B-GENE-N
intestinal	I-GENE-N
α	I-GENE-N
-	I-GENE-N
glycosidase	I-GENE-N
,	O
only	O
analogs	O
with	O
N2	O
-	O
aromatic	O
substituents	O
displayed	O
varying	O
degrees	O
of	O
inhibitory	O
activities	O
on	O
rat	B-GENE-N
intestinal	I-GENE-N
maltase	I-GENE-N
and	O
lactase	B-GENE-N
and	O
nearly	O
all	O
compounds	O
showed	O
no	O
inhibition	O
against	O
rat	B-GENE-N
intestinal	I-GENE-N
α	I-GENE-N
-	I-GENE-N
amylase	I-GENE-N
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
indicated	O
that	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
toluenesulfonylamino	I-CHEMICAL
)	I-CHEMICAL
phthalimide	I-CHEMICAL
moiety	O
is	O
a	O
favorable	O
scaffold	O
to	O
exert	O
the	O
α	B-GENE-N
-	I-GENE-N
glucosidase	I-GENE-N
inhibitory	O
activity	O
and	O
substituents	O
at	O
the	O
N2	O
position	O
have	O
considerable	O
influence	O
on	O
the	O
efficacy	O
of	O
the	O
inhibition	O
activities	O
.	O

Effects	O
of	O
chronic	O
social	O
defeat	O
stress	O
on	O
behavior	O
and	O
choline	B-GENE-Y
acetyltransferase	I-GENE-Y
,	O
78	B-GENE-Y
-	I-GENE-Y
kDa	I-GENE-Y
glucose	I-GENE-Y
-	I-GENE-Y
regulated	I-GENE-Y
protein	I-GENE-Y
,	O
and	O
CCAAT	B-GENE-Y
/	I-GENE-Y
enhancer	I-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	I-GENE-Y
C	I-GENE-Y
/	I-GENE-Y
EBP	I-GENE-Y
)	I-GENE-Y
homologous	I-GENE-Y
protein	I-GENE-Y
in	O
adult	O
mice	O
.	O

RATIONALE	O
:	O
Social	O
defeat	O
stress	O
induces	O
physiological	O
and	O
behavioral	O
symptoms	O
,	O
including	O
anxiety	O
,	O
anhedonia	O
,	O
immune	O
deficits	O
,	O
and	O
altered	O
expression	O
of	O
key	O
brain	O
genes	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
social	O
defeat	O
stress	O
on	O
the	O
behaviors	O
and	O
expressions	O
of	O
Chat	B-GENE-Y
,	O
Grp78	B-GENE-Y
,	O
and	O
chop	B-GENE-Y
in	O
the	O
brains	O
of	O
adult	O
mice	O
.	O

METHODS	O
:	O
Adult	O
mice	O
were	O
divided	O
into	O
susceptible	O
and	O
unsusceptible	O
groups	O
after	O
10	O
days	O
of	O
social	O
defeat	O
stress	O
.	O

In	O
experiment	O
1	O
,	O
behavioral	O
tests	O
were	O
conducted	O
,	O
and	O
brains	O
were	O
processed	O
for	O
Western	O
blotting	O
at	O
day	O
27	O
after	O
stress	O
.	O

In	O
experiment	O
2	O
,	O
social	O
avoidance	O
tests	O
were	O
conducted	O
,	O
and	O
brains	O
were	O
processed	O
for	O
Western	O
blotting	O
at	O
day	O
12	O
after	O
stress	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
decreased	O
and	O
increased	O
locomotion	O
and	O
anxiety	O
behavior	O
in	O
all	O
defeated	O
mice	O
.	O

Decrease	O
in	O
social	O
interaction	O
,	O
increased	O
immobility	O
,	O
and	O
impaired	O
memory	O
performance	O
were	O
only	O
observed	O
in	O
susceptible	O
mice	O
.	O

A	O
decrease	O
in	O
the	O
Chat	O
level	O
at	O
days	O
12	O
and	O
27	O
was	O
noted	O
in	O
the	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
,	O
amygdala	O
(	O
Amyg	O
)	O
,	O
and	O
dorsal	O
hippocampus	O
(	O
HIP	O
)	O
in	O
defeated	O
mice	O
.	O

The	O
expression	O
levels	O
of	O
Grp78	B-GENE-Y
and	O
chop	B-GENE-Y
measured	O
on	O
days	O
12	O
and	O
27	O
were	O
significantly	O
greater	O
in	O
the	O
Amyg	O
of	O
susceptible	O
mice	O
.	O

In	O
the	O
PFC	O
and	O
HIP	O
,	O
defeated	O
mice	O
displayed	O
different	O
patterns	O
in	O
the	O
levels	O
of	O
Grp78	B-GENE-Y
and	O
chop	B-GENE-Y
expressions	O
measured	O
on	O
days	O
12	O
and	O
27	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrated	O
that	O
chronic	O
social	O
defeat	O
stress	O
in	O
mice	O
produces	O
stress	O
-	O
related	O
behaviors	O
.	O

Different	O
response	O
patterns	O
were	O
noted	O
for	O
Grp78	B-GENE-Y
and	O
chop	B-GENE-Y
expression	O
among	O
the	O
groups	O
in	O
terms	O
of	O
brain	O
regions	O
and	O
time	O
-	O
course	O
effects	O
.	O

Global	O
analysis	O
of	O
Drosophila	B-GENE-N
Cys2	I-GENE-N
-	I-GENE-N
His2	I-GENE-N
zinc	I-GENE-N
finger	I-GENE-N
proteins	I-GENE-N
reveals	O
a	O
multitude	O
of	O
novel	O
recognition	O
motifs	O
and	O
binding	O
determinants	O
.	O

Cys2	B-GENE-N
-	I-GENE-N
His2	I-GENE-N
zinc	I-GENE-N
finger	I-GENE-N
proteins	I-GENE-N
(	O
ZFPs	B-GENE-N
)	O
are	O
the	O
largest	O
group	O
of	O
transcription	O
factors	O
in	O
higher	O
metazoans	O
.	O

A	O
complete	O
characterization	O
of	O
these	O
ZFPs	B-GENE-N
and	O
their	O
associated	O
target	O
sequences	O
is	O
pivotal	O
to	O
fully	O
annotate	O
transcriptional	O
regulatory	O
networks	O
in	O
metazoan	O
genomes	O
.	O

As	O
a	O
first	O
step	O
in	O
this	O
process	O
,	O
we	O
have	O
characterized	O
the	O
DNA	O
-	O
binding	O
specificities	O
of	O
129	O
zinc	B-GENE-N
finger	I-GENE-N
sets	O
from	O
Drosophila	O
using	O
a	O
bacterial	O
one	O
-	O
hybrid	O
system	O
.	O

This	O
data	O
set	O
contains	O
the	O
DNA	O
-	O
binding	O
specificities	O
for	O
at	O
least	O
one	O
encoded	O
ZFP	B-GENE-N
from	O
70	O
unique	O
genes	O
and	O
23	O
alternate	O
splice	O
isoforms	O
representing	O
the	O
largest	O
set	O
of	O
characterized	O
ZFPs	B-GENE-N
from	O
any	O
organism	O
described	O
to	O
date	O
.	O

These	O
recognition	O
motifs	O
can	O
be	O
used	O
to	O
predict	O
genomic	O
binding	O
sites	O
for	O
these	O
factors	O
within	O
the	O
fruit	O
fly	O
genome	O
.	O

Subsets	O
of	O
fingers	O
from	O
these	O
ZFPs	B-GENE-N
were	O
characterized	O
to	O
define	O
their	O
orientation	O
and	O
register	O
on	O
their	O
recognition	O
sequences	O
,	O
thereby	O
allowing	O
us	O
to	O
define	O
the	O
recognition	O
diversity	O
within	O
this	O
finger	O
set	O
.	O

We	O
find	O
that	O
the	O
characterized	O
fingers	O
can	O
specify	O
47	O
of	O
the	O
64	O
possible	O
DNA	O
triplets	O
.	O

To	O
confirm	O
the	O
utility	O
of	O
our	O
finger	O
recognition	O
models	O
,	O
we	O
employed	O
subsets	O
of	O
Drosophila	O
fingers	O
in	O
combination	O
with	O
an	O
existing	O
archive	O
of	O
artificial	O
zinc	B-GENE-N
finger	I-GENE-N
modules	O
to	O
create	O
ZFPs	B-GENE-N
with	O
novel	O
DNA	O
-	O
binding	O
specificity	O
.	O

These	O
hybrids	O
of	O
natural	O
and	O
artificial	O
fingers	O
can	O
be	O
used	O
to	O
create	O
functional	O
zinc	B-GENE-N
finger	I-GENE-N
nucleases	I-GENE-N
for	O
editing	O
vertebrate	O
genomes	O
.	O

Iron	B-CHEMICAL
and	O
diabetes	O
risk	O
.	O

Iron	B-CHEMICAL
overload	O
is	O
a	O
risk	O
factor	O
for	O
diabetes	O
.	O

The	O
link	O
between	O
iron	B-CHEMICAL
and	O
diabetes	O
was	O
first	O
recognized	O
in	O
pathologic	O
conditions	O
-	O
hereditary	O
hemochromatosis	O
and	O
thalassemia	O
-	O
but	O
high	O
levels	O
of	O
dietary	O
iron	B-CHEMICAL
also	O
impart	O
diabetes	O
risk	O
.	O

Iron	B-CHEMICAL
plays	O
a	O
direct	O
and	O
causal	O
role	O
in	O
diabetes	O
pathogenesis	O
mediated	O
both	O
by	O
β	O
cell	O
failure	O
and	O
insulin	B-GENE-Y
resistance	O
.	O

Iron	B-CHEMICAL
also	O
regulates	O
metabolism	O
in	O
most	O
tissues	O
involved	O
in	O
fuel	O
homeostasis	O
,	O
with	O
the	O
adipocyte	O
in	O
particular	O
serving	O
an	O
iron	B-CHEMICAL
-	O
sensing	O
role	O
.	O

The	O
underlying	O
molecular	O
mechanisms	O
mediating	O
these	O
effects	O
are	O
numerous	O
and	O
incompletely	O
understood	O
but	O
include	O
oxidant	O
stress	O
and	O
modulation	O
of	O
adipokines	B-GENE-N
and	O
intracellular	O
signal	O
transduction	O
pathways	O
.	O

In	O
vivo	O
HIF	B-GENE-N
-	O
mediated	O
reductive	O
carboxylation	O
is	O
regulated	O
by	O
citrate	B-CHEMICAL
levels	O
and	O
sensitizes	O
VHL	B-GENE-Y
-	O
deficient	O
cells	O
to	O
glutamine	B-CHEMICAL
deprivation	O
.	O

Hypoxic	O
and	O
VHL	B-GENE-Y
-	O
deficient	O
cells	O
use	O
glutamine	B-CHEMICAL
to	O
generate	O
citrate	B-CHEMICAL
and	O
lipids	O
through	O
reductive	O
carboxylation	O
(	O
RC	O
)	O
of	O
α	B-CHEMICAL
-	I-CHEMICAL
ketoglutarate	I-CHEMICAL
.	O

To	O
gain	O
insights	O
into	O
the	O
role	O
of	O
HIF	B-GENE-N
and	O
the	O
molecular	O
mechanisms	O
underlying	O
RC	O
,	O
we	O
took	O
advantage	O
of	O
a	O
panel	O
of	O
disease	O
-	O
associated	O
VHL	B-GENE-Y
mutants	O
and	O
showed	O
that	O
HIF	B-GENE-N
expression	O
is	O
necessary	O
and	O
sufficient	O
for	O
the	O
induction	O
of	O
RC	O
in	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
cells	O
.	O

HIF	B-GENE-N
expression	O
drastically	O
reduced	O
intracellular	O
citrate	B-CHEMICAL
levels	O
.	O

Feeding	O
VHL	B-GENE-Y
-	O
deficient	O
RCC	O
cells	O
with	O
acetate	B-CHEMICAL
or	O
citrate	B-CHEMICAL
or	O
knocking	O
down	O
PDK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
ACLY	B-GENE-Y
restored	O
citrate	B-CHEMICAL
levels	O
and	O
suppressed	O
RC	O
.	O

These	O
data	O
suggest	O
that	O
HIF	B-GENE-N
-	O
induced	O
low	O
intracellular	O
citrate	B-CHEMICAL
levels	O
promote	O
the	O
reductive	O
flux	O
by	O
mass	O
action	O
to	O
maintain	O
lipogenesis	O
.	O

Using	O
[	B-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
glutamine	I-CHEMICAL
,	O
we	O
demonstrated	O
in	O
vivo	O
RC	O
activity	O
in	O
VHL	B-GENE-Y
-	O
deficient	O
tumors	O
growing	O
as	O
xenografts	O
in	O
mice	O
.	O

Lastly	O
,	O
HIF	B-GENE-N
rendered	O
VHL	B-GENE-Y
-	O
deficient	O
cells	O
sensitive	O
to	O
glutamine	B-CHEMICAL
deprivation	O
in	O
vitro	O
,	O
and	O
systemic	O
administration	O
of	O
glutaminase	B-GENE-N
inhibitors	O
suppressed	O
the	O
growth	O
of	O
RCC	O
cells	O
as	O
mice	O
xenografts	O
.	O

Degradation	O
of	O
MAC13243	B-CHEMICAL
and	O
studies	O
of	O
the	O
interaction	O
of	O
resulting	O
thiourea	B-CHEMICAL
compounds	O
with	O
the	O
lipoprotein	B-GENE-N
targeting	O
chaperone	B-GENE-N
LolA	B-GENE-N
.	O

The	O
discovery	O
of	O
novel	O
small	O
molecules	O
that	O
function	O
as	O
antibacterial	O
agents	O
or	O
cellular	O
probes	O
of	O
biology	O
is	O
hindered	O
by	O
our	O
limited	O
understanding	O
of	O
bacterial	O
physiology	O
and	O
our	O
ability	O
to	O
assign	O
mechanism	O
of	O
action	O
.	O

We	O
previously	O
employed	O
a	O
chemical	O
genomic	O
strategy	O
to	O
identify	O
a	O
novel	O
small	O
molecule	O
,	O
MAC13243	B-CHEMICAL
,	O
as	O
a	O
likely	O
inhibitor	O
of	O
the	O
bacterial	B-GENE-N
lipoprotein	I-GENE-N
targeting	O
chaperone	B-GENE-N
,	O
LolA	B-GENE-N
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
degradation	O
of	O
MAC13243	B-CHEMICAL
into	O
the	O
active	O
species	O
,	O
S	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
chlorobenzyl	I-CHEMICAL
)	I-CHEMICAL
isothiourea	I-CHEMICAL
.	O

Analogs	O
of	O
this	O
compound	O
(	O
e	O
.	O
g	O
.	O
,	O
A22	O
)	O
have	O
previously	O
been	O
characterized	O
as	O
inhibitors	O
of	O
the	O
bacterial	B-GENE-N
actin	I-GENE-N
-	I-GENE-N
like	I-GENE-N
protein	I-GENE-N
,	O
MreB	B-GENE-N
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
the	O
antibacterial	O
activity	O
of	O
MAC13243	B-CHEMICAL
and	O
the	O
thiourea	B-CHEMICAL
compounds	O
are	O
similar	O
;	O
these	O
activities	O
are	O
suppressed	O
or	O
sensitized	O
in	O
response	O
to	O
increases	O
or	O
decreases	O
of	O
LolA	B-GENE-N
copy	O
number	O
,	O
respectively	O
.	O

We	O
provide	O
STD	O
NMR	O
data	O
which	O
confirms	O
a	O
physical	O
interaction	O
between	O
LolA	B-GENE-N
and	O
the	O
thiourea	B-CHEMICAL
degradation	O
product	O
of	O
MAC13243	B-CHEMICAL
,	O
with	O
a	O
Kd	O
of	O
~	O
150	O
μM	O
.	O

Taken	O
together	O
,	O
we	O
conclude	O
that	O
the	O
thiourea	B-CHEMICAL
series	O
of	O
compounds	O
share	O
a	O
similar	O
cellular	O
mechanism	O
that	O
includes	O
interaction	O
with	O
LolA	B-GENE-N
in	O
addition	O
to	O
the	O
well	O
-	O
characterized	O
target	O
MreB	B-GENE-N
.	O

Absence	O
of	O
correlation	O
between	O
oxysterol	B-CHEMICAL
accumulation	O
in	O
lipid	B-GENE-N
raft	I-GENE-N
microdomains	I-GENE-N
,	O
calcium	B-CHEMICAL
increase	O
,	O
and	O
apoptosis	O
induction	O
on	O
158N	O
murine	O
oligodendrocytes	O
.	O

There	O
is	O
some	O
evidence	O
that	O
oxidized	O
derivatives	O
of	O
cholesterol	B-CHEMICAL
,	O
7	B-CHEMICAL
-	I-CHEMICAL
ketocholesterol	I-CHEMICAL
(	O
7KC	B-CHEMICAL
)	O
and	O
7β	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
(	O
7βOHC	B-CHEMICAL
)	O
,	O
are	O
increased	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
neurodegenerative	O
diseases	O
associated	O
with	O
demyelinization	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

It	O
was	O
therefore	O
of	O
interest	O
to	O
investigate	O
the	O
effects	O
of	O
these	O
oxysterols	B-CHEMICAL
on	O
oligodendrocytes	O
,	O
the	O
myelin	O
-	O
forming	O
cells	O
in	O
the	O
CNS	O
.	O

To	O
this	O
end	O
,	O
158N	O
murine	O
oligodendrocytes	O
were	O
treated	O
with	O
7KC	B-CHEMICAL
or	O
7βOHC	B-CHEMICAL
inducing	O
an	O
apoptotic	O
mode	O
of	O
cell	O
death	O
characterized	O
by	O
condensation	O
/	O
fragmentation	O
of	O
the	O
nuclei	O
,	O
dephosphorylation	O
of	O
Akt	B-GENE-Y
and	O
GSK3	B-GENE-N
,	O
mitochondrial	O
depolarization	O
involving	O
Mcl	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activation	O
.	O

In	O
contrast	O
,	O
under	O
treatment	O
with	O
27	B-CHEMICAL
-	I-CHEMICAL
hydroxycholesterol	I-CHEMICAL
(	O
27OHC	O
)	O
,	O
no	O
cell	O
death	O
was	O
observed	O
.	O

When	O
the	O
cells	O
were	O
stained	O
with	O
Fura	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	O
no	O
significant	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
rise	O
was	O
found	O
with	O
the	O
different	O
oxysterols	B-CHEMICAL
,	O
whereas	O
strong	O
signals	O
were	O
detected	O
with	O
ionomycin	B-CHEMICAL
used	O
as	O
positive	O
control	O
.	O

At	O
concentrations	O
which	O
induced	O
apoptosis	O
,	O
7KC	B-CHEMICAL
but	O
not	O
7βOHC	B-CHEMICAL
accumulated	O
in	O
lipid	O
rafts	O
.	O

Although	O
not	O
cytotoxic	O
,	O
27OHC	B-CHEMICAL
was	O
mainly	O
detected	O
in	O
lipid	O
rafts	O
.	O

It	O
is	O
noteworthy	O
that	O
α	B-CHEMICAL
-	I-CHEMICAL
tocopherol	I-CHEMICAL
(	O
but	O
not	O
ellagic	B-CHEMICAL
acid	I-CHEMICAL
and	O
resveratrol	B-CHEMICAL
)	O
was	O
able	O
to	O
counteract	O
7KC	B-CHEMICAL
-	O
and	O
7βOHC	B-CHEMICAL
-	O
induced	O
apoptosis	O
and	O
to	O
decrease	O
the	O
accumulation	O
of	O
7KC	B-CHEMICAL
and	O
27OHC	B-CHEMICAL
in	O
lipid	O
rafts	O
.	O

Thus	O
,	O
in	O
158N	O
cells	O
,	O
the	O
ability	O
of	O
oxysterols	B-CHEMICAL
to	O
trigger	O
a	O
mode	O
of	O
cell	O
death	O
by	O
apoptosis	O
involving	O
GSK	B-GENE-N
-	I-GENE-N
3	I-GENE-N
and	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activation	O
is	O
independent	O
of	O
the	O
increase	O
in	O
the	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
level	O
and	O
of	O
their	O
accumulation	O
in	O
lipid	O
raft	O
microdomains	O
.	O

Inverted	O
CdSe	B-CHEMICAL
/	O
CdS	B-CHEMICAL
/	O
ZnS	B-CHEMICAL
quantum	O
dot	O
light	O
emitting	O
devices	O
with	O
titanium	B-CHEMICAL
dioxide	I-CHEMICAL
as	O
an	O
electron	O
-	O
injection	O
contact	O
.	O

We	O
demonstrated	O
the	O
fabrication	O
of	O
inverted	O
CdSe	B-CHEMICAL
/	O
CdS	B-CHEMICAL
/	O
ZnS	B-CHEMICAL
quantum	O
dot	O
light	O
emitting	O
devices	O
(	O
QD	O
-	O
LEDs	O
)	O
using	O
titanium	B-CHEMICAL
dioxide	I-CHEMICAL
(	O
TiO2	B-CHEMICAL
)	O
as	O
an	O
electron	O
-	O
injection	O
layer	O
and	O
investigated	O
the	O
operating	O
mechanism	O
by	O
utilizing	O
different	O
hole	O
-	O
transport	O
materials	O
,	O
4	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
dicarbazole	I-CHEMICAL
-	I-CHEMICAL
biphenyl	I-CHEMICAL
(	O
CBP	B-CHEMICAL
)	O
and	O
4	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tris	I-CHEMICAL
(	I-CHEMICAL
carbazol	I-CHEMICAL
-	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
triphenylamine	I-CHEMICAL
(	O
TCTA	B-CHEMICAL
)	O
.	O

A	O
more	O
efficient	O
device	O
with	O
CBP	O
as	O
the	O
hole	O
-	O
transport	O
layer	O
(	O
HTL	O
)	O
was	O
obtained	O
compared	O
with	O
the	O
TCTA	B-CHEMICAL
based	O
device	O
.	O

The	O
peak	O
efficiency	O
of	O
6	O
.	O
70	O
cd	O
A	O
(	O
-	O
1	O
)	O
for	O
the	O
CBP	O
based	O
device	O
was	O
found	O
to	O
be	O
about	O
74	O
.	O
5	O
%	O
higher	O
than	O
the	O
TCTA	B-CHEMICAL
based	O
device	O
(	O
3	O
.	O
84	O
cd	O
A	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
studies	O
on	O
the	O
time	O
-	O
resolved	O
photoluminescence	O
spectra	O
of	O
the	O
QD	O
-	O
HTL	O
composite	O
structures	O
showed	O
that	O
the	O
energy	O
transfer	O
(	O
ET	O
)	O
efficiencies	O
from	O
the	O
two	O
HTLs	O
to	O
the	O
QD	O
layer	O
were	O
similar	O
and	O
the	O
charge	O
separation	O
between	O
QDs	O
and	O
HTLs	O
could	O
be	O
neglected	O
.	O

The	O
enhancement	O
in	O
the	O
performance	O
of	O
the	O
CBP	O
based	O
device	O
was	O
attributed	O
to	O
the	O
more	O
efficient	O
hole	O
-	O
injection	O
from	O
CBP	O
to	O
QDs	O
.	O

Influence	O
of	O
the	O
novel	O
histamine	B-GENE-Y
H3	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
ST1283	O
on	O
voluntary	O
alcohol	B-CHEMICAL
consumption	O
and	O
ethanol	B-CHEMICAL
-	O
induced	O
place	O
preference	O
in	O
mice	O
.	O

RATIONALE	O
:	O
Growing	O
evidence	O
supports	O
a	O
role	O
for	O
the	O
central	O
histaminergic	O
system	O
to	O
have	O
a	O
modulatory	O
influence	O
on	O
drug	O
addiction	O
in	O
general	O
and	O
alcohol	B-CHEMICAL
-	O
use	O
disorders	O
in	O
particular	O
through	O
histamine	B-GENE-Y
H3	I-GENE-Y
receptors	I-GENE-Y
(	O
H3R	B-GENE-Y
)	O
.	O

OBJECTIVE	O
:	O
In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
systemic	O
injection	O
of	O
the	O
newly	O
synthesized	O
H3R	B-GENE-Y
antagonist	O
ST1283	O
on	O
ethanol	B-CHEMICAL
(	O
EtOH	B-CHEMICAL
)	O
voluntary	O
intake	O
and	O
EtOH	B-CHEMICAL
-	O
conditioned	O
reward	O
in	O
mice	O
have	O
been	O
investigated	O
.	O

METHODS	O
:	O
Oral	O
EtOH	B-CHEMICAL
,	O
saccharin	B-CHEMICAL
,	O
and	O
quinine	B-CHEMICAL
intake	O
was	O
assessed	O
in	O
a	O
two	O
-	O
bottle	O
choice	O
paradigm	O
using	O
escalating	O
concentrations	O
of	O
alcohol	B-CHEMICAL
or	O
tastant	O
solutions	O
.	O

EtOH	B-CHEMICAL
-	O
induced	O
place	O
preference	O
(	O
CPP	O
)	O
,	O
EtOH	B-CHEMICAL
-	O
induced	O
locomotor	O
activity	O
,	O
and	O
blood	O
ethanol	B-CHEMICAL
concentration	O
(	O
BEC	O
)	O
were	O
also	O
measured	O
.	O

RESULTS	O
:	O
Following	O
administration	O
of	O
the	O
H3R	B-GENE-Y
antagonist	O
(	O
2	O
.	O
5	O
,	O
5	O
,	O
and	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
,	O
there	O
was	O
a	O
significant	O
dose	O
-	O
dependent	O
decrease	O
in	O
alcohol	B-CHEMICAL
consumption	O
and	O
preference	O
.	O

Importantly	O
,	O
vehicle	O
-	O
and	O
ST1283	O
(	O
5	O
mg	O
/	O
kg	O
)	O
-	O
treated	O
mice	O
showed	O
similar	O
consumption	O
and	O
preference	O
to	O
increasing	O
concentration	O
of	O
both	O
sweet	O
and	O
bitter	O
tastes	O
.	O

More	O
interestingly	O
,	O
systemic	O
administration	O
of	O
ST1283	O
inhibited	O
EtOH	B-CHEMICAL
-	O
CPP	O
and	O
EtOH	B-CHEMICAL
-	O
enhanced	O
locomotion	O
.	O

This	O
inhibition	O
was	O
blocked	O
when	O
mice	O
were	O
pretreated	O
with	O
the	O
selective	O
H3R	B-GENE-Y
agonist	O
R	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
alpha	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
histamine	I-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
)	O
.	O

Finally	O
,	O
vehicle	O
-	O
and	O
ST1283	O
-	O
treated	O
mice	O
had	O
similar	O
BECs	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
ST1283	O
may	O
decrease	O
voluntary	O
EtOH	B-CHEMICAL
consumption	O
and	O
EtOH	B-CHEMICAL
-	O
CPP	O
by	O
altering	O
its	O
reinforcing	O
effects	O
,	O
suggesting	O
a	O
novel	O
role	O
for	O
histamine	B-CHEMICAL
signaling	O
in	O
regulation	O
of	O
alcoholism	O
.	O

Lastly	O
,	O
the	O
results	O
add	O
to	O
the	O
growing	O
literature	O
on	O
H3R	B-GENE-Y
modulation	O
in	O
the	O
pharmacotherapy	O
of	O
EtOH	B-CHEMICAL
addiction	O
.	O

In	O
situ	O
forming	O
reduction	O
-	O
sensitive	O
degradable	O
nanogels	O
for	O
facile	O
loading	O
and	O
triggered	O
intracellular	O
release	O
of	O
proteins	O
.	O

In	O
situ	O
forming	O
reduction	O
-	O
sensitive	O
degradable	O
nanogels	O
were	O
designed	O
and	O
developed	O
based	O
on	O
poly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
glycol	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
-	I-CHEMICAL
poly	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
hydroxyethyl	I-CHEMICAL
)	I-CHEMICAL
methacrylate	I-CHEMICAL
-	I-CHEMICAL
co	I-CHEMICAL
-	I-CHEMICAL
acryloyl	I-CHEMICAL
carbonate	I-CHEMICAL
)	I-CHEMICAL
(	O
PEG	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
(	I-CHEMICAL
HEMA	I-CHEMICAL
-	I-CHEMICAL
co	I-CHEMICAL
-	I-CHEMICAL
AC	I-CHEMICAL
)	I-CHEMICAL
)	O
block	O
copolymers	O
for	O
efficient	O
loading	O
as	O
well	O
as	O
triggered	O
intracellular	O
release	O
of	O
proteins	O
.	O

PEG	B-CHEMICAL
-	I-CHEMICAL
P	I-CHEMICAL
(	I-CHEMICAL
HEMA	I-CHEMICAL
-	I-CHEMICAL
co	I-CHEMICAL
-	I-CHEMICAL
AC	I-CHEMICAL
)	I-CHEMICAL
copolymers	O
were	O
prepared	O
with	O
controlled	O
Mn	O
of	O
9	O
.	O
1	O
,	O
9	O
.	O
5	O
,	O
and	O
9	O
.	O
9	O
kg	O
/	O
mol	O
and	O
varying	O
numbers	O
of	O
AC	O
units	O
per	O
molecule	O
of	O
7	O
,	O
9	O
and	O
11	O
,	O
respectively	O
(	O
denoted	O
as	O
copolymer	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
by	O
reversible	O
addition	O
-	O
fragmentation	O
chain	O
transfer	O
copolymerization	O
.	O

These	O
copolymers	O
were	O
freely	O
soluble	O
in	O
phosphate	B-CHEMICAL
buffer	O
but	O
formed	O
disulfide	B-CHEMICAL
-	O
cross	O
-	O
linked	O
nanogels	O
with	O
defined	O
sizes	O
ranging	O
from	O
72	O
.	O
5	O
to	O
124	O
.	O
1	O
nm	O
in	O
the	O
presence	O
of	O
cystamine	B-CHEMICAL
via	O
ring	O
-	O
opening	O
reaction	O
with	O
cyclic	B-CHEMICAL
carbonate	I-CHEMICAL
groups	O
.	O

The	O
sizes	O
of	O
nanogels	O
decreased	O
with	O
increasing	O
AC	O
units	O
as	O
a	O
result	O
of	O
increased	O
cross	O
-	O
linking	O
density	O
.	O

Dynamic	O
light	O
scattering	O
studies	O
showed	O
that	O
these	O
nanogels	O
though	O
stable	O
at	O
physiological	O
conditions	O
were	O
rapidly	O
dissociated	O
in	O
response	O
to	O
10	O
mM	O
dithiothreitol	B-CHEMICAL
(	O
DTT	B-CHEMICAL
)	O
.	O

Interestingly	O
,	O
FITC	B-CHEMICAL
-	O
labeled	O
cytochrome	B-GENE-Y
C	I-GENE-Y
(	O
FITC	B-CHEMICAL
-	O
CC	B-GENE-Y
)	O
could	O
be	O
readily	O
loaded	O
into	O
nanogels	O
with	O
remarkable	O
loading	O
efficiencies	O
(	O
up	O
to	O
98	O
.	O
2	O
%	O
)	O
and	O
loading	O
contents	O
(	O
up	O
to	O
48	O
.	O
2	O
wt	O
.	O
%	O
)	O
.	O

The	O
in	O
vitro	O
release	O
studies	O
showed	O
that	O
release	O
of	O
FITC	B-CHEMICAL
-	O
CC	B-GENE-Y
was	O
minimal	O
under	O
physiological	O
conditions	O
but	O
significantly	O
enhanced	O
under	O
reductive	O
conditions	O
in	O
the	O
presence	O
of	O
10	O
mM	O
DTT	B-CHEMICAL
with	O
about	O
96	O
.	O
8	O
%	O
of	O
FITC	B-CHEMICAL
-	O
CC	B-GENE-Y
released	O
in	O
22	O
h	O
from	O
nanogel	O
1	O
.	O

In	O
contrast	O
,	O
protein	O
release	O
from	O
1	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
butanediamine	I-CHEMICAL
cross	O
-	O
linked	O
nanogels	O
(	O
reduction	O
-	O
insensitive	O
control	O
)	O
remained	O
low	O
under	O
otherwise	O
the	O
same	O
conditions	O
.	O

MTT	B-CHEMICAL
assays	O
showed	O
that	O
these	O
nanogels	O
were	O
nontoxic	O
to	O
HeLa	O
cells	O
up	O
to	O
a	O
tested	O
concentration	O
of	O
2	O
mg	O
/	O
mL	O
.	O

Confocal	O
microscopy	O
results	O
showed	O
that	O
nanogel	O
1	O
delivered	O
and	O
released	O
FITC	B-CHEMICAL
-	O
CC	B-GENE-Y
into	O
the	O
perinuclei	O
region	O
of	O
HeLa	O
cells	O
following	O
8	O
h	O
incubation	O
.	O

CC	B-GENE-Y
-	O
loaded	O
reductively	O
degradable	O
nanogels	O
demonstrated	O
apparently	O
better	O
apoptotic	O
activity	O
than	O
free	O
CC	B-GENE-Y
as	O
well	O
as	O
reduction	O
-	O
insensitive	O
controls	O
.	O

These	O
in	O
situ	O
forming	O
,	O
surfactant	O
and	O
oil	O
-	O
free	O
,	O
and	O
reduction	O
-	O
sensitive	O
degradable	O
nanogels	O
are	O
highly	O
promising	O
for	O
targeted	O
protein	O
therapy	O
.	O

Cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
inhibits	O
rac1	B-GENE-Y
activation	O
in	O
breast	O
cancer	O
cells	O
by	O
a	O
reactive	O
oxygen	B-CHEMICAL
species	O
-	O
mediated	O
mechanism	O
and	O
independently	O
of	O
janus	B-GENE-Y
tyrosine	I-GENE-Y
kinase	I-GENE-Y
2	I-GENE-Y
and	O
p	B-GENE-Y
-	I-GENE-Y
rex1	I-GENE-Y
.	O

The	O
small	O
GTPase	B-GENE-N
Rac1	B-GENE-Y
has	O
been	O
widely	O
implicated	O
in	O
mammary	O
tumorigenesis	O
and	O
metastasis	O
.	O

Previous	O
studies	O
established	O
that	O
stimulation	O
of	O
ErbB	B-GENE-Y
receptors	O
in	O
breast	O
cancer	O
cells	O
activates	O
Rac1	B-GENE-Y
and	O
enhances	O
motility	O
via	O
the	O
Rac	B-GENE-N
-	I-GENE-N
guanine	I-GENE-N
nucleotide	I-GENE-N
exchange	I-GENE-N
factor	I-GENE-N
P	B-GENE-Y
-	I-GENE-Y
Rex1	I-GENE-Y
.	O

As	O
the	O
Janus	B-GENE-Y
tyrosine	I-GENE-Y
kinase	I-GENE-Y
2	I-GENE-Y
(	O
Jak2	B-GENE-Y
)	O
/	O
signal	B-GENE-Y
transducer	I-GENE-Y
and	I-GENE-Y
activator	I-GENE-Y
of	I-GENE-Y
transcription	I-GENE-Y
3	I-GENE-Y
(	O
Stat3	B-GENE-Y
)	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
functionally	O
associated	O
with	O
ErbB	B-GENE-Y
receptors	O
,	O
we	O
asked	O
if	O
this	O
pathway	O
could	O
mediate	O
P	B-GENE-Y
-	I-GENE-Y
Rex1	I-GENE-Y
/	O
Rac1	B-GENE-Y
activation	O
in	O
response	O
to	O
ErbB	B-GENE-Y
ligands	O
.	O

Here	O
we	O
found	O
that	O
the	O
anticancer	O
agent	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
,	O
a	O
Jak2	B-GENE-N
inhibitor	O
,	O
reduced	O
the	O
activation	O
of	O
Rac1	B-GENE-Y
and	O
motility	O
in	O
response	O
to	O
the	O
ErbB3	B-GENE-Y
ligand	O
heregulin	B-GENE-Y
in	O
breast	O
cancer	O
cells	O
.	O

However	O
,	O
Rac1	B-GENE-Y
activation	O
was	O
not	O
affected	O
by	O
Jak2	B-GENE-Y
or	O
Stat3	B-GENE-Y
RNA	O
interference	O
,	O
suggesting	O
that	O
the	O
effect	O
of	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
occurs	O
through	O
a	O
Jak2	B-GENE-N
-	O
independent	O
mechanism	O
.	O

Cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
also	O
failed	O
to	O
affect	O
the	O
activation	O
of	O
P	B-GENE-Y
-	I-GENE-Y
Rex1	I-GENE-Y
by	O
heregulin	B-GENE-Y
.	O

Subsequent	O
analysis	O
revealed	O
that	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
strongly	O
activates	O
RhoA	B-GENE-N
and	O
the	O
Rho	B-GENE-N
effector	O
Rho	B-GENE-N
kinase	I-GENE-N
(	O
ROCK	B-GENE-N
)	O
in	O
breast	O
cancer	O
cells	O
and	O
induces	O
the	O
formation	O
of	O
stress	O
fibers	O
.	O

Interestingly	O
,	O
disruption	O
of	O
the	O
RhoA	B-GENE-N
-	O
ROCK	B-GENE-N
pathway	O
prevented	O
the	O
inhibitory	O
effect	O
of	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
on	O
Rac1	B-GENE-Y
activation	O
by	O
heregulin	B-GENE-Y
.	O

Lastly	O
,	O
we	O
found	O
that	O
RhoA	B-GENE-N
activation	O
by	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
is	O
mediated	O
by	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
.	O

The	O
ROS	O
scavenger	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
l	I-CHEMICAL
-	I-CHEMICAL
cysteine	I-CHEMICAL
and	O
the	O
mitochondrial	O
antioxidant	O
Mito	O
-	O
TEMPO	O
rescued	O
the	O
inhibitory	O
effect	O
of	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
on	O
Rac1	B-GENE-Y
activation	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
indicate	O
that	O
ErbB	B-GENE-Y
-	O
driven	O
Rac1	B-GENE-Y
activation	O
in	O
breast	O
cancer	O
cells	O
proceeds	O
independently	O
of	O
the	O
Jak2	B-GENE-N
pathway	O
.	O

Moreover	O
,	O
they	O
established	O
that	O
the	O
inhibitory	O
effect	O
of	O
cucurbitacin	B-CHEMICAL
I	I-CHEMICAL
on	O
Rac1	B-GENE-Y
activity	O
involves	O
the	O
alteration	O
of	O
the	O
balance	O
between	O
Rho	B-GENE-N
and	O
Rac	B-GENE-N
.	O

[	B-CHEMICAL
6	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
gingerol	I-CHEMICAL
:	O
a	O
novel	O
AT₁	B-GENE-Y
antagonist	O
for	O
the	O
treatment	O
of	O
cardiovascular	O
disease	O
.	O

Considering	O
the	O
prevalence	O
of	O
cardiovascular	O
disease	O
in	O
public	O
health	O
and	O
the	O
limited	O
validated	O
therapeutic	O
options	O
,	O
this	O
study	O
aimed	O
to	O
find	O
novel	O
compounds	O
targeting	O
the	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
,	O
accepted	O
as	O
a	O
therapeutic	O
target	O
in	O
cardiovascular	O
disease	O
.	O

A	O
small	O
library	O
consisting	O
of	O
89	O
compounds	O
from	O
39	O
Chinese	O
herbs	O
was	O
profiled	O
using	O
a	O
cell	O
-	O
based	O
calcium	O
mobilization	O
assay	O
which	O
was	O
developed	O
and	O
characterized	O
for	O
high	O
-	O
throughput	O
screening	O
.	O

[	B-CHEMICAL
6	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
Gingerol	I-CHEMICAL
derived	O
from	O
Zingiber	O
officinale	O
Roscoe	O
(	O
ginger	O
)	O
was	O
identified	O
as	O
a	O
novel	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
with	O
an	O
IC50	O
value	O
of	O
8	O
.	O
173	O
µM	O
.	O

The	O
hit	O
was	O
further	O
tested	O
by	O
a	O
specificity	O
assay	O
indicating	O
that	O
it	O
had	O
no	O
antagonistic	O
effects	O
on	O
other	O
evaluated	O
GPCRs	B-GENE-N
,	O
such	O
as	O
endothelin	B-GENE-N
receptors	I-GENE-N
.	O

The	O
major	O
ingredient	O
of	O
ginger	O
,	O
[	B-CHEMICAL
6	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
gingerol	I-CHEMICAL
,	O
could	O
inhibit	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
activation	O
,	O
which	O
partially	O
clarified	O
the	O
mechanism	O
of	O
ginger	O
regulating	O
blood	O
pressure	O
and	O
strengthening	O
heart	O
in	O
the	O
cardiovascular	O
system	O
.	O

Efficient	O
MRI	O
labeling	O
of	O
endothelial	O
progenitor	O
cells	O
:	O
Design	O
of	O
thiolated	O
surface	O
stabilized	O
superparamagnetic	O
iron	B-CHEMICAL
oxide	I-CHEMICAL
nanoparticles	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
design	O
thiolated	O
surface	O
stabilized	O
superparamagnetic	O
iron	B-CHEMICAL
oxide	I-CHEMICAL
nanoparticles	O
(	O
TSS	O
-	O
SPIONs	O
)	O
for	O
efficient	O
internalization	O
with	O
high	O
MRI	O
sensitivity	O
.	O

TSS	O
-	O
SPIONs	O
were	O
developed	O
by	O
chelation	O
between	O
thiolated	O
chitosan	O
-	O
thioglycolic	B-CHEMICAL
acid	I-CHEMICAL
(	O
chitosan	O
-	O
TGA	B-CHEMICAL
)	O
hydrogel	O
and	O
iron	B-CHEMICAL
ions	O
(	O
Fe	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
/	O
Fe	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
)	O
.	O

Likely	O
,	O
unmodified	O
chitosan	O
hydrogel	O
SPIONs	O
(	O
UC	O
-	O
SPIONs	O
)	O
and	O
uncoated	O
SPIONs	O
were	O
used	O
as	O
control	O
.	O

Moreover	O
,	O
TSS	O
-	O
SPIONs	O
were	O
investigated	O
regarding	O
to	O
their	O
iron	B-CHEMICAL
core	O
size	O
,	O
hydrodynamic	O
diameter	O
,	O
zeta	O
potential	O
,	O
iron	B-CHEMICAL
contents	O
,	O
molar	O
relaxivities	O
(	O
r1	O
and	O
r2	O
)	O
,	O
and	O
cellular	O
internalization	O
.	O

TSS	O
-	O
SPIONs	O
demonstrated	O
an	O
iron	B-CHEMICAL
oxide	I-CHEMICAL
core	O
diameter	O
(	O
crystallite	O
size	O
by	O
XRD	O
)	O
of	O
3	O
.	O
1	O
±	O
0	O
.	O
02nm	O
,	O
a	O
hydrodynamic	O
diameter	O
of	O
94	O
±	O
20nm	O
,	O
a	O
zeta	O
potential	O
of	O
+	O
21	O
±	O
5mV	O
,	O
and	O
an	O
iron	B-CHEMICAL
content	O
of	O
3	O
.	O
6	O
±	O
0	O
.	O
9mg	O
/	O
mL	O
.	O

In	O
addition	O
,	O
internalization	O
of	O
TSS	O
-	O
SPIONs	O
into	O
human	O
endothelial	O
progenitor	O
cells	O
(	O
EPC	O
)	O
from	O
umbilical	O
cord	O
blood	O
was	O
more	O
than	O
threefold	O
and	O
17	O
-	O
fold	O
higher	O
in	O
contrast	O
to	O
UC	O
-	O
SPIONs	O
and	O
SPIONs	O
,	O
respectively	O
.	O

With	O
twofold	O
lower	O
incubation	O
iron	B-CHEMICAL
concentration	O
of	O
TSS	O
-	O
SPIONs	O
,	O
more	O
than	O
threefold	O
higher	O
internalization	O
was	O
achieved	O
as	O
compared	O
to	O
Resovist	O
®	O
.	O

Also	O
,	O
cell	O
viability	O
of	O
more	O
than	O
90	O
%	O
was	O
observed	O
in	O
the	O
presence	O
of	O
TSS	O
-	O
SPIONs	O
after	O
24h	O
.	O

The	O
molar	O
MR	O
relaxivities	O
(	O
r2	O
)	O
value	O
at	O
1	O
.	O
5T	O
was	O
threefold	O
higher	O
than	O
that	O
of	O
Resovist	O
®	O
and	O
demonstrated	O
that	O
TSS	O
-	O
SPIONs	O
have	O
the	O
potential	O
as	O
very	O
effective	O
T2	O
contrast	O
-	O
enhancement	O
agent	O
.	O

According	O
to	O
these	O
findings	O
,	O
TSS	O
-	O
SPIONs	O
with	O
efficient	O
internalization	O
,	O
lower	O
cytotoxicity	O
,	O
and	O
high	O
MRI	O
sensitivity	O
seem	O
to	O
be	O
promising	O
for	O
cell	O
tracking	O
.	O

Modulation	O
of	O
cellular	O
insulin	B-GENE-N
signaling	O
and	O
PTP1B	B-GENE-Y
effects	O
by	O
lipid	O
metabolites	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Normal	O
glucose	B-CHEMICAL
regulation	O
is	O
achieved	O
by	O
having	O
adequate	O
insulin	B-GENE-Y
secretion	O
and	O
effective	O
glucose	B-CHEMICAL
uptake	O
/	O
disposal	O
.	O

Excess	O
lipids	O
in	O
peripheral	O
tissues	O
-	O
skeletal	O
muscle	O
,	O
liver	O
and	O
adipose	O
tissue	O
-	O
may	O
attenuate	O
insulin	B-GENE-Y
signaling	O
through	O
the	O
protein	B-GENE-N
kinase	I-GENE-N
B	I-GENE-N
(	O
AKt	B-GENE-N
)	O
pathway	O
and	O
up	O
-	O
regulate	O
protein	B-GENE-Y
tyrosine	I-GENE-Y
phosphatase	I-GENE-Y
1B	I-GENE-Y
(	O
PTP1B	B-GENE-Y
)	O
,	O
a	O
negative	O
regulator	O
of	O
insulin	B-GENE-Y
signaling	O
.	O

We	O
studied	O
accumulation	O
of	O
lipid	O
metabolites	O
[	O
triglycerides	B-CHEMICAL
(	O
TAGs	B-CHEMICAL
)	O
,	O
diglycerides	B-CHEMICAL
(	O
DAGs	B-CHEMICAL
)	O
]	O
and	O
ceramides	B-CHEMICAL
in	O
relation	O
to	O
insulin	B-GENE-N
signaling	O
and	O
expression	O
and	O
phosphorylation	O
of	O
PTP1B	B-GENE-Y
by	O
preincubating	O
rat	O
skeletal	O
muscle	O
cells	O
(	O
L6	O
myotubes	O
)	O
with	O
three	O
saturated	O
and	O
three	O
unsaturated	O
free	O
fatty	B-CHEMICAL
acids	I-CHEMICAL
(	O
FFAs	O
)	O
(	O
200	O
μM	O
)	O
.	O

Cells	O
were	O
also	O
evaluated	O
in	O
the	O
presence	O
of	O
wortmannin	B-CHEMICAL
,	O
an	O
inhibitor	O
of	O
phosphatidylinositol	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinases	I-GENE-N
and	O
thus	O
AKt	B-GENE-N
(	O
0	O
-	O
100	O
nM	O
)	O
.	O

Unsaturated	O
FFAs	O
increased	O
DAGs	B-CHEMICAL
,	O
TAGs	B-CHEMICAL
and	O
PTP1B	B-GENE-Y
expression	O
significantly	O
,	O
but	O
cells	O
remained	O
insulin	B-GENE-N
sensitive	O
as	O
assessed	O
by	O
robust	O
AKt	B-GENE-N
and	O
PTP1B	B-GENE-Y
phosphorylation	O
at	O
serine	B-CHEMICAL
(	O
Ser	B-CHEMICAL
)	O
50	O
,	O
Ser	B-CHEMICAL
398	O
and	O
tyrosine	B-CHEMICAL
152	O
.	O

Saturated	O
palmitic	B-CHEMICAL
and	I-CHEMICAL
stearic	I-CHEMICAL
acids	I-CHEMICAL
increased	O
ceramides	B-CHEMICAL
,	O
up	O
-	O
regulated	O
PTP1B	B-GENE-Y
,	O
and	O
had	O
AKt	B-GENE-N
and	O
PTP1B	B-GENE-Y
phosphorylation	O
at	O
Ser	B-CHEMICAL
50	O
impaired	O
.	O

We	O
show	O
a	O
significant	O
correlation	O
between	O
phosphorylation	O
levels	O
of	O
AKt	B-GENE-N
and	O
of	O
PTP1B	B-GENE-Y
at	O
Ser	O
50	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
84	O
,	O
P	O
<	O
.	O
05	O
)	O
.	O

The	O
same	O
was	O
observed	O
with	O
increasing	O
wortmannin	B-CHEMICAL
dose	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
73	O
,	O
P	O
<	O
.	O
05	O
)	O
.	O

Only	O
FFAs	O
that	O
increased	O
ceramides	B-CHEMICAL
caused	O
impairment	O
of	O
AKt	B-GENE-N
and	O
PTP1B	B-GENE-Y
phosphorylation	O
at	O
Ser	B-CHEMICAL
50	O
.	O

PTP1B	B-GENE-Y
overexpression	O
in	O
the	O
presence	O
of	O
excess	O
lipids	O
may	O
not	O
directly	O
cause	O
insulin	B-GENE-N
resistance	O
unless	O
it	O
is	O
accompanied	O
by	O
decreased	O
PTP1B	B-GENE-Y
phosphorylation	O
.	O

A	O
clear	O
relationship	O
between	O
PTP1B	B-GENE-Y
phosphorylation	O
levels	O
at	O
Ser	B-CHEMICAL
50	O
and	O
its	O
negative	O
effect	O
on	O
insulin	B-GENE-N
signaling	O
is	O
shown	O
.	O

Conformation	O
Guides	O
Molecular	O
Efficacy	O
in	O
Docking	O
Screens	O
of	O
Activated	O
β	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
Adrenergic	I-GENE-Y
G	I-GENE-Y
Protein	I-GENE-Y
Coupled	I-GENE-Y
Receptor	I-GENE-Y
.	O

A	O
prospective	O
,	O
large	O
library	O
virtual	O
screen	O
against	O
an	O
activated	O
β2	B-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
(	O
β2AR	B-GENE-Y
)	O
structure	O
returned	O
potent	O
agonists	O
to	O
the	O
exclusion	O
of	O
inverse	O
-	O
agonists	O
,	O
providing	O
the	O
first	O
complement	O
to	O
the	O
previous	O
virtual	O
screening	O
campaigns	O
against	O
inverse	O
-	O
agonist	O
-	O
bound	O
G	B-GENE-N
protein	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
(	O
GPCR	B-GENE-N
)	O
structures	O
,	O
which	O
predicted	O
only	O
inverse	O
-	O
agonists	O
.	O

In	O
addition	O
,	O
two	O
hits	O
recapitulated	O
the	O
signaling	O
profile	O
of	O
the	O
co	O
-	O
crystal	O
ligand	O
with	O
respect	O
to	O
the	O
G	B-GENE-N
protein	I-GENE-N
and	O
arrestin	B-GENE-N
mediated	O
signaling	O
.	O

This	O
functional	O
fidelity	O
has	O
important	O
implications	O
in	O
drug	O
design	O
,	O
as	O
the	O
ability	O
to	O
predict	O
ligands	O
with	O
predefined	O
signaling	O
properties	O
is	O
highly	O
desirable	O
.	O

However	O
,	O
the	O
agonist	O
-	O
bound	O
state	O
provides	O
an	O
uncertain	O
template	O
for	O
modeling	O
the	O
activated	O
conformation	O
of	O
other	O
GPCRs	B-GENE-N
,	O
as	O
a	O
dopamine	B-GENE-N
D2	I-GENE-N
receptor	I-GENE-N
(	O
DRD2	B-GENE-Y
)	O
activated	O
model	O
templated	O
on	O
the	O
activated	O
β2AR	B-GENE-Y
structure	O
returned	O
few	O
hits	O
of	O
only	O
marginal	O
potency	O
.	O

A	O
systematic	O
comparison	O
of	O
the	O
properties	O
of	O
clinically	O
used	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
.	O

Angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
(	O
ARBs	O
)	O
have	O
become	O
an	O
important	O
drug	O
class	O
in	O
the	O
treatment	O
of	O
hypertension	O
and	O
heart	O
failure	O
and	O
the	O
protection	O
from	O
diabetic	O
nephropathy	O
.	O

Eight	O
ARBs	O
are	O
clinically	O
available	O
[	O
azilsartan	B-CHEMICAL
,	O
candesartan	B-CHEMICAL
,	O
eprosartan	B-CHEMICAL
,	O
irbesartan	B-CHEMICAL
,	O
losartan	B-CHEMICAL
,	O
olmesartan	B-CHEMICAL
,	O
telmisartan	B-CHEMICAL
,	O
valsartan	B-CHEMICAL
]	O
.	O

Azilsartan	B-CHEMICAL
(	O
in	O
some	O
countries	O
)	O
,	O
candesartan	B-CHEMICAL
,	O
and	O
olmesartan	B-CHEMICAL
are	O
orally	O
administered	O
as	O
prodrugs	O
,	O
whereas	O
the	O
blocking	O
action	O
of	O
some	O
is	O
mediated	O
through	O
active	O
metabolites	O
.	O

On	O
the	O
basis	O
of	O
their	O
chemical	O
structures	O
,	O
ARBs	O
use	O
different	O
binding	O
pockets	O
in	O
the	O
receptor	O
,	O
which	O
are	O
associated	O
with	O
differences	O
in	O
dissociation	O
times	O
and	O
,	O
in	O
most	O
cases	O
,	O
apparently	O
insurmountable	O
antagonism	O
.	O

The	O
physicochemical	O
differences	O
between	O
ARBs	O
also	O
manifest	O
in	O
different	O
tissue	O
penetration	O
,	O
including	O
passage	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Differences	O
in	O
binding	O
mode	O
and	O
tissue	O
penetration	O
are	O
also	O
associated	O
with	O
differences	O
in	O
pharmacokinetic	O
profile	O
,	O
particularly	O
duration	O
of	O
action	O
.	O

Although	O
generally	O
highly	O
specific	O
for	O
angiotensin	B-GENE-Y
II	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
receptors	I-GENE-Y
,	O
some	O
ARBs	O
,	O
particularly	O
telmisartan	B-CHEMICAL
,	O
are	O
partial	O
agonists	O
at	O
peroxisome	B-GENE-Y
proliferator	I-GENE-Y
-	I-GENE-Y
activated	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
.	O

All	O
of	O
these	O
properties	O
are	O
comprehensively	O
reviewed	O
in	O
this	O
article	O
.	O

Although	O
there	O
is	O
general	O
consensus	O
that	O
a	O
continuous	O
receptor	O
blockade	O
over	O
a	O
24	O
-	O
hour	O
period	O
is	O
desirable	O
,	O
the	O
clinical	O
relevance	O
of	O
other	O
pharmacological	O
differences	O
between	O
individual	O
ARBs	O
remains	O
to	O
be	O
assessed	O
.	O

The	O
use	O
of	O
insulin	B-GENE-Y
analogues	O
in	O
pregnancy	O
.	O

Excellent	O
glycaemic	O
control	O
is	O
essential	O
in	O
pregnancy	O
to	O
optimise	O
maternal	O
and	O
foetal	O
outcomes	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
assess	O
the	O
efficacy	O
and	O
safety	O
of	O
insulin	B-GENE-Y
analogues	O
in	O
pregnancy	O
.	O

Insulin	B-GENE-Y
lispro	O
and	O
insulin	B-GENE-Y
aspart	O
are	O
safe	O
in	O
pregnancy	O
and	O
may	O
improve	O
post	O
-	O
prandial	O
glycaemic	O
control	O
in	O
women	O
with	O
type	O
1	O
diabetes	O
.	O

However	O
,	O
a	O
lack	O
of	O
data	O
indicating	O
improved	O
foetal	O
outcomes	O
would	O
suggest	O
that	O
there	O
is	O
no	O
imperative	O
to	O
switch	O
to	O
a	O
short	O
-	O
acting	O
analogue	O
where	O
the	O
woman	O
'	O
s	O
diabetes	O
is	O
well	O
controlled	O
with	O
human	B-GENE-Y
insulin	I-GENE-Y
.	O

There	O
are	O
no	O
reports	O
of	O
the	O
use	O
of	O
insulin	B-GENE-Y
glulisine	O
in	O
pregnancy	O
and	O
so	O
its	O
use	O
cannot	O
be	O
recommended	O
.	O

Most	O
studies	O
of	O
insulin	B-GENE-Y
glargine	O
in	O
pregnancy	O
are	O
small	O
,	O
retrospective	O
and	O
include	O
women	O
with	O
pre	O
-	O
existing	O
diabetes	O
and	O
gestational	O
diabetes	O
.	O

There	O
appear	O
to	O
be	O
no	O
major	O
safety	O
concerns	O
and	O
so	O
it	O
seems	O
reasonable	O
to	O
continue	O
insulin	B-GENE-Y
glargine	O
if	O
required	O
to	O
achieve	O
excellent	O
glycaemic	O
control	O
.	O

A	O
head	O
-	O
to	O
-	O
head	O
comparison	O
between	O
insulin	B-GENE-Y
detemir	O
and	O
NPH	O
insulin	B-GENE-Y
in	O
women	O
with	O
type	O
1	O
diabetes	O
showed	O
that	O
while	O
foetal	O
outcomes	O
did	O
not	O
differ	O
,	O
fasting	O
plasma	O
glucose	B-CHEMICAL
improved	O
with	O
insulin	B-GENE-Y
detemir	O
without	O
an	O
increased	O
incidence	O
of	O
hypoglycaemia	O
.	O

The	O
greater	O
evidence	O
base	O
supports	O
the	O
use	O
of	O
insulin	B-GENE-Y
detemir	O
as	O
the	O
first	O
line	O
long	O
-	O
acting	O
analogue	O
in	O
pregnancy	O
but	O
the	O
lack	O
of	O
definitive	O
foetal	O
benefits	O
means	O
that	O
there	O
is	O
no	O
strong	O
need	O
to	O
switch	O
a	O
woman	O
who	O
is	O
well	O
controlled	O
on	O
NPH	O
insulin	B-GENE-Y
.	O

There	O
seems	O
little	O
justification	O
in	O
using	O
long	O
acting	O
insulin	B-GENE-Y
analogues	O
in	O
women	O
with	O
gestational	O
diabetes	O
or	O
type	O
2	O
diabetes	O
where	O
the	O
risk	O
of	O
hypoglycaemia	O
is	O
low	O
.	O

Identification	O
and	O
synthesis	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
thiophen	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
benzamide	I-CHEMICAL
derivatives	O
as	O
BRAF	B-GENE-Y
(	O
V600E	B-GENE-N
)	O
inhibitors	O
.	O

The	O
V600E	B-GENE-N
BRAF	B-GENE-Y
kinase	B-GENE-N
mutation	O
,	O
which	O
activates	O
the	O
downstream	O
MAPK	B-GENE-N
signaling	O
pathway	O
,	O
commonly	O
occurs	O
in	O
about	O
8	O
%	O
of	O
all	O
human	O
malignancies	O
and	O
about	O
50	O
%	O
of	O
all	O
melanomas	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
virtual	O
screening	O
and	O
chemical	O
synthesis	O
to	O
identify	O
a	O
series	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
thiophen	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
benzamide	I-CHEMICAL
derivatives	O
as	O
potent	O
BRAF	B-GENE-Y
(	O
V600E	B-GENE-N
)	O
inhibitors	O
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
of	O
these	O
derivatives	O
revealed	O
that	O
compounds	O
b40	O
and	O
b47	O
are	O
the	O
two	O
most	O
potent	O
BRAF	B-GENE-Y
(	O
V600E	B-GENE-N
)	O
inhibitors	O
in	O
this	O
series	O
.	O

Creb1	B-GENE-Y
-	O
Mecp2	B-GENE-Y
-	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpG	I-CHEMICAL
complex	O
transactivates	O
postnatal	O
murine	O
neuronal	O
glucose	B-GENE-Y
transporter	I-GENE-Y
isoform	I-GENE-Y
3	I-GENE-Y
expression	O
.	O

The	O
murine	O
neuronal	O
facilitative	O
glucose	B-GENE-Y
transporter	I-GENE-Y
isoform	I-GENE-Y
3	I-GENE-Y
(	O
Glut3	B-GENE-Y
)	O
is	O
developmentally	O
regulated	O
,	O
peaking	O
in	O
expression	O
at	O
postnatal	O
day	O
(	O
PN	O
)	O
14	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
characterized	O
a	O
canonical	O
CpG	B-CHEMICAL
island	O
spanning	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
glut3	B-GENE-Y
gene	O
.	O

Methylation	O
-	O
specific	O
PCR	O
and	O
bisulfite	B-CHEMICAL
sequencing	O
identified	O
methylation	O
of	O
this	O
CpG	B-CHEMICAL
(	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpG	I-CHEMICAL
)	O
island	O
of	O
the	O
glut3	B-GENE-Y
gene	O
,	O
frequency	O
of	O
methylation	O
increasing	O
2	O
.	O
5	O
-	O
fold	O
with	O
a	O
1	O
.	O
6	O
-	O
fold	O
increase	O
in	O
DNA	B-GENE-Y
methyl	I-GENE-Y
transferase	I-GENE-Y
3a	I-GENE-Y
concentrations	O
noted	O
with	O
advancing	O
postnatal	O
age	O
(	O
PN14	O
vs	O
PN3	O
)	O
.	O

5	O
'	O
-	O
flanking	O
region	O
of	O
glut3	B-GENE-Y
-	O
luciferase	O
reporter	O
transient	O
transfection	O
in	O
HT22	O
hippocampal	O
neurons	O
demonstrated	O
that	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpGs	I-CHEMICAL
inhibit	O
glut3	B-GENE-Y
transcription	O
.	O

Contrary	O
to	O
this	O
biological	O
function	O
,	O
glut3	B-GENE-Y
expression	O
rises	O
synchronously	O
with	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpGs	I-CHEMICAL
in	O
PN14	O
vs	O
PN3	O
neurons	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
IP	O
)	O
revealed	O
that	O
methyl	B-GENE-Y
-	I-GENE-Y
CpG	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
2	I-GENE-Y
(	O
Mecp2	B-GENE-Y
)	O
bound	O
the	O
glut3	B-GENE-Y
-	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpGs	I-CHEMICAL
.	O

Depending	O
on	O
association	O
with	O
specific	O
coregulators	O
,	O
Mecp2	B-GENE-Y
,	O
a	O
dual	O
regulator	O
of	O
gene	O
transcription	O
,	O
may	O
repress	O
or	O
activate	O
a	O
downstream	O
gene	O
.	O

Sequential	O
chromatin	O
IP	O
uncovered	O
the	O
glut3	B-GENE-Y
-	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpGs	I-CHEMICAL
to	O
bind	O
Mecp2	B-GENE-Y
exponentially	O
upon	O
recruitment	O
of	O
Creb1	B-GENE-Y
rather	O
than	O
histone	B-GENE-Y
deacetylase	I-GENE-Y
1	I-GENE-Y
.	O

Co	O
-	O
IP	O
and	O
coimmunolocalization	O
confirmed	O
that	O
Creb1	B-GENE-Y
associated	O
with	O
Mecp2	B-GENE-Y
and	O
cotransfection	O
with	O
glut3	B-GENE-Y
-	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpG	I-CHEMICAL
in	O
HT22	O
cells	O
enhanced	O
glut3	B-GENE-Y
transcription	O
.	O

Separate	O
5	B-CHEMICAL
-	I-CHEMICAL
aza	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
deoxycytidine	I-CHEMICAL
pretreatment	O
or	O
in	O
combination	O
with	O
trichostatin	B-CHEMICAL
A	I-CHEMICAL
reduced	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpG	I-CHEMICAL
and	O
specific	O
small	O
interference	O
RNAs	O
targeting	O
Mecp2	B-GENE-Y
and	O
Creb1	B-GENE-Y
separately	O
or	O
together	O
depleting	O
Mecp2	B-GENE-Y
and	O
/	O
or	O
Creb1	B-GENE-Y
binding	O
of	O
glut3	B-GENE-Y
-	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpGs	I-CHEMICAL
reduced	O
glut3	B-GENE-Y
expression	O
in	O
HT22	O
cells	O
.	O

We	O
conclude	O
that	O
Glut3	B-GENE-Y
is	O
a	O
methylation	O
-	O
sensitive	O
neuronal	O
gene	O
that	O
recruits	O
Mecp2	B-GENE-Y
.	O

Recruitment	O
of	O
Creb1	B-GENE-Y
-	O
Mecp2	B-GENE-Y
by	O
glut3	B-GENE-Y
-	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpG	I-CHEMICAL
contributes	O
towards	O
transactivation	O
,	O
formulating	O
an	O
escape	O
from	O
(	B-CHEMICAL
m	I-CHEMICAL
)	I-CHEMICAL
CpG	I-CHEMICAL
-	O
induced	O
gene	O
suppression	O
,	O
and	O
thereby	O
promoting	O
developmental	O
neuronal	O
glut3	B-GENE-Y
gene	O
transcription	O
and	O
expression	O
.	O

LDL	B-GENE-N
Cholesterol	B-CHEMICAL
Goals	O
in	O
High	O
-	O
Risk	O
Patients	O
:	O
How	O
Low	O
Do	O
We	O
Go	O
and	O
How	O
Do	O
We	O
Get	O
There	O
?	O

It	O
is	O
widely	O
recognised	O
that	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
cholesterol	B-CHEMICAL
(	O
LDL	B-GENE-N
-	O
C	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
and	O
modifiable	O
risk	O
factors	O
for	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
.	O

Statins	O
(	O
HMG	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
inhibitors	O
)	O
have	O
consistently	O
been	O
shown	O
to	O
decrease	O
both	O
LDL	B-GENE-N
-	O
C	O
and	O
CVD	O
risk	O
in	O
almost	O
all	O
patient	O
categories	O
,	O
with	O
the	O
exception	O
of	O
heart	O
and	O
kidney	O
failure	O
as	O
well	O
as	O
advanced	O
aortic	O
stenosis	O
.	O

As	O
a	O
consequence	O
,	O
statins	O
have	O
become	O
the	O
cornerstone	O
in	O
current	O
prevention	O
guidelines	O
.	O

In	O
patients	O
who	O
do	O
not	O
reach	O
the	O
LDL	B-GENE-N
-	O
C	O
target	O
,	O
combination	O
therapy	O
with	O
additional	O
LDL	B-GENE-N
-	O
C	O
lowering	O
drugs	O
(	O
e	O
.	O
g	O
.	O
ezetimibe	B-CHEMICAL
,	O
bile	B-CHEMICAL
acid	I-CHEMICAL
sequestrants	O
or	O
fibrates	B-CHEMICAL
)	O
should	O
be	O
considered	O
.	O

Guidelines	O
provide	O
different	O
LDL	B-GENE-N
-	O
C	O
levels	O
to	O
strive	O
for	O
,	O
depending	O
on	O
the	O
CVD	O
risk	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
rationale	O
for	O
these	O
LDL	B-GENE-N
-	O
C	O
targets	O
and	O
how	O
these	O
goals	O
might	O
be	O
reached	O
by	O
current	O
and	O
future	O
therapies	O
.	O

Synthesis	O
and	O
Structure	O
-	O
Activity	O
Relationship	O
Studies	O
of	O
Derivatives	O
of	O
the	O
Dual	O
Aromatase	B-GENE-Y
-	O
Sulfatase	B-GENE-Y
Inhibitor	O
4	B-CHEMICAL
-	I-CHEMICAL
{	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Cyanophenyl	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
4H	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
triazol	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
amino	I-CHEMICAL
]	I-CHEMICAL
methyl	I-CHEMICAL
}	I-CHEMICAL
phenyl	I-CHEMICAL
sulfamate	I-CHEMICAL
.	O

4	B-CHEMICAL
-	I-CHEMICAL
{	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
Cyanophenyl	I-CHEMICAL
)	I-CHEMICAL
(	I-CHEMICAL
4H	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
triazol	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
amino	I-CHEMICAL
]	I-CHEMICAL
methyl	I-CHEMICAL
}	I-CHEMICAL
phenyl	I-CHEMICAL
sulfamate	I-CHEMICAL
and	O
its	O
ortho	O
-	O
halogenated	O
(	O
F	B-CHEMICAL
,	O
Cl	B-CHEMICAL
,	O
Br	B-CHEMICAL
)	O
derivatives	O
are	O
first	O
-	O
generation	O
dual	O
aromatase	B-GENE-Y
and	O
sulfatase	B-GENE-Y
inhibitors	O
(	O
DASIs	O
)	O
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
were	O
performed	O
on	O
these	O
compounds	O
,	O
and	O
various	O
modifications	O
were	O
made	O
to	O
their	O
structures	O
involving	O
relocation	O
of	O
the	O
halogen	B-CHEMICAL
atom	O
,	O
introduction	O
of	O
more	O
halogen	B-CHEMICAL
atoms	O
,	O
replacement	O
of	O
the	O
halogen	B-CHEMICAL
with	O
another	O
group	O
,	O
replacement	O
of	O
the	O
methylene	B-CHEMICAL
linker	O
with	O
a	O
difluoromethylene	B-CHEMICAL
linker	O
,	O
replacement	O
of	O
the	O
para	B-CHEMICAL
-	I-CHEMICAL
cyanophenyl	I-CHEMICAL
ring	O
with	O
other	O
ring	O
structures	O
,	O
and	O
replacement	O
of	O
the	O
triazolyl	B-CHEMICAL
group	O
with	O
an	O
imidazolyl	B-CHEMICAL
group	O
.	O

The	O
most	O
potent	O
in	O
vitro	O
DASI	O
discovered	O
is	O
an	O
imidazole	B-CHEMICAL
derivative	O
with	O
IC50	O
values	O
against	O
aromatase	B-GENE-Y
and	O
steroid	B-GENE-Y
sulfatase	I-GENE-Y
in	O
a	O
JEG	O
-	O
3	O
cell	O
preparation	O
of	O
0	O
.	O
2	O
and	O
2	O
.	O
5	O
nM	O
,	O
respectively	O
.	O

The	O
parent	O
phenol	B-CHEMICAL
of	O
this	O
compound	O
inhibits	O
aromatase	B-GENE-Y
with	O
an	O
IC50	O
value	O
of	O
0	O
.	O
028	O
nM	O
in	O
the	O
same	O
assay	O
.	O

Targeting	O
protein	O
-	O
protein	O
interactions	O
within	O
the	O
cyclic	B-CHEMICAL
AMP	I-CHEMICAL
signaling	O
system	O
as	O
a	O
therapeutic	O
strategy	O
for	O
cardiovascular	O
disease	O
.	O

The	O
cAMP	B-CHEMICAL
signaling	O
system	O
can	O
trigger	O
precise	O
physiological	O
cellular	O
responses	O
that	O
depend	O
on	O
the	O
fidelity	O
of	O
many	O
protein	O
-	O
protein	O
interactions	O
,	O
which	O
act	O
to	O
bring	O
together	O
signaling	O
intermediates	O
at	O
defined	O
locations	O
within	O
cells	O
.	O

In	O
the	O
heart	O
,	O
cAMP	B-CHEMICAL
participates	O
in	O
the	O
fine	O
control	O
of	O
excitation	O
-	O
contraction	O
coupling	O
,	O
hence	O
,	O
any	O
disregulation	O
of	O
this	O
signaling	O
cascade	O
can	O
lead	O
to	O
cardiac	O
disease	O
.	O

Due	O
to	O
the	O
ubiquitous	O
nature	O
of	O
the	O
cAMP	B-CHEMICAL
pathway	O
,	O
general	O
inhibitors	O
of	O
cAMP	B-CHEMICAL
signaling	O
proteins	O
such	O
as	O
PKA	B-GENE-N
,	O
EPAC	B-GENE-Y
and	O
PDEs	B-GENE-N
would	O
act	O
non	O
-	O
specifically	O
and	O
universally	O
,	O
increasing	O
the	O
likelihood	O
of	O
serious	O
'	O
off	O
target	O
'	O
effects	O
.	O

Recent	O
advances	O
in	O
the	O
discovery	O
of	O
peptides	O
and	O
small	O
molecules	O
that	O
disrupt	O
the	O
protein	O
-	O
protein	O
interactions	O
that	O
underpin	O
cellular	O
targeting	O
of	O
cAMP	B-CHEMICAL
signaling	O
proteins	O
are	O
described	O
and	O
discussed	O
.	O

Synthesis	O
and	O
in	O
vitro	O
evaluation	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
Aryl	I-CHEMICAL
pyrido	I-CHEMICAL
-	I-CHEMICAL
quinazolines	I-CHEMICAL
derivatives	O
as	O
potent	O
EGFR	B-GENE-Y
inhibitors	O
.	O

A	O
series	O
of	O
pyrido	B-CHEMICAL
-	I-CHEMICAL
quinazolines	I-CHEMICAL
have	O
been	O
synthesised	O
,	O
characterised	O
and	O
tested	O
for	O
their	O
in	O
vitro	O
EGFR	B-GENE-Y
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitory	O
activity	O
.	O

The	O
compounds	O
were	O
prepared	O
from	O
Alkylideno	B-CHEMICAL
/	I-CHEMICAL
arylideno	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
-	I-CHEMICAL
ureas	I-CHEMICAL
.	O

Their	O
final	O
structure	O
of	O
the	O
compounds	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectral	O
studies	O
(	O
IR	O
.	O
,	O
1H	B-CHEMICAL
NMR	O
,	O
FT	O
-	O
IR	O
and	O
EI	O
-	O
MS	O
)	O
.	O

The	O
cellular	O
EGFR	B-GENE-Y
internalization	O
response	O
of	O
selected	O
compounds	O
was	O
evaluated	O
using	O
HeLa	O
cells	O
.	O

Most	O
of	O
the	O
synthesized	O
compounds	O
displayed	O
potent	O
EGFR	B-GENE-Y
-	O
TK	B-GENE-N
inhibitory	O
activity	O
and	O
structurally	O
halogenated	O
derivatives	O
had	O
a	O
pronounced	O
effect	O
in	O
inhibiting	O
EGFR	B-GENE-Y
internalization	O
.	O

©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
A	O
/	O
S	O
.	O

The	O
vascular	O
protective	O
properties	O
of	O
kinsenoside	B-CHEMICAL
isolated	O
from	O
Anoectochilus	O
roxburghii	O
under	O
high	O
glucose	B-CHEMICAL
condition	O
.	O

Anoectochilus	O
roxburghii	O
is	O
a	O
traditional	O
Chinese	O
herb	O
used	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
some	O
other	O
diseases	O
.	O

The	O
vascular	O
protective	O
effect	O
of	O
its	O
major	O
active	O
ingredient	O
,	O
kinsenoside	B-CHEMICAL
,	O
in	O
high	O
glucose	B-CHEMICAL
conditions	O
was	O
investigated	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
experiments	O
.	O

In	O
in	O
vivo	O
tests	O
,	O
kinsenoside	B-CHEMICAL
(	O
50	O
and	O
100mg	O
/	O
kg	O
)	O
efficiently	O
lowered	O
blood	O
glucose	B-CHEMICAL
and	O
cholesterol	B-CHEMICAL
levels	O
and	O
it	O
enhanced	O
the	O
oxidation	O
resistance	O
of	O
diabetic	O
mice	O
induced	O
by	O
streptozotocin	B-CHEMICAL
.	O

In	O
the	O
in	O
vitro	O
assay	O
,	O
kinsenoside	B-CHEMICAL
(	O
20	O
and	O
50μg	O
/	O
mL	O
)	O
markedly	O
inhibited	O
changes	O
in	O
various	O
biochemical	O
substances	O
(	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
,	O
lactic	B-GENE-N
dehydrogenase	I-GENE-N
(	O
LDH	B-GENE-N
)	O
,	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
,	O
and	O
catalase	B-GENE-Y
(	O
CAT	B-GENE-Y
)	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
damaged	O
by	O
high	O
glucose	B-CHEMICAL
(	O
35mM	O
)	O
and	O
restored	O
vascular	O
endothelial	O
structure	O
by	O
balancing	O
the	O
matrix	B-GENE-N
metalloproteinases	I-GENE-N
-	O
the	O
tissue	B-GENE-N
inhibitors	I-GENE-N
of	I-GENE-N
matrix	I-GENE-N
metalloproteinases	I-GENE-N
(	O
MMP	B-GENE-N
-	O
TIMP	B-GENE-N
)	O
system	O
.	O

The	O
vascular	O
protective	O
effects	O
of	O
kinsenoside	B-CHEMICAL
were	O
speculated	O
to	O
be	O
attributed	O
to	O
oxidative	O
stress	O
inhibition	O
and	O
the	O
reduction	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
mRNA	O
expression	O
levels	O
in	O
high	O
glucose	B-CHEMICAL
conditions	O
.	O

Moreover	O
,	O
histological	O
examination	O
,	O
including	O
hematoxylin	B-CHEMICAL
-	O
eosin	B-CHEMICAL
(	O
H	O
&	O
E	O
)	O
staining	O
,	O
masson	O
trichrome	O
(	O
Masson	O
)	O
staining	O
,	O
and	O
periodic	O
Schiff	O
-	O
methenamine	B-CHEMICAL
(	O
PASM	O
)	O
staining	O
,	O
greatly	O
supported	O
the	O
morphological	O
and	O
functional	O
amelioration	O
of	O
diabetes	O
-	O
related	O
changes	O
in	O
mice	O
aortas	O
after	O
kinsenoside	B-CHEMICAL
(	O
20	O
and	O
50μg	O
/	O
mL	O
)	O
treatment	O
.	O

These	O
results	O
indicated	O
that	O
kinsenoside	B-CHEMICAL
might	O
be	O
a	O
promising	O
agent	O
for	O
the	O
treatment	O
of	O
diabetic	O
vascular	O
disease	O
.	O

Oxysterols	B-CHEMICAL
in	O
cancer	O
cell	O
proliferation	O
and	O
death	O
.	O

Oxysterols	B-CHEMICAL
have	O
been	O
shown	O
to	O
interfere	O
with	O
proliferation	O
and	O
cause	O
the	O
death	O
of	O
many	O
cancer	O
cell	O
types	O
,	O
such	O
as	O
leukaemia	O
,	O
glioblastoma	O
,	O
colon	O
,	O
breast	O
and	O
prostate	O
cancer	O
cells	O
,	O
while	O
they	O
have	O
little	O
or	O
no	O
effect	O
on	O
senescent	O
cells	O
.	O

The	O
mechanisms	O
by	O
which	O
oxysterols	B-CHEMICAL
may	O
influence	O
proliferation	O
are	O
manifold	O
:	O
they	O
control	O
the	O
transcription	O
and	O
the	O
turnover	O
of	O
the	O
key	O
enzyme	O
in	O
cholesterol	B-CHEMICAL
synthesis	O
,	O
3	B-GENE-Y
-	I-GENE-Y
hydroxy	I-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
methylglutaryl	I-GENE-Y
CoA	I-GENE-Y
reductase	I-GENE-Y
,	O
by	O
binding	O
to	O
Insig	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
Insig	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
liver	B-GENE-N
X	I-GENE-N
receptors	I-GENE-N
.	O

Oxysterols	B-CHEMICAL
are	O
thought	O
to	O
be	O
generated	O
in	O
proportion	O
to	O
the	O
rate	O
of	O
cholesterol	B-CHEMICAL
synthesis	O
.	O

Although	O
there	O
is	O
no	O
consensus	O
about	O
the	O
mechanism	O
by	O
which	O
these	O
oxysterols	B-CHEMICAL
are	O
generated	O
in	O
vivo	O
,	O
it	O
clearly	O
has	O
to	O
be	O
ubiquitous	O
.	O

The	O
25	B-GENE-N
-	I-GENE-N
and	I-GENE-N
the	I-GENE-N
27	I-GENE-N
-	I-GENE-N
cholesterol	I-GENE-N
hydroxylases	I-GENE-N
,	O
present	O
in	O
almost	O
all	O
tissues	O
,	O
are	O
possible	O
candidates	O
.	O

Cholesterol	B-CHEMICAL
uptake	O
from	O
lipoproteins	B-GENE-N
,	O
intracellular	O
vesicle	O
transport	O
and	O
lipid	O
transfer	O
are	O
also	O
modified	O
by	O
oxysterols	B-CHEMICAL
.	O

Oxysterols	B-CHEMICAL
interfere	O
with	O
ERK	B-GENE-N
,	O
hedgehog	B-GENE-N
and	O
wnt	B-GENE-N
pathways	O
of	O
proliferation	O
and	O
differentiation	O
.	O

When	O
administered	O
in	O
vitro	O
to	O
cancer	O
cell	O
lines	O
,	O
oxysterols	B-CHEMICAL
invariably	O
both	O
slow	O
down	O
proliferation	O
and	O
provoke	O
cell	O
death	O
.	O

Perhaps	O
is	O
it	O
sufficient	O
to	O
stop	O
proliferation	O
of	O
a	O
cancer	O
to	O
provoke	O
its	O
eradication	O
.	O

Therefore	O
,	O
the	O
two	O
facets	O
of	O
oxysterol	B-CHEMICAL
action	O
that	O
seem	O
important	O
for	O
cancer	O
treatment	O
,	O
cytostaticity	O
and	O
cytotoxicity	O
,	O
will	O
be	O
discussed	O
.	O

Activation	O
of	O
ALDH2	B-GENE-Y
with	O
ethanol	B-CHEMICAL
attenuates	O
diabetes	O
induced	O
myocardial	O
injury	O
in	O
rats	O
.	O

This	O
study	O
assessed	O
changes	O
in	O
myocardial	O
ALDH2	B-GENE-Y
expression	O
in	O
the	O
diabetic	O
rat	O
,	O
in	O
particular	O
the	O
diabetic	O
rat	O
pretreated	O
with	O
ALDH2	B-GENE-Y
activator	O
ethanol	B-CHEMICAL
(	O
EtOH	B-CHEMICAL
)	O
.	O

The	O
rats	O
were	O
divided	O
into	O
six	O
groups	O
:	O
control	O
,	O
EtOH	B-CHEMICAL
control	O
,	O
diabetic	O
rat	O
at	O
4th	O
week	O
(	O
DM4W	O
)	O
,	O
8th	O
week	O
(	O
DM8W	O
)	O
,	O
12th	O
week	O
(	O
DM12W	O
)	O
and	O
EtOH	B-CHEMICAL
+	O
DM8W	O
groups	O
.	O

Compared	O
with	O
control	O
group	O
,	O
fasting	O
blood	O
glucose	B-CHEMICAL
(	O
FBG	O
)	O
and	O
glycosylated	B-GENE-N
hemoglobin	I-GENE-N
(	O
HbA1c	B-GENE-N
)	O
levels	O
were	O
increased	O
in	O
DM	O
groups	O
.	O

HbA1c	B-GENE-N
level	O
in	O
DM12W	O
group	O
was	O
higher	O
than	O
in	O
DM4W	O
group	O
,	O
HbA1c	B-GENE-N
level	O
in	O
EtOH	B-CHEMICAL
+	O
DM8W	O
group	O
was	O
lower	O
than	O
in	O
DM8W	O
group	O
.	O

Compared	O
with	O
control	O
group	O
,	O
there	O
were	O
no	O
changes	O
of	O
LVDP	O
,	O
HR	O
and	O
±	O
dp	O
/	O
dtmax	O
in	O
DM4W	O
group	O
,	O
but	O
there	O
were	O
decreased	O
in	O
DM8W	O
and	O
DM12W	O
groups	O
,	O
and	O
increased	O
in	O
the	O
EtOH	B-CHEMICAL
+	O
DM8W	O
group	O
.	O

In	O
DM	O
groups	O
,	O
SOD	B-GENE-N
activity	O
,	O
ALDH2	B-GENE-Y
mRNA	O
and	O
protein	O
levels	O
were	O
reduced	O
,	O
MDA	B-CHEMICAL
content	O
was	O
increased	O
compared	O
with	O
control	O
group	O
;	O
which	O
decreased	O
further	O
as	O
diabetes	O
progressed	O
.	O

Compared	O
with	O
DM8W	O
group	O
,	O
SOD	B-GENE-N
and	O
ALDH2	B-GENE-Y
in	O
EtOH	B-CHEMICAL
+	O
DM8W	O
group	O
was	O
increased	O
,	O
MDA	B-CHEMICAL
was	O
decreased	O
.	O

Our	O
results	O
indicated	O
with	O
the	O
development	O
of	O
diabetes	O
,	O
myocardial	O
ALDH2	B-GENE-Y
expression	O
was	O
further	O
decreased	O
accompanying	O
decreased	O
ventricular	O
function	O
.	O

However	O
,	O
activation	O
of	O
ALDH2	B-GENE-Y
can	O
decrease	O
diabetes	O
induced	O
myocardial	O
injury	O
.	O

ALDH2	B-GENE-Y
may	O
be	O
one	O
key	O
endogenous	O
cardiac	O
protective	O
factor	O
in	O
diabetic	O
individuals	O
.	O

EROD	B-GENE-N
activity	O
induction	O
in	O
peripheral	O
blood	O
lymphocytes	O
,	O
liver	O
and	O
brain	O
tissues	O
of	O
rats	O
orally	O
exposed	O
to	O
polycyclic	B-CHEMICAL
aromatic	I-CHEMICAL
hydrocarbons	I-CHEMICAL
.	O

Little	O
is	O
known	O
in	O
terms	O
of	O
multi	O
-	O
matrix	O
cytochrome	B-GENE-N
P450	I-GENE-N
activity	O
induction	O
under	O
repeated	O
oral	O
exposure	O
to	O
planar	O
halogenated	B-CHEMICAL
and	I-CHEMICAL
polycyclic	I-CHEMICAL
aromatic	I-CHEMICAL
hydrocarbons	I-CHEMICAL
(	O
PHH	O
,	O
PAH	B-CHEMICAL
)	O
.	O

In	O
the	O
present	O
study	O
,	O
60	O
rats	O
were	O
daily	O
exposed	O
,	O
during	O
28days	O
,	O
to	O
oral	O
ingestion	O
of	O
a	O
mixture	O
consisting	O
of	O
phenanthrene	B-CHEMICAL
,	O
pyrene	B-CHEMICAL
and	O
benzo	B-CHEMICAL
(	I-CHEMICAL
a	I-CHEMICAL
)	I-CHEMICAL
pyrene	I-CHEMICAL
at	O
0	O
,	O
6	O
or	O
600μg	O
/	O
day	O
.	O

EROD	B-CHEMICAL
activity	O
,	O
reflecting	O
almost	O
exclusively	O
CYP1A1	B-GENE-Y
and	O
CYP1B1	B-GENE-Y
activities	O
,	O
was	O
measured	O
in	O
brain	O
and	O
liver	O
microsomes	O
as	O
well	O
as	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
.	O

All	O
induction	O
kinetics	O
could	O
be	O
appropriately	O
fitted	O
using	O
logistic	O
-	O
like	O
models	O
.	O

After	O
28days	O
of	O
exposure	O
to	O
a	O
6μg	O
/	O
day	O
dose	O
,	O
EROD	B-CHEMICAL
activity	O
was	O
found	O
to	O
be	O
91	O
,	O
152	O
and	O
94	O
-	O
fold	O
increased	O
in	O
lymphocytes	O
,	O
liver	O
and	O
brain	O
,	O
respectively	O
,	O
compared	O
to	O
day	O
0	O
.	O

Plateau	O
activities	O
could	O
be	O
appropriately	O
fitted	O
versus	O
ingested	O
doses	O
using	O
Hill	O
or	O
Michaelis	O
-	O
Menten	O
models	O
.	O

Correlations	O
between	O
matrices	O
made	O
it	O
possible	O
to	O
conclude	O
that	O
EROD	B-CHEMICAL
activity	O
in	O
PBL	O
should	O
be	O
considered	O
as	O
a	O
sensitive	O
,	O
convenient	O
and	O
non	O
-	O
destructive	O
approach	O
for	O
(	O
i	O
)	O
evaluating	O
EROD	B-CHEMICAL
activity	O
in	O
liver	O
,	O
which	O
was	O
found	O
to	O
represent	O
98	O
%	O
of	O
the	O
observed	O
EROD	B-CHEMICAL
activities	O
in	O
the	O
three	O
tested	O
matrices	O
and	O
(	O
ii	O
)	O
evaluating	O
oral	O
exposure	O
of	O
homogeneous	O
groups	O
of	O
farm	O
animals	O
(	O
race	O
,	O
diet	O
)	O
to	O
CYP	B-GENE-N
inducing	O
PAH	O
and	O
PHH	B-CHEMICAL
.	O

Diverse	O
effects	O
of	O
macromolecular	O
crowding	O
on	O
the	O
sequential	O
glycan	O
-	O
processing	O
pathway	O
involved	O
in	O
glycoprotein	O
quality	O
control	O
.	O

Compared	O
with	O
in	O
vitro	O
conditions	O
,	O
the	O
intracellular	O
environment	O
is	O
highly	O
crowded	O
with	O
biomolecules	O
;	O
this	O
has	O
numerous	O
effects	O
on	O
protein	O
functions	O
,	O
including	O
enzymatic	O
activity	O
.	O

We	O
examined	O
the	O
effects	O
of	O
macromolecular	O
crowding	O
on	O
glycan	O
processing	O
of	O
N	B-CHEMICAL
-	O
glycoprotein	O
in	O
the	O
endoplasmic	O
reticulum	O
as	O
a	O
model	O
sequential	O
metabolic	O
pathway	O
.	O

Experiments	O
with	O
synthetic	O
substrates	O
of	O
physiological	O
glycan	O
structure	O
clearly	O
showed	O
that	O
the	O
first	O
half	O
of	O
the	O
pathway	O
(	O
glucose	B-CHEMICAL
trimming	O
)	O
was	O
accelerated	O
,	O
whereas	O
the	O
second	O
(	O
mannose	B-CHEMICAL
trimming	O
)	O
was	O
decelerated	O
under	O
molecular	O
crowding	O
conditions	O
.	O

Furthermore	O
,	O
calreticulin	B-GENE-Y
,	O
a	O
lectin	B-GENE-N
-	O
like	O
molecular	O
chaperone	O
,	O
bound	O
more	O
strongly	O
to	O
a	O
glycan	O
-	O
processing	O
intermediate	O
under	O
these	O
conditions	O
.	O

This	O
study	O
demonstrates	O
the	O
diverse	O
effects	O
of	O
molecular	O
crowding	O
on	O
sequential	O
enzymatic	O
processing	O
,	O
and	O
the	O
importance	O
of	O
the	O
effects	O
of	O
macromolecular	O
crowding	O
on	O
in	O
vitro	O
assays	O
for	O
understanding	O
sequential	O
metabolic	O
pathways	O
.	O

New	O
selective	O
inhibitors	O
of	O
MMP	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
for	O
inflammatory	O
diseases	O
:	O
a	O
patent	O
evaluation	O
(	O
W02012151158	O
)	O
.	O

A	O
series	O
of	O
compounds	O
incorporating	O
an	O
aromatic	O
scaffold	O
based	O
on	O
isoxazolines	B-CHEMICAL
were	O
prepared	O
in	O
the	O
patent	O
application	O
(	O
WO2012151158	O
)	O
.	O

The	O
new	O
compounds	O
from	O
the	O
patent	O
are	O
defined	O
to	O
be	O
biologically	O
active	O
metabolites	O
,	O
prodrugs	O
,	O
isomers	O
,	O
stereoisomers	O
,	O
solvates	O
,	O
hydrates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
they	O
are	O
claimed	O
to	O
be	O
useful	O
for	O
treating	O
immunological	O
conditions	O
because	O
of	O
their	O
inhibitory	O
activities	O
on	O
matrix	B-GENE-N
metalloproteinase	I-GENE-N
(	O
MMP	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
)	O
,	O
although	O
no	O
specific	O
MMP	B-GENE-Y
-	I-GENE-Y
13	I-GENE-Y
inhibition	O
data	O
or	O
other	O
rationale	O
to	O
explain	O
their	O
biological	O
effects	O
is	O
provided	O
.	O

The	O
compounds	O
have	O
a	O
broad	O
potential	O
utility	O
with	O
osteoarthritis	O
,	O
rheumatoid	O
arthritis	O
,	O
juvenile	O
arthritis	O
,	O
psoriatic	O
arthritis	O
,	O
degenerative	O
joint	O
disease	O
or	O
systemic	O
lupus	O
erythematosus	O
among	O
the	O
likely	O
preferred	O
indications	O
.	O

A	O
novel	O
benzo	B-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
imidazole	I-CHEMICAL
derivate	O
prevents	O
the	O
development	O
of	O
dextran	O
sulfate	O
sodium	B-CHEMICAL
-	O
induced	O
murine	O
experimental	O
colitis	O
via	O
inhibition	O
of	O
NLRP3	B-GENE-Y
inflammasome	O
.	O

NLRP3	B-GENE-Y
inflammasome	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
various	O
kinds	O
of	O
immunological	O
diseases	O
including	O
colitis	O
.	O

However	O
,	O
there	O
are	O
few	O
drug	O
candidates	O
targeting	O
inflammasomes	O
for	O
the	O
treatment	O
of	O
colitis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
at	O
examining	O
the	O
effect	O
of	O
1	B-CHEMICAL
-	I-CHEMICAL
ethyl	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1H	I-CHEMICAL
-	I-CHEMICAL
benzo	I-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
imidazole	I-CHEMICAL
,	O
a	O
synthetic	O
small	O
molecular	O
compound	O
also	O
named	O
Fc11a	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	O
for	O
the	O
treatment	O
of	O
dextran	O
sulfate	B-CHEMICAL
sodium	B-CHEMICAL
(	O
DSS	O
)	O
-	O
induced	O
experimental	O
colitis	O
in	O
mice	O
via	O
targeting	O
NLRP3	B-GENE-Y
inflammasome	O
.	O

Treatment	O
with	O
Fc11a	O
-	O
2	O
dose	O
-	O
dependently	O
attenuated	O
the	O
loss	O
of	O
body	O
weight	O
and	O
shortening	O
of	O
colon	O
length	O
induced	O
by	O
DSS	O
.	O

In	O
addition	O
,	O
the	O
disease	O
activity	O
index	O
,	O
histopathologic	O
scores	O
and	O
myeloperoxidase	B-GENE-N
activity	O
were	O
also	O
significantly	O
reduced	O
by	O
Fc11a	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
treatment	O
.	O

Moreover	O
,	O
protein	O
and	O
mRNA	O
levels	O
of	O
DSS	O
-	O
induced	O
proinflammatory	O
cytokines	B-GENE-N
in	O
colon	O
,	O
including	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
18	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
17A	I-GENE-Y
and	O
IFN	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
,	O
were	O
markedly	O
suppressed	O
by	O
Fc11a	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
.	O

Furthermore	O
,	O
a	O
decreased	O
CD11c	O
(	O
+	O
)	O
macrophage	O
infiltration	O
in	O
colons	O
and	O
inactivation	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
in	O
peritoneal	O
macrophages	O
were	O
detected	O
in	O
Fc11a	B-CHEMICAL
-	O
2	O
-	O
treated	O
mice	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
Fc11a	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
was	O
related	O
to	O
the	O
inhibition	O
of	O
the	O
cleavage	O
of	O
pro	B-GENE-Y
-	I-GENE-Y
caspase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
pro	B-GENE-Y
-	I-GENE-Y
IL	I-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
and	O
pro	B-GENE-Y
-	I-GENE-Y
IL	I-GENE-Y
-	I-GENE-Y
18	I-GENE-Y
which	O
in	O
turn	O
suppressed	O
the	O
activation	O
of	O
NLRP3	B-GENE-Y
inflammasome	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
ability	O
of	O
Fc11a	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
to	O
inhibit	O
NLRP3	B-GENE-Y
inflammasome	O
activation	O
and	O
its	O
potential	O
use	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
diseases	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
aminothiazoles	I-CHEMICAL
with	O
improved	O
pharmacotherapeutic	O
properties	O
for	O
treatment	O
of	O
prion	O
disease	O
.	O

Recently	O
,	O
we	O
described	O
the	O
aminothiazole	B-CHEMICAL
lead	O
(	B-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
biphenyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
ylthiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
methylpyridin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
amine	I-CHEMICAL
(	O
1	O
)	O
,	O
which	O
exhibits	O
many	O
desirable	O
properties	O
,	O
including	O
excellent	O
stability	O
in	O
liver	O
microsomes	O
,	O
oral	O
bioavailability	O
of	O
∼	O
40	O
%	O
,	O
and	O
high	O
exposure	O
in	O
the	O
brains	O
of	O
mice	O
.	O

Despite	O
its	O
good	O
pharmacokinetic	O
properties	O
,	O
compound	O
1	O
exhibited	O
only	O
modest	O
potency	O
in	O
mouse	O
neuroblastoma	O
cells	O
overexpressing	O
the	O
disease	O
-	O
causing	O
prion	B-GENE-Y
protein	I-GENE-Y
PrP	I-GENE-Y
(	I-GENE-Y
Sc	I-GENE-Y
)	I-GENE-Y
.	O

Accordingly	O
,	O
we	O
sought	O
to	O
identify	O
analogues	O
of	O
1	O
with	O
improved	O
antiprion	O
potency	O
in	O
ScN2a	O
-	O
cl3	O
cells	O
while	O
retaining	O
similar	O
or	O
superior	O
properties	O
.	O

Herein	O
we	O
report	O
the	O
discovery	O
of	O
improved	O
lead	O
compounds	O
such	O
as	O
(	B-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
methylpyridin	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
pyridin	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
)	I-CHEMICAL
thiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
]	I-CHEMICAL
amine	I-CHEMICAL
and	O
cyclopropanecarboxylic	B-CHEMICAL
acid	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
biphenylthiazol	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
amide	I-CHEMICAL
,	O
which	O
exhibit	O
brain	O
exposure	O
/	O
EC50	O
ratios	O
at	O
least	O
tenfold	O
greater	O
than	O
that	O
of	O
compound	O
1	O
.	O

High	B-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
as	O
a	O
source	O
of	O
cholesterol	B-CHEMICAL
for	O
adrenal	O
steroidogenesis	O
:	O
a	O
study	O
in	O
individuals	O
with	O
low	O
plasma	O
HDL	B-GENE-N
-	O
C	O
.	O

Few	O
studies	O
have	O
addressed	O
the	O
delivery	O
of	O
lipoprotein	B-GENE-N
-	O
derived	O
cholesterol	B-CHEMICAL
to	O
the	O
adrenals	O
for	O
steroid	B-CHEMICAL
production	O
in	O
humans	O
.	O

While	O
there	O
is	O
evidence	O
against	O
a	O
role	O
for	O
low	B-GENE-N
-	I-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
(	O
LDL	B-GENE-N
)	O
,	O
it	O
is	O
unresolved	O
whether	O
high	B-GENE-N
density	I-GENE-N
lipoprotein	I-GENE-N
(	O
HDL	B-GENE-N
)	O
contributes	O
to	O
adrenal	O
steroidogenesis	O
.	O

To	O
study	O
this	O
,	O
steroid	B-CHEMICAL
hormone	I-CHEMICAL
profiles	O
in	O
urine	O
were	O
assessed	O
in	O
male	O
subjects	O
suffering	O
from	O
functional	O
mutations	O
in	O
ATP	B-GENE-Y
binding	I-GENE-Y
cassette	I-GENE-Y
transporter	I-GENE-Y
A1	I-GENE-Y
(	O
ABCA1	B-GENE-Y
)	O
(	O
n	O
=	O
24	O
)	O
,	O
lecithin	B-GENE-Y
:	I-GENE-Y
cholesterol	I-GENE-Y
acyltransferase	I-GENE-Y
(	O
LCAT	B-GENE-Y
)	O
(	O
n	O
=	O
40	O
)	O
,	O
as	O
well	O
as	O
in	O
11	O
subjects	O
with	O
low	O
HDL	B-GENE-N
cholesterol	B-CHEMICAL
(	O
HDL	B-GENE-N
-	O
C	O
)	O
without	O
ABCA1	B-GENE-Y
/	O
LCAT	B-GENE-Y
mutations	O
.	O

HDL	B-GENE-N
-	O
C	O
levels	O
were	O
39	O
%	O
lower	O
in	O
the	O
ABCA1	B-GENE-Y
,	O
LCAT	B-GENE-Y
,	O
and	O
low	O
HDL	B-GENE-N
-	O
C	O
groups	O
compared	O
with	O
controls	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
all	O
groups	O
with	O
low	O
HDL	B-GENE-N
-	O
C	O
levels	O
,	O
urinary	O
excretion	O
of	O
17	B-CHEMICAL
-	I-CHEMICAL
ketogenic	I-CHEMICAL
steroids	I-CHEMICAL
was	O
reduced	O
by	O
33	O
%	O
,	O
27	O
%	O
,	O
and	O
32	O
%	O
compared	O
with	O
controls	O
(	O
all	O
P	O
<	O
0	O
.	O
04	O
)	O
.	O

In	O
seven	O
carriers	O
of	O
either	O
type	O
of	O
mutation	O
,	O
adrenocorticotropic	B-GENE-Y
hormone	I-GENE-Y
(	O
ACTH	B-GENE-Y
)	O
stimulation	O
did	O
not	O
reveal	O
differences	O
from	O
normolipidemic	O
controls	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
shows	O
that	O
basal	O
but	O
not	O
stimulated	O
corticosteroid	O
metabolism	O
is	O
attenuated	O
in	O
subjects	O
with	O
low	O
HDL	B-GENE-N
-	O
C	O
,	O
irrespective	O
of	O
its	O
molecular	O
origin	O
.	O

These	O
findings	O
lend	O
support	O
to	O
a	O
role	O
for	O
HDL	B-GENE-N
as	O
a	O
cholesterol	B-CHEMICAL
donor	O
for	O
basal	O
adrenal	O
steroidogenesis	O
in	O
humans	O
.	O

The	O
role	O
of	O
platelet	O
/	O
lymphocyte	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
in	O
depression	O
and	O
beyond	O
.	O

A	O
large	O
amount	O
of	O
the	O
data	O
gathered	O
in	O
the	O
last	O
50	O
years	O
support	O
the	O
hypothesis	O
that	O
alterations	O
of	O
the	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
neurotransmission	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathophysiology	O
of	O
not	O
only	O
major	O
depression	O
(	O
MD	O
)	O
,	O
but	O
also	O
of	O
different	O
neuropsychiatric	O
disorders	O
.	O

Research	O
in	O
this	O
field	O
has	O
been	O
substantially	O
promoted	O
by	O
the	O
evidence	O
that	O
the	O
reuptake	O
protein	O
(	O
SERT	B-GENE-Y
)	O
,	O
present	O
in	O
presynaptic	O
neurons	O
,	O
is	O
a	O
key	O
element	O
in	O
terminating	O
the	O
activity	O
of	O
the	O
neurotransmitter	O
in	O
the	O
synaptic	O
cleft	O
.	O

For	O
this	O
reason	O
,	O
it	O
was	O
specifically	O
targeted	O
for	O
the	O
development	O
of	O
second	O
-	O
generation	O
antidepressants	O
,	O
in	O
particular	O
of	O
selective	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
with	O
the	O
aim	O
of	O
increasing	O
the	O
intrasynaptic	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
concentrations	O
.	O

Moreover	O
,	O
since	O
a	O
lot	O
of	O
studies	O
showed	O
that	O
circulating	O
platelets	O
and	O
,	O
more	O
recently	O
,	O
lymphocytes	O
possess	O
functional	O
SERT	B-GENE-Y
proteins	O
,	O
they	O
have	O
been	O
widely	O
used	O
as	O
peripheral	O
mirrors	O
of	O
the	O
same	O
structures	O
located	O
in	O
the	O
central	O
nervous	O
system	O
.	O

The	O
presence	O
of	O
functional	O
SERT	B-GENE-Y
in	O
blood	O
cells	O
suggests	O
strict	O
relationships	O
between	O
the	O
nervous	O
and	O
the	O
immune	O
system	O
that	O
need	O
to	O
be	O
better	O
clarified	O
in	O
MD	O
,	O
as	O
well	O
as	O
the	O
possibility	O
of	O
reciprocal	O
modulation	O
of	O
the	O
two	O
systems	O
by	O
different	O
drugs	O
.	O

This	O
paper	O
aims	O
to	O
review	O
briefly	O
the	O
literature	O
on	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
hypothesis	O
of	O
depression	O
with	O
a	O
major	O
focus	O
on	O
the	O
possible	O
role	O
of	O
SERT	B-GENE-Y
in	O
this	O
disorder	O
,	O
while	O
highlighting	O
how	O
recent	O
data	O
are	O
more	O
oriented	O
on	O
dimensional	O
rather	O
than	O
nosological	O
involvement	O
of	O
this	O
structure	O
in	O
different	O
conditions	O
spanning	O
from	O
normality	O
to	O
pathology	O
.	O

Fisetin	B-CHEMICAL
regulates	O
obesity	O
by	O
targeting	O
mTORC1	B-GENE-N
signaling	O
.	O

Fisetin	B-CHEMICAL
,	O
a	O
flavonol	B-CHEMICAL
present	O
in	O
vegetables	O
and	O
fruits	O
,	O
possesses	O
antioxidative	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
demonstrated	O
that	O
fisetin	B-CHEMICAL
prevents	O
diet	O
-	O
induced	O
obesity	O
through	O
regulation	O
of	O
the	O
signaling	O
of	O
mammalian	B-GENE-N
target	I-GENE-N
of	I-GENE-N
rapamycin	I-GENE-N
complex	I-GENE-N
1	I-GENE-N
(	O
mTORC1	B-GENE-N
)	O
,	O
a	O
central	O
mediator	O
of	O
cellular	O
growth	O
,	O
cellular	O
proliferation	O
and	O
lipid	O
biosynthesis	O
.	O

To	O
evaluate	O
whether	O
fisetin	B-CHEMICAL
regulates	O
mTORC1	B-GENE-N
signaling	O
,	O
we	O
investigated	O
the	O
phosphorylation	O
and	O
kinase	B-GENE-N
activity	O
of	O
the	O
70	B-GENE-Y
-	I-GENE-Y
kDa	I-GENE-Y
ribosomal	I-GENE-Y
protein	I-GENE-Y
S6	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
(	O
S6K1	B-GENE-Y
)	O
and	O
mTORC1	B-GENE-N
in	O
3T3	O
-	O
L1	O
preadipocytes	O
.	O

Fisetin	B-CHEMICAL
treatment	O
of	O
preadipocytes	O
reduced	O
the	O
phosphorylation	O
of	O
S6K1	B-GENE-Y
and	O
mTORC1	B-GENE-N
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

To	O
further	O
our	O
understanding	O
of	O
how	O
fisetin	B-CHEMICAL
negatively	O
regulates	O
mTORC1	B-GENE-N
signaling	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
of	O
S6K1	B-GENE-Y
,	O
mTOR	B-GENE-Y
and	O
Akt	B-GENE-N
in	O
fisetin	B-CHEMICAL
-	O
treated	O
TSC2	B-GENE-Y
-	O
knockdown	O
cells	O
.	O

The	O
results	O
suggested	O
that	O
fisetin	B-CHEMICAL
treatment	O
inhibits	O
mTORC1	B-GENE-N
activity	O
in	O
an	O
Akt	B-GENE-N
-	O
dependent	O
manner	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
adipocyte	O
differentiation	O
is	O
dependent	O
on	O
mTORC1	B-GENE-N
activity	O
.	O

Fisetin	B-CHEMICAL
treatment	O
inhibited	O
adipocyte	O
differentiation	O
,	O
consistent	O
with	O
the	O
negative	O
effect	O
of	O
fisetin	B-CHEMICAL
on	O
mTOR	B-GENE-Y
.	O

The	O
inhibitory	O
effect	O
of	O
fisetin	B-CHEMICAL
on	O
adipogenesis	O
is	O
dependent	O
of	O
mTOR	B-GENE-Y
activity	O
,	O
suggesting	O
that	O
fisetin	B-CHEMICAL
inhibits	O
adipogenesis	O
and	O
the	O
accumulation	O
of	O
intracellular	O
triglycerides	B-CHEMICAL
during	O
adipocyte	O
differentiation	O
by	O
targeting	O
mTORC1	B-GENE-N
signaling	O
.	O

Fisetin	B-CHEMICAL
supplementation	O
in	O
mice	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
significantly	O
attenuated	O
HFD	O
-	O
induced	O
increases	O
in	O
body	O
weight	O
and	O
white	O
adipose	O
tissue	O
.	O

We	O
also	O
observed	O
that	O
fisetin	B-CHEMICAL
efficiently	O
suppressed	O
the	O
phosphorylation	O
of	O
Akt	B-GENE-N
,	O
S6K1	B-GENE-Y
and	O
mTORC1	B-GENE-N
in	O
adipose	O
tissue	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
mTORC1	B-GENE-N
signaling	O
by	O
fisetin	B-CHEMICAL
prevents	O
adipocyte	O
differentiation	O
of	O
3T3	O
-	O
L1	O
preadipocytes	O
and	O
obesity	O
in	O
HFD	O
-	O
fed	O
mice	O
.	O

Therefore	O
,	O
fisetin	B-CHEMICAL
may	O
be	O
a	O
useful	O
phytochemical	O
agent	O
for	O
attenuating	O
diet	O
-	O
induced	O
obesity	O
.	O

Pregnane	B-GENE-Y
X	I-GENE-Y
Receptor	I-GENE-Y
Mediates	O
Dyslipidemia	O
Induced	O
by	O
the	O
HIV	B-GENE-N
Protease	I-GENE-N
Inhibitor	O
Amprenavir	B-CHEMICAL
in	O
Mice	O
.	O

HIV	B-GENE-Y
protease	I-GENE-Y
inhibitors	O
(	O
PIs	O
)	O
have	O
been	O
used	O
successfully	O
in	O
extending	O
the	O
lifespan	O
of	O
people	O
infected	O
with	O
HIV	O
.	O

The	O
use	O
of	O
PIs	O
has	O
also	O
been	O
associated	O
with	O
dyslipidemia	O
and	O
an	O
increased	O
risk	O
of	O
cardiovascular	O
disease	O
but	O
the	O
underlying	O
mechanisms	O
remain	O
elusive	O
.	O

Several	O
PIs	O
have	O
been	O
implicated	O
to	O
activate	O
the	O
nuclear	O
receptor	O
pregnane	B-GENE-Y
X	I-GENE-Y
receptor	I-GENE-Y
(	O
PXR	B-GENE-Y
)	O
,	O
which	O
acts	O
as	O
a	O
xenobiotic	O
sensor	O
to	O
regulate	O
xenobiotic	O
metabolism	O
in	O
the	O
liver	O
and	O
intestine	O
.	O

Recent	O
studies	O
indicate	O
that	O
PXR	B-GENE-Y
may	O
also	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
lipid	O
homeostasis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
amprenavir	B-CHEMICAL
,	O
a	O
widely	O
used	O
HIV	O
PI	O
,	O
as	O
a	O
potent	O
PXR	B-GENE-Y
-	O
selective	O
agonist	O
.	O

Computational	O
docking	O
studies	O
combined	O
with	O
site	O
-	O
direct	O
mutagenesis	O
identified	O
several	O
key	O
residues	O
within	O
the	O
ligand	O
binding	O
pocket	O
of	O
PXR	B-GENE-Y
that	O
constitute	O
points	O
of	O
interaction	O
with	O
amprenavir	B-CHEMICAL
.	O

Amprenavir	B-CHEMICAL
efficiently	O
activated	O
PXR	B-GENE-Y
and	O
induced	O
PXR	B-GENE-Y
target	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Short	O
-	O
term	O
exposure	O
to	O
amprenavir	B-CHEMICAL
significantly	O
increased	O
plasma	O
total	O
cholesterol	B-CHEMICAL
and	O
atherogenic	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	B-CHEMICAL
levels	O
in	O
wild	O
-	O
type	O
mice	O
,	O
but	O
not	O
in	O
PXR	B-GENE-Y
-	O
deficient	O
mice	O
.	O

Amprenavir	B-CHEMICAL
-	O
mediated	O
PXR	B-GENE-Y
activation	O
stimulated	O
the	O
expression	O
of	O
several	O
key	O
intestinal	O
genes	O
involved	O
in	O
lipid	O
homeostasis	O
.	O

These	O
findings	O
provide	O
critical	O
mechanistic	O
insight	O
for	O
understanding	O
the	O
impact	O
of	O
PIs	O
on	O
cardiovascular	O
disease	O
and	O
demonstrate	O
a	O
potential	O
role	O
of	O
PXR	B-GENE-Y
in	O
mediating	O
adverse	O
effects	O
of	O
HIV	O
PIs	O
in	O
humans	O
.	O

Potent	O
fibrinolysis	O
inhibitor	O
discovered	O
by	O
shape	O
and	O
electrostatic	O
complementarity	O
to	O
the	O
drug	O
tranexamic	B-CHEMICAL
Acid	I-CHEMICAL
.	O

Protein	O
-	O
protein	O
interfaces	O
provide	O
an	O
important	O
class	O
of	O
drug	O
targets	O
currently	O
receiving	O
increased	O
attention	O
.	O

The	O
typical	O
design	O
strategy	O
to	O
inhibit	O
protein	O
-	O
protein	O
interactions	O
usually	O
involves	O
large	O
molecules	O
such	O
as	O
peptides	O
and	O
macrocycles	O
.	O

One	O
exception	O
is	O
tranexamic	B-CHEMICAL
acid	I-CHEMICAL
(	O
TXA	B-CHEMICAL
)	O
,	O
which	O
,	O
as	O
a	O
lysine	B-CHEMICAL
mimetic	O
,	O
inhibits	O
binding	O
of	O
plasminogen	B-GENE-Y
to	O
fibrin	B-GENE-N
.	O

However	O
,	O
the	O
daily	O
dose	O
of	O
TXA	B-CHEMICAL
is	O
high	O
due	O
to	O
its	O
modest	O
potency	O
and	O
pharmacokinetic	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
a	O
computational	O
approach	O
,	O
where	O
the	O
focus	O
was	O
on	O
finding	O
electrostatic	O
potential	O
similarities	O
to	O
TXA	B-CHEMICAL
.	O

Coupling	O
this	O
computational	O
technique	O
with	O
a	O
high	O
-	O
quality	O
low	O
-	O
throughput	O
screen	O
identified	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
piperidyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
isoxazolol	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
PIOL	I-CHEMICAL
)	O
as	O
a	O
potent	O
plasminogen	B-GENE-Y
binding	O
inhibitor	O
with	O
the	O
potential	O
for	O
the	O
treatment	O
of	O
various	O
bleeding	O
disorders	O
.	O

Remarkably	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
PIOL	I-CHEMICAL
was	O
found	O
to	O
be	O
more	O
than	O
four	O
times	O
as	O
potent	O
as	O
the	O
drug	O
TXA	B-CHEMICAL
.	O

Design	O
and	O
synthesis	O
of	O
highly	O
selective	O
,	O
orally	O
active	O
Polo	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
Plk	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
inhibitors	O
.	O

Polo	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
kinase	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
Plk	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
is	O
a	O
potential	O
therapeutic	O
target	O
for	O
Parkinson	O
'	O
s	O
disease	O
and	O
this	O
Letter	O
describes	O
the	O
SAR	O
of	O
a	O
series	O
of	O
dihydropteridinone	B-CHEMICAL
based	O
Plk	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
.	O

By	O
optimizing	O
both	O
the	O
N	O
-	O
8	O
substituent	O
and	O
the	O
biaryl	O
region	O
of	O
the	O
inhibitors	O
we	O
obtained	O
single	O
digit	O
nanomolar	O
compounds	O
such	O
as	O
37	O
with	O
excellent	O
selectivity	O
for	O
Plk	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
over	O
Plk	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

When	O
dosed	O
orally	O
in	O
rats	O
,	O
compound	O
37	O
demonstrated	O
a	O
41	O
-	O
45	O
%	O
reduction	O
of	O
pS129	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
-	I-GENE-Y
synuclein	I-GENE-Y
levels	O
in	O
the	O
cerebral	O
cortex	O
.	O

In	O
silico	O
identification	O
of	O
poly	B-GENE-Y
(	I-GENE-Y
ADP	I-GENE-Y
-	I-GENE-Y
ribose	I-GENE-Y
)	I-GENE-Y
polymerase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
and	O
their	O
chemosensitizing	O
effects	O
against	O
cisplatin	B-CHEMICAL
-	O
resistant	O
human	O
gastric	O
cancer	O
cells	O
.	O

Poly	B-GENE-Y
(	I-GENE-Y
ADP	I-GENE-Y
-	I-GENE-Y
ribose	I-GENE-Y
)	I-GENE-Y
polymerase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
enzyme	O
is	O
involved	O
in	O
the	O
repair	O
of	O
DNA	O
damages	O
made	O
by	O
certain	O
anticancer	O
agents	O
.	O

It	O
is	O
suggested	O
that	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
potentiate	O
the	O
cytotoxic	O
effects	O
and	O
circumvent	O
the	O
resistance	O
of	O
DNA	O
-	O
modifying	O
anticancer	O
agents	O
such	O
as	O
cisplatin	B-CHEMICAL
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
virtual	O
screening	O
of	O
Korea	O
Chemical	O
Bank	O
database	O
targeting	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
identified	O
several	O
potent	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
with	O
submicromolar	O
IC50	O
values	O
(	O
77	O
-	O
79nM	O
)	O
.	O

We	O
then	O
examined	O
the	O
chemosensitization	O
of	O
cisplatin	B-CHEMICAL
by	O
pre	O
-	O
treatment	O
of	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
in	O
cisplatin	B-CHEMICAL
-	O
resistant	O
human	O
gastric	O
cancer	O
cells	O
.	O

Our	O
results	O
show	O
that	O
PARP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitors	O
suppress	O
the	O
formation	O
of	O
poly	B-CHEMICAL
(	I-CHEMICAL
ADP	I-CHEMICAL
-	I-CHEMICAL
ribose	I-CHEMICAL
)	I-CHEMICAL
and	O
enhance	O
the	O
cytotoxicity	O
of	O
cisplatin	B-CHEMICAL
.	O

Protective	O
effect	O
of	O
crocin	B-CHEMICAL
on	O
diazinon	B-CHEMICAL
induced	O
cardiotoxicity	O
in	O
rats	O
in	O
subchronic	O
exposure	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
crocin	B-CHEMICAL
,	O
main	O
component	O
of	O
Crocus	O
sativus	O
L	O
.	O

(	O
Saffron	O
)	O
against	O
subchronic	O
diazinon	B-CHEMICAL
(	O
DZN	B-CHEMICAL
)	O
induced	O
cardiotoxicity	O
in	O
rats	O
.	O

METHODS	O
:	O
Rats	O
were	O
divided	O
into	O
7	O
groups	O
;	O
control	O
(	O
corn	O
oil	O
,	O
gavage	O
)	O
,	O
DZN	O
(	O
15mg	O
/	O
kg	O
/	O
day	O
,	O
gavage	O
,	O
)	O
,	O
crocin	B-CHEMICAL
(	O
12	O
.	O
5	O
,	O
25	O
or	O
50mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O
p	O
)	O
plus	O
DZN	B-CHEMICAL
,	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
(	O
200IU	O
/	O
kg	O
,	O
i	O
.	O
p	O
,	O
three	O
times	O
per	O
week	O
)	O
plus	O
DZN	B-CHEMICAL
and	O
crocin	B-CHEMICAL
(	O
50mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O
p	O
)	O
groups	O
.	O

Treatments	O
were	O
continued	O
for	O
4weeks	O
.	O

Creatine	B-GENE-N
phosphokinase	I-GENE-N
MB	I-GENE-N
(	O
CK	B-GENE-N
-	I-GENE-N
MB	I-GENE-N
)	O
,	O
malondealdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
and	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
levels	O
were	O
evaluated	O
in	O
heart	O
tissue	O
at	O
the	O
end	O
of	O
treatments	O
.	O

Levels	O
of	O
apoptotic	O
proteins	O
(	O
Bax	B-GENE-Y
,	O
Bcl2	B-GENE-Y
,	O
caspase	B-GENE-Y
3	I-GENE-Y
)	O
and	O
cytosolic	B-GENE-Y
cytochrome	I-GENE-Y
c	I-GENE-Y
were	O
analyzed	O
by	O
Western	O
blotting	O
.	O

Transcript	O
levels	O
of	O
Bax	B-GENE-Y
and	O
Bcl2	B-GENE-Y
were	O
also	O
determined	O
using	O
qRT	O
PCR	O
.	O

RESULTS	O
:	O
DZN	B-CHEMICAL
induced	O
histophatological	O
damages	O
and	O
elevated	O
the	O
level	O
of	O
cardiac	O
marker	O
CK	B-GENE-N
-	I-GENE-N
MB	I-GENE-N
.	O

These	O
effects	O
were	O
associated	O
with	O
increased	O
MDA	B-CHEMICAL
level	O
,	O
lower	O
level	O
of	O
reduced	O
GSH	B-CHEMICAL
and	O
induction	O
of	O
apoptosis	O
through	O
elevation	O
of	O
Bax	B-GENE-Y
/	O
Bcl2	B-GENE-Y
ratio	O
(	O
both	O
protein	O
and	O
mRNA	O
levels	O
)	O
,	O
cytochrome	B-GENE-Y
c	I-GENE-Y
release	O
to	O
the	O
cytosol	O
and	O
activation	O
caspase	B-GENE-Y
3	I-GENE-Y
in	O
cardiac	O
tissue	O
.	O

Crocin	B-CHEMICAL
(	O
25	O
and	O
50mg	O
/	O
kg	O
)	O
or	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
improved	O
histopathological	O
damages	O
,	O
decreased	O
MDA	B-CHEMICAL
and	O
CK	B-GENE-N
-	I-GENE-N
MB	I-GENE-N
,	O
increased	O
GSH	B-CHEMICAL
content	O
and	O
attenuated	O
the	O
increase	O
of	O
Bax	B-GENE-Y
/	O
Bcl2	B-GENE-Y
ratio	O
,	O
activation	O
of	O
caspase	B-GENE-Y
3	I-GENE-Y
and	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
to	O
the	O
cytosol	O
induced	O
by	O
DZN	B-CHEMICAL
.	O

In	O
summary	O
,	O
DZN	B-CHEMICAL
induced	O
mitochondrial	O
-	O
mediated	O
apoptosis	O
in	O
heart	O
tissue	O
of	O
rat	O
following	O
subchronic	O
exposure	O
.	O

Crocin	B-CHEMICAL
,	O
as	O
an	O
antioxidant	O
,	O
showed	O
protective	O
effects	O
against	O
DZN	B-CHEMICAL
cardiotoxicity	O
by	O
reducing	O
lipid	O
peroxidation	O
and	O
alleviating	O
apoptosis	O
.	O

Effect	O
of	O
quercetin	B-CHEMICAL
-	O
rich	O
onion	O
peel	O
extracts	O
on	O
arterial	O
thrombosis	O
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
oral	O
supplementation	O
of	O
quercetin	B-CHEMICAL
-	O
rich	O
onion	O
peel	O
extract	O
(	O
OPE	O
)	O
influences	O
blood	O
coagulation	O
and	O
arterial	O
thrombosis	O
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

24	O
male	O
rats	O
,	O
5weeks	O
old	O
,	O
were	O
divided	O
into	O
three	O
groups	O
with	O
different	O
diets	O
(	O
C	O
:	O
control	O
,	O
2mg	O
OPE	O
:	O
chow	O
diet	O
with	O
2mg	O
OPE	O
supplementation	O
,	O
10mg	O
OPE	O
:	O
chow	O
diet	O
with	O
10mg	O
OPE	O
supplementation	O
)	O
for	O
6weeks	O
.	O

Blood	O
coagulation	O
parameters	O
including	O
prothrombin	B-GENE-Y
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	B-GENE-Y
time	O
(	O
aPTT	O
)	O
and	O
platelet	O
aggregation	O
were	O
examined	O
.	O

The	O
OPE	O
did	O
not	O
affect	O
blood	O
cholesterol	B-CHEMICAL
levels	O
but	O
significantly	O
decreased	O
blood	O
triglyceride	B-CHEMICAL
and	O
glucose	B-CHEMICAL
levels	O
.	O

PT	O
,	O
aPTT	O
and	O
platelet	O
aggregation	O
were	O
not	O
significantly	O
different	O
among	O
all	O
tested	O
groups	O
.	O

However	O
,	O
in	O
vivo	O
arterial	O
thrombosis	O
was	O
significantly	O
delayed	O
in	O
groups	O
that	O
were	O
fed	O
2mg	O
and	O
10mg	O
OPE	O
diets	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
addition	O
,	O
the	O
OPE	O
greatly	O
diminished	O
thrombin	B-GENE-Y
-	O
induced	O
expression	O
of	O
tissue	B-GENE-Y
factor	I-GENE-Y
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
a	O
coagulation	O
initiator	O
.	O

In	O
addition	O
,	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
and	O
c	B-GENE-Y
-	I-GENE-Y
Jun	I-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
kinase	I-GENE-Y
(	O
JNK	B-GENE-Y
)	O
signaling	O
pathways	O
activated	O
by	O
thrombin	B-GENE-Y
treatment	O
were	O
prevented	O
by	O
the	O
OPE	O
pre	O
-	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
OPE	O
may	O
have	O
anti	O
-	O
thrombotic	O
effects	O
through	O
restricting	O
the	O
induced	O
expression	O
of	O
tissue	B-GENE-Y
factor	I-GENE-Y
via	O
down	O
-	O
regulating	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
activation	O
upon	O
coagulation	O
stimulus	O
,	O
leading	O
to	O
the	O
prolongation	O
of	O
time	O
for	O
arterial	O
thrombosis	O
.	O

Cross	O
-	O
talk	O
between	O
constitutive	B-GENE-Y
androstane	I-GENE-Y
receptor	I-GENE-Y
and	O
hypoxia	B-GENE-N
-	I-GENE-N
inducible	I-GENE-N
factor	I-GENE-N
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

Hypoxia	B-GENE-N
inducible	I-GENE-N
factor	I-GENE-N
(	O
HIF	B-GENE-N
)	O
and	O
5	B-GENE-N
'	I-GENE-N
-	I-GENE-N
AMP	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
are	O
often	O
activated	O
under	O
similar	O
physiological	O
conditions	O
.	O

Constitutive	B-GENE-Y
androstane	I-GENE-Y
receptor	I-GENE-Y
(	O
CAR	B-GENE-Y
)	O
translocates	O
into	O
the	O
nucleus	O
in	O
accordance	O
with	O
5	B-GENE-N
'	I-GENE-N
-	I-GENE-N
AMP	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
and	O
thus	O
confers	O
transactivation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
a	O
possible	O
link	O
between	O
CAR	B-GENE-Y
and	O
HIFα	B-GENE-Y
.	O

Phenobarbital	B-CHEMICAL
(	O
PB	O
)	O
,	O
a	O
typical	O
CAR	B-GENE-Y
activator	O
,	O
increased	O
the	O
gene	O
expression	O
of	O
HIF	B-GENE-N
-	O
target	O
genes	O
in	O
the	O
livers	O
of	O
mice	O
,	O
including	O
erythropoietin	B-GENE-Y
,	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
a	I-GENE-Y
.	O

PB	O
induced	O
an	O
accumulation	O
of	O
nuclear	O
HIF	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
and	O
an	O
increase	O
in	O
the	O
HIF	B-GENE-N
-	I-GENE-N
responsive	I-GENE-N
element	I-GENE-N
-	O
mediated	O
transactivation	O
in	O
HepG2	O
cells	O
.	O

Cobalt	B-CHEMICAL
chloride	I-CHEMICAL
,	O
a	O
typical	O
HIF	B-GENE-N
activator	O
,	O
induced	O
the	O
gene	O
expression	O
of	O
CAR	B-GENE-Y
-	O
target	O
genes	O
,	O
including	O
cyp2b9	B-GENE-Y
and	O
cyp2b10	B-GENE-Y
,	O
an	O
accumulation	O
of	O
nuclear	O
CAR	B-GENE-Y
and	O
an	O
increase	O
in	O
the	O
PB	B-GENE-N
-	I-GENE-N
responsive	I-GENE-N
enhancer	I-GENE-N
module	I-GENE-N
-	O
mediated	O
transactivation	O
in	O
the	O
mouse	O
liver	O
.	O

Immunoprecipitation	O
-	O
immunoblot	O
and	O
chromatin	O
immunoprecipitation	O
analyses	O
suggest	O
that	O
CAR	B-GENE-Y
binds	O
to	O
the	O
PB	B-GENE-N
-	I-GENE-N
responsive	I-GENE-N
enhancer	I-GENE-N
module	I-GENE-N
with	O
HIF	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
in	O
the	O
liver	O
of	O
untreated	O
mice	O
and	O
that	O
the	O
complex	O
dissociates	O
upon	O
PB	O
treatment	O
.	O

Taken	O
together	O
these	O
results	O
suggest	O
that	O
CAR	B-GENE-Y
and	O
HIF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
interact	O
and	O
reciprocally	O
modulate	O
the	O
functions	O
of	O
each	O
other	O
.	O

Universal	O
rule	O
on	O
chirality	O
-	O
dependent	O
bandgaps	O
in	O
graphene	B-CHEMICAL
antidot	O
lattices	O
.	O

Graphene	B-CHEMICAL
with	O
periodically	O
patterned	O
antidots	O
has	O
attracted	O
intense	O
research	O
attention	O
as	O
it	O
represents	O
a	O
facile	O
route	O
to	O
open	O
a	O
bandgap	O
for	O
graphene	B-CHEMICAL
electronics	O
.	O

However	O
,	O
not	O
all	O
graphene	B-CHEMICAL
antidot	O
lattices	O
(	O
GALs	O
)	O
can	O
open	O
a	O
bandgap	O
and	O
a	O
guiding	O
rule	O
is	O
missing	O
.	O

Here	O
,	O
through	O
systematic	O
first	O
-	O
principles	O
calculations	O
,	O
it	O
is	O
found	O
that	O
bandgaps	O
in	O
triangular	O
GALs	O
are	O
surprisingly	O
well	O
defined	O
by	O
a	O
chirality	O
vector	O
R	O
=	O
n	O
a1	O
+	O
ma2	O
connecting	O
two	O
neighboring	O
antidots	O
,	O
where	O
a1	O
and	O
a2	O
are	O
the	O
basis	O
vectors	O
of	O
graphene	B-CHEMICAL
.	O

The	O
bandgap	O
opens	O
in	O
the	O
GALs	O
with	O
(	O
n	O
-	O
m	O
)	O
mod3	O
=	O
0	O
but	O
remains	O
closed	O
in	O
those	O
with	O
(	O
n	O
-	O
m	O
)	O
mod3	O
=	O
±	O
1	O
,	O
reminiscent	O
of	O
the	O
gap	O
-	O
chirality	O
rule	O
in	O
carbon	B-CHEMICAL
nanotubes	O
.	O

Remarkably	O
,	O
the	O
gap	O
value	O
in	O
GALs	O
allows	O
ample	O
modulation	O
by	O
adjusting	O
the	O
length	O
of	O
chirality	O
vectors	O
,	O
shape	O
and	O
size	O
of	O
the	O
antidots	O
.	O

The	O
gap	O
-	O
chirality	O
relation	O
in	O
GALs	O
stems	O
from	O
the	O
chirality	O
-	O
dependent	O
atomic	O
structures	O
of	O
GALs	O
as	O
revealed	O
by	O
a	O
super	O
-	O
atom	O
model	O
as	O
well	O
as	O
Clar	O
sextet	O
analyses	O
.	O

This	O
chirality	O
-	O
dependent	O
bandgap	O
is	O
further	O
shown	O
to	O
be	O
a	O
generic	O
behavior	O
in	O
any	O
parallelogram	O
GAL	O
and	O
thus	O
serves	O
as	O
an	O
essential	O
stepping	O
stone	O
for	O
experimenters	O
to	O
realize	O
graphene	B-CHEMICAL
devices	O
by	O
antidot	O
engineering	O
.	O

Chalcogenopyrylium	B-CHEMICAL
Dyes	O
as	O
Differential	O
Modulators	O
of	O
Organic	O
Anion	O
Transport	O
by	O
MRP1	B-GENE-Y
,	O
MRP2	B-GENE-Y
and	O
MRP4	B-GENE-Y
.	O

Multidrug	B-GENE-N
resistance	I-GENE-N
proteins	I-GENE-N
(	O
MRPs	B-GENE-N
)	O
mediate	O
the	O
ATP	B-CHEMICAL
-	O
dependent	O
efflux	O
of	O
structurally	O
diverse	O
compounds	O
,	O
including	O
anticancer	O
drugs	O
and	O
physiological	O
organic	O
anions	O
.	O

Five	O
classes	O
of	O
chalcogenopyrylium	B-CHEMICAL
dyes	O
(	O
CGPs	B-CHEMICAL
)	O
were	O
examined	O
for	O
their	O
ability	O
to	O
modulate	O
transport	O
of	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
estradiol	I-CHEMICAL
glucuronide	I-CHEMICAL
(	O
E217βG	B-CHEMICAL
)	O
(	O
a	O
prototypical	O
MRP	B-GENE-N
substrate	O
)	O
into	O
MRP	B-GENE-N
-	O
enriched	O
inside	O
-	O
out	O
membrane	O
vesicles	O
.	O

Additionally	O
,	O
some	O
CGPs	B-CHEMICAL
were	O
tested	O
in	O
intact	O
transfected	O
cells	O
using	O
a	O
calcein	B-CHEMICAL
efflux	O
assay	O
.	O

Sixteen	O
of	O
34	O
CGPs	B-CHEMICAL
inhibited	O
MRP1	B-GENE-Y
-	O
mediated	O
E217βG	B-CHEMICAL
uptake	O
by	O
>	O
50	O
%	O
(	O
IC50	O
'	O
s	O
0	O
.	O
7	O
-	O
7	O
.	O
6	O
μM	O
)	O
.	O

Of	O
9	O
CGPs	B-CHEMICAL
with	O
IC50	O
'	O
s	O
≤	O
2	O
μM	O
,	O
two	O
belonged	O
to	O
Class	O
I	O
,	O
two	O
to	O
Class	O
III	O
and	O
five	O
to	O
Class	O
V	O
.	O
When	O
tested	O
in	O
the	O
intact	O
cells	O
,	O
only	O
4	O
of	O
16	O
CGPs	B-CHEMICAL
(	O
at	O
10	O
μM	O
)	O
inhibited	O
MRP1	B-GENE-Y
-	O
mediated	O
calcein	B-CHEMICAL
efflux	O
by	O
>	O
50	O
%	O
(	O
III	O
-	O
1	O
,	O
V	O
-	O
3	O
,	O
-	O
4	O
,	O
-	O
6	O
)	O
while	O
a	O
fifth	O
(	O
I	O
-	O
5	O
)	O
inhibited	O
efflux	O
by	O
just	O
23	O
%	O
.	O

These	O
five	O
CGPs	B-CHEMICAL
also	O
inhibited	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
E217βG	I-CHEMICAL
uptake	O
by	O
MRP4	B-GENE-Y
.	O

In	O
contrast	O
,	O
their	O
effects	O
on	O
MRP2	B-GENE-Y
varied	O
with	O
two	O
(	O
V	O
-	O
4	O
,	O
V	O
-	O
6	O
)	O
inhibiting	O
E217βG	B-CHEMICAL
transport	O
(	O
IC50	O
'	O
s	O
2	O
.	O
0	O
,	O
9	O
.	O
2	O
μM	O
)	O
,	O
two	O
(	O
V	O
-	O
3	O
,	O
III	O
-	O
1	O
)	O
stimulating	O
transport	O
(	O
>	O
2	O
-	O
fold	O
)	O
,	O
while	O
CGP	B-CHEMICAL
I	O
-	O
5	O
had	O
no	O
effect	O
.	O

Strikingly	O
,	O
although	O
V	O
-	O
3	O
and	O
V	O
-	O
4	O
had	O
opposite	O
effects	O
on	O
MRP2	B-GENE-Y
activity	O
,	O
they	O
are	O
structurally	O
identical	O
except	O
for	O
their	O
chalcogen	B-CHEMICAL
atom	O
(	O
Se	B-CHEMICAL
versus	O
Te	B-CHEMICAL
)	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
identify	O
Class	O
V	O
CGPs	O
with	O
their	O
distinctive	O
methine	B-CHEMICAL
or	O
trimethine	B-CHEMICAL
linkage	O
between	O
two	O
disubstituted	O
pyrylium	B-CHEMICAL
moieties	O
as	O
a	O
particularly	O
potent	O
class	O
of	O
MRP	B-GENE-N
modulators	O
and	O
also	O
show	O
that	O
within	O
this	O
core	O
structure	O
,	O
differences	O
in	O
the	O
electronegativity	O
associated	O
with	O
a	O
chalcogen	B-CHEMICAL
atom	O
can	O
be	O
the	O
sole	O
determinant	O
of	O
whether	O
a	O
compound	O
will	O
stimulate	O
or	O
inhibit	O
MRP2	B-GENE-Y
.	O

Bioinspired	O
Water	O
-	O
Enhanced	O
Mechanical	O
Gradient	O
Nanocomposite	O
Films	O
That	O
Mimic	O
the	O
Architecture	O
and	O
Properties	O
of	O
the	O
Squid	O
Beak	O
.	O

Inspired	O
by	O
the	O
water	O
-	O
enhanced	O
mechanical	O
gradient	O
character	O
of	O
the	O
squid	O
beak	O
,	O
we	O
herein	O
report	O
a	O
nanocomposite	O
that	O
mimics	O
both	O
the	O
architecture	O
and	O
properties	O
of	O
this	O
interesting	O
natural	O
material	O
.	O

Similar	O
to	O
the	O
squid	O
beak	O
,	O
we	O
have	O
developed	O
nanocomposites	O
where	O
the	O
degree	O
of	O
cross	O
-	O
linking	O
is	O
controlled	O
along	O
the	O
length	O
of	O
the	O
film	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
tunicate	O
cellulose	O
nanocrystals	O
as	O
the	O
nanofiller	O
that	O
are	O
functionalized	O
with	O
allyl	B-CHEMICAL
moieties	O
.	O

Using	O
photoinduced	O
thiol	B-CHEMICAL
-	O
ene	O
chemistry	O
,	O
we	O
have	O
been	O
able	O
to	O
cross	O
-	O
link	O
the	O
CNC	O
nanofiller	O
.	O

In	O
the	O
dry	O
state	O
where	O
strong	O
CNC	O
interactions	O
can	O
occur	O
,	O
only	O
a	O
small	O
mechanical	O
contrast	O
is	O
observed	O
between	O
the	O
cross	O
-	O
linked	O
and	O
uncross	O
-	O
linked	O
samples	O
.	O

However	O
,	O
when	O
the	O
films	O
are	O
exposed	O
to	O
water	O
,	O
which	O
"	O
switches	O
off	O
"	O
the	O
noncovalent	O
CNC	O
interactions	O
,	O
a	O
significant	O
mechanical	O
contrast	O
is	O
observed	O
between	O
the	O
same	O
films	O
.	O

For	O
example	O
,	O
at	O
20	O
wt	O
%	O
CNC	O
(	O
in	O
the	O
dry	O
film	O
)	O
,	O
an	O
increase	O
in	O
wet	O
modulus	O
from	O
60	O
to	O
300	O
MPa	O
(	O
∼	O
500	O
%	O
increase	O
)	O
is	O
observed	O
after	O
photoirradiation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
wet	O
modulus	O
can	O
be	O
controlled	O
by	O
altering	O
the	O
UV	O
exposure	O
time	O
which	O
allows	O
access	O
to	O
mechanical	O
gradient	O
films	O
.	O

HISTONE	B-GENE-N
DEACETYLASE	I-GENE-N
INHIBITION	O
AFFECTS	O
SODIUM	B-GENE-Y
IODIDE	I-GENE-Y
SYMPORTER	I-GENE-Y
(	O
NIS	B-GENE-Y
)	O
EXPRESSION	O
AND	O
INDUCES	O
¹³¹I	B-CHEMICAL
CYTOTOXICITY	O
IN	O
ANAPLASTIC	O
THYROID	O
CANCER	O
CELLS	O
.	O

Background	O
:	O
Anaplastic	O
thyroid	O
cancers	O
(	O
ATC	O
)	O
represent	O
only	O
1	O
-	O
2	O
%	O
of	O
all	O
thyroid	O
tumors	O
,	O
but	O
they	O
account	O
for	O
up	O
to	O
50	O
%	O
of	O
the	O
mortality	O
.	O

Treatment	O
of	O
differentiated	O
thyroid	O
carcinomas	O
is	O
well	O
standardized	O
and	O
the	O
use	O
of	O
radioiodine	B-CHEMICAL
represents	O
an	O
essential	O
step	O
;	O
in	O
contrast	O
,	O
there	O
is	O
no	O
standardized	O
therapeutic	O
approach	O
for	O
anaplastic	O
tumors	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O

The	O
resistance	O
of	O
anaplastic	O
thyroid	O
cancer	O
to	O
radioiodine	B-CHEMICAL
treatment	O
is	O
principally	O
due	O
to	O
the	O
absence	O
of	O
expression	O
of	O
the	O
sodium	B-GENE-Y
iodide	I-GENE-Y
symporter	I-GENE-Y
(	O
NIS	B-GENE-Y
)	O
,	O
mainly	O
due	O
to	O
epigenetic	O
silencing	O
.	O

The	O
acetylation	O
status	O
of	O
histones	B-GENE-N
is	O
involved	O
in	O
the	O
epigenetic	O
control	O
of	O
gene	O
expression	O
and	O
is	O
usually	O
disrupted	O
in	O
advanced	O
thyroid	O
cancer	O
.	O

Histone	B-GENE-N
deacetylase	I-GENE-N
inhibitors	O
have	O
been	O
demonstrated	O
as	O
potent	O
anticancer	O
drugs	O
with	O
several	O
different	O
effects	O
on	O
cell	O
viability	O
and	O
differentiation	O
.	O

Methods	O
:	O
Stabilized	O
anaplastic	O
thyroid	O
cancer	O
cell	O
lines	O
(	O
BHT	O
-	O
101	O
and	O
CAL	O
-	O
62	O
)	O
and	O
primary	O
cultures	O
from	O
patients	O
who	O
underwent	O
thyroidectomy	O
for	O
anaplastic	O
thyroid	O
cancer	O
were	O
treated	O
with	O
the	O
histone	B-GENE-N
deacetylase	I-GENE-N
inhibitor	O
LBH589	B-CHEMICAL
.	O

After	O
treatment	O
,	O
we	O
evaluated	O
the	O
expression	O
and	O
function	O
of	O
NIS	B-GENE-Y
.	O

Gene	O
expression	O
was	O
evaluated	O
by	O
real	O
-	O
time	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
;	O
NIS	B-GENE-N
promoter	I-GENE-N
activity	O
was	O
determined	O
with	O
a	O
luciferase	O
reporter	O
assay	O
;	O
and	O
protein	O
expression	O
was	O
assessed	O
through	O
immunofluorescence	O
.	O

We	O
tested	O
the	O
protein	O
function	O
by	O
125I	B-CHEMICAL
uptake	O
and	O
efflux	O
experiments	O
;	O
finally	O
the	O
cytotoxic	O
effect	O
of	O
131I	B-CHEMICAL
was	O
determined	O
with	O
a	O
clonogenic	O
assay	O
.	O

Results	O
:	O
Our	O
results	O
demonstrate	O
that	O
treatment	O
with	O
LBH589	B-CHEMICAL
leads	O
to	O
NIS	B-GENE-Y
RNA	O
expression	O
as	O
shown	O
by	O
RT	O
-	O
PCR	O
and	O
luciferase	O
assay	O
,	O
and	O
to	O
protein	O
expression	O
as	O
determined	O
by	O
immunofluorescence	O
in	O
vitro	O
and	O
by	O
immunohistochemistry	O
in	O
xenograft	O
tumors	O
.	O

Moreover	O
,	O
125I	B-CHEMICAL
uptake	O
and	O
efflux	O
experiments	O
show	O
the	O
correct	O
protein	O
function	O
and	O
iodine	B-CHEMICAL
retention	O
,	O
that	O
translate	O
into	O
cytotoxicity	O
effects	O
,	O
as	O
demonstrated	O
by	O
a	O
clonogenic	O
assay	O
with	O
131I	B-CHEMICAL
.	O

Conclusions	O
:	O
This	O
study	O
supplies	O
a	O
new	O
potential	O
strategy	O
for	O
the	O
treatment	O
of	O
ATC	O
by	O
modifying	O
gene	O
expression	O
with	O
the	O
aim	O
of	O
inducing	O
responsiveness	O
towards	O
radioiodine	B-CHEMICAL
therapy	O
.	O

Transport	O
Function	O
and	O
Transcriptional	O
Regulation	O
of	O
a	O
Liver	O
-	O
Enriched	O
Human	B-GENE-Y
Organic	I-GENE-Y
Anion	I-GENE-Y
Transporting	I-GENE-Y
Polypeptide	I-GENE-Y
2B1	I-GENE-Y
Transcriptional	O
Start	O
Site	O
Variant	O
.	O

Human	B-GENE-Y
Organic	I-GENE-Y
Anion	I-GENE-Y
Transporting	I-GENE-Y
Polypeptide	I-GENE-Y
2B1	I-GENE-Y
(	O
OATP2B1	B-GENE-Y
)	O
is	O
a	O
membrane	O
transporter	O
that	O
facilitates	O
the	O
cellular	O
uptake	O
of	O
a	O
number	O
of	O
endogenous	O
compounds	O
and	O
drugs	O
.	O

OATP2B1	B-GENE-Y
is	O
widely	O
expressed	O
in	O
tissues	O
including	O
the	O
small	O
intestine	O
,	O
liver	O
,	O
kidney	O
,	O
placenta	O
,	O
heart	O
,	O
skeletal	O
muscle	O
and	O
platelets	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
differential	O
promoter	O
usage	O
in	O
tissues	O
results	O
in	O
expression	O
of	O
five	O
OATP2B1	B-GENE-Y
transcriptional	O
start	O
site	O
variants	O
which	O
utilize	O
distinct	O
first	O
exons	O
but	O
share	O
common	O
subsequent	O
exons	O
.	O

These	O
variants	O
are	O
expected	O
to	O
encode	O
either	O
a	O
full	O
length	O
(	O
OATP2B1	B-GENE-Y
-	I-GENE-Y
FL	I-GENE-Y
)	O
or	O
shortened	O
protein	O
lacking	O
22	O
N	B-CHEMICAL
-	O
terminus	O
amino	B-CHEMICAL
acids	I-CHEMICAL
(	O
OATP2B	B-GENE-Y
-	I-GENE-Y
Short	I-GENE-Y
)	O
.	O

Little	O
is	O
known	O
regarding	O
the	O
transport	O
activity	O
and	O
regulation	O
of	O
OATP2B1	B-GENE-Y
variants	O
with	O
N	B-CHEMICAL
-	O
terminus	O
truncation	O
.	O

Here	O
,	O
using	O
absolute	O
quantitative	O
polymerase	O
chain	O
reaction	O
we	O
find	O
the	O
full	O
length	O
variant	O
is	O
the	O
major	O
form	O
expressed	O
in	O
duodenum	O
but	O
the	O
short	O
variant	O
predominates	O
in	O
liver	O
.	O

Using	O
a	O
transient	O
heterologous	O
cell	O
expression	O
system	O
,	O
we	O
find	O
that	O
the	O
transport	O
activities	O
of	O
the	O
short	B-GENE-Y
OATP2B1	I-GENE-Y
variant	O
towards	O
substrates	O
estrone	B-CHEMICAL
sulfate	I-CHEMICAL
and	O
rosuvastatin	B-CHEMICAL
are	O
similar	O
to	O
the	O
well	O
-	O
characterized	O
full	O
length	O
variant	O
.	O

Transcriptional	O
activity	O
screening	O
of	O
the	O
liver	O
enriched	O
OATP2B1	B-GENE-N
variant	I-GENE-N
promoter	I-GENE-N
identified	O
hepatocyte	B-GENE-Y
nuclear	I-GENE-Y
factor	I-GENE-Y
4	I-GENE-Y
alpha	I-GENE-Y
(	O
HNF4α	B-GENE-Y
)	O
as	O
a	O
novel	O
transacting	O
factor	O
.	O

With	O
a	O
combination	O
of	O
in	O
silico	O
screening	O
,	O
promoter	O
mutation	O
in	O
cell	O
-	O
based	O
reporter	O
assays	O
,	O
siRNA	O
knockdown	O
and	O
chromatin	O
immunoprecipitation	O
studies	O
,	O
we	O
identified	O
a	O
functional	O
HNF4α	B-GENE-Y
binding	O
site	O
close	O
to	O
the	O
transcription	O
start	O
site	O
(	O
-	O
17	O
to	O
-	O
4	O
bp	O
)	O
.	O

We	O
conclude	O
that	O
the	O
major	O
OATP2B1	B-GENE-Y
protein	O
form	O
in	O
liver	O
is	O
transport	O
competent	O
and	O
its	O
hepatic	O
expression	O
is	O
regulated	O
by	O
HNF4α	B-GENE-Y
.	O

The	O
Protective	O
Effects	O
of	O
α	B-CHEMICAL
-	I-CHEMICAL
Lipoic	I-CHEMICAL
Acid	I-CHEMICAL
on	O
Kidneys	O
in	O
Type	O
2	O
Diabetic	O
Goto	O
-	O
Kakisaki	O
Rats	O
via	O
Reducing	O
Oxidative	O
Stress	O
.	O

To	O
evaluate	O
the	O
protective	O
effects	O
of	O
α	B-CHEMICAL
-	I-CHEMICAL
lipoic	I-CHEMICAL
acid	I-CHEMICAL
on	O
the	O
kidneys	O
of	O
Goto	O
-	O
Kakisaki	O
(	O
GK	O
)	O
diabetic	O
rats	O
,	O
ten	O
GK	O
diabetic	O
rats	O
were	O
randomly	O
divided	O
into	O
a	O
diabetic	O
control	O
group	O
and	O
a	O
lipoic	B-CHEMICAL
acid	I-CHEMICAL
-	O
treated	O
diabetic	O
group	O
with	O
α	B-CHEMICAL
-	I-CHEMICAL
lipoic	I-CHEMICAL
acid	I-CHEMICAL
35	O
mg	O
·	O
Kg	O
-	O
1	O
intraperitoneal	O
injections	O
.	O

Four	O
healthy	O
Wistar	O
rats	O
served	O
as	O
normal	O
controls	O
.	O

Malonaldehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
,	O
ascorbic	B-CHEMICAL
acid	I-CHEMICAL
(	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
)	O
,	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
,	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
and	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
levels	O
in	O
renal	O
homogenate	O
,	O
and	O
urine	O
protein	O
excretion	O
were	O
measured	O
.	O

The	O
expression	O
of	O
mRNA	O
for	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
NADPH	B-GENE-N
oxidase	I-GENE-N
subunits	O
p22phox	B-GENE-Y
and	O
p47phox	B-GENE-Y
in	O
renal	O
tissue	O
was	O
examined	O
by	O
realtime	O
PCR	O
.	O

Pathological	O
changes	O
in	O
renal	O
tissue	O
were	O
evaluated	O
by	O
light	O
and	O
electron	O
microscopy	O
.	O

There	O
were	O
significant	O
increases	O
in	O
urine	O
protein	O
excretion	O
,	O
MDA	B-CHEMICAL
levels	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
p22phox	B-GENE-Y
and	O
p47phox	B-GENE-Y
,	O
and	O
significant	O
decreases	O
in	O
GSH	B-CHEMICAL
,	O
SOD	B-GENE-N
,	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
and	O
vitamin	B-CHEMICAL
E	I-CHEMICAL
levels	O
in	O
the	O
diabetic	O
control	O
group	O
compared	O
with	O
the	O
normal	O
control	O
group	O
.	O

Pathological	O
changes	O
of	O
renal	O
tissue	O
were	O
more	O
progressive	O
in	O
the	O
diabetic	O
control	O
group	O
than	O
in	O
the	O
normal	O
control	O
group	O
.	O

All	O
the	O
parameters	O
above	O
were	O
improved	O
in	O
the	O
α	B-CHEMICAL
-	I-CHEMICAL
lipoic	I-CHEMICAL
acid	I-CHEMICAL
-	O
treated	O
diabetic	O
group	O
.	O

Oxidative	O
stress	O
is	O
increased	O
in	O
the	O
kidney	O
of	O
type	O
2	O
diabetic	O
GK	O
rats	O
.	O

It	O
is	O
associated	O
with	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
.	O

α	B-CHEMICAL
-	I-CHEMICAL
lipoic	I-CHEMICAL
acid	I-CHEMICAL
can	O
protect	O
renal	O
function	O
in	O
diabetic	O
rats	O
via	O
its	O
antioxidant	O
activity	O
.	O

Adrenocortical	O
reserves	O
in	O
hyperthyroidism	O
.	O

Explicit	O
data	O
regarding	O
the	O
changes	O
in	O
adrenocortical	O
reserves	O
during	O
hyperthyroidism	O
do	O
not	O
exist	O
.	O

We	O
aimed	O
to	O
document	O
the	O
capability	O
(	O
response	O
)	O
of	O
adrenal	O
gland	O
to	O
secrete	O
cortisol	B-CHEMICAL
and	O
DHEA	B-CHEMICAL
-	O
S	O
during	O
hyperthyroidism	O
compared	O
to	O
euthyroidism	O
,	O
and	O
to	O
describe	O
factors	O
associated	O
with	O
these	O
responses	O
.	O

A	O
standard	O
-	O
dose	O
(	O
0	O
.	O
25	O
mg	O
/	O
i	O
.	O
v	O
.	O
)	O
ACTH	B-GENE-Y
stimulation	O
test	O
was	O
performed	O
to	O
the	O
same	O
patients	O
before	O
hyperthyroidism	O
treatment	O
,	O
and	O
after	O
attainment	O
of	O
euthyroidism	O
.	O

Baseline	O
cortisol	B-CHEMICAL
(	O
Cor0	O
)	O
,	O
DHEA	B-CHEMICAL
-	O
S	O
(	O
DHEA	B-CHEMICAL
-	O
S0	O
)	O
,	O
cortisol	B-GENE-Y
binding	I-GENE-Y
globulin	I-GENE-Y
(	O
CBG	B-GENE-Y
)	O
,	O
ACTH	B-GENE-Y
,	O
calculated	O
free	O
cortisol	B-CHEMICAL
(	O
by	O
Coolen	O
'	O
s	O
equation	O
=	O
CFC	O
)	O
,	O
free	O
cortisol	B-CHEMICAL
index	O
(	O
FCI	O
)	O
,	O
60	O
-	O
min	O
cortisol	B-CHEMICAL
(	O
Cor60	O
)	O
,	O
and	O
DHEA	B-CHEMICAL
-	O
S	O
(	O
DHEA	B-CHEMICAL
-	O
S60	O
)	O
,	O
delta	B-CHEMICAL
cortisol	I-CHEMICAL
(	O
ΔCor	B-CHEMICAL
)	O
,	O
delta	B-CHEMICAL
DHEA	I-CHEMICAL
-	O
S	O
(	O
ΔDHEA	B-CHEMICAL
-	O
S	O
)	O
responses	O
were	O
evaluated	O
.	O

Forty	O
-	O
one	O
patients	O
[	O
22	O
females	O
,	O
49	O
.	O
5	O
±	O
15	O
.	O
2	O
years	O
old	O
,	O
32	O
Graves	O
disease	O
,	O
nine	O
toxic	O
nodular	O
goiter	O
]	O
had	O
similar	O
Cor0	O
,	O
DHEA	B-CHEMICAL
-	O
S0	O
,	O
CFC	O
,	O
FCI	O
,	O
and	O
DHEA	B-CHEMICAL
-	O
S60	O
in	O
hyperthyroid	O
and	O
euthyroid	O
states	O
.	O

Cor60	O
,	O
ΔCor	B-CHEMICAL
,	O
and	O
ΔDHEA	B-CHEMICAL
-	O
S	O
were	O
lower	O
in	O
hyperthyroidism	O
.	O

In	O
four	O
(	O
10	O
%	O
)	O
patients	O
the	O
peak	O
ACTH	B-GENE-Y
-	O
stimulated	O
cortisol	B-CHEMICAL
values	O
were	O
lower	O
than	O
18	O
μg	O
/	O
dL	O
.	O

When	O
the	O
test	O
repeated	O
after	O
attainment	O
of	O
euthyroidism	O
,	O
all	O
of	O
the	O
patients	O
had	O
normal	O
cortisol	B-CHEMICAL
response	O
.	O

Regression	O
analysis	O
demonstrated	O
an	O
independent	O
association	O
of	O
Cor60	O
with	O
free	O
T3	O
in	O
hyperthyroidism	O
.	O

However	O
,	O
the	O
predictors	O
of	O
CFC	O
,	O
FCI	O
,	O
and	O
DHEA	B-CHEMICAL
-	O
S	O
levels	O
were	O
serum	O
creatinine	B-CHEMICAL
levels	O
in	O
hyperthyroidism	O
,	O
and	O
both	O
creatinine	B-CHEMICAL
and	O
transaminase	B-GENE-N
levels	O
in	O
euthyroidism	O
.	O

ACTH	B-GENE-Y
-	O
stimulated	O
peak	O
cortisol	B-CHEMICAL
,	O
delta	B-CHEMICAL
cortisol	I-CHEMICAL
,	O
and	O
delta	B-CHEMICAL
DHEA	I-CHEMICAL
-	O
S	O
levels	O
are	O
decreased	O
during	O
hyperthyroidism	O
,	O
probably	O
due	O
to	O
increased	O
turnover	O
.	O

Since	O
about	O
10	O
%	O
of	O
the	O
subjects	O
with	O
hyperthyroidism	O
are	O
at	O
risk	O
for	O
adrenal	O
insufficiency	O
,	O
clinicians	O
dealing	O
with	O
Graves	O
'	O
disease	O
should	O
be	O
alert	O
to	O
the	O
possibility	O
of	O
adrenal	O
insufficiency	O
during	O
hyperthyroid	O
stage	O
.	O

Synthesis	O
and	O
in	O
Vitro	O
Characterisation	O
of	O
Ifenprodil	B-CHEMICAL
-	O
Based	O
Fluorescein	B-CHEMICAL
Conjugates	O
as	O
GluN1	B-GENE-Y
/	O
GluN2B	B-GENE-Y
N	B-GENE-N
-	I-GENE-N
Methyl	I-GENE-N
-	I-GENE-N
D	I-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
Receptor	I-GENE-N
Antagonists	O
.	O

GluN2B	B-GENE-Y
-	O
containing	O
NMDA	B-GENE-N
receptors	I-GENE-N
are	O
involved	O
in	O
many	O
important	O
physiological	O
functions	O
and	O
play	O
a	O
pivotal	O
role	O
in	O
mediating	O
pain	O
as	O
well	O
as	O
in	O
several	O
neurodegenerative	O
disorders	O
.	O

We	O
aimed	O
to	O
develop	O
fluorescent	O
probes	O
to	O
target	O
the	O
GluN2B	B-GENE-Y
subunit	O
selectively	O
in	O
order	O
to	O
allow	O
better	O
understanding	O
of	O
the	O
relationships	O
between	O
receptor	O
localisation	O
and	O
physiological	O
importance	O
.	O

Ifenprodil	B-CHEMICAL
,	O
known	O
as	O
the	O
GluNR2B	B-GENE-Y
antagonist	O
of	O
reference	O
,	O
was	O
chosen	O
as	O
the	O
template	O
for	O
the	O
elaboration	O
of	O
probes	O
.	O

We	O
had	O
previously	O
reported	O
a	O
fluorescein	B-CHEMICAL
conjugate	O
that	O
was	O
shown	O
(	O
by	O
confocal	O
microscopy	O
imaging	O
of	O
DS	O
-	O
red	O
-	O
labelled	O
cortical	O
neurons	O
)	O
to	O
bind	O
specifically	O
to	O
GluN2B	B-GENE-Y
.	O

To	O
elaborate	O
this	O
probe	O
,	O
we	O
explored	O
the	O
influence	O
of	O
both	O
the	O
nature	O
and	O
the	O
attachment	O
point	O
of	O
the	O
spacer	O
between	O
the	O
fluorophore	O
and	O
the	O
parent	O
compound	O
,	O
ifenprodil	B-CHEMICAL
.	O

We	O
performed	O
chemical	O
modifications	O
of	O
ifenprodil	B-CHEMICAL
at	O
the	O
benzylic	B-CHEMICAL
position	O
and	O
on	O
the	O
phenol	B-CHEMICAL
ring	O
by	O
introducing	O
secondary	B-CHEMICAL
amine	I-CHEMICAL
or	I-CHEMICAL
amide	I-CHEMICAL
functions	O
and	O
evaluated	O
alkyl	O
chains	O
from	O
two	O
to	O
20	O
bonds	O
either	O
including	O
or	O
not	O
including	O
secondary	B-CHEMICAL
amide	I-CHEMICAL
functions	O
as	O
spacers	O
.	O

The	O
previously	O
developed	O
probe	O
was	O
found	O
to	O
display	O
the	O
greatest	O
activity	O
in	O
the	O
inhibition	O
of	O
NMDA	B-CHEMICAL
-	O
induced	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
influx	O
by	O
calcium	B-CHEMICAL
imaging	O
experiments	O
on	O
HEK293	O
cells	O
transfected	O
with	O
the	O
cDNA	O
encoding	O
for	O
GluN1	B-GENE-Y
-	I-GENE-Y
1A	I-GENE-Y
and	O
GluN2B	B-GENE-Y
.	O

Further	O
investigations	O
revealed	O
that	O
this	O
probe	O
had	O
a	O
neuroprotective	O
effect	O
equivalent	O
to	O
that	O
of	O
ifenprodil	B-CHEMICAL
in	O
a	O
standard	O
test	O
for	O
neurotoxicity	O
.	O

Despite	O
effects	O
of	O
lesser	O
amplitude	O
with	O
these	O
probes	O
relative	O
to	O
ifenprodil	B-CHEMICAL
,	O
we	O
demonstrated	O
that	O
they	O
displaced	O
[	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
]	I-CHEMICAL
ifenprodil	I-CHEMICAL
in	O
mouse	O
brain	O
slices	O
in	O
a	O
similar	O
manner	O
.	O

Antithrombotic	O
activity	O
of	O
a	O
newly	O
synthesized	O
coumarin	B-CHEMICAL
derivative	O
3	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
dimethyl	I-CHEMICAL
-	I-CHEMICAL
chroman	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
{	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
dimethyl	I-CHEMICAL
-	I-CHEMICAL
chroman	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
propionylamino	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
ethyl	I-CHEMICAL
}	I-CHEMICAL
-	I-CHEMICAL
propionamide	I-CHEMICAL
.	O

Anti	O
-	O
platelet	O
therapy	O
is	O
a	O
useful	O
strategy	O
to	O
prevent	O
acute	O
thromboembolic	O
artery	O
occlusions	O
.	O

This	O
study	O
was	O
designed	O
to	O
assess	O
the	O
efficacy	O
of	O
seselin	B-CHEMICAL
derivatives	O
against	O
murine	O
pulmonary	O
thromboembolism	O
,	O
bleeding	O
time	O
,	O
platelet	O
activation	O
and	O
thrombosis	O
.	O

Administration	O
of	O
C3	O
(	O
16	O
mg	O
/	O
kg	O
)	O
offered	O
70	O
%	O
protection	O
against	O
collagen	B-GENE-N
-	O
and	O
epinephrine	B-CHEMICAL
-	O
induced	O
pulmonary	O
thromboembolism	O
and	O
30	O
%	O
protection	O
against	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
-	O
induced	O
death	O
in	O
mice	O
,	O
without	O
adversely	O
affecting	O
bleeding	O
time	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
by	O
C3	O
in	O
ferric	B-CHEMICAL
chloride	I-CHEMICAL
-	O
induced	O
arterial	O
thrombosis	O
in	O
rats	O
.	O

Significant	O
reduction	O
in	O
thrombus	O
weight	O
was	O
observed	O
in	O
arteriovenous	O
shunt	O
model	O
.	O

In	O
rat	O
PRP	O
,	O
C3	O
reduced	O
ADP	B-CHEMICAL
and	O
collagen	B-GENE-N
-	O
induced	O
platelet	O
aggregation	O
.	O

In	O
chronic	O
hamster	O
model	O
of	O
dyslipidemia	O
,	O
administration	O
of	O
C3	O
(	O
16	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
for	O
90	O
days	O
)	O
had	O
no	O
effect	O
on	O
plasma	O
lipids	O
,	O
vasoreactivity	O
and	O
platelet	O
adhesion	O
.	O

C3	O
fed	O
hamsters	O
showed	O
reduced	O
whole	O
-	O
blood	O
aggregation	O
response	O
to	O
ADP	B-CHEMICAL
and	O
collagen	B-GENE-N
compared	O
to	O
HC	O
-	O
fed	O
hamsters	O
.	O

In	O
addition	O
,	O
C3	O
augmented	O
thrombin	O
time	O
;	O
however	O
,	O
time	O
to	O
occlusion	O
was	O
not	O
increased	O
.	O

These	O
results	O
convincingly	O
demonstrated	O
that	O
C3	O
is	O
a	O
novel	O
molecule	O
that	O
reduces	O
the	O
risk	O
of	O
thrombosis	O
and	O
alleviates	O
prothrombotic	O
state	O
associated	O
with	O
hyperlipidemia	O
without	O
any	O
adverse	O
effect	O
on	O
bleeding	O
time	O
.	O

The	O
high	O
benefit	O
/	O
risk	O
ratio	O
of	O
this	O
compound	O
makes	O
it	O
a	O
suitable	O
candidate	O
for	O
future	O
valid	O
studies	O
.	O

Novel	O
analgesic	O
/	O
anti	O
-	O
inflammatory	O
agents	O
:	O
1	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diarylpyrrole	I-CHEMICAL
nitrooxyalkyl	I-CHEMICAL
ethers	I-CHEMICAL
and	O
related	O
compounds	O
as	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibiting	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
donors	O
.	O

A	O
series	O
of	O
3	B-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diarylpyrroles	I-CHEMICAL
bearing	O
a	O
nitrooxyalkyl	B-CHEMICAL
side	O
chain	O
linked	O
to	O
different	O
spacers	O
were	O
designed	O
.	O

New	O
classes	O
of	O
pyrrole	B-CHEMICAL
-	O
derived	O
nitrooxyalkyl	B-CHEMICAL
inverse	O
esters	B-CHEMICAL
,	O
carbonates	B-CHEMICAL
,	O
and	O
ethers	B-CHEMICAL
(	O
7	O
-	O
10	O
)	O
as	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
selective	O
inhibitors	O
and	O
NO	B-CHEMICAL
donors	O
were	O
synthesized	O
and	O
are	O
herein	O
reported	O
.	O

By	O
taking	O
into	O
account	O
the	O
metabolic	O
conversion	O
of	O
nitrooxyalkyl	B-CHEMICAL
ethers	I-CHEMICAL
(	O
9	O
,	O
10	O
)	O
into	O
corresponding	O
alcohols	B-CHEMICAL
,	O
derivatives	O
17	O
and	O
18	O
were	O
also	O
studied	O
.	O

Nitrooxy	B-CHEMICAL
derivatives	O
showed	O
NO	B-CHEMICAL
-	O
dependent	O
vasorelaxing	O
properties	O
,	O
while	O
most	O
of	O
the	O
compounds	O
proved	O
to	O
be	O
very	O
potent	O
and	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitors	O
in	O
in	O
vitro	O
experimental	O
models	O
.	O

Further	O
in	O
vivo	O
studies	O
on	O
compounds	O
9a	O
,	O
c	O
and	O
17a	O
highlighted	O
good	O
anti	O
-	O
inflammatory	O
and	O
antinociceptive	O
activities	O
.	O

Compound	O
9c	O
was	O
able	O
to	O
inhibit	O
glycosaminoglycan	O
(	O
GAG	O
)	O
release	O
induced	O
by	O
interleukin	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
)	O
,	O
showing	O
cartilage	O
protective	O
properties	O
.	O

Finally	O
,	O
molecular	O
modeling	O
and	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
-	O
and	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
-	O
NMR	O
studies	O
performed	O
on	O
compounds	O
6c	O
,	O
d	O
,	O
9c	O
,	O
and	O
10b	O
allowed	O
the	O
right	O
conformation	O
of	O
nitrooxyalkyl	B-CHEMICAL
ester	I-CHEMICAL
and	I-CHEMICAL
ether	I-CHEMICAL
side	O
chain	O
of	O
these	O
molecules	O
within	O
the	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
active	O
site	O
to	O
be	O
assessed	O
.	O

Synthesis	O
and	O
structure	O
-	O
activity	O
relationship	O
of	O
pyripyropene	B-CHEMICAL
A	I-CHEMICAL
derivatives	O
as	O
potent	O
and	O
selective	O
acyl	B-GENE-Y
-	I-GENE-Y
CoA	I-GENE-Y
:	I-GENE-Y
cholesterol	I-GENE-Y
acyltransferase	I-GENE-Y
2	I-GENE-Y
(	O
ACAT2	B-GENE-Y
)	O
inhibitors	O
:	O
Part	O
2	O
.	O

Synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
7	B-CHEMICAL
-	I-CHEMICAL
O	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
cyanobenzoyl	I-CHEMICAL
pyripyropene	I-CHEMICAL
A	I-CHEMICAL
derivatives	O
with	O
modification	O
at	O
C1	O
and	O
11	O
are	O
described	O
.	O

Regioselective	O
mono	O
-	O
deprotection	O
of	O
di	B-CHEMICAL
-	I-CHEMICAL
tert	I-CHEMICAL
-	I-CHEMICAL
butylsilylene	I-CHEMICAL
acetal	I-CHEMICAL
was	O
critical	O
in	O
their	O
synthesis	O
.	O

An	O
overview	O
on	O
the	O
marine	O
neurotoxin	O
,	O
saxitoxin	B-CHEMICAL
:	O
genetics	O
,	O
molecular	O
targets	O
,	O
methods	O
of	O
detection	O
and	O
ecological	O
functions	O
.	O

Marine	O
neurotoxins	O
are	O
natural	O
products	O
produced	O
by	O
phytoplankton	O
and	O
select	O
species	O
of	O
invertebrates	O
and	O
fish	O
.	O

These	O
compounds	O
interact	O
with	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
,	I-GENE-N
potassium	I-GENE-N
and	I-GENE-N
calcium	I-GENE-N
channels	I-GENE-N
and	O
modulate	O
the	O
flux	O
of	O
these	O
ions	O
into	O
various	O
cell	O
types	O
.	O

This	O
review	O
provides	O
a	O
summary	O
of	O
marine	O
neurotoxins	O
,	O
including	O
their	O
structures	O
,	O
molecular	O
targets	O
and	O
pharmacologies	O
.	O

Saxitoxin	B-CHEMICAL
and	O
its	O
derivatives	O
,	O
collectively	O
referred	O
to	O
as	O
paralytic	O
shellfish	O
toxins	O
(	O
PSTs	O
)	O
,	O
are	O
unique	O
among	O
neurotoxins	O
in	O
that	O
they	O
are	O
found	O
in	O
both	O
marine	O
and	O
freshwater	O
environments	O
by	O
organisms	O
inhabiting	O
two	O
kingdoms	O
of	O
life	O
.	O

Prokaryotic	O
cyanobacteria	O
are	O
responsible	O
for	O
PST	O
production	O
in	O
freshwater	O
systems	O
,	O
while	O
eukaryotic	O
dinoflagellates	O
are	O
the	O
main	O
producers	O
in	O
marine	O
waters	O
.	O

Bioaccumulation	O
by	O
filter	O
-	O
feeding	O
bivalves	O
and	O
fish	O
and	O
subsequent	O
transfer	O
through	O
the	O
food	O
web	O
results	O
in	O
the	O
potentially	O
fatal	O
human	O
illnesses	O
,	O
paralytic	O
shellfish	O
poisoning	O
and	O
saxitoxin	B-CHEMICAL
pufferfish	O
poisoning	O
.	O

These	O
illnesses	O
are	O
a	O
result	O
of	O
saxitoxin	B-CHEMICAL
'	O
s	O
ability	O
to	O
bind	O
to	O
the	O
voltage	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
sodium	I-GENE-N
channel	I-GENE-N
,	O
blocking	O
the	O
passage	O
of	O
nerve	O
impulses	O
and	O
leading	O
to	O
death	O
via	O
respiratory	O
paralysis	O
.	O

Recent	O
advances	O
in	O
saxitoxin	B-CHEMICAL
research	O
are	O
discussed	O
,	O
including	O
the	O
molecular	O
biology	O
of	O
toxin	O
synthesis	O
,	O
new	O
protein	O
targets	O
,	O
association	O
with	O
metal	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
motifs	I-GENE-N
and	O
methods	O
of	O
detection	O
.	O

The	O
eco	O
-	O
evolutionary	O
role	O
(	O
s	O
)	O
PSTs	O
may	O
serve	O
for	O
phytoplankton	O
species	O
that	O
produce	O
them	O
are	O
also	O
discussed	O
.	O

Modulation	O
of	O
the	O
JAK	B-GENE-N
/	O
ERK	B-GENE-N
/	O
STAT	B-GENE-N
signaling	O
in	O
melanocortin	B-GENE-Y
-	O
induced	O
inhibition	O
of	O
local	O
and	O
systemic	O
responses	O
to	O
myocardial	O
ischemia	O
/	O
reperfusion	O
.	O

The	O
janus	B-GENE-N
kinases	I-GENE-N
(	O
JAK	B-GENE-N
)	O
,	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinases	I-GENE-N
(	O
ERK	B-GENE-N
)	O
and	O
signal	B-GENE-N
transducers	I-GENE-N
and	I-GENE-N
activators	I-GENE-N
of	I-GENE-N
transcription	I-GENE-N
(	O
STAT	B-GENE-N
)	O
pathways	O
have	O
been	O
shown	O
to	O
play	O
a	O
cardioprotective	O
role	O
.	O

We	O
previously	O
gave	O
evidence	O
that	O
melanocortins	B-GENE-Y
afford	O
cardioprotection	O
in	O
conditions	O
of	O
myocardial	O
ischemia	O
/	O
reperfusion	O
.	O

Here	O
we	O
aimed	O
to	O
investigate	O
the	O
influence	O
of	O
melanocortins	B-GENE-Y
on	O
the	O
JAK	B-GENE-N
/	O
ERK	B-GENE-N
/	O
STAT	B-GENE-N
signaling	O
in	O
cardiac	O
and	O
systemic	O
responses	O
to	O
prolonged	O
myocardial	O
ischemia	O
/	O
reperfusion	O
.	O

Ischemia	O
was	O
produced	O
in	O
rats	O
by	O
ligature	O
of	O
the	O
left	O
anterior	O
descending	O
coronary	O
artery	O
for	O
30min	O
.	O

At	O
the	O
end	O
of	O
the	O
2	O
-	O
h	O
reperfusion	O
,	O
western	O
blot	O
analysis	O
of	O
the	O
cardioprotective	O
transcription	O
factors	O
pJAK2	B-GENE-Y
,	O
pERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
,	O
pTyr	B-GENE-Y
-	I-GENE-Y
STAT3	I-GENE-Y
and	O
pSer	B-GENE-Y
-	I-GENE-Y
STAT3	I-GENE-Y
,	O
the	O
inflammatory	O
mediator	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
the	O
pro	O
-	O
apoptotic	O
factors	O
BAX	B-GENE-Y
and	O
c	B-GENE-N
-	I-GENE-N
jun	I-GENE-N
N	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinases	I-GENE-N
(	O
pJNK	B-GENE-N
)	O
,	O
the	O
anti	O
-	O
apoptotic	O
protein	O
Bcl	B-GENE-Y
-	I-GENE-Y
XL	I-GENE-Y
,	O
as	O
well	O
as	O
of	O
the	O
cardioprotective	O
enzyme	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
,	O
was	O
performed	O
in	O
the	O
left	O
ventricle	O
and	O
spleen	O
.	O

Intravenous	O
treatment	O
,	O
during	O
coronary	O
artery	O
occlusion	O
,	O
with	O
the	O
melanocortin	B-GENE-Y
analogs	O
[	O
Nle	B-CHEMICAL
(	O
4	O
)	O
,	O
D	B-CHEMICAL
-	I-CHEMICAL
Phe	I-CHEMICAL
(	O
7	O
)	O
]	O
α	B-GENE-Y
-	I-GENE-Y
melanocyte	I-GENE-Y
-	I-GENE-Y
stimulating	I-GENE-Y
hormone	I-GENE-Y
(	O
NDP	O
-	O
α	B-GENE-Y
-	I-GENE-Y
MSH	I-GENE-Y
)	O
and	O
adrenocorticotropic	B-GENE-Y
hormone	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
24	I-GENE-Y
[	O
ACTH	B-GENE-Y
-	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
24	I-GENE-Y
)	I-GENE-Y
]	O
,	O
induced	O
a	O
left	O
ventricle	O
up	O
-	O
regulation	O
of	O
pJAK2	B-GENE-Y
,	O
pERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
pTyr	B-GENE-Y
-	I-GENE-Y
STAT3	I-GENE-Y
(	O
JAK	B-GENE-N
-	O
dependent	O
)	O
,	O
and	O
a	O
reduction	O
in	O
pJNK	B-GENE-N
and	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
levels	O
;	O
these	O
effects	O
of	O
NDP	O
-	O
α	B-GENE-Y
-	I-GENE-Y
MSH	I-GENE-Y
and	O
ACTH	B-GENE-Y
-	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
24	I-GENE-Y
)	I-GENE-Y
were	O
associated	O
with	O
over	O
-	O
expression	O
of	O
the	O
pro	O
-	O
survival	O
proteins	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
Bcl	B-GENE-Y
-	I-GENE-Y
XL	I-GENE-Y
,	O
and	O
marked	O
decrease	O
of	O
the	O
myocardial	O
infarct	O
size	O
.	O

Melanocortin	B-GENE-Y
treatment	O
did	O
not	O
affect	O
left	O
ventricle	O
pSer	B-GENE-Y
-	I-GENE-Y
STAT3	I-GENE-Y
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
-	O
dependent	O
)	O
and	O
BAX	B-GENE-Y
levels	O
.	O

In	O
the	O
spleen	O
,	O
NDP	O
-	O
α	B-GENE-Y
-	I-GENE-Y
MSH	I-GENE-Y
and	O
ACTH	B-GENE-Y
-	I-GENE-Y
(	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
24	I-GENE-Y
)	I-GENE-Y
induced	O
similar	O
effects	O
on	O
the	O
expression	O
of	O
the	O
above	O
transcription	O
factors	O
/	O
proteins	O
,	O
except	O
for	O
pERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
(	O
down	O
-	O
regulated	O
)	O
and	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
unaffected	O
)	O
.	O

Blockade	O
of	O
JAK	B-GENE-N
and	O
ERK	B-GENE-N
pathways	O
with	O
AG490	B-CHEMICAL
and	O
U0126	B-CHEMICAL
,	O
respectively	O
,	O
abrogated	O
the	O
myocardial	O
infarct	O
size	O
reduction	O
by	O
NDP	O
-	O
α	B-GENE-Y
-	I-GENE-Y
MSH	I-GENE-Y
.	O

These	O
results	O
indicate	O
that	O
melanocortins	B-GENE-Y
inhibit	O
local	O
and	O
systemic	O
inflammatory	O
and	O
apoptotic	O
cascades	O
triggered	O
by	O
prolonged	O
myocardial	O
ischemia	O
/	O
reperfusion	O
,	O
with	O
consequent	O
reduction	O
in	O
myocardium	O
infarct	O
size	O
,	O
seemingly	O
via	O
activation	O
of	O
the	O
JAK	B-GENE-N
/	O
STAT	B-GENE-N
signaling	O
and	O
with	O
modulation	O
of	O
an	O
ERK	B-GENE-N
(	O
STAT	B-GENE-N
unrelated	O
)	O
signaling	O
pathway	O
.	O

Differential	O
effects	O
of	O
organic	O
and	O
inorganic	O
selenium	B-CHEMICAL
compounds	O
on	O
adenosine	B-GENE-Y
deaminase	I-GENE-Y
activity	O
and	O
scavenger	O
capacity	O
in	O
cerebral	O
cortex	O
slices	O
of	O
young	O
rats	O
.	O

Selenium	B-CHEMICAL
(	O
Se	B-CHEMICAL
)	O
has	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
and	O
is	O
necessary	O
for	O
the	O
development	O
and	O
normal	O
function	O
of	O
the	O
central	O
nervous	O
system	O
.	O

This	O
study	O
was	O
aimed	O
to	O
compare	O
the	O
in	O
vitro	O
effects	O
of	O
3	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
phenylseleno	I-CHEMICAL
)	I-CHEMICAL
oct	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
one	I-CHEMICAL
(	O
C21H2HOSe	B-CHEMICAL
;	O
organoselenium	B-CHEMICAL
)	O
and	O
sodium	B-CHEMICAL
selenate	I-CHEMICAL
(	O
inorganic	O
Se	B-CHEMICAL
)	O
on	O
adenosine	B-GENE-Y
deaminase	I-GENE-Y
(	O
ADA	B-GENE-Y
)	O
activity	O
,	O
cell	O
viability	O
,	O
lipid	O
peroxidation	O
,	O
scavenger	O
of	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
and	O
nonprotein	O
thiols	B-CHEMICAL
(	O
NP	O
-	O
SH	B-CHEMICAL
)	O
content	O
in	O
the	O
cerebral	O
cortex	O
slices	O
of	O
the	O
young	O
rats	O
.	O

A	O
decrease	O
in	O
ADA	B-GENE-Y
activity	O
was	O
observed	O
when	O
the	O
slices	O
were	O
exposed	O
to	O
organoselenium	B-CHEMICAL
at	O
the	O
concentrations	O
of	O
1	O
,	O
10	O
and	O
30	O
µM	O
.	O

The	O
same	O
compound	O
showed	O
higher	O
scavenger	O
capacity	O
of	O
NO	B-CHEMICAL
than	O
the	O
inorganic	O
compound	O
.	O

Inorganic	O
Se	B-CHEMICAL
was	O
able	O
to	O
protect	O
against	O
sodium	B-CHEMICAL
nitroprusside	I-CHEMICAL
-	O
induced	O
oxidative	O
damage	O
and	O
increased	O
the	O
NP	O
-	O
SH	B-CHEMICAL
content	O
.	O

Both	O
the	O
compounds	O
displayed	O
distinctive	O
antioxidant	O
capacities	O
and	O
were	O
not	O
cytotoxic	O
for	O
the	O
cerebral	O
cortex	O
slices	O
in	O
the	O
conditions	O
tested	O
.	O

These	O
findings	O
are	O
likely	O
to	O
be	O
related	O
to	O
immunomodulatory	O
and	O
antioxidant	O
properties	O
of	O
this	O
compound	O
.	O

Amino	B-CHEMICAL
acids	I-CHEMICAL
as	O
co	O
-	O
amorphous	O
stabilizers	O
for	O
poorly	O
water	O
soluble	O
drugs	O
-	O
Part	O
1	O
:	O
Preparation	O
,	O
stability	O
and	O
dissolution	O
enhancement	O
.	O

Poor	O
aqueous	O
solubility	O
of	O
an	O
active	O
pharmaceutical	O
ingredient	O
(	O
API	O
)	O
is	O
one	O
of	O
the	O
most	O
pressing	O
problems	O
in	O
pharmaceutical	O
research	O
and	O
development	O
because	O
up	O
to	O
90	O
%	O
of	O
new	O
API	O
candidates	O
under	O
development	O
are	O
poorly	O
water	O
soluble	O
.	O

These	O
drugs	O
usually	O
have	O
a	O
low	O
and	O
variable	O
oral	O
bioavailability	O
,	O
and	O
therefore	O
an	O
unsatisfactory	O
therapeutic	O
effect	O
.	O

One	O
of	O
the	O
most	O
promising	O
approaches	O
to	O
increase	O
dissolution	O
rate	O
and	O
solubility	O
of	O
these	O
drugs	O
is	O
the	O
conversion	O
of	O
a	O
crystalline	O
form	O
of	O
the	O
drug	O
into	O
its	O
respective	O
amorphous	O
form	O
,	O
usually	O
by	O
incorporation	O
into	O
hydrophilic	O
polymers	O
,	O
forming	O
glass	O
solutions	O
.	O

However	O
,	O
this	O
strategy	O
only	O
led	O
to	O
a	O
small	O
number	O
of	O
marketed	O
products	O
usually	O
because	O
of	O
inadequate	O
physical	O
stability	O
of	O
the	O
drug	O
(	O
crystallization	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
fundamentally	O
different	O
approach	O
to	O
stabilize	O
the	O
amorphous	O
form	O
of	O
drugs	O
,	O
namely	O
the	O
use	O
of	O
amino	B-CHEMICAL
acids	I-CHEMICAL
as	O
small	O
molecular	O
weight	O
excipients	O
that	O
form	O
specific	O
molecular	O
interactions	O
with	O
the	O
drug	O
resulting	O
in	O
co	O
-	O
amorphous	O
forms	O
.	O

The	O
two	O
poorly	O
water	O
soluble	O
drugs	O
carbamazepine	B-CHEMICAL
and	O
indomethacin	B-CHEMICAL
were	O
combined	O
with	O
amino	B-CHEMICAL
acids	I-CHEMICAL
from	O
the	O
binding	O
sites	O
of	O
the	O
biological	O
receptors	O
of	O
these	O
drugs	O
.	O

Mixtures	O
of	O
drug	O
and	O
the	O
amino	B-CHEMICAL
acids	I-CHEMICAL
arginine	B-CHEMICAL
,	O
phenylalanine	B-CHEMICAL
,	O
tryptophan	B-CHEMICAL
and	O
tyrosine	B-CHEMICAL
were	O
prepared	O
by	O
vibrational	O
ball	O
milling	O
.	O

Solid	O
-	O
state	O
characterization	O
with	O
X	O
-	O
ray	O
powder	O
diffraction	O
(	O
XRPD	O
)	O
and	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
revealed	O
that	O
the	O
various	O
blends	O
could	O
be	O
prepared	O
as	O
homogeneous	O
,	O
single	O
phase	O
co	O
-	O
amorphous	O
formulations	O
indicated	O
by	O
the	O
appearance	O
of	O
an	O
amorphous	O
halo	O
in	O
the	O
XRPD	O
diffractograms	O
and	O
a	O
single	O
glass	O
transition	O
temperature	O
(	O
Tg	O
)	O
in	O
the	O
DSC	O
measurements	O
.	O

In	O
addition	O
,	O
the	O
Tgs	O
of	O
the	O
co	O
-	O
amorphous	O
mixtures	O
were	O
significantly	O
increased	O
over	O
those	O
of	O
the	O
individual	O
drugs	O
.	O

The	O
drugs	O
remained	O
chemically	O
stable	O
during	O
the	O
milling	O
process	O
and	O
the	O
co	O
-	O
amorphous	O
formulations	O
were	O
generally	O
physically	O
stable	O
over	O
at	O
least	O
6months	O
at	O
40	O
°	O
C	O
under	O
dry	O
conditions	O
.	O

The	O
dissolution	O
rate	O
of	O
all	O
co	O
-	O
amorphous	O
drug	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
mixtures	O
was	O
significantly	O
increased	O
over	O
that	O
of	O
the	O
respective	O
crystalline	O
and	O
amorphous	O
pure	O
drugs	O
.	O

Amino	B-CHEMICAL
acids	I-CHEMICAL
thus	O
appear	O
as	O
promising	O
excipients	O
to	O
solve	O
challenges	O
connected	O
with	O
the	O
stability	O
and	O
dissolution	O
of	O
amorphous	O
drugs	O
.	O

Integrated	O
chemical	O
and	O
biological	O
analysis	O
to	O
explain	O
estrogenic	O
potency	O
in	O
bile	O
extracts	O
of	O
red	O
mullet	O
(	O
Mullus	O
barbatus	O
)	O
.	O

A	O
biological	O
screening	O
was	O
performed	O
to	O
establish	O
the	O
total	O
exposure	O
to	O
estrogenic	O
compounds	O
of	O
red	O
mullet	O
(	O
Mullus	O
barbatus	O
)	O
collected	O
at	O
several	O
sites	O
along	O
the	O
Spanish	O
Mediterranean	O
coast	O
by	O
testing	O
male	O
fish	O
bile	O
extracts	O
using	O
the	O
in	O
vitro	O
ER	B-GENE-Y
-	O
LUC	O
reporter	O
gene	O
assay	O
.	O

In	O
addition	O
,	O
major	O
metabolites	O
were	O
identified	O
and	O
measurements	O
of	O
OH	B-CHEMICAL
-	I-CHEMICAL
PAHs	I-CHEMICAL
(	O
1	B-CHEMICAL
-	I-CHEMICAL
naphthol	I-CHEMICAL
,	O
9	B-CHEMICAL
-	I-CHEMICAL
phenantrol	I-CHEMICAL
,	O
9	B-CHEMICAL
-	I-CHEMICAL
fluorenol	I-CHEMICAL
,	O
1	B-CHEMICAL
-	I-CHEMICAL
pyrenol	I-CHEMICAL
,	O
1OH	B-CHEMICAL
-	I-CHEMICAL
BaP	I-CHEMICAL
and	O
3OH	B-CHEMICAL
-	I-CHEMICAL
BaP	I-CHEMICAL
)	O
and	O
alkylphenols	B-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
nonylphenol	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
NP	I-CHEMICAL
)	O
and	O
4	B-CHEMICAL
-	I-CHEMICAL
tertoctylphenol	I-CHEMICAL
(	O
4	B-CHEMICAL
-	I-CHEMICAL
tert	I-CHEMICAL
-	I-CHEMICAL
OP	I-CHEMICAL
)	O
)	O
in	O
the	O
same	O
fish	O
bile	O
extracts	O
were	O
taken	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
in	O
electron	O
ionization	O
mode	O
(	O
GC	O
-	O
EI	O
-	O
MS	O
)	O
.	O

Relative	O
in	O
vitro	O
estrogenic	O
potencies	O
of	O
the	O
chemically	O
quantified	O
compounds	O
were	O
also	O
tested	O
.	O

The	O
highest	O
biliary	O
concentrations	O
of	O
1	B-CHEMICAL
-	I-CHEMICAL
pyrenol	I-CHEMICAL
,	O
9	B-CHEMICAL
-	I-CHEMICAL
fluorenol	I-CHEMICAL
and	O
4	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
NP	I-CHEMICAL
were	O
found	O
in	O
fish	O
from	O
Barcelona	O
and	O
from	O
the	O
Mar	O
Menor	O
coastal	O
lagoon	O
.	O

However	O
,	O
these	O
concentrations	O
can	O
be	O
considered	O
relatively	O
low	O
compared	O
to	O
values	O
reported	O
in	O
red	O
mullet	O
from	O
other	O
polluted	O
waters	O
in	O
the	O
Mediterranean	O
Sea	O
.	O

The	O
contribution	O
of	O
1	B-CHEMICAL
-	I-CHEMICAL
pyrenol	I-CHEMICAL
,	O
4	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
NP	I-CHEMICAL
and	O
4	B-CHEMICAL
-	I-CHEMICAL
tert	I-CHEMICAL
-	I-CHEMICAL
OP	I-CHEMICAL
to	O
the	O
total	O
estrogenic	O
potency	O
measured	O
in	O
male	O
fish	O
bile	O
was	O
found	O
to	O
be	O
negligible	O
,	O
indicating	O
the	O
presence	O
of	O
other	O
estrogenic	O
compounds	O
in	O
red	O
mullet	O
bile	O
.	O

Estrogenic	O
potency	O
in	O
bile	O
from	O
male	O
fish	O
was	O
markedly	O
elevated	O
in	O
Mar	O
Menor	O
lagoon	O
(	O
234	O
.	O
8	O
±	O
5	O
.	O
7pgE2EQ	O
/	O
μl	O
)	O
,	O
and	O
further	O
research	O
will	O
be	O
necessary	O
to	O
explain	O
whether	O
the	O
presence	O
of	O
natural	O
and	O
synthetic	O
-	O
hormones	O
in	O
the	O
lagoon	O
contributed	O
to	O
this	O
finding	O
.	O

Values	O
of	O
approximately	O
15	O
-	O
16E2EQpg	O
/	O
mg	O
bile	O
can	O
be	O
regarded	O
as	O
preliminary	O
baseline	O
levels	O
of	O
bile	O
estrogenicity	O
in	O
male	O
red	O
mullet	O
from	O
the	O
western	O
Mediterranean	O
Sea	O
.	O

Anticancer	O
activity	O
of	O
novel	O
hybrid	O
molecules	O
containing	O
5	B-CHEMICAL
-	I-CHEMICAL
benzylidene	I-CHEMICAL
thiazolidine	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
.	O

Hybridization	O
of	O
two	O
different	O
bioactive	O
molecules	O
with	O
different	O
mechanism	O
of	O
action	O
is	O
one	O
of	O
the	O
methods	O
that	O
are	O
being	O
adopted	O
to	O
treat	O
cancer	O
.	O

Molecules	O
bearing	O
a	O
thiazolidine	B-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dione	I-CHEMICAL
scaffold	O
have	O
been	O
recognized	O
as	O
antineoplastic	O
agents	O
with	O
a	O
broad	O
spectrum	O
of	O
activity	O
against	O
many	O
cancer	O
cell	O
lines	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
described	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
two	O
series	O
of	O
N	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
arylidene	I-CHEMICAL
thiazolidine	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
diones	I-CHEMICAL
,	O
bearing	O
the	O
α	B-CHEMICAL
-	I-CHEMICAL
bromoacryloylamido	I-CHEMICAL
moiety	O
at	O
the	O
para	O
-	O
or	O
meta	O
-	O
position	O
on	O
the	O
phenyl	B-CHEMICAL
of	O
the	O
arylidene	B-CHEMICAL
portion	O
.	O

We	O
have	O
observed	O
that	O
selected	O
compounds	O
5a	O
,	O
5c	O
and	O
5g	O
suppress	O
proliferation	O
of	O
human	O
myeloid	O
leukaemia	O
HL	O
-	O
60	O
and	O
U937	O
cells	O
by	O
triggering	O
morphological	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
,	O
which	O
are	O
well	O
-	O
known	O
features	O
of	O
apoptosis	O
.	O

Finally	O
,	O
our	O
results	O
indicated	O
that	O
the	O
investigated	O
compounds	O
induced	O
apoptotic	O
cell	O
death	O
through	O
a	O
mechanism	O
that	O
involved	O
activation	O
of	O
multiple	O
caspases	B-GENE-N
and	O
was	O
also	O
associated	O
with	O
the	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
from	O
the	O
mitochondria	O
.	O

Activating	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
-	O
ERK	B-GENE-N
signaling	O
pathway	O
contributes	O
to	O
ginsenoside	B-CHEMICAL
Rg1	I-CHEMICAL
protection	O
against	O
β	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
peptide	I-GENE-Y
-	O
induced	O
human	O
endothelial	O
cells	O
apoptosis	O
.	O

The	O
deposition	O
of	O
β	B-GENE-Y
-	I-GENE-Y
amyloid	I-GENE-Y
(	O
Aβ	B-GENE-Y
)	O
in	O
neurons	O
and	O
vascular	O
cells	O
of	O
the	O
brain	O
has	O
been	O
characterized	O
in	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Ginsenoside	B-CHEMICAL
Rg1	I-CHEMICAL
(	O
Rg1	B-CHEMICAL
)	O
is	O
an	O
active	O
components	O
in	O
Panax	O
ginseng	O
,	O
a	O
famous	O
traditional	O
Chinese	O
medicines	O
recorded	O
in	O
Compendium	O
of	O
Materia	O
Medica	O
.	O

Present	O
study	O
attempted	O
to	O
evaluate	O
the	O
potential	O
mechanisms	O
of	O
Aβ	B-GENE-Y
-	O
mediated	O
insult	O
and	O
the	O
protective	O
effects	O
of	O
Rg1	B-CHEMICAL
on	O
human	O
endothelial	O
cells	O
.	O

Rg1	B-CHEMICAL
attenuated	O
the	O
Aβ25	B-GENE-Y
-	I-GENE-Y
35	I-GENE-Y
-	O
associated	O
mitochondrial	O
apoptotic	O
events	O
,	O
accompanied	O
by	O
inhibiting	O
HIF	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
expression	O
followed	O
by	O
intracellular	O
reactive	O
nitrogen	B-CHEMICAL
species	O
generation	O
,	O
and	O
protein	O
nitrotyrosination	O
.	O

These	O
protective	O
effects	O
were	O
abolished	O
by	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
(	O
GR	B-GENE-Y
)	O
antagonist	O
RU486	B-CHEMICAL
or	O
p	B-GENE-N
-	I-GENE-N
ERK	I-GENE-N
inhibitor	O
U0126	B-CHEMICAL
rather	O
than	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
α	I-GENE-Y
antagonist	O
ICI	B-CHEMICAL
82	I-CHEMICAL
,	I-CHEMICAL
780	I-CHEMICAL
.	O

Taken	O
together	O
,	O
our	O
results	O
suggested	O
that	O
Rg1	B-CHEMICAL
protected	O
against	O
Aβ25	B-GENE-Y
-	I-GENE-Y
35	I-GENE-Y
-	O
induced	O
apoptosis	O
at	O
least	O
in	O
part	O
by	O
two	O
complementary	O
GR	B-GENE-Y
-	O
dependent	O
ERK	B-GENE-N
phosphorylation	O
pathways	O
:	O
(	O
1	O
)	O
down	O
-	O
regulating	O
HIF	B-GENE-Y
-	I-GENE-Y
1α	I-GENE-Y
initiated	O
protein	O
nitrotyrosination	O
,	O
and	O
(	O
2	O
)	O
inhibiting	O
mitochondrial	O
apoptotic	O
cascades	O
.	O

These	O
data	O
provided	O
a	O
novel	O
insight	O
to	O
the	O
mechanisms	O
of	O
Rg1protective	B-CHEMICAL
effects	O
on	O
Aβ25	B-GENE-Y
-	I-GENE-Y
35	I-GENE-Y
-	O
induced	O
endothelial	O
cells	O
apoptosis	O
,	O
suggesting	O
that	O
GR	B-GENE-Y
-	O
ERK	B-GENE-N
signaling	O
pathway	O
might	O
play	O
an	O
important	O
role	O
in	O
it	O
.	O

p38	B-GENE-N
Mitogen	B-GENE-N
Activated	I-GENE-N
Protein	I-GENE-N
Kinase	I-GENE-N
Regulates	O
the	O
Nuclear	B-GENE-N
Receptor	I-GENE-N
CAR	B-GENE-Y
to	O
Activate	O
the	O
CYP2B6	B-GENE-Y
Gene	O
.	O

The	O
constitutive	B-GENE-Y
active	I-GENE-Y
/	I-GENE-Y
androstane	I-GENE-Y
receptor	I-GENE-Y
(	O
CAR	B-GENE-Y
)	O
regulates	O
hepatic	O
drug	O
metabolism	O
by	O
activating	O
genes	O
such	O
as	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	O
CYP	B-GENE-N
)	O
and	O
certain	O
transferases	B-GENE-N
.	O

p38	B-GENE-N
mitogen	B-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
is	O
highly	O
activated	O
in	O
human	O
primary	O
hepatocytes	O
but	O
barely	O
in	O
human	O
hepatoma	O
cell	O
-	O
lines	O
including	O
HepG2	O
cells	O
.	O

Liganded	O
-	O
CAR	B-GENE-Y
induced	O
CYP2B6	B-GENE-Y
mRNA	O
in	O
human	O
primary	O
hepatocytes	O
far	O
more	O
effectively	O
than	O
in	O
HepG2	O
cells	O
ectopically	O
expressing	O
CAR	B-GENE-Y
.	O

Here	O
,	O
we	O
have	O
now	O
found	O
that	O
activation	O
of	O
p38	B-GENE-N
MAPK	B-GENE-N
by	O
anisomycin	B-CHEMICAL
potentiated	O
induction	O
of	O
CYP2B6	B-GENE-Y
mRNA	O
by	O
CAR	B-GENE-Y
ligand	O
in	O
HepG2	O
cells	O
to	O
levels	O
observed	O
in	O
ligand	O
-	O
treated	O
human	O
primary	O
hepatocytes	O
.	O

siRNA	O
knockdown	O
of	O
p38	B-GENE-N
MAPK	B-GENE-N
abrogated	O
the	O
ability	O
of	O
anisomycin	B-CHEMICAL
to	O
synergistically	O
induce	O
CYP2B6	B-GENE-Y
mRNA	O
.	O

In	O
addition	O
to	O
CYP2B6	B-GENE-Y
,	O
anisomycin	B-CHEMICAL
co	O
-	O
treatment	O
potentiated	O
an	O
increase	O
in	O
CYP2A7	B-GENE-Y
and	O
CYP2C9	B-GENE-Y
mRNAs	O
but	O
not	O
CYP3A4	B-GENE-Y
or	O
UDP	B-GENE-Y
-	I-GENE-Y
glucuronosyltransferase	I-GENE-Y
1A1	I-GENE-Y
mRNAs	O
.	O

Thus	O
,	O
activated	O
p38	B-GENE-N
MAPK	B-GENE-N
is	O
required	O
for	O
liganded	O
-	O
CAR	B-GENE-Y
to	O
selectively	O
activate	O
a	O
set	O
of	O
genes	O
that	O
encode	O
drug	O
metabolizing	O
enzymes	O
.	O

Our	O
present	O
results	O
suggest	O
that	O
CAR	B-GENE-Y
-	O
mediated	O
induction	O
of	O
these	O
enzymes	O
can	O
not	O
be	O
understood	O
by	O
ligand	O
binding	O
alone	O
because	O
the	O
specificity	O
and	O
magnitude	O
of	O
induction	O
are	O
co	O
-	O
determined	O
by	O
a	O
given	O
cell	O
signaling	O
such	O
as	O
p38	B-GENE-N
MAPK	B-GENE-N
;	O
both	O
physiological	O
and	O
pathophysiological	O
states	O
of	O
cell	O
signaling	O
may	O
have	O
a	O
strong	O
impact	O
in	O
hepatic	O
drug	O
metabolizing	O
capability	O
during	O
therapeutic	O
treatments	O
.	O

Anti	O
-	O
inflammatory	O
effect	O
of	O
essential	O
oil	O
and	O
its	O
constituents	O
from	O
fingered	O
citron	O
(	O
Citrus	O
medica	O
L	O
.	O
var	O
.	O
sarcodactylis	O
)	O
through	O
blocking	O
JNK	B-GENE-N
,	O
ERK	B-GENE-N
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
pathways	O
in	O
LPS	O
-	O
activated	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

We	O
investigated	O
the	O
composition	O
of	O
essential	O
oil	O
from	O
fingered	O
citron	O
(	O
Citrus	O
medica	O
L	O
.	O
var	O
.	O
sarcodactylis	O
)	O
(	O
FCEO	O
)	O
peels	O
by	O
GC	O
-	O
MS	O
and	O
its	O
anti	O
-	O
inflammatory	O
effects	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
mouse	O
macrophage	O
(	O
RAW	O
264	O
.	O
7	O
)	O
cells	O
.	O

Fifteen	O
compounds	O
,	O
representing	O
98	O
.	O
97	O
%	O
of	O
the	O
essential	O
oil	O
,	O
were	O
tentatively	O
identified	O
;	O
the	O
main	O
constituents	O
were	O
limonene	B-CHEMICAL
(	O
52	O
.	O
44	O
%	O
)	O
and	O
γ	B-CHEMICAL
-	I-CHEMICAL
terpinene	I-CHEMICAL
(	O
28	O
.	O
41	O
%	O
)	O
.	O

FCEO	O
significantly	O
inhibited	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
and	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
PGE2	B-CHEMICAL
)	O
by	O
suppressing	O
the	O
protein	O
expression	O
of	O
inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
and	O
cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
respectively	O
.	O

Additionally	O
,	O
FCEO	O
suppressed	O
the	O
production	O
of	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
.	O

FCEO	O
attenuated	O
LPS	O
-	O
induced	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
activation	O
via	O
inhibition	O
of	O
inhibitor	B-GENE-Y
κB	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
phosphorylation	O
.	O

Furthermore	O
,	O
FCEO	O
blocked	O
activation	O
of	O
c	B-GENE-N
-	I-GENE-N
Jun	I-GENE-N
N	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
(	O
JNK	B-GENE-N
)	O
and	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
(	O
ERK	B-GENE-N
)	O
but	O
not	O
that	O
of	O
p38	B-GENE-N
mitogen	I-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
.	O

These	O
results	O
indicate	O
that	O
FCEO	O
inhibits	O
LPS	O
-	O
stimulated	O
inflammation	O
by	O
blocking	O
the	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
JNK	B-GENE-N
,	O
and	O
ERK	B-GENE-N
pathways	O
in	O
macrophages	O
,	O
and	O
demonstrate	O
that	O
FCEO	O
possesses	O
anti	O
-	O
inflammatory	O
properties	O
.	O

Aldosterone	B-CHEMICAL
-	O
induced	O
ENaC	B-GENE-N
and	O
basal	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
/	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
trafficking	O
via	O
protein	B-GENE-Y
kinase	I-GENE-Y
D1	I-GENE-Y
-	O
phosphatidylinositol	B-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
kinaseIIIβ	I-GENE-Y
trans	O
Golgi	O
signalling	O
in	O
M1	O
cortical	O
collecting	O
duct	O
cells	O
.	O

Aldosterone	B-CHEMICAL
regulates	O
Na	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
transport	O
in	O
the	O
distal	O
nephron	O
through	O
multiple	O
mechanisms	O
that	O
include	O
the	O
transcriptional	O
control	O
of	O
epithelial	O
sodium	B-GENE-N
channel	I-GENE-N
(	O
ENaC	B-GENE-N
)	O
and	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
/	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
subunits	O
.	O

Aldosterone	B-CHEMICAL
also	O
induces	O
the	O
rapid	O
phosphorylation	O
of	O
Protein	B-GENE-Y
Kinase	I-GENE-Y
D1	I-GENE-Y
(	O
PKD1	B-GENE-Y
)	O
.	O

PKD	B-GENE-Y
isoforms	O
regulate	O
protein	O
trafficking	O
,	O
by	O
the	O
control	O
of	O
vesicle	O
fission	O
from	O
the	O
trans	O
Golgi	O
network	O
(	O
TGN	O
)	O
through	O
activation	O
of	O
phosphatidylinositol	B-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
kinaseIIIβ	I-GENE-Y
(	O
PI4KIIIβ	B-GENE-Y
)	O
.	O

We	O
report	O
rapid	O
ENaCγ	B-GENE-Y
translocation	O
to	O
the	O
plasma	O
membrane	O
after	O
30min	O
aldosterone	O
treatment	O
in	O
polarized	O
M1	O
cortical	O
collecting	O
duct	O
cells	O
,	O
which	O
was	O
significantly	O
impaired	O
in	O
PKD1	B-GENE-Y
shRNA	O
-	O
mediated	O
knockdown	O
cells	O
.	O

In	O
PKD1	B-GENE-Y
-	O
deficient	O
cells	O
,	O
the	O
ouabain	B-CHEMICAL
-	O
sensitive	O
current	O
was	O
significantly	O
reduced	O
and	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
/	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
α	I-GENE-N
and	I-GENE-N
β	I-GENE-N
subunits	O
showed	O
aberrant	O
localization	O
.	O

PKD1	B-GENE-Y
and	O
PI4KIIIβ	B-GENE-Y
localize	O
to	O
the	O
TGN	O
,	O
and	O
aldosterone	B-CHEMICAL
induced	O
an	O
interaction	O
between	O
PKD1	B-GENE-Y
and	O
PI4KIIIβ	B-GENE-Y
following	O
aldosterone	B-CHEMICAL
treatment	O
.	O

This	O
study	O
reveals	O
a	O
novel	O
mechanism	O
for	O
rapid	O
regulation	O
of	O
ENaC	B-GENE-N
and	O
the	O
Na	B-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
/	I-GENE-N
K	I-GENE-N
(	I-GENE-N
+	I-GENE-N
)	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
,	O
via	O
directed	O
trafficking	O
through	O
PKD1	B-GENE-Y
-	O
PI4KIIIβ	B-GENE-Y
signalling	O
at	O
the	O
level	O
of	O
the	O
TGN	O
.	O

Osteochondral	O
tissue	O
regeneration	O
using	O
a	O
bilayered	O
composite	O
hydrogel	O
with	O
modulating	O
dual	O
growth	O
factor	O
release	O
kinetics	O
in	O
a	O
rabbit	O
model	O
.	O

Biodegradable	O
oligo	B-CHEMICAL
(	I-CHEMICAL
poly	I-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
glycol	I-CHEMICAL
)	I-CHEMICAL
fumarate	I-CHEMICAL
)	I-CHEMICAL
(	O
OPF	B-CHEMICAL
)	O
composite	O
hydrogels	O
have	O
been	O
investigated	O
for	O
the	O
delivery	O
of	O
growth	O
factors	O
(	O
GFs	O
)	O
with	O
the	O
aid	O
of	O
gelatin	O
microparticles	O
(	O
GMPs	O
)	O
and	O
stem	O
cell	O
populations	O
for	O
osteochondral	O
tissue	O
regeneration	O
.	O

In	O
this	O
study	O
,	O
a	O
bilayered	O
OPF	B-CHEMICAL
composite	O
hydrogel	O
that	O
mimics	O
the	O
distinctive	O
hierarchical	O
structure	O
of	O
native	O
osteochondral	O
tissue	O
was	O
utilized	O
to	O
investigate	O
the	O
effect	O
of	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
(	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
)	O
with	O
varying	O
release	O
kinetics	O
and	O
/	O
or	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
on	O
osteochondral	O
tissue	O
regeneration	O
in	O
a	O
rabbit	O
full	O
-	O
thickness	O
osteochondral	O
defect	O
model	O
.	O

The	O
four	O
groups	O
investigated	O
included	O
(	O
i	O
)	O
a	O
blank	O
control	O
(	O
no	O
GFs	O
)	O
,	O
(	O
ii	O
)	O
GMP	O
-	O
loaded	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
alone	O
,	O
(	O
iii	O
)	O
GMP	O
-	O
loaded	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
gel	O
-	O
loaded	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
,	O
and	O
(	O
iv	O
)	O
GMP	O
-	O
loaded	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
GMP	O
-	O
loaded	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
in	O
OPF	B-CHEMICAL
composite	O
hydrogels	O
.	O

The	O
results	O
of	O
an	O
in	O
vitro	O
release	O
study	O
demonstrated	O
that	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
release	O
kinetics	O
could	O
be	O
modulated	O
by	O
the	O
GF	O
incorporation	O
method	O
.	O

At	O
12weeks	O
post	O
-	O
implantation	O
,	O
the	O
quality	O
of	O
tissue	O
repair	O
in	O
both	O
chondral	O
and	O
subchondral	O
layers	O
was	O
analyzed	O
based	O
on	O
quantitative	O
histological	O
scoring	O
.	O

All	O
groups	O
incorporating	O
GFs	O
resulted	O
in	O
a	O
significant	O
improvement	O
in	O
cartilage	O
morphology	O
compared	O
to	O
the	O
control	O
.	O

Single	O
delivery	O
of	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
showed	O
higher	O
scores	O
in	O
subchondral	O
bone	O
morphology	O
as	O
well	O
as	O
chondrocyte	O
and	O
glycosaminoglycan	O
amount	O
in	O
adjacent	O
cartilage	O
tissue	O
when	O
compared	O
to	O
a	O
dual	O
delivery	O
of	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
,	O
independent	O
of	O
the	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
release	O
kinetics	O
.	O

The	O
results	O
suggest	O
that	O
although	O
the	O
dual	O
delivery	O
of	O
TGF	B-GENE-Y
-	I-GENE-Y
β3	I-GENE-Y
and	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
may	O
not	O
synergistically	O
enhance	O
the	O
quality	O
of	O
engineered	O
tissue	O
,	O
the	O
delivery	O
of	O
IGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
alone	O
from	O
bilayered	O
composite	O
hydrogels	O
positively	O
affects	O
osteochondral	O
tissue	O
repair	O
and	O
holds	O
promise	O
for	O
osteochondral	O
tissue	O
engineering	O
applications	O
.	O

Oxidative	O
status	O
in	O
ICU	O
patients	O
with	O
septic	O
shock	O
.	O

The	O
aim	O
of	O
this	O
pilot	O
study	O
was	O
to	O
investigate	O
variability	O
of	O
oxidative	O
stress	O
during	O
sepsis	O
evolution	O
.	O

ICU	O
patients	O
with	O
the	O
diagnosis	O
of	O
septic	O
shock	O
were	O
included	O
.	O

Thiobarbituric	B-CHEMICAL
-	I-CHEMICAL
acid	I-CHEMICAL
reactive	O
substances	O
,	O
total	O
antioxidant	O
capacity	O
,	O
protein	O
carbonyls	B-CHEMICAL
in	O
plasma	O
,	O
reduced	O
,	O
oxidized	O
glutathione	B-CHEMICAL
and	O
catalase	O
activity	O
in	O
erythrocyte	O
lysate	O
were	O
assessed	O
in	O
the	O
1st	O
,	O
3rd	O
,	O
5th	O
and	O
8thday	O
after	O
sepsis	O
appearance	O
.	O

A	O
total	O
of	O
17	O
patients	O
were	O
divided	O
in	O
two	O
groups	O
:	O
survivors	O
(	O
n	O
=	O
7	O
)	O
and	O
non	O
-	O
survivors	O
(	O
n	O
=	O
10	O
)	O
.	O

APACHE	O
II	O
was	O
11	O
.	O
5	O
±	O
5	O
.	O
4	O
and	O
19	O
.	O
9	O
±	O
4	O
.	O
97	O
in	O
survivors	O
and	O
non	O
-	O
survivors	O
respectively	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
while	O
mean	O
age	O
and	O
SOFA	O
score	O
at	O
sepsis	O
diagnosis	O
,	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

GSH	B-CHEMICAL
levels	O
,	O
catalase	O
activity	O
and	O
protein	O
carbonyls	B-CHEMICAL
presented	O
significant	O
different	O
course	O
in	O
time	O
between	O
survivors	O
and	O
non	O
-	O
survivors	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Catalase	B-GENE-Y
activity	O
was	O
significantly	O
higher	O
in	O
survivors	O
(	O
238	O
.	O
8	O
±	O
51	O
.	O
5	O
)	O
than	O
non	O
-	O
survivors	O
(	O
166	O
.	O
4	O
±	O
40	O
.	O
2	O
;	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
while	O
protein	O
carbonyls	B-CHEMICAL
levels	O
were	O
significantly	O
lower	O
in	O
survivors	O
(	O
0	O
.	O
32	O
±	O
0	O
.	O
09	O
)	O
than	O
non	O
-	O
survivors	O
(	O
0	O
.	O
48	O
±	O
0	O
.	O
16	O
;	O
p	O
=	O
0	O
.	O
036	O
)	O
on	O
the	O
1stday	O
.	O

Yet	O
,	O
non	O
-	O
survivors	O
exhibited	O
a	O
declining	O
course	O
in	O
GSH	B-CHEMICAL
levels	O
during	O
time	O
,	O
while	O
GSH	B-CHEMICAL
levels	O
were	O
maintained	O
in	O
survivors	O
.	O

Conclusively	O
,	O
a	O
longstanding	O
antioxidant	O
deficiency	O
in	O
non	O
-	O
surviving	O
patients	O
was	O
noted	O
.	O

This	O
phenomenon	O
was	O
clearly	O
prominent	O
in	O
patients	O
'	O
erythrocytes	O
.	O

Ethanol	B-CHEMICAL
extract	O
of	O
Adiantum	O
capillus	O
-	O
veneris	O
L	O
.	O
suppresses	O
the	O
production	O
of	O
inflammatory	O
mediators	O
by	O
inhibiting	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Adiantum	O
capillus	O
-	O
veneris	O
L	O
.	O

is	O
a	O
wildly	O
distributed	O
plant	O
species	O
and	O
has	O
been	O
extensively	O
used	O
in	O
south	O
of	O
China	O
as	O
traditional	O
folk	O
medicine	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
To	O
investigate	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
ethanolic	O
extracts	O
of	O
Adiantum	O
capillus	O
-	O
veneris	O
L	O
.	O
and	O
the	O
involvement	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
in	O
the	O
regulation	O
of	O
inflammation	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
plant	O
ethanolic	O
extracts	O
were	O
initially	O
tested	O
against	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
induced	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
(	O
PGE2	B-CHEMICAL
)	O
production	O
in	O
RAW264	O
.	O
7	O
mouse	O
macrophages	O
,	O
and	O
interleukin	B-GENE-Y
6	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
)	O
and	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
(	O
TNF	B-GENE-Y
)	O
production	O
in	O
human	O
U937	O
monocytes	O
.	O

The	O
effect	O
of	O
the	O
plant	O
extracts	O
on	O
the	O
transcription	O
factor	O
nuclear	B-GENE-N
factor	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
(	B-GENE-N
NF	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
pathway	O
was	O
evaluated	O
in	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
stimulated	O
HepG2	O
cells	O
by	O
luciferase	O
gene	O
reporter	O
assay	O
and	O
Western	O
blotting	O
at	O
the	O
transcriptional	O
and	O
translational	O
levels	O
.	O

Subsequently	O
,	O
the	O
inhibition	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
downstream	O
gene	O
expression	O
(	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
and	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
by	O
the	O
plant	O
extracts	O
was	O
assessed	O
via	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
qPCR	O
)	O
.	O

Lastly	O
,	O
the	O
anti	O
-	O
inflammatory	O
activities	O
of	O
the	O
plant	O
extracts	O
in	O
vivo	O
were	O
evaluated	O
by	O
testing	O
spleen	O
index	O
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
related	O
protein	O
expression	O
in	O
LPS	O
-	O
stimulated	O
CD1	O
mice	O
.	O

RESULTS	O
:	O
The	O
plant	O
ethanolic	O
extracts	O
effectively	O
suppressed	O
PGE2	B-CHEMICAL
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
and	O
TNF	B-GENE-Y
release	O
with	O
an	O
IC50	O
less	O
than	O
50μg	O
/	O
ml	O
.	O

Moreover	O
,	O
luciferase	O
expression	O
could	O
be	O
specifically	O
blocked	O
in	O
HepG2	O
cells	O
,	O
not	O
in	O
HEK293	O
cells	O
,	O
showing	O
that	O
the	O
plant	O
extracts	O
displayed	O
a	O
cell	O
-	O
specific	O
pattern	O
on	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
gene	O
transcription	O
.	O

The	O
assayed	O
biological	O
activity	O
also	O
depended	O
on	O
the	O
order	O
of	O
adding	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
and	O
the	O
plant	O
extracts	O
because	O
the	O
plant	O
extracts	O
could	O
only	O
block	O
the	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
if	O
added	O
earlier	O
but	O
were	O
unable	O
to	O
stop	O
the	O
signal	O
when	O
added	O
after	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
.	O

However	O
,	O
the	O
plant	O
extracts	O
did	O
not	O
exert	O
any	O
effect	O
on	O
ubiquitination	O
which	O
regulates	O
several	O
steps	O
in	O
the	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
pathway	O
.	O

Additionally	O
,	O
the	O
plant	O
extracts	O
down	O
-	O
regulated	O
phosphorylation	O
of	O
IKKα	B-GENE-N
/	I-GENE-N
β	I-GENE-N
at	O
S176	O
/	O
180	O
,	O
p38	B-GENE-N
at	O
T180	O
/	O
Y182	O
and	O
p65	B-GENE-Y
at	O
S536	O
,	O
but	O
not	O
p65	B-GENE-Y
at	O
S276	O
.	O

This	O
was	O
confirmed	O
by	O
their	O
ability	O
to	O
selectively	O
abrogate	O
the	O
induction	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
transcription	O
,	O
whereas	O
the	O
ICAM	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
gene	O
,	O
which	O
is	O
not	O
transcribed	O
selectively	O
by	O
an	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
complex	O
containing	O
a	O
form	O
of	O
p65	B-GENE-Y
phosphorylated	O
on	O
Ser536	B-CHEMICAL
,	O
did	O
not	O
change	O
.	O

Finally	O
,	O
the	O
plant	O
extracts	O
at	O
200μg	O
/	O
mg	O
could	O
normalize	O
the	O
LPS	O
-	O
induced	O
elevation	O
of	O
spleen	O
index	O
as	O
well	O
as	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
and	O
p38	B-GENE-N
activations	O
in	O
CD1	O
mice	O
.	O

CONCLUSION	O
:	O
The	O
present	O
studies	O
presents	O
the	O
potential	O
utilization	O
of	O
this	O
plant	O
extracts	O
,	O
as	O
a	O
natural	O
resources	O
for	O
the	O
development	O
of	O
an	O
anti	O
-	O
inflammatory	O
medicine	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
hexamethoxyflavone	I-CHEMICAL
inhibits	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
production	O
in	O
lipopolysaccharide	O
-	O
stimulated	O
BV2	O
microglia	O
via	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
suppression	O
and	O
Nrf	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
dependent	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
induction	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
'	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
hexamethoxyflavone	I-CHEMICAL
(	O
5HHMF	B-CHEMICAL
)	O
from	O
Hizikia	O
fusiforme	O
considerably	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
NO	B-CHEMICAL
production	O
by	O
suppressing	O
the	O
expression	O
of	O
inducible	B-GENE-Y
NO	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
in	O
BV2	O
microglia	O
.	O

In	O
addition	O
,	O
5HHMF	B-CHEMICAL
blocked	O
LPS	O
-	O
induced	O
phosphorylation	O
of	O
IκB	B-GENE-N
,	O
resulting	O
in	O
suppression	O
of	O
the	O
nuclear	O
translocation	O
of	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
κB	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
subunits	O
,	O
namely	O
p65	B-GENE-Y
and	O
p50	B-GENE-Y
,	O
which	O
are	O
important	O
molecules	O
involved	O
in	O
the	O
regulation	O
of	O
iNOS	B-GENE-Y
expression	O
.	O

Pyrrolidine	B-CHEMICAL
dithiocarbamate	I-CHEMICAL
(	O
PDTC	B-CHEMICAL
)	O
,	O
a	O
specific	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
inhibitor	O
,	O
along	O
with	O
20S	B-GENE-N
proteasome	I-GENE-N
inhibitor	O
(	O
PSI	O
)	O
significantly	O
inhibited	O
LPS	O
-	O
induced	O
iNOS	B-GENE-Y
expression	O
,	O
which	O
indirectly	O
suggested	O
that	O
5HHMF	B-CHEMICAL
downregulated	O
iNOS	B-GENE-Y
expression	O
by	O
suppressing	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activity	O
.	O

Thus	O
,	O
we	O
found	O
that	O
5HHMF	B-CHEMICAL
enhances	O
heme	B-GENE-Y
oxygenase	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
expression	O
via	O
nuclear	B-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
erythroid	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
Nrf2	B-GENE-Y
)	O
activation	O
.	O

In	O
addition	O
,	O
cobalt	B-CHEMICAL
protoporphyrin	I-CHEMICAL
(	O
CoPP	B-CHEMICAL
)	O
,	O
a	O
specific	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inducer	O
,	O
predominantly	O
suppressed	O
LPS	O
-	O
induced	O
NO	B-CHEMICAL
production	O
.	O

In	O
contrast	O
,	O
zinc	B-CHEMICAL
protoporphyrin	I-CHEMICAL
(	O
ZnPP	B-CHEMICAL
)	O
,	O
a	O
specific	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
inhibitor	O
,	O
showed	O
a	O
partial	O
suppressive	O
effect	O
of	O
5HHMF	B-CHEMICAL
on	O
LPS	O
-	O
induced	O
NO	B-CHEMICAL
production	O
.	O

Further	O
,	O
5HHMF	B-CHEMICAL
increased	O
specific	O
DNA	O
-	O
binding	O
activity	O
of	O
Nrf2	B-GENE-Y
,	O
and	O
transient	O
knockdown	O
with	O
Nrf2	B-GENE-Y
siRNA	O
subsequently	O
reversed	O
5HHMF	B-CHEMICAL
-	O
induced	O
NO	B-CHEMICAL
inhibition	O
,	O
which	O
was	O
followed	O
by	O
suppression	O
of	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
5HHMF	B-CHEMICAL
suppresses	O
NO	B-CHEMICAL
production	O
through	O
modulation	O
of	O
iNOS	B-GENE-Y
,	O
consequently	O
suppressing	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activity	O
and	O
induction	O
of	O
Nrf2	B-GENE-Y
-	O
dependent	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
.	O

A	O
novel	O
method	O
for	O
preparing	O
complete	O
antigens	O
of	O
gonyautoxin	B-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
and	O
their	O
feature	O
of	O
immunogenicity	O
.	O

In	O
this	O
paper	O
,	O
a	O
novel	O
method	O
was	O
proposed	O
to	O
prepare	O
artificial	O
antigens	O
of	O
gonyaulax	O
parlaytic	O
shellfish	O
toxin	O
2	O
and	O
3	O
(	O
GTX2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
)	O
.	O

An	O
intermediate	O
GTX2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
aldehyde	I-CHEMICAL
was	O
first	O
synthesized	O
by	O
activating	O
the	O
NH2	B-CHEMICAL
group	O
of	O
the	O
2nd	O
and	O
8th	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residues	O
with	O
three	O
different	O
aldehydes	B-CHEMICAL
and	O
two	O
artificial	O
complete	O
antigens	O
GTX2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
aldehyde	I-CHEMICAL
-	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
BSA	B-GENE-Y
)	O
and	O
GTX2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
aldehyde	I-CHEMICAL
-	O
keyhole	B-GENE-N
limpet	I-GENE-N
hemocyanin	I-GENE-N
(	O
KLH	B-GENE-N
)	O
were	O
then	O
prepared	O
by	O
cross	O
-	O
linking	O
the	O
intermediate	O
with	O
BSA	B-GENE-Y
or	O
KLH	B-GENE-N
.	O

The	O
successful	O
preparation	O
of	O
the	O
two	O
complete	O
antigens	O
was	O
confirmed	O
by	O
UV	O
spectral	O
scanning	O
,	O
HPLC	O
,	O
production	O
of	O
antibodies	O
with	O
titer	O
of	O
1	O
.	O
28	O
×	O
10	O
(	O
4	O
)	O
from	O
mice	O
immunized	O
with	O
the	O
two	O
complete	O
antigens	O
,	O
indirect	O
ELISA	O
and	O
Western	O
-	O
blot	O
.	O

In	O
conclusion	O
,	O
the	O
synthesized	O
complete	O
antigens	O
have	O
strong	O
immunogenicity	O
,	O
which	O
provides	O
a	O
solid	O
foundation	O
for	O
preparing	O
GTX2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
monoclonal	O
antibody	O
and	O
rapid	O
detection	O
kit	O
.	O

A	O
Re	O
-	O
evaluation	O
of	O
the	O
Role	O
of	O
hCTR1	B-GENE-Y
,	O
the	O
Human	B-GENE-N
High	I-GENE-N
Affinity	I-GENE-N
Cu	I-GENE-N
Transporter	I-GENE-N
in	O
Pt	B-CHEMICAL
-	O
Drug	O
Entry	O
into	O
Human	O
Cells	O
.	O

Cisplatin	B-CHEMICAL
(	O
cDDP	B-CHEMICAL
)	O
is	O
an	O
anti	O
-	O
cancer	O
drug	O
used	O
in	O
a	O
number	O
of	O
malignancies	O
including	O
testicular	O
,	O
ovarian	O
,	O
cervical	O
,	O
bladder	O
,	O
lung	O
,	O
head	O
,	O
and	O
neck	O
cancers	O
.	O

Its	O
use	O
is	O
limited	O
by	O
the	O
development	O
of	O
resistance	O
,	O
often	O
rationalized	O
via	O
effects	O
on	O
cellular	O
uptake	O
.	O

It	O
has	O
been	O
claimed	O
that	O
hCTR1	B-GENE-Y
,	O
the	O
human	B-GENE-N
high	I-GENE-N
affinity	I-GENE-N
copper	I-GENE-N
transporter	I-GENE-N
,	O
is	O
the	O
major	O
entry	O
pathway	O
for	O
cDDP	B-CHEMICAL
and	O
related	O
drugs	O
via	O
a	O
mechanism	O
that	O
mimics	O
copper	O
.	O

This	O
is	O
an	O
unexpected	O
property	O
of	O
hCTR1	B-GENE-Y
,	O
a	O
highly	O
selective	O
copper	B-GENE-N
(	I-GENE-N
I	I-GENE-N
)	I-GENE-N
transporter	I-GENE-N
.	O

We	O
compared	O
the	O
uptake	O
rates	O
of	O
copper	O
with	O
cDDP	O
(	O
and	O
several	O
analogs	O
)	O
into	O
HEK293	O
cells	O
over	O
-	O
expressing	O
wild	O
-	O
type	O
or	O
mutant	O
hCTR1	B-GENE-Y
,	O
mouse	O
embryonic	O
fibroblasts	O
(	O
mefs	O
)	O
that	O
do	O
or	O
do	O
not	O
express	O
CTR1	B-GENE-Y
,	O
and	O
human	O
ovarian	O
tumor	O
cells	O
,	O
sensitive	O
or	O
resistant	O
to	O
cDDP	B-CHEMICAL
.	O

We	O
have	O
also	O
compared	O
the	O
effects	O
of	O
extracellular	O
copper	B-CHEMICAL
,	O
which	O
causes	O
regulatory	O
endocytosis	O
of	O
hCTR1	B-GENE-Y
,	O
to	O
those	O
of	O
cDDP	B-CHEMICAL
.	O

We	O
confirm	O
the	O
correlation	O
between	O
higher	O
hCTR1	B-GENE-Y
levels	O
and	O
higher	O
Pt	B-CHEMICAL
-	O
drug	O
uptake	O
in	O
tumor	O
cells	O
sensitive	O
to	O
the	O
drug	O
.	O

However	O
,	O
we	O
show	O
that	O
hCTR1	B-GENE-Y
is	O
not	O
the	O
major	O
entry	O
route	O
of	O
platinum	B-CHEMICAL
-	O
drugs	O
and	O
that	O
the	O
copper	B-CHEMICAL
transporter	O
is	O
not	O
internalized	O
in	O
response	O
to	O
extracellular	O
drug	O
.	O

Our	O
data	O
suggest	O
the	O
major	O
entry	O
pathway	O
for	O
platinum	B-CHEMICAL
-	O
drugs	O
is	O
not	O
saturable	O
at	O
relevant	O
concentrations	O
and	O
not	O
protein	O
-	O
mediated	O
.	O

Clinical	O
trials	O
have	O
been	O
initiated	O
that	O
depend	O
upon	O
regulating	O
membrane	O
levels	O
of	O
hCTR1	B-GENE-Y
.	O

If	O
reduced	O
drug	O
uptake	O
is	O
a	O
major	O
factor	O
in	O
resistance	O
,	O
hCTR1	B-GENE-Y
is	O
unlikely	O
to	O
be	O
a	O
productive	O
target	O
in	O
attempts	O
to	O
enhance	O
efficacy	O
,	O
although	O
the	O
proteins	O
involved	O
in	O
copper	B-CHEMICAL
homeostasis	O
may	O
play	O
a	O
role	O
.	O

Identification	O
of	O
a	O
new	O
interaction	O
mode	O
between	O
the	O
Src	B-GENE-N
homology	I-GENE-N
2	I-GENE-N
(	I-GENE-N
SH2	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
of	O
C	B-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
Src	I-GENE-Y
kinase	I-GENE-Y
(	O
Csk	B-GENE-Y
)	O
and	O
Csk	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	O
Cbp	B-GENE-Y
)	O
/	O
phosphoprotein	B-GENE-Y
associated	I-GENE-Y
with	I-GENE-Y
glycosphingolipid	I-GENE-Y
microdomains	I-GENE-Y
(	O
PAG	B-GENE-Y
)	O
.	O

Proteins	O
with	O
Src	B-GENE-N
homology	I-GENE-N
2	I-GENE-N
(	I-GENE-N
SH2	I-GENE-N
)	I-GENE-N
domains	I-GENE-N
play	O
major	O
roles	O
in	O
tyrosine	B-GENE-N
kinase	I-GENE-N
signaling	O
.	O

Structures	O
of	O
many	O
SH2	B-GENE-N
domains	I-GENE-N
have	O
been	O
studied	O
,	O
and	O
the	O
regions	O
involved	O
in	O
their	O
interactions	O
with	O
ligands	O
have	O
been	O
elucidated	O
.	O

However	O
,	O
these	O
analyses	O
have	O
been	O
performed	O
using	O
short	O
peptides	O
comprising	O
phosphotyrosine	B-CHEMICAL
followed	O
by	O
a	O
few	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
which	O
are	O
described	O
as	O
the	O
canonical	O
recognition	O
sites	O
.	O

Here	O
we	O
report	O
the	O
solution	O
structure	O
of	O
the	O
SH2	B-GENE-N
domain	I-GENE-N
of	O
C	B-GENE-Y
-	I-GENE-Y
terminal	I-GENE-Y
Src	I-GENE-Y
kinase	I-GENE-Y
(	O
Csk	B-GENE-Y
)	O
in	O
complex	O
with	O
a	O
longer	O
phosphopeptide	O
from	O
Csk	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	O
Cbp	B-GENE-Y
)	O
.	O

This	O
structure	O
,	O
together	O
with	O
biochemical	O
experiments	O
,	O
revealed	O
the	O
existence	O
of	O
a	O
novel	O
binding	O
region	O
in	O
addition	O
to	O
the	O
canonical	O
phosphotyrosine	B-CHEMICAL
-	O
314	O
binding	O
site	O
of	O
Cbp	B-GENE-Y
.	O

Mutational	O
analysis	O
of	O
this	O
second	O
region	O
in	O
cells	O
showed	O
that	O
both	O
canonical	O
and	O
novel	O
binding	O
sites	O
are	O
required	O
for	O
tumor	O
suppression	O
through	O
the	O
Cbp	B-GENE-Y
-	O
Csk	B-GENE-Y
interaction	O
.	O

Furthermore	O
,	O
the	O
data	O
indicate	O
an	O
allosteric	O
connection	O
between	O
Cbp	B-GENE-Y
binding	O
and	O
Csk	B-GENE-Y
activation	O
that	O
arises	O
from	O
residues	O
in	O
the	O
βB	O
/	O
βC	O
loop	O
of	O
the	O
SH2	B-GENE-N
domain	I-GENE-N
.	O

2	B-CHEMICAL
-	I-CHEMICAL
Hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylanthraquinone	I-CHEMICAL
from	O
Hedyotis	O
diffusa	O
Willd	O
induces	O
apoptosis	O
in	O
human	O
leukemic	O
U937	O
cells	O
through	O
modulation	O
of	O
MAPK	B-GENE-N
pathways	O
.	O

The	O
herb	O
of	O
Hedyotis	O
diffusa	O
Willd	O
(	O
H	O
.	O
diffusa	O
Willd	O
)	O
,	O
an	O
annual	O
herb	O
distributed	O
in	O
northeastern	O
Asia	O
,	O
has	O
been	O
known	O
as	O
a	O
traditional	O
oriental	O
medicine	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Recently	O
,	O
Chinese	O
researchers	O
have	O
discovered	O
that	O
two	O
anthraquinones	B-CHEMICAL
isolated	O
from	O
a	O
water	O
extract	O
of	O
H	O
.	O
diffusa	O
Willd	O
showed	O
apoptosis	O
-	O
inducing	O
effects	O
against	O
cancer	O
cells	O
.	O

However	O
,	O
the	O
cellular	O
and	O
molecular	O
mechanisms	O
responsible	O
for	O
this	O
phenomenon	O
are	O
poorly	O
understood	O
.	O

The	O
current	O
study	O
determines	O
the	O
role	O
of	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
(	O
MAPK	B-GENE-N
)	O
in	O
human	O
leukemic	O
U937	O
cells	O
apoptosis	O
induced	O
by	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylanthraquinone	I-CHEMICAL
from	O
H	O
.	O
diffusa	O
.	O

Our	O
results	O
showed	O
that	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylanthraquinone	I-CHEMICAL
decreased	O
phosphorylation	O
-	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
(	O
p	B-GENE-N
-	I-GENE-N
ERK1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
,	O
and	O
increased	O
p	B-GENE-N
-	I-GENE-N
p38MAPK	I-GENE-N
,	O
but	O
did	O
not	O
affect	O
expressions	O
of	O
p	B-GENE-N
-	I-GENE-N
JNK1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
in	O
U937	O
cells	O
.	O

Moreover	O
,	O
treatment	O
of	O
U937	O
cells	O
with	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylanthraquinone	I-CHEMICAL
resulted	O
in	O
activation	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
.	O

Furthermore	O
,	O
PD98059	B-CHEMICAL
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
inhibitor	O
)	O
significantly	O
enhanced	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylanthraquinone	I-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
U937	O
cells	O
,	O
whereas	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
inhibitor	O
or	O
SB203580	B-CHEMICAL
(	O
p	B-GENE-N
-	I-GENE-N
p38MAPK	I-GENE-N
inhibitor	O
)	O
,	O
decreased	O
apoptosis	O
in	O
U937	O
cells	O
.	O

Taken	O
together	O
,	O
our	O
study	O
for	O
the	O
first	O
time	O
suggests	O
that	O
2	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
methylanthraquinone	I-CHEMICAL
is	O
able	O
to	O
enhance	O
apoptosis	O
of	O
U937	O
cells	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
activation	O
of	O
p	B-GENE-N
-	I-GENE-N
p38MAPK	I-GENE-N
and	O
downregulation	O
of	O
p	B-GENE-N
-	I-GENE-N
ERK1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
.	O

Moreover	O
,	O
the	O
triggering	O
of	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activation	O
mediated	O
apoptotic	O
induction	O
.	O

The	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
6	I-GENE-Y
Allele	O
Significantly	O
Alters	O
the	O
N	O
-	O
demethylation	O
of	O
Ketamine	B-CHEMICAL
Enantiomers	O
In	O
Vitro	O
.	O

Ketamine	B-CHEMICAL
is	O
primarily	O
metabolized	O
to	O
norketamine	B-CHEMICAL
by	O
hepatic	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
(	I-GENE-Y
CYP	I-GENE-Y
)	I-GENE-Y
2B6	I-GENE-Y
and	O
CYP3A4	B-GENE-Y
-	O
mediated	O
N	O
-	O
demethylation	O
.	O

However	O
,	O
the	O
relative	O
contribution	O
from	O
each	O
enzyme	O
remains	O
controversial	O
.	O

The	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
6	I-GENE-Y
allele	O
is	O
associated	O
with	O
reduced	O
enzyme	O
expression	O
and	O
activity	O
that	O
may	O
lead	O
to	O
interindividual	O
variability	O
in	O
ketamine	B-CHEMICAL
metabolism	O
.	O

We	O
examined	O
the	O
N	O
-	O
demethylation	O
of	O
individual	O
ketamine	B-CHEMICAL
enantiomers	O
using	O
human	O
liver	O
microsomes	O
(	O
HLMs	O
)	O
genotyped	O
for	O
the	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
6	I-GENE-Y
allele	O
,	O
insect	O
cell	O
expressed	O
recombinant	O
CYP2B6	B-GENE-Y
and	O
CYP3A4	B-GENE-Y
enzymes	O
and	O
COS	O
-	O
1	O
cell	O
expressed	O
recombinant	O
CYP2B6	B-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
and	O
CYP2B6	B-GENE-Y
.	I-GENE-Y
6	I-GENE-Y
protein	O
variant	O
.	O

Effects	O
of	O
CYP	B-GENE-N
-	O
selective	O
inhibitors	O
on	O
norketamine	B-CHEMICAL
formation	O
were	O
also	O
determined	O
in	O
HLMs	O
.	O

The	O
two	O
-	O
enzyme	O
Michaelis	O
-	O
Menten	O
model	O
best	O
fitted	O
the	O
HLM	O
kinetic	O
data	O
.	O

The	O
Km	O
value	O
for	O
the	O
high	O
affinity	O
enzyme	O
and	O
the	O
low	O
affinity	O
enzyme	O
were	O
similar	O
to	O
those	O
for	O
the	O
expressed	O
CYP2B6	B-GENE-Y
and	O
CYP3A4	B-GENE-Y
,	O
respectively	O
.	O

The	O
intrinsic	O
clearance	O
for	O
both	O
ketamine	B-CHEMICAL
enantiomers	O
by	O
the	O
high	O
affinity	O
enzyme	O
in	O
HLMs	O
with	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
1	I-GENE-Y
/	O
*	O
1	O
genotype	O
were	O
at	O
least	O
2	O
-	O
fold	O
and	O
6	O
-	O
fold	O
higher	O
,	O
respectively	O
,	O
than	O
those	O
for	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
1	I-GENE-Y
/	O
*	O
6	O
genotype	O
and	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
6	I-GENE-Y
/	O
*	O
6	O
genotype	O
.	O

The	O
Vmax	O
and	O
Km	O
values	O
for	O
CYP2B6	B-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
were	O
approximately	O
160	O
%	O
and	O
70	O
%	O
of	O
those	O
for	O
CYP2B6	B-GENE-Y
.	I-GENE-Y
6	I-GENE-Y
,	O
respectively	O
.	O

ThioTEPA	B-CHEMICAL
(	O
CYP2B6	B-GENE-Y
inhibitor	O
,	O
25	O
μM	O
)	O
and	O
the	O
monoclonal	O
antibody	O
against	O
CYP2B6	B-GENE-Y
but	O
not	O
troleandomycin	B-CHEMICAL
(	O
CYP3A4	B-GENE-Y
inhibitor	O
,	O
25	O
μM	O
)	O
or	O
the	O
monoclonal	O
antibody	O
against	O
CYP3A4	B-GENE-Y
inhibited	O
ketamine	B-CHEMICAL
N	O
-	O
demethylation	O
at	O
clinically	O
relevant	O
concentrations	O
.	O

The	O
degree	O
of	O
inhibition	O
was	O
significantly	O
reduced	O
in	O
HLMs	O
with	O
the	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
6	I-GENE-Y
allele	O
(	O
gene	O
-	O
dose	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
indicate	O
a	O
major	O
role	O
of	O
CYP2B6	B-GENE-Y
in	O
ketamine	B-CHEMICAL
N	O
-	O
demethylation	O
in	O
vitro	O
and	O
a	O
significant	O
impact	O
of	O
the	O
CYP2B6	B-GENE-Y
*	I-GENE-Y
6	I-GENE-Y
allele	O
on	O
enzyme	O
-	O
ketamine	B-CHEMICAL
binding	O
and	O
catalytic	O
activity	O
.	O

A	O
high	O
throughput	O
assay	O
for	O
the	O
glucuronidation	O
of	O
7	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
trifluoromethylcoumarin	I-CHEMICAL
by	O
recombinant	O
human	B-GENE-N
UDP	I-GENE-N
-	I-GENE-N
glucuronosyltransferases	I-GENE-N
and	O
liver	O
microsomes	O
.	O

Abstract	O
1	O
.	O

UDP	B-GENE-N
-	I-GENE-N
glucuronosyltransferases	I-GENE-N
(	O
UGTs	B-GENE-N
)	O
are	O
versatile	O
and	O
important	O
conjugation	O
enzymes	O
in	O
the	O
metabolism	O
of	O
drugs	O
and	O
other	O
xenobiotics	O
.	O

2	O
.	O

We	O
have	O
developed	O
a	O
convenient	O
quantitative	O
multi	O
-	O
well	O
plate	O
assay	O
to	O
measure	O
the	O
glucuronidation	O
rate	O
of	O
7	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
trifluoromethylcoumarin	I-CHEMICAL
(	O
HFC	B-CHEMICAL
)	O
for	O
several	O
UGTs	B-GENE-N
.	O

3	O
.	O

We	O
have	O
used	O
this	O
method	O
to	O
screen	O
11	O
recombinant	O
human	B-GENE-N
UGTs	I-GENE-N
for	O
HFC	B-CHEMICAL
glucuronidation	O
activity	O
and	O
studied	O
the	O
reaction	O
kinetics	O
with	O
the	O
most	O
active	O
enzymes	O
.	O

We	O
have	O
also	O
examined	O
the	O
HFC	B-CHEMICAL
glucuronidation	O
activity	O
of	O
liver	O
microsomes	O
from	O
human	O
,	O
pig	O
,	O
rabbit	O
and	O
rat	O
.	O

4	O
.	O

At	O
a	O
substrate	O
concentration	O
of	O
20	O
µM	O
,	O
the	O
most	O
active	O
HFC	B-CHEMICAL
glucuronidation	O
catalysts	O
were	O
UGT1A10	B-GENE-Y
followed	O
by	O
UGT1A6	B-GENE-Y
>	O
UGT1A7	B-GENE-Y
>	O
UGT2A1	B-GENE-Y
,	O
whereas	O
at	O
300	O
µM	O
UGT1A6	B-GENE-Y
was	O
about	O
10	O
times	O
better	O
catalyst	O
than	O
the	O
other	O
recombinant	O
UGTs	B-GENE-N
.	O

The	O
activities	O
of	O
UGTs	B-GENE-N
1A3	I-GENE-N
,	I-GENE-N
1A8	I-GENE-N
,	I-GENE-N
1A9	I-GENE-N
,	I-GENE-N
2B4	I-GENE-N
and	I-GENE-N
2B7	I-GENE-N
were	O
low	O
,	O
whereas	O
UGT1A1	B-GENE-Y
and	O
UGT2B17	B-GENE-Y
exhibited	O
no	O
HFC	B-CHEMICAL
glucuronidation	O
activity	O
.	O

UGT1A6	B-GENE-Y
exhibited	O
a	O
significantly	O
higher	O
Vmax	O
and	O
Km	O
values	O
toward	O
both	O
HFC	B-CHEMICAL
and	O
UDP	B-CHEMICAL
-	O
glucuronic	B-CHEMICAL
acid	I-CHEMICAL
than	O
the	O
other	O
UGTs	B-GENE-N
.	O

5	O
.	O

Human	O
,	O
pig	O
and	O
rabbit	O
,	O
but	O
not	O
rat	O
liver	O
microsomes	O
,	O
catalyzed	O
HFC	B-CHEMICAL
glucuronidation	O
at	O
high	O
rates	O
.	O

6	O
.	O

This	O
new	O
method	O
is	O
particularly	O
suitable	O
for	O
fast	O
activity	O
screenings	O
of	O
UGTs	B-GENE-N
1A6	I-GENE-N
,	I-GENE-N
1A7	I-GENE-N
,	I-GENE-N
1A10	I-GENE-N
and	I-GENE-N
2A1	I-GENE-N
and	O
HFC	B-CHEMICAL
glucuronidation	O
activity	O
determination	O
from	O
various	O
samples	O
.	O

Low	O
-	O
Dose	O
Dexamethasone	B-CHEMICAL
Treatment	O
Promotes	O
Pro	O
-	O
Survival	O
Signalling	O
Pathway	O
In	O
Adult	O
Rat	O
Prefrontal	O
Cortex	O
.	O

Synthetic	O
glucocorticoid	O
dexamethasone	B-CHEMICAL
(	O
DEX	B-CHEMICAL
)	O
,	O
a	O
highly	O
potent	O
anti	O
-	O
inflammatory	O
and	O
immunosuppressive	O
agent	O
,	O
is	O
widely	O
used	O
in	O
treatments	O
of	O
brain	O
cancer	O
,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O

The	O
objective	O
of	O
the	O
current	O
study	O
was	O
to	O
determine	O
whether	O
a	O
low	O
-	O
dose	O
subchronic	O
DEX	B-CHEMICAL
treatment	O
(	O
100	O
μg	O
/	O
kg	O
for	O
8	O
consecutive	O
days	O
)	O
exerts	O
long	O
-	O
term	O
effects	O
on	O
apoptosis	O
in	O
the	O
adult	O
rat	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
by	O
examining	O
the	O
expression	O
of	O
cell	O
death	O
-	O
promoting	O
molecules	O
(	O
poly	B-GENE-N
(	I-GENE-N
ADP	I-GENE-N
-	I-GENE-N
ribose	I-GENE-N
)	I-GENE-N
polymerase	I-GENE-N
(	O
PARP	B-GENE-N
)	O
,	O
p53	B-GENE-Y
,	O
procaspase	B-GENE-Y
3	I-GENE-Y
,	O
cleaved	O
caspase	B-GENE-Y
3	I-GENE-Y
,	O
Bax	B-GENE-Y
)	O
and	O
cell	O
-	O
survival	O
molecules	O
(	O
AKT	B-GENE-N
,	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

Our	O
results	O
revealed	O
that	O
body	O
,	O
thymus	O
and	O
adrenal	O
weight	O
as	O
well	O
corticosterone	B-CHEMICAL
level	O
in	O
the	O
serum	O
and	O
PFC	O
were	O
reduced	O
a	O
day	O
following	O
last	O
DEX	B-CHEMICAL
injection	O
.	O

In	O
PFC	O
,	O
DEX	B-CHEMICAL
caused	O
activation	O
of	O
AKT	B-GENE-N
,	O
augmentation	O
of	O
pro	O
-	O
survival	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
protein	O
and	O
enhanced	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
/	O
Bax	B-GENE-Y
protein	O
ratio	O
,	O
as	O
well	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
translocation	O
to	O
mitochondria	O
.	O

The	O
unaltered	O
profile	O
in	O
the	O
protein	O
expression	O
of	O
apoptotic	O
molecules	O
PARP	B-GENE-N
,	O
procaspase	B-GENE-Y
3	I-GENE-Y
and	O
Bax	B-GENE-Y
was	O
detected	O
,	O
while	O
the	O
p53	B-GENE-Y
protein	O
was	O
decreased	O
.	O

Results	O
of	O
RT	O
-	O
PCR	O
analysis	O
showed	O
decrease	O
of	O
p53	B-GENE-Y
mRNA	O
level	O
and	O
no	O
significant	O
difference	O
in	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
Bax	B-GENE-Y
mRNA	O
expressions	O
in	O
DEX	B-CHEMICAL
-	O
treated	O
rats	O
.	O

Finally	O
,	O
the	O
DNA	O
fragmentation	O
assay	O
and	O
Fluoro	O
-	O
Jade	O
staining	O
demonstrated	O
no	O
considerable	O
changes	O
in	O
the	O
apoptosis	O
in	O
rat	O
PFC	O
.	O

Our	O
findings	O
support	O
the	O
concept	O
that	O
a	O
low	O
-	O
dose	O
DEX	B-CHEMICAL
creates	O
the	O
hypocorticoid	O
state	O
in	O
the	O
brain	O
and	O
indicate	O
that	O
subchronic	O
DEX	B-CHEMICAL
treatment	O
activates	O
pro	O
-	O
survival	O
signalling	O
pathway	O
but	O
does	O
not	O
change	O
apoptotic	O
markers	O
in	O
rat	O
PFC	O
.	O

This	O
mechanism	O
might	O
be	O
relevant	O
for	O
DEX	B-CHEMICAL
-	O
induced	O
apoptosis	O
resistance	O
observed	O
during	O
and	O
after	O
chemotherapy	O
of	O
patients	O
with	O
brain	O
tumours	O
.	O

©	O
2013	O
British	O
Society	O
for	O
Neuroendocrinology	O
.	O

Cis	O
-	O
silencing	O
of	O
PIP5K1B	B-GENE-Y
evidenced	O
in	O
Friedreich	O
'	O
s	O
ataxia	O
patient	O
cells	O
results	O
in	O
cytoskeleton	O
anomalies	O
.	O

Friedreich	O
'	O
s	O
ataxia	O
(	O
FRDA	O
)	O
is	O
a	O
progressive	O
neurodegenerative	O
disease	O
characterized	O
by	O
ataxia	O
,	O
variously	O
associating	O
heart	O
disease	O
,	O
diabetes	O
mellitus	O
and	O
/	O
or	O
glucose	B-CHEMICAL
intolerance	O
.	O

It	O
results	O
from	O
intronic	O
expansion	O
of	O
GAA	B-GENE-N
triplet	I-GENE-N
repeats	I-GENE-N
at	O
the	O
FXN	B-GENE-Y
locus	O
.	O

Homozygous	O
expansions	O
cause	O
silencing	O
of	O
the	O
FXN	B-GENE-Y
gene	O
and	O
subsequent	O
decreased	O
expression	O
of	O
the	O
encoded	O
mitochondrial	O
frataxin	B-GENE-Y
.	O

Detailed	O
analyses	O
in	O
fibroblasts	O
and	O
neuronal	O
tissues	O
from	O
FRDA	O
patients	O
have	O
revealed	O
profound	O
cytoskeleton	O
anomalies	O
.	O

So	O
far	O
,	O
however	O
,	O
the	O
molecular	O
mechanism	O
underlying	O
these	O
cytoskeleton	O
defects	O
remains	O
unknown	O
.	O

We	O
show	O
here	O
that	O
gene	O
silencing	O
spreads	O
in	O
cis	O
over	O
the	O
PIP5K1B	B-GENE-Y
gene	O
in	O
cells	O
from	O
FRDA	O
patients	O
(	O
circulating	O
lymphocytes	O
and	O
primary	O
fibroblasts	O
)	O
,	O
correlating	O
with	O
expanded	O
GAA	O
repeat	O
size	O
.	O

PIP5K1B	B-GENE-Y
encodes	O
phosphatidylinositol	B-GENE-Y
4	I-GENE-Y
-	I-GENE-Y
phosphate	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
kinase	I-GENE-Y
β	I-GENE-Y
type	I-GENE-Y
I	I-GENE-Y
(	O
pip5k1β	B-GENE-Y
)	O
,	O
an	O
enzyme	O
functionally	O
linked	O
to	O
actin	B-GENE-N
cytoskeleton	O
dynamics	O
that	O
phosphorylates	O
phosphatidylinositol	B-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
[	O
PI	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
)	I-CHEMICAL
P	I-CHEMICAL
]	O
to	O
generate	O
phosphatidylinositol	B-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
bisphosphate	I-CHEMICAL
[	O
PI	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
P2	I-CHEMICAL
]	O
.	O

Accordingly	O
,	O
loss	O
of	O
pip5k1β	B-GENE-Y
function	O
in	O
FRDA	O
cells	O
was	O
accompanied	O
by	O
decreased	O
PI	B-CHEMICAL
(	I-CHEMICAL
4	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
)	I-CHEMICAL
P2	I-CHEMICAL
levels	O
and	O
was	O
shown	O
instrumental	O
for	O
destabilization	O
of	O
the	O
actin	O
network	O
and	O
delayed	O
cell	O
spreading	O
.	O

Knockdown	O
of	O
PIP5K1B	B-GENE-Y
in	O
control	O
fibroblasts	O
using	O
shRNA	O
reproduced	O
abnormal	O
actin	B-GENE-N
cytoskeleton	O
remodeling	O
,	O
whereas	O
over	O
-	O
expression	O
of	O
PIP5K1B	B-GENE-Y
,	O
but	O
not	O
FXN	B-GENE-Y
,	O
suppressed	O
this	O
phenotype	O
in	O
FRDA	O
cells	O
.	O

In	O
addition	O
to	O
provide	O
new	O
insights	O
into	O
the	O
consequences	O
of	O
the	O
FXN	B-GENE-Y
gene	O
expansion	O
,	O
these	O
findings	O
raise	O
the	O
question	O
whether	O
PIP5K1B	B-GENE-Y
silencing	O
may	O
contribute	O
to	O
the	O
variable	O
manifestation	O
of	O
this	O
complex	O
disease	O
.	O

Lipoxygenase	B-GENE-N
and	O
urease	B-GENE-N
inhibition	O
of	O
the	O
aerial	O
parts	O
of	O
the	O
Polygonatum	O
verticillatum	O
.	O

Over	O
expression	O
of	O
lipoxygenase	B-GENE-N
(	O
LOX	B-GENE-N
)	O
and	O
urease	B-GENE-N
has	O
already	O
contributed	O
to	O
the	O
pathology	O
of	O
different	O
human	O
disease	O
.	O

Targeting	O
the	O
inhibition	O
of	O
these	O
enzymes	O
has	O
proved	O
great	O
clinical	O
utility	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
scrutinised	O
the	O
inhibitory	O
profile	O
of	O
the	O
aerial	O
parts	O
of	O
the	O
Polygonatum	O
verticillatum	O
enzyme	O
against	O
LOX	B-GENE-N
,	O
urease	B-GENE-N
,	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
and	O
butyrylcholinesterase	B-GENE-Y
(	O
BChE	B-GENE-Y
)	O
using	O
standard	O
experimental	O
protocols	O
.	O

When	O
checked	O
against	O
lipoxygenase	B-GENE-N
,	O
the	O
extracts	O
revealed	O
significant	O
attenuation	O
.	O

Of	O
the	O
tested	O
extracts	O
,	O
the	O
ethyl	B-CHEMICAL
acetate	I-CHEMICAL
fraction	O
was	O
the	O
most	O
potent	O
(	O
half	O
-	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
:	O
97	O
µg	O
/	O
mL	O
)	O
followed	O
by	O
aqueous	O
fraction	O
IC50	O
:	O
109	O
µg	O
/	O
mL	O
)	O
.	O

Regarding	O
urease	B-GENE-N
inhibition	O
,	O
n	B-CHEMICAL
-	I-CHEMICAL
butanol	I-CHEMICAL
was	O
the	O
most	O
potent	O
fraction	O
(	O
IC50	O
:	O
97	O
µg	O
/	O
mL	O
)	O
.	O

However	O
,	O
the	O
extracts	O
did	O
not	O
show	O
significant	O
inhibition	O
on	O
AChE	B-GENE-Y
and	O
BChE	B-GENE-Y
.	O

In	O
the	O
preliminary	O
phytochemical	O
tests	O
,	O
the	O
aerial	O
parts	O
of	O
the	O
plant	O
showed	O
the	O
presence	O
of	O
saponins	B-CHEMICAL
,	O
alkaloids	O
,	O
flavonoids	B-CHEMICAL
,	O
phenols	B-CHEMICAL
,	O
tannins	B-CHEMICAL
and	O
terpenoids	B-CHEMICAL
.	O

The	O
current	O
findings	O
could	O
be	O
attributed	O
to	O
these	O
groups	O
of	O
compounds	O
.	O

Dioscin	B-CHEMICAL
-	O
induced	O
autophagy	O
mitigates	O
cell	O
apoptosis	O
through	O
modulation	O
of	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
and	O
ERK	B-GENE-N
and	O
JNK	B-GENE-N
signaling	O
pathways	O
in	O
human	O
lung	O
cancer	O
cell	O
lines	O
.	O

Our	O
previous	O
study	O
has	O
revealed	O
that	O
dioscin	B-CHEMICAL
,	O
a	O
compound	O
with	O
anti	O
-	O
inflammatory	O
,	O
lipid	O
-	O
lowering	O
,	O
anticancer	O
and	O
hepatoprotective	O
effects	O
,	O
may	O
induce	O
autophagy	O
in	O
hepatoma	O
cells	O
.	O

Autophagy	O
is	O
a	O
lysosomal	O
degradation	O
pathway	O
that	O
is	O
essential	O
for	O
cell	O
survival	O
and	O
tissue	O
homeostasis	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
autophagy	O
and	O
related	O
signaling	O
pathways	O
during	O
dioscin	B-CHEMICAL
-	O
induced	O
apoptosis	O
in	O
human	O
lung	O
cancer	O
cells	O
was	O
investigated	O
.	O

Results	O
from	O
4	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
diamidino	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
phenylindole	I-CHEMICAL
and	O
annexin	O
-	O
V	O
/	O
PI	O
double	O
-	O
staining	O
assay	O
showed	O
that	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
-	O
and	O
caspase	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
-	O
dependent	O
,	O
and	O
dose	O
-	O
dependent	O
apoptoses	O
were	O
detected	O
after	O
a	O
24	O
-	O
h	O
dioscin	B-CHEMICAL
treatment	O
.	O

Meanwhile	O
,	O
autophagy	O
was	O
detected	O
as	O
early	O
as	O
12	O
h	O
after	O
an	O
exposure	O
to	O
low	O
-	O
dose	O
dioscin	B-CHEMICAL
,	O
as	O
indicated	O
by	O
an	O
up	O
-	O
regulated	O
expression	O
of	O
LC3	B-GENE-Y
-	I-GENE-Y
II	I-GENE-Y
and	O
beclin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
proteins	O
.	O

Blockade	O
of	O
autophagy	O
with	O
bafilomycin	B-CHEMICAL
A1	I-CHEMICAL
or	O
3	B-CHEMICAL
-	I-CHEMICAL
methyladenine	I-CHEMICAL
sensitized	O
the	O
A549	O
and	O
H1299	O
cells	O
to	O
apoptosis	O
.	O

Treatment	O
of	O
A549	O
and	O
H1299	O
cells	O
with	O
dioscin	B-CHEMICAL
caused	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
JNK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activity	O
,	O
accompanied	O
with	O
a	O
decreased	O
PI3K	B-GENE-N
expression	O
and	O
decreased	O
phosphorylation	O
of	O
Akt	B-GENE-N
and	O
mTOR	B-GENE-N
.	O

Taken	O
together	O
,	O
this	O
study	O
demonstrated	O
for	O
the	O
first	O
time	O
that	O
autophagy	O
occurred	O
earlier	O
than	O
apoptosis	O
during	O
dioscin	B-CHEMICAL
-	O
induced	O
human	O
lung	O
cancer	O
cell	O
line	O
apoptosis	O
.	O

Dioscin	B-CHEMICAL
-	O
induced	O
autophagy	O
via	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
and	O
JNK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
pathways	O
may	O
provide	O
a	O
protective	O
mechanism	O
for	O
cell	O
survival	O
against	O
dioscin	B-CHEMICAL
-	O
induced	O
apoptosis	O
to	O
act	O
as	O
a	O
cytoprotective	O
reaction	O
.	O

Furanodiene	B-CHEMICAL
Presents	O
Synergistic	O
Anti	O
-	O
proliferative	O
Activity	O
With	O
Paclitaxel	B-CHEMICAL
Via	O
Altering	O
Cell	O
Cycle	O
and	O
Integrin	B-GENE-N
Signaling	O
in	O
95	O
-	O
D	O
Lung	O
Cancer	O
Cells	O
.	O

Furanodiene	B-CHEMICAL
(	O
FUR	B-CHEMICAL
)	O
is	O
a	O
natural	O
terpenoid	B-CHEMICAL
isolated	O
from	O
Rhizoma	O
Curcumae	O
,	O
a	O
well	O
-	O
known	O
Chinese	O
medicinal	O
herb	O
that	O
presents	O
anti	O
-	O
proliferative	O
activities	O
in	O
several	O
cancer	O
cell	O
lines	O
.	O

Recently	O
,	O
we	O
found	O
that	O
the	O
combined	O
treatment	O
of	O
FUR	B-CHEMICAL
with	O
paclitaxel	B-CHEMICAL
(	O
TAX	B-CHEMICAL
)	O
showed	O
synergetic	O
anti	O
-	O
proliferative	O
activities	O
in	O
95	O
-	O
D	O
lung	O
cancer	O
cells	O
.	O

Herein	O
,	O
we	O
showed	O
that	O
FUR	B-CHEMICAL
reduced	O
the	O
cell	O
numbers	O
distributed	O
in	O
mitosis	O
phase	O
induced	O
by	O
TAX	B-CHEMICAL
while	O
increased	O
those	O
in	O
G1	O
phase	O
.	O

The	O
protein	O
levels	O
of	O
cyclin	B-GENE-Y
D1	I-GENE-Y
,	O
cyclin	B-GENE-Y
B1	I-GENE-Y
,	O
CDK6	B-GENE-Y
and	O
c	B-GENE-Y
-	I-GENE-Y
Myc	I-GENE-Y
were	O
all	O
down	O
-	O
regulated	O
in	O
the	O
group	O
of	O
combined	O
treatment	O
.	O

The	O
dramatically	O
down	O
-	O
regulated	O
expression	O
of	O
integrin	B-GENE-Y
β4	I-GENE-Y
,	O
focal	B-GENE-Y
adhesion	I-GENE-Y
kinase	I-GENE-Y
and	O
paxillin	B-GENE-Y
might	O
partially	O
contribute	O
to	O
the	O
synergic	O
effect	O
.	O

Though	O
FUR	B-CHEMICAL
alone	O
obviously	O
induced	O
endoplasmic	O
reticulum	O
stress	O
,	O
this	O
signaling	O
pathway	O
may	O
not	O
contribute	O
to	O
the	O
synergetic	O
anti	O
-	O
proliferative	O
effect	O
as	O
the	O
protein	O
expression	O
of	O
CHOP	B-GENE-Y
and	O
BIP	B-GENE-Y
was	O
similar	O
in	O
FUR	B-CHEMICAL
alone	O
and	O
combined	O
treatment	O
group	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Association	O
of	O
ATP	B-GENE-N
-	I-GENE-N
binding	I-GENE-N
cassette	I-GENE-N
transporter	I-GENE-N
variants	O
with	O
the	O
risk	O
of	O
Alzheimer	O
'	O
s	O
disease	O
.	O

Aim	O
:	O
A	O
number	O
of	O
studies	O
have	O
demonstrated	O
that	O
ABCB1	B-GENE-Y
and	O
BCRP	B-GENE-Y
(	O
ABCG2	B-GENE-Y
)	O
actively	O
transport	O
Aβ	B-GENE-Y
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
of	O
genetic	O
variants	O
of	O
selected	O
multidrug	B-GENE-N
transporters	I-GENE-N
with	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
in	O
histopathologically	O
confirmed	O
AD	O
cases	O
and	O
controls	O
.	O

Materials	O
&	O
methods	O
:	O
DNA	O
from	O
brain	O
tissue	O
of	O
71	O
AD	O
cases	O
with	O
Consortium	O
to	O
Establish	O
a	O
Registry	O
for	O
Alzheimer	O
'	O
s	O
Disease	O
(	O
CERAD	O
)	O
neuropathological	O
stages	O
B	O
/	O
C	O
and	O
81	O
controls	O
was	O
genotyped	O
for	O
selected	O
variants	O
in	O
ABCA1	B-GENE-Y
,	O
ABCA7	B-GENE-Y
,	O
ABCB1	B-GENE-Y
,	O
ABCC2	B-GENE-Y
and	O
ABCG2	B-GENE-Y
.	O

In	O
addition	O
,	O
the	O
APOE4	B-GENE-Y
status	O
was	O
analyzed	O
.	O

Results	O
:	O
The	O
novel	O
ABCA7	B-GENE-Y
SNP	O
,	O
rs3752246	O
,	O
tended	O
to	O
be	O
associated	O
with	O
AD	O
in	O
our	O
study	O
.	O

Variants	O
in	O
ABCB1	B-GENE-Y
were	O
significantly	O
less	O
frequent	O
in	O
AD	O
cases	O
older	O
than	O
65	O
years	O
of	O
age	O
and	O
among	O
females	O
.	O

This	O
association	O
of	O
ABCB1	B-GENE-Y
2677G	B-GENE-N
>	I-GENE-N
T	I-GENE-N
(	O
rs2032582	O
)	O
was	O
more	O
pronounced	O
in	O
APOE4	B-GENE-Y
-	O
negative	O
cases	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

However	O
,	O
only	O
ABCC2	B-GENE-Y
3972C	B-GENE-N
>	I-GENE-N
T	I-GENE-N
(	O
rs3740066	O
)	O
was	O
significantly	O
associated	O
with	O
AD	O
risk	O
after	O
logistic	O
regression	O
analysis	O
including	O
all	O
variants	O
.	O

Other	O
transporters	O
showed	O
a	O
lack	O
of	O
association	O
.	O

Conclusion	O
:	O
Our	O
results	O
support	O
the	O
hypothesis	O
that	O
ABCB1	B-GENE-Y
and	O
possibly	O
other	O
ABC	B-GENE-N
-	I-GENE-N
transporters	I-GENE-N
are	O
involved	O
in	O
the	O
process	O
of	O
Aβ	B-GENE-Y
accumulation	O
in	O
the	O
aging	O
brain	O
and	O
may	O
modulate	O
the	O
risk	O
for	O
AD	O
in	O
an	O
allele	O
-	O
specific	O
manner	O
,	O
and	O
thus	O
might	O
represent	O
a	O
new	O
target	O
for	O
prevention	O
and	O
treatment	O
of	O
AD	O
.	O

Original	O
submitted	O
8	O
October	O
2012	O
;	O
Revision	O
submitted	O
22	O
January	O
2013	O
.	O

mTOR	B-GENE-Y
Regulates	O
Nox4	B-GENE-Y
-	O
Mediated	O
Podocyte	O
Depletion	O
in	O
Diabetic	O
Renal	O
Injury	O
.	O

Podocyte	O
apoptosis	O
is	O
a	O
critical	O
mechanism	O
for	O
excessive	O
loss	O
of	O
urinary	O
albumin	B-GENE-Y
that	O
eventuates	O
in	O
kidney	O
fibrosis	O
.	O

Pharmacological	O
doses	O
of	O
the	O
mTOR	B-GENE-Y
inhibitor	O
rapamycin	B-CHEMICAL
reduce	O
albuminura	O
in	O
diabetes	O
.	O

We	O
explored	O
the	O
hypothesis	O
that	O
mTOR	B-GENE-Y
mediates	O
podocyte	O
injury	O
in	O
diabetes	O
.	O

High	O
glucose	B-CHEMICAL
(	O
HG	O
)	O
induces	O
apoptosis	O
of	O
podocytes	O
,	O
inhibits	O
AMPK	B-GENE-N
activation	O
,	O
inactivates	O
tuberin	B-GENE-Y
and	O
activates	O
mTOR	B-GENE-Y
.	O

HG	O
also	O
increases	O
the	O
levels	O
of	O
Nox4	B-GENE-Y
and	O
Nox1	B-GENE-Y
and	O
NADPH	B-GENE-N
oxidase	I-GENE-N
activity	O
.	O

Inhibition	O
of	O
mTOR	B-GENE-Y
by	O
low	O
dose	O
rapamycin	B-CHEMICAL
decreases	O
HG	O
-	O
induced	O
Nox4	B-GENE-Y
and	O
Nox1	B-GENE-Y
,	O
NADPH	B-GENE-N
oxidase	I-GENE-N
activity	O
and	O
podocyte	O
apoptosis	O
.	O

Inhibition	O
of	O
mTOR	B-GENE-Y
had	O
no	O
effect	O
on	O
AMPK	B-GENE-N
or	O
tuberin	B-GENE-Y
phosphorylation	O
indicating	O
that	O
mTOR	B-GENE-Y
is	O
downstream	O
of	O
these	O
signaling	O
molecules	O
.	O

In	O
isolated	O
glomeruli	O
of	O
OVE26	O
mice	O
,	O
there	O
is	O
similar	O
decrease	O
in	O
the	O
activation	O
of	O
AMPK	B-GENE-N
and	O
tuberin	B-GENE-Y
and	O
activation	O
of	O
mTOR	B-GENE-Y
with	O
increase	O
in	O
Nox4	B-GENE-Y
and	O
NADPH	B-GENE-N
oxidase	I-GENE-N
activity	O
.	O

Inhibition	O
of	O
mTOR	B-GENE-Y
by	O
small	O
dose	O
of	O
rapamycin	B-CHEMICAL
reduces	O
podocyte	O
apoptosis	O
,	O
attenuates	O
glomerular	O
injury	O
and	O
albuminuria	O
.	O

Our	O
data	O
provide	O
evidence	O
for	O
a	O
novel	O
function	O
of	O
mTOR	B-GENE-Y
in	O
Nox4	B-GENE-Y
-	O
derived	O
ROS	O
generation	O
and	O
podocyte	O
apoptosis	O
that	O
contributes	O
to	O
urinary	O
albumin	B-GENE-Y
excretion	O
in	O
type	O
1	O
diabetes	O
.	O

Thus	O
mTOR	B-GENE-Y
and	O
or	O
NADPH	B-GENE-N
oxidase	I-GENE-N
inhibition	O
may	O
represent	O
a	O
therapeutic	O
modality	O
of	O
diabetic	O
kidney	O
disease	O
.	O

Impaired	O
in	O
vivo	O
binding	O
of	O
MeCP2	B-GENE-Y
to	O
chromatin	O
in	O
the	O
absence	O
of	O
its	O
DNA	B-GENE-N
methyl	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
.	O

MeCP2	B-GENE-Y
is	O
a	O
methyl	B-GENE-N
-	I-GENE-N
CpG	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
that	O
is	O
a	O
main	O
component	O
of	O
brain	O
chromatin	O
in	O
vertebrates	O
.	O

In	O
vitro	O
studies	O
have	O
determined	O
that	O
in	O
addition	O
to	O
its	O
specific	O
methyl	B-GENE-N
-	I-GENE-N
CpG	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
(	O
MBD	B-GENE-N
)	O
MeCP2	B-GENE-Y
also	O
has	O
several	O
chromatin	B-GENE-N
association	I-GENE-N
domains	I-GENE-N
.	O

However	O
,	O
the	O
specific	O
interactions	O
of	O
MeCP2	B-GENE-Y
with	O
methylated	O
or	O
non	O
-	O
methylated	O
chromatin	O
regions	O
and	O
the	O
structural	O
characteristics	O
of	O
the	O
resulting	O
DNA	O
associations	O
in	O
vivo	O
remain	O
poorly	O
understood	O
.	O

We	O
analysed	O
the	O
role	O
of	O
the	O
MBD	B-GENE-N
in	O
MeCP2	B-GENE-Y
-	O
chromatin	O
associations	O
in	O
vivo	O
using	O
an	O
MeCP2	B-GENE-Y
mutant	O
Rett	O
syndrome	O
mouse	O
model	O
(	O
Mecp2	B-GENE-Y
(	O
tm	O
)	O
(	O
1	O
)	O
(	O
.	O
)	O
(	O
1	O
)	O
(	O
Jae	O
)	O
)	O
in	O
which	O
exon	O
3	O
deletion	O
results	O
in	O
an	O
N	B-CHEMICAL
-	O
terminal	O
truncation	O
of	O
the	O
protein	O
,	O
including	O
most	O
of	O
the	O
MBD	B-GENE-N
.	O

Our	O
results	O
show	O
that	O
in	O
mutant	O
mice	O
,	O
the	O
truncated	O
form	O
of	O
MeCP2	B-GENE-Y
(	O
ΔMeCP2	B-GENE-Y
)	O
is	O
expressed	O
in	O
different	O
regions	O
of	O
the	O
brain	O
and	O
liver	O
,	O
albeit	O
at	O
50	O
%	O
of	O
its	O
wild	O
-	O
type	O
(	O
wt	O
)	O
counterpart	O
.	O

In	O
contrast	O
to	O
the	O
punctate	O
nuclear	O
distribution	O
characteristic	O
of	O
wt	O
MeCP2	B-GENE-Y
,	O
ΔMeCP2	B-GENE-Y
exhibits	O
both	O
diffuse	O
nuclear	O
localization	O
and	O
a	O
substantial	O
retention	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
a	O
dysfunction	O
of	O
nuclear	O
transport	O
.	O

In	O
mutant	O
brain	O
tissue	O
,	O
neuronal	O
nuclei	O
are	O
smaller	O
,	O
and	O
ΔMeCP2	B-GENE-Y
chromatin	O
is	O
digested	O
faster	O
by	O
nucleases	B-GENE-N
,	O
producing	O
a	O
characteristic	O
nuclease	O
-	O
resistant	O
dinucleosome	O
.	O

Although	O
a	O
fraction	O
of	O
ΔMeCP2	B-GENE-Y
is	O
found	O
associated	O
with	O
nucleosomes	O
,	O
its	O
interaction	O
with	O
chromatin	O
is	O
transient	O
and	O
weak	O
.	O

Thus	O
,	O
our	O
results	O
unequivocally	O
demonstrate	O
that	O
in	O
vivo	O
the	O
MBD	B-GENE-N
of	O
MeCP2	B-GENE-Y
together	O
with	O
its	O
adjacent	O
region	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
are	O
critical	O
for	O
the	O
proper	O
interaction	O
of	O
the	O
protein	O
with	O
chromatin	O
,	O
which	O
cannot	O
be	O
replaced	O
by	O
any	O
other	O
of	O
its	O
protein	O
domains	O
.	O

Enhancing	O
Raman	O
Scattering	O
without	O
Plasmons	O
:	O
Unprecedented	O
Sensitivity	O
Achieved	O
by	O
TiO2	B-CHEMICAL
Shell	O
-	O
Based	O
Resonators	O
.	O

A	O
remarkable	O
enhancement	O
of	O
Raman	O
scattering	O
is	O
achieved	O
by	O
TiO2	B-CHEMICAL
shell	O
-	O
based	O
spherical	O
resonators	O
in	O
the	O
absence	O
of	O
plasmonic	O
enhancers	O
.	O

This	O
effect	O
is	O
ascribed	O
to	O
the	O
synergistic	O
combination	O
of	O
high	O
refractive	O
index	O
of	O
the	O
shell	O
layer	O
,	O
multiple	O
light	O
scattering	O
through	O
the	O
spheres	O
,	O
and	O
related	O
geometrical	O
factors	O
and	O
can	O
be	O
exploited	O
to	O
fabricate	O
a	O
new	O
generation	O
of	O
self	O
-	O
diagnostic	O
,	O
recyclable	O
SERS	O
-	O
active	O
substrates	O
.	O

Research	O
on	O
the	O
preparation	O
of	O
antioxidant	O
peptides	O
derived	O
from	O
egg	O
white	O
with	O
assisting	O
of	O
high	O
-	O
intensity	O
pulsed	O
electric	O
field	O
.	O

Egg	O
white	O
protein	O
powder	O
,	O
one	O
of	O
the	O
main	O
egg	O
products	O
,	O
was	O
hydrolysed	O
by	O
Alcalase	B-GENE-Y
,	O
Trypsin	B-GENE-N
,	O
and	O
Pepsin	B-GENE-N
respectively	O
to	O
prepare	O
antioxidant	O
peptides	O
.	O

All	O
hydrolysates	O
were	O
assayed	O
by	O
determination	O
of	O
reducing	O
power	O
(	O
RP	O
)	O
ability	O
.	O

Three	O
kinds	O
of	O
hydrolysates	O
were	O
prepared	O
under	O
optimal	O
enzymatic	O
parameters	O
that	O
were	O
obtained	O
from	O
the	O
preliminary	O
one	O
-	O
factor	O
-	O
at	O
-	O
a	O
-	O
time	O
(	O
OFAT	O
)	O
and	O
response	O
surface	O
methodology	O
(	O
RSM	O
)	O
experiments	O
.	O

The	O
results	O
showed	O
that	O
the	O
Alcalase	B-GENE-Y
hydrolysates	O
exerted	O
the	O
best	O
RP	O
ability	O
.	O

Thereafter	O
,	O
the	O
Alcalase	B-GENE-Y
hydrolysates	O
were	O
sequentially	O
fractionated	O
by	O
ultra	O
filtration	O
membranes	O
in	O
cut	O
-	O
off	O
molecular	O
weight	O
(	O
MW	O
)	O
of	O
30	O
,	O
10	O
,	O
and	O
1kDa	O
,	O
and	O
tested	O
their	O
antioxidant	O
activities	O
in	O
terms	O
of	O
RP	O
ability	O
,	O
DPPH	B-CHEMICAL
radical	O
scavenging	O
ability	O
,	O
ABTS	B-CHEMICAL
radical	O
scavenging	O
ability	O
,	O
and	O
FRAP	O
assay	O
.	O

Effects	O
of	O
high	O
intensity	O
pulsed	O
electric	O
field	O
treatment	O
were	O
further	O
investigated	O
on	O
antioxidant	O
peptides	O
to	O
improve	O
their	O
activities	O
.	O

The	O
results	O
showed	O
that	O
Alcalase	B-GENE-Y
hydrolysates	O
possessed	O
the	O
strongest	O
antioxidant	O
ability	O
compared	O
with	O
the	O
other	O
two	O
hydrolysates	O
,	O
particularly	O
for	O
the	O
Fraction	O
-	O
3	O
with	O
MW	O
<	O
1kDa	O
.	O

After	O
PEF	O
treatment	O
,	O
this	O
fraction	O
showed	O
a	O
significant	O
improvement	O
of	O
RP	O
ability	O
within	O
5h	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Correlation	O
between	O
activation	O
of	O
PPARγ	B-GENE-Y
and	O
resistin	B-GENE-Y
downregulation	O
in	O
a	O
mouse	O
adipocyte	O
cell	O
line	O
by	O
a	O
series	O
of	O
thiazolidinediones	B-CHEMICAL
.	O

The	O
present	O
study	O
shows	O
significant	O
correlations	O
between	O
the	O
EC50	O
for	O
PPARγ	B-GENE-Y
activation	O
in	O
a	O
reporter	O
gene	O
cell	O
line	O
and	O
resistin	B-GENE-Y
downregulation	O
in	O
mouse	O
adipocytes	O
,	O
and	O
between	O
the	O
IC50	O
for	O
resistin	B-GENE-Y
downregulation	O
and	O
the	O
already	O
published	O
minimum	O
effective	O
dose	O
for	O
antihyperglycemic	O
activity	O
in	O
a	O
mouse	O
model	O
.	O

These	O
correlations	O
indicate	O
that	O
PPARγ	B-GENE-Y
mediated	O
downregulation	O
of	O
resistin	O
might	O
promote	O
insulin	B-GENE-N
sensitivity	O
and	O
that	O
downregulation	O
of	O
resistin	B-GENE-Y
in	O
mouse	O
adipocytes	O
provides	O
an	O
adequate	O
and	O
possibly	O
more	O
direct	O
bioassay	O
for	O
screening	O
of	O
newly	O
developed	O
antihyperglycemic	O
compounds	O
.	O

Because	O
of	O
the	O
higher	O
throughput	O
of	O
the	O
PPARγ	B-GENE-Y
the	O
resistin	B-GENE-Y
downregulation	O
assays	O
seems	O
most	O
suitable	O
to	O
be	O
used	O
as	O
a	O
second	O
tier	O
in	O
a	O
tiered	O
screening	O
strategy	O
.	O

No	O
mutations	O
in	O
the	O
serotonin	B-CHEMICAL
related	O
TPH1	B-GENE-Y
and	O
HTR1B	B-GENE-Y
genes	O
in	O
patients	O
with	O
monogenic	O
sclerosing	O
bone	O
disorders	O
.	O

Since	O
the	O
identification	O
of	O
LRP5	B-GENE-Y
as	O
the	O
causative	O
gene	O
for	O
the	O
osteoporosis	O
pseudoglioma	O
syndrome	O
(	O
OPPG	O
)	O
as	O
well	O
as	O
the	O
high	O
bone	O
mass	O
(	O
HBM	O
)	O
phenotype	O
,	O
LRP5	B-GENE-Y
and	O
the	O
Wnt	B-GENE-N
/	O
β	B-GENE-Y
-	I-GENE-Y
catenin	I-GENE-Y
signaling	O
have	O
been	O
extensively	O
studied	O
for	O
their	O
role	O
in	O
the	O
differentiation	O
and	O
proliferation	O
of	O
osteoblasts	O
,	O
in	O
the	O
apoptosis	O
of	O
osteoblasts	O
and	O
osteocytes	O
and	O
in	O
the	O
response	O
of	O
bone	O
to	O
mechanical	O
loading	O
.	O

However	O
,	O
more	O
recently	O
the	O
direct	O
effect	O
of	O
LRP5	B-GENE-Y
on	O
osteoblasts	O
and	O
bone	O
formation	O
has	O
been	O
questioned	O
.	O

Gene	O
expression	O
studies	O
showed	O
that	O
mice	O
lacking	O
lrp5	B-GENE-Y
have	O
increased	O
expression	O
of	O
tph1	B-GENE-Y
,	O
the	O
rate	O
limiting	O
enzyme	O
for	O
the	O
production	O
of	O
serotonin	B-CHEMICAL
in	O
the	O
gut	O
.	O

Furthermore	O
mice	O
lacking	O
either	O
tph1	B-GENE-Y
or	O
htr1B	B-GENE-Y
,	O
the	O
receptor	O
for	O
serotonin	B-CHEMICAL
on	O
the	O
osteoblasts	O
,	O
were	O
reported	O
to	O
have	O
an	O
increased	O
bone	O
mass	O
due	O
to	O
increased	O
bone	O
formation	O
.	O

This	O
led	O
to	O
the	O
still	O
controversial	O
hypothesis	O
that	O
LRP5	B-GENE-Y
influences	O
bone	O
formation	O
indirectly	O
by	O
regulating	O
the	O
expression	O
of	O
thp1	B-GENE-Y
and	O
as	O
a	O
consequence	O
influencing	O
the	O
production	O
of	O
serotonin	B-CHEMICAL
in	O
the	O
gut	O
.	O

Based	O
on	O
these	O
data	O
we	O
decided	O
to	O
evaluate	O
the	O
role	O
of	O
TPH1	B-GENE-Y
and	O
HTR1B	B-GENE-Y
in	O
the	O
development	O
of	O
craniotubular	O
hyperostoses	O
,	O
a	O
group	O
of	O
monogenic	O
sclerosing	O
bone	O
dysplasias	O
.	O

We	O
screened	O
the	O
coding	O
regions	O
of	O
both	O
genes	O
in	O
53	O
patients	O
lacking	O
a	O
mutation	O
in	O
the	O
known	O
causative	O
genes	O
LRP5	B-GENE-Y
,	O
LRP4	B-GENE-Y
and	O
SOST	B-GENE-Y
.	O

We	O
could	O
not	O
find	O
disease	O
-	O
causing	O
coding	O
variants	O
in	O
neither	O
of	O
the	O
tested	O
genes	O
and	O
therefore	O
,	O
we	O
cannot	O
provide	O
support	O
for	O
an	O
important	O
function	O
of	O
TPH1	B-GENE-Y
and	O
HTR1B	B-GENE-Y
in	O
the	O
pathogenesis	O
of	O
sclerosing	O
bone	O
dysplasias	O
in	O
our	O
tested	O
patient	O
cohort	O
.	O

Vinblastine	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
is	O
mediated	O
by	O
Ras	B-GENE-Y
homologous	I-GENE-Y
A	I-GENE-Y
protein	I-GENE-Y
(	O
Rho	B-GENE-Y
A	I-GENE-Y
)	O
via	O
mitochondrial	O
and	O
non	O
-	O
mitochondrial	O
-	O
dependent	O
mechanisms	O
.	O

Despite	O
the	O
availability	O
of	O
melanoma	O
treatment	O
at	O
the	O
primary	O
site	O
,	O
the	O
recurrence	O
of	O
local	O
melanoma	O
can	O
metastasize	O
to	O
any	O
distant	O
organ	O
.	O

Currently	O
,	O
the	O
available	O
therapies	O
for	O
the	O
treatment	O
of	O
metastatic	O
melanoma	O
are	O
of	O
limited	O
benefit	O
.	O

Thus	O
,	O
the	O
functional	O
analysis	O
of	O
conventional	O
therapies	O
may	O
help	O
to	O
improve	O
their	O
efficiency	O
in	O
the	O
treatment	O
of	O
metastatic	O
melanoma	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
exposure	O
of	O
melanoma	O
cells	O
to	O
vinblastine	B-CHEMICAL
was	O
found	O
to	O
trigger	O
apoptosis	O
as	O
evidenced	O
by	O
the	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
the	O
release	O
of	O
both	O
cytochrome	B-GENE-Y
c	I-GENE-Y
and	O
apoptosis	B-GENE-Y
inducing	I-GENE-Y
factor	I-GENE-Y
,	O
activation	O
of	O
caspase	B-GENE-N
-	I-GENE-N
9	I-GENE-N
and	I-GENE-N
3	I-GENE-N
,	O
and	O
cleavage	O
of	O
Poly	B-GENE-N
(	I-GENE-N
ADP	I-GENE-N
-	I-GENE-N
ribose	I-GENE-N
)	I-GENE-N
-	I-GENE-N
Polymerase	I-GENE-N
.	O

Also	O
,	O
vinblastine	B-CHEMICAL
enhances	O
the	O
phosphorylation	O
of	O
Ras	B-GENE-Y
homologous	I-GENE-Y
protein	I-GENE-Y
A	I-GENE-Y
,	O
the	O
accumulation	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
,	O
the	O
release	O
of	O
intracellular	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
,	O
as	O
well	O
as	O
the	O
activation	O
of	O
apoptosis	B-GENE-Y
signal	I-GENE-Y
-	I-GENE-Y
regulating	I-GENE-Y
kinase	I-GENE-Y
1	I-GENE-Y
,	O
c	B-GENE-N
-	I-GENE-N
jun	I-GENE-N
-	I-GENE-N
N	I-GENE-N
-	I-GENE-N
terminal	I-GENE-N
kinase	I-GENE-N
,	O
p38	B-GENE-N
,	O
inhibitor	B-GENE-Y
of	I-GENE-Y
kappaBα	I-GENE-Y
(	O
IκBα	B-GENE-Y
)	O
kinase	B-GENE-N
,	O
and	O
inositol	B-GENE-Y
requiring	I-GENE-Y
enzyme	I-GENE-Y
1α	I-GENE-Y
.	O

In	O
addition	O
,	O
vinblastine	B-CHEMICAL
induces	O
the	O
DNA	O
-	O
binding	O
activities	O
of	O
the	O
transcription	O
factor	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
HSF1	B-GENE-Y
,	O
AP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
ATF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
together	O
with	O
the	O
expression	O
of	O
HSP70	B-GENE-N
and	O
Bax	B-GENE-Y
proteins	O
.	O

Moreover	O
,	O
inhibitory	O
experiments	O
addressed	O
a	O
central	O
role	O
for	O
Rho	B-GENE-Y
A	I-GENE-Y
in	O
the	O
regulation	O
of	O
vinblastine	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
via	O
mitochondrial	O
and	O
non	O
-	O
mitochondrial	O
-	O
dependent	O
mechanisms	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
addresses	O
for	O
the	O
first	O
time	O
a	O
central	O
role	O
for	O
Rho	B-GENE-Y
A	I-GENE-Y
in	O
the	O
modulation	O
of	O
vinblastine	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
and	O
thereby	O
provides	O
an	O
insight	O
into	O
the	O
molecular	O
action	O
of	O
vinblastine	B-CHEMICAL
in	O
melanoma	O
treatment	O
.	O

Expansion	O
of	O
the	O
Homeostasis	O
Model	O
Assessment	O
of	O
β	O
-	O
Cell	O
Function	O
and	O
Insulin	B-GENE-Y
Resistance	O
to	O
Enable	O
Clinical	O
Trial	O
Outcome	O
Modeling	O
Through	O
the	O
Interactive	O
Adjustment	O
of	O
Physiology	O
and	O
Treatment	O
Effects	O
-	O
-	O
iHOMA2	O
.	O

OBJECTIVETo	O
describe	O
and	O
make	O
available	O
an	O
interactive	O
,	O
24	O
-	O
variable	O
homeostasis	O
model	O
assessment	O
(	O
iHOMA2	O
)	O
that	O
extends	O
the	O
HOMA2	O
model	O
,	O
enabling	O
the	O
modeling	O
of	O
physiology	O
and	O
treatment	O
effects	O
,	O
to	O
present	O
equations	O
of	O
the	O
HOMA2	O
and	O
iHOMA2	O
models	O
,	O
and	O
to	O
exemplify	O
iHOMA2	O
in	O
two	O
widely	O
differing	O
scenarios	O
:	O
changes	O
in	O
insulin	B-GENE-N
sensitivity	O
with	O
thiazolidinediones	B-CHEMICAL
and	O
changes	O
in	O
renal	O
threshold	O
with	O
sodium	B-GENE-N
glucose	I-GENE-N
transporter	I-GENE-N
(	O
SGLT2	B-GENE-Y
)	O
inhibition	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODSiHOMA2	O
enables	O
a	O
user	O
of	O
the	O
available	O
software	O
to	O
examine	O
and	O
modify	O
the	O
mathematical	O
functions	O
describing	O
the	O
organs	O
and	O
tissues	O
involved	O
in	O
the	O
glucose	B-CHEMICAL
and	O
hormonal	O
compartments	O
.	O

We	O
exemplify	O
this	O
with	O
SGLT2	B-GENE-Y
inhibition	O
modeling	O
(	O
by	O
changing	O
the	O
renal	O
threshold	O
parameters	O
)	O
using	O
published	O
data	O
of	O
renal	O
effect	O
,	O
showing	O
that	O
the	O
modeled	O
effect	O
is	O
concordant	O
with	O
the	O
effects	O
on	O
fasting	O
glucose	B-CHEMICAL
from	O
independent	O
data	O
.	O
RESULTSiHOMA2	O
modeling	O
of	O
thiazolidinediones	B-CHEMICAL
effect	O
suggested	O
that	O
changes	O
in	O
insulin	O
sensitivity	O
in	O
the	O
fasting	O
state	O
are	O
predominantly	O
hepatic	O
.	O

SGLT2	B-GENE-Y
inhibition	O
modeled	O
by	O
iHOMA2	O
resulted	O
in	O
a	O
decrease	O
in	O
mean	O
glucose	B-CHEMICAL
of	O
1	O
.	O
1	O
mmol	O
/	O
L	O
.	O

Observed	O
data	O
showed	O
a	O
decrease	O
in	O
glucose	B-CHEMICAL
of	O
0	O
.	O
9	O
mmol	O
/	O
L	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
model	O
and	O
the	O
independent	O
data	O
.	O

Manipulation	O
of	O
iHOMA2s	O
renal	O
excretion	O
threshold	O
variable	O
suggested	O
that	O
a	O
decrease	O
of	O
17	O
%	O
was	O
required	O
to	O
obtain	O
a	O
0	O
.	O
9	O
mmol	O
/	O
L	O
decrease	O
in	O
mean	O
glucose	B-CHEMICAL
.	O
CONCLUSIONSiHOMA2	O
is	O
an	O
extended	O
mathematical	O
model	O
for	O
the	O
assessment	O
of	O
insulin	B-GENE-Y
resistance	O
and	O
β	O
-	O
cell	O
function	O
.	O

The	O
model	O
can	O
be	O
used	O
to	O
evaluate	O
therapeutic	O
agents	O
and	O
predict	O
effects	O
on	O
fasting	O
glucose	B-CHEMICAL
and	O
insulin	O
and	O
on	O
β	O
-	O
cell	O
function	O
and	O
insulin	B-GENE-Y
sensitivity	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
novel	O
aliphatic	B-CHEMICAL
amido	I-CHEMICAL
-	I-CHEMICAL
quaternary	I-CHEMICAL
ammonium	I-CHEMICAL
salts	I-CHEMICAL
for	O
anticancer	O
chemotherapy	O
:	O
Part	O
II	O
.	O

A	O
series	O
of	O
novel	O
aliphatic	B-CHEMICAL
amido	I-CHEMICAL
-	I-CHEMICAL
quaternary	I-CHEMICAL
ammonium	I-CHEMICAL
salts	I-CHEMICAL
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
anticancer	O
effects	O
involving	O
induction	O
of	O
RhoB	B-GENE-Y
.	O

Most	O
of	O
these	O
compounds	O
,	O
featuring	O
open	O
-	O
ring	O
forms	O
of	O
aliphatic	B-CHEMICAL
amido	I-CHEMICAL
-	I-CHEMICAL
quaternary	I-CHEMICAL
ammonium	I-CHEMICAL
salts	I-CHEMICAL
,	O
exhibited	O
potent	O
anti	O
-	O
proliferative	O
activities	O
in	O
human	O
cancer	O
cell	O
lines	O
,	O
including	O
PC	O
-	O
3	O
,	O
NUGC	O
-	O
3	O
,	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
ACHN	O
,	O
HCT	O
-	O
15	O
,	O
and	O
NCI	O
-	O
H23	O
.	O

In	O
further	O
evaluation	O
,	O
the	O
representative	O
compound	O
N	B-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
diethyl	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methyltetradecanamido	I-CHEMICAL
)	I-CHEMICAL
ethyl	I-CHEMICAL
)	I-CHEMICAL
prop	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
en	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
aminium	I-CHEMICAL
bromide	I-CHEMICAL
(	O
3b	O
)	O
exhibited	O
potent	O
pro	O
-	O
apoptotic	O
activity	O
,	O
through	O
RhoB	B-GENE-Y
activation	O
,	O
in	O
HeLa	O
cells	O
.	O

Synthesis	O
of	O
novel	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
trisubstituted	I-CHEMICAL
pyrazoles	I-CHEMICAL
as	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
agents	O
.	O

Some	O
novel	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
trisubstituted	I-CHEMICAL
pyrazoles	I-CHEMICAL
were	O
synthesized	O
and	O
screened	O
for	O
their	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
activities	O
as	O
well	O
as	O
their	O
ulcerogenic	O
liability	O
.	O

They	O
showed	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
activities	O
with	O
better	O
GIT	O
tolerance	O
than	O
the	O
standard	O
drug	O
phenylbutazone	B-CHEMICAL
.	O

In	O
addition	O
,	O
IC50	O
values	O
for	O
5e	O
and	O
8e	O
were	O
recorded	O
.	O

Compound	O
5e	O
was	O
found	O
to	O
be	O
the	O
most	O
active	O
one	O
as	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
agent	O
.	O

On	O
the	O
other	O
hand	O
,	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
/	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
isozyme	O
selectivity	O
was	O
also	O
done	O
which	O
showed	O
equal	O
inhibition	O
to	O
both	O
isoforms	O
.	O

Design	O
,	O
synthesis	O
and	O
antiproliferative	O
properties	O
of	O
some	O
new	O
5	B-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
iminobenzimidazole	I-CHEMICAL
derivatives	O
.	O

Some	O
new	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dihydro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
imino	I-CHEMICAL
-	I-CHEMICAL
benzimidazoles	I-CHEMICAL
were	O
synthesized	O
under	O
solid	O
-	O
liquid	O
phase	O
transfer	O
catalysis	O
conditions	O
using	O
5	B-CHEMICAL
-	I-CHEMICAL
substituted	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminobenzimidazoles	I-CHEMICAL
as	O
precursors	O
in	O
order	O
to	O
assess	O
their	O
cytotoxicity	O
respectively	O
proliferative	O
activity	O
.	O

The	O
structures	O
of	O
the	O
compounds	O
were	O
confirmed	O
by	O
IR	O
,	O
(	B-CHEMICAL
1	I-CHEMICAL
)	I-CHEMICAL
H	I-CHEMICAL
NMR	O
,	O
(	B-CHEMICAL
13	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
NMR	O
and	O
elemental	O
analysis	O
.	O

Compounds	O
9	O
-	O
10	O
,	O
12	O
and	O
16	O
-	O
17	O
were	O
evaluated	O
for	O
their	O
cytotoxical	O
effect	O
on	O
four	O
cancer	O
cell	O
lines	O
:	O
HT	O
-	O
29	O
,	O
breast	O
cancer	O
cells	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
HeLa	O
,	O
HepG2	O
and	O
as	O
well	O
as	O
human	O
diploid	O
cell	O
line	O
Lep	O
-	O
3	O
.	O

Significant	O
cytotoxicity	O
of	O
hydrazone	B-CHEMICAL
16	O
against	O
MDA	O
-	O
MB	O
-	O
231	O
was	O
established	O
by	O
biologically	O
study	O
,	O
the	O
IC50	O
was	O
6	O
.	O
2	O
nM	O
while	O
the	O
EC50	O
value	O
to	O
Lep	O
3	O
is	O
0	O
.	O
21	O
nM	O
.	O

Relative	O
high	O
antiproliferative	O
effects	O
of	O
the	O
acetate	B-CHEMICAL
12	O
and	O
compound	O
16	O
against	O
HT	O
-	O
29	O
were	O
ascertained	O
and	O
the	O
calculated	O
IC50	O
values	O
were	O
IC50	O
-	O
0	O
.	O
85	O
nM	O
and	O
IC50	O
-	O
2	O
.	O
83	O
nM	O
respectively	O
.	O

Cytotoxic	O
activity	O
against	O
HeLa	O
and	O
HepG2	O
cells	O
was	O
demonstrated	O
by	O
hydrazone	B-CHEMICAL
17	O
,	O
IC50	O
was	O
7	O
.	O
2	O
nM	O
and	O
117	O
nM	O
respectively	O
.	O

All	O
tested	O
compounds	O
revealed	O
proliferative	O
activities	O
to	O
human	O
diploid	O
cell	O
line	O
Lep	O
-	O
3	O
.	O

The	O
EC50	O
values	O
were	O
in	O
the	O
range	O
from	O
0	O
.	O
05	O
to	O
16	O
.	O
91	O
nM	O
.	O

The	O
obtained	O
results	O
prove	O
the	O
selective	O
cytotoxicity	O
of	O
the	O
tested	O
compounds	O
and	O
are	O
promising	O
for	O
further	O
evaluation	O
of	O
the	O
investigated	O
compounds	O
in	O
vivo	O
experiments	O
using	O
experimentally	O
induced	O
tumors	O
in	O
laboratory	O
animals	O
.	O

Identification	O
of	O
novel	O
FLT3	B-GENE-Y
kinase	B-GENE-N
inhibitors	O
.	O

FLT3	B-GENE-Y
and	O
PDGFR	B-GENE-N
tyrosine	B-GENE-N
kinases	I-GENE-N
are	O
important	O
targets	O
for	O
therapy	O
of	O
different	O
types	O
of	O
leukemia	O
.	O

Several	O
FLT3	B-GENE-Y
/	O
PDGFR	B-GENE-N
inhibitors	O
are	O
currently	O
under	O
clinical	O
investigation	O
for	O
combination	O
with	O
standard	O
therapy	O
for	O
treatment	O
of	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
however	O
these	O
agents	O
only	O
induce	O
partial	O
remission	O
and	O
development	O
of	O
resistance	O
has	O
been	O
reported	O
.	O

In	O
this	O
work	O
we	O
describe	O
the	O
identification	O
of	O
potent	O
and	O
novel	O
dual	O
FLT3	B-GENE-Y
/	O
PDGFR	B-GENE-N
inhibitors	O
that	O
resulted	O
from	O
our	O
efforts	O
to	O
screen	O
a	O
library	O
of	O
25	O
,	O
607	O
small	O
molecules	O
against	O
the	O
FLT3	B-GENE-Y
dependent	O
cell	O
line	O
MOLM	O
-	O
13	O
and	O
the	O
PDGFR	B-GENE-N
dependent	O
cell	O
line	O
EOL	O
-	O
1	O
.	O

This	O
effort	O
led	O
to	O
the	O
identification	O
of	O
five	O
compounds	O
that	O
were	O
confirmed	O
to	O
be	O
active	O
on	O
additional	O
FLT3	B-GENE-Y
dependent	O
cell	O
lines	O
(	O
cellular	O
EC50	O
values	O
between	O
35	O
and	O
700	O
nM	O
)	O
,	O
while	O
having	O
no	O
significant	O
effect	O
on	O
24	O
other	O
tyrosine	B-GENE-N
kinases	I-GENE-N
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
a	O
phosphatase	B-GENE-N
domain	I-GENE-N
within	O
yeast	O
general	O
transcription	O
factor	O
TFIIIC	B-GENE-Y
.	O

Saccharomyces	B-GENE-Y
cerevisiae	I-GENE-Y
τ55	I-GENE-Y
,	O
a	O
subunit	O
of	O
the	O
RNA	B-GENE-N
polymerase	I-GENE-N
III	I-GENE-N
-	O
specific	O
general	O
transcription	O
factor	O
TFIIIC	B-GENE-Y
,	O
comprises	O
an	O
N	B-GENE-N
-	I-GENE-N
terminal	I-GENE-N
histidine	I-GENE-N
phosphatase	I-GENE-N
domain	I-GENE-N
(	O
τ55	B-GENE-Y
-	O
HPD	B-GENE-N
)	O
whose	O
catalytic	O
activity	O
and	O
cellular	O
function	O
is	O
poorly	O
understood	O
.	O

We	O
solved	O
the	O
crystal	O
structures	O
of	O
τ55	B-GENE-Y
-	O
HPD	B-GENE-N
and	O
its	O
closely	O
related	O
paralogue	O
Huf	B-GENE-N
and	O
used	O
in	O
silico	O
docking	O
methods	O
to	O
identify	O
phospho	B-CHEMICAL
-	I-CHEMICAL
serine	I-CHEMICAL
and	O
phospho	B-CHEMICAL
-	I-CHEMICAL
tyrosine	I-CHEMICAL
containing	O
peptides	O
as	O
possible	O
substrates	O
that	O
were	O
subsequently	O
validated	O
using	O
in	O
vitro	O
phosphatase	B-GENE-N
assays	O
.	O

A	O
comparative	O
phospho	B-CHEMICAL
-	O
proteomic	O
study	O
identified	O
additional	O
phosphopeptides	O
as	O
possible	O
targets	O
,	O
which	O
show	O
the	O
involvement	O
of	O
these	O
two	O
phosphatases	B-GENE-N
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

Our	O
results	O
identify	O
τ55	B-GENE-Y
-	O
HPD	B-GENE-N
and	O
Huf	O
as	O
bona	O
fide	O
protein	B-GENE-N
phosphatases	I-GENE-N
,	O
characterize	O
their	O
substrate	O
specificities	O
and	O
provide	O
a	O
small	O
set	O
of	O
regulated	O
phosphosite	O
targets	O
in	O
vivo	O
.	O

Suppression	O
of	O
nuclear	B-GENE-Y
factor	I-GENE-Y
erythroid	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
via	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
kinase	I-GENE-N
contributes	O
to	O
bleomycin	B-CHEMICAL
-	O
induced	O
oxidative	O
stress	O
and	O
fibrogenesis	O
.	O

Pulmonary	O
fibrosis	O
is	O
a	O
serious	O
and	O
irreversible	O
lung	O
injury	O
with	O
obscure	O
etiologic	O
mechanisms	O
and	O
no	O
effective	O
treatment	O
to	O
date	O
.	O

This	O
study	O
explored	O
a	O
crucial	O
link	O
between	O
oxidative	O
stress	O
and	O
pulmonary	O
fibrogenesis	O
,	O
focusing	O
on	O
nuclear	B-GENE-Y
factor	I-GENE-Y
erythroid	I-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
factor	I-GENE-Y
2	I-GENE-Y
(	O
Nrf2	B-GENE-Y
)	O
,	O
a	O
core	O
transcription	O
factor	O
in	O
antioxidative	O
regulation	O
systems	O
.	O

Treatment	O
of	O
C57	O
BL	O
/	O
6	O
mice	O
with	O
bleomycin	B-CHEMICAL
increased	O
fibroblast	O
viability	O
and	O
collagen	B-GENE-N
production	O
and	O
significantly	O
downregulated	O
Nrf2	B-GENE-N
.	O

In	O
addition	O
,	O
prominent	O
oxidative	O
stress	O
was	O
indicated	O
by	O
changes	O
in	O
superoxide	B-GENE-N
dismutase	I-GENE-N
,	O
catalase	B-GENE-N
activity	O
,	O
and	O
glutathione	B-CHEMICAL
and	O
thiobarbituric	B-CHEMICAL
acid	I-CHEMICAL
-	O
reactive	O
substance	O
levels	O
.	O

In	O
a	O
cell	O
-	O
based	O
model	O
,	O
bleomycin	B-CHEMICAL
suppressed	O
Nrf2	B-GENE-Y
activation	O
via	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
related	I-GENE-N
kinase	I-GENE-N
phosphorylation	O
,	O
enhancing	O
intracellular	O
reactive	O
oxygen	B-CHEMICAL
species	O
in	O
lung	O
fibroblasts	O
and	O
stimulating	O
abnormal	O
cell	O
proliferation	O
and	O
collagen	O
secretion	O
.	O

To	O
confirm	O
this	O
novel	O
mechanism	O
of	O
bleomycin	B-CHEMICAL
-	O
induced	O
fibrogenesis	O
,	O
we	O
attempted	O
to	O
upregulate	O
Nrf2	B-GENE-Y
and	O
related	O
antioxidant	O
proteins	O
in	O
bleomycin	O
-	O
treated	O
fibroblasts	O
using	O
a	O
putative	O
Nrf2	B-GENE-Y
activator	O
,	O
caffeic	B-CHEMICAL
acid	I-CHEMICAL
phenethyl	I-CHEMICAL
ester	I-CHEMICAL
,	O
and	O
the	O
results	O
showed	O
that	O
bleomycin	B-CHEMICAL
-	O
induced	O
fibroblast	O
proliferation	O
and	O
collagen	B-GENE-N
content	O
were	O
attenuated	O
through	O
improved	O
redox	O
balance	O
.	O

Collectively	O
,	O
these	O
results	O
disclose	O
a	O
potential	O
regulatory	O
mechanism	O
in	O
pulmonary	O
fibrosis	O
that	O
will	O
aid	O
the	O
development	O
of	O
new	O
therapies	O
.	O

The	O
Ras	B-GENE-N
-	O
GTPase	B-GENE-N
activity	O
of	O
neurofibromin	B-GENE-Y
restrains	O
ERK	B-GENE-N
-	O
dependent	O
FGFR	B-GENE-N
signaling	O
during	O
endochondral	O
bone	O
formation	O
.	O

The	O
severe	O
defects	O
in	O
growth	O
plate	O
development	O
caused	O
by	O
chondrocyte	O
extracellular	B-GENE-N
signal	I-GENE-N
-	I-GENE-N
regulated	I-GENE-N
protein	I-GENE-N
kinases	I-GENE-N
1	I-GENE-N
and	I-GENE-N
2	I-GENE-N
(	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
)	O
gain	O
or	O
loss	O
-	O
of	O
-	O
function	O
suggest	O
that	O
tight	O
spatial	O
and	O
temporal	O
regulation	O
of	O
mitogen	B-GENE-N
-	I-GENE-N
activated	I-GENE-N
protein	I-GENE-N
kinase	I-GENE-N
signaling	O
is	O
necessary	O
to	O
achieve	O
harmonious	O
growth	O
plate	O
elongation	O
and	O
structure	O
.	O

We	O
provide	O
here	O
evidence	O
that	O
neurofibromin	B-GENE-Y
,	O
via	O
its	O
Ras	B-GENE-N
guanosine	B-GENE-N
triphosphatase	I-GENE-N
-	O
activating	O
activity	O
,	O
controls	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
-	O
dependent	O
fibroblast	B-GENE-N
growth	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
(	O
FGFR	B-GENE-N
)	O
signaling	O
in	O
chondrocytes	O
.	O

We	O
show	O
first	O
that	O
neurofibromin	B-GENE-Y
is	O
expressed	O
in	O
FGFR	B-GENE-N
-	O
positive	O
prehypertrophic	O
and	O
hypertrophic	O
chondrocytes	O
during	O
growth	O
plate	O
endochondral	O
ossification	O
.	O

Using	O
mice	O
lacking	O
neurofibromin	B-GENE-Y
1	I-GENE-Y
(	O
Nf1	B-GENE-Y
)	O
in	O
type	B-GENE-N
II	I-GENE-N
collagen	I-GENE-N
-	O
expressing	O
cells	O
,	O
(	O
Nf1col2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mutant	O
mice	O
)	O
,	O
we	O
then	O
show	O
that	O
lack	O
of	O
neurofibromin	B-GENE-Y
in	O
post	O
-	O
mitotic	O
chondrocytes	O
triggers	O
a	O
number	O
of	O
phenotypes	O
reminiscent	O
of	O
the	O
ones	O
observed	O
in	O
mice	O
characterized	O
by	O
FGFR	B-GENE-N
gain	O
-	O
of	O
-	O
function	O
mutations	O
.	O

Those	O
include	O
dwarfism	O
,	O
constitutive	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activation	O
,	O
strongly	O
reduced	O
Ihh	B-GENE-Y
expression	O
and	O
decreased	O
chondrocyte	O
proliferation	O
and	O
maturation	O
,	O
increased	O
chondrocytic	O
expression	O
of	O
Rankl	B-GENE-Y
,	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
9	I-GENE-Y
(	O
Mmp9	B-GENE-Y
)	O
and	O
Mmp13	B-GENE-Y
and	O
enhanced	O
growth	O
plate	O
osteoclastogenesis	O
,	O
as	O
well	O
as	O
increased	O
sensitivity	O
to	O
caspase	B-GENE-Y
-	I-GENE-Y
9	I-GENE-Y
mediated	O
apoptosis	O
.	O

Using	O
wildtype	O
(	O
WT	O
)	O
and	O
Nf1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
chondrocyte	O
cultures	O
in	O
vitro	O
,	O
we	O
show	O
that	O
FGF2	B-GENE-Y
pulse	O
-	O
stimulation	O
triggers	O
rapid	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
phosphorylation	O
in	O
both	O
genotypes	O
,	O
but	O
that	O
return	O
to	O
the	O
basal	O
level	O
is	O
delayed	O
in	O
Nf1	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
chondrocytes	O
.	O

Importantly	O
,	O
in	O
vivo	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
inhibition	O
by	O
daily	O
injection	O
of	O
a	O
recombinant	O
form	O
of	O
C	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
to	O
post	O
-	O
natal	O
pups	O
for	O
18	O
days	O
was	O
able	O
to	O
correct	O
the	O
short	O
stature	O
of	O
Nf1col2	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Together	O
,	O
these	O
results	O
underscore	O
the	O
requirement	O
of	O
neurofibromin	O
and	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
for	O
normal	O
endochondral	O
bone	O
formation	O
and	O
support	O
the	O
notion	O
that	O
neurofibromin	O
,	O
by	O
restraining	O
RAS	B-GENE-N
-	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
signaling	O
,	O
is	O
a	O
negative	O
regulator	O
of	O
FGFR	B-GENE-N
signaling	O
in	O
differentiating	O
chondrocytes	O
.	O

A	O
Role	O
for	O
Cargo	B-GENE-N
in	O
the	O
Activation	O
of	O
ADP	B-GENE-N
-	I-GENE-N
Ribosylation	I-GENE-N
Factors	I-GENE-N
(	O
Arf	B-GENE-N
)	O
and	O
Adaptor	B-GENE-N
Recruitment	O
.	O

Membrane	O
traffic	O
requires	O
the	O
specific	O
concentration	O
of	O
protein	B-GENE-N
cargos	I-GENE-N
and	O
exclusion	O
of	O
other	O
proteins	O
into	O
nascent	O
carriers	O
.	O

Critical	O
components	O
of	O
this	O
selectivity	O
are	O
the	O
protein	B-GENE-N
adaptors	I-GENE-N
that	O
bind	O
to	O
short	O
,	O
linear	O
motifs	O
in	O
the	O
cytoplasmic	O
tails	O
of	O
transmembrane	O
protein	B-GENE-N
cargos	I-GENE-N
and	O
sequester	O
them	O
into	O
nascent	O
carriers	O
.	O

The	O
recruitment	O
of	O
the	O
adaptors	O
is	O
mediated	O
by	O
activated	O
Arf	B-GENE-N
GTPases	B-GENE-N
and	O
the	O
Arf	B-GENE-N
-	O
adaptor	B-GENE-N
complexes	O
mark	O
sites	O
of	O
carrier	O
formation	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
signal	O
(	O
s	O
)	O
that	O
initiate	O
carrier	O
biogenesis	O
remains	O
unknown	O
.	O

We	O
examined	O
the	O
specificity	O
and	O
initial	O
sites	O
of	O
recruitment	O
of	O
Arf	B-GENE-N
-	O
dependent	O
adaptors	B-GENE-N
(	O
AP	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	O
GGAs	B-GENE-N
)	O
in	O
response	O
to	O
the	O
Golgi	O
or	O
endosomal	O
localization	O
of	O
specific	O
cargo	B-GENE-N
proteins	I-GENE-N
(	O
furin	B-GENE-Y
,	O
mannose	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
-	I-GENE-Y
phosphate	I-GENE-Y
receptor	I-GENE-Y
(	O
M6PR	B-GENE-Y
)	O
and	O
M6PR	B-GENE-Y
lacking	O
a	O
C	B-CHEMICAL
-	O
terminal	O
domain	O
M6PRΔC	B-GENE-Y
)	O
.	O

We	O
find	O
that	O
cargo	B-GENE-N
promotes	O
the	O
recruitment	O
of	O
specific	O
adaptors	B-GENE-N
,	O
suggesting	O
that	O
it	O
is	O
part	O
of	O
an	O
upstream	O
signaling	O
event	O
.	O

Cargos	B-GENE-N
do	O
not	O
promote	O
adaptor	B-GENE-N
recruitment	O
to	O
all	O
compartments	O
in	O
which	O
they	O
reside	O
and	O
thus	O
additional	O
factors	O
regulate	O
the	O
cargo	B-GENE-N
'	I-GENE-N
s	I-GENE-N
ability	O
to	O
promote	O
Arf	B-GENE-N
activation	O
and	O
adaptor	B-GENE-N
recruitment	O
.	O

We	O
document	O
that	O
within	O
a	O
given	O
compartment	O
different	O
cargos	B-GENE-N
recruit	O
different	O
adaptors	B-GENE-N
suggesting	O
that	O
there	O
is	O
little	O
or	O
no	O
free	O
,	O
activated	O
Arf	B-GENE-N
at	O
the	O
membrane	O
and	O
that	O
Arf	B-GENE-N
activation	O
is	O
spatially	O
and	O
temporally	O
coupled	O
to	O
the	O
cargo	B-GENE-N
and	O
the	O
adaptor	B-GENE-N
.	O

Using	O
temperature	O
block	O
,	O
Brefeldin	B-CHEMICAL
A	I-CHEMICAL
,	O
and	O
recovery	O
from	O
each	O
,	O
we	O
found	O
that	O
the	O
cytoplasmic	O
tail	O
of	O
M6PR	B-GENE-Y
causes	O
the	O
recruitment	O
of	O
AP	B-GENE-N
-	I-GENE-N
1	I-GENE-N
and	O
GGAs	B-GENE-N
to	O
recycling	O
endosomes	O
and	O
not	O
at	O
the	O
Golgi	O
,	O
as	O
predicted	O
by	O
steady	O
state	O
staining	O
profiles	O
.	O

These	O
results	O
are	O
discussed	O
with	O
respect	O
to	O
the	O
generation	O
of	O
novel	O
models	O
for	O
cargo	B-GENE-N
-	O
dependent	O
regulation	O
of	O
membrane	O
traffic	O
.	O

Effects	O
of	O
17α	B-CHEMICAL
-	I-CHEMICAL
ethynylestradiol	I-CHEMICAL
-	O
induced	O
cholestasis	O
on	O
the	O
pharmacokinetics	O
of	O
doxorubicin	B-CHEMICAL
in	O
rats	O
:	O
reduced	O
biliary	O
excretion	O
and	O
hepatic	O
metabolism	O
of	O
doxorubicin	B-CHEMICAL
.	O

Abstract	O
1	O
.	O

Since	O
the	O
prevalent	O
hormonal	O
combination	O
therapy	O
with	O
estrogen	B-CHEMICAL
analogues	O
in	O
cancer	O
patients	O
has	O
frequency	O
and	O
possibility	O
to	O
induce	O
the	O
cholestasis	O
,	O
the	O
frequent	O
combination	O
therapy	O
with	O
17α	B-CHEMICAL
-	I-CHEMICAL
ethynylestradiol	I-CHEMICAL
(	O
EE	O
,	O
an	O
oral	O
contraceptive	O
)	O
and	O
doxorubicin	B-CHEMICAL
(	O
an	O
anticancer	O
drug	O
)	O
might	O
be	O
monitored	O
in	O
aspect	O
of	O
efficacy	O
and	O
safety	O
.	O

Doxorubicin	B-CHEMICAL
is	O
mainly	O
excreted	O
into	O
the	O
bile	O
via	O
P	B-GENE-N
-	I-GENE-N
glycoprotein	I-GENE-N
(	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
and	O
multidrug	B-GENE-Y
resistance	I-GENE-Y
-	I-GENE-Y
associated	I-GENE-Y
protein	I-GENE-Y
2	I-GENE-Y
(	O
Mrp2	B-GENE-Y
)	O
in	O
hepatobiliary	O
route	O
and	O
metabolized	O
via	O
cytochrome	B-GENE-N
P450	I-GENE-N
(	I-GENE-N
CYP	I-GENE-N
)	I-GENE-N
3A	I-GENE-N
subfamily	O
.	O

Also	O
the	O
hepatic	O
Mrp2	B-GENE-Y
(	O
not	O
P	B-GENE-N
-	I-GENE-N
gp	I-GENE-N
)	O
and	O
CYP3A	B-GENE-N
subfamily	O
levels	O
were	O
reduced	O
in	O
EE	O
-	O
induced	O
cholestatic	O
(	O
EEC	O
)	O
rats	O
.	O

Thus	O
,	O
we	O
herein	O
report	O
the	O
pharmacokinetic	O
changes	O
of	O
doxorubicin	B-CHEMICAL
with	O
respect	O
to	O
the	O
changes	O
in	O
its	O
biliary	O
excretion	O
and	O
hepatic	O
metabolism	O
in	O
EEC	O
rats	O
.	O

2	O
.	O

The	O
pharmacokinetic	O
study	O
of	O
doxorubicin	B-CHEMICAL
after	O
intravenous	O
administration	O
of	O
its	O
hydrochloride	B-CHEMICAL
was	O
conducted	O
along	O
with	O
the	O
investigation	O
of	O
bile	O
flow	O
rate	O
and	O
hepatobiliary	O
excretion	O
of	O
doxorubicin	B-CHEMICAL
in	O
control	O
and	O
EEC	O
rats	O
.	O

3	O
.	O

The	O
significantly	O
greater	O
AUC	O
(	O
58	O
.	O
7	O
%	O
increase	O
)	O
of	O
doxorubicin	B-CHEMICAL
in	O
EEC	O
rats	O
was	O
due	O
to	O
the	O
slower	O
CL	O
(	O
32	O
.	O
9	O
%	O
decrease	O
)	O
.	O

The	O
slower	O
CL	O
was	O
due	O
to	O
the	O
reduction	O
of	O
hepatic	O
biliary	O
excretion	O
(	O
67	O
.	O
0	O
%	O
decrease	O
)	O
and	O
hepatic	O
CYP3A	B-GENE-N
subfamily	O
-	O
mediated	O
metabolism	O
(	O
21	O
.	O
9	O
%	O
decrease	O
)	O
of	O
doxorubicin	B-CHEMICAL
.	O

These	O
results	O
might	O
have	O
broader	O
implications	O
to	O
understand	O
the	O
altered	O
pharmacokinetics	O
and	O
/	O
or	O
pharmacologic	O
effects	O
of	O
doxorubicin	B-CHEMICAL
via	O
biliary	O
excretion	O
and	O
hepatic	O
metabolism	O
in	O
experimental	O
and	O
clinical	O
estrogen	B-CHEMICAL
-	O
induced	O
cholestasis	O
.	O

Sodium	B-CHEMICAL
fluoride	I-CHEMICAL
induces	O
apoptosis	O
in	O
odontoblasts	O
via	O
a	O
JNK	B-GENE-N
-	O
dependent	O
mechanism	O
.	O

Sodium	B-CHEMICAL
fluoride	I-CHEMICAL
(	O
NaF	B-CHEMICAL
)	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
dental	O
caries	O
and	O
dentin	O
hypersensitivity	O
.	O

However	O
,	O
its	O
pro	O
-	O
apoptotic	O
effect	O
on	O
odontoblasts	O
may	O
lead	O
to	O
harmful	O
side	O
-	O
effects	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
pro	O
-	O
apoptotic	O
effects	O
of	O
NaF	B-CHEMICAL
in	O
odontoblasts	O
and	O
elucidate	O
the	O
possible	O
underlying	O
molecular	O
mechanisms	O
.	O

NaF	B-CHEMICAL
generated	O
cytotoxic	O
effects	O
in	O
odontoblast	O
-	O
lineage	O
cell	O
(	O
OLC	O
)	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

Exposure	O
of	O
cells	O
to	O
4mM	O
NaF	B-CHEMICAL
for	O
24h	O
induced	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
activation	O
,	O
ultrastructural	O
alterations	O
,	O
and	O
resulted	O
in	O
the	O
translocation	O
of	O
Bax	B-GENE-Y
to	O
the	O
mitochondria	O
and	O
the	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
from	O
the	O
mitochondrial	O
inter	O
-	O
membrane	O
space	O
into	O
the	O
cytosol	O
,	O
indicating	O
that	O
fluoride	B-CHEMICAL
-	O
mediated	O
apoptosis	O
is	O
mitochondria	O
-	O
dependent	O
.	O

Fluoride	B-CHEMICAL
treatment	O
also	O
increased	O
phosphorylation	O
of	O
JNK	B-GENE-N
and	O
ERK	B-GENE-N
,	O
but	O
not	O
p38	B-GENE-N
,	O
and	O
apoptosis	O
induced	O
by	O
fluoride	B-CHEMICAL
was	O
notably	O
or	O
partly	O
suppressed	O
by	O
treatment	O
with	O
JNK	B-GENE-N
or	O
ERK	B-GENE-N
inhibitors	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
NaF	B-CHEMICAL
induces	O
apoptosis	O
in	O
OLC	O
odontoblasts	O
through	O
a	O
JNK	B-GENE-N
-	O
dependent	O
mitochondrial	O
pathway	O
.	O

Significance	O
of	O
the	O
transient	B-GENE-Y
receptor	I-GENE-Y
potential	I-GENE-Y
canonical	I-GENE-Y
2	I-GENE-Y
(	O
TRPC2	B-GENE-Y
)	O
channel	O
in	O
the	O
regulation	O
of	O
rat	O
thyroid	O
FRTL	O
-	O
5	O
cell	O
proliferation	O
,	O
migration	O
,	O
adhesion	O
and	O
invasion	O
.	O

Mammalian	B-GENE-N
transient	I-GENE-N
receptor	I-GENE-N
potential	I-GENE-N
(	I-GENE-N
TRP	I-GENE-N
)	I-GENE-N
channels	I-GENE-N
are	O
involved	O
in	O
many	O
physiologically	O
important	O
processes	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
significance	O
of	O
the	O
TRPC2	B-GENE-Y
channel	O
in	O
the	O
regulation	O
of	O
rat	O
thyroid	O
FRTL	O
-	O
5	O
cell	O
proliferation	O
,	O
migration	O
,	O
adhesion	O
and	O
invasion	O
,	O
using	O
stable	O
TRPC2	B-GENE-Y
(	O
shTRPC2	B-GENE-Y
)	O
knock	O
-	O
down	O
cells	O
.	O

In	O
the	O
shTRPC2	B-GENE-Y
cells	O
,	O
proliferation	O
was	O
decreased	O
due	O
to	O
a	O
prolonged	O
G1	O
/	O
S	O
cell	O
cycle	O
phase	O
.	O

The	O
tumor	B-GENE-Y
suppressor	I-GENE-Y
p53	I-GENE-Y
and	O
the	O
cyclin	B-GENE-Y
-	I-GENE-Y
dependant	I-GENE-Y
kinase	I-GENE-Y
inhibitors	I-GENE-Y
p27	I-GENE-Y
and	O
p21	B-GENE-Y
were	O
upregulated	O
.	O

Cell	O
invasion	O
,	O
adhesion	O
and	O
migration	O
were	O
also	O
attenuated	O
in	O
shTRPC2	B-GENE-Y
cells	O
,	O
probably	O
due	O
to	O
decreased	O
activity	O
of	O
both	O
Rac	B-GENE-N
and	O
calpain	B-GENE-N
,	O
and	O
a	O
decreased	O
secretion	O
and	O
activity	O
of	O
matrix	B-GENE-Y
metalloproteinase	I-GENE-Y
2	I-GENE-Y
.	O

The	O
attenuated	O
proliferation	O
,	O
migration	O
,	O
invasion	O
and	O
ATP	B-CHEMICAL
-	O
evoked	O
calcium	B-CHEMICAL
entry	O
was	O
mimicked	O
by	O
overexpressing	O
a	O
non	O
-	O
conducting	O
,	O
truncated	O
TRPC2	B-GENE-Y
(	O
TRPC2	B-GENE-Y
-	O
DN	O
)	O
in	O
wild	O
type	O
cells	O
,	O
and	O
was	O
reversed	O
by	O
overexpression	O
of	O
TRPC2	B-GENE-Y
-	O
GFP	O
in	O
shTRPC2	B-GENE-Y
cells	O
.	O

In	O
conclusion	O
,	O
TRPC2	B-GENE-Y
is	O
an	O
important	O
regulator	O
of	O
rat	O
thyroid	O
cell	O
function	O
.	O

Glutathione	B-CHEMICAL
conjugation	O
attenuates	O
biological	O
activities	O
of	O
6	B-CHEMICAL
-	I-CHEMICAL
dehydroshogaol	I-CHEMICAL
from	O
ginger	O
.	O

6	B-CHEMICAL
-	I-CHEMICAL
Dehydroshogaol	I-CHEMICAL
(	O
6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
)	O
is	O
a	O
bioactive	O
α	B-CHEMICAL
,	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
unsaturated	I-CHEMICAL
carbonyl	I-CHEMICAL
compound	O
isolated	O
from	O
fresh	O
ginger	O
with	O
anti	O
-	O
inflammatory	O
and	O
phase	O
II	O
enzyme	O
inducing	O
activities	O
.	O

Here	O
we	O
describe	O
the	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
-	O
dependent	O
metabolism	O
and	O
the	O
effect	O
of	O
this	O
metabolic	O
transformation	O
on	O
the	O
biological	O
activities	O
of	O
6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
.	O

Compared	O
with	O
other	O
ginger	O
compounds	O
,	O
such	O
as	O
6	B-CHEMICAL
-	I-CHEMICAL
gingerol	I-CHEMICAL
and	O
6	B-CHEMICAL
-	I-CHEMICAL
shogaol	I-CHEMICAL
,	O
6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
showed	O
the	O
most	O
potent	O
anti	O
-	O
inflammatory	O
effect	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
stimulated	O
RAW	O
264	O
.	O
7	O
cells	O
.	O

The	O
biological	O
activities	O
of	O
6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
were	O
attenuated	O
by	O
sulfhydryl	B-CHEMICAL
antioxidants	O
such	O
as	O
glutathione	B-CHEMICAL
(	O
GSH	B-CHEMICAL
)	O
or	O
N	B-CHEMICAL
-	I-CHEMICAL
acetyl	I-CHEMICAL
cysteine	I-CHEMICAL
(	O
NAC	B-CHEMICAL
)	O
,	O
but	O
not	O
ascorbic	B-CHEMICAL
acid	I-CHEMICAL
(	O
ASC	B-CHEMICAL
)	O
.	O

6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
was	O
metabolised	O
by	O
GSH	B-CHEMICAL
to	O
form	O
a	O
GSH	B-CHEMICAL
conjugate	O
(	O
GS	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
)	O
in	O
RAW	O
264	O
.	O
7	O
cells	O
,	O
via	O
a	O
potential	O
mechanism	O
involving	O
the	O
catalytic	O
activity	O
of	O
glutathione	B-GENE-N
-	I-GENE-N
S	I-GENE-N
-	I-GENE-N
transferase	I-GENE-N
(	O
GST	B-GENE-N
)	O
.	O

GS	B-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
showed	O
reduced	O
biological	O
activities	O
compared	O
with	O
6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
in	O
multiple	O
biological	O
assays	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
GSH	B-CHEMICAL
conjugation	O
attenuates	O
the	O
biological	O
activities	O
of	O
6	B-CHEMICAL
-	I-CHEMICAL
DHSG	I-CHEMICAL
and	O
other	O
α	B-CHEMICAL
,	I-CHEMICAL
β	I-CHEMICAL
-	I-CHEMICAL
unsaturated	I-CHEMICAL
carbonyl	I-CHEMICAL
compounds	O
.	O

Conjugated	O
linoleic	B-CHEMICAL
acid	I-CHEMICAL
and	O
calcium	B-CHEMICAL
co	O
-	O
supplementation	O
improves	O
bone	O
health	O
in	O
ovariectomised	O
mice	O
.	O

Osteoporosis	O
is	O
a	O
significant	O
health	O
concern	O
for	O
the	O
elderly	O
;	O
conjugated	O
linoleic	B-CHEMICAL
acid	I-CHEMICAL
(	O
CLA	O
)	O
has	O
been	O
shown	O
to	O
improve	O
overall	O
bone	O
mass	O
when	O
calcium	B-CHEMICAL
is	O
included	O
as	O
a	O
co	O
-	O
supplement	O
.	O

However	O
,	O
potential	O
effects	O
of	O
CLA	O
and	O
calcium	B-CHEMICAL
on	O
bone	O
mass	O
during	O
a	O
period	O
of	O
bone	O
loss	O
have	O
not	O
been	O
reported	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
how	O
dietary	O
calcium	B-CHEMICAL
modulates	O
the	O
effects	O
of	O
conjugated	O
linoleic	B-CHEMICAL
acid	I-CHEMICAL
(	O
CLA	O
)	O
in	O
preventing	O
bone	O
loss	O
,	O
using	O
an	O
ovariectomised	O
mouse	O
model	O
.	O

CLA	O
supplementation	O
significantly	O
prevented	O
ovariectomy	O
-	O
associated	O
weight	O
and	O
fat	O
mass	O
gain	O
,	O
compared	O
to	O
non	O
-	O
supplemented	O
controls	O
.	O

CLA	O
significantly	O
increased	O
bone	O
markers	O
without	O
major	O
changes	O
in	O
bone	O
mineral	O
composition	O
in	O
the	O
femur	O
compared	O
to	O
respective	O
controls	O
.	O

CLA	O
treatment	O
increased	O
serum	O
parathyroid	B-GENE-Y
hormone	I-GENE-Y
(	O
PTH	B-GENE-Y
)	O
significantly	O
(	O
p	O
=	O
0	O
.	O
0172	O
)	O
,	O
while	O
serum	O
1	B-CHEMICAL
,	I-CHEMICAL
25	I-CHEMICAL
-	I-CHEMICAL
dihydroxyvitamin	I-CHEMICAL
D3	I-CHEMICAL
concentration	O
was	O
not	O
changed	O
by	O
CLA	O
.	O

Meanwhile	O
,	O
CLA	O
significantly	O
reduced	O
femur	O
tartrate	B-GENE-Y
resistant	I-GENE-Y
acid	I-GENE-Y
phosphatase	I-GENE-Y
(	O
TRAP	B-GENE-Y
)	O
activity	O
,	O
suggesting	O
potential	O
reduction	O
of	O
osteoclastogenesis	O
.	O

The	O
data	O
suggest	O
that	O
CLA	O
,	O
along	O
with	O
dietary	O
calcium	B-CHEMICAL
,	O
has	O
great	O
potential	O
to	O
be	O
used	O
to	O
prevent	O
bone	O
loss	O
and	O
weight	O
gain	O
associated	O
with	O
menopause	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
carbamoylmethylene	B-CHEMICAL
linked	O
prodrugs	O
of	O
BMS	B-CHEMICAL
-	I-CHEMICAL
582949	I-CHEMICAL
,	O
a	O
clinical	O
p38α	B-GENE-Y
inhibitor	O
.	O

A	O
series	O
of	O
carbamoylmethylene	B-CHEMICAL
linked	O
prodrugs	O
of	O
1	O
(	O
BMS	B-CHEMICAL
-	I-CHEMICAL
582949	I-CHEMICAL
)	O
,	O
a	O
clinical	O
p38α	B-GENE-Y
inhibitor	O
,	O
were	O
synthesized	O
and	O
evaluated	O
.	O

Though	O
the	O
phosphoryloxymethylene	B-CHEMICAL
carbamates	I-CHEMICAL
(	O
3	O
,	O
4	O
,	O
and	O
5	O
)	O
and	O
α	B-CHEMICAL
-	I-CHEMICAL
aminoacyloxymethylene	I-CHEMICAL
carbamates	I-CHEMICAL
(	O
22	O
,	O
23	O
,	O
and	O
26	O
)	O
were	O
found	O
unstable	O
at	O
neutral	O
pH	O
values	O
,	O
fumaric	B-CHEMICAL
acid	I-CHEMICAL
derived	O
acyloxymethylene	B-CHEMICAL
carbamates	I-CHEMICAL
(	O
2	O
,	O
28	O
,	O
and	O
31	O
)	O
were	O
highly	O
stable	O
under	O
both	O
acidic	O
and	O
neutral	O
conditions	O
.	O

Prodrugs	O
2	O
and	O
31	O
were	O
also	O
highly	O
soluble	O
at	O
both	O
acidic	O
and	O
neutral	O
pH	O
values	O
.	O

At	O
a	O
solution	O
dose	O
of	O
14	O
.	O
2mpk	O
(	O
equivalent	O
to	O
10mpk	O
of	O
1	O
)	O
,	O
2	O
gave	O
essentially	O
the	O
same	O
exposure	O
of	O
1	O
compared	O
to	O
dosing	O
10mpk	O
of	O
1	O
itself	O
.	O

At	O
a	O
suspension	O
dose	O
of	O
142mpk	O
(	O
equivalent	O
to	O
100mpk	O
of	O
1	O
)	O
,	O
2	O
demonstrated	O
that	O
it	O
could	O
overcome	O
the	O
solubility	O
issue	O
associated	O
with	O
1	O
and	O
provide	O
a	O
much	O
higher	O
exposure	O
of	O
1	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
unique	O
type	O
of	O
prodrugs	O
like	O
2	O
,	O
28	O
,	O
and	O
31	O
was	O
not	O
reported	O
in	O
the	O
past	O
and	O
could	O
represent	O
a	O
novel	O
prodrug	O
approach	O
for	O
secondary	B-CHEMICAL
amides	I-CHEMICAL
,	O
a	O
class	O
of	O
molecules	O
frequently	O
identified	O
as	O
drug	O
candidates	O
.	O

Conformationally	O
restricted	O
homotryptamines	B-CHEMICAL
.	O

Part	O
6	O
:	O
Indole	B-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
cycloalkyl	I-CHEMICAL
methylamines	I-CHEMICAL
as	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
.	O

Racemic	B-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminomethylcyclopropyl	I-CHEMICAL
)	I-CHEMICAL
indoles	I-CHEMICAL
,	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminomethylcyclopentyl	I-CHEMICAL
)	I-CHEMICAL
indoles	I-CHEMICAL
,	O
and	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
cis	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminomethylcyclopentyl	I-CHEMICAL
)	I-CHEMICAL
indoles	I-CHEMICAL
were	O
synthesized	O
and	O
evaluated	O
as	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
.	O

These	O
analogs	O
followed	O
SAR	O
trends	O
similar	O
to	O
those	O
previously	O
reported	O
for	O
3	B-CHEMICAL
-	I-CHEMICAL
cycloalkyl	I-CHEMICAL
substituted	I-CHEMICAL
indoles	I-CHEMICAL
.	O

The	O
most	O
potent	O
analogs	O
exhibited	O
single	O
digit	O
nanomolar	O
inhibition	O
at	O
the	O
human	B-GENE-Y
serotonin	I-GENE-Y
transporter	I-GENE-Y
but	O
were	O
10	O
-	O
fold	O
less	O
active	O
than	O
the	O
previously	O
reported	O
compounds	O
.	O

Monoacylglycerol	B-GENE-Y
lipase	I-GENE-Y
inhibition	O
-	O
induced	O
changes	O
in	O
plasma	O
corticosterone	B-CHEMICAL
levels	O
,	O
anxiety	O
and	O
locomotor	O
activity	O
in	O
male	O
CD1	O
mice	O
.	O

The	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
-	O
axis	O
is	O
strongly	O
controlled	O
by	O
the	O
endocannabinoid	O
system	O
.	O

The	O
specific	O
impact	O
of	O
enhanced	O
2	B-CHEMICAL
-	I-CHEMICAL
arachidonoylglycerol	I-CHEMICAL
signaling	O
on	O
corticosterone	B-CHEMICAL
plasma	O
levels	O
,	O
however	O
,	O
was	O
not	O
investigated	O
so	O
far	O
.	O

Here	O
we	O
studied	O
the	O
effects	O
of	O
the	O
recently	O
developed	O
monoacylglycerol	B-GENE-Y
lipase	I-GENE-Y
inhibitor	O
JZL184	B-CHEMICAL
on	O
basal	O
and	O
stress	O
-	O
induced	O
corticosterone	B-CHEMICAL
levels	O
in	O
male	O
CD1	O
mice	O
,	O
and	O
found	O
that	O
this	O
compound	O
dramatically	O
increased	O
basal	O
levels	O
without	O
affecting	O
stress	O
responses	O
.	O

Since	O
acute	O
changes	O
in	O
corticosterone	B-CHEMICAL
levels	O
can	O
affect	O
behavior	O
,	O
JZL184	B-CHEMICAL
was	O
administered	O
concurrently	O
with	O
the	O
corticosterone	B-CHEMICAL
synthesis	O
inhibitor	O
metyrapone	B-CHEMICAL
,	O
to	O
investigate	O
whether	O
the	O
previously	O
shown	O
behavioral	O
effects	O
of	O
JZL184	B-CHEMICAL
are	O
dependent	O
on	O
corticosterone	B-CHEMICAL
.	O

We	O
found	O
that	O
in	O
the	O
elevated	O
plus	O
-	O
maze	O
,	O
the	O
effects	O
of	O
JZL184	B-CHEMICAL
on	O
"	O
classical	O
"	O
anxiety	O
-	O
related	O
measures	O
were	O
abolished	O
by	O
corticosterone	B-CHEMICAL
synthesis	O
blockade	O
.	O

By	O
contrast	O
,	O
effects	O
on	O
the	O
"	O
ethological	O
"	O
measures	O
of	O
anxiety	O
(	O
i	O
.	O
e	O
.	O
risk	O
assessment	O
)	O
were	O
not	O
affected	O
by	O
metyrapone	B-CHEMICAL
.	O

In	O
the	O
open	O
-	O
field	O
,	O
the	O
locomotion	O
-	O
enhancing	O
effects	O
of	O
the	O
compound	O
were	O
not	O
changed	O
either	O
.	O

These	O
findings	O
show	O
that	O
monoacylglycerol	B-GENE-Y
lipase	I-GENE-Y
inhibition	O
dramatically	O
increases	O
basal	O
levels	O
of	O
corticosterone	B-CHEMICAL
.	O

This	O
endocrine	O
effect	O
partly	O
affects	O
the	O
anxiolytic	O
,	O
but	O
not	O
the	O
locomotion	O
-	O
enhancing	O
effects	O
of	O
monoacylglycerol	B-GENE-Y
lipase	I-GENE-Y
blockade	O
.	O

Mechanisms	O
of	O
Glucose	B-CHEMICAL
Lowering	O
of	O
Dipeptidyl	B-GENE-Y
Peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
Inhibitor	O
Sitagliptin	B-CHEMICAL
When	O
Used	O
Alone	O
or	O
With	O
Metformin	B-CHEMICAL
in	O
Type	O
2	O
Diabetes	O
:	O
A	O
double	O
-	O
tracer	O
study	O
.	O

OBJECTIVETo	O
assess	O
glucose	B-CHEMICAL
-	O
lowering	O
mechanisms	O
of	O
sitagliptin	B-CHEMICAL
(	O
S	O
)	O
,	O
metformin	B-CHEMICAL
(	O
M	O
)	O
,	O
and	O
the	O
two	O
combined	O
(	O
M	O
+	O
S	O
)	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
randomized	O
16	O
patients	O
with	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
to	O
four	O
6	O
-	O
week	O
treatments	O
with	O
placebo	O
(	O
P	O
)	O
,	O
M	O
,	O
S	O
,	O
and	O
M	O
+	O
S	O
.	O

After	O
each	O
period	O
,	O
subjects	O
received	O
a	O
6	O
-	O
h	O
meal	O
tolerance	O
test	O
(	O
MTT	B-CHEMICAL
)	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
glucose	I-CHEMICAL
to	O
calculate	O
glucose	B-CHEMICAL
kinetics	O
.	O

Fasting	O
plasma	O
glucose	B-CHEMICAL
(	O
FPG	O
)	O
,	O
fasting	O
plasma	O
insulin	B-GENE-Y
,	O
C	B-GENE-Y
-	I-GENE-Y
peptide	I-GENE-Y
(	O
insulin	B-GENE-Y
secretory	O
rate	O
[	O
ISR	O
]	O
)	O
,	O
fasting	O
plasma	O
glucagon	B-GENE-Y
,	O
and	O
bioactive	O
glucagon	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
(	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
gastrointestinal	B-GENE-Y
insulinotropic	I-GENE-Y
peptide	I-GENE-Y
(	O
GIP	B-GENE-Y
)	O
was	O
measured	O
.	O
RESULTSFPG	O
decreased	O
from	O
P	O
,	O
160	O
±	O
4	O
to	O
M	O
,	O
150	O
±	O
4	O
;	O
S	O
,	O
154	O
±	O
4	O
;	O
and	O
M	O
+	O
S	O
,	O
125	O
±	O
3	O
mg	O
/	O
dL	O
.	O

Mean	O
post	O
-	O
MTT	B-CHEMICAL
PG	O
decreased	O
from	O
P	O
,	O
207	O
±	O
5	O
to	O
M	O
,	O
191	O
±	O
4	O
;	O
S	O
,	O
195	O
±	O
4	O
;	O
and	O
M	O
+	O
S	O
,	O
161	O
±	O
3	O
mg	O
/	O
dL	O
(	O
P	O
<	O
0	O
.	O
01	O
]	O
.	O

The	O
increase	O
in	O
mean	O
post	O
-	O
MTT	B-CHEMICAL
plasma	O
insulin	B-GENE-Y
and	O
in	O
ISR	O
was	O
similar	O
in	O
P	O
,	O
M	O
,	O
and	O
S	O
and	O
slightly	O
greater	O
in	O
M	O
+	O
S	O
.	O

Fasting	O
plasma	O
glucagon	B-GENE-Y
was	O
equal	O
(	O
∼	O
65	O
-	O
75	O
pg	O
/	O
mL	O
)	O
with	O
all	O
treatments	O
,	O
but	O
there	O
was	O
a	O
significant	O
drop	O
during	O
the	O
initial	O
120	O
min	O
with	O
S	O
24	O
%	O
and	O
M	O
+	O
S	O
34	O
%	O
(	O
both	O
P	O
<	O
0	O
.	O
05	O
)	O
vs	O
.	O
P	O
17	O
%	O
and	O
M	O
16	O
%	O
.	O

Fasting	O
and	O
mean	O
post	O
-	O
MTT	B-CHEMICAL
plasma	O
bioactive	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
after	O
S	O
and	O
M	O
+	O
S	O
vs	O
.	O
M	O
and	O
P	O
.	O

Basal	O
endogenous	O
glucose	B-CHEMICAL
production	O
(	O
EGP	O
)	O
fell	O
from	O
P	O
2	O
.	O
0	O
±	O
0	O
.	O
1	O
to	O
S	O
1	O
.	O
8	O
±	O
0	O
.	O
1	O
mg	O
/	O
kg	O
⋅	O
min	O
,	O
M	O
1	O
.	O
8	O
±	O
0	O
.	O
2	O
mg	O
/	O
kg	O
⋅	O
min	O
[	O
both	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
P	O
)	O
,	O
and	O
M	O
+	O
S	O
1	O
.	O
5	O
±	O
0	O
.	O
1	O
mg	O
/	O
kg	O
⋅	O
min	O
(	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O
P	O
)	O
.	O

Although	O
the	O
EGP	O
slope	O
of	O
decline	O
was	O
faster	O
in	O
M	O
and	O
M	O
+	O
S	O
vs	O
.	O
S	O
,	O
all	O
had	O
comparable	O
greater	O
post	O
-	O
MTT	O
EGP	O
inhibition	O
vs	O
.	O
P	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
CONCLUSIONSM	O
+	O
S	O
combined	O
produce	O
additive	O
effects	O
to	O
1	O
)	O
reduce	O
FPG	O
and	O
postmeal	O
PG	O
,	O
2	O
)	O
augment	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
secretion	O
and	O
β	O
-	O
cell	O
function	O
,	O
3	O
)	O
decrease	O
plasma	O
glucagon	B-GENE-Y
,	O
and	O
4	O
)	O
inhibit	O
fasting	O
and	O
postmeal	O
EGP	O
compared	O
with	O
M	O
or	O
S	O
monotherapy	O
.	O

Anti	O
-	O
asthmatic	O
Effects	O
of	O
Baicalin	B-CHEMICAL
in	O
a	O
Mouse	O
Model	O
of	O
Allergic	O
Asthma	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
anti	O
-	O
asthmatic	O
effects	O
of	O
baicalin	B-CHEMICAL
(	O
BA	O
)	O
and	O
the	O
possible	O
mechanisms	O
.	O

Asthma	O
model	O
was	O
established	O
by	O
ovalbumin	B-GENE-Y
(	O
OVA	B-GENE-Y
)	O
intraperitoneal	O
injection	O
.	O

A	O
total	O
of	O
60	O
mice	O
were	O
randomly	O
assigned	O
to	O
six	O
experimental	O
groups	O
:	O
control	O
,	O
model	O
,	O
dexamethasone	B-CHEMICAL
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
and	O
BA	O
(	O
10	O
mg	O
/	O
kg	O
,	O
20	O
mg	O
/	O
kg	O
,	O
40	O
mg	O
/	O
kg	O
)	O
.	O

Airway	O
resistance	O
(	O
RI	O
)	O
and	O
lung	O
compliance	O
(	O
Cdyn	O
)	O
were	O
measured	O
,	O
histological	O
studies	O
were	O
evaluated	O
by	O
the	O
hematoxylin	B-CHEMICAL
and	O
eosin	B-CHEMICAL
staining	O
,	O
Th1	O
/	O
Th2	O
,	O
OVA	B-GENE-Y
-	O
specific	O
serum	O
,	O
and	O
BALF	O
IgE	B-GENE-N
levels	O
and	O
Th17	O
cytokines	B-GENE-N
were	O
evaluated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
,	O
and	O
Th17	O
cells	O
was	O
evaluated	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

Our	O
study	O
demonstrated	O
that	O
BA	O
inhibited	O
OVA	B-GENE-Y
-	O
induced	O
increases	O
in	O
RI	O
and	O
eosinophil	O
count	O
;	O
interleukin	O
(	B-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
17A	I-GENE-Y
levels	O
,	O
and	O
Cdyn	O
were	O
recovered	O
and	O
increased	O
IFN	B-GENE-Y
-	I-GENE-Y
γ	I-GENE-Y
level	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

Histological	O
studies	O
demonstrated	O
that	O
BA	O
substantially	O
inhibited	O
OVA	B-GENE-Y
-	O
induced	O
eosinophilia	O
in	O
lung	O
tissue	O
and	O
airway	O
tissue	O
.	O

FCM	O
studies	O
demonstrated	O
that	O
BA	O
substantially	O
inhibited	O
Th17	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
BA	O
may	O
effectively	O
ameliorate	O
the	O
progression	O
of	O
asthma	O
and	O
could	O
be	O
used	O
as	O
a	O
therapy	O
for	O
patients	O
with	O
allergic	O
asthma	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Anti	O
-	O
Ulcerative	O
Colitis	O
Activity	O
of	O
Compounds	O
from	O
Euphorbia	O
granuleta	O
Forssk	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
anti	O
-	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
activity	O
of	O
the	O
total	O
alcohol	B-CHEMICAL
extracts	O
of	O
Euphorbia	O
granuleta	O
Forssk	O
.	O

(	O
Euphorpiaceae	O
)	O
,	O
isolate	O
and	O
identify	O
the	O
active	O
compounds	O
that	O
could	O
be	O
responsible	O
for	O
the	O
activity	O
,	O
in	O
addition	O
to	O
determination	O
of	O
the	O
possible	O
mechanism	O
of	O
action	O
.	O

Six	O
compounds	O
were	O
isolated	O
and	O
identified	O
from	O
this	O
plant	O
:	O
three	O
phenolic	B-CHEMICAL
compounds	O
(	O
kampferol	B-CHEMICAL
,	O
kampferol	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
glucoside	I-CHEMICAL
and	O
kampferol	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
galactoside	I-CHEMICAL
)	O
in	O
addition	O
to	O
three	O
steroidal	O
compounds	O
(	O
1	B-CHEMICAL
-	I-CHEMICAL
ethoxypentacosane	I-CHEMICAL
,	O
heptacosan	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
ol	I-CHEMICAL
and	O
β	B-CHEMICAL
-	I-CHEMICAL
sitosterol	I-CHEMICAL
)	O
.	O

Three	O
compounds	O
(	O
heptacosan	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
ol	I-CHEMICAL
,	O
β	B-CHEMICAL
-	I-CHEMICAL
sitosterol	I-CHEMICAL
and	O
kampferol	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
galactoside	I-CHEMICAL
)	O
were	O
found	O
to	O
be	O
responsible	O
for	O
the	O
anti	O
-	O
UC	O
activity	O
of	O
E	O
.	O
granuleta	O
extract	O
.	O

The	O
anti	O
-	O
UC	O
activity	O
of	O
these	O
compounds	O
may	O
be	O
explained	O
by	O
reducing	O
the	O
pro	O
-	O
inflammatory	O
cytokine	B-GENE-N
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
in	O
addition	O
to	O
reduction	O
of	O
colonic	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
contents	O
.	O

No	O
side	O
effects	O
were	O
reported	O
on	O
liver	O
and	O
kidney	O
functions	O
.	O

The	O
active	O
compounds	O
reduced	O
both	O
serum	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
and	O
mucosal	O
MDA	B-CHEMICAL
levels	O
.	O

Copyright	O
©	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

Optoelectronic	O
Processes	O
in	O
Squaraine	B-CHEMICAL
Dye	I-CHEMICAL
-	O
Doped	O
OLEDs	O
for	O
Emission	O
in	O
the	O
Near	O
-	O
Infrared	O
.	O

A	O
novel	O
all	O
-	O
organic	O
host	O
-	O
guest	O
system	O
for	O
emission	O
in	O
the	O
NIR	O
is	O
introduced	O
and	O
investigated	O
with	O
respect	O
to	O
its	O
opto	O
-	O
electronic	O
processes	O
.	O

The	O
good	O
agreement	O
between	O
theoretical	O
and	O
experimental	O
results	O
highlights	O
the	O
model	O
character	O
of	O
this	O
system	O
and	O
its	O
potential	O
for	O
electroluminescent	O
application	O
.	O

Comparative	O
measurements	O
provide	O
access	O
to	O
the	O
recombination	O
mechanisms	O
on	O
molecular	O
length	O
scale	O
and	O
show	O
that	O
the	O
emission	O
behavior	O
of	O
the	O
device	O
under	O
operation	O
is	O
controlled	O
by	O
charge	O
carrier	O
dynamics	O
.	O

Pharmacological	O
Inhibition	O
of	O
Platelet	O
-	O
tumor	O
Cell	O
Cross	O
-	O
talk	O
Prevents	O
Platelet	O
-	O
induced	O
Overexpression	O
of	O
Cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
in	O
HT29	O
Human	O
Colon	O
Carcinoma	O
Cells	O
.	O

Cyclooxygenase	B-GENE-Y
(	I-GENE-Y
COX	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
derived	O
prostanoids	B-CHEMICAL
can	O
influence	O
several	O
processes	O
that	O
are	O
linked	O
to	O
carcinogenesis	O
.	O

We	O
aimed	O
to	O
address	O
the	O
hypothesis	O
that	O
platelets	O
contribute	O
to	O
aberrant	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
in	O
HT29	O
colon	O
carcinoma	O
cells	O
and	O
to	O
reveal	O
the	O
role	O
of	O
platelet	O
-	O
induced	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
on	O
the	O
expression	O
of	O
proteins	O
involved	O
in	O
malignancy	O
and	O
marker	O
genes	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Human	O
platelets	O
co	O
-	O
cultured	O
with	O
HT29	O
cells	O
rapidly	O
adhered	O
to	O
cancer	O
cells	O
and	O
induced	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mRNA	O
expression	O
,	O
but	O
not	O
protein	O
synthesis	O
which	O
required	O
the	O
late	O
release	O
of	O
platelet	O
PDGF	B-GENE-N
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
mRNA	O
stabilization	O
.	O

Platelet	O
-	O
induced	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
-	O
dependent	O
PGE2	B-CHEMICAL
synthesis	O
in	O
HT29	O
cells	O
was	O
involved	O
in	O
downregulation	O
of	O
p21	B-GENE-Y
(	O
WAF1	B-GENE-Y
/	O
CIP1	B-GENE-Y
)	O
and	O
upregulation	O
of	O
cyclinB1	B-GENE-Y
,	O
since	O
these	O
effects	O
were	O
prevented	O
by	O
rofecoxib	B-CHEMICAL
(	O
a	O
selective	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
inhibitor	O
)	O
and	O
rescued	O
by	O
exogenous	O
PGE2	B-CHEMICAL
.	O

Galectin	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
highly	O
expressed	O
in	O
HT29	O
cells	O
,	O
is	O
unique	O
among	O
galectins	O
because	O
it	O
contains	O
a	O
collagen	B-GENE-N
-	I-GENE-N
like	I-GENE-N
domain	I-GENE-N
.	O

Thus	O
,	O
we	O
studied	O
the	O
role	O
of	O
galectin	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
and	O
platelet	B-GENE-Y
collagen	I-GENE-Y
receptors	I-GENE-Y
in	O
platelet	O
-	O
induced	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
overexpression	O
.	O

Inhibitors	O
of	O
galectin	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
function	O
(	O
β	B-CHEMICAL
-	I-CHEMICAL
lactose	I-CHEMICAL
,	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
galectin	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
,	O
Gal	B-GENE-Y
-	I-GENE-Y
3C	I-GENE-Y
,	O
and	O
anti	O
-	O
galectin	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
antibody	O
M3	O
/	O
38	O
)	O
or	O
collagen	B-GENE-Y
receptor	I-GENE-Y
-	O
mediated	O
platelet	O
adhesion	O
(	O
revacept	O
,	O
a	O
dimeric	O
collagen	B-GENE-Y
receptor	I-GENE-Y
GPVI	B-GENE-Y
-	O
Fc	B-GENE-N
)	O
prevented	O
aberrant	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
.	O

Inhibition	O
of	O
platelet	O
-	O
cancer	O
cell	O
interaction	O
by	O
revacept	O
was	O
more	O
effective	O
than	O
rofecoxib	B-CHEMICAL
in	O
preventing	O
platelet	O
-	O
induced	O
mRNA	O
changes	O
of	O
EMT	O
markers	O
suggesting	O
that	O
direct	O
cell	O
-	O
cell	O
contact	O
and	O
aberrant	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
synergistically	O
induced	O
gene	O
expression	O
modifications	O
associated	O
with	O
EMT	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
provide	O
the	O
rationale	O
for	O
testing	O
blockers	O
of	O
collagen	B-GENE-N
binding	I-GENE-N
sites	I-GENE-N
,	O
such	O
as	O
revacept	O
,	O
and	O
galectin	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
inhibitors	O
in	O
the	O
prevention	O
of	O
colon	O
cancer	O
metastasis	O
in	O
animal	O
models	O
followed	O
by	O
studies	O
in	O
patients	O
.	O

Synthesis	O
and	O
antitumor	O
activity	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
oxadiazole	I-CHEMICAL
possessing	O
1	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
benzodioxan	I-CHEMICAL
moiety	O
as	O
a	O
novel	O
class	O
of	O
potent	O
methionine	B-GENE-Y
aminopeptidase	I-GENE-Y
type	I-GENE-Y
II	I-GENE-Y
inhibitors	O
.	O

A	O
series	O
of	O
1	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
oxadiazole	I-CHEMICAL
derivatives	O
containing	O
1	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
benzodioxan	I-CHEMICAL
moiety	O
(	O
7a	O
-	O
7q	O
)	O
have	O
been	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
for	O
their	O
antitumor	O
activity	O
.	O

Most	O
of	O
the	O
synthesized	O
compounds	O
were	O
proved	O
to	O
have	O
potent	O
antitumor	O
activity	O
and	O
low	O
toxicity	O
.	O

Among	O
them	O
,	O
compound	O
7a	O
showed	O
the	O
most	O
potent	O
biological	O
activity	O
against	O
Human	O
Umbilical	O
Vein	O
Endothelial	O
cells	O
,	O
which	O
was	O
comparable	O
to	O
the	O
positive	O
control	O
.	O

The	O
results	O
of	O
apoptosis	O
and	O
flow	O
cytometry	O
(	O
FCM	O
)	O
demonstrated	O
that	O
compound	O
7a	O
induce	O
cell	O
apoptosis	O
by	O
the	O
inhibition	O
of	O
MetAP2	B-GENE-Y
pathway	O
.	O

Molecular	O
docking	O
was	O
performed	O
to	O
position	O
compound	O
7a	O
into	O
MetAP2	B-GENE-Y
binding	O
site	O
in	O
order	O
to	O
explore	O
the	O
potential	O
target	O
.	O

Quinone	B-CHEMICAL
compounds	O
regulate	O
the	O
level	O
of	O
ROS	O
production	O
by	O
the	O
NADPH	B-GENE-N
oxidase	I-GENE-N
Nox4	B-GENE-Y
.	O

NADPH	B-GENE-N
oxidase	I-GENE-N
Nox4	B-GENE-Y
is	O
expressed	O
in	O
a	O
wide	O
range	O
of	O
tissues	O
and	O
plays	O
a	O
role	O
in	O
cellular	O
signaling	O
by	O
providing	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
as	O
intracellular	O
messengers	O
.	O

Nox4	B-GENE-Y
oxidase	B-GENE-N
activity	O
is	O
thought	O
to	O
be	O
constitutive	O
and	O
regulated	O
at	O
the	O
transcriptional	O
level	O
;	O
however	O
,	O
we	O
challenge	O
this	O
point	O
of	O
view	O
and	O
suggest	O
that	O
specific	O
quinone	B-CHEMICAL
derivatives	O
could	O
modulate	O
this	O
activity	O
.	O

In	O
fact	O
,	O
we	O
demonstrated	O
a	O
significant	O
stimulation	O
of	O
Nox4	B-GENE-Y
activity	O
by	O
4	O
quinone	B-CHEMICAL
derivatives	O
(	O
AA	B-CHEMICAL
-	I-CHEMICAL
861	I-CHEMICAL
,	O
tBuBHQ	B-CHEMICAL
,	O
tBuBQ	B-CHEMICAL
,	O
and	O
duroquinone	B-CHEMICAL
)	O
observed	O
in	O
3	O
different	O
cellular	O
models	O
,	O
HEK293E	O
,	O
T	O
-	O
REx	O
™	O
,	O
and	O
chondrocyte	O
cell	O
lines	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
effect	O
is	O
specific	O
toward	O
Nox4	B-GENE-Y
versus	O
Nox2	B-GENE-Y
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
NAD	B-GENE-Y
(	I-GENE-Y
P	I-GENE-Y
)	I-GENE-Y
H	I-GENE-Y
:	I-GENE-Y
quinone	I-GENE-Y
oxidoreductase	I-GENE-Y
(	O
NQO1	B-GENE-Y
)	O
may	O
participate	O
in	O
this	O
stimulation	O
.	O

Interestingly	O
,	O
Nox4	B-GENE-Y
activity	O
is	O
also	O
stimulated	O
by	O
reducing	O
agents	O
that	O
possibly	O
act	O
by	O
reducing	O
the	O
disulfide	B-CHEMICAL
bridge	O
(	O
Cys226	B-CHEMICAL
,	O
Cys270	B-CHEMICAL
)	O
located	O
in	O
the	O
extracellular	B-GENE-N
E	I-GENE-N
-	I-GENE-N
loop	I-GENE-N
of	O
Nox4	B-GENE-Y
.	O

Such	O
model	O
of	O
Nox4	B-GENE-Y
activity	O
regulation	O
could	O
provide	O
new	O
insight	O
into	O
the	O
understanding	O
of	O
the	O
molecular	O
mechanism	O
of	O
the	O
electron	O
transfer	O
through	O
the	O
enzyme	O
,	O
i	O
.	O
e	O
.	O
,	O
its	O
potential	O
redox	O
regulation	O
,	O
and	O
could	O
also	O
define	O
new	O
therapeutic	O
targets	O
in	O
diseases	O
in	O
which	O
quinones	B-CHEMICAL
and	O
Nox4	B-GENE-Y
are	O
implicated	O
.	O

Short	O
-	O
term	O
heating	O
reduces	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
fresh	O
raw	O
garlic	O
extracts	O
on	O
the	O
LPS	O
-	O
induced	O
production	O
of	O
NO	B-CHEMICAL
and	O
pro	O
-	O
inflammatory	O
cytokines	B-GENE-N
by	O
downregulating	O
allicin	B-CHEMICAL
activity	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

Garlic	O
has	O
a	O
variety	O
of	O
biologic	O
activities	O
,	O
including	O
anti	O
-	O
inflammatory	O
properties	O
.	O

Although	O
garlic	O
has	O
several	O
biologic	O
activities	O
,	O
some	O
people	O
dislike	O
eating	O
fresh	O
raw	O
garlic	O
because	O
of	O
its	O
strong	O
taste	O
and	O
smell	O
.	O

Therefore	O
,	O
garlic	O
formulations	O
involving	O
heating	O
procedures	O
have	O
been	O
developed	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
short	O
-	O
term	O
heating	O
affects	O
the	O
anti	O
-	O
inflammatory	O
properties	O
of	O
garlic	O
.	O

Fresh	O
and	O
heated	O
raw	O
garlic	O
extracts	O
(	O
FRGE	O
and	O
HRGE	O
)	O
were	O
prepared	O
with	O
incubation	O
at	O
25	O
°	O
C	O
and	O
95	O
°	O
C	O
,	O
respectively	O
,	O
for	O
2h	O
.	O

Treatment	O
with	O
FRGE	O
and	O
HRGE	O
significantly	O
reduced	O
the	O
LPS	O
-	O
induced	O
increase	O
in	O
the	O
pro	O
-	O
inflammatory	O
cytokine	B-GENE-N
concentration	O
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
,	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
)	O
and	O
NO	B-CHEMICAL
through	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
upregulation	O
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
.	O

The	O
anti	O
-	O
inflammatory	O
effect	O
was	O
greater	O
in	O
FRGE	O
than	O
in	O
HRGE	O
.	O

The	O
allicin	B-CHEMICAL
concentration	O
was	O
higher	O
in	O
FRGE	O
than	O
in	O
HRGE	O
.	O

Allicin	B-CHEMICAL
treatment	O
showed	O
reduced	O
production	O
of	O
pro	O
-	O
inflammatory	O
cytokines	B-GENE-N
and	O
NO	B-CHEMICAL
and	O
increased	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
.	O

The	O
results	O
show	O
that	O
the	O
decrease	O
in	O
LPS	O
-	O
induced	O
NO	B-CHEMICAL
and	O
pro	O
-	O
inflammatory	O
cytokines	B-GENE-N
in	O
RAW	O
264	O
.	O
7	O
macrophages	O
through	O
HO	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
induction	O
was	O
greater	O
for	O
FRGE	O
compared	O
with	O
HRGE	O
.	O

Additionally	O
,	O
the	O
results	O
indicate	O
that	O
allicin	B-CHEMICAL
is	O
responsible	O
for	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
FRGE	O
.	O

Our	O
results	O
suggest	O
a	O
potential	O
therapeutic	O
use	O
of	O
allicin	B-CHEMICAL
in	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
disease	O
.	O

2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
Tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
-	O
induced	O
inflammatory	O
activation	O
is	O
mediated	O
by	O
intracellular	O
free	O
calcium	B-CHEMICAL
in	O
microglial	O
cells	O
.	O

2	B-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
-	I-CHEMICAL
Tetrachlorodibenzo	I-CHEMICAL
-	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
dioxin	I-CHEMICAL
(	O
TCDD	B-CHEMICAL
)	O
has	O
been	O
known	O
to	O
induce	O
inflammatory	O
signaling	O
in	O
a	O
number	O
of	O
cell	O
types	O
and	O
tissues	O
.	O

However	O
,	O
the	O
adverse	O
effects	O
of	O
TCDD	B-CHEMICAL
on	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
have	O
not	O
been	O
entirely	O
elucidated	O
.	O

In	O
this	O
study	O
,	O
using	O
reverse	O
transcriptase	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
ELISA	O
,	O
we	O
showed	O
that	O
TCDD	B-CHEMICAL
up	O
-	O
regulated	O
the	O
expression	O
and	O
secretion	O
of	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
in	O
cultured	O
HAPI	O
microglial	O
cells	O
.	O

TCDD	B-CHEMICAL
also	O
caused	O
a	O
fast	O
(	O
within	O
30min	O
as	O
judged	O
by	O
the	O
increase	O
in	O
its	O
mRNA	O
level	O
)	O
activation	O
of	O
cytosolic	B-GENE-Y
phospholipase	I-GENE-Y
A2	I-GENE-Y
(	O
cPLA2	B-GENE-Y
)	O
.	O

This	O
initial	O
action	O
was	O
accompanied	O
by	O
up	O
-	O
regulation	O
of	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
an	O
important	O
inflammation	O
marker	O
within	O
1h	O
after	O
TCDD	B-CHEMICAL
treatment	O
.	O

These	O
pro	O
-	O
inflammatory	O
responses	O
were	O
inhibited	O
by	O
two	O
types	O
of	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
blockers	O
,	O
bis	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
o	I-CHEMICAL
-	I-CHEMICAL
aminophenoxy	I-CHEMICAL
)	I-CHEMICAL
ethane	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
'	I-CHEMICAL
,	I-CHEMICAL
N	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
tetra	I-CHEMICAL
-	I-CHEMICAL
acetic	I-CHEMICAL
acid	I-CHEMICAL
acetoxymethyl	I-CHEMICAL
ester	I-CHEMICAL
(	O
BAPTA	B-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
)	O
and	O
nifedipine	B-CHEMICAL
,	O
thus	O
,	O
indicating	O
that	O
the	O
effects	O
are	O
triggered	O
by	O
initial	O
increase	O
in	O
the	O
intracellular	O
concentration	O
of	O
free	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
(	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
i	O
)	O
.	O

Further	O
,	O
TCDD	B-CHEMICAL
exposure	O
could	O
induce	O
phosphorylation	O
-	O
and	O
ubiquitination	O
-	O
dependent	O
degradation	O
of	O
IкBα	B-GENE-Y
,	O
and	O
the	O
translocation	O
of	O
NF	B-GENE-Y
-	I-GENE-Y
κB	I-GENE-Y
p65	I-GENE-Y
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
in	O
this	O
microglial	O
cell	O
line	O
.	O

Thus	O
,	O
the	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
pathway	O
can	O
be	O
activated	O
after	O
TCDD	B-CHEMICAL
treatment	O
.	O

However	O
,	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
blockers	O
also	O
obviously	O
attenuated	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
and	O
transnuclear	O
transport	O
induced	O
by	O
TCDD	B-CHEMICAL
.	O

In	O
concert	O
with	O
these	O
results	O
,	O
we	O
highlighted	O
that	O
the	O
secretion	O
of	O
pro	O
-	O
inflammatory	O
cytokine	B-GENE-N
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
induced	O
by	O
TCDD	B-CHEMICAL
can	O
be	O
mediated	O
by	O
elevation	O
of	O
[	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
]	O
i	O
in	O
HAPI	O
microglial	O
cells	O
.	O

Effect	O
of	O
bioactive	O
peptide	O
of	O
Carapax	O
Trionycis	O
on	O
TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
-	O
induced	O
intracellular	O
events	O
in	O
hepatic	O
stellate	O
cells	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
In	O
traditional	O
Chinese	O
medicines	O
for	O
hepatic	O
fibrosis	O
therapy	O
,	O
Carapax	O
Trionycis	O
is	O
used	O
usually	O
as	O
an	O
indispensable	O
component	O
and	O
has	O
a	O
long	O
history	O
of	O
medical	O
use	O
in	O
China	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
extracts	O
of	O
Carapax	O
Trionycis	O
were	O
able	O
to	O
protect	O
liver	O
against	O
fibrosis	O
in	O
CCl4	O
animal	O
models	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
verify	O
the	O
inhibitory	O
effect	O
and	O
the	O
underlying	O
mechanisms	O
of	O
Carapax	O
Trionycis	O
extract	O
peptide	O
(	O
CTEP	O
)	O
on	O
activated	O
hepatic	O
stellate	O
cells	O
which	O
play	O
a	O
central	O
role	O
in	O
liver	O
fibrogenesis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Hepatic	O
stellate	O
cells	O
induced	O
by	O
TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
were	O
applied	O
to	O
evaluate	O
the	O
anti	O
-	O
fibrotic	O
effect	O
of	O
CTEP	O
in	O
vitro	O
.	O

MTS	B-CHEMICAL
assay	O
,	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
western	O
blotting	O
were	O
then	O
used	O
to	O
further	O
investigate	O
the	O
molecular	O
mechanisms	O
.	O

RESULTS	O
:	O
The	O
results	O
show	O
that	O
the	O
contents	O
of	O
collagen	B-GENE-N
I	I-GENE-N
,	O
collagen	B-GENE-N
III	I-GENE-N
and	O
TIMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
were	O
significantly	O
inhibited	O
and	O
the	O
level	O
of	O
collagen	B-GENE-N
I	I-GENE-N
,	O
collagen	B-GENE-N
III	I-GENE-N
,	O
p	B-GENE-Y
-	I-GENE-Y
Smad	I-GENE-Y
3	I-GENE-Y
,	O
TIMP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
α	B-GENE-Y
-	I-GENE-Y
SMA	I-GENE-Y
proteins	O
decreased	O
significantly	O
in	O
a	O
concentration	O
-	O
dependence	O
manner	O
after	O
treatment	O
with	O
CTEP	O
.	O

Interestingly	O
,	O
the	O
level	O
of	O
Smad	B-GENE-Y
3	I-GENE-Y
protein	O
was	O
not	O
different	O
significantly	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
indicate	O
that	O
CTEP	O
efficiently	O
inhibits	O
cultured	O
HSC	O
-	O
T6	O
cell	O
activation	O
and	O
proliferation	O
via	O
the	O
TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
/	O
Smad	B-GENE-N
pathway	O
as	O
well	O
as	O
by	O
the	O
elimination	O
of	O
the	O
extracellular	O
matrix	O
.	O

Induction	O
of	O
the	O
metabolic	O
regulator	O
Txnip	B-GENE-Y
in	O
fasting	O
-	O
induced	O
and	O
natural	O
torpor	O
.	O

Torpor	O
is	O
a	O
physiological	O
state	O
characterised	O
by	O
controlled	O
lowering	O
of	O
metabolic	O
rate	O
and	O
core	O
body	O
temperature	O
,	O
allowing	O
substantial	O
energy	O
savings	O
during	O
periods	O
of	O
reduced	O
food	O
availability	O
or	O
harsh	O
environmental	O
conditions	O
.	O

The	O
hypothalamus	O
coordinates	O
energy	O
homeostasis	O
and	O
thermoregulation	O
,	O
and	O
plays	O
a	O
key	O
role	O
in	O
directing	O
torpor	O
.	O

We	O
recently	O
showed	O
that	O
mice	O
lacking	O
the	O
orphan	B-GENE-N
G	I-GENE-N
protein	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
Gpr50	B-GENE-Y
readily	O
enter	O
torpor	O
in	O
response	O
to	O
fasting	O
,	O
and	O
have	O
now	O
used	O
these	O
mice	O
to	O
conduct	O
a	O
microarray	O
analysis	O
of	O
hypothalamic	O
gene	O
expression	O
changes	O
related	O
to	O
the	O
torpor	O
state	O
.	O

This	O
revealed	O
a	O
strong	O
induction	O
of	O
thioredoxin	B-GENE-Y
interacting	I-GENE-Y
protein	I-GENE-Y
(	O
Txnip	B-GENE-Y
)	O
in	O
the	O
hypothalamus	O
of	O
torpid	O
mice	O
,	O
which	O
was	O
confirmed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analyses	O
.	O

In	O
situ	O
hybridisation	O
identified	O
the	O
ependyma	O
lining	O
the	O
third	O
ventricle	O
as	O
the	O
principal	O
site	O
of	O
torpor	O
-	O
related	O
expression	O
of	O
Txnip	B-GENE-Y
.	O

To	O
characterise	O
further	O
the	O
relationship	O
between	O
Txnip	B-GENE-Y
and	O
torpor	O
,	O
we	O
profiled	O
Txnip	B-GENE-Y
expression	O
in	O
mice	O
during	O
prolonged	O
fasting	O
,	O
cold	O
exposure	O
,	O
and	O
2	B-CHEMICAL
-	I-CHEMICAL
deoxyglucose	I-CHEMICAL
-	O
induced	O
hypometabolism	O
,	O
as	O
well	O
as	O
in	O
naturally	O
occurring	O
torpor	O
bouts	O
in	O
the	O
Siberian	O
hamster	O
.	O

Strikingly	O
,	O
pronounced	O
upregulation	O
of	O
Txnip	B-GENE-Y
expression	O
was	O
only	O
observed	O
in	O
WT	O
mice	O
when	O
driven	O
into	O
torpor	O
,	O
and	O
during	O
torpor	O
in	O
the	O
Siberian	O
hamster	O
.	O

Increase	O
of	O
Txnip	B-GENE-Y
was	O
not	O
limited	O
to	O
the	O
hypothalamus	O
,	O
with	O
exaggerated	O
expression	O
in	O
white	O
adipose	O
tissue	O
,	O
brown	O
adipose	O
tissue	O
,	O
and	O
liver	O
also	O
demonstrated	O
in	O
torpid	O
mice	O
.	O

Given	O
the	O
recent	O
identification	O
of	O
Txnip	B-GENE-Y
as	O
a	O
molecular	O
nutrient	O
sensor	O
important	O
in	O
the	O
regulation	O
of	O
energy	O
metabolism	O
,	O
our	O
data	O
suggest	O
that	O
elevated	O
Txnip	B-GENE-Y
expression	O
is	O
critical	O
to	O
regulating	O
energy	O
expenditure	O
and	O
fuel	O
utilisation	O
during	O
the	O
extreme	O
hypometabolic	O
state	O
of	O
torpor	O
.	O

Vandetanib	B-CHEMICAL
:	O
opening	O
a	O
new	O
treatment	O
practice	O
in	O
advanced	O
medullary	O
thyroid	O
carcinoma	O
.	O

Medullary	O
thyroid	O
cancer	O
(	O
MTC	O
)	O
is	O
frequently	O
diagnosed	O
in	O
a	O
locally	O
advanced	O
or	O
metastatic	O
stage	O
,	O
and	O
10	O
-	O
year	O
survival	O
rates	O
in	O
these	O
cases	O
are	O
below	O
20	O
%	O
.	O

Cytotoxic	O
chemotherapy	O
has	O
no	O
significant	O
impact	O
on	O
overall	O
or	O
progression	O
-	O
free	O
survival	O
.	O

Vandetanib	B-CHEMICAL
(	O
Caprelsa	B-CHEMICAL
(	O
®	O
)	O
,	O
AstraZeneca	O
)	O
is	O
a	O
once	O
-	O
daily	O
oral	O
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitor	O
that	O
selectively	O
inhibits	O
signalling	O
mediated	O
by	O
growth	B-GENE-N
-	I-GENE-N
factor	I-GENE-N
receptor	I-GENE-N
tyrosine	I-GENE-N
kinase	I-GENE-N
RET	B-GENE-Y
(	O
constitutively	O
activated	O
in	O
roughly	O
60	O
%	O
of	O
all	O
MTCs	O
)	O
,	O
vascular	B-GENE-N
endothelial	I-GENE-N
growth	I-GENE-N
-	I-GENE-N
factor	I-GENE-N
receptors	I-GENE-N
2	I-GENE-N
and	I-GENE-N
3	I-GENE-N
,	O
and	O
epidermal	B-GENE-Y
growth	I-GENE-Y
-	I-GENE-Y
factor	I-GENE-Y
receptors	I-GENE-Y
.	O

It	O
is	O
the	O
first	O
systemic	O
drug	O
with	O
demonstrated	O
anti	O
-	O
tumor	O
benefits	O
in	O
advanced	O
MTC	O
,	O
and	O
it	O
has	O
recently	O
been	O
approved	O
for	O
locally	O
advanced	O
or	O
metastatic	O
MTC	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
(	O
April	O
2011	O
)	O
and	O
the	O
European	O
Medicines	O
Agency	O
(	O
February	O
2012	O
)	O
.	O

This	O
review	O
,	O
starting	O
from	O
the	O
phases	O
II	O
and	O
III	O
efficacy	O
and	O
safety	O
data	O
that	O
led	O
to	O
these	O
approvals	O
,	O
explores	O
important	O
issues	O
related	O
to	O
dosing	O
,	O
patient	O
selection	O
,	O
and	O
strategies	O
for	O
managing	O
the	O
substantial	O
risk	O
of	O
toxicity	O
associated	O
with	O
the	O
drug	O
(	O
including	O
life	O
-	O
threatening	O
cardiac	O
events	O
that	O
are	O
the	O
subject	O
of	O
a	O
black	O
-	O
box	O
warning	O
in	O
the	O
United	O
States	O
)	O
.	O

All	O
these	O
issues	O
still	O
remain	O
to	O
be	O
defined	O
.	O

Vandetanib	B-CHEMICAL
is	O
becoming	O
a	O
standard	O
of	O
care	O
for	O
symptomatic	O
,	O
progressive	O
,	O
metastatic	O
MTCs	O
,	O
to	O
be	O
used	O
selectively	O
in	O
those	O
patients	O
who	O
are	O
likely	O
to	O
benefit	O
from	O
it	O
.	O

NMDA	B-GENE-N
Receptor	I-GENE-N
Activation	O
Down	O
-	O
Regulates	O
Expression	O
of	O
δ	B-GENE-Y
Subunit	I-GENE-Y
-	I-GENE-Y
Containing	I-GENE-Y
GABA	I-GENE-Y
-	I-GENE-Y
A	I-GENE-Y
Receptors	I-GENE-Y
in	O
Cultured	O
Hippocampal	O
Neurons	O
.	O

Neurosteroids	O
are	O
endogenous	O
allosteric	O
modulators	O
of	O
γ	B-GENE-N
amino	I-GENE-N
-	I-GENE-N
butyric	I-GENE-N
acid	I-GENE-N
type	I-GENE-N
A	I-GENE-N
receptors	I-GENE-N
(	O
GABARs	B-GENE-N
)	O
,	O
and	O
enhance	O
GABAR	B-GENE-N
-	O
mediated	O
inhibition	O
.	O

However	O
,	O
GABARs	B-GENE-N
expressed	O
on	O
hippocampal	O
dentate	O
granule	O
neurons	O
of	O
epileptic	O
animals	O
are	O
modified	O
such	O
that	O
their	O
neurosteroid	O
sensitivity	O
is	O
reduced	O
and	O
δ	O
subunit	O
expression	O
is	O
diminished	O
.	O

The	O
molecular	O
mechanisms	O
triggering	O
this	O
GABAR	B-GENE-N
plasticity	O
were	O
explored	O
.	O

In	O
the	O
cultured	O
hippocampal	O
neurons	O
treatment	O
with	O
NMDA	B-CHEMICAL
(	O
10	O
μM	O
)	O
for	O
48	O
hrs	O
reduced	O
surface	O
expression	O
of	O
δ	O
and	O
α4	O
subunits	O
,	O
but	O
did	O
not	O
increase	O
expression	O
of	O
γ2	O
subunits	O
.	O

The	O
tonic	O
current	O
recorded	O
from	O
neurons	O
in	O
NMDA	B-CHEMICAL
-	O
treated	O
cultures	O
was	O
reduced	O
,	O
and	O
its	O
neurosteroid	O
modulation	O
was	O
also	O
diminished	O
.	O

In	O
contrast	O
,	O
synaptic	O
inhibition	O
and	O
its	O
modulation	O
by	O
neurosteroids	O
were	O
preserved	O
in	O
these	O
neurons	O
.	O

The	O
time	O
course	O
of	O
NMDA	B-CHEMICAL
effects	O
on	O
surface	O
and	O
total	O
δ	O
subunit	O
expression	O
were	O
distinct	O
;	O
shorter	O
(	O
6	O
hrs	O
)	O
treatment	O
decreased	O
surface	O
expression	O
,	O
whereas	O
longer	O
treatment	O
reduced	O
both	O
surface	O
and	O
total	O
expression	O
.	O

APV	B-CHEMICAL
blocked	O
NMDA	B-CHEMICAL
effects	O
on	O
δ	O
subunit	O
expression	O
.	O

Chelation	O
of	O
calcium	B-CHEMICAL
ions	O
by	O
BAPTA	B-CHEMICAL
-	I-CHEMICAL
AM	I-CHEMICAL
or	O
blockade	O
of	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activation	O
by	O
UO126	B-CHEMICAL
also	O
prevented	O
the	O
NMDA	B-CHEMICAL
effects	O
.	O

Thus	O
prolonged	O
activation	O
of	O
NMDA	B-GENE-N
receptors	I-GENE-N
in	O
hippocampal	O
neurons	O
reduced	O
GABAR	B-GENE-Y
δ	I-GENE-Y
subunit	I-GENE-Y
expression	O
through	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
entry	O
and	O
at	O
least	O
in	O
part	O
by	O
ERK1	B-GENE-N
/	I-GENE-N
2	I-GENE-N
activation	O
.	O

Acute	O
and	O
chronic	O
interference	O
with	O
BDNF	B-GENE-Y
/	O
TrkB	B-GENE-Y
-	O
signaling	O
impair	O
LTP	O
selectively	O
at	O
mossy	O
fiber	O
synapses	O
in	O
the	O
CA3	O
region	O
of	O
mouse	O
hippocampus	O
.	O

Brain	B-GENE-Y
-	I-GENE-Y
derived	I-GENE-Y
neurotrophic	I-GENE-Y
factor	I-GENE-Y
(	O
BDNF	B-GENE-Y
)	O
signaling	O
via	O
TrkB	B-GENE-Y
crucially	O
regulates	O
synaptic	O
plasticity	O
in	O
the	O
brain	O
.	O

Although	O
BDNF	B-GENE-Y
is	O
abundant	O
at	O
hippocampal	O
mossy	O
fiber	O
(	O
MF	O
)	O
synapses	O
,	O
which	O
critically	O
contribute	O
to	O
hippocampus	O
dependent	O
memory	O
,	O
its	O
role	O
in	O
MF	O
synaptic	O
plasticity	O
(	O
long	O
-	O
term	O
potentiation	O
,	O
LTP	O
)	O
remained	O
largely	O
unclear	O
.	O

Using	O
field	O
potential	O
recordings	O
in	O
CA3	O
of	O
adult	O
heterozygous	O
BDNF	B-GENE-Y
knockout	O
(	O
ko	O
,	O
BDNF	B-GENE-Y
+	O
/	O
-	O
)	O
mice	O
we	O
observed	O
impaired	O
(	O
∼	O
50	O
%	O
)	O
NMDAR	B-GENE-N
-	O
independent	O
MF	O
-	O
LTP	O
.	O

In	O
contrast	O
to	O
MF	O
synapses	O
,	O
LTP	O
at	O
neighboring	O
associative	O
/	O
commissural	O
(	O
A	O
/	O
C	O
)	O
fiber	O
synapses	O
remained	O
unaffected	O
.	O

To	O
exclude	O
that	O
impaired	O
MF	O
-	O
LTP	O
in	O
BDNF	B-GENE-Y
+	O
/	O
-	O
mice	O
was	O
due	O
to	O
developmental	O
changes	O
in	O
response	O
to	O
chronically	O
reduced	O
BDNF	B-GENE-Y
levels	O
,	O
and	O
to	O
prove	O
the	O
importance	O
of	O
acute	O
availability	O
of	O
BDNF	B-GENE-Y
in	O
MF	O
-	O
LTP	O
,	O
we	O
also	O
tested	O
effects	O
of	O
acute	O
interference	O
with	O
BDNF	B-GENE-Y
/	O
TrkB	B-GENE-Y
signaling	O
.	O

Inhibition	O
of	O
TrkB	B-GENE-Y
tyrosine	B-GENE-N
kinase	I-GENE-N
signaling	O
with	O
k252a	O
,	O
or	O
with	O
the	O
selective	O
BDNF	B-GENE-Y
scavenger	O
TrkB	B-GENE-Y
-	O
Fc	O
,	O
both	O
inhibited	O
MF	O
-	O
LTP	O
to	O
the	O
same	O
extent	O
as	O
observed	O
in	O
BDNF	B-GENE-Y
+	O
/	O
-	O
mice	O
.	O

Basal	O
synaptic	O
transmission	O
,	O
short	O
-	O
term	O
plasticity	O
,	O
and	O
synaptic	O
fatigue	O
during	O
LTP	O
induction	O
were	O
not	O
significantly	O
altered	O
by	O
treatment	O
with	O
k252a	O
or	O
TrkB	B-GENE-Y
-	O
Fc	O
,	O
or	O
by	O
chronic	O
BDNF	B-GENE-Y
reduction	O
in	O
BDNF	B-GENE-Y
+	O
/	O
-	O
mice	O
.	O

Since	O
the	O
acute	O
interference	O
with	O
BDNF	B-GENE-Y
-	O
signaling	O
did	O
not	O
completely	O
block	O
MF	O
-	O
LTP	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
an	O
additional	O
mechanism	O
besides	O
BDNF	B-GENE-Y
induced	O
TrkB	B-GENE-Y
signaling	O
contributes	O
to	O
this	O
type	O
of	O
LTP	O
.	O

Our	O
results	O
prove	O
for	O
the	O
first	O
time	O
a	O
mechanistic	O
action	O
of	O
acute	O
BDNF	B-GENE-Y
/	O
TrkB	B-GENE-Y
signaling	O
in	O
presynaptic	O
expression	O
of	O
MF	O
-	O
LTP	O
in	O
adult	O
hippocampus	O
.	O

Wired	O
Enzyme	O
Electrodes	O
-	O
A	O
Retroperspective	O
Story	O
about	O
an	O
Exciting	O
Time	O
at	O
University	O
of	O
Texas	O
at	O
Austin	O
and	O
Its	O
Impact	O
on	O
My	O
Scientific	O
Career	O
.	O

The	O
present	O
paper	O
features	O
an	O
exciting	O
time	O
in	O
the	O
late	O
1980s	O
when	O
I	O
,	O
as	O
a	O
visiting	O
scientist	O
,	O
had	O
the	O
privilege	O
to	O
participate	O
in	O
the	O
early	O
and	O
very	O
exciting	O
development	O
of	O
the	O
in	O
vivo	O
redox	O
-	O
polymer	O
-	O
wired	O
glucose	B-CHEMICAL
sensor	O
in	O
Professor	O
Adam	O
Heller	O
'	O
s	O
laboratory	O
at	O
the	O
Department	O
of	O
Chemical	O
Engineering	O
at	O
University	O
of	O
Texas	O
at	O
Austin	O
.	O

This	O
story	O
is	O
followed	O
by	O
an	O
overview	O
of	O
the	O
research	O
my	O
visit	O
initiated	O
at	O
Uppsala	O
University	O
.	O

In	O
collaboration	O
with	O
Swedish	O
colleagues	O
,	O
we	O
explored	O
a	O
few	O
of	O
the	O
many	O
possibilities	O
to	O
form	O
new	O
biosensors	O
by	O
utilizing	O
Prof	O
.	O

Heller	O
'	O
s	O
concept	O
of	O
cross	O
-	O
linked	O
redox	O
-	O
polymer	O
/	O
redox	O
-	O
enzyme	O
electrodes	O
.	O

Fibrillar	O
Morphology	O
of	O
Derivatives	O
of	O
Poly	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
alkylthiophene	I-CHEMICAL
)	I-CHEMICAL
s	I-CHEMICAL
by	O
Solvent	O
Vapor	O
Annealing	O
:	O
Effects	O
of	O
Conformational	O
Transition	O
and	O
Conjugate	O
Length	O
.	O

A	O
fibrillar	O
morphology	O
was	O
obtained	O
,	O
compared	O
to	O
the	O
featherless	O
pristine	O
films	O
,	O
via	O
solvent	O
annealing	O
the	O
films	O
of	O
a	O
series	O
of	O
derivatives	O
of	O
poly	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
alkylthiophene	I-CHEMICAL
)	I-CHEMICAL
s	I-CHEMICAL
(	O
P3ATs	B-CHEMICAL
)	O
:	O
poly	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dodecylthiophene	I-CHEMICAL
)	I-CHEMICAL
(	O
P3DDT	B-CHEMICAL
)	O
,	O
poly	B-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
‴	I-CHEMICAL
-	I-CHEMICAL
didodecyl	I-CHEMICAL
-	I-CHEMICAL
quaterthiophene	I-CHEMICAL
)	I-CHEMICAL
(	O
PQT12	B-CHEMICAL
)	O
,	O
and	O
poly	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
bis	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dodecylthiophen	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
thieno	I-CHEMICAL
[	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
]	I-CHEMICAL
thiophene	I-CHEMICAL
)	I-CHEMICAL
(	O
pBTTT12	B-CHEMICAL
)	O
.	O

Among	O
the	O
solvents	O
used	O
,	O
including	O
dichloromethane	B-CHEMICAL
,	O
chloroform	B-CHEMICAL
,	O
tetrahydrofuran	B-CHEMICAL
,	O
and	O
carbon	B-CHEMICAL
disulfide	I-CHEMICAL
(	O
CS2	B-CHEMICAL
)	O
,	O
CS2	B-CHEMICAL
was	O
the	O
best	O
to	O
induce	O
fibril	O
formation	O
because	O
its	O
solubility	O
parameter	O
is	O
closest	O
to	O
those	O
of	O
the	O
P3AT	B-CHEMICAL
derivatives	O
.	O

It	O
was	O
found	O
that	O
higher	O
critical	O
CS2	B-CHEMICAL
vapor	O
pressures	O
were	O
needed	O
to	O
form	O
crystal	O
nuclei	O
with	O
increasing	O
conjugation	O
length	O
and	O
molecular	O
weight	O
of	O
the	O
P3AT	B-CHEMICAL
derivatives	O
;	O
i	O
.	O
e	O
.	O
,	O
the	O
critical	O
vapor	O
pressures	O
for	O
P3DDT	B-CHEMICAL
13	O
.	O
9k	O
and	O
PQT12	B-CHEMICAL
15	O
.	O
5k	O
were	O
59	O
.	O
0	O
%	O
and	O
80	O
.	O
7	O
%	O
,	O
respectively	O
,	O
and	O
there	O
were	O
no	O
nuclei	O
of	O
fibrils	O
for	O
pBTTT12	B-CHEMICAL
15	O
.	O
6k	O
with	O
the	O
highest	O
conjugation	O
length	O
,	O
even	O
at	O
a	O
CS2	B-CHEMICAL
vapor	O
pressure	O
of	O
98	O
.	O
3	O
%	O
.	O

Meanwhile	O
,	O
at	O
the	O
highest	O
vapor	O
pressure	O
,	O
the	O
fibril	O
density	O
decreased	O
with	O
increasing	O
conjugation	O
length	O
and	O
molecular	O
weight	O
of	O
the	O
P3AT	B-CHEMICAL
derivatives	O
.	O

This	O
is	O
attributed	O
to	O
the	O
rod	O
-	O
like	O
conformation	O
prevailing	O
for	O
polymers	O
with	O
larger	O
conjugation	O
length	O
and	O
higher	O
molecular	O
weight	O
during	O
solvent	O
annealing	O
,	O
making	O
the	O
conformational	O
transition	O
toward	O
coils	O
more	O
difficult	O
and	O
hindering	O
diffusion	O
of	O
molecules	O
.	O

The	O
results	O
presented	O
here	O
are	O
expected	O
to	O
be	O
helpful	O
for	O
the	O
design	O
and	O
processing	O
of	O
conjugated	O
semiconductor	O
polymers	O
.	O

Interacting	O
Glutamate	B-GENE-N
Receptor	I-GENE-N
-	O
Like	O
Proteins	O
in	O
Phloem	O
Regulate	O
Lateral	O
Root	O
Initiation	O
in	O
Arabidopsis	O
.	O

Molecular	O
,	O
genetic	O
,	O
and	O
electrophysiological	O
evidence	O
indicates	O
that	O
at	O
least	O
one	O
of	O
the	O
plant	O
Glu	B-GENE-N
receptor	I-GENE-N
-	O
like	O
molecules	O
,	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
,	O
functions	O
as	O
an	O
amino	B-GENE-N
acid	I-GENE-N
-	I-GENE-N
gated	I-GENE-N
Ca	I-GENE-N
(	I-GENE-N
2	I-GENE-N
+	I-GENE-N
)	I-GENE-N
channel	I-GENE-N
at	O
the	O
plasma	O
membrane	O
.	O

The	O
aspect	O
of	O
plant	O
physiology	O
,	O
growth	O
,	O
or	O
development	O
to	O
which	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
contributes	O
is	O
an	O
open	O
question	O
.	O

Protein	O
localization	O
studies	O
performed	O
here	O
provide	O
important	O
information	O
.	O

In	O
roots	O
,	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
and	O
the	O
related	O
GLR3	B-GENE-N
.	I-GENE-N
2	I-GENE-N
protein	O
were	O
present	O
primarily	O
in	O
the	O
phloem	O
,	O
especially	O
in	O
the	O
vicinity	O
of	O
the	O
sieve	O
plates	O
.	O

GLR3	B-GENE-N
.	I-GENE-N
3	I-GENE-N
was	O
expressed	O
in	O
most	O
cells	O
of	O
the	O
growing	O
primary	O
root	O
but	O
was	O
not	O
enriched	O
in	O
the	O
phloem	O
,	O
including	O
the	O
sieve	O
plate	O
area	O
.	O

GLR3	B-GENE-N
.	I-GENE-N
2	I-GENE-N
and	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
physically	O
interacted	O
with	O
each	O
other	O
better	O
than	O
with	O
themselves	O
as	O
evidenced	O
by	O
a	O
biophotonic	O
assay	O
performed	O
in	O
human	O
embryonic	O
kidney	O
cells	O
and	O
Nicotiana	O
benthamiana	O
leaf	O
cells	O
.	O

GLR3	B-GENE-N
.	I-GENE-N
3	I-GENE-N
interacted	O
poorly	O
with	O
itself	O
or	O
the	O
other	O
two	O
GLRs	B-GENE-N
.	O

Mutations	O
in	O
GLR3	B-GENE-N
.	I-GENE-N
2	I-GENE-N
,	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
,	O
or	O
GLR3	B-GENE-N
.	I-GENE-N
2	I-GENE-N
and	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
caused	O
the	O
same	O
and	O
equally	O
severe	O
phenotype	O
,	O
namely	O
,	O
a	O
large	O
overproduction	O
and	O
aberrant	O
placement	O
of	O
lateral	O
root	O
primordia	O
.	O

Loss	O
of	O
GLR3	B-GENE-N
.	I-GENE-N
3	I-GENE-N
did	O
not	O
affect	O
lateral	O
root	O
primordia	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
apoplastic	O
amino	B-CHEMICAL
acids	I-CHEMICAL
acting	O
through	O
heteromeric	O
GLR3	B-GENE-N
.	I-GENE-N
2	I-GENE-N
/	O
GLR3	B-GENE-N
.	I-GENE-N
4	I-GENE-N
channels	O
affect	O
lateral	O
root	O
development	O
via	O
Ca	B-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
signaling	O
in	O
the	O
phloem	O
.	O

Nutrient	O
signaling	O
in	O
protein	O
homeostasis	O
:	O
an	O
increase	O
in	O
quantity	O
at	O
the	O
expense	O
of	O
quality	O
.	O

The	O
discovery	O
that	O
rapamycin	B-CHEMICAL
extends	O
the	O
life	O
span	O
of	O
diverse	O
organisms	O
has	O
triggered	O
many	O
studies	O
aimed	O
at	O
identifying	O
the	O
underlying	O
molecular	O
mechanisms	O
.	O

Mammalian	B-GENE-N
target	I-GENE-N
of	I-GENE-N
rapamycin	I-GENE-N
complex	I-GENE-N
1	I-GENE-N
(	O
mTORC1	B-GENE-N
)	O
regulates	O
cell	O
growth	O
and	O
may	O
regulate	O
organismal	O
aging	O
by	O
controlling	O
mRNA	O
translation	O
.	O

However	O
,	O
how	O
inhibiting	O
mTORC1	B-GENE-N
and	O
decreasing	O
protein	O
synthesis	O
can	O
extend	O
life	O
span	O
remains	O
an	O
unresolved	O
issue	O
.	O

We	O
showed	O
that	O
constitutively	O
active	O
mTORC1	B-GENE-N
signaling	O
increased	O
general	O
protein	O
synthesis	O
but	O
unexpectedly	O
reduced	O
the	O
quality	O
of	O
newly	O
synthesized	O
polypeptides	O
.	O

We	O
demonstrated	O
that	O
constitutively	O
active	O
mTORC1	B-GENE-N
decreased	O
translation	O
fidelity	O
by	O
increasing	O
the	O
speed	O
of	O
ribosomal	O
elongation	O
.	O

Conversely	O
,	O
rapamycin	B-CHEMICAL
treatment	O
restored	O
the	O
quality	O
of	O
newly	O
synthesized	O
polypeptides	O
mainly	O
by	O
slowing	O
the	O
rate	O
of	O
ribosomal	O
elongation	O
.	O

We	O
also	O
found	O
distinct	O
roles	O
for	O
mTORC1	B-GENE-N
downstream	O
targets	O
in	O
maintaining	O
protein	O
homeostasis	O
.	O

Loss	O
of	O
S6	B-GENE-N
kinases	I-GENE-N
,	O
but	O
not	O
4E	B-GENE-N
-	I-GENE-N
BP	I-GENE-N
family	O
proteins	O
,	O
which	O
are	O
both	O
involved	O
in	O
regulation	O
of	O
translation	O
,	O
attenuated	O
the	O
effects	O
of	O
rapamycin	B-CHEMICAL
on	O
the	O
quality	O
of	O
newly	O
translated	O
proteins	O
.	O

Our	O
results	O
reveal	O
a	O
mechanistic	O
connection	O
between	O
mTORC1	B-GENE-N
and	O
protein	O
quality	O
,	O
highlighting	O
the	O
central	O
role	O
of	O
nutrient	O
signaling	O
in	O
growth	O
and	O
aging	O
.	O

Development	O
and	O
validation	O
of	O
NIR	O
-	O
chemometric	O
methods	O
for	O
chemical	O
and	O
pharmaceutical	O
characterization	O
of	O
meloxicam	B-CHEMICAL
tablets	O
.	O

Abstract	O
Context	O
:	O
Near	O
-	O
Infrared	O
(	O
NIR	O
)	O
spectroscopy	O
is	O
an	O
important	O
component	O
of	O
a	O
Process	O
Analytical	O
Technology	O
(	O
PAT	O
)	O
toolbox	O
and	O
is	O
a	O
key	O
technology	O
for	O
enabling	O
the	O
rapid	O
analysis	O
of	O
pharmaceutical	O
tablets	O
.	O

Objective	O
:	O
The	O
aim	O
of	O
this	O
research	O
work	O
was	O
to	O
develop	O
and	O
validate	O
NIR	O
-	O
chemometric	O
methods	O
not	O
only	O
for	O
the	O
determination	O
of	O
active	O
pharmaceutical	O
ingredients	O
content	O
but	O
also	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
,	O
disintegration	O
time	O
)	O
of	O
meloxicam	B-CHEMICAL
tablets	O
.	O

Materials	O
and	O
methods	O
:	O
The	O
development	O
of	O
the	O
method	O
for	O
active	O
content	O
assay	O
was	O
performed	O
on	O
samples	O
corresponding	O
to	O
80	O
%	O
,	O
90	O
%	O
,	O
100	O
%	O
,	O
110	O
%	O
and	O
120	O
%	O
of	O
meloxicam	B-CHEMICAL
content	O
and	O
the	O
development	O
of	O
the	O
methods	O
for	O
pharmaceutical	O
characterization	O
was	O
performed	O
on	O
samples	O
prepared	O
at	O
seven	O
different	O
compression	O
forces	O
(	O
ranging	O
from	O
7	O
to	O
45	O
kN	O
)	O
using	O
NIR	O
transmission	O
spectra	O
of	O
intact	O
tablets	O
and	O
PLS	O
as	O
a	O
regression	O
method	O
.	O

Results	O
:	O
The	O
results	O
show	O
that	O
the	O
developed	O
methods	O
have	O
good	O
trueness	O
,	O
precision	O
and	O
accuracy	O
and	O
are	O
appropriate	O
for	O
direct	O
active	O
content	O
assay	O
in	O
tablets	O
(	O
ranging	O
from	O
12	O
to	O
18	O
mg	O
/	O
tablet	O
)	O
and	O
also	O
for	O
predicting	O
crushing	O
strength	O
and	O
disintegration	O
time	O
of	O
intact	O
meloxicam	B-CHEMICAL
tablets	O
.	O

Discussion	O
:	O
The	O
comparative	O
data	O
show	O
that	O
the	O
proposed	O
methods	O
are	O
in	O
good	O
agreement	O
with	O
the	O
reference	O
methods	O
currently	O
used	O
for	O
the	O
characterization	O
of	O
meloxicam	B-CHEMICAL
tablets	O
(	O
HPLC	O
-	O
UV	O
methods	O
for	O
the	O
assay	O
and	O
European	O
Pharmacopeia	O
methods	O
for	O
determining	O
the	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
.	O

Conclusion	O
:	O
The	O
results	O
show	O
the	O
possibility	O
to	O
predict	O
both	O
chemical	O
properties	O
(	O
active	O
content	O
)	O
and	O
physical	O
/	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
directly	O
,	O
without	O
any	O
sample	O
preparation	O
,	O
from	O
the	O
same	O
NIR	O
transmission	O
spectrum	O
of	O
meloxicam	B-CHEMICAL
tablets	O
.	O

Anti	O
-	O
inflammatory	O
effect	O
of	O
prunetin	B-CHEMICAL
via	O
the	O
suppression	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
pathway	O
.	O

Prunetin	B-CHEMICAL
is	O
an	O
O	B-CHEMICAL
-	I-CHEMICAL
methylated	I-CHEMICAL
isoflavone	I-CHEMICAL
,	O
which	O
is	O
found	O
in	O
Prunus	O
yedoensis	O
.	O

To	O
date	O
no	O
report	O
has	O
been	O
published	O
on	O
anti	O
-	O
inflammatory	O
activities	O
of	O
prunetin	B-CHEMICAL
.	O

In	O
the	O
present	O
study	O
,	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
prunetin	B-CHEMICAL
on	O
LPS	O
-	O
stimulated	O
RAW	O
264	O
.	O
7	O
macrophage	O
and	O
LPS	O
-	O
induced	O
septic	O
shock	O
model	O
were	O
investigated	O
.	O

Inducible	B-GENE-Y
nitric	I-GENE-Y
oxide	I-GENE-Y
synthase	I-GENE-Y
(	O
iNOS	B-GENE-Y
)	O
,	O
cyclooxygenase	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
,	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
α	I-GENE-Y
)	O
,	O
interleukin	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
)	O
,	O
and	O
interleukin	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
1β	I-GENE-Y
)	O
expressions	O
were	O
determined	O
by	O
western	O
blot	O
and	O
or	O
realtime	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
.	O

To	O
elucidate	O
its	O
underlying	O
mechanism	O
,	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κb	I-GENE-N
)	O
activation	O
and	O
its	O
downstream	O
pathways	O
were	O
investigated	O
by	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
transcription	O
factor	O
assay	O
,	O
reporter	O
gene	O
expression	O
,	O
and	O
western	O
blot	O
.	O

In	O
vivo	O
anti	O
-	O
inflammatory	O
effects	O
of	O
prunetin	B-CHEMICAL
were	O
evaluated	O
in	O
LPS	O
-	O
induced	O
endotoxemia	O
.	O

Promoter	O
assay	O
revealed	O
that	O
prunetin	B-CHEMICAL
inhibits	O
LPS	O
-	O
induced	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
and	O
prostaglandin	B-CHEMICAL
E2	I-CHEMICAL
production	O
through	O
the	O
suppression	O
of	O
iNOS	B-GENE-Y
and	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
at	O
the	O
transcriptional	O
level	O
.	O

In	O
addition	O
,	O
prunetin	B-CHEMICAL
inhibits	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
-	O
dependent	O
inflammatory	O
responses	O
by	O
modulating	O
IκB	B-GENE-N
kinase	I-GENE-N
(	O
IKK	B-GENE-N
)	O
-	O
inhibitor	B-GENE-Y
κBα	I-GENE-Y
(	O
IκBα	B-GENE-Y
)	O
-	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
signaling	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
prunetin	B-CHEMICAL
significantly	O
reduced	O
serum	O
levels	O
of	O
inflammatory	O
cytokines	B-GENE-N
and	O
mortality	O
in	O
mice	O
challenged	O
with	O
lipopolysaccharide	O
.	O

These	O
findings	O
offer	O
a	O
potential	O
mechanism	O
for	O
the	O
anti	O
-	O
inflammatory	O
activity	O
of	O
prunetin	B-CHEMICAL
.	O

5	B-GENE-Y
-	I-GENE-Y
Lipoxygenase	I-GENE-Y
inhibitors	O
:	O
a	O
review	O
of	O
recent	O
patents	O
(	O
2010	O
-	O
2012	O
)	O
.	O

Introduction	O
:	O
5	B-GENE-Y
-	I-GENE-Y
Lipoxygenase	I-GENE-Y
(	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
)	O
is	O
a	O
crucial	O
enzyme	O
of	O
the	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
(	O
AA	O
)	O
cascade	O
and	O
catalyzes	O
the	O
formation	O
of	O
bioactive	O
leukotrienes	O
(	O
LTs	O
)	O
with	O
the	O
help	O
of	O
FLAP	B-GENE-Y
,	O
the	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
-	I-GENE-Y
activating	I-GENE-Y
protein	I-GENE-Y
.	O

LTs	O
are	O
inflammatory	O
mediators	O
playing	O
a	O
pathophysiological	O
role	O
in	O
different	O
diseases	O
like	O
asthma	O
,	O
allergic	O
rhinitis	O
as	O
well	O
as	O
cardiovascular	O
diseases	O
and	O
certain	O
types	O
of	O
cancer	O
.	O

With	O
the	O
rising	O
number	O
of	O
indications	O
for	O
anti	O
-	O
LT	O
therapy	O
,	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibitor	O
drug	O
development	O
becomes	O
increasingly	O
important	O
.	O

Areas	O
covered	O
:	O
Here	O
,	O
both	O
recent	O
findings	O
regarding	O
the	O
pathophysiological	O
role	O
of	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
and	O
the	O
patents	O
claimed	O
for	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
inhibitors	O
are	O
discussed	O
.	O

Focusing	O
on	O
direct	O
inhibitors	O
,	O
several	O
patents	O
disclosing	O
FLAP	B-GENE-Y
antagonists	O
are	O
also	O
subject	O
of	O
this	O
review	O
.	O

Novel	O
compounds	O
include	O
1	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
diarylpyrazoles	I-CHEMICAL
,	O
indolizines	B-CHEMICAL
and	O
indoles	B-CHEMICAL
and	O
several	O
natural	O
product	O
extracts	O
.	O

Expert	O
opinion	O
:	O
Evaluation	O
of	O
the	O
patent	O
activities	O
revealed	O
only	O
quite	O
moderate	O
action	O
.	O

Nevertheless	O
,	O
several	O
auspicious	O
drug	O
-	O
like	O
molecules	O
were	O
disclosed	O
.	O

It	O
seems	O
that	O
in	O
the	O
near	O
future	O
,	O
FLAP	B-GENE-Y
inhibitors	O
can	O
be	O
expected	O
to	O
enter	O
the	O
market	O
for	O
the	O
treatment	O
of	O
asthma	O
.	O

With	O
the	O
resolved	O
structure	O
of	O
5	B-GENE-Y
-	I-GENE-Y
LO	I-GENE-Y
,	O
structure	O
-	O
based	O
drug	O
design	O
is	O
now	O
applicable	O
.	O

Together	O
with	O
the	O
identification	O
of	O
downstream	O
enzyme	O
inhibitors	O
and	O
dual	O
-	O
targeting	O
drugs	O
within	O
the	O
AA	O
cascade	O
,	O
several	O
tools	O
are	O
at	O
hand	O
to	O
cope	O
with	O
5	B-GENE-Y
-	I-GENE-Y
LOs	I-GENE-Y
increasing	O
pathophysiological	O
roles	O
.	O

CASK	B-GENE-Y
is	O
a	O
new	O
intracellular	O
modulator	O
of	O
P2X3	B-GENE-Y
receptors	I-GENE-Y
.	O

ATP	B-GENE-Y
-	I-GENE-Y
gated	I-GENE-Y
P2X3	I-GENE-Y
receptors	I-GENE-Y
of	O
sensory	O
ganglion	O
neurons	O
are	O
important	O
transducers	O
of	O
painful	O
stimuli	O
and	O
are	O
modulated	O
by	O
extracellular	O
algogenic	O
substances	O
,	O
via	O
changes	O
in	O
the	O
receptor	O
phosphorylation	O
state	O
.	O

The	O
present	O
study	O
investigated	O
the	O
role	O
of	O
calcium	B-GENE-Y
/	I-GENE-Y
calmodulin	I-GENE-Y
-	I-GENE-Y
dependent	I-GENE-Y
serine	I-GENE-Y
protein	I-GENE-Y
kinase	I-GENE-Y
CASK	B-GENE-Y
in	O
interacting	O
and	O
controlling	O
P2X3	B-GENE-Y
receptor	I-GENE-Y
expression	O
and	O
function	O
in	O
mouse	O
trigeminal	O
ganglia	O
.	O

Most	O
ganglion	O
neurons	O
in	O
situ	O
or	O
in	O
culture	O
co	O
-	O
expressed	O
P2X3	B-GENE-Y
and	O
CASK	B-GENE-Y
.	O

CASK	B-GENE-Y
was	O
immunoprecipitated	O
with	O
P2X3	B-GENE-Y
receptors	O
from	O
trigeminal	O
ganglia	O
and	O
from	O
P2X3	B-GENE-Y
/	O
CASK	B-GENE-Y
-	O
cotransfected	O
HEK	O
cells	O
.	O

Recombinant	O
P2X3	B-GENE-Y
/	O
CASK	B-GENE-Y
expression	O
in	O
HEK	O
cells	O
increased	O
serine	B-CHEMICAL
phosphorylation	O
of	O
P2X3	B-GENE-Y
receptors	O
,	O
typically	O
associated	O
with	O
receptor	O
upregulation	O
.	O

CASK	B-GENE-Y
deletion	O
mutants	O
also	O
enhanced	O
P2X3	B-GENE-Y
subunit	O
expression	O
.	O

After	O
silencing	O
CASK	B-GENE-Y
,	O
cell	O
surface	O
P2X3	B-GENE-Y
receptor	O
expression	O
was	O
decreased	O
,	O
which	O
is	O
consistent	O
with	O
depressed	O
P2X3	B-GENE-Y
currents	O
.	O

The	O
reduction	O
of	O
P2X3	B-GENE-Y
expression	O
levels	O
was	O
reversed	O
by	O
the	O
proteasomal	O
inhibitor	O
MG	B-CHEMICAL
-	I-CHEMICAL
132	I-CHEMICAL
.	O

Moreover	O
,	O
neuronal	O
CASK	B-GENE-Y
/	O
P2X3	B-GENE-Y
interaction	O
was	O
upregulated	O
by	O
NGF	B-GENE-Y
signaling	O
and	O
downregulated	O
by	O
P2X3	B-GENE-Y
agonist	O
-	O
induced	O
desensitization	O
.	O

These	O
data	O
suggest	O
a	O
novel	O
interaction	O
between	O
CASK	B-GENE-Y
and	O
P2X3	B-GENE-Y
receptors	O
with	O
positive	O
outcome	O
for	O
receptor	O
stability	O
and	O
function	O
.	O

As	O
CASK	B-GENE-Y
-	O
mediated	O
control	O
of	O
P2X3	B-GENE-Y
receptors	O
was	O
dependent	O
on	O
the	O
receptor	O
activation	O
state	O
,	O
CASK	B-GENE-Y
represents	O
an	O
intracellular	O
gateway	O
to	O
regulate	O
purinergic	O
nociceptive	O
signaling	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Nutrients	O
and	O
bioactive	O
compounds	O
of	O
Thai	O
indigenous	O
fruits	O
.	O

This	O
study	O
determined	O
the	O
nutritional	O
potential	O
of	O
Thai	O
indigenous	O
fruits	O
in	O
terms	O
of	O
nutrients	O
,	O
bioactive	O
compounds	O
,	O
and	O
antioxidant	O
activities	O
.	O

Three	O
indigenous	O
fruits	O
were	O
collected	O
at	O
two	O
conservation	O
areas	O
in	O
Kanchanaburi	O
province	O
,	O
Thailand	O
.	O

The	O
results	O
showed	O
that	O
Phyllanthus	O
emblica	O
L	O
.	O
exhibited	O
the	O
highest	O
levels	O
of	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
(	O
575	O
±	O
452mg	O
/	O
100g	O
)	O
,	O
total	O
phenolics	B-CHEMICAL
(	O
TP	O
)	O
(	O
3703	O
±	O
1244mGAE	O
/	O
100g	O
)	O
,	O
and	O
antioxidant	O
activities	O
,	O
as	O
measured	O
by	O
DPPH	B-CHEMICAL
,	O
FRAP	O
and	O
ORAC	O
assays	O
.	O

Compared	O
to	O
the	O
other	O
two	O
fruits	O
,	O
Antidesma	O
velutinosum	O
Blume	O
contained	O
higher	O
levels	O
of	O
most	O
nutrients	O
and	O
dietary	O
fibre	O
(	O
15	O
.	O
6	O
±	O
5	O
.	O
9g	O
/	O
100g	O
)	O
,	O
as	O
well	O
as	O
carotenoids	O
(	O
335	O
±	O
98μg	O
/	O
100g	O
)	O
and	O
phytosterols	B-CHEMICAL
(	O
22	O
.	O
1	O
±	O
3	O
.	O
9mg	O
/	O
100g	O
)	O
.	O

Spondias	O
pinnata	O
(	O
L	O
.	O
f	O
.	O
)	O
Kurz	O
was	O
high	O
in	O
total	O
phenolics	B-CHEMICAL
(	O
3178	O
±	O
887mGAE	O
/	O
100g	O
)	O
and	O
antioxidant	O
activity	O
.	O

Moreover	O
,	O
high	O
correlations	O
were	O
found	O
between	O
TP	O
and	O
antioxidant	O
activities	O
(	O
r	O
>	O
0	O
.	O
9	O
)	O
.	O

These	O
Thai	O
indigenous	O
fruits	O
are	O
potentially	O
good	O
sources	O
of	O
nutrients	O
,	O
bioactive	O
compounds	O
,	O
and	O
antioxidant	O
activities	O
.	O

Conservation	O
and	O
utilisation	O
should	O
be	O
promoted	O
for	O
food	O
security	O
and	O
consumption	O
as	O
part	O
of	O
a	O
healthy	O
diet	O
.	O

Robust	O
autoactivation	O
,	O
chymotrypsin	B-GENE-Y
C	I-GENE-Y
independence	O
and	O
diminished	O
secretion	O
define	O
a	O
subset	O
of	O
hereditary	O
pancreatitis	O
associated	O
cationic	B-GENE-Y
trypsinogen	I-GENE-Y
mutants	O
.	O

Mutations	O
in	O
human	B-GENE-Y
cationic	I-GENE-Y
trypsinogen	I-GENE-Y
cause	O
hereditary	O
pancreatitis	O
by	O
altering	O
its	O
proteolytic	O
regulation	O
of	O
activation	O
and	O
degradation	O
by	O
chymotrypsin	B-GENE-Y
C	I-GENE-Y
(	O
CTRC	B-GENE-Y
)	O
.	O

CTRC	B-GENE-Y
stimulates	O
trypsinogen	O
autoactivation	O
by	O
processing	O
the	O
activation	O
peptide	O
to	O
a	O
shorter	O
form	O
but	O
also	O
promotes	O
degradation	O
by	O
cleaving	O
the	O
calcium	B-GENE-N
binding	I-GENE-N
loop	I-GENE-N
in	O
trypsinogen	O
.	O

Mutations	O
render	O
trypsinogen	O
resistant	O
to	O
CTRC	B-GENE-Y
-	O
mediated	O
degradation	O
and	O
/	O
or	O
increase	O
processing	O
of	O
the	O
activation	O
peptide	O
by	O
CTRC	B-GENE-N
.	O

Here	O
we	O
demonstrate	O
that	O
activation	O
peptide	O
mutations	O
D19A	B-GENE-N
,	O
D22G	B-GENE-N
,	O
K23R	B-GENE-N
and	O
K23	B-GENE-N
_	I-GENE-N
I24insIDK	I-GENE-N
robustly	O
increased	O
the	O
rate	O
of	O
trypsinogen	O
autoactivation	O
,	O
both	O
in	O
the	O
presence	O
and	O
absence	O
of	O
CTRC	B-GENE-Y
.	O

Degradation	O
of	O
the	O
mutants	O
by	O
CTRC	B-GENE-Y
was	O
unchanged	O
and	O
processing	O
of	O
the	O
activation	O
peptide	O
was	O
increased	O
only	O
in	O
the	O
D19A	B-GENE-N
mutant	O
by	O
4	O
-	O
fold	O
.	O

Surprisingly	O
,	O
however	O
,	O
this	O
increased	O
processing	O
had	O
only	O
a	O
minimal	O
effect	O
on	O
autoactivation	O
.	O

The	O
tetra	B-GENE-N
-	I-GENE-N
aspartate	I-GENE-N
motif	I-GENE-N
in	O
the	O
trypsinogen	O
activation	O
peptide	O
binds	O
calcium	B-CHEMICAL
(	O
KD	O
~	O
1	O
.	O
6	O
mM	O
)	O
,	O
which	O
stimulates	O
autoactivation	O
.	O

Unexpectedly	O
,	O
calcium	B-CHEMICAL
binding	O
was	O
not	O
compromised	O
by	O
any	O
of	O
the	O
activation	O
peptide	O
mutations	O
.	O

Despite	O
normal	O
binding	O
,	O
autoactivation	O
of	O
mutants	O
D22G	B-GENE-N
and	O
K23	B-GENE-N
_	I-GENE-N
I24insIDK	I-GENE-N
was	O
not	O
stimulated	O
by	O
calcium	B-CHEMICAL
.	O

Finally	O
,	O
the	O
activation	O
peptide	O
mutants	O
exhibited	O
reduced	O
secretion	O
from	O
transfected	O
cells	O
,	O
and	O
secreted	O
trypsinogen	O
levels	O
were	O
inversely	O
proportional	O
with	O
autoactivation	O
rates	O
.	O

We	O
conclude	O
that	O
D19A	B-GENE-N
,	O
D22G	B-GENE-N
,	O
K23R	B-GENE-N
and	O
K23	B-GENE-N
_	I-GENE-N
I24insIDK	I-GENE-N
form	O
a	O
mechanistically	O
distinct	O
subset	O
of	O
hereditary	O
pancreatitis	O
associated	O
mutations	O
,	O
which	O
exert	O
their	O
effect	O
primarily	O
through	O
direct	O
stimulation	O
of	O
autoactivation	O
,	O
independently	O
of	O
CTRC	B-GENE-Y
.	O

The	O
potentially	O
severe	O
clinical	O
impact	O
of	O
the	O
markedly	O
increased	O
autoactivation	O
is	O
offset	O
by	O
diminished	O
secretion	O
,	O
resulting	O
in	O
a	O
clinical	O
phenotype	O
indistinguishable	O
from	O
typical	O
hereditary	O
pancreatitis	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
phosphorylated	B-CHEMICAL
flavonoids	I-CHEMICAL
as	O
potent	O
and	O
selective	O
inhibitors	O
of	O
cholesterol	B-GENE-Y
esterase	I-GENE-Y
.	O

A	O
series	O
of	O
phosphorylated	B-CHEMICAL
flavonoids	I-CHEMICAL
were	O
synthesized	O
and	O
investigated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
pancreatic	O
cholesterol	B-GENE-Y
esterase	I-GENE-Y
(	O
CEase	B-GENE-Y
)	O
and	O
acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
.	O

The	O
results	O
showed	O
that	O
most	O
of	O
the	O
synthesized	O
compounds	O
exhibited	O
nanomolar	O
potency	O
against	O
CEase	B-GENE-Y
,	O
much	O
better	O
than	O
the	O
parent	O
flavonoids	B-CHEMICAL
.	O

Furthermore	O
,	O
these	O
phosphorylated	B-CHEMICAL
flavonoids	I-CHEMICAL
demonstrated	O
good	O
to	O
high	O
selectivity	O
for	O
CEase	B-GENE-Y
over	O
AChE	B-GENE-Y
,	O
which	O
only	O
showed	O
micromolar	O
potency	O
inhibition	O
of	O
AChE	B-GENE-Y
.	O

The	O
most	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CEase	B-GENE-Y
(	O
3e	O
)	O
had	O
IC50	O
value	O
of	O
0	O
.	O
72	O
nM	O
and	O
11800	O
-	O
fold	O
selectivity	O
for	O
CEase	B-GENE-Y
over	O
AChE	B-GENE-Y
.	O

The	O
structure	O
-	O
activity	O
relationships	O
revealed	O
that	O
the	O
free	O
hydroxyl	B-CHEMICAL
group	O
at	O
position	O
5	O
and	O
phosphate	B-CHEMICAL
group	O
at	O
position	O
7	O
of	O
the	O
phosphorylated	B-CHEMICAL
flavonoids	I-CHEMICAL
are	O
favorable	O
to	O
the	O
inhibition	O
of	O
CEase	B-GENE-Y
.	O

The	O
inhibition	O
mechanism	O
and	O
kinetic	O
characterization	O
studies	O
indicated	O
that	O
they	O
are	O
irreversible	O
competitive	O
inhibitors	O
of	O
CEase	B-GENE-Y
.	O

Pasireotide	B-CHEMICAL
:	O
A	O
Review	O
of	O
Its	O
Use	O
in	O
Cushing	O
'	O
s	O
Disease	O
.	O

Pasireotide	B-CHEMICAL
(	O
Signifor	B-CHEMICAL
(	O
®	O
)	O
)	O
is	O
a	O
new	O
subcutaneous	O
somatostatin	B-CHEMICAL
analogue	O
that	O
acts	O
via	O
somatostatin	B-GENE-N
receptors	I-GENE-N
to	O
inhibit	O
the	O
secretion	O
of	O
corticotropin	B-GENE-Y
from	O
the	O
pituitary	O
adenoma	O
in	O
patients	O
with	O
Cushing	O
'	O
s	O
disease	O
.	O

Pasireotide	B-CHEMICAL
has	O
a	O
receptor	O
binding	O
profile	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
somatostatin	B-CHEMICAL
analogues	O
,	O
binding	O
with	O
high	O
affinity	O
to	O
somatostatin	B-GENE-Y
receptor	I-GENE-Y
subtype	I-GENE-Y
5	I-GENE-Y
,	O
which	O
is	O
strongly	O
over	O
expressed	O
in	O
corticotroph	O
adenoma	O
cells	O
.	O

Pasireotide	B-CHEMICAL
is	O
the	O
first	O
pituitary	O
-	O
directed	O
agent	O
to	O
be	O
approved	O
for	O
use	O
in	O
Cushing	O
'	O
s	O
disease	O
.	O

In	O
a	O
phase	O
III	O
clinical	O
trial	O
in	O
patients	O
with	O
Cushing	O
'	O
s	O
disease	O
,	O
twice	O
-	O
daily	O
pasireotide	B-CHEMICAL
600	O
or	O
900	O
μg	O
for	O
6	O
months	O
led	O
to	O
normalization	O
of	O
urinary	O
free	O
cortisol	B-CHEMICAL
(	O
UFC	O
)	O
levels	O
in	O
up	O
to	O
a	O
quarter	O
of	O
all	O
patients	O
(	O
primary	O
endpoint	O
)	O
and	O
significantly	O
reduced	O
mean	O
UFC	O
levels	O
.	O

The	O
reduction	O
in	O
UFC	O
levels	O
is	O
rapid	O
(	O
within	O
one	O
to	O
two	O
months	O
)	O
and	O
sustained	O
(	O
up	O
to	O
24	O
months	O
)	O
.	O

Most	O
patients	O
who	O
do	O
not	O
have	O
an	O
early	O
response	O
to	O
pasireotide	B-CHEMICAL
do	O
not	O
respond	O
at	O
a	O
later	O
time	O
point	O
.	O

Decreases	O
in	O
UFC	O
levels	O
achieved	O
during	O
pasireotide	B-CHEMICAL
treatment	O
are	O
accompanied	O
by	O
decreases	O
in	O
serum	O
and	O
salivary	O
cortisol	B-CHEMICAL
levels	O
,	O
as	O
well	O
as	O
improvements	O
in	O
clinical	O
signs	O
and	O
symptoms	O
,	O
including	O
body	O
weight	O
,	O
blood	O
pressure	O
and	O
health	O
-	O
related	O
quality	O
-	O
of	O
-	O
life	O
.	O

Pasireotide	B-CHEMICAL
has	O
a	O
generally	O
similar	O
tolerability	O
profile	O
to	O
that	O
of	O
other	O
somatostatin	B-CHEMICAL
analogues	O
,	O
but	O
is	O
associated	O
with	O
a	O
relatively	O
high	O
incidence	O
of	O
hyperglycaemia	O
,	O
requiring	O
the	O
addition	O
or	O
intensification	O
of	O
glucose	B-CHEMICAL
-	O
lowering	O
medication	O
in	O
a	O
substantial	O
proportion	O
of	O
patients	O
.	O

Thus	O
,	O
pasireotide	B-CHEMICAL
,	O
together	O
with	O
on	O
-	O
going	O
patient	O
monitoring	O
,	O
provides	O
a	O
promising	O
new	O
option	O
for	O
the	O
medical	O
management	O
of	O
Cushing	O
'	O
s	O
disease	O
.	O

A	O
Model	O
-	O
Based	O
Approach	O
to	O
Predict	O
Longitudinal	O
HbA1c	B-GENE-Y
,	O
Using	O
Early	O
Phase	O
Glucose	B-CHEMICAL
Data	O
From	O
Type	O
2	O
Diabetes	O
Mellitus	O
Patients	O
After	O
Anti	O
-	O
Diabetic	O
Treatment	O
.	O

Predicting	O
late	O
phase	O
outcomes	O
from	O
early	O
-	O
phase	O
findings	O
can	O
help	O
inform	O
decisions	O
in	O
drug	O
development	O
.	O

If	O
the	O
measurements	O
in	O
early	O
-	O
phase	O
differ	O
from	O
those	O
in	O
late	O
phase	O
,	O
forecasting	O
is	O
more	O
challenging	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
a	O
model	O
-	O
based	O
approach	O
for	O
predicting	O
glycosylated	B-GENE-Y
hemoglobin	I-GENE-Y
(	O
HbA1c	B-GENE-Y
)	O
in	O
late	O
phase	O
using	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-Y
concentrations	O
from	O
an	O
early	O
-	O
phase	O
study	O
,	O
investigating	O
an	O
anti	O
-	O
diabetic	O
treatment	O
.	O

Two	O
previously	O
published	O
models	O
were	O
used	O
;	O
an	O
integrated	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-Y
(	O
IGI	O
)	O
model	O
for	O
meal	O
tolerance	O
tests	O
and	O
an	O
integrated	O
glucose	B-CHEMICAL
-	O
red	O
blood	O
cell	O
-	O
HbA1c	B-GENE-Y
(	O
IGRH	O
)	O
model	O
predicting	O
the	O
formation	O
of	O
HbA1c	B-GENE-Y
from	O
the	O
average	O
glucose	B-CHEMICAL
concentration	O
(	O
Cg	O
,	O
av	O
)	O
.	O

Output	O
from	O
the	O
IGI	O
model	O
was	O
used	O
as	O
input	O
to	O
the	O
IGRH	O
model	O
.	O

Parameters	O
of	O
the	O
IGI	O
model	O
and	O
drug	O
effects	O
were	O
estimated	O
using	O
data	O
from	O
a	O
phase1	O
study	O
in	O
59	O
diabetic	O
patients	O
receiving	O
various	O
doses	O
of	O
a	O
glucokinase	B-GENE-Y
activator	O
.	O

Cg	O
,	O
av	O
values	O
were	O
simulated	O
according	O
to	O
a	O
Phase	O
2	O
study	O
design	O
and	O
used	O
in	O
the	O
IGRH	O
model	O
for	O
predictions	O
of	O
HbA1c	B-GENE-Y
.	O

The	O
performance	O
of	O
the	O
model	O
-	O
based	O
approach	O
was	O
assessed	O
by	O
comparing	O
the	O
predicted	O
to	O
the	O
actual	O
outcome	O
of	O
the	O
Phase	O
2	O
study	O
.	O

We	O
have	O
shown	O
that	O
this	O
approach	O
well	O
predicts	O
the	O
longitudinal	O
HbA1c	B-GENE-Y
response	O
in	O
a	O
12	O
-	O
week	O
study	O
using	O
only	O
information	O
from	O
a	O
1	O
-	O
week	O
study	O
where	O
glucose	B-CHEMICAL
and	O
insulin	B-GENE-Y
concentrations	O
were	O
measured	O
.	O

Novel	O
therapeutic	O
targets	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Oncogenic	O
driver	O
mutations	O
frequently	O
occur	O
in	O
lung	O
cancer	O
and	O
play	O
role	O
in	O
carcinogenesis	O
.	O

These	O
mutations	O
are	O
usually	O
associated	O
with	O
distinct	O
clinical	O
and	O
histological	O
features	O
and	O
are	O
attractive	O
targets	O
for	O
anticancer	O
therapy	O
.	O

Recently	O
,	O
several	O
molecularly	O
distinct	O
phenotypes	O
of	O
NSCLC	O
based	O
on	O
specific	O
and	O
mutually	O
exclusive	O
genetic	O
derangements	O
have	O
been	O
described	O
.	O

Few	O
targets	O
like	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
(	O
EGFR	B-GENE-Y
)	O
mutations	O
and	O
anaplastic	B-GENE-Y
lymphoma	I-GENE-Y
kinase	I-GENE-Y
(	O
ALK	B-GENE-Y
)	O
gene	O
rearrangements	O
have	O
successfully	O
been	O
targeted	O
with	O
EGFR	B-GENE-Y
tyrosine	B-GENE-N
kinase	I-GENE-N
inhibitors	O
(	O
TKIs	O
)	O
and	O
crizotinib	B-CHEMICAL
,	O
respectively	O
.	O

Many	O
more	O
inhibitors	O
of	O
specific	O
driver	O
mutations	O
involving	O
genes	O
like	O
ROS	B-GENE-Y
,	O
c	B-GENE-Y
-	I-GENE-Y
MET	I-GENE-Y
,	O
FGFR	B-GENE-N
,	O
mTOR	B-GENE-Y
,	O
IGFR	B-GENE-Y
and	O
RET	B-GENE-Y
are	O
currently	O
under	O
development	O
.	O

However	O
,	O
efforts	O
to	O
target	O
some	O
mutated	O
genes	O
like	O
K	B-GENE-Y
-	I-GENE-Y
RAS	I-GENE-Y
have	O
been	O
unsuccessful	O
.	O

Moreover	O
,	O
the	O
emerging	O
challenge	O
of	O
acquired	O
resistance	O
to	O
initially	O
effective	O
therapy	O
is	O
becoming	O
another	O
major	O
concern	O
.	O

In	O
this	O
review	O
recent	O
data	O
on	O
novel	O
molecular	O
targets	O
and	O
their	O
future	O
prospects	O
are	O
discussed	O
.	O

In	O
vitro	O
exploration	O
of	O
potential	O
mechanisms	O
of	O
toxicity	O
of	O
the	O
human	O
hepatotoxic	O
drug	O
fenclozic	B-CHEMICAL
acid	I-CHEMICAL
.	O

The	O
carboxylic	B-CHEMICAL
acid	I-CHEMICAL
NSAID	O
fenclozic	B-CHEMICAL
acid	I-CHEMICAL
exhibited	O
an	O
excellent	O
preclinical	O
safety	O
profile	O
and	O
promising	O
clinical	O
efficacy	O
,	O
yet	O
was	O
withdrawn	O
from	O
clinical	O
development	O
in	O
1971	O
due	O
to	O
hepatotoxicity	O
observed	O
in	O
clinical	O
trials	O
.	O

A	O
variety	O
of	O
modern	O
in	O
vitro	O
approaches	O
have	O
been	O
used	O
to	O
explore	O
potential	O
underlying	O
mechanisms	O
.	O

Covalent	O
binding	O
studies	O
were	O
undertaken	O
with	O
[	B-CHEMICAL
(	I-CHEMICAL
14	I-CHEMICAL
)	I-CHEMICAL
C	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
fenclozic	I-CHEMICAL
acid	I-CHEMICAL
to	O
investigate	O
the	O
possible	O
role	O
of	O
reactive	O
metabolites	O
.	O

Time	O
-	O
dependent	O
covalent	O
binding	O
to	O
protein	O
was	O
observed	O
in	O
NADPH	B-CHEMICAL
-	O
supplemented	O
liver	O
microsomes	O
,	O
although	O
no	O
metabolites	O
were	O
detected	O
in	O
these	O
incubations	O
or	O
in	O
reactive	O
metabolite	O
trapping	O
experiments	O
.	O

In	O
human	O
hepatocytes	O
,	O
covalent	O
binding	O
was	O
observed	O
at	O
lower	O
levels	O
than	O
in	O
microsomes	O
and	O
a	O
minor	O
uncharacterizable	O
metabolite	O
was	O
also	O
observed	O
.	O

In	O
addition	O
,	O
covalent	O
binding	O
was	O
observed	O
in	O
incubations	O
undertaken	O
with	O
dog	O
and	O
rat	O
hepatocytes	O
,	O
where	O
a	O
taurine	B-CHEMICAL
conjugate	O
of	O
the	O
drug	O
was	O
detected	O
.	O

Although	O
an	O
acyl	B-CHEMICAL
glucuronide	I-CHEMICAL
metabolite	O
was	O
detected	O
when	O
liver	O
microsomes	O
from	O
human	O
,	O
rat	O
and	O
dog	O
were	O
supplemented	O
with	O
UDPGA	B-CHEMICAL
,	O
there	O
was	O
no	O
detectable	O
UDPGA	B-CHEMICAL
-	O
dependent	O
covalent	O
binding	O
.	O

No	O
effects	O
were	O
observed	O
when	O
fenclozic	B-CHEMICAL
acid	I-CHEMICAL
was	O
assessed	O
for	O
P450	B-GENE-N
-	O
dependent	O
and	O
P450	B-GENE-N
-	O
independent	O
cytotoxicity	O
to	O
THLE	O
cell	O
lines	O
,	O
time	O
-	O
dependent	O
inhibition	O
of	O
five	O
major	O
human	B-GENE-N
cytochrome	I-GENE-N
P450	I-GENE-N
enzymes	O
,	O
inhibition	O
of	O
the	O
biliary	O
efflux	B-GENE-N
transporters	I-GENE-N
BSEP	B-GENE-Y
and	O
MRP2	B-GENE-Y
or	O
mitochondrial	O
toxicity	O
to	O
THLE	O
or	O
HepG2	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
Phase	O
1	O
bioactivation	O
plays	O
a	O
role	O
in	O
the	O
hepatotoxicity	O
of	O
fenclozic	B-CHEMICAL
acid	I-CHEMICAL
and	O
highlight	O
the	O
unique	O
insight	O
into	O
mechanisms	O
of	O
human	O
drug	O
toxicity	O
that	O
can	O
be	O
provided	O
by	O
investigations	O
of	O
biotransformation	O
and	O
covalent	O
binding	O
to	O
proteins	O
.	O

Drugs	O
in	O
Development	O
for	O
Relapsing	O
Multiple	O
Sclerosis	O
.	O

Drug	O
development	O
for	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
,	O
as	O
with	O
any	O
other	O
neurological	O
disease	O
,	O
faces	O
numerous	O
challenges	O
,	O
with	O
many	O
drugs	O
failing	O
at	O
various	O
stages	O
of	O
development	O
.	O

The	O
disease	O
-	O
modifying	O
therapies	O
(	O
DMTs	O
)	O
first	O
introduced	O
for	O
MS	O
are	O
only	O
moderately	O
effective	O
,	O
but	O
given	O
the	O
lack	O
of	O
competition	O
,	O
they	O
have	O
been	O
widely	O
accepted	O
in	O
clinical	O
practice	O
.	O

Although	O
safety	O
and	O
efficacy	O
continue	O
to	O
be	O
the	O
two	O
main	O
metrics	O
by	O
which	O
drugs	O
will	O
be	O
judged	O
,	O
the	O
newer	O
agents	O
in	O
the	O
market	O
also	O
face	O
challenges	O
of	O
a	O
more	O
comparative	O
nature	O
-	O
are	O
they	O
more	O
efficacious	O
than	O
the	O
currently	O
available	O
drugs	O
on	O
the	O
market	O
?	O

Are	O
they	O
safer	O
or	O
better	O
tolerated	O
?	O

Do	O
they	O
offer	O
any	O
practical	O
advantages	O
over	O
current	O
treatments	O
?	O

Fingolimod	B-CHEMICAL
represented	O
a	O
milestone	O
following	O
its	O
approval	O
as	O
an	O
oral	O
drug	O
for	O
MS	O
in	O
2010	O
,	O
offering	O
patients	O
a	O
far	O
more	O
convenient	O
administration	O
route	O
.	O

However	O
,	O
association	O
with	O
cardiovascular	O
complications	O
has	O
led	O
to	O
a	O
more	O
cautious	O
approach	O
in	O
its	O
initial	O
prescribing	O
,	O
now	O
requiring	O
cardiac	O
monitoring	O
for	O
the	O
first	O
6	O
h	O
as	O
well	O
as	O
subsequent	O
monitoring	O
of	O
blood	O
pressure	O
and	O
for	O
macular	O
oedema	O
.	O

Natalizumab	O
,	O
amongst	O
licensed	O
drugs	O
,	O
represents	O
the	O
current	O
benchmark	O
for	O
efficacy	O
.	O

The	O
risk	O
of	O
progressive	O
multifocal	O
leukoencephalopathy	O
during	O
natalizumab	O
treatment	O
is	O
now	O
more	O
quantifiable	O
.	O

Other	O
monoclonal	O
antibodies	O
are	O
in	O
various	O
phases	O
of	O
development	O
.	O

Marketing	O
authorisation	O
for	O
alemtuzumab	O
has	O
been	O
filed	O
,	O
and	O
whilst	O
trial	O
data	O
suggest	O
that	O
its	O
efficacy	O
outperforms	O
both	O
licensed	O
drugs	O
and	O
others	O
in	O
development	O
,	O
there	O
is	O
a	O
significant	O
risk	O
of	O
secondary	O
autoimmunity	O
.	O

Its	O
once	O
-	O
yearly	O
administration	O
,	O
however	O
,	O
seems	O
particularly	O
advantageous	O
.	O

Rituximab	O
is	O
unlikely	O
to	O
be	O
developed	O
further	O
as	O
its	O
license	O
will	O
expire	O
,	O
but	O
ocrelizumab	O
,	O
another	O
monoclonal	O
antibody	O
directly	O
targeting	O
B	O
cells	O
,	O
is	O
currently	O
in	O
phase	O
2	O
development	O
and	O
looks	O
promising	O
.	O

Daclizumab	O
is	O
also	O
moderately	O
efficacious	O
but	O
may	O
struggle	O
to	O
establish	O
itself	O
given	O
its	O
monthly	O
subcutaneous	O
dosing	O
.	O

There	O
are	O
new	O
oral	O
drugs	O
in	O
development	O
,	O
and	O
it	O
is	O
likely	O
that	O
BG	B-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
will	O
be	O
licensed	O
this	O
year	O
.	O

This	O
has	O
been	O
licensed	O
for	O
psoriasis	O
so	O
there	O
are	O
good	O
safety	O
data	O
in	O
humans	O
that	O
may	O
also	O
hold	O
true	O
in	O
MS	O
;	O
however	O
,	O
its	O
three	O
times	O
daily	O
dosage	O
will	O
probably	O
impact	O
on	O
patient	O
compliance	O
.	O

Laquinimod	B-CHEMICAL
has	O
lower	O
efficacy	O
than	O
BG	B-CHEMICAL
-	I-CHEMICAL
12	I-CHEMICAL
but	O
appears	O
safe	O
and	O
could	O
find	O
a	O
place	O
as	O
a	O
first	O
-	O
line	O
agent	O
.	O

Teriflunomide	B-CHEMICAL
has	O
just	O
been	O
licensed	O
by	O
the	O
US	O
FDA	O
and	O
may	O
challenge	O
the	O
current	O
injectable	O
first	O
-	O
line	O
therapies	O
as	O
it	O
has	O
a	O
similar	O
efficacy	O
but	O
the	O
advantage	O
of	O
being	O
taken	O
orally	O
.	O

However	O
,	O
risk	O
of	O
teratogenicity	O
may	O
caution	O
against	O
its	O
use	O
in	O
some	O
women	O
of	O
child	O
-	O
bearing	O
potential	O
.	O

This	O
review	O
will	O
examine	O
drugs	O
that	O
have	O
been	O
recently	O
approved	O
as	O
well	O
as	O
those	O
that	O
are	O
in	O
late	O
phase	O
2	O
or	O
3	O
development	O
as	O
treatment	O
for	O
relapsing	O
MS	O
,	O
highlighting	O
their	O
mechanism	O
of	O
action	O
as	O
well	O
as	O
the	O
clinical	O
trial	O
and	O
safety	O
data	O
before	O
discussing	O
their	O
potential	O
for	O
success	O
in	O
an	O
increasingly	O
florid	O
and	O
complex	O
DMT	O
armamentarium	O
.	O

LIVER	B-GENE-N
X	I-GENE-N
RECEPTORS	I-GENE-N
,	O
NERVOUS	O
SYSTEM	O
AND	O
LIPID	O
METABOLISM	O
.	O

Lipids	O
in	O
the	O
nervous	O
system	O
are	O
represented	O
by	O
cholesterol	B-CHEMICAL
and	O
phospholipids	O
as	O
constituents	O
of	O
cell	O
membranes	O
and	O
,	O
in	O
particular	O
,	O
of	O
myelin	O
.	O

Therefore	O
,	O
lipids	O
are	O
finely	O
regulated	O
to	O
guarantee	O
physiological	O
functions	O
.	O

In	O
the	O
central	O
nervous	O
system	O
,	O
cholesterol	B-CHEMICAL
is	O
locally	O
synthesized	O
due	O
to	O
the	O
presence	O
of	O
the	O
blood	O
brain	O
barrier	O
.	O

In	O
the	O
peripheral	O
nervous	O
system	O
cholesterol	B-CHEMICAL
is	O
either	O
uptaken	O
by	O
lipoproteins	O
and	O
/	O
or	O
produced	O
by	O
de	O
novo	O
biosynthesis	O
.	O

Defects	O
in	O
lipid	O
homeostasis	O
in	O
these	O
tissues	O
lead	O
to	O
structural	O
and	O
functional	O
changes	O
that	O
often	O
result	O
in	O
different	O
pathological	O
conditions	O
depending	O
on	O
the	O
affected	O
pathways	O
(	O
i	O
.	O
e	O
.	O
cholesterol	B-CHEMICAL
biosynthesis	O
,	O
cholesterol	B-CHEMICAL
efflux	O
,	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
biosynthesis	O
etc	O
.	O
)	O
.	O

Alterations	O
in	O
cholesterol	B-CHEMICAL
metabolism	O
in	O
the	O
central	O
nervous	O
system	O
are	O
linked	O
to	O
several	O
disorders	O
such	O
as	O
Alzheimer	O
'	O
s	O
disease	O
,	O
Huntington	O
disease	O
,	O
Parkinson	O
disease	O
,	O
Multiple	O
Sclerosis	O
,	O
Smith	O
-	O
Lemli	O
-	O
Opitz	O
syndrome	O
,	O
Niemann	O
-	O
Pick	O
type	O
C	O
disease	O
,	O
and	O
glioblastoma	O
.	O

In	O
the	O
peripheral	O
nervous	O
system	O
changes	O
in	O
lipid	O
metabolism	O
are	O
associated	O
with	O
the	O
development	O
of	O
peripheral	O
neuropathy	O
that	O
may	O
be	O
caused	O
by	O
metabolic	O
disorders	O
,	O
injuries	O
,	O
therapeutics	O
and	O
autoimmune	O
diseases	O
.	O

Transcription	O
factors	O
,	O
such	O
as	O
the	O
Liver	B-GENE-N
X	I-GENE-N
receptors	I-GENE-N
(	O
LXRs	B-GENE-N
)	O
,	O
regulate	O
both	O
cholesterol	B-CHEMICAL
and	O
fatty	B-CHEMICAL
acid	I-CHEMICAL
metabolism	O
in	O
several	O
tissues	O
including	O
the	O
nervous	O
system	O
.	O

In	O
the	O
last	O
few	O
years	O
several	O
studies	O
elucidated	O
the	O
biology	O
of	O
LXRs	B-GENE-N
in	O
nervous	O
system	O
due	O
to	O
the	O
availability	O
of	O
knock	O
-	O
out	O
mice	O
and	O
the	O
development	O
of	O
synthetic	O
ligands	O
.	O

Here	O
,	O
we	O
review	O
a	O
survey	O
of	O
the	O
literature	O
focused	O
on	O
central	O
and	O
peripheral	O
nervous	O
system	O
and	O
in	O
physiological	O
and	O
pathological	O
settings	O
with	O
particular	O
attention	O
on	O
the	O
roles	O
played	O
by	O
LXRs	B-GENE-N
in	O
both	O
districts	O
.	O

Profiling	O
976	O
ToxCast	O
chemicals	O
across	O
331	O
enzymatic	O
and	O
receptor	O
signaling	O
assays	O
.	O

Understanding	O
potential	O
health	O
risks	O
is	O
a	O
significant	O
challenge	O
due	O
to	O
large	O
numbers	O
of	O
diverse	O
chemicals	O
with	O
poorly	O
characterized	O
exposures	O
and	O
mechanisms	O
of	O
toxicities	O
.	O

The	O
present	O
study	O
analyzes	O
976	O
chemicals	O
(	O
including	O
failed	O
pharmaceuticals	O
,	O
alternative	O
plasticizers	O
,	O
food	O
additives	O
,	O
and	O
pesticides	O
)	O
in	O
Phase	O
I	O
and	O
II	O
of	O
the	O
U	O
.	O
S	O
.	O

EPA	O
'	O
s	O
ToxCast	O
™	O
project	O
across	O
331	O
cell	O
-	O
free	O
enzymatic	O
and	O
ligand	O
-	O
binding	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
assays	O
.	O

Half	O
-	O
maximal	O
activity	O
concentrations	O
(	O
AC50	O
)	O
were	O
identified	O
for	O
729	O
chemicals	O
in	O
256	O
assays	O
(	O
7	O
,	O
135	O
chemical	O
-	O
assay	O
pairs	O
)	O
.	O

Some	O
of	O
the	O
most	O
commonly	O
affected	O
assays	O
were	O
CYPs	B-GENE-N
(	O
CYP2C9	B-GENE-Y
,	O
CYP2C19	B-GENE-Y
)	O
,	O
transporters	O
(	O
mitochondrial	O
TSPO	O
,	O
norepinephrine	B-CHEMICAL
,	O
dopaminergic	O
)	O
,	O
and	O
GPCRs	B-GENE-N
(	O
aminergic	O
)	O
.	O

Heavy	O
metals	O
,	O
surfactants	O
,	O
and	O
dithiocarbamate	B-CHEMICAL
fungicides	O
showed	O
promiscuous	O
,	O
but	O
distinctly	O
different	O
patterns	O
of	O
activity	O
whereas	O
many	O
of	O
the	O
pharma	O
compounds	O
showed	O
promiscuous	O
activity	O
across	O
GPCRs	B-GENE-N
.	O

Literature	O
analysis	O
confirmed	O
>	O
50	O
%	O
of	O
the	O
activities	O
for	O
the	O
most	O
potent	O
chemical	O
-	O
assay	O
pairs	O
(	O
56	O
)	O
,	O
but	O
also	O
revealed	O
10	O
missed	O
interactions	O
.	O

Twenty	O
-	O
two	O
chemicals	O
with	O
known	O
estrogenic	O
activity	O
were	O
correctly	O
identified	O
for	O
the	O
majority	O
(	O
77	O
%	O
)	O
,	O
missing	O
only	O
the	O
weaker	O
interactions	O
.	O

In	O
many	O
cases	O
,	O
novel	O
findings	O
for	O
previously	O
unreported	O
chemical	O
-	O
target	O
combinations	O
clustered	O
with	O
known	O
chemical	O
-	O
target	O
interactions	O
.	O

Results	O
from	O
this	O
large	O
inventory	O
of	O
chemical	O
-	O
biological	O
interactions	O
can	O
inform	O
read	O
-	O
across	O
methods	O
as	O
well	O
as	O
to	O
link	O
potential	O
targets	O
to	O
molecular	O
initiating	O
events	O
in	O
adverse	O
outcome	O
pathways	O
for	O
diverse	O
toxicities	O
.	O

This	O
abstract	O
does	O
not	O
necessarily	O
reflect	O
U	O
.	O
S	O
.	O

EPA	O
policy	O
.	O

Sphingosine	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
promotes	O
the	O
nuclear	O
translocation	O
of	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
and	O
thereby	O
induces	O
osteoprotegerin	B-GENE-N
gene	O
expression	O
in	O
osteoblast	O
-	O
like	O
cell	O
lines	O
.	O

Sphingosine	B-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
S1P	B-CHEMICAL
)	O
is	O
a	O
well	O
-	O
known	O
signaling	O
sphingolipid	B-CHEMICAL
and	O
bioactive	O
lipid	O
mediator	O
.	O

Recently	O
,	O
it	O
was	O
reported	O
that	O
S1P	B-CHEMICAL
inhibits	O
osteoclast	O
differentiation	O
and	O
bone	O
resorption	O
.	O

On	O
the	O
other	O
hand	O
,	O
S1P	B-CHEMICAL
effects	O
on	O
osteoblasts	O
and	O
bone	O
formation	O
are	O
little	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
S1P	B-CHEMICAL
on	O
osteoblasts	O
,	O
using	O
two	O
osteoblast	O
-	O
like	O
cell	O
lines	O
,	O
SaOS	O
-	O
2	O
and	O
MC3T3	O
-	O
E1	O
.	O

S1P	B-CHEMICAL
activated	O
phosphatidylinositol	B-GENE-N
3	I-GENE-N
-	I-GENE-N
kinase	I-GENE-N
(	O
PI3K	B-GENE-N
)	O
/	O
Akt	B-GENE-N
signaling	O
,	O
leading	O
to	O
the	O
inhibition	O
of	O
glycogen	B-GENE-N
synthase	I-GENE-N
kinase	I-GENE-N
-	I-GENE-N
3β	I-GENE-N
and	O
the	O
nuclear	O
translocation	O
of	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
,	O
followed	O
by	O
the	O
increase	O
of	O
the	O
transcriptional	O
activity	O
by	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
/	O
T	B-GENE-N
-	I-GENE-N
cell	I-GENE-N
factor	I-GENE-N
complex	O
formation	O
in	O
both	O
SaOS	O
-	O
2	O
cells	O
and	O
MC3T3	O
-	O
E1	O
cells	O
.	O

The	O
inhibitors	O
of	O
PI3K	B-GENE-N
and	O
Akt	B-GENE-N
suppressed	O
S1P	B-CHEMICAL
-	O
induced	O
nuclear	O
localization	O
of	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
.	O

We	O
further	O
investigated	O
the	O
effects	O
of	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
signaling	O
on	O
the	O
Wnt	B-GENE-N
/	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
signaling	O
pathway	O
,	O
since	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
takes	O
a	O
central	O
role	O
in	O
this	O
signaling	O
pathway	O
.	O

Both	O
inhibitors	O
for	O
PI3K	B-GENE-N
and	O
Akt	B-GENE-N
suppressed	O
the	O
nuclear	O
localization	O
of	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
and	O
T	B-GENE-N
-	I-GENE-N
cell	I-GENE-N
factor	I-GENE-N
transcriptional	O
activity	O
induced	O
by	O
Wnt	B-GENE-N
-	I-GENE-N
3a	I-GENE-N
.	O

S1P	B-CHEMICAL
increased	O
the	O
amount	O
of	O
osteoprotegerin	B-GENE-N
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
,	O
and	O
increased	O
the	O
activity	O
of	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
,	O
leading	O
to	O
the	O
mineralization	O
.	O

These	O
findings	O
suggest	O
that	O
S1P	B-CHEMICAL
activates	O
the	O
PI3K	B-GENE-N
/	O
Akt	B-GENE-N
signaling	O
pathway	O
leading	O
to	O
the	O
promotion	O
of	O
nuclear	O
translocation	O
of	O
β	B-GENE-N
-	I-GENE-N
catenin	I-GENE-N
in	O
osteoblast	O
-	O
like	O
cells	O
,	O
resulting	O
in	O
the	O
upregulation	O
of	O
osteoptotegerin	B-GENE-N
and	O
osteoblast	O
differentiation	O
markers	O
including	O
alkaline	B-GENE-N
phosphatase	I-GENE-N
,	O
probably	O
relating	O
to	O
the	O
inhibition	O
of	O
osteoclast	O
formation	O
and	O
the	O
mineralization	O
,	O
respectively	O
.	O

Comparative	O
phosphoproteomic	O
analysis	O
of	O
checkpoint	O
recovery	O
identifies	O
new	O
regulators	O
of	O
the	O
DNA	O
damage	O
response	O
.	O

How	O
cells	O
recover	O
from	O
a	O
DNA	O
damage	O
-	O
induced	O
arrest	O
is	O
currently	O
poorly	O
understood	O
.	O

We	O
performed	O
large	O
-	O
scale	O
quantitative	O
phosphoproteomics	O
to	O
identify	O
changes	O
in	O
protein	O
phosphorylation	O
that	O
occurred	O
during	O
recovery	O
from	O
arrest	O
in	O
the	O
G2	O
phase	O
of	O
the	O
cell	O
cycle	O
caused	O
by	O
DNA	O
damage	O
.	O

We	O
identified	O
154	O
proteins	O
that	O
were	O
differentially	O
phosphorylated	O
,	O
and	O
systematic	O
depletion	O
of	O
each	O
of	O
these	O
differentially	O
phosphorylated	O
proteins	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
identified	O
at	O
least	O
10	O
potential	O
regulators	O
of	O
recovery	O
.	O

Astrin	B-CHEMICAL
,	O
a	O
protein	O
associated	O
with	O
the	O
mitotic	O
spindle	O
,	O
was	O
among	O
the	O
potential	O
regulators	O
of	O
recovery	O
.	O

We	O
found	O
that	O
astrin	B-GENE-Y
controlled	O
the	O
abundance	O
of	O
the	O
cell	O
cycle	O
regulator	O
p53	B-GENE-Y
during	O
DNA	O
damage	O
-	O
induced	O
arrest	O
.	O

Cells	O
in	O
which	O
astrin	B-CHEMICAL
was	O
depleted	O
had	O
decreased	O
murine	B-GENE-Y
double	I-GENE-Y
minute	I-GENE-Y
2	I-GENE-Y
(	O
MDM2	B-GENE-Y
)	O
abundance	O
and	O
increased	O
p53	B-GENE-Y
at	O
the	O
later	O
stages	O
of	O
the	O
DNA	O
damage	O
response	O
.	O

Astrin	B-CHEMICAL
was	O
required	O
for	O
continued	O
expression	O
of	O
genes	O
encoding	O
proteins	O
that	O
promote	O
cell	O
cycle	O
progression	O
in	O
arrested	O
cells	O
.	O

Thus	O
,	O
by	O
controlling	O
p53	B-GENE-Y
abundance	O
in	O
cells	O
recovering	O
from	O
DNA	O
damage	O
,	O
astrin	B-GENE-Y
maintains	O
the	O
cells	O
in	O
a	O
state	O
competent	O
to	O
resume	O
the	O
cell	O
cycle	O
.	O

Grb10	B-GENE-Y
-	O
mediated	O
Negative	O
Regulation	O
of	O
IGF1R	B-GENE-Y
-	O
Activated	O
Signalling	O
Pathway	O
Results	O
in	O
Cognitive	O
Disorder	O
in	O
Diabetic	O
Rats	O
.	O

Growth	B-GENE-Y
factor	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
bound	I-GENE-Y
protein	I-GENE-Y
10	I-GENE-Y
(	O
Grb10	B-GENE-Y
)	O
is	O
a	O
Src	B-GENE-N
homology	I-GENE-N
2	I-GENE-N
(	I-GENE-N
SH2	I-GENE-N
)	I-GENE-N
domain	I-GENE-N
-	O
containing	O
protein	O
and	O
one	O
of	O
the	O
binding	O
partners	O
for	O
several	O
trans	O
-	O
membrane	O
tyrosine	B-GENE-N
-	I-GENE-N
kinase	I-GENE-N
receptors	I-GENE-N
,	O
including	O
insulin	B-GENE-Y
receptor	I-GENE-Y
(	O
IR	B-GENE-Y
)	O
and	O
insulin	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
(	O
IGF1	B-GENE-Y
-	I-GENE-Y
R	I-GENE-Y
)	O
.	O

The	O
hippocampus	O
,	O
which	O
is	O
critical	O
for	O
cognitive	O
functions	O
,	O
is	O
one	O
of	O
the	O
main	O
distribution	O
areas	O
of	O
Grb10	B-GENE-Y
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
recent	O
years	O
,	O
diabetic	O
encephalopathy	O
has	O
been	O
defined	O
as	O
a	O
third	O
type	O
of	O
diabetes	O
and	O
the	O
IGF1	B-GENE-Y
-	I-GENE-Y
IR	I-GENE-Y
pathway	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
the	O
neuropathogenic	O
process	O
of	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

However	O
,	O
the	O
role	O
of	O
endogenous	O
Grb10	B-GENE-Y
in	O
regulating	O
the	O
IGF1	B-GENE-Y
-	I-GENE-Y
IR	I-GENE-Y
pathway	O
and	O
neurobehavioral	O
changes	O
is	O
not	O
explicit	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
in	O
vivo	O
function	O
of	O
endogenous	O
Grb10	B-GENE-Y
in	O
diabetic	O
encephalopathy	O
and	O
the	O
underlying	O
mechanisms	O
.	O

Using	O
stereotaxic	O
surgical	O
techniques	O
and	O
lentiviral	O
vectors	O
expressing	O
specific	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
,	O
we	O
could	O
steadily	O
knock	O
down	O
Grb10	B-GENE-Y
expression	O
in	O
the	O
hippocampus	O
.	O

More	O
importantly	O
,	O
we	O
demonstrated	O
that	O
hippocampus	O
-	O
specific	O
modulation	O
of	O
Grb10	B-GENE-Y
protein	O
levels	O
led	O
to	O
a	O
prominent	O
remission	O
of	O
cognitive	O
disorder	O
,	O
including	O
improvements	O
in	O
both	O
ultrastructural	O
pathology	O
and	O
abnormal	O
neurobehavioural	O
changes	O
.	O

Our	O
findings	O
indicate	O
that	O
endogenous	O
overexpression	O
of	O
Grb10	B-GENE-Y
functions	O
as	O
a	O
suppressor	O
of	O
the	O
IGF1	B-GENE-Y
-	I-GENE-Y
IR	I-GENE-Y
pathway	O
,	O
which	O
may	O
represent	O
an	O
important	O
mechanism	O
that	O
regulates	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Toxicological	O
impact	O
of	O
inhaled	O
electric	O
mosquito	O
-	O
repellent	O
liquid	O
on	O
the	O
rat	O
:	O
a	O
hematological	O
,	O
cytokine	B-GENE-N
indications	O
,	O
oxidative	O
stress	O
and	O
tumor	O
markers	O
.	O

Abstract	O
Context	O
:	O
High	O
malaria	O
burden	O
has	O
led	O
to	O
the	O
increased	O
use	O
of	O
insecticides	O
in	O
the	O
tropics	O
and	O
subtropics	O
.	O

This	O
study	O
thus	O
aimed	O
at	O
assessing	O
the	O
hematological	O
effects	O
alteration	O
of	O
pyrethroid	B-CHEMICAL
insecticide	O
exposure	O
using	O
the	O
experimental	O
animal	O
model	O
.	O

Objective	O
:	O
A	O
commonly	O
available	O
Electric	O
Mosquito	O
-	O
Repellent	O
Liquid	O
pyrethroid	B-CHEMICAL
insecticide	O
containing	O
prallethrin	B-CHEMICAL
1	O
.	O
6	O
%	O
w	O
/	O
w	O
is	O
widely	O
used	O
for	O
mosquito	O
control	O
in	O
Saudi	O
Arabia	O
.	O

The	O
immunotoxic	O
effects	O
after	O
inhalation	O
exposures	O
to	O
the	O
preparation	O
for	O
a	O
continuous	O
period	O
of	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
were	O
investigated	O
in	O
rats	O
.	O

Methods	O
and	O
materials	O
:	O
Rats	O
were	O
exposed	O
to	O
prallethrin	B-CHEMICAL
1	O
.	O
6	O
%	O
w	O
/	O
w	O
by	O
inhalation	O
for	O
72	O
consecutive	O
hours	O
.	O

Total	O
blood	O
count	O
,	O
blood	O
indices	O
of	O
creatine	B-GENE-N
kinase	I-GENE-N
(	O
CK	B-GENE-N
)	O
,	O
gamma	B-GENE-Y
-	I-GENE-Y
glutamyltranspeptidase	I-GENE-Y
(	O
γ	B-GENE-Y
-	I-GENE-Y
GT	I-GENE-Y
)	O
,	O
superoxide	B-GENE-N
dismutase	I-GENE-N
(	O
SOD	B-GENE-N
)	O
,	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
,	O
malondialdehyde	B-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
,	O
interleukin	B-GENE-Y
(	I-GENE-Y
IL	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factors	I-GENE-Y
(	I-GENE-Y
TNF	I-GENE-Y
)	I-GENE-Y
α	I-GENE-Y
,	O
alpha	B-GENE-Y
-	I-GENE-Y
fetoprotein	I-GENE-Y
(	O
AFP	B-GENE-Y
)	O
,	O
carbohydrate	B-GENE-N
antigen	I-GENE-N
(	I-GENE-N
CA	I-GENE-N
)	I-GENE-N
19	I-GENE-N
.	I-GENE-N
9	I-GENE-N
and	O
carcinoembrionic	B-GENE-N
antigen	I-GENE-N
(	O
CEA	B-GENE-N
)	O
were	O
assayed	O
.	O

Results	O
:	O
The	O
administration	O
of	O
prallethrin	B-CHEMICAL
1	O
.	O
6	O
%	O
w	O
/	O
w	O
created	O
significant	O
increased	O
changes	O
in	O
the	O
levels	O
of	O
total	O
WBC	O
,	O
lymphocytes	O
,	O
RBC	O
,	O
hemoglobin	B-GENE-N
,	O
packed	O
cell	O
volume	O
,	O
platelets	O
,	O
mean	O
corpuscular	O
volume	O
,	O
and	O
mean	O
corpuscular	O
hemoglobin	B-GENE-N
in	O
rats	O
after	O
24	O
,	O
48	O
,	O
and	O
72	O
h	O
of	O
continuous	O
inhalation	O
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
reduction	O
in	O
neutrophils	O
at	O
transient	O
reduction	O
in	O
the	O
monocytes	O
after	O
24	O
and	O
48	O
h	O
to	O
return	O
to	O
normal	O
after	O
72	O
h	O
.	O

Significant	O
increases	O
in	O
the	O
levels	O
of	O
CK	B-GENE-N
,	O
γ	B-GENE-Y
-	I-GENE-Y
GT	I-GENE-Y
,	O
SOD	B-GENE-N
,	O
NO	B-CHEMICAL
,	O
MDA	B-CHEMICAL
,	O
AFP	B-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
and	O
TNFα	B-GENE-Y
were	O
recorded	O
.	O

CA	B-GENE-N
and	O
CEA	B-GENE-N
did	O
not	O
exhibit	O
any	O
change	O
.	O

Conclusions	O
:	O
Continuous	O
inhalation	O
to	O
prallethrin	B-CHEMICAL
1	O
.	O
6	O
%	O
insecticides	O
poses	O
toxicity	O
on	O
hematological	O
variables	O
.	O

It	O
is	O
also	O
concluded	O
that	O
pyrethroid	B-CHEMICAL
group	O
of	O
insecticide	O
may	O
cause	O
hematological	O
,	O
biochemical	O
,	O
cytokine	B-GENE-N
disturbances	O
and	O
possible	O
mutagenic	O
damage	O
to	O
the	O
tissues	O
.	O

Vitamin	B-CHEMICAL
C	I-CHEMICAL
forestalls	O
cigarette	O
smoke	O
induced	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
in	O
alveolar	O
epithelial	O
cells	O
.	O

Cigarette	O
smoking	O
causes	O
cellular	O
oxidative	O
stress	O
resulting	O
in	O
inflammatory	O
diseases	O
of	O
lung	O
wherein	O
transcription	O
factor	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
plays	O
an	O
important	O
role	O
.	O

It	O
is	O
possible	O
that	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
,	O
an	O
antioxidant	O
,	O
may	O
prevent	O
cigarette	O
smoke	O
(	O
CS	O
)	O
-	O
induced	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
that	O
involves	O
degradation	O
of	O
I	B-GENE-Y
-	I-GENE-Y
κBε	I-GENE-Y
and	O
nuclear	O
translocation	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Rel	I-GENE-Y
/	O
p50	B-GENE-Y
in	O
alveolar	O
epithelial	O
cells	O
.	O

Therefore	O
,	O
to	O
examine	O
the	O
hypothesis	O
,	O
we	O
verified	O
the	O
effect	O
of	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
on	O
CS	O
-	O
induced	O
expression	O
of	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
driven	O
luciferase	O
reporter	O
and	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
binding	O
at	O
its	O
target	O
DNA	O
by	O
EMSA	O
in	O
alveolar	O
epithelial	O
A549	O
cells	O
.	O

We	O
also	O
examined	O
the	O
level	O
of	O
I	B-GENE-Y
-	I-GENE-Y
κBε	I-GENE-Y
and	O
sub	O
-	O
cellular	O
distribution	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Rel	I-GENE-Y
by	O
western	O
blotting	O
and	O
immunofluorescence	O
respectively	O
in	O
CSE	O
-	O
treated	O
A549	O
cells	O
with	O
or	O
without	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
pretreatment	O
.	O

We	O
observed	O
a	O
significant	O
reduction	O
in	O
CSE	O
induced	O
luciferase	O
expression	O
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
DNA	O
binding	O
,	O
I	B-GENE-Y
-	I-GENE-Y
κBε	I-GENE-Y
degradation	O
and	O
c	B-GENE-Y
-	I-GENE-Y
Rel	I-GENE-Y
nuclear	O
translocation	O
in	O
cells	O
pretreated	O
with	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
.	O

To	O
further	O
validate	O
the	O
result	O
,	O
we	O
examined	O
sub	O
-	O
cellular	O
distribution	O
of	O
c	B-GENE-Y
-	I-GENE-Y
Rel	I-GENE-Y
in	O
lungs	O
of	O
CS	O
-	O
exposed	O
guinea	O
pigs	O
treated	O
or	O
untreated	O
with	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
.	O

Result	O
showed	O
that	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
treatment	O
resulted	O
in	O
markedly	O
reduced	O
c	B-GENE-Y
-	I-GENE-Y
Rel	I-GENE-Y
nuclear	O
translocation	O
.	O

All	O
these	O
results	O
demonstrate	O
that	O
vitamin	B-CHEMICAL
C	I-CHEMICAL
prevents	O
CS	O
(	O
E	O
)	O
-	O
induced	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
activation	O
and	O
thus	O
it	O
could	O
be	O
used	O
for	O
the	O
prevention	O
of	O
CS	O
-	O
induced	O
inflammatory	O
diseases	O
.	O

Selective	O
Bisubstrate	O
Inhibitors	O
with	O
Sub	O
-	O
nanomolar	O
Affinity	O
for	O
Protein	B-GENE-N
Kinase	I-GENE-N
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Potent	O
and	O
selective	O
:	O
The	O
unique	O
nature	O
of	O
the	O
ATP	B-CHEMICAL
binding	O
pocket	O
structure	O
of	O
Pim	B-GENE-N
family	O
protein	B-GENE-N
kinases	I-GENE-N
(	O
PKs	B-GENE-N
)	O
was	O
used	O
for	O
the	O
development	O
of	O
bisubstrate	O
inhibitors	O
and	O
a	O
fluorescent	O
probe	O
with	O
sub	O
-	O
nanomolar	O
affinity	O
.	O

Conjugates	O
of	O
arginine	B-CHEMICAL
-	O
rich	O
peptides	O
with	O
two	O
ATP	B-CHEMICAL
mimetic	O
scaffolds	O
were	O
synthesized	O
and	O
tested	O
as	O
inhibitors	O
of	O
Pim	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Against	O
a	O
panel	O
of	O
124	O
protein	B-GENE-N
kinases	I-GENE-N
,	O
a	O
novel	O
ARC	O
-	O
PIM	B-GENE-N
conjugate	O
selectively	O
inhibited	O
PKs	B-GENE-N
of	O
the	O
Pim	B-GENE-N
family	O
.	O

Smad3	B-GENE-Y
mediates	O
cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
induction	O
of	O
VEGF	B-GENE-Y
release	O
by	O
human	O
fetal	O
lung	O
fibroblasts	O
.	O

Cigarette	O
smoke	O
is	O
the	O
major	O
cause	O
of	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
yet	O
pathogenic	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Vascular	B-GENE-Y
endothelial	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
VEGF	B-GENE-Y
)	O
is	O
one	O
of	O
the	O
major	O
regulators	O
of	O
endothelial	O
cell	O
survival	O
and	O
is	O
believed	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
COPD	O
.	O

Fibroblasts	O
are	O
a	O
significant	O
source	O
of	O
VEGF	B-GENE-Y
in	O
the	O
lungs	O
;	O
however	O
the	O
effect	O
of	O
cigarette	O
smoke	O
exposure	O
on	O
VEGF	B-GENE-Y
release	O
by	O
fibroblasts	O
is	O
not	O
fully	O
understood	O
.	O

We	O
hypothesized	O
that	O
cigarette	O
smoke	O
-	O
induced	O
disturbed	O
VEGF	B-GENE-Y
release	O
by	O
human	O
lung	O
fibroblasts	O
is	O
a	O
potential	O
pathogenic	O
mechanism	O
that	O
could	O
contribute	O
to	O
COPD	O
.	O

Cigarette	O
smoke	O
extract	O
(	O
CSE	O
)	O
was	O
prepared	O
by	O
modification	O
of	O
the	O
methods	O
of	O
Carp	O
and	O
Janoff	O
(	O
American	O
Review	O
of	O
Respiratory	O
Disease	O
,	O
1978	O
)	O
.	O

Human	O
fetal	O
lung	O
fibroblasts	O
(	O
HFL	O
-	O
1	O
)	O
were	O
exposed	O
to	O
different	O
concentrations	O
of	O
CSE	O
and	O
for	O
different	O
durations	O
.	O

VEGF	B-GENE-Y
release	O
into	O
the	O
media	O
was	O
measured	O
using	O
ELISA	O
.	O

TGF	B-GENE-Y
-	I-GENE-Y
β1	I-GENE-Y
receptor	I-GENE-Y
(	O
TβR1	B-GENE-Y
)	O
/	O
Smad3	B-GENE-Y
as	O
a	O
potential	O
pathway	O
for	O
CSE	O
modulated	O
VEGF	B-GENE-Y
release	O
was	O
also	O
investigated	O
using	O
biochemical	O
analyses	O
and	O
siRNA	O
inhibition	O
of	O
Smad3	B-GENE-Y
and	O
siRNA	O
and	O
pharmacologic	O
inhibition	O
of	O
TβR1	B-GENE-Y
.	O

CSE	O
induced	O
VEGF	B-GENE-Y
release	O
by	O
HFL	O
-	O
1	O
in	O
concentration	O
and	O
time	O
dependent	O
manner	O
.	O

This	O
was	O
confirmed	O
in	O
two	O
additional	O
types	O
of	O
primary	O
human	O
fetal	O
lung	O
fibroblasts	O
.	O

CSE	O
induced	O
Smad3	B-GENE-Y
phosphorylation	O
and	O
nuclear	O
translocation	O
in	O
HFL	O
-	O
1	O
cells	O
.	O

Silencing	O
of	O
Smad3	B-GENE-Y
by	O
siRNA	O
not	O
only	O
eliminated	O
the	O
stimulatory	O
effect	O
of	O
CSE	O
on	O
VEGF	B-GENE-Y
release	O
but	O
also	O
inhibited	O
baseline	O
VEGF	B-GENE-Y
production	O
.	O

Suppression	O
of	O
TβR1	B-GENE-Y
by	O
the	O
pharmacological	O
inhibitor	O
(	O
SB431542	B-CHEMICAL
)	O
markedly	O
reduced	O
VEGF	B-GENE-Y
release	O
by	O
HFL	O
-	O
1	O
in	O
response	O
to	O
CSE	O
and	O
this	O
effect	O
was	O
confirmed	O
by	O
TβR1	B-GENE-Y
siRNA	O
.	O

In	O
contrast	O
,	O
nicotine	O
inhibited	O
VEGF	B-GENE-Y
release	O
by	O
HFL	O
-	O
1	O
in	O
a	O
dose	O
and	O
time	O
dependent	O
manner	O
.	O

Our	O
findings	O
indicate	O
that	O
CSE	O
stimulates	O
Smad3	B-GENE-Y
-	O
mediated	O
VEGF	B-GENE-Y
release	O
by	O
lung	O
fibroblasts	O
.	O

Nicotine	B-CHEMICAL
does	O
not	O
account	O
for	O
the	O
CSE	O
stimulation	O
of	O
VEGF	B-GENE-Y
in	O
HFL	O
-	O
1	O
.	O

The	O
ability	O
of	O
lung	O
fibroblasts	O
to	O
produce	O
VEGF	B-GENE-Y
may	O
play	O
a	O
role	O
in	O
pathogenesis	O
of	O
cigarette	O
smoke	O
induced	O
lung	O
disease	O
.	O

Rapamycin	B-CHEMICAL
allosterically	O
inhibits	O
the	O
proteasome	B-GENE-N
.	O

Rapamycin	B-CHEMICAL
is	O
a	O
canonical	O
allosteric	O
inhibitor	O
of	O
the	O
mTOR	B-GENE-Y
kinase	B-GENE-N
with	O
immunosuppressive	O
and	O
pro	O
-	O
apoptotic	O
activities	O
.	O

We	O
found	O
that	O
in	O
vitro	O
rapamycin	B-CHEMICAL
also	O
regulates	O
the	O
proteasome	B-GENE-N
,	O
an	O
essential	O
intracellular	O
protease	O
of	O
the	O
ubiquitin	B-GENE-N
-	O
proteasome	B-GENE-N
pathway	O
.	O

Rapamycin	B-CHEMICAL
inhibits	O
proteinase	B-GENE-N
and	O
selected	O
peptidase	B-GENE-N
activities	O
of	O
the	O
catalytic	O
core	O
proteasome	B-GENE-N
at	O
low	O
micromolar	O
concentrations	O
.	O

Moreover	O
,	O
the	O
drug	O
interferes	O
with	O
binding	O
of	O
the	O
19S	O
cap	O
essential	O
for	O
processing	O
of	O
polyubiquitinylated	O
substrates	O
,	O
and	O
the	O
PA200	B-GENE-Y
activator	O
to	O
the	O
20S	B-GENE-N
catalytic	I-GENE-N
core	I-GENE-N
proteasome	I-GENE-N
.	O

These	O
protein	O
complexes	O
are	O
known	O
to	O
bind	O
to	O
specific	O
grooves	O
on	O
the	O
α	O
face	O
region	O
of	O
the	O
20S	O
core	O
.	O

A	O
treatment	O
with	O
rapamycin	B-CHEMICAL
affects	O
conformational	O
dynamics	O
of	O
the	O
proteasomal	O
gate	O
,	O
a	O
centrally	O
positioned	O
within	O
the	O
α	O
face	O
and	O
allosterically	O
regulated	O
element	O
responsible	O
for	O
the	O
intake	O
of	O
substrates	O
.	O

Interestingly	O
,	O
we	O
showed	O
that	O
rapamycin	B-CHEMICAL
shares	O
all	O
the	O
proteasome	B-GENE-N
targeting	O
properties	O
not	O
only	O
with	O
other	O
two	O
-	O
domain	O
,	O
closed	O
-	O
ring	O
analogs	O
(	O
rapalogs	O
)	O
,	O
but	O
also	O
with	O
its	O
single	O
domain	O
mimics	O
,	O
and	O
with	O
seco	B-CHEMICAL
-	I-CHEMICAL
rapamycin	I-CHEMICAL
.	O

The	O
latter	O
is	O
the	O
first	O
in	O
vivo	O
open	O
-	O
ring	O
metabolite	O
of	O
rapamycin	B-CHEMICAL
that	O
does	O
not	O
affect	O
mTOR	B-GENE-Y
.	O

We	O
hypothesize	O
that	O
the	O
rapamycin	B-CHEMICAL
and	O
related	O
compounds	O
bind	O
to	O
the	O
α	O
face	O
and	O
allosterically	O
impact	O
the	O
proteasome	B-GENE-N
function	O
.	O

The	O
implications	O
of	O
our	O
finding	O
for	O
mechanism	O
of	O
in	O
vivo	O
actions	O
of	O
rapamycin	B-CHEMICAL
and	O
for	O
design	O
of	O
novel	O
allosteric	O
drugs	O
targeting	O
the	O
proteasome	B-GENE-N
are	O
discussed	O
.	O

A	O
New	O
Proposed	O
Rodent	O
Model	O
of	O
Chemically	O
Induced	O
Prostate	O
Carcinogenesis	O
:	O
Distinct	O
Time	O
-	O
Course	O
Prostate	O
Cancer	O
Progression	O
in	O
the	O
Dorsolateral	O
and	O
Ventral	O
Lobes	O
.	O

BACKGROUND	O
:	O
Characterization	O
of	O
novel	O
rodent	O
models	O
for	O
prostate	O
cancer	O
studies	O
requires	O
evaluation	O
of	O
either	O
spontaneous	O
and	O
carcinogen	O
-	O
induced	O
tumors	O
as	O
well	O
as	O
tumor	O
incidence	O
in	O
different	O
prostatic	O
lobes	O
.	O

We	O
propose	O
a	O
new	O
short	O
-	O
term	O
rodent	O
model	O
of	O
chemically	O
induced	O
prostate	O
carcinogenesis	O
in	O
which	O
prostate	O
cancer	O
progression	O
occurs	O
differentially	O
in	O
the	O
dorsolateral	O
and	O
ventral	O
lobes	O
.	O

METHODS	O
:	O
Adult	O
gerbils	O
were	O
treated	O
with	O
MNU	B-CHEMICAL
alone	O
or	O
associated	O
with	O
testosterone	B-CHEMICAL
for	O
3	O
or	O
6	O
months	O
of	O
treatment	O
.	O

Tumor	O
incidence	O
,	O
latency	O
,	O
localization	O
,	O
and	O
immunohistochemistry	O
(	O
AR	B-GENE-N
,	O
PCNA	B-GENE-N
,	O
smooth	B-GENE-N
muscle	I-GENE-N
α	I-GENE-N
-	I-GENE-N
actin	I-GENE-N
,	O
p63	B-GENE-N
,	O
MGMT	B-GENE-N
,	O
and	O
E	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
)	O
were	O
studied	O
in	O
both	O
lobes	O
.	O

RESULTS	O
:	O
Comparisons	O
between	O
both	O
lobes	O
revealed	O
that	O
lesions	O
developed	O
first	O
in	O
the	O
DL	O
while	O
the	O
VL	O
presented	O
longer	O
tumor	O
latency	O
.	O

However	O
,	O
after	O
6	O
months	O
,	O
there	O
was	O
a	O
dramatic	O
increase	O
in	O
tumor	O
multiplicity	O
in	O
the	O
VL	O
,	O
mainly	O
in	O
MNU	B-CHEMICAL
-	O
treated	O
groups	O
.	O

Lesions	O
clearly	O
progressed	O
from	O
a	O
premalignant	O
to	O
a	O
malignant	O
phenotype	O
over	O
time	O
and	O
tumor	O
latency	O
was	O
decreased	O
by	O
MNU	B-CHEMICAL
+	O
testosterone	B-CHEMICAL
administration	O
.	O

Three	O
-	O
dimensional	O
reconstruction	O
of	O
the	O
prostatic	O
complex	O
showed	O
that	O
the	O
DL	O
developed	O
tumors	O
exclusively	O
in	O
the	O
periurethral	O
area	O
and	O
showed	O
intense	O
AR	B-GENE-N
,	O
PCNA	B-GENE-N
,	O
and	O
MGMT	B-GENE-N
immunostaining	O
.	O

Moreover	O
,	O
VL	O
lesions	O
emerged	O
throughout	O
the	O
entire	O
lobe	O
.	O

MNU	B-CHEMICAL
-	O
induced	O
lesions	O
presented	O
markers	O
indicative	O
of	O
an	O
aggressive	O
phenotype	O
:	O
lack	O
of	O
basal	O
cells	O
,	O
rupture	O
of	O
the	O
smooth	O
muscle	O
cell	O
layer	O
,	O
loss	O
of	O
E	B-GENE-Y
-	I-GENE-Y
cadherin	I-GENE-Y
,	O
and	O
high	O
MGMT	B-GENE-N
staining	O
.	O

CONCLUSIONS	O
:	O
There	O
are	O
distinct	O
pathways	O
involved	O
in	O
tumor	O
progression	O
in	O
gerbil	O
prostate	O
lobes	O
.	O

This	O
animal	O
provides	O
a	O
good	O
model	O
for	O
prostate	O
cancer	O
since	O
it	O
allows	O
the	O
investigation	O
of	O
advanced	O
steps	O
of	O
carcinogenesis	O
with	O
shorter	O
latency	O
periods	O
in	O
both	O
lobes	O
.	O

Prostate	O
©	O
2013	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Profile	O
of	O
certolizumab	O
and	O
its	O
potential	O
in	O
the	O
treatment	O
of	O
psoriatic	O
arthritis	O
.	O

Psoriatic	O
arthritis	O
(	O
PsA	O
)	O
is	O
a	O
chronic	O
inflammatory	O
arthropathy	O
associated	O
with	O
psoriasis	O
(	O
PsO	O
)	O
.	O

PsA	O
could	O
be	O
considered	O
an	O
enthesal	O
disease	O
because	O
of	O
the	O
link	O
between	O
mechanical	O
stress	O
(	O
entheses	O
)	O
and	O
immunologically	O
active	O
tissue	O
(	O
synovium	O
)	O
.	O

Evidence	O
of	O
efficacy	O
of	O
anti	O
-	O
tumor	B-GENE-Y
necrosis	I-GENE-Y
factor	I-GENE-Y
alpha	I-GENE-Y
(	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
)	O
is	O
supported	O
by	O
reduction	O
of	O
histological	O
vascularity	O
and	O
immune	O
cell	O
infiltrates	O
in	O
synovial	O
tissue	O
after	O
treatment	O
.	O

Certolizumab	O
pegol	O
(	O
CZP	O
)	O
is	O
a	O
polyethylene	O
glycolylated	O
(	O
PEGylated	O
)	O
Fab	B-GENE-N
'	O
fragment	O
of	O
a	O
humanized	O
monoclonal	O
antibody	O
that	O
binds	O
and	O
neutralizes	O
human	B-GENE-Y
TNF	I-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
.	O

The	O
PEG	B-CHEMICAL
moiety	O
of	O
the	O
Fab	B-GENE-N
fragment	O
,	O
markedly	O
increases	O
the	O
half	O
-	O
life	O
of	O
CZP	O
and	O
confers	O
to	O
the	O
drug	O
a	O
unique	O
structure	O
that	O
differs	O
from	O
the	O
other	O
anti	O
-	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
agents	O
tested	O
for	O
the	O
treatment	O
of	O
Crohn	O
'	O
s	O
disease	O
,	O
rheumatoid	O
arthritis	O
,	O
ankylosing	O
spondylitis	O
,	O
axial	O
spondyloarthritis	O
,	O
nonradiographic	O
spondyloarthritis	O
,	O
PsO	O
,	O
and	O
PsA	O
.	O

In	O
contrast	O
to	O
other	O
anti	O
-	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
agents	O
,	O
CZP	O
did	O
not	O
mediate	O
increased	O
levels	O
of	O
apoptosis	O
,	O
suggesting	O
that	O
these	O
mechanisms	O
are	O
not	O
essential	O
for	O
the	O
anti	O
-	O
TNF	B-GENE-Y
-	I-GENE-Y
alpha	I-GENE-Y
efficacy	O
in	O
Crohn	O
'	O
s	O
disease	O
.	O

As	O
CZP	O
,	O
infliximab	O
,	O
and	O
adalimumab	O
,	O
but	O
not	O
etanercept	O
,	O
almost	O
completely	O
inhibited	O
lipopolysaccharide	O
-	O
induced	O
interleukin	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
beta	I-GENE-Y
release	O
from	O
monocytes	O
,	O
this	O
cytokine	B-GENE-N
-	O
production	O
inhibition	O
may	O
be	O
relevant	O
for	O
drug	O
efficacy	O
.	O

Due	O
to	O
these	O
characteristics	O
,	O
it	O
has	O
been	O
demonstrated	O
in	O
clinical	O
studies	O
that	O
CZP	O
effectively	O
improves	O
signs	O
and	O
symptoms	O
of	O
arthritis	O
and	O
physical	O
function	O
and	O
skin	O
manifestations	O
of	O
PsO	O
,	O
with	O
a	O
safety	O
profile	O
similar	O
to	O
rheumatoid	O
arthritis	O
.	O

This	O
drug	O
can	O
be	O
considered	O
as	O
a	O
valid	O
treatment	O
in	O
patients	O
affected	O
by	O
PsA	O
.	O

The	O
efficacy	O
and	O
tolerability	O
profiles	O
suggest	O
CZP	O
as	O
a	O
suitable	O
antipsoriatic	O
drug	O
in	O
the	O
treatment	O
of	O
PsA	O
.	O

Small	O
molecule	O
mediated	O
proliferation	O
of	O
primary	O
retinal	B-CHEMICAL
pigment	O
epithelial	O
cells	O
.	O

Retinal	B-CHEMICAL
pigment	O
epithelial	O
(	O
RPE	O
)	O
cells	O
form	O
a	O
monolayer	O
adjacent	O
to	O
the	O
retina	O
and	O
play	O
a	O
critical	O
role	O
in	O
the	O
visual	O
light	O
cycle	O
.	O

Degeneration	O
of	O
this	O
layer	O
results	O
in	O
vision	O
loss	O
,	O
causing	O
retinal	O
disorders	O
such	O
as	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

Cell	O
transplant	O
therapies	O
exist	O
to	O
restore	O
vision	O
loss	O
;	O
however	O
,	O
risks	O
associated	O
with	O
and	O
an	O
inadequate	O
supply	O
of	O
donor	O
cells	O
have	O
limited	O
their	O
therapeutic	O
success	O
.	O

The	O
identification	O
of	O
factors	O
that	O
proliferate	O
RPE	O
cells	O
ex	O
vivo	O
could	O
provide	O
a	O
renewable	O
source	O
of	O
cells	O
for	O
the	O
treatment	O
of	O
such	O
disorders	O
.	O

We	O
show	O
that	O
a	O
small	O
molecule	O
(	O
WS3	O
)	O
can	O
reversibly	O
proliferate	O
primary	O
RPE	O
cells	O
isolated	O
from	O
fetal	O
and	O
adult	O
human	O
donors	O
.	O

Following	O
withdrawal	O
of	O
WS3	O
,	O
RPE	O
cells	O
differentiate	O
into	O
a	O
functional	O
monolayer	O
,	O
as	O
exhibited	O
by	O
their	O
expression	O
of	O
mature	O
RPE	O
genes	O
and	O
phagocytosis	O
of	O
photoreceptor	O
outer	O
segments	O
.	O

Furthermore	O
,	O
chemically	O
expanded	O
RPE	O
cells	O
preserve	O
vision	O
when	O
transplanted	O
into	O
dystrophic	O
Royal	O
College	O
of	O
Surgeons	O
(	O
RCS	O
)	O
rats	O
,	O
a	O
well	O
-	O
established	O
model	O
of	O
retinal	O
degeneration	O
.	O

Adolescence	O
methylphenidate	B-CHEMICAL
treatment	O
in	O
a	O
rodent	O
model	O
of	O
attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
:	O
Dopamine	B-GENE-Y
transporter	I-GENE-Y
function	O
and	O
cellular	O
distribution	O
in	O
adulthood	O
.	O

Attention	O
deficit	O
/	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
is	O
attributed	O
to	O
dysfunction	O
of	O
the	O
prefrontal	O
cortex	O
.	O

Methylphenidate	B-CHEMICAL
,	O
an	O
inhibitor	O
of	O
dopamine	B-GENE-N
and	I-GENE-N
norepinephrine	I-GENE-N
transporters	I-GENE-N
(	O
DAT	B-GENE-Y
and	O
NET	B-GENE-Y
,	O
respectively	O
)	O
,	O
is	O
a	O
standard	O
treatment	O
for	O
ADHD	O
.	O

The	O
Spontaneously	O
Hypertensive	O
Rat	O
(	O
SHR	O
)	O
is	O
a	O
well	O
-	O
established	O
animal	O
model	O
of	O
ADHD	O
.	O

Our	O
previous	O
results	O
showed	O
that	O
methylphenidate	B-CHEMICAL
treatment	O
in	O
adolescent	O
SHR	O
enhanced	O
cocaine	B-CHEMICAL
self	O
-	O
administration	O
during	O
adulthood	O
,	O
and	O
alterations	O
in	O
DAT	B-GENE-Y
function	O
in	O
prefrontal	O
cortex	O
play	O
a	O
role	O
in	O
this	O
response	O
.	O

Importantly	O
,	O
prefrontal	O
cortex	O
subregions	O
,	O
orbitofrontal	O
cortex	O
(	O
OFC	O
)	O
and	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
,	O
have	O
been	O
shown	O
to	O
have	O
distinct	O
roles	O
in	O
ADHD	O
and	O
cocaine	B-CHEMICAL
self	O
-	O
administration	O
.	O

In	O
the	O
current	O
study	O
,	O
SHR	O
,	O
Wistar	O
-	O
Kyoto	O
(	O
WKY	O
)	O
and	O
Wistar	O
(	O
WIS	O
)	O
rats	O
received	O
a	O
therapeutically	O
relevant	O
dose	O
of	O
methylphenidate	B-CHEMICAL
(	O
1	O
.	O
5mg	O
/	O
kg	O
,	O
p	O
.	O
o	O
.	O
)	O
or	O
vehicle	O
during	O
adolescence	O
and	O
then	O
OFC	O
and	O
mPFC	O
DAT	B-GENE-Y
function	O
and	O
cellular	O
expression	O
were	O
assessed	O
during	O
adulthood	O
.	O

In	O
both	O
OFC	O
and	O
mPFC	O
,	O
no	O
strain	O
differences	O
in	O
Vmax	O
or	O
Km	O
for	O
dopamine	B-CHEMICAL
uptake	O
into	O
synaptosomes	O
were	O
found	O
between	O
vehicle	O
-	O
treated	O
SHR	O
,	O
WKY	O
and	O
WIS	O
.	O

Methylphenidate	B-CHEMICAL
increased	O
DAT	B-GENE-Y
Vmax	O
in	O
SHR	O
mPFC	O
and	O
decreased	O
DAT	B-GENE-Y
Vmax	O
in	O
WKY	O
OFC	O
.	O

Also	O
,	O
methylphenidate	B-CHEMICAL
decreased	O
DAT	B-GENE-Y
Km	O
in	O
WIS	O
OFC	O
.	O

Further	O
,	O
methylphenidate	B-CHEMICAL
did	O
not	O
alter	O
DAT	B-GENE-Y
cellular	O
localization	O
,	O
indicating	O
that	O
methylphenidate	B-CHEMICAL
treatment	O
during	O
adolescence	O
regulated	O
DAT	B-GENE-Y
function	O
in	O
SHR	O
mPFC	O
in	O
a	O
trafficking	O
-	O
independent	O
manner	O
.	O

Thus	O
,	O
the	O
increase	O
in	O
mPFC	O
DAT	B-GENE-Y
function	O
was	O
an	O
SHR	O
-	O
specific	O
long	O
term	O
consequence	O
of	O
methylphenidate	B-CHEMICAL
treatment	O
during	O
adolescence	O
,	O
which	O
may	O
be	O
responsible	O
for	O
the	O
treatment	O
-	O
induced	O
alterations	O
in	O
behavior	O
including	O
the	O
observed	O
increases	O
in	O
cocaine	B-CHEMICAL
self	O
-	O
administration	O
.	O

Antiaggressive	O
activity	O
of	O
central	O
oxytocin	B-CHEMICAL
in	O
male	O
rats	O
.	O

RATIONALE	O
:	O
A	O
substantial	O
body	O
of	O
research	O
suggests	O
that	O
the	O
neuropeptide	O
oxytocin	B-CHEMICAL
promotes	O
social	O
affiliative	O
behaviors	O
in	O
a	O
wide	O
range	O
of	O
animals	O
including	O
humans	O
.	O

However	O
,	O
its	O
antiaggressive	O
action	O
has	O
not	O
been	O
unequivocally	O
demonstrated	O
in	O
male	O
laboratory	O
rodents	O
.	O

OBJECTIVE	O
:	O
Our	O
primary	O
goal	O
was	O
to	O
examine	O
the	O
putative	O
serenic	O
effect	O
of	O
oxytocin	B-CHEMICAL
in	O
a	O
feral	O
strain	O
(	O
wild	O
type	O
Groningen	O
,	O
WTG	O
)	O
of	O
rats	O
that	O
generally	O
show	O
a	O
much	O
broader	O
variation	O
and	O
higher	O
levels	O
of	O
intermale	O
aggression	O
than	O
commonly	O
used	O
laboratory	O
strains	O
of	O
rats	O
.	O

METHODS	O
:	O
Resident	O
animals	O
were	O
intracerebroventricularly	O
(	O
icv	O
)	O
administered	O
with	O
different	O
doses	O
of	O
synthetic	O
oxytocin	B-CHEMICAL
and	O
oxytocin	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
,	O
alone	O
and	O
in	O
combination	O
,	O
in	O
order	O
to	O
manipulate	O
brain	O
oxytocin	B-CHEMICAL
functioning	O
and	O
to	O
assess	O
their	O
behavioral	O
response	O
to	O
an	O
intruder	O
.	O

RESULTS	O
:	O
Our	O
data	O
clearly	O
demonstrate	O
that	O
acute	O
icv	O
administered	O
oxytocin	B-CHEMICAL
produces	O
dose	O
-	O
dependent	O
and	O
receptor	O
-	O
selective	O
changes	O
in	O
social	O
behavior	O
,	O
reducing	O
aggression	O
and	O
potentiating	O
social	O
exploration	O
.	O

These	O
antiaggressive	O
effects	O
are	O
stronger	O
in	O
the	O
more	O
offensive	O
rats	O
.	O

On	O
the	O
other	O
hand	O
,	O
administration	O
of	O
an	O
oxytocin	B-GENE-Y
receptor	I-GENE-Y
antagonist	O
tends	O
to	O
increase	O
(	O
nonsignificantly	O
)	O
aggression	O
only	O
in	O
low	O
-	O
medium	O
aggressive	O
animals	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
transiently	O
enhancing	O
brain	O
oxytocin	B-CHEMICAL
function	O
has	O
potent	O
antiaggressive	O
effects	O
,	O
whereas	O
its	O
attenuation	O
tends	O
to	O
enhance	O
aggressiveness	O
.	O

In	O
addition	O
,	O
a	O
possible	O
inverse	O
relationship	O
between	O
trait	O
aggression	O
and	O
endogenous	O
oxytocinergic	O
signaling	O
is	O
revealed	O
.	O

Overall	O
,	O
this	O
study	O
emphasizes	O
the	O
importance	O
of	O
brain	O
oxytocinergic	O
signaling	O
for	O
regulating	O
intermale	O
offensive	O
aggression	O
.	O

This	O
study	O
supports	O
the	O
suggestion	O
that	O
oxytocin	B-GENE-Y
receptor	I-GENE-Y
agonists	O
could	O
clinically	O
be	O
useful	O
for	O
curbing	O
heightened	O
aggression	O
seen	O
in	O
a	O
range	O
of	O
neuropsychiatric	O
disorders	O
like	O
antisocial	O
personality	O
disorder	O
,	O
autism	O
,	O
and	O
addiction	O
.	O

The	O
effects	O
of	O
the	O
adenosine	B-GENE-Y
A3	I-GENE-Y
receptor	I-GENE-Y
agonist	O
IB	B-CHEMICAL
-	I-CHEMICAL
MECA	I-CHEMICAL
on	O
sodium	B-CHEMICAL
taurocholate	I-CHEMICAL
-	O
induced	O
experimental	O
acute	O
pancreatitis	O
.	O

The	O
role	O
of	O
adenosine	B-GENE-Y
A3	I-GENE-Y
receptors	I-GENE-Y
and	O
their	O
distribution	O
in	O
the	O
gastrointestinal	O
tract	O
have	O
been	O
widely	O
investigated	O
.	O

Most	O
of	O
the	O
reports	O
discuss	O
their	O
role	O
in	O
intestinal	O
inflammations	O
.	O

However	O
,	O
the	O
role	O
of	O
adenosine	B-GENE-Y
A3	I-GENE-Y
receptor	I-GENE-Y
agonist	O
in	O
pancreatitis	O
has	O
not	O
been	O
well	O
established	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
(	O
Ed	O
note	O
:	O
Purpose	O
statements	O
should	O
be	O
in	O
present	O
tense	O
)	O
to	O
evaluate	O
the	O
effects	O
of	O
the	O
adenosine	B-GENE-Y
A3	I-GENE-Y
receptor	I-GENE-Y
agonist	O
on	O
the	O
course	O
of	O
sodium	B-CHEMICAL
taurocholate	I-CHEMICAL
-	O
induced	O
experimental	O
acute	O
pancreatitis	O
(	O
EAP	O
)	O
.	O

The	O
experiments	O
were	O
performed	O
on	O
80	O
male	O
Wistar	O
rats	O
,	O
58	O
of	O
which	O
survived	O
,	O
subdivided	O
into	O
3	O
groups	O
:	O
C	O
-	O
control	O
rats	O
,	O
I	O
-	O
EAP	O
group	O
,	O
and	O
II	O
-	O
EAP	O
group	O
treated	O
with	O
the	O
adenosine	B-GENE-Y
A3	I-GENE-Y
receptor	I-GENE-Y
agonist	O
IB	B-CHEMICAL
-	I-CHEMICAL
MECA	I-CHEMICAL
(	B-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
deoxy	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
[	I-CHEMICAL
[	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
iodophenyl	I-CHEMICAL
)	I-CHEMICAL
methyl	I-CHEMICAL
]	I-CHEMICAL
amino	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
9H	I-CHEMICAL
-	I-CHEMICAL
purin	I-CHEMICAL
-	I-CHEMICAL
9	I-CHEMICAL
-	I-CHEMICAL
yl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
B	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
ribofuronamide	I-CHEMICAL
at	O
a	O
dose	O
of	O
0	O
.	O
75	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O

i	O
.	O
p	O
.	O
at	O
48	O
,	O
24	O
,	O
12	O
and	O
1	O
h	O
before	O
and	O
1	O
h	O
after	O
the	O
injection	O
of	O
5	O
%	O
sodium	B-CHEMICAL
taurocholate	I-CHEMICAL
solution	O
into	O
the	O
biliary	O
-	O
pancreatic	O
duct	O
.	O

Serum	O
for	O
α	B-GENE-N
-	I-GENE-N
amylase	I-GENE-N
and	O
lipase	B-GENE-N
determinations	O
and	O
tissue	O
samples	O
for	O
morphological	O
examinations	O
were	O
collected	O
at	O
2	O
,	O
6	O
,	O
and	O
24	O
h	O
of	O
the	O
experiment	O
.	O

In	O
the	O
IB	B-CHEMICAL
-	I-CHEMICAL
MECA	I-CHEMICAL
group	O
,	O
α	B-GENE-N
-	I-GENE-N
amylase	I-GENE-N
activity	O
was	O
decreased	O
with	O
statistically	O
high	O
significance	O
compared	O
to	O
group	O
I	O
.	O

The	O
activity	O
of	O
lipase	B-GENE-N
was	O
not	O
significantly	O
different	O
among	O
the	O
experimental	O
groups	O
but	O
higher	O
than	O
in	O
the	O
control	O
group	O
.	O

The	O
administration	O
of	O
IB	B-CHEMICAL
-	I-CHEMICAL
MECA	I-CHEMICAL
attenuated	O
the	O
histological	O
parameters	O
of	O
inflammation	O
as	O
compared	O
to	O
untreated	O
animals	O
.	O

The	O
use	O
of	O
A3	B-GENE-Y
receptor	I-GENE-Y
agonist	O
IB	B-CHEMICAL
-	I-CHEMICAL
MECA	I-CHEMICAL
attenuates	O
EAP	O
.	O

Our	O
findings	O
suggest	O
that	O
stimulation	O
of	O
adenosine	B-GENE-Y
A3	I-GENE-Y
receptors	I-GENE-Y
plays	O
a	O
positive	O
role	O
in	O
the	O
sodium	B-CHEMICAL
taurocholate	I-CHEMICAL
-	O
induced	O
EAP	O
in	O
rats	O
.	O

Superparamagnetic	O
Hollow	O
Hybrid	O
Nanogels	O
as	O
a	O
Potential	O
Guidable	O
Vehicle	O
System	O
of	O
Stimuli	O
-	O
Mediated	O
MR	O
Imaging	O
and	O
Multiple	O
Cancer	O
Therapeutics	O
.	O

Hollow	O
hybrid	O
nanogels	O
were	O
prepared	O
first	O
by	O
co	O
-	O
assembly	O
of	O
the	O
citric	B-CHEMICAL
acid	I-CHEMICAL
-	O
coated	O
superparamagnetic	O
iron	B-CHEMICAL
oxide	I-CHEMICAL
nanoparticles	O
(	O
SPIONs	O
)	O
(	O
44	O
wt	O
%	O
)	O
with	O
the	O
graft	O
copolymer	O
(	O
56	O
wt	O
%	O
)	O
comprising	O
acrylic	B-CHEMICAL
acid	I-CHEMICAL
and	O
2	B-CHEMICAL
-	I-CHEMICAL
methacryloylethyl	I-CHEMICAL
acrylate	I-CHEMICAL
units	O
as	O
the	O
backbone	O
and	O
poly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
glycol	I-CHEMICAL
)	I-CHEMICAL
and	O
poly	B-CHEMICAL
(	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
isopropylacrylamide	I-CHEMICAL
)	I-CHEMICAL
as	O
the	O
grafts	O
in	O
aqueous	O
phase	O
of	O
pH	O
3	O
.	O
0	O
into	O
the	O
hybrid	O
vesicle	O
structure	O
,	O
followed	O
by	O
in	O
situ	O
covalent	O
stabilization	O
via	O
the	O
photo	O
-	O
initiated	O
polymerization	O
of	O
MEA	B-CHEMICAL
residues	O
within	O
vesicles	O
.	O

The	O
resultant	O
hollow	O
nanogels	O
,	O
though	O
slightly	O
swollen	O
,	O
satisfactorily	O
retain	O
the	O
structural	O
integrity	O
while	O
the	O
medium	O
pH	O
being	O
adjusted	O
to	O
7	O
.	O
4	O
.	O

Confining	O
SPION	O
clusters	O
to	O
such	O
a	O
high	O
level	O
(	O
44	O
wt	O
%	O
)	O
within	O
the	O
pH	O
-	O
responsive	O
thin	O
gel	O
layer	O
remarkably	O
enhances	O
the	O
transverse	O
relaxivity	O
(	O
r2	O
)	O
and	O
renders	O
the	O
MR	O
imaging	O
highly	O
pH	O
-	O
tunable	O
.	O

For	O
example	O
,	O
with	O
the	O
pH	O
being	O
adjusted	O
from	O
4	O
.	O
0	O
to	O
7	O
.	O
4	O
,	O
the	O
r2	O
value	O
can	O
be	O
dramatically	O
increased	O
from	O
138	O
.	O
5	O
to	O
265	O
.	O
5	O
mM	O
-	O
1	O
s	O
-	O
1	O
.	O

The	O
DOX	O
-	O
loaded	O
hybrid	O
nanogels	O
also	O
exhibit	O
accelerated	O
drug	O
release	O
in	O
response	O
to	O
both	O
pH	O
reduction	O
and	O
temperature	O
increase	O
due	O
to	O
the	O
substantial	O
disruption	O
of	O
the	O
interactions	O
between	O
drug	O
molecules	O
and	O
copolymer	O
components	O
.	O

With	O
magnetic	O
transport	O
guidance	O
toward	O
the	O
target	O
and	O
subsequent	O
exposure	O
to	O
alternating	O
magnetic	O
field	O
,	O
this	O
DOX	O
-	O
loaded	O
nanogel	O
system	O
possessing	O
combined	O
capabilities	O
of	O
hyperthermia	O
and	O
stimuli	O
-	O
triggered	O
drug	O
release	O
showed	O
superior	O
in	O
vitro	O
cytotoxicity	O
against	O
HeLa	O
cells	O
as	O
compared	O
to	O
the	O
case	O
with	O
only	O
free	O
drug	O
or	O
hyperthermia	O
alone	O
.	O

This	O
work	O
demonstrates	O
that	O
the	O
hollow	O
inorganic	O
/	O
organic	O
hybrid	O
nanogels	O
show	O
great	O
potential	O
to	O
serve	O
as	O
a	O
multimodal	O
theranostic	O
vehicle	O
functionalized	O
with	O
such	O
desirable	O
features	O
as	O
guidable	O
delivery	O
of	O
stimuli	O
-	O
mediated	O
diagnostic	O
imaging	O
and	O
hyperthermia	O
/	O
chemotherapies	O
.	O

Cyclopenta	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
phenanthrenes	I-CHEMICAL
-	O
Chemistry	O
and	O
biological	O
activity	O
.	O

Despite	O
cyclopenta	B-CHEMICAL
-	I-CHEMICAL
fused	I-CHEMICAL
polycyclic	I-CHEMICAL
aromatic	I-CHEMICAL
hydrocarbons	I-CHEMICAL
(	O
CP	B-CHEMICAL
-	I-CHEMICAL
PAHs	I-CHEMICAL
)	O
having	O
been	O
detected	O
in	O
the	O
environment	O
,	O
the	O
ability	O
of	O
these	O
compounds	O
to	O
induce	O
cellular	O
and	O
tissue	O
responses	O
remains	O
poorly	O
characterized	O
.	O

In	O
this	O
review	O
,	O
we	O
look	O
at	O
the	O
chemistry	O
and	O
biological	O
activity	O
of	O
the	O
cyclopenta	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
phenanthrenes	I-CHEMICAL
(	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
)	O
as	O
potential	O
chemicals	O
of	O
concern	O
in	O
the	O
process	O
of	O
risk	O
assessment	O
.	O

The	O
first	O
part	O
of	O
the	O
review	O
deals	O
with	O
the	O
environmental	O
occurrence	O
and	O
chemistry	O
of	O
CP	B-CHEMICAL
-	I-CHEMICAL
PAHs	I-CHEMICAL
,	O
focusing	O
on	O
available	O
methods	O
of	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
chemical	O
synthesis	O
.	O

The	O
most	O
interesting	O
structural	O
feature	O
of	O
the	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
is	O
the	O
presence	O
of	O
a	O
pseudo	O
fjord	O
-	O
region	O
constructed	O
by	O
the	O
cyclopentane	B-CHEMICAL
ring	O
.	O

This	O
compound	O
can	O
be	O
treated	O
either	O
as	O
a	O
structurally	O
similar	O
one	O
to	O
B	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
,	O
or	O
as	O
a	O
phenanthrene	B-CHEMICAL
skeleton	O
with	O
an	O
electrodonating	O
alkyl	B-CHEMICAL
substituent	O
in	O
the	O
bay	O
-	O
region	O
of	O
the	O
molecule	O
.	O

The	O
second	O
thread	O
,	O
providing	O
available	O
data	O
on	O
the	O
adverse	O
effects	O
of	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
compounds	O
on	O
cells	O
and	O
tissues	O
of	O
living	O
organisms	O
,	O
mainly	O
fish	O
,	O
improves	O
our	O
understanding	O
of	O
these	O
possible	O
environmental	O
hazards	O
.	O

The	O
data	O
show	O
that	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
is	O
less	O
potent	O
at	O
inducing	O
CYP1A	B-GENE-N
gene	O
expression	O
in	O
rainbow	O
trout	O
than	O
benzo	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
pyrene	I-CHEMICAL
(	O
B	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
P	I-CHEMICAL
)	O
,	O
a	O
well	O
-	O
known	O
Ah	O
-	O
receptor	O
agonist	O
.	O

Interestingly	O
,	O
the	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
dependent	O
up	O
-	O
regulation	O
of	O
CYP1A	B-GENE-N
mRNA	O
is	O
positively	O
correlated	O
with	O
the	O
incidences	O
of	O
clastogenic	O
changes	O
in	O
rainbow	O
trout	O
erythrocytes	O
.	O

CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
has	O
,	O
comparably	O
to	O
B	B-CHEMICAL
[	I-CHEMICAL
a	I-CHEMICAL
]	I-CHEMICAL
P	I-CHEMICAL
,	O
a	O
potential	O
to	O
repress	O
expression	O
of	O
tumor	B-GENE-Y
suppressor	I-GENE-Y
p53	I-GENE-Y
,	O
in	O
the	O
head	O
kidney	O
of	O
rainbow	O
trout	O
.	O

Furthermore	O
,	O
estrogen	B-CHEMICAL
responsive	O
genes	O
in	O
fish	O
liver	O
,	O
ERα	B-GENE-Y
and	O
VTG	B-GENE-Y
,	O
are	O
not	O
induced	O
by	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Ph	I-CHEMICAL
,	O
suggesting	O
that	O
the	O
compound	O
has	O
no	O
endocrine	O
disrupting	O
potential	O
.	O

However	O
,	O
some	O
CP	B-CHEMICAL
[	I-CHEMICAL
c	I-CHEMICAL
]	I-CHEMICAL
Phs	I-CHEMICAL
show	O
mutagenic	O
activity	O
when	O
investigated	O
in	O
the	O
Ames	O
test	O
,	O
and	O
exhibit	O
genotoxic	O
properties	O
in	O
in	O
vitro	O
micronucleus	O
assay	O
.	O

The	O
above	O
characteristics	O
suggest	O
that	O
CP	B-CHEMICAL
-	I-CHEMICAL
PAHs	I-CHEMICAL
are	O
chemicals	O
of	O
concern	O
for	O
which	O
potential	O
pathways	O
of	O
exposure	O
should	O
be	O
further	O
identified	O
.	O

Down	O
-	O
regulation	O
of	O
LRRK2	B-GENE-Y
in	O
control	O
and	O
DAT	B-GENE-Y
transfected	O
HEK	O
cells	O
increases	O
manganese	B-CHEMICAL
-	O
induced	O
oxidative	O
stress	O
and	O
cell	O
toxicity	O
.	O

The	O
extra	O
-	O
pyramidal	O
symptoms	O
associated	O
with	O
manganism	B-CHEMICAL
often	O
overlap	O
with	O
that	O
seen	O
in	O
Parkinsonism	O
suggesting	O
a	O
common	O
link	O
between	O
the	O
two	O
disorders	O
.	O

Since	O
wide	O
deviations	O
are	O
observed	O
in	O
susceptibility	O
and	O
characteristics	O
of	O
the	O
symptoms	O
observed	O
in	O
manganism	B-CHEMICAL
,	O
these	O
differences	O
may	O
be	O
due	O
to	O
underlying	O
genetic	O
variability	O
.	O

Genes	O
linked	O
to	O
early	O
onset	O
of	O
Parkinsonism	O
which	O
includes	O
ATP13A2	B-GENE-Y
and	O
parkin	B-GENE-Y
have	O
already	O
been	O
suggested	O
to	O
promote	O
development	O
of	O
Mn	B-CHEMICAL
toxicity	O
.	O

Of	O
the	O
other	O
Parkinson	O
-	O
linked	O
genes	O
,	O
mutations	O
in	O
LRRK2	B-GENE-Y
,	O
an	O
autosomal	O
dominant	O
gene	O
,	O
represent	O
another	O
likely	O
candidate	O
involved	O
in	O
the	O
development	O
of	O
manganism	B-CHEMICAL
.	O

In	O
this	O
paper	O
the	O
effect	O
of	O
shRNA	O
LRRK2	B-GENE-Y
knock	O
-	O
down	O
on	O
Mn	B-CHEMICAL
toxicity	O
was	O
examined	O
in	O
control	O
and	O
DAT	B-GENE-Y
transfected	O
HEK293	O
cells	O
.	O

Results	O
demonstrate	O
that	O
LRRK2	B-GENE-Y
down	O
-	O
regulation	O
potentiates	O
Mn	B-CHEMICAL
toxicity	O
in	O
both	O
control	O
and	O
DAT	B-GENE-Y
-	O
transfected	O
cell	O
as	O
well	O
as	O
potentiates	O
DA	O
toxicity	O
.	O

Combined	O
treatment	O
of	O
Mn	B-CHEMICAL
and	O
DA	O
further	O
augments	O
cell	O
toxicity	O
,	O
ROS	O
production	O
and	O
JNK	B-GENE-N
phosphorylation	O
in	O
LRRK2	B-GENE-Y
deficient	O
cells	O
compared	O
to	O
controls	O
.	O

Consistent	O
with	O
studies	O
demonstrating	O
that	O
LRRK2	B-GENE-N
plays	O
a	O
role	O
in	O
the	O
phosphorylation	O
of	O
p38	B-GENE-N
,	O
our	O
results	O
similarly	O
demonstrate	O
a	O
decrease	O
in	O
p38	B-GENE-N
activation	O
in	O
LRRK2	B-GENE-Y
knock	O
-	O
down	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
null	O
mutations	O
in	O
LRRK2	B-GENE-Y
which	O
cause	O
Parkinsonism	O
potentiate	O
Mn	B-CHEMICAL
toxicity	O
and	O
increase	O
susceptibility	O
to	O
develop	O
manganism	B-CHEMICAL
.	O

In	O
ovo	O
effects	O
of	O
two	O
organophosphate	B-CHEMICAL
flame	O
retardants	O
,	O
TCPP	B-CHEMICAL
and	O
TDCPP	B-CHEMICAL
,	O
on	O
pipping	O
success	O
,	O
development	O
,	O
mRNA	O
expression	O
and	O
thyroid	O
hormone	O
levels	O
in	O
chicken	O
embryos	O
.	O

Tris	B-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
propyl	I-CHEMICAL
)	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
TCPP	B-CHEMICAL
)	O
and	O
tris	B-CHEMICAL
(	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dichloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
propyl	I-CHEMICAL
)	I-CHEMICAL
phosphate	I-CHEMICAL
(	O
TDCPP	B-CHEMICAL
)	O
are	O
organic	O
flame	O
retardants	O
detected	O
in	O
the	O
environment	O
and	O
biota	O
for	O
which	O
toxicological	O
data	O
for	O
avian	O
species	O
are	O
limited	O
.	O

In	O
this	O
study	O
,	O
domestic	O
chicken	O
eggs	O
were	O
injected	O
with	O
TCPP	B-CHEMICAL
or	O
TDCPP	B-CHEMICAL
(	O
maximum	O
dose	O
=	O
51600	O
and	O
45000	O
ng	O
/	O
g	O
egg	O
,	O
respectively	O
)	O
to	O
determine	O
dose	O
-	O
dependent	O
effects	O
on	O
pipping	O
success	O
,	O
development	O
,	O
hepatic	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
expression	O
levels	O
of	O
genes	O
associated	O
with	O
xenobiotic	O
metabolism	O
and	O
the	O
thyroid	O
hormone	O
(	O
TH	O
)	O
pathway	O
,	O
and	O
TH	O
levels	O
following	O
20	O
-	O
22	O
days	O
of	O
incubation	O
.	O

Neither	O
compound	O
reduced	O
pipping	O
success	O
;	O
however	O
,	O
TCPP	B-CHEMICAL
significantly	O
delayed	O
pipping	O
at	O
9240	O
and	O
51600	O
ng	O
/	O
g	O
and	O
reduced	O
tarsus	O
length	O
at	O
51600	O
ng	O
/	O
g	O
.	O

TDCPP	B-CHEMICAL
exposure	O
resulted	O
in	O
significant	O
decreases	O
in	O
head	O
plus	O
bill	O
length	O
,	O
embryo	O
mass	O
and	O
gallbladder	O
size	O
at	O
45000	O
ng	O
/	O
g	O
and	O
reduced	O
plasma	O
free	O
T4	O
levels	O
at	O
7640	O
ng	O
/	O
g	O
.	O

Type	B-GENE-Y
I	I-GENE-Y
deiodinase	I-GENE-Y
,	O
liver	B-GENE-Y
fatty	I-GENE-Y
-	I-GENE-Y
acid	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
and	O
cytochrome	B-GENE-Y
P450	I-GENE-Y
(	I-GENE-Y
CYP	I-GENE-Y
)	I-GENE-Y
3A37	I-GENE-Y
mRNA	O
levels	O
were	O
significantly	O
induced	O
by	O
TCPP	B-CHEMICAL
,	O
while	O
TDCPP	B-CHEMICAL
induced	O
CYP3A37	B-GENE-Y
and	O
CYP2H1	B-GENE-Y
.	O

Chemical	O
analysis	O
of	O
egg	O
contents	O
at	O
incubation	O
days	O
0	O
,	O
5	O
,	O
11	O
,	O
18	O
,	O
and	O
19	O
revealed	O
that	O
>	O
92	O
%	O
of	O
the	O
injected	O
TCPP	B-CHEMICAL
or	O
TDCPP	B-CHEMICAL
concentration	O
was	O
detectable	O
up	O
to	O
day	O
5	O
;	O
however	O
,	O
<	O
1	O
%	O
was	O
detected	O
by	O
day	O
19	O
.	O

The	O
observed	O
phenotypic	O
responses	O
to	O
TCPP	B-CHEMICAL
and	O
TDCPP	B-CHEMICAL
exposure	O
may	O
be	O
associated	O
with	O
disruption	O
of	O
the	O
TH	O
-	O
axis	O
,	O
which	O
is	O
critical	O
for	O
normal	O
growth	O
and	O
development	O
in	O
birds	O
.	O

The	O
effects	O
of	O
TDCPP	B-CHEMICAL
on	O
the	O
gallbladder	O
indicate	O
that	O
the	O
disturbance	O
of	O
lipid	O
metabolism	O
is	O
a	O
likely	O
target	O
in	O
its	O
mechanism	O
of	O
toxicity	O
.	O

X	O
-	O
ray	O
structure	O
analysis	O
of	O
a	O
solid	O
solution	O
of	O
milbemycins	B-CHEMICAL
A3	I-CHEMICAL
and	I-CHEMICAL
A4	I-CHEMICAL
.	O

Milbemycins	B-CHEMICAL
A3	I-CHEMICAL
and	I-CHEMICAL
A4	I-CHEMICAL
are	O
pharmaceutically	O
and	O
agriculturally	O
useful	O
macrolides	O
isolated	O
from	O
Streptomyces	O
species	O
.	O

The	O
molecular	O
structures	O
of	O
the	O
title	O
compounds	O
were	O
unambiguously	O
established	O
by	O
a	O
single	O
crystal	O
X	O
-	O
ray	O
analysis	O
of	O
the	O
solid	O
solution	O
of	O
both	O
compounds	O
.	O

The	O
crystals	O
present	O
trigonal	O
system	O
,	O
space	O
group	O
P32	O
with	O
Z	O
=	O
3	O
,	O
unit	O
cell	O
dimensions	O
:	O
a	O
=	O
12	O
.	O
2211	O
(	O
4	O
)	O
,	O
c	O
=	O
17	O
.	O
5372	O
(	O
7	O
)	O
Å	O
;	O
V	O
=	O
2268	O
.	O
4	O
(	O
1	O
)	O
Å	O
(	O
3	O
)	O
,	O
μ	O
=	O
0	O
.	O
082	O
mm	O
(	O
-	O
1	O
)	O
;	O
d	O
=	O
1	O
.	O
183	O
g	O
cm	O
(	O
-	O
3	O
)	O
.	O

An	O
interesting	O
system	O
of	O
intramolecular	O
hydrogen	B-CHEMICAL
bonds	O
and	O
weak	O
intermolecular	O
CH	B-CHEMICAL
…	O
O	B-CHEMICAL
type	O
hydrogen	B-CHEMICAL
bond	O
was	O
observed	O
in	O
the	O
solid	O
state	O
.	O

Possible	O
Therapeutic	O
Uses	O
of	O
Salvia	O
triloba	O
and	O
Piper	O
nigrum	O
in	O
Alzheimer	O
'	O
s	O
Disease	O
-	O
Induced	O
Rats	O
.	O

Abstract	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
Salvia	O
triloba	O
L	O
.	O
and	O
Piper	O
nigrum	O
extracts	O
in	O
ameliorating	O
neuroinflammatory	O
insults	O
characteristic	O
of	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
in	O
an	O
experimentally	O
induced	O
rat	O
model	O
.	O

Adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
classified	O
into	O
Group	O
1	O
(	O
n	O
=	O
10	O
)	O
:	O
normal	O
healthy	O
animals	O
serving	O
as	O
the	O
negative	O
control	O
group	O
;	O
Group	O
2	O
(	O
n	O
=	O
60	O
)	O
:	O
the	O
AD	O
-	O
induced	O
group	O
.	O

After	O
AD	O
induction	O
,	O
animals	O
in	O
the	O
AD	O
-	O
induced	O
group	O
were	O
divided	O
randomly	O
and	O
equally	O
into	O
6	O
subgroups	O
.	O

The	O
first	O
subgroup	O
served	O
as	O
AD	O
control	O
;	O
the	O
second	O
one	O
,	O
which	O
served	O
as	O
positive	O
control	O
,	O
was	O
treated	O
orally	O
with	O
the	O
conventional	O
therapy	O
for	O
AD	O
(	O
rivastigmine	B-CHEMICAL
)	O
at	O
a	O
dose	O
of	O
0	O
.	O
3	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
b	O
.	O
w	O
.	O
)	O
daily	O
for	O
3	O
months	O
.	O

The	O
third	O
and	O
fourth	O
subgroups	O
were	O
,	O
respectively	O
,	O
treated	O
orally	O
with	O
the	O
S	O
.	O
triloba	O
extract	O
at	O
a	O
dose	O
of	O
750	O
and	O
375	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
daily	O
for	O
3	O
months	O
.	O

The	O
fifth	O
and	O
sixth	O
subgroups	O
were	O
,	O
respectively	O
,	O
treated	O
orally	O
with	O
the	O
P	O
.	O
nigrum	O
extract	O
at	O
a	O
dose	O
of	O
187	O
.	O
5	O
and	O
93	O
.	O
75	O
mg	O
/	O
kg	O
b	O
.	O
w	O
.	O
daily	O
for	O
3	O
months	O
.	O

Levels	O
of	O
brain	O
acetylcholine	B-CHEMICAL
(	O
Ach	O
)	O
,	O
serum	O
and	O
brain	O
acetylcholinesterase	B-GENE-Y
(	O
AchE	B-GENE-Y
)	O
activity	O
,	O
C	B-GENE-Y
-	I-GENE-Y
reactive	I-GENE-Y
protein	I-GENE-Y
(	O
CRP	B-GENE-Y
)	O
,	O
total	O
nuclear	B-GENE-N
factor	I-GENE-N
kappa	I-GENE-N
-	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
)	O
,	O
and	O
monocyte	B-GENE-Y
chemoattractant	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
were	O
estimated	O
.	O

The	O
results	O
showed	O
that	O
administration	O
of	O
AlCl3	B-CHEMICAL
resulted	O
in	O
a	O
significant	O
elevation	O
in	O
the	O
levels	O
of	O
AchE	B-GENE-Y
activity	O
,	O
CRP	B-GENE-Y
,	O
NF	B-GENE-N
-	I-GENE-N
κB	I-GENE-N
,	O
and	O
MCP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
accompanied	O
with	O
a	O
significant	O
depletion	O
in	O
the	O
Ach	O
level	O
.	O

Treatment	O
of	O
AD	O
rats	O
with	O
each	O
of	O
the	O
selected	O
medicinal	O
plant	O
extracts	O
caused	O
marked	O
improvement	O
in	O
the	O
measured	O
biochemical	O
parameters	O
.	O

In	O
conclusion	O
,	O
S	O
.	O
triloba	O
and	O
P	O
.	O
nigrum	O
methanolic	O
extracts	O
have	O
potent	O
anti	O
-	O
inflammatory	O
effects	O
against	O
neuroinflammation	O
characterizing	O
AD	O
.	O

Identification	O
of	O
an	O
Allosteric	O
Modulator	O
of	O
Serotonin	B-GENE-Y
Transporter	I-GENE-Y
with	O
Novel	O
Mechanism	O
of	O
Action	O
.	O

Serotonin	B-GENE-Y
transporters	I-GENE-Y
(	O
SERT	B-GENE-Y
)	O
play	O
an	O
essential	O
role	O
in	O
the	O
termination	O
and	O
regulation	O
of	O
serotonin	B-CHEMICAL
signaling	O
in	O
the	O
brain	O
.	O

SERT	B-GENE-Y
is	O
also	O
the	O
target	O
of	O
antidepressants	O
and	O
psychostimulants	O
.	O

Molecules	O
with	O
novel	O
activities	O
and	O
modes	O
of	O
interaction	O
with	O
regard	O
to	O
SERT	B-GENE-Y
function	O
are	O
of	O
great	O
scientific	O
and	O
clinical	O
interest	O
.	O

We	O
explored	O
structural	O
regions	O
outside	O
the	O
putative	O
serotonin	B-CHEMICAL
translocation	O
pathway	O
to	O
identify	O
potential	O
binding	O
sites	O
for	O
allosteric	O
transporter	O
modulators	O
(	O
ATMs	O
)	O
.	O

Mutational	O
studies	O
revealed	O
a	O
pocket	O
of	O
amino	B-CHEMICAL
acids	I-CHEMICAL
outside	O
the	O
orthosteric	O
substrate	O
binding	O
sites	O
located	O
in	O
the	O
interface	O
between	O
extracellular	O
loops	O
1	O
and	O
3	O
that	O
when	O
mutated	O
affect	O
transporter	O
function	O
.	O

Using	O
the	O
structure	O
of	O
the	O
bacterial	O
transporter	O
homologue	O
leucine	B-GENE-N
transporter	I-GENE-N
as	O
a	O
template	O
,	O
we	O
developed	O
a	O
structural	O
model	O
of	O
SERT	B-GENE-Y
.	O

We	O
performed	O
molecular	O
dynamics	O
simulations	O
to	O
further	O
characterize	O
the	O
allosteric	O
pocket	O
that	O
was	O
identified	O
by	O
site	O
-	O
directed	O
mutagenesis	O
studies	O
and	O
employed	O
this	O
pocket	O
in	O
a	O
virtual	O
screen	O
for	O
small	O
-	O
molecule	O
modulators	O
of	O
SERT	B-GENE-Y
function	O
.	O

In	O
functional	O
transport	O
assays	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
identified	O
molecules	O
,	O
ATM7	O
,	O
increased	O
the	O
reuptake	O
of	O
serotonin	B-CHEMICAL
,	O
possibly	O
by	O
facilitating	O
the	O
interaction	O
of	O
serotonin	B-CHEMICAL
with	O
transport	O
-	O
ready	O
conformations	O
of	O
SERT	B-GENE-Y
when	O
concentrations	O
of	O
serotonin	B-CHEMICAL
were	O
low	O
and	O
rate	O
limiting	O
.	O

In	O
addition	O
,	O
ATM7	O
potentiates	O
3	B-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methylamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
,	O
"	O
Ecstasy	O
"	O
)	O
-	O
induced	O
reversed	O
transport	O
by	O
SERT	B-GENE-Y
.	O

Taking	O
advantage	O
of	O
a	O
conformationally	O
sensitive	O
residue	O
in	O
transmembrane	O
domain	O
6	O
,	O
we	O
demonstrate	O
that	O
ATM7	O
mechanistically	O
stabilizes	O
an	O
outward	O
-	O
facing	O
conformation	O
of	O
SERT	B-GENE-Y
.	O

Taken	O
together	O
these	O
observations	O
demonstrate	O
that	O
ATM7	O
acts	O
through	O
a	O
novel	O
mechanism	O
that	O
involves	O
allosteric	O
modulation	O
of	O
SERT	B-GENE-Y
function	O
.	O

Clock	B-GENE-Y
Gene	O
Expression	O
in	O
the	O
Liver	O
of	O
Streptozotocin	B-CHEMICAL
-	O
induced	O
and	O
Spontaneous	O
Type	O
1	O
Diabetic	O
Rats	O
.	O

Several	O
investigations	O
have	O
shown	O
a	O
relation	O
between	O
diabetes	O
and	O
alterations	O
of	O
the	O
liver	O
circadian	O
clock	B-GENE-Y
.	O

We	O
investigated	O
the	O
diurnal	O
expression	O
of	O
clock	B-GENE-Y
genes	O
and	O
clock	B-GENE-N
-	I-GENE-N
controlled	I-GENE-N
genes	I-GENE-N
(	O
CCGs	B-GENE-N
)	O
in	O
3	O
-	O
hour	O
intervals	O
for	O
a	O
24	O
-	O
h	O
period	O
in	O
the	O
livers	O
of	O
male	O
streptozotocin	B-CHEMICAL
(	O
STZ	B-CHEMICAL
)	O
-	O
treated	O
rats	O
,	O
male	O
spontaneous	O
type	O
1	O
diabetic	O
LEW	O
.	O
1AR1	O
-	O
iddm	O
(	O
Iddm	O
)	O
rats	O
,	O
and	O
Iddm	O
rats	O
treated	O
for	O
10	O
days	O
with	O
insulin	B-GENE-Y
.	O

Hepatic	O
mRNA	O
was	O
extracted	O
,	O
and	O
the	O
relative	O
expression	O
of	O
clock	B-GENE-Y
genes	O
(	O
Per1	B-GENE-Y
,	O
Per2	B-GENE-Y
,	O
Bmal1	B-GENE-Y
,	O
Clock	B-GENE-Y
,	O
Cry1	B-GENE-Y
)	O
,	O
as	O
well	O
as	O
CCGs	B-GENE-N
(	O
Dbp	B-GENE-Y
,	O
E4bp4	B-GENE-Y
,	O
RevErbα	B-GENE-Y
,	O
Rorα	B-GENE-N
,	O
Pparγ	B-GENE-Y
)	O
,	O
was	O
analyzed	O
by	O
reverse	O
transcription	O
followed	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Diabetic	O
STZ	B-CHEMICAL
and	O
Iddm	O
rats	O
,	O
as	O
well	O
as	O
insulin	B-GENE-Y
-	O
substituted	O
Iddm	O
rats	O
,	O
exhibited	O
a	O
significant	O
diurnal	O
expression	O
pattern	O
of	O
clock	B-GENE-Y
genes	O
as	O
determined	O
by	O
Cosinor	O
analysis	O
;	O
however	O
,	O
the	O
MESOR	O
(	O
midline	O
estimating	O
statistic	O
of	O
rhythm	O
)	O
of	O
Bmal1	B-GENE-Y
,	O
Per2	B-GENE-Y
,	O
and	O
Clock	B-GENE-Y
transcript	O
expression	O
was	O
altered	O
in	O
Iddm	O
and	O
insulin	B-GENE-Y
-	O
substituted	O
Iddm	O
rats	O
.	O

The	O
hepatic	O
expression	O
of	O
the	O
CCGs	B-GENE-N
Dbp	B-GENE-Y
and	O
RevErbα	B-GENE-Y
revealed	O
a	O
diurnal	O
rhythm	O
in	O
all	O
investigated	O
groups	O
.	O

Insulin	B-GENE-Y
administration	O
to	O
Iddm	O
rats	O
normalized	O
the	O
enhanced	O
MESOR	O
in	O
the	O
expression	O
of	O
Dbp	B-GENE-Y
,	O
RevErbα	B-GENE-Y
,	O
and	O
E4bp4	B-GENE-Y
to	O
the	O
levels	O
of	O
normoglycemic	O
controls	O
.	O

Cosinor	O
analysis	O
indicated	O
no	O
diurnal	O
rhythm	O
of	O
Pparγ	B-GENE-Y
expression	O
in	O
the	O
livers	O
of	O
diabetic	O
STZ	B-CHEMICAL
or	O
Iddm	O
rats	O
or	O
in	O
those	O
of	O
insulin	B-GENE-Y
-	O
substituted	O
Iddm	O
rats	O
.	O

Also	O
,	O
insulin	B-GENE-Y
substitution	O
could	O
not	O
reverse	O
the	O
decreased	O
MESOR	O
of	O
Pparγ	B-GENE-Y
expression	O
in	O
Iddm	O
rats	O
.	O

In	O
consequence	O
of	O
the	O
diabetic	O
disease	O
,	O
changes	O
in	O
the	O
expression	O
of	O
clock	B-GENE-Y
genes	O
and	O
CCGs	B-GENE-N
suggest	O
alterations	O
in	O
the	O
hepatic	O
peripheral	O
clock	B-GENE-Y
mechanism	O
.	O

Loss	O
of	O
Kruppel	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
Factor	I-GENE-Y
3	I-GENE-Y
(	O
KLF3	B-GENE-Y
/	O
BKLF	B-GENE-Y
)	O
leads	O
to	O
upregulation	O
of	O
the	O
insulin	B-GENE-Y
-	I-GENE-Y
sensitizing	I-GENE-Y
factor	I-GENE-Y
adipolin	I-GENE-Y
(	O
FAM132A	B-GENE-Y
/	O
CTRP12	B-GENE-Y
/	O
C1qdc2	B-GENE-Y
)	O
.	O

Krüppel	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
Factor	I-GENE-Y
3	I-GENE-Y
(	O
KLF3	B-GENE-Y
)	O
is	O
a	O
transcriptional	O
regulator	O
that	O
we	O
have	O
shown	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
adipogenesis	O
in	O
vitro	O
.	O

Here	O
we	O
report	O
that	O
KLF3	B-GENE-Y
null	O
mice	O
are	O
lean	O
and	O
protected	O
from	O
diet	O
-	O
induced	O
obesity	O
and	O
glucose	B-CHEMICAL
intolerance	O
.	O

On	O
a	O
chow	O
diet	O
,	O
plasma	O
levels	O
of	O
leptin	B-GENE-Y
are	O
decreased	O
,	O
and	O
adiponectin	B-GENE-Y
is	O
increased	O
.	O

Despite	O
significant	O
reductions	O
in	O
body	O
weight	O
and	O
adiposity	O
,	O
wildtype	O
and	O
knockout	O
animals	O
show	O
equivalent	O
energy	O
intake	O
,	O
expenditure	O
and	O
excretion	O
.	O

To	O
investigate	O
the	O
molecular	O
events	O
underlying	O
these	O
observations	O
,	O
we	O
used	O
microarray	O
analysis	O
to	O
compare	O
gene	O
expression	O
in	O
Klf3	B-GENE-Y
(	O
+	O
/	O
+	O
)	O
and	O
Klf3	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
tissues	O
.	O

We	O
found	O
that	O
mRNA	O
expression	O
of	O
Fam132a	B-GENE-Y
,	O
which	O
encodes	O
a	O
newly	O
identified	O
insulin	B-GENE-N
-	O
sensitizing	O
adipokine	B-GENE-N
,	O
adipolin	B-GENE-Y
,	O
is	O
significantly	O
upregulated	O
in	O
the	O
absence	O
of	O
KLF3	B-GENE-Y
.	O

We	O
confirmed	O
that	O
KLF3	B-GENE-Y
binds	O
the	O
Fam132a	B-GENE-N
promoter	I-GENE-N
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
this	O
leads	O
to	O
repression	O
of	O
promoter	O
activity	O
.	O

Further	O
,	O
plasma	O
adipolin	B-GENE-Y
levels	O
were	O
significantly	O
increased	O
in	O
Klf3	B-GENE-Y
(	O
-	O
/	O
-	O
)	O
mice	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

Boosting	O
levels	O
of	O
adipolin	B-GENE-Y
via	O
targeting	O
of	O
KLF3	B-GENE-Y
offers	O
a	O
novel	O
potential	O
therapeutic	O
strategy	O
for	O
the	O
treatment	O
of	O
insulin	B-GENE-N
resistance	O
.	O

Involvement	O
of	O
serotonin	B-CHEMICAL
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptors	O
in	O
the	O
modulation	O
of	O
noradrenergic	O
transmission	O
by	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
:	O
a	O
microdialysis	O
study	O
in	O
rat	O
brain	O
.	O

RATIONALE	O
:	O
Selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
in	O
addition	O
to	O
being	O
able	O
to	O
enhance	O
serotonergic	O
neurotransmission	O
,	O
are	O
able	O
to	O
modulate	O
other	O
brain	O
systems	O
involved	O
in	O
depression	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
evaluates	O
the	O
neurochemical	O
effect	O
of	O
the	O
SSRI	O
citalopram	O
on	O
brain	O
noradrenergic	O
activity	O
and	O
the	O
serotonin	B-GENE-N
receptor	I-GENE-N
involved	O
in	O
this	O
effect	O
.	O

METHODS	O
:	O
Dual	O
-	O
probe	O
microdialysis	O
in	O
the	O
locus	O
coeruleus	O
(	O
LC	O
)	O
and	O
prefrontal	O
cortex	O
(	O
PFC	O
)	O
was	O
performed	O
in	O
freely	O
awake	O
rats	O
.	O

RESULTS	O
:	O
Systemic	O
citalopram	B-CHEMICAL
(	O
10	O
mg	O
/	O
kg	O
,	O
i	O
.	O
p	O
.	O
)	O
increased	O
noradrenaline	B-CHEMICAL
(	O
NA	O
)	O
in	O
the	O
LC	O
(	O
E	O
max	O
=	O
141	O
±	O
13	O
%	O
)	O
and	O
simultaneously	O
decreased	O
NA	O
in	O
the	O
PFC	O
(	O
Emax	O
=	O
-	O
46	O
±	O
7	O
%	O
)	O
.	O

In	O
the	O
local	O
presence	O
into	O
the	O
LC	O
of	O
the	O
α2	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
RS79948	B-CHEMICAL
(	O
1	O
μM	O
)	O
,	O
systemic	O
citalopram	B-CHEMICAL
increased	O
NA	O
in	O
the	O
LC	O
(	O
Emax	O
=	O
157	O
±	O
25	O
%	O
)	O
and	O
PFC	O
(	O
Emax	O
=	O
175	O
±	O
24	O
%	O
)	O
.	O

Local	O
citalopram	B-CHEMICAL
(	O
0	O
.	O
1	O
-	O
100	O
μM	O
)	O
into	O
the	O
LC	O
induced	O
NA	O
increase	O
in	O
the	O
LC	O
(	O
Emax	O
=	O
210	O
±	O
25	O
%	O
)	O
and	O
decrease	O
in	O
the	O
PFC	O
(	O
Emax	O
=	O
-	O
38	O
±	O
9	O
%	O
)	O
.	O

Local	O
LC	O
citalopram	B-CHEMICAL
effect	O
was	O
abolished	O
by	O
LC	O
presence	O
of	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptor	O
antagonist	O
MDL72222	B-CHEMICAL
(	O
1	O
μM	O
)	O
but	O
not	O
the	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
/	I-GENE-N
2	I-GENE-N
receptor	O
antagonist	O
methiothepin	B-CHEMICAL
(	O
1	O
μM	O
)	O
.	O

Systemic	O
citalopram	B-CHEMICAL
in	O
the	O
LC	O
presence	O
of	O
MDL72222	B-CHEMICAL
did	O
not	O
modify	O
NA	O
in	O
the	O
LC	O
but	O
increased	O
NA	O
in	O
the	O
PFC	O
(	O
Emax	O
=	O
158	O
±	O
26	O
%	O
)	O
.	O

Local	O
citalopram	B-CHEMICAL
into	O
the	O
PFC	O
enhanced	O
NA	O
(	O
Emax	O
=	O
376	O
±	O
18	O
%	O
)	O
in	O
the	O
area	O
,	O
which	O
was	O
prevented	O
by	O
MDL72222	B-CHEMICAL
.	O

CONCLUSIONS	O
:	O
The	O
SSRI	O
citalopram	B-CHEMICAL
modulates	O
central	O
noradrenergic	O
neurotransmission	O
by	O
activation	O
,	O
through	O
endogenous	O
serotonin	B-CHEMICAL
,	O
of	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptors	O
expressed	O
in	O
the	O
somatodendritic	O
(	O
LC	O
)	O
and	O
terminal	O
(	O
PFC	O
)	O
areas	O
,	O
which	O
subsequently	O
promote	O
an	O
enhancement	O
of	O
local	O
NA	O
.	O

Therefore	O
,	O
5	B-GENE-Y
-	I-GENE-Y
HT3	I-GENE-Y
receptors	O
and	O
somatodendritic	O
α2	B-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
the	O
LC	O
play	O
an	O
important	O
role	O
in	O
the	O
global	O
effect	O
of	O
SSRIs	O
.	O

The	O
Atrial	B-GENE-Y
Natriuretic	I-GENE-Y
Peptide	I-GENE-Y
Genetic	O
Variant	O
Rs5068	B-GENE-Y
Is	O
Associated	O
With	O
a	O
Favorable	O
Cardiometabolic	O
Phenotype	O
in	O
a	O
Mediterranean	O
Population	O
.	O

OBJECTIVEWe	O
hypothesized	O
that	O
the	O
minor	O
allele	O
of	O
the	O
atrial	B-GENE-Y
natriuretic	I-GENE-Y
peptide	I-GENE-Y
(	O
ANP	B-GENE-Y
)	O
genetic	O
variant	O
rs5068	B-GENE-Y
is	O
associated	O
with	O
a	O
favorable	O
cardiometabolic	O
phenotype	O
in	O
a	O
general	O
Mediterranean	O
population	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
genotyped	O
a	O
random	O
sample	O
of	O
the	O
residents	O
of	O
Ventimiglia	O
di	O
Sicilia	O
,	O
Sicily	O
,	O
for	O
rs5068	B-GENE-Y
.	O
RESULTSGenotype	O
frequencies	O
of	O
rs5068	B-GENE-Y
are	O
AA	O
,	O
93	O
.	O
5	O
%	O
;	O
AG	O
,	O
6	O
.	O
4	O
%	O
;	O
and	O
GG	O
,	O
0	O
.	O
1	O
%	O
.	O

All	O
subsequent	O
analyses	O
are	O
AA	O
versus	O
AG	O
+	O
GG	O
.	O

After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
the	O
minor	O
G	O
allele	O
is	O
associated	O
with	O
lower	O
BMI	O
(	O
estimate	O
[	O
SE	O
]	O
:	O
-	O
1	O
.	O
7	O
kg	O
/	O
m	O
(	O
2	O
)	O
[	O
0	O
.	O
8	O
]	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

In	O
the	O
AG	O
+	O
GG	O
group	O
,	O
males	O
with	O
HDL	B-GENE-N
cholesterol	B-CHEMICAL
levels	O
<	O
40	O
mg	O
/	O
dL	O
are	O
less	O
frequent	O
(	O
P	O
=	O
0	O
.	O
05	O
)	O
and	O
obesity	O
tends	O
to	O
be	O
less	O
prevalent	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Importantly	O
,	O
the	O
G	O
allele	O
is	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
metabolic	O
syndrome	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

After	O
adjusting	O
for	O
BMI	O
,	O
the	O
above	O
associations	O
were	O
attenuated	O
.	O

Independently	O
of	O
age	O
,	O
sex	O
,	O
and	O
BMI	O
,	O
the	O
minor	O
allele	O
is	O
also	O
associated	O
with	O
lower	O
systolic	O
blood	O
pressure	O
(	O
-	O
6	O
.	O
0	O
mmHg	O
[	O
2	O
.	O
5	O
]	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
and	O
lower	O
prevalence	O
of	O
hypertension	O
(	O
odds	O
ratio	O
0	O
.	O
41	O
[	O
95	O
%	O
CI	O
0	O
.	O
20	O
-	O
0	O
.	O
83	O
]	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O
CONCLUSIONSThe	O
association	O
between	O
the	O
minor	O
allele	O
of	O
rs5068	B-GENE-Y
and	O
a	O
favorable	O
cardiometabolic	O
phenotype	O
that	O
we	O
previously	O
reported	O
in	O
a	O
U	O
.	O
S	O
.	O
population	O
is	O
now	O
replicated	O
in	O
a	O
Mediterranean	O
population	O
in	O
which	O
the	O
G	O
allele	O
of	O
rs5068	B-GENE-Y
is	O
associated	O
with	O
lower	O
blood	O
pressure	O
,	O
BMI	O
,	O
and	O
prevalence	O
of	O
hypertension	O
and	O
metabolic	O
syndrome	O
.	O

These	O
findings	O
may	O
lead	O
to	O
a	O
diagnostic	O
strategy	O
to	O
assess	O
cardiometabolic	O
risk	O
and	O
lay	O
the	O
foundation	O
for	O
the	O
future	O
development	O
of	O
an	O
ANP	B-GENE-Y
or	O
ANP	B-GENE-Y
-	O
like	O
therapy	O
for	O
metabolic	O
syndrome	O
.	O

Cyperi	O
Rhizoma	O
inhibits	O
the	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
tetrahydropyridine	I-CHEMICAL
-	O
induced	O
reduction	O
in	O
nigrostriatal	O
dopaminergenic	O
neurons	O
in	O
estrogen	B-CHEMICAL
-	O
deprived	O
mice	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Cyperi	O
Rhizoma	O
has	O
commonly	O
been	O
used	O
for	O
the	O
treatment	O
of	O
gynecological	O
and	O
neuropsychiatric	O
disorders	O
in	O
traditional	O
medicine	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
estrogenic	O
properties	O
and	O
neuroprotective	O
effects	O
of	O
Cyperi	O
Rhizoma	O
under	O
estrogen	B-CHEMICAL
-	O
deprived	O
condition	O
in	O
female	O
mice	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
To	O
determine	O
the	O
estrogen	B-CHEMICAL
-	O
like	O
effect	O
of	O
Cyperi	O
Rhizoma	O
extract	O
(	O
CRE	O
)	O
,	O
we	O
measured	O
luciferase	O
expression	O
after	O
transfection	O
of	O
a	O
promoter	O
construct	O
containing	O
an	O
estrogen	B-GENE-N
response	I-GENE-N
element	I-GENE-N
(	O
ERE	B-GENE-N
)	O
and	O
treatment	O
of	O
CRE	O
.	O

To	O
evaluate	O
the	O
neuroprotective	O
effect	O
of	O
CRE	O
,	O
we	O
measured	O
striatal	O
dopamine	B-CHEMICAL
,	O
movement	O
ability	O
,	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
(	O
TH	B-GENE-Y
)	O
immunoreactivity	O
,	O
and	O
apoptosis	O
-	O
related	O
protein	O
expression	O
levels	O
after	O
treatment	O
of	O
CRE	O
either	O
with	O
or	O
without	O
1	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
phenyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
tetrahydropyridine	I-CHEMICAL
(	O
MPTP	B-CHEMICAL
)	O
in	O
ovariectomized	O
female	O
mice	O
.	O

RESULTS	O
:	O
CRE	O
significantly	O
induced	O
the	O
luciferase	O
expression	O
driven	O
by	O
an	O
ERE	B-GENE-N
in	O
PC12	O
cells	O
,	O
a	O
dopaminergic	O
cell	O
line	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
mice	O
,	O
MPTP	B-CHEMICAL
significantly	O
decreased	O
the	O
levels	O
of	O
dopamine	B-CHEMICAL
in	O
the	O
striatum	O
and	O
behavior	O
performance	O
;	O
in	O
contrast	O
,	O
both	O
CRE	O
and	O
17β	B-CHEMICAL
-	I-CHEMICAL
estradiol	I-CHEMICAL
benzoate	I-CHEMICAL
(	O
EB	O
)	O
recovered	O
these	O
parameters	O
to	O
normal	O
levels	O
.	O

CRE	O
and	O
EB	O
treatment	O
also	O
recovered	O
TH	B-GENE-Y
immunopositive	O
fibers	O
and	O
cells	O
,	O
respectively	O
,	O
from	O
MPTP	B-CHEMICAL
toxicity	O
.	O

Additionally	O
,	O
MPTP	B-CHEMICAL
significantly	O
down	O
-	O
regulated	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
expression	O
in	O
the	O
mitochondria	O
of	O
dopaminergic	O
cells	O
in	O
the	O
SN	O
,	O
followed	O
by	O
an	O
increase	O
in	O
Bax	B-GENE-Y
expression	O
,	O
cytochrome	B-GENE-Y
C	I-GENE-Y
translocation	O
to	O
the	O
cytosol	O
,	O
andcleaved	O
-	O
caspase	B-GENE-Y
-	I-GENE-Y
3	I-GENE-Y
expression	O
,	O
whereas	O
these	O
were	O
inhibited	O
by	O
CRE	O
or	O
EB	O
treatment	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
CRE	O
has	O
estrogen	B-CHEMICAL
-	O
like	O
and	O
neuroprotective	O
effects	O
on	O
dopaminergic	O
neurons	O
in	O
estrogen	B-CHEMICAL
-	O
deprived	O
mice	O
treated	O
with	O
MPTP	B-CHEMICAL
-	O
toxin	O
.	O

Enzyme	O
-	O
responsive	O
surface	O
erosion	O
of	O
poly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
carbonate	I-CHEMICAL
)	I-CHEMICAL
for	O
controlled	O
drug	O
release	O
.	O

Cholesterol	B-GENE-Y
esterase	I-GENE-Y
(	O
CE	B-GENE-Y
)	O
induced	O
surface	O
erosion	O
of	O
poly	B-CHEMICAL
(	I-CHEMICAL
ethylene	I-CHEMICAL
carbonate	I-CHEMICAL
)	I-CHEMICAL
(	O
PEC	B-CHEMICAL
)	O
and	O
drug	O
release	O
from	O
PEC	B-CHEMICAL
under	O
mild	O
physiological	O
environment	O
was	O
investigated	O
.	O

The	O
degradation	O
process	O
was	O
monitored	O
by	O
changes	O
of	O
mass	O
and	O
molecular	O
weight	O
(	O
MW	O
)	O
and	O
surface	O
morphology	O
of	O
polymer	O
films	O
.	O

During	O
the	O
whole	O
period	O
of	O
degradation	O
,	O
MW	O
of	O
PEC	B-CHEMICAL
was	O
unchanged	O
.	O

Water	O
uptake	O
of	O
the	O
polymer	O
was	O
only	O
2	O
.	O
8	O
and	O
0	O
.	O
2	O
%	O
for	O
PEC	B-CHEMICAL
with	O
the	O
MW	O
of	O
200	O
kDa	O
(	O
PEC200	B-CHEMICAL
)	O
and	O
PEC	B-CHEMICAL
with	O
the	O
MW	O
of	O
41	O
kDa	O
(	O
PEC41	B-CHEMICAL
)	O
,	O
respectively	O
.	O

Degradation	O
of	O
less	O
hydrophilic	O
PEC41	B-CHEMICAL
with	O
higher	O
density	O
was	O
slower	O
than	O
that	O
of	O
PEC200	B-CHEMICAL
.	O

By	O
this	O
mechanism	O
,	O
CE	B-GENE-Y
-	O
responsive	O
drug	O
in	O
vitro	O
release	O
from	O
PEC	B-CHEMICAL
in	O
situ	O
forming	O
depots	O
(	O
ISFD	O
)	O
was	O
conducted	O
successfully	O
.	O

As	O
expected	O
,	O
less	O
bovine	B-GENE-Y
serum	I-GENE-Y
albumin	I-GENE-Y
(	O
BSA	B-GENE-Y
)	O
was	O
released	O
from	O
PEC41	B-CHEMICAL
compared	O
with	O
that	O
of	O
PEC200	B-CHEMICAL
in	O
the	O
same	O
time	O
period	O
.	O

In	O
conclusion	O
,	O
this	O
work	O
enabled	O
the	O
in	O
vitro	O
drug	O
release	O
evaluation	O
of	O
existing	O
PEC	B-CHEMICAL
devices	O
and	O
implied	O
a	O
new	O
candidate	O
for	O
the	O
development	O
of	O
enzyme	O
-	O
responsive	O
systems	O
.	O

The	O
design	O
and	O
realization	O
of	O
a	O
large	O
-	O
area	O
flexible	O
nanofiber	O
-	O
based	O
mat	O
for	O
pollutant	O
degradation	O
:	O
an	O
application	O
in	O
photocatalysis	O
.	O

This	O
work	O
demonstrates	O
a	O
novel	O
multifunctional	O
nanofibrous	O
mat	O
for	O
photocatalytic	O
applications	O
based	O
on	O
TiO2	B-CHEMICAL
nanocables	O
functionalized	O
by	O
Ag	B-CHEMICAL
nanoparticles	O
and	O
coated	O
with	O
a	O
thin	O
(	O
∼	O
2	O
nm	O
)	O
graphitic	B-CHEMICAL
shell	O
.	O

In	O
this	O
mat	O
,	O
which	O
was	O
realized	O
by	O
an	O
electrospinning	O
technique	O
,	O
each	O
component	O
serves	O
a	O
unique	O
function	O
:	O
the	O
carbon	B-CHEMICAL
coating	O
acts	O
as	O
both	O
an	O
adsorption	O
material	O
for	O
capturing	O
pollutants	O
and	O
as	O
a	O
charge	O
-	O
transfer	O
material	O
,	O
the	O
Ag	B-CHEMICAL
nanoparticles	O
act	O
as	O
a	O
visible	O
-	O
light	O
sensitizing	O
agent	O
and	O
also	O
as	O
a	O
charge	O
-	O
transfer	O
material	O
,	O
finally	O
the	O
TiO2	B-CHEMICAL
nanocable	O
mat	O
acts	O
as	O
a	O
UV	O
sensitive	O
photocatalytic	O
matrix	O
and	O
as	O
the	O
flexible	O
substrate	O
for	O
the	O
other	O
functional	O
components	O
.	O

This	O
multicomponent	O
nanocable	O
mat	O
exhibits	O
excellent	O
photocatalytic	O
activity	O
under	O
simulated	O
solar	O
irradiation	O
for	O
the	O
degradation	O
of	O
model	O
pollutants	O
including	O
RhB	B-CHEMICAL
and	O
phenol	B-CHEMICAL
.	O

The	O
significant	O
photocatalytic	O
properties	O
are	O
attributed	O
to	O
the	O
synergetic	O
effect	O
of	O
the	O
three	O
functional	O
components	O
and	O
the	O
unique	O
charge	O
transport	O
"	O
freeway	O
"	O
property	O
of	O
the	O
nanofibrous	O
mat	O
.	O

In	O
addition	O
,	O
the	O
porous	O
carbon	B-CHEMICAL
coating	O
infiltrated	O
into	O
the	O
nanocable	O
matrix	O
endows	O
the	O
mat	O
with	O
excellent	O
flexibility	O
and	O
enables	O
robust	O
,	O
large	O
-	O
area	O
(	O
10	O
×	O
10	O
cm	O
)	O
fabrication	O
,	O
representing	O
a	O
significant	O
advantage	O
over	O
previous	O
brittle	O
ceramic	O
nanofibrous	O
mat	O
photocatalyst	O
substrates	O
.	O

This	O
study	O
provides	O
new	O
insight	O
into	O
the	O
design	O
and	O
preparation	O
of	O
an	O
advanced	O
,	O
yet	O
commercially	O
practical	O
and	O
scaleable	O
photocatalytic	O
composite	O
membrane	O
material	O
.	O

The	O
as	O
-	O
prepared	O
photocatalytic	O
mat	O
might	O
also	O
be	O
of	O
interest	O
in	O
solar	O
cell	O
,	O
catalysis	O
,	O
separation	O
technology	O
,	O
biomedical	O
engineering	O
,	O
and	O
nanotechnology	O
.	O

Progesterone	B-GENE-Y
receptor	I-GENE-Y
induces	O
bcl	B-GENE-Y
-	I-GENE-Y
x	I-GENE-Y
expression	O
through	O
intragenic	B-GENE-N
binding	I-GENE-N
sites	I-GENE-N
favoring	O
RNA	B-GENE-N
polymerase	I-GENE-N
II	I-GENE-N
elongation	O
.	O

Steroid	B-GENE-N
receptors	I-GENE-N
were	O
classically	O
described	O
for	O
regulating	O
transcription	O
by	O
binding	O
to	O
target	O
gene	O
promoters	O
.	O

However	O
,	O
genome	O
-	O
wide	O
studies	O
reveal	O
that	O
steroid	B-GENE-N
receptors	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
sites	I-GENE-N
are	O
mainly	O
located	O
at	O
intragenic	O
regions	O
.	O

To	O
determine	O
the	O
role	O
of	O
these	O
sites	O
,	O
we	O
examined	O
the	O
effect	O
of	O
progestins	O
on	O
the	O
transcription	O
of	O
the	O
bcl	B-GENE-Y
-	I-GENE-Y
x	I-GENE-Y
gene	O
,	O
where	O
only	O
intragenic	B-GENE-N
progesterone	I-GENE-N
receptor	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
sites	I-GENE-N
(	O
PRbs	B-GENE-N
)	O
were	O
identified	O
.	O

We	O
found	O
that	O
in	O
response	O
to	O
hormone	O
treatment	O
,	O
the	O
PR	B-GENE-Y
is	O
recruited	O
to	O
these	O
sites	O
along	O
with	O
two	O
histone	B-GENE-N
acetyltransferases	I-GENE-N
CREB	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	O
CBP	B-GENE-Y
)	O
and	O
GCN5	B-GENE-Y
,	O
leading	O
to	O
an	O
increase	O
in	O
histone	B-GENE-N
H3	I-GENE-N
and	O
H4	B-GENE-N
acetylation	O
and	O
to	O
the	O
binding	O
of	O
the	O
SWI	B-GENE-N
/	I-GENE-N
SNF	I-GENE-N
complex	I-GENE-N
.	O

Concomitant	O
,	O
a	O
more	O
relaxed	O
chromatin	O
was	O
detected	O
along	O
bcl	B-GENE-Y
-	I-GENE-Y
x	I-GENE-Y
gene	O
mainly	O
in	O
the	O
regions	O
surrounding	O
the	O
intragenic	O
PRbs	B-GENE-N
.	O

PR	B-GENE-Y
also	O
mediated	O
the	O
recruitment	O
of	O
the	O
positive	B-GENE-N
elongation	I-GENE-N
factor	I-GENE-N
pTEFb	B-GENE-N
,	O
favoring	O
RNA	B-GENE-N
polymerase	I-GENE-N
II	I-GENE-N
(	O
Pol	B-GENE-N
II	I-GENE-N
)	O
elongation	O
activity	O
.	O

Together	O
these	O
events	O
promoted	O
the	O
re	O
-	O
distribution	O
of	O
the	O
active	O
Pol	B-GENE-N
II	I-GENE-N
toward	O
the	O
3	O
'	O
-	O
end	O
of	O
the	O
gene	O
and	O
a	O
decrease	O
in	O
the	O
ratio	O
between	O
proximal	O
and	O
distal	O
transcription	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
PR	B-GENE-Y
regulates	O
gene	O
expression	O
by	O
facilitating	O
the	O
proper	O
passage	O
of	O
the	O
polymerase	B-GENE-N
along	O
hormone	O
-	O
dependent	O
genes	O
.	O

Cavity	O
Ringdown	O
Spectroscopy	O
of	O
the	O
Hydroxy	B-CHEMICAL
-	I-CHEMICAL
Methyl	I-CHEMICAL
-	I-CHEMICAL
Peroxy	I-CHEMICAL
Radical	O
.	O

We	O
report	O
vibrational	O
and	O
electronic	O
spectra	O
of	O
the	O
hydroxyl	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
peroxy	I-CHEMICAL
radical	O
(	O
HOCH2OO	B-CHEMICAL
,	O
or	O
HMP	B-CHEMICAL
)	O
,	O
the	O
primary	O
product	O
of	O
the	O
reaction	O
of	O
the	O
hydroperoxy	B-CHEMICAL
radical	O
,	O
HO2	B-CHEMICAL
,	O
and	O
formaldehyde	B-CHEMICAL
,	O
HCHO	B-CHEMICAL
.	O

The	O
ν1	O
vibrational	O
(	O
OH	B-CHEMICAL
stretch	O
)	O
spectrum	O
and	O
the	O
Ã	O
-	O
X	O
electronic	O
spectrum	O
of	O
HMP	B-CHEMICAL
were	O
detected	O
by	O
Infrared	O
Cavity	O
Ringdown	O
Spectroscopy	O
(	O
IR	O
-	O
CRDS	O
)	O
,	O
and	O
assignments	O
were	O
verified	O
with	O
density	O
functional	O
calculations	O
.	O

The	O
HMP	B-CHEMICAL
radical	O
was	O
generated	O
in	O
reactions	O
of	O
HCHO	B-CHEMICAL
with	O
HO2	B-CHEMICAL
.	O

Free	O
radical	O
reactions	O
were	O
initiated	O
by	O
pulsed	O
laser	O
photolysis	O
(	O
PLP	O
)	O
of	O
Cl2	B-CHEMICAL
in	O
the	O
presence	O
of	O
HCHO	B-CHEMICAL
and	O
O2	B-CHEMICAL
in	O
a	O
flow	O
reactor	O
at	O
300	O
-	O
330	O
Torr	O
and	O
295K	O
.	O

IR	O
-	O
CRDS	O
spectra	O
were	O
measured	O
in	O
mid	O
-	O
IR	O
and	O
near	O
-	O
IR	O
regions	O
over	O
the	O
ranges	O
3525	O
-	O
3700	O
cm	O
(	O
-	O
1	O
)	O
(	O
ν1	O
)	O
and	O
7250	O
-	O
7800	O
cm	O
(	O
-	O
1	O
)	O
(	O
Ã	O
-	O
X	O
)	O
(	O
respectively	O
,	O
at	O
a	O
delay	O
time	O
100	O
µs	O
after	O
photolysis	O
.	O

The	O
ν1	O
spectrum	O
had	O
an	O
origin	O
at	O
3622	O
cm	O
(	O
-	O
1	O
)	O
and	O
exhibited	O
partially	O
resolved	O
P	O
-	O
and	O
R	O
-	O
branch	O
contours	O
and	O
a	O
small	O
Q	O
branch	O
.	O

At	O
these	O
short	O
delay	O
times	O
,	O
spectral	O
interference	O
from	O
HOOH	B-CHEMICAL
and	O
HCOOH	B-CHEMICAL
was	O
minimal	O
,	O
and	O
could	O
be	O
subtracted	O
.	O

From	O
B3LYP	O
/	O
6	O
-	O
31G	O
+	O
(	O
d	O
,	O
p	O
)	O
calculations	O
,	O
we	O
found	O
that	O
the	O
anharmonic	O
vibrational	O
frequency	O
and	O
band	O
contour	O
predicted	O
for	O
the	O
lowest	O
energy	O
conformer	O
,	O
HMP	B-CHEMICAL
-	O
A	O
,	O
The	O
calculated	O
anharmonic	O
vibrational	O
frequency	O
and	O
band	O
contour	O
computed	O
using	O
B3LYP	O
/	O
63	O
-	O
1G	O
(	O
d	O
,	O
p	O
)	O
level	O
were	O
in	O
good	O
agreement	O
with	O
the	O
observed	O
spectrum	O
.	O

In	O
the	O
near	O
-	O
IR	O
,	O
we	O
observed	O
four	O
well	O
spaced	O
vibronic	O
bands	O
,	O
each	O
with	O
partially	O
resolved	O
rotational	O
contours	O
.	O

We	O
assigned	O
the	O
apparent	O
origin	O
of	O
the	O
electronic	O
spectrum	O
of	O
HMP	B-CHEMICAL
at	O
7392	O
cm	O
(	O
-	O
1	O
)	O
and	O
two	O
bands	O
to	O
the	O
blue	O
to	O
a	O
progression	O
in	O
ν15	O
'	O
,	O
the	O
lowest	O
torsional	O
mode	O
of	O
the	O
state	O
(	O
ν15	O
'	O
=	O
171	O
cm	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
band	O
furthest	O
to	O
the	O
red	O
was	O
assigned	O
as	O
a	O
hot	O
band	O
in	O
ν15	O
"	O
,	O
leading	O
to	O
a	O
ground	O
state	O
torsional	O
frequency	O
of	O
(	O
ν15	O
"	O
=	O
122	O
cm	O
(	O
-	O
1	O
)	O
)	O
.	O

We	O
simulated	O
the	O
spectrum	O
using	O
second	O
order	O
vibrational	O
perturbation	O
theory	O
(	O
VPT2	O
)	O
with	O
B3LYP	O
/	O
6	O
-	O
31	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
calculations	O
at	O
the	O
minimum	O
energy	O
geometries	O
of	O
the	O
HMP	B-CHEMICAL
-	O
A	O
conformer	O
on	O
the	O
X	O
̃	O
and	O
A	O
̃	O
states	O
.	O

The	O
predictions	O
of	O
the	O
electronic	O
origin	O
frequency	O
,	O
torsional	O
frequencies	O
,	O
anharmonicities	O
and	O
rotational	O
band	O
contours	O
matched	O
the	O
observed	O
spectrum	O
.	O

We	O
investigated	O
the	O
torsional	O
modes	O
more	O
explicitly	O
by	O
computing	O
potential	O
energy	O
surfaces	O
of	O
HMP	B-CHEMICAL
as	O
a	O
function	O
of	O
the	O
two	O
dihedral	O
angles	O
τOCOH	B-CHEMICAL
and	O
τOOCO	B-CHEMICAL
.	O

Wave	O
functions	O
and	O
energy	O
levels	O
were	O
calculated	O
based	O
on	O
this	O
potential	O
surface	O
;	O
these	O
results	O
were	O
used	O
to	O
calculate	O
the	O
Franck	O
-	O
Condon	O
factors	O
,	O
which	O
reproduced	O
the	O
vibronic	O
band	O
intensities	O
in	O
the	O
observed	O
electronic	O
spectrum	O
.	O

The	O
transitions	O
that	O
we	O
observed	O
all	O
involved	O
states	O
with	O
wave	O
functions	O
localized	O
on	O
the	O
minimum	O
energy	O
conformer	O
,	O
HMP	B-CHEMICAL
-	O
A	O
.	O

Our	O
calculations	O
indicated	O
that	O
the	O
observed	O
near	O
-	O
IR	O
spectrum	O
was	O
that	O
of	O
the	O
minimum	O
energy	O
conformer	O
HMP	B-CHEMICAL
-	O
A	O
,	O
but	O
that	O
this	O
conformer	O
is	O
not	O
the	O
lowest	O
energy	O
conformer	O
in	O
the	O
state	O
,	O
which	O
remains	O
unobserved	O
.	O

We	O
estimated	O
that	O
the	O
energy	O
of	O
this	O
lowest	O
conformer	O
(	O
HMP	B-CHEMICAL
-	O
B	O
)	O
of	O
the	O
Ã	O
state	O
to	O
be	O
T0	O
(	O
Ã	O
)	O
≈	O
7200	O
cm	O
(	O
-	O
1	O
)	O
,	O
based	O
on	O
the	O
energy	O
difference	O
E0	O
(	O
HMP	B-CHEMICAL
-	O
B	O
)	O
-	O
E0	O
(	O
HMP	B-CHEMICAL
-	O
A	O
)	O
on	O
the	O
Ã	O
state	O
computed	O
at	O
the	O
B3LYP	O
/	O
6	O
-	O
31	O
+	O
G	O
(	O
d	O
,	O
p	O
)	O
level	O
.	O

Copolymerization	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
methylene	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dioxepane	I-CHEMICAL
and	O
glycidyl	B-CHEMICAL
methacrylate	I-CHEMICAL
,	O
a	O
well	O
-	O
defined	O
and	O
efficient	O
process	O
for	O
achieving	O
functionalized	O
polyesters	B-CHEMICAL
for	O
covalent	O
binding	O
of	O
bioactive	O
molecules	O
.	O

The	O
understanding	O
of	O
cell	O
-	O
material	O
interactions	O
is	O
important	O
for	O
creating	O
personalized	O
implants	O
for	O
tissue	O
engineering	O
.	O

This	O
has	O
resulted	O
in	O
an	O
interest	O
in	O
developing	O
polymers	O
with	O
functional	O
groups	O
with	O
the	O
possibility	O
of	O
controlling	O
the	O
macromolecular	O
surface	O
.	O

We	O
have	O
in	O
a	O
one	O
-	O
pot	O
reaction	O
synthesized	O
a	O
series	O
of	O
amorphous	O
and	O
degradable	O
polyester	B-CHEMICAL
-	O
based	O
copolymers	O
with	O
active	O
functional	O
groups	O
by	O
copolymerization	O
of	O
2	B-CHEMICAL
-	I-CHEMICAL
methylene	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
dioxepane	I-CHEMICAL
and	O
glycidyl	B-CHEMICAL
methacrylate	I-CHEMICAL
.	O

The	O
properties	O
of	O
the	O
final	O
polymers	O
were	O
varied	O
by	O
varying	O
the	O
feed	O
ratios	O
of	O
the	O
monomers	O
and	O
it	O
was	O
seen	O
that	O
it	O
was	O
possible	O
to	O
control	O
the	O
amount	O
of	O
active	O
functional	O
groups	O
.	O

The	O
resulting	O
epoxy	B-CHEMICAL
-	I-CHEMICAL
functionalized	I-CHEMICAL
polyester	I-CHEMICAL
was	O
further	O
modified	O
by	O
covalent	O
immobilization	O
of	O
heparin	O
.	O

The	O
heparinization	O
was	O
done	O
in	O
order	O
,	O
in	O
a	O
future	O
aspect	O
,	O
to	O
enhance	O
the	O
osteogenic	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
.	O

Heparin	O
binds	O
directly	O
with	O
the	O
growth	O
factor	O
bone	B-GENE-Y
morphogenetic	I-GENE-Y
protein	I-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
helps	O
to	O
retain	O
its	O
activity	O
.	O

The	O
molecular	O
structure	O
of	O
the	O
copolymers	O
was	O
characterized	O
by	O
nuclear	O
magnetic	O
resonance	O
,	O
size	O
exclusion	O
chromatography	O
,	O
and	O
fourier	O
transform	O
infrared	O
spectroscopy	O
.	O

Differential	O
scanning	O
calorimetry	O
and	O
tensile	O
testing	O
showed	O
that	O
the	O
monomer	O
feed	O
ratio	O
had	O
a	O
great	O
influence	O
on	O
the	O
properties	O
of	O
the	O
final	O
polymer	O
and	O
that	O
it	O
thus	O
was	O
possible	O
to	O
control	O
the	O
mechanical	O
properties	O
to	O
suit	O
an	O
intended	O
application	O
.	O

The	O
presence	O
of	O
heparin	O
was	O
verified	O
by	O
toluidine	B-CHEMICAL
blue	I-CHEMICAL
staining	O
and	O
all	O
the	O
films	O
tested	O
showed	O
positive	O
signals	O
for	O
heparin	O
.	O

Carbonic	B-GENE-N
anhydrase	I-GENE-N
inhibitors	O
.	O

Benzenesulfonamides	B-CHEMICAL
incorporating	O
cyanoacrylamide	B-CHEMICAL
moieties	O
strongly	O
inhibit	O
Saccharomyces	B-GENE-Y
cerevisiae	I-GENE-Y
β	I-GENE-Y
-	I-GENE-Y
carbonic	I-GENE-Y
anhydrase	I-GENE-Y
.	O

A	O
series	O
of	O
benzenesulfonamides	B-CHEMICAL
incorporating	O
cyanoacrylamide	B-CHEMICAL
moieties	O
(	O
tyrphostine	B-CHEMICAL
analogs	O
)	O
were	O
assayed	O
as	O
inhibitors	O
of	O
the	O
β	B-GENE-Y
-	I-GENE-Y
carbonic	I-GENE-Y
anhydrase	I-GENE-Y
(	O
CA	B-GENE-N
,	O
EC	B-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
)	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
ScCA	B-GENE-Y
.	O

Some	O
of	O
these	O
compounds	O
were	O
low	O
nanomolar	O
or	O
subnanomolar	O
ScCA	B-GENE-Y
inhibitors	O
and	O
showed	O
selectivity	O
ratios	O
in	O
the	O
range	O
of	O
4	O
.	O
91	O
-	O
69	O
.	O
86	O
for	O
inhibiting	O
the	O
yeast	O
enzyme	O
over	O
the	O
offtarget	O
human	O
(	O
h	O
)	O
isoforms	O
hCA	B-GENE-Y
I	I-GENE-Y
and	O
of	O
6	O
.	O
46	O
-	O
13	O
.	O
52	O
for	O
inhibiting	O
ScCA	B-GENE-Y
over	O
hCA	B-GENE-Y
II	I-GENE-Y
.	O

The	O
model	O
organism	O
S	O
.	O
cerevisiae	O
and	O
this	O
particular	O
enzyme	O
may	O
be	O
useful	O
for	O
detecting	O
antifungals	O
with	O
a	O
novel	O
mechanism	O
of	O
action	O
compared	O
to	O
the	O
classical	O
azole	B-CHEMICAL
drugs	O
to	O
which	O
significant	O
drug	O
resistance	O
emerged	O
.	O

Indeed	O
,	O
some	O
of	O
these	O
sulfonamides	B-CHEMICAL
inhibited	O
the	O
growth	O
of	O
the	O
yeast	O
with	O
CC50	O
-	O
s	O
in	O
the	O
range	O
of	O
0	O
.	O
73	O
-	O
6	O
.	O
54μM	O
.	O

Water	O
extract	O
of	O
licorice	O
had	O
anti	O
-	O
viral	O
activity	O
against	O
human	O
respiratory	O
syncytial	O
virus	O
in	O
human	O
respiratory	O
tract	O
cell	O
lines	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Licorice	O
(	O
Glycyrrhiza	O
uralensis	O
Fisch	O
.	O
,	O
Leguminosae	O
)	O
has	O
been	O
used	O
in	O
herbal	O
medicine	O
and	O
food	O
supplement	O
worldwide	O
for	O
centuries	O
.	O

Licorice	O
is	O
a	O
common	O
ingredient	O
of	O
several	O
prescriptions	O
of	O
traditional	O
Chinese	O
medicine	O
which	O
have	O
been	O
proved	O
to	O
inhibit	O
infection	O
of	O
human	O
respiratory	O
syncytial	O
virus	O
(	O
HRSV	O
)	O
.	O

There	O
are	O
two	O
preparations	O
of	O
licorice	O
,	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
licorice	O
or	O
which	O
preparation	O
of	O
licorice	O
is	O
effective	O
against	O
HRSV	O
,	O
nor	O
is	O
its	O
active	O
constituent	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
We	O
tested	O
the	O
hypothesis	O
that	O
Radix	O
Glycyrrhizae	O
can	O
effectively	O
decrease	O
HRSV	O
-	O
induced	O
plaque	O
formation	O
in	O
respiratory	O
mucosal	O
cell	O
lines	O
.	O

We	O
also	O
tried	O
to	O
find	O
out	O
the	O
active	O
constituent	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Anti	O
-	O
HRSV	O
activities	O
of	O
hot	O
water	O
extracts	O
of	O
preparations	O
of	O
licorice	O
,	O
glycyrrhizin	B-CHEMICAL
and	O
18β	B-CHEMICAL
-	I-CHEMICAL
glycyrrhetinic	I-CHEMICAL
acid	I-CHEMICAL
(	O
18β	B-CHEMICAL
-	I-CHEMICAL
GA	I-CHEMICAL
)	O
,	O
the	O
active	O
constituents	O
of	O
licorice	O
,	O
were	O
examined	O
by	O
plaque	O
reduction	O
assay	O
in	O
both	O
human	O
upper	O
(	O
HEp	O
-	O
2	O
)	O
and	O
low	O
(	O
A549	O
)	O
respiratory	O
tract	O
cell	O
lines	O
.	O

Abilities	O
of	O
crude	O
licorice	O
to	O
inhibit	O
viral	O
replication	O
and	O
to	O
stimulate	O
IFN	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
were	O
evaluated	O
by	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
dose	O
-	O
dependently	O
inhibited	O
HRSV	O
-	O
induced	O
plaque	O
formation	O
in	O
both	O
HEp	O
-	O
2	O
and	O
A549	O
cell	O
lines	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
effect	O
of	O
Radix	O
Glycyrrhizae	O
was	O
better	O
than	O
that	O
of	O
Radix	O
Glycyrrhizae	O
Preparata	O
on	O
HEp	O
-	O
2	O
cells	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
of	O
their	O
anti	O
-	O
HRSV	O
effects	O
on	O
A549	O
cells	O
.	O

Besides	O
,	O
glycyrrhizin	B-CHEMICAL
was	O
ineffective	O
at	O
all	O
.	O

Nevertheless	O
,	O
18β	B-CHEMICAL
-	I-CHEMICAL
GA	I-CHEMICAL
showed	O
a	O
potent	O
anti	O
-	O
HRSV	O
activity	O
.	O

Radix	O
Glycyrrhizae	O
was	O
more	O
effective	O
when	O
given	O
before	O
viral	O
inoculation	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
which	O
may	O
be	O
due	O
to	O
its	O
inhibition	O
of	O
viral	O
attachment	O
on	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
penetration	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
into	O
the	O
host	O
cells	O
.	O

The	O
anti	O
-	O
HRSV	O
activity	O
of	O
Radix	O
Glycyrrhizae	O
was	O
further	O
confirmed	O
by	O
RT	O
-	O
PCR	O
and	O
qRT	O
-	O
PCR	O
.	O

300μg	O
/	O
ml	O
Radix	O
Glycyrrhizae	O
markedly	O
decreased	O
the	O
viral	O
amounts	O
within	O
the	O
cells	O
and	O
in	O
the	O
suspension	O
.	O

Radix	O
Glycyrrhizae	O
might	O
further	O
stimulate	O
mucosal	O
cells	O
to	O
secrete	O
IFN	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
to	O
counteract	O
viral	O
infection	O
.	O

CONCLUSIONS	O
:	O
Both	O
Radix	O
Glycyrrhizae	O
and	O
Radix	O
Glycyrrhizae	O
Preparata	O
are	O
effective	O
against	O
HRSV	O
infection	O
on	O
airway	O
epithelial	O
cells	O
.	O

Radix	O
Glycyrrhizae	O
inhibited	O
HRSV	O
mainly	O
by	O
preventing	O
viral	O
attachment	O
,	O
internalization	O
,	O
and	O
by	O
stimulating	O
IFN	B-GENE-N
secretion	O
.	O

18β	B-CHEMICAL
-	I-CHEMICAL
GA	I-CHEMICAL
may	O
be	O
one	O
of	O
its	O
active	O
constituents	O
.	O

Juglone	B-CHEMICAL
,	O
isolated	O
from	O
Juglans	O
mandshurica	O
Maxim	O
,	O
induces	O
apoptosis	O
via	O
down	O
-	O
regulation	O
of	O
AR	B-GENE-Y
expression	O
in	O
human	O
prostate	O
cancer	O
LNCaP	O
cells	O
.	O

Juglone	B-CHEMICAL
is	O
a	O
natural	O
compound	O
which	O
has	O
been	O
isolated	O
from	O
Juglans	O
mandshurica	O
Maxim	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
juglone	B-CHEMICAL
had	O
various	O
pharmacological	O
effects	O
such	O
as	O
anti	O
-	O
viral	O
,	O
anti	O
-	O
bacterial	O
and	O
anti	O
-	O
cancer	O
.	O

However	O
,	O
its	O
anti	O
-	O
cancer	O
activity	O
on	O
human	O
prostate	O
cancer	O
LNCaP	O
cell	O
has	O
not	O
been	O
examined	O
.	O

Thus	O
,	O
the	O
current	O
study	O
was	O
designed	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
apoptosis	O
induced	O
by	O
juglone	B-CHEMICAL
in	O
androgen	B-CHEMICAL
-	O
sensitive	O
prostate	O
cancer	O
LNCaP	O
cells	O
.	O

MTT	B-CHEMICAL
assay	O
was	O
performed	O
to	O
examine	O
the	O
anti	O
-	O
proliferative	O
effect	O
of	O
juglone	B-CHEMICAL
.	O

Occurrence	O
of	O
apoptosis	O
was	O
detected	O
by	O
Hoechst	B-CHEMICAL
33342	I-CHEMICAL
staining	O
and	O
flow	O
cytometry	O
in	O
LNCaP	O
cells	O
treated	O
with	O
juglone	B-CHEMICAL
for	O
24h	O
.	O

The	O
result	O
shown	O
that	O
juglone	B-CHEMICAL
inhibited	O
the	O
growth	O
of	O
LNCaP	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Morphological	O
changes	O
of	O
apoptotic	O
body	O
formation	O
after	O
juglone	B-CHEMICAL
treatment	O
were	O
observed	O
by	O
Hoechst	B-CHEMICAL
33342	I-CHEMICAL
staining	O
.	O

This	O
apoptotic	O
induction	O
was	O
associated	O
with	O
loss	O
of	O
mitochondrial	O
membrane	O
potential	O
,	O
and	O
caspase	B-GENE-N
-	I-GENE-N
3	I-GENE-N
,	I-GENE-N
-	I-GENE-N
9	I-GENE-N
activation	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
juglone	B-CHEMICAL
significantly	O
inhibited	O
the	O
expression	O
levels	O
of	O
androgen	B-GENE-Y
receptor	I-GENE-Y
(	O
AR	B-GENE-Y
)	O
and	O
prostate	B-GENE-Y
-	I-GENE-Y
specific	I-GENE-Y
antigen	I-GENE-Y
(	O
PSA	B-GENE-Y
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
as	O
well	O
as	O
abrogated	O
up	O
-	O
regulation	O
of	O
AR	B-GENE-Y
and	O
PSA	B-GENE-Y
genes	O
with	O
and	O
/	O
or	O
without	O
dihydrotestosterone	B-CHEMICAL
(	O
DHT	B-CHEMICAL
)	O
.	O

Take	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
juglone	B-CHEMICAL
might	O
induce	O
the	O
apoptosis	O
in	O
LNCaP	O
cell	O
via	O
down	O
-	O
regulation	O
of	O
AR	B-GENE-Y
expression	O
.	O

Therefore	O
,	O
our	O
results	O
indicated	O
that	O
juglone	B-CHEMICAL
may	O
be	O
a	O
potential	O
candidate	O
of	O
drug	O
for	O
androgen	B-CHEMICAL
-	O
sensitive	O
prostate	O
cancer	O
.	O

Prosocial	O
effects	O
of	O
oxytocin	B-CHEMICAL
in	O
two	O
mouse	O
models	O
of	O
autism	O
spectrum	O
disorders	O
.	O

Clinical	O
evidence	O
suggests	O
that	O
oxytocin	B-CHEMICAL
treatment	O
improves	O
social	O
deficits	O
and	O
repetitive	O
behavior	O
in	O
autism	O
spectrum	O
disorders	O
(	O
ASDs	O
)	O
.	O

However	O
,	O
the	O
neuropeptide	B-GENE-N
has	O
a	O
short	O
plasma	O
half	O
-	O
life	O
and	O
poor	O
ability	O
to	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

In	O
order	O
to	O
facilitate	O
the	O
development	O
of	O
more	O
bioavailable	O
oxytocinergic	O
compounds	O
as	O
therapeutics	O
to	O
treat	O
core	O
ASD	O
symptoms	O
,	O
small	O
animal	O
models	O
must	O
be	O
validated	O
for	O
preclinical	O
screens	O
.	O

This	O
study	O
examined	O
the	O
preclinical	O
utility	O
of	O
two	O
inbred	O
mouse	O
strains	O
,	O
BALB	O
/	O
cByJ	O
and	O
C58	O
/	O
J	O
,	O
that	O
exhibit	O
phenotypes	O
relevant	O
to	O
core	O
ASD	O
symptoms	O
.	O

Mice	O
from	O
both	O
strains	O
were	O
intraperitoneally	O
administered	O
oxytocin	B-CHEMICAL
,	O
using	O
either	O
acute	O
or	O
sub	O
-	O
chronic	O
regimens	O
.	O

Acute	O
oxytocin	B-CHEMICAL
did	O
not	O
increase	O
sociability	O
in	O
BALB	O
/	O
cByJ	O
;	O
however	O
,	O
sub	O
-	O
chronic	O
oxytocin	B-CHEMICAL
had	O
significant	O
prosocial	O
effects	O
in	O
both	O
BALB	O
/	O
cByJ	O
and	O
C58	O
/	O
J	O
.	O

Increased	O
sociability	O
was	O
observed	O
24	O
hours	O
following	O
the	O
final	O
oxytocin	B-CHEMICAL
dose	O
in	O
BALB	O
/	O
cByJ	O
,	O
while	O
prosocial	O
effects	O
of	O
oxytocin	B-CHEMICAL
emerged	O
1	O
-	O
2	O
weeks	O
post	O
-	O
treatment	O
in	O
C58	O
/	O
J	O
.	O

Furthermore	O
,	O
acute	O
oxytocin	B-CHEMICAL
decreased	O
motor	O
stereotypy	O
in	O
C58	O
/	O
J	O
and	O
did	O
not	O
induce	O
hypoactivity	O
or	O
anxiolytic	O
-	O
like	O
effects	O
in	O
an	O
open	O
field	O
test	O
.	O

This	O
study	O
demonstrates	O
that	O
oxytocin	B-CHEMICAL
administration	O
can	O
attenuate	O
social	O
deficits	O
and	O
repetitive	O
behavior	O
in	O
mouse	O
models	O
of	O
ASD	O
,	O
dependent	O
on	O
dose	O
regimen	O
and	O
genotype	O
.	O

These	O
findings	O
provide	O
validation	O
of	O
the	O
BALB	O
/	O
cByJ	O
and	O
C58	O
/	O
J	O
models	O
as	O
useful	O
platforms	O
for	O
screening	O
novel	O
drugs	O
for	O
intervention	O
in	O
ASDs	O
and	O
for	O
elucidating	O
the	O
mechanisms	O
contributing	O
to	O
the	O
prosocial	O
effects	O
of	O
oxytocin	B-CHEMICAL
.	O

Streptococcus	B-GENE-Y
pneumoniae	I-GENE-Y
ClpP	I-GENE-Y
protease	B-GENE-N
induces	O
apoptosis	O
via	O
caspase	B-GENE-N
-	O
independent	O
pathway	O
in	O
human	O
neuroblastoma	O
cells	O
:	O
cytoplasmic	O
relocalization	O
of	O
p53	B-GENE-Y
.	O

Streptococcus	O
pneumoniae	O
causes	O
the	O
most	O
severe	O
form	O
of	O
the	O
bacterial	O
meningitis	O
which	O
is	O
the	O
major	O
cause	O
of	O
bacterial	O
meningitis	O
.	O

Virulence	O
factors	O
produced	O
by	O
S	O
.	O
pneumoniae	O
have	O
been	O
known	O
to	O
contribute	O
significantly	O
to	O
the	O
disease	O
process	O
.	O

ClpP	B-GENE-Y
protease	B-GENE-N
(	O
ClpP	B-GENE-Y
)	O
which	O
is	O
essential	O
for	O
virulence	O
and	O
survival	O
under	O
stress	O
conditions	O
in	O
S	O
.	O
pneumonia	O
was	O
examined	O
for	O
the	O
ability	O
to	O
induce	O
apoptosis	O
and	O
the	O
mechanism	O
of	O
the	O
induction	O
of	O
apoptosis	O
in	O
human	O
neuron	O
-	O
like	O
cells	O
,	O
SK	O
-	O
N	O
-	O
SH	O
neuroblastoma	O
cells	O
.	O

ClpP	B-GENE-Y
inhibited	O
cell	O
growth	O
and	O
induced	O
apoptosis	O
in	O
SK	O
-	O
N	O
-	O
SH	O
cells	O
.	O

Treatment	O
with	O
ClpP	B-GENE-Y
resulted	O
in	O
hypodiploid	O
DNA	O
contents	O
,	O
increased	O
Bax	B-GENE-Y
/	O
Bcl	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
ratio	O
and	O
induction	O
of	O
reactive	O
oxygen	B-CHEMICAL
species	O
(	O
ROS	O
)	O
production	O
.	O

The	O
release	O
of	O
cytochrome	B-GENE-Y
c	I-GENE-Y
from	O
mitochondria	O
into	O
the	O
cytosol	O
,	O
which	O
is	O
an	O
initiator	O
of	O
the	O
activation	O
of	O
caspase	B-GENE-N
cascades	O
,	O
was	O
not	O
observed	O
in	O
ClpP	B-GENE-Y
-	O
treated	O
cells	O
.	O

In	O
addition	O
,	O
pretreatment	O
with	O
Z	B-CHEMICAL
-	I-CHEMICAL
Val	I-CHEMICAL
-	I-CHEMICAL
Ala	I-CHEMICAL
-	I-CHEMICAL
Asp	I-CHEMICAL
-	I-CHEMICAL
fluoromethylketone	I-CHEMICAL
(	O
Z	B-CHEMICAL
-	I-CHEMICAL
VAD	I-CHEMICAL
-	I-CHEMICAL
fmk	I-CHEMICAL
)	O
,	O
a	O
broad	O
spectrum	O
of	O
caspase	B-GENE-N
inhibitor	O
,	O
could	O
not	O
rescue	O
apoptotic	O
cells	O
from	O
ClpP	B-GENE-Y
toxicity	O
.	O

Coincidently	O
,	O
caspase	B-GENE-N
-	I-GENE-N
3	I-GENE-N
and	I-GENE-N
-	I-GENE-N
8	I-GENE-N
activation	O
and	O
cleavage	O
of	O
PARP	B-GENE-N
were	O
not	O
detected	O
.	O

Moreover	O
,	O
caspase	B-GENE-N
independent	O
apoptosis	B-GENE-Y
-	I-GENE-Y
inducing	I-GENE-Y
factor	I-GENE-Y
(	O
AIF	B-GENE-Y
)	O
was	O
released	O
from	O
mitochondria	O
and	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
ClpP	B-GENE-Y
.	O

We	O
also	O
found	O
that	O
ClpP	B-GENE-Y
treatment	O
resulted	O
in	O
the	O
increase	O
of	O
p53	B-GENE-Y
activity	O
and	O
cytoplasmic	O
p53	B-GENE-Y
levels	O
were	O
increased	O
by	O
ClpP	B-GENE-Y
,	O
suggesting	O
that	O
functional	O
activation	O
of	O
p53	B-GENE-Y
is	O
intact	O
despite	O
increased	O
cytoplasmic	O
accumulation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
ClpP	B-GENE-Y
contributes	O
to	O
neuronal	O
damage	O
in	O
meningitis	O
and	O
provide	O
further	O
insight	O
into	O
the	O
mechanisms	O
underlying	O
action	O
of	O
pneumococcal	O
virulence	O
factors	O
during	O
bacterial	O
pathogenesis	O
.	O

Induction	O
of	O
the	O
liver	O
cancer	O
-	O
down	O
-	O
regulated	O
long	O
noncoding	O
RNA	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
mediates	O
trichostatin	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
liver	O
cancer	O
cells	O
.	O

Differential	O
expression	O
of	O
long	O
non	O
-	O
coding	O
RNAs	O
(	O
lncRNAs	O
)	O
plays	O
critical	O
roles	O
in	O
hepatocarcinogenesis	O
.	O

Considerable	O
attention	O
has	O
focused	O
on	O
the	O
antitumor	O
effect	O
of	O
histone	B-GENE-N
deacetylase	I-GENE-N
inhibitor	O
(	O
Trichostatin	B-CHEMICAL
A	I-CHEMICAL
,	O
TSA	B-CHEMICAL
)	O
as	O
well	O
as	O
the	O
coding	O
gene	O
expression	O
-	O
induced	O
apoptosis	O
of	O
cancer	O
cells	O
.	O

However	O
,	O
it	O
is	O
not	O
known	O
whether	O
lncRNA	O
has	O
a	O
role	O
in	O
TSA	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
human	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
cells	O
.	O

The	O
global	O
expression	O
of	O
lncRNAs	O
and	O
coding	O
genes	O
was	O
analyzed	O
with	O
the	O
Human	O
LncRNA	O
Array	O
V2	O
.	O
0	O
after	O
24h	O
treatment	O
.	O

Expression	O
was	O
verified	O
in	O
cell	O
lines	O
and	O
tissues	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

The	O
data	O
showed	O
that	O
4	O
.	O
8	O
%	O
(	O
959	O
)	O
of	O
lncRNA	O
and	O
6	O
.	O
1	O
%	O
(	O
1849	O
)	O
of	O
protein	O
coding	O
gene	O
were	O
significantly	O
differentially	O
expressed	O
.	O

The	O
differential	O
expressions	O
of	O
lncRNA	O
and	O
protein	O
coding	O
genes	O
had	O
distinguishable	O
hierarchical	O
clustering	O
expression	O
profiling	O
pattern	O
.	O

Among	O
these	O
differentially	O
expressed	O
lncRNAs	O
,	O
the	O
greatest	O
change	O
was	O
noted	O
for	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
,	O
which	O
had	O
more	O
than	O
300	O
folds	O
induction	O
upon	O
TSA	B-CHEMICAL
treatment	O
.	O

TSA	B-CHEMICAL
selectively	O
induced	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
in	O
four	O
studied	O
HCC	O
cell	O
lines	O
.	O

Compared	O
with	O
normal	O
human	O
hepatocytes	O
and	O
adjacent	O
noncancerous	O
tissues	O
,	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
expression	O
level	O
was	O
significantly	O
lower	O
in	O
the	O
HCC	O
cell	O
lines	O
and	O
liver	O
cancer	O
tissues	O
.	O

The	O
TSA	B-CHEMICAL
-	O
induced	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
expression	O
was	O
positively	O
correlated	O
with	O
the	O
apoptotic	O
effect	O
of	O
TSA	B-CHEMICAL
in	O
HCC	O
cells	O
.	O

In	O
addition	O
,	O
knockdown	O
the	O
expression	O
of	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
significantly	O
reduced	O
TSA	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
Huh7cells	O
.	O

Therefore	O
,	O
TSA	B-CHEMICAL
-	O
induced	O
apoptosis	O
of	O
HCC	O
cells	O
is	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
dependent	O
and	O
reduced	O
expression	O
of	O
uc002mbe	B-GENE-Y
.	I-GENE-Y
2	I-GENE-Y
may	O
be	O
associated	O
with	O
liver	O
carcinogenesis	O
.	O

Steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
from	O
the	O
bulbs	O
of	O
Easter	O
lily	O
(	O
Lilium	O
longiflorum	O
Thunb	O
.	O
)	O
promote	O
dermal	O
fibroblast	O
migration	O
in	O
vitro	O
.	O

ETHNOPHARMACOLOGICAL	O
RELEVANCE	O
:	O
Preparations	O
derived	O
from	O
bulbs	O
of	O
various	O
Lilium	O
species	O
have	O
been	O
used	O
to	O
promote	O
the	O
healing	O
of	O
skin	O
abrasions	O
,	O
sores	O
and	O
burns	O
and	O
to	O
aid	O
in	O
healing	O
wounds	O
in	O
Traditional	O
Chinese	O
and	O
Greco	O
-	O
Roman	O
Medicine	O
.	O

AIM	O
OF	O
THE	O
STUDY	O
:	O
To	O
evaluate	O
fractionated	O
Easter	O
lily	O
bulb	O
extracts	O
and	O
their	O
steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
(	O
1	O
-	O
5	O
)	O
for	O
the	O
promotion	O
of	O
dermal	O
fibroblast	O
migration	O
in	O
vitro	O
,	O
as	O
a	O
model	O
for	O
the	O
early	O
events	O
in	O
wound	O
healing	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
An	O
activity	O
-	O
guided	O
screening	O
approach	O
was	O
used	O
by	O
coupling	O
sequential	O
solvent	O
extraction	O
,	O
gel	O
permeation	O
chromatography	O
(	O
GPC	O
)	O
,	O
and	O
semi	O
-	O
preparative	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
RP	O
-	O
HPLC	O
)	O
with	O
an	O
in	O
vitro	O
dermal	O
fibroblast	O
migration	O
assay	O
.	O

Cytotoxicity	O
was	O
evaluated	O
with	O
methyl	B-CHEMICAL
thiazole	I-CHEMICAL
tetrazolium	I-CHEMICAL
(	O
MTT	B-CHEMICAL
)	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mode	O
of	O
action	O
of	O
the	O
steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
,	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
(	O
NO	B-CHEMICAL
)	O
production	O
,	O
and	O
expression	O
of	O
genes	O
for	O
transforming	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
beta	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
TGF	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
)	O
and	O
its	O
receptors	O
were	O
evaluated	O
.	O

RESULTS	O
:	O
Fractionated	O
bulb	O
extracts	O
and	O
the	O
two	O
isolated	O
steroidal	B-CHEMICAL
glycoalkaloids	I-CHEMICAL
(	O
1	O
)	O
and	O
(	O
2	O
)	O
induced	O
NO	B-CHEMICAL
production	O
and	O
TGF	B-GENE-Y
-	I-GENE-Y
β	I-GENE-Y
receptor	I-GENE-Y
I	I-GENE-Y
mRNA	O
expression	O
in	O
fibroblast	O
cell	O
culture	O
.	O

In	O
a	O
cytotoxicity	O
assay	O
,	O
steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
(	O
1	O
)	O
and	O
(	O
3	O
)	O
had	O
IC50	O
values	O
of	O
8	O
.	O
2	O
and	O
8	O
.	O
7µM	O
,	O
but	O
the	O
natural	O
acetylation	O
of	O
the	O
C	O
-	O
6	O
″	O
'	O
hydroxy	B-CHEMICAL
of	O
the	O
terminal	O
glucose	B-CHEMICAL
unit	O
in	O
(	O
2	O
)	O
resulted	O
in	O
a	O
3	O
-	O
fold	O
decrease	O
in	O
cell	O
cytotoxicity	O
when	O
compared	O
with	O
(	O
1	O
)	O
.	O

Results	O
from	O
the	O
dermal	O
fibroblast	O
migration	O
assay	O
revealed	O
that	O
the	O
steroidal	B-CHEMICAL
glycoalkaloids	I-CHEMICAL
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
and	O
the	O
furostanol	B-CHEMICAL
saponin	I-CHEMICAL
(	O
3	O
)	O
promoted	O
fibroblast	O
migration	O
from	O
the	O
range	O
of	O
23	O
.	O
7	O
±	O
5	O
.	O
7	O
to	O
37	O
.	O
7	O
±	O
5	O
.	O
1	O
%	O
,	O
as	O
compared	O
with	O
the	O
control	O
.	O

CONCLUSION	O
:	O
Collectively	O
,	O
our	O
data	O
demonstrate	O
that	O
the	O
steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
present	O
in	O
Easter	O
lily	O
bulbs	O
induce	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
observed	O
dermal	O
fibroblast	O
migration	O
activity	O
of	O
the	O
bulb	O
extracts	O
.	O

This	O
is	O
the	O
first	O
evidence	O
that	O
steroidal	B-CHEMICAL
glycosides	I-CHEMICAL
from	O
L	O
.	O
longiflorum	O
may	O
potentially	O
play	O
a	O
role	O
in	O
the	O
wound	O
healing	O
process	O
and	O
may	O
provide	O
a	O
scientific	O
basis	O
for	O
the	O
historical	O
use	O
of	O
lily	O
bulbs	O
for	O
this	O
purpose	O
.	O

Albiglutide	O
:	O
a	O
new	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
agonist	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
.	O

OBJECTIVE	O
:	O
To	O
review	O
the	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
safety	O
,	O
and	O
efficacy	O
of	O
albiglutide	O
,	O
a	O
glucagon	B-GENE-Y
-	I-GENE-Y
like	I-GENE-Y
peptide	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
receptor	I-GENE-Y
agonist	O
(	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
RA	I-GENE-Y
)	O
in	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
.	O

DATA	O
SOURCES	O
:	O
A	O
MEDLINE	O
search	O
(	O
1950	O
-	O
June	O
2014	O
)	O
was	O
conducted	O
using	O
the	O
keyword	O
albiglutide	O
.	O

References	O
were	O
reviewed	O
to	O
identify	O
additional	O
sources	O
.	O

STUDY	O
SELECTION	O
AND	O
DATA	O
EXTRACTION	O
:	O
Articles	O
evaluating	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
safety	O
,	O
or	O
efficacy	O
of	O
albiglutide	O
were	O
included	O
.	O

DATA	O
SYNTHESIS	O
:	O
Albiglutide	O
is	O
a	O
long	O
-	O
acting	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
RA	I-GENE-Y
that	O
lowers	O
glycosylated	B-GENE-Y
hemoglobin	I-GENE-Y
(	O
A1C	B-GENE-Y
)	O
and	O
reduces	O
weight	O
by	O
stimulating	O
glucose	B-CHEMICAL
-	O
dependent	O
insulin	B-GENE-Y
secretion	O
,	O
suppressing	O
glucagon	B-GENE-Y
secretion	O
,	O
delaying	O
gastric	O
emptying	O
,	O
and	O
promoting	O
satiety	O
.	O

Albiglutide	O
has	O
a	O
long	O
half	O
-	O
life	O
as	O
a	O
result	O
of	O
resistance	O
to	O
degradation	O
by	O
dipeptidyl	B-GENE-Y
peptidase	I-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
fusion	O
to	O
albumin	B-GENE-Y
,	O
thus	O
allowing	O
once	O
-	O
weekly	O
dosing	O
.	O

Albiglutide	O
has	O
been	O
studied	O
as	O
monotherapy	O
and	O
add	O
-	O
on	O
therapy	O
to	O
metformin	B-CHEMICAL
,	O
sulfonylureas	B-CHEMICAL
,	O
thiazolidinediones	B-CHEMICAL
,	O
insulin	B-GENE-Y
glargine	O
,	O
and	O
varying	O
combinations	O
of	O
these	O
agents	O
.	O

Clinical	O
studies	O
have	O
shown	O
albiglutide	O
to	O
be	O
superior	O
to	O
placebo	O
,	O
sitagliptin	B-CHEMICAL
,	O
and	O
glimepiride	B-CHEMICAL
and	O
noninferior	O
to	O
insulin	B-GENE-Y
glargine	O
and	O
insulin	B-GENE-Y
lispro	O
at	O
reducing	O
A1C	B-GENE-Y
in	O
T2D	O
patients	O
,	O
with	O
A1C	B-GENE-Y
changes	O
from	O
baseline	O
ranging	O
from	O
-	O
0	O
.	O
55	O
%	O
to	O
-	O
0	O
.	O
9	O
%	O
.	O

Noninferiority	O
was	O
not	O
achieved	O
when	O
compared	O
to	O
liraglutide	O
and	O
pioglitazone	B-CHEMICAL
.	O

Weight	O
changes	O
ranged	O
from	O
+	O
0	O
.	O
28	O
to	O
-	O
1	O
.	O
21	O
kg	O
.	O

The	O
most	O
common	O
side	O
effects	O
are	O
upper	O
-	O
respiratory	O
-	O
tract	O
infections	O
,	O
diarrhea	O
,	O
nausea	O
,	O
and	O
injection	O
-	O
site	O
reactions	O
.	O

CONCLUSION	O
:	O
Albiglutide	O
is	O
the	O
fourth	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
RA	I-GENE-Y
approved	O
in	O
the	O
United	O
States	O
.	O

Advantages	O
include	O
once	O
-	O
weekly	O
dosing	O
and	O
fewer	O
gastrointestinal	O
side	O
effects	O
compared	O
with	O
liraglutide	O
,	O
but	O
it	O
is	O
less	O
effective	O
at	O
reducing	O
A1C	B-GENE-Y
and	O
weight	O
compared	O
to	O
liraglutide	O
.	O

It	O
has	O
not	O
been	O
compared	O
head	O
to	O
head	O
with	O
other	O
GLP	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
RAs	I-GENE-Y
.	O

Acute	O
effects	O
of	O
brexpiprazole	B-CHEMICAL
on	O
serotonin	B-CHEMICAL
,	O
dopamine	B-CHEMICAL
,	O
and	O
norepinephrine	B-CHEMICAL
systems	O
:	O
an	O
in	O
vivo	O
electrophysiologic	O
characterization	O
.	O

Brexpiprazole	B-CHEMICAL
,	O
a	O
compound	O
sharing	O
structural	O
molecular	O
characteristics	O
with	O
aripiprazole	B-CHEMICAL
,	O
is	O
currently	O
under	O
investigation	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
and	O
depression	O
.	O

Using	O
electrophysiologic	O
techniques	O
,	O
the	O
present	O
study	O
assessed	O
the	O
in	O
vivo	O
action	O
of	O
brexpiprazole	B-CHEMICAL
on	O
serotonin	B-GENE-N
(	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
subtypes	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
,	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
,	O
and	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
;	O
dopamine	B-GENE-Y
(	I-GENE-Y
DA	I-GENE-Y
)	I-GENE-Y
D2	I-GENE-Y
autoreceptors	I-GENE-Y
,	O
and	O
alpha1	B-GENE-N
-	I-GENE-N
and	I-GENE-N
alpha2	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
.	O

In	O
addition	O
,	O
the	O
effects	O
on	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
autoreceptors	O
in	O
the	O
dorsal	O
raphe	O
nucleus	O
(	O
DRN	O
)	O
and	O
D2	B-GENE-Y
autoreceptors	I-GENE-Y
in	O
the	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
were	O
compared	O
with	O
those	O
of	O
aripiprazole	B-CHEMICAL
,	O
an	O
agent	O
in	O
wide	O
clinical	O
use	O
.	O

In	O
the	O
DRN	O
,	O
brexpiprazole	B-CHEMICAL
completely	O
inhibited	O
the	O
firing	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
neurons	O
via	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
agonism	O
and	O
was	O
more	O
potent	O
than	O
aripiprazole	B-CHEMICAL
(	O
ED50	O
=	O
230	O
and	O
700	O
mug	O
/	O
kg	O
,	O
respectively	O
)	O
.	O

In	O
the	O
locus	O
coeruleus	O
,	O
brexpiprazole	B-CHEMICAL
reversed	O
the	O
inhibitory	O
effect	O
of	O
the	O
preferential	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
receptor	O
agonist	O
DOI	B-CHEMICAL
(	O
2	B-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
dimethoxy	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
iodoamphetamine	I-CHEMICAL
)	O
on	O
norepinephrine	B-CHEMICAL
neuronal	O
firing	O
(	O
ED50	O
=	O
110	O
mug	O
/	O
kg	O
)	O
,	O
demonstrating	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
antagonistic	O
action	O
.	O

Brexpiprazole	B-CHEMICAL
reversed	O
the	O
inhibitory	O
effect	O
of	O
the	O
DA	B-CHEMICAL
agonist	O
apomorphine	B-CHEMICAL
on	O
VTA	O
DA	O
neurons	O
(	O
ED50	O
=	O
61	O
mug	O
/	O
kg	O
)	O
,	O
whereas	O
it	O
was	O
ineffective	O
when	O
administered	O
alone	O
,	O
indicating	O
partial	O
agonistic	O
action	O
on	O
D2	B-GENE-Y
receptors	I-GENE-Y
.	O

Compared	O
with	O
aripiprazole	B-CHEMICAL
,	O
which	O
significantly	O
inhibited	O
the	O
firing	O
activity	O
of	O
VTA	O
DA	B-CHEMICAL
neurons	O
,	O
brexpiprazole	B-CHEMICAL
displayed	O
less	O
efficacy	O
at	O
D2	B-GENE-Y
receptors	I-GENE-Y
.	O

In	O
the	O
hippocampus	O
,	O
brexpiprazole	B-CHEMICAL
acted	O
as	O
a	O
full	O
agonist	O
at	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptors	O
on	O
pyramidal	O
neurons	O
.	O

Furthermore	O
,	O
it	O
increased	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
release	O
by	O
terminal	O
alpha2	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
heteroceptor	I-GENE-N
but	O
not	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
autoreceptor	O
antagonism	O
.	O

In	O
the	O
lateral	O
geniculate	O
nucleus	O
,	O
brexpiprazole	B-CHEMICAL
displayed	O
alpha1B	B-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonistic	O
action	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
insight	O
into	O
the	O
in	O
vivo	O
action	O
of	O
brexpiprazole	B-CHEMICAL
on	O
monoamine	B-CHEMICAL
targets	O
relevant	O
in	O
the	O
treatment	O
of	O
depression	O
and	O
schizophrenia	O
.	O

Effect	O
of	O
minaprine	B-CHEMICAL
on	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	O
in	O
mice	O
.	O

The	O
effects	O
of	O
minaprine	B-CHEMICAL
on	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	O
were	O
investigated	O
in	O
a	O
step	O
-	O
down	O
passive	O
avoidance	O
task	O
in	O
mice	O
.	O

Minaprine	B-CHEMICAL
significantly	O
improved	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	O
.	O

This	O
effect	O
was	O
inhibited	O
by	O
scopolamine	B-CHEMICAL
,	O
but	O
was	O
potentiated	O
by	O
physostigmine	B-CHEMICAL
.	O

The	O
anti	O
-	O
amnesic	O
effect	O
of	O
minaprine	B-CHEMICAL
on	O
the	O
cycloheximide	B-CHEMICAL
-	O
induced	O
memory	O
impairment	O
was	O
also	O
antagonized	O
by	O
a	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
releaser	O
,	O
p	B-CHEMICAL
-	I-CHEMICAL
chloroamphetamine	I-CHEMICAL
,	O
and	O
by	O
a	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
precursor	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptophan	I-CHEMICAL
,	O
whereas	O
a	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
-	O
selective	O
agonist	O
,	O
8	B-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
di	I-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
propylamino	I-CHEMICAL
)	I-CHEMICAL
tetralin	I-CHEMICAL
,	O
was	O
inactive	O
.	O

The	O
memory	O
-	O
improving	O
effect	O
of	O
minaprine	B-CHEMICAL
on	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	O
was	O
potentiated	O
by	O
a	O
selective	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
antagonist	O
,	O
ritanserin	B-CHEMICAL
.	O

These	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
minaprine	B-CHEMICAL
on	O
cycloheximide	B-CHEMICAL
-	O
induced	O
amnesia	O
may	O
be	O
related	O
not	O
only	O
to	O
cholinergic	O
but	O
also	O
serotonergic	O
neuronal	O
systems	O
(	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptors	I-GENE-N
)	O
.	O

Nonsedating	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
.	O

The	O
chemistry	O
,	O
pharmacology	O
,	O
pharmacokinetics	O
,	O
clinical	O
efficacy	O
,	O
adverse	O
effects	O
,	O
and	O
dosages	O
of	O
the	O
nonsedating	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
terfenadine	B-CHEMICAL
,	O
astemizole	B-CHEMICAL
,	O
loratadine	B-CHEMICAL
,	O
and	O
acrivastine	B-CHEMICAL
are	O
reviewed	O
.	O

Terfenadine	B-CHEMICAL
and	O
astemizole	B-CHEMICAL
are	O
chemically	O
unrelated	O
to	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
such	O
as	O
diphenhydramine	B-CHEMICAL
and	O
chlorpheniramine	B-CHEMICAL
.	O

Loratadine	B-CHEMICAL
is	O
structurally	O
related	O
to	O
the	O
antihistamine	O
azatadine	B-CHEMICAL
,	O
and	O
acrivastine	B-CHEMICAL
is	O
a	O
side	O
-	O
chain	O
-	O
reduced	O
metabolite	O
of	O
the	O
antihistamine	O
triprolidine	B-CHEMICAL
.	O

Like	O
other	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonists	O
,	O
they	O
competitively	O
block	O
histamine	B-GENE-N
receptor	I-GENE-N
sites	O
rather	O
than	O
inhibiting	O
histamine	B-CHEMICAL
release	O
.	O

All	O
four	O
drugs	O
have	O
relatively	O
long	O
half	O
-	O
lives	O
and	O
are	O
rapidly	O
absorbed	O
after	O
oral	O
administration	O
.	O

Terfenadine	B-CHEMICAL
,	O
astemizole	B-CHEMICAL
,	O
and	O
loratadine	B-CHEMICAL
are	O
metabolized	O
extensively	O
in	O
the	O
liver	O
;	O
terfenadine	B-CHEMICAL
and	O
astemizole	B-CHEMICAL
are	O
both	O
97	O
%	O
protein	O
bound	O
.	O

Terfenadine	B-CHEMICAL
60	O
mg	O
twice	O
daily	O
has	O
been	O
shown	O
to	O
be	O
as	O
effective	O
as	O
conventional	O
antihistamines	O
for	O
the	O
treatment	O
of	O
seasonal	O
allergic	O
rhinitis	O
.	O

In	O
clinical	O
trials	O
,	O
astemizole	B-CHEMICAL
10	O
mg	O
daily	O
was	O
comparable	O
to	O
or	O
better	O
than	O
chlorpheniramine	B-CHEMICAL
for	O
treatment	O
of	O
chronic	O
rhinitis	O
.	O

Both	O
terfenadine	B-CHEMICAL
and	O
astemizole	B-CHEMICAL
were	O
effective	O
for	O
treatment	O
of	O
chronic	O
urticaria	O
.	O

For	O
treatment	O
of	O
seasonal	O
allergic	O
rhinitis	O
,	O
loratadine	B-CHEMICAL
combined	O
with	O
pseudoephedrine	B-CHEMICAL
may	O
be	O
preferable	O
to	O
triprolidine	B-CHEMICAL
-	O
pseudoephedrine	B-CHEMICAL
and	O
acrivastine	B-CHEMICAL
-	O
pseudoephedrine	B-CHEMICAL
combinations	O
that	O
require	O
more	O
frequent	O
dosing	O
.	O

Acrivastine	B-CHEMICAL
must	O
be	O
administered	O
more	O
frequently	O
than	O
the	O
other	O
nonsedating	O
antihistamines	O
.	O

None	O
of	O
these	O
four	O
agents	O
impairs	O
psychomotor	O
activity	O
.	O

Infrequently	O
reported	O
adverse	O
effects	O
include	O
dry	O
mouth	O
,	O
skin	O
reactions	O
,	O
and	O
weight	O
gain	O
.	O

The	O
absence	O
of	O
substantial	O
sedative	O
effects	O
and	O
the	O
less	O
-	O
frequent	O
dosing	O
schedules	O
make	O
these	O
agents	O
good	O
alternatives	O
to	O
the	O
classic	O
antihistamines	O
for	O
treatment	O
of	O
seasonal	O
and	O
chronic	O
rhinitis	O
and	O
chronic	O
urticaria	O
.	O

Nonthrombolytic	O
intervention	O
in	O
acute	O
myocardial	O
infarction	O
.	O

Alternative	O
interventions	O
are	O
available	O
for	O
patients	O
in	O
whom	O
thrombolytic	O
therapy	O
is	O
inappropriate	O
after	O
an	O
acute	O
myocardial	O
infarction	O
.	O

Administration	O
of	O
a	O
beta	O
blocker	O
within	O
the	O
first	O
24	O
hours	O
of	O
the	O
patient	O
'	O
s	O
admission	O
to	O
the	O
coronary	O
care	O
unit	O
can	O
reduce	O
overall	O
morbidity	O
and	O
mortality	O
within	O
the	O
first	O
7	O
days	O
by	O
about	O
15	O
%	O
.	O

Maintenance	O
therapy	O
with	O
an	O
oral	O
beta	O
blocker	O
can	O
reduce	O
mortality	O
within	O
the	O
succeeding	O
3	O
years	O
by	O
about	O
25	O
%	O
.	O

Esmolol	B-CHEMICAL
,	O
a	O
unique	O
cardioselective	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
blocker	O
with	O
a	O
half	O
-	O
life	O
of	O
9	O
minutes	O
,	O
can	O
enable	O
some	O
patients	O
with	O
relative	O
contraindications	O
to	O
beta	O
blockers	O
to	O
nevertheless	O
benefit	O
from	O
early	O
beta	O
-	O
blocking	O
therapy	O
.	O

It	O
also	O
is	O
useful	O
in	O
screening	O
patients	O
for	O
subsequent	O
therapy	O
with	O
beta	O
blockers	O
.	O

Those	O
who	O
tolerate	O
the	O
esmolol	B-CHEMICAL
infusion	O
can	O
be	O
given	O
a	O
long	O
-	O
acting	O
beta	O
blocker	O
.	O

For	O
patients	O
who	O
exhibit	O
intolerance	O
to	O
esmolol	B-CHEMICAL
,	O
the	O
infusion	O
can	O
be	O
terminated	O
with	O
rapid	O
return	O
to	O
baseline	O
hemodynamics	O
.	O

Differential	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptor	I-GENE-N
expression	O
in	O
renal	O
allograft	O
recipients	O
treated	O
with	O
an	O
anti	O
-	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antibody	O
.	O

Patients	O
were	O
entered	O
into	O
a	O
randomized	O
trial	O
of	O
prophylaxis	O
for	O
renal	O
allograft	O
rejection	O
by	O
the	O
administration	O
of	O
an	O
anti	O
-	O
human	B-GENE-N
IL	I-GENE-N
-	I-GENE-N
2	I-GENE-N
receptor	I-GENE-N
antibody	O
,	O
anti	O
-	O
Tac	O
,	O
during	O
the	O
first	O
ten	O
days	O
posttransplant	O
.	O

Interleukin	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptor	I-GENE-N
(	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
)	O
expression	O
was	O
measured	O
using	O
two	O
anti	O
-	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
monoclonal	O
antibodies	O
(	O
moAbs	O
)	O
,	O
anti	O
-	O
Tac	O
and	O
1HT4	O
-	O
4H3	O
.	O

These	O
two	O
antibodies	O
recognize	O
closely	O
spaced	O
epitopes	O
on	O
the	O
55	O
kD	O
chain	O
of	O
the	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
.	O

IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
expression	O
was	O
examined	O
on	O
peripheral	O
blood	O
small	O
lymphocytes	O
in	O
three	O
groups	O
of	O
patients	O
who	O
received	O
:	O
(	B-CHEMICAL
A	I-CHEMICAL
)	I-CHEMICAL
cyclosporine	I-CHEMICAL
CsA	B-CHEMICAL
and	O
prednisone	B-CHEMICAL
for	O
baseline	O
immunosuppression	O
(	O
n	O
=	O
9	O
)	O
;	O
(	O
B	O
)	O
anti	O
-	O
Tac	O
with	O
CsA	B-CHEMICAL
and	O
prednisone	B-CHEMICAL
as	O
baseline	O
immunosuppression	O
(	O
n	O
=	O
12	O
)	O
;	O
and	O
(	O
C	O
)	O
anti	O
-	O
Tac	O
with	O
azathioprine	B-CHEMICAL
and	O
prednisone	B-CHEMICAL
as	O
baseline	O
immunosuppression	O
(	O
n	O
=	O
5	O
)	O
.	O

We	O
found	O
that	O
large	O
numbers	O
of	O
T	O
cells	O
express	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptors	I-GENE-N
despite	O
the	O
presence	O
of	O
anti	O
-	O
Tac	O
(	O
average	O
of	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
-	O
positive	O
cells	O
at	O
day	O
of	O
peak	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
expression	O
56	O
.	O
0	O
+	O
/	O
-	O
20	O
.	O
8	O
%	O
in	O
group	O
A	O
,	O
65	O
.	O
2	O
+	O
/	O
-	O
26	O
.	O
6	O
%	O
in	O
group	O
B	O
,	O
21	O
.	O
0	O
+	O
/	O
-	O
7	O
.	O
4	O
%	O
in	O
group	O
C	O
)	O
.	O

IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
R	I-GENE-N
expression	O
did	O
not	O
correlate	O
with	O
clinical	O
activity	O
,	O
and	O
the	O
presence	O
or	O
accessibility	O
of	O
epitopes	O
on	O
the	O
same	O
55	O
kD	O
chain	O
varied	O
dramatically	O
from	O
patient	O
to	O
patient	O
.	O

Effects	O
of	O
felodipine	B-CHEMICAL
(	O
a	O
dihydropyridine	B-CHEMICAL
calcium	B-GENE-N
channel	I-GENE-N
blocker	O
)	O
and	O
analogues	O
on	O
calmodulin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
enzymes	I-GENE-N
.	O

We	O
have	O
examined	O
the	O
effects	O
on	O
the	O
activities	O
of	O
three	O
calmodulin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
enzymes	I-GENE-N
(	O
cAMP	B-GENE-N
phosphodiesterase	I-GENE-N
,	O
caldesmon	B-GENE-N
kinase	I-GENE-N
and	O
myosin	B-GENE-Y
light	I-GENE-Y
chain	I-GENE-Y
kinase	I-GENE-Y
)	O
of	O
the	O
dihydropyridine	B-CHEMICAL
Ca2	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
blocker	O
felodipine	B-CHEMICAL
and	O
three	O
analogues	O
(	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
,	O
oxidized	O
and	O
t	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
)	O
exhibiting	O
different	O
pharmacological	O
potencies	O
.	O

The	O
cAMP	B-GENE-N
phosphodiesterase	I-GENE-N
was	O
inhibited	O
completely	O
by	O
felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
with	O
IC50	O
values	O
of	O
3	O
.	O
7	O
and	O
1	O
.	O
5	O
microM	O
respectively	O
.	O

The	O
oxidized	O
and	O
t	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
analogues	O
were	O
relatively	O
ineffective	O
in	O
inhibiting	O
cAMP	B-GENE-N
phosphodiesterase	I-GENE-N
.	O

Felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
inhibited	O
the	O
basal	O
(	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
/	O
calmodulin	O
-	O
independent	O
)	O
activity	O
of	O
cAMP	B-GENE-N
phosphodiesterase	I-GENE-N
as	O
well	O
as	O
the	O
calmodulin	B-GENE-Y
-	O
stimulated	O
activity	O
.	O

Calmodulin	B-GENE-Y
was	O
relatively	O
ineffective	O
in	O
preventing	O
inhibition	O
of	O
cAMP	B-GENE-N
phosphodiesterase	I-GENE-N
by	O
felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
.	O

These	O
observations	O
suggest	O
that	O
felodipine	B-CHEMICAL
may	O
act	O
directly	O
on	O
the	O
phosphodiesterase	B-GENE-N
as	O
well	O
as	O
through	O
calmodulin	B-GENE-Y
.	O

Felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
inhibited	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
/	O
calmodulin	B-GENE-Y
-	O
dependent	O
caldesmon	B-GENE-N
kinase	I-GENE-N
with	O
similar	O
potencies	O
(	O
IC50	O
=	O
17	O
.	O
4	O
microM	O
)	O
,	O
whereas	O
the	O
oxidized	O
and	O
t	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
analogues	O
caused	O
no	O
inhibition	O
.	O

Similarly	O
,	O
felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
inhibited	O
myosin	B-GENE-Y
light	I-GENE-Y
chain	I-GENE-Y
kinase	I-GENE-Y
activity	O
whether	O
the	O
isolated	O
20	O
kD	O
light	O
chain	O
(	O
IC50	O
=	O
12	O
.	O
6	O
microM	O
)	O
or	O
intact	O
myosin	B-GENE-N
(	O
IC50	O
=	O
11	O
.	O
0	O
microM	O
)	O
was	O
used	O
as	O
substrate	O
.	O

Inhibition	O
in	O
each	O
case	O
was	O
prevented	O
by	O
excess	O
calmodulin	B-GENE-Y
.	O

The	O
oxidized	O
and	O
t	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
derivatives	O
caused	O
little	O
or	O
no	O
inhibition	O
.	O

Finally	O
,	O
the	O
effects	O
of	O
felodipine	B-CHEMICAL
and	O
the	O
three	O
analogues	O
on	O
two	O
processes	O
which	O
are	O
dependent	O
on	O
myosin	B-GENE-N
phosphorylation	O
were	O
examined	O
,	O
namely	O
the	O
actin	B-GENE-N
-	O
activated	O
Mg2	B-GENE-N
+	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
activity	O
of	O
myosin	B-GENE-N
and	O
the	O
assembly	O
of	O
myosin	B-GENE-N
filaments	O
.	O

Felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
inhibited	O
the	O
actin	B-GENE-N
-	O
activated	O
Mg2	B-GENE-N
+	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
activity	O
of	O
smooth	O
muscle	O
myosin	B-GENE-N
(	O
IC50	O
=	O
25	O
.	O
1	O
microM	O
)	O
.	O

The	O
oxidized	O
and	O
t	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
analogues	O
exhibited	O
no	O
inhibition	O
.	O

Similarly	O
,	O
felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
blocked	O
myosin	B-GENE-N
filament	O
assembly	O
induced	O
by	O
low	O
concentrations	O
of	O
calmodulin	B-GENE-Y
,	O
whereas	O
the	O
oxidized	O
and	O
t	B-CHEMICAL
-	I-CHEMICAL
butyl	I-CHEMICAL
analogues	O
did	O
not	O
.	O

Again	O
,	O
inhibition	O
of	O
the	O
actin	B-GENE-N
-	O
activated	O
myosin	B-GENE-N
Mg2	B-GENE-N
+	I-GENE-N
-	I-GENE-N
ATPase	I-GENE-N
and	O
myosin	B-GENE-N
filament	O
assembly	O
by	O
felodipine	B-CHEMICAL
and	O
the	O
p	B-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
analogue	O
could	O
be	O
reversed	O
by	O
raising	O
the	O
calmodulin	B-GENE-Y
concentration	O
.	O

These	O
observations	O
suggest	O
that	O
some	O
of	O
the	O
pharmacological	O
actions	O
of	O
felodipine	B-CHEMICAL
on	O
smooth	O
muscle	O
may	O
involve	O
inhibition	O
of	O
calmodulin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
enzymes	I-GENE-N
which	O
are	O
functionally	O
involved	O
in	O
the	O
regulation	O
of	O
smooth	O
muscle	O
contraction	O
.	O

Loperamide	B-CHEMICAL
,	O
an	O
opiate	O
analog	O
,	O
differently	O
modifies	O
the	O
adrenocorticotropin	B-GENE-Y
responses	O
to	O
corticotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
and	O
lysine	B-CHEMICAL
vasopressin	I-CHEMICAL
in	O
patients	O
with	O
Addison	O
'	O
s	O
disease	O
.	O

Loperamide	B-CHEMICAL
is	O
a	O
peripheral	O
opiate	O
agonist	O
able	O
to	O
inhibit	O
ACTH	B-GENE-Y
secretion	O
.	O

In	O
this	O
work	O
,	O
the	O
interactions	O
between	O
loperamide	B-CHEMICAL
and	O
two	O
ACTH	B-GENE-Y
secretagogues	O
,	O
lysine	B-CHEMICAL
vasopressin	I-CHEMICAL
(	O
LVP	B-CHEMICAL
)	O
and	O
corticotropin	B-GENE-Y
-	I-GENE-Y
releasing	I-GENE-Y
hormone	I-GENE-Y
(	O
CRH	B-GENE-Y
)	O
,	O
were	O
investigated	O
in	O
patients	O
with	O
Addison	O
'	O
s	O
disease	O
.	O

After	O
loperamide	B-CHEMICAL
(	O
16	O
mg	O
orally	O
)	O
or	O
placebo	O
administration	O
,	O
5	O
patients	O
received	O
LVP	B-CHEMICAL
(	O
0	O
.	O
06	O
IU	O
/	O
kg	O
i	O
.	O
v	O
.	O
over	O
1	O
h	O
)	O
and	O
6	O
patients	O
received	O
oCRH	B-GENE-Y
(	O
1	O
micrograms	O
/	O
kg	O
i	O
.	O
v	O
.	O
as	O
bolus	O
)	O
.	O

In	O
all	O
patients	O
loperamide	B-CHEMICAL
induced	O
a	O
significant	O
fall	O
in	O
plasma	O
ACTH	B-GENE-Y
levels	O
.	O

LVP	B-CHEMICAL
increased	O
ACTH	B-GENE-Y
levels	O
after	O
both	O
loperamide	B-CHEMICAL
(	O
from	O
48	O
+	O
/	O
-	O
17	O
.	O
3	O
to	O
a	O
peak	O
of	O
95	O
+	O
/	O
-	O
21	O
pmol	O
/	O
l	O
)	O
and	O
placebo	O
(	O
from	O
231	O
+	O
/	O
-	O
59	O
.	O
5	O
to	O
365	O
+	O
/	O
-	O
86	O
.	O
6	O
pmol	O
/	O
l	O
)	O
:	O
the	O
interaction	O
between	O
treatments	O
and	O
time	O
was	O
not	O
significant	O
.	O

CRH	B-GENE-Y
caused	O
a	O
rise	O
in	O
plasma	O
ACTH	B-GENE-Y
after	O
both	O
loperamide	B-CHEMICAL
(	O
from	O
30	O
+	O
/	O
-	O
16	O
.	O
6	O
to	O
a	O
peak	O
of	O
108	O
+	O
/	O
-	O
31	O
pmol	O
/	O
l	O
)	O
and	O
placebo	O
(	O
from	O
98	O
.	O
5	O
+	O
/	O
-	O
47	O
to	O
211	O
+	O
/	O
-	O
61	O
.	O
7	O
pmol	O
/	O
l	O
)	O
:	O
the	O
interaction	O
between	O
treatments	O
and	O
time	O
was	O
significant	O
,	O
and	O
the	O
first	O
phase	O
of	O
CRH	B-GENE-Y
-	O
induced	O
ACTH	B-GENE-Y
secretion	O
was	O
significantly	O
lower	O
after	O
loperamide	B-CHEMICAL
.	O

These	O
data	O
demonstrate	O
that	O
loperamide	B-CHEMICAL
differently	O
modifies	O
the	O
stimulatory	O
action	O
of	O
LVP	B-CHEMICAL
and	O
CRH	B-GENE-Y
on	O
ACTH	B-GENE-Y
secretion	O
:	O
namely	O
,	O
LVP	B-CHEMICAL
and	O
loperamide	B-CHEMICAL
act	O
in	O
an	O
additive	O
manner	O
,	O
while	O
CRH	B-GENE-Y
and	O
loperamide	B-CHEMICAL
interact	O
in	O
a	O
non	O
additive	O
way	O
.	O

Although	O
these	O
findings	O
might	O
be	O
explained	O
by	O
the	O
involvement	O
of	O
different	O
intracellular	O
ACTH	B-GENE-Y
-	O
secreting	O
mechanisms	O
,	O
an	O
influence	O
of	O
loperamide	B-CHEMICAL
on	O
some	O
suprapituitary	O
factors	O
modulating	O
the	O
ACTH	B-GENE-Y
response	O
is	O
suggested	O
.	O

A	O
naloxone	B-CHEMICAL
-	I-CHEMICAL
steroid	I-CHEMICAL
hybrid	I-CHEMICAL
azine	I-CHEMICAL
with	O
selective	O
and	O
long	O
-	O
acting	O
opioid	O
antagonism	O
at	O
delta	B-GENE-Y
receptors	I-GENE-Y
in	O
vitro	O
.	O

The	O
interaction	O
of	O
naloxone	B-CHEMICAL
estrone	I-CHEMICAL
azine	I-CHEMICAL
(	O
N	B-CHEMICAL
-	I-CHEMICAL
EH	I-CHEMICAL
)	O
with	O
various	O
opioid	B-GENE-N
receptor	I-GENE-N
types	O
was	O
studied	O
in	O
vitro	O
.	O

Its	O
potency	O
as	O
an	O
antagonist	O
of	O
opioid	O
effects	O
was	O
compared	O
to	O
that	O
of	O
naloxone	B-CHEMICAL
on	O
the	O
electrically	O
evoked	O
contractions	O
of	O
mouse	O
vas	O
deferens	O
(	O
Mvd	O
)	O
and	O
guinea	O
pig	O
ileum	O
myenteric	O
plexus	O
longitudinal	O
muscle	O
(	O
Gpi	O
)	O
preparations	O
.	O

N	B-CHEMICAL
-	I-CHEMICAL
EH	I-CHEMICAL
was	O
found	O
to	O
be	O
9	O
-	O
fold	O
more	O
potent	O
than	O
naloxone	B-CHEMICAL
in	O
antagonizing	O
the	O
effects	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
Ala2	I-CHEMICAL
-	I-CHEMICAL
Leu5	I-CHEMICAL
-	I-CHEMICAL
enkephalin	I-CHEMICAL
in	O
the	O
Mvd	O
and	O
22	O
-	O
fold	O
less	O
potent	O
in	O
antagonizing	O
normorphine	B-CHEMICAL
in	O
the	O
Gpi	O
.	O

In	O
the	O
Mvd	O
,	O
the	O
recovery	O
half	O
-	O
time	O
for	O
N	B-CHEMICAL
-	I-CHEMICAL
EH	I-CHEMICAL
was	O
longer	O
than	O
1000	O
min	O
.	O

Neither	O
compound	O
showed	O
agonism	O
.	O

The	O
two	O
compounds	O
were	O
also	O
compared	O
for	O
their	O
capacity	O
to	O
displace	O
the	O
binding	O
of	O
3H	B-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
Ala2	I-CHEMICAL
-	I-CHEMICAL
Leu5	I-CHEMICAL
-	I-CHEMICAL
enkephalin	I-CHEMICAL
,	O
3H	B-CHEMICAL
-	I-CHEMICAL
dihydromorphine	I-CHEMICAL
,	O
and	O
3H	B-CHEMICAL
-	I-CHEMICAL
ethylketocyclazocine	I-CHEMICAL
to	O
rat	O
brain	O
membranes	O
under	O
conditions	O
where	O
delta	O
,	O
mu	O
,	O
and	O
kappa	O
sites	O
were	O
labeled	O
.	O

The	O
relative	O
affinities	O
were	O
0	O
.	O
70	O
,	O
0	O
.	O
16	O
,	O
and	O
0	O
.	O
14	O
for	O
N	B-CHEMICAL
-	I-CHEMICAL
EH	I-CHEMICAL
and	O
0	O
.	O
05	O
,	O
0	O
.	O
87	O
,	O
and	O
0	O
.	O
08	O
for	O
naloxone	B-CHEMICAL
,	O
respectively	O
.	O

Thus	O
,	O
compared	O
to	O
naloxone	B-CHEMICAL
,	O
which	O
is	O
mu	O
selective	O
,	O
N	B-CHEMICAL
-	I-CHEMICAL
EH	I-CHEMICAL
is	O
a	O
delta	O
-	O
selective	O
antagonist	O
.	O

Actions	O
of	O
nizatidine	B-CHEMICAL
,	O
a	O
selective	O
histamine	B-GENE-N
H2	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
on	O
gastric	O
acid	O
secretion	O
in	O
dogs	O
,	O
rats	O
and	O
frogs	O
.	O

Nizatidine	B-CHEMICAL
(	O
LY139037	B-CHEMICAL
)	O
,	O
a	O
selective	O
histamine	B-GENE-N
H2	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
gastric	O
acid	O
secretion	O
.	O

It	O
was	O
17	O
.	O
8	O
times	O
as	O
active	O
as	O
cimetidine	B-CHEMICAL
on	O
histamine	B-CHEMICAL
(	O
10	O
(	O
-	O
5	O
)	O
M	O
)	O
-	O
induced	O
secretion	O
from	O
the	O
isolated	O
gastric	O
mucosa	O
of	O
the	O
bullfrog	O
.	O

Nizatidine	B-CHEMICAL
was	O
8	O
.	O
9	O
times	O
as	O
active	O
as	O
cimetidine	B-CHEMICAL
on	O
basal	O
acid	O
secretion	O
of	O
the	O
chronic	O
gastric	O
fistula	O
rats	O
after	O
s	O
.	O
c	O
.	O
administration	O
.	O

Against	O
acid	O
secretion	O
from	O
the	O
vagally	O
innervated	O
gastric	O
fistula	O
and	O
Heidenhain	O
pouch	O
of	O
dogs	O
stimulated	O
with	O
submaximal	O
doses	O
of	O
histamine	B-CHEMICAL
,	O
methacholine	B-CHEMICAL
and	O
gastrin	B-GENE-Y
,	O
nizatidine	B-CHEMICAL
was	O
,	O
respectively	O
,	O
6	O
.	O
5	O
,	O
5	O
and	O
4	O
.	O
7	O
times	O
as	O
active	O
as	O
cimetidine	B-CHEMICAL
by	O
i	O
.	O
v	O
.	O
administration	O
.	O

Nizatidine	B-CHEMICAL
was	O
very	O
well	O
absorbed	O
from	O
the	O
gut	O
and	O
was	O
5	O
to	O
10	O
times	O
as	O
active	O
as	O
cimetidine	B-CHEMICAL
on	O
gastric	O
acid	O
secretion	O
of	O
dogs	O
induced	O
by	O
submaximal	O
and	O
maximal	O
doses	O
of	O
histamine	B-CHEMICAL
when	O
given	O
p	O
.	O
o	O
.	O

Equal	O
molar	O
doses	O
of	O
nizatidine	B-CHEMICAL
showed	O
equal	O
peak	O
effects	O
when	O
given	O
i	O
.	O
v	O
.	O
,	O
s	O
.	O
c	O
.	O
or	O
i	O
.	O
m	O
.	O

Pharmacological	O
data	O
indicate	O
that	O
nizatidine	B-CHEMICAL
is	O
safe	O
and	O
effective	O
as	O
an	O
agent	O
for	O
the	O
control	O
of	O
excessive	O
gastric	O
acid	O
secretion	O
.	O

Effects	O
of	O
ORF	B-CHEMICAL
17583	I-CHEMICAL
,	O
other	O
histamine	B-GENE-N
H2	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonists	O
and	O
omeprazole	B-CHEMICAL
on	O
gastric	O
acid	O
secretory	O
states	O
in	O
rats	O
and	O
dogs	O
.	O

ORF	B-CHEMICAL
17583	I-CHEMICAL
,	O
a	O
histamine	B-GENE-N
H2	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonist	O
,	O
inhibited	O
gastric	O
acid	O
secretion	O
in	O
pylorus	O
-	O
ligated	O
rats	O
(	O
ED50	O
=	O
4	O
.	O
9	O
mg	O
/	O
kg	O
intraduodenal	O
;	O
3	O
.	O
4	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
;	O
and	O
0	O
.	O
21	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
and	O
in	O
total	O
gastric	O
fistula	O
or	O
Heidenhain	O
pouch	O
dogs	O
stimulated	O
by	O
betazole	B-CHEMICAL
(	O
ED50	O
=	O
0	O
.	O
12	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
and	O
0	O
.	O
08	O
mg	O
/	O
kg	O
i	O
.	O
v	O
.	O
)	O
,	O
histamine	B-CHEMICAL
,	O
tetragastrin	B-CHEMICAL
,	O
bethanechol	B-CHEMICAL
,	O
2	B-CHEMICAL
-	I-CHEMICAL
deoxy	I-CHEMICAL
-	I-CHEMICAL
D	I-CHEMICAL
-	I-CHEMICAL
glucose	I-CHEMICAL
or	O
a	O
meal	O
(	O
ED50	O
values	O
ranged	O
from	O
0	O
.	O
11	O
-	O
0	O
.	O
26	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

The	O
nonspecific	O
inhibition	O
of	O
gastric	O
acid	O
by	O
ORF	B-CHEMICAL
17583	I-CHEMICAL
supports	O
the	O
existence	O
of	O
interdependence	O
between	O
histamine	B-GENE-N
and	I-GENE-N
the	I-GENE-N
gastrin	I-GENE-N
and	I-GENE-N
cholinergic	I-GENE-N
receptors	I-GENE-N
on	O
the	O
parietal	O
cell	O
surface	O
.	O

Antisecretory	O
potency	O
of	O
ORF	B-CHEMICAL
17583	I-CHEMICAL
after	O
intraduodenal	O
administration	O
in	O
pylorus	O
-	O
ligated	O
rats	O
was	O
6	O
.	O
4	O
times	O
greater	O
than	O
cimetidine	B-CHEMICAL
,	O
1	O
.	O
8	O
times	O
greater	O
than	O
ranitidine	B-CHEMICAL
,	O
equal	O
to	O
that	O
of	O
omeprazole	B-CHEMICAL
and	O
8	O
times	O
less	O
than	O
that	O
of	O
famotidine	B-CHEMICAL
.	O

Oral	O
antisecretory	O
potency	O
of	O
ORF	B-CHEMICAL
17583	I-CHEMICAL
in	O
gastric	O
fistula	O
dogs	O
was	O
31	O
times	O
greater	O
than	O
cimetidine	B-CHEMICAL
,	O
3	O
.	O
7	O
times	O
greater	O
than	O
ranitidine	B-CHEMICAL
and	O
equal	O
to	O
that	O
of	O
omeprazole	B-CHEMICAL
and	O
famotidine	B-CHEMICAL
.	O

Studies	O
using	O
equieffective	O
antisecretory	O
doses	O
of	O
ORF	B-CHEMICAL
17583	I-CHEMICAL
and	O
ranitidine	B-CHEMICAL
in	O
dogs	O
suggested	O
that	O
ORF	B-CHEMICAL
17583	I-CHEMICAL
has	O
a	O
short	O
duration	O
of	O
antisecretory	O
activity	O
similar	O
to	O
that	O
of	O
ranitidine	B-CHEMICAL
.	O

Tamoxifen	B-CHEMICAL
and	O
fluoxymesterone	B-CHEMICAL
versus	O
tamoxifen	B-CHEMICAL
and	O
danazol	B-CHEMICAL
in	O
metastatic	O
breast	O
cancer	O
-	O
-	O
a	O
randomized	O
study	O
.	O

A	O
prospective	O
randomized	O
trial	O
of	O
tamoxifen	B-CHEMICAL
and	O
fluoxymesterone	B-CHEMICAL
versus	O
tamoxifen	B-CHEMICAL
and	O
danazol	B-CHEMICAL
in	O
metastatic	O
breast	O
cancer	O
was	O
conducted	O
from	O
December	O
1980	O
to	O
September	O
1985	O
.	O

Patients	O
were	O
eligible	O
regardless	O
of	O
site	O
of	O
disease	O
,	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
status	O
,	O
or	O
age	O
.	O

Sixty	O
-	O
two	O
of	O
sixty	O
-	O
three	O
randomized	O
patients	O
were	O
evaluable	O
for	O
response	O
.	O

Overall	O
response	O
for	O
tamoxifen	B-CHEMICAL
and	O
fluoxymesterone	B-CHEMICAL
was	O
11	O
%	O
with	O
61	O
%	O
stabilization	O
of	O
disease	O
,	O
versus	O
12	O
%	O
response	O
rate	O
for	O
tamoxifen	B-CHEMICAL
and	O
danazol	B-CHEMICAL
with	O
59	O
%	O
stabilization	O
.	O

Toxicities	O
with	O
tamoxifen	B-CHEMICAL
and	O
fluoxymesterone	B-CHEMICAL
were	O
greater	O
with	O
an	O
increase	O
in	O
masculinization	O
.	O

We	O
conclude	O
that	O
the	O
response	O
rates	O
to	O
the	O
combinations	O
of	O
tamoxifen	B-CHEMICAL
and	O
fluoxymesterone	B-CHEMICAL
or	O
tamoxifen	B-CHEMICAL
and	O
danazol	B-CHEMICAL
reported	O
are	O
equivalent	O
in	O
this	O
study	O
but	O
that	O
the	O
increased	O
toxicity	O
with	O
tamoxifen	B-CHEMICAL
and	O
fluoxymesterone	B-CHEMICAL
would	O
make	O
tamoxifen	B-CHEMICAL
and	O
danazol	B-CHEMICAL
the	O
treatment	O
of	O
choice	O
if	O
a	O
combination	O
were	O
to	O
be	O
used	O
.	O

Interleukin	B-GENE-Y
2	I-GENE-Y
toxin	O
:	O
a	O
step	O
toward	O
selective	O
immunomodulation	O
.	O

We	O
have	O
used	O
protein	O
engineering	O
and	O
recombinant	O
DNA	O
methodologies	O
to	O
genetically	O
replace	O
the	O
eukaryotic	B-GENE-N
cell	I-GENE-N
receptor	I-GENE-N
binding	I-GENE-N
domain	I-GENE-N
of	O
diphtheria	O
toxin	O
with	O
interleukin	B-GENE-Y
2	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

The	O
toxin	O
-	O
related	O
T	B-GENE-N
cell	I-GENE-N
growth	I-GENE-N
factor	I-GENE-N
fusion	O
gene	O
has	O
been	O
cloned	O
in	O
Escherichia	O
coli	O
K12	O
.	O

Recombinant	O
strains	O
of	O
E	O
coli	O
produce	O
a	O
68	O
,	O
086	O
K	O
hybrid	O
toxin	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
toxin	O
that	O
retains	O
immunologic	O
properties	O
intrinsic	O
to	O
both	O
its	O
diphtheria	O
toxin	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
components	O
.	O

IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
toxin	O
has	O
been	O
found	O
to	O
selectively	O
inhibit	O
protein	O
synthesis	O
in	O
both	O
human	O
and	O
murine	O
T	O
cell	O
lines	O
that	O
bear	O
high	O
affinity	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptors	I-GENE-N
,	O
whereas	O
the	O
hybrid	O
toxin	O
is	O
not	O
active	O
against	O
cells	O
that	O
do	O
not	O
bear	O
this	O
receptor	O
.	O

The	O
cytotoxic	O
action	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
toxin	O
is	O
specifically	O
blocked	O
by	O
free	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
monoclonal	O
antibodies	O
that	O
bind	O
to	O
the	O
p55	B-GENE-Y
(	O
Tac	B-GENE-N
antigen	O
)	O
subunit	O
of	O
the	O
high	O
affinity	O
IL	B-GENE-N
-	I-GENE-N
2	I-GENE-N
receptor	I-GENE-N
.	O

In	O
addition	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
toxin	O
,	O
like	O
diphtheria	O
toxin	O
itself	O
,	O
must	O
pass	O
through	O
an	O
acidic	O
compartment	O
in	O
order	O
to	O
deliver	O
its	O
adenosine	B-GENE-N
diphosphate	I-GENE-N
ribosyl	I-GENE-N
transferase	I-GENE-N
activity	O
to	O
the	O
cytosol	O
of	O
target	O
T	O
cells	O
.	O

In	O
a	O
murine	O
delayed	O
type	O
hypersensitivity	O
(	O
DTH	O
)	O
model	O
system	O
,	O
we	O
have	O
shown	O
that	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
toxin	O
treatment	O
induces	O
a	O
marked	O
immunosuppression	O
.	O

Localization	O
of	O
L	B-GENE-N
-	I-GENE-N
glutamate	I-GENE-N
decarboxylase	I-GENE-N
and	O
GABA	B-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
in	O
the	O
sympathetic	O
ganglia	O
of	O
the	O
rat	O
.	O

The	O
location	O
of	O
L	B-GENE-N
-	I-GENE-N
glutamate	I-GENE-N
decarboxylase	I-GENE-N
and	O
gamma	B-GENE-Y
-	I-GENE-Y
aminobutyrate	I-GENE-Y
(	I-GENE-Y
GABA	I-GENE-Y
)	I-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
in	O
the	O
superior	O
cervical	O
ganglion	O
and	O
in	O
the	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
of	O
the	O
rat	O
was	O
studied	O
by	O
an	O
indirect	O
immunofluorescence	O
method	O
and	O
by	O
immunoelectron	O
microscopy	O
,	O
with	O
specific	O
antisera	O
raised	O
in	O
rabbits	O
against	O
the	O
corresponding	O
enzymes	O
.	O

In	O
light	O
microscopy	O
,	O
several	O
glutamate	B-GENE-N
decarboxylase	I-GENE-N
-	O
or	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
-	O
immunoreactive	O
principal	O
nerve	O
cells	O
were	O
detected	O
in	O
the	O
superior	O
cervical	O
ganglion	O
and	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
.	O

In	O
addition	O
,	O
numerous	O
small	O
cells	O
in	O
both	O
the	O
superior	O
cervical	O
ganglion	O
and	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
showed	O
intense	O
immunoreactivity	O
to	O
glutamate	B-GENE-N
decarboxylase	I-GENE-N
or	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
.	O

The	O
small	O
cells	O
were	O
10	O
-	O
20	O
micron	O
in	O
diameter	O
and	O
resembled	O
in	O
size	O
and	O
morphology	O
the	O
small	O
intensely	O
fluorescent	O
cells	O
.	O

In	O
consecutive	O
sections	O
,	O
the	O
small	O
glutamate	B-GENE-N
decarboxylase	I-GENE-N
-	O
immunoreactive	O
cell	O
clusters	O
also	O
showed	O
immunoreactivity	O
to	O
tyrosine	B-GENE-Y
hydroxylase	I-GENE-Y
,	O
suggesting	O
that	O
these	O
cells	O
contain	O
the	O
enzymes	O
for	O
both	O
GABA	B-CHEMICAL
and	O
catecholamine	B-CHEMICAL
synthesis	O
.	O

In	O
the	O
superior	O
cervical	O
ganglion	O
and	O
in	O
the	O
coeliac	O
-	O
superior	O
mesenteric	O
ganglion	O
complex	O
,	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
was	O
also	O
localized	O
in	O
fibre	O
-	O
like	O
processes	O
around	O
and	O
between	O
the	O
principal	O
nerve	O
cells	O
,	O
in	O
nerve	O
trunks	O
traversing	O
the	O
ganglia	O
,	O
and	O
around	O
or	O
in	O
close	O
contact	O
with	O
ganglionic	O
blood	O
vessels	O
.	O

Furthermore	O
,	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
was	O
observed	O
in	O
fibre	O
-	O
like	O
structures	O
close	O
to	O
the	O
capsule	O
of	O
the	O
ganglia	O
.	O

Division	O
of	O
the	O
preganglionic	O
nerve	O
trunk	O
of	O
the	O
superior	O
cervical	O
ganglion	O
caused	O
no	O
detectable	O
change	O
in	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
in	O
the	O
ganglion	O
.	O

In	O
immunoelectron	O
microscopy	O
of	O
the	O
superior	O
cervical	O
ganglion	O
,	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
was	O
localized	O
in	O
nerve	O
fibres	O
in	O
association	O
with	O
neurotubules	O
.	O

A	O
large	O
number	O
of	O
GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
labelled	O
principal	O
nerve	O
cells	O
were	O
detected	O
,	O
containing	O
immunoreactivity	O
evenly	O
distributed	O
in	O
their	O
cytoplasm	O
.	O

GABA	B-GENE-Y
-	I-GENE-Y
transaminase	I-GENE-Y
immunoreactivity	O
was	O
also	O
observed	O
in	O
satellite	O
cells	O
and	O
their	O
processes	O
in	O
the	O
superior	O
cervical	O
ganglion	O
.	O

The	O
present	O
immunocytochemical	O
results	O
provide	O
evidence	O
that	O
the	O
rat	O
sympathetic	O
ganglia	O
contain	O
an	O
intrinsic	O
neuronal	O
system	O
showing	O
histochemical	O
markers	O
for	O
GABA	B-CHEMICAL
synthesis	O
and	O
inactivation	O
,	O
but	O
its	O
functional	O
role	O
in	O
the	O
modulation	O
of	O
ganglionic	O
neurotransmission	O
remains	O
to	O
be	O
established	O
.	O

Effects	O
of	O
some	O
mono	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
bisquaternary	I-CHEMICAL
ammonium	I-CHEMICAL
compounds	O
on	O
the	O
reactivatability	O
of	O
soman	B-CHEMICAL
-	O
inhibited	O
human	B-GENE-Y
acetylcholinesterase	I-GENE-Y
in	O
vitro	O
.	O

Acetylcholinesterase	B-GENE-Y
(	O
AChE	B-GENE-Y
)	O
inhibited	O
by	O
the	O
organophosphate	B-CHEMICAL
soman	B-CHEMICAL
(	O
1	B-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
trimethyl	I-CHEMICAL
-	I-CHEMICAL
propylmethylphosphonofluoridate	I-CHEMICAL
)	O
rapidly	O
becomes	O
resistant	O
to	O
reactivation	O
by	O
oximes	B-CHEMICAL
due	O
to	O
dealkylation	O
of	O
the	O
soman	B-CHEMICAL
-	O
enzyme	O
complex	O
.	O

This	O
reaction	O
is	O
called	O
aging	O
.	O

The	O
effect	O
of	O
the	O
four	O
mono	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
bisquaternary	I-CHEMICAL
ammonium	I-CHEMICAL
compounds	O
tetramethylammonium	B-CHEMICAL
(	O
TMA	B-CHEMICAL
)	O
,	O
hexamethonium	B-CHEMICAL
,	O
decamethonium	B-CHEMICAL
and	O
suxamethonium	B-CHEMICAL
on	O
the	O
reactivatability	O
of	O
soman	B-CHEMICAL
-	O
inhibited	O
,	O
solubilized	O
AChE	B-GENE-Y
from	O
human	O
erythrocytes	O
was	O
investigated	O
in	O
vitro	O
.	O

All	O
compounds	O
were	O
reversible	O
inhibitors	O
of	O
AChE	B-GENE-Y
;	O
the	O
respective	O
dissociation	O
constants	O
and	O
the	O
type	O
of	O
inhibition	O
exhibited	O
considerable	O
differences	O
.	O

The	O
affinities	O
to	O
both	O
the	O
active	O
and	O
the	O
allosteric	O
site	O
were	O
considerably	O
higher	O
for	O
suxamethonium	B-CHEMICAL
(	O
Kii	O
81	O
.	O
3	O
microM	O
;	O
Ki	O
15	O
.	O
9	O
microM	O
)	O
and	O
decamethonium	B-CHEMICAL
(	O
Kii	O
15	O
.	O
4	O
microM	O
;	O
Ki	O
4	O
.	O
4	O
microM	O
)	O
than	O
for	O
TMA	B-CHEMICAL
(	O
Kii	O
1	O
mM	O
;	O
Ki	O
289	O
.	O
6	O
microM	O
)	O
and	O
hexamethonium	B-CHEMICAL
(	O
Kii	O
4	O
.	O
5	O
mM	O
;	O
Ki	O
331	O
.	O
8	O
microM	O
)	O
.	O

The	O
reactivation	O
experiments	O
were	O
performed	O
in	O
a	O
four	O
-	O
step	O
procedure	O
(	O
soman	B-CHEMICAL
-	O
inhibition	O
at	O
0	O
degree	O
and	O
pH	O
10	O
,	O
aging	O
at	O
37	O
degrees	O
and	O
pH	O
7	O
.	O
3	O
,	O
reactivation	O
by	O
the	O
oxime	B-CHEMICAL
HI	O
6	O
at	O
37	O
degrees	O
and	O
pH	O
7	O
.	O
3	O
followed	O
by	O
AChE	B-GENE-Y
assay	O
)	O
.	O

After	O
these	O
four	O
steps	O
(	O
total	O
duration	O
55	O
min	O
)	O
,	O
AChE	B-GENE-Y
was	O
inhibited	O
by	O
soman	O
to	O
95	O
-	O
100	O
%	O
.	O

HI	O
6	O
could	O
reactivate	O
about	O
20	O
%	O
of	O
the	O
inhibited	O
enzyme	O
.	O

All	O
effectors	O
increased	O
the	O
AChE	B-GENE-Y
reactivatability	O
by	O
HI	O
6	O
when	O
added	O
before	O
aging	O
was	O
started	O
.	O

The	O
maximal	O
increase	O
in	O
reactivatability	O
was	O
higher	O
in	O
the	O
presence	O
of	O
1	O
.	O
6	O
mM	O
suxamethonium	B-CHEMICAL
(	O
+	O
35	O
.	O
8	O
%	O
)	O
and	O
150	O
microM	O
decamethonium	B-CHEMICAL
(	O
+	O
40	O
%	O
)	O
than	O
of	O
22	O
mM	O
TMA	B-CHEMICAL
(	O
+	O
22	O
.	O
5	O
%	O
)	O
and	O
8	O
.	O
3	O
mM	O
hexamethonium	B-CHEMICAL
(	O
+	O
19	O
.	O
2	O
%	O
)	O
.	O

If	O
the	O
effectors	O
were	O
added	O
after	O
5	O
min	O
of	O
aging	O
they	O
increased	O
the	O
activity	O
of	O
soman	B-CHEMICAL
-	O
inhibited	O
AChE	B-GENE-Y
,	O
but	O
to	O
a	O
considerably	O
smaller	O
extent	O
than	O
HI	O
6	O
.	O

A	O
good	O
correlation	O
of	O
the	O
respective	O
Kii	O
values	O
and	O
the	O
effective	O
concentrations	O
of	O
these	O
drugs	O
was	O
observed	O
,	O
indicating	O
that	O
an	O
allosteric	O
binding	O
site	O
of	O
AChE	B-GENE-Y
might	O
be	O
involved	O
in	O
the	O
protective	O
effect	O
of	O
these	O
drugs	O
.	O

Pharmacological	O
properties	O
of	O
lorglumide	B-CHEMICAL
as	O
a	O
member	O
of	O
a	O
new	O
class	O
of	O
cholecystokinin	B-GENE-Y
antagonists	O
.	O

Derivatives	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
dipentylamino	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
pentanoic	I-CHEMICAL
acid	I-CHEMICAL
are	O
a	O
new	O
class	O
of	O
non	O
-	O
peptide	O
cholecystokinin	B-GENE-Y
(	O
CCK	B-GENE-Y
)	O
antagonists	O
.	O

The	O
most	O
potent	O
compound	O
,	O
D	B-CHEMICAL
,	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
dichlorobenzoylamino	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
dipentylamino	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
5	I-CHEMICAL
-	I-CHEMICAL
oxo	I-CHEMICAL
-	I-CHEMICAL
pen	I-CHEMICAL
tanoic	I-CHEMICAL
acid	I-CHEMICAL
(	O
lorglumide	B-CHEMICAL
,	O
CR	B-CHEMICAL
1409	I-CHEMICAL
)	O
,	O
has	O
a	O
great	O
affinity	O
for	O
the	O
pancreatic	O
CCK	B-GENE-N
receptors	I-GENE-N
and	O
is	O
a	O
competitive	O
,	O
specific	O
and	O
potent	O
CCK	B-GENE-Y
antagonist	O
on	O
the	O
smooth	O
muscles	O
of	O
the	O
gall	O
bladder	O
and	O
ileum	O
of	O
the	O
guinea	O
pig	O
and	O
on	O
the	O
CCK	B-GENE-Y
-	O
induced	O
amylase	B-GENE-N
secretion	O
of	O
isolated	O
pancreatic	O
acini	O
.	O

In	O
vivo	O
lorglumide	B-CHEMICAL
antagonizes	O
the	O
contraction	O
of	O
the	O
gall	O
bladder	O
of	O
the	O
guinea	O
pig	O
and	O
of	O
the	O
dog	O
provoked	O
by	O
i	O
.	O
v	O
.	O
CCK	B-GENE-N
-	I-GENE-N
8	I-GENE-N
or	O
ceruletide	B-CHEMICAL
(	O
caerulein	B-CHEMICAL
)	O
.	O

It	O
antagonizes	O
the	O
satiety	O
effect	O
of	O
CCK	B-GENE-Y
-	I-GENE-Y
8	I-GENE-Y
in	O
the	O
rat	O
and	O
is	O
protective	O
against	O
ceruletide	B-CHEMICAL
-	O
,	O
taurocholate	B-CHEMICAL
-	O
and	O
diet	O
-	O
induced	O
pancreatitis	O
.	O

Lorglumide	B-CHEMICAL
is	O
therefore	O
a	O
useful	O
pharmacological	O
tool	O
to	O
study	O
the	O
functions	O
of	O
CCK	B-GENE-Y
.	O

For	O
its	O
pharmacological	O
properties	O
,	O
its	O
relatively	O
low	O
toxicity	O
and	O
because	O
it	O
is	O
active	O
also	O
after	O
oral	O
administration	O
,	O
lorglumide	B-CHEMICAL
is	O
a	O
candidate	O
for	O
diagnostic	O
or	O
therapeutic	O
use	O
in	O
man	O
when	O
an	O
involvement	O
of	O
CCK	B-GENE-Y
is	O
suspected	O
.	O

Mechanism	O
of	O
the	O
haemostatic	O
effect	O
of	O
ethanolamine	B-CHEMICAL
oleate	I-CHEMICAL
in	O
the	O
injection	O
sclerotherapy	O
for	O
oesophageal	O
varices	O
.	O

Changes	O
in	O
coagulation	O
and	O
fibrinolysis	O
were	O
investigated	O
in	O
20	O
patients	O
with	O
oesophageal	O
varices	O
,	O
who	O
underwent	O
endoscopic	O
injection	O
sclerotherapy	O
(	O
EIS	O
)	O
with	O
5	O
per	O
cent	O
ethanolamine	B-CHEMICAL
oleate	I-CHEMICAL
(	O
EO	B-CHEMICAL
)	O
,	O
by	O
means	O
of	O
serial	O
determination	O
of	O
plasma	O
fibrinopeptide	B-GENE-Y
A	I-GENE-Y
(	O
FPA	B-GENE-Y
)	O
and	O
fibrinopeptide	B-GENE-Y
B	I-GENE-Y
beta	I-GENE-Y
15	I-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
(	O
B	B-GENE-Y
beta	I-GENE-Y
15	I-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
)	O
.	O

One	O
hour	O
after	O
the	O
completion	O
of	O
EIS	O
,	O
the	O
value	O
of	O
FPA	B-GENE-Y
was	O
significantly	O
increased	O
to	O
38	O
.	O
1	O
+	O
/	O
-	O
11	O
.	O
1	O
ng	O
/	O
ml	O
(	O
mean	O
+	O
/	O
-	O
s	O
.	O
e	O
.	O
m	O
.	O
)	O
from	O
a	O
pre	O
-	O
EIS	O
value	O
of	O
7	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
4	O
ng	O
/	O
ml	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
it	O
gradually	O
returned	O
to	O
normal	O
range	O
by	O
48	O
h	O
after	O
EIS	O
.	O

A	O
very	O
similar	O
change	O
was	O
observed	O
in	O
the	O
value	O
of	O
B	B-GENE-Y
beta	I-GENE-Y
15	I-GENE-Y
-	I-GENE-Y
42	I-GENE-Y
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

These	O
observations	O
indicated	O
that	O
EIS	O
provokes	O
transient	O
activation	O
of	O
coagulation	O
and	O
fibrinolysis	O
.	O

In	O
vitro	O
studies	O
,	O
however	O
,	O
revealed	O
that	O
EO	B-CHEMICAL
inhibits	O
fibrin	B-GENE-N
clot	O
formation	O
because	O
of	O
the	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
chelating	O
ability	O
of	O
its	O
constituent	O
ethanolamine	B-CHEMICAL
,	O
although	O
oleate	B-CHEMICAL
or	O
benzyl	B-CHEMICAL
alcohol	I-CHEMICAL
exhibited	O
procoagulant	O
activity	O
in	O
FPA	B-GENE-Y
formation	O
in	O
vitro	O
.	O

Nevertheless	O
,	O
an	O
external	O
application	O
of	O
EO	B-CHEMICAL
or	O
oleate	B-CHEMICAL
over	O
decapsulized	O
kidney	O
of	O
rat	O
resulted	O
in	O
a	O
significant	O
accumulation	O
of	O
125I	B-CHEMICAL
-	O
labelled	O
fibrin	B-GENE-N
(	I-GENE-N
ogen	I-GENE-N
)	I-GENE-N
.	O

From	O
these	O
results	O
it	O
was	O
suggested	O
that	O
intravascular	O
injection	O
of	O
EO	B-CHEMICAL
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
coagulation	O
in	O
vitro	O
,	O
activates	O
the	O
local	O
coagulation	O
system	O
.	O

The	O
activation	O
may	O
be	O
accelerated	O
by	O
an	O
acute	O
inflammatory	O
process	O
provoked	O
by	O
oleate	B-CHEMICAL
,	O
which	O
is	O
supported	O
by	O
such	O
clinical	O
manifestations	O
as	O
mild	O
fever	O
,	O
retrosternal	O
pain	O
leukocytosis	O
and	O
an	O
increase	O
in	O
plasma	O
fibrinogen	B-GENE-N
level	O
which	O
was	O
observed	O
in	O
all	O
during	O
the	O
period	O
.	O

Astemizole	B-CHEMICAL
,	O
a	O
potent	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
:	O
effect	O
in	O
allergic	O
rhinoconjunctivitis	O
,	O
on	O
antigen	O
and	O
histamine	B-CHEMICAL
induced	O
skin	O
weal	O
responses	O
and	O
relationship	O
to	O
serum	O
levels	O
.	O

The	O
efficacy	O
of	O
astemizole	B-CHEMICAL
,	O
a	O
new	O
,	O
long	O
acting	O
,	O
oral	O
histamine	B-GENE-Y
H1	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
was	O
compared	O
to	O
placebo	O
for	O
the	O
treatment	O
of	O
allergic	O
rhinitis	O
and	O
conjunctivitis	O
during	O
the	O
grass	O
pollen	O
season	O
of	O
1982	O
.	O

Sixty	O
-	O
three	O
patients	O
with	O
a	O
positive	O
skin	O
prick	O
test	O
to	O
grass	O
pollen	O
and	O
current	O
symptoms	O
participated	O
in	O
an	O
8	O
week	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
study	O
.	O

Astemizole	B-CHEMICAL
,	O
10	O
mg	O
,	O
was	O
significantly	O
better	O
than	O
placebo	O
in	O
alleviating	O
both	O
nose	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
eye	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
symptoms	O
despite	O
significantly	O
greater	O
use	O
of	O
the	O
reserve	O
medication	O
,	O
clemastine	B-CHEMICAL
,	O
by	O
the	O
placebo	O
group	O
(	O
P	O
less	O
than	O
0	O
.	O
003	O
)	O
.	O

There	O
was	O
a	O
lag	O
period	O
of	O
5	O
days	O
after	O
initiation	O
of	O
therapy	O
before	O
treatment	O
benefit	O
became	O
manifest	O
.	O

Subdivision	O
of	O
nasal	O
symptoms	O
indicated	O
significant	O
improvement	O
compared	O
to	O
placebo	O
over	O
the	O
8	O
weeks	O
for	O
sneezing	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
and	O
runny	O
nose	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
but	O
not	O
blocked	O
nose	O
.	O

The	O
absence	O
of	O
effect	O
on	O
nasal	O
blockage	O
was	O
confirmed	O
by	O
parallel	O
measurement	O
of	O
nasal	O
calibre	O
by	O
body	O
plethysmography	O
.	O

The	O
antihistaminic	O
potency	O
of	O
astemizole	B-CHEMICAL
was	O
indicated	O
by	O
an	O
80	O
%	O
inhibition	O
of	O
the	O
histamine	B-CHEMICAL
induced	O
skin	O
weal	O
response	O
after	O
8	O
weeks	O
therapy	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
serum	O
drug	O
levels	O
and	O
%	O
inhibition	O
of	O
histamine	B-CHEMICAL
skin	O
weal	O
(	O
r	O
=	O
0	O
.	O
64	O
,	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Astemizole	B-CHEMICAL
was	O
free	O
from	O
adverse	O
sedative	O
or	O
anticholinergic	O
effects	O
but	O
did	O
cause	O
a	O
mean	O
increase	O
in	O
weight	O
of	O
1	O
.	O
3	O
kg	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
after	O
8	O
weeks	O
therapy	O
,	O
not	O
found	O
with	O
placebo	O
.	O

Characterization	O
of	O
rat	B-GENE-Y
brain	I-GENE-Y
aldosterone	I-GENE-Y
receptors	I-GENE-Y
reveals	O
high	O
affinity	O
for	O
corticosterone	B-CHEMICAL
.	O

The	O
two	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
aldosterone	I-CHEMICAL
-	O
binding	O
proteins	O
of	O
rat	O
brain	O
cytosol	O
were	O
characterized	O
by	O
a	O
dextran	O
-	O
coated	O
charcoal	O
method	O
.	O

With	O
molybdate	B-CHEMICAL
present	O
to	O
stabilize	O
receptors	O
,	O
the	O
affinities	O
of	O
the	O
two	O
sites	O
for	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
aldosterone	I-CHEMICAL
in	O
adrenalectomized	O
perfused	O
rat	O
brain	O
cytosols	O
were	O
0	O
.	O
28	O
and	O
18	O
.	O
0	O
nM	O
at	O
4	O
C	O
.	O

High	O
affinity	O
sites	O
comprised	O
15	O
%	O
of	O
the	O
total	O
receptor	O
number	O
.	O

A	O
small	O
contamination	O
of	O
perfused	O
brain	O
cytosol	O
preparations	O
with	O
corticosteroid	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
globulin	I-GENE-Y
(	O
CBG	B-GENE-Y
)	O
was	O
found	O
.	O

However	O
,	O
due	O
to	O
the	O
very	O
high	O
affinity	O
of	O
CBG	B-GENE-Y
for	O
corticosterone	B-CHEMICAL
at	O
4	O
C	O
,	O
this	O
slight	O
contamination	O
resulted	O
in	O
significant	O
alterations	O
in	O
the	O
apparent	O
affinity	O
of	O
steroids	B-CHEMICAL
competing	O
for	O
aldosterone	B-CHEMICAL
-	O
binding	O
sites	O
.	O

Selective	O
precipitation	O
of	O
cytosol	O
receptors	O
with	O
36	O
%	O
(	B-CHEMICAL
NH4	I-CHEMICAL
)	I-CHEMICAL
2SO4	I-CHEMICAL
reduced	O
CBG	B-GENE-Y
concentrations	O
to	O
negligible	O
levels	O
.	O

After	O
blockade	O
of	O
low	O
affinity	O
sites	O
with	O
a	O
highly	O
selective	O
glucocorticoid	O
(	O
RU	B-CHEMICAL
26988	I-CHEMICAL
)	O
,	O
the	O
order	O
of	O
steroids	B-CHEMICAL
in	O
competing	O
for	O
the	O
high	O
affinity	O
receptor	O
was	O
desoxycorticosterone	B-CHEMICAL
greater	O
than	O
fludrocortisone	B-CHEMICAL
greater	O
than	O
corticosterone	B-CHEMICAL
greater	O
than	O
aldosterone	B-CHEMICAL
greater	O
than	O
progesterone	B-CHEMICAL
greater	O
than	O
dexamethasone	B-CHEMICAL
.	O

Readdition	O
of	O
a	O
small	O
quantity	O
of	O
dialyzed	O
serum	O
to	O
cytosol	O
preparations	O
yielded	O
a	O
profile	O
of	O
steroid	B-CHEMICAL
binding	O
similar	O
to	O
that	O
of	O
the	O
kidney	O
mineralocorticoid	B-GENE-Y
receptor	I-GENE-Y
(	O
aldosterone	B-CHEMICAL
greater	O
than	O
desoxycorticosterone	B-CHEMICAL
greater	O
than	O
corticosterone	B-CHEMICAL
)	O
.	O

The	O
distribution	O
of	O
both	O
receptors	O
in	O
brain	O
regions	O
of	O
adrenalectomized	O
rats	O
was	O
determined	O
.	O

Both	O
receptors	O
were	O
at	O
greatest	O
density	O
in	O
the	O
hippocampus	O
and	O
lowest	O
density	O
in	O
the	O
hypothalamus	O
.	O

The	O
high	O
affinity	O
site	O
was	O
at	O
greatest	O
density	O
in	O
limbic	O
regions	O
,	O
whereas	O
the	O
low	O
affinity	O
receptor	O
,	O
apparently	O
identical	O
to	O
the	O
glucocorticoid	B-GENE-N
type	I-GENE-N
II	I-GENE-N
receptor	I-GENE-N
,	O
was	O
at	O
greatest	O
density	O
in	O
cortex	O
and	O
cerebellum	O
.	O

It	O
is	O
concluded	O
that	O
the	O
high	O
affinity	O
aldosterone	B-GENE-Y
receptor	I-GENE-Y
of	O
rat	O
brain	O
,	O
which	O
had	O
been	O
identified	O
in	O
preliminary	O
studies	O
as	O
a	O
mineralocorticoid	B-GENE-Y
receptor	I-GENE-Y
,	O
may	O
bind	O
either	O
corticosterone	B-CHEMICAL
or	O
aldosterone	B-CHEMICAL
in	O
vivo	O
.	O

The	O
pure	O
antiandrogen	O
RU	B-CHEMICAL
23908	I-CHEMICAL
(	O
Anandron	B-CHEMICAL
)	O
,	O
a	O
candidate	O
of	O
choice	O
for	O
the	O
combined	O
antihormonal	O
treatment	O
of	O
prostatic	O
cancer	O
:	O
a	O
review	O
.	O

The	O
nonsteroidal	O
antiandrogen	O
RU	B-CHEMICAL
23908	I-CHEMICAL
(	O
Anandron	B-CHEMICAL
)	O
weakly	O
interacts	O
with	O
the	O
prostatic	O
cytosolic	O
androgen	B-GENE-Y
receptor	I-GENE-Y
and	O
shows	O
a	O
fast	O
dissociation	O
rate	O
.	O

When	O
administered	O
to	O
immature	O
castrated	O
rats	O
up	O
to	O
the	O
daily	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
,	O
it	O
is	O
devoid	O
of	O
any	O
androgenic	O
activity	O
but	O
efficiently	O
blocks	O
the	O
growth	O
-	O
promoting	O
activity	O
of	O
androgens	B-CHEMICAL
on	O
ventral	O
prostate	O
and	O
seminal	O
vesicle	O
weight	O
,	O
thus	O
showing	O
the	O
characteristics	O
of	O
a	O
pure	O
antiandrogen	O
.	O

In	O
intact	O
animals	O
,	O
on	O
the	O
other	O
hand	O
,	O
the	O
antiandrogen	O
administered	O
alone	O
exerts	O
only	O
a	O
partial	O
inhibition	O
of	O
prostate	O
and	O
seminal	O
vesicle	O
weight	O
.	O

This	O
is	O
due	O
to	O
the	O
property	O
of	O
the	O
pure	O
antiandrogen	O
to	O
neutralize	O
the	O
inhibitory	O
feedback	O
effect	O
of	O
androgens	B-CHEMICAL
at	O
the	O
pituitary	O
level	O
on	O
the	O
LH	B-GENE-N
responsiveness	O
to	O
LHRH	B-GENE-Y
,	O
as	O
illustrated	O
in	O
vitro	O
in	O
rat	O
anterior	O
pituitary	O
cells	O
in	O
culture	O
as	O
well	O
as	O
in	O
vivo	O
in	O
intact	O
and	O
castrated	O
animals	O
.	O

In	O
intact	O
animals	O
,	O
neutralization	O
of	O
the	O
inhibitory	O
feedback	O
action	O
of	O
endogenous	O
androgens	B-CHEMICAL
leads	O
to	O
an	O
increased	O
LH	B-GENE-N
and	O
testosterone	B-CHEMICAL
secretion	O
,	O
which	O
partly	O
overcomes	O
the	O
direct	O
action	O
of	O
the	O
antiandrogen	O
at	O
the	O
level	O
of	O
the	O
prostate	O
and	O
seminal	O
vesicles	O
.	O

In	O
fact	O
,	O
the	O
plasma	O
testosterone	B-CHEMICAL
concentration	O
is	O
more	O
than	O
doubled	O
6	O
hr	O
after	O
the	O
administration	O
of	O
10	O
mg	O
of	O
RU	B-CHEMICAL
23908	I-CHEMICAL
while	O
plasma	O
LH	B-GENE-N
and	O
testosterone	B-CHEMICAL
levels	O
are	O
increased	O
by	O
7	O
-	O
and	O
17	O
-	O
fold	O
,	O
respectively	O
,	O
after	O
14	O
days	O
of	O
similar	O
daily	O
treatment	O
.	O

Efficient	O
neutralization	O
of	O
the	O
androgenic	O
action	O
at	O
the	O
prostatic	O
level	O
in	O
intact	O
animals	O
thus	O
requires	O
prevention	O
of	O
this	O
escape	O
phenomenon	O
through	O
inhibition	O
of	O
LH	B-GENE-N
secretion	O
.	O

Although	O
inhibition	O
of	O
LH	B-GENE-N
release	O
can	O
be	O
achieved	O
by	O
estrogen	B-CHEMICAL
and	O
progestins	B-CHEMICAL
,	O
an	O
optimal	O
inhibitory	O
effect	O
on	O
the	O
prostate	O
is	O
obtained	O
by	O
the	O
combined	O
administration	O
of	O
the	O
antiandrogen	O
with	O
an	O
LHRH	B-GENE-Y
agonist	O
that	O
causes	O
a	O
specific	O
blockage	O
of	O
testicular	O
androgen	B-CHEMICAL
biosynthesis	O
as	O
well	O
as	O
an	O
inhibition	O
of	O
the	O
LH	B-GENE-N
responsiveness	O
to	O
LHRH	B-GENE-Y
.	O

Deduced	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
from	O
the	O
bovine	B-GENE-Y
oxytocin	I-GENE-Y
-	I-GENE-Y
neurophysin	I-GENE-Y
I	I-GENE-Y
precursor	I-GENE-Y
cDNA	O
.	O

The	O
nonapeptide	O
hormone	O
oxytocin	B-CHEMICAL
-	O
like	O
arginine	B-GENE-Y
-	I-GENE-Y
vasopressin	I-GENE-Y
(	O
AVP	B-CHEMICAL
)	O
is	O
synthesized	O
as	O
part	O
of	O
a	O
larger	O
precursor	O
polypeptide	O
.	O

The	O
precursor	O
also	O
includes	O
the	O
neurophysin	B-GENE-N
molecule	O
with	O
which	O
the	O
hormone	O
is	O
associated	O
in	O
the	O
neurosecretory	O
granules	O
of	O
the	O
hypothalamo	O
-	O
pituitary	O
tract	O
.	O

A	O
protein	O
of	O
molecular	O
weight	O
(	O
Mr	O
)	O
approximately	O
20	O
,	O
000	O
has	O
been	O
isolated	O
from	O
supraoptic	O
nuclei	O
of	O
rat	O
hypothalami	O
which	O
,	O
after	O
tryptic	O
cleavage	O
,	O
released	O
a	O
neurophysin	B-GENE-N
-	O
like	O
molecule	O
of	O
Mr	O
approximately	O
10	O
,	O
000	O
and	O
an	O
oligopeptide	O
related	O
to	O
oxytocin	B-CHEMICAL
.	O

This	O
result	O
was	O
complemented	O
by	O
in	O
vitro	O
translation	O
of	O
bovine	O
hypothalamic	O
mRNA	O
.	O

Among	O
the	O
primary	O
translation	O
products	O
a	O
single	O
polypeptide	O
of	O
Mr	O
approximately	O
16	O
,	O
500	O
was	O
shown	O
to	O
contain	O
antigenic	O
determinants	O
recognized	O
by	O
specific	O
antisera	O
against	O
bovine	B-GENE-Y
neurophysin	I-GENE-Y
I	I-GENE-Y
and	O
oxytocin	B-CHEMICAL
.	O

Here	O
we	O
report	O
the	O
amino	B-CHEMICAL
acid	I-CHEMICAL
sequence	O
of	O
the	O
bovine	B-GENE-Y
oxytocin	I-GENE-Y
-	I-GENE-Y
neurophysin	I-GENE-Y
I	I-GENE-Y
(	I-GENE-Y
OT	I-GENE-Y
-	I-GENE-Y
NpI	I-GENE-Y
)	I-GENE-Y
precursor	I-GENE-Y
which	O
was	O
derived	O
from	O
sequence	O
analysis	O
of	O
the	O
cloned	O
cDNA	O
.	O

As	O
is	O
the	O
case	O
for	O
the	O
bovine	B-GENE-Y
arginine	I-GENE-Y
-	I-GENE-Y
vasopressin	I-GENE-Y
-	I-GENE-Y
neurophysin	I-GENE-Y
II	I-GENE-Y
(	I-GENE-Y
AVP	I-GENE-Y
-	I-GENE-Y
NpII	I-GENE-Y
)	I-GENE-Y
precursor	I-GENE-Y
,	O
the	O
signal	O
sequence	O
of	O
the	O
OT	B-GENE-Y
-	I-GENE-Y
NpI	I-GENE-Y
precursor	O
is	O
immediately	O
followed	O
by	O
the	O
nonapeptide	O
hormone	O
which	O
is	O
connected	O
to	O
neurophysin	B-GENE-Y
I	I-GENE-Y
by	O
a	O
Gly	B-CHEMICAL
-	I-CHEMICAL
Lys	I-CHEMICAL
-	I-CHEMICAL
Arg	I-CHEMICAL
sequence	O
.	O

A	O
striking	O
feature	O
of	O
the	O
nucleic	O
acid	O
sequence	O
is	O
the	O
197	O
-	O
nucleotide	O
long	O
perfect	O
homology	O
with	O
the	O
AVP	B-GENE-Y
-	I-GENE-Y
NpII	I-GENE-Y
precursor	I-GENE-Y
mRNA	O
sequence	O
encoding	O
the	O
conserved	O
middle	O
part	O
of	O
neurophysins	B-GENE-N
I	I-GENE-N
and	I-GENE-N
II	I-GENE-N
.	O

Inhibition	O
of	O
the	O
uterotropic	O
activity	O
of	O
estrogens	O
and	O
antiestrogens	O
by	O
the	O
short	O
acting	O
antiestrogen	O
LY117018	B-CHEMICAL
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
the	O
dihydroxylated	O
antiestrogen	O
LY117018	B-CHEMICAL
,	O
with	O
a	O
high	O
affinity	O
for	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
and	O
low	O
intrinsic	O
estrogenic	O
activity	O
,	O
could	O
inhibit	O
the	O
uterotropic	O
actions	O
of	O
steroidal	O
[	O
estradiol	B-CHEMICAL
-	I-CHEMICAL
17	I-CHEMICAL
beta	I-CHEMICAL
(	O
E2	B-CHEMICAL
)	O
]	O
and	O
nonsteroidal	O
[	O
ICI	O
3188	O
and	O
trianisylchloroethylene	B-CHEMICAL
(	O
TACE	B-CHEMICAL
)	O
]	O
estrogens	O
in	O
immature	O
rats	O
and	O
also	O
the	O
uterotropic	O
actions	O
of	O
tamoxifen	B-CHEMICAL
and	O
monohydroxytamoxifen	B-CHEMICAL
in	O
the	O
ovariectomized	O
mouse	O
and	O
immature	O
rat	O
.	O

In	O
the	O
first	O
series	O
of	O
experiments	O
,	O
LY117018	B-CHEMICAL
was	O
compared	O
with	O
monohydroxytamoxifen	B-CHEMICAL
.	O

Both	O
antiestrogens	O
inhibited	O
the	O
uterotropic	O
actions	O
of	O
E2	B-CHEMICAL
(	O
0	O
.	O
32	O
micrograms	O
daily	O
)	O
,	O
ICI	O
3188	O
(	O
5	O
micrograms	O
daily	O
)	O
,	O
and	O
TACE	O
(	O
40	O
and	O
160	O
micrograms	O
daily	O
)	O
in	O
a	O
dose	O
-	O
related	O
manner	O
(	O
0	O
.	O
32	O
-	O
82	O
micrograms	O
daily	O
)	O
.	O

The	O
potency	O
of	O
the	O
antiestrogens	O
against	O
E2	O
and	O
ICI	O
3188	O
was	O
similar	O
,	O
however	O
,	O
at	O
higher	O
doses	O
(	O
20	O
.	O
48	O
and	O
82	O
micrograms	O
daily	O
)	O
LY117018	B-CHEMICAL
reduced	O
uterine	O
weights	O
to	O
below	O
the	O
lowest	O
level	O
achieved	O
by	O
monohydroxytamoxifen	B-CHEMICAL
.	O

In	O
contrast	O
,	O
LY117018	B-CHEMICAL
was	O
less	O
effective	O
against	O
the	O
long	O
acting	O
estrogen	O
TACE	O
.	O

The	O
competitive	O
interaction	O
of	O
LY117018	B-CHEMICAL
with	O
tamoxifen	B-CHEMICAL
and	O
monohydroxytamoxifen	B-CHEMICAL
was	O
compared	O
in	O
3	O
-	O
day	O
ovariectomized	O
mouse	O
and	O
immature	O
rat	O
uterine	O
weight	O
tests	O
.	O

Tamoxifen	B-CHEMICAL
and	O
monohydroxytamoxifen	B-CHEMICAL
were	O
fully	O
estrogenic	O
in	O
the	O
mouse	O
(	O
5	O
micrograms	O
daily	O
)	O
and	O
partially	O
estrogenic	O
in	O
the	O
rat	O
(	O
1	O
.	O
5	O
-	O
20	O
micrograms	O
daily	O
)	O
.	O

LY117018	B-CHEMICAL
was	O
a	O
partial	O
estrogen	O
in	O
the	O
mouse	O
and	O
a	O
weekly	O
active	O
partial	O
estrogen	O
in	O
the	O
rat	O
(	O
2	O
.	O
5	O
-	O
120	O
micrograms	O
daily	O
)	O
.	O

LY117018	B-CHEMICAL
produced	O
dose	O
-	O
related	O
decreases	O
in	O
the	O
uterine	O
weight	O
increases	O
induced	O
by	O
tamoxifen	B-CHEMICAL
and	O
monohydroxytamoxifen	B-CHEMICAL
in	O
both	O
species	O
.	O

However	O
,	O
in	O
the	O
rat	O
,	O
LY117018	B-CHEMICAL
was	O
more	O
effective	O
against	O
the	O
less	O
potent	O
compound	O
tamoxifen	B-CHEMICAL
,	O
at	O
a	O
6	O
:	O
1	O
dosage	O
ratio	O
compared	O
with	O
a	O
24	O
:	O
1	O
dosage	O
ratio	O
required	O
for	O
the	O
potent	O
compound	O
monohydroxytamoxifen	B-CHEMICAL
.	O

LY117018	B-CHEMICAL
had	O
a	O
short	O
duration	O
of	O
action	O
as	O
an	O
antiestrogen	O
when	O
compared	O
with	O
monohydroxytamoxifen	B-CHEMICAL
.	O

LY117018	B-CHEMICAL
(	O
120	O
micrograms	O
)	O
was	O
only	O
completely	O
effective	O
as	O
an	O
antiestrogen	O
if	O
administered	O
repeatedly	O
with	O
E2	B-CHEMICAL
whereas	O
a	O
single	O
injection	O
of	O
monohydroxytamoxifen	B-CHEMICAL
(	O
120	O
micrograms	O
)	O
was	O
sufficient	O
to	O
inhibit	O
fully	O
E2	B-CHEMICAL
action	O
in	O
the	O
uterus	O
for	O
up	O
to	O
4	O
days	O
.	O

Because	O
LY117018	B-CHEMICAL
has	O
a	O
shorter	O
duration	O
of	O
action	O
than	O
monohydroxytamoxifen	B-CHEMICAL
,	O
a	O
high	O
dosage	O
ratio	O
of	O
LY117018	B-CHEMICAL
over	O
monohydroxytamoxifen	B-CHEMICAL
is	O
required	O
to	O
maintain	O
effective	O
competitive	O
antagonism	O
in	O
the	O
uterus	O
.	O

Overall	O
,	O
these	O
findings	O
suggest	O
that	O
monohydroxytamoxifen	B-CHEMICAL
and	O
LY117018	B-CHEMICAL
probably	O
act	O
through	O
the	O
same	O
mechanism	O
of	O
action	O
via	O
the	O
estrogen	B-GENE-Y
receptor	I-GENE-Y
.	O

Keratinocyte	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
and	O
acidic	B-GENE-Y
fibroblast	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
are	O
mitogens	O
for	O
primary	O
cultures	O
of	O
mammary	O
epithelium	O
.	O

Mammary	O
epithelial	O
cells	O
derived	O
from	O
the	O
entire	O
mammary	O
parenchyma	O
or	O
only	O
end	O
buds	O
were	O
isolated	O
by	O
collagenase	B-GENE-N
digestion	O
of	O
mammary	O
glands	O
from	O
virgin	O
mice	O
.	O

Cells	O
were	O
cultured	O
within	O
collagen	O
gels	O
in	O
serum	O
-	O
free	O
medium	O
containing	O
insulin	B-GENE-Y
.	O

Keratinocyte	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
KGF	B-GENE-Y
or	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
)	O
and	O
acidic	B-GENE-Y
fibroblast	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
aFGF	B-GENE-Y
or	O
FGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
stimulated	O
multifold	O
proliferation	O
when	O
added	O
alone	O
to	O
this	O
medium	O
.	O

Growth	O
occurred	O
as	O
three	O
-	O
dimensional	O
colonies	O
within	O
the	O
collagen	B-GENE-N
gel	O
matrix	O
.	O

KGF	B-GENE-Y
stimulated	O
growth	O
was	O
unaffected	O
by	O
adding	O
heparin	O
.	O

Conversely	O
,	O
multifold	O
growth	O
stimulation	O
by	O
acidic	B-GENE-Y
FGF	I-GENE-Y
required	O
heparin	O
.	O

Since	O
end	O
buds	O
are	O
the	O
actively	O
proliferating	O
cell	O
population	O
of	O
ductal	O
glands	O
,	O
organ	O
cultures	O
of	O
these	O
structures	O
were	O
prepared	O
.	O

KGF	B-GENE-Y
stimulated	O
3H	B-CHEMICAL
-	I-CHEMICAL
thymidine	I-CHEMICAL
incorporation	O
in	O
these	O
end	O
buds	O
in	O
the	O
absence	O
and	O
presence	O
of	O
epidermal	B-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
.	O

These	O
data	O
suggest	O
that	O
acidic	B-GENE-Y
FGF	I-GENE-Y
and	O
KGF	B-GENE-Y
may	O
represent	O
in	O
vivo	O
stromal	O
factors	O
capable	O
of	O
regulating	O
mammary	O
gland	O
development	O
.	O

Characterization	O
of	O
an	O
alpha	B-GENE-Y
1D	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
mediating	O
the	O
contractile	O
response	O
of	O
rat	O
aorta	O
to	O
noradrenaline	B-CHEMICAL
.	O

1	O
.	O

The	O
affinities	O
of	O
a	O
number	O
of	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
were	O
determined	O
by	O
displacement	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
prazosin	I-CHEMICAL
binding	O
from	O
cloned	O
human	B-GENE-Y
alpha	I-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
(	O
previously	O
designated	O
cloned	O
alpha	O
1c	O
subtype	O
)	O
,	O
alpha	O
1B	O
alpha	O
1D	O
and	O
rat	B-GENE-Y
alpha	I-GENE-Y
1D	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
,	O
stably	O
expressed	O
in	O
rat	O
-	O
1	O
fibroblasts	O
.	O

Functional	O
affinity	O
estimates	O
for	O
these	O
compounds	O
were	O
also	O
determined	O
from	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
.	O

2	O
.	O

BMY	B-CHEMICAL
7378	I-CHEMICAL
displayed	O
high	O
affinity	O
for	O
cloned	O
human	B-GENE-Y
alpha	I-GENE-Y
1D	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
(	O
pKi	O
=	O
8	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
10	O
)	O
and	O
was	O
selective	O
over	O
alpha	O
1A	O
(	O
pKi	O
=	O
6	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
10	O
)	O
and	O
alpha	O
1B	O
subtypes	O
(	O
6	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
11	O
)	O
.	O

WB	O
4101	O
,	O
benoxathian	B-CHEMICAL
and	O
phentolamine	B-CHEMICAL
displayed	O
high	O
affinity	O
for	O
alpha	B-GENE-N
1A	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
1D	I-GENE-N
adrenoceptors	I-GENE-N
compared	O
to	O
the	O
alpha	O
1B	O
subtype	O
.	O

Spiperone	B-CHEMICAL
displayed	O
high	O
affinity	O
and	O
selectivity	O
for	O
alpha	B-GENE-Y
1B	I-GENE-Y
adrenoceptors	I-GENE-Y
(	O
pKi	O
8	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
16	O
)	O
.	O

5	B-CHEMICAL
-	I-CHEMICAL
Methyl	I-CHEMICAL
-	I-CHEMICAL
urapidil	I-CHEMICAL
was	O
selective	O
for	O
cloned	O
alpha	B-GENE-Y
1A	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

3	O
.	O

Comparative	O
binding	O
affinities	O
(	O
pKi	O
)	O
for	O
compounds	O
at	O
cloned	O
human	B-GENE-N
and	I-GENE-N
rat1D	I-GENE-N
adrenoceptors	I-GENE-N
were	O
almost	O
identical	O
(	O
r	O
=	O
0	O
.	O
99	O
,	O
slope	O
=	O
1	O
.	O
08	O
)	O
.	O

4	O
.	O

Prazosin	B-CHEMICAL
,	O
doxazosin	B-CHEMICAL
and	O
5	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
urapidil	I-CHEMICAL
were	O
potent	O
,	O
competitive	O
antagonists	O
of	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
(	O
pA2	O
values	O
of	O
9	O
.	O
8	O
,	O
8	O
.	O
8	O
and	O
7	O
.	O
8	O
respectively	O
)	O
.	O

The	O
selective	O
alpha	O
1D	O
antagonist	O
BMY	B-CHEMICAL
7378	I-CHEMICAL
was	O
also	O
a	O
potent	O
antagonist	O
on	O
rat	O
aorta	O
(	O
pKB	O
=	O
8	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
1	O
)	O
but	O
the	O
interaction	O
of	O
this	O
compound	O
was	O
not	O
consistent	O
with	O
competitive	O
antagonism	O
at	O
a	O
single	O
population	O
of	O
receptors	O
.	O

5	O
.	O

Functional	O
affinities	O
for	O
compounds	O
determined	O
against	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
correlated	O
well	O
with	O
binding	O
affinities	O
at	O
cloned	O
alpha	B-GENE-Y
1D	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
(	O
r	O
=	O
0	O
.	O
96	O
)	O
,	O
but	O
not	O
with	O
alpha	O
1A	O
(	O
r	O
=	O
0	O
.	O
61	O
)	O
or	O
alpha	O
1B	O
(	O
r	O
=	O
0	O
.	O
46	O
)	O
subtypes	O
.	O

6	O
.	O

Noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
were	O
sensitive	O
to	O
the	O
alkylating	O
effects	O
of	O
chlorethylclonidine	B-CHEMICAL
(	O
CEC	B-CHEMICAL
)	O
.	O

CEC	O
(	O
10	O
microM	O
)	O
caused	O
a	O
small	O
rightward	O
shift	O
in	O
the	O
noradrenaline	B-CHEMICAL
concentration	O
-	O
response	O
curve	O
.	O

CEC	B-CHEMICAL
at	O
100	O
microM	O
caused	O
a	O
further	O
shift	O
and	O
suppression	O
of	O
the	O
maximum	O
response	O
to	O
noradrenaline	B-CHEMICAL
.	O
7	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
noradrenaline	B-CHEMICAL
predominantly	O
,	O
but	O
not	O
exclusively	O
,	O
mediates	O
contraction	O
of	O
rat	O
aorta	O
through	O
the	O
activation	O
of	O
an	O
alphalD	B-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
.	O

Alprenolol	B-CHEMICAL
and	O
bromoacetylalprenololmenthane	B-CHEMICAL
are	O
competitive	O
slowly	O
reversible	O
antagonists	O
at	O
the	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
of	O
rat	O
left	O
atria	O
.	O

We	O
studied	O
the	O
effects	O
of	O
alprenolol	B-CHEMICAL
and	O
bromoacetylalprenololmenthane	B-CHEMICAL
(	O
BAAM	B-CHEMICAL
)	O
on	O
rat	O
left	O
atria	O
.	O

Alprenolol	B-CHEMICAL
and	O
BAAM	B-CHEMICAL
at	O
10	O
(	O
-	O
7	O
)	O
,	O
3	O
x	O
10	O
(	O
-	O
7	O
)	O
,	O
and	O
10	O
(	O
-	O
6	O
)	O
M	O
inhibited	O
the	O
cardiac	O
stimulation	O
response	O
slightly	O
,	O
which	O
is	O
indicative	O
of	O
membrane	O
-	O
stabilizing	O
activity	O
independent	O
of	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
blockade	O
.	O

This	O
membrane	O
-	O
stabilizing	O
activity	O
was	O
readily	O
reversible	O
.	O

Alprenolol	B-CHEMICAL
and	O
BAAM	B-CHEMICAL
also	O
caused	O
surmountable	O
antagonism	O
of	O
isoprenaline	B-CHEMICAL
responses	O
,	O
and	O
this	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonism	O
was	O
slowly	O
reversible	O
.	O

Inhibition	O
of	O
the	O
isoprenaline	B-CHEMICAL
responses	O
with	O
alprenolol	B-CHEMICAL
and	O
BAAM	B-CHEMICAL
at	O
10	O
(	O
-	O
6	O
)	O
M	O
was	O
at	O
equilibrium	O
after	O
60	O
min	O
,	O
which	O
is	O
indicative	O
of	O
reversible	O
antagonism	O
.	O

We	O
conclude	O
that	O
alprenolol	B-CHEMICAL
and	O
BAAM	B-CHEMICAL
are	O
competitive	O
slowly	O
reversible	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonists	O
on	O
rat	O
left	O
atria	O
.	O

Cloning	O
and	O
expression	O
of	O
a	O
novel	O
serotonin	B-GENE-N
receptor	I-GENE-N
with	O
high	O
affinity	O
for	O
tricyclic	B-CHEMICAL
psychotropic	O
drugs	O
.	O

We	O
have	O
used	O
the	O
polymerase	O
chain	O
reaction	O
technique	O
to	O
selectively	O
amplify	O
a	O
guanine	B-GENE-N
nucleotide	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
protein	I-GENE-N
-	I-GENE-N
coupled	I-GENE-N
receptor	I-GENE-N
cDNA	O
sequence	O
from	O
rat	O
striatal	O
mRNA	O
that	O
exhibits	O
high	O
homology	O
to	O
previously	O
cloned	O
serotonin	B-GENE-N
receptors	I-GENE-N
.	O

Sequencing	O
of	O
a	O
full	O
length	O
clone	O
isolated	O
from	O
a	O
rat	O
striatal	O
cDNA	O
library	O
revealed	O
an	O
open	O
reading	O
frame	O
of	O
1311	O
base	O
pairs	O
,	O
encoding	O
a	O
437	O
-	O
residue	O
protein	O
with	O
seven	O
hydrophobic	O
regions	O
.	O

Within	O
these	O
hydrophobic	O
regions	O
,	O
this	O
receptor	O
was	O
found	O
to	O
be	O
41	O
-	O
36	O
%	O
identical	O
to	O
the	O
following	O
serotonin	B-GENE-N
[	I-GENE-N
5	I-GENE-N
-	I-GENE-N
hydroxytryptamine	I-GENE-N
(	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
)	I-GENE-N
]	I-GENE-N
receptors	I-GENE-N
:	O
5	B-GENE-Y
-	I-GENE-Y
HT2	I-GENE-Y
>	O
5	B-GENE-Y
-	I-GENE-Y
HT1D	I-GENE-Y
>	O
5	B-GENE-Y
-	I-GENE-Y
HT1C	I-GENE-Y
>	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
>	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
>	O
5	B-GENE-Y
-	I-GENE-Y
HT1E	I-GENE-Y
.	O

Northern	O
blots	O
revealed	O
a	O
approximately	O
4	O
.	O
2	O
-	O
kilobase	O
transcript	O
localized	O
in	O
various	O
brain	O
regions	O
,	O
with	O
the	O
following	O
rank	O
order	O
of	O
abundance	O
:	O
striatum	O
>	O
>	O
olfactory	O
tubercle	O
>	O
cerebral	O
cortex	O
>	O
hippocampus	O
.	O

Expression	O
of	O
this	O
clone	O
in	O
COS	O
-	O
7	O
cells	O
resulted	O
in	O
the	O
appearance	O
of	O
high	O
affinity	O
,	O
saturable	O
binding	O
of	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
iodolysergic	I-CHEMICAL
acid	I-CHEMICAL
diethylamide	I-CHEMICAL
(	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
LSD	I-CHEMICAL
)	O
with	O
a	O
Kd	O
of	O
1	O
.	O
26	O
nM	O
.	O

Among	O
endogenous	O
biogenic	O
amines	O
,	O
only	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
completely	O
inhibited	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
LSD	I-CHEMICAL
binding	O
(	O
Ki	O
=	O
150	O
nM	O
)	O
.	O

The	O
inhibition	O
of	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
LSD	I-CHEMICAL
binding	O
by	O
other	O
serotonergic	O
agonists	O
and	O
antagonists	O
revealed	O
a	O
pharmacological	O
profile	O
that	O
does	O
not	O
correlate	O
with	O
that	O
of	O
any	O
previously	O
described	O
serotonin	B-GENE-N
receptor	I-GENE-N
subtype	O
.	O

In	O
addition	O
,	O
this	O
receptor	O
exhibits	O
high	O
affinity	O
for	O
a	O
number	O
of	O
tricyclic	B-CHEMICAL
antipsychotic	O
and	O
antidepressant	O
drugs	O
,	O
including	O
clozapine	B-CHEMICAL
,	O
amoxipine	B-CHEMICAL
,	O
and	O
amitriptyline	B-CHEMICAL
.	O

In	O
HEK	O
-	O
293	O
cells	O
stably	O
transfected	O
with	O
this	O
receptor	O
,	O
serotonin	B-CHEMICAL
elicits	O
a	O
potent	O
stimulation	O
of	O
adenylyl	B-GENE-N
cyclase	I-GENE-N
activity	O
,	O
which	O
is	O
blocked	O
by	O
antipsychotic	O
and	O
antidepressant	O
drugs	O
.	O

The	O
distinct	O
structural	O
and	O
pharmacological	O
properties	O
of	O
this	O
receptor	O
site	O
indicate	O
that	O
it	O
represents	O
a	O
completely	O
novel	O
subtype	O
of	O
serotonin	B-GENE-N
receptor	I-GENE-N
.	O

Based	O
on	O
its	O
affinity	O
for	O
tricyclic	B-CHEMICAL
psychotropic	O
drugs	O
and	O
its	O
localization	O
to	O
limbic	O
and	O
cortical	O
regions	O
of	O
the	O
brain	O
,	O
it	O
is	O
likely	O
that	O
this	O
receptor	O
may	O
play	O
a	O
role	O
in	O
several	O
neuropsychiatric	O
disorders	O
that	O
involve	O
serotonergic	O
systems	O
.	O

Norethisterone	B-CHEMICAL
metabolites	O
modulate	O
the	O
uteroglobin	B-GENE-Y
and	O
progesterone	B-GENE-Y
receptor	I-GENE-Y
gene	O
expression	O
in	O
prepubertal	O
rabbits	O
.	O

Norethisterone	B-CHEMICAL
(	O
NET	B-CHEMICAL
)	O
is	O
a	O
synthetic	O
progestin	B-CHEMICAL
,	O
used	O
as	O
a	O
contraceptive	O
agent	O
,	O
that	O
is	O
biotransformed	O
at	O
target	O
tissues	O
into	O
5	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
and	O
3	B-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
,	O
which	O
possess	O
different	O
pharmacological	O
properties	O
.	O

The	O
effects	O
of	O
these	O
metabolites	O
on	O
the	O
expression	O
of	O
uteroglobin	B-GENE-Y
(	O
UG	B-GENE-Y
)	O
and	O
progesterone	B-GENE-N
receptor	I-GENE-N
(	O
PR	B-GENE-N
)	O
genes	O
,	O
both	O
regulated	O
by	O
progesterone	B-CHEMICAL
(	I-CHEMICAL
P4	I-CHEMICAL
)	I-CHEMICAL
,	O
were	O
evaluated	O
in	O
the	O
uterus	O
of	O
prepubertal	O
female	O
rabbits	O
that	O
were	O
simultaneously	O
treated	O
with	O
P4	O
(	O
1	O
.	O
0	O
mg	O
)	O
for	O
5	O
consecutive	O
days	O
.	O

As	O
determined	O
by	O
Western	O
and	O
Northern	O
blot	O
analyses	O
,	O
5	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
inhibited	O
the	O
P4	O
-	O
induced	O
UG	B-GENE-Y
gene	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

A	O
similar	O
inhibition	O
was	O
observed	O
with	O
the	O
administration	O
of	O
RU	B-CHEMICAL
-	I-CHEMICAL
486	I-CHEMICAL
.	O

The	O
estrogenic	O
agent	O
3	B-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
and	O
estradiol	B-CHEMICAL
at	O
a	O
dose	O
of	O
1	O
.	O
0	O
mg	O
also	O
inhibited	O
the	O
UG	B-GENE-Y
gene	O
expression	O
induced	O
by	O
P4	O
.	O

Both	O
5	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
and	O
3	B-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
blocked	O
the	O
PR	B-GENE-Y
down	O
-	O
regulation	O
induced	O
by	O
P4	O
as	O
assessed	O
by	O
Western	O
and	O
Northern	O
blot	O
methods	O
.	O

The	O
inhibition	O
of	O
UG	B-GENE-Y
synthesis	O
and	O
PR	B-GENE-Y
down	O
-	O
regulation	O
by	O
5	B-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
and	O
3	B-CHEMICAL
beta	I-CHEMICAL
,	I-CHEMICAL
5	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
NET	I-CHEMICAL
indicates	O
that	O
these	O
NET	B-CHEMICAL
metabolites	O
possess	O
antiprogestational	O
properties	O
.	O

Discriminative	O
stimulus	O
effects	O
of	O
esteratic	O
local	O
anesthetics	O
in	O
squirrel	O
monkeys	O
.	O

A	O
number	O
of	O
esteratic	O
local	O
anesthetics	O
serve	O
as	O
positive	O
reinforcers	O
and	O
produce	O
cocaine	B-CHEMICAL
-	O
like	O
discriminative	O
stimulus	O
effects	O
in	O
animals	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
affinity	O
of	O
these	O
compounds	O
for	O
a	O
site	O
on	O
the	O
dopamine	B-GENE-Y
transporter	I-GENE-Y
,	O
and	O
not	O
their	O
local	O
anesthetic	O
actions	O
,	O
is	O
responsible	O
for	O
these	O
abuse	O
-	O
related	O
behavioral	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
local	O
anesthetics	O
previously	O
shown	O
to	O
be	O
self	O
-	O
administered	O
in	O
animals	O
were	O
examined	O
in	O
squirrel	O
monkeys	O
trained	O
to	O
discriminate	O
cocaine	B-CHEMICAL
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
from	O
saline	O
in	O
a	O
two	O
-	O
lever	O
,	O
food	O
-	O
reinforced	O
procedure	O
.	O

Dimethocaine	B-CHEMICAL
(	O
0	O
.	O
1	O
-	O
3	O
.	O
0	O
mg	O
/	O
kg	O
)	O
fully	O
and	O
dose	O
-	O
dependently	O
substituted	O
for	O
cocaine	B-CHEMICAL
.	O

Doses	O
of	O
dimethocaine	B-CHEMICAL
(	O
1	O
.	O
7	O
mg	O
/	O
kg	O
)	O
and	O
cocaine	B-CHEMICAL
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
which	O
produced	O
full	O
(	O
>	O
80	O
%	O
)	O
substitution	O
for	O
cocaine	B-CHEMICAL
were	O
administered	O
in	O
combination	O
with	O
the	O
dopamine	B-GENE-Y
D1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
SCH	B-CHEMICAL
39166	I-CHEMICAL
(	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
trans	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
,	I-CHEMICAL
7a	I-CHEMICAL
,	I-CHEMICAL
8	I-CHEMICAL
,	I-CHEMICAL
9	I-CHEMICAL
,	I-CHEMICAL
13b	I-CHEMICAL
-	I-CHEMICAL
hexahydro	I-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
chloro	I-CHEMICAL
-	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
hydroxy	I-CHEMICAL
-	I-CHEMICAL
N	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
5H	I-CHEMICAL
-	I-CHEMICAL
benzo	I-CHEMICAL
[	I-CHEMICAL
d	I-CHEMICAL
]	I-CHEMICAL
naphtho	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
1	I-CHEMICAL
-	I-CHEMICAL
b	I-CHEMICAL
)	I-CHEMICAL
azepine	I-CHEMICAL
)	O
and	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
raclopride	B-CHEMICAL
(	O
both	O
at	O
0	O
.	O
003	O
-	O
0	O
.	O
03	O
mg	O
/	O
kg	O
)	O
.	O

SCH	B-CHEMICAL
39166	I-CHEMICAL
fully	O
blocked	O
the	O
cocaine	B-CHEMICAL
-	O
like	O
discriminative	O
stimulus	O
effects	O
of	O
dimethocaine	B-CHEMICAL
and	O
cocaine	B-CHEMICAL
,	O
but	O
raclopride	B-CHEMICAL
produced	O
only	O
partial	O
antagonism	O
of	O
cocaine	B-CHEMICAL
-	O
lever	O
selection	O
.	O

In	O
addition	O
,	O
there	O
was	O
some	O
evidence	O
that	O
raclopride	B-CHEMICAL
blocked	O
cocaine	B-CHEMICAL
-	O
lever	O
responding	O
produced	O
by	O
a	O
lower	O
dose	O
of	O
dimethocaine	B-CHEMICAL
.	O

In	O
substitution	O
studies	O
,	O
neither	O
procaine	B-CHEMICAL
(	O
1	O
-	O
10	O
mg	O
/	O
kg	O
)	O
nor	O
chloroprocaine	B-CHEMICAL
(	O
1	O
-	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
cocaine	B-CHEMICAL
-	O
like	O
effects	O
.	O

These	O
results	O
support	O
a	O
role	O
for	O
dopamine	B-CHEMICAL
in	O
the	O
behavioral	O
effects	O
of	O
some	O
local	O
anesthetics	O
.	O

Effect	O
of	O
the	O
R	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
isomers	I-CHEMICAL
of	I-CHEMICAL
MDA	I-CHEMICAL
and	O
MDMA	B-CHEMICAL
on	O
phosphatidyl	B-CHEMICAL
inositol	I-CHEMICAL
turnover	O
in	O
cultured	O
cells	O
expressing	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
.	O

The	O
effect	O
of	O
the	O
R	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
isomers	I-CHEMICAL
of	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxyamphetamine	I-CHEMICAL
(	O
MDA	B-CHEMICAL
)	O
and	O
its	O
N	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
analog	I-CHEMICAL
3	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
methylenedioxymethamphetamine	I-CHEMICAL
(	O
MDMA	B-CHEMICAL
)	O
on	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
inositol	I-CHEMICAL
monophosphate	I-CHEMICAL
accumulation	O
was	O
studied	O
in	O
cells	O
expressing	O
either	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
.	O

The	O
isomers	O
of	O
MDA	B-CHEMICAL
produced	O
a	O
concentration	O
dependent	O
increase	O
in	O
phosphatidyl	B-CHEMICAL
inositol	I-CHEMICAL
(	O
PI	B-CHEMICAL
)	O
hydrolysis	O
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
receptors	O
,	O
with	O
the	O
R	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
isomer	I-CHEMICAL
of	I-CHEMICAL
MDA	I-CHEMICAL
being	O
more	O
potent	O
than	O
the	O
S	O
(	O
+	O
)	O
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
receptor	O
.	O

The	O
R	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
isomers	I-CHEMICAL
of	I-CHEMICAL
MDMA	I-CHEMICAL
were	O
significantly	O
less	O
efficacious	O
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
receptor	O
as	O
compared	O
to	O
MDA	B-CHEMICAL
;	O
S	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
MDMA	I-CHEMICAL
had	O
no	O
effect	O
.	O

At	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
,	O
both	O
R	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
MDA	I-CHEMICAL
were	O
equipotent	O
at	O
stimulating	O
PI	B-CHEMICAL
hydrolysis	O
,	O
with	O
the	O
S	B-CHEMICAL
(	I-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
isomer	I-CHEMICAL
of	I-CHEMICAL
MDMA	I-CHEMICAL
being	O
more	O
efficacious	O
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptor	O
compared	O
with	O
the	O
R	O
(	O
-	O
)	O
isomer	O
.	O

In	O
all	O
cases	O
at	O
both	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
,	O
the	O
affinities	O
of	O
the	O
isomers	O
of	O
MDMA	B-CHEMICAL
and	O
MDA	B-CHEMICAL
were	O
at	O
least	O
2	O
-	O
3	O
orders	O
of	O
magnitude	O
less	O
than	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
.	O

Despite	O
the	O
weak	O
effect	O
of	O
these	O
compounds	O
at	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT2C	I-GENE-Y
receptors	O
,	O
these	O
substituted	O
amphetamines	B-CHEMICAL
do	O
possess	O
intrinsic	O
activity	O
which	O
may	O
contribute	O
to	O
their	O
neurotoxic	O
effects	O
when	O
administered	O
at	O
high	O
doses	O
.	O

Expression	O
and	O
selective	O
inhibition	O
of	O
the	O
constitutive	B-GENE-N
and	I-GENE-N
inducible	I-GENE-N
forms	I-GENE-N
of	I-GENE-N
human	I-GENE-N
cyclo	I-GENE-N
-	I-GENE-N
oxygenase	I-GENE-N
.	O

The	O
enzyme	O
cyclo	B-GENE-N
-	I-GENE-N
oxygenase	I-GENE-N
catalyses	O
the	O
oxygenation	O
of	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
,	O
leading	O
to	O
the	O
formation	O
of	O
prostaglandins	B-CHEMICAL
.	O

Recently	O
two	O
forms	O
of	O
cyclo	B-GENE-N
-	I-GENE-N
oxygenase	I-GENE-N
have	O
been	O
described	O
:	O
a	O
constitutive	O
(	O
COX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
enzyme	O
present	O
in	O
most	O
cells	O
and	O
tissues	O
,	O
and	O
an	O
inducible	O
(	O
COX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
isoenzyme	O
observed	O
in	O
many	O
cells	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
cytokines	B-GENE-N
.	O

Constitutive	B-GENE-N
and	I-GENE-N
inducible	I-GENE-N
forms	I-GENE-N
of	I-GENE-N
human	I-GENE-N
cyclo	I-GENE-N
-	I-GENE-N
oxygenase	I-GENE-N
(	O
hCOX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
hCOX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
were	O
cloned	O
and	O
expressed	O
in	O
insect	O
cells	O
,	O
utilizing	O
a	O
baculovirus	O
expression	O
system	O
.	O

hCOX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
had	O
a	O
specific	O
activity	O
of	O
18	O
.	O
8	O
mumol	O
of	O
O2	B-CHEMICAL
/	O
mg	O
with	O
a	O
Km	O
of	O
13	O
.	O
8	O
microM	O
for	O
arachidonate	B-CHEMICAL
and	O
Vmax	O
.	O
of	O
1500	O
nmol	O
of	O
O2	O
/	O
nmol	O
of	O
enzyme	O
,	O
whereas	O
hCOX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
had	O
a	O
specific	O
activity	O
of	O
12	O
.	O
2	O
mumol	O
of	O
O2	B-CHEMICAL
/	O
mg	O
with	O
a	O
Km	O
of	O
8	O
.	O
7	O
microM	O
for	O
arachidonate	B-CHEMICAL
and	O
a	O
Vmax	O
.	O
of	O
1090	O
nmol	O
of	O
O2	B-CHEMICAL
/	O
nmol	O
of	O
enzyme	O
.	O

Indomethacin	B-CHEMICAL
inhibited	O
both	O
hCOX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
hCOX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
whereas	O
NS	B-CHEMICAL
-	I-CHEMICAL
398	I-CHEMICAL
and	O
Dup	B-CHEMICAL
-	I-CHEMICAL
697	I-CHEMICAL
selectively	O
inhibited	O
hCOX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

Both	O
NS	B-CHEMICAL
-	I-CHEMICAL
398	I-CHEMICAL
and	O
Dup	B-CHEMICAL
-	I-CHEMICAL
697	I-CHEMICAL
exhibited	O
time	O
-	O
dependent	O
inactivation	O
of	O
hCOX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
as	O
did	O
indomethacin	B-CHEMICAL
on	O
both	O
enzymes	O
.	O

The	O
competitive	O
inhibitor	O
of	O
hCOX	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
mefenamic	B-CHEMICAL
acid	I-CHEMICAL
,	O
also	O
displayed	O
competitive	O
inhibition	O
of	O
hCOX	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
.	O

These	O
results	O
demonstrate	O
the	O
ability	O
to	O
generate	O
selective	O
non	O
-	O
steroidal	B-CHEMICAL
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
which	O
could	O
provide	O
useful	O
improvement	O
therapeutically	O
in	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
disease	O
.	O

Conformational	O
transitions	O
linked	O
to	O
active	O
site	O
ligation	O
in	O
human	B-GENE-Y
thrombin	I-GENE-Y
:	O
effect	O
on	O
the	O
interaction	O
with	O
fibrinogen	B-GENE-N
and	O
the	O
cleavable	B-GENE-N
platelet	I-GENE-N
receptor	I-GENE-N
.	O

An	O
experimental	O
strategy	O
based	O
on	O
solution	O
viscosity	O
perturbation	O
allowed	O
us	O
to	O
study	O
the	O
energetics	O
of	O
amide	B-CHEMICAL
-	O
substrates	O
,	O
p	B-CHEMICAL
-	I-CHEMICAL
aminobenzamidine	I-CHEMICAL
(	O
p	B-CHEMICAL
-	I-CHEMICAL
ABZ	I-CHEMICAL
)	O
and	O
proflavin	B-CHEMICAL
binding	O
to	O
the	O
catalytic	O
site	O
of	O
two	O
proteolyzed	O
forms	O
of	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
,	O
i	O
.	O
e	O
.	O
zeta	B-GENE-N
-	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
T	I-GENE-N
-	I-GENE-N
thrombin	I-GENE-N
.	O

These	O
thrombin	B-GENE-Y
derivatives	O
are	O
cleaved	O
at	O
the	O
Leu144	O
-	O
Gly150	O
loop	O
and	O
at	O
the	O
fibrinogen	B-GENE-N
recognition	I-GENE-N
exosite	I-GENE-N
(	O
FRS	B-GENE-N
)	O
,	O
respectively	O
.	O

A	O
phenomenological	O
analysis	O
of	O
thermodynamic	O
data	O
showed	O
that	O
the	O
amide	B-CHEMICAL
substrates	O
and	O
p	B-CHEMICAL
-	I-CHEMICAL
ABZ	I-CHEMICAL
interactions	O
with	O
zeta	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
were	O
respectively	O
,	O
associated	O
with	O
a	O
chemical	O
compensation	O
(	O
i	O
.	O
e	O
.	O
the	O
linear	O
relationship	O
between	O
entropy	O
and	O
enthalpy	O
of	O
binding	O
)	O
and	O
a	O
hydrophobic	O
phenomenon	O
(	O
i	O
.	O
e	O
.	O
a	O
change	O
in	O
the	O
standard	O
heat	O
capacity	O
)	O
.	O

The	O
latter	O
was	O
slightly	O
lower	O
than	O
that	O
previously	O
observed	O
for	O
a	O
alpha	B-GENE-Y
-	I-GENE-Y
thrombin	I-GENE-Y
(	O
0	O
.	O
78	O
+	O
/	O
-	O
0	O
.	O
25	O
versus	O
1	O
.	O
01	O
+	O
/	O
-	O
0	O
.	O
17	O
kcal	O
/	O
mol	O
K	O
)	O
.	O

Both	O
phenomenon	O
were	O
absent	O
in	O
gamma	O
T	O
-	O
thrombin	O
.	O

The	O
interaction	O
of	O
a	O
alpha	B-GENE-N
-	I-GENE-N
,	I-GENE-N
zeta	I-GENE-N
-	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
T	I-GENE-N
-	I-GENE-N
thrombin	I-GENE-N
with	O
macromolecular	O
substrates	O
that	O
"	O
bridge	O
-	O
bind	O
"	O
to	O
both	O
the	O
catalytic	O
site	O
(	O
CS	O
)	O
and	O
fibrinogen	B-GENE-N
recognition	I-GENE-N
exosite	I-GENE-N
(	O
FRS	B-GENE-N
)	O
,	O
such	O
as	O
fibrinogen	B-GENE-N
and	O
the	O
cleavable	B-GENE-N
platelet	I-GENE-N
receptor	I-GENE-N
(	O
CPR	B-GENE-N
)	O
,	O
was	O
also	O
evaluated	O
.	O

These	O
interactions	O
were	O
studied	O
by	O
following	O
fibrinopeptide	B-GENE-Y
A	I-GENE-Y
(	O
FpA	B-GENE-Y
)	O
release	O
and	O
by	O
measuring	O
intraplatelet	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
changes	O
induced	O
by	O
thrombin	B-GENE-Y
-	O
CPR	B-GENE-N
interaction	O
.	O

It	O
was	O
found	O
that	O
the	O
free	O
energy	O
of	O
activation	O
(	O
RT	O
ln	O
Kcat	O
/	O
Km	O
)	O
for	O
both	O
fibrinogen	B-GENE-N
and	O
CPR	B-GENE-N
hydrolysis	O
followed	O
the	O
same	O
hierarchy	O
,	O
i	O
.	O
e	O
.	O
alpha	O
>	O
zeta	O
>	O
gamma	O
.	O

Moreover	O
,	O
the	O
values	O
of	O
delta	O
Cp	O
for	O
alpha	B-GENE-N
-	I-GENE-N
,	I-GENE-N
zeta	I-GENE-N
-	I-GENE-N
and	I-GENE-N
gamma	I-GENE-N
T	I-GENE-N
-	I-GENE-N
thrombin	I-GENE-N
interaction	O
with	O
p	B-CHEMICAL
-	I-CHEMICAL
ABZ	I-CHEMICAL
were	O
found	O
to	O
be	O
linearly	O
correlated	O
to	O
the	O
free	O
energy	O
of	O
activation	O
for	O
both	O
fibrinogen	B-GENE-N
and	O
CPR	B-GENE-N
cleavage	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
the	O
Leu144	O
-	O
Gly150	O
loop	O
and	O
the	O
FRS	B-GENE-N
are	O
both	O
involved	O
in	O
the	O
conformational	O
transition	O
linked	O
to	O
the	O
binding	O
of	O
p	B-CHEMICAL
-	I-CHEMICAL
aminobenzamidine	I-CHEMICAL
to	O
the	O
thrombin	B-GENE-Y
active	O
site	O
;	O
(	O
2	O
)	O
the	O
extent	O
of	O
thrombin	B-GENE-Y
'	I-GENE-Y
s	I-GENE-Y
capacity	O
to	O
undergo	O
conformational	O
transitions	O
in	O
alpha	O
-	O
,	O
zeta	O
-	O
and	O
gamma	O
T	O
forms	O
is	O
positively	O
correlated	O
to	O
the	O
free	O
energy	O
of	O
activation	O
for	O
hydrolysis	O
of	O
macromolecular	O
substrates	O
interacting	O
with	O
both	O
the	O
catalytic	O
domain	O
and	O
the	O
FRS	B-GENE-N
.	O

Drosophila	B-GENE-N
GABA	I-GENE-N
-	I-GENE-N
gated	I-GENE-N
chloride	I-GENE-N
channel	I-GENE-N
:	O
modified	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
EBOB	I-CHEMICAL
binding	O
site	O
associated	O
with	O
Ala	B-CHEMICAL
-	O
-	O
>	O
Ser	B-CHEMICAL
or	O
Gly	B-CHEMICAL
mutants	O
of	O
Rdl	B-GENE-Y
subunit	O
.	O

The	O
non	O
-	O
competitive	O
blocker	O
site	O
of	O
the	O
GABA	B-GENE-N
-	I-GENE-N
gated	I-GENE-N
chloride	I-GENE-N
ion	I-GENE-N
channel	I-GENE-N
in	O
normal	O
susceptible	O
strains	O
of	O
Drosophila	O
melanogaster	O
and	O
simulans	O
binds	O
4	B-CHEMICAL
-	I-CHEMICAL
n	I-CHEMICAL
-	I-CHEMICAL
[	I-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
propyl	I-CHEMICAL
-	I-CHEMICAL
4	I-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
ethynylbicycloorthobenzoate	I-CHEMICAL
(	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
EBOB	I-CHEMICAL
)	O
at	O
specific	O
sites	O
with	O
KdS	O
of	O
1	O
.	O
6	O
-	O
1	O
.	O
9	O
nM	O
and	O
BmaxS	O
of	O
171	O
-	O
181	O
fmol	O
/	O
mg	O
protein	O
.	O

This	O
specific	O
binding	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
EBOB	I-CHEMICAL
is	O
strongly	O
inhibited	O
by	O
:	O
a	O
large	O
number	O
and	O
variety	O
of	O
insecticidal	O
channel	O
blockers	O
at	O
20	O
nM	O
(	O
lindane	B-CHEMICAL
,	O
alpha	B-CHEMICAL
-	I-CHEMICAL
endosulfan	I-CHEMICAL
,	O
dieldrin	B-CHEMICAL
,	O
12	B-CHEMICAL
-	I-CHEMICAL
ketoendrin	I-CHEMICAL
,	O
fipronil	B-CHEMICAL
,	O
and	O
a	O
representative	O
bicycloorthobenzoate	B-CHEMICAL
and	O
dithiane	B-CHEMICAL
)	O
or	O
200	O
nM	O
(	O
picrotoxinin	B-CHEMICAL
)	O
;	O
the	O
insecticidal	O
channel	O
activators	O
avermectin	B-CHEMICAL
and	O
moxidectin	B-CHEMICAL
at	O
20	O
nM	O
;	O
muscimol	B-CHEMICAL
at	O
30	O
microM	O
and	O
GABA	B-CHEMICAL
at	O
300	O
microM	O
.	O

Cyclodiene	B-CHEMICAL
resistance	O
in	O
D	O
.	O
melanogaster	O
has	O
been	O
attributed	O
to	O
a	O
mutation	O
resulting	O
in	O
an	O
Ala302	B-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
Ser	I-GENE-N
replacement	O
in	O
the	O
Rdl	B-GENE-Y
GABA	I-GENE-Y
receptor	I-GENE-Y
subunit	O
and	O
in	O
D	O
.	O
simulans	O
to	O
an	O
homologous	O
Ala	B-CHEMICAL
-	O
-	O
>	O
Ser	B-CHEMICAL
or	O
Gly	B-CHEMICAL
replacement	O
.	O

These	O
mutations	O
are	O
shown	O
here	O
to	O
greatly	O
reduce	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
EBOB	I-CHEMICAL
binding	O
,	O
i	O
.	O
e	O
.	O
lower	O
affinity	O
and	O
apparent	O
number	O
of	O
binding	O
sites	O
.	O

The	O
Ala	B-CHEMICAL
-	O
-	O
>	O
Ser	B-CHEMICAL
replacement	O
with	O
both	O
melanogaster	O
and	O
simulans	O
almost	O
always	O
reduces	O
the	O
potency	O
in	O
inhibiting	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
EBOB	I-CHEMICAL
binding	O
of	O
each	O
of	O
eight	O
channel	O
blockers	O
and	O
of	O
muscimol	B-CHEMICAL
and	O
GABA	B-CHEMICAL
.	O

The	O
Ala	B-CHEMICAL
-	O
-	O
>	O
Gly	B-CHEMICAL
replacement	O
in	O
D	O
.	O
simulans	O
is	O
generally	O
less	O
effective	O
than	O
the	O
Ala	B-CHEMICAL
-	O
-	O
>	O
Ser	B-CHEMICAL
modification	O
in	O
reducing	O
sensitivity	O
to	O
the	O
channel	O
blockers	O
and	O
to	O
muscimol	B-CHEMICAL
and	O
GABA	B-CHEMICAL
.	O

The	O
channel	O
activators	O
avermectin	B-CHEMICAL
and	O
moxidectin	B-CHEMICAL
usually	O
retain	O
their	O
inhibitory	O
potency	O
in	O
the	O
Rdl	B-GENE-Y
subunit	O
mutants	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
replacement	O
of	O
Ala	B-CHEMICAL
by	O
Ser	B-CHEMICAL
generally	O
modifies	O
the	O
non	O
-	O
competitive	O
blocker	O
site	O
and	O
its	O
coupling	O
to	O
the	O
GABA	B-CHEMICAL
-	O
recognition	O
site	O
with	O
less	O
effect	O
on	O
the	O
channel	O
activator	O
site	O
.	O

In	O
contrast	O
,	O
the	O
Ala	B-CHEMICAL
-	O
-	O
>	O
Gly	B-CHEMICAL
replacement	O
has	O
less	O
impact	O
in	O
protecting	O
the	O
chloride	B-GENE-N
channel	I-GENE-N
from	O
the	O
action	O
of	O
insecticidal	O
blockers	O
.	O

Each	O
of	O
the	O
resistant	O
strains	O
has	O
the	O
same	O
level	O
of	O
resistance	O
to	O
the	O
lethal	O
action	O
of	O
the	O
five	O
channel	O
blockers	O
examined	O
but	O
none	O
to	O
avermectins	B-CHEMICAL
and	O
muscimol	B-CHEMICAL
.	O

Agmatine	B-CHEMICAL
:	O
an	O
endogenous	O
clonidine	B-CHEMICAL
-	O
displacing	O
substance	O
in	O
the	O
brain	O
.	O

Clonidine	B-CHEMICAL
,	O
an	O
antihypertensive	O
drug	O
,	O
binds	O
to	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
and	I-GENE-N
imidazoline	I-GENE-N
receptors	I-GENE-N
.	O

The	O
endogenous	O
ligand	O
for	O
imidazoline	B-GENE-N
receptors	I-GENE-N
may	O
be	O
a	O
clonidine	B-CHEMICAL
-	O
displacing	O
substance	O
,	O
a	O
small	O
molecule	O
isolated	O
from	O
bovine	O
brain	O
.	O

This	O
clonidine	B-CHEMICAL
-	O
displacing	O
substance	O
was	O
purified	O
and	O
determined	O
by	O
mass	O
spectroscopy	O
to	O
be	O
agmatine	B-CHEMICAL
(	O
decarboxylated	B-CHEMICAL
arginine	I-CHEMICAL
)	O
,	O
heretofore	O
not	O
detected	O
in	O
brain	O
.	O

Agmatine	B-CHEMICAL
binds	O
to	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
and	I-GENE-N
imidazoline	I-GENE-N
receptors	I-GENE-N
and	O
stimulates	O
release	O
of	O
catecholamines	B-CHEMICAL
from	O
adrenal	O
chromaffin	O
cells	O
.	O

Its	O
biosynthetic	O
enzyme	O
,	O
arginine	B-GENE-Y
decarboxylase	I-GENE-Y
,	O
is	O
present	O
in	O
brain	O
.	O

Agmatine	B-CHEMICAL
,	O
locally	O
synthesized	O
,	O
is	O
an	O
endogenous	O
agonist	O
at	O
imidazoline	B-GENE-N
receptors	I-GENE-N
,	O
a	O
noncatecholamine	B-CHEMICAL
ligand	O
at	O
alpha	B-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
and	O
may	O
act	O
as	O
a	O
neurotransmitter	O
.	O

Cardiac	O
effects	O
of	O
the	O
beta	B-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
BRL35135	B-CHEMICAL
in	O
man	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
cardiac	O
effects	O
of	O
the	O
beta	B-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
BRL35135	B-CHEMICAL
,	O
and	O
determine	O
whether	O
beta	B-GENE-Y
3	I-GENE-Y
-	I-GENE-Y
receptors	I-GENE-Y
are	O
involved	O
in	O
mediating	O
chronotropic	O
or	O
inotropic	O
responses	O
in	O
man	O
.	O

Eight	O
normal	O
males	O
received	O
single	O
oral	O
doses	O
of	O
BRL35135	B-CHEMICAL
8	O
mg	O
(	O
BRL	B-CHEMICAL
)	O
or	O
the	O
selective	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
agonist	O
salbutamol	B-CHEMICAL
8	O
mg	O
(	O
SAL	B-CHEMICAL
)	O
,	O
after	O
pretreatment	O
with	O
either	O
placebo	O
(	O
PL	O
)	O
,	O
bisoprolol	B-CHEMICAL
5	O
mg	O
(	O
B5	O
)	O
as	O
a	O
selective	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
,	O
or	O
nadolol	B-CHEMICAL
20	O
mg	O
(	O
N20	O
)	O
to	O
block	O
beta	B-GENE-N
1	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
2	I-GENE-N
-	I-GENE-N
but	I-GENE-N
not	I-GENE-N
beta	I-GENE-N
3	I-GENE-N
-	I-GENE-N
receptors	I-GENE-N
.	O

Both	O
BRL	B-CHEMICAL
and	O
SAL	B-CHEMICAL
produced	O
a	O
significant	O
increase	O
in	O
postural	O
finger	O
tremor	O
in	O
keeping	O
with	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
stimulation	O
,	O
and	O
this	O
response	O
was	O
totally	O
abolished	O
by	O
pretreatment	O
with	O
N20	O
.	O

Significant	O
increases	O
in	O
systolic	O
blood	O
pressure	O
and	O
Doppler	O
stroke	O
distance	O
occurred	O
with	O
BRL	B-CHEMICAL
and	O
SAL	B-CHEMICAL
which	O
were	O
unaffected	O
by	O
pretreatment	O
with	O
B5	O
and	O
completely	O
blocked	O
by	O
N20	O
,	O
in	O
keeping	O
with	O
beta	B-GENE-Y
2	I-GENE-Y
-	O
mediated	O
effects	O
.	O

BRL	B-CHEMICAL
and	O
SAL	B-CHEMICAL
produced	O
significant	O
chronotropic	O
and	O
minute	O
distance	O
responses	O
which	O
were	O
unaffected	O
by	O
beta	B-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
blockade	O
.	O

However	O
,	O
whereas	O
N20	O
blocked	O
these	O
responses	O
to	O
SAL	B-CHEMICAL
,	O
a	O
small	O
but	O
significant	O
response	O
occurred	O
with	O
BRL	B-CHEMICAL
in	O
comparison	O
with	O
placebo	O
despite	O
complete	O
blockade	O
of	O
co	O
-	O
existing	O
beta	B-GENE-Y
2	I-GENE-Y
-	O
mediated	O
effects	O
.	O

Compared	O
with	O
PL	O
,	O
the	O
mean	O
responses	O
to	O
N20	O
/	O
BRL	B-CHEMICAL
,	O
and	O
the	O
95	O
%	O
confidence	O
interval	O
for	O
the	O
differences	O
between	O
the	O
means	O
were	O
7	O
.	O
4	O
beats	O
min	O
-	O
1	O
[	O
3	O
.	O
2	O
to	O
11	O
.	O
6	O
]	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
for	O
heart	O
rate	O
,	O
and	O
208	O
.	O
8	O
cm	O
[	O
38	O
.	O
3	O
to	O
379	O
.	O
3	O
]	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
for	O
minute	O
distance	O
responses	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Catalytic	O
properties	O
of	O
mouse	B-GENE-Y
carbonic	I-GENE-Y
anhydrase	I-GENE-Y
V	I-GENE-Y
.	O

A	O
cDNA	O
encoding	O
the	O
mouse	B-GENE-Y
carbonic	I-GENE-Y
anhydrase	I-GENE-Y
V	I-GENE-Y
gene	O
was	O
isolated	O
by	O
reverse	O
transcription	O
and	O
polymerase	O
chain	O
reaction	O
from	O
BALB	O
/	O
c	O
mouse	O
liver	O
mRNA	O
.	O

Vectors	O
containing	O
the	O
full	O
coding	O
sequence	O
as	O
well	O
as	O
two	O
different	O
NH2	B-CHEMICAL
-	O
terminal	O
truncated	O
genes	O
expressed	O
enzymatically	O
active	O
protein	O
in	O
Escherichia	O
coli	O
.	O

The	B-GENE-Y
carbonic	I-GENE-Y
anhydrase	I-GENE-Y
V	I-GENE-Y
produced	O
by	O
a	O
vector	O
containing	O
the	O
full	O
coding	O
sequence	O
,	O
which	O
includes	O
a	O
possible	O
NH2	B-CHEMICAL
-	O
terminal	O
mitochondrial	O
targeting	O
signal	O
,	O
was	O
proteolytically	O
processed	O
by	O
E	O
.	O
coli	O
and	O
contained	O
several	O
amino	B-CHEMICAL
-	O
terminal	O
ends	O
.	O

The	O
two	O
NH2	B-CHEMICAL
-	O
terminal	O
truncated	O
vectors	O
deleted	O
,	O
respectively	O
,	O
1	O
)	O
the	O
29	O
-	O
amino	B-CHEMICAL
acid	I-CHEMICAL
putative	O
targeting	O
sequence	O
and	O
2	O
)	O
51	O
amino	B-CHEMICAL
acids	I-CHEMICAL
,	O
yielding	O
a	O
protein	O
equivalent	O
to	O
a	O
carbonic	B-GENE-Y
anhydrase	I-GENE-Y
(	I-GENE-Y
CA	I-GENE-Y
)	I-GENE-Y
V	I-GENE-Y
isolated	O
from	O
mouse	O
liver	O
mitochondria	O
;	O
and	O
both	O
vectors	O
produced	O
homogeneous	O
protein	O
fractions	O
.	O

These	O
latter	O
two	O
forms	O
of	O
CA	B-GENE-Y
V	I-GENE-Y
had	O
identical	O
steady	O
-	O
state	O
constants	O
for	O
the	O
hydration	O
of	O
CO2	B-CHEMICAL
,	O
with	O
maximal	O
values	O
of	O
kcat	O
/	O
Km	O
at	O
3	O
x	O
10	O
(	O
7	O
)	O
M	O
-	O
1	O
s	O
-	O
1	O
and	O
kcat	O
at	O
3	O
x	O
10	O
(	O
5	O
)	O
s	O
-	O
1	O
with	O
an	O
apparent	O
pKa	O
for	O
catalysis	O
of	O
7	O
.	O
4	O
determined	O
from	O
kcat	O
/	O
Km	O
.	O

In	O
catalytic	O
properties	O
,	O
mouse	B-GENE-Y
CA	I-GENE-Y
V	I-GENE-Y
is	O
closest	O
to	O
CA	B-GENE-Y
I	I-GENE-Y
;	O
however	O
,	O
in	O
inhibition	O
by	O
acetazolamide	B-CHEMICAL
,	O
ethoxzolamide	B-CHEMICAL
,	O
and	O
cyanate	B-CHEMICAL
,	O
CA	B-GENE-Y
V	I-GENE-Y
is	O
very	O
similar	O
to	O
CA	B-GENE-Y
II	I-GENE-Y
.	O

Mouse	B-GENE-Y
CA	I-GENE-Y
V	I-GENE-Y
has	O
a	O
tyrosine	O
at	O
position	O
64	O
,	O
where	O
the	O
highly	O
active	O
isozyme	O
II	O
has	O
histidine	B-CHEMICAL
serving	O
as	O
a	O
proton	O
shuttle	O
in	O
the	O
catalytic	O
pathway	O
.	O

Investigation	O
of	O
a	O
site	O
-	O
specific	O
mutant	O
of	O
CA	B-GENE-Y
V	I-GENE-Y
containing	O
the	O
replacement	O
Tyr64	B-GENE-N
-	I-GENE-N
-	I-GENE-N
>	I-GENE-N
His	I-GENE-N
showed	O
that	O
the	O
unique	O
kinetic	O
properties	O
of	O
CA	B-GENE-Y
V	I-GENE-Y
are	O
not	O
due	O
to	O
the	O
presence	O
of	O
tyrosine	B-CHEMICAL
at	O
position	O
64	O
.	O

2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
Aminoethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
quinoline	I-CHEMICAL
(	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
)	O
:	O
a	O
novel	O
agonist	O
at	O
5	B-GENE-N
-	I-GENE-N
hydroxytryptamine1	I-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
in	O
the	O
canine	O
basilar	O
artery	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
mechanisms	O
involved	O
in	O
the	O
contractile	O
effects	O
produced	O
by	O
the	O
novel	O
quinoline	B-CHEMICAL
derivative	O
,	O
2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
-	I-CHEMICAL
aminoethyl	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
quinoline	I-CHEMICAL
(	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
)	O
,	O
in	O
the	O
canine	O
isolated	O
basilar	O
artery	O
.	O

For	O
comparison	O
,	O
the	O
effects	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
were	O
also	O
evaluated	O
on	O
rat	O
aorta	O
.	O

Canine	O
basilar	O
artery	O
and	O
rat	O
aortic	O
rings	O
were	O
prepared	O
and	O
mounted	O
in	O
organ	O
baths	O
to	O
record	O
isometric	O
tension	O
changes	O
.	O

The	O
contractile	O
effects	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
in	O
the	O
basilar	O
artery	O
were	O
compared	O
with	O
those	O
produced	O
by	O
5	B-CHEMICAL
-	I-CHEMICAL
hydroxytryptamine	I-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
and	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptor	I-GENE-N
agonist	O
quipazine	B-CHEMICAL
.	O

Thus	O
,	O
4	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
(	O
10	O
(	O
-	O
10	O
)	O
-	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
,	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
(	O
3	O
.	O
1	O
x	O
10	O
(	O
-	O
8	O
)	O
-	O
10	O
(	O
-	O
4	O
)	O
M	O
)	O
and	O
quipazine	B-CHEMICAL
(	O
3	O
.	O
1	O
x	O
10	O
(	O
-	O
7	O
)	O
-	O
10	O
(	O
-	O
4	O
)	O
M	O
)	O
each	O
caused	O
concentration	O
-	O
dependent	O
contractions	O
of	O
the	O
canine	O
basilar	O
artery	O
with	O
a	O
rank	O
order	O
of	O
agonist	O
potency	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
>	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
>	O
quipazine	B-CHEMICAL
.	O

5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
exhibited	O
similar	O
maximum	O
effects	O
which	O
were	O
higher	O
than	O
that	O
of	O
quipazine	B-CHEMICAL
.	O

Similar	O
concentrations	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
failed	O
to	O
produce	O
contraction	O
in	O
rat	O
aorta	O
.	O

The	O
effects	O
of	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
in	O
the	O
basilar	O
artery	O
were	O
not	O
modified	O
by	O
incubation	O
with	O
either	O
the	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
antagonist	O
ketanserin	B-CHEMICAL
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
,	O
the	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
and	O
5	B-GENE-Y
-	I-GENE-Y
HT4	I-GENE-Y
receptor	O
antagonist	O
ICS205930	O
(	O
tropisetron	B-CHEMICAL
;	O
0	O
.	O
1	O
-	O
10	O
microM	O
)	O
,	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
receptor	O
antagonist	O
spiroxatrine	B-CHEMICAL
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
,	O
the	O
beta	B-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
blocker	O
with	O
high	O
affinity	O
for	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
and	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
binding	O
sites	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
pindolol	I-CHEMICAL
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
,	O
or	O
the	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonist	O
prazosin	B-CHEMICAL
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
the	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
-	O
induced	O
responses	O
were	O
potently	O
and	O
concentration	O
-	O
dependently	O
antagonized	O
by	O
the	O
mixed	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
-	I-GENE-N
like	I-GENE-N
and	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
antagonist	O
methiothepin	B-CHEMICAL
(	O
0	O
.	O
01	O
-	O
1	O
microM	O
)	O
.	O

It	O
is	O
concluded	O
that	O
D	B-CHEMICAL
-	I-CHEMICAL
1997	I-CHEMICAL
contracts	O
the	O
canine	O
basilar	O
artery	O
by	O
stimulating	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
-	I-GENE-N
like	I-GENE-N
receptors	I-GENE-N
unrelated	O
to	O
either	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT1A	I-GENE-Y
or	O
5	B-GENE-Y
-	I-GENE-Y
HT1B	I-GENE-Y
receptor	O
subtypes	O
.	O

The	O
compound	O
seems	O
to	O
be	O
devoid	O
of	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
receptor	I-GENE-N
agonist	O
properties	O
in	O
rat	O
aorta	O
.	O

Sucralfate	B-CHEMICAL
:	O
the	O
Bangkok	O
review	O
.	O

Sucralfate	B-CHEMICAL
is	O
a	O
site	O
-	O
protective	O
ulcer	O
healing	O
drug	O
with	O
a	O
remarkable	O
range	O
of	O
mechanisms	O
of	O
action	O
.	O

Recent	O
studies	O
highlight	O
the	O
capacity	O
of	O
sucralfate	B-CHEMICAL
to	O
bind	O
basic	B-GENE-Y
fibroblast	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
(	O
bFGF	B-GENE-Y
)	O
and	O
deliver	O
it	O
in	O
high	O
concentration	O
to	O
the	O
ulcer	O
.	O

Basic	B-GENE-Y
fibroblast	I-GENE-Y
growth	I-GENE-Y
factor	I-GENE-Y
stimulates	O
the	O
production	O
of	O
granulation	O
tissue	O
,	O
angiogenesis	O
and	O
re	O
-	O
epithelization	O
,	O
thus	O
improving	O
the	O
quality	O
of	O
ulcer	O
healing	O
.	O

The	O
effect	O
of	O
sucralfate	B-CHEMICAL
in	O
reducing	O
parietal	O
cell	O
sensitivity	O
may	O
be	O
another	O
factor	O
important	O
in	O
the	O
lower	O
relapse	O
rate	O
demonstrated	O
after	O
duodenal	O
ulcer	O
healing	O
.	O

Sucralfate	B-CHEMICAL
has	O
been	O
demonstrated	O
to	O
be	O
efficacious	O
in	O
healing	O
both	O
duodenal	O
and	O
gastric	O
ulcers	O
together	O
with	O
mild	O
oesophagitis	O
,	O
and	O
it	O
is	O
safe	O
for	O
both	O
short	O
-	O
term	O
use	O
and	O
maintenance	O
.	O

In	O
stress	O
ulcer	O
prophylaxis	O
it	O
is	O
as	O
effective	O
as	O
acid	O
suppression	O
or	O
neutralization	O
and	O
has	O
the	O
advantage	O
of	O
lesser	O
rates	O
of	O
nosocomial	O
pneumonia	O
than	O
are	O
demonstrated	O
with	O
antacids	O
or	O
H2	O
antagonists	O
.	O

The	O
potential	O
advantages	O
of	O
sucralfate	B-CHEMICAL
lie	O
in	O
the	O
better	O
quality	O
of	O
ulcer	O
healing	O
associated	O
with	O
longer	O
duration	O
of	O
remission	O
.	O

Effects	O
of	O
labor	O
and	O
delivery	O
on	O
fibrinolysis	O
.	O

Because	O
timing	O
of	O
sampling	O
is	O
crucial	O
in	O
an	O
investigation	O
of	O
the	O
effects	O
of	O
labor	O
and	O
delivery	O
on	O
fibrinolysis	O
we	O
conducted	O
a	O
study	O
of	O
fibrinolytic	O
markers	O
in	O
plasma	O
of	O
10	O
healthy	O
multiparous	O
women	O
in	O
whom	O
labor	O
was	O
induced	O
,	O
which	O
allowed	O
standardization	O
of	O
sampling	O
times	O
in	O
relation	O
to	O
the	O
course	O
of	O
labor	O
and	O
delivery	O
.	O

Blood	O
samples	O
were	O
taken	O
5	O
min	O
before	O
the	O
start	O
of	O
oxytocin	B-CHEMICAL
infusion	O
,	O
at	O
full	O
cervical	O
dilatation	O
,	O
and	O
within	O
5	O
min	O
after	O
delivery	O
of	O
the	O
placenta	O
.	O

A	O
sample	O
of	O
mixed	O
free	O
flowing	O
cord	O
blood	O
was	O
obtained	O
after	O
delivery	O
with	O
the	O
placenta	O
in	O
situ	O
.	O

Variables	O
determined	O
were	O
tissue	B-GENE-Y
-	I-GENE-Y
type	I-GENE-Y
plasminogen	I-GENE-Y
-	I-GENE-Y
activator	I-GENE-Y
(	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
)	O
and	O
the	O
plasminogen	B-GENE-Y
activator	I-GENE-Y
inhibitors	I-GENE-Y
type	I-GENE-Y
1	I-GENE-Y
(	O
PAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
and	O
type	O
2	O
(	O
PAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
)	O
.	O

The	O
only	O
significant	O
change	O
between	O
the	O
beginning	O
of	O
the	O
induction	O
of	O
labor	O
and	O
the	O
end	O
of	O
the	O
first	O
stage	O
of	O
labor	O
was	O
a	O
rise	O
in	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
antigen	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

All	O
variables	O
,	O
except	O
PAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
antigen	O
,	O
changed	O
significantly	O
after	O
delivery	O
of	O
the	O
placenta	O
:	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
antigen	O
and	O
activity	O
showed	O
a	O
rise	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
accompanied	O
by	O
a	O
fall	O
in	O
PAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
antigen	O
and	O
activity	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

T	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
activity	O
in	O
cord	O
plasma	O
was	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
comparison	O
with	O
maternal	O
plasma	O
concentrations	O
at	O
the	O
end	O
of	O
the	O
first	O
stage	O
of	O
labor	O
,	O
t	B-GENE-Y
-	I-GENE-Y
PA	I-GENE-Y
antigen	O
levels	O
were	O
similar	O
,	O
and	O
PAI	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
antigen	O
and	O
activity	O
and	O
PAI	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
antigen	O
were	O
lower	O
in	O
cord	O
plasma	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Our	O
study	O
shows	O
that	O
activation	O
of	O
the	O
maternal	O
fibrinolytic	O
system	O
can	O
already	O
be	O
detected	O
during	O
labor	O
,	O
with	O
a	O
marked	O
further	O
increase	O
in	O
fibrinolytic	O
potential	O
after	O
placental	O
separation	O
.	O

Murine	O
chromosomal	O
location	O
of	O
the	O
mu	B-GENE-N
and	I-GENE-N
kappa	I-GENE-N
opioid	I-GENE-N
receptor	I-GENE-N
genes	O
.	O

Opioid	B-GENE-N
receptors	I-GENE-N
are	O
the	O
membrane	O
proteins	O
that	O
mediate	O
the	O
pain	O
-	O
relieving	O
effect	O
of	O
opioid	O
drugs	O
,	O
such	O
as	O
morphine	B-CHEMICAL
and	O
fentanyl	B-CHEMICAL
as	O
well	O
as	O
endogenous	B-GENE-N
opioid	I-GENE-N
peptides	I-GENE-N
enkephalins	B-CHEMICAL
and	O
endorphins	B-GENE-N
.	O

Using	O
cDNAs	O
for	O
the	O
mu	B-GENE-N
and	I-GENE-N
the	I-GENE-N
kappa	I-GENE-N
opioid	I-GENE-N
receptors	I-GENE-N
,	O
we	O
mapped	O
the	O
chromosomal	O
locations	O
of	O
their	O
genes	O
in	O
mouse	O
.	O

Multilocus	O
cross	O
analysis	O
located	O
the	O
mu	B-GENE-Y
receptor	I-GENE-Y
gene	O
Oprm	B-GENE-Y
on	O
Chr	O
10	O
and	O
the	O
kappa	B-GENE-Y
receptor	I-GENE-Y
gene	O
Oprk1	B-GENE-Y
on	O
Chr	O
1	O
.	O

Both	O
genes	O
are	O
near	O
centromere	O
,	O
with	O
no	O
markers	O
more	O
centromeric	O
.	O

These	O
data	O
indicate	O
that	O
the	O
two	O
opioid	B-GENE-N
receptors	I-GENE-N
are	O
different	O
gene	O
products	O
,	O
ruling	O
out	O
the	O
possibility	O
that	O
they	O
may	O
be	O
differential	O
splicing	O
products	O
from	O
the	O
same	O
gene	O
.	O

Heterogeneous	O
expression	O
and	O
polymorphic	O
genotype	O
of	O
glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferases	I-GENE-N
in	O
human	O
lung	O
.	O

BACKGROUND	O
:	O
Glutathione	B-GENE-N
S	I-GENE-N
-	I-GENE-N
transferases	I-GENE-N
(	O
GSTs	B-GENE-N
)	O
are	O
involved	O
in	O
the	O
detoxification	O
of	O
xenobiotics	O
by	O
conjugation	O
with	O
glutathione	B-CHEMICAL
.	O

One	O
of	O
the	O
mu	O
class	O
genes	O
of	O
this	O
superfamily	O
of	O
enzymes	O
,	O
GSTM1	B-GENE-Y
,	O
is	O
polymorphic	O
because	O
of	O
a	O
partial	O
gene	O
deletion	O
.	O

This	O
results	O
in	O
a	O
failure	O
to	O
express	O
GSTM1	B-GENE-Y
in	O
approximately	O
50	O
%	O
of	O
individuals	O
.	O

Several	O
studies	O
have	O
linked	O
GSTM1	B-GENE-Y
null	O
status	O
to	O
an	O
increased	O
risk	O
of	O
lung	O
carcinoma	O
.	O

This	O
study	O
investigated	O
the	O
expression	O
and	O
distribution	O
of	O
GST	B-GENE-N
isoenzymes	O
in	O
human	O
lung	O
,	O
and	O
developed	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
which	O
would	O
allow	O
genotyping	O
of	O
archival	O
,	O
paraffin	O
embedded	O
lung	O
tissue	O
.	O

METHODS	O
:	O
Distribution	O
was	O
examined	O
using	O
a	O
panel	O
of	O
polyclonal	O
anti	O
-	O
GST	B-GENE-N
antibodies	O
for	O
immunohistochemistry	O
in	O
normal	O
tissue	O
of	O
21	O
tumour	O
-	O
bearing	O
lungs	O
.	O

DNA	O
for	O
PCR	O
was	O
extracted	O
from	O
paraffin	O
blocks	O
and	O
a	O
control	O
group	O
of	O
350	O
blood	O
lysates	O
.	O

As	O
a	O
positive	O
control	O
each	O
assay	O
amplified	O
part	O
of	O
GSTM4	B-GENE-Y
,	O
a	O
mu	O
class	O
gene	O
which	O
is	O
not	O
polymorphic	O
but	O
which	O
shows	O
strong	O
sequence	O
homology	O
to	O
GSTM1	B-GENE-Y
.	O

The	O
presence	O
of	O
GST	B-GENE-N
in	O
bronchoalveolar	O
lavage	O
fluid	O
was	O
sought	O
by	O
Western	O
analysis	O
.	O

RESULTS	O
:	O
Proximal	O
airways	O
contained	O
pi	B-GENE-Y
class	I-GENE-Y
GST	I-GENE-Y
,	O
alpha	B-GENE-N
class	I-GENE-N
GST	I-GENE-N
,	O
and	O
mu	B-GENE-N
class	I-GENE-N
GST	I-GENE-N
with	O
expression	O
concentrated	O
in	O
the	O
brush	O
border	O
.	O

In	O
distal	O
airspaces	O
no	O
alpha	B-GENE-N
GST	I-GENE-N
was	O
expressed	O
but	O
pi	B-GENE-Y
GST	I-GENE-Y
and	O
mu	B-GENE-N
GST	I-GENE-N
were	O
present	O
in	O
alveolar	O
cells	O
and	O
also	O
alveolar	O
macrophages	O
.	O

Pi	B-GENE-Y
class	I-GENE-Y
GST	I-GENE-Y
was	O
present	O
in	O
bronchoalveolar	O
lavage	O
fluid	O
.	O

The	O
PCR	O
assay	O
enabled	O
genotypic	O
determination	O
using	O
DNA	O
extracted	O
from	O
archival	O
material	O
.	O

Of	O
the	O
control	O
group	O
56	O
%	O
were	O
null	O
at	O
the	O
GSTM1	B-GENE-Y
locus	O
.	O

CONCLUSIONS	O
:	O
The	O
distribution	O
of	O
GST	B-GENE-N
isoenzymes	O
in	O
the	O
lung	O
is	O
heterogeneous	O
with	O
an	O
apparent	O
decrease	O
in	O
GST	B-GENE-N
in	O
distal	O
lung	O
.	O

Since	O
GSTM1	B-GENE-Y
status	O
has	O
already	O
been	O
associated	O
with	O
susceptibility	O
to	O
disease	O
,	O
the	O
PCR	O
assay	O
developed	O
will	O
allow	O
further	O
studies	O
of	O
the	O
relation	O
between	O
genotype	O
and	O
structural	O
disorders	O
in	O
the	O
lung	O
using	O
archival	O
pathological	O
material	O
.	O

Folding	O
pathway	O
of	O
guanidine	B-CHEMICAL
-	O
denatured	O
disulfide	B-CHEMICAL
-	O
intact	O
wild	O
-	O
type	O
and	O
mutant	O
bovine	B-GENE-Y
pancreatic	I-GENE-Y
ribonuclease	I-GENE-Y
A	I-GENE-Y
.	O

The	O
refolding	O
kinetics	O
of	O
guanidine	B-CHEMICAL
-	O
denatured	O
disulfide	B-CHEMICAL
-	O
intact	O
bovine	B-GENE-Y
pancreatic	I-GENE-Y
ribonuclease	I-GENE-Y
A	I-GENE-Y
(	O
RNase	B-GENE-Y
A	I-GENE-Y
)	O
and	O
its	O
proline	B-GENE-N
-	I-GENE-N
42	I-GENE-N
-	I-GENE-N
to	I-GENE-N
-	I-GENE-N
alanine	I-GENE-N
mutant	O
(	O
Pro42Ala	B-GENE-N
)	O
have	O
been	O
studied	O
by	O
monitoring	O
tyrosine	B-CHEMICAL
burial	O
and	O
2	B-CHEMICAL
'	I-CHEMICAL
-	I-CHEMICAL
cytidine	I-CHEMICAL
monophosphate	I-CHEMICAL
(	O
2	B-CHEMICAL
'	I-CHEMICAL
CMP	I-CHEMICAL
)	O
inhibitor	O
binding	O
.	O

The	O
folding	O
rate	O
for	O
wild	O
-	O
type	O
RNase	B-GENE-Y
A	I-GENE-Y
is	O
faster	O
in	O
the	O
presence	O
of	O
the	O
inhibitor	O
2	B-CHEMICAL
'	I-CHEMICAL
CMP	I-CHEMICAL
than	O
in	O
its	O
absence	O
,	O
indicating	O
that	O
the	O
transition	O
-	O
state	O
structure	O
in	O
the	O
rate	O
-	O
determining	O
step	O
is	O
stabilized	O
by	O
2	B-CHEMICAL
'	I-CHEMICAL
CMP	I-CHEMICAL
.	O

The	O
folding	O
rate	O
monitored	O
by	O
2	B-CHEMICAL
'	I-CHEMICAL
CMP	I-CHEMICAL
binding	O
to	O
the	O
major	O
slow	O
-	O
folding	O
species	O
of	O
Pro42Ala	B-GENE-N
RNase	B-GENE-Y
A	I-GENE-Y
is	O
faster	O
than	O
the	O
folding	O
rate	O
monitored	O
by	O
tyrosine	B-CHEMICAL
burial	O
;	O
however	O
,	O
the	O
folding	O
rate	O
monitored	O
by	O
inhibitor	O
binding	O
to	O
the	O
minor	O
slow	O
-	O
folding	O
species	O
is	O
decreased	O
significantly	O
over	O
the	O
folding	O
rate	O
monitored	O
by	O
tyrosine	B-CHEMICAL
burial	O
,	O
indicating	O
that	O
the	O
major	O
and	O
minor	O
slow	O
-	O
folding	O
species	O
of	O
Pro42Ala	B-GENE-N
fold	O
to	O
the	O
native	O
state	O
with	O
different	O
transition	O
-	O
state	O
conformations	O
in	O
the	O
rate	O
-	O
determining	O
step	O
.	O

Inhibition	O
of	O
NF	B-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
by	O
sodium	O
salicylate	O
and	O
aspirin	O
.	O

The	O
transcription	O
factor	O
nuclear	B-GENE-N
factor	I-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
(	O
NF	B-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	O
and	O
viral	O
genes	O
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin	B-GENE-N
-	I-GENE-N
1	I-GENE-N
(	O
IL	B-GENE-N
-	I-GENE-N
1	I-GENE-N
)	O
,	O
IL	B-GENE-Y
-	I-GENE-Y
6	I-GENE-Y
,	O
and	O
adhesion	O
molecules	O
.	O

The	O
anti	O
-	O
inflammatory	O
drugs	O
sodium	B-CHEMICAL
salicylate	I-CHEMICAL
and	O
aspirin	B-CHEMICAL
inhibited	O
the	O
activation	O
of	O
NF	B-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF	B-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
inhibitor	O
,	O
I	B-GENE-N
kappa	I-GENE-N
B	I-GENE-N
,	O
and	O
therefore	O
NF	B-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	B-CHEMICAL
salicylate	I-CHEMICAL
and	O
aspirin	B-CHEMICAL
also	O
inhibited	O
NF	B-GENE-N
-	I-GENE-N
kappa	I-GENE-N
B	I-GENE-N
-	O
dependent	O
transcription	O
from	O
the	O
Ig	B-GENE-Y
kappa	I-GENE-Y
enhancer	O
and	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
transfected	O
T	O
cells	O
.	O

Comparisons	O
of	O
beta	O
-	O
adrenergic	O
blocking	O
properties	O
of	O
S	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
R	I-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
in	O
humans	O
.	O

In	O
animals	O
,	O
the	O
R	B-CHEMICAL
-	I-CHEMICAL
enantiomer	I-CHEMICAL
of	I-CHEMICAL
timolol	I-CHEMICAL
causes	O
a	O
significant	O
reduction	O
in	O
intraocular	O
pressure	O
but	O
had	O
only	O
1	O
/	O
80	O
the	O
activity	O
of	O
the	O
S	O
-	O
enantiomer	O
at	O
extraocular	B-GENE-N
receptors	I-GENE-N
.	O

The	O
beta	B-GENE-N
1	I-GENE-N
-	I-GENE-N
and	I-GENE-N
beta	I-GENE-N
2	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
blocking	O
properties	O
of	O
orally	O
administered	O
R	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
were	O
compared	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
controlled	O
trial	O
in	O
two	O
groups	O
of	O
healthy	O
men	O
.	O

Each	O
subject	O
in	O
group	O
A	O
(	O
n	O
=	O
6	O
)	O
received	O
placebo	O
,	O
1	O
and	O
3	O
mg	O
S	B-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
and	O
25	O
and	O
75	O
mg	O
R	B-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
in	O
random	O
order	O
,	O
group	O
B	O
(	O
n	O
=	O
5	O
)	O
received	O
placebo	O
,	O
0	O
.	O
5	O
,	O
and	O
1	O
mg	O
S	B-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
and	O
3	O
and	O
10	O
mg	O
R	B-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
.	O

In	O
both	O
groups	O
,	O
R	B-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
S	I-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
comparably	O
inhibited	O
isoproterenol	B-CHEMICAL
-	O
induced	O
increases	O
in	O
heart	O
rate	O
(	O
P	O
<	O
.	O
05	O
)	O
,	O
forearm	O
blood	O
flow	O
(	O
P	O
<	O
.	O
05	O
,	O
except	O
at	O
3	O
micrograms	O
/	O
minute	O
of	O
isoproterenol	B-CHEMICAL
after	O
the	O
R	O
-	O
doses	O
in	O
group	O
B	O
)	O
,	O
and	O
finger	O
tremor	O
(	O
P	O
<	O
.	O
05	O
)	O
in	O
comparison	O
with	O
placebo	O
.	O

The	O
findings	O
for	O
the	O
R	O
-	O
enantiomer	O
in	O
this	O
study	O
were	O
unexpected	O
based	O
on	O
the	O
animal	O
studies	O
and	O
previous	O
studies	O
that	O
demonstrated	O
marked	O
differences	O
in	O
beta	O
blocking	O
effects	O
of	O
other	O
beta	O
-	O
blockers	O
in	O
which	O
the	O
R	O
-	O
enantiomers	O
were	O
less	O
inhibitory	O
.	O

Dopamine	B-GENE-Y
D2	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
imaging	O
with	O
123I	B-CHEMICAL
-	I-CHEMICAL
iodobenzamide	I-CHEMICAL
SPECT	O
in	O
migraine	O
patients	O
abusing	O
ergotamine	B-CHEMICAL
:	O
does	O
ergotamine	B-CHEMICAL
cross	O
the	O
blood	O
brain	O
barrier	O
?	O

Two	O
migraine	O
patients	O
were	O
studied	O
by	O
in	O
vivo	O
SPECT	O
using	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
specific	O
radioligand	O
123I	B-CHEMICAL
-	I-CHEMICAL
3	I-CHEMICAL
-	I-CHEMICAL
iodo	I-CHEMICAL
-	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
methoxybenzamide	I-CHEMICAL
(	O
123I	B-CHEMICAL
-	I-CHEMICAL
IBZM	I-CHEMICAL
)	O
during	O
ergotamine	B-CHEMICAL
abuse	O
and	O
after	O
withdrawal	O
.	O

Results	O
were	O
compared	O
with	O
15	O
healthy	O
controls	O
.	O

Striatum	O
/	O
cerebellum	O
and	O
striatum	O
/	O
occipital	O
cortex	O
ratios	O
of	O
count	O
rate	O
density	O
were	O
calculated	O
as	O
a	O
semiquantitative	O
measurement	O
for	O
striatal	O
dopamine	B-GENE-Y
D2	I-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
binding	O
potential	O
.	O

No	O
differences	O
were	O
found	O
in	O
striatal	O
uptake	O
of	O
123I	B-CHEMICAL
-	I-CHEMICAL
IBZM	I-CHEMICAL
between	O
healthy	O
controls	O
and	O
the	O
patients	O
when	O
on	O
or	O
off	O
ergotamine	B-CHEMICAL
.	O

Preliminary	O
evidence	O
suggests	O
that	O
ergotamine	B-CHEMICAL
may	O
not	O
occupy	O
striatal	O
dopamine	B-GENE-Y
D2	I-GENE-Y
-	I-GENE-Y
receptors	I-GENE-Y
to	O
a	O
large	O
extent	O
and	O
thus	O
may	O
not	O
cross	O
the	O
blood	O
brain	O
barrier	O
in	O
large	O
quantities	O
.	O

Nonadrenergic	O
imidazoline	B-CHEMICAL
binding	O
sites	O
on	O
human	O
platelets	O
.	O

Human	O
platelets	O
are	O
shown	O
to	O
possess	O
at	O
least	O
two	O
high	O
-	O
affinity	O
,	O
imidazol	B-CHEMICAL
(	I-CHEMICAL
in	I-CHEMICAL
)	I-CHEMICAL
e	I-CHEMICAL
-	O
preferring	O
binding	O
sites	O
that	O
are	O
pharmacologically	O
distinct	O
from	O
alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptors	I-GENE-N
.	O

These	O
nonadrenergic	O
sites	O
were	O
radiolabeled	O
even	O
in	O
the	O
presence	O
of	O
a	O
10	O
microM	O
norepinephrine	B-CHEMICAL
mask	O
of	O
alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptors	I-GENE-N
.	O

Heterogeneity	O
at	O
the	O
nonadrenergic	O
sites	O
was	O
demonstrated	O
by	O
comparing	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
idazoxan	I-CHEMICAL
(	O
IDX	B-CHEMICAL
)	O
binding	O
vs	O
.	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
p	I-CHEMICAL
-	I-CHEMICAL
iodoclonidine	I-CHEMICAL
(	O
PIC	B-CHEMICAL
)	O
binding	O
.	O

Nonadrenergic	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
PIC	I-CHEMICAL
-	O
labeled	O
sites	O
were	O
enriched	O
in	O
platelet	O
plasma	O
membranes	O
,	O
whereas	O
the	O
nonadrenergic	O
sites	O
labeled	O
by	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
IDX	I-CHEMICAL
were	O
codistributed	O
between	O
plasma	O
and	O
internal	O
membranes	O
(	O
nonadrenergic	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
PIC	I-CHEMICAL
-	O
labeled	O
sites	O
had	O
Bmax	O
=	O
62	O
fmol	O
/	O
mg	O
in	O
plasma	O
membranes	O
and	O
20	O
fmol	O
/	O
mg	O
in	O
internal	O
membranes	O
vs	O
.	O
the	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
IDX	I-CHEMICAL
-	O
labeled	O
sites	O
had	O
Bmax	O
=	O
141	O
fmol	O
/	O
mg	O
in	O
plasma	O
membranes	O
and	O
192	O
fmol	O
/	O
mg	O
in	O
internal	O
membranes	O
)	O
.	O

Furthermore	O
,	O
competition	O
binding	O
studies	O
in	O
the	O
presence	O
of	O
a	O
10	O
microM	O
norepinephrine	B-CHEMICAL
mask	O
revealed	O
major	O
(	O
approximately	O
75	O
%	O
)	O
and	O
minor	O
(	O
approximately	O
25	O
%	O
)	O
binding	O
components	O
on	O
plasma	O
membranes	O
for	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
PIC	I-CHEMICAL
.	O

Affinities	O
for	O
the	O
major	O
nonadrenergic	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
PIC	I-CHEMICAL
binding	O
site	O
were	O
highly	O
comparable	O
to	O
human	B-GENE-Y
subtype	I-GENE-Y
-	I-GENE-Y
I1	I-GENE-Y
imidazol	I-GENE-Y
(	I-GENE-Y
in	I-GENE-Y
)	I-GENE-Y
e	I-GENE-Y
receptor	I-GENE-Y
sites	O
in	O
the	O
brain	O
stem	O
(	O
rank	O
order	O
:	O
moxonidine	B-CHEMICAL
>	O
clonidine	B-CHEMICAL
>	O
cirazoline	B-CHEMICAL
>	O
IDX	B-CHEMICAL
>	O
amiloride	B-CHEMICAL
)	O
.	O

However	O
,	O
the	O
minor	O
component	O
of	O
[	B-CHEMICAL
125I	I-CHEMICAL
]	I-CHEMICAL
PIC	I-CHEMICAL
binding	O
was	O
similar	O
to	O
a	O
site	O
reported	O
in	O
kidney	O
,	O
having	O
low	O
affinities	O
for	O
all	O
compounds	O
tested	O
,	O
except	O
guanabenz	B-CHEMICAL
.	O

Finally	O
,	O
a	O
third	O
nonadrenergic	O
internal	O
membrane	O
site	O
,	O
labeled	O
by	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
IDX	I-CHEMICAL
,	O
was	O
consistent	O
with	O
a	O
subtype	B-GENE-N
-	I-GENE-N
I2	I-GENE-N
imidazol	I-GENE-N
(	I-GENE-N
in	I-GENE-N
)	I-GENE-N
e	I-GENE-N
receptor	I-GENE-N
site	O
(	O
rank	O
order	O
:	O
cirazoline	B-CHEMICAL
>	O
IDX	O
>	O
>	O
amiloride	B-CHEMICAL
>	O
moxonidine	B-CHEMICAL
>	O
clonidine	B-CHEMICAL
)	O
.	O

Thus	O
,	O
based	O
on	O
differential	O
subcellular	O
distributions	O
and	O
affinity	O
constants	O
,	O
human	O
platelets	O
appear	O
to	O
possess	O
imidazoline	B-GENE-N
receptors	I-GENE-N
(	O
subtype	B-GENE-Y
-	I-GENE-Y
I1	I-GENE-Y
imidazol	I-GENE-Y
(	I-GENE-Y
in	I-GENE-Y
)	I-GENE-Y
e	I-GENE-Y
receptor	I-GENE-Y
and	O
subtype	B-GENE-N
-	I-GENE-N
I2	I-GENE-N
imidazol	I-GENE-N
(	I-GENE-N
in	I-GENE-N
)	I-GENE-N
e	I-GENE-N
receptor	I-GENE-N
)	O
,	O
plus	O
a	O
novel	O
guanabenz	B-CHEMICAL
-	O
sensitive	O
site	O
,	O
as	O
well	O
as	O
an	O
alpha	B-GENE-Y
-	I-GENE-Y
2A	I-GENE-Y
adrenoceptor	I-GENE-Y
.	O

These	O
nonadrenoceptor	O
binding	O
sites	O
may	O
explain	O
certain	O
novel	O
platelet	O
aggregatory	O
properties	O
previously	O
ascribed	O
to	O
clonidine	B-CHEMICAL
and	O
endogenous	O
clonidine	B-CHEMICAL
-	O
displacing	O
substance	O
(	O
s	O
)	O
,	O
and	O
may	O
serve	O
as	O
markers	O
of	O
imidazoline	B-GENE-N
receptors	I-GENE-N
in	O
humans	O
.	O

A	O
cocaine	B-CHEMICAL
-	O
sensitive	O
Drosophila	B-GENE-Y
serotonin	I-GENE-Y
transporter	I-GENE-Y
:	O
cloning	O
,	O
expression	O
,	O
and	O
electrophysiological	O
characterization	O
.	O

A	O
cocaine	B-CHEMICAL
-	O
sensitive	O
,	O
high	O
-	O
affinity	O
Drosophila	B-GENE-Y
serotonin	I-GENE-Y
(	I-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
hydroxytryptamine	I-GENE-Y
;	I-GENE-Y
5HT	I-GENE-Y
)	I-GENE-Y
transporter	I-GENE-Y
cDNA	O
,	O
denoted	O
dSERT1	B-GENE-Y
,	O
was	O
isolated	O
and	O
characterized	O
in	O
oocytes	O
.	O

dSERT1	B-GENE-Y
shows	O
little	O
transport	O
of	O
other	O
monoamines	B-CHEMICAL
and	O
is	O
Na	B-CHEMICAL
+	I-CHEMICAL
and	O
Cl	B-CHEMICAL
-	I-CHEMICAL
dependent	O
.	O

Sequence	O
analysis	O
indicates	O
12	O
putative	O
transmembrane	O
domains	O
and	O
strong	O
homologies	O
(	O
approximately	O
50	O
%	O
)	O
among	O
dSERT1	B-GENE-Y
and	O
mammalian	B-GENE-N
5HT	I-GENE-N
,	I-GENE-N
norepinephrine	I-GENE-N
,	I-GENE-N
and	I-GENE-N
dopamine	I-GENE-N
transporters	I-GENE-N
.	O

Interestingly	O
,	O
the	O
pharmacological	O
properties	O
of	O
dSERT1	B-GENE-Y
,	O
including	O
sensitivity	O
to	O
antidepressants	O
,	O
are	O
more	O
similar	O
to	O
those	O
of	O
mammalian	B-GENE-N
catecholamine	I-GENE-N
transporters	I-GENE-N
than	O
to	O
mammalian	B-GENE-N
5HT	I-GENE-N
transporters	I-GENE-N
.	O

Two	O
-	O
electrode	O
voltage	O
-	O
clamp	O
analysis	O
demonstrated	O
5HT	B-CHEMICAL
-	O
induced	O
,	O
voltage	O
-	O
dependent	O
currents	O
.	O

Cloning	O
and	O
characterization	O
of	O
dSERT1	B-GENE-Y
adds	O
significantly	O
to	O
our	O
knowledge	O
of	O
the	O
diversity	O
of	O
5HT	B-GENE-Y
transporters	I-GENE-Y
with	O
regard	O
to	O
primary	O
sequence	O
,	O
pharmacological	O
profile	O
,	O
and	O
permeation	O
properties	O
.	O

Glucocorticosteroids	O
affect	O
functions	O
of	O
airway	O
-	O
and	O
blood	O
-	O
derived	O
human	O
T	O
-	O
cell	O
clones	O
,	O
favoring	O
the	O
Th1	O
profile	O
through	O
two	O
mechanisms	O
.	O

Glucocorticosteroids	O
(	O
GCS	B-CHEMICAL
)	O
are	O
beneficial	O
in	O
allergic	O
asthma	O
.	O

GCS	B-CHEMICAL
therapy	O
results	O
in	O
reduced	O
mRNA	O
expression	O
of	O
interleukin	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
)	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
in	O
cells	O
from	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
but	O
not	O
of	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
.	O

In	O
vitro	O
studies	O
with	O
blood	O
-	O
derived	O
T	O
cells	O
,	O
however	O
,	O
show	O
inhibition	O
of	O
all	O
three	O
cytokines	B-GENE-N
by	O
GCS	B-CHEMICAL
.	O

We	O
studied	O
the	O
effects	O
of	O
GCS	B-CHEMICAL
on	O
T	O
cells	O
from	O
BAL	O
in	O
vitro	O
,	O
namely	O
Th0	O
-	O
,	O
Th1	O
,	O
and	O
Th2	O
-	O
like	O
clones	O
;	O
and	O
we	O
compared	O
BAL	O
-	O
with	O
blood	O
-	O
derived	O
clones	O
.	O

Dexamethasone	B-CHEMICAL
(	O
DEX	B-CHEMICAL
)	O
inhibited	O
the	O
anti	O
-	O
CD3	B-GENE-N
-	O
induced	O
production	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
,	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
and	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
in	O
all	O
20	O
clones	O
tested	O
.	O

IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
production	O
was	O
inhibited	O
significantly	O
less	O
than	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
.	O

DEX	B-CHEMICAL
enhanced	O
the	O
ratio	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
/	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
(	O
mean	O
+	O
/	O
-	O
SEM	O
:	O
control	O
,	O
28	O
.	O
7	O
+	O
/	O
-	O
17	O
.	O
6	O
;	O
with	O
10	O
-	O
7	O
M	O
DEX	O
,	O
55	O
.	O
0	O
+	O
/	O
-	O
27	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
005	O
)	O
.	O

Interestingly	O
,	O
two	O
categories	O
of	O
clones	O
were	O
distinguished	O
based	O
on	O
the	O
effects	O
of	O
GCS	B-CHEMICAL
on	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
production	O
and	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
expression	O
and	O
proliferation	O
;	O
1	O
)	O
In	O
low	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
producers	O
DEX	B-CHEMICAL
blocked	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
production	O
and	O
decreased	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
expression	O
and	O
proliferation	O
;	O
2	O
)	O
In	O
high	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
producers	O
DEX	B-CHEMICAL
inhibited	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
production	O
partially	O
and	O
enhanced	O
IL	B-GENE-Y
-	I-GENE-Y
2R	I-GENE-Y
alpha	I-GENE-Y
expression	O
and	O
proliferation	O
.	O

Anti	O
-	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
anti	O
-	O
IL2R	B-GENE-Y
alpha	I-GENE-Y
blocked	O
the	O
DEX	B-CHEMICAL
-	O
induced	O
increase	O
in	O
proliferation	O
.	O

High	O
levels	O
of	O
added	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
induced	O
the	O
second	O
type	O
of	O
response	O
.	O

In	O
conclusion	O
,	O
the	O
production	O
of	O
IL	B-GENE-Y
-	I-GENE-Y
4	I-GENE-Y
and	O
IL	B-GENE-Y
-	I-GENE-Y
5	I-GENE-Y
by	O
T	O
-	O
cell	O
clones	O
(	O
derived	O
either	O
from	O
BAL	O
or	O
blood	O
)	O
was	O
more	O
sensitive	O
to	O
inhibition	O
by	O
DEX	B-CHEMICAL
than	O
that	O
of	O
IFN	B-GENE-Y
-	I-GENE-Y
gamma	I-GENE-Y
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticosteroids	O
in	O
patients	O
with	O
asthma	O
.	O

The	O
differential	O
effects	O
of	O
DEX	B-CHEMICAL
on	O
the	O
proliferation	O
of	O
high	O
and	O
low	O
IL	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
producers	O
in	O
vitro	O
may	O
implicate	O
a	O
selective	O
outgrowth	O
of	O
Th1	O
-	O
like	O
T	O
cells	O
in	O
vivo	O
in	O
patients	O
treated	O
with	O
steroids	B-CHEMICAL
.	O

Structural	O
features	O
of	O
the	O
central	O
cannabinoid	B-CHEMICAL
CB1	B-GENE-Y
receptor	O
involved	O
in	O
the	O
binding	O
of	O
the	O
specific	O
CB1	B-GENE-Y
antagonist	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
.	O

The	O
antagonist	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
has	O
a	O
high	O
specificity	O
for	O
the	O
central	O
CB1	B-GENE-Y
cannabinoid	B-GENE-N
receptor	I-GENE-N
and	O
negligeable	O
affinity	O
for	O
the	O
peripheral	O
CB2	B-GENE-Y
receptor	O
,	O
making	O
it	O
an	O
excellent	O
tool	O
for	O
probing	O
receptor	O
structure	O
-	O
activity	O
relationships	O
.	O

From	O
binding	O
experiments	O
with	O
mutated	O
CB1	B-GENE-Y
and	O
with	O
chimeric	O
CB1	B-GENE-Y
/	O
CB2	B-GENE-Y
receptors	O
we	O
have	O
begun	O
to	O
identify	O
the	O
domains	O
of	O
CB1	B-GENE-Y
implicated	O
in	O
the	O
recognition	O
of	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
.	O

Receptors	O
were	O
transiently	O
expressed	O
in	O
COS	O
-	O
3	O
cells	O
,	O
and	O
their	O
binding	O
characteristics	O
were	O
studied	O
with	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
and	O
with	O
CP	B-CHEMICAL
55	I-CHEMICAL
,	I-CHEMICAL
940	I-CHEMICAL
,	O
an	O
agonist	O
recognized	O
equally	O
well	O
by	O
the	O
two	O
receptors	O
.	O

The	O
region	O
delineated	O
by	O
the	O
fourth	O
and	O
fifth	O
transmembrane	O
helices	O
of	O
CB1	B-GENE-Y
proved	O
to	O
be	O
crucial	O
for	O
high	O
affinity	O
binding	O
of	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
.	O

The	O
CB1	B-GENE-Y
and	O
CB2	B-GENE-Y
second	O
extracellular	O
loops	O
,	O
e2	O
,	O
were	O
exchanged	O
,	O
modifications	O
that	O
had	O
no	O
effect	O
on	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
binding	O
in	O
the	O
CB1	B-GENE-Y
variant	O
but	O
that	O
eliminated	O
CP	B-CHEMICAL
55	I-CHEMICAL
,	I-CHEMICAL
940	I-CHEMICAL
binding	O
in	O
both	O
mutants	O
.	O

The	O
replacement	O
of	O
the	O
conserved	O
cysteine	B-CHEMICAL
residues	O
in	O
e2	O
of	O
CB2	B-GENE-Y
by	O
serine	B-CHEMICAL
also	O
eliminated	O
CP	B-CHEMICAL
55	I-CHEMICAL
,	I-CHEMICAL
940	I-CHEMICAL
binding	O
,	O
but	O
replacement	O
of	O
those	O
in	O
CB1	B-GENE-Y
resulted	O
in	O
the	O
sequestration	O
of	O
the	O
mutated	O
receptors	O
in	O
the	O
cell	O
cytoplasm	O
.	O

The	O
e2	B-GENE-N
domain	I-GENE-N
thus	O
plays	O
some	O
role	O
in	O
CP	B-CHEMICAL
55	I-CHEMICAL
,	I-CHEMICAL
940	I-CHEMICAL
binding	O
but	O
none	O
in	O
SR	B-CHEMICAL
141716A	I-CHEMICAL
recognition	O
,	O
binding	O
of	O
the	O
latter	O
clearly	O
implicating	O
residues	O
in	O
the	O
adjoining	O
transmembrane	O
helices	O
.	O

Fluticasone	B-CHEMICAL
propionate	I-CHEMICAL
:	O
safety	O
profile	O
.	O

Fluticasone	B-CHEMICAL
propionate	I-CHEMICAL
is	O
a	O
potent	O
fluorinated	O
corticosteroid	O
used	O
for	O
the	O
topical	O
therapy	O
of	O
dermatoses	O
and	O
as	O
inhalation	O
therapy	O
for	O
bronchial	O
asthma	O
and	O
allergic	O
rhinitis	O
.	O

This	O
agent	O
has	O
a	O
good	O
safety	O
profile	O
with	O
a	O
low	O
propensity	O
for	O
systemic	O
side	O
effects	O
,	O
such	O
as	O
suppression	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
,	O
and	O
a	O
low	O
incidence	O
of	O
local	O
side	O
effects	O
such	O
as	O
pruritus	O
,	O
burning	O
,	O
or	O
skin	O
atrophy	O
.	O

The	O
pharmacologic	O
properties	O
of	O
fluticasone	B-CHEMICAL
propionate	I-CHEMICAL
-	O
including	O
high	O
lipophilicity	O
,	O
high	O
selectivity	O
and	O
affinity	O
for	O
the	O
glucocorticoid	B-GENE-Y
receptor	I-GENE-Y
,	O
low	O
systemic	O
absorption	O
,	O
and	O
rapid	O
metabolism	O
and	O
clearance	O
-	O
combine	O
to	O
give	O
fluticasone	B-CHEMICAL
propionate	I-CHEMICAL
a	O
high	O
therapeutic	O
index	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
activate	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
by	O
a	O
direct	O
mechanism	O
of	O
action	O
.	O

Previous	O
studies	O
by	O
this	O
research	O
team	O
proved	O
that	O
vasodilating	O
prostaglandins	B-CHEMICAL
(	O
PGs	B-CHEMICAL
)	O
E1	O
,	O
E2	O
and	O
I2	O
inhibit	O
carbonic	B-GENE-N
anhydrase	I-GENE-N
(	O
CA	B-GENE-N
)	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
which	O
suggested	O
involvement	O
of	O
CA	B-GENE-N
in	O
gastric	O
acid	O
secretion	O
inhibition	O
and	O
the	O
increase	O
of	O
gastric	O
mucosa	O
blood	O
flow	O
produced	O
by	O
this	O
group	O
of	O
PGs	B-CHEMICAL
.	O

Relying	O
on	O
these	O
findings	O
,	O
as	O
well	O
as	O
on	O
our	O
clinical	O
observations	O
,	O
we	O
studied	O
in	O
vitro	O
and	O
in	O
vivo	O
the	O
effects	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
on	O
CA	B-GENE-Y
I	I-GENE-Y
and	O
CA	B-GENE-Y
II	I-GENE-Y
.	O

We	O
also	O
followed	O
in	O
vitro	O
the	O
effects	O
on	O
these	O
isozymes	O
of	O
NSAIDs	O
associated	O
to	O
histamine	B-CHEMICAL
,	O
Ca	B-CHEMICAL
,	O
PGE2	O
and	O
acetazolamide	B-CHEMICAL
.	O

The	O
results	O
show	O
that	O
the	O
NSAIDs	O
used	O
here	O
,	O
which	O
reduce	O
the	O
activity	O
of	O
cyclooxygenase	B-GENE-N
and	O
PG	B-CHEMICAL
production	O
,	O
activated	O
CA	B-GENE-Y
I	I-GENE-Y
and	O
CA	B-GENE-Y
II	I-GENE-Y
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
a	O
mechanism	O
of	O
the	O
noncompetitive	O
type	O
.	O

Histamine	B-CHEMICAL
and	O
Ca	B-CHEMICAL
added	O
to	O
NSAIDs	O
amplified	O
the	O
activating	O
effect	O
of	O
the	O
latter	O
on	O
CA	B-GENE-Y
II	I-GENE-Y
.	O

Association	O
of	O
PGE2	O
or	O
acetazolamide	B-CHEMICAL
to	O
NSAIDs	O
reduced	O
NSAID	O
-	O
induced	O
activation	O
of	O
CA	B-GENE-Y
I	I-GENE-Y
and	O
CA	B-GENE-Y
II	I-GENE-Y
.	O

Indomethacin	B-CHEMICAL
abolished	O
the	O
inhibitory	O
effect	O
of	O
acetazolamide	B-CHEMICAL
on	O
CA	B-GENE-Y
I	I-GENE-Y
and	O
CA	B-GENE-Y
II	I-GENE-Y
.	O

Our	O
data	O
imply	O
that	O
between	O
CA	B-GENE-N
and	O
cyclooxygenase	B-GENE-N
there	O
is	O
an	O
inverse	O
relationship	O
,	O
CA	B-GENE-N
activation	O
being	O
accompanied	O
by	O
reduction	O
of	O
cyclooxygenase	B-GENE-N
activity	O
,	O
a	O
reduction	O
achieved	O
by	O
the	O
pH	O
modifications	O
induced	O
by	O
CA	B-GENE-N
activation	O
.	O

In	O
this	O
way	O
,	O
cyclooxygenase	B-GENE-N
,	O
inhibition	O
occurs	O
"	O
via	O
CA	B-GENE-N
,	O
"	O
with	O
the	O
pH	O
variations	O
it	O
brings	O
about	O
.	O

Evaluation	O
of	O
the	O
pharmacological	O
selectivity	O
profile	O
of	O
alpha	B-GENE-N
1	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
at	O
prostatic	O
alpha	B-GENE-N
1	I-GENE-N
adrenoceptors	I-GENE-N
:	O
binding	O
,	O
functional	O
and	O
in	O
vivo	O
studies	O
.	O

1	O
.	O

The	O
profile	O
of	O
a	O
range	O
of	O
alpha	B-GENE-N
1	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
was	O
determined	O
in	O
vitro	O
against	O
cloned	O
human	B-GENE-N
alpha	I-GENE-N
1A	I-GENE-N
,	I-GENE-N
alpha	I-GENE-N
1B	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
1D	I-GENE-N
adrenoceptors	I-GENE-N
and	O
against	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
and	O
human	O
prostate	O
.	O

The	O
in	O
vivo	O
profile	O
of	O
compounds	O
was	O
determined	O
in	O
an	O
anaesthetized	O
dog	O
model	O
which	O
allowed	O
the	O
simultaneous	O
assessment	O
of	O
antagonist	O
potency	O
against	O
phenylephrine	B-CHEMICAL
-	O
mediated	O
increases	O
in	O
blood	O
pressure	O
and	O
prostatic	O
pressure	O
.	O

2	O
.	O

The	O
quinazoline	B-CHEMICAL
antagonists	O
,	O
prazosin	B-CHEMICAL
,	O
doxazosin	B-CHEMICAL
and	O
alfuzosin	B-CHEMICAL
displayed	O
high	O
affinity	O
but	O
were	O
non	O
selective	O
for	O
the	O
three	O
cloned	O
human	B-GENE-N
alpha	I-GENE-N
1	I-GENE-N
adrenoceptors	I-GENE-N
.	O

Indoramin	B-CHEMICAL
and	O
SNAP	B-CHEMICAL
1069	I-CHEMICAL
showed	O
selectivity	O
for	O
alpha	B-GENE-N
1A	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
1B	I-GENE-N
adrenoceptors	I-GENE-N
relative	O
to	O
the	O
alpha	B-GENE-Y
1D	I-GENE-Y
subtype	I-GENE-Y
.	O

Rec	B-CHEMICAL
15	I-CHEMICAL
/	I-CHEMICAL
2739	I-CHEMICAL
,	O
WB	B-CHEMICAL
4101	I-CHEMICAL
,	O
SL	B-CHEMICAL
89	I-CHEMICAL
,	I-CHEMICAL
0591	I-CHEMICAL
,	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
showed	O
selectivity	O
for	O
alpha	B-GENE-N
1A	I-GENE-N
and	I-GENE-N
alpha	I-GENE-N
1D	I-GENE-N
adrenoceptors	I-GENE-N
relative	O
to	O
the	O
alpha	B-GENE-Y
1B	I-GENE-Y
subtype	I-GENE-Y
.	O

RS	B-CHEMICAL
17053	I-CHEMICAL
showed	O
high	O
affinity	O
and	O
selectivity	O
for	O
alpha	B-GENE-Y
1A	I-GENE-Y
adrenoceptors	I-GENE-Y
(	O
pKi	O
8	O
.	O
6	O
)	O
relative	O
to	O
alpha	B-GENE-Y
1B	I-GENE-Y
(	O
pKi	O
=	O
7	O
.	O
3	O
)	O
and	O
alpha	B-GENE-Y
1D	I-GENE-Y
(	O
pKi	O
=	O
7	O
.	O
1	O
)	O
subtypes	O
.	O

3	O
.	O

(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Tamsulosin	I-CHEMICAL
,	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
,	O
SL	B-CHEMICAL
89	I-CHEMICAL
,	I-CHEMICAL
0591	I-CHEMICAL
,	O
Rec	B-CHEMICAL
15	I-CHEMICAL
/	I-CHEMICAL
2739	I-CHEMICAL
,	O
SNAP	B-CHEMICAL
1069	I-CHEMICAL
and	O
RS	B-CHEMICAL
17053	I-CHEMICAL
appeared	O
to	O
act	O
as	O
competitive	O
antagonists	O
of	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
rat	O
aorta	O
yielding	O
pA2	O
affinity	O
estimates	O
which	O
were	O
similar	O
to	O
binding	O
affinities	O
at	O
cloned	O
human	B-GENE-Y
alpha	I-GENE-Y
1D	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

The	O
following	O
rank	O
order	O
was	O
obtained	O
:	O
prazosin	B-CHEMICAL
=	O
(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
>	O
doxazosin	B-CHEMICAL
>	O
SL	B-CHEMICAL
89	I-CHEMICAL
,	I-CHEMICAL
0591	I-CHEMICAL
=	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
>	O
Rec	B-CHEMICAL
15	I-CHEMICAL
/	I-CHEMICAL
2739	I-CHEMICAL
>	O
RS	B-CHEMICAL
17053	I-CHEMICAL
=	O
SNAP	B-CHEMICAL
1069	I-CHEMICAL
.	O

4	O
.	O

(	B-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Tamsulosin	I-CHEMICAL
was	O
a	O
very	O
potent	O
,	O
insurmountable	O
antagonist	O
of	O
noradrenaline	B-CHEMICAL
-	O
mediated	O
contractions	O
of	O
human	O
prostate	O
,	O
yielding	O
an	O
approximate	O
pA2	O
estimate	O
of	O
9	O
.	O
8	O
at	O
1	O
nM	O
.	O

The	O
corresponding	O
(	O
+	O
)	O
-	O
enantiomer	O
was	O
30	O
fold	O
weaker	O
.	O

SL	O
89	O
,	O
0591	O
,	O
SNAP	O
1069	O
and	O
Rec	O
15	O
/	O
2739	O
yielded	O
pA2	O
estimates	O
which	O
compared	O
well	O
with	O
their	O
alpha	B-GENE-Y
1A	I-GENE-Y
binding	O
affinities	O
.	O

The	O
affinity	O
estimate	O
for	O
prazosin	B-CHEMICAL
on	O
human	O
prostate	O
was	O
lower	O
than	O
the	O
corresponding	O
binding	O
affinity	O
determined	O
at	O
alpha	B-GENE-Y
1A	I-GENE-Y
adrenoceptors	I-GENE-Y
and	O
RS	B-CHEMICAL
17053	I-CHEMICAL
was	O
a	O
very	O
weak	O
antagonist	O
on	O
human	O
prostate	O
(	O
pA2	O
=	O
6	O
.	O
0	O
)	O
relative	O
to	O
the	O
high	O
affinity	O
(	O
pKi	O
=	O
8	O
.	O
6	O
)	O
determined	O
at	O
cloned	O
human	B-GENE-Y
alpha	I-GENE-Y
1A	I-GENE-Y
adrenoceptors	I-GENE-Y
.	O

5	O
.	O

In	O
the	O
anaesthetized	O
dog	O
,	O
in	O
vivo	O
pseudo	O
"	O
pA2	O
'	O
values	O
showed	O
that	O
doxazosin	B-CHEMICAL
,	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
and	I-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
inhibited	O
phenylephrine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
prostatic	O
and	O
blood	O
pressure	O
with	O
similar	O
affinity	O
,	O
implying	O
that	O
these	O
agents	O
show	O
little	O
or	O
no	O
selectivity	O
for	O
prostatic	O
responses	O
in	O
this	O
model	O
.	O

SL	O
89	O
,	O
0591	O
and	O
SNAP	O
1069	O
were	O
moderately	O
selective	O
(	O
3	O
and	O
6	O
fold	O
respectively	O
)	O
for	O
prostatic	O
pressure	O
relative	O
to	O
blood	O
pressure	O
.	O

Rec	B-CHEMICAL
15	I-CHEMICAL
/	I-CHEMICAL
2739	I-CHEMICAL
was	O
a	O
more	O
potent	O
antagonist	O
of	O
phenylephrine	B-CHEMICAL
-	O
mediated	O
increases	O
in	O
prostatic	O
pressure	O
(	O
"	O
pA2	O
'	O
=	O
8	O
.	O
74	O
)	O
compared	O
to	O
blood	O
pressure	O
(	O
"	O
pA2	O
'	O
=	O
7	O
.	O
51	O
)	O
.	O

6	O
.	O

Data	O
in	O
this	O
study	O
suggest	O
that	O
the	O
alpha	B-GENE-N
1	I-GENE-N
adrenoceptor	I-GENE-N
mediating	O
noradrenaline	B-CHEMICAL
-	O
induced	O
contractions	O
of	O
human	O
prostate	O
,	O
whilst	O
having	O
some	O
of	O
the	O
characteristics	O
of	O
an	O
alpha	B-GENE-Y
1A	I-GENE-Y
adrenoceptor	I-GENE-Y
,	O
cannot	O
be	O
satisfactorily	O
aligned	O
with	O
cloned	O
alpha	B-GENE-N
1A	I-GENE-N
,	I-GENE-N
alpha	I-GENE-N
1B	I-GENE-N
or	I-GENE-N
alpha	I-GENE-N
1D	I-GENE-N
adrenoceptors	I-GENE-N
.	O

In	O
addition	O
,	O
studies	O
in	O
the	O
anaesthetized	O
dog	O
have	O
shown	O
that	O
agents	O
having	O
high	O
affinity	O
and	O
selectivity	O
for	O
prostatic	O
alpha	B-GENE-N
1	I-GENE-N
adrenoceptors	I-GENE-N
,	O
particularly	O
over	O
the	O
alpha	B-GENE-Y
1D	I-GENE-Y
subtype	I-GENE-Y
,	O
appear	O
to	O
inhibit	O
phenylephrine	B-CHEMICAL
-	O
induced	O
increases	O
in	O
prostatic	O
pressure	O
selectively	O
compared	O
to	O
blood	O
pressure	O
.	O

Alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
causing	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
-	O
mediated	O
vascular	O
relaxation	O
in	O
rats	O
.	O

The	O
alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
and	O
its	O
signal	O
transduction	O
pathway	O
mediating	O
vascular	O
relaxation	O
in	O
rats	O
were	O
studied	O
in	O
vitro	O
using	O
rings	O
of	O
superior	O
mesenteric	O
arteries	O
.	O

Removal	O
of	O
endothelium	O
or	O
incubation	O
with	O
NG	B-CHEMICAL
-	I-CHEMICAL
nitro	I-CHEMICAL
-	I-CHEMICAL
L	I-CHEMICAL
-	I-CHEMICAL
arginine	I-CHEMICAL
completely	O
blocked	O
relaxant	O
responses	O
to	O
UK14	B-CHEMICAL
,	I-CHEMICAL
304	I-CHEMICAL
,	O
suggesting	O
endothelium	O
-	O
derived	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
mediates	O
relaxation	O
.	O

The	O
order	O
of	O
potency	O
for	O
full	O
(	O
F	O
)	O
or	O
partial	O
(	O
P	O
)	O
agonists	O
causing	O
relaxation	O
was	O
guanabenz	B-CHEMICAL
(	O
P	O
)	O
>	O
UK14	B-CHEMICAL
,	I-CHEMICAL
304	I-CHEMICAL
(	O
F	O
)	O
>	O
clonidine	B-CHEMICAL
(	O
P	O
)	O
>	O
epinephrine	B-CHEMICAL
(	O
F	O
)	O
>	O
norepinephrine	B-CHEMICAL
(	O
F	O
)	O
.	O

Affinities	O
(	O
Ka	O
)	O
of	O
alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
-	O
selective	O
drugs	O
for	O
blocking	O
relaxation	O
were	O
obtained	O
in	O
side	O
-	O
by	O
-	O
side	O
experiments	O
comparing	O
rat	O
mesenteric	O
arteries	O
with	O
pig	O
coronary	O
arteries	O
.	O

Relaxation	O
of	O
pig	O
coronary	O
arteries	O
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
alpha	B-GENE-Y
-	I-GENE-Y
2A	I-GENE-Y
adrenoceptor	I-GENE-Y
subtype	O
.	O

Ka	O
values	O
in	O
nM	O
for	O
rauwolscine	B-CHEMICAL
(	O
19	O
)	O
,	O
WB	B-CHEMICAL
-	I-CHEMICAL
4101	I-CHEMICAL
(	O
265	O
)	O
,	O
SKF	B-CHEMICAL
-	I-CHEMICAL
104078	I-CHEMICAL
(	O
197	O
)	O
,	O
spiroxatrine	B-CHEMICAL
(	O
128	O
)	O
,	O
and	O
prazosin	B-CHEMICAL
(	O
1531	O
)	O
for	O
blocking	O
relaxation	O
in	O
rat	O
arteries	O
were	O
consistent	O
with	O
their	O
affinities	O
for	O
binding	O
at	O
the	O
alpha	B-GENE-Y
-	I-GENE-Y
2D	I-GENE-Y
adrenoceptor	I-GENE-Y
subtype	O
.	O

Ka	O
values	O
for	O
rauwolscine	B-CHEMICAL
and	O
WB	B-CHEMICAL
-	I-CHEMICAL
4101	I-CHEMICAL
,	O
drugs	O
distinguishing	O
the	O
alpha	O
-	O
2D	O
from	O
the	O
alpha	B-GENE-Y
-	I-GENE-Y
2A	I-GENE-Y
adrenoceptor	I-GENE-Y
subtype	O
,	O
were	O
significantly	O
higher	O
in	O
blocking	O
relaxation	O
of	O
rat	O
arteries	O
compared	O
with	O
pig	O
arteries	O
,	O
suggesting	O
the	O
alpha	B-GENE-Y
-	I-GENE-Y
2D	I-GENE-Y
adrenoceptor	I-GENE-Y
subtype	O
mediates	O
NO	B-CHEMICAL
-	O
induced	O
relaxation	O
in	O
rat	O
arteries	O
.	O

We	O
used	O
forskolin	B-CHEMICAL
to	O
oppose	O
alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptor	I-GENE-N
-	O
mediated	O
inhibition	O
of	O
cAMP	B-CHEMICAL
formation	O
by	O
directly	O
stimulating	O
cAMP	B-CHEMICAL
formation	O
in	O
endothelium	O
.	O

Forskolin	B-CHEMICAL
did	O
not	O
affect	O
the	O
relaxant	O
response	O
to	O
UK14	B-CHEMICAL
,	I-CHEMICAL
304	I-CHEMICAL
,	O
suggesting	O
that	O
cAMP	B-CHEMICAL
is	O
not	O
involved	O
in	O
the	O
coupling	O
of	O
alpha	B-GENE-N
-	I-GENE-N
2	I-GENE-N
adrenoceptors	I-GENE-N
to	O
nitric	B-CHEMICAL
oxide	I-CHEMICAL
-	O
induced	O
vascular	O
relaxation	O
.	O

Epinastine	B-CHEMICAL
(	O
WAL	B-CHEMICAL
801CL	I-CHEMICAL
)	O
modulates	O
the	O
noncholinergic	O
contraction	O
in	O
guinea	O
-	O
pig	O
airways	O
in	O
vitro	O
by	O
a	O
prejunctional	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
.	O

Electrical	O
field	O
stimulation	O
(	O
EFS	O
)	O
of	O
guinea	O
-	O
pig	O
airways	O
,	O
in	O
vitro	O
,	O
evokes	O
an	O
excitatory	O
nonadrenergic	O
noncholinergic	O
(	O
eNANC	O
)	O
contraction	O
mediated	O
by	O
release	O
of	O
tachykinins	O
from	O
sensory	O
nerve	O
endings	O
.	O

Epinastine	B-CHEMICAL
(	O
WAL	B-CHEMICAL
801CL	I-CHEMICAL
)	O
is	O
an	O
antihistaminic	O
drug	O
with	O
binding	O
affinity	O
at	O
certain	O
other	O
receptors	O
,	O
including	O
alpha	B-GENE-N
-	I-GENE-N
adrenergic	I-GENE-N
receptors	I-GENE-N
and	O
various	O
serotonin	B-GENE-N
(	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
)	I-GENE-N
receptor	I-GENE-N
subtypes	O
.	O

It	O
is	O
used	O
in	O
asthma	O
treatment	O
;	O
however	O
,	O
its	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
fully	O
defined	O
.	O

We	O
have	O
investigated	O
whether	O
epinastine	B-CHEMICAL
could	O
modulate	O
the	O
eNANC	O
contraction	O
in	O
guinea	O
-	O
pig	O
airways	O
in	O
vitro	O
,	O
and	O
have	O
tried	O
to	O
elucidate	O
its	O
receptor	O
mechanism	O
.	O

Epinastine	B-CHEMICAL
(	O
0	O
.	O
1	O
-	O
100	O
microM	O
)	O
produced	O
a	O
concentration	O
-	O
dependent	O
inhibition	O
of	O
the	O
noncholinergic	O
contraction	O
,	O
with	O
a	O
maximum	O
inhibition	O
of	O
91	O
+	O
/	O
-	O
7	O
%	O
at	O
100	O
microM	O
.	O

Pretreatment	O
of	O
the	O
tissues	O
with	O
combined	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
/	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
antagonists	O
,	O
methysergide	B-CHEMICAL
(	O
1	O
microM	O
)	O
or	O
methiothepin	B-CHEMICAL
(	O
0	O
.	O
1	O
microM	O
)	O
,	O
significantly	O
attenuated	O
the	O
inhibitory	O
effect	O
of	O
epinastine	B-CHEMICAL
on	O
the	O
noncholinergic	O
contraction	O
.	O

Pretreatment	O
with	O
tropisetron	B-CHEMICAL
(	O
1	O
microM	O
)	O
,	O
a	O
5	B-GENE-N
-	I-GENE-N
HT3	I-GENE-N
antagonist	O
,	O
ketanserin	B-CHEMICAL
(	O
10	O
microM	O
)	O
,	O
a	O
5	B-GENE-N
-	I-GENE-N
HT2	I-GENE-N
antagonist	O
,	O
thioperamide	B-CHEMICAL
(	O
10	O
microM	O
)	O
,	O
a	O
histamine	B-GENE-Y
H3	I-GENE-Y
antagonist	O
,	O
or	O
phentolamine	B-CHEMICAL
(	O
10	O
microM	O
)	O
,	O
an	O
alpha	O
-	O
adrenergic	O
antagonist	O
,	O
however	O
,	O
had	O
no	O
effect	O
.	O

Chlorpheniramine	B-CHEMICAL
(	O
10	O
microM	O
)	O
,	O
another	O
histamine	B-GENE-Y
H1	I-GENE-Y
receptor	I-GENE-Y
antagonist	O
without	O
significant	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
receptor	I-GENE-N
binding	O
affinity	O
,	O
did	O
not	O
produce	O
any	O
inhibition	O
of	O
the	O
eNANC	O
contraction	O
.	O

Epinastine	B-CHEMICAL
(	O
100	O
microM	O
)	O
did	O
not	O
displace	O
the	O
dose	O
-	O
response	O
curve	O
to	O
exogenously	O
applied	O
substance	B-GENE-Y
P	I-GENE-Y
(	O
0	O
.	O
01	O
-	O
10	O
microM	O
)	O
.	O

These	O
results	O
suggest	O
that	O
epinastine	B-CHEMICAL
,	O
although	O
identified	O
as	O
a	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
antagonist	O
,	O
acts	O
as	O
a	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
agonist	O
and	O
that	O
it	O
inhibits	O
the	O
noncholinergic	O
contraction	O
in	O
guinea	O
-	O
pig	O
airways	O
through	O
stimulation	O
of	O
a	O
prejunctional	O
5	B-GENE-N
-	I-GENE-N
HT1	I-GENE-N
-	I-GENE-N
like	I-GENE-N
receptor	I-GENE-N
,	O
located	O
to	O
sensory	O
nerves	O
.	O

(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
,	O
an	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
,	O
inhibits	O
the	O
positive	O
inotropic	O
effect	O
but	O
not	O
the	O
accumulation	O
of	O
inositol	B-CHEMICAL
phosphates	I-CHEMICAL
in	O
rabbit	O
heart	O
.	O

The	O
influence	O
of	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
,	O
a	O
selective	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonist	O
,	O
on	O
the	O
positive	O
inotropic	O
effect	O
and	O
the	O
accumulation	O
of	O
inositol	B-CHEMICAL
phosphates	I-CHEMICAL
that	O
are	O
induced	O
via	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
was	O
studied	O
in	O
comparison	O
with	O
that	O
of	O
another	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
ligand	O
oxymetazoline	B-CHEMICAL
in	O
the	O
rabbit	O
ventricular	O
myocardium	O
.	O

Phenylephrine	B-CHEMICAL
elicited	O
a	O
concentration	O
-	O
dependent	O
positive	O
inotropic	O
effect	O
via	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
in	O
the	O
presence	O
of	O
either	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
bupranolol	I-CHEMICAL
or	O
S	B-CHEMICAL
(	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
timolol	I-CHEMICAL
.	O

The	O
mode	O
of	O
antagonism	O
induced	O
by	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
on	O
the	O
effect	O
of	O
phenylephrine	B-CHEMICAL
was	O
dependent	O
or	O
the	O
concentration	O
applied	O
:	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
at	O
1	O
and	O
3	O
nM	O
acted	O
in	O
a	O
competitive	O
manner	O
,	O
the	O
slope	O
of	O
the	O
regression	O
line	O
of	O
the	O
Schild	O
plot	O
being	O
unity	O
and	O
the	O
pA2	O
value	O
being	O
9	O
.	O
12	O
;	O
at	O
10	O
nM	O
,	O
it	O
shifted	O
further	O
the	O
concentration	O
-	O
response	O
curve	O
to	O
the	O
right	O
without	O
affecting	O
the	O
maximal	O
response	O
but	O
the	O
slope	O
became	O
less	O
than	O
unity	O
.	O

At	O
100	O
nM	O
and	O
higher	O
,	O
it	O
suppressed	O
the	O
maximal	O
response	O
to	O
phenylephrine	B-CHEMICAL
.	O

(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Tamsulosin	I-CHEMICAL
effectively	O
antagonized	O
the	O
positive	O
inotropic	O
effect	O
of	O
phenylephrine	B-CHEMICAL
even	O
after	O
inactivation	O
of	O
alpha	B-GENE-Y
1B	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
by	O
treatment	O
with	O
chlorethylclonidine	B-CHEMICAL
,	O
which	O
is	O
an	O
indication	O
that	O
the	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
-	O
sensitive	O
subtype	O
belongs	O
to	O
a	O
class	O
resistant	O
to	O
chlorethylclonidine	B-CHEMICAL
.	O

(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
Tamsulosin	I-CHEMICAL
,	O
over	O
the	O
range	O
of	O
concentrations	O
at	O
which	O
it	O
antagonized	O
the	O
positive	O
inotropic	O
effect	O
mediated	O
by	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
did	O
not	O
affect	O
the	O
accumulation	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
inositol	I-CHEMICAL
phosphates	I-CHEMICAL
that	O
was	O
induced	O
by	O
10	O
microM	O
phenylephrine	B-CHEMICAL
.	O

Oxymetazoline	B-CHEMICAL
antagonized	O
the	O
positive	O
inotropic	O
effect	O
of	O
phenylephrine	B-CHEMICAL
in	O
a	O
competitive	O
manner	O
without	O
affecting	O
the	O
accumulation	O
of	O
inositol	B-CHEMICAL
monophosphate	I-CHEMICAL
induced	O
by	O
phenylephrine	B-CHEMICAL
.	O

These	O
results	O
indicate	O
that	O
the	O
positive	O
inotropic	O
effect	O
,	O
mediated	O
via	O
(	B-CHEMICAL
+	I-CHEMICAL
/	I-CHEMICAL
-	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
tamsulosin	I-CHEMICAL
-	O
and	O
oxymetazoline	B-CHEMICAL
-	O
sensitive	O
subtype	O
of	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
is	O
exerted	O
by	O
a	O
subcellular	O
mechanism	O
that	O
is	O
independent	O
of	O
the	O
accumulation	O
of	O
inositol	B-CHEMICAL
phosphates	I-CHEMICAL
.	O

In	O
functional	O
experiments	O
,	O
risperidone	B-CHEMICAL
is	O
selective	O
,	O
not	O
for	O
the	O
B	O
,	O
but	O
for	O
the	O
A	O
subtype	O
of	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
.	O

The	O
potency	O
of	O
the	O
antipsychotic	O
drug	O
,	O
risperidone	B-CHEMICAL
,	O
to	O
antagonize	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
contraction	O
in	O
rat	O
vas	O
deferens	O
and	O
vasoconstriction	O
in	O
rat	O
perfused	O
kidney	O
,	O
and	O
alpha	B-GENE-Y
1B	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
-	O
mediated	O
contractions	O
in	O
spleen	O
from	O
guinea	O
-	O
pig	O
and	O
mouse	O
was	O
evaluated	O
and	O
compared	O
to	O
that	O
of	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
subtype	O
-	O
discriminating	O
antagonists	O
.	O

Prazosin	B-CHEMICAL
was	O
found	O
to	O
be	O
unselective	O
;	O
2	B-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
2	I-CHEMICAL
,	I-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
dimethoxyphenoxyethyl	I-CHEMICAL
)	I-CHEMICAL
aminomethyl	I-CHEMICAL
-	I-CHEMICAL
1	I-CHEMICAL
,	I-CHEMICAL
4	I-CHEMICAL
-	I-CHEMICAL
benzodioxane	I-CHEMICAL
(	O
WB	B-CHEMICAL
4101	I-CHEMICAL
)	O
,	O
5	B-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
-	I-CHEMICAL
urapidil	I-CHEMICAL
,	O
indoramin	B-CHEMICAL
and	O
(	B-CHEMICAL
+	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
niguldipine	I-CHEMICAL
were	O
confirmed	O
as	O
selective	O
for	O
the	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
,	O
whereas	O
spiperone	B-CHEMICAL
was	O
weakly	O
alpha	O
1B	O
-	O
selective	O
.	O

Risperidone	B-CHEMICAL
was	O
equipotent	O
to	O
prazosin	B-CHEMICAL
at	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptors	I-GENE-Y
in	O
rat	O
vas	O
deferens	O
and	O
kidney	O
.	O

However	O
,	O
at	O
guinea	B-GENE-N
-	I-GENE-N
pig	I-GENE-N
and	I-GENE-N
mouse	I-GENE-N
splenic	I-GENE-N
alpha	I-GENE-N
1B	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
,	O
the	O
affinity	O
values	O
of	O
risperidone	B-CHEMICAL
were	O
10	O
-	O
fold	O
lower	O
than	O
those	O
of	O
prazosin	B-CHEMICAL
.	O

Thus	O
,	O
in	O
functional	O
experiments	O
the	O
presumed	O
high	O
selectivity	O
of	O
risperidone	B-CHEMICAL
for	O
the	O
B	O
subtype	O
of	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptors	I-GENE-N
could	O
not	O
be	O
confirmed	O
,	O
the	O
drug	O
instead	O
appears	O
to	O
be	O
moderately	O
selective	O
(	O
10	O
-	O
fold	O
)	O
for	O
the	O
A	O
subtype	O
.	O

Cloning	O
,	O
functional	O
expression	O
and	O
brain	O
localization	O
of	O
a	O
novel	O
unconventional	O
outward	B-GENE-N
rectifier	I-GENE-N
K	I-GENE-N
+	I-GENE-N
channel	I-GENE-N
.	O

Human	B-GENE-Y
TWIK	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
which	O
has	O
been	O
cloned	O
recently	O
,	O
is	O
a	O
new	O
structural	O
type	O
of	O
weak	O
inward	B-GENE-N
rectifier	I-GENE-N
K	I-GENE-N
+	I-GENE-N
channel	I-GENE-N
.	O

Here	O
we	O
report	O
the	O
structural	O
and	O
functional	O
properties	O
of	O
TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
a	O
mammalian	B-GENE-Y
TWIK	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
related	I-GENE-Y
K	I-GENE-Y
+	I-GENE-Y
channel	I-GENE-Y
.	O

Despite	O
a	O
low	O
amino	B-CHEMICAL
acid	I-CHEMICAL
identity	O
between	O
TWIK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
and	O
TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
approximately	O
28	O
%	O
)	O
,	O
both	O
channel	O
proteins	O
share	O
the	O
same	O
overall	O
structural	O
arrangement	O
consisting	O
of	O
two	O
pore	B-GENE-N
-	I-GENE-N
forming	I-GENE-N
domains	I-GENE-N
and	O
four	O
transmembrane	O
segments	O
(	O
TMS	O
)	O
.	O

This	O
structural	O
similarity	O
does	O
not	O
give	O
rise	O
to	O
a	O
functional	O
analogy	O
.	O

K	B-CHEMICAL
+	I-CHEMICAL
currents	O
generated	O
by	O
TWIK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
are	O
inwardly	O
rectifying	O
while	O
K	B-CHEMICAL
+	I-CHEMICAL
currents	O
generated	O
by	O
TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
are	O
outwardly	O
rectifying	O
.	O

These	O
channels	O
have	O
a	O
conductance	O
of	O
14	O
pS	O
.	O

TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
currents	O
are	O
insensitive	O
to	O
pharmacological	O
agents	O
that	O
block	O
TWIK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
such	O
as	O
quinine	B-CHEMICAL
and	O
quinidine	B-CHEMICAL
.	O

Extensive	O
inhibitions	O
of	O
TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
activity	O
are	O
observed	O
after	O
activation	O
of	O
protein	B-GENE-N
kinases	I-GENE-N
A	I-GENE-N
and	I-GENE-N
C	I-GENE-N
.	O

TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
currents	O
are	O
sensitive	O
to	O
extracellular	O
K	B-CHEMICAL
+	I-CHEMICAL
and	O
Na	B-CHEMICAL
+	I-CHEMICAL
.	O

TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
mRNA	O
is	O
expressed	O
in	O
most	O
tissues	O
and	O
is	O
particularly	O
abundant	O
in	O
the	O
lung	O
and	O
in	O
the	O
brain	O
.	O

Its	O
localization	O
in	O
this	O
latter	O
tissue	O
has	O
been	O
studied	O
by	O
in	O
situ	O
hybridization	O
.	O

TREK	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
expression	O
is	O
high	O
in	O
the	O
olfactory	O
bulb	O
,	O
hippocampus	O
and	O
cerebellum	O
.	O

These	O
results	O
provide	O
the	O
first	O
evidence	O
for	O
the	O
existence	O
of	O
a	O
K	B-GENE-N
+	I-GENE-N
channel	I-GENE-N
family	O
with	O
four	O
TMS	O
and	O
two	O
pore	B-GENE-N
domains	I-GENE-N
in	O
the	O
nervous	O
system	O
of	O
mammals	O
.	O

They	O
also	O
show	O
that	O
different	O
members	O
in	O
this	O
structural	O
family	O
can	O
have	O
totally	O
different	O
functional	O
properties	O
.	O

Atypical	O
neuroleptics	O
have	O
low	O
affinity	O
for	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptors	I-GENE-Y
or	O
are	O
selective	O
for	O
D4	B-GENE-Y
receptors	I-GENE-Y
.	O

This	O
review	O
examines	O
the	O
possible	O
receptor	O
basis	O
of	O
the	O
atypical	O
action	O
of	O
those	O
atypical	O
antipsychotic	O
drugs	O
that	O
elicit	O
low	O
levels	O
of	O
Parkinsonism	O
.	O

Such	O
an	O
examination	O
requires	O
consistent	O
and	O
accurate	O
dissociation	O
constants	O
for	O
the	O
antipsychotic	O
drugs	O
at	O
the	O
relevant	O
dopamine	B-GENE-N
and	I-GENE-N
serotonin	I-GENE-N
receptors	I-GENE-N
.	O

It	O
has	O
long	O
been	O
known	O
,	O
however	O
,	O
that	O
the	O
dissociation	O
constant	O
of	O
a	O
given	O
antipsychotic	O
drug	O
at	O
the	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptor	I-GENE-Y
varies	O
between	O
laboratories	O
.	O

Although	O
such	O
variation	O
depends	O
on	O
several	O
factors	O
,	O
it	O
has	O
recently	O
been	O
recognized	O
that	O
the	O
radioligand	O
used	O
to	O
measure	O
the	O
competition	O
between	O
the	O
antipsychotic	O
drug	O
and	O
the	O
radioligand	O
is	O
an	O
important	O
variable	O
.	O

The	O
present	O
review	O
summarizes	O
information	O
on	O
this	O
radioligand	O
dependence	O
.	O

In	O
general	O
,	O
a	O
radioligand	O
of	O
low	O
solubility	O
in	O
the	O
membrane	O
(	O
i	O
.	O
e	O
.	O
,	O
low	O
tissue	O
:	O
buffer	O
partition	O
)	O
results	O
in	O
a	O
low	O
value	O
for	O
the	O
antipsychotic	O
dissociation	O
constant	O
when	O
the	O
drug	O
competes	O
with	O
the	O
radioligand	O
.	O

Hence	O
,	O
by	O
first	O
obtaining	O
the	O
antipsychotic	O
dissociation	O
constants	O
using	O
different	O
radioligands	O
of	O
different	O
solubility	O
in	O
the	O
membrane	O
,	O
one	O
can	O
then	O
extrapolate	O
the	O
data	O
to	O
low	O
or	O
"	O
zero	O
"	O
ligand	O
solubility	O
.	O

The	O
extrapolated	O
value	O
represents	O
the	O
radioligand	O
-	O
independent	O
dissociation	O
constant	O
of	O
the	O
antipsychotic	O
.	O

These	O
values	O
are	O
here	O
given	O
for	O
dopamine	B-GENE-N
D2	I-GENE-N
and	I-GENE-N
D4	I-GENE-N
receptors	I-GENE-N
,	O
as	O
well	O
as	O
for	O
serotonin	B-GENE-Y
5	I-GENE-Y
-	I-GENE-Y
HT2A	I-GENE-Y
receptors	I-GENE-Y
.	O

These	O
values	O
,	O
moreover	O
,	O
agree	O
with	O
the	O
dissociation	O
constant	O
directly	O
obtained	O
with	O
the	O
radioactive	O
antipsychotic	O
itself	O
.	O

For	O
example	O
,	O
clozapine	B-CHEMICAL
revealed	O
a	O
radioligand	O
-	O
independent	O
value	O
of	O
1	O
.	O
6	O
nM	O
at	O
the	O
dopamine	B-GENE-Y
D4	I-GENE-Y
receptor	I-GENE-Y
,	O
agreeing	O
with	O
the	O
value	O
directly	O
measured	O
with	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
-	I-CHEMICAL
clozapine	I-CHEMICAL
at	O
D4	B-GENE-Y
.	O

However	O
,	O
because	O
clozapine	B-CHEMICAL
competes	O
with	O
endogenous	O
dopamine	B-CHEMICAL
,	O
the	O
in	O
vivo	O
concentration	O
of	O
clozapine	B-CHEMICAL
(	O
to	O
occupy	O
dopamine	B-GENE-Y
D4	I-GENE-Y
receptors	I-GENE-Y
)	O
can	O
be	O
derived	O
to	O
be	O
about	O
13	O
nM	O
,	O
agreeing	O
with	O
the	O
value	O
of	O
12	O
to	O
20	O
nM	O
in	O
the	O
plasma	O
water	O
or	O
spinal	O
fluid	O
observed	O
in	O
treated	O
patients	O
.	O

The	O
atypical	O
neuroleptics	O
remoxipride	B-CHEMICAL
,	O
clozapine	B-CHEMICAL
,	O
perlapine	B-CHEMICAL
,	O
seroquel	B-CHEMICAL
,	O
and	O
melperone	B-CHEMICAL
had	O
low	O
affinity	O
for	O
the	O
dopamine	B-CHEMICAL
D2	B-GENE-Y
receptor	I-GENE-Y
(	O
radioligand	O
-	O
independent	O
dissociation	O
constants	O
of	O
30	O
to	O
90	O
nM	O
)	O
.	O

Such	O
low	O
affinity	O
makes	O
these	O
latter	O
five	O
drugs	O
readily	O
displaceable	O
by	O
high	O
levels	O
of	O
endogenous	O
dopamine	B-CHEMICAL
in	O
the	O
caudate	O
or	O
putamen	O
.	O

Most	O
typical	O
neuroleptics	O
have	O
radioligand	O
-	O
independent	O
values	O
of	O
0	O
.	O
3	O
to	O
5	O
nM	O
at	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptors	I-GENE-Y
,	O
making	O
them	O
more	O
resistant	O
to	O
displacement	O
by	O
endogenous	O
dopamine	B-CHEMICAL
.	O

Finally	O
,	O
a	O
relation	O
was	O
found	O
between	O
the	O
neuroleptic	O
doses	O
for	O
rat	O
catalepsy	O
and	O
the	O
D2	B-GENE-Y
:	O
D4	B-GENE-Y
ratio	O
of	O
the	O
radioligand	O
-	O
independent	O
K	O
values	O
for	O
these	O
two	O
receptors	O
.	O

Thus	O
,	O
the	O
atypical	O
neuroleptics	O
appear	O
to	O
fall	O
into	O
two	O
groups	O
,	O
those	O
that	O
have	O
a	O
low	O
affinity	O
for	O
dopamine	B-GENE-Y
D2	I-GENE-Y
receptors	I-GENE-Y
and	O
those	O
that	O
are	O
selective	O
for	O
dopamine	B-GENE-Y
D4	I-GENE-Y
receptors	I-GENE-Y
.	O

Endogenous	O
opioid	O
systems	O
and	O
alcohol	B-CHEMICAL
addiction	O
.	O

Alcohol	B-CHEMICAL
exerts	O
numerous	O
pharmacological	O
effects	O
through	O
its	O
interaction	O
with	O
various	O
neurotransmitters	O
and	O
neuromodulators	O
.	O

Among	O
the	O
latter	O
,	O
the	O
endogenous	O
opioids	O
play	O
a	O
key	O
role	O
in	O
the	O
rewarding	O
(	O
addictive	O
)	O
properties	O
of	O
ethanol	B-CHEMICAL
.	O

Three	O
types	O
of	O
opioid	B-GENE-N
receptors	I-GENE-N
(	I-GENE-N
mu	I-GENE-N
,	I-GENE-N
delta	I-GENE-N
and	I-GENE-N
kappa	I-GENE-N
)	I-GENE-N
represent	O
the	O
respective	O
targets	O
of	O
the	O
major	O
opioid	B-GENE-N
peptides	I-GENE-N
(	O
beta	B-GENE-Y
-	I-GENE-Y
endorphin	I-GENE-Y
,	O
enkephalins	B-CHEMICAL
and	O
dynorphins	B-GENE-Y
,	O
respectively	O
)	O
.	O

The	O
rewarding	O
(	O
reinforcing	O
)	O
properties	O
of	O
mu	B-GENE-N
-	I-GENE-N
and	I-GENE-N
delta	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
ligands	O
are	O
brought	O
by	O
activation	O
of	O
the	O
mesolimbic	O
dopamine	O
system	O
which	O
ascends	O
from	O
the	O
ventral	O
tegmentum	O
of	O
the	O
midbrain	O
(	O
VTA	O
)	O
to	O
rostral	O
structures	O
;	O
of	O
these	O
,	O
the	O
nucleus	O
accumbens	O
(	O
NAC	O
)	O
is	O
of	O
particular	O
importance	O
in	O
drug	O
addiction	O
.	O

In	O
contrast	O
,	O
dysphoria	O
results	O
from	O
activation	O
of	O
kappa	B-GENE-N
-	I-GENE-N
receptors	I-GENE-N
.	O

The	O
neurochemical	O
manifestations	O
of	O
these	O
opposing	O
effects	O
are	O
,	O
respectively	O
,	O
increases	O
and	O
decreases	O
in	O
dopamine	B-CHEMICAL
release	O
in	O
the	O
NAC	O
.	O

Several	O
lines	O
of	O
evidence	O
indicate	O
that	O
alcohol	B-CHEMICAL
interferes	O
with	O
endogenous	O
opioid	O
mechanisms	O
which	O
are	O
closely	O
linked	O
with	O
dopamine	B-CHEMICAL
transmission	O
in	O
the	O
mesolimbic	O
pathway	O
.	O

The	O
view	O
that	O
condensation	O
products	O
of	O
dopamine	B-CHEMICAL
and	O
alcohol	B-CHEMICAL
-	O
derived	O
aldehyde	B-CHEMICAL
(	O
tetrahydroisoquinolines	B-CHEMICAL
)	O
play	O
a	O
role	O
remains	O
controversial	O
.	O

There	O
is	O
,	O
however	O
,	O
much	O
information	O
on	O
the	O
direct	O
(	O
acute	O
and	O
chronic	O
)	O
effects	O
of	O
alcohol	B-CHEMICAL
on	O
the	O
binding	O
properties	O
of	O
opioid	B-GENE-N
receptors	I-GENE-N
,	O
as	O
well	O
as	O
modulation	O
of	O
opioid	B-GENE-N
peptide	I-GENE-N
synthesis	O
and	O
secretion	O
(	O
e	O
.	O
g	O
.	O
a	O
suggested	O
increase	O
in	O
beta	B-GENE-Y
-	I-GENE-Y
endorphin	I-GENE-Y
release	O
)	O
.	O

In	O
view	O
of	O
the	O
reinforcing	O
properties	O
of	O
alcohol	B-CHEMICAL
,	O
it	O
is	O
relevant	O
to	O
consider	O
behavioural	O
studies	O
involving	O
alcohol	B-CHEMICAL
self	O
-	O
administration	O
in	O
rodents	O
and	O
primates	O
.	O

Low	O
doses	O
of	O
morphine	O
have	O
been	O
found	O
to	O
increase	O
,	O
and	O
higher	O
doses	O
of	O
the	O
opiate	O
to	O
decrease	O
,	O
alcohol	B-CHEMICAL
consumption	O
.	O

Conversely	O
,	O
opioid	O
antagonists	O
such	O
as	O
naloxone	B-CHEMICAL
and	O
naltrexone	B-CHEMICAL
(	O
which	O
bind	O
to	O
non	O
-	O
selectively	O
opioid	B-GENE-N
receptors	I-GENE-N
)	O
have	O
been	O
shown	O
to	O
decrease	O
alcohol	B-CHEMICAL
consumption	O
under	O
various	O
experimental	O
conditions	O
.	O

Similar	O
results	O
have	O
been	O
reported	O
when	O
selective	O
mu	B-GENE-N
-	I-GENE-N
or	I-GENE-N
delta	I-GENE-N
-	I-GENE-N
receptor	I-GENE-N
antagonists	O
are	O
administered	O
.	O

Results	O
obtained	O
in	O
genetic	O
models	O
of	O
high	O
preference	O
for	O
alcohol	B-CHEMICAL
also	O
support	O
the	O
view	O
that	O
alcohol	O
intake	O
depends	O
on	O
the	O
activity	O
of	O
the	O
endogenous	O
opioid	O
reward	O
system	O
and	O
that	O
alcohol	B-CHEMICAL
consumption	O
may	O
serve	O
to	O
compensate	O
for	O
inherent	O
deficits	O
in	O
this	O
system	O
.	O

One	O
hypothetical	O
model	O
proposes	O
that	O
reward	O
results	O
from	O
activation	O
of	O
mu	B-GENE-Y
-	I-GENE-Y
opioid	I-GENE-Y
receptors	I-GENE-Y
in	O
the	O
VTA	O
and	O
/	O
or	O
delta	B-GENE-Y
-	I-GENE-Y
receptor	I-GENE-Y
in	O
the	O
NAC	O
;	O
both	O
these	O
nuclei	O
are	O
targets	O
of	O
endogenous	O
beta	B-GENE-Y
-	I-GENE-Y
endorphin	I-GENE-Y
.	O

It	O
is	O
suggested	O
that	O
alcohol	B-CHEMICAL
interferes	O
with	O
this	O
reward	O
pathway	O
either	O
directly	O
or	O
indirectly	O
.	O

The	O
available	O
experimental	O
data	O
accord	O
well	O
with	O
those	O
obtained	O
from	O
clinical	O
studies	O
which	O
opioid	O
antagonists	O
have	O
been	O
used	O
to	O
prevent	O
relapse	O
in	O
alcoholics	O
.	O

Conceptual	O
considerations	O
concerning	O
communalities	O
between	O
various	O
forms	O
of	O
addictions	O
are	O
also	O
discussed	O
in	O
this	O
review	O
.	O

Activation	O
-	O
dependent	O
exposure	O
of	O
the	O
inter	B-GENE-N
-	I-GENE-N
EGF	I-GENE-N
sequence	I-GENE-N
Leu83	B-GENE-N
-	I-GENE-N
Leu88	I-GENE-N
in	O
factor	B-GENE-Y
Xa	I-GENE-Y
mediates	O
ligand	O
binding	O
to	O
effector	B-GENE-Y
cell	I-GENE-Y
protease	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

Binding	O
of	O
factor	B-GENE-Y
Xa	I-GENE-Y
to	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
is	O
contributed	O
by	O
effector	B-GENE-Y
cell	I-GENE-Y
protease	I-GENE-Y
receptor	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
(	O
EPR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
.	O

The	O
structural	O
requirements	O
of	O
this	O
recognition	O
were	O
investigated	O
.	O

Factor	B-GENE-Y
Xa	I-GENE-Y
or	O
catalytically	O
inactive	O
5	B-CHEMICAL
-	I-CHEMICAL
dimethylaminonaphthalene	I-CHEMICAL
-	I-CHEMICAL
1sulfonyl	I-CHEMICAL
(	I-CHEMICAL
dansyl	I-CHEMICAL
)	I-CHEMICAL
Glu	I-CHEMICAL
-	I-CHEMICAL
Gly	I-CHEMICAL
-	I-CHEMICAL
Arg	I-CHEMICAL
-	I-CHEMICAL
(	I-CHEMICAL
DEGR	I-CHEMICAL
)	I-CHEMICAL
-	I-CHEMICAL
chloromethylketone	I-CHEMICAL
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
bound	O
indistinguishably	O
to	O
HUVEC	O
and	O
EPR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
transfectants	O
,	O
and	O
inhibited	O
equally	O
well	O
the	O
binding	O
of	O
125I	O
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
to	O
these	O
cells	O
.	O

Similarly	O
,	O
factor	B-GENE-Y
Xa	I-GENE-Y
active	O
site	O
inhibitors	O
TAP	O
or	O
NAP5	O
did	O
not	O
reduce	O
ligand	O
binding	O
to	O
EPR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
.	O

A	O
factor	B-GENE-Y
X	I-GENE-Y
peptide	O
duplicating	O
the	O
inter	B-GENE-N
-	I-GENE-N
EGF	I-GENE-N
sequence	I-GENE-N
Leu83	B-GENE-N
-	I-GENE-N
Phe84	I-GENE-N
-	I-GENE-N
Thr85	I-GENE-N
-	I-GENE-N
Arg86	I-GENE-N
-	I-GENE-N
Lys87	I-GENE-N
-	I-GENE-N
Leu88	I-GENE-N
-	I-GENE-N
(	I-GENE-N
Gly	I-GENE-N
)	I-GENE-N
inhibited	O
factor	B-GENE-Y
V	I-GENE-Y
/	I-GENE-Y
Va	I-GENE-Y
-	O
independent	O
prothrombin	B-GENE-Y
activation	O
by	O
HUVEC	O
and	O
blocked	O
binding	O
of	O
125I	B-CHEMICAL
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
to	O
these	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
IC50	O
approximately	O
20	O
-	O
40	O
microM	O
)	O
.	O

In	O
contrast	O
,	O
none	O
of	O
the	O
other	O
factor	B-GENE-Y
X	I-GENE-Y
peptides	O
tested	O
or	O
a	O
control	O
peptide	O
with	O
the	O
inter	B-GENE-N
-	I-GENE-N
EGF	I-GENE-N
sequence	I-GENE-N
in	O
scrambled	O
order	O
was	O
effective	O
.	O

A	O
recombinant	O
chimeric	O
molecule	O
expressing	O
the	O
factor	B-GENE-Y
X	I-GENE-Y
sequence	O
Leu83	B-GENE-N
-	I-GENE-N
Leu88	I-GENE-N
within	O
a	O
factor	B-GENE-Y
IX	I-GENE-Y
backbone	O
inhibited	O
binding	O
of	O
125I	B-CHEMICAL
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
to	O
HUVEC	O
and	O
EPR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
transfectants	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
while	O
recombinant	O
factor	B-GENE-Y
IX	I-GENE-Y
or	O
plasma	O
IXa	B-GENE-Y
had	O
no	O
effect	O
.	O

An	O
antibody	O
generated	O
against	O
the	O
factor	B-GENE-Y
X	I-GENE-Y
peptide	O
83	O
-	O
88	O
,	O
and	O
designated	O
JC15	O
,	O
inhibited	O
125I	O
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
binding	O
to	O
HUVEC	O
.	O

The	O
JC15	O
antibody	O
bound	O
to	O
factor	B-GENE-Y
Xa	I-GENE-Y
and	O
the	O
recombinant	O
IX	O
/	O
X83	O
-	O
88	O
chimera	O
in	O
a	O
concentration	O
dependent	O
manner	O
,	O
while	O
no	O
specific	O
reactivity	O
with	O
factors	B-GENE-N
X	I-GENE-N
or	I-GENE-N
IXa	I-GENE-N
was	O
observed	O
.	O

Furthermore	O
,	O
binding	O
of	O
125I	B-CHEMICAL
-	O
factor	B-GENE-Y
Xa	I-GENE-Y
to	O
immobilized	O
JC15	O
was	O
inhibited	O
by	O
molar	O
excess	O
of	O
unlabeled	O
factor	B-GENE-Y
Xa	I-GENE-Y
,	O
but	O
not	O
by	O
comparable	O
concentrations	O
of	O
factors	B-GENE-N
X	I-GENE-N
or	I-GENE-N
IXa	I-GENE-N
.	O

These	O
findings	O
identify	O
the	O
inter	B-GENE-N
-	I-GENE-N
EGF	I-GENE-N
sequence	I-GENE-N
Leu83	B-GENE-N
-	I-GENE-N
Leu88	I-GENE-N
in	O
factor	B-GENE-Y
Xa	I-GENE-Y
as	O
a	O
novel	O
recognition	O
site	O
for	O
EPR	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
and	O
suggest	O
its	O
potential	O
role	O
as	O
a	O
protease	O
activation	O
-	O
dependent	O
neo	O
-	O
epitope	O
.	O

This	O
interacting	O
motif	O
may	O
help	O
elucidate	O
the	O
contribution	O
of	O
factor	B-GENE-Y
Xa	I-GENE-Y
to	O
cellular	O
assembly	O
of	O
coagulation	O
and	O
vascular	O
injury	O
.	O

Differential	O
binding	O
of	O
fibroblast	B-GENE-N
growth	I-GENE-N
factor	I-GENE-N
-	I-GENE-N
2	I-GENE-N
and	I-GENE-N
-	I-GENE-N
7	I-GENE-N
to	O
basement	O
membrane	O
heparan	O
sulfate	B-CHEMICAL
:	O
comparison	O
of	O
normal	O
and	O
abnormal	O
human	O
tissues	O
.	O

Fibroblast	B-GENE-N
growth	I-GENE-N
factors	I-GENE-N
(	O
FGFs	B-GENE-N
)	O
play	O
multiple	O
roles	O
during	O
development	O
and	O
in	O
adult	O
tissues	O
as	O
paracrine	O
regulators	O
of	O
growth	O
and	O
differentiation	O
.	O

FGFs	B-GENE-N
signal	O
through	O
transmembrane	B-GENE-N
receptor	I-GENE-N
tyrosine	I-GENE-N
kinases	I-GENE-N
,	O
but	O
heparan	O
sulfate	B-CHEMICAL
is	O
also	O
required	O
for	O
signaling	O
by	O
members	O
of	O
the	O
FGF	B-GENE-N
family	O
.	O

In	O
addition	O
,	O
heparan	O
sulfate	O
may	O
be	O
involved	O
in	O
determining	O
tissue	O
distribution	O
of	O
FGFs	B-GENE-N
.	O

Using	O
biotinylated	O
FGF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
and	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
(	O
KGF	B-GENE-Y
)	O
as	O
probes	O
,	O
we	O
have	O
identified	O
specific	O
interactions	O
between	O
FGFs	B-GENE-N
and	O
heparan	O
sulfates	B-CHEMICAL
in	O
human	O
tissues	O
.	O

Both	O
FGF	B-GENE-N
species	O
bind	O
to	O
tissue	O
mast	O
cells	O
and	O
to	O
epithelial	O
cell	O
membranes	O
.	O

Binding	O
to	O
basement	O
membrane	O
heparan	O
sulfate	B-CHEMICAL
is	O
tissue	O
source	O
dependent	O
and	O
specific	O
.	O

Although	O
FGF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
strongly	O
binds	O
to	O
basement	O
membrane	O
heparan	O
sulfate	B-CHEMICAL
in	O
skin	O
and	O
most	O
other	O
tissue	O
sites	O
examined	O
,	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
fails	O
to	O
bind	O
to	O
basement	O
membrane	O
heparan	O
sulfate	B-CHEMICAL
in	O
most	O
locations	O
.	O

However	O
,	O
in	O
subendothelial	O
matrix	O
in	O
blood	O
vessels	O
and	O
in	O
the	O
basement	O
membrane	O
of	O
a	O
papillary	O
renal	O
cell	O
carcinoma	O
,	O
strong	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
binding	O
is	O
seen	O
.	O

In	O
summary	O
,	O
distinct	O
and	O
specific	O
affinities	O
of	O
heparan	O
sulfates	B-CHEMICAL
for	O
different	O
FGFs	B-GENE-N
were	O
identified	O
that	O
may	O
affect	O
growth	O
factor	O
activation	O
and	O
local	O
distribution	O
.	O

Heparan	O
sulfate	B-CHEMICAL
may	O
have	O
a	O
gatekeeper	O
function	O
to	O
either	O
restrict	O
or	O
permit	O
diffusion	O
of	O
heparin	O
-	O
binding	O
growth	O
factors	O
across	O
the	O
basement	O
membrane	O
.	O

Mechanisms	O
of	O
inhibition	O
of	O
calmodulin	B-GENE-N
-	I-GENE-N
stimulated	I-GENE-N
cyclic	I-GENE-N
nucleotide	I-GENE-N
phosphodiesterase	I-GENE-N
by	O
dihydropyridine	O
calcium	O
antagonists	O
.	O

Calmodulin	B-GENE-N
-	I-GENE-N
dependent	I-GENE-N
cyclic	I-GENE-N
nucleotide	I-GENE-N
phosphodiesterase	I-GENE-N
(	O
CaMPDE	B-GENE-N
)	O
is	O
one	O
of	O
the	O
key	O
enzymes	O
involved	O
in	O
the	O
complex	O
interaction	O
between	O
the	O
cyclic	O
nucleotide	B-CHEMICAL
and	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
second	O
-	O
messenger	O
systems	O
.	O

CaMPDE	B-GENE-N
exists	O
as	O
tissue	O
-	O
specific	O
isozymes	O
,	O
and	O
initially	O
these	O
isozymes	O
were	O
designated	O
according	O
to	O
their	O
respective	O
subunit	O
molecular	O
mass	O
.	O

A	O
variety	O
of	O
pharmacological	O
agents	O
have	O
been	O
used	O
to	O
inhibit	O
CaMPDE	B-GENE-N
,	O
and	O
this	O
inhibition	O
occurs	O
mostly	O
via	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
-	O
dependent	O
association	O
with	O
the	O
proteins	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
dihydropyridine	B-CHEMICAL
Ca2	B-GENE-N
+	I-GENE-N
-	I-GENE-N
channel	I-GENE-N
blockers	O
felodipine	B-CHEMICAL
and	O
nicardipine	B-CHEMICAL
on	O
CaMPDE	B-GENE-N
.	O

The	O
results	O
suggest	O
that	O
the	O
63	O
-	O
kDa	O
(	O
PDE	B-GENE-Y
1B1	I-GENE-Y
)	O
and	O
60	O
-	O
kDa	O
(	O
PDE	B-GENE-Y
1A2	I-GENE-Y
)	O
CaMPDE	B-GENE-N
isozymes	O
are	O
inhibited	O
by	O
felodipine	B-CHEMICAL
and	O
nicardipine	B-CHEMICAL
by	O
partial	O
competitive	O
inhibition	O
and	O
that	O
these	O
two	O
Ca2	B-CHEMICAL
+	I-CHEMICAL
antagonists	O
appear	O
to	O
counteract	O
each	O
other	O
.	O

This	O
study	O
further	O
demonstrates	O
the	O
existence	O
of	O
a	O
specific	O
site	O
,	O
distinct	O
from	O
the	O
active	O
site	O
on	O
CaMPDE	B-GENE-N
,	O
that	O
exhibits	O
high	O
-	O
affinity	O
binding	O
of	O
these	O
drugs	O
.	O

Felodipine	B-CHEMICAL
and	O
nicardipine	B-CHEMICAL
have	O
similar	O
affinities	O
for	O
60	O
-	O
kDa	O
CaMPDE	B-GENE-N
isozymes	O
but	O
bring	O
about	O
different	O
levels	O
of	O
enzyme	O
inhibition	O
,	O
suggesting	O
the	O
possibility	O
of	O
designing	O
specific	O
drugs	O
that	O
can	O
protect	O
the	O
enzyme	O
from	O
inhibition	O
by	O
dihydropyridine	B-CHEMICAL
Ca2	B-GENE-N
+	I-GENE-N
-	I-GENE-N
channel	I-GENE-N
blockers	O
.	O

Pre	O
-	O
clinical	O
pharmacology	O
of	O
zolmitriptan	B-CHEMICAL
(	O
Zomig	B-CHEMICAL
;	O
formerly	B-CHEMICAL
311C90	B-CHEMICAL
)	O
,	O
a	O
centrally	O
and	O
peripherally	O
acting	O
5HT1B	B-GENE-N
/	I-GENE-N
1D	I-GENE-N
agonist	O
for	O
migraine	O
.	O

Zolmitriptan	B-CHEMICAL
(	O
Zomig	B-CHEMICAL
;	O
formerly	B-CHEMICAL
311C90	B-CHEMICAL
)	O
is	O
a	O
novel	O
5	B-GENE-N
-	I-GENE-N
hydroxytryptamine	I-GENE-N
(	I-GENE-N
5HT	I-GENE-N
)	I-GENE-N
1B	I-GENE-N
/	I-GENE-N
1D	I-GENE-N
receptor	O
agonist	O
with	O
proven	O
efficacy	O
in	O
the	O
acute	O
treatment	O
of	O
migraine	O
with	O
or	O
without	O
preceding	O
aura	O
.	O

The	O
drug	O
differs	O
from	O
presently	O
available	O
members	O
of	O
this	O
drug	O
class	O
in	O
that	O
it	O
combines	O
5HT1B	B-GENE-N
/	I-GENE-N
1D	I-GENE-N
receptor	O
partial	O
agonist	O
activity	O
with	O
robust	O
oral	O
pharmacokinetics	O
and	O
an	O
ability	O
to	O
inhibit	O
trigeminovascular	O
activation	O
centrally	O
as	O
well	O
as	O
peripherally	O
in	O
preclinical	O
studies	O
.	O

Consistent	O
with	O
its	O
selectivity	O
for	O
5HT1B	B-GENE-N
/	I-GENE-N
1D	I-GENE-N
receptors	O
,	O
zolmitriptan	B-CHEMICAL
produces	O
constriction	O
of	O
various	O
isolated	O
blood	O
vessels	O
,	O
most	O
notably	O
cranial	O
arteries	O
.	O

In	O
anaesthetized	O
animals	O
,	O
these	O
vascular	O
effects	O
manifest	O
as	O
a	O
selective	O
constriction	O
of	O
cranial	O
arterio	O
-	O
venous	O
anastomoses	O
resulting	O
in	O
a	O
redistribution	O
of	O
carotid	O
arterial	O
blood	O
flow	O
.	O

This	O
effect	O
is	O
produced	O
without	O
significant	O
effects	O
on	O
heart	O
rate	O
,	O
blood	O
pressure	O
or	O
blood	O
flow	O
to	O
the	O
brain	O
,	O
heart	O
or	O
lungs	O
.	O

Zolmitriptan	B-CHEMICAL
also	O
inhibits	O
trigeminal	O
-	O
evoked	O
increases	O
in	O
cerebral	O
blood	O
flow	O
in	O
anaesthetized	O
cats	O
and	O
blocks	O
trigeminal	O
-	O
evoked	O
plasma	O
protein	O
extravasation	O
in	O
the	O
dura	O
of	O
guinea	O
-	O
pigs	O
.	O

These	O
actions	O
are	O
consistent	O
with	O
a	O
pre	O
-	O
junctional	O
inhibition	O
of	O
neuropeptide	O
release	O
from	O
perivascular	O
afferents	O
of	O
the	O
trigeminal	O
nerve	O
,	O
as	O
confirmed	O
by	O
independent	O
studies	O
showing	O
that	O
zolmitriptan	B-CHEMICAL
blocks	O
elevations	O
of	O
calcitonin	B-GENE-N
-	I-GENE-N
gene	I-GENE-N
-	I-GENE-N
related	I-GENE-N
peptide	I-GENE-N
in	O
jugular	O
venous	O
blood	O
during	O
electrical	O
stimulation	O
of	O
the	O
trigeminal	O
ganglion	O
.	O

In	O
all	O
of	O
these	O
effects	O
,	O
zolmitriptan	B-CHEMICAL
is	O
three	O
to	O
four	O
times	O
more	O
potent	O
than	O
sumatriptan	B-CHEMICAL
,	O
but	O
produces	O
the	O
same	O
maximum	O
response	O
.	O

Zolmitriptan	B-CHEMICAL
crosses	O
the	O
intact	O
blood	O
-	O
brain	O
barrier	O
to	O
inhibit	O
trigeminovascular	O
activation	O
in	O
the	O
brainstem	O
.	O

This	O
was	O
shown	O
initially	O
by	O
the	O
ability	O
of	O
the	O
drug	O
to	O
block	O
a	O
brainstem	O
reflex	O
provoking	O
vasoactive	O
intestinal	O
peptide	O
release	O
from	O
the	O
VIIth	O
cranial	O
(	O
facial	O
)	O
nerve	O
during	O
trigeminal	O
stimulation	O
.	O

Subsequent	O
ex	O
vivo	O
autoradiography	O
confirmed	O
that	O
intravenously	O
injected	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
zolmitriptan	I-CHEMICAL
labels	O
a	O
discrete	O
population	O
of	O
cells	O
in	O
the	O
trigeminal	O
nucleus	O
caudalis	O
(	O
TNC	O
)	O
and	O
nucleus	O
tractus	O
solitarius	O
.	O

Direct	O
evidence	O
for	O
a	O
central	O
neuromodulatory	O
effect	O
of	O
zolmitriptan	B-CHEMICAL
was	O
provided	O
by	O
electrophysiological	O
experiments	O
which	O
clearly	O
demonstrated	O
that	O
the	O
drug	O
inhibits	O
the	O
excitability	O
of	O
cells	O
in	O
the	O
TNC	O
after	O
systemic	O
administration	O
.	O

This	O
novel	O
pre	O
-	O
clinical	O
profile	O
not	O
only	O
distinguishes	O
zolmitriptan	B-CHEMICAL
from	O
sumatriptan	B-CHEMICAL
,	O
but	O
raises	O
intriguing	O
questions	O
about	O
the	O
clinical	O
relevance	O
of	O
a	O
dual	O
action	O
.	O

Studies	O
to	O
date	O
show	O
that	O
zolmitriptan	B-CHEMICAL
indeed	O
modulates	O
cranial	O
sensory	O
processing	O
in	O
humans	O
,	O
yet	O
central	O
side	O
-	O
effects	O
are	O
no	O
different	O
from	O
sumatriptan	B-CHEMICAL
.	O

This	O
property	O
may	O
account	O
for	O
the	O
remarkable	O
consistency	O
in	O
clinical	O
efficacy	O
observed	O
in	O
clinical	O
trials	O
.	O

Differential	O
interactions	O
of	O
heparin	O
and	O
heparan	O
sulfate	O
glycosaminoglycans	O
with	O
the	O
selectins	B-GENE-N
.	O

Implications	O
for	O
the	O
use	O
of	O
unfractionated	O
and	O
low	O
molecular	O
weight	O
heparins	O
as	O
therapeutic	O
agents	O
.	O

The	O
selectins	B-GENE-N
are	O
calcium	B-CHEMICAL
-	O
dependent	O
C	B-GENE-N
-	I-GENE-N
type	I-GENE-N
lectins	I-GENE-N
that	O
bind	O
certain	O
sialylated	O
,	O
fucosylated	O
,	O
sulfated	O
glycoprotein	O
ligands	O
.	O

L	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
also	O
recognizes	O
endothelial	O
proteoglycans	O
in	O
a	O
calcium	B-CHEMICAL
-	O
dependent	O
manner	O
,	O
via	O
heparan	O
sulfate	O
(	O
HS	O
)	O
glycosaminoglycan	O
chains	O
enriched	O
in	O
unsubstituted	O
glucosamine	B-CHEMICAL
units	O
.	O

We	O
now	O
show	O
that	O
these	O
HS	O
chains	O
can	O
also	O
bind	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
but	O
not	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
.	O

However	O
,	O
while	O
L	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
binding	O
requires	O
micromolar	O
levels	O
of	O
free	O
calcium	O
,	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
recognition	O
is	O
largely	O
divalent	O
cation	O
-	O
independent	O
.	O

Despite	O
this	O
,	O
HS	O
chains	O
bound	O
to	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
are	O
eluted	O
by	O
ethylenediamine	B-CHEMICAL
tetraacetic	I-CHEMICAL
acid	I-CHEMICAL
(	O
EDTA	B-CHEMICAL
)	O
,	O
but	O
only	O
at	O
high	O
concentrations	O
.	O

Porcine	O
intestinal	O
mucosal	O
(	O
mast	O
cell	O
-	O
derived	O
)	O
heparin	O
(	O
PIM	O
-	O
heparin	O
)	O
shows	O
similar	O
properties	O
,	O
with	O
no	O
binding	O
to	O
E	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
calcium	B-CHEMICAL
-	O
dependent	O
binding	O
of	O
a	O
subfraction	O
to	O
L	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
and	O
to	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
and	O
calcium	B-CHEMICAL
-	O
independent	O
binding	O
of	O
a	O
larger	O
fraction	O
to	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
,	O
the	O
latter	O
being	O
disrupted	O
by	O
high	O
EDTA	B-CHEMICAL
concentrations	O
.	O

Analysis	O
of	O
defined	O
heparin	O
fragment	O
pools	O
shows	O
a	O
size	O
dependence	O
for	O
interaction	O
,	O
with	O
tetradecasaccharides	B-CHEMICAL
showing	O
easily	O
detectable	O
binding	O
to	O
L	B-GENE-N
-	I-GENE-N
and	I-GENE-N
P	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
affinity	O
columns	O
.	O

L	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
binding	O
fragments	O
include	O
more	O
heavily	O
sulfated	O
and	O
epimerized	O
regions	O
and	O
,	O
as	O
with	O
the	O
endothelial	O
HS	O
chains	O
,	O
they	O
are	O
enriched	O
in	O
free	B-CHEMICAL
amino	I-CHEMICAL
groups	O
.	O

The	O
P	B-GENE-Y
-	I-GENE-Y
selectin	I-GENE-Y
binding	O
component	O
includes	O
this	O
fraction	O
as	O
well	O
as	O
some	O
less	O
highly	O
modified	O
regions	O
.	O

Thus	O
,	O
endothelium	O
-	O
derived	O
HS	O
chains	O
and	O
mast	O
cell	O
-	O
derived	O
heparins	O
could	O
play	O
a	O
role	O
in	O
modulating	O
the	O
biology	O
of	O
selectins	B-GENE-N
in	O
vivo	O
.	O

Notably	O
,	O
P	B-GENE-N
-	I-GENE-N
and	I-GENE-N
L	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
binding	O
to	O
sialyl	O
-	O
Lewisx	O
and	O
to	O
HL	O
-	O
60	O
cells	O
(	O
which	O
are	O
known	O
to	O
carry	O
the	O
native	O
ligand	O
PSGL	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
)	O
is	O
inhibited	O
by	O
unfractionated	O
pharmaceutical	O
heparin	O
preparations	O
at	O
concentrations	O
12	O
-	O
50	O
-	O
fold	O
lower	O
than	O
those	O
recommended	O
for	O
effective	O
anticoagulation	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
two	O
low	O
molecular	O
weight	O
heparins	O
currently	O
considered	O
as	O
clinical	O
replacements	O
for	O
unfractionated	O
heparin	O
are	O
much	O
poorer	O
inhibitors	O
.	O

Thus	O
,	O
patients	O
undergoing	O
heparin	O
therapy	O
for	O
other	O
reasons	O
may	O
be	O
experiencing	O
clinically	O
significant	O
inhibition	O
of	O
L	B-GENE-N
-	I-GENE-N
and	I-GENE-N
P	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
function	O
,	O
and	O
the	O
current	O
switchover	O
to	O
low	O
-	O
molecular	O
weight	O
heparins	O
may	O
come	O
at	O
some	O
loss	O
of	O
this	O
effect	O
.	O

Low	O
-	O
dose	O
unfractionated	O
heparin	O
should	O
be	O
investigated	O
as	O
a	O
treatment	O
option	O
for	O
acute	O
and	O
chronic	O
diseases	O
in	O
which	O
P	B-GENE-N
-	I-GENE-N
and	I-GENE-N
L	I-GENE-N
-	I-GENE-N
selectin	I-GENE-N
play	O
pathological	O
roles	O
.	O

Exogenous	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
activates	O
c	B-GENE-N
-	I-GENE-N
fos	I-GENE-N
serum	I-GENE-N
response	I-GENE-N
element	I-GENE-N
via	O
Rac	B-GENE-N
-	O
dependent	O
signalling	O
pathway	O
.	O

Ceramide	B-CHEMICAL
is	O
an	O
important	O
regulatory	O
molecule	O
implicated	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
in	O
response	O
to	O
stress	O
and	O
cytokines	B-GENE-N
.	O

To	O
understand	O
the	O
signal	O
transduction	O
pathway	O
of	O
ceramide	B-CHEMICAL
to	O
the	O
nucleus	O
,	O
in	O
the	O
present	O
study	O
,	O
we	O
examined	O
whether	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
,	O
a	O
cell	O
permeable	O
ceramide	B-CHEMICAL
,	O
activates	O
c	B-GENE-N
-	I-GENE-N
fos	I-GENE-N
serum	I-GENE-N
response	I-GENE-N
element	I-GENE-N
(	O
SRE	B-GENE-N
)	O
.	O

Treatment	O
of	O
Rat	O
-	O
2	O
fibroblast	O
cells	O
with	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
caused	O
the	O
stimulation	O
of	O
c	B-GENE-N
-	I-GENE-N
fos	I-GENE-N
SRE	I-GENE-N
-	O
dependent	O
reporter	O
gene	O
activity	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
by	O
transient	O
transfection	O
analysis	O
.	O

Next	O
,	O
we	O
examined	O
the	O
role	O
of	O
Rho	B-GENE-N
family	O
GTPases	B-GENE-N
in	O
the	O
ceramide	B-CHEMICAL
-	O
induced	O
signalling	O
to	O
SRE	B-GENE-N
activation	O
.	O

By	O
reporter	O
gene	O
analysis	O
following	O
transient	O
transfections	O
with	O
various	O
plasmids	O
expressing	O
a	O
dominant	O
negative	O
mutant	O
form	O
of	O
Cdc42	B-GENE-Y
,	O
Rac1	B-GENE-Y
or	O
RhoA	B-GENE-Y
,	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
-	O
induced	O
SRE	B-GENE-N
activation	O
was	O
shown	O
to	O
be	O
selectively	O
repressed	O
by	O
pEXV	O
-	O
RacN17	O
encoding	O
a	O
dominant	O
negative	O
mutant	O
of	O
Rac1	B-GENE-Y
,	O
suggesting	O
that	O
Rac	B-GENE-N
activity	O
is	O
essential	O
for	O
the	O
signalling	O
cascade	O
of	O
ceramide	B-CHEMICAL
to	O
the	O
nucleus	O
.	O

In	O
a	O
further	O
study	O
to	O
analyse	O
the	O
downstream	O
mediator	O
of	O
Rac	B-GENE-N
in	O
the	O
ceramide	B-CHEMICAL
-	O
signalling	O
pathway	O
,	O
we	O
observed	O
that	O
either	O
pretreatment	O
with	O
mepacrine	B-CHEMICAL
,	O
a	O
potent	O
and	O
specific	O
inhibitor	O
of	O
phospholipase	O
A2	O
,	O
or	O
co	O
-	O
transfection	O
with	O
antisense	O
cytosolic	B-GENE-Y
phospholipase	I-GENE-Y
A2	I-GENE-Y
(	O
cPLA2	B-GENE-Y
)	O
oligonucleotide	O
repressed	O
the	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
-	O
induced	O
SRE	B-GENE-N
activation	O
selectively	O
,	O
implying	O
a	O
critical	O
role	O
of	O
cPLA2	B-GENE-Y
in	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
-	O
induced	O
signalling	O
to	O
nucleus	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
translocation	O
of	O
cPLA2	B-GENE-Y
protein	O
as	O
well	O
as	O
the	O
release	O
of	O
arachidonic	B-CHEMICAL
acid	I-CHEMICAL
,	O
a	O
principal	O
product	O
of	O
phospholipase	B-GENE-Y
A2	I-GENE-Y
,	O
was	O
rapidly	O
induced	O
by	O
the	O
addition	O
of	O
C2	B-CHEMICAL
-	I-CHEMICAL
ceramide	I-CHEMICAL
in	O
a	O
Rac	B-GENE-N
-	O
dependent	O
manner	O
.	O

Together	O
,	O
our	O
findings	O
suggest	O
the	O
critical	O
role	O
of	O
'	O
Rac	B-GENE-N
and	O
subsequent	O
activation	O
of	O
phospholipase	B-GENE-Y
A2	I-GENE-Y
'	O
in	O
ceramide	B-CHEMICAL
-	O
signalling	O
to	O
nucleus	O
.	O

Adrenergic	O
agonists	O
suppress	O
the	O
proliferation	O
of	O
microglia	O
through	O
beta	B-GENE-Y
2	I-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
.	O

The	O
effects	O
of	O
several	O
cyclic	B-CHEMICAL
adenosine	I-CHEMICAL
monophosphate	I-CHEMICAL
(	O
cAMP	B-CHEMICAL
)	O
-	O
elevating	O
agents	O
on	O
the	O
proliferation	O
of	O
cultured	O
rat	O
microglia	O
were	O
investigated	O
by	O
immunocytochemical	O
staining	O
with	O
an	O
antibody	O
against	O
proliferating	B-GENE-Y
cell	I-GENE-Y
nuclear	I-GENE-Y
antigen	I-GENE-Y
(	O
PCNA	B-GENE-Y
)	O
.	O

Epinephrine	B-CHEMICAL
,	O
isoproterenol	B-CHEMICAL
,	O
forskolin	B-CHEMICAL
and	O
8Br	B-CHEMICAL
-	I-CHEMICAL
cAMP	I-CHEMICAL
suppressed	O
the	O
microglial	O
proliferation	O
.	O

A	O
beta2	O
-	O
selective	O
agonist	O
terbutaline	B-CHEMICAL
but	O
not	O
a	O
beta1	O
-	O
selective	O
agonist	O
dobutamine	B-CHEMICAL
mimicked	O
the	O
effect	O
of	O
the	O
above	O
cAMP	B-CHEMICAL
-	O
elevating	O
agents	O
.	O

Furthermore	O
,	O
a	O
non	O
-	O
selective	O
beta	O
-	O
receptor	O
antagonist	O
oxprenolol	B-CHEMICAL
and	O
a	O
beta2	O
-	O
selective	O
antagonist	O
acebutalol	B-CHEMICAL
,	O
but	O
not	O
a	O
beta1	O
-	O
selective	O
antagonist	O
butoxamine	B-CHEMICAL
,	O
counteracted	O
the	O
suppressive	O
effects	O
of	O
the	O
beta	O
-	O
agonists	O
on	O
microglial	O
proliferation	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
beta	O
-	O
agonists	O
suppress	O
the	O
proliferation	O
of	O
microglia	O
by	O
elevating	O
intracellular	O
cAMP	B-CHEMICAL
level	O
through	O
an	O
action	O
on	O
beta2	B-GENE-Y
-	I-GENE-Y
adrenergic	I-GENE-Y
receptor	I-GENE-Y
.	O

Biosynthesis	O
,	O
assembly	O
and	O
secretion	O
of	O
coagulation	B-GENE-Y
factor	I-GENE-Y
VIII	I-GENE-Y
.	O

Factor	B-GENE-Y
VIII	I-GENE-Y
is	O
a	O
large	O
complex	O
glycoprotein	O
that	O
is	O
deficient	O
in	O
hemophilia	O
A	O
.	O

It	O
has	O
a	O
domain	O
organization	O
consisting	O
of	O
A1	B-GENE-N
-	I-GENE-N
A2	I-GENE-N
-	I-GENE-N
B	I-GENE-N
-	I-GENE-N
A3	I-GENE-N
-	I-GENE-N
C1	I-GENE-N
-	I-GENE-N
C2	I-GENE-N
where	O
the	O
B	B-GENE-N
domain	I-GENE-N
is	O
a	O
heavily	O
glycosylated	O
region	O
that	O
is	O
dispensable	O
for	O
procoagulant	O
activity	O
.	O

Factor	B-GENE-Y
VIII	I-GENE-Y
expression	O
is	O
10	O
-	O
to	O
20	O
-	O
fold	O
lower	O
than	O
the	O
homologous	O
coagulation	B-GENE-Y
factor	I-GENE-Y
V	I-GENE-Y
.	O

Factor	B-GENE-Y
VIII	I-GENE-Y
expression	O
is	O
limited	O
due	O
to	O
a	O
low	O
level	O
of	O
steady	O
-	O
state	O
messenger	O
RNA	O
in	O
the	O
cytoplasm	O
and	O
inefficient	O
transport	O
of	O
the	O
primary	O
translation	O
product	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
apparatus	O
.	O

Within	O
the	O
secretory	O
pathway	O
,	O
factor	B-GENE-Y
VIII	I-GENE-Y
is	O
processed	O
to	O
a	O
heterodimer	O
of	O
the	O
heavy	O
chain	O
(	O
domains	B-GENE-N
A1	I-GENE-N
-	I-GENE-N
A2	I-GENE-N
-	I-GENE-N
B	I-GENE-N
)	O
in	O
a	O
metal	O
ion	O
association	O
with	O
the	O
light	O
chain	O
(	O
domains	B-GENE-N
A3	I-GENE-N
-	I-GENE-N
C1	I-GENE-N
-	I-GENE-N
C2	I-GENE-N
)	O
.	O

Upon	O
secretion	O
from	O
the	O
cell	O
,	O
von	B-GENE-Y
Willebrand	I-GENE-Y
factor	I-GENE-Y
binds	O
the	O
light	B-GENE-Y
chain	I-GENE-Y
of	I-GENE-Y
factor	I-GENE-Y
VIII	I-GENE-Y
and	O
stabilizes	O
the	O
factor	O
,	O
preventing	O
degradation	O
.	O

Protein	O
folding	O
within	O
the	O
mammalian	O
secretory	O
pathway	O
is	O
facilitated	O
by	O
molecular	B-GENE-N
chaperones	I-GENE-N
.	O

Within	O
the	O
endoplasmic	O
reticulum	O
,	O
factor	B-GENE-Y
VIII	I-GENE-Y
exhibits	O
stable	O
interaction	O
with	O
protein	O
chaperones	O
identified	O
as	O
the	O
immunoglobulin	B-GENE-Y
-	I-GENE-Y
binding	I-GENE-Y
protein	I-GENE-Y
(	O
BiP	B-GENE-Y
)	O
,	O
calnexin	B-GENE-Y
and	O
calreticulin	B-GENE-Y
.	O

BiP	B-GENE-Y
is	O
a	O
peptide	O
-	O
dependent	O
ATPase	B-GENE-N
that	O
interacts	O
with	O
exposed	O
hydrophobic	O
surfaces	O
on	O
unfolded	O
proteins	O
or	O
unassembled	O
protein	O
subunits	O
.	O

A	O
potential	O
BiP	B-GENE-N
binding	I-GENE-N
site	I-GENE-N
within	O
factor	B-GENE-Y
VIII	I-GENE-Y
has	O
been	O
identified	O
.	O

Mutation	O
of	O
a	O
single	O
amino	B-CHEMICAL
acid	I-CHEMICAL
residue	O
in	O
the	O
potential	O
BiP	B-GENE-N
binding	I-GENE-N
site	I-GENE-N
increased	O
the	O
secretion	O
efficiency	O
of	O
factor	B-GENE-Y
VIII	I-GENE-Y
by	O
threefold	O
.	O

Interestingly	O
,	O
the	O
proposed	O
BiP	B-GENE-N
binding	I-GENE-N
site	I-GENE-N
is	O
adjacent	O
to	O
a	O
type	B-GENE-N
-	I-GENE-N
1	I-GENE-N
copper	I-GENE-N
binding	I-GENE-N
site	I-GENE-N
within	O
the	O
A1	B-GENE-N
domain	I-GENE-N
that	O
is	O
required	O
for	O
interaction	O
between	O
the	O
factor	B-GENE-N
VIII	I-GENE-N
A1	I-GENE-N
domain	I-GENE-N
and	O
the	O
A3	B-GENE-N
domain	I-GENE-N
.	O

We	O
propose	O
that	O
Cu	B-CHEMICAL
(	I-CHEMICAL
I	I-CHEMICAL
)	I-CHEMICAL
binds	O
the	O
type	B-GENE-N
-	I-GENE-N
1	I-GENE-N
copper	I-GENE-N
ion	I-GENE-N
-	I-GENE-N
binding	I-GENE-N
site	I-GENE-N
in	O
the	O
A1	B-GENE-N
domain	I-GENE-N
and	O
provides	O
the	O
essential	O
requirement	O
for	O
a	O
stable	O
interaction	O
between	O
the	O
heavy	O
and	O
light	O
chains	O
.	O

Calnexin	B-GENE-Y
and	O
calreticulin	B-GENE-Y
are	O
transmembrane	O
and	O
lumenal	O
proteins	O
,	O
respectively	O
,	O
localized	O
to	O
the	O
endoplasmic	O
reticulum	O
,	O
which	O
associate	O
transiently	O
with	O
many	O
soluble	O
and	O
membrane	O
glycoproteins	O
during	O
folding	O
and	O
subunit	O
assembly	O
.	O

The	O
calnexin	B-GENE-Y
and	O
calreticulin	B-GENE-Y
interaction	O
with	O
factor	B-GENE-Y
VIII	I-GENE-Y
occurs	O
primarily	O
through	O
amino	B-CHEMICAL
-	O
terminal	O
linked	O
oligosaccharides	O
within	O
the	O
heavily	O
glycosylated	O
factor	B-GENE-N
VIII	I-GENE-N
B	I-GENE-N
domain	I-GENE-N
and	O
this	O
interaction	O
appears	O
to	O
be	O
required	O
for	O
factor	B-GENE-Y
VIII	I-GENE-Y
secretion	O
.	O

The	O
findings	O
suggest	O
that	O
factor	B-GENE-Y
VIII	I-GENE-Y
cycles	O
through	O
interactions	O
with	O
BiP	B-GENE-Y
,	O
calnexin	B-GENE-Y
and	O
calreticulin	B-GENE-Y
.	O

Although	O
the	O
interaction	O
with	O
BiP	B-GENE-Y
does	O
not	O
appear	O
to	O
be	O
required	O
for	O
factor	B-GENE-Y
VIII	I-GENE-Y
secretion	O
,	O
data	O
suggest	O
that	O
the	O
calnexin	B-GENE-Y
and	O
/	O
or	O
calreticulin	B-GENE-Y
interaction	O
is	O
required	O
for	O
secretion	O
.	O

The	O
observations	O
suggest	O
a	O
unique	O
requirement	O
for	O
carbohydrate	B-CHEMICAL
processing	O
and	O
calnexin	B-GENE-Y
/	O
calreticulin	B-GENE-Y
interaction	O
that	O
may	O
limit	O
the	O
productive	O
secretion	O
of	O
factor	B-GENE-Y
VIII	I-GENE-Y
and	O
have	O
implications	O
for	O
approaches	O
towards	O
somatic	O
cell	O
gene	O
therapy	O
for	O
hemophilia	O
A	O
.	O

Mechanism	O
of	O
action	O
of	O
dopaminergic	O
agents	O
in	O
Parkinson	O
'	O
s	O
disease	O
.	O

As	O
the	O
substantia	O
nigra	O
degenerates	O
in	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
,	O
the	O
nigrostriatal	O
pathway	O
is	O
disrupted	O
,	O
reducing	O
striatal	O
dopamine	B-CHEMICAL
and	O
producing	O
PD	O
symptoms	O
.	O

Although	O
dopamine	B-CHEMICAL
does	O
not	O
readily	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
its	O
precursor	O
,	O
levodopa	B-CHEMICAL
,	O
does	O
.	O

Levodopa	B-CHEMICAL
is	O
absorbed	O
in	O
the	O
small	O
bowel	O
and	O
is	O
rapidly	O
catabolized	O
by	O
aromatic	B-GENE-Y
-	I-GENE-Y
L	I-GENE-Y
-	I-GENE-Y
amino	I-GENE-Y
-	I-GENE-Y
acid	I-GENE-Y
decarboxylase	I-GENE-Y
(	O
AADC	B-GENE-Y
)	O
and	O
catechol	B-GENE-Y
-	I-GENE-Y
O	I-GENE-Y
-	I-GENE-Y
methyltransferase	I-GENE-Y
(	O
COMT	B-GENE-Y
)	O
.	O

Because	O
gastric	O
AADC	B-GENE-Y
and	O
COMT	B-GENE-Y
degrade	O
levodopa	B-CHEMICAL
,	O
the	O
drug	O
is	O
given	O
with	O
inhibitors	O
of	O
AADC	B-GENE-Y
(	O
carbidopa	B-CHEMICAL
or	O
benserazide	B-CHEMICAL
)	O
,	O
and	O
inhibitors	O
of	O
COMT	B-GENE-Y
will	O
also	O
enter	O
clinical	O
use	O
.	O

Although	O
the	O
exact	O
site	O
of	O
decarboxylation	O
of	O
exogenous	O
levodopa	B-CHEMICAL
to	O
dopamine	B-CHEMICAL
in	O
the	O
brain	O
is	O
unknown	O
,	O
most	O
striatal	O
AADC	B-GENE-Y
is	O
located	O
in	O
nigrostriatal	O
dopaminergic	O
nerve	O
terminals	O
.	O

Newly	O
synthesized	O
dopamine	O
is	O
stored	O
in	O
the	O
terminals	O
and	O
then	O
released	O
,	O
stimulating	O
postsynaptic	O
dopamine	B-GENE-N
receptors	I-GENE-N
and	O
mediating	O
the	O
antiparkinsonian	O
action	O
of	O
levodopa	B-CHEMICAL
.	O

Dopamine	B-CHEMICAL
agonists	O
act	O
directly	O
on	O
postsynaptic	O
dopamine	B-GENE-N
receptors	I-GENE-N
,	O
thus	O
obviating	O
the	O
need	O
for	O
metabolic	O
conversion	O
,	O
storage	O
,	O
and	O
release	O
.	O

How	O
the	O
actions	O
of	O
dopaminergic	O
drugs	O
produce	O
side	O
effects	O
and	O
how	O
these	O
side	O
effects	O
should	O
be	O
managed	O
are	O
discussed	O
.	O

Mechanism	O
of	O
action	O
of	O
leflunomide	B-CHEMICAL
in	O
rheumatoid	O
arthritis	O
.	O

Leflunomide	B-CHEMICAL
,	O
a	O
novel	O
drug	O
with	O
proven	O
efficacy	O
in	O
rheumatoid	O
arthritis	O
,	O
is	O
an	O
isoxazol	B-CHEMICAL
derivative	O
structurally	O
unrelated	O
to	O
other	O
immunomodulatory	O
drugs	O
.	O

Leflunomide	B-CHEMICAL
is	O
rapidly	O
metabolized	O
to	O
its	O
active	O
form	O
,	O
A77	B-CHEMICAL
1726	I-CHEMICAL
.	O

Two	O
mechanisms	O
of	O
action	O
have	O
been	O
identified	O
for	O
A77	B-CHEMICAL
1726	I-CHEMICAL
:	O
inhibition	O
of	O
dihydroorotate	B-GENE-Y
dehydrogenase	I-GENE-Y
(	O
DHODH	B-GENE-Y
)	O
and	O
inhibition	O
of	O
tyrosine	B-GENE-N
kinases	I-GENE-N
.	O

DHODH	B-GENE-Y
inhibition	O
occurs	O
at	O
lower	O
concentrations	O
of	O
A77	B-CHEMICAL
1726	I-CHEMICAL
than	O
that	O
of	O
tyrosine	B-GENE-N
kinases	I-GENE-N
and	O
is	O
currently	O
considered	O
the	O
major	O
mode	O
of	O
action	O
.	O

Stimulated	O
lymphocytes	O
must	O
increase	O
ribonucleotide	O
levels	O
from	O
8	O
to	O
16	O
-	O
fold	O
before	O
proceeding	O
from	O
the	O
G1	O
into	O
the	O
S	O
phase	O
.	O

Increased	O
levels	O
of	O
ribonucleotides	O
can	O
only	O
be	O
met	O
by	O
de	O
novo	O
ribonucleotide	O
synthesis	O
.	O

At	O
low	O
levels	O
of	O
ribonucleotides	O
,	O
p53	B-GENE-Y
,	O
a	O
"	O
sensor	O
"	O
molecule	O
,	O
gets	O
activated	O
and	O
prevents	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Therefore	O
,	O
an	O
inhibitor	O
of	O
de	O
novo	O
uridine	B-CHEMICAL
monophosphate	I-CHEMICAL
synthesis	O
would	O
predictably	O
arrest	O
stimulated	O
cells	O
at	O
the	O
G1	O
phase	O
.	O

In	O
support	O
of	O
this	O
mechanism	O
of	O
action	O
,	O
in	O
vitro	O
mitogen	O
stimulated	O
human	O
peripheral	O
blood	O
lymphocytes	O
treated	O
with	O
A77	B-CHEMICAL
1726	I-CHEMICAL
undergo	O
arrest	O
at	O
the	O
G1	O
phase	O
;	O
this	O
inhibition	O
is	O
reversed	O
by	O
uridine	B-CHEMICAL
.	O

Affinities	O
of	O
venlafaxine	B-CHEMICAL
and	O
various	O
reuptake	O
inhibitors	O
for	O
the	O
serotonin	B-GENE-N
and	I-GENE-N
norepinephrine	I-GENE-N
transporters	I-GENE-N
.	O

In	O
vitro	O
radioligand	O
binding	O
studies	O
were	O
carried	O
out	O
in	O
rat	O
brain	O
membranes	O
to	O
assess	O
the	O
affinity	O
of	O
various	O
reuptake	O
inhibitors	O
for	O
the	O
serotonin	B-GENE-N
(	I-GENE-N
5	I-GENE-N
-	I-GENE-N
hydroxytryptamine	I-GENE-N
,	I-GENE-N
5	I-GENE-N
-	I-GENE-N
HT	I-GENE-N
)	I-GENE-N
and	I-GENE-N
the	I-GENE-N
norepinephrine	I-GENE-N
transporters	I-GENE-N
using	O
the	O
selective	O
ligands	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
cyanoimipramine	I-CHEMICAL
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
nisoxetine	I-CHEMICAL
,	O
respectively	O
.	O

The	O
selective	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
reuptake	O
inhibitors	O
paroxetine	B-CHEMICAL
,	O
indalpine	B-CHEMICAL
and	O
fluvoxamine	B-CHEMICAL
displayed	O
a	O
high	O
affinity	O
for	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
transporter	I-GENE-Y
,	O
whereas	O
the	O
norepinephrine	B-CHEMICAL
reuptake	O
inhibitor	O
desipramine	B-CHEMICAL
had	O
a	O
high	O
affinity	O
for	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
.	O

Duloxetine	B-CHEMICAL
,	O
a	O
dual	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
reuptake	O
inhibitor	O
,	O
displayed	O
a	O
high	O
affinity	O
for	O
both	O
the	O
5	B-GENE-N
-	I-GENE-N
HT	I-GENE-N
and	I-GENE-N
the	I-GENE-N
norepinephrine	I-GENE-N
transporters	I-GENE-N
.	O

Interestingly	O
,	O
venlafaxine	B-CHEMICAL
,	O
a	O
dual	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
reuptake	O
inhibitor	O
,	O
displayed	O
only	O
a	O
moderate	O
affinity	O
for	O
the	O
5	B-GENE-Y
-	I-GENE-Y
HT	I-GENE-Y
transporter	I-GENE-Y
(	O
Ki	O
=	O
74	O
nM	O
)	O
and	O
a	O
very	O
low	O
affinity	O
for	O
the	O
norepinephrine	B-GENE-Y
transporter	I-GENE-Y
(	O
Ki	O
=	O
1	O
.	O
26	O
microM	O
)	O
.	O

The	O
relatively	O
low	O
affinities	O
of	O
venlafaxine	B-CHEMICAL
contrast	O
with	O
its	O
potent	O
in	O
vivo	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
reuptake	O
blocking	O
properties	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
the	O
in	O
vivo	O
effects	O
on	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
and	O
norepinephrine	B-CHEMICAL
reuptake	O
observed	O
with	O
venlafaxine	B-CHEMICAL
may	O
not	O
be	O
mediated	O
solely	O
by	O
its	O
binding	O
to	O
the	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
cyanoimipramine	I-CHEMICAL
and	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
nisoxetine	I-CHEMICAL
binding	O
sites	O
.	O

Purification	O
and	O
multimeric	O
structure	O
of	O
bovine	O
N	B-GENE-Y
-	I-GENE-Y
acetylglucosamine	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
phosphodiester	I-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
acetylglucosaminidase	I-GENE-Y
.	O

N	B-GENE-Y
-	I-GENE-Y
Acetylglucosamine	I-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
-	I-GENE-Y
phosphodiester	I-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
N	I-GENE-Y
-	I-GENE-Y
Acetylglucosaminidase	I-GENE-Y
(	O
EC	B-GENE-Y
3	I-GENE-Y
.	I-GENE-Y
1	I-GENE-Y
.	I-GENE-Y
4	I-GENE-Y
.	I-GENE-Y
45	I-GENE-Y
;	O
phosphodiester	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
GlcNAcase	I-GENE-Y
)	O
catalyzes	O
the	O
second	O
step	O
in	O
the	O
synthesis	O
of	O
the	O
mannose	B-CHEMICAL
6	I-CHEMICAL
-	I-CHEMICAL
phosphate	I-CHEMICAL
determinant	O
required	O
for	O
efficient	O
intracellular	O
targeting	O
of	O
newly	O
synthesized	O
lysosomal	O
hydrolases	O
to	O
the	O
lysosome	O
.	O

A	O
partially	O
purified	O
preparation	O
of	O
phosphodiester	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
GlcNAcase	I-GENE-Y
from	O
bovine	O
pancreas	O
was	O
used	O
to	O
generate	O
a	O
panel	O
of	O
murine	O
monoclonal	O
antibodies	O
.	O

The	O
anti	O
-	O
phosphodiester	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
GlcNAcase	I-GENE-Y
monoclonal	O
antibody	O
UC1	O
was	O
coupled	O
to	O
a	O
solid	O
support	O
and	O
used	O
to	O
immunopurify	O
the	O
bovine	O
liver	O
enzyme	O
670	O
,	O
000	O
-	O
fold	O
in	O
two	O
steps	O
to	O
apparent	O
homogeneity	O
with	O
an	O
overall	O
yield	O
of	O
14	O
%	O
.	O

The	O
purified	O
phosphodiester	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
GlcNAcase	I-GENE-Y
has	O
a	O
specific	O
activity	O
of	O
498	O
micromol	O
of	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
GlcNAc	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
phosphomannose	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
cleaved	O
per	O
h	O
per	O
mg	O
of	O
protein	O
using	O
0	O
.	O
5	O
mM	O
[	B-CHEMICAL
3H	I-CHEMICAL
]	I-CHEMICAL
GlcNAc	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
phosphomannose	I-CHEMICAL
-	I-CHEMICAL
alpha	I-CHEMICAL
-	I-CHEMICAL
methyl	I-CHEMICAL
as	O
substrate	O
.	O

The	O
subunit	O
structure	O
of	O
the	O
enzyme	O
was	O
determined	O
using	O
a	O
combination	O
of	O
analytical	O
gel	O
filtration	O
chromatography	O
,	O
SDS	B-CHEMICAL
-	O
polyacrylamide	B-CHEMICAL
gel	O
electrophoresis	O
,	O
and	O
amino	O
-	O
terminal	O
sequencing	O
.	O

The	O
data	O
indicate	O
that	O
bovine	O
phosphodiester	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
GlcNAcase	I-GENE-Y
is	O
a	O
272	O
,	O
000	O
-	O
Da	O
complex	O
of	O
four	O
identical	O
68	O
,	O
000	O
-	O
Da	O
glycoprotein	O
subunits	O
arranged	O
as	O
two	O
disulfide	B-CHEMICAL
-	O
linked	O
homodimers	O
.	O

A	O
soluble	O
form	O
of	O
the	O
enzyme	O
,	O
isolated	O
from	O
fetal	O
bovine	O
serum	O
,	O
showed	O
the	O
same	O
subunit	O
structure	O
.	O

Both	O
forms	O
of	O
the	O
enzyme	O
reacted	O
with	O
a	O
rabbit	O
antibody	O
raised	O
to	O
the	O
amino	B-CHEMICAL
-	O
terminal	O
peptide	O
of	O
the	O
liver	O
enzyme	O
,	O
suggesting	O
that	O
phosphodiester	B-GENE-Y
alpha	I-GENE-Y
-	I-GENE-Y
GlcNAcase	I-GENE-Y
is	O
a	O
type	B-GENE-N
I	I-GENE-N
membrane	I-GENE-N
-	I-GENE-N
spanning	I-GENE-N
glycoprotein	I-GENE-N
with	O
its	O
amino	B-CHEMICAL
terminus	O
in	O
the	O
lumen	O
of	O
the	O
Golgi	O
apparatus	O
.	O

Medical	O
therapy	O
and	O
quality	O
of	O
life	O
.	O

The	O
risk	O
of	O
mortality	O
and	O
long	O
-	O
term	O
morbidity	O
,	O
including	O
loss	O
of	O
sexual	O
function	O
,	O
associated	O
with	O
surgical	O
procedures	O
for	O
symptomatic	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
has	O
prompted	O
research	O
into	O
alternative	O
medical	O
therapies	O
.	O

Phytotherapy	O
involves	O
the	O
use	O
of	O
herbal	O
formulations	O
,	O
where	O
the	O
mechanisms	O
of	O
action	O
are	O
usually	O
obscure	O
and	O
although	O
studies	O
have	O
confirmed	O
their	O
effectiveness	O
in	O
symptom	O
relief	O
and	O
improving	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
,	O
few	O
placebo	O
-	O
controlled	O
trials	O
exist	O
.	O

Both	O
the	O
5	B-GENE-N
alpha	I-GENE-N
-	I-GENE-N
reductase	I-GENE-N
inhibitor	O
finasteride	B-CHEMICAL
and	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
(	O
e	O
.	O
g	O
.	O
alfuzosin	B-CHEMICAL
,	O
doxazosin	B-CHEMICAL
,	O
prazosin	B-CHEMICAL
,	O
tamsulosin	B-CHEMICAL
and	O
terazosin	B-CHEMICAL
)	O
have	O
been	O
recommended	O
as	O
appropriate	O
treatment	O
options	O
for	O
patients	O
with	O
lower	O
urinary	O
tract	O
symptoms	O
(	O
LUTS	O
)	O
associated	O
with	O
benign	O
prostatic	O
obstruction	O
(	O
BPO	O
)	O
,	O
and	O
their	O
efficacy	O
has	O
been	O
proven	O
in	O
several	O
placebo	O
-	O
controlled	O
trials	O
.	O

Finasteride	B-CHEMICAL
reduces	O
the	O
static	O
component	O
of	O
BPO	O
-	O
-	O
by	O
reducing	O
the	O
size	O
of	O
the	O
prostate	O
-	O
-	O
and	O
,	O
as	O
a	O
result	O
,	O
symptom	O
relief	O
is	O
slow	O
(	O
6	O
-	O
12	O
months	O
)	O
and	O
is	O
predominantly	O
restricted	O
to	O
patients	O
with	O
large	O
prostates	O
(	O
>	O
40	O
g	O
)	O
.	O

The	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
,	O
on	O
the	O
other	O
hand	O
,	O
reduce	O
the	O
dynamic	O
component	O
of	O
obstruction	O
-	O
-	O
relaxation	O
of	O
smooth	O
muscle	O
in	O
the	O
prostate	O
,	O
urethra	O
and	O
bladder	O
neck	O
-	O
-	O
and	O
provide	O
rapid	O
symptom	O
relief	O
after	O
only	O
a	O
few	O
doses	O
,	O
relieving	O
LUTS	O
more	O
effectively	O
than	O
finasteride	B-CHEMICAL
and	O
irrespective	O
of	O
prostate	O
size	O
.	O

All	O
of	O
the	O
various	O
alpha	B-GENE-N
1	I-GENE-N
-	I-GENE-N
adrenoceptor	I-GENE-N
antagonists	O
provide	O
effective	O
and	O
comparable	O
relief	O
of	O
LUTS	O
,	O
and	O
an	O
improvement	O
in	O
bothersomeness	O
and	O
symptom	O
-	O
related	O
QOL	O
.	O

However	O
,	O
it	O
is	O
also	O
important	O
that	O
the	O
therapy	O
is	O
fast	O
acting	O
and	O
acceptable	O
to	O
the	O
patient	O
,	O
in	O
that	O
it	O
does	O
not	O
interfere	O
with	O
other	O
medication	O
or	O
produce	O
unpleasant	O
side	O
effects	O
.	O

These	O
documented	O
properties	O
of	O
the	O
alpha	B-GENE-Y
1A	I-GENE-Y
-	I-GENE-Y
adrenoceptor	I-GENE-Y
antagonists	O
make	O
them	O
an	O
ideal	O
choice	O
for	O
the	O
medical	O
treatment	O
of	O
symptomatic	O
BPH	O
.	O

Common	O
and	O
specific	O
determinants	O
for	O
fibroblast	B-GENE-N
growth	I-GENE-N
factors	I-GENE-N
in	O
the	O
ectodomain	O
of	O
the	O
receptor	B-GENE-N
kinase	I-GENE-N
complex	O
.	O

The	O
assembly	O
and	O
activation	O
of	O
oligomeric	O
complexes	O
of	O
FGF	B-GENE-N
,	O
the	O
transmembrane	B-GENE-N
receptor	I-GENE-N
kinase	I-GENE-N
(	O
FGFR	B-GENE-N
)	O
,	O
and	O
heparan	O
sulfate	B-CHEMICAL
transmit	O
intracellular	O
signals	O
regulating	O
growth	O
and	O
function	O
of	O
cells	O
.	O

An	O
understanding	O
of	O
the	O
structural	O
relationships	O
between	O
the	O
three	O
subunits	O
and	O
their	O
redundancy	O
and	O
specificity	O
is	O
essential	O
for	O
understanding	O
the	O
ubiquitous	O
FGF	B-GENE-N
signaling	O
system	O
in	O
health	O
and	O
disease	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
a	O
primary	O
heparin	O
or	O
heparan	O
sulfate	B-CHEMICAL
binding	O
site	O
resides	O
in	O
a	O
distinct	O
sequence	O
in	O
immunoglobulin	B-GENE-N
(	I-GENE-N
Ig	I-GENE-N
)	I-GENE-N
-	I-GENE-N
like	I-GENE-N
module	I-GENE-N
II	I-GENE-N
of	O
the	O
three	O
modules	O
of	O
FGFR	B-GENE-N
.	O

Here	O
we	O
report	O
that	O
in	O
the	O
absence	O
of	O
flanking	O
sequences	O
,	O
isolated	O
Ig	B-GENE-N
module	I-GENE-N
II	I-GENE-N
of	O
FGFR1	B-GENE-Y
supports	O
the	O
binding	O
of	O
FGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
FGF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
and	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
in	O
respective	O
order	O
of	O
affinity	O
.	O

None	O
of	O
the	O
three	O
FGFs	B-GENE-N
detectably	O
bind	O
Ig	B-GENE-N
module	I-GENE-N
I	I-GENE-N
or	I-GENE-N
the	I-GENE-N
IIIb	I-GENE-N
and	I-GENE-N
IIIc	I-GENE-N
splice	O
variants	O
of	O
Ig	B-GENE-N
module	I-GENE-N
III	I-GENE-N
in	O
the	O
absence	O
of	O
flanking	O
sequences	O
.	O

Ig	B-GENE-N
module	I-GENE-N
I	I-GENE-N
and	O
the	O
C	B-CHEMICAL
-	O
terminus	O
of	O
Ig	B-GENE-N
module	I-GENE-N
III	I-GENE-N
are	O
dispensable	O
for	O
high	O
-	O
affinity	O
binding	O
of	O
FGF	B-GENE-Y
-	I-GENE-Y
1	I-GENE-Y
,	O
FGF	B-GENE-Y
-	I-GENE-Y
2	I-GENE-Y
,	O
and	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
.	O

Alterations	O
in	O
highly	O
conserved	O
Ig	B-GENE-N
module	I-GENE-N
II	I-GENE-N
in	O
the	O
heparin	O
binding	O
domain	O
and	O
substitution	O
of	O
individual	O
sequence	O
domains	O
spanning	O
the	O
entire	O
sequence	O
of	O
Ig	B-GENE-N
module	I-GENE-N
II	I-GENE-N
with	O
those	O
from	O
Ig	B-GENE-N
module	I-GENE-N
I	I-GENE-N
obliterated	O
FGF	B-GENE-N
binding	O
.	O

Addition	O
of	O
a	O
specific	O
number	O
of	O
FGFR	B-GENE-N
sequences	O
to	O
the	O
C	B-CHEMICAL
-	O
terminus	O
of	O
Ig	B-GENE-N
module	I-GENE-N
II	I-GENE-N
resulted	O
in	O
a	O
gain	O
in	O
affinity	O
for	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
.	O

Several	O
site	O
-	O
specific	O
alterations	O
in	O
the	O
C	B-CHEMICAL
-	O
terminus	O
of	O
full	O
-	O
length	O
FGFR1IIIc	B-GENE-N
,	O
an	O
isoform	O
that	O
otherwise	O
absolutely	O
rejects	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
,	O
resulted	O
in	O
gain	O
of	O
FGF	B-GENE-Y
-	I-GENE-Y
7	I-GENE-Y
binding	O
.	O

These	O
results	O
suggest	O
that	O
a	O
complex	O
of	O
Ig	B-GENE-N
module	I-GENE-N
II	I-GENE-N
and	O
heparan	O
sulfate	B-CHEMICAL
is	O
the	O
base	O
common	O
active	O
core	O
of	O
the	O
FGFR	B-GENE-N
ectodomain	I-GENE-N
and	O
that	O
flanking	O
structural	O
domains	O
modify	O
FGF	B-GENE-N
affinity	O
and	O
determine	O
specificity	O
.	O

Serotonin	B-GENE-Y
transporter	I-GENE-Y
function	O
in	O
vivo	O
:	O
assessment	O
by	O
chronoamperometry	O
.	O

Local	O
application	O
of	O
selective	O
serotonin	B-CHEMICAL
reuptake	O
inhibitors	O
,	O
fluvoxamine	B-CHEMICAL
and	O
citalopram	B-CHEMICAL
,	O
prolonged	O
the	O
clearance	O
of	O
exogenously	O
administered	O
serotonin	B-CHEMICAL
(	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
)	O
in	O
both	O
the	O
dentate	O
gyrus	O
and	O
CA3	O
region	O
of	O
the	O
dorsal	O
hippocampus	O
,	O
as	O
measured	O
using	O
in	O
vivo	O
chronoamperometry	O
.	O

These	O
effects	O
were	O
abolished	O
in	O
rats	O
pretreated	O
with	O
5	B-CHEMICAL
,	I-CHEMICAL
7	I-CHEMICAL
-	I-CHEMICAL
dihydroxytryptamine	I-CHEMICAL
.	O

The	O
NE	B-CHEMICAL
uptake	O
inhibitors	O
,	O
desipramine	B-CHEMICAL
and	O
protriptyline	B-CHEMICAL
,	O
did	O
not	O
alter	O
the	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
signal	O
in	O
the	O
CA3	O
region	O
,	O
but	O
prolonged	O
the	O
clearance	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
in	O
the	O
dentate	O
gyrus	O
;	O
this	O
effect	O
was	O
absent	O
in	O
rats	O
pretreated	O
with	O
6	B-CHEMICAL
-	I-CHEMICAL
hydroxydopamine	I-CHEMICAL
.	O

From	O
these	O
data	O
,	O
it	O
is	O
inferred	O
that	O
both	O
the	O
SERT	B-GENE-Y
and	O
NET	B-GENE-Y
contribute	O
to	O
the	O
active	O
clearance	O
of	O
exogenously	O
applied	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
in	O
the	O
dentate	O
gyrus	O
.	O

In	O
another	O
experiment	O
,	O
cyanopindolol	B-CHEMICAL
,	O
an	O
antagonist	O
of	O
the	O
serotonin	B-GENE-N
terminal	I-GENE-N
autoreceptor	I-GENE-N
,	O
also	O
prolonged	O
the	O
clearance	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
from	O
the	O
CA3	O
region	O
.	O

These	O
and	O
other	O
data	O
have	O
generated	O
a	O
working	O
hypothesis	O
that	O
activation	O
of	O
the	O
terminal	O
serotonin	B-GENE-N
autoreceptor	I-GENE-N
enhances	O
the	O
kinetics	O
of	O
5	B-CHEMICAL
-	I-CHEMICAL
HT	I-CHEMICAL
uptake	O
through	O
an	O
effect	O
on	O
the	O
serotonin	B-GENE-Y
transporter	I-GENE-Y
.	O

